﻿FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Moriarity, A
   O'Sullivan, J
   Kennedy, J
   Mehigan, B
   McCormick, P
AF Moriarity, Andrew
   O'Sullivan, Jacintha
   Kennedy, John
   Mehigan, Brian
   McCormick, Paul
TI Current targeted therapies in the treatment of advanced colorectal
   cancer: a review
SO THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
LA English
DT Review
DE biomarkers; colorectal cancer; signaling; targeted therapy
ID ENDOTHELIAL GROWTH-FACTOR; CETUXIMAB PLUS IRINOTECAN; FACTOR RECEPTOR
   EXPRESSION; RANDOMIZED PHASE-III; WILD-TYPE KRAS; 1ST-LINE TREATMENT;
   LYMPH-NODE; OPEN-LABEL; SIGNAL-TRANSDUCTION; TUMOR ANGIOGENESIS
AB Treatment strategies for metastatic colorectal cancer (mCRC) patients have undergone dramatic changes in the past decade and despite improved patient outcomes, there still exist areas for continued development. The introduction of targeted agents has provided clinicians with additional treatment options in mCRC, however, results have been mixed at best. These novel therapies were designed to interfere with specific molecules involved in the cellular carcinogenesis pathway and ultimately deliver a more focused treatment. Currently, their use in mCRC has been limited primarily as an adjunct to conventional chemotherapy regimens. This review explores the relevant cell-signaling networks in colorectal cancer, provides focus on the current targeted agent armamentarium approved for use in mCRC and explores the usefulness of predictive mCRC biomarkers.
C1 [Moriarity, Andrew] St James Hosp, Surg Oncol, St Jamess St, Dublin 8, Ireland.
   [O'Sullivan, Jacintha; Kennedy, John; Mehigan, Brian; McCormick, Paul] St James Hosp, Dublin, Ireland.
C3 Trinity College Dublin; Trinity College Dublin
RP Moriarity, A (corresponding author), St James Hosp, Surg Oncol, St Jamess St, Dublin 8, Ireland.
EM andrewmoriarity@gmail.com
OI Mehigan, Brian J/0000-0001-5602-4325; mccormick,
   Paul/0000-0002-3531-8575; O'Sullivan, Jacintha/0000-0001-8622-9858
CR Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X
   Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], J PROBABILITY STAT
   [Anonymous], 2009, United States cancer statistics: 1999-2005 incidence and mortality Web-based report
   Ardekani GS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047054
   Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145
   Baselga J, 2001, EUR J CANCER, V37, pS16
   Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Berlin J., 2006, J CLIN ONCOL, V24, P3548, DOI [DOI 10.1200/JCO.2006.24.18_SUPPL.3548, 10.1200/jco.2006.24.18_suppl.3548]
   Bhargava P, 2011, CURR ONCOL REP, V13, P103, DOI 10.1007/s11912-011-0154-3
   Blanke CD, 2009, J CLIN ONCOL, V27, P655, DOI 10.1200/JCO.2008.21.2522
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Bogdan S, 2001, CURR BIOL, V11, pR292, DOI 10.1016/S0960-9822(01)00167-1
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0
   BOS JL, 1989, CANCER RES, V49, P4682
   CADENA DL, 1992, FASEB J, V6, P2332, DOI 10.1096/fasebj.6.6.1312047
   Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007
   Chau I, 2009, BRIT J CANCER, V100, P1704, DOI 10.1038/sj.bjc.6605061
   Chu E, 2012, CLIN COLORECTAL CANC, V11, P1, DOI 10.1016/j.clcc.2011.05.005
   Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962
   Cohen S, 1981, Prog Clin Biol Res, V66 Pt A, P557
   COHEN S, 1975, P NATL ACAD SCI USA, V72, P1317, DOI 10.1073/pnas.72.4.1317
   Cohen SJ, 2005, J CLIN ONCOL, V23, P5374, DOI 10.1200/JCO.2005.02.194
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Fiore F, 2010, BRIT J CANCER, V103, P1765, DOI 10.1038/sj.bjc.6606008
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Eichholz A, 2010, ONCOTARGETS THER, V3, P69
   Eklöf V, 2013, BRIT J CANCER, V108, P2153, DOI 10.1038/bjc.2013.212
   Ellis LM, 2006, SEMIN ONCOL, V33, pS1, DOI 10.1053/j.seminoncol.2006.08.002
   ElShamy W., 2005, CANC THERAPY, V3, P443
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 1997, ENDOCR REV, V18, P4, DOI 10.1210/er.18.1.4
   Figueras A, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-125
   Fischer OM, 2003, BIOCHEM SOC T, V31, P1203
   Fiske WH, 2009, EXP CELL RES, V315, P583, DOI 10.1016/j.yexcr.2008.10.043
   FOLKMAN J, 1971, J EXP MED, V133, P275, DOI 10.1084/jem.133.2.275
   FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664
   Fuchs CS, 2008, J CLIN ONCOL, V26, P689, DOI 10.1200/JCO.2007.15.5390
   Geiger-Gritsch S, 2010, ONCOLOGIST, V15, P1179, DOI 10.1634/theoncologist.2009-0155
   George AL, 2011, J HEMATOL ONCOL, V4, DOI 10.1186/1756-8722-4-24
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Giusti RM, 2007, ONCOLOGIST, V12, P577, DOI 10.1634/theoncologist.12-5-577
   Goel G, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0183-8
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Gordon MS, 2001, J CLIN ONCOL, V19, P843, DOI 10.1200/JCO.2001.19.3.843
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guerrero S, 2000, CANCER RES, V60, P6750
   HAYASHI N, 1995, LANCET, V345, P1257, DOI 10.1016/S0140-6736(95)90922-2
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Hubbard J, 2010, CURR OPIN ONCOL, V22, P374, DOI 10.1097/CCO.0b013e328339524e
   Hubbard Joleen M, 2013, Gastrointest Cancer Res, V6, P47
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz HI, 2009, ONCOLOGIST, V14, P22, DOI 10.1634/theoncologist.2008-0213
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Ibrahim EM, 2011, MED ONCOL, V28, pS310, DOI 10.1007/s12032-010-9760-4
   Irahara N, 2010, DIAGN MOL PATHOL, V19, P157, DOI 10.1097/PDM.0b013e3181c93fd1
   Jimeno A, 2009, J CLIN ONCOL, V27, P1130, DOI 10.1200/JCO.2008.19.8168
   JOHNSON JP, 1989, J CANCER RES CLIN, V115, P494, DOI 10.1007/BF00393348
   Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5
   Jung YD, 2002, EUR J CANCER, V38, P1133, DOI 10.1016/S0959-8049(02)00013-8
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   KAKLAMANIS L, 1992, BRIT J CANCER, V66, P712, DOI 10.1038/bjc.1992.343
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kimura H, 2007, CANCER SCI, V98, P1275, DOI 10.1111/j.1349-7006.2007.00510.x
   Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083
   Lemmon MA, 2010, CELL, V141, P1117, DOI 10.1016/j.cell.2010.06.011
   Lenz HJ, 2015, CANCER TREAT REV, V41, P777, DOI 10.1016/j.ctrv.2015.06.001
   Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Liu Y, 2006, NAT CHEM BIOL, V2, P358, DOI 10.1038/nchembio799
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   MATTHEWS W, 1991, P NATL ACAD SCI USA, V88, P9026, DOI 10.1073/pnas.88.20.9026
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meyer M, 1999, EMBO J, V18, P363, DOI 10.1093/emboj/18.2.363
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Moscatello DK, 1996, ONCOGENE, V13, P85
   MUSTONEN T, 1995, J CELL BIOL, V129, P895, DOI 10.1083/jcb.129.4.895
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nathanson SD, 2003, CANCER, V98, P413, DOI 10.1002/cncr.11464
   National Cancer Institute (NCI), 2015, DRUGS APPR COL RECT
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3
   Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111
   O'Connell JB, 2004, JNCI-J NATL CANCER I, V96, P1420, DOI 10.1093/jnci/djh275
   Pedersen MW, 2005, J CELL BIOCHEM, V96, P412, DOI 10.1002/jcb.20554
   Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541
   Peters GJ, 2015, THER ADV MED ONCOL, V7, P340, DOI 10.1177/1758834015603313
   PIEDBOIS P, 1992, J CLIN ONCOL, V10, P896
   Pirker R, 2009, LANCET, V373, P1525, DOI 10.1016/S0140-6736(09)60569-9
   Pugh CW, 2003, NAT MED, V9, P677, DOI 10.1038/nm0603-677
   Risau W, 1997, NATURE, V386, P671, DOI 10.1038/386671a0
   Roberts N, 2006, CANCER RES, V66, P2650, DOI 10.1158/0008-5472.CAN-05-1843
   Robinson DR, 2000, ONCOGENE, V19, P5548, DOI 10.1038/sj.onc.1203957
   Rocha-Lima Caio M, 2007, Cancer Control, V14, P295
   Sahin IH, 2013, J CANCER, V4, P320, DOI 10.7150/jca.3619
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Saltz Leonard, 2006, Nat Rev Drug Discov, V5, P987, DOI 10.1038/nrd2204
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Saltz LB, 2007, J CLIN ONCOL, V25, P4557, DOI 10.1200/JCO.2007.12.0949
   Scagliotti GV, 2004, CLIN CANCER RES, V10, p4227S, DOI 10.1158/1078-0432.CCR-040007
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Schrag D, 2004, NEW ENGL J MED, V351, P317, DOI 10.1056/NEJMp048143
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Sclafani F, 2013, CRIT REV ONCOL HEMAT, V87, P55, DOI 10.1016/j.critrevonc.2012.11.003
   Shaheen RM, 2001, BRIT J CANCER, V85, P584, DOI 10.1054/bjoc.2001.1936
   Shibuya M, 2001, CELL STRUCT FUNCT, V26, P25, DOI 10.1247/csf.26.25
   SHIBUYA M, 1990, ONCOGENE, V5, P519
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Simon R, 2008, CLIN CANCER RES, V14, P5984, DOI 10.1158/1078-0432.CCR-07-4531
   Spaulding DC, 2002, SEMIN ONCOL, V29, P45, DOI 10.1053/sonc.2002.35647
   Strimpakos AS, 2009, PHARMACOGENOMICS J, V9, P147, DOI 10.1038/tpj.2009.8
   Stuart D, 2009, CURR OPIN CELL BIOL, V21, P304, DOI 10.1016/j.ceb.2009.02.001
   Tabernero J, 2007, J CLIN ONCOL, V25, P5225, DOI 10.1200/JCO.2007.13.2183
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   TAKAHASHI Y, 1995, CANCER RES, V55, P3964
   Takahashi Y, 1996, J NATL CANCER I, V88, P1146, DOI 10.1093/jnci/88.16.1146
   Tan DSW, 2009, CANCER J, V15, P406, DOI 10.1097/PPO.0b013e3181bd0445
   Tanigawa N, 1997, CANCER RES, V57, P1043
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tonini T, 2003, ONCOGENE, V22, P6549, DOI 10.1038/sj.onc.1206816
   Tortora G, 2008, NAT CLIN PRACT ONCOL, V5, P521, DOI 10.1038/ncponc1161
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Vale CL, 2012, CANCER TREAT REV, V38, P618, DOI 10.1016/j.ctrv.2011.11.002
   Van Cutsem E, 2007, J CLIN ONCOL, V25
   Van Cutsem E, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.2
   Van Cutsem E, 2010, ANN ONCOL, V21, pv93, DOI 10.1093/annonc/mdq222
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
   Vecchione L, 2011, EXP CELL RES, V317, P2765, DOI 10.1016/j.yexcr.2011.08.021
   Vincenzi B, 2010, CURR CANCER DRUG TAR, V10, P80, DOI 10.2174/156800910790980241
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Wek RC, 2010, EMBO J, V29, P1946, DOI 10.1038/emboj.2010.110
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Winau F, 2004, MICROBES INFECT, V6, P786, DOI 10.1016/j.micinf.2004.04.003
   Wolmark N, 1998, J CLIN ONCOL, V16, P301
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Workman P, 2006, JNCI-J NATL CANCER I, V98, P580, DOI 10.1093/jnci/djj162
   Wu SJ, 2013, J CANCER RES CLIN, V139, P891, DOI 10.1007/s00432-013-1400-x
   Yancopoulos GD, 2000, NATURE, V407, P242, DOI 10.1038/35025215
   Yang JC, 2003, NEW ENGL J MED, V349, P427, DOI 10.1056/NEJMoa021491
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   YASUI W, 1988, CANCER RES, V48, P137
   Yau T, 2009, CANCER-AM CANCER SOC, V115, P428, DOI 10.1002/cncr.24029
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
   Zhang XB, 2001, CANCER RES, V61, P6050
NR 169
TC 92
Z9 98
U1 0
U2 13
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1758-8340
EI 1758-8359
J9 THER ADV MED ONCOL
JI Ther. Adv. Med. Oncol.
PD JUL
PY 2016
VL 8
IS 4
BP 276
EP 293
DI 10.1177/1758834016646734
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DT3LZ
UT WOS:000381384000004
PM 27482287
OA Bronze, Green Published
DA 2025-01-04
ER

PT J
AU Chi-Chen, F
   Tao-Yeuan, W
   Chien-Min, K
AF Chi-Chen, Fan
   Tao-Yeuan, Wang
   Chien-Min, Kung
TI Epidermal Growth Factor Receptor Inconsistency by Immunohistochemistry
   Method Using Different Monoclonal Antibodies in Colorectal Cancer
   Patients
SO CLINICAL LABORATORY
LA English
DT Article
DE colorectal cancer; EGFR; targeted drug therapy; immunohistochemistry
ID EGFR INHIBITORS; EPIDEMIOLOGY; THERAPY; EXPRESSION; ERLOTINIB; PROTEINS;
   IMPACT
AB Background: Targeted therapy is typically used to treat colorectal cancer (CRC). The epidermal growth factor receptor (EGFR) was recognized as a potential therapeutic target. Does the EGFR protein express consistently using different monoclonal antibodies in clinics?
   Methods: One hundred and sixty-four patients (mean age 61.80 +/- 12.78 years) who suffered from CRC were selected at Mackay Memorial Hospital in Taiwan. Formalin-fixed and paraffin-embedded tissue sections from all patients were tested simultaneously using two commercial antibodies, Dako-EGFR (mouse monoclonal anti-EGFR clone 2-18C9, pharmDx (TM)) and NCL-EGFR (NCL-EGFR-384, Novocastra (TM)) monoclonal antibodies, to study the commutability or equality of the qualities of EGFR expression by standard immunohistochemistry (HIC) procedures.
   Results: The EGFR expressions that were obtained by IHC staining using different monoclonal antibodies with Dako-EGFR (46.95%) and NCL-EGFR (32.32%) were fairly concordant.
   Conclusions: Although IHC is a convenient and feasible method for detecting the expression of EGFR, it yields controversial staining results concerning EGFR expression using various commercial antibodies in a CRC tumor section.
C1 [Chi-Chen, Fan; Chien-Min, Kung] Yuanpei Univ Med Technol, Coll Biomed Sci & Technol, Dept Med Lab Sci & Biotechnol, Hsinchu 300, Taiwan.
   [Chi-Chen, Fan] Mackay Mem Hosp, Dept Physiol, Taipei, Taiwan.
   [Tao-Yeuan, Wang] Mackay Med Nursing & Management Coll, Mackay Med Coll, Mackay Mem Hosp, Dept Pathol, Taipei, Taiwan.
C3 Mackay Memorial Hospital; Mackay Medical College; Mackay Memorial
   Hospital; Mackay Junior College of Medicine, Nursing & Management
RP Chien-Min, K (corresponding author), Yuanpei Univ Med Technol, Coll Biomed Sci & Technol, Dept Med Lab Sci & Biotechnol, 306 St Yuanpei, Hsinchu 300, Taiwan.
EM jameskung@mail.ypu.edu.tw
CR Ambroise MM, 2010, ASIAN PAC J CANCER P, V11, P1079
   [Anonymous], 1983, WORLD HLTH STAT ANN
   Bazley LA, 2005, ENDOCR-RELAT CANCER, V12, pS17, DOI 10.1677/erc.1.01032
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Bond JH, 2000, AM J GASTROENTEROL, V95, P3053
   Chen CJ, 2002, JPN J CLIN ONCOL, V32, pS66, DOI 10.1093/jjco/hye138
   Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Cooley EK, 2009, DIS COLON RECTUM, V52, P222, DOI 10.1007/DCR.0b013e31819a3f07
   Crawford JM, 1991, ROBBINS PATHOLOGIC B, P897
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   El Zouhairi Majed, 2011, Gastrointest Cancer Res, V4, P15
   Fakih M, 2010, CURR ONCOL, V17, pS3
   Frederick LG, 2002, AJCC CANC STAGING HD
   Goldstein NS, 2001, CANCER, V92, P1331, DOI 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
   Gulati S, 2010, DIAGN PATHOL, V5, DOI 10.1186/1746-1596-5-18
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hawkins NJ, 2001, J NATL CANCER I, V93, P1307, DOI 10.1093/jnci/93.17.1307
   Heinemann V, 2009, CANCER TREAT REV, V35, P262, DOI 10.1016/j.ctrv.2008.11.005
   Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083
   Levine JS, 2006, NEW ENGL J MED, V355, P2551, DOI 10.1056/NEJMcp063038
   Mathieu A, 2010, LUNG CANCER, V69, P46, DOI 10.1016/j.lungcan.2009.09.003
   Metro G, 2006, ANN ONCOL, V17, P42, DOI 10.1093/annonc/mdj920
   Modjtahedi H, 2012, BRIT J CANCER, V106, P883, DOI 10.1038/bjc.2012.27
   Molinari F, 2009, BRIT J CANCER, V100, P1087, DOI 10.1038/sj.bjc.6604848
   Pérez-Soler R, 2004, J CLIN ONCOL, V22, P3238, DOI 10.1200/JCO.2004.11.057
   Pignone M, 2002, ANN INTERN MED, V137, P96, DOI 10.7326/0003-4819-137-2-200207160-00007
   Rozen P, 2011, EUR J CANCER PREV, V20, P46, DOI 10.1097/CEJ.0b013e328341e309
   Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   SELBY JV, 1992, NEW ENGL J MED, V326, P653, DOI 10.1056/NEJM199203053261001
   Siegel RL, 2020, ANTI-CANCER DRUG, V70, P7, DOI [DOI 10.3322/CAAC.21590, DOI 10.1097/CAD.0000000000000617]
   Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280
   Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006
   Su SY, 2012, INT J COLORECTAL DIS, V27, P1665, DOI 10.1007/s00384-012-1521-8
   Torp SH, 2007, J EXP CLIN CANC RES, V26, P353
   Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736
   Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97
   Yee YK, 2009, J GASTROEN HEPATOL, V24, P1810, DOI 10.1111/j.1440-1746.2009.06138.x
   Yip YL, 2001, J IMMUNOL, V166, P5271, DOI 10.4049/jimmunol.166.8.5271
NR 40
TC 2
Z9 2
U1 0
U2 1
PU CLIN LAB PUBL
PI HEIDELBERG
PA IM BREITSPIEL 15, HEIDELBERG, D-69126, GERMANY
SN 1433-6510
J9 CLIN LAB
JI Clin. Lab.
PY 2015
VL 61
IS 11
BP 1635
EP 1641
DI 10.7754/Clin.Lab.2015.150330
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA CX1LA
UT WOS:000365456500006
PM 26731987
DA 2025-01-04
ER

PT J
AU Aoyama, R
   Hida, K
   Hasegawa, S
   Yamaguchi, T
   Manaka, D
   Kato, S
   Yamada, M
   Yamanokuchi, S
   Kyogoku, T
   Kanazawa, A
   Kawada, K
   Sakamoto, T
   Goto, S
   Sakai, Y
   Obama, K
AF Aoyama, Ryuhei
   Hida, Koya
   Hasegawa, Suguru
   Yamaguchi, Takashi
   Manaka, Dai
   Kato, Shigeru
   Yamada, Masahiro
   Yamanokuchi, Satoshi
   Kyogoku, Takahisa
   Kanazawa, Akiyoshi
   Kawada, Kenji
   Sakamoto, Takashi
   Goto, Saori
   Sakai, Yoshiharu
   Obama, Kazutaka
TI Long-term results of a phase 2 study of neoadjuvant chemotherapy with
   molecularly targeted agents for locally advanced rectal cancer
SO INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE Neoadjuvant therapy; Molecularly targeted therapy; Rectal neoplasms;
   Survival
ID TOTAL MESORECTAL EXCISION; SHORT-COURSE RADIOTHERAPY; PREOPERATIVE
   RADIOTHERAPY; POSTOPERATIVE CHEMOTHERAPY; CHEMORADIOTHERAPY REGIMENS;
   GERMAN CAO/ARO/AIO-04; RANDOMIZED-TRIAL; MULTICENTER; OXALIPLATIN;
   CHEMORADIATION
AB Background We previously reported the feasibility and efficacy of neoadjuvant chemotherapy without radiotherapy for locally advanced rectal cancer. Here, we report the results of a long-term follow-up study.Methods This was a multi-institutional, prospective phase 2 study of patients with locally advanced rectal cancer. Patients received neoadjuvant chemotherapy with molecularly targeted agents before undergoing total mesorectal excision. Six cycles of modified FOLFOX (mFOLFOX6) with bevacizumab were administered to KRAS-mutant patients, and mFOLFOX6 with cetuximab was administered to KRAS-wild-type patients. Here, we report the secondary end points of overall survival, relapse-free survival, and local recurrence rate.Results Sixty patients were enrolled in this study. R0 resection was achieved in 98.3% (59/60) patients, and pathological complete response was achieved in 16.7% (10/60) patients. After a median follow-up of 5.4 years, the 5 year overall survival was 81.6%, the 5 year relapse-free survival was 71.7%, and the 5 year local recurrence rate was 12.6%. None of the patients who achieved pathological complete response developed recurrence within 5 years.Conclusions The use of molecularly targeted agents in the neoadjuvant setting for locally advanced rectal cancer has an acceptable prognosis.
C1 [Aoyama, Ryuhei; Hida, Koya; Kawada, Kenji; Sakamoto, Takashi; Goto, Saori; Obama, Kazutaka] Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan.
   [Hasegawa, Suguru] Fukuoka Univ, Dept Gastroenterol Surg, Fukuoka, Japan.
   [Yamaguchi, Takashi] Kyoto Med Ctr, Dept Surg, Kyoto, Japan.
   [Manaka, Dai] Kyoto Katsura Hosp, Dept Surg, Kyoto, Japan.
   [Kato, Shigeru] Tenri Yorozu Hosp, Dept Gastrointestinal Surg, Nara, Japan.
   [Yamada, Masahiro] Shiga Gen Hosp, Dept Surg, Moriyama, Shiga, Japan.
   [Yamanokuchi, Satoshi; Sakai, Yoshiharu] Osaka Red Cross Hosp, Dept Surg, Osaka, Japan.
   [Kyogoku, Takahisa] Nishi Kobe Med Ctr, Dept Surg, Kobe, Japan.
   [Kanazawa, Akiyoshi] Kitano Hosp, Dept Gastroenterol Surg & Oncol, Med Res Inst, Osaka, Japan.
C3 Kyoto University; Fukuoka University; Osaka Red Cross Hospital; Kobe
   City Medical Center General Hospital; Kitano Hospital
RP Hida, K (corresponding author), Kyoto Univ, Grad Sch Med, Dept Surg, Kyoto, Japan.
EM hidakoya@kuhp.kyoto-u.ac.jp
RI OBAMA, KAZUTAKA/AAW-8263-2021
OI Hida, Koya/0000-0001-7210-7075; Goto, Saori/0000-0001-7811-7397
FU Senko Medical Instrument
FX This study was funded by Senko Medical Instrument and is in compliance
   with the conflict-of-interest policy. We have no other financial
   associations.
CR Allegra CJ, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv248
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Aschele C, 2011, J CLIN ONCOL, V29, P2773, DOI 10.1200/JCO.2010.34.4911
   Azria D, 2017, ANN ONCOL, V28, P2436, DOI 10.1093/annonc/mdx351
   Benson A III, 2018, J NATL COMPR CANC NE, V16, P874, DOI 10.6004/jnccn.2018.0061
   Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829
   Bujko K, 2006, BRIT J SURG, V93, P1215, DOI 10.1002/bjs.5506
   Dahlberg M, 1998, DIS COLON RECTUM, V41, P543, DOI 10.1007/BF02235256
   Fujita S, 2017, ANN SURG, V266, P201, DOI 10.1097/SLA.0000000000002212
   Gérard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629
   Gérard JP, 2010, J CLIN ONCOL, V28, P1638, DOI 10.1200/JCO.2009.25.8376
   Glynne-Jones R, 2017, ANN ONCOL, V28, P22, DOI 10.1093/annonc/mdx224
   Gressett SM, 2009, ANN PHARMACOTHER, V43, P490, DOI 10.1345/aph.1L426
   Hapani S, 2009, LANCET ONCOL, V10, P559, DOI 10.1016/S1470-2045(09)70112-3
   Hasegawa S, 2017, ANN SURG ONCOL, V24, P3587, DOI 10.1245/s10434-017-5967-3
   Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z
   Hida K, 2021, ANN SURG ONCOL, V28, P6179, DOI 10.1245/s10434-021-10312-7
   Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580
   Kotake K, 2019, J ANUS RECTUM COLON, V3, P175, DOI 10.23922/jarc.2019-018
   Liu S, 2021, ONCOLOGIST, V26, pE1555, DOI 10.1002/onco.13824
   Martin ST, 2012, BRIT J SURG, V99, P918, DOI 10.1002/bjs.8702
   Nagtegaal ID, 2008, J CLIN ONCOL, V26, P303, DOI 10.1200/JCO.2007.12.7027
   Ngan SY, 2012, J CLIN ONCOL, V30, P3827, DOI 10.1200/JCO.2012.42.9597
   O'Connell MJ, 2014, J CLIN ONCOL, V32, P1927, DOI 10.1200/JCO.2013.53.7753
   Peeters KCMJ, 2007, ANN SURG, V246, P693, DOI 10.1097/01.sla.0000257358.56863.ce
   Rödel C, 2015, LANCET ONCOL, V16, P979, DOI 10.1016/S1470-2045(15)00159-X
   Rödel C, 2012, LANCET ONCOL, V13, P679, DOI 10.1016/S1470-2045(12)70187-0
   Sakamoto T, 2020, J SURG ONCOL, V122, P1647, DOI 10.1002/jso.26222
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Scappaticci FA, 2005, J SURG ONCOL, V91, P173, DOI 10.1002/jso.20301
   Schrag D, 2014, J CLIN ONCOL, V32, P513, DOI 10.1200/JCO.2013.51.7904
   Tomida A, 2019, INT J CLIN ONCOL, V24, P403, DOI 10.1007/s10147-018-1372-6
   Usiskin I, 2021, BREAST CANCER RES TR, V186, P191, DOI 10.1007/s10549-020-05994-8
   Wiltink LM, 2014, EUR J CANCER, V50, P2390, DOI 10.1016/j.ejca.2014.06.020
NR 34
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER JAPAN KK
PI TOKYO
PA SHIROYAMA TRUST TOWER 5F, 4-3-1 TORANOMON, MINATO-KU, TOKYO, 105-6005,
   JAPAN
SN 1341-9625
EI 1437-7772
J9 INT J CLIN ONCOL
JI Int. J. Clin. Oncol.
PD MAR
PY 2023
VL 28
IS 3
SI SI
BP 392
EP 399
DI 10.1007/s10147-023-02291-4
EA JAN 2023
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 9P1KM
UT WOS:000911317700001
PM 36622469
DA 2025-01-04
ER

PT J
AU Zarrilli, G
   Galuppini, F
   Angerilli, V
   Munari, G
   Sabbadin, M
   Lazzarin, V
   Nicolè, L
   Biancotti, R
   Fassan, M
AF Zarrilli, Giovanni
   Galuppini, Francesca
   Angerilli, Valentina
   Munari, Giada
   Sabbadin, Marianna
   Lazzarin, Vanni
   Nicole, Lorenzo
   Biancotti, Rachele
   Fassan, Matteo
TI miRNAs Involved in Esophageal Carcinogenesis and miRNA-Related
   Therapeutic Perspectives in Esophageal Carcinoma
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE microRNAs; esophageal cancer; carcinogenetic cascade; predictive
   biomarker; targeted therapy
ID SQUAMOUS-CELL CARCINOMA; EPITHELIAL-MESENCHYMAL TRANSITION;
   CANCER-CELLS; TUMOR-SUPPRESSOR; SIGNALING PATHWAYS; BARRETTS-ESOPHAGUS;
   COLORECTAL-CANCER; PROMOTES APOPTOSIS; INHIBITS MIGRATION;
   DOWN-REGULATION
AB MicroRNAs (miRNAs) are small non-coding RNAs that play a pivotal role in many aspects of cell biology, including cancer development. Within esophageal cancer, miRNAs have been proved to be involved in all phases of carcinogenesis, from initiation to metastatic spread. Several miRNAs have been found to be dysregulated in esophageal premalignant lesions, namely Barrett's esophagus, Barrett's dysplasia, and squamous dysplasia. Furthermore, numerous studies have investigated the alteration in the expression levels of many oncomiRNAs and tumor suppressor miRNAs in esophageal squamous cell carcinoma and esophageal adenocarcinoma, thus proving how miRNAs are able modulate crucial regulatory pathways of cancer development. Considering these findings, miRNAs may have a role not only as a diagnostic and prognostic tool, but also as predictive biomarker of response to anti-cancer therapies and as potential therapeutic targets. This review aims to summarize several studies on the matter, focusing on the possible diagnostic-therapeutic implications.
C1 [Zarrilli, Giovanni; Galuppini, Francesca; Angerilli, Valentina; Sabbadin, Marianna; Lazzarin, Vanni; Nicole, Lorenzo; Biancotti, Rachele; Fassan, Matteo] Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, I-35121 Padua, Italy.
   [Munari, Giada; Fassan, Matteo] IRCCS, Veneto Inst Oncol IOV, I-35128 Padua, Italy.
C3 University of Padua; IRCCS Istituto Oncologico Veneto (IOV)
RP Fassan, M (corresponding author), Univ Padua, Dept Med DIMED, Surg Pathol & Cytopathol Unit, I-35121 Padua, Italy.; Fassan, M (corresponding author), IRCCS, Veneto Inst Oncol IOV, I-35128 Padua, Italy.
EM giovanni.zarrilli@gmail.com; francesca.galuppini@unipd.it;
   valentina.angerilli@gmail.com; giada.munari@gmail.com;
   mariannasabbadin310@gmail.com; vanni.lazzarin@unipd.it;
   lorenzo.nic86@gmail.com; racheb@hotmail.it; matteo.fassan@unipd.it
RI Galuppini, Francesca/AAC-2047-2019; Fassan, Matteo/F-5152-2012; Nicole,
   Lorenzo/AAB-2202-2022
OI Galuppini, Francesca/0000-0002-3245-2322; Fassan,
   Matteo/0000-0001-6515-5482; Nicole, Lorenzo/0000-0001-8126-9674;
   Sabbadin, Marianna/0009-0004-7795-415X
FU Italian Health Ministry's research programNET-2016-02363853
FX This research was partially funded by a grant from the Italian Health
   Ministry's research programNET-2016-02363853. The funding agency had no
   role in the design and performance of the study.
CR Angerilli V, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9030318
   Valer JA, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111366
   Bajan S, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010137
   Banumathy G, 2010, CANCER BIOL THER, V10, P658, DOI 10.4161/cbt.10.7.13247
   Beishline K, 2015, FEBS J, V282, P224, DOI 10.1111/febs.13148
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Bujanda Daniel E, 2018, Mo Med, V115, P211
   Byrnes KA, 2016, ONCOTARGET, V7, P8756, DOI 10.18632/oncotarget.6752
   Cai HF, 2020, MEDIAT INFLAMM, V2020, DOI 10.1155/2020/3420946
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Cao DR, 2020, J CANCER, V11, P1315, DOI 10.7150/jca.39044
   Chalhoub N, 2009, ANNU REV PATHOL-MECH, V4, P127, DOI 10.1146/annurev.pathol.4.110807.092311
   Chan JA, 2005, CANCER RES, V65, P6029, DOI 10.1158/0008-5472.CAN-05-0137
   Chen H, 2020, ONCOTARGETS THER, V13, P8463, DOI 10.2147/OTT.S258680
   Chen Y, 2021, KAOHSIUNG J MED SCI, V37, P181, DOI 10.1002/kjm2.12318
   Chen ZL, 2011, J BIOL CHEM, V286, P10725, DOI 10.1074/jbc.M110.165654
   Chen ZY, 2018, J CANCER, V9, P3660, DOI 10.7150/jca.27124
   Cheng Y, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1303-0
   Cisneros-Soberanis F, 2016, SPRINGERPLUS, V5, DOI 10.1186/s40064-016-2475-z
   Coolen M, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00220
   Cui YT, 2017, J INT MED RES, V45, P1310, DOI 10.1177/0300060517709370
   Cummins JM, 2006, P NATL ACAD SCI USA, V103, P3687, DOI 10.1073/pnas.0511155103
   Da CX, 2017, ONCOTARGET, V8, P8131, DOI 10.18632/oncotarget.14101
   Drahos J, 2016, CANCER EPIDEM BIOMAR, V25, P429, DOI 10.1158/1055-9965.EPI-15-0161
   Ebrahimi F, 2014, EXP MOL PATHOL, V96, P98, DOI 10.1016/j.yexmp.2013.12.004
   Esquela-Kerscher A, 2006, NAT REV CANCER, V6, P259, DOI 10.1038/nrc1840
   Farooqi AA, 2015, EXP MOL MED, V47, DOI 10.1038/emm.2015.70
   Fassan M, 2012, DIS ESOPHAGUS, V25, P263, DOI 10.1111/j.1442-2050.2011.01236.x
   Fassan M, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152907
   Fassan M, 2017, WORLD J GASTROENTERO, V23, P7653, DOI 10.3748/wjg.v23.i43.7653
   Fassan M, 2017, AM J CLIN PATHOL, V147, P301, DOI [10.1093/AJCP/AQX004, 10.1093/ajcp/aqx004]
   Fassan M, 2013, HUM PATHOL, V44, P1804, DOI 10.1016/j.humpath.2013.01.023
   Fassan M, 2013, CLIN TRANSL GASTROEN, V4, DOI 10.1038/ctg.2013.5
   Fassan M, 2011, WORLD J GASTROENTERO, V17, P5231, DOI 10.3748/wjg.v17.i48.5231
   Ferrara N, 2016, NAT REV DRUG DISCOV, V15, P385, DOI 10.1038/nrd.2015.17
   Gabriela-Freitas M, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9120769
   Galoczova M, 2018, CELL MOL BIOL LETT, V23, DOI 10.1186/s11658-018-0078-0
   Gambari R, 2016, INT J ONCOL, V49, P5, DOI 10.3892/ijo.2016.3503
   Gao XT, 2017, THORAC CANCER, V8, P501, DOI 10.1111/1759-7714.12476
   Gao XY, 2019, INT J CLIN EXP PATHO, V12, P275
   Ghasemi M, 2018, J CANCER RES THER, V14, pS132, DOI 10.4103/0973-1482.171361
   Ghosh AK, 2009, BLOOD, V113, P5568, DOI 10.1182/blood-2008-10-185686
   Hahne JC, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00226
   He B, 2013, ONCOL REP, V29, P1115, DOI 10.3892/or.2012.2199
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   He ZY, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0533-3
   Hu CM, 2017, ONCOL LETT, V13, P4769, DOI 10.3892/ol.2017.6098
   Hu SL, 2019, J BUON, V24, P805
   Hu YX, 2011, INT J CANCER, V128, P132, DOI 10.1002/ijc.25330
   Huse JT, 2009, GENE DEV, V23, P1327, DOI 10.1101/gad.1777409
   Ichigotani Y, 2002, CANCER RES, V62, P2215
   Iorio MV, 2005, CANCER RES, V65, P7065, DOI 10.1158/0008-5472.CAN-05-1783
   Jiang GB, 2018, MOL MED REP, V18, P5417, DOI 10.3892/mmr.2018.9587
   Jiang PH, 2006, WORLD J GASTROENTERO, V12, P691, DOI 10.3748/wjg.v12.i5.691
   Jiang YZ, 2015, ONCOL LETT, V9, P471, DOI 10.3892/ol.2014.2701
   Jin FF, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2016.461
   Kang W, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0323-3
   Khan AQ., 2019, CELLS-BASEL, V8, P840, DOI [DOI 10.3390/cells8080840, 10.3390/cells8080840]
   Kong RR, 2016, CELL MOL BIOL LETT, V21, DOI 10.1186/s11658-016-0004-2
   Larki Pegah, 2018, Iranian Biomedical Journal, V22, P367, DOI 10.29252/.22.6.367
   Ledford H, 2010, NATURE, V468, P487, DOI 10.1038/468487a
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee YS, 2009, ANNU REV PATHOL-MECH, V4, P199, DOI 10.1146/annurev.pathol.4.110807.092222
   Lei W, 2018, BMC CANCER, V18, DOI [10.1186/s12885-018-4460-0, 10.1186/S12885-018-4460-0]
   Li B, 2019, THERANOSTICS, V9, P1599, DOI 10.7150/thno.30372
   Li CL, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12632
   Li DJ, 2017, ONCOTARGET, V8, P50193, DOI 10.18632/oncotarget.16745
   Li JH, 2012, J CANCER RES CLIN, V138, P763, DOI 10.1007/s00432-012-1154-x
   Li J, 2017, GENE, V625, P1, DOI [10.1016/j.gene.2017.0.001, 10.1016/j.gene.2017.05.001]
   Li XL, 2015, MOL MED REP, V12, P4071, DOI 10.3892/mmr.2015.3905
   Li X, 2019, INT J MOL MED, V44, P973, DOI 10.3892/ijmm.2019.4258
   Li Y, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/8317913
   Liang JT, 2017, ONCOTARGET, V8, P82991, DOI 10.18632/oncotarget.19635
   Lin CY, 2018, CLIN CANCER RES, V24, P486, DOI 10.1158/1078-0432.CCR-17-1851
   Lin JJ, 2016, OPEN MED-WARSAW, V11, P31, DOI 10.1515/med-2016-0007
   Lin ZY, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-77119-6
   Liu AB, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0669-9
   Liu HF, 2019, INT J CLIN EXP PATHO, V12, P466
   Liu J, 2019, ONCOL LETT, V17, P1453, DOI 10.3892/ol.2018.9745
   Liu RH, 2015, CLIN CANCER RES, V21, P854, DOI 10.1158/1078-0432.CCR-14-1740
   Liu RJ, 2009, INT J BIOCHEM CELL B, V41, P1371, DOI 10.1016/j.biocel.2008.12.002
   Liu XD, 2016, ONCOTARGETS THER, V9, P3039, DOI 10.2147/OTT.S98923
   Lu TX, 2018, J ALLERGY CLIN IMMUN, V141, P1202, DOI 10.1016/j.jaci.2017.08.034
   Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888
   Luo WG, 2020, ONCOL REP, V43, P1692, DOI 10.3892/or.2020.7535
   Luo WY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01421
   Lv HB, 2016, AM J TRANSL RES, V8, P3288
   Lynam-Lennon N, 2016, MOL MED, V22, P388, DOI 10.2119/molmed.2016.00020
   Ma J, 2017, ONCOTARGET, V8, P86410, DOI 10.18632/oncotarget.21195
   Ma Y, 2016, ONCOTARGET, V7, P42805, DOI 10.18632/oncotarget.8715
   Mei LL, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185636
   Mullokandov G, 2012, NAT METHODS, V9, P840, DOI [10.1038/nmeth.2078, 10.1038/NMETH.2078]
   Nagata K, 1998, EMBO J, V17, P149, DOI 10.1093/emboj/17.1.149
   Naini BV, 2016, AM J SURG PATHOL, V40, pE45, DOI 10.1097/PAS.0000000000000598
   Nie ZC, 2015, INT J CLIN EXP PATHO, V8, P4745
   Ohtsuka M, 2015, J CLIN MED, V4, P1651, DOI 10.3390/jcm4081651
   Osako Y, 2016, INT J ONCOL, V49, P2255, DOI 10.3892/ijo.2016.3745
   Phatak Pornima, 2018, Oncotarget, V9, P28391, DOI 10.18632/oncotarget.25375
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Prevo LJ, 1999, CANCER RES, V59, P4784
   Qin J, 2017, ONCOTARGET, V8, P2745, DOI 10.18632/oncotarget.13740
   Ramírez-Moya J, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00430
   Ruggieri V, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317705757
   Russo D, 2018, BIOMED REP, V9, P275, DOI 10.3892/br.2018.1136
   Rzepakowska A, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0239550
   Sailo BL, 2019, CANCERS, V11, DOI 10.3390/cancers11020246
   Shao Y, 2016, ONCOTARGET, V7, P15173, DOI 10.18632/oncotarget.7908
   Shen Y, 2019, CANCER EPIDEM BIOMAR, V28, P1212, DOI 10.1158/1055-9965.EPI-18-1199
   Shi L, 2019, BIOMED PHARMACOTHER, V109, P902, DOI 10.1016/j.biopha.2018.10.080
   Shi X, 2015, INT J CLIN EXP MED, V8, P4795
   Shindo Tetsuya, 2018, Oncotarget, V9, P24457, DOI 10.18632/oncotarget.25326
   SLAUGHTER DP, 1953, CANCER, V6, P963, DOI 10.1002/1097-0142(195309)6:5<963::AID-CNCR2820060515>3.0.CO;2-Q
   Smith CM, 2011, WORLD J GASTROENTERO, V17, P1036, DOI 10.3748/wjg.v17.i8.1036
   Song Y, 2014, ONCOTARGET, V5, P11669, DOI 10.18632/oncotarget.2581
   Su C, 2019, ONCOL LETT, V18, P2825, DOI 10.3892/ol.2019.10629
   Sun NN, 2014, INT J CLIN EXP PATHO, V7, P6871
   Svoronos AA, 2016, CANCER RES, V76, P3666, DOI 10.1158/0008-5472.CAN-16-0359
   Takahashi R, 2019, CANCER SCI, V110, P1140, DOI 10.1111/cas.13965
   Tan Y, 2020, ONCOTARGETS THER, V13, P8079, DOI 10.2147/OTT.S248925
   Tian WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029551
   Tian XF, 2016, ONCOL LETT, V11, P1645, DOI 10.3892/ol.2016.4101
   Ueda T, 2010, LANCET ONCOL, V11, P136, DOI 10.1016/S1470-2045(09)70343-2
   Vallone C, 2018, GENES-BASEL, V9, DOI 10.3390/genes9040187
   van Soest EM, 2005, GUT, V54, P1062, DOI 10.1136/gut.2004.063685
   Vuruskan BA, 2018, J BUON, V23, P1125
   Wang B, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0164105
   Wang F, 2020, J CANCER, V11, P4771, DOI 10.7150/jca.44833
   Wang L, 2019, INT J BIOL MARKER, V34, P148, DOI 10.1177/1724600819827964
   Wang LQ, 2015, ONCOTARGET, V6, P44422, DOI 10.18632/oncotarget.6251
   Wang Q, 2018, BIOL CELL, V110, P169, DOI 10.1111/boc.201800014
   Wang WT, 2019, WORLD J GASTROENTERO, V25, P5604, DOI 10.3748/wjg.v25.i37.5604
   Wang X, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2020.100894
   Wang YY, 2018, J CELL MOL MED, V22, P3857, DOI 10.1111/jcmm.13659
   Wang ZP, 2013, CARCINOGENESIS, V34, P678, DOI 10.1093/carcin/bgs361
   Weber JA, 2010, CLIN CHEM, V56, P1733, DOI 10.1373/clinchem.2010.147405
   Wei QD, 2019, INT J CLIN EXP PATHO, V12, P1565
   Wen SW, 2015, GENET MOL RES, V14, P8810, DOI 10.4238/2015.August.3.4
   Wen SW, 2015, GENET MOL RES, V14, P6578, DOI 10.4238/2015.June.12.12
   Won SY, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-018-0204-0
   World Health Organization, 2019, DIG SYST TUM WHO CLA, V5th
   Wu M, 2020, BIOMED PHARMACOTHER, V122, DOI 10.1016/j.biopha.2019.109696
   Wu Q, 2017, ASIAN PAC J TROP MED, V10, P474, DOI 10.1016/j.apjtm.2017.05.007
   Wu XF, 2013, CANCER PREV RES, V6, P196, DOI 10.1158/1940-6207.CAPR-12-0276
   Wu XZ, 2015, INT J CLIN EXP MED, V8, P15556
   Xiao Q, 2018, MOL MED REP, V18, P3631, DOI 10.3892/mmr.2018.9372
   Xiao XH, 2018, MOLECULES, V23, DOI 10.3390/molecules23040787
   Xin CX, 2019, MED SCI MONITOR, V25, P5543, DOI 10.12659/MSM.915314
   Xu H, 2019, EXP THER MED, V17, P1509, DOI 10.3892/etm.2018.7106
   Xu L, 2017, ONCOL REP, V38, P725, DOI 10.3892/or.2017.5712
   Xue XY, 2016, ONCOTARGET, V7, P84508, DOI 10.18632/oncotarget.13022
   Yan JW, 2014, INT J CANCER, V135, P1011, DOI 10.1002/ijc.28563
   Yanaihara N, 2006, CANCER CELL, V9, P189, DOI 10.1016/j.ccr.2006.01.025
   Yang B, 2020, MOL MED REP, V21, P2073, DOI 10.3892/mmr.2020.11002
   Yang D, 2017, SCI REP-UK, V7, DOI 10.1038/srep43109
   Yang M, 2014, MOL CELLS, V37, P873, DOI 10.14348/molcells.2014.0147
   Yang R, 2020, ONCOGENE, V39, P1983, DOI 10.1038/s41388-019-1120-z
   Yang XL, 2019, MOL MED REP, V19, P1481, DOI 10.3892/mmr.2018.9780
   Yu QY, 2017, INT J CLIN EXP PATHO, V10, P8452
   Yu ZJ, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2019.152792
   Zang CB, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0689-6
   Zang RK, 2018, EUR REV MED PHARMACO, V22, P4532, DOI 10.26355/eurrev_201807_15508
   Zarrilli G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218102
   Zeki SS, 2011, DISCOV MED, V12, P371
   Zeng W, 2019, BIOMED PHARMACOTHER, V111, P476, DOI 10.1016/j.biopha.2018.12.057
   Zhang BX, 2019, EUR REV MED PHARMACO, V23, P6497, DOI 10.26355/eurrev_201908_18533
   Zhang DK, 2017, BIOCHEM BIOPH RES CO, V486, P300, DOI 10.1016/j.bbrc.2017.03.032
   Zhang HF, 2016, CARCINOGENESIS, V37, P858, DOI 10.1093/carcin/bgw079
   Zhang HF, 2015, ONCOTARGET, V6, P28949, DOI 10.18632/oncotarget.5027
   Zhang J, 2014, INT J CLIN EXP PATHO, V7, P602
   Zhang KQ, 2016, AM J CANCER RES, V6, P2713
   Zhang LJ, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108825
   Zhang LM, 2019, J CELL BIOCHEM, V120, P19345, DOI 10.1002/jcb.28699
   Zhang L, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw332
   Zhang W, 2018, EUR REV MED PHARMACO, V22, P7323, DOI 10.26355/eurrev_201811_16269
   Zhang W, 2016, INT J ONCOL, V48, P1877, DOI 10.3892/ijo.2016.3437
   Zhang XJ, 2013, MOL CELL, V52, P157, DOI 10.1016/j.molcel.2013.10.008
   Zhang XY, 2018, ONCOTARGET, V9, P2105, DOI 10.18632/oncotarget.23249
   Zhang YH, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027893
   Zhao FY, 2015, INT J CLIN EXP PATHO, V8, P1451
   Zhao HY, 2018, CELL PHYSIOL BIOCHEM, V48, P1595, DOI 10.1159/000492281
   Zhou L, 2016, ONCOTARGET, V7, P51943, DOI 10.18632/oncotarget.10460
   Zhou X, 2017, ONCOTARGET, V8, P82174, DOI 10.18632/oncotarget.19066
   Zhou ZJ, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/1654780
   Zhu YH, 2020, MOL CARCINOGEN, V59, P265, DOI 10.1002/mc.23150
   Zong FY, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004289
NR 185
TC 14
Z9 15
U1 1
U2 23
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD APR
PY 2021
VL 22
IS 7
AR 3640
DI 10.3390/ijms22073640
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA RK9ZB
UT WOS:000638643600001
PM 33807389
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Khessairi, N
   Mallek, I
   Mbarek, M
   Zaafouri, EB
   Gharbi, L
   Boufaroua, AL
   Bacha, D
   Ben-Slama, S
AF Khessairi, Nayssem
   Mallek, Ines
   Mbarek, Mehdi
   Zaafouri, Elmontassar Belleh
   Gharbi, Lassaad
   Boufaroua, Ahlem Lahmar
   Bacha, Dhouha
   Ben-Slama, Sana
TI NEOADJUVANT TREATMENT OF LIVER METASTASES OF COLORECTAL CANCER:
   PREDICTIVE FACTORS OF PATHOLOGICAL RESPONSE
SO ABCD-ARQUIVOS BRASILEIROS DE CIRURGIA DIGESTIVA-BRAZILIAN ARCHIVES OF
   DIGESTIVE SURGERY
LA English
DT Article
DE Colorectal Neoplasms; Neoplasm Metastasis; Liver; Prognosis; Neoadjuvant
   Therapy
ID 1ST-LINE TREATMENT; TUMOR-RESPONSE; CHEMOTHERAPY; BEVACIZUMAB;
   CETUXIMAB; RESECTION; SURGERY; FOLFIRI; GRADE
AB - BACKGROUND: Surgery after neoadjuvant chemotherapy (CT) improves the prognosis of colorectal liver metastases (CRLM). AIMS: The aim of this study was to evaluate the predictive factors- : O tratamento de escolha para pacientes com hipertens & atilde;o portal of the histological response of CRLM after neoadjuvant treatment. METHODS: A retrospective monocentric study including patients with CRLM operated after neoadjuvant treatment. Assessment esquistossom & oacute;tica com sangramento de varizes & eacute; a desconex & atilde;o & aacute;zigo-portal mais of histological response was based on the Rubbia-Brandt tumor regression grading score. The scores esplenectomia (DAPE) associada & agrave; terapia endosc & oacute;pica. Por & eacute;mo estudos mostram aumento were grouped into two types of response: Response Group (R) and No Response Group (NR). doRESULTS:calibre dasThe study varizes em included alguns 77 patients pacientes (mean durante age=56 o years, seguimento sex emratio=1.57).longo prazo.Node : metastases Avaliar o impacto da DAPE e tratamento endosc & oacute;pico p & oacute;s-operat & oacute;rio no comportamento were noticed in 62% of cases. Synchronous liver metastasis was present in 42 cases (55%) and das varizes esof & aacute;gicas e recidiva hemorr & aacute;gicao de pacientes esquistossom & oacute;ticos. M & eacute;todos: metachronous liver metastasis in 45%. Neoadjuvant treatment consisted of CT only in 52 patients (68%) and CT with targeted therapy in 25 patients (32%). Chemo-induced lesions were present in Foram estudados 36 pacientes com seguimento superior a cinco anoso distribu & iacute;dos em 44 patients (57%). Histological response was presented (Group R) in 36 cases (47%) and absent dois grupos: queda da press & atilde;o portal abaixo de 30% e acima de 30% comparados com o (Group NR) in 41 cases (53%). The overall survival of our patients was 32 months. For Group R, calibre survival das was varizes significantly esof & aacute;gicas greater no (p=0.001). p & oacute;s-operat & oacute;rio The predictive precoce factors e tardio of al & eacute;m histological do & iacute;ndiceresponsede identifrecidivaied hemorr & aacute;gica.were delay in the onset of liver metastasis greater than 14 months (p=0.027) and neoadjuvant esof & aacute;gicas queo durante o seguimento aumentaram de calibre e foram controladas com treatment combining CT and targeted therapy (p=0.031). In multivariate analysis, the type of neoadjuvant treatment (p=0.035) was an independent predictive factor of histological response. CONCLUSIONS: Predictive factors of histological response would allow us to identify patients who o comportamento do calibre das varizes no p & oacute;s-operat & oacute;rio precoce nem tardio nem os would benefit most from neoadjuvant treatment. These patients with CRLM onset of more than 14 & iacute;ndicesmonthsde and recidiva treated with hemorr & aacute;gica. CT combined with targeted therapy would be the best candidates for a neoadjuvant CT strategy followed by surgical resection.
C1 [Khessairi, Nayssem; Mbarek, Mehdi] Salah Azaiz Inst, Surg Oncol Dept, Tunis, Tunisia.
   [Khessairi, Nayssem; Mallek, Ines; Mbarek, Mehdi; Zaafouri, Elmontassar Belleh; Gharbi, Lassaad; Boufaroua, Ahlem Lahmar; Bacha, Dhouha; Ben-Slama, Sana] Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia.
   [Mallek, Ines; Boufaroua, Ahlem Lahmar; Bacha, Dhouha; Ben-Slama, Sana] Mongi Slim Univ Hosp, Pathol Dept La Marsa, Tunis, Tunisia.
   [Zaafouri, Elmontassar Belleh; Gharbi, Lassaad] Mongi Slim Univ Hosp, Digest Surg Dept La Marsa, Tunis, Tunisia.
C3 Universite de Tunis-El-Manar; Institut Salah Azaiez; Universite de
   Tunis-El-Manar; Faculte de Medecine de Tunis (FMT)
RP Khessairi, N (corresponding author), Salah Azaiz Inst, Surg Oncol Dept, Tunis, Tunisia.; Khessairi, N (corresponding author), Univ Tunis El Manar, Fac Med Tunis, Tunis, Tunisia.
EM nayssemkhessairi@gmail.com
RI Bacha, D/AAW-4810-2020
OI Bacha, Dhouha/0000-0002-8430-0072; MALLEK, Ines/0009-0009-9269-8365
CR Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
   Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388
   Arru M, 2008, WORLD J SURG, V32, P93, DOI 10.1007/s00268-007-9285-y
   Basilio L, 2022, ABCD-ARQ BRAS CIR DI, V35, DOI 10.1590/0102-672020210002e1647
   Blazer DG, 2008, J CLIN ONCOL, V26, P5344, DOI 10.1200/JCO.2008.17.5299
   Brouquet A, 2009, SURGERY, V145, P362, DOI 10.1016/j.surg.2008.12.002
   Cai YB, 2019, J CANCER, V10, P5852, DOI 10.7150/jca.31493
   Chan G, 2010, HPB, V12, P277, DOI 10.1111/j.1477-2574.2010.00170.x
   Chun YS, 2009, LANCET ONCOL, V10, P278, DOI 10.1016/S1470-2045(09)70064-6
   Dagenborg VJ, 2020, CANCER BIOL THER, V21, P432, DOI 10.1080/15384047.2020.1721252
   de Jong MC, 2009, J GASTROINTEST SURG, V13, P2141, DOI 10.1007/s11605-009-1050-0
   de Oliveira JW, 2023, ABCD-ARQ BRAS CIR DI, V36, DOI 10.1590/0102-672020230053e1771
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Klinger M, 2010, ANN SURG ONCOL, V17, P2059, DOI 10.1245/s10434-010-0972-9
   Knijn N, 2013, HISTOPATHOLOGY, V63, P149, DOI 10.1111/his.12124
   Masson E., 2012, EM-Consulte, V149, pS6, DOI [10.1016/S1878-786X(12)70095-5, DOI 10.1016/S1878-786X(12)70095-5]
   Nagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975
   Rubbia-Brandt L, 2007, ANN ONCOL, V18, P299, DOI 10.1093/annonc/mdl386
   Serrablo A, 2020, DIGEST SURG, V37, P383, DOI 10.1159/000506105
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Vecchio FM, 2005, INT J RADIAT ONCOL, V62, P752, DOI 10.1016/j.ijrobp.2004.11.017
   Venook AP., 2014, J Clin Oncol., V32, pLBA3, DOI [10.1200/jco.2014.32.18_suppl.lba3, DOI 10.1200/JCO.2014.32.15_SUPPL.LBA3]
   Vera R, 2014, CLIN TRANSL ONCOL, V16, P739, DOI 10.1007/s12094-013-1142-x
   Vera R, 2020, CANCERS, V12, DOI 10.3390/cancers12082259
   Viganò L, 2013, ANN SURG, V258, P731, DOI 10.1097/SLA.0b013e3182a6183e
   Wang Y, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0244-1
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Zhang C, 2021, J SURG ONCOL, V124, P1431, DOI 10.1002/jso.26651
NR 31
TC 0
Z9 0
U1 0
U2 0
PU COLEGIO BRASILEIRO CIRURGIA DIGESTIVA-CBCD
PI SAO PAULO SP
PA AV BRIGADEIRO LUIZ ANTONIO, 278-6-SALAS 10 E 11, SAO PAULO SP,
   01318-901, BRAZIL
SN 0102-6720
EI 2317-6326
J9 ABCD-ARQ BRAS CIR DI
JI ABCD-Arq. Bras. Cir. Dig.-Braz. Arch. Dig. Surg.
PY 2024
VL 37
AR e1829
DI 10.1590/0102-6720202400036e1829
PG 5
WC Gastroenterology & Hepatology
WE Emerging Sources Citation Index (ESCI)
SC Gastroenterology & Hepatology
GA K6Z3W
UT WOS:001345336500005
PM 39475884
OA gold, Green Accepted
DA 2025-01-04
ER

PT J
AU Lin, MT
   Zheng, G
   Rodriguez, E
   Tseng, LH
   Parini, V
   Xian, RN
   Zou, Y
   Gocke, CD
   Eshleman, JR
AF Lin, Ming-Tseh
   Zheng, Gang
   Rodriguez, Erika
   Tseng, Li-Hui
   Parini, Vamsi
   Xian, Rena
   Zou, Ying
   Gocke, Christopher D.
   Eshleman, James R.
TI Double <i>PIK3CA</i> Alterations and Parallel Evolution in Colorectal
   Cancers
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE Colorectal cancer; Double PIK3CA; Multiclonal CRC; Parallel evolution;
   mTOR pathway
ID CLINICAL MUTATION DETECTION; RAS MUTATIONS; LUNG CANCERS; SENSITIVITY;
   ACTIVATION; INHIBITOR; ALPELISIB; INSIGHTS; MUTANTS
AB Objectives To demonstrate clinicopathologic features and evaluate the clonality of double PIK3CA alterations in colorectal cancers (CRCs). Methods Clonality was examined in 13 CRCs with double PIK3CA alterations (1.7% of CRCs or 9.6% of PIK3CA-mutated CRCs). Multiregional analyses were performed to confirm subclonal PIK3CA alterations. Results PIK3CA alterations were detected within exon 9 (51%), exon 20 (23%), exon 1 (15%), and exon 7 (6.0%). CRCs with exon 7 alterations showed a significantly higher incidence of double PIK3CA alterations. Most double PIK3CA alterations consisted of a hotpsot alteration and an uncommon alteration; they were often clonal and present within a single tumor population. Multiregional analyses of CRCs with predicted subclonal double-alterations revealed multiclonal CRCs with divergent PIK3CA variant status originating from a common APC- and KRAS-mutated founder lineage of adenoma. Conclusions The findings supported multiclonal CRCs resulting from parallel evolution during the progression from adenoma to adenocarcinoma within the mitogen-activated protein kinase pathway, as previously demonstrated, or the mammalian target of rapamycin pathway. Further studies are warranted to elucidate clinical significance and potential targeted therapy for CRC patients with double PIK3CA alterations and impacts on clinical decision-making in patients with multiclonal CRCs harboring divergent PIK3CA mutational status.
C1 [Lin, Ming-Tseh; Zheng, Gang; Rodriguez, Erika; Tseng, Li-Hui; Parini, Vamsi; Xian, Rena; Zou, Ying; Gocke, Christopher D.; Eshleman, James R.] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
   [Zheng, Gang] Mayo Clin, Dept Pathol & Lab Med, Rochester, MN USA.
   [Tseng, Li-Hui] Natl Taiwan Univ, Grad Inst Med Genom & Prote, Taipei, Taiwan.
   [Xian, Rena; Gocke, Christopher D.; Eshleman, James R.] Johns Hopkins Univ, Sch Med, Dept Oncol, Baltimore, MD 21205 USA.
C3 Johns Hopkins University; Mayo Clinic; National Taiwan University; Johns
   Hopkins University
RP Lin, MT (corresponding author), Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA.
EM mlin36@jhmi.edu
RI parini, vamsi/HZK-9008-2023; zheng, gang/KMX-5568-2024
OI Zou, Ying S./0000-0003-2787-1917
CR André F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904
   Chen GL, 2016, BIOMED RES INT-UK, V2016, DOI 10.1155/2016/9850690
   Chen YR, 2006, ONCOGENE, V25, P1205, DOI 10.1038/sj.onc.1209159
   Chen Z, 2008, ONCOGENE, V27, P4336, DOI 10.1038/onc.2008.71
   De Marchi F, 2019, ARCH PATHOL LAB MED, V143, P174, DOI 10.5858/arpa.2017-0495-OA
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678
   Felsenstein M, 2018, GUT, V67, P1652, DOI 10.1136/gutjnl-2017-315062
   Godin-Heymann N, 2007, CANCER RES, V67, P7319, DOI 10.1158/0008-5472.CAN-06-4625
   Haley L, 2015, MODERN PATHOL, V28, P1390, DOI 10.1038/modpathol.2015.86
   Hanker AB, 2019, CANCER DISCOV, V9, P482, DOI 10.1158/2159-8290.CD-18-1175
   Illei PB, 2017, ONCOTARGET, V8, P96684, DOI 10.18632/oncotarget.18042
   Janku F, 2018, NAT REV CLIN ONCOL, V15, P273, DOI 10.1038/nrclinonc.2018.28
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Juric D, 2019, JAMA ONCOL, V5, DOI 10.1001/jamaoncol.2018.4475
   Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107
   Kinross KM, 2012, J CLIN INVEST, V122, P553, DOI 10.1172/JCI59309
   Lin MT, 2020, HUM PATHOL, V98, P120, DOI 10.1016/j.humpath.2020.03.002
   Mayer IA, 2017, CLIN CANCER RES, V23, P26, DOI 10.1158/1078-0432.CCR-16-0134
   McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018
   McGranahan N, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa1408
   Messersmith WA, 2019, J NATL COMPR CANC NE, V17, P599, DOI 10.6004/jnccn.2019.5014
   Mulloy R, 2007, CANCER RES, V67, P2325, DOI 10.1158/0008-5472.CAN-06-4293
   Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807
   Shen RL, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw520
   Szpiech ZA, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183273
   Thorvaldsdóttir H, 2013, BRIEF BIOINFORM, V14, P178, DOI 10.1093/bib/bbs017
   Tseng LH, 2019, AM J CLIN PATHOL, V152, P570, DOI 10.1093/ajcp/aqz077
   Vasan N, 2019, SCIENCE, V366, P714, DOI 10.1126/science.aaw9032
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   von Loga K, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14602-8
   Yun CH, 2007, CANCER CELL, V11, P217, DOI 10.1016/j.ccr.2006.12.017
   Zhang J, 2015, SCI REP-UK, V5, DOI 10.1038/srep18678
   Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105
   Zheng G, 2019, HUM PATHOL, V86, P12, DOI 10.1016/j.humpath.2018.11.014
   Zheng G, 2016, AM J CLIN PATHOL, V145, P696, DOI [10.1093/AJCP/AQW043, 10.1093/ajcp/aqw043]
   Zheng G, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1811-y
NR 38
TC 1
Z9 1
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD FEB 3
PY 2022
VL 157
IS 2
BP 244
EP 251
DI 10.1093/ajcp/aqab119
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA YZ0ZT
UT WOS:000755212500010
PM 34519764
DA 2025-01-04
ER

PT J
AU Saúde-Conde, R
   Rasschaert, G
   Bregni, G
   Hendlisz, A
   Sclafani, F
AF Saude-Conde, Rita
   Rasschaert, Gertjan
   Bregni, Giacomo
   Hendlisz, Alain
   Sclafani, Francesco
TI Mind the target: human epidermal growth factor receptor 2 in colorectal
   cancer
SO CURRENT OPINION IN ONCOLOGY
LA English
DT Review
DE colorectal cancer; epidermal growth factor receptor; human epidermal
   growth factor receptor 2; targeted therapy
ID OPEN-LABEL; HER2; TRASTUZUMAB; EXPRESSION; THERAPY; OVEREXPRESSION;
   LAPATINIB; SYSTEM; TUMORS
AB Purpose of review In this article, we briefly summarise the current knowledge about human epidermal growth factor receptor 2 (HER2) alterations in colorectal cancer (CRC) and provide an overview of the latest published evidence especially regarding standardisation of detection methods/diagnostic criteria, prognostication, prediction and targeted treatments. Recent findings Over the last 18 months, the results of many studies have been presented confirming the therapeutic potential of established anti-HER2 agents either as a monotherapy or in combination, as well as new anti-HER2 agents like antibody-drug-conjugates and tyrosine kinase inhibitors. Also, we have seen confirmation of the utility of liquid biopsy and ctDNA analyses as tool for HER2 detection and patient selection. Despite concerning only 5% of metastatic CRC, HER2 represents a valuable target for emerging anti-HER2 therapies that might significantly improve the outcome of these patients. Standardising HER2 detection methods/diagnostic criteria, and producing high-quality, randomised evidence are the next challenges to meet the standards of regulatory authorities and ultimately have anti-HER2 agents available for use in routine practice.
C1 [Saude-Conde, Rita; Rasschaert, Gertjan; Bregni, Giacomo; Hendlisz, Alain; Sclafani, Francesco] Inst Jules Bordet, Gastrointestinal Unit, Dept Med Oncol, Brussels, Belgium.
   [Rasschaert, Gertjan] Vrije Univ Brussel, Univ Ziekenhuis Brussel, Dept Gastroenterol & Hepatol, Brussels, Belgium.
   [Bregni, Giacomo; Hendlisz, Alain; Sclafani, Francesco] Univ Libre Bruxelles, Brussels, Belgium.
C3 Institut Jules Bordet; Vrije Universiteit Brussel; University Hospital
   Brussels; Universite Libre de Bruxelles
RP Sclafani, F (corresponding author), Inst Jules Bordet, Rue Meylemeersch 90, B-1070 Anderlecht, Belgium.
EM francesco.sclafani@bordet.be
OI Saude Conde, Rita/0000-0002-4376-6896
CR Amatu A, 2021, ANN ONCOL, V32, pS557, DOI 10.1016/j.annonc.2021.08.967
   Aprile G, 2013, INT J MOL SCI, V14, P2370, DOI 10.3390/ijms14022370
   Bang YJ, 2010, LANCET, V376, P1302
   Bekaii-Saab TS, 2009, MOL CANCER THER, V8, P2983, DOI 10.1158/1535-7163.MCT-09-0820
   Cen SY, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188605
   Clark J.W., 2003, Onkologie, V26, P13
   Conradi LC, 2013, AM J SURG PATHOL, V37, P522, DOI 10.1097/PAS.0b013e318272ff4d
   De Cuyper A, 2020, CLIN COLORECTAL CANC, V19, P65, DOI 10.1016/j.clcc.2020.02.007
   Edenfield WJ., 2014, MOL PROFILING HER2 P, V32, pe14508
   Fujii S, 2020, JCO PRECIS ONCOL, V4, P6, DOI 10.1200/PO.19.00154
   Gupta R, 2020, J CLIN ONCOL, V38
   Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Jacobs SA, 2021, CLIN CANCER RES, V27, P1612, DOI 10.1158/1078-0432.CCR-20-1831
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Kruszewski WJ, 2010, DIS MARKERS, V29, P207, DOI [10.1155/2010/109063, 10.3233/DMA-2010-0742]
   Laurent-Puig P, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw370.8
   Li Q, 2021, ANN ONCOL, V32, pS558, DOI 10.1016/j.annonc.2021.08.971
   Li WH, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.097
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275
   Nakada T, 2016, BIOORG MED CHEM LETT, V26, P1542, DOI 10.1016/j.bmcl.2016.02.020
   Nakamura Y, 2021, NAT MED, V27, P1899, DOI 10.1038/s41591-021-01553-w
   Nam SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151865
   Okamoto W, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3555
   Osako T, 1998, ONCOLOGY-BASEL, V55, P548, DOI 10.1159/000011911
   Raghav KPS, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3589
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Ross JS, 2018, CANCER-AM CANCER SOC, V124, P1358, DOI 10.1002/cncr.31125
   Sartore-Bianchi A, 2020, ANN ONCOL, V31, pS455, DOI 10.1016/j.annonc.2020.08.617
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2019, ONCOLOGIST, V24, P1395, DOI 10.1634/theoncologist.2018-0785
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sawada K, 2018, CLIN COLORECTAL CANC, V17, P198, DOI 10.1016/j.clcc.2018.05.006
   Sharma M, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2549
   Shimada Y, 2017, HUM PATHOL, V66, P1, DOI 10.1016/j.humpath.2017.02.004
   Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100
   Siena S., 2021, 386O EXPLORATORY BIO
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Siravegna G, 2019, CLIN CANCER RES, V25, P3046, DOI 10.1158/1078-0432.CCR-18-3389
   Strickler JH, 2019, ANN ONCOL, V30
   Tosi F, 2020, CLIN COLORECTAL CANC, V19, P256, DOI 10.1016/j.clcc.2020.06.009
   Tsurutani J, 2020, CANCER DISCOV, V10, P688, DOI 10.1158/2159-8290.CD-19-1014
   Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98
   Wolff AC, 2018, J CLIN ONCOL, V36, P2105, DOI [10.1200/JCO.2018.77.8738, 10.5858/arpa.2018-0902-SA]
   Wu ZH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3524
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yoshino T, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.119
   Yuan Y, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.e15554
NR 51
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-8746
EI 1531-703X
J9 CURR OPIN ONCOL
JI Curr. Opin. Oncol.
PD JUL
PY 2022
VL 34
IS 4
BP 382
EP 388
DI 10.1097/CCO.0000000000000842
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 2X7DF
UT WOS:000825359500021
PM 35730499
DA 2025-01-04
ER

PT J
AU Ju, F
   Li, N
   Wang, WM
   Yuan, HC
AF Ju, Fang
   Li, Na
   Wang, Wenming
   Yuan, Haicheng
TI Effects of varying radiation dosages on MMP1 expression, and MMP1
   knockdown on the viability and migration of SW620 cells
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE colorectal cancer; invasion; matrix metalloproteinase 1; radiation
   dosages; viability
ID MATRIX METALLOPROTEINASES; PREOPERATIVE RADIOTHERAPY; COLORECTAL-CANCER;
   RECTAL-CANCER; CHEMORADIOTHERAPY; POLYMORPHISM
AB Colorectal cancer (CRC), also known as bowel cancer, is one of the leading causes of cancer-associated mortality worldwide at present. The aim of the present study was to detect the effects of matrix metalloproteinase 1 (MMP1) on the viability and migration of a CRC cell line in the presence or absence of variation X-ray radiation doses. The CRC cell line, SW620, was cultured and treated with different X-ray doses (0, 0.1, 0.5, 1, 3 and 6 Gy). MMP1 expression was downregulated via the application of a specific small interfering (si)-RNA. The viability and migration of SW620 cells prior to and following transfection were detected with MTT and Transwell chamber assays, respectively. The application of siRNA transfection to silence MMP1 in SW620 cells resulted in reduced cell viability and migration (P<0.05). Compared with the control, the cell viability and migration of cells were significantly reduced when exposed to 0.5, 1, 3, and 6 Gy X-ray radiation (P<0.05). In SW620 cells treated with different X-ray doses, the mRNA expression levels of MMP1 were significantly reduced (P<0.05). Cells treated with 0.5 Gy X-ray exposure exhibited the lowest mRNA expression levels of MMP1 when compared with other doses of X-ray radiation. The expression of MMP1 was associated with the promotion of the viability and migration of SW620 cells. X-ray radiation with 6 Gy dosages significantly reduced cell viability when compared with the control. Thus, MMP1-targeted therapy combined with radiotherapy could be used for treating CRC.
C1 [Ju, Fang; Wang, Wenming] Qingdao Cent Hosp, Dept Oncol, Qingdao 266042, Shandong, Peoples R China.
   [Li, Na] Linyi Peoples Hosp, Dept Resp Med, Linyi 276003, Shandong, Peoples R China.
   [Yuan, Haicheng] Qingdao Cent Hosp, Dept Neurol, 127 Siliunan Rd, Qingdao 266042, Shandong, Peoples R China.
RP Yuan, HC (corresponding author), Qingdao Cent Hosp, Dept Neurol, 127 Siliunan Rd, Qingdao 266042, Shandong, Peoples R China.
EM haichengyuan2866@163.com
CR Angenete E, 2009, ACTA ONCOL, V48, P1144, DOI 10.3109/02841860903150510
   Arakaki PA, 2009, J BIOSCIENCES, V34, P313, DOI 10.1007/s12038-009-0035-1
   Artacho-Cordón F, 2012, SURG ONCOL, V21, pE143, DOI 10.1016/j.suronc.2012.06.001
   Bendardaf R, 2007, SCAND J GASTROENTERO, V42, P1473, DOI 10.1080/00365520701485449
   Braendengen M, 2008, J CLIN ONCOL, V26, P3687, DOI 10.1200/JCO.2007.15.3858
   Drzymala M, 2009, BRIT J RADIOL, V82, P321, DOI 10.1259/bjr/57848689
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Häfner MF, 2016, VISC MED, V32, P172, DOI 10.1159/000446486
   Han GD, 2014, INT J CLIN EXP MED, V7, P2992
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   HOLM T, 1994, BRIT J SURG, V81, P452, DOI 10.1002/bjs.1800810344
   Jo S, 2016, ANN COLOPROCTOL, V32, P66, DOI 10.3393/ac.2016.32.2.66
   Kao PS, 2010, J SURG ONCOL, V102, P771, DOI 10.1002/jso.21711
   Kim JY, 2007, INT J COLORECTAL DIS, V22, P373, DOI 10.1007/s00384-006-0166-x
   Lange F, 2014, BIOMED RES INT-UK, V2014, DOI 10.1155/2014/568693
   Langenskiöld M, 2013, SCAND J GASTROENTERO, V48, P563, DOI 10.3109/00365521.2012.708939
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   Murray GI, 1996, NAT MED, V2, P461, DOI 10.1038/nm0496461
   Nishioka M, 2011, CANCER GENOM PROTEOM, V8, P87
   Park IJ, 2014, WORLD J GASTROENTERO, V20, P2023, DOI 10.3748/wjg.v20.i8.2023
   Parsons SL, 1997, BRIT J SURG, V84, P160, DOI 10.1002/bjs.1800840206
   Sanghera P, 2008, CLIN ONCOL-UK, V20, P176, DOI 10.1016/j.clon.2007.11.013
   [孙凯 Sun Kai], 2013, [肿瘤防治研究, Cancer Research on Prevention and Treatment], V40, P921
   Supiot S, 2013, WORLD J GASTROENTERO, V19, P3249, DOI 10.3748/wjg.v19.i21.3249
   Tahara K, 2010, ANN SURG ONCOL, V17, P3362, DOI 10.1245/s10434-010-1149-2
   Teran BL, 2013, FASEB J, V27
   Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Westermarck J, 1999, FASEB J, V13, P781, DOI 10.1096/fasebj.13.8.781
   Zinzindohoué F, 2005, CLIN CANCER RES, V11, P594
   Zucker S, 2004, CANCER METAST REV, V23, P101, DOI 10.1023/A:1025867130437
NR 32
TC 5
Z9 5
U1 1
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD APR
PY 2019
VL 19
IS 4
BP 2503
EP 2508
DI 10.3892/mmr.2019.9899
PG 6
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA HQ7YD
UT WOS:000462639100006
PM 30720073
OA Green Submitted, Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Fang, GD
   Xu, DL
   Zhang, T
   Qiu, L
   Gao, XZ
   Wang, G
   Miao, YC
AF Fang, Guida
   Xu, Dalai
   Zhang, Tao
   Qiu, Lei
   Gao, Xuzhu
   Wang, Gang
   Miao, Yongchang
TI Effects of hsa_circ_0074854 on colorectal cancer progression,
   construction of a circRNA-miRNA-mRNA network, and analysis of immune
   infiltration
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Colorectal cancer; CircRNA; CeRNA network; Immunoinfiltration;
   Diagnostic and therapeutic biomarker
ID ANALYSIS REVEALS; HUR
AB PurposeCircular RNAs have been demonstrated to be closely associated with the onset and metastasis of colorectal cancer. However, the roles and clinical diagnostic value of most circRNAs in colorectal cancer remain unclear.MethodsWe detected the differential expression of circRNAs in CRC tissues and cells and investigated their relationship in conjunction with clinical pathological features. Additionally, we performed cellular functional experiments in CRC cell lines to explore the functions of circRNAs. To further validate the potential ceRNA network, qPCR was performed to assess the expression of miRNA and mRNA in CRC cells after differential expression of circRNAs knockdown. Furthermore, database analysis was utilized to explore the relationship between the predicted mRNAs and immune infiltration in CRC.ResultsOur research findings indicate a positive correlation between hsa_circ_0074854 expression and advanced clinical pathological features, as well as an unfavorable prognosis. Knockdown of hsa_circ_0074854 was observed to inhibit proliferation and migration capabilities of colorectal cancer cells, affecting the cell cycle progression, and simultaneously promoting apoptosis. A competing endogenous RNA mechanism may exist among circRNAs, miRNAs, and mRNAs. Furthermore, the expression of target genes displayed correlations with the abundance of certain immune cells.ConclusionWe propose a novel ceRNA network and evaluate the interplay between target genes and immune cells, providing novel insights for the diagnosis and targeted therapy of CRC.
C1 [Fang, Guida; Xu, Dalai; Zhang, Tao; Qiu, Lei; Wang, Gang; Miao, Yongchang] Lianyungang Second Peoples Hosp, Bengbu Med Coll, Dept Gastrointestinal Surg, Clin Coll, Lianyungang 222002, Jiangsu, Peoples R China.
   [Xu, Dalai; Qiu, Lei; Gao, Xuzhu; Wang, Gang; Miao, Yongchang] Nanjing Med Univ, Peoples Hosp Lianyungang City 2, Dept Gastrointestinal Surg, Kangda Coll, Lianyungang 222002, Jiangsu, Peoples R China.
   [Gao, Xuzhu] Canc Hosp Lianyungang, Peoples Hosp Lianyungang City 2, Inst Clin Oncol, Lianyungang 222002, Jiangsu, Peoples R China.
C3 Bengbu Medical University; Nanjing Medical University
RP Wang, G; Miao, YC (corresponding author), Lianyungang Second Peoples Hosp, Bengbu Med Coll, Dept Gastrointestinal Surg, Clin Coll, Lianyungang 222002, Jiangsu, Peoples R China.; Wang, G; Miao, YC (corresponding author), Nanjing Med Univ, Peoples Hosp Lianyungang City 2, Dept Gastrointestinal Surg, Kangda Coll, Lianyungang 222002, Jiangsu, Peoples R China.
EM whiteching@foxmail.com; lygeymyc@163.com
RI Xuzhu, Gao/JPA-0501-2023
FU Jiangsu University clinical medical science and technology development
   fund project [TLY2021085, LYG06521202127]; Lianyungang Health General
   Science [202218]; Graduate Research and Innovation Projects of Bengbu
   Medical College [Byycx22124]
FX This study is supported by Jiangsu University clinical medical science
   and technology development fund project (TLY2021085, The sixth "521
   Project" scientific research project of Lianyungang City
   (LYG06521202127), Lianyungang Health General Science (202218), and the
   Graduate Research and Innovation Projects of Bengbu Medical College
   (Byycx22124)
CR Bazzini AA, 2012, SCIENCE, V336, P233, DOI 10.1126/science.1215704
   Bergsland CH, 2022, MODERN PATHOL, V35, P1236, DOI 10.1038/s41379-022-01086-8
   Béthune J, 2012, EMBO REP, V13, P716, DOI 10.1038/embor.2012.82
   Bian XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0973-7
   Chen DS, 2018, CELL CYCLE, V17, P2080, DOI 10.1080/15384101.2018.1515553
   Chen DL, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01475-8
   Chen JX, 2021, THERANOSTICS, V11, P7507, DOI 10.7150/thno.59546
   Ding BS, 2020, AGING-US, V12, P5259, DOI 10.18632/aging.102945
   Djuranovic S, 2012, SCIENCE, V336, P237, DOI 10.1126/science.1215691
   Dube U, 2019, NAT NEUROSCI, V22, P1903, DOI 10.1038/s41593-019-0501-5
   Fang GD, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1138481
   Fiala O, 2019, ANTICANCER RES, V39, P5645, DOI 10.21873/anticanres.13761
   Geh D, 2022, NAT REV GASTRO HEPAT, V19, P257, DOI 10.1038/s41575-021-00568-5
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Hou JC, 2019, EPIGENOMICS-UK, V11, P199, DOI 10.2217/epi-2017-0167
   Hu CH, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01501-3
   Hu XT, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01783-9
   Hua JH, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01595-9
   Huang XY, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-1529-9
   Huang YX, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00771-y
   Hume DA, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00370
   Ji H, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01667-w
   Jian XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1134-8
   Jiang Y, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02518-8
   Liu JF, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.993727
   Liu ZH, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1287-1
   Lv JC, 2023, J EXP CLIN CANC RES, V42, DOI 10.1186/s13046-023-02614-3
   Mantovani A, 2005, IMMUNITY, V23, P344, DOI 10.1016/j.immuni.2005.10.001
   Memczak S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141214
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl-2022-327736
   Ouakrim DA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4970
   Pamudurti NR, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110740
   Pascut D, 2020, CANCERS, V12, DOI 10.3390/cancers12040823
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Qian L, 2018, BBA-REV CANCER, V1870, P247, DOI 10.1016/j.bbcan.2018.06.002
   Sakshi S, 2021, MOL THER-NUCL ACIDS, V26, P1291, DOI 10.1016/j.omtn.2021.11.007
   Sang YT, 2019, MOL THER, V27, P1638, DOI 10.1016/j.ymthe.2019.05.011
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Wang HH, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.670031
   Wang JQ, 2021, CANCER BIOL MED, V18, P421, DOI 10.20892/j.issn.2095-3941.2020.0312
   Wang Y, 2021, INT J NANOMED, V16, P2803, DOI 10.2147/IJN.S284560
   Wei CY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01191-9
   Xing LL, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01651-8
   Xu HY, 2015, SCI REP-UK, V5, DOI 10.1038/srep12453
   Xue C, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01582-0
   Yang J, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04732-w
   Yu D, 2022, NAT IMMUNOL, V23, P1157, DOI 10.1038/s41590-022-01253-8
   Zang XY, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01606-9
   Zhang Q, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12406
   Zhu Y, 2023, LIFE SCI, V326, DOI 10.1016/j.lfs.2023.121792
NR 50
TC 2
Z9 2
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD NOV
PY 2023
VL 149
IS 17
BP 15439
EP 15456
DI 10.1007/s00432-023-05315-8
EA AUG 2023
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA W2SE4
UT WOS:001063901400001
PM 37644235
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Barranha, R
   Costa, JL
   Carneiro, F
   Machado, JC
AF Barranha, Rui
   Costa, Jose Luis
   Carneiro, Fatima
   Machado, Jose Carlos
TI Genetic Heterogeneity in Colorectal Cancer and its Clinical Implications
SO ACTA MEDICA PORTUGUESA
LA English
DT Article
DE Colorectal Neoplasms/genetics; Genetic Heterogeneity; Molecular Targeted
   Therapy; Translational Medical Research
ID GROWTH-FACTOR RECEPTOR; TUMOR HETEROGENEITY; MUTATION STATUS; KRAS
   MUTATIONS; MOLECULAR EVOLUTION; ACQUIRED-RESISTANCE; CETUXIMAB THERAPY;
   CLONAL EVOLUTION; BREAST-CANCER; EGFR
AB Despite the recent advances in the development of complementary diagnostic exams and modern targeted therapies, colorectal cancer remains a major cause of morbidity and mortality worldwide. In this context, a lot of research has been conducted in the last years to find new markers of poor prognosis. The existence of a complex tumour architecture formed by multiple subclones genetically heterogeneous has been increasingly considered in recent studies as an element of particular importance. This feature seems to influence factors as relevant as the representativeness of tumour biopsies for genetic diagnosis and the efficacy of targeted therapies. There is growing evidence suggesting a relation between genetic heterogeneity and the patients' prognosis. The widespread use of next-generation sequencing techniques will allow a better understanding of the true degree of genetic heterogeneity in colorectal tumours, its causes and impact on the course of the disease. In this review we intend to analyse the recent findings related to the genetic heterogeneity of colorectal cancer, as well as its major clinical implications.
C1 [Barranha, Rui; Carneiro, Fatima; Machado, Jose Carlos] Univ Porto, Fac Med, Dept Pathol & Oncol, P-4100 Oporto, Portugal.
   [Barranha, Rui; Costa, Jose Luis; Carneiro, Fatima; Machado, Jose Carlos] Univ Porto, IPATIMUP, Inst Patol Mol & Imunol, P-4100 Oporto, Portugal.
   [Carneiro, Fatima] Hosp de S Joao, Dept Pathol, Oporto, Portugal.
C3 Universidade do Porto; Universidade do Porto; Sao Joao Hospital
RP Barranha, R (corresponding author), Univ Porto, Fac Med, Dept Pathol & Oncol, Rua Campo Alegre 823, P-4100 Oporto, Portugal.
EM ruibarranha@gmail.com
RI Barranha, Rui/GSN-3848-2022; Costa, Jose Luis/B-7126-2008; Carneiro,
   Fatima/J-6432-2013; Machado, Jose Carlos/C-5907-2009
OI Barranha, Rui/0000-0002-7458-4331; Costa, Jose Luis/0000-0001-7132-4094;
   Carneiro, Fatima/0000-0002-1964-1006; Machado, Jose
   Carlos/0000-0003-4741-8415
CR Almendro V, 2013, ANNU REV PATHOL-MECH, V8, P277, DOI 10.1146/annurev-pathol-020712-163923
   [Anonymous], 2012, Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012
   Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446
   Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496
   Des Guetz G, 2006, BRIT J CANCER, V94, P1823, DOI 10.1038/sj.bjc.6603176
   Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Etienne-Grimaldi MC, 2008, CLIN CANCER RES, V14, P4830, DOI 10.1158/1078-0432.CCR-07-4906
   Fadhil W, 2012, HISTOPATHOLOGY, V61, P1117, DOI 10.1111/j.1365-2559.2012.04321.x
   Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581
   Fridman WH, 2012, NAT REV CANCER, V12, P298, DOI 10.1038/nrc3245
   Gargis AS, 2012, NAT BIOTECHNOL, V30, P1033, DOI 10.1038/nbt.2403
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Hajdu SI, 2012, CANCER-AM CANCER SOC, V118, P1155, DOI 10.1002/cncr.26320
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hecht JR, 2010, CLIN CANCER RES, V16, P2205, DOI 10.1158/1078-0432.CCR-09-2017
   Hurwitz HI, 2005, J CLIN ONCOL, V23, P3502, DOI 10.1200/JCO.2005.10.017
   Inda MD, 2010, GENE DEV, V24, P1731, DOI 10.1101/gad.1890510
   Italiano A, 2010, ANN SURG ONCOL, V17, P1429, DOI 10.1245/s10434-009-0864-z
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Knijn N, 2011, BRIT J CANCER, V104, P1020, DOI 10.1038/bjc.2011.26
   Krol LC, 2012, EUR J CANCER, V48, P1108, DOI 10.1016/j.ejca.2012.02.054
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Loeb LA, 1998, ADV CANCER RES, V72, P25, DOI 10.1016/S0065-230X(08)60699-5
   Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021
   Mao Q, 2013, J CANCER RES CLIN, V139, P211, DOI 10.1007/s00432-012-1310-3
   Martinez P, 2013, J PATHOL, V230, P356, DOI 10.1002/path.4214
   Marusyk A, 2012, NAT REV CANCER, V12, P323, DOI 10.1038/nrc3261
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Messersmith WA, 2008, NEW ENGL J MED, V359, P1834, DOI 10.1056/NEJMe0806778
   Miranda E, 2013, CANCER-AM CANCER SOC, V119, P266, DOI 10.1002/cncr.27722
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137
   Noterdaeme O, 2010, BRIT J RADIOL, V83, P166, DOI 10.1259/bjr/76979647
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Ohuchida K, 2004, CANCER RES, V64, P3215, DOI 10.1158/0008-5472.CAN-03-2464
   Park JH, 2011, CANCER CHEMOTH PHARM, V68, P1045, DOI 10.1007/s00280-011-1586-z
   Place AE, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2912
   Richman SD, 2011, ANAL CELL PATHOL, V34, P61, DOI [10.1155/2011/393521, 10.3233/ACP-2011-0005]
   Russnes HG, 2011, J CLIN INVEST, V121, P3810, DOI 10.1172/JCI57088
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Smith RA, 2014, CA-CANCER J CLIN, V64, P31, DOI 10.3322/caac.21212
   Stoecklein NH, 2010, INT J CANCER, V126, P589, DOI 10.1002/ijc.24916
   Thirlwell C, 2010, GASTROENTEROLOGY, V138, P1441, DOI 10.1053/j.gastro.2010.01.033
   Tlsty TD, 2006, ANNU REV PATHOL-MECH, V1, P119, DOI 10.1146/annurev.pathol.1.110304.100224
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994
   Vermaat JS, 2012, CLIN CANCER RES, V18, P688, DOI 10.1158/1078-0432.CCR-11-1965
   Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825
   Yachida S, 2010, NATURE, V467, P1114, DOI 10.1038/nature09515
   Zielinski C, 2013, ANN ONCOL, V24, P1170, DOI 10.1093/annonc/mds647
NR 59
TC 11
Z9 12
U1 0
U2 6
PU ORDEM MEDICOS
PI LISBON
PA AV ALMIRANTE GAGO COUTINHO, 151, LISBON, 1749-084, PORTUGAL
SN 0870-399X
EI 1646-0758
J9 ACTA MEDICA PORT
JI Acta Medica Port.
PD MAY-JUN
PY 2015
VL 28
IS 3
BP 370
EP 375
DI 10.20344/amp.5398
PG 6
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CO1WJ
UT WOS:000358946500015
PM 26421790
OA Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Huang, JR
   Lee, MH
   Li, WS
   Wu, HC
AF Huang, Jiao-Ren
   Lee, Mei-Hsien
   Li, Wen-Shan
   Wu, Han-Chun
TI Liposomal Irinotecan for Treatment of Colorectal Cancer in a Preclinical
   Model
SO CANCERS
LA English
DT Article
DE colorectal cancer; liposomal irinotecan; combination targeted therapy;
   drug delivery system; microbiota
ID INDUCED DIARRHEA; TOPOISOMERASE-I; CAMPTOTHECIN NSC-100880; ANTITUMOR
   EFFICACY; PANCREATIC-CANCER; CPT-11; DRUG; LACTONE; PHARMACOKINETICS;
   5-FLUOROURACIL
AB Colorectal cancer (CRC) is the most frequently diagnosed cancer and leading cause of cancer-related deaths worldwide. Because of the use of first-line CRC treatments, such as irinotecan (IRI), is hindered by dose-limiting side effects, improved drug delivery systems may have major clinical benefits for CRC treatment. In this study, we generate and characterize liposomal irinotecan (Lipo-IRI), a lipid-based nanoparticle, which shows excellent bioavailability and pharmacokinetics. Additionally, this formulation allows IRI to be maintained in active form and prolongs its half-life in circulation compared to IRI in solution. Compared with IRI statistically, the level of prostaglandin E2 (PGE2) in colonic tissue decreases, and Bifidobacterium spp. (beneficial intestinal microbiota) content increases in the Lipo-IRI-treated group. Moreover, no damage is observed by the hematoxylin and eosin staining of the normal tissue samples from the Lipo-IRI-treated group. In a xenograft mouse model, CRC tumors shrink markedly following Lipo-IRI treatment, and mice receiving a targeted combination of Lipo-IRI and liposomal doxorubicin (Lipo-Dox) extend their survival rate significantly. Overall, our results demonstrate that this formulation of Lipo-IRI shows a great potential for the treatment of colorectal cancer.
C1 [Huang, Jiao-Ren] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Mol Biol & Drug Discovery, Taipei 110, Taiwan.
   [Huang, Jiao-Ren] Acad Sinica, Taipei 110, Taiwan.
   [Huang, Jiao-Ren; Wu, Han-Chun] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
   [Lee, Mei-Hsien] Taipei Med Univ, Coll Pharm, Grad Inst Pharmacognosy, Taipei 110, Taiwan.
   [Li, Wen-Shan] Acad Sinica, Inst Chem, Taipei 115, Taiwan.
C3 Taipei Medical University; Academia Sinica - Taiwan; Academia Sinica -
   Taiwan; Taipei Medical University; Academia Sinica - Taiwan
RP Wu, HC (corresponding author), Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
EM jaran0707@gmail.com; lmh@tmu.edu.tw; wenshan@gate.sinica.edu.tw;
   hcw0928@gate.sinica.edu.tw
RI Wu, Han/JGM-4539-2023; Li, Wen-Shan/F-1972-2015
OI Li, Wen-Shan/0000-0002-8359-4582
FU Academia Sinica; Ministry of Science and Technology [MOST
   106-0210-01-15-02, MOST 107-0210-01-19-01]
FX This research was supported by Academia Sinica and Ministry of Science
   and Technology [MOST 106-0210-01-15-02] and [MOST 107-0210-01-19-01].
CR Armand JP, 1996, SEMIN ONCOL, V23, P27
   BARTLETT GR, 1959, J BIOL CHEM, V234, P466
   Benson AB, 2004, J CLIN ONCOL, V22, P2918, DOI 10.1200/jco.2004.04.132
   Chen LT, 2018, EUR J CANCER, V105, P71, DOI 10.1016/j.ejca.2018.09.010
   Danhier F, 2016, J CONTROL RELEASE, V244, P108, DOI 10.1016/j.jconrel.2016.11.015
   Dromi S, 2007, CLIN CANCER RES, V13, P2722, DOI 10.1158/1078-0432.CCR-06-2443
   Drummond DC, 2006, CANCER RES, V66, P3271, DOI 10.1158/0008-5472.CAN-05-4007
   Drummond DC, 1999, PHARMACOL REV, V51, P691
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Giovanella BC, 2000, ANN NY ACAD SCI, V922, P27
   Greish K, 2003, CLIN PHARMACOKINET, V42, P1089, DOI 10.2165/00003088-200342130-00002
   Heldin CH, 2004, NAT REV CANCER, V4, P806, DOI 10.1038/nrc1456
   HERTZBERG RP, 1989, J MED CHEM, V32, P715, DOI 10.1021/jm00123a038
   Hoarau D, 2004, PHARM RES-DORDR, V21, P1783, DOI 10.1023/B:PHAM.0000045229.87844.21
   HSIANG YH, 1988, CANCER RES, V48, P1722
   HSIANG YH, 1989, CANCER RES, V49, P5077
   Hu ZP, 2006, TOXICOL APPL PHARM, V216, P225, DOI 10.1016/j.taap.2006.05.020
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Kanterman J, 2014, CANCER RES, V74, P6022, DOI 10.1158/0008-5472.CAN-14-0657
   Kase Y, 1997, JPN J PHARMACOL, V75, P399, DOI 10.1254/jjp.75.399
   KAWATO Y, 1991, CANCER RES, V51, P4187
   Kehrer DFS, 2001, CLIN CANCER RES, V7, P1136
   Klebanoff SJ, 2005, J LEUKOCYTE BIOL, V77, P598, DOI 10.1189/jlb.1204697
   Kurita A, 2000, CANCER CHEMOTH PHARM, V46, P211, DOI 10.1007/s002800000151
   Levin B, 2008, GASTROENTEROLOGY, V134, P1570, DOI 10.1053/j.gastro.2008.02.002
   Lo A, 2008, MOL CANCER THER, V7, P579, DOI 10.1158/1535-7163.MCT-07-2359
   Mathijssen RHJ, 2001, CLIN CANCER RES, V7, P2182
   MOERTEL CG, 1972, CANCER CHEMOTH REP 1, V56, P95
   MUGGIA FM, 1972, CANCER CHEMOTH REP 1, V56, P515
   Nichols JW, 2014, J CONTROL RELEASE, V190, P451, DOI 10.1016/j.jconrel.2014.03.057
   Northfelt DW, 1996, J CLIN PHARMACOL, V36, P55, DOI 10.1002/j.1552-4604.1996.tb04152.x
   de Alencar NMN, 2017, PHYTOTHER RES, V31, P312, DOI 10.1002/ptr.5752
   Ohtsuka K, 2003, LUNG CANCER, V41, P187, DOI 10.1016/S0169-5002(03)00223-X
   Pal A, 2005, ANTICANCER RES, V25, P331
   Park JW, 2002, BREAST CANCER RES, V4, P93
   Patankar N, 2011, PHARM RES-DORDR, V28, P848, DOI 10.1007/s11095-010-0340-2
   Ramsay E, 2008, EUR J PHARM BIOPHARM, V68, P607, DOI 10.1016/j.ejpb.2007.08.011
   Ramsay E, 2006, PHARM RES-DORDR, V23, P2799, DOI 10.1007/s11095-006-9111-5
   Rothenberg ML, 2001, ONCOLOGIST, V6, P66, DOI 10.1634/theoncologist.6-1-66
   Rothenberg ML, 2001, ANN ONCOL, V12, P1631, DOI 10.1023/A:1013157727506
   Rothenberg ML, 2001, J CLIN ONCOL, V19, P3801, DOI 10.1200/JCO.2001.19.18.3801
   Sparreboom A, 1998, CLIN CANCER RES, V4, P2747
   Stewart SL, 2006, CANCER-AM CANCER SOC, V107, P1128, DOI 10.1002/cncr.22010
   Swami U, 2013, CURR DRUG TARGETS, V14, P777, DOI 10.2174/1389450111314070007
   Taggar AS, 2006, J CONTROL RELEASE, V114, P78, DOI 10.1016/j.jconrel.2006.05.019
   Taïeb J, 2007, ANN ONCOL, V18, P498, DOI 10.1093/annonc/mdl427
   Teufel A, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-38
   Wang-Gillam A, 2019, EUR J CANCER, V108, P78, DOI 10.1016/j.ejca.2018.12.007
   Warner DL, 1997, J CHROMATOGR B, V691, P161, DOI 10.1016/S0378-4347(96)00426-4
   Wu CH, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0223-x
   Wu CH, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa9391
   Wu MH, 2002, CLIN CANCER RES, V8, P2696
   Xu G, 2002, CLIN CANCER RES, V8, P2605
   Xue HY, 2007, CLIN CANCER RES, V13, P7146, DOI 10.1158/1078-0432.CCR-07-0823
   Yarmolenko PS, 2010, INT J HYPERTHER, V26, P485, DOI 10.3109/02656731003789284
NR 55
TC 23
Z9 24
U1 0
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2019
VL 11
IS 3
AR 281
DI 10.3390/cancers11030281
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HZ0RT
UT WOS:000468550200011
PM 30818855
OA gold, Green Published, Green Submitted
DA 2025-01-04
ER

PT J
AU Su, HI
   Connell, MW
   Bazhenova, LA
AF Su, H. Irene
   Connell, Meghan W.
   Bazhenova, Lyudmila A.
TI Ovarian stimulation in young adult cancer survivors on targeted cancer
   therapies
SO FERTILITY AND STERILITY
LA English
DT Article
DE Crizotinib; denosumab; fertility preservation; ovarian stimulation;
   targeted cancer treatment
ID INFERTILITY
AB Objective: To describe a clinical approach to and outcomes of IVF in reproductive-aged cancer survivors receiving targeted cancer therapies.
   Design: Case report.
   Setting: Not applicable.
   Patient(s): The first case is of a female patient with metastatic lung cancer receiving long-term crizotinib, an anaplastic lymphoma kinase inhibitor. The second case is of a female patient with metastatic colon cancer receiving long-term denosumab, a RANKL antibody. Both patients presented desiring fertility.
   Intervention(s): In vitro fertilization.
   Main Outcome Measure(s): Live birth and embryo banking.
   Result(s): The potential impact of targeted therapy on oocytes and pregnancy was investigated via literature review and pharmaceutical company inquiries. After oncologic, fertility, and psychological counseling, both survivors underwent ovarian stimulation, IVF, and preimplantation genetic screening. One couple achieved live births of dizygotic twins via gestational surrogacy. The second couple froze one euploid blastocyst for future fertility. Both survivors are stable from their cancer standpoints.
   Conclusion(s): Successful fertility treatments are possible in the context of exposure to crizotinib and denosumab. (C) 2016 by American Society for Reproductive Medicine.
C1 [Su, H. Irene] Univ Calif San Diego, Dept Reprod Med, La Jolla, CA 92093 USA.
   [Su, H. Irene; Bazhenova, Lyudmila A.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Connell, Meghan W.] Reprod Partners Med Grp San Diego, La Jolla, CA USA.
C3 University of California System; University of California San Diego;
   University of California System; University of California San Diego
RP Su, HI (corresponding author), Univ Calif San Diego, Reprod Med, Moores UCSD Canc Ctr, 3855 Hlth Sci Dr,Dept 0901, La Jolla, CA 92093 USA.
EM hisu@ucsd.edu
OI Su, H. Irene/0000-0002-6671-5151; Bazhenova,
   Lyudmila/0000-0001-8764-4359
FU National Institutes of Health [R01 HD 080952-02]; California Breast
   Cancer Research Program [20OB-0144]
FX Funding was provided by National Institutes of Health (grant R01 HD
   080952-02) and California Breast Cancer Research Program (grant
   20OB-0144).
CR American Cancer Society, 2014, CANC TREATM SURV FAC
   Barton SE, 2013, LANCET ONCOL, V14, P873, DOI 10.1016/S1470-2045(13)70251-1
   Bussiere JL, 2013, REPROD TOXICOL, V42, P27, DOI 10.1016/j.reprotox.2013.07.018
   Garze VG, 2013, FERTIL STERIL, V100, pS523, DOI 10.1016/j.fertnstert.2013.07.262
   Letourneau JM, 2012, CANCER-AM CANCER SOC, V118, P4579, DOI 10.1002/cncr.26649
   Lipton A, 2016, EUR J CANCER, V53, P75, DOI 10.1016/j.ejca.2015.09.011
   Schover LR, 2002, J CLIN ONCOL, V20, P1880, DOI 10.1200/JCO.2002.07.175
   Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886
NR 8
TC 9
Z9 9
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD NOV
PY 2016
VL 106
IS 6
BP 1475
EP 1478
DI 10.1016/j.fertnstert.2016.08.011
PG 4
WC Obstetrics & Gynecology; Reproductive Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Obstetrics & Gynecology; Reproductive Biology
GA EA7RP
UT WOS:000386829800036
PM 27565250
OA Green Accepted, Bronze
DA 2025-01-04
ER

PT J
AU Zhang, SL
   Carlsen, L
   Borrero, LH
   Seyhan, AA
   Tian, XB
   El-Deiry, WS
AF Zhang, Shengliang
   Carlsen, Lindsey
   Hernandez Borrero, Liz
   Seyhan, Attila A.
   Tian, Xiaobing
   El-Deiry, Wafik S.
TI Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant
   p53 in Cancer
SO BIOMOLECULES
LA English
DT Review
DE P53; mutant p53; targeting therapy; immunotherapy; cancer
ID TUMOR-SUPPRESSOR FUNCTION; IN-VIVO; COLORECTAL-CANCER; INDUCED
   APOPTOSIS; KNOCKOUT MICE; MOUSE MODELS; RESISTANCE MECHANISMS; HIGH
   SUSCEPTIBILITY; MDM2 ANTAGONIST; BREAST-CANCER
AB TP53 is a tumor suppressor gene that encodes a sequence-specific DNA-binding transcription factor activated by stressful stimuli; it upregulates target genes involved in growth suppression, cell death, DNA repair, metabolism, among others. TP53 is the most frequently mutated gene in tumors, with mutations not only leading to loss-of-function (LOF), but also gain-of-function (GOF) that promotes tumor progression, and metastasis. The tumor-specific status of mutant p53 protein has suggested it is a promising target for cancer therapy. We summarize the current progress of targeting wild-type and mutant p53 for cancer therapy through biotherapeutic and biopharmaceutical methods for (1) boosting p53 activity in cancer, (2) p53-dependent and p53-independent strategies for targeting p53 pathway functional restoration in p53-mutated cancer, (3) targeting p53 in immunotherapy, and (4) combination therapies targeting p53, p53 checkpoints, or mutant p53 for cancer therapy.
C1 [Zhang, Shengliang; Carlsen, Lindsey; Hernandez Borrero, Liz; Seyhan, Attila A.; Tian, Xiaobing; El-Deiry, Wafik S.] Brown Univ, Warren Alpert Med Sch, Lab Translat Oncol & Expt Canc Therapeut, Providence, RI 02912 USA.
   [Zhang, Shengliang; Seyhan, Attila A.; Tian, Xiaobing; El-Deiry, Wafik S.] Brown Univ, Warren Alpert Med Sch, Dept Pathol & Lab Med, Providence, RI 02912 USA.
   [Zhang, Shengliang; Seyhan, Attila A.; Tian, Xiaobing; El-Deiry, Wafik S.] Lifespan Hlth Syst, Joint Program Canc Biol, Providence, RI 02912 USA.
   [Zhang, Shengliang; Seyhan, Attila A.; Tian, Xiaobing; El-Deiry, Wafik S.] Brown Univ, Providence, RI 02912 USA.
   [Zhang, Shengliang; Seyhan, Attila A.; Tian, Xiaobing; El-Deiry, Wafik S.] Brown Univ, Legorreta Canc Ctr, Providence, RI 02912 USA.
   [Carlsen, Lindsey] Brown Univ, Warren Alpert Med Sch, Pathobiol Grad Program, Providence, RI 02912 USA.
   [El-Deiry, Wafik S.] Lifespan Hlth Syst, Dept Med, Hematol Oncol Div, Providence, RI 02912 USA.
C3 Brown University; Brown University; Brown University; Brown University;
   Brown University
RP Zhang, SL; El-Deiry, WS (corresponding author), Brown Univ, Warren Alpert Med Sch, Lab Translat Oncol & Expt Canc Therapeut, Providence, RI 02912 USA.; Zhang, SL; El-Deiry, WS (corresponding author), Brown Univ, Warren Alpert Med Sch, Dept Pathol & Lab Med, Providence, RI 02912 USA.; Zhang, SL; El-Deiry, WS (corresponding author), Lifespan Hlth Syst, Joint Program Canc Biol, Providence, RI 02912 USA.; Zhang, SL; El-Deiry, WS (corresponding author), Brown Univ, Providence, RI 02912 USA.; Zhang, SL; El-Deiry, WS (corresponding author), Brown Univ, Legorreta Canc Ctr, Providence, RI 02912 USA.; El-Deiry, WS (corresponding author), Lifespan Hlth Syst, Dept Med, Hematol Oncol Div, Providence, RI 02912 USA.
EM shengliang_zhang@brown.edu; lindsey_carlsen@brown.edu;
   liz_hernandez_borrero@alumni.brown.edu; attila_seyhan@brown.edu;
   xiaobing_tian@brown.edu; wafik@brown.edu
OI Seyhan, Attila A/0000-0003-1276-8466; El-Deiry,
   Wafik/0000-0002-9577-8266; Carlsen, Lindsey/0000-0003-0512-1760
FU Teymour Alireza P'98, P'00 Family Cancer Research Fund [GFT640730]
FX This work was supported in part by the Teymour Alireza P'98, P'00 Family
   Cancer Research Fund. grant number GFT640730, established by the Alireza
   Family.
CR Ahmed A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.42
   Alexandrova EM, 2015, NATURE, V523, P352, DOI 10.1038/nature14430
   Allen MA, 2014, ELIFE, V3, DOI 10.7554/eLife.02200
   Andreeff M, 2016, CLIN CANCER RES, V22, P868, DOI 10.1158/1078-0432.CCR-15-0481
   Armstrong JL, 2007, APOPTOSIS, V12, P613, DOI 10.1007/s10495-006-0020-1
   Aubrey BJ, 2018, CELL DEATH DIFFER, V25, P104, DOI 10.1038/cdd.2017.169
   Bae SK, 2011, BIOCHEM BIOPH RES CO, V409, P75, DOI 10.1016/j.bbrc.2011.04.108
   Barta JA, 2019, MOL CANCER RES, V17, P3, DOI 10.1158/1541-7786.MCR-18-0357
   Batir MB, 2019, MOL BIOL REP, V46, P6471, DOI 10.1007/s11033-019-05093-y
   Baud MGJ, 2018, EUR J MED CHEM, V152, P101, DOI 10.1016/j.ejmech.2018.04.035
   Bauer MR, 2019, FUTURE MED CHEM, V11, P2491, DOI 10.4155/fmc-2019-0181
   Bauer MR, 2016, P NATL ACAD SCI USA, V113, pE5271, DOI 10.1073/pnas.1610421113
   Blagih J, 2020, CELL REP, V30, P481, DOI 10.1016/j.celrep.2019.12.028
   Blandino G, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0705-7
   Boeckler FM, 2008, P NATL ACAD SCI USA, V105, P10360, DOI 10.1073/pnas.0805326105
   Borrero LH, 2021, ELIFE, V10, DOI 10.7554/eLife.70429
   Bourdon JC, 2005, GENE DEV, V19, P2122, DOI 10.1101/gad.1339905
   Bragado P, 2007, APOPTOSIS, V12, P1733, DOI 10.1007/s10495-007-0082-8
   Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693
   Broz DK, 2013, GENE DEV, V27, P1016, DOI 10.1101/gad.212282.112
   Broz DK, 2010, CARCINOGENESIS, V31, P1311, DOI 10.1093/carcin/bgp331
   Butler JS, 2003, BIOCHEMISTRY-US, V42, P2396, DOI 10.1021/bi026635n
   Bykov VJN, 2005, J BIOL CHEM, V280, P30384, DOI 10.1074/jbc.M501664200
   Bykov VJN, 2005, ONCOGENE, V24, P3484, DOI 10.1038/sj.onc.1208419
   Bykov VJN, 2002, NAT MED, V8, P282, DOI 10.1038/nm0302-282
   Bykov VJN, 2018, NAT REV CANCER, V18, P89, DOI 10.1038/nrc.2017.109
   Carr MI, 2016, TRANSL CANCER RES, V5, P707, DOI 10.21037/tcr.2016.11.75
   Carvajal LA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aao3003
   Chapeau EA, 2017, P NATL ACAD SCI USA, V114, P3151, DOI 10.1073/pnas.1620262114
   Chen JD, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026104
   Chira S, 2018, TRENDS BIOTECHNOL, V36, P653, DOI 10.1016/j.tibtech.2018.01.014
   Christophorou MA, 2005, NAT GENET, V37, P718, DOI 10.1038/ng1572
   Chung V, 2019, CLIN TRANSL ONCOL, V21, P363, DOI 10.1007/s12094-018-1932-2
   DeLeo AB, 2020, J IMMUNOL, V204, P2321, DOI 10.4049/jimmunol.1901343
   Demma M, 2010, J BIOL CHEM, V285, P10198, DOI 10.1074/jbc.M109.083469
   Ding QJ, 2013, J MED CHEM, V56, P5979, DOI 10.1021/jm400487c
   Duffy MJ, 2022, SEMIN CANCER BIOL, V79, P58, DOI 10.1016/j.semcancer.2020.07.005
   Duffy MJ, 2017, EUR J CANCER, V83, P258, DOI 10.1016/j.ejca.2017.06.023
   ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45
   Espadinha M, 2018, CURR TOP MED CHEM, V18, P647, DOI 10.2174/1568026618666180604080119
   Fischer M, 2017, ONCOGENE, V36, P3943, DOI 10.1038/onc.2016.502
   Foggetti G, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181345
   Foster BA, 1999, SCIENCE, V286, P2507, DOI 10.1126/science.286.5449.2507
   French JE, 2001, CARCINOGENESIS, V22, P99, DOI 10.1093/carcin/22.1.99
   Fujihara KM, 2021, MOL CANCER THER, V20, P1858, DOI 10.1158/1535-7163.MCT-21-0067
   Gadhikar MA, 2013, MOL CANCER THER, V12, P1860, DOI 10.1158/1535-7163.MCT-13-0157
   Galbraith MD, 2021, METHODS MOL BIOL, V2267, P19, DOI 10.1007/978-1-0716-1217-0_3
   Galea C, 2005, PROTEIN SCI, V14, P2993, DOI 10.1110/ps.051622005
   Gasparian AV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002530
   Geenen JJJ, 2017, CLIN CANCER RES, V23, P4540, DOI 10.1158/1078-0432.CCR-17-0520
   Gomes AS, 2021, CANCERS, V13, DOI 10.3390/cancers13133344
   Gomes AS, 2020, BBA-GEN SUBJECTS, V1864, DOI 10.1016/j.bbagen.2019.129440
   Gomes S, 2019, CANCERS, V11, DOI 10.3390/cancers11081151
   Gorecki L, 2021, CANCERS, V13, DOI 10.3390/cancers13040795
   Grandela C, 2008, STEM CELL RES, V1, P116, DOI 10.1016/j.scr.2007.10.003
   Graves B, 2012, P NATL ACAD SCI USA, V109, P11788, DOI 10.1073/pnas.1203789109
   Grellety T, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1667-1
   Grinkevich VV, 2009, CANCER CELL, V15, P441, DOI 10.1016/j.ccr.2009.03.021
   Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x
   Hanel W, 2013, CELL DEATH DIFFER, V20, P898, DOI 10.1038/cdd.2013.17
   Hao Q, 2021, J MOL CELL BIOL, V13, P690, DOI 10.1093/jmcb/mjab049
   Hardwick NR, 2014, CLIN CANCER RES, V20, P4459, DOI 10.1158/1078-0432.CCR-13-3361
   Haronikova L, 2021, CELL MOL BIOL LETT, V26, DOI 10.1186/s11658-021-00293-6
   HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225
   Haupt Y, 1997, NATURE, V387, P296, DOI 10.1038/387296a0
   Heise C, 1997, NAT MED, V3, P639, DOI 10.1038/nm0697-639
   Her NG, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0825-1
   Hernandez-Borrero LJ, 2018, CELL CYCLE, V17, P557, DOI 10.1080/15384101.2017.1346762
   Hong B, 2014, CANCER RES, V74, P1153, DOI 10.1158/0008-5472.CAN-13-0955
   Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697
   Hu CQ, 2011, BIOORGAN MED CHEM, V19, P5454, DOI 10.1016/j.bmc.2011.07.050
   Hu ZY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031067
   Huang J, 2021, PHARMACOL THERAPEUT, V220, DOI 10.1016/j.pharmthera.2020.107720
   Issaeva N, 2004, NAT MED, V10, P1321, DOI 10.1038/nm1146
   Jenkins LMM, 2012, CARCINOGENESIS, V33, P1441, DOI 10.1093/carcin/bgs145
   Ji ZY, 2013, CLIN CANCER RES, V19, P4383, DOI 10.1158/1078-0432.CCR-13-0074
   Jiang LR, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2445-9
   Joerger AC, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000919
   Joruiz SM, 2016, CSH PERSPECT MED, V6, DOI 10.1101/cshperspect.a026039
   Kaar JL, 2010, PROTEIN SCI, V19, P2267, DOI 10.1002/pro.507
   Kado S, 2001, CANCER RES, V61, P2395
   Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028
   Kersten K, 2017, EMBO MOL MED, V9, P137, DOI 10.15252/emmm.201606857
   Khoury MP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a000927
   Kong A, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912-021-01098-8
   Kravchenko JE, 2008, P NATL ACAD SCI USA, V105, P6302, DOI 10.1073/pnas.0802091105
   Kunimura N, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74660-2
   Lain S, 2008, CANCER CELL, V13, P454, DOI 10.1016/j.ccr.2008.03.004
   Lambert JMR, 2009, CANCER CELL, V15, P376, DOI 10.1016/j.ccr.2009.03.003
   Lane DP, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001222
   Lang GA, 2004, CELL, V119, P861, DOI 10.1016/j.cell.2004.11.006
   Leijen S, 2016, J CLIN ONCOL, V34, P4354, DOI 10.1200/JCO.2016.67.5942
   Levine AJ, 2019, ANNU REV CANC BIOL, V3, P21, DOI 10.1146/annurev-cancerbio-030518-055455
   Li D, 2011, CELL DEATH DIFFER, V18, P1904, DOI 10.1038/cdd.2011.71
   Li D, 2011, MOL CANCER RES, V9, P577, DOI 10.1158/1541-7786.MCR-10-0534
   Li H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235999
   Li M, 2021, APOPTOSIS, V26, P235, DOI 10.1007/s10495-021-01667-z
   Li Y, 2005, MOL CANCER THER, V4, P901, DOI 10.1158/1535-7163.MCT-04-0206
   Liebl MC, 2019, BIOESSAYS, V41, DOI 10.1002/bies.201900127
   Lin AB, 2017, CLIN CANCER RES, V23, P3232, DOI 10.1158/1078-0432.CCR-16-0083
   Lin K, 2008, ONCOGENE, V27, P2445, DOI 10.1038/sj.onc.1210893
   Lindemann A, 2019, CLIN CANCER RES, V25, P5650, DOI 10.1158/1078-0432.CCR-19-0096
   Liu DS, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14844
   Lopes EA, 2019, CURR MED CHEM, V26, P7323, DOI 10.2174/0929867325666181116124308
   Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765
   Magrini R, 2008, J CELL BIOCHEM, V104, P2363, DOI 10.1002/jcb.21794
   Martins CP, 2006, CELL, V127, P1323, DOI 10.1016/j.cell.2006.12.007
   Menendez D, 2013, NUCLEIC ACIDS RES, V41, P7286, DOI 10.1093/nar/gkt504
   Meng XB, 2018, CANCERS, V10, DOI 10.3390/cancers10050149
   Menichini P, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010098
   Messina RL, 2012, INT J CANCER, V130, P2259, DOI 10.1002/ijc.26228
   Mirgayazova R, 2020, GENES-BASEL, V11, DOI 10.3390/genes11060704
   Mohell N, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.143
   Moore EC, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1404216
   Oda H, 1997, CANCER RES, V57, P646
   Olivares-Illana V, 2010, ONCOGENE, V29, P5113, DOI 10.1038/onc.2010.266
   Olive KP, 2004, CELL, V119, P847, DOI 10.1016/j.cell.2004.11.004
   Olivier M, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001008
   Oza AM, 2020, CLIN CANCER RES, V26, P4767, DOI 10.1158/1078-0432.CCR-20-0219
   Ozaki K, 1998, CANCER RES, V58, P3806
   Pairawan S, 2021, BREAST CANCER RES, V23, DOI 10.1186/s13058-021-01406-x
   Parrales A, 2016, NAT CELL BIOL, V18, P1233, DOI 10.1038/ncb3427
   Patnaik A, 2015, CANCER CHEMOTH PHARM, V76, P587, DOI 10.1007/s00280-015-2830-8
   Pearson S, 2004, NAT BIOTECHNOL, V22, P3, DOI 10.1038/nbt0104-3
   Peng YH, 2001, J BIOL CHEM, V276, P40583, DOI 10.1074/jbc.M102817200
   Perdrix A, 2017, CANCERS, V9, DOI 10.3390/cancers9120172
   Pérez-Galán P, 2006, BLOOD, V107, P257, DOI 10.1182/blood-2005-05-2091
   Proia DA, 2014, CANCER RES, V74, P1294, DOI 10.1158/0008-5472.CAN-13-3263
   Punganuru SR, 2016, EUR J MED CHEM, V107, P233, DOI 10.1016/j.ejmech.2015.10.052
   Qi ZW, 2021, BIOORG CHEM, V111, DOI 10.1016/j.bioorg.2021.104901
   Rajeshkumar NV, 2011, CLIN CANCER RES, V17, P2799, DOI 10.1158/1078-0432.CCR-10-2580
   Ray-Coquard I, 2012, LANCET ONCOL, V13, P1133, DOI 10.1016/S1470-2045(12)70474-6
   Reed D, 2010, J BIOL CHEM, V285, P10786, DOI 10.1074/jbc.M109.056747
   Richardson C, 2017, CELL CYCLE, V16, P1719, DOI 10.1080/15384101.2017.1356514
   Robles AI, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001016
   Roy S, 2020, CANCERS, V12, DOI 10.3390/cancers12082253
   Sabapathy K, 2018, NAT REV CLIN ONCOL, V15, P13, DOI 10.1038/nrclinonc.2017.151
   Saha MN, 2014, BRIT J CANCER, V110, P2224, DOI 10.1038/bjc.2014.164
   Saha MN, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030215
   Sakai H, 2003, J CANCER RES CLIN, V129, P335, DOI 10.1007/s00432-003-0443-9
   Saleh Mansoor N, 2021, Clin Cancer Res, V27, P5236, DOI 10.1158/1078-0432.CCR-21-0715
   Salim KY, 2016, ONCOTARGET, V7, P41363, DOI 10.18632/oncotarget.9133
   Sallman DA, 2021, J CLIN ONCOL, V39, P1584, DOI 10.1200/JCO.20.02341
   Sanz G, 2019, J MOL CELL BIOL, V11, P586, DOI 10.1093/jmcb/mjz075
   SCHLICHTHOLZ B, 1992, CANCER RES, V52, P6380
   SCHLICHTHOLZ B, 1994, BRIT J CANCER, V69, P809, DOI 10.1038/bjc.1994.159
   Schwitalla S, 2013, CANCER CELL, V23, P93, DOI 10.1016/j.ccr.2012.11.014
   Shadfan M, 2012, TRANSL CANCER RES, V1, P88, DOI 10.3978/j.issn.2218-676X.2012.04.02
   Sharma K, 2018, MOL ONCOL, V12, P788, DOI 10.1002/1878-0261.12172
   Shi Y, 2014, CELL DEATH DIFFER, V21, P612, DOI 10.1038/cdd.2013.186
   Soares J, 2016, ONCOTARGET, V7, P4326, DOI 10.18632/oncotarget.6775
   Sobol RE, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.645745
   Soragni A, 2016, CANCER CELL, V29, P90, DOI 10.1016/j.ccell.2015.12.002
   Sun X, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2021456118
   Sun YF, 2016, AM J CANCER RES, V6, P114
   Surget S, 2014, ONCOTARGETS THER, V7, P57, DOI 10.2147/OTT.S53876
   Synnott NC, 2020, BREAST CANCER RES TR, V179, P47, DOI 10.1007/s10549-019-05435-1
   Tal P, 2016, ONCOTARGET, V7, P11817, DOI 10.18632/oncotarget.7857
   Tchelebi Leila, 2014, Subcell Biochem, V85, P133, DOI 10.1007/978-94-017-9211-0_8
   Tian XB, 2021, NEOPLASIA, V23, P304, DOI 10.1016/j.neo.2021.01.004
   Tratar UL, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00268
   Vakifahmetoglu-Norberg H, 2013, GENE DEV, V27, P1718, DOI 10.1101/gad.220897.113
   Valente JFA, 2018, CURR DRUG TARGETS, V19, P1801, DOI 10.2174/1389450119666180115165447
   Vance SM, 2011, CELL CYCLE, V10, P4321, DOI 10.4161/cc.10.24.18661
   Vareki SM, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191766
   Vatsyayan R, 2013, MOL CARCINOGEN, V52, P39, DOI 10.1002/mc.20875
   Vega-Stromberg Teri, 2003, J Infus Nurs, V26, P353, DOI 10.1097/00129804-200311000-00004
   Verreault M, 2016, CLIN CANCER RES, V22, P1185, DOI 10.1158/1078-0432.CCR-15-1015
   Vieler M, 2018, CANCERS, V10, DOI 10.3390/cancers10090288
   Wang SM, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026245
   Wang WG, 2006, P NATL ACAD SCI USA, V103, P11003, DOI 10.1073/pnas.0604507103
   Wang XX, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12819
   Warfel NA, 2013, CURR OPIN ONCOL, V25, P52, DOI 10.1097/CCO.0b013e32835b639e
   Weilbacher A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.284
   Wiegering A, 2017, NEOPLASIA, V19, P301, DOI 10.1016/j.neo.2017.01.007
   Wurz RP, 2019, J MED CHEM, V62, P445, DOI 10.1021/acs.jmedchem.8b01945
   Xie Q, 2016, WORLD J GASTROENTERO, V22, P7342, DOI 10.3748/wjg.v22.i32.7342
   Yamamoto M, 2000, CARCINOGENESIS, V21, P1891, DOI 10.1093/carcin/21.10.1891
   Yang J, 2009, MOL CELL BIOL, V29, P2243, DOI 10.1128/MCB.00959-08
   Yap TA, 2013, J CLIN ONCOL, V31, P1592, DOI 10.1200/JCO.2011.37.6418
   Yin YP, 2018, MOL MED REP, V17, P3344, DOI 10.3892/mmr.2017.8230
   Yu X, 2012, CANCER CELL, V21, P614, DOI 10.1016/j.ccr.2012.03.042
   Zache N, 2008, MOL ONCOL, V2, P70, DOI 10.1016/j.molonc.2008.02.004
   Zawacka-Pankau J, 2015, J INTERN MED, V277, P248, DOI 10.1111/joim.12336
   Zhang Q, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0463-7
   Zhang SL, 2022, MOL CANCER RES, V20, P622, DOI 10.1158/1541-7786.MCR-21-0149
   Zhang SL, 2015, CANCER RES, V75, P3842, DOI 10.1158/0008-5472.CAN-13-1079
   Zhang SY, 2021, J MED CHEM, V64, P10621, DOI 10.1021/acs.jmedchem.1c00940
   Zhang WW, 2018, HUM GENE THER, V29, P160, DOI 10.1089/hum.2017.218
   Zhang YW, 2014, INT J CANCER, V134, P1013, DOI 10.1002/ijc.28226
   Zhou XL, 2021, CANCER DISCOV, V11, P3090, DOI 10.1158/2159-8290.CD-20-1741
   Zhu GY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.595187
NR 192
TC 34
Z9 35
U1 7
U2 41
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD APR
PY 2022
VL 12
IS 4
AR 548
DI 10.3390/biom12040548
PG 26
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA 0T5FQ
UT WOS:000786993700001
PM 35454137
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Shen, CY
   Yang, C
   Xia, B
   You, ML
AF Shen, Chongyang
   Yang, Chuan
   Xia, Bing
   You, Mingliang
TI Long non-coding RNAs: Emerging regulators for chemo/immunotherapy
   resistance in cancer stem cells
SO CANCER LETTERS
LA English
DT Article
DE lncRNA; CSCs; Chemo/immunotherapy; Chemoresistance; Cancer immunotherapy
   resistance
ID EPITHELIAL-MESENCHYMAL TRANSITION; PREDICTS POOR-PROGNOSIS; HLA-G
   EXPRESSION; LUNG-CANCER; COLORECTAL-CANCER; PROSTATE-CANCER; PROMOTES;
   AUTOPHAGY; HOTAIR; CHEMOSENSITIVITY
AB Cancer stem cells (CSCs) are a small subpopulation of tumor cells critical for tumor development. Their unique abilities, such as self-renewal, have resulted in tumor resistance to various cancer treatments, including traditional chemotherapy and latest immunotherapy. CSCs-targeting therapy is a promising treatment to overcome the therapeutic resistances to different tumors. However, despite their significance, the regulatory mechanism generating therapy-resistant CSCs is still obscure. Long non-coding RNAs (lncRNAs) are key regulators in various biological processes, including cell proliferation, apoptosis, migration, and invasion. Recent studies have revealed that lncRNAs play an important role in the therapeutic resistance of CSCs. Here we summarize the latest studies on the regulatory role of lncRNAs in sustaining the stemness of CSCs, and discuss the associated mechanisms behind these behavior changes in CSCs-related chemo- and immune-resistance. Future research implications are also discussed, shedding light on the potential CSCs-targeted strategies to break through the resistance of current therapies.
C1 [Shen, Chongyang] Chengdu Univ Tradit Chinese Med, Basic Med Sch, Chengdu 611137, Peoples R China.
   [Shen, Chongyang] Anhui Univ Chinese Med, Key Lab Xinan Med, Minist Educ, Hefei 230038, Anhui, Peoples R China.
   [Yang, Chuan] Sichuan Univ, Dept Resp & Crit Care Med, West China Hosp, Clin Res Ctr Resp Dis, Chengdu 610041, Peoples R China.
   [Yang, Chuan] Sichuan Univ, Frontiers Sci Ctr Dis Related Mol Network, Lab Pulm Immunol & Inflammat, Chengdu 610041, Peoples R China.
   [Xia, Bing] Hangzhou Canc Hosp, Dept Radiat Oncol, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310002, Peoples R China.
   [You, Mingliang] Hangzhou Canc Hosp, Hangzhou Canc Inst, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310002, Peoples R China.
C3 Chengdu University of Traditional Chinese Medicine; Anhui University of
   Chinese Medicine; Sichuan University; Sichuan University
RP You, ML (corresponding author), Hangzhou Canc Hosp, Hangzhou Canc Inst, Key Lab Clin Canc Pharmacol & Toxicol Res Zhejian, Hangzhou 310002, Peoples R China.
EM youml@zjhealth.org
RI Yang, Chuan/GMW-4748-2022
OI Yang, Chuan/0000-0003-0725-7207
FU Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research
   of Zhejiang Province [2020E10021]; National Natural Science Foundation
   of China [81603478]; Key research program of science technology
   department of Sichuan province [2019YFS0317, 2020YFQ004]; Sichuan Youth
   Science and Technology Innovation Research Team of Experimental
   Formulology [2020JDTD0022]; Sichuan National (International) High-end
   Talents Introduction Project [SYZ202069]
FX This work was supported by Key Laboratory of Clinical Cancer
   Pharmacology and Toxicology Research of Zhejiang Province (2020E10021),
   National Natural Science Foundation of China (81603478), Key research
   program of science technology department of Sichuan province
   (2019YFS0317,2020YFQ004), Sichuan Youth Science and Technology
   Innovation Research Team of Experimental Formulology (2020JDTD0022),
   Sichuan National (International) High-end Talents Introduction Project
   in 2020 (SYZ202069). We thank LetPub (www.letpub.com) for its linguistic
   assistance during the preparation of this manuscript.
CR Abdolmaleki F, 2020, GENOMICS, V112, P677, DOI 10.1016/j.ygeno.2019.04.020
   Barbato L, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080926
   Chakravarty D, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6383
   Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012
   Chen X, 2019, CLIN CANCER RES, V25, P1389, DOI 10.1158/1078-0432.CCR-18-1656
   Chen ZZ, 2018, J BIOL CHEM, V293, P7982, DOI 10.1074/jbc.RA117.001321
   Colak S, 2014, FEBS J, V281, P4779, DOI 10.1111/febs.13023
   D'Angelo Edoardo, 2018, Noncoding RNA Res, V3, P174, DOI 10.1016/j.ncrna.2018.08.002
   Ding K, 2018, BIOCHEM BIOPH RES CO, V502, P194, DOI 10.1016/j.bbrc.2018.05.143
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Esfandi F, 2020, EXP MOL PATHOL, V113, DOI 10.1016/j.yexmp.2020.104383
   Farooqi AA, 2020, CELL MOL BIOL, V66, P215, DOI 10.14715/cmb/2020.66.3.35
   Fu T, 2021, GASTRIC CANCER, V24, P45, DOI 10.1007/s10120-020-01096-y
   Gao JJ, 2017, NAT MED, V23, P551, DOI 10.1038/nm.4308
   Han DF, 2019, J CANCER, V10, P6738, DOI 10.7150/jca.35770
   Hardy SD, 2017, ONCOTARGET, V8, P103302, DOI 10.18632/oncotarget.21871
   Hatano Y, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071446
   Hou ZH, 2020, AM J PHYSIOL-CELL PH, V318, pC649, DOI 10.1152/ajpcell.00510.2018
   Hu QS, 2019, NAT IMMUNOL, V20, P835, DOI 10.1038/s41590-019-0400-7
   Hung CL, 2014, P NATL ACAD SCI USA, V111, P18697, DOI 10.1073/pnas.1415669112
   Jan M, 2011, P NATL ACAD SCI USA, V108, P5009, DOI 10.1073/pnas.1100551108
   Ji J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0528-7
   Jiang P, 2018, J CELL PHYSIOL, V233, P4852, DOI 10.1002/jcp.26288
   Jiao PF, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109164
   Jun BH, 2020, CANCERS, V12, DOI 10.3390/cancers12092553
   Kim SS, 2018, NUCLEIC ACIDS RES, V46, P1424, DOI 10.1093/nar/gkx1221
   Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Lee SP, 2020, CANCERS, V12, DOI 10.3390/cancers12051073
   Li H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00615
   Li X, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19102958
   Li ZX, 2020, FUNCT INTEGR GENOMIC, V20, P17, DOI 10.1007/s10142-019-00696-x
   Libring S, 2020, CANCERS, V12, DOI 10.3390/cancers12051270
   Lin ZY, 2018, MOL THER, V26, P1494, DOI 10.1016/j.ymthe.2018.04.002
   Liu F, 2020, CANCER MED-US, V9, P1079, DOI 10.1002/cam4.2746
   Liu J, 2019, IMMUNITY, V50, P600, DOI 10.1016/j.immuni.2019.01.021
   Liu KS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01162-0
   Liu Y, 2015, TOXICOL APPL PHARM, V282, P9, DOI 10.1016/j.taap.2014.10.022
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Maccalli C, 2015, CANCER IMMUNOL IMMUN, V64, P91, DOI 10.1007/s00262-014-1592-1
   Mazor G, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1477-5
   Messmer D, 2004, J IMMUNOL, V173, P307, DOI 10.4049/jimmunol.173.1.307
   Prensner JR, 2013, NAT GENET, V45, P1392, DOI 10.1038/ng.2771
   Qiu H, 2015, CELL MOL LIFE SCI, V72, P3411, DOI 10.1007/s00018-015-1920-4
   Qu L, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12692
   Reifenberger G, 2017, NAT REV CLIN ONCOL, V14, P434, DOI 10.1038/nrclinonc.2016.204
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Restifo NP, 2016, NAT REV CANCER, V16, P121, DOI 10.1038/nrc.2016.2
   Sáez PJ, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aah7107
   Salama EA, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01459
   Saleh R, 2019, VACCINES-BASEL, V7, DOI 10.3390/vaccines7040149
   Shang WC, 2019, CANCER IMMUNOL RES, V7, P813, DOI 10.1158/2326-6066.CIR-18-0443
   Shin VY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1513-5
   Shinde A, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0204-5
   Shinde A, 2019, CANCER RES, V79, P1831, DOI 10.1158/0008-5472.CAN-18-2636
   Shinde A, 2018, MOL CANCER RES, V16, P1579, DOI 10.1158/1541-7786.MCR-18-0151
   Song BT, 2015, BIOCHEM BIOPH RES CO, V464, P807, DOI 10.1016/j.bbrc.2015.07.040
   Stem J, 2019, REGEN MED, V14, P331, DOI 10.2217/rme-2018-0146
   Sun B, 2021, CELL ONCOL, V44, P179, DOI 10.1007/s13402-020-00560-2
   Sun J, 2014, INT J MOL SCI, V15, P20434, DOI 10.3390/ijms151120434
   Sun JB, 2016, INT J ONCOL, V49, P943, DOI 10.3892/ijo.2016.3589
   Sun W, 2017, ONCOL REP, V38, P3347, DOI 10.3892/or.2017.6056
   Sznarkowska A, 2020, CANCERS, V12, DOI 10.3390/cancers12051155
   Tang YY, 2017, ONCOTARGET, V8, P39001, DOI 10.18632/oncotarget.16545
   Uzunalli Gozde, 2019, Oncotarget, V10, P6334, DOI 10.18632/oncotarget.27274
   Wang JH, 2019, MOL CELL BIOCHEM, V454, P67, DOI 10.1007/s11010-018-3453-2
   Wang LJ, 2014, INT J ONCOL, V44, P2041, DOI 10.3892/ijo.2014.2363
   Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456
   Wang S, 2016, CELL REPROGRAM, V18, P319, DOI 10.1089/cell.2016.0001
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wang X, 2016, J HEPATOL, V64, P1283, DOI 10.1016/j.jhep.2016.01.019
   Wei SQ, 2019, INT J IMMUNOPATH PH, V33, DOI 10.1177/2058738419859699
   Wu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2426-z
   Wu MJ, 2020, PEERJ, V8, DOI 10.7717/peerj.8961
   Xi ZW, 2019, INT J ONCOL, V54, P239, DOI 10.3892/ijo.2018.4609
   Xia H, 2018, EUR REV MED PHARMACO, V22, P1020, DOI 10.26355/eurrev_201802_14384
   Xiong H, 2017, ONCOGENE, V36, P3528, DOI 10.1038/onc.2016.521
   Xu S, 2016, ONCOL REP, V36, P10, DOI 10.3892/or.2016.4791
   Yang C, 2019, GENE, V687, P73, DOI 10.1016/j.gene.2018.10.087
   Yang C, 2019, J LEUKOCYTE BIOL, V105, P63, DOI 10.1002/JLB.1RU0518-197RR
   Yang Y, 2018, HUM CELL, V31, P232, DOI 10.1007/s13577-018-0206-1
   Yang YH, 2018, ONCOTARGETS THER, V11, P3649, DOI 10.2147/OTT.S165290
   Ye YB, 2018, J CELL BIOCHEM, V119, P2951, DOI 10.1002/jcb.26509
   Yin DH, 2020, ONCOTARGETS THER, V13, P7111, DOI 10.2147/OTT.S243542
   You J, 2014, INDIAN J CANCER, V51, P77, DOI 10.4103/0019-509X.154055
   Yu XF, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3731-5
   Yuan ZN, 2019, J CELL PHYSIOL, V234, P23111, DOI 10.1002/jcp.28874
   Zhang DX, 2018, SEMIN CANCER BIOL, V52, P94, DOI 10.1016/j.semcancer.2018.05.001
   Zhang GX, 2019, J CELL PHYSIOL, V234, P13097, DOI 10.1002/jcp.27980
   Zhang H, 2016, HEPATOLOGY, V64, P1033, DOI 10.1002/hep.28698
   Zhang PH, 2019, MED MOL MORPHOL, V52, P114, DOI 10.1007/s00795-018-0209-8
   Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0
   Zhang W, 2020, AM J REPROD IMMUNOL, V83, DOI 10.1111/aji.13239
   Zhang YQ, 2020, BREAST CANCER-TOKYO, V27, P573, DOI 10.1007/s12282-020-01048-5
   Zhang Y, 2019, MOL THER-NUCL ACIDS, V17, P362, DOI 10.1016/j.omtn.2019.05.030
   Zhang YF, 2020, LIFE SCI, V244, DOI 10.1016/j.lfs.2020.117280
   Zhao LN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1886-5
   Zhao YC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1375-9
   Zhou QF, 2018, J CANCER, V9, P2436, DOI 10.7150/jca.24796
   Zhu MZ, 2019, BMC COMPLEM ALTERN M, V19, DOI 10.1186/s12906-019-2577-6
NR 100
TC 29
Z9 33
U1 0
U2 27
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAR 1
PY 2021
VL 500
BP 244
EP 252
DI 10.1016/j.canlet.2020.11.010
EA JAN 2021
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PR4II
UT WOS:000607200800023
PM 33242560
DA 2025-01-04
ER

PT J
AU Abas, MDM
   Asri, MFM
   Yusafawi, NAS
   Rosman, NAZ
   Baharudin, NAZ
   Taher, M
   Susanti, D
   Khotib, J
AF Abas, Muhammad Dhiyauddin Mohd
   Asri, Muhammad Fareez Mohd
   Yusafawi, Nur Anis Suffiah
   Rosman, Nur Anis Zahra
   Baharudin, Nur Arifah Zahidah
   Taher, Muhammad
   Susanti, Deny
   Khotib, Junaidi
TI Advancements of gene therapy in cancer treatment: A comprehensive review
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Review
DE Breast cancer; Lung cancer; Colon cancer; Cancer treatment; Gene
   therapy; Gene delivery; Gene vectors
ID MESENCHYMAL STEM-CELLS; BREAST-CANCER; ONCOLYTIC VIRUS; COLON-CANCER;
   RISK-FACTORS; SMOKING; VECTORS
AB Cancer is the main contributor for mortality in the world. Conventional therapy that available as the treatment options are chemotherapy, radiotherapy and surgery. However, these treatments are hardly cell-specific most of the time. Nowadays, extensive research and investigations are made to develop cell-specific approaches prior to cancer treatment. Some of them are photodynamic therapy, hyperthermia, immunotherapy, stem cell transplantation and targeted therapy. This review article will be focusing on the development of gene therapy in cancer. The objective of gene therapy is to correct specific mutant genes causing the excessive proliferation of the cell that leads to cancer. There are lots of explorations in the approach to modify the gene. The delivery of this therapy plays a big role in its success. If the inserted gene does not find its way to the target, the therapy is considered a failure. Hence, vectors are needed and the common vectors used are viral, non viral or synthetic, polymer based and lipid based vectors. The advancement of gene therapy in cancer treatment will be focussing on the top three cancer cases in the world which are breast, lung and colon cancer. In breast cancer, the discussed therapy are CRISPR/Cas9, siRNA and gene silencing whereas in colon cancer miRNA and suicide gene therapy and in lung cancer, replacement of tumor suppressor gene, CRISPR/Cas9 and miRNA.
C1 [Abas, Muhammad Dhiyauddin Mohd; Asri, Muhammad Fareez Mohd; Yusafawi, Nur Anis Suffiah; Rosman, Nur Anis Zahra; Baharudin, Nur Arifah Zahidah; Taher, Muhammad] Int Islamic Univ Malaysia, Fac Pharm, Dept Pharmaceut Technol, Jalan Sultan Ahmad Shah, Kuantan 25200, Pahang, Malaysia.
   [Susanti, Deny] Int Islamic Univ Malaysia, Fac Sci, Dept Chem, Jalan Sultan Ahmad Shah, Kuantan 25200, Pahang, Malaysia.
   [Khotib, Junaidi] Airlangga Univ, Fac Pharm, Dept Pharm Practice, Surabaya 60115, Indonesia.
C3 International Islamic University Malaysia; International Islamic
   University Malaysia; Airlangga University
RP Taher, M (corresponding author), Int Islamic Univ Malaysia, Fac Pharm, Dept Pharmaceut Technol, Jalan Sultan Ahmad Shah, Kuantan 25200, Pahang, Malaysia.; Susanti, D (corresponding author), Int Islamic Univ Malaysia, Fac Sci, Dept Chem, Jalan Sultan Ahmad Shah, Kuantan 25200, Pahang, Malaysia.; Khotib, J (corresponding author), Airlangga Univ, Fac Pharm, Dept Pharm Practice, Surabaya 60115, Indonesia.
EM mtaher@iium.edu.my; deny@iium.edu.my; junaidi-k@ff.unair.ac.id
RI Khotib, Junaidi/AAJ-7238-2020
FU Research Scheme IRCON ARF Universitas Airlangga 2014
FX This study was supported by Research Scheme IRCON ARF Universitas
   Airlangga 2014.
CR Ahmed M, 2020, GASTROENTEROL RES, V13, P1, DOI 10.14740/gr1239
   Akhtar N, 2017, CURR PROB CANCER, V41, P328, DOI 10.1016/j.currproblcancer.2017.07.002
   Alkhaifi M, 2022, J BREAST CANCER, V25, P278, DOI 10.4048/jbc.2022.25.e23
   Altorki N, 2023, NEW ENGL J MED, V388, P489, DOI 10.1056/NEJMoa2212083
   AM Azizah M., Malaysia National CancerRegistry Report 2012-2016.2019
   American Cancer Society, 2021, about us
   Amitay EL, 2020, BRIT J CANCER, V122, P1604, DOI 10.1038/s41416-020-0803-0
   Arabi F, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113324
   Atiya H, 2020, ADV EXP MED BIOL, V1234, P31, DOI 10.1007/978-3-030-37184-5_3
   Ay C, 2024, WIEN KLIN WOCHENSCHR, DOI 10.1007/s00508-024-02368-8
   Bao CJ, 2023, NANO-MICRO LETT, V15, DOI 10.1007/s40820-023-01153-y
   Blackburn MR, 2012, J IMMUNOL, V188, P933, DOI 10.4049/jimmunol.1103519
   Botteri E, 2020, AM J GASTROENTEROL, V115, P1940, DOI 10.14309/ajg.0000000000000803
   Buck J, 2019, ACS NANO, V13, P3754, DOI 10.1021/acsnano.8b07858
   Bulcha JT, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00487-6
   Butt MH, 2022, GENES-BASEL, V13, DOI 10.3390/genes13081370
   Cardano M, 2020, CURR CANCER DRUG TAR, V20, P240, DOI 10.2174/1568009620666200115162814
   Carr Alaina L, 2023, PEC Innov, V3, P100226, DOI 10.1016/j.pecinn.2023.100226
   Castro D, 2017, ONCOTARGET, V8, P81679, DOI 10.18632/oncotarget.20955
   Centers for Disease Control Prevention, 2023, About us
   Cesur-Erguen B, 2023, J GENE MED, V25, DOI 10.1002/jgm.3550
   Chan HK, 2014, ASIAN PAC J CANCER P, V15, P5305, DOI 10.7314/APJCP.2014.15.13.5305
   Chaudhary S, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22784
   Chen CK, 2020, INT J NANOMED, V15, P2131, DOI 10.2147/IJN.S222419
   Dastjerd NT, 2022, CELL BIOCHEM FUNCT, V40, P28, DOI 10.1002/cbf.3676
   Del Pup L, 2019, CRIT REV ONCOL HEMAT, V137, P123, DOI 10.1016/j.critrevonc.2019.03.001
   Deng F, 2017, ONCOL LETT, V13, P2359, DOI 10.3892/ol.2017.5711
   Deng HY, 2019, MOL THER ONCOLYTICS, V14, P266, DOI 10.1016/j.omto.2019.07.003
   Durand S, 2011, VIRUSES-BASEL, V3, P132, DOI 10.3390/v3020132
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Fukuhara H, 2016, CANCER SCI, V107, P1373, DOI 10.1111/cas.13027
   Gallardo J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22105240
   García-Fernández C, 2020, CANCERS, V12, DOI 10.3390/cancers12061609
   Gardezi SJS, 2019, J MED INTERNET RES, V21, DOI 10.2196/14464
   Gasperino J, 2011, MED HYPOTHESES, V76, P328, DOI 10.1016/j.mehy.2010.10.030
   Ghafouri-Fard S, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.658636
   Giaquinto AN, 2022, CA-CANCER J CLIN, V72, P524, DOI 10.3322/caac.21754
   Gibbons DL, 2014, MOL CANCER RES, V12, P3, DOI 10.1158/1541-7786.MCR-13-0539
   Godbey W.T., 2014, An Introduction to Biotechnology: The Science, Technology and Medical Applications
   Guo CT, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1143157
   He SH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00283-8
   Hernanda PY, 2015, ONCOGENE, V34, P5055, DOI 10.1038/onc.2014.425
   Herzog R.W., 2020, Fast Facts: Gene Ther, DOI [10.1159/isbn.978-3-318-06667-8, DOI 10.1159/ISBN.978-3-318-06667-8]
   Hsu LH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18081713
   Huang J, 2018, THORAC CANCER, V9, P745, DOI 10.1111/1759-7714.12637
   Iqbal MA, 2019, MOL ASPECTS MED, V70, P3, DOI 10.1016/j.mam.2018.07.003
   Kadota T, 2018, MOL ASPECTS MED, V60, P92, DOI 10.1016/j.mam.2017.11.005
   Karn V, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935-022-02654-3
   Katsaounou K, 2022, METABOLITES, V12, DOI 10.3390/metabo12060499
   Katta B, 2023, CUREUS J MED SCIENCE, V15, DOI 10.7759/cureus.38301
   Kooshkaki O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072578
   Kooti W, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.761015
   Kusnierczyk P, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1063716
   Lara-Guerra Humberto, 2016, Critical Reviews in Oncogenesis, V21, P115, DOI 10.1615/CritRevOncog.2016016084
   Lawis MRM, 2023, BMC PUBLIC HEALTH, V23, DOI 10.1186/s12889-023-16833-y
   Lega IC, 2020, ENDOCR REV, V41, P33, DOI 10.1210/endrev/bnz014
   Leong B.D.K., 2009, Malays.: a Probl. Lack. Aware. Singap. Med J., V50, P772
   Liu BL, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392-024-01856-7
   Liu GB, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18020367
   Milone MC, 2018, LEUKEMIA, V32, P1529, DOI 10.1038/s41375-018-0106-0
   Ministry of Health Malaysia, 2019, Clinical Practice Guidelines, V3
   Momenimovahed Z, 2019, BREAST CANCER-TARGET, V11, P151, DOI 10.2147/BCTT.S176070
   Muthu V, 2019, LUNG INDIA, V36, P32, DOI 10.4103/lungindia.lungindia_321_17
   Naam R., 2005, The New York TimesJuly 3
   O'Driscoll J, 2023, EUR J RADIOL OPEN, V11, DOI 10.1016/j.ejro.2023.100510
   O'Keeffe LM, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2018-021611
   Ozaki Toshinori, 2011, Cancers (Basel), V3, P994, DOI 10.3390/cancers3010994
   Pastorakova A, 2020, CANCERS, V12, DOI 10.3390/cancers12051096
   Peng SH, 2023, SCI TOTAL ENVIRON, V903, DOI 10.1016/j.scitotenv.2023.166060
   Redman M, 2016, ARCH DIS CHILDHOOD-E, V101, P213, DOI 10.1136/archdischild-2016-310459
   Robles AI, 2002, ONCOGENE, V21, P6898, DOI 10.1038/sj.onc.1205563
   Rodriguez-Lara V., 2017, Endocrine Research, P1
   Rodriguez-Lara V, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.600121
   Ryu CH, 2012, BIOCHEM BIOPH RES CO, V421, P585, DOI 10.1016/j.bbrc.2012.04.050
   Schabath MB, 2019, CANCER EPIDEM BIOMAR, V28, P1563, DOI 10.1158/1055-9965.EPI-19-0221
   Sheng SH, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20181895
   Skolnik J., 2011, Encycl. Life Sci., DOI [10.1002/9780470015902.a0001475.pub2, DOI 10.1002/9780470015902.A0001475.PUB2]
   Song C, 2011, HUM GENE THER, V22, P439, DOI 10.1089/hum.2010.116
   Sun NH, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00210-3
   Tyagi A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20733-9
   Uddin Arif, 2018, J Cell Physiol, DOI 10.1002/jcp.26607
   Uddin F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01387
   Unnisa A, 2023, CURR NEUROPHARMACOL, V21, P1001, DOI 10.2174/1570159X20666220327222921
   Wahane A, 2020, MOLECULES, V25, DOI 10.3390/molecules25122866
   Wang MQ, 2023, BIOMED PHARMACOTHER, V160, DOI 10.1016/j.biopha.2023.114373
   Watkins EJ, 2019, JAAPA-J AM ACAD PHYS, V32, P13, DOI 10.1097/01.JAA.0000580524.95733.3d
   World Health Organization, 2022, CANCER
   World Health Organization WHO, 2023, About us
   Wu S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05467-z
   Xu FJ, 2011, PROG POLYM SCI, V36, P1099, DOI 10.1016/j.progpolymsci.2010.11.005
   Xue JX, 2022, BIOTECHNOL APPL BIOC, V69, P1166, DOI 10.1002/bab.2193
   Yang JY, 2019, CANCER MANAG RES, V11, P8443, DOI 10.2147/CMAR.S209880
   Yin H, 2014, NAT BIOTECHNOL, V32, P551, DOI 10.1038/nbt.2884
   Zarogoulidis P., 2013, J. Genet. Syndr. Gene Ther., V04, DOI [10.4172/2157-7412.1000139, DOI 10.4172/2157-7412.1000139]
   Zhang HM, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01431-6
   Zhang ZM, 2023, J CANCER RES CLIN, V149, P3447, DOI 10.1007/s00432-022-04266-w
   Zhao Y, 2014, ADV GENET, V88, P13, DOI 10.1016/B978-0-12-800148-6.00002-X
   Zheng CX, 2018, ANAT REC, V301, P825, DOI 10.1002/ar.23723
NR 98
TC 0
Z9 0
U1 19
U2 19
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
EI 1618-0631
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD SEP
PY 2024
VL 261
AR 155509
DI 10.1016/j.prp.2024.155509
EA AUG 2024
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA D0P1U
UT WOS:001293283300001
PM 39121791
DA 2025-01-04
ER

PT J
AU Lei, X
   He, QL
   Li, ZQ
   Zou, Q
   Xu, PR
   Yu, HB
   Ding, YL
   Zhu, W
AF Lei, Xue
   He, Qinglian
   Li, Ziqi
   Zou, Qian
   Xu, Pingrong
   Yu, Haibing
   Ding, Yuanlin
   Zhu, Wei
TI Cancer stem cells in colorectal cancer and the association with
   chemotherapy resistance
SO MEDICAL ONCOLOGY
LA English
DT Review
DE Colorectal cancer; Cancer stem cells; Surface markers; Chemotherapeutic
   resistance
ID EPITHELIAL-MESENCHYMAL TRANSITION; MULTIDRUG-RESISTANCE; BREAST-CANCER;
   HEMATOPOIETIC STEM; ABC TRANSPORTERS; TUMOR-GROWTH; SIGNALING PATHWAY;
   P-GLYCOPROTEIN; NOTCH PATHWAY; SELF-RENEWAL
AB The incidence and mortality of colorectal cancer (CRC) have always been among the highest in the world, although the diagnosis and treatment are becoming more and more advanced. At present, the main reason is that patients have acquired drug resistance after long-term conventional drug treatment. An increasing number of evidences confirm the existence of cancer stem cells (CSCs), which are a group of special cells in cancer, only a small part of cancer cells. These special cell populations are not eliminated by chemotherapeutic drugs and result in tumor recurrence and metastasis after drug treatment. CSCs have the ability of self-renewal and multidirectional differentiation, which is associated with the occurrence and development of cancer. CSCs can be screened and identified by related surface markers. In this paper, the characteristic surface markers of CSCs in CRC and the related mechanism of drug resistance will be discussed in detail. A better understanding of the mechanism of CSCs resistance to chemotherapy may lead to better targeted therapy.
C1 [Lei, Xue; He, Qinglian; Li, Ziqi; Zou, Qian; Xu, Pingrong; Zhu, Wei] Guangdong Med Univ, Dept Pathol, 1 Xincheng Rd, Dongguan 523808, Guangdong, Peoples R China.
   [Yu, Haibing; Ding, Yuanlin] Guangdong Med Univ, Sch Publ Hlth, Dongguan 523808, Guangdong, Peoples R China.
C3 Guangdong Medical University; Guangdong Medical University
RP Zhu, W (corresponding author), Guangdong Med Univ, Dept Pathol, 1 Xincheng Rd, Dongguan 523808, Guangdong, Peoples R China.
EM zhuwei@gdmu.edu.cn
RI Yu, Haibing/LWI-6746-2024; li, ziqi/JDC-9141-2023; 雷, 雪/ABD-3365-2020
OI Zhu, Wei/0000-0002-1217-1718
FU National Natural Science Foundation of China [81472275]; Natural Science
   Foundation of Guangdong Province [2020A151501303, 2014A030313542]; Major
   projects of key platforms for colleges and universities in Guangdong
   Province [2020KTSCX045, 2019KTSCX046]; Research Fund of Guangdong
   Medical University [GDMUZ2020001]
FX This work was supported by National Natural Science Foundation of China
   (81472275), Natural Science Foundation of Guangdong Province
   (2020A151501303, 2014A030313542), Major projects of key platforms for
   colleges and universities in Guangdong Province (2020KTSCX045,
   2019KTSCX046), and Research Fund of Guangdong Medical University
   (GDMUZ2020001).
CR Aghajani M, 2019, J CELL PHYSIOL, V234, P21642, DOI 10.1002/jcp.28824
   Akbari M, 2020, CELL BIOL INT, V44, P368, DOI 10.1002/cbin.11243
   Al-Othman Nihad, 2020, Breast Dis, V39, P1, DOI 10.3233/BD-190409
   Amawi H, 2019, ADV EXP MED BIOL, V1141, P549, DOI 10.1007/978-981-13-7647-4_12
   Andrei L, 2020, DRUG RESIST UPDATE, V48, DOI 10.1016/j.drup.2019.100658
   Ashley N, 2019, J PATHOL, V247, P293, DOI 10.1002/path.5179
   Ba-Sang DZ, 2016, ONCOTARGET, V7, P84468, DOI 10.18632/oncotarget.12994
   Baker A, 2018, ONCOGENE, V37, P4489, DOI 10.1038/s41388-018-0251-y
   Baker AM, 2015, SCI REP-UK, V5, DOI 10.1038/srep08654
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Basakran NS, 2015, SAUDI MED J, V36, P273, DOI 10.15537/smj.2015.3.9622
   Boddy AV, 2000, CLIN PHARMACOKINET, V38, P291, DOI 10.2165/00003088-200038040-00001
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Borst P, 2002, ANNU REV BIOCHEM, V71, P537, DOI 10.1146/annurev.biochem.71.102301.093055
   Cai Cheng, 2017, Zhejiang Da Xue Xue Bao Yi Xue Ban, V46, P36
   Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010
   Catalano V, 2012, EXPERT OPIN THER TAR, V16, P259, DOI 10.1517/14728222.2012.667404
   Chen ZS, 2011, FEBS J, V278, P3226, DOI 10.1111/j.1742-4658.2011.08235.x
   Cheng XF, 2019, BIOMED PHARMACOTHER, V110, P473, DOI 10.1016/j.biopha.2018.11.082
   Cheung TH, 2013, NAT REV MOL CELL BIO, V14, P329, DOI 10.1038/nrm3591
   Chikazawa N, 2010, ANTICANCER RES, V30, P2041
   Choi JE, 2017, ONCOL REP, V38, P1695, DOI 10.3892/or.2017.5790
   Collins AT, 2005, CANCER RES, V65, P10946, DOI 10.1158/0008-5472.CAN-05-2018
   Corbeil D, 2000, J BIOL CHEM, V275, P5512, DOI 10.1074/jbc.275.8.5512
   Corrêa S, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-303
   Cui HG, 2015, CURR DRUG TARGETS, V16, P1356, DOI 10.2174/1389450116666150330113506
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4
   Dontu G, 2004, TRENDS ENDOCRIN MET, V15, P193, DOI 10.1016/j.tem.2004.05.011
   Dou J, 2016, AM J TRANSL RES, V8, P98
   Doyle LA, 1998, P NATL ACAD SCI USA, V95, P15665, DOI 10.1073/pnas.95.26.15665
   El-Awady Raafat, 2016, Front Pharmacol, V7, P535, DOI 10.3389/fphar.2016.00535
   Fan CW, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.337
   Fanale D, 2016, ADV EXP MED BIOL, V937, P93, DOI 10.1007/978-3-319-42059-2_5
   Feng HL, 2018, BRIT J CANCER, V118, P224, DOI 10.1038/bjc.2017.363
   Flahaut M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2820-1
   Francescangeli F, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1505-4
   Fujita K, 2018, EXPERT OPIN THER TAR, V22, P123, DOI 10.1080/14728222.2018.1420167
   Galizia G, 2012, ARCH SURG-CHICAGO, V147, P18, DOI 10.1001/archsurg.2011.795
   Gansler T, 2010, CA-CANCER J CLIN, V60, P1, DOI [10.3322/caac.20073, 10.3322/caac.20049]
   Ghadi M, 2019, CURR PHARM DESIGN, V25, P4192
   Giebel B, 2004, BLOOD, V104, P2332, DOI 10.1182/blood-2004-02-0511
   Goel A., 2020, SEMIN CANCER BIOL
   Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118
   Goodell MA, 1996, J EXP MED, V183, P1797, DOI 10.1084/jem.183.4.1797
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Hatina J, 2019, ADV EXP MED BIOL, V1139, P201, DOI 10.1007/978-3-030-14366-4_12
   Hooijberg JH, 1999, CANCER RES, V59, P2532
   Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x
   Hu YB, 2019, ONCOGENE, V38, P1951, DOI 10.1038/s41388-018-0557-9
   Hu Y, 2017, ANTI-CANCER DRUG, V28, P243, DOI 10.1097/CAD.0000000000000455
   Huang R, 2015, MOL MED REP, V12, P2417, DOI 10.3892/mmr.2015.3694
   Hutvágner G, 2002, SCIENCE, V297, P2056, DOI 10.1126/science.1073827
   Itaba N, 2015, SCI REP-UK, V5, DOI 10.1038/srep16169
   Jang JW, 2017, LIFE SCI, V184, P25, DOI 10.1016/j.lfs.2017.07.008
   Johnson ZL, 2018, CELL, V172, P81, DOI 10.1016/j.cell.2017.12.005
   Kashii-Magaribuchi K, 2016, ACTA HISTOCHEM CYTOC, V49, P149, DOI 10.1267/ahc.16031
   Khorrami S, 2015, IRAN J CANCER PREV, V8, DOI 10.17795/ijcp-3446
   Kim WT, 2017, BMB REP, V50, P285, DOI 10.5483/BMBRep.2017.50.6.039
   Kobayashi S, 2012, STEM CELLS, V30, P2631, DOI 10.1002/stem.1257
   Leonard GD, 2003, ONCOLOGIST, V8, P411, DOI 10.1634/theoncologist.8-5-411
   Leslie EM, 2005, TOXICOL APPL PHARM, V204, P216, DOI 10.1016/j.taap.2004.10.012
   Li LP, 2016, SCI REP-UK, V6, DOI 10.1038/srep20460
   Liu XD, 2019, ADV EXP MED BIOL, V1141, P13, DOI 10.1007/978-981-13-7647-4_2
   Liu YS, 2013, BIOMED PHARMACOTHER, V67, P791, DOI 10.1016/j.biopha.2013.08.001
   Luo M, 2020, WORLD J STEM CELLS, V12, DOI 10.4252/wjsc.v12.i11.1307
   Lv L, 2016, TUMOR BIOL, V37, P8811, DOI 10.1007/s13277-015-4755-6
   Ma LJ, 2016, TUMOR BIOL, V37, P12889, DOI 10.1007/s13277-016-5209-5
   Machida K, 2017, HEPATOL INT, V11, P143, DOI 10.1007/s12072-016-9777-7
   Mächtel R, 2019, RES MICROBIOL, V170, P321, DOI 10.1016/j.resmic.2019.09.004
   Mao QC, 2015, AAPS J, V17, P65, DOI 10.1208/s12248-014-9668-6
   Matzke-Ogi A, 2016, GASTROENTEROLOGY, V150, P513, DOI 10.1053/j.gastro.2015.10.020
   Maugeri-Saccà M, 2011, CLIN CANCER RES, V17, P4942, DOI 10.1158/1078-0432.CCR-10-2538
   McClanahan T, 2006, CANCER BIOL THER, V5, P419, DOI 10.4161/cbt.5.4.2521
   Mele L, 2018, METHODS MOL BIOL, V1692, P43, DOI 10.1007/978-1-4939-7401-6_4
   Meng RD, 2009, CANCER RES, V69, P573, DOI 10.1158/0008-5472.CAN-08-2088
   Morath I, 2016, INT J BIOCHEM CELL B, V81, P166, DOI 10.1016/j.biocel.2016.09.009
   Mordvinov VA, 2017, MOL BIOCHEM PARASIT, V216, P60, DOI 10.1016/j.molbiopara.2017.07.001
   Morgan RG, 2018, BRIT J CANCER, V118, P1410, DOI 10.1038/s41416-018-0118-6
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   Najafi M, 2019, J CELL PHYSIOL, V234, P8381, DOI 10.1002/jcp.27740
   Nasr R, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64400-x
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ouyang SR, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0784-3
   Pascolo L, 2003, BIOCHEM BIOPH RES CO, V303, P259, DOI 10.1016/S0006-291X(03)00327-9
   Peterson BG, 2017, PHARMACOL RES, V119, P313, DOI 10.1016/j.phrs.2017.02.024
   Polgar O, 2008, EXPERT OPIN DRUG MET, V4, P1, DOI [10.1517/17425255.4.1.1, 10.1517/17425255.4.1.1 ]
   Rahmani F, 2018, J CELL PHYSIOL, V233, P811, DOI 10.1002/jcp.25897
   Samanta D, 2014, P NATL ACAD SCI USA, V111, pE5429, DOI 10.1073/pnas.1421438111
   Sand A, 2020, CANCER LETT, V472, P119, DOI 10.1016/j.canlet.2019.12.023
   Sarkadi B, 2020, FEBS LETT, V594, P4012, DOI 10.1002/1873-3468.13947
   Shen WW, 2013, J MOL MED, V91, P989, DOI 10.1007/s00109-013-1037-x
   Siemens H, 2013, ONCOTARGET, V4, P1399, DOI 10.18632/oncotarget.1202
   Soeda A, 2009, ONCOGENE, V28, P3949, DOI 10.1038/onc.2009.252
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-96
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063
   Toden S, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125294
   Toden S, 2015, CARCINOGENESIS, V36, P355, DOI 10.1093/carcin/bgv006
   Toledo-Guzmán ME, 2019, CURR STEM CELL RES T, V14, P375, DOI 10.2174/1574888X13666180810120012
   Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920
   Urushibara S, 2017, ANTICANCER RES, V37, P4085, DOI 10.21873/anticanres.11795
   Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1
   Vasiliou V, 2004, DRUG METAB REV, V36, P279, DOI 10.1081/DMR-120034001
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Vinson KE, 2016, INT J CANCER, V138, P1835, DOI 10.1002/ijc.29800
   Vira D, 2012, CANCER METAST REV, V31, P733, DOI 10.1007/s10555-012-9382-8
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang J, 2015, DRUG DEVELOP RES, V76, P368, DOI 10.1002/ddr.21275
   Wang L, 2018, METHODS MOL BIOL, V1692, P31, DOI 10.1007/978-1-4939-7401-6_3
   Wang XK, 2014, CANCER RES, V74, P4431, DOI 10.1158/0008-5472.CAN-13-3553
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(19)32319-0
   Wong SHM, 2018, CRIT REV ONCOL HEMAT, V121, P11, DOI 10.1016/j.critrevonc.2017.11.010
   Wu WD, 2016, ONCOTARGET, V7, P81144, DOI 10.18632/oncotarget.13214
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu XT, 2012, BRIT J CANCER, V106, P1320, DOI 10.1038/bjc.2012.88
   Yaghjyan L, 2019, CANCER CAUSE CONTROL, V30, P1103, DOI 10.1007/s10552-019-01207-w
   Yamada T, 2000, CANCER RES, V60, P4761
   Ye J, 2017, MOL MED REP, V15, P1037, DOI 10.3892/mmr.2017.6135
   Yeung TM, 2010, P NATL ACAD SCI USA, V107, P3722, DOI 10.1073/pnas.0915135107
   Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011
   Yu YJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0725-5
   Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7
   Yu YJ, 2013, TRANSL ONCOL, V6, P180, DOI 10.1593/tlo.12397
   Yu YJ, 2012, CARCINOGENESIS, V33, P68, DOI 10.1093/carcin/bgr246
   Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522
   Zhao YC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1375-9
   Zhou H, 2020, J CELL BIOCHEM, V121, P2510, DOI 10.1002/jcb.29473
   Zhou S, 2001, NAT MED, V7, P1028, DOI 10.1038/nm0901-1028
   Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607
   Zolnerciks JK, 2014, FASEB J, V28, P4335, DOI 10.1096/fj.13-245639
NR 135
TC 29
Z9 30
U1 1
U2 14
PU HUMANA PRESS INC
PI TOTOWA
PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA
SN 1357-0560
EI 1559-131X
J9 MED ONCOL
JI Med. Oncol.
PD APR
PY 2021
VL 38
IS 4
AR 43
DI 10.1007/s12032-021-01488-9
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QY9PI
UT WOS:000630367500001
PM 33738588
DA 2025-01-04
ER

PT J
AU Li, JS
   Su, XL
   Dai, L
   Chen, N
   Fang, C
   Dong, ZX
   Fu, JM
   Yu, Y
   Wang, WS
   Zhang, HT
   Wang, HL
   Ji, YH
   Liu, Y
   Cheng, L
   Shi, G
   Zhang, S
   Yang, Y
   Deng, HX
AF Li, Junshu
   Su, Xiaolan
   Dai, Lei
   Chen, Na
   Fang, Chao
   Dong, Zhexu
   Fu, Jiamei
   Yu, Yan
   Wang, Wenshuang
   Zhang, Hantao
   Wang, Huiling
   Ji, Yanhong
   Liu, Yi
   Cheng, Lin
   Shi, Gang
   Zhang, Shuang
   Yang, Yang
   Deng, Hongxin
TI Temporal DNA methylation pattern and targeted therapy in
   colitis-associated cancer
SO CARCINOGENESIS
LA English
DT Article
ID COLORECTAL NEOPLASIA; COLON; EXPRESSION; CELLS; RISK; GENE; BAD;
   INFLAMMATION; EPIGENETICS; PROGRESSION
AB DNA methylation plays a crucial role in the pathogenesis of various diseases, including colorectal cancer (CRC). However, the global and temporal DNA methylation pattern during initiation and progression of colitis-associated cancer (CAC) are still unknown, including the potential therapeutic strategy of targeting methylation for CAC. In the present study, the global DNA methylation pattern was determined at different time points during CAC using DNA methylation sequencing, followed by the Starburst plot integrating alterations and potential functional prediction analysis. After demonstrating the regulatory role of DNA methyltransferases (DNMTs) on the expression of hub-genes in CRC cells, DNMT inhibitors were administered to treat CAC mice. Our results indicated that 811 genes were hypermethylated at different time points during initiation and progression of CAC. Genes that were downregulated and hypermethylated during CAC, including hub-genes BAD and inositol polyphosphate phosphatase-like 1 (INPPL1), were involved in MAPK signaling pathways, kit receptor signaling pathways, apoptosis and EGF/EGFR signaling pathways. Upregulated DNMTs (DNMT1, DNMT3A and DNMT3B) mediated downregulation and hypermethylation of BAD and INPPL1 in CAC and CRC cells. Low doses of DNMT inhibitors (decitabine (DAC) and azacitidine (AZA)) exerted efficient antitumor effects in CAC, accompanied with upregulation of BAD and INPPL1 expression, and apoptosis induction. In summary, the present study demonstrates the temporal DNA methylation pattern during CAC and provides a novel therapeutic strategy for treating this disease.
C1 [Li, Junshu; Su, Xiaolan; Dai, Lei; Chen, Na; Fang, Chao; Dong, Zhexu; Fu, Jiamei; Yu, Yan; Wang, Wenshuang; Zhang, Hantao; Wang, Huiling; Ji, Yanhong; Liu, Yi; Cheng, Lin; Shi, Gang; Yang, Yang; Deng, Hongxin] Sichuan Univ, State Key Lab Biotherapy, Ke Yuan Rd 4,1 Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
   [Li, Junshu; Su, Xiaolan; Dai, Lei; Chen, Na; Dong, Zhexu; Fu, Jiamei; Yu, Yan; Wang, Wenshuang; Zhang, Hantao; Wang, Huiling; Ji, Yanhong; Liu, Yi; Cheng, Lin; Shi, Gang; Zhang, Shuang; Yang, Yang; Deng, Hongxin] Sichuan Univ, West China Hosp, Ctr Canc, Ke Yuan Rd 4,1 Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
   [Li, Junshu; Su, Xiaolan; Dai, Lei; Chen, Na; Dong, Zhexu; Fu, Jiamei; Yu, Yan; Wang, Wenshuang; Zhang, Hantao; Wang, Huiling; Ji, Yanhong; Liu, Yi; Cheng, Lin; Shi, Gang; Zhang, Shuang; Yang, Yang; Deng, Hongxin] Collaborat Innovat Ctr Biotherapy, Ke Yuan Rd 4,1 Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
   [Fang, Chao] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Dai, L; Deng, HX (corresponding author), Sichuan Univ, State Key Lab Biotherapy, Ke Yuan Rd 4,1 Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.; Dai, L; Deng, HX (corresponding author), Sichuan Univ, West China Hosp, Ctr Canc, Ke Yuan Rd 4,1 Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.; Dai, L; Deng, HX (corresponding author), Collaborat Innovat Ctr Biotherapy, Ke Yuan Rd 4,1 Gao Peng St, Chengdu 610041, Sichuan, Peoples R China.
EM dailei2016@scu.edu.cn; denghongx@scu.edu.cn
RI jiang, lei/IWE-1124-2023; Fang, Chao/AFG-2861-2022; Yu,
   Yan/HCG-9743-2022; Liu, Yiqi/KFR-3869-2024
OI Ji, Yanhong/0000-0003-2782-6825
FU National Natural Science Foundation of China Program grant [81702349,
   81772939]; National Key R&D Program of China [2017YFA0105702];
   Postdoctoral Foundation of China [2017M612974]; Fundamental Research
   Funds for the Central Universities [2017SCU12033]; Special Foundation of
   China Postdoctoral Science [2018T110980]; Post-Doctor Research Project,
   West China Hospital, Sichuan University [2019HXBH033]
FX This study was supported by the National Natural Science Foundation of
   China Program grant (81702349, 81772939); the National Key R&D Program
   of China grant (2017YFA0105702); the Postdoctoral Foundation of China
   (2017M612974); the Fundamental Research Funds for the Central
   Universities (2017SCU12033); the Special Foundation of China
   Postdoctoral Science (2018T110980); Post-Doctor Research Project, West
   China Hospital, Sichuan University (2019HXBH033).
CR Alam KJ, 2017, INT J CANCER, V141, P1614, DOI 10.1002/ijc.30861
   Andersen GB, 2018, METHODS MOL BIOL, V1708, P3, DOI 10.1007/978-1-4939-7481-8_1
   Brandes JC, 2005, CARCINOGENESIS, V26, P1152, DOI 10.1093/carcin/bgi058
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Buysschaert I, 2008, J CELL MOL MED, V12, P2533, DOI 10.1111/j.1582-4934.2008.00515.x
   Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x
   Cao XH, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00512
   Chen EC, 2015, GASTROENTEROLOGY, V149, P705, DOI 10.1053/j.gastro.2015.05.042
   Dumitrescu RG, 2018, METHODS MOL BIOL, V1856, P3, DOI 10.1007/978-1-4939-8751-1_1
   Dziaman T, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0505-0
   Eaden J, 2004, ALIMENT PHARM THER, V20, P24, DOI 10.1111/j.1365-2036.2004.02046.x
   Fujii S, 2010, DIGESTION, V82, P179, DOI 10.1159/000311064
   Gupta RB, 2007, GASTROENTEROLOGY, V133, P1099, DOI 10.1053/j.gastro.2007.08.001
   Huang YS, 2018, INT J MOL MED, V41, P1397, DOI 10.3892/ijmm.2017.3345
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
   Katsurano M, 2012, ONCOGENE, V31, P342, DOI 10.1038/onc.2011.241
   Kellermayer R, 2017, EPIGENOMICS-UK, V9, P527, DOI 10.2217/epi-2016-0155
   KRAAK LVD, 2015, WORLD J GASTROENTERO, V21, P11688
   Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384
   Li BQ, 2017, ONCOL LETT, V14, P2315, DOI 10.3892/ol.2017.6455
   Lin YC, 2015, NEW ENGL J MED, V373, P194, DOI 10.1056/NEJMc1505689
   Lind GE, 2004, MOL CANCER, V3, DOI 10.1186/1476-4598-3-28
   Lou YT, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0123973
   Lu P, 2019, MOL PHARMACEUT, V16, P3386, DOI 10.1021/acs.molpharmaceut.9b00136
   Maiuri AR, 2019, EPIGENETICS-US, V14, P1209, DOI 10.1080/15592294.2019.1634986
   Nakamura K, 2015, ANTICANCER RES, V35, P1411
   Pfütze K, 2015, GENOMICS, V106, P348, DOI 10.1016/j.ygeno.2015.10.002
   Popivanova BK, 2007, CANCER SCI, V98, P321, DOI 10.1111/j.1349-7006.2007.00390.x
   RADHIKA D, 2018, CURR ENV HLTH REP, V5, P317
   Schulz WA, 2006, J CELL MOL MED, V10, P100, DOI 10.1111/j.1582-4934.2006.tb00293.x
   Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033
   Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7
   Subramaniam D, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00080
   Swets M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010036
   Tsai HC, 2012, CANCER CELL, V21, P430, DOI 10.1016/j.ccr.2011.12.029
   Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057
   Webster TMU, 2018, EPIGENETICS-US, V13, P1191, DOI 10.1080/15592294.2018.1554520
   Yang XJ, 2014, CANCER CELL, V26, P577, DOI 10.1016/j.ccr.2014.07.028
   Yu JH, 2018, EXP THER MED, V16, P847, DOI 10.3892/etm.2018.6250
   Zhang L, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20181228
   Zwaenepoel K, 2010, FASEB J, V24, P538, DOI 10.1096/fj.09-140228
NR 41
TC 15
Z9 16
U1 1
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD FEB
PY 2020
VL 41
IS 2
BP 235
EP 244
DI 10.1093/carcin/bgz199
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LT9DI
UT WOS:000537366000012
PM 31802101
OA Bronze
DA 2025-01-04
ER

PT J
AU Mueller, AL
   Brockmueller, A
   Fahimi, N
   Ghotbi, T
   Hashemi, S
   Sadri, S
   Khorshidi, N
   Kunnumakkara, AB
   Shakibaei, M
AF Mueller, Anna-Lena
   Brockmueller, Aranka
   Fahimi, Niusha
   Ghotbi, Tahere
   Hashemi, Sara
   Sadri, Sadaf
   Khorshidi, Negar
   Kunnumakkara, Ajaikumar B.
   Shakibaei, Mehdi
TI Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment
SO BIOMEDICINES
LA English
DT Review
DE colorectal cancer; biotherapeutical toxins; bacteriocins; bacterial
   peptides; bacteriotherapy; microbiota
ID NON-HDM2-MEDIATED PEPTIDE INHIBITOR; FECAL MICROBIOTA TRANSPLANTATION;
   TO-CELL SPREAD; GUT MICROBIOTA; COLON-CANCER; PSEUDOMONAS-AERUGINOSA;
   LISTERIA-MONOCYTOGENES; DRUG-METABOLISM; DELIVERY-SYSTEM;
   BIFIDOBACTERIUM-LONGUM
AB Colorectal cancer (CRC) is one of the most common tumors worldwide, with a higher rate of distant metastases than other malignancies and with regular occurrence of drug resistance. Therefore, scientists are forced to further develop novel and innovative therapeutic treatment strategies, whereby it has been discovered microorganisms, albeit linked to CRC pathogenesis, are able to act as highly selective CRC treatment agents. Consequently, researchers are increasingly focusing on bacteriotherapy as a novel therapeutic strategy with less or no side effects compared to standard cancer treatment methods. With multiple successful trials making use of various bacteria-associated mechanisms, bacteriotherapy in cancer treatment is on its way to become a promising tool in CRC targeting therapy. In this study, we describe the anti-cancer effects of bacterial therapy focusing on the treatment of CRC as well as diverse modulatory mechanisms and techniques that bacteriotherapy offers such as bacterial-related biotherapeutics including peptides, toxins, bacteriocins or the use of bacterial carriers and underlying molecular processes to target colorectal tumors.
C1 [Mueller, Anna-Lena; Brockmueller, Aranka; Shakibaei, Mehdi] Ludwig Maximilian Univ Munich, Fac Med, Inst Anat, Musculoskeletal Res Grp, D-80336 Munich, Germany.
   [Mueller, Anna-Lena; Brockmueller, Aranka; Shakibaei, Mehdi] Ludwig Maximilian Univ Munich, Fac Med, Inst Anat, Tumor Biol,Chair Vegetat Anat, D-80336 Munich, Germany.
   [Fahimi, Niusha] Comenius Univ, Fac Pharm, Bratislava 83232, Slovakia.
   [Ghotbi, Tahere] Shiraz Univ Med Sci, Dept Nursing, Shiraz 7134814336, Iran.
   [Hashemi, Sara] Islamic Azad Univ, Cent Tehran Branch, Tehran 1955847881, Iran.
   [Sadri, Sadaf] Univ Mazandaran, Dept Microbiol, Babolsar 4741613534, Iran.
   [Khorshidi, Negar] Islamic Azad Univ, Dept Med Chem, Med Sci Branch, Tehran 1913674711, Iran.
   [Kunnumakkara, Ajaikumar B.] Indian Inst Technol IIT Guwahati, Canc Biol Lab, Gauhati 781039, India.
   [Kunnumakkara, Ajaikumar B.] Indian Inst Technol IIT Guwahati, DBT AIST Int Ctr Translat & Environm Res DAICENTE, Dept Biosci & Bioengn, Gauhati 781039, India.
C3 University of Munich; University of Munich; Comenius University
   Bratislava; Shiraz University of Medical Science; Islamic Azad
   University; University of Mazandaran; Islamic Azad University; Indian
   Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT) - Guwahati
RP Shakibaei, M (corresponding author), Ludwig Maximilian Univ Munich, Fac Med, Inst Anat, Musculoskeletal Res Grp, D-80336 Munich, Germany.; Shakibaei, M (corresponding author), Ludwig Maximilian Univ Munich, Fac Med, Inst Anat, Tumor Biol,Chair Vegetat Anat, D-80336 Munich, Germany.
EM a.mueller@med.uni-muenchen.de; aranka.brockmueller@med.uni-muenchen.de;
   niyoosha.fahimi@yahoo.com; ghotbit@sums.ac.ir; shashemi336@gmail.com;
   dr.sf1376@gmail.com; n.khorshidi73@yahoo.com; kunnumakkara@iitg.ac.in;
   mehdi.shakibaei@med.uni-muenchen.de
RI Kunnumakkara, Ajaikumar/AAH-5214-2019; Shakibaei, Prof. Dr.
   Mehdi/AAA-7004-2020; Ghotbi, Tahere/AAD-6790-2020; Kunnumakkara,
   Ajaikumar/H-8566-2012
OI Brockmueller, Aranka/0000-0001-8101-2828; Kunnumakkara,
   Ajaikumar/0000-0001-9121-6816; Shakibaei, Prof. Dr.
   Mehdi/0000-0002-6304-7506
CR Aggarwal BB, 2006, BIOCHEM PHARMACOL, V72, P1605, DOI 10.1016/j.bcp.2006.06.029
   Agrawal S, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00828
   Ahmadi S, 2017, MICROB PATHOGENESIS, V111, P193, DOI 10.1016/j.micpath.2017.08.037
   Al-Hazmi NE, 2022, J GASTROINTEST CANC, V53, P537, DOI 10.1007/s12029-021-00654-6
   Ambalam P, 2016, BEST PRACT RES CL GA, V30, P119, DOI 10.1016/j.bpg.2016.02.009
   Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279
   Asolkar RN, 2010, J NAT PROD, V73, P796, DOI 10.1021/np900560x
   Azadi A, 2021, BIOL PROCED ONLINE, V23, DOI 10.1186/s12575-021-00147-7
   Baindara P, 2018, APPL MICROBIOL BIOT, V102, P10393, DOI 10.1007/s00253-018-9420-8
   Brandi G, 2006, CLIN CANCER RES, V12, P1299, DOI 10.1158/1078-0432.CCR-05-0750
   Brenner H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2467
   Brockmueller A, 2021, CANCERS, V13, DOI 10.3390/cancers13020188
   Buhrmann C, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.650603
   Buhrmann C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.699842
   Buhrmann C, 2020, MOLECULES, V25, DOI 10.3390/molecules25184292
   Buhrmann C, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8080236
   Buhrmann C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072393
   Buhrmann C, 2017, NUTRIENTS, V9, DOI 10.3390/nu9101073
   Buhrmann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107514
   Buss GP, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0251951
   Byun WS, 2020, J NAT PROD, V83, P118, DOI 10.1021/acs.jnatprod.9b00918
   Candéias SM, 2016, ANTI-CANCER AGENT ME, V16, P101, DOI 10.2174/1871520615666150824153523
   Carneiro BA, 2020, NAT REV CLIN ONCOL, V17, P395, DOI 10.1038/s41571-020-0341-y
   Céspedes MV, 2020, ADV MATER, V32, DOI 10.1002/adma.201907348
   Chassaing Benoit, 2014, Biomed J, V37, P246, DOI 10.4103/2319-4170.130922
   Cheng YW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615056
   Cho JY, 2007, J NAT PROD, V70, P1321, DOI 10.1021/np070101b
   Choi SS, 2005, J MICROBIOL, V43, P493
   Chumchalová J, 2003, FOLIA MICROBIOL, V48, P111, DOI 10.1007/BF02931286
   Ciorba MA, 2012, GUT, V61, P829, DOI 10.1136/gutjnl-2011-300367
   Clara JA, 2020, NAT REV CLIN ONCOL, V17, P204, DOI 10.1038/s41571-019-0293-2
   Cui M, 2017, EMBO MOL MED, V9, P448, DOI 10.15252/emmm.201606932
   Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698
   Dasgupta D, 2015, APPL MICROBIOL BIOT, V99, P8653, DOI 10.1007/s00253-015-6707-x
   De Almeida CV, 2019, WORLD J GASTROENTERO, V25, P151, DOI 10.3748/wjg.v25.i2.151
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Drider D, 2016, PROBIOTICS ANTIMICRO, V8, P177, DOI 10.1007/s12602-016-9223-0
   Dzutsev A, 2015, EUR J IMMUNOL, V45, P17, DOI 10.1002/eji.201444972
   Ebrahimzadeh S, 2021, BMC MICROBIOL, V21, DOI 10.1186/s12866-021-02274-3
   EISEMAN B, 1958, SURGERY, V44, P854
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Elyasifar B, 2019, PHARM SCI-IRAN, V25, P70, DOI 10.15171/PS.2019.11
   Erdman SE, 2003, CANCER RES, V63, P6042
   Field K, 2007, WORLD J GASTROENTERO, V13, P3806
   Fong WN, 2020, ONCOGENE, V39, P4925, DOI 10.1038/s41388-020-1341-1
   Foti RS, 2015, DRUG METAB DISPOS, V43, P1156, DOI 10.1124/dmd.115.064576
   Fox ME, 1996, GENE THER, V3, P173
   Fujiwara-Tani Rina, 2018, Oncotarget, V9, P37367, DOI 10.18632/oncotarget.26427
   Gagnière J, 2016, WORLD J GASTROENTERO, V22, P501, DOI 10.3748/wjg.v22.i2.501
   Gang W, 2018, CANCER MED-US, V7, P1578, DOI 10.1002/cam4.1386
   Gao M, 2017, PROTEIN SCI, V26, P2334, DOI 10.1002/pro.3310
   Gao R, 2017, EUR J CLIN MICROBIOL, V36, P757, DOI 10.1007/s10096-016-2881-8
   Garizo AR, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091194
   Gedde MM, 2000, INFECT IMMUN, V68, P999, DOI 10.1128/IAI.68.2.999-1003.2000
   Goldberg RM, 2007, ONCOLOGIST, V12, P38, DOI 10.1634/theoncologist.12-1-38
   Gunn GR, 2001, J IMMUNOL, V167, P6471, DOI 10.4049/jimmunol.167.11.6471
   Gupta S, 2016, THER ADV GASTROENTER, V9, P229, DOI 10.1177/1756283X15607414
   Guthrie L, 2019, ELIFE, V8, DOI 10.7554/eLife.42866
   Haiser HJ, 2013, SCIENCE, V341, P295, DOI 10.1126/science.1235872
   Han S, 2021, NATURE, V595, P415, DOI 10.1038/s41586-021-03707-9
   Hetz C, 2002, P NATL ACAD SCI USA, V99, P2696, DOI 10.1073/pnas.052709699
   IGLEWSKI BH, 1975, P NATL ACAD SCI USA, V72, P2284, DOI 10.1073/pnas.72.6.2284
   Igney FH, 2002, NAT REV CANCER, V2, P277, DOI 10.1038/nrc776
   Iida N, 2013, SCIENCE, V342, P967, DOI 10.1126/science.1240527
   Jacouton E, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01553
   Jariwala PB, 2020, ACS CHEM BIOL, V15, P217, DOI 10.1021/acschembio.9b00788
   Javdan B, 2020, CELL, V181, P1661, DOI 10.1016/j.cell.2020.05.001
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jenab A, 2020, DRUG DES DEV THER, V14, P3787, DOI 10.2147/DDDT.S261283
   Jia LJ, 2005, CANCER BIOL THER, V4, P840, DOI 10.4161/cbt.4.8.1891
   Johnson CH, 2015, CELL METAB, V21, P891, DOI 10.1016/j.cmet.2015.04.011
   Kanoh K, 2005, J ANTIBIOT, V58, P289, DOI 10.1038/ja.2005.36
   Karpinski TM, 2018, PHARMACEUTICS, V10, DOI 10.3390/pharmaceutics10020054
   Kasai C, 2016, ONCOL REP, V35, P325, DOI 10.3892/or.2015.4398
   Kasper SH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62139-z
   Kennedy RK, 2015, CHEM-BIOL INTERACT, V231, P71, DOI 10.1016/j.cbi.2015.03.002
   Kim E, 2021, FRONT MICROBIOL, V12, DOI 10.3389/fmicb.2021.626881
   Kinnari TJ, 2015, CURR OPIN OTOLARYNGO, V23, P448, DOI 10.1097/MOO.0000000000000200
   Kohoutova D, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6512-5
   Komor U, 2012, MICROBES INFECT, V14, P951, DOI 10.1016/j.micinf.2012.04.002
   Kong J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19313-8
   Kucerova P, 2016, ANTI-CANCER DRUG, V27, P269, DOI 10.1097/CAD.0000000000000337
   Lagos R, 2009, CURR PHARM BIOTECHNO, V10, P74, DOI 10.2174/138920109787048643
   Laliani G, 2020, LIFE SCI, V246, DOI 10.1016/j.lfs.2020.117398
   Lancaster LE, 2007, BLOOD CELL MOL DIS, V38, P15, DOI 10.1016/j.bcmd.2006.10.006
   Lee DK, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-310
   Leone RD, 2020, NAT REV CANCER, V20, P516, DOI 10.1038/s41568-020-0273-y
   Leschner S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006692
   Lewies A, 2018, Cytotoxicity, V21, DOI [10.5772/intechopen.71927, DOI 10.5772/INTECHOPEN.71927]
   Li H, 2013, CLIN PHARMACOL THER, V94, P574, DOI 10.1038/clpt.2013.157
   Li X, 2003, CANCER GENE THER, V10, P105, DOI 10.1038/sj.cgt.7700530
   Liscano Y, 2020, MOLECULES, V25, DOI 10.3390/molecules25184245
   Loeffler DIM, 2006, INFECT IMMUN, V74, P3946, DOI 10.1128/IAI.00112-06
   Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344
   Lucas C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061310
   Ludgate CM, 2012, CLIN CANCER RES, V18, P4522, DOI 10.1158/1078-0432.CCR-12-1175
   Lulla RR, 2016, NEURO-ONCOLOGY, V18, P1319, DOI 10.1093/neuonc/now047
   Lutz MB, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.28223
   Duong MTQ, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0297-0
   Maier L, 2018, NATURE, V555, P623, DOI 10.1038/nature25979
   Mantovani A, 2010, CURR MOL MED, V10, P369, DOI 10.2174/156652410791316968
   Martarelli D, 2009, CHEMOTHERAPY, V55, P425, DOI 10.1159/000264689
   Masso-Welch P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010085
   Matsuo Y, 2007, J ANTIBIOT, V60, P251, DOI 10.1038/ja.2007.30
   Mehta Ridhi, 2013, Recent Pat Biotechnol, V7, P172
   Mengesha A, 2007, FRONT BIOSCI-LANDMRK, V12, P3880, DOI 10.2741/2357
   Min JJ, 2008, MOL IMAGING BIOL, V10, P54, DOI 10.1007/s11307-007-0120-5
   Mitsala A, 2021, CURR ONCOL, V28, P1581, DOI 10.3390/curroncol28030149
   Miyake K, 1996, CYTOTECHNOLOGY, V22, P205, DOI 10.1007/BF00353940
   Mody K, 2018, CANCER J, V24, P165, DOI 10.1097/PPO.0000000000000328
   MOUNIER J, 1990, INFECT IMMUN, V58, P1048, DOI 10.1128/IAI.58.4.1048-1058.1990
   Muthukumaran S, 2017, BIOMED PHARMACOTHER, V86, P185, DOI 10.1016/j.biopha.2016.12.024
   Nes IF, 2000, BIOPOLYMERS, V55, P50, DOI 10.1002/1097-0282(2000)55:1<50::AID-BIP50>3.0.CO;2-3
   Netea MG, 2010, PLOS PATHOG, V6, DOI 10.1371/journal.ppat.1000661
   Nguyen VH, 2010, CANCER RES, V70, P18, DOI 10.1158/0008-5472.CAN-09-3453
   Niethammer AG, 2002, NAT MED, V8, P1369, DOI 10.1038/nm794
   Norouzi Z, 2018, MICROB PATHOGENESIS, V123, P183, DOI 10.1016/j.micpath.2018.07.006
   Nougayrède JP, 2005, TRENDS MICROBIOL, V13, P103, DOI 10.1016/j.tim.2005.01.002
   Okumura S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25965-x
   Pahle J, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3123-x
   Payandeh Z, 2020, J CELL PHYSIOL, V235, P5461, DOI 10.1002/jcp.29494
   Raman M, 2013, GUT MICROBES, V4, P181, DOI 10.4161/gmic.23919
   REDDY BS, 1977, CANCER-AM CANCER SOC, V39, P2533, DOI 10.1002/1097-0142(197706)39:6<2533::AID-CNCR2820390634>3.0.CO;2-X
   Riedl S, 2011, CHEM PHYS LIPIDS, V164, P766, DOI 10.1016/j.chemphyslip.2011.09.004
   Roy R, 2018, VIRULENCE, V9, P522, DOI 10.1080/21505594.2017.1313372
   Rubinstein MR, 2019, EMBO REP, V20, DOI 10.15252/embr.201847638
   Sakatani A, 2016, ANTICANCER RES, V36, P591
   Sambi M, 2017, BREAST CANCER-TARGET, V9, P85, DOI 10.2147/BCTT.S130838
   Sampson TR, 2015, CELL HOST MICROBE, V17, P565, DOI 10.1016/j.chom.2015.04.011
   Sasaki T, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21113877
   Sender R, 2016, PLOS BIOL, V14, DOI 10.1371/journal.pbio.1002533
   Seyfi R, 2020, INT J PEPT RES THER, V26, P1451, DOI 10.1007/s10989-019-09946-9
   Shahabi V, 2011, CANCER GENE THER, V18, P53, DOI 10.1038/cgt.2010.48
   Shakibaei M, 2005, ANTIOXID REDOX SIGN, V7, P482, DOI 10.1089/ars.2005.7.482
   Shapira S, 2011, GASTROENTEROLOGY, V140, P935, DOI 10.1053/j.gastro.2010.12.004
   Shiao SL, 2021, CANCER CELL, V39, P1202, DOI 10.1016/j.ccell.2021.07.002
   Shinohara H, 2000, INT J ONCOL, V17, P643
   Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255
   Soleimanpour S, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117754
   Song SY, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0180-y
   Sousa T, 2014, J PHARM SCI-US, V103, P3171, DOI 10.1002/jps.24103
   Stern C, 2015, INT J CANCER, V137, P2019, DOI 10.1002/ijc.29567
   Taniguchi S, 2010, CANCER SCI, V101, P1925, DOI 10.1111/j.1349-7006.2010.01628.x
   Tao WT, 2009, MED HYPOTHESES, V72, P477, DOI 10.1016/j.mehy.2008.11.012
   Taper HS, 2005, IN VIVO, V19, P201
   Tarhriz V, 2020, PHARM SCI-IRAN, V26, P88, DOI 10.34172/PS.2019.56
   Torfoss V, 2012, J PEPT SCI, V18, P609, DOI 10.1002/psc.2441
   Um S, 2013, J ORG CHEM, V78, P12321, DOI 10.1021/jo401974g
   Vallera DA, 2002, J NATL CANCER I, V94, P597
   van Leerdam ME, 2019, ENDOSCOPY, V51, P1082, DOI 10.1055/a-1016-4977
   Varas MA, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00405
   Venkatesan N, 2015, FUTURE MICROBIOL, V10, P1743, DOI 10.2217/fmb.15.69
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Villarante KI, 2011, WORLD J MICROB BIOT, V27, P975, DOI 10.1007/s11274-010-0541-1
   Walia S, 2018, DIGEST DIS SCI, V63, P900, DOI 10.1007/s10620-018-4949-z
   Wallace BD, 2015, CHEM BIOL, V22, P1238, DOI 10.1016/j.chembiol.2015.08.005
   Warso MA, 2013, BRIT J CANCER, V108, P1061, DOI 10.1038/bjc.2013.74
   Weerakkody LR, 2019, LIFE SCI, V235, DOI 10.1016/j.lfs.2019.116839
   Westphal K, 2008, CANCER RES, V68, P2952, DOI 10.1158/0008-5472.CAN-07-2984
   Wolf P, 2009, INT J MED MICROBIOL, V299, P161, DOI 10.1016/j.ijmm.2008.08.003
   Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87
   Xu YF, 2007, CANCER GENE THER, V14, P151, DOI 10.1038/sj.cgt.7701003
   Yaghoubi A, 2020, INT J COLORECTAL DIS, V35, P595, DOI 10.1007/s00384-020-03535-9
   Yoshimura K, 2006, CANCER RES, V66, P1096, DOI 10.1158/0008-5472.CAN-05-2307
   Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937
   Zacharakis M, 2010, ANTICANCER RES, V30, P653
   Zhang HL, 2004, CHEM PHARM BULL, V52, P1029, DOI 10.1248/cpb.52.1029
   Zhang QY, 2021, MILITARY MED RES, V8, DOI 10.1186/s40779-021-00343-2
   Zhao M, 2005, P NATL ACAD SCI USA, V102, P755, DOI 10.1073/pnas.0408422102
   Zimmermann M, 2019, NATURE, V570, P462, DOI 10.1038/s41586-019-1291-3
   Zimmermann M, 2019, SCIENCE, V363, P600, DOI 10.1126/science.aat9931
   Zuckerman DS, 2008, CANCER-AM CANCER SOC, V112, P1879, DOI 10.1002/cncr.23409
NR 172
TC 4
Z9 5
U1 1
U2 18
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD APR
PY 2022
VL 10
IS 4
AR 832
DI 10.3390/biomedicines10040832
PG 23
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA 0R2FY
UT WOS:000785419000001
PM 35453581
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Hofheinz, RD
   Anchisi, S
   Grünberger, B
   Derigs, HG
   Zahn, MO
   Geffriaud-Ricouard, C
   Gueldner, M
   Windemuth-Kieselbach, C
   Pederiva, S
   Bohanes, P
   Scholten, F
   Piringer, G
   Thaler, J
   von Moos, R
AF Hofheinz, Ralf-Dieter
   Anchisi, Sandro
   Grunberger, Birgit
   Derigs, Hans G.
   Zahn, Mark-Oliver
   Geffriaud-Ricouard, Christine
   Gueldner, Max
   Windemuth-Kieselbach, Christine
   Pederiva, Stefanie
   Bohanes, Pierre
   Scholten, Felicitas
   Piringer, Gudrun
   Thaler, Josef
   von Moos, Roger
TI Real-World Evaluation of Quality of Life, Effectiveness, and Safety of
   Aflibercept Plus FOLFIRI in Patients with Metastatic Colorectal Cancer:
   The Prospective QoLiTrap Study
SO CANCERS
LA English
DT Article
DE colorectal cancer; aflibercept; VEGF; EGFR inhibitors; quality of life;
   anti-angiogenics
ID RAS MUTATIONS; DOUBLE-BLIND; PHASE-III; BEVACIZUMAB; IRINOTECAN;
   FLUOROURACIL; RAMUCIRUMAB; OXALIPLATIN; LEUCOVORIN; CARCINOMA
AB Simple Summary Colorectal cancer (CRC) is the third most frequently diagnosed malignancy worldwide and the second leading cause of cancer-related mortality. In VELOUR phase III trial, aflibercept combined with FOLFIRI has been shown to prolong overall survival versus FOLFIRI plus placebo in metastatic CRC (mCRC) patients previously treated with an oxaliplatin-based regimen. However, VELOUR did not evaluate patient quality of life and, outcomes following treatment with epidermal growth factor receptor inhibitors (EGFR-I) were unknown. In this prospective study conducted in daily practice, mCRC patients treated with aflibercept plus FOLFIRI maintained their quality of life as assessed by the EORTC QLQ-C30 questionnaire. Aflibercept plus FOLFIRI was also associated with a high objective tumor response and retained its activity regardless of sex, RAS status, and prior targeted therapy, especially after EGFR-I. Adverse events were consistent with the known safety profile of aflibercept plus FOLFIRI. Aflibercept plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer after the failure of oxaliplatin-containing therapy. QoLiTrap prospectively evaluated the quality of life (QoL) and effectiveness of this regimen in daily clinical practice, according to RAS status, sex, and prior targeted therapy, especially epidermal growth factor receptor inhibitors (EGFR-I). The primary endpoint was the percentage of patients whose EORTC QLQ-C30 global health status (GHS) improved or reduced by <5% from baseline during the first 12 weeks of therapy. Secondary endpoints included objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. One thousand two hundred and seventy-seven patients were treated with aflibercept plus FOLFIRI and 872 were evaluable for QoL. GHS improved or decreased by <5% in 40.3% of cases. The ORR was 20.8%, the median PFS was 7.8 months (95% confidence interval (CI), 7.3-8.3), and the median OS was 14.4 months (95% CI, 13.1-18.1). After prior EGFR-I, the ORR was 23.7%, median PFS was 9.4 months (95% CI, 6.5-12.9), and median OS was 17.4 months (95% CI, 10.5-33.7). The safety profile was consistent with previously reported data. Aflibercept plus FOLFIRI given in daily practice maintained QoL in mCRC patients, was associated with a high objective tumor response, and retained its activity regardless of sex, RAS status, and prior EGFR-I therapy.
C1 [Hofheinz, Ralf-Dieter] Univ Hosp Mannheim, Dept Oncol, Theodor Kutzer Ufer 1, D-68167 Mannheim, Germany.
   [Anchisi, Sandro] Valais Hosp, Valais Romand Hosp Ctr, Dept Oncol, Av Grand Champsec 86, CH-1951 Sion, Switzerland.
   [Grunberger, Birgit] Hosp Wiener Neustadt, Dept Internal Med Hematol & Oncol, Corvinusring 3-5, A-2700 Wiener Neustadt, Austria.
   [Derigs, Hans G.; Scholten, Felicitas] Frankfurt Hochst Clin, Dept Internal Med Hematol Oncol Palliat Med & Pne, Gotenstr 6-8, D-65929 Frankfurt, Germany.
   [Zahn, Mark-Oliver] MVZ Oncol Cooperat Harz, Dept Internal Med Hematol & Oncol, Kosliner Str 14, D-38642 Goslar, Germany.
   [Geffriaud-Ricouard, Christine] Sanofi, Global Med Oncol, 54 Rue La Boetie, F-75008 Paris, France.
   [Gueldner, Max] Sanofi, Potsdamer Str 8, D-10785 Berlin, Germany.
   [Windemuth-Kieselbach, Christine] Alcedis, Dept Biometry, Winchesterstr 3, D-35394 Giessen, Germany.
   [Pederiva, Stefanie] Cantonal Hosp, Ctr Oncol & Hematol, CH-5404 Baden, Switzerland.
   [Bohanes, Pierre] Ctr Chemotherapy, Dept Oncol & Internal Med, CH-1004 Lausanne, Switzerland.
   [Piringer, Gudrun; Thaler, Josef] Wels Grieskirchen Hosp, Dept Internal Med 4, Grieskirchner Str 42, A-4600 Wels, Austria.
   [Piringer, Gudrun] Johannes Kepler Univ Linz, Altenberger Str 69, A-4040 Linz, Austria.
   [von Moos, Roger] Cantonal Hosp Graubuenden, Dept Oncol, Loestr 170, CH-7000 Chur, Switzerland.
C3 Ruprecht Karls University Heidelberg; Sanofi-Aventis; Sanofi France;
   Sanofi-Aventis; Johannes Kepler University Linz
RP Hofheinz, RD (corresponding author), Univ Hosp Mannheim, Dept Oncol, Theodor Kutzer Ufer 1, D-68167 Mannheim, Germany.
EM ralf.hofheinz@umm.de; sandro.anchisi@hopitalvs.ch;
   birgit.gruenberger@wienerneustadt.lknoe.at; derigs@klinikumfrankfurt.de;
   m-o.zahn@onkologie-goslar.de; christine.geffriaud-ricouard@sanofi.com;
   max.gueldner@sanofi.com; cwk@alcedis.de; stefanie.pederiva@ksb.ch;
   pierre.bohanes@ccac.ch; felicitas.scholten@klinikumfrankfurt.de;
   gudrun.piringer@hotmail.com; josef.thaler@klinikum-wegr.at;
   roger.vonmoos@ksgr.ch
OI von Moos, Roger/0000-0003-2362-8514
FU Sanofi
FX This study was sponsored and funded by Sanofi. None of the authors have
   received honorarium for writing the manuscript.
CR AARONSON NK, 1993, J NATL CANCER I, V85, P365, DOI 10.1093/jnci/85.5.365
   Adam R, 2017, EUR J CANCER, V78, P7, DOI 10.1016/j.ejca.2017.03.009
   [Anonymous], 1975, SEER CANC STAT REV
   [Anonymous], 2008, NATL COMPREHENSIVE C
   Aparicio J, 2020, J CLIN MED, V9, DOI 10.3390/jcm9123889
   Bennouna J, 2019, JAMA ONCOL, V5, P83, DOI 10.1001/jamaoncol.2018.4465
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   BRAY F, 2018, CA-CANCER J CLIN, V68, P394, DOI [DOI 10.3322/CANJCLIN.49.1.33, DOI 10.3322/CAAC.21492]
   Chambers AC, 2020, BRIT J SURG, V107, P595, DOI 10.1002/bjs.11486
   Chau I, 2020, CANCERS, V12, DOI 10.3390/cancers12030657
   Chiron M, 2014, MOL CANCER THER, V13, P1636, DOI 10.1158/1535-7163.MCT-13-0753
   Dello Russo C, 2020, EUR J CLIN PHARMACOL, V76, P1083, DOI 10.1007/s00228-020-02895-z
   Di Maio M, 2020, ONCOLOGIST, V25, pE746, DOI 10.1634/theoncologist.2019-0647
   Fayers PM, 2001, EORTC QLQ-C30 Scoring Man, V30, P1
   Healy FM, 2022, BRIT J PHARMACOL, V179, P2844, DOI 10.1111/bph.15420
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Jo H, 2022, CLIN ONCOL-UK, V34, pE323, DOI 10.1016/j.clon.2022.02.011
   Kanat O, 2019, WORLD J CLIN ONCOL, V10, P52, DOI 10.5306/wjco.v10.i2.52
   Obermannová R, 2016, ANN ONCOL, V27, P2082, DOI 10.1093/annonc/mdw402
   Osterlund P, 2021, LANCET REG HEALTH-EU, V3, DOI 10.1016/j.lanepe.2021.100049
   Ottaiano A, 2020, CANCERS, V12, DOI 10.3390/cancers12071919
   Ottaiano A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00766
   Parisi A, 2020, CANCERS, V12, DOI 10.3390/cancers12051259
   Pastorino A, 2018, CLIN COLORECTAL CANC, V17, pE457, DOI 10.1016/j.clcc.2018.03.002
   Peeters M, 2015, EUR J CANCER, V51, P1704, DOI 10.1016/j.ejca.2015.05.017
   Riechelmann RP, 2019, CLIN COLORECTAL CANC, V18, P183, DOI 10.1016/j.clcc.2019.05.003
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Torregrosa C, 2022, INT J CANCER, V151, P1978, DOI 10.1002/ijc.34166
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174
   Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738
NR 33
TC 4
Z9 4
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUL
PY 2022
VL 14
IS 14
AR 3522
DI 10.3390/cancers14143522
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 3J3ZK
UT WOS:000833336400001
PM 35884583
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Yang, MY
   Fang, XF
   Li, J
   Xu, D
   Xiao, Q
   Yu, SJ
   Hu, HG
   Weng, SS
   Ding, KF
   Yuan, Y
AF Yang, Mengyuan
   Fang, Xuefeng
   Li, Jun
   Xu, Dong
   Xiao, Qian
   Yu, Shaojun
   Hu, Hanguang
   Weng, Shanshan
   Ding, Kefeng
   Yuan, Ying
TI Afatinib treatment for her-2 amplified metastatic colorectal cancer
   based on patient-derived xenograft models and next generation sequencing
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE Patient-derived xenograft models; next generation sequencing; afatinib;
   colorectal cancer; individual therapy; case report
ID PLUS IRINOTECAN; MONOTHERAPY; CHALLENGES; PLATFORM; PLACEBO
AB Background: Substantial progress has been made in metastatic colorectal cancer (mCRC) treatment, but there is still a fraction of patients cannot find any effective therapeutic strategy after guideline-recommended standard chemotherapy and molecular targeted therapy. Case presentation: Here we present a KRAS/NRAS/BRAF wild-type mCRC patient who has been previously treated with FOLFIRI (fluorouracil, leucovorin, and irinotecan), XELOX (capecitabine and oxaliplatin), cetuximab and bevacizumab, and then received the next generation sequencing (NGS) and whose metastatic subcutaneous nodule was resected to generate patient-derived xenograft (PDX) models. The NGS revealed HER-2 amplification as well as an activating mutation S310F and PDX models tested several drugs finding that afatinib was the optimal agent with notable efficacy and well tolerance among 6 regimens. Therefore, this patient started to take afatinib orally and achieved 3 months progression-free survival (PFS) and relief of clinical symptoms without severe adverse effects. Conclusions: NGS and PDX models have great significance for precision and individualized medicine in the mCRC treatment, especially for patients whose diseases have been progressed after multiline standard therapies.
C1 [Yang, Mengyuan; Fang, Xuefeng; Hu, Hanguang; Weng, Shanshan; Yuan, Ying] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, 88 Jiefang Rd, Hangzhou, Zhejiang, Peoples R China.
   [Li, Jun; Xu, Dong; Xiao, Qian; Yu, Shaojun; Ding, Kefeng] Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Yuan, Y (corresponding author), Zhejiang Univ, Affiliated Hosp 2, Sch Med, Dept Med Oncol, 88 Jiefang Rd, Hangzhou, Zhejiang, Peoples R China.
EM yuanying1999@zju.edu.cn
RI xiao, qian/IWM-0785-2023
OI Ying, Yuan/0000-0002-3922-9553
FU National Key R&D Program of China [2017YFC0908200]; Natural Science
   Foundation of China [81101580]; Zhejiang Provincial Natural
   ScienceFoundation of China [LY16H160027]
FX This work was supported by National Key R&D Program of China under Grant
   2017YFC0908200; Natural Science Foundation of China under Grant
   81101580; and Zhejiang Provincial Natural ScienceFoundation of China
   under Grant No. LY16H160027.
CR Aparicio S, 2015, NAT REV CANCER, V15, P311, DOI 10.1038/nrc3944
   Bang YJ, 2010, LANCET, V376, P1302
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Biesecker LG, 2012, GENET MED, V14, P393, DOI 10.1038/gim.2011.78
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Dienstmann R, 2015, CANCER DISCOV, V5, P118, DOI 10.1158/2159-8290.CD-14-1118
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Friedman AA, 2015, NAT REV CANCER, V15, P747, DOI 10.1038/nrc4015
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hidalgo M, 2011, MOL CANCER THER, V10, P1311, DOI 10.1158/1535-7163.MCT-11-0233
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Majumder B, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7169
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Ross JS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3583
   Rubio-Viqueira B, 2006, CLIN CANCER RES, V12, P4652, DOI 10.1158/1078-0432.CCR-06-0113
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Siena S, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.3508
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Stebbing J, 2014, CANCER-AM CANCER SOC, V120, P2006, DOI 10.1002/cncr.28696
   Taber KAJ, 2014, JAMA INTERN MED, V174, P275, DOI 10.1001/jamainternmed.2013.12048
NR 25
TC 11
Z9 12
U1 0
U2 7
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD APR 3
PY 2019
VL 20
IS 4
BP 391
EP 396
DI 10.1080/15384047.2018.1529120
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HO0XU
UT WOS:000460630100001
PM 30307354
OA Green Published, Bronze
DA 2025-01-04
ER

PT J
AU Hammond, WA
   Swaika, A
   Mody, K
AF Hammond, William A.
   Swaika, Abhisek
   Mody, Kabir
TI Pharmacologic resistance in colorectal cancer: a review
SO THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
LA English
DT Review
DE colon adenocarcinoma; colon cancer; resistance
ID GROWTH-FACTOR RECEPTOR; GENE COPY NUMBER; THYMIDINE PHOSPHORYLASE
   EXPRESSION; THYMIDYLATE SYNTHASE EXPRESSION; TOPOISOMERASE-I GENE; DNA
   MISMATCH REPAIR; PHASE-III TRIAL; OXALIPLATIN-BASED CHEMOTHERAPY;
   FLUOROURACIL PLUS LEUCOVORIN; ANTI-EGFR THERAPY
AB Colorectal cancer (CRC) persists as one of the most prevalent and deadly tumor types in both men and women worldwide. This is in spite of widespread, effective measures of preventive screening, and also major advances in treatment options. Despite advances in cytotoxic and targeted therapy, resistance to chemotherapy remains one of the greatest challenges in long-term management of incurable metastatic disease and eventually contributes to death as tumors accumulate means of evading treatment. We performed a comprehensive literature search on the data available through PubMed, Medline, Scopus, and the ASCO Annual Symposium abstracts through June 2015 for the purpose of this review. We discuss the current state of knowledge of clinically relevant mechanisms of resistance to cytotoxic and targeted therapies now in use for the treatment of CRC.
C1 [Mody, Kabir] Mayo Clin, Ctr Canc, Div Hematol Oncol, Jacksonville, FL 32224 USA.
   [Hammond, William A.; Swaika, Abhisek] Mayo Clin, Div Hematol Oncol, Jacksonville, FL 32224 USA.
C3 Mayo Clinic; Mayo Clinic
RP Mody, K (corresponding author), Mayo Clin, Ctr Canc, Div Hematol Oncol, 4500 San Pablo Rd S, Jacksonville, FL 32224 USA.
EM mody.kabir@mayo.edu
OI Hammond, William/0000-0002-7565-8558
CR Abdalla EK, 2004, ANN SURG, V239, P818, DOI 10.1097/01.sla.0000128305.90650.71
   Adam R, 2004, ANN SURG, V240, P644, DOI 10.1097/01.sla.0000141198.92114.16
   Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], AM J CLIN ONCOL
   [Anonymous], J CLIN ONCOL S3
   Baba H, 2012, BRIT J CANCER, V107, P1950, DOI 10.1038/bjc.2012.502
   Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Bécouarn Y, 1998, J CLIN ONCOL, V16, P2739, DOI 10.1200/JCO.1998.16.8.2739
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   BERGER SH, 1985, MOL PHARMACOL, V28, P461
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Boyer J, 2004, CLIN CANCER RES, V10, P2158, DOI 10.1158/1078-0432.CCR-03-0362
   Cao CX, 2014, CANCER SCI, V105, P1008, DOI 10.1111/cas.12465
   Cappuzzo F, 2008, ANN ONCOL, V19, P717, DOI 10.1093/annonc/mdm492
   Carethers JM, 2004, GASTROENTEROLOGY, V126, P394, DOI 10.1053/j.gastro.2003.12.023
   Carlini LE, 2005, CLIN CANCER RES, V11, P1226
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Cassidy J, 2011, ANN ONCOL, V22, P2604, DOI 10.1093/annonc/mdr031
   Choi YH, 2012, ONCOLOGY-BASEL, V82, P290, DOI 10.1159/000337989
   CHU E, 1993, MOL PHARMACOL, V43, P527
   Ciardiello F, 2000, CLIN CANCER RES, V6, P3739
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Ciardiello F, 2011, CANCER DISCOV, V1, P472, DOI 10.1158/2159-8290.CD-11-0261
   Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
   Crawford Y, 2009, CANCER CELL, V15, P21, DOI 10.1016/j.ccr.2008.12.004
   Cummings J, 2002, BIOCHEM PHARMACOL, V63, P607, DOI 10.1016/S0006-2952(01)00812-7
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   De Palma M, 2005, CANCER CELL, V8, P211, DOI 10.1016/j.ccr.2005.08.002
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   De Stefano A, 2014, WORLD J GASTROENTERO, V20, P9732, DOI 10.3748/wjg.v20.i29.9732
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Diaz-Rubio E, 1998, ANN ONCOL, V9, P105, DOI 10.1023/A:1008200825886
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Du R, 2008, CANCER CELL, V13, P206, DOI 10.1016/j.ccr.2008.01.034
   Esposito C, 2013, CANCER BIOL THER, V14, P1143, DOI 10.4161/cbt.26340
   Etienne-Grimaldi MC, 2010, BRIT J CLIN PHARMACO, V69, P58, DOI 10.1111/j.1365-2125.2009.03556.x
   Fedier A, 2003, INT J ONCOL, V22, P1169
   Feng JH, 2004, J BIOL CHEM, V279, P35510, DOI 10.1074/jbc.M404936200
   Fink D, 1998, CLIN CANCER RES, V4, P1
   Fink D, 1997, CANCER RES, V57, P1841
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Fujiwara Y, 2010, PHARMACOGENOMICS, V11, P391, DOI 10.2217/PGS.10.19
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Gongora C, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-64
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hattori K, 2002, NAT MED, V8, P841, DOI 10.1038/nm740
   Hector S, 2001, CANCER CHEMOTH PHARM, V48, P398, DOI 10.1007/s002800100363
   HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0
   Hirschi B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-122
   Hobor S, 2014, CLIN CANCER RES, V20, P6429, DOI 10.1158/1078-0432.CCR-14-0774
   Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282
   Hohla F, 2014, WORLD J GASTROENTERO, V20, P6102, DOI 10.3748/wjg.v20.i20.6102
   Holzer AK, 2006, MOL PHARMACOL, V70, P1390, DOI 10.1124/mol.106.022624
   Hong YS, 2012, LANCET ONCOL, V13, P1125, DOI 10.1016/S1470-2045(12)70363-7
   HOUGHTON JA, 1983, EUR J CANCER CLIN ON, V19, P807, DOI 10.1016/0277-5379(83)90013-5
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116
   Isshi Kimio, 2002, Int J Clin Oncol, V7, P335, DOI 10.1007/s101470200051
   Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659
   JOHNSTON PG, 1995, CANCER RES, V55, P1407
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Jürgensmeier JM, 2013, BRIT J CANCER, V108, P1316, DOI 10.1038/bjc.2013.79
   Kamba T, 2007, BRIT J CANCER, V96, P1788, DOI 10.1038/sj.bjc.6603813
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   KELLAND LR, 1993, CRIT REV ONCOL HEMAT, V15, P191, DOI 10.1016/1040-8428(93)90042-3
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kim SY, 2013, BRIT J CANCER, V109, P1420, DOI 10.1038/bjc.2013.479
   Kojima A, 1998, CANCER RES, V58, P4368
   Koopman M, 2009, EUR J CANCER, V45, P1999, DOI 10.1016/j.ejca.2009.04.017
   Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252
   LEICHMAN CG, 1995, J CLIN ONCOL, V13, P1303, DOI 10.1200/JCO.1995.13.6.1303
   Leichman CG, 1997, J CLIN ONCOL, V15, P3223, DOI 10.1200/JCO.1997.15.10.3223
   Li D, 2014, CANCER LETT, V346, P45, DOI 10.1016/j.canlet.2013.12.004
   Liang J, 2010, CANCER CHEMOTH PHARM, V66, P493, DOI 10.1007/s00280-009-1186-3
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lindskog EB, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-25
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Longley DB, 2002, CANCER RES, V62, P2644
   LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B
   Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612
   Marcuello E, 2006, CANCER CHEMOTH PHARM, V57, P835, DOI 10.1007/s00280-005-0089-1
   Marcuello E, 2004, BRIT J CANCER, V91, P678, DOI 10.1038/sj.bjc.6602042
   Maxwell PH, 1997, P NATL ACAD SCI USA, V94, P8104, DOI 10.1073/pnas.94.15.8104
   MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   McLeod HL, 1996, BRIT J CANCER, V74, P508, DOI 10.1038/bjc.1996.394
   MEIJER C, 1992, CANCER RES, V52, P6885
   Meriggi F, 2014, REV RECENT CLIN TRIA, V9, P8, DOI 10.2174/1568026614666140423121525
   Meropol NJ, 2006, J CLIN ONCOL, V24, P4069, DOI 10.1200/JCO.2005.05.2084
   Mésange P, 2014, ONCOTARGET, V5, P4709, DOI 10.18632/oncotarget.1671
   Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595
   Meyers M, 2001, CANCER RES, V61, P5193
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mitchell EP, 2013, CLIN COLORECTAL CANC, V12, P73, DOI 10.1016/j.clcc.2012.08.001
   Mizukami Y, 2005, NAT MED, V11, P992, DOI 10.1038/nm1294
   MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   Moutinho C, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt322
   Muhale FA, 2011, PHARMACOGENOMICS, V12, P341, DOI [10.2217/PGS.10.188, 10.2217/pgs.10.188]
   Muro K, 2010, LANCET ONCOL, V11, P853, DOI 10.1016/S1470-2045(10)70181-9
   Nicum S, 2000, J ROY SOC MED, V93, P416, DOI 10.1177/014107680009300807
   Nygård SB, 2014, SCAND J GASTROENTERO, V49, P84, DOI 10.3109/00365521.2013.856464
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pan Q, 2007, CANCER CELL, V11, P53, DOI 10.1016/j.ccr.2006.10.018
   Panczyk M, 2014, WORLD J GASTROENTERO, V20, P9775, DOI 10.3748/wjg.v20.i29.9775
   Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541
   Petrioli R, 2010, ANTI-CANCER DRUG, V21, P313, DOI 10.1097/CAD.0b013e328334d88a
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Popat S, 2004, J CLIN ONCOL, V22, P529, DOI 10.1200/JCO.2004.05.064
   Porebska I, 2000, TUMOR BIOL, V21, P105, DOI 10.1159/000030116
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Qiu LX, 2008, INT J CANCER, V123, P2384, DOI 10.1002/ijc.23822
   Rajput A, 2007, CANCER RES, V67, P665, DOI 10.1158/0008-5472.CAN-06-2773
   Raymond E, 2002, MOL CANCER THER, V1, P227
   Ribatti D, 2008, ANGIOGENESIS, V11, P215, DOI 10.1007/s10456-008-9114-4
   Ridgway J, 2006, NATURE, V444, P1083, DOI 10.1038/nature05313
   Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002
   Roskoski R, 2012, PHARMACOL RES, V66, P105, DOI 10.1016/j.phrs.2012.04.005
   Rougier P, 1998, LANCET, V352, P1407, DOI 10.1016/S0140-6736(98)03085-2
   Rouits E, 2004, CLIN CANCER RES, V10, P5151, DOI 10.1158/1078-0432.CCR-03-0548
   Rubenstein JL, 2000, NEOPLASIA, V2, P306, DOI 10.1038/sj.neo.7900102
   Sakuramoto S, 2007, NEW ENGL J MED, V357, P1810, DOI 10.1056/NEJMoa072252
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Salonga D, 2000, CLIN CANCER RES, V6, P1322
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Samuel S, 2011, ONCOGENE, V30, P1205, DOI 10.1038/onc.2010.496
   Saridaki Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015980
   Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956
   Sartore-Bianchi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007287
   SCHWARTZ PM, 1985, BIOCHEM PHARMACOL, V34, P3585, DOI 10.1016/0006-2952(85)90737-3
   Shimada Y, 1996, EUR J CANCER, V32A, pS13, DOI 10.1016/0959-8049(96)00292-4
   Shirao K, 2004, J CLIN ONCOL, V22, P3466, DOI 10.1200/JCO.2004.05.017
   Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298
   Shojaei F, 2007, NAT BIOTECHNOL, V25, P911, DOI 10.1038/nbt1323
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Smith DH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060613
   Sohn KJ, 2004, JNCI-J NATL CANCER I, V96, P134, DOI 10.1093/jnci/djh015
   Sood A, 2012, CLIN COLORECTAL CANC, V11, P143, DOI 10.1016/j.clcc.2011.12.001
   Soong R, 2008, ANN ONCOL, V19, P915, DOI 10.1093/annonc/mdm599
   Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057
   Stark M, 2011, J BIOL CHEM, V286, P3741, DOI 10.1074/jbc.M110.163444
   Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tabernero J, 2014, EUR J CANCER, V50, P320, DOI 10.1016/j.ejca.2013.09.013
   Takebe N, 2001, CANCER GENE THER, V8, P966, DOI 10.1038/sj.cgt.7700393
   Tejpar S, 2012, ONCOLOGIST, V17, P1039, DOI 10.1634/theoncologist.2012-0068
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Thomas Hilary, 2003, Cancer Control, V10, P159
   Tokunaga Y, 2007, SURGERY, V141, P346, DOI 10.1016/j.surg.2006.06.025
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Tsunoda A, 2011, ANN ONCOL, V22, P355, DOI 10.1093/annonc/mdq358
   Tsurutani J, 2002, LUNG CANCER-J IASLC, V35, P299, DOI 10.1016/S0169-5002(01)00425-1
   Vallböhmer D, 2007, INT J ONCOL, V31, P413
   Vallböhmer D, 2006, INT J ONCOL, V28, P527
   Vallböhmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/jco.2005.23.16_suppl.3536
   Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2009, J CLIN ONCOL, V27, P3117, DOI 10.1200/JCO.2008.21.6663
   Van Emburgh BO, 2014, MOL ONCOL, V8, P1084, DOI 10.1016/j.molonc.2014.05.003
   Wang HJ, 2011, PHARMACOGENOMICS, V12, P481, DOI [10.2217/pgs.10.202, 10.2217/PGS.10.202]
   Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148
   Wilson PM, 2014, NAT REV CLIN ONCOL, V11, P282, DOI 10.1038/nrclinonc.2014.51
   Xie HG, 2004, PHARMACOGENOMICS, V5, P243, DOI 10.1517/phgs.5.3.243.29833
   Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337
   Yamada KM, 2001, J CELL SCI, V114, P2375
   Yanagisawa Y, 2007, SCAND J GASTROENTERO, V42, P477, DOI 10.1080/00365520600994418
   Yang L, 2004, CANCER CELL, V6, P409, DOI 10.1016/j.ccr.2004.08.031
   Ye Dian-Jun, 2013, Cancer Biology Medicine, V10, P10, DOI 10.7497/j.issn.2095-3941.2013.01.002
   Ye FH, 2013, CANCER CHEMOTH PHARM, V71, P733, DOI 10.1007/s00280-012-2067-8
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Yoshino T, 2012, LANCET ONCOL, V13, P993, DOI 10.1016/S1470-2045(12)70345-5
   Zhang SZ, 2006, CANCER RES, V66, P8847, DOI 10.1158/0008-5472.CAN-06-0769
   Zhao J, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0802-6
NR 189
TC 375
Z9 400
U1 4
U2 96
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1758-8340
EI 1758-8359
J9 THER ADV MED ONCOL
JI Ther. Adv. Med. Oncol.
PD JAN
PY 2016
VL 8
IS 1
BP 57
EP 84
DI 10.1177/1758834015614530
PG 28
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ9SQ
UT WOS:000367437700004
PM 26753006
OA Green Published, Bronze
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Wang, XC
   Yao, YZ
   Zhu, XG
AF Wang, Xuchao
   Yao, Yizhou
   Zhu, Xinguo
TI The influence of aberrant expression of GLI1/p-S6K on colorectal cancer
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colorectal cancer; GLI1; p-S6K; Prognosis; Hedgehog; mTOR
ID HEDGEHOG SIGNALING PATHWAY; ACTIVATED PROTEIN-KINASE;
   CELL-PROLIFERATION; METASTASIS; GROWTH; MTOR; GLI1; CROSSTALK; MTOR/S6K1
AB Colorectal cancer (CRC) is one of the most common cancers worldwide. Recent studies have reported that PI3K/AKT/mTOR pathway regulated the GLI1 expression level via SMO-independent pathway in a variety of tumor types. We detected the expression level of GLI1/p-S6K in CRC tissues. We found the expression of GLI1/p-S6K was apparently close with lymph node metastasis and TNM stage and patients with positive GLI1/p-S6K expression had shorter survival time and patients with both GLI1 and p-S6K positive expression had an even worse overall survival than those with single positive expression. Moreover, GLI1 and p-S6K expression was considered to be independent prognostic factors in CRC patient and the positive co-expression of GLI1/p-S6K had greater influence than single expression positive on the prognosis of postoperative patients with tumor size >= 5 cm, well differentiation, positive lymph node metastasis, venous invasion, neural invasion and TNM Meanwhile, the GLI1/p-S6K expression had impact on more clinicopathologic features in colon-side carcinoma than in rectum-side carcinoma and the mTOR/S6K/GLI1 axis played an important role in CRC especially in advanced stage. Hence, further studies are underway to explore the molecular mechanism between GLI1 and p-S6K in CRC, and in addition, it offers novel facilities for molecular targeting therapy for CRC. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Wang, Xuchao; Yao, Yizhou; Zhu, Xinguo] Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou 215006, Peoples R China.
C3 Soochow University - China
RP Zhu, XG (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Gen Surg, Suzhou 215006, Peoples R China.
EM wxcjm1993@163.com; yaoyizhou2014@163.com; xgzhu45@163.com
RI wang, wei/JYP-7819-2024; yao, yizhou/ABE-8728-2020
OI Yao, Yizhou/0000-0001-7976-1133
FU National Science Foundation of Jiangsu Province, China [BK20161225];
   Nature Science Foundation of China [81672348]
FX This work was supported by Project of National Science Foundation of
   Jiangsu Province, China (BK20161225) and Nature Science Foundation of
   China (81672348).
CR Ahmad R, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0608-9
   Bouvier AM, 2015, INT J CANCER, V137, P2133, DOI 10.1002/ijc.29578
   Brechbiel J, 2014, CANCER TREAT REV, V40, P750, DOI 10.1016/j.ctrv.2014.02.003
   Buonamici S, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001599
   Cheng Y, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160593
   Dann SG, 2007, TRENDS MOL MED, V13, P252, DOI 10.1016/j.molmed.2007.04.002
   Das S, 2013, J BIOL CHEM, V288, P11824, DOI 10.1074/jbc.M112.432302
   Filbin MG, 2013, NAT MED, V19, P1518, DOI 10.1038/nm.3328
   Gentilella A, 2015, BBA-GENE REGUL MECH, V1849, P812, DOI 10.1016/j.bbagrm.2015.02.005
   Hao K, 2013, ONCOL REP, V29, P1124, DOI 10.3892/or.2012.2210
   Huo HZ, 2014, BIOCHEM BIOPH RES CO, V443, P406, DOI 10.1016/j.bbrc.2013.11.099
   Kaylani SZ, 2013, BIOCHEM BIOPH RES CO, V435, P557, DOI 10.1016/j.bbrc.2013.05.001
   Kebenko M, 2015, CELL SIGNAL, V27, P373, DOI 10.1016/j.cellsig.2014.11.022
   Li YH, 2015, CELL REP, V12, P599, DOI 10.1016/j.celrep.2015.06.054
   Lu JT, 2012, ACTA PHARMACOL SIN, V33, P691, DOI 10.1038/aps.2012.24
   Mueller MT, 2009, GASTROENTEROLOGY, V137, P1102, DOI 10.1053/j.gastro.2009.05.053
   Papadopoulos V, 2016, CLIN COLORECTAL CANC, V15, P116, DOI 10.1016/j.clcc.2016.02.010
   Razaviyan J., 2018, APPL BIOCH BIOTECHNO
   Romano G, 2018, CANCER DISCOV, V8, P556, DOI 10.1158/2159-8290.CD-17-0745
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Stecca B, 2007, P NATL ACAD SCI USA, V104, P5895, DOI 10.1073/pnas.0700776104
   Taipale J, 2001, NATURE, V411, P349, DOI 10.1038/35077219
   Wang DJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0491-7
   Wang Y, 2012, CANCER CELL, V21, P374, DOI 10.1016/j.ccr.2011.12.028
   Wei LY, 2011, INT J CANCER, V129, P275, DOI 10.1002/ijc.25673
   Wu CQ, 2017, ONCOTARGETS THER, V10, P3249, DOI 10.2147/OTT.S139639
   Xu QR, 2014, INT J MOL MED, V34, P733, DOI 10.3892/ijmm.2014.1847
   Yang H, 2017, ONCOL LETT, V14, P7970, DOI 10.3892/ol.2017.7254
   Yang KK, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0158-1
   Yao YZ, 2016, GENES-BASEL, V7, DOI 10.3390/genes7100083
   Yoo YA, 2011, CANCER RES, V71, P7061, DOI 10.1158/0008-5472.CAN-11-1338
   Zhang C, 2016, ONCOTARGET, V7, P86134, DOI 10.18632/oncotarget.13348
   Zhang K, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0368-y
NR 33
TC 6
Z9 7
U1 0
U2 2
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD SEP 18
PY 2018
VL 503
IS 4
BP 3198
EP 3204
DI 10.1016/j.bbrc.2018.08.124
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA GT8MM
UT WOS:000444791600149
PM 30143258
DA 2025-01-04
ER

PT J
AU Kitaguchi, D
   Oda, T
   Enomoto, T
   Ohara, Y
   Owada, Y
   Akashi, Y
   Furuta, T
   Yu, Y
   Kimura, S
   Kuroda, Y
   Kurimori, K
   Miyazaki, Y
   Furuya, K
   Shimomura, O
   Tateno, H
AF Kitaguchi, Daichi
   Oda, Tatsuya
   Enomoto, Tsuyoshi
   Ohara, Yusuke
   Owada, Yohei
   Akashi, Yoshimasa
   Furuta, Tomoaki
   Yu, Yang
   Kimura, Sota
   Kuroda, Yukihito
   Kurimori, Ko
   Miyazaki, Yoshihiro
   Furuya, Kinji
   Shimomura, Osamu
   Tateno, Hiroaki
TI Lectin drug conjugate therapy for colorectal cancer
SO CANCER SCIENCE
LA English
DT Article
DE colorectal cancer; lectin; lectin drug conjugate; rBC2LCN; targeted
   therapy
ID PLURIPOTENT STEM-CELLS; FUCOSYL-TRANSFERASE; PROGNOSTIC-FACTOR;
   EXPRESSION; GLYCAN; METASTASIS; ADHESION; ALPHA(1,6)FUCOSYLTRANSFERASE;
   TRANSFECTION; PREDICTORS
AB Drug resistance represents an obstacle in colorectal cancer (CRC) treatment because of its association with poor prognosis. rBC2LCN is a lectin isolated from Burkholderia that binds cell surface glycans that have fucose moieties. Because fucosylation is enhanced in many types of cancers, this lectin could be an efficient drug carrier if CRC cells specifically present such glycans. Therefore, we examined the therapeutic efficacy and toxicity of lectin drug conjugate therapy in CRC mouse xenograft models. The affinity of rBC2LCN for human CRC cell lines HT-29, LoVo, LS174T, and DLD-1 was assessed in vitro. The cytocidal efficacy of a lectin drug conjugate, rBC2LCN-38 kDa domain of pseudomonas exotoxin A (PE38) was evaluated by MTT assay. The therapeutic effects and toxicity for each CRC cell line-derived mouse xenograft model were compared between the intervention and control groups. LS174T and DLD-1 cell lines showed a strong affinity for rBC2LCN. In the xenograft model, the tumor volume in the rBC2LCN-PE38 group was significantly reduced compared with that using control treatment alone. However, the HT-29 cell line showed weak affinity and poor therapeutic efficacy. No significant toxicities or adverse responses were observed. In conclusion, we demonstrated that rBC2LCN lectin binds CRC cells and that rBC2LCN-PE38 significantly suppresses tumor growth in vivo. In addition, the efficacy of the drug conjugate correlated with its binding affinity for each CRC cell line. These results suggest that lectin drug conjugate therapy has potential as a novel targeted therapy for CRC cell surface glycans.
C1 [Kitaguchi, Daichi; Oda, Tatsuya; Enomoto, Tsuyoshi; Ohara, Yusuke; Owada, Yohei; Akashi, Yoshimasa; Furuta, Tomoaki; Yu, Yang; Kimura, Sota; Kuroda, Yukihito; Kurimori, Ko; Miyazaki, Yoshihiro; Furuya, Kinji; Shimomura, Osamu] Univ Tsukuba, Fac Med, Dept Gastrointestinal & Hepatobiliary Pancreat Su, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
   [Tateno, Hiroaki] Natl Inst Adv Ind Sci & Technol, Biotechnol Res Inst Drug Discovery, Tsukuba, Ibaraki, Japan.
C3 University of Tsukuba; National Institute of Advanced Industrial Science
   & Technology (AIST)
RP Oda, T (corresponding author), Univ Tsukuba, Fac Med, Dept Gastrointestinal & Hepatobiliary Pancreat Su, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan.
EM tatoda@md.tsukuba.ac.jp
RI Tateno, Hiroaki/M-2706-2018; yu, yang/HIZ-9682-2022
OI Kitaguchi, Daichi/0000-0002-8197-6317; Miyazaki,
   Yoshihiro/0000-0002-1851-964X; Kimura, Sota/0000-0001-5878-4459
FU JSPS KAKENHI [JP20K16404]; Grants-in-Aid for Scientific Research
   [20K09097, 20K16404] Funding Source: KAKEN
FX JSPS KAKENHI, Grant/Award Number: JP20K16404
CR Adamová L, 2014, MICROSC RES TECHNIQ, V77, P841, DOI 10.1002/jemt.22407
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Cervoni GE, 2020, BIOCHEM J, V477, P1541, DOI 10.1042/BCJ20180103
   Chen CY, 2013, P NATL ACAD SCI USA, V110, P630, DOI 10.1073/pnas.1220425110
   Deyasi S K, 1975, Indian J Pathol Bacteriol, V18, P16
   FILELLA X, 1992, ANN SURG, V216, P55, DOI 10.1097/00000658-199207000-00008
   Grabowski P, 2000, INT J CANCER, V88, P281, DOI 10.1002/1097-0215(20001015)88:2<281::AID-IJC21>3.0.CO;2-2
   HAKOMORI S, 1983, JNCI-J NATL CANCER I, V71, P231
   Hiller KM, 2000, MOL CARCINOGEN, V27, P280, DOI 10.1002/(SICI)1098-2744(200004)27:4<280::AID-MC6>3.3.CO;2-C
   Hirabayashi J, 2015, ADV HEALTHC MATER, V4, P2520, DOI 10.1002/adhm.201400837
   Hirakawa M, 2014, BRIT J CANCER, V110, P156, DOI 10.1038/bjc.2013.699
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244
   Kannagi R, 2004, CANCER SCI, V95, P377, DOI 10.1111/j.1349-7006.2004.tb03219.x
   Koike T, 2004, P NATL ACAD SCI USA, V101, P8132, DOI 10.1073/pnas.0402088101
   KOPROWSKI H, 1981, SCIENCE, V212, P53, DOI 10.1126/science.6163212
   KOURI M, 1992, J SURG ONCOL, V49, P78, DOI 10.1002/jso.2930490204
   Li J, 2013, BRIT J CANCER, V109, P3014, DOI 10.1038/bjc.2013.690
   Liu F, 2001, BRIT J CANCER, V84, P1556, DOI 10.1054/bjoc.2001.1815
   Liu F, 2001, EUR J BIOCHEM, V268, P3501, DOI 10.1046/j.1432-1327.2001.02254.x
   Matsumoto K, 2008, CANCER SCI, V99, P1611, DOI 10.1111/j.1349-7006.2008.00847.x
   Mawaribuchi S, 2019, BIOCHEM BIOPH RES CO, V515, P176, DOI 10.1016/j.bbrc.2019.05.108
   Miyoshi E, 2008, J BIOCHEM, V143, P725, DOI 10.1093/jb/mvn011
   Muinelo-Romay L, 2011, HUM PATHOL, V42, P1740, DOI 10.1016/j.humpath.2011.01.021
   Muinelo-Romay L, 2008, INT J CANCER, V123, P641, DOI 10.1002/ijc.23521
   Nakagoe T, 2002, J EXP CLIN CANC RES, V21, P107
   Petrioli R, 2012, CANCER INVEST, V30, P65, DOI 10.3109/07357907.2011.629380
   Saito S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22450-2
   Sawke NG, 2010, INDIAN J CANCER, V47, P452, DOI 10.4103/0019-509X.73549
   Shimomura O, 2018, MOL CANCER THER, V17, P183, DOI 10.1158/1535-7163.MCT-17-0232
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Sulák O, 2010, STRUCTURE, V18, P59, DOI 10.1016/j.str.2009.10.021
   Tang C, 2011, NAT BIOTECHNOL, V29, P829, DOI 10.1038/nbt.1947
   Tateno H, 2008, GLYCOBIOLOGY, V18, P789, DOI 10.1093/glycob/cwn068
   Tateno H, 2007, NAT PROTOC, V2, P2529, DOI 10.1038/nprot.2007.357
   Tateno H, 2017, MOLECULES, V22, DOI 10.3390/molecules22071151
   Tateno H, 2015, STEM CELL REP, V4, P811, DOI 10.1016/j.stemcr.2015.02.016
   Tateno H, 2011, J BIOL CHEM, V286, P20345, DOI 10.1074/jbc.M111.231274
   TRAINER DL, 1988, INT J CANCER, V41, P287, DOI 10.1002/ijc.2910410221
   Wang LW, 2003, CLIN CANCER RES, V9, P6371
   Wang YC, 2011, CELL RES, V21, P1551, DOI 10.1038/cr.2011.148
   Weston BW, 1999, CANCER RES, V59, P2127
   Yan XM, 2015, BIOMED PHARMACOTHER, V70, P299, DOI 10.1016/j.biopha.2014.12.048
NR 42
TC 12
Z9 12
U1 2
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD DEC
PY 2020
VL 111
IS 12
BP 4548
EP 4557
DI 10.1111/cas.14687
EA NOV 2020
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PE0QC
UT WOS:000583325100001
PM 33058342
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Wiersma, VR
   de Bruyn, M
   Wei, YW
   van Ginkel, RJ
   Hirashima, M
   Niki, T
   Nishi, N
   Zhou, J
   Pouwels, SD
   Samplonius, DF
   Nijman, HW
   Eggleton, P
   Helfrich, W
   Bremer, E
AF Wiersma, Valerie R.
   de Bruyn, Marco
   Wei, Yunwei
   van Ginkel, Robert J.
   Hirashima, Mitsuomi
   Niki, Toshiro
   Nishi, Nozomu
   Zhou, Jin
   Pouwels, Simon D.
   Samplonius, Douwe F.
   Nijman, Hans W.
   Eggleton, Paul
   Helfrich, Wijnand
   Bremer, Edwin
TI The epithelial polarity regulator LGALS9/galectin-9 induces fatal
   frustrated autophagy in KRAS mutant colon carcinoma that depends on
   elevated basal autophagic flux
SO AUTOPHAGY
LA English
DT Article
DE autophagy; colon cancer; galectin-9; KRAS mutation; lysosomes
ID COLORECTAL-CANCER; CELL-DEATH; K-RAS; B-RAF; PROGNOSTIC-FACTOR;
   BREAST-CANCER; IN-VITRO; C-RAF; GALECTIN-9; RESISTANCE
AB Oncogenic mutation of KRAS (Kirsten rat sarcoma viral oncogene homolog) in colorectal cancer (CRC) confers resistance to both chemotherapy and EGFR (epidermal growth factor receptor)-targeted therapy. We uncovered that KRAS mutant (KRAS(mut)) CRC is uniquely sensitive to treatment with recombinant LGALS9/Galectin-9 (rLGALS9), a recently established regulator of epithelial polarity. Upon treatment of CRC cells, rLGALS9 rapidly internalizes via early- and late-endosomes and accumulates in the lysosomal compartment. Treatment with rLGALS9 is accompanied by induction of frustrated autophagy in KRAS(mut) CRC, but not in CRC with BRAF (B-Raf proto-oncogene, serine/threonine kinase) mutations (BRAF(mut)). In KRAS(mut) CRC, rLGALS9 acts as a lysosomal inhibitor that inhibits autophagosome-lysosome fusion, leading to autophagosome accumulation, excessive lysosomal swelling and cell death. This antitumor activity of rLGALS9 directly correlates with elevated basal autophagic flux in KRAS(mut) cancer cells. Thus, rLGALS9 has potent antitumor activity toward refractory KRAS(mut) CRC cells that may be exploitable for therapeutic use.
C1 [Wiersma, Valerie R.; Wei, Yunwei; van Ginkel, Robert J.; Samplonius, Douwe F.; Helfrich, Wijnand; Bremer, Edwin] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Translat Surg Oncol, Groningen, Netherlands.
   [de Bruyn, Marco; Nijman, Hans W.] Univ Groningen, Univ Med Ctr Groningen, Dept Obstet & Gynecol, Groningen, Netherlands.
   [Wei, Yunwei] Harbin Med Univ, Affiliated Hosp 1, Oncol & Endoscop Surg Dept, Harbin, Peoples R China.
   [Hirashima, Mitsuomi; Niki, Toshiro] Kagawa Univ, Fac Med, Dept Immunol & Immunopathol, Takamatsu, Kagawa 760, Japan.
   [Hirashima, Mitsuomi; Niki, Toshiro] GalPharma Co Ltd, Takamatsu, Kagawa, Japan.
   [Nishi, Nozomu] Kagawa Univ, Life Sci Res Ctr, Div Res Instrument & Equipment, Takamatsu, Kagawa 760, Japan.
   [Zhou, Jin; Helfrich, Wijnand] Harbin Med Univ, Affiliated Hosp 1, Dept Hematol,Key Lab Cell Transplantat, Heilongjiang Inst Hematol & Oncol,Minist Hlth, Harbin, Peoples R China.
   [Pouwels, Simon D.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, Dept Pathol & Med Biol,Expt Pulmonol & Inflammat, Groningen, Netherlands.
   [Eggleton, Paul; Bremer, Edwin] Univ Exeter, Sch Med, Exeter EX4 4QJ, Devon, England.
C3 University of Groningen; University of Groningen; Harbin Medical
   University; Kagawa University; Kagawa University; Harbin Medical
   University; University of Groningen; University of Exeter
RP Bremer, E (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Translat Surg Oncol, Groningen, Netherlands.
EM e.bremer@umcg.nl
RI Eggleton, Paul/A-9089-2015; Pouwels, Simon/A-4399-2013; Bremer,
   Edwin/B-7508-2016
OI Bremer, Edwin/0000-0002-0325-7376; de Bruyn, Marco/0000-0001-9819-9131;
   Helfrich, Wijnand/0000-0001-7004-3995; Wiersma, Valerie
   R./0000-0001-8012-0376; Eggleton, Paul/0000-0001-8244-2125; Nishi,
   Nozomu/0000-0001-7050-3226; Pouwels, Simon/0000-0001-7345-8061
FU Dutch Cancer Society grant [RUG2009-4355, RUG2009-4542, RUG2011-5206,
   RUG2012-5541, RUG2013-6209]; Netherlands Organization for Scientific
   Research; Melanoma Research Alliance; Alexander von Humboldt Foundation;
   Grants-in-Aid for Scientific Research [25460592] Funding Source: KAKEN
FX This work was supported by Dutch Cancer Society grants RUG2009-4355
   (E.B.), RUG2009-4542, RUG2011-5206, RUG2012-5541, RUG2013-6209 (to
   E.B./W.H.), the Netherlands Organization for Scientific Research (E.B.),
   the Melanoma Research Alliance (E.B.), and the Alexander von Humboldt
   Foundation (E.B/M.B.).
CR Barault L, 2008, INT J CANCER, V122, P2255, DOI 10.1002/ijc.23388
   Blasco RB, 2011, CANCER CELL, V19, P652, DOI 10.1016/j.ccr.2011.04.002
   Charette N, 2014, CURR OPIN ONCOL, V26, P454, DOI 10.1097/CCO.0000000000000088
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Fehrenbacher N, 2008, CANCER RES, V68, P6623, DOI 10.1158/0008-5472.CAN-08-0463
   Freeman Alyson K, 2013, Small GTPases, V4, P180, DOI 10.4161/sgtp.26117
   Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018
   Fuster MM, 2005, NAT REV CANCER, V5, P526, DOI 10.1038/nrc1649
   Gooden MJM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0065616
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   HAKOMORI S, 1984, ANNU REV IMMUNOL, V2, P103, DOI 10.1146/annurev.immunol.2.1.103
   Irie A, 2005, CLIN CANCER RES, V11, P2962, DOI 10.1158/1078-0432.CCR-04-0861
   Kageshita T, 2002, INT J CANCER, V99, P809, DOI 10.1002/ijc.10436
   Karreth FA, 2011, CANCER DISCOV, V1, P128, DOI 10.1158/2159-8290.CD-10-0044
   Kim JS, 2004, CANCER RES, V64, P1932, DOI 10.1158/0008-5472.CAN-03-3862
   Kim MJ, 2011, J BIOL CHEM, V286, P12924, DOI 10.1074/jbc.M110.138958
   Klibi J, 2009, BLOOD, V113, P1957, DOI 10.1182/blood-2008-02-142596
   Lai K, 2014, J CLIN PATHOL, V67, P854, DOI 10.1136/jclinpath-2014-202529
   Lakshminarayan R, 2014, NAT CELL BIOL, V16, P592, DOI 10.1038/ncb2970
   Lavoie H, 2013, NAT CHEM BIOL, V9, P428, DOI [10.1038/NCHEMBIO.1257, 10.1038/nchembio.1257]
   Leisching G, 2015, INT J GYNECOL CANCER, V25, P380, DOI 10.1097/IGC.0000000000000365
   Liang M, 2008, J CANCER RES CLIN, V134, P899, DOI 10.1007/s00432-008-0352-z
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Maddodi N, 2010, J INVEST DERMATOL, V130, P1657, DOI 10.1038/jid.2010.26
   Magudia K, 2012, J CELL BIOL, V198, P185, DOI 10.1083/jcb.201202108
   Mancias JD, 2011, ONCOTARGET, V2, P1302
   Martin-Belmonte F, 2012, NAT REV CANCER, V12, P23, DOI 10.1038/nrc3169
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mishra R, 2010, P NATL ACAD SCI USA, V107, P17633, DOI 10.1073/pnas.1012424107
   Mo D, 2012, MOL BIOL CELL, V23, P3636, DOI 10.1091/mbc.E12-04-0329
   Morgan MJ, 2014, AUTOPHAGY, V10, P1814, DOI 10.4161/auto.32135
   Mosesson Y, 2008, NAT REV CANCER, V8, P835, DOI 10.1038/nrc2521
   Nagae M, 2008, J MOL BIOL, V375, P119, DOI 10.1016/j.jmb.2007.09.060
   Nagahara K, 2008, J IMMUNOL, V181, P7660, DOI 10.4049/jimmunol.181.11.7660
   Nishi N, 2005, FEBS LETT, V579, P2058, DOI 10.1016/j.febslet.2005.02.054
   Nobumoto A, 2008, GLYCOBIOLOGY, V18, P735, DOI 10.1093/glycob/cwn062
   Nobumoto A, 2009, CLIN IMMUNOL, V130, P322, DOI 10.1016/j.clim.2008.09.014
   ONO K, 1994, J HISTOCHEM CYTOCHEM, V42, P659, DOI 10.1177/42.5.7512587
   Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118
   Preto A, 2008, J PATHOL, V214, P320, DOI 10.1002/path.2295
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Schneider D, 2010, EUR J CELL BIOL, V89, P788, DOI 10.1016/j.ejcb.2010.07.001
   Straube T, 2013, TRAFFIC, V14, P1014, DOI 10.1111/tra.12086
   Strohecker AM, 2014, AUTOPHAGY, V10, P384, DOI 10.4161/auto.27320
   Strohecker AM, 2013, CANCER DISCOV, V3, P1272, DOI 10.1158/2159-8290.CD-13-0397
   Thurston TLM, 2012, NATURE, V482, P414, DOI 10.1038/nature10744
   Wei MF, 2014, AUTOPHAGY, V10, P1179, DOI 10.4161/auto.28679
   Wiersma VR, 2012, J INVEST DERMATOL, V132, P2302, DOI 10.1038/jid.2012.133
   Wiersma VR, 2013, MED RES REV, V33, pE102, DOI 10.1002/med.20249
   Yamauchi A, 2006, BREAST J, V12, pS196, DOI 10.1111/j.1075-122X.2006.00334.x
   Yoon YH, 2010, INVEST OPHTH VIS SCI, V51, P6030, DOI 10.1167/iovs.10-5278
NR 53
TC 41
Z9 44
U1 1
U2 14
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 1554-8627
EI 1554-8635
J9 AUTOPHAGY
JI Autophagy
PD AUG
PY 2015
VL 11
IS 8
BP 1373
EP 1388
DI 10.1080/15548627.2015.1063767
PG 16
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CP6DZ
UT WOS:000359975900014
PM 26086204
OA Bronze, Green Published, Green Accepted
DA 2025-01-04
ER

PT J
AU Crucitta, S
   Cucchiara, F
   Mathijssen, R
   Mateo, J
   Jager, A
   Joosse, A
   Passaro, A
   Attili, I
   Petrini, I
   van Schaik, R
   Danesi, R
   Del Re, M
AF Crucitta, Stefania
   Cucchiara, Federico
   Mathijssen, Ron
   Mateo, Joaquin
   Jager, Agnes
   Joosse, Arjen
   Passaro, Antonio
   Attili, Ilaria
   Petrini, Iacopo
   van Schaik, Ron
   Danesi, Romano
   Del Re, Marzia
TI Treatment-driven tumour heterogeneity and drug resistance: Lessons from
   solid tumours
SO CANCER TREATMENT REVIEWS
LA English
DT Review
DE Tumour heterogeneity; Resistance to treatment; CRC; CRPC; NSCLC; mBC;
   Melanoma
ID CELL LUNG-CANCER; ANTI-EGFR THERAPY; METASTATIC BREAST-CANCER; ACQUIRED
   ENDOCRINE RESISTANCE; BRAF INHIBITOR RESISTANCE; PROSTATE-CANCER; ESR1
   MUTATIONS; COLORECTAL-CANCER; KRAS MUTATIONS; ALK INHIBITOR
AB Molecular heterogeneity characterizes tumours' evolution and adaptation and, because of its dynamics and continuous changes under external pressure, it is one of the major causes of drug resistance, contributing to therapy failure. Several studies reported evidence of molecular events occuring in individual tumours, including monoclonal or polyclonal resistance, and primary or secondary resistance mechanisms. While primary resistance is a phenomenon already present at the diagnosis of a tumor, the acquired one is strongly related to the selective pressure of treatments administered. Therefore, the pharmacological characteristics of a drug, including its potency, binding affinity and structure, largely influence the mechanism of resistance that will arise at the progression of the disease. As an example, the lung cancer experience clearly demonstrated that the highest is the potency of a drug on its target, the more are the possibilities that the mechanism of resistance will arise independently of the target itself. The present review is focused on tumour heterogeneity and its relation to resistance to targeted-therapy, based on treatment selective pressure across different tumour types, including lung, colorectal, prostate, breast cancer and melanoma. The mechanisms of resistance based on the drug potency and the selective pressure of treatments are discussed, leading to new drug developments or new therapeutic combinations.
C1 [Crucitta, Stefania; Cucchiara, Federico; Danesi, Romano; Del Re, Marzia] Univ Pisa, Dept Clin & Expt Med, Unit Clin Pharmacol & Pharmacogenet, Pisa, Italy.
   [Mathijssen, Ron; Jager, Agnes; Joosse, Arjen] Erasmus MC Canc Inst, Dept Med Oncol, Rotterdam, Netherlands.
   [Mateo, Joaquin] Vall dHebron Univ Hosp, Vall dHebron Inst Oncol VHIO, Barcelona, Spain.
   [Passaro, Antonio; Attili, Ilaria] European Inst Oncol IRCCS, Div Thorac Oncol, Milan, Italy.
   [Petrini, Iacopo] Univ Hosp Pisa, Dept Translat Res & New Technol Med, Unit Pathol, Pisa, Italy.
   [van Schaik, Ron] Unit Dept Clin Chem, Erasmus MC, Rotterdam, Netherlands.
   [Danesi, Romano] Univ Hosp Pisa, Dept Clin & Expt Med, Unit Clin Pharmacol & Pharmacogenet, I-56126 Pisa, Italy.
C3 University of Pisa; Erasmus University Rotterdam; Erasmus MC; Erasmus MC
   Cancer Institute; Vall d'Hebron Institut d'Oncologia (VHIO); Hospital
   Universitari Vall d'Hebron; IRCCS European Institute of Oncology (IEO);
   University of Pisa; Azienda Ospedaliero Universitaria Pisana; Erasmus
   University Rotterdam; Erasmus MC; University of Pisa; Azienda
   Ospedaliero Universitaria Pisana
RP Danesi, R (corresponding author), Univ Pisa, Dept Clin & Expt Med, Unit Clin Pharmacol & Pharmacogenet, Pisa, Italy.; Danesi, R (corresponding author), Univ Hosp Pisa, Dept Clin & Expt Med, Unit Clin Pharmacol & Pharmacogenet, I-56126 Pisa, Italy.
EM romano.danesi@unipi.it
RI Danesi, Romano/AAC-9410-2019; Crucitta, Stefania/AAC-5818-2022;
   Cucchiara, Federico/AAV-1872-2020; Mateo, Joaquin/AAG-9213-2019; Attili,
   Ilaria/AAO-4195-2020; Petrini, Iacopo/P-9318-2019; Passaro,
   Antonio/M-1888-2016; Del Re, Marzia/J-6468-2018; Petrini,
   Iacopo/K-7316-2016
OI Del Re, Marzia/0000-0001-7343-6161; Mathijssen, Ron/0000-0001-5667-5697;
   Cucchiara, Federico/0000-0002-0946-750X; Petrini,
   Iacopo/0000-0002-7752-6866
CR Abe H, 2011, ACS MED CHEM LETT, V2, P320, DOI 10.1021/ml200004g
   Abeshouse A, 2015, CELL, V163, P1011, DOI 10.1016/j.cell.2015.10.025
   Adua D, 2017, MOL CLIN ONCOL, V7, P113, DOI 10.3892/mco.2017.1270
   Agarwal P, 2019, CELL STEM CELL, V24, P769, DOI 10.1016/j.stem.2019.02.018
   Amaral T, 2017, EUR J CANCER, V73, P85, DOI 10.1016/j.ejca.2016.12.010
   Angus L, 2017, CANCER TREAT REV, V52, P33, DOI 10.1016/j.ctrv.2016.11.001
   Antonarakis ES, 2017, J CLIN ONCOL, V35, P2149, DOI 10.1200/JCO.2016.70.1961
   Aragon IM, 2019, ANN ONCOL, V30, P346
   Arcila ME, 2011, CLIN CANCER RES, V17, P1169, DOI 10.1158/1078-0432.CCR-10-2277
   Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   Arozarena I, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.09
   Arrigoni E, 2018, STEM CELL TRANSL MED, V7, P305, DOI 10.1002/sctm.17-0175
   Ascierto PA, 2016, LANCET ONCOL, V17, P1248, DOI 10.1016/S1470-2045(16)30122-X
   Asic K, 2016, CRIT REV ONCOL HEMAT, V97, P178, DOI 10.1016/j.critrevonc.2015.08.004
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Beije N, 2018, MOL ONCOL, V12, P48, DOI 10.1002/1878-0261.12147
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Bidard FC, 2019, ANN ONCOL, V30, P105
   Blair BG, 2014, J PATHOL, V232, P244, DOI 10.1002/path.4278
   Bode AM, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0055-0
   Boyd LK, 2012, NAT REV UROL, V9, P652, DOI 10.1038/nrurol.2012.185
   Bozic I, 2010, P NATL ACAD SCI USA, V107, P18545, DOI 10.1073/pnas.1010978107
   Brock A, 2009, NAT REV GENET, V10, P336, DOI 10.1038/nrg2556
   Buck SAJ, 2021, DRUG RESIST UPDATE, V56, DOI 10.1016/j.drup.2021.100761
   Cahill DP, 1999, TRENDS CELL BIOL, V9, pM57, DOI 10.1016/S0962-8924(99)01661-X
   Cai WJ, 2015, J CLIN ONCOL, V33, P3701, DOI 10.1200/JCO.2014.58.8293
   Cassell A, 2010, EXPERT OPIN INV DRUG, V19, P709, DOI 10.1517/13543781003769844
   Chandarlapaty S, 2016, JAMA ONCOL, V2, P1310, DOI 10.1001/jamaoncol.2016.1279
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Chen J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017933
   Chi KN, 2019, NEW ENGL J MED, V381, P13, DOI 10.1056/NEJMoa1903307
   Chiari R, 2014, J CLIN ONCOL, V32, pE30, DOI 10.1200/JCO.2012.47.7141
   Choo EF, 2013, CANCER CHEMOTH PHARM, V71, P133, DOI 10.1007/s00280-012-1988-6
   Cole AJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131486
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337
   Crucitta S, 2020, CANCER CHEMOTH PHARM, V86, P527, DOI 10.1007/s00280-020-04133-w
   Cucchiara F, 2021, PHARMACOL RES, V169, DOI 10.1016/j.phrs.2021.105643
   Cucchiara F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.593831
   Das Thakur M, 2013, NATURE, V494, P251, DOI 10.1038/nature11814
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Del Re M, 2021, PROSTATE CANCER P D, V24, P524, DOI 10.1038/s41391-020-00309-w
   Del Re M, 2019, BJU Int
   Del Re M, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105241
   Del Re M, 2021, CANCER IMMUNOL IMMUN, V70, P1667, DOI 10.1007/s00262-020-02810-6
   Del Re M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000724
   Del Re M, 2020, CLIN LUNG CANCER, V21, P232, DOI 10.1016/j.cllc.2019.10.003
   Del Re M, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20163951
   Del Re M, 2019, BREAST CANCER RES TR, V178, P57, DOI 10.1007/s10549-019-05365-y
   Del Re M, 2018, STEM CELLS, V36, P633, DOI 10.1002/stem.2787
   Del Re M, 2018, CRIT REV ONCOL HEMAT, V125, P51, DOI 10.1016/j.critrevonc.2018.03.002
   Del Re M, 2017, ONCOTARGET, V8, P13611, DOI 10.18632/oncotarget.6957
   Del Re M, 2017, EUR UROL, V71, P680, DOI 10.1016/j.eururo.2016.08.012
   Della Corte CM, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0776-2
   Dembinski JL, 2009, CLIN EXP METASTAS, V26, P611, DOI 10.1007/s10585-009-9260-0
   Denmeade SR, 2020, J CLIN ONCOL, V38
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Dienstmann Rodrigo, 2014, Am Soc Clin Oncol Educ Book, P91, DOI 10.14694/EdBook_AM.2014.34.91
   Doebele RC, 2012, CLIN CANCER RES, V18, P1472, DOI 10.1158/1078-0432.CCR-11-2906
   Dummer R, 2018, LANCET ONCOL, V19, P1315, DOI 10.1016/S1470-2045(18)30497-2
   Ellsworth RE, 2017, SEMIN CELL DEV BIOL, V64, P65, DOI 10.1016/j.semcdb.2016.08.025
   Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106
   Fizazi K, 2017, NEW ENGL J MED, V377, P352, DOI 10.1056/NEJMoa1704174
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Frey N, 2018, NAT REV GASTRO HEPAT, V15, P81, DOI 10.1038/nrgastro.2017.146
   Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061
   Friboulet L, 2014, CANCER DISCOV, V4, P662, DOI 10.1158/2159-8290.CD-13-0846
   Gainor JF, 2016, CANCER DISCOV, V6, P1118, DOI 10.1158/2159-8290.CD-16-0596
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gilmartin AG, 2011, CLIN CANCER RES, V17, P989, DOI 10.1158/1078-0432.CCR-10-2200
   Gouji T, 2014, J THORAC ONCOL, V9, pE27, DOI 10.1097/JTO.0000000000000113
   Greaves M, 2012, NATURE, V481, P306, DOI 10.1038/nature10762
   Grothey A, 2008, J CLIN ONCOL, V26, P5326, DOI 10.1200/JCO.2008.16.3212
   Grzywa TM, 2017, TRANSL ONCOL, V10, P956, DOI 10.1016/j.tranon.2017.09.007
   Gudmundsson J, 2008, NAT GENET, V40, P281, DOI 10.1038/ng.89
   Hagan Suzanne, 2013, EPMA J, V4, P3, DOI 10.1186/1878-5085-4-3
   Haibe Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00221
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059
   Hanker AB, 2020, CANCER CELL, V37, P496, DOI 10.1016/j.ccell.2020.03.009
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Heck MM, 2012, BJU INT, V110, pE635, DOI 10.1111/j.1464-410X.2012.11364.x
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Howard N, 2019, SEMIN CANCER BIOL, V57, P111, DOI 10.1016/j.semcancer.2018.09.003
   Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jeselsohn R, 2015, NAT REV CLIN ONCOL, V12, P573, DOI 10.1038/nrclinonc.2015.117
   Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627
   Johnson DB, 2015, EUR J CANCER, V51, P2792, DOI 10.1016/j.ejca.2015.08.022
   Joseph JD, 2013, CANCER DISCOV, V3, DOI 10.1158/2159-8290.CD-13-0226
   Kaklamani VG, 2017, ONCOLOGIST, V22, P507, DOI 10.1634/theoncologist.2015-0464
   Katayama R, 2014, CLIN CANCER RES, V20, P5686, DOI 10.1158/1078-0432.CCR-14-1511
   Katayama R, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003316
   Kattan J, 2019, ANTI-CANCER DRUG, V30, P1052, DOI 10.1097/CAD.0000000000000827
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Keats JJ, 2012, BLOOD, V120, P1067, DOI 10.1182/blood-2012-01-405985
   Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914
   Kircher SM, 2016, CANCER J, V22, P182, DOI 10.1097/PPO.0000000000000192
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Koelblinger P, 2018, CURR OPIN ONCOL, V30, P125, DOI 10.1097/CCO.0000000000000426
   Kogita A, 2015, INT J ONCOL, V46, P1025, DOI 10.3892/ijo.2014.2797
   Kosmidou V, 2014, HUM MUTAT, V35, P329, DOI 10.1002/humu.22496
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868
   Leto SM, 2015, CLIN CANCER RES, V21, P5519, DOI 10.1158/1078-0432.CCR-14-3066
   Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109
   Lin JJ, 2017, CANCER DISCOV, V7, P137, DOI 10.1158/2159-8290.CD-16-1123
   Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067
   Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009
   Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176
   Long GV, 2015, LANCET, V386, P444, DOI 10.1016/S0140-6736(15)60898-4
   Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694
   Lopez-Tarruella S, 2007, CLIN CANCER RES, V13, P6921, DOI 10.1158/1078-0432.CCR-07-1399
   Lovly CM, 2014, NAT MED, V20, P1027, DOI 10.1038/nm.3667
   Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915
   Martínez-Pérez C, 2019, EXPERT REV ANTICANC, V19, P121, DOI 10.1080/14737140.2019.1552138
   Martini G, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102023
   Marusiak AA, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4901
   McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Merenbakh-Lamin K, 2013, CANCER RES, V73, P6856, DOI 10.1158/0008-5472.CAN-13-1197
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Messina C, 2020, J ONCOL, V2020, DOI 10.1155/2020/4986365
   Mills JN, 2018, CURR OPIN PHARMACOL, V41, P59, DOI 10.1016/j.coph.2018.04.009
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Miyawaki M, 2017, MOL CANCER RES, V15, P106, DOI 10.1158/1541-7786.MCR-16-0211
   Mohan S, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004271
   Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Morelli MP, 2015, ANN ONCOL, V26, P731, DOI 10.1093/annonc/mdv005
   Morgan GJ, 2012, NAT REV CANCER, V12, P335, DOI 10.1038/nrc3257
   Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018
   Mostaghel EA, 2011, CLIN CANCER RES, V17, P5913, DOI 10.1158/1078-0432.CCR-11-0728
   Mulder TAM, 2021, CANCERS, V13, DOI 10.3390/cancers13040771
   Murray D., 2013, J NUCL MED RAD THER, V6, P18
   Nardone A, 2015, BREAST, V24, pS60, DOI 10.1016/j.breast.2015.07.015
   Navin N, 2010, GENOME RES, V20, P68, DOI 10.1101/gr.099622.109
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Neri E, 2018, INSIGHTS IMAGING, V9, P915, DOI 10.1007/s13244-018-0657-7
   O'Leary B, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03215-x
   Osborne CK, 2011, ANNU REV MED, V62, P233, DOI 10.1146/annurev-med-070909-182917
   Ou SHI, 2014, J THORAC ONCOL, V9, P549, DOI 10.1097/JTO.0000000000000094
   Oxnard G, 2017, J THORAC ONCOL, V12, pS1767, DOI 10.1016/j.jtho.2017.09.376
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   Passaro A, 2021, NAT CANCER, V2, P377, DOI 10.1038/s43018-021-00195-8
   Passaro A, 2021, J THORAC ONCOL, V16, P764, DOI 10.1016/j.jtho.2020.12.002
   Passaro A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000919
   Patel HK, 2018, PHARMACOL THERAPEUT, V186, P1, DOI 10.1016/j.pharmthera.2017.12.012
   Piotrowska Z, 2017, INT J RADIAT ONCOL, V98, P220, DOI 10.1016/j.ijrobp.2017.01.037
   Piotrowska Z, 2017, J CLIN ONCOL, V35
   Pisco AO, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3467
   Piscuoglio S, 2018, ANN ONCOL, V29, P787, DOI 10.1093/annonc/mdy081
   Planchard D, 2018, ANN ONCOL, V29, P192, DOI 10.1093/annonc/mdy275
   Puig I, 2018, J CLIN INVEST, V128, P3887, DOI 10.1172/JCI96393
   Raghav KPS, 2016, J CLIN ONCOL, V34
   Ramalingam SS, 2018, ANN ONCOL, V29
   Rathkopf DE, 2017, ANN ONCOL, V28, P2264, DOI 10.1093/annonc/mdx283
   Razavi P, 2018, CANCER CELL, V34, P427, DOI 10.1016/j.ccell.2018.08.008
   Rheault TR, 2013, ACS MED CHEM LETT, V4, P358, DOI 10.1021/ml4000063
   Rizos H, 2014, CLIN CANCER RES, V20, P1965, DOI 10.1158/1078-0432.CCR-13-3122
   Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690
   Robey RW, 2018, NAT REV CANCER, V18, P452, DOI 10.1038/s41568-018-0005-8
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Romanel A, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac9511
   Ross-Adams H, 2015, EBIOMEDICINE, V2, P1133, DOI 10.1016/j.ebiom.2015.07.017
   Salvi S, 2015, BRIT J CANCER, V112, P1717, DOI 10.1038/bjc.2015.128
   Sameen S, 2016, J THEOR BIOL, V389, P263, DOI 10.1016/j.jtbi.2015.10.019
   Sánchez-Martín FJ, 2016, CLIN CANCER RES, V22, P3260, DOI 10.1158/1078-0432.CCR-15-2400
   Santos-de-Frutos K, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02257-0
   Sarkisian S, 2018, DRUG DES DEV THER, V12, P2553, DOI 10.2147/DDDT.S131721
   Sartore-Bianchi A, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3506
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sasaki T, 2011, CANCER RES, V71, P6051, DOI 10.1158/0008-5472.CAN-11-1340
   Schiavon G, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7551
   Sequist LV, 2020, LANCET ONCOL, V21, P373, DOI 10.1016/S1470-2045(19)30785-5
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Shackleton M, 2009, CELL, V138, P822, DOI 10.1016/j.cell.2009.08.017
   Shannan B, 2016, CANCER TREAT RES, V167, P1, DOI 10.1007/978-3-319-22539-5_1
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shaw AT, 2016, NEW ENGL J MED, V374, P54, DOI 10.1056/NEJMoa1508887
   Shi HB, 2014, CANCER DISCOV, V4, P69, DOI 10.1158/2159-8290.CD-13-0279
   Shi HB, 2012, CANCER DISCOV, V2, P414, DOI 10.1158/2159-8290.CD-12-0022
   Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100
   Siena S., 2016, Ann. Oncol, V27, piv39, DOI [10.1093/annonc/mdw335.01, DOI 10.1093/ANNONC/MDW335.01]
   Smolle E, 2021, CANCERS, V13, DOI 10.3390/cancers13040699
   Solomon BJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.9009
   Song CJ, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0672-2
   Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137
   Spagnolo F, 2014, ONCOTARGET, V5, P10206, DOI 10.18632/oncotarget.2602
   Spoerke JM, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11579
   Steinestel Julie, 2019, Oncotarget, V10, P4213, DOI 10.18632/oncotarget.3925
   Su KY, 2012, J CLIN ONCOL, V30, P433, DOI 10.1200/JCO.2011.38.3224
   Sumiyoshi T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40719-y
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Tanizaki J, 2012, CLIN CANCER RES, V18, P6219, DOI 10.1158/1078-0432.CCR-12-0392
   Thompson N, 2005, CURR OPIN PHARMACOL, V5, P350, DOI 10.1016/j.coph.2005.04.007
   Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854
   Tougeron D, 2013, ANN ONCOL, V24, P1267, DOI 10.1093/annonc/mds620
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Toyokawa G, 2014, J THORAC ONCOL, V9, pE86, DOI 10.1097/JTO.0000000000000358
   Tripathy D, 2004, J CLIN ONCOL, V22, P1063, DOI 10.1200/JCO.2004.06.557
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
   Wang T, 2015, CLIN CANCER RES, V21, P1652, DOI 10.1158/1078-0432.CCR-14-1554
   Wang YB, 2018, LUNG CANCER, V118, P105, DOI 10.1016/j.lungcan.2018.02.007
   Wei JC, 2018, CANCERS, V10, DOI 10.3390/cancers10010010
   Wei L, 2017, EUR UROL, V71, P183, DOI 10.1016/j.eururo.2016.07.008
   Wilson FH, 2015, CANCER CELL, V27, P397, DOI 10.1016/j.ccell.2015.02.005
   Wu LL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.602762
   Wu SG, 2016, ONCOTARGET, V7, P12404, DOI 10.18632/oncotarget.7189
   Xu CR, 2017, THORAC CANCER, V8, P51, DOI 10.1111/1759-7714.12382
   Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336
   Yin AY, 2019, CPT-PHARMACOMET SYST, V8, P720, DOI 10.1002/psp4.12450
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012
   Zheng BB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5481-z
   Zhuo ML, 2014, MOL CLIN ONCOL, V2, P953, DOI 10.3892/mco.2014.359
NR 224
TC 29
Z9 32
U1 5
U2 19
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0305-7372
EI 1532-1967
J9 CANCER TREAT REV
JI Cancer Treat. Rev.
PD MAR
PY 2022
VL 104
AR 102340
DI 10.1016/j.ctrv.2022.102340
EA FEB 2022
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 1K9JR
UT WOS:000798911200014
PM 35151155
DA 2025-01-04
ER

PT J
AU Chang, YT
   Chen, CC
   Chang, SC
   Chang, YY
   Lin, BW
   Chen, HH
   Hsieh, YY
   Hsu, HC
   Hsieh, MC
   Kuan, FC
   Wu, CC
   Lu, WC
   Su, YL
   Liang, YH
   Chen, JB
   Huang, SY
   Huang, CW
   Wang, JY
AF Chang, Yu-Tang
   Chen, Chou-Chen
   Chang, Shih-Ching
   Chang, Yu-Yao
   Lin, Bo-Wen
   Chen, Hong-Hwa
   Hsieh, Yao-Yu
   Hsu, Hung-Chih
   Hsieh, Meng-Che
   Kuan, Feng-Che
   Wu, Chih-Chien
   Lu, Wei-Chen
   Su, Yu-Li
   Liang, Yi-Hsin
   Chen, Joe-Bin
   Huang, Shuan-Yuan
   Huang, Ching-Wen
   Wang, Jaw-Yuan
TI Efficacy and Safety of a Parenteral Nutrition Program for Patients with
   <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Administered
   First-Line Cetuximab Plus Chemotherapy: A Propensity Score Matching
   Study
SO NUTRIENTS
LA English
DT Article
DE cetuximab; RAS wild-type; metastatic colorectal cancer; supplementary
   home parenteral nutrition
ID HOME; COMPLICATIONS; BEVACIZUMAB; IRINOTECAN
AB Malnutrition is a common problem in patients with metastatic colorectal cancer (mCRC) receiving targeted therapy plus chemotherapy, resulting in severe toxicity and decreased survival rates. This retrospective study employing propensity score matching (PSM) examined the efficacy and safety of a supplemental home parenteral nutrition (HPN) program for patients with RAS wild-type mCRC receiving cetuximab plus chemotherapy. This retrospective nationwide registry study included data from 14 medical centers/hospitals across Taiwan, and the data period ranged from November 2016 to December 2020. Patients with RAS wild-type mCRC receiving cetuximab plus chemotherapy as their first-line therapy were included and divided into HPN and non-HPN program groups. HPN was initiated based on patient-specific factors, such as baseline nutritional status, treatment-related toxicities, and comorbidities. Clinical outcomes were evaluated using response to therapy, duration of response (DoR), progression-free survival (PFS), and overall survival (OS). This study recruited 758 patients, of whom 110 and 648 were included in the HPN and non-HPN program groups, respectively. After 1:3 PSM, the data of 109 and 327 patients from the HPN and non-HPN program groups were analyzed, respectively. The HPN program group had a higher metastasectomy rate (33.9% vs. 20.2%, p = 0.005), and longer duration of treatment and DoR than the non-HPN program group (13.6 vs. 10.3 and 13.6 vs. 9.9 months, p = 0.001 and < 0.001, respectively). The HPN program group tended to have a longer median PFS (18.2 vs. 13.9 months, p = 0.102). Moreover, we noted a significant improvement in the median OS in the same group (53.4 vs. 34.6 months, p = 0.002). Supplemental HPN programs may be recommended for select patients with mCRC receiving targeted therapy plus chemotherapy to improve oncological outcomes.
C1 [Chang, Yu-Tang] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Pediat Surg, Kaohsiung 80708, Taiwan.
   [Chang, Yu-Tang; Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg, Kaohsiung 80708, Taiwan.
   [Chen, Chou-Chen] Taichung Vet Gen Hosp, Dept Surg, Taichung 40705, Taiwan.
   [Chang, Shih-Ching] Vet Gen Hosp, Dept Surg, Div Colon & Rectal Surg, Taipei 11217, Taiwan.
   [Chang, Yu-Yao; Huang, Shuan-Yuan] Changhua Christian Hosp, Dept Colorectal Surg, Changhua 50006, Taiwan.
   [Chang, Yu-Yao] Natl Chung Hsing Univ, Coll Med, Dept Postbaccalaureate Med, Taichung 40227, Taiwan.
   [Lin, Bo-Wen] Natl Cheng Kung Univ Hosp, Dept Surg, Tainan 70457, Taiwan.
   [Chen, Hong-Hwa] Chang Gung Mem Hosp, Dept Surg, Div Colon & Rectal Surg, Kaohsiung 83301, Taiwan.
   [Hsieh, Yao-Yu] Taipei Med Univ, Shuang Ho Hosp, Div Hematol & Oncol, New Taipei City 23561, Taiwan.
   [Hsieh, Yao-Yu] Taipei Med Univ, Coll Med, Sch Med, Div Hematol & Oncol,Dept Internal Med, Taipei 11031, Taiwan.
   [Hsu, Hung-Chih] Chang Gung Mem Hosp Linkou, Dept Internal Med, Div Hematol Oncol, Taoyuan 33305, Taiwan.
   [Hsu, Hung-Chih] Chang Gung Univ, Coll Med, Taoyuan 33305, Taiwan.
   [Hsieh, Meng-Che] I Shou Univ, E Da Hosp, Dept Internal Med, Div Hematol Oncol, Kaohsiung 84001, Taiwan.
   [Kuan, Feng-Che] Chang Gung Mem Hosp, Dept Hematol & Oncol, Chiayi 61363, Taiwan.
   [Wu, Chih-Chien] Kaohsiung Vet Gen Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung 81362, Taiwan.
   [Wu, Chih-Chien] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei 30010, Taiwan.
   [Lu, Wei-Chen] Natl Taiwan Univ Hosp, Dept Oncol, Yunlin Branch, Yunlin 64041, Taiwan.
   [Su, Yu-Li] Chang Gung Mem Hosp, Dept Internal Med, Div Hematol & Oncol, Kaohsiung 33305, Taiwan.
   [Liang, Yi-Hsin] Natl Taiwan Univ Hosp, Dept Oncol, Taipei 10002, Taiwan.
   [Chen, Joe-Bin] Chung Shan Med Univ Hosp, Dept Surg, Taichung 40201, Taiwan.
   [Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung 80756, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 80708, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 80708, Taiwan.
   [Wang, Jaw-Yuan] Minist Hlth & Welf, Pingtung Hosp, Pingtung 90054, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Taichung Veterans General Hospital;
   Changhua Christian Hospital; National Chung Hsing University; National
   Cheng Kung University; National Cheng Kung University Hospital; Chang
   Gung Memorial Hospital; Taipei Medical University; Taipei Medical
   University; Chang Gung Memorial Hospital; Chang Gung University; I Shou
   University; E-Da Hospital; Chang Gung Memorial Hospital; Kaohsiung
   Veterans General Hospital; National Yang Ming Chiao Tung University;
   National Taiwan University; National Taiwan University Hospital; Chang
   Gung Memorial Hospital; National Taiwan University; National Taiwan
   University Hospital; Chung Shan Medical University; Chung Shan Medical
   University Hospital; Kaohsiung Medical University; Kaohsiung Medical
   University Hospital; Kaohsiung Medical University; Kaohsiung Medical
   University
RP Huang, CW; Wang, JY (corresponding author), Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg, Kaohsiung 80708, Taiwan.; Huang, CW; Wang, JY (corresponding author), Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung 80756, Taiwan.; Wang, JY (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 80708, Taiwan.; Wang, JY (corresponding author), Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 80708, Taiwan.; Wang, JY (corresponding author), Minist Hlth & Welf, Pingtung Hosp, Pingtung 90054, Taiwan.
EM 890300@ms.kmuh.org.tw; ccchen24615237@gmail.com; scchang3@ym.edu.tw;
   177176@cch.org.tw; wen276@gmail.com; hs168@adm.cgmh.org.tw;
   alecto39@gmail.com; b12117@adm.cgmh.org.tw; it905180@gmail.com;
   pauleoswu@gmail.com; coste@ms16.hinet.net; yolisu@cgmh.org.tw;
   crsmyway@gmail.com; 140111@cch.org.tw; baseball5824@yahoo.com.tw;
   cy614112@ms14.hinet.net
RI Jaw-Yuan, Wang/AFS-8845-2022; Chen, Chou-Chen/AAL-1779-2021
OI Chang, Yu-Yao/0000-0002-4504-9030; Hsieh, Yao-Yu/0000-0003-4368-4281;
   chen, chou-chen/0000-0003-3323-8739; Wang, Jaw-Yuan/0000-0002-7705-2621;
   LIANG, YI-HSIN/0000-0002-7224-9687
FU Merck Ltd., Taipei, Taiwan, an affiliate of Merck KGaA, Darmstadt,
   Germany; Ministry of Science and Technology [MOST
   111-2314-B-037-070-MY3, MOST 111-2314-B-037-049, 12D1-IVMOHW02];
   Ministry of Health and Welfare [KMUH111-1R31]; health and welfare
   surcharge on tobacco products; Kaohsiung Medical University Hospital
   [KMUH111-1R32, KMUH111-1M28, KMUH111-1M29, KMUH111-1M31, KMU-TC112A04];
   Kaohsiung Medical University Research Center Grant; Taiwan Precision
   Medicine Initiative; Taiwan Biobank; Academia Sinica, Taiwan, R.O.C; 
   [MOST 109-2314-B-037-046-MY3]
FX This research was financially supported by Merck Ltd., Taipei, Taiwan,
   an affiliate of Merck KGaA, Darmstadt, Germany (CrossRef Funder ID:
   10.13039/100009945). This work was supported by grants through funding
   from the Ministry of Science and Technology (MOST
   109-2314-B-037-046-MY3, MOST 111-2314-B-037-070-MY3, MOST
   111-2314-B-037-049) and the Ministry of Health and Welfare
   (12D1-IVMOHW02) and funded by the health and welfare surcharge on
   tobacco products, and the Kaohsiung Medical University Hospital
   (KMUH111-1R31, KMUH111-1R32, KMUH111-1M28, KMUH111-1M29, KMUH111-1M31)
   and Kaohsiung Medical University Research Center Grant (KMU-TC112A04).
   In addition, this study was supported by the Grant of the Taiwan
   Precision Medicine Initiative and Taiwan Biobank, Academia Sinica,
   Taiwan, R.O.C.
CR Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Chen HH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.764912
   Correa E, 2021, DRUG AGING, V38, P639, DOI 10.1007/s40266-021-00869-z
   Cotogni P, 2016, ANN PALLIAT MED, V5, P42, DOI 10.3978/j.issn.2224-5820.2016.01.05
   de Burgoa LJ, 2006, J INFUS MURS, V29, P74, DOI 10.1097/00129804-200603000-00004
   Di Costanzo F., 2018, ANN ONCOL, V29, P618, DOI [10.1093/annonc/mdy300.047, DOI 10.1093/ANNONC/MDY300.047]
   DiBaise JK, 2022, NUTRIENTS, V14, DOI 10.3390/nu14132558
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Fakih M, 2010, CURR ONCOL, V17, pS18
   Fakih M, 2010, CURR ONCOL, V17, pS3
   Gillanders L, 2012, CLIN NUTR, V31, P30, DOI 10.1016/j.clnu.2011.09.009
   Giordano G, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147717
   Gössling GCL, 2021, ONCOLOGIST, V26, pE1581, DOI 10.1002/onco.13802
   Health Promotion Administration The Ministry of Health and Welfare of Taiwan, 2020, CANC INC STAT
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Howard L, 2006, GASTROENTEROLOGY, V130, pS52, DOI 10.1053/j.gastro.2005.09.065
   Huang CW, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-02086-1
   Huang SC, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.808808
   Kumpf VJ, 2012, NUTR CLIN PRACT, V27, P749, DOI 10.1177/0884533612464888
   Lewandowska A, 2022, INT J ENV RES PUB HE, V19, DOI 10.3390/ijerph19116881
   Li R, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00868
   Liu YX, 2020, TRANSL CANCER RES, V9, P382, DOI 10.21037/tcr.2019.11.39
   Ma CJ, 2021, SUPPORT CARE CANCER, V29, P1977, DOI 10.1007/s00520-020-05687-4
   Mahmoud N, 2010, DIS COLON RECTUM, V53, P1080, DOI 10.1007/DCR.0b013e3181dcadbc
   Muscaritoli M, 2021, CLIN NUTR, V40, P2898, DOI 10.1016/j.clnu.2021.02.005
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Rochford A, 2021, FRONTLINE GASTROENTE, V12, P128, DOI 10.1136/flgastro-2019-101230
   Roeland EJ, 2020, J CLIN ONCOL, V38, P2438, DOI 10.1200/JCO.20.00611
   Snyder Lorraine C, 2005, Clin Colorectal Cancer, V5 Suppl 2, pS71, DOI 10.3816/CCC.2005.s.010
   Staun M, 2009, CLIN NUTR, V28, P467, DOI 10.1016/j.clnu.2009.04.001
   Travers A, 2021, CLIN COLORECTAL CANC, V20, pE21, DOI 10.1016/j.clcc.2020.08.002
   Tsai HL, 2021, ONCOL RES, V29, P47, DOI 10.3727/096504022X16451187313084
   Tsai HL, 2020, EUR J CANCER, V138, P19, DOI 10.1016/j.ejca.2020.05.031
   Yeh YS, 2022, ONCOL RES, V30, P65, DOI 10.32604/or.2022.026659
   Zenonos K, 2013, WORLD J GASTRO ONCOL, V5, P97, DOI 10.4251/wjgo.v5.i5.97
NR 35
TC 0
Z9 0
U1 4
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6643
J9 NUTRIENTS
JI Nutrients
PD JUL
PY 2023
VL 15
IS 13
AR 2971
DI 10.3390/nu15132971
PG 13
WC Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Nutrition & Dietetics
GA M6IN5
UT WOS:001031234200001
PM 37447297
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Lim, Y
   Han, SW
   Yoon, JH
   Lee, JM
   Lee, JM
   Paeng, JC
   Won, JK
   Kang, GH
   Jeong, SY
   Park, KJ
   Lee, KH
   Kim, JH
   Kim, TY
AF Lim, Yoojoo
   Han, Sae-Won
   Yoon, Jeong Hee
   Lee, Jeong Min
   Lee, Jung Min
   Paeng, Jin Chul
   Won, Jae-Kyung
   Kang, Gyeong Hoon
   Jeong, Seung-Yong
   Park, Kyu Joo
   Lee, Kyung-Hun
   Kim, Jee Hyun
   Kim, Tae-You
TI Clinical Implication of Anti-Angiogenic Effect of Regorafenib in
   Metastatic Colorectal Cancer
SO PLOS ONE
LA English
DT Article
ID RESPONSE EVALUATION CRITERIA; RENAL-CELL CARCINOMA; PHASE-3 TRIAL;
   LUNG-CANCER; HEPATOCELLULAR-CARCINOMA; COMPUTED-TOMOGRAPHY; TARGETED
   THERAPY; TUMOR CAVITATION; MODIFIED RECIST; BAY 73-4506
AB Background
   Regorafenib induces distinct radiological changes that represent its anti-angiogenic effect. However, clinical implication of the changes is unclear.
   Methods
   Tumor attenuation as measured by Hounsfield units (HU) in contrast-enhanced computed tomography (CT) and cavitary changes of lung metastases were analyzed in association with treatment outcome of metastatic colorectal cancer patients (N = 80) treated with regorafenib in a prospective study.
   Results
   141 lesions in 72 patients were analyzed with HU. After 2 cycles of regorafenib, 87.5% of patients showed decrease of HU (Median change -23.9%, range -61.5%-20.7%). Lesional attenuation change was modestly associated with metabolic changes of 18-fluoro-deoxyglucose positron emission tomography-CT (Pearson's r = 0.37, p = 0.002). Among 53 patients with lung metastases, 17 (32.1%) developed cavitary changes. There were no differences in disease control rate, progression-free survival, or overall survival according to the radiological changes. At the time of progressive disease (PD) according to RECIST 1.1, HU was lower than baseline in 86.0% (43/50) and cavitary change of lung metastasis persisted without refilling in 84.6% (11/13).
   Conclusion
   Regorafenib showed prominent anti-angiogenic effect in colorectal cancer, but the changes were not associated with treatment outcome. However, the anti-angiogenic effects persisted at the time of PD, which suggests that we may need to develop new treatment strategies.
C1 [Lim, Yoojoo; Han, Sae-Won; Lee, Kyung-Hun; Kim, Tae-You] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
   [Han, Sae-Won; Kim, Tae-You] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul, South Korea.
   [Yoon, Jeong Hee; Lee, Jeong Min] Seoul Natl Univ Hosp, Dept Radiol, Seoul 110744, South Korea.
   [Lee, Jung Min; Paeng, Jin Chul] Seoul Natl Univ Hosp, Dept Nucl Med, Seoul 110744, South Korea.
   [Won, Jae-Kyung; Kang, Gyeong Hoon] Seoul Natl Univ Hosp, Dept Pathol, Seoul 110744, South Korea.
   [Jeong, Seung-Yong; Park, Kyu Joo] Seoul Natl Univ Hosp, Dept Surg, Seoul 110744, South Korea.
   [Kim, Jee Hyun] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, Geyonggi Do, South Korea.
   [Kim, Tae-You] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Mol Med & Biopharmaceut Sci, Seoul, South Korea.
C3 Seoul National University (SNU); Seoul National University Hospital;
   Seoul National University (SNU); Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University Hospital; Seoul National University (SNU); Seoul
   National University (SNU)
RP Kim, TY (corresponding author), Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
EM kimty@snu.ac.kr
RI Kim, Jee/J-5441-2012; Lee, Jeong/V-3429-2019; Park, Kyu/J-5480-2012;
   Lee, Jung-Min/L-8227-2016; Yoon, Jeong Hee/ABA-5127-2021; Kang, Gyeong
   Hoon/F-1051-2010
OI Lee, Jeong Min/0000-0003-0561-8777; Lim, Yoojoo/0000-0002-4181-2916;
   Won, Jae-Kyung/0000-0003-1459-8093; Kang, Gyeong
   Hoon/0000-0003-2380-6675; Yoon, Jeong Hee/0000-0002-9925-9973
FU Korea Health Technology R&D Project through the Korea Health Industry
   Development Institute (KHIDI); Ministry of Health & Welfare, Republic of
   Korea [HI14C1277]
FX This research was supported by a grant of the Korea Health Technology
   R&D Project through the Korea Health Industry Development Institute
   (KHIDI, http://www.khidi.or.kr), funded by the Ministry of Health &
   Welfare, Republic of Korea (grant number: HI14C1277), to TYK.
   Regorafenib was provided by Bayer Pharma AG (http://pharma.bayer.com).
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Abou-Elkacem L, 2013, MOL CANCER THER, V12, P1322, DOI 10.1158/1535-7163.MCT-12-1162
   [Anonymous], ASCO M
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049
   Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755
   Crabb SJ, 2009, J CLIN ONCOL, V27, P404, DOI 10.1200/JCO.2008.16.2545
   Cyran CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076009
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
   Edeline J, 2012, CANCER-AM CANCER SOC, V118, P147, DOI 10.1002/cncr.26255
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Jeffers M, 2013, ASCO M S, V31, P381
   Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132
   Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
   Marom EM, 2008, J THORAC ONCOL, V3, P351, DOI 10.1097/JTO.0b013e318168c7e9
   Nishino M, 2012, CANCER IMAGING, V12, P225, DOI 10.1102/1470-7330.2012.0027
   O'Connor JPB, 2012, CLIN CANCER RES, V18, P6588, DOI 10.1158/1078-0432.CCR-12-1501
   Ricotta R, 2013, LANCET, V381, P1537, DOI 10.1016/S0140-6736(13)60976-9
   Schmieder R, 2014, INT J CANCER, V135, P1487, DOI 10.1002/ijc.28669
   Shinagare AB, 2014, EUR J CANCER, V50, P981, DOI 10.1016/j.ejca.2013.11.037
   Smith AD, 2010, AM J ROENTGENOL, V194, P1470, DOI 10.2214/AJR.09.3456
   Smith AD, 2010, AM J ROENTGENOL, V194, P157, DOI 10.2214/AJR.09.2941
   Strumberg D, 2012, BRIT J CANCER, V106, P1722, DOI 10.1038/bjc.2012.153
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
NR 24
TC 19
Z9 19
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 15
PY 2015
VL 10
IS 12
AR e0145004
DI 10.1371/journal.pone.0145004
PG 13
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CY9HZ
UT WOS:000366719300038
PM 26671465
OA gold, Green Published, Green Submitted
DA 2025-01-04
ER

PT J
AU Tomida, C
   Aibara, K
   Yamagishi, N
   Yano, C
   Nagano, H
   Abe, T
   Ohno, A
   Hirasaka, K
   Nikawa, T
   Teshima-Kondo, S
AF Tomida, Chisato
   Aibara, Kana
   Yamagishi, Naoko
   Yano, Chiaki
   Nagano, Hikaru
   Abe, Tomoki
   Ohno, Ayako
   Hirasaka, Katsuya
   Nikawa, Takeshi
   Teshima-Kondo, Shigetada
TI The malignant progression effects of regorafenib in human colon cancer
   cells
SO JOURNAL OF MEDICAL INVESTIGATION
LA English
DT Article
DE angiogenesis inhibitor; VEGF receptor tyrosine kinase inhibitor;
   regorafenib; colon cancer cells; malignant phenotype
AB A number of anti-angiogenic drugs targeting vascular endothelial growth factor receptors ( VEGF-R) have developed and enabled significant advances in cancer therapy including colorectal cancer. However, acquired resistance to the drugs occurs, leading to disease progression, such as invasion and metastasis. How tumors become the resistance and promote their malignancy remains fully uncertain. One ofpossiblemechanisms for the resistance and the progression may be the direct effect of VEGF-R inhibitors on tumor cells expressing VEGF-R. We investigated here the direct effect of a VEGF-R-targeting agent, regorafenib, which is the first small molecule inhibitor of VEGF-Rs for the treatment of patients with colorectal cancer, on phenotype changes in colon cancer HCT116 cells. Treatment of cells with regorafenib for only 2 days activated cell migration and invasion, while vehicle- treated control cells showed less activity. Intriguingly, chronic exposure to regorafenib for 90 days dramatically increased migration and invasion activities and induced a resistance to hypoxia-induced apoptosis. These results suggest that loss of VEGF signaling in cancer cells may induce the acquired resistance to VEGF/VEGF-R targeting therapy by gaining two major malignant phenotypes, apoptosis resistance and activation of migration/invasion.
C1 [Tomida, Chisato; Aibara, Kana; Yamagishi, Naoko; Yano, Chiaki; Abe, Tomoki; Ohno, Ayako; Nikawa, Takeshi; Teshima-Kondo, Shigetada] Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Physiol Nutr, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
   [Hirasaka, Katsuya] Nagasaki Univ, Grad Sch Fisheries Sci & Environm Studies, Nagasaki 8528521, Japan.
   [Nagano, Hikaru] Sagami Womens Univ, Fac Nutrit Sci, Sagamihara, Kanagawa 2520383, Japan.
C3 Tokushima University; Nagasaki University
RP Teshima-Kondo, S (corresponding author), Univ Tokushima, Grad Sch, Inst Biomed Sci, Dept Physiol Nutr, 3-18-15 Kuramoto Cho, Tokushima 7708503, Japan.
RI Abe, Tomoki/AAY-2125-2020; Hirasaka, Katsuya/J-5283-2019
OI Abe, Tomoki/0000-0002-0349-8487; Hirasaka, Katsuya/0000-0003-2645-8450
FU JSPS [23390198]; Takeda Science Foundation; Mochida Memorial Foundation
   for Medical and Pharmaceutical Research; Grants-in-Aid for Scientific
   Research [23390198] Funding Source: KAKEN
FX This work was supported in parts by grants from Grants-in-Aid for
   Scientific Research (23390198) from JSPS (to STK), Takeda Science
   Foundation (to STK), and The Mochida Memorial Foundation for Medical and
   Pharmaceutical Research (to STK).
CR Bachelder RE, 2001, CANCER RES, V61, P5736
   Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Bottsford-Miller JN, 2012, J CLIN ONCOL, V30, P4026, DOI 10.1200/JCO.2012.41.9242
   Carter NJ, 2014, DRUG AGING, V31, P67, DOI 10.1007/s40266-013-0140-6
   Ebos JML, 2009, CLIN CANCER RES, V15, P5020, DOI 10.1158/1078-0432.CCR-09-0095
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Ellis LM, 2008, CLIN CANCER RES, V14, P6371, DOI 10.1158/1078-0432.CCR-07-5287
   Escudier B, 2008, EXPERT REV ANTICANC, V8, P1545, DOI 10.1586/14737140.8.10.1545
   Fakih M, 2013, EXPERT REV ANTICANC, V13, P427, DOI [10.1586/ERA.13.20, 10.1586/era.13.20]
   Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246
   Fan F, 2011, BRIT J CANCER, V104, P1270, DOI 10.1038/bjc.2011.81
   Frank NY, 2011, CANCER RES, V71, P1474, DOI 10.1158/0008-5472.CAN-10-1660
   Köhne CH, 2009, ONCOLOGIST, V14, P478, DOI 10.1634/theoncologist.2008-0202
   Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037
   Martinod E, 2013, EUR J MED RES, V18, DOI 10.1186/2047-783X-18-25
   Mitchell EP, 2013, CLIN COLORECTAL CANC, V12, P73, DOI 10.1016/j.clcc.2012.08.001
   Pàez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Saika Kumiko, 2013, Gan To Kagaku Ryoho, V40, P2475
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Sennino B, 2012, CANCER DISCOV, V2, P270, DOI 10.1158/2159-8290.CD-11-0240
   Tomida C, 2015, J MED INVESTIG, V62, P75, DOI 10.2152/jmi.62.75
   Vakkalanka BK, 2008, CURR OPIN UROL, V18, P481, DOI 10.1097/MOU.0b013e32830a70cf
   Yamagishi N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-229
NR 24
TC 15
Z9 15
U1 0
U2 7
PU UNIV TOKUSHIMA SCH MEDICINE
PI TOKUSHIMA
PA 3-18-15, KURAMOTO-CHO, TOKUSHIMA, 00000, JAPAN
SN 1343-1420
EI 1349-6867
J9 J MED INVESTIG
JI J. Med. Investig.
PD AUG
PY 2015
VL 62
IS 3-4
BP 195
EP 198
PG 4
WC Medicine, Research & Experimental
WE Emerging Sources Citation Index (ESCI)
SC Research & Experimental Medicine
GA V3P9N
UT WOS:000218480200018
PM 26399347
OA Bronze
DA 2025-01-04
ER

PT J
AU Fujino, S
   Miyoshi, N
   Ito, A
   Yasui, M
   Ohue, M
   Ogino, T
   Takahashi, H
   Uemura, M
   Matsuda, C
   Mizushima, T
   Doki, Y
   Eguchi, H
AF Fujino, Shiki
   Miyoshi, Norikatsu
   Ito, Aya
   Yasui, Masayoshi
   Ohue, Masayuki
   Ogino, Takayuki
   Takahashi, Hidekazu
   Uemura, Mamoru
   Matsuda, Chu
   Mizushima, Tsunekazu
   Doki, Yuichiro
   Eguchi, Hidetoshi
TI Crenolanib Regulates ERK and AKT/mTOR Signaling Pathways in
   RAS/BRAF-Mutated Colorectal Cancer Cells and Organoids
SO MOLECULAR CANCER RESEARCH
LA English
DT Article
ID PDGFR-BETA; RESISTANCE; ACTIVATION; OCT4; GUIDELINES; MIGRATION; MODELS
AB Recently developed molecularly targeted therapies such as EGFR inhibitors have notably improved the prognosis of patients with cancer. However, patients with KRAS and BRAF mutations do not currently benefit from these therapies. Here, we aimed to examine potential effects of crenolanib as a new molecularly targeted therapy in colorectal cancer. We used multiple colorectal cancer cell lines to investigate the growth-inhibitory effect of crenolanib and its effect in combination with other cytotoxic agents. Primary cultures of patient-derived organoids (PDO), a model that reflects the heterogeneity of clinical colorectal cancer, were used to further validate the effects of crenolanib. Unlike cetuximab, crenolanib remarkably suppressed ERK and AKT/mTOR pathways in HT29 cells with BRAF mutation and in HCT116 cells with KRAS mutation with corresponding growth-suppressing effects. Additive or synergistic effects were observed in treatments with combination of crenolanib and other cytotoxic drugs. Moreover, crenolanib suppressed the expression of stem cell markers, such as OCT4, NANOG, and SOX2. These observations were substantiated in seven PDOs with KRAS mutation and two PDOs without KRAS/BRAF mutations, with crenolanib suppressing the growth of all PDOs regardless of their KRAS mutation status. Furthermore, crenolanib abrogated PDGF- and TGF beta-induced increase of OCT4-positive cells in PDOs. Together, these findings suggest that crenolanib may have clinical utility for patients with colorectal cancer, especially patients with KRAS/BRAF mutations.
   Implications: These findings indicate that crenolanib can be a useful target agent for patients with colorectal cancer, especially patients with KRAS/BRAF mutations.
C1 [Fujino, Shiki; Miyoshi, Norikatsu; Ogino, Takayuki; Takahashi, Hidekazu; Uemura, Mamoru; Matsuda, Chu; Mizushima, Tsunekazu; Doki, Yuichiro; Eguchi, Hidetoshi] Osaka Univ, Dept Surg Gastroenterol, Grad Sch Med, Suita, Osaka, Japan.
   [Fujino, Shiki; Miyoshi, Norikatsu; Ito, Aya] Osaka Int Canc Inst, Innovat Oncol Res & Translat Med, Osaka, Japan.
   [Yasui, Masayoshi; Ohue, Masayuki] Osaka Int Canc Inst, Dept Surg, Osaka, Japan.
C3 Osaka University
RP Miyoshi, N (corresponding author), Osaka Univ, Dept Surg Gastroenterol, Suita, Osaka 5650871, Japan.
EM nmiyoshi@gesurg.med.osaka-u.ac.jp
RI Mizushima, Tsunekazu/AAS-7245-2020; Uemura, Mamoru/AFR-1048-2022
OI Fujino, Shiki/0000-0003-0302-5337; Uemura, Mamoru/0000-0001-6285-5619
FU KAKENHI [17K16542, 19K18145]; 38th Japan Medical Woman's Association
   Academic research grant; JSS Young Researcher Award; Grants-in-Aid for
   Scientific Research [21K08709, 20K09056, 19K18145, 17K16542] Funding
   Source: KAKEN
FX This work was supported by the KAKENHI grant numbers 17K16542 and
   19K18145, a 38th Japan Medical Woman's Association Academic research
   grant, and a JSS Young Researcher Award. The results here are in part
   based upon data generated by the TCGA Research Network:
   https://www.cancer.gov/tcga.We would like to thank Editage
   (www.editage.com) for English language editing.
CR Bahrami A, 2018, J CELL BIOCHEM, V119, P2460, DOI 10.1002/jcb.25950
   Berndsen RH, 2019, BRIT J CANCER, V121, P139, DOI 10.1038/s41416-019-0498-2
   Bhattacharya R, 2017, BRIT J CANCER, V117, P848, DOI 10.1038/bjc.2017.238
   Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2
   Blaj C, 2017, CANCER RES, V77, P1763, DOI 10.1158/0008-5472.CAN-16-2821
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Cao Z, 2019, CANCER LETT, V459, P30, DOI 10.1016/j.canlet.2019.05.025
   Chiou SH, 2010, CANCER RES, V70, P10433, DOI 10.1158/0008-5472.CAN-10-2638
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086
   Daver N, 2019, LEUKEMIA, V33, P299, DOI 10.1038/s41375-018-0357-9
   Deng JL, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5824-9
   Fessler E, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0420-3
   Fournier PGJ, 2015, CANCER CELL, V27, P809, DOI 10.1016/j.ccell.2015.04.009
   Frödin M, 2017, BRIT J CANCER, V116, P195, DOI 10.1038/bjc.2016.407
   Fujino S, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/7896524
   Fujino S, 2019, BIOCHEM BIOPH RES CO, V513, P332, DOI 10.1016/j.bbrc.2019.03.173
   Fujino S, 2018, ONCOL REP, V39, P2178, DOI 10.3892/or.2018.6290
   Gotzmann J, 2006, ONCOGENE, V25, P3170, DOI 10.1038/sj.onc.1209083
   Gril B, 2013, AM J PATHOL, V182, P2368, DOI 10.1016/j.ajpath.2013.02.043
   Hayashi Y, 2015, GASTROENTEROLOGY, V149, P420, DOI 10.1053/j.gastro.2015.04.006
   Heinrich MC, 2012, CLIN CANCER RES, V18, P4375, DOI 10.1158/1078-0432.CCR-12-0625
   Heske CM, 2016, TRANSL ONCOL, V9, P540, DOI 10.1016/j.tranon.2016.09.002
   Hoadley KA, 2018, CELL, V173, P291, DOI 10.1016/j.cell.2018.03.022
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Joglekar-Javadekar M, 2017, NEOPLASIA, V19, P564, DOI 10.1016/j.neo.2017.03.002
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Nakano M, 2019, ONCOGENE, V38, P780, DOI 10.1038/s41388-018-0480-0
   Piccart-Gebhart M, 2016, J CLIN ONCOL, V34, P1034, DOI 10.1200/JCO.2015.62.1797
   Sabbatino F, 2014, ONCOTARGET, V5, P1926, DOI 10.18632/oncotarget.1878
   Slamon DJ, 2018, J CLIN ONCOL, V36, P2465, DOI 10.1200/JCO.2018.78.9909
   Smith CC, 2014, P NATL ACAD SCI USA, V111, P5319, DOI 10.1073/pnas.1320661111
   Stein E, 2019, PHARMACOECONOMICS, V37, P239, DOI 10.1007/s40273-018-0732-4
   Steller EJA, 2013, NEOPLASIA, V15, P204, DOI 10.1593/neo.121726
   Vigneri PG, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00230
   Wang J, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00552
   Wang P, 2014, ONCOTARGETS THER, V7, P1761, DOI 10.2147/OTT.S68773
   Wang Y, 2016, GROWTH FACTORS, V34, P64, DOI 10.1080/08977194.2016.1180293
   Watanabe T, 2018, INT J CLIN ONCOL, V23, P1, DOI 10.1007/s10147-017-1101-6
   WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922
   Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738
   Zimmerman EI, 2013, BLOOD, V122, P3607, DOI 10.1182/blood-2013-07-513044
NR 45
TC 7
Z9 7
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1541-7786
EI 1557-3125
J9 MOL CANCER RES
JI Mol. Cancer Res.
PD MAY 1
PY 2021
VL 19
IS 5
BP 812
EP 822
DI 10.1158/1541-7786.MCR-20-0600
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA RZ3TA
UT WOS:000648518400007
PM 33579816
OA Green Submitted, Bronze
DA 2025-01-04
ER

PT J
AU Bronte, E
   Bronte, G
   Novo, G
   Bronte, F
   Bavetta, MG
   Lo Re, G
   Brancatelli, G
   Bazan, V
   Natoli, C
   Novo, S
   Russo, A
AF Bronte, Enrico
   Bronte, Giuseppe
   Novo, Giuseppina
   Bronte, Fabrizio
   Bavetta, Maria Grazia
   Lo Re, Giuseppe
   Brancatelli, Giuseppe
   Bazan, Viviana
   Natoli, Clara
   Novo, Salvatore
   Russo, Antonio
TI What links BRAF to the heart function? new insights from the
   cardiotoxicity of BRAF inhibitors in cancer treatment
SO ONCOTARGET
LA English
DT Article
DE B-RAF; B-RAF inhibitors; cardio-oncology; cardiotoxicity; dabrafenib
ID RENAL-CELL CARCINOMA; MUTATED METASTATIC MELANOMA; HERG K+ CHANNEL;
   OPEN-LABEL; PHASE-III; COLORECTAL-CANCER; TARGETED THERAPY; 1ST-LINE
   THERAPY; EXPANDED ACCESS; MEK INHIBITION
AB The RAS-related signalling cascade has a fundamental role in cell. It activates differentiation and survival. It is particularly important one of its molecules, B-RAF. B-RAF has been a central point for research, especially in melanoma. Indeed, it lacked effective therapeutic weapons since the early years of its study. Molecules targeting B-RAF have been developed. Nowadays, two classes of molecules are approved by FDA. Multi-target molecules, such as Sorafenib and Regorafenib, and selective molecules, such as Vemurafenib and Dabrafenib. Many other molecules are still under investigation. Most of them are studied in phase 1 trials. Clinical studies correlate B-RAF inhibitors and QT prolongation. Though this cardiovascular side effect is not common using these drugs, it must be noticed early and recognize its signals. Indeed, Oncologists and Cardiologists should work in cooperation to prevent lethal events, such as fatal arrhythmias or sudden cardiac death. These events could originate from an uncontrolled QT prolongation.
C1 [Bronte, Enrico; Bronte, Giuseppe; Bazan, Viviana; Russo, Antonio] Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy.
   [Novo, Giuseppina; Novo, Salvatore] Univ Palermo, Dept Internal Med & Cardiovasc Dis, Palermo, Italy.
   [Bronte, Fabrizio; Bavetta, Maria Grazia] Univ Palermo, Gastroenterol Sect, DiBiMIS, Palermo, Italy.
   [Lo Re, Giuseppe; Brancatelli, Giuseppe] Univ Palermo, Dept Radiol, Palermo, Italy.
   [Natoli, Clara] Univ G DAnnunzio, Dept Med Oral & Biotechnol Sci, Chieti, Italy.
C3 University of Palermo; University of Palermo; University of Palermo;
   University of Palermo; G d'Annunzio University of Chieti-Pescara
RP Russo, A (corresponding author), Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Palermo, Italy.
EM antonio.russo@usa.net
RI novo, giuseppina/K-6580-2016; brancatelli, giuseppe/ADI-3570-2022;
   Natoli, Clara/E-1378-2013; Lo Re, Giovanni/ABE-1780-2020; Lo Re,
   Giuseppe/C-1303-2013; Bronte, Fabrizio/L-6365-2015
OI Bronte, Giuseppe/0000-0002-2306-2445; BRANCATELLI,
   Giuseppe/0000-0001-6136-9088; Natoli, Clara/0000-0001-7295-0230; Lo Re,
   Giovanni/0000-0003-1169-2359; Lo Re, Giuseppe/0000-0002-7479-948X;
   Bronte, Fabrizio/0000-0003-0896-830X
CR Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3
   [Anonymous], 2013, ONCOLOGY-NY, V27, P164
   [Anonymous], 2011, Oncology (Williston Park), V25, P906
   [Anonymous], 2012, ONCOLOGY-NY, V26, P896
   Ascierto PA, 2013, J CLIN ONCOL, V31, P3205, DOI 10.1200/JCO.2013.49.8691
   Basile KJ, 2014, PIGM CELL MELANOMA R, V27, P479, DOI 10.1111/pcmr.12218
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Brennan P, 1997, IMMUNITY, V7, P679, DOI 10.1016/S1074-7613(00)80388-X
   Bronte E, 2013, MED HYPOTHESES, V81, P923, DOI 10.1016/j.mehy.2013.08.016
   Bronte F, 2014, CURR MED CHEM, V21, P966, DOI 10.2174/09298673113209990234
   Bronte G, 2015, EXPERT OPIN DRUG SAF, V14, P253, DOI 10.1517/14740338.2015.986092
   Bronte G, 2014, EXPERT OPIN BIOL TH, V14, P743, DOI 10.1517/14712598.2014.902926
   Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9
   Bruix J, 2013, EUR J CANCER, V49, P3412, DOI 10.1016/j.ejca.2013.05.028
   Cainap C, 2015, J CLIN ONCOL, V33, P172, DOI 10.1200/JCO.2013.54.3298
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen JC, 2003, J BIOL CHEM, V278, P2807, DOI 10.1074/jbc.M207943200
   Chen J, 2009, AM J PHYSIOL-HEART C, V296, pH1244, DOI 10.1152/ajpheart.01252.2008
   Cheng AL, 2013, J CLIN ONCOL, V31, P4067, DOI 10.1200/JCO.2012.45.8372
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Choueiri TK, 2010, J CLIN ONCOL, V28, P2280, DOI 10.1200/JCO.2009.27.2757
   Chow AKM, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0352-y
   Courtney KD, 2010, J CLIN ONCOL, V28, P1075, DOI 10.1200/JCO.2009.25.3641
   Cui J, 2000, CURR BIOL, V10, P671, DOI 10.1016/S0960-9822(00)00516-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
   Dhandapany PS, 2014, NAT GENET, V46, P635, DOI 10.1038/ng.2963
   Drosten M, 2010, EMBO J, V29, P1091, DOI 10.1038/emboj.2010.7
   Du KY, 1998, J BIOL CHEM, V273, P32377, DOI 10.1074/jbc.273.49.32377
   Dugan LL, 1999, J BIOL CHEM, V274, P25842, DOI 10.1074/jbc.274.36.25842
   Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Flaherty L, 2014, CANCER J, V20, P18, DOI 10.1097/PPO.0000000000000024
   Funakoshi T, 2013, J HUM HYPERTENS, V27, P601, DOI 10.1038/jhh.2013.30
   Garcia-Gomez A, 2013, INVEST NEW DRUG, V31, P200, DOI 10.1007/s10637-012-9845-3
   Gray-Schopfer V, 2007, NATURE, V445, P851, DOI 10.1038/nature05661
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Gysin Stephan, 2011, Genes Cancer, V2, P359, DOI 10.1177/1947601911412376
   Hasinoff BB, 2010, CARDIOVASC TOXICOL, V10, P1, DOI 10.1007/s12012-009-9056-0
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   How-Kit A, 2014, ANAL BIOANAL CHEM, V406, P5513, DOI 10.1007/s00216-014-7975-5
   Hutson TE, 2013, LANCET ONCOL, V14, P1287, DOI 10.1016/S1470-2045(13)70465-0
   Iddawela M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-581
   Jäger D, 2015, CLIN GENITOURIN CANC, V13, P156, DOI 10.1016/j.clgc.2014.07.007
   Johnson DB, 2014, J CLIN ONCOL, V32, P3697, DOI 10.1200/JCO.2014.57.3535
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Jonsson MKB, 2012, J MOL CELL CARDIOL, V53, P369, DOI 10.1016/j.yjmcc.2012.06.011
   Kane LP, 1999, CURR BIOL, V9, P601, DOI 10.1016/S0960-9822(99)80265-6
   Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358
   Kim G, 2014, CLIN CANCER RES, V20, P4994, DOI 10.1158/1078-0432.CCR-14-0776
   Kudo M, 2011, EUR J CANCER, V47, P2117, DOI 10.1016/j.ejca.2011.05.007
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868
   Larkin J, 2014, LANCET ONCOL, V15, P436, DOI 10.1016/S1470-2045(14)70051-8
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Long GV, 2012, LANCET ONCOL, V13, P1087, DOI 10.1016/S1470-2045(12)70431-X
   Mahoney KM, 2013, J CLIN ONCOL, V31, pE364, DOI 10.1200/JCO.2012.47.0104
   Marchant J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-519
   McCubrey JA, 2012, ONCOTARGET, V3, P954, DOI 10.18632/oncotarget.652
   Menzies AM, 2012, DRUG DES DEV THER, V6, P391, DOI 10.2147/DDDT.S38998
   Motzer RJ, 2014, LANCET ONCOL, V15, P286, DOI 10.1016/S1470-2045(14)70030-0
   Motzer RJ, 2013, J CLIN ONCOL, V31, P3791, DOI 10.1200/JCO.2012.47.4940
   Muslin AJ, 2005, TRENDS CARDIOVAS MED, V15, P225, DOI 10.1016/j.tcm.2005.06.008
   Nakamura A, 2013, CANCER RES, V73, P7043, DOI 10.1158/0008-5472.CAN-13-1825
   Organ-Darling LE, 2013, AM J PHYSIOL-HEART C, V304, pH589, DOI 10.1152/ajpheart.00385.2012
   Pakladok T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087457
   Raschi E, 2008, PHARMACOL RES, V57, P181, DOI 10.1016/j.phrs.2008.01.009
   Ravi S, 2014, CORE EVID, V9, P81, DOI 10.2147/CE.S48626
   Rey JB, 2015, TARGET ONCOL, V10, P199, DOI 10.1007/s11523-014-0333-x
   Rini BI, 2015, TARGET ONCOL, V10, P45, DOI 10.1007/s11523-014-0307-z
   Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9
   Rizzo S, 2010, CANCER TREAT REV, V36, pS56, DOI 10.1016/S0305-7372(10)70021-9
   Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690
   Rolfo C, 2014, EXPERT REV GASTROENT, V8, P875, DOI 10.1586/17474124.2014.922870
   Russo A, 2009, ONCOLOGY-BASEL, V77, P57, DOI 10.1159/000258497
   Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281
   Sanguinetti MC, 2006, NATURE, V440, P463, DOI 10.1038/nature04710
   Schmidinger M, 2008, J CLIN ONCOL, V26, P5204, DOI 10.1200/JCO.2007.15.6331
   Sharma A, 2012, DRUGS, V72, P2207, DOI 10.2165/11640870-000000000-00000
   Stadler WM, 2010, CANCER-AM CANCER SOC, V116, P1272, DOI 10.1002/cncr.24864
   Su YJ, 2012, CLIN CANCER RES, V18, P2184, DOI 10.1158/1078-0432.CCR-11-1122
   Swaika A, 2014, DRUG DES DEV THER, V8, P775, DOI 10.2147/DDDT.S31143
   Takahashi H, 2004, ARCH DERMATOL RES, V296, P74, DOI 10.1007/s00403-004-0478-z
   Tolcher AW, 2011, CANCER CHEMOTH PHARM, V67, P751, DOI 10.1007/s00280-010-1372-3
   TRUDEAU MC, 1995, SCIENCE, V269, P92, DOI 10.1126/science.7604285
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Trinh VA, 2014, CHIN CLIN ONCOL, V3, DOI 10.3978/j.issn.2304-3865.2014.05.10
   von Lintig FC, 2000, BREAST CANCER RES TR, V62, P51, DOI 10.1023/A:1006491619920
   Vossler MR, 1997, CELL, V89, P73, DOI 10.1016/S0092-8674(00)80184-1
   Wani R, 2011, CELL CYCLE, V10, P3263, DOI 10.4161/cc.10.19.17738
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Yamaguchi O, 2004, J CLIN INVEST, V114, P937, DOI 10.1172/JCI200420317
NR 92
TC 49
Z9 53
U1 0
U2 2
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 3
PY 2015
VL 6
IS 34
BP 35589
EP 35601
DI 10.18632/oncotarget.5853
PG 13
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CY0QZ
UT WOS:000366111900046
PM 26431495
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Shimada, Y
   Tajima, Y
   Kameyama, H
   Yagi, R
   Okamura, T
   Hirose, Y
   Sakata, J
   Kobayashi, T
   Matsuda, Y
   Ajioka, Y
   Kosugi, S
   Wakai, T
AF Shimada, Yoshifumi
   Tajima, Yosuke
   Kameyama, Hitoshi
   Yagi, Ryoma
   Okamura, Takuma
   Hirose, Yuki
   Sakata, Jun
   Kobayashi, Takashi
   Matsuda, Yasunobu
   Ajioka, Yoichi
   Kosugi, Shin-ichi
   Wakai, Toshifumi
TI Clinical significance of MED12 expression in colorectal cancer
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE MED12; EMT; TGF-beta; RAS; immunohistochemistry; colorectal cancer
ID EPITHELIAL-MESENCHYMAL TRANSITION; TGF-BETA; DRUG-RESISTANCE; RAS
   MUTATIONS; METASTASIS; MULTICENTER; INVASION; DISEASE; COMPLEX; KRAS
AB MED12 is a transcriptional mediator complex subunit, which negatively regulates the transforming growth factor beta (TGF-beta) pathway. The TGF-beta pathway plays a major role in the induction of epithelial-mesenchymal transition 9EMT). MED12 loss induces activation of the TGF-beta pathway, resulting in EMT and drug resistance to epidermal growth factor receptor (EGFR)-targeted therapy. We aimed to investigate the clinical significance of MED12 loss detected by immunohistochemistry in patients with colorectal cancer (CRC). A total of 100 patients diagnosed with stage I-IV CRC were enrolled in this retrospective study. MED12 expression was evaluated immunohistochemically, and classified as either positive (>= 20%) or negative (<20%) with regard to the percentage of immunoreactive cells. The relationships between MED12 loss and clinicopathological characteristics and RAS mutation status were analyzed. Overall, 79 and 21 patients were classified as MED12 positive and MED12 negative, respectively. MED12 negativity was significantly associated with tumor budding (P = 0.034), N category (P = 0.010), and M category (P = 0.031). Among stage IV CRC patients, 18 of 31 patients had the RAS wild-type gene; 6 of these patients were MED12 negative, and were considered to have the potential for resistance to EGFR-targeted therapy despite the presence of the wild-type gene. In conclusion, MED12 loss is associated with tumor budding, nodal metastasis, and distant metastasis in patients with CRC, suggesting that MED12 loss induces activation of the TGF-beta pathway resulting in EMT. Future treatment strategies focusing on patients MED12 loss may improve the prognosis of patients with CRC.
C1 [Shimada, Yoshifumi; Tajima, Yosuke; Kameyama, Hitoshi; Yagi, Ryoma; Okamura, Takuma; Hirose, Yuki; Sakata, Jun; Kobayashi, Takashi; Wakai, Toshifumi] Niigata Univ, Grad Sch Med & Dent Sci, Div Digest & Gen Surg, Niigata, Japan.
   [Matsuda, Yasunobu] Niigata Univ, Grad Sch Hlth Sci, Dept Med Technol, Niigata, Japan.
   [Ajioka, Yoichi] Niigata Univ, Grad Sch Med & Dent Sci, Div Mol & Diagnost Pathol, Niigata, Japan.
   [Kosugi, Shin-ichi] Niigata Univ, Med & Dent Hosp, Dept Digest & Gen Surg, Uonuma Inst Community Med, Niigata, Japan.
C3 Niigata University; Niigata University; Niigata University; Niigata
   University
RP Shimada, Y (corresponding author), Niigata Univ, Grad Sch Med & Dent Sci, Div Digest & Gen Surg, Chuo Ku, 1-757 Asahimachi Dori, Niigata 9518510, Japan.
EM shimaday@med.niigata-u.ac.jp
RI Tajima, Yosuke/HDN-8985-2022; Kosugi, S./K-5142-2019; Hirose,
   Yuki/Q-6520-2016
OI Hirose, Yuki/0000-0001-6879-7886
FU Ministry of Education, Culture, Sports, Science, and Technology of Japan
   [15K10130]; Grants-in-Aid for Scientific Research [15K10130] Funding
   Source: KAKEN
FX This study was supported in part by a Grant-in-Aid for Scientific
   Research, no. 15K10130 (Y.S.), from the Ministry of Education, Culture,
   Sports, Science, and Technology of Japan.
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Bhangu A, 2012, SURG ONCOL, V21, P316, DOI 10.1016/j.suronc.2012.08.003
   Brunen D, 2013, CELL CYCLE, V12, P2960, DOI 10.4161/cc.26034
   Comijn J, 2001, MOL CELL, V7, P1267, DOI 10.1016/S1097-2765(01)00260-X
   Dawson H, 2015, FRONT MED-LAUSANNE, V2, DOI 10.3389/fmed.2015.00011
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Edge S.B., 2010, AJCC cancer staging manual, V649
   Graham RP, 2015, AM J SURG PATHOL, V39, P1340, DOI 10.1097/PAS.0000000000000504
   Guo X, 2012, CELL, V151, P927, DOI 10.1016/j.cell.2012.11.003
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Huang SD, 2012, CELL, V151, P937, DOI 10.1016/j.cell.2012.10.035
   Janda E, 2002, J CELL BIOL, V156, P299, DOI 10.1083/jcb.200109037
   Kawachi H, 2015, MODERN PATHOL, V28, P872, DOI 10.1038/modpathol.2015.36
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Malik S, 2010, NAT REV GENET, V11, P761, DOI 10.1038/nrg2901
   McCarthy N, 2013, NAT REV CANCER, V13, DOI 10.1038/nrc3630
   Oft M, 1998, CURR BIOL, V8, P1243, DOI 10.1016/S0960-9822(07)00533-7
   Rosell R, 2013, NEW ENGL J MED, V368, P1551, DOI 10.1056/NEJMcibr1214549
   Taatjes DJ, 2010, TRENDS BIOCHEM SCI, V35, P315, DOI 10.1016/j.tibs.2010.02.004
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Ueno H, 2002, HISTOPATHOLOGY, V40, P127, DOI 10.1046/j.1365-2559.2002.01324.x
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Yoshino T, 2015, EBIOMEDICINE, V2, P317, DOI 10.1016/j.ebiom.2015.02.007
   Zlobec I, 2010, ONCOTARGET, V1, P651, DOI 10.18632/oncotarget.199
NR 25
TC 0
Z9 0
U1 0
U2 4
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2016
VL 9
IS 7
BP 6937
EP 6944
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA DT8GY
UT WOS:000381729200032
DA 2025-01-04
ER

PT J
AU Jacobsen, A
   Siebler, J
   Grützmann, R
   Stürzl, M
   Naschberger, E
AF Jacobsen, Anne
   Siebler, Juergen
   Gruetzmann, Robert
   Stuerzl, Michael
   Naschberger, Elisabeth
TI Blood Vessel-Targeted Therapy in Colorectal Cancer: Current Strategies
   and Future Perspectives
SO CANCERS
LA English
DT Review
DE antiangiogenic treatment; cancer; colorectal cancer; endothelial cells;
   tumor microenvironment; bevacizumab; ramucirumab; aflibercept;
   regorafenib; fruquintinib; angiocrine; vasculature; vascular
   heterogeneity
ID ENDOTHELIAL-CELL HETEROGENEITY; BEVACIZUMAB PLUS MFOLFOX6;
   ANTI-ANGIOGENIC THERAPY; OXALIPLATIN-BASED CHEMOTHERAPY; RANDOMIZED
   PHASE-III; 1ST-LINE TREATMENT; DOUBLE-BLIND; OPEN-LABEL; METRONOMIC
   CHEMOTHERAPY; TUMOR MICROENVIRONMENT
AB Simple Summary This review summarizes the history and current clinical applications of antiangiogenic treatment. It specifically discusses current challenges of the treatment and opportunities for optimization, including normalization of the tumor vasculature, modulation of milieu-dependent heterogeneity of the vasculature, and targeting of angiocrine protein functions.Abstract The vasculature is a key player and regulatory component in the multicellular microenvironment of solid tumors and, consequently, a therapeutic target. In colorectal carcinoma (CRC), antiangiogenic treatment was approved almost 20 years ago, but there are still no valid predictors of response. In addition, treatment resistance has become a problem. Vascular heterogeneity and plasticity due to species-, organ-, and milieu-dependent phenotypic and functional differences of blood vascular cells reduced the hope of being able to apply a standard approach of antiangiogenic therapy to all patients. In addition, the pathological vasculature in CRC is characterized by heterogeneous perfusion, impaired barrier function, immunosuppressive endothelial cell anergy, and metabolic competition-induced microenvironmental stress. Only recently, angiocrine proteins have been identified that are specifically released from vascular cells and can regulate tumor initiation and progression in an autocrine and paracrine manner. In this review, we summarize the history and current strategies for applying antiangiogenic treatment and discuss the associated challenges and opportunities, including normalizing the tumor vasculature, modulating milieu-dependent vascular heterogeneity, and targeting functions of angiocrine proteins. These new strategies could open perspectives for future vascular-targeted and patient-tailored therapy selection in CRC.
C1 [Jacobsen, Anne; Stuerzl, Michael; Naschberger, Elisabeth] Friedrich Alexander Univ Erlangen Nurnberg FAU, Translat Res Ctr, Div Mol & Expt Surg, Univ Klinikum Erlangen, Kussmaulallee 12, D-91054 Erlangen, Germany.
   [Jacobsen, Anne; Siebler, Juergen; Gruetzmann, Robert; Stuerzl, Michael; Naschberger, Elisabeth] Comprehens Canc Ctr Erlangen EMN CCC ER EMN, D-91054 Erlangen, Germany.
   [Jacobsen, Anne; Gruetzmann, Robert] Friedrich Alexander Univ Erlangen Nurnberg FAU, Univ Klinikum Erlangen, Dept Gen & Visceral Surg, D-91054 Erlangen, Germany.
   [Siebler, Juergen] Friedrich Alexander Univ Erlangen Nurnberg FAU, Dept Med Gastroenterol 1, Univ Klinikum Erlangen, D-91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg; University of Erlangen Nuremberg;
   University of Erlangen Nuremberg
RP Naschberger, E (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg FAU, Translat Res Ctr, Div Mol & Expt Surg, Univ Klinikum Erlangen, Kussmaulallee 12, D-91054 Erlangen, Germany.; Naschberger, E (corresponding author), Comprehens Canc Ctr Erlangen EMN CCC ER EMN, D-91054 Erlangen, Germany.
EM anne.jacobsen@uk-erlangen.de; juergen.siebler@uk-erlangen.de;
   robert.gruetzmann@uk-erlangen.de; michael.stuerzl@uk-erlangen.de;
   elisabeth.naschberger@uk-erlangen.de
RI Naschberger, Elisabeth/AAV-5289-2021; Sturzl, Michael/B-3019-2015
OI Sturzl, Michael/0000-0002-9276-2824; Naschberger,
   Elisabeth/0000-0003-1291-622X
FU German Research Foundation (DFG) FOR 2438, subproject 2
FX No Statement Available
CR Akino T, 2009, AM J PATHOL, V175, P2657, DOI 10.2353/ajpath.2009.090202
   Arnold M, 2020, GASTROENTEROLOGY, V159, P335, DOI 10.1053/j.gastro.2020.02.068
   Baraniskin A, 2019, EUR J CANCER, V106, P37, DOI 10.1016/j.ejca.2018.10.009
   Bendell JC, 2020, ONCOLOGIST, V25, pE451, DOI 10.1634/theoncologist.2019-0291
   Bendell JC, 2013, CLIN COLORECTAL CANC, V12, P239, DOI 10.1016/j.clcc.2013.09.001
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Benson A, 2021, J NATL COMPR CANC NE, V19, P329, DOI 10.6004/jnccn.2021.0012
   Benson AB III, 2016, CLIN CANCER RES, V22, P5058, DOI 10.1158/1078-0432.CCR-15-3117
   Boehm T, 1997, NATURE, V390, P404, DOI 10.1038/37126
   Bridgeman VL, 2017, J PATHOL, V241, P362, DOI 10.1002/path.4845
   Cao YH, 2008, P NATL ACAD SCI USA, V105, P13203, DOI 10.1073/pnas.0806582105
   Cao YH, 2023, NAT REV DRUG DISCOV, V22, P476, DOI 10.1038/s41573-023-00671-z
   Cao ZW, 2014, CANCER CELL, V25, P350, DOI 10.1016/j.ccr.2014.02.005
   Cervantes A, 2023, ANN ONCOL, V34, P10, DOI 10.1016/j.annonc.2022.10.003
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Cremolini C, 2019, EUR J CANCER, V109, P175, DOI 10.1016/j.ejca.2018.12.028
   Cunningham D, 2013, BRIT J CANCER, V108, P493, DOI 10.1038/bjc.2012.545
   Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
   Dasari A, 2023, LANCET, V402, P41, DOI 10.1016/S0140-6736(23)00772-9
   Di Tacchio M, 2019, CANCER IMMUNOL RES, V7, P1910, DOI 10.1158/2326-6066.CIR-18-0865
   Dirkx AEM, 2003, CANCER RES, V63, P2322
   Dunleavey James M, 2012, Curr Angiogenes, V1, P133
   Ettrich TJ, 2021, INT J CANCER, V148, P1428, DOI 10.1002/ijc.33296
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Folkman J., 2001, Antiangiogenesis Agents, in Cancer: Principles and Practice of Oncology
   Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197
   Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017
   García-Carbonero R, 2017, ONCOLOGIST, V22, P1281, DOI 10.1634/theoncologist.2016-0133erratum
   Gerhardt H, 2003, J CELL BIOL, V161, P1163, DOI 10.1083/jcb.200302047
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Grávalos C, 2018, CLIN COLORECTAL CANC, V17, pE323, DOI 10.1016/j.clcc.2018.02.004
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guruceaga X, 2020, TOXINS, V12, DOI 10.3390/toxins12010007
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen TF, 2021, CANCERS, V13, DOI 10.3390/cancers13051031
   HANSON FR, 1949, J BACTERIOL, V58, P527, DOI 10.1128/JB.58.4.527-529.1949
   Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z
   Hashimoto T, 2023, FUTURE ONCOL, V19, P1593, DOI 10.2217/fon-2023-0097
   Hecht JR, 2011, J CLIN ONCOL, V29, P1997, DOI 10.1200/JCO.2010.29.4496
   Hegewisch-Becker S, 2015, LANCET ONCOL, V16, P1355, DOI 10.1016/S1470-2045(15)00042-X
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Helfrich I, 2010, J EXP MED, V207, P491, DOI 10.1084/jem.20091846
   Hendrikx S, 2019, CELL REP, V26, P1227, DOI 10.1016/j.celrep.2019.01.016
   Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031
   Holch JW, 2017, EUR J CANCER, V70, P87, DOI 10.1016/j.ejca.2016.10.007
   Hu HG, 2012, CLIN CANCER RES, V18, P5438, DOI 10.1158/1078-0432.CCR-12-0124
   Huang XY, 2010, J EXP MED, V207, P505, DOI 10.1084/jem.20090397
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Infante JR, 2013, CANCER-AM CANCER SOC, V119, P2555, DOI 10.1002/cncr.28112
   INGBER D, 1990, NATURE, V348, P555, DOI 10.1038/348555a0
   Jackstadt R, 2019, CANCER CELL, V36, P319, DOI 10.1016/j.ccell.2019.08.003
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Kerbel RS, 2017, CANCER LETT, V400, P293, DOI 10.1016/j.canlet.2017.02.005
   Khan KA, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.201708253
   Kocaturk H, 2021, ADV CLIN EXP MED, V30, P1175, DOI 10.17219/acem/140440
   Kolata G., 1998, The New York Times3 May
   Kumar R, 2009, BRIT J CANCER, V101, P1717, DOI 10.1038/sj.bjc.6605366
   Lamplugh Z, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.811485
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Li Q, 2020, CLIN CANCER RES, V26, P1712, DOI 10.1158/1078-0432.CCR-19-2179
   Loupakis F, 2018, BRIT J CANCER, V119, P1451, DOI 10.1038/s41416-018-0304-6
   Martin JD, 2019, ANNU REV PHYSIOL, V81, P505, DOI 10.1146/annurev-physiol-020518-114700
   Masi G, 2015, ANN ONCOL, V26, P724, DOI 10.1093/annonc/mdv012
   Mettu NB, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.49040
   Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541
   Nambiar DK, 2019, J CLIN INVEST, V129, P5553, DOI 10.1172/JCI129025
   Naschberger E, 2023, CANCER COMMUN, V43, P1280, DOI 10.1002/cac2.12489
   Naschberger E, 2016, J CLIN INVEST, V126, P4187, DOI 10.1172/JCI78260
   Nolan DJ, 2013, DEV CELL, V26, P204, DOI 10.1016/j.devcel.2013.06.017
   O'Neil BH, 2014, CLIN COLORECTAL CANC, V13, P156, DOI 10.1016/j.clcc.2014.04.001
   Ohga N, 2012, AM J PATHOL, V180, P1294, DOI 10.1016/j.ajpath.2011.11.035
   OReilly MS, 1996, NAT MED, V2, P689, DOI 10.1038/nm0696-689
   OREILLY MS, 1994, CELL, V79, P315, DOI 10.1016/0092-8674(94)90200-3
   OReilly MS, 1997, CELL, V88, P277, DOI 10.1016/S0092-8674(00)81848-6
   Otsu S, 2023, CANCERS, V15, DOI 10.3390/cancers15184564
   Passardi A, 2015, ANN ONCOL, V26, P1201, DOI 10.1093/annonc/mdv130
   Peeters M, 2013, BRIT J CANCER, V108, P503, DOI 10.1038/bjc.2012.594
   Prager GW, 2023, NEW ENGL J MED, V388, P1657, DOI 10.1056/NEJMoa2214963
   Ribatti D, 2008, ANGIOGENESIS, V11, P3, DOI 10.1007/s10456-008-9092-6
   Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Schellerer VS, 2007, LAB INVEST, V87, P1159, DOI 10.1038/labinvest.3700671
   Schmittnaegel M, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9670
   Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Shigeta K, 2020, HEPATOLOGY, V71, P1247, DOI 10.1002/hep.30889
   Shirley M, 2018, DRUGS, V78, P1757, DOI 10.1007/s40265-018-0998-z
   Siu LL, 2013, J CLIN ONCOL, V31, P2477, DOI 10.1200/JCO.2012.46.0543
   Souglakos J, 2012, BRIT J CANCER, V106, P453, DOI 10.1038/bjc.2011.594
   Streubel B, 2004, NEW ENGL J MED, V351, P250, DOI 10.1056/NEJMoa033153
   Sun YM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.727822
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tampellini M, 2016, EXPERT OPIN INV DRUG, V25, P507, DOI 10.1517/13543784.2016.1161754
   Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723
   Thomas H., 2016, Gastroenterol. Hepatol, V13, P682
   Ugai T, 2022, NAT REV CLIN ONCOL, V19, P656, DOI 10.1038/s41571-022-00672-8
   van Beijnum JR, 2015, PHARMACOL REV, V67, P441, DOI 10.1124/pr.114.010215
   Van Cutsem E, 2018, ANN ONCOL, V29, P1955, DOI 10.1093/annonc/mdy241
   Van Cutsem E, 2015, ANN ONCOL, V26, P2085, DOI 10.1093/annonc/mdv286
   Van Cutsem E, 2009, ANN ONCOL, V20, P1842, DOI 10.1093/annonc/mdp233
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2004, DOI 10.1200/JCO.2010.29.5436
   van der Schaft DWJ, 2004, JNCI-J NATL CANCER I, V96, P1473, DOI 10.1093/jnci/djh267
   Varga J, 2020, J EXP MED, V217, DOI 10.1084/jem.20191515
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Wang QR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03050-0
   Wang R, 2010, NATURE, V468, P829, DOI 10.1038/nature09624
   Watson J.D., 1998, The New York Times
   Weiss A, 2015, ANGIOGENESIS, V18, P233, DOI 10.1007/s10456-015-9462-9
   Winkler F, 2004, CANCER CELL, V6, P553, DOI 10.1016/S1535-6108(04)00305-8
   World Health Organization (WHO), 2023, Colorectal cancer
   Xu RH, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0263-y
   Yan Y, 2006, ACTA PHARMACOL SIN, V27, P821, DOI 10.1111/j.1745-7254.2006.00390.x
   Yang TS, 2009, J CLIN ONCOL, V27
   Yang YL, 2013, P NATL ACAD SCI USA, V110, P12018, DOI 10.1073/pnas.1301331110
   Zhang Y, 2019, CANCER MANAG RES, V11, P7787, DOI 10.2147/CMAR.S215533
   Zhao CJ, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0007-8
   Zhao Q, 2018, CANCER RES, V78, P2370, DOI 10.1158/0008-5472.CAN-17-2728
   Zheng YN, 2023, CANCER RES, V83, P3577, DOI 10.1158/0008-5472.CAN-23-0025
NR 122
TC 2
Z9 2
U1 3
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2024
VL 16
IS 5
AR 890
DI 10.3390/cancers16050890
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KV5S9
UT WOS:001182757700001
PM 38473252
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Fang, JY
AF Jing-Yuan Fang
TI Chinese consensus on prevention of colorectal neoplasia (2021, Shanghai)
SO JOURNAL OF DIGESTIVE DISEASES
LA English
DT Article
DE adenoma; colorectal neoplasms; environmental exposure; genetic factors;
   tertiary prevention
ID FAMILIAL ADENOMATOUS POLYPOSIS; ENDOSCOPIC SUBMUCOSAL DISSECTION;
   INFLAMMATORY-BOWEL-DISEASE; PRIMARY SCLEROSING CHOLANGITIS; RANDOMIZED
   CONTROLLED-TRIAL; MISMATCH REPAIR-DEFICIENT; TOTAL MESORECTAL EXCISION;
   RESECTABLE RECTAL-CANCER; SURGICAL ADJUVANT BREAST; PEUTZ-JEGHERS
   SYNDROME
AB Most patients with colorectal cancer (CRC) were diagnosed in advanced stage and the prognosis is poor. Therefore, early detection and prevention of CRC are very important. As with other cancers, there is also the tertiary prevention for CRC. The primary prevention is etiological prevention, which is mainly the treatment of adenoma or inflammation for preventing the development into cancer. The secondary prevention is the early diagnosis and early treatment for avoiding progressing to advanced cancer. The tertiary prevention belongs to the broad category of prevention, mainly for advanced CRC, through surgical treatment and postoperative adjuvant chemotherapy, radiotherapy, targeted therapy, immunotherapy for preventing tumor recurrence or metastasis. This consensus is based on the recent domestic and international consensus guidelines and the latest progress of international researches in the past five years. This consensus opinion seminar was hosted by the Chinese Society of Gastroenterology and Cancer Collaboration Group of Chinese Society of Gastroenterology, and was organized by the Division of Gastroenterology and Hepatology & Shanghai Institute of Digestive Disease, Renji Hospital, School of Medicine, Shanghai Jiao Tong University. The consensus opinion contains 60 statement clauses, the standard and basis of the evidence-based medicine grade and voting grade of the statement strictly complied with the relevant international regulations and practice.
C1 [Jing-Yuan Fang] Shanghai Jiao Tong Univ, Sch Med,State Key Lab Oncogenes & Related Genes, Renji Hosp,Key Lab Gastroenterol & Hepatol,Minist, Shanghai Inst Digest Dis,Shanghai Canc Inst,Div G, 145 Shandong Rd, Shanghai 200001, Peoples R China.
C3 Shanghai Jiao Tong University
RP Fang, JY (corresponding author), Shanghai Jiao Tong Univ, Sch Med,State Key Lab Oncogenes & Related Genes, Renji Hosp,Key Lab Gastroenterol & Hepatol,Minist, Shanghai Inst Digest Dis,Shanghai Canc Inst,Div G, 145 Shandong Rd, Shanghai 200001, Peoples R China.
EM jingyuanfang@sjtu.edu.cn
RI FANG, Jing-Yuan/JOZ-1388-2023
CR Acharya A, 2017, ANN SURG ONCOL, V24, P1165, DOI 10.1245/s10434-016-5717-y
   Ahlawat SK, 2011, J CLIN GASTROENTEROL, V45, P347, DOI 10.1097/MCG.0b013e3181f3a2e0
   Ahmad II, 2016, J CLIN GASTROENTEROL, V50, P644, DOI 10.1097/MCG.0000000000000497
   Ajioka Y., 2016, Daicho Shikkan Now, P63
   Aldridge AJ, 2001, EUR J SURG, V167, P777
   Aleksandrova K, 2013, EUR J CANCER, V49, P3526, DOI 10.1016/j.ejca.2013.06.021
   Allegra CJ, 2013, J CLIN ONCOL, V31, P359, DOI 10.1200/JCO.2012.44.4711
   American Cancer Society, 2018, CA-CANCER J CLIN, V68, P282
   Anderson JC, 2018, AM J GASTROENTEROL, V113, P1828, DOI 10.1038/s41395-018-0393-0
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   [Anonymous], 2001, CANC PRINCIPLES PRAC
   [Anonymous], NCCN CLIN PRACTICE G
   Arber N, 2006, NEW ENGL J MED, V355, P885, DOI 10.1056/NEJMoa061652
   Atkin W, 2017, LANCET ONCOL, V18, P823, DOI 10.1016/S1470-2045(17)30187-0
   Atkinson NSS, 2019, GASTROENTEROLOGY, V157, P462, DOI 10.1053/j.gastro.2019.04.014
   Aune D, 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d6617
   Botrel TEA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2734-y
   Bagnardi V, 2001, BRIT J CANCER, V85, P1700, DOI 10.1054/bjoc.2001.2140
   [柏愚 Bai Yu], 2019, [中华消化内镜杂志, Chinese Journal of Digestive Endoscopy], V36, P427
   Bailie L, 2017, GASTROENTEROLOGY, V152, P92, DOI 10.1053/j.gastro.2016.09.003
   Baron JA, 1999, NEW ENGL J MED, V340, P101, DOI 10.1056/NEJM199901143400204
   Baron JA, 2006, GASTROENTEROLOGY, V131, P1674, DOI 10.1053/j.gastro.2006.08.079
   Baron JA, 2015, NEW ENGL J MED, V373, P1519, DOI 10.1056/NEJMoa1500409
   Barry EL, 2017, JAMA ONCOL, V3, P628, DOI 10.1001/jamaoncol.2016.5917
   Beaton C, 2013, COLORECTAL DIS, V15, P788, DOI 10.1111/codi.12129
   Beaugerie L, 2015, NEW ENGL J MED, V372, P1441, DOI 10.1056/NEJMra1403718
   Beaugerie L, 2013, GASTROENTEROLOGY, V145, P166, DOI 10.1053/j.gastro.2013.03.044
   Beggs AD, 2010, GUT, V59, P975, DOI 10.1136/gut.2009.198499
   Ben QW, 2014, GASTROENTEROLOGY, V146, P689, DOI 10.1053/j.gastro.2013.11.003
   Ben QW, 2012, GASTROENTEROLOGY, V142, P762, DOI 10.1053/j.gastro.2011.12.050
   Benson AB., 2021, J. Natl. Compr. Canc. Netw., V19, P329, DOI DOI 10.6004/JNCCN.2021.0012
   Berman JM, 2000, LANCET, V355, P395, DOI 10.1016/S0140-6736(99)06552-6
   Bertagnolli MM, 2006, NEW ENGL J MED, V355, P873, DOI 10.1056/NEJMoa061355
   Bibbins-Domingo K, 2016, ANN INTERN MED, V164, P836, DOI 10.7326/M16-0577
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Bingham SA, 2003, LANCET, V361, P1496, DOI 10.1016/S0140-6736(03)13174-1
   Bleijenberg AGC, 2020, GUT, V69, P112, DOI 10.1136/gutjnl-2018-318134
   Boland PM, 2018, CA-CANCER J CLIN, V68, P217, DOI 10.3322/caac.21448
   Bonovas S, 2017, ALIMENT PHARM THER, V45, P1179, DOI 10.1111/apt.14023
   Bopanna S, 2017, LANCET GASTROENTEROL, V2, P269, DOI 10.1016/S2468-1253(17)30004-3
   BORGELT B, 1980, INT J RADIAT ONCOL, V6, P1, DOI 10.1016/0360-3016(80)90195-9
   Botteri E, 2008, JAMA-J AM MED ASSOC, V300, P2765, DOI 10.1001/jama.2008.839
   Botteri E, 2020, AM J GASTROENTEROL, V115, P1940, DOI 10.14309/ajg.0000000000000803
   Brenner H, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g2467
   Brosens LAA, 2007, GUT, V56, P965, DOI 10.1136/gut.2006.116913
   Bülow S, 2004, GUT, V53, P381, DOI 10.1136/gut.2003.027771
   Burt RW, 2004, GASTROENTEROLOGY, V127, P444, DOI 10.1053/j.gastro.2004.05.003
   Calderwood AH, 2019, CANCER PREV RES, V12, P295, DOI 10.1158/1940-6207.CAPR-19-0023
   Cammà C, 2000, JAMA-J AM MED ASSOC, V284, P1008, DOI 10.1001/jama.284.8.1008
   Cao Y, 2018, GUT, V67, P672, DOI 10.1136/gutjnl-2016-313413
   Caraglia M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01102
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chan AT, 2004, ANN INTERN MED, V140, P157, DOI 10.7326/0003-4819-140-3-200402030-00006
   Chao G, 2019, TECH COLOPROCTOL, V23, P821, DOI 10.1007/s10151-019-02076-w
   Chapman Christopher G, 2014, Gastrointest Endosc Clin N Am, V24, P353, DOI 10.1016/j.giec.2014.03.008
   Chen H D, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P1655, DOI 10.3760/cma.j.cn112338-20200227-00196
   Chen HD, 2020, AM J GASTROENTEROL, V115, P1264, DOI 10.14309/ajg.0000000000000624
   Chen HD, 2019, GUT, V68, P1450, DOI 10.1136/gutjnl-2018-317124
   Chen LM, 2007, OBSTET GYNECOL, V110, P18, DOI 10.1097/01.AOG.0000267500.27329.85
   Chen WQ., 2014, PREVENTION CONTROL C
   Chen YX, 2020, LANCET GASTROENTEROL, V5, P267, DOI 10.1016/S2468-1253(19)30409-1
   Chinese Society of Digestive Endoscopology China Anti-Cancer Association of Endoscopy Professional Committee, 2015, CHIN J GASTROENTEROL, V20, P345
   Chinese Society of Gastroenterology Tumor Cooperative Group of the Chinese Society of Gastroenterology, 2016, CHIN J DIGESTION, V36, P721
   中华人民共和国国家卫生健康委员会医政医管局, 2020, [中国实用外科杂志, Chinese Journal of Practical Surgery], V40, P601
   Cho E, 2004, JNCI-J NATL CANCER I, V96, P1015, DOI 10.1093/jnci/djh185
   Chow E, 2005, J GASTROEN HEPATOL, V20, P1634, DOI 10.1111/j.1440-1746.2005.03865.x
   Clarke WT, 2019, WORLD J GASTROENTERO, V25, P4148, DOI 10.3748/wjg.v25.i30.4148
   Cohen S, 2019, J PEDIATR GASTR NUTR, V68, P453, DOI 10.1097/MPG.0000000000002246
   Cole BF, 2007, JAMA-J AM MED ASSOC, V297, P2351, DOI 10.1001/jama.297.21.2351
   Cooperative Group on Endoscopic Diagnosis and Treatment of Early Gastrointestinal Cancer Chinese Society of Digestive Endoscopology; Gastrointestinal Tumor Cooperative Group Chinese Society of Gastroenterology; Intestinal Diseases Group Chinese Society of Digestive Endoscopology; Digestive Pathology Group Chinese Society of Gastroenterology, 2015, CHINESE J INTERN MED, V54, P375
   Cruz-Correa M, 2002, GASTROENTEROLOGY, V122, P641, DOI 10.1053/gast.2002.31890
   [崔伟佳 CUI Wei-jia], 2009, [基础医学与临床, Basic & Clinical Medicine], V29, P589
   de Gramont A, 2012, LANCET ONCOL, V13, P1225, DOI 10.1016/S1470-2045(12)70509-0
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   de Vries E, 2010, EUR J CANCER, V46, P2605, DOI 10.1016/j.ejca.2010.07.040
   Dekker E, 2020, GASTROENTEROLOGY, V158, P1520, DOI 10.1053/j.gastro.2019.11.310
   Dube C, 2007, ANN INTERN MED, V146, P365, DOI 10.7326/0003-4819-146-5-200703060-00009
   Dubé C, 2017, AM J GASTROENTEROL, V112, P1790, DOI 10.1038/ajg.2017.360
   Dulai PS, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6188
   Eaton JE, 2011, AM J GASTROENTEROL, V106, P1638, DOI 10.1038/ajg.2011.156
   Elwood PC, 2009, LANCET, V373, P1301, DOI 10.1016/S0140-6736(09)60243-9
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Fedirko V, 2010, AM J EPIDEMIOL, V172, P489, DOI 10.1093/aje/kwq157
   Feldman D, 2014, NAT REV CANCER, V14, P342, DOI 10.1038/nrc3691
   Ferrández A, 2012, BEST PRACT RES CL GA, V26, P185, DOI 10.1016/j.bpg.2012.01.009
   Fiorillo C, 2021, CANCERS, V13, DOI 10.3390/cancers13030574
   Flossmann E, 2007, LANCET, V369, P1603, DOI 10.1016/S0140-6736(07)60747-8
   Francois Y, 1999, J CLIN ONCOL, V17, P2396, DOI 10.1200/JCO.1999.17.8.2396
   Friedenreich C, 2006, CANCER EPIDEM BIOMAR, V15, P2398, DOI 10.1158/1055-9965.EPI-06-0595
   Fu L, 2013, CELL ONCOL, V36, P225, DOI 10.1007/s13402-013-0130-z
   FUCHS CS, 1994, NEW ENGL J MED, V331, P1669, DOI 10.1056/NEJM199412223312501
   Fujiya M, 2015, GASTROINTEST ENDOSC, V81, P583, DOI 10.1016/j.gie.2014.07.034
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Gall TMH, 2014, COLORECTAL DIS, V16, pO1, DOI 10.1111/codi.12445
   GANN PH, 1993, JNCI-J NATL CANCER I, V85, P1220, DOI 10.1093/jnci/85.15.1220
   Gao QY, 2013, CANCER PREV RES, V6, P744, DOI 10.1158/1940-6207.CAPR-13-0013
   Gao Qin-Yan, 2010, Front Med China, V4, P436, DOI 10.1007/s11684-010-0200-9
   Gao YF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21048-y
   Garaci E, 2003, INT IMMUNOPHARMACOL, V3, P1145, DOI 10.1016/S1567-5769(03)00053-5
   Genetics Group of the Committee of Colorectal Cancer CAA, 2018, J PRACT ONCOL, V33, P3
   GIARDIELLO FM, 1993, NEW ENGL J MED, V328, P1313, DOI 10.1056/NEJM199305063281805
   GIOVANNUCCI E, 1994, ANN INTERN MED, V121, P241, DOI 10.7326/0003-4819-121-4-199408150-00001
   Giovannucci E, 2002, GASTROENTEROL CLIN N, V31, P925, DOI 10.1016/S0889-8553(02)00057-2
   Grau MV, 2007, JNCI-J NATL CANCER I, V99, P129, DOI 10.1093/jnci/djk016
   Gray R, 2001, LANCET, V358, P1291
   Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709
   Grover S, 2012, JAMA-J AM MED ASSOC, V308, P485, DOI 10.1001/jama.2012.8780
   Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8
   Guarinos C, 2014, CLIN CANCER RES, V20, P1158, DOI 10.1158/1078-0432.CCR-13-1490
   Guidelines Working Committee of Chinese Society of Clinical Oncology, 2020, GUID CHIN SOC CLIN O
   Guidelines Working Committee of Chinese Society of Clinical Oncology, 2019, GUIDELINES CHINESE S, DOI DOI 10.13699/J.CNKI.1001-6821.2015.03.008
   Gupta N, 2012, GASTROINTEST ENDOSC, V75, P1022, DOI 10.1016/j.gie.2012.01.020
   Haruki S, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/621512
   Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z
   Hayashi N, 2013, GASTROINTEST ENDOSC, V78, P625, DOI 10.1016/j.gie.2013.04.185
   He EY, 2016, J PATHOL CLIN RES, V2, P127, DOI 10.1002/cjp2.44
   [何慧 He Hui], 2021, [中华健康管理学杂志, Chinese Journal of Health Management], V15, P263
   Hearle N, 2006, CLIN CANCER RES, V12, P3209, DOI 10.1158/1078-0432.CCR-06-0083
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   Helsingen LM, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5515
   Hendriks YMC, 2006, CA-CANCER J CLIN, V56, P213, DOI 10.3322/canjclin.56.4.213
   Hewett DG, 2012, GASTROINTEST ENDOSC, V76, P374, DOI 10.1016/j.gie.2012.04.446
   Higuchi T, 2003, CLIN CANCER RES, V9, P4756
   Higurashi T, 2016, LANCET ONCOL, V17, P475, DOI 10.1016/S1470-2045(15)00565-3
   Hirota C, 1996, CANCER-AM CANCER SOC, V78, P1660
   Hirschfield GM, 2013, LANCET, V382, P1587, DOI 10.1016/S0140-6736(13)60096-3
   Holme O, 2018, ANN INTERN MED, V168, P775, DOI 10.7326/M17-1441
   Holme O, 2017, BMJ-BRIT MED J, V356, DOI 10.1136/bmj.i6673
   Hull MA, 2018, LANCET, V392, P2583, DOI 10.1016/S0140-6736(18)31775-6
   Huxley RR, 2009, INT J CANCER, V125, P171, DOI 10.1002/ijc.24343
   Ibraheim H, 2018, FRONTLINE GASTROENTE, V9, P271, DOI 10.1136/flgastro-2017-100919
   IJspeert JEG, 2017, GUT, V66, P278, DOI 10.1136/gutjnl-2015-310630
   IJspeert JEG, 2016, AM J GASTROENTEROL, V111, P516, DOI 10.1038/ajg.2016.58
   Ikehara H, 2010, J GASTROEN HEPATOL, V25, P905, DOI 10.1111/j.1440-1746.2010.06275.x
   Ikematsu H, 2013, GASTROENTEROLOGY, V144, P551, DOI 10.1053/j.gastro.2012.12.003
   Imperiale TF, 2019, ANN INTERN MED, V170, P319, DOI 10.7326/M18-2390
   Imperiale TF, 2014, NEW ENGL J MED, V371, P187, DOI [10.1056/NEJMoa1311194, 10.1056/NEJMc1405215]
   Inflammatory Bowel Disease Group Chinese Society of Gastroenterology Chinese Medical Association, 2018, Chin J Dig, V38, P292
   Ishikawa H, 2014, GUT, V63, P1755, DOI 10.1136/gutjnl-2013-305827
   Iveson TJ, 2021, J CLIN ONCOL, V39, P631, DOI 10.1200/JCO.20.01330
   Japanese Society for Cancer of the Colon and Rectum, 2005, JSCCR GUID 2005 TREA
   Jayasekara H, 2016, ALCOHOL ALCOHOLISM, V51, P315, DOI 10.1093/alcalc/agv110
   Ji JG, 2018, GASTROENTEROLOGY, V154, P86, DOI 10.1053/j.gastro.2017.09.009
   Jia K, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000013792, 10.1097/md.0000000000013792]
   Johnson CD, 2008, NEW ENGL J MED, V359, P1207, DOI 10.1056/NEJMoa0800996
   Jung SJ, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56090463
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Kabir M, 2020, ALIMENT PHARM THER, V52, P5, DOI 10.1111/apt.15778
   Kaneko I, 2007, WORLD J GASTROENTERO, V13, P3829
   Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580
   Kempers MJE, 2011, LANCET ONCOL, V12, P49, DOI 10.1016/S1470-2045(10)70265-5
   Kerr RS, 2016, LANCET ONCOL, V17, P1543, DOI 10.1016/S1470-2045(16)30172-3
   Keum N, 2015, JNCI-J NATL CANCER I, V107, DOI [10.1093/jnci/djv088, 10.1093/jnci/dju428]
   Kim TJ, 2017, ANN SURG ONCOL, V24, P1085, DOI 10.1245/s10434-016-5633-1
   Kitajima K, 2004, J GASTROENTEROL, V39, P534, DOI 10.1007/s00535-004-1339-4
   Knudsen AB, 2021, JAMA-J AM MED ASSOC, V325, P1998, DOI 10.1001/jama.2021.5746
   Knudsen AB, 2016, JAMA-J AM MED ASSOC, V315, P2595, DOI 10.1001/jama.2016.6828
   Kobayashi H, 2011, J GASTROENTEROL, V46, P203, DOI 10.1007/s00535-010-0341-2
   Konstantinov SR, 2013, NAT REV GASTRO HEPAT, V10, P741, DOI 10.1038/nrgastro.2013.178
   Kudo S, 1997, WORLD J SURG, V21, P694, DOI 10.1007/s002689900293
   KURTZ JM, 1981, INT J RADIAT ONCOL, V7, P891, DOI 10.1016/0360-3016(81)90005-5
   Laine L, 2015, GASTROENTEROLOGY, V148, P639, DOI 10.1053/j.gastro.2015.01.031
   Laiyemo AO, 2009, CLIN GASTROENTEROL H, V7, P192, DOI 10.1016/j.cgh.2008.08.031
   Lappe JM, 2007, AM J CLIN NUTR, V85, P1586, DOI 10.1093/ajcn/85.6.1586
   Larsson SC, 2006, INT J CANCER, V119, P2657, DOI 10.1002/ijc.22170
   Latchford AR, 2011, DIS COLON RECTUM, V54, P1547, DOI 10.1097/DCR.0b013e318233a11f
   Latchford A, 2019, J PEDIATR GASTR NUTR, V68, P442, DOI 10.1097/MPG.0000000000002248
   Latchford AR, 2012, DIS COLON RECTUM, V55, P1038, DOI 10.1097/DCR.0b013e31826278b3
   Latchford AR, 2009, CLIN GASTROENTEROL H, V7, P659, DOI 10.1016/j.cgh.2009.02.028
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018
   Li CG, 2017, J GASTROEN HEPATOL, V32, P1723, DOI 10.1111/jgh.13776
   [李景南 Li Jingnan], 2010, [中华消化杂志, Chinese Journal of Digestion], V30, P808
   [李明阳 Li Mingyang], 2010, [中华消化杂志, Chinese Journal of Digestion], V30, P803
   Li N, 2019, J GASTROEN HEPATOL, V34, P1497, DOI 10.1111/jgh.14704
   Lieberman DA, 2003, JAMA-J AM MED ASSOC, V290, P2959, DOI 10.1001/jama.290.22.2959
   Lindor NM, 2006, JAMA-J AM MED ASSOC, V296, P1507, DOI 10.1001/jama.296.12.1507
   Liu PH, 2019, JAMA ONCOL, V5, P37, DOI 10.1001/jamaoncol.2018.4280
   Logan RFA, 2008, GASTROENTEROLOGY, V134, P29, DOI 10.1053/j.gastro.2007.10.014
   Lonez C, 2018, CURR RES TRANSL MED, V66, P53, DOI 10.1016/j.retram.2018.03.001
   Lu ZH., 2016, CHIN J HEPAT SURG, V5, P181
   Lugli A, 2017, MODERN PATHOL, V30, P1299, DOI 10.1038/modpathol.2017.46
   Luowei Wang., 2015, CHIN J DIG ENDOSC, V32, P501, DOI [DOI 10.3760/CMA.J.ISSN.1007-5232.2015.08.001, 10.3760/cma.j.issn.1007-5232.2015.08.001]
   [马丽萍 Ma Liping], 2021, [中华高血压杂志, Chinese Journal of Hypertension], V29, P157
   Ma YL, 2011, J CLIN ONCOL, V29, P3775, DOI 10.1200/JCO.2011.35.7566
   MacPhail ME, 2019, GASTROINTEST ENDOSC, V90, P96, DOI 10.1016/j.gie.2018.11.016
   Magee MS, 2018, CANCER IMMUNOL RES, V6, P509, DOI 10.1158/2326-6066.CIR-16-0362
   Magro F, 2017, J CROHNS COLITIS, V11, P649, DOI 10.1093/ecco-jcc/jjx008
   Mak JWY, 2020, SCAND J GASTROENTERO, V55, P279, DOI 10.1080/00365521.2020.1731760
   Manson JE, 2019, NEW ENGL J MED, V380, P33, DOI [10.1056/NEJMoa1809944, 10.1056/nejmoa1809944]
   Marks AR, 2015, CANCER EPIDEM BIOMAR, V24, P1692, DOI 10.1158/1055-9965.EPI-15-0559
   Martínez ME, 2009, GASTROENTEROLOGY, V136, P832, DOI 10.1053/j.gastro.2008.12.007
   Martínez ME, 2001, GASTROENTEROLOGY, V120, P1077, DOI 10.1053/gast.2001.23247
   Massat NJ, 2013, J MED SCREEN, V20, P125, DOI 10.1177/0969141313501292
   Matsuda T, 2009, JPN J CLIN ONCOL, V39, P435, DOI [10.1093/jjco/hyp077, 10.1093/jjco/hyp047]
   McNabb S, 2020, INT J CANCER, V146, P861, DOI 10.1002/ijc.32377
   Mehta RS, 2017, JAMA ONCOL, V3, P921, DOI 10.1001/jamaoncol.2016.6374
   Memon S, 2015, COLORECTAL DIS, V17, P748, DOI 10.1111/codi.12976
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Michels KB, 2020, AM J CLIN NUTR, V112, P1566, DOI 10.1093/ajcn/nqaa244
   MICKALIDE AD, 1986, PEDIATR CLIN N AM, V33, P1007
   Min M, 2017, GASTROINTEST ENDOSC, V86, P724, DOI 10.1016/j.gie.2017.02.035
   Moazzen S, 2018, CLIN NUTR, V37, P1926, DOI 10.1016/j.clnu.2017.10.010
   Moisio AL, 2002, GUT, V50, P845, DOI 10.1136/gut.50.6.845
   Moller P, 2017, GUT, V66, P464, DOI 10.1136/gutjnl-2015-309675
   Monahan KJ, 2020, GUT, V69, P411, DOI 10.1136/gutjnl-2019-319915
   Murphy N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039361
   Naber SK, 2018, GASTROENTEROLOGY, V154, P105, DOI 10.1053/j.gastro.2017.09.021
   Nakajima T, 2013, SURG ENDOSC, V27, P3262, DOI 10.1007/s00464-013-2903-x
   National Cancer Center China Expert Group of the Development of China Guideline for the Screening Early Detection and Early Treatment of Colorectal Cancer, 2021, Zhonghua Zhong Liu Za Zhi, V43, P16, DOI 10.3760/cma.j.cn112152-20210105-00010
   Pham NM, 2012, JPN J CLIN ONCOL, V42, P2, DOI 10.1093/jjco/hyr160
   Nieuwenhuis MH, 2012, GUT, V61, P734, DOI 10.1136/gut.2010.229104
   Nishizawa T, 2019, ENDOSCOPY, V51, pE204, DOI 10.1055/a-0866-9302
   Norat T, 2002, INT J CANCER, V98, P241, DOI 10.1002/ijc.10126
   NUGENT KP, 1993, BRIT J SURG, V80, P1618, DOI 10.1002/bjs.1800801244
   Oh K, 2007, AM J EPIDEMIOL, V165, P1178, DOI 10.1093/aje/kwm026
   Ohnita K, 2011, DIGEST DIS SCI, V56, P2715, DOI 10.1007/s10620-011-1638-6
   Oka S, 2015, AM J GASTROENTEROL, V110, P697, DOI 10.1038/ajg.2015.96
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pahlman L, 1997, NEW ENGL J MED, V336, P980
   Pangarkar S, 2021, ABDOM RADIOL, V46, P498, DOI 10.1007/s00261-020-02708-y
   Park CH, 2020, CLIN ENDOSC, V53, P142, DOI 10.5946/ce.2020.032
   Park CH, 2019, GASTROINTEST ENDOSC, V89, P1204, DOI 10.1016/j.gie.2019.02.023
   Passarelli MN, 2019, AM J CLIN NUTR, V110, P903, DOI 10.1093/ajcn/nqz160
   Pickhardt PJ, 2011, RADIOLOGY, V259, P393, DOI 10.1148/radiol.11101887
   Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618
   Pietrantonio F, 2015, CRIT REV ONCOL HEMAT, V96, P156, DOI 10.1016/j.critrevonc.2015.05.016
   Pinto C, 2011, ONCOLOGIST, V16, P228, DOI 10.1634/theoncologist.2010-0298
   Ponugoti PL, 2017, DIGEST LIVER DIS, V49, P34, DOI 10.1016/j.dld.2016.06.025
   Puli S, 2009, ANN SURG ONCOL, V16, P254, DOI 10.1245/s10434-008-0231-5
   Qi WX, 2014, CLIN DRUG INVEST, V34, P231, DOI 10.1007/s40261-014-0174-5
   Qiu XY, 2017, ONCOTARGET, V8, P1031, DOI 10.18632/oncotarget.13715
   Qu CY, 2015, WORLD J GASTROENTERO, V21, P5072, DOI 10.3748/wjg.v21.i16.5072
   Rostom A, 2007, ANN INTERN MED, V146, P376, DOI 10.7326/0003-4819-146-5-200703060-00010
   Rubin DT, 2019, AM J GASTROENTEROL, V114, P384, DOI 10.14309/ajg.0000000000000152
   Saito Y, 2010, SURG ENDOSC, V24, P343, DOI 10.1007/s00464-009-0562-8
   Saitoh Y, 2001, GASTROENTEROLOGY, V120, P1657, DOI 10.1053/gast.2001.24886
   Sakamoto T, 2012, CLIN GASTROENTEROL H, V10, P22, DOI 10.1016/j.cgh.2011.10.007
   Samad AKA, 2005, COLORECTAL DIS, V7, P204, DOI 10.1111/j.1463-1318.2005.00747.x
   Samadder NJ, 2018, JAMA ONCOL, V4, P671, DOI 10.1001/jamaoncol.2017.5431
   Sandhu MS, 2001, CANCER EPIDEM BIOMAR, V10, P439
   Sano Y, 2016, DIGEST ENDOSC, V28, P526, DOI 10.1111/den.12644
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sears CL, 2014, CELL HOST MICROBE, V15, P317, DOI 10.1016/j.chom.2014.02.007
   Sebag-Montefiore D, 2009, LANCET, V373, P811, DOI 10.1016/S0140-6736(09)60484-0
   Selby K, 2017, ANN INTERN MED, V167, P565, DOI 10.7326/M17-1361
   Shaukat A, 2021, AM J GASTROENTEROL, V116, P458, DOI 10.14309/ajg.0000000000001122
   Shaukat A, 2013, NEW ENGL J MED, V369, P1106, DOI 10.1056/NEJMoa1300720
   Sheng JQ, 2010, WORLD J GASTROENTERO, V16, P1522, DOI 10.3748/wjg.v16.i12.1522
   Siddiqui Ali A, 2006, Int Semin Surg Oncol, V3, P36, DOI 10.1186/1477-7800-3-36
   Silva IL, 2017, TECH COLOPROCTOL, V21, P847, DOI 10.1007/s10151-017-1707-8
   Simons-Linares CR, 2020, CLEV CLIN J MED, V87, P175, DOI 10.3949/ccjm.87a.19003
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Snook AE, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0576-2
   Soetikno R, 2018, GASTROINTEST ENDOSC, V87, P1085, DOI 10.1016/j.gie.2018.01.013
   Solomon SD, 2005, NEW ENGL J MED, V352, P1071, DOI 10.1056/NEJMoa050405
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Steinbach G, 2000, NEW ENGL J MED, V342, P1946, DOI 10.1056/NEJM200006293422603
   Su P, 2013, COLORECTAL DIS, V15, pE1, DOI 10.1111/codi.12033
   Sung JJY, 2015, GUT, V64, P121, DOI 10.1136/gutjnl-2013-306503
   Sung JJY, 2018, J GASTROEN HEPATOL, V33, P187, DOI 10.1111/jgh.13835
   Syngal S, 2015, AM J GASTROENTEROL, V110, P223, DOI 10.1038/ajg.2014.435
   Tanaka A, 2014, J HEPATO-BIL-PAN SCI, V21, P43, DOI 10.1002/jhbp.50
   Tanaka S, 2001, GASTROINTEST ENDOSC, V54, P62, DOI 10.1067/mge.2001.115729
   Tanaka S, 2000, ONCOL REP, V7, P783
   Tanaka S, 2008, J GASTROENTEROL, V43, P641, DOI 10.1007/s00535-008-2223-4
   Tanaka S, 2021, J GASTROENTEROL, V56, P323, DOI 10.1007/s00535-021-01776-1
   Tanaka S, 2020, DIGEST ENDOSC, V32, P219, DOI 10.1111/den.13545
   Tate DJ, 2017, GASTROINTEST ENDOSC, V85, P647, DOI 10.1016/j.gie.2016.11.027
   Terasaki M, 2012, J GASTROEN HEPATOL, V27, P734, DOI 10.1111/j.1440-1746.2011.06977.x
   The Society of Colorectal Cancer China Anti-Cancer Association, 2017, CHINA ONCOLOGIA, V27, P41
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tonelli F, 2000, J SURG ONCOL, V74, P15, DOI 10.1002/1096-9098(200005)74:1<15::AID-JSO4>3.0.CO;2-Z
   Torres-Maravilla E, 2021, MICROORGANISMS, V9, DOI 10.3390/microorganisms9051021
   Toyonaga T, 2009, DIGEST ENDOSC, V21, pS31, DOI 10.1111/j.1443-1661.2009.00872.x
   Trivedi PJ, 2020, GASTROENTEROLOGY, V159, P915, DOI 10.1053/j.gastro.2020.05.049
   Troelsen FS, 2021, ENDOSCOPY, V53, P1023, DOI 10.1055/a-1322-6574
   Tulchinsky H, 2005, ARCH SURG-CHICAGO, V140, P159, DOI 10.1001/archsurg.140.2.159
   U.S. Preventive Services Task Force, 2021, JAMA-J AM MED ASSOC, V325, p962
   Ueno H, 2004, GASTROENTEROLOGY, V127, P385, DOI 10.1053/j.gastro.2004.04.022
   Ueno H, 2010, AM J CLIN PATHOL, V134, P312, DOI 10.1309/AJCPMQ7I5ZTTZSOM
   van Gijn W, 2011, LANCET ONCOL, V12, P575, DOI 10.1016/S1470-2045(11)70097-3
   van Lier MGF, 2011, AM J GASTROENTEROL, V106, P940, DOI 10.1038/ajg.2010.473
   van Schaik FDM, 2012, GUT, V61, P235, DOI 10.1136/gut.2011.237412
   Vasen HFA, 2022, FAM CANCER, V21, P49, DOI 10.1007/s10689-020-00225-x
   von Renteln D, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.6
   Vuik FER, 2021, ENDOSCOPY, V53, P815, DOI 10.1055/a-1308-1297
   Wan DS., 2018, J PRACT ONCOL, V33, P41
   Wang CSE, 2018, WORLD J GASTROENTERO, V24, P4254, DOI 10.3748/wjg.v24.i37.4254
   Wang C, 2019, BMC MICROBIOL, V19, DOI 10.1186/s12866-019-1610-8
   Wang F, 2020, CANCER COMMUN, V40, P467, DOI 10.1002/cac2.12095
   Wang H, 2020, Zhonghua Liu Xing Bing Xue Za Zhi, V41, P429, DOI 10.3760/cma.j.issn.0254-6450.2020.03.028
   Wang YN, 2017, J DIGEST DIS, V18, P684, DOI 10.1111/1751-2980.12558
   Wang Z, 2019, CHIN J CANCER, V38, P145
   Wei MY, 2008, CANCER EPIDEM BIOMAR, V17, P2958, DOI 10.1158/1055-9965.EPI-08-0402
   Wild N, 2010, CLIN CANCER RES, V16, P6111, DOI 10.1158/1078-0432.CCR-10-0119
   WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701
   Wolin KY, 2009, BRIT J CANCER, V100, P611, DOI 10.1038/sj.bjc.6604917
   Wolmark N, 2000, JNCI-J NATL CANCER I, V92, P388, DOI 10.1093/jnci/92.5.388
   Wong MCS, 2018, AM J GASTROENTEROL, V113, P1819, DOI 10.1038/s41395-018-0075-y
   Wu K, 2009, AM J CLIN NUTR, V90, P1623, DOI 10.3945/ajcn.2009.28319
   Xicola RM, 2007, JNCI-J NATL CANCER I, V99, P244, DOI 10.1093/jnci/djk033
   Yan PG, 2019, INFLAMM BOWEL DIS, V25, P1293, DOI 10.1093/ibd/izz020
   Yilmaz A, 2020, INT J COLORECTAL DIS, V35, P351, DOI 10.1007/s00384-019-03454-4
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370
   Zell JA, 2009, CANCER PREV RES, V2, P209, DOI 10.1158/1940-6207.CAPR-08-0203
   Zhang Q., 2017, CHIN J INFLAMM BOWEL, V1, P155
   Zhang XF, 2021, EUR J NUTR, V60, P2855, DOI 10.1007/s00394-021-02503-5
   Zhang XH, 2016, NEW ENGL J MED, V374, P791, DOI 10.1056/NEJMc1514501
   Zhang ZF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090135
   Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012
   Zheng XB, 2020, GUT, V69, DOI 10.1136/gutjnl-2019-318374
   Zhou Q, 2019, GASTROENT RES PRACT, V2019, DOI 10.1155/2019/5363261
NR 316
TC 6
Z9 6
U1 3
U2 20
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-2972
EI 1751-2980
J9 J DIGEST DIS
JI J. Dig. Dis.
PD FEB
PY 2022
VL 23
IS 2
BP 58
EP 90
DI 10.1111/1751-2980.13079
PG 33
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA ZL4KM
UT WOS:000763647200002
PM 34984819
DA 2025-01-04
ER

PT J
AU McFall, T
   Diedrich, JK
   Mengistu, M
   Littlechild, SL
   Paskvan, KV
   Sisk-Hackworth, L
   Moresco, JJ
   Shaw, AS
   Stites, EC
AF McFall, Thomas
   Diedrich, Jolene K.
   Mengistu, Meron
   Littlechild, Stacy L.
   Paskvan, Kendra V.
   Sisk-Hackworth, Laura
   Moresco, James J.
   Shaw, Andrey S.
   Stites, Edward C.
TI A systems mechanism for KRAS mutant allele-specific responses to
   targeted therapy
SO SCIENCE SIGNALING
LA English
DT Article
ID GTPASE-ACTIVATING PROTEINS; RAS PROTEINS; N-RAS; CETUXIMAB;
   FLUORESCENCE; CHEMOTHERAPY; DOMAIN; ASSOCIATION; IRINOTECAN; MUTATIONS
AB Cancer treatment decisions are increasingly guided by which specific genes are mutated within each patient's tumor. For example, agents inhibiting the epidermal growth factor receptor (EGFR) benefit many colorectal cancer (CRC) patients, with the general exception of those whose tumor includes a KRAS mutation. However, among the various KRAS mutations, that which encodes the G13D mutant protein (KRAS(G13D)) behaves differently; for unknown reasons, KRAS(G13D) CRC patients benefit from the EGFR-blocking antibody cetuximab. Controversy surrounds this observation, because it contradicts the well-established mechanisms of EGFR signaling with regard to RAS mutations. Here, we identified a systems-level, mechanistic explanation for why KRAS(G13D) cancers respond to EGFR inhibition. A computational model of RAS signaling revealed that the biophysical differences between the three most common KRAS mutants were sufficient to generate different sensitivities to EGFR inhibition. Integrated computation with experimentation then revealed a nonintuitive, mutant-specific dependency of wild-type RAS activation by EGFR that is determined by the interaction strength between KRAS and the tumor suppressor neurofibromin (NF1). KRAS mutants that strongly interacted with and competitively inhibited NF1 drove wild-type RAS activation in an EGFR-independent manner, whereas KRAS(G13D) weakly interacted with and could not competitively inhibit NF1 and, thus, KRAS(G13D) cells remained dependent on EGFR for wild-type RAS activity. Overall, our work demonstrates how systems approaches enable mechanism-based inference in genomic medicine and can help identify patients for selective therapeutic strategies.
C1 [McFall, Thomas; Littlechild, Stacy L.; Paskvan, Kendra V.; Sisk-Hackworth, Laura; Stites, Edward C.] Salk Inst Biol Studies, Integrat Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.
   [Diedrich, Jolene K.; Moresco, James J.] Salk Inst Biol Studies, Mass Spectrometry Core Prote & Metab, La Jolla, CA 92037 USA.
   [Diedrich, Jolene K.] Scripps Res Inst, Dept Mol Med, La Jolla, CA 92037 USA.
   [Mengistu, Meron; Shaw, Andrey S.] Genentech Inc, Dept Res Biol, San Francisco, CA 94080 USA.
C3 Salk Institute; Salk Institute; Scripps Research Institute; Roche
   Holding; Genentech
RP Stites, EC (corresponding author), Salk Inst Biol Studies, Integrat Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM estites@salk.edu
OI Stites, Edward/0000-0002-3783-7336; Diedrich,
   Jolene/0000-0001-6489-4558; Sisk-Hackworth, Laura/0000-0002-0710-385X;
   Shaw, Andrey/0000-0001-5685-0272; Moresco, James/0000-0003-1178-1642
FU NIH [K22CA216318, T32CA009370, P30CA014195]; Mass Spectrometry Core of
   the Salk Institute; Helmsley Center for Genomic Medicine
FX Support for this work was provided by NIH K22CA216318, NIH T32CA009370,
   and the Mass Spectrometry Core of the Salk Institute with funding from
   NIH P30CA014195 and the Helmsley Center for Genomic Medicine.
CR Ahmadian MR, 1997, BIOCHEMISTRY-US, V36, P4535, DOI 10.1021/bi962556y
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   CHUANG E, 1994, MOL CELL BIOL, V14, P5318, DOI 10.1128/MCB.14.8.5318
   CorbalanGarcia S, 1996, MOL CELL BIOL, V16, P5674
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   Donovan S, 2002, BBA-REV CANCER, V1602, P23, DOI 10.1016/S0304-419X(01)00041-5
   Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909
   ECCLESTON JF, 1991, BIOCHEM SOC T, V19, P432, DOI 10.1042/bst0190432
   Fischbach MA, 2003, CANCER RES, V63, P4089
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Grabocka E, 2014, CANCER CELL, V25, P243, DOI 10.1016/j.ccr.2014.01.005
   Gremer L, 2008, BIOL CHEM, V389, P1163, DOI 10.1515/BC.2008.132
   Hood FE, 2019, MOL BIOL CELL, V30, P1108, DOI 10.1091/mbc.E18-10-0676
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Keller JW, 2007, ONCOGENE, V26, P3051, DOI 10.1038/sj.onc.1210103
   Lenzen C, 1998, BIOCHEMISTRY-US, V37, P7420, DOI 10.1021/bi972621j
   Lim KH, 2008, NATURE, V452, P646, DOI 10.1038/nature06778
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392
   MacLean B, 2010, BIOINFORMATICS, V26, P966, DOI 10.1093/bioinformatics/btq054
   Mageean CJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142674
   Morelli MP, 2012, J CLIN ONCOL, V30, P3565, DOI 10.1200/JCO.2012.43.6535
   Nakamura M, 2017, CANCER CHEMOTH PHARM, V79, P29, DOI 10.1007/s00280-016-3203-7
   Omerovic J, 2008, ONCOGENE, V27, P2754, DOI 10.1038/sj.onc.1210925
   Palmioli A, 2009, BIOCHEM BIOPH RES CO, V386, P593, DOI 10.1016/j.bbrc.2009.06.069
   Peeters M, 2013, J CLIN ONCOL, V31, P759, DOI 10.1200/JCO.2012.45.1492
   Rudolph MG, 2001, J BIOL CHEM, V276, P23914, DOI 10.1074/jbc.M011600200
   Segelov E, 2016, J CLIN ONCOL, V34, P2258, DOI 10.1200/JCO.2015.65.6843
   Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017
   STITES EC, 2014, 005397 BIORXIV
   Stites EC, 2007, SCIENCE, V318, P463, DOI 10.1126/science.1144642
   Stites EC, 2018, CPT-PHARMACOMET SYST, V7, P342, DOI 10.1002/psp4.12291
   Stites EC, 2015, CELL REP, V10, P307, DOI 10.1016/j.celrep.2014.12.035
   Stites Edward C, 2012, Methods Mol Biol, V880, P69, DOI 10.1007/978-1-61779-833-7_5
   Stites EC, 2012, WIRES SYST BIOL MED, V4, P117, DOI 10.1002/wsbm.156
   Stites EC, 2010, ADV EXP MED BIOL, V680, P661, DOI 10.1007/978-1-4419-5913-3_73
   Sydor JR, 1998, BIOCHEMISTRY-US, V37, P14292, DOI 10.1021/bi980764f
   Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231
NR 44
TC 40
Z9 47
U1 0
U2 9
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
EI 1937-9145
J9 SCI SIGNAL
JI Sci. Signal.
PD SEP 24
PY 2019
VL 12
IS 600
AR eaaw8288
DI 10.1126/scisignal.aaw8288
PG 14
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA JA1MJ
UT WOS:000487580800002
PM 31551296
OA Green Accepted, Green Submitted
DA 2025-01-04
ER

PT J
AU Zhao, J
   Xu, J
   Zhang, R
AF Zhao, Jian
   Xu, Jian
   Zhang, Rui
TI MicroRNA-539 inhibits colorectal cancer progression by directly
   targeting SOX4
SO ONCOLOGY LETTERS
LA English
DT Article
DE colorectal cancer; microRNA-539; SRY-box 4; proliferation; invasion
ID POOR-PROGNOSIS; INCREASED EXPRESSION; PROSTATE-CANCER; INVASION;
   DYSREGULATION; CARCINOMA; MIR-539; GENES; METASTASIS; BIOGENESIS
AB Colorectal cancer (CRC) is the third most prevalent cancer and the fourth most common cause of cancer-associated mortality in males and females globally. Aberrant expression of microRNA-539 (miR-539) has been reported in multiple types of cancer. However, miR-539 expression, function and underlying mechanisms have not been clearly elucidated in CRC. In the present study, miR-539 expression was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) in CRC tissues and cell lines. The effects of miR-539 on CRC cells were further examined in in vitro studies. In addition, the direct targets of miR-539 in CRC were investigated using bioinformatics, luciferase reporter assays, RT-qPCR and western blotting. miR-539 was revealed to be significantly downregulated in CRC cell lines and tissues. Decreased miR-539 expression was associated with lymph node metastasis and tumor-node-metastasis stage in patients with CRC. Functional assays revealed that the rescue of miR-539 expression attenuated CRC cell proliferation and invasion in vitro. Additionally, SRY-box 4 (SOX4) was validated as a direct target gene of miR-539 in CRC. Furthermore, SOX4 was revealed to be upregulated in CRC tissues at the mRNA and protein level. A significant negative correlation between miR-539 and SOX4 mRNA expression levels was observed in CRC tissues. Furthermore, upregulation of SOX4 partially restored the tumor suppressive effects of miR-539 on CRC cell proliferation and invasion. Taken together, this suggests that miR-539 may serve tumor-suppressive functions in CRC during the process of malignant transformation, by directly targeting SOX4. miR-539/SOX4-based targeted therapy may represent a potential novel treatment for patients with CRC.
C1 [Zhao, Jian; Xu, Jian; Zhang, Rui] China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Colorectal Surg, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China.
C3 China Medical University
RP Zhang, R (corresponding author), China Med Univ, Liaoning Canc Hosp & Inst, Canc Hosp, Dept Colorectal Surg, 44 Xiaoheyan Rd, Shenyang 110042, Liaoning, Peoples R China.
EM ruizhang_cmu@163.com
FU Clinical Capability Construction Project for Liaoning Provincial
   Hospitals [LNCCC-D42-2015]
FX The present study was supported by the Clinical Capability Construction
   Project for Liaoning Provincial Hospitals (grant no. LNCCC-D42-2015).
CR Abdelsatir Azza Ali, 2015, Asian Pac J Cancer Prev, V16, P8053
   Andersen CL, 2009, BRIT J CANCER, V100, P511, DOI 10.1038/sj.bjc.6604884
   Bao ZQ, 2016, J HUAZHONG U SCI-MED, V36, P193, DOI 10.1007/s11596-016-1565-z
   Bardhan Kankana, 2013, Cancers (Basel), V5, P676, DOI 10.3390/cancers5020676
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Calin GA, 2004, P NATL ACAD SCI USA, V101, P2999, DOI 10.1073/pnas.0307323101
   Chen PS, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-90
   Cheung M, 2000, MOL BRAIN RES, V79, P180, DOI 10.1016/S0169-328X(00)00109-1
   Cui FY, 2016, ONCOL REP, V36, P487, DOI 10.3892/or.2016.4834
   Dong F, 2017, ONCOTARGET, V8, P27547, DOI 10.18632/oncotarget.15173
   Fang CL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052804
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Griffiths-Jones S, 2006, NUCLEIC ACIDS RES, V34, pD140, DOI 10.1093/nar/gkj112
   Gu LX, 2015, BIOCHEM BIOPH RES CO, V464, P1128, DOI 10.1016/j.bbrc.2015.07.090
   Guda K, 2015, P NATL ACAD SCI USA, V112, P1149, DOI 10.1073/pnas.1417064112
   Hu H, 2012, ONCOL LETT, V4, P1037, DOI 10.3892/ol.2012.866
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Jiang HP, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21888
   Jin H, 2015, INT J CLIN EXP PATHO, V8, P8075
   Konda B, 2015, WORLD J GASTRO ONCOL, V7, P71, DOI 10.4251/wjgo.v7.i7.71
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Kozomara A, 2011, NUCLEIC ACIDS RES, V39, pD152, DOI 10.1093/nar/gkq1027
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li GJ, 2015, BIOMED PHARMACOTHER, V73, P154, DOI 10.1016/j.biopha.2015.05.010
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lv LY, 2015, CELL BIOCHEM FUNCT, V33, P534, DOI 10.1002/cbf.3152
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Mirghasemi A, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0237-6
   Porkka KP, 2007, CANCER RES, V67, P6130, DOI 10.1158/0008-5472.CAN-07-0533
   Qu ST, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046010
   Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X
   Shenouda SK, 2009, CANCER METAST REV, V28, P369, DOI 10.1007/s10555-009-9188-5
   Shia J, 2012, SEMIN DIAGN PATHOL, V29, P142, DOI 10.1053/j.semdp.2012.02.001
   SIEGEL RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Tagscherer KE, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0321-6
   Vaiopoulos AG, 2014, BBA-MOL BASIS DIS, V1842, P971, DOI 10.1016/j.bbadis.2014.02.006
   Varol U, 2014, TUMORI J, V100, P370, DOI 10.1700/1636.17888
   Wang BC, 2016, TUMOR BIOL, V37, P9131, DOI 10.1007/s13277-015-4756-5
   Wang DM, 2015, MOL CELL BIOCHEM, V402, P75, DOI 10.1007/s11010-014-2315-9
   Wang L, 2013, PROSTATE CANCER P D, V16, P301, DOI 10.1038/pcan.2013.25
   Wegner M, 1999, NUCLEIC ACIDS RES, V27, P1409, DOI 10.1093/nar/27.6.1409
   Yu H, 2013, INT J CLIN EXP PATHO, V6, P2904
   Zhang HT, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0337-8
   Zheng Jiang-hua, 2010, Nan Fang Yi Ke Da Xue Xue Bao, V30, P818
   Zhou L, 2016, ONCOTARGET, V7, P51943, DOI 10.18632/oncotarget.10460
   Zhou LQ, 2016, CELL PHYSIOL BIOCHEM, V38, P1785, DOI 10.1159/000443117
NR 47
TC 18
Z9 19
U1 12
U2 19
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD AUG
PY 2018
VL 16
IS 2
BP 2693
EP 2700
DI 10.3892/ol.2018.8892
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GT8EJ
UT WOS:000444768100067
PM 30013665
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Awasthi, A
   Kumar, P
   Srikanth, C
   Sahi, S
   Puria, R
AF Awasthi, Ankita
   Kumar, Pharvendra
   Srikanth, Chittur V.
   Sahi, Shakti
   Puria, Rekha
TI <i>Invitro</i> Evaluation of Torin2 and 2, 6-Dihydroxyacetophenone in
   Colorectal Cancer Therapy
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE mTOR; Kinase inhibitor; Drug development; Docking; Natural Compound
ID PI3K/AKT/MTOR PATHWAY; MTOR PATHWAY; INHIBITOR; MUTATIONS; DOCKING;
   GLIDE; CELLS
AB Colorectal cancer (CRC) is one of the most prevalent cancers diagnosed worldwide. Despite recent advances, resistance to cytotoxic and targeted therapy remains one of the greatest challenges in long-term management of colorectal cancer therapy. Recently established role of mTOR signaling in proliferation of CRC has incited for evaluation of mTOR kinase specific inhibitors in CRC therapy. Second generation mTOR kinase inhibitors including Torin2 has demonstrated efficient anticancer properties against variety of cancers and are in various stages of drug development. The time and financial constraints concomitant from discovery to development of efficient chemical inhibitors has redirected attention towards investigation of wide spread naturally occurring largely inexpensive compounds for their therapeutic potential. One such naturally occurring compound acetophenone derivative polyphenolic compound 2, 6-Dihydroxyacetophenone (DHAP) inhibits cell growth in different conditions. We investigated anticancer properties of both Torin2 and DHAP against colorectal cancer in HCT8 cell lines. Both Torin2 and DHAP inhibited growth of CRC cells at different concentrations by restricting multiple cellular functions e.g., cell cycle progression, cell migration and induced apoptosis. Treatment of HCT8 cells with natural compound DHAP resulted in reduced expression of mTOR pathway specific genes p70S6K1 and AKT1. In silico docking studies showed affinity of DHAP to mTOR kinase like Torin2. Taken together, our result vouches for role of Torin2 in CRC therapy and recommends DHAP an mTOR inhibitor, as a potential lead in the development of new therapeutic regimes against colorectal cancer.
C1 [Awasthi, Ankita; Sahi, Shakti; Puria, Rekha] Gautam Buddha Univ, Sch Biotechnol, Greater Noida 201312, Gautam Budh Nag, India.
   [Kumar, Pharvendra; Srikanth, Chittur V.] Reg Ctr Biotechnol, NCR Biotech Cluster Milestone 3, Faridabad, Haryana, India.
   [Kumar, Pharvendra] KIIT Univ, Kalinga Inst Ind Technol, Bhubaneswar 751024, Odisha, India.
C3 Gautam Buddha University; Department of Biotechnology (DBT) India;
   Regional Centre for Biotechnology; Kalinga Institute of Industrial
   Technology (KIIT)
RP Puria, R (corresponding author), Gautam Buddha Univ, Sch Biotechnol, Greater Noida 201312, Gautam Budh Nag, India.
EM rpuria@gbu.ac.in
OI Kumar, Pharvendra/0000-0002-4953-9336; Sahi, Shakti/0000-0002-9931-7993;
   puria, rekha/0000-0002-5320-5099; Srikanth, Chittur/0000-0001-9381-1213
FU Department of Biotechnology, Ministry of Science and Technology, Govt of
   India
FX The work was supported by research grant to RP from Department of
   Biotechnology, Ministry of Science and Technology, Govt of India.
CR Ahmed M, 2014, CARCINOGENESIS, V35, P1564, DOI 10.1093/carcin/bgu051
   [Anonymous], 2014, American Cancer Society, V2014, P1
   Badr CE, 2013, JNCI-J NATL CANCER I, V105, P643, DOI 10.1093/jnci/djt037
   Beck D.E., 2009, Rev. Gastroenterol. Mex, V8, P2, DOI [10.1038/nrgastro.2011.208, DOI 10.1038/NRGASTRO.2011.208]
   Benjamin D, 2011, NAT REV DRUG DISCOV, V10, P868, DOI 10.1038/nrd3531
   Blaser B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-86
   Bracht K, 2010, BRIT J CANCER, V103, P340, DOI 10.1038/sj.bjc.6605780
   Cai ZR, 2014, ANN SURG ONCOL, V21, P179, DOI 10.1245/s10434-013-3146-8
   Chresta CM, 2010, CANCER RES, V70, P288, DOI 10.1158/0008-5472.CAN-09-1751
   Efeyan A, 2010, CURR OPIN CELL BIOL, V22, P169, DOI 10.1016/j.ceb.2009.10.007
   Erdemgil FZ, 2007, TALANTA, V72, P489, DOI 10.1016/j.talanta.2006.11.007
   Evan GI, 2001, NATURE, V411, P342, DOI 10.1038/35077213
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Friesner RA, 2004, J MED CHEM, V47, P1739, DOI 10.1021/jm0306430
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Fujishita T, 2008, P NATL ACAD SCI USA, V105, P13544, DOI 10.1073/pnas.0800041105
   Grabiner BC, 2014, CANCER DISCOV, V4, P554, DOI 10.1158/2159-8290.CD-13-0929
   Guertin DA, 2005, TRENDS MOL MED, V11, P353, DOI 10.1016/j.molmed.2005.06.007
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Jiang BH, 2008, DRUG RESIST UPDATE, V11, P63, DOI 10.1016/j.drup.2008.03.001
   Lee C, 1998, DEEP-SEA RES PT II, V45, P2489, DOI 10.1016/S0967-0645(98)00079-4
   Li W, 2015, MIRNA 99B 5P SUPPRES, P6
   Liang CC, 2007, NAT PROTOC, V2, P329, DOI 10.1038/nprot.2007.30
   Link A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057709
   Liu QS, 2013, CANCER RES, V73, P2574, DOI 10.1158/0008-5472.CAN-12-1702
   Liu Qingsong, 2009, Drug Discov Today Ther Strateg, V6, P47
   LoPiccolo J, 2008, DRUG RESIST UPDATE, V11, P32, DOI 10.1016/j.drup.2007.11.003
   Manning G, 2002, SCIENCE, V298, P1912, DOI 10.1126/science.1075762
   Martínez-Luis S, 2007, PHYTOCHEMISTRY, V68, P1882, DOI 10.1016/j.phytochem.2007.02.025
   Miller J.M., 2003, Analysis, V52, P2
   Murugan AK, 2013, J BIOL CHEM, V288, P6511, DOI 10.1074/jbc.M112.399485
   Nakamura ES, 2002, CANCER LETT, V177, P119, DOI 10.1016/S0304-3835(01)00708-X
   Passtoors WM, 2013, AGING CELL, V12, P24, DOI 10.1111/acel.12015
   Pursh PC, 2014, POLYPHENOLS ANTIPROL, P11045, DOI [10.3390/molecules190811045, DOI 10.3390/MOLECULES190811045]
   Riquelme I, 2016, PATHOL ONCOL RES, V22, P797, DOI 10.1007/s12253-016-0066-5
   Roulin D, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-90
   Sadowski SM, 2015, ONCOTARGET, V6, P18038, DOI 10.18632/oncotarget.3833
   Sigurdsson S, 2005, IN VIVO, V19, P191
   Simioni C, ACTIVITY NOVEL MTOR, P5
   Udayakumar D, 2016, RADIAT RES, V185, P527, DOI 10.1667/RR14373.1
   Wang C, 2015, NOVEL MTOR INHIBITOR, P1708, DOI [10.3892/or.2015.4146, DOI 10.3892/OR.2015.4146]
   Wang N, 2014, CHINESE SCI BULL, V59, P2927, DOI 10.1007/s11434-014-0417-0
   Wang XW, 2014, WORLD J GASTROENTERO, V20, P4178, DOI 10.3748/wjg.v20.i15.4178
   Zhao XH, 2013, INT J BIOL MACROMOL, V55, P98, DOI 10.1016/j.ijbiomac.2012.12.006
NR 44
TC 6
Z9 6
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JAN
PY 2019
VL 25
IS 1
BP 301
EP 309
DI 10.1007/s12253-017-0347-7
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA HJ1IL
UT WOS:000456915500034
PM 29103204
DA 2025-01-04
ER

PT J
AU Liu, WK
   Song, YQ
   Ma, Y
   Li, X
   Chen, P
   Luo, F
   Li, JH
   Li, Z
   Yang, L
   Tan, H
   Zhou, ZG
AF Liu, Wen Kai
   Song, Yuan Qing
   Ma, Yan
   Li, Xin
   Chen, Peng
   Luo, Feng
   Li, Jie Hua
   Li, Zhen
   Yang, Lie
   Tan, Hong
   Zhou, Zong Guang
TI PEGylated Active Carbon Nanoparticles with Improved Dispersivity in
   Water and Potential Application in Lymphatic Targeted Therapy of
   Colorectal Cancer
SO JOURNAL OF NANO RESEARCH
LA English
DT Article
DE active carbon; drug loading; lymphatic tracer; lymphatic targeting;
   dispersivity
ID DRUG CARRIER; MESOPOROUS CARBON; NODE DISSECTION; DELIVERY;
   CHEMOTHERAPY; EFFICIENT; SMART; SKIN
AB A series of PEGylated active carbon nanoparticles were fabricated with improved dispersity in water and were explored for their ability for carrying drugs and potential application in lymphatic targeted tracing and chemotherapy of colorectal cancer. The active carbon nanoparticles were oxidized in a mild condition with 30% H2O2 solution and then mPEG-NH2 was grafted to the nanoparticles. Compared with the original carbon nanoparticles, the oxidized and PEGylated nanoparticles all present improved stability and initial solubility in water and the PEGylated nanoparticles perform best. Size of the nanoparticles was well controlled in a rational area which can fulfill the requirement for lymphatic targeting. The PEGylated nanoparticles have excellent drug loading properties and allow for sustained release under physiological conditions. The MTT results show the drug-loaded nanoparticles can effectively kill SW480 cells (Human Colon Cancer Cells). These characteristics make the PEGylated nanoparticles become a promising candidate for using as drug-loaded powder for both lymphatic targeted tracing and chemo-therapy without using suspending agent in tumor treatment.
C1 [Chen, Peng; Yang, Lie; Zhou, Zong Guang] Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Peoples R China.
   [Chen, Peng; Yang, Lie; Zhou, Zong Guang] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Liu, Wen Kai; Song, Yuan Qing; Ma, Yan; Li, Xin; Luo, Feng; Li, Jie Hua; Li, Zhen; Tan, Hong] Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Yang, L (corresponding author), Sichuan Univ, West China Hosp, Dept Gastrointestinal Surg, Chengdu 610041, Peoples R China.; Yang, L (corresponding author), Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.; Tan, H (corresponding author), Sichuan Univ, Coll Polymer Sci & Engn, State Key Lab Polymer Mat Engn, Chengdu 610065, Peoples R China.
EM lie-222@163.com; hongtan@scu.edu.cn
RI zhang, junfeng/JHT-7871-2023
OI , Zongguang/0000-0002-7616-1199
FU Key Projects of Applicative Basic Research of Science and Technology
   Department in Sichuan Province [2017JY0020]
FX We acknowledge the support of the Key Projects of Applicative Basic
   Research of Science and Technology Department in Sichuan Province.
   (2017JY0020)
CR Abellán-Pose R, 2016, CURR PHARM DESIGN, V22, P1194, DOI 10.2174/1381612822666151216150809
   Bhandari A, 2017, J INVEST MED, V65, P311, DOI 10.1136/jim-2016-000229
   Bradatsch A, 2016, ANTICANCER RES, V36, P2993
   Brigger I, 2002, ADV DRUG DELIVER REV, V54, P631, DOI 10.1016/S0169-409X(02)00044-3
   Cao Y, 2020, DRUG DELIV, V27, P258, DOI 10.1080/10717544.2020.1718801
   Chingombe P, 2005, CARBON, V43, P3132, DOI 10.1016/j.carbon.2005.06.021
   Cote B, 2019, ADV DRUG DELIVER REV, V144, P16, DOI 10.1016/j.addr.2019.08.009
   Ding MM, 2012, ADV MATER, V24, P3639, DOI 10.1002/adma.201200954
   Fadeel B, 2020, NAT NANOTECHNOL, V15, P164, DOI 10.1038/s41565-020-0654-0
   Fadeel B, 2018, ACS NANO, V12, P10582, DOI 10.1021/acsnano.8b04758
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   He CZ, 2019, INT IMMUNOPHARMACOL, V70, P241, DOI 10.1016/j.intimp.2019.02.036
   Hong GS, 2015, CHEM REV, V115, P10816, DOI 10.1021/acs.chemrev.5b00008
   Karimi M, 2016, CHEM SOC REV, V45, P1457, DOI 10.1039/c5cs00798d
   Khandare JJ, 2012, NANOSCALE, V4, P837, DOI 10.1039/c1nr11540e
   Kim JH, 2015, WORLD J GASTROENTERO, V21, P5158, DOI 10.3748/wjg.v21.i17.5158
   Kotake K, 2015, INT J COLORECTAL DIS, V30, P813, DOI 10.1007/s00384-015-2194-x
   Liao KH, 2011, ACS APPL MATER INTER, V3, P2607, DOI 10.1021/am200428v
   Lipka J, 2010, BIOMATERIALS, V31, P6574, DOI 10.1016/j.biomaterials.2010.05.009
   Liu L, 2017, MINERVA CHIR, V72, P475, DOI 10.23736/S0026-4733.17.07298-4
   Miriyala N, 2017, EUR J PHARM BIOPHARM, V115, P197, DOI 10.1016/j.ejpb.2017.03.002
   MORENOCASTILLA C, 1995, LANGMUIR, V11, P4386, DOI 10.1021/la00011a035
   Ngambenjawong C, 2017, ADV DRUG DELIVER REV, V114, P206, DOI 10.1016/j.addr.2017.04.010
   Niu X, 2013, INT J PHARMACEUT, V452, P382, DOI 10.1016/j.ijpharm.2013.05.016
   Pang L, 2017, NANOSCALE RES LETT, V12, DOI 10.1186/s11671-017-2317-0
   Permana AD, 2019, J CONTROL RELEASE, V316, P34, DOI 10.1016/j.jconrel.2019.10.004
   Pradhan BK, 1999, CARBON, V37, P1323, DOI 10.1016/S0008-6223(98)00328-5
   Ryan GM, 2014, J CONTROL RELEASE, V193, P241, DOI 10.1016/j.jconrel.2014.04.051
   Siram K, 2016, INT J NANOMED, V11, P2867, DOI 10.2147/IJN.S105852
   Slepicka P, 2015, J NANOPART RES, V17, DOI 10.1007/s11051-014-2850-z
   Tauriello DVF, 2016, TRENDS CANCER, V2, P495, DOI 10.1016/j.trecan.2016.08.001
   Tu XL, 2014, J MATER CHEM B, V2, P2184, DOI 10.1039/c3tb21750g
   Wang LY, 2017, ONCOTARGETS THER, V10, DOI 10.2147/OTT.S146627
   Wu JW, 2016, J NANO RES-SW, V42, P80, DOI 10.4028/www.scientific.net/JNanoR.42.80
   Yenisoy-Karakas S, 2004, CARBON, V42, P477, DOI 10.1016/j.carbon.2003.11.019
   Zhang Y, 2016, J MATER CHEM B, V4, P5178, DOI 10.1039/c6tb00987e
   Zhang Z., 2011, CLIN MED CHINA, V27, P830
   Zhou L, 2015, CARBON, V82, P479, DOI 10.1016/j.carbon.2014.10.091
NR 38
TC 1
Z9 1
U1 2
U2 44
PU TRANS TECH PUBLICATIONS LTD
PI DURNTEN-ZURICH
PA KREUZSTRASSE 10, DURNTEN-ZURICH, 8635, SWITZERLAND
SN 1662-5250
EI 1661-9897
J9 J NANO RES-SW
JI J. Nano Res.
PY 2021
VL 66
BP 85
EP 102
DI 10.4028/www.scientific.net/JNanoR.66.85
PG 18
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary;
   Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Materials Science; Physics
GA QP0IJ
UT WOS:000623519300008
DA 2025-01-04
ER

PT J
AU Eisterer, W
   Prager, G
AF Eisterer, Wolfgang
   Prager, Gerald
TI Chemotherapy, Still an Option in the Twenty-First Century in Metastatic
   Colorectal Cancer?
SO CARDIOVASCULAR AND INTERVENTIONAL RADIOLOGY
LA English
DT Review
DE Metastatic colorectal cancer; Chemotherapy; Immune therapy; Targeted
   therapy; Oligometastatic disease
ID DURABLE CLINICAL BENEFIT; RANDOMIZED PHASE-III; DNA MISMATCH REPAIR;
   1ST-LINE TREATMENT; MICROSATELLITE INSTABILITY; OPEN-LABEL; INFUSIONAL
   FLUOROURACIL; PLUS CAPECITABINE; POOLED-ANALYSIS; RAS MUTATIONS
AB Substantial improvements have been made in the systemic treatment of colorectal cancer over the last two decades. Median overall survival (OS) of patients with metastatic colorectal cancer (mCRC) has been constantly increased and the most recent first-line studies exceeded the 30-month median overall survival. The standard first-line regimen for mCRC is a combination of chemotherapy plus a biological agent either targeting the main angiogenic growth factor vascular endothelial growth factor (VEGF) via Bevacizumab or by antibodies targeting the epidermal growth factor receptor (EGRF) via Panitumumab or Cetuximab. Recent improvements have been shown in the efficacy of the biological agent by stratifying these agents according to the primary tumor location. In this context EGFR-inhibitors showed improved OS when used first-line in tumors derived from the left-sided colon or rectum, while tumor sidedness was not predictive for anti-VEGF-antibodies. Furthermore, the biological activity of anti-EGFR antibodies is restricted to tumors with a rat sarcoma virus (RAS)-wild-type genotype but not RAS-mutated tumors. The RAS-mutation status is not predictive for VEGF-inhibitors. Recent developments in the molecular characterisation of tumor cells led to the development of specific so called targeted therapies in colorectal cancer.
C1 [Eisterer, Wolfgang] Klinikum Klagenfurt aW, Dept Internal Med & Hematol & Med Oncol, Klagenfurt, Austria.
   [Prager, Gerald] Med Univ Vienna, Dept Internal Med 1, Vienna, Austria.
C3 Medical University of Vienna
RP Eisterer, W (corresponding author), Klinikum Klagenfurt aW, Dept Internal Med & Hematol & Med Oncol, Klagenfurt, Austria.
EM Wolfgang.eisterer@kabeg.at
RI Prager, Gerald/AAS-8674-2021
OI Prager, M.D., Gerald/0000-0002-7854-7781
CR [Anonymous], 2018, J CLIN ONCOL S
   Arkenau HT, 2008, J CLIN ONCOL, V26, P5910, DOI 10.1200/JCO.2008.16.7759
   Bekaii-Saab TS, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.611
   Bendell J, 2018, ANN ONCOL, V29, P123, DOI 10.1093/annonc/mdy208.003
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898
   Chalabi M, 2018, ANN ONCOL, V29, P731
   Colucci G, 2005, J CLIN ONCOL, V23, P4866, DOI 10.1200/JCO.2005.07.113
   Corcoran RB, 2016, ANN ONCOL S, V27, pvi556
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Heinemann V, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3600
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   KOPETZ S, 2017, J CLIN ONCOL S, V35, DOI DOI 10.1200/JCO.2017.35.4_suppl.520
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Lacouture ME, 2010, J CLIN ONCOL, V28, P1351, DOI 10.1200/JCO.2008.21.7828
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lenz HJJ, 2018, ANN ONCOL, V29, P714
   Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
   Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meguid RA, 2008, ANN SURG ONCOL, V15, P2388, DOI 10.1245/s10434-008-0015-y
   Meijerink MR, 2018, CARDIOVASC INTER RAD, V41, P1189, DOI 10.1007/s00270-018-1959-3
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Modest DP, 2017, ONCOTARGET, V8, P105749, DOI 10.18632/oncotarget.22396
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Petrelli F, 2012, MED ONCOL, V29, P1020, DOI 10.1007/s12032-011-9958-0
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sinicrope FA, 2013, J CLIN ONCOL, V31, P3664, DOI 10.1200/JCO.2013.48.9591
   Söreide K, 2006, BRIT J SURG, V93, P395, DOI 10.1002/bjs.5328
   Sugarbaker PH, 2016, EXPERT REV GASTROENT, V10, P205, DOI 10.1586/17474124.2016.1110019
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Venook AP, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3504
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Wasan HS, 2017, LANCET ONCOL, V18, P1159, DOI 10.1016/S1470-2045(17)30457-6
NR 53
TC 10
Z9 11
U1 0
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0174-1551
EI 1432-086X
J9 CARDIOVASC INTER RAD
JI Cardiovasc. Interv. Radiol.
PD SEP
PY 2019
VL 42
IS 9
BP 1213
EP 1220
DI 10.1007/s00270-019-02278-7
PG 8
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
   Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
   Medical Imaging
GA IV1DS
UT WOS:000484018100002
PM 31270570
DA 2025-01-04
ER

PT J
AU Wang, XJ
   Wu, WC
   Zheng, ZF
   Chi, P
AF Wang, Xiaojie
   Wu, Wenchuan
   Zheng, Zhifang
   Chi, Pan
TI Exploring Better Strategies for RAS Mutation-Associated EGFR-Targeted
   Resistance in Colorectal Cancer: From the Perspective of Cancer
   Community Ecology
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE EGFR; resistance; RAS; cancer community ecology; colorectal cancer
ID ACQUIRED-RESISTANCE; GENE-EXPRESSION; CETUXIMAB; THERAPY; KRAS;
   HETEROGENEITY; PANITUMUMAB; BIOMARKER; EFFICACY; COLON
AB RAS is the most common mutated gene in colorectal cancer (CRC), and its occurrence is associated with primary and acquired resistance to anti-epidermal growth factor receptor (EGFR) blockade. Cancer community ecology, such as the competitive exclusion principle, is a valuable focus and would contribute to the understanding of drug resistance. We have presented several articles on RAS mutant clonal evolution monitoring during anti-EGFR treatment in CRC. In these articles, the availability of serially collected samples provided a unique opportunity to model the tumor evolutionary process from the perspective of cancer community ecology in those patients upon treatment. In this perspective article, we presented a theoretical basis and evidence from several experimental or phase II clinical trials for the contemporary application of ecological mechanisms in CRC treatment. In general, a reduction in targetable RAS wild-type cells to a maximum tolerated extent, such as continuous treatment, might lead to the competitive release of inextirpable RAS mutant cells and cancer progression. A full understanding of subclonal competition might be beneficial in managing CRC. Several ecological strategies, including anti-EGFR treatment reintroduced at an appropriate point of time for RAS mutant patients, intermittent treatment instead of continuous treatment, the appropriate sequence of nonselective targeted therapy, and combination therapy, were proposed.</p>
C1 [Wang, Xiaojie; Zheng, Zhifang; Chi, Pan] Fujian Med Univ, Union Hosp, Dept Colorectal Surg, Fuzhou, Peoples R China.
   [Wu, Wenchuan] Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China.
C3 Fujian Medical University; Fudan University
RP Wang, XJ; Chi, P (corresponding author), Fujian Med Univ, Union Hosp, Dept Colorectal Surg, Fuzhou, Peoples R China.; Wu, WC (corresponding author), Fudan Univ, Zhongshan Hosp, Dept Gen Surg, Shanghai, Peoples R China.
EM xjwang363@163.com; wu.wenchuan@zs-hospital.sh.cn; chipan363@163.com
RI Wu, Wenchuan/H-6751-2019
FU National Natural Science Foundation of China [81902378]
FX Funding This study was financially supported by the National Natural
   Science Foundation of China (81902378).
CR Cardone C, 2020, EUR J CANCER, V138, P1, DOI 10.1016/j.ejca.2020.07.010
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Cushman SM, 2015, CLIN CANCER RES, V21, P1078, DOI 10.1158/1078-0432.CCR-14-2313
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Kobayashi T, 2015, ANTICANCER RES, V35, P6577
   Kosmidou V, 2014, HUM MUTAT, V35, P329, DOI 10.1002/humu.22496
   Kotler BP, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820951776
   Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818
   Lorenzato A, 2020, CANCERS, V12, DOI 10.3390/cancers12030685
   Maddalena F, 2020, MOL ONCOL, V14, P3030, DOI 10.1002/1878-0261.12814
   Mao C, 2015, SCI REP-UK, V5, DOI 10.1038/srep08065
   Martini G, 2019, MOL CANCER THER, V18, P845, DOI 10.1158/1535-7163.MCT-18-0539
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Moati E, 2020, INT J CANCER, V147, P1185, DOI 10.1002/ijc.32657
   Raimondi C., 2019, ANN ONCOL, V30, pIV38
   Seligmann JF, 2020, ANN ONCOL, V31, P1021, DOI 10.1016/j.annonc.2020.04.476
   Seligmann JF, 2016, JAMA ONCOL, V2, P633, DOI 10.1001/jamaoncol.2015.6065
   Shitara K, 2019, ANN ONCOL, V30, P259, DOI 10.1093/annonc/mdy526
   Tan ZL, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aax5576
   Wang G, 2020, CLIN TRANSL ONCOL, V22, P813, DOI 10.1007/s12094-019-02213-9
   Wasan H, 2014, LANCET ONCOL, V15, P631, DOI 10.1016/S1470-2045(14)70106-8
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
NR 24
TC 3
Z9 3
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 22
PY 2021
VL 11
AR 754220
DI 10.3389/fonc.2021.754220
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WU2ES
UT WOS:000716364100001
PM 34745987
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Liu, XD
   Wu, SS
   Dang, WX
   Shen, H
   Sun, MJ
   Chen, YL
   Zhang, ZH
   Li, MG
   Cai, ZR
   Wang, HY
   Gao, F
   He, YF
AF Liu, Xudong
   Wu, Shusheng
   Dang, Wenxi
   Shen, Hao
   Sun, Mingjie
   Chen, Yaolin
   Zhang, Zhihua
   Li, Mengge
   Cai, Zhirun
   Wang, Haoyu
   Gao, Fei
   He, Yifu
TI The application of QCT in the prognostic assessment of mCRC undergoing
   first-line treatment based on bevacizumab
SO FUTURE ONCOLOGY
LA English
DT Article; Early Access
DE Targeted therapy; body components; chemotherapy; visceral fat area;
   nomogram
ID METASTATIC COLORECTAL-CANCER; BODY-COMPOSITION; SARCOPENIA; SURVIVAL;
   CACHEXIA; PHASE-3
AB BackgroundBevacizumab induces muscle atrophy by changing the gene expression level of muscle tissue. Quantitative computed tomography (QCT) enables precise measurement of various body compositions, including muscle area.Materials & MethodsA total of 102 patients with metastatic colorectal cancer (mCRC) undergoing first-line chemotherapy based on bevacizumab were enrolled at thirst Affiliated Hospital of the University of Science and Technology of China. Their body compositions were measured respectively 1 month before and 1 month after the treatment.ResultsTreatment-related decline in skeletal muscle index and visceral fat infiltration significantly affect patient prognosis.ConclusionA predictive model constructed by integrating changes in body composition with patient clinical characteristics effectively predicts the 9-month progression-free survival (PFS) of patients with mCRC.
C1 [Liu, Xudong; Sun, Mingjie; Chen, Yaolin; Cai, Zhirun] Wannan Med Coll, Grad Sch, Wuhu, Anhui, Peoples R China.
   [Wu, Shusheng; Li, Mengge; Gao, Fei; He, Yifu] USTC, Gastrointestinal Oncol Dept, Affiliated Hosp 1, Hefei 23003, Anhui, Peoples R China.
   [Dang, Wenxi; Shen, Hao] Anhui Med Univ, Grad Sch, Hefei, Anhui, Peoples R China.
   [Zhang, Zhihua; Wang, Haoyu] Univ Sci & Technol China, Grad Sch, Hefei, Anhui, Peoples R China.
C3 Wannan Medical College; Chinese Academy of Sciences; University of
   Science & Technology of China, CAS; Anhui Medical University; Chinese
   Academy of Sciences; University of Science & Technology of China, CAS
RP Gao, F; He, YF (corresponding author), USTC, Gastrointestinal Oncol Dept, Affiliated Hosp 1, Hefei 23003, Anhui, Peoples R China.
EM 15956912758@163.com; yifuhe@fsyy.ustc.edu.cn
RI Liu, Xudong/HPG-4513-2023; SUN, MINGJIE/GQQ-0374-2022
FU Health Commission of Anhui Province Scientific Research Project
   [AHWJ2023BAc10031, AHWJ2023A30183]
FX The work was supported by the Health Commission of Anhui Province
   Scientific Research Project [NO. AHWJ2023BAc10031 and AHWJ2023A30183].
   The funders had no role in study design, data collec-tion and analysis,
   decision to publish, or preparation of the manuscript
CR Baazim H, 2022, NAT REV IMMUNOL, V22, P309, DOI 10.1038/s41577-021-00624-w
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Chen WZ, 2022, SURGERY, V172, P1185, DOI 10.1016/j.surg.2022.05.031
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   De Nardi P, 2022, WORLD J GASTRO ONCOL, V14, P423, DOI 10.4251/wjgo.v14.i2.423
   Di Nardo P, 2024, DIGEST LIVER DIS, V56, P786, DOI 10.1016/j.dld.2023.07.013
   Dolly A, 2020, CLIN NUTR, V39, P3319, DOI 10.1016/j.clnu.2020.02.017
   Doyle SL, 2012, P NUTR SOC, V71, P181, DOI 10.1017/S002966511100320X
   Fang PH, 2023, J CACHEXIA SARCOPENI, V14, P3, DOI 10.1002/jcsm.13126
   Findlay M, 2021, J CACHEXIA SARCOPENI, V12, P2187, DOI 10.1002/jcsm.12829
   Jang MK, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.941496
   Jeejeebhoy KN, 2012, CURR OPIN CLIN NUTR, V15, P213, DOI 10.1097/MCO.0b013e328352694f
   Kuboki Y, 2023, BRIT J CANCER, V128, P1897, DOI 10.1038/s41416-023-02212-2
   Kurk SA, 2020, CANCER MED-US, V9, P1033, DOI 10.1002/cam4.2787
   Lee J, 2019, J CACHEXIA SARCOPENI, V10, P814, DOI 10.1002/jcsm.12440
   Martin A, 2023, J CACHEXIA SARCOPENI, V14, P1150, DOI 10.1002/jcsm.13073
   Martin A, 2022, J CACHEXIA SARCOPENI, V13, P1686, DOI 10.1002/jcsm.12939
   Matsuoka H, 2022, INT J CLIN ONCOL, V27, P1859, DOI 10.1007/s10147-022-02243-4
   Modest DP, 2019, EUR J CANCER, V109, P70, DOI 10.1016/j.ejca.2018.12.019
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl-2022-327736
   da Fonseca GWP, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072321
   Peterson SJ, 2017, NUTR CLIN PRACT, V32, P30, DOI 10.1177/0884533616680354
   Poterucha T, 2012, MED ONCOL, V29, P1005, DOI 10.1007/s12032-011-9894-z
   Rupert JE, 2021, J EXP MED, V218, DOI 10.1084/jem.20190450
   Sanchez A, 2020, UROL ONCOL-SEMIN ORI, V38, P713, DOI 10.1016/j.urolonc.2020.03.017
   Trestini I, 2023, NUTRITION, V105, DOI 10.1016/j.nut.2022.111858
   Wade KNS, 2019, GYNECOL ONCOL, V155, P69, DOI 10.1016/j.ygyno.2019.07.020
   Xu Q, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.897495
   Zheng XM, 2021, CANCER CONTROL, V28, DOI 10.1177/10732748211038445
   Zhuang B, 2022, HEAD NECK-J SCI SPEC, V44, P2046, DOI 10.1002/hed.27065
NR 30
TC 0
Z9 0
U1 2
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD 2024 NOV 20
PY 2024
DI 10.1080/14796694.2024.2430160
EA NOV 2024
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA M6H8P
UT WOS:001358534700001
PM 39558658
DA 2025-01-04
ER

PT J
AU Ng, JYS
   Lu, CT
   Lam, AKY
AF Ng, Jessica Yan-Seen
   Lu, Cu Tai
   Lam, Alfred King-yin
TI <i>BRAF</i> mutation: Current and future clinical pathological
   applications in colorectal carcinoma
SO HISTOLOGY AND HISTOPATHOLOGY
LA English
DT Review
DE BRAF; Colorectal carcinoma; Pathology; Genetic
ID RESOLUTION MELTING ANALYSIS; NEOPLASTIC PROGRESSION; INSTABILITY
   PATHWAY; PIK3CA MUTATIONS; GENE-MUTATIONS; KRAS-MUTATION; COLON-CANCER;
   SURVIVAL; PCR; BRAF(V600E)
AB The aims are to review the relevance of the BRAF mutations in the clinical settings of colorectal carcinoma. All the literature concerning BRAF mutations and colorectal carcinoma published in PubMed from 2010 to 2018 was reviewed. Multiple variants of BRAF mutations exist in colorectal cancer, the most common type being V600E. The mutation is found in 5 to 15% of colorectal carcinomas and is less common in Asian populations. BRAF mutations are linked with older age, female gender, cigarette smoking and are more common in the right (proximal) portion of the large intestine. BRAF mutations are associated with carcinomas of high histological grade and advanced cancer stages. Often BRAF mutated carcinomas demonstrate adverse histological features such as lymphovascular invasion, perineural invasion, tumour budding and lymph node metastases. BRAF mutations are found in serrated polyposis syndrome and have a negative correlation with hereditary nonpolyposis colorectal cancer (HNPCC). An array of methods of detection of BRAF mutation in colorectal carcinoma are available, such as immunohistochemistry and next generation sequencing, etc. Combinatorial approaches involving anti-BRAF therapies targeting both MAPK signalling as well as the PI3K/mTOR pathway could be a new approach for treatment of metastatic colorectal carcinoma. To conclude, BRAF mutation is important in the pathogenesis of colorectal cancer. Further research on the detection method as well as its role in target therapy will help to improve the management of patients with colorectal cancer.
C1 [Ng, Jessica Yan-Seen; Lu, Cu Tai] Griffith Univ, Gold Coast Hosp, Dept Surg, Gold Coast, Qld, Australia.
   [Lam, Alfred King-yin] Griffith Univ, Canc Mol Pathol, Sch Med, Gold Coast, Qld, Australia.
C3 Gold Coast University Hospital; Griffith University; Griffith University
   - Gold Coast Campus; Griffith University; Griffith University - Gold
   Coast Campus
RP Lam, AKY (corresponding author), Griffith Med Sch, Pathol, Gold Coast Campus, Gold Coast, Qld 4222, Australia.
EM a.lam@griffith.edu
RI ; Lam, Alfred/C-1652-2008
OI Lu, Cu Tai/0000-0001-9565-3749; Lam, Alfred/0000-0003-2771-564X
FU - [-] Funding Source: Medline
CR Anforth R, 2013, LANCET ONCOL, V14, pE11, DOI 10.1016/S1470-2045(12)70413-8
   [Anonymous], CANCER
   [Anonymous], BR J CANC
   Arcila M, 2011, J MOL DIAGN, V13, P64, DOI 10.1016/j.jmoldx.2010.11.005
   Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248
   Bond CE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091739
   Boparai KS, 2011, AM J PATHOL, V178, P2700, DOI 10.1016/j.ajpath.2011.02.023
   Borràs E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-406
   Brändstedt J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098964
   Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7
   Buchanan DD, 2013, CANCER EPIDEM BIOMAR, V22, P917, DOI 10.1158/1055-9965.EPI-12-1211
   Burnett-Hartman AN, 2013, CANCER RES, V73, P2863, DOI 10.1158/0008-5472.CAN-12-3462
   C. R. UK, 2018, BOWEL CANC STAT
   Capper D, 2013, INT J CANCER, V133, P1624, DOI 10.1002/ijc.28183
   Chan E., 2018, MOL PROFILING COLORE
   Chen D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090607
   Coffee EM, 2013, CLIN CANCER RES, V19, P2688, DOI 10.1158/1078-0432.CCR-12-2556
   Day F, 2015, TARGET ONCOL, V10, P99, DOI 10.1007/s11523-014-0319-8
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Dienstmann R, 2011, CANCER J, V17, P114, DOI 10.1097/PPO.0b013e318212f844
   Eklöf V, 2013, BRIT J CANCER, V108, P2153, DOI 10.1038/bjc.2013.212
   El-Deiry WS, 2015, CANCER BIOL THER, V16, P1726, DOI 10.1080/15384047.2015.1113356
   Etienne-Grimaldi MC, 2014, BRIT J CANCER, V110, P2728, DOI 10.1038/bjc.2014.213
   Fernández-Peralta AM, 2005, CANCER GENET CYTOGEN, V157, P18, DOI 10.1016/j.cancergencyto.2004.05.008
   Gaiser T, 2013, INT J CANCER, V132, P1800, DOI 10.1002/ijc.27869
   Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115
   Haley L, 2015, MODERN PATHOL, V28, P1390, DOI 10.1038/modpathol.2015.86
   Hanna MC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074950
   Hempelmann JA, 2015, J MOL DIAGN, V17, P705, DOI 10.1016/j.jmoldx.2015.05.008
   Hernowo BS, 2014, ACTA MED INDONES, V46, P104
   Herreros-Villanueva M, 2011, MOL BIOL REP, V38, P1315, DOI 10.1007/s11033-010-0232-x
   Hirschi B, 2013, INT J CANCER, V133, P590, DOI 10.1002/ijc.28061
   Hsieh LL, 2012, CLIN CHIM ACTA, V413, P1605, DOI 10.1016/j.cca.2012.04.029
   Ito M, 2014, INT J CANCER, V135, P2507, DOI 10.1002/ijc.28920
   Kakar S, 2012, MODERN PATHOL, V25, P1040, DOI 10.1038/modpathol.2012.44
   Kang M, 2013, CANCER BIOMARK, V13, P359, DOI 10.3233/CBM-130366
   Karagkounis G, 2013, CANCER-AM CANCER SOC, V119, P4137, DOI 10.1002/cncr.28347
   Kawakami H, 2016, MOL CANCER THER, V15, P3015, DOI 10.1158/1535-7163.MCT-16-0017
   Kim B, 2014, WORLD J GASTROENTERO, V20, P4370, DOI 10.3748/wjg.v20.i15.4370
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kuan SF, 2014, HUM PATHOL, V45, P464, DOI 10.1016/j.humpath.2013.10.026
   Kwon MJ, 2011, PATHOL RES PRACT, V207, P762, DOI 10.1016/j.prp.2011.10.002
   Laszlo Landherr, 2010, Magy Onkol, V54, P383, DOI 10.1556/MOnkol.54.2010.4.13
   Lenos K, 2015, ONCOTARGET, V6, P26278, DOI 10.18632/oncotarget.4495
   Levidou G, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-47
   Li TT, 2014, ANN SURG ONCOL, V21, P4164, DOI 10.1245/s10434-014-3888-y
   Loupakis F, 2016, BRIT J CANCER, V114, P30, DOI 10.1038/bjc.2015.399
   Lundberg IV, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2509-5
   Lundberg IV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101957
   Mancini I, 2010, J MOL DIAGN, V12, P705, DOI 10.2353/jmoldx.2010.100018
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   Nam S, 2016, ADV MATER INTERFACES, V3, DOI 10.1002/admi.201600415
   Negru S, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2013-004652
   Nishihara R, 2013, AM J EPIDEMIOL, V178, P84, DOI 10.1093/aje/kws431
   Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d
   Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269
   Patel N, 2016, LANCET, V388, P86
   Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Rahman MA, 2014, CRIT REV ONCOL HEMAT, V90, P220, DOI 10.1016/j.critrevonc.2013.12.008
   Rahman MA, 2013, EXP MOL PATHOL, V95, P336, DOI 10.1016/j.yexmp.2013.10.005
   Rahman MA, 2015, EXP CELL RES, V339, P342, DOI 10.1016/j.yexcr.2015.09.010
   Rahman MA, 2014, CURR CANCER DRUG TAR, V14, P128, DOI 10.2174/1568009614666140121150930
   Rosty C, 2013, AM J SURG PATHOL, V37, P434, DOI 10.1097/PAS.0b013e318270f748
   Rozek LS, 2010, CANCER EPIDEM BIOMAR, V19, P838, DOI 10.1158/1055-9965.EPI-09-1112
   Russo AL, 2014, CANCER-AM CANCER SOC, V120, P1482, DOI 10.1002/cncr.28599
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Saridaki Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084604
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Sefrioui D, 2017, CLIN BIOCHEM, V50, P963, DOI 10.1016/j.clinbiochem.2017.06.005
   Sekal M, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0326-9
   Simi L, 2008, AM J CLIN PATHOL, V130, P247, DOI 10.1309/LWDY1AXHXUULNVHQ
   Siraj AK, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-168
   Sorbye H, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131046
   Suhaimi NAM, 2015, MOL ONCOL, V9, P850, DOI 10.1016/j.molonc.2014.12.011
   Sylvester BE, 2012, CLIN CANCER RES, V18, P350, DOI 10.1158/1078-0432.CCR-11-1397
   Szymonek M, 2017, ONCOTARGET, V8, P74897, DOI 10.18632/oncotarget.20451
   Tie J, 2011, CLIN CANCER RES, V17, P1122, DOI 10.1158/1078-0432.CCR-10-1720
   Tsai JH, 2014, MODERN PATHOL, V27, P1375, DOI 10.1038/modpathol.2014.35
   Ung L, 2014, CLIN TRANSL ONCOL, V16, P425, DOI 10.1007/s12094-013-1154-6
   Vakana E, 2017, ONCOTARGET, V8, P9251, DOI 10.18632/oncotarget.14002
   Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994
   van den Broek E, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138141
   Voorham QJM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041963
   Wickenden JA, 2008, ONCOGENE, V27, P7150, DOI 10.1038/onc.2008.335
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yokota T, 2012, ANTI-CANCER AGENT ME, V12, P163, DOI 10.2174/187152012799014968
   Zhu ML, 2018, VIRCHOWS ARCH, V473, P371, DOI 10.1007/s00428-018-2393-2
NR 89
TC 15
Z9 16
U1 0
U2 13
PU F HERNANDEZ
PI MURCIA
PA PLAZA FUENSANTA 2-7 C, 30008 MURCIA, SPAIN
SN 0213-3911
EI 1699-5848
J9 HISTOL HISTOPATHOL
JI Histol. Histopath.
PD MAY
PY 2019
VL 34
IS 5
BP 469
EP 477
DI 10.14670/HH-18-079
PG 9
WC Cell Biology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Pathology
GA HS4RR
UT WOS:000463853800003
PM 30592501
DA 2025-01-04
ER

PT J
AU Chan, KH
   Lakkasani, S
   Ramahi, A
   Shaaban, HS
AF Chan, Kok Hoe
   Lakkasani, Saraswathi
   Ramahi, Amr
   Shaaban, Hamid S.
TI Hyperprogressive Disease in an Advanced Stage Colon Cancer Patient on
   Pembrolizumab: A Case Report
SO CUREUS JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE hyperprogressive; colon cancer; anti-pd1; pembrolizumab
ID IMMUNOTHERAPY; GUIDELINES; CRITERIA
AB The emergence of immune checkpoint inhibitors (ICIs) in recent years has transformed the landscape of the management of solid tumors. The advancement of immunotherapy has resulted in a brand new set of adverse outcomes not previously seen in classical chemotherapy. One such adverse effect has been termed as hyperprogressive disease (HPD), a phenomenon characterized by rapid tumor progression, which often leads to devastating outcomes. In this report, we present a unique case of a 48-year-old African American female who initially presented with abdominal pain, fatigue, and weight loss. Subsequent CT scan showed extensive irregular wall and luminal narrowing with an eccentric mass and adenopathy along the portacaval space. Tumor markers were found to be elevated and genetic testing was done. The patient was diagnosed with stage IIIC colon cancer with K-RAS wild type, associated with Lynch syndrome. The patient underwent surgical resection, chemotherapy, and targeted therapy for progressive/stage IV disease. In light of the progression of the disease, pembrolizumab was introduced into the treatment regimen. One month after the treatment, a repeat CT scan showed enlargement of the metastatic lesion with almost double the size. The progression of the disease was so rapid and, ultimately, pembrolizumab administration was withheld and the patient passed away after about two months on pembrolizumab. To our knowledge, this is one of the few cases of HPD reported in patients with advanced colon cancer, particularly in one with Lynch syndrome. Further studies are warranted to understand why some individuals benefit from immunotherapy, whereas others experience grave outcomes.
C1 [Chan, Kok Hoe; Lakkasani, Saraswathi; Ramahi, Amr] St Michaels Hosp, Internal Med, Newark, NJ 07102 USA.
   [Shaaban, Hamid S.] St Michaels Hosp, Hematol & Oncol, Newark, NJ USA.
RP Chan, KH (corresponding author), St Michaels Hosp, Internal Med, Newark, NJ 07102 USA.
EM kokhoedelcos.chan@gmail.com
RI Chan, Kok/AAN-7838-2020; Lakkasani, Saraswathi/KIJ-0653-2024
OI ramahi, amr/0000-0002-8976-1839; Chan, Kok Hoe/0000-0002-2550-1122
CR Caramella C, 2017, ANN ONCOL, V28, DOI [10.1093/annonc/mdx376.029, DOI 10.1093/annonc/mdx376.029]
   Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741
   Ferrara R, 2018, JAMA ONCOL, V4, P1543, DOI 10.1001/jamaoncol.2018.3676
   Hodi FS, 2018, J CLIN ONCOL, V36, P850, DOI 10.1200/JCO.2017.75.1644
   Kato S, 2017, CLIN CANCER RES, V23, P4242, DOI 10.1158/1078-0432.CCR-16-3133
   Kieler M, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000084
   Krieg C, 2018, NAT MED, V24, P144, DOI 10.1038/nm.4466
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee JH, 2018, JAMA ONCOL, V4, P717, DOI 10.1001/jamaoncol.2017.5332
   Moreira L, 2012, JAMA-J AM MED ASSOC, V308, P1555, DOI 10.1001/jama.2012.13088
   Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8
   Xiong DH, 2018, ISCIENCE, V9, P258, DOI 10.1016/j.isci.2018.10.021
   Xu-Monette ZY, 2018, BLOOD, V131, P68, DOI 10.1182/blood-2017-07-740993
NR 13
TC 3
Z9 3
U1 0
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2168-8184
J9 CUREUS J MED SCIENCE
JI Cureus J Med Sci
PD APR 21
PY 2020
VL 12
IS 4
AR e7764
DI 10.7759/cureus.7764
PG 9
WC Medicine, General & Internal
WE Emerging Sources Citation Index (ESCI)
SC General & Internal Medicine
GA LF1VF
UT WOS:000527212200011
PM 32455081
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Laham, AJ
   El-Awady, R
   Lebrun, JJ
   Ayad, MS
AF Laham, Amina Jamal
   El-Awady, Raafat
   Lebrun, Jean-Jacques
   Ayad, Maha Saber
TI A Bioinformatics Evaluation of the Role of Dual-Specificity
   Tyrosine-Regulated Kinases in Colorectal Cancer
SO CANCERS
LA English
DT Article
DE colorectal cancer; dual-specificity tyrosine-regulated kinases (DYRKs);
   DYRK1A; kinases; targeted therapy; bioinformatics
ID EPITHELIAL-MESENCHYMAL-TRANSITION; CELL-CYCLE; APOPTOTIC RESPONSE;
   MIRK/DYRK1B KINASE; LIVER METASTASIS; PROTEIN-KINASES; BREAST-CANCER;
   DYRK FAMILY; SURVIVAL; PHOSPHORYLATION
AB Simple Summary The dual-specificity tyrosine-regulated kinase (DYRK) family has been implicated in various diseases, including cancer. However, its role in colorectal cancer has not been elucidated. In this research, we used publicly available web-based tools to investigate DYRKs status in colorectal cancer. Our results showed that among DYRKs, only DYRK1A was upregulated significantly in late tumor stages, and it is associated with poor prognosis for colorectal cancer patients. These finding comprehensively characterized DYRK1A as a potential new therapeutic approach in CRC, especially in late tumor stages. Colorectal cancer (CRC) is the third most common cancer worldwide and has an increasing incidence in younger populations. The dual-specificity tyrosine-regulated kinase (DYRK) family has been implicated in various diseases, including cancer. However, the role and contribution of the distinct family members in regulating CRC tumorigenesis has not been addressed yet. Herein, we used publicly available CRC patient datasets (TCGA RNA sequence) and several bioinformatics webtools to perform in silico analysis (GTEx, GENT2, GEPIA2, cBioPortal, GSCALite, TIMER2, and UALCAN). We aimed to investigate the DYRK family member expression pattern, prognostic value, and oncological roles in CRC. This study shed light on the role of distinct DYRK family members in CRC and their potential outcome predictive value. Based on mRNA level, DYRK1A is upregulated in late tumor stages, with lymph node and distant metastasis. All DYRKs were found to be implicated in cancer-associated pathways, indicating their key role in CRC pathogenesis. No significant DYRK mutations were identified, suggesting that DYRK expression variation in normal vs. tumor samples is likely linked to epigenetic regulation. The expression of DYRK1A and DYRK3 expression correlated with immune-infiltrating cells in the tumor microenvironment and was upregulated in MSI subtypes, pointing to their potential role as biomarkers for immunotherapy. This comprehensive bioinformatics analysis will set directions for future biological studies to further exploit the molecular basis of these findings and explore the potential of DYRK1A modulation as a novel targeted therapy for CRC.
C1 [Laham, Amina Jamal; El-Awady, Raafat; Ayad, Maha Saber] Univ Sharjah, Sharjah Inst Med Res, Sharjah 27272, U Arab Emirates.
   [Laham, Amina Jamal; Ayad, Maha Saber] Univ Sharjah, Coll Med, Sharjah 27272, U Arab Emirates.
   [Laham, Amina Jamal; El-Awady, Raafat] Univ Sharjah, Coll Pharm, Sharjah 27272, U Arab Emirates.
   [Lebrun, Jean-Jacques] McGill Univ, Hlth Ctr, Dept Med, Canc Res Program, Montreal, PQ H4A 3J1, Canada.
C3 University of Sharjah; University of Sharjah; University of Sharjah;
   McGill University
RP El-Awady, R; Ayad, MS (corresponding author), Univ Sharjah, Sharjah Inst Med Res, Sharjah 27272, U Arab Emirates.; Ayad, MS (corresponding author), Univ Sharjah, Coll Med, Sharjah 27272, U Arab Emirates.; El-Awady, R (corresponding author), Univ Sharjah, Coll Pharm, Sharjah 27272, U Arab Emirates.
EM amina.laham@mail.mcgill.ca; relawady@sharjah.ac.ae; jj.lebrun@mcgill.ca;
   msaber@sharjah.ac.ae
RI Saber-Ayad, Maha/AAQ-2386-2021; Lebrun, Jean-Jacques/GNP-5222-2022
OI Saber-Ayad, Maha/0000-0002-9287-7621; Lebrun,
   Jean-Jacques/0000-0001-5809-1409
FU University of Sharjah [2001110343]; MBRU-AlMahmeed Research Award, (ALM)
   [1914]; Al-Jalila Foundation Seed Grant [AJF2017-68]
FX A.J.L. and R.E.-A. are funded by the University of Sharjah, targeted
   Research Project No.: 2001110343. M.S.-A. is funded by the
   MBRU-AlMahmeed Research Award, (ALM#1914) and Al-Jalila Foundation Seed
   Grant (#AJF2017-68).
CR Abbassi R, 2015, PHARMACOL THERAPEUT, V151, P87, DOI 10.1016/j.pharmthera.2015.03.004
   Abu Jhaisha S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06874-w
   Al Bandar MH, 2017, ONCOL REP, V37, P2553, DOI 10.3892/or.2017.5531
   An LW, 2018, P NATL ACAD SCI USA, V115, pEB286, DOI 10.1073/pnas.1804823115
   Aranda S, 2011, FASEB J, V25, P449, DOI 10.1096/fj.10-165837
   Becker W, 2018, FEBS J, V285, P1203, DOI 10.1111/febs.14347
   Becker W, 2012, CELL CYCLE, V11, P3389, DOI 10.4161/cc.21404
   Bhansali RS, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI135937
   Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2
   Boni J, 2020, CANCERS, V12, DOI 10.3390/cancers12082106
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chang JC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004766
   Chen Hua, 2018, Oncotarget, V9, P13154, DOI 10.18632/oncotarget.22743
   Chen YY, 2017, HUM PATHOL, V66, P48, DOI 10.1016/j.humpath.2017.02.033
   Cicenas J, 2018, CANCERS, V10, DOI 10.3390/cancers10030063
   Deng XB, 2014, CARCINOGENESIS, V35, P1968, DOI 10.1093/carcin/bgu058
   Di Vona C, 2015, MOL CELL, V57, P506, DOI 10.1016/j.molcel.2014.12.026
   Dirice E, 2016, DIABETES, V65, P1660, DOI 10.2337/db15-1127
   Gallagher DJ, 2010, ONCOLOGY-BASEL, V78, P237, DOI 10.1159/000315730
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Gao JC, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-2
   Gao JC, 2012, INT J ONCOL, V40, P1203, DOI 10.3892/ijo.2011.1293
   Garcia-Foncillas J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00849
   Glenewinkel F, 2016, SCI REP-UK, V6, DOI 10.1038/srep28241
   Guard SE, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42990-5
   Guo X, 2016, NAT CELL BIOL, V18, P202, DOI 10.1038/ncb3289
   Guo XM, 2010, J BIOL CHEM, V285, P13223, DOI 10.1074/jbc.M110.102574
   Hämmerle B, 2011, DEVELOPMENT, V138, P2543, DOI 10.1242/dev.066167
   Hille S, 2016, CARDIOVASC RES, V110, P381, DOI 10.1093/cvr/cvw074
   Ito D, 2017, CANCER SCI, V108, P1565, DOI 10.1111/cas.13280
   Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2
   Kazerounian S, 2018, J CELL COMMUN SIGNAL, V12, P171, DOI 10.1007/s12079-017-0433-3
   Kim K, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22062982
   Kow AWC, 2019, J GASTROINTEST ONCOL, V10, P1274, DOI 10.21037/jgo.2019.08.06
   Kuhn C, 2009, J BIOL CHEM, V284, P17320, DOI 10.1074/jbc.M109.006759
   Laham AJ, 2021, CELL MOL LIFE SCI, V78, P603, DOI 10.1007/s00018-020-03626-4
   Li TW, 2020, NUCLEIC ACIDS RES, V48, pW509, DOI 10.1093/nar/gkaa407
   Li YL, 2019, J CELL MOL MED, V23, P7427, DOI 10.1111/jcmm.14609
   Litovchick L, 2011, GENE DEV, V25, P801, DOI 10.1101/gad.2034211
   Liu CJ, 2018, BIOINFORMATICS, V34, P3771, DOI 10.1093/bioinformatics/bty411
   Liu H, 2021, CANCER MED-US, V10, P6416, DOI 10.1002/cam4.4159
   Liu Q, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098853
   Lochhead PA, 2005, CELL, V121, P925, DOI 10.1016/j.cell.2005.03.034
   Luna J, 2019, GUT, V68, P1465, DOI 10.1136/gutjnl-2018-316128
   Luo C, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0361-0
   Martin CE, 2021, EXP CELL RES, V405, DOI 10.1016/j.yexcr.2021.112656
   Mimoto R, 2013, CANCER LETT, V339, P214, DOI 10.1016/j.canlet.2013.06.005
   Müller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3
   Najas S, 2015, EBIOMEDICINE, V2, P120, DOI 10.1016/j.ebiom.2015.01.010
   Nihira NT, 2015, CELL CYCLE, V14, P802, DOI 10.1080/15384101.2015.1007751
   Park SJ, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0514-7
   Pozo N, 2013, J CLIN INVEST, V123, P2475, DOI 10.1172/JCI63623
   Rai AK, 2018, NATURE, V559, P211, DOI 10.1038/s41586-018-0279-8
   Rozen EJ, 2018, CELL REP, V23, P1867, DOI 10.1016/j.celrep.2018.04.008
   Sato K, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24878-z
   Singh R, 2017, ONCOTARGET, V8, P833, DOI 10.18632/oncotarget.13662
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Taira N, 2007, MOL CELL, V25, P725, DOI 10.1016/j.molcel.2007.02.007
   Taira N, 2010, J BIOL CHEM, V285, P4909, DOI 10.1074/jbc.M109.042341
   Tandon V, 2021, J BIOL CHEM, V296, DOI 10.1074/jbc.REV120.015217
   Tang ZF, 2019, NUCLEIC ACIDS RES, V47, pW556, DOI 10.1093/nar/gkz430
   Thyssen G, 2006, MOL CELL BIOL, V26, P8857, DOI 10.1128/MCB.01031-06
   Varjosalo M, 2013, CELL REP, V3, P1306, DOI 10.1016/j.celrep.2013.03.027
   Wippich F, 2013, CELL, V152, P791, DOI 10.1016/j.cell.2013.01.033
   Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397
   Yamaguchi N, 2015, TUMOR BIOL, V36, P5913, DOI 10.1007/s13277-015-3264-y
   Yamamoto T, 2017, FEBS LETT, V591, P842, DOI 10.1002/1873-3468.12596
   Yan HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159954
   Zacharakis M, 2010, ANTICANCER RES, V30, P653
   Zheng H, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00068
   Zou YL, 2004, J BIOL CHEM, V279, P27790, DOI 10.1074/jbc.M403042200
NR 73
TC 8
Z9 8
U1 1
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD APR
PY 2022
VL 14
IS 8
AR 2034
DI 10.3390/cancers14082034
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 0R2MA
UT WOS:000785434800001
PM 35454940
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Trumpi, K
   Ubink, I
   Trinh, A
   Djafarihamedani, M
   Jongen, JM
   Govaert, KM
   Elias, SG
   van Hooff, SR
   Medema, JP
   Lacle, MM
   Vermeulen, L
   Rinkes, IHMB
   Kranenburg, O
AF Trumpi, K.
   Ubink, I.
   Trinh, A.
   Djafarihamedani, M.
   Jongen, J. M.
   Govaert, K. M.
   Elias, S. G.
   van Hooff, S. R.
   Medema, J. P.
   Lacle, M. M.
   Vermeulen, L.
   Rinkes, I. H. M. Borel
   Kranenburg, O.
TI Neoadjuvant chemotherapy affects molecular classification of colorectal
   tumors
SO ONCOGENESIS
LA English
DT Article
ID GENE-EXPRESSION; COLON-CANCER; BREAST-CANCER; TRIAL; OXALIPLATIN;
   SUBTYPES; BEVACIZUMAB; MUTATIONS; CETUXIMAB; PATTERNS
AB The recent discovery of 'molecular subtypes' in human primary colorectal cancer has revealed correlations between subtype, propensity to metastasize and response to therapy. It is currently not known whether the molecular tumor subtype is maintained after distant spread. If this is the case, molecular subtyping of the primary tumor could guide subtype-targeted therapy of metastatic disease. In this study, we classified paired samples of primary colorectal carcinomas and their corresponding liver metastases (n = 129) as epithelial-like or mesenchymal-like, using a recently developed immunohistochemistry-based classification tool. We observed considerable discordance (45%) in the classification of primary tumors and their liver metastases. Discordant classification was significantly associated with the use of neoadjuvant chemotherapy. Furthermore, gene expression analysis of chemotherapy-exposed versus chemotherapy naive liver metastases revealed expression of a mesenchymal program in pre-treated tumors. To explore whether chemotherapy could cause gene expression changes influencing molecular subtyping, we exposed patient-derived colonospheres to six short cycles of 5-fluorouracil. Gene expression profiling and signature enrichment analysis subsequently revealed that the expression of signatures identifying mesenchymal-like tumors was strongly increased in chemotherapy-exposed tumor cultures. Unsupervised clustering of large cohorts of human colon tumors with the chemotherapy-induced gene expression program identified a poor prognosis mesenchymal-like subgroup. We conclude that neoadjuvant chemotherapy induces a mesenchymal phenotype in residual tumor cells and that this may influence the molecular classification of colorectal tumors.
C1 [Trumpi, K.; Ubink, I.; Djafarihamedani, M.; Jongen, J. M.; Govaert, K. M.; Rinkes, I. H. M. Borel; Kranenburg, O.] Univ Med Ctr, UMC Utrecht Canc Ctr, Dept Surg Oncol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
   [Trinh, A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Elias, S. G.] Univ Med Ctr, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [van Hooff, S. R.; Medema, J. P.; Vermeulen, L.] Univ Amsterdam, Acad Med Ctr, CEMM, Lab Expt Oncol & Radiobiol LEXOR, Amsterdam, Netherlands.
   [Lacle, M. M.] Univ Med Ctr, UMC Utrecht Canc Ctr, Dept Pathol, Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Harvard
   University; Dana-Farber Cancer Institute; Utrecht University; Utrecht
   University Medical Center; University of Amsterdam; Academic Medical
   Center Amsterdam; Utrecht University; Utrecht University Medical Center
RP Rinkes, IHMB; Kranenburg, O (corresponding author), Univ Med Ctr, UMC Utrecht Canc Ctr, Dept Surg Oncol, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
EM i.h.m.borelrinkes@umcutrecht.nl; kranenburg@umcutrecht.nl
RI Elias, Sjoerd/E-6057-2011
OI Trinh, Anne/0000-0001-7261-6734; Medema, Jan Paul/0000-0003-3045-2924
FU PON foundation; Vrienden UMCU; Dutch Cancer Foundation [UU2014-6617,
   UU2013-5865, UU2010-4608]; Dalijn foundation; Dirkzwager-Assink Fund;
   Gieskes-Strijbis Fund; Dutch Cancer Society [UU2014-6617, UU2013-5865,
   UU2010-4608]
FX We would like to thank Dr J van Gorp from the Diakonessenhuis, Dr CA
   Seldenrijk from the Antonius Hospital in Nieuwegein and Dr J Meijer from
   the Rijnstate Hospital in Arnhem for their help providing patient
   material. Furthermore we thank D Castigliego of the Department of
   Pathology for the excellent technical assistance. KT was supported by
   grants from the PON foundation and 'Vrienden UMCU'. IU, JMJ and KMG were
   supported by grants from the Dutch Cancer Foundation (IU (UU2014-6617),
   JMJ (UU2013-5865) and KMG (UU2010-4608)). The study was supported by KT,
   IU, JMJ, KMG from PON foundation, Dalijn foundation, Dirkzwager-Assink
   Fund, Gieskes-Strijbis Fund, Dutch Cancer Society UU2014-6617,
   UU2013-5865, UU2010-4608.
CR André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Bendell JC, 2012, ONCOLOGIST, V17, P1486, DOI 10.1634/theoncologist.2012-0190
   Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212
   Chau I, 2009, BRIT J CANCER, V100, P1704, DOI 10.1038/sj.bjc.6605061
   Creighton CJ, 2009, P NATL ACAD SCI USA, V106, P13820, DOI 10.1073/pnas.0905718106
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Han CB, 2012, CANCER INVEST, V30, P741, DOI 10.3109/07357907.2012.732159
   Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224
   Kaçar S, 2008, ACTA CHIR BELG, V108, P518, DOI 10.1080/00015458.2008.11680278
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Klintman M, 2016, CLIN CANCER RES, V22, P2405, DOI 10.1158/1078-0432.CCR-15-1488
   Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1
   Magbanua MJM, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0582-3
   Mao C, 2015, SCI REP-UK, V5, DOI 10.1038/srep08065
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Midgley R, 1999, LANCET, V353, P391, DOI 10.1016/S0140-6736(98)07127-X
   Oh SC, 2012, GUT, V61, P1291, DOI 10.1136/gutjnl-2011-300812
   Roepman P, 2014, INT J CANCER, V134, P552, DOI 10.1002/ijc.28387
   Sadanandam A, 2014, CELL CYCLE, V13, P353, DOI 10.4161/cc.27769
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836
   Schlicker A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-66
   Snoeren N, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049442
   Song N, 2016, JAMA ONCOL, V2, P1162, DOI 10.1001/jamaoncol.2016.2314
   Tato-Costa J, 2016, CLIN COLORECTAL CANC, V15, P170, DOI 10.1016/j.clcc.2015.09.003
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Trinh A, 2017, CLIN CANCER RES, V23, P387, DOI 10.1158/1078-0432.CCR-16-0680
   Ubink I, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw303
   Valent A, 2013, CANCER GENET-NY, V206, P37, DOI 10.1016/j.cancergen.2012.12.001
   Vellinga TT, 2016, ONCOGENE, V35, P5263, DOI 10.1038/onc.2016.60
   Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038
NR 32
TC 36
Z9 40
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 2157-9024
J9 ONCOGENESIS
JI Oncogenesis
PD JUL
PY 2017
VL 6
AR e357
DI 10.1038/oncsis.2017.48
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FE3UG
UT WOS:000408140600001
PM 28692036
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Roda, D
   Castillo, J
   Telechea-Fernández, M
   Gil, A
   López-Rodas, G
   Franco, L
   González-Rodríguez, P
   Roselló, S
   Pérez-Fidalgo, JA
   García-Trevijano, ER
   Cervantes, A
   Zaragozá, R
AF Roda, Desamparados
   Castillo, Josefa
   Telechea-Fernandez, Marcelino
   Gil, Anabel
   Lopez-Rodas, Gerardo
   Franco, Luis
   Gonzalez-Rodriguez, Patricia
   Rosello, Susana
   Alejandro Perez-Fidalgo, J.
   Garcia-Trevijano, Elena R.
   Cervantes, Andres
   Zaragoza, Rosa
TI EGF-Induced Acetylation of Heterogeneous Nuclear Ribonucleoproteins Is
   Dependent on <i>KRAS</i> Mutational Status in Colorectal Cancer Cells
SO PLOS ONE
LA English
DT Article
ID K-RAS MUTATIONS; MAMMARY-GLAND; CODON 61; CETUXIMAB; RESISTANCE;
   ADENOCARCINOMA; APOPTOSIS; PATHWAYS; THERAPY; KINASE
AB KRAS mutational status is considered a negative predictive marker of the response to anti-EGFR therapies in colorectal cancer (CRC) patients. However, conflicting data exist regarding the variable response to EGFR-targeted therapy. The effects of oncogenic KRAS on downstream targets were studied in cell lines with different KRAS mutations. Cells harboring a single KRAS(G13D) allele showed the most tumorigenic profile, with constitutive activation of the downstream pathway, rendering them EGF-unresponsive. Conversely, KRAS(A146T) cells showed a full EGF-response in terms of signal transduction pathways, cell proliferation, migration or adhesion. Moreover, the global acetylome of CRC cells was also dependent on KRAS mutational status. Several hnRNP family members were identified within the 36 acetylated-proteins. Acetylation status is known to be involved in the modulation of EGF-response. In agreement with results presented herein, hnRNPA1 and L acetylation was induced in response to EGF in KRAS(A146T) cells, whereas acetyl-hnRNPA1 and L levels remained unchanged after growth factor treatment in KRASG13D unresponsive cells. Our results showed that hnRNPs induced-acetylation is dependent on KRAS mutational status. Nevertheless hnRNPs acetylation might also be the point where different oncogenic pathways converge.
C1 [Roda, Desamparados; Castillo, Josefa; Telechea-Fernandez, Marcelino; Gil, Anabel; Rosello, Susana; Alejandro Perez-Fidalgo, J.; Cervantes, Andres; Zaragoza, Rosa] Univ Valencia, INCLIVA Biomed Res Inst, Dept Haematol & Med Oncol, Valencia, Spain.
   [Lopez-Rodas, Gerardo; Franco, Luis; Gonzalez-Rodriguez, Patricia; Garcia-Trevijano, Elena R.] Univ Valencia, INCLIVA Biomed Res Inst, Dept Biochem & Mol Biol, Valencia, Spain.
C3 University of Valencia; University of Valencia
RP Cervantes, A (corresponding author), Univ Valencia, INCLIVA Biomed Res Inst, Dept Haematol & Med Oncol, Valencia, Spain.
EM Andres.cervantes@uv.es
RI Gil, Anabel/LWI-4455-2024; Ruiz García-Trevijano, Elena
   R./ABE-1014-2021; Perez-Fidalgo, Alejandro/P-2944-2014;
   González-Rodríguez, Patricia/AAA-1492-2022; LOPEZ-RODAS,
   GERARDO/I-1349-2015; Cervantes, Andres/J-8713-2013; Rosello Keranen,
   Susana/E-7734-2015
OI Zaragoza, Rosa/0000-0001-8280-5838; Castillo Aliaga,
   Josefa/0000-0002-4092-0085; LOPEZ-RODAS, GERARDO/0000-0001-8367-653X;
   Cervantes, Andres/0000-0003-3806-3691; Perez-Fidalgo, J.
   Alejandro/0000-0003-3568-4345; Ruiz Garcia-Trevijano,
   Elena/0000-0002-3985-1270; Rosello Keranen, Susana/0000-0003-3915-4130;
   Franco, Luis/0000-0001-9610-6448
FU Spanish government, Ministerio de Economia y Competitividad and FEDER
   [FIS PI09/02480, PI12/02767, FIS PI12/02394, FIS PI12/02110];
   Generalitat Valenciana [PROMETEO 2013-005]; Ministerio de Ciencia e
   Innovacion (Rio Hortega Program); Sociedad Espanola Oncologia Medica
   (SEOM); Spanish Association Against Cancer (AECC, Provincial Board of
   Baleares)
FX This work was supported in part by grants from Spanish government,
   Ministerio de Economia y Competitividad and FEDER grants (FIS PI09/02480
   and PI12/02767 to AC; FIS PI12/02394 to ERGT and FIS PI12/02110 to GLR)
   and Generalitat Valenciana (PROMETEO 2013-005 to AC). DR held a
   fellowship from Ministerio de Ciencia e Innovacion (Rio Hortega Program)
   and from Sociedad Espanola Oncologia Medica (SEOM); MTM is a
   pre-doctoral fellow from Generalitat Valenciana (Prometeo) and AG is a
   recipient of postdoctoral fellowship from Spanish Association Against
   Cancer (AECC, Provincial Board of Baleares).
CR [Anonymous], LIMMA LINEAR MODELS
   Arnandis T, 2012, CELL DEATH DIFFER, V19, P1536, DOI 10.1038/cdd.2012.46
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079
   Chen LC, 2009, ONCOGENE, V28, P1904, DOI 10.1038/onc.2009.55
   Choudhary C, 2009, SCIENCE, V325, P834, DOI 10.1126/science.1175371
   Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Dourdin N, 2001, J BIOL CHEM, V276, P48382, DOI 10.1074/jbc.M108893200
   Emonds E, 2010, WORLD J GASTROENTERO, V16, P1970, DOI 10.3748/wjg.v16.i16.1970
   Er TK, 2014, CANCER LETT, V343, P1, DOI 10.1016/j.canlet.2013.09.012
   Gryder BE, 2012, FUTURE MED CHEM, V4, P505, DOI [10.4155/fmc.12.3, 10.4155/FMC.12.3]
   Guil S, 2006, MOL CELL BIOL, V26, P5744, DOI 10.1128/MCB.00224-06
   Han SP, 2010, BIOCHEM J, V430, P379, DOI 10.1042/BJ20100396
   Hartman DJ, 2012, INT J CANCER, V131, P1810, DOI 10.1002/ijc.27461
   Hayashi H, 2008, GENES CELLS, V13, P941, DOI 10.1111/j.1365-2443.2008.01218.x
   Imamura Y, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-135
   Jeannot V, 2014, INT J CANCER, V134, P2560, DOI 10.1002/ijc.28594
   Jung JW, 2005, CANCER LETT, V225, P199, DOI 10.1016/j.canlet.2004.11.029
   Kalikaki A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0104902
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   LaBonte MJ, 2011, CANCER RES, V71, P3635, DOI 10.1158/0008-5472.CAN-10-2430
   Liu L, 2010, BIOCHEM BIOPH RES CO, V392, P190, DOI 10.1016/j.bbrc.2010.01.011
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Ma YL, 2009, J PROTEOME RES, V8, P4525, DOI 10.1021/pr900365e
   Parikh N, 2012, MOL CANCER RES, V10, P845, DOI 10.1158/1541-7786.MCR-12-0089
   Sánchez-Quiles V, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M111.009126
   Smith G, 2010, BRIT J CANCER, V102, P693, DOI 10.1038/sj.bjc.6605534
   Tan Gong-Jun, 2013, World J Biol Chem, V4, P91, DOI 10.4331/wjbc.v4.i4.91
   Tyner JW, 2009, BLOOD, V113, P1749, DOI 10.1182/blood-2008-04-152157
   Ushigome M, 2005, INT J ONCOL, V26, P635
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Schaeybroeck S, 2011, CANCER RES, V71, P1071, DOI 10.1158/0008-5472.CAN-10-0714
   Wang HL, 2010, ADV ANAT PATHOL, V17, P23, DOI 10.1097/PAP.0b013e3181c6962f
   Yuen HF, 2012, BIOSCIENCE REP, V32, P413, DOI 10.1042/BSR20120050
   Zaragozá R, 2005, BIOCHEM J, V391, P581, DOI 10.1042/BJ20050507
NR 39
TC 7
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2015
VL 10
IS 6
AR e0130543
DI 10.1371/journal.pone.0130543
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA CL4OY
UT WOS:000356933800062
PM 26110767
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Wu, YP
   Tang, L
   Wang, BK
   Sun, QM
   Zhao, PW
   Li, WF
AF Wu, Yanping
   Tang, Li
   Wang, Baikui
   Sun, Qiming
   Zhao, Pengwei
   Li, Weifen
TI The role of autophagy in maintaining intestinal mucosal barrier
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
DE autophagy; intestinal mucosal barrier; IECs; intestinal diseases;
   therapy
ID GENOME-WIDE ASSOCIATION; INFLAMMATORY-BOWEL-DISEASE; PANETH CELL
   AUTOPHAGY; STEM-CELLS; EPITHELIAL-CELLS; COLORECTAL-CANCER; OXIDATIVE
   STRESS; CROHN-DISEASE; COLON-CANCER; NECROTIZING ENTEROCOLITIS
AB The intestinal mucosal barrier is the first line to defense against luminal content penetration and performs numerous biological functions. The intestinal epithelium contains a huge surface that is lined by a monolayer of intestinal epithelial cells (IECs). IECs are dominant mediators in maintaining intestinal homeostasis that drive diverse functions including nutrient absorption, physical segregation, secretion of antibacterial peptides, and modulation of immune responses. Autophagy is a cellular self-protection mechanism in response to various stresses, and accumulating studies have revealed its importance in participating physiological processes of IECs. The regulatory effects of autophagy depend on the specific IEC types. This review aims to elucidate the myriad roles of autophagy in regulating the functions of different IECs (stem cells, enterocytes, goblet cells, and Paneth cells), and present the progress of autophagy-targeting therapy in intestinal diseases. Understanding the involved mechanisms can provide new preventive and therapeutic strategies for gastrointestinal dysfunction and diseases.
C1 [Wu, Yanping; Tang, Li; Wang, Baikui; Li, Weifen] Zhejiang Univ, Key Lab Mol Anim Nutr, Minist Educ, Coll Anim Sci, Hangzhou, Zhejiang, Peoples R China.
   [Sun, Qiming; Zhao, Pengwei] Zhejiang Univ, Sch Med, Dept Biochem, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Zhao, PW (corresponding author), Zhejiang Univ, Sch Med, Dept Biochem, Hangzhou 310058, Zhejiang, Peoples R China.; Li, WF (corresponding author), Zhejiang Univ, Coll Anim Sci, Key Lab Mol Anim Nutr, Hangzhou 310058, Zhejiang, Peoples R China.
EM zhaopengwei625@163.com; wfli@zju.edu.cn
RI yanping, wu/AAR-4840-2021; Tang, Li/AAU-6216-2021; Wang,
   Baikui/AID-7770-2022
OI Wang, Baikui/0000-0001-5283-7337; Weifen, Li/0000-0001-8159-9876
FU National High-Tech R&D Program (863) of China [2013AA102803D]; National
   Natural Science Foundation of China [31472128, 31672460]
FX National High-Tech R&D Program (863) of China, Grant/Award Number: No.
   2013AA102803D; National Natural Science Foundation of China, Grant/Award
   Numbers: 31472128, No. 31672460
CR Abada A, 2014, EMBO REP, V15, P839, DOI 10.15252/embr.201439076
   Adolph TE, 2013, NATURE, V503, P272, DOI 10.1038/nature12599
   Amar J, 2011, EMBO MOL MED, V3, P559, DOI 10.1002/emmm.201100159
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Arrieta MC, 2009, GUT, V58, P41, DOI 10.1136/gut.2008.150888
   Artis D, 2008, NAT REV IMMUNOL, V8, P411, DOI 10.1038/nri2316
   Asano J, 2017, CELL REP, V20, P1050, DOI 10.1016/j.celrep.2017.07.019
   Bach SP, 2000, CARCINOGENESIS, V21, P469, DOI 10.1093/carcin/21.3.469
   Barrett JC, 2008, NAT GENET, V40, P955, DOI 10.1038/ng.175
   Benjamin JL, 2013, CELL HOST MICROBE, V13, P723, DOI 10.1016/j.chom.2013.05.004
   Bevins CL, 2011, NAT REV MICROBIOL, V9, P356, DOI 10.1038/nrmicro2546
   Billmann-Born S, 2011, EUR J CELL BIOL, V90, P593, DOI 10.1016/j.ejcb.2010.10.015
   Botti-Millet J, 2016, AM J PHYSIOL-CELL PH, V311, pC351, DOI 10.1152/ajpcell.00129.2016
   Boya P, 2013, NAT CELL BIOL, V15, P713, DOI 10.1038/ncb2788
   Bretin A, 2016, AUTOPHAGY, V12, P770, DOI 10.1080/15548627.2016.1156823
   Burada F, 2015, WORLD J GASTRO ONCOL, V7, P271, DOI 10.4251/wjgo.v7.i11.271
   Burger E, 2018, CELL HOST MICROBE, V23, P177, DOI 10.1016/j.chom.2018.01.001
   Cabrera S, 2013, AUTOPHAGY, V9, P1188, DOI 10.4161/auto.24797
   Cadwell K, 2008, NATURE, V456, P259, DOI 10.1038/nature07416
   Cadwell K, 2010, CELL, V141, P1135, DOI 10.1016/j.cell.2010.05.009
   Cadwell K, 2009, AUTOPHAGY, V5, P250, DOI 10.4161/auto.5.2.7560
   Cederlund A, 2011, FEBS J, V278, P3942, DOI 10.1111/j.1742-4658.2011.08302.x
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI 10.1056/NEJMc1303158
   Chung HC, 2012, CELL, V149, P1578, DOI 10.1016/j.cell.2012.04.037
   Clark JA, 2006, AM J PHYSIOL-GASTR L, V291, pG938, DOI 10.1152/ajpgi.00090.2006
   Colombel JF, 2010, NEW ENGL J MED, V362, P1383, DOI 10.1056/NEJMoa0904492
   Conway KL, 2013, GASTROENTEROLOGY, V145, P1347, DOI 10.1053/j.gastro.2013.08.035
   Delorme-Axford E, 2018, AUTOPHAGY, V14, P365, DOI 10.1080/15548627.2017.1401425
   Deplancke B, 2001, AM J CLIN NUTR, V73, p1131S
   Deretic V, 2008, DEV CELL, V15, P641, DOI 10.1016/j.devcel.2008.10.009
   Duan JL, 2015, FREE RADICAL RES, V49, P210, DOI 10.3109/10715762.2014.993627
   Duerkop BA, 2009, IMMUNITY, V31, P368, DOI 10.1016/j.immuni.2009.08.009
   Eisenberg-Lerner A, 2009, APOPTOSIS, V14, P376, DOI 10.1007/s10495-008-0307-5
   Filomeni G, 2015, CELL DEATH DIFFER, V22, P377, DOI 10.1038/cdd.2014.150
   Fritz T, 2011, GUT, V60, P1580, DOI 10.1136/gut.2009.206466
   Gardet A, 2012, CURR OPIN IMMUNOL, V24, P522, DOI 10.1016/j.coi.2012.08.001
   Garrison AP, 2009, AM J PHYSIOL-GASTR L, V296, pG643, DOI 10.1152/ajpgi.90588.2008
   Geng JF, 2008, EMBO REP, V9, P859, DOI 10.1038/embor.2008.163
   Giepmans BNG, 2009, BBA-BIOMEMBRANES, V1788, P820, DOI 10.1016/j.bbamem.2008.07.015
   Gill SR, 2006, SCIENCE, V312, P1355, DOI 10.1126/science.1124234
   Green DR, 2011, SCIENCE, V333, P1109, DOI 10.1126/science.1201940
   Groulx JF, 2012, AUTOPHAGY, V8, P893, DOI 10.4161/auto.19738
   Guo WJ, 2014, AUTOPHAGY, V10, P972, DOI 10.4161/auto.28374
   Gutierrez MG, 2004, CELL, V119, P753, DOI 10.1016/j.cell.2004.11.038
   Hampe J, 2007, NAT GENET, V39, P207, DOI 10.1038/ng1954
   Nguyen HTT, 2014, GASTROENTEROLOGY, V146, P508, DOI 10.1053/j.gastro.2013.10.021
   Hooper KM, 2017, J CROHNS COLITIS, V11, P118, DOI 10.1093/ecco-jcc/jjw127
   Hooper LV, 2010, NAT REV IMMUNOL, V10, P159, DOI 10.1038/nri2710
   Ishibashi K, 2012, MOL BIOL CELL, V23, P3193, DOI 10.1091/mbc.E12-01-0010
   Jiang PD, 2014, CELL RES, V24, P69, DOI 10.1038/cr.2013.161
   Johansson MEV, 2009, J PROTEOME RES, V8, P3549, DOI 10.1021/pr9002504
   Jung CH, 2009, MOL BIOL CELL, V20, P1992, DOI 10.1091/mbc.E08-12-1249
   Kabat AM, 2016, FRONT IMMUNOL, V7, P1, DOI 10.3389/fimmu.2016.00240
   Kaser A, 2008, CELL, V134, P743, DOI 10.1016/j.cell.2008.07.021
   Kobayashi KS, 2005, SCIENCE, V307, P731, DOI 10.1126/science.1104911
   Koenig JE, 2011, P NATL ACAD SCI USA, V108, P4578, DOI 10.1073/pnas.1000081107
   Kondo Y, 2006, AUTOPHAGY, V2, P85, DOI 10.4161/auto.2.2.2463
   Kostic AD, 2014, GASTROENTEROLOGY, V146, P1489, DOI 10.1053/j.gastro.2014.02.009
   Lapaquette P, 2012, CELL MICROBIOL, V14, P791, DOI 10.1111/j.1462-5822.2012.01768.x
   Lassen KG, 2014, P NATL ACAD SCI USA, V111, P7741, DOI 10.1073/pnas.1407001111
   Levine B, 2005, CELL, V120, P159, DOI 10.1016/j.cell.2005.01.005
   Levine B, 2011, NATURE, V469, P323, DOI 10.1038/nature09782
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Liu B, 2013, AM J PHYSIOL-GASTR L, V305, pG573, DOI 10.1152/ajpgi.00071.2013
   Liu ZZ, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/352723
   Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028
   Martens EC, 2018, NAT REV MICROBIOL, V16, P457, DOI 10.1038/s41579-018-0036-x
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Mathis D, 2012, IMMUNOL REV, V245, P239, DOI 10.1111/j.1600-065X.2011.01084.x
   Maynard AA, 2010, AM J PHYSIOL-GASTR L, V299, pG614, DOI 10.1152/ajpgi.00076.2010
   McElroy SJ, 2013, NEONATOLOGY, V103, P10, DOI 10.1159/000342340
   McGovern DPB, 2010, NAT GENET, V42, P332, DOI 10.1038/ng.549
   McGuckin MA, 2010, AM J PHYSIOL-GASTR L, V298, pG820, DOI 10.1152/ajpgi.00063.2010
   Mei Y, 2015, BBA-MOL BASIS DIS, V1852, P243, DOI 10.1016/j.bbadis.2014.05.005
   Metcalfe C, 2014, CELL STEM CELL, V14, P149, DOI 10.1016/j.stem.2013.11.008
   Miki H, 2012, INT J ONCOL, V40, P1020, DOI 10.3892/ijo.2012.1325
   Molodecky NA, 2012, GASTROENTEROLOGY, V142, P46, DOI 10.1053/j.gastro.2011.10.001
   Muñoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166
   Murrow L, 2013, ANNU REV PATHOL-MECH, V8, P105, DOI 10.1146/annurev-pathol-020712-163918
   Murthy A, 2014, NATURE, V506, P456, DOI 10.1038/nature13044
   Na HJ, 2018, BIOCHEM BIOPH RES CO, V498, P18, DOI 10.1016/j.bbrc.2018.02.191
   Nagy P, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23065-3
   Nakagawa I, 2004, SCIENCE, V306, P1037, DOI 10.1126/science.1103966
   Nakamura S, 2017, J CELL SCI, V130, P1209, DOI 10.1242/jcs.196352
   Naves JE, 2015, J CROHNS COLITIS, V9, pS98
   Neal MD, 2013, J IMMUNOL, V190, P3541, DOI 10.4049/jimmunol.1202264
   Negroni A, 2016, INFLAMM RES, V65, P803, DOI 10.1007/s00011-016-0964-8
   Ng SC, 2017, LANCET, V390, P2769, DOI 10.1016/S0140-6736(17)32448-0
   Nighot P, 2016, TISSUE BARRIERS, V4, DOI 10.1080/21688370.2016.1171284
   Nighot PK, 2015, J BIOL CHEM, V290, P7234, DOI 10.1074/jbc.M114.597492
   Patel KK, 2013, EMBO J, V32, P3130, DOI 10.1038/emboj.2013.233
   Pickert G, 2009, J EXP MED, V206, P1465, DOI 10.1084/jem.20082683
   Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016
   Poprac P, 2017, TRENDS PHARMACOL SCI, V38, P592, DOI 10.1016/j.tips.2017.04.005
   Porter EM, 2002, CELL MOL LIFE SCI, V59, P156, DOI 10.1007/s00018-002-8412-z
   Pott J, 2018, CELL HOST MICROBE, V23, P191, DOI 10.1016/j.chom.2017.12.017
   Proikas-Cezanne T, 2015, J CELL SCI, V128, P207, DOI 10.1242/jcs.146258
   Qu XP, 2007, CELL, V128, P931, DOI 10.1016/j.cell.2006.12.044
   Ra EA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11726
   Raina K, 2013, AUTOPHAGY, V9, P697, DOI 10.4161/auto.23960
   Reggiori F, 2017, J MOL BIOL, V429, P486, DOI 10.1016/j.jmb.2017.01.002
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Rioux JD, 2007, NAT GENET, V39, P596, DOI 10.1038/ng2032
   Roda G, 2010, WORLD J GASTROENTERO, V16, P4264, DOI 10.3748/wjg.v16.i34.4264
   Round JL, 2009, NAT REV IMMUNOL, V9, P313, DOI 10.1038/nri2515
   Ruart M, 2019, J HEPATOL, V70, P458, DOI 10.1016/j.jhep.2018.10.015
   Rybstein MD, 2018, NAT CELL BIOL, V20, P243, DOI 10.1038/s41556-018-0042-2
   Saitoh T, 2008, NATURE, V456, P264, DOI 10.1038/nature07383
   Sandler NG, 2011, GASTROENTEROLOGY, V141, P1220, DOI 10.1053/j.gastro.2011.06.063
   Sasaki K, 2012, ANTI-CANCER DRUG, V23, P675, DOI 10.1097/CAD.0b013e328353f8c7
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Shaffiey S., 2014, J SURG RES, V186, P650
   Shakeri A, 2019, J CELL PHYSIOL, V234, P5643, DOI 10.1002/jcp.27404
   Shen L, 2011, ANNU REV PHYSIOL, V73, P283, DOI 10.1146/annurev-physiol-012110-142150
   Shibutani ST, 2015, NAT IMMUNOL, V16, P1014, DOI 10.1038/ni.3273
   Singh V, 2017, J BIOL CHEM, V292, P1847, DOI 10.1074/jbc.M116.759456
   Snoeck V, 2005, MICROBES INFECT, V7, P997, DOI 10.1016/j.micinf.2005.04.003
   SPECIAN RD, 1991, AM J PHYSIOL, V260, pC183, DOI 10.1152/ajpcell.1991.260.2.C183
   Stappenbeck TS, 2009, GASTROENTEROLOGY, V137, P30, DOI 10.1053/j.gastro.2009.05.013
   Stephenson LM, 2009, AUTOPHAGY, V5, P625, DOI 10.4161/auto.5.5.8133
   Suh HW, 2017, CURR MED CHEM, V24, P898, DOI 10.2174/0929867323666161202151856
   Thachil E, 2012, GASTROENTEROLOGY, V142, pS682
   Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408
   Tiwari S., 2018, J CANADIAN ASS GASTR, V1, P459, DOI [10.1093/jcag/gwy008.265, DOI 10.1093/JCAG/GWY008.265]
   Treveil A, 2019, J CROHNS COLITIS, V13, pS31, DOI 10.1093/ecco-jcc/jjy222.043
   Tsuboyama K, 2016, SCIENCE, V354, P1036, DOI 10.1126/science.aaf6136
   Turner JR, 2009, NAT REV IMMUNOL, V9, P799, DOI 10.1038/nri2653
   Vaishnava S, 2008, P NATL ACAD SCI USA, V105, P20858, DOI 10.1073/pnas.0808723105
   van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145
   Van der Sluis M, 2006, GASTROENTEROLOGY, V131, P117, DOI 10.1053/j.gastro.2006.04.020
   Van Itallie CM, 2008, J CELL SCI, V121, P298, DOI 10.1242/jcs.021485
   Wang SL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00693
   Weidberg H, 2010, EMBO J, V29, P1792, DOI 10.1038/emboj.2010.74
   Wildenberg ME, 2017, MUCOSAL IMMUNOL, V10, P352, DOI 10.1038/mi.2016.65
   Wittkopf N, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/278059
   Wlodarska M, 2014, CELL, V156, P1045, DOI 10.1016/j.cell.2014.01.026
   Wu YP, 2017, FRONT MICROBIOL, V8, DOI 10.3389/fmicb.2017.00469
   Wu YH, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0031-8
   Yang Y, 2015, AMINO ACIDS, V47, P2177, DOI 10.1007/s00726-014-1844-6
   Yang ZF, 2010, NAT CELL BIOL, V12, P814, DOI 10.1038/ncb0910-814
   Yilmaz ÖH, 2012, NATURE, V486, P490, DOI 10.1038/nature11163
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010157
   Zhang H, 2017, IMMUNOBIOLOGY, V222, P831, DOI 10.1016/j.imbio.2017.03.002
   Zhang LZ, 2019, MOL MED REP, V19, P3053, DOI 10.3892/mmr.2019.9974
   Zhu Y, 2008, J PHYSIOL-LONDON, V586, P1977, DOI 10.1113/jphysiol.2007.149310
NR 147
TC 81
Z9 92
U1 4
U2 85
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD NOV
PY 2019
VL 234
IS 11
BP 19406
EP 19419
DI 10.1002/jcp.28722
PG 14
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA IM5EX
UT WOS:000478018200026
PM 31020664
DA 2025-01-04
ER

PT J
AU Werner, J
   Boonekamp, KE
   Zhan, TZ
   Boutros, M
AF Werner, Johannes
   Boonekamp, Kim E.
   Zhan, Tianzuo
   Boutros, Michael
TI The Roles of Secreted Wnt Ligands in Cancer
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE Wnt signaling; Wnt ligands; cancer; non-canonical Wnt signaling; tumor
   microenvironment; metastasis; immunotherapy; targeted therapy
ID HEMATOPOIETIC STEM-CELLS; SUPPRESSES COLON-CANCER; COLORECTAL-CANCER;
   WNT/BETA-CATENIN; BETA-CATENIN; PROTEIN STABILIZATION; DISEASE
   PROGRESSION; THERAPY RESISTANCE; LUNG-CANCER; PHASE-I
AB Wnt ligands are secreted signaling proteins that display a wide range of biological effects. They play key roles in stimulating Wnt signaling pathways to facilitate processes such as tissue homeostasis and regeneration. Dysregulation of Wnt signaling is a hallmark of many cancers and genetic alterations in various Wnt signaling components, which result in ligand-independent or ligand-dependent hyperactivation of the pathway that have been identified. Recently, research is focusing on the impact of Wnt signaling on the interaction between tumor cells and their micro-environment. This Wnt-mediated crosstalk can act either in a tumor promoting or suppressing fashion. In this review, we comprehensively outline the function of Wnt ligands in different tumor entities and their impact on key phenotypes, including cancer stemness, drug resistance, metastasis, and immune evasion. Lastly, we elaborate approaches to target Wnt ligands in cancer therapy.
C1 [Werner, Johannes; Boonekamp, Kim E.; Boutros, Michael] Heidelberg Univ, Med Fac Mannheim, German Canc Res Ctr DKFZ, Div Signaling & Funct Genom, D-69120 Heidelberg, Germany.
   [Werner, Johannes] Heidelberg Univ, Med Fac Heidelberg, D-69120 Heidelberg, Germany.
   [Zhan, Tianzuo] Heidelberg Univ, Mannheim Univ Hosp, Med Fac Mannheim, Dept Med 2, D-68167 Mannheim, Germany.
   [Zhan, Tianzuo] Heidelberg Univ, Med Fac Mannheim, Mannheim Canc Ctr, D-68167 Mannheim, Germany.
   [Zhan, Tianzuo; Boutros, Michael] Univ Med Ctr Mannheim, DKFZ Hector Canc Inst, D-68167 Mannheim, Germany.
C3 Ruprecht Karls University Heidelberg; Helmholtz Association; German
   Cancer Research Center (DKFZ); Ruprecht Karls University Heidelberg;
   Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Ruprecht Karls University Heidelberg
RP Boutros, M (corresponding author), Heidelberg Univ, Med Fac Mannheim, German Canc Res Ctr DKFZ, Div Signaling & Funct Genom, D-69120 Heidelberg, Germany.; Boutros, M (corresponding author), Univ Med Ctr Mannheim, DKFZ Hector Canc Inst, D-68167 Mannheim, Germany.
EM tianzuo.zhan@umm.de; m.boutros@dkfz.de
RI Boutros, Michael/C-3566-2008
OI Zhan, Tianzuo/0000-0002-9346-3180; Werner, Johannes/0000-0002-3895-5879;
   Boutros, Michael/0000-0002-9458-817X; Boonekamp, Kim/0000-0002-9968-5382
FU DFG (German Research Foundation) [CRC 1324]
FX J.W. was supported by the Herbert-Steinbeisser M.D. fellowship provided
   by the CRC 1324 (Mechanism and Functions of Wnt Signaling) of the DFG
   (German Research Foundation). Work in the research groups of M. Boutros
   and T. Zhan is supported by the CRC 1324.
CR Abdul-Ghani M, 2011, MOL CELL BIOL, V31, P163, DOI 10.1128/MCB.01539-09
   Acebron SP, 2014, MOL CELL, V54, P663, DOI 10.1016/j.molcel.2014.04.014
   Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156
   [Anonymous], ONCOLOGYPRO PHASE 1
   Arensman MD, 2014, ONCOGENE, V33, P899, DOI 10.1038/onc.2013.23
   Asem M, 2020, CANCER RES, V80, P1156, DOI 10.1158/0008-5472.CAN-19-1601
   Bagby SM, 2020, CANCER RES, V80, DOI 10.1158/1538-7445.AM2020-6647
   Bakker ERM, 2013, CARCINOGENESIS, V34, P2629, DOI 10.1093/carcin/bgt215
   Bänziger C, 2006, CELL, V125, P509, DOI 10.1016/j.cell.2006.02.049
   Bartscherer K, 2006, CELL, V125, P523, DOI 10.1016/j.cell.2006.04.009
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Beatty GL, 2015, CLIN CANCER RES, V21, P687, DOI 10.1158/1078-0432.CCR-14-1860
   Bergenfelz C, 2012, J IMMUNOL, V188, P5448, DOI 10.4049/jimmunol.1103378
   Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x
   Bisson JA, 2015, DEV BIOL, V398, P80, DOI 10.1016/j.ydbio.2014.11.015
   Chen LJ, 2018, MOL MED REP, V18, P2571, DOI 10.3892/mmr.2018.9287
   Chen Y, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0171751
   Cheng RF, 2014, J CELL PHYSIOL, V229, P1908, DOI 10.1002/jcp.24566
   Choi MY, 2018, CELL STEM CELL, V22, P951, DOI 10.1016/j.stem.2018.05.018
   Clevers H, 2013, CELL, V154, P274, DOI 10.1016/j.cell.2013.07.004
   Coombs GS, 2010, J CELL SCI, V123, P3357, DOI 10.1242/jcs.072132
   Corda G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.69
   Cui B, 2016, BLOOD, V128, P2931, DOI 10.1182/blood-2016-04-712562
   Davis SL, 2020, INVEST NEW DRUG, V38, P821, DOI [10.1038/s41564-019-0492-8, 10.1007/s10637-019-00824-1]
   de Andrés MP, 2023, GUT, V72, P535, DOI 10.1136/gutjnl-2021-325803
   de Groot REA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076971
   Debela DT, 2021, SAGE OPEN MED, V9, DOI 10.1177/20503121211034366
   Degirmenci B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103369
   Deraz EM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025438
   Deryugina EI, 2006, CANCER METAST REV, V25, P9, DOI 10.1007/s10555-006-7886-9
   DeVito NC, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109071
   Dey N, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-537
   Diamond JR, 2020, BREAST CANCER RES TR, V184, P53, DOI 10.1007/s10549-020-05817-w
   Diarra D, 2007, NAT MED, V13, P156, DOI 10.1038/nm1538
   Dissanayake SK, 2008, CANCER RES, V68, P10205, DOI 10.1158/0008-5472.CAN-08-2149
   Dong JJ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0743-z
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4
   Dotan E, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.369
   DU SJ, 1995, MOL CELL BIOL, V15, P2625
   Esfahani K, 2020, CURR ONCOL, V27, pS87, DOI 10.3747/co.27.5223
   Fares J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0134-x
   Flanagan DJ, 2021, NATURE, V594, P430, DOI 10.1038/s41586-021-03525-z
   Fleming HE, 2008, CELL STEM CELL, V2, P274, DOI 10.1016/j.stem.2008.01.003
   Flores-Hernández E, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109636
   Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510
   Frenquelli M, 2020, LEUKEMIA, V34, P257, DOI 10.1038/s41375-019-0486-9
   Gan HZ, 2019, THORAC CANCER, V10, P744, DOI 10.1111/1759-7714.12992
   Gao L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09295-7
   GBD Causes Death Collaborators, 2018, LANCET, V392, P2170, DOI [10.1016/s0140-6736(18)32203-7, 10.1016/S0140-6736(18)32203-7]
   Giraudet AL, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4544-x
   Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175
   Gödde NJ, 2014, EXP CELL RES, V328, P249, DOI 10.1016/j.yexcr.2014.08.036
   Gonçalves CS, 2018, THERANOSTICS, V8, P4805, DOI 10.7150/thno.25025
   Gorroño-Etxebarria I, 2019, CANCERS, V11, DOI 10.3390/cancers11070908
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Guo Y, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420-022-00884-y
   Han T, 2017, NAT COMMUN, V8, P1, DOI 10.1038/ncomms15945
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Hasan MK, 2021, LEUKEMIA, V35, P1621, DOI 10.1038/s41375-020-01055-7
   Herr P, 2012, DEV BIOL, V361, P392, DOI 10.1016/j.ydbio.2011.11.003
   Holstein TW, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007922
   Holtzhausen A, 2015, CANCER IMMUNOL RES, V3, P1082, DOI 10.1158/2326-6066.CIR-14-0167
   Hu YB, 2019, ONCOGENE, V38, P1951, DOI 10.1038/s41388-018-0557-9
   Huang CB, 2015, AM J CANCER RES, V5, P1032
   Huang XJ, 2018, J BIOL CHEM, V293, P6693, DOI 10.1074/jbc.RA118.001689
   Huang Z, 2018, INT J BIOL SCI, V14, P2094, DOI 10.7150/ijbs.28288
   Huels DJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03426-2
   Jiang GZ, 2017, GENET TEST MOL BIOMA, V21, P74, DOI 10.1089/gtmb.2016.0162
   Jiang XM, 2013, P NATL ACAD SCI USA, V110, P12649, DOI 10.1073/pnas.1307218110
   Jiang Y, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-020-01808-3
   Jimeno A, 2017, CLIN CANCER RES, V23, P7490, DOI 10.1158/1078-0432.CCR-17-2157
   Jun S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10994
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6
   Jung YS, 2015, ONCOTARGET, V6, P37257, DOI 10.18632/oncotarget.6133
   Kaur A, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202013349
   Kerdidani D, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09370-z
   Kim Y, 2012, LAB INVEST, V92, P466, DOI 10.1038/labinvest.2011.161
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Koch S, 2021, CANCERS, V13, DOI 10.3390/cancers13143446
   Kohn AD, 2005, CELL CALCIUM, V38, P439, DOI 10.1016/j.ceca.2005.06.022
   Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112
   Kopetz S., 2022, J. Clin. Oncol., V40, DOI 10.1200/JCO.2022.40.16suppl.TPS3637
   Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144
   Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
   Lei X, 2020, CANCER LETT, V470, P126, DOI 10.1016/j.canlet.2019.11.009
   Li BY, 2018, MOL GENET GENOMICS, V293, P1245, DOI 10.1007/s00438-018-1457-y
   Lim XH, 2016, P NATL ACAD SCI USA, V113, pE1498, DOI 10.1073/pnas.1601599113
   Lin YC, 2021, LIFE SCI ALLIANCE, V4, DOI 10.26508/lsa.202000855
   Liu C, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-016-0372-8
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu Q, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00557-2
   Liu YF, 2021, CANCER SCI, V112, P629, DOI 10.1111/cas.14738
   Liu YZ, 2019, J CELL BIOCHEM, V120, P18142, DOI 10.1002/jcb.29118
   Louis I, 2008, IMMUNITY, V29, P57, DOI 10.1016/j.immuni.2008.04.023
   Luga V, 2013, CANCER RES, V73, P6843, DOI 10.1158/0008-5472.CAN-13-1791
   Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Madan B, 2016, ONCOGENE, V35, P2197, DOI 10.1038/onc.2015.280
   Madan B, 2018, J CLIN INVEST, V128, P5620, DOI 10.1172/JCI122383
   Majidpoor J, 2021, MED ONCOL, V38, DOI 10.1007/s12032-020-01447-w
   McCarthy N, 2020, NAT CELL BIOL, V22, P1033, DOI 10.1038/s41556-020-0567-z
   McWhirter JR, 1999, P NATL ACAD SCI USA, V96, P11464, DOI 10.1073/pnas.96.20.11464
   Mehta S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.714746
   Melenhorst JJ, 2022, NATURE, V602, P503, DOI 10.1038/s41586-021-04390-6
   Menck K, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02187-z
   Moore KN, 2019, GYNECOL ONCOL, V154, P294, DOI 10.1016/j.ygyno.2019.04.001
   Mounir M, 2019, PLOS COMPUT BIOL, V15, DOI 10.1371/journal.pcbi.1006701
   MUNEMITSU S, 1995, P NATL ACAD SCI USA, V92, P3046, DOI 10.1073/pnas.92.7.3046
   Murciano-Goroff YR, 2020, CELL RES, V30, P507, DOI 10.1038/s41422-020-0337-2
   Murillo-Garzón V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04042-w
   Najafi M, 2019, J CELL BIOCHEM, V120, P2756, DOI 10.1002/jcb.27646
   Nemeth MJ, 2007, P NATL ACAD SCI USA, V104, P15436, DOI 10.1073/pnas.0704747104
   Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Nishimura T, 2012, CELL, V149, P1084, DOI 10.1016/j.cell.2012.04.021
   Nishioka M, 2013, MOL CARCINOGEN, V52, P207, DOI 10.1002/mc.21845
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Niu Q, 2019, YONSEI MED J, V60, P1146, DOI 10.3349/ymj.2019.60.12.1146
   Noy R, 2014, IMMUNITY, V41, P49, DOI 10.1016/j.immuni.2014.06.010
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   Nygaard R, 2021, CELL, V184, P194, DOI 10.1016/j.cell.2020.11.038
   Nygren MK, 2007, BRIT J HAEMATOL, V136, P400, DOI 10.1111/j.1365-2141.2006.06442.x
   O'Connell MP, 2013, CANCER DISCOV, V3, P1378, DOI 10.1158/2159-8290.CD-13-0005
   Oderup C, 2013, J IMMUNOL, V190, P6126, DOI 10.4049/jimmunol.1203002
   Ojalvo LS, 2010, J IMMUNOL, V184, P702, DOI 10.4049/jimmunol.0902360
   Pacella I, 2018, CANCER IMMUNOL RES, V6, P953, DOI 10.1158/2326-6066.CIR-17-0713
   Peng L, 2017, ONCOL REP, V38, P301, DOI 10.3892/or.2017.5705
   Poppova L, 2016, BRIT J HAEMATOL, V175, P851, DOI 10.1111/bjh.14312
   Prieto-Vila M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122574
   Proffitt KD, 2013, CANCER RES, V73, P502, DOI 10.1158/0008-5472.CAN-12-2258
   Pukrop T, 2006, P NATL ACAD SCI USA, V103, P5454, DOI 10.1073/pnas.0509703103
   Raghavan S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0666-1
   Rodon J, 2021, BRIT J CANCER, V125, P28, DOI 10.1038/s41416-021-01389-8
   Rodriguez-Hernandez I, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18951-2
   RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518
   Samanta S, 2018, CELL REP, V23, P2559, DOI 10.1016/j.celrep.2018.04.113
   Schinzari V, 2018, CANCER IMMUNOL RES, V6, P941, DOI 10.1158/2326-6066.CIR-17-0712
   Schlange T, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1769
   Schwab RHM, 2018, DEV DYNAM, V247, P521, DOI 10.1002/dvdy.24527
   Seifert JRK, 2007, NAT REV GENET, V8, P126, DOI 10.1038/nrg2042
   Seino T, 2018, CELL STEM CELL, V22, P454, DOI 10.1016/j.stem.2017.12.009
   Shah K, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105532
   Sharma R.P., 1973, DROS INFORM SERV, V50, P134
   SMOLICH BD, 1993, MOL BIOL CELL, V4, P1267, DOI 10.1091/mbc.4.12.1267
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Steinbichler TB, 2018, SEMIN CANCER BIOL, V53, P156, DOI 10.1016/j.semcancer.2018.11.006
   Stolz A, 2015, EMBO REP, V16, P490, DOI 10.15252/embr.201439410
   Storm EE, 2016, NATURE, V529, P97, DOI 10.1038/nature16466
   Sugimura R, 2012, CELL, V150, P351, DOI 10.1016/j.cell.2012.05.041
   Sumitomo R, 2022, ONCOL REP, V48, DOI 10.3892/or.2022.8404
   Sun Y, 2012, NAT MED, V18, P1359, DOI 10.1038/nm.2890
   Takada R, 2006, DEV CELL, V11, P791, DOI 10.1016/j.devcel.2006.10.003
   Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334
   Tan D., 2018, Ann. Oncol, V29, pix23, DOI [DOI 10.1093/ANNONC/MDY430.002, 10.1093/annonc/mdy430.002]
   Tenjin Y, 2019, LAB INVEST, V99, P1622, DOI 10.1038/s41374-019-0277-y
   Theivanthiran B, 2020, J CLIN INVEST, V130, P2570, DOI 10.1172/JCI133055
   Thrasivoulou C, 2013, J BIOL CHEM, V288, P35651, DOI 10.1074/jbc.M112.437913
   Tian E, 2003, NEW ENGL J MED, V349, P2483, DOI 10.1056/NEJMoa030847
   Tian Q, 2005, DEV GROWTH DIFFER, V47, P273
   Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123
   Unterleuthner D, 2020, ANGIOGENESIS, V23, P159, DOI 10.1007/s10456-019-09688-8
   Valencia J, 2011, J IMMUNOL, V187, P4129, DOI 10.4049/jimmunol.1101243
   van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053
   Van den Berg DJ, 1998, BLOOD, V92, P3189, DOI 10.1182/blood.V92.9.3189.421k45_3189_3202
   van Neerven SM, 2021, NATURE, V594, P436, DOI 10.1038/s41586-021-03558-4
   Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610
   Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5
   Wang HY, 2012, INT J GYNECOL CANCER, V22, P755, DOI 10.1097/IGC.0b013e3182540284
   Wang JW, 2018, NEOPLASIA, V20, P499, DOI 10.1016/j.neo.2018.03.001
   Wang LL, 2019, ONCOL LETT, V17, P3219, DOI 10.3892/ol.2019.9955
   Wang ML, 2022, NEJM Evidence, V1
   Webster MR, 2020, MOL CELL, V77, P633, DOI [10.1016/j.molcel.2019.11.009, 10.1016/j.molcel.2020.01.005]
   Wellenstein MD, 2019, NATURE, V572, P538, DOI 10.1038/s41586-019-1450-6
   Wilson MA, 2017, STRUCTURE, V25, P1781, DOI 10.1016/j.str.2017.11.009
   Wolf LM, 2021, J CELL SCI, V134, DOI 10.1242/jcs.257790
   Xu H, 2019, ONCOL REP, V41, P1180, DOI 10.3892/or.2018.6862
   Xue J, 2018, ONCOGENE, V37, P953, DOI 10.1038/onc.2017.401
   Yamamoto H, 2013, J CELL SCI, V126, P2931, DOI 10.1242/jcs.126052
   Yang DM, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01774-w
   Yang PT, 2008, DEV CELL, V14, P140, DOI 10.1016/j.devcel.2007.12.004
   Yang Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0818-0
   Yin P, 2018, CANCER SCI, V109, P3368, DOI 10.1111/cas.13771
   Ying JM, 2008, CLIN CANCER RES, V14, P55, DOI 10.1158/1078-0432.CCR-07-1644
   Yu J, 2017, LEUKEMIA, V31, P1333, DOI 10.1038/leu.2016.368
   Yuan G, 2013, ONCOGENE, V32, P375, DOI 10.1038/onc.2012.40
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang F, 2019, BIOSCI BIOTECH BIOCH, V83, P1289, DOI 10.1080/09168451.2019.1606697
   Zhang Q, 2020, ONCOGENE, V39, P1484, DOI 10.1038/s41388-019-1071-4
   Zhang WJ, 2018, EUR J PHARMACOL, V825, P75, DOI 10.1016/j.ejphar.2018.02.019
   Zhang ZB, 2021, CANCER MED-US, V10, P3332, DOI 10.1002/cam4.3819
   Zhao F, 2018, IMMUNITY, V48, P147, DOI 10.1016/j.immuni.2017.12.004
   Zhao L, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0060-y
   Zhao YY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0466-4
   Zheng DL, 2013, MOL CANCER RES, V11, P482, DOI 10.1158/1541-7786.MCR-12-0520
   Zhong Z, 2019, ONCOGENE, V38, P6662, DOI 10.1038/s41388-019-0908-1
   Zhou FL, 2013, BLOOD REV, V27, P261, DOI 10.1016/j.blre.2013.08.002
   Zimmerli D, 2017, BRIT J PHARMACOL, V174, P4600, DOI 10.1111/bph.13864
NR 199
TC 12
Z9 13
U1 2
U2 21
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD MAR
PY 2023
VL 24
IS 6
AR 5349
DI 10.3390/ijms24065349
PG 27
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA A9EP1
UT WOS:000958080100001
PM 36982422
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Zhang, SL
   Guo, Y
   Zhang, SJ
   Wang, Z
   Zhang, YW
   Zuo, S
AF Zhang, Shilong
   Guo, Yi
   Zhang, Shenjie
   Wang, Zhi
   Zhang, Yewei
   Zuo, Shi
TI Targeting the deubiquitinase USP2 for malignant tumor therapy
SO ONCOLOGY REPORTS
LA English
DT Review
DE ubiquitin-proteasome system; deubiquitination; ubiquitin-specific
   protease 2; malignant tumors; targeted therapy
ID UBIQUITIN-SPECIFIC PROTEASE; EPITHELIAL-MESENCHYMAL TRANSITION;
   BREAST-CANCER; CELL-CYCLE; LYMPHOBLASTIC-LEUKEMIA; COLORECTAL-CANCER;
   DOWN-REGULATION; GROWTH; INHIBITION; PROMOTES
AB The ubiquitin-proteasome system is a major degradation pathway for >80% of proteins in vivo. Deubiquitylases, which remove ubiquitinated tags to stabilize substrate proteins, are important components involved in regulating the degradation of ubiquitinated proteins. In addition, they serve multiple roles in tumor development by participating in physiological processes such as protein metabolism, cell cycle regulation, DNA damage repair and gene transcription. The present review systematically summarized the role of ubiquitin-specific protease 2 (USP2) in malignant tumors and the specific molecular mechanisms underlying the involvement of USP2 in tumor-associated pathways. USP2 reverses ubiquitin-mediated degradation of proteins and is involved in aberrant proliferation, migration, invasion, apoptosis and drug resistance of tumors. Additionally, the present review summarized studies reporting on the use of USP2 as a therapeutic target for malignancies such as breast, liver, ovarian, colorectal, bladder and prostate cancers and glioblastoma and highlights the current status of pharmacological research on USP2. The clinical significance of USP2 as a therapeutic target for malignant tumors warrants further investigation.
C1 [Zhang, Shilong; Guo, Yi; Zhang, Shenjie; Wang, Zhi; Zhang, Yewei; Zuo, Shi] Guizhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, Guiyang, Peoples R China.
   [Zuo, Shi] Guizhou Med Univ, Precis Med Res Inst Guizhou, Affiliated Hosp, Guiyang 550004, Guizhou, Peoples R China.
   [Zuo, Shi] Guizhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, 28 Guiyi St, Guiyang 550004, Guizhou, Peoples R China.
C3 Guizhou Medical University; Guizhou Medical University; Guizhou Medical
   University
RP Zuo, S (corresponding author), Guizhou Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp, 28 Guiyi St, Guiyang 550004, Guizhou, Peoples R China.
EM drzuoshi@gmc.edu.cn
RI yang, rui/JHI-3328-2023
FU Not applicable.
FX Not applicable.
CR Ahangari F, 2022, AM J RESP CRIT CARE, V206, P1463, DOI 10.1164/rccm.202010-3832OC
   Aleo E, 2006, CANCER RES, V66, P9235, DOI 10.1158/0008-5472.CAN-06-0702
   Altun M, 2011, CHEM BIOL, V18, P1401, DOI 10.1016/j.chembiol.2011.08.018
   An ZC, 2018, P NATL ACAD SCI USA, V115, P1123, DOI 10.1073/pnas.1714177115
   Assoun S, 2019, INTENS CARE MED, V45, P988, DOI 10.1007/s00134-019-05650-w
   Baek SH, 1997, J BIOL CHEM, V272, P25560, DOI 10.1074/jbc.272.41.25560
   Bedard N, 2011, BIOL REPROD, V85, P594, DOI 10.1095/biolreprod.110.088542
   Blackburn PR, 2020, GENE CHROMOSOME CANC, V59, P422, DOI 10.1002/gcc.22842
   Blenman KRM, 2022, CLIN CANCER RES, V28, P2587, DOI 10.1158/1078-0432.CCR-21-3215
   Bonacci T, 2020, SEMIN CANCER BIOL, V67, P145, DOI 10.1016/j.semcancer.2020.03.008
   Cai JT, 2018, PROTEIN CELL, V9, P754, DOI 10.1007/s13238-017-0486-3
   Cao HJ, 2023, CELL DEATH DIFFER, V30, P383, DOI 10.1038/s41418-022-01090-0
   Capecchi MR, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9763
   Chen JT, 2021, THERANOSTICS, V11, P1345, DOI 10.7150/thno.51383
   Chen JJ, 2011, CHEM BIOL, V18, P1390, DOI 10.1016/j.chembiol.2011.08.014
   Chen SP, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.882372
   Chen SY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094546
   Chen W, 2023, BIOACT MATER, V23, P1, DOI 10.1016/j.bioactmat.2022.10.004
   Cheng JC, 2013, J CLIN INVEST, V123, P4344, DOI 10.1172/JCI64791
   Chuang SJ, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21476-w
   Cruz L, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14090848
   Cui YN, 2022, ACTA BIOMATER, V152, P380, DOI 10.1016/j.actbio.2022.08.024
   Davis MI, 2016, J BIOL CHEM, V291, P24628, DOI 10.1074/jbc.M116.738567
   Ding Y, 2022, CHEM SOC REV, V51, P8832, DOI 10.1039/d2cs00624c
   Dobbelstein M, 2020, CANCER SCI, V111, P2203, DOI 10.1111/cas.14433
   Estlin EJ, 2001, CANCER TREAT REV, V27, P351, DOI 10.1053/ctrv.2002.0245
   Feng X, 2019, AUTOPHAGY, V15, P1130, DOI 10.1080/15548627.2019.1570063
   Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241
   Gerhard DS, 2004, GENOME RES, V14, P2121, DOI 10.1101/gr.2596504
   Girish V, 2023, SCIENCE, V381, P848, DOI 10.1126/science.adg4521
   Gousseva N, 2003, GENE EXPRESSION, V11, P163, DOI 10.3727/000000003108749053
   Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8
   Gu YZ, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf9915
   Guo BQ, 2020, CANCER MANAG RES, V12, P10541, DOI 10.2147/CMAR.S268863
   Gupta SC, 2010, CANCER METAST REV, V29, P405, DOI 10.1007/s10555-010-9235-2
   Haimerl F, 2009, J BIOL CHEM, V284, P495, DOI 10.1074/jbc.M803533200
   Harakandi C, 2021, BIOORG CHEM, V116, DOI 10.1016/j.bioorg.2021.105273
   Hashimoto M, 2022, J NEUROSCI, V42, P4607, DOI 10.1523/JNEUROSCI.2504-21.2022
   Hassin O, 2023, NAT REV DRUG DISCOV, V22, P127, DOI 10.1038/s41573-022-00571-8
   He JB, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1512-6
   He QY, 2022, THYROID, V32, P1411, DOI 10.1089/thy.2022.0317
   Hsu J, 2016, CELL CYCLE, V15, P3183, DOI 10.1080/15384101.2016.1234551
   Hu WB, 2020, ONCOL REP, V43, P1964, DOI 10.3892/or.2020.7565
   Huang YT, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04176-8
   Iemura K, 2021, J CELL BIOL, V220, DOI 10.1083/jcb.202006116
   Ikeda J, 2019, GENE CHROMOSOME CANC, V58, P669, DOI 10.1002/gcc.22751
   Issaenko OA, 2012, CELL CYCLE, V11, P1804, DOI 10.4161/cc.20174
   Iyer AKV, 2011, J IMMUNOL, V187, P3256, DOI 10.4049/jimmunol.1002915
   Jang JH, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13521
   Ji YR, 2021, ACS APPL MATER INTER, V13, P59400, DOI 10.1021/acsami.1c21027
   Jiang TY, 2023, GASTROENTEROLOGY, V164, P424, DOI 10.1053/j.gastro.2022.11.025
   Joseph JV, 2022, NEURO-ONCOLOGY, V24, P541, DOI 10.1093/neuonc/noab212
   Karbowski M, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-022-04604-8
   Kim J, 2012, CELL CYCLE, V11, P1123, DOI 10.4161/cc.11.6.19550
   Kim JY, 2022, ONCOGENE, V41, P3289, DOI 10.1038/s41388-022-02269-y
   Kim JC, 2018, AM J CANCER RES, V8, P1823
   Kitamura H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031209
   Kitamura H, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/6909415
   Kitamura H, 2013, FASEB J, V27, P4940, DOI 10.1096/fj.13-233528
   Leow CC, 2009, MOL CANCER THER, V8, P2131, DOI 10.1158/1535-7163.MCT-08-1038
   Li BY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04330-2
   Li DY, 2020, AM J TRANSL RES, V12, P5670
   Li H, 2022, EMBO REP, V23, DOI 10.15252/embr.202254603
   Li P, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04973-9
   Li WJ, 2022, BIOCHEM PHARMACOL, V205, DOI 10.1016/j.bcp.2022.115253
   Li Y, 2015, J IMMUNOL, V195, P2648, DOI 10.4049/jimmunol.1500139
   Liang XR, 2023, CANCER MANAG RES, V15, P547, DOI 10.2147/CMAR.S407371
   Lim JH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1776
   Lin HC, 2021, INT J BIOL MACROMOL, V176, P490, DOI 10.1016/j.ijbiomac.2021.02.072
   Liu CY, 2022, LAB INVEST, V102, P524, DOI 10.1038/s41374-021-00725-z
   Liu D, 2018, ONCOL REP, V40, P2206, DOI 10.3892/or.2018.6606
   Liu JX, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-005116
   Liu JX, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00418-x
   Liu M, 2022, INT J BIOL SCI, V18, P2515, DOI 10.7150/ijbs.70960
   Liu XQ, 2022, ONCOGENE, V41, P502, DOI 10.1038/s41388-021-02112-w
   Liu ZC, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01398-4
   Lopes BA, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.749472
   Luo H, 2022, ONCOLOGIE, V24, P85, DOI 10.32604/oncologie.2022.021705
   Maertens GN, 2010, EMBO J, V29, P2553, DOI 10.1038/emboj.2010.129
   Magiera K, 2017, CELL CHEM BIOL, V24, P458, DOI 10.1016/j.chembiol.2017.03.002
   Mahul-Mellier AL, 2012, BBA-MOL CELL RES, V1823, P1353, DOI 10.1016/j.bbamcr.2012.05.022
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Mansilla A, 2016, CELL DEATH DIFFER, V23, P405, DOI 10.1038/cdd.2015.108
   Mao X, 2016, EXP MOL PATHOL, V101, P249, DOI 10.1016/j.yexmp.2016.09.005
   Mattiroli F, 2021, TRENDS GENET, V37, P566, DOI 10.1016/j.tig.2020.12.005
   Mejía-Hernández JO, 2022, CANCERS, V14, DOI 10.3390/cancers14163947
   Meng XG, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.02.141
   Metzig M, 2011, INT J CANCER, V129, P607, DOI 10.1002/ijc.26124
   Meyer C, 2019, LEUKEMIA, V33, P2306, DOI 10.1038/s41375-019-0451-7
   Min HY, 2022, EXP MOL MED, V54, P1670
   Miyazawa K, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022095
   Mizutani N, 2015, J BIOCHEM, V158, P309, DOI 10.1093/jb/mvv039
   Mladinich M, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5285892
   Modi S, 2011, CLIN CANCER RES, V17, P5132, DOI 10.1158/1078-0432.CCR-11-0072
   Moghadami AA, 2020, CELL STRESS CHAPERON, V25, P909, DOI 10.1007/s12192-020-01125-w
   Molusky MM, 2012, DIABETES, V61, P1025, DOI 10.2337/db11-0970
   MOREMEN KW, 1991, J BIOL CHEM, V266, P16876
   Nadolny C, 2021, AM J CANCER RES, V11, P4746
   Nakahashi K, 2022, EXP DERMATOL, V31, P1693, DOI 10.1111/exd.14641
   Nan YB, 2023, MOL THER, V31, P552, DOI 10.1016/j.ymthe.2022.10.006
   Nepal S, 2015, MOL CELL ENDOCRINOL, V412, P44, DOI 10.1016/j.mce.2015.05.029
   Nguyen TT., 2021, Int J Mol Sci, V22, DOI [10.3390/ijms221910209, DOI 10.3390/IJMS221910209]
   Nicholson B, 2008, PROTEIN SCI, V17, P1035, DOI 10.1110/ps.083450408
   O'Brien S, 2022, EMBO REP, V23, DOI 10.15252/embr.202255044
   Ohayon S, 2015, ANGEW CHEM INT EDIT, V54, P599, DOI 10.1002/anie.201408411
   Ota T, 2004, NAT GENET, V36, P40, DOI 10.1038/ng1285
   Park SH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abe2261
   Peinado H, 2008, NAT CELL BIOL, V10, P253, DOI 10.1038/ncb0308-253
   Pichiorri F, 2022, CANCER CELL, V40, P1441, DOI 10.1016/j.ccell.2022.10.006
   Pirnia F, 2002, CELL DEATH DIFFER, V9, P905, DOI 10.1038/sj.cdd.4401062
   Poukkula M, 2005, J BIOL CHEM, V280, P27345, DOI 10.1074/jbc.M504019200
   Pouly D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0145155
   Qu Q, 2015, TUMOR BIOL, V36, P5415, DOI 10.1007/s13277-015-3207-7
   Qu XH, 2019, CANCER LETT, V454, P90, DOI 10.1016/j.canlet.2019.04.016
   Quintavalle C, 2017, CELL DEATH DIFFER, V24, P1134, DOI 10.1038/cdd.2017.7
   Rasaei R, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218090
   Renatus M, 2006, STRUCTURE, V14, P1293, DOI 10.1016/j.str.2006.06.012
   Roberts JZ, 2022, CELL DEATH DIFFER, V29, P272, DOI 10.1038/s41418-021-00922-9
   Rosenberg T, 2022, NEURO-ONCOLOGY, V24, P1964, DOI 10.1093/neuonc/noac096
   Sato Y, 2015, NAT STRUCT MOL BIOL, V22, P222, DOI 10.1038/nsmb.2970
   Savage RE, 2008, DRUG METAB DISPOS, V36, P753, DOI 10.1124/dmd.107.018655
   Sesto N, 2013, NAT REV MICROBIOL, V11, P75, DOI 10.1038/nrmicro2934
   Shan J, 2009, MOL CELL, V36, P469, DOI 10.1016/j.molcel.2009.10.018
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shi Y, 2011, J BIOL CHEM, V286, P38960, DOI 10.1074/jbc.M111.231498
   Shih YY, 2022, REDOX BIOL, V57, DOI 10.1016/j.redox.2022.102501
   Shrestha M, 2016, KOREAN J PHYSIOL PHA, V20, P487, DOI 10.4196/kjpp.2016.20.5.487
   Sinam IS, 2022, J CACHEXIA SARCOPENI, V13, P3122, DOI 10.1002/jcsm.13100
   Smith ER, 2022, DRUG RESIST UPDATE, V65, DOI 10.1016/j.drup.2022.100881
   Stevenson LF, 2007, EMBO J, V26, P976, DOI 10.1038/sj.emboj.7601567
   Stine ZE, 2015, CANCER DISCOV, V5, P1024, DOI 10.1158/2159-8290.CD-15-0507
   Su DX, 2021, NUCLEIC ACIDS RES, V49, P4421, DOI 10.1093/nar/gkab209
   Sun TS, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01262-x
   Tatari N, 2022, ACTA NEUROPATHOL, V144, P1127, DOI 10.1007/s00401-022-02506-4
   Tomala MD, 2018, EUR J MED CHEM, V150, P261, DOI 10.1016/j.ejmech.2018.03.009
   Tong X, 2012, J BIOL CHEM, V287, P25280, DOI 10.1074/jbc.M112.340786
   Tsai HK, 2022, BLOOD ADV, V6, P4236, DOI 10.1182/bloodadvances.2022007613
   Tsai KW, 2018, ANTICANCER RES, V38, P4607, DOI 10.21873/anticanres.12765
   Tu YM, 2022, ONCOGENE, V41, P2597, DOI 10.1038/s41388-022-02275-0
   Tuersuntuoheti A, 2023, BBA-MOL CELL RES, V1870, DOI 10.1016/j.bbamcr.2023.119548
   Ullah S, 2023, MOL DIVERS, V27, P1323, DOI 10.1007/s11030-022-10499-1
   Vamisetti GB, 2019, CHEMBIOCHEM, V20, P282, DOI 10.1002/cbic.201800612
   van der Wal T, 2020, OPEN BIOL, V10, DOI 10.1098/rsob.200267
   Vieyra-Garcia PA, 2021, PHARMACOL THERAPEUT, V222, DOI 10.1016/j.pharmthera.2020.107784
   Vora A, 2006, LANCET, V368, P1339, DOI 10.1016/S0140-6736(06)69558-5
   Wang CL, 2014, CARCINOGENESIS, V35, P1500, DOI 10.1093/carcin/bgu015
   Wang J, 2022, DRUG DELIV, V29, P588, DOI 10.1080/10717544.2022.2036871
   Wang K, 2022, BBA-REV CANCER, V1877, DOI 10.1016/j.bbcan.2022.188723
   Wang SX, 2010, PATHOL INT, V60, P184, DOI 10.1111/j.1440-1827.2010.02496.x
   Wang WD, 2022, ACTA PHARMACOL SIN, V43, P2956, DOI 10.1038/s41401-022-00905-7
   Wang XY, 2020, CELL DEATH DIFFER, V27, P1747, DOI 10.1038/s41418-019-0458-7
   Wei TL, 2016, ONCOTARGET, V7, P48391, DOI 10.18632/oncotarget.10268
   Workman P, 2007, ANN NY ACAD SCI, V1113, P202, DOI 10.1196/annals.1391.012
   Wu BG, 2022, CANCER CELL, V40, P1276, DOI 10.1016/j.ccell.2022.10.020
   Wu CH, 2007, P NATL ACAD SCI USA, V104, P13028, DOI 10.1073/pnas.0701953104
   Wu L, 2021, THERANOSTICS, V11, P700, DOI 10.7150/thno.47800
   Xiao WJ, 2022, AUTOPHAGY, V18, P2615, DOI 10.1080/15548627.2022.2044651
   Xiao ZH, 2021, CANCER CHEMOTH PHARM, V88, P1021, DOI 10.1007/s00280-021-04348-5
   Xie HB, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2119854119
   Xu Q, 2021, J CELL MOL MED, V25, P1001, DOI 10.1111/jcmm.16162
   Yan XH, 2016, J BIOL CHEM, V291, P382, DOI 10.1074/jbc.M115.694281
   Yang H, 2008, CURR PROTEIN PEPT SC, V9, P227, DOI 10.2174/138920308784533998
   Yang Ying, 2007, Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi, V23, P504
   Yi JJ, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-37617-3
   Zhang FW, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101109
   Zhang JR, 2020, CELL DEATH DIFFER, V27, P2710, DOI 10.1038/s41418-020-0538-8
   Zhang L, 2015, J CELL MOL MED, V19, P799, DOI 10.1111/jcmm.12426
   Zhang L, 2016, TOHOKU J EXP MED, V239, P165, DOI 10.1620/tjem.239.165
   Zhang L, 2023, CANCER COMMUN, V43, P123, DOI 10.1002/cac2.12386
   Zhang ZW, 2021, TRANSL LUNG CANCER R, V10, P3995, DOI 10.21037/tlcr-21-767
   Zhao Y, 2018, CELL REP, V22, P2442, DOI 10.1016/j.celrep.2018.02.007
   Zhou F, 2020, MOL MED REP, V22, P1382, DOI 10.3892/mmr.2020.11188
   Zhou JQ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6713-y
   Zhou XY, 2023, LEUKEMIA, V37, P226, DOI 10.1038/s41375-022-01741-8
   Zhou Y, 2023, MOL PLANT, V16, P232, DOI 10.1016/j.molp.2022.11.008
   Zhu HQ, 2017, INT J BIOL SCI, V13, P1489, DOI 10.7150/ijbs.21637
   Zhu LH, 2022, BIOMED RES INT, V2022, DOI 10.1155/2022/1525216
   Zhu M., 2021, BIOSCIENCE REP, V41, pBSR20210486, DOI [10.1042/BSR20210486, DOI 10.1042/BSR20210486]
   Zhu MY, 2022, FASEB J, V36, DOI 10.1096/fj.202101914RR
   Zhu YH, 2020, CELL DEATH DIFFER, V27, P1316, DOI 10.1038/s41418-019-0417-3
   Zhuang D, 2008, ONCOGENE, V27, P6623, DOI 10.1038/onc.2008.258
NR 181
TC 1
Z9 1
U1 3
U2 28
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1021-335X
EI 1791-2431
J9 ONCOL REP
JI Oncol. Rep.
PD OCT
PY 2023
VL 50
IS 4
AR 176
DI 10.3892/or.2023.8613
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA Q4RU6
UT WOS:001057417100001
PM 37594087
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Amirkhah, R
   Farazmand, A
   Irfan-Maqsood, M
   Wolkenhauer, O
   Schmitz, U
AF Amirkhah, R.
   Farazmand, A.
   Irfan-Maqsood, M.
   Wolkenhauer, O.
   Schmitz, U.
TI The role of microRNAs in the resistance to colorectal cancer treatments
SO CELLULAR AND MOLECULAR BIOLOGY
LA English
DT Article
DE Colorectal cancer; MicroRNA; Chemotherapy; Radiotherapy; Biomarker
ID NOTCH SIGNALING PATHWAY; DRUG-RESISTANCE; 5-FLUOROURACIL; APOPTOSIS;
   CELLS; SENSITIVITY; MODULATION; CHEMOSENSITIVITY; OXALIPLATIN;
   EXPRESSION
AB Colorectal cancer (CRC) is one of the leading cancer-related causes of death in the world. Several approaches such as surgery, chemotherapy, radiotherapy, targeted therapy, or combinations thereof have been used to treat CRC patients. However, the fact that many patients develop a drug resistance during the course of the treatment is a major obstacle. Understanding the mechanisms underlying resistance is critical in order to develop more effective targeted treatments. Recently, several studies have reported on the regulatory role of microRNAs (miRNAs) in the response to anti-cancer drugs and suggested them as a source of predictive biomarkers for the purpose of patient stratification and for the prognosis of treatment success. For example, overexpressing miR-34a, a master regulator of tumor suppression attenuates chemoresistance to 5-FU by downregulating silent information regulator 1 (SIRT1) and E2F3. MRX34, a miR-34a replacement is the first synthetic miRNA mimic to enter clinical testing. MiR-34a antagonizes cancer stemness, metastasis, and chemoresistance processes that are necessary for cancer viability. This example shows that miRNAs are coming into focus for the design of enhanced cancer therapies that aim to sensitise tumor cells for anti-cancer drugs. In this review, we provide an overview on the role of miRNAs in the resistance to current colorectal cancer therapies. Furthermore, we discuss the value of miRNAs as biomarkers for predicting chemosensitivity and their potential to enhance treatment strategies.
C1 [Amirkhah, R.; Farazmand, A.] Univ Tehran, Coll Sci, Sch Biol, Dept Cell & Mol Biol, Tehran, Iran.
   [Irfan-Maqsood, M.] Ferdowsi Univ Mashhad, Dept Biol, Fac Sci, Mashhad, Iran.
   [Wolkenhauer, O.; Schmitz, U.] Univ Rostock, Inst Comp Sci, Dept Syst Biol & Bioinformat, D-18055 Rostock, Germany.
   [Wolkenhauer, O.] Univ Stellenbosch, Wallenberg Res Ctr, Stellenbosch Inst Adv Study STIAS, ZA-7600 Stellenbosch, South Africa.
   [Schmitz, U.] Centenary Inst, Gene & Stem Cell Therapy Program, Camperdown, NSW 2050, Australia.
   [Schmitz, U.] Univ Sydney, Sydney Med Sch, Sydney, NSW 2006, Australia.
C3 University of Tehran; Ferdowsi University Mashhad; University of
   Rostock; Stellenbosch University; University of Sydney; Centenary
   Institute; University of Sydney
RP Farazmand, A (corresponding author), Univ Tehran, Fac Sci, Dept Biol, Tehran, Iran.
EM afarazmand@khayam.ut.ac.ir
RI Irfan-Maqsood, Dr. Muhammad/ABA-2788-2022; Schmitz, Ulf/B-5400-2010;
   Irfan-maqsood, Muhammad/K-1842-2013
OI Amirkhah, Raheleh/0000-0003-3494-271X; Schmitz, Ulf/0000-0001-5806-4662;
   Irfan-maqsood, Muhammad/0000-0002-7737-1745
FU Ministry of Science, Research and Technology (MSRT) of Iran; Research
   Council of the University of Tehran
FX This work was supported by the Ministry of Science, Research and
   Technology (MSRT) of Iran; the Research Council of the University of
   Tehran.
CR Ahmadi M, 2015, CELL MOL BIOL, V61, P100
   Akao Y, 2011, CANCER LETT, V300, P197, DOI 10.1016/j.canlet.2010.10.006
   Allen KE, 2010, MOL CANCER THER, V9, P3126, DOI 10.1158/1535-7163.MCT-10-0397
   Alymani NA, 2010, EUR J CANCER, V46, P869, DOI 10.1016/j.ejca.2010.01.001
   Amirkhah R, 2015, GENE CHROMOSOME CANC, V54, P129, DOI 10.1002/gcc.22231
   [Anonymous], MICRORNA CANC REGULA
   [Anonymous], ONCOTARGET
   Attar R, 2015, CELL MOL BIOL, V61, P62
   Borralho PM, 2009, FEBS J, V276, P6689, DOI 10.1111/j.1742-4658.2009.07383.x
   Bushati N, 2007, ANNU REV CELL DEV BI, V23, P175, DOI 10.1146/annurev.cellbio.23.090506.123406
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chong LW, 2015, CELL MOL BIOL, V61, P85
   Czabotar PE, 2009, CELL DEATH DIFFER, V16, P1187, DOI 10.1038/cdd.2009.83
   Deng J, 2014, BIOCHEM BIOPH RES CO, V443, P789, DOI 10.1016/j.bbrc.2013.11.064
   Fang LK, 2014, ONCOTARGET, V5, P2974, DOI 10.18632/oncotarget.1614
   Galbiatti-Dias ALS, 2015, CELL MOL BIOL, V61, P39
   Glavinas Hristos, 2004, Current Drug Delivery, V1, P27, DOI 10.2174/1567201043480036
   Hsu YC, 2015, CELL MOL BIOL, V61, P69
   Jiang QH, 2009, NUCLEIC ACIDS RES, V37, pD98, DOI 10.1093/nar/gkn714
   Karaayvaz M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.193
   Kim SA, 2015, ARCH PHARM RES, V38, P239, DOI 10.1007/s12272-014-0528-9
   Kurkjian C, 2009, AM J THER, V16, P412, DOI 10.1097/MJT.0b013e3181907ed9
   Li J, 2011, MOL CELL BIOCHEM, V357, P31, DOI 10.1007/s11010-011-0872-8
   Li JA, 2011, CANCER LETT, V304, P52, DOI 10.1016/j.canlet.2011.02.003
   Li Y, 2015, CELL MOL BIOL, V61, P2
   Liao Q, 2011, NUCLEIC ACIDS RES, V39, pW118, DOI 10.1093/nar/gkr432
   Limami Y, 2015, CELL MOL BIOL, V61, P33
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   MacDonagh L, 2015, CANCER TREAT REV, V41, P160, DOI 10.1016/j.ctrv.2014.12.009
   Marani M, 2002, MOL CELL BIOL, V22, P3577, DOI 10.1128/MCB.22.11.3577-3589.2002
   Martinez LA, 2010, MOL CELL BIOL, V30, P524, DOI 10.1128/MCB.00938-09
   Masood N, 2015, CELL MOL BIOL, V61, P9
   Migliore C, 2013, TRENDS MOL MED, V19, P633, DOI 10.1016/j.molmed.2013.08.002
   Mlcochova J, 2013, J CANCER RES CLIN, V139, P1615, DOI 10.1007/s00432-013-1470-9
   Musella A, 2015, CELL MOL BIOL, V61, P44
   Nakazawa K, 2014, FEBS J, V281, P2937, DOI 10.1111/febs.12831
   Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1
   Nita ME, 1998, BRIT J CANCER, V78, P986, DOI 10.1038/bjc.1998.617
   Pabla N, 2011, J BIOL CHEM, V286, P10411, DOI 10.1074/jbc.M110.210989
   Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250
   Qian X, 2013, CELL CYCLE, V12, P1385, DOI 10.4161/cc.24477
   Qu J, 2015, J CELL PHYSIOL, V230, P535, DOI 10.1002/jcp.24366
   Smina TP, 2015, CELL MOL BIOL, V61, P92
   Stahlhut C, 2013, GENOME MED, V5, DOI 10.1186/gm516
   Supek F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021800
   Suto T, 2015, CARCINOGENESIS, V36, P338, DOI 10.1093/carcin/bgu242
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   van den Bergh RCN, 2009, CANCER-AM CANCER SOC, V115, P3868, DOI 10.1002/cncr.24446
   Wang Z, 2015, CELL MOL BIOL, V61, P24
   Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001
   Xiong L, 2007, J CELL BIOL, V178, P995, DOI 10.1083/jcb.200703044
   Xu K, 2013, MOL CARCINOGEN, V52, P70, DOI 10.1002/mc.21832
   Xu K, 2012, BIOCHEM J, V446, P291, DOI 10.1042/BJ20120386
   Yamakuchi M, 2008, P NATL ACAD SCI USA, V105, P13421, DOI 10.1073/pnas.0801613105
   Yang XD, 2015, AM J CANCER RES, V5, P545
   Yu HW, 2015, EXPERT OPIN BIOL TH, V15, P923, DOI 10.1517/14712598.2015.1030390
   Zahoor A, 2015, CELL MOL BIOL, V61, P108
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang Y, 2015, J BIOL CHEM, V290, P6215, DOI 10.1074/jbc.M114.620252
   Zhang YQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093917
   Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782
   Zhou YF, 2014, MOL ONCOL, V8, P83, DOI 10.1016/j.molonc.2013.09.004
NR 62
TC 29
Z9 29
U1 0
U2 9
PU C M B  ASSOC
PI POITIERS
PA 34 BOULEVARD SOLFERINO, 86000 POITIERS, FRANCE
SN 0145-5680
EI 1165-158X
J9 CELL MOL BIOL
JI Cell. Mol. Biol.
PY 2015
VL 61
IS 6
BP 17
EP 23
PG 7
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DB4AF
UT WOS:000368454400004
PM 26518892
DA 2025-01-04
ER

PT J
AU Blauz, A
   Rychlik, B
   Plazuk, D
   Peccati, F
   Jiménez-Osés, G
   Steinke, U
   Sierant, M
   Trzeciak, K
   Skorupska, E
   Miksa, B
AF Blauz, Andrzej
   Rychlik, Blazej
   Plazuk, Damian
   Peccati, Francesca
   Jimenez-Oses, Gonzalo
   Steinke, Urszula
   Sierant, Malgorzata
   Trzeciak, Katarzyna
   Skorupska, Ewa
   Miksa, Beata
TI Biotin-phenosafranin as a new photosensitive conjugate for targeted
   therapy and imaging
SO NEW JOURNAL OF CHEMISTRY
LA English
DT Article
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; FALCIPARUM IN-VITRO; CANCER-CELLS;
   MOLECULAR ASPECTS; PAMAM DENDRIMERS; ANTITUMOR AGENTS; PHENAZINIUM DYES;
   DRUG-DELIVERY; AVIDIN; BINDING
AB A biotinylated phenazine compound as a phenosafranin conjugate (Biot-PSF) was synthesized and reported for the first time. The new conjugate was found to be useful as a chemotherapeutic agent with a cancer targeting unit for imaging. We conjugated a molecule recognition moiety with the photosensitive phenosafranin (PSF) to apply the innovative compound in antineoplastic therapy and diagnostics. A new Biot-PSF sensing (bio)probe was established as a biotin-avidin ligand receptor. Thus, Biot-PSF can be an efficient pre-targeting agent for therapeutic and imaging applications. Moreover, the Biot-PSF conjugate exhibits good activity against colorectal carcinoma (HCT116) and adenocarcinoma (COLO 205, SW620) cancer cell lines.
C1 [Blauz, Andrzej; Rychlik, Blazej] Univ Lodz, Fac Biol & Environm Protect, Dept Mol Biophys, Cytometry Lab, Pomorska 141-143, PL-90236 Lodz, Poland.
   [Plazuk, Damian] Univ Lodz, Dept Organ Chem, Fac Chem, Tamka 12, PL-91403 Lodz, Poland.
   [Peccati, Francesca; Jimenez-Oses, Gonzalo] Ctr Cooperat Res Biosci Bizkaia Sci & Technol Pk, CIC bioGUNE, Computat Chem Lab, Bldg 800, Derio Bizkaia 48160, Spain.
   [Steinke, Urszula; Sierant, Malgorzata; Trzeciak, Katarzyna; Skorupska, Ewa; Miksa, Beata] Polish Acad Sci, Ctr Mol & Macromol Studies, Sienkiewicza 112, PL-90363 Lodz, Poland.
C3 University of Lodz; University of Lodz; CIC bioGUNE; Polish Academy of
   Sciences; Centre of Molecular & Macromolecular Studies of the Polish
   Academy of Sciences
RP Miksa, B (corresponding author), Polish Acad Sci, Ctr Mol & Macromol Studies, Sienkiewicza 112, PL-90363 Lodz, Poland.
EM miksa@cbmm.lodz.pl
RI Miksa, Beata/AAT-6924-2021; Rychlik, Blazej/J-3197-2019; Sierant,
   Malgorzata/K-8333-2014; Peccati, Francesca/J-7958-2017; Jimenez-Oses,
   Gonzalo/B-8057-2014; Blauz, Andrzej/T-8347-2018
OI Sierant, Malgorzata/0000-0002-4655-1882; Rychlik,
   Blazej/0000-0001-8928-5900; Trzeciak, Katarzyna/0000-0002-8810-3703;
   Peccati, Francesca/0000-0002-7813-8216; , Steinke/0000-0003-1637-662X;
   Jimenez-Oses, Gonzalo/0000-0003-0105-4337; Plazuk,
   Damian/0000-0002-2898-6604; Blauz, Andrzej/0000-0002-8037-0268; Miksa,
   Beata/0000-0003-1288-4125
FU Centre of Molecular and Macromolecular Studies, Polish Academy of
   Science; National Science Centre of Poland, Poland
   [UMO-2016/23/B/NZ1/02316]
FX This work was supported by statutory funds of the Centre of Molecular
   and Macromolecular Studies, Polish Academy of Science and by the
   National Science Centre of Poland, Poland [UMO-2016/23/B/NZ1/02316].
CR Abken HJ, 1998, J BACTERIOL, V180, P2027, DOI 10.1128/JB.180.8.2027-2032.1998
   Babak MV, 2015, CHEM-EUR J, V21, P5110, DOI 10.1002/chem.201403974
   Balan V, 2012, J NANOPART RES, V14, DOI 10.1007/s11051-012-0730-y
   BARBUCCI R, 1991, BIOPOLYMERS, V31, P827, DOI 10.1002/bip.360310703
   Barth A, 2007, BBA-BIOENERGETICS, V1767, P1073, DOI 10.1016/j.bbabio.2007.06.004
   Biancalana L, 2020, EUR J INORG CHEM, V2020, P1061, DOI 10.1002/ejic.201900922
   Bilal M, 2017, WORLD J MICROB BIOT, V33, DOI 10.1007/s11274-017-2356-9
   Bolognese A, 2006, J MED CHEM, V49, P5110, DOI 10.1021/jm050745l
   Borgolia M.F., 2006, J PHOTOCH PHOTOBIO A, V180, P143
   BRADBURY JH, 1979, J MAGN RESON, V35, P217, DOI 10.1016/0022-2364(79)90230-0
   Broglia MF, 2005, J PHOTOCH PHOTOBIO A, V173, P115, DOI 10.1016/j.jphotochem.2005.01.010
   Broglia MF, 2005, J PHOTOCH PHOTOBIO A, V170, P261, DOI 10.1016/j.jphotochem.2004.08.017
   Celej MS, 2004, BIOCHEM BIOPH RES CO, V325, P922, DOI 10.1016/j.bbrc.2004.10.118
   CHAIET L, 1964, ARCH BIOCHEM BIOPHYS, V106, P1, DOI 10.1016/0003-9861(64)90150-X
   Chen SY, 2010, BIOCONJUGATE CHEM, V21, P979, DOI 10.1021/bc9005656
   Ciric-Marjanovic G, 2007, J PHYS CHEM B, V111, P2188, DOI 10.1021/jp067407w
   Danielson S.J., 1993, European PatENT, Patent No. [93201432.8, 932014328]
   Das S, 2008, J MOL STRUCT, V872, P56, DOI 10.1016/j.molstruc.2007.02.016
   de Andrade-Neto VF, 2004, BIOORG MED CHEM LETT, V14, P1145, DOI 10.1016/j.bmcl.2003.12.069
   de Souza NB, 2014, MEM I OSWALDO CRUZ, V109, P546, DOI 10.1590/0074-0276130603
   DIAMANDIS EP, 1991, CLIN CHEM, V37, P625
   do Nascimento GM, 2010, J PHOTOCH PHOTOBIO A, V211, P99, DOI 10.1016/j.jphotochem.2010.01.019
   Duan XX, 2012, NAT NANOTECHNOL, V7, P401, DOI [10.1038/nnano.2012.82, 10.1038/NNANO.2012.82]
   Dutta RK, 1996, COLLOID SURFACE A, V106, P127, DOI 10.1016/0927-7757(95)03374-2
   Emami M, 2008, SPECTROCHIM ACTA A, V71, P1516, DOI 10.1016/j.saa.2008.05.020
   Emoto T, 2000, TETRAHEDRON LETT, V41, P355, DOI 10.1016/S0040-4039(99)02061-4
   Fahrer J, 2010, BIOCONJUGATE CHEM, V21, P130, DOI 10.1021/bc900365b
   Fischer BB, 2004, ENVIRON SCI TECHNOL, V38, P6307, DOI 10.1021/es049673y
   Frey BL, 1996, ANAL CHEM, V68, P3187, DOI 10.1021/ac9605861
   Goldenberg DM, 2006, J CLIN ONCOL, V24, P823, DOI 10.1200/JCO.2005.03.8471
   GOPIDAS KR, 1990, J PHYS CHEM-US, V94, P4723, DOI 10.1021/j100374a064
   GOPIDAS KR, 1989, J PHOTOCH PHOTOBIO A, V48, P291, DOI 10.1016/1010-6030(89)87010-8
   Green N M, 1975, Adv Protein Chem, V29, P85, DOI 10.1016/S0065-3233(08)60411-8
   GREEN NM, 1966, BIOCHEM J, V101, P774, DOI 10.1042/bj1010774
   Haddour N, 2004, CHEM COMMUN, P324, DOI 10.1039/b311566f
   HASSAN HM, 1980, J BACTERIOL, V141, P156, DOI 10.1128/JB.141.1.156-163.1980
   He QY, 2015, RSC ADV, V5, P38571, DOI 10.1039/c5ra07185b
   Hernandez ME, 2004, APPL ENVIRON MICROB, V70, P921, DOI 10.1128/AEM.70.2.921-928.2004
   Hussain H, 2011, J MED CHEM, V54, P4913, DOI 10.1021/jm200302d
   Iqbal M, 2010, IEEE J SEL TOP QUANT, V16, P654, DOI 10.1109/JSTQE.2009.2032510
   Jain A, 2017, J CONTROL RELEASE, V245, P27, DOI 10.1016/j.jconrel.2016.11.016
   Kada G, 1999, BBA-GEN SUBJECTS, V1427, P44, DOI 10.1016/S0304-4165(98)00177-9
   Kassis AI, 1996, J NUCL MED, V37, P343
   Kawahara S, 1998, Kekkaku, V73, P77
   KNOWLES JR, 1989, ANNU REV BIOCHEM, V58, P195, DOI 10.1146/annurev.bi.58.070189.001211
   Laitinen OH, 2006, CELL MOL LIFE SCI, V63, P2992, DOI 10.1007/s00018-006-6288-z
   Laitinen OH, 2007, TRENDS BIOTECHNOL, V25, P269, DOI 10.1016/j.tibtech.2007.04.001
   Lapin NA, 2009, J PHYS CHEM B, V113, P8776, DOI 10.1021/jp809096m
   Laursen JB, 2004, CHEM REV, V104, P1663, DOI 10.1021/cr020473j
   Lee MH, 2015, ACCOUNTS CHEM RES, V48, P2935, DOI 10.1021/acs.accounts.5b00406
   Lee YH, 2016, CHEM COMMUN, V52, P11247, DOI 10.1039/c6cc06158c
   LIN HJ, 1977, ANAL BIOCHEM, V81, P442, DOI 10.1016/0003-2697(77)90715-1
   LIVNAH O, 1993, P NATL ACAD SCI USA, V90, P5076, DOI 10.1073/pnas.90.11.5076
   Look DC, 2005, J IMMUNOL, V175, P4017, DOI 10.4049/jimmunol.175.6.4017
   Makgatho ME, 2000, DRUG DEVELOP RES, V50, P195, DOI 10.1002/1098-2299(200006)50:2<195::AID-DDR10>3.0.CO;2-T
   MARSHALL D, 1995, BRIT J CANCER, V71, P18, DOI 10.1038/bjc.1995.5
   Martin H, 2008, ANAL BIOCHEM, V381, P107, DOI 10.1016/j.ab.2008.06.025
   MCCORMICK DB, 1970, ANAL BIOCHEM, V34, P226, DOI 10.1016/0003-2697(70)90102-8
   Mentel M, 2009, CHEMBIOCHEM, V10, P2295, DOI 10.1002/cbic.200900323
   METHCOHN O, 1994, J CHEM SOC PERK T 1, P5, DOI 10.1039/p19940000005
   Miksa B, 2017, COLLOID SURFACE B, V159, P820, DOI 10.1016/j.colsurfb.2017.08.045
   MIWA H, 1985, J CHROMATOGR, V321, P165, DOI 10.1016/S0021-9673(01)90433-9
   NATARAJAN P, 1988, J MACROMOL SCI CHEM, VA25, P1285, DOI 10.1080/00222338808053422
   Nelson D, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/789069
   Neves-Pinto C, 2002, J MED CHEM, V45, P2112, DOI 10.1021/jm010377v
   Nojiri S, 1998, J PHARMACEUT BIOMED, V16, P1357, DOI 10.1016/S0731-7085(97)00157-X
   Nordlund HR, 2005, J BIOL CHEM, V280, P13250, DOI 10.1074/jbc.M414336200
   Ochoa-Ruiz E, 2015, MOL GENET METAB, V116, P204, DOI 10.1016/j.ymgme.2015.08.009
   OConnor R, 1995, DRUG METAB REV, V27, P591, DOI 10.3109/03602539508994208
   Pardridge WM, 2007, ADV DRUG DELIVER REV, V59, P141, DOI 10.1016/j.addr.2007.03.008
   Pardridge WM, 2006, CURR OPIN PHARMACOL, V6, P494, DOI 10.1016/j.coph.2006.06.001
   Pardridge WM, 2002, NAT REV DRUG DISCOV, V1, P131, DOI 10.1038/nrd725
   Pei H, 2011, CHEM COMMUN, V47, P6254, DOI 10.1039/c1cc11660f
   Pérez-Luna VH, 1999, J AM CHEM SOC, V121, P6469, DOI 10.1021/ja983984p
   Peters R, 2004, J CHROMATOGR A, V1031, P35, DOI 10.1016/j.chroma.2003.10.100
   Pierson LS, 2010, APPL MICROBIOL BIOT, V86, P1659, DOI 10.1007/s00253-010-2509-3
   Plazuk D, 2013, ORGANOMETALLICS, V32, P5774, DOI 10.1021/om4003126
   Plazuk D, 2011, ORG BIOMOL CHEM, V9, P408, DOI 10.1039/c0ob00319k
   Price-Whelan A, 2006, NAT CHEM BIOL, V2, P71, DOI 10.1038/nchembio764
   Proevska LI, 1998, DYES PIGMENTS, V36, P177, DOI 10.1016/S0143-7208(97)00011-9
   Reddy VM, 1999, J ANTIMICROB CHEMOTH, V43, P615, DOI 10.1093/jac/43.5.615
   REICHARDT C, 1994, CHEM REV, V94, P2319, DOI 10.1021/cr00032a005
   REWCASTLE GW, 1987, J MED CHEM, V30, P843, DOI 10.1021/jm00388a017
   Rozga-Wijas K, 2019, DYES PIGMENTS, V161, P261, DOI 10.1016/j.dyepig.2018.09.067
   Russell-Jones G, 2004, J INORG BIOCHEM, V98, P1625, DOI 10.1016/j.jinorgbio.2004.07.009
   Said HM, 2009, J NUTR, V139, P158, DOI 10.3945/jn.108.092023
   Sarkar D, 2008, J PHYS CHEM B, V112, P9243, DOI 10.1021/jp801659d
   SCHECHTER B, 1991, INT J CANCER, V48, P167, DOI 10.1002/ijc.2910480203
   Sedel F, 2016, NEUROPHARMACOLOGY, V110, P644, DOI 10.1016/j.neuropharm.2015.08.028
   Sett R, 2018, ACS OMEGA, V3, P1374, DOI 10.1021/acsomega.7b01820
   Shafiqul D.-M, 1999, PHYS CHEM CHEM PHYS, V1, P3737
   Silva TMBE, 2011, LETT ORG CHEM, V8, P752
   Song XD, 2001, ANAL CHIM ACTA, V442, P79, DOI 10.1016/S0003-2670(01)01128-X
   Spicer JA, 2000, J MED CHEM, V43, P1350, DOI 10.1021/jm990423f
   STEIN J, 1992, ANAL BIOCHEM, V200, P89, DOI 10.1016/0003-2697(92)90281-B
   Struthers L, 1998, ANAL BIOCHEM, V255, P20, DOI 10.1006/abio.1997.2354
   Sun Q, 2014, CHEM COMMUN, V50, P8518, DOI 10.1039/c4cc03315a
   Swamy MJ, 1996, BIOPHYS J, V71, P840, DOI 10.1016/S0006-3495(96)79285-8
   Tanaka K, 2012, BIOORGAN MED CHEM, V20, P1865, DOI 10.1016/j.bmc.2011.12.043
   Tripodo G., 2014, Med. Chem., VS1-004, P1, DOI [10.4172/2161-0444.S1-004, DOI 10.4172/2161-0444.S1-004]
   Uchida Y, 2015, J NEUROCHEM, V134, P97, DOI 10.1111/jnc.13092
   Vadlapudi AD, 2012, CURR DRUG TARGETS, V13, P994
   Valiokas R, 1999, LANGMUIR, V15, P3390, DOI 10.1021/la981647o
   Verdoliva A, 2010, J BIOL CHEM, V285, P9090, DOI 10.1074/jbc.M109.080457
   Veremeenko EG, 2010, MICROBIOLOGY+, V79, P439, DOI 10.1134/S0026261710040041
   Walash M I, 2008, Int J Biomed Sci, V4, P238
   Wang H, 2009, MOL PHARMACEUT, V6, P285, DOI 10.1021/mp800185h
   Wang WY, 2000, BIOORG MED CHEM LETT, V10, P1151, DOI 10.1016/S0960-894X(00)00217-1
   WEBER PC, 1989, SCIENCE, V243, P85, DOI 10.1126/science.2911722
   Yang WJ, 2009, EUR J MED CHEM, V44, P862, DOI 10.1016/j.ejmech.2008.04.021
   Yellepeddi VK, 2011, ANTICANCER RES, V31, P897
   Yellepeddi VK, 2009, ANTICANCER RES, V29, P2933
   Yomota C, 2007, J CHROMATOGR A, V1142, P231, DOI 10.1016/j.chroma.2006.12.058
   YOSHIDA T, 1988, J CHROMATOGR, V456, P421, DOI 10.1016/0021-9673(86)80042-5
   Zhang GM, 2005, J PHOTOCH PHOTOBIO A, V169, P153, DOI 10.1016/j.jphotochem.2004.06.016
NR 115
TC 6
Z9 6
U1 0
U2 27
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
SN 1144-0546
EI 1369-9261
J9 NEW J CHEM
JI New J. Chem.
PD JUN 7
PY 2021
VL 45
IS 21
BP 9691
EP 9702
DI 10.1039/d0nj06170k
EA MAY 2021
PG 12
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Chemistry
GA SL1MT
UT WOS:000650317100001
DA 2025-01-04
ER

PT J
AU Proske, A
   Bossen, J
   von Frieling, J
   Roeder, T
AF Proske, Alina
   Bossen, Judith
   von Frieling, Jakob
   Roeder, Thomas
TI Low-protein diet applied as part of combination therapy or stand-alone
   normalizes lifespan and tumor proliferation in a model of intestinal
   cancer
SO AGING-US
LA English
DT Article
DE dietary protein restriction; afatinib; EGFR; Drosophila; stem cells;
   cancer
ID GROWTH-FACTOR RECEPTOR; FACTOR-I RECEPTOR; COLORECTAL-CANCER; ANTICANCER
   ACTIVITY; COLON-CANCER; PHASE-II; RESTRICTION; EXPRESSION; DROSOPHILA;
   CALORIE
AB Tumors of the intestinal tract are among the most common tumor diseases in humans, but, like many other tumor entities, show an unsatisfactory prognosis with a need for effective therapies. To test whether nutritional interventions and a combination with a targeted therapy can effectively cure these cancers, we used the fruit fly Drosophila as a model. In this system, we induced tumors by EGFR overexpression in intestinal stem cells. Limiting the amount of protein in the diet restored life span to that of control animals. In combination with a specific EGFR inhibitor, all major tumor-associated phenotypes could be rescued. This form of treatment was also successful in a real treatment scenario, which means when they started after the full tumor phenotype was expressed. In conclusion, reduced protein administration can be a very promising form of adjuvant cancer therapy.
C1 [Proske, Alina; Bossen, Judith; von Frieling, Jakob; Roeder, Thomas] Univ Kiel, Zool Inst, Dept Mol Physiol, Kiel, Germany.
   [Bossen, Judith; Roeder, Thomas] German Ctr Lung Res DZL, Airway Res Ctr North ARCN, Kiel, Germany.
C3 University of Kiel
RP Roeder, T (corresponding author), Univ Kiel, Zool Inst, Dept Mol Physiol, Kiel, Germany.; Roeder, T (corresponding author), German Ctr Lung Res DZL, Airway Res Ctr North ARCN, Kiel, Germany.
EM troeder@zoologie.uni-kiel.de
RI Roeder, Thomas/B-9016-2011
OI Von Frieling, Jakob/0009-0004-4428-9333
FU DFG [CRC 1182]; BMBF; Jurgen Manchot Foundation
FX This research was funded by the DFG (CRC 1182, Project C2) , the BMBF
   (Project: DroLuCa2, Alternativen zum Tierexperiment) and supported by
   the Jurgen Manchot Foundation.
CR Antonello ZA, 2015, EMBO J, V34, P2025, DOI 10.15252/embj.201591517
   Arends J, 2017, CLIN NUTR, V36, P11, DOI 10.1016/j.clnu.2016.07.015
   Arnold M, 2020, GASTROENTEROLOGY, V159, P335, DOI 10.1053/j.gastro.2020.02.068
   Bangi E, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aav6528
   Bangi E, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13615
   Baracos VE, 2018, NAT REV DIS PRIMERS, V4, DOI 10.1038/nrdp.2017.105
   Bauersfeld SP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4353-2
   Bianchi G, 2015, ONCOTARGET, V6, P11806, DOI 10.18632/oncotarget.3688
   Bossen J, 2019, MOL CANCER THER, V18, P1659, DOI 10.1158/1535-7163.MCT-19-0168
   BRAND AH, 1993, DEVELOPMENT, V118, P401
   Brückl W, 2017, EXPERT REV ANTICANC, V17, P143, DOI 10.1080/14737140.2017.1266265
   Caffa I, 2015, ONCOTARGET, V6, P11820, DOI 10.18632/oncotarget.3689
   D'Aronzo M, 2015, ONCOTARGET, V6, P18545, DOI 10.18632/oncotarget.4186
   de Groot S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1663-5
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   Dorff TB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2370-6
   Durando X, 2010, ONCOLOGY-BASEL, V78, P205, DOI 10.1159/000313700
   Eitan E, 2017, AGING CELL, V16, P1430, DOI 10.1111/acel.12657
   Fearon KCH, 2008, EUR J CANCER, V44, P1124, DOI 10.1016/j.ejca.2008.02.033
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fine EJ, 2012, NUTRITION, V28, P1028, DOI 10.1016/j.nut.2012.05.001
   Fontana L, 2008, AGING CELL, V7, P681, DOI 10.1111/j.1474-9726.2008.00417.x
   Fontana L, 2015, CELL, V161, P106, DOI 10.1016/j.cell.2015.02.020
   Fontana L, 2013, ONCOTARGET, V4, P2451, DOI 10.18632/oncotarget.1586
   Fontana L, 2006, AM J CLIN NUTR, V84, P1456, DOI 10.1093/ajcn/84.6.1456
   Ganapathy-Kanniappan S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-152
   Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3
   Goldstein NS, 2001, CANCER, V92, P1331, DOI 10.1002/1097-0142(20010901)92:5<1331::AID-CNCR1455>3.0.CO;2-M
   GOSEKI N, 1995, JPN J CANCER RES, V86, P484, DOI 10.1111/j.1349-7006.1995.tb03082.x
   Haselton A, 2010, CELL CYCLE, V9, P3063, DOI 10.4161/cc.9.15.12458
   Hens JR, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2367-1
   Hildebrandt A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023796
   Inamura K, 2018, CANCERS, V10, DOI 10.3390/cancers10010026
   Jouinot A, 2020, CLIN NUTR, V39, P1893, DOI 10.1016/j.clnu.2019.08.003
   Kang JS, 2020, NUTR METAB, V17, DOI 10.1186/s12986-020-00439-x
   Kapahi P, 2017, AGEING RES REV, V39, P3, DOI 10.1016/j.arr.2016.12.005
   Krasinskas Alyssa M, 2011, Patholog Res Int, V2011, P932932, DOI 10.4061/2011/932932
   Krittika S, 2019, BIOGERONTOLOGY, V20, P723, DOI 10.1007/s10522-019-09827-0
   Lamming DW, 2015, ONCOTARGET, V6, P31233, DOI 10.18632/oncotarget.5180
   Lee C, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003293
   Lee CH, 2010, CANCER RES, V70, P1564, DOI 10.1158/0008-5472.CAN-09-3228
   Levine ME, 2014, CELL METAB, V19, P407, DOI 10.1016/j.cmet.2014.02.006
   Lo Re O, 2018, J CELL PHYSIOL, V233, P1202, DOI 10.1002/jcp.25987
   Lowman XH, 2019, CELL REP, V26, P3051, DOI 10.1016/j.celrep.2019.02.037
   Markman B, 2010, ADV CLIN CHEM, V51, P71, DOI 10.1016/S0065-2423(10)51004-7
   Markstein M, 2014, P NATL ACAD SCI USA, V111, P4530, DOI 10.1073/pnas.1401160111
   McGuire Sean E, 2004, Sci STKE, V2004, ppl6, DOI 10.1126/stke.2202004pl6
   McKay JA, 2002, EUR J CANCER, V38, P2258, DOI 10.1016/S0959-8049(02)00234-4
   Nakagawa S, 2012, AGING CELL, V11, P401, DOI 10.1111/j.1474-9726.2012.00798.x
   Orillion A, 2018, CLIN CANCER RES, V24, P6383, DOI 10.1158/1078-0432.CCR-18-0980
   Pathria G, 2021, CELL METAB, V33, P9, DOI 10.1016/j.cmet.2020.12.009
   Piper MDW, 2017, CELL METAB, V25, P1206, DOI 10.1016/j.cmet.2017.04.020
   Qi HW, 2011, EXP THER MED, V2, P1091, DOI 10.3892/etm.2011.324
   Raffaghello L, 2008, P NATL ACAD SCI USA, V105, P8215, DOI 10.1073/pnas.0708100105
   Ramalingam SS, 2011, J CLIN ONCOL, V29, P4574, DOI 10.1200/JCO.2011.36.6799
   Renehan AG, 2008, LANCET, V371, P569, DOI 10.1016/S0140-6736(08)60269-X
   Resnick MB, 2004, CLIN CANCER RES, V10, P3069, DOI 10.1158/1078-0432.CCR-03-0462
   Romey-Glüsing R, 2018, FASEB J, V32, P1993, DOI 10.1096/fj.201700934R
   Saavedra P, 2019, ADV EXP MED BIOL, V1167, P191, DOI 10.1007/978-3-030-23629-8_11
   Safdie F, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044603
   Safdie FM, 2009, AGING-US, V1, P988, DOI 10.18632/aging.100114
   Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057
   Steck SE, 2020, NAT REV CANCER, V20, P125, DOI 10.1038/s41568-019-0227-4
   Thivat E, 2009, ANTICANCER RES, V29, P5235
   Tinkum KL, 2015, P NATL ACAD SCI USA, V112, pE7148, DOI 10.1073/pnas.1509249112
   Tong WM, 1998, BRIT J CANCER, V77, P1792, DOI 10.1038/bjc.1998.298
   von Frieling J, 2020, IUBMB LIFE, V72, P814, DOI 10.1002/iub.2224
   Wang R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18442-4
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yu DY, 2019, CELL REP, V29, P236, DOI 10.1016/j.celrep.2019.08.084
   Zisman AL, 2006, ARCH INTERN MED, V166, P629, DOI 10.1001/archinte.166.6.629
NR 71
TC 6
Z9 6
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD NOV 15
PY 2021
VL 13
IS 21
BP 24017
EP 24036
PG 20
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA WZ6IB
UT WOS:000720067200008
PM 34766923
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Zheng, ZG
   Ma, BQ
   Xiao, Y
   Wang, TX
   Yu, T
   Huo, YH
   Wang, QQ
   Shan, MJ
   Meng, LB
   Han, J
AF Zheng, Zhi Gang
   Ma, Bao Qing
   Xiao, Yu
   Wang, Tian Xi
   Yu, Tian
   Huo, Yu Hu
   Wang, Qing Qing
   Shan, Meng Jie
   Meng, Ling Bing
   Han, Jing
TI Identification of biomarkers for the diagnosis and treatment of primary
   colorectal cancer based on microarray technology
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Primary colorectal cancer (PCRC); differentially expressed genes; gene
   set enrichment analysis (GSEA); hub genes
AB Background: Primary colorectal cancer (PCRC) is one of the most common malignant tumors in clinic, and is characterized by high heterogeneity occurring between tumors and intracellularly. Therefore, this study aimed to explore potential gene targets for the diagnosis and treatment of PCRC via bioinformatic technology.
   Methods: Gene Expression Omnibus (GEO) was used to download the data used in this study. Differently expressed genes (DEGs) were identified with GEO2R, and the gene set enrichment analysis (GSEA) was implemented for enrichment analysis. Then, the researchers constructed a protein-protein interaction (PPI) network, a significant module, and a hub genes network.
   Results: The GSE81558 dataset was downloaded, and a total of 97 DEGs were found. There were 23 upregulated DEGs and 74 down-regulated DEGs in the PCRC samples, compared with the control group. The PPI network included a total of 42 nodes and 63 edges. One module network consisted of 11 nodes and 25 edges. Another module network consisted of 4 nodes and 6 edges. The hub genes network was created by cytoHubba using GCG, GUCA2B, CLCA4, ZG16, TMIGD1, GUCA2A, CHGA, PYY, SST, and MS4A12.
   Conclusions: Ten hub genes were found from the genomic samples of patients with PCRC and normal controls by bioinformatics analysis. The hub genes might provide novel ideas and evidence for the diagnosis and targeted therapy of PCRC.
C1 [Zheng, Zhi Gang] First Hosp Shijiazhuang, Gen Surg Dept, Ward 1, Shijiazhuang 050011, Hebei, Peoples R China.
   [Ma, Bao Qing] Dezhou Peoples Hosp, Dept Gastrointestinal Surg, Dezhou 253000, Peoples R China.
   [Xiao, Yu] Peking Univ, Sch Basic Med, Beijing 100191, Peoples R China.
   [Wang, Tian Xi] Hebei Univ Technol, Sch Artificial Intelligence, Tianjin 300401, Peoples R China.
   [Yu, Tian] Beijing Hosp, Natl Ctr Gerontol, Dept Surg, Beijing 100730, Peoples R China.
   [Huo, Yu Hu] Tongji Univ, Shanghai Peoples Hosp 10, Sch Med, Dept Breast & Thyroid Surg, Shanghai 200072, Peoples R China.
   [Wang, Qing Qing] Tianjin Med Univ, Canc Inst & Hosp, Dept Biotherapy, Tianjin 300060, Peoples R China.
   [Shan, Meng Jie] Chinese Acad Med Sci & Peking Union Med Coll, Grad Sch, Beijing 100730, Peoples R China.
   [Meng, Ling Bing] Beijing Hosp, Natl Ctr Gerontol, Neurol Dept, Beijing 100730, Peoples R China.
   [Han, Jing] Hebei Med Univ, Hosp 4, Dept Med Oncol, 12 Jiankang Rd, Shijiazhuang 050000, Hebei, Peoples R China.
C3 Peking University; Hebei University of Technology; Beijing Hospital;
   Tongji University; Tianjin Medical University; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College; Beijing Hospital; Hebei Medical University
RP Han, J (corresponding author), Hebei Med Univ, Hosp 4, Dept Med Oncol, 12 Jiankang Rd, Shijiazhuang 050000, Hebei, Peoples R China.
EM hanjing15696@163.com
RI Wang, Qingqing/KPA-9705-2024; wang, wang/GWQ-7272-2022
CR [Anonymous], COMB CHEM HIGH THROU
   [Anonymous], BIOMED RES INT
   [Anonymous], ONCOTARGET
   [Anonymous], J CELL PHYSL
   Carbon S, 2019, NUCLEIC ACIDS RES, V47, pD330, DOI 10.1093/nar/gky1055
   Cattaneo E, 2011, EMBO MOL MED, V3, P334, DOI 10.1002/emmm.201100141
   Clancy C, 2014, ANN SURG ONCOL, V21, P3900, DOI 10.1245/s10434-014-3805-4
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Díaz-Tasende J, 2018, REV ESP ENFERM DIG, V110, P681, DOI 10.17235/reed.2018.5870/2018
   Donovan MG, 2017, FRONT NUTR, V4, DOI 10.3389/fnut.2017.00059
   Falzone L, 2018, AGING-US, V10, P1000, DOI 10.18632/aging.101444
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Iyer SV, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13561
   Kim SM, 2018, FOOD CHEM TOXICOL, V121, P657, DOI 10.1016/j.fct.2018.09.023
   Liu CL, 2019, WORLD ALLERGY ORGAN, V12, DOI 10.1016/j.waojou.2019.100077
   Mura CV, 2017, BMC NEUROSCI, V18, DOI 10.1186/s12868-017-0379-7
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Wang ZC, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12846
   Yan L, 2018, AGING-US, V10, P3774, DOI 10.18632/aging.101671
   Yang GD, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01207
   Zhao YZ, 2016, J AM STAT ASSOC, V111, P1427, DOI 10.1080/01621459.2016.1164051
NR 21
TC 2
Z9 2
U1 0
U2 5
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD MAY
PY 2020
VL 9
IS 5
BP 3453
EP 3467
DI 10.21037/tcr-19-2290
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LU8TA
UT WOS:000538020100031
PM 35117711
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Spitzer, E
   Cervera, P
   André, T
   Cohen, R
AF Spitzer, Eleonore
   Cervera, Pascale
   Andre, Thierry
   Cohen, Romain
TI Targeting<i> HER2</i> in colorectal cancer
SO BULLETIN DU CANCER
LA English
DT Article
DE Colorectal cancer; HER2; Trastuzumab; Targeted therapy
ID CONSENSUS MOLECULAR SUBTYPES; CIRCULATING TUMOR DNA; OPEN-LABEL;
   TRASTUZUMAB; OVEREXPRESSION; AMPLIFICATION; CHEMOTHERAPY; IRINOTECAN;
   THERAPY; PICCOLO
AB Among the molecular subgroups of interest in metastatic colorectal cancer (mCRC), innovations are underway for tumors with overexpression of HER2 (Human Epidermal Growth Factor Receptor 2). Overexpression of the HER2 protein concerns 2 to 5% of CRC at any stage mainly located in the distal colon and rectum. Diagnosis is based on immunohistochemistry, in situ hybridization with appropriate criteria for colorectal localization, and molecular biology (NGS: next-generation sequencing). Overexpression of HER2 is a predictive factor for resistance to treatments targeting EGFR which are indicated in the case where the tumor is wild-type RAS. It seems to be associated with a poor prognosis of mCRC with a higher risk of brain metastasis. Regarding treatments targeting HER2, no randomized controlled phase III has been published to date. However, several combinations have been evaluated in phase II with clinically meaningful objective response rates: trastuzumab-deruxtecan (45%), trastuzumab-tucatinib (46%), trastuzumab-pyrotinib (45%), trastuzumab-pertuzumab (30%) ou trastuzumab-lapatinib (30%). In this literature review, we present here the current state of knowledge on the diagnostic methods of HER2 overexpression in CRC, the main clinical, molecular and prognostic characteristics, and the efficacy results of the different therapeutic combinations for the patients with HER2 overexpressed mCRC. This justifies, despite the lack of marketing authorization in France and in Europe for agents targeting HER2 in CRC, the systematic evaluation of the HER2 status, as recommended in particular by the NCCN (National Comprehensive Cancer Network).
C1 [Spitzer, Eleonore; Andre, Thierry; Cohen, Romain] Paris Sorbonne Univ, St Antoine Hosp, AP HP, Equipe Instabilite Microsatellites & Canc,Unite M, 184 Rue Faubourg St Antoine, F-75012 Paris, France.
   [Cervera, Pascale] Sorbonne Univ, Hop St Antoine, AP HP, Serv Anat & Cytol Pathol,Equipe Instabilite Micro, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; Hopital
   Universitaire Saint-Antoine - APHP; Assistance Publique Hopitaux Paris
   (APHP); Sorbonne Universite; Hopital Universitaire Saint-Antoine - APHP
RP Cohen, R (corresponding author), Paris Sorbonne Univ, St Antoine Hosp, AP HP, Equipe Instabilite Microsatellites & Canc,Unite M, 184 Rue Faubourg St Antoine, F-75012 Paris, France.
EM romain.cohen@aphp.fr
RI André, Thierry/N-8830-2017; Cohen, Romain/AAC-9089-2019
OI Cohen, Romain/0000-0001-9602-5162
CR [Anonymous], COL CANC VERS 2 2021
   Benedix F, 2010, DIS COLON RECTUM, V53, P57, DOI 10.1007/DCR.0b013e3181c703a4
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bray F, 2018, CA-CANCER J CLIN, V68, P394, DOI 10.3322/caac.21492
   Conradi LC, 2013, AM J SURG PATHOL, V37, P522, DOI 10.1097/PAS.0b013e318272ff4d
   Franchet C, 2021, ANN PATHOL, V41, P507, DOI 10.1016/j.annpat.2021.07.014
   Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gupta R, 2022, JCO PRECIS ONCOL, V6, DOI [10.1200/PO.22.00306, DOI 10.1200/PO.22.00306]
   Gupta R, 2020, J CLIN ONCOL, V38
   Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Hu XC, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.1024
   Kavanagh DO, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-1
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Klus Pharma Inc, 2022, PHAS 1 2 FIH STUD A1
   Lee WS, 2014, CANCER MED-US, V3, P674, DOI 10.1002/cam4.228
   Li JL, 2019, BMC CLIN PATHOL, V19, DOI 10.1186/s12907-019-0085-8
   Li WH, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.097
   Martini G, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920936089
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Merker JD, 2018, J CLIN ONCOL, V36, P1631, DOI 10.1200/JCO.2017.76.8671
   Morano F, 2019, J CLIN ONCOL, V37, P3099, DOI 10.1200/JCO.19.01254
   Müller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3
   Nakamura Y., 2017, Ann Oncol, V28, pV207, DOI [10.1093/annonc/mdx393.137, DOI 10.1093/ANNONC/MDX393.137]
   nature, Nature Medicine
   ncbi.nlm.nih, ASS HER2 SCOR SYST C
   ncbi.nlm.nih, ACT ERBB2 SIGN CAUS
   ncbi.nlm.nih, HUM EP GROWTH FACT R
   ncbi.nlm.nih, NT HARM PROV DIAGN C
   ncbi.nlm.nih, DET ERBB2 AMPL NEXT
   ncbi.nlm.nih, CLIN CHAR HER2 POS M
   ncbi-nlm-nih, DOES OV HER 2 CORR C
   Okamoto W, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3555
   Pant S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.TPS352
   Pietrantonio F, 2019, JAMA ONCOL, V5, P1268, DOI 10.1001/jamaoncol.2019.1467
   Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863
   Raghav K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00226
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Rebersek M, 2020, RADIOL ONCOL, V54, P272, DOI 10.2478/raon-2020-0031
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Ros J, 2021, CURR TREAT OPTION ON, V22, DOI 10.1007/s11864-021-00913-5
   Rüschoff J, 2010, VIRCHOWS ARCH, V457, P299, DOI 10.1007/s00428-010-0952-2
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2020, JAMA ONCOL, V6, P927, DOI 10.1001/jamaoncol.2020.0571
   Sartore-Bianchi A, 2019, ONCOLOGIST, V24, P1395, DOI 10.1634/theoncologist.2018-0785
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sawada K, 2018, CLIN COLORECTAL CANC, V17, P198, DOI 10.1016/j.clcc.2018.05.006
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Seo S, 2019, GASTRIC CANCER, V22, P527, DOI 10.1007/s10120-018-0891-1
   Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Shan LN, 2018, J CANCER RES CLIN, V144, P2275, DOI 10.1007/s00432-018-2744-z
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Siravegna G, 2019, CLIN CANCER RES, V25, P3046, DOI 10.1158/1078-0432.CCR-18-3389
   Strickler JH, 2021, ANN ONCOL, V32, pS554, DOI 10.1016/j.annonc.2021.08.960
   Strickler JH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.TPS153
   Sveen A, 2018, CLIN CANCER RES, V24, P794, DOI 10.1158/1078-0432.CCR-17-1234
   Takegawa N, 2016, ONCOTARGET, V7, P3443, DOI 10.18632/oncotarget.6498
   Tosi F, 2020, CLIN COLORECTAL CANC, V19, P256, DOI 10.1016/j.clcc.2020.06.009
   Yagisawa M, 2021, CLIN COLORECTAL CANC, V20, P113, DOI 10.1016/j.clcc.2020.11.002
   Zymeworks Inc, 2022, PHAS 1 TRIAL ZW25 PA
   Zymeworks Inc, 2022, PHAS 2 STUD ZW25 PLU
NR 63
TC 2
Z9 2
U1 2
U2 9
PU ELSEVIER MASSON, CORP OFF
PI PARIS
PA 65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE
SN 0007-4551
EI 1769-6917
J9 B CANCER
JI Bull. Cancer
PD APR
PY 2023
VL 110
IS 4
BP 402
EP 411
DI 10.1016/j.bulcan.2023.01.013
EA MAR 2023
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA C8HV8
UT WOS:000964273500001
PM 36870811
OA Bronze
DA 2025-01-04
ER

PT J
AU Liu, SX
   Jin, J
AF Liu, Shixin
   Jin, Jing
TI Radiotherapy guidelines for rectal cancer in China (2020 Edition)
SO PRECISION RADIATION ONCOLOGY
LA English
DT Article
DE guidelines; radiotherapy; rectal cancer
ID NONPOLYPOSIS COLORECTAL-CANCER; PREOPERATIVE CHEMORADIOTHERAPY;
   RADIATION-THERAPY; POOLED ANALYSIS; CAPECITABINE; CHEMOTHERAPY;
   MULTICENTER; OXALIPLATIN; MRI; CHEMORADIATION
AB Rectal cancer is one of the most common malignant tumors. In China, rectal cancer has been the third most frequently diagnosed cancer and the fifth leading cause of cancer death, with changes of residents' lifestyle factors and diets. The best treatment for rectal cancer depends on many factors. Multidisciplinary Treatment has become the basis for improving the therapeutic effect, in which radiology is increasingly necessary for treating patients with rectal cancer. For patients who have extensive, fixed, bulky tumors or obvious nodal disease, radiotherapy and chemotherapy combined with surgery has emerged as the standard of care. For patients with metastatic disease, the reasonable combination of local and systemic therapy might be an alternative. Improvements in imaging, pathological diagnosis and radiation techniques provide a solid foundation for promoting the level of clinical practice in rectal cancer. High-quality magnetic resonance imaging distinguishing risk stratification, molecular markers predicting therapeutic effect and prognosis, magnetic resonance imaging in delineating target volumes drawn, intensity-modulated radiation therapy, and image-guides radiation therapy for precision treatment delivery are all being widely applied in multiple centers. Furthermore, as the role of targeted therapy and immune therapy has become increasingly prominent, the attempt of combined radiotherapy is also ongoing. In view of the characteristics and current situation of diagnosis and treatment of rectal cancer in China, the guidelines will present the basis and reference for combined treatment and standardized treatments. Meanwhile, there may be continuous new advances in clinical practice, and that will be a new basis to update the guidelines, directly benefiting all rectal cancer patients and facilitating discipline developments.
C1 [Liu, Shixin; Jin, Jing] Chinese Med Assoc, Radiat Oncol Soc, Beijing, Peoples R China.
   [Liu, Shixin; Jin, Jing] Anticanc Assoc China, Canc Radiotherapy Comm, Beijing, Peoples R China.
RP Liu, SX (corresponding author), Jilin Canc Hosp, Dept Radiat Oncol, Changchun 130012, Jilin, Peoples R China.
EM liushixin1964@sina.com; jinjing@csco.org.cn
CR Afshari K, 2019, SURG ONCOL, V29, P102, DOI 10.1016/j.suronc.2019.04.005
   Al-Haidari G, 2020, ACTA ONCOL, V59, P534, DOI 10.1080/0284186X.2020.1725111
   [Anonymous], NCCN CLIN PRACTICE G
   Appelt AL, 2016, CURR OPIN ONCOL, V28, P353, DOI 10.1097/CCO.0000000000000306
   Appelt AL, 2015, LANCET ONCOL, V16, P919, DOI 10.1016/S1470-2045(15)00120-5
   Battersby NJ, 2016, ANN SURG, V263, P751, DOI 10.1097/SLA.0000000000001193
   Beets-Tan RGH, 2018, EUR RADIOL, V28, P1465, DOI 10.1007/s00330-017-5026-2
   Cella L, 2009, MED DOSIM, V34, P75, DOI 10.1016/j.meddos.2008.04.001
   Cercek A, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0071
   Choi SH, 2018, J MAGN RESON IMAGING, V47, P1237, DOI 10.1002/jmri.25852
   D'Souza N, 2019, ANN SURG, V270, P955, DOI 10.1097/SLA.0000000000003251
   Daza JE, 2019, EJSO-EUR J SURG ONC, V45, P1341, DOI 10.1016/j.ejso.2019.03.025
   DELEON MP, 1993, CANCER, V71, P3493, DOI 10.1002/1097-0142(19930601)71:11<3493::AID-CNCR2820711106>3.0.CO;2-H
   Deng YH, 2019, J CLIN ONCOL, V37, P3223, DOI 10.1200/JCO.18.02309
   Detering R, 2019, EJSO-EUR J SURG ONC, V45, P2059, DOI 10.1016/j.ejso.2019.06.016
   Diagnosis and Treatment Guidelines for Colorectal Cancer Working Group (CSOCOC, 2019, Chin J Cancer Res, V31, P117
   Dizdarevic E, 2020, INT J RADIAT ONCOL, V106, P556, DOI 10.1016/j.ijrobp.2019.10.046
   Downing A, 2015, J CLIN ONCOL, V33, P616, DOI 10.1200/JCO.2014.56.6539
   Fernandez-Martos C, 2015, ANN ONCOL, V26, P1722, DOI 10.1093/annonc/mdv223
   Gao YH, 2014, INT J RADIAT ONCOL, V90, P1153, DOI 10.1016/j.ijrobp.2014.07.021
   Garcia-Aguilar J, 2015, LANCET ONCOL, V16, P957, DOI 10.1016/S1470-2045(15)00004-2
   Glynne-Jones R, 2017, ANN ONCOL, V28, P22, DOI 10.1093/annonc/mdx224
   Gray R, 2001, LANCET, V358, P1291
   Hagemans JAW, 2020, EJSO-EUR J SURG ONC, V46, P448, DOI 10.1016/j.ejso.2019.10.037
   Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z
   Hofheinz RD, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70116-X
   Holyoake DLP, 2019, RADIOTHER ONCOL, V138, P38, DOI 10.1016/j.radonc.2019.05.001
   Jadon R, 2019, RADIAT ONCOL, V14, DOI 10.1186/s13014-019-1262-8
   Jianming Yin., 2001, Chin J Integr Tradit West Med, V21, P304
   Kanai T, 2019, PHYS MEDICA, V57, P160, DOI 10.1016/j.ejmp.2018.12.013
   Keller DS, 2020, NAT REV GASTRO HEPAT, V17, P414, DOI 10.1038/s41575-020-0275-y
   Kim TH, 2005, INT J RADIAT ONCOL, V62, P769, DOI 10.1016/j.ijrobp.2004.11.015
   Kok END, 2020, BRIT J SURG, V107, P537, DOI 10.1002/bjs.11418
   Lai HW, 2019, POSTGRAD MED, V131, P163, DOI 10.1080/00325481.2019.1568016
   Lanciano R, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00023
   Lefevre JH, 2016, J CLIN ONCOL, V34, P3773, DOI 10.1200/JCO.2016.67.6049
   Liu WY, 2021, J GERIATR ONCOL, V12, P572, DOI 10.1016/j.jgo.2020.10.016
   Liu ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103910
   Lu XG, 2019, BIOSCI TRENDS, V13, P182, DOI 10.5582/bst.2019.01044
   LYNCH HT, 1993, GASTROENTEROLOGY, V104, P1535, DOI 10.1016/0016-5085(93)90368-M
   Marks LB, 2010, INT J RADIAT ONCOL, V76, pS1, DOI 10.1016/j.ijrobp.2009.08.075
   McCormack S, 2005, MED PHYS, V32, P483, DOI 10.1118/1.1852792
   Nagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975
   National Health Commission of the People's Republic of China, 2020, Zhonghua Wai Ke Za Zhi, V58, P561, DOI 10.3760/cma.j.cn112139-20200518-00390
   Ngan SY, 2012, J CLIN ONCOL, V30, P3827, DOI 10.1200/JCO.2012.42.9597
   Nilsson PJ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-279
   Nogué M, 2011, ONCOLOGIST, V16, P614, DOI 10.1634/theoncologist.2010-0285
   O'Connell E, 2020, COLORECTAL DIS, V22, P1076, DOI 10.1111/codi.15015
   O'Connell MJ, 2014, J CLIN ONCOL, V32, P1927, DOI 10.1200/JCO.2013.53.7753
   O'Neill BDP, 2009, BRIT J RADIOL, V82, P509, DOI 10.1259/bjr/60198873
   Pappalardo G, 2017, ANN ITAL CHIR, V88, P183
   Petrelli F, 2016, ANN SURG, V263, P458, DOI 10.1097/SLA.0000000000000368
   Rödel C, 2015, LANCET ONCOL, V16, P979, DOI 10.1016/S1470-2045(15)00159-X
   Sauer R, 2003, Colorectal Dis, V5, P406
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Schmoll HJ, 2021, J CLIN ONCOL, V39, P17, DOI 10.1200/JCO.20.01740
   Sclafani F, 2016, ANN ONCOL, V27, P1557, DOI 10.1093/annonc/mdw215
   Sclafani F, 2017, BRIT J CANCER, V117, P1478, DOI 10.1038/bjc.2017.320
   Seo N, 2019, KOREAN J RADIOL, V20, P1003, DOI 10.3348/kjr.2018.0611
   Shu Zhang., 2018, J Pract Oncol, V33, P102
   Tao Wang., 2019, Shandong Med, V59, P38
   van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X
   Vieillot S, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-92
   Wenshuang Zou., 2015, J Mod Integr Tradit Chin West Med, V24, P2311
   Westberg K, 2018, EJSO-EUR J SURG ONC, V44, P100, DOI 10.1016/j.ejso.2017.11.013
   yuan Tang., 2018, Chin J Radiat Oncol, V27, P227
   Yurgelun MB, 2017, J CLIN ONCOL, V35, P1086, DOI 10.1200/JCO.2016.71.0012
   Zaborowski A, 2019, BRIT J SURG, V106, P979, DOI 10.1002/bjs.11171
   Zhao J, 2016, INT J RADIAT ONCOL, V95, P1357, DOI 10.1016/j.ijrobp.2016.03.024
NR 69
TC 5
Z9 5
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2398-7324
J9 PRECIS RADIAT ONCOL
JI Precis. Radiat. Oncol.
PD MAR
PY 2022
VL 6
IS 1
BP 4
EP 31
DI 10.1002/pro6.1141
PG 28
WC Radiology, Nuclear Medicine & Medical Imaging
WE Emerging Sources Citation Index (ESCI)
SC Radiology, Nuclear Medicine & Medical Imaging
GA I7R9L
UT WOS:001332204400001
OA gold
DA 2025-01-04
ER

PT J
AU Patel, A
   Gulhati, P
AF Patel, Aakash
   Gulhati, Pat
TI Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
SO CANCERS
LA English
DT Review
DE colorectal cancer; targeted therapy; immunotherapy; next generation
   sequencing; young-onset colorectal cancer
ID POSITIVE SOLID TUMORS; OPEN-LABEL; MICROSATELLITE INSTABILITY; SUBGROUP
   ANALYSES; PLUS CETUXIMAB; FUSION GENE; HUMAN COLON; MULTICENTER;
   BEVACIZUMAB; MECHANISMS
AB Simple Summary Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. Genetic alterations promote cancer development and its spread to distant sites. Medications that counteract the effects of these alterations/mutations, called targeted therapies, are used to treat CRC. Immunotherapy, another class of medications that promotes immune system mediated recognition and destruction of cancer cells, is used for treatment of a small subset of CRC patients. Here we review the current state of knowledge and ongoing research into biomarkers, targeted therapy, and immunotherapy for CRC treatment.Abstract Colorectal cancer (CRC) is the second leading cause of cancer deaths worldwide. Although the overall incidence of CRC is decreasing, the incidence of young-onset CRC, characterized by a diagnosis of CRC before age 50, is increasing. Outcomes for CRC patients are improving, partly due to comprehensive molecular characterization of tumors and novel therapeutic strategies. Advances in genomic and transcriptomic analyses using blood- and tumor-tissue-based sequencing have facilitated identification of distinct tumor subtypes harboring unique biological characteristics and therapeutic vulnerabilities. These insights have led to the development and incorporation of targeted therapies and immunotherapy in CRC treatment. In this review, we discuss the molecular landscape and key oncogenes/tumor suppressors contributing to CRC tumorigenesis, metastasis, and therapeutic resistance. We also discuss personalized therapeutic strategies for subsets of CRC patients and provide an overview of evolving novel treatments being evaluated in clinical trials.
C1 [Patel, Aakash; Gulhati, Pat] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Div Med Oncol, New Brunswick, NJ 08901 USA.
   [Patel, Aakash; Gulhati, Pat] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers Cancer Institute of New Jersey
RP Gulhati, P (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Div Med Oncol, New Brunswick, NJ 08901 USA.; Gulhati, P (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.
EM pat.gulhati@rutgers.edu
OI Gulhati, Pat/0000-0003-2625-313X
FU Elsa Pardee Foundation
FX No Statement Available
CR Ahcene Djaballah Selma, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_351354
   Akimoto N, 2021, NAT REV CLIN ONCOL, V18, P230, DOI 10.1038/s41571-020-00445-1
   Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187
   André F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   [Anonymous], 2022, ONCOTARGETS THER, V15, P747, DOI 10.2147/OTT.S340392
   [Anonymous], Encorafenib, Cetuximab, and Nivolumab in Treating Patients with Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
   [Anonymous], Toripalimab Plus Bevacizumab and Chemotherapy as Neoadjuvant Therapy in Advanced MSI-H or dMMR Colorectal Cancer
   [Anonymous], A Study of Tucatinib with Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-Line HER2+ Metastatic Colorectal Cancer-Full Text View-ClinicalTrials.gov
   [Anonymous], Evaluation of RMC-6236 in Subjects with Advanced Solid Tumors Harboring Specific Mutations in KRAS
   [Anonymous], Evaluation of Co-Formulated Pembrolizumab/Quavonlimab (MK-1308A) Versus Other Treatments in Participants with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Cancer (CRC) (MK-1308A-008)
   [Anonymous], Study of MK-3475 in Patients with Microsatellite Unstable (MSI) Tumors (Cohorts A, B and C)
   [Anonymous], A Study of Encorafenib Plus Cetuximab Taken Together with Pembrolizumab Compared to Pembrolizumab Alone in People with Previously Untreated Metastatic Colorectal Cancer-Full Text View-ClinicalTrials.gov
   [Anonymous], Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive Metastatic Colorectal Cancer in Molecularly Selected Patients, 3T Study
   [Anonymous], RC48 Plus Tislelizumab, Low-Dose Capecitabine and Celecoxib for HER2-Positive Metastatic Colorectal Cancer-Full Text View-ClinicalTrials.gov
   [Anonymous], 2023, NCCN CLIN PRACTICE G
   [Anonymous], Neoadjuvant Encorafenib, Binimetinib and Cetuximab for Patients with BRAF V600E Mutated/pMMR Localized Colorectal Cancer-Full Text View-ClinicalTrials.gov
   [Anonymous], Safety and Efficacy Study of TAK-700 in Patients With Nonmetastatic Castration-resistant Prostate Cancer and a Rising Prostate-specific Antigen
   [Anonymous], Study of Onvansertib in Combination with FOLFIRI and Bevacizumab Versus FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer in Participants with a Kirsten Rat Sarcoma Virus Gene (KRAS) or Neuroblastoma-RAS (NRAS) Mutation
   [Anonymous], Tolerability and Safety of HF1K16 Injection in Patients with Refractory Solid Tumors
   [Anonymous], have to speak of its mutation or second concretion: Panofsky has dem
   [Anonymous], Study of Encorafenib + Cetuximab Plus or Minus Binimetinib vs. Irinotecan/Cetuximab or Infusional 5-Fluorouracil(5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab with a Safety Lead-in of Encorafenib + Binimetinib + Cetuximab in Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer-Full Text View-ClinicalTrials.gov
   [Anonymous], RC48-ADC Combined with Bevacizumab in HER2-Positive Advanced Colorectal Cancer
   [Anonymous], Envafolimab as Neoadjuvant Immunotherapy in Resectable Locally Advanced dMMR/MSI-H Colorectal Cancer
   [Anonymous], A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects with MSI-H/dMMR Metastatic Colorectal Cancer
   [Anonymous], To Evaluate IAH0968 in Combination with CAPEOX in HER2-Positive Metastatic Colorectal Cancer
   [Anonymous], Study of Covalent Menin Inhibitor BMF-219 in Adult Patients with KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
   [Anonymous], Study of Tislelizumab Combined with DisitamabVedotin and Pyrotinib Maleate in HER2-Positive or Mutated Advanced Colorectal Cancer Who Failed Standard Therapy
   [Anonymous], Phase 3 Study of MRTX849 with Cetuximab vs Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation (KRYSTAL-10)
   [Anonymous], Study of MRTX1133 in Patients with Advanced Solid Tumors Harboring a KRAS G12D Mutation
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Bhakat KK, 2022, DNA REPAIR, V109, DOI 10.1016/j.dnarep.2021.103246
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Cann CG, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1176950
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Carmeliet P, 2005, ONCOLOGY-BASEL, V69, P4, DOI 10.1159/000088478
   Cecchini M, 2022, J CLIN ONCOL, V40
   Center for Drug Evaluation Research, FDA Approves Larotrectinib for Solid Tumors with NTRK Gene Fusions
   Center for Drug Evaluation Research, FDA Grants Nivolumab Accelerated Approval for MSI-H or dMMR Colorectal Cancer
   Center for Drug Evaluation Research, FDA Grants Accelerated Approval to Ipilimumab for MSI-H or dMMR Metastatic Colorectal Cancer
   Cercek A, 2022, NEW ENGL J MED, V386, P2363, DOI 10.1056/NEJMoa2201445
   Chakravarty D, 2022, J CLIN ONCOL, V40, P1231, DOI 10.1200/JCO.21.02767
   Chalabi M, 2022, ANN ONCOL, V33, pS1389, DOI 10.1016/j.annonc.2022.08.016
   Chu JE, 2020, CLIN CANCER RES, V26, P4599, DOI 10.1158/1078-0432.CCR-20-1024
   Ciombor KK, 2022, J CLIN ONCOL, V40, P2706, DOI 10.1200/JCO.21.02541
   Ciombor KK, 2023, J CLIN ONCOL, V41, P139
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Dasari A, 2023, LANCET, V402, P41, DOI 10.1016/S0140-6736(23)00772-9
   De' Angelis Gian Luigi, 2018, Acta Biomed, V89, P97, DOI 10.23750/abm.v89i9-S.7960
   Doebele RC, 2020, LANCET ONCOL, V21, P271, DOI 10.1016/S1470-2045(19)30691-6
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448
   Eng C, 2022, LANCET ONCOL, V23, pE116, DOI 10.1016/S1470-2045(21)00588-X
   Fakih MG, 2022, LANCET ONCOL, V23, P115, DOI 10.1016/S1470-2045(21)00605-7
   FDA, Approves Entrectinib for NTRK Solid Tumors and ROS-1 NSCLC
   FDA, Approves Selpercatinib for Locally Advanced or Metastatic RET Fusion-Positive Solid Tumors
   Fishel R, 2015, J BIOL CHEM, V290, P26395, DOI 10.1074/jbc.R115.660142
   Garcia H, 2013, CELL REP, V4, P159, DOI 10.1016/j.celrep.2013.06.013
   Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017
   Gasparian AV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002530
   Goel G, 2018, CANCER MANAG RES, V10, P425, DOI 10.2147/CMAR.S88825
   Goey KKH, 2017, ANN ONCOL, V28, P2128, DOI 10.1093/annonc/mdx322
   Grassi E, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.601722
   Grothey A, 2021, ANN ONCOL, V32, P959, DOI 10.1016/j.annonc.2021.03.206
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gupta R, 2020, J CLIN ONCOL, V38
   Heinemann V, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3591
   Holch JW, 2017, EUR J CANCER, V70, P87, DOI 10.1016/j.ejca.2016.10.007
   Holowatyj AN, 2020, GASTROENTEROLOGY, V158, P1155, DOI 10.1053/j.gastro.2019.11.012
   Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239
   Hosseini SAK, 2020, J CLIN ONCOL, V38
   Hsiao SY, 2021, CASE REP ONCOL, V14, P232, DOI 10.1159/000511069
   Hua HJ, 2023, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.974793
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hussung S, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.160
   Jardim DL, 2021, CANCER CELL, V39, P154, DOI 10.1016/j.ccell.2020.10.001
   Jin ZH, 2022, J CLIN ONCOL, V40, P2735, DOI 10.1200/JCO.21.02691
   Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3706, DOI 10.1200/JCO.2005.00.232
   Kapiteijn E, 2001, J PATHOL, V195, P171, DOI 10.1002/path.918
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Koopman M, 2009, BRIT J CANCER, V100, P266, DOI 10.1038/sj.bjc.6604867
   Kopetz S, 2022, ANN ONCOL, V33, pS681, DOI 10.1016/j.annonc.2022.07.454
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2023, J CLIN ONCOL, V41, P119
   Kopetz S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.TPS3619
   Lange AM, 2018, CANCERS, V10, DOI 10.3390/cancers10040105
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lietman Caressa D, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_351333
   Lin C, 2015, CANCER BIOL THER, V16, P1019, DOI 10.1080/15384047.2015.1046649
   Liu C, 2021, CLIN CANCER RES, V27, P342, DOI 10.1158/1078-0432.CCR-20-2718
   Lou K, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9450
   Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942
   Lundqvist E, 2022, SURG ONCOL, V41, DOI 10.1016/j.suronc.2022.101741
   Malla M, 2022, J CLIN ONCOL, V40, P2846, DOI 10.1200/JCO.21.02615
   Mauri G, 2019, MOL ONCOL, V13, P109, DOI 10.1002/1878-0261.12417
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Molina-Arcas M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw7999
   Morimoto Y, 2023, CANCER LETT, V559, DOI 10.1016/j.canlet.2023.216116
   Nagasaka M, 2023, TRANSL ONCOL, V36, DOI 10.1016/j.tranon.2023.101744
   Nakamura Y, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1063-5
   Office of the Commissioner, FDA Approves First Cancer Treatment for Any Solid Tumor with a Specific Genetic Feature
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Parikh A, 2021, CLIN CANCER RES, V27, P5586, DOI [DOI 10.1158/1078-0432.CCR-21-0410, 10.1158/1078-0432.CCR-21-0410]
   Parseghian CM, 2023, J CLIN ONCOL, V41, P460, DOI 10.1200/JCO.22.01423
   Pearlman R, 2017, JAMA ONCOL, V3, P464, DOI 10.1001/jamaoncol.2016.5194
   Pelka K, 2021, CELL, V184, P4734, DOI 10.1016/j.cell.2021.08.003
   Pietrantonio F, 2018, ANN ONCOL, V29, P1394, DOI 10.1093/annonc/mdy090
   Ratti M, 2021, EXPERT OPIN THER TAR, V25, P677, DOI 10.1080/14728222.2021.1978070
   Roeflands J, 2023, NAT MED, V29, P1273, DOI 10.1038/s41591-023-02324-5
   Sabari JK, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.TPS146
   Sahin Ibrahim Halil, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_349811
   Sartore-Bianchi A, 2022, NAT MED, V28, P1612, DOI 10.1038/s41591-022-01886-0
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI 10.3322/caac.21763
   Siena S., 2016, Ann. Oncol, V27, piv39, DOI [10.1093/annonc/mdw335.01, DOI 10.1093/ANNONC/MDW335.01]
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Sigismund S, 2018, MOL ONCOL, V12, P3, DOI 10.1002/1878-0261.12155
   Sinicrope FA, 2022, NEW ENGL J MED, V386, P1547, DOI 10.1056/NEJMra2200869
   Sinicrope FA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e15169
   Sinicrope FA, 2018, NEW ENGL J MED, V379, P764, DOI 10.1056/NEJMcp1714533
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Song HY, 2020, MOL CANCER THER, V19, P258, DOI 10.1158/1535-7163.MCT-19-0600
   Sotorasib and Panitumumab Versus Investigator's Choice for Participants with Kirsten Rat Sarcoma (KRAS), G12C Mutation-Full Text View-ClinicalTrials.gov
   Strickler JH, 2023, LANCET ONCOL, V24, P496, DOI 10.1016/S1470-2045(23)00150-X
   Subbiah V, 2022, LANCET ONCOL, V23, P1261, DOI 10.1016/S1470-2045(22)00541-1
   Sullivan BG, 2023, ANN SURG ONCOL, V30, P278, DOI 10.1245/s10434-022-12399-y
   Sullivan RJ, 2018, CANCER DISCOV, V8, P184, DOI 10.1158/2159-8290.CD-17-1119
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Suwaidan AA, 2022, CANCER TREAT REV, V105, DOI 10.1016/j.ctrv.2022.102363
   Tabernero Josep, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_349561
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272
   Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797
   ten Hoorn S, 2022, JNCI-J NATL CANCER I, V114, P503, DOI 10.1093/jnci/djab106
   Thein KZ, 2021, TRENDS CANCER, V7, P1074, DOI 10.1016/j.trecan.2021.07.003
   Vasaikar S, 2019, CELL, V177, P1035, DOI 10.1016/j.cell.2019.03.030
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Vernieri C, 2019, CRIT REV ONCOL HEMAT, V139, P53, DOI 10.1016/j.critrevonc.2019.05.001
   Verschoor YL, 2022, J CLIN ONCOL, V40
   Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923
   Wang H, 2022, CANCER MED-US, V11, P2541, DOI 10.1002/cam4.4561
   Yaeger R, 2023, NEW ENGL J MED, V388, P44, DOI 10.1056/NEJMoa2212419
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Yoshikawa A, 2023, CANCERS, V15, DOI 10.3390/cancers15010183
   Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438
   Zheng G, 2019, HUM PATHOL, V86, P12, DOI 10.1016/j.humpath.2018.11.014
   Zhu GM, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01441-4
NR 152
TC 1
Z9 1
U1 3
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD APR
PY 2024
VL 16
IS 8
AR 1551
DI 10.3390/cancers16081551
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QI3A3
UT WOS:001220195900001
PM 38672633
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Thangaraju, P
   Singh, H
   Chakrabarti, A
AF Thangaraju, P.
   Singh, H.
   Chakrabarti, A.
TI Regorafenib: A novel tyrosine kinase inhibitor: A brief review of its
   therapeutic potential in the treatment of metastatic colorectal
   carcinoma and advanced gastrointestinal stromal tumors
SO INDIAN JOURNAL OF CANCER
LA English
DT Review
DE Colorectal carcinoma; gastrointestinal stromal tumor; regorafenib;
   targeted therapy control
ID BAY 73-4506; PHASE-I; BEVACIZUMAB; SPECTRUM; IMATINIB; KIT
AB Regorafenib is a novel oral multitargeted tyrosine kinase inhibitor having both antitumor and anti-angiogenic activities. Regorafenib was recently approved by US Food and Drug Administration in February 25, 2013 in the treatment for patients with advanced gastrointestinal stromal tumor and for the treatment of patients with metastatic colorectal carcinoma after disease progression or intolerance to imatinib mesylate and sunitinib therapy. Oral regorafenib demonstrates a high level of efficacy with acceptable tolerability with the 160 mg daily for 3 weeks followed by 1 week off schedule; a continuous schedule could be of interest. Hypertension, mucositis, hand foot skin reaction, diarrhea and asthenia are the most common side-effects. Regardless of these encouraging results, studies investigating, adjuvant and neoadjuvant settings are awaited, as well as trials using regorafenib in combination with chemotherapy or other targeted therapies. Clinical trials investigating regorafenib in other tumor types are ongoing.
C1 [Thangaraju, P.; Singh, H.; Chakrabarti, A.] PGIMER, Dept Pharmacol, Chandigarh, India.
C3 Post Graduate Institute of Medical Education & Research (PGIMER),
   Chandigarh
RP Singh, H (corresponding author), PGIMER, Dept Pharmacol, Chandigarh, India.
EM harman_gmcp@yahoo.com
RI Singh, Harmanjit/AAF-5763-2020; , PUGAZHENTHAN/A-4707-2019
OI Singh, Harmanjit/0000-0002-4521-3443; , PUGAZHENTHAN/0000-0002-4090-2004
CR Ahmad T, 2004, CLIN CANCER RES, V10, p6388S, DOI 10.1158/1078-0432.CCR-040028
   [Anonymous], ASCO M ABSTR S
   [Anonymous], J CLIN ONCOL
   Christensen O, 2010, ANN ONCOL S8, V21, P619
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
   Eisen T, 2009, J CLIN ONCOL, V27, P5033
   Hedbom S, 2007, J CLIN ONCOL, V25
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kang HJ, 2006, PROTEOMICS, V6, P1151, DOI 10.1002/pmic.200500372
   Kerbel R, 2002, NAT REV CANCER, V2, P727, DOI 10.1038/nrc905
   Medeiros F, 2004, AM J SURG PATHOL, V28, P889, DOI 10.1097/00000478-200407000-00007
   Melichar B, 2005, INTERNAL MED, V44, P1163, DOI 10.2169/internalmedicine.44.1163
   Miettinen M, 2000, MODERN PATHOL, V13, P1134, DOI 10.1038/modpathol.3880210
   Mross K, 2012, CLIN CANCER RES, V18, P2658, DOI 10.1158/1078-0432.CCR-11-1900
   Mross K, 2008, J CLIN ONCOL, V26, P5511, DOI 10.1200/JCO.2008.16.1547
   Rajendra R, 2013, FUTURE ONCOL, V9, P193, DOI [10.2217/fon.12.178, 10.2217/FON.12.178]
   Schultheis B, 2011, J CLIN ONCOL, V29, P3585
   Shimizu T, 2010, J CLIN ONCOL, V28, P3035, DOI DOI 10.1200/jco.2010.28.15_suppl.3035
   Strumberg D, 2012, BRIT J CANCER, V106, P1722, DOI 10.1038/bjc.2012.153
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
NR 22
TC 8
Z9 10
U1 0
U2 2
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, 400059, INDIA
SN 0019-509X
EI 1998-4774
J9 INDIAN J CANCER
JI Indian J. Cancer
PD JUL-SEP
PY 2015
VL 52
IS 3
BP 257
EP U312
DI 10.4103/0019-509X.176690
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DF8TH
UT WOS:000371631600001
PM 26905101
DA 2025-01-04
ER

PT J
AU Liu, FR
   Ren, C
   Jin, Y
   Xi, SY
   He, CY
   Wang, F
   Wang, ZX
   Xu, RH
   Wang, F
AF Liu, Furong
   Ren, Chao
   Jin, Ying
   Xi, Shaoyan
   He, Caiyun
   Wang, Fang
   Wang, Zixian
   Xu, Rui-hua
   Wang, Feng
TI Assessment of two different HER2 scoring systems and clinical relevance
   for colorectal cancer
SO VIRCHOWS ARCHIV
LA English
DT Article
DE HER2; Colorectal cancer; Methodology; Prognosis
ID BREAST-CANCER; SURVIVAL; EXPRESSION; OVEREXPRESSION; AMPLIFICATION;
   ASSOCIATION; DISEASE; BENEFIT; ERBB2; STAGE
AB Although the positivity of human epidermal growth factor receptor 2 (HER2) is low in colorectal cancer (CRC), anti-HER2 is becoming a new target therapy in metastatic colorectal cancer (mCRC). However, assessment of the HER2 scoring system was still not established in CRC. The purpose of our study was to evaluate HER2 status and its correlation with clinicopathological characteristics and survival according to the HER2 diagnostic criteria for gastroesophageal adenocarcinoma (GEA criteria) and the HERACLES diagnostic criteria (HERACLES criteria) in a large cohort of Chinese CRC patients. The HER2 positivity was 2.9% (43/1490) and 2.6% (39/1490) in CRCs based on the GEA criteria and the HERACLES criteria, and 3.7% (9/243) in mCRC according to both criteria. HER2 status was associated with primary tumor location (P = 0.037), regional lymph node metastasis (P = 0.035), and TNM stage (P = 0.022) in CRCs based on the HERACLES criteria. No such association was found based on the GEA criteria. Furthermore, HER2 positive only presented in patients with RAS gene wild type (P = 0.001). Significant difference was only observed between the HER2-positive and HER2-negative groups in terms of disease-free survival for stage II-III CRCs (P = 0.048) according to the HERACLES criteria, but not based on the GEA criteria. Our findings suggest that the frequency of HER2 overexpression or amplification was low in Chinese CRC patients, and provide a rationale for further evaluation of HER2 in CRC based on the HERACLES criteria and the HER2 diagnostic criteria for gastroesophageal adenocarcinoma.
C1 [Liu, Furong; Ren, Chao; Jin, Ying; Xi, Shaoyan; He, Caiyun; Wang, Fang; Wang, Zixian; Xu, Rui-hua; Wang, Feng] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
   [Liu, Furong; Ren, Chao; Jin, Ying; Wang, Zixian; Xu, Rui-hua; Wang, Feng] Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
   [Xi, Shaoyan] Sun Yat Sen Univ, Dept Pathol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
   [He, Caiyun; Wang, Fang] Sun Yat Sen Univ, Dept Mol Diagnost, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
C3 Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen
   University; Sun Yat Sen University; Sun Yat Sen University
RP Wang, F (corresponding author), Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.; Wang, F (corresponding author), Sun Yat Sen Univ, Dept Med Oncol, Canc Ctr, 651 Dongfeng Rd East, Guangzhou 510060, Guangdong, Peoples R China.
EM wangfeng@sysucc.org.cn
RI REN, CHAO/KRO-9616-2024; Xu, Rui-Hua/AAW-4766-2021
OI Xu, Rui-Hua/0000-0001-9771-8534; Wang, Feng/0000-0001-7668-9674; , REN
   CHAO/0009-0006-5629-9947
FU National Key Research and Development Program of China [2017YFC1308900];
   National Natural Science Foundation of China [81872011]; Sun Yat-sen
   University Clinical Research 5010 Program [2018014]; Guangzhou Health
   andMedical Collaborative Innovation Project [201704020220]
FX This study was funded by, in part, by the National Key Research and
   Development Program of China (2017YFC1308900), National Natural Science
   Foundation of China (81872011), and the Sun Yat-sen University Clinical
   Research 5010 Program (2018014), Guangzhou Health andMedical
   Collaborative Innovation Project (201704020220). Feng Wang is the Young
   Physician Scientist Program of Sun Yat-sen University Cancer Center.
CR Arnold D, 2010, GUT, V59, P838, DOI 10.1136/gut.2009.196006
   Bang YJ, 2010, LANCET, V376, P1302
   Barros-Silva JD, 2009, BRIT J CANCER, V100, P487, DOI 10.1038/sj.bjc.6604885
   Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836
   Blok EJ, 2013, CLIN MED INSIGHTS-ON, V7, P41, DOI 10.4137/CMO.S10811
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Chen WQ, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.04.05
   Conradi LC, 2013, AM J SURG PATHOL, V37, P522, DOI 10.1097/PAS.0b013e318272ff4d
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3
   Karaca H, 2012, ASIAN PAC J CANCER P, V13, P6221, DOI 10.7314/APJCP.2012.13.12.6221
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Lee WS, 2014, CANCER MED-US, V3, P674, DOI 10.1002/cam4.228
   Leufkens AM, 2011, SCAND J GASTROENTERO, V46, P887, DOI 10.3109/00365521.2011.574732
   Li QG, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-277
   McKay JA, 2002, BRIT J CANCER, V86, P568, DOI 10.1038/sj.bjc.6600127
   Mendelsohn J, 2006, SEMIN ONCOL, V33, P369, DOI 10.1053/j.seminoncol.2006.04.003
   Mendes D, 2015, BREAST CANCER RES, V17, DOI 10.1186/s13058-015-0648-2
   Park JS, 2018, VIRCHOWS ARCH, V473, P413, DOI 10.1007/s00428-018-2409-y
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Shabbir A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2912-y
   Shi Q, 2015, J CLIN ONCOL, V33, P22, DOI 10.1200/JCO.2014.56.5887
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Sun SJ, 2016, J CANCER RES THER, V12, P323, DOI 10.4103/0973-1482.155977
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Terashima M, 2012, CLIN CANCER RES, V18, P5992, DOI 10.1158/1078-0432.CCR-12-1318
   Torabizadeh Zhila, 2016, Middle East J Dig Dis, V8, P24, DOI 10.15171/mejdd.2016.03
   Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98
NR 30
TC 19
Z9 21
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0945-6317
EI 1432-2307
J9 VIRCHOWS ARCH
JI Virchows Arch.
PD MAR
PY 2020
VL 476
IS 3
BP 391
EP 398
DI 10.1007/s00428-019-02668-9
EA NOV 2019
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA KW0FT
UT WOS:000496412300001
PM 31720832
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Moretto, R
   Germani, MM
   Ros, J
   Daniel, F
   Ghelardi, F
   Vetere, G
   Giordano, M
   Toledo, RD
   Bergamo, F
   Randon, G
   Elez, E
   Lonardi, S
   Pietrantonio, F
   Vignali, P
   Rossini, D
   Matito, J
   Ugolini, C
   Fontanini, G
   Masi, G
   Cremolini, C
AF Moretto, Roberto
   Germani, Marco Maria
   Ros, Javier
   Daniel, Francesca
   Ghelardi, Filippo
   Vetere, Guglielmo
   Giordano, Mirella
   Toledo, Rodrigo De Almeida
   Bergamo, Francesca
   Randon, Giovanni
   Elez, Elena
   Lonardi, Sara
   Pietrantonio, Filippo
   Vignali, Paola
   Rossini, Daniele
   Matito, Judit
   Ugolini, Clara
   Fontanini, Gabriella
   Masi, Gianluca
   Cremolini, Chiara
TI Predictive Impact of <i>RNF43</i> Mutations in Patients With Proficient
   Mismatch Repair/Microsatellite Stable <i>BRAFV600E</i>-Mutated
   Metastatic Colorectal Cancer Treated With Target Therapy or Chemotherapy
SO JCO PRECISION ONCOLOGY
LA English
DT Article
ID CETUXIMAB; GENE
AB PURPOSE Target therapy (TT) with encorafenib plus cetuximab is a standard option in patients with BRAFV600E-mutated (mut) pretreated metastatic colorectal cancer (mCRC). Recently, mutations in RNF43, encoding a negative regulator of the WNT pathway, were associated with longer progression-free survival (PFS) and overall survival (OS) in patients with proficient mismatch repair/microsatellite stable (pMMR/MSS) BRAFV600E-mut mCRC treated with TT. Here, we explored the effect of RNF43 mutations on the efficacy of second-line TT versus standard chemotherapy (CT). METHODS A retrospective cohort of patients with pMMR/MSS BRAFV600E-mut tumors, available RNF43 mutational status, and treated with second-line TT or oxaliplatin- and/or irinotecan-based CT was analyzed. RESULTS One hundred thirty-two patients with pMMR/MSS BRAFV600E-mut mCRC were included. RNF43 was found mut in 34 (26%) cases. Among RNF43 mutants, TT was associated with longer PFS (7.7 v 3.0 months; P = .002) and higher overall response rate (ORR; 45% v 0%; P = .009) compared with CT. Conversely, among RNF43 wild-type (wt) patients, only a trend for longer PFS (4.5 v 3.7 months; P = .064) favoring TT, with no differences in ORR (P = .14), was observed. After excluding 36 patients receiving TT in third line or beyond, a longer OS (19.4 v 10.1 months; P = .022) and a numerically OS advantage (10.6 v 6.6 months; P = .068) were reported for TT both in the RNF43-mut and in the RNF43 wt groups. However, no interaction effect was reported between RNF43 mutational status and treatment in ORR (P-interaction = .96), PFS (P-interaction = .13), and OS (P-interaction = .44). CONCLUSION Patients with pMMR/MSS BRAFV600E-mut mCRC achieve benefit from TT versus CT independently of RNF43 mutational status, although a higher magnitude of benefit from TT is observed in RNF43-mut tumors. These findings deserve confirmation in concluded and ongoing randomized trials.
C1 [Moretto, Roberto; Germani, Marco Maria; Vetere, Guglielmo; Rossini, Daniele; Masi, Gianluca; Cremolini, Chiara] Azienda Osped Univ Pisana, Unit Med Oncol 2, Pisa, Italy.
   [Germani, Marco Maria; Vetere, Guglielmo; Giordano, Mirella; Rossini, Daniele; Masi, Gianluca; Cremolini, Chiara] Univ Pisa, Dept Translat Res & New Technol Med & Surg, Pisa, Italy.
   [Ros, Javier; Toledo, Rodrigo De Almeida; Elez, Elena] Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Med Oncol Dept, Barcelona, Spain.
   [Daniel, Francesca; Bergamo, Francesca; Lonardi, Sara] Veneto Inst Oncol IOV IRCSS, Dept Oncol, Padua, Italy.
   [Ghelardi, Filippo; Randon, Giovanni; Pietrantonio, Filippo] Fdn IRCCS Ist Nazl Tumori, Med Oncol Dept, Milan, Italy.
   [Vignali, Paola; Ugolini, Clara; Fontanini, Gabriella] Univ Pisa, Dept Surg Med Mol Pathol & Crit Area, Pisa, Italy.
   [Matito, Judit] Vall dHebron Barcelona Hosp Campus, Vall dHebron Inst Oncol VHIO, Canc Genom Grp, Barcelona, Spain.
   [Cremolini, Chiara] Azienda Osped Univ Pisana, Unit Med Oncol, Via Roma 67, I-56126 Pisa, Italy.
C3 University of Pisa; Azienda Ospedaliero Universitaria Pisana; University
   of Pisa; Vall d'Hebron Institut d'Oncologia (VHIO); IRCCS Istituto
   Oncologico Veneto (IOV); Fondazione IRCCS Istituto Nazionale Tumori
   Milan; University of Pisa; Vall d'Hebron Institut d'Oncologia (VHIO);
   University of Pisa; Azienda Ospedaliero Universitaria Pisana
RP Cremolini, C (corresponding author), Azienda Osped Univ Pisana, Unit Med Oncol, Via Roma 67, I-56126 Pisa, Italy.
EM chiaracremolini@gmail.com
RI UGOLINI, CLARA/AAI-6489-2021; Lonardi, Sara/F-4228-2014; Cremolini,
   Chiara/AAC-1889-2019; Pietrantonio, Filippo/C-2180-2017; Ros,
   Javier/HKF-1171-2023; Moretto, Roberto/AAB-3013-2022; Bergamo,
   Francesca/AAB-9010-2019; Rossini, Daniele/GPW-8241-2022; Toledo,
   Rodrigo/N-4078-2013; Bergamo, Francesca/G-3134-2014
OI Toledo, Rodrigo/0000-0003-3070-6795; Bergamo,
   Francesca/0000-0002-8795-4653; VIGNALI, PAOLA/0009-0001-4181-4903;
   CREMOLINI, CHIARA/0000-0002-0520-4841; GERMANI, MARCO
   MARIA/0000-0002-1036-5869; Ros, Javier/0000-0002-8137-5415; Vetere,
   Guglielmo/0000-0001-6943-2897
FU ARCO Foundations
FX The authors are grateful to GONO and ARCO Foundations, and to all
   participating patients and their families.
CR Ascierto Paolo A, 2021, Clin Cancer Res, V27, P5225, DOI 10.1158/1078-0432.CCR-21-0809
   Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140
   Caris MI, 2023, Clinical test
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Dummer R, 2022, J CLIN ONCOL, V40, P4178, DOI 10.1200/JCO.21.02659
   ecancer, 2023, Tiirkiye 2023 Report
   Elez E, 2022, NAT MED, V28, P2162, DOI 10.1038/s41591-022-01976-z
   fda, 2020, FDA APPR ENC COMB CE
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Luchini C, 2019, ANN ONCOL, V30, P1232, DOI 10.1093/annonc/mdz116
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Milbury CA, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0264138
   Pfizer, 2023, An open-label, multicenter, randomized phase 3 study of first-line encorafenib plus cetuximab with or without chemotherapy versus standard of care therapy with a safety lead-in of encorafenib and cetuximab plus chemotherapy in participants with metastatic BRAF V600E-mutant colorectal cancer
   Quintanilha JCF, 2023, ONCOLOGIST, DOI 10.1093/oncolo/oyac265
   Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Vikas P, 2023, J CLIN ONCOL, V41, P1943, DOI 10.1200/JCO.22.02462
NR 23
TC 3
Z9 3
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
EI 2473-4284
J9 JCO PRECIS ONCOL
JI JCO Precis. Oncol.
PD OCT
PY 2023
VL 7
AR e2300255
DI 10.1200/PO.23.00255
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KC1L5
UT WOS:001177668900002
PM 37797285
DA 2025-01-04
ER

PT J
AU Fathi, A
   Mosaad, H
   Hussein, S
   Roshdy, M
   Ismail, EI
AF Fathi, Anan
   Mosaad, Hala
   Hussein, Samia
   Roshdy, Mona
   Ismail, Eman I.
TI Prognostic Significance of CD133 and Ezrin Expression in Colorectal
   Carcinoma
SO IUBMB LIFE
LA English
DT Article
DE RT-PCR; immunohistochemistry; colorectal cancer; CD133; ezrin;
   biomarkers; prognosis
ID MESSENGER-RNA; POOR-PROGNOSIS; STAGE-II; CANCER; MARKER; STEM;
   PROGRESSION; PREDICT; CELLS
AB Despite the improvement in the diagnostic and the therapeutic modalities, colorectal cancer (CRC) morbidity and mortality remain high in both the developed and the developing countries. So, we are in a need to recognize new efficient diagnostic and prognostic biomarkers of CRC. That may help in providing individualized targeted therapy for this lethal malignancy. In this study, we investigated the expression and the prognostic significance of CD133 and ezrin mRNA and protein by quantitative RT-PCR and immunohistochemical analysis in primary CRC cases and the surrounding normal colonic mucosa. The correlations between the expression of both markers and clinicopathological parameters were performed. Compared to control, the expression of CD133 and ezrin mRNA and protein in CRC were significantly upregulated (P < 0.05). In addition, a strong positive correlation between both markers was found (r = 0.867, P < 0.001). Moreover, elevated levels of both markers were significantly associated with the stage, lymph node involvement, distant metastasis, and recurrence at both mRNA and protein levels (P < 0.05). In conclusion, there is a clinical significance of CD133 and ezrin as potential biomarkers for predicting CRC patients of aggressive behavior and poor prognosis. (C) 2017
C1 [Fathi, Anan; Roshdy, Mona] Zagazig Univ, Pathol Dept, Fac Med, Zagazig, Egypt.
   [Mosaad, Hala; Hussein, Samia] Zagazig Univ, Med Biochem & Mol Biol Dept, Fac Med, Zagazig, Egypt.
   [Ismail, Eman I.] Zagazig Univ, Clin Oncol & Nucl Med Dept, Fac Med, Zagazig, Egypt.
C3 Egyptian Knowledge Bank (EKB); Zagazig University; Egyptian Knowledge
   Bank (EKB); Zagazig University; Egyptian Knowledge Bank (EKB); Zagazig
   University
RP Hussein, S (corresponding author), Zagazig Univ, Med Biochem & Mol Biol Dept, Fac Med, Zagazig, Egypt.
EM samiahussein82@hotmail.com
RI Hussein, Samia/AAW-9408-2020
OI Mosaad, Hala/0000-0002-4423-2503; Hussein, Samia/0000-0002-7407-1608
CR [Anonymous], 2014, INT J ADV RES
   [Anonymous], CANC BIOL THER
   [Anonymous], TRANSL GASTROINTEST
   [Anonymous], J AM SCI
   [Anonymous], 2015, MED J SDU
   Oliver JA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-511
   Artells R, 2010, EUR J CANCER, V46, P642, DOI 10.1016/j.ejca.2009.11.003
   Çelik H, 2015, MOL CELL BIOL, V35, P3145, DOI 10.1128/MCB.00332-15
   Chen SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056380
   Cherciu Irina, 2014, Curr Health Sci J, V40, P153, DOI 10.12865/CHSJ.40.03.01
   Chew Man-Fong, 2012, Malays J Pathol, V34, P25
   Coco C, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-71
   Edge SB., 2010, AJCC Cancer Staging Handbook, V7th, P173
   Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030
   Garza-Treviño EN, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0163-7
   Giebel B, 2004, BLOOD, V104, P2332, DOI 10.1182/blood-2004-02-0511
   Hongo K, 2012, MED ONCOL, V29, P2849, DOI 10.1007/s12032-012-0161-8
   Horst D, 2009, EUR J CANCER, V45, P2034, DOI 10.1016/j.ejca.2009.04.004
   Huh JW, 2010, J SURG ONCOL, V102, P765, DOI 10.1002/jso.21734
   Jao SW, 2012, ANN SURG ONCOL, V19, P3432, DOI 10.1245/s10434-012-2394-3
   Jin JC, 2012, DIAGN PATHOL, V7, DOI 10.1186/1746-1596-7-135
   Jin TF, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-191
   Keysar SB, 2010, MOL CANCER THER, V9, P2450, DOI 10.1158/1535-7163.MCT-10-0530
   Kojima M, 2008, CANCER SCI, V99, P1578, DOI 10.1111/j.1349-7006.2008.00849.x
   Koon N, 2004, GUT, V53, P235, DOI 10.1136/gut.2003.021238
   Li H, 2012, INT J COLORECTAL DIS, V27, P1015, DOI 10.1007/s00384-012-1421-y
   Li L, 2011, PATHOL ONCOL RES, V17, P909, DOI 10.1007/s12253-011-9402-y
   Lin EH, 2007, CANCER-AM CANCER SOC, V110, P534, DOI 10.1002/cncr.22774
   Lin LJ, 2013, MOL MED REP, V8, P61, DOI 10.3892/mmr.2013.1490
   Mehra N, 2006, CLIN CANCER RES, V12, P4859, DOI 10.1158/1078-0432.CCR-06-0422
   Mia-Jan K, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-166
   Patara M, 2011, PATHOL ONCOL RES, V17, P827, DOI 10.1007/s12253-011-9389-4
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Silinsky J, 2013, J SURG RES, V185, P113, DOI 10.1016/j.jss.2013.05.049
   Wang K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-573
   Zhang NH, 2012, EXP THER MED, V3, P973, DOI 10.3892/etm.2012.527
   Zhou B, 2014, J SURG RES, V188, P396, DOI 10.1016/j.jss.2014.01.014
NR 37
TC 12
Z9 15
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1521-6543
EI 1521-6551
J9 IUBMB LIFE
JI IUBMB Life
PD MAY
PY 2017
VL 69
IS 5
BP 328
EP 340
DI 10.1002/iub.1609
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA ES7LP
UT WOS:000399732000007
PM 28261953
OA Bronze
DA 2025-01-04
ER

PT J
AU Beuselinck, B
   Jean-Baptiste, J
   Schöffski, P
   Couchy, G
   Meiller, C
   Rolland, F
   Allory, Y
   Joniau, S
   Verkarre, V
   Elaidi, R
   Lerut, E
   Roskams, T
   Patard, JJ
   Oudard, S
   Méjean, A
   Lambrechts, D
   Zucman-Rossi, J
AF Beuselinck, Benoit
   Jean-Baptiste, Johnny
   Schoffski, Patrick
   Couchy, Gabrielle
   Meiller, Clement
   Rolland, Frederic
   Allory, Yves
   Joniau, Steven
   Verkarre, Virginie
   Elaidi, Reza
   Lerut, Evelyne
   Roskams, Tania
   Patard, Jean-Jacques
   Oudard, Stephane
   Mejean, Arnaud
   Lambrechts, Diether
   Zucman-Rossi, Jessica
TI Validation of VEGFR1 rs9582036 as predictive biomarker in metastatic
   clear-cell renal cell carcinoma patients treated with sunitinib
SO BJU INTERNATIONAL
LA English
DT Article
DE clear-cell renal cell carcinoma; polymorphisms; predictive factors;
   sunitinib; VEGFR1
ID SINGLE-NUCLEOTIDE POLYMORPHISMS; RETROSPECTIVE ANALYSIS;
   COLORECTAL-CANCER; TARGETED THERAPY; INTERFERON-ALPHA; BEVACIZUMAB;
   CHEMOTHERAPY; SURVIVAL; EFFICACY; PATHWAY
AB Objectives
   To validate vascular endothelial growth factor receptor-1 (VEGFR1) single nucleotide polymorphism (SNP) rs9582036 as a potential predictive biomarker in metastatic clear-cell renal cell carcinoma (m-ccRCC) patients treated with sunitinib.
   Materials and Methods
   m-ccRCC patients receiving sunitinib as first-line targeted therapy were included. We assessed response rate (RR), progression-free survival (PFS), overall survival (OS), and clinical and biochemical parameters associated with outcome. We genotyped five VEGFR1 SNPs: rs9582036, rs7993418, rs9554320, rs9554316 and rs9513070. Association with outcome was studied by univariate analysis and by multivariate Cox regression. Additionally, we updated survival data of our discovery cohort as described previously.
   Results
   Sixty-nine patients were included in the validation cohort. rs9582036 CC-carriers had a poorer PFS (8 vs 12 months, P = 0.02) and OS (11 vs 27 months, P = 0.003) compared to AC/AA-carriers. rs7993418 CC-carriers had a poorer OS (8 vs 24 months, P = 0.004) compared to TC/TT-carriers. rs9554320 AA-carriers had a poorer RR (0% vs 53%, P = 0.009), PFS (5 vs 12 months, P = 0.003) and OS (10 vs 25 months, P = 0.004) compared to AC/CC-carriers. When pooling patients from the discovery cohort, as described previously (n = 88), and the validation cohort, in the total series of 157 patients, rs9582036 CC-carriers had a poorer RR (8% vs 49%, P = 0.004), PFS (8 vs 14 months, P = 0.003) and OS (13 vs 30 months, P = 0.0004) compared to AC/AA-carriers. Unfavorable prognostic markers at start of sunitinib were well balanced between rs9582036 CC-and AC/AAcarriers.
   Conclusion
   VEGFR1 rs9582036 is a candidate predictive biomarker in m-ccRCC-patients treated with sunitinib.
C1 [Beuselinck, Benoit; Jean-Baptiste, Johnny; Couchy, Gabrielle; Meiller, Clement; Zucman-Rossi, Jessica] IUH, INSERM, Genom Fonct Tumeurs Solides, UMR 1162, Paris, France.
   [Beuselinck, Benoit; Jean-Baptiste, Johnny; Couchy, Gabrielle; Meiller, Clement; Oudard, Stephane; Zucman-Rossi, Jessica] Univ Paris 05, Fac Med, Sorbonne Paris Cite, Paris, France.
   [Beuselinck, Benoit; Schoffski, Patrick] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Gen Med Oncol, Leuven Canc Inst, Leuven, Belgium.
   [Beuselinck, Benoit; Schoffski, Patrick] Katholieke Univ Leuven, Univ Hosp Leuven, Expt Oncol Lab, Leuven Canc Inst, Leuven, Belgium.
   [Rolland, Frederic] Inst Cancerol Ouest, Dept Med Oncol, St Herblain, France.
   [Allory, Yves] Hop Henri Mondor, AP HP, Dept Pathol, Creteil, France.
   [Joniau, Steven] Katholieke Univ Leuven, Leuven Canc Inst, Univ Hosp Leuven, Dept Urol, Leuven, Belgium.
   [Verkarre, Virginie] Hop Necker Enfants Malad, AP HP, Dept Pathol, Paris, France.
   [Elaidi, Reza; Oudard, Stephane; Zucman-Rossi, Jessica] Hop Europeen Georges Pompidou, AP HP, Dept Med Oncol, Paris, France.
   [Lerut, Evelyne; Roskams, Tania] Katholieke Univ Leuven, Univ Hosp Leuven, Dept Pathol, Leuven, Belgium.
   [Patard, Jean-Jacques] Hop Bicetre, Dept Urol, Le Kremlin Bicetre, France.
   [Mejean, Arnaud] Hop Europeen Georges Pompidou, AP HP, Dept Urol, Paris, France.
   [Lambrechts, Diether] Katholieke Univ Leuven, Lab Translat Genet, Dept Oncol, Leuven, Belgium.
   [Lambrechts, Diether] VIB, Vesalius Res Ctr, Leuven, Belgium.
C3 Universite Paris Cite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite Paris Cite; KU Leuven; University Hospital
   Leuven; KU Leuven; University Hospital Leuven; UNICANCER; Institut de
   Cancerologie de l'Ouest (ICO); Universite Paris-Est-Creteil-Val-de-Marne
   (UPEC); Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Henri-Mondor - APHP; KU Leuven; University Hospital Leuven; Assistance
   Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital
   Universitaire Necker-Enfants Malades - APHP; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Europeen Georges-Pompidou - APHP; KU Leuven; University Hospital Leuven;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Antoine-Beclere - APHP; Universite Paris Saclay; Hopital Universitaire
   Bicetre - APHP; Assistance Publique Hopitaux Paris (APHP); Universite
   Paris Cite; Hopital Universitaire Europeen Georges-Pompidou - APHP; KU
   Leuven; Flanders Institute for Biotechnology (VIB)
RP Beuselinck, B (corresponding author), Leuven Canc Inst, Herestr 49, B-3000 Leuven, Belgium.
EM benoit.beuselinck@uzleuven.be
RI Lambrechts, Diether/AAJ-3167-2020; joniau, steven/K-7655-2013;
   zucman-rossi, Jessica/B-5098-2009
OI Beuselinck, Benoit/0000-0001-7427-9102; OUDARD,
   Stephane/0000-0003-0893-285X; Lambrechts, Diether/0000-0002-3429-302X;
   joniau, steven/0000-0003-3195-9890; zucman-rossi,
   Jessica/0000-0002-5687-0334; Roskams, Tania/0000-0002-2816-1530
FU Fondation Martine Midy (Paris, France); Fonds voor Wetenschappelijk
   Onderzoek Vlaanderen (Belgium); Stichting Tegen Kanker;
   Hoffman-La-Roche; ARTUR (Association pour la recherche sur les tumeurs
   du rein, Paris, France); ARC (Fondation ARC pour la recherche sur le
   cancer)
FX Benoit Beuselinck received a grant from Fondation Martine Midy (Paris,
   France) and Fonds voor Wetenschappelijk Onderzoek Vlaanderen (Belgium).
   Diether Lambrechts is supported by the Stichting Tegen Kanker. He
   received research support from Hoffman-La-Roche and Sanofi-Aventis to
   conduct research projects related to the discovery of biomarkers for
   bevacizumab therapy. Diether Lambrechts is named as co-inventor on a
   patent application which value may be affected by publication. Evelyne
   Lerut received fundings from Fonds voor Wetenschappelijk Onderzoek
   Vlaanderen (Belgium) and Stichting tegen Kanker. Johnny Jean-Baptiste
   received a research grant from ARTUR (Association pour la recherche sur
   les tumeurs du rein, Paris, France) and ARC (Fondation ARC pour la
   recherche sur le cancer).
CR Beuselinck B, 2011, ANN ONCOL, V22, P794, DOI 10.1093/annonc/mdq554
   Beuselinck B, 2015, CLIN CANCER RES, V21, P1329, DOI 10.1158/1078-0432.CCR-14-1128
   Beuselinck B, 2014, CLIN GENITOURIN CANC, V12, pE205, DOI 10.1016/j.clgc.2014.04.004
   Beuselinck B, 2014, ACTA ONCOL, V53, P103, DOI 10.3109/0284186X.2013.770600
   Dornbusch J, 2016, J CANCER RES CLIN, V142, P1171, DOI 10.1007/s00432-016-2137-0
   Dornbusch J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076386
   Escudier B, 2015, CLIN GENITOURIN CANC, V13, P328, DOI 10.1016/j.clgc.2015.02.007
   Hansen TF, 2012, INT J COLORECTAL DIS, V27, P715, DOI 10.1007/s00384-011-1382-6
   Heng DYC, 2009, J CLIN ONCOL, V27, P5794, DOI 10.1200/JCO.2008.21.4809
   Lambrechts D, 2013, J CLIN ONCOL, V31, P1219, DOI 10.1200/JCO.2012.46.2762
   Lambrechts D, 2012, LANCET ONCOL, V13, P724, DOI 10.1016/S1470-2045(12)70231-0
   Loupakis F, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066774
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2009, J CLIN ONCOL, V27, P3584, DOI 10.1200/JCO.2008.20.1293
   Patil S, 2011, ANN ONCOL, V22, P295, DOI 10.1093/annonc/mdq342
   Popova T, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-11-r128
   Reumers J, 2012, NAT BIOTECHNOL, V30, P61, DOI 10.1038/nbt.2053
   Rini BI, 2009, LANCET ONCOL, V10, P992, DOI 10.1016/S1470-2045(09)70240-2
   Sohn BS, 2014, ONCOLOGY-BASEL, V87, P280, DOI 10.1159/000365593
NR 19
TC 22
Z9 24
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1464-4096
EI 1464-410X
J9 BJU INT
JI BJU Int.
PD DEC
PY 2016
VL 118
IS 6
BP 890
EP 901
DI 10.1111/bju.13585
PG 12
WC Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Urology & Nephrology
GA EC9QL
UT WOS:000388479100014
PM 27417418
OA Bronze
DA 2025-01-04
ER

PT J
AU Rihawi, K
   Giampieri, R
   Scartozzi, M
   Pusceddu, V
   Bonotto, M
   Fasola, G
   Cascinu, S
   Aprile, G
AF Rihawi, Karim
   Giampieri, Riccardo
   Scartozzi, Mario
   Pusceddu, Valeria
   Bonotto, Marta
   Fasola, Gianpiero
   Cascinu, Stefano
   Aprile, Giuseppe
TI Role and mechanisms of resistance of epidermal growth factor receptor
   antagonists in the treatment of colorectal cancer
SO EXPERT OPINION ON INVESTIGATIONAL DRUGS
LA English
DT Review
DE acquired resistance; BRAF; colorectal cancer; EGFR inhibitors;
   MEHD7945A; MM-151; RAS; Sym004
ID CETUXIMAB PLUS IRINOTECAN; PHASE-III TRIAL; ANTI-EGFR TREATMENT; CELL
   LUNG-CANCER; 1ST-LINE TREATMENT; PIK3CA MUTATIONS; KRAS MUTATIONS;
   ACQUIRED-RESISTANCE; TARGETED THERAPY; DRUG DEVELOPMENT
AB Introduction: Although epidermal growth factor receptor (EGFR) inhibitors have progressively become a relevant therapeutic arm in the treatment of patients with advanced colorectal cancer, the responses achieved are not durable and resistance invariably occurs. The advances in sequencing technology have allowed not only a more profound molecular tumor characterization but also the identification of the different molecular pathways involved in drug resistance and disease progression. These biological improvements have encouraged researchers to design clinical studies testing novel target therapies.
   Areas covered: After discussing the results of key Phase III randomized trials and providing commentary on the most promising novel agents (Sym004, MM-151, GA201 and MEHD7945A), the authors present the future steps ahead toward a real tailored treatment.
   Expert opinion: EGFR inhibitors are highly effective in the advanced disease setting. Although the negative predictive role of RAS and possibly BRAF mutations has already been established, more comprehensive efforts are needed to optimize the use of these drugs. At the same time, understanding the underlying biology will help basic scientists to develop new compounds able to overcome both primary and acquired resistance and help clinical researchers to test novel drugs within adequately designed trials whose results eventually are expected to reshape the overall treatment strategy.
C1 [Rihawi, Karim; Bonotto, Marta; Fasola, Gianpiero; Aprile, Giuseppe] Univ & Gen Hosp, Dept Med Oncol, I-33100 Udine, Italy.
   [Giampieri, Riccardo; Cascinu, Stefano] Univ Politecn Marche, Dept Med Oncol, Azienda Osped Riuniti, Ancona, Italy.
   [Scartozzi, Mario; Pusceddu, Valeria] Univ & Gen Hosp Cagliari, Dept Med Oncol, Cagliari, Italy.
C3 University of Udine; University Hospital of Udine; Marche Polytechnic
   University
RP Aprile, G (corresponding author), Univ & Gen Hosp, Dept Med Oncol, Piazzale S Maria Misericordia 1, I-33100 Udine, Italy.
EM aprile.giuseppe@aoud.sanita.fvg.it
RI pusceddu, valeria/GZM-3173-2022; Cascinu, Stefano/AAN-1923-2020; Rihawi,
   Karim/AAC-5431-2021; Fasola, Gianpiero/AAC-3629-2022; Bonotto,
   Marta/AAM-3253-2021; Cascinu, Stefano/G-2399-2017
OI Fasola, Gianpiero/0000-0002-1254-4705; SCARTOZZI,
   MARIO/0000-0001-5977-5546; Bonotto, Marta/0000-0003-3757-3702; Cascinu,
   Stefano/0000-0003-2215-0731
CR Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], 2014, J CLIN ONCOL S
   [Anonymous], J CLIN ONCOL S
   Aprile G, 2013, WORLD J GASTROENTERO, V19, P8474, DOI 10.3748/wjg.v19.i46.8474
   Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   Arnedos M, 2014, CANCER TREAT REV, V40, P1192, DOI 10.1016/j.ctrv.2014.07.002
   Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Bridgewater JA, 2015, J CLIN ONCOL S, V33
   Brule SY, 2013, J CLIN ONCOL, V31
   Buch I, 2013, J CHEM INF MODEL, V53, P3123, DOI 10.1021/ci400456m
   Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439
   Cappuzzo F, 2009, ANN ONCOL, V20, P298, DOI 10.1093/annonc/mdn635
   Cervantes-Ruiperez A, 2012, J CLIN ONCOL S30
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Clement PM, 2014, ANN ONCOL         S4, V25, piv340
   Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530
   Connolly K, 2014, CURR ONCOL, V21, pE151, DOI 10.3747/co.21.1661
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Custodio A, 2013, CRIT REV ONCOL HEMAT, V85, P45, DOI 10.1016/j.critrevonc.2012.05.001
   Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Dienstmann R, 2011, J CLIN ONCOL, V29
   Dienstmann R, 2015, CANC DISCOV
   Dienstmann R, 2012, MOL ONCOL, V6, P15, DOI 10.1016/j.molonc.2011.11.009
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Fakih MG, 2015, J CLIN ONCOL
   Fiske WH, 2009, EXP CELL RES, V315, P583, DOI 10.1016/j.yexcr.2008.10.043
   Foltran L, 2015, FUTURE ONCOL, V11, P629, DOI 10.2217/fon.14.279
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Gerdes CA, 2014, CLIN CANCER RES, V20, P1055, DOI 10.1158/1078-0432.CCR-13-2699
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Giampieri R, 2014, CURR DRUG TARGETS, V15, P1225, DOI 10.2174/1389450115666141109212801
   Giampieri R, 2013, CRIT REV ONCOL HEMAT, V88, P272, DOI 10.1016/j.critrevonc.2013.05.008
   Grothey A, 2012, J CLIN ONCOL, V30, P1735, DOI 10.1200/JCO.2011.40.4194
   Harb W, 2014, ANN ONCOL, V25
   Harstrick A, 1998, ANTI-CANCER DRUG, V9, P625, DOI 10.1097/00001813-199808000-00008
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Iida M, 2013, NEOPLASIA, V15, P1182, DOI 10.1593/neo.131584
   Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970
   Kearns JD, 2015, MOL CANC THER
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Loupakis F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju427
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Metges J, 2010, J CLIN ONCOL, V28
   Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275
   Montagut C, 2015, ANN ONCOL
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Morelli M. P., 2015, ANN ONCOL
   Napolitano S., 2015, CLIN CANC RES
   Newhall K, 2014, ANN ONCOL S, V25
   Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947
   Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417
   Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541
   Pietrantonio F, 2013, CANCER BIOL THER, V14, P1098, DOI 10.4161/cbt.26343
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prenen H, 2009, CLIN CANCER RES, V15, P3184, DOI 10.1158/1078-0432.CCR-08-2961
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Saif MW, 2010, CLIN COLORECTAL CANC, V9, P315, DOI 10.3816/CCC.2010.n.046
   Saif MW, 2009, CANCER CHEMOTH PHARM, V63, P1017, DOI 10.1007/s00280-008-0831-6
   Santini D, 2012, ANN ONCOL, V23, P2313, DOI 10.1093/annonc/mdr623
   Sartore-Bianchi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007287
   Scartozzi M, 2011, ONCOLOGIST, V16, P53, DOI 10.1634/theoncologist.2010-0119
   Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003
   Schirripa M, 2015, INT J CANCER, V136, P83, DOI 10.1002/ijc.28955
   Seiwert TY, 2014, ANN ONCOL, V25, P1813, DOI 10.1093/annonc/mdu216
   Sridhar SS, 2005, MOL CANCER THER, V4, P677, DOI 10.1158/1535-7163.MCT-04-0297
   Stintzing S, 2014, ANN ONCOL, V25, DOI 10.1093/annonc/mdu438.9
   Stinzing S, 2014, EUR J CANC S, V49
   Tan G, 2011, MOL CANC THER S, V10
   Tian S, 2013, GUT, V62, P540, DOI 10.1136/gutjnl-2012-302423
   Tol J, 2010, EUR J CANCER, V46, P1997, DOI 10.1016/j.ejca.2010.03.036
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tougeron D, 2013, ANN ONCOL, V24, P1267, DOI 10.1093/annonc/mds620
   Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Vivanco I, 2002, NAT REV CANCER, V2, P489, DOI 10.1038/nrc839
   Wadlow R, 2012, ONCOLOGIST, V17, pE27, DOI 10.1634/theoncologist.2011-0452
   Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Younis S, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1337-3
NR 104
TC 4
Z9 4
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1354-3784
EI 1744-7658
J9 EXPERT OPIN INV DRUG
JI Expert Opin. Investig. Drugs
PY 2015
VL 24
IS 9
BP 1185
EP 1198
DI 10.1517/13543784.2015.1054479
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA CQ9EU
UT WOS:000360915900004
PM 26044119
DA 2025-01-04
ER

PT J
AU Xiao, H
   Wang, G
   Zhao, M
   Shuai, W
   Ouyang, L
   Sun, Q
AF Xiao, Huan
   Wang, Guan
   Zhao, Min
   Shuai, Wen
   Ouyang, Liang
   Sun, Qiu
TI Ras superfamily GTPase activating proteins in cancer: Potential
   therapeutic targets?
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Review
DE Ras superfamily; GTPase activating proteins (GAPs); Cancer; Target
   therapy
ID ABERRANT PROMOTER METHYLATION; TUMOR-SUPPRESSOR GENE;
   EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA CELLS;
   NEGATIVE BREAST-CANCER; TBC1 DOMAIN FAMILY; COLORECTAL-CANCER;
   DOWN-REGULATION; PROSTATE-CANCER; POOR-PROGNOSIS
AB To search more therapeutic strategies for Ras-mutant tumors, regulators of the Ras superfamily involved in the GTP/GDP (guanosine triphosphate/guanosine diphosphate) cycle have been well concerned for their anti-tumor potentials. GTPase activating proteins (GAPs) provide the catalytic group necessary for the hydrolysis of GTPs, which accelerate the switch by cycling between GTP-bound active and GDP-bound inactive forms. Inactivated GAPs lose their function in activating GTPase, leading to the continuous activation of downstream signaling pathways, uncontrolled cell proliferation, and eventually carcinogenesis. A growing number of evidence has shown the close link between GAPs and human tumors, and as a result, GAPs are believed as potential anti-tumor targets. The present review mainly summarizes the critically important role of GAPs in human tumors by introducing the classification, function and regulatory mechanism. Moreover, we comprehensively describe the relationship between dysregulated GAPs and the certain type of tumor. Finally, the current status, research progress, and clinical value of GAPs as therapeutic targets are also discussed, as well as the challenges and future direction in the cancer therapy.
C1 [Sun, Qiu] Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   Sichuan Univ, West China Hosp, Canc Ctr, Nursing Key Lab Sichuan Prov,Collaborat Innovat Ct, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University
RP Sun, Q (corresponding author), Sichuan Univ, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
EM sunqiu@scu.edu.cn
RI Sun, Qiu/AAT-2241-2020
OI Sun, Qiu/0000-0001-5122-2226
FU Natural Science Foundation of Sichuan Province (China) [2022NSFSC1290,
   2023NSFSC1839]; National Natural Science Foundation of China [22177083];
   Non-profit Central Research Institute Fund of Chinese Academy of Medical
   Sciences (China) [2020-JKCS-014]
FX This work was supported by the Natural Science Foundation of Sichuan
   Province (Grant 2023NSFSC1839, China) , National Natural Science
   Foundation of China (Grant 22177083,) , Natural Science Foundation of
   Sichuan Province (Grant 2022NSFSC1290, China) , and the Non-profit
   Central Research Institute Fund of Chinese Academy of Medical Sciences
   (Grant 2020-JKCS-014, China) .
CR Akavia UD, 2010, CELL, V143, P1005, DOI 10.1016/j.cell.2010.11.013
   Akhave NS, 2021, CANCER DISCOV, V11, P1345, DOI 10.1158/2159-8290.CD-20-1616
   Aktories K, 2011, NAT REV MICROBIOL, V9, P487, DOI 10.1038/nrmicro2592
   Aleskandarany MA, 2017, BRIT J CANCER, V117, P1176, DOI 10.1038/bjc.2017.261
   Allouche J, 2015, P NATL ACAD SCI USA, V112, P9034, DOI 10.1073/pnas.1501032112
   Aly RM, 2014, BLOOD CELL MOL DIS, V53, P185, DOI 10.1016/j.bcmd.2014.07.004
   Alzahrani AS, 2019, SEMIN CANCER BIOL, V59, P125, DOI 10.1016/j.semcancer.2019.07.009
   [Anonymous], 2015, Cell, V161, P1681, DOI DOI 10.1016/J.CELL.2015.05.044
   Bartolomé RA, 2008, CANCER RES, V68, P8221, DOI 10.1158/0008-5472.CAN-08-0561
   Bartolomé RA, 2014, CELL SIGNAL, V26, P2551, DOI 10.1016/j.cellsig.2014.07.008
   Basak P, 2018, GENE CHROMOSOME CANC, V57, P182, DOI 10.1002/gcc.22519
   Behnia R, 2005, NATURE, V438, P597, DOI 10.1038/nature04397
   Bernards A, 2004, TRENDS CELL BIOL, V14, P377, DOI 10.1016/j.tcb.2004.05.003
   Bigarella CL, 2009, BBA-MOL CELL RES, V1793, P806, DOI 10.1016/j.bbamcr.2009.02.010
   Bizimungu C, 2005, BIOCHEM BIOPH RES CO, V335, P883, DOI 10.1016/j.bbrc.2005.07.159
   Blair HA, 2021, DRUGS, V81, P1573, DOI 10.1007/s40265-021-01574-2
   Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018
   BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0
   Brock EJ, 2016, MINI-REV MED CHEM, V16, P358, DOI 10.2174/1389557515666151001154002
   Burotto M, 2014, CANCER-AM CANCER SOC, V120, P3446, DOI 10.1002/cncr.28864
   Campbell JD, 2016, NAT GENET, V48, P607, DOI 10.1038/ng.3564
   Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]
   Cao HH, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0881-3
   Cao X, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8721
   Carles A, 2006, ONCOGENE, V25, P1821, DOI 10.1038/sj.onc.1209203
   Carroll B, 2013, DEV CELL, V25, P15, DOI 10.1016/j.devcel.2013.03.005
   Chang JS, 2015, ONCOTARGET, V6, P36278, DOI 10.18632/oncotarget.5531
   Chang T, 2013, J CLIN INVEST, V123, P335, DOI 10.1172/JCI63193
   Chen H, 2003, J BIOL CHEM, V278, P3121, DOI 10.1074/jbc.M208230200
   Chen H, 2013, ASIAN PAC J CANCER P, V14, P6261, DOI 10.7314/APJCP.2013.14.11.6261
   Chen JZ, 2018, AGING-US, V10, P3371, DOI 10.18632/aging.101645
   Chen L, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0145-1
   Chen R, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0344-z
   Chen WT, 2013, APMIS, V121, P1131, DOI 10.1111/apm.12060
   Chen XR, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0236-0
   Cheng JC, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-14
   Chiu JH, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1192-x
   Christensen JG, 2020, J INTERN MED, V288, P183, DOI 10.1111/joim.13057
   Cichowski K, 2001, CELL, V104, P593, DOI 10.1016/S0092-8674(01)00245-8
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   Dai XP, 2018, MED SCI MONITOR, V24, P8669, DOI 10.12659/MSM.911394
   Dang CV, 2017, NAT REV CANCER, V17, P502, DOI 10.1038/nrc.2017.36
   de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741
   Dechamps C, 2006, BIOTECHNOL LETT, V28, P223, DOI 10.1007/s10529-005-5523-2
   Degirmenci U, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010198
   Deng Z, 2016, INT J ONCOL, V48, P153, DOI 10.3892/ijo.2015.3228
   Di Minin G, 2014, MOL CELL, V56, P617, DOI 10.1016/j.molcel.2014.10.013
   Dibble CC, 2012, MOL CELL, V47, P535, DOI 10.1016/j.molcel.2012.06.009
   Dong GY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1033-8
   Dong PX, 2006, CANCER LETT, V243, P120, DOI 10.1016/j.canlet.2005.11.024
   Dong PX, 2016, ONCOTARGET, V7, P20260, DOI 10.18632/oncotarget.7754
   Dongol S, 2020, ONCOL LETT, V20, P1179, DOI 10.3892/ol.2020.11664
   Dote H, 2004, CLIN CANCER RES, V10, P2082, DOI 10.1158/1078-0432.CCR-03-0236
   Dote H, 2005, BRIT J CANCER, V92, P1117, DOI 10.1038/sj.bjc.6602458
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Duan YF, 2020, TECHNOL CANCER RES T, V19, DOI 10.1177/1533033819895494
   Durkin ME, 2007, J CELL MOL MED, V11, P1185, DOI 10.1111/j.1582-4934.2007.00098.x
   Ehlers JP, 2005, CLIN CANCER RES, V11, P3609, DOI 10.1158/1078-0432.CCR-04-1941
   El-Sitt S, 2012, ONCOL REP, V28, P511, DOI 10.3892/or.2012.1819
   Eldridge AG, 2006, CELL, V124, P367, DOI 10.1016/j.cell.2005.10.038
   Espelage L, 2020, J MOL ENDOCRINOL, V64, pR1, DOI 10.1530/JME-19-0143
   Fang Y, 2015, ONCOTARGET, V6, P13164, DOI 10.18632/oncotarget.3754
   Fang ZY, 2006, MOL CELL PROTEOMICS, V5, P1437, DOI 10.1074/mcp.M600050-MCP200
   Feng M, 2014, J CLIN INVEST, V124, P5291, DOI 10.1172/JCI76711
   Feng MH, 2011, MOL BIOL REP, V38, P1915, DOI 10.1007/s11033-010-0311-z
   Fetics SK, 2015, STRUCTURE, V23, P505, DOI 10.1016/j.str.2014.12.017
   Frasa MAM, 2012, NAT REV MOL CELL BIO, V13, P67, DOI 10.1038/nrm3267
   Frittoli E, 2008, MOL BIOL CELL, V19, P1304, DOI 10.1091/mbc.E07-06-0594
   Gao F, 2018, ONCOTARGETS THER, V11, P5371, DOI 10.2147/OTT.S170775
   Gao JY, 2020, FOOD FUNCT, V11, P9573, DOI [10.1039/d0fo00996b, 10.1039/D0FO00996B]
   Gao K, 2012, ONCOL LETT, V4, P988, DOI 10.3892/ol.2012.854
   Gen Y, 2009, CANCER LETT, V275, P27, DOI 10.1016/j.canlet.2008.09.036
   Gong B, 2015, WORLD J GASTROENTERO, V21, P1488, DOI 10.3748/wjg.v21.i5.1488
   Goueli BS, 2012, P NATL ACAD SCI USA, V109, P15787, DOI 10.1073/pnas.1204540109
   Gray JL, 2020, ANGEW CHEM INT EDIT, V59, P6342, DOI 10.1002/anie.201900585
   Guo DJ, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040835
   Guo FJ, 2010, PATHOL ONCOL RES, V16, P319, DOI 10.1007/s12253-009-9226-1
   Ha VL, 2008, J BIOL CHEM, V283, P14915, DOI 10.1074/jbc.M709717200
   Han YL, 2021, J CANCER, V12, P1779, DOI 10.7150/jca.51551
   Hanna S, 2014, INT J ONCOL, V44, P1499, DOI 10.3892/ijo.2014.2330
   Hashimoto S, 2006, P NATL ACAD SCI USA, V103, P7036, DOI 10.1073/pnas.0509166103
   Hayashi T, 2018, CLIN CANCER RES, V24, P1436, DOI 10.1158/1078-0432.CCR-17-2343
   Healy KD, 2008, MOL CARCINOGEN, V47, P326, DOI 10.1002/mc.20389
   Heering J, 2009, EXP CELL RES, V315, P2505, DOI 10.1016/j.yexcr.2009.05.022
   Hensel J, 2015, MOL CANCER RES, V13, P1306, DOI 10.1158/1541-7786.MCR-15-0130
   Heraud C, 2019, CELLS-BASEL, V8, P351, DOI [10.3390/cells8040351, DOI 10.3390/cells8040351]
   Heulot M, 2016, ONCOTARGET, V7, P64342, DOI 10.18632/oncotarget.11841
   Hodzic D, 2006, GENOMICS, V88, P731, DOI 10.1016/j.ygeno.2006.05.009
   Holst MR, 2017, CELL REP, V20, P1893, DOI 10.1016/j.celrep.2017.08.006
   Holub AS, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218175
   Horpaopan S, 2015, INT J CANCER, V136, pE578, DOI 10.1002/ijc.29215
   Hou T, 2014, INT J CLIN EXP PATHO, V7, P280
   Hu GW, 2019, MED SCI MONITOR, V25, P7666, DOI 10.12659/MSM.915642
   Hu W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44048-y
   Hua X, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.584450
   Huang GH, 2017, MOL CELL NEUROSCI, V80, P18, DOI 10.1016/j.mcn.2017.01.007
   Huang WC, 2014, CANCER RES, V74, P751, DOI 10.1158/0008-5472.CAN-13-1297
   Huang YT, 2014, ONCOTARGET, V5, P6734, DOI 10.18632/oncotarget.2244
   Hui K, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0898-x
   Humphries B, 2017, CANCER RES, V77, P4051, DOI 10.1158/0008-5472.CAN-16-3141
   Hyun S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222212142
   Itoh T, 2011, J CELL BIOL, V192, P839, DOI 10.1083/jcb.201008107
   Jaafar L, 2021, HUM CELL, V34, P607, DOI 10.1007/s13577-020-00479-8
   Jaafar L, 2020, HUM CELL, V33, P437, DOI 10.1007/s13577-020-00358-2
   Jacob B, 2010, BLOOD, V115, P1610, DOI 10.1182/blood-2009-07-232249
   Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165
   Jia ZM, 2017, ONCOL LETT, V13, P1379, DOI 10.3892/ol.2017.5581
   Jiang NN, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152950
   Jin SH, 2008, INT J CANCER, V122, P1040, DOI 10.1002/ijc.23181
   Jinawath N, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10081194
   Johnson BA, 2010, GENES IMMUN, V11, P343, DOI 10.1038/gene.2009.81
   Johnstone CN, 2004, GENE, V336, P59, DOI 10.1016/j.gene.2004.01.025
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kandpal RP, 2006, CURR PROTEIN PEPT SC, V7, P355
   Kawai K, 2007, BIOCHEM BIOPH RES CO, V364, P783, DOI 10.1016/j.bbrc.2007.10.052
   Kim T, 2009, CANCER METAST REV, V28, P77, DOI 10.1007/s10555-008-9167-2
   Kim YE, 2019, MOL CELLS, V42, P441, DOI 10.14348/molcells.2019.0037
   Krauthammer M, 2015, NAT GENET, V47, P996, DOI 10.1038/ng.3361
   Kumar D, 2022, MOL CANCER RES, V20, P77, DOI 10.1158/1541-7786.MCR-20-1044
   Kumar D, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03673-0
   Lawrence MS, 2014, NATURE, V505, P495, DOI 10.1038/nature12912
   Lazarini M, 2013, BBA-MOL BASIS DIS, V1832, P365, DOI 10.1016/j.bbadis.2012.11.010
   Leung THY, 2010, LIVER INT, V30, P1315, DOI 10.1111/j.1478-3231.2010.02307.x
   Li JP, 2016, TUMOR BIOL, V37, P1411, DOI 10.1007/s13277-015-4502-z
   Li L, 2016, AM J TRANSL RES, V8, P4405
   Li N, 2014, BIOCHEM BIOPH RES CO, V455, P358, DOI 10.1016/j.bbrc.2014.11.020
   Li QL, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26600-5
   Li Y, 1996, CANCER RES, V56, P2872
   Li Y, 2015, ONCOTARGET, V6, P2421, DOI 10.18632/oncotarget.2965
   Li YF, 2019, BIOCHEMISTRY-US, V58, P1423, DOI 10.1021/acs.biochem.8b01323
   Liao YC, 2008, CANCER RES, V68, P7718, DOI 10.1158/0008-5472.CAN-08-2042
   Lim KC, 2013, NEUROSCIENCE, V252, P262, DOI 10.1016/j.neuroscience.2013.07.037
   Lin M, 2019, AM J CANCER RES, V9, P285
   Liu DX, 2013, JNCI-J NATL CANCER I, V105, P1617, DOI 10.1093/jnci/djt249
   Liu JQ, 2019, J CELL BIOCHEM, V120, P15790, DOI 10.1002/jcb.28849
   Liu L, 2016, ONCOTARGET, V7, P3766, DOI 10.18632/oncotarget.6501
   Liu ZD, 2019, EUR REV MED PHARMACO, V23, P5840, DOI 10.26355/eurrev_201907_18326
   Liu Z, 2010, CLIN CANCER RES, V16, P6009, DOI 10.1158/1078-0432.CCR-10-1627
   Liu Z, 2020, ONCOTARGETS THER, V13, P8299, DOI 10.2147/OTT.S257729
   Lu SY, 2016, CHEM REV, V116, P6607, DOI 10.1021/acs.chemrev.5b00542
   Ludwig Kirsten, 2011, Genes Cancer, V2, P20, DOI 10.1177/1947601911402680
   Lukasik D, 2011, ONCOL LETT, V2, P763, DOI 10.3892/ol.2011.345
   Luo RB, 2012, J BIOL CHEM, V287, P17176, DOI 10.1074/jbc.M111.334458
   Ma Qian-Qian, 2020, Oncotarget, V11, P4448, DOI 10.18632/oncotarget.24065
   Maertens Ophelia, 2014, Advances in Biological Regulation, V55, P1, DOI 10.1016/j.jbior.2014.04.002
   Maertens O, 2013, CANCER DISCOV, V3, P338, DOI 10.1158/2159-8290.CD-12-0313
   Mafakheri S, 2018, BIOCHEM SOC T, V46, P683, DOI 10.1042/BST20170479
   Maldonado MD, 2018, CANCER RES, V78, P3101, DOI 10.1158/0008-5472.CAN-18-0619
   Martinu L, 2004, MOL CELL BIOL, V24, P9752, DOI 10.1128/MCB.24.22.9752-9762.2004
   Masuda-Robens JM, 2003, MOL CELL BIOL, V23, P2151, DOI 10.1128/MCB.23.6.2151-2161.2003
   Matsumoto Y, 2004, FEBS LETT, V572, P135, DOI 10.1016/j.febslet.2004.07.023
   McDonald KL, 2007, J NEUROPATH EXP NEUR, V66, P405, DOI 10.1097/nen.0b013e31804567d7
   McGillicuddy LT, 2009, CANCER CELL, V16, P44, DOI 10.1016/j.ccr.2009.05.009
   McLaughlin SK, 2013, CANCER CELL, V24, P365, DOI 10.1016/j.ccr.2013.08.004
   Min J, 2010, NAT MED, V16, P286, DOI 10.1038/nm.2100
   Min W, 2008, CIRC RES, V102, P840, DOI 10.1161/CIRCRESAHA.107.168153
   Mishra R, 2019, ENDOCR-RELAT CANCER, V26, pR673, DOI 10.1530/ERC-19-0347
   Mokarram P, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007012
   Molina-Ortiz I, 2009, J BIOL CHEM, V284, P15147, DOI 10.1074/jbc.M807834200
   Müller T, 2010, ONCOGENE, V29, P2393, DOI 10.1038/onc.2010.6
   Nabeshima K, 2002, CANCER LETT, V176, P101, DOI 10.1016/S0304-3835(01)00742-X
   Naim N, 2021, CRIT REV ONCOL HEMAT, V168, DOI 10.1016/j.critrevonc.2021.103524
   Nakajima EC, 2022, CLIN CANCER RES, V28, P1482, DOI 10.1158/1078-0432.CCR-21-3074
   Nasrallah A, 2014, ONCOL REP, V31, P505, DOI 10.3892/or.2013.2861
   Nissan MH, 2014, CANCER RES, V74, P2340, DOI 10.1158/0008-5472.CAN-13-2625
   Notsuda H, 2013, INT J ONCOL, V43, P1569, DOI 10.3892/ijo.2013.2096
   Nozima BH, 2019, ENDOCR-RELAT CANCER, V26, P227, DOI 10.1530/ERC-17-0530
   O'Brien JB, 2019, J BIOL CHEM, V294, P18571, DOI 10.1074/jbc.REV119.007060
   Ohta M, 2009, GASTROENTEROLOGY, V136, P206, DOI 10.1053/j.gastro.2008.09.063
   Okabe H, 2004, INT J ONCOL, V24, P43
   Oliveira AM, 2004, CANCER RES, V64, P1920, DOI 10.1158/0008-5472.CAN-03-2827
   Olsen SN, 2017, CANCER DISCOV, V7, P202, DOI 10.1158/2159-8290.CD-16-0520
   Organ SL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086103
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Otaño-Joos M, 2000, CYTOGENET CELL GENET, V90, P86, DOI 10.1159/000015640
   Ouyang X, 2008, CANCER RES, V68, P2132, DOI 10.1158/0008-5472.CAN-07-6055
   Pan XJ, 2006, NATURE, V442, P303, DOI 10.1038/nature04847
   Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622
   Paulding CA, 2003, P NATL ACAD SCI USA, V100, P2507, DOI 10.1073/pnas.0437015100
   Pei L, 2002, CANCER RES, V62, P5420
   Peng H, 2015, AM J PATHOL, V185, P1135, DOI 10.1016/j.ajpath.2014.12.016
   Peng YM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27309-1
   Post Jasmin B, 2019, Oncotarget, V10, P1440, DOI 10.18632/oncotarget.26677
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612
   Qi TYF, 2020, PROTEOMICS, V20, DOI 10.1002/pmic.201900347
   Qian XL, 2007, P NATL ACAD SCI USA, V104, P9012, DOI 10.1073/pnas.0703033104
   Quah SY, 2016, PHARMACOL THERAPEUT, V162, P35, DOI 10.1016/j.pharmthera.2016.03.010
   Roberti MC, 2009, VIRCHOWS ARCH, V454, P311, DOI 10.1007/s00428-009-0732-z
   Roberts T, 1998, HUM MOL GENET, V7, P1169, DOI 10.1093/hmg/7.7.1169
   Roy NS, 2019, J BIOL CHEM, V294, P17354, DOI 10.1074/jbc.RA119.009269
   Rudack T, 2012, P NATL ACAD SCI USA, V109, P15295, DOI 10.1073/pnas.1204333109
   Sato H, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-17
   Sato N, 2010, GENE CHROMOSOME CANC, V49, P353, DOI 10.1002/gcc.20747
   Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333
   Schmidt VA, 2008, MOL CELL BIOL, V28, P1489, DOI 10.1128/MCB.01090-07
   Shen CH, 2008, CANCER RES, V68, P7779, DOI 10.1158/0008-5472.CAN-08-0997
   Shen CL, 2005, J BIOL CHEM, V280, P35967, DOI 10.1074/jbc.M505220200
   Shen YH, 2020, ONCOTARGETS THER, V13, P389, DOI 10.2147/OTT.S227644
   Shen YH, 2019, ONCOTARGETS THER, V12, P5003, DOI 10.2147/OTT.S207560
   Shen YH, 2019, CARCINOGENESIS, V40, P1405, DOI 10.1093/carcin/bgz067
   Shi YJ, 2017, J TRANSL MED, V15, DOI 10.1186/s12967-017-1275-8
   Shigeto M, 2017, J MOL MED, V95, P361, DOI 10.1007/s00109-017-1508-6
   Shimizu D, 2019, ANTICANCER RES, V39, P99, DOI 10.21873/anticanres.13084
   Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009
   Singh MK, 2015, BIOORG MED CHEM LETT, V25, P4838, DOI 10.1016/j.bmcl.2015.06.062
   Smits M, 2012, CLIN CANCER RES, V18, P4048, DOI 10.1158/1078-0432.CCR-12-0399
   Song LJ, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0470-x
   Stefanska B, 2014, CLIN CANCER RES, V20, P3118, DOI 10.1158/1078-0432.CCR-13-0283
   Stewart DRH, 2020, J CELL SCI, V133, DOI 10.1242/jcs.238865
   Strassheim D, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060551
   Su DY, 2017, ONCOTARGETS THER, V10, P1549, DOI 10.2147/OTT.S128564
   Sun D, 2015, BRIT J CANCER, V112, P1491, DOI 10.1038/bjc.2015.107
   Sun DF, 2013, J BIOL CHEM, V288, P9508, DOI 10.1074/jbc.M112.367763
   Sun L, 2019, MOL MED REP, V19, P4881, DOI 10.3892/mmr.2019.10146
   Sun Z, 2017, CANCER SCI, V108, P61, DOI 10.1111/cas.13118
   Takagi K, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030804
   Tang JT, 2017, ONCOL REP, V38, P2251, DOI 10.3892/or.2017.5862
   Tang TJ, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08086-y
   Tao WY, 2016, J CANCER, V7, P1653, DOI 10.7150/jca.14762
   Tcherkezian J, 2007, BIOL CELL, V99, P67, DOI 10.1042/BC20060086
   Teng JP, 2017, ONCOL LETT, V14, P4613, DOI 10.3892/ol.2017.6729
   Tian HY, 2017, CANCER SCI, V108, P1544, DOI 10.1111/cas.13281
   Tian T, 2020, THERANOSTICS, V10, P5998, DOI 10.7150/thno.43427
   Tisi R, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111535
   Tona R, 2019, HUM MOL GENET, V28, P1530, DOI 10.1093/hmg/ddy445
   Tripathi SC, 2012, MODERN PATHOL, V25, P14, DOI 10.1038/modpathol.2011.145
   Tsao H, 2012, GENE DEV, V26, P1131, DOI 10.1101/gad.191999.112
   Ullmannova V, 2007, CANCER DETECT PREV, V31, P110, DOI 10.1016/j.cdp.2007.02.005
   van Adrichem AJ, 2015, COMB CHEM HIGH T SCR, V18, P3, DOI 10.2174/1386207318666141205112730
   Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617
   Varghese S, 2010, ANN SURG ONCOL, V17, P1870, DOI 10.1245/s10434-010-0998-z
   Vetter IR, 2001, SCIENCE, V294, P1299, DOI 10.1126/science.1062023
   Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960
   Vitali Teresa, 2019, Small GTPases, V10, P280, DOI 10.1080/21541248.2017.1299271
   Vizoso M, 2015, NAT MED, V21, P741, DOI 10.1038/nm.3863
   von Bergh ARM, 2004, GENE CHROMOSOME CANC, V39, P324, DOI 10.1002/gcc.20004
   Wainszelbaum MJ, 2008, J BIOL CHEM, V283, P13233, DOI 10.1074/jbc.M800234200
   Wainszelbaum MJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031225
   Wang B, 2017, CANCER LETT, V408, P60, DOI 10.1016/j.canlet.2017.08.021
   Wang DR, 2020, CANCER RES, V80, P3568, DOI 10.1158/0008-5472.CAN-19-3984
   Wang DR, 2016, ONCOTARGET, V7, P45144, DOI 10.18632/oncotarget.9266
   Wang J, 2014, ONCOGENE, V33, P1181, DOI 10.1038/onc.2013.42
   Wang JM, 2015, ONCOTARGET, V6, P27427, DOI 10.18632/oncotarget.4861
   Wang L, 2020, CARCINOGENESIS, V41, P711, DOI 10.1093/carcin/bgz144
   Wang L, 2019, MED SCI MONITOR, V25, P21, DOI 10.12659/MSM.911503
   Wang L, 2017, MOL BIOSYST, V13, P2564, DOI 10.1039/c7mb00406k
   Wang XL, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01688
   Wang Z, 2002, J BIOL CHEM, V277, P12622, DOI 10.1074/jbc.M110568200
   Wang ZL, 2015, INT J CLIN EXP MED, V8, P18765
   Wei T, 2021, CANCERS, V13, DOI 10.3390/cancers13163940
   Wei Tao, 2020, Oncoscience, V7, P49, DOI 10.18632/oncoscience.511
   Welz T, 2014, TRENDS CELL BIOL, V24, P407, DOI 10.1016/j.tcb.2014.02.004
   Wennerberg K, 2005, J CELL SCI, V118, P843, DOI 10.1242/jcs.01660
   White CD, 2012, CELL SIGNAL, V24, P826, DOI 10.1016/j.cellsig.2011.12.005
   Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470
   Winter JJG, 2015, J MED CHEM, V58, P2265, DOI 10.1021/jm501660t
   Wolosz D, 2019, EUR J HISTOCHEM, V63, P32, DOI 10.4081/ejh.2019.2981
   Wong CCL, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002779
   Wouters J, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0851-3
   Wu GT, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-3474
   Wu J, 2019, INT J BIOL MARKER, V34, P348, DOI 10.1177/1724600819876951
   Wu MH, 2014, ONCOGENE, V33, P5109, DOI 10.1038/onc.2014.125
   Wu PP, 2015, NEOPLASMA, V62, P705, DOI 10.4149/neo_2015_084
   Wu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048917
   Wu YK, 2019, ONCOL REP, V41, P2281, DOI 10.3892/or.2019.7031
   Xia FD, 2014, ASIAN PAC J CANCER P, V15, P4951, DOI 10.7314/APJCP.2014.15.12.4951
   Xie DX, 2010, P NATL ACAD SCI USA, V107, P2485, DOI 10.1073/pnas.0908133107
   Xie DX, 2009, P NATL ACAD SCI USA, V106, P19878, DOI 10.1073/pnas.0908458106
   Xie YY, 2019, TRANSL ONCOL, V12, P236, DOI 10.1016/j.tranon.2018.10.009
   Xie YY, 2012, BBA-MOL BASIS DIS, V1822, P875, DOI 10.1016/j.bbadis.2012.02.019
   Xu F, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00416-0
   Xu GS, 2016, ONCOTARGET, V7, P51829, DOI 10.18632/oncotarget.10386
   Xu L, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21061968
   Xu WH, 2016, AM J TRANSL RES, V8, P5421
   Xu Y, 2019, UROL ONCOL-SEMIN ORI, V37, P86, DOI 10.1016/j.urolonc.2018.10.023
   Xu YT, 2015, FEBS LETT, V589, P1127, DOI 10.1016/j.febslet.2015.03.027
   Xue W, 2008, GENE DEV, V22, P1439, DOI 10.1101/gad.1672608
   Yan MS, 2016, ONCOL REP, V36, P65, DOI 10.3892/or.2016.4767
   Yang HR, 2016, PROTEIN CELL, V7, P878, DOI 10.1007/s13238-016-0346-6
   Yang Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097578
   Yano M, 2005, INT J CANCER, V113, P59, DOI 10.1002/ijc.20531
   Yao F, 2015, CELL REP, V12, P272, DOI 10.1016/j.celrep.2015.06.020
   Yin GY, 2004, MOL CELL BIOL, V24, P875, DOI 10.1128/MCB.24.2.875-885.2004
   Yoo Sungsoo M, 2020, Small GTPases, V11, P77, DOI 10.1080/21541248.2017.1362496
   Yoo SM, 2012, J BIOL CHEM, V287, P31462, DOI 10.1074/jbc.M112.353615
   Yu L, 2019, AGING-US, V11, P5300, DOI 10.18632/aging.102092
   Yuan J, 2017, CANCER RES, V77, P6614, DOI 10.1158/0008-5472.CAN-17-1143
   Zeng FY, 2018, MED SCI MONITOR, V24, P3315, DOI 10.12659/MSM.909916
   Zeng YL, 2020, CANCER LETT, V493, P254, DOI 10.1016/j.canlet.2020.08.042
   Zhang H, 2017, BIOTECHNOL LETT, V39, P207, DOI 10.1007/s10529-016-2253-6
   Zhang HF, 2008, J CLIN INVEST, V118, P3904, DOI 10.1172/JCI36168
   Zhang QS, 2007, P NATL ACAD SCI USA, V104, P7444, DOI 10.1073/pnas.0702136104
   Zhang R, 2007, J BIOL CHEM, V282, P14788, DOI 10.1074/jbc.M701148200
   Zhang SL, 2018, ONCOTARGETS THER, V11, P2955, DOI 10.2147/OTT.S154524
   Zhang T, 2018, ONCOL LETT, V15, P4432, DOI 10.3892/ol.2018.7834
   Zhang TT, 2015, INT J RADIAT BIOL, V91, P368, DOI 10.3109/09553002.2015.1001531
   Zhang XJ, 2012, J GASTROEN HEPATOL, V27, P1117, DOI 10.1111/j.1440-1746.2011.07049.x
   Zhao HY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113713
   Zhao HZ, 2017, ONCOTARGET, V8, P36383, DOI 10.18632/oncotarget.16756
   Zhao JM, 2014, TUMOR BIOL, V35, P12449, DOI 10.1007/s13277-014-2563-z
   Zhao Y, 2021, MOL ONCOL, V15, P1088, DOI 10.1002/1878-0261.12902
   Zheng XN, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01452-1
   Zheng ZY, 2020, CANCER CELL, V37, P387, DOI 10.1016/j.ccell.2020.02.003
   Zhou X, 2008, INT J ONCOL, V32, P1285
   Zhou YL, 2002, BIOCHEM BIOPH RES CO, V290, P830, DOI 10.1006/bbrc.2001.6257
   Zhu XH, 2017, INT J CANCER, V141, P172, DOI 10.1002/ijc.30701
   Zhu YJ, 2009, J BIOL CHEM, V284, P13489, DOI 10.1074/jbc.M900469200
   Zoheir KMA, 2016, TUMOR BIOL, V37, P13927, DOI 10.1007/s13277-016-5283-8
   Zoheir KM, 2015, INT J CLIN EXP PATHO, V8, P8821
   Zohrabian VM, 2007, ONCOL REP, V18, P321
NR 310
TC 4
Z9 4
U1 7
U2 28
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD FEB 15
PY 2023
VL 248
AR 115104
DI 10.1016/j.ejmech.2023.115104
EA JAN 2023
PG 19
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 8L3CB
UT WOS:000923662000001
PM 36641861
DA 2025-01-04
ER

PT J
AU Maron, SB
   Xu, J
   Janjigian, YY
AF Maron, Steven B.
   Xu, James
   Janjigian, Yelena Y.
TI Targeting EGFR in Esophagogastric Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE esophageal cancer; gastric cancer; gastroesophageal cancer; epidermal
   growth factor receptor; cetuximab; panitumumab; targeted therapy; ctDNA
ID PHASE-II TRIAL; METASTATIC GASTRIC-CANCER; SQUAMOUS-CELL CARCINOMA;
   GROWTH-FACTOR RECEPTOR; ADVANCED ESOPHAGEAL; 2ND-LINE TREATMENT;
   1ST-LINE TREATMENT; BIOMARKER ANALYSIS; COLORECTAL-CANCER; MODIFIED
   FOLFOX6
AB Esophagogastric cancer (EGC) remains a major cause of cancer-related mortality. Overall survival in the metastatic setting remains poor, with few molecular targeted approaches having been successfully incorporated into routine care to-date: only first line anti-HER2 therapy in ERBB2-expressing tumors, second line anti-VEGFR2 therapy with ramucirumab in unselected patients, and pembrolizumab in PD-L1 expressing or MSI-H patients. EGFR inhibitors were extensively studied in EGC, including phase III trials with cetuximab (EXPAND), panitumumab (REAL3), and gefitinib (COG). All three trials were conducted in unselected populations, and therefore, failed to demonstrate clinical benefit. Here, we review previous attempts at targeting EGFR in EGC and potential future biomarkers for targeting this pathway in patients with EGFR-amplified tumors.
C1 [Maron, Steven B.; Janjigian, Yelena Y.] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, Div Solid Tumor Oncol, 1275 York Ave, New York, NY 10021 USA.
   [Xu, James] Columbia Univ, Comp Engn Program, New York, NY USA.
C3 Memorial Sloan Kettering Cancer Center; Columbia University
RP Maron, SB (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, Div Solid Tumor Oncol, 1275 York Ave, New York, NY 10021 USA.
EM marons@mskcc.org
OI Xu, James/0000-0001-7420-2842
CR [Anonymous], 2020, J CLIN ONCOL S, DOI DOI 10.1200/JCO.2020.38.15_suppl.9512
   [Anonymous], 2020, J CLIN ONCOL S, DOI DOI 10.1200/JCO.2020.38.4_suppl.356
   [Anonymous], 2020, J CLIN ONCOL S, DOI DOI 10.1200/JCO.2020.38.15_suppl.3550
   Bang YJ, 2010, LANCET, V376, P1302
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Carneiro BA, 2020, J CLIN ONCOL, V38, p15s
   Chan JA, 2011, ANN ONCOL, V22, P1367, DOI 10.1093/annonc/mdq604
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Du F, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000000958
   Dutton SJ, 2014, LANCET ONCOL, V15, P894, DOI 10.1016/S1470-2045(14)70024-5
   Enzinger PC, 2016, J CLIN ONCOL, V34, P2736, DOI 10.1200/JCO.2015.65.5092
   Feng KC, 2016, SCI CHINA LIFE SCI, V59, P468, DOI 10.1007/s11427-016-5023-8
   Gold PJ, 2010, J THORAC ONCOL, V5, P1472, DOI 10.1097/JTO.0b013e3181e77a92
   Han SW, 2009, BRIT J CANCER, V100, P298, DOI 10.1038/sj.bjc.6604861
   Huang J, 2016, J THORAC ONCOL, V11, P910, DOI 10.1016/j.jtho.2016.02.020
   Iyer R, 2013, ONCOLOGY-BASEL, V85, P53, DOI 10.1159/000351617
   Janjigian YY, 2014, AM J CLIN ONCOL-CANC, V37, P126, DOI 10.1097/COC.0b013e318271b14f
   Janmaat ML, 2006, J CLIN ONCOL, V24, P1612, DOI 10.1200/JCO.2005.03.4900
   Kato S, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00180
   Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805
   Kim MA, 2008, HISTOPATHOLOGY, V52, P738, DOI 10.1111/j.1365-2559.2008.03021.x
   LaBonte MJ, 2016, MOL CANCER THER, V15, P2251, DOI 10.1158/1535-7163.MCT-15-0908
   Liu X, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3174-z
   Lordick F, 2010, BRIT J CANCER, V102, P500, DOI 10.1038/sj.bjc.6605521
   Lordick F, 2013, J CLIN ONCOL, V31
   Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5
   Lorenzen S, 2009, ANN ONCOL, V20, P1667, DOI 10.1093/annonc/mdp069
   Luber B, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-509
   Lum LG, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1773201
   Lundy J, 2020, J CLIN ONCOL, V38
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Maron SB, 2019, CLIN CANCER RES, V25, P7098, DOI 10.1158/1078-0432.CCR-19-1704
   Maron SB, 2018, CANCER DISCOV, V8, P696, DOI 10.1158/2159-8290.CD-17-1260
   Moehler M, 2011, ANN ONCOL, V22, P1358, DOI 10.1093/annonc/mdq591
   Moehler M, 2018, CANCER CHEMOTH PHARM, V82, P733, DOI 10.1007/s00280-018-3667-8
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Nagatsuma AK, 2015, GASTRIC CANCER, V18, P227, DOI 10.1007/s10120-014-0360-4
   Petty RD, 2017, J CLIN ONCOL, V35, P2279, DOI 10.1200/JCO.2016.70.3934
   Pinto C, 2007, ANN ONCOL, V18, P510, DOI 10.1093/annonc/mdl459
   Pinto C, 2009, BRIT J CANCER, V101, P1261, DOI 10.1038/sj.bjc.6605319
   Rao S, 2010, ANN ONCOL, V21, P2213, DOI 10.1093/annonc/mdq247
   Richards D, 2013, EUR J CANCER, V49, P2823, DOI 10.1016/j.ejca.2013.04.022
   Satoh T, 2015, GASTRIC CANCER, V18, P824, DOI 10.1007/s10120-014-0420-9
   Schonnemann KR, 2012, EUR J CANCER, V48, P510, DOI 10.1016/j.ejca.2011.12.005
   Schulze WX, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100012
   Smyth E, 2018, ANN ONCOL, V29
   Stachler MD, 2015, NAT GENET, V47, P1047, DOI 10.1038/ng.3343
   Stintzing S, 2016, LANCET ONCOL, V17, P1426, DOI 10.1016/S1470-2045(16)30269-8
   Tebbutt NC, 2016, BRIT J CANCER, V114, P505, DOI 10.1038/bjc.2015.440
   Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797
   Terashima M, 2012, CLIN CANCER RES, V18, P5992, DOI 10.1158/1078-0432.CCR-12-1318
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2
   Wainberg ZA, 2011, BRIT J CANCER, V105, P760, DOI 10.1038/bjc.2011.280
   Wang KL, 2007, CANCER-AM CANCER SOC, V109, P658, DOI 10.1002/cncr.22445
   Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6
   Wöll E, 2011, ANTICANCER RES, V31, P4439
   Yano S, 2003, ANTICANCER RES, V23, P3639
   Yoon H, 2018, ONCOLOGIST, V23, P1004, DOI 10.1634/theoncologist.2017-0657
   Zang ZJ, 2011, CANCER RES, V71, P29, DOI 10.1158/0008-5472.CAN-10-1749
NR 64
TC 14
Z9 15
U1 1
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD DEC 8
PY 2020
VL 10
AR 553876
DI 10.3389/fonc.2020.553876
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PH7US
UT WOS:000600613300001
PM 33364187
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Freund, E
   Liedtke, KR
   Miebach, L
   Wende, K
   Heidecke, A
   Kaushik, NK
   Choi, EH
   Partecke, LI
   Bekeschus, S
AF Freund, Eric
   Liedtke, Kim-Rouven
   Miebach, Lea
   Wende, Kristian
   Heidecke, Amanda
   Kaushik, Nagendra Kumar
   Choi, Eun Ha
   Partecke, Lars-Ivo
   Bekeschus, Sander
TI Identification of Two Kinase Inhibitors with Synergistic Toxicity with
   Low-Dose Hydrogen Peroxide in Colorectal Cancer Cells In vitro
SO CANCERS
LA English
DT Article
DE anticancer drugs; pancreatic cancer; screening; tumor spheroids
ID GROWTH-FACTOR RECEPTOR; HEATED INTRAPERITONEAL OXALIPLATIN;
   PROTEIN-KINASE; CYCLE ARREST; CYTOREDUCTIVE SURGERY; PERITONEAL
   METASTASIS; PHOTODYNAMIC THERAPY; CLINICAL-RESPONSE; TARGETED THERAPY;
   REDOX REGULATION
AB Colorectal carcinoma is among the most common types of cancers. With this disease, diffuse scattering in the abdominal area (peritoneal carcinosis) often occurs before diagnosis, making surgical removal of the entire malignant tissue impossible due to a large number of tumor nodules. Previous treatment options include radiation and its combination with intraperitoneal heat-induced chemotherapy (HIPEC). Both options have strong side effects and are often poor in therapeutic efficacy. Tumor cells often grow and proliferate dysregulated, with enzymes of the protein kinase family often playing a crucial role. The present study investigated whether a combination of protein kinase inhibitors and low-dose induction of oxidative stress (using hydrogen peroxide, H2O2) has an additive cytotoxic effect on murine, colorectal tumor cells (CT26). Protein kinase inhibitors from a library of 80 substances were used to investigate colorectal cancer cells for their activity, morphology, and immunogenicity (immunogenic cancer cell death, ICD) upon mono or combination. Toxic compounds identified in 2D cultures were confirmed in 3D cultures, and additive cytotoxicity was identified for the substances lavendustin A, GF109203X, and rapamycin. Toxicity was concomitant with cell cycle arrest, but except HMGB1, no increased expression of immunogenic markers was identified with the combination treatment. The results were validated for GF109203X and rapamycin but not lavendustin A in the 3D model of different colorectal (HT29, SW480) and pancreatic cancer cell lines (MiaPaca, Panc01). In conclusion, our in vitro data suggest that combining oxidative stress with chemotherapy would be conceivable to enhance antitumor efficacy in HIPEC.
C1 [Freund, Eric; Liedtke, Kim-Rouven; Miebach, Lea; Partecke, Lars-Ivo] Greifswald Univ, Med Ctr, Dept Gen Visceral Thorac & Vasc Surg, D-17475 Greifswald, Germany.
   [Freund, Eric; Miebach, Lea; Wende, Kristian; Heidecke, Amanda; Bekeschus, Sander] Leibniz Inst Plasma Sci & Technol INP Greifswald, Ctr Innovat Competence ZIK Plasmatis, D-17489 Greifswald, Germany.
   [Kaushik, Nagendra Kumar; Choi, Eun Ha] Kwangwoon Univ, PBRC, Seoul 139710, South Korea.
   [Partecke, Lars-Ivo] Helios Clin Schleswig, Gen Visceral & Thorac Surg, D-24837 Schleswig, Germany.
C3 Leibniz Institut fur Plasmaforschung und Technologie; Kwangwoon
   University
RP Bekeschus, S (corresponding author), Leibniz Inst Plasma Sci & Technol INP Greifswald, Ctr Innovat Competence ZIK Plasmatis, D-17489 Greifswald, Germany.
EM eric.freund@inp-greifswald.de; Kim.Liedtke@med.uni-greifswald.de;
   miebachlea.uni@gmail.com; Kristian.wende@inp-greifswald.de;
   amanda.k.heidecke@gmail.com; kaushik.nagendra@kw.ac.kr;
   choipdp@gmail.com; partecke@googlemail.com;
   sander.bekeschus@inp-greifswald.de
RI Choi, Eun/AFN-9488-2022; Bekeschus, Sander/KSM-1629-2024; Wende,
   Kristian/AAE-8810-2020; Kaushik, Nagendra/J-7033-2012; Kaushik, Nagendra
   Kumar/H-5534-2018
OI Kaushik, Nagendra Kumar/0000-0002-4965-5046; Liedtke, Kim
   R./0000-0002-0273-509X; Freund, Eric/0000-0003-2950-0984; Choi, Eun
   Ha/0000-0001-5385-1878
FU Federal German Ministry of Education and Research [03Z22DN11]
FX S.B. and E.F. are supported by the Federal German Ministry of Education
   and Research (grant no. 03Z22DN11).
CR Abe J, 1996, J BIOL CHEM, V271, P16586, DOI 10.1074/jbc.271.28.16586
   Adkins I, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.968434
   Adler A, 2014, BMC GASTROENTEROL, V14, DOI 10.1186/1471-230X-14-183
   Agarwal A, 2018, NUTR RES, V51, P67, DOI 10.1016/j.nutres.2017.12.011
   Agostinis P, 2011, CA-CANCER J CLIN, V61, P250, DOI 10.3322/caac.20114
   Alexander HR, 2018, ANN SURG ONCOL, V25, P2159, DOI 10.1245/s10434-018-6337-5
   Alexandrova AY, 2006, EXP CELL RES, V312, P2066, DOI 10.1016/j.yexcr.2006.03.004
   Alimbetov D, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061690
   Allen RG, 2000, FREE RADICAL BIO MED, V28, P463, DOI 10.1016/S0891-5849(99)00242-7
   [Anonymous], 2016, ELIFE
   Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145
   Augestad KM, 2014, WORLD J GASTRO ONCOL, V6, P104, DOI 10.4251/wjgo.v6.i5.104
   AUGUST DA, 1984, CANCER METAST REV, V3, P303, DOI 10.1007/BF00051457
   Azad MB, 2009, ANTIOXID REDOX SIGN, V11, P777, DOI [10.1089/ars.2008.2270, 10.1089/ARS.2008.2270]
   Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Baratti D, 2016, CRIT REV ONCOL HEMAT, V100, P209, DOI 10.1016/j.critrevonc.2016.01.017
   Baselga J, 2002, ONCOLOGIST, V7, P2
   Bekeschus S, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/8535163
   Bekeschus S, 2018, CLIN PLASMA MED, V12, P17, DOI 10.1016/j.cpme.2018.10.001
   Bekeschus S, 2018, IEEE T RADIAT PLASMA, V2, P138, DOI 10.1109/TRPMS.2017.2766027
   BENADE L, 1969, ONCOLOGY-BASEL, V23, P33, DOI 10.1159/000224465
   Beroukhim R, 2010, NATURE, V463, P899, DOI 10.1038/nature08822
   BLOBE GC, 1993, J BIOL CHEM, V268, P658
   Bown S., 2017, PHOTODIAGN PHOTODYN, V17, pA28, DOI [10.1016/j.pdpdt.2017.01.063, DOI 10.1016/J.PDPDT.2017.01.063]
   Brenner H, 2015, CLIN GASTROENTEROL H, V13, P717, DOI 10.1016/j.cgh.2014.08.036
   BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248
   Burke AJ, 2016, ANTICANCER RES, V36, P633
   Cao XH, 2011, CHEM-BIOL INTERACT, V190, P16, DOI 10.1016/j.cbi.2011.01.010
   Cavaliere F, 2000, EUR J SURG ONCOL, V26, P486, DOI 10.1053/ejso.1999.0927
   Chen CH, 2011, FOOD CHEM TOXICOL, V49, P494, DOI 10.1016/j.fct.2010.11.031
   Chiarugi P, 2007, CELL SIGNAL, V19, P672, DOI 10.1016/j.cellsig.2006.11.009
   Choi HS, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0392-z
   Choi KM, 2007, ONCOL REP, V17, P1183
   COUSSENS L, 1986, SCIENCE, V233, P859, DOI 10.1126/science.3755548
   Davalli P, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/2389523
   Dutta PR, 2007, CANCER LETT, V254, P165, DOI 10.1016/j.canlet.2007.02.006
   Duval K, 2017, PHYSIOLOGY, V32, P266, DOI 10.1152/physiol.00036.2016
   Elias D, 2002, ONCOLOGY-BASEL, V63, P346, DOI 10.1159/000066229
   Erudaitius D, 2018, FREE RADICAL BIO MED, V120, P356, DOI 10.1016/j.freeradbiomed.2018.03.044
   Erudaitius D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170442
   Fabbro D, 2015, BRIT J PHARMACOL, V172, P2675, DOI 10.1111/bph.13096
   Fan CY, 2013, ELECTROPHORESIS, V34, P3305, DOI 10.1002/elps.201300250
   Flaherty KT, 2006, CLIN CANCER RES, V12, p2366S, DOI 10.1158/1078-0432.CCR-05-2505
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Freund E, 2019, APPL SCI-BASEL, V9, DOI 10.3390/app9122530
   Fucikova J, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00402
   Fuke H, 2007, BIOCHEM BIOPH RES CO, V363, P738, DOI 10.1016/j.bbrc.2007.09.049
   Fung MKL, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0509-9
   Fuse E, 1998, CANCER RES, V58, P3248
   Galluzzi L, 2015, CELL DEATH DIFFER, V22, P58, DOI 10.1038/cdd.2014.137
   Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107
   Gandhirajan RK, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-31031-2
   Garg AD, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00588
   Garg AD, 2017, IMMUNOL REV, V280, P126, DOI 10.1111/imr.12574
   Garg AD, 2014, PHOTOCH PHOTOBIO SCI, V13, P474, DOI 10.1039/c3pp50333j
   Gasparovic Ana Cipak, 2013, Methods Mol Biol, V965, P283, DOI 10.1007/978-1-62703-239-1_19
   Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298
   Glockzin Gabriel, 2016, World J Gastrointest Pharmacol Ther, V7, P343, DOI 10.4292/wjgpt.v7.i3.343
   GOODE N, 1992, J BIOL CHEM, V267, P16878
   Grandis JR, 2004, PHARMACOL THERAPEUT, V102, P37, DOI 10.1016/j.pharmthera.2004.01.002
   Grimes DR, 2018, J R SOC INTERFACE, V15, DOI 10.1098/rsif.2018.0256
   Grune T, 2001, J GERONTOL A-BIOL, V56, pB459, DOI 10.1093/gerona/56.11.B459
   Gulhati P, 2009, CLIN CANCER RES, V15, P7207, DOI 10.1158/1078-0432.CCR-09-1249
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanschmann EM, 2013, ANTIOXID REDOX SIGN, V19, P1539, DOI 10.1089/ars.2012.4599
   Heavey S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19688-1
   HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495
   HU DE, 1995, BRIT J PHARMACOL, V114, P262
   Ichijo H, 1997, SCIENCE, V275, P90, DOI 10.1126/science.275.5296.90
   Iglesias-Bartolome R, 2011, CURR OPIN CELL BIOL, V23, P716, DOI 10.1016/j.ceb.2011.08.002
   Inoue H, 2014, CELL DEATH DIFFER, V21, P39, DOI 10.1038/cdd.2013.84
   Jacquet P, 1998, ONCOLOGY-BASEL, V55, P130, DOI 10.1159/000011847
   JANEWAY CA, 1992, IMMUNOL TODAY, V13, P11, DOI 10.1016/0167-5699(92)90198-G
   Janssen YMW, 1997, AM J PHYSIOL-LUNG C, V273, pL789, DOI 10.1152/ajplung.1997.273.4.L789
   Jiang XH, 2004, CANCER RES, V64, P5787, DOI 10.1158/0008-5472.CAN-03-1172
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Juusola M, 2018, PANCREAS, V47, P1397
   Kecmanovic DM, 2005, EJSO-EUR J SURG ONC, V31, P147, DOI 10.1016/j.ejso.2004.09.021
   Khalili M, 2019, J PHYS D APPL PHYS, V52, DOI 10.1088/1361-6463/ab31c1
   Kontzias A, 2012, CURR OPIN PHARMACOL, V12, P464, DOI 10.1016/j.coph.2012.06.008
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Kusamura S, 2008, J SURG ONCOL, V98, P247, DOI 10.1002/jso.21051
   Lee KY, 2006, EUR J MED CHEM, V41, P991, DOI 10.1016/j.ejmech.2006.04.008
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Li XX, 2008, JNCI-J NATL CANCER I, V100, P672, DOI 10.1093/jnci/djn123
   Lin A, 2019, ADV SCI, V6, DOI 10.1002/advs.201802062
   Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X
   Lo YYC, 1996, J BIOL CHEM, V271, P15703, DOI 10.1074/jbc.271.26.15703
   Makino N, 2004, BBA-GEN SUBJECTS, V1673, P149, DOI 10.1016/j.bbagen.2004.04.011
   Malaviya R, 1999, J BIOL CHEM, V274, P38276
   Malvezzi M, 2014, ANN ONCOL, V25, P1650, DOI 10.1093/annonc/mdu138
   Matsuzawa A, 2005, NAT IMMUNOL, V6, P587, DOI 10.1038/ni1200
   Mehta AM, 2017, ANN SURG ONCOL, V24, P990, DOI 10.1245/s10434-016-5665-6
   Metelmann HR, 2018, CLIN PLASMA MED, V9, P6, DOI 10.1016/j.cpme.2017.09.001
   Metelmann HR, 2015, CLIN PLASMA MED, V3, P17, DOI 10.1016/j.cpme.2015.02.001
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   Mounce LTA, 2017, BRIT J CANCER, V116, P1536, DOI 10.1038/bjc.2017.127
   Nagata H, 2017, ANN SURG ONCOL, V24, P1269, DOI 10.1245/s10434-016-5732-z
   Nakao M, 1996, LEUKEMIA, V10, P1911
   Network The Cancer Genome Atlas Research, 2013, Nature, V494, P506, DOI 10.1038/nature11903
   Ng CF, 2007, FREE RADICAL RES, V41, P1201, DOI 10.1080/10715760701625075
   Nishitoh H, 1998, MOL CELL, V2, P389, DOI 10.1016/S1097-2765(00)80283-X
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Obeid M, 2007, NAT MED, V13, P54, DOI 10.1038/nm1523
   Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014
   Ohno S, 2009, ANTICANCER RES, V29, P809
   ONODA T, 1989, J NAT PROD, V52, P1252, DOI 10.1021/np50066a009
   Pandurangan AK, 2013, ASIAN PAC J CANCER P, V14, P2201, DOI 10.7314/APJCP.2013.14.4.2201
   Patel NR, 2015, THER DELIV, V6, P509, DOI [10.4155/tde.15.1, 10.4155/TDE.15.1]
   PIETRAS RJ, 1995, ONCOGENE, V10, P2435
   PONGRACZ J, 1995, INT J CANCER, V61, P35, DOI 10.1002/ijc.2910610107
   Postovit L, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/6135739
   Privat-Maldonado A, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/9062098
   Propper DJ, 2001, J CLIN ONCOL, V19, P1485, DOI 10.1200/JCO.2001.19.5.1485
   Quintás-Cardama A, 2013, CLIN CANCER RES, V19, P1933, DOI 10.1158/1078-0432.CCR-12-0284
   Rad E, 2018, CANCERS, V10, DOI 10.3390/cancers10010005
   Ravi M, 2015, J CELL PHYSIOL, V230, P16, DOI 10.1002/jcp.24683
   Ray PD, 2012, CELL SIGNAL, V24, P981, DOI 10.1016/j.cellsig.2012.01.008
   Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sartore-Bianchi A, 2016, ANN ONCOL, V27, P1456, DOI 10.1093/annonc/mdw191
   Schmitt CA, 2007, BBA-REV CANCER, V1775, P5, DOI 10.1016/j.bbcan.2006.08.005
   SCHWARTZ GK, 1993, J NATL CANCER I, V85, P402, DOI 10.1093/jnci/85.5.402
   Sciegienka S, 2018, PANCREAS, V47, P354
   Shapira M, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1000-4
   Shawver LK, 2002, CANCER CELL, V1, P117, DOI 10.1016/S1535-6108(02)00039-9
   Shida D, 2018, ANN SURG ONCOL, V25, P173, DOI 10.1245/s10434-017-6133-7
   SHIRAKAWA F, 1989, MOL CELL BIOL, V9, P2424, DOI 10.1128/MCB.9.6.2424
   Sievers D, 2018, MOL CLIN ONCOL, V8, P323, DOI 10.3892/mco.2017.1514
   Sihvola R, 1999, CIRCULATION, V99, P2295, DOI 10.1161/01.CIR.99.17.2295
   Sim SH, 2017, AM J PATHOL, V187, P980, DOI 10.1016/j.ajpath.2017.01.004
   Smith KM, 2003, MOL CELL, V12, P27, DOI 10.1016/S1097-2765(03)00274-0
   STABEL S, 1991, PHARMACOL THERAPEUT, V51, P71, DOI 10.1016/0163-7258(91)90042-K
   Strauss L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005994
   Taddei ML, 2007, ANTIOXID REDOX SIGN, V9, P469, DOI 10.1089/ars.2006.1392
   Tarek N, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.26768
   Tee AR, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030880
   Thiagarajah JR, 2017, P NATL ACAD SCI USA, V114, P568, DOI 10.1073/pnas.1612921114
   Tobiume K, 2001, EMBO REP, V2, P222, DOI 10.1093/embo-reports/kve046
   Trachootham D, 2008, ANTIOXID REDOX SIGN, V10, P1343, DOI 10.1089/ars.2007.1957
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K
   Vaidyanathan A, 2018, CLIN CANCER RES, V24, P79
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Vincent A, 2011, LANCET, V378, P607, DOI 10.1016/S0140-6736(10)62307-0
   Wang LL, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/3481710
   Winter J, 2014, J PHYS D APPL PHYS, V47, DOI 10.1088/0022-3727/47/28/285401
   Wu HM, 2010, CANCER LETT, V298, P16, DOI 10.1016/j.canlet.2010.05.022
   Wu Q, 2014, CANCER LETT, V347, P159, DOI 10.1016/j.canlet.2014.03.013
   Xiong ZL, 2017, J PHYS D APPL PHYS, V50, DOI 10.1088/1361-6463/50/5/05LT01
   Xue L, 2018, BIOMED PHARMACOTHER, V98, P694, DOI 10.1016/j.biopha.2017.12.106
   Zhang YJ, 2009, ANN SURG ONCOL, V16, P2617, DOI 10.1245/s10434-009-0555-9
NR 155
TC 16
Z9 18
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JAN
PY 2020
VL 12
IS 1
AR 122
DI 10.3390/cancers12010122
PG 26
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KQ3KZ
UT WOS:000516826700122
PM 31906582
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Zhang, JF
   Hu, SF
   Li, YS
AF Zhang, Jingfeng
   Hu, Sifeng
   Li, Yansen
TI KRT18 is correlated with the malignant status and acts as an oncogene in
   colorectal cancer
SO BIOSCIENCE REPORTS
LA English
DT Article
ID SQUAMOUS-CELL CARCINOMA; MOLECULAR CHARACTERIZATION; TARGETED THERAPY;
   EXPRESSION; GENE; CYTOKERATINS; MIGRATION; CK18
AB Keratin 18 (KRT18) has been suggested to be overexpressed in most types of human tumor, but the expression pattern of KRT18 in colorectal cancer (CRC) remained unknown. In our research, KRT18 protein expression was markedly increased in CRC cancer tissues and cell lines compared with adjacent normal colorectal tissues and normal colonic epithelial cell line, respectively. Meanwhile, we observed high KRT18 expression was associated with advanced clinical stage, deep tumor invasion, lymph node metastasis, distant metastasis, poor differentiation and unfavorable prognosis in CRC patients. Multivariate Cox regression analysis showed high expression of KRT18 was an unfavorable independent predictor for overall survival in CRC patients. The in vitro studies indicated down-regulation of KRT18 expression depressed CRC cell viability, migration and invasion. In conclusion, KRT18 serves as an oncogenic role in CRC progression and may be a therapeutic target for promoting CRC patients' prognosis.
C1 [Zhang, Jingfeng; Li, Yansen] Jining Med Univ, Dept Anorectal Surg, Affiliated Hosp, Jining 272029, Shandong, Peoples R China.
   [Hu, Sifeng] Zhoucheng Peoples Hosp, Dept Gen Surg, Zhoucheng 27350012, Shandong, Peoples R China.
C3 Jining Medical University
RP Li, YS (corresponding author), Jining Med Univ, Dept Anorectal Surg, Affiliated Hosp, Jining 272029, Shandong, Peoples R China.
EM liyansenjn@126.com
CR Afrem MC, 2016, ROM J MORPHOL EMBRYO, V57, P167
   Akiba J, 2016, J CLIN PATHOL, V69, P846, DOI 10.1136/jclinpath-2015-203491
   Bettermann K, 2016, ONCOTARGET, V7, P73309, DOI 10.18632/oncotarget.12325
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Catto JWF, 2010, EUR UROL, V57, P398, DOI 10.1016/j.eururo.2009.10.029
   Chalabi N., 2008, Cancer Genomics & Proteomics, V5, P253
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Doebar SC, 2017, AM J PATHOL, V187, P1648, DOI 10.1016/j.ajpath.2017.03.012
   Drew JE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113071
   Fortier AM, 2013, J BIOL CHEM, V288, P11555, DOI 10.1074/jbc.M112.428920
   Golob-Schwarzi N, 2019, TRANSL ONCOL, V12, P256, DOI 10.1016/j.tranon.2018.10.010
   Huang Shuo, 2015, Lin Chung Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V29, P111
   Kilic-Baygutalp N, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15038583
   Koehler DR, 2001, MOL THER, V4, P58, DOI 10.1006/mthe.2001.0412
   Kolostova K, 2016, AM J CANCER RES, V6, P973
   Lähdeniemi IA, 2017, CELL DEATH DIFFER, V24, P984, DOI 10.1038/cdd.2017.28
   Lai YCC, 2017, CANCER GENOM PROTEOM, V14, P219, DOI 10.21873/cgp.20033
   Lebherz-Eichinger D, 2013, ADV CLIN CHEM, V62, P123, DOI 10.1016/B978-0-12-800096-0.00003-2
   Lee CF, 2009, WORLD J GASTROENTERO, V15, P356, DOI 10.3748/wjg.15.356
   Liu JW, 2012, THORAC CANCER, V3, P207, DOI 10.1111/j.1759-7714.2011.00092.x
   Lorente L, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17091524
   Morisaki T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110736
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nagashio R, 2010, PATHOL INT, V60, P71, DOI 10.1111/j.1440-1827.2009.02487.x
   Nagel Michael, 2018, Tumour Biol, V40, p1010428318764007, DOI 10.1177/1010428318764007
   Ohhara Y, 2016, WORLD J GASTRO ONCOL, V8, P642, DOI 10.4251/wjgo.v8.i9.642
   Owens DW, 2004, J PATHOL, V204, P377, DOI 10.1002/path.1646
   Peduk S, 2018, DIS MARKERS, V2018, DOI 10.1155/2018/5604702
   Santamaría L, 2018, HISTOL HISTOPATHOL, V33, P1099, DOI 10.14670/HH-18-009
   Seeber A, 2016, ONCOL RES TREAT, V39, P796, DOI 10.1159/000453027
   Walsh N, 2009, PROTEOME SCI, V7, DOI 10.1186/1477-5956-7-3
   Wild P J, 2007, Verh Dtsch Ges Pathol, V91, P308
   Wilt C, 2018, ONCOLOGY-NY, V32, P494
   Xu W, 2005, WORLD J GASTROENTERO, V11, P6530, DOI 10.3748/wjg.v11.i41.6530
   Yaghoubi N, 2019, BIOMED PHARMACOTHER, V110, P312, DOI 10.1016/j.biopha.2018.11.105
   Yamauchi K, 2011, J CLIN PATHOL, V64, P875, DOI 10.1136/jclinpath-2011-200085
   Yang Z Y, 2018, Zhonghua Bing Li Xue Za Zhi, V47, P834, DOI 10.3760/cma.j.issn.0529-5807.2018.11.004
   Yin B, 2016, INT J ONCOL, V48, P1730, DOI 10.3892/ijo.2016.3396
   Zhang B, 2016, J CANCER RES CLIN, V142, P2479, DOI 10.1007/s00432-016-2253-x
   Zhang HH, 2014, SCI REP-UK, V4, DOI 10.1038/srep05416
   Zhang Yue, 2015, Zhonghua Liu Xing Bing Xue Za Zhi, V36, P709
NR 41
TC 50
Z9 53
U1 1
U2 13
PU PORTLAND PRESS LTD
PI LONDON
PA 1ST FLR, 10 QUEEN STREET PLACE, LONDON, ENGLAND
SN 0144-8463
EI 1573-4935
J9 BIOSCIENCE REP
JI Biosci. Rep.
PD AUG 13
PY 2019
VL 39
AR BSR20190884
DI 10.1042/BSR20190884
PN 8
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA IS9YE
UT WOS:000482503000001
PM 31345960
OA Green Submitted, gold, Green Published
DA 2025-01-04
ER

PT J
AU Piercey, O
   Chantrill, L
   Hsu, HC
   Ma, B
   Price, T
   Tan, IB
   Teng, HW
   Tie, J
   Desai, J
AF Piercey, Oliver
   Chantrill, Lorraine
   Hsu, Hung-Chih
   Ma, Brigette
   Price, Timothy
   Tan, Iain Beehuat
   Teng, Hao-Wei
   Tie, Jeanne
   Desai, Jayesh
TI Expert consensus on the optimal management of
   <i>BRAF<SUP>V600E</SUP></i>-mutant metastatic colorectal cancer in the
   Asia-Pacific region
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article; Early Access
DE Asia-Pacific; <italic>BRAF(V600E)</italic> mutation; immunotherapy;
   metastatic colorectal cancer; targeted therapy
ID MISMATCH REPAIR-DEFICIENT; SEVERE INFUSION REACTION; MICROSATELLITE
   INSTABILITY; BRAF MUTATION; OPEN-LABEL; 1ST-LINE TREATMENT; PHASE-III;
   SUBGROUP ANALYSES; PROGNOSTIC-FACTOR; RANDOMIZED-TRIAL
AB The burden of colorectal cancer (CRC) is high in the Asia-Pacific region, and several countries in this region have among the highest and/or fastest growing rates of CRC in the world. A significant proportion of patients will present with or develop metastatic CRC (mCRC), and BRAFV600E-mutant mCRC represents a particularly aggressive phenotype that is less responsive to standard chemotherapies. In light of recent therapeutic advances, an Asia-Pacific expert consensus panel was convened to develop evidence-based recommendations for the diagnosis, treatment, and management of patients with BRAFV600E-mutant mCRC. The expert panel comprised nine medical oncologists from Australia, Hong Kong, Singapore, and Taiwan (the authors), who met to review current literature and develop eight consensus statements that describe the optimal management of BRAFV600E-mutant mCRC in the Asia-Pacific region. As agreed by the expert panel, the consensus statements recommend molecular testing at diagnosis to guide individualized treatment decisions, propose optimal treatment pathways according to microsatellite stability status, advocate for more frequent monitoring of BRAFV600E-mutant mCRC, and discuss local treatment strategies for oligometastatic disease. Together, these expert consensus statements are intended to optimize treatment and improve outcomes for patients with BRAFV600E-mutant mCRC in the Asia-Pacific region.
C1 [Piercey, Oliver; Tie, Jeanne; Desai, Jayesh] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
   [Chantrill, Lorraine] Illawarra Shoalhaven Local Hlth Dist, Illawarra, NSW, Australia.
   [Chantrill, Lorraine] Univ Wollongong, Fac Sci Med & Hlth, Wollongong, NSW, Australia.
   [Hsu, Hung-Chih] Tucheng Chang Gung Mem Hosp, Dept Hematol & Oncol, New Taipei 23652, Taiwan.
   [Hsu, Hung-Chih] Chang Gung Univ, Coll Med, Taoyuan, Taiwan.
   [Ma, Brigette] Chinese Univ Hong Kong, Hong Kong Canc Inst, Sir YK Pao Ctr Canc, State Key Lab Translat Oncol,Dept Clin Oncol, Hong Kong, Peoples R China.
   [Price, Timothy] Queen Elizabeth Hosp, Adelaide, SA, Australia.
   [Tan, Iain Beehuat] Natl Canc Ctr, Div Med Oncol, Singapore, Singapore.
   [Teng, Hao-Wei] Taipei Vet Gen Hosp, Dept Oncol, Taipei, Taiwan.
   [Tie, Jeanne; Desai, Jayesh] Univ Melbourne, Sir Peter MacCallum Dept Oncol, 305 Grattan St, Melbourne, Vic 3000, Australia.
C3 Peter Maccallum Cancer Center; University of Wollongong; Chang Gung
   University; Chinese University of Hong Kong; National Cancer Centre
   Singapore (NCCS); Taipei Veterans General Hospital; University of
   Melbourne; Peter Maccallum Cancer Center
RP Desai, J (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, 305 Grattan St, Melbourne, Vic 3000, Australia.
EM jayesh.desai@petermac.org
RI Desai, Jayesh/AAV-1237-2021
OI Desai, Jayesh/0000-0003-4246-9344; Tan, Iain/0000-0003-4951-0354
FU Pierre Fabre
FX We would like to thank Karina Hamilton-Peel, PhD, CMPP, of Springer
   Healthcare Ltd, who wrote the outline and subsequent drafts of this
   manuscript. This medical writing assistance was funded by Pierre Fabre.
   This work was supported by Pierre Fabre, whose only involvement was to
   invite the expert consensus panel and provide them with third-party
   medical writing support. Pierre Fabre did not participate in the expert
   consensus meetings, nor in the development of the consensus statements
   and subsequent publication.
CR Adam R, 2024, J CLIN ONCOL, V42
   Afolabi H, 2022, BIOMED RES INT-UK, V2022, DOI 10.1155/2022/5824183
   Ahmed TA, 2019, CELL REP, V26, P65, DOI 10.1016/j.celrep.2018.12.013
   AndrT T, 2022, ANN ONCOL, V33, P1052, DOI 10.1016/j.annonc.2022.06.008
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Andre T., 2024, J Clin Oncol, V42
   Araghi M, 2019, LANCET GASTROENTEROL, V4, P511, DOI 10.1016/S2468-1253(19)30147-5
   Baratti D, 2021, ANN SURG ONCOL, V28, P3332, DOI 10.1245/s10434-020-09161-7
   Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140
   Bellio H, 2021, CANCERS, V13, DOI 10.3390/cancers13092201
   Boukouris AE, 2022, CRIT REV ONCOL HEMAT, V173, DOI 10.1016/j.critrevonc.2022.103663
   Cancer Council Australia C, 2023, Clinical Guidelines Internet
   Caponetto P, 2015, J ALLER CL IMM-PRACT, V3, P982, DOI 10.1016/j.jaip.2015.06.015
   Cartwright TH, 2008, CLIN COLORECTAL CANC, V7, P202, DOI 10.3816/CCC.2008.n.027
   Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898
   Cervantes A, 2023, ANN ONCOL, V34, P10, DOI 10.1016/j.annonc.2022.10.003
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Cheng HH, 2018, INT J COLORECTAL DIS, V33, P1173, DOI 10.1007/s00384-018-3095-6
   Chinuki Y, 2019, ALLERGOL INT, V68, P296, DOI 10.1016/j.alit.2019.04.001
   Chiorean EG, 2020, JCO GLOB ONCOL, V6, P414, DOI 10.1200/JGO.19.00367
   Chung CH, 2008, NEW ENGL J MED, V358, P1109, DOI 10.1056/NEJMoa074943
   Ciardiello F, 2022, CA-CANCER J CLIN, V72, P372, DOI 10.3322/caac.21728
   Ciombor KK, 2022, J CLIN ONCOL, V40, P2706, DOI 10.1200/JCO.21.02541
   ClinicalTrials.gov, 2023, ZNc3 in adult participants with metastatic colorectal cancerInternet
   ClinicalTrials.gov, 2023, A study of encorafenib plus cetuximab taken together with pembrolizumab compared to pembrolizumab alone in people with previously untreated metastatic colorectal cancer (SEAMARK)Internet
   ClinicalTrials.gov, 2023, A study of nivolumab, nivolumab plus ipilimumab, or investigator's choice chemotherapy for the treatment of participants with deficient mismatch repair (dMMR)/microsatellite instability high (MSIH) metastatic colorectal cancer (mCRC) (CheckMate 8HW) Internet
   ClinicalTrials.gov, 2023, Testing the addition of nivolumab to standard treatment for patients with metastatic or unresectable colorectal cancer that have a BRAF mutationInternet
   ClinicalTrials.gov, 2023, A study of select drug combinations in adult patients with advanced/metastatic BRAF V600 colorectal cancerInternet
   Colle R, 2023, ONCOLOGIST, V28, P771, DOI 10.1093/oncolo/oyad082
   Commins SP, 2011, J ALLERGY CLIN IMMUN, V127, P1286, DOI 10.1016/j.jaci.2011.02.019
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2023, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.946850
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Dasari NA, 2022, ANN ONCOL, V33, pS1391, DOI 10.1016/j.annonc.2022.08.021
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Day F, 2015, TARGET ONCOL, V10, P99, DOI 10.1007/s11523-014-0319-8
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Desai J, 2020, J CLIN ONCOL, V38, P2140, DOI 10.1200/JCO.19.02654
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Diaz LA, 2022, LANCET ONCOL, V23, P659, DOI 10.1016/S1470-2045(22)00197-8
   Ducreux M, 2023, EUR J CANCER, V184, P137, DOI 10.1016/j.ejca.2023.01.023
   Dupont M, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-10192-4
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   European Medicines Agency, 2023, Braftovi (encorafenib): product information
   European Medicines Agency, 2020, European public assessment report: Braftovi (encorafenib)Internet
   Fanelli GN, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1117-2
   Flood MP, 2022, EJSO-EUR J SURG ONC, V48, P2218, DOI 10.1016/j.ejso.2022.06.014
   Fowler M, 2023, SUPPORT CARE CANCER, V31, DOI 10.1007/s00520-023-07579-9
   Graf W, 2020, ANN SURG ONCOL, V27, P293, DOI 10.1245/s10434-019-07452-2
   Grothey A, 2021, ANN ONCOL, V32, P959, DOI 10.1016/j.annonc.2021.03.206
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Heun J, 2007, CLIN COLORECTAL CANC, V6, P529, DOI 10.3816/CCC.2007.n.019
   Huijberts SCFA, 2021, BRIT J CANCER, V124, P176, DOI 10.1038/s41416-020-01147-2
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   ImClone LLC, 2021, ERBITUX (cetuximab) prescribing information
   Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174
   Japanese Pharmaceuticals and Medical Devices Agency, 2020, Review report: Braftovi capsules (colorectal cancer)
   Javed S, 2022, WORLD J SURG ONCOL, V20, DOI 10.1186/s12957-022-02594-2
   Johnson Benny, 2019, JCO Precis Oncol, V3, DOI 10.1200/PO.19.00102
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Kasi PM, 2020, J GASTROINTEST ONCOL, V11, P236, DOI 10.21037/jgo.2019.12.08
   Kjeldsen BJ, 1997, INT J COLORECTAL DIS, V12, P329, DOI 10.1007/s003840050118
   Klute KA, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.22.00191
   Kopetz S, 2022, ANN ONCOL, V33, pS681, DOI 10.1016/j.annonc.2022.07.454
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2023, J CLIN ONCOL, V41, pTPS268
   Kopetz S, 2023, J CLIN ONCOL, V41
   Kopetz S, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.134
   Kopetz S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3513
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kotani D, 2023, J CLIN ONCOL, V41, pTPS264
   Kranenburg O, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.650098
   Langerak A, 2009, CLIN COLORECTAL CANC, V8, P49, DOI 10.3816/CCC.2009.n.008
   Larsen SG, 2022, BRIT J CANCER, V126, P726, DOI 10.1038/s41416-021-01620-6
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Levin-Sparenberg E, 2020, GASTROENTEROL RES, V13, P184, DOI 10.14740/gr1167
   Li J, 2022, WORLD J SURG ONCOL, V20, DOI 10.1186/s12957-022-02666-3
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
   Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
   Lungulescu CV, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-78497-7
   Lv ZC, 2014, TUMOR BIOL, V35, P11741, DOI 10.1007/s13277-014-2227-z
   Ma BB, 2015, ASIA-PAC J CLIN ONCO, V11, P160, DOI 10.1111/ajco.12342
   Margonis GA, 2018, JAMA SURG, V153, DOI 10.1001/jamasurg.2018.0996
   Martinelli E, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100603
   Martinelli E, 2023, CANCER TREAT REV, V115, DOI 10.1016/j.ctrv.2023.102541
   Mauri G, 2022, BRIT J CANCER, V127, P394, DOI 10.1038/s41416-022-01769-8
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meng XB, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.737951
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl-2022-327736
   Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   Morris VK, 2023, J CLIN ONCOL, V41, pTPS265
   Morris VK, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.012
   Morris V, 2023, J CLIN ONCOL, V41, P678, DOI 10.1200/JCO.22.01690
   Neugut AI, 2019, CLIN COLORECTAL CANC, V18, P133, DOI 10.1016/j.clcc.2019.01.005
   O'Neil BH, 2007, J CLIN ONCOL, V25, P3644, DOI 10.1200/JCO.2007.11.7812
   Osumi H, 2019, INT J CANCER, V145, P2488, DOI 10.1002/ijc.32320
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Petrelli F, 2018, RADIOTHER ONCOL, V129, P427, DOI 10.1016/j.radonc.2018.06.035
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Prager GW, 2023, NEW ENGL J MED, V388, P1657, DOI 10.1056/NEJMoa2214963
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prasanna T, 2021, CURR PROB CANCER, V45, DOI 10.1016/j.currproblcancer.2020.100637
   Prasanna T, 2018, ACTA ONCOL, V57, P1438, DOI 10.1080/0284186X.2018.1487581
   Quénet F, 2021, LANCET ONCOL, V22, P256, DOI 10.1016/S1470-2045(20)30599-4
   Ros J, 2023, ANN ONCOL, V34, P543, DOI 10.1016/j.annonc.2023.02.016
   Ros J, 2022, THER ADV GASTROENTER, V15, DOI 10.1177/17562848221110644
   Saberzadeh-Ardestani B, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.0400
   Saif MW, 2009, CANCER CHEMOTH PHARM, V63, P1017, DOI 10.1007/s00280-008-0831-6
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807
   Sharma R, 2022, LANCET GASTROENTEROL, V7, P627, DOI 10.1016/S2468-1253(22)00044-9
   Shiu KK, 2023, ANN ONCOL, V34, pS1271, DOI 10.1016/j.annonc.2023.10.024
   SIEGEL RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Siu DHW, 2022, ASIA-PAC J CLIN ONCO, V18, P660, DOI 10.1111/ajco.13745
   Skarderud MR, 2018, CANCER TREAT REV, V62, P61, DOI 10.1016/j.ctrv.2017.10.011
   Sullivan RJ, 2020, MOL CANCER THER, V19, P460, DOI 10.1158/1535-7163.MCT-19-0681
   Sullivan RJ, 2018, CANCER DISCOV, V8, P184, DOI 10.1158/2159-8290.CD-17-1119
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Sung JJY, 2019, AM J GASTROENTEROL, V114, P322, DOI 10.14309/ajg.0000000000000133
   Symonds LK, 2019, GASTROENTEROL REP, V7, P301, DOI 10.1093/gastro/goz035
   Tabernero J, 2022, ANN ONCOL, V33, pS1392, DOI 10.1016/j.annonc.2022.08.022
   Tabernero J, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100328
   Tabernero Josep, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_349561
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Taieb J, 2023, CLIN COLORECTAL CANC, V22, P59, DOI 10.1016/j.clcc.2022.12.003
   Tan LVN, 2023, CLIN CANCER RES, V29, P1017, DOI 10.1158/1078-0432.CCR-22-3094
   Tian J, 2023, NAT MED, V29, P458, DOI 10.1038/s41591-022-02181-8
   Tie J, 2011, INT J CANCER, V128, P2075, DOI 10.1002/ijc.25555
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   US Food and Drug Administration, 2020, FDA approves encorafenib in combination with cetuximab for metastatic colorectal cancer with a BRAF V600E mutationInternet
   Van Cutsem E, 2023, J CLIN ONCOL, V41, P2628, DOI 10.1200/JCO.22.01693
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Wang JW, 2020, CANCER MED-US, V9, P361, DOI 10.1002/cam4.2673
   Wang Z, 2022, EUR J CANCER, V163, P152, DOI 10.1016/j.ejca.2021.12.028
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Xu JM, 2018, J CLIN ONCOL, V36, P350, DOI 10.1200/JCO.2017.74.3245
   Xu T, 2022, THER ADV MED ONCOL, V14, DOI 10.1177/17588359221105022
   Yaeger R, 2014, CANCER-AM CANCER SOC, V120, P2316, DOI 10.1002/cncr.28729
   Ye LF, 2022, DRUG RESIST UPDATE, V65, DOI 10.1016/j.drup.2022.100883
   Yokota T, 2011, BRIT J CANCER, V104, P856, DOI 10.1038/bjc.2011.19
   Yoshino T, 2023, ESMO OPEN, V8, DOI 10.1016/j.esmoop.2023.101558
   Yoshino T, 2023, CANCER SCI, V114, P1026, DOI 10.1111/cas.15650
   Young JP, 2015, J GASTROEN HEPATOL, V30, P6, DOI 10.1111/jgh.12792
   Yuile A, 2021, ASIA-PAC J CLIN ONCO, V17, P448, DOI 10.1111/ajco.13465
   Zeineddine FA, 2023, NPJ PRECIS ONCOL, V7, DOI 10.1038/s41698-023-00353-4
NR 156
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD 2024 OCT 25
PY 2024
DI 10.1111/ajco.14132
EA OCT 2024
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA K0Q8M
UT WOS:001341026000001
PM 39456063
OA hybrid
DA 2025-01-04
ER

PT J
AU Zhang, Q
   Wang, Y
   Liu, FS
AF Zhang, Qing
   Wang, Yang
   Liu, Fusheng
TI Cancer-associated fibroblasts: Versatile mediators in remodeling the
   tumor microenvironment
SO CELLULAR SIGNALLING
LA English
DT Article
DE Cancer-associated fibroblasts; Tumor microenvironment; Tumor
   progression; CAF-targeting therapy
ID CARCINOMA-ASSOCIATED FIBROBLASTS; ACTIVATION PROTEIN ALPHA; PHASE-II
   TRIAL; COLORECTAL-CANCER; MONOCLONAL-ANTIBODY; IMMUNE-RESPONSES;
   COLON-CANCER; T-CELLS; PROMOTE; GROWTH
AB Current cancer therapeutic strategies are generally not sufficient to eradicate malignancy, as cancer stroma cells contribute to tumor evasion and therapeutic resistance. Cancer-associated fibroblasts (CAFs) constitute a largely heterogeneous type of stromal cell population and are important components of the tumor microenvironment (TME). CAFs are the most abundant stromal cell type and are actively involved in tumor progression through complex mechanisms involving effects on other cell types. Research conducted in recent years has emphasized an emerging function of CAFs in the remodeling of the TME that promotes tumor progression with effects on response to treatment by various molecular mechanisms. A comprehensive mechanism of tumor-promoting activities of CAFs could facilitate the development of novel diagnostic and therapeutic approaches. In this re-view, the biological characterization of CAFs and the mechanisms of their effects on TME remodeling are summarized. Furthermore, we also highlight currently available therapeutic strategies targeting CAF in the context of optimizing the success of immunotherapies and briefly discuss possible future perspectives and challenges related to CAF studies.
C1 [Zhang, Qing; Wang, Yang] Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurosurg, Beijing 100020, Peoples R China.
   [Liu, Fusheng] Capital Med Univ, Beijing Neurosurg Inst, Brain Tumor Res Ctr, Beijing 100070, Peoples R China.
   [Liu, Fusheng] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurosurg, Beijing 100070, Peoples R China.
   [Liu, Fusheng] Beijing Lab Biomed Mat, Beijing 100070, Peoples R China.
   [Liu, Fusheng] Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Brain Tumor Res Ctr,Dept Neurosurg,Beijing Lab Bio, Beijing 100070, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Capital Medical University
RP Wang, Y (corresponding author), Capital Med Univ, Beijing Chaoyang Hosp, Dept Neurosurg, Beijing 100020, Peoples R China.; Liu, FS (corresponding author), Capital Med Univ, Beijing Tiantan Hosp, Beijing Neurosurg Inst, Brain Tumor Res Ctr,Dept Neurosurg,Beijing Lab Bio, Beijing 100070, Peoples R China.
EM wangyang7839@163.com; liufusheng@ccmu.edu.cn
RI yu, yang/HIZ-9682-2022
FU National Natural Science Foundation of China [81972344]; Beijing Natural
   Science Foundation Program and Scientific Research Key Program of the
   Beijing Municipal Commission of Education [KZ202010025034]; Capital's
   Funds for Health Improvement and Research (CFH) [2020-1-1071]; Beijing
   Laboratory of Biomedical Materials Foundation; Beijing Chao -Yang
   Hospital Golden Seeds Foundation [CYJZ202201]
FX This work was supported by the National Natural Science Foundation of
   China (No. 81972344) , the Beijing Natural Science Foundation Pro- gram
   and Scientific Research Key Program of the Beijing Municipal Commission
   of Education (KZ202010025034) , the Capital?s Funds for Health
   Improvement and Research (CFH, 2020-1-1071) , the Beijing Laboratory of
   Biomedical Materials Foundation and Beijing Chao -Yang Hospital Golden
   Seeds Foundation (CYJZ202201) .
CR An YY, 2020, J CELL MOL MED, V24, P13, DOI 10.1111/jcmm.14745
   Bai YP, 2015, CANCER SCI, V106, P1278, DOI 10.1111/cas.12745
   Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808
   Berdiel-Acer M, 2014, MOL ONCOL, V8, P1290, DOI 10.1016/j.molonc.2014.04.006
   Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019
   Busch S, 2015, ONCOGENE, V34, P27, DOI 10.1038/onc.2013.527
   Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225
   Chakravarthy A, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06654-8
   Chen B, 2021, THERANOSTICS, V11, P3932, DOI 10.7150/thno.53412
   Chen J, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.472
   Chen XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1507-2
   Chen Y, 2021, NAT REV CLIN ONCOL, V18, P792, DOI 10.1038/s41571-021-00546-5
   Chen ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18916-5
   Cheng YS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0458-4
   Dai XY, 2022, CANCER BIOL THER, V23, P76, DOI 10.1080/15384047.2021.2017222
   Deep G, 2014, MUTAT RES-FUND MOL M, V768, P35, DOI 10.1016/j.mrfmmm.2014.05.002
   DeLeon-Pennell KY, 2020, MATRIX BIOL, V91-92, P1, DOI 10.1016/j.matbio.2020.05.006
   Desbois M, 2021, IMMUNOL REV, V302, P241, DOI 10.1111/imr.12982
   Dijkgraaf EM, 2015, ANN ONCOL, V26, P2141, DOI 10.1093/annonc/mdv309
   Dou DW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02026
   Erdogan B, 2017, BIOCHEM SOC T, V45, P229, DOI 10.1042/BST20160387
   Faivre S, 2019, LIVER INT, V39, P1468, DOI 10.1111/liv.14113
   Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2
   Gao H, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.764204
   Gentric G, 2021, CANCERS, V13, DOI 10.3390/cancers13030399
   Giraldo NA, 2019, BRIT J CANCER, V120, P45, DOI 10.1038/s41416-018-0327-z
   Gokyavuz B, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-39553-z
   Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396
   Goulet CR, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5353-6
   Harper J, 2014, SEMIN CANCER BIOL, V25, P69, DOI 10.1016/j.semcancer.2013.12.005
   Hartmann N, 2014, CLIN CANCER RES, V20, P3422, DOI 10.1158/1078-0432.CCR-13-2972
   Hassona Y, 2014, BRIT J CANCER, V111, P1230, DOI 10.1038/bjc.2014.438
   Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863
   Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224
   Itoh G, 2022, MOL ONCOL, V16, P166, DOI 10.1002/1878-0261.13077
   Jia CC, 2020, INT J BIOL SCI, V16, P2542, DOI 10.7150/ijbs.45446
   Jiang H, 2016, NAT MED, V22, P851, DOI 10.1038/nm.4123
   Kay EJ, 2022, NAT METAB, V4, P693, DOI 10.1038/s42255-022-00582-0
   Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0
   Koustoulidou S, 2021, CANCERS, V13, DOI 10.3390/cancers13051100
   Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144
   Lakins MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03347-0
   Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019
   LeBleu VS, 2018, DIS MODEL MECH, V11, DOI 10.1242/dmm.029447
   Lee FT, 2005, CLIN CANCER RES, V11, p7080S, DOI 10.1158/1078-0432.CCR-1004-0019
   Lee J, 2005, CANCER RES, V65, P11156, DOI 10.1158/0008-5472.CAN-05-2805
   Lee J, 2010, CANCER RES, V70, P10131, DOI 10.1158/0008-5472.CAN-10-2740
   Lei X, 2020, CANCER LETT, V470, P126, DOI 10.1016/j.canlet.2019.11.009
   Li C, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01463-y
   Li HB, 2019, AM J TRANSL RES, V11, P4077
   Li YY, 2018, EBIOMEDICINE, V36, P209, DOI 10.1016/j.ebiom.2018.09.006
   Li YQ, 2020, CANCERS, V12, DOI 10.3390/cancers12010138
   Li ZZ, 2021, THERANOSTICS, V11, P8322, DOI 10.7150/thno.62378
   Li ZL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17395-y
   Li ZQ, 2019, INT J CANCER, V145, P1946, DOI 10.1002/ijc.32278
   Linderholm BK, 2009, ANN ONCOL, V20, P1639, DOI 10.1093/annonc/mdp062
   Liu TY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0770-1
   Lu SL, 2006, GENE DEV, V20, P1331, DOI 10.1101/gad.1413306
   Mace TA, 2018, GUT, V67, P320, DOI 10.1136/gutjnl-2016-311585
   Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01428-1
   Melisi D, 2018, BRIT J CANCER, V119, P1208, DOI 10.1038/s41416-018-0246-z
   Miyai Y, 2020, CANCER SCI, V111, P1047, DOI 10.1111/cas.14346
   Mosa MH, 2020, CANCER RES, V80, P5569, DOI 10.1158/0008-5472.CAN-20-0263
   Murakami M, 2013, CANCER RES, V73, P4862, DOI 10.1158/0008-5472.CAN-13-0062
   Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748
   Nakamura Y, 2022, GASTRIC CANCER, V25, P515, DOI 10.1007/s10120-021-01275-5
   Nandi A, 2022, CANCER RES, V82, DOI 10.1158/0008-5472.CAN-21-1225
   Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874
   Neri S, 2016, J CANCER RES CLIN, V142, P437, DOI 10.1007/s00432-015-2046-7
   Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193
   Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4
   Özdemir BC, 2014, CANCER CELL, V25, P719, DOI [10.1016/j.ccr.2014.04.005, 10.1016/j.ccell.2015.11.002]
   Ohshio Y, 2015, CANCER SCI, V106, P134, DOI 10.1111/cas.12584
   Prakash J, 2016, TRENDS CANCER, V2, P277, DOI 10.1016/j.trecan.2016.04.005
   Provenzano PP, 2012, CANCER CELL, V21, P418, DOI 10.1016/j.ccr.2012.01.007
   Qian LW, 2018, J BIOMED NANOTECHNOL, V14, P1826, DOI 10.1166/jbn.2018.2616
   Qin X, 2022, THERANOSTICS, V12, P1730, DOI 10.7150/thno.69175
   Rapisarda A, 2012, ADV CANCER RES, V114, P237, DOI 10.1016/B978-0-12-386503-8.00006-5
   Raskov H, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.668731
   Ren B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0858-1
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1
   Salmon H, 2012, J CLIN INVEST, V122, P899, DOI 10.1172/JCI45817
   Schuberth PC, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-187
   Sebastian A, 2020, CANCERS, V12, DOI 10.3390/cancers12051307
   Shi L, 2020, AGING-US, V12, P8549, DOI 10.18632/aging.103157
   Su SC, 2018, CELL, V172, P841, DOI 10.1016/j.cell.2018.01.009
   Sung PJ, 2019, CANCER RES, V79, P3651, DOI 10.1158/0008-5472.CAN-18-2952
   Underwood TJ, 2015, J PATHOL, V235, P466, DOI 10.1002/path.4467
   Unterleuthner D, 2020, ANGIOGENESIS, V23, P159, DOI 10.1007/s10456-019-09688-8
   Wan XY, 2021, THERANOSTICS, V11, P4975, DOI 10.7150/thno.55074
   Wang LCS, 2014, CANCER IMMUNOL RES, V2, P154, DOI 10.1158/2326-6066.CIR-13-0027
   Wang RF, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0995-9
   Wang XF, 2017, INT J CANCER, V141, P998, DOI 10.1002/ijc.30801
   Watanabe K, 2022, INT J ONCOL, V60, DOI 10.3892/ijo.2021.5293
   Wen SY, 2019, CANCER LETT, V442, P320, DOI 10.1016/j.canlet.2018.10.015
   Wu HJ, 2020, ONCOGENE, V39, P2539, DOI 10.1038/s41388-020-1162-2
   Xi L, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12146
   Xia Q, 2016, VACCINE, V34, P4526, DOI 10.1016/j.vaccine.2016.07.054
   Xia Q, 2016, CANCER IMMUNOL IMMUN, V65, P613, DOI 10.1007/s00262-016-1827-4
   Xiang HD, 2020, CANCER IMMUNOL RES, V8, P436, DOI 10.1158/2326-6066.CIR-19-0507
   Xie JQ, 2021, CELL ONCOL, V44, P661, DOI 10.1007/s13402-021-00592-2
   Yang FM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0718-4
   Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973
   Yin H, 2021, CELL SIGNAL, V84, DOI 10.1016/j.cellsig.2021.110029
   Yin ZY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0782-x
   Zhang HY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01168-8
   Zhang RS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1435-2
   Zhang TC, 2022, GASTRIC CANCER, V25, P346, DOI 10.1007/s10120-021-01259-5
   Zhang ZL, 2022, IMMUNOLOGY, V167, P1, DOI 10.1111/imm.13496
   Zhou SY, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202007017
   Zhou Z, 2020, CANCER LETT, V473, P62, DOI 10.1016/j.canlet.2019.12.039
NR 112
TC 10
Z9 10
U1 1
U2 11
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0898-6568
EI 1873-3913
J9 CELL SIGNAL
JI Cell. Signal.
PD MAR
PY 2023
VL 103
AR 110567
DI 10.1016/j.cellsig.2022.110567
EA DEC 2022
PG 8
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 7U7HH
UT WOS:000912299900001
PM 36538999
DA 2025-01-04
ER

PT J
AU Yamamoto, Y
   Kasashima, H
   Fukui, Y
   Tsujio, G
   Yashiro, M
   Maeda, K
AF Yamamoto, Yurie
   Kasashima, Hiroaki
   Fukui, Yasuhiro
   Tsujio, Gen
   Yashiro, Masakazu
   Maeda, Kiyoshi
TI The heterogeneity of cancer-associated fibroblast subpopulations: Their
   origins, biomarkers, and roles in the tumor microenvironment
SO CANCER SCIENCE
LA English
DT Review
DE cancer-associated fibroblast; heterogeneity; immune therapy;
   subpopulation; tumor microenvironment
ID CARCINOMA-ASSOCIATED FIBROBLASTS; STROMAL FIBROBLASTS; ADIPOSE-TISSUE;
   COLON-CANCER; T-CELLS; PHASE-I; IMMUNOSUPPRESSION; PROGRESSION; GROWTH;
   MYOFIBROBLASTS
AB The prognosis for patients with cancers known for a highly activated stromal reaction, including diffuse-type (scirrhous) gastric cancer, consensus molecular subtype 4 (CMS4) colorectal cancer, and pancreatic ductal adenocarcinoma, is extremely poor. To explore the resistance of conventional therapy for those refractory cancers, detailed classification and investigation of the different subsets of cancer-associated fibroblasts (CAFs) involved are needed. Recent studies with a single-cell transcriptomics strategy (single-cell RNA-seq) have demonstrated that CAF subpopulations contain different origins and marker proteins with the capacity to either promote or suppress cancer progression. Through multiple signaling pathways, CAFs can promote tumor growth, metastasis, and angiogenesis with extracellular matrix (ECM) remodeling; they can also interact with tumor-infiltrating immune cells and modulate the antitumor immunological state in the tumor microenvironment (TME). Here, we review the recent literature on the various subpopulations of CAFs to improve our understanding of the cell-cell interactions in the TME and highlight future avenues for CAF-targeted therapy.
C1 [Yamamoto, Yurie; Kasashima, Hiroaki; Tsujio, Gen; Yashiro, Masakazu] Osaka Metropolitan Univ, Mol Oncol & Therapeut, Grad Sch Med, Osaka, Japan.
   [Kasashima, Hiroaki; Fukui, Yasuhiro; Tsujio, Gen; Maeda, Kiyoshi] Osaka Metropolitan Univ, Dept Gastroenterol Surg, Grad Sch Med, Osaka, Japan.
C3 Osaka Metropolitan University; Osaka Metropolitan University
RP Kasashima, H (corresponding author), 1-4-3 Asahi Machi,Abeno Ku, Osaka 5458585, Japan.
EM hkasashima@omu.ac.jp
RI KASASHIMA, HIROAKI/HNP-0833-2023
OI KASASHIMA, HIROAKI/0000-0001-5234-4030; FUKUI,
   YASUHIRO/0000-0001-8878-883X; Tsujio, Gen/0009-0005-5958-7939; Yamamoto,
   Yurie/0000-0003-0277-5814
FU JST SPRING [JPMJSP2139]; JSPS KAKENHI [JP21K16428]; KANAE FOUNDATION for
   the Promotion of Medical Science; Uehara Memorial Foundation; Takeda
   Science Foundation; Kobayashi Foundation for Cancer Research; SGH
   Foundation; Grants-in-Aid for Scientific Research [21K16428] Funding
   Source: KAKEN
FX This work was supported by JST SPRING (Grant Number JPMJSP2139) to Y.Y.,
   JSPS KAKENHI (Grant Number JP21K16428), KANAE FOUNDATION for the
   Promotion of Medical Science, SGH Foundation, The Uehara Memorial
   Foundation, Takeda Science Foundation, and Kobayashi Foundation for
   Cancer Research to H.K.
CR Arina A, 2016, P NATL ACAD SCI USA, V113, P7551, DOI 10.1073/pnas.1600363113
   Bailey JM, 2008, CLIN CANCER RES, V14, P5995, DOI 10.1158/1078-0432.CCR-08-0291
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bochet L, 2013, CANCER RES, V73, P5657, DOI 10.1158/0008-5472.CAN-13-0530
   Catenacci DVT, 2015, J CLIN ONCOL, V33, P4284, DOI 10.1200/JCO.2015.62.8719
   Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573-018-0004-1
   Chen Y, 2021, NAT REV CLIN ONCOL, V18, P792, DOI 10.1038/s41571-021-00546-5
   Chen Y, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201809085
   Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024
   Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011
   Elyada E, 2019, CANCER DISCOV, V9, P1102, DOI 10.1158/2159-8290.CD-19-0094
   Ene-Obong A, 2013, GASTROENTEROLOGY, V145, P1121, DOI 10.1053/j.gastro.2013.07.025
   Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041
   Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110
   Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2
   Friedman G, 2020, NAT CANCER, V1, P692, DOI 10.1038/s43018-020-0082-y
   Gerling M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12321
   Gieniec KA, 2019, BRIT J CANCER, V121, P293, DOI 10.1038/s41416-019-0509-3
   Han YL, 2015, TUMOR BIOL, V36, P1385, DOI 10.1007/s13277-015-3230-8
   Harper J, 2014, SEMIN CANCER BIOL, V25, P69, DOI 10.1016/j.semcancer.2013.12.005
   Hecht JR, 2017, ONCOLOGIST, V22, P243, DOI 10.1634/theoncologist.2016-0479
   Helms E, 2020, CANCER DISCOV, V10, P648, DOI 10.1158/2159-8290.CD-19-1353
   Herrera M, 2013, CLIN CANCER RES, V19, P5914, DOI 10.1158/1078-0432.CCR-13-0694
   Hosaka K, 2016, P NATL ACAD SCI USA, V113, pE5618, DOI 10.1073/pnas.1608384113
   Hsia LT, 2016, P NATL ACAD SCI USA, V113, pE2162, DOI 10.1073/pnas.1603534113
   Huang HC, 2022, CANCER CELL, V40, P659, DOI 10.1016/j.ccell.2022.04.011
   Huang JF, 2018, CANCER CELL, V33, P770, DOI 10.1016/j.ccell.2018.03.001
   Jena BC, 2021, CANCER LETT, V520, P222, DOI 10.1016/j.canlet.2021.08.002
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kasashima H, 2015, BRIT J CANCER, V113, P443, DOI 10.1038/bjc.2015.236
   Kasashima H, 2021, DEV CELL, V56, P95, DOI 10.1016/j.devcel.2020.10.014
   Kasashima H, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0178635
   Kasashima H, 2016, AM J PATHOL, V186, P3028, DOI 10.1016/j.ajpath.2016.07.024
   Kasashima H, 2014, CANCER LETT, V354, P438, DOI 10.1016/j.canlet.2014.08.014
   Kato T, 2018, CLIN CANCER RES, V24, P4820, DOI 10.1158/1078-0432.CCR-18-0205
   Kerdidani D, 2022, J EXP MED, V219, DOI 10.1084/jem.20210815
   Kim R, 2006, IMMUNOLOGY, V119, P254, DOI 10.1111/j.1365-2567.2006.02430.x
   Kinoshita H, 2015, CARCINOGENESIS, V36, P1511, DOI 10.1093/carcin/bgv134
   Kinoshita K, 2010, INT J ONCOL, V37, P869, DOI 10.3892/ijo_00000738
   Kinoshita T, 2013, CANCER SCI, V104, P409, DOI 10.1111/cas.12099
   Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0
   Lakins MA, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03347-0
   Li HP, 2017, NAT GENET, V49, P708, DOI 10.1038/ng.3818
   Li X, 2019, EXP CELL RES, V378, P131, DOI 10.1016/j.yexcr.2019.03.013
   Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01428-1
   Mezawa Y, 2016, CELL TISSUE RES, V365, P675, DOI 10.1007/s00441-016-2471-1
   Miyai Y, 2020, CANCER SCI, V111, P1047, DOI 10.1111/cas.14346
   Mizutani Y, 2019, CANCER RES, V79, P5367, DOI 10.1158/0008-5472.CAN-19-0454
   Neesse A, 2019, GUT, V68, P159, DOI 10.1136/gutjnl-2018-316451
   Neesse A, 2015, GUT, V64, P1476, DOI 10.1136/gutjnl-2015-309304
   Neri S, 2017, CANCER LETT, V395, P20, DOI 10.1016/j.canlet.2017.02.026
   Norton J, 2020, CANCERS, V12, DOI 10.3390/cancers12051347
   Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193
   O'Connell JT, 2011, P NATL ACAD SCI USA, V108, P16002, DOI 10.1073/pnas.1109493108
   Özdemir BC, 2014, CANCER CELL, V25, P719, DOI [10.1016/j.ccr.2014.04.005, 10.1016/j.ccell.2015.11.002]
   Öhlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Ostermann E, 2008, CLIN CANCER RES, V14, P4584, DOI 10.1158/1078-0432.CCR-07-5211
   Pein M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15188-x
   Pereira BA, 2019, TRENDS CANCER, V5, P724, DOI 10.1016/j.trecan.2019.09.010
   Pothula SP, 2016, CANCER LETT, V381, P194, DOI 10.1016/j.canlet.2015.10.035
   Rhim AD, 2014, CANCER CELL, V25, P735, DOI 10.1016/j.ccr.2014.04.021
   Rhim AD, 2012, CELL, V148, P349, DOI 10.1016/j.cell.2011.11.025
   Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988
   Scott AM, 2003, CLIN CANCER RES, V9, P1639
   Sebastian A, 2020, CANCERS, V12, DOI 10.3390/cancers12051307
   Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902
   Steele NG, 2021, CLIN CANCER RES, V27, P2023, DOI 10.1158/1078-0432.CCR-20-3715
   Strong AL, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/9216502
   Sun QQ, 2018, THERANOSTICS, V8, P5072, DOI 10.7150/thno.26546
   Tanaka R, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09847-z
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Vaquero J, 2018, CLIN CANCER RES, V24, P4282, DOI 10.1158/1078-0432.CCR-17-3725
   von Ahrens D, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0448-5
   Waghray M, 2016, CANCER DISCOV, V6, P886, DOI 10.1158/2159-8290.CD-15-0947
   WELT S, 1994, J CLIN ONCOL, V12, P1193, DOI 10.1200/JCO.1994.12.6.1193
   Whittle MC, 2019, GASTROENTEROLOGY, V156, P2085, DOI 10.1053/j.gastro.2018.12.044
   Yang XG, 2016, CANCER RES, V76, P4124, DOI 10.1158/0008-5472.CAN-15-2973
   Yashiro M, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12299
   Yashiro M, 2010, CANCER MICROENVIRON, V3, P127, DOI 10.1007/s12307-010-0036-5
   Zhang Y, 2009, CANCER RES, V69, P5259, DOI 10.1158/0008-5472.CAN-08-3444
NR 82
TC 49
Z9 52
U1 4
U2 25
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD JAN
PY 2023
VL 114
IS 1
BP 16
EP 24
DI 10.1111/cas.15609
EA OCT 2022
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 7Q6TY
UT WOS:000869628800001
PM 36197901
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Roviello, G
   D'Angelo, A
   Petrioli, R
   Roviello, F
   Cianchi, F
   Nobili, S
   Mini, E
   Lavacchi, D
AF Roviello, Giandomenico
   D'Angelo, Alberto
   Petrioli, Roberto
   Roviello, Franco
   Cianchi, Fabio
   Nobili, Stefania
   Mini, Enrico
   Lavacchi, Daniele
TI Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal
   Cancer
SO TRANSLATIONAL ONCOLOGY
LA English
DT Review
ID OPEN-LABEL; MICROSATELLITE INSTABILITY; TARGETED THERAPY; EGFR
   INHIBITION; RAS MUTATIONS; PHASE IB; BENEFIT; VEMURAFENIB; METAANALYSIS;
   DABRAFENIB
AB BRAFV600-mutated colorectal cancer (CRC) accounts for 8% to 12% of all CRC diagnoses. These tumors are often associated with specific patient features, including right-sided primary tumor location, peritoneal and non -regional lymph node involvement, and poor prognosis. In approximately 30% of cases, a simultaneous mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) phenotype is identified. The prognostic impact of the BRAF mutation appears to be less marked in patients with MSI-H CRC than in patients with microsatellite stable (MSS) tumor. The treatment of BRAFV600-mutated CRC is still a challenge for the clinicians, mainly due to the poor survival out-comes obtained with traditional chemotherapy regimens. In recent years, two novel treatment strategies have offered remarkable changes in the treatment of this specific patient subgroup. The first approach has included targeted therapies directed against BRAF and MEK, with support from the epidermal growth factor receptor (EGFR) blockade. The second approach has included immunotherapeutic agents that have been shown to be particularly promising for patients with simultaneous dMMR/MSI-H phenotype. Here we review the clinical trials that specifically enrolled patients with BRAF-mutated CRC, from the phase I/II studies to the phase III trial BEACON CRC. We also examine the future directions towards a molecularly guided therapy for patients with BRAF-mutated CRC and the crucial role of a molecularly and clinically based algorithm in order to offer the best choice of treatment for these patients.
C1 [Roviello, Giandomenico; Nobili, Stefania; Mini, Enrico] Univ Florence, Dept Hlth Sci, Viale Pieraccini 6, I-50139 Florence, Italy.
   [D'Angelo, Alberto] Univ Bath, Dept Biol & Biochem, Bath BA2 7AY, Avon, England.
   [Petrioli, Roberto] Univ Siena, Dept Med Surg & Neurosci, Med Oncol Unit, Siena, Italy.
   [Roviello, Franco] Univ Siena, Dept Med Surg & Neurosci, Unit Gen Surg & Surg Oncol, Policlin Le Scotte, Viale Bracci, I-53100 Siena, Italy.
   [Cianchi, Fabio] Univ Florence, Dept Expt & Clin Med, Largo Brambilla 3, I-50134 Florence, Italy.
   [Lavacchi, Daniele] Univ Hosp Florence, Azienda Osped Careggi, I-50134 Florence, Italy.
   [Lavacchi, Daniele] Univ Florence, I-50134 Florence, Italy.
C3 University of Florence; University of Bath; University of Siena;
   University of Siena; University of Florence; University of Florence;
   Azienda Ospedaliero Universitaria Careggi; University of Florence
RP Roviello, G (corresponding author), Univ Florence, Dept Hlth Sci, Viale Pieraccini 6, I-50139 Florence, Italy.
EM giandomenicoroviello@hotmail.it
RI Lavacchi, Daniele/AAC-3109-2022; D'Angelo, Alberto/AAC-7434-2021;
   Nobili, Stefania/AAA-5917-2019; Roviello, Giandomenico/AAA-5310-2019
OI CIANCHI, FABIO/0000-0002-6936-8693; D'Angelo,
   Alberto/0000-0001-8417-9172; Roviello, Giandomenico/0000-0001-5504-8237
CR [Anonymous], 2019, J CLIN ONCOL S
   [Anonymous], 2020, J CLIN ONCOL S
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   Dummer R, 2018, LANCET ONCOL, V19, P603, DOI 10.1016/S1470-2045(18)30142-6
   Ellis LM, 2008, NAT REV CANCER, V8, P579, DOI 10.1038/nrc2403
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   Fong YM, 1997, J CLIN ONCOL, V15, P938, DOI 10.1200/JCO.1997.15.3.938
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hutchins G, 2011, J CLIN ONCOL, V29, P1261, DOI 10.1200/JCO.2010.30.1366
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3505
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009
   Loupakis F, 2019, EUR J CANCER, V118, P121, DOI 10.1016/j.ejca.2019.06.008
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Rosen SA, 2000, ARCH SURG-CHICAGO, V135, P530, DOI 10.1001/archsurg.135.5.530
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Steinberg S.M., 1986, CANCER
   Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
NR 43
TC 30
Z9 32
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1936-5233
J9 TRANSL ONCOL
JI Transl. Oncol.
PD SEP
PY 2020
VL 13
IS 9
AR 100795
DI 10.1016/j.tranon.2020.100795
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA MP8RI
UT WOS:000552466200006
PM 32470910
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Luo, P
   Tan, X
   Luo, SL
   Wang, ZW
   Long, L
   Wang, YW
   Liao, FY
   Chen, L
   Zhang, C
   He, JT
   Huang, YH
   Liu, ZJ
   Gan, YB
   Chen, ZL
   Wang, Y
   Liu, YS
   Wang, Y
   Shi, CM
AF Luo, Peng
   Tan, Xu
   Luo, Shenglin
   Wang, Ziwen
   Long, Lei
   Wang, Yawei
   Liao, Fengying
   Chen, Long
   Zhang, Chi
   He, Jintao
   Huang, Yinghui
   Liu, Zujuan
   Gan, Yibo
   Chen, Zelin
   Wang, Yang
   Liu, Yunsheng
   Wang, Yu
   Shi, Chunmeng
TI An NIR-Fluorophore-Based Inhibitor of SOD1 Induces Apoptosis by
   Targeting Transcription Cofactor PC4
SO ADVANCED THERAPEUTICS
LA English
DT Article
DE cancer theranostics; near-infrared imaging; positive cofactor 4;
   superoxide dismutase 1 (SOD1) inhibitor; tumur-targeted agents
ID COLORECTAL-CANCER; MULTIFUNCTIONAL NANOPARTICLES; DRUG-DELIVERY; CELLS;
   DNA; COACTIVATOR; STATISTICS; ACTIVATION; DIAGNOSIS; PRODRUG
AB Colorectal cancer (CRC) is one of the leading causes of cancer-related death worldwide. Development of novel therapies has focused on new oncogenes and few tumor-targeted theranostic agents. Recent studies show that the increased oxidative stress that results from abnormal metabolism makes cancer cells more dependent on antioxidant systems, indicating a proper therapeutic target. As a major antioxidant enzyme, superoxide dismutase 1 (SOD1) is overexpressed in cancer cells and closely related to carcinogenesis and therapeutic effects. However, there is still a lack of tumor-targeted agents to effectively inhibit the expression of SOD1. Here, a novel near-infrared heptamethine cyanine dye, IR-37, is designed, synthesized, and screened that preferentially accumulates in tumor cells with an intrinsic structure-inherent targeting property, significantly inhibits the expression of SOD1 and induces excessive reactive oxygen species (ROS)-mediated apoptosis. IR-37 also has excellent optical properties, implying its potential application in tumor-targeted imaging. Moreover, a novel CRC-related oncogene, positive cofactor 4 (PC4), is identified that is involved in the killing effects of IR-37 through the SOD1-ROS-c-Jun N-terminal kinase (JNK) pathway. Together, these findings suggest that IR-37 may be a promising theranostic agent for personalized tumor-targeted therapy and imaging, and that PC4 is a novel oncogene for the diagnosis and therapy of CRC.
C1 [Luo, Peng; Tan, Xu; Luo, Shenglin; Wang, Ziwen; Long, Lei; Wang, Yawei; Liao, Fengying; Chen, Long; Zhang, Chi; He, Jintao; Huang, Yinghui; Liu, Zujuan; Gan, Yibo; Chen, Zelin; Wang, Yang; Liu, Yunsheng; Wang, Yu; Shi, Chunmeng] Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Inst Rocket Force Med, Chongqing 400038, Peoples R China.
C3 Army Medical University
RP Shi, CM (corresponding author), Third Mil Med Univ, State Key Lab Trauma Burns & Combined Injury, Inst Rocket Force Med, Chongqing 400038, Peoples R China.
EM shicm@tmmu.edu.cn
RI chen, zelin/CAA-7042-2022; huang, ikky/IWM-6280-2023; Wang,
   Ziwen/AAG-9607-2021; shenglin, luo/HOA-5594-2023; long,
   chen/ABL-9171-2022
OI Luo, Shenglin/0000-0002-0804-9891
FU National Key Research and Development Program [2016YFC1000805]; Natural
   Science Foundation Programs [81372727, 81773352, 81801747]; University
   Innovation Team Building Program of Chongqing [CXTDG201602020]
FX This work was supported by National Key Research and Development Program
   (2016YFC1000805), Natural Science Foundation Programs (81372727,
   81773352, and 81801747), and University Innovation Team Building Program
   of Chongqing (CXTDG201602020).
CR [Anonymous], SCI REP
   Ardestani A, 2014, NAT MED, V20, P385, DOI 10.1038/nm.3482
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Chakravarthi BVSK, 2016, ONCOGENE, V35, P6330, DOI 10.1038/onc.2016.164
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chiang YT, 2015, BIOMATERIALS, V61, P150, DOI 10.1016/j.biomaterials.2015.05.007
   Dhanasekaran DN, 2008, ONCOGENE, V27, P6245, DOI 10.1038/onc.2008.301
   Diehn M, 2009, NATURE, V458, P780, DOI 10.1038/nature07733
   Du ZF, 2014, J AM CHEM SOC, V136, P2948, DOI 10.1021/ja410678y
   Galadari S, 2017, FREE RADICAL BIO MED, V104, P144, DOI 10.1016/j.freeradbiomed.2017.01.004
   Gao M, 2017, CHEM SOC REV, V46, P2237, DOI 10.1039/c6cs00908e
   GE H, 1994, CELL, V78, P513, DOI 10.1016/0092-8674(94)90428-6
   Glasauer A, 2014, BIOCHEM PHARMACOL, V92, P90, DOI 10.1016/j.bcp.2014.07.017
   Glasauer A, 2014, J CLIN INVEST, V124, P117, DOI 10.1172/JCI71714
   Hour TC, 2010, BIOCHEM PHARMACOL, V80, P325, DOI 10.1016/j.bcp.2010.04.007
   Huang P, 2000, NATURE, V407, P390, DOI 10.1038/35030140
   Huang YH, 2018, GUT, V67, P307, DOI 10.1136/gutjnl-2016-311909
   Jin BB, 2018, ADV THEOR SIMUL, V1, DOI 10.1002/adts.201800070
   Kim K, 2010, J CONTROL RELEASE, V146, P219, DOI 10.1016/j.jconrel.2010.04.004
   Konishi H, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12365
   KRETZSCHMAR M, 1994, CELL, V78, P525, DOI 10.1016/0092-8674(94)90429-4
   Lee K, 2013, FREE RADICAL BIO MED, V60, P157, DOI 10.1016/j.freeradbiomed.2013.02.003
   Lee MH, 2018, CHEM SOC REV, V47, P28, DOI 10.1039/c7cs00557a
   Lee SY, 2016, BIOMATERIALS, V86, P92, DOI 10.1016/j.biomaterials.2016.01.068
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Luo SL, 2016, ADV FUNCT MATER, V26, P2826, DOI 10.1002/adfm.201600159
   Luo SL, 2013, BIOMATERIALS, V34, P2244, DOI 10.1016/j.biomaterials.2012.11.057
   Mortusewicz O, 2016, ONCOGENE, V35, P761, DOI 10.1038/onc.2015.135
   Nie SM, 2010, NANOMEDICINE-UK, V5, P523, DOI 10.2217/NNM.10.23
   Panieri E, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.105
   Papa L., 2014, GENES CANC, V5, P15, DOI 10.18632/genesandcancer.4
   Pelicano H, 2004, DRUG RESIST UPDATE, V7, P97, DOI 10.1016/j.drup.2004.01.004
   Peng Y, 2012, CANCER GENE THER, V19, P690, DOI 10.1038/cgt.2012.52
   Qian D, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.416
   Schumacker PT, 2015, CANCER CELL, V27, P156, DOI 10.1016/j.ccell.2015.01.007
   Sharma A, 2018, BIOMATERIALS, V155, P145, DOI 10.1016/j.biomaterials.2017.11.019
   Shi CM, 2007, IN VITRO CELL DEV-AN, V43, P290, DOI 10.1007/s11626-007-9056-y
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Somwar R, 2011, P NATL ACAD SCI USA, V108, P16375, DOI 10.1073/pnas.1113554108
   Song XY, 2018, THERANOSTICS, V8, P2217, DOI 10.7150/thno.24041
   Srinivasarao M, 2015, NAT REV DRUG DISCOV, V14, P203, DOI 10.1038/nrd4519
   Tan X, 2017, ADV MATER, V29, DOI 10.1002/adma.201704196
   Tan X, 2012, BIOMATERIALS, V33, P2230, DOI 10.1016/j.biomaterials.2011.11.081
   Tao SL, 2015, AM J CANCER RES, V5, P1878
   Trachootham D, 2009, NAT REV DRUG DISCOV, V8, P579, DOI 10.1038/nrd2803
   Tsang CK, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4446
   Wang H, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-02915-8
   Wang JY, 2004, MOL CELL BIOL, V24, P6084, DOI 10.1128/MCB.24.13.6084-6093.2004
   Wang X, 2016, ADV FUNCT MATER, V26, P8397, DOI 10.1002/adfm.201600996
   Wang Y, 2018, ADV MATER, V30, DOI 10.1002/adma.201800475
   Wang Y, 2018, ADV SCI, V5, DOI 10.1002/advs.201700392
   Wright Paul D, 2012, Front Biosci (Elite Ed), V4, P2701
   Xu B, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.176
   Yang Y, 2013, CURR MED CHEM, V20, P3677, DOI 10.2174/0929867311320999165
   Yu MK, 2012, THERANOSTICS, V2, P3, DOI 10.7150/thno.3463
   Yuan ZW, 2018, ACS APPL MATER INTER, V10, P30994, DOI 10.1021/acsami.8b09841
NR 56
TC 1
Z9 1
U1 0
U2 22
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2366-3987
J9 ADV THER-GERMANY
JI Adv. Therap.
PD MAY
PY 2019
VL 2
IS 5
AR 1800148
DI 10.1002/adtp.201800148
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KB2VK
UT WOS:000506357600004
DA 2025-01-04
ER

PT J
AU Pierantoni, C
   Cosentino, L
   Ricciardiello, L
AF Pierantoni, Chiara
   Cosentino, Lorenzo
   Ricciardiello, Luigi
TI Molecular Pathways of Colorectal Cancer Development: Mechanisms of
   Action and Evolution of Main Systemic Therapy Compunds
SO DIGESTIVE DISEASES
LA English
DT Review
DE Colorectal cancer; Immunotherapy; Targeted therapy
ID GROWTH-FACTOR RECEPTOR; INSTABILITY; TAS-102
AB Background: Colorectal cancer is known as one of the "big killers" in oncology given its burden in terms on morbidity and mortality. Since the second half of the last century, similarly to what happened for other solid tumors, a large series of cytotoxic molecules have been developed and tested to treat this disease. Summary: Following new discoveries in terms of colorectal cancer pathogenesis and specific pathways involved such as angiogenesis, a new series of drugs have been developed: targeted therapies. Key Messages: In this review, we will briefly describe colorectal cancer molecular biology and its main pathways in order to retrace the main stages of oncological treatment development for colorectal cancer from the first available treatments to novel approaches to the disease.
C1 [Pierantoni, Chiara; Cosentino, Lorenzo; Ricciardiello, Luigi] Policlin St Orsola, IRCCS Azienda Osped Univ Bologna, Bologna, Italy.
   [Cosentino, Lorenzo; Ricciardiello, Luigi] Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.
C3 IRCCS Azienda Ospedaliero-Universitaria di Bologna; University of
   Bologna
RP Ricciardiello, L (corresponding author), Policlin St Orsola, IRCCS Azienda Osped Univ Bologna, Bologna, Italy.; Ricciardiello, L (corresponding author), Univ Bologna, Dept Med & Surg Sci, Bologna, Italy.
EM lorenzo.cosentino1@outlook.it
RI pierantoni, chiara/LSK-6168-2024; Cosentino, Lorenzo/KHT-6073-2024;
   RICCIARDIELLO, LUIGI/K-7269-2016
OI RICCIARDIELLO, LUIGI/0000-0003-2568-6208
CR Ahmad S, 2010, CHEM BIODIVERS, V7, P543, DOI 10.1002/cbdv.200800340
   Al-Salama ZT, 2021, DRUGS, V81, P849, DOI 10.1007/s40265-021-01501-5
   Arai H, 2019, CANCER TREAT REV, V81, DOI 10.1016/j.ctrv.2019.101912
   Boland CR, 1998, CANCER RES, V58, P5248
   Burness CB, 2016, DRUGS, V76, P1393, DOI 10.1007/s40265-016-0633-9
   Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047
   Cervantes A, 2023, ANN ONCOL, V34, P10, DOI 10.1016/j.annonc.2022.10.003
   Cervantes A, 2024, ANN ONCOL, V35, P241, DOI 10.1016/j.annonc.2023.10.129
   Chhabra N, 2021, J MED TOXICOL, V17, P411, DOI 10.1007/s13181-021-00833-8
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   De Palma FDE, 2019, CANCERS, V11, DOI 10.3390/cancers11071017
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Fornasier G, 2018, ADV THER, V35, P1497, DOI 10.1007/s12325-018-0791-0
   Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234
   Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017
   Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076
   Grothey A, 2021, ANN ONCOL, V32, P959, DOI 10.1016/j.annonc.2021.03.206
   HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0
   IJspeert JEG, 2015, NAT REV GASTRO HEPAT, V12, P401, DOI 10.1038/nrgastro.2015.73
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Johnson DB, 2022, NAT REV CLIN ONCOL, V19, P254, DOI 10.1038/s41571-022-00600-w
   Kooshkaki O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124427
   Lenz HJ, 2015, CANCER TREAT REV, V41, P777, DOI 10.1016/j.ctrv.2015.06.001
   Lu YT, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01273-9
   Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878
   Malki A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010130
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   O'Neill V J, 2005, Future Oncol, V1, P183, DOI 10.1517/14796694.1.2.183
   Olejarz W, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165840
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Riese DJ, 2014, SEMIN CELL DEV BIOL, V28, P49, DOI 10.1016/j.semcdb.2014.03.005
   Roth MT, 2021, EXPERT REV ANTICANC, V21, P229, DOI 10.1080/14737140.2021.1851201
   Shinji S, 2022, J NIPPON MED SCH, V89, P246, DOI 10.1272/jnms.JNMS.2022_89-310
   Simon K, 2016, CLIN INTERV AGING, V11, DOI 10.2147/CIA.S109285
   Tanaka Fumihiro, 2000, Current Pharmaceutical Biotechnology, V1, P137, DOI 10.2174/1389201003378979
   Wainberg ZA, 2007, EXPERT REV ANTICANC, V7, P967, DOI 10.1586/14737140.7.7.967
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(19)32319-0
   Wong CC, 2023, NAT REV CLIN ONCOL, V20, P429, DOI 10.1038/s41571-023-00766-x
   Xu WD, 2016, FRONT BIOSCI-LANDMRK, V21, P410, DOI 10.2741/4397
   YASUI W, 1988, CANCER RES, V48, P137
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6
NR 45
TC 1
Z9 1
U1 0
U2 1
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 0257-2753
EI 1421-9875
J9 DIGEST DIS
JI Dig. Dis.
PD JUL
PY 2024
VL 42
IS 4
BP 319
EP 324
DI 10.1159/000538511
EA MAR 2024
PG 6
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA ZF1U3
UT WOS:001241944400001
PM 38531339
DA 2025-01-04
ER

PT J
AU Zhou, Y
   Wu, S
   Qu, FJ
AF Zhou, Yi
   Wu, Shuang
   Qu, Fan-Jie
TI Therapeutic strategies targeting the epidermal growth factor receptor
   signaling pathway in metastatic colorectal cancer
SO WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Review
DE Metastatic colorectal cancer; Epidermal growth factor receptor; B-type
   RAF mutation; Kirsten rat sarcoma viral oncogene wild type; Kirsten rat
   sarcoma viral oncogene G12C mutation; Human epidermal growth factor
   receptor 2 overexpression/ amplification
ID FOLFIRI PLUS BEVACIZUMAB; 1ST-LINE TREATMENT; WILD-TYPE; OPEN-LABEL;
   SUBGROUP ANALYSES; COMBINED BRAF; CETUXIMAB; INHIBITION; CHEMOTHERAPY;
   PHASE-3
AB More than 1.9 million new colorectal cancer (CRC) cases and 935000 deaths were estimated to occur worldwide in 2020, representing about one in ten cancer cases and deaths. Overall, colorectal ranks third in incidence, but second in mortality. More than half of the patients are in advanced stages at diagnosis. Treatment options are complex because of the heterogeneity of the patient population, including different molecular subtypes. Treatments have included conventional fluorouracil-based chemotherapy, targeted therapy, immunotherapy, etc. In recent years, with the development of genetic testing technology, more and more targeted drugs have been applied to the treatment of CRC, which has further prolonged the survival of metastatic CRC patients.
C1 [Zhou, Yi; Wu, Shuang; Qu, Fan-Jie] Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, 40 Qianshan Rd, Dalian 116033, Liaoning, Peoples R China.
C3 Dalian Medical University
RP Qu, FJ (corresponding author), Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, 40 Qianshan Rd, Dalian 116033, Liaoning, Peoples R China.
EM wyb960419@163.com
CR Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4
   Hyman David M, 2015, N Engl J Med, V373, P726, DOI 10.1056/NEJMoa1502309
   Aranda E, 2018, EUR J CANCER, V101, P263, DOI 10.1016/j.ejca.2018.06.024
   Arkhipov A, 2013, ELIFE, V2, DOI 10.7554/eLife.00708
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Artale S, 2008, J CLIN ONCOL, V26, P4217, DOI 10.1200/JCO.2008.18.7286
   Bando H, 2023, NAT REV GASTRO HEPAT, V20, P306, DOI 10.1038/s41575-022-00736-1
   Bhattacharya S, 2023, CRIT REV ONCOL HEMAT, V183, DOI 10.1016/j.critrevonc.2023.103916
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Chang JJ, 2022, CLIN COLORECTAL CANC, V21, P347, DOI 10.1016/j.clcc.2022.07.003
   Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344
   Corcoran R, 2020, ANN ONCOL, V31, pS226, DOI 10.1016/j.annonc.2020.04.041
   Corcoran RB, 2015, J GASTROINTEST ONCOL, V6, P650, DOI 10.3978/j.issn.2078-6891.2015.076
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Cremolini C, 2018, JAMA ONCOL, V4, P529, DOI 10.1001/jamaoncol.2017.5314
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   De Palma FDE, 2019, CANCERS, V11, DOI 10.3390/cancers11071017
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Fakih MG, 2022, LANCET ONCOL, V23, P115, DOI 10.1016/S1470-2045(21)00605-7
   Fanelli GN, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1117-2
   Gupta R, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.22.00306
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Henry JT, 2021, JCO PRECIS ONCOL, V5, P613, DOI 10.1200/PO.20.00256
   Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Izawa N, 2023, TARGET ONCOL, V18, P369, DOI 10.1007/s11523-023-00963-9
   Jacobs S.A., 2021, CLIN CANCER RES, V27, P1612, DOI [10.1158/1078-0432.CCR-20-1831, DOI 10.1158/1078-0432.CCR-20-1831]
   Kanat O, 2018, WORLD J CLIN CASES, V6, P418, DOI 10.12998/wjcc.v6.i11.418
   Klein-Scory S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01115
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Lee A, 2020, DRUGS, V80, P1033, DOI 10.1007/s40265-020-01340-w
   Leporrier J, 2006, BRIT J SURG, V93, P465, DOI 10.1002/bjs.5278
   Leto SM, 2015, CLIN CANCER RES, V21, P5519, DOI 10.1158/1078-0432.CCR-14-3066
   Li HS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.548867
   Li QH, 2020, GASTROENTEROL REP, V8, P179, DOI 10.1093/gastro/goaa026
   Li X, 2017, EUR J PHARM SCI, V110, P51, DOI 10.1016/j.ejps.2017.01.021
   Martín-Richard M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10030470
   Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915
   Martini G, 2023, CANCER MED-US, V12, P9392, DOI 10.1002/cam4.5699
   Martini G, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1069370
   Masuishi T, 2020, BRIT J CANCER, V123, P1490, DOI 10.1038/s41416-020-01042-w
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Modest DP, 2022, J CLIN ONCOL, V40, P72, DOI 10.1200/JCO.21.01332
   Nakamura Y, 2021, NAT MED, V27, P1899, DOI 10.1038/s41591-021-01553-w
   Napolitano S, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.940523
   Narita Y, 2022, JCO CLIN CANCER INFO, V6, DOI 10.1200/CCI.22.00022
   Neumann J, 2009, PATHOL RES PRACT, V205, P858, DOI 10.1016/j.prp.2009.07.010
   Ogitani Y, 2016, CLIN CANCER RES, V22, P5097, DOI 10.1158/1078-0432.CCR-15-2822
   Ogitani Y, 2016, CANCER SCI, V107, P1039, DOI 10.1111/cas.12966
   Osumi H, 2023, TRANSL ONCOL, V35, DOI 10.1016/j.tranon.2023.101718
   Osumi H, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2022-063071
   Osumi H, 2021, EUR J CANCER, V153, P86, DOI 10.1016/j.ejca.2021.05.010
   Pahuja KB, 2018, CANCER CELL, V34, P792, DOI 10.1016/j.ccell.2018.09.010
   Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105
   Pietrantonio F, 2023, ANN ONCOL, V34, pS1266, DOI 10.1016/j.annonc.2023.10.016
   Pietrantonio F, 2019, JAMA ONCOL, V5, P1268, DOI 10.1001/jamaoncol.2019.1467
   Prasanna T, 2021, CURR PROB CANCER, V45, DOI 10.1016/j.currproblcancer.2020.100637
   Quan M, 2023, INT J CANCER, V153, P1877, DOI 10.1002/ijc.34531
   Raghav KPS, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.TPS3620
   Rossini D, 2023, EUR J CANCER, V184, P106, DOI 10.1016/j.ejca.2023.02.006
   Sanchez-Ibarra HE, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0235490
   Santini D, 2012, ANN ONCOL, V23, P2313, DOI 10.1093/annonc/mdr623
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Schram AM, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3086
   Schulz MS, 2022, CANCERS, V14, DOI 10.3390/cancers14071641
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345
   Sorah JD, 2022, ONCOLOGIST, V27, P1006, DOI 10.1093/oncolo/oyac222
   Stintzing S, 2023, J CLIN ONCOL, V41, P4143, DOI 10.1200/JCO.22.01420
   Strickler JH, 2023, LANCET ONCOL, V24, P496, DOI 10.1016/S1470-2045(23)00150-X
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabernero J., J Clin Oncol, DOI [10.1200/JCO.22.01693, DOI 10.1200/JCO.22.01693]
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Takashima A., J Clin Oncol
   Tejpar S, 2018, EUR J CANCER, V99, P66, DOI 10.1016/j.ejca.2018.05.009
   Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106
   Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915
   Van Cutsem E, 2023, J CLIN ONCOL, V41, P2628, DOI 10.1200/JCO.22.01693
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Wang L, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.11036
   Wasan H, 2014, LANCET ONCOL, V15, P631, DOI 10.1016/S1470-2045(14)70106-8
   Waters N, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3097
   Yaeger R, 2023, NEW ENGL J MED, V388, P44, DOI 10.1056/NEJMoa2212419
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yalcin S, 2013, ONCOLOGY-BASEL, V85, P328, DOI 10.1159/000355914
   Yang L, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09447-x
   Yoshino T, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-38032-4
   Zhou J, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02130-2
NR 94
TC 0
Z9 0
U1 1
U2 1
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1948-5204
J9 WORLD J GASTRO ONCOL
JI World J. Gastrointest. Oncol.
PD JUN 15
PY 2024
VL 16
IS 6
DI 10.4251/wjgo.v16.i6.2362
PG 19
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA ZG1G1
UT WOS:001274044200018
PM 38994135
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Hu, QQ
   Tong, ZX
   Yalikong, A
   Ge, LP
   Shi, Q
   Du, XY
   Wang, P
   Liu, XY
   Zhan, WQ
   Gao, X
   Sun, D
   Fu, T
   Ye, D
   Fan, CH
   Liu, J
   Zhong, YS
   Jiang, YZ
   Gu, HZ
AF Hu, Qinqin
   Tong, Zongxuan
   Yalikong, Ayimukedisi
   Ge, Li-Ping
   Shi, Qiang
   Du, Xinyu
   Wang, Pu
   Liu, Xi-Yu
   Zhan, Wuqiang
   Gao, Xia
   Sun, Di
   Fu, Tong
   Ye, Dan
   Fan, Chunhai
   Liu, Jie
   Zhong, Yun-Shi
   Jiang, Yi-Zhou
   Gu, Hongzhou
TI DNAzyme-based faithful probing and pulldown to identify candidate
   biomarkers of low abundance
SO NATURE CHEMISTRY
LA English
DT Article
ID TRANSFER-RNA SYNTHETASE; NUCLEIC-ACID DETECTION; MASS-SPECTROMETRY;
   CELL; DNA; EXPRESSION; SELECTION; PROTEIN; TUMORS
AB Biomarker discovery is essential for the understanding, diagnosis, targeted therapy and prognosis assessment of malignant diseases. However, it remains a huge challenge due to the lack of sensitive methods to identify disease-specific rare molecules. Here we present MORAC, molecular recognition based on affinity and catalysis, which enables the effective identification of candidate biomarkers with low abundance. MORAC relies on a class of DNAzymes, each cleaving a sole RNA linkage embedded in their DNA chain upon specifically sensing a complex system with no prior knowledge of the system's molecular content. We show that signal amplification from catalysis ensures the DNAzymes high sensitivity (for target probing); meanwhile, a simple RNA-to-DNA mutation can shut down their RNA cleavage ability and turn them into a pure affinity tool (for target pulldown). Using MORAC, we identify previously unknown, low-abundance candidate biomarkers with clear clinical value, including apolipoprotein L6 in breast cancer and seryl-tRNA synthetase 1 in polyps preceding colon cancer.
   The discovery of biomarkers remains challenging owing to a lack of methods sensitive enough to identify such rare molecules. Now, by simultaneously exploiting the catalysis and affinity of a DNAzyme, candidate biomarkers with low abundance in cancers can be pulled down for identification and validation.
C1 [Hu, Qinqin; Tong, Zongxuan; Yalikong, Ayimukedisi; Ge, Li-Ping; Shi, Qiang; Du, Xinyu; Wang, Pu; Liu, Xi-Yu; Zhan, Wuqiang; Gao, Xia; Sun, Di; Fu, Tong; Ye, Dan; Zhong, Yun-Shi; Jiang, Yi-Zhou; Gu, Hongzhou] Fudan Univ, Shanghai Stomatol Hosp, Shanghai Canc Ctr, Inst Biomed Sci,Dept Breast Surg,Key Lab Breast Ca, Shanghai, Peoples R China.
   [Hu, Qinqin; Tong, Zongxuan; Yalikong, Ayimukedisi; Ge, Li-Ping; Shi, Qiang; Du, Xinyu; Wang, Pu; Liu, Xi-Yu; Zhan, Wuqiang; Gao, Xia; Sun, Di; Fu, Tong; Ye, Dan; Zhong, Yun-Shi; Jiang, Yi-Zhou; Gu, Hongzhou] Fudan Univ, Zhongshan Hosp, Endoscopy Ctr, Shanghai, Peoples R China.
   [Hu, Qinqin; Fan, Chunhai; Gu, Hongzhou] Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Biol, Shanghai, Peoples R China.
   [Hu, Qinqin; Fan, Chunhai; Gu, Hongzhou] Shanghai Jiao Tong Univ, Sch Global Hlth, Shanghai, Peoples R China.
   [Fan, Chunhai] Shanghai Jiao Tong Univ, Renji Hosp, Inst Mol Med, Sch Med,Shanghai Key Lab Nucl Acids Chem & Nanomed, Shanghai, Peoples R China.
   [Fan, Chunhai] Shanghai Jiao Tong Univ, Frontiers Sci Ctr Transformat Mol, New Cornerstone Sci Lab, Shanghai, Peoples R China.
   [Fan, Chunhai] Shanghai Jiao Tong Univ, Natl Ctr Translat Med, Shanghai, Peoples R China.
   [Fan, Chunhai] Zhangjiang Lab, Shanghai, Peoples R China.
   [Liu, Jie] Fudan Univ, Huashan Hosp, Dept Digest Dis, Shanghai, Peoples R China.
C3 Fudan University; Fudan University; Shanghai Jiao Tong University;
   Shanghai Jiao Tong University; Shanghai Jiao Tong University; Shanghai
   Jiao Tong University; Shanghai Jiao Tong University; Zhangjiang
   Laboratory; Fudan University
RP Zhong, YS; Jiang, YZ; Gu, HZ (corresponding author), Fudan Univ, Shanghai Stomatol Hosp, Shanghai Canc Ctr, Inst Biomed Sci,Dept Breast Surg,Key Lab Breast Ca, Shanghai, Peoples R China.; Zhong, YS; Jiang, YZ; Gu, HZ (corresponding author), Fudan Univ, Zhongshan Hosp, Endoscopy Ctr, Shanghai, Peoples R China.; Gu, HZ (corresponding author), Shanghai Jiao Tong Univ, Sch Chem & Chem Engn, Dept Chem Biol, Shanghai, Peoples R China.; Gu, HZ (corresponding author), Shanghai Jiao Tong Univ, Sch Global Hlth, Shanghai, Peoples R China.
EM zhong.yunshi@zs-hospital.sh.cn; yizhoujiang@fudan.edu.cn;
   hongzhou.gu@fudan.edu.cn
RI Liu, Zezhong/AFA-5381-2022; XINYU, DU/AHE-6763-2022; Liu,
   xiyu/KEJ-2349-2024; Gu, Hongzhou/H-5308-2011; Hu, Qinqin/GNM-5529-2022;
   Fan, Chunhai/A-7569-2011
OI Fan, Chunhai/0000-0002-7171-7338; Hu, Qinqin/0000-0001-5726-9279; Wang,
   Pu/0000-0002-9185-1913
FU National Key Research and Development Program of China [2020YFA0908901];
   National Natural Science Foundation of China [82121002, 91859104,
   21991134, T2188102]; Program of Shanghai Academic Research Leader
   [22XD1421500]; New Cornerstone Science Foundation
FX We acknowledge funding by the National Key Research and Development
   Program of China (2020YFA0908901 to H.G.), the National Natural Science
   Foundation of China (82121002 and 91859104 to H.G.; 21991134 and
   T2188102 to C.F.), the Program of Shanghai Academic Research Leader
   (22XD1421500 to H.G.) and the New Cornerstone Science Foundation (to
   C.F.). The funders had no role in the study design, data collection and
   analysis, decision to publish or preparation of the manuscript.
CR Aguirre SD, 2013, BIOMOLECULES, V3, DOI 10.3390/biom3030563
   Ali MM, 2011, ANGEW CHEM INT EDIT, V50, P3751, DOI 10.1002/anie.201100477
   Andy Hu C.-A., 2020, J INTEGR CARDIOL OPE, DOI [10.31487/j.JICOA.2020.04.10, DOI 10.31487/J.JICOA.2020.04.10]
   Andy HuC.-A., Clin. Oncol. Res, P2020, DOI [DOI 10.31487/J.COR.2020.07.12, 10.31487/j.cor.2020.07.12]
   [Anonymous], 2021, COMB CHROM TECHN PUR
   Breaker R R, 1994, Chem Biol, V1, P223, DOI 10.1016/1074-5521(94)90014-0
   Chen JS, 2018, SCIENCE, V360, P436, DOI 10.1126/science.aar6245
   Cilento EM, 2019, J NEUROCHEM, V151, P397, DOI 10.1111/jnc.14635
   Crosby D, 2022, SCIENCE, V375, P1244, DOI 10.1126/science.aay9040
   Daniels DA, 2003, P NATL ACAD SCI USA, V100, P15416, DOI 10.1073/pnas.2136683100
   Drabovich AP, 2010, J PROTEOME RES, V9, P1236, DOI 10.1021/pr900729g
   Fukui H, 2009, CIRC RES, V104, P1253, DOI 10.1161/CIRCRESAHA.108.191189
   Gaudet RG, 2021, SCIENCE, V373, DOI 10.1126/science.abf8113
   Geng XF, 2020, ANAL CHIM ACTA, V1123, P28, DOI 10.1016/j.aca.2020.04.069
   Gootenberg JS, 2018, SCIENCE, V360, P439, DOI 10.1126/science.aaq0179
   Guan C, 2017, INORG CHEM, V56, P438, DOI 10.1021/acs.inorgchem.6b02334
   He SN, 2015, ANAL CHEM, V87, P569, DOI 10.1021/ac5031557
   Herzog W, 2009, CIRC RES, V104, P1260, DOI 10.1161/CIRCRESAHA.108.191718
   Imashimizu Masahiko, 2018, Biol Methods Protoc, V3, pbpy004, DOI 10.1093/biomethods/bpy004
   Keshishian H, 2007, MOL CELL PROTEOMICS, V6, P2212, DOI 10.1074/mcp.M700354-MCP200
   Kim D, 2018, INT J BIOL MACROMOL, V109, P704, DOI 10.1016/j.ijbiomac.2017.12.075
   Kobayashi M, 2020, SEMIN IMMUNOL, V47, DOI 10.1016/j.smim.2020.101388
   Krug K, 2020, CELL, V183, P1436, DOI 10.1016/j.cell.2020.10.036
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Nagtegaal ID, 2020, HISTOPATHOLOGY, V76, P182, DOI 10.1111/his.13975
   Pérez-Morga D, 2005, SCIENCE, V309, P469, DOI 10.1126/science.1114566
   Ray P, 2012, J CLIN INVEST, V122, P1734, DOI 10.1172/JCI62385
   Schlosser K, 2009, CHEM BIOL, V16, P311, DOI 10.1016/j.chembiol.2009.01.008
   Sefah K, 2010, NAT PROTOC, V5, P1169, DOI 10.1038/nprot.2010.66
   Shen ZF, 2016, ANGEW CHEM INT EDIT, V55, P2431, DOI 10.1002/anie.201510125
   Silverman SK, 2010, ANGEW CHEM INT EDIT, V49, P7180, DOI 10.1002/anie.200906345
   Smith EE, 2009, GENOME RES, V19, P850, DOI 10.1101/gr.085647.108
   Thomas S, 2016, PROTEOM CLIN APPL, V10, P358, DOI 10.1002/prca.201500102
   Vanhamme L, 2003, NATURE, V422, P83, DOI 10.1038/nature01461
   Wang M, 2012, MOL CELL PROTEOMICS, V11, P492, DOI 10.1074/mcp.O111.014704
   WIKSTRAND CJ, 1982, CANCER RES, V42, P267
   Wu SZ, 2021, NAT GENET, V53, P1334, DOI 10.1038/s41588-021-00911-1
   Xiong HJ, 2019, INT J BIOL MACROMOL, V132, P190, DOI 10.1016/j.ijbiomac.2019.03.165
   Xu XL, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1686
   Zhou WH, 2016, ACS SENSORS, V1, P600, DOI 10.1021/acssensors.5b00306
   Zhu XZ, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01930-w
NR 41
TC 13
Z9 14
U1 37
U2 108
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1755-4330
EI 1755-4349
J9 NAT CHEM
JI Nat. Chem.
PD JAN
PY 2024
VL 16
IS 1
DI 10.1038/s41557-023-01328-5
EA SEP 2023
PG 17
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA LR8P6
UT WOS:001068069300001
PM 37710046
DA 2025-01-04
ER

PT J
AU Mojarad-Jabali, S
   Mahdinloo, S
   Farshbaf, M
   Sarfraz, M
   Fatahi, Y
   Atyabi, F
   Valizadeh, H
AF Mojarad-Jabali, Solmaz
   Mahdinloo, Somayeh
   Farshbaf, Masoud
   Sarfraz, Muhammad
   Fatahi, Yousef
   Atyabi, Fatemeh
   Valizadeh, Hadi
TI Transferrin receptor-mediated liposomal drug delivery: recent trends in
   targeted therapy of cancer
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE Liposomes; drug delivery; active targeting; receptor-mediated
   endocytosis; transferrin
ID BLOOD-BRAIN-BARRIER; IN-VIVO; PROTEIN CORONA; MONOCLONAL-ANTIBODY;
   IRON-METABOLISM; COLON-CANCER; FUNCTIONALIZED LIPOSOMES; INTRACELLULAR
   DELIVERY; ANTICANCER EFFICACY; FOLATE RECEPTOR
AB Introduction Compared to normal cells, malignant cancer cells require more iron for their growth and rapid proliferation, which can be supplied by a high expression level of transferrin receptor (TfR). It is well known that the expression of TfR on the tumor cells is considerably higher than that of normal cells, which makes TfR an attractive target in cancer therapy. Areas covered In this review, the primary focus is on the role of TfR as a valuable tool for cancer-targeted drug delivery, followed by the full coverage of available TfR ligands and their conjugation chemistry to the surface of liposomes. Finally, the most recent studies investigating the potential of TfR-targeted liposomes as promising drug delivery vehicles to different cancer cells are highlighted with emphasis on their improvement possibilities to become a part of future cancer medicines. Expert opinion Liposomes as a valuable class of nanocarriers have gained much attention toward cancer therapy. From all the studies that have exploited the therapeutic and diagnostic potential of TfR on cancer cells, it can be realized that the systematic assessment of TfR ligands applied for liposomal targeted delivery has yet to be entirely accomplished.
C1 [Mojarad-Jabali, Solmaz; Mahdinloo, Somayeh; Valizadeh, Hadi] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut, Tabriz, Iran.
   [Mojarad-Jabali, Solmaz; Mahdinloo, Somayeh; Farshbaf, Masoud] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Farshbaf, Masoud] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Nanotechnol, Tabriz, Iran.
   [Sarfraz, Muhammad] Al Ain Univ, Coll Pharm, Al Ain, U Arab Emirates.
   [Fatahi, Yousef] Univ Tehran Med Sci, Fac Pharm, Nanotechnol Res Ctr, Tehran, Iran.
   [Atyabi, Fatemeh] Univ Tehran Med Sci, Fac Pharm, Dept Pharmaceut Nanotechnol, Tehran, Iran.
   [Valizadeh, Hadi] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science; Tehran University of
   Medical Sciences; Tehran University of Medical Sciences; Tabriz
   University of Medical Science
RP Valizadeh, H (corresponding author), Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz 51664, Iran.; Valizadeh, H (corresponding author), Tabriz Univ Med Sci, Fac Pharm, Tabriz 51664, Iran.
EM valizadeh@tbzmed.ac.ir
RI Bagheri, Fatemeh/JUU-6250-2023; Valizadeh, Hadi/AAA-3650-2019; Sarfraz,
   Muhammad/KRP-2724-2024; farshbaf, masoud/Q-1767-2017; Fatahi,
   Yousef/S-6193-2016
OI Farshbaf, Masoud/0000-0003-4260-7380; Sarfraz,
   Muhammad/0000-0002-0516-4966; Fatahi, Yousef/0000-0003-0374-2141
FU 'Faculty of Pharmacy' of Tabriz University of Medical Sciences; 'Drug
   Applied Research Center' of Tabriz University of Medical Sciences
FX The financial support from the 'Faculty of Pharmacy' and 'Drug Applied
   Research Center' of Tabriz University of Medical Sciences is greatly
   acknowledged.
CR Alexander JJ, 2018, MOL IMMUNOL, V102, P26, DOI 10.1016/j.molimm.2018.06.267
   AlSawaftah NM, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90349-6
   Anderson GJ, 2009, CELL MOL LIFE SCI, V66, P3241, DOI 10.1007/s00018-009-0051-1
   [Anonymous], 2015, DRUG DELIV
   Arbyn M, 2020, LANCET GLOB HEALTH, V8, pE191, DOI 10.1016/S2214-109X(19)30482-6
   Arosio P, 2009, BBA-GEN SUBJECTS, V1790, P589, DOI 10.1016/j.bbagen.2008.09.004
   Ashrafzadeh MS, 2020, INT J NANOMED, V15, P7035, DOI 10.2147/IJN.S255902
   Assaraf YG, 2014, DRUG RESIST UPDATE, V17, P89, DOI 10.1016/j.drup.2014.10.002
   Balmanno K, 2009, INT J CANCER, V125, P2332, DOI 10.1002/ijc.24604
   Bao HM, 2012, J MATER SCI-MATER M, V23, P1891, DOI 10.1007/s10856-012-4658-7
   Barui AK, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.201900124
   Belfiore L, 2018, J CONTROL RELEASE, V277, P1, DOI 10.1016/j.jconrel.2018.02.040
   Belletti D, 2017, EXPERT OPIN DRUG DEL, V14, P825, DOI 10.1080/17425247.2017.1243528
   Bi Y, 2017, ANTICANCER RES, V37, P5207, DOI 10.21873/anticanres.11944
   Brooks D, 1995, CLIN CANCER RES, V1, P1259
   Bukowski K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093233
   Candelaria PV, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.607692
   Canfell K, 2020, LANCET, V395, P591, DOI 10.1016/S0140-6736(20)30157-4
   Caracciolo G, 2014, J MATER CHEM B, V2, P7419, DOI 10.1039/c4tb01316f
   Caracciolo G, 2001, EUR BIOPHYS J BIOPHY, V30, P163, DOI 10.1007/s002490000128
   Caracciolo G, 2018, ACS APPL MATER INTER, V10, P22951, DOI 10.1021/acsami.8b04962
   Caracciolo G, 2011, APPL PHYS LETT, V99, DOI 10.1063/1.3615055
   Chai ZL, 2017, J CONTROL RELEASE, V264, P102, DOI 10.1016/j.jconrel.2017.08.027
   Chen CHB, 2008, P NATL ACAD SCI USA, V105, P15908, DOI 10.1073/pnas.0808360105
   Chen CT, 2017, ACS APPL MATER INTER, V9, P5864, DOI 10.1021/acsami.6b15831
   Chen JX, 2009, TRAFFIC, V10, P1488, DOI 10.1111/j.1600-0854.2009.00961.x
   Chen QK, 2018, INT J NANOMED, V13, P6009, DOI 10.2147/IJN.S176012
   Chen ZZ, 2013, INT J PHARMACEUT, V456, P73, DOI 10.1016/j.ijpharm.2013.08.017
   Chen ZZ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101414
   COLLAWN JF, 1990, CELL, V63, P1061, DOI 10.1016/0092-8674(90)90509-D
   Crépin R, 2010, CANCER RES, V70, P5497, DOI 10.1158/0008-5472.CAN-10-0938
   Dai XY, 2014, TROP J PHARM RES, V13, P331, DOI 10.4314/tjpr.v13i3.3
   Dams ETM, 2000, J PHARMACOL EXP THER, V292, P1071
   Davis ME, 2008, NAT REV DRUG DISCOV, V7, P771, DOI 10.1038/nrd2614
   de Mattos AC, 2016, EUR J PHARM SCI, V84, P83, DOI 10.1016/j.ejps.2016.01.012
   Deng ZY, 2017, ONCOTARGET, V8, P82231, DOI 10.18632/oncotarget.19288
   Deshpande P, 2018, DRUG DELIV, V25, P517, DOI 10.1080/10717544.2018.1435747
   Digiacomo L, 2017, BIOMATER SCI-UK, V5, P1884, DOI 10.1039/c7bm00387k
   Dostalova S, 2016, ACS APPL MATER INTER, V8, P14430, DOI 10.1021/acsami.6b04286
   ELLIOTT RL, 1993, ANN NY ACAD SCI, V698, P159, DOI 10.1111/j.1749-6632.1993.tb17204.x
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Farshbaf M, 2022, J CONTROL RELEASE, V345, P371, DOI 10.1016/j.jconrel.2022.03.019
   Farshbaf M, 2022, INT J PHARMACEUT, V614, DOI 10.1016/j.ijpharm.2022.121458
   Farshbaf M, 2020, J CONTROL RELEASE, V328, P932, DOI 10.1016/j.jconrel.2020.10.055
   Feng M, 2020, INNOVATION-AMSTERDAM, V1, DOI 10.1016/j.xinn.2020.100032
   Fernandes MA, 2021, COLLOID SURFACE A, V611, DOI 10.1016/j.colsurfa.2020.125806
   Gabizon A, 2008, CANCER CHEMOTH PHARM, V61, P695, DOI 10.1007/s00280-007-0525-5
   Gammella E, 2017, METALLOMICS, V9, P1367, DOI 10.1039/c7mt00143f
   Gao SQ, 2016, J CONTROL RELEASE, V243, P357, DOI 10.1016/j.jconrel.2016.10.027
   Ge CC, 2015, ARCH TOXICOL, V89, P519, DOI 10.1007/s00204-015-1458-0
   Giannetti AM, 2004, J BIOL CHEM, V279, P25866, DOI 10.1074/jbc.M401467200
   Giannetti AM, 2005, STRUCTURE, V13, P1613, DOI 10.1016/j.str.2005.07.016
   Gkouvatsos K, 2012, BBA-GEN SUBJECTS, V1820, P188, DOI 10.1016/j.bbagen.2011.10.013
   Gomme PT, 2005, DRUG DISCOV TODAY, V10, P267, DOI 10.1016/S1359-6446(04)03333-1
   Gu WX, 2021, J CONTROL RELEASE, V329, P676, DOI 10.1016/j.jconrel.2020.10.003
   Guan J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05384-1
   Han L, 2021, ACTA PHARM SIN B, V11, P2306, DOI 10.1016/j.apsb.2020.11.023
   Han L, 2016, ACS NANO, V10, P4209, DOI 10.1021/acsnano.5b07573
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Haq AI, 2009, LANCET ONCOL, V10, P1128, DOI 10.1016/S1470-2045(09)70157-3
   Harrison PM, 1996, BBA-BIOENERGETICS, V1275, P161, DOI 10.1016/0005-2728(96)00022-9
   Head JF, 1997, ADV ENZYME REGUL, V37, P147, DOI 10.1016/S0065-2571(96)00010-6
   Hernández-Pedro NY, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/351031
   Högemann-Savellano D, 2003, NEOPLASIA, V5, P495
   Holmström P, 2006, LIVER INT, V26, P976, DOI 10.1111/j.1478-3231.2006.01316.x
   Howlader N, 2020, NEW ENGL J MED, V383, P640, DOI 10.1056/NEJMoa1916623
   International Agency for Research on Cancer (IARC), Cancer Today
   Isacchi B, 2012, EUR J PHARM BIOPHARM, V80, P528, DOI 10.1016/j.ejpb.2011.11.015
   Jaferian S, 2016, BIOMED PHARMACOTHER, V84, P780, DOI 10.1016/j.biopha.2016.10.004
   Jhaveri A, 2019, J DRUG TARGET, V27, P601, DOI 10.1080/1061186X.2018.1550647
   Jhaveri A, 2018, J CONTROL RELEASE, V277, P89, DOI 10.1016/j.jconrel.2018.03.006
   Jhaveri A, 2016, EXPERT OPIN DRUG DEL, V13, P49, DOI 10.1517/17425247.2015.1086745
   Johnsen KB, 2019, PROG NEUROBIOL, V181, DOI 10.1016/j.pneurobio.2019.101665
   Johnsen KB, 2016, J CONTROL RELEASE, V222, P32, DOI 10.1016/j.jconrel.2015.11.032
   Johnson IRD, 2014, MOL CANCER RES, V12, P1851, DOI 10.1158/1541-7786.MCR-14-0074
   Kang SM, 2020, THERANOSTICS, V10, P4308, DOI 10.7150/thno.41322
   Karim R, 2016, J CONTROL RELEASE, V227, P23, DOI 10.1016/j.jconrel.2016.02.026
   KATZ JH, 1961, J CLIN INVEST, V40, P2143, DOI 10.1172/JCI104440
   Kawabata H, 2019, FREE RADICAL BIO MED, V133, P46, DOI 10.1016/j.freeradbiomed.2018.06.037
   Kawamoto M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-359
   KEMP SF, 1984, J PEDIATR-US, V105, P394, DOI 10.1016/S0022-3476(84)80011-6
   Khan A, 2020, J TRACE ELEM MED BIO, V62, DOI 10.1016/j.jtemb.2020.126582
   Khan NEEL, 2021, ACTA PHARM SIN B, V11, P1341, DOI 10.1016/j.apsb.2020.10.015
   Kiaie SH, 2020, INT J PHARMACEUT, V581, DOI 10.1016/j.ijpharm.2020.119269
   Kibria G, 2011, J CONTROL RELEASE, V153, P141, DOI 10.1016/j.jconrel.2011.03.012
   Kilic MA, 2012, J BIOMED NANOTECHNOL, V8, P508, DOI 10.1166/jbn.2012.1406
   김성일, 2008, [Journal of Life Science, 생명과학회지], V18, P298
   Kim SS, 2015, CANCER LETT, V369, P250, DOI 10.1016/j.canlet.2015.08.022
   Kleven MD, 2018, BIOCHEMISTRY-US, V57, P1552, DOI 10.1021/acs.biochem.8b00006
   Knezevic I, 2015, BIOLOGICALS, V43, P307, DOI 10.1016/j.biologicals.2015.06.009
   Koshkaryev A, 2012, CANCER BIOL THER, V13, P50, DOI 10.4161/cbt.13.1.18871
   Krieger ML, 2010, INT J PHARMACEUT, V389, P10, DOI 10.1016/j.ijpharm.2009.12.061
   Kukulj S, 2010, MED ONCOL, V27, P268, DOI 10.1007/s12032-009-9203-2
   Kumari S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06888-4
   Lakkadwala S, 2020, NANOMED-NANOTECHNOL, V23, DOI 10.1016/j.nano.2019.102112
   Lakkadwala S, 2019, J CONTROL RELEASE, V307, P247, DOI 10.1016/j.jconrel.2019.06.033
   Lakkadwala S, 2019, COLLOID SURFACE B, V173, P27, DOI 10.1016/j.colsurfb.2018.09.047
   Lakkadwala S, 2018, J PHARM SCI-US, V107, P2902, DOI 10.1016/j.xphs.2018.07.020
   Laverman P, 2001, J PHARMACOL EXP THER, V298, P607
   Le TT, 2013, ANAL CHIM ACTA, V761, P143, DOI 10.1016/j.aca.2012.11.016
   Lee JH, 2001, EUR J BIOCHEM, V268, P2004, DOI 10.1046/j.1432-1327.2001.02073.x
   Leoh LS, 2018, J IMMUNOL, V200, P3485, DOI 10.4049/jimmunol.1700787
   Leto I, 2016, CHEMMEDCHEM, V11, P1745, DOI 10.1002/cmdc.201500586
   Li L, 2010, P NATL ACAD SCI USA, V107, P3505, DOI 10.1073/pnas.0913192107
   Li LL, 2017, CHEM PHARM BULL, V65, P1004, DOI 10.1248/cpb.c17-00267
   Li XM, 2009, INT J PHARMACEUT, V373, P116, DOI 10.1016/j.ijpharm.2009.01.023
   Liu C, 2017, INT J NANOMED, V12, P2407, DOI 10.2147/IJN.S131367
   Liu ZD, 2015, DRUG DEV IND PHARM, V41, P353, DOI 10.3109/03639045.2013.861478
   Lu J, 2006, CANCER RES, V66, P4410, DOI 10.1158/0008-5472.CAN-05-3310
   Luck AN, 2013, ADV DRUG DELIVER REV, V65, P1012, DOI 10.1016/j.addr.2012.11.001
   Luck AN, 2012, CURR TOP MEMBR, V69, P3, DOI 10.1016/B978-0-12-394390-3.00001-X
   Lundqvist M, 2008, P NATL ACAD SCI USA, V105, P14265, DOI 10.1073/pnas.0805135105
   Luo YA, 2015, BIOMATER SCI-UK, V3, P1386, DOI 10.1039/c5bm00067j
   Lv Q, 2013, INT J PHARMACEUT, V444, P1, DOI 10.1016/j.ijpharm.2013.01.025
   Macdonald J, 2017, ACS CHEM NEUROSCI, V8, P777, DOI 10.1021/acschemneuro.6b00369
   Macdonald J, 2016, NUCLEIC ACID THER, V26, P348, DOI 10.1089/nat.2015.0585
   Madni A, 2014, J PHARM PHARM SCI, V17, P401, DOI 10.18433/J3CP55
   Maier KE, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.32
   Marianecci C, 2017, DRUG DES DEV THER, V11, P325, DOI 10.2147/DDDT.S100075
   Mason AB, 2009, J MOL RECOGNIT, V22, P521, DOI 10.1002/jmr.979
   Messori L, 1994, Met Based Drugs, V1, P161, DOI 10.1155/MBD.1994.161
   Milani S, 2012, ACS NANO, V6, P2532, DOI 10.1021/nn204951s
   MIYAMOTO T, 1994, INT J ORAL MAX SURG, V23, P430, DOI 10.1016/S0901-5027(05)80039-6
   Moghimipour E, 2018, LIFE SCI, V194, P104, DOI 10.1016/j.lfs.2017.12.026
   Mojarad-Jabali S, 2022, INT J PHARMACEUT, V613, DOI 10.1016/j.ijpharm.2021.121395
   Mojarad-Jabali S, 2021, INT J PHARMACEUT, V602, DOI 10.1016/j.ijpharm.2021.120645
   Monopoli MP, 2011, J AM CHEM SOC, V133, P2525, DOI 10.1021/ja107583h
   MONTEMIGLIO L, NAT COMMUN, P1
   Moos T, 2000, CELL MOL NEUROBIOL, V20, P77, DOI 10.1023/A:1006948027674
   Moosavian SA, 2019, CANCER LETT, V448, P144, DOI 10.1016/j.canlet.2019.01.045
   Morris ME, 2017, AAPS J, V19, P1317, DOI 10.1208/s12248-017-0110-8
   Moura IC, 2004, BLOOD, V103, P1838, DOI 10.1182/blood-2003-07-2440
   Moura RP, 2019, EXPERT OPIN DRUG DEL, V16, P271, DOI 10.1080/17425247.2019.1583205
   Mu LM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03805-7
   Nagai K, 2014, CANCER MED-US, V3, P1085, DOI 10.1002/cam4.267
   Neiveyans M, 2019, MABS-AUSTIN, V11, P593, DOI 10.1080/19420862.2018.1564510
   Neuzillet C, 2014, PHARMACOL THERAPEUT, V141, P160, DOI 10.1016/j.pharmthera.2013.10.001
   Nogueira E, 2015, COLLOID SURFACE B, V136, P514, DOI 10.1016/j.colsurfb.2015.09.034
   O'Shannessy DJ, 2012, ONCOTARGET, V3, P414, DOI 10.18632/oncotarget.519
   Ostrom QT, 2014, NEURO-ONCOLOGY, V16, P896, DOI 10.1093/neuonc/nou087
   Oswald M, 2016, INT J PHARMACEUT, V514, P93, DOI 10.1016/j.ijpharm.2016.06.116
   Oussoren C, 1999, J LIPOSOME RES, V9, P349, DOI 10.3109/08982109909018655
   Papadia K, 2017, EUR J PHARM SCI, V102, P180, DOI 10.1016/j.ejps.2017.03.010
   Peng HF, 2017, ONCOTARGET, V8, P45597, DOI 10.18632/oncotarget.17316
   Peng JL, 2007, BIOCHEM BIOPH RES CO, V354, P864, DOI 10.1016/j.bbrc.2007.01.052
   PETRINI M, 1989, CANCER RES, V49, P6989
   Peyrin-Biroulet L, 2015, AM J CLIN NUTR, V102, P1585, DOI 10.3945/ajcn.114.103366
   Pooja D, 2015, RSC ADV, V5, P49122, DOI 10.1039/c5ra03316k
   Porciani D, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.9
   Porciani D, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2013.71
   Prutki M, 2006, CANCER LETT, V238, P188, DOI 10.1016/j.canlet.2005.07.001
   Qin L, 2014, ONCOL LETT, V8, P2000, DOI 10.3892/ol.2014.2449
   Qin X, 2013, PROTEIN PEPTIDE LETT, V20, P96, DOI 10.2174/092986613804096838
   Riaz MK, 2019, INT J NANOMED, V14, P2879, DOI 10.2147/IJN.S192219
   Saadat M, 2021, J DRUG DELIV SCI TEC, V63, DOI 10.1016/j.jddst.2021.102557
   Salvati E, 2013, INT J NANOMED, V8, DOI 10.2147/IJN.S42783
   Santi M, 2017, BIOCONJUGATE CHEM, V28, P471, DOI 10.1021/acs.bioconjchem.6b00611
   SAUVAGE CA, 1987, CANCER RES, V47, P747
   Shah V, 2018, RECENT PAT ANTI-CANC, V13, P70, DOI 10.2174/1574892812666171129142023
   Sharma A, 2017, COLLOID SURFACE B, V155, P200, DOI 10.1016/j.colsurfb.2017.04.020
   Shen JY, 2019, ARTIF CELL NANOMED B, V47, P192, DOI 10.1080/21691401.2018.1548471
   Shen Y, 2018, AM J CANCER RES, V8, P916
   Shimosaki S, 2017, BIOCHEM BIOPH RES CO, V485, P144, DOI 10.1016/j.bbrc.2017.02.039
   Simsek E, 2005, J MAGN MAGN MATER, V293, P509, DOI 10.1016/j.jmmm.2005.01.066
   Sonali, 2016, DRUG DELIV, V23, P1261, DOI 10.3109/10717544.2016.1162878
   Song XL, 2017, EUR J PHARM SCI, V96, P129, DOI 10.1016/j.ejps.2016.09.024
   Sonkar R, 2021, MAT SCI ENG C-MATER, V120, DOI 10.1016/j.msec.2020.111652
   Sriraman SK, 2016, EUR J PHARM BIOPHARM, V105, P40, DOI 10.1016/j.ejpb.2016.05.023
   Sriraman SK, 2015, J CONTROL RELEASE, V220, P160, DOI 10.1016/j.jconrel.2015.10.037
   Staquicini FI, 2011, J CLIN INVEST, V121, P161, DOI 10.1172/JCI44798
   Sun HZ, 1999, CHEM REV, V99, P2817, DOI 10.1021/cr980430w
   Suntres ZE, 2011, J TOXICOL-US, V2011, DOI 10.1155/2011/152474
   Suzuki T, 2014, INT J PHARMACEUT, V476, P205, DOI 10.1016/j.ijpharm.2014.09.047
   Tabuchi M, 2000, J BIOL CHEM, V275, P22220, DOI 10.1074/jbc.M001478200
   TAETLE R, 1983, INT J CANCER, V32, P343, DOI 10.1002/ijc.2910320314
   Tan YY, 2018, ANAL BIOANAL CHEM, V410, P1071, DOI 10.1007/s00216-017-0664-4
   Tang JJ, 2019, ACTA BIOMATER, V83, P379, DOI 10.1016/j.actbio.2018.11.002
   Tenzer S, 2013, NAT NANOTECHNOL, V8, P772, DOI 10.1038/nnano.2013.181
   Tenzer S, 2011, ACS NANO, V5, P7155, DOI 10.1021/nn201950e
   Tortorella S, 2014, J MEMBRANE BIOL, V247, P291, DOI 10.1007/s00232-014-9637-0
   Trinder D, 2003, INT J BIOCHEM CELL B, V35, P292, DOI 10.1016/S1357-2725(02)00258-3
   van Rooy I, 2011, J CONTROL RELEASE, V150, P30, DOI 10.1016/j.jconrel.2010.11.014
   Vieira DB, 2016, INT J NANOMED, V11, P5381, DOI 10.2147/IJN.S117210
   Wang D, 2018, EXPERT OPIN DRUG DEL, V15, P893, DOI 10.1080/17425247.2018.1517747
   Wang GY, 2015, CELL MOL NEUROBIOL, V35, P1105, DOI 10.1007/s10571-015-0204-8
   Wang SQ, 2020, PHARM DEV TECHNOL, V25, P1063, DOI 10.1080/10837450.2020.1786116
   Wang X, 2019, MOLECULES, V24, DOI 10.3390/molecules24193540
   Watt RK, 2011, BIOMETALS, V24, P489, DOI 10.1007/s10534-011-9415-8
   Wei L, 2016, INT J PHARMACEUT, V510, P394, DOI 10.1016/j.ijpharm.2016.06.127
   Wei YH, 2021, J CONTROL RELEASE, V337, P521, DOI 10.1016/j.jconrel.2021.07.048
   Wei YH, 2020, J CONTROL RELEASE, V319, P407, DOI 10.1016/j.jconrel.2020.01.012
   West AP, 2000, J BIOL CHEM, V275, P38135, DOI 10.1074/jbc.C000664200
   Wilner SE, 2012, MOL THER-NUCL ACIDS, V1, DOI 10.1038/mtna.2012.14
   Wu XQ, 2019, J AM CHEM SOC, V141, P10760, DOI 10.1021/jacs.9b03720
   Wu XQ, 2015, THERANOSTICS, V5, P985, DOI 10.7150/thno.11938
   Xia HB, 2000, J VIROL, V74, P11359, DOI 10.1128/JVI.74.23.11359-11366.2000
   Xiao W, 2018, INT J PHARMACEUT, V552, P328, DOI 10.1016/j.ijpharm.2018.10.011
   Xie JB, 2019, BIOMATERIALS, V224, DOI 10.1016/j.biomaterials.2019.119491
   Xu ZH, 2005, INT J PHARMACEUT, V288, P361, DOI 10.1016/j.ijpharm.2004.10.009
   Yan Q, 2015, RSC ADV, V5, P69939, DOI 10.1039/c5ra13844b
   Yan W, 2020, NANOMEDICINE-UK, V15, P303, DOI 10.2217/nnm-2019-0308
   Ye Q, 2006, CANCER IMMUNOL IMMUN, V55, P1111, DOI 10.1007/s00262-005-0105-7
   Yoon S, 2019, MOL THER-NUCL ACIDS, V18, P142, DOI 10.1016/j.omtn.2019.08.017
   Zhai MF, 2018, DRUG DELIV, V25, P1013, DOI 10.1080/10717544.2018.1464082
   Zhang DL, 2020, BIOMATERIALS, V230, DOI 10.1016/j.biomaterials.2019.119646
   Zhang JL, 2010, MOL PHARMACEUT, V7, P1159, DOI 10.1021/mp1000235
   Zhang SS, 2021, J MATER CHEM B, V9, P8768, DOI 10.1039/d1tb01619a
   Zhang YD, 2021, J CONTROL RELEASE, V329, P1117, DOI 10.1016/j.jconrel.2020.10.039
   Zhang Y, 2017, DRUG DELIV, V24, P1045, DOI 10.1080/10717544.2017.1344334
   Zhao YX, 2012, EUR J PHARM BIOPHARM, V81, P506, DOI 10.1016/j.ejpb.2012.04.023
   Zheng CY, 2015, INT J CLIN EXP MED, V8, P1658
   Zheng Q, 2013, PROTEIN EXPRES PURIF, V89, P181, DOI 10.1016/j.pep.2013.03.009
   Zhou YQ, 2018, J CONTROL RELEASE, V270, P290, DOI 10.1016/j.jconrel.2017.12.015
   Zong TL, 2014, MOL PHARMACEUT, V11, P2346, DOI 10.1021/mp500057n
NR 214
TC 19
Z9 19
U1 3
U2 38
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD JUN 3
PY 2022
VL 19
IS 6
BP 685
EP 705
DI 10.1080/17425247.2022.2083106
EA JUN 2022
PG 21
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2S3HB
UT WOS:000811113200001
PM 35698794
DA 2025-01-04
ER

PT J
AU Emami, J
   Maghzi, P
   Hasanzadeh, F
   Sadeghi, H
   Mirian, M
   Rostami, M
AF Emami, Jaber
   Maghzi, Parnian
   Hasanzadeh, Farshid
   Sadeghi, Hojjat
   Mirian, Mina
   Rostami, Mahboubeh
TI PLGA-PEG-RA-based polymeric micelles for tumor targeted delivery of
   irinotecan
SO PHARMACEUTICAL DEVELOPMENT AND TECHNOLOGY
LA English
DT Article
DE Irinotecan; PLGA; PEG; retinoic acid; micelle; HepG2; HT-29
ID TRANS-RETINOIC ACID; FOLATE-RECEPTOR; CANCER-THERAPY; NANOPARTICLES;
   DOXORUBICIN; LIPOSOMES; PHARMACOKINETICS; BIODISTRIBUTION; PHARMACOLOGY;
   CHEMOTHERAPY
AB To develop an effective therapeutic treatment, the potential of poly (lactic-co-glycolic acid)-polyethylene glycol-retinoic acid (PLGA-PEG-RA) polymeric micelles for targeted delivery of irinotecan to hepatocellular carcinoma (HepG2) and colorectal cancer cell lines (HT-29) was evaluated. PLGA-PEG-RA was synthesized by amide reaction of PLGA with NH2-PEG-NH2 and then PLGA-PEG-NH2 with RA and confirmed by FTIR and H-1 NMR spectroscopy. Irinotecan-loaded nanomicelles were prepared using thin-film hydration method and the impact of various formulation variables on their particle size (PS), polydispersity index (PDI), zeta potential (ZP), entrapment efficiency (EE), and mean release time (MRT) were assessed using a Taguchi design. TEM was used to observe morphology of the nanomicelles and the CMC was determined by fluorescence spectroscopy. Adopted PLGA-PEG-RA nanomicelle exhibited PS of 160 +/- 9.13nm, PDI of 0.20 +/- 0.05, ZP of -24.9 +/- 4.03mV, EE of 83.9 +/- 3.61%, MRT of 3.28 +/- 0.35h, and CMC value of 25.7g/mL. Cytotoxicity of the targeted nanomicelles on HepG2 and HT-29 cell lines was significantly higher than that of non-targeted nanomicelles and the free drug. These results suggest that PLGA-PEG-RA nanomicelles could be an efficient delivery system of irinotecan for targeted therapy of colorectal cancer and hepatocellular carcinoma.
C1 [Emami, Jaber; Maghzi, Parnian] Isfahan Univ Med Sci, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut, Esfahan, Iran.
   [Hasanzadeh, Farshid; Rostami, Mahboubeh] Isfahan Univ Med Sci, Sch Pharm, Dept Med Chem, Esfahan, Iran.
   [Sadeghi, Hojjat; Mirian, Mina] Isfahan Univ Med Sci, Sch Pharm & Pharmaceut Sci, Dept Biotechnol, Esfahan, Iran.
C3 Isfahan University of Medical Sciences; Isfahan University of Medical
   Sciences; Isfahan University of Medical Sciences
RP Emami, J (corresponding author), Isfahan Univ Med Sci, Sch Pharm & Pharmaceut Sci, Dept Pharmaceut, Esfahan, Iran.
EM Emami@pharm.mui.ac.ir
RI baferani, Jaber/W-2995-2017; Mirian, Mina/F-3134-2018; Rostami,
   Mahboubeh/V-8036-2017
OI Mirian, Mina/0000-0002-9322-2707; Rostami,
   Mahboubeh/0000-0001-9968-821X; Emami-Baferani, Jaber/0000-0002-5262-1875
FU Research Department of Isfahan University of Medical Sciences, Isfahan,
   I.R. Iran [391408]
FX The content of this article is extracted from the Pharm.D thesis No.
   391408 submitted by Parnian Maghzi, which was financially supported by
   the Research Department of Isfahan University of Medical Sciences,
   Isfahan, I.R. Iran.
CR Adamson, 1996, Oncologist, V1, P305
   AKIMOTO K, 1994, CHEM PHARM BULL, V42, P2135, DOI 10.1248/cpb.42.2135
   Allen TM, 2004, SCIENCE, V303, P1818, DOI 10.1126/science.1095833
   Berry DC, 2014, CANCER RES, V74, P6341, DOI 10.1158/0008-5472.CAN-14-1052
   Boddu SaiHS., 2012, Medicinal Chemistry, V2, P068, DOI DOI 10.4172/2161-0444.1000117
   Boige V, 2006, EUR J CANCER, V42, P456, DOI 10.1016/j.ejca.2005.09.034
   Brtko J, 2003, CURR PHARM DESIGN, V9, P2067, DOI 10.2174/1381612033454144
   Bukhari MH, 2007, INT J DERMATOL, V46, P1160, DOI 10.1111/j.1365-4632.2007.03425.x
   Cheng J, 2007, BIOMATERIALS, V28, P869, DOI 10.1016/j.biomaterials.2006.09.047
   Costa P, 2001, EUR J PHARM SCI, V13, P123, DOI 10.1016/S0928-0987(01)00095-1
   DETHE H, 1990, NATURE, V347, P558, DOI 10.1038/347558a0
   Ebrahimnejad P, 2010, NANOMED-NANOTECHNOL, V6, P478, DOI 10.1016/j.nano.2009.10.003
   Emami J, 2015, PHARM DEV TECHNOL, V20, P791, DOI 10.3109/10837450.2014.920360
   Emami J, 2015, DRUG DEV IND PHARM, V41, P1137, DOI 10.3109/03639045.2014.935390
   Emami J, 2012, J NANOMATER, V2012, DOI 10.1155/2012/358782
   Esmaeili F, 2008, J DRUG TARGET, V16, P415, DOI [10.1080/10611860802088630, 10.1080/10611860802088630 ]
   Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016/j.ctrv.2006.07.001
   Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641
   Gershenson DM, 2002, ONCOLOGY-NY, V16, P29
   Green MR, 2000, ONCOLOGY-NY, V14, P31
   Hami Z, 2014, DARU, V22, DOI 10.1186/2008-2231-22-30
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Hong WK, 1997, SCIENCE, V278, P1073, DOI 10.1126/science.278.5340.1073
   HSIANG YH, 1988, BIOCHEM PHARMACOL, V37, P1801, DOI 10.1016/0006-2952(88)90453-4
   HSIANG YH, 1989, CANCER RES, V49, P5077
   HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567
   Jindal N, 2015, COLLOID SURFACE B, V129, P100, DOI 10.1016/j.colsurfb.2015.03.030
   Kaparissides C., 2006, J. Nanotech. Online, V2, P1
   Kawaguchi R, 2015, MEMBRANES, V5, P425, DOI 10.3390/membranes5030425
   Kudgus RA, 2014, SCI REP-UK, V4, DOI 10.1038/srep05669
   Kwon GS, 2003, CRIT REV THER DRUG, V20, P357, DOI 10.1615/CritRevTherDrugCarrierSyst.v20.i5.20
   Kwon S, 2003, LANGMUIR, V19, P10188, DOI 10.1021/la0350608
   Li WJ, 2013, PROG POLYM SCI, V38, P421, DOI 10.1016/j.progpolymsci.2012.07.006
   Mahalwar A., 2012, International Journal of Biological and Pharmaceutical Research, V3, P431
   Miller WH, 1998, CANCER, V83, P1471, DOI 10.1002/(SICI)1097-0142(19981015)83:8<1471::AID-CNCR1>3.0.CO;2-6
   Mishra P, 2016, ASIAN J PHARM SCI, V11, P337, DOI 10.1016/j.ajps.2015.08.011
   Mullangi R, 2010, BIOMED CHROMATOGR, V24, P104, DOI 10.1002/bmc.1345
   Nagarwal RC, 2009, J CONTROL RELEASE, V136, P2, DOI 10.1016/j.jconrel.2008.12.018
   Nason-Burchenal K., 1999, HANDB EXP PHARM, V139, P301
   Ojima I, 2008, ACCOUNTS CHEM RES, V41, P108, DOI 10.1021/ar700093f
   PEPPAS NA, 1989, INT J PHARMACEUT, V57, P169, DOI 10.1016/0378-5173(89)90306-2
   POTMESIL M, 1994, CANCER RES, V54, P1431
   Rezazadeh M, 2016, DRUG DELIV, V23, P1707, DOI 10.3109/10717544.2014.954281
   RITGER P L, 1987, Journal of Controlled Release, V5, P23, DOI 10.1016/0168-3659(87)90034-4
   Robert J, 1998, DRUGS TODAY, V34, P777, DOI 10.1358/dot.1998.34.9.485276
   Sadzuka Y, 1999, JPN J CANCER RES, V90, P226, DOI 10.1111/j.1349-7006.1999.tb00737.x
   Saxena V, 2012, COLLOID SURFACE B, V94, P274, DOI 10.1016/j.colsurfb.2012.02.001
   Sharma S, 2016, ARAB J CHEM, V9, pS1368, DOI 10.1016/j.arabjc.2012.02.012
   Siddikuzzaman, 2011, IMMUNOPHARM IMMUNOT, V33, P241, DOI 10.3109/08923973.2010.521507
   Sun R, 2015, BIOMATERIALS, V37, P405, DOI 10.1016/j.biomaterials.2014.10.018
   Szeto W, 2001, CANCER RES, V61, P4197
   Tochilin VP., 2001, J CONTROL RELEASE, V56, P337
   Torchilin Vladimir P, 2010, Handb Exp Pharmacol, P3, DOI 10.1007/978-3-642-00477-3_1
   Tortorella S, 2014, J MEMBRANE BIOL, V247, P291, DOI 10.1007/s00232-014-9637-0
   Vanhoefer U, 2001, J CLIN ONCOL, V19, P1501, DOI 10.1200/JCO.2001.19.5.1501
   Varshosaz J, 2013, J NANOMATER, V2013, DOI 10.1155/2013/254127
   Vredenburgh JJ, 2009, NEURO-ONCOLOGY, V11, P80, DOI 10.1215/15228517-2008-075
   Wamoto T., 2013, BIOL PHARM BULL, V36, P715
   Wang FH, 2012, INT J NANOMED, V7, P325, DOI 10.2147/IJN.S27823
   Xu ZF, 2016, BMC CANCER, V16, DOI 10.1186/s12885-015-2010-6
   Yarmolenko PS, 2010, INT J HYPERTHER, V26, P485, DOI 10.3109/02656731003789284
   Yoo HS, 2004, J CONTROL RELEASE, V96, P273, DOI 10.1016/j.jconrel.2004.02.003
   Zhang L, 2013, EUR REV MED PHARMACO, V17, P3347
   Zhang ZQ, 2012, AAPS PHARMSCITECH, V13, P802, DOI 10.1208/s12249-012-9776-5
   Zhou J, 2010, MACROMOL CHEM PHYS, V211, P404, DOI 10.1002/macp.200900514
   Zwicke GL, 2012, NANO REV EXP, V3, DOI 10.3402/nano.v3i0.18496
NR 66
TC 26
Z9 28
U1 2
U2 66
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1083-7450
EI 1097-9867
J9 PHARM DEV TECHNOL
JI Pharm. Dev. Technol.
PY 2018
VL 23
IS 1
BP 41
EP 54
DI 10.1080/10837450.2017.1340950
PG 14
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FQ1BY
UT WOS:000418092300005
PM 28608760
DA 2025-01-04
ER

PT J
AU Sabit, H
   Arneth, B
   Abdel-Ghany, S
   Madyan, EF
   Ghaleb, AH
   Selvaraj, P
   Shin, DM
   Bommireddy, R
   Elhashash, A
AF Sabit, Hussein
   Arneth, Borros
   Abdel-Ghany, Shaimaa
   Madyan, Engy F.
   Ghaleb, Ashraf H.
   Selvaraj, Periasamy
   Shin, Dong M.
   Bommireddy, Ramireddy
   Elhashash, Ahmed
TI Beyond Cancer Cells: How the Tumor Microenvironment Drives Cancer
   Progression
SO CELLS
LA English
DT Review
DE tumor microenvironment; TME; ECM; liver cancer; immunotherapy; targeted
   therapy
ID NEUTROPHIL-LYMPHOCYTE RATIO; NATURAL-KILLER-CELLS; REGULATORY T-CELLS;
   EXTRACELLULAR-MATRIX; DENDRITIC CELLS; HEPATOCELLULAR-CARCINOMA; STROMAL
   FIBROBLASTS; COLORECTAL-CANCER; MAST-CELLS; BETA
AB Liver cancer represents a substantial global health challenge, contributing significantly to worldwide morbidity and mortality. It has long been understood that tumors are not composed solely of cancerous cells, but also include a variety of normal cells within their structure. These tumor-associated normal cells encompass vascular endothelial cells, fibroblasts, and various inflammatory cells, including neutrophils, monocytes, macrophages, mast cells, eosinophils, and lymphocytes. Additionally, tumor cells engage in complex interactions with stromal cells and elements of the extracellular matrix (ECM). Initially, the components of what is now known as the tumor microenvironment (TME) were thought to be passive bystanders in the processes of tumor proliferation and local invasion. However, recent research has significantly advanced our understanding of the TME's active role in tumor growth and metastasis. Tumor progression is now known to be driven by an intricate imbalance of positive and negative regulatory signals, primarily influenced by specific growth factors produced by both inflammatory and neoplastic cells. This review article explores the latest developments and future directions in understanding how the TME modulates liver cancer, with the aim of informing the design of novel therapies that target critical components of the TME.
C1 [Sabit, Hussein; Madyan, Engy F.] Misr Univ Sci & Technol, Coll Biotechnol, Dept Med Biotechnol, POB 77, Giza, Egypt.
   [Arneth, Borros] Philipps Univ Marburg, Hosp Univ Giessen & Marburg UKGM, Inst Lab Med & Pathobiochemistry, Mol Diagnost, Baldinger Str, D-35043 Marburg, Germany.
   [Arneth, Borros] Justus Liebig Univ Giessen, Hosp Univ Giessen & Marburg UKGM, Inst Lab Med & Pathobiochem, Mol Diagnost, Feulgenstr 12, D-35392 Giessen, Germany.
   [Abdel-Ghany, Shaimaa] Misr Univ Sci & Technol, Coll Biotechnol, Dept Environm Biotechnol, POB 77, Giza, Egypt.
   [Ghaleb, Ashraf H.] Misr Univ Sci & Technol, Coll Med, Dept Surg, POB 77, Giza, Egypt.
   [Ghaleb, Ashraf H.] Cairo Univ, Coll Med, Dept Surg, Giza 12613, Egypt.
   [Selvaraj, Periasamy; Bommireddy, Ramireddy] Emory Univ, Sch Med, Dept Pathol & Lab Med, Atlanta, GA 30322 USA.
   [Shin, Dong M.] Emory Univ, Sch Med, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
   [Elhashash, Ahmed] Texas A&M Univ, Dept Biol, 3258 TAMU 1, College Stn, TX 77843 USA.
C3 Egyptian Knowledge Bank (EKB); Misr University for Science & Technology;
   Philipps University Marburg; University Hospital of Giessen & Marburg;
   University Hospital of Giessen & Marburg; Justus Liebig University
   Giessen; Egyptian Knowledge Bank (EKB); Misr University for Science &
   Technology; Egyptian Knowledge Bank (EKB); Misr University for Science &
   Technology; Egyptian Knowledge Bank (EKB); Cairo University; Emory
   University; Emory University; Texas A&M University System; Texas A&M
   University College Station
RP Arneth, B (corresponding author), Philipps Univ Marburg, Hosp Univ Giessen & Marburg UKGM, Inst Lab Med & Pathobiochemistry, Mol Diagnost, Baldinger Str, D-35043 Marburg, Germany.; Arneth, B (corresponding author), Justus Liebig Univ Giessen, Hosp Univ Giessen & Marburg UKGM, Inst Lab Med & Pathobiochem, Mol Diagnost, Feulgenstr 12, D-35392 Giessen, Germany.
EM hussein.sabit@must.edu.eg; arneth@staff.uni-marburg.de;
   shaimaa.ibraheem@must.edu.eg; engy.madyan@must.edu.eg;
   ashraf.ghaleb@must.edu.eg; pselvar@emory.edu; dmshin@emory.edu;
   ramireddy.bommireddy@emory.edu
RI Madyan, Engy/AFK-2219-2022; Arneth, Borros/KPY-3521-2024
OI Arneth, Borros/0000-0002-9793-0970; ibraheem,
   shaimaa/0000-0002-3883-2000
CR Adoor Dayyan, 2021, Am J Kidney Dis, V78, pA16, DOI 10.1053/j.ajkd.2021.05.025
   Alfei F, 2021, ONCOGENE, V40, P5253, DOI 10.1038/s41388-021-01946-8
   Alhabbab RY, 2019, IMMUNOL REV, V292, P164, DOI 10.1111/imr.12800
   Ammendola M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/154702
   Aponte-López A, 2020, ADV EXP MED BIOL, V1273, P159, DOI 10.1007/978-3-030-49270-0_9
   Arai Y, 2021, ACTA BIOMATER, V125, P219, DOI 10.1016/j.actbio.2021.02.042
   Arneth B, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56010015
   Atri C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19061801
   Bader JE, 2020, MOL CELL, V78, P1019, DOI 10.1016/j.molcel.2020.05.034
   Bagordakis E, 2016, TUMOR BIOL, V37, P9045, DOI 10.1007/s13277-015-4629-y
   Bao MHR, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071715
   Benjamin D, 2018, CELL REP, V25, P3047, DOI 10.1016/j.celrep.2018.11.043
   Bhandari V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14052-x
   Bieniasz-Krzywiec P, 2019, CELL METAB, V30, P917, DOI 10.1016/j.cmet.2019.07.015
   Biffi G, 2021, PHYSIOL REV, V101, P147, DOI 10.1152/physrev.00048.2019
   Biffi G, 2019, CANCER DISCOV, V9, P282, DOI 10.1158/2159-8290.CD-18-0710
   Bogdanov A, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.979154
   Bose S, 2021, ADV EXP MED BIOL, V1311, P3, DOI 10.1007/978-3-030-65768-0_1
   Bouleftour W, 2021, MED SCI MONITOR, V27, DOI 10.12659/MSM.934116
   Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011
   Brassart-Pasco S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00397
   Brencicova E, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175712
   Brezovakova V, 2020, J COMP NEUROL, V528, P2021, DOI 10.1002/cne.24870
   Brunner SM, 2017, ONCOTARGET, V8, P71002, DOI 10.18632/oncotarget.20238
   Cabeza-Cabrerizo M, 2021, ANNU REV IMMUNOL, V39, P131, DOI 10.1146/annurev-immunol-061020-053707
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Caon I, 2020, SEMIN CANCER BIOL, V62, P9, DOI 10.1016/j.semcancer.2019.07.007
   Cassim S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010157
   Chen RS, 2021, ACAD RADIOL, V28, pE227, DOI 10.1016/j.acra.2020.05.015
   Chen XF, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/1580967
   Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573-018-0004-1
   Cheung EC, 2022, NAT REV CANCER, V22, P280, DOI 10.1038/s41568-021-00435-0
   Chiu DKC, 2020, GASTROENTEROLOGY, V159, P609, DOI 10.1053/j.gastro.2020.03.074
   Cho H, 2018, CLIN CANCER RES, V24, P5407, DOI 10.1158/1078-0432.CCR-18-0125
   Colegio OR, 2014, NATURE, V513, P559, DOI 10.1038/nature13490
   Corbet C, 2017, NAT REV CANCER, V17, P577, DOI 10.1038/nrc.2017.77
   Cords L, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-39762-1
   Costa A, 2014, SEMIN CANCER BIOL, V25, P23, DOI 10.1016/j.semcancer.2013.12.007
   Courtwright AM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45309-6
   Cui N, 2017, PROG MOL BIOL TRANSL, V147, P1, DOI 10.1016/bs.pmbts.2017.02.005
   Curtis M, 2019, CELL METAB, V29, P141, DOI 10.1016/j.cmet.2018.08.007
   Curtis NJ, 2017, ONCOTARGET, V8, P69219, DOI 10.18632/oncotarget.18215
   Damaghi M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9752
   Debnath S, 2021, INT J BIOL MACROMOL, V183, P528, DOI 10.1016/j.ijbiomac.2021.04.109
   Del Prete A, 2023, CELL MOL IMMUNOL, V20, P432, DOI 10.1038/s41423-023-00990-6
   Deng L, 2021, INT J MED SCI, V18, P2109, DOI 10.7150/ijms.56003
   Denton AE, 2018, ADV EXP MED BIOL, V1060, P99, DOI 10.1007/978-3-319-78127-3_6
   Di Pilato M, 2021, CELL, V184, P4512, DOI 10.1016/j.cell.2021.07.015
   Dong C, 2021, ANNU REV IMMUNOL, V39, P51, DOI 10.1146/annurev-immunol-061020-053702
   Du NW, 2021, CANCERS, V13, DOI 10.3390/cancers13164129
   Elia I, 2019, NATURE, V568, P117, DOI 10.1038/s41586-019-0977-x
   Ferrari E, 2021, BIOMED MATER, V16, DOI 10.1088/1748-605X/ac0454
   Filippone EJ, 2020, TRANSPLANTATION, V104, P2011, DOI 10.1097/TP.0000000000003163
   Fischer GM, 2019, CANCER DISCOV, V9, P628, DOI 10.1158/2159-8290.CD-18-1489
   Fuhrmann DC, 2017, REDOX BIOL, V12, P208, DOI 10.1016/j.redox.2017.02.012
   Ganeshan K, 2014, ANNU REV IMMUNOL, V32, P609, DOI 10.1146/annurev-immunol-032713-120236
   Garantziotis S, 2019, MATRIX BIOL, V78-79, P1, DOI 10.1016/j.matbio.2019.02.002
   Gardner A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00924
   Gardner A, 2016, TRENDS IMMUNOL, V37, P855, DOI 10.1016/j.it.2016.09.006
   GARINCHESA P, 1990, P NATL ACAD SCI USA, V87, P7235, DOI 10.1073/pnas.87.18.7235
   Garris CS, 2020, CLIN CANCER RES, V26, P3901, DOI 10.1158/1078-0432.CCR-19-1321
   Gentles AJ, 2015, NAT MED, V21, P938, DOI 10.1038/nm.3909
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Goulet CR, 2018, MOL CANCER RES, V16, P1196, DOI 10.1158/1541-7786.MCR-17-0784
   Grisaru-Tal S, 2022, NAT IMMUNOL, V23, P1309, DOI 10.1038/s41590-022-01291-2
   Grisaru-Tal S, 2020, NAT REV CANCER, V20, P594, DOI 10.1038/s41568-020-0283-9
   Gu HF, 2018, OXID MED CELL LONGEV, V2018, DOI 10.1155/2018/5801209
   Gunaydin G, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.668349
   Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068
   Harrison SP, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.574047
   He ZC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.741305
   Hernanda PY, 2015, ONCOGENE, V34, P5055, DOI 10.1038/onc.2014.425
   Hinshaw DC, 2019, CANCER RES, V79, P4557, DOI 10.1158/0008-5472.CAN-18-3962
   Horikawa N, 2020, BRIT J CANCER, V122, P778, DOI 10.1038/s41416-019-0725-x
   Hu Y, 2018, ACTA PHARMACOL SIN, V39, P167, DOI 10.1038/aps.2017.125
   Hwang I, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02618-z
   Imbert C, 2020, ADV EXP MED BIOL, V1273, P91, DOI 10.1007/978-3-030-49270-0_5
   Jang M, 2022, ACTA BIOMATER, V141, P255, DOI 10.1016/j.actbio.2022.01.040
   Jiang WQ, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.622509
   Ju MY, 2021, ONCOTARGETS THER, V14, P5065, DOI 10.2147/OTT.S326784
   Kaps L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092027
   Karagiannis P, 2021, MOL CELLS, V44, P541, DOI 10.14348/molcells.2021.0078
   Karamanos NK, 2021, TRENDS MOL MED, V27, P1000, DOI 10.1016/j.molmed.2021.07.009
   Karamanos NK, 2021, FEBS J, V288, P6850, DOI 10.1111/febs.15776
   Kerever A, 2021, FRONT NEUROANAT, V15, DOI 10.3389/fnana.2021.764458
   Kim H, 2019, ANN SURG TREAT RES, V96, P191, DOI 10.4174/astr.2019.96.4.191
   Kim MS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179185
   Kim M, 2023, BIOMATER RES, V27, DOI 10.1186/s40824-023-00343-4
   Komi DEA, 2020, CLIN REV ALLERG IMMU, V58, P313, DOI 10.1007/s12016-019-08753-w
   Korneev KV, 2017, CYTOKINE, V89, P127, DOI 10.1016/j.cyto.2016.01.021
   Kumagai S, 2022, CANCER CELL, V40, P201, DOI 10.1016/j.ccell.2022.01.001
   Lee WS, 2020, EXP MOL MED, V52, P1475, DOI 10.1038/s12276-020-00500-y
   Li C, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01463-y
   Li M, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00745-7
   Li XY, 2018, INT J BIOL SCI, V14, P1621, DOI 10.7150/ijbs.26520
   Lichterman JN, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10061270
   Lim AR, 2020, ELIFE, V9, DOI 10.7554/eLife.55185
   Lin WF, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.755394
   Lindau D, 2013, IMMUNOLOGY, V138, P105, DOI 10.1111/imm.12036
   Liu H, 2017, CLIN CANCER RES, V23, P478, DOI 10.1158/1078-0432.CCR-16-1203
   Liu J, 2011, CANCER METAST REV, V30, P177, DOI 10.1007/s10555-011-9276-1
   Liu K, 2021, BIOENGINEERED, V12, P7950, DOI 10.1080/21655979.2021.1984004
   Liu K, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01561-5
   Liu SZ, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01014-w
   Liu W, 2023, J CLIN INVEST, V133, DOI 10.1172/JCI157937
   Lodillinsky C, 2021, ONCOGENE, V40, P4019, DOI 10.1038/s41388-021-01826-1
   Lv YP, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0530-3
   Ma LC, 2019, CANCER CELL, V36, P418, DOI 10.1016/j.ccell.2019.08.007
   Makkouk A, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003441
   Mao XY, 2018, PHARMACOL THERAPEUT, V183, P137, DOI 10.1016/j.pharmthera.2017.10.012
   Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01428-1
   Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501
   Martinez-Outschoorn UE, 2017, NAT REV CLIN ONCOL, V14, P113, DOI 10.1038/nrclinonc.2017.1
   Massalha H, 2020, MOL SYST BIOL, V16, DOI 10.15252/msb.20209682
   Matsushita T, 2019, J DERMATOL SCI, V93, P2, DOI 10.1016/j.jdermsci.2018.11.008
   Mattei F, 2020, ADV EXP MED BIOL, V1273, P1, DOI 10.1007/978-3-030-49270-0_1
   McNamee EN, 2013, IMMUNOL RES, V55, P58, DOI 10.1007/s12026-012-8349-8
   Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613
   Michaud D, 2021, IMMUNOL REV, V299, P74, DOI 10.1111/imr.12939
   Mills CD, 2016, CANCER RES, V76, P513, DOI 10.1158/0008-5472.CAN-15-1737
   Mizushima N, 2011, CELL, V147, P728, DOI 10.1016/j.cell.2011.10.026
   Moek KL, 2018, AM J PATHOL, V188, P1973, DOI 10.1016/j.ajpath.2018.05.014
   Morell C, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0162977
   Morgan A, 2023, BIOLOGY-BASEL, V12, DOI 10.3390/biology12081044
   Muppala Santoshi, 2020, Critical Reviews in Oncogenesis, V25, P1, DOI 10.1615/CritRevOncog.2020034987
   Murata M, 2018, ENVIRON HEALTH PREV, V23, DOI 10.1186/s12199-018-0740-1
   Nurmik M, 2020, INT J CANCER, V146, P895, DOI 10.1002/ijc.32193
   O'Neill LAJ, 2016, J EXP MED, V213, P15, DOI 10.1084/jem.20151570
   Oderup C, 2006, IMMUNOLOGY, V118, P240, DOI 10.1111/j.1365-2567.2006.02362.x
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Padda J, 2021, CUREUS J MED SCIENCE, V13, DOI 10.7759/cureus.17732
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Parker TM, 2021, EMBO J, V40, DOI 10.15252/embj.2020107271
   Peng H, 2022, BIOMARK RES, V10, DOI 10.1186/s40364-022-00406-z
   Peppicelli S, 2016, CELL CYCLE, V15, P1908, DOI 10.1080/15384101.2016.1191706
   Persi E, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05261-x
   Porporato PE, 2018, CELL RES, V28, P265, DOI 10.1038/cr.2017.155
   Qiang ZY, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957-021-02426-9
   Qin FX, 2020, J CANCER, V11, P2580, DOI 10.7150/jca.38179
   Qin MM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.647854
   Reichman H, 2016, TRENDS CANCER, V2, P664, DOI 10.1016/j.trecan.2016.10.002
   Reinke S, 2020, BLOOD, V136, P2851, DOI 10.1182/blood.2020008553
   Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075
   Ribatti D, 2016, ONCOTARGET, V7, P46668, DOI 10.18632/oncotarget.8694
   Ribatti D, 2012, BBA-MOL BASIS DIS, V1822, P2, DOI 10.1016/j.bbadis.2010.11.010
   Rogatzki MJ, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00022
   Romero Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158335
   Saikolappan S, 2019, CANCER LETT, V452, P132, DOI 10.1016/j.canlet.2019.03.020
   Scharping NE, 2017, CANCER IMMUNOL RES, V5, P9, DOI 10.1158/2326-6066.CIR-16-0103
   Schlereth SL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/639058
   Scott EN, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.702726
   Seliger B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.910595
   Sharonov GV, 2020, NAT REV IMMUNOL, V20, P294, DOI 10.1038/s41577-019-0257-x
   Shi Y., 2020, medRxiv, DOI [10.1101/2020.03.12.20034736, DOI 10.1101/2020.03.12.20034736]
   Shrestha S, 2020, MOL MED, V26, DOI 10.1186/s10020-020-00204-z
   Simiczyjew A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218359
   Singh N, 2019, ANN AFR MED, V18, P121, DOI 10.4103/aam.aam_56_18
   Stanly TA, 2020, J BIOL CHEM, V295, P5036, DOI 10.1074/jbc.RA119.011992
   Steenbrugge J, 2021, CANCER RES, V81, P27, DOI 10.1158/0008-5472.CAN-20-2339
   Steffen JBM, 2021, J EXP BIOL, V224, DOI 10.1242/jeb.243082
   Sun XH, 2021, BIOENGINEERED, V12, P4191, DOI 10.1080/21655979.2021.1951926
   Taipale J, 1998, ADV CANCER RES, V75, P87, DOI 10.1016/S0065-230X(08)60740-X
   Takai K, 2016, ONCOTARGET, V7, P82889, DOI 10.18632/oncotarget.12658
   Takeishi K, 2011, SURG TODAY, V41, P1016, DOI [10.1007/s00595-011-0058-8, 10.1007/s00595-010-4392-z]
   Tamura R, 2020, MED ONCOL, V37, DOI 10.1007/s12032-019-1329-2
   Tan LL, 2021, MATH BIOSCI ENG, V18, P7743, DOI 10.3934/mbe.2021384
   Tan YF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.693517
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Tian SB, 2022, GUT, V71, P2489, DOI 10.1136/gutjnl-2021-325137
   Tiberio L, 2018, CELL MOL IMMUNOL, V15, P346, DOI 10.1038/s41423-018-0005-3
   Uhm TG, 2012, ALLERGY ASTHMA IMMUN, V4, P68, DOI 10.4168/aair.2012.4.2.68
   Vaupel P, 2014, ADV EXP MED BIOL, V812, P19, DOI 10.1007/978-1-4939-0620-8_3
   Venning FA, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01944-4
   Wakefield LM, 2002, CURR OPIN GENET DEV, V12, P22, DOI 10.1016/S0959-437X(01)00259-3
   Walker C, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103028
   Walsh JC, 2014, ANTIOXID REDOX SIGN, V21, P1516, DOI 10.1089/ars.2013.5378
   Wang L, 2021, BIOMED PHARMACOTHER, V133, DOI 10.1016/j.biopha.2020.110978
   Warmoes MO, 2014, BIOCHEM PHARMACOL, V92, P12, DOI 10.1016/j.bcp.2014.07.019
   Wculek SK, 2020, NAT REV IMMUNOL, V20, P7, DOI 10.1038/s41577-019-0210-z
   Webb BA, 2011, NAT REV CANCER, V11, P671, DOI 10.1038/nrc3110
   Weinberg F, 2019, CANCERS, V11, DOI 10.3390/cancers11081191
   Wojtkowiak JW, 2012, CANCER RES, V72, P3938, DOI 10.1158/0008-5472.CAN-11-3881
   Wu CAC, 2022, ANAL CHEM, V94, P165, DOI 10.1021/acs.analchem.1c03104
   Wu SY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01238-x
   Xie XY, 2020, TRANSL CANCER RES, V9, P5566, DOI 10.21037/tcr-20-1335a
   Xu SC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.731048
   Yan YL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1172-5
   Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00978
   Yang MY, 2021, BIOACT MATER, V6, P1973, DOI 10.1016/j.bioactmat.2020.12.010
   Yilmaz A, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00998-9
   Yin HJ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24315-1
   Ying F, 2023, CELL MOL GASTROENTER, V15, P985, DOI 10.1016/j.jcmgh.2023.01.006
   Young MK, 2018, BIOMATERIALS, V164, P54, DOI 10.1016/j.biomaterials.2018.01.038
   Yu JL, 2021, NAT MED, V27, P152, DOI 10.1038/s41591-020-1131-x
   Yue HR, 2021, GYNECOL ONCOL, V160, P530, DOI 10.1016/j.ygyno.2020.11.026
   Yuen VWH, 2020, J CLIN INVEST, V130, P5052, DOI 10.1172/JCI137553
   Zeng DQ, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002467
   Zhang C, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00060
   Zhang WL, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1051998
   Zhang XB, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00590
   Zhang YQ, 2022, J LEUKOCYTE BIOL, V111, P1269, DOI 10.1002/JLB.5RU0222-082R
   Zhang Z, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1571388
   Zheng GP, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0357-6
   Zhou YQ, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01737-7
   Zou YM, 2023, NANOSCALE, V15, P10715, DOI 10.1039/d3nr01050c
NR 205
TC 0
Z9 0
U1 2
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD OCT
PY 2024
VL 13
IS 19
AR 1666
DI 10.3390/cells13191666
PG 23
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA I7A0J
UT WOS:001331734300001
PM 39404428
OA gold
DA 2025-01-04
ER

PT J
AU Hao, SM
   Meng, QF
   Sun, HH
   Li, YK
   Li, Y
   Gu, LT
   Liu, B
   Zhang, YH
   Zhou, HL
   Xu, ZX
   Wang, YS
AF Hao, Shiming
   Meng, Qingfei
   Sun, Huihui
   Li, Yunkuo
   Li, Yao
   Gu, Liting
   Liu, Bin
   Zhang, Yanghe
   Zhou, Honglan
   Xu, Zhixiang
   Wang, Yishu
TI The role of transketolase in human cancer progression and therapy
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE Cancer treatment; TKT; Metabolism; Tumor progression; Pentose phosphate
   pathway
ID SQUAMOUS-CELL CARCINOMA; PENTOSE-PHOSPHATE PATHWAY; COLORECTAL-CANCER;
   CERVICAL-CANCER; GLUCOSE-METABOLISM; MALIGNANT PROGRESSION; PROTEIN-1
   EXPRESSION; ULCERATIVE-COLITIS; THYROID-CANCER; POOR-PROGNOSIS
AB Transketolase (TKT) is an enzyme that is ubiquitously expressed in all living organisms and has been identified as an important regulator of cancer. Recent studies have shown that the TKT family includes the TKT gene and two TKT-like (TKTL) genes; TKTL1 and TKTL2. TKT and TKTL1 have been reported to be involved in the regulation of multiple cancer-related events, such as cancer cell proliferation, metastasis, invasion, epithelial-mesenchymal transition, chemoradiotherapy resistance, and patient survival and prognosis. Therefore, TKT may be an ideal target for cancer treatment. More importantly, the levels of TKTL1 were detected using EDIM technology for the early detection of some malignancies, and TKTL1 was more sensitive and specific than traditional tumor markers. Detecting TKTL1 levels before and after surgery could be used to evaluate the surgery's effect. While targeted TKT suppresses cancer in multiple ways, in some cases, it has detrimental effects on the organism. In this review, we discuss the role of TKT in different tumors and the detailed mechanisms while evaluating its value and limitations in clinical applications. Therefore, this review provides a basis for the clinical application of targeted therapy for TKT in the future, and a strategy for subsequent cancer-related research.
C1 [Hao, Shiming; Meng, Qingfei; Sun, Huihui; Li, Yao; Gu, Liting; Zhang, Yanghe; Xu, Zhixiang; Wang, Yishu] Jilin Univ, Key Lab Pathobiol, Minist Educ, Changchun 130021, Peoples R China.
   [Li, Yunkuo; Liu, Bin; Zhou, Honglan] Jilin Univ, Hosp 1, Dept Urol, Changchun 130021, Peoples R China.
C3 Jilin University; Jilin University
RP Xu, ZX; Wang, YS (corresponding author), Jilin Univ, Key Lab Pathobiol, Minist Educ, Changchun 130021, Peoples R China.; Zhou, HL (corresponding author), Jilin Univ, Hosp 1, Dept Urol, Changchun 130021, Peoples R China.
EM walkerzhouhl@163.com; zhixiangxu@jlu.edu.cn; wangys@jlu.edu.cn
RI zhang, ying/HJB-1230-2022; wang, wei/JBS-7400-2023
FU International Coopera- tion project of the Department of Science and
   Technology of Jilin Province [20210402005GH]; National Natural Science
   Foundation of China [82020108024]; Department of Finance of Jilin
   Province [JLSWSRCZX2021-015]
FX Funding This work was supported by grants from the International
   Coopera- tion project of the Department of Science and Technology of
   Jilin Province (No: 20210402005GH) , National Natural Science Foundation
   of China (No: 82020108024) , and Department of Finance of Jilin Province
   (Nos. JLSWSRCZX2021-015) .
CR Ahmad F, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.117
   Ahopelto K, 2020, ONCOLOGY-BASEL, V98, P643, DOI 10.1159/000507350
   Ahopelto K, 2016, CANCER BIOL THER, V17, P163, DOI 10.1080/15384047.2015.1121347
   Bajpai VK, 2021, PHARMACOL RES, V163, DOI 10.1016/j.phrs.2020.105313
   Bedell SL, 2020, SEX MED REV, V8, P28, DOI 10.1016/j.sxmr.2019.09.005
   Benito A, 2017, ONCOTARGET, V8, P106693, DOI 10.18632/oncotarget.21601
   Bentz S, 2013, DIGESTION, V88, P182, DOI 10.1159/000355015
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Bojkova D, 2021, METABOLITES, V11, DOI 10.3390/metabo11100699
   Boldrini L, 2019, PATHOL ONCOL RES, V25, P1423, DOI 10.1007/s12253-018-0479-4
   Bopanna S, 2017, LANCET GASTROENTEROL, V2, P269, DOI 10.1016/S2468-1253(17)30004-3
   Boros LG, 1997, CANCER RES, V57, P4242
   Bräsen C, 2014, MICROBIOL MOL BIOL R, V78, P89, DOI 10.1128/MMBR.00041-13
   Brunner JS, 2021, MOL CELL, V81, P3878, DOI 10.1016/j.molcel.2021.06.021
   Cao L, 2021, EUR J PHARMACOL, V890, DOI 10.1016/j.ejphar.2020.173647
   Chao YK, 2016, J CANCER, V7, P1804, DOI 10.7150/jca.15467
   Chen H, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-43
   Chen YN, 2019, MED SCI MONITOR, V25, P288, DOI 10.12659/MSM.911478
   Chen YY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02048
   Ci YQ, 2016, MOLECULES, V21, DOI 10.3390/molecules21121634
   Coy JF, 1996, GENOMICS, V32, P309, DOI 10.1006/geno.1996.0124
   Coy JF, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040878
   Cramer JD, 2019, NAT REV CLIN ONCOL, V16, P669, DOI 10.1038/s41571-019-0227-z
   da Costa IA, 2018, UROL ONCOL-SEMIN ORI, V36, DOI 10.1016/j.urolonc.2018.06.010
   Dasgupta S, 2018, NATURE, V556, P249, DOI 10.1038/s41586-018-0018-1
   de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022
   Deshpande GP, 2019, BMC STRUCT BIOL, V19, DOI 10.1186/s12900-018-0099-y
   Diaz-Moralli S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025323
   Ding XC, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01102-5
   Dong SH, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-021-02229-6
   Dong YK, 2017, BIOMED PHARMACOTHER, V85, P672, DOI 10.1016/j.biopha.2016.11.078
   Duffy MJ, 2018, BREAST CANCER RES TR, V170, P213, DOI 10.1007/s10549-018-4753-7
   Duffy MJ, 2017, EUR J CANCER, V83, P258, DOI 10.1016/j.ejca.2017.06.023
   Fernández CA, 2009, J ENDOCRINOL INVEST, V32, P228, DOI 10.1007/BF03346457
   Földi M, 2007, ONCOL REP, V17, P841
   Fritz P, 2012, PATHOL RES PRACT, V208, P203, DOI 10.1016/j.prp.2012.01.007
   Fuchs CD, 2022, NAT REV GASTRO HEPAT, V19, P432, DOI 10.1038/s41575-021-00566-7
   Gao X, 2022, BIOCHEM BIOPH RES CO, V586, P34, DOI 10.1016/j.bbrc.2021.11.061
   Ge TX, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.00365
   Grimm M, 2016, ORAL MAXILLOFAC SURG, V20, P295, DOI 10.1007/s10006-016-0549-2
   Grimm M, 2016, CLIN ORAL INVEST, V20, P329, DOI 10.1007/s00784-015-1518-0
   Grimm M, 2016, OR SURG OR MED OR PA, V121, P301, DOI 10.1016/j.oooo.2015.10.024
   Grimm M, 2014, OR SURG OR MED OR PA, V117, P743, DOI 10.1016/j.oooo.2014.02.007
   Grimm M, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-569
   Grimm M, 2013, OR SURG OR MED OR PA, V116, pE173, DOI 10.1016/j.oooo.2011.12.022
   Grochowski LL, 2005, J BACTERIOL, V187, P7382, DOI 10.1128/JB.187.21.7382-7389.2005
   Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059
   Harami-Papp H, 2016, ONCOTARGET, V7, P67183, DOI 10.18632/oncotarget.11594
   Heller S, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082168
   Hernandez C, 2018, J CLIN INVEST, V128, P2436, DOI 10.1172/JCI91786
   Hirano H, 2019, JPN J CLIN ONCOL, V49, P412, DOI 10.1093/jjco/hyz034
   Huang R, 2021, ACTA PHARM SIN B, V11, P3481, DOI 10.1016/j.apsb.2021.05.009
   Huh HD, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060600
   Jayachandran A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2185-5
   Johnson DE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00224-3
   Ju HQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00326-0
   Jung SN, 2015, BIOCHEM PHARMACOL, V97, P38, DOI 10.1016/j.bcp.2015.06.033
   Kavarthapu R, 2021, CANCERS, V13, DOI 10.3390/cancers13184685
   Kayser G, 2011, PATHOLOGY, V43, P719, DOI 10.1097/PAT.0b013e32834c352b
   Kazandjian D, 2016, CLIN CANCER RES, V22, P1307, DOI 10.1158/1078-0432.CCR-15-2266
   Kim I, 2007, CARCINOGENESIS, V28, P940, DOI 10.1093/carcin/bgl249
   Kloska SM, 2022, SCI REP-UK, V12, DOI 10.1038/s41598-022-08463-y
   Kristensen LS, 2019, NAT REV GENET, V20, P675, DOI 10.1038/s41576-019-0158-7
   Krockenberger M, 2007, INT J GYNECOL CANCER, V17, P101, DOI 10.1111/j.1525-1438.2007.00799.x
   Langbein S, 2006, BRIT J CANCER, V94, P578, DOI 10.1038/sj.bjc.6602962
   Li J, 2015, BIOMED PHARMACOTHER, V74, P71, DOI 10.1016/j.biopha.2015.07.004
   Li LC, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094760
   Li ML, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04575-5
   Li ML, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2225-6
   Li ML, 2019, CANCER RES, V79, P3689, DOI 10.1158/0008-5472.CAN-18-3776
   Li Y, 2020, ADV EXP MED BIOL, V1287, P59, DOI 10.1007/978-3-030-55031-8_5
   Lin CC, 2011, EUR RESPIR J, V37, P1453, DOI 10.1183/09031936.00015710
   LINDQVIST Y, 1992, EMBO J, V11, P2373, DOI 10.1002/j.1460-2075.1992.tb05301.x
   Liu CL, 2020, MOL CELL ENDOCRINOL, V499, DOI 10.1016/j.mce.2019.110595
   Liu MY, 2020, GASTROENTEROLOGY, V158, P679, DOI 10.1053/j.gastro.2019.10.038
   Luengo A, 2021, MOL CELL, V81, P691, DOI 10.1016/j.molcel.2020.12.012
   Ma LM, 2021, J SURG RES, V260, P64, DOI 10.1016/j.jss.2020.11.052
   Maguire D, 2018, CLIN NUTR ESPEN, V25, P8, DOI 10.1016/j.clnesp.2018.02.007
   Mao WH, 2021, THERANOSTICS, V11, P1753, DOI 10.7150/thno.53438
   Maslova AO, 2012, BIOCHEMISTRY-MOSCOW+, V77, P296, DOI 10.1134/S000629791203008X
   Meshalkina LE, 2013, BBA-MOL BASIS DIS, V1832, P387, DOI 10.1016/j.bbadis.2012.12.004
   Millares L, 2018, LUNG CANCER, V122, P124, DOI 10.1016/j.lungcan.2018.06.015
   Milne JV, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-83979-3
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016
   Moon HG, 2015, BREAST CANCER RES TR, V154, P13, DOI 10.1007/s10549-015-3585-y
   Ni XL, 2017, DRUG DELIV, V24, P1501, DOI 10.1080/10717544.2017.1384862
   Nie HZ, 2021, THERANOSTICS, V11, P3898, DOI 10.7150/thno.51712
   Nooreldeen R, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168661
   Ocvirk S, 2021, SEMIN CANCER BIOL, V73, P347, DOI 10.1016/j.semcancer.2020.10.003
   Park MK, 2021, CELL METAB, V33, P2380, DOI 10.1016/j.cmet.2021.11.011
   Park W, 2021, JAMA-J AM MED ASSOC, V326, P851, DOI 10.1001/jama.2021.13027
   Peltonen R, 2020, CANCER BIOL THER, V21, P826, DOI 10.1080/15384047.2020.1803008
   Qin C, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01169-7
   Qin ZY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1131-1
   Raïs B, 1999, FEBS LETT, V456, P113, DOI 10.1016/S0014-5793(99)00924-2
   Rather GM, 2021, PHARMACOL THERAPEUT, V226, DOI 10.1016/j.pharmthera.2021.107864
   Ricciardelli C, 2015, CLIN EXP METASTAS, V32, P441, DOI 10.1007/s10585-015-9718-1
   Robinson NJ, 2022, CANCERS, V14, DOI 10.3390/cancers14030808
   Rogler G, 2014, CANCER LETT, V345, P235, DOI 10.1016/j.canlet.2013.07.032
   Saman S, 2020, CANCER BIOMARK, V27, P129, DOI 10.3233/CBM-190414
   Samatiwat P, 2016, TUMOR BIOL, V37, P11495, DOI 10.1007/s13277-016-5015-0
   Schabath MB, 2019, CANCER EPIDEM BIOMAR, V28, P1563, DOI 10.1158/1055-9965.EPI-19-0221
   Schizas D, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102016
   Schmidt M, 2010, J CANCER RES CLIN, V136, P219, DOI 10.1007/s00432-009-0652-y
   Schwaab J, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-363
   Seo J, 2020, COMMUN BIOL, V3, DOI 10.1038/s42003-020-01367-5
   Sequeda-Juárez A, 2020, ANTICANCER RES, V40, P6273, DOI 10.21873/anticanres.14648
   Shan C, 2021, INT J BIOL SCI, V17, P134, DOI 10.7150/ijbs.50773
   Shi ZX, 2015, TUMOR BIOL, V36, P8519, DOI 10.1007/s13277-015-3608-7
   Shukla SK, 2017, CANCER CELL, V32, P71, DOI 10.1016/j.ccell.2017.06.004
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Solomon B, 2018, SEMIN CANCER BIOL, V52, P228, DOI 10.1016/j.semcancer.2018.01.008
   Song Y, 2015, CANCER BIOMARK, V15, P591, DOI 10.3233/CBM-150499
   Stagno MJ, 2022, BRIT J CANCER, V127, P1324, DOI 10.1038/s41416-022-01855-x
   Staiger WI, 2006, ONCOL REP, V16, P657
   Stincone A, 2015, BIOL REV, V90, P927, DOI 10.1111/brv.12140
   Sun LL, 2021, NAT REV GASTRO HEPAT, V18, P335, DOI 10.1038/s41575-020-00404-2
   Sun WY, 2010, CLIN CANCER RES, V16, P857, DOI 10.1158/1078-0432.CCR-09-2604
   Tang YC, 2021, THERANOSTICS, V11, P5232, DOI 10.7150/thno.53417
   Tian N, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04142-4
   Tian N, 2020, DIABETES, V69, P1355, DOI 10.2337/db19-1087
   Todenhöfer T, 2017, PROSTATE, V77, P1251, DOI 10.1002/pros.23384
   Tsaur I, 2016, CENT EUR J UROL, V69, P247, DOI 10.5173/ceju.2016.820
   Tseng CW, 2018, CANCER RES, V78, P2799, DOI 10.1158/0008-5472.CAN-17-2906
   Vagia E, 2020, CANCERS, V12, DOI 10.3390/cancers12040916
   Vizán P, 2009, INT J CANCER, V124, P2789, DOI 10.1002/ijc.24262
   Völker HU, 2007, EUR ARCH OTO-RHINO-L, V264, P1431, DOI 10.1007/s00405-007-0394-x
   Wang CD, 2020, CANCER LETT, V492, P106, DOI 10.1016/j.canlet.2020.08.013
   Wang CY, 2018, J INVEST MED, V66, P935, DOI 10.1136/jim-2017-000634
   Wang YW, 2021, THERANOSTICS, V11, P4839, DOI 10.7150/thno.56747
   Wang ZY, 2022, BASIC RES CARDIOL, V117, DOI 10.1007/s00395-022-00925-8
   Wanka C, 2012, J BIOL CHEM, V287, P33436, DOI 10.1074/jbc.M112.384578
   Xu IMJ, 2016, P NATL ACAD SCI USA, V113, pE725, DOI 10.1073/pnas.1508779113
   Xu XJ, 2009, INT J CANCER, V124, P1330, DOI 10.1002/ijc.24078
   Xu ZP, 2002, MOL CELL BIOL, V22, P6142, DOI 10.1128/MCB.22.17.6142-6147.2002
   Yang F, 2007, CANCER RES, V67, P863, DOI 10.1158/0008-5472.CAN-06-1078
   Yang H, 2016, AM J CANCER RES, V6, P2690
   Yang KY, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01513-z
   Zerilli M, 2008, CANCER, V113, P936, DOI 10.1002/cncr.23683
   Zhang F, 2016, KIDNEY INT, V90, P396, DOI 10.1016/j.kint.2016.03.010
   Zhang J, 2022, NEUROIMMUNOMODULAT, V29, P44, DOI 10.1159/000518084
   Zhang S, 2007, CANCER LETT, V253, P108, DOI 10.1016/j.canlet.2007.01.010
   Zhao F, 2010, ONCOGENE, V29, P2962, DOI 10.1038/onc.2010.67
   Zheng XJ, 2021, CELL METAB, V33, P791, DOI 10.1016/j.cmet.2020.11.017
   Zheng X, 2018, BIOCHEM BIOPH RES CO, V503, P572, DOI 10.1016/j.bbrc.2018.06.011
   Zheng YF, 2019, J BIOL CHEM, V294, P4815, DOI 10.1074/jbc.RA118.005739
   Zhou JY, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-019-14138-6
   Zhu H, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01167-9
   Zhu YP, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02383-z
NR 150
TC 21
Z9 23
U1 1
U2 30
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD OCT
PY 2022
VL 154
AR 113607
DI 10.1016/j.biopha.2022.113607
EA AUG 2022
PG 13
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 4X7YV
UT WOS:000861054000005
PM 36030587
OA gold
DA 2025-01-04
ER

PT J
AU Gao, HQ
   Zhang, ZY
AF Gao, Huiqiao
   Zhang, Zhenyu
TI Systematic Analysis of Endometrial Cancer-Associated Hub Proteins Based
   on Text Mining
SO BIOMED RESEARCH INTERNATIONAL
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; JAK-STAT PATHWAY; THERAPEUTIC TARGET;
   COLORECTAL-CANCER; PI3K PATHWAY; EXPRESSION; MUTATIONS; MECHANISM
AB Objective. The aim of this study was to systematically characterize the expression of endometrial cancer-(EC-) associated genes and to analysis the functions, pathways, and networks of EC-associated hub proteins. Methods. Gene data for EC were extracted from the PubMed (MEDLINE) database using text mining based on NLP. PPI networks and pathways were integrated and obtained from the KEGG and other databases. Proteins that interacted with at least 10 other proteins were identified as the hub proteins of the EC-related genes network. Results. A total of 489 genes were identified as EC-related with P < 0.05, and 32 pathways were identified as significant (P < 0.05, FDR < 0.05). A network of EC-related proteins that included 271 interactions was constructed. The 17 proteins that interact with 10 or more other proteins (P < 0.05, FDR < 0.05) were identified as the hub proteins of this PPI network of EC-related genes. These 17 proteins are EGFR, MET, PDGFRB, CCND1, JUN, FGFR2, MYC, PIK3CA, PIK3R1, PIK3R2, KRAS, MAPK3, CTNNB1, RELA, JAK2, AKT1, and AKT2. Conclusion. Our data may help to reveal the molecular mechanisms of EC development and provide implications for targeted therapy for EC. However, corrections between certain proteins and EC continue to require additional exploration.
C1 [Gao, Huiqiao; Zhang, Zhenyu] Capital Med Univ, Beijing Chao Yang Hosp, Dept Obstet & Gynecol, Beijing 100020, Peoples R China.
C3 Capital Medical University
RP Zhang, ZY (corresponding author), Capital Med Univ, Beijing Chao Yang Hosp, Dept Obstet & Gynecol, Beijing 100020, Peoples R China.
EM zhenyuzhang2010@163.com
RI Zhang, Zhen-Yu/HTQ-2725-2023
FU Chinese High-tech RD (863) Program
FX This study was supported in part by the Chinese High-tech R&D (863)
   Program. The authors also wish to express their gratitude to Shanghai
   Sensichip Co., Ltd., for bioinformatics analysis.
CR Achiwa Y, 2007, BIOSCI BIOTECH BIOCH, V71, P31, DOI 10.1271/bbb.60288
   Castellano Esther, 2011, Genes Cancer, V2, P261, DOI 10.1177/1947601911408079
   Cheung LWT, 2011, CANCER DISCOV, V1, P170, DOI 10.1158/2159-8290.CD-11-0039
   Constantinescu SN, 2008, TRENDS BIOCHEM SCI, V33, P122, DOI 10.1016/j.tibs.2007.12.002
   Cully M, 2006, NAT REV CANCER, V6, P184, DOI 10.1038/nrc1819
   Djordjeyic B, 2012, MODERN PATHOL, V25, P699, DOI 10.1038/modpathol.2011.208
   Ferrajoli A, 2006, CURR CANCER DRUG TAR, V6, P671, DOI 10.2174/156800906779010227
   Gao JC, 2009, CANCER SCI, V100, P389, DOI 10.1111/j.1349-7006.2008.01053.x
   Gatius S, 2011, MODERN PATHOL, V24, P1500, DOI 10.1038/modpathol.2011.110
   Harding TC, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3005414
   Hwang RF, 2003, CLIN CANCER RES, V9, P6534
   Iglesias DA, 2013, MOL CANCER THER, V12, P2847, DOI 10.1158/1535-7163.MCT-13-0439
   Katoh M, 2014, MED RES REV, V34, P280, DOI 10.1002/med.21288
   Konecny GE, 2013, MOL CANCER THER, V12, P632, DOI 10.1158/1535-7163.MCT-12-0999
   Lai SY, 2010, DRUG RESIST UPDATE, V13, P67, DOI 10.1016/j.drup.2010.04.001
   Liegl B, 2007, HISTOPATHOLOGY, V50, P448, DOI 10.1111/j.1365-2559.2007.02634.x
   Liu Y, 2011, J HUAZHONG U SCI-MED, V31, P365, DOI 10.1007/s11596-011-0382-7
   Maglott D, 2011, NUCLEIC ACIDS RES, V39, pD52, DOI 10.1093/nar/gkq1237
   Nout RA, 2012, GYNECOL ONCOL, V126, P466, DOI 10.1016/j.ygyno.2012.05.012
   Östman A, 2007, ADV CANCER RES, V97, P247, DOI 10.1016/S0065-230X(06)97011-0
   Pallarés J, 2008, MODERN PATHOL, V21, P691, DOI 10.1038/modpathol.2008.38
   Pavlidou A, 2014, SCI WORLD J, DOI 10.1155/2014/709736
   Pinto MP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-735
   Rudd ML, 2011, CLIN CANCER RES, V17, P1331, DOI 10.1158/1078-0432.CCR-10-0540
   Santos FPS, 2011, BLOOD REV, V25, P53, DOI 10.1016/j.blre.2010.10.004
   Settles B, 2005, BIOINFORMATICS, V21, P3191, DOI 10.1093/bioinformatics/bti475
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Slomovitz BM, 2012, CLIN CANCER RES, V18, P5856, DOI 10.1158/1078-0432.CCR-12-0662
   Spano JP, 2006, EUR J CANCER, V42, P2668, DOI 10.1016/j.ejca.2006.07.006
   Spasic I, 2014, INT J MED INFORM, V83, P605, DOI 10.1016/j.ijmedinf.2014.06.009
   Srdelic Mihalj S, 2015, HISTOPATHOLOGY, V67, P206, DOI 10.1111/his.12633
   Vijayakrishnan L, 2011, TRENDS PHARMACOL SCI, V32, P25, DOI 10.1016/j.tips.2010.10.004
   Vogt PK, 2011, CURR TOP MICROBIOL, V347, P79, DOI 10.1007/82_2010_80
   Wang J, 2014, CYTOKINE, V68, P94, DOI 10.1016/j.cyto.2014.04.005
   Wehler TC, 2008, ONCOL REP, V19, P697
   Weigelt B, 2013, CLIN CANCER RES, V19, P3533, DOI 10.1158/1078-0432.CCR-12-3815
   Zhu F, 2013, J BIOMED INFORM, V46, P200, DOI 10.1016/j.jbi.2012.10.007
   Zwick E, 2001, ENDOCR-RELAT CANCER, V8, P161, DOI 10.1677/erc.0.0080161
NR 38
TC 6
Z9 7
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2314-6133
EI 2314-6141
J9 BIOMED RES INT-UK
JI Biomed Res. Int.
PY 2015
VL 2015
AR 615825
DI 10.1155/2015/615825
PG 6
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA CQ6WJ
UT WOS:000360744400001
PM 26366417
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Xu, DC
   Liu, A
   Wang, X
   Chen, YD
   Shen, YY
   Tan, Z
   Qiu, MS
AF Xu, Dongchao
   Liu, Ajuan
   Wang, Xuan
   Chen, Yidan
   Shen, Yunyun
   Tan, Zhou
   Qiu, Mengsheng
TI Repression of Septin9 and Septin2 suppresses tumor growth of human
   glioblastoma cells
SO CELL DEATH & DISEASE
LA English
DT Article
ID CENTRAL-NERVOUS-SYSTEM; MAMMALIAN SEPTINS; COLORECTAL-CANCER; MALIGNANT
   GLIOMAS; DNA METHYLATION; DOWN-REGULATION; MULTIFORME; COMBINATION;
   EXPRESSION; COMPLEXES
AB Glioblastoma (GBM) is the most common primary malignancy of the central nervous system (CNS) with <10% 5-year survival rate The growth and invasion of GBM cells into normal brain make the resection and treatment difficult A better understanding of the biology of GBM cells is crucial to the targeted therapies for the disease In this study, we identified Septin9 (SEPT9) and Septin2 (SEPT2) as GBM related genes through integrated multi-omics analysis across independent transcriptomic and proteomic studies Further studies revealed that expression of SEPT9 and SEPT2 was elevated in glioma tissues and cell lines (A172, U87 MG) Knockdown of SEPT9 and SEPT2 in A172/U87 MG was able to inhibit GBM cell proliferation and arrest cell cycle progression in the S phase in a synergistic mechanism Moreover, suppression of SEPT9 and SEPT2 decreased the GBM cell invasive capability and significantly impaired the growth of glioma xenografts in nude mice Furthermore, the decrease in GBM cell growth caused by SEPT9 and SEPT2 RNAi appears to involve two parallel signaling pathway including the p53/p21 axis and MEK/ERK activation Together, our integration of multi-omics analysis has revealed previously unrecognized synergistic role of SEPT9 and SEPT2 in GBM, and provided novel insights into the targeted therapy of GBM
C1 [Xu, Dongchao; Liu, Ajuan; Wang, Xuan; Chen, Yidan; Tan, Zhou; Qiu, Mengsheng] Hangzhou Normal Univ, Coll Life & Environm Sci, Inst Life Sci, Key Lab Organ Dev & Regenerat Zhejiang Prov, Hangzhou 311121, Zhejiang, Peoples R China.
   [Shen, Yunyun] Zhejiang Sci Tech Univ, Inst Cognit Neurosci, Hangzhou, Zhejiang, Peoples R China.
   [Shen, Yunyun] Zhejiang Sci Tech Univ, Dept Psychol, Hangzhou, Zhejiang, Peoples R China.
   [Qiu, Mengsheng] Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.
C3 Hangzhou Normal University; Zhejiang Sci-Tech University; Zhejiang
   Sci-Tech University; University of Louisville
RP Tan, Z; Qiu, MS (corresponding author), Hangzhou Normal Univ, Coll Life & Environm Sci, Inst Life Sci, Key Lab Organ Dev & Regenerat Zhejiang Prov, Hangzhou 311121, Zhejiang, Peoples R China.; Qiu, MS (corresponding author), Univ Louisville, Dept Anat Sci & Neurobiol, Louisville, KY 40292 USA.
EM tanzhou@hznu.edu.cn; m0qiu001@yahoo.com
OI , Zhou/0000-0002-5071-7945
FU Zhejiang Province Medical and Health Research Program [2013KYA148];
   high-level students returning to China (team) project in Hangzhou;
   Zhejiang Provincial Natural Science Foundation of China [LQ18C090009];
   National Natural Science Foundation of China [81200961, 31471955,
   31572224, 31771621]
FX This work was supported by grants from Zhejiang Province Medical and
   Health Research Program (2013KYA148), high-level students returning to
   China (team) project in Hangzhou (2017), Zhejiang Provincial Natural
   Science Foundation of China (no. LQ18C090009), and National Natural
   Science Foundation of China (81200961, 31471955, 31572224, 31771621).
CR Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bennett KL, 2008, CANCER RES, V68, P4494, DOI 10.1158/0008-5472.CAN-07-6509
   Bianco J, 2017, CELL MOL LIFE SCI, V74, P2451, DOI 10.1007/s00018-017-2483-3
   Cao LQ, 2015, CANCER LETT, V359, P127, DOI 10.1016/j.canlet.2015.01.004
   Chen MF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028203
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Connolly D, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2924
   Connolly D, 2011, BIOL CHEM, V392, P725, DOI 10.1515/BC.2011.073
   Diesenberg K, 2015, J CELL SCI, V128, P397, DOI 10.1242/jcs.162206
   Doherty L, 2006, NEUROLOGY, V67, P156, DOI 10.1212/01.wnl.0000223844.77636.29
   Dolecek TA, 2012, NEURO-ONCOLOGY, V14, pv1, DOI 10.1093/neuonc/nos218
   Efferth T, 2004, BIOCHEM PHARMACOL, V67, P1689, DOI 10.1016/j.bcp.2003.12.035
   Fan QW, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001017
   Friday BB, 2008, CLIN CANCER RES, V14, P342, DOI 10.1158/1078-0432.CCR-07-4790
   Friedman HS, 2009, J CLIN ONCOL, V27, P4733, DOI 10.1200/JCO.2008.19.8721
   Froidevaux-Klipfel L, 2015, ONCOTARGET, V6, P36063, DOI 10.18632/oncotarget.5373
   Froidevaux-Klipfel L, 2011, PROTEOMICS, V11, P3877, DOI 10.1002/pmic.201000789
   Gilad R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0124251
   Gravendeel LAM, 2009, CANCER RES, V69, P9065, DOI 10.1158/0008-5472.CAN-09-2307
   Griesinger AM, 2013, J IMMUNOL, V191, P4880, DOI 10.4049/jimmunol.1301966
   Grzmil M, 2011, CANCER RES, V71, P2392, DOI 10.1158/0008-5472.CAN-10-3112
   HARTWELL LH, 1974, SCIENCE, V183, P46, DOI 10.1126/science.183.4120.46
   Holland EC, 2000, P NATL ACAD SCI USA, V97, P6242, DOI 10.1073/pnas.97.12.6242
   Hu QC, 2010, SCIENCE, V329, P436, DOI 10.1126/science.1191054
   Jia ZF, 2010, J NEURO-ONCOL, V98, P329, DOI 10.1007/s11060-009-0092-1
   Jiang HW, 2014, ONCOL REP, V31, P2261, DOI 10.3892/or.2014.3055
   Kartmann B, 2001, J CELL SCI, V114, P839
   Kinoshita M, 2003, J BIOCHEM, V134, P491, DOI 10.1093/jb/mvg182
   Kremer BE, 2007, CELL, V130, P837, DOI 10.1016/j.cell.2007.06.053
   Kuo YC, 2015, J CELL SCI, V128, P923, DOI 10.1242/jcs.158998
   Lofton-Day C, 2008, CLIN CHEM, V54, P414, DOI 10.1373/clinchem.2007.095992
   Longtine MS, 1996, CURR OPIN CELL BIOL, V8, P106, DOI 10.1016/S0955-0674(96)80054-8
   Louis DN, 2016, ACTA NEUROPATHOL, V131, P803, DOI 10.1007/s00401-016-1545-1
   Macara IG, 2002, MOL BIOL CELL, V13, P4111, DOI 10.1091/mbc.E02-07-0438
   Martínez C, 2004, BIOCHEM J, V382, P783, DOI 10.1042/BJ20040372
   McDade SS, 2007, HUM MOL GENET, V16, P742, DOI 10.1093/hmg/ddm003
   Morgan AA, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-S9-S6
   Mostowy S, 2012, NAT REV MOL CELL BIO, V13, P183, DOI 10.1038/nrm3284
   NAITO S, 1986, CANCER RES, V46, P4109
   Neubauer K, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00003
   Omuro A, 2013, JAMA-J AM MED ASSOC, V310, P1842, DOI 10.1001/jama.2013.280319
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Peng XR, 2002, MOL CELL BIOL, V22, P378, DOI 10.1128/MCB.22.1.378-387.2002
   Peterson EA, 2010, CLIN GENET, V77, P511, DOI 10.1111/j.1399-0004.2010.01392.x
   Reddy SP, 2008, CLIN CANCER RES, V14, P2978, DOI 10.1158/1078-0432.CCR-07-4821
   Russell SEH, 2000, CANCER RES, V60, P4729
   Scott M, 2005, ONCOGENE, V24, P4688, DOI 10.1038/sj.onc.1208574
   Sellin ME, 2011, MOL BIOL CELL, V22, P3152, DOI 10.1091/mbc.E11-03-0253
   Spiliotis ET, 2005, SCIENCE, V307, P1781, DOI 10.1126/science.1106823
   Sun CY, 2013, NEUROSCI BULL, V29, P83, DOI 10.1007/s12264-012-1296-5
   Sun LX, 2006, CANCER CELL, V9, P287, DOI 10.1016/j.ccr.2006.03.003
   Tan Z, 2011, J IMMUNOL METHODS, V365, P149, DOI 10.1016/j.jim.2010.12.012
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   Tong JJ, 2016, RES VET SCI, V105, P10, DOI 10.1016/j.rvsc.2016.01.008
   Valadares Napoleao Fonseca, 2017, Biophys Rev, V9, P481, DOI 10.1007/s12551-017-0320-4
   Walid Mohammad Sami, 2008, Perm J, V12, P45
   Wasserkort R, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-398
   Weirich CS, 2008, NAT REV MOL CELL BIO, V9, P478, DOI 10.1038/nrm2407
   Yan Y, 2015, J CANCER RES CLIN, V141, P827, DOI 10.1007/s00432-014-1861-6
   Yue X, 2016, NEURO-ONCOLOGY, V18, P1288, DOI 10.1093/neuonc/now044
   Zhang GB, 2012, J CLIN NEUROSCI, V19, P1636, DOI 10.1016/j.jocn.2011.12.028
   Zhang NZ, 2016, ONCOTARGET, V7, P61587, DOI 10.18632/oncotarget.11402
NR 62
TC 36
Z9 40
U1 3
U2 16
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD MAY 3
PY 2018
VL 9
AR 14
DI 10.1038/s41419-018-0547-4
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA GF2RT
UT WOS:000431788100009
PM 29724999
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Farooqi, AA
   Tang, JY
   Li, RN
   Ismail, M
   Chang, YT
   Shu, CW
   Yuan, SSF
   Liu, JR
   Mansoor, Q
   Huang, CJ
   Chang, HW
AF Farooqi, Ammad Ahmad
   Tang, Jen-Yang
   Li, Ruei-Nian
   Ismail, Muhammad
   Chang, Yung-Ting
   Shu, Chih-Wen
   Yuan, Shyng-Shiou F.
   Liu, Jing-Ru
   Mansoor, Qaisar
   Huang, Chih-Jen
   Chang, Hsueh-Wei
TI Epigenetic mechanisms in cancer: push and pull between kneaded erasers
   and fate writers
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Review
DE epigenetic; modification; methylation; natural products; cancer
ID WNT/BETA-CATENIN PATHWAY; DNA METHYLATION; COLORECTAL-CANCER;
   TUMOR-SUPPRESSOR; OVARIAN-CANCER; BREAST-CANCER; CELL-GROWTH;
   NASOPHARYNGEAL CARCINOMA; MESENCHYMAL TRANSITION; RASSF1A EXPRESSION
AB Research concerning the epigenome over the years has systematically and sequentially shown substantial development and we have moved from global inhibition of modifications of the epigenome toward identification and targeted therapy against tumor-specific epigenetic mechanisms. In accordance with this approach, several drugs with epigenetically modulating activity have received considerable attention and appreciation, and recently emerging scientific evidence is uncovering details of their mode of action. High-throughput technologies have considerably improved our existing understanding of tumor suppressors, oncogenes, and signaling pathways that are key drivers of cancer. In this review, we summarize the general epigenetic mechanisms in cancer, including: the post-translational modification of DNA methyltransferase and its mediated inactivation of Ras association domain family 1 isoform A, Sonic hedgehog signaling, Wnt signaling, Notch signaling, transforming growth factor signaling, and natural products with epigenetic modification ability. Moreover, we introduce the importance of nano-medicine for delivery of natural products with modulating ability to epigenetic machinery in cancer cells. Such in-depth and comprehensive knowledge regarding epigenetic dysregulation will be helpful in the upcoming era of molecular genomic pathology for both detection and treatment of cancer. Epigenetic information will also be helpful when nanotherapy is used for epigenetic modification.
C1 [Farooqi, Ammad Ahmad; Ismail, Muhammad; Mansoor, Qaisar] KRL Hosp, IBGE, Islamabad, Pakistan.
   [Tang, Jen-Yang; Huang, Chih-Jen] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Radiat Oncol, Kaohsiung 80708, Taiwan.
   [Tang, Jen-Yang; Huang, Chih-Jen] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Radiat Oncol, Kaohsiung 80708, Taiwan.
   [Tang, Jen-Yang] Kaohsiung Med Univ, Kaohsiung Municipal Ta Tung Hosp, Dept Radiat Oncol, Kaohsiung 80708, Taiwan.
   [Li, Ruei-Nian; Liu, Jing-Ru; Chang, Hsueh-Wei] Kaohsiung Med Univ, Dept Biomed Sci & Environm Biol, Kaohsiung 80708, Taiwan.
   [Chang, Yung-Ting] Natl Sun Yat Sen Univ, Acad Sinica, Doctor Degree Program Marine Biotechnol, Kaohsiung 80424, Taiwan.
   [Shu, Chih-Wen] Kaohsiung Med Univ, Kaohsiung Vet Gen Hosp, Dept Med Educ & Res, Kaohsiung 80708, Taiwan.
   [Yuan, Shyng-Shiou F.] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Translat Res Ctr, Kaohsiung 80708, Taiwan.
   [Yuan, Shyng-Shiou F.; Chang, Hsueh-Wei] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Ctr Canc, Kaohsiung 80708, Taiwan.
   [Chang, Hsueh-Wei] Natl Sun Yat Sen Univ, Inst Med Sci & Technol, Kaohsiung 80424, Taiwan.
   [Chang, Hsueh-Wei] Kaohsiung Med Univ, Res Ctr Environm Med, Kaohsiung 80708, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Kaohsiung
   Municipal Ta-Tung Hospital; Kaohsiung Medical University; National Sun
   Yat Sen University; Academia Sinica - Taiwan; Kaohsiung Medical
   University; Kaohsiung Veterans General Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital; National Sun Yat Sen
   University; Kaohsiung Medical University
RP Huang, CJ (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Biomed Sci & Environm Biol, Dept Radiat Oncol, Kaohsiung 80708, Taiwan.
EM ccjjhh@kmu.edu.tw; changhw@kmu.edu.tw
RI Huang, Chih-Jen/A-2004-2010; Chang, Hsueh-Wei/C-9654-2009; Farooqi,
   Ammad/O-9760-2018; Liu, Jingru/IQU-6455-2023; Chen,
   Chien-Chin/A-9977-2016; Yaylim, Ilhan/AAB-1154-2020
OI Mansoor, Qaisar/0000-0003-1341-7174; Farooqi, Ammad/0000-0003-2899-5014;
   yuan, shyng-shiou/0000-0002-4753-788X; Shu, Chih-Wen/0000-0002-7774-0002
FU Ministry of Science and Technology [103-2320-B-037-008]; Kaohsiung
   Medical University "Aim for the Top Universities Grant" [KMU-TP103A33];
   National Sun Yat-sen University-KMU Joint Research Project [NSYSU-KMU
   104-p036]; Kaohsiung Municipal Ta-Tung Hospital [kmtth-102-011]; Health
   and Welfare Surcharge of Tobacco Products; Ministry of Health and
   Welfare, Taiwan, Republic of China [MOHW104-TDU-B-212-124-003,
   MOHW103-TDU-212-114007]; CheMei-KMU Joint Project [103CM-KMU-09]
FX This work was supported by funds from the Ministry of Science and
   Technology (103-2320-B-037-008), the Kaohsiung Medical University "Aim
   for the Top Universities Grant" (KMU-TP103A33), the National Sun Yat-sen
   University-KMU Joint Research Project (NSYSU-KMU 104-p036), the
   Kaohsiung Municipal Ta-Tung Hospital (kmtth-102-011), the Health and
   Welfare Surcharge of Tobacco Products, the Ministry of Health and
   Welfare, Taiwan, Republic of China (MOHW104-TDU-B-212-124-003,
   MOHW103-TDU-212-114007), and CheMei-KMU Joint Project (103CM-KMU-09). We
   also thank Hans-Uwe Dahms for assistance with English editing.
CR Agarwal S, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-99
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Groh IAM, 2013, J NUTR METAB, V2013, DOI 10.1155/2013/821082
   [Anonymous], EVID BASED COMPLEMEN
   Arumugam TV, 2011, MOL PHARMACOL, V80, P23, DOI 10.1124/mol.111.071076
   Bai L, 2011, MOL CELL, V42, P465, DOI 10.1016/j.molcel.2011.03.028
   Baud MGJ, 2012, J MED CHEM, V55, P1731, DOI 10.1021/jm2016182
   Baylin SB, 2011, NAT REV CANCER, V11, P726, DOI 10.1038/nrc3130
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Bernstein C, 2008, CANCER LETT, V260, P1, DOI 10.1016/j.canlet.2007.11.027
   Bestor TH, 2000, HUM MOL GENET, V9, P2395, DOI 10.1093/hmg/9.16.2395
   Cardenas H, 2014, EPIGENETICS-US, V9, P1461, DOI 10.4161/15592294.2014.971608
   Castel D, 2013, GENE DEV, V27, P1059, DOI 10.1101/gad.211912.112
   Chan M, 2008, NEOPLASIA, V10, P908, DOI 10.1593/neo.08540
   Choi JH, 2014, NUTR CANCER, V66, P140, DOI 10.1080/01635581.2014.853087
   Choi JH, 2008, CANCER RES, V68, P5716, DOI 10.1158/0008-5472.CAN-08-0001
   Chou RH, 2014, DEV CELL, V30, P224, DOI 10.1016/j.devcel.2014.06.008
   Chow KH, 2014, CANCER RES, V74, P4864, DOI 10.1158/0008-5472.CAN-13-3293
   Christophorou MA, 2014, NATURE, V507, P104, DOI 10.1038/nature12942
   Deplus R, 2014, NUCLEIC ACIDS RES, V42, P8285, DOI 10.1093/nar/gku522
   Donninger H, 2007, J CELL SCI, V120, P3163, DOI 10.1242/jcs.010389
   Duan MX, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-91
   ECHELARD Y, 1993, CELL, V75, P1417, DOI 10.1016/0092-8674(93)90627-3
   Gong C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6406
   Groot AJ, 2012, ADV EXP MED BIOL, V727, P15, DOI 10.1007/978-1-4614-0899-4_2
   Guo W, 2014, CANCER-AM CANCER SOC, V120, P2412, DOI 10.1002/cncr.28764
   Han H, 2011, HUM MOL GENET, V20, P4299, DOI 10.1093/hmg/ddr356
   Hesson LB, 2007, DIS MARKERS, V23, P73, DOI 10.1155/2007/291538
   Ikushima H, 2010, NAT REV CANCER, V10, P415, DOI 10.1038/nrc2853
   Jia LQ, 2013, BMC COMPLEM ALTERN M, V13, DOI 10.1186/1472-6882-13-33
   Jin BL, 2013, ADV EXP MED BIOL, V754, P3, DOI 10.1007/978-1-4419-9967-2_1
   Jones PA, 2012, NAT REV GENET, V13, P484, DOI 10.1038/nrg3230
   Kang YJ, 2012, MOL PHARMACOL, V82, P168, DOI 10.1124/mol.112.078535
   Katoh M, 2007, INT J ONCOL, V31, P461
   Kim HJ, 2012, RADIAT ONCOL, V7, DOI 10.1186/1748-717X-7-39
   Kim HY, 2015, FASEB J, V29, P300, DOI 10.1096/fj.14-253997
   Kim SO, 2013, INT J ONCOL, V42, P349, DOI 10.3892/ijo.2012.1686
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kong DJ, 2012, AM J TRANSL RES, V4, P14
   Kuang SQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061807
   Lee C, 2013, CURR CANCER DRUG TAR, V13, P500
   Legut M, 2014, INT J NANOMED, V9, P653, DOI 10.2147/IJN.S54911
   Li BL, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-44
   Li SY, 2014, J CONTROL R IN PRESS, DOI [10.1016/j.jconrel.2014.1011.1011, DOI 10.1016/J.JCONREL.2014.1011.1011]
   Liu MX, 2014, ONCOTARGET, V5, P944, DOI 10.18632/oncotarget.1458
   Liu Q, 2014, MOL MED REP, V10, P2045, DOI 10.3892/mmr.2014.2395
   Liu Y, 2014, FEBS J, V281, P3315, DOI 10.1111/febs.12863
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Man CH, 2012, J PATHOL, V226, P471, DOI 10.1002/path.2997
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Meng J, 2011, NANOSCALE, V3, P4713, DOI 10.1039/c1nr10898k
   Miao Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112258
   Miele L, 2011, P NATL ACAD SCI USA, V108, P14715, DOI 10.1073/pnas.1110570108
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Nam Y, 2006, CELL, V124, P973, DOI 10.1016/j.cell.2005.12.037
   Naselli F, 2014, BIOCHEM BIOPH RES CO, V450, P652, DOI 10.1016/j.bbrc.2014.06.029
   Oswald F, 2001, MOL CELL BIOL, V21, P7761, DOI 10.1128/MCB.21.22.7761-7774.2001
   Qian Q, 2014, INT J ONCOL, V44, P874, DOI 10.3892/ijo.2014.2255
   Qin HY, 2013, CELL STEM CELL, V13, P577, DOI 10.1016/j.stem.2013.08.010
   Qiu XM, 2014, ONCOL REP, V31, P202, DOI 10.3892/or.2013.2848
   Rönsch K, 2015, MOL ONCOL, V9, P335, DOI 10.1016/j.molonc.2014.08.016
   Samaei NM, 2014, J BIOMED SCI, V21, DOI 10.1186/s12929-014-0073-3
   Shahi MH, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-614
   Shi XM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6425
   Shiah SG, 2014, CANCER RES, V74, P7560, DOI 10.1158/0008-5472.CAN-14-0978
   Silva AL, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-891
   Su XW, 2013, MOL PHARMACEUT, V10, P1901, DOI 10.1021/mp300675c
   Su ZY, 2013, CHEM RES TOXICOL, V26, P477, DOI 10.1021/tx300524p
   Tong X, 2014, ONCOTARGET, V5, P10571, DOI 10.18632/oncotarget.2512
   Valcz G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106143
   Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608
   Wang AB, 2013, J IMMUNOL, V191, P4908, DOI 10.4049/jimmunol.1300433
   Wang HJ, 2012, TECHNOLOGICAL ENTREPRENEURSHIP IN CHINA: HOW DOES IT WORK, P1
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Wu FL, 2015, CANC LETT IN PRESS, DOI [10.1016/j.canlet.2015.1001.1006, DOI 10.1016/J.CANLET.2015.1001.1006]
   Xie Q, 2014, INT J CANCER, V135, P635, DOI 10.1002/ijc.28697
   Yan WJ, 2014, J CELL MOL MED, V18, P2499, DOI 10.1111/jcmm.12325
   Yaqinuddin A, 2008, CANCER CELL INT, V8, DOI 10.1186/1475-2867-8-13
   Yin XD, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3399
   Zampieri M, 2014, BBA-GENE REGUL MECH, V1839, P813, DOI 10.1016/j.bbagrm.2014.06.017
   Zhang J, 2014, NAT PRODUCT BIOPROSP, V4, P135, DOI 10.1007/s13659-014-0016-4
   Zhang S, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-109
   Zhao ZY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112336
   Zhu HB, 2013, HEPATOLOGY, V58, P2012, DOI 10.1002/hep.26587
NR 84
TC 13
Z9 13
U1 0
U2 31
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2015
VL 10
BP 3183
EP 3191
DI 10.2147/IJN.S82527
PG 9
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA CG9KS
UT WOS:000353634500003
PM 25995628
OA gold, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU Luo, S
   Xu, JJ
   Mo, CE
   Gong, WW
   Li, CH
   Hou, XL
   Ou, ML
AF Luo, Sha
   Xu, Jiajun
   Mo, Chune
   Gong, Weiwei
   Li, Chunhong
   Hou, Xianliang
   Ou, Minglin
TI High-throughput sequencing reveals twelve cell death pattern prognostic
   target genes as potential drug-response-associated genes in the
   treatment of colorectal cancer cells with palmatine hydrochloride
SO ONCOLOGIE
LA English
DT Article; Early Access
DE colorectal cancer; palmatine hydrochloride; targeted therapy;
   high-throughput sequencing; prognosis
ID APOPTOSIS
AB Objectives: Palmatine Hydrochloride (PaH), an isoquinoline alkaloid from Phellodendron amurense and Coptis chinensis, has analgesic, anti-inflammatory, and anticancer properties. This study aimed to assess PaH's effectiveness against SW480 colorectal cancer (CRC) cells and explore its molecular mechanisms. Methods: PaH's effects on SW480 CRC cells were evaluated using MTT assays for proliferation, scratch assays for migration, and flow cytometry for apoptosis. Differentially expressed genes (DEGs) were identified through high-throughput sequencing. Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses assessed DEG roles. Prognostic significance related to programmed cell death (PCD) was analyzed using R-Package with TCGA data. RT-qPCR validated key genes identified. Results: PaH significantly inhibited SW480 cell growth, invasion, and apoptosis. The MTT assay showed inhibition rates increased from 5.49 % at 25 mu g/mL to 52.48 % at 400 mu g/mL. Scratch assays indicated reduced cell invasion over 24, 48, and 72 h. Apoptosis rose from 12.36 % in controls to 45.54 % at 400 mu g/mL. Sequencing identified 3,385 significant DEGs, primarily in cancer pathways (p=0.004). Among 35 PCD-related DEGs, Lasso Cox regression highlighted 12 key genes, including TERT, TGFBR1, WNT4, and TP53. RT-qPCR confirmed TERT and TGFBR1 downregulation (0.614-fold, p=0.008; 0.41-fold, p<0.001) and TP53 and WNT4 upregulation (5.634-fold, p<0.001; 5.124-fold, p=0.002). Conclusions: PaH inhibits CRC cell proliferation, migration, and invasion by modulating key PCD genes, suggesting its potential as a CRC therapeutic agent.
C1 [Luo, Sha; Xu, Jiajun; Mo, Chune; Gong, Weiwei; Li, Chunhong; Hou, Xianliang; Ou, Minglin] Guilin Med Univ, Affiliated Hosp 2, Lab Ctr, Guangxi Hlth Commiss Key Lab Glucose & Lipid Metab, Guilin 541199, Peoples R China.
   [Luo, Sha; Xu, Jiajun; Mo, Chune; Gong, Weiwei; Li, Chunhong; Hou, Xianliang; Ou, Minglin] Guilin Med Univ, Affiliated Hosp 2, Lab Ctr, Guangxi Key Lab Metab Reprogramming & Intelligent, Guilin 541199, Peoples R China.
C3 Guilin Medical University; Guilin Medical University
RP Hou, XL; Ou, ML (corresponding author), Guilin Med Univ, Affiliated Hosp 2, Lab Ctr, Guangxi Hlth Commiss Key Lab Glucose & Lipid Metab, Guilin 541199, Peoples R China.; Hou, XL; Ou, ML (corresponding author), Guilin Med Univ, Affiliated Hosp 2, Lab Ctr, Guangxi Key Lab Metab Reprogramming & Intelligent, Guilin 541199, Peoples R China.
EM houxl115@126.com; minglinou@glmc.edu.cn
RI Hou, Xianliang/IXN-8243-2023; li, chunhong/ABD-9811-2020
OI Ou, Minglin/0000-0001-7583-5190
FU Science and Technology Plan of Guilin [20220139-8-4]; Guangxi Medical
   and health key cultivation discipline construction project; Guangxi
   Health Commission Key Laboratory of Glucose and Lipid Metabolism
   Disorders [19-xkjs-05]
FX This work was supported by Science and Technology Plan of Guilin
   (20220139-8-4), Guangxi Medical and health key cultivation discipline
   construction project and Guangxi Health Commission Key Laboratory of
   Glucose and Lipid Metabolism Disorders (grant no. 19-xkjs-05).
CR Abedizadeh R, 2024, CANCER METAST REV, V43, P729, DOI 10.1007/s10555-023-10158-3
   Alhoshani NM, 2022, SAUDI J BIOL SCI, V29, DOI 10.1016/j.sjbs.2022.103392
   Alvarado-Ortiz E, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.607670
   Ativui S, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.853230
   Banias L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23169455
   Bedoui S, 2020, NAT REV MOL CELL BIO, V21, P678, DOI 10.1038/s41580-020-0270-8
   Benslimane Y, 2021, AGING CELL, V20, DOI 10.1111/acel.13331
   Borges G, 2022, MOL ONCOL, V16, P3380, DOI 10.1002/1878-0261.13299
   Bracken CP, 2024, SEMIN CANCER BIOL, V102, P4, DOI 10.1016/j.semcancer.2024.06.001
   Bronikowska J, 2022, BIOMED PHARMACOTHER, V145, DOI 10.1016/j.biopha.2021.112428
   Dandoti S, 2021, BIOCELL, V45, P863, DOI 10.32604/biocell.2021.013993
   De Fazio L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136761
   Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1
   Ding XM, 2021, TRENDS FOOD SCI TECH, V107, P455, DOI 10.1016/j.tifs.2020.11.015
   Mello ALD, 2022, CHEM BIOL DRUG DES, V99, P944, DOI 10.1111/cbdd.14043
   Dogan F, 2021, CANCERS, V13, DOI 10.3390/cancers13061213
   Dratwa M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.589929
   Ekeuku SO, 2020, DRUG DES DEV THER, V14, P4963, DOI 10.2147/DDDT.S280520
   Fanelli GN, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1117-2
   Fu Y, 2024, THERANOSTICS, V14, P3385, DOI 10.7150/thno.94943
   Grabarska A, 2021, MOLECULES, V26, DOI 10.3390/molecules26206253
   Guo JT, 2020, BMC GENOMICS, V21, DOI 10.1186/s12864-020-06848-9
   Guterres AN, 2020, ONCOGENE, V39, P5811, DOI 10.1038/s41388-020-01405-w
   Hardiman KM, 2021, DIS COLON RECTUM, V64, P517, DOI 10.1097/DCR.0000000000001984
   Hayat R, 2022, CELL BIOL INT, V46, P863, DOI 10.1002/cbin.11797
   He LY, 2022, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.775084
   Hossain MS, 2022, CANCERS, V14, DOI 10.3390/cancers14071732
   Ismail AB, 2022, ZYGOTE, V30, P536, DOI 10.1017/S0967199422000028
   Jaiswal SK, 2021, GENES-BASEL, V12, DOI 10.3390/genes12111675
   Jang JW, 2021, CANCERS, V13, DOI 10.3390/cancers13092160
   Ji HX, 2022, PHARMACOL RES, V177, DOI 10.1016/j.phrs.2021.106013
   Jiang ZM, 2021, J BIOMATER APPL, V35, P869, DOI 10.1177/0885328220950060
   Johnson-Ajinwo OR, 2019, TOXINS, V11, DOI 10.3390/toxins11040237
   Kapeleris J, 2020, CLIN EXP PHARMACOL P, V47, P838, DOI 10.1111/1440-1681.13247
   Kasprzak A, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21103494
   Katsaounou K, 2022, METABOLITES, V12, DOI 10.3390/metabo12060499
   Khaksari M, 2021, ARCH PHYSIOL BIOCHEM, V127, P273, DOI 10.1080/13813455.2019.1633354
   Kong Y, 2022, EXPERT OPIN THER PAT, V32, P211, DOI 10.1080/13543776.2021.1974001
   Liu XJ, 2020, BIOCHEM PHARMACOL, V175, DOI 10.1016/j.bcp.2020.113933
   Liu YQ, 2022, CELL DEATH DIFFER, V29, P895, DOI 10.1038/s41418-022-00943-y
   Lorente L, 2023, MED INTENSIVA, V47, P691, DOI [10.1016/j.medine.2023.05.007, 10.1016/j.medin.2023.04.016]
   Lossi L, 2022, BIOCHEM J, V479, P357, DOI 10.1042/BCJ20210854
   Marei HE, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02396-8
   Mihanfar A, 2021, BIOIMPACTS, V11, P253, DOI 10.34172/bi.2021.36
   Mohd Y, 2021, J GASTROINTEST CANC, V52, P1022, DOI 10.1007/s12029-020-00535-4
   Moreau JLM, 2023, bioRxiv, DOI [10.1101/2023.11.19.567482, 10.1101/2023.11.19.567482, DOI 10.1101/2023.11.19.567482]
   Nakonieczna S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810330
   Nelson VK, 2023, FRONT ENDOCRINOL, V14, DOI 10.3389/fendo.2023.1201198
   Ni BY, 2024, FRONT ONCOL, V14, DOI 10.3389/fonc.2024.1412370
   Ni CL, 2023, EXP THER MED, V25, DOI 10.3892/etm.2022.11774
   Obeng E., 2021, Braz. J. Biol., V81, P1133, DOI 10.1590/1519-6984.228437
   Okechukwu PN, 2021, CURR PHARM BIOTECHNO, V22, P288, DOI 10.2174/1389201021666200730124208
   Papoutsoglou P, 2020, CANCER SCI, V111, P2672, DOI 10.1111/cas.14509
   Pei HY, 2023, J BIOCHEM MOL TOXIC, V37, DOI 10.1002/jbt.23225
   Prieto JM, 2022, ANTIOXIDANTS-BASEL, V11, DOI 10.3390/antiox11040611
   Rahman MA, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.761080
   Rai NK, 2020, ONCOL LETT, V20, DOI 10.3892/ol.2020.12176
   Saraiva MR, 2023, WORLD J GASTROENTERO, V29, P1289, DOI 10.3748/wjg.v29.i8.1289
   Scarpitta A, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.731598
   Sevimli M, 2022, J TRACE ELEM MED BIO, V71, DOI 10.1016/j.jtemb.2022.126958
   Shi T, 2020, ANTIOXID REDOX SIGN, V33, P839, DOI 10.1089/ars.2020.8074
   Shiau JP, 2022, ANTIOXIDANTS-BASEL, V11, DOI 10.3390/antiox11091845
   Shim D, 2021, CANCER DRUG RESIST, V4, P85, DOI 10.20517/cdr.2020.85
   Shinji S, 2020, BIOSCI BIOTECH BIOCH, V84, P63, DOI 10.1080/09168451.2019.1659714
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Signorile ML, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24087597
   Song Y, 2021, J PHARMACEUT BIOMED, V203, DOI 10.1016/j.jpba.2021.114226
   Sprooten J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9081823
   Tarabasz D, 2020, PHYTOTHER RES, V34, P33, DOI 10.1002/ptr.6504
   Tauriello DVF, 2022, NAT REV CANCER, V22, P25, DOI 10.1038/s41568-021-00413-6
   Tilaoui M, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.719694
   Wang YQ, 2022, CELL MOL IMMUNOL, V19, P867, DOI 10.1038/s41423-022-00866-1
   Wu XL, 2023, EXPERT REV MOL MED, V25, DOI 10.1017/erm.2023.16
   Xi H., 2022, Oncology Reports, V48, P1
   Xu JJ, 2024, ONCOLOGIE, V26, P643, DOI 10.1515/oncologie-2024-0073
   Xu R, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420-023-01517-8
   Xu XF, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01276-5
   Xue VW, 2020, CANCERS, V12, DOI 10.3390/cancers12113099
   Yan G., 2020, World Acad. Sci. J, V2, P39, DOI [10.3892/wasj.2020.40, DOI 10.3892/WASJ.2020.40]
   Yang DM, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01774-w
   Yoo MJ, 2023, BMC VET RES, V19, DOI 10.1186/s12917-023-03782-2
   Zha SJ, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.826785
   Zhang MD, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.786728
   Zhang XY, 2021, BIOSCI TRENDS, V15, P283, DOI 10.5582/bst.2021.01318
   Zhao JA, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.809806
   Zhou JC, 2021, CHINESE J CANCER RES, V33, P1, DOI 10.21147/j.issn.1000-9604.2021.01.01
   Zhou SY, 2020, FRONT NEUROSCI-SWITZ, V14, DOI 10.3389/fnins.2020.589042
   Zou YT, 2022, INT J SURG, V107, DOI 10.1016/j.ijsu.2022.106936
   Zuo H, 2024, INFLAMMATION, V47, P1793, DOI 10.1007/s10753-024-02009-2
NR 89
TC 0
Z9 0
U1 0
U2 0
PU WALTER DE GRUYTER GMBH
PI BERLIN
PA GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY
SN 1292-3818
EI 1765-2839
J9 ONCOLOGIE
JI Oncologie
PD 2024 NOV 5
PY 2024
DI 10.1515/oncologie-2024-0378
EA NOV 2024
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA L0D7R
UT WOS:001347521700001
OA hybrid
DA 2025-01-04
ER

PT J
AU Vinchhi, P
   Patel, MM
AF Vinchhi, Preksha
   Patel, Mayur M.
TI Triumph against cancer: invading colorectal cancer with nanotechnology
SO EXPERT OPINION ON DRUG DELIVERY
LA English
DT Review
DE Chemotherapy; anti-cancer agent; nanodiagnostics; nanotherapy; targeted
   therapy
ID SOLID LIPID NANOPARTICLES; TARGETED DRUG-DELIVERY; MESOPOROUS SILICA
   NANOPARTICLES; IN-VITRO EVALUATION; COLON-CANCER; POLYMERIC
   NANOPARTICLES; OXIDE NANOPARTICLES; GOLD NANOPARTICLES; CT COLONOGRAPHY;
   EARLY-DIAGNOSIS
AB Introduction: Recent statistics have reported colorectal cancer (CRC) as the second leading cause of cancer-associated deaths in the world. Early diagnosis of CRC may help to reduce the mortality and associated complications. However, the conventional diagnostic techniques often lead to misdiagnosis, fail to differentiate benign from malignant tissue or diagnose only at an advanced stage. For the treatment of CRC, surgery, chemotherapy, immunotherapy, and radiotherapy have been employed. However, the quality of living of the CRC patients is highly compromised after employing current therapeutic approaches owing to the toxicity issues and relapse.
   Area covered: This review accentuates the molecular mechanisms involved in the pathogenesis, stages of CRC, conventional approaches for diagnosis and therapy of CRC and the issues confronted thereby. It provides an outlook on the advantages of employing nanotechnology-based approaches for prevention, early diagnosis, and treatment of CRC.
   Expert opinion: Employing nanotechnology-based approaches has demonstrated promising outcomes in the prevention, diagnosis, and treatment of CRC. Nanotechnology-based approaches can surmount the major drawbacks of traditional diagnostic and therapeutic approaches. Nanotechnology bestows the advantage of early detection of CRC which helps to undertake instant steps for offering efficient therapy and reducing the mortality rates. For the treatment of CRC, nanocarriers offer the benefit of achieving controlled drug release, improved drug bioavailability, enhanced tumor targetability and reduced adverse effects.
C1 [Vinchhi, Preksha; Patel, Mayur M.] Nirma Univ, Inst Pharm, Dept Pharmaceut, SG Highway, Ahmadabad, Gujarat, India.
C3 Nirma University
RP Patel, MM (corresponding author), Nirma Univ, Inst Pharm, Dept Pharmaceut, SG Highway, Ahmadabad, Gujarat, India.
EM drmayurmpatel@gmail.com
RI Patel, Mayur/AGD-7273-2022
CR Ahlquist DA, 2000, GASTROENTEROLOGY, V119, P1219, DOI 10.1053/gast.2000.19580
   Algra AM, 2012, LANCET ONCOL, V13, P518, DOI 10.1016/S1470-2045(12)70112-2
   Alibolandi M, 2018, INT J PHARMACEUT, V549, P67, DOI 10.1016/j.ijpharm.2018.07.052
   Alibolandi M, 2017, INT J PHARMACEUT, V519, P352, DOI 10.1016/j.ijpharm.2017.01.044
   Alizadeh AM, 2012, EUR J PHARMACOL, V689, P226, DOI 10.1016/j.ejphar.2012.06.016
   Alomrani A, 2019, SAUDI PHARM J, V27, P603, DOI 10.1016/j.jsps.2019.02.008
   Asfour MH, 2018, J ADV RES, V9, P17, DOI 10.1016/j.jare.2017.10.003
   Azhdarzadeh M, 2016, COLLOID SURFACE B, V143, P224, DOI 10.1016/j.colsurfb.2016.02.058
   Banerjee A, 2017, DRUG DISCOV TODAY, V22, P1224, DOI 10.1016/j.drudis.2017.05.006
   Barret M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068947
   Bertrand N, 2014, ADV DRUG DELIVER REV, V66, P2, DOI 10.1016/j.addr.2013.11.009
   Bharali Dhruba J, 2011, Cancers (Basel), V3, P4024, DOI 10.3390/cancers3044024
   Bhattacharya S, 2020, INT J BIOL MACROMOL, V151, P104, DOI 10.1016/j.ijbiomac.2020.02.151
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Bray F., 2018, CA-CANCER J CLIN, V68, pP.
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Bruheim K, 2010, ACTA ONCOL, V49, P826, DOI 10.3109/0284186X.2010.486411
   Chang T, 2016, COLLOID SURFACE B, V144, P257, DOI 10.1016/j.colsurfb.2016.04.019
   Chaudhary A, 2011, CANCER PREV RES, V4, P1655, DOI 10.1158/1940-6207.CAPR-11-0129
   Cheng GL, 2019, COLLOID SURFACE B, V181, P822, DOI 10.1016/j.colsurfb.2019.06.020
   Chibaudel B, 2016, CANCER MED-US, V5, P676, DOI 10.1002/cam4.635
   Chung S, 2018, BIOSENS BIOELECTRON, V100, P396, DOI 10.1016/j.bios.2017.09.031
   Cohen S, 2013, MAT SCI ENG C-MATER, V33, P923, DOI 10.1016/j.msec.2012.11.022
   Lima SAC, 2017, MAT SCI ENG C-MATER, V75, P1420, DOI 10.1016/j.msec.2017.03.049
   Dai ZW, 2018, MICROBIOME, V6, DOI 10.1186/s40168-018-0451-2
   De Rosa M, 2015, ONCOL REP, V34, P1087, DOI 10.3892/or.2015.4108
   Dehvari K, 2016, J BIOMED NANOTECHNOL, V12, P1734, DOI 10.1166/jbn.2016.2283
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   DuRoss AN, 2021, CANCER LETT, V500, P208, DOI 10.1016/j.canlet.2020.11.021
   Fitzgerald, 2017, Patent No. [2017172678A1, 2017172678]
   Flemer B, 2017, GUT, V66, P633, DOI 10.1136/gutjnl-2015-309595
   Foroushani MS, 2019, J DRUG DELIV SCI TEC, V54, DOI 10.1016/j.jddst.2019.101223
   Fox ME, 2009, MOL PHARMACEUT, V6, P1562, DOI 10.1021/mp9001206
   Goel A, 2010, CURR OPIN GASTROEN, V26, P47, DOI 10.1097/MOG.0b013e328332b850
   Golan T, 2015, CANCER MED-US, V4, P1472, DOI 10.1002/cam4.491
   González N, 2017, ONCOTARGET, V8, P18456, DOI 10.18632/oncotarget.14472
   Grady WM, 2015, DIGEST DIS SCI, V60, P762, DOI 10.1007/s10620-014-3444-4
   Graser A, 2009, GUT, V58, P241, DOI 10.1136/gut.2008.156448
   Gu XL, 2019, J CONTROL RELEASE, V301, P110, DOI 10.1016/j.jconrel.2019.03.005
   Gulbake A, 2016, WORLD J GASTROENTERO, V22, P582, DOI 10.3748/wjg.v22.i2.582
   Nguyen HT, 2018, ONCOL LETT, V16, P9, DOI 10.3892/ol.2018.8679
   Hainaut, 2018, ENCY CANC, P425
   Handali S, 2018, BIOMED PHARMACOTHER, V108, P1259, DOI 10.1016/j.biopha.2018.09.128
   Handali S, 2019, INT J BIOL MACROMOL, V124, P1299, DOI 10.1016/j.ijbiomac.2018.09.119
   Hao M, 2019, ACTA BIOMATER, V83, P414, DOI 10.1016/j.actbio.2018.10.032
   Hashkavayi AB, 2017, BIOSENS BIOELECTRON, V92, P630, DOI 10.1016/j.bios.2016.10.042
   Helm J., 2003, CANCER CONTROL, V10
   Hong Y, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108764
   Hosseinzadeh H, 2017, INT J PHARMACEUT, V526, P339, DOI 10.1016/j.ijpharm.2017.04.060
   Hung Kenneth E, 2006, Drug Discov Today Dis Mech, V3, P439, DOI 10.1016/j.ddmec.2006.10.005
   Ishida, 2012, Patent No. [2012301537A1, 2012301537]
   Jalalian SH, 2013, EUR J PHARM SCI, V50, P191, DOI 10.1016/j.ejps.2013.06.015
   Jayaprakasha GK, 2016, EUR J PHARMACOL, V789, P291, DOI 10.1016/j.ejphar.2016.07.017
   Khan S, 2019, J TRACE ELEM MED BIO, V52, P12, DOI 10.1016/j.jtemb.2018.11.003
   Khiavi MA, 2019, COLLOID SURFACE A, V572, P333, DOI 10.1016/j.colsurfa.2019.04.019
   Klippstein R, 2015, SMALL, V11, P4704, DOI 10.1002/smll.201403799
   Knudsen AB, 2010, JNCI-J NATL CANCER I, V102, P1238, DOI 10.1093/jnci/djq242
   Kotelevets L, 2016, INT J PHARMACEUT, V514, P24, DOI 10.1016/j.ijpharm.2016.06.005
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lamberti M, 2014, EXPERT OPIN DRUG DEL, V11, P1087, DOI 10.1517/17425247.2014.913568
   Ledebo A, 2018, COLORECTAL DIS, V20, pO123, DOI 10.1111/codi.14229
   Lee CS, 2017, EUR J MED CHEM, V142, P416, DOI 10.1016/j.ejmech.2017.08.063
   Lin D, 2011, OPT EXPRESS, V19, P13565, DOI 10.1364/OE.19.013565
   Liu ZL, 2019, J DRUG DELIV SCI TEC, V52, P1, DOI 10.1016/j.jddst.2019.04.010
   Lord I., 2019, MEDICINE, V47
   Lorente C, 2018, COLLOID SURFACE B, V171, P553, DOI 10.1016/j.colsurfb.2018.07.070
   Lotfi-Attari J, 2017, NUTR CANCER, V69, P1290, DOI 10.1080/01635581.2017.1367932
   Lungu II, 2019, MOLECULES, V24, DOI 10.3390/molecules24193547
   Lyon PC, 2017, J THER ULTRASOUND, V5, DOI 10.1186/s40349-017-0104-0
   Matos AI, 2019, J CONTROL RELEASE, V307, P108, DOI 10.1016/j.jconrel.2019.06.017
   Mattar Mark C, 2011, Gastrointest Cancer Res, V4, P53
   Mayur MP., 2009, ACTA PHARM SCI, V51, P251
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Moesinger R., 2016, ADV STUD MED, V6
   Mohamed JM, 2021, CARBOHYD POLYM, V252, DOI 10.1016/j.carbpol.2020.117180
   Montalban-Arques A, 2019, EBIOMEDICINE, V48, P648, DOI 10.1016/j.ebiom.2019.09.050
   Moskvin M, 2018, COLLOID SURFACE B, V161, P35, DOI 10.1016/j.colsurfb.2017.10.034
   de Escalona MM, 2016, INT J PHARMACEUT, V504, P11, DOI 10.1016/j.ijpharm.2016.03.005
   Nagorni A, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008361.pub2
   Nair HB, 2010, BIOCHEM PHARMACOL, V80, P1833, DOI 10.1016/j.bcp.2010.07.021
   Nakayama G, 2013, GASTROINTEST TUMORS, V1, P25, DOI 10.1159/000354995
   Narmani A, 2018, PROCESS BIOCHEM, V69, P178, DOI 10.1016/j.procbio.2018.01.014
   Negi LM, 2015, INT J BIOL MACROMOL, V73, P222, DOI 10.1016/j.ijbiomac.2014.11.026
   Nirei T, 2017, J SURG RES, V218, P334, DOI 10.1016/j.jss.2017.06.056
   Okumura M, 2018, DRUG DELIV, V25, P1192, DOI 10.1080/10717544.2018.1475517
   Oliveira ALCDL, 2021, MAT SCI ENG C-MATER, V120, DOI 10.1016/j.msec.2020.111678
   Öztürk K, 2017, PHARM DEV TECHNOL, V22, P635, DOI 10.3109/10837450.2015.1116565
   Pan G, 2017, COLLOID SURFACE B, V159, P375, DOI 10.1016/j.colsurfb.2017.08.013
   Patel M, 2007, CRIT REV THER DRUG, V24, P147, DOI 10.1615/CritRevTherDrugCarrierSyst.v24.i2.20
   Patel MM, 2018, EUR J PHARM SCI, V121, P188, DOI 10.1016/j.ejps.2018.05.026
   Patel MM, 2017, DRUG DELIV TRANSL RE, V7, P312, DOI 10.1007/s13346-017-0358-7
   Patel MM, 2015, EXPERT OPIN DRUG DEL, V12, P1389, DOI 10.1517/17425247.2015.1060217
   Patel MM, 2014, EXPERT OPIN DRUG DEL, V11, P1343, DOI 10.1517/17425247.2014.927440
   Patel MM, 2011, CRIT REV THER DRUG, V28, P489, DOI 10.1615/CritRevTherDrugCarrierSyst.v28.i6.10
   Patel MM, 2011, EXPERT OPIN DRUG DEL, V8, P1247, DOI 10.1517/17425247.2011.597739
   Patel MM, 2011, DRUG DELIV, V18, P281, DOI 10.3109/10717544.2010.538447
   Patel MM, 2009, PHARM DEV TECHNOL, V14, P62, DOI 10.1080/10837450802409412
   Patel MM, 2013, EXPERT OPIN DRUG DEL, V10, P731, DOI 10.1517/17425247.2013.782284
   Pathak, 2019, ADV NUTRACEUTICAL AP, P61
   Peeters KCMJ, 2005, J CLIN ONCOL, V23, P6199, DOI 10.1200/JCO.2005.14.779
   Pereira I, 2018, INT J PHARMACEUT, V549, P397, DOI 10.1016/j.ijpharm.2018.08.016
   Pickhardt PJ, 2003, NEW ENGL J MED, V349, P2191, DOI 10.1056/NEJMoa031618
   Pox CP, 2012, GASTROENTEROLOGY, V142, P1460, DOI 10.1053/j.gastro.2012.03.022
   Rajasree PH, 2018, J DRUG DELIV SCI TEC, V46, P302, DOI 10.1016/j.jddst.2018.05.025
   Rajpoot K, 2018, ARTIF CELL NANOMED B, V46, P1236, DOI 10.1080/21691401.2017.1366338
   Reimondez-Troitiño S, 2019, EUR J PHARM BIOPHARM, V142, P449, DOI 10.1016/j.ejpb.2019.07.016
   Ren YT, 2019, EUR J PHARM SCI, V128, P279, DOI 10.1016/j.ejps.2018.12.007
   Rivory LP., 2002, AUST PRESCR, V25
   Rosman AS, 2007, AM J MED, V120, P203, DOI 10.1016/j.amjmed.2006.05.061
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Segnan N, 2011, J NATL CANCER I, V103, P1310, DOI 10.1093/jnci/djr284
   Sen K, 2019, COLLOID SURFACE B, V180, P9, DOI 10.1016/j.colsurfb.2019.04.035
   Shah N., 2011, J PHARMA ED RES, V2
   Shakeri-Zadeh A, 2014, J BIOMATER APPL, V29, P548, DOI 10.1177/0885328214536940
   Shen MY, 2019, BIOMATERIALS, V197, P86, DOI 10.1016/j.biomaterials.2019.01.019
   Siddiqui L, 2020, INT J BIOL MACROMOL, V152, P786, DOI 10.1016/j.ijbiomac.2020.02.311
   Siddiqui L, 2018, MED HYPOTHESES, V121, P10, DOI 10.1016/j.mehy.2018.09.003
   Soler M, 2016, ANAL CHIM ACTA, V930, P31, DOI 10.1016/j.aca.2016.04.059
   Sosna J, 2003, AM J ROENTGENOL, V181, P1593, DOI 10.2214/ajr.181.6.1811593
   Sousa AR, 2019, INT J PHARMACEUT, V568, DOI 10.1016/j.ijpharm.2019.118530
   Sun JH, 2016, J BIOMED NANOTECHNOL, V12, P1709, DOI 10.1166/jbn.2016.2285
   Swarbrick J., 2013, ENCY PHARM SCI TECHN, Vsix, P1091
   Tao L, 2012, BIOSENS BIOELECTRON, V35, P186, DOI 10.1016/j.bios.2012.02.044
   Tian RR, 2019, BIOMATERIALS, V212, P64, DOI 10.1016/j.biomaterials.2019.05.010
   Tivony R, 2014, J BIOMED NANOTECHNOL, V10, P1041, DOI 10.1166/jbn.2014.1799
   Ünal S, 2020, INT J PHARMACEUT, V584, DOI 10.1016/j.ijpharm.2020.119468
   Van De Velde CJH., 2014, EUR J SURG ONCOL, V40
   van de Velde CJH, 2014, EUR J CANCER, V50, DOI 10.1016/j.ejca.2013.06.048
   von Karsa L, 2013, ENDOSCOPY, V45, P51, DOI 10.1055/s-0032-1325997
   Wen P, 2019, FOOD FUNCT, V10, P1816, DOI 10.1039/c8fo02447b
   Wen P, 2018, FOOD FUNCT, V9, P5999, DOI 10.1039/c8fo01216d
   WINAWER SJ, 1993, NEW ENGL J MED, V329, P1977, DOI 10.1056/NEJM199312303292701
   Xie XD, 2016, EUR J PHARM SCI, V83, P28, DOI 10.1016/j.ejps.2015.12.014
   Xing XH, 2015, BIOMATERIALS, V48, P16, DOI 10.1016/j.biomaterials.2015.01.011
   Xu QM, 2012, BIOMATERIALS, V33, P3909, DOI 10.1016/j.biomaterials.2012.02.014
   Yang HL, 2019, INT J PHARMACEUT, V566, P585, DOI 10.1016/j.ijpharm.2019.06.020
   Yoon SM, 2011, DIGEST DIS SCI, V56, P3005, DOI 10.1007/s10620-011-1685-z
   Yu YL, 2012, COLLOID SURFACE B, V95, P247, DOI 10.1016/j.colsurfb.2012.03.011
   Zauber AG, 2012, NEW ENGL J MED, V366, P687, DOI 10.1056/NEJMoa1100370
   Zhu, 2018, Patent No. 20180125976
NR 140
TC 20
Z9 21
U1 1
U2 18
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1742-5247
EI 1744-7593
J9 EXPERT OPIN DRUG DEL
JI Expert Opin. Drug Deliv.
PD SEP 2
PY 2021
VL 18
IS 9
BP 1169
EP 1191
DI 10.1080/17425247.2021.1889512
EA MAR 2021
PG 23
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UM5FI
UT WOS:000631948400001
PM 33567909
DA 2025-01-04
ER

PT J
AU Li, S
   Han, T
AF Li, Shuang
   Han, Ting
TI Frequent loss of FAM126A expression in colorectal cancer results in
   selective FAM126B dependency
SO ISCIENCE
LA English
DT Article
ID SYNTHETIC LETHALITY; RESISTANCE; TARGET
AB Most advanced colorectal cancer (CRC) patients cannot benefit from targeted therapy due to lack of actionable targets. By mining data from the DepMap, we identified FAM126B as a specific vulnerability in CRC cell lines exhibiting low FAM126A expression. Employing a combination of genetic perturbation and inducible protein degradation techniques, we demonstrate that FAM126A and FAM126B function in a redundant manner to facilitate the recruitment of PI4KIII a to the plasma membrane for PI4P synthesis. Examination of data from TCGA and GTEx revealed that over 7% of CRC tumor samples exhibited loss of FAM126A expression, contrasting with uniform FAM126A expression in normal tissues. In both CRC cell lines and tumor samples, promoter hypermethylation correlated with the loss of FAM126A expression, which could be reversed by DNA methylation inhibitors. In conclusion, our study reveals that loss of FAM126A expression results in FAM126B dependency, thus proposing FAM126B as a therapeutic target for CRC treatment.
C1 [Li, Shuang; Han, Ting] Peking Univ, Sch Life Sci, PTN Joint Grad Program, Beijing 100871, Peoples R China.
   [Li, Shuang; Han, Ting] Natl Inst Biol Sci, Beijing 102206, Peoples R China.
   [Han, Ting] Tsinghua Univ, Tsinghua Inst Multidisciplinary Biomed Res, Beijing 102206, Peoples R China.
C3 Peking University; National Institute of Biological Sciences, Beijing;
   Tsinghua University
RP Han, T (corresponding author), Peking Univ, Sch Life Sci, PTN Joint Grad Program, Beijing 100871, Peoples R China.; Han, T (corresponding author), Natl Inst Biol Sci, Beijing 102206, Peoples R China.; Han, T (corresponding author), Tsinghua Univ, Tsinghua Inst Multidisciplinary Biomed Res, Beijing 102206, Peoples R China.
EM hanting@nibs.ac.cn
OI Han, Ting/0000-0003-3168-8699
FU Bei- jing Municipal Commission of Science and Technology
   [Z201100005320010]; National Institute of Biological Sci- ences, Beijing
   and Tsinghua Institute of Multidisciplinary Biomedical Research
FX ACKNOWLEDGMENTS We thank Dr. Lilin Du for sharing the improved AID
   system and Dr. Xiangbing Qi for synthesizing 5-Ad-IAA. This work was
   supported by Bei- jing Municipal Commission of Science and Technology
   (Z201100005320010) and startup funding from National Institute of
   Biological Sci- ences, Beijing and Tsinghua Institute of
   Multidisciplinary Biomedical Research.
CR Balla T, 2013, PHYSIOL REV, V93, P1019, DOI 10.1152/physrev.00028.2012
   Baskin JM, 2016, NAT CELL BIOL, V18, P132, DOI 10.1038/ncb3271
   Battaglin F, 2018, CLIN ADV HEMATOL ONC, V16, P735
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Chan EM, 2019, NATURE, V568, P551, DOI 10.1038/s41586-019-1102-x
   Chang L, 2021, CANCER CELL, V39, P466, DOI 10.1016/j.ccell.2020.12.008
   Dandage R, 2019, MOL SYST BIOL, V15, DOI 10.15252/msb.20198871
   Datta Jharna, 2012, Genes Cancer, V3, P71, DOI 10.1177/1947601912452665
   De Kegel B, 2019, PLOS GENET, V15, DOI 10.1371/journal.pgen.1008466
   Dempster JM, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02540-7
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Farmer H, 2005, NATURE, V434, P917, DOI 10.1038/nature03445
   Feng WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12234-1
   Gallo D, 2022, NATURE, V604, P749, DOI 10.1038/s41586-022-04638-9
   Ghoshal K, 2005, MOL CELL BIOL, V25, P4727, DOI 10.1128/MCB.25.11.4727-4741.2005
   Gong XQ, 2019, CANCER DISCOV, V9, P248, DOI 10.1158/2159-8290.CD-18-0469
   Hammond GRV, 2014, J CELL BIOL, V205, P113, DOI 10.1083/jcb.201312072
   Hammond GRV, 2012, SCIENCE, V337, P727, DOI 10.1126/science.1222483
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Hart T, 2015, CELL, V163, DOI 10.1016/j.cell.2015.11.015
   Hu LX, 2020, CANCER DISCOV, V10, P460, DOI 10.1158/2159-8290.CD-19-0837
   Huang A, 2020, NAT REV DRUG DISCOV, V19, P23, DOI 10.1038/s41573-019-0046-z
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Koch A, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1847-z
   Koonin EV, 2005, ANNU REV GENET, V39, P309, DOI 10.1146/annurev.genet.39.073003.114725
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kryukov GV, 2016, SCIENCE, V351, P1214, DOI 10.1126/science.aad5214
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lees JA, 2017, P NATL ACAD SCI USA, V114, P13720, DOI 10.1073/pnas.1718471115
   Levin R, 2017, MOL BIOL CELL, V28, P128, DOI 10.1091/mbc.E16-06-0451
   Li W, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0554-4
   Li YZ, 2023, CANCER CELL, V41, P1397, DOI 10.1016/j.ccell.2023.06.009
   Liao YX, 2023, CELL SYST, V14, P777, DOI 10.1016/j.cels.2023.07.007
   Lieb S, 2019, ELIFE, V8, DOI 10.7554/eLife.43333
   Lin A, 2020, NAT REV GENET, V21, P671, DOI 10.1038/s41576-020-0247-7
   Lord CJ, 2017, SCIENCE, V355, P1152, DOI 10.1126/science.aam7344
   Lv L, 2020, ELIFE, V9, DOI 10.7554/eLife.59994
   Malone CF, 2021, CANCER DISCOV, V11, P2282, DOI 10.1158/2159-8290.CD-20-1213
   Mavrakis KJ, 2016, SCIENCE, V351, P1208, DOI 10.1126/science.aad5944
   Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Neggers JE, 2020, CELL REP, V33, DOI 10.1016/j.celrep.2020.108493
   O'Neil NJ, 2017, NAT REV GENET, V18, P613, DOI 10.1038/nrg.2017.47
   Parrish PCR, 2021, CELL REP, V36, DOI 10.1016/j.celrep.2021.109597
   Parvin S, 2019, CANCER CELL, V36, P237, DOI 10.1016/j.ccell.2019.07.007
   Ryan CJ, 2023, TRENDS CANCER, V9, P397, DOI 10.1016/j.trecan.2023.02.002
   Schreiber SL, 2021, CELL, V184, P3, DOI 10.1016/j.cell.2020.12.020
   Shields JA, 2022, CANCER RES, V82, P4044, DOI 10.1158/0008-5472.CAN-21-4443
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Szymanska E, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910812
   Tao ZC, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2208844119
   Thompson NA, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21478-9
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tsherniak A, 2017, CELL, V170, P564, DOI 10.1016/j.cell.2017.06.010
   van Wietmarschen N, 2020, NATURE, V586, P292, DOI 10.1038/s41586-020-2769-8
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Zhang XR, 2022, G3-GENES GENOM GENET, V12, DOI 10.1093/g3journal/jkab393
NR 57
TC 1
Z9 1
U1 1
U2 1
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2589-0042
J9 ISCIENCE
JI iScience
PD MAY 17
PY 2024
VL 27
IS 5
AR 109646
DI 10.1016/j.isci.2024.109646
PG 17
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA SL3E2
UT WOS:001234560700001
PM 38638566
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Morshedzadeh, F
   Abbaszadegan, MR
   Peymani, M
   Mozaffari-Jovin, S
AF Morshedzadeh, Firouzeh
   Abbaszadegan, Mohammad Reza
   Peymani, Maryam
   Mozaffari-Jovin, Sina
TI <i>KRAS</i> mutations detection methodology: from RFLP to CRISPR/Cas
   based methods
SO FUNCTIONAL & INTEGRATIVE GENOMICS
LA English
DT Review
DE KRAS; RAS family; Molecular diagnostic methods; Personalized cancer
   medicine
ID RAS GENE-MUTATIONS; SENSITIVE DETECTION; COLORECTAL-CANCER; TECHNOLOGY;
   PCR; STRIPASSAY; SYSTEM
AB In personalized cancer medicine, the identification of KRAS mutations is essential for making treatment decisions and improving patient outcomes. This work presents a comprehensive review of the current approaches for detection of KRAS mutations in different cancers. We highlight the value of fast and reliable KRAS mutations discovery and the effectiveness of molecular testing for selecting individuals who might benefit from targeted therapy. We provide an overview of various methods and tools available for detecting KRAS mutations, such as digital droplet PCR, next-generation sequencing (NGS), and polymerase chain reaction (PCR). We also address the difficulties and limitations in the identification of KRAS mutations, namely tumor heterogeneity and the emergence of resistance mechanisms. This article aims to guide clinicians in KRAS mutation identification.
C1 [Morshedzadeh, Firouzeh; Peymani, Maryam] Islamic Azad Univ, Fac Basic Sci, Dept Genet, Shahrekord Branch, Shahrekord, Iran.
   [Abbaszadegan, Mohammad Reza; Mozaffari-Jovin, Sina] Mashhad Univ Med Sci, Fac Med, Dept Med Genet & Mol Med, Mashhad, Iran.
   [Abbaszadegan, Mohammad Reza] Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Iran.
C3 Islamic Azad University; Mashhad University of Medical Sciences; Mashhad
   University of Medical Sciences
RP Peymani, M (corresponding author), Islamic Azad Univ, Fac Basic Sci, Dept Genet, Shahrekord Branch, Shahrekord, Iran.; Abbaszadegan, MR (corresponding author), Mashhad Univ Med Sci, Fac Med, Dept Med Genet & Mol Med, Mashhad, Iran.; Abbaszadegan, MR (corresponding author), Mashhad Univ Med Sci, Med Genet Res Ctr, Mashhad, Iran.
EM Abbaszadeganmr@mums.ac.ir; m.peymani@iau.ir
CR Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062
   Anderson SM, 2011, EXPERT REV MOL DIAGN, V11, P635, DOI [10.1586/ERM.11.42, 10.1586/erm.11.42]
   Bender G, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-021-00772-0
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   CHANG EH, 1982, NATURE, V297, P479, DOI 10.1038/297479a0
   Choi HS, 2014, CLIN BIOCHEM, V47, P1091, DOI 10.1016/j.clinbiochem.2014.03.024
   Chubarov AS, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25010617
   Chubarov AS, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10110872
   Cree Ian A, 2016, Biomol Detect Quantif, V8, P29, DOI 10.1016/j.bdq.2016.05.001
   Darwanto A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3328-z
   Dong LH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27368-3
   El Kader YA, 2013, J EGYPT NATL CANCER, V25, P37, DOI 10.1016/j.jnci.2012.12.003
   Eslahi A, 2023, GENE, V867, DOI 10.1016/j.gene.2023.147358
   Franczak C, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0227294
   Franklin WA, 2010, J MOL DIAGN, V12, P43, DOI 10.2353/jmoldx.2010.080131
   Garritano S, 2009, BMC GENET, V10, DOI 10.1186/1471-2156-10-5
   Gaudet M, 2009, METHODS MOL BIOL, V578, P415, DOI 10.1007/978-1-60327-411-1_26
   Guarnaccia M, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18010131
   Hillary VE, 2023, MOL BIOTECHNOL, V65, P311, DOI 10.1007/s12033-022-00567-0
   Hu YP, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.834646
   Huang MY, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-147
   Huo GR, 2023, FUNCT INTEGR GENOMIC, V23, DOI 10.1007/s10142-023-01024-0
   Iemmolo R, 2019, Lab-on-Disk Platform for KRAS Mutation Testing, DOI [10.1007/978-3-030-04324-753, DOI 10.1007/978-3-030-04324-753]
   Ishige T, 2018, ADV CLIN CHEM, V83, P53, DOI 10.1016/bs.acc.2017.10.002
   Itonaga M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151654
   Jancik S, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-79
   Jia CQ, 2018, GENE, V641, P55, DOI 10.1016/j.gene.2017.10.023
   Jie G., 2016, BMJ Open, V6, DOI [DOI 10.1136/BMJOPEN-2015, 10.1136/bmjopen-2015]
   Jogam P, 2022, INT J BIOL MACROMOL, V219, P1261, DOI 10.1016/j.ijbiomac.2022.08.182
   Kalligosfyri PM, 2022, BIOSENSORS-BASEL, V12, DOI 10.3390/bios12020097
   Kavuri NR, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11172665
   Kerachian MA, 2020, CELL ONCOL, V43, P949, DOI 10.1007/s13402-020-00536-2
   Kim W, 2018, GENOME RES, V28, P374, DOI 10.1101/gr.223891.117
   Kriegshäuser G, 2011, J CLIN PATHOL, V64, P252, DOI 10.1136/jcp.2010.081414
   Kriegsmann M, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0364-3
   Krypuy M, 2006, BMC CANCER, V6, DOI 10.1186/1471-2407-6-295
   Lee J, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23344
   Li C, 2023, GENOM PROTEOM BIOINF, V21, P108, DOI 10.1016/j.gpb.2022.02.006
   Li C, 2021, J ZHEJIANG UNIV-SC B, V22, P253, DOI 10.1631/jzus.B2100009
   Little S, 2001, Curr Protoc Hum Genet, VChapter 9, DOI 10.1002/0471142905.hg0908s07
   Liu YP, 2014, SCI REP-UK, V4, DOI 10.1038/srep07521
   Lone SN, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01543-7
   Lotfi M, 2023, STEM CELL REV REP, V19, P2576, DOI 10.1007/s12015-023-10585-3
   Malapelle U, 2012, J CLIN PATHOL, V65, P940, DOI 10.1136/jclinpath-2012-200773
   Mancini I, 2010, J MOL DIAGN, V12, P705, DOI 10.2353/jmoldx.2010.100018
   McKinzie PB, 2002, MUTAT RES-GEN TOX EN, V517, P209, DOI 10.1016/S1383-5718(02)00077-3
   Miranda RR, 2019, BIOMED REP, V11, P269, DOI 10.3892/br.2019.1254
   Morandi L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036084
   Morlan J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004584
   Morshedzadeh F, 2024, MOL BIOTECHNOL, V66, P179, DOI 10.1007/s12033-023-00724-z
   Nacchio M, 2020, J THORAC DIS, V12, P3836, DOI 10.21037/jtd.2020.01.19
   Nollau P, 1996, INT J CANCER, V66, P332, DOI 10.1002/(SICI)1097-0215(19960503)66:3<332::AID-IJC11>3.0.CO;2-D
   Norman RL, 2021, NANOSCALE, V13, P20401, DOI 10.1039/d1nr03180e
   Norman RL, 2020, RAPID COMMUN MASS SP, V34, DOI 10.1002/rcm.8657
   Ogino S, 2005, J MOL DIAGN, V7, P413, DOI 10.1016/S1525-1578(10)60571-5
   López SO, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040484
   Orue A, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163070
   Pepe F, 2019, J CLIN PATHOL, V72, P38, DOI 10.1136/jclinpath-2018-205386
   Petrelli F, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0650-4
   Poulin ML, 2016, CANCER RES, V76, DOI 10.1158/1538-7445.AM2016-1829
   Prix L, 2002, CLIN CHEM, V48, P428
   Rejali NA, 2018, CLIN CHEM, V64, P801, DOI 10.1373/clinchem.2017.282285
   Sarasqueta AF, 2011, J MOL DIAGN, V13, P199, DOI 10.1016/j.jmoldx.2010.10.006
   Seekhuntod S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0147672
   Shackelford Rodney E, 2012, Genes Cancer, V3, P459, DOI 10.1177/1947601912460547
   Shi XD, 2013, GENE, V530, P95, DOI 10.1016/j.gene.2013.07.060
   SUZUKI Y, 1990, ONCOGENE, V5, P1037
   TADA M, 1993, CANCER RES, V53, P2472
   Taylor CF, 2009, BIOCHEM SOC T, V37, P433, DOI 10.1042/BST0370433
   Timar J, 2020, CANCER METAST REV, V39, P1029, DOI 10.1007/s10555-020-09915-5
   Tsiatis AC, 2010, J MOL DIAGN, V12, P425, DOI 10.2353/jmoldx.2010.090188
   Vasef M. A., 2016, Diagnostic Pathology: Molecular Oncology, P2, DOI [10.1016/B978-0-323-37678-5., DOI 10.1016/B978-0-323-37678-5]
   Wang HY, 2013, J MOL DIAGN, V15, P62, DOI 10.1016/j.jmoldx.2012.08.007
   Winter G, 2011, GUIDELINES FOR MOLECULAR ANALYSIS IN ARCHIVE TISSUES, P143, DOI 10.1007/978-3-642-17890-0_27
   Yan FC, 2019, CELL BIOL TOXICOL, V35, P489, DOI 10.1007/s10565-019-09489-1
   Yang XG, 2023, FUNCT INTEGR GENOMIC, V23, DOI 10.1007/s10142-023-01117-w
   Ye P, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021171
   Zhou HF, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11010125
   Zopf A, 2015, BIOTECHNIQUES, V58, P126, DOI 10.2144/000114264
NR 79
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1438-793X
EI 1438-7948
J9 FUNCT INTEGR GENOMIC
JI Funct. Integr. Genomics
PD OCT
PY 2024
VL 24
IS 5
AR 183
DI 10.1007/s10142-024-01421-z
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA I2Y5X
UT WOS:001328966000003
PM 39367162
DA 2025-01-04
ER

PT J
AU Zhao, XR
   Wang, Y
   Yu, QF
   Yu, P
   Zheng, QY
   Yang, X
   Gao, D
AF Zhao, Xiaorui
   Wang, Yue
   Yu, Qiongfang
   Yu, Pei
   Zheng, Qiaoyu
   Yang, Xue
   Gao, Dian
TI Circular RNAs in gastrointestinal cancer: Current knowledge, biomarkers
   and targeted therapy (Review)
SO INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
LA English
DT Review
DE circular RNAs; miRNA sponges; gastrointestinal cancer; regulation;
   biomarkers
ID HEPATOCELLULAR-CARCINOMA PROGRESSION; EPITHELIAL-MESENCHYMAL TRANSITION;
   PROMOTES CELL-PROLIFERATION; HUMAN GASTRIC-CANCER; COLORECTAL-CANCER;
   TUMOR-GROWTH; 5-FLUOROURACIL RESISTANCE; SUPPRESSES MIGRATION;
   EXPRESSION PROFILE; EMERGING ROLES
AB Circular RNAs (circRNAs) are a type of endogenous non-coding RNAs that are connected at the 3' and 5' ends by exon or intron cyclization, which forms a covalently closed loop. They are stable, well conserved, exhibit specific expression in mammalian cells and can function as microRNA (miRNA or miR) sponges to regulate the target genes of miRNAs, which influences biological processes. Such as tumor proliferation, invasion, metastasis, apoptosis and tumor stage. circRNAs represent promising candidates for clinical diagnosis and treatment. In the present review, the biogenesis, classification and functions of circRNAs in tumors are briefly summarized and discussed. In addition, the participation of circRNAs in signal transduction pathways regulating gastrointestinal cancer cellular functions is highlighted.
C1 [Zhao, Xiaorui; Wang, Yue; Yu, Pei; Zheng, Qiaoyu; Yang, Xue; Gao, Dian] Nanchang Univ, Dept Pathogen Biol & Immunol, Med Coll, 461 Bayi Ave, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhao, Xiaorui; Wang, Yue; Yang, Xue] Nanchang Univ, Clin Med Coll 2, Nanchang 330006, Jiangxi, Peoples R China.
   [Yu, Qiongfang; Zheng, Qiaoyu] Nanchang Univ, Affiliated Hosp 2, Dept Gastroenterol & Hepatol, Nanchang 330006, Jiangxi, Peoples R China.
   [Yu, Pei] Nanchang Univ, Clin Med Coll 1, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University
RP Gao, D (corresponding author), Nanchang Univ, Dept Pathogen Biol & Immunol, Med Coll, 461 Bayi Ave, Nanchang 330006, Jiangxi, Peoples R China.
EM gaodian@ncu.edu.cn
RI GAO, DIAN/E-4494-2014
OI ZHAO, XIAORUI/0000-0002-5087-8490
FU National Natural Science Foundation of China [81760550, 81460462];
   Postgraduate Innovation Fund Project of Nanchang University [X2019168]
FX The current study was supported by grants from the National Natural
   Science Foundation of China (grant nos. 81760550 and 81460462), the
   Postgraduate Innovation Fund Project of Nanchang University (grant no.C
   X2019168).
CR Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788
   Aliahmad P, 2008, J EXP MED, V205, P245, DOI 10.1084/jem.20071944
   [Anonymous], 2020, CANCER CELL INT, DOI DOI 10.1186/s12935-020-01346-0
   [Anonymous], 2020, J CELL PHYSIOL 0121
   [Anonymous], 2020, CANC BIOL THER
   Benitez-Herreros J, 2015, RETINA-J RET VIT DIS, V35, P288, DOI 10.1097/IAE.0000000000000299
   Bian LJ, 2018, BIOCHEM BIOPH RES CO, V505, P346, DOI 10.1016/j.bbrc.2018.09.073
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Cai XP, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1093
   Cao CW, 2019, CANCER MANAG RES, V11, P9675, DOI 10.2147/CMAR.S213830
   Cao S, 2019, IMMUNOL CELL BIOL, V97, P218, DOI 10.1111/imcb.12213
   Cao YJ, 2021, DIGEST DIS SCI, V66, P1524, DOI 10.1007/s10620-020-06416-x
   Chang P, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180538
   Chen C, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01594-y
   Chen H, 2020, ONCOTARGETS THER, V13, P5939, DOI 10.2147/OTT.S253468
   Chen HY, 2020, ONCOTARGETS THER, V13, P423, DOI 10.2147/OTT.S233338
   Chen LH, 2019, BIOCHEM BIOPH RES CO, V517, P253, DOI 10.1016/j.bbrc.2019.07.065
   Chen LL, 2016, NAT REV MOL CELL BIO, V17, P205, DOI 10.1038/nrm.2015.32
   Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271
   Chen MS, 2020, CANCER MANAG RES, V12, P4899, DOI 10.2147/CMAR.S254185
   Chen PJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02757-7
   Chen S, 2018, ONCOL REP, V39, P2499, DOI 10.3892/or.2018.6372
   Chen ZL, 2020, ONCOTARGETS THER, V13, P4035, DOI 10.2147/OTT.S254133
   Chen ZM, 2020, DIGEST DIS SCI, V65, P2272, DOI 10.1007/s10620-019-05973-0
   Chen ZH, 2019, MOL THER-NUCL ACIDS, V18, P617, DOI 10.1016/j.omtn.2019.08.012
   Cheng J, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1582-8
   Dai XL, 2019, AGING-US, V11, P9689, DOI 10.18632/aging.102414
   Deng GX, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1487-2
   Deng ZW, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00357
   Ding DY, 2020, EUR REV MED PHARMACO, V24, P3004, DOI 10.26355/eurrev_202003_20665
   Ding K, 2018, BIOCHEM BIOPH RES CO, V503, P863, DOI 10.1016/j.bbrc.2018.06.088
   Ding Y, 2019, ONCOL LETT, V18, P5255, DOI 10.3892/ol.2019.10908
   Ding ZH, 2020, ANN HEPATOL, V19, P269, DOI 10.1016/j.aohep.2020.01.002
   Du HP, 2020, ONCOL LETT, V20, P266, DOI 10.3892/ol.2020.11547
   Du WB, 2019, ARTIF CELL NANOMED B, V47, P4120, DOI 10.1080/21691401.2019.1671857
   Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027
   Ebbesen KK, 2016, BBA-GENE REGUL MECH, V1859, P163, DOI 10.1016/j.bbagrm.2015.07.007
   Ebert MS, 2010, RNA, V16, P2043, DOI 10.1261/rna.2414110
   Fang G, 2018, BIOCHEM BIOPH RES CO, V504, P184, DOI 10.1016/j.bbrc.2018.08.152
   Fang L, 2018, CELL DEATH DIFFER, V25, P2195, DOI 10.1038/s41418-018-0115-6
   Feng WM, 2019, MOL THER-NUCL ACIDS, V18, P375, DOI 10.1016/j.omtn.2019.08.024
   Fu LY, 2017, ONCOTARGET, V8, P58405, DOI 10.18632/oncotarget.16881
   Fu LY, 2017, ONCOTARGET, V8, P43878, DOI 10.18632/oncotarget.16709
   Fu XY, 2020, J CANCER, V11, P3318, DOI 10.7150/jca.36500
   Gao J, 2020, MOL ONCOL, V14, P447, DOI 10.1002/1878-0261.12603
   Gao S, 2020, CELL SIGNAL, V72, DOI 10.1016/j.cellsig.2020.109621
   Geng HH, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151753
   Guan EC, 2020, BIOCHEM CELL BIOL, V98, P164, DOI 10.1139/bcb-2019-0079
   Guo JB, 2019, BIOCHEM BIOPH RES CO, V513, P812, DOI 10.1016/j.bbrc.2019.03.214
   Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z
   Guo X, 2020, MOL THER NUCL ACIDS, V21, P577, DOI 10.1016/j.omtn.2020.06.026
   Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270
   Harder JM, 2017, P NATL ACAD SCI USA, V114, pE3839, DOI 10.1073/pnas.1608769114
   He JH, 2018, CELL PHYSIOL BIOCHEM, V49, P1539, DOI 10.1159/000493457
   He YK, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2441-0
   He YR, 2020, ONCOTARGETS THER, V13, P1001, DOI 10.2147/OTT.S228216
   Hou LD, 2017, INT J IMMUNOPATH PH, V30, P1, DOI 10.1177/0394632016686985
   Hou Y, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112142
   Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883
   Hu B, 2021, CANCER BIOTHER RADIO, V36, P45, DOI 10.1089/cbr.2019.3291
   Hu KF, 2020, MOL CELL PROBE, V52, DOI 10.1016/j.mcp.2020.101562
   Hu ZY, 2017, J BIOL CHEM, V292, P18062, DOI 10.1074/jbc.M116.764795
   Huang EM, 2020, EPIGENOMICS-UK, V12, P587, DOI 10.2217/epi-2019-0404
   Huang GL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131225
   Huang XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01213-6
   Huang X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1098-8
   Huang YS, 2017, MOL MED REP, V16, P2469, DOI 10.3892/mmr.2017.6916
   Jeck WR, 2014, NAT BIOTECHNOL, V32, P453, DOI 10.1038/nbt.2890
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Jia BL, 2020, ONCOTARGETS THER, V13, P4893, DOI 10.2147/OTT.S251300
   Jia CC, 2021, J CELL PHYSIOL, V236, P1252, DOI 10.1002/jcp.29931
   Jian XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1134-8
   Jiang WD, 2018, BIOCHEM BIOPH RES CO, V500, P211, DOI 10.1016/j.bbrc.2018.04.041
   Jin JL, 2020, AGING-US, V12, P11623, DOI 10.18632/aging.103324
   Jin YD, 2019, EUR REV MED PHARMACO, V23, P3311, DOI 10.26355/eurrev_201904_17693
   Kakaei F, 2015, UPDATES SURG, V67, P339, DOI 10.1007/s13304-015-0328-x
   Kim Y, 2020, CANCER RES TREAT, V52, P481, DOI 10.4143/crt.2019.370
   Kong S, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00878
   Kulcheski FR, 2016, J BIOTECHNOL, V238, P42, DOI 10.1016/j.jbiotec.2016.09.011
   Lan XY, 2019, BIOCHEM BIOPH RES CO, V516, P357, DOI 10.1016/j.bbrc.2019.06.044
   Lee KH, 2009, PANCREATOLOGY, V9, P293, DOI 10.1159/000186051
   Lee WS, 2012, SURG ONCOL, V21, P45, DOI 10.1016/j.suronc.2010.10.003
   Legnini I, 2017, MOL CELL, V66, P22, DOI 10.1016/j.molcel.2017.02.017
   Li B, 2017, INT J ONCOL, V50, P753, DOI 10.3892/ijo.2017.3846
   Li BJ, 2020, GENE, V750, DOI 10.1016/j.gene.2020.144753
   Li Chang, 2020, Cancer Cell Int, V20, P84, DOI 10.1186/s12935-020-01168-0
   Li C, 2020, CANCER MED-US, V9, P6710, DOI 10.1002/cam4.3332
   Li F, 2015, ONCOTARGET, V6, P6001, DOI 10.18632/oncotarget.3469
   Li G, 2018, J CELL PHYSL, V234, P3020
   Li HB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6017-2
   Li HB, 2018, J CELL BIOCHEM, V119, P9543, DOI 10.1002/jcb.27271
   Li H, 2021, DIGEST DIS SCI, V66, P2261, DOI 10.1007/s10620-020-06516-8
   Li HM, 2019, WIRES RNA, V10, DOI 10.1002/wrna.1538
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li J, 2020, J CELL MOL MED, V24, P5152, DOI 10.1111/jcmm.15162
   Li J, 2017, ONCOTARGETS THER, V10, P3521, DOI 10.2147/OTT.S136347
   Li J, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.749
   Li MF, 2018, BIOMED PHARMACOTHER, V99, P848, DOI 10.1016/j.biopha.2018.01.150
   Li PF, 2017, BRIT J CANCER, V116, P626, DOI 10.1038/bjc.2016.451
   Li QQ, 2019, GENE, V711, DOI 10.1016/j.gene.2019.143953
   Li RC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0852-y
   Li SB, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2616-8
   Li TW, 2018, J MOL MED, V96, P85, DOI 10.1007/s00109-017-1600-y
   Li WL, 2020, DNA CELL BIOL, V39, P118, DOI 10.1089/dna.2019.5139
   Li X, 2019, EUR REV MED PHARMACO, V23, P555, DOI 10.26355/eurrev_201902_16868
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Li XM, 2018, J PATHOL, V246, P166, DOI 10.1002/path.5125
   Li XS, 2019, BIOCHEM BIOPH RES CO, V511, P926, DOI 10.1016/j.bbrc.2019.03.010
   Li Y, 2020, CLIN EXP PHARMACOL P, V47, P1291, DOI 10.1111/1440-1681.13273
   Li YT, 2020, BIOMED PHARMACOTHER, V127, DOI 10.1016/j.biopha.2020.110219
   Li ZX, 2019, CLIN EXP MED, V19, P23, DOI 10.1007/s10238-018-0535-0
   Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959
   Li ZQ, 2020, AGING-US, V12, P2485, DOI 10.18632/aging.102756
   Li ZH, 2019, CLIN CHIM ACTA, V492, P37, DOI 10.1016/j.cca.2019.02.001
   Liang L, 2020, ONCOTARGETS THER, V13, P6279, DOI 10.2147/OTT.S221633
   Liang M, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12661
   Lin GW, 2019, ONCOL LETT, V17, P3537, DOI 10.3892/ol.2019.9970
   Lin J, 2020, MOL THER NUCL ACIDS, V21, P121, DOI 10.1016/j.omtn.2020.05.007
   Lin S, 2020, FASEB J, V34, P8187, DOI 10.1096/fj.201903246R
   Lin TY, 2019, CANCER MANAG RES, V11, P9133, DOI 10.2147/CMAR.S222716
   Lin XM, 2018, MED SCI MONIT BASIC, V24, P70, DOI 10.12659/MSMBR.909737
   Lin Y, 2020, ONCOTARGETS THER, V13, P4509, DOI 10.2147/OTT.S240261
   Liu CF, 2019, HUM GENE THER CL DEV, V30, P152, DOI 10.1089/humc.2019.079
   Liu HY, 2018, BIOCHEM BIOPH RES CO, V503, P2659, DOI 10.1016/j.bbrc.2018.08.020
   Liu J, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01256-1
   Liu JJ, 2020, ONCOTARGETS THER, V13, P3987, DOI 10.2147/OTT.S239789
   Liu JQ, 2019, AGING-US, V11, P12412, DOI 10.18632/aging.102580
   Liu L, 2019, CELL CYCLE, V18, P2939, DOI 10.1080/15384101.2019.1664223
   Liu PL, 2020, EXP CELL RES, V394, DOI 10.1016/j.yexcr.2020.112141
   Liu RH, 2018, GASTROENTEROLOGY, V154, P637, DOI 10.1053/j.gastro.2017.09.045
   Liu TL, 2018, CANCER RES TREAT, V50, P1396, DOI 10.4143/crt.2017.537
   Liu W, 2021, CANCER BIOTHER RADIO, V36, P863, DOI 10.1089/cbr.2019.3472
   Liu Z, 2019, EUR REV MED PHARMACO, V23, P9411, DOI 10.26355/eurrev_201911_19433
   Liu ZJ, 2020, J CELL BIOCHEM, V121, P2354, DOI 10.1002/jcb.29458
   Liu Z, 2018, BIOCHEM BIOPH RES CO, V503, P2370, DOI 10.1016/j.bbrc.2018.06.163
   Liu ZG, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2089-9
   Lu C, 2020, J CELL PHYSIOL, V235, P2273, DOI 10.1002/jcp.29135
   Lu CX, 2020, ARCH BIOCHEM BIOPHYS, V689, DOI 10.1016/j.abb.2020.108434
   Lu J, 2020, J CELL PHYSIOL, V235, P6287, DOI 10.1002/jcp.29556
   Lu J, 2020, CANCER LETT, V471, P38, DOI 10.1016/j.canlet.2019.11.038
   Lu J, 2019, BIOCHEM BIOPH RES CO, V512, P29, DOI 10.1016/j.bbrc.2019.02.111
   Lu XH, 2019, MED SCI MONITOR, V25, P6872, DOI 10.12659/MSM.916064
   Luo Z, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01203-8
   Ma Y, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1122-5
   Ma YF, 2020, LIFE SCI, V259, DOI 10.1016/j.lfs.2020.118168
   Ma ZF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2514-0
   Mao WP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1136-9
   McNamara MG, 2013, CURR OPIN ONCOL, V25, P425, DOI 10.1097/CCO.0b013e3283620fd8
   Meng J, 2018, CANCER RES, V78, P4150, DOI 10.1158/0008-5472.CAN-17-3009
   Mo WL, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4030826
   Namlos HM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0048086
   Pamudurti NR, 2017, MOL CELL, V66, P9, DOI 10.1016/j.molcel.2017.02.021
   Pan HL, 2019, J CELL BIOCHEM, V120, P11350, DOI 10.1002/jcb.28411
   Pan ZH, 2019, AGING-US, V11, P11937, DOI 10.18632/aging.102519
   Pei FL., 2020, J BIOCHEM, V167, P55, DOI [DOI 10.1093/jb/mvz078, 10.1093/jb/mvz078]
   Peng L, 2017, ONCOTARGET, V8, P808, DOI 10.18632/oncotarget.13656
   Piwecka M, 2017, SCIENCE, V357, DOI 10.1126/science.aam8526
   Pu J, 2024, J CELL MOL MED, V28, DOI 10.1111/jcmm.15010
   Qi SX, 2019, WORLD J GASTROENTERO, V25, P1964, DOI 10.3748/wjg.v25.i16.1964
   Qian L, 2018, BBA-REV CANCER, V1870, P247, DOI 10.1016/j.bbcan.2018.06.002
   Qin ML, 2016, CANCER BIOMARK, V16, P161, DOI 10.3233/CBM-150552
   Quan JZ, 2020, J BIOCHEM MOL TOXIC, V34, DOI 10.1002/jbt.22458
   Ren CF, 2020, BIOL CHEM, V401, P487, DOI 10.1515/hsz-2019-0350
   Ren TJ, 2020, EUR REV MED PHARMACO, V24, P1743, DOI 10.26355/eurrev_202002_20351
   Ren XX, 2017, ONCOL LETT, V14, P7016, DOI 10.3892/ol.2017.7118
   Sang MX, 2018, CANCER LETT, V426, P37, DOI 10.1016/j.canlet.2018.03.049
   SANGER HL, 1976, P NATL ACAD SCI USA, V73, P3852, DOI 10.1073/pnas.73.11.3852
   Shang AQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01235-0
   Shang XC, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003811
   Shao YF, 2017, CANCER MED-US, V6, P1173, DOI 10.1002/cam4.1055
   Shen P, 2018, J PHYS D APPL PHYS, V51, DOI 10.1088/1361-6463/aaa0ec
   Shen T, 2019, ARTIF CELL NANOMED B, V47, P4038, DOI 10.1080/21691401.2019.1669620
   Song CL, 2019, J CELL PHYSIOL, V234, P2460, DOI 10.1002/jcp.26764
   Song H, 2019, EUR REV MED PHARMACO, V23, P8274, DOI 10.26355/eurrev_201910_19138
   Song H, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.109941
   Song LS, 2020, MAR PETROL GEOL, V114, DOI 10.1016/j.marpetgeo.2020.104226
   Su BB, 2012, WORLD J GASTROENTERO, V18, P2121, DOI 10.3748/wjg.v18.i17.2121
   Su HF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0977-7
   Su Y, 2019, AGING-US, V11, P3362, DOI 10.18632/aging.101988
   Sun B, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23215
   Sun HD, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27837-9
   Sun HD, 2018, CANCER BIOMARK, V21, P299, DOI 10.3233/CBM-170379
   Sun J, 2020, ONCOTARGETS THER, V13, P6315, DOI 10.2147/OTT.S255485
   Sun Q, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01287-8
   Sung YN, 2020, CANCER RES TREAT, V52, P455, DOI 10.4143/crt.2019.271
   Tan AC, 2019, ARCH BIOCHEM BIOPHYS, V661, P196, DOI 10.1016/j.abb.2018.11.020
   Tang WT, 2017, ONCOTARGETS THER, V10, P2045, DOI 10.2147/OTT.S131597
   Tian F, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12635
   Tu FL, 2020, AM J TRANSL RES, V12, P281
   Wang CJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-616
   Wang JJ, 2020, BIOCHEM BIOPH RES CO, V527, P503, DOI 10.1016/j.bbrc.2020.03.165
   Wang JY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1119-0
   Wang N, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109876
   Wang Q, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152507
   Wang QH, 2018, J MOL NEUROSCI, V65, P546, DOI 10.1007/s12031-018-1125-z
   Wang S, 2019, P ACM COMPUT GRAPH I, V2, P18
   Wang S, 2019, BIOMED ENG ONLINE, V18, DOI 10.1186/s12938-019-0739-x
   Wang T, 2017, CANCER LETT, V387, P77, DOI 10.1016/j.canlet.2016.03.045
   Wang W, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109517
   Wang XY, 2020, MOL ONCOL, V14, P539, DOI 10.1002/1878-0261.12629
   Wang X, 2020, J CELL MOL MED, V24, P9908, DOI 10.1111/jcmm.15590
   Wang XB, 2020, ONCOTARGETS THER, V13, P1941, DOI 10.2147/OTT.S240642
   Wang Y, 2020, AGING-US, V12, P9793, DOI 10.18632/aging.103244
   Wang Y, 2018, BIOMED PHARMACOTHER, V102, P1188, DOI 10.1016/j.biopha.2018.03.085
   Wang YX, 2020, ONCOTARGETS THER, V13, P4533, DOI 10.2147/OTT.S244358
   Wang YG, 2019, CANCER LETT, V460, P128, DOI 10.1016/j.canlet.2019.06.007
   Wang YM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0598-7
   Wei CC, 2017, CHEMOSPHERE, V175, P228, DOI 10.1016/j.chemosphere.2017.02.042
   Wei WY, 2020, CANCER MANAG RES, V12, P15, DOI 10.2147/CMAR.S219307
   Wei XL, 2020, CELL CYCLE, V19, P817, DOI 10.1080/15384101.2020.1731945
   Wei YP, 2020, HEPATOLOGY, V71, P130, DOI 10.1002/hep.30795
   Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541
   Wilusz JE, 2018, WIRES RNA, V9, DOI 10.1002/wrna.1478
   Wu HB, 2020, AM J TRANSL RES, V12, P2554
   Wu JM, 2020, CELL BIOCHEM FUNCT, V38, P932, DOI 10.1002/cbf.3519
   Wu LG, 2019, EXP MOL PATHOL, V110, DOI 10.1016/j.yexmp.2019.104273
   Wu Q, 2020, BIOCHEM BIOPH RES CO, V521, P303, DOI 10.1016/j.bbrc.2019.10.117
   Wu Y, 2020, CLIN EXP PHARMACOL P, V47, P1283, DOI 10.1111/1440-1681.13269
   Xia TF, 2020, CANCER MED-US, V9, P4299, DOI 10.1002/cam4.3057
   Xiao H, 2021, J CELL PHYSIOL, V236, P2572, DOI 10.1002/jcp.30015
   Xie HJ, 2016, ONCOTARGET, V7, P26680, DOI 10.18632/oncotarget.8589
   Xie MY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01208-3
   Xiong W, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8421614
   [熊莹 Xiong Ying], 2017, [中国肿瘤临床, Chinese Journal of Clinical Oncology], V44, P778
   Xu LL, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1041-2
   Xu LL, 2017, J CANCER RES CLIN, V143, P17, DOI 10.1007/s00432-016-2256-7
   Xu WG, 2020, INT J MED SCI, V17, P1569, DOI 10.7150/ijms.46261
   Xu XW, 2017, ONCOTARGET, V8, P91674, DOI 10.18632/oncotarget.21748
   Xu ZQ, 2020, IUBMB LIFE, V72, P426, DOI 10.1002/iub.2202
   Yan Y, 2020, BIOCHEM BIOPH RES CO, V524, P839, DOI 10.1016/j.bbrc.2020.01.055
   Yang BR, 2020, J CELL MOL MED, V24, P3431, DOI 10.1111/jcmm.15019
   Yang J, 2020, MOL MED REP, V21, P2395, DOI 10.3892/mmr.2020.11069
   Yang W, 2020, EUR REV MED PHARMACO, V24, P2347, DOI 10.26355/eurrev_202003_20501
   Yang XY, 2019, J CELL PHYSIOL, V234, P21937, DOI 10.1002/jcp.28757
   Yang X, 2019, DIGEST LIVER DIS, V51, P1446, DOI 10.1016/j.dld.2019.04.012
   Yang YB, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx166
   Yang Y, 2017, CELL RES, V27, P626, DOI 10.1038/cr.2017.31
   Yang ZF, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1150-1
   Yao ZC, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2176-y
   Yin WZ, 2020, ONCOTARGETS THER, V13, P3689, DOI 10.2147/OTT.S238338
   Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012
   Yu L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158347
   Yu X, 2020, TRANSBOUND EMERG DIS, V67, P1697, DOI 10.1111/tbed.13604
   Yu XT, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01623-y
   Yu XY, 2020, GENE, V748, DOI 10.1016/j.gene.2020.144678
   Yuan Y, 2018, BIOCHEM BIOPH RES CO, V503, P870, DOI 10.1016/j.bbrc.2018.06.089
   Zang HL, 2020, CANCER MANAG RES, V12, P3457, DOI 10.2147/CMAR.S244024
   Zeng KX, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0454-8
   Zeng YJ, 2017, INT J MOL MED, V40, P1818, DOI 10.3892/ijmm.2017.3189
   Zhang HB, 2019, ARTIF CELL NANOMED B, V47, P308, DOI 10.1080/21691401.2018.1553787
   Zhang J, 2019, J CELL BIOCHEM, V120, P3027, DOI 10.1002/jcb.27355
   Zhang J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0719-3
   Zhang J, 2019, J CELL BIOCHEM, V120, P9487, DOI 10.1002/jcb.28224
   Zhang L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2707-6
   Zhang LW, 2020, BIOCHEM BIOPH RES CO, V525, P841, DOI 10.1016/j.bbrc.2020.02.100
   Zhang ML, 2018, ONCOGENE, V37, P1805, DOI 10.1038/s41388-017-0019-9
   Zhang MC, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0569-5
   Zhang PF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1031-1
   Zhang Q, 2019, WORLD J GASTROENTERO, V25, P5300, DOI 10.3748/wjg.v25.i35.5300
   Zhang W, 2020, BIOSCI REP, V40
   Zhang XW, 2018, ONCOTARGETS THER, V11, P2853, DOI 10.2147/OTT.S158008
   Zhang X, 2014, BIOCHEM BIOPH RES CO, V443, P1078, DOI 10.1016/j.bbrc.2013.12.095
   Zhang XO, 2014, CELL, V159, P134, DOI 10.1016/j.cell.2014.09.001
   Zhang XY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01178-y
   Zhang XL, 2017, CELL BIOL INT, V41, P1056, DOI 10.1002/cbin.10826
   Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017
   Zhang Y, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23428
   Zhang Y, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0624-z
   Zhang YH, 2020, ONCOTARGETS THER, V13, P5165, DOI 10.2147/OTT.S242001
   Zhang ZJ, 2020, EUR REV MED PHARMACO, V24, P2387, DOI 10.26355/eurrev_202003_20506
   Zhang Z, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1106-5
   Zhang ZR, 2018, EBIOMEDICINE, V34, P267, DOI 10.1016/j.ebiom.2018.07.036
   Zhang ZW, 2017, BIOMED PHARMACOTHER, V95, P1644, DOI 10.1016/j.biopha.2017.09.052
   Zhang ZZ, 2020, GASTRIC CANCER, V23, P437, DOI 10.1007/s10120-019-01018-7
   Zhao MY, 2020, J CELL BIOCHEM, V121, P4440, DOI 10.1002/jcb.29672
   Zhao ZJ, 2017, RNA BIOL, V14, P514, DOI 10.1080/15476286.2015.1122162
   Zheng B, 2019, ONCOL LETT, V18, P6836, DOI 10.3892/ol.2019.11003
   Zheng HF, 2019, CANCER MANAG RES, V11, P443, DOI 10.2147/CMAR.S189338
   Zheng QP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11215
   Zheng TT, 2019, BIOMED PHARMACOTHER, V117, DOI 10.1016/j.biopha.2019.109117
   Zheng X, 2020, EUR REV MED PHARMACO, V24, P4190, DOI 10.26355/eurrev_202004_20999
   Zhong D, 2019, INT J BIOL MARKER, V34, P284, DOI 10.1177/1724600819872765
   Zhong SL, 2018, EPIGENOMICS-UK, V10, P1301, DOI 10.2217/epi-2017-0173
   Zhou C, 2020, MOL THER, V28, P914, DOI 10.1016/j.ymthe.2019.12.008
   Zhu MC, 2017, BIOMED PHARMACOTHER, V88, P138, DOI 10.1016/j.biopha.2016.12.097
   Zhu Q, 2018, BIOCHEM BIOPH RES CO, V497, P626, DOI 10.1016/j.bbrc.2018.02.119
   Zhu YX, 2019, PLANTS-BASEL, V8, DOI 10.3390/plants8060147
   Zhu ZL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1054-7
   Zou HB, 2019, CELL CYCLE, V18, P2398, DOI 10.1080/15384101.2019.1618120
NR 289
TC 6
Z9 6
U1 2
U2 21
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1107-3756
EI 1791-244X
J9 INT J MOL MED
JI Int. J. Mol. Med.
PD NOV
PY 2020
VL 46
IS 5
BP 1611
EP 1632
DI 10.3892/ijmm.2020.4731
PG 22
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA PA0HX
UT WOS:000595299000003
PM 33000182
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Wang, T
   Chen, S
   Wang, ZL
   Li, SY
   Fei, XC
   Wang, T
   Zhang, MJ
AF Wang, Tao
   Chen, Shuo
   Wang, Ziliang
   Li, Siyu
   Fei, Xichang
   Wang, Tong
   Zhang, Mingjun
TI KIRREL promotes the proliferation of gastric cancer cells and
   angiogenesis through the PI3K/AKT/mTOR pathway
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE angiogenesis; gastric cancer; KIRREL; PI3K/AKT/mTOR; targeted therapy
ID METASTATIC COLORECTAL-CANCER; DOUBLE-BLIND; TUMOR ANGIOGENESIS;
   SIGNALING PATHWAY; 1ST-LINE THERAPY; PHASE-II; PLACEBO; RAMUCIRUMAB;
   SURVIVAL; MULTICENTER
AB Anti-angiogenesis is a promising therapeutic strategy for delaying tumour progression that offers, new hope for gastric cancer targeted therapy. The purpose of this study was to investigate the precise mechanism by which Kin of IRRE-like protein 1 (KIRREL) contributes to the development of gastric cancer, particularly in terms of tumour angiogenesis. Differential expression of KIRREL in tissues and cells was detected using quantitative real-time polymerase chain reaction, western blotting and immunohistochemistry. A bioinformatics analysis was conducted to screen for the function and pathway enrichment of KIRREL in gastric cancer. Lentivirus-induced KIRREL silencing in SNU-5 cells and lentivirus-induced KIRREL overexpression in AGS cells were used to study the effect of KIRREL on the proliferation, cell cycle and angiogenesis of gastric cancer cells. Moreover, the expressions of PI3K, P-PI3K, AKT, P-AKT, mTOR, P-mTOR, HIF-1 alpha and VEGF were also detected. Gastric cancer tissues and cells had high levels of KIRREL expression, which is associated with the proliferation, cell cycle and angiogenesis of gastric cancer cells. After silencing and overexpressing KIRREL in SNU-5 and AGS cells, respectively, the proliferation and angiogenesis of SNU-5 cells were inhibited, while the proliferation and angiogenesis of AGS cells were promoted. According to a bioinformatics analysis of the KIRREL gene, angiogenesis regulation and the PI3K/AKT pathway were highly connected. The PI3K/AKT/mTOR pathway was repressed and stimulated by KIRREL silencing and overexpression, respectively. IGF-1, an AKT agonist, and LY294002, an inhibitor, reversed the effects of KIRREL silencing and overexpression on the PI3K/AKT/mTOR pathway and on gastric cancer cell proliferation and angiogenesis. KIRREL may mediate the proliferation and angiogenesis of gastric cancer cells through the PI3K/AKT/mTOR signalling pathway. These findings could help in the further development of potential anti-angiogenesis targets.
C1 [Wang, Tao; Chen, Shuo; Wang, Ziliang; Li, Siyu; Fei, Xichang; Zhang, Mingjun] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei, Anhui, Peoples R China.
   [Wang, Tong] Anhui Med Univ, Dept Gen Practice, Affiliated Hosp 2, Hefei, Anhui, Peoples R China.
   [Zhang, Mingjun] Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei 230601, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University
RP Zhang, MJ (corresponding author), Anhui Med Univ, Dept Oncol, Affiliated Hosp 2, Hefei 230601, Anhui, Peoples R China.
EM zhangmjayd@126.com
RI Wang, Tong/A-2750-2011
OI Wang, Tong/0000-0002-1828-5935; Wang, Tao/0000-0002-0578-0750
FU The authors thank TCGA and GEPIA databases for providing valuable data
   sets. The authors also thank the Natural Science Foundation of Anhui for
   its financial support.; Natural Science Foundation of Anhui
FX The authors thank TCGA and GEPIA databases for providing valuable data
   sets. The authors also thank the Natural Science Foundation of Anhui for
   its financial support.
CR Ahmad S, 2015, THROMB HAEMOSTASIS, V113, P329, DOI 10.1160/TH14-01-0002
   Albini A, 2012, NAT REV CLIN ONCOL, V9, P498, DOI 10.1038/nrclinonc.2012.120
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Cao W, 2021, CHINESE MED J-PEKING, V134, P783, DOI 10.1097/CM9.0000000000001474
   Chan MMK, 2015, BIOL-TARGETS THER, V9, P93, DOI 10.2147/BTT.S62777
   Chen KX, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153000
   Chen Q, 2019, J BUON, V24, P2499
   Chen Z, 2020, DRUG TODAY, V56, P469, DOI 10.1358/dot.2020.56.7.3112071
   Chung HC, 2021, FUTURE ONCOL, V17, P491, DOI 10.2217/fon-2020-0737
   Donoviel DB, 2001, MOL CELL BIOL, V21, P4829, DOI 10.1128/MCB.21.14.4829-4836.2001
   Ferlay J, 2019, INT J CANCER, V144, P1941, DOI 10.1002/ijc.31937
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Fontana E, 2014, INDIAN J MED PAEDIAT, V35, P253, DOI 10.4103/0971-5851.144985
   Gerke P, 2006, J COMP NEUROL, V498, P466, DOI 10.1002/cne.21064
   Ghafouri S, 2021, WORLD J UROL, V39, P741, DOI 10.1007/s00345-020-03213-z
   Gimenez-Xavier P, 2017, MOL CANCER THER, V16, P1366, DOI 10.1158/1535-7163.MCT-17-0104
   Haas NB, 2016, LANCET, V387, P2008, DOI 10.1016/S0140-6736(16)00559-6
   Hickey MM, 2006, CURR TOP DEV BIOL, V76, P217, DOI 10.1016/S0070-2153(06)76007-0
   Huber TB, 2003, MOL CELL BIOL, V23, P4917, DOI 10.1128/MCB.23.14.4917-4928.2003
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jin ZJ, 2017, CELL PHYSIOL BIOCHEM, V44, P1471, DOI 10.1159/000485583
   Johnston FM, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0820-4
   Joshi SS, 2021, CA-CANCER J CLIN, V71, P264, DOI 10.3322/caac.21657
   Khan KA, 2018, NAT REV CLIN ONCOL, V15, P310, DOI 10.1038/nrclinonc.2018.9
   Kuczynski EA, 2019, NAT REV CLIN ONCOL, V16, P469, DOI 10.1038/s41571-019-0181-9
   Li GZ, 2022, JAMA SURG, V157, P446, DOI 10.1001/jamasurg.2022.0182
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Lundgren S, 2019, BIOMARK RES, V7, DOI 10.1186/s40364-018-0153-8
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Martini M, 2014, ANN MED, V46, P372, DOI 10.3109/07853890.2014.912836
   Moehler M, 2011, EUR J CANCER, V47, P1511, DOI 10.1016/j.ejca.2011.04.006
   Nihalani D, 2019, J BIOL CHEM, V294, P10104, DOI 10.1074/jbc.RA119.008362
   Peng Y, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.819128
   Qi SY, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23136934
   Rajabi M, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020034
   Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075
   Saisana M, 2022, GASTRIC CANCER, V25, P107, DOI 10.1007/s10120-021-01236-y
   Saisana M, 2016, ONCOTARGET, V7, P54445, DOI 10.18632/oncotarget.10642
   Sellin L, 2002, FASEB J, V16, P115, DOI 10.1096/fj.02-0242fje
   Semenza GL, 2012, CELL, V148, P399, DOI 10.1016/j.cell.2012.01.021
   Sever R, 2015, CSH PERSPECT MED, V5, DOI 10.1101/cshperspect.a006098
   Sexton RE, 2020, CANCER METAST REV, V39, P1179, DOI 10.1007/s10555-020-09925-3
   Shan F, 2016, CANCER LETT, V380, P598, DOI 10.1016/j.canlet.2015.12.023
   Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948
   Solanki AK, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101079
   Song ZY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317714626
   Sun WJ, 2010, J CLIN ONCOL, V28, P2947, DOI 10.1200/JCO.2009.27.7988
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4
   Teleanu RI, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010084
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9
   Walther C, 2015, LAB INVEST, V95, P1071, DOI 10.1038/labinvest.2015.83
   Wang C, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2121779119
   Wang FH, 2021, CANCER COMMUN, V41, P747, DOI 10.1002/cac2.12193
   Wang Q, 2017, MOL MED REP, V16, P901, DOI 10.3892/mmr.2017.6635
   Weavers H, 2009, NATURE, V457, P322, DOI 10.1038/nature07526
   Wei ZW, 2015, CANCER LETT, V359, P335, DOI 10.1016/j.canlet.2015.01.033
   Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6
   Wu YL, 2017, ONCOTARGET, V8, P1262, DOI 10.18632/oncotarget.13605
   Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075
   Zhang MJ, 2018, MED SCI MONITOR, V24, P2711, DOI 10.12659/MSM.910386
   Zhu AX, 2015, LANCET ONCOL, V16, P859, DOI 10.1016/S1470-2045(15)00050-9
NR 64
TC 4
Z9 4
U1 3
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD JAN
PY 2024
VL 28
IS 1
DI 10.1111/jcmm.18020
EA NOV 2023
PG 16
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA JD5D6
UT WOS:001094664000001
PM 37909722
OA gold
DA 2025-01-04
ER

PT J
AU Khan, FA
   Akhtar, S
   Almohazey, D
   Alomari, M
   Almofty, SA
   Eliassari, A
AF Khan, Firdos Alam
   Akhtar, Sultan
   Almohazey, Dana
   Alomari, Munthar
   Almofty, Sarah Ameen
   Eliassari, Abdelhamid
TI Fluorescent magnetic submicronic polymer (FMSP) nanoparticles induce
   cell death in human colorectal carcinoma cells
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Fluorescent magnetic submicronic polymer nanoparticles; colon cancer; in
   vitro cell culture; anticancer; cytotoxicity
ID ZINC-OXIDE NANOPARTICLES; IN-VITRO; OXIDATIVE STRESS; TARGETED THERAPY;
   CANCER CELLS; COLON-CANCER; PARTICLES; APOPTOSIS; PROLIFERATION;
   RESPONSES
AB Nanoparticles have many advantages such as high biocompatibility, bioavailability and effective therapeutic capabilities. The aim of the present study is to examine whether fluorescent magnetic submicronic polymer nanoparticles (FMSP-nanoparticles) have any impact on human colorectal cancer cells. In the present study, we have tested FMSP-nanoparticles with an average size of 100-200nm on human colorectal carcinoma cells (HCT-116) to check their cytotoxic and anti-cancer capabilities. The effects of FMSP-nanoparticles on cancer cells were observed after 6h, 24h and 48 h intervals. The response of FMSP-nanoparticles-treated cells was evaluated by Trypan Blue, 4lue-diamidino-2-phenylindole (DAPI) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Our MTT analysis results revealed that FMSP-nanoparticles produced dose-dependent effects on cancer cells, FMSP-nanoparticles with dose of 1.25 mu g/mL did not decrease cell survivability, whereas dosages of 12.5 mu g/mL and 50 mu g/mL respectively showed 23.59% and 59.47% decrease in the cancer cell survivability. In conclusion, our results demonstrate FMSP-nanoparticles have a potential anti-cancer capability and hold a great promise for colon cancer treatments.
C1 [Khan, Firdos Alam; Almohazey, Dana; Alomari, Munthar; Almofty, Sarah Ameen] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Dept Stem Cell Biol, Post Box 1982, Dammam 31441, Saudi Arabia.
   [Akhtar, Sultan] Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Dept Biophys, Dammam, Saudi Arabia.
   [Eliassari, Abdelhamid] Univ Lyon, Lyon, France.
   [Eliassari, Abdelhamid] Univ Lyon 1, LAGEP CPE, CNRS, UMR 5007, Villeurbanne, France.
C3 Imam Abdulrahman Bin Faisal University; Imam Abdulrahman Bin Faisal
   University; Universite Claude Bernard Lyon 1; Centre National de la
   Recherche Scientifique (CNRS); CNRS - Institute for Engineering &
   Systems Sciences (INSIS)
RP Khan, FA (corresponding author), Imam Abdulrahman Bin Faisal Univ, Inst Res & Med Consultat, Dept Stem Cell Biol, Post Box 1982, Dammam 31441, Saudi Arabia.
EM fakhan@iau.edu.sa
RI Almohazey, Dana/D-8048-2017; Alomari, Munther/T-1955-2018; Akhtar,
   Sultan/B-6069-2015; Alomari, Munther/D-2126-2018; KHAN,
   FIRDOS/A-5190-2017; Almofty, Sarah/P-1770-2016
OI Alomari, Munther/0000-0001-5705-2926; KHAN, FIRDOS/0000-0002-6892-1530;
   Almofty, Sarah/0000-0002-2271-8262
FU Deanship of Scientific Research, Imam Abdulrahman Bin Faisal University,
   Dammam, Saudi Arabia [2018-004-IRMC]
FX Financial support received from Deanship of Scientific Research, Imam
   Abdulrahman Bin Faisal University, Dammam, Saudi Arabia (Grant Number:
   2018-004-IRMC).
CR Afrimzon E, 2008, CLIN EXP METASTAS, V25, P213, DOI 10.1007/s10585-007-9135-1
   Aftab S, 2018, INT J PHARMACEUT, V540, P132, DOI 10.1016/j.ijpharm.2018.02.007
   [Anonymous], CANC STAT FACTS OV C
   [Anonymous], CANC PROGR REP
   Asif M, 2017, CHIN J NAT MEDICINES, V15, P505, DOI 10.1016/S1875-5364(17)30076-6
   Aswathanarayan JB, 2018, ARTIF CELL NANOMED B, V46, P1444, DOI 10.1080/21691401.2017.1373655
   Barar J, 2014, BIOIMPACTS, V4, P3, DOI 10.5681/bi.2014.011
   Cain K, 2003, DRUG METAB REV, V35, P337, DOI 10.1081/DMR-120026497
   Chen H, 2013, INT J PHARMACEUT, V448, P142, DOI 10.1016/j.ijpharm.2013.03.032
   Darfarin G, 2018, ARTIF CELL NANOMED B, V46, P836, DOI 10.1080/21691401.2018.1470526
   Fan YX, 2017, EXP THER MED, V13, P989, DOI 10.3892/etm.2017.4079
   Gottlieb E, 2003, CELL DEATH DIFFER, V10, P709, DOI 10.1038/sj.cdd.4401231
   Govindaiah P, 2010, J COLLOID INTERF SCI, V343, P484, DOI 10.1016/j.jcis.2009.11.059
   Grafton MMG, 2011, INTEGR BIOL-UK, V3, P451, DOI [10.1039/c0ib00132e, 10.1039/c0ib00132c]
   Hanley C, 2008, NANOTECHNOLOGY, V19, DOI 10.1088/0957-4484/19/29/295103
   He Y, 2016, INT J NANOMED, V11, DOI 10.2147/IJN.S103695
   Huang H, 2002, BIOPHYS J, V82, P2211, DOI 10.1016/S0006-3495(02)75567-7
   Jahanfar F, 2016, ADV PHARM BULL, V6, P367, DOI 10.15171/apb.2016.048
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jiang HP, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-017-2302-4
   Kaewsaneha C, 2014, J COLLOID INTERF SCI, V424, P98, DOI 10.1016/j.jcis.2014.03.011
   Khosroushahi AY, 2012, J NANOBIOTECHNOL, V10, DOI 10.1186/1477-3155-10-2
   Lansalot M, 2005, COLLOID POLYM SCI, V283, P1267, DOI 10.1007/s00396-005-1334-1
   Lin YY, 2017, J ETHNOPHARMACOL, V209, P305, DOI 10.1016/j.jep.2017.08.011
   Locatelli E, 2014, NANOMEDICINE-UK, V9, P839, DOI [10.2217/NNM.14.1, 10.2217/nnm.14.1]
   Long GB, 2013, APPL SPECTROSC, V67, P688, DOI 10.1366/12-06963
   Majd MH, 2013, ADV PHARM BULL, V3, P189, DOI 10.5681/apb.2013.031
   Mathew R, 2011, CURR OPIN GENET DEV, V21, P113, DOI 10.1016/j.gde.2010.12.008
   Matsuoka K, 2017, BIOCHEM BIOPH RES CO, V494, P249, DOI 10.1016/j.bbrc.2017.10.044
   Matthaiou EI, 2014, INT J NANOMED, V9, P1855, DOI 10.2147/IJN.S51880
   Mazewski C, 2018, FOOD CHEM, V242, P378, DOI 10.1016/j.foodchem.2017.09.086
   Moogooee M, 2011, J PHARM SCI-US, V100, P1057, DOI 10.1002/jps.22351
   Omidi Y, 2011, BIOIMPACTS, V1, P145, DOI 10.5681/bi.2011.019
   Pati R, 2016, TOXICOL SCI, V150, P454, DOI 10.1093/toxsci/kfw010
   Rasmussen JW, 2010, EXPERT OPIN DRUG DEL, V7, P1063, DOI 10.1517/17425247.2010.502560
   Serpe L, 2014, PHARMACOGEN PERS MED, V7, P31, DOI 10.2147/PGPM.S58374
   Sinha A, 2017, BIOMED PHARMACOTHER, V92, P509, DOI 10.1016/j.biopha.2017.05.108
   Smalley KSM, 2006, MINI-REV MED CHEM, V6, P387, DOI 10.2174/138955706776361402
   Sudeep H V, 2018, Pharmacogn Mag, V13, pS801, DOI 10.4103/pm.pm_121_17
   Thomas TP, 2012, MOL PHARMACEUT, V9, P2669, DOI 10.1021/mp3002232
   Turcotte S, 2008, CANCER CELL, V14, P90, DOI 10.1016/j.ccr.2008.06.004
   Unfried K, 2007, NANOTOXICOLOGY, V1, P52, DOI 10.1080/00222930701314932
   Wang HH, 2009, ENVIRON POLLUT, V157, P1171, DOI 10.1016/j.envpol.2008.11.004
   Wang XL, 2014, BBA-MOL BASIS DIS, V1842, P1240, DOI 10.1016/j.bbadis.2013.10.015
   Wood A, 2005, BIOCHEM CELL BIOL, V83, P460, DOI 10.1139/O05-116
   Xu G, 2018, ANGEW CHEM INT EDIT, V57, P3626, DOI 10.1002/anie.201712528
   Yaffee P, 2015, J GASTROINTEST ONCOL, V6, P185, DOI 10.3978/j.issn.2078-6891.2014.112
   Zeng MX, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658-017-0041-5
   Zhao JS, 2011, J TOXICOL ENV HEAL B, V14, P593, DOI 10.1080/10937404.2011.615113
   Zielinska E, 2018, ONCOTARGET, V9, P4675, DOI 10.18632/oncotarget.22563
NR 50
TC 32
Z9 32
U1 1
U2 5
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2018
VL 46
SU 3
BP S247
EP S253
DI 10.1080/21691401.2018.1491476
PG 7
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA HN4GH
UT WOS:000460141900023
PM 30043653
OA Bronze
DA 2025-01-04
ER

PT J
AU Caspi, M
   Wittenstein, A
   Kazelnik, M
   Shor-Nareznoy, Y
   Rosin-Arbesfeld, R
AF Caspi, Michal
   Wittenstein, Amnon
   Kazelnik, Michal
   Shor-Nareznoy, Yarden
   Rosin-Arbesfeld, Rina
TI Therapeutic targeting of the oncogenic Wnt signaling pathway for
   treating colorectal cancer and other colonic disorders
SO ADVANCED DRUG DELIVERY REVIEWS
LA English
DT Review
DE Wnt signalling; Colorectal cancer; Colonic delivery
ID ADENOMATOUS POLYPOSIS-COLI; SMALL-MOLECULE INHIBITOR; MUTATION CLUSTER
   REGION; TUMOR-SUPPRESSOR PROTEIN; BETA-CATENIN DEGRADATION; INTESTINAL
   STEM-CELLS; IN-VIVO PERFORMANCE; WNT/BETA-CATENIN; DRUG-DELIVERY;
   SOMATIC MUTATIONS
AB The canonical Wnt pathway is one of the key cellular signaling cascades that regulates, via the transcriptional co-activator beta-catenin, numerous embryogenic developmental processes, as well as tissue homeostasis. It is therefore not surprising that misregulation of the Wnt/beta-catenin pathway has been implicated in carcinogenesis. Aberrant Wnt signaling has been reported in a variety of malignancies, and its role in both hereditary and sporadic colorectal cancer (CRC), has been the subject of intensive study. Interestingly, the vast majority of colorectal tumors harbor mutations in the tumor suppressor gene adenomatous polyposis coli (APC). The Wnt pathway is complex, and despite decades of research, the mechanisms that underlie its functions are not completely known. Thus, although the Wnt cascade is an attractive target for therapeutic intervention against CRC, one of the malignancies with the highest morbidity and mortality rates, achieving efficacy and safety is yet extremely challenging.
   Here, we review the current knowledge of the Wnt different epistatic signaling components and the mechanism/s by which the signal is transduced in both health and disease, focusing on CRC. We address some of the important questions in the field and describe various therapeutic strategies designed to combat unregulated Wnt signaling, the development of targeted therapy approaches and the emerging challenges that are associated with these advanced methods. (c) 2020 Elsevier B.V. All rights reserved.
C1 [Caspi, Michal; Wittenstein, Amnon; Kazelnik, Michal; Shor-Nareznoy, Yarden; Rosin-Arbesfeld, Rina] Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-6997801 Tel Aviv, Israel.
C3 Tel Aviv University
RP Rosin-Arbesfeld, R (corresponding author), Tel Aviv Univ, Sackler Sch Med, Dept Clin Microbiol & Immunol, IL-6997801 Tel Aviv, Israel.
EM arina@tauex.tau.ac.il
CR Aberle H, 1997, EMBO J, V16, P3797, DOI 10.1093/emboj/16.13.3797
   Acebron SP, 2014, MOL CELL, V54, P663, DOI 10.1016/j.molcel.2014.04.014
   Aghabozorgi AS, 2020, LIFE SCI, V256, DOI 10.1016/j.lfs.2020.118006
   Ahuja A, 1997, DRUG DEV IND PHARM, V23, P489, DOI 10.4103/0975-7406.76478
   Albuquerque C, 2002, HUM MOL GENET, V11, P1549, DOI 10.1093/hmg/11.13.1549
   Amidon S, 2015, AAPS PHARMSCITECH, V16, P731, DOI 10.1208/s12249-015-0350-9
   Amin N, 2012, FRONT BIOSCI-LANDMRK, V17, P784, DOI 10.2741/3957
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   Angers S, 2009, NAT REV MOL CELL BIO, V10, P468, DOI 10.1038/nrm2717
   ANTENUCCI RN, 1984, J AGR FOOD CHEM, V32, P1316, DOI 10.1021/jf00126a025
   Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485
   Atlasi Y, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003424
   AUSTOKER J, 1994, BRIT MED J, V309, P382, DOI 10.1136/bmj.309.6951.382
   Ayub AD, 2019, ARTIF CELL NANOMED B, V47, P353, DOI 10.1080/21691401.2018.1557672
   Azzouz L.L., 2020, PHYSIOLOGY
   Bachmann IM, 2005, CLIN CANCER RES, V11, P8606, DOI 10.1158/1078-0432.CCR-05-0011
   BAEG GH, 1995, EMBO J, V14, P5618, DOI 10.1002/j.1460-2075.1995.tb00249.x
   Bak A, 2018, ADV DRUG DELIVER REV, V136, P2, DOI 10.1016/j.addr.2018.10.009
   Banerjee A, 2017, DRUG DISCOV TODAY, V22, P1224, DOI 10.1016/j.drudis.2017.05.006
   Baran B, 2018, GASTROENTEROL RES, V11, P264, DOI 10.14740/gr1062w
   Barker N, 2007, NATURE, V449, P1003, DOI 10.1038/nature06196
   Barker N, 2014, NAT REV MOL CELL BIO, V15, P19, DOI 10.1038/nrm3721
   Barker N, 2009, NATURE, V457, P608, DOI 10.1038/nature07602
   Bartscherer K, 2008, EMBO REP, V9, P977, DOI 10.1038/embor.2008.167
   Basit A.W., 2017, ON Drug Deliv, V2017, P22
   Bel S, 2014, P NATL ACAD SCI USA, V111, P4964, DOI 10.1073/pnas.1319114111
   Belali N, 2019, J ADV PHARM TECHNOL, V10, P100, DOI 10.4103/japtr.JAPTR_26_19
   Bienz M, 2000, CELL, V103, P311, DOI 10.1016/S0092-8674(00)00122-7
   Bienz M, 2020, CELL, V182, P799, DOI 10.1016/j.cell.2020.07.037
   Bovolenta P, 2008, J CELL SCI, V121, P737, DOI 10.1242/jcs.026096
   Bowcutt R, 2014, WORLD J GASTROENTERO, V20, P15216, DOI 10.3748/wjg.v20.i41.15216
   Brantjes H, 2001, NUCLEIC ACIDS RES, V29, P1410, DOI 10.1093/nar/29.7.1410
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816
   Bui N, 2017, ONCOTARGET, V8, P90608, DOI 10.18632/oncotarget.21293
   Byrne RM, 2018, ANN GASTROENTEROL, V31, P24, DOI 10.20524/aog.2017.0218
   Cadigan KM, 1997, GENE DEV, V11, P3286, DOI 10.1101/gad.11.24.3286
   Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x
   Carmon KS, 2011, P NATL ACAD SCI USA, V108, P11452, DOI 10.1073/pnas.1106083108
   Carvalho JR, 2019, ELIFE, V8, DOI 10.7554/eLife.45853
   Cavallo RA, 1998, NATURE, V395, P604, DOI 10.1038/26982
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen DF, 2020, CANCER LETT, V469, P456, DOI 10.1016/j.canlet.2019.11.019
   Chen J, 2017, SEMIN IMMUNOL, V32, P43, DOI 10.1016/j.smim.2017.09.006
   Chen TA, 2003, CANCER RES, V63, P4368
   Cheng CK, 2008, BLOOD, V112, P3391, DOI 10.1182/blood-2008-02-137083
   Cheng HL, 2019, CANCER LETT, V443, P80, DOI 10.1016/j.canlet.2018.11.013
   Cheng XF, 2019, BIOMED PHARMACOTHER, V110, P473, DOI 10.1016/j.biopha.2018.11.082
   Chien AJ, 2009, P NATL ACAD SCI USA, V106, P1193, DOI 10.1073/pnas.0811902106
   Christie M, 2013, ONCOGENE, V32, P4675, DOI 10.1038/onc.2012.486
   Cleary AS, 2014, NATURE, V508, P113, DOI 10.1038/nature13187
   Clements WM, 2002, CANCER RES, V62, P3503
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cramer JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0118792
   D'Haene N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138245
   Dahmen RP, 2001, CANCER RES, V61, P7039
   Damsky WE, 2011, CANCER CELL, V20, P741, DOI 10.1016/j.ccr.2011.10.030
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   de Lau W, 2011, NATURE, V476, P293, DOI 10.1038/nature10337
   de Lau WBM, 2012, GENOME BIOL, V13, DOI 10.1186/gb-2012-13-3-242
   De Marchis ML, 2017, ANTICANCER RES, V37, P3357, DOI 10.21873/anticanres.11702
   de Sousa E.M. F., 2016, Cancers, V8
   de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008
   DeAlmeida VI, 2007, CANCER RES, V67, P5371, DOI 10.1158/0008-5472.CAN-07-0266
   Delmas V, 2007, GENE DEV, V21, P2923, DOI 10.1101/gad.450107
   Diosdado B, 2010, CLIN CANCER RES, V16, P1391, DOI 10.1158/1078-0432.CCR-09-1773
   Dongowski G, 2000, APPL ENVIRON MICROB, V66, P1321, DOI 10.1128/AEM.66.4.1321-1327.2000
   Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033
   Duchmann R, 1995, CLIN EXP IMMUNOL, V102, P448
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   FALLINGBORG J, 1989, ALIMENT PHARM THER, V3, P605
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07
   Fiedler M, 2015, ELIFE, V4, DOI 10.7554/eLife.09073
   Fiskus W, 2015, LEUKEMIA, V29, P1267, DOI 10.1038/leu.2014.340
   Flanagan DJ, 2015, STEM CELL REP, V4, P759, DOI 10.1016/j.stemcr.2015.03.003
   Foulquier S, 2018, PHARMACOL REV, V70, P68, DOI 10.1124/pr.117.013896
   Fujii N, 2007, CANCER RES, V67, P573, DOI 10.1158/0008-5472.CAN-06-2726
   Fukukawa C, 2008, CANCER SCI, V99, P432, DOI 10.1111/j.1349-7006.2007.00701.x
   Fumagalli A, 2017, P NATL ACAD SCI USA, V114, pE2357, DOI 10.1073/pnas.1701219114
   Fuster JJ, 2015, DIABETES, V64, P1235, DOI 10.2337/db14-1164
   Gagnière J, 2016, WORLD J GASTROENTERO, V22, P501, DOI 10.3748/wjg.v22.i2.501
   Galluzzi L, 2019, TRENDS CELL BIOL, V29, P44, DOI 10.1016/j.tcb.2018.08.005
   Gammons M, 2018, CURR OPIN CELL BIOL, V51, P42, DOI 10.1016/j.ceb.2017.10.008
   Gammons MV, 2020, ELIFE, V9, DOI 10.7554/eLife.59879
   Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199
   García-Reyes B, 2018, J MED CHEM, V61, P4087, DOI 10.1021/acs.jmedchem.8b00095
   Gaspar C, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000547
   Gehart H, 2019, NAT REV GASTRO HEPAT, V16, P19, DOI 10.1038/s41575-018-0081-y
   Geyer FC, 2011, MODERN PATHOL, V24, P209, DOI 10.1038/modpathol.2010.205
   Giambra V, 2015, BLOOD, V125, P3917, DOI 10.1182/blood-2014-10-609370
   Giraudet AL, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4544-x
   Glebov OK, 2003, CANCER EPIDEM BIOMAR, V12, P755
   Glinka A, 2011, EMBO REP, V12, P1055, DOI 10.1038/embor.2011.175
   Goldsberry WN, 2019, CANCERS, V11, DOI 10.3390/cancers11060771
   Gómez-Orte E, 2013, TRENDS GENET, V29, P545, DOI 10.1016/j.tig.2013.06.003
   Gordon MD, 2006, J BIOL CHEM, V281, P22429, DOI 10.1074/jbc.R600015200
   Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967
   Goyal L., 2020, CLIN CANC RES
   Grandy D, 2009, J BIOL CHEM, V284, P16256, DOI 10.1074/jbc.M109.009647
   Green JL, 2008, CELL, V134, P646, DOI 10.1016/j.cell.2008.06.026
   Grifantini R, 2018, J CONTROL RELEASE, V280, P76, DOI 10.1016/j.jconrel.2018.04.052
   Groves C, 2002, AM J PATHOL, V160, P2055, DOI 10.1016/S0002-9440(10)61155-8
   Groves CJ, 2002, GUT, V50, P636, DOI 10.1136/gut.50.5.636
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Guimaraes PPG, 2018, J CONTROL RELEASE, V290, P75, DOI 10.1016/j.jconrel.2018.09.025
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo W, 2008, NATURE, V453, P529, DOI 10.1038/nature06933
   Guo Y., 2018, MOLECULES, V23
   Gupta A., 2011, RUSSIAN J BIOPHARM, V3
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   Harel E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024202
   Hashem FM, 2013, BRIT J PHARM RES, V3, P420, DOI 10.9734/BJPR/2013/3195
   Haupt S, 2002, CRIT REV THER DRUG, V19, P499
   Hengartner AC, 2020, NEUROSURG FOCUS, V48, DOI 10.3171/2019.10.FOCUS19705
   Hengeveld AF, 1999, EUR J BIOCHEM, V265, P1098, DOI 10.1046/j.1432-1327.1999.00852.x
   Holtslag-Broekhof S, 2018, R COMPL REAL PROP, P8
   Homayun B, 2018, ARCH PHARM RES, V41, P848, DOI 10.1007/s12272-018-1062-y
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Ibekwe VC, 2008, ALIMENT PHARM THER, V28, P911, DOI 10.1111/j.1365-2036.2008.03810.x
   Ibekwe VC, 2008, PHARM RES-DORDR, V25, P1828, DOI 10.1007/s11095-008-9580-9
   Ibekwe VC, 2006, J PHARM SCI-US, V95, P2760, DOI 10.1002/jps.20742
   Ireland H, 2004, GASTROENTEROLOGY, V126, P1236, DOI 10.1053/j.gastro.2004.03.020
   Isella C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15107
   Iyer DN, 2019, WORLD J STEM CELLS, V11, P519, DOI 10.4252/wjsc.v11.i8.519
   Janney A, 2020, NATURE, V585, P509, DOI 10.1038/s41586-020-2729-3
   Ji L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12143-3
   Juan J, 2014, GENE DEV, V28, P561, DOI 10.1101/gad.233627.113
   Kadosh E, 2020, NATURE, V586, P133, DOI 10.1038/s41586-020-2541-0
   Kageshita T, 2001, BRIT J DERMATOL, V145, P210, DOI 10.1046/j.1365-2133.2001.04336.x
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kaplan KB, 2001, NAT CELL BIOL, V3, P429, DOI 10.1038/35070123
   Kariv R, 2020, INT J CANCER, V146, P1064, DOI 10.1002/ijc.32557
   Karner CM, 2017, CELL MOL LIFE SCI, V74, P1649, DOI 10.1007/s00018-016-2425-5
   Kato Y, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-89
   Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129
   Kaveri D, 2013, BLOOD, V122, P694, DOI 10.1182/blood-2012-12-471904
   Khalaf AM, 2018, J HEPATOCELL CARCINO, V5, P61, DOI 10.2147/JHC.S156701
   Kielman MF, 2002, NAT GENET, V32, P594, DOI 10.1038/ng1045
   Kikuchi A, 2012, ACTA PHYSIOL, V204, P17, DOI 10.1111/j.1748-1716.2011.02294.x
   Kim DS, 2019, INT J NANOMED, V14, P4949, DOI 10.2147/IJN.S211014
   KIM HG, 1994, AM J PATHOL, V145, P148
   Kim JK, 2015, BIOPOLYMERS, V103, P321, DOI 10.1002/bip.22615
   Kim JH, 2018, ARCH PHARM RES, V41, P765, DOI 10.1007/s12272-018-1046-y
   Kim KA, 2006, CELL CYCLE, V5, P23, DOI 10.4161/cc.5.1.2305
   Kim KO, 2019, CLIN ENDOSC, V52, P137, DOI 10.5946/ce.2019.009
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Kinzler KW, 1997, NATURE, V386, P761, DOI 10.1038/386761a0
   Kitagawa M, 1999, EMBO J, V18, P2401, DOI 10.1093/emboj/18.9.2401
   Klaus A, 2008, NAT REV CANCER, V8, P387, DOI 10.1038/nrc2389
   Kohler EM, 2008, HUM MOL GENET, V17, P1978, DOI 10.1093/hmg/ddn095
   Kono Y, 2019, DRUG DELIV, V26, P935, DOI 10.1080/10717544.2019.1662515
   Koo BK, 2014, GASTROENTEROLOGY, V147, P289, DOI 10.1053/j.gastro.2014.05.007
   Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Korinek V, 1998, NAT GENET, V19, P379, DOI 10.1038/1270
   Kotla NG, 2019, ADV DRUG DELIVER REV, V146, P248, DOI 10.1016/j.addr.2018.06.021
   Krausova M, 2014, CELL SIGNAL, V26, P570, DOI 10.1016/j.cellsig.2013.11.032
   Kretzschmar K, 2017, DEV BIOL, V428, P273, DOI 10.1016/j.ydbio.2017.05.015
   Lalic-Popovic M, 2013, J DIABETES RES, V2013, DOI 10.1155/2013/598603
   Lamprecht A, 2005, J PHARMACOL EXP THER, V315, P196, DOI 10.1124/jpet.105.088146
   Lamprecht A, 2001, PHARM RES-DORDR, V18, P788, DOI 10.1023/A:1011032328064
   Lamprecht S, 2016, TRENDS CANCER, V2, P395, DOI 10.1016/j.trecan.2016.06.006
   Lane SW, 2011, BLOOD, V118, P2849, DOI 10.1182/blood-2011-03-345165
   Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562
   Lavelle A, 2019, GASTROENTEROL CLIN N, V48, P221, DOI 10.1016/j.gtc.2019.02.003
   Lavergne E, 2011, ONCOGENE, V30, P423, DOI 10.1038/onc.2010.432
   Lebensohn AM, 2016, ELIFE, V5, DOI 10.7554/eLife.21459
   Lee H, 2019, ISCIENCE, V19, P267, DOI 10.1016/j.isci.2019.07.039
   Lee JH, 2020, BLOOD ADV, V4, P2032, DOI 10.1182/bloodadvances.2019000757
   Lee S.H., 2020, PHARMACEUTICS, V12
   Leedham SJ, 2013, GUT, V62, P83, DOI 10.1136/gutjnl-2011-301601
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9
   Li MM, 2016, ANAEROBE, V39, P19, DOI 10.1016/j.anaerobe.2016.02.003
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Lim XH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008029
   Lin SY, 2000, P NATL ACAD SCI USA, V97, P4262, DOI 10.1073/pnas.060025397
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Liu HJ, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001249
   Liu WZ, 2015, BIOINFORMATICS, V31, P3359, DOI 10.1093/bioinformatics/btv362
   Lloyd-Price J, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0307-y
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lu DS, 2004, P NATL ACAD SCI USA, V101, P3118, DOI 10.1073/pnas.0308648100
   Lu JM, 2009, BIOORG MED CHEM LETT, V19, P3825, DOI 10.1016/j.bmcl.2009.04.040
   Luis TC, 2012, LEUKEMIA, V26, P414, DOI 10.1038/leu.2011.387
   Lybrand DB, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.164145
   Ma Xiangyu, 2018, Journal of Pharmaceutical Investigation, V48, P61, DOI 10.1007/s40005-017-0372-2
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Madan B, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0017-8
   Maroni A, 2017, EXPERT OPIN DRUG DEL, V14, P1027, DOI 10.1080/17425247.2017.1360864
   Maroni A, 2012, ADV DRUG DELIVER REV, V64, P540, DOI 10.1016/j.addr.2011.10.006
   Marshman E, 2002, BIOESSAYS, V24, P91, DOI 10.1002/bies.10028
   Maurer JM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0129076
   MCKELLAR RC, 1989, APPL MICROBIOL BIOT, V31, P537, DOI 10.1007/BF00270790
   Mirabelli C.K., 2020, LID, DOI [10.1126/scisignal.aay4494eaay4494, DOI 10.1126/SCISIGNAL.AAY4494EAAY4494]
   MIYAKI M, 1994, CANCER RES, V54, P3011
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Mælandsmo GM, 2003, CLIN CANCER RES, V9, P3383
   Momtazi-borojeni AA, 2018, J CELL PHYSIOL, V233, P2871, DOI 10.1002/jcp.26006
   Moon RT, 2002, SCIENCE, V296, P1644, DOI 10.1126/science.1071549
   Moon RT, 2004, NAT REV GENET, V5, P689, DOI 10.1038/nrg1427
   Mooranian A, 2018, DRUG DELIV TRANSL RE, V8, P543, DOI 10.1007/s13346-017-0473-5
   Moskalev EA, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-213
   Mrsny RJ, 2012, J CONTROL RELEASE, V161, P247, DOI 10.1016/j.jconrel.2012.01.017
   Mukherjee A, 2018, ISCIENCE, V6, P13, DOI 10.1016/j.isci.2018.07.007
   Müller-Tidow C, 2004, MOL CELL BIOL, V24, P2890, DOI 10.1128/MCB.24.7.2890-2904.2004
   Mutalik S, 2016, INT J BIOL MACROMOL, V86, P709, DOI 10.1016/j.ijbiomac.2015.11.092
   Naeem M, 2020, ARCH PHARM RES, V43, P153, DOI 10.1007/s12272-020-01219-0
   Naeem M, 2015, DRUG DES DEV THER, V9, P3789, DOI 10.2147/DDDT.S88672
   Nathke IS, 1996, J CELL BIOL, V134, P165, DOI 10.1083/jcb.134.1.165
   Newton A. M. J., 2012, Int. J. Appl. Res. Nat. Prod, V5, P1
   Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   Okazaki H, 2019, EXP LUNG RES, V45, P188, DOI 10.1080/01902148.2019.1638466
   Olsen I, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2018.1563410
   Palomer E, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00227
   Patel MM, 2011, EXPERT OPIN DRUG DEL, V8, P1247, DOI 10.1517/17425247.2011.597739
   Pawlikowski JS, 2013, P NATL ACAD SCI USA, V110, P16009, DOI 10.1073/pnas.1303491110
   Philip Anil K, 2010, Oman Med J, V25, P79, DOI 10.5001/omj.2010.24
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Plummer R, 2020, BRIT J CANCER, V123, P525, DOI 10.1038/s41416-020-0916-5
   Polakis P, 2000, GENE DEV, V14, P1837
   Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5
   Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052
   POTTEN CS, 1988, J CELL SCI, P45
   POTTEN CS, 1978, CELL, V15, P899, DOI 10.1016/0092-8674(78)90274-X
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Preston SL, 2003, CANCER RES, V63, P3819
   Proffitt KD, 2012, J BIOL CHEM, V287, P34167, DOI 10.1074/jbc.M112.381970
   Qiao HZ, 2017, DRUG DELIV, V24, P233, DOI 10.1080/10717544.2016.1245367
   Raghav K, 2013, NAT REV CLIN ONCOL, V10, P534, DOI 10.1038/nrclinonc.2013.132
   Rajilic-Stojanovic M, 2014, FEMS MICROBIOL REV, V38, P996, DOI 10.1111/1574-6976.12075
   Rao KA, 2004, BRIT J SPORT MED, V38, P482, DOI 10.1136/bjsm.2003.006825
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   REDDY BS, 1974, CANCER RES, V34, P2368
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Roberts DM, 2011, MOL BIOL CELL, V22, P1845, DOI 10.1091/mbc.E10-11-0871
   Roldo M, 2007, EXPERT OPIN DRUG DEL, V4, P547, DOI 10.1517/17425247.4.5.547
   Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352
   RUBINFELD B, 1993, SCIENCE, V262, P1731, DOI 10.1126/science.8259518
   Rubinstein MR, 2019, EMBO REP, V20, DOI 10.15252/embr.201847638
   Ruffner H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040976
   Sahu KK, 2019, PHARM DEV TECHNOL, V24, P166, DOI 10.1080/10837450.2018.1444639
   SALYERS AA, 1977, APPL ENVIRON MICROB, V34, P529, DOI 10.1128/AEM.34.5.529-533.1977
   SALYERS AA, 1977, APPL ENVIRON MICROB, V33, P319, DOI 10.1128/AEM.33.2.319-322.1977
   SALYERS AA, 1980, J BACTERIOL, V143, P772, DOI 10.1128/JB.143.2.772-780.1980
   Santos SL, 2000, BRAZ J MED BIOL RES, V33, P43, DOI 10.1590/S0100-879X2000000100006
   Satoh S, 2000, NAT GENET, V24, P245, DOI 10.1038/73448
   Schaefer KN, 2019, DEV CELL, V48, P429, DOI 10.1016/j.devcel.2019.01.025
   Schaefer KN, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007339
   Schepers A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007989
   Schneikert J, 2007, HUM MOL GENET, V16, P199, DOI 10.1093/hmg/ddl464
   Schwarz-Romond T, 2007, NAT STRUCT MOL BIOL, V14, P484, DOI 10.1038/nsmb1247
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   Segditsas S, 2009, ONCOGENE, V28, P146, DOI 10.1038/onc.2008.361
   Shan JF, 2005, BIOCHEMISTRY-US, V44, P15495, DOI 10.1021/bi0512602
   Shang QS, 2016, INT J BIOL MACROMOL, V86, P112, DOI 10.1016/j.ijbiomac.2016.01.055
   Shaw Holly V, 2019, Swiss Med Wkly, V149, pw20129, DOI 10.4414/smw.2019.20129
   Shih LM, 2001, P NATL ACAD SCI USA, V98, P2640, DOI 10.1073/pnas.051629398
   Si XY, 2016, WORLD J GASTROENTERO, V22, P7718, DOI 10.3748/wjg.v22.i34.7718
   Song QL, 2019, NANOSCALE, V11, P15958, DOI 10.1039/c9nr03802g
   Stakheev D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41182-5
   Stamos JL, 2014, ELIFE, V3, DOI 10.7554/eLife.01998
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Steed KP, 1997, J CONTROL RELEASE, V49, P115, DOI 10.1016/S0168-3659(97)00062-X
   SU LK, 1993, SCIENCE, V262, P1734, DOI 10.1126/science.8259519
   Taelman VF, 2010, CELL, V143, P1136, DOI 10.1016/j.cell.2010.11.034
   Taketo MM, 2006, ONCOGENE, V25, P7522, DOI 10.1038/sj.onc.1210058
   Tam BY, 2020, CANCER LETT, V473, P186, DOI 10.1016/j.canlet.2019.09.009
   Taniguchi K, 2002, ONCOGENE, V21, P4863, DOI 10.1038/sj.onc.1205591
   Teruel AH, 2018, J CONTROL RELEASE, V281, P58, DOI 10.1016/j.jconrel.2018.05.007
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tian A, 2018, J DEV BIOL, V6, DOI 10.3390/jdb6020008
   Tian H, 2011, NATURE, V478, P255, DOI 10.1038/nature10408
   Tomasetti C, 2015, SCIENCE, V347, P78, DOI 10.1126/science.1260825
   Tortelote GG, 2017, CELL SIGNAL, V40, P30, DOI 10.1016/j.cellsig.2017.08.008
   Tozaki H, 1999, LIFE SCI, V64, P1155, DOI 10.1016/S0024-3205(99)00044-2
   Tozaki H, 1997, J PHARM SCI, V86, P1016, DOI 10.1021/js970018g
   van der Flier LG, 2009, ANNU REV PHYSIOL, V71, P241, DOI 10.1146/annurev.physiol.010908.163145
   van Es JH, 2012, MOL CELL BIOL, V32, P1918, DOI 10.1128/MCB.06288-11
   van Tienen LM, 2017, ELIFE, V6, DOI [10.7554/eLife.20882, 10.7554/eLife.20882.001]
   Varum KM, 1997, CARBOHYD RES, V299, P99, DOI 10.1016/S0008-6215(96)00332-1
   Visetvichaporn V, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118772
   Vivarelli S, 2019, CANCERS, V11, DOI 10.3390/cancers11010038
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Waaler J, 2012, CANCER RES, V72, P2822, DOI 10.1158/0008-5472.CAN-11-3336
   Wagle SR, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64355-z
   Wall JA, 2020, EXPERT OPIN INV DRUG, V29, P639, DOI 10.1080/13543784.2020.1769065
   Walton SJ, 2017, FAM CANCER, V16, P363, DOI 10.1007/s10689-017-9966-0
   Wan WB, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/301575
   Wang BJ, 2018, TRENDS PHARMACOL SCI, V39, P648, DOI 10.1016/j.tips.2018.03.008
   Wang J, 2013, INFLAMMATION, V36, P1393, DOI 10.1007/s10753-013-9679-y
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Webster MR, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004114
   Wei W, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-76
   Wen YF, 2014, MACROMOL RAPID COMM, V35, P1819, DOI 10.1002/marc.201400406
   Wheeler JMD, 2002, GUT, V50, P218, DOI 10.1136/gut.50.2.218
   Wiese KE, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.165902
   Williams BA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102203
   Wirbel J, 2019, NAT MED, V25, P679, DOI 10.1038/s41591-019-0406-6
   Wong SH, 2017, GASTROENTEROLOGY, V153, P1621, DOI 10.1053/j.gastro.2017.08.022
   Wong WM, 2002, GUT, V50, P212, DOI 10.1136/gut.50.2.212
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Xiao B, 2012, EXPERT OPIN DRUG DEL, V9, P1393, DOI 10.1517/17425247.2012.730517
   Xing YZ, 2016, INT J MED SCI, V13, P603, DOI 10.7150/ijms.15571
   Yan KS, 2017, NATURE, V545, P238, DOI 10.1038/nature22313
   Yan KS, 2012, P NATL ACAD SCI USA, V109, P466, DOI 10.1073/pnas.1118857109
   Yan MC, 2017, EXP BIOL MED, V242, P1185, DOI 10.1177/1535370217708198
   Yeung J, 2010, CANCER CELL, V18, P606, DOI 10.1016/j.ccr.2010.10.032
   You L, 2004, CANCER RES, V64, P5385, DOI 10.1158/0008-5472.CAN-04-1227
   Zacharakis M, 2010, ANTICANCER RES, V30, P653
   Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang L, 2016, J DRUG TARGET, V24, P579, DOI 10.3109/1061186X.2015.1128941
   Zhang L, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw332
   Zhou LL, 2017, J CLIN PERIODONTOL, V44, P1112, DOI 10.1111/jcpe.12777
   Zhu LQ, 2009, NATURE, V457, P603, DOI 10.1038/nature07589
   Zoetendal EG, 2012, ISME J, V6, P1415, DOI 10.1038/ismej.2011.212
NR 328
TC 61
Z9 66
U1 1
U2 48
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0169-409X
EI 1872-8294
J9 ADV DRUG DELIVER REV
JI Adv. Drug Deliv. Rev.
PD FEB
PY 2021
VL 169
BP 118
EP 136
DI 10.1016/j.addr.2020.12.010
PG 19
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA PZ6NY
UT WOS:000612857800008
PM 33346022
DA 2025-01-04
ER

PT J
AU van der Steen, SCHA
   Raavé, R
   Langerak, S
   van Houdt, L
   van Duijnhoven, SMJ
   van Lith, SAM
   Massuger, LFAG
   Daamen, WF
   Leenders, WP
   van Kuppevelt, TH
AF van der Steen, Sophieke C. H. A.
   Raave, Rene
   Langerak, Sjoerd
   van Houdt, Laurens
   van Duijnhoven, Sander M. J.
   van Lith, Sanne A. M.
   Massuger, Leon F. A. G.
   Daamen, Willeke F.
   Leenders, William P.
   van Kuppevelt, Toin H.
TI Targeting the extracellular matrix of ovarian cancer using
   functionalized, drug loaded lyophilisomes
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Ovarian cancer; Extracellular matrix; Targeted therapy; Drug-delivery
   system; Lyophilisomes; Glycosaminoglycans; Chondroitin sulfate
ID SULFATED CHONDROITIN SULFATES; INTRAPERITONEAL CISPLATIN;
   SURFACE-PROTEINS; TUMOR MICROENVIRONMENT; LIPOSOMAL DOXORUBICIN;
   DELIVERY SYSTEMS; PHASE-III; PACLITAXEL; CARCINOMA; CELLS
AB Epithelial ovarian cancer is characterized by a high mortality rate and is in need for novel therapeutic avenues to improve patient outcome. The tumor's extracellular matrix ("stroma") offers new possibilities for targeted drug-delivery. Recently we identified highly sulfated chondroitin sulfate (CS-E) as a component abundantly present in the ovarian cancer extracellular matrix, and as a novel target for anti-cancer therapy. Here, we report on the functionalization of drug-loaded lyophilisomes (albumin-based biocapsules) to specifically target the stroma of ovarian carcinomas with the potential to eliminate cancer cells. To achieve specific targeting, we conjugated single chain antibodies reactive with CS-E to lyophilisomes using a two-step approach comprising sortase-mediated ligation and bioorthogonal click chemistry. Antibody-functionalized lyophilisomes specifically targeted the ovarian cancer stroma through CS-E. In a CS-E rich micro-environment in vitro lyophilisomes induced cell death by extracellular release of doxorubicin which localized to the nucleus. Immunohistochemistry identified CS-E rich stroma in a variety of solid tumors other than ovarian cancer, including breast, lung and colon cancer indicating the potential versatility of matrix therapy and the use of highly sulfated chondroitin sulfates in cancer stroma as a micro-environmental hook for targeted drug delivery. (C) 2016 The Authors. Published by Elsevier B.V.
C1 [van der Steen, Sophieke C. H. A.; Raave, Rene; Langerak, Sjoerd; van Houdt, Laurens; Daamen, Willeke F.; van Kuppevelt, Toin H.] Radboud Univ Nijmegen, Med Ctr, Dept Biochem, POB 9101, NL-6500 HB Nijmegen, Netherlands.
   [van der Steen, Sophieke C. H. A.; Massuger, Leon F. A. G.] Radboud Univ Nijmegen, Med Ctr, Dept Obstet & Gynaecol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
   [van Duijnhoven, Sander M. J.; van Lith, Sanne A. M.; Leenders, William P.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, POB 9101, NL-6500 HB Nijmegen, Netherlands.
C3 Radboud University Nijmegen; Radboud University Nijmegen; Radboud
   University Nijmegen
RP Daamen, WF (corresponding author), Radboud Univ Nijmegen, Med Ctr, Dept Biochem 280, POB 9101, NL-6500 HB Nijmegen, Netherlands.
EM Willeke.Daamen@radboudumc.nl
RI Massuger, Leon/H-8072-2014; Raave, Rene/R-3193-2019; van Lith,
   Sanne/D-9732-2016; van der Steen, Sophieke/L-2568-2015; van Kuppevelt,
   A.H.M.S.M./L-4463-2015; Leenders, William/O-2541-2019; Leenders,
   William/O-9843-2014; Raave, Rene/E-2860-2016; Daamen, Willeke
   F./D-5854-2015
OI Leenders, William/0000-0003-0066-220X; Raave, Rene/0000-0001-6066-4448;
   Daamen, Willeke F./0000-0003-3155-3030; van Lith,
   Sanne/0000-0001-8584-2546
FU Radboud university medical center
FX This project was funded by the Radboud university medical center. The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Afratis N, 2012, FEBS J, V279, P1177, DOI 10.1111/j.1742-4658.2012.08529.x
   Alt K, 2015, ANGEW CHEM INT EDIT, V54, P7515, DOI 10.1002/anie.201411507
   Armstrong DK, 2006, NEW ENGL J MED, V354, P34, DOI 10.1056/NEJMoa052985
   Bae YH, 2011, J CONTROL RELEASE, V153, P198, DOI 10.1016/j.jconrel.2011.06.001
   Bajaj G, 2010, PHARM RES-DORDR, V27, P735, DOI 10.1007/s11095-009-0031-z
   Bamberger ES, 2002, J CLIN PATHOL-MOL PA, V55, P348, DOI 10.1136/mp.55.6.348
   Cirri P, 2012, CANCER METAST REV, V31, P195, DOI 10.1007/s10555-011-9340-x
   Coleman RL, 2011, GYNECOL ONCOL, V122, P111, DOI 10.1016/j.ygyno.2011.03.036
   Daamen WF, 2007, ADV MATER, V19, P673, DOI 10.1002/adma.200601947
   Engels B, 2012, SEMIN CANCER BIOL, V22, P41, DOI 10.1016/j.semcancer.2011.12.008
   Gordon AN, 2001, J CLIN ONCOL, V19, P3312, DOI 10.1200/JCO.2001.19.14.3312
   Hansen JM, 2016, EUR J CANCER, V56, P131, DOI 10.1016/j.ejca.2015.12.016
   Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS161, DOI 10.1016/S0020-7292(06)60033-7
   Heintz APM, 2006, INT J GYNECOL OBSTET, V95, pS145, DOI 10.1016/S0020-7292(06)60032-5
   Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005
   Kobashigawa Y, 2009, J BIOMOL NMR, V43, P145, DOI 10.1007/s10858-008-9296-5
   Labiche A, 2010, INT J GYNECOL CANCER, V20, P28, DOI 10.1111/IGC.0b013e3181bda1cb
   Lammers T, 2012, J CONTROL RELEASE, V161, P175, DOI 10.1016/j.jconrel.2011.09.063
   Lesnock JL, 2013, BRIT J CANCER, V108, P1231, DOI 10.1038/bjc.2013.70
   Liang H, 2015, J CONTROL RELEASE, V209, P101, DOI 10.1016/j.jconrel.2015.04.029
   Mao Y, 2013, CANCER METAST REV, V32, P303, DOI 10.1007/s10555-012-9415-3
   Markman M, 2001, J CLIN ONCOL, V19, P1001, DOI 10.1200/JCO.2001.19.4.1001
   Mikami T, 2013, BBA-GEN SUBJECTS, V1830, P4719, DOI 10.1016/j.bbagen.2013.06.006
   Muggia FM, 1997, J CLIN ONCOL, V15, P987, DOI 10.1200/JCO.1997.15.3.987
   NAVARRE WW, 1994, MOL MICROBIOL, V14, P115, DOI 10.1111/j.1365-2958.1994.tb01271.x
   Raavé R, 2015, PEERJ, V3, DOI 10.7717/peerj.1489
   SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sun XX, 2015, ACTA PHARMACOL SIN, V36, P1219, DOI 10.1038/aps.2015.92
   Swart AMC, 2008, ANN ONCOL, V19, P688, DOI 10.1093/annonc/mdm518
   ten Dam GB, 2007, AM J PATHOL, V171, P1324, DOI 10.2353/ajpath.2007.070111
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Ton-That H, 1999, P NATL ACAD SCI USA, V96, P12424, DOI 10.1073/pnas.96.22.12424
   Vallen MJE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111806
   Vallen MJE, 2012, GYNECOL ONCOL, V127, P202, DOI 10.1016/j.ygyno.2012.06.022
   van Bracht E, 2015, EUR J PHARM BIOPHARM, V94, P141, DOI 10.1016/j.ejpb.2015.04.020
   van Bracht E, 2014, EUR J PHARM BIOPHARM, V87, P80, DOI 10.1016/j.ejpb.2014.01.005
   van Bracht E, 2012, INT J PHARMACEUT, V439, P127, DOI 10.1016/j.ijpharm.2012.10.008
   van de Westerlo EMA, 2002, BLOOD, V99, P2427, DOI 10.1182/blood.V99.7.2427
   van der Steen SCHA, 2016, GYNECOL ONCOL, V140, P527, DOI 10.1016/j.ygyno.2015.12.024
   Vaughan S, 2011, NAT REV CANCER, V11, P719, DOI 10.1038/nrc3144
   Wegrowski Y, 2004, CRIT REV ONCOL HEMAT, V49, P259, DOI 10.1016/j.critrevonc.2003.10.005
   Witte MD, 2013, NAT PROTOC, V8, P1808, DOI 10.1038/nprot.2013.103
   Yasunaga M, 2011, BIOCONJUGATE CHEM, V22, P1776, DOI 10.1021/bc200158j
NR 44
TC 23
Z9 25
U1 0
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD APR
PY 2017
VL 113
BP 229
EP 239
DI 10.1016/j.ejpb.2016.12.010
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EO8PY
UT WOS:000396953400021
PM 28034806
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Deb, B
   Sengupta, P
   Sambath, J
   Kumar, P
AF Deb, Barnali
   Sengupta, Pratyay
   Sambath, Janani
   Kumar, Prashant
TI Bioinformatics Analysis of Global Proteomic and Phosphoproteomic Data
   Sets Revealed Activation of NEK2 and AURKA in Cancers
SO BIOMOLECULES
LA English
DT Article
DE clear cell renal cell carcinoma; lung adenocarcinoma; uterine corpus
   endometrial carcinoma; phosphorylation; CPTAC; drug targets
ID OVARIAN-CANCER; AURORA-KINASE; PHOSPHORYLATION; RESISTANCE; INHIBITORS;
   MUTATIONS
AB Tumor heterogeneity attributes substantial challenges in determining the treatment regimen. Along with the conventional treatment, such as chemotherapy and radiotherapy, targeted therapy has greater impact in cancer management. Owing to the recent advancements in proteomics, we aimed to mine and re-interrogate the Clinical Proteomic Tumor Analysis Consortium (CPTAC) data sets which contain deep scale, mass spectrometry (MS)-based proteomic and phosphoproteomic data sets conducted on human tumor samples. Quantitative proteomic and phosphoproteomic data sets of tumor samples were explored and downloaded from the CPTAC database for six different cancers types (breast cancer, clear cell renal cell carcinoma (CCRCC), colon cancer, lung adenocarcinoma (LUAD), ovarian cancer, and uterine corpus endometrial carcinoma (UCEC)). We identified 880 phosphopeptide signatures for differentially regulated phosphorylation sites across five cancer types (breast cancer, colon cancer, LUAD, ovarian cancer, and UCEC). We identified the cell cycle to be aberrantly activated across these cancers. The correlation of proteomic and phosphoproteomic data sets identified changes in the phosphorylation of 12 kinases with unchanged expression levels. We further investigated phosphopeptide signature across five cancer types which led to the prediction of aurora kinase A (AURKA) and kinases-serine/threonine-protein kinase Nek2 (NEK2) as the most activated kinases targets. The drug designed for these kinases could be repurposed for treatment across cancer types.
C1 [Deb, Barnali; Sambath, Janani; Kumar, Prashant] Inst Bioinformat, Int Technol Pk, Bangalore 560066, Karnataka, India.
   [Deb, Barnali; Kumar, Prashant] MAHE, Manipal 576104, India.
   [Sengupta, Pratyay] Natl Inst Technol Durgapur, Dept Biotechnol, Mahatma Gandhi Ave, Durgapur 713209, W Bengal, India.
C3 National Institute of Technology (NIT System); National Institute of
   Technology Durgapur
RP Kumar, P (corresponding author), Inst Bioinformat, Int Technol Pk, Bangalore 560066, Karnataka, India.; Kumar, P (corresponding author), MAHE, Manipal 576104, India.
EM barnali@ibioinformatics.org; pratyaysengupta1628@gmail.com;
   janani@ibioinformatics.org; prashant@ibioinformatics.org
RI Kumar, Prashant/O-9273-2015
OI SENGUPTA, PRATYAY/0000-0002-0184-9335; Deb, Barnali/0000-0002-4996-2070;
   , Dr. Prashant Kumar/0000-0001-8975-5108
FU Department of Science and Technology (DST), Ramanujan Fellowship,
   Government of India [SB/S2/RJN-077/2015]
FX This research was funded by the Department of Science and Technology
   (DST), Ramanujan Fellowship, Government of India, grant number
   SB/S2/RJN-077/2015 and the APC was funded by SB/S2/RJN-077/2015, the
   Department of Science and Technology (DST), Ramanujan Fellowship,
   Government of India.
CR Aasen SN, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174235
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Baldi Alfonso, 2011, Patholog Res Int, V2011, P605042, DOI 10.4061/2011/605042
   Bhullar KS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0804-2
   Casorzo L, 2015, HUM PATHOL, V46, P411, DOI 10.1016/j.humpath.2014.11.016
   Cicenas J, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0758-4
   Cicenas J, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.61
   Cicenas J, 2014, CANCERS, V6, P2224, DOI 10.3390/cancers6042224
   Cicenas J, 2011, J CANCER RES CLIN, V137, P1409, DOI 10.1007/s00432-011-1039-4
   Cirak Y, 2015, J BUON, V20, P1414
   Coxon CR, 2017, ONCOTARGET, V8, P19089, DOI 10.18632/oncotarget.13249
   D'Andrilli G, 2004, CLIN CANCER RES, V10, P8132, DOI 10.1158/1078-0432.CCR-04-0886
   Davidson B, 2014, VIRCHOWS ARCH, V464, P701, DOI 10.1007/s00428-014-1577-7
   Dazert E, 2016, P NATL ACAD SCI USA, V113, P1381, DOI 10.1073/pnas.1523434113
   Deb B, 2020, METHODS MOL BIOL, V2051, P241, DOI 10.1007/978-1-4939-9744-2_10
   Deb B, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050703
   Do TV, 2014, ONCOGENE, V33, P539, DOI 10.1038/onc.2012.632
   Drake JM, 2016, CELL, V166, P1041, DOI 10.1016/j.cell.2016.07.007
   Fang YF, 2016, CELL CYCLE, V15, P895, DOI 10.1080/15384101.2016.1152430
   Franceschini A, 2013, NUCLEIC ACIDS RES, V41, pD808, DOI 10.1093/nar/gks1094
   García-Aranda M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122543
   Gharwan H, 2016, NAT REV CLIN ONCOL, V13, P209, DOI 10.1038/nrclinonc.2015.213
   Giannone G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092353
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Katsha A, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0375-4
   Klaeger S, 2017, SCIENCE, V358, DOI 10.1126/science.aan4368
   KREK W, 1992, NEW BIOL, V4, P323
   Landolt L, 2017, PHYSIOL REP, V5, DOI 10.14814/phy2.13305
   Lombardo LJ, 2004, J MED CHEM, V47, P6658, DOI 10.1021/jm049486a
   Lunt SY, 2011, ANNU REV CELL DEV BI, V27, P441, DOI 10.1146/annurev-cellbio-092910-154237
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Mohan SV, 2020, METHODS MOL BIOL, V2051, P277, DOI 10.1007/978-1-4939-9744-2_12
   Mullany Lila E, 2018, Genes Cancer, V9, P53, DOI 10.18632/genesandcancer.167
   Nagy A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-27521-y
   NORBURY C, 1991, EMBO J, V10, P3321, DOI 10.1002/j.1460-2075.1991.tb04896.x
   Otto T, 2017, NAT REV CANCER, V17, P93, DOI 10.1038/nrc.2016.138
   Rellos P, 2007, J BIOL CHEM, V282, P6833, DOI 10.1074/jbc.M609721200
   Shah NP, 2004, SCIENCE, V305, P399, DOI 10.1126/science.1099480
   Singh V, 2017, PROTEIN J, V36, P1, DOI 10.1007/s10930-017-9696-z
   Staderini F, 2015, INT J SURG CASE REP, V11, P29, DOI 10.1016/j.ijscr.2015.03.009
   Thu KL, 2018, CELL CYCLE, V17, P1871, DOI 10.1080/15384101.2018.1502567
   Vincenzi B, 2006, HISTOL HISTOPATHOL, V21, P423, DOI 10.14670/HH-21.423
   Wu CF, 2010, MOL BIOL CELL, V21, P1470, DOI 10.1091/mbc.E09-06-0486
   Xia JL, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/862461
   Xie Jianling, 2016, F1000Res, V5, DOI 10.12688/f1000research.9207.1
   Xu J, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-200
   Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069
   Zhang T, 2010, AM J PATHOL, V177, P2816, DOI 10.2353/ajpath.2010.100047
NR 48
TC 16
Z9 17
U1 2
U2 17
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2218-273X
J9 BIOMOLECULES
JI Biomolecules
PD FEB
PY 2020
VL 10
IS 2
AR 237
DI 10.3390/biom10020237
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA KX8QD
UT WOS:000522138500185
PM 32033228
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Adamopoulos, C
   Ahmed, TA
   Tucker, MR
   Ung, PMU
   Xiao, M
   Karoulia, Z
   Amabile, A
   Wu, XW
   Aaronson, SA
   Ang, C
   Rebecca, VW
   Brown, BD
   Schlessinger, A
   Herlyn, M
   Wang, Q
   Shaw, DE
   Poulikakos, PI
AF Adamopoulos, Christos
   Ahmed, Tamer A.
   Tucker, Maxwell R.
   Ung, Peter M. U.
   Xiao, Min
   Karoulia, Zoi
   Amabile, Angelo
   Wu, Xuewei
   Aaronson, Stuart A.
   Ang, Celina
   Rebecca, Vito W.
   Brown, Brian D.
   Schlessinger, Avner
   Herlyn, Meenhard
   Wang, Qi
   Shaw, David E.
   Poulikakos, Poulikos, I
TI Exploiting Allosteric Properties of RAF and MEK Inhibitors to Target
   Therapy-Resistant Tumors Driven by Oncogenic BRAF Signaling
SO CANCER DISCOVERY
LA English
DT Article
ID ANTITUMOR-ACTIVITY; ACQUIRED-RESISTANCE; COMPLEX REVEALS; KINASE;
   CANCER; MUTANT; MELANOMA; FEEDBACK; ACTIVATION; MUTATIONS
AB Current clinical RAF inhibitors (RAFi) inhibit monomeric BRAF (mBRAF) but are less potent against dimeric BRAF (dBRAF). RAFi equipotent for mBRAF and dBRAF have been developed but are predicted to have lower therapeutic index. Here we identify a third class of RAFi that selectively inhibits dBRAF over mBRAF. Molecular dynamic simulations reveal restriction of the movement of the BRAF aC-helix as the basis of inhibitor selectivity. Combination of inhibitors based on their conformation selectivity (mBRAF-plus dBRAF-selective plus the most potent BRAF-MEK disruptor MEK inhibitor) promoted suppression of tumor growth in BRAF(V600E) therapy-resistant models. Strikingly, the triple combination showed no toxicities, whereas dBRAF-selective plus MEK inhibitor treatment caused weight loss in mice. Finally, the triple combination achieved durable response and improved clinical well-being in a patient with stage IV colorectal cancer. Thus, exploiting allosteric properties of RAF and MEK inhibitors enables the design of effective and well-tolerated therapies for BRAF(V600E) tumors.
   SIGNIFICANCE: This work identifies a new class of RAFi that are selective for dBRAF over mBRAF and determines the basis of their selectivity. A rationally designed combination of RAF and MEK inhibitors based on their conformation selectivity achieved increased efficacy and a high therapeutic index when used to target BRAF(V600E) tumors.
C1 [Adamopoulos, Christos; Ahmed, Tamer A.; Karoulia, Zoi; Wu, Xuewei; Aaronson, Stuart A.; Poulikakos, Poulikos, I] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Oncol Sci, New York, NY 10029 USA.
   [Tucker, Maxwell R.; Wang, Qi; Shaw, David E.] DE Shaw Res, 120 W 4th St,39th Floor, New York, NY 10036 USA.
   [Ung, Peter M. U.; Schlessinger, Avner] Icahn Sch Med Mt Sinai, Dept Pharmacol Sci, New York, NY 10029 USA.
   [Xiao, Min; Rebecca, Vito W.; Herlyn, Meenhard] Wistar Inst Anat & Biol, 3601 Spruce St, Philadelphia, PA 19104 USA.
   [Amabile, Angelo; Brown, Brian D.] Icahn Sch Med Mt Sinai, Precis Immunol Inst, Dept Genet & Genom Sci, New York, NY 10029 USA.
   [Ang, Celina] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, New York, NY 10029 USA.
   [Shaw, David E.] Columbia Univ, Dept Biochem & Mol Biophys, New York, NY 10027 USA.
C3 Icahn School of Medicine at Mount Sinai; D. E. Shaw Research; Icahn
   School of Medicine at Mount Sinai; The Wistar Institute; Icahn School of
   Medicine at Mount Sinai; Icahn School of Medicine at Mount Sinai;
   Columbia University
RP Shaw, DE (corresponding author), DE Shaw Res, 120 W 4th St,39th Floor, New York, NY 10036 USA.; Poulikakos, PI (corresponding author), Icahn Sch Med Mt Sinai, Tisch Canc Inst, 1 Gustave L Levy Pl,Box 1044A,1470 Madison Ave, New York, NY 10029 USA.
EM David.Shaw@DEShawResearch.com; poulikakos.poulikakos@mssm.edu
RI Adamopoulos, Christos/JMQ-6589-2023; Brown, Brian D./JOZ-4915-2023
OI Tucker, Maxwell/0000-0002-1606-8806; Adamopoulos,
   Christos/0000-0001-6323-4216
FU Tisch Cancer Institute (TCI); NIH/NCI [R01CA204314, R01 CA240362,
   R01CA238229]; Irma T. Hirschl Trust; Manhasset Women's Coalition Against
   Breast Cancer; Breast Cancer Alliance; Melanoma Research Foundation;
   Melanoma Research Alliance; NIH [RO1 CA238237, U54 CA224070, PO1
   CA114046, R01AT011326, R33CA223947]; Dr. Miriam and Sheldon G. Adelson
   Medical Research Foundation; Cancer Research Institute; Breast Cancer
   Research Foundation; Robin Chemers Neustein Postdoctoral Fellowship; 
   [T32CA078207]; National Cancer Institute [R01CA204314, U54CA224070]
   Funding Source: NIH RePORTER
FX The authors thank Paul Maragakis for helpful discussions. P.I.
   Poulikakos is supported by Tisch Cancer Institute (TCI) developmental
   awards, the NIH/NCI (R01CA204314, R01 CA240362, and R01CA238229), the
   Irma T. Hirschl Trust, the Manhasset Women's Coalition Against Breast
   Cancer, the Breast Cancer Alliance, the Melanoma Research Foundation,
   and the Melanoma Research Alliance. M. Herlyn is supported by NIH grants
   RO1 CA238237, U54 CA224070, and PO1 CA114046 and the Dr. Miriam and
   Sheldon G. Adelson Medical Research Foundation. B.D. Brown was supported
   by funding from the Cancer Research Institute and NIH R01AT011326 and
   R33CA223947. S.A. Aaronson is supported by the Breast Cancer Research
   Foundation. T.A. Ahmed is supported by grant T32CA078207. Z. Karoulia
   received the 2017 Robin Chemers Neustein Postdoctoral Fellowship.
CR Agudo J, 2015, NAT BIOTECHNOL, V33, P1287, DOI 10.1038/nbt.3386
   Ahmed TA, 2019, CELL REP, V26, P65, DOI 10.1016/j.celrep.2018.12.013
   [Anonymous], 2006, P ACM IEEE C SUP SC
   Bekaii-Saab TS, 2019, LANCET ONCOL, V20, P1070, DOI 10.1016/S1470-2045(19)30272-4
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cotto-Rios XM, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18123-2
   Dardaei L, 2018, NAT MED, V24, P512, DOI 10.1038/nm.4497
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Davis MI, 2011, NAT BIOTECHNOL, V29, P1046, DOI 10.1038/nbt.1990
   Dong Q, 2011, BIOORG MED CHEM LETT, V21, P1315, DOI 10.1016/j.bmcl.2011.01.071
   Dummer R, 2018, LANCET ONCOL, V19, P603, DOI 10.1016/S1470-2045(18)30142-6
   Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093
   Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010
   Freeman AK, 2013, MOL CELL, V49, P751, DOI 10.1016/j.molcel.2012.12.018
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Haling JR, 2014, CANCER CELL, V26, P402, DOI 10.1016/j.ccr.2014.07.007
   Harder E, 2016, J CHEM THEORY COMPUT, V12, P281, DOI 10.1021/acs.jctc.5b00864
   Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Hornak V, 2006, PROTEINS, V65, P712, DOI 10.1002/prot.21123
   Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061
   Ishii N, 2013, CANCER RES, V73, P4050, DOI 10.1158/0008-5472.CAN-12-3937
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jacobson MP, 2002, J MOL BIOL, V320, P597, DOI 10.1016/S0022-2836(02)00470-9
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   JORGENSEN WL, 1983, J CHEM PHYS, V79, P926, DOI 10.1063/1.445869
   Karoulia Z, 2016, CANCER CELL, V30, P485, DOI 10.1016/j.ccell.2016.06.024
   Kemper K, 2016, CELL REP, V16, P263, DOI 10.1016/j.celrep.2016.05.064
   Kondo Y, 2019, SCIENCE, V366, P109, DOI 10.1126/science.aay0543
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Krepler C, 2017, CELL REP, V21, P1953, DOI 10.1016/j.celrep.2017.10.021
   Krepler C, 2016, CLIN CANCER RES, V22, P1592, DOI 10.1158/1078-0432.CCR-15-1762
   Krissinel E, 2007, J MOL BIOL, V372, P774, DOI 10.1016/j.jmb.2007.05.022
   Liau NPD, 2020, NAT STRUCT MOL BIOL, V27, P134, DOI 10.1038/s41594-019-0365-0
   Lindorff-Larsen K, 2010, PROTEINS, V78, P1950, DOI 10.1002/prot.22711
   Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011
   Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009
   Long GV, 2014, NEW ENGL J MED, V371, P1877, DOI 10.1056/NEJMoa1406037
   MARTYNA GJ, 1994, J CHEM PHYS, V101, P4177, DOI 10.1063/1.467468
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018
   Nakamura A, 2013, CANCER RES, V73, P7043, DOI 10.1158/0008-5472.CAN-13-1825
   Nichols RJ, 2018, NAT CELL BIOL, V20, P1064, DOI 10.1038/s41556-018-0169-1
   O'Hare T, 2009, CANCER CELL, V16, P401, DOI 10.1016/j.ccr.2009.09.028
   Okaniwa M, 2013, J MED CHEM, V56, P6478, DOI 10.1021/jm400778d
   Park E, 2019, NATURE, V575, P545, DOI 10.1038/s41586-019-1660-y
   Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002
   Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Predescu C, 2020, J CHEM PHYS, P152
   Predescu C, 2012, MOL PHYS, V110, P967, DOI 10.1080/00268976.2012.681311
   Rahman R, 2019, NUCLEIC ACIDS RES, V47, pD361, DOI 10.1093/nar/gky916
   Ramurthy S, 2020, J MED CHEM, V63, P2013, DOI 10.1021/acs.jmedchem.9b00161
   Samatar AA, 2014, NAT REV DRUG DISCOV, V13, P928, DOI 10.1038/nrd4281
   Shao WL, 2018, CANCER RES, V78, P1537, DOI 10.1158/0008-5472.CAN-17-2033
   Shaw DE, 2014, INT CONF HIGH PERFOR, P41, DOI 10.1109/SC.2014.9
   Subbiah V, 2020, TRENDS CANCER, V6, P797, DOI 10.1016/j.trecan.2020.05.009
   Sun C, 2014, TRENDS BIOCHEM SCI, V39, P465, DOI 10.1016/j.tibs.2014.08.010
   Tang ZY, 2015, MOL CANCER THER, V14, P2187, DOI 10.1158/1535-7163.MCT-15-0262
   TUCKERMAN M, 1992, J CHEM PHYS, V97, P1990, DOI 10.1063/1.463137
   Ung PMU, 2018, CELL CHEM BIOL, V25, P916, DOI 10.1016/j.chembiol.2018.05.002
   Vido MJ, 2018, CELL REP, V25, P1501, DOI 10.1016/j.celrep.2018.10.049
   Wang JM, 2004, J COMPUT CHEM, V25, P1157, DOI 10.1002/jcc.20035
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Wilhelm SM, 2004, CANCER RES, V64, P7099, DOI 10.1158/0008-5472.CAN-04-1443
   Wroblewska A, 2018, CELL, V175, P1141, DOI 10.1016/j.cell.2018.09.022
   Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001
   Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
NR 76
TC 37
Z9 39
U1 2
U2 12
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD JUL
PY 2021
VL 11
IS 7
BP 1716
EP 1735
DI 10.1158/2159-8290.CD-20-1351
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TF2MH
UT WOS:000670545600029
PM 33568355
OA Green Accepted, Bronze, Green Submitted
DA 2025-01-04
ER

PT J
AU Goyal, L
   Saha, SK
   Liu, LY
   Siravegna, G
   Leshchiner, I
   Ahronian, LG
   Lennerz, JK
   Vu, P
   Deshpande, V
   Kambadakone, A
   Mussolin, B
   Reyes, S
   Henderson, L
   Sun, JE
   Van Seventer, EE
   Gurski, JM
   Baltschukat, S
   Schacher-Engstler, B
   Barys, L
   Stamm, C
   Furet, P
   Ryan, DP
   Stone, JR
   Iafrate, AJ
   Getz, G
   Porta, DG
   Tiedt, R
   Bardelli, A
   Juric, D
   Corcoran, RB
   Bardeesy, N
   Zhu, AX
AF Goyal, Lipika
   Saha, Supriya K.
   Liu, Leah Y.
   Siravegna, Giulia
   Leshchiner, Ignaty
   Ahronian, Leanne G.
   Lennerz, Jochen K.
   Vu, Phuong
   Deshpande, Vikram
   Kambadakone, Avinash
   Mussolin, Benedetta
   Reyes, Stephanie
   Henderson, Laura
   Sun, Jiaoyuan Elisabeth
   Van Seventer, Emily E.
   Gurski, Joseph M., Jr.
   Baltschukat, Sabrina
   Schacher-Engstler, Barbara
   Barys, Louise
   Stamm, Christelle
   Furet, Pascal
   Ryan, David P.
   Stone, James R.
   Iafrate, A. John
   Getz, Gad
   Porta, Diana Graus
   Tiedt, Ralph
   Bardelli, Alberto
   Juric, Dejan
   Corcoran, Ryan B.
   Bardeesy, Nabeel
   Zhu, Andrew X.
TI Polyclonal Secondary <i>FGFR2</i> Mutations Drive Acquired Resistance to
   FGFR Inhibition in Patients with FGFR2 Fusion-Positive
   Cholangiocarcinoma
SO CANCER DISCOVERY
LA English
DT Article
ID CANCER DRUG-RESISTANCE; COLORECTAL-CANCER; TARGETED THERAPY;
   INTRAHEPATIC CHOLANGIOCARCINOMA; TYROSINE KINASE; TUMORS; HETEROGENEITY;
   NVP-BGJ398; LANDSCAPE; PROTEIN
AB Genetic alterations in the fibroblast growth factor receptor (FGFR) pathway are promising therapeutic targets in many cancers, including intrahepatic cholangiocarcinoma (ICC). The FGFR inhibitor BGJ398 displayed encouraging efficacy in patients with FGFR2 fusion-positive ICC in a phase II trial, but the durability of response was limited in some patients. Here, we report the molecular basis for acquired resistance to BGJ398 in three patients via integrative genomic characterization of cell-free circulating tumor DNA (cfDNA), primary tumors, and metastases. Serial analysis of cfDNA demonstrated multiple recurrent point mutations in the FGFR2 kinase domain at progression. Accordingly, biopsy of post-progression lesions and rapid autopsy revealed marked inter-and intralesional heterogeneity, with different FGFR2 mutations in individual resistant clones. Molecular modeling and in vitro studies indicated that each mutation led to BGJ398 resistance and was surmountable by structurally distinct FGFR inhibitors. Thus, polyclonal secondary FGFR2 mutations represent an important clinical resistance mechanism that may guide the development of future therapeutic strategies. SIGNIFICANCE: We report the first genetic mechanisms of clinical acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive ICC. Our findings can inform future strategies for detecting resistance mechanisms and inducing more durable remissions in ICC and in the wide variety of cancers where the FGFR pathway is being explored as a therapeutic target. (C) 2016 AACR.
C1 [Goyal, Lipika; Saha, Supriya K.; Liu, Leah Y.; Gurski, Joseph M., Jr.; Ryan, David P.; Porta, Diana Graus; Corcoran, Ryan B.] Harvard Med Sch, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
   [Siravegna, Giulia; Kambadakone, Avinash; Gurski, Joseph M., Jr.; Stamm, Christelle; Iafrate, A. John] Andiolo Canc Inst FPO, IRCCS, Candiolo, Turin, Italy.
   [Goyal, Lipika; Siravegna, Giulia; Ahronian, Leanne G.; Kambadakone, Avinash; Reyes, Stephanie; Sun, Jiaoyuan Elisabeth; Barys, Louise; Ryan, David P.] Univ Turin, Dept Oncol, Turin, Italy.
   [Siravegna, Giulia; Henderson, Laura; Gurski, Joseph M., Jr.] FIRC, IFOM, Milan, Italy.
   [Goyal, Lipika; Vu, Phuong; Reyes, Stephanie; Barys, Louise; Ryan, David P.] Inst Technol & Harvard, Broad Inst, Cambridge, MA USA.
   [Siravegna, Giulia; Kambadakone, Avinash; Stamm, Christelle; Ryan, David P.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA.
   [Liu, Leah Y.; Deshpande, Vikram; Kambadakone, Avinash; Sun, Jiaoyuan Elisabeth; Barys, Louise] Massachusetts Gen Hosp, Dept Radiol, Boston, MA USA.
   [Deshpande, Vikram; Kambadakone, Avinash; Sun, Jiaoyuan Elisabeth; Van Seventer, Emily E.; Gurski, Joseph M., Jr.; Ryan, David P.] Novartis Inst BioMed Res, Oncol Translat Res, Basel, Switzerland.
   [Leshchiner, Ignaty; Furet, Pascal] Novartis Inst Biomed Res, Global Discovery Chem, Basel, Switzerland.
C3 Harvard University; Massachusetts General Hospital; Harvard Medical
   School; IRCCS Fondazione del Piemonte per l'Oncologia; University of
   Turin; IFOM - FIRC Institute of Molecular Oncology; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute; Harvard
   University; Massachusetts General Hospital; Harvard University;
   Massachusetts General Hospital; Novartis; Novartis
RP Corcoran, RB; Zhu, AX (corresponding author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,LH POB 232, Boston, MA 02114 USA.; Bardeesy, N (corresponding author), Massachusetts Gen Hosp, 185 Cambridge St, Boston, MA 02114 USA.
EM rbcorcoran@partners.org; nbardeesy@partners.org; azhu@partners.org
RI Siravegna, Giulia/Z-2826-2019; Getz, Gad/ABW-5118-2022; Saha,
   Supriya/AAC-5365-2019; Deshpande, Vikram/AEN-2602-2022; Stone,
   James/IAN-5882-2023; Juric, Dejan/C-5214-2008; BARDELLI,
   Alberto/J-9721-2018
OI Stone, James R./0000-0001-9122-3311; BARDELLI,
   Alberto/0000-0003-1647-5070; Leshchiner, Ignaty/0000-0001-8942-9265;
   Diallo, Jiaoyuan Elisabeth/0000-0002-2732-4289; Siravegna,
   Giulia/0000-0002-7132-6484; MUSSOLIN, BENEDETTA/0000-0001-5723-5685
FU MGH Executive Committee on Research Fund for Medical Discovery Award;
   Cholangiocarcinoma Foundation Research Fellowship; NIH Loan Repayment
   Program Grant; NCI Mentored Clinical Scientist Research Career
   Development Award [1K08CA194268-01]; HMS Laboratory for Systems
   Pharmacology [P50GM107618]; Susan Eid Tumor Heterogeneity Initiative;
   TargetCancer Foundation; Translational Research Grant Award from the V
   Foundation for Cancer Research; NIH/NCI Gastrointestinal Cancer SPORE
   [P50 CA127003]; Damon Runyon Clinical Investigator Award; NIH/NCI
   [1K08CA166510, 1R01CA208437]; Jonathan Kraft Translational Award;
   Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille,
   Ministero della Salute; AIRC IG [16788]
FX L. Goyal is supported by the MGH Executive Committee on Research Fund
   for Medical Discovery Award, the Cholangiocarcinoma Foundation Research
   Fellowship, and the NIH Loan Repayment Program Grant. S.K. Saha is
   supported by an NCI Mentored Clinical Scientist Research Career
   Development Award (1K08CA194268-01). D. Juric is supported by the HMS
   Laboratory for Systems Pharmacology Grant (P50GM107618) and the Susan
   Eid Tumor Heterogeneity Initiative. N. Bardeesy is the holder of the
   Gallagher Chair in Gastrointestinal Cancer Research at MGH. N. Bardeesy
   and A.X. Zhu are supported by the TargetCancer Foundation and by a
   Translational Research Grant Award from the V Foundation for Cancer
   Research. This work was also supported by grants from the NIH/NCI
   Gastrointestinal Cancer SPORE P50 CA127003 (to L. Goyal, S.K. Saha, R.B.
   Corcoran, and N. Bardeesy). R.B. Corcoran acknowledges support from a
   Damon Runyon Clinical Investigator Award and NIH/NCI 1K08CA166510 and
   1R01CA208437. L. Goyal, N. Bardeesy, and A.X. Zhu are supported by the
   Jonathan Kraft Translational Award. A. Bardelli is supported by
   Fondazione Piemontese per la Ricerca sul Cancro-ONLUS 5 per mille 2011,
   Ministero della Salute and AIRC IG n. 16788
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   [Anonymous], J CLIN ONCOL S4S
   Arai Y, 2014, HEPATOLOGY, V59, P1427, DOI 10.1002/hep.26890
   BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Borad MJ, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004135
   Byron SA, 2013, NEOPLASIA, V15, P975, DOI 10.1593/neo.121106
   Chen HB, 2007, MOL CELL, V27, P717, DOI 10.1016/j.molcel.2007.06.028
   Choi YL, 2010, NEW ENGL J MED, V363, P1734, DOI 10.1056/NEJMoa1007478
   Dienstmann R, 2014, ANN ONCOL, V25, P552, DOI 10.1093/annonc/mdt419
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Gainor JF, 2016, CANCER DISCOV, V6, P1118, DOI 10.1158/2159-8290.CD-16-0596
   Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012
   Graham RP, 2014, HUM PATHOL, V45, P1630, DOI 10.1016/j.humpath.2014.03.014
   Guagnano V, 2012, CANCER DISCOV, V2, P1118, DOI 10.1158/2159-8290.CD-12-0210
   Guagnano V, 2011, J MED CHEM, V54, P7066, DOI 10.1021/jm2006222
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Huang ZF, 2013, STRUCTURE, V21, P1889, DOI 10.1016/j.str.2013.07.017
   Kim ST, 2015, ONCOTARGET, V6, P40360, DOI 10.18632/oncotarget.5465
   Lanman RB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140712
   Liegl B, 2008, J PATHOL, V216, P64, DOI 10.1002/path.2382
   Lim KH, 2008, MED ONCOL, V25, P207, DOI 10.1007/s12032-007-9014-2
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Nogova L, 2016, J CLIN ONCOL
   Notredame C, 2000, J MOL BIOL, V302, P205, DOI 10.1006/jmbi.2000.4042
   Ochiiwa H, 2013, MOL CANCER THER, V12, DOI 10.1158/1535-7163.TARG-13-A270
   Patani H, 2016, ONCOTARGET, V7, P24252, DOI 10.18632/oncotarget.8132
   Pearson A, 2016, CANCER DISCOV, V6, P838, DOI 10.1158/2159-8290.CD-15-1246
   Ross JS, 2014, ONCOLOGIST, V19, P235, DOI 10.1634/theoncologist.2013-0352
   Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283
   Saha SK, 2016, ONCOLOGIST, V21, P594, DOI 10.1634/theoncologist.2015-0446
   Shaib Y, 2004, SEMIN LIVER DIS, V24, P115, DOI 10.1055/s-2004-828889
   Sia D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7087
   Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846
   Tan L, 2014, P NATL ACAD SCI USA, V111, pE4869, DOI 10.1073/pnas.1403438111
   Tiedt R, 2011, CANCER RES, V71, P5255, DOI 10.1158/0008-5472.CAN-10-4433
   Turner N, 2010, NAT REV CANCER, V10, P116, DOI 10.1038/nrc2780
   Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721
   Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617
   Voss JS, 2013, HUM PATHOL, V44, P1216, DOI 10.1016/j.humpath.2012.11.006
   VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V
   Wang Y, 2016, CANCER LETT, V380, P163, DOI 10.1016/j.canlet.2016.05.017
   Wu YM, 2013, CANCER DISCOV, V3, P636, DOI 10.1158/2159-8290.CD-13-0050
   Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729
NR 44
TC 387
Z9 413
U1 3
U2 40
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD MAR
PY 2017
VL 7
IS 3
BP 252
EP 263
DI 10.1158/2159-8290.CD-16-1000
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EN5AP
UT WOS:000396018300020
PM 28034880
OA Green Accepted, Green Submitted, Bronze
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Su, CQ
AF Su, Changqing
TI Survivin in survival of hepatocellular carcinoma
SO CANCER LETTERS
LA English
DT Review
DE Survivin; Hepatocellular carcinoma; Survival; Apoptosis; Targeted
   therapy
ID GASTRIC-CANCER CELL; TARGETING SURVIVIN; GENE-EXPRESSION;
   MOLECULAR-MECHANISM; PROMISING STRATEGY; COLORECTAL-CANCER; INDUCED
   APOPTOSIS; CCND1 EXPRESSION; PROTEIN SURVIVIN; DOWN-REGULATION
AB Survivin is an anti-apoptotic protein belonging to the inhibitor of apoptosis protein (IAP) family. It is involved in the regulation of important physiological and pathological processes in cells and functions to inhibit cell apoptosis and promote cell proliferation. Normally and terminally differentiated tissues are nearly negative for survivin. In contrast, survivin is highly expressed in most human tumor tissues, including hepatocellular carcinoma (HCC). The abnormal overexpression of survivin is closely related to the malignant biological behaviors of tumors. During the development and progression of HCC, the high level of survivin expression promotes cancer cell proliferation, inhibits cancer cell apoptosis, induces tumor stromal angiogenesis, reduces the sensitivity of cancer cells to radiotherapy and chemotherapy, and ultimately affects the prognosis of patients with HCC. Survivin expression is regulated by a large number of factors. The latest discovery indicated that the transcription factor octamer-binding transcription factor 4 (OCT4) enhances the expression of survivin though cyclin D1 (CCND1), which, in part, accounts for tumor cell proliferation, recurrence and metastasis. Survivin plays key roles in HCC, which renders it an ideal target for the treatment of HCC. The present article reviews the research progress on the relationship between survivin and HCC and on the HCC treatment strategies targeting survivin. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Su, Changqing] Second Mil Med Univ, Dept Mol Oncol, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China.
   [Su, Changqing] Second Mil Med Univ, Natl Ctr Liver Canc, Shanghai 200438, Peoples R China.
C3 Naval Medical University; Naval Medical University
RP Su, CQ (corresponding author), Second Mil Med Univ, Dept Mol Oncol, Eastern Hepatobiliary Surg Hosp, Shanghai 200438, Peoples R China.; Su, CQ (corresponding author), Second Mil Med Univ, Natl Ctr Liver Canc, Shanghai 200438, Peoples R China.
EM suchangqing@gmail.com
OI Su, Changqing/0000-0002-3396-7248
FU National Natural Science Foundation of China [81370552, 81402565];
   National Science and Technology Major Significant Projects of New Drugs
   Creation [2014ZX09101003]
FX We gratefully acknowledge the support from the National Natural Science
   Foundation of China (81370552, 81402565), and the National Science and
   Technology Major Significant Projects of New Drugs Creation
   (2014ZX09101003).
CR Altieri DC, 2013, CANCER LETT, V332, P225, DOI 10.1016/j.canlet.2012.03.005
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Aspe JR, 2010, ONCOTARGETS THER, V3, P247, DOI 10.2147/OTT.S15293
   Athanasoula KC, 2014, CANCER LETT, V347, P175, DOI 10.1016/j.canlet.2014.02.014
   Bao LL, 2013, CANCER LETT, V337, P226, DOI 10.1016/j.canlet.2013.05.007
   Barrett RMA, 2009, CELL CYCLE, V8, P278, DOI 10.4161/cc.8.2.7587
   Cao L, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-82
   Carew JS, 2015, MOL CANCER THER, V14, P1404, DOI 10.1158/1535-7163.MCT-14-1036
   Carrasco RA, 2011, MOL CANCER THER, V10, P221, DOI 10.1158/1535-7163.MCT-10-0756
   Chang BH, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0132-6
   Chang YJ, 2014, TUMOR BIOL, V35, P9957, DOI 10.1007/s13277-014-2257-6
   Chen Y, 2013, SURGERY, V153, P4, DOI 10.1016/j.surg.2012.03.030
   Cheung CHA, 2013, ONCOTARGETS THER, V6, P1453, DOI 10.2147/OTT.S33374
   de Necochea-Campion R, 2013, CANCER LETT, V339, P167, DOI 10.1016/j.canlet.2013.06.007
   Fernández JG, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-209
   Galuppo R, 2014, ANTICANCER RES, V34, P1709
   Gao Xiaohua, 2014, J Exp Ther Oncol, V10, P275
   Garcia-Saez I, 2011, J MOL BIOL, V405, P331, DOI 10.1016/j.jmb.2010.10.046
   Giodini A, 2002, CANCER RES, V62, P2462
   Gritsko T, 2006, CLIN CANCER RES, V12, P11, DOI 10.1158/1078-0432.CCR-04-1752
   Guo Y, 2008, STEM CELLS, V26, P30, DOI 10.1634/stemcells.2007-0401
   Han G, 2015, CANCER BIOL THER, V16, P77, DOI 10.4161/15384047.2014.987021
   He GQ, 2012, J CANCER RES CLIN, V138, P657, DOI 10.1007/s00432-011-1138-2
   Hu HZ, 2015, ONCOTARGET, V6, P1079, DOI 10.18632/oncotarget.2835
   Hu HZ, 2011, GUT, V60, P710, DOI 10.1136/gut.2010.220020
   Hu YH, 2015, BREAST CANCER RES TR, V151, P269, DOI 10.1007/s10549-015-3372-9
   Ito T, 2000, HEPATOLOGY, V31, P1080, DOI 10.1053/he.2000.6496
   Jiang XX, 2015, J BIOCHEM MOL TOXIC, V29, P458, DOI 10.1002/jbt.21712
   Jin Y, 2014, TUMOR BIOL, V35, P9905, DOI 10.1007/s13277-014-2279-0
   Kanwar JR, 2013, MED RES REV, V33, P765, DOI 10.1002/med.21264
   Kanwar JR, 2011, DRUG DISCOV TODAY, V16, P485, DOI 10.1016/j.drudis.2011.04.001
   Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4
   Kim SA, 2014, ONCOL LETT, V7, P1589, DOI 10.3892/ol.2014.1948
   Knauer SK, 2007, FASEB J, V21, P207, DOI 10.1096/fj.06-5741com
   Leng AM, 2012, CELL BIOL INT, V36, P893, DOI 10.1042/CBI20110473
   Li JS, 2008, CANCER LETT, V272, P91, DOI 10.1016/j.canlet.2008.06.032
   Li ZG, 2014, CANCER LETT, V354, P77, DOI 10.1016/j.canlet.2014.07.049
   Liu C, 2011, MOL ONCOL, V5, P545, DOI 10.1016/j.molonc.2011.10.001
   Liu JL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083350
   Liu L, 2014, ONCOL LETT, V7, P963, DOI 10.3892/ol.2014.1848
   Liu WS, 2013, ONCOL REP, V29, P1183, DOI 10.3892/or.2012.2196
   Marusawa H, 2003, EMBO J, V22, P2729, DOI 10.1093/emboj/cdg263
   Melucci E, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-13
   Minczuk M, 2005, FEBS J, V272, P5008, DOI 10.1111/j.1742-4658.2005.04910.x
   Mityaev MV, 2010, BIOCHEMISTRY-MOSCOW+, V75, P182, DOI 10.1134/S0006297910020082
   Mityaev M, 2008, BIOCHEMISTRY-MOSCOW+, V73, P1183, DOI 10.1134/S0006297908110035
   Miura K, 2011, SURG TODAY, V41, P175, DOI 10.1007/s00595-010-4390-1
   O'Connor DS, 2000, AM J PATHOL, V156, P393, DOI 10.1016/S0002-9440(10)64742-6
   O'Connor DS, 2000, P NATL ACAD SCI USA, V97, P13103, DOI 10.1073/pnas.240390697
   Oh SH, 2008, CLIN CANCER RES, V14, P1581, DOI 10.1158/1078-0432.CCR-07-0952
   Or YYY, 2014, MOL MED REP, V10, P2025, DOI 10.3892/mmr.2014.2413
   Ou DL, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-2
   Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200
   Pennati M, 2008, EXPERT OPIN THER TAR, V12, P463, DOI [10.1517/14728222.12.4.463, 10.1517/14728222.12.4.463 ]
   Qiu Y., 2015, Oncotarget
   Rauch A., 1845, BIOCHIM BIOPHYS ACTA, V2014, P202
   Salzano G, 2014, CANCER LETT, V343, P224, DOI 10.1016/j.canlet.2013.09.037
   Shin S, 2001, BIOCHEMISTRY-US, V40, P1117, DOI 10.1021/bi001603q
   Singh N, 2015, DRUG DISCOV TODAY, V20, P578, DOI 10.1016/j.drudis.2014.11.013
   Song ZY, 2003, J BIOL CHEM, V278, P23130, DOI 10.1074/jbc.M300957200
   Stauber RH, 2007, CANCER RES, V67, P5999, DOI 10.1158/0008-5472.CAN-07-0494
   Sun B, 2013, ONCOL REP, V30, P385, DOI 10.3892/or.2013.2479
   Suzuki A, 2000, ONCOGENE, V19, P1346, DOI 10.1038/sj.onc.1203429
   Tamm I, 1998, CANCER RES, V58, P5315
   Tapias A, 2008, CELL CYCLE, V7, P2856, DOI 10.4161/cc.7.18.6671
   Trabulo S, 2011, MOL PHARMACEUT, V8, P1120, DOI 10.1021/mp100426e
   Tsubaki M, 2015, LEUKEMIA RES, V39, P445, DOI 10.1016/j.leukres.2015.01.016
   Valenzuela MMA, 2015, ONCOTARGETS THER, V8, P495, DOI 10.2147/OTT.S79647
   Wang JF, 2015, CANCER LETT, V362, P83, DOI 10.1016/j.canlet.2015.03.025
   Weng Y, 2012, ONCOL RES, V20, P411, DOI 10.3727/096504013X13657689383094
   Wheatley SP, 2015, CELL CYCLE, V14, P261, DOI 10.4161/15384101.2014.979680
   Xia HP, 2015, ONCOTARGET, V6, P5990, DOI 10.18632/oncotarget.3337
   Xu GY, 2014, ONCOTARGET, V5, P5029, DOI 10.18632/oncotarget.2078
   Yamamoto H, 2008, CANCER SCI, V99, P1709, DOI 10.1111/j.1349-7006.2008.00870.x
   Yang W, 2010, INT J RADIAT BIOL, V86, P445, DOI 10.3109/09553001003668006
   Zarogoulidis P, 2015, CELL SIGNAL, V27, P1576, DOI 10.1016/j.cellsig.2015.04.009
   Zhang RF, 2015, CANCER LETT, V357, P141, DOI 10.1016/j.canlet.2014.11.023
   Zhang R, 2008, CANCER BIOL THER, V7, P547, DOI 10.4161/cbt.7.4.5484
   Zhang WY, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-128
   Zhang Y, 2013, MOL ONCOL, V7, P346, DOI 10.1016/j.molonc.2012.10.007
   Zou HF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070494
NR 81
TC 89
Z9 99
U1 0
U2 36
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD SEP 1
PY 2016
VL 379
IS 2
SI SI
BP 184
EP 190
DI 10.1016/j.canlet.2015.06.016
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DT6KJ
UT WOS:000381592800006
PM 26118774
DA 2025-01-04
ER

PT J
AU Ros, J
   Rodríguez-Castells, M
   Saoudi, N
   Baraibar, I
   Salva, F
   Tabernero, J
   Élez, E
AF Ros, Javier
   Rodriguez-Castells, Marta
   Saoudi, Nadia
   Baraibar, Iosune
   Salva, Francesc
   Tabernero, Josep
   Elez, Elena
TI Treatment of <i>BRAF</i>-V600E mutant metastatic colorectal cancer: new
   insights and biomarkers
SO EXPERT REVIEW OF ANTICANCER THERAPY
LA English
DT Article
DE Biomarkers; BRAF V600E mutation; colon cancer; EGFR;
   encorafenib-cetuximab-binimetinib; liquid biopsy; RNF43 mutation; VEGF;
   >
ID CETUXIMAB PLUS IRINOTECAN; PHASE-III TRIAL; BRAF MUTATION; OPEN-LABEL;
   MICROSATELLITE INSTABILITY; 1ST-LINE TREATMENT; SUBGROUP ANALYSES; EGFR
   INHIBITION; DOSE-ESCALATION; ENCORAFENIB
AB IntroductionThe presence of a BRAF-V600E mutation in metastatic colorectal cancer (mCRC) is observed in approximately 12% of cases and is associated with poor prognosis and aggressive disease. Unlike melanoma, the development of successful BRAF blockade in colorectal cancer has been complex. The phase III BEACON trial made significant progress in the development of BRAF inhibitors by establishing encorafenib-cetuximab as the new standard of care for patients with mCRC who have progressed to one or two previous lines of treatment. Nonetheless, not all patients respond to encorafenib-based combinations, and some responses are short-lived. Identifying new strategies to boost antitumor activity and improve survival is paramount.Areas coveredThe development of targeted therapy for BRAF-V600E mCRC starting with BRAF inhibitors as monotherapy through novel combinations with anti-VEGF or anti-PD1 agents to enhance antitumor activity is reviewed, with a particular focus on the development of predictive and prognostic biomarkers.Expert opinionThere is a crucial need to better understand tumor biology and develop accurate and reliable biomarkers to enhance the antitumor activity of encorafenib-based combinations. The RNF43 mutation is an accurate and reliable predictive biomarker of response, and combinations that target crosstalk between the MAPK pathway, the immune system, and WNT pathways seem promising.
C1 [Ros, Javier; Rodriguez-Castells, Marta; Saoudi, Nadia; Baraibar, Iosune; Salva, Francesc; Tabernero, Josep; Elez, Elena] Vall Dhebron Univ Hosp, Barcelona, Spain.
   [Ros, Javier; Rodriguez-Castells, Marta; Saoudi, Nadia; Baraibar, Iosune; Salva, Francesc; Tabernero, Josep; Elez, Elena] Vall Dhebron Inst Oncol, Med Oncol Dept, Barcelona, Spain.
C3 Hospital Universitari Vall d'Hebron; Vall d'Hebron Institut d'Oncologia
   (VHIO)
RP Élez, E (corresponding author), Vall Dhebron Univ Hosp, Barcelona, Spain.
RI Baraibar, Iosune/GXF-7067-2022; Ros, Javier/HKF-1171-2023; Gonzalez,
   Nadia/AAM-9354-2021
OI Ros, Javier/0000-0002-8137-5415; Saoudi Gonzalez,
   Nadia/0000-0001-6044-1703
CR Akhoundova D, 2021, JCO PRECIS ONCOL, V5, P1082, DOI 10.1200/PO.21.00107
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Hyman David M, 2015, N Engl J Med, V373, P726, DOI 10.1056/NEJMoa1502309
   [Anonymous], 2018, J Clin Oncol
   Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bottos A, 2012, P NATL ACAD SCI USA, V109, pE353, DOI 10.1073/pnas.1105026109
   Cervantes A, 2023, ANN ONCOL, V34, P10, DOI 10.1016/j.annonc.2022.10.003
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Comunanza V, 2017, EMBO MOL MED, V9, P219, DOI 10.15252/emmm.201505774
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Di Nicolantonio F, 2021, NAT REV CLIN ONCOL, V18, P506, DOI 10.1038/s41571-021-00495-z
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Elez E, 2023, NAT MED, V29, P307, DOI 10.1038/s41591-022-02192-5
   Elez E, 2022, NAT MED, V28, P2162, DOI 10.1038/s41591-022-01976-z
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Gomez-Roca C. A., 2014, Ann Oncol, DOI [10.1093/annonc/mdu333.38, DOI 10.1093/ANNONC/MDU333.38]
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Inagaki C, 2023, FUTURE ONCOL, V19, P1165, DOI 10.2217/fon-2023-0209
   Ince WL, 2005, JNCI-J NATL CANCER I, V97, P981, DOI 10.1093/jnci/dji174
   Karapetis CS, 2014, CLIN CANCER RES, V20, P744, DOI 10.1158/1078-0432.CCR-13-0606
   Klute KA, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.22.00191
   Kopetz S, 2022, ANN ONCOL, V33, pS681, DOI 10.1016/j.annonc.2022.07.454
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3513
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Middleton G, 2020, CLIN CANCER RES, V26, P2466, DOI 10.1158/1078-0432.CCR-19-3579
   Morris VK, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.012
   Parsons MT, 2012, J MED GENET, V49, P151, DOI 10.1136/jmedgenet-2011-100714
   Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Quintanilha JCF, 2023, ONCOLOGIST, DOI 10.1093/oncolo/oyac265
   Ros J, 2023, ANN ONCOL, V34, P543, DOI 10.1016/j.annonc.2023.02.016
   Ros J, 2022, EUR J CANCER, V172, P326, DOI 10.1016/j.ejca.2022.06.026
   Ros J, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835921992974
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Ruiz-Saenz A, 2023, NAT CANCER, V4, P240, DOI 10.1038/s43018-022-00508-5
   Saridaki Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084604
   Seligmann JF, 2017, ANN ONCOL, V28, P562, DOI 10.1093/annonc/mdw645
   Siegel RL, 2023, CA-CANCER J CLIN, V73, P233, DOI 10.3322/caac.21772
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Stintzing S, 2017, EUR J CANCER, V79, P50, DOI 10.1016/j.ejca.2017.03.023
   Tabernero J, 2022, ANN ONCOL, V33, pS1392, DOI 10.1016/j.annonc.2022.08.022
   Tabernero Josep, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_349561
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tan LVN, 2023, CLIN CANCER RES, V29, P1017, DOI 10.1158/1078-0432.CCR-22-3094
   Tian J, 2023, NAT MED, V29, P458, DOI 10.1038/s41591-022-02181-8
   Van Cutsem E, 2023, J CLIN ONCOL, V41, P2628, DOI 10.1200/JCO.22.01693
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
NR 68
TC 11
Z9 11
U1 1
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1473-7140
EI 1744-8328
J9 EXPERT REV ANTICANC
JI Expert Rev. Anticancer Ther
PD AUG 3
PY 2023
VL 23
IS 8
BP 797
EP 806
DI 10.1080/14737140.2023.2236794
EA JUL 2023
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA P2XA3
UT WOS:001032169600001
PM 37482749
DA 2025-01-04
ER

PT J
AU Zhou, J
   Ji, Q
   Li, Q
AF Zhou, Jing
   Ji, Qing
   Li, Qi
TI Resistance to anti-EGFR therapies in metastatic colorectal cancer:
   underlying mechanisms and reversal strategies
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Review
DE Metastatic colorectal cancer; Anti-epidermal growth factor receptor
   targeted therapies; Drug resistance; Reversal strategies
ID GROWTH-FACTOR RECEPTOR; PHASE-II TRIAL; WILD-TYPE KRAS; CETUXIMAB PLUS
   IRINOTECAN; K-RAS MUTATIONS; COLON-CANCER; MONOCLONAL-ANTIBODY; 1ST-LINE
   TREATMENT; ACQUIRED-RESISTANCE; TGF-ALPHA
AB Cetuximab and panitumumab are monoclonal antibodies (mAbs) against epidermal growth factor receptor (EGFR) that are effective agents for metastatic colorectal cancer (mCRC). Cetuximab can prolong survival by 8.2 months in RAS wild-type (WT) mCRC patients. Unfortunately, resistance to targeted therapy impairs clinical use and efficiency. The mechanisms of resistance refer to intrinsic and extrinsic alterations of tumours. Multiple therapeutic strategies have been investigated extensively to overcome resistance to anti-EGFR mAbs. The intrinsic mechanisms include EGFR ligand overexpression, EGFR alteration, RAS/RAF/PI3K gene mutations, ERBB2/MET/IGF-1R activation, metabolic remodelling, microsatellite instability and autophagy. For intrinsic mechanisms, therapies mainly cover the following: new EGFR-targeted inhibitors, a combination of multitargeted inhibitors, and metabolic regulators. In addition, new cytotoxic drugs and small molecule compounds increase the efficiency of cetuximab. Extrinsic alterations mainly disrupt the tumour microenvironment, specifically immune cells, cancer-associated fibroblasts (CAFs) and angiogenesis. The directions include the modification or activation of immune cells and suppression of CAFs and anti-VEGFR agents. In this review, we focus on the mechanisms of resistance to anti-EGFR monoclonal antibodies (anti-EGFR mAbs) and discuss diverse approaches to reverse resistance to this therapy in hopes of identifying more mCRC treatment possibilities.
C1 [Zhou, Jing; Ji, Qing; Li, Qi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, Shanghai 201203, Peoples R China.
   [Zhou, Jing; Ji, Qing; Li, Qi] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Canc, Shanghai 201203, Peoples R China.
   [Li, Qi] Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai 201203, Peoples R China.
C3 Shanghai University of Traditional Chinese Medicine; Shanghai University
   of Traditional Chinese Medicine; Shanghai University of Traditional
   Chinese Medicine
RP Ji, Q; Li, Q (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Med Oncol, Shanghai 201203, Peoples R China.; Ji, Q; Li, Q (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Inst Canc, Shanghai 201203, Peoples R China.; Li, Q (corresponding author), Shanghai Univ Tradit Chinese Med, Acad Integrat Med, Shanghai 201203, Peoples R China.
EM ttt99118@hotmail.com; qili@shutcm.edu.cn
OI Li, Qi/0000-0003-2004-6885; Ji, Qing/0000-0002-1899-0204
FU National Science Foundation of China [81830120, 82074225]; Clinical
   Research Plan of Shanghai Hospital Development Center [SHDC2020CR4043]
FX This work was supported by National Science Foundation of China
   (81830120 to Q.L., 82074225 to Q.J.) and Clinical Research Plan of
   Shanghai Hospital Development Center (SHDC2020CR4043 to Y.W.).
CR Akkaya M, 2018, NAT IMMUNOL, V19, P255, DOI 10.1038/s41590-018-0052-z
   Alonso V, 2018, NEOPLASIA, V20, P678, DOI 10.1016/j.neo.2018.05.004
   [Anonymous], ASCO M LIB 2021
   [Anonymous], ASCO M LIB 2021
   Arai H, 2021, EUR J CANCER, V150, P133, DOI 10.1016/j.ejca.2021.03.048
   Arena S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5640
   Baba Y, 2017, MOL ONCOL, V11, P1065, DOI 10.1002/1878-0261.12074
   Bagchi A, 2018, MOL CANCER THER, V17, P521, DOI 10.1158/1535-7163.MCT-17-0575
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Bellier J, 2020, CELL REP, V30, P1400, DOI 10.1016/j.celrep.2020.01.012
   Bennouna J, 2015, INVEST NEW DRUG, V33, P138, DOI 10.1007/s10637-014-0142-1
   Berasain C, 2016, HEPATOLOGY, V63, P371, DOI 10.1002/hep.28246
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bibeau F, 2009, J CLIN ONCOL, V27, P1122, DOI 10.1200/JCO.2008.18.0463
   Blons H, 2014, ANN ONCOL, V25, P2378, DOI 10.1093/annonc/mdu464
   Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Borner M, 2008, ANN ONCOL, V19, P1288, DOI 10.1093/annonc/mdn058
   Bowles DW, 2016, CLIN COLORECTAL CANC, V15, P337, DOI 10.1016/j.clcc.2016.03.004
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Calemma R, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-232
   Cappuzzo F, 2008, BRIT J CANCER, V99, P83, DOI 10.1038/sj.bjc.6604439
   Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen P, 2020, THERANOSTICS, V10, P5107, DOI 10.7150/thno.44705
   Chen Z, 2016, AM J TRANSL RES, V8, P1190
   Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230
   Ciardiello F, 2011, CANCER DISCOV, V1, P472, DOI 10.1158/2159-8290.CD-11-0261
   Cohen AS, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100828
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Cuneo KC, 2019, TRANSL ONCOL, V12, P209, DOI 10.1016/j.tranon.2018.10.005
   Damiano V, 2006, CLIN CANCER RES, V12, P577, DOI 10.1158/1078-0432.CCR-05-1943
   Damiano V, 2007, P NATL ACAD SCI USA, V104, P12468, DOI 10.1073/pnas.0705226104
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Angelis ML, 2016, STEM CELL TRANSL MED, V5, P511, DOI 10.5966/sctm.2015-0214
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Delord JP, 2020, INVEST NEW DRUG, V38, P1774, DOI 10.1007/s10637-020-00928-z
   Deming DA, 2016, INVEST NEW DRUG, V34, P168, DOI 10.1007/s10637-015-0314-7
   Dienstmann R, 2015, CANCER DISCOV, V5, P598, DOI 10.1158/2159-8290.CD-14-1432
   Ding CB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2834-8
   Du ZG, 2018, CELL REP, V22, P2677, DOI 10.1016/j.celrep.2018.02.037
   Duldulao MP, 2013, ANN SURG ONCOL, V20, P2166, DOI 10.1245/s10434-013-2910-0
   Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430
   Elez E, 2016, BRIT J CANCER, V114, P372, DOI 10.1038/bjc.2015.480
   Eng C, 2016, INT J CANCER, V139, P177, DOI 10.1002/ijc.30049
   Foster P, 2015, MOL CANCER THER, V14, P931, DOI 10.1158/1535-7163.MCT-14-0833
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Gao LL, 2019, AM J CANCER RES, V9, P2531
   Han Y, 2020, ADV SCI, V7, DOI 10.1002/advs.202000112
   Hong CS, 2020, CANCER SCI, V111, P3268, DOI 10.1111/cas.14526
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hong S, 2016, CANCER MED-US, V5, P248, DOI 10.1002/cam4.591
   Houot R, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/21624011.2014.941740
   Huang F, 2012, CLIN CANCER RES, V18, P1156, DOI 10.1158/1078-0432.CCR-11-1135
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Innocenti F, 2019, J CLIN ONCOL, V37, P1217, DOI 10.1200/JCO.18.01798
   Ishiguro N, 2020, ARTHRITIS RHEUMATOL, V72, P166, DOI 10.1002/art.41052
   Jacobs B, 2009, J CLIN ONCOL, V27, P5068, DOI 10.1200/JCO.2008.21.3744
   Jacobs SA, 2021, CLIN CANCER RES, V27, P1612, DOI 10.1158/1078-0432.CCR-20-1831
   Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659
   Jung SA, 2016, FREE RADICAL BIO MED, V95, P200, DOI 10.1016/j.freeradbiomed.2016.03.009
   Jutten B, 2018, AUTOPHAGY, V14, P283, DOI 10.1080/15548627.2017.1409926
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Kloth M, 2016, GUT, V65, P1296, DOI 10.1136/gutjnl-2014-309026
   Kohrt HE, 2014, J CLIN INVEST, V124, P2668, DOI 10.1172/JCI73014
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Koustas E, 2017, CANCER LETT, V396, P94, DOI 10.1016/j.canlet.2017.03.023
   Kuwada SK, 2004, INT J CANCER, V109, P291, DOI 10.1002/ijc.11686
   Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796
   Lee HW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235894
   Lee J, 2011, JNCI-J NATL CANCER I, V103, P674, DOI 10.1093/jnci/djr070
   Li XQ, 2010, CANCER RES, V70, P5942, DOI 10.1158/0008-5472.CAN-10-0157
   Liao HW, 2015, J CLIN INVEST, V125, P4529, DOI 10.1172/JCI82826
   Lim Y, 2016, MOL CANCER THER, V15, P251, DOI 10.1158/1535-7163.MCT-15-0679
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568
   Loupakis F, 2014, TARGET ONCOL, V9, P205, DOI 10.1007/s11523-013-0284-7
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796
   Luca T, 2014, CELL PROLIFERAT, V47, P435, DOI 10.1111/cpr.12125
   Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T
   Lutterbuese R, 2010, P NATL ACAD SCI USA, V107, P12605, DOI 10.1073/pnas.1000976107
   Maddalena F, 2020, MOL ONCOL, V14, P3030, DOI 10.1002/1878-0261.12814
   Mao C, 2012, ANN ONCOL, V23, P1518, DOI 10.1093/annonc/mdr464
   Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007
   Medema JP, 2017, NEW ENGL J MED, V377, P888, DOI 10.1056/NEJMcibr1706541
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595
   Mimeault M, 2007, J CELL MOL MED, V11, P981, DOI 10.1111/j.1582-4934.2007.00088.x
   Misale S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9305
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947
   Modest DP, 2015, J CLIN ONCOL, V33, P3718, DOI 10.1200/JCO.2015.61.2887
   Molinari F, 2009, BRIT J CANCER, V100, P1087, DOI 10.1038/sj.bjc.6604848
   Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137
   Montagut C, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.5245
   Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6
   Mortara L, 2018, TARGET ONCOL, V13, P657, DOI 10.1007/s11523-018-0586-x
   Mutsaers AJ, 2009, CLIN CANCER RES, V15, P2397, DOI 10.1158/1078-0432.CCR-08-1627
   Napolitano S, 2015, CLIN CANCER RES, V21, P2975, DOI 10.1158/1078-0432.CCR-15-0020
   Negri FV, 2010, BRIT J CANCER, V102, P162, DOI 10.1038/sj.bjc.6605471
   Okada J, 2018, CLIN COLORECTAL CANC, V17, pE45, DOI 10.1016/j.clcc.2017.09.005
   Oliveras-Ferraros C, 2011, J CELL BIOCHEM, V112, P10, DOI 10.1002/jcb.22952
   Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d
   Pander J, 2011, CLIN CANCER RES, V17, P5668, DOI 10.1158/1078-0432.CCR-11-0239
   Parseghian CM, 2017, CLIN CANCER RES, V23, P4146, DOI 10.1158/1078-0432.CCR-16-3138
   Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541
   Poindessous V, 2011, CLIN CANCER RES, V17, P6522, DOI 10.1158/1078-0432.CCR-11-1607
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price T, 2020, CANCER BIOL THER, V21, P891, DOI 10.1080/15384047.2020.1798695
   Reidy DL, 2010, J CLIN ONCOL, V28, P4240, DOI 10.1200/JCO.2010.30.4154
   Rimassa L, 2019, CLIN COLORECTAL CANC, V18, P125, DOI 10.1016/j.clcc.2019.02.004
   Rosa R, 2011, CLIN CANCER RES, V17, P6531, DOI 10.1158/1078-0432.CCR-10-3376
   Sánchez-Martín FJ, 2016, CLIN CANCER RES, V22, P3260, DOI 10.1158/1078-0432.CCR-15-2400
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Schirripa M, 2017, INT J CANCER, V141, P383, DOI 10.1002/ijc.30715
   Sclafani F, 2013, ANN ONCOL, V24, P3123, DOI 10.1093/annonc/mdt408
   Sclafani F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv258
   Shapiro GI, 2014, CLIN CANCER RES, V20, P233, DOI 10.1158/1078-0432.CCR-13-1777
   Shin Wookjin, 2018, Exp Mol Med, V50, P1, DOI 10.1038/s12276-018-0102-5
   Shinozaki E, 2017, BRIT J CANCER, V117, P1450, DOI 10.1038/bjc.2017.308
   Sidaway P, 2019, NAT REV CLIN ONCOL, V16, P527, DOI 10.1038/s41571-019-0259-4
   Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695
   Skvortsov S, 2004, MOL CANCER THER, V3, P1551
   Rocca YS, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00413
   Song N, 2014, INT J MOL SCI, V15, P5838, DOI 10.3390/ijms15045838
   Subbiah V, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.90380
   Tabernero J, 2007, J CLIN ONCOL, V25, P5225, DOI 10.1200/JCO.2007.13.2183
   Troiani T, 2015, CLIN CANCER RES, V21, P4153, DOI 10.1158/1078-0432.CCR-15-0211
   Troiani T, 2014, CLIN CANCER RES, V20, P3775, DOI 10.1158/1078-0432.CCR-13-2181
   Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423
   Vallböhmer D, 2005, J CLIN ONCOL, V23, P3536, DOI 10.1200/jco.2005.23.16_suppl.3536
   Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
   Veluchamy JP, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00087
   Vinagre J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3185
   Vincenzi B, 2007, PHARMACOGENOMICS, V8, P319, DOI 10.2217/14622416.8.4.319
   Vlacich G, 2011, CANCER CELL, V20, P423, DOI 10.1016/j.ccr.2011.10.006
   Wang F, 2017, CELL RES, V27, P540, DOI 10.1038/cr.2017.7
   Wang JY, 2003, INT J CANCER, V107, P387, DOI 10.1002/ijc.11417
   Winder T, 2010, CLIN CANCER RES, V16, P5591, DOI 10.1158/1078-0432.CCR-10-2092
   Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013
   Wu YL, 2018, J CLIN ONCOL, V36, P3101, DOI 10.1200/JCO.2018.77.7326
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Ye H, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00584-z
   Yen LC, 2010, ANN SURG, V251, P254, DOI 10.1097/SLA.0b013e3181bc9d96
   Yoon J, 2011, CANCER RES, V71, P445, DOI 10.1158/0008-5472.CAN-10-3058
   Zaal EA, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00500
NR 153
TC 106
Z9 110
U1 4
U2 14
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD OCT 18
PY 2021
VL 40
IS 1
AR 328
DI 10.1186/s13046-021-02130-2
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WI6PP
UT WOS:000708480300001
PM 34663410
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Loft, M
   To, YH
   Gibbs, P
   Tie, JN
AF Loft, Matthew
   To, Yat Hang
   Gibbs, Peter
   Tie, Jeanne
TI Clinical application of circulating tumour DNA in colorectal cancer
SO LANCET GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
ID ADVANCED RECTAL-CANCER; ANTI-EGFR THERAPIES; LIQUID BIOPSY;
   ACQUIRED-RESISTANCE; ADJUVANT THERAPY; OPEN-LABEL; PREOPERATIVE
   CHEMORADIOTHERAPY; MICROSATELLITE INSTABILITY; 1ST-LINE CHEMOTHERAPY;
   PLUS CETUXIMAB
AB Liquid biopsies that detect circulating tumour DNA (ctDNA) have the potential to revolutionise the personalised management of colorectal cancer. For patients with early-stage disease, emerging clinical applications include the assessment of molecular residual disease after surgery, the monitoring of adjuvant chemotherapy efficacy, and early detection of recurrence during surveillance. In the advanced disease setting, data highlight the potential of ctDNA levels as a prognostic marker and as an early indicator of treatment response. ctDNA assessment can complement standard tissue-based testing for molecular characterisation, with the added ability to monitor emerging mutations under the selective pressure of targeted therapy. Here we provide an overview of the evidence supporting the use of ctDNA in colorectal cancer, the studies underway to address some of the outstanding questions, and the barriers to widespread clinical uptake.
C1 [Loft, Matthew; To, Yat Hang; Gibbs, Peter; Tie, Jeanne] Walter & Eliza Hall Inst Med Res, Div Personalised Oncol, Parkville, Vic, Australia.
   [Loft, Matthew; To, Yat Hang; Gibbs, Peter; Tie, Jeanne] Univ Melbourne, Dept Med Biol, Parkville, Vic, Australia.
   [Loft, Matthew; Gibbs, Peter] Western Hlth, Dept Med Oncol, Footscray, Vic, Australia.
   [To, Yat Hang; Tie, Jeanne] Peter MacCallum Canc Ctr, Dept Med Oncol, Parkville, Vic, Australia.
   [Tie, Jeanne] Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3000, Australia.
C3 Walter & Eliza Hall Institute; University of Melbourne; Peter Maccallum
   Cancer Center; University of Melbourne; Peter Maccallum Cancer Center
RP Tie, JN (corresponding author), Univ Melbourne, Sir Peter MacCallum Dept Oncol, Parkville, Vic 3000, Australia.
EM jeanne.tie@petermac.org
CR André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   Awad MM, 2021, NEW ENGL J MED, V384, P2382, DOI 10.1056/NEJMoa2105281
   Bachet JB, 2018, ANN ONCOL, V29, P1211, DOI 10.1093/annonc/mdy061
   Bahadoer RR, 2021, LANCET ONCOL, V22, P29, DOI 10.1016/S1470-2045(20)30555-6
   Bando H, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.21.00535
   Bando H, 2019, BRIT J CANCER, V120, P982, DOI 10.1038/s41416-019-0457-y
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Battaglin F, 2018, CLIN ADV HEMATOL ONC, V16, P735
   Benson AB., 2021, J. Natl. Compr. Canc. Netw., V19, P329, DOI DOI 10.6004/JNCCN.2021.0012
   Bidard FC, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060516
   Bob TL, 2022, J CLIN ONCOL, V40
   Booth CM, 2021, J CLIN ONCOL, V39, P3767, DOI 10.1200/JCO.21.01972
   Cervantes A, 2023, ANN ONCOL, V34, P10, DOI 10.1016/j.annonc.2022.10.003
   Chen EX, 2020, JAMA ONCOL, V6, P831, DOI 10.1001/jamaoncol.2020.0910
   Chen G, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01089-z
   Clifton K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.19.00141
   Conroy T, 2021, LANCET ONCOL, V22, P702, DOI 10.1016/S1470-2045(21)00079-6
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Crisafulli G, 2022, CANCER DISCOV, V12, P1656, DOI 10.1158/2159-8290.CD-21-1434
   Dasari A, 2020, NAT REV CLIN ONCOL, V17, P757, DOI 10.1038/s41571-020-0392-0
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   El Messaoudi S, 2016, CLIN CANCER RES, V22, P3067, DOI 10.1158/1078-0432.CCR-15-0297
   Faulkner LG, 2023, BRIT J CANCER, V128, P297, DOI 10.1038/s41416-022-02017-9
   Garlan F, 2017, CLIN CANCER RES, V23, P5416, DOI 10.1158/1078-0432.CCR-16-3155
   Grasselli J, 2017, ANN ONCOL, V28, P1294, DOI 10.1093/annonc/mdx112
   Hazar-Rethinam M, 2018, CANCER DISCOV, V8, P417, DOI 10.1158/2159-8290.CD-17-1227
   Henriksen TV, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.11
   Henriksen TV, 2022, CLIN CANCER RES, V28, P507, DOI 10.1158/1078-0432.CCR-21-2404
   Israeli E, 2022, ISR MED ASSOC J, V24, P481, DOI 10.1056/NEJMoa2200075
   Khan KH, 2018, CANCER DISCOV, V8, P1270, DOI 10.1158/2159-8290.CD-17-0891
   Kim S, 2022, BRIT J CANCER, V127, P898, DOI 10.1038/s41416-022-01837-z
   Kopetz S, 2022, Ann Oncol, V33, P33
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Kotani D, 2023, NAT MED, V29, P127, DOI 10.1038/s41591-022-02115-4
   LABIANCA R, 1995, LANCET, V345, P939
   Lee S, 2021, CANCERS, V13, DOI 10.3390/cancers13092231
   LEON SA, 1977, CANCER RES, V37, P646
   Liu WY, 2022, EBIOMEDICINE, V78, DOI 10.1016/j.ebiom.2022.103945
   Loupakis F, 2021, JCO PRECIS ONCOL, V5, P1166, DOI 10.1200/PO.21.00101
   Lu L, 2018, J GENET GENOMICS, V45, P79, DOI 10.1016/j.jgg.2017.11.006
   Ludford K, 2023, J CLIN ONCOL, V41, P2181, DOI 10.1200/JCO.22.01351
   Lueong SS, 2020, CLIN CHEM, V66, P1510, DOI 10.1093/clinchem/hvaa223
   Lyskjær I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47708-1
   Ma MW, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.09.29
   Ma XJM, 2020, CLIN CANCER RES, V26, P4010, DOI 10.1158/1078-0432.CCR-19-1209
   Manca P, 2022, BRIT J CANCER, V126, P449, DOI 10.1038/s41416-021-01591-8
   MANDEL P, 1948, CR SOC BIOL, V142, P241
   Marmorino F, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.22.00244
   Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915
   Mason MC, 2021, J AM COLL SURGEONS, V233, P82, DOI 10.1016/j.jamcollsurg.2021.02.011
   Maurel J, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00289
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Moding EJ, 2021, CANCER DISCOV, V11, P2968, DOI 10.1158/2159-8290.CD-21-0634
   MOERTEL CG, 1990, NEW ENGL J MED, V322, P352, DOI 10.1056/NEJM199002083220602
   Montagut C, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.5245
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Murray DH, 2018, J CANCER RES CLIN, V144, P1741, DOI 10.1007/s00432-018-2701-x
   Nakamura Y, 2021, NAT MED, V27, P1899, DOI 10.1038/s41591-021-01553-w
   Newhook TE, 2023, ANN SURG, V277, P813, DOI 10.1097/SLA.0000000000005461
   Normanno N, 2018, ANN ONCOL, V29, P112, DOI 10.1093/annonc/mdx417
   Osumi H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53711-3
   Overman MJ, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3522
   Parikh A R., 2021, CLIN CANCER RES, V27, pOF1, DOI DOI 10.1158/1078-0432.CCR-21-0410
   Parikh AR, 2020, CLIN CANCER RES, V26, P1877, DOI 10.1158/1078-0432.CCR-19-3467
   Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9
   Parseghian CM, 2019, ANN ONCOL, V30, P243, DOI 10.1093/annonc/mdy509
   Parseghian CM, 2023, J CLIN ONCOL, V41, P460, DOI 10.1200/JCO.22.01423
   Pascual J, 2022, ANN ONCOL, V33, P750, DOI 10.1016/j.annonc.2022.05.520
   Peeters M, 2019, CLIN CANCER RES, V25, P1216, DOI 10.1158/1078-0432.CCR-18-2072
   Pinheiro M, 2022, INT J COLORECTAL DIS, V37, P895, DOI 10.1007/s00384-022-04126-6
   Raghav K, 2023, J CLIN ONCOL, V41, P472, DOI 10.1200/JCO.22.00365
   Rebuzzi SE, 2020, CANCERS, V12, DOI 10.3390/cancers12092584
   Rehman AU, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01577-x
   Reinert T, 2019, JAMA ONCOL, V5, P1124, DOI 10.1001/jamaoncol.2019.0528
   Vivas CS, 2022, ANN ONCOL, V33, pS291, DOI 10.1016/j.annonc.2022.04.208
   Sartore-Bianchi A, 2022, NAT MED, V28, P1612, DOI 10.1038/s41591-022-01886-0
   Schmiegel W, 2017, MOL ONCOL, V11, P208, DOI 10.1002/1878-0261.12023
   Shitara K, 2023, J CLIN ONCOL, V41, P11
   Siena S, 2021, ANN ONCOL, V32, pS532, DOI 10.1016/j.annonc.2021.08.908
   Siravegna G, 2019, CLIN CANCER RES, V25, P3046, DOI 10.1158/1078-0432.CCR-18-3389
   Siravegna G, 2018, CANCER CELL, V34, P148, DOI 10.1016/j.ccell.2018.06.004
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Sorbye H, 2004, ACTA ONCOL, V43, P495, DOI 10.1080/02841860410032380
   Strickler JH, 2018, CANCER DISCOV, V8, P164, DOI 10.1158/2159-8290.CD-17-1009
   Taly V., 2021, CLIN CANCER RES, V27, P5638
   Tan LVN, 2023, CLIN CANCER RES, V29, P1017, DOI 10.1158/1078-0432.CCR-22-3094
   Tarazona N, 2019, ANN ONCOL, V30, P1804, DOI 10.1093/annonc/mdz390
   Thomsen CB, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920918472
   Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177
   Tie J, 2022, Ann Oncol, V33, P33
   Tie J, 2022, Ann Oncol, V33, pS136
   Tie J, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003620
   Tie J, 2021, INT J CANCER, V148, P1014, DOI 10.1002/ijc.33312
   Tie J, 2019, JAMA ONCOL, V5, P1710, DOI 10.1001/jamaoncol.2019.3616
   Tie J, 2019, GUT, V68, P663, DOI 10.1136/gutjnl-2017-315852
   Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219
   To YH, 2021, PHARMACOECONOMICS, V39, P953, DOI 10.1007/s40273-021-01047-0
   van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
   van 't Erve I, 2023, CLIN CANCER RES, V29, P899, DOI 10.1158/1078-0432.CCR-22-2538
   Vidal J, 2017, ANN ONCOL, V28, P1325, DOI 10.1093/annonc/mdx125
   Vidal J, 2023, CLIN CANCER RES, V29, P379, DOI 10.1158/1078-0432.CCR-22-1696
   Vidal J, 2021, CLIN CANCER RES, V27, P2890, DOI 10.1158/1078-0432.CCR-20-4769
   Wang YQ, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003741
   Wang YX, 2019, JAMA ONCOL, V5, P1118, DOI 10.1001/jamaoncol.2019.0512
   Watanabe J, 2023, JAMA-J AM MED ASSOC, V329, P1271, DOI 10.1001/jama.2023.4428
   Willis J, 2019, CLIN CANCER RES, V25, P7035, DOI 10.1158/1078-0432.CCR-19-1324
   Xue J, 2023, ANZ J SURG, V93, P506, DOI 10.1111/ans.18078
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Yothers G, 2011, J CLIN ONCOL, V29, P3768, DOI 10.1200/JCO.2011.36.4539
   Yu LZ, 2022, PLOS ONE, V17, DOI 10.1371/journal.pone.0266889
NR 112
TC 13
Z9 13
U1 4
U2 24
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
EI 2468-1253
J9 LANCET GASTROENTEROL
JI Lancet Gastroenterol. Hepatol.
PD SEP
PY 2023
VL 8
IS 9
BP 837
EP 852
DI 10.1016/S2468-1253(23)00146-2
EA AUG 2023
PG 16
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA R3LT0
UT WOS:001063407200001
PM 37499673
DA 2025-01-04
ER

PT J
AU Fang, Q
   Ni, CD
   Cai, Z
   Li, WY
   Xie, JJ
AF Fang, Qian
   Ni, Chuandou
   Cai, Zhun
   Li, Wangyong
   Xie, Jianjin
TI Prognostic significance of hsa_circ_0048122 to predict liver metastasis
   in early-stage colorectal cancer
SO JOURNAL OF CLINICAL LABORATORY ANALYSIS
LA English
DT Article
DE biomarker; colorectal cancer; hsa_circ_0048122; liver metastasis;
   therapy
ID TUMOR-METASTASIS; CIRCULAR RNAS; BIOMARKER
AB Background Liver metastasis is the primary cause of lethal colorectal cancer (CRC). The predominant risk of poor patient prognosis in early-stage CRC emerges as metachronous liver metastasis. This necessitates the search for potential biomarkers for this metastasis to assess treatment outcomes and provide targeted therapy. Methods The role of hsa_circ_0048122 in predicting liver metastasis in CRC was probed in this work. This retrospective and multi-center investigation entailed exploration and identification stages with 158 and 176 patients. While RT-qPCR was employed to scrutinize hsa_circ_0048122 expression, Kaplan-Meier survival, and multivariate analyses were used to probe its prognostic impact in early-stage CRC and stage IV CRC cases, respectively. Results A strong correlation between liver metastases and hsa_circ_0048122 expression in stage IV CRC patients with a high hsa_circ_0048122 profile indicated a poor overall survival. Likewise, a high expression level of hsa_circ_0048122 appears as a potential predictor of liver metastases in patients' initial stages. Conclusions Predicting liver metastasis can be plausibly facilitated using Hsa_circ_0048122 as a biomarker in early-stage CRC cases.
C1 [Fang, Qian; Ni, Chuandou; Cai, Zhun; Li, Wangyong] First Peoples Hosp Wenling, Gen Surg, Wenling, Peoples R China.
   [Xie, Jianjin] First Peoples Hosp Wenling, Anorectal Surg, 333 Chuanan South Rd,Chengxi St, Wenling 317500, Zhejiang, Peoples R China.
RP Xie, JJ (corresponding author), First Peoples Hosp Wenling, Anorectal Surg, 333 Chuanan South Rd,Chengxi St, Wenling 317500, Zhejiang, Peoples R China.
EM xiejianjinwl@126.com
RI Fang, Qian/ISV-1712-2023
CR Chen LY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01272-9
   Fu B, 2018, EPIGENOMICS-UK, V10, P1619, DOI 10.2217/epi-2018-0090
   Geiger TR, 2009, BBA-REV CANCER, V1796, P293, DOI 10.1016/j.bbcan.2009.07.006
   He BY, 2021, BIOCHEM BIOPH RES CO, V551, P100, DOI 10.1016/j.bbrc.2021.02.121
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Jemal A., 2011, CA Cancer J Clin, V61, P69, DOI [10.3322/caac.20107, DOI 10.3322/CAAC.21239]
   Jemal Ahmedin., 2009, CA Cancer J Clin, V59, P1, DOI [10.1002/caac.20073.Available, DOI 10.3322/caac.21208, 10.3322/caac.21551, DOI 10.3322/caac.20073]
   Ji WX, 2018, BIOCHEM BIOPH RES CO, V497, P122, DOI 10.1016/j.bbrc.2018.02.036
   Kulcheski FR, 2016, J BIOTECHNOL, V238, P42, DOI 10.1016/j.jbiotec.2016.09.011
   Li J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0822-3
   Liang YK, 2021, MOL THER-NUCL ACIDS, V23, P355, DOI 10.1016/j.omtn.2020.11.012
   Liu DR, 2020, MOL ONCOL, V14, P1365, DOI 10.1002/1878-0261.12637
   Liu HD, 2016, ONCOTARGET, V7, P81223, DOI 10.18632/oncotarget.13219
   Lu YQ, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.23866
   Manfredi S, 2006, ANN SURG, V244, P254, DOI 10.1097/01.sla.0000217629.94941.cf
   Omid-Shafaat R, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.24008
   Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777
   Shang AQ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01235-0
   Shen T, 2019, ARTIF CELL NANOMED B, V47, P4038, DOI 10.1080/21691401.2019.1669620
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Steeg PS, 2006, NAT MED, V12, P895, DOI 10.1038/nm1469
   Tang WW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0888-8
   Tian JH, 2019, CANCER MANAG RES, V11, P5413, DOI 10.2147/CMAR.S199436
   Wang LQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0889-7
   Wu MQ, 2021, CARCINOGENESIS, V42, P601, DOI 10.1093/carcin/bgaa140
   Xu HC, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01799-1
   Yan JN, 2022, DIGEST DIS SCI, V67, P3753, DOI 10.1007/s10620-021-07211-y
   Yang HB, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1139-3
   Yang H, 2015, ONCOTARGET, V6, P6310, DOI 10.18632/oncotarget.3355
   Yang N, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021224
   Yuan Y, 2018, BIOCHEM BIOPH RES CO, V503, P870, DOI 10.1016/j.bbrc.2018.06.089
   Zhang CJ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03714-8
   Zhang X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0935-5
NR 33
TC 2
Z9 2
U1 1
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN, NJ 07030 USA
SN 0887-8013
EI 1098-2825
J9 J CLIN LAB ANAL
JI J. Clin. Lab. Anal.
PD AUG
PY 2022
VL 36
IS 8
AR e24577
DI 10.1002/jcla.24577
EA JUL 2022
PG 7
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 3Y7AR
UT WOS:000821039700001
PM 35792043
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Turchini, J
   Andrici, J
   Sioson, L
   Clarkson, A
   Watson, N
   Toon, CW
   Shepherd, P
   Ng, D
   Dixon-McIver, A
   Oei, P
   Gill, AJ
AF Turchini, John
   Andrici, Juliana
   Sioson, Loretta
   Clarkson, Adele
   Watson, Nicole
   Toon, Christopher W.
   Shepherd, Phillip
   Ng, Daniel
   Dixon-McIver, Amanda
   Oei, Paul
   Gill, Anthony J.
TI NRAS<SUP>Q61R</SUP> Mutation-specific Immunohistochemistry is Highly
   Specific for Either <i>NRAS<SUP>Q61R</SUP></i> or
   <i>KRAS<SUP>Q61R</SUP></i> Mutation in Colorectal Carcinoma
SO APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
LA English
DT Article
DE NRAS; KRAS; colorectal carcinoma; immunohistochemistry
ID RAS MUTATIONS; BRAFV600E IMMUNOHISTOCHEMISTRY; TUMOR PROGRESSION; NRAS
   MUTATIONS; K-RAS; N-RAS; KRAS; CANCER; TOOL; SURVIVAL
AB Anti-epidermal growth factor receptor-targeted therapy is only indicated in RAS wild-type colorectal carcinomas (CRCs). It is recommended that both NRAS and KRAS mutation testing to be performed before a CRC is considered RAS wild-type. Given that mutation-specific immunohistochemistry (IHC) has been shown to be sensitive and specific for the detection of NRAS(Q61R) mutations in melanoma, we assessed the specificity of NRAS(Q61R) mutation-specific IHC in CRC. IHC was performed on tissue microarrays containing 2823 consecutive CRC undergoing surgery with curative intent using a novel mutation-specific antibody to the protein produced by the NRAS(Q61R) mutation (clone SP174). Tissue microarrays were assessed by 2 observers and all IHC-positive or equivocal cases were repeated on whole sections to confirm the result. Positive cases then underwent molecular testing by matrix-assisted laser desorption/ionization-time of flight polymerase chain reaction. In total, 22 of 2823 (0.8%) CRCs demonstrated confirmed positive staining with complete interobserver concordance. RAS mutations were confirmed in all IHC-positive CRCs. In total, 11 cases harbored the NRASQ61R mutation. Surprisingly, 11 cases demonstrated the KRASQ61R mutation. We conclude that mutation-specific IHC with this currently available NRASQ61R antibody is highly specific for the presence of either NRASQ61R or KRASQ61R mutations in CRC. We caution that we did not assess the sensitivity of IHC and that this antibody does not detect other RAS mutations. Therefore, negative staining does not exclude a clinically significant RAS mutation. However, positive staining confirms the presence of an NRASQ61R or KRASQ61R mutation without the need for further molecular testing.
C1 [Turchini, John; Andrici, Juliana; Gill, Anthony J.] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia.
   [Turchini, John; Andrici, Juliana; Sioson, Loretta; Clarkson, Adele; Watson, Nicole; Toon, Christopher W.; Gill, Anthony J.] Kolling Inst Med Res, Canc Diag & Pathol Res Grp, St Leonards, NSW, Australia.
   [Turchini, John; Andrici, Juliana; Clarkson, Adele; Toon, Christopher W.] Sydney Vital Translat Res Ctr, St Leonards, NSW, Australia.
   [Turchini, John; Clarkson, Adele; Gill, Anthony J.] Royal North Shore Hosp, Dept Anat Pathol, Pacific Highway, St Leonards, NSW 2065, Australia.
   [Toon, Christopher W.] Histopath Pathol, N Ryde, NSW, Australia.
   [Shepherd, Phillip] Auckland UniServ Sequenom Facil, Liggins Inst, Auckland, New Zealand.
   [Ng, Daniel; Dixon-McIver, Amanda; Oei, Paul] IGENZ Ltd, Auckland, New Zealand.
C3 University of Sydney; University of Sydney; Kolling Institute of Medical
   Research; Royal North Shore Hospital; University of Auckland
RP Gill, AJ (corresponding author), Royal North Shore Hosp, Dept Anat Pathol, Pacific Highway, St Leonards, NSW 2065, Australia.
EM affgill@med.usyd.edu.au
RI Toon, Christopher/G-3610-2012; Gill, Anthony/D-4215-2015
OI Turchini, John/0000-0003-4281-7134; Castellano,
   Juliana/0000-0001-6581-2243; Gill, Anthony/0000-0002-9447-1967
FU Cancer Institute NSW
FX Supported by funding from the Cancer Institute NSW as part of a
   translational research centre grant.
CR BALL NJ, 1994, J INVEST DERMATOL, V102, P285, DOI 10.1111/1523-1747.ep12371783
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Demunter A, 2001, J INVEST DERMATOL, V117, P1483, DOI 10.1046/j.0022-202x.2001.01601.x
   Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685
   Domagala P, 2012, POL J PATHOL, V63, P145, DOI 10.5114/PJP.2012.31499
   Haigis KM, 2008, NAT GENET, V40, P600, DOI 10.1038/ng.115
   Hecht JR, 2015, CANCER TREAT REV, V41, P653, DOI 10.1016/j.ctrv.2015.05.008
   Houang M, 2015, APPL IMMUNOHISTO M M, V23, P134, DOI 10.1097/PAI.0000000000000025
   Ilie M, 2015, J AM ACAD DERMATOL, V72, P786, DOI 10.1016/j.jaad.2015.01.012
   Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724
   Kriegsmann M, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0364-3
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Luey N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106105
   Massil D, 2015, MODERN PATHOL, V28, P487, DOI 10.1038/modpathol.2014.137
   Muirhead D, 2010, ARCH PATHOL LAB MED, V134, P1164, DOI 10.1043/2000-0401-OA.1
   Peeters M, 2015, EUR J CANCER, V51, P1704, DOI 10.1016/j.ejca.2015.05.017
   Piton N, 2015, CANCER EPIDEM BIOMAR, V24, P1416, DOI 10.1158/1055-9965.EPI-15-0059
   Piton N, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/753903
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Toon CW, 2014, MODERN PATHOL, V27, P644, DOI 10.1038/modpathol.2013.200
   Toon CW, 2013, AM J SURG PATHOL, V37, P1592, DOI 10.1097/PAS.0b013e31828f233d
   Uguen A, 2015, HUM PATHOL, V46, P1582, DOI 10.1016/j.humpath.2015.06.023
   Uguen A, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0359-0
   Vagaja NN, 2015, J CLIN PATHOL, V68, P657, DOI 10.1136/jclinpath-2015-202969
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
NR 25
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1541-2016
EI 1533-4058
J9 APPL IMMUNOHISTO M M
JI Appl. Immunohistochem.
PD AUG
PY 2017
VL 25
IS 7
BP 475
EP 480
DI 10.1097/PAI.0000000000000333
PG 6
WC Anatomy & Morphology; Medical Laboratory Technology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Anatomy & Morphology; Medical Laboratory Technology; Pathology
GA FD1KW
UT WOS:000407297200007
PM 26862952
DA 2025-01-04
ER

PT J
AU Xu, R
   Feng, HY
   Liang, HJ
   Li, YP
AF Xu, Rui
   Feng, Huayun
   Liang, Haojie
   Li, Yaoping
TI Identification of candidate biomarkers and prognostic analysis of
   recurrence in colorectal cancer
SO CANCER BIOMARKERS
LA English
DT Article
DE Colorectal cancer; biological information; prognostic analysis;
   recurrence; immune infiltration
ID GENES
AB Colorectal cancer (CRC) is one of the most common digestive tract malignant tumors, which has a high mortality rate especially for patients with CRC recurrence. However, the pathological mechanism of recurrence of CRC is unclear. In this study, we integrated multiple cohort datasets and databases to clarify and verify potential key candidate biomarkers and signal transduction pathways in recurrence of CRC. As results, 628 DEGs were identified from GSE33113 and GSE2630 datasets and their function and pathway were analyzed. 14 hub genes related to CRC recurrence were screened from and their influence on survival were analyzed. Two key genes (IL1B and DDAH1) regarded as prognostic factors were further screened. Relapse-free survival results indicated the interaction between IL1B and DDAH1 genes and B cells was the most obvious and correlated with survival, with statistical significance (P <0.05). Specially, cox regression analysis suggested that patients with T1 and N0 stages had a higher risk of recurrence than patients with T2 and N1. This work would provide potential value for prognosis, and would promote molecular targeting therapy for CRC recurrence.
C1 [Xu, Rui; Feng, Huayun; Li, Yaoping] Shanxi Med Univ, Shanxi Prov Peoples Hosp, Colorectal & Anal Surg Dept, Taiyuan 030012, Peoples R China.
   [Liang, Haojie] Taiyuan Univ Technol, Key Lab Interface Sci Engn Adv Mat, Minist Educ, Taiyuan, Peoples R China.
C3 Shanxi Medical University; Shanxi People's Hospital; Taiyuan University
   of Technology
RP Li, YP (corresponding author), Shanxi Med Univ, Shanxi Prov Peoples Hosp, Colorectal & Anal Surg Dept, Taiyuan 030012, Peoples R China.
EM liyaoping1600@sina.com
RI Liang, Haojie/KSL-9599-2024
FU Fundamental Re-search Program of Shanxi Province [202303021222360
   202103021223086]
FX This work was supported by the Fundamental Re-search Program of Shanxi
   Province (202303021222360 202103021223086) .
CR Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Cohen SA, 2022, ANN ONCOL, V33, pS683, DOI 10.1016/j.annonc.2022.07.457
   Ding X, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00045
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gutierrez M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e15123
   Hu J, 2018, MOL MED REP, V18, P5109, DOI 10.3892/mmr.2018.9505
   Hutter C, 2018, CELL, V173, P283, DOI 10.1016/j.cell.2018.03.042
   Huyghe JR, 2019, NAT GENET, V51, P76, DOI 10.1038/s41588-018-0286-6
   Kanehisa M, 2017, NUCLEIC ACIDS RES, V45, pD353, DOI 10.1093/nar/gkw1092
   Kruschewski M, 2012, LANGENBECK ARCH SURG, V397, P1059, DOI 10.1007/s00423-012-0975-z
   Liu HY, 2017, CANCER GENE THER, V24, P244, DOI 10.1038/cgt.2017.8
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Morgan E, 2023, GUT, V72, P338, DOI 10.1136/gutjnl-2022-327736
   Ni MW, 2018, FRONT GENET, V9, DOI 10.3389/fgene.2018.00469
   Parikh A, 2021, CLIN CANCER RES, V27, P5586, DOI [DOI 10.1158/1078-0432.CCR-21-0410, 10.1158/1078-0432.CCR-21-0410]
   Shendure J, 2008, NAT BIOTECHNOL, V26, P1135, DOI 10.1038/nbt1486
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Teloken PE, 2016, ANZ J SURG, V86, P49, DOI 10.1111/ans.13254
   Wu SS, 2017, ONCOL REP, V38, P2043, DOI 10.3892/or.2017.5930
   Yu LF, 2022, INT J GEN MED, V15, P7569, DOI 10.2147/IJGM.S380208
   Zhai XF, 2017, MOL MED REP, V16, P6499, DOI 10.3892/mmr.2017.7412
   Zhang T, 2019, ONCOL REP, V41, P279, DOI 10.3892/or.2018.6840
   Zhao B, 2019, CANCER CONTROL, V26, DOI 10.1177/1073274819831260
NR 24
TC 0
Z9 0
U1 7
U2 7
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2024
VL 40
IS 3-4
BP 251
EP 262
DI 10.3233/CBM-230390
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA F6T8R
UT WOS:001311131500003
PM 39031341
OA Green Published
DA 2025-01-04
ER

PT J
AU Marisi, G
   Scarpi, E
   Passardi, A
   Nanni, O
   Pagan, F
   Valgiusti, M
   Gardini, AC
   Neri, LM
   Frassineti, GL
   Amadori, D
   Ulivi, P
AF Marisi, Giorgia
   Scarpi, Emanuela
   Passardi, Alessandro
   Nanni, Oriana
   Pagan, Flavia
   Valgiusti, Martina
   Gardini, Andrea Casadei
   Neri, Luca Maria
   Frassineti, Giovanni Luca
   Amadori, Dino
   Ulivi, Paola
TI IL-8 and thrombospondin-1 as prognostic markers in patients with
   metastatic colorectal cancer receiving bevacizumab
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE scrum biomarkers; targeted therapy; IL-8; angiogenesis; chemotherapy
ID ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; COLON-CANCER; BREAST-CANCER;
   INTERLEUKIN-8; ANGIOGENESIS; BIOMARKERS; EFFICACY; THERAPY; RESISTANCE
AB Purpose: Bevacizumab (B) plus chemotherapy (CT) is a common choice for first-line treatment of metastatic colorectal cancer. Molecular predictors of B efficacy have still not been identified. We analyzed the role of 22 angiogenesis-associated proteins in patient outcome.
   Patients and methods: Serum samples collected at baseline and at the first clinical evaluation were available for 58 patients enrolled in the randomized multicenter ITACa trial and who received CT+ B. Serum protein levels were determined using multiplex ELISA.
   Results: Patients with baseline >= 145 pg/mL IL-8 showed shorter median progression-free survival and overall survival (OS) than those with lower levels (6.5 vs 6. 12.6 months; HR 7.39, P<0.0001 and 8.7 vs 28.8 months, HR 7.68, P<0.001, respectively). Moreover, patients with baseline thrombospondin-1 levels >= 12,000 ng/mL had a better median OS than those with lower levels (34.5 vs 13.1 months, HR 0.43, P=0.007). Patients with a >= 20% reduction in IL-8 levels from baseline to first clinical evaluation showed a better progression-free survival and OS than the others (HR 0.41, P=0.005 and HR 0.43, P=0.007, respectively).
   Condusion: Baseline IL-8 and thrombospondin-1 levels and reduced IL-8 during B treatment could represent potential prognostic markers in metastatic colorectal cancer.
C1 [Marisi, Giorgia; Ulivi, Paola] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biosci Lab, I-47014 Meldola, Italy.
   [Scarpi, Emanuela; Nanni, Oriana; Pagan, Flavia] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Unit Biostat & Clin Trials, I-47014 Meldola, Italy.
   [Scarpi, Emanuela; Nanni, Oriana; Pagan, Flavia] Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Dept Med Oncol, I-47014 Meldola, Italy.
   [Neri, Luca Maria] Univ Ferrara, Dept Morphol Surg & Expt Med, I-44100 Ferrara, Italy.
C3 IRCCS Meldola (IRST); IRCCS Meldola (IRST); IRCCS Meldola (IRST);
   University of Ferrara
RP Marisi, G (corresponding author), Ist Sci Romagnolo Studio & Cura Tumori IRST IRCCS, Biosci Lab, I-47014 Meldola, Italy.
EM giorgia.marisi@irst.emr.it
RI Neri, Luca/J-2462-2017; Marisi, Giorgia/J-9223-2016; passardi,
   alessandro/AAH-4786-2019; Scarpi, Emanuela/AAD-7036-2019; NANNI,
   ORIANA/K-3240-2016; Casadei gardini, Andrea/F-1830-2016
OI passardi, alessandro/0000-0002-7099-240X; Scarpi,
   Emanuela/0000-0001-7230-9267; Frassineti, Giovanni
   Luca/0000-0002-0277-5622; NANNI, ORIANA/0000-0001-7338-2896; Casadei
   gardini, Andrea/0000-0001-6289-7202
FU Roche S.p.A.; Italian Medicines Agency (AIFA)
FX The authors would like to thank Drs Nadia Dani and Davide Barberio for
   their help with data analysis. This work was partially supported by
   Roche S.p.A. and by the Italian Medicines Agency (AIFA).
CR Abajo A, 2012, BRIT J CANCER, V107, P287, DOI 10.1038/bjc.2012.242
   Backen A, 2014, CLIN CANCER RES, V20, P4549, DOI 10.1158/1078-0432.CCR-13-3248
   Brostjan C, 2008, CLIN CANCER RES, V14, P2065, DOI 10.1158/1078-0432.CCR-07-4081
   Bünger S, 2011, J BIOMOL SCREEN, V16, P1018, DOI 10.1177/1087057111414894
   Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006
   Di Salvatore M, 2017, ONCOTARGET, V8, P16887, DOI 10.18632/oncotarget.14810
   Ellis LM, 2008, CLIN CANCER RES, V14, P6371, DOI 10.1158/1078-0432.CCR-07-5287
   Godiska R, 1997, J EXP MED, V185, P1595, DOI 10.1084/jem.185.9.1595
   Goede V, 2010, BRIT J CANCER, V103, P1407, DOI 10.1038/sj.bjc.6605925
   Hildebrand F, 2007, CYTOKINE, V37, P192, DOI 10.1016/j.cyto.2007.03.008
   Hull J, 2000, THORAX, V55, P1023, DOI 10.1136/thorax.55.12.1023
   Jubb AM, 2011, CLIN CANCER RES, V17, P372, DOI 10.1158/1078-0432.CCR-10-1791
   Kaseb AO, 2012, ONCOLOGY-BASEL, V82, P67, DOI 10.1159/000335963
   KOCH AE, 1992, SCIENCE, V258, P1798, DOI 10.1126/science.1281554
   Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Labussière M, 2016, CANCER INVEST, V34, P39, DOI 10.3109/07357907.2015.1088948
   Lam SW, 2016, CLIN CANCER RES, V22, P1611, DOI 10.1158/1078-0432.CCR-15-1005
   Li AH, 2003, J IMMUNOL, V170, P3369, DOI 10.4049/jimmunol.170.6.3369
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Liu YM, 2013, CANCER MED-US, V2, P234, DOI 10.1002/cam4.71
   Loupakis F, 2011, BRIT J CANCER, V104, P1262, DOI 10.1038/bjc.2011.85
   Maeda K, 2000, INT J MOL MED, V5, P373
   Motzer RJ, 2014, CANCER CHEMOTH PHARM, V74, P739, DOI 10.1007/s00280-014-2539-0
   Passardi A, 2015, ANN ONCOL, V26, P1201, DOI 10.1093/annonc/mdv130
   Pogue-Geile K, 2013, JNCI-J NATL CANCER I, V105, P989, DOI 10.1093/jnci/djt140
   Raman D, 2007, CANCER LETT, V256, P137, DOI 10.1016/j.canlet.2007.05.013
   Taguchi A, 2005, CANCER EPIDEM BIOMAR, V14, P2487, DOI 10.1158/1055-9965.EPI-05-0326
   Ulivi P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061240
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Varney ML, 2002, IN VIVO, V16, P471
   Venook AP, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3504
   Wallyn F, 2013, PROSPECTIVE STUDY IN
   Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771
   Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8
NR 35
TC 8
Z9 8
U1 0
U2 0
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2018
VL 10
BP 5659
EP 5666
DI 10.2147/CMAR.S181570
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HA6LX
UT WOS:000450392100001
PM 30532588
OA Green Published, gold, Green Submitted
DA 2025-01-04
ER

PT J
AU Huang, YH
   Lin, PC
   Su, WC
   Chan, RH
   Chen, PC
   Lin, BW
   Shen, MR
   Chen, SH
   Yeh, YM
AF Huang, Yi-Hsuan
   Lin, Peng-Chan
   Su, Wu-Chou
   Chan, Ren-Hao
   Chen, Po-Chuan
   Lin, Bo-Wen
   Shen, Meng-Ru
   Chen, Shang-Hung
   Yeh, Yu-Min
TI Association between Altered Oncogenic Signaling Pathways and Overall
   Survival of Patients with Metastatic Colorectal Cancer
SO DIAGNOSTICS
LA English
DT Article
DE metastatic colorectal cancer; next-generation sequencing; genomic
   profiling; oncogenic signaling pathways
ID C-MYC; RESISTANCE; INHIBITION; EVOLUTION; SUBTYPES
AB Systemic characterization of genomic alterations into signaling pathways helps to understand the molecular pathogenies of colorectal cancer; however, their clinical implications remain unclear. Here, 128 patients with metastatic colorectal cancer (mCRC) receiving targeted next generation sequencing were retrospectively enrolled to analyze the impact of altered oncogenic pathways on clinical outcome. The datasets from Memorial Sloan Kettering Cancer Center were used for validation. In 123 patients with non-MSI-high tumor, the most common mutated gene was TP53 (84.6%), followed by APC (78.0%), KRAS (49.6%), and SMAD4 (22.8%). When mutated genes were allocated into signaling pathways defined as The Cancer Genome Atlas Pan-Cancer Analysis Project, alterations of cell cycle, Wnt, p53, RTK-RAS, PI3K, TGF-beta, Notch, and Myc pathways were identified in 88%, 87%, 85%, 75%, 28%, 26%, 17%, and 10% of mCRC tissues, respectively. The survival analyses revealed that Myc and TGF-beta pathway alterations were associated with a shorter overall survival (OS) (hazard ratio [HR]: 2.412; 95% confidence interval [CI]: 1.139-5.109; p = 0.018 and HR: 2.754; 95% CI: 1.044-7.265; p = 0.033, respectively). The negative prognostic impact of altered TGF-beta pathway was maintained in patients receiving an anti-EGFR antibody. The OS of patients with mCRC carrying MYC and BRAF mutation was shorter than those with either MYC or BRAF mutation (HR: 4.981, 95% CI: 0.296-83.92; p = 0.02). These findings have clinical implications, such as prognosis prediction, treatment guidance, and molecular-targeted therapy development.
C1 [Huang, Yi-Hsuan] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Internal Med, Coll Med, Tainan 70456, Taiwan.
   [Lin, Peng-Chan; Su, Wu-Chou; Chen, Shang-Hung; Yeh, Yu-Min] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Oncol, Coll Med, Tainan 70456, Taiwan.
   [Chan, Ren-Hao; Chen, Po-Chuan; Lin, Bo-Wen] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Div Colorectal Surg, Dept Surg,Coll Med, Tainan 70456, Taiwan.
   [Shen, Meng-Ru] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Obstet & Gynecol, Coll Med, Tainan 70456, Taiwan.
   [Chen, Shang-Hung] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 70456, Taiwan.
C3 National Cheng Kung University; National Cheng Kung University Hospital;
   National Cheng Kung University; National Cheng Kung University Hospital;
   National Cheng Kung University; National Cheng Kung University Hospital;
   National Cheng Kung University; National Cheng Kung University Hospital;
   National Health Research Institutes - Taiwan
RP Chen, SH; Yeh, YM (corresponding author), Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Dept Oncol, Coll Med, Tainan 70456, Taiwan.; Chen, SH (corresponding author), Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 70456, Taiwan.
EM huangyh9184@gmail.com; pengchanlin@gmail.com; sunnysu@mail.ncku.edu.tw;
   buoy2610@gmail.com; cpc324@gmail.com; wen276@gmail.com;
   mrshen@mail.ncku.edu.tw; Bryanchen@nhri.edu.tw; i5485111@gmail.com
RI Chen, Huanhuan/HTO-5007-2023; Chan, Ren-Hao/GPW-6295-2022
OI Huang, Yi-Hsuan/0000-0002-3429-2094
FU National Cheng Kung University Hospital [NCKUH-11004007]; Ministry of
   Science and Technology [MOST 110-2634-F-006-014]; Ministry of Health and
   Welfare [MOHW 110-TDU-B-211-144018]
FX FundingThis study was funded by the National Cheng Kung University
   Hospital (NCKUH-11004007), Ministry of Science and Technology (MOST
   110-2634-F-006-014), and Ministry of Health and Welfare (MOHW
   110-TDU-B-211-144018).
CR Ahmad R, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4847
   Bahceci I, 2017, BIOINFORMATICS, V33, P2238, DOI 10.1093/bioinformatics/btx149
   Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140
   Bedi A, 2012, MOL CANCER THER, V11, P2429, DOI 10.1158/1535-7163.MCT-12-0101-T
   Böckelman C, 2015, ACTA ONCOL, V54, P5, DOI 10.3109/0284186X.2014.975839
   Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013
   Caravagna G, 2018, NAT METHODS, V15, P707, DOI 10.1038/s41592-018-0108-x
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2
   Chen XL, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3215-7
   Ciardiello D, 2020, ANN ONCOL, V31, P1336, DOI 10.1016/j.annonc.2020.07.009
   Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217
   Dienstmann Rodrigo, 2018, Am Soc Clin Oncol Educ Book, V38, P231, DOI 10.1200/EDBK_200929
   Dienstmann R, 2016, CANCER J, V22, P149, DOI 10.1097/PPO.0000000000000191
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Grbcic P, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126174
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Nguyen HT, 2018, ONCOL LETT, V16, P9, DOI 10.3892/ol.2018.8679
   He WL, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01549
   Huang CY, 2021, BIOMED PHARMACOTHER, V134, DOI 10.1016/j.biopha.2020.111046
   Huynh LK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110743
   Isoniemi H, 2021, BRIT J SURG, V108, P817, DOI 10.1093/bjs/znaa145
   Itatani Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235822
   Jung B, 2017, GASTROENTEROLOGY, V152, P36, DOI 10.1053/j.gastro.2016.10.015
   Kato T, 2021, IN VIVO, V35, P203, DOI 10.21873/invivo.12249
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kuzyk A, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014373
   Lee KS, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2770-7
   Lee KS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139727
   Lin ZL, 2019, MOL MED REP, V20, P3735, DOI 10.3892/mmr.2019.10597
   McQuade RM, 2017, CURR MED CHEM, V24, P1537, DOI 10.2174/0929867324666170111152436
   Meyer N, 2008, NAT REV CANCER, V8, P976, DOI 10.1038/nrc2231
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Molina-Cerrillo J, 2020, CANCERS, V12, DOI 10.3390/cancers12061571
   Parseghian CM, 2019, CLIN CANCER RES, V25, P6899, DOI 10.1158/1078-0432.CCR-19-0823
   Prochownik EV, 2008, CURR MOL MED, V8, P446, DOI 10.2174/156652408785747988
   Pyndiah S, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001556
   Reyes-González JM, 2015, MOL CANCER THER, V14, P2260, DOI 10.1158/1535-7163.MCT-14-0801
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Schrock AB, 2019, ANN ONCOL, V30, P1096, DOI 10.1093/annonc/mdz134
   Seligmann JF, 2017, ANN ONCOL, V28, P562, DOI 10.1093/annonc/mdw645
   Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345
   Siegel Rebecca L, 2020, CA Cancer J Clin, V70, P7, DOI 10.3322/caac.21590
   Strippoli A, 2020, CANCERS, V12, DOI 10.3390/cancers12030638
   Sugarbaker PH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/782890
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tiwari A, 2018, WORLD J GASTROENTERO, V24, P4428, DOI 10.3748/wjg.v24.i39.4428
   Toon CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087456
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Zhou ZJ, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.623424
NR 54
TC 5
Z9 5
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2075-4418
J9 DIAGNOSTICS
JI Diagnostics
PD DEC
PY 2021
VL 11
IS 12
AR 2308
DI 10.3390/diagnostics11122308
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA XX5YA
UT WOS:000736369500001
PM 34943546
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Johnson, DB
   Puzanov, I
AF Johnson, Douglas B.
   Puzanov, Igor
TI Treatment of <i>NRAS</i>-Mutant Melanoma
SO CURRENT TREATMENT OPTIONS IN ONCOLOGY
LA English
DT Article
DE Melanoma; NRAS; Mutation; MEK inhibitor; CDK4; MAPK; Immunotherapy;
   Trametinib; Binimetinib
ID ORAL MEK INHIBITOR; KINASE KINASE-1/2 INHIBITOR; METASTATIC MELANOMA;
   PHASE-II; OPEN-LABEL; COLORECTAL-CANCER; PANCREATIC-CANCER; EFFECTOR
   PATHWAYS; IMPROVED SURVIVAL; RNA INTERFERENCE
AB NRAS mutations in codons 12, 13, and 61 arise in 15-20 % of all melanomas. These alterations have been associated with aggressive clinical behavior and a poor prognosis. Until recently, there has been a paucity of promising genetically targeted therapy approaches for NRAS-mutant melanoma (and RAS-mutant malignancies in general). MEK inhibitors, particularly binimetinib, have shown activity in this cohort. Based on preclinical and early clinical studies, combining MEK inhibitors with agents inhibiting the cell cycling and the PI3K-AKT pathway appears to provide additional benefit. In particular, a strategy of MEK inhibition and CDK4/ 6 inhibition is likely to be a viable treatment option in the future, and is the most promising genetically targeted treatment strategy for NRASmutant melanoma developed to date. In addition, immune-based therapies have shown increasing activity in advanced melanoma and may be particularly effective in those with NRAS mutations. Combination strategies of immune and targeted therapies may also play a role in the future although clinical trials testing these approaches are in early stages.
C1 [Johnson, Douglas B.] Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol,Vanderbilt Ingram Canc Ctr, Nashville, TN 37232 USA.
C3 Vanderbilt University
RP Johnson, DB (corresponding author), Vanderbilt Univ, Med Ctr, Dept Med, Div Hematol Oncol,Vanderbilt Ingram Canc Ctr, 777 Preston Res Bldg,2220 Pierce Ave, Nashville, TN 37232 USA.
EM douglas.b.johnson@vanderbilt.edu
RI PUZANOV, IGOR/AAP-2966-2020
OI Puzanov, Igor/0000-0002-9803-3497
FU NIH [K12 CA 0906525]
FX Douglas B. Johnson was supported by NIH grant K12 CA 0906525.
CR Adjei AA, 2008, J CLIN ONCOL, V26, P2139, DOI 10.1200/JCO.2007.14.4956
   Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X
   Atkins MB, 1999, J CLIN ONCOL, V17, P2105, DOI 10.1200/JCO.1999.17.7.2105
   Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118
   Brown AP, 2007, CANCER CHEMOTH PHARM, V59, P671, DOI 10.1007/s00280-006-0323-5
   Carlino MS, 2014, BRIT J CANCER, V111, P292, DOI 10.1038/bjc.2014.287
   Carlino MS, 2014, MOL ONCOL, V8, P544, DOI 10.1016/j.molonc.2014.01.003
   Carvajal RD, 2014, JAMA-J AM MED ASSOC, V311, P2397, DOI 10.1001/jama.2014.6096
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Charbel C, 2014, J INVEST DERMATOL, V134, P1067, DOI 10.1038/jid.2013.429
   Conrad WH, 2012, CELL CYCLE, V11, P3724, DOI 10.4161/cc.21645
   Curtin JA, 2005, NEW ENGL J MED, V353, P2135, DOI 10.1056/NEJMoa050092
   Curtin JA, 2006, J CLIN ONCOL, V24, P4340, DOI 10.1200/JCO.2006.06.2984
   Davis ME, 2010, NATURE, V464, P1067, DOI 10.1038/nature08956
   Devitt B, 2011, PIGM CELL MELANOMA R, V24, P666, DOI 10.1111/j.1755-148X.2011.00873.x
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Eskandarpour M, 2005, INT J CANCER, V115, P65, DOI 10.1002/ijc.20873
   Falchook GS, 2012, LANCET ONCOL, V13, P782, DOI 10.1016/S1470-2045(12)70269-3
   Fedorenko IV, 2013, ONCOGENE, V32, P3009, DOI 10.1038/onc.2012.453
   Feng YM, 2013, PIGM CELL MELANOMA R, V26, P136, DOI 10.1111/pcmr.12033
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Gajewski TF, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-246
   Haarberg HE, 2013, MOL CANCER THER, V12, P901, DOI 10.1158/1535-7163.MCT-12-1003
   Halait H, 2012, DIAGN MOL PATHOL, V21, P1, DOI 10.1097/PDM.0b013e31823b216f
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441
   Haura EB, 2010, CLIN CANCER RES, V16, P2450, DOI 10.1158/1078-0432.CCR-09-1920
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Jaiswal BS, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0005717
   Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724
   Jameson KL, 2013, NAT MED, V19, P626, DOI 10.1038/nm.3165
   Johnson DB, 2014, CLIN CANCER RES, V20, P4186, DOI 10.1158/1078-0432.CCR-13-3270
   Johnson DB, 2013, J CLIN ONCOL, V31
   Joseph RW, 2012, J IMMUNOTHER, V35, P66, DOI 10.1097/CJI.0b013e3182372636
   Kirkwood JM, 2012, CLIN CANCER RES, V18, P555, DOI 10.1158/1078-0432.CCR-11-1491
   Kirschbaum MH, 2011, LEUKEMIA, V25, P1543, DOI 10.1038/leu.2011.124
   KOHL NE, 1994, P NATL ACAD SCI USA, V91, P9141, DOI 10.1073/pnas.91.19.9141
   Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221
   Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359
   Kwong LN, 2012, NAT MED, V18, P1503, DOI 10.1038/nm.2941
   LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883
   LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415
   Lovly CM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035309
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   McDermott D, 2014, CANCER TREAT REV, V40, P1056, DOI 10.1016/j.ctrv.2014.06.012
   Means-Powell JA, 2012, J CLIN ONCOL, V30
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070
   Pecot CV, 2011, NAT REV CANCER, V11, P59, DOI 10.1038/nrc2966
   Posch C, 2013, P NATL ACAD SCI USA, V110, P4015, DOI 10.1073/pnas.1216013110
   Poynter JN, 2006, MELANOMA RES, V16, P267, DOI 10.1097/01.cmr.0000222600.73179.f3
   Prieto PA, 2012, CLIN CANCER RES, V18, P2039, DOI 10.1158/1078-0432.CCR-11-1823
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Rao S, 2004, J CLIN ONCOL, V22, P3950, DOI 10.1200/JCO.2004.10.037
   Rebecca VW, 2014, PIGM CELL MELANOMA R, V27, P1154, DOI 10.1111/pcmr.12303
   Ribas A, 2014, LANCET ONCOL, V15, P954, DOI 10.1016/S1470-2045(14)70301-8
   Ribas A, 2013, NEW ENGL J MED, V368, P1365, DOI 10.1056/NEJMc1302338
   Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185
   Robert C, 2014, LANCET, V384, P1109, DOI 10.1016/S0140-6736(14)60958-2
   Robert C, 2013, LANCET ONCOL, V14, P733, DOI 10.1016/S1470-2045(13)70237-7
   Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
   ROSENBERG SA, 1994, JAMA-J AM MED ASSOC, V271, P907, DOI 10.1001/jama.271.12.907
   Schwartzentruber DJ, 2001, J IMMUNOTHER, V24, P287, DOI 10.1097/00002371-200107000-00004
   Sharfman WH, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8508
   Sheppard KE, 2013, CLIN CANCER RES, V19, P5320, DOI 10.1158/1078-0432.CCR-13-0259
   Sosman JA, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.9009
   Su YJ, 2012, CLIN CANCER RES, V18, P2184, DOI 10.1158/1078-0432.CCR-11-1122
   Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Van Cutsem E, 2004, J CLIN ONCOL, V22, P1430, DOI 10.1200/JCO.2004.10.112
   Weber JS, 2013, J CLIN ONCOL, V31
   Weber JS, 2013, J CLIN ONCOL, V31, P4311, DOI 10.1200/JCO.2013.51.4802
   Yeh TC, 2007, CLIN CANCER RES, V13, P1576, DOI 10.1158/1078-0432.CCR-06-1150
   Young RJ, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12228
   Zimmer L, 2014, CLIN CANCER RES, V20, P4251, DOI 10.1158/1078-0432.CCR-14-0341
NR 78
TC 96
Z9 109
U1 0
U2 15
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527-2729
EI 1534-6277
J9 CURR TREAT OPTION ON
JI Curr. Treat. Options Oncol.
PD APR
PY 2015
VL 16
IS 4
AR 15
DI 10.1007/s11864-015-0330-z
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CH1OS
UT WOS:000353791800002
PM 25796376
OA Green Accepted
DA 2025-01-04
ER

PT J
AU Lupo, B
   Sassi, F
   Pinnelli, M
   Galimi, F
   Zanella, ER
   Vurchio, V
   Migliardi, G
   Gagliardi, PA
   Puliafito, A
   Manganaro, D
   Luraghi, P
   Kragh, M
   Pedersen, MW
   Horak, ID
   Boccaccio, C
   Medico, E
   Primo, L
   Nichol, D
   Spiteri, I
   Heide, T
   Vatsiou, A
   Graham, TA
   Élez, E
   Argiles, G
   Nuciforo, P
   Sottoriva, A
   Dienstmann, R
   Pasini, D
   Grassi, E
   Isella, C
   Bertotti, A
   Trusolino, L
AF Lupo, Barbara
   Sassi, Francesco
   Pinnelli, Marika
   Galimi, Francesco
   Zanella, Eugenia R.
   Vurchio, Valentina
   Migliardi, Giorgia
   Gagliardi, Paolo Armando
   Puliafito, Alberto
   Manganaro, Daria
   Luraghi, Paolo
   Kragh, Michael
   Pedersen, Mikkel W.
   Horak, Ivan D.
   Boccaccio, Carla
   Medico, Enzo
   Primo, Luca
   Nichol, Daniel
   Spiteri, Inmaculada
   Heide, Timon
   Vatsiou, Alexandra
   Graham, Trevor A.
   Elez, Elena
   Argiles, Guillem
   Nuciforo, Paolo
   Sottoriva, Andrea
   Dienstmann, Rodrigo
   Pasini, Diego
   Grassi, Elena
   Isella, Claudio
   Bertotti, Andrea
   Trusolino, Livio
TI Colorectal cancer residual disease at maximal response to EGFR blockade
   displays a druggable Paneth cell-like phenotype
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Article
ID EPIDERMAL-GROWTH-FACTOR; LGR5(+) STEM-CELLS; COLON-CANCER; ANTIBODY
   MIXTURE; RAS MUTATIONS; RESISTANCE; RECEPTOR; INHIBITION; CETUXIMAB;
   HER3
AB Blockade of epidermal growth factor receptor (EGFR) causes tumor regression in some patients with metastatic colorectal cancer (mCRC). However, residual disease reservoirs typically remain even after maximal response to therapy, leading to relapse. Using patient-derived xenografts (PDX5), we observed that mCRC cells surviving EGFR inhibition exhibited gene expression patterns similar to those of a quiescent subpopulation of normal intestinal secretory precursors with Paneth cell characteristics. Compared with untreated tumors, these pseudodifferentiated tumor remnants had reduced expression of genes encoding EGFR-activating ligands, enhanced activity of human epidermal growth factor receptor 2 (HER2) and HER3, and persistent signaling along the phosphatidylinositol 3-kinase (PI3K) pathway. Clinically, properties of residual disease cells from the PDX models were detected in lingering tumors of responsive patients and in tumors of individuals who had experienced early recurrence. Mechanistically, residual tumor reprogramming after EGFR neutralization was mediated by inactivation of Yes-associated protein (YAP), a master regulator of intestinal epithelium recovery from injury. In preclinical trials, Pan-HER antibodies minimized residual disease, blunted PI3K signaling, and induced long-term tumor control after treatment discontinuation. We found that tolerance to EGFR inhibition is characterized by inactivation of an intrinsic lineage program that drives both regenerative signaling during intestinal repair and EGFR-dependent tumorigenesis. Thus, our results shed light on CRC lineage plasticity as an adaptive escape mechanism from EGFR-targeted therapy and suggest opportunities to preemptively target residual disease.
C1 [Lupo, Barbara; Pinnelli, Marika; Galimi, Francesco; Vurchio, Valentina; Migliardi, Giorgia; Gagliardi, Paolo Armando; Puliafito, Alberto; Boccaccio, Carla; Medico, Enzo; Primo, Luca; Isella, Claudio; Bertotti, Andrea; Trusolino, Livio] Univ Torino, Dept Oncol, I-10060 Turin, Italy.
   [Lupo, Barbara; Sassi, Francesco; Pinnelli, Marika; Galimi, Francesco; Zanella, Eugenia R.; Vurchio, Valentina; Migliardi, Giorgia; Gagliardi, Paolo Armando; Puliafito, Alberto; Luraghi, Paolo; Boccaccio, Carla; Medico, Enzo; Primo, Luca; Grassi, Elena; Isella, Claudio; Bertotti, Andrea; Trusolino, Livio] Candiolo Canc Inst FPO IRCCS, I-10060 Turin, Italy.
   [Manganaro, Daria; Pasini, Diego] European Inst Oncol, I-20139 Milan, Italy.
   [Kragh, Michael; Pedersen, Mikkel W.; Horak, Ivan D.] Symphogen AS, DK-2750 Ballerup, Denmark.
   [Nichol, Daniel; Spiteri, Inmaculada; Heide, Timon; Vatsiou, Alexandra; Sottoriva, Andrea] Inst Canc Res, London SW7 3RP, England.
   [Graham, Trevor A.] Queen Mary Univ London, Barts & London Sch Med & Dent, Barts Canc Inst, Ctr Genom & Computat Biol, London EC1M 6BQ, England.
   [Elez, Elena; Argiles, Guillem; Nuciforo, Paolo; Dienstmann, Rodrigo] Vall dHebron Inst Oncol VHIO, Barcelona 08035, Spain.
   [Pasini, Diego] Univ Milan, Dept Hlth Sci, I-20142 Milan, Italy.
   [Gagliardi, Paolo Armando] Univ Bern, Inst Cell Biol, CH-3012 Bern, Switzerland.
   [Luraghi, Paolo] IFOM FIRC Inst Mol Oncol, I-20139 Milan, Italy.
   [Kragh, Michael] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark.
   [Horak, Ivan D.] Thessa Therapeut, Singapore 038988, Singapore.
C3 University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia;
   IRCCS European Institute of Oncology (IEO); Symphogen; University of
   London; Institute of Cancer Research - UK; Royal Marsden NHS Foundation
   Trust; University of London; Queen Mary University London; Vall d'Hebron
   Institut d'Oncologia (VHIO); University of Milan; University of Bern;
   IFOM - FIRC Institute of Molecular Oncology; Novo Nordisk
RP Bertotti, A; Trusolino, L (corresponding author), Univ Torino, Dept Oncol, I-10060 Turin, Italy.; Bertotti, A; Trusolino, L (corresponding author), Candiolo Canc Inst FPO IRCCS, I-10060 Turin, Italy.
EM andrea.bertotti@ircc.it; livio.trusolino@ircc.it
RI sassi, francesco/AAB-6844-2020; Nuciforo, Paolo/Q-2885-2019; Puliafito,
   Alberto/K-2462-2018; Trusolino, Livio/A-3896-2011; Boccaccio,
   Carla/AHE-7875-2022; Zanella, Eugenia/AAC-2369-2022; Manganaro,
   Daria/AAT-6884-2020; Medico, Enzo/AAC-3185-2021; Migliardi,
   Giorgia/AAB-6619-2020; Grassi, Elena/AAB-3099-2020; Graham,
   Trevor/B-4571-2011; Pasini, Diego/J-9674-2012; Medico, Enzo/K-8497-2018;
   Lupo, Barbara/HSG-9173-2023; Gagliardi, Paolo Armando/D-1836-2018;
   Isella, Claudio/F-7327-2012; Argiles, Guillem/KQU-7406-2024
OI Zanella, Eugenia Rosalinda/0000-0002-8036-3789; Pasini,
   Diego/0000-0002-9879-6486; Sottoriva, Andrea/0000-0001-6709-9533;
   Puliafito, Alberto/0000-0002-0096-1536; Pinnelli,
   Marika/0000-0002-3565-2493; Trusolino, Livio/0000-0002-6379-3365; PRIMO,
   Luca/0000-0002-1294-0441; Valentina, Vurchio/0000-0002-8699-2164;
   Grassi, Elena/0000-0003-1066-927X; Boccaccio, Carla/0000-0003-2620-9083;
   Medico, Enzo/0000-0002-3917-2438; Sassi, Francesco/0000-0002-4741-0408;
   Lupo, Barbara/0000-0002-4383-6882; GALIMI,
   Francesco/0000-0002-5939-6922; Gagliardi, Paolo
   Armando/0000-0002-4818-035X; Manganaro, Daria/0000-0003-4756-763X;
   Isella, Claudio/0000-0003-0679-4756; Argiles,
   Guillem/0000-0002-1487-7108; Bertotti, Andrea/0000-0001-8196-7608
FU AIRC, Associazione Italiana per la Ricerca sul Cancro [20697, 12944,
   20290, 22802]; AIRC 5x1000 grant [21091]; AIRC/CRUK/FC AECC Accelerator
   Award [22795]; My First AIRC Grant [19047]; European Research Council
   [724748 -BEAT]; H2020 grant [754923 COLOSSUS]; H2020 INFRAIA grant
   [731105 EDIReX]; Transcan, TACTIC; Fondazione Piemontese per la Ricerca
   sul Cancro-ONLUS, 5x1000 Ministero della Salute 2015; Fondazione
   Piemontese per la Ricerca sul Cancro-ONLUS, 5x1000 Ministero della
   Salute 2016; Fondazione Piemontese per la Ricerca sul Cancro-ONLUS,
   5x1000 Ministero della Salute 2014; Fondazione Umberto Veronesi
FX Y Supported by AIRC, Associazione Italiana per la Ricerca sul Cancro,
   Investigator Grants 20697 (to A.B.), 12944 (to E.M.), 20290 (to D.P.),
   and 22802 (to L.T.); AIRC 5x1000 grant 21091 (to A.B., E.M., and L.T.);
   AIRC/CRUK/FC AECC Accelerator Award 22795 (to L.T.); My First AIRC Grant
   19047 (to C.I.); European Research Council Consolidator Grant 724748
   -BEAT (to A.B.); H2020 grant agreement no. 754923 COLOSSUS (to L.T.);
   H2020 INFRAIA grant agreement no. 731105 EDIReX (to A.B. and E.M.);
   Transcan, TACTIC (to L.T.); and Fondazione Piemontese per la Ricerca sul
   Cancro-ONLUS, 5x1000 Ministero della Salute 2015 (to E.M. and L.T.) and
   2014 and 2016 (to L.T.). A.B., E.M., and L.T. are members of the EurOPDX
   Consortium. A.P. is the recipient of a fellowship from Fondazione
   Umberto Veronesi.
CR Alimandi M, 1997, EMBO J, V16, P5608, DOI 10.1093/emboj/16.18.5608
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Baralis E, 2012, J MED SYST, V36, pS81, DOI 10.1007/s10916-012-9891-6
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Barker N, 2012, CELL STEM CELL, V11, P452, DOI 10.1016/j.stem.2012.09.009
   Barriga FM, 2017, CELL STEM CELL, V20, P801, DOI 10.1016/j.stem.2017.02.007
   Basak O, 2017, CELL STEM CELL, V20, P177, DOI 10.1016/j.stem.2016.11.001
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bivona TG, 2016, NAT MED, V22, P472, DOI 10.1038/nm.4091
   Blumenthal GM, 2015, J CLIN ONCOL, V33, P1008, DOI 10.1200/JCO.2014.59.0489
   Bosch-Vilaró A, 2017, ONCOTARGET, V8, P4277, DOI 10.18632/oncotarget.13834
   Buczacki SJA, 2013, NATURE, V495, P65, DOI 10.1038/nature11965
   Budiyanto A, 2003, J INVEST DERMATOL, V121, P1088, DOI 10.1046/j.1523-1747.2003.12529.x
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Clevers H, 2013, NATURE, V495, P53, DOI 10.1038/nature11958
   Clevers HC, 2013, ANNU REV PHYSIOL, V75, P289, DOI 10.1146/annurev-physiol-030212-183744
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539
   Dienstmann R, 2015, CANCER DISCOV, V5, P598, DOI 10.1158/2159-8290.CD-14-1432
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Dunham I, 2012, NATURE, V489, P57, DOI 10.1038/nature11247
   Dupont S, 2011, NATURE, V474, P179, DOI 10.1038/nature10137
   Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549
   Gregorieff A, 2015, NATURE, V526, P715, DOI 10.1038/nature15382
   Haber AL, 2017, NATURE, V551, P333, DOI 10.1038/nature24489
   Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040
   Hrustanovic G, 2015, NAT MED, V21, P1038, DOI 10.1038/nm.3930
   Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017
   Isella C, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15107
   Jacobsen HJ, 2015, CLIN CANCER RES, V21, P4110, DOI 10.1158/1078-0432.CCR-14-3312
   Jammula S, 2016, EPIGENET CHROMATIN, V9, DOI 10.1186/s13072-016-0095-z
   Jani TS, 2010, J BIOL CHEM, V285, P19162, DOI 10.1074/jbc.M109.091645
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Leto SM, 2015, CLIN CANCER RES, V21, P5519, DOI 10.1158/1078-0432.CCR-14-3066
   Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218
   Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T
   Mancini M, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa0725
   Misale S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9305
   Piessevaux H, 2009, ANN ONCOL, V20, P1375, DOI 10.1093/annonc/mdp011
   Piessevaux H, 2013, J CLIN ONCOL, V31, P3764, DOI 10.1200/JCO.2012.42.8532
   Pinkas-Kramarski R, 1998, ONCOGENE, V16, P1249, DOI 10.1038/sj.onc.1201642
   Pupo E, 2016, CANCER RES, V76, P5019, DOI 10.1158/0008-5472.CAN-15-3107
   Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025
   Ramirez M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10690
   Reddy BVVG, 2013, DEV CELL, V24, P459, DOI 10.1016/j.devcel.2013.01.020
   Rodriguez-Brenes IA, 2013, TRENDS ECOL EVOL, V28, P597, DOI 10.1016/j.tree.2013.05.020
   Sasaki N, 2016, P NATL ACAD SCI USA, V113, pE5399, DOI 10.1073/pnas.1607327113
   Sathe A, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0190854
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Song CY, 2017, CANCER DISCOV, V7, P1248, DOI 10.1158/2159-8290.CD-17-0401
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Zanella ER, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010445
   Zhao YL, 2018, MOL CANCER RES, V16, P1046, DOI 10.1158/1541-7786.MCR-17-0593
   Zou M, 2017, CANCER DISCOV, V7, P736, DOI 10.1158/2159-8290.CD-16-1174
NR 64
TC 39
Z9 40
U1 0
U2 4
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
EI 1946-6242
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD AUG 5
PY 2020
VL 12
IS 555
AR eaax8313
DI 10.1126/scitranslmed.aax8313
PG 17
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA MZ0NG
UT WOS:000558819900002
PM 32759276
OA Green Submitted
DA 2025-01-04
ER

PT J
AU Zhai, PS
   Tong, T
   Wang, XN
   Li, CW
   Liu, C
   Qin, X
   Li, S
   Xie, F
   Mao, JY
   Zhang, JJ
   Guo, HY
AF Zhai, Peisong
   Tong, Tong
   Wang, Xiaoning
   Li, Chuwen
   Liu, Chun
   Qin, Xing
   Li, Shu
   Xie, Fei
   Mao, Jiayi
   Zhang, Jianjun
   Guo, Haiyan
TI Nuclear miR-451a activates KDM7A and leads to cetuximab resistance in
   head and neck squamous cell carcinoma
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE Nuclear miRNAs; Noncoding RNA; Cetuximab; Head and neck squamous cell
   carcinoma
ID GROWTH-FACTOR RECEPTOR; OVERCOMING RESISTANCE; COLORECTAL-CANCER;
   MOLECULAR-MECHANISMS; MAMMALIAN-CELLS; MICRORNAS; TRANSCRIPTION;
   BIOGENESIS; EXPRESSION; PROTEINS
AB Cetuximab resistance has been a major challenge for head and neck squamous cell carcinoma (HNSCC) patients receiving targeted therapy. However, the mechanism that causes cetuximab resistance, especially microRNA (miRNA) regulation, remains unclear. Growing evidence suggests that miRNAs may act as "nuclear activating miRNAs" for targeting promoter regions or enhancers related to target genes. This study elucidates a novel mechanism underlying cetuximab resistance in HNSCC involving the nuclear activation of KDM7A transcription via miR-451a. Herein, small RNA sequencing, quantitative real-time polymerase chain reaction (qRT-PCR) and fluorescence in situ hybridization (FISH) results provided compelling evidence of miR-451a nuclear enrichment in response to cetuximab treatment. Chromatin isolation via RNA purification, microarray analysis, and bioinformatic analysis revealed that miR-451a interacts with an enhancer region in KDM7A, activating its expression and further facilitating cetuximab resistance. It has also been demonstrated that the activation of KDM7A by nuclear miR-451a is induced by cetuximab treatment and is AGO2 dependent. Logistic regression analyses of 87 HNSCC samples indicated the significance of miR-451a and KDM7A in the development of cetuximab resistance. These discoveries support the potential of miR-451a and KDM7A as valuable biomarkers for cetuximab resistance and emphasize the function of nuclear-activating miRNAs.
C1 [Zhai, Peisong; Wang, Xiaoning; Li, Chuwen; Liu, Chun; Qin, Xing; Xie, Fei; Zhang, Jianjun] Shanghai Jiao Tong Univ, Natl Clin Res Ctr Oral Dis,Sch Med,Coll Stomatol, Shanghai Peoples Hosp 9,Shanghai Key Lab Stomat, Dept Oral & Maxillofacial Head & Neck Oncol,Natl C, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.
   [Tong, Tong] Fudan Univ, Shanghai Stomatol Hosp, Dept Oral & Maxillofacial Surg, Shanghai 200011, Peoples R China.
   [Tong, Tong] Fudan Univ, Shanghai Key Lab Craniomaxillofacial Dev & Dis, Shanghai 200002, Peoples R China.
   [Li, Shu; Guo, Haiyan] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Clin Lab, Sch Med, Shanghai 200011, Peoples R China.
   [Mao, Jiayi] Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Plast & Reconstruct Surg, Sch Med, Shanghai 200011, Peoples R China.
C3 Shanghai Jiao Tong University; Fudan University; Fudan University;
   Shanghai Jiao Tong University; Shanghai Jiao Tong University
RP Zhang, JJ (corresponding author), Shanghai Jiao Tong Univ, Natl Clin Res Ctr Oral Dis,Sch Med,Coll Stomatol, Shanghai Peoples Hosp 9,Shanghai Key Lab Stomat, Dept Oral & Maxillofacial Head & Neck Oncol,Natl C, 639 Zhizaoju Rd, Shanghai 200011, Peoples R China.; Guo, HY (corresponding author), Shanghai Jiao Tong Univ, Shanghai Peoples Hosp 9, Dept Clin Lab, Sch Med, Shanghai 200011, Peoples R China.
EM zjjshuobo@163.com; sxguohaiyan@126.com
RI 建军, 张/R-3679-2019; Li, Chuwen/AAP-2187-2021
FU National Natural Science Foundation of China [82273267, 82173148,
   82073036]
FX This work was supported by the National Natural Science Foundation of
   China (Grant Nos. 82273267, 82173148, and 82073036)
CR Bai YS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136721
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0
   Burtness B, 2013, LANCET ONCOL, V14, pE302, DOI 10.1016/S1470-2045(13)70085-8
   Cao D, 2022, J BONE ONCOL, V33, DOI 10.1016/j.jbo.2022.100412
   Cheloufi S, 2010, NATURE, V465, P584, DOI 10.1038/nature09092
   Chen LF, 2010, CLIN CANCER RES, V16, P2489, DOI 10.1158/1078-0432.CCR-09-2318
   Chu C, 2011, MOL CELL, V44, P667, DOI 10.1016/j.molcel.2011.08.027
   Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037
   Citron F, 2021, EMBO MOL MED, V13, DOI 10.15252/emmm.202012872
   Cutilli T, 2013, BRIT J ORAL MAX SURG, V51, P922, DOI 10.1016/j.bjoms.2013.05.150
   Dittmann K, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189087
   El Fatimy R, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01494-z
   Gomes INF, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11010154
   Huang V, 2012, RNA BIOL, V9, P269, DOI 10.4161/rna.19354
   Izumi H, 2020, MOL CANCER THER, V19, P1562, DOI 10.1158/1535-7163.MCT-19-1036
   Janowski BA, 2007, NAT CHEM BIOL, V3, P166, DOI 10.1038/nchembio860
   Johnson DE, 2020, NAT REV DIS PRIMERS, V6, DOI 10.1038/s41572-020-00224-3
   Ju HY, 2020, AM J CANCER RES, V10, P454
   Kagohara LT, 2020, BRIT J CANCER, V123, P101, DOI 10.1038/s41416-020-0851-5
   Kakumani PK, 2023, NUCLEIC ACIDS RES, V51, P9385, DOI 10.1093/nar/gkad619
   Kang MR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160961
   Katz S, 2016, CELL REP, V17, P1383, DOI 10.1016/j.celrep.2016.09.088
   Khordadmehr M, 2019, J CELL PHYSIOL, V234, P21716, DOI 10.1002/jcp.28888
   Kretov DA, 2020, MOL CELL, V78, P317, DOI 10.1016/j.molcel.2020.02.020
   Leblanc O, 2020, CANCER BIOL MED, V17, P208, DOI 10.20892/j.issn.2095-3941.2019.0153
   Lee KH, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21165658
   Lee KH, 2018, INT J CANCER, V143, P2849, DOI 10.1002/ijc.31843
   Leonard B, 2018, CANCER RES, V78, P4331, DOI 10.1158/0008-5472.CAN-18-0459
   Li HP, 2020, MOL THER-NUCL ACIDS, V19, P132, DOI 10.1016/j.omtn.2019.11.006
   Li HP, 2019, CIRC RES, V125, P1106, DOI 10.1161/CIRCRESAHA.119.314898
   Li LC, 2006, P NATL ACAD SCI USA, V103, P17337, DOI 10.1073/pnas.0607015103
   Liang Y, 2021, NUCLEIC ACIDS RES, V49, P8556, DOI 10.1093/nar/gkab626
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Liu HY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0765-5
   Liu JJ, 2022, INT J MOL MED, V50, DOI 10.3892/ijmm.2022.5148
   Liu SS, 2023, CARCINOGENESIS, V44, P153, DOI 10.1093/carcin/bgac102
   López-Verdín S, 2018, CANCERS, V10, DOI 10.3390/cancers10100376
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   Madoz-Gúrpide J, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0633-7
   Matsui M, 2013, NUCLEIC ACIDS RES, V41, P10086, DOI 10.1093/nar/gkt777
   Meng ZZ, 2020, J CELL PHYSIOL, V235, P932, DOI 10.1002/jcp.29008
   Muraro E, 2021, CRIT REV ONCOL HEMAT, V164, DOI 10.1016/j.critrevonc.2021.103424
   Nazer E, 2022, MOL CELL, V82, P503, DOI 10.1016/j.molcel.2021.11.005
   Nishi K, 2013, RNA, V19, P17, DOI 10.1261/rna.034769.112
   Pearson HE, 2018, MOL CANCER THER, V17, P204, DOI 10.1158/1535-7163.MCT-17-0384
   Pestova TV, 2001, P NATL ACAD SCI USA, V98, P7029, DOI 10.1073/pnas.111145798
   Place RF, 2008, P NATL ACAD SCI USA, V105, P1608, DOI 10.1073/pnas.0707594105
   Portnoy V, 2016, CELL RES, V26, P320, DOI 10.1038/cr.2016.22
   Qu HX, 2015, HUM MOL GENET, V24, P2539, DOI 10.1093/hmg/ddv018
   Rabinowits G, 2012, ORAL ONCOL, V48, P1085, DOI 10.1016/j.oraloncology.2012.06.016
   Rampias T, 2014, CLIN CANCER RES, V20, P2933, DOI 10.1158/1078-0432.CCR-13-2721
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Schraivogel D, 2015, NUCLEIC ACIDS RES, V43, P7447, DOI 10.1093/nar/gkv705
   Shen J, 2013, NATURE, V497, P383, DOI 10.1038/nature12080
   Solomon B, 2018, SEMIN CANCER BIOL, V52, P228, DOI 10.1016/j.semcancer.2018.01.008
   Sun LN, 2019, THERANOSTICS, V9, P8409, DOI 10.7150/thno.36605
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tay Y, 2008, NATURE, V455, P1124, DOI 10.1038/nature07299
   Thomas H, 2017, NAT REV GASTRO HEPAT, V14, P691, DOI 10.1038/nrgastro.2017.156
   Wang J, 2015, STEM CELLS DEV, V24, P345, DOI 10.1089/scd.2014.0290
   Wei Y, 2014, J BIOL CHEM, V289, P10270, DOI 10.1074/jbc.C113.541417
   Willey CD, 2019, BIOCHEM BIOPH RES CO, V517, P36, DOI 10.1016/j.bbrc.2019.06.159
   Xiao M, 2017, RNA BIOL, V14, P1326, DOI 10.1080/15476286.2015.1112487
   Yang S, 2021, HEAD NECK-J SCI SPEC, V43, P2712, DOI 10.1002/hed.26742
   Yao YL, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00908-0
   Younger ST, 2011, NUCLEIC ACIDS RES, V39, P5682, DOI 10.1093/nar/gkr155
   Zhang Q, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419-022-05536-8
NR 69
TC 0
Z9 0
U1 12
U2 12
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD DEC
PY 2024
VL 81
IS 1
AR 282
DI 10.1007/s00018-024-05324-x
PG 21
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA WZ3P3
UT WOS:001258659400002
PM 38943031
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Abou-Fayçal, C
   Hatat, AS
   Gazzeri, S
   Eymin, B
AF Abou-Faycal, Cherine
   Hatat, Anne-Sophie
   Gazzeri, Sylvie
   Eymin, Beatrice
TI Splice Variants of the RTK Family: Their Role in Tumour Progression and
   Response to Targeted Therapy
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE alternative splicing; angiogenesis; cancer; EGFR; receptor tyrosine
   kinases; tumourigenesis; targeted therapies; VEGFR
ID GROWTH-FACTOR-RECEPTOR; ACTIVATED PROTEIN-KINASE; CELL LUNG-CANCER;
   MESSENGER-RNA; SOLUBLE VEGFR-1; TYROSINE KINASE; COLORECTAL-CANCER;
   BREAST-CANCER; GENE-TRANSFER; PHASE-II
AB Receptor tyrosine kinases (RTKs) belong to a family of transmembrane receptors that display tyrosine kinase activity and trigger the activation of downstream signalling pathways mainly involved in cell proliferation and survival. RTK amplification or somatic mutations leading to their constitutive activation and oncogenic properties have been reported in various tumour types. Numerous RTK-targeted therapies have been developed to counteract this hyperactivation. Alternative splicing of pre-mRNA has recently emerged as an important contributor to cancer development and tumour maintenance. Interestingly, RTKs are alternatively spliced. However, the biological functions of RTK splice variants, as well as the upstream signals that control their expression in tumours, remain to be understood. More importantly, it remains to be determined whether, and how, these splicing events may affect the response of tumour cells to RTK-targeted therapies, and inversely, whether these therapies may impact these splicing events. In this review, we will discuss the role of alternative splicing of RTKs in tumour progression and response to therapies, with a special focus on two major RTKs that control proliferation, survival, and angiogenesis, namely, epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor-1 (VEGFR1).
C1 [Abou-Faycal, Cherine; Hatat, Anne-Sophie; Gazzeri, Sylvie; Eymin, Beatrice] Univ Grenoble Alpes, Team RNA Splicing Cell Signaling & Response Thera, Inst Adv Biosci, INSERM U1209,CNRS UMR5309, F-38702 Grenoble, France.
C3 Centre National de la Recherche Scientifique (CNRS); CNRS - National
   Institute for Biology (INSB); Communaute Universite Grenoble Alpes;
   Universite Grenoble Alpes (UGA); Institut National de la Sante et de la
   Recherche Medicale (Inserm)
RP Eymin, B (corresponding author), Univ Grenoble Alpes, Team RNA Splicing Cell Signaling & Response Thera, Inst Adv Biosci, INSERM U1209,CNRS UMR5309, F-38702 Grenoble, France.
EM cherineaf@gmail.com; anne-sophie.hatat@univ-grenoble-alpes.fr;
   sylvie.gazzeri@univ-grenoble-alpes.fr;
   beatrice.eymin@univ-grenoble-alpes.fr
RI gazzeri, sylvie/U-4669-2019; eymin, beatrice/U-4670-2019; eymin,
   beatrice/M-1962-2013
OI eymin, beatrice/0000-0002-7311-3810; Abou Faycal,
   Cherine/0000-0003-4339-9210
FU Institute National de la Sante et de la Recherche Medicale; Fondation
   ARC pour la recherche sur le cancer, la Ligue Nationale contre Le Cancer
   Comites de Savoie et de l'Isere and Agir pour les Maladies Chroniques;
   French Research Ministry, and Cherine Abou-Faycal; Ligue Nationale
   contre Le Cancer
FX This work was supported by the Institute National de la Sante et de la
   Recherche Medicale, the Fondation ARC pour la recherche sur le cancer,
   la Ligue Nationale contre Le Cancer Comites de Savoie et de l'Isere and
   Agir pour les Maladies Chroniques. Anne-Sophie Hatat was supported by
   the French Research Ministry, and Cherine Abou-Faycal was supported by
   la Ligue Nationale contre Le Cancer.
CR Ahmad S, 2004, CIRC RES, V95, P884, DOI 10.1161/01.RES.0000147365.86159.f5
   Ahmad S, 2011, VASC CELL, V3, DOI 10.1186/2045-824X-3-15
   Albuquerque RJC, 2009, NAT MED, V15, P1023, DOI 10.1038/nm.2018
   Ambati BK, 2007, BRIT J OPHTHALMOL, V91, P505, DOI 10.1136/bjo.2006.107417
   Ambati BK, 2006, NATURE, V443, P993, DOI 10.1038/nature05249
   Anton L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122707
   Arcondéguy T, 2013, NUCLEIC ACIDS RES, V41, P7997, DOI 10.1093/nar/gkt539
   Aref S, 2005, HEMATOLOGY, V10, P131, DOI 10.1080/10245330500065797
   Asgeirsson KS, 2007, BREAST CANCER RES, V9, DOI 10.1186/bcr1788
   Bando H, 2005, BRIT J CANCER, V92, P553, DOI 10.1038/sj.bjc.6602374
   Baron AT, 2003, CANCER EPIDEM BIOMAR, V12, P103
   Bates DO, 2002, CANCER RES, V62, P4123
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108
   Brivanlou AH, 2002, SCIENCE, V295, P813, DOI 10.1126/science.1066355
   Cha JY, 2008, MOL CANCER RES, V6, P435, DOI 10.1158/1541-7786.MCR-07-0187
   Chang YT, 2008, PANCREAS, V37, P145, DOI 10.1097/MPA.0b013e318164548a
   Chen GW, 2008, PANCREAS, V37, P159, DOI 10.1097/MPA.0b013e31816618a4
   Choi JH, 1997, CANCER-AM CANCER SOC, V79, P1879, DOI 10.1002/(SICI)1097-0142(19970515)79:10<1879::AID-CNCR6>3.0.CO;2-B
   David CJ, 2010, GENE DEV, V24, P2343, DOI 10.1101/gad.1973010
   de Figueiredo-Pontes LL, 2014, J THORAC ONCOL, V9, P248, DOI 10.1097/JTO.0000000000000050
   Duda DG, 2010, ONCOLOGIST, V15, P577, DOI 10.1634/theoncologist.2010-0029
   Eichmann A, 2012, CURR OPIN CELL BIOL, V24, P188, DOI 10.1016/j.ceb.2012.02.002
   EKSTRAND AJ, 1991, CANCER RES, V51, P2164
   EKSTRAND AJ, 1992, P NATL ACAD SCI USA, V89, P4309, DOI 10.1073/pnas.89.10.4309
   Eller JL, 2002, NEUROSURGERY, V51, P1005, DOI 10.1227/01.NEU.0000029020.56466.17
   Eming SA, 2004, J INVEST DERMATOL, V123, P799, DOI 10.1111/j.0022-202X.2004.23310.x
   Emlet DR, 2014, CANCER RES, V74, P1238, DOI 10.1158/0008-5472.CAN-13-1407
   Eswarakumar VP, 2005, CYTOKINE GROWTH F R, V16, P139, DOI 10.1016/j.cytogfr.2005.01.001
   Fan XJ, 2014, J CLIN INVEST, V124, P4941, DOI 10.1172/JCI76864
   Feldkamp MM, 1999, NEUROSURGERY, V45, P1442, DOI 10.1097/00006123-199912000-00034
   Ferguson KM, 2008, ANNU REV BIOPHYS, V37, P353, DOI 10.1146/annurev.biophys.37.032807.125829
   Ferrara N, 2004, ENDOCR REV, V25, P581, DOI 10.1210/er.2003-0027
   FLICKINGER TW, 1992, MOL CELL BIOL, V12, P883, DOI 10.1128/MCB.12.2.883
   Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285
   Gan HK, 2013, FEBS J, V280, P5350, DOI 10.1111/febs.12393
   Gan HK, 2009, J CLIN NEUROSCI, V16, P748, DOI 10.1016/j.jocn.2008.12.005
   Ge H, 2002, INT J CANCER, V98, P357, DOI 10.1002/ijc.10224
   Ghigna C, 2010, RNA BIOL, V7, P495, DOI 10.4161/rna.7.4.12744
   Goldman CK, 1998, P NATL ACAD SCI USA, V95, P8795, DOI 10.1073/pnas.95.15.8795
   Guillaudeau A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037204
   Halatsch ME, 2004, J NEUROSURG, V100, P523, DOI 10.3171/jns.2004.100.3.0523
   Harris AL, 2001, CLIN CANCER RES, V7, P1992
   Heist RS, 2015, P NATL ACAD SCI USA, V112, P1547, DOI 10.1073/pnas.1424024112
   Heydarian M, 2009, PLACENTA, V30, P250, DOI 10.1016/j.placenta.2008.12.010
   Hornig C, 2000, LAB INVEST, V80, P443, DOI 10.1038/labinvest.3780050
   Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6
   Ilhan N, 2004, CLIN BIOCHEM, V37, P840, DOI 10.1016/j.clinbiochem.2004.03.012
   Jantus-Lewintre E, 2011, CLIN LUNG CANCER, V12, P320, DOI 10.1016/j.cllc.2011.03.031
   Jebbink J, 2011, HYPERTENSION, V58, P70, DOI 10.1161/HYPERTENSIONAHA.110.164079
   Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8
   Kang CS, 2006, CANCER GENE THER, V13, P530, DOI 10.1038/sj.cgt.7700932
   Kangsamaksin T, 2015, CANCER DISCOV, V5, P182, DOI 10.1158/2159-8290.CD-14-0650
   Karumanchi SA, 2004, ENDOCRINOLOGY, V145, P4835, DOI 10.1210/en.2004-1028
   Kawamura H, 2008, CANCER RES, V68, P4683, DOI 10.1158/0008-5472.CAN-07-6577
   Kearney JB, 2004, BLOOD, V103, P4527, DOI 10.1182/blood-2003-07-2315
   KENDALL RL, 1993, P NATL ACAD SCI USA, V90, P10705, DOI 10.1073/pnas.90.22.10705
   Kendall RL, 1996, BIOCHEM BIOPH RES CO, V226, P324, DOI 10.1006/bbrc.1996.1355
   Kim NH, 2005, KIDNEY INT, V67, P167, DOI 10.1111/j.1523-1755.2005.00067.x
   Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252
   Krishnaswamy S, 2016, LUNG CANCER, V92, P41, DOI 10.1016/j.lungcan.2015.12.002
   Kulapaditharom B, 2012, J ONCOL, V2012, DOI 10.1155/2012/687934
   Kumai Y, 2007, J CEREBR BLOOD F MET, V27, P1152, DOI 10.1038/sj.jcbfm.9600420
   Lambrechts D, 2013, J CLIN ONCOL, V31, P1219, DOI 10.1200/JCO.2012.46.2762
   Lamszus K, 2003, CLIN CANCER RES, V9, P1399
   Lee JE, 2015, MOL CANCER THER, V14, P470, DOI 10.1158/1535-7163.MCT-14-0968-T
   Lee SCW, 2016, NAT MED, V22, P672, DOI 10.1038/nm.4097
   Lemos-González Y, 2007, BRIT J CANCER, V96, P1569, DOI 10.1038/sj.bjc.6603770
   Levine RJ, 2004, NEW ENGL J MED, V350, P672, DOI 10.1056/NEJMoa031884
   Li LN, 2010, J NEUROSURG, V113, P192, DOI 10.3171/2010.2.JNS091211
   Lococo F, 2015, INT J MOL SCI, V16, P19612, DOI 10.3390/ijms160819612
   Malakar P, 2016, SCI REP-UK, V6, DOI 10.1038/srep31222
   Malhotra R, 2013, PULM CIRC, V3, P369, DOI 10.4103/2045-8932.110445
   Maramotti S, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17040593
   Maynard SE, 2003, J CLIN INVEST, V111, P649, DOI 10.1172/JCI200317189
   Meyerhardt JA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038231
   Mitra D, 2009, MOL CANCER THER, V8, P2152, DOI 10.1158/1535-7163.MCT-09-0295
   Miyake T, 2016, SCI REP-UK, V6, DOI 10.1038/srep24853
   MOSCATELLO DK, 1995, CANCER RES, V55, P5536
   Moscatello DK, 1997, CANCER RES, V57, P1419
   Müller V, 2006, ANTICANCER RES, V26, P1479
   Nagane M, 1996, CANCER RES, V56, P5079
   Nagaoka S, 2010, ONCOL REP, V23, P1647, DOI 10.3892/or_00000807
   Nieto Y, 2007, J CLIN ONCOL, V25, P4405, DOI 10.1200/JCO.2006.09.8822
   OBRYAN JP, 1991, MOL CELL BIOL, V11, P5016, DOI 10.1128/MCB.11.10.5016
   Olsson AK, 2006, NAT REV MOL CELL BIO, V7, P359, DOI 10.1038/nrm1911
   Oltean S, 2014, ONCOGENE, V33, P5311, DOI 10.1038/onc.2013.533
   Orecchia A, 2003, J CELL SCI, V116, P3479, DOI 10.1242/jcs.00673
   Owen LA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033576
   Padfield E, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00005
   Pan Q, 2008, NAT GENET, V40, P1413, DOI 10.1038/ng.259
   Perez-Torres M, 2008, EXP CELL RES, V314, P2907, DOI 10.1016/j.yexcr.2008.07.013
   Piccione EC, 2012, ONCOGENE, V31, P2953, DOI 10.1038/onc.2011.465
   Pillay V, 2009, NEOPLASIA, V11, P448, DOI 10.1593/neo.09230
   Pines G, 2010, ONCOGENE, V29, P5850, DOI 10.1038/onc.2010.313
   Reiter JL, 1996, NUCLEIC ACIDS RES, V24, P4050, DOI 10.1093/nar/24.20.4050
   Reiter JL, 2001, GENOMICS, V71, P1, DOI 10.1006/geno.2000.6341
   Richardson DS, 2012, MOL BIOL CELL, V23, P3838, DOI 10.1091/mbc.E12-02-0114
   Roskoski R, 2007, CRIT REV ONCOL HEMAT, V62, P179, DOI 10.1016/j.critrevonc.2007.01.006
   Ruffini F, 2011, BRIT J DERMATOL, V164, P1061, DOI 10.1111/j.1365-2133.2010.10200.x
   Salton M, 2016, TRENDS MOL MED, V22, P28, DOI 10.1016/j.molmed.2015.11.005
   Salton M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8103
   Sampson JH, 2011, NEURO-ONCOLOGY, V13, P324, DOI 10.1093/neuonc/noq157
   Sanderson MP, 2008, J CELL BIOCHEM, V103, P1783, DOI 10.1002/jcb.21569
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Sela S, 2008, CIRC RES, V102, P1566, DOI 10.1161/CIRCRESAHA.108.171504
   Shiose S, 2000, INVEST OPHTH VIS SCI, V41, P2395
   Song F, 2016, FEBS LETT, V590, P1345, DOI 10.1002/1873-3468.12166
   Suarez SC, 2006, CELL MOL LIFE SCI, V63, P2067, DOI 10.1007/s00018-006-6254-9
   Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342
   Sundvall M, 2008, P NATL ACAD SCI USA, V105, P4162, DOI 10.1073/pnas.0708333105
   Szalai G, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119547
   Takayama K, 2000, CANCER RES, V60, P2169
   Thielemann A, 2013, ANN AGR ENV MED, V20, P293
   Thomas CP, 2009, J CLIN ENDOCR METAB, V94, P2524, DOI 10.1210/jc.2009-0017
   Thomas-Schoemann A, 2015, J CLIN PHARMACOL, V55, P478, DOI 10.1002/jcph.429
   Toi M, 2002, INT J CANCER, V98, P14, DOI 10.1002/ijc.10121
   Tolaney SM, 2015, P NATL ACAD SCI USA, V112, P14325, DOI 10.1073/pnas.1518808112
   Tsao PN, 2007, CRIT CARE MED, V35, P1955, DOI 10.1097/01.CCM.0000275273.56547.B8
   ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K
   Vaishnavi A, 2015, CANCER DISCOV, V5, P25, DOI 10.1158/2159-8290.CD-14-0765
   Verrax J, 2011, MOL PHARMACEUT, V8, P701, DOI 10.1021/mp100268t
   Vogel W, 1997, MOL CELL, V1, P13, DOI 10.1016/S1097-2765(00)80003-9
   Vorlová S, 2011, MOL CELL, V43, P927, DOI 10.1016/j.molcel.2011.08.009
   Wada T, 2013, J INFLAMM-LOND, V10, DOI 10.1186/1476-9255-10-6
   Wierzbowska A, 2003, EUR CYTOKINE NETW, V14, P149
   Willett CG, 2009, J CLIN ONCOL, V27, P3020, DOI 10.1200/JCO.2008.21.1771
   Wu FTH, 2010, J CELL MOL MED, V14, P528, DOI 10.1111/j.1582-4934.2009.00941.x
   Xia L, 2016, J MICROBIOL IMMUNOL, V49, P344, DOI 10.1016/j.jmii.2014.06.008
   Xiong YL, 2009, J CELL PHYSIOL, V220, P632, DOI 10.1002/jcp.21800
   Yamaguchi T, 2007, CANCER SCI, V98, P405, DOI 10.1111/j.1349-7006.2007.00402.x
   YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513
   Zampino MG, 2008, CANCER CHEMOTH PHARM, V63, P139, DOI 10.1007/s00280-008-0722-x
   Zhang P, 2006, ARCH BIOCHEM BIOPHYS, V450, P50, DOI 10.1016/j.abb.2006.03.017
   Zhang XQ, 2006, J BIOL CHEM, V281, P15694, DOI 10.1074/jbc.M601252200
   Zheng DF, 2016, ONCOTARGET, V7, P41691, DOI 10.18632/oncotarget.9541
   Zhou M, 2013, CANCER RES, V73, P7056, DOI 10.1158/0008-5472.CAN-13-0194
   Zhou YQ, 2003, ONCOGENE, V22, P186, DOI 10.1038/sj.onc.1206075
   Zhu AX, 2013, CLIN CANCER RES, V19, P6614, DOI 10.1158/1078-0432.CCR-13-1442
   Zhu AX, 2009, J CLIN ONCOL, V27, P3027, DOI 10.1200/JCO.2008.20.9908
NR 140
TC 39
Z9 42
U1 0
U2 14
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD FEB
PY 2017
VL 18
IS 2
AR 383
DI 10.3390/ijms18020383
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EM6YD
UT WOS:000395457700151
PM 28208660
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Xu, P
   Wang, JH
   Sun, B
   Xiao, ZD
AF Xu, Peng
   Wang, Junhua
   Sun, Bo
   Xiao, Zhongdang
TI Comprehensive analysis of miRNAs expression profiles revealed potential
   key miRNA/mRNAs regulating colorectal cancer stem cell self-renewal
SO GENE
LA English
DT Article
DE Bioengineering; Colorectal cancer; miRNA; Cancer stem cell; Self-renewal
ID TARGET PREDICTION; GENE-REGULATION; BREAST; PROLIFERATION; STATISTICS;
   MICRORNAS; CIRCUITRY; MIR-21; OCT4
AB Self-renewal is essential for the malignant biological behaviors of colorectal cancer stem cells. While the self renewal molecular mechanisms of colorectal cancer stem cells are not yet fully understood. Recently, miRNAs are reported to be relevant to the self-renewal ability of cancer stem cells. In this study, we first isolated colorectal cancer stem cell from colorectal cancer cell line HCT-116 by 1% low serum culture. Then we conducted a comprehensive analysis based on the miRNAs profiles data of both colorectal cancer stem cells and normal cultured colorectal cancer cells. Pathway analysis revealed multiple pathways including Jak-STAT, TGF-beta, PI3K-Akt and MAPK signaling pathway that are correlated to colorectal cancer. Further, we constructed a miRNA-mRNA network, based on which, several miRNA/mRNA pairs were ranked according to their impact index to the self-renewal of colorectal cancer stem cells. Further biological experiment showed that up-regulation of miR-92a-3p led to cell cycle arrest and reduced colony formation. This work provides clues to find the new potential biomarkers for colorectal cancer stem cell diagnosis and select effective miRNAs for targeted therapy.
C1 [Xu, Peng; Wang, Junhua; Sun, Bo; Xiao, Zhongdang] Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
   [Wang, Junhua] Henan Polytech Univ, Sch Med, Jiaozuo 454003, Henan, Peoples R China.
C3 Southeast University - China; Henan Polytechnic University
RP Sun, B; Xiao, ZD (corresponding author), Southeast Univ, Sch Biol Sci & Med Engn, State Key Lab Bioelect, Nanjing 210096, Jiangsu, Peoples R China.
EM sunbo@seu.edu.cn; zdxiao@seu.edu.cn
RI Xu, Peng/N-9241-2013; sun, bo/JFA-9978-2023
OI Xu, Peng/0000-0001-7028-9987
FU National Natural Science Foundation of China (NSFC) [31371003,
   81671807]; Major State Basic Research Development Program of China (973
   Program) [2013CB932902]; Postdoctoral Science Foundation of Jiangsu
   Province [1501017C, 1601003C]; "111" Project (Ministry of Education of
   China) [B17011]
FX This work was supported by grants from the National Natural Science
   Foundation of China (NSFC) (No. 31371003, 81671807), the Major State
   Basic Research Development Program of China (973 Program) (No.
   2013CB932902), the Postdoctoral Science Foundation of Jiangsu Province
   (1501017C, 1601003C), and the "111" Project (B17011, Ministry of
   Education of China). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Agarwal V, 2015, ELIFE, V4, DOI 10.7554/eLife.05005
   Al Moustafa Ala-Eddin, 2012, Front Biosci (Schol Ed), V4, P671
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Al-Hajj M, 2004, ONCOGENE, V23, P7274, DOI 10.1038/sj.onc.1207947
   An JD, 2013, INT J ONCOL, V43, P995, DOI 10.3892/ijo.2013.2047
   Betel D, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-8-r90
   Boo L, 2016, INT J BIOL SCI, V12, P427, DOI 10.7150/ijbs.12777
   Boyer LA, 2005, CELL, V122, P947, DOI 10.1016/j.cell.2005.08.020
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   Dean M, 2006, MOL INTERV, V6, P140, DOI 10.1124/mi.6.3.5
   Dean Michael, 2005, Discov Med, V5, P278
   Edwards BK, 2014, CANCER-AM CANCER SOC, V120, P1290, DOI 10.1002/cncr.28509
   Fabian MR, 2010, ANNU REV BIOCHEM, V79, P351, DOI 10.1146/annurev-biochem-060308-103103
   Feng Y, 2012, CELL PROLIFERAT, V45, P413, DOI 10.1111/j.1365-2184.2012.00837.x
   Flynt AS, 2008, NAT REV GENET, V9, P831, DOI 10.1038/nrg2455
   Hayashi H, 2015, ONCOGENE, V34, P199, DOI 10.1038/onc.2013.547
   Hobert O, 2008, SCIENCE, V319, P1785, DOI 10.1126/science.1151651
   Hoffman LM, 2005, NAT BIOTECHNOL, V23, P699, DOI 10.1038/nbt1102
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Jaenisch R, 2008, CELL, V132, P567, DOI 10.1016/j.cell.2008.01.015
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kim JH, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007166
   Kozomara A, 2014, NUCLEIC ACIDS RES, V42, pD68, DOI 10.1093/nar/gkt1181
   Li L, 2015, HEPATOLOGY, V61, P574, DOI 10.1002/hep.27543
   Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011
   Pichler M, 2017, CLIN CANCER RES, V23, P1323, DOI 10.1158/1078-0432.CCR-16-0497
   Rodda DJ, 2005, J BIOL CHEM, V280, P24731, DOI 10.1074/jbc.M502573200
   Scheel C, 2011, CELL, V145, P926, DOI 10.1016/j.cell.2011.04.029
   Schiff R, 2003, CLIN CANCER RES, V9, p447S
   Schwarzenbacher D, 2013, INT J MOL SCI, V14, P14712, DOI 10.3390/ijms140714712
   Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Sun B, 2013, BMC GENET, V14, DOI 10.1186/1471-2156-14-120
   Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takahashi R, 2014, FRONT GENET, V4, DOI 10.3389/fgene.2013.00295
   TAKEDA J, 1992, NUCLEIC ACIDS RES, V20, P4613, DOI 10.1093/nar/20.17.4613
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Trohatou O, 2014, STEM CELL TRANSL MED, V3, P54, DOI 10.5966/sctm.2013-0081
   Tsuchida A, 2011, CANCER SCI, V102, P2264, DOI 10.1111/j.1349-7006.2011.02081.x
   Vasudevan S, 2007, SCIENCE, V318, P1931, DOI 10.1126/science.1149460
   Velasco-Velázquez MA, 2012, INT J BIOCHEM CELL B, V44, P573, DOI 10.1016/j.biocel.2011.12.020
   Wagner GP, 2012, THEOR BIOSCI, V131, P281, DOI 10.1007/s12064-012-0162-3
   Wang JH, 2016, RSC ADV, V6, P23345, DOI 10.1039/c5ra24226f
   Wong N, 2015, NUCLEIC ACIDS RES, V43, pD146, DOI 10.1093/nar/gku1104
   Wu Q, 2013, J CELL SCI, V126, P4220, DOI 10.1242/jcs.127944
   Xu P, 2016, SCI REP-UK, V6, DOI 10.1038/srep20616
   Yu YJ, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0372-7
   Yu Zuoren, 2012, Frontiers in Genetics, V3, P191, DOI 10.3389/fgene.2012.00191
NR 51
TC 8
Z9 8
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD MAY 20
PY 2018
VL 656
BP 30
EP 39
DI 10.1016/j.gene.2018.02.065
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GE0KZ
UT WOS:000430904000005
PM 29496555
DA 2025-01-04
ER

PT J
AU Cohen, R
   Sroussi, M
   Pilati, C
   Houry, S
   Laurent-Puig, P
   André, T
AF Cohen, Romain
   Sroussi, Marine
   Pilati, Camilla
   Houry, Sidney
   Laurent-Puig, Pierre
   Andre, Thierry
TI Unresectable metastatic colorectal cancer patient cured with
   cetuximab-based chemotherapy: a case report with new molecular insights
SO JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Epidermal growth factor receptor (EGFR); MUTYH; colorectal cancer (CRC);
   targeted therapy
ID GROWTH-FACTOR RECEPTOR; KRAS MUTATION; THERAPY; EGFR
AB Here we report the case of a 20-year-old patient who was diagnosed in 2002 with a metastatic colorectal cancer (CRC). He achieved a complete response under cetuximab-based therapy and remains without disease recurrence until now while chemotherapy was discontinued in 2009. The tumor exhibited high level of epidermal growth factor receptor (EGFR) amplification, no mutation in KRAS, NRAS or BRAF genes and a microsatellite-stable (MSS) phenotype. Intriguingly this young patient was carrying a monoallelic germline mutation of MUTYH that was associated with an inactivation of the second allele by loss of heterozygosity on tumor DNA. Moreover, this mutation was associated with a specific mutational signature on tumor level characterized by C > A single base substitutions and a higher mutational load than usually observed in MSS neoplasms. This case report paves the way for further researches on MUTYH-associated cancers' sensitivity to anticancer therapies.
C1 [Cohen, Romain; Sroussi, Marine; Andre, Thierry] Sorbonne Univ, Hop St Antoine, AP HP, Dept Oncol, Paris, France.
   [Pilati, Camilla; Laurent-Puig, Pierre] Univ Paris 05, Lab Med Personnalisee Pharmacogen & Optimisat The, Sorbonne Paris Cite, UMR S1147,INSERM, Paris, France.
   [Houry, Sidney] Sorbonne Univ, Tenon Hosp, AP HP, Dept Digest Surg, Paris, France.
   [Laurent-Puig, Pierre] Hop Europeen Georges Pompidou, AP HP, Pole Biol, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Sorbonne Universite; Hopital
   Universitaire Saint-Antoine - APHP; Universite Paris Cite; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Assistance
   Publique Hopitaux Paris (APHP); Sorbonne Universite; Hopital
   Universitaire Tenon - APHP; Assistance Publique Hopitaux Paris (APHP);
   Universite Paris Cite; Hopital Universitaire Europeen Georges-Pompidou -
   APHP
RP Cohen, R (corresponding author), Hop St Antoine, Serv Oncol Med, 148 Rue Faubourg St Antoine, F-75571 Paris 12, France.
EM romain.cohen@aphp.fr
RI Pilati, Camilla/KLC-8127-2024; André, Thierry/N-8830-2017; Cohen,
   Romain/AAC-9089-2019; Laurent-Puig, Pierre/B-2226-2013
OI Laurent-Puig, Pierre/0000-0001-8475-5459; SROUSSI,
   Marine/0000-0003-3545-5518; Cohen, Romain/0000-0001-9602-5162; Pilati,
   Camilla/0000-0002-1781-5180
CR Aimé A, 2015, CANCER GENET-NY, V208, P390, DOI 10.1016/j.cancergen.2015.04.005
   Al-Tassan N, 2002, NAT GENET, V30, P227, DOI 10.1038/ng828
   Boudrias-Dalle E, 2017, J ONCOL PHARM PRACT
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673
   Jones S, 2004, BRIT J CANCER, V90, P1591, DOI 10.1038/sj.bjc.6601747
   Lefevre JH, 2010, FAM CANCER, V9, P589, DOI 10.1007/s10689-010-9367-0
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   Perkins G, 2014, PHARMACOGENOMICS, V15, P1043, DOI 10.2217/pgs.14.66
   Pilati C, 2017, J PATHOL, V242, P10, DOI 10.1002/path.4880
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Timmermann B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015661
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Yen LC, 2010, ANN SURG, V251, P254, DOI 10.1097/SLA.0b013e3181bc9d96
NR 15
TC 5
Z9 6
U1 0
U2 3
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2078-6891
EI 2219-679X
J9 J GASTROINTEST ONCOL
JI J. Gastrointest. Oncol.
PD AUG
PY 2018
VL 9
IS 4
BP E23
EP E27
DI 10.21037/jgo.2018.05.10
PG 5
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA GN5EM
UT WOS:000439070300002
PM 30151276
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Li, H
   Dong, W
   Hou, J
   He, D
AF Li, Hong
   Dong, Wei
   Hou, Jie
   He, De
TI LINC 01436 is overexpressed in colorectal cancer and promotes cancer
   cell proliferation by suppressing tumor-suppressive miR-466 maturation
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Article
DE Colorectal cancer; LINC 01436; miR-466; Maturation
ID TARGETED THERAPY; PROGNOSIS
AB LINC 01436 (lncRNA) promotes lung and gastric cancers. However, it is unclear whether it participates in colorectal cancer (CRC) progression. Therefore, the study was carried out to analyze the role of LINC 01436 in CRC. LINC 01436 expressions in CRC tissues were analyzed by RT-qPCR, and its prognostic value was investigated in a follow-up study. Correlation between LINC 01436 and mature miR-466 or miR-466 precursor was analyzed by linear regression. Mature miR-466 and miR-466 precursor levels in CRC cells with LINC 01436 overexpression were studied using RT-qPCR. CRC cell proliferation was evaluated using CCK-8 assay. LINC 01436 was upregulated in CRC and predicted poor survival. LINC 01436 was inversely correlated with mature miR-466, but not miR-466 precursor. LINC 01436 was predicted to bind with miR-466 precursor. Their interaction was further verified by dual-luciferase activity assay. In CRC cells, LINC 01436 overexpression downregulated mature miR-466 but not miR-466 precursor. Cell proliferation analysis showed that LINC 01436 overexpression rescued cell proliferation reduced by miR-466. LINC 01436 is overexpressed in CRC and promotes cancer cell proliferation by suppressing miR-466 maturation.
C1 [Li, Hong; Hou, Jie; He, De] Peoples Hosp Baoan Dist, Dept Gen Surg, 118 Longjing Second Rd, Shenzhen 518101, Peoples R China.
   [Dong, Wei] Shenzhen Baoan Shiyan Peoples Hosp, Bone & Joint Surg, Shenzhen 518101, Peoples R China.
RP He, D (corresponding author), Peoples Hosp Baoan Dist, Dept Gen Surg, 118 Longjing Second Rd, Shenzhen 518101, Peoples R China.
EM dehebaoan@163.com
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Colden M, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.15
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011
   Johnson CM, 2013, CANCER CAUSE CONTROL, V24, P1207, DOI 10.1007/s10552-013-0201-5
   Mahasneh A, 2017, EXP MOL PATHOL, V102, P475, DOI 10.1016/j.yexmp.2017.05.005
   Mitchell EP, 2013, CLIN COLORECTAL CANC, V12, P73, DOI 10.1016/j.clcc.2012.08.001
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Siegel RL, 2017, JAMA-J AM MED ASSOC, V318, P572, DOI 10.1001/jama.2017.7630
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tong F, 2018, BOSNIAN J BASIC MED, V18, P252, DOI 10.17305/bjbms.2018.2376
   Vargas AJ, 2012, NUTR CLIN PRACT, V27, P613, DOI 10.1177/0884533612454885
   Xie JH, 2021, INT J GEN MED, V14, P6517, DOI 10.2147/IJGM.S335396
   Yu YJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0725-5
   Yuan S, 2019, MOL ONCOL, V13, P840, DOI 10.1002/1878-0261.12437
   Zhang Y, 2020, CELL BIOL INT, V44, P882, DOI 10.1002/cbin.11287
NR 18
TC 3
Z9 3
U1 0
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1071-2690
EI 1543-706X
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD FEB
PY 2022
VL 58
IS 2
BP 109
EP 115
DI 10.1007/s11626-021-00642-x
EA FEB 2022
PG 7
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA ZO6BF
UT WOS:000756246300001
PM 35171402
OA Green Submitted
DA 2025-01-04
ER

PT J
AU Padgaonkar, M
   Shendre, S
   Chatterjee, P
   Banerjee, S
AF Padgaonkar, Mrunali
   Shendre, Saket
   Chatterjee, Prarthana
   Banerjee, Satarupa
TI Cancer secretome: finding out hidden messages in extracellular
   secretions
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Review
DE Cancer; Secretome; Tumor microenvironment; Proteomics; Biomarker;
   Targeted therapy
ID COLORECTAL-CANCER; MESENCHYMAL TRANSITION; PROSTATE-CANCER; TUMOR
   MICROENVIRONMENT; COLON-CANCER; LUNG-CANCER; STEM-CELLS; MICRORNAS;
   BIOMARKERS; DISPARITIES
AB Secretome analysis has gained popularity recently as a very well-designed proteomic approach that is being used to study various interactions and their effects on cellular activity. This analysis is especially helpful while studying the effects of the cells on their microenvironment, paracrine and autocrine processes, their therapeutic purposes, and as a new diagnostic perspective. Cancer is a condition rather than a specific type of disease and is still yet to be fully understood. Cancer secretome is a fairly new concept that is being implemented to examine the interactions taking place in the tumor microenvironment and can help to understand the phenomena like induction of tumorigenesis, stimulation of immune cells, etc. The secretome analysis helps to gain a different perspective on the existing knowledge on cancer and its effects. The recent advances in secretome studies are directed toward secreted components as drug targets, biomarkers, and companion tools for diagnostic and prognostic purposes in cancer. This review aims to find the interactors in different types of cancer and understand the existing unstructured secretome data and its application in prognosis, diagnosis, and in biomarker study.
C1 [Padgaonkar, Mrunali; Shendre, Saket; Chatterjee, Prarthana; Banerjee, Satarupa] Vellore Inst Technol, Sch Biosci & Technol, Vellore 632014, Tamil Nadu, India.
C3 Vellore Institute of Technology (VIT); VIT Vellore
RP Banerjee, S (corresponding author), Vellore Inst Technol, Sch Biosci & Technol, Vellore 632014, Tamil Nadu, India.
EM satarupabando@gmail.com
RI BANERJEE, SATARUPA/H-4198-2019
OI Banerjee, Satarupa/0000-0002-0986-2796
CR [Anonymous], 2022, CANC SECRETOME CURRE
   [Anonymous], CLINICOPATHOLOGICAL
   Bailey MH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18151-y
   Bhardwaj A, 2017, FRONT BIOSCI-LANDMRK, V22, P772, DOI 10.2741/4515
   Booth AM, 2006, J CELL BIOL, V172, P923, DOI 10.1083/jcb.200508014
   Bou-Dargham MJ, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0237222
   Bovell LC, 2013, BIOTECH HISTOCHEM, V88, P388, DOI 10.3109/10520295.2013.788735
   Bronisz A, 2011, Nat Cell Biol, V14, P159, DOI 10.1038/ncb2396
   Camussi G, 2011, AM J CANCER RES, V1, P98
   Cevenini A, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56090443
   Chen CL, 2015, MOL CELL PROTEOMICS, V14, P2466, DOI 10.1074/mcp.M115.051524
   Ciardiello C, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/6392198
   da Cunha BR, 2019, J CANCER, V10, P4574, DOI 10.7150/jca.21780
   Dhondt B, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1736935
   Dieters-Castator D, 2022, EMBRYONIC PROTEIN NO
   Ding M, 2020, SLAS DISCOV, V25, P535, DOI 10.1177/2472555220917113
   do Canto LM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-45151-w
   Eltoukhy HS, 2018, BIOCHIMIE, V155, P92, DOI 10.1016/j.biochi.2018.05.018
   Fang M, 2017, CANCER RES, V77, P2735, DOI 10.1158/0008-5472.CAN-16-1602
   Fertig EJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep12133
   Feser R, 2022, REVIEW, DOI [10.21203/rs.3.rs-1328838/v1, DOI 10.21203/RS.3.RS-1328838/V1]
   Fidler IJ, 2002, SEMIN CANCER BIOL, V12, P89, DOI 10.1006/scbi.2001.0416
   Fitzmaurice C, 2017, JAMA ONCOL, V3, P524, DOI [10.1001/jamaoncol.2016.5688, 10.1001/jamaoncol.2018.2706]
   Gao YA, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.638357
   Giangreco A, 2007, AM J RESP CRIT CARE, V175, P547, DOI 10.1164/rccm.200607-984PP
   Gregory PA, 2008, NAT CELL BIOL, V10, P593, DOI 10.1038/ncb1722
   Guo J, 2016, J PROTEOME RES, V15, P2164, DOI 10.1021/acs.jproteome.6b00106
   Hanash S, 2014, GENOME MED, V6, DOI 10.1186/gm529
   Hawkins AG, 2018, MOL CELL PROTEOMICS, V17, P901, DOI 10.1074/mcp.RA118.000596
   Hellinger JW, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-74838-8
   Hsu YL, 2018, MOL THER, V26, P568, DOI 10.1016/j.ymthe.2017.11.016
   Hung CH, 2016, INT J CANCER, V138, P714, DOI 10.1002/ijc.29802
   Iorio MV, 2012, CARCINOGENESIS, V33, P1126, DOI 10.1093/carcin/bgs140
   Jelski W, 2020, CANCER MANAG RES, V12, P4789, DOI 10.2147/CMAR.S253369
   Katkoori VR, 2009, CLIN CANCER RES, V15, P2406, DOI 10.1158/1078-0432.CCR-08-1719
   Kohlhapp FJ, 2015, ONCOGENE, V34, P5857, DOI 10.1038/onc.2015.89
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Lázaro-Ibáñez E, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3087-x
   Leone A, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2597581
   Li E, 2014, INT J ONCOL, V45, P587, DOI 10.3892/ijo.2014.2469
   Li H, 2003, P NATL ACAD SCI USA, V100, P8412, DOI 10.1073/pnas.1430846100
   Liem M, 2017, PROTEOMICS, V17, DOI 10.1002/pmic.201600371
   Link-Lenczowski P, 2019, BBA-MOL CELL RES, V1866, DOI 10.1016/j.bbamcr.2019.118555
   Liu FY, 2017, CELL, V169, P85, DOI 10.1016/j.cell.2017.02.024
   Madden EC, 2020, TRENDS CANCER, V6, P489, DOI 10.1016/j.trecan.2020.02.020
   Majumder M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18612-3
   Manne U, 2016, CURR COLORECT CANC R, V12, P332, DOI 10.1007/s11888-016-0338-1
   Marcella S, 2001, J CLIN EPIDEMIOL, V54, P359, DOI 10.1016/S0895-4356(00)00316-4
   Martin DN, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004531
   Mondal A, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00144
   Mukherjee P, 2013, BBA-PROTEINS PROTEOM, V1834, P2226, DOI 10.1016/j.bbapap.2013.01.022
   Nedjadi T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67929-z
   Nuhn P, 2019, EUR UROL, V75, P88, DOI 10.1016/j.eururo.2018.03.028
   Paltridge JL, 2013, BBA-PROTEINS PROTEOM, V1834, P2233, DOI 10.1016/j.bbapap.2013.03.014
   Papaleo E, 2017, EXPERT REV PROTEOMIC, V14, P1021, DOI 10.1080/14789450.2017.1387053
   Patel Swati G, 2018, Curr Gastroenterol Rep, V20, P15, DOI 10.1007/s11894-018-0618-9
   Pathan M, 2019, NUCLEIC ACIDS RES, V47, pD516, DOI 10.1093/nar/gky1029
   Pavlou MP, 2010, J PROTEOMICS, V73, P1896, DOI 10.1016/j.jprot.2010.04.003
   Ren D, 2017, ONCOTARGET, V8, P49807, DOI 10.18632/oncotarget.17971
   Saad F, 2015, UROLOGY, V86, P852, DOI 10.1016/j.urology.2015.07.034
   Sánchez CA, 2016, ONCOTARGET, V7, P3993, DOI 10.18632/oncotarget.6540
   Schliekelman MJ, 2011, CANCER RES, V71, P7670, DOI 10.1158/0008-5472.CAN-11-0964
   Shephard AP, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12150
   Shin B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164039
   Shin J, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183896
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   SOLOVY A, 1988, HOSPITALS, V62, P30
   Tang XM, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0314-y
   Theodore SC, MICRORNA PROFILING N
   Tse JC, 2007, J CELL BIOCHEM, V101, P816, DOI 10.1002/jcb.21215
   Tu Shi-Ming, 2004, Cancer Treat Res, V118, P23
   Yang W, 2018, METHODS MOL BIOL, V1729, P173, DOI 10.1007/978-1-4939-7577-8_16
   Zhang C, 2018, ONCOL REP, V39, P376, DOI 10.3892/or.2017.6085
   Zhang J, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.00542
   Zhang MH, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10925-7
   Zhao LX, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.731393
   Zhu J, 2015, ONCOTARGET, V6, P43819, DOI 10.18632/oncotarget.6102
NR 77
TC 5
Z9 5
U1 0
U2 2
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1699-048X
EI 1699-3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD MAY
PY 2023
VL 25
IS 5
BP 1145
EP 1155
DI 10.1007/s12094-022-03027-y
EA DEC 2022
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA E1IC6
UT WOS:000899737800001
PM 36525229
DA 2025-01-04
ER

PT J
AU Li, WW
   Ma, YM
   He, LM
   Li, HW
   Chu, Y
   Jiang, Z
   Zhao, XH
   Nie, YZ
   Wang, XS
   Wang, HY
AF Li, Weiwei
   Ma, Yiming
   He, Longmei
   Li, Hongwei
   Chu, Yi
   Jiang, Zheng
   Zhao, Xinhua
   Nie, Yongzhan
   Wang, Xishan
   Wang, Hongying
TI Protease-activated receptor 2 stabilizes Bcl-xL and regulates
   EGFR-targeted therapy response in colorectal cancer
SO CANCER LETTERS
LA English
DT Article
DE Bcl-xL; PAR2; EGFR; Colorectal cancer; RNF152
ID GROWTH-FACTOR RECEPTOR; SIGNALING PATHWAYS; OPEN-LABEL; UBIQUITINATION;
   BEVACIZUMAB; APOPTOSIS; CELLS; TRANSACTIVATION; TRANSLOCATION;
   EXPRESSION
AB The Bcl-2 homolog Bcl-xL is emerging as a key factor in tumorigenesis due to its prominent pro-survival and cell death-independent functions. However, the regulation of Bcl-xL by microenvironment and its implication in cancer therapy of colorectal carcinoma (CRC) are unclear. Here, we demonstrated that Bcl-xL expression was positively associated with protease-activated receptor 2 (PAR2) in CRC. Activation of PAR2 stabilized Bcl-xL protein in a proteasome-dependent manner, whereas E3 ligase RING finger protein 152 (RNF152) accelerated the ubiquitination and degradation of Bcl-xL. RNF152 silencing by specific siRNAs rescued the expression of BclxL in PAR2-deficient cells. Moreover, RNF152 physically interacted with Bcl-xL, which was disturbed by PAR2 activation. Further studies with serial mutation of Bcl-xL revealed that phosphorylation of Bcl-xL at S145 reduced its binding affinity for RNF152 and stabilized Bcl-xL. Importantly, inhibition of PAR2 signaling by its gene silencing or specific chemical inhibitors increased apoptosis induced by different EGFR-targeted therapies. In patient-derived xenograft model, inhibition of PAR2 increased the response of CRC to different EGFR-targeted therapies. These results indicate that PAR2 stabilizes Bcl-xL by altering RNF152 signaling and that PAR2 inhibition sensitizes CRC to EGFR-targeted therapies in vivo.
C1 [Li, Weiwei; Ma, Yiming; He, Longmei; Zhao, Xinhua; Wang, Hongying] Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.
   [Li, Hongwei; Chu, Yi; Nie, Yongzhan] Fourth Mil Med Univ, State Key Lab Canc Biol, Natl Clin Res Ctr Digest Dis, Xian 710032, Peoples R China.
   [Li, Hongwei; Chu, Yi; Nie, Yongzhan] Fourth Mil Med Univ, Xijing Hosp Digest Dis, Xian 710032, Peoples R China.
   [Jiang, Zheng; Wang, Xishan] Chinese Acad Med Sci & Peking Union Med Coll, Dept Colorectal Canc Surg, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Cancer Institute & Hospital - CAMS; Peking Union Medical College; Air
   Force Military Medical University; Air Force Military Medical
   University; Chinese Academy of Medical Sciences - Peking Union Medical
   College; Cancer Institute & Hospital - CAMS; Peking Union Medical
   College
RP Wang, HY (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, State Key Lab Mol Oncol, Natl Canc Ctr, Natl Clin Res Ctr Canc,Canc Hosp, Beijing 100021, Peoples R China.
EM hongyingwang@cicams.ac.cn
RI Ma, Yiming/AAG-3479-2019; Zhang, Xiaotong/HIR-6204-2022
OI Li, Weiwei/0000-0002-8298-2719; Wang, Xishan/0000-0003-3899-5923; Wang,
   Hongying/0000-0001-8443-3839
FU National Nature Sci-ence Foundation of China [81472560,
   81672451,81672891, 81970467]; CAMS Innovation Fund for Medical Sciences
   (CIFMS) [2016I2M1001,2017I2M1006, 2019I2M1003]; National Key research
   and development program of the Ministry of Science and Technology of
   China [2016YFC0905301]; State key laboratory of molecular oncology
FX This work was supported by funding from the National Nature Sci-ence
   Foundation of China (81472560, 81672451,81672891, 81970467) , CAMS
   Innovation Fund for Medical Sciences (CIFMS) (2016I2M1001,2017I2M1006,
   2019I2M1003) , National Key research and development program of the
   Ministry of Science and Technology of China (2016YFC0905301) , and State
   key laboratory of molecular oncology.
CR Amundson SA, 2000, CANCER RES, V60, P6101
   Biroccio A, 2001, AM J PATHOL, V158, P1289, DOI 10.1016/S0002-9440(10)64080-1
   BOISE LH, 1993, CELL, V74, P597, DOI 10.1016/0092-8674(93)90508-N
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Caruso R, 2006, AM J PATHOL, V169, P268, DOI 10.2353/ajpath.2006.050841
   Chung H, 2013, J BIOL CHEM, V288, P37319, DOI 10.1074/jbc.M113.492793
   Darmoul D, 2004, J BIOL CHEM, V279, P20927, DOI 10.1074/jbc.M401430200
   Deng L, 2019, CELL RES, V29, P136, DOI 10.1038/s41422-018-0120-9
   Deng L, 2015, MOL CELL, V58, P804, DOI 10.1016/j.molcel.2015.03.033
   Grillot DAM, 1997, J IMMUNOL, V158, P4750
   Han HS, 2006, J GASTROEN HEPATOL, V21, P1108, DOI 10.1111/j.1440-1746.2006.04325.x
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040
   He LM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0995-x
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Iablokov V, 2014, J BIOL CHEM, V289, P34366, DOI 10.1074/jbc.M114.610485
   Kajihara R, 2014, J IMMUNOL, V192, P5720, DOI 10.4049/jimmunol.1302643
   Kelley LA, 2015, NAT PROTOC, V10, P845, DOI 10.1038/nprot.2015.053
   Kharbanda S, 2000, J BIOL CHEM, V275, P322, DOI 10.1074/jbc.275.1.322
   Lawrence RE, 2019, NAT CELL BIOL, V21, P133, DOI 10.1038/s41556-018-0244-7
   Li WW, 2019, INFLAMM BOWEL DIS, V25, P1187, DOI 10.1093/ibd/izz007
   Liu Y, 2018, REDOX BIOL, V17, P143, DOI 10.1016/j.redox.2018.04.012
   Ma YM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072383
   Mason KD, 2007, CELL, V128, P1173, DOI 10.1016/j.cell.2007.01.037
   Matsumura T, 2014, ANN SURG ONCOL, V21, pS743, DOI 10.1245/s10434-014-3889-x
   Merino D, 2018, CANCER CELL, V34, P879, DOI 10.1016/j.ccell.2018.11.004
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Pawar NR, 2019, CANCER RES, V79, P301, DOI 10.1158/0008-5472.CAN-18-1745
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Ramachandran R, 2012, NAT REV DRUG DISCOV, V11, P69, DOI 10.1038/nrd3615
   Scherr AL, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.233
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Serrano-Puebla A, 2018, BIOCHEM SOC T, V46, P207, DOI 10.1042/BST20170130
   Steck N, 2012, GUT, V61, P1610, DOI 10.1136/gutjnl-2011-300775
   Suen JY, 2012, BRIT J PHARMACOL, V165, P1413, DOI 10.1111/j.1476-5381.2011.01610.x
   Tortora G, 2003, CLIN CANCER RES, V9, P866
   Tournigand C, 2015, LANCET ONCOL, V16, P1493, DOI 10.1016/S1470-2045(15)00216-8
   Vliagoftis A, 2000, J ALLERGY CLIN IMMUN, V106, P537, DOI 10.1067/mai.2000.109058
   Volkmann N, 2014, CELL DEATH DIFFER, V21, P206, DOI 10.1038/cdd.2013.153
   Werneburg NW, 2012, J BIOL CHEM, V287, P24427, DOI 10.1074/jbc.M112.342238
   Winder T, 2010, GASTROENTEROLOGY, V138, P2163, DOI 10.1053/j.gastro.2010.02.005
   Yang JS, 2011, ACTA HISTOCHEM, V113, P810, DOI 10.1016/j.acthis.2011.01.002
   Yang L, 2015, J BIOL CHEM, V290, P26627, DOI 10.1074/jbc.M115.667717
   Zhang H., 2015, MOL CANC, V14
   Zhang SL, 2010, PROTEIN CELL, V1, P656, DOI 10.1007/s13238-010-0083-1
   Zhang YL, 2008, WORLD J GASTROENTERO, V14, P3069, DOI 10.3748/wjg.14.3069
   Zhao R, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2519-3
NR 47
TC 9
Z9 9
U1 2
U2 9
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD OCT 1
PY 2021
VL 517
BP 14
EP 23
DI 10.1016/j.canlet.2021.05.040
EA JUN 2021
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TQ7CR
UT WOS:000678437900002
PM 34098062
OA hybrid
DA 2025-01-04
ER

PT J
AU Li, SC
   Ma, R
   Wu, JZ
   Xiao, X
   Wu, W
   Li, G
   Chen, B
   Sharma, A
   Bai, S
   Dun, BY
   She, JX
   Tang, JH
AF Li, Shu-Chun
   Ma, Rong
   Wu, Jian-Zhong
   Xiao, Xia
   Wu, Wei
   Li, Gang
   Chen, Bo
   Sharma, Ashok
   Bai, Shan
   Dun, Bo-Ying
   She, Jin-Xiong
   Tang, Jin-Hai
TI Delineation of gastric cancer subtypes by co-regulated expression of
   receptor tyrosine kinases and chemosensitivity genes
SO AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH
LA English
DT Article
DE Gastric cancer; gene expression; co-regulation; chemotherapy
ID MESSENGER-RNA EXPRESSION; CELL LUNG-CANCER; REAL-TIME PCR;
   COLORECTAL-CANCER; HOUSEKEEPING GENES; PREDICT SURVIVAL; RT-PCR;
   CHEMOTHERAPY; SELECTION; ERCC1
AB Chemotherapy plays a key role in improving disease-free survival and overall survival of gastric cancer (GC); however, response rates are variable and a non-negligible proportion of patients undergo toxic and costly chemotherapeutic regimens without a survival benefit. Several studies have shown the existence of GC subtypes which may predict survival and respond differently to chemotherapy. It is also known that the expression level of chemotherapy-related and target therapy-related genes correlates with response to specific antitumor drugs. Nevertheless, these genes have not been considered jointly to define GC subtypes. In this study, we evaluated seven genes known to influence chemotherapeutic response (ERCC1, BRCA1, RRM1, TUBB3, STMN1, TYMS and TOP2A) and five receptor tyrosine kinases (RTKs) (EGFR, ERBB2, PDGFRB, VEGFR1 and VEGFR2). We demonstrate significant heterogeneity of gene expression among GC patients and identified four GC subtypes using the expression profiles of eight genes in two co-regulation groups: chemosensitivity (BRCA1, STMN1, TYMS and TOP2A) and RTKs (EGFR, PDGFRB, VEGFR1 and VEGFR2). The results are of immediate translational value regarding GC diagnostics and therapeutics, as many of these genes are curently widely used in relevant clinical testing.
C1 [Li, Shu-Chun; Ma, Rong; Wu, Jian-Zhong; Li, Gang; Tang, Jin-Hai] Jiangsu Canc Hosp, Clin Oncol Res Ctr, Nanjing, Jiangsu, Peoples R China.
   [Li, Shu-Chun; Chen, Bo; Sharma, Ashok; Bai, Shan; Dun, Bo-Ying; She, Jin-Xiong] Georgia Regents Univ, Med Coll Georgia, Ctr Biotechnol & Genom Med, Augusta, GA USA.
   [Li, Shu-Chun; Xiao, Xia; Chen, Bo] Nanjing Tech Univ, Sino Amer Inst Translat Med, Nanjing, Jiangsu, Peoples R China.
   [Wu, Wei] Zhenjiang Jintai Life Technol, Zhenjiang, Jiangsu, Peoples R China.
C3 Nanjing Medical University; University System of Georgia; Augusta
   University; Nanjing Tech University
RP Tang, JH (corresponding author), Jiangsu Canc Hosp, Nanjing, Jiangsu, Peoples R China.
EM jschtjh@126.com
RI wu, wei/J-2797-2019; ma, rong/GVU-3096-2022; Sharma,
   Ashok/JVP-3558-2024; Li, Shuchun/IXN-5567-2023
OI Li, Shuchun/0000-0003-4636-4005; Sharma, Ashok/0000-0001-9597-4374
FU National Science Foundation of China [81272244]; Plan for Technology
   Infra-structure Construction of Jiagsu Province [BM2011118]
FX This research is supported by The National Science Foundation of China
   (grant number 81272244), the Plan for Technology Infra-structure
   Construction of Jiagsu Province (BM2011118).
CR Akhtar J, 2014, J GASTROEN HEPATOL, V29, P1685, DOI 10.1111/jgh.12594
   Andersen CL, 2004, CANCER RES, V64, P5245, DOI 10.1158/0008-5472.CAN-04-0496
   Bang YJ, 2010, LANCET, V376, P1302
   Cai J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095974
   Dheda K, 2004, BIOTECHNIQUES, V37, P112, DOI 10.2144/04371RR03
   Dundas J, 2012, THEOR BIOSCI, V131, P215, DOI 10.1007/s12064-012-0152-5
   Glasgow SC, 2005, BRIT J CANCER, V92, P259, DOI 10.1038/sj.bjc.6602330
   Gustavsson B, 2009, INT J CANCER, V124, P1220, DOI 10.1002/ijc.23852
   Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   del Pozo CH, 2010, OBESITY, V18, P897, DOI 10.1038/oby.2009.374
   Jackman DM, 2009, CLIN CANCER RES, V15, P5267, DOI 10.1158/1078-0432.CCR-09-0888
   Jeon TY, 2010, BRIT J CANCER, V102, P710, DOI 10.1038/sj.bjc.6605537
   Kurokawa Y, 2014, ANN SURG ONCOL, V21, pS584, DOI 10.1245/s10434-014-3690-x
   Lei ZD, 2013, GASTROENTEROLOGY, V145, P554, DOI 10.1053/j.gastro.2013.05.010
   Liang ZY, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-363
   Maltseva Diana V, 2013, J Clin Bioinforma, V3, P13, DOI 10.1186/2043-9113-3-13
   Papadaki C, 2012, J THORAC ONCOL, V7, P663, DOI 10.1097/JTO.0b013e318244bdd4
   Parkin DM, 1999, INT J CANCER, V80, P827, DOI 10.1002/(SICI)1097-0215(19990315)80:6<827::AID-IJC6>3.0.CO;2-P
   Pfaffl MW, 2004, BIOTECHNOL LETT, V26, P509, DOI 10.1023/B:BILE.0000019559.84305.47
   Qiu LX, 2008, INT J CANCER, V123, P2384, DOI 10.1002/ijc.23822
   Radonic A, 2004, BIOCHEM BIOPH RES CO, V313, P856, DOI 10.1016/j.bbrc.2003.11.177
   Ramalingam SS, 2015, J CLIN ONCOL, V33, P433, DOI 10.1200/JCO.2014.55.7173
   Rose JS, 2011, ONCOTARGETS THER, V4, P21, DOI 10.2147/OTT.S10188
   Schmittgen TD, 2000, J BIOCHEM BIOPH METH, V46, P69, DOI 10.1016/S0165-022X(00)00129-9
   Sergina NV, 2007, TRENDS MOL MED, V13, P527, DOI 10.1016/j.molmed.2007.10.002
   Shah MA, 2011, CLIN CANCER RES, V17, P2693, DOI 10.1158/1078-0432.CCR-10-2203
   Shirota Y, 2001, J CLIN ONCOL, V19, P4298, DOI 10.1200/JCO.2001.19.23.4298
   Silver N, 2006, BMC MOL BIOL, V7, DOI 10.1186/1471-2199-7-33
   Tan IB, 2011, GASTROENTEROLOGY, V141, P476, DOI 10.1053/j.gastro.2011.04.042
   Taron M, 2004, HUM MOL GENET, V13, P2443, DOI 10.1093/hmg/ddh260
   Vandesompele J, 2002, GENOME BIOL, V3, DOI 10.1186/gb-2002-3-7-research0034
   Wang HJ, 2015, EXP MOL PATHOL, V98, P375, DOI 10.1016/j.yexmp.2014.10.014
   Wang P, 2014, ONCOTARGETS THER, V7, P1761, DOI 10.2147/OTT.S68773
   Weberpals J, 2009, INT J CANCER, V124, P806, DOI 10.1002/ijc.23987
   Wu XY, 2013, CANCER LETT, V335, P128, DOI 10.1016/j.canlet.2013.02.002
   Yamaguchi H, 2013, EXP MOL PATHOL, V95, P131, DOI 10.1016/j.yexmp.2013.06.005
   Zhang LH, 2013, SCI REP-UK, V3, DOI 10.1038/srep02992
NR 38
TC 6
Z9 7
U1 0
U2 5
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1943-8141
J9 AM J TRANSL RES
JI Am. J. Transl. Res.
PY 2015
VL 7
IS 8
BP 1429
EP 1439
PG 11
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA CR7VC
UT WOS:000361558600010
PM 26396673
DA 2025-01-04
ER

PT J
AU Zhang, W
   Wang, HS
   Sun, MY
   Deng, XT
   Wu, XR
   Ma, YL
   Li, MJ
   Shuoa, SM
   You, Q
   Miao, L
AF Zhang, Wen
   Wang, Huishan
   Sun, Mingyang
   Deng, Xueting
   Wu, Xueru
   Ma, Yilan
   Li, Mengjing
   Shuoa, Said Maisam
   You, Qiang
   Miao, Lin
TI CXCL5/CXCR2 axis in tumor microenvironment as potential diagnostic
   biomarker and therapeutic target
SO CANCER COMMUNICATIONS
LA English
DT Review
DE biomarker; CXCL5; CXCR2; molecular targeted therapy; tumor
   microenvironment
ID EPITHELIAL-MESENCHYMAL TRANSITION; CELL CARCINOMA; NEUTROPHIL
   INFILTRATION; COLORECTAL-CANCER; PROGNOSTIC MARKER; CXCL5 PROMOTES;
   POOR-PROGNOSIS; CXCR2 EXPRESSION; RECEPTOR 2; IN-VITRO
AB The components of the tumor microenvironment (TME) in solid tumors, especially chemokines, are currently attracting much attention from scientists. C-X-C motif chemokine ligand 5 (CXCL5) is one of the important chemokines in TME. Overexpression of CXCL5 is closely related to the survival time, recurrence and metastasis of cancer patients. In TME, CXCL5 binds to its receptors, such as C-X-C motif chemokine receptor 2 (CXCR2), to participate in the recruitment of immune cells and promote angiogenesis, tumor growth, and metastasis. The CXCL5/CXCR2 axis can act as a bridge between tumor cells and host cells in TME. Blocking the transmission of CXCL5/CXCR2 signals can increase the sensitivity and effectiveness of immunotherapy and slow down tumor progression. CXCL5 and CXCR2 are also regarded as biomarkers for predicting prognosis and molecular targets for customizing the treatment. In this review, we summarized the current literature regarding the biological functions and clinical significance of CXCL5/CXCR2 axis in TME. The possibility to use CXCL5 and CXCR2 as potential prognostic biomarkers and therapeutic targets in cancer is also discussed
C1 [Zhang, Wen; Wang, Huishan; Deng, Xueting; Wu, Xueru; Ma, Yilan; Shuoa, Said Maisam; You, Qiang; Miao, Lin] Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, 121 Jiangjiayuan, Nanjing 210011, Jiangsu, Peoples R China.
   [Sun, Mingyang] Nanjing Med Univ, Affiliated Hosp 2, Dept Surg, Nanjing 210011, Jiangsu, Peoples R China.
   [Li, Mengjing; You, Qiang] Nanjing Med Univ, Affiliated Hosp 2, Dept Biotherapy, 121 Jiangjiayuan, Nanjing 210011, Jiangsu, Peoples R China.
   [Li, Mengjing; You, Qiang] Nanjing Med Univ, Key Lab Aging & Dis, Nanjing 210011, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University
RP Miao, L (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Med Ctr Digest Dis, 121 Jiangjiayuan, Nanjing 210011, Jiangsu, Peoples R China.; You, Q (corresponding author), Nanjing Med Univ, Affiliated Hosp 2, Dept Biotherapy, 121 Jiangjiayuan, Nanjing 210011, Jiangsu, Peoples R China.
EM qiangyou2013@163.com; linmiao@njmu.edu.cn
RI Ma, Yilan/LWH-6529-2024; mengjing, li/HOA-6517-2023
CR An HM, 2015, EUR J CANCER, V51, P1953, DOI 10.1016/j.ejca.2015.06.125
   Begley LA, 2008, NEOPLASIA, V10, P244, DOI 10.1593/neo.07976
   Bièche I, 2007, ENDOCR-RELAT CANCER, V14, P1039, DOI 10.1677/erc.1.01301
   Chen C, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1431-6
   Cui D, 2018, BIOCHIMIE, V148, P1, DOI 10.1016/j.biochi.2018.02.009
   Dai ZJ, 2016, ONCOL REP, V36, P3303, DOI 10.3892/or.2016.5155
   Dang HS, 2017, ONCOL RES, V25, P177, DOI 10.3727/096504016X14732772150343
   de Visser KE, 2006, NAT REV CANCER, V6, P24, DOI 10.1038/nrc1782
   Dimberg J, 2007, INT J ONCOL, V31, P97
   Duchene J, 2007, J IMMUNOL, V179, P4849, DOI 10.4049/jimmunol.179.7.4849
   Feng XN, 2018, BIOMED PHARMACOTHER, V107, P1496, DOI 10.1016/j.biopha.2018.08.149
   Forsthuber A, 2019, J INVEST DERMATOL, V139, P186, DOI 10.1016/j.jid.2018.07.006
   Galdiero MR, 2013, IMMUNOBIOLOGY, V218, P1402, DOI 10.1016/j.imbio.2013.06.003
   Gao Y, 2015, INT J ONCOL, V47, P690, DOI 10.3892/ijo.2015.3041
   Gil-Bernabé AM, 2012, BLOOD, V119, P3164, DOI 10.1182/blood-2011-08-376426
   Giuliano S, 2019, THERANOSTICS, V9, P1181, DOI 10.7150/thno.29093
   Gold KA, 2014, CLIN CANCER RES, V20, P1946, DOI 10.1158/1078-0432.CCR-13-1959
   Griffith JW, 2014, ANNU REV IMMUNOL, V32, P659, DOI 10.1146/annurev-immunol-032713-120145
   Guan ZF, 2016, SCI REP-UK, V6, DOI 10.1038/srep37085
   Haider C, 2019, HEPATOLOGY, V69, P222, DOI 10.1002/hep.30166
   Han L, 2012, MED ONCOL, V29, P2466, DOI 10.1007/s12032-011-0152-1
   Highfill SL, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007974
   Hsu YL, 2013, ONCOGENE, V32, P4436, DOI 10.1038/onc.2012.444
   Hu BW, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0562-7
   Huang ZX, 2019, INT J ONCOL, V54, P1555, DOI 10.3892/ijo.2019.4729
   Ijichi H, 2011, J CLIN INVEST, V121, P4106, DOI 10.1172/JCI42754
   Jiang SH, 2019, GUT, V68, P1994, DOI 10.1136/gutjnl-2018-317479
   Kawamura M, 2012, EUR J CANCER, V48, P2244, DOI 10.1016/j.ejca.2011.11.032
   Klemm F, 2015, TRENDS CELL BIOL, V25, P198, DOI 10.1016/j.tcb.2014.11.006
   Korkolopoulou P, 2012, MOL MED, V18, P379, DOI 10.2119/molmed.2011.00449
   Kowalczuk O, 2014, TUMOR BIOL, V35, P4619, DOI 10.1007/s13277-014-1605-x
   Kuo PL, 2014, INT J CANCER, V135, P96, DOI 10.1002/ijc.28673
   Labelle M, 2014, P NATL ACAD SCI USA, V111, pE3053, DOI 10.1073/pnas.1411082111
   Lee E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5715
   Lee SJ, 2018, TRANSL ONCOL, V11, P353, DOI 10.1016/j.tranon.2018.01.007
   Li AH, 2011, AM J PATHOL, V178, P1340, DOI 10.1016/j.ajpath.2010.11.058
   Li L, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0247-1
   Li ZQ, 2019, INT J CANCER, V145, P1946, DOI 10.1002/ijc.32278
   Liang B, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0089-2
   Lim JB, 2015, CYTOKINE, V73, P16, DOI 10.1016/j.cyto.2015.01.010
   Ma SB, 2014, CANCER RES, V74, P1969, DOI 10.1158/0008-5472.CAN-13-2534
   Miyazaki H, 2006, CANCER RES, V66, P4279, DOI 10.1158/0008-5472.CAN-05-4398
   Miyazaki H, 2006, ORAL ONCOL, V42, P240, DOI 10.1016/j.oraloncology.2005.07.006
   Mollaoglu G, 2018, IMMUNITY, V49, P764, DOI 10.1016/j.immuni.2018.09.020
   Najjar YG, 2017, CLIN CANCER RES, V23, P2346, DOI 10.1158/1078-0432.CCR-15-1823
   Ning Y, 2012, MOL CANCER THER, V11, P1353, DOI 10.1158/1535-7163.MCT-11-0915
   Nishi T, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0658-7
   Novitskiy SV, 2011, CANCER DISCOV, V1, P430, DOI 10.1158/2159-8290.CD-11-0100
   Okabe H, 2012, INT J CANCER, V131, P2234, DOI 10.1002/ijc.27496
   Park JY, 2007, J CANCER RES CLIN, V133, P835, DOI 10.1007/s00432-007-0225-x
   Park Y, 2010, MED ONCOL, V27, P1192, DOI 10.1007/s12032-009-9358-x
   Peng Y, 2019, CANCER LETT, V442, P181, DOI 10.1016/j.canlet.2018.10.027
   Persson T, 2003, CLIN EXP ALLERGY, V33, P531, DOI 10.1046/j.1365-2222.2003.01609.x
   Pold M, 2004, CANCER RES, V64, P1853, DOI 10.1158/0008-5472.CAN-03-3262
   Qi YL, 2018, INT J ONCOL, V53, P358, DOI 10.3892/ijo.2018.4388
   Qiu WZ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0722-6
   Que ZJ, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0735-z
   Rajkumar T, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-45
   Rezakhaniha B, 2016, IUBMB LIFE, V68, P629, DOI 10.1002/iub.1520
   Roca H, 2018, J CLIN INVEST, V128, P248, DOI 10.1172/JCI92466
   Rousselle A, 2013, J CLIN INVEST, V123, P1343, DOI 10.1172/JCI66580
   Rubie C, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-178
   Saintigny P, 2013, CANCER RES, V73, P571, DOI 10.1158/0008-5472.CAN-12-0263
   Sakabe T, 2017, ANTICANCER RES, V37, P4881, DOI 10.21873/anticanres.11897
   Schott AF, 2017, CLIN CANCER RES, V23, P5358, DOI 10.1158/1078-0432.CCR-16-2748
   Soler-Cardona A, 2018, J INVEST DERMATOL, V138, P1627, DOI 10.1016/j.jid.2018.01.035
   Spaks A, 2017, J THORAC DIS, V9, pS164, DOI 10.21037/jtd.2017.03.61
   Speetjens FM, 2008, CLIN CANCER RES, V14, P2276, DOI 10.1158/1078-0432.CCR-07-4045
   Stofas A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-149
   Sui P, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0809-z
   Wang CJ, 2018, BIOCHEM BIOPH RES CO, V498, P862, DOI 10.1016/j.bbrc.2018.03.071
   Wang L, 2018, J PHYSIOL BIOCHEM, V74, P313, DOI 10.1007/s13105-018-0619-z
   Wang ZL, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1793-9
   Wong YF, 2007, ONCOGENE, V26, P1971, DOI 10.1038/sj.onc.1209986
   Wu KJ, 2017, ONCOTARGETS THER, V10, P5561, DOI 10.2147/OTT.S148772
   Xiang Z, 2017, ONCOGENE, V36, P5122, DOI 10.1038/onc.2017.108
   Xu WW, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14399
   Xu Xiao-jing, 2012, Zhonghua Yi Xue Za Zhi, V92, P2716
   Yanagawa J, 2009, CLIN CANCER RES, V15, P6820, DOI 10.1158/1078-0432.CCR-09-1558
   Yang G, 2010, CLIN CANCER RES, V16, P3875, DOI 10.1158/1078-0432.CCR-10-0483
   Yang L, 2008, CANCER CELL, V13, P23, DOI 10.1016/j.ccr.2007.12.004
   Yang Y, 2017, ONCOL LETT, V14, P7977, DOI 10.3892/ol.2017.7236
   Yu PF, 2017, ONCOGENE, V36, P482, DOI 10.1038/onc.2016.217
   Zhang D, 2017, CLIN IMMUNOL, V175, P34, DOI 10.1016/j.clim.2016.11.009
   Zhang HR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063477
   Zhang XY, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0425-1
   Zhao JK, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0629-4
   Zhao YY, 2018, ONCOL LETT, V15, P1403, DOI 10.3892/ol.2017.7522
   Zhou SL, 2015, CANCER LETT, V358, P124, DOI 10.1016/j.canlet.2014.11.044
   Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397
   Zhou SL, 2012, HEPATOLOGY, V56, P2242, DOI 10.1002/hep.25907
   Zhou Y, 2018, CANCER RES, V78, P5927, DOI 10.1158/0008-5472.CAN-18-1702
   Zhou Z, 2019, CLIN CANC RES
   Zhu X, 2016, TUMOR BIOL, V37, P4569, DOI 10.1007/s13277-015-4275-4
   Zhuang XQ, 2019, TRENDS PHARMACOL SCI, V40, P419, DOI 10.1016/j.tips.2019.04.005
   Zlotnik A, 2012, IMMUNITY, V36, P705, DOI 10.1016/j.immuni.2012.05.008
   Zou BJ, 2018, CANCER MANAG RES, V10, P5303, DOI 10.2147/CMAR.S176152
NR 97
TC 136
Z9 147
U1 3
U2 60
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2523-3548
J9 CANCER COMMUN
JI Cancer Commun.
PD MAR
PY 2020
VL 40
IS 2-3
BP 69
EP 80
DI 10.1002/cac2.12010
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LA1KH
UT WOS:000523713300001
PM 32237072
OA Green Published
DA 2025-01-04
ER

PT J
AU Seeber, A
   Gastl, G
AF Seeber, Andreas
   Gastl, Gunther
TI Targeted Therapy of Colorectal Cancer
SO ONCOLOGY RESEARCH AND TREATMENT
LA English
DT Review
DE Colorectal cancer; Molecular targeted drugs; Angiogenesis inhibitors;
   Epidermal growth factor receptor inhibitors; Novel therapeutics; RAS
   mutation
ID EPIDERMAL-GROWTH-FACTOR; WILD-TYPE KRAS; FOLFIRI PLUS BEVACIZUMAB;
   PHASE-III TRIAL; 1ST-LINE TREATMENT; OPEN-LABEL; RANDOMIZED-TRIAL;
   COLON-CANCER; FLUOROURACIL; LEUCOVORIN
AB Over the past decades, considerable progress has been made in the management of colorectal cancer (CRC), leading to a significant improvement in overall survival. Although part of this success has been rightly attributed to aggressive surgical management and advances in other adjunct treatments, our understanding of the pathogenesis of CRC and emergence of newer molecular targets for colon cancer has created a powerful impact. In this review article, we will discuss various targeted therapies in the management of metastatic CRC (mCRC). In particular, vascular endothelial growth factor (VEGF)- and epidermal growth factor receptor (EGFR)-targeting monoclonal antibodies have become integral components of the first-line treatment strategies for mCRC. Newer agents on the horizon soon to be incorporated in clinical practice will be briefly reviewed as well. Currently, the only predictive biomarker for treatment selection in patients with mCRC is tumor RAS mutational status. (C) 2016 S. Karger GmbH, Freiburg
C1 [Seeber, Andreas; Gastl, Gunther] Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Anichstr 35, A-6020 Innsbruck, Austria.
C3 Medical University of Innsbruck
RP Gastl, G (corresponding author), Med Univ Innsbruck, Dept Internal Med Hematol & Oncol 5, Anichstr 35, A-6020 Innsbruck, Austria.
EM guenther.gastl@i-med.ac.at
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385
   Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855
   [Anonymous], 2014, J CLIN ONCOL S
   [Anonymous], J CLIN ONCOL S
   [Anonymous], ONCOTARGET
   Arnold D, 2014, J CLIN ONCOL, V32, P5
   Belum VR, 2013, INVEST NEW DRUG, V31, P1078, DOI 10.1007/s10637-013-9977-0
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Cassidy J, 2011, BRIT J CANCER, V105, P58, DOI 10.1038/bjc.2011.201
   Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   COHEN S, 1975, P NATL ACAD SCI USA, V72, P1317, DOI 10.1073/pnas.72.4.1317
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Engstrom PF, 2009, J NATL COMPR CANC NE, V7, P778, DOI 10.6004/jnccn.2009.0056
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hecht JR, 2010, CLIN CANCER RES, V16, P2205, DOI 10.1158/1078-0432.CCR-09-2017
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Helbling D, 2013, ANN ONCOL, V24, P718, DOI 10.1093/annonc/mds519
   Hendlisz A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2014-007189
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Koeberle D, 2015, ANN ONCOL, V26, P709, DOI 10.1093/annonc/mdv011
   Langleben A, 2013, J CLIN ONCOL, V31
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Pai SG, 2016, WORLD J GASTRO ONCOL, V8, P99, DOI 10.4251/wjgo.v8.i1.99
   Petrovic N, 2016, J PHARM PHARM SCI, V19, P226, DOI 10.18433/jpps.v19i2.27608
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Rechsteiner M, 2015, ANN ONCOL, V26, P246, DOI 10.1093/annonc/mdu471
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Stintzing S, 2016, LANCET ONCOL, V17, P1426, DOI 10.1016/S1470-2045(16)30269-8
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tabernero J, 2014, EUR J CANCER, V50, P320, DOI 10.1016/j.ejca.2013.09.013
   Tol J, 2010, NEW ENGL J MED, V363, P2573
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
NR 49
TC 37
Z9 39
U1 0
U2 3
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 2296-5270
EI 2296-5262
J9 ONCOL RES TREAT
JI Oncol. Res. Treat.
PY 2016
VL 39
IS 12
BP 796
EP 802
DI 10.1159/000453027
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ED0BW
UT WOS:000388509000006
PM 27889786
DA 2025-01-04
ER

PT J
AU Jesinghaus, M
   Wolf, T
   Pfarr, N
   Muckenhuber, A
   Ahadova, A
   Warth, A
   Goeppert, B
   Sers, C
   Kloor, M
   Endris, V
   Stenzinger, A
   Weichert, W
AF Jesinghaus, Moritz
   Wolf, Thomas
   Pfarr, Nicole
   Muckenhuber, Alexander
   Ahadova, Aysel
   Warth, Arne
   Goeppert, Benjamin
   Sers, Christine
   Kloor, Matthias
   Endris, Volker
   Stenzinger, Albrecht
   Weichert, Wilko
TI Distinctive Spatiotemporal Stability of Somatic Mutations in
   Metastasized Microsatellite-stable Colorectal Cancer
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE colon cancer; adenocarcinoma; somatic mutation; metastasis;
   next-generation sequencing; tumor evolution; FFPE
ID INTRATUMOR HETEROGENEITY; TARGETED THERAPY; MATCHED PRIMARY; EVOLUTION;
   INSTABILITY; CONSEQUENCES; SELECTION; CETUXIMAB; VARIANTS; PATTERNS
AB A multistep model of disease progression and genomic landscape has been firmly established for colorectal cancer (CRC) primaries, but the genetic makeup of related metastases and the dynamics of genetic changes during metastatic progression are scarcely known. To address these issues, we used multigene high-coverage next-generation sequencing of 24 microsatellite-stable CRC primaries, matched normal tissue, and related multiple metastases to nodes, liver, lung, and brain with a CRC-specific gene panel to infer the degree of clonal evolution during metastatic progression of the disease. Somatic mutations were detected in 40% of CRC-related genes, and we observed a striking 100% genetic concordance between primary and multiple secondary sites for APC, KRAS, FBXW7, PIK3CA, BRAF, SMAD4, and ACVR2A. Except for true de novo mutations in 4 cases (affecting SYNE1, CTNNB1, TP53, and PTEN), all remaining cases (84.4%) shared the genetic lesions of the primary tumors with all investigated metastases irrespective of the site of metastasis or time lapse between primary tumor resection and the occurrence of metastatic spread. Putative biomarkers and druggable targets were identified in 25% of the cases. Our data proves that genetic alterations occurring early in CRC carcinogenesis are remarkably stable during metastatic progression, indicating (i) a very low degree of genetic heterogeneity between primary and multiple secondary sites with respect to CRC driver mutations and (ii) that genetic interrogation of archived primary tumor samples appears to be sufficient for the application of cancer precision medicine in the metastatic setting.
C1 [Jesinghaus, Moritz; Wolf, Thomas; Pfarr, Nicole; Muckenhuber, Alexander; Warth, Arne; Goeppert, Benjamin; Endris, Volker; Stenzinger, Albrecht; Weichert, Wilko] Univ Heidelberg Hosp, Dept Gen Pathol, D-69120 Heidelberg, Germany.
   [Ahadova, Aysel; Kloor, Matthias] Univ Heidelberg Hosp, Inst Pathol, Dept Appl Tumor Biol, D-69120 Heidelberg, Germany.
   [Ahadova, Aysel; Kloor, Matthias] DKFZ, Clin Cooperat Unit Appl Tumor Biol, Heidelberg, Germany.
   [Weichert, Wilko] Natl Ctr Tumor Dis NCT, Heidelberg, Germany.
   [Sers, Christine] Charite, Inst Pathol, D-13353 Berlin, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ);
   Helmholtz Association; German Cancer Research Center (DKFZ); Ruprecht
   Karls University Heidelberg; Berlin Institute of Health; Free University
   of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin
RP Stenzinger, A (corresponding author), Univ Heidelberg Hosp, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
EM albrecht.stenzinger@med.uni-heidelberg.de
RI Sers, Christine/B-5438-2010; Goeppert, Benjamin/AAC-2303-2022
OI Goeppert, Benjamin/0000-0002-4135-9250; Sers,
   christine/0000-0002-6219-1514
FU German Cancer Consortium (DKTK)
FX Funded by the German Cancer Consortium (DKTK; to W.W. and C.S.). The
   authors have disclosed that they have no significant relationships with,
   or financial interest in, any commercial companies pertaining to this
   article.
CR Adzhubei IA, 2010, NAT METHODS, V7, P248, DOI 10.1038/nmeth0410-248
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627
   Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Briggs S, 2013, J PATHOL, V230, P148, DOI 10.1002/path.4185
   Budczies J, 2015, ONCOTARGET, V6, P570, DOI 10.18632/oncotarget.2677
   Burrell RA, 2013, NATURE, V501, P338, DOI 10.1038/nature12625
   CHO KR, 1992, CANCER, V70, P1727, DOI 10.1002/1097-0142(19920915)70:4+<1727::AID-CNCR2820701613>3.0.CO;2-P
   Crockford A, 2014, J PATHOL, V232, P264, DOI 10.1002/path.4270
   Dienstmann R, 2012, MOL CANCER THER, V11, P2062, DOI 10.1158/1535-7163.MCT-12-0290
   Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Findeisen P, 2005, CANCER RES, V65, P8072, DOI 10.1158/0008-5472.CAN-04-4146
   Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201
   Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011
   Jones S, 2008, P NATL ACAD SCI USA, V105, P4283, DOI 10.1073/pnas.0712345105
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Knijn N, 2011, BRIT J CANCER, V104, P1020, DOI 10.1038/bjc.2011.26
   Lassmann T, 2011, BIOINFORMATICS, V27, P130, DOI 10.1093/bioinformatics/btq614
   Lee SY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090459
   Li H, 2014, BIOINFORMATICS, V30, P2843, DOI 10.1093/bioinformatics/btu356
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   NOWELL PC, 1976, SCIENCE, V194, P23, DOI 10.1126/science.959840
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Rimmer A, 2014, NAT GENET, V46, P912, DOI 10.1038/ng.3036
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Shah SP, 2009, NATURE, V461, P809, DOI 10.1038/nature08489
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Stenzinger A, 2014, CANCER MED-US, V3, P1527, DOI 10.1002/cam4.305
   Stenzinger A, 2014, ONCOTARGET, V5, P6404, DOI 10.18632/oncotarget.2223
   Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994
   Van Cutsem E, 2010, ANN ONCOL, V21, pv93, DOI 10.1093/annonc/mdq222
   Van Cutsem E, 2013, EUR J CANCER, V49, P2476, DOI 10.1016/j.ejca.2013.03.026
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Vermaat JS, 2012, CLIN CANCER RES, V18, P688, DOI 10.1158/1078-0432.CCR-11-1965
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Weichert W, 2010, J MOL DIAGN, V12, P35, DOI 10.2353/jmoldx.2010.090079
   Wu X, 2012, NATURE, V482, P529, DOI 10.1038/nature10825
   Xie T, 2014, GENOMICS, V104, P234, DOI 10.1016/j.ygeno.2014.07.012
   Yates LR, 2012, NAT REV GENET, V13, P795, DOI 10.1038/nrg3317
   Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438
NR 50
TC 31
Z9 33
U1 0
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD AUG
PY 2015
VL 39
IS 8
BP 1140
EP 1147
DI 10.1097/PAS.0000000000000423
PG 8
WC Pathology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology; Surgery
GA CN4RL
UT WOS:000358417800015
PM 25786087
DA 2025-01-04
ER

PT J
AU Kim, K
   Ryu, TY
   Lee, J
   Son, MY
   Kim, DS
   Kim, SK
   Cho, HS
AF Kim, Kwangho
   Ryu, Tae Young
   Lee, Jinkwon
   Son, Mi-Young
   Kim, Dae-Soo
   Kim, Sang Kyum
   Cho, Hyun-Soo
TI Epigenetic Silencing of CHOP Expression by the Histone Methyltransferase
   EHMT1 Regulates Apoptosis in Colorectal Cancer Cells
SO MOLECULES AND CELLS
LA English
DT Article
DE apoptosis; C/EBP homologous protein; colorectal cancer; euchromatic
   histone-lysine N-methyltransferase 1
ID ENDOPLASMIC-RETICULUM STRESS; CYCLE ARREST; INDUCE APOPTOSIS; GENE;
   PATHWAY
AB Colorectal cancer (CRC) has a high mortality rate among cancers worldwide. To reduce this mortality rate, chemotherapy (5-fluorouracil, oxaliplatin, and irinotecan) or targeted therapy (bevacizumab, cetuximab, and panitumumab) has been used to treat CRC. However, due to various side effects and poor responses to CRC treatment, novel therapeutic targets for drug development are needed. In this study, we identified the overexpression of EHMT1 in CRC using RNA sequencing (RNA-seq) data derived from TCGA, and we observed that knocking down EHMT1 expression suppressed cell growth by inducing cell apoptosis in CRC cell lines. In Gene Ontology (GO) term analysis using RNA-seq data, apoptosis-related terms were enriched after EHMT1 knockdown. Moreover, we identified the CHOP gene as a direct target of EHMT1 using a ChIP (chromatin immunoprecipitation) assay with an anti-histone 3 lysine 9 dimethylation (H3K9me2) antibody. Finally, after cotransfection with siEHMT1 and siCHOP, we again confirmed that CHOP-mediated cell apoptosis was induced by EHMT1 knockdown. Our findings reveal that EHMT1 plays a key role in regulating CRC cell apoptosis, suggesting that EHMT1 may be a therapeutic target for the development of cancer inhibitors.
C1 [Kim, Kwangho; Ryu, Tae Young; Lee, Jinkwon; Son, Mi-Young; Kim, Dae-Soo; Cho, Hyun-Soo] Korea Res Inst Biosci & Biotechnol, Daejeon 34141, South Korea.
   [Lee, Jinkwon; Son, Mi-Young; Kim, Dae-Soo; Cho, Hyun-Soo] Korea Univ Sci & Technol, Dept Funct Genom, Daejeon 34113, South Korea.
   [Kim, Kwangho; Kim, Sang Kyum] Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
C3 Korea Research Institute of Bioscience & Biotechnology (KRIBB);
   University of Science & Technology (UST); Chungnam National University
RP Cho, HS (corresponding author), Korea Res Inst Biosci & Biotechnol, Daejeon 34141, South Korea.; Cho, HS (corresponding author), Korea Univ Sci & Technol, Dept Funct Genom, Daejeon 34113, South Korea.; Kim, SK (corresponding author), Chungnam Natl Univ, Coll Pharm, Daejeon 34134, South Korea.
EM sangkim@cnu.ac.kr; chohs@kribb.re.kr
RI Kim, Young Hoon/F-5424-2012; Kim, Jung Oh/JDC-5061-2023
OI Son, Mi-Young/0000-0001-7590-8812; RYU, TAE YOUNG/0000-0001-8429-383X;
   Kim, Kwangho/0000-0001-9387-7642; cho, Hyun-soo/0000-0002-8242-9390
FU Ministry of Trade, Industry & Energy (MOTIE, Korea) [20008777]; National
   Research Foundation of Korea (NRF) - Ministry of Science, ICT, and
   Future Planning [NRF-2020R1A2B5B01002028, NRF-2018M3A9H3023077,
   NRF-2021M3A9H3016046]; Korean Fund for Regenerative Medicine (KFRM) -
   Korean government (the Ministry of Science and ICT); KRIBB Research
   Initiative Program; Ministry of Health Welfare [21A0404L1]
FX This work was supported by a grant from the Technology Innovation
   Program (No. 20008777) funded by the Ministry of Trade, Industry &
   Energy (MOTIE, Korea), a National Research Foundation of Korea (NRF)
   grant funded by the Ministry of Science, ICT, and Future Planning
   (NRF-2020R1A2B5B01002028, NRF-2018M3A9H3023077/NRF-2021M3A9H3016046), a
   Korean Fund for Regenerative Medicine (KFRM) grant funded by the Korean
   government (the Ministry of Science and ICT, the Ministry of Health &
   Welfare, 21A0404L1), and the KRIBB Research Initiative Program. The
   funders had no role in the study design, data collection or analysis,
   decision to publish, or preparation of the manuscript.
CR Ausserlechner MJ, 2004, CELL DEATH DIFFER, V11, P165, DOI 10.1038/sj.cdd.4401328
   Baretti M, 2018, CURR PROB CANCER, V42, P530, DOI 10.1016/j.currproblcancer.2018.03.001
   Carracedo A, 2006, CANCER RES, V66, P6748, DOI 10.1158/0008-5472.CAN-06-0169
   Cebrian A, 2006, CARCINOGENESIS, V27, P1661, DOI 10.1093/carcin/bgi375
   Chitnis NS, 2012, MOL CELL, V48, P353, DOI 10.1016/j.molcel.2012.08.025
   Ea CK, 2012, J BIOL CHEM, V287, P31207, DOI 10.1074/jbc.M112.365601
   Guan XJ, 2014, MOL CLIN ONCOL, V2, P76, DOI 10.3892/mco.2013.207
   Guha P, 2017, ONCOTARGET, V8, P68191, DOI 10.18632/oncotarget.19277
   Han XQ, 2020, MOL CELLS, V43, P793, DOI 10.14348/molcells.2020.2307
   Herz HM, 2013, TRENDS BIOCHEM SCI, V38, P621, DOI 10.1016/j.tibs.2013.09.004
   Hsin IL, 2012, TOXICOL APPL PHARM, V263, P330, DOI 10.1016/j.taap.2012.07.005
   Huang T, 2017, THER ADV GASTROENTER, V10, P114, DOI 10.1177/1756283X16671287
   Hwang S, 2020, BMB REP, V53, P576, DOI 10.5483/BMBRep.2020.53.11.055
   Jung G, 2020, NAT REV GASTRO HEPAT, V17, P111, DOI 10.1038/s41575-019-0230-y
   Kim K, 2019, MOL MED REP, V20, P1569, DOI 10.3892/mmr.2019.10431
   Kim S, 2020, MOL CELLS, V43, P619, DOI 10.14348/molcells.2020.0075
   Kleefstra T, 2012, AM J HUM GENET, V91, P73, DOI 10.1016/j.ajhg.2012.05.003
   Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lee J, 2021, MOL ONCOL, V15, P2989, DOI 10.1002/1878-0261.13050
   Lin SZ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/629750
   Ohno H, 2013, NATURE, V504, P163, DOI 10.1038/nature12652
   Olsen JB, 2016, STEM CELL REP, V7, P454, DOI 10.1016/j.stemcr.2016.06.012
   Park JW, 2007, ONCOL REP, V18, P1269
   Park SK, 2010, BREAST CANCER RES TR, V124, P361, DOI 10.1007/s10549-010-0786-2
   Renneville A, 2015, BLOOD, V126, P1930, DOI 10.1182/blood-2015-06-649087
   Rozpedek W, 2016, CURR MOL MED, V16, P533, DOI 10.2174/1566524016666160523143937
   Ryu TY, 2019, ONCOL REP, V41, P1691, DOI 10.3892/or.2018.6938
   Sanchez-Lopez E, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.453
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Thienpont B, 2017, J CLIN INVEST, V127, P335, DOI 10.1172/JCI88353
   Wang F, 2009, BMB REP, V42, P725, DOI 10.5483/BMBRep.2009.42.11.725
   Wang Y, 2020, ONCOL REP, V44, P849, DOI 10.3892/or.2020.7659
   Wang Y, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00402-6
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yang Y, 2018, ONCOL LETT, V15, P9480, DOI 10.3892/ol.2018.8506
   Yuan L, 2015, MOL MED REP, V11, P2459, DOI 10.3892/mmr.2014.3100
   Zhang MZ, 2018, CHEM-BIOL INTERACT, V292, P65, DOI 10.1016/j.cbi.2018.06.013
NR 38
TC 8
Z9 8
U1 0
U2 0
PU KOREAN SOC MOLECULAR & CELLULAR  BIOLOGY
PI SEOUL
PA 635-4, YUCKSAM-DONG, GANGNAM-GU, SEOUL 135-703, SOUTH KOREA
SN 1016-8478
EI 0219-1032
J9 MOL CELLS
JI Mol. Cells
PD SEP
PY 2022
VL 45
IS 9
BP 622
EP 630
DI 10.14348/molcells.2022.0014
PG 9
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA 8J8RW
UT WOS:000922680800004
PM 35748228
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Marjaneh, RM
   Hassanian, SM
   Ghobadi, N
   Ferns, GA
   Karimi, A
   Jazayeri, MH
   Nasiri, M
   Avan, A
   Khazaei, M
AF Marjaneh, Reyhaneh Moradi
   Hassanian, Seyed Mahdi
   Ghobadi, Niloofar
   Ferns, Gordon A.
   Karimi, Afshin
   Jazayeri, Mir Hadi
   Nasiri, Mohammadreza
   Avan, Amir
   Khazaei, Majid
TI Targeting the death receptor signaling pathway as a potential
   therapeutic target in the treatment of colorectal cancer
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
DE colorectal cancer; death receptor signaling pathway; targeted therapy
ID TUMOR-NECROSIS-FACTOR; APOPTOSIS-INDUCING LIGAND; OVERCOMES TRAIL
   RESISTANCE; HUMAN COLON ADENOCARCINOMA; FOLFOX6 PLUS BEVACIZUMAB;
   PHASE-II TRIAL; MONOCLONAL-ANTIBODY; MEDIATED APOPTOSIS;
   DOWN-REGULATION; FUSION PROTEIN
AB Despite advances in the diagnosis and treatment of colorectal cancer (CRC), it remains a major cause of cancer related death globally. There are currently no chemotherapeutic agents that have been found to eradicate the disease without adverse effects. A defect in the death receptor signaling pathway is a feature of CRC. The ligand of these receptors belongs to the tumor necrosis factor family, and that are particularly expressed by cells of the immune system, and that induce apoptosis in a caspase dependent manner. The fact that malignant cells are particularly sensitive to these ligands, compared to normal cells, has led to work on the assessment of compounds that activate this pathway in the treatment of CRC. Phase I trials have shown that these death receptor agonists are safe. Phase II and III trials are currently investigating the efficacy of these therapeutic agents in the treatment of CRC. In this review, we describe the biochemical death receptor signaling pathway and its relationship to CRC. We also summarize the current clinical studies that are targeting this signaling pathway in CRC treatment.
C1 [Marjaneh, Reyhaneh Moradi; Khazaei, Majid] Mashhad Univ Med Sci, Dept Physiol, Fac Med, Mashhad, Iran.
   [Hassanian, Seyed Mahdi; Ghobadi, Niloofar; Avan, Amir] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran.
   [Hassanian, Seyed Mahdi] Mashhad Univ Med Sci, Dept Med Biochem, Fac Med, Mashhad, Iran.
   [Hassanian, Seyed Mahdi] Mashhad Univ Med Sci, Microanat Res Ctr, Mashhad, Iran.
   [Ferns, Gordon A.] Brighton & Sussex Med Sch, Div Med Educ, Brighton, E Sussex, England.
   [Karimi, Afshin] Mashhad Mild Powder Ind, Qual Dept Nutricia, Mashhad, Iran.
   [Jazayeri, Mir Hadi] Iran Univ Med Sci, Sch Med, Immunol Res Ctr, Tehran, Iran.
   [Jazayeri, Mir Hadi] Iran Univ Med Sci, Sch Med, Dept Immunol, Tehran, Iran.
   [Nasiri, Mohammadreza] Ferdowsi Univ Mashhad, Biotechnol Res Inst, Recombinant Prot Res Grp, Mashhad, Iran.
   [Avan, Amir] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran.
   [Avan, Amir] Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran.
   [Avan, Amir] Mashhad Univ Med Sci, Surg Oncol Res Ctr, Mashhad, Iran.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; Mashhad University of Medical Sciences; Mashhad University of
   Medical Sciences; University of Sussex; University of Brighton; Iran
   University of Medical Sciences; Iran University of Medical Sciences;
   Ferdowsi University Mashhad; Mashhad University of Medical Sciences;
   Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences
RP Khazaei, M (corresponding author), Mashhad Univ Med Sci, Dept Physiol, Fac Med, Mashhad, Iran.; Avan, A (corresponding author), Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran.; Avan, A (corresponding author), Mashhad Univ Med Sci, Dept Modern Sci & Technol, Fac Med, Mashhad, Iran.
EM avana@mums.ac.ir; khazaeim@mums.ac.ir
RI shahidsales, soudabe/AAY-2920-2020; Hassanian, Seyed
   Mahdi/KAL-9917-2024; Nassiri, Mohammadreza/JCD-9415-2023; Nassiri,
   Mohammadreza/P-4844-2015; Khazaei, Majid/A-6143-2018; Jazayeri, Mir
   Hadi/Y-6213-2018; Avan, Amir/G-3852-2013
OI Nassiri, Mohammadreza/0000-0001-7119-8155; Khazaei,
   Majid/0000-0002-7979-5699; Jazayeri, Mir Hadi/0000-0003-3566-2787; Avan,
   Amir/0000-0002-4968-0962; naseri, shahrokh/0000-0001-8974-2120
FU Mashhad University of Medical Sciences [961061]; National Institute for
   Medical Research Development [958349, 962782]; Biotechnology Development
   Council of the Islamic Republic of Iran [960208]
FX Mashhad University of Medical Sciences, Grant number: 961061; National
   Institute for Medical Research Development, Grant numbers: 958349,
   962782; The Biotechnology Development Council of the Islamic Republic of
   Iran, Grant number: 960208
CR Amarante-Mendes GP, 2015, PHARMACOL THERAPEUT, V155, P117, DOI 10.1016/j.pharmthera.2015.09.001
   Andersson-Rolf A, 2017, PHYSIOLOGY, V32, P278, DOI 10.1152/physiol.00005.2017
   [Anonymous], 2011, J CLIN ONCOL S
   [Anonymous], NCCN CLIN PRACT GUID
   [Anonymous], 2017, Tumor Biol
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bennett MW, 2001, J CLIN PATHOL, V54, P598, DOI 10.1136/jcp.54.8.598
   Burvenich IJG, 2013, CLIN CANCER RES, V19, P5984, DOI 10.1158/1078-0432.CCR-12-3104
   Chen LN, 2010, INFLAMM BOWEL DIS, V16, P1071, DOI 10.1002/ibd.21191
   Ciprotti M, 2015, J CLIN ONCOL, V33, P2609, DOI 10.1200/JCO.2014.60.4256
   Citrin D, 2010, ONCOLOGY-BASEL, V79, P382, DOI 10.1159/000323488
   Cohn AL, 2013, ANN ONCOL, V24, P1777, DOI 10.1093/annonc/mdt057
   Danielli R, 2015, CANCER IMMUNOL IMMUN, V64, P113, DOI 10.1007/s00262-014-1621-0
   DeSantis CE, 2014, CA-CANCER J CLIN, V64, P252, DOI 10.3322/caac.21235
   Devetzi M, 2016, SCI REP-UK, V6, DOI 10.1038/srep36532
   Ding J, 2012, J BIOL CHEM, V287, P641, DOI 10.1074/jbc.M111.286526
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   FIEDLER W, 1991, KLIN WOCHENSCHR, V69, P261, DOI 10.1007/BF01666852
   Fischer U, 2005, CELL DEATH DIFFER, V12, P942, DOI 10.1038/sj.cdd.4401556
   Forero-Torres A, 2010, CANCER BIOTHER RADIO, V25, P13, DOI 10.1089/cbr.2009.0673
   Fouqué A, 2014, BBA-REV CANCER, V1846, P130, DOI 10.1016/j.bbcan.2014.04.007
   Fuchs CS, 2013, CANCER-AM CANCER SOC, V119, P4290, DOI 10.1002/cncr.28353
   Fulda S, 2004, BBA-REV CANCER, V1705, P27, DOI 10.1016/j.bbcan.2004.09.003
   Goda AE, 2008, ONCOGENE, V27, P3435, DOI 10.1038/sj.onc.1211008
   He Q, 2004, ONCOGENE, V23, P2554, DOI 10.1038/sj.onc.1207351
   Hemmerle T, 2013, BRIT J CANCER, V109, P1206, DOI 10.1038/bjc.2013.421
   Herbst RS, 2010, CLIN CANCER RES, V16, P5883, DOI 10.1158/1078-0432.CCR-10-0631
   Herman JM, 2013, J CLIN ONCOL, V31, P886, DOI 10.1200/JCO.2012.44.7516
   Hoogwater FJH, 2012, BBA-REV CANCER, V1826, P189, DOI 10.1016/j.bbcan.2012.03.007
   Hori T, 2010, CANCER LETT, V287, P98, DOI 10.1016/j.canlet.2009.06.002
   Horinaka M., 2007, AACR, V5, P945
   Johnson TR, 2003, ONCOGENE, V22, P4953, DOI 10.1038/sj.onc.1206656
   Johnston S, 2017, CLIN COLORECTAL CANC, V16, P386, DOI 10.1016/j.clcc.2017.03.014
   Johnstone RW, 2008, NAT REV CANCER, V8, P782, DOI 10.1038/nrc2465
   Jost PJ, 2009, NATURE, V460, P1035, DOI 10.1038/nature08229
   Kali A, 2015, INDIAN J PHARMACOL, V47, P479, DOI 10.4103/0253-7613.165190
   Kaplan-Lefko PJ, 2010, CANCER BIOL THER, V9, P618, DOI 10.4161/cbt.9.8.11264
   Kasubhai SM, 2012, J CLIN ONCOL, V30
   Kauntz H, 2011, APOPTOSIS, V16, P1042, DOI 10.1007/s10495-011-0631-z
   KEMENY N, 1990, CANCER-AM CANCER SOC, V66, P659, DOI 10.1002/1097-0142(19900815)66:4<659::AID-CNCR2820660410>3.0.CO;2-2
   Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x
   Koehler BC, 2014, WORLD J GASTROENTERO, V20, P1923, DOI 10.3748/wjg.v20.i8.1923
   Koornstra JJ, 2003, J PATHOL, V200, P327, DOI 10.1002/path.1364
   Lejeune F.J., 2006, B CANC, V93, P90
   Lepage C, 2011, CANCER LETT, V301, P193, DOI 10.1016/j.canlet.2010.12.003
   Li M, 2012, MOL THER, V20, P46, DOI 10.1038/mt.2011.197
   Lima CMR, 2012, CANCER INVEST, V30, P727, DOI 10.3109/07357907.2012.732163
   Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240
   Liu KB, 2003, J IMMUNOL, V170, P5973, DOI 10.4049/jimmunol.170.12.5973
   Lu JV, 2014, SEMIN CELL DEV BIOL, V35, P33, DOI 10.1016/j.semcdb.2014.07.003
   Lu L, 2015, J CONTROL RELEASE, V210, P134, DOI 10.1016/j.jconrel.2015.05.282
   Mahmood Z, 2010, EXP CELL RES, V316, P887, DOI 10.1016/j.yexcr.2009.12.011
   Micheau O, 2002, J BIOL CHEM, V277, P45162, DOI 10.1074/jbc.M206882200
   Mocarski ES, 2014, J IMMUNOL, V192, P2019, DOI 10.4049/jimmunol.1302426
   Möller Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107165
   Moller P, 1996, AM J PATHOL, V149, P9
   Moradi-Marjaneh R., 2017, J CELLULAR PHYSL, P1
   Motoki K, 2005, CLIN CANCER RES, V11, P3126, DOI 10.1158/1078-0432.CCR-04-1867
   Nakamoto Y, 2002, J EXP MED, V196, P1105, DOI 10.1084/jem.20020633
   Nozoe T, 2003, ONCOLOGY-BASEL, V65, P83, DOI 10.1159/000071208
   Oikonomou E, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021632
   Park SM, 2010, INFLAMM BOWEL DIS, V16, P1063, DOI 10.1002/ibd.21195
   Paschall AV, 2015, J IMMUNOL, V195, P1868, DOI 10.4049/jimmunol.1402243
   Peter ME, 2015, CELL DEATH DIFFER, V22, P549, DOI 10.1038/cdd.2015.3
   Pintzas A, 2012, CANCER BIOL THER, V13, P458, DOI 10.4161/cbt.19600
   Psahoulia FH, 2007, MOL CANCER THER, V6, P2591, DOI 10.1158/1535-7163.MCT-07-0001
   Qiu YH, 2012, IUBMB LIFE, V64, P757, DOI 10.1002/iub.1064
   Riedl SJ, 2005, NATURE, V434, P926, DOI 10.1038/nature03465
   Riley JS, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.213
   Russo M, 2010, BIOCHEM PHARMACOL, V80, P674, DOI 10.1016/j.bcp.2010.03.011
   Saltz L, 2009, J CLIN ONCOL, V27
   Santoro A, 2010, EUR J CANCER, V46, P2746, DOI 10.1016/j.ejca.2010.07.012
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   SCHAADT M, 1990, J BIOL RESP MODIF, V9, P247
   Schug ZT, 2011, CELL DEATH DIFFER, V18, P538, DOI 10.1038/cdd.2010.135
   Sessler T, 2013, PHARMACOL THERAPEUT, V140, P186, DOI 10.1016/j.pharmthera.2013.06.009
   Sharma S, 2014, INVEST NEW DRUG, V32, P135, DOI 10.1007/s10637-013-9952-9
   Shen J, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0944-3
   Smakman N, 2006, CANCER RES, V66, P5403, DOI 10.1158/0008-5472.CAN-05-4108
   Song X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.104
   Song XX, 2012, MOL CANCER RES, V10, P1567, DOI 10.1158/1541-7786.MCR-12-0209-T
   Spitaleri G, 2013, J CANCER RES CLIN, V139, P447, DOI 10.1007/s00432-012-1327-7
   Stolfi C, 2012, INT J MOL SCI, V13, P7886, DOI 10.3390/ijms13077886
   Sträter J, 2005, GUT, V54, P661, DOI 10.1136/gut.2004.052696
   Sträter J, 2003, VIRCHOWS ARCH, V442, P218, DOI 10.1007/s00428-003-0760-z
   Sträter J, 2002, GASTROENTEROLOGY, V122, P659, DOI 10.1053/gast.2002.31889
   Sträter J, 2000, ANN NY ACAD SCI, V915, P162
   Su RY, 2008, MOL CANCER THER, V7, P3429, DOI 10.1158/1535-7163.MCT-08-0498
   Su RY, 2007, MOL CANCER THER, V6, P1562, DOI 10.1158/1535-7163.MCT-06-0800
   Takeuchi H, 2005, CLIN CANCER RES, V11, P7621, DOI 10.1158/1078-0432.CCR-05-0479
   Taniguchi H, 2008, CANCER RES, V68, P8918, DOI 10.1158/0008-5472.CAN-08-1120
   Tillman DM, 2003, CANCER RES, V63, P5118
   Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507
   Tuettenberg J, 2012, INT IMMUNOPHARMACOL, V13, P93, DOI 10.1016/j.intimp.2012.03.004
   Tur V, 2008, J BIOL CHEM, V283, P20560, DOI 10.1074/jbc.M800457200
   Van Geelen CMM, 2010, INT J ONCOL, V37, P1031, DOI 10.3892/ijo_00000755
   Van Geelen CMM, 2004, DRUG RESIST UPDATE, V7, P345, DOI 10.1016/j.drup.2004.11.002
   Vasilevskaya IA, 2005, BIOCHEM PHARMACOL, V70, P580, DOI 10.1016/j.bcp.2005.05.018
   Wahl K, 2013, HEPATOLOGY, V57, P625, DOI 10.1002/hep.26082
   Wainberg ZA, 2013, CLIN COLORECTAL CANC, V12, P248, DOI 10.1016/j.clcc.2013.06.002
   Walczak H., 2013, COLD SPRING HARBOR P, V5
   Watson AJM, 2004, GUT, V53, P1701, DOI 10.1136/gut.2004.052704
   Weichselbaum RR, 2009, CANCER GENE THER, V16, P609, DOI 10.1038/cgt.2009.37
   Westphal D, 2014, CELL DEATH DIFFER, V21, P196, DOI 10.1038/cdd.2013.139
   Xu YY, 2003, J IMMUNOL, V171, P562, DOI 10.4049/jimmunol.171.2.562
   Yada A, 2008, ANN ONCOL, V19, P1060, DOI 10.1093/annonc/mdn015
   Yadav VR, 2012, BRIT J PHARMACOL, V165, P741, DOI 10.1111/j.1476-5381.2011.01603.x
   Yao H, 2004, BRIT J CANCER, V91, P1718, DOI 10.1038/sj.bjc.6602136
   Yee L, 2009, J CLIN ONCOL, V27
   Yolcu ES, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00342
   Yoshida Tatsushi, 2008, Environmental Health and Preventive Medicine, V13, P281, DOI 10.1007/s12199-008-0041-1
   Yoshida T, 2008, BIOCHEM BIOPH RES CO, V375, P129, DOI 10.1016/j.bbrc.2008.07.131
   Yu R, 2014, CANCER BIOL THER, V15, P1658, DOI 10.4161/15384047.2014.972183
   Zhang P, 2010, J BIOL CHEM, V285, P8953, DOI 10.1074/jbc.M109.070680
   Zhong B., 2015, J IMMUNOL RES, V2015, P1
NR 116
TC 31
Z9 31
U1 0
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD OCT
PY 2018
VL 233
IS 10
BP 6538
EP 6549
DI 10.1002/jcp.26640
PG 12
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA GM7GX
UT WOS:000438352300020
PM 29741789
DA 2025-01-04
ER

PT J
AU Shao, SY
   Rong, WQ
   Talukder, S
   Jia, R
   Chen, ZS
AF Shao, Shi-yun
   Rong, Wen-qing
   Talukder, Salehikram
   Jia, Ru
   Chen, Zhe-Sheng
TI GTPase KRAS (G12C mutant) inhibitor Treatment of non-small cell lung
   cancer Treatment of colorectal cancer
SO DRUGS OF THE FUTURE
LA English
DT Article
DE KRASG12C mutation inhibitors; Colorectal Cancer; Non-small cell lung
   cancer; Adagrasib; MRTX-849; Targeted&nbsp; therapy
ID ADAGRASIB MRTX849; CETUXIMAB; STANDARD; CARE; CRC
AB Colorectal cancer (CRC) is one of the cancers with high mor-bidity and mortality worldwide, and its treatment and prog-nosis have undergone tremendous changes because of the emergence of molecular targeted therapy. Kirsten rat sarco-ma viral oncogene homologue (KRAS) is the most frequently mutated oncogene in CRC. For a long time, due to the diffi- culty of effectively blocking KRAS function with traditional small-molecule inhibitors, KRAS protein was considered as an "undruggable" target. There has been amazing progress in directly targeting drugs against KRAS for cancer treatment, especially KRASG12C inhibitors, that have achieved promising outcomes in clinical studies. Adagrasib is a first-in-class co- valent small-molecule inhibitor against KRASG12C. This article reviews the mechanism of action of adagrasib and the latest preclinical and clinical research in the treatment of CRC and other cancers to provide a reference for the development of antitumor drugs.
C1 [Shao, Shi-yun; Rong, Wen-qing; Jia, Ru] Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Oncol, Dept Med Oncol, Shanghai, Peoples R China.
   [Talukder, Salehikram; Chen, Zhe-Sheng] St Johns Univ, Inst Biotechnol, Queens, NY USA.
   [Chen, Zhe-Sheng] St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Queens, NY 11439 USA.
C3 Shanghai University of Traditional Chinese Medicine; Saint John's
   University; Saint John's University
RP Jia, R (corresponding author), Shanghai Univ Tradit Chinese Med, Shuguang Hosp, Dept Oncol, Dept Med Oncol, Shanghai, Peoples R China.; Chen, ZS (corresponding author), St Johns Univ, Inst Biotechnol, Queens, NY USA.; Chen, ZS (corresponding author), St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Queens, NY 11439 USA.
EM jiaru2468@gmail.com; chenz@stjohns.edu
RI Chen, Zhe-Sheng/AAI-7465-2020
FU National Natural Science Foundation of China [82104619]; Shanghai
   Municipal Health Commission Health Industry Clinical Research Project
   [20214Y0455]; Shanghai University of Traditional Chinese Medicine Budget
   Project [2020LK048]
FX This work was supported by the National Natural Science Foundation of
   China (No. 82104619), Shanghai Municipal Health Commission Health
   Industry Clinical Research Project (20214Y0455) and Shanghai University
   of Traditional Chinese Medicine Budget Project (2020LK048).
CR [Anonymous], PHAS 3 STUD MRTX849
   [Anonymous], PHAS 2 TRIAL MRTX849
   [Anonymous], 2021, MIR THER AD REC BREA
   [Anonymous], 2022, MIR THER SUBM MARK A
   [Anonymous], 2021, SMALL MOL INH KRAS G
   [Anonymous], AD COMB BI 1701963 P
   Awad MM, 2021, NEW ENGL J MED, V384, P2382, DOI 10.1056/NEJMoa2105281
   Bekaii-Saab T.S., 2022, GASTROINTEST CANCERS
   Blake J.F., KRAS G12CA inhibitors, Patent No. [US2019144444, 2019144444]
   Briere DM, 2021, MOL CANCER THER, V20, P975, DOI 10.1158/1535-7163.MCT-20-0462
   Chen C., 2022, 263 AM CHEM SOC ACS
   Chen H, 2019, CANCER LETT, V446, P103, DOI 10.1016/j.canlet.2019.01.013
   Cho K, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10200
   Diehl JN, 2022, ADV CANCER RES, V153, P101, DOI 10.1016/bs.acr.2021.07.008
   Fell JB, 2020, J MED CHEM, V63, P6679, DOI 10.1021/acs.jmedchem.9b02052
   Fischer J.P., KRas G12C inhibitors, Patent No. [WO2017201161, 2017201161]
   Gao P.M., KRAS mutant protein inhibitor, Patent No. [WO2021023247, 2021023247]
   Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167
   Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239
   Hunter JC, 2015, MOL CANCER RES, V13, P1325, DOI 10.1158/1541-7786.MCR-15-0203
   Innocenti F, 2022, CLIN CANCER RES, V28, P1690, DOI 10.1158/1078-0432.CCR-21-3202
   Jaenne PA, 2022, NEW ENGL J MED, V387, P120, DOI 10.1056/NEJMoa2204619
   Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006
   Jia R, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.618793
   Johnson ML, 2020, EUR J CANCER, V138, pS2
   Kim N, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.768022
   Lin ZY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003554
   Marx M.A., KRAS G12CA inhibitors, Patent No. [WO2020101736, 2020101736]
   Marx M.A., KRas G12C inhibitors, Patent No. [WO2020047192, 2020047192]
   Marx M.A., KRas G12C inhibitors, Patent No. [US2020308170, 2020308170]
   Marx M.A., KRas G12C inhibitors, Patent No. [US2020262837, 2020262837]
   Marx M.A., KRas G12C inhibitors, Patent No. [US2019270743, 2019270743]
   Marx M.A., KRas G12C inhibitors, Patent No. [WO2021141628, 2021141628]
   Osterweil N, 2022, CANCER DISCOV, V12, P878, DOI 10.1158/2159-8290.CD-NB2022-0015
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Ou SHI, 2022, J CLIN ONCOL, V40, P2530, DOI 10.1200/JCO.21.02752
   Pietrantonio F, 2020, CLIN CANCER RES, V26, P1017, DOI 10.1158/1078-0432.CCR-19-3024
   Qin SK, 2018, J CLIN ONCOL, V36, P3031, DOI 10.1200/JCO.2018.78.3183
   Rahma OE, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003569
   Riely G., 2021, J THORAC ONCOL EUR L, V16
   Rose S, 2021, CANCER DISCOV, V11, P2664, DOI 10.1158/2159-8290.CD-NB2021-0385
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Spira A.I., 2022, J CLIN ONCOL, P40
   Sullivan RJ, 2020, CLIN CANCER RES, V26, P5102, DOI 10.1158/1078-0432.CCR-19-3550
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Thein KZ, 2021, ANNU REV MED, V72, P349, DOI 10.1146/annurev-med-080819-033145
   Tiwari A, 2018, WORLD J GASTROENTERO, V24, P4428, DOI 10.3748/wjg.v24.i39.4428
   U.S. Food and Drug Administration (FDA), 2022, ACC MIR THER NEW DRU
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Wang LQ, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.743
   Weiss J, 2021, ANN ONCOL, V32, pS1294, DOI 10.1016/j.annonc.2021.08.2093
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Zhang L., Novel KRAS G12C protein inhibitor, preparation method therefor, and use thereof, Patent No. [WO2021068898, 2021068898]
   Zheng XT, 2022, DRUG TODAY, V58, P175, DOI 10.1358/dot.2022.58.4.3400573
   Zhu GM, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01441-4
NR 55
TC 0
Z9 0
U1 1
U2 7
PU PROUS SCIENCE, SAU-THOMSON REUTERS
PI BARCELONA
PA 398 PROVENCA, 08025 BARCELONA, SPAIN
SN 0377-8282
EI 2013-0368
J9 DRUG FUTURE
JI Drug Future
PD NOV
PY 2022
VL 47
IS 11
BP 783
EP 795
DI 10.1358/dof.2022.47.11.3447917
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 6I6HY
UT WOS:000886232200001
DA 2025-01-04
ER

PT J
AU Pal, S
   Sharma, A
   Mathew, SP
   Jaganathan, BG
AF Pal, Soumik
   Sharma, Amit
   Mathew, Sam Padalumavunkal
   Jaganathan, Bithiah Grace
TI Targeting cancer-specific metabolic pathways for developing novel cancer
   therapeutics
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE cancer; cancer metabolism; metabolic reprogramming; cancer
   microenvironment; targeted therapy
ID FATTY-ACID SYNTHASE; ACTIVATED PROTEIN-KINASE;
   POSITRON-EMISSION-TOMOGRAPHY; ACUTE LYMPHOBLASTIC-LEUKEMIA;
   GLUCOSE-TRANSPORTER GLUT1; MITOCHONDRIAL-COMPLEX-III; HYPOXIA-INDUCIBLE
   FACTORS; HUMAN COLORECTAL-CANCER; T-CELL-ACTIVATION; BREAST-CANCER
AB Cancer is a heterogeneous disease characterized by various genetic and phenotypic aberrations. Cancer cells undergo genetic modifications that promote their proliferation, survival, and dissemination as the disease progresses. The unabated proliferation of cancer cells incurs an enormous energy demand that is supplied by metabolic reprogramming. Cancer cells undergo metabolic alterations to provide for increased energy and metabolite requirement; these alterations also help drive the tumor progression. Dysregulation in glucose uptake and increased lactate production via "aerobic glycolysis" were described more than 100 years ago, and since then, the metabolic signature of various cancers has been extensively studied. However, the extensive research in this field has failed to translate into significant therapeutic intervention, except for treating childhood-ALL with amino acid metabolism inhibitor L-asparaginase. Despite the growing understanding of novel metabolic alterations in tumors, the therapeutic targeting of these tumor-specific dysregulations has largely been ineffective in clinical trials. This chapter discusses the major pathways involved in the metabolism of glucose, amino acids, and lipids and highlights the inter-twined nature of metabolic aberrations that promote tumorigenesis in different types of cancer. Finally, we summarise the therapeutic interventions which can be used as a combinational therapy to target metabolic dysregulations that are unique or common in blood, breast, colorectal, lung, and prostate cancer.
C1 [Pal, Soumik; Sharma, Amit; Mathew, Sam Padalumavunkal; Jaganathan, Bithiah Grace] Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Stem Cells & Canc Biol Res Grp, Gauhati, Assam, India.
   [Jaganathan, Bithiah Grace] Indian Inst Technol Guwahati, Jyoti & Bhupat Mehta Sch Hlth Sci & Technol, Gauhati, Assam, India.
C3 Indian Institute of Technology System (IIT System); Indian Institute of
   Technology (IIT) - Guwahati; Indian Institute of Technology System (IIT
   System); Indian Institute of Technology (IIT) - Guwahati
RP Jaganathan, BG (corresponding author), Indian Inst Technol Guwahati, Dept Biosci & Bioengn, Stem Cells & Canc Biol Res Grp, Gauhati, Assam, India.; Jaganathan, BG (corresponding author), Indian Inst Technol Guwahati, Jyoti & Bhupat Mehta Sch Hlth Sci & Technol, Gauhati, Assam, India.
EM bithiahgj@iitg.ac.in
OI Pal, Soumik/0000-0001-7014-0998
FU Ministry of Education (MoE), Government of India; Science and
   Engineering Research Board (SERB), Government of India
FX SP, AS and SM were supported by Ministry of Education (MoE), Government
   of India. This study was supported by grant from Science and Engineering
   Research Board (SERB), Government of India to BJ.
CR Abbaszadeh Z, 2020, GENE, V726, DOI 10.1016/j.gene.2019.144158
   Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Agnihotri S, 2016, NEURO-ONCOLOGY, V18, P160, DOI 10.1093/neuonc/nov125
   Aguilera O, 2016, ONCOTARGET, V7, P47954, DOI 10.18632/oncotarget.10087
   Ahmad F, 2019, CANCERS, V11, DOI 10.3390/cancers11020146
   Aird KM, 2015, CANCER LETT, V356, P204, DOI 10.1016/j.canlet.2014.01.017
   Akins NS, 2018, CURR TOP MED CHEM, V18, P494, DOI 10.2174/1568026618666180523111351
   Alfarouk KO, 2020, METABOLITES, V10, DOI 10.3390/metabo10070285
   Altman BJ, 2016, NAT REV CANCER, V16, P619, DOI 10.1038/nrc.2016.71
   Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9
   Amelio I, 2014, TRENDS BIOCHEM SCI, V39, P191, DOI 10.1016/j.tibs.2014.02.004
   Andrianesis V, 2016, THER ADV ENDOCRINOL, V7, P212, DOI 10.1177/2042018816676239
   Arif T, 2017, NEURO-ONCOLOGY, V19, P951, DOI 10.1093/neuonc/now297
   Azevedo-Silva J, 2016, J BIOENERG BIOMEMBR, V48, P349, DOI 10.1007/s10863-016-9670-z
   Baenke F, 2013, DIS MODEL MECH, V6, P1353, DOI 10.1242/dmm.011338
   Bantug GR, 2018, NAT REV IMMUNOL, V18, P19, DOI 10.1038/nri.2017.99
   Bar EE, 2010, AM J PATHOL, V177, P1491, DOI 10.2353/ajpath.2010.091021
   Barber CN, 2019, FRONT CELL NEUROSCI, V13, DOI 10.3389/fncel.2019.00212
   Bathaie SZ, 2017, CURR MOL PHARMACOL, V10, P77, DOI 10.2174/1874467209666160112123205
   Baumann P, 2009, MOL CANCER THER, V8, P366, DOI 10.1158/1535-7163.MCT-08-0664
   Baysal BE, 2000, SCIENCE, V287, P848, DOI 10.1126/science.287.5454.848
   Becker LM, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107701
   Bellafante E, 2014, P NATL ACAD SCI USA, V111, pE4523, DOI 10.1073/pnas.1415279111
   Beloribi-Djefaflia S, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2015.49
   Ben-Sahra I, 2016, SCIENCE, V351, P728, DOI 10.1126/science.aad0489
   Ben-Sahra I, 2013, SCIENCE, V339, P1323, DOI 10.1126/science.1228792
   Benjamin D, 2018, CELL REP, V25, P3047, DOI 10.1016/j.celrep.2018.11.043
   Bertolini G, 2015, CANCER RES, V75, P3636, DOI 10.1158/0008-5472.CAN-14-3781
   Beyaz S, 2016, NATURE, V531, P53, DOI 10.1038/nature17173
   Billiard J, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-19
   Bola BM, 2014, MOL CANCER THER, V13, P2805, DOI 10.1158/1535-7163.MCT-13-1091
   Bonate PL, 2006, NAT REV DRUG DISCOV, V5, P855, DOI 10.1038/nrd2055
   Bonnet S, 2007, CANCER CELL, V11, P37, DOI 10.1016/j.ccr.2006.10.020
   BORREGAARD N, 1982, J CLIN INVEST, V70, P550, DOI 10.1172/JCI110647
   Bouchez CL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01333
   Boutté AM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022446
   Brand A, 2016, CELL METAB, V24, P657, DOI 10.1016/j.cmet.2016.08.011
   Brandalise SR, 2010, J CLIN ONCOL, V28, P1911, DOI 10.1200/JCO.2009.25.6115
   Budanov AV, 2008, CELL, V134, P451, DOI 10.1016/j.cell.2008.06.028
   Burns JE, 2021, CANCER SCI, V112, P3822, DOI 10.1111/cas.15047
   Cai H, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7619
   Calvisi DF, 2011, GASTROENTEROLOGY, V140, P1071, DOI 10.1053/j.gastro.2010.12.006
   Camici M, 2019, CANCERS, V11, DOI 10.3390/cancers11091354
   Cantelmo AR, 2016, CANCER CELL, V30, P968, DOI 10.1016/j.ccell.2016.10.006
   Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394
   Chang LG, 2020, J CANCER, V11, P1403, DOI 10.7150/jca.31406
   Chantranupong L, 2016, CELL, V165, P153, DOI 10.1016/j.cell.2016.02.035
   Chen CL, 2016, CELL METAB, V23, P206, DOI 10.1016/j.cmet.2015.12.004
   Chen H, 2021, J NANOMATER, V2021, DOI 10.1155/2021/5164100
   Chen QC, 2017, ONCOTARGET, V8, P91052, DOI 10.18632/oncotarget.19409
   Cheng ST, 2019, CLIN SCI, V133, P1745, DOI 10.1042/CS20190587
   Cheung EC, 2013, DEV CELL, V25, P463, DOI 10.1016/j.devcel.2013.05.001
   Chong DL, 2017, ANTI-CANCER DRUG, V28, P831, DOI 10.1097/CAD.0000000000000517
   Choudhary D, 2015, UROL ONCOL-SEMIN ORI, V33, DOI 10.1016/j.urolonc.2014.12.009
   Christian S, 2019, LEUKEMIA, V33, P2403, DOI 10.1038/s41375-019-0461-5
   Cinquin O, 2002, CR BIOL, V325, P1085, DOI 10.1016/S1631-0691(02)01533-0
   Clem BF, 2013, MOL CANCER THER, V12, P1461, DOI 10.1158/1535-7163.MCT-13-0097
   Colangelo T, 2017, BBA-REV CANCER, V1867, P1, DOI 10.1016/j.bbcan.2016.11.001
   Conde E, 2007, HUM PATHOL, V38, P1351, DOI 10.1016/j.humpath.2007.01.022
   Conrad PW, 1999, J BIOL CHEM, V274, P33709, DOI 10.1074/jbc.274.47.33709
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011
   Costello LC, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-17
   Csanadi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126357
   CURTHOYS NP, 1995, ANNU REV NUTR, V15, P133, DOI 10.1146/annurev.nu.15.070195.001025
   Cutruzzolà F, 2017, FRONT PHYSIOL, V8, DOI 10.3389/fphys.2017.00097
   D'Erchia AM, 2006, CELL CYCLE, V5, P750, DOI 10.4161/cc.5.7.2622
   D'Errico I, 2011, P NATL ACAD SCI USA, V108, P6603, DOI 10.1073/pnas.1016354108
   Dai XY, 2016, ONCOTARGET, V7, P6933, DOI 10.18632/oncotarget.6903
   Dang CV, 2012, GENE DEV, V26, P877, DOI 10.1101/gad.189365.112
   De Bock K, 2013, CELL, V154, P651, DOI 10.1016/j.cell.2013.06.037
   De Marchi T, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02296-w
   DeBerardinis RJ, 2007, P NATL ACAD SCI USA, V104, P19345, DOI 10.1073/pnas.0709747104
   DeBerardinis RJ, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600200
   DeBerardinis RJ, 2008, GENET MED, V10, P267, DOI 10.1097/GIM.0b013e31818b0d9b
   Deep G, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17071061
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Dey Prasanta, 2019, Cell Physiol Biochem, V52, P1535, DOI 10.33594/000000107
   Dhillon S, 2018, DRUGS, V78, P1509, DOI 10.1007/s40265-018-0978-3
   Di Tommaso L, 2007, HEPATOLOGY, V45, P725, DOI 10.1002/hep.21531
   Dias AS, 2019, EUR J CANCER, V121, P154, DOI 10.1016/j.ejca.2019.09.002
   Dolfi SC, 2013, CANCER METAB, V1, DOI 10.1186/2049-3002-1-20
   Dong LF, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0412-6
   Dossou AS, 2019, CANCERS, V11, DOI 10.3390/cancers11101422
   Dunbar EM, 2014, INVEST NEW DRUG, V32, P452, DOI 10.1007/s10637-013-0047-4
   Earl HM, 2017, LANCET ONCOL, V18, P755, DOI 10.1016/S1470-2045(17)30319-4
   Eberhardy SR, 2001, J BIOL CHEM, V276, P48562, DOI 10.1074/jbc.M109014200
   ELION GB, 1989, SCIENCE, V244, P41, DOI 10.1126/science.2649979
   Faderl S, 2012, J CLIN ONCOL, V30, P2492, DOI 10.1200/JCO.2011.37.9743
   Fallarino F, 2006, J IMMUNOL, V176, P6752, DOI 10.4049/jimmunol.176.11.6752
   Fan TJ, 2019, CANCERS, V11, DOI 10.3390/cancers11030317
   Fang HT, 2013, CAN J MICROBIOL, V59, P374, DOI 10.1139/cjm-2012-0758
   Fang ST, 2016, BIOMED REP, V5, P289, DOI 10.3892/br.2016.719
   Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0
   Fang WZ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0015-7
   Faubert B, 2020, SCIENCE, V368, P152, DOI 10.1126/science.aaw5473
   Fazolini NPB, 2015, CELL CYCLE, V14, P2667, DOI 10.1080/15384101.2015.1041684
   Feng YB, 2018, CANCER MED-US, V7, P6124, DOI 10.1002/cam4.1820
   Fernie AR, 2004, CURR OPIN PLANT BIOL, V7, P254, DOI 10.1016/j.pbi.2004.03.007
   Flaig TW, 2017, ONCOTARGET, V8, P56051, DOI 10.18632/oncotarget.17359
   Flavin R, 2011, J PATHOL, V223, P283, DOI 10.1002/path.2809
   Flavin R, 2010, FUTURE ONCOL, V6, P551, DOI 10.2217/FON.10.11
   Fontaine E, 2018, FRONT ENDOCRINOL, V9, DOI 10.3389/fendo.2018.00753
   Fossati G, 2003, J IMMUNOL, V170, P1964, DOI 10.4049/jimmunol.170.4.1964
   Franklin Renty B, 2006, BMC Biochem, V7, P10, DOI 10.1186/1471-2091-7-10
   Fu YJ, 2017, ONCOTARGET, V8, P57813, DOI 10.18632/oncotarget.18175
   Gandhi V, 2006, NAT REV DRUG DISCOV, V5, P17, DOI 10.1038/nrd1933
   Gao WC, 2013, GASTROENTEROLOGY, V145, P636, DOI 10.1053/j.gastro.2013.05.049
   Garon EB, 2014, J CANCER RES CLIN, V140, P443, DOI 10.1007/s00432-014-1583-9
   GATZEMEIER U, 1991, SEMIN ONCOL, V18, P42
   Geng F, 2016, CLIN CANCER RES, V22, P5337, DOI 10.1158/1078-0432.CCR-15-2973
   Gingras AC, 2001, GENE DEV, V15, P807, DOI 10.1101/gad.887201
   Gorchs L, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00087
   Gorrell A, 2002, J BIOL CHEM, V277, P8817, DOI 10.1074/jbc.M111810200
   Gottlob K, 2001, GENE DEV, V15, P1406, DOI 10.1101/gad.889901
   Graner E, 2004, CANCER CELL, V5, P253, DOI 10.1016/S1535-6108(04)00055-8
   Grigoryan RS, 2004, IN VIVO, V18, P107
   Grube S, 2015, J NEURO-ONCOL, V123, P35, DOI 10.1007/s11060-015-1772-7
   Gu X, 2017, SCIENCE, V358, P813, DOI 10.1126/science.aao3265
   Gugiatti E, 2018, HAEMATOLOGICA, V103, pE531, DOI 10.3324/haematol.2017.175414
   Gupta S, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00068
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   Hale JS, 2014, STEM CELLS, V32, P1746, DOI 10.1002/stem.1716
   Hambardzumyan D, 2016, NAT NEUROSCI, V19, P20, DOI 10.1038/nn.4185
   Hamid O, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.6010
   Han JM, 2012, CELL, V149, P410, DOI 10.1016/j.cell.2012.02.044
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hardie DG, 2012, NAT REV MOL CELL BIO, V13, P251, DOI 10.1038/nrm3311
   Harding JJ, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.2512
   Harris JC, 2018, CURR OPIN PSYCHIATR, V31, P96, DOI 10.1097/YCO.0000000000000388
   Hashimoto A, 2016, J CELL BIOL, V213, P81, DOI 10.1083/jcb.201510002
   Hattori A, 2017, NATURE, V545, P500, DOI 10.1038/nature22314
   Hatzivassiliou G, 2005, CANCER CELL, V8, P311, DOI 10.1016/j.ccr.2005.09.008
   Hay N, 2016, NAT REV CANCER, V16, P635, DOI 10.1038/nrc.2016.77
   Heczey A, 2017, MOL THER, V25, P2214, DOI 10.1016/j.ymthe.2017.05.012
   HEIDELBERGER C, 1957, NATURE, V179, P663, DOI 10.1038/179663a0
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Herling CD, 2019, LANCET ONCOL, V20, P1576, DOI 10.1016/S1470-2045(19)30503-0
   HERTER FP, 1961, CANCER RES, V21, P31
   Hirata E, 2015, CANCER CELL, V27, P574, DOI 10.1016/j.ccell.2015.03.008
   Hollander MC, 2011, NAT REV CANCER, V11, P289, DOI 10.1038/nrc3037
   Hollmén M, 2015, SCI REP-UK, V5, DOI 10.1038/srep09188
   Holowiecki J, 2012, J CLIN ONCOL, V30, P2441, DOI 10.1200/JCO.2011.37.1286
   Hsueh EC, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-17
   Huang Q, 2013, CANCER RES, V73, P4992, DOI 10.1158/0008-5472.CAN-13-0308
   Huang YX, 2020, CANCERS, V12, DOI 10.3390/cancers12113332
   Jain M, 2012, SCIENCE, V336, P1040, DOI 10.1126/science.1218595
   Jardé T, 2011, EUR J CANCER, V47, P33, DOI 10.1016/j.ejca.2010.09.005
   Jia YL, 2015, CANCER MED-US, V4, P1730, DOI 10.1002/cam4.521
   Jian SL, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.192
   Jiang BH, 2001, CELL GROWTH DIFFER, V12, P363
   Jiang J, 2021, METABOLITES, V11, DOI 10.3390/metabo11060402
   Jiang P, 2014, PROTEIN CELL, V5, P592, DOI 10.1007/s13238-014-0082-8
   Jiang Z, 2019, PROTEOM CLIN APPL, V13, DOI 10.1002/prca.201800038
   Jiménez-González V, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20164005
   Jin L, 2019, ONCOL LETT, V17, P4213, DOI 10.3892/ol.2019.10112
   Juliusson G, 1996, J CLIN ONCOL, V14, P2160, DOI 10.1200/JCO.1996.14.7.2160
   Jung J, 2015, MOL CELL BIOL, V35, P2479, DOI 10.1128/MCB.00125-15
   Kado Karl, 2012, Front Biosci (Elite Ed), V4, P546
   Kaelin WG, 2013, CELL, V153, P56, DOI 10.1016/j.cell.2013.03.004
   Kalezic A, 2021, CANCERS, V13, DOI 10.3390/cancers13112731
   Kalyanaraman B, 2018, REDOX BIOL, V14, P316, DOI 10.1016/j.redox.2017.09.020
   Kalyanaraman B, 2017, REDOX BIOL, V12, P833, DOI 10.1016/j.redox.2017.04.018
   Kapoor K, 2016, P NATL ACAD SCI USA, V113, P4711, DOI 10.1073/pnas.1603735113
   Karpel-Massler G, 2016, ONCOTARGET, V7, P33512, DOI 10.18632/oncotarget.9257
   Karran P, 2008, NAT REV CANCER, V8, P24, DOI 10.1038/nrc2292
   Kawada K, 2012, CLIN CANCER RES, V18, P1696, DOI 10.1158/1078-0432.CCR-11-1909
   Keku TO, 2015, AM J PHYSIOL-GASTR L, V308, pG351, DOI 10.1152/ajpgi.00360.2012
   Kim ES, 2017, DRUGS, V77, P1705, DOI 10.1007/s40265-017-0813-2
   kim EY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-40617-3
   Kim JW, 2006, CELL METAB, V3, P177, DOI 10.1016/j.cmet.2006.02.002
   Kim KH, 2007, GASTROENTEROLOGY, V132, P1955, DOI 10.1053/j.gastro.2007.03.039
   Kim RH, 2009, CANCER RES, V69, P700, DOI 10.1158/0008-5472.CAN-08-3157
   Klimova T, 2008, CELL DEATH DIFFER, V15, P660, DOI 10.1038/sj.cdd.4402307
   Kochuparambil ST, 2011, J PHARMACOL EXP THER, V336, P496, DOI 10.1124/jpet.110.174870
   KOHLER E, 1970, FEBS LETT, V6, P225, DOI 10.1016/0014-5793(70)80063-1
   Kollareddy M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8389
   Koundouros N, 2020, BRIT J CANCER, V122, P4, DOI 10.1038/s41416-019-0650-z
   Kowalik MA, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00087
   Kreuzaler P, 2020, MOL METAB, V33, P83, DOI 10.1016/j.molmet.2019.08.021
   Kwiatkowska E, 2016, J BIOENERG BIOMEMBR, V48, P23, DOI 10.1007/s10863-015-9637-5
   Läsche M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00409
   Lancaster MA, 2013, NATURE, V501, P373, DOI 10.1038/nature12517
   Lane AN, 2011, OMICS, V15, P173, DOI 10.1089/omi.2010.0088
   Le A, 2012, CELL METAB, V15, P110, DOI 10.1016/j.cmet.2011.12.009
   Le A, 2010, P NATL ACAD SCI USA, V107, P2037, DOI 10.1073/pnas.0914433107
   LeBleu VS, 2014, NAT CELL BIOL, V16, P992, DOI 10.1038/ncb3039
   Lee DC, 2015, CELL, V161, P595, DOI 10.1016/j.cell.2015.03.011
   Lee M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20167386
   Lemberg KM, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI148550
   Leone RD, 2019, SCIENCE, V366, P1013, DOI 10.1126/science.aav2588
   Lewis CA, 2015, ONCOGENE, V34, P5128, DOI 10.1038/onc.2014.439
   Lewis ND, 2011, J IMMUNOL, V186, P3632, DOI 10.4049/jimmunol.1003431
   Li CS, 2016, GENE, V587, P42, DOI 10.1016/j.gene.2016.04.029
   Li XB, 2015, THORAC CANCER, V6, P17, DOI 10.1111/1759-7714.12148
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Liem Minh Phan, 2014, Cancer Biology Medicine, V11, P1, DOI 10.7497/j.issn.2095-3941.2014.01.001
   Lin H, 2017, NEURO-ONCOLOGY, V19, P43, DOI 10.1093/neuonc/now128
   Lin SS, 2017, ONCOTARGET, V8, P110426, DOI 10.18632/oncotarget.22786
   Lindemalm S, 2004, CANCER LETT, V210, P171, DOI 10.1016/j.canlet.2004.03.007
   Liou GY, 2010, FREE RADICAL RES, V44, P479, DOI 10.3109/10715761003667554
   Liu D, 2017, J PROTEOME RES, V16, P288, DOI 10.1021/acs.jproteome.6b00604
   Liu HH, 2011, J CELL BIOCHEM, V112, P3695, DOI 10.1002/jcb.23303
   Liu JY, 2020, MOL THER, V28, P2358, DOI 10.1016/j.ymthe.2020.08.021
   Liu YC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002722
   Liu Y, 2012, MOL CANCER THER, V11, P1672, DOI 10.1158/1535-7163.MCT-12-0131
   Lonardo E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076518
   Long J, 2011, HEPATOL INT, V5, P698, DOI 10.1007/s12072-010-9230-2
   Long YC, 2006, J CLIN INVEST, V116, P1776, DOI 10.1172/JCI29044
   Lu JR, 2015, CANCER LETT, V356, P156, DOI 10.1016/j.canlet.2014.04.001
   Lu SY, 2010, INT J CANCER, V126, P416, DOI 10.1002/ijc.24761
   Luengo A, 2017, CELL CHEM BIOL, V24, P1161, DOI 10.1016/j.chembiol.2017.08.028
   Lukey MJ, 2013, FUTURE MED CHEM, V5, P1685, DOI 10.4155/fmc.13.130
   Luo DK, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/4845360
   Luo DX, 2011, MOL CELL BIOCHEM, V357, P255, DOI 10.1007/s11010-011-0896-0
   Luo XJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0646-3
   Luo ZJ, 2010, FUTURE ONCOL, V6, P457, DOI [10.2217/fon.09.174, 10.2217/FON.09.174]
   Lv X, 2017, GENES DIS, V4, P19, DOI 10.1016/j.gendis.2016.11.003
   Ma L, 2013, CELL, V152, P599, DOI 10.1016/j.cell.2012.12.028
   Maan M, 2018, BIOCHEM BIOPH RES CO, V504, P582, DOI 10.1016/j.bbrc.2018.02.097
   Macintyre AN, 2014, CELL METAB, V20, P61, DOI 10.1016/j.cmet.2014.05.004
   MacKenzie ED, 2007, MOL CELL BIOL, V27, P3282, DOI 10.1128/MCB.01927-06
   Madak JT, 2019, PHARMACOL THERAPEUT, V195, P111, DOI 10.1016/j.pharmthera.2018.10.012
   Makhov PB, 2011, CARCINOGENESIS, V32, P1773, DOI 10.1093/carcin/bgr212
   Mannava S, 2008, CELL CYCLE, V7, P2392, DOI 10.4161/cc.6390
   Marin-Valencia I, 2012, CELL METAB, V15, P827, DOI 10.1016/j.cmet.2012.05.001
   Martel PM, 2006, EXP CELL RES, V312, P278, DOI 10.1016/j.yexcr.2005.10.022
   Martinez-Outschoorn U, 2014, SEMIN ONCOL, V41, P195, DOI 10.1053/j.seminoncol.2014.03.002
   Mashima T, 2009, BRIT J CANCER, V100, P1369, DOI 10.1038/sj.bjc.6605007
   Massari F, 2018, CANCER TREAT REV, V64, P11, DOI 10.1016/j.ctrv.2017.12.007
   Mathupala SP, 1997, J BIOL CHEM, V272, P22776, DOI 10.1074/jbc.272.36.22776
   Mattaini KR, 2016, J CELL BIOL, V214, P248, DOI 10.1083/jcb.201604085
   McCubrey JA, 2012, ONCOTARGET, V3, P954, DOI 10.18632/oncotarget.652
   Mehrmohamadi M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13666
   Mele L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0635-5
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Michael AOA, 2019, CELL METAB, V29, P1135, DOI 10.1016/j.cmet.2019.01.002
   Michalek RD, 2011, J IMMUNOL, V186, P3299, DOI 10.4049/jimmunol.1003613
   Michelakis ED, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3000677
   Mini E, 2006, ANN ONCOL, V17, pV7, DOI 10.1093/annonc/mdj941
   Miricescu D, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010173
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mishra P, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723556.2014.992217
   Mittal S, 2018, EXPERT REV MOL DIAGN, V18, P227, DOI 10.1080/14737159.2018.1439382
   Miyake T, 2012, ONCOGENE, V31, P1431, DOI 10.1038/onc.2011.332
   Moldogazieva NT, 2020, CANCERS, V12, DOI 10.3390/cancers12040862
   Mondal S, 2019, INT J CANCER, V144, P178, DOI 10.1002/ijc.31868
   Mor A, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14070606
   Moreno-Sánchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x
   Morrell JA, 2003, BIOCHEM SOC T, V31, P1168
   Movahed ZG, 2019, BIOMED PHARMACOTHER, V112, DOI 10.1016/j.biopha.2019.108690
   Munn DH, 2005, IMMUNITY, V22, P633, DOI 10.1016/j.immuni.2005.03.013
   Nawrocki ST, 2012, EXPERT OPIN INV DRUG, V21, P1563, DOI 10.1517/13543784.2012.707192
   Nomura DK, 2010, CELL, V140, P49, DOI 10.1016/j.cell.2009.11.027
   Notarnicola Maria, 2012, J Gastrointest Cancer, V43, P508, DOI 10.1007/s12029-011-9300-2
   O'Connor RS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24676-6
   Özdemir BC, 2014, CANCER CELL, V25, P719, DOI [10.1016/j.ccr.2014.04.005, 10.1016/j.ccell.2015.11.002]
   Pan TJ, 2015, BIOCHEM BIOPH RES CO, V456, P452, DOI 10.1016/j.bbrc.2014.11.105
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Pardee TS, 2019, FUTURE ONCOL, V15, P3197, DOI 10.2217/fon-2019-0201
   Paris L, 2010, BREAST CANCER RES, V12, DOI 10.1186/bcr2575
   Park JK, 2021, ADV EXP MED BIOL, V1311, P39, DOI 10.1007/978-3-030-65768-0_3
   Parker WB, 2009, CHEM REV, V109, P2880, DOI 10.1021/cr900028p
   Pate KT, 2014, EMBO J, V33, P1454, DOI 10.15252/embj.201488598
   Patel D, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51865-8
   Pavlides S, 2009, CELL CYCLE, V8, P3984, DOI 10.4161/cc.8.23.10238
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Payen VL, 2020, MOL METAB, V33, P48, DOI 10.1016/j.molmet.2019.07.006
   Peiris-Pagès M, 2015, ONCOTARGET, V6, P10728, DOI 10.18632/oncotarget.3828
   Pemble CW, 2007, NAT STRUCT MOL BIOL, V14, P704, DOI 10.1038/nsmb1265
   Pértega-Gomes N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-352
   Phillips CM, 2017, CANCER RES, V77, P5741, DOI 10.1158/0008-5472.CAN-16-3480
   Pietrak B, 2011, BIOCHEMISTRY-US, V50, P4804, DOI 10.1021/bi200499m
   Pirmoradi L, 2019, J INVEST MED, V67, P715, DOI 10.1136/jim-2018-000962
   Pisarsky L, 2016, CELL REP, V15, P1161, DOI 10.1016/j.celrep.2016.04.028
   Pistollato F, 2007, MOL CELL NEUROSCI, V35, P424, DOI 10.1016/j.mcn.2007.04.003
   Puccini A, 2017, BBA-REV CANCER, V1868, P439, DOI 10.1016/j.bbcan.2017.09.003
   Purkey HE, 2016, ACS MED CHEM LETT, V7, P896, DOI 10.1021/acsmedchemlett.6b00190
   Qin JJ, 2010, NATURE, V464, P59, DOI 10.1038/nature08821
   Qiu FM, 2015, CANCER LETT, V364, P1, DOI 10.1016/j.canlet.2015.04.020
   Qiu YP, 2014, CLIN CANCER RES, V20, P2136, DOI 10.1158/1078-0432.CCR-13-1939
   Qu Q, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.132
   Quail DF, 2017, CANCER CELL, V31, P326, DOI 10.1016/j.ccell.2017.02.009
   Quintela-Fandino M, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.2552
   Raez LE, 2013, CANCER CHEMOTH PHARM, V71, P523, DOI 10.1007/s00280-012-2045-1
   Ralser M, 2008, P NATL ACAD SCI USA, V105, P17807, DOI 10.1073/pnas.0803090105
   Rastogi S, 2007, CANCER LETT, V257, P244, DOI 10.1016/j.canlet.2007.07.021
   Rath M, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00532
   Ravagnan L, 1999, ONCOGENE, V18, P2537, DOI 10.1038/sj.onc.1202625
   Ravishankar B, 2015, P NATL ACAD SCI USA, V112, P10774, DOI 10.1073/pnas.1504276112
   Real S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0016163
   Rebsamen M, 2015, NATURE, V519, P477, DOI 10.1038/nature14107
   Reina-Campos M, 2017, CURR OPIN CELL BIOL, V48, P47, DOI 10.1016/j.ceb.2017.05.006
   Reznik E, 2016, ELIFE, V5, DOI 10.7554/eLife.10769
   Rice CM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07505-2
   Rich TA, 2004, J CLIN ONCOL, V22, P2214, DOI 10.1200/JCO.2004.08.009
   Robinson MM, 2007, BIOCHEM J, V406, P407, DOI 10.1042/BJ20070039
   Robitaille AM, 2013, SCIENCE, V339, P1320, DOI 10.1126/science.1228771
   Rodriguez PC, 2004, CANCER RES, V64, P5839, DOI 10.1158/0008-5472.CAN-04-0465
   ROZENCWEIG M, 1977, ANN INTERN MED, V86, P803, DOI 10.7326/0003-4819-86-6-803
   Sang NL, 2003, J BIOL CHEM, V278, P14013, DOI 10.1074/jbc.M209702200
   Santana-Codina N, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07472-8
   Santos CR, 2012, FEBS J, V279, P2610, DOI 10.1111/j.1742-4658.2012.08644.x
   Sardesai SD, 2020, J CLIN ONCOL, V38
   Sarwono AEY, 2019, J ENZYM INHIB MED CH, V34, P171, DOI 10.1080/14756366.2018.1540474
   Satoh K, 2017, P NATL ACAD SCI USA, V114, pE7697, DOI 10.1073/pnas.1710366114
   Satriano L, 2019, NAT REV GASTRO HEPAT, V16, P748, DOI 10.1038/s41575-019-0217-8
   Saxton RA, 2017, CELL, V168, P960, DOI [10.1016/j.cell.2017.02.004, 10.1016/j.cell.2017.03.035]
   Schell JC, 2014, MOL CELL, V56, P400, DOI 10.1016/j.molcel.2014.09.026
   Schmall A, 2015, AM J RESP CRIT CARE, V191, P437, DOI 10.1164/rccm.201406-1137OC
   Schöder H, 2004, SEMIN NUCL MED, V34, P274, DOI 10.1053/j.semnuclmed.2004.06.004
   Scholtes MP, 2021, CANCERS, V13, DOI 10.3390/cancers13020288
   Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846
   Sciacovelli M, 2016, FREE RADICAL BIO MED, V100, P175, DOI 10.1016/j.freeradbiomed.2016.04.025
   Sebastián C, 2012, CELL, V151, P1185, DOI 10.1016/j.cell.2012.10.047
   Sellers K, 2015, J CLIN INVEST, V125, P687, DOI 10.1172/JCI72873
   Semenza GL, 2002, BIOCHEM PHARMACOL, V64, P993, DOI 10.1016/S0006-2952(02)01168-1
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009
   Sevic I., 2019, Hepatocellular Carcinoma
   Seyfried TN, 2015, FRONT CELL DEV BIOL, V3, DOI 10.3389/fcell.2015.00043
   Shi LZ, 2011, J EXP MED, V208, P1367, DOI 10.1084/jem.20110278
   Shi LL, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.44
   Shimano H, 2017, NAT REV ENDOCRINOL, V13, P710, DOI 10.1038/nrendo.2017.91
   Shoshan MC, 2012, J BIOENERG BIOMEMBR, V44, P7, DOI 10.1007/s10863-012-9419-2
   Shukla K, 2012, J MED CHEM, V55, P10551, DOI 10.1021/jm301191p
   Shuvalov O, 2017, ONCOTARGET, V8, P23955, DOI 10.18632/oncotarget.15053
   Song Z, 2017, ONCOL LETT, V14, P3117, DOI 10.3892/ol.2017.6538
   Sonveaux P, 2010, RADIOTHER ONCOL, V96, pS57
   Sonveaux P, 2008, J CLIN INVEST, V118, P3930, DOI 10.1172/JCI36843
   Soth MJ, 2020, J MED CHEM, V63, P12957, DOI 10.1021/acs.jmedchem.0c01398
   Soucy TA, 2009, NATURE, V458, P732, DOI 10.1038/nature07884
   Soukupova J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12837-y
   Sprinzl MF, 2013, HEPATOLOGY, V57, P2358, DOI 10.1002/hep.26328
   Sprowl-Tanio S, 2016, CANCER METAB, V4, DOI 10.1186/s40170-016-0159-3
   Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084
   Stein M, 2010, PROSTATE, V70, P1388, DOI 10.1002/pros.21172
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabernero J, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.4512
   Takebe N, 2004, CLIN CANCER RES, V10, P8301, DOI 10.1158/1078-0432.CCR-04-0747
   Takeuchi Y, 2018, BIOCHEM BIOPH RES CO, V495, P761, DOI 10.1016/j.bbrc.2017.11.088
   Tanaka K, 2015, J CLIN INVEST, V125, P1591, DOI 10.1172/JCI78239
   Tang WY, 2006, ACTA CRYSTALLOGR F, V62, P432, DOI 10.1107/S1744309106009067
   Tao LL, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0168-5
   Tennant DA, 2010, NAT REV CANCER, V10, P267, DOI 10.1038/nrc2817
   Testa C, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00225
   Thapa N, 2015, J BIOL CHEM, V290, P18843, DOI 10.1074/jbc.M114.596742
   Toda K, 2016, NEOPLASIA, V18, P654, DOI 10.1016/j.neo.2016.09.004
   Tomimoto A, 2008, CANCER SCI, V99, P2136, DOI 10.1111/j.1349-7006.2008.00933.x
   Tomlinson BK, 2015, CLIN CANCER RES, V21, P2480, DOI 10.1158/1078-0432.CCR-14-2610
   Tomlinson IPM, 2002, NAT GENET, V30, P406, DOI 10.1038/ng849
   Tong X, 2018, ANTIVIR RES, V149, P34, DOI 10.1016/j.antiviral.2017.11.004
   TURKA LA, 1991, J CLIN INVEST, V87, P940, DOI 10.1172/JCI115101
   Uehara T, 2016, ANN SURG ONCOL, V23, P206, DOI 10.1245/s10434-015-4459-6
   Uzzo RG, 2002, CLIN CANCER RES, V8, P3579
   VAITKEVICIUS V, 1961, CANCER, V14, P131, DOI 10.1002/1097-0142(196101/02)14:1<131::AID-CNCR2820140118>3.0.CO;2-3
   Valvezan AJ, 2017, CANCER CELL, V32, P624, DOI 10.1016/j.ccell.2017.09.013
   VANELLA A, 1983, NEUROCHEM RES, V8, P151, DOI 10.1007/BF00963915
   Vanhove K, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01215
   Vié N, 2008, MOL CANCER, V7, DOI 10.1186/1476-4598-7-14
   Vora A, 2006, LANCET, V368, P1339, DOI 10.1016/S0140-6736(06)69558-5
   VORA S, 1985, CANCER RES, V45, P2993
   Wang C, 2020, AGING-US, V12, P15374, DOI 10.18632/aging.103598
   Wang HW, 2020, PURINERG SIGNAL, V16, P347, DOI 10.1007/s11302-020-09711-4
   Wang J, 2015, ONCOTARGET, V6, P19456, DOI 10.18632/oncotarget.3318
   Wang JX, 2012, TUMOR BIOL, V33, P95, DOI 10.1007/s13277-011-0251-9
   Wang LY, 2016, NUCLEOS NUCLEOT NUCL, V35, P578, DOI 10.1080/15257770.2015.1125001
   Wang SY, 2015, SCIENCE, V347, P188, DOI 10.1126/science.1257132
   Wang WJ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.605154
   Wang XT, 1997, ONCOGENE, V15, P2991, DOI 10.1038/sj.onc.1201450
   Wang YN, 2018, ONCOGENE, V37, P6025, DOI 10.1038/s41388-018-0384-z
   Wang YT, 2019, CELL REP, V28, P512, DOI 10.1016/j.celrep.2019.06.026
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wei AH, 2020, NEW ENGL J MED, V383, P2526, DOI 10.1056/NEJMoa2004444
   Wei Z, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.603837
   Welin M, 2010, BIOCHEM BIOPH RES CO, V396, P157, DOI 10.1016/j.bbrc.2010.04.054
   Wen YA, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.21
   Wenes M, 2016, CELL METAB, V24, P701, DOI 10.1016/j.cmet.2016.09.008
   White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882
   Wilde L, 2017, SEMIN ONCOL, V44, P198, DOI 10.1053/j.seminoncol.2017.10.004
   Willems L, 2013, BLOOD, V122, P3521, DOI 10.1182/blood-2013-03-493163
   Wise DR, 2008, P NATL ACAD SCI USA, V105, P18782, DOI 10.1073/pnas.0810199105
   Witkiewicz AK, 2012, CELL CYCLE, V11, P1108, DOI 10.4161/cc.11.6.19530
   Wong Nicholas, 2013, Int J Cell Biol, V2013, P242513, DOI 10.1155/2013/242513
   Wood TE, 2008, MOL CANCER THER, V7, P3546, DOI 10.1158/1535-7163.MCT-08-0569
   Woolbright BL, 2018, MOL CANCER THER, V17, P2004, DOI 10.1158/1535-7163.MCT-18-0063
   Wroblewski LE, 2013, GASTROENTEROL CLIN N, V42, P285, DOI 10.1016/j.gtc.2013.01.006
   Wu KH, 2018, J FOOD DRUG ANAL, V26, P221, DOI 10.1016/j.jfda.2017.03.009
   Wu WC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0961-7
   Wu X, 2016, P NATL ACAD SCI USA, V113, pE6965, DOI 10.1073/pnas.1609934113
   Wu ZM, 2015, CELL STEM CELL, V17, P47, DOI 10.1016/j.stem.2015.05.016
   Xia YJ, 2021, CANCER MED-US, V10, P6374, DOI 10.1002/cam4.4177
   Xiang LS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1291-5
   Xiang XQ, 2004, BIOCHEM BIOPH RES CO, V321, P161, DOI 10.1016/j.bbrc.2004.06.133
   Xiao B, 2007, NATURE, V449, P496, DOI 10.1038/nature06161
   Xu DH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0974-1
   Yalcin A, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.292
   Yamaoka T, 1996, Nihon Rinsho, V54, P3188
   Yang C, 2019, J CANCER, V10, P918, DOI 10.7150/jca.27226
   Yang F, 2008, J HEPATOL, V48, P12, DOI 10.1016/j.jhep.2007.06.021
   Yang J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0954-x
   Yang LF, 2016, CELL METAB, V24, P685, DOI 10.1016/j.cmet.2016.10.011
   Yang YA, 2002, EXP CELL RES, V279, P80, DOI 10.1006/excr.2002.5600
   Yoon S, 2007, J BIOL CHEM, V282, P26122, DOI 10.1074/jbc.M702854200
   Yoshida S, 2018, CELL MOL LIFE SCI, V75, P1227, DOI 10.1007/s00018-017-2710-y
   Yu M, 2011, LIFE SCI, V89, P65, DOI 10.1016/j.lfs.2011.05.010
   Yu YJ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04120-w
   Yuan LW, 2016, WORLD J GASTROENTERO, V22, P2046, DOI 10.3748/wjg.v22.i6.2046
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
   Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015
   Zadra G, 2013, BBA-MOL CELL BIOL L, V1831, P1518, DOI 10.1016/j.bbalip.2013.03.010
   Zahra K, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00159
   Zaidi N, 2013, PROG LIPID RES, V52, P585, DOI 10.1016/j.plipres.2013.08.005
   Zarei Mahboubeh, 2019, Recent Pat Biotechnol, V13, P124, DOI 10.2174/1872208313666181220121400
   Zeng H, 2017, CURR OPIN IMMUNOL, V46, P103, DOI 10.1016/j.coi.2017.04.005
   Zhang B, 2013, BRIT J CANCER, V109, P14, DOI 10.1038/bjc.2013.293
   Zhang C, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3935
   Zhang DS, 2014, CANCER LETT, V355, P176, DOI 10.1016/j.canlet.2014.09.003
   Zhang Feng, 2012, World J Biol Chem, V3, P167, DOI 10.4331/wjbc.v3.i8.167
   Zhang H, 2016, BIOCHEM BIOPH RES CO, V476, P146, DOI 10.1016/j.bbrc.2016.05.026
   Zhang Q, 2018, MOL IMMUNOL, V94, P27, DOI 10.1016/j.molimm.2017.12.011
   Zhang W, 2012, NAT CELL BIOL, V14, P276, DOI 10.1038/ncb2432
   Zhang ZJ, 2011, DIABETES CARE, V34, P2323, DOI 10.2337/dc11-0512
   Zhao F, 2018, IMMUNITY, V48, P147, DOI 10.1016/j.immuni.2017.12.004
   Zhao L, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04821-w
   Zheng X, 2020, EUR RESPIR REV, V29, DOI 10.1183/16000617.0134-2020
   Zhong DS, 2009, J BIOL CHEM, V284, P23225, DOI 10.1074/jbc.M109.005280
   Zhou CC, 2021, LANCET RESP MED, V9, P305, DOI 10.1016/S2213-2600(20)30365-9
   Zhou CH, 2015, SCI REP-UK, V5, DOI 10.1038/srep13834
   Zhou G, 2014, MOL CELL, V54, P960, DOI 10.1016/j.molcel.2014.04.024
   Zhou M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-33
   Zhou WH, 2019, CANCERS, V11, DOI 10.3390/cancers11091231
   Zhou YF, 2011, J BIOL CHEM, V286, P32843, DOI 10.1074/jbc.M111.260935
   Zhu AZ, 2011, SEMIN ONCOL, V38, P55, DOI 10.1053/j.seminoncol.2010.11.012
   Zhu W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163768
   Zhuang X, 2020, CARCINOGENESIS, V41, P972, DOI 10.1093/carcin/bgz174
NR 436
TC 21
Z9 21
U1 2
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD DEC 22
PY 2022
VL 13
AR 955476
DI 10.3389/fimmu.2022.955476
PG 28
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA 7N7WJ
UT WOS:000907545600001
PM 36618350
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Martini, G
   Troiani, T
   Cardone, C
   Vitiello, P
   Sforza, V
   Ciardiello, D
   Napolitano, S
   Della Corte, CM
   Morgillo, F
   Raucci, A
   Cuomo, A
   Selvaggi, F
   Ciardiello, F
   Martinelli, E
AF Martini, Giulia
   Troiani, Teresa
   Cardone, Claudia
   Vitiello, Pietropaolo
   Sforza, Vincenzo
   Ciardiello, Davide
   Napolitano, Stefania
   Della Corte, Carminia Maria
   Morgillo, Floriana
   Raucci, Antonio
   Cuomo, Antonio
   Selvaggi, Francesco
   Ciardiello, Fortunato
   Martinelli, Erika
TI Present and future of metastatic colorectal cancer treatment: A review
   of new candidate targets
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Novel biomarkers; Monoclonal antibodies; Resistance; Mutation; RAS;
   Target therapy; Metastatic colorectal cancer
ID WILD-TYPE KRAS; CETUXIMAB PLUS IRINOTECAN; III COLON-CANCER;
   GROWTH-FACTOR; 1ST-LINE TREATMENT; RAS MUTATIONS; PHASE-II; PTEN
   EXPRESSION; MISMATCH-REPAIR; OPEN-LABEL
AB In the last two decades, great efforts have been made in the treatment of metastatic colorectal cancer (mCRC) due to the approval of new target agents for cytotoxic drugs. Unfortunately, a large percentage of patients present with metastasis at the time of diagnosis or relapse after a few months. The complex molecular heterogeneity of this disease is not completely understood; to date, there is a lack of predictive biomarkers that can be used to select subsets of patients who may respond to target drugs. Only the RAS-mutation status is used to predict resistance to anti-epidermal growth factor receptor agents in patients with mCRC. In this review, we describe approved targeted therapies for the management of metastatic mCRC and discuss new candidate targets on the horizon.
C1 [Martini, Giulia; Troiani, Teresa; Cardone, Claudia; Vitiello, Pietropaolo; Sforza, Vincenzo; Ciardiello, Davide; Napolitano, Stefania; Della Corte, Carminia Maria; Morgillo, Floriana; Ciardiello, Fortunato; Martinelli, Erika] Univ Campania Luigi Vanvitelli, Inst Med Oncol, Dept Internal & Expt Med F Magrassi & A Lanzara, Via Pansini 5, I-80131 Naples, Italy.
   [Raucci, Antonio] Univ Campania Luigi Vanvitelli, Inst Radiol, Dept Internal & Expt Med Magrassi Lanzara, I-80138 Naples, Italy.
   [Cuomo, Antonio] Osped Umberto I, Gastroenterol Unit, I-84104 Nocera Inferiore, Italy.
   [Selvaggi, Francesco] Univ Campania Luigi Vanvitelli, Unit Colorectal Surg, Dept Med Surg Neurol Metab & Ageing Sci, I-80138 Naples, Italy.
C3 Universita della Campania Vanvitelli; Universita della Campania
   Vanvitelli; Universita della Campania Vanvitelli
RP Martinelli, E (corresponding author), Univ Campania Luigi Vanvitelli, Inst Med Oncol, Dept Internal & Expt Med F Magrassi & A Lanzara, Via Pansini 5, I-80131 Naples, Italy.
EM erika.martinelli@unina2.it
RI Della Corte, Carminia/ABE-1377-2021; Martini, Giulia/AIB-8246-2022;
   Napolitano, Stefania/AAM-6696-2020; Vitiello, Pietro
   Paolo/HKN-2581-2023; Ciardiello, Davide/AAC-4613-2022; Cardone,
   Claudia/Y-5406-2019
OI Sforza, Vincenzo/0000-0001-7828-3854; Napolitano,
   Stefania/0000-0003-3504-8349; Cardone, Claudia/0000-0003-4502-1932;
   MARTINI, Giulia/0000-0003-4093-2681; MORGILLO,
   Floriana/0000-0002-9167-323X; Della Corte, Carminia
   Maria/0000-0002-3396-8099; Vitiello, Pietro Paolo/0000-0002-4060-7662;
   Raucci, Antonio/0000-0003-4688-5097
CR Ahn SM, 2016, ONCOTARGET, V7, P68638, DOI 10.18632/oncotarget.11862
   Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385
   Allegra CJ, 2013, J CLIN ONCOL, V31, P359, DOI 10.1200/JCO.2012.44.4711
   André T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238
   [Anonymous], J CLIN CONCOL
   [Anonymous], 2013, ANN ONCOL
   Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087
   Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   Atreya CE, 2013, CANCER MED-US, V2, P496, DOI 10.1002/cam4.97
   Bendell JC, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3502
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Burrell RA, 2014, MOL ONCOL, V8, P1095, DOI 10.1016/j.molonc.2014.06.005
   Cervantes-Ruiperez A, 2012, J CLIN ONCOL, V30
   Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Ciombor KK, 2015, ANNU REV MED, V66, P83, DOI 10.1146/annurev-med-051513-102539
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Dienstmann R, 2015, CANCER DISCOV, V5, P598, DOI 10.1158/2159-8290.CD-14-1432
   Domingo E, 2016, LANCET GASTROENTEROL, V1, P207, DOI 10.1016/S2468-1253(16)30014-0
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Hecht JR, 2010, CLIN CANCER RES, V16, P2205, DOI 10.1158/1078-0432.CCR-09-2017
   Hegewisch-Becker S, 2015, LANCET ONCOL, V16, P1355, DOI 10.1016/S1470-2045(15)00042-X
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Helbling D, 2013, ANN ONCOL, V24, P718, DOI 10.1093/annonc/mds519
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100
   Huang CH, 2007, SCIENCE, V318, P1744, DOI 10.1126/science.1150799
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012
   Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659
   Karakas B, 2006, BRIT J CANCER, V94, P455, DOI 10.1038/sj.bjc.6602970
   Kearns JD, 2015, MOL CANCER THER, V14, P1625, DOI 10.1158/1535-7163.MCT-14-0772
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Liao XY, 2012, CLIN CANCER RES, V18, P2257, DOI 10.1158/1078-0432.CCR-11-2410
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796
   Mao C, 2015, SCI REP-UK, V5, DOI 10.1038/srep08065
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Normanno N, 2015, ANN ONCOL, V26, P1710, DOI 10.1093/annonc/mdv176
   Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417
   Petrovic N, 2016, J PHARM PHARM SCI, V19, P226, DOI 10.18433/jpps.v19i2.27608
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Scartozzi M, 2011, ONCOLOGIST, V16, P53, DOI 10.1634/theoncologist.2010-0119
   Schaefer G, 2011, CANCER CELL, V20, P472, DOI 10.1016/j.ccr.2011.09.003
   Schirripa M, 2015, ANN ONCOL, V26, P2503, DOI 10.1093/annonc/mdv385
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Segelov E, 2016, J CLIN ONCOL, V34, P2258, DOI 10.1200/JCO.2015.65.6843
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Sridhar SS, 2005, MOL CANCER THER, V4, P677, DOI 10.1158/1535-7163.MCT-04-0297
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tabernero J, 2014, EUR J CANCER, V50, P320, DOI 10.1016/j.ejca.2013.09.013
   Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Troiani T, 2014, CURR MED CHEM, V21, P1639, DOI 10.2174/09298673113209990224
   Valtorta E, 2013, INT J CANCER, V133, P1259, DOI 10.1002/ijc.28106
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2015, ANN ONCOL, V26, P149, DOI 10.1093/annonc/mdu496
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2014, CLIN CANCER RES, V20, P4240, DOI 10.1158/1078-0432.CCR-13-2752
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Ziemke EK, 2016, CLIN CANCER RES, V22, P405, DOI 10.1158/1078-0432.CCR-15-0829
NR 93
TC 90
Z9 97
U1 0
U2 13
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD JUL 14
PY 2017
VL 23
IS 26
BP 4675
EP 4688
DI 10.3748/wjg.v23.i26.4675
PG 14
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA FA1VS
UT WOS:000405229400003
PM 28765689
OA Green Submitted, Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Shi, RR
   Li, YB
   Ran, L
   Dong, Y
   Zhou, XM
   Tang, JW
   Han, L
   Wang, MS
   Pang, LW
   Qi, YM
   Wu, YH
   Gao, YF
AF Shi, Ranran
   Li, Yubing
   Ran, Ling
   Dong, Yu
   Zhou, Xiuman
   Tang, Jingwen
   Han, Lu
   Wang, Mingshuang
   Pang, Liwei
   Qi, Yuanming
   Wu, Yahong
   Gao, Yanfeng
TI Screening and identification of HLA-A2-restricted neoepitopes for
   immunotherapy of non-microsatellite instability-high colorectal cancer
SO SCIENCE CHINA-LIFE SCIENCES
LA English
DT Article
DE non-MSI-H colorectal cancer; PD-1; neoantigen; epitope; cancer
   immunotherapy
ID T-LYMPHOCYTE EPITOPE; CELLS; PD-1; IMMUNOGENICITY; MELANOMA; PEPTIDE;
   TUMORS; COLON
AB Colorectal cancer has one of the highest mortality rates among malignant tumors, and most patients with non-microsatellite instability-high (MSI-H) colorectal cancer do not benefit from targeted therapy or immune checkpoint inhibitors. Identification of immunogenic neoantigens is a promising strategy for inducing specific antitumor T cells for cancer immunotherapy. Here, we screened potential high-frequency neoepitopes from non-MSI-H colorectal cancer and tested their abilities to induce tumor-specific cytotoxic T cell responses. Three HLA-A2-restricted neoepitopes (P31, P50, and P52) were immunogenic and could induce cytotoxic T lymphocytes in peripheral blood mononuclear cells from healthy donors and colorectal cancer patients. Cytotoxic T lymphocytes induced in HLA-A2.1/K-b transgenic mice could recognize and lyse mutant neoepitope-transfected HLA-A2(+) cancer cells. Adoptive transfer of cytotoxic T lymphocytes induced by the peptide pool of these three neoepitopes effectively inhibited tumor growth and increased the therapeutic effects of anti-PD-1 antibody. These results revealed the potential of high-frequency mutation-specific peptide-based immunotherapy as a personalized treatment approach for patients with non-MSI-H colorectal cancer. The combination of adoptive T cell therapy based on these neoepitopes with immune checkpoint inhibitors, such as anti-PD-1, could provide a promising treatment strategy for non-MSI-H colorectal cancer.
C1 [Shi, Ranran; Li, Yubing; Ran, Ling; Dong, Yu; Zhou, Xiuman; Wang, Mingshuang; Pang, Liwei; Qi, Yuanming; Wu, Yahong; Gao, Yanfeng] Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Peoples R China.
   [Gao, Yanfeng] Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen 518107, Peoples R China.
   [Qi, Yuanming; Wu, Yahong] Zhengzhou Univ, Henan Key Lab Bioact Macromol, Zhengzhou 450001, Peoples R China.
   [Han, Lu] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China.
   [Tang, Jingwen; Han, Lu] Henan Canc Hosp, Zhengzhou 450008, Peoples R China.
   [Tang, Jingwen] Zhengzhou Univ, Dept Integrated Chinse & Western Med, Affiliated Canc Hosp, Zhengzhou 450008, Peoples R China.
C3 Zhengzhou University; Sun Yat Sen University; Zhengzhou University;
   Zhengzhou University; Zhengzhou University; Zhengzhou University
RP Wu, YH; Gao, YF (corresponding author), Zhengzhou Univ, Sch Life Sci, Zhengzhou 450001, Peoples R China.; Gao, YF (corresponding author), Sun Yat Sen Univ, Sch Pharmaceut Sci Shenzhen, Shenzhen 518107, Peoples R China.; Wu, YH (corresponding author), Zhengzhou Univ, Henan Key Lab Bioact Macromol, Zhengzhou 450001, Peoples R China.
EM yahongwu@zzu.edu.cn; gaoyf29@mail.sysu.edu.cn
RI Zhou, Xiuman/V-1459-2019; Wang, Mingshuang/AAB-1662-2022; Wang,
   Hongfei/JCF-2357-2023; Gao, Yanfeng/E-1461-2014
OI yahong, Wu/0000-0001-6381-611X; Gao, Yanfeng/0000-0001-5533-7100
FU National Natural Science Foundation of China [U20A20369, 81822043,
   81601448]; Foundation of Henan Province [19A180007]
FX This work was supported by the National Natural Science Foundation of
   China (U20A20369, 81822043, and 81601448), and the Foundation of Henan
   Province (19A180007).
CR Ahn E, 2018, P NATL ACAD SCI USA, V115, P4749, DOI 10.1073/pnas.1718217115
   Aurisicchio L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0751-1
   Balachandran VP, 2017, NATURE, V551, P512, DOI 10.1038/nature24462
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Chen FJ, 2019, J CLIN INVEST, V129, P2056, DOI 10.1172/JCI99538
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chheda ZS, 2018, J EXP MED, V215, P141, DOI 10.1084/jem.20171046
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Ding W, 2017, BLOOD, V129, P3419, DOI 10.1182/blood-2017-02-765685
   Eso Y, 2020, J GASTROENTEROL, V55, P15, DOI 10.1007/s00535-019-01620-7
   Filby A, 2015, METHODS, V82, P29, DOI 10.1016/j.ymeth.2015.02.016
   Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Ghiringhelli F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01816
   Han L, 2020, CANCER IMMUNOL IMMUN, V69, P1493, DOI 10.1007/s00262-020-02562-3
   Hermel DJ, 2019, J PERS MED, V9, DOI 10.3390/jpm9010005
   Inderberg EM, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1302631
   Ito H, 2015, IMMUNOLOGY, V144, P621, DOI 10.1111/imm.12413
   Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0787-5
   Karasaki T, 2016, J THORAC ONCOL, V11, P324, DOI 10.1016/j.jtho.2015.11.006
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Liao YW, 2019, CANCER MED-US, V8, P5673, DOI 10.1002/cam4.2458
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Lu YC, 2014, CLIN CANCER RES, V20, P3401, DOI 10.1158/1078-0432.CCR-14-0433
   Malekzadeh P, 2019, J CLIN INVEST, V129, P1109, DOI 10.1172/JCI123791
   Meng QQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02193
   Mennonna D, 2017, GUT, V66, P454, DOI 10.1136/gutjnl-2015-309453
   Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025
   Nakagawa Y, 2011, BIOMED RES-TOKYO, V32, P159, DOI 10.2220/biomedres.32.159
   Nelde A, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1219825
   NIJMAN HW, 1993, EUR J IMMUNOL, V23, P1215, DOI 10.1002/eji.1830230603
   Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Peng M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1055-6
   Rosenberg SA, 2015, SCIENCE, V348, P62, DOI 10.1126/science.aaa4967
   Shi RR, 2013, CANCER IMMUNOL IMMUN, V62, P1723, DOI 10.1007/s00262-013-1478-7
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Tourdot S, 2000, EUR J IMMUNOL, V30, P3411, DOI 10.1002/1521-4141(2000012)30:12<3411::AID-IMMU3411>3.0.CO;2-R
   Wu Y, 2018, J IMMUNOL RES, V2018, P1
   Wu YH, 2012, SCAND J IMMUNOL, V76, P278, DOI 10.1111/j.1365-3083.2012.02738.x
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu ZH, 2013, J CONTROL RELEASE, V172, P259, DOI 10.1016/j.jconrel.2013.08.021
   Yan YY, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01739
   Yang Y, 2020, SCI CHINA LIFE SCI, V63, P1499, DOI 10.1007/s11427-019-1622-5
   Yarchoan M, 2017, NAT REV CANCER, V17, DOI [10.1038/nrc.2017.74, 10.1038/nrc.2016.154]
   Zhai WJ, 2021, SCI CHINA LIFE SCI, V64, P548, DOI 10.1007/s11427-020-1740-8
   Zhou GY, 2017, GASTROENTEROLOGY, V153, P1107, DOI 10.1053/j.gastro.2017.06.017
   Zhu B, 2003, CLIN CANCER RES, V9, P1850
NR 51
TC 9
Z9 9
U1 2
U2 28
PU SCIENCE PRESS
PI BEIJING
PA 16 DONGHUANGCHENGGEN NORTH ST, BEIJING 100717, PEOPLES R CHINA
SN 1674-7305
EI 1869-1889
J9 SCI CHINA LIFE SCI
JI Sci. China-Life Sci.
PD MAR
PY 2022
VL 65
IS 3
BP 572
EP 587
DI 10.1007/s11427-021-1944-5
EA JUL 2021
PG 16
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA ZI9TU
UT WOS:000672336400001
PM 34236583
DA 2025-01-04
ER

PT J
AU Liu, M
AF Liu, Meng
TI CircFAT1 is Overexpressed in Colorectal Cancer and Suppresses Cancer
   Cell Proliferation, Invasion and Migration by Increasing the Maturation
   of miR-10a
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE colorectal cancer; circFAT1; miR-10a; maturation; invasion; migration
ID TARGETED THERAPY; CIRCRNAS
AB Purpose: It has been reported that circFAT1 plays opposite roles in gastric cancer and osteosarcoma. This study aimed to explore the involvement of circFAT1 in colorectal cancer (CRC).
   Patients and Methods: Paired CRC and non-tumor tissues from 64 CRC patients were subjected to RNA preparations and RT-qPCRs to determine the expression of circFAT1, premature miR-10a, and mature miR-10a. In CRC cells, the effects of circFAT1 overexpression on miR-10a maturation were analyzed by determining the expression of both premature miR-10a and mature miR-10a using RT-qPCRs. The role of circFAT1 and miR-10a in regulating the proliferation, invasion, and migration of CRC cells was analyzed by BrdU and Transwell assays, respectively.
   Results: We found that circFAT1 was upregulated in CRC. Mature miR-10a, but not premature miR-10a, was overexpressed in CRC and positively correlated with circFAT1. CircFAT1 overexpression increased the expression of mature miR-10a, but not premature miR-10a. Overexpression of circFAT1 and miR-10a increased cell proliferation, invasion and migration, and miR-10a inhibitor suppressed cell behaviors and reversed the effects of circFAT1 overexpression.
   Conclusion: circFAT1 is overexpressed in CRC and may suppress CRC cell proliferation, invasion and migration by increasing miR-10a maturation.
C1 [Liu, Meng] China Japan Friendship Hosp, Dept Oncol, 2 East Yinghua St, Beijing 100029, Peoples R China.
C3 China-Japan Friendship Hospital
RP Liu, M (corresponding author), China Japan Friendship Hosp, Dept Oncol, 2 East Yinghua St, Beijing 100029, Peoples R China.
EM zhiqiangchengoncol@163.com
CR De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   Edwards MS, 2012, COLORECTAL DIS, V14, pe31, DOI 10.1111/j.1463-1318.2011.02765.x
   El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286
   Fang J, 2019, CANCER LETT, V442, P222, DOI 10.1016/j.canlet.2018.10.040
   Gu HJ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/3589871
   Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007
   Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011
   Lei B, 2019, INT J MED SCI, V16, P292, DOI 10.7150/ijms.28047
   Liu SZ, 2015, CHINESE J CANCER RES, V27, P22, DOI 10.3978/j.issn.1000-9604.2015.02.01
   Liu YK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.61
   Long MJ, 2012, CANCER LETT, V324, P186, DOI 10.1016/j.canlet.2012.05.022
   Sanna V, 2014, INT J NANOMED, V9, P467, DOI 10.2147/IJN.S36654
   Shang QF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0934-6
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Zhou RY, 2018, CANCER LETT, V425, P134, DOI 10.1016/j.canlet.2018.03.035
NR 16
TC 4
Z9 4
U1 0
U2 1
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2021
VL 13
BP 4309
EP 4315
DI 10.2147/CMAR.S287230
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SM8FD
UT WOS:000657833500001
PM 34103986
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Ubink, I
   Elias, SG
   Moelans, CB
   Laclé, MM
   van Grevenstein, WMU
   van Diest, PJ
   Rinkes, IHMB
   Kranenburg, O
AF Ubink, Inge
   Elias, Sjoerd G.
   Moelans, Cathy B.
   Lacle, Miangela M.
   van Grevenstein, Wilhelmina M. U.
   van Diest, Paul J.
   Rinkes, Inne H. M. Borel
   Kranenburg, Onno
TI A Novel Diagnostic Tool for Selecting Patients With Mesenchymal-Type
   Colon Cancer Reveals Intratumor Subtype Heterogeneity
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID DECISION CURVE ANALYSIS; COLORECTAL-CANCER; GROWTH-FACTOR; TYROSINE
   KINASE; TUMOR-CELLS; STAGE-II; EXPRESSION; METASTASIS; CARCINOMA;
   RECEPTOR
AB Background: Consensus molecular subtype 4 (CMS4) is a recently identified aggressive colon cancer subtype for which platelet-derived growth factor receptors (PDGFRs) and KIT are potential therapeutic targets. We aimed to develop a clinically applicable CMS4 reverse transcription polymerase chain reaction (RT-qPCR) test to select patients for PDGFR/KIT-targeted therapy.
   Methods: We used logistic regression to develop a CMS4 prediction rule based on microarray expression values of PDGFRA, PDGFRB, PDGFC, and KIT (566 training and 1259 test samples, using the 273-gene random forest classifier as CMS4 reference standard). We next translated the prediction rule into a single-sample RT-qPCR test, which we independently validated in 29 fresh tumor samples. To study intratumor CMS4 heterogeneity, we used the RT-qPCR test to analyze five random regions of 20 colon tumors.
   Results: The microarray-based prediction rule diagnosed CMS4-type tumors extremely well in both training and independent test samples (training: area under the curve [AUC] = 0.95, 95% confidence interval [CI] = 0.94 to 0.97; test: AUC = 0.95, 95% CI = 0.94 to 0.96), with excellent calibration and approximately 80% overall net benefit over a large threshold range. Translation into an RT-qPCR test did not affect discrimination (AUC = 0.97, 95% CI = 0.93 to 1.00, independent validation). RT-qPCR analysis of five random tumor regions revealed extensive intratumor CMS4 heterogeneity in nine out of 20 tumors. At least two regions likely have to be analyzed to identify patients that are predominantly CMS4 positive (> 50% average CMS4 chance).
   Conclusion: The CMS4 RT-qPCR test is a promising clinical tool for selecting individual patients for CMS4-subtype-targeted therapy.
C1 [Ubink, Inge; van Grevenstein, Wilhelmina M. U.; Rinkes, Inne H. M. Borel; Kranenburg, Onno] Univ Med Ctr Utrecht, Ctr Canc, Utrecht, Netherlands.
   [Elias, Sjoerd G.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
   [Moelans, Cathy B.; Lacle, Miangela M.; van Diest, Paul J.] Univ Med Ctr Utrecht, Dept Pathol, Utrecht, Netherlands.
C3 Utrecht University; Utrecht University Medical Center; Utrecht
   University; Utrecht University Medical Center; Utrecht University;
   Utrecht University Medical Center
RP Kranenburg, O (corresponding author), Univ Med Ctr Utrecht, POB 85500, NL-3508 GA Utrecht, Netherlands.
EM o.kranenburg@umcutrecht.nl
RI Elias, Sjoerd/E-6057-2011
FU Dutch Cancer Society [UU2014-6617]; ZonMw [95104001]
FX This work was supported by grants from the Dutch Cancer Society
   (UU2014-6617 to IU) and ZonMw (95104001).
CR Abelson S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083651
   Ågesen TH, 2012, GUT, V61, P1560, DOI 10.1136/gutjnl-2011-301179
   Bellone G, 2004, CANCER BIOL THER, V3, P385, DOI 10.4161/cbt.3.4.727
   Blanke CD, 2008, J CLIN ONCOL, V26, P626, DOI 10.1200/JCO.2007.13.4452
   Böckelman C, 2015, ACTA ONCOL, V54, P5, DOI 10.3109/0284186X.2014.975839
   Braun K, 2016, EUR UROL, V69, P505, DOI 10.1016/j.eururo.2015.04.028
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Chen EC, 2015, GASTROENTEROLOGY, V149, P705, DOI 10.1053/j.gastro.2015.05.042
   Chu JS, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-16
   Collins GS, 2015, J CLIN EPIDEMIOL, V68, P112, DOI [10.7326/M14-0697, 10.1136/bmj.g7594, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1016/j.eururo.2014.11.025, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z, 10.1038/bjc.2014.639]
   Edge SB, 2010, AJCC Cancer Staging Manual, V7th
   Fatrai S, 2015, GASTROENTEROLOGY, V149, P692, DOI 10.1053/j.gastro.2015.05.003
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Heldin CH, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009100
   HENRIKSEN R, 1993, CANCER RES, V53, P4550
   Huang YQ, 2016, J CLIN ONCO IN PRESS
   Isella C, 2015, NAT GENET, V47, P312, DOI 10.1038/ng.3224
   Jechlinger M, 2006, J CLIN INVEST, V116, P1561, DOI 10.1172/JCI24652
   Kim TM, 2015, CLIN CANCER RES, V21, P4461, DOI 10.1158/1078-0432.CCR-14-2413
   Kitadai Y, 2006, AM J PATHOL, V169, P2054, DOI 10.2353/ajpath.2006.060653
   Kogita A, 2015, BIOCHEM BIOPH RES CO, V458, P52, DOI 10.1016/j.bbrc.2015.01.064
   Lohmann S, 2013, METHODS, V59, P10, DOI 10.1016/j.ymeth.2012.07.003
   Maak M, 2013, ANN SURG, V257, P1053, DOI 10.1097/SLA.0b013e31827c1180
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Moons KGM, 2012, CLIN CHEM, V58, P1408, DOI 10.1373/clinchem.2012.182550
   Pisco AO, 2015, BRIT J CANCER, V112, P1725, DOI 10.1038/bjc.2015.146
   Rousson V, 2011, BMC MED INFORM DECIS, V11, DOI 10.1186/1472-6947-11-45
   Shinagawa K, 2013, INT J CANCER, V132, P813, DOI 10.1002/ijc.27735
   Song N, 2016, JAMA ONCOL IN PRESS
   Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214
   Steller EJA, 2013, NEOPLASIA, V15, P204, DOI 10.1593/neo.121726
   Sulzbacher I, 2003, AM J CLIN PATHOL, V120, P107, DOI 10.1309/LQ9EMK8QKE75NGGX
   Vickers AJ, 2006, MED DECIS MAKING, V26, P565, DOI 10.1177/0272989X06295361
   Vickers AJ, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i6
NR 36
TC 29
Z9 30
U1 1
U2 12
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JUL
PY 2017
VL 109
IS 7
AR djw303
DI 10.1093/jnci/djw303
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FA5PQ
UT WOS:000405496200005
PM 28376187
OA Bronze
DA 2025-01-04
ER

PT J
AU Zhu, YJ
   Li, X
   Chen, TT
   Wang, JX
   Zhou, YX
   Mu, XL
   Du, Y
   Wang, JL
   Tang, J
   Liu, JY
AF Zhu, Ya-Juan
   Li, Xiong
   Chen, Ting-Ting
   Wang, Jia-Xiang
   Zhou, Yi-Xin
   Mu, Xiao-Li
   Du, Yang
   Wang, Jia-Ling
   Tang, Jie
   Liu, Ji-Yan
TI Personalised neoantigen-based therapy in colorectal cancer
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Review
DE cancer vaccine; colorectal cancer; immunotherapy; neoantigens; targeted
   therapy
ID T-CELL HELP; TUMOR NEOANTIGENS; MASS-SPECTROMETRY; MISMATCH REPAIR;
   LUNG-CANCER; IMMUNOTHERAPY; VACCINE; PREDICTION; ANTI-PD-1; EPITOPES
AB Colorectal cancer (CRC) has become one of the most common tumours with high morbidity, mortality and distinctive evolution mechanism. The neoantigens arising from the somatic mutations have become considerable treatment targets in the management of CRC. As cancer-specific aberrant peptides, neoantigens can trigger the robust host immune response and exert anti-tumour effects while minimising the emergence of adverse events commonly associated with alternative therapeutic regimens. In this review, we summarised the mechanism, generation, identification and prognostic significance of neoantigens, as well as therapeutic strategies challenges of neoantigen-based therapy in CRC. The evidence suggests that the establishment of personalised neoantigen-based therapy holds great promise as an effective treatment approach for patients with CRC.
   Critical Points:Peptide vaccine and neoantigens pulsed DC can trigger a robust antitumor immune response with less emergence of adverse events than other therapeutic regimens.DNA vaccine can spontaneously induce T cell response against tumor and inhibit tumor growth with low cost.mRNA vaccines have been shown to safely induce neoantigen-specific T-cell responses without MHC haplotype restriction.Personalized immunotherapy based on neoantigens will be an effective treatments for patients with CRC.image
C1 [Zhu, Ya-Juan; Zhou, Yi-Xin; Mu, Xiao-Li; Du, Yang; Wang, Jia-Ling; Liu, Ji-Yan] Sichuan Univ, West China Hosp, Dept Biotherapy, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Zhu, Ya-Juan; Zhou, Yi-Xin; Mu, Xiao-Li; Du, Yang; Wang, Jia-Ling; Liu, Ji-Yan] Sichuan Univ, West China Hosp, Canc Ctr, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.
   [Li, Xiong] Xi An Jiao Tong Univ, Affiliated Hosp 2, Dept Gastroenterol, Xian, Peoples R China.
   [Chen, Ting-Ting] Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China.
   [Wang, Jia-Xiang] Peking Univ, Canc Hosp & Inst, Dept Renal Canc & Melanoma, Beijing, Peoples R China.
   [Tang, Jie] Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Xi'an Jiaotong University;
   Lanzhou University; Peking University; Sichuan University
RP Liu, JY (corresponding author), Sichuan Univ, West China Hosp, Dept Biotherapy, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.; Liu, JY (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, State Key Lab Biotherapy, Chengdu 610041, Peoples R China.; Tang, J (corresponding author), Sichuan Univ, West China Hosp, Clin Trial Ctr, Chengdu, Peoples R China.
EM cc300j@163.com; liujiyan1972@163.com
RI Wang, Jiaxiang/KHX-6982-2024
FU We thank Dr. Yang Shu from the West China hospital for his suggestions
   on the revision of our manuscript.
FX We thank Dr. Yang Shu from the West China hospital for his suggestions
   on the revision of our manuscript.
CR Abd-Aziz N, 2022, J ONCOL, V2022, DOI 10.1155/2022/9749363
   Abelin JG, 2017, IMMUNITY, V46, P315, DOI 10.1016/j.immuni.2017.02.007
   Abidi A, 2021, CANCERS, V13, DOI 10.3390/cancers13102345
   Ajina A, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0294-6
   Alspach E, 2019, NATURE, V574, P696, DOI 10.1038/s41586-019-1671-8
   Alzahrani SM, 2021, MOL CLIN ONCOL, V15, DOI 10.3892/mco.2021.2433
   Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828
   Anagnostou VK, 2015, CLIN CANCER RES, V21, P976, DOI 10.1158/1078-0432.CCR-14-1187
   Andini KD, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1127329
   Andreatta M, 2015, IMMUNOGENETICS, V67, P641, DOI 10.1007/s00251-015-0873-y
   Antunes DA, 2018, CURR TOP MED CHEM, V18, P2239, DOI 10.2174/1568026619666181224101744
   Awad MM, 2022, CANCER CELL, V40, P1010, DOI 10.1016/j.ccell.2022.08.003
   Bernal-Estévez D, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2625-2
   Bijker MS, 2007, J IMMUNOL, V179, P5033, DOI 10.4049/jimmunol.179.8.5033
   Biswas N, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1105420
   Bjerregaard AM, 2017, CANCER IMMUNOL IMMUN, V66, P1123, DOI 10.1007/s00262-017-2001-3
   Blass E, 2021, NAT REV CLIN ONCOL, V18, P215, DOI 10.1038/s41571-020-00460-2
   Bol KF, 2016, CLIN CANCER RES, V22, P1897, DOI 10.1158/1078-0432.CCR-15-1399
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Buckowitz A, 2005, BRIT J CANCER, V92, P1746, DOI 10.1038/sj.bjc.6602534
   Bulik-Sullivan B, 2019, NAT BIOTECHNOL, V37, P55, DOI 10.1038/nbt.4313
   Capietto AH, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231710131
   Carreno BM, 2015, SCIENCE, V348, P803, DOI 10.1126/science.aaa3828
   Chatani PD, 2020, CLIN CANCER RES, V26, P537, DOI 10.1158/1078-0432.CCR-19-2138
   Chen C, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2861240
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen R, 2021, MASS SPECTROM REV, V40, P110, DOI 10.1002/mas.21616
   Chen ZL, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.691605
   Choucair K, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5254
   Comber Joseph D, 2014, Ther Adv Vaccines, V2, P77, DOI 10.1177/2051013614525375
   Currais P, 2022, WORLD J GASTRO ONCOL, V14, P654, DOI 10.4251/wjgo.v14.i3.654
   De Mattos-Arruda L, 2020, ANN ONCOL, V31, P978, DOI 10.1016/j.annonc.2020.05.008
   Deng XY, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0428-0
   Donoghue MTA, 2020, NAT CANCER, V1, P774, DOI 10.1038/s43018-020-0100-0
   Esprit A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8040776
   Fan CM, 2019, CANCER SCI, V110, P2180, DOI 10.1111/cas.14034
   Fotakis G, 2021, Immunooncol Technol, V12, P100052, DOI 10.1016/j.iotech.2021.100052
   Freudenmann LK, 2018, IMMUNOLOGY, V154, P331, DOI 10.1111/imm.12936
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gao L, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10081272
   Gopanenko AV, 2020, CANCERS, V12, DOI 10.3390/cancers12102879
   Hambach L, 2010, J IMMUNOL, V185, P4582, DOI 10.4049/jimmunol.1000213
   Heide T, 2022, NATURE, V611, P733, DOI 10.1038/s41586-022-05202-1
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Hopkins AC, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.122092
   Hsiue EHC, 2021, SCIENCE, V371, P1009, DOI 10.1126/science.abc8697
   Hu ZT, 2021, NAT MED, V27, P515, DOI 10.1038/s41591-020-01206-4
   Huang KCY, 2023, CANCER IMMUNOL RES, V11, P123, DOI 10.1158/2326-6066.CIR-22-0318
   Hundal J, 2020, CANCER IMMUNOL RES, V8, P409, DOI 10.1158/2326-6066.CIR-19-0401
   Imyanitov E, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232113129
   Jhunjhunwala S, 2021, NAT REV CANCER, V21, P298, DOI 10.1038/s41568-021-00339-z
   Jia WQ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.942235
   Jiang T, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0787-5
   Jin K, 2019, CELL MOL LIFE SCI, V76, P4275, DOI 10.1007/s00018-019-03222-1
   Jin ZH, 2022, J CLIN ONCOL, V40, P2735, DOI 10.1200/JCO.21.02691
   Johanns TM, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561106
   Jou J, 2021, CLIN CANCER RES, V27, P689, DOI 10.1158/1078-0432.CCR-20-0245
   Keshavarz-Fathi M, 2021, ARCH IMMUNOL THER EX, V69, DOI 10.1007/s00005-021-00604-x
   Kirchmair A, 2020, METHODS MOL BIOL, V2120, P129, DOI 10.1007/978-1-0716-0327-7_9
   Klebanoff CA, 2022, CANCER IMMUNOL RES, V10, P919, DOI 10.1158/2326-6066.CIR-22-0386
   Kloor M, 2020, CLIN CANCER RES, V26, P4503, DOI 10.1158/1078-0432.CCR-19-3517
   Kodysh J, 2020, METHODS MOL BIOL, V2120, P147, DOI 10.1007/978-1-0716-0327-7_10
   Kotani D, 2022, LANCET ONCOL, V23, P463, DOI 10.1016/S1470-2045(22)00142-5
   Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426
   Kye Y, 2022, CANCERS, V14, DOI 10.3390/cancers14174255
   Lam H, 2021, CANCER DISCOV, V11, P696, DOI 10.1158/2159-8290.CD-20-0377
   Lanzarotti E, 2018, MOL IMMUNOL, V94, P91, DOI 10.1016/j.molimm.2017.12.019
   Li FS, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14091809
   Liepe J, 2019, CANCER IMMUNOL RES, V7, P62, DOI 10.1158/2326-6066.CIR-18-0424
   Liu JJ, 2020, ASIAN J PHARM SCI, V15, P576, DOI 10.1016/j.ajps.2019.10.006
   Liu QF, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01735-9
   Liu S, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0629-6
   Liu ZL, 2020, CELL, V183, P1117, DOI 10.1016/j.cell.2020.09.048
   Lopes A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1154-7
   Low L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13305-z
   Lundegaard C, 2012, EXPERT REV VACCINES, V11, P43, DOI [10.1586/erv.11.160, 10.1586/ERV.11.160]
   Maby P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1115943
   Malekshahi ZV, 2019, IRAN J IMMUNOL, V16, P235, DOI [10.22034/iji.2019.80274, 10.22034/IJI.2019.80274]
   Malekzadeh P, 2019, J CLIN INVEST, V129, P1109, DOI 10.1172/JCI123791
   Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447
   Maruggi G, 2019, MOL THER, V27, P757, DOI 10.1016/j.ymthe.2019.01.020
   McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490
   Miller MS, 2019, J BIOL CHEM, V294, P19322, DOI 10.1074/jbc.RA119.010251
   Morano F, 2022, J CLIN ONCOL, V40, P1562, DOI 10.1200/JCO.21.02583
   Newey A, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0769-8
   Okada M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23052594
   Oliveira G, 2022, NATURE, V605, P532, DOI 10.1038/s41586-022-04682-5
   Oliveira G, 2021, NATURE, V596, P119, DOI 10.1038/s41586-021-03704-y
   Olsen HE, 2021, NEURO-ONCOL ADV, V3, DOI 10.1093/noajnl/vdab027
   Ott PA, 2020, CELL, V183, P347, DOI 10.1016/j.cell.2020.08.053
   Ott PA, 2017, NATURE, V547, P217, DOI 10.1038/nature22991
   Palmer CD, 2022, NAT MED, V28, P1619, DOI 10.1038/s41591-022-01937-6
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272
   Pastor DM, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912-021-01085-z
   Pearlman AH, 2021, NAT CANCER, V2, P487, DOI 10.1038/s43018-021-00210-y
   Pei BK, 2020, IMMUNOGENETICS, V72, P295, DOI 10.1007/s00251-020-01163-9
   Perez SA, 2010, CANCER-AM CANCER SOC, V116, P2071, DOI 10.1002/cncr.24988
   Pfuderer PL, 2019, BRIT J CANCER, V121, P395, DOI 10.1038/s41416-019-0514-6
   Picard E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00369
   Pilla L, 2020, CANCERS, V12, DOI 10.3390/cancers12113456
   Poran A, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100141
   Prickett TD, 2016, CANCER IMMUNOL RES, V4, P669, DOI 10.1158/2326-6066.CIR-15-0215
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Pyke R.M., 2021, Mol. Cell. Proteomics, V20
   Raeker Maide O, 2020, J Cancer Immunol (Wilmington), V2, P116, DOI 10.33696/cancerimmunol.2.024
   Randrian V, 2021, CANCERS, V13, DOI 10.3390/cancers13123063
   Reynisson B, 2020, J PROTEOME RES, V19, P2304, DOI 10.1021/acs.jproteome.9b00874
   Richters MM, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0666-2
   Riley TP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02047
   Rock KL, 2016, TRENDS IMMUNOL, V37, P724, DOI 10.1016/j.it.2016.08.010
   Roesner LM, 2014, INT J MOL SCI, V15, P13932, DOI 10.3390/ijms150813932
   Rong L, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02349-7
   Rosenberg SA, 2004, NAT MED, V10, P909, DOI 10.1038/nm1100
   Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112
   Sahin U, 2017, NATURE, V547, P222, DOI 10.1038/nature23003
   Sanghera C, 2019, CUREUS J MED SCIENCE, V11, DOI 10.7759/cureus.5938
   Sato V, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.121062
   Sawayama H, 2020, ANN GASTROENT SURG, V4, P528, DOI 10.1002/ags3.12362
   Saxena M, 2021, NAT REV CANCER, V21, P360, DOI 10.1038/s41568-021-00346-0
   Schoenberger SP, 1998, NATURE, V393, P480, DOI 10.1038/31002
   Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971
   Singh A, 2022, NEUROGASTROENT MOTIL, V34, DOI 10.1111/nmo.14099
   Skora AD, 2015, P NATL ACAD SCI USA, V112, P9967, DOI 10.1073/pnas.1511996112
   Slingluff CL, 2011, CANCER J, V17, P343, DOI 10.1097/PPO.0b013e318233e5b2
   Song YL, 2022, INT IMMUNOPHARMACOL, V112, DOI 10.1016/j.intimp.2022.109236
   Tang YY, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0825-x
   Tondini E, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1652539
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102
   Ulreich K, 2022, CANCERS, V14, DOI 10.3390/cancers14061553
   Valenzuela G, 2021, WORLD J CLIN ONCOL, V12, P1000, DOI 10.5306/wjco.v12.i11.1000
   van der Burg SH, 2006, ADV DRUG DELIVER REV, V58, P916, DOI 10.1016/j.addr.2005.11.003
   van Rooij N, 2013, J CLIN ONCOL, V31, pE439, DOI 10.1200/JCO.2012.47.7521
   Vergati M, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/596432
   Vigneron N, 2019, MOL IMMUNOL, V113, P93, DOI 10.1016/j.molimm.2018.03.030
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wagner S, 2018, WORLD J GASTROENTERO, V24, P5418, DOI 10.3748/wjg.v24.i48.5418
   Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648
   Wang TY, 2019, BIOINFORMATICS, V35, P4159, DOI 10.1093/bioinformatics/btz193
   Wang Xiupeng, 2016, Adv Healthc Mater, V5, P1246, DOI 10.1002/adhm.201670051
   Wedén S, 2011, INT J CANCER, V128, P1120, DOI 10.1002/ijc.25449
   Wei F, 2018, BRIT J CANCER, V118, P233, DOI 10.1038/bjc.2017.385
   Wei SX, 2022, FRONT GENET, V13, DOI 10.3389/fgene.2022.1068112
   Wen J, 2021, INT J BIOL SCI, V17, P3923, DOI 10.7150/ijbs.64953
   Westcott PMK, 2021, NAT CANCER, V2, P1071, DOI 10.1038/s43018-021-00247-z
   Woller N, 2015, MOL THER, V23, P1630, DOI 10.1038/mt.2015.115
   Wu WT, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01166-3
   Wu YF, 2019, J CANCER, V10, P2185, DOI 10.7150/jca.30222
   Xia MF, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0289-8
   Xie GZ, 2021, NAT BIOMED ENG, V5, P399, DOI 10.1038/s41551-020-00625-5
   Xie N, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392-022-01270-x
   Yadav M, 2014, NATURE, V515, P572, DOI 10.1038/nature14001
   Yu YJ, 2022, HUM VACC IMMUNOTHER, V18, P1, DOI 10.1080/21645515.2021.1891814
   Zander R, 2019, IMMUNITY, V51, P1028, DOI 10.1016/j.immuni.2019.10.009
   Zhang B, 2007, J EXP MED, V204, P49, DOI 10.1084/jem.20062056
   Zhang Q, 2022, CHINESE MED J-PEKING, V135, P1285, DOI 10.1097/CM9.0000000000002181
   Zhang R, 2020, CANCER IMMUNOL IMMUN, V69, P135, DOI 10.1007/s00262-019-02448-z
   Zhang Y, 2021, J INFLAMM RES, V14, P5403, DOI 10.2147/JIR.S331010
   Zhang ZY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.672356
   Zhao X, 2021, BIOMARK RES, V9, DOI 10.1186/s40364-021-00315-7
   Zhao ZM, 2020, CANCER LETT, V485, P14, DOI 10.1016/j.canlet.2020.04.013
   Zheng Y, 2022, DIS MARKERS, V2022, DOI 10.1155/2022/8270305
   Zhou C, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0679-x
   Zhou Z, 2017, ROY SOC OPEN SCI, V4, DOI 10.1098/rsos.170050
NR 168
TC 7
Z9 7
U1 9
U2 15
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001-1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD NOV
PY 2023
VL 13
IS 11
AR e1461
DI 10.1002/ctm2.1461
PG 21
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA W5UI5
UT WOS:001092272300001
PM 37921274
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Wu, CWK
   Reid, M
   Leedham, S
   Lui, RN
AF Wu, Claudia W. K.
   Reid, Madeleine
   Leedham, Simon
   Lui, Rashid N.
TI The emerging era of personalized medicine in advanced colorectal cancer
SO JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY
LA English
DT Review
DE chemotherapy; colorectal cancer; immune checkpoint inhibition;
   personalized medicine; signaling pathway; targeted therapy; tumor
   microenvironment; precision oncology
ID GROWTH-FACTOR RECEPTOR; IMMUNE CHECKPOINT INHIBITORS; INTESTINAL
   STEM-CELLS; BRAF MUTATION STATUS; R-SPONDIN FUSIONS; TGF-BETA;
   MICROSATELLITE INSTABILITY; PHASE-I; TUMOR MICROENVIRONMENT; RANDOMIZED
   PHASE-3
AB Colorectal cancer (CRC) is a genetically heterogeneous disease with its pathogenesis often driven by varying genetic or epigenetic alterations. This has led to a substantial number of patients developing chemoresistance and treatment failure, resulting in a high mortality rate for advanced disease. Deep molecular analysis has allowed for the discovery of key intestinal signaling pathways which impacts colonic epithelial cell fate, and the integral role of the tumor microenvironment on cancer growth and dissemination. Through transitioning pre-clinical knowledge in research into clinical practice, many potential druggable targets within these pathways have been discovered in the hopes of overcoming the roadblocks encountered by conventional therapies. A personalized approach tailoring treatment according to the histopathological and molecular features of individual tumors can hopefully translate to better patient outcomes, and reduce the rate of recurrence in patients with advanced CRC. Herein, the latest understanding on the molecular science behind CRC tumorigenesis, and the potential treatment targets currently at the forefront of research are summarized.
C1 [Wu, Claudia W. K.; Lui, Rashid N.] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China.
   [Lui, Rashid N.] Chinese Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Wu, Claudia W. K.; Lui, Rashid N.] Prince Wales Hosp, Dept Med & Therapeut, Div Gastroenterol & Hepatol, Hong Kong, Peoples R China.
   [Reid, Madeleine; Leedham, Simon] Univ Oxford, John Radcliffe Hosp, Translat Gastroenterol Unit, Oxford, England.
   [Reid, Madeleine; Leedham, Simon] Univ Oxford, Wellcome Ctr Human Genet, Nuffield Dept Med, Oxford, England.
C3 Chinese University of Hong Kong; Chinese University of Hong Kong;
   Chinese University of Hong Kong; Prince of Wales Hospital; University of
   Oxford; University of Oxford; Wellcome Centre for Human Genetics
RP Lui, RN (corresponding author), Prince Wales Hosp, Dept Med & Therapeut, Div Gastroenterol & Hepatol, Shatin, Hong Kong, Peoples R China.
EM rashidlui@cuhk.edu.hk
OI Leedham, Simon/0000-0003-1476-6982; Wu, Claudia/0000-0003-1401-0173;
   Reid, Madeleine/0009-0006-4715-6346
FU Wellcome Trust Senior Clinical Research Fellowship [206314/Z/17/Z]
FX This work is supported by a Wellcome Trust Senior Clinical Research
   Fellowship (206314/Z/17/Z) to SL.
CR Abdulla MH, 2021, MOL CLIN ONCOL, V15, DOI 10.3892/mco.2021.2413
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   [Anonymous], CANC COL RECT CANC S
   Aretz S, 2007, J MED GENET, V44, P702, DOI 10.1136/jmg.2007.052506
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025
   Atreya CE, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.103
   Bai XG, 2019, ONCOTARGETS THER, V12, P9527, DOI 10.2147/OTT.S224013
   Basu Sayon, 2016, F1000Res, V5, DOI 10.12688/f1000research.7579.1
   Battaglin F, 2018, EXPERT REV ANTICANC, V18, P251, DOI 10.1080/14737140.2018.1428092
   Beech J, 2018, FUTURE ONCOL, V14, P2531, DOI 10.2217/fon-2018-0187
   Belardinilli F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00560
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Beumer J, 2022, CELL REP, V38, DOI 10.1016/j.celrep.2022.110438
   Beumer J, 2016, DEVELOPMENT, V143, P3639, DOI 10.1242/dev.133132
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Blaukat A, 1999, J BIOL CHEM, V274, P14893, DOI 10.1074/jbc.274.21.14893
   Boasberg PD, 2011, CANCER CHEMOTH PHARM, V68, P547, DOI 10.1007/s00280-011-1620-1
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Bui QL, 2022, CANCERS, V14, DOI 10.3390/cancers14020406
   Buikhuisen JY, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00250-6
   Cai WQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01249
   Cain RJ, 2009, BIOL CELL, V101, P13, DOI 10.1042/BC20080079
   Calon A, 2014, SEMIN CANCER BIOL, V25, P15, DOI 10.1016/j.semcancer.2013.12.008
   Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Carvajal-Carmona LG, 2018, BRIT J CANCER, V119, P913, DOI 10.1038/s41416-018-0219-2
   Chen GQ, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00135
   Chiavarina B, 2021, THERANOSTICS, V11, P1626, DOI 10.7150/thno.51507
   Ciombor KK, 2013, CLIN CANCER RES, V19, P1920, DOI 10.1158/1078-0432.CCR-12-2911
   Cohen R, 2021, J CLIN ONCOL, V39, P642, DOI 10.1200/JCO.20.01600
   Cohen R, 2020, TARGET ONCOL, V15, P11, DOI 10.1007/s11523-019-00690-0
   Cohen R, 2019, JAMA ONCOL, V5, P551, DOI 10.1001/jamaoncol.2018.4942
   Cook N, 2021, ANN ONCOL, V32, pS586, DOI 10.1016/j.annonc.2021.08.1039
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Davis H, 2015, NAT MED, V21, P62, DOI 10.1038/nm.3750
   Degirmenci B, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.103369
   Dienstmann Rodrigo, 2015, Am Soc Clin Oncol Educ Book, pe149, DOI 10.14694/EdBook_AM.2015.35.e149
   Elemam NM, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10020301
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Endo E, 2020, MOL CANCER RES, V18, P1402, DOI 10.1158/1541-7786.MCR-20-0308
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Farran B, 2019, CYTOKINE GROWTH F R, V48, P11, DOI 10.1016/j.cytogfr.2019.07.001
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Fischer MM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15704-y
   Foley TM, 2017, MOL CANCER RES, V15, P317, DOI [10.1158/1541-7786.MCR-16-0256-T, 10.1158/1541-7786.MCR-16-0256]
   FOLKMAN J, 1972, ANN SURG, V175, P409, DOI 10.1097/00000658-197203000-00014
   Franke TF, 2003, ONCOGENE, V22, P8983, DOI 10.1038/sj.onc.1207115
   Fujita S, 2018, BONE, V106, P156, DOI 10.1016/j.bone.2017.10.017
   Gacche RN, 2014, BBA-REV CANCER, V1846, P161, DOI 10.1016/j.bbcan.2014.05.002
   Gay DM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08586-3
   Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127
   Glimelius B, 2021, CANCER TREAT REV, V98, DOI 10.1016/j.ctrv.2021.102218
   Gong S, 2018, CELL PHYSIOL BIOCHEM, V47, P680, DOI 10.1159/000490022
   Gough NR, 2021, GASTROENTEROLOGY, V161, P434, DOI 10.1053/j.gastro.2021.04.064
   Grady WM, 2015, DIGEST DIS SCI, V60, P762, DOI 10.1007/s10620-014-3444-4
   Grassi E, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.601722
   Grauel AL, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19920-5
   Grimaldi AM, 2017, AM J CLIN DERMATOL, V18, P745, DOI 10.1007/s40257-017-0292-y
   Grothey A, 2020, NEW ENGL J MED, V383, P2283, DOI 10.1056/NEJMe2031294
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo X, 2009, CELL RES, V19, P71, DOI 10.1038/cr.2008.302
   Han J, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-020-01025-7
   Harmey JH, 2002, BIOESSAYS, V24, P280, DOI 10.1002/bies.10043
   He KF, 2012, ONCOTARGETS THER, V5, P59, DOI 10.2147/OTT.S29719
   He XC, 2004, NAT GENET, V36, P1117, DOI 10.1038/ng1430
   Hemmings BA, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011189
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Innocenti F, 2019, J CLIN ONCOL, V37, P1217, DOI 10.1200/JCO.18.01798
   Ishiguro K, 2006, GUT, V55, P695, DOI 10.1136/gut.2005.079459
   Itatani Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235822
   Jaeger E, 2012, NAT GENET, V44, P699, DOI 10.1038/ng.2263
   Jimeno A, 2017, CLIN CANCER RES, V23, P7490, DOI 10.1158/1078-0432.CCR-17-2157
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Ju M, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020618
   Jung A, 2001, AM J PATHOL, V159, P1613, DOI 10.1016/S0002-9440(10)63007-6
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Jurisic V, 2018, ANAL CELL PATHOL, V2018, DOI 10.1155/2018/6192187
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Kakar S, 2004, MODERN PATHOL, V17, P696, DOI 10.1038/modpathol.3800093
   Kaps L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092027
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kawazoe A, 2020, CANCER CHEMOTH PHARM, V85, P855, DOI 10.1007/s00280-020-04059-3
   Kazemi M, 2016, CANCER GENE THER, V23, P125, DOI 10.1038/cgt.2016.12
   Keating GM, 2010, DRUGS, V70, P1059, DOI 10.2165/11205090-000000000-00000
   KIM KJ, 1993, NATURE, V362, P841, DOI 10.1038/362841a0
   Kim TW, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3573
   Kleeman SO, 2020, CANCERS, V12, DOI 10.3390/cancers12113355
   Kleeman SO, 2020, GUT, V69, P1092, DOI 10.1136/gutjnl-2019-319126
   Kobayashi H, 2021, GASTROENTEROLOGY, V160, P1224, DOI 10.1053/j.gastro.2020.11.011
   Komiya Yuko, 2008, Organogenesis, V4, P68
   Kosinski C, 2007, P NATL ACAD SCI USA, V104, P15418, DOI 10.1073/pnas.0707210104
   Krasinskas Alyssa M, 2011, Patholog Res Int, V2011, P932932, DOI 10.4061/2011/932932
   Lai E, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.637823
   Latham A, 2019, J CLIN ONCOL, V37, P286, DOI 10.1200/JCO.18.00283
   Lawler M, 2018, GUT, V67, P179, DOI 10.1136/gutjnl-2017-315333
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Lee JJX, 2015, CANCER BIOL MED, V12, P342, DOI 10.7497/j.issn.2095-3941.2015.0089
   Lee SY, 2017, MOL CANCER, V16, DOI 10.1186/s12943-016-0577-4
   Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471
   Li NN, 2019, ONCOGENESIS, V8, DOI 10.1038/s41389-019-0125-3
   Li QH, 2020, GASTROENTEROL REP, V8, P179, DOI 10.1093/gastro/goaa026
   Li YQ, 2020, PROTEIN CELL, V11, P292, DOI 10.1007/s13238-020-00691-0
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Lorente-Trigos A, 2010, J MOL CELL BIOL, V2, P318, DOI 10.1093/jmcb/mjq035
   LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415
   Macarulla T, 2020, EXPERT OPIN BIOL TH, V20, P15, DOI 10.1080/14712598.2020.1677603
   Madan B, 2018, BONE RES, V6, DOI 10.1038/s41413-018-0017-8
   Mah AT, 2016, J PHYSIOL-LONDON, V594, P4837, DOI 10.1113/JP271754
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Mehta S, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.714746
   Miguel JC, 2017, J CELL SCI, V130, P90, DOI 10.1242/jcs.182584
   Mitsudomi T, 2010, FEBS J, V277, P301, DOI 10.1111/j.1742-4658.2009.07448.x
   Miyazono K, 2005, CYTOKINE GROWTH F R, V16, P251, DOI 10.1016/j.cytogfr.2005.01.009
   Mizukami T, 2019, DRUGS, V79, P633, DOI 10.1007/s40265-019-01113-0
   Moore KN, 2019, GYNECOL ONCOL, V154, P294, DOI 10.1016/j.ygyno.2019.04.001
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Mukai T, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020195
   Nasir A, 2016, ANTICANCER RES, V36, P2683
   Nautiyal J, 2010, CURR PROTEIN PEPT SC, V11, P436, DOI 10.2174/138920310791824110
   Neckmann U, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0467-7
   O'Bryan JP, 1998, J BIOL CHEM, V273, P20431, DOI 10.1074/jbc.273.32.20431
   Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014
   Oden-Gangloff A, 2009, BRIT J CANCER, V100, P1330, DOI 10.1038/sj.bjc.6605008
   Overman Michael J, 2018, Am Soc Clin Oncol Educ Book, V38, P239, DOI 10.1200/EDBK_200821
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pavlidis ET, 2013, WORLD J GASTROENTERO, V19, P5051, DOI 10.3748/wjg.v19.i31.5051
   Pawlik TM, 2004, DIS MARKERS, V20, P199, DOI 10.1155/2004/368680
   Pearson G, 2001, ENDOCR REV, V22, P153, DOI 10.1210/er.22.2.153
   Peddareddigari VG, 2010, CANCER MICROENVIRON, V3, P149, DOI 10.1007/s12307-010-0038-3
   Peeters M, 2014, ANN ONCOL, V25, P107, DOI 10.1093/annonc/mdt523
   Perochon J, 2018, GENES-BASEL, V9, DOI 10.3390/genes9030138
   Picard E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00369
   Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603
   Pietrantonio F, 2015, CRIT REV ONCOL HEMAT, V96, P156, DOI 10.1016/j.critrevonc.2015.05.016
   Porta C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00064
   Principe DR, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt369
   Putoczki TL, 2013, CANCER CELL, V24, P257, DOI 10.1016/j.ccr.2013.06.017
   Radtke F, 2005, SCIENCE, V307, P1904, DOI 10.1126/science.1104815
   Rasmussen ML, 2018, GENES-BASEL, V9, DOI 10.3390/genes9020109
   Reita D, 2019, CANCERS, V11, DOI 10.3390/cancers11101581
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Rodon J, 2021, BRIT J CANCER, V125, P28, DOI 10.1038/s41416-021-01389-8
   Ruan XS, 2015, J MOL CELL BIOL, V7, P105, DOI 10.1093/jmcb/mjv015
   Ruff P, 2018, J GERIATR ONCOL, V9, P32, DOI 10.1016/j.jgo.2017.07.010
   Sahin IH, 2019, BRIT J CANCER, V121, P809, DOI 10.1038/s41416-019-0599-y
   Salvatore L, 2019, CANCERS, V11, DOI 10.3390/cancers11111765
   Santos AJM, 2018, TRENDS CELL BIOL, V28, P1062, DOI 10.1016/j.tcb.2018.08.001
   Schatoff EM, 2017, CURR COLORECT CANC R, V13, P101, DOI 10.1007/s11888-017-0354-9
   Schrock AB, 2019, ANN ONCOL, V30, P1096, DOI 10.1093/annonc/mdz134
   Schunk SJ, 2021, NAT REV NEPHROL, V17, P172, DOI 10.1038/s41581-020-00343-w
   Scoville DH, 2008, GASTROENTEROLOGY, V134, P849, DOI 10.1053/j.gastro.2008.01.079
   Seeber A, 2022, CLIN CANCER RES, V28, P1863, DOI 10.1158/1078-0432.CCR-21-3018
   Sekine S, 2016, J PATHOL, V239, P133, DOI 10.1002/path.4709
   Seppälä TT, 2015, BRIT J CANCER, V112, P1966, DOI 10.1038/bjc.2015.160
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shah K, 2021, PHARMACOL RES, V167, DOI 10.1016/j.phrs.2021.105532
   Shaw Holly V, 2019, Swiss Med Wkly, V149, pw20129, DOI 10.4414/smw.2019.20129
   Sidorkiewicz I, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5558-8
   Silvestris N, 2009, ONCOLOGY-BASEL, V77, P69, DOI 10.1159/000258498
   Sin-Aye Park, 2018, [Biomedical Science Letters, 대한의생명과학회지], V24, P285, DOI 10.15616/BSL.2018.24.4.285
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Sow HS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8040320
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Strosberg JR, 2012, EUR J CANCER, V48, P997, DOI 10.1016/j.ejca.2012.02.056
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Takeda H, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.602194
   Tariq K, 2016, CANCER BIOL MED, V13, P120, DOI 10.28092/j.issn.2095-3941.2015.0103
   Tauriello DVF, 2022, NAT REV CANCER, V22, P25, DOI 10.1038/s41568-021-00413-6
   Tauriello DVF, 2017, MOL ONCOL, V11, P97, DOI 10.1002/1878-0261.12018
   Tay RY, 2015, CANCER MANAG RES, V7, P189, DOI 10.2147/CMAR.S71821
   ter Steege EJ, 2021, ONCOGENE, V40, P6469, DOI 10.1038/s41388-021-02059-y
   Thanki Ketan, 2017, Int Biol Biomed J, V3, P105
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Tomlinson I, 2015, ANN CLIN BIOCHEM, V52, P690, DOI 10.1177/0004563215597944
   Tougeron D, 2020, INT J CANCER, V147, P285, DOI 10.1002/ijc.32879
   van Cruijsen H, 2005, INT J CANCER, V117, P883, DOI 10.1002/ijc.21479
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   van der Heijden M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0962-x
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   van Herwaarden YJ, 2021, HISTOPATHOLOGY, V78, P749, DOI 10.1111/his.14286
   Vanpouille-Box C, 2015, CANCER RES, V75, P2232, DOI 10.1158/0008-5472.CAN-14-3511
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Wang RN, 2014, GENES DIS, V1, P87, DOI 10.1016/j.gendis.2014.07.005
   Wieduwilt MJ, 2008, CELL MOL LIFE SCI, V65, P1566, DOI 10.1007/s00018-008-7440-8
   Wong MCS, 2019, INTEST RES, V17, P317, DOI 10.5217/ir.2019.00021
   Yamada T, 2020, INT J CLIN ONCOL, V25, P1523, DOI 10.1007/s10147-020-01691-0
   Yan YF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.799772
   Ye J, 2020, BIOMED REP, V13, P43, DOI 10.3892/br.2020.1303
   Yu FY, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00701-5
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012
   Zhao PF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0738-1
   Zhao Y, 2017, ONCOL REP, V38, P3055, DOI 10.3892/or.2017.5955
   Zhao Z, 2018, J CANCER, V9, P3407, DOI 10.7150/jca.24201
   Zhong LH, 2020, NEOPLASIA, V22, P365, DOI 10.1016/j.neo.2020.06.001
   Zhong Y, 2016, TOXICOL PATHOL, V44, P267, DOI 10.1177/0192623315621192
   Zhou Y, 2019, CURR PROTEIN PEPT SC, V20, P829, DOI 10.2174/1389203720666190507094441
NR 205
TC 7
Z9 8
U1 1
U2 9
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0815-9319
EI 1440-1746
J9 J GASTROEN HEPATOL
JI J. Gastroenterol. Hepatol.
PD AUG
PY 2022
VL 37
IS 8
SI SI
BP 1411
EP 1425
DI 10.1111/jgh.15937
EA JUL 2022
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 3M4QE
UT WOS:000827889600001
PM 35815339
DA 2025-01-04
ER

PT J
AU Tysarowski, A
   Nasierowska-Guttmejer, A
AF Tysarowski, Andrzej
   Nasierowska-Guttmejer, Anna
TI Quality and practical aspects of pathological and molecular diagnostics
   in metastatic colorectal cancer (mCRC)
SO WSPOLCZESNA ONKOLOGIA-CONTEMPORARY ONCOLOGY
LA English
DT Review
DE colorectal cancer; KRAS; NRAS; BRAF; diagnostic; mCRC
ID K-RAS GENE; EPIDERMAL-GROWTH-FACTOR; CELL-CYCLE; MUTATIONS; CODON-12;
   THERAPY; TISSUES
AB Colorectal cancer (CRC) is one of the most common malignancies worldwide. In recent years novel therapies targeted at EGFR receptor have been developed. However, this treatment can only be beneficial if no mutation in specific loci of KRAS/NRAS and BRAF genes is found in tumour specimen. Therefore, clinically useful pathological diagnosis of CRC in the era of personalised medicine is a multistep procedure, requiring good cooperation between the clinician/surgeon, pathomorphologist, and molecular biologist. Herein we propose the guidelines of colorectal cancer operating material proceedings for clinicians and pathomorphologists, which determines the correct pathomorphological diagnosis, and we discuss the colorectal cancer molecular biology issues useful in the selection of individual molecular targeted therapy. We discuss and stress the importance of each diagnostic phase: from tumour resection and sample collection at preanalytical stage, through proper pathological preparation, evaluation and selection of material for molecular testing, to molecular analysis and finally preparation of a pathological molecular report.
C1 [Tysarowski, Andrzej] Maria Sklodowska Curie Mem Canc Ctr, Dept Pathol & Lab Med, Warsaw, Poland.
   [Tysarowski, Andrzej] Inst Oncol, 5 Roentgena WK St, PL-02781 Warsaw, Poland.
   [Tysarowski, Andrzej] Maria Sklodowska Curie Mem Canc Ctr, Dept Mol & Translat Oncol, Warsaw, Poland.
   [Nasierowska-Guttmejer, Anna] Jan Kochanowski Univ Kielce, Dept Pathol, Kielce, Poland.
   [Nasierowska-Guttmejer, Anna] Cent Clin Hosp MSWiA Warsaw, Dept Pathol, Warsaw, Poland.
C3 Maria Sklodowska-Curie National Research Institute of Oncology; Maria
   Sklodowska-Curie National Research Institute of Oncology; Maria
   Sklodowska-Curie National Research Institute of Oncology; Jan
   Kochanowski University
RP Tysarowski, A (corresponding author), Inst Oncol, 5 Roentgena WK St, PL-02781 Warsaw, Poland.; Tysarowski, A (corresponding author), Maria Sklodowska Curie Mem Canc Ctr, Dept Mol & Translat Oncol, Warsaw, Poland.; Tysarowski, A (corresponding author), Maria Sklodowska Curie Mem Canc Ctr, Dept Pathol & Lab Med, Dept Mol & Translat Oncol, 5 Roentgena WK St, PL-02781 Warsaw, Poland.
EM a.tysarowski@coi.waw.pl
RI Tysarowski, Andrzej/AAM-7177-2021
OI Tysarowski, Andrzej/0000-0001-7726-490X; Nasierowska-Guttmejer,
   Anna/0000-0001-7182-5841
CR Amin MB, 2017, CA-CANCER J CLIN, V67, P93, DOI 10.3322/caac.21388
   [Anonymous], 2017, GENERAL REPORT
   Bartczak M, 2010, NOWOTWORY, V60, P147
   Bazan V, 2002, ANN ONCOL, V13, P1438, DOI 10.1093/annonc/mdf226
   Biocartis, ID SPEC
   BOS JL, 1989, CANCER RES, V49, P4682
   BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0
   Brierley JD., 2017, TNM CLASSIFICATION M
   CAPELLA G, 1991, ENVIRON HEALTH PERSP, V93, P125, DOI 10.2307/3431180
   Chen GL, 2016, BIOMED RES INT-UK, V2016, DOI 10.1155/2016/9850690
   Cree IA, 2014, J CLIN PATHOL, V67, P923, DOI 10.1136/jclinpath-2014-202404
   Crespo P, 2000, CELL MOL LIFE SCI, V57, P1613, DOI 10.1007/PL00000645
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Didkowska J, 2015, KRAJOWY REJESTR NOWO, P48
   Downward J, 1998, CURR OPIN GENET DEV, V8, P49, DOI 10.1016/S0959-437X(98)80061-0
   Ellis CA, 2000, CELL SIGNAL, V12, P425, DOI 10.1016/S0898-6568(00)00084-X
   Garnett MJ, 2004, CANCER CELL, V6, P313, DOI 10.1016/j.ccr.2004.09.022
   GROSS ME, 1991, CANCER RES, V51, P1452
   Gulley ML, 2007, ARCH PATHOL LAB MED, V131, P852
   Jessup JM, AJCC CANC STAGING MA, P251
   Kluftinger A M, 1992, Surg Oncol, V1, P97, DOI 10.1016/0960-7404(92)90062-P
   Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221
   Linardou H, 2011, CANCER TREAT REV, V37, P221, DOI 10.1016/j.ctrv.2010.07.008
   Macaluso M, 2002, J CELL PHYSIOL, V192, P125, DOI 10.1002/jcp.10109
   Messa C, 1998, ACTA ONCOL, V37, P285, DOI 10.1080/028418698429595
   National Comprehensive Cancer Network (NCCN), 2016, COL CANC VERS 2
   Plowman SJ, 2006, J EXP CLIN CANC RES, V25, P259
   RADINSKY R, 1995, CLIN CANCER RES, V1, P19
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Senagore AJ, 1997, SURGERY, V122, P765, DOI 10.1016/S0039-6060(97)90085-4
   Sepulveda AR, 2017, J MOL DIAGN, V19, P187, DOI 10.1016/j.jmoldx.2016.11.001
   Shackelford Rodney E, 2012, Genes Cancer, V3, P459, DOI 10.1177/1947601912460547
   Sluijter CE, 2016, VIRCHOWS ARCH, V468, P639, DOI 10.1007/s00428-016-1935-8
   Tysarowski A, 2008, ONCOL CLIN PRACT, V4, P232
   van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y
   Vidal J, 2017, ANN ONCOL, V28, P1325, DOI 10.1093/annonc/mdx125
   Wang Y, 2001, EXP LUNG RES, V27, P255, DOI 10.1080/019021401300054028
   Wojtukiewicz MZ, 2007, ONCOL CLIN PRACT, V3, P286
NR 40
TC 3
Z9 3
U1 0
U2 2
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA 2, POZNAN, 61-615, POLAND
SN 1428-2526
EI 1897-4309
J9 WSPOLCZESNA ONKOL
JI Wspolczesna Onkol.
PY 2018
VL 22
IS 2
BP 75
EP 85
DI 10.5114/wo.2018.77047
PG 11
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA GN5CY
UT WOS:000439064100002
PM 30150883
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Liskova, A
   Samec, M
   Koklesova, L
   Brockmueller, A
   Zhai, K
   Abdellatif, B
   Siddiqui, M
   Biringer, K
   Kudela, E
   Pec, M
   Gadanec, LK
   Sudomová, M
   Hassan, STS
   Zulli, A
   Shakibaei, M
   Giordano, FA
   Büsselberg, D
   Golubnitschaja, O
   Kubatka, P
AF Liskova, Alena
   Samec, Marek
   Koklesova, Lenka
   Brockmueller, Aranka
   Zhai, Kevin
   Abdellatif, Basma
   Siddiqui, Manaal
   Biringer, Kamil
   Kudela, Erik
   Pec, Martin
   Gadanec, Laura Kate
   Sudomova, Miroslava
   Hassan, Sherif T. S.
   Zulli, Anthony
   Shakibaei, Mehdi
   Giordano, Frank A.
   Busselberg, Dietrich
   Golubnitschaja, Olga
   Kubatka, Peter
TI Flavonoids as an effective sensitizer for anti-cancer therapy: insights
   into multi-faceted mechanisms and applicability towards individualized
   patient profiles
SO EPMA JOURNAL
LA English
DT Review
DE Predictive preventive personalized medicine (3PM; PPPM); Phytochemicals;
   Flavonoids; Flavanones; Flavonols; Flavones; Flavanols; Isoflavonoids;
   Chalcones; Anthocyanidins; Anti-cancer agents; Drug-sensitizing effect;
   Targeted therapy; Radiotherapy; Chemotherapy; Immunotherapy; Therapy
   resistance; Anti-inflammation; Anti-bacterial; Anti-viral; COVID-19;
   Signalling pathways; Therapy efficacy; Nano-carrier delivery; Disease
   management; Health economy; Health policy
ID COLON-CANCER CELLS; DNA-DAMAGE REPAIR; HUMAN LUNG-CANCER; BREAST-CANCER;
   PROSTATE-CANCER; IN-VIVO; HEPATOCELLULAR-CARCINOMA;
   MOLECULAR-MECHANISMS; TARGETED THERAPIES; DRUG-RESISTANCE
AB Cost-efficacy of currently applied treatments is an issue in overall cancer management challenging healthcare and causing tremendous economic burden to societies around the world. Consequently, complex treatment models presenting concepts of predictive diagnostics followed by targeted prevention and treatments tailored to the personal patient profiles earn global appreciation as benefiting the patient, healthcare economy, and the society at large. In this context, application of flavonoids as a spectrum of compounds and their nano-technologically created derivatives is extensively under consideration, due to their multi-faceted anti-cancer effects applicable to the overall cost-effective cancer management, primary, secondary, and even tertiary prevention. This article analyzes most recently updated data focused on the potent capacity of flavonoids to promote anti-cancer therapeutic effects and interprets all the collected research achievements in the frame-work of predictive, preventive, and personalized (3P) medicine. Main pillars considered are: - Predictable anti-neoplastic, immune-modulating, drug-sensitizing effects; - Targeted molecular pathways to improve therapeutic outcomes by increasing sensitivity of cancer cells and reversing their resistance towards currently applied therapeutic modalities.
C1 [Liskova, Alena; Samec, Marek; Koklesova, Lenka; Biringer, Kamil; Kudela, Erik] Comenius Univ, Jessenius Fac Med, Dept Obstet & Gynecol, Martin 03601, Slovakia.
   [Brockmueller, Aranka; Shakibaei, Mehdi] Ludwig Maximilian Univ Munich, Fac Med, Inst Anat, Musculoskeletal Res Grp & Tumor Biol,Chair Vegeta, D-80336 Munich, Germany.
   [Zhai, Kevin; Abdellatif, Basma; Siddiqui, Manaal; Busselberg, Dietrich] Qatar Fdn, Weill Cornell Med Qatar, Doha 24144, Qatar.
   [Pec, Martin; Kubatka, Peter] Comenius Univ, Jessenius Fac Med, Dept Med Biol, Martin 03601, Slovakia.
   [Gadanec, Laura Kate; Zulli, Anthony] Victoria Univ, Inst Hlth & Sport, Melbourne, Vic 3030, Australia.
   [Sudomova, Miroslava] Museum Literature Moravia, Klaster 1, Rajhrad 66461, Czech Republic.
   [Hassan, Sherif T. S.] Czech Univ Life Sci Prague, Fac Environm Sci, Dept Appl Ecol, Kamycka 129, Prague 16500, Czech Republic.
   [Giordano, Frank A.] Rheinische Friedrich Wilhelms Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Bonn, Germany.
   [Golubnitschaja, Olga] Rheinische Friedrich Wilhelms Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Predict Prevent & Personalised 3P Med, D-53127 Bonn, Germany.
C3 Comenius University Bratislava; University of Munich; Qatar Foundation
   (QF); Weill Cornell Medical College Qatar; Comenius University
   Bratislava; Victoria University; Czech University of Life Sciences
   Prague; University of Bonn; University of Bonn
RP Büsselberg, D (corresponding author), Qatar Fdn, Weill Cornell Med Qatar, Doha 24144, Qatar.; Kubatka, P (corresponding author), Comenius Univ, Jessenius Fac Med, Dept Med Biol, Martin 03601, Slovakia.; Golubnitschaja, O (corresponding author), Rheinische Friedrich Wilhelms Univ Bonn, Univ Hosp Bonn, Dept Radiat Oncol, Predict Prevent & Personalised 3P Med, D-53127 Bonn, Germany.
EM dib2015@qatar-med.cornell.edu; Olga.Golubnitschaja@ukbonn.de;
   peter.kubatka@uniba.sk
RI Shakibaei, Prof. Dr. Mehdi/AAA-7004-2020; Zhai, Kevin/AAL-5702-2021;
   Kudela, Erik/AAQ-2730-2021; Biringer, Kamil/AAM-3696-2021; Hassan,
   Sherif T.S./F-5265-2016; Biringer, Kamil/X-7804-2018
OI Hassan, Sherif T.S./0000-0003-3922-2738; Shakibaei, Prof. Dr.
   Mehdi/0000-0002-6304-7506; Koklesova, Lenka/0009-0000-2732-066X;
   Golubnitschaja, Prof. Dr., Olga/0000-0001-5427-2018; Biringer,
   Kamil/0000-0002-3471-0508; Gadanec, Laura Kate/0000-0002-4801-8061;
   Brockmueller, Aranka/0000-0001-8101-2828; Zhai,
   Kevin/0000-0003-2556-5641; Busselberg, Dietrich/0000-0001-5196-3366;
   Kubatka, Peter/0000-0003-4312-5076
FU Scientific Grant Agency of the Ministry of Education, Science, Research
   and Sport of the Slovak Republic (Bratislava, Slovak Republic) [VEGA
   1/0136/19]; Slovak Research and Development Agency [APVV-16-0021];
   LISPER project [313011V446]; European Association for Predictive,
   Preventive and Personalised Medicine; Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL. The present
   study was supported by the Scientific Grant Agency of the Ministry of
   Education, Science, Research and Sport of the Slovak Republic
   (Bratislava, Slovak Republic; grant no. VEGA 1/0136/19), Slovak Research
   and Development Agency under Contract No. APVV-16-0021 and LISPER
   project (grant Nr. 313011V446) in bilateral agreement with the European
   Association for Predictive, Preventive and Personalised Medicine.
CR Abdraboh ME, 2020, BIOMED PHARMACOTHER, V131, DOI 10.1016/j.biopha.2020.110620
   Abotaleb M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020221
   AL-Ishaq RK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9090430
   Ashrafizadeh M, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01634-9
   Ashrafizadeh Milad, 2020, J Basic Clin Physiol Pharmacol, V31, DOI 10.1515/jbcpp-2019-0191
   Ashrafizadeh M, 2020, PHYTOTHER RES, V34, P1745, DOI 10.1002/ptr.6642
   Ashrafizadeh M, 2020, PHYTOTHER RES, V34, P911, DOI 10.1002/ptr.6577
   Ashrafizadeh M, 2020, J CELL PHYSIOL, V235, P4135, DOI 10.1002/jcp.29327
   Awan FT, 2016, ANN HEMATOL, V95, P1137, DOI 10.1007/s00277-016-2683-1
   Bae S, 2018, EUR J PHARM SCI, V117, P27, DOI 10.1016/j.ejps.2018.02.004
   Bahar E, 2019, CANCERS, V11, DOI 10.3390/cancers11030338
   Bailly C, 2020, CHEM-BIOL INTERACT, V325, DOI 10.1016/j.cbi.2020.109124
   Baudino Troy A, 2015, Curr Drug Discov Technol, V12, P3
   Begicevic RR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112362
   Bhia M, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020291
   Bieg D, 2018, ARCH GYNECOL OBSTET, V298, P1181, DOI 10.1007/s00404-018-4912-4
   Buhrmann C, 2020, MOLECULES, V25, DOI 10.3390/molecules25184292
   Buhrmann C, 2019, NUTRIENTS, V11, DOI 10.3390/nu11122904
   Bukowski K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21093233
   Chen DH, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0047-1
   Chen HHW, 2017, ONCOTARGET, V8, P62742, DOI 10.18632/oncotarget.18409
   Chen ZS, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00260
   Cho Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00764
   Choi HJ, 2019, GYNECOL ONCOL, V153, P135, DOI 10.1016/j.ygyno.2019.01.012
   Cimini A, 2017, J CELL PHYSIOL, V232, P312, DOI 10.1002/jcp.25421
   Crigna AT, 2020, EPMA J, V11, P603, DOI 10.1007/s13167-020-00226-x
   Darzi S, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/3291737
   Draghi A, 2019, SEMIN IMMUNOPATHOL, V41, P31, DOI 10.1007/s00281-018-0692-y
   Falzone L., 2018, Frontiers in Pharmacology, V9
   Fan XQ, 2019, TOXICOL IN VITRO, V61, DOI 10.1016/j.tiv.2019.104642
   Fan Y, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5471-1
   Farsad-Naeimi A, 2018, FOOD FUNCT, V9, P2025, DOI [10.1039/c7fo01898c, 10.1039/C7FO01898C]
   Fröhlich H, 2018, EPMA J, V9, P175, DOI 10.1007/s13167-018-0131-0
   Furukawa K, 2020, MOLECULES, V25, DOI 10.3390/molecules25173900
   Gerner C, 2020, MASS SPECTROM REV, V39, P442, DOI 10.1002/mas.21612
   Goldstein E, 2020, EPMA J, V11, P505, DOI 10.1007/s13167-020-00221-2
   Golubnitschaja O., 2019, Flammer Syndrome: From Phenotype to Associated Pathologies, Prediction, Prevention and Personalisation
   Golubnitschaja O, 2018, EPMA J, V9, P271, DOI 10.1007/s13167-018-0146-6
   Golubnitschaja O, 2017, EPMA J, V8, P17, DOI 10.1007/s13167-017-0086-6
   Gou Q, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03140-2
   Grech G, 2015, EPMA J, V6, DOI 10.1186/s13167-015-0030-6
   Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004
   Guo SH, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109225
   Harrison PT, 2018, ESSAYS BIOCHEM, V62, P583, DOI 10.1042/EBC20180016
   Hassanzadeh Parichehr, 2011, Gastroenterol Hepatol Bed Bench, V4, P127
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Hsiao YH, 2019, PHYTOMEDICINE, V62, DOI 10.1016/j.phymed.2019.152964
   Hua R, 2020, J BUON, V25, P262
   Huang SJ, 2020, J CANCER, V11, P2123, DOI 10.7150/jca.34981
   Hussain Y, 2020, CURR TOP MED CHEM, V20, P1791, DOI 10.2174/1568026620666200502005411
   Inthagard J, 2019, CLIN SCI, V133, P181, DOI 10.1042/CS20181003
   Jabri T, 2019, DRUG DEV IND PHARM, V45, P703, DOI 10.1080/03639045.2018.1550091
   Januchowski R, 2013, BIOMED PHARMACOTHER, V67, P669, DOI 10.1016/j.biopha.2013.04.005
   Jiang CH, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00530
   Kapinova A, 2018, ENVIRON HEALTH PREV, V23, DOI 10.1186/s12199-018-0724-1
   Kapinova A, 2019, J CANCER RES CLIN, V145, P1087, DOI 10.1007/s00432-019-02892-5
   Karachaliou N, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.06.47
   Khonkarn R, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01657-5
   Kim B, 2020, INT J ONCOL, V56, P821, DOI 10.3892/ijo.2020.4970
   Kim EK, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8100471
   Koh SY, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030624
   KOKLESOVA L, 2020, CANCERS BASEL, V12
   Koklesova L, 2021, EPMA J, V12, P477, DOI 10.1007/s13167-021-00263-0
   Koklesova L, 2020, EPMA J, V11, P261, DOI 10.1007/s13167-020-00210-5
   Kong WC, 2020, INT J MOL MED, V45, P1213, DOI 10.3892/ijmm.2020.4485
   Kopustinskiene DM, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020457
   Koukourakis MI, 2019, INT J RADIAT BIOL, V95, P408, DOI 10.1080/09553002.2018.1490041
   Kozlowska Aleksandra, 2014, Rocz Panstw Zakl Hig, V65, P79
   Kubatka P., 2019, Int. J. Mol. Sci, V20
   Kubatka P, 2020, MOLECULES, V25, DOI 10.3390/molecules25061399
   Kubatka P, 2017, J CELL MOL MED, V21, P2837, DOI 10.1111/jcmm.13197
   Kubatka P, 2017, EUR J NUTR, V56, P1303, DOI 10.1007/s00394-016-1181-5
   Kubatka P, 2016, NUTR CANCER, V68, P611, DOI 10.1080/01635581.2016.1154577
   Kubatka P, 2016, EUR J NUTR, V55, P955, DOI 10.1007/s00394-015-0910-5
   Kucera R, 2020, EPMA J, V11, P399, DOI 10.1007/s13167-020-00214-1
   Kumar S, 2013, SCI WORLD J, DOI 10.1155/2013/162750
   Lan CY, 2019, J FOOD DRUG ANAL, V27, P887, DOI 10.1016/j.jfda.2019.07.001
   Lazzeroni M, 2017, CANCER PREV RES, V10, P363, DOI 10.1158/1940-6207.CAPR-16-0298
   Leu YL, 2020, MOLECULES, V25, DOI 10.3390/molecules25040941
   LI B, 2021, FOOD FUNCT
   Li L, 2020, INT J CLIN EXP PATHO, V13, P212
   Li SZ, 2018, PHYTOTHER RES, V32, P1530, DOI 10.1002/ptr.6081
   Li X, 2016, MOL MED REP, V13, P4007, DOI 10.3892/mmr.2016.4990
   Li Y, 2020, BIOCHEM BIOPH RES CO, V523, P947, DOI 10.1016/j.bbrc.2020.01.048
   Lievens Y, 2020, MOL ONCOL, V14, P1461, DOI 10.1002/1878-0261.12690
   LISKOVA A, 2020, CANCERS BASEL, V12
   LISKOVA A, 2020, J CANCER RES CLIN
   Liskova A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042007
   Liskova A, 2021, BIOMED PHARMACOTHER, V138, DOI 10.1016/j.biopha.2021.111430
   Liskova A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9092749
   Liskova A, 2019, MOLECULES, V24, DOI 10.3390/molecules24050899
   Liu JY, 2020, FITOTERAPIA, V143, DOI 10.1016/j.fitote.2020.104590
   Liu R, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02998-6
   Liu S, 2020, MOL PHARMACEUT, V17, P1415, DOI 10.1021/acs.molpharmaceut.0c00138
   Liu XX, 2016, ONCOTARGET, V7, P27267, DOI 10.18632/oncotarget.8403
   Liu YS, 2019, CANCERS, V11, DOI 10.3390/cancers11070918
   Lu XX, 2020, INT J BIOL SCI, V16, P1121, DOI 10.7150/ijbs.41686
   Lv WL, 2019, J CELL PHYSIOL, V234, P23169, DOI 10.1002/jcp.28883
   MA L, 2020, FRONT ONCOL, V10
   Medhat A, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317717259
   Moradzadeh M, 2018, J CELL BIOCHEM, V119, P2288, DOI 10.1002/jcb.26391
   Nair B, 2020, ADV PHARM BULL, V10, P472, DOI 10.34172/apb.2020.058
   Namdeo AG, 2020, CURR PHARM DESIGN, V26, P1712, DOI 10.2174/1381612826666200128095248
   Nikolaou M, 2018, CLIN EXP METASTAS, V35, P309, DOI 10.1007/s10585-018-9903-0
   Nowicki TS, 2018, CANCER J, V24, P47, DOI 10.1097/PPO.0000000000000303
   Pan ST, 2016, CLIN EXP PHARMACOL P, V43, P723, DOI 10.1111/1440-1681.12581
   Panche AN, 2016, J NUTR SCI, V5, DOI 10.1017/jns.2016.41
   Pichler C, 2017, CANCER PREV RES, V10, P153, DOI 10.1158/1940-6207.CAPR-15-0378
   Pintova S, 2019, CANCER CHEMOTH PHARM, V84, P591, DOI 10.1007/s00280-019-03886-3
   Riahi-Chebbi I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-36808-z
   Riganti C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194783
   Sabnis AJ, 2019, TRENDS MOL MED, V25, P185, DOI 10.1016/j.molmed.2018.12.009
   Sakthivel KM, 2017, BIOMED PHARMACOTHER, V93, P1238, DOI 10.1016/j.biopha.2017.07.035
   Salehan MR, 2013, BRIT J BIOMED SCI, V70, P31, DOI 10.1080/09674845.2013.11669927
   Sambi M, 2019, CURRENT APPL OVERCOM, P978
   Samec M, 2021, CANCERS, V13, DOI 10.3390/cancers13010130
   Samec M, 2020, EPMA J, V11, P377, DOI 10.1007/s13167-020-00217-y
   Saraswati S, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0430-7
   Scagliarini A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040932
   Sellam LS, 2020, ARCH BIOCHEM BIOPHYS, V690, DOI 10.1016/j.abb.2020.108479
   Silbermann K, 2019, EUR J MED CHEM, V164, P193, DOI 10.1016/j.ejmech.2018.12.019
   Sim EHA, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006847.pub2
   Sindhu RK, 2021, J DRUG TARGET, V29, P822, DOI 10.1080/1061186X.2021.1892122
   Singh MP, 2019, CANCERS, V11, DOI 10.3390/cancers11070986
   Sirin N, 2020, GENE, V737, DOI 10.1016/j.gene.2020.144428
   Solnier J, 2021, PHYTOCHEM REV, V20, P773, DOI 10.1007/s11101-020-09720-6
   Suraweera A, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00092
   Taguchi K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00085
   Takahashi A, 2014, RADIAT RES, V182, P338, DOI 10.1667/RR13782.1
   Tang HL, 2019, J PHARMACOL EXP THER, V368, P401, DOI 10.1124/jpet.118.254359
   Tang QS, 2018, ONCOL REP, V40, P579, DOI 10.3892/or.2018.6468
   Tang WW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0187-x
   Thapa B, 2020, J CONTROL RELEASE, V326, P335, DOI 10.1016/j.jconrel.2020.07.013
   Tiwari P, 2020, INT J RADIAT BIOL, V96, P360, DOI 10.1080/09553002.2020.1694193
   Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237
   Varghese E, 2018, CANCERS, V10, DOI 10.3390/cancers10100346
   Wang BJ, 2020, DRUG DELIV, V27, P607, DOI 10.1080/10717544.2020.1754529
   Wang F, 2014, CURR PHARM DESIGN, V20, P6714, DOI 10.2174/1381612820666140929100735
   Wang HP, 2020, THORAC CANCER, V11, P594, DOI 10.1111/1759-7714.13302
   Wang X, 2019, CANCER DRUG RESIST, V2, P141, DOI 10.20517/cdr.2019.10
   Wang ZY, 2021, PHYTOMEDICINE, V82, DOI 10.1016/j.phymed.2020.153414
   Wen MM, 2018, BIOL-TARGETS THER, V12, P183, DOI 10.2147/BTT.S169305
   Wilkens Stephan, 2015, F1000Prime Rep, V7, P14, DOI 10.12703/P7-14
   Wong ILK, 2018, J MED CHEM, V61, P9931, DOI 10.1021/acs.jmedchem.8b00834
   Wu ZQ, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/2491304
   Xu L, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0929-6
   Ye QM, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00487
   Yeh BW, 2020, TOXICOL APPL PHARM, V402, DOI 10.1016/j.taap.2020.115129
   Yin SY, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00386
   Zhai K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10111469
   Zhai K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114177
   Zhang LL, 2018, ONCOL REP, V40, P1046, DOI 10.3892/or.2018.6499
   Zhang XY, 2020, ONCOTARGETS THER, V13, P513, DOI 10.2147/OTT.S228453
   Zhang ZM, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18755-3
   Zhao LJ, 2021, PHYTOTHER RES, V35, P278, DOI 10.1002/ptr.6798
NR 155
TC 80
Z9 83
U1 4
U2 26
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1878-5077
EI 1878-5085
J9 EPMA J
JI EPMA J.
PD JUN
PY 2021
VL 12
IS 2
SI SI
BP 155
EP 176
DI 10.1007/s13167-021-00242-5
EA MAY 2021
PG 22
WC Medicine, General & Internal; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine; Research & Experimental Medicine
GA SP9TF
UT WOS:000651542500001
PM 34025826
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Catenacci, DVT
   Moya, S
   Lomnicki, S
   Chase, LM
   Peterson, BF
   Reizine, N
   Alpert, L
   Setia, N
   Xiao, SY
   Hart, J
   Siddiqui, UD
   Hogarth, DK
   Eng, OS
   Turaga, K
   Roggin, K
   Posner, MC
   Chang, P
   Narula, S
   Rampurwala, M
   Ji, Y
   Karrison, T
   Liao, CY
   Polite, BN
   Kindler, HL
AF Catenacci, Daniel V. T.
   Moya, Stephanie
   Lomnicki, Samantha
   Chase, Leah M.
   Peterson, Bryan F.
   Reizine, Natalie
   Alpert, Lindsay
   Setia, Namrata
   Xiao, Shu-Yuan
   Hart, John
   Siddiqui, Uzma D.
   Hogarth, D. Kyle
   Eng, Oliver S.
   Turaga, Kiran
   Roggin, Kevin
   Posner, Mitchell C.
   Chang, Paul
   Narula, Sunil
   Rampurwala, Murtuza
   Ji, Yuan
   Karrison, Theodore
   Liao, Chih-Yi
   Polite, Blase N.
   Kindler, Hedy L.
TI Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A
   Phase II Study Evaluating an Individualized Treatment Strategy for
   Metastatic Disease
SO CANCER DISCOVERY
LA English
DT Article
ID ADVANCED GASTRIC-CANCER; ADVANCED ESOPHAGOGASTRIC CANCER; ADVANCED
   COLORECTAL-CANCER; JUNCTION G/GEJ CANCER; OPEN-LABEL; DOUBLE-BLIND; PLUS
   CHEMOTHERAPY; TARGETED THERAPY; 1ST-LINE THERAPY; SINGLE-ARM
AB The one-year and median overall survival (mOS) rates of advanced gastroesopha- geal adenocarcinomas (GEA) are similar to 50% and <12 months, respectively. Baseline spatial and temporal molecular heterogeneity of targetable alterations may be a cause of failure of targeted/immunooncologic therapies. This heterogeneity, coupled with infrequent incidence of some biomarkers, has resulted in stalled therapeutic progress. We hypothesized that a personalized treatment strategy, applied at first diagnosis then serially over up to three treatment lines using monoclonal antibodies combined with optimally sequenced chemotherapy, could contend with these hurdles. This was tested using a novel clinical expansion-platform type II design with a survival primary endpoint. Of 68 patients by intention-to-treat, the one-year survival rate was 66% and mOS was 15.7 months, meeting the primary efficacy endpoint (one-sided P = 0.0024). First-line response rate (74%), disease control rate (99%), and median progression-free survival (8.2 months) were superior to historical controls. The PANGEA strategy led to improved outcomes warranting a larger randomized study.
   SIGNIFICANCE: This study highlights excellent outcomes achieved by individually optimizing chemotherapy, biomarker profiling, and matching of targeted therapies at baseline and over time for GEA. Testing a predefined treatment strategy resulted in improved outcomes versus historical controls. Therapeutic resistance observed in correlative analyses suggests that dual targeted inhibition may be beneficial.
C1 [Catenacci, Daniel V. T.; Moya, Stephanie; Lomnicki, Samantha; Chase, Leah M.; Peterson, Bryan F.; Reizine, Natalie; Liao, Chih-Yi; Polite, Blase N.; Kindler, Hedy L.] Univ Chicago, Sect Hematol Oncol, Dept Med, Chicago, IL 60637 USA.
   [Alpert, Lindsay; Setia, Namrata; Xiao, Shu-Yuan; Hart, John] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
   [Siddiqui, Uzma D.] Univ Chicago, Dept Med, Ctr Endoscop Res & Therapeut CERT, Chicago, IL 60637 USA.
   [Hogarth, D. Kyle] Univ Chicago, Dept Med, Sect Pulmonol, Chicago, IL 60637 USA.
   [Eng, Oliver S.; Turaga, Kiran; Roggin, Kevin; Posner, Mitchell C.] Univ Chicago, Dept Surg, Chicago, IL 60637 USA.
   [Chang, Paul] Univ Chicago, Dept Radiol, Chicago, IL 60637 USA.
   [Narula, Sunil] Univ Chicago, New Lennox, IL USA.
   [Rampurwala, Murtuza] Univ Chicago, Orland Pk, IL USA.
   [Ji, Yuan; Karrison, Theodore] Univ Chicago, Dept Publ Hlth Sci, Chicago, IL 60637 USA.
C3 University of Chicago; University of Chicago; University of Chicago;
   University of Chicago; University of Chicago; University of Chicago;
   University of Chicago; University of Chicago; University of Chicago
RP Catenacci, DVT (corresponding author), Univ Chicago, 900 East 57th St,Suite 7128, Chicago, IL 60637 USA.
EM dcatenac@bsd.uchicago.edu
RI Hogarth, Douglas/AAI-7152-2021; Xiao, Shu-Yuan/AAR-7167-2020; Roggin,
   Kevin/AAL-6743-2020
FU NIH [CA178203-01A1]; University of Chicago Comprehensive Cancer Center
   (UCCCC) [P30CA014599]; UCCCC Ullman Scholar Award for immunotherapy
FX This work was supported by the following peer-reviewed grants: NIH K23
   award (CA178203-01A1) PANGEA: Personalized ANtibodies for
   GastroEsophageal Adenocarcinoma Pilot Trial, University of Chicago
   Comprehensive Cancer Center (UCCCC) Award in Precision Oncology-Cancer
   Center Support Grant (CCSG; P30CA014599), and the UCCCC Ullman Scholar
   Award for immunotherapy (DVTC). DVTC had full access to all the data in
   the study and had final responsibility for the decision to submit for
   publication. We thank the many philanthropic gifts from the Castle
   Foundation, the LLK (Live Like Katie) Foundation, and the Jennifer and
   Isaac Goldman, the Sal Ferrara II, the Joe Carey, the Lodi Vercelli and
   the Fred Foster Funds for PANGEA, including many other donations from a
   number of generous donors. We thank AbbVie for provision of the
   anti-EGFR antibody ABT-806. We thank the compassionate use program of
   BMS where anti-PD-1 antibody nivolumab was obtained. We thank the whole
   clinical staff involved in the excellent care of our patients. We thank
   our patients and caregivers who participated in this study and for their
   commitment to improving our understanding of this lethal disease toward
   better therapeutic options in the future.
CR Abrams Jeffrey, 2014, Am Soc Clin Oncol Educ Book, P71, DOI 10.14694/EdBook_AM.2014.34.71
   Ali SM, 2015, ONCOLOGIST, V20, P499, DOI 10.1634/theoncologist.2014-0378
   An E, 2017, ANN ONCOL, V28, P110, DOI 10.1093/annonc/mdw442
   Bang YJ, 2018, ANN ONCOL, V29, P2052, DOI 10.1093/annonc/mdy264
   Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X
   Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Boku N, 2020, ANN ONCOL, V31, pS1192, DOI 10.1016/j.annonc.2020.08.2297
   BRAY F, 2018, CA-CANCER J CLIN, V68, P394, DOI [DOI 10.3322/CANJCLIN.49.1.33, DOI 10.3322/CAAC.21492]
   Catenacci DVT, 2021, FUTURE ONCOL, V17, P1155, DOI 10.2217/fon-2020-1007
   Catenacci DVT, 2020, J CLIN ONCOL, V38
   Catenacci DVT, 2020, LANCET ONCOL, V21, P1066, DOI 10.1016/S1470-2045(20)30326-0
   Catenacci DVT, 2020, J CLIN ONCOL, V38
   Catenacci DVT, 2020, J CLIN ONCOL, V38, P2418, DOI 10.1200/JCO.19.01834
   Catenacci DVT, 2019, FUTURE ONCOL, V15, P2073, DOI 10.2217/fon-2019-0141
   Catenacci DVT, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00359
   Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1
   Catenacci DVT, 2017, CANCER-AM CANCER SOC, V123, P1061, DOI 10.1002/cncr.30437
   Catenacci DVT, 2016, GASTRIC CANCER, V19, P1066, DOI 10.1007/s10120-015-0566-0
   Catenacci DVT, 2015, LANCET ONCOL, V16, P1276, DOI 10.1016/S1470-2045(15)00224-7
   Catenacci DVT, 2015, MOL ONCOL, V9, P967, DOI 10.1016/j.molonc.2014.09.011
   Catenacci DVT, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100586
   Chao J, 2020, J CLIN ONCOL, V38
   Chon HJ, 2009, CANCER RES TREAT, V41, P196, DOI 10.4143/crt.2009.41.4.196
   Cleary JM, 2015, INVEST NEW DRUG, V33, P671, DOI 10.1007/s10637-015-0234-6
   Dowlati A, 2001, CLIN CANCER RES, V7, P2971
   Dutton SJ, 2014, LANCET ONCOL, V15, P894, DOI 10.1016/S1470-2045(14)70024-5
   Flaherty KT, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.03010
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013
   Fuchs CS, 2019, LANCET ONCOL, V20, P420, DOI 10.1016/S1470-2045(18)30791-5
   Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Go PH, 2011, CANCER-AM CANCER SOC, V117, P3630, DOI 10.1002/cncr.25940
   Gomez-Martin C, 2013, J CLIN ONCOL, V31, P4445, DOI 10.1200/JCO.2013.48.9070
   Hembrough Todd, 2012, Clin Proteomics, V9, P5, DOI 10.1186/1559-0275-9-5
   Herbst RS, 2019, LANCET ONCOL, V20, P1109, DOI 10.1016/S1470-2045(19)30458-9
   Hong DS, 2019, CLIN CANCER RES, V25, P2403, DOI 10.1158/1078-0432.CCR-18-1341
   Hurvitz SA, 2019, CLIN CANCER RES, V25, P2433, DOI 10.1158/1078-0432.CCR-18-2366
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Ibe J, 2018, J CLIN ONCOL, V36
   Janjigian YY, 2020, LANCET ONCOL, V21, P821, DOI 10.1016/S1470-2045(20)30169-8
   Johnson ML, 2019, ANN ONCOL, V30, P34
   Kato K, 2020, ANN ONCOL, V31, pS1192, DOI 10.1016/j.annonc.2020.08.2298
   Kawazoe A, 2020, LANCET ONCOL, V21, P1057, DOI 10.1016/S1470-2045(20)30271-0
   Killock D, 2017, NAT REV CLIN ONCOL, V14, DOI 10.1038/nrclinonc.2017.19
   Kim J, 2017, NATURE, V541, P169, DOI 10.1038/nature20805
   Kim J, 2014, J CLIN INVEST, V124, P5145, DOI 10.1172/JCI75200
   Klempner SJ, 2019, ONCOLOGIST, V24, P475, DOI 10.1634/theoncologist.2018-0602
   Kojima T, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01888
   Kulangara K, 2019, ARCH PATHOL LAB MED, V143, P330, DOI 10.5858/arpa.2018-0043-OA
   Kwak EL, 2015, CANCER DISCOV, V5, P1271, DOI 10.1158/2159-8290.CD-15-0748
   Labianca R, 2011, ANN ONCOL, V22, P1236, DOI 10.1093/annonc/mdq580
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6
   Lee J, 2019, CANCER DISCOV, V9, P1388, DOI 10.1158/2159-8290.CD-19-0442
   Liu L, 2011, MOL CANCER THER, V10, P518, DOI 10.1158/1535-7163.MCT-10-0698
   Lo Nigro C, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.01.42
   Lopez-Chavez A, 2015, J CLIN ONCOL, V33, P1000, DOI 10.1200/JCO.2014.58.2007
   Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5
   Makiyama A, 2020, J CLIN ONCOL, V38, P1919, DOI 10.1200/JCO.19.03077
   Maron SB, 2019, CLIN CANCER RES, V25, P7098, DOI 10.1158/1078-0432.CCR-19-1704
   Maron SB, 2018, CANCER DISCOV, V8, P696, DOI 10.1158/2159-8290.CD-17-1260
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Moehler M, 2020, ANN ONCOL, V31, pS1191, DOI 10.1016/j.annonc.2020.08.2296
   Moehler MH, 2020, J CLIN ONCOL, V38
   Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3
   Odegaard JI, 2018, CLIN CANCER RES, V24, P3539, DOI 10.1158/1078-0432.CCR-17-3831
   Ohtsu A, 2011, J CLIN ONCOL, V29, P3968, DOI 10.1200/JCO.2011.36.2236
   Park JS, 2011, CANCER RES TREAT, V43, P236, DOI 10.4143/crt.2011.43.4.236
   Pectasides E, 2018, CANCER DISCOV, V8, P37, DOI 10.1158/2159-8290.CD-17-0395
   Petty RD, 2017, J CLIN ONCOL, V35, P2279, DOI 10.1200/JCO.2016.70.3934
   Pietrantonio F, 2018, CLIN CANCER RES, V24, P1082, DOI 10.1158/1078-0432.CCR-17-2781
   Reizine N, 2020, JCO PRECIS ONCOL, V4, P1180, DOI 10.1200/PO.20.00239
   Roy A, 2012, BRIT J CANCER, V107, P435, DOI 10.1038/bjc.2012.286
   Satoh T, 2014, J CLIN ONCOL, V32, P2039, DOI 10.1200/JCO.2013.53.6136
   Shah MA, 2017, JAMA ONCOL, V3, P620, DOI 10.1001/jamaoncol.2016.5580
   Shen L, 2015, GASTRIC CANCER, V18, P168, DOI 10.1007/s10120-014-0351-5
   Shitara K, 2020, JAMA ONCOL, V6, P1571, DOI 10.1001/jamaoncol.2020.3370
   Shitara K, 2020, NEW ENGL J MED, V382, P2419, DOI 10.1056/NEJMoa2004413
   Shitara K, 2018, LANCET ONCOL, V19, P1437, DOI 10.1016/S1470-2045(18)30739-3
   Shitara K, 2018, LANCET, V392, P123, DOI 10.1016/S0140-6736(18)31257-1
   Sun MH, 2009, CLIN CANCER RES, V15, P4829, DOI 10.1158/1078-0432.CCR-08-2921
   Tabernero J, 2018, LANCET ONCOL, V19, P1372, DOI 10.1016/S1470-2045(18)30481-9
   Tejani MA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.91
   Thuss-Patience PC, 2017, LANCET ONCOL, V18, P640, DOI 10.1016/S1470-2045(17)30111-0
   Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106
   Van Cutsem E, 2019, CLIN CANCER RES, V25, P2414, DOI 10.1158/1078-0432.CCR-18-1337
   Vasudev NS, 2014, ANGIOGENESIS, V17, P471, DOI 10.1007/s10456-014-9420-y
   Vrdoljak E, 2016, ANN ONCOL, V27, P2046, DOI 10.1093/annonc/mdw316
   Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2
   Wagner AD, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004064.pub3
   Weiner GJ, 2015, NAT REV CANCER, V15, P361, DOI 10.1038/nrc3930
   Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744
   Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6
   Wong GS, 2018, NAT MED, V24, P968, DOI 10.1038/s41591-018-0022-x
   Yoshikawa T, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.8243
   Zhang Y, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010144
   Zhou KI, 2020, CLIN CANCER RES, V26, P6453, DOI 10.1158/1078-0432.CCR-20-2085
   Zhu AX, 2019, LANCET ONCOL, V20, P282, DOI 10.1016/S1470-2045(18)30937-9
NR 100
TC 48
Z9 48
U1 0
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2159-8274
EI 2159-8290
J9 CANCER DISCOV
JI Cancer Discov.
PD FEB
PY 2021
VL 11
IS 2
BP 308
EP 325
DI 10.1158/2159-8290.CD-20-1408
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QH3XK
UT WOS:000618210000027
PM 33234578
OA Bronze, Green Submitted, Green Accepted
DA 2025-01-04
ER

PT J
AU Darwanto, A
   Hein, AM
   Strauss, S
   Kong, Y
   Sheridan, A
   Richards, D
   Lader, E
   Ngowe, M
   Pelletier, T
   Adams, D
   Ricker, A
   Patel, N
   Kühne, A
   Hughes, S
   Shiffman, D
   Zimmermann, D
   te Kaat, K
   Rothmann, T
AF Darwanto, Agus
   Hein, Anne-Mette
   Strauss, Sascha
   Kong, Yi
   Sheridan, Andrew
   Richards, Dan
   Lader, Eric
   Ngowe, Monika
   Pelletier, Timothy
   Adams, Danielle
   Ricker, Austin
   Patel, Nishit
   Kuehne, Andreas
   Hughes, Simon
   Shiffman, Dan
   Zimmermann, Dirk
   te Kaat, Kai
   Rothmann, Thomas
TI Use of the QIAGEN GeneReader NGS system for detection of KRAS mutations,
   validated by the QIAGEN <i>Therascreen</i> PCR kit and alternative NGS
   platform
SO BMC CANCER
LA English
DT Article
DE GeneReader; Kras; Mutation; Cancer; Ngs
ID PARAFFIN-EMBEDDED TISSUES; PANCREATIC DUCTAL ADENOCARCINOMA;
   COLORECTAL-CANCER; MULTIPLEXED PCR; CANDIDATE GENES; DNA; EXTRACTION;
   DIAGNOSIS; RESOURCE; BIOPSIES
AB Background: The detection of somatic mutations in primary tumors is critical for the understanding of cancer evolution and targeting therapy. Multiple technologies have been developed to enable the detection of such mutations. Next generation sequencing (NGS) is a new platform that is gradually becoming the technology of choice for genotyping cancer samples, owing to its ability to simultaneously interrogate many genomic loci at massively high efficiency and increasingly lower cost. However, multiple barriers still exist for its broader adoption in clinical research practice, such as fragmented workflow and complex bioinformatics analysis and interpretation.
   Methods: We performed validation of the QIAGEN GeneReader NGS System using the QIAact Actionable Insights Tumor Panel, focusing on clinically meaningful mutations by using DNA extracted from formalin-fixed paraffin-embedded (FFPE) colorectal tissue with known KRAS mutations. The performance of the GeneReader was evaluated and compared to data generated from alternative technologies (PCR and pyrosequencing) as well as an alternative NGS platform. The results were further confirmed with Sanger sequencing.
   Results: The data generated from the GeneReader achieved 100% concordance with reference technologies. Furthermore, the GeneReader workflow provides a truly integrated workflow, eliminating artifacts resulting from routine sample preparation; and providing up-to-date interpretation of test results.
   Conclusion: The GeneReader NGS system offers an effective and efficient method to identify somatic (KRAS) cancer mutations.
C1 [Hein, Anne-Mette; Lader, Eric; Hughes, Simon; Rothmann, Thomas] IQIAGEN Waltham, 35 Gatehouse Dr, Waltham, MA 02451 USA.
   [Sheridan, Andrew; Ngowe, Monika; Adams, Danielle] QIAGEN Arhus, Silkeborgvej 2, DK-8000 Aarhus, Denmark.
   [Patel, Nishit; Kuehne, Andreas; Shiffman, Dan; te Kaat, Kai] QIAGEN GmbH, QIAGEN Str 1, Nordrhein, Germany.
   [Patel, Nishit; Hughes, Simon; Zimmermann, Dirk] QIAGEN Redwood City, 1700 Seaport Blvd, Redwood City, CA USA.
   [Adams, Danielle; Patel, Nishit] QIAGEN Frederick, Executive Way, Frederick, MD 21703 USA.
   [Kuehne, Andreas; Hughes, Simon; Zimmermann, Dirk] QIAGEN Manchester, Manchester M15 6SH, Lancs, England.
C3 QIAGEN GmbH
RP Rothmann, T (corresponding author), IQIAGEN Waltham, 35 Gatehouse Dr, Waltham, MA 02451 USA.
EM Thomas.rothmann@qiagen.com
RI Hughes, Simon/B-5217-2008
FU QIAGEN
FX This work was supported by QIAGEN.
CR Beadling C, 2013, J MOL DIAGN, V15, P171, DOI 10.1016/j.jmoldx.2012.09.003
   Betge J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0127146
   Bourgon R, 2014, CLIN CANCER RES, V20, P2080, DOI 10.1158/1078-0432.CCR-13-3114
   Casadio C, 2015, AM J CLIN PATHOL, V144, P629, DOI 10.1309/AJCPXGRAIMB4CTQ3
   Castera L, 2014, EUR J HUM GENET, V22, P1305, DOI 10.1038/ejhg.2014.16
   Chung JY, 2008, J HISTOCHEM CYTOCHEM, V56, P1033, DOI 10.1369/jhc.2008.951863
   D'Haene N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138245
   Di Marco M, 2015, MOL MED REP, V12, P7479, DOI 10.3892/mmr.2015.4344
   Do HD, 2012, ONCOTARGET, V3, P546
   Frickmann H, 2015, BIOMED RES INT, V2015
   Frickmann H, 2013, DIAGN MOL PATHOL, V22, P236, DOI 10.1097/PDM.0b013e3182936936
   Gao J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009532
   Hosein AN, 2013, LAB INVEST, V93, P701, DOI 10.1038/labinvest.2013.54
   Huang JQ, 2015, CLIN CHEM, V61, P1408, DOI 10.1373/clinchem.2015.238543
   Kokkat TJ, 2013, BIOPRESERV BIOBANK, V11, P101, DOI 10.1089/bio.2012.0052
   Le Mercier M, 2015, HISTOPATHOLOGY, V66, P215, DOI 10.1111/his.12461
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Martinez DA, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000906
   Masucci GV, 2016, J IMMUNOTHER CANCER, V4, DOI 10.1186/s40425-016-0178-1
   McCourt CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069604
   Metzger GJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033520
   Metzker ML, 2010, NAT REV GENET, V11, P31, DOI 10.1038/nrg2626
   Obersteller S, 2016, EUR J MICROBIOL IMMU, V6, P244, DOI 10.1556/1886.2016.00028
   Papadopoulou E, 2015, ONCOL LETT, V10, P2176, DOI 10.3892/ol.2015.3600
   Rodriguez R, 2014, J COMMUNITY SUPPORT, V12, P27, DOI 10.12788/jcso.0006
   Sah S, 2013, GENOME MED, V5, DOI 10.1186/gm481
   Sakai K, 2015, SPRINGERPLUS, V4, DOI 10.1186/2193-1801-4-7
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Sundström M, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-660
   Tuononen K, 2013, GENE CHROMOSOME CANC, V52, P503, DOI 10.1002/gcc.22047
   Zook JM, 2014, NAT BIOTECHNOL, V32, P246, DOI 10.1038/nbt.2835
NR 31
TC 16
Z9 16
U1 0
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD MAY 22
PY 2017
VL 17
AR 358
DI 10.1186/s12885-017-3328-z
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EV7IY
UT WOS:000401950300006
PM 28532404
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Giordano, G
   Remo, A
   Porras, A
   Pancione, M
AF Giordano, Guido
   Remo, Andrea
   Porras, Almudena
   Pancione, Massimo
TI Immune Resistance and EGFR Antagonists in Colorectal Cancer
SO CANCERS
LA English
DT Review
DE colorectal cancer; EGFR; resistance; targeted therapies; immune
   microenvironment
ID MONOCLONAL-ANTIBODIES; CETUXIMAB RESISTANCE; ACQUIRED-RESISTANCE;
   TARGETED THERAPY; ERBB RECEPTORS; HETEROGENEITY; POLYMORPHISMS;
   EFFICACY; MUTATION; REVEALS
AB Targeting the epidermal growth factor receptor (EGFR) either alone or in combination with chemotherapy in patients with RAS wild type metastatic colorectal cancer (mCRC) has revolutionized the treatment of CRC, but with less results than initially envisaged. In recent years, the discovery of multiple pathways leading to the escape from anti-EGFR therapy has revealed an enormous complexity and heterogeneity of human CRC due to the intrinsic genomic instability and immune/cancer cell interaction. Therefore, understanding the mechanistic basis of acquired resistance to targeted therapies represents a major challenge to improve the clinical outcomes of patients with CRC. The latest findings strongly suggest that complex molecular alterations coupled with changes of the immune tumor microenvironment may substantially contribute to the clinical efficacy of EGFR antagonist. In this review, we discuss the most recent findings that contribute to both primary and acquired anti-EGFR therapy resistance. In addition, we analyze how strategies aiming to enhance the favorable effects in the tumor microenvironment may contribute to overcome resistance to EGFR therapies.
C1 [Giordano, Guido] Azienda Ospedal Univ, Osped Riuniti, UOC Med Oncol, I-251 Foggia, Italy.
   [Remo, Andrea] Mater Salutis Hosp AULSS9 Scaligera, Pathol Unit, I-37122 Verona, Italy.
   [Porras, Almudena; Pancione, Massimo] Univ Complutense Madrid, Fac Pharm, Dept Biochem & Mol Biol, Madrid 28040, Spain.
   [Porras, Almudena] Hosp Clin San Carlos IdISSC, Hlth Res Inst, Madrid 28040, Spain.
   [Pancione, Massimo] Univ Sannio, Dept Sci & Technol, I-82100 Benevento, Italy.
C3 Complutense University of Madrid; Hospital Clinico San Carlos;
   University of Sannio
RP Porras, A; Pancione, M (corresponding author), Univ Complutense Madrid, Fac Pharm, Dept Biochem & Mol Biol, Madrid 28040, Spain.; Porras, A (corresponding author), Hosp Clin San Carlos IdISSC, Hlth Res Inst, Madrid 28040, Spain.; Pancione, M (corresponding author), Univ Sannio, Dept Sci & Technol, I-82100 Benevento, Italy.
EM maporras@ucm.es; massimo.pancione@unisannio.it
RI Pancione, Massimo/AAF-2109-2019; Giordano, Guido/IQU-6240-2023; remo,
   andrea/Q-7746-2016; Porras, Almudena/N-2121-2015
OI Giordano, Guido/0000-0002-9310-1075; remo, andrea/0000-0002-2564-2988;
   Porras, Almudena/0000-0002-6495-3308; PANCIONE,
   Massimo/0000-0003-1728-8816
FU Italian Ministry of University and Research (MIUR) [4982]; Spanish
   Ministry of Economy and Competitiveness [SAF2016-76588-C2-1-R]
FX This work was supported by a grant to M.P (FFABR n. 4982) from the
   Italian Ministry of University and Research (MIUR) and by a grant to AP
   from the Spanish Ministry of Economy and Competitiveness
   (SAF2016-76588-C2-1-R).
CR Ahmad R, 2017, ONCOTARGET, V8, P87718, DOI 10.18632/oncotarget.21190
   Ali M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15617
   Anderson GR, 2017, CELL REP, V20, P999, DOI 10.1016/j.celrep.2017.07.006
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Ashraf SQ, 2012, P NATL ACAD SCI USA, V109, P21046, DOI 10.1073/pnas.1218750110
   Bae JA, 2016, CLIN CANCER RES, V22, P1284, DOI 10.1158/1078-0432.CCR-15-0306
   Belli V, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1230-z
   Bonin S, 2016, TUMOR BIOL, V37, P7295, DOI 10.1007/s13277-015-4543-3
   Bormann F, 2019, INT J CANCER, V144, P569, DOI 10.1002/ijc.31892
   Borrero-Palacios A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43809-z
   Cao WG, 2019, MOL CANCER THER, V18, P1158, DOI 10.1158/1535-7163.MCT-18-1247
   Cardoso AP, 2014, ONCOGENE, V33, P2123, DOI 10.1038/onc.2013.154
   Chen MS, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5364-3
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Cremolini C, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000489
   Della Corte CM, 2014, BIOMEDICINES, V2, P345, DOI 10.3390/biomedicines2040345
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Gao YJ, 2019, CANCER DISCOV, V9, P1182, DOI 10.1158/2159-8290.CD-19-0356
   Garcia-Albeniz X, 2019, ONCOLOGIST, V24, pE1115, DOI 10.1634/theoncologist.2018-0728
   Gbenedio OM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.127552
   Gelfo V, 2016, ONCOTARGET, V7, P72167, DOI 10.18632/oncotarget.12354
   Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075
   Giordano G, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1019-5
   Giordano G, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0225-7
   Greening DW, 2015, ONCOTARGET, V6, P38166, DOI 10.18632/oncotarget.6241
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Jaka A, 2014, EXP DERMATOL, V23, P751, DOI 10.1111/exd.12510
   Jia JQ, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00305
   Kanat O, 2018, WORLD J CLIN CASES, V6, P418, DOI 10.12998/wjcc.v6.i11.418
   Klesmith JR, 2019, MOL PHARMACEUT, V16, P3544, DOI 10.1021/acs.molpharmaceut.9b00418
   Kohrt HE, 2014, J CLIN INVEST, V124, P2668, DOI 10.1172/JCI73014
   Kubach J, 2015, INT J CANCER, V136, P821, DOI 10.1002/ijc.29037
   Lanaya H, 2014, NAT CELL BIOL, V16, P972, DOI 10.1038/ncb3031
   Ledys F, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0438-3
   Lee SJ, 2018, CLIN COLORECTAL CANC, V17, P165, DOI 10.1016/j.clcc.2018.02.013
   Lieu Christopher H, 2019, Am Soc Clin Oncol Educ Book, V39, P207, DOI 10.1200/EDBK_240839
   Lipsick J, 2019, CSH PERSPECT BIOL, V11, DOI 10.1101/cshperspect.a035592
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   Mardiana S, 2017, CANCER RES, V77, P1296, DOI 10.1158/0008-5472.CAN-16-1831
   Marzi L, 2016, BRIT J CANCER, V115, P1223, DOI 10.1038/bjc.2016.313
   Mauri G, 2019, CANCER TREAT REV, V73, P41, DOI 10.1016/j.ctrv.2018.12.006
   Montagut C, 2018, ANN ONCOL, V29, P1083, DOI 10.1093/annonc/mdy091
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Murphy N, 2019, MOL ASPECTS MED, V69, P2, DOI 10.1016/j.mam.2019.06.005
   Okazaki S, 2017, INT J CANCER, V141, P1222, DOI 10.1002/ijc.30810
   Pancione M, 2017, CURR MED CHEM, V24, P1383, DOI 10.2174/0929867324666170227114356
   Papaccio F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113595
   Patnaik S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00588
   Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Rachiglio AM, 2019, CANCERS, V11, DOI 10.3390/cancers11060859
   Raghav K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00226
   Rimassa L, 2019, CLIN COLORECTAL CANC, V18, P125, DOI 10.1016/j.clcc.2019.02.004
   Ruiz-Saenz A, 2018, CANCER RES, V78, P3645, DOI 10.1158/0008-5472.CAN-18-0430
   Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283
   Saito R, 2013, ANTICANCER RES, V33, P4995
   Sandhu J, 2019, J SURG ONCOL, V119, P564, DOI 10.1002/jso.25421
   Sartore-Bianchi A, 2019, ONCOLOGIST, V24, P1395, DOI 10.1634/theoncologist.2018-0785
   Sartore-Bianchi A, 2016, CANCER TREAT REV, V51, P54, DOI 10.1016/j.ctrv.2016.10.006
   Shen MH, 2018, FRONT MED-PRC, V12, P426, DOI 10.1007/s11684-018-0663-7
   Shi XJ, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aau1207
   Srivatsa S, 2017, GASTROENTEROLOGY, V153, P178, DOI 10.1053/j.gastro.2017.03.053
   Takegawa N, 2019, INT J CANCER, V145, P3414, DOI 10.1002/ijc.32408
   Turin I, 2018, J IMMUNOTHER, V41, P190, DOI 10.1097/CJI.0000000000000205
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Veluchamy JP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157830
   Vigano S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00925
   Vitiello PP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1035-0
   Weitsman G, 2017, ONCOGENE, V36, P3618, DOI 10.1038/onc.2016.522
   Xynos ID, 2013, ONCOLOGY-BASEL, V84, P273, DOI 10.1159/000343282
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Ying HQ, 2015, ONCOTARGET, V6, P28071, DOI 10.18632/oncotarget.4872
   Yu YY, 2016, ONCOTARGET, V7, P80888, DOI 10.18632/oncotarget.13105
   Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023
   Zhai ZH, 2017, SEMIN CELL DEV BIOL, V64, P107, DOI 10.1016/j.semcdb.2016.08.033
   Zhang WN, 2016, ONCOTARGET, V7, P75366, DOI 10.18632/oncotarget.12207
   Zheng P, 2018, J ONCOL, V2018, DOI 10.1155/2018/5072987
NR 77
TC 35
Z9 38
U1 0
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD AUG
PY 2019
VL 11
IS 8
AR 1089
DI 10.3390/cancers11081089
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IV7HU
UT WOS:000484438000049
PM 31370270
OA Green Published, gold, Green Accepted, Green Submitted
DA 2025-01-04
ER

PT J
AU Fong, ELS
   Toh, TB
   Lin, XX
   Liu, Z
   Hooi, L
   Rashid, MBMA
   Benoukraf, T
   Chow, EKH
   Huynh, TH
   Yu, HR
AF Fong, Eliza Li Shan
   Toh, Tan Boon
   Lin, Xiaoxuan
   Liu, Zheng
   Hooi, Lissa
   Rashid, Masturah Bte Mohd Abdul
   Benoukraf, Touati
   Chow, Edward Kai-Hua
   Huynh, The Hung
   Yu, Hanry
TI Generation of matched patient-derived xenograft <i>in vitro</i>-<i>in
   vivo</i> models using 3D macroporous hydrogels for the study of liver
   cancer
SO BIOMATERIALS
LA English
DT Article
DE Hepatocellular carcinoma; Patient-derived xenograft; Drug testing; 3D
   tumor model; Organoids
ID HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; HETEROGENEITY; TUMORS;
   GROWTH; SENSITIVITY; SORAFENIB; BIOBANK; GENES
AB Hepatocellular carcinoma (HCC) is the third leading cause of cancer death worldwide, often manifesting at the advanced stage when cure is no longer possible. The discrepancy between preclinical findings and clinical outcome in HCC is well-recognized. So far, sorafenib is the only targeted therapy approved as first-line therapy for patients with advanced HCC. There is an urgent need for improved preclinical models for the development of HCC-targeted therapies. Patient-derived xenograft (PDX) tumor models have been shown to closely recapitulate human tumor biology and predict patient drug response. However, the use of PDX models is currently limited by high costs and low throughput. In this study, we engineered in vitro conditions conducive for the culture of HCC-PDX organoids derived from a panel of 14 different HCC-PDX lines through the use of a three-dimensional macroporous cellulosic sponge system. To validate the in vitro HCC-PDX models, both in vivo and in vitro HCC-PDX models were subjected to whole exome sequencing and RNA-sequencing. Correlative studies indicate strong concordance in genomic and transcriptomic profiles as well as intra-tumoral heterogeneity between each matched in vitro-in vivo HCC-PDX pairs. Furthermore, we demonstrate the feasibility of using these in vitro HCC-PDX models for drug testing, paving the way for more efficient preclinical studies in HCC drug development. (C) 2018 Elsevier Ltd. All rights reserved.
C1 [Fong, Eliza Li Shan] Natl Univ Singapore, Dept Biomed Engn, Singapore, Singapore.
   [Toh, Tan Boon; Lin, Xiaoxuan; Hooi, Lissa; Rashid, Masturah Bte Mohd Abdul; Benoukraf, Touati; Chow, Edward Kai-Hua] Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.
   [Liu, Zheng; Yu, Hanry] ASTAR, Inst Bioengn & Nanotechnol, Singapore, Singapore.
   [Huynh, The Hung] Natl Canc Ctr Singapore, Singapore, Singapore.
   [Yu, Hanry] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore.
   [Yu, Hanry] Natl Univ Singapore, Mechanobiol Inst, Singapore, Singapore.
   [Yu, Hanry] Singapore MIT Alliance Res & Technol, BioSyM, Singapore, Singapore.
   [Yu, Hanry] Southern Med Univ, Nanfang Hosp, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China.
   [Yu, Hanry] Natl Univ Singapore, NUS Grad Sch Integrat Sci & Engn, Singapore, Singapore.
   [Chow, Edward Kai-Hua] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.
C3 National University of Singapore; National University of Singapore;
   Agency for Science Technology & Research (A*STAR); A*STAR - Institute of
   Bioengineering & Bioimaging (IBB); A*STAR - Institute of Bioengineering
   & Nanotechnology (IBN); National Cancer Centre Singapore (NCCS);
   National University of Singapore; National University of Singapore;
   Singapore-MIT Alliance for Research & Technology Centre (SMART);
   Southern Medical University - China; National University of Singapore;
   National University of Singapore
RP Fong, ELS (corresponding author), Natl Univ Singapore, Dept Biomed Engn, Singapore, Singapore.; Chow, EKH (corresponding author), Natl Univ Singapore, Canc Sci Inst Singapore, Singapore, Singapore.; Huynh, TH (corresponding author), Natl Canc Ctr Singapore, Singapore, Singapore.; Chow, EKH (corresponding author), Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore, Singapore.
EM bieflse@nus.edu.sg; csikce@nus.edu.sg; cmrhth@nccs.com.sg
RI Toh, Tan/J-5178-2019; Yu, Hanry/L-6050-2019; Benoukraf,
   Touati/K-9978-2019; Chow, Edward/C-4697-2015
OI Huynh, Hung The/0000-0001-7847-3981; Lin, Xiao Xuan/0000-0002-7167-2627;
   Fong, Eliza/0000-0001-5770-0700; Benoukraf, Touati/0000-0002-4789-8028;
   Toh, Tan Boon/0000-0003-0292-6985
FU National Medical Research Council of Singapore
   [NMRC/MOHIAF-CAT2/006/2016]; National Research Foundation Cancer Science
   Institute of Singapore RCE Main Grant, Ministry of Education Academic
   Research Fund (MOE AcRF) [MOE2015-T2-2-126, T1-BSRG 2014-05]; NMRC
   Translational and Clinical Research (TCR) Flagship Programme
   [NMRC/TCR/015-NCC/2016]; Mechanobiology Institute (National University
   of Singapore, Singapore) [R-714-006-008-271]; Institute of
   Bioengineering and Nanotechnology (A*STAR, Singapore); Singapore-MIT
   Alliance for Research and Technology; National Medical Research Council
   (Ministry of Health, Singapore) [R-185-000-294-511]; Joint Council
   Office grants (A*STAR, Singapore)
FX T.H. Huynh would like to acknowledge funding from the National Medical
   Research Council of Singapore (NMRC/MOHIAF-CAT2/006/2016). E.K-H. Chow
   would like to acknowledge funding from the National Research Foundation
   Cancer Science Institute of Singapore RCE Main Grant, Ministry of
   Education Academic Research Fund (MOE AcRF Tier 2, MOE2015-T2-2-126,
   Seed Fund Grant T1-BSRG 2014-05) and NMRC Translational and Clinical
   Research (TCR) Flagship Programme (NMRC/TCR/015-NCC/2016). H. Yu would
   like to acknowledge funding from the Mechanobiology Institute (National
   University of Singapore, Singapore, Grant number: R-714-006-008-271),
   Institute of Bioengineering and Nanotechnology (A*STAR, Singapore),
   Singapore-MIT Alliance for Research and Technology, National Medical
   Research Council (Ministry of Health, Singapore, Grant Number:
   R-185-000-294-511) and Joint Council Office grants (A*STAR, Singapore).
   We would also like to acknowledge Dr. Melanie Lee (Mechanobiology
   Institute, National University of Singapore) for her help with graphic
   illustration, and the National University Health System Confocal
   Microscopy Unit for help with confocal microscopy.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   [Anonymous], BR J CANC
   [Anonymous], DATA DESCRIBING GROW
   [Anonymous], NUCL ACIDS RES
   Bruna A, 2016, CELL, V167, P260, DOI 10.1016/j.cell.2016.08.041
   Chaisaingmongkol J, 2017, CANCER CELL, V32, P57, DOI 10.1016/j.ccell.2017.05.009
   Chang HK, 2009, J PEDIATR GASTR NUTR, V49, P323, DOI 10.1097/MPG.0b013e31819de7ba
   Cheung PFY, 2016, CANCER CELL INT, V16, DOI 10.1186/s12935-016-0322-5
   Cho CS, 2006, BIOMATERIALS, V27, P576, DOI 10.1016/j.biomaterials.2005.06.008
   Choi SYC, 2014, ADV DRUG DELIVER REV, V79-80, P222, DOI 10.1016/j.addr.2014.09.009
   Curcio E, 2007, BIOMATERIALS, V28, P5487, DOI 10.1016/j.biomaterials.2007.08.033
   Danecek P, 2011, BIOINFORMATICS, V27, P2156, DOI 10.1093/bioinformatics/btr330
   Daniel VC, 2009, CANCER RES, V69, P3364, DOI 10.1158/0008-5472.CAN-08-4210
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Fischbach C, 2007, NAT METHODS, V4, P855, DOI 10.1038/NMETH1085
   Fong ELS, 2014, MOL PHARMACEUT, V11, P2040, DOI 10.1021/mp500085p
   Fong ELS, 2013, P NATL ACAD SCI USA, V110, P6500, DOI 10.1073/pnas.1221403110
   Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003
   Gao H, 2015, NAT MED, V21, P1318, DOI 10.1038/nm.3954
   Gao Q, 2017, GASTROENTEROLOGY, V152, P232, DOI 10.1053/j.gastro.2016.09.008
   Goossens N, 2015, HEPAT ONCOL, V2, P371, DOI 10.2217/hep.15.26
   Heinz S, 2010, MOL CELL, V38, P576, DOI 10.1016/j.molcel.2010.05.004
   Hidalgo M, 2014, CANCER DISCOV, V4, P998, DOI 10.1158/2159-8290.CD-14-0001
   Ho DWH, 2015, FRONT MED-PRC, V9, P322, DOI 10.1007/s11684-015-0408-9
   Huynh H, 2006, CLIN CANCER RES, V12, P4306, DOI 10.1158/1078-0432.CCR-05-2568
   Huynh H, 2012, J HEPATOL, V56, P595, DOI 10.1016/j.jhep.2011.09.017
   Huynh H, 2010, J HEPATOL, V52, P79, DOI 10.1016/j.jhep.2009.10.008
   Huynh H, 2009, J CELL MOL MED, V13, P2673, DOI 10.1111/j.1582-4934.2009.00692.x
   Huynh H, 2009, J CELL MOL MED, V13, P1371, DOI 10.1111/j.1582-4934.2008.00364.x
   Jacks T, 2002, CELL, V111, P923, DOI 10.1016/S0092-8674(02)01229-1
   Gómez-Lechón MJ, 2014, EXPERT OPIN DRUG MET, V10, P1553, DOI 10.1517/17425255.2014.967680
   Jung HR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10828-7
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Ledford H, 2016, NATURE, V530, P391, DOI 10.1038/nature.2016.19364
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]
   McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Nugraha B, 2011, BIOMATERIALS, V32, P6982, DOI 10.1016/j.biomaterials.2011.05.087
   Qiu ZX, 2016, SCI REP-UK, V6, DOI 10.1038/srep27411
   Schmidt B, 2016, INT J CANCER, V138, P1494, DOI 10.1002/ijc.29893
   Schütte M, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14262
   Takai A, 2016, SCI REP-UK, V6, DOI 10.1038/srep21174
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053
   Wang WN, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1814-8
   Wu SD, 2012, CANCER TREAT REV, V38, P218, DOI 10.1016/j.ctrv.2011.06.010
   Xin H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085308
   Yue ZL, 2010, BIOMATERIALS, V31, P8141, DOI 10.1016/j.biomaterials.2010.07.059
NR 50
TC 53
Z9 56
U1 6
U2 82
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD MAR
PY 2018
VL 159
BP 229
EP 240
DI 10.1016/j.biomaterials.2017.12.026
PG 12
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA FW1PC
UT WOS:000425070900019
PM 29353739
DA 2025-01-04
ER

PT J
AU Nigam, J
   Chandra, A
   Kazmi, HR
   Parmar, D
   Singh, D
   Gupta, V
AF Nigam, Jaya
   Chandra, Abhijit
   Kazmi, Hasan Raza
   Parmar, Devendra
   Singh, Devendra
   Gupta, Vishal
TI Prognostic significance of survivin in resected gallbladder cancer
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Cholelithiasis; ELISA; Gallbladder cancer; Prognosis; Real time PCR;
   Survivin
ID ANTI-APOPTOSIS GENE; COLORECTAL-CANCER; PHASE-II; EXPRESSION; CARCINOMA;
   INHIBITION; SUPPRESSOR; LYMPHOMA; PROTEINS; TARGET
AB Background: Survivin, a novel inhibitor of apoptosis, plays a role in oncogenesis and has been correlated with poor prognosis. We investigated its expression in gallbladder tissues of control, cholelithiasis, and gallbladder cancer (GBC). Survivin expression was correlated with different clinicopathologic parameters including prognosis in patients with GBC.
   Materials and methods: Gallbladder tissue samples were collected from GBC (n = 39), cholelithiasis (n = 30), and control (n = 25). Expression of survivin messenger RNA (mRNA) was evaluated by real time polymerase chain reaction. Protein quantification was done by enzyme-linked immunosorbent assay.
   Results: Significantly higher expression of survivin mRNA was observed in GBC (2.9-fold) and cholelithiasis (1.85-fold) as compared with control (P < 0.0001). In GBC, increased survivin expression (mRNA and protein) was significantly associated with higher tumor stage (stage III versus stage II) (P < 0.0001) and poor tumor differentiation (poor and moderate versus well) (P < 0.0001). No significant correlation was observed with any of the other clinicopathologic factors studied. Increased expression of survivin was associated with shorter survival (median survival 11.5 mo versus 18 mo).
   Conclusions: Differential expression of survivin in GBC suggests its possible role in gallbladder carcinogenesis. Its overexpression is associated with poor prognosis. Assessment of survivin might be used to stratify GBC patients for optimal treatment modalities, including targeted therapy. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Nigam, Jaya; Chandra, Abhijit; Kazmi, Hasan Raza; Gupta, Vishal] King Georges Med Univ, Dept Surg Gastroenterol, Lucknow 226003, Uttar Pradesh, India.
   [Parmar, Devendra] Indian Inst Toxicol Res, Div Dev Toxicol, Lucknow, Uttar Pradesh, India.
   [Singh, Devendra] King Georges Med Univ, Dept Surg, Lucknow 226003, Uttar Pradesh, India.
C3 King George's Medical University; Council of Scientific & Industrial
   Research (CSIR) - India; CSIR - Indian Institute of Toxicology Research
   (IITR); King George's Medical University
RP Chandra, A (corresponding author), King Georges Med Univ, Dept Surg Gastroenterol, Lucknow 226003, Uttar Pradesh, India.
EM abhijitchandra@hotmail.com
RI Kazmi, Hasan/AAY-1682-2021; Nigam, Jaya/HSH-8055-2023; Gupta,
   Vishal/ABG-4280-2020
OI Gupta, Vishal/0000-0003-3574-1805
FU Indian Council of Medical Research, New Delhi, India
   [3/2/2/130/2012/NCD-III]
FX This work was supported by the Indian Council of Medical Research, New
   Delhi, India (Grant No. 3/2/2/130/2012/NCD-III).
CR Altieri DC, 2003, NAT REV CANCER, V3, P46, DOI 10.1038/nrc968
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Chen WC, 2004, WORLD J GASTROENTERO, V10, P2886
   Cheng Qiuying, 2012, Int J Biochem Mol Biol, V3, P179
   Cheson BD, 2012, CANCER-AM CANCER SOC, V118, P3128, DOI 10.1002/cncr.26510
   Deveraux QL, 1998, EMBO J, V17, P2215, DOI 10.1093/emboj/17.8.2215
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Idenoue S, 2005, CLIN CANCER RES, V11, P1474, DOI 10.1158/1078-0432.CCR-03-0817
   Kapoor VK, 2003, NATL MED J INDIA, V16, P209
   Kappler M, 2003, CLIN CANCER RES, V9, P1098
   Kato J, 2001, INT J CANCER, V95, P92
   Kawasaki H, 1998, CANCER RES, V58, P5071
   Kazmi HR, 2013, DIGEST SURG, V30, P233, DOI 10.1159/000353133
   Krepela E, 2009, INT J ONCOL, V35, P1449, DOI 10.3892/ijo_00000464
   Krieg A, 2002, BRIT J CANCER, V86, P737, DOI 10.1038/sj.bjc.6600153
   Lee GH, 2006, EUR J GASTROEN HEPAT, V18, P957, DOI 10.1097/01.meg.0000230086.83792.56
   Li FZ, 2005, INT J CANCER, V114, P509, DOI 10.1002/ijc.20768
   Liu BB, 2011, WORLD J CLIN ONCOL, V2, P164, DOI 10.5306/wjco.v2.i3.164
   Maurya SK, 2012, SURG ONCOL, V21, P37, DOI 10.1016/j.suronc.2010.09.003
   Misra S, 2003, LANCET ONCOL, V4, P167, DOI 10.1016/S1470-2045(03)01021-0
   Mita AC, 2008, CLIN CANCER RES, V14, P5000, DOI 10.1158/1078-0432.CCR-08-0746
   Monzó M, 1999, J CLIN ONCOL, V17, P2100, DOI 10.1200/JCO.1999.17.7.2100
   Nigam Pallavi, 2010, Trop Gastroenterol, V31, P96
   Qiao JG, 2004, WORLD J GASTROENTERO, V10, P2759, DOI 10.3748/wjg.v10.i18.2759
   Randi G, 2006, INT J CANCER, V118, P1591, DOI 10.1002/ijc.21683
   Sarela AI, 2000, GUT, V46, P645, DOI 10.1136/gut.46.5.645
   Sarela AI, 2001, ANN SURG ONCOL, V8, P305
   Satoh K, 2001, CANCER, V92, P271, DOI 10.1002/1097-0142(20010715)92:2<271::AID-CNCR1319>3.0.CO;2-0
   Steele RJC, 1998, BRIT J SURG, V85, P1460
   Swana HS, 1999, NEW ENGL J MED, V341, P452, DOI 10.1056/NEJM199908053410614
   Takai N, 2002, CANCER LETT, V184, P105, DOI 10.1016/S0304-3835(02)00190-8
   Tolcher AW, 2012, ANN ONCOL, V23, P968, DOI 10.1093/annonc/mdr353
   Waligorska-Stachura J, 2012, GINEKOL POL, V83, P537
   Wen SF, 2003, CANCER GENE THER, V10, P224, DOI 10.1038/sj.cgt.7700562
   Won HS, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-564
   Yang D, 2004, P NATL ACAD SCI USA, V101, P15100, DOI 10.1073/pnas.0406665101
NR 36
TC 10
Z9 14
U1 0
U2 0
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
EI 1095-8673
J9 J SURG RES
JI J. Surg. Res.
PD MAR
PY 2015
VL 194
IS 1
BP 57
EP 62
DI 10.1016/j.jss.2014.07.054
PG 6
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA CC5FH
UT WOS:000350384000008
PM 25472573
DA 2025-01-04
ER

PT J
AU Liao, MY
   Lai, JK
   Kuo, MYP
   Lu, RM
   Lin, CW
   Cheng, PC
   Liang, KH
   Wu, HC
AF Liao, Mei-Ying
   Lai, Jun-Kai
   Kuo, Mark Yen-Ping
   Lu, Ruei-Min
   Lin, Cheng-Wei
   Cheng, Ping-Chang
   Liang, Kang-Hao
   Wu, Han-Chung
TI An anti-EpCAM antibody EpAb2-6 for the treatment of colon cancer
SO ONCOTARGET
LA English
DT Article
DE colorectal carcinoma; EpCAM; therapeutic antibody; targeting imaging;
   cancer therapy
ID CIRCULATING TUMOR-CELLS; EPITHELIAL-MESENCHYMAL TRANSITION;
   HEPATOCELLULAR-CARCINOMA CELLS; ADHESION MOLECULE EPCAM;
   MONOCLONAL-ANTIBODY; EP-CAM; COLORECTAL-CANCER; BREAST-CANCER;
   PANCREATIC-CANCER; IMMUNOTHERAPEUTIC TARGET
AB Epithelial cell adhesion molecule (EpCAM) is known to be overexpressed in epithelial cancers associated with enhanced malignant potential, particularly colorectal carcinoma (CRC) and head and neck squamous cell carcinoma (HNSCC). However, it is unknown whether progression of malignance can be directly inhibited by targeting EpCAM. Here, we have generated five novel monoclonal antibodies (mAbs) against EpCAM. One of these anti-EpCAM mAbs, EpAb2-6, was found to induce cancer cell apoptosis in vitro, inhibit tumor growth, and prolong the overall survival of both a pancreatic cancer metastatic mouse model and mice with human colon carcinoma xenografts. EpAb2-6 also increases the therapeutic efficacy of irinotecan, fluorouracil, and leucovorin (IFL) therapy in a colon cancer animal model and gemcitabine therapy in a pancreatic cancer animal model. Furthermore, EpAb2-6, which binds to positions Y95 and D96 of the EGF-II/TY domain of EpCAM, inhibits production of EpICD, thereby decreasing its translocation and subsequent signal activation. Collectively, our results indicate that the novel anti-EpCAM mAb can potentially be used for cancer-targeted therapy.
C1 [Liao, Mei-Ying; Lai, Jun-Kai; Lu, Ruei-Min; Lin, Cheng-Wei; Cheng, Ping-Chang; Liang, Kang-Hao; Wu, Han-Chung] Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
   [Liao, Mei-Ying; Kuo, Mark Yen-Ping] Natl Taiwan Univ, Sch Dent, Grad Inst Clin Dent, Taipei 10764, Taiwan.
   [Wu, Han-Chung] Acad Sinica, Genom Res Ctr, Taipei 115, Taiwan.
C3 Academia Sinica - Taiwan; National Taiwan University; Academia Sinica -
   Taiwan
RP Wu, HC (corresponding author), Acad Sinica, Inst Cellular & Organism Biol, Taipei 115, Taiwan.
EM hcw0928@gate.sinica.edu.tw
RI Wu, Han-Chung/B-1209-2011; Lu, Ruei-Min/ABF-4388-2021
OI Lu, Ruei-Min/0000-0003-3792-5499; Liang, Kang-Hao/0000-0003-3942-0259
FU Academia Sinica; Ministry of Science and Technology [104-0210-01-09-02];
   National Science Council, Taiwan [NSC103-2321-B-001-064]
FX This research was supported by grants from Academia Sinica, the Ministry
   of Science and Technology (104-0210-01-09-02), and the National Science
   Council (NSC103-2321-B-001-064), Taiwan (to H-C Wu).
CR Akita H, 2011, ONCOGENE, V30, P3468, DOI 10.1038/onc.2011.59
   Allard WJ, 2004, CLIN CANCER RES, V10, P6897, DOI 10.1158/1078-0432.CCR-04-0378
   Armstrong AJ, 2011, MOL CANCER RES, V9, P997, DOI 10.1158/1541-7786.MCR-10-0490
   Baeuerle PA, 2007, BRIT J CANCER, V96, P417, DOI 10.1038/sj.bjc.6603494
   Balzar M, 1999, EXP CELL RES, V246, P108, DOI 10.1006/excr.1998.4263
   Brischwein K, 2006, MOL IMMUNOL, V43, P1129, DOI 10.1016/j.molimm.2005.07.034
   Brosh R, 2009, NAT REV CANCER, V9, P701, DOI 10.1038/nrc2693
   Burris HA, 1997, J CLIN ONCOL, V15, P2403, DOI 10.1200/JCO.1997.15.6.2403
   Chaudry MA, 2007, BRIT J CANCER, V96, P1013, DOI 10.1038/sj.bjc.6603505
   Chiba T, 2006, HEPATOLOGY, V44, P240, DOI 10.1002/hep.21227
   Chong JM, 2001, J BIOL CHEM, V276, P5804, DOI 10.1074/jbc.M008839200
   Cioffi M, 2012, CLIN CANCER RES, V18, P465, DOI 10.1158/1078-0432.CCR-11-1270
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   de Boer CJ, 1999, J PATHOL, V188, P201, DOI 10.1002/(SICI)1096-9896(199906)188:2<201::AID-PATH339>3.0.CO;2-8
   de Bono JS, 2004, CLIN CANCER RES, V10, P7555, DOI 10.1158/1078-0432.CCR-04-0729
   Deng G, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2131
   Denzel S, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-402
   Di Paolo C, 2003, CLIN CANCER RES, V9, P2837
   Driemel C, 2014, ONCOGENE, V33, P4904, DOI 10.1038/onc.2013.441
   Fagotto F, 1996, DEV BIOL, V180, P445, DOI 10.1006/dbio.1996.0318
   Fanciullino R, 2007, BRIT J CANCER, V97, P919, DOI 10.1038/sj.bjc.6603970
   Fields ALA, 2009, J CLIN ONCOL, V27, P1941, DOI 10.1200/JCO.2008.18.5710
   Fong D, 2008, J CLIN PATHOL, V61, P31, DOI 10.1136/jcp.2006.037333
   Gastl G, 2000, LANCET, V356, P1981, DOI 10.1016/S0140-6736(00)03312-2
   Gires O, 2009, NAT REV CANCER, V9, P143, DOI 10.1038/nrc2499-c1
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hachmeister M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071836
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   HOLLSTEIN M, 1991, SCIENCE, V253, P49, DOI 10.1126/science.1905840
   Huang HP, 2011, J BIOL CHEM, V286, P33520, DOI 10.1074/jbc.M111.256164
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277
   KOHLER G, 1975, NATURE, V256, P495, DOI 10.1038/256495a0
   Kurtz JE, 2010, EXPERT OPIN BIOL TH, V10, P951, DOI 10.1517/14712598.2010.482098
   Li DH, 2004, LANCET, V363, P1049, DOI 10.1016/S0140-6736(04)15841-8
   Liao MY, 2015, INT J ONCOL, V46, P1788, DOI 10.3892/ijo.2015.2876
   Lin CW, 2012, J BIOL CHEM, V287, DOI 10.1074/jbc.M112.386235
   LIN CT, 1993, LAB INVEST, V68, P716
   Liu IJ, 2011, J BIOL CHEM, V286, P9726, DOI 10.1074/jbc.M110.170993
   Liu MR, 2009, P NATL ACAD SCI USA, V106, P19035, DOI 10.1073/pnas.0910009106
   Lo A, 2008, MOL CANCER THER, V7, P579, DOI 10.1158/1535-7163.MCT-07-2359
   Lu TY, 2010, J BIOL CHEM, V285, P8719, DOI 10.1074/jbc.M109.077081
   Maaser K, 2008, BRIT J CANCER, V99, P1635, DOI 10.1038/sj.bjc.6604725
   Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824
   Mechtersheimer S, 2001, J CELL BIOL, V155, P661, DOI 10.1083/jcb.200101099
   Meh P, 2005, BIOL CHEM, V386, P75, DOI 10.1515/BC.2005.010
   Molina F, 1996, EUR J BIOCHEM, V240, P125, DOI 10.1111/j.1432-1033.1996.0125h.x
   Münz M, 2010, CANCER CELL INT, V10, DOI 10.1186/1475-2867-10-44
   Nagrath S, 2007, NATURE, V450, P1235, DOI 10.1038/nature06385
   Naundorf S, 2002, INT J CANCER, V100, P101, DOI 10.1002/ijc.10443
   Ni J, 2013, INT J BIOCHEM CELL B, V45, P2736, DOI 10.1016/j.biocel.2013.09.008
   Nomura T, 2005, J MED INVESTIG, V52, P1, DOI 10.2152/jmi.52.1
   Ocvirk J, 2010, WORLD J GASTROENTERO, V16, P3133, DOI 10.3748/wjg.v16.i25.3133
   Olive KP, 2009, SCIENCE, V324, P1457, DOI 10.1126/science.1171362
   Patriarca C, 2012, CANCER TREAT REV, V38, P68, DOI 10.1016/j.ctrv.2011.04.002
   Pavsic M, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5764
   Punt CJA, 2002, LANCET, V360, P671, DOI 10.1016/S0140-6736(02)09836-7
   Ralhan R, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014130
   Riedle S, 2009, BIOCHEM J, V420, P391, DOI 10.1042/BJ20081625
   RIETHMULLER G, 1994, LANCET, V343, P1177, DOI 10.1016/S0140-6736(94)92398-1
   Riethmüller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788
   Ruf P, 2007, BRIT J CANCER, V97, P315, DOI 10.1038/sj.bjc.6603881
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Sankpal NV, 2009, CANCER RES, V69, P753, DOI 10.1158/0008-5472.CAN-08-2708
   Schmidt M, 2010, ANN ONCOL, V21, P275, DOI 10.1093/annonc/mdp314
   Schulze K, 2013, INT J CANCER, V133, P2165, DOI 10.1002/ijc.28230
   Schwartzberg LS, 2001, CRIT REV ONCOL HEMAT, V40, P17, DOI 10.1016/S1040-8428(01)00131-7
   SEARS HF, 1982, LANCET, V1, P762
   SIMON B, 1990, P NATL ACAD SCI USA, V87, P2755, DOI 10.1073/pnas.87.7.2755
   Simon M, 2013, EXPERT OPIN DRUG DEL, V10, P451, DOI 10.1517/17425247.2013.759938
   STRNAD J, 1989, CANCER RES, V49, P314
   SZALA S, 1990, P NATL ACAD SCI USA, V87, P6833, DOI 10.1073/pnas.87.17.6833
   Tung KH, 2013, CANCER LETT, V331, P58, DOI 10.1016/j.canlet.2012.12.001
   Turk V, 2012, BBA-PROTEINS PROTEOM, V1824, P68, DOI 10.1016/j.bbapap.2011.10.002
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Welch SA, 2007, J CLIN ONCOL, V25, P2159, DOI 10.1200/JCO.2006.09.9788
   Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924
   Xiang R, 1997, CANCER RES, V57, P4948
   Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908
   Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004
   Zeidler R, 1999, J IMMUNOL, V163, P1246
NR 81
TC 38
Z9 45
U1 0
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 22
PY 2015
VL 6
IS 28
BP 24947
EP 24968
DI 10.18632/oncotarget.4453
PG 22
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA CT9TS
UT WOS:000363160100035
PM 26317650
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Wang, WT
   Zhang, L
   Morlock, L
   Williams, NS
   Shay, JW
   De Brabander, JK
AF Wang, Wentian
   Zhang, Lu
   Morlock, Lorraine
   Williams, Noelle S.
   Shay, Jerry W.
   De Brabander, Jef K.
TI Design and Synthesis of TASIN Analogues Specifically Targeting
   Colorectal Cancer Cell Lines with Mutant Adenomatous Polyposis Coli
   (APC)
SO JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
ID TUMOR-SUPPRESSOR APC; MUTATION; BINDING; FUTURE; POTENT; MODEL; SITE;
   ASEF
AB Despite advances in targeted anticancer therapies, there are still no small-molecule-based therapies available that specifically target colorectal cancer (CRC) development and progression, the second leading cause of cancer deaths. We previously disclosed the discovery of truncating adenomatous polyposis coli (APC)-selective inhibitor 1 (TASIN-1), a small molecule that specifically targets colorectal cancer cells lines with truncating mutations in the adenomatous polyposis coli (APC) tumor suppressor gene through inhibition of cholesterol biosynthesis. Here, we report a medicinal chemistry evaluation of a collection of TASIN analogues and activity against colon cancer cell lines and an isogenic cell line pair reporting on the status of APC-dependent selectivity. A number of potent and selective analogues were identified, including compounds with good metabolic stability and pharmacokinetic properties. The compounds reported herein represent a first-in-class genotype-selective series that specifically target apc mutations present in the majority of CRC patients and serve as a translational platform toward a targeted therapy for colon cancer.
C1 [Wang, Wentian; Morlock, Lorraine; Williams, Noelle S.; De Brabander, Jef K.] Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
   [Zhang, Lu; Shay, Jerry W.] Univ Texas Southwestern Med Ctr Dallas, Dept Cell Biol, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
C3 University of Texas System; University of Texas Southwestern Medical
   Center Dallas; University of Texas System; University of Texas
   Southwestern Medical Center Dallas
RP De Brabander, JK (corresponding author), Univ Texas Southwestern Med Ctr Dallas, Dept Biochem, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM Jef.DeBrabander@UTSouthwestern.edu
RI Shay, Jerry/F-7878-2011
FU Cancer Prevention and Research Institute of Texas [RP130189, RP160180];
   Welch Foundation [1-1422]; Institute for Innovations in Medicine
FX This work was supported by the Cancer Prevention and Research Institute
   of Texas (grants RP130189 and RP160180). J.K.D.B. acknowledges the
   support of the Welch Foundation (Grant 1-1422). N.S.W. and the
   Preclinical Pharmacology Core were supported in part by institutional
   funds from the Institute for Innovations in Medicine. HRMS data were
   obtained from the Shimadzu Center for Advanced Analytical Chemistry
   (SCAAC) at UT Arlington. J.K.D.B. holds the Julie and Louis Beecherl,
   Jr., Chair in Medical Science, and J.W.S. holds the distinguished
   Southland Financial Corporation Chair in Geriatrics Research. The
   authors thank Karen MacMillan for the synthesis of select analogues.
CR AbdelMagid AF, 1996, J ORG CHEM, V61, P3849, DOI 10.1021/jo960057x
   Akhtar R, 2014, WORLD J GASTRO ONCOL, V6, P177, DOI 10.4251/wjgo.v6.i6.177
   Aoki K, 2007, J CELL SCI, V120, P3327, DOI 10.1242/jcs.03485
   Chen HJ, 2013, J MED CHEM, V56, P952, DOI 10.1021/jm3014162
   Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033
   Ellis GL, 2008, J MED CHEM, V51, P2170, DOI 10.1021/jm701435h
   Engler TA, 2000, J ORG CHEM, V65, P2444, DOI 10.1021/jo9916176
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Goss KH, 2000, J CLIN ONCOL, V18, P1967, DOI 10.1200/JCO.2000.18.9.1967
   Green RA, 2003, J CELL BIOL, V163, P949, DOI 10.1083/jcb.200307070
   Han Q, 2000, J MED CHEM, V43, P4398, DOI 10.1021/jm000113t
   Hinoi T, 2007, CANCER RES, V67, P9721, DOI 10.1158/0008-5472.CAN-07-2735
   Kalvass JC, 2002, BIOPHARM DRUG DISPOS, V23, P327, DOI 10.1002/bdd.325
   Kawasaki Y, 2003, NAT CELL BIOL, V5, P211, DOI 10.1038/ncb937
   Kawasaki Y, 2000, SCIENCE, V289, P1194, DOI 10.1126/science.289.5482.1194
   Kazmi F, 2013, DRUG METAB DISPOS, V41, P897, DOI 10.1124/dmd.112.050054
   Kim SB, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00135-18
   Kwon Y., 2001, The Handbook of Essential Pharmacokinetics, Pharmacodynamics, and Drug Metabolism for Industrial Scientists, P231
   Lamlum H, 1999, NAT MED, V5, P1071, DOI 10.1038/12511
   LIEN EA, 1991, CANCER RES, V51, P4837
   Ma DW, 2003, ORG LETT, V5, P2453, DOI 10.1021/ol0346584
   MACINTYRE AC, 1988, BIOPHARM DRUG DISPOS, V9, P513, DOI 10.1002/bod.2510090602
   Martini G, 2017, WORLD J GASTROENTERO, V23, P4675, DOI 10.3748/wjg.v23.i26.4675
   McNaney CA, 2008, ASSAY DRUG DEV TECHN, V6, P121, DOI 10.1089/adt.2007.103
   Miyoshi Yasuo, 1992, Human Molecular Genetics, V1, P229
   Moriarity A, 2016, THER ADV MED ONCOL, V8, P276, DOI 10.1177/1758834016646734
   Nieuwenhuis MH, 2007, CRIT REV ONCOL HEMAT, V61, P153, DOI 10.1016/j.critrevonc.2006.07.004
   Polakis P, 1997, BBA-REV CANCER, V1332, pF127, DOI 10.1016/S0304-419X(97)00008-5
   POWELL SM, 1992, NATURE, V359, P235, DOI 10.1038/359235a0
   Reasor MJ, 2006, EXPERT OPIN DRUG SAF, V5, P567, DOI 10.1517/14740338.5.4.567
   Roberts DM, 2011, MOL BIOL CELL, V22, P1845, DOI 10.1091/mbc.E10-11-0871
   Roig AI, 2010, GASTROENTEROLOGY, V138, P1012, DOI 10.1053/j.gastro.2009.11.052
   Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352
   Tighe A, 2004, J CELL SCI, V117, P6339, DOI 10.1242/jcs.01556
   TOPLISS JG, 1972, J MED CHEM, V15, P1066, DOI 10.1021/jm00280a017
   TOPLISS JG, 1977, J MED CHEM, V20, P463, DOI 10.1021/jm00214a001
   van de Wetering M, 2002, CELL, V111, P241, DOI 10.1016/S0092-8674(02)01014-0
   Wang CG, 2013, J PHARMACEUT BIOMED, V75, P112, DOI 10.1016/j.jpba.2012.11.018
   Zhang L, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8127
NR 39
TC 14
Z9 15
U1 1
U2 16
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 0022-2623
EI 1520-4804
J9 J MED CHEM
JI J. Med. Chem.
PD MAY 23
PY 2019
VL 62
IS 10
BP 5217
EP 5241
DI 10.1021/acs.jmedchem.9b00532
PG 25
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA IA1FK
UT WOS:000469304500024
PM 31070915
OA Green Accepted
DA 2025-01-04
ER

PT J
AU Dong, CP
   Cui, DN
   Liu, G
   Xu, HL
   Peng, XQ
   Duan, J
   Liu, L
AF Dong, Chuanpeng
   Cui, Danni
   Liu, Gang
   Xu, Huilin
   Peng, Xueqing
   Duan, Juan
   Liu, Lei
TI Cancer stem cell associated eight gene-based signature predicts clinical
   outcomes of colorectal cancer
SO ONCOLOGY LETTERS
LA English
DT Article
DE gene signature; cancer stem cell; colorectal cancer; prognosis
ID COLON; EXPRESSION; RECURRENCE; HEDGEHOG; TRANSITION; PATHWAYS; SURVIVAL;
   RECEPTOR; NOTCH; RISK
AB Previous studies have suggested that cancer stem cells serve crucial functions in tumorigenesis, metastasis and therapy failure. Stem cell signaling transduction pathways are frequently dysregulated in cancer and associated with tumorigenesis, metastasis and the cell cycle, which are necessary for cancer proliferation. However, cancer stem cell-associated gene signatures have not been established for predicting patient outcomes in colorectal cancer. Using a gene-mining approach, the present study performed mRNA expression profiling in large colorectal cancer cohorts from The Cancer Genome Atlas (TCGA) and the Gene Expression Omnibus (GEO) database, including a TCGA colorectal cancer cohort (n=383) and three independent validation series GSE39582 (n=582), GSE17536 (n=177) and GSE17537 (n=55). The present study identified that an eight-gene signature in cancer stem cell signaling was associated with the overall survival and disease/recurrence-free survival of patients with colorectal. On the basis of this signature, patients in the TCGA training sets were divided into high-risk and low-risk subgroups with a significantly different overall survival rate (hazard ratio, 2.38; P=0.0005). The prognostic value of this signature was confirmed using three independent GEO colorectal cancer sets. Identifying this prognostic stem cell signaling signature may provide an efficient classification tool for clinical prognosis evaluation, and facilitate cancer stem cell-targeted therapy.
C1 [Dong, Chuanpeng; Cui, Danni; Liu, Gang; Xu, Huilin; Peng, Xueqing; Liu, Lei] Fudan Univ, Inst Biomed Sci, 131 Dongan Rd, Shanghai 200032, Peoples R China.
   [Duan, Juan] Fujian Med Univ, Dept Biochem & Mol Biol, Sch Basic Med Sci, Fuzhou 350004, Fujian, Peoples R China.
   [Duan, Juan] Fujian Med Univ, Translat Med Inst, Fuzhou 350004, Fujian, Peoples R China.
C3 Fudan University; Fujian Medical University; Fujian Medical University
RP Liu, L (corresponding author), Fudan Univ, Inst Biomed Sci, 131 Dongan Rd, Shanghai 200032, Peoples R China.
EM liulei_fdu@163.com
RI xu, huilin/HHZ-3153-2022; Liu, Gang/H-6420-2019; Peng,
   Xueqing/GSN-3085-2022
FU National High Technology Research and Development Program of China (863
   Program) [2015AA020104]
FX The present study was supported by the National High Technology Research
   and Development Program of China (863 Program; grant no. 2015AA020104).
CR Ågesen TH, 2012, GUT, V61, P1560, DOI 10.1136/gutjnl-2011-301179
   Andersen RK, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12352
   Asfaha S, 2015, CELL STEM CELL, V16, P627, DOI 10.1016/j.stem.2015.04.013
   Bao B, 2011, CANCER LETT, V307, P26, DOI 10.1016/j.canlet.2011.03.012
   Cases O, 2013, J BIOL CHEM, V288, P16655, DOI 10.1074/jbc.M113.451070
   Christ A, 2012, DEV CELL, V22, P268, DOI 10.1016/j.devcel.2011.11.023
   Clark-Langone KM, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-691
   Cline MS, 2013, SCI REP-UK, V3, DOI 10.1038/srep02652
   Freeman TJ, 2012, GASTROENTEROLOGY, V142, P562, DOI 10.1053/j.gastro.2011.11.026
   Georges RB, 2011, CANCER BIOL THER, V12, P69, DOI 10.4161/cbt.12.1.15719
   Gray RG, 2011, J CLIN ONCOL, V29, P4611, DOI 10.1200/JCO.2010.32.8732
   Han LF, 2014, CANCER RES, V74, P6509, DOI 10.1158/0008-5472.CAN-14-0816
   He J, 2006, J BIOL CHEM, V281, P35598, DOI 10.1074/jbc.C600200200
   Hsieh TH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19156
   Kawaguchi A, 2012, CLIN CANCER RES, V18, P5672, DOI 10.1158/1078-0432.CCR-12-0596
   Keyomarsi K, 2002, NEW ENGL J MED, V347, P1566, DOI 10.1056/NEJMoa021153
   Lan YT, 2012, INT J COLORECTAL DIS, V27, P657, DOI 10.1007/s00384-011-1366-6
   Lu CH, 2007, CANCER RES, V67, P1757, DOI 10.1158/0008-5472.CAN-06-3700
   Lu XL, 2016, TUMOR BIOL, V37, P253, DOI 10.1007/s13277-015-3792-5
   Luo T, 2016, INFECT IMMUN, V84, P686, DOI 10.1128/IAI.01289-15
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Meng J, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0084-7
   O'Connell MJ, 2010, J CLIN ONCOL, V28, P3937, DOI 10.1200/JCO.2010.28.9538
   Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001
   Park YY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060778
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Pils D, 2014, EUR J CANCER, V50, P99, DOI 10.1016/j.ejca.2013.09.011
   Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077
   Schneider M, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-96
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Simon R, 2007, CANCER INFORM, V3, P11
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Sun Y, 2016, ONCOGENE, V35, P4321, DOI 10.1038/onc.2015.494
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Varnat F, 2010, EMBO MOL MED, V2, P440, DOI 10.1002/emmm.201000098
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Zhang XQ, 2013, NEUROBIOL DIS, V58, P123, DOI 10.1016/j.nbd.2013.05.011
   Zhao C, 2009, NATURE, V458, P776, DOI 10.1038/nature07737
NR 39
TC 6
Z9 6
U1 1
U2 7
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD JAN
PY 2019
VL 17
IS 1
BP 442
EP 449
DI 10.3892/ol.2018.9533
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HG3BT
UT WOS:000454845500054
PM 30655785
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Mahmood, TH
   Al-Samydai, A
   Al Sulaibi, M
   Alqaraleh, M
   Abed, AI
   Shalan, N
   Alsanabrah, A
   Alsotari, ST
   Nsairat, H
   Alshaer, W
AF Mahmood, Tabarek H.
   Al-Samydai, Ali
   Al Sulaibi, Mazen
   Alqaraleh, Moath
   Abed, Anas Ibrahim
   Shalan, Naeem
   Alsanabrah, Alaa
   Alsotari, Shrouq Taiseer
   Nsairat, Hamdi
   Alshaer, Walhan
TI Development of Pegylated Nano-Phytosome Formulation with Oleuropein and
   Rutin to Compare Anti-Colonic Cancer Activity with Olea Europaea Leaves
   Extract
SO CHEMISTRY & BIODIVERSITY
LA English
DT Article
DE olive leaf extract; oleuropein; rutin; PEGylated nano-phytosomes;
   anticancer activity
ID BIOAVAILABILITY
AB Olive leaf extract is a valuable source of phenolic compounds; primarily, oleuropein (major component) and rutin. This natural olive leaf extract has potential use as a therapeutic agent for cancer treatment. However, its clinical application is hindered by poor pharmacokinetics and low stability. To overcome these limitations, this study aimed to enhance the anticancer activity and stability of oleuropein and rutin by loading them into PEGylated Nano-phytosomes. The developed PEGylated Nano-phytosomes exhibited favorable characteristics in terms of size, charge, and stability. Notably, the anticolonic cancer activity of the Pegylated Nano-phytosomes loaded with oleuropein (IC50=0.14 & mu;M) and rutin (IC50=0.44 & mu;M) surpassed that of pure oleuropein and rutin alone. This outcome highlights the advantageous impact of Nano-phytosomes to augment the anticancer potential of oleuropein and rutin. These results present a promising pathway for the future development of oleuropein and rutin Nano-phytosomes as effective options for passive tumor-targeted therapy, given their improved stability and efficacy.
C1 [Mahmood, Tabarek H.; Al-Samydai, Ali; Al Sulaibi, Mazen; Alqaraleh, Moath; Abed, Anas Ibrahim; Shalan, Naeem; Alsanabrah, Alaa; Alsotari, Shrouq Taiseer; Nsairat, Hamdi; Alshaer, Walhan] Al Ahliyya Amman Univ, Fac Pharm Pharmacol & Diagnost Res Ctr, Amman, Jordan.
   [Alsotari, Shrouq Taiseer; Alshaer, Walhan] Univ Jordan, Cell Therapy Ctr, Amman 11942, Jordan.
C3 Al-Ahliyya Amman University; University of Jordan
RP Al-Samydai, A; Nsairat, H (corresponding author), Al Ahliyya Amman Univ, Fac Pharm Pharmacol & Diagnost Res Ctr, Amman, Jordan.
EM a.alsamydai@ammanu.edu.jo; h.alnseirat@ammanu.edu.jo
RI Alshaer, Walhan/A-7403-2018; Nsairat, Hamdi/ABF-6488-2022; Al-Samydai,
   Ali/AAH-7808-2019
OI Abed, Anas/0000-0003-2828-1011
CR Al Safi A, 2020, LECT NOTES COMPUT SC, V12080, P1, DOI 10.1007/978-3-030-44584-3_1
   Al-Karald R, 2020, PHARM CHEM J+, V53, P1118, DOI 10.1007/s11094-020-02133-x
   Al-Nema M., 2022, PLOS ONE, V17(12)
   Al-Samydai A, 2021, NUTRIENTS, V13, DOI 10.3390/nu13113995
   Albogami S, 2021, MOLECULES, V26, DOI 10.3390/molecules26134069
   Alshaer W, 2019, RSC ADV, V9, P30976, DOI 10.1039/c9ra05636j
   Amir Abbas Momtazi-Borojeni., 2022, PRECLINICAL TOXICITY, P2542
   Ansari M, 2011, J IRAN CHEM SOC, V8, P38, DOI 10.1007/BF03246200
   Chivte P. S., 2017, J DRUG DELIVERY THER, V7(5), P17
   De SMT, 2023, CANCERS, V15, DOI 10.3390/cancers15030993
   G?m?sbulut G., 2020, EXTRACTION OLEUROPEI, P1
   Ghomari Oumaima, 2019, Biotechnology Reports, V23, pe00347, DOI 10.1016/j.btre.2019.e00347
   Gullón B, 2017, TRENDS FOOD SCI TECH, V67, P220, DOI 10.1016/j.tifs.2017.07.008
   Gunasekaran Thirumurugan, 2014, Asian Pacific Journal of Tropical Biomedicine, V4, pS1, DOI 10.12980/APJTB.4.2014C980
   Han J, 2009, CYTOTECHNOLOGY, V59, P45, DOI 10.1007/s10616-009-9191-2
   Hoai TT, 2020, J NANOMATER, V2020, DOI 10.1155/2020/8867669
   Hong B, 2016, BIOMED MICRODEVICES, V18, DOI 10.1007/s10544-016-0054-2
   Kuntic V, 2007, J PHARMACEUT BIOMED, V43, P718, DOI 10.1016/j.jpba.2006.07.019
   Le Floch F, 1998, TALANTA, V46, P1123, DOI 10.1016/S0039-9140(97)00375-5
   Lee MR, 2006, J CHROMATOGR A, V1120, P244, DOI 10.1016/j.chroma.2006.01.075
   Lu M, 2019, ASIAN J PHARM SCI, V14, P265, DOI 10.1016/j.ajps.2018.05.011
   Maki MAA, 2019, ACS OMEGA, V4, P8767, DOI 10.1021/acsomega.9b00109
   Markopoulos C, 2009, J PHARM PHARMACOL, V61, P143, DOI [10.1211/jpp/61.02.0002, 10.1211/jpp.61.02.0002]
   Mojtahedi Z, 2021, CANCER MANAG RES, V13, P7569, DOI 10.2147/CMAR.S330448
   Moran J. M., 2016, NAT PROD COMMUN, V11(4)
   Pandey P, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14111069
   Pandian SRK, 2021, N-S ARCH PHARMACOL, V394, P735, DOI 10.1007/s00210-020-02015-9
   Patel RB, 2010, J CONTROL RELEASE, V147, P350, DOI 10.1016/j.jconrel.2010.08.020
   Paudel KR, 2021, LIFE SCI, V276, DOI 10.1016/j.lfs.2021.119436
   Prasad Rajesh, 2019, A J P P, V5, P1, DOI DOI 10.31024/AJPP.2019.5.S1.1
   Rabbani M, 2021, LWT-FOOD SCI TECHNOL, V151, DOI 10.1016/j.lwt.2021.112093
   Rahiman S, 2019, INDIAN J BIOCHEM BIO, V56, P263
   Rishmawi S., 2022, LIFE, V12(8), P1140
   Romani A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11081776
   Romero C, 2017, J SCI FOOD AGR, V97, P1725, DOI 10.1002/jsfa.7920
   Ruzzolini J, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10101577
   Ruzzolini J, 2018, NUTRIENTS, V10, DOI 10.3390/nu10121950
   Samydai A., 2022, NUTRIENTS, V14(23), P5170
   Saputra Y. E., EVALUATION NANOPHYTO
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Tresserra-Rimbau A., 2017, HINDAWI, V2017, P2
   Tsarbopoulos A, 2003, J CHROMATOGR B, V785, P157, DOI 10.1016/S1570-0232(02)00905-4
   Vankudri R., 2016, J APPL PHARM SCI, V6(1), P090
   Vishvakrama P., 2014, Journal of Drug Delivery and Therapeutics, P47
   Yateem H., 2014, OPTIMUM CONDITIONS O, V4(5), P1
   Zhu Y, 2015, ARCH PHARM RES, V38, P512, DOI 10.1007/s12272-014-0481-7
NR 46
TC 10
Z9 10
U1 3
U2 8
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1612-1872
EI 1612-1880
J9 CHEM BIODIVERS
JI Chem. Biodivers.
PD AUG
PY 2023
VL 20
IS 8
DI 10.1002/cbdv.202300534
EA AUG 2023
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA W7MT7
UT WOS:001042355000001
PM 37498138
DA 2025-01-04
ER

PT J
AU Li, YF
   Liu, L
   Li, B
AF Li, Yafei
   Liu, Lu
   Li, Bo
TI Role of ENO1 and its targeted therapy in tumors
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
ID BREAST-CANCER; COLORECTAL-CANCER; C-MYC; ENOLASE; GLYCOLYSIS; GROWTH;
   EXPRESSION; PROMOTES; PROTEIN; MICROENVIRONMENT
AB ENO1, also called 2-phospho-D-glycerate hydrolase in cellular glycolysis, is an enzyme that converts 2-phosphoglycerate to phosphoenolpyruvate and plays an important role in the Warburg effect. In various tumors, ENO1 overexpression correlates with poor prognosis. ENO1 is a multifunctional oncoprotein that, when located on the cell surface, acts as a "moonlighting protein" to promote tumor invasion and metastasis. When located intracellularly, ENO1 facilitates glycolysis to dysregulate cellular energy and sustain tumor proliferation. Additionally, it promotes tumor progression by activating oncogenic signaling pathways. ENO1 is a tumor biomarker and represents a promising target for tumor therapy. This review summarizes recent advances from 2020 to 2024 in understanding the relationship between ENO1 and tumors and explores the latest targeted therapeutic strategies involving ENO1.
C1 [Li, Yafei; Liu, Lu; Li, Bo] Jilin Univ, Hosp Stomatol, Dept Oral Anat & Physiol, Jilin Prov Key Lab Oral Biomed Engn, Changchun 130021, Peoples R China.
C3 Jilin University
RP Li, B (corresponding author), Jilin Univ, Hosp Stomatol, Dept Oral Anat & Physiol, Jilin Prov Key Lab Oral Biomed Engn, Changchun 130021, Peoples R China.
EM lbo@jlu.edu.cn
OI LI, BO/0000-0002-6005-6351
FU Natural Science Foundation of Jilin Province [YDZJ202401228ZYTS]
FX This research was funded by Natural Science Foundation of Jilin Province
   (YDZJ202401228ZYTS).
CR Hoang AT, 2021, INT J MED SCI, V18, P1406, DOI 10.7150/ijms.52688
   Bahar ME, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392-023-01705-z
   Cai C, 2021, BMC Gastroenterol, P21
   Chen JY, 2022, MED ONCOL, V39, DOI 10.1007/s12032-022-01676-1
   Chen ML, 2022, MOL CANCER THER, V21, P1337, DOI 10.1158/1535-7163.MCT-21-0285
   Chen M, 2019, CANCER MANAG RES, V11, P741, DOI 10.2147/CMAR.S189445
   Chen R, 2020, J CELL MOL MED, V24, P2123, DOI 10.1111/jcmm.14763
   Chen X, 2021, NAT REV CLIN ONCOL, V18, P280, DOI 10.1038/s41571-020-00462-0
   Chen XZ, 2023, WORLD J SURG ONCOL, V21, DOI 10.1186/s12957-023-03078-7
   Chung IC, 2023, Oncol Rep, P50
   CRAS P, 1988, ACTA NEUROPATHOL, V75, P377, DOI 10.1007/BF00687791
   Cui H, 2021, Front Cell Dev Biology, P9
   Cui Y, 2022, Translational Oncol, P22
   Curcio C, 2023, CLIN EXP MED, V23, P5089, DOI 10.1007/s10238-023-01236-5
   De Vitis C, 2023, J EXP CLIN CANC RES, V42, DOI 10.1186/s13046-023-02641-0
   Deng TY, 2021, THERANOSTICS, V11, P8112, DOI 10.7150/thno.54961
   Díaz-Ramos A, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/156795
   Feng TN, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01652-5
   Gan L, 2023, Biol Direct, P18
   Gong W, 2020, HUM CELL, V33, P790, DOI 10.1007/s13577-020-00356-4
   Gu JM, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1003639
   Hippner M, 2022, DIAGNOSTICS, V12, DOI 10.3390/diagnostics12020254
   Hong J, 2021, GUT, V70, P2123, DOI 10.1136/gutjnl-2020-322780
   Hou JY, 2021, BIOCHEM BIOPH RES CO, V578, P77, DOI 10.1016/j.bbrc.2021.09.027
   Hsu CC, 2022, SEMIN CANCER BIOL, V85, P52, DOI 10.1016/j.semcancer.2021.04.006
   Hu T, 2020, THERANOSTICS, V10, P4056, DOI 10.7150/thno.40860
   Hua Q, 2021, Cancer Cell Int, P21
   Huang CK, 2023, CLIN TRANSL ONCOL, V25, P2250, DOI 10.1007/s12094-023-03114-8
   Huang RX, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0150-x
   Huang SS, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.638311
   Huang ZN, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03509-1
   Jiang KQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03179-1
   Jiang RS, 2023, MOLECULES, V28, DOI 10.3390/molecules28217309
   Jing ZL, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02412-3
   Jung DW, 2013, ACS CHEM BIOL, V8, P1271, DOI 10.1021/cb300687k
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Khan MZI, 2022, J PROTEOMICS, V262, DOI 10.1016/j.jprot.2022.104600
   Kumari S, 2015, CANCER GROWTH METAST, V8, P35, DOI 10.4137/CGM.S27335
   Lai YW, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10081890
   Li HJ, 2021, CANCER RES, V81, P4094, DOI 10.1158/0008-5472.CAN-20-3543
   Li J, 2021, OncoImmunology, P10
   Li J, 2023, Cell Oncol
   Li J, 2022, CANCER RES, V82, DOI 10.1158/0008-5472.CAN-21-1259
   Li K-X, 2021, Cancers, P13
   Li KX, 2022, THERANOSTICS, V12, P3084, DOI 10.7150/thno.70549
   Li N, 2021, Translational Oncol, P14
   Li X, 2023, Int J Mol Sci, P24
   Li Y, 2022, Cell Death Discovery, P8
   Li ZW, 2021, CANCER IMMUNOL RES, V9, P1383, DOI 10.1158/2326-6066.CIR-21-0258
   Liang XS, 2023, CANCER GENE THER, V30, P481, DOI 10.1038/s41417-022-00569-9
   Lin Y, 2023, Int J Mol Sci, P24
   Lin YH, 2020, NAT METAB, V2, DOI 10.1038/s42255-020-00313-3
   Lincz LF, 2024, CANCERS, V16, DOI 10.3390/cancers16050884
   Liu F, 2024, Int Immunopharmacol, P130
   Liu J, 2020, CANCER MANAG RES, V12, P7219, DOI 10.2147/CMAR.S251348
   Liu SZ, 2021, THERANOSTICS, V11, P8517, DOI 10.7150/thno.61006
   Liu WH, 2022, CLIN PROTEOM, V19, DOI 10.1186/s12014-022-09357-x
   Liu XH, 2021, FRONT ENDOCRINOL, V12, DOI 10.3389/fendo.2021.678947
   Liu Y, 2024, Experimental Therapeutic Med, P27
   Lu JJ, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-21-6648
   Luo JT, 2023, BIOCHEM GENET, V61, P316, DOI 10.1007/s10528-022-10253-0
   Luo M, 2022, Front Genet, P13
   Luo X, 2022, INQUIRY: J Health Care Organ Provis Financing, P59
   Ma HQ, 2024, MOL CARCINOGEN, V63, P1221, DOI 10.1002/mc.23719
   Ma J, 2023, Cancer Lett, P560
   Ma J, 2022, Life Sci, P306
   Ma LF, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-021-02200-5
   Mandili G, 2020, J Immunother Cancer, P8
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martell E, 2023, ACTA NEUROPATHOL COM, V11, DOI 10.1186/s40478-023-01604-y
   Martínez-Esquivias F, 2022, BIOMED RES INT-UK, V2022, DOI 10.1155/2022/6828837
   Mittal L, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64128-8
   Mohapatra P, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.143643
   Mowers EE, 2018, FEBS J, V285, P1751, DOI 10.1111/febs.14388
   Muller FL, 2012, NATURE, V488, P337, DOI 10.1038/nature11331
   Nie Q, 2023, PeerJ, P11
   Ou BC, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04028-5
   Park MK, 2021, CELL METAB, V33, P2380, DOI 10.1016/j.cmet.2021.11.011
   Peng C, 2021, J CELL PHYSIOL, V236, P981, DOI 10.1002/jcp.29909
   Peng JH, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13379
   Qin L, 2023, MEDIAT INFLAMM, V2023, DOI 10.1155/2023/4965223
   Ran R, 2023, Med Oncol, P40
   Ray A, 2020, ONCOGENE, V39, P2786, DOI 10.1038/s41388-020-1172-0
   ROYDS JA, 1984, J CLIN PATHOL, V37, P905, DOI 10.1136/jcp.37.8.905
   Shen DX, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419-023-05770-8
   Shi YY, 2023, J INFLAMM RES, V16, P493, DOI 10.2147/JIR.S396321
   Shi YQ, 2023, HYPERTENSION, V80, P1035, DOI 10.1161/HYPERTENSIONAHA.122.19857
   Shu X, 2021, Stem Cell Res Ther, P12
   Shu X, 2024, PeerJ, P12
   Song K, 2021, Pharmaceuticals, P14
   Song QR, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1119886
   Song YC, 2021, BMC MED GENOMICS, V14, DOI 10.1186/s12920-021-00876-4
   Stroggilos R, 2022, CANCERS, V14, DOI 10.3390/cancers14102542
   Su XT, 2021, DRUG DES DEV THER, V15, P2769, DOI 10.2147/DDDT.S306602
   Su Z, 2024, Sci Rep, P14
   Sun HZ, 2022, CANCER BIOL MED, V19, P1598, DOI 10.20892/j.issn.2095-3941.2022.0451
   Sun LC, 2023, NAT CHEM BIOL, V19, P1492, DOI 10.1038/s41589-023-01391-6
   Sun MM, 2023, ACTA PHARM SIN B, V13, P157, DOI 10.1016/j.apsb.2022.05.019
   Sun X, 2022, Front Genet, P13
   Tang C, 2023, KAOHSIUNG J MED SCI, V39, P904, DOI 10.1002/kjm2.12720
   Tang Y, 2022, J CELL MOL MED, V26, P3837, DOI 10.1111/jcmm.17418
   Tian MQ, 2020, EXP CELL RES, V395, DOI 10.1016/j.yexcr.2020.112188
   Toh B, 2011, PLOS BIOL, V9, DOI 10.1371/journal.pbio.1001162
   Udawant S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10113065
   Ullah R, 2022, SEMIN CANCER BIOL, V85, P123, DOI 10.1016/j.semcancer.2021.05.010
   Vishnubalaji R, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12081182
   Vishnubalaji R, 2021, MOL THER ONCOLYTICS, V23, P151, DOI 10.1016/j.omto.2021.09.002
   VONDEIMLING A, 1990, ACTA NEUROPATHOL, V79, P473, DOI 10.1007/BF00296105
   Wang G, 2020, ARTIF CELL NANOMED B, V48, P1231, DOI 10.1080/21691401.2020.1825092
   Wang G, 2020, NUTR CANCER, V72, P293, DOI 10.1080/01635581.2019.1631858
   Wang JY, 2022, INT J COGN INFORM NA, V16, DOI 10.4018/IJCINI.314782
   Wang J, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000030589
   Wang N, 2023, J GASTROINTEST ONCOL, V14, P585, DOI 10.21037/jgo-23-151
   Wang YH, 2022, PROCEEDINGS OF THE 2022 INTERNATIONAL CONFERENCE ON MULTIMEDIA RETRIEVAL, ICMR 2022, P24, DOI 10.1145/3512527.3531427
   Wang ZW, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420-022-01014-4
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Wu MJ, 2021, THERANOSTICS, V11, P7779, DOI 10.7150/thno.58729
   Wu XA, 2024, TRANSL CANCER RES, V13, DOI 10.21037/tcr-23-1537
   Xia P, 2023, CANCER COMMUN, V43, P338, DOI 10.1002/cac2.12403
   Xiao W, 2022, Cell Death Dis, P13
   Xie F, 2023, MedComm, P4
   Xu B, 2022, Front Cell Dev Biology, P10
   Xu LG, 2020, ONCOGENE, V39, P7005, DOI 10.1038/s41388-020-01512-8
   Xu W, 2021, Front Oncol, P10
   Xu X, 2024, INT J BIOL SCI, V20, P1492, DOI 10.7150/ijbs.90774
   Xu YH, 2013, ONCOL LETT, V5, P411, DOI 10.3892/ol.2012.1015
   Yang T, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03087-4
   Yuan Y, 2021, BIOCHEM BIOPH RES CO, V560, P172, DOI 10.1016/j.bbrc.2021.04.083
   Yuan ZM, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03823-4
   Zhang CY, 2021, CELL MOL IMMUNOL, V18, P2045, DOI 10.1038/s41423-021-00710-y
   Zhang GP, 2022, CANCER BIOL THER, V23, P243, DOI 10.1080/15384047.2022.2054244
   Zhang K, 2022, MOL BIOL REP, V49, P8241, DOI 10.1007/s11033-022-07540-9
   Zhang L, 2022, COMPUT INTEL NEUROSC, V2022, DOI 10.1155/2022/4064747
   Zhang QW, 2024, CELL DEATH DISCOV, V10, DOI 10.1038/s41420-024-01903-w
   Zhang T, 2022, NAT CANCER, V3, P75, DOI 10.1038/s43018-021-00299-1
   Zhang WY, 2020, LIFE SCI, V258, DOI 10.1016/j.lfs.2020.118151
   Zhang WY, 2020, CANCERS, V12, DOI 10.3390/cancers12020311
   Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00990-3
   Zhang YH, 2024, LUNG CANCER, V188, DOI 10.1016/j.lungcan.2023.107449
   Zhang ZH, 2023, CELL SIGNAL, V109, DOI 10.1016/j.cellsig.2023.110747
   Zhang ZY, 2022, INT J BIOL SCI, V18, P4171, DOI 10.7150/ijbs.69332
   Zhou L, 2023, J GASTROINTEST ONCOL, V14, P1504, DOI 10.21037/jgo-23-301
   Zubair H, 2020, J PROTEOME RES, V19, P794, DOI 10.1021/acs.jproteome.9b00641
NR 143
TC 0
Z9 0
U1 6
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD NOV 14
PY 2024
VL 22
IS 1
AR 1025
DI 10.1186/s12967-024-05847-8
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA M2I5B
UT WOS:001355826200005
PM 39543641
OA Green Accepted, gold
DA 2025-01-04
ER

PT J
AU Baldin, P
   Van den Eynde, M
   Hubert, C
   Jouret-Mourin, A
   Komuta, M
AF Baldin, P.
   Van den Eynde, M.
   Hubert, C.
   Jouret-Mourin, A.
   Komuta, M.
TI The role of the pathologist and clinical implications in colorectal
   liver metastasis
SO ACTA GASTRO-ENTEROLOGICA BELGICA
LA English
DT Review
DE tumour regression grading; histopathological growth pattern;
   chemotherapy related liver injury; Immunoscore; RAS; prognostic scoring
   system
ID NODULAR REGENERATIVE HYPERPLASIA; HEPATIC RESECTION; MARGIN STATUS;
   NEOADJUVANT CHEMOTHERAPY; PREDICTING SURVIVAL; SURGICAL RESECTION;
   PROGNOSTIC IMPACT; SCORING SYSTEM; TUMOR-RESPONSE; BRAF MUTATION
AB Colorectal liver metastases (CRLM) affect about 50% of colorectal cancer patients. With the improvement of neoadjuvant chemotherapy and the introduction of targeted therapy, resectability of CRLM and survival rates have improved over time. However, 60-70% of patients still recur. Several pathological and molecular parameters have been described as prognostic factors after CRLM resection. These parameters encompass not only tumoral features, but also non-tumoral ones, such as chemotherapy related liver injury, or factors related to tumour environment, namely Immunoscore. This review summarizes these prognostic indicators to clarify which patho-molecular parameters should be addressed in the pathological report.
C1 [Baldin, P.; Jouret-Mourin, A.; Komuta, M.] UCL, Clin Univ St Luc, Dept Pathol, Ave Hippocrate 10, B-1200 Brussels, Belgium.
   [Van den Eynde, M.] UCL, Clin Univ St Luc, Dept Med Oncol, Brussels, Belgium.
   [Hubert, C.] UCL, Clin Univ St Luc, Dept Abdominal Surg & Transplantat, Hepatobiliary Surg Unit, Brussels, Belgium.
C3 Universite Catholique Louvain; Cliniques Universitaires Saint-Luc;
   Universite Catholique Louvain; Cliniques Universitaires Saint-Luc;
   Universite Catholique Louvain; Cliniques Universitaires Saint-Luc
RP Komuta, M (corresponding author), UCL, Clin Univ St Luc, Dept Pathol, Ave Hippocrate 10, B-1200 Brussels, Belgium.
EM mina.komuta@uclouvain.be
OI KOMUTA, MINA/0000-0002-3999-1417
CR Adam R, 2012, ONCOLOGIST, V17, P1225, DOI 10.1634/theoncologist.2012-0121
   Adam R, 2009, J CLIN ONCOL, V27, P1829, DOI 10.1200/JCO.2008.19.9273
   Allegra CJ, 2016, J ONCOL PRACT, V12, P180, DOI 10.1200/JOP.2015.007898
   Andreou A, 2013, ANN SURG, V257, P1079, DOI 10.1097/SLA.0b013e318283a4d1
   [Anonymous], HPB OXFORD
   [Anonymous], J NATL CANC I
   Ayez N, 2012, ANN SURG ONCOL, V19, P1618, DOI 10.1245/s10434-011-2114-4
   Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446
   Berghoff AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1057388
   Blazer DG, 2008, J CLIN ONCOL, V26, P5344, DOI 10.1200/JCO.2008.17.5299
   Brouquet A, 2009, SURGERY, V145, P362, DOI 10.1016/j.surg.2008.12.002
   Brudvik KW, 2015, BRIT J SURG, V102, P1175, DOI 10.1002/bjs.9870
   Carrasco J, 2015, BRIT J CANCER, V113, P1298, DOI 10.1038/bjc.2015.321
   Chung JY, 2008, J HISTOCHEM CYTOCHEM, V56, P1033, DOI 10.1369/jhc.2008.951863
   de Haas RJ, 2008, ANN SURG, V248, P626, DOI 10.1097/SLA.0b013e31818a07f1
   de Jong MC, 2009, ANN SURG, V250, P440, DOI 10.1097/SLA.0b013e3181b4539b
   Dhir M, 2011, ANN SURG, V254, P234, DOI 10.1097/SLA.0b013e318223c609
   Eefsen RL, 2015, CLIN EXP METASTAS, V32, P369, DOI 10.1007/s10585-015-9715-4
   Fernández-Aceñero MJ, 2015, PATHOL RES PRACT, V211, P665, DOI 10.1016/j.prp.2015.06.007
   Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004
   Frentzas S, 2016, NAT MED, V22, P1294, DOI 10.1038/nm.4197
   Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287
   Galon J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-1
   Gilson N, 2009, ACTA GASTRO-ENT BELG, V72, P321
   Grundmann RT, 2011, WORLD J GASTRO SURG, V3, P183, DOI 10.4240/wjgs.v3.i12.183
   Holowko Waclaw, 2015, Pol Przegl Chir, V87, P53, DOI 10.1515/pjs-2015-0019
   Hubert C, 2013, HPB, V15, P858, DOI 10.1111/hpb.12047
   Iwatsuki S, 1999, J AM COLL SURGEONS, V189, P291, DOI 10.1016/S1072-7515(99)00089-7
   Konopke R, 2009, LIVER INT, V29, P89, DOI 10.1111/j.1478-3231.2008.01845.x
   Lee WS, 2008, LANGENBECK ARCH SURG, V393, P13, DOI 10.1007/s00423-007-0231-0
   Lise M, 2001, WORLD J SURG, V25, P638, DOI 10.1007/s002680020138
   Malik HZ, 2007, ANN SURG, V246, P806, DOI 10.1097/SLA.0b013e318142d964
   Maru DM, 2010, AM J SURG PATHOL, V34, P1287, DOI 10.1097/PAS.0b013e3181eb2f7b
   Mentha G, 2009, BRIT J SURG, V96, P95, DOI 10.1002/bjs.6436
   Nagashima I, 2004, J HEPATO-BILIARY-PAN, V11, P79, DOI 10.1007/s00534-002-0778-7
   Nash GM, 2010, ANN SURG ONCOL, V17, P572, DOI 10.1245/s10434-009-0605-3
   Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.3.CO;2-R
   Pawlik TM, 2005, ANN SURG, V241, P715, DOI 10.1097/01.sla.0000160703.75808.7d
   Poultsides GA, 2012, ANN SURG ONCOL, V19, P2797, DOI 10.1245/s10434-012-2335-1
   Rees M, 2008, ANN SURG, V247, P125, DOI 10.1097/SLA.0b013e31815aa2c2
   Reissfelder C, 2009, ANN SURG ONCOL, V16, P3279, DOI 10.1245/s10434-009-0654-7
   Robinson SM, 2013, BRIT J CANCER, V109, P2396, DOI 10.1038/bjc.2013.604
   Rubbia-Brandt L, 2007, ANN ONCOL, V18, P299, DOI 10.1093/annonc/mdl386
   Rubbia-Brandt L, 2010, HISTOPATHOLOGY, V56, P430, DOI 10.1111/j.1365-2559.2010.03511.x
   Ryan P, 2010, AM J SURG PATHOL, V34, P784, DOI 10.1097/PAS.0b013e3181dc242c
   Sasaki K, 2017, ANN SURG ONCOL, V24, P2438, DOI 10.1245/s10434-017-5904-5
   Schindl M, 2005, ARCH SURG-CHICAGO, V140, P183, DOI 10.1001/archsurg.140.2.183
   Schott AF, 2005, BREAST CANCER RES TR, V92, P231, DOI 10.1007/s10549-005-2510-1
   Serrablo A, 2016, EJSO-EUR J SURG ONC, V42, P1268, DOI 10.1016/j.ejso.2016.02.013
   Smith MD, 2009, BRIT J SURG, V96, P1101, DOI 10.1002/bjs.6735
   Tamandl D, 2011, ANN SURG ONCOL, V18, P421, DOI 10.1245/s10434-010-1317-4
   Teng HW, 2012, J SURG ONCOL, V106, P123, DOI 10.1002/jso.23063
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Tranchart H, 2013, WORLD J SURG, V37, P2647, DOI 10.1007/s00268-013-2186-3
   Ueno H, 2000, ANN SURG, V231, P59, DOI 10.1097/00000658-200001000-00009
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   van Dam PJ, 2017, BRIT J CANCER, V117, P1427, DOI 10.1038/bjc.2017.334
   Van den Eynden GG, 2012, CLIN EXP METASTAS, V29, P541, DOI 10.1007/s10585-012-9469-1
   Vauthey JN, 2006, J CLIN ONCOL, V24, P2065, DOI 10.1200/JCO.2005.05.3074
   Vermeulen PB, 2001, J PATHOL, V195, P336, DOI 10.1002/path.966
   Vigano L, 2017, J HEPATOL, V67, P84, DOI 10.1016/j.jhep.2017.02.031
   Viganò L, 2015, ANN SURG ONCOL, V22, P4149, DOI 10.1245/s10434-015-4533-0
   Viganò L, 2013, ANN SURG, V258, P731, DOI 10.1097/SLA.0b013e3182a6183e
   Wang Y, 2018, CANCER IMMUNOL IMMUN, V67, P435, DOI 10.1007/s00262-017-2094-8
   Watanabe T, 2011, DIS COLON RECTUM, V54, P1170, DOI 10.1097/DCR.0b013e31821d37a3
   Xu LH, 2011, WORLD J GASTROENTERO, V17, P4654, DOI 10.3748/wjg.v17.i42.4654
   Yaeger R, 2014, CANCER-AM CANCER SOC, V120, P2316, DOI 10.1002/cncr.28729
   Zakaria S, 2007, ANN SURG, V246, P183, DOI 10.1097/SLA.0b013e3180603039
   Zauber P, 2003, J CLIN PATHOL-MOL PA, V56, P137, DOI 10.1136/mp.56.3.137
NR 69
TC 8
Z9 8
U1 0
U2 3
PU UNIV CATHOLIQUE LOUVAIN-UCL
PI BRUSSELS
PA CLIN UNIV SAINT LUC, AVE HIPPOCRATE 10, BRUSSELS, B-1200, BELGIUM
SN 1784-3227
J9 ACTA GASTRO-ENT BELG
JI Acta Gastro-Enterol. Belg.
PD JUL-SEP
PY 2018
VL 81
IS 3
BP 419
EP 426
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA HG7ZK
UT WOS:000455215500011
PM 30350532
DA 2025-01-04
ER

PT J
AU Kibriya, MG
   Raza, M
   Quinn, A
   Kamal, M
   Ahsan, H
   Jasmine, F
AF Kibriya, Muhammad G.
   Raza, Maruf
   Quinn, Anthony
   Kamal, Mohammed
   Ahsan, Habibul
   Jasmine, Farzana
TI A Transcriptome and Methylome Study Comparing Tissues of Early and Late
   Onset Colorectal Carcinoma
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE colorectal carcinoma; early onset CRC; multi-omics; lymphovascular
   invasion; perineural invasion; DNA damage repair; DNA replication
   repair; MMR; base excision repair; FASN; CTLA4; HAVCR2
ID MICROSATELLITE INSTABILITY; CANCER; FEATURES; ADENOCARCINOMA;
   ASSOCIATION; PREVALENCE; SURVIVAL; INVASION; LEPTIN; YOUNG
AB There is an increase in the incidence of early onset colorectal carcinoma (EOCRC). To better understand if there is any difference in molecular pathogenesis of EOCRC and late onset colorectal carcinoma (LOCRC), we compared the clinical, histological, transcriptome, and methylome profile of paired CRC and healthy colonic tissue from 67 EOCRC and 98 LOCRC patients. The frequency of stage 3 CRC, lymph node involvement, lymphovascular invasion, and perineural invasion was higher in the EOCRC group. Many of the cancer related pathways were differentially expressed in CRC tissue in both EOCRC and LOCRC patients. However, the magnitude of differential expression for some groups of genes, such as DNA damage repair genes and replication stress genes, were significantly less pronounced in the EOCRC group, suggesting less efficient DNA damage repair to be associated with EOCRC. A more marked methylation of "growth factor receptor" genes in LOCRC correlated with a more pronounced down-regulation of those genes in that group. From a therapeutic point of view, more over-expression of fatty acid synthase (FASN) among the LOCRC patients may suggest a better response of FASN targeted therapy in that group. The age of onset of CRC did not appear to modify the response of cis-platin or certain immune checkpoint inhibitors. We found some differences in the molecular pathogenesis in EOCRC and LOCRC that may have some biological and therapeutic significance.
C1 [Kibriya, Muhammad G.; Quinn, Anthony; Ahsan, Habibul; Jasmine, Farzana] Univ Chicago, Inst Populat & Precis Hlth IPPH, Biol Sci Div, Chicago, IL 60637 USA.
   [Raza, Maruf] Jahurul Islam Med Coll, Dept Pathol, Kishoregonj 2336, Bangladesh.
   [Kamal, Mohammed] Lab Dhaka, Dept Pathol, Dhaka 1205, Bangladesh.
C3 University of Chicago
RP Kibriya, MG (corresponding author), Univ Chicago, Inst Populat & Precis Hlth IPPH, Biol Sci Div, Chicago, IL 60637 USA.
EM mkibriya@bsd.uchicago.edu
RI RAZA, AKM/P-2736-2019; RAZA, AKM MARUF/S-6883-2016
OI Jasmine, Farzana/0000-0002-5980-1174; Kibriya,
   Muhammad/0000-0001-9784-6958; RAZA, AKM MARUF/0000-0003-0251-4518;
   Quinn, Anthony/0000-0003-3668-4566
FU NIH [P20CA210305, P30ES027792]
FX This study was partially supported by NIH funds P20CA210305 and
   P30ES027792.
CR Ågesen TH, 2011, GENES IMMUN, V12, P653, DOI 10.1038/gene.2011.43
   [Anonymous], 2000, TUMOURS COLON RECTUM
   Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190
   Barlow JH, 2013, CELL, V152, P620, DOI 10.1016/j.cell.2013.01.006
   Beale AL, 2005, COLORECTAL DIS, V7, P398
   Berg M, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-100
   Burnett-Hartman AN, 2019, CANCER CAUSE CONTROL, V30, P747, DOI 10.1007/s10552-019-01181-3
   Chang DT, 2012, MODERN PATHOL, V25, P1128, DOI 10.1038/modpathol.2012.61
   Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593
   Crosbie AB, 2018, CANCER MED-US, V7, P4077, DOI 10.1002/cam4.1621
   Demanelis K, 2020, SCIENCE, V369, P1333, DOI 10.1126/science.aaz6876
   Deschoolmeester V, 2008, J MOL DIAGN, V10, P154, DOI 10.2353/jmoldx.2008.070087
   Downey T, 2006, METHOD ENZYMOL, V411, P256, DOI 10.1016/S0076-6879(06)11013-7
   Drury J, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126510
   EISENHART C, 1947, BIOMETRICS, V3, P1, DOI 10.2307/3001534
   Findeisen P, 2005, CANCER RES, V65, P8072, DOI 10.1158/0008-5472.CAN-04-4146
   Harris EI, 2008, AM J SURG PATHOL, V32, P1816, DOI 10.1097/PAS.0b013e3181816083
   Hong Y, 2007, CLIN CANCER RES, V13, P1107, DOI 10.1158/1078-0432.CCR-06-1633
   Janavicius R, 2010, CLIN CHEM, V56, P1750, DOI 10.1373/clinchem.2010.150680
   Jandova J, 2016, J SURG RES, V204, P251, DOI 10.1016/j.jss.2016.04.068
   Jasmine F, 2021, CANCERS, V13, DOI 10.3390/cancers13194956
   Jasmine F, 2018, AM J HUM BIOL, V30, DOI 10.1002/ajhb.23118
   Joo JE, 2021, CANCERS, V13, DOI 10.3390/cancers13112589
   Khan SA, 2016, J PEDIATR SURG, V51, P1812, DOI 10.1016/j.jpedsurg.2016.07.015
   Kibriya MG, 2022, CANCERS, V14, DOI 10.3390/cancers14092250
   Kibriya MG, 2014, CANCER EPIDEM BIOMAR, V23, P2667, DOI 10.1158/1055-9965.EPI-14-0610
   Kibriya MG, 2011, BMC MED GENOMICS, V4, DOI 10.1186/1755-8794-4-50
   Kolarich A, 2018, CANCER-AM CANCER SOC, V124, P3510, DOI 10.1002/cncr.31527
   La Cava A, 2004, J MOL MED, V82, P4, DOI 10.1007/s00109-003-0492-1
   Lee JK, 2022, GASTROENTEROLOGY, V162, P325, DOI 10.1053/j.gastro.2021.09.034
   Li HJ, 2021, AM J GASTROENTEROL, V116, P2173, DOI 10.14309/ajg.0000000000001393
   Liang JT, 2003, BRIT J SURG, V90, P205, DOI 10.1002/bjs.4015
   Liebig C, 2009, J CLIN ONCOL, V27, P5131, DOI 10.1200/JCO.2009.22.4949
   Lim DR, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008241
   Liu PH, 2019, JAMA ONCOL, V5, P37, DOI 10.1001/jamaoncol.2018.4280
   Losi L, 2005, AM J GASTROENTEROL, V100, P2280, DOI 10.1111/j.1572-0241.2005.00223.x
   Lu T, 2019, ONCOTARGETS THER, V12, P3339, DOI 10.2147/OTT.S199369
   Macheret M, 2020, CELL RES, V30, P997, DOI 10.1038/s41422-020-0358-x
   Matsubara M, 2002, EUR J ENDOCRINOL, V147, P173, DOI 10.1530/eje.0.1470173
   Mauri G, 2019, MOL ONCOL, V13, P109, DOI 10.1002/1878-0261.12417
   Mo XQ, 2020, ONCOL LETT, V19, P177, DOI 10.3892/ol.2019.11073
   Nikberg M, 2016, ACTA ONCOL, V55, P1418, DOI 10.1080/0284186X.2016.1230274
   Nikolic N, 2023, J ADOLESC YOUNG ADUL, V12, P207, DOI 10.1089/jayao.2021.0230
   O'Connell JB, 2004, WORLD J SURG, V28, P558, DOI 10.1007/s00268-004-7306-7
   Ogino S, 2007, HUM PATHOL, V38, P842, DOI 10.1016/j.humpath.2006.11.018
   Ottaiano A, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.852445
   Perea J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79118-z
   Powell AGMT, 2012, COLORECTAL DIS, V14, P1493, DOI 10.1111/j.1463-1318.2012.03048.x
   Qiao L, 2009, CARCINOGENESIS, V30, P1979, DOI 10.1093/carcin/bgp236
   Saltzstein SL, 2007, J CLIN GASTROENTEROL, V41, P173, DOI 10.1097/01.mcg.0000225550.26751.6a
   Saraste D, 2020, BRIT J SURG, V107, P301, DOI 10.1002/bjs.11333
   Scheurlen KM, 2022, CYTOKINE GROWTH F R, V67, P25, DOI 10.1016/j.cytogfr.2022.06.002
   Sengupta N, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-1
   SIEGEL RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Tunca B, 2013, J CANCER RES CLIN, V139, P691, DOI 10.1007/s00432-013-1372-x
   Uddin S, 2009, AM J GASTROENTEROL, V104, P1790, DOI 10.1038/ajg.2009.230
   Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592
   Zaborowski AM, 2020, BRIT J SURG, V107, P606, DOI 10.1002/bjs.11526
   Zaborowski A, 2021, JAMA SURG, V156, P865, DOI 10.1001/jamasurg.2021.2380
NR 59
TC 6
Z9 7
U1 2
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD NOV
PY 2022
VL 23
IS 22
AR 14261
DI 10.3390/ijms232214261
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA 6K4ZE
UT WOS:000887511400001
PM 36430738
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Carvalho, MR
   Carvalho, CR
   Maia, FR
   Caballero, D
   Kundu, SC
   Reis, RL
   Oliveira, JM
AF Carvalho, Mariana R.
   Carvalho, Cristiana R.
   Maia, F. Raquel
   Caballero, David
   Kundu, Subhas C.
   Reis, Rui L.
   Oliveira, Joaquim M.
TI Peptide-Modified Dendrimer Nanoparticles for Targeted Therapy of
   Colorectal Cancer
SO ADVANCED THERAPEUTICS
LA English
DT Article
DE cancer cells targeting; colorectal cancer; dendrimers; nanoparticles;
   peptides
ID 67-KDA LAMININ RECEPTOR; CELLULAR UPTAKE; CELLS; EXPRESSION
AB Peptides have recently emerged as a promising class of targeting ligands for specific drug delivery in cancer treatment, which avoid undesirable side effects of the systemic administration of chemotherapeutics. Their conjugation with nanoparticles has been demonstrated to improve the functionality of peptides resulting in a versatile platform for biomedical applications. In this work, the development of carboxymethylchitosan/poly(amidoamine) (CMCht/PAMAM) dendrimer nanoparticles functionalized with YIGSR laminin receptor binding peptide for the active targeting and specific delivery of therapeutic agents into colorectal cancer cells is described. The successful functionalization is confirmed by several physico-chemical characterization techniques. The selectivity of the YIGSR-CMCht/PAMAM dendrimer nanoparticles is first validated in vitro using a micropatterned array of 67 kDa laminin receptor. Next, the specificity of YIGSR-CMCht/PAMAM dendrimers nanoparticles toward laminin receptor is further confirmed both in 2D and 3D settings using HCT-116 colorectal cancer cells and L929 fibroblasts in co-culture. Finally, gemcitabine-loaded YIGSR-CMCht/PAMAM dendrimer nanoparticles induce a targeted mortality on HCT-116 cancer cells in a co-culture scenario. Overall, the study shows solid evidence that YIGSR laminin receptor binding peptide coupled to CMCht/PAMAM dendrimer nanoparticles may be employed as an anticancerous target for the specific and intracellular delivery of chemotherapeutic agents.
C1 [Carvalho, Mariana R.; Carvalho, Cristiana R.; Maia, F. Raquel; Caballero, David; Kundu, Subhas C.; Reis, Rui L.; Oliveira, Joaquim M.] Univ Minho, Headquarters European Inst Excellence Tissue Engn, I3Bs Res Inst Biomat Biodegradables & Biomimet, 3Bs Res Grp, AvePk,Parque Ciencia & Tecnol, P-4805017 Barco, Guimaraes, Portugal.
   [Carvalho, Mariana R.; Carvalho, Cristiana R.; Maia, F. Raquel; Caballero, David; Kundu, Subhas C.; Reis, Rui L.; Oliveira, Joaquim M.] PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal.
   [Carvalho, Mariana R.; Carvalho, Cristiana R.; Maia, F. Raquel; Reis, Rui L.; Oliveira, Joaquim M.] Headquarters Univ Minho, Discoveries Ctr Regenerat & Precis Med, AvePk, P-4805017 Barco, Guimaraes, Portugal.
C3 Universidade do Minho
RP Oliveira, JM (corresponding author), Univ Minho, Headquarters European Inst Excellence Tissue Engn, I3Bs Res Inst Biomat Biodegradables & Biomimet, 3Bs Res Grp, AvePk,Parque Ciencia & Tecnol, P-4805017 Barco, Guimaraes, Portugal.; Oliveira, JM (corresponding author), PT Govt Associate Lab, ICVS 3Bs, Braga, Portugal.; Oliveira, JM (corresponding author), Headquarters Univ Minho, Discoveries Ctr Regenerat & Precis Med, AvePk, P-4805017 Barco, Guimaraes, Portugal.
EM miguel.oliveira@i3bs.uminho.pt
RI Reis, Rui/A-8938-2008; Carvalho, Cristiana/AAC-8104-2020; Kundu, Subhas
   C/AAC-1317-2020; Caballero, David/I-4571-2015; Maia, Raquel/B-5297-2017;
   Oliveira, Joaquim Miguel/H-8636-2012
OI Kundu, Subhas C./0000-0002-7170-2291; Carvalho,
   Cristiana/0000-0001-9215-280X; Caballero, David/0000-0001-7930-2535;
   Maia, Raquel/0000-0002-2271-515X; Carvalho, Mariana/0000-0003-2081-3909;
   Oliveira, Joaquim Miguel/0000-0001-7052-8837
FU project FROnTHERA, Norte Portugal Regional Operational Programme (NORTE
   2020), under the Portugal 2020 Partnership Agreement, through the
   European Regional Development Fund (ERDF) [NORTE-01-0145-FEDER-000023];
   Programa Operacional Regional do Norte, Fundo Social Europeu, Norte 2020
   TERMSC [NORTE-08-5369-FSE-000044]; EMBO Short-Term Fellowship
   [NORTE-08-5369-FSE-000044, 7232]; FCT [IF/00423/2012, IF/01285/2015, DL
   57/2016 (CTTI-57/18-I3BS(5))]; Portuguese Foundation for Science and
   Technology (FCT) under the program CEEC Individual 2017
   [CEECIND/00352/2017]; Programa Operacional Regional do Norte - European
   Regional Development Funds (ERDF) [PTDC/BTMORG/28070/2017]; IET Harvey
   Engineering Research Award 2018 (ENG ThE CANCER); European Union
   Framework Program for Research and Innovation Horizon 2020 on FoReCaST
   project [668983]
FX This work was financially supported through the project FROnTHERA
   (NORTE-01-0145-FEDER-000023), Norte Portugal Regional Operational
   Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement,
   through the European Regional Development Fund (ERDF); M.R.C. for her
   Ph.D. scholarship NORTE-08-5369-FSE-000044, funded by Programa
   Operacional Regional do Norte, Fundo Social Europeu, Norte 2020 TERM&SC
   and EMBO Short-Term Fellowship 7232. J.M.O. for his distinction
   attributed under the FCT Investigator program (IF/00423/2012 and
   IF/01285/2015; F.R.M. acknowledges FCT for her work contract under the
   Transitional Rule DL 57/2016 (CTTI-57/18-I3BS(5)). D.C. acknowledges the
   financial support from the Portuguese Foundation for Science and
   Technology (FCT) under the program CEEC Individual 2017
   (CEECIND/00352/2017). D.C. and S.C.K. for the Portuguese Foundation for
   Science and Technology (FCT) under the scope of the project 2MATCH
   (PTDC/BTMORG/28070/2017) funded by the Programa Operacional Regional do
   Norte supported by European Regional Development Funds (ERDF). This work
   is also partially supported by the IET Harvey Engineering Research Award
   2018 (ENG ThE CANCER) and the European Union Framework Program for
   Research and Innovation Horizon 2020 on FoReCaST project under Grant
   Agreement No. 668983.
CR Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Ardini E, 2002, CANCER RES, V62, P1321
   Bae KH, 2011, MOL CELLS, V31, P295, DOI 10.1007/s10059-011-0051-5
   Carvalho MR, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw1317
   Carvalho MR, 2017, NANOMEDICINE-UK, V12, P581, DOI 10.2217/nnm-2016-0344
   Cerqueira SR, 2012, MACROMOL BIOSCI, V12, P591, DOI 10.1002/mabi.201100294
   Cisterna BA, 2016, NANOMEDICINE-UK, V11, P2443, DOI 10.2217/nnm-2016-0194
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jiménez-Fonseca P, 2015, CLIN TRANSL ONCOL, V17, P384, DOI 10.1007/s12094-014-1243-1
   Kedar U, 2010, NANOMED-NANOTECHNOL, V6, P714, DOI 10.1016/j.nano.2010.05.005
   Kopansky E, 2011, J DRUG TARGET, V19, P933, DOI 10.3109/1061186X.2011.632011
   Kumazoe M, 2013, J CLIN INVEST, V123, P787, DOI 10.1172/JCI64768
   Maia FR, 2014, ACTA BIOMATER, V10, P3197, DOI 10.1016/j.actbio.2014.02.049
   Mendes LP, 2017, MOLECULES, V22, DOI 10.3390/molecules22091401
   Oliveira JM, 2008, ADV FUNCT MATER, V18, P1840, DOI 10.1002/adfm.200800165
   Maia FR, 2014, MACROMOL BIOSCI, V14, P759, DOI 10.1002/mabi.201300567
   Rea V E A, 2012, Infez Med, V20 Suppl 2, P8
   Rudolf Emil, 2005, Acta Medica (Hradec Kralove), V48, P29
   Sarfati G, 2011, BIOMATERIALS, V32, P152, DOI 10.1016/j.biomaterials.2010.09.014
   Senapati S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0004-3
   Sharma M, 2013, J BIOMED NANOTECHNOL, V9, P96, DOI 10.1166/jbn.2013.1474
   SHI YE, 1993, CLIN EXP METASTAS, V11, P251, DOI 10.1007/BF00121168
   Sztandera K, 2019, MOL PHARMACEUT, V16, P1, DOI 10.1021/acs.molpharmaceut.8b00810
   VACCA A, 1993, CANCER, V72, P455, DOI 10.1002/1097-0142(19930715)72:2<455::AID-CNCR2820720222>3.0.CO;2-8
   Valodkar M, 2011, MATER CHEM PHYS, V128, P83, DOI 10.1016/j.matchemphys.2011.02.039
   Wu HL, 2018, CHEM ENG J, V349, P129, DOI 10.1016/j.cej.2018.05.082
   Yu B, 2010, MOL MEMBR BIOL, V27, P286, DOI 10.3109/09687688.2010.521200
NR 27
TC 34
Z9 34
U1 2
U2 27
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2366-3987
J9 ADV THER-GERMANY
JI Adv. Therap.
PD NOV
PY 2019
VL 2
IS 11
AR 1900132
DI 10.1002/adtp.201900132
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA KB2WR
UT WOS:000506361200012
OA Green Published
DA 2025-01-04
ER

PT J
AU Wang, HP
   Ye, T
   Cai, YK
   Chen, WJ
   Xie, HW
   Ke, CW
AF Wang, Huipeng
   Ye, Tao
   Cai, Yuankun
   Chen, Wenjie
   Xie, Hongwei
   Ke, Chongwei
TI Downregulation of Ascl2 promotes cell apoptosis by enhancing autophagy
   in colorectal cancer cells
SO JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Autophagy; Ascl2; apoptosis; colorectal cancer (CRC)
ID BECLIN-1; LC3
AB Background: Colorectal cancer (CRC) is the third most common cancer, according to recently published literature. While the incidence and the mortality of CRC has decreased due to effective cancer screening measures, there has been an increase in the number of young patients diagnosed with colon cancer due to unclear reasons. As a target molecule of the Wnt signaling pathway, Ascl2 is an important marker of CRC stem cells and plays an important role in maintaining the nature of colon cancer stem/precursor cells. However, the role of Ascl2 in autophagy in CRC cells is rarely elucidated.
   Methods: In this study, we found that Ascl2 was increased in CRC compared with adjacent tissue. Downregulation of Ascl2 in CRC cells could suppress proliferation and invasion, and induce apoptosis, of CRC cells. Moreover, we found that autophagy-relative protein LC3 increased after Ascl2 knockdown. Furthermore, we treated CRC cells with autophagy inhibitors 3- MA (3-Methyladenine) and CQ (Chloroquine).
   Results: The results showed that autophagy inhibitors could prevent apoptosis, which was induced by Ascl2 knockdown. Finally, we confirmed that the downregulation of Ascl2 in CRC cells could alleviate the pathological process in vivo by xenograft experiment.
   Conclusions: Our findings indicated that si-Ascl2 (small/short interfering) exerted a tumor suppression function in CRC by inducing autophagic cell death, and suggest that Ascl2 targeted therapy represents a novel strategy for CRC treatment.
C1 [Wang, Huipeng; Ye, Tao; Cai, Yuankun; Chen, Wenjie; Xie, Hongwei; Ke, Chongwei] Fudan Univ, Peoples Hosp Shanghai 5, Dept Gen Surg, 801 Heqing Rd, Shanghai 200240, Peoples R China.
C3 Fudan University
RP Xie, HW; Ke, CW (corresponding author), Fudan Univ, Peoples Hosp Shanghai 5, Dept Gen Surg, 801 Heqing Rd, Shanghai 200240, Peoples R China.
EM 13816819761@163.com; dr_kecw@163.com
FU Natural Science Foundation of Minhang, Shanghai [2018MHZ025,
   2018MHZ037]; Great Discipline Construction Project from The Fifth
   People's Hospital of Shanghai [2020WYZDZK02]; Leading Talent Foundation
   of Minhang, Shanghai [10-1]
FX This study was supported by the Natural Science Foundation of Minhang,
   Shanghai (No. 2018MHZ025), Natural Science Foundation of Minhang,
   Shanghai (No. 2018MHZ037) and the Great Discipline Construction Project
   from The Fifth People's Hospital of Shanghai (No. 2020WYZDZK02). Leading
   Talent Foundation of Minhang, Shanghai (No. 10-1).
CR François S, 2019, STEM CELL TRANSL MED, V8, P285, DOI 10.1002/sctm.18-0117
   Giatromanolaki A, 2010, J CLIN PATHOL, V63, P867, DOI 10.1136/jcp.2010.079525
   Guo GF, 2019, WORLD J GASTROENTERO, V25, P1840, DOI 10.3748/wjg.v25.i15.1840
   Guo GF, 2011, WORLD J GASTROENTERO, V17, P4779, DOI 10.3748/wjg.v17.i43.4779
   Hale AN, 2013, AUTOPHAGY, V9, P951, DOI 10.4161/auto.24273
   Jubb AM, 2006, ONCOGENE, V25, P3445, DOI 10.1038/sj.onc.1209382
   Lévy J, 2015, NAT CELL BIOL, V17, P1062, DOI 10.1038/ncb3206
   Lucas C, 2020, GASTROENTEROLOGY, V158, P1373, DOI 10.1053/j.gastro.2019.12.026
   Nozawa H, 2020, INT J COLORECTAL DIS, V35, P177, DOI 10.1007/s00384-019-03461-5
   Nozawa H, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919838960
   Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x
   Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026
   Ryter SW, 2013, MOL CELLS, V36, P7, DOI 10.1007/s10059-013-0140-8
   Sato K, 2007, CANCER RES, V67, P9677, DOI 10.1158/0008-5472.CAN-07-1462
   Schmitz KJ, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0946-x
   Shang Y, 2021, ONCOL, V12, P630, DOI [10.21037/jgo-21-183, DOI 10.21037/JGO-21-183]
   Shen T, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0638-9
   Singh SS, 2018, ONCOGENE, V37, P1142, DOI 10.1038/s41388-017-0046-6
   Sun K, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-35
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tanaka T, 2019, ANN SURG ONCOL, V26, P1401, DOI 10.1245/s10434-019-07172-7
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Thorburn A, 2014, PLOS BIOL, V12, DOI 10.1371/journal.pbio.1001967
   van der Flier LG, 2009, CELL, V136, P903, DOI 10.1016/j.cell.2009.01.031
   Wang C, 2017, DEVELOPMENT, V144, P235, DOI 10.1242/dev.138099
   Wang QS, 2018, BIOCHEM BIOPH RES CO, V498, P1058, DOI 10.1016/j.bbrc.2018.03.118
   Zhang C, 2019, INT J COLORECTAL DIS, V34, P1661, DOI 10.1007/s00384-019-03362-7
   Zhou HY, 2016, CANCER BIOMARK, V17, P1, DOI 10.3233/CBM-160613
NR 28
TC 8
Z9 9
U1 2
U2 9
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2078-6891
EI 2219-679X
J9 J GASTROINTEST ONCOL
JI J. Gastrointest. Oncol.
PD APR
PY 2021
VL 12
IS 2
BP 630
EP 638
DI 10.21037/jgo-21-183
PG 9
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA RV8MM
UT WOS:000646081100036
PM 34012655
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Parenti, MD
   Naldi, M
   Manoni, E
   Fabini, E
   Cederfelt, D
   Talibov, VO
   Gressani, V
   Guven, U
   Grossi, V
   Fasano, C
   Sanese, P
   De Marco, K
   Shtil, AA
   Kurkin, AV
   Altieri, A
   Danielson, UH
   Caretti, G
   Simone, C
   Varchi, G
   Bartolini, M
   Del Rio, A
AF Parenti, Marco Daniele
   Naldi, Marina
   Manoni, Elisabetta
   Fabini, Edoardo
   Cederfelt, Daniela
   Talibov, Vladimir O.
   Gressani, Valeria
   Guven, Ummu
   Grossi, Valentina
   Fasano, Candida
   Sanese, Paola
   De Marco, Katia
   Shtil, Alexander A.
   V. Kurkin, Alexander
   Altieri, Andrea
   Danielson, U. Helena
   Caretti, Giuseppina
   Simone, Cristiano
   Varchi, Greta
   Bartolini, Manuela
   Del Rio, Alberto
TI Discovery of the 4-aminopiperidine-based compound EM127 for the
   site-specific covalent inhibition of SMYD3
SO EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
LA English
DT Article
DE Covalent inhibitor; SMYD3; Lysine methyltransferase; Epigenetic
   inhibitors; Cancer target therapy
ID HISTONE METHYLTRANSFERASE; PROSTATE-CANCER; OVEREXPRESSION;
   PROLIFERATION; APOPTOSIS; GROWTH; GENES
AB Recent findings support the hypothesis that inhibition of SMYD3 methyltransferase may be a therapeutic avenue for some of the deadliest cancer types. Herein, active site-selective covalent SMYD3 inhibitors were designed by introducing an appropriate reactive cysteine trap into reversible first-generation SMYD3 inhibitors. The 4-amino-piperidine derivative EM127 (11C) bearing a 2-chloroethanoyl group as reactive warhead showed selectivity for Cys186, located in the substrate/histone binding pocket. Selectivity towards Cys186 was retained even at high inhibitor/enzyme ratio, as shown by mass spectrometry. The mode of interaction with the SMYD3 substrate/ histone binding pocket was revealed by crystallographic studies. In enzymatic assays, 11C showed a stronger SMYD3 inhibitory effect compared to the reference inhibitor EPZ031686. Remarkably, 11C attenuated the proliferation of MDA-MB-231 breast cancer cell line at the same low micromolar range of concentrations that reduced SMYD3 mediated ERK signaling in HCT116 colorectal cancer and MDA-MB-231 breast cancer cells. Furthermore, 11C (5 mu M) strongly decreased the steady-state mRNA levels of genes important for tumor biology such as cyclin dependent kinase 2, c-MET, N-cadherin and fibronectin 1, all known to be regulated, at least in part, by SMYD3. Thus, 11C is as a first example of second generation SMYD3 inhibitors; this agent represents a covalent and a site specific SMYD3 binder capable of potent and prolonged attenuation of methyltransferase activity.
C1 [Parenti, Marco Daniele; Manoni, Elisabetta; Varchi, Greta; Del Rio, Alberto] Photoreact Natl Res Council, Inst Organ Synth, I-40129 Bologna, Italy.
   [Del Rio, Alberto] Innovamol Consulting Srl, Via San Faustino 167, I-41126 Modena, Italy.
   [Naldi, Marina; Fabini, Edoardo; Bartolini, Manuela] Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.
   [Naldi, Marina] Univ Bologna, Ctr Appl Biomed Res, Bologna, Italy.
   [Cederfelt, Daniela; Talibov, Vladimir O.; Danielson, U. Helena] Uppsala Univ, Dept Chem, BMC, Uppsala 75123, Sweden.
   [Danielson, U. Helena] Uppsala Univ, Sci Life Lab, Uppsala, Sweden.
   [Talibov, Vladimir O.] BioMAX beam line, MAX IV Lab, Lund 22484, Sweden.
   [Gressani, Valeria; Guven, Ummu; Caretti, Giuseppina] Univ Milan, Dept Biosci, I-20133 Milan, Italy.
   [Grossi, Valentina; Fasano, Candida; Sanese, Paola; De Marco, Katia; Simone, Cristiano] IRCCSS Bellis Res Hosp, Med Genet Natl Inst Gastroenterol, Castellana Grotte, Italy.
   [Simone, Cristiano] Univ Bari Aldo Moro, Dept Biomed Sci & Human Oncol DIMO, Med Genet, I-70124 Bari, Italy.
   [Shtil, Alexander A.; V. Kurkin, Alexander; Altieri, Andrea] Lomonosov Moscow State Univ, Dept Chem, Moscow 119991, Russia.
   [Shtil, Alexander A.] Blokhin Natl Med Res Ctr Oncol, Moscow 115478, Russia.
   [Altieri, Andrea] EDASA Sci Srls, I-66050 San Salvo, CH, Italy.
C3 University of Bologna; University of Bologna; Uppsala University;
   Uppsala University; University of Milan; Universita degli Studi di Bari
   Aldo Moro; Lomonosov Moscow State University
RP Del Rio, A (corresponding author), Photoreact Natl Res Council, Inst Organ Synth, I-40129 Bologna, Italy.; Bartolini, M (corresponding author), Alma Mater Studiorum Univ Bologna, Dept Pharm & Biotechnol, Bologna, Italy.
EM manuela.bartolini3@unibo.it; alberto.delrio@gmail.com
RI Naldi, Marina/H-1855-2012; Del Rio, Alberto/F-5230-2010; Bartolini,
   Manuela/L-8678-2014; Grossi, Valentina/K-9821-2016; Guven,
   Ummu/AAY-1196-2020; Sanese, Paola/AAC-1991-2019; Fasano,
   Candida/K-3372-2018; Danielson, Helena/A-4217-2012; SIMONE,
   Cristiano/K-3452-2018; Varchi, Greta/J-9722-2018
OI Fasano, Candida/0000-0001-5878-3480; Danielson,
   Helena/0000-0003-2728-0340; Guven, Ummu/0000-0002-5427-263X; Sanese,
   Paola/0000-0001-8872-7498; SIMONE, Cristiano/0000-0002-2628-7658;
   Varchi, Greta/0000-0002-8358-3437
FU Italian Association for Cancer Research (AIRC) [IG 19172, IG 23794, IG
   21353]; Emilia Romagna region POR FSE 2014/2020 project ONCO- PENTA;
   RFBR [20-53-7808]; Bilateral CNR/RFBR grant; Italian Ministry of Health
   [SG -2019-12371540]; Italian Ministry of Education, University and
   Research (MIUR) "PRIN-Research Projects of National Relevance"(PRIN
   2017) [2017WNKSLRLS4]; Cariplo [2017-0604]
FX This work was supported by the Italian Association for Cancer Research
   (AIRC) IG 19172 to A.D.R, IG 23794 to C.S. and IG 21353 to G. C, the
   Emilia Romagna region POR FSE 2014/2020 project ONCO- PENTA to A.D.R.
   and M.B, RFBR N# grant 20-53-7808 to A.S., Bilateral CNR/RFBR grant to
   A.D.R., the Italian Ministry of Health "Ricerca Corrente; 2019-2021 " to
   C.S. and "Starting Grant" SG -2019-12371540 to P.S., by the Italian
   Ministry of Education, University and Research (MIUR) "PRIN-Research
   Projects of National Relevance"(PRIN 2017, n.2017WNKSLRLS4) to C.S. and
   Cariplo 2017-0604 to G.C.. Authors are thankful to the BioMAX beamline
   staff (MAX IV laboratory, Lund, Sweden) for the assistance with
   diffraction data collection and Doreen Dobritzsch for support in the
   structural analysis.
CR Andreoli F, 2014, DRUG DISCOV TODAY, V19, P1372, DOI 10.1016/j.drudis.2014.05.005
   Bernard BJ, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01021-9
   Bottino C, 2020, CANCERS, V12, DOI 10.3390/cancers12010142
   Bradshaw JM, 2015, NAT CHEM BIOL, V11, P525, DOI [10.1038/NCHEMBIO.1817, 10.1038/nchembio.1817]
   Chen VB, 2010, ACTA CRYSTALLOGR D, V66, P12, DOI 10.1107/S0907444909042073
   Cheng Y, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0095-0
   Cock-Rada AM, 2012, CANCER RES, V72, P810, DOI 10.1158/0008-5472.CAN-11-1052
   Del Rio A, 2016, EPI-INFORMATICS: DISCOVERY AND DEVELOPMENT OF SMALL MOLECULE EPIGENETIC DRUGS AND PROBES, P257, DOI 10.1016/B978-0-12-802808-7.00009-5
   Emsley P, 2010, ACTA CRYSTALLOGR D, V66, P486, DOI 10.1107/S0907444910007493
   Fabini E, 2019, BIOCHEMISTRY-US, V58, P3634, DOI 10.1021/acs.biochem.9b00420
   Fabini E, 2019, FUTURE MED CHEM, V11, P901, DOI 10.4155/fmc-2018-0380
   Fasano C, 2022, COMPUT STRUCT BIOTEC, V20, P1860, DOI 10.1016/j.csbj.2022.03.037
   Fei X, 2017, TOHOKU J EXP MED, V243, P219, DOI 10.1620/tjem.243.219
   Fenizia C, 2019, NUCLEIC ACIDS RES, V47, P1278, DOI 10.1093/nar/gky1221
   Gradl S, 2021, SLAS DISCOV, V26, P947, DOI 10.1177/24725552211019409
   Hamamoto R, 2004, NAT CELL BIOL, V6, P731, DOI 10.1038/ncb1151
   Hamamoto R, 2006, CANCER SCI, V97, P113, DOI 10.1111/j.1349-7006.2006.00146.x
   Huang CH, 2019, ACS MED CHEM LETT, V10, P978, DOI 10.1021/acsmedchemlett.9b00170
   Huang L, 2017, AM J TRANSL RES, V9, P1
   Jasinski P, 2008, TRANSL RES, V152, P203, DOI 10.1016/j.trsl.2008.09.001
   Jiang YH, 2019, J CANCER, V10, P4072, DOI 10.7150/jca.29861
   Li J, 2020, INT J ONCOL, V57, P756, DOI 10.3892/ijo.2020.5095
   Liebschner D, 2019, ACTA CRYSTALLOGR D, V75, P861, DOI 10.1107/S2059798319011471
   Lin FJ, 2019, INFLAMM RES, V68, P739, DOI 10.1007/s00011-019-01257-5
   Liu C, 2013, JNCI-J NATL CANCER I, V105, P1719, DOI 10.1093/jnci/djt304
   Luo XG, 2014, CANCER LETT, V344, P129, DOI 10.1016/j.canlet.2013.10.026
   Ma SJ, 2018, BIOSCIENCE REP, V38, DOI [10.1042/BSR20170656, 10.1042/bsr20170656]
   Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320
   Mccoy AJ, 2007, J APPL CRYSTALLOGR, V40, P658, DOI 10.1107/S0021889807021206
   Mitchell LH, 2016, ACS MED CHEM LETT, V7, P134, DOI 10.1021/acsmedchemlett.5b00272
   Mons E, 2022, CURR PROTOC, V2, DOI 10.1002/cpz1.419
   Murshudov GN, 2011, ACTA CRYSTALLOGR D, V67, P355, DOI 10.1107/S0907444911001314
   Peserico A, 2015, J CELL PHYSIOL, V230, P2447, DOI 10.1002/jcp.24975
   Proserpio V, 2013, GENE DEV, V27, P1299, DOI 10.1101/gad.217240.113
   Sanese P, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101604
   Sarris ME, 2016, CANCER CELL, V29, P354, DOI 10.1016/j.ccell.2016.01.013
   Singh J, 2011, NAT REV DRUG DISCOV, V10, P307, DOI 10.1038/nrd3410
   Su DS, 2020, ACS MED CHEM LETT, V11, P133, DOI 10.1021/acsmedchemlett.9b00493
   Talibov VO, 2021, CHEMBIOCHEM, V22, P1597, DOI 10.1002/cbic.202000736
   Thomenius MJ, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0197372
   Vieira FQ, 2015, ONCOTARGET, V6, P13644, DOI 10.18632/oncotarget.3767
   Yoshioka Y, 2017, CANCER MED-US, V6, P1665, DOI 10.1002/cam4.1099
   Yoshioka Y, 2016, ONCOTARGET, V7, P75023, DOI 10.18632/oncotarget.11898
NR 43
TC 9
Z9 9
U1 1
U2 14
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0223-5234
EI 1768-3254
J9 EUR J MED CHEM
JI Eur. J. Med. Chem.
PD DEC 5
PY 2022
VL 243
AR 114683
DI 10.1016/j.ejmech.2022.114683
EA SEP 2022
PG 13
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED); Index Chemicus (IC)
SC Pharmacology & Pharmacy
GA 5A1PW
UT WOS:000862667200009
PM 36116234
DA 2025-01-04
ER

PT J
AU Liu, YW
   Li, XH
   Pen, RQ
   Zuo, W
   Chen, Y
   Sun, XY
   Gou, JH
   Guo, QW
   Wen, ML
   Li, WQ
   Yu, SJ
   Liu, H
   Huang, M
AF Liu, Yongwei
   Li, Xinghui
   Pen, Renqun
   Zuo, Wei
   Chen, Ya
   Sun, Xiuying
   Gou, Juhua
   Guo, Qianwen
   Wen, Maoling
   Li, Wuqi
   Yu, Shuangjiang
   Liu, Hao
   Huang, Min
TI Targeted delivery of irinotecan to colon cancer cells using epidermal
   growth factor receptor-conjugated liposomes
SO BIOMEDICAL ENGINEERING ONLINE
LA English
DT Article
DE Irinotecan (CPT-11); DSPE-PEG(2000); EGFR; Colorectal cancer; SW620 cell
ID CONVECTION-ENHANCED DELIVERY; BREAST-CANCER; IN-VITRO; CPT-11;
   NANOPARTICLES; IMPROVEMENT; TOXICITY; TUMORS; SN-38
AB Background CPT-11 (irinotecan) is one of the most efficient agents used for colorectal cancer chemotherapy. However, as for many other chemotherapeutic drugs, how to minimize the side effects of CPT-11 still needs to be thoroughly described. Objectives This study aimed to develop the CPT-11-loaded DSPE-PEG 2000 targeting EGFR liposomal delivery system and characterize its targeting specificity and therapeutic effect on colorectal cancer (CRC) cells in vitro and in vivo. Results The synthesized liposome exhibited spherical shapes (84.6 +/- 1.2 nm to 150.4 nm +/- 0.8 nm of estimated average sizes), good stability, sustained release, and enough drug loading (55.19%). For in vitro experiments, SW620 cells treated with CPT-11-loaded DSPE-PEG(2000) targeting EGFR liposome showed lower survival extended level of intracellular ROS production. In addition, it generated an enhanced apoptotic cell rate by upregulating the protein expression of both cleaved-caspase-3 and cleaved-caspase-9 compared with those of SW620 cells treated with free CPT-11. Importantly, the xenograft model showed that both the non-target and EGFR-targeted liposomes significantly inhibited tumor growth compared to free CPT-11. Conclusions Compared with the non-target CPT-11-loaded DSPE-PEG(2000) liposome, CPT-11-loaded DSPE-PEG2000 targeting EGFR liposome treatment showed much better antitumor activity in vitro in vivo. Thus, our findings provide new assets and expectations for CRC targeting therapy.
C1 [Liu, Yongwei] Rongchang Dist Peoples Hosp Chongqing, Dept Infect, 11 Changyuan St Sq North Rd, Chongqing 402460, Peoples R China.
   [Li, Xinghui; Pen, Renqun; Zuo, Wei; Chen, Ya; Sun, Xiuying; Gou, Juhua; Guo, Qianwen; Wen, Maoling; Li, Wuqi; Liu, Hao] Rongchang Dist Peoples Hosp Chongqing, Dept Digest, 11 Changyuan St Sq North Rd, Chongqing 402460, Peoples R China.
   [Yu, Shuangjiang] Army Mil Med Univ, Dept Neurosurg, Hosp 1, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Huang, Min] North Sichuan Med Coll, Dept Digest, Affiliated Hosp, 1 MaoYuan South Rd, Nanchong 637000, Sichuan, Peoples R China.
C3 Army Medical University; North Sichuan Medical University
RP Liu, YW (corresponding author), Rongchang Dist Peoples Hosp Chongqing, Dept Infect, 11 Changyuan St Sq North Rd, Chongqing 402460, Peoples R China.; Liu, H (corresponding author), Rongchang Dist Peoples Hosp Chongqing, Dept Digest, 11 Changyuan St Sq North Rd, Chongqing 402460, Peoples R China.; Huang, M (corresponding author), North Sichuan Med Coll, Dept Digest, Affiliated Hosp, 1 MaoYuan South Rd, Nanchong 637000, Sichuan, Peoples R China.
EM 564536726@qq.com; xiaolouliu2258@qq.com; 249873814@qq.com
FU Talent training project of medical and health institutions in Rongchang
   District of Chongqing [2018.425]
FX Talent training project of medical and health institutions in Rongchang
   District of Chongqing in 2018 [Grant number: 2018.425. No.1].
CR Anderson Benjamin O, 2003, Breast J, V9 Suppl 2, pS51, DOI 10.1046/j.1524-4741.9.s2.4.x
   Andreyev J, 2014, LANCET ONCOL, V15, pE447, DOI 10.1016/S1470-2045(14)70006-3
   Ashley CE, 2011, NAT MATER, V10, P389, DOI [10.1038/NMAT2992, 10.1038/nmat2992]
   Bleiberg H, 1999, EUR J CANCER, V35, P371, DOI 10.1016/S0959-8049(98)00423-7
   Cisterna BA, 2016, NANOMEDICINE-UK, V11, P2443, DOI 10.2217/nnm-2016-0194
   Fang YP, 2018, INT J NANOMED, V13, P2789, DOI 10.2147/IJN.S158426
   Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016/j.ctrv.2006.07.001
   Gu MJ, 2018, BMC CANCER, V18, DOI 10.1186/s12885-017-3968-z
   He YY, 2006, ONCOGENE, V25, P1521, DOI 10.1038/sj.onc.1209184
   Huang MY, 2016, APOPTOSIS, V21, P130, DOI 10.1007/s10495-015-1193-2
   Jahn A, 2007, LANGMUIR, V23, P6289, DOI 10.1021/la070051a
   Jahn A, 2010, ACS NANO, V4, P2077, DOI 10.1021/nn901676x
   KAWATO Y, 1991, CANCER RES, V51, P4187
   Kim JS, 2018, J CONTROL RELEASE, V269, P245, DOI 10.1016/j.jconrel.2017.11.026
   Li Y, 2018, NANOSCALE, V10, P16738, DOI 10.1039/c8nr05803b
   Lim SB, 2012, J CONTROL RELEASE, V163, P34, DOI 10.1016/j.jconrel.2012.06.002
   Maeda H, 2013, ADV DRUG DELIVER REV, V65, P71, DOI 10.1016/j.addr.2012.10.002
   Mahmud M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167787
   Nag OK, 2013, INT J PHARMACEUT, V446, P119, DOI 10.1016/j.ijpharm.2013.02.026
   Noble CO, 2014, NANOMEDICINE-UK, V9, P2099, DOI [10.2217/NNM.13.201, 10.2217/nnm.13.201]
   Noble CO, 2006, CANCER RES, V66, P2801, DOI 10.1158/0008-5472.CAN-05-3535
   Ohtsuka K, 2003, LUNG CANCER, V41, P187, DOI 10.1016/S0169-5002(03)00223-X
   Ouakrim DA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4970
   Rauch Anke, 2018, Oncotarget, V9, P27835, DOI 10.18632/oncotarget.25600
   Rothenberg ML, 2001, ONCOLOGIST, V6, P66, DOI 10.1634/theoncologist.6-1-66
   Saito R, 2004, CANCER RES, V64, P2572, DOI 10.1158/0008-5472.CAN-03-3631
   Sercombe L, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00286
   SHIMADA Y, 1993, J CLIN ONCOL, V11, P909, DOI 10.1200/JCO.1993.11.5.909
   Staff NP, 2017, ANN NEUROL, V81, P772, DOI 10.1002/ana.24951
   Takano S, 2010, J NEURO-ONCOL, V99, P177, DOI 10.1007/s11060-010-0118-8
   Wang AZ, 2012, ANNU REV MED, V63, P185, DOI 10.1146/annurev-med-040210-162544
   Wang ZJ, 2019, J CONTROL RELEASE, V316, P22, DOI 10.1016/j.jconrel.2019.10.037
   Wu D, 2017, INT J NANOMED, V12, P5879, DOI 10.2147/IJN.S123437
   Wu H, 2013, BIOMATERIALS, V34, P1213, DOI 10.1016/j.biomaterials.2012.08.072
   Xu HL, 2015, ACTA BIOMATER, V16, P156, DOI 10.1016/j.actbio.2015.01.039
   Ychou M, 2002, CANCER CHEMOTH PHARM, V50, P383, DOI 10.1007/s00280-002-0506-7
   Ying X, 2010, J CONTROL RELEASE, V141, P183, DOI 10.1016/j.jconrel.2009.09.020
   Zalba S, 2016, NANOMEDICINE-UK, V11, P465, DOI 10.2217/nnm.15.208
NR 38
TC 13
Z9 14
U1 2
U2 28
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-925X
J9 BIOMED ENG ONLINE
JI Biomed. Eng. Online
PD AUG 2
PY 2022
VL 21
IS 1
AR 53
DI 10.1186/s12938-022-01012-8
PG 16
WC Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering
GA 3N6LW
UT WOS:000836259000001
PM 35918704
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Akbarzadeh-Khiavi, M
   Safary, A
   Omidi, Y
AF Akbarzadeh-Khiavi, Mostafa
   Safary, Azam
   Omidi, Yadollah
TI Targeting long non-coding RNAs as new modulators in anti-EGFR resistance
   mechanisms
SO BIOIMPACTS
LA English
DT Article
DE LncRNAs; EGFR; Colorectal cancer; Anti-EGFR resistance; Targeting
   therapy
ID COLORECTAL-CANCER; CETUXIMAB RESISTANCE; EXPRESSION; NANOPARTICLES;
   PROGRESSION; THERAPY
AB Epidermal growth factor receptor (EGFR) is a cell surface protein that plays a vital role in regulating cell growth and division. However, certain tumors, such as colorectal cancer (CRC), can exhibit an overexpression of EGFR, resulting in uncontrolled cell growth and tumor progression. To address this issue, therapies targeting and inhibiting EGFR activity have been developed to suppress cancer growth. Nevertheless, resistance to these therapies poses a significant obstacle in cancer treatment. Recent research has focused on comprehending the underlying mechanisms contributing to anti-EGFR resistance and identifying new targets to overcome this striking challenge. Long noncoding RNAs (lncRNAs) are a class of RNA molecules that do not encode proteins but play pivotal roles in gene regulation and cellular processes. Emerging evidence suggests that lncRNAs may participate in modulating resistance to anti-EGFR therapies in CRC. Consequently, combining lncRNA targeting with the existing treatment modalities could potentially yield improved clinical outcomes. Illuminating the involvement of lncRNAs in anti-EGFR resistance mechanisms of cancer cells can provide valuable insights into the development of novel anti-EGFR therapies in several solid tumors.
C1 [Akbarzadeh-Khiavi, Mostafa] Tabriz Univ Med Sci, Liver & Gastrointestinal Dis Res Ctr, Tabriz, Iran.
   [Akbarzadeh-Khiavi, Mostafa] Tabriz Univ Med Sci, Biomed Inst, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran.
   [Safary, Azam] Tabriz Univ Med Sci, Connect Tissue Dis Res Ctr, Tabriz, Iran.
   [Omidi, Yadollah] Nova Southeastern Univ, Barry & Judy Silverman Coll Pharm, Dept Pharmaceut Sci, Ft Lauderdale, FL 33328 USA.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science; Nova Southeastern
   University
RP Omidi, Y (corresponding author), Nova Southeastern Univ, Barry & Judy Silverman Coll Pharm, Dept Pharmaceut Sci, Ft Lauderdale, FL 33328 USA.
EM yomidi@nova.edu
RI Omidi, Yadollah/U-2397-2019; Akbarzadeh Khiavi, Mostafa/AAU-1896-2020;
   Safary, Azam/W-2941-2017; Omidi, Yadollah/E-8452-2013
OI Akbarzadeh Khiavi, Mostafa/0000-0002-1552-6537; Omidi,
   Yadollah/0000-0003-0067-2475; Safary, Azam/0000-0002-8997-2003
FU Liver and Gastrointestinal Diseases Research Center at Tabriz University
   of Medical Sciences [69709]
FX Funding sources The support provided by the Liver and Gastrointestinal
   Diseases Research Center at Tabriz University of Medical Sciences (grant
   #69709) to MAK is acknowledged.
CR Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99
   Bakhtiary Z, 2017, DRUG DEV IND PHARM, V43, P1244, DOI 10.1080/03639045.2017.1310223
   Baradaran Behzad, 2014, Human Antibodies, V23, P13, DOI 10.3233/HAB-140278
   Bianco R, 2007, INT J BIOCHEM CELL B, V39, P1416, DOI 10.1016/j.biocel.2007.05.008
   Chen GQ, 2021, BIOCHEM GENET, V59, P560, DOI 10.1007/s10528-020-10017-8
   Chu JJ, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.801319
   Hahne JC, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00226
   Hao LF, 2020, CLIN INVEST MED, V43, pE35, DOI 10.25011/cim.v43i4.34703
   Huang WM, 2019, CELL CYCLE, V18, P69, DOI 10.1080/15384101.2018.1558872
   Ji H, 2019, CANCER SCI, V110, P72, DOI 10.1111/cas.13838
   Jin ZC, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.843064
   Jing CW, 2019, CANCER MED-US, V8, P1641, DOI 10.1002/cam4.2004
   Khiavi MA, 2020, CELL MOL LIFE SCI, V77, P997, DOI 10.1007/s00018-019-03305-z
   Khiavi MA, 2019, BIOIMPACTS, V9, P123, DOI 10.15171/bi.2019.16
   Li QH, 2020, GASTROENTEROL REP, V8, P179, DOI 10.1093/gastro/goaa026
   Ling H, 2013, GENOME RES, V23, P1446, DOI 10.1101/gr.152942.112
   Liu CG, 2021, MOL THER-ONCOLYTICS, V22, P336, DOI 10.1016/j.omto.2021.07.001
   Lu M, 2017, J CANCER RES CLIN, V143, P71, DOI 10.1007/s00432-016-2252-y
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   Luan YP, 2020, MOL THER NUCL ACIDS, V19, P790, DOI 10.1016/j.omtn.2019.12.009
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Najar AG, 2013, ASIAN PAC J CANCER P, V14, P495, DOI 10.7314/APJCP.2013.14.1.495
   Nourazarian AR, 2012, ASIAN PAC J CANCER P, V13, P4751, DOI 10.7314/APJCP.2012.13.9.4751
   Nourazarian AR, 2012, ASIAN PAC J CANCER P, V13, P2235, DOI 10.7314/APJCP.2012.13.5.2235
   Omidi Y, 2022, J DRUG TARGET, V30, P687, DOI 10.1080/1061186X.2022.2055045
   Ouyang SR, 2017, ONCOTARGET, V8, P92815, DOI 10.18632/oncotarget.21590
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Sana J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-103
   Shang AQ, 2020, AGING-US, V12, P8301, DOI 10.18632/aging.103139
   Shen XD, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5231
   Stintzing S, 2016, LANCET ONCOL, V17, P1426, DOI 10.1016/S1470-2045(16)30269-8
   Tang Y, 2017, CANCER LETT, V391, P12, DOI 10.1016/j.canlet.2017.01.010
   Tsang WP, 2010, CARCINOGENESIS, V31, P350, DOI 10.1093/carcin/bgp181
   Wang DL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.751903
   Wu HL, 2020, MOL THER-NUCL ACIDS, V20, P438, DOI 10.1016/j.omtn.2020.03.006
   Xu CA, 2011, INT J ONCOL, V39, P169, DOI 10.3892/ijo.2011.1007
   Yang MH, 2015, BBA-MOL BASIS DIS, V1852, P166, DOI 10.1016/j.bbadis.2014.11.013
   Yang T, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01633-8
   Yuan HH, 2022, J CANCER, V13, P253, DOI 10.7150/jca.65687
   Zhou J, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02130-2
NR 40
TC 1
Z9 1
U1 0
U2 1
PU TABRIZ UNIV MEDICAL SCIENCES & HEALTH SERVICES
PI TABRIZ
PA DANESHGHAH ST, TABRIZ, REPUBLIC ISLAMIC 51664-14766, IRAN
SN 2228-5652
EI 2228-5660
J9 BIOIMPACTS
JI BioImpacts
PD JAN
PY 2024
VL 14
IS 1
AR 27696
DI 10.34172/bi.2023.27696
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA II1V9
UT WOS:001165615700001
PM 38327631
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Tan, T
   Mouradov, D
   Lee, MRR
   Gard, G
   Hirokawa, Y
   Li, S
   Lin, C
   Li, FQ
   Luo, HJ
   Wu, K
   Palmieri, M
   Leong, E
   Clarke, J
   Sakthianandeswaren, A
   Brasier, H
   Tie, JN
   Tebbutt, NC
   Jalali, A
   Wong, RC
   Burgess, AW
   Gibbs, P
   Sieber, OM
AF Tan, Tao
   Mouradov, Dmitri
   Lee, Margaret
   Gard, Grace
   Hirokawa, Yumiko
   Li, Shan
   Lin, Cong
   Li, Fuqiang
   Luo, Huijuan
   Wu, Kui
   Palmieri, Michelle
   Leong, Evelyn
   Clarke, Jordan
   Sakthianandeswaren, Anuratha
   Brasier, Helen
   Tie, Jeanne
   Tebbutt, Niall C.
   Jalali, Azim
   Wong, Rachel
   Burgess, Antony W.
   Gibbs, Peter
   Sieber, Oliver M.
TI Unified framework for patient-derived, tumor- organoid-based predictive
   testing of standard-of- care therapies in metastatic colorectal cancer
SO CELL REPORTS
LA English
DT Article
ID MICROSATELLITE INSTABILITY; MULTITARGETED ANTIFOLATE; 1ST-LINE
   TREATMENT; PD-1 BLOCKADE; PHASE-III; PANITUMUMAB; CETUXIMAB; SURVIVAL;
   LY231514; DATABASE
AB Predictive drug testing of patient-derived tumor organoids (PDTOs) holds promise for personalizing treat-ment of metastatic colorectal cancer (mCRC), but prospective data are limited to chemotherapy regimens with conflicting results. We describe a unified framework for PDTO-based predictive testing across stan-dard-of-care chemotherapy and biologic and targeted therapy options. In an Australian community cohort, PDTO predictions based on treatment-naive patients (n = 56) and response rates from first-line mCRC clinical trials achieve 83% accuracy for forecasting responses in patients receiving palliative treatments (18 patients, 29 treatments). Similar assay accuracy is achieved in a prospective study of third-line or later mCRC treat-ment, AGITG FORECAST-1 (n = 30 patients). "Resistant"predictions are associated with inferior progres-sion-free survival; misclassification rates are similar by regimen. Liver metastases are the optimal site for sampling, with testing achievable within 7 weeks for 68.8% cases. Our findings indicate that PDTO drug panel testing can provide predictive information for multifarious standard-of-care therapies for mCRC.
C1 [Tan, Tao; Mouradov, Dmitri; Lee, Margaret; Gard, Grace; Hirokawa, Yumiko; Li, Shan; Palmieri, Michelle; Leong, Evelyn; Clarke, Jordan; Sakthianandeswaren, Anuratha; Brasier, Helen; Tie, Jeanne; Jalali, Azim; Burgess, Antony W.; Gibbs, Peter; Sieber, Oliver M.] Walter & Eliza Hall Inst Med Res, Personalised Oncol Div, Parkville, Vic 3052, Australia.
   [Tan, Tao; Mouradov, Dmitri; Palmieri, Michelle; Sakthianandeswaren, Anuratha; Tie, Jeanne; Burgess, Antony W.; Gibbs, Peter; Sieber, Oliver M.] Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia.
   [Lee, Margaret; Gard, Grace; Tie, Jeanne; Jalali, Azim; Gibbs, Peter] Western Hlth, Dept Med Oncol, Footscray, Vic 3011, Australia.
   [Lee, Margaret; Wong, Rachel] Eastern Hlth, Dept Med Oncol, Box Hill, Vic 3128, Australia.
   [Lee, Margaret; Wong, Rachel] Monash Univ, Fac Med Nursing & Hlth Sci, Eastern Hlth Clin Sch, Box Hill, Vic 3128, Australia.
   [Lin, Cong; Li, Fuqiang; Luo, Huijuan] Chinese Acad Sci, Zhejiang Canc Hosp, Hangzhou Inst Med, HIM BGI Omics Ctr,BGI Res, Hangzhou 310000, Peoples R China.
   [Lin, Cong; Li, Fuqiang; Luo, Huijuan; Wu, Kui] BGI Res, Guangdong Prov Key Lab Human Dis Genom, Shenzhen Key Lab Genom, Shenzhen 518083, Peoples R China.
   [Tebbutt, Niall C.] Austin Hlth, Olivia Newton John Canc Wellness & Res Ctr, Dept Med Oncol, Heidelberg, Vic 3084, Australia.
   [Jalali, Azim] Latrobe Reg Hosp, Dept Canc Serv, Traralogon, Vic 3844, Australia.
   [Jalali, Azim] Northern Hosp, Dept Med Oncol, Epping, Vic 3076, Australia.
   [Sieber, Oliver M.] Univ Melbourne, Dept Surg, Parkville, Vic 3050, Australia.
   [Sieber, Oliver M.] Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
C3 Walter & Eliza Hall Institute; University of Melbourne; Eastern Health;
   Monash University; Chinese Academy of Sciences; Hangzhou Institute of
   Medicine, CAS; Zhejiang Cancer Hospital; Beijing Genomics Institute
   (BGI); Florey Institute of Neuroscience & Mental Health; Austin Research
   Institute; La Trobe University; Olivia Newton-John Cancer Research
   Institute; Latrobe Regional Health; University of Melbourne; Monash
   University
RP Sieber, OM (corresponding author), Walter & Eliza Hall Inst Med Res, Personalised Oncol Div, Parkville, Vic 3052, Australia.; Sieber, OM (corresponding author), Univ Melbourne, Dept Med Biol, Parkville, Vic 3052, Australia.; Sieber, OM (corresponding author), Univ Melbourne, Dept Surg, Parkville, Vic 3050, Australia.; Sieber, OM (corresponding author), Monash Univ, Dept Biochem & Mol Biol, Clayton, Vic 3800, Australia.
EM sieber.o@wehi.edu.au
RI Palmieri, Michelle/AAE-7340-2020; Sieber, Oliver/M-9473-2015; Wu,
   Kui/JHT-4169-2023
OI Sieber, Oliver/0000-0001-9480-0786; Tan, Tao/0000-0001-5924-4112;
   Mouradov, Dmitri/0000-0001-8149-816X; Wu, Kui/0000-0002-6857-7231
FU tional Infrastructure support grant; China Scholarship Council
   [201706190314]; Guangdong Provincial Key Laboratory of Human Disease
   Genomics [2020B1212070028]; Victorian Cancer Biobank through the Cancer
   Council Victoria; Victorian government through the Victorian Cancer
   Agency, a business unit of the Department of Health
FX This study was supported by an Innovation Grant from the Australasian
   Gastro-Intestinal Trials Group (AGITG), the Stafford Fox Medical
   Research Foundation, Cancer Australia through the 2017 Priority-driven
   Collaborative Cancer Research Scheme (GNT1145907), a Beijing Genomics
   Institute Genome Decode Program grant, an Independent Research
   Institutes Infra-structure Support Scheme grant, and a Victorian State
   Government Operational Infrastructure support grant. T.T. is supported
   by the China Scholarship Council (award number: 201706190314) . O.M.S.
   is a National Health and Medical Research Council Senior Research Fellow
   (GNT1136119) . This work was supported by the Guangdong Provincial Key
   Laboratory of Human Disease Genomics (2020B1212070028) and by the China
   National Gene Bank with computational and sequencing resources. The
   FORECAST-1 study was endorsed by the AGITG. The authors thank the
   Victorian Cancer BioBank and Biogrid Australia for provision of patient
   specimens and clinical data. The Victorian Cancer Biobank through the
   Cancer Council Victoria as Lead Agency is supported by the Victorian
   government through the Victorian Cancer Agency, a business unit of the
   Department of Health.r tional Infrastructure support grant. T.T. is
   supported by the China Scholarship Council (award number: 201706190314)
   . O.M.S. is a National Health and Med-ical Research Council Senior
   Research Fellow (GNT1136119) . This work was supported by the Guangdong
   Provincial Key Laboratory of Human Disease Genomics (2020B1212070028)
   and by the China National GeneBank with computational and sequencing
   resources. The FORECAST-1 study was endorsed by the AGITG. The authors
   thank the Victorian Cancer BioBank and Biogrid Australia for provision
   of patient specimens and clinical data. The Victorian Cancer Biobank
   through the Cancer Council Victoria as Lead Agency is supported by the
   Victorian government through the Victorian Cancer Agency, a business
   unit of the Department of Health.
CR André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Botrel TEA, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2734-y
   Boland CR, 1998, CANCER RES, V58, P5248
   Bruun J, 2020, CLIN CANCER RES, V26, P4107, DOI 10.1158/1078-0432.CCR-19-3637
   Cameron DL, 2021, GENOME BIOL, V22, DOI 10.1186/s13059-021-02423-x
   Casale F, 2004, PHARMACOL RES, V50, P173, DOI 10.1016/j.phrs.2004.01.006
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chen Fengzhen, 2020, Yichuan, V42, P799, DOI 10.16288/j.yczz.20-080
   Chen YX, 2017, GIGASCIENCE, V7, DOI 10.1093/gigascience/gix120
   Cripps C, 1999, ANN ONCOL, V10, P1175, DOI 10.1023/A:1008372529239
   Demmers LC, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19142-9
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Field K, 2013, INTERN MED J, V43, P1224, DOI 10.1111/imj.12230
   Freed D., 2017, bioRxiv, DOI 10.1101/115717
   Fujii M, 2018, CELL STEM CELL, V23, P787, DOI 10.1016/j.stem.2018.11.016
   Fujii M, 2016, CELL STEM CELL, V18, P827, DOI 10.1016/j.stem.2016.04.003
   Ganesh K, 2019, NAT MED, V25, P1607, DOI 10.1038/s41591-019-0584-2
   Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127
   Guo XQ, 2020, DATABASE-OXFORD, DOI 10.1093/database/baaa055
   Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010
   Hirokawa Y, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02607-y
   Janda CY, 2017, NATURE, V545, P234, DOI 10.1038/nature22306
   Jenkins RW, 2018, CANCER DISCOV, V8, P196, DOI 10.1158/2159-8290.CD-17-0833
   Jensen LH, 2023, J EXP CLIN CANC RES, V42, DOI 10.1186/s13046-023-02683-4
   Jiménez-Fonseca P, 2015, CLIN TRANSL ONCOL, V17, P384, DOI 10.1007/s12094-014-1243-1
   John W, 2000, CANCER-AM CANCER SOC, V88, P1807, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1807::AID-CNCR8>3.0.CO;2-L
   Kim J, 2020, NAT REV MOL CELL BIO, V21, P571, DOI 10.1038/s41580-020-0259-3
   Kosmider S, 2008, ANZ J SURG, V78, P803, DOI 10.1111/j.1445-2197.2008.04655.x
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Levy EB, 2020, J CLIN ONCOL, V38, P1633, DOI 10.1200/JCO.19.02322
   Li H., 2013, arXiv, DOI DOI 10.48550/ARXIV.1303.3997
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Lindor NM, 2002, J CLIN ONCOL, V20, P1043, DOI 10.1200/JCO.20.4.1043
   Liston DR, 2017, CLIN CANCER RES, V23, P3489, DOI 10.1158/1078-0432.CCR-16-3083
   Louvet Christophe, 2004, Oncology (Williston Park), V18, P56
   Lv T, 2023, INT J CANCER, V152, P524, DOI 10.1002/ijc.34302
   Merl MY, 2009, EXPERT OPIN INV DRUG, V18, P1257, DOI 10.1517/13543780903136724
   Mo SB, 2022, ADV SCI, V9, DOI 10.1002/advs.202204097
   Narasimhan V, 2020, CLIN CANCER RES, V26, P3662, DOI 10.1158/1078-0432.CCR-20-0073
   Ooft SN, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100103
   Ooft SN, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aay2574
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Peeters M, 2015, CLIN CANCER RES, V21, P5469, DOI 10.1158/1078-0432.CCR-15-0526
   Pietrantonio F, 2014, ANN ONCOL, V25, P404, DOI 10.1093/annonc/mdt547
   Ponnapalli SP, 2020, APL BIOENG, V4, DOI 10.1063/1.5142559
   Priestley P, 2019, NATURE, V575, P210, DOI 10.1038/s41586-019-1689-y
   R Code Team, 2022, R LANG ENV STAT COMP
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/nmeth.2019, 10.1038/NMETH.2019]
   Shale C, 2022, CELL GENOM, V2, DOI 10.1016/j.xgen.2022.100112
   Van der Auwera Geraldine A, 2013, Curr Protoc Bioinformatics, V43, DOI [10.1002/0471250953.bi1201s43, 10.1002/0471250953.bi1110s43]
   Strelez C, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102509
   Strickler JH, 2023, LANCET ONCOL, V24, P496, DOI 10.1016/S1470-2045(23)00150-X
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Tan T, 2022, BIO-PROTOCOL, V12, DOI 10.21769/BioProtoc.4394
   Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797
   Van Cutsem E, 2020, ANN ONCOL, V31, P1160, DOI 10.1016/j.annonc.2020.05.024
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053
   Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774
   Wang T, 2021, DIS COLON RECTUM, V64, P833, DOI 10.1097/DCR.0000000000001971
   Wensink GE, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00168-1
   Yao Y, 2020, CELL STEM CELL, V26, P17, DOI 10.1016/j.stem.2019.10.010
   Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333
NR 64
TC 9
Z9 9
U1 5
U2 14
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2211-1247
J9 CELL REP
JI Cell Reports
PD DEC 19
PY 2023
VL 4
IS 12
AR 101335
DI 10.1016/j.xcrm.2023.101335
EA DEC 2023
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA ES9X8
UT WOS:001141045000001
PM 38118423
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Parseghian, CM
   Napolitano, S
   Loree, JM
   Kopetz, S
AF Parseghian, Christine M.
   Napolitano, Stefania
   Loree, Jonathan M.
   Kopetz, Scott
TI Mechanisms of Innate and Acquired Resistance to Anti-EGFR Therapy: A
   Review of Current Knowledge with a Focus on Rechallenge Therapies
SO CLINICAL CANCER RESEARCH
LA English
DT Review
ID METASTATIC COLORECTAL-CANCER; K-RAS MUTATIONS; FOLFIRI PLUS CETUXIMAB;
   CIRCULATING TUMOR DNA; PHASE-II TRIAL; TARGETED THERAPY; 1ST-LINE
   TREATMENT; MOLECULAR LANDSCAPE; GENOMIC LANDSCAPE; CLONAL SELECTION
AB Innate and acquired resistance to anti-EGFR therapy (EGFRi) is a major limitation in the treatment of metastatic colorectal cancer (mCRC). Although RAS genes are the most commonly mutated innate and acquired oncogenes in cancer, there are a number of other mechanisms that limit the effectiveness of EGFRi. Patients with innate resistance have been found to contain BRAFV600E mutations, and possibly MET, MEK, PIK3CA, PTEN, and HER2 alterations. Meanwhile, BRAFV600E mutations may also be involved in acquired resistance to EGFRi, in addition to EGFR ectodomain mutations, MET alterations, and possibly HER2 amplification. In addition, paracrine effects and cell-fate mechanisms of resistance are being increasingly described as contributing to acquired resistance. Utilization of circulating tumor DNA has been paramount in monitoring the dynamic nature of acquired resistance and has helped to guide treatment decisions, particularly in the EGFRi rechallenge setting. Herein, we provide an in-depth review of EGFRi-resistance mechanisms and describe the current therapeutic landscape in the hopes of identifying effective rechallenge strategies.
C1 [Parseghian, Christine M.; Napolitano, Stefania; Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Div Canc Med, Houston, TX 77030 USA.
   [Loree, Jonathan M.] BC Canc, Vancouver, BC, Canada.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Parseghian, CM (corresponding author), Univ Texas MD Anderson Canc Ctr, 1515 Holcombe Blvd,Unit 426, Houston, TX 77030 USA.
EM cparseghian@mdanderson.org
RI Kopetz, Scott/AAC-1387-2019; Napolitano, Stefania/AAM-6696-2020
OI Parseghian, Christine/0000-0002-2047-097X; Loree,
   Jonathan/0000-0001-8189-2132; Napolitano, Stefania/0000-0003-3504-8349
FU Conquer Cancer Foundation Merit Award; NIH [R01 CA187238]
FX The authors acknowledge Ryan Nini for help in the design of the figures.
   C.M. Parseghian was funded by a Conquer Cancer Foundation Merit Award
   for this work. S. Kopetz was funded by NIH Grant (grant number R01
   CA187238).
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], 2019, J CLIN ONCOL S
   Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Bardelli A, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.2626
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Bregni G, 2019, JAMA ONCOL, V5, P605, DOI 10.1001/jamaoncol.2018.7229
   Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Buck E, 2007, MOL CANCER THER, V6, P532, DOI 10.1158/1535-7163.MCT-06-0462
   Cappuzzo F, 2009, ANN ONCOL, V20, P298, DOI 10.1093/annonc/mdn635
   Cappuzzo F, 2014, CLIN COLORECTAL CANC, V13, P37, DOI 10.1016/j.clcc.2013.11.006
   Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Ciardiello F, 2011, CANCER DISCOV, V1, P472, DOI 10.1158/2159-8290.CD-11-0261
   Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Fernandes MS, 2013, INT J CANCER, V132, P251, DOI 10.1002/ijc.27696
   Francipane MG, 2014, ONCOTARGET, V5, P49, DOI 10.18632/oncotarget.1548
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Guo F, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24306-1
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hobor S, 2014, CLIN CANCER RES, V20, P6429, DOI 10.1158/1078-0432.CCR-14-0774
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Husain H, 2017, CLIN CANCER RES, V23, P4716, DOI 10.1158/1078-0432.CCR-17-0454
   Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475
   Igarashi H, 2015, ANN SURG ONCOL, V22, P2640, DOI 10.1245/s10434-014-4264-7
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Karani A, J CLIN ONCOL S, V37, P683
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Khan KH, 2018, CANCER DISCOV, V8, P1270, DOI 10.1158/2159-8290.CD-17-0891
   Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796
   Lee MS, 2016, BRIT J CANCER, V114, P1352, DOI 10.1038/bjc.2016.87
   Liao HW, 2015, J CLIN INVEST, V125, P4529, DOI 10.1172/JCI82826
   Liu X, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1701-3
   Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067
   Loree JM, 2018, CLIN CANCER RES, V24, P1062, DOI 10.1158/1078-0432.CCR-17-2484
   Loree JM, 2017, THER ADV MED ONCOL, V9, P551, DOI 10.1177/1758834017714997
   Loupakis F, 2014, TARGET ONCOL, V9, P205, DOI 10.1007/s11523-013-0284-7
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796
   Manceau G, 2014, CLIN CANCER RES, V20, P3338, DOI 10.1158/1078-0432.CCR-13-2750
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mlcochova J, 2015, ONCOTARGET, V6, P38695, DOI 10.18632/oncotarget.5735
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Morelli MP, 2015, ANN ONCOL, V26, P731, DOI 10.1093/annonc/mdv005
   Murugan AK, 2009, CELL CYCLE, V8, P2122, DOI 10.4161/cc.8.13.8710
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nogueira A, 2016, ANN ONCOL, V27, P49
   Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111
   Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396
   Ohhara Y, J CLIN ONCOL S, V37, P585
   Osawa H, 2018, ANN ONCOL, V29
   Parseghian CM, 2019, ANN ONCOL, V30, P243, DOI 10.1093/annonc/mdy509
   Peeters M, 2015, EUR J CANCER, V51, P1704, DOI 10.1016/j.ejca.2015.05.017
   Peeters M, 2019, CLIN CANCER RES, V25, P1216, DOI 10.1158/1078-0432.CCR-18-2072
   Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
   Perrone F, 2009, ANN ONCOL, V20, P84, DOI 10.1093/annonc/mdn541
   Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Pietrantonio F, 2013, CANCER BIOL THER, V14, P1098, DOI 10.4161/cbt.26343
   Raghav K, 2019, JCO PRECISION ONCOL, P1
   Raghav K, 2018, CANCER TREAT REV, V66, P95, DOI 10.1016/j.ctrv.2018.04.008
   Rankin A, 2016, ONCOLOGIST, V21, P1306, DOI 10.1634/theoncologist.2016-0148
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283
   Saif MW, 2010, CLIN COLORECTAL CANC, V9, P315, DOI 10.3816/CCC.2010.n.046
   Santini D, 2012, ANN ONCOL, V23, P2313, DOI 10.1093/annonc/mdr623
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Shinde SR, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10689
   Siena S, 2018, ANN ONCOL, V29, P119, DOI 10.1093/annonc/mdx504
   Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14
   Siravegna G, 2015, NAT MED, V21, P827, DOI 10.1038/nm0715-827b
   Smith G, 2010, BRIT J CANCER, V102, P693, DOI 10.1038/sj.bjc.6605534
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Stintzing S, 2015, MOL CANCER THER, V14, P2374, DOI 10.1158/1535-7163.MCT-15-0121
   Strickler JH, 2018, CANCER DISCOV, V8, P164, DOI 10.1158/2159-8290.CD-17-1009
   Tabernero J, 2007, J CLIN ONCOL, V25, P5225, DOI 10.1200/JCO.2007.13.2183
   Thierry AR, 2017, CLIN CANCER RES, V23, P4578, DOI 10.1158/1078-0432.CCR-17-0232
   Troiani T, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000088
   Troiani T, 2014, CLIN CANCER RES, V20, P3775, DOI 10.1158/1078-0432.CCR-13-2181
   Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423
   Tsuji A, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw370.58
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
   van Engeland M, 2002, ONCOGENE, V21, P3792, DOI 10.1038/sj.onc.1205466
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Wadlow R, 2012, ONCOLOGIST, V17, pE27, DOI 10.1634/theoncologist.2011-0452
   Wang Y, 2019, ANN ONCOL, V30, P147, DOI 10.1093/annonc/mdy477
   Wasan H, 2014, LANCET ONCOL, V15, P631, DOI 10.1016/S1470-2045(14)70106-8
   Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
NR 107
TC 79
Z9 87
U1 0
U2 19
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 1
PY 2019
VL 25
IS 23
BP 6899
EP 6908
DI 10.1158/1078-0432.CCR-19-0823
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JT4IA
UT WOS:000500953700005
PM 31263029
OA Green Accepted, Bronze
DA 2025-01-04
ER

PT J
AU Xue, L
   Yang, D
AF Xue, Liang
   Yang, Dong
TI MiR-421 inhibited the proliferation and metastasis o f colorectal cancer
   by targeting MTA1
SO JOURNAL OF BUON
LA English
DT Article
DE colorectal cancer; epithelial-mesenchymal transition;
   metastasis-associated protein 1(MTA1); MiR-421
ID EPITHELIAL-MESENCHYMAL TRANSITION; HEPATOCELLULAR-CARCINOMA;
   PROSTATE-CANCER; DOWN-REGULATION; OVEREXPRESSION; STATISTICS; MICRORNAS;
   PROGNOSIS; INVASION; RECEPTOR
AB Purpose: To investigate the role and molecular mechanism of miR-421 in the development of colorectal cancer (CRC), providing a theoretical basis for the search for new CRC therapeutic targets.
   Methods: 30 pairs of human CRC and cancer-adjacent normal tissue samples were collected. The expression of miR-421 was detected in CRC tissues and cells. On-line target gene prediction software was applied to screen metastasis-associated protein 1 (MTA1), the potential downstream target gene of miR-421. The role of miR-421 in regulating MTA1 and its effect on the expression of epithelial-mesenchymal transition (EMT) markers (E-cadherinand Vimentin) were detected.
   Results: Compared with that in adjacent normal tissues and normal human intestinal epithelial cells, the miR-42lexpression level in CRC tissues and cells was significantly reduced. The potential target of miR-421 was analyzed by three public databases, in which we found that MTA1 was a direct target of miR-421, and miR-421 inhibited the proliferation, invasion, migration and EMT of CRC cells through the targeted regulation of the expression of target gene MTA, thus effectively suppressing the ability of CRC cells.
   Conclusions: This research demonstrated the suppressive function of miR-421 in CRC. Therefore, the miR-421/MAT1 axis is expected to be one of the targets of CRC targeted therapy.
C1 [Xue, Liang] Nanjing Med Univ, Kangda Coll, Affiliated Hosp, Peoples Hosp Lianyungang 1,Dept Gastrointestinal, Tongguan North Rd 182, Lianyungang 222002, Jiangsu, Peoples R China.
   [Yang, Dong] Nanjing Med Univ, Kangda Coll, Affiliated Hosp, Peoples Hosp Lianyungang 1,Dept Anorectal Surg, Lianyungang, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Xue, L (corresponding author), Nanjing Med Univ, Kangda Coll, Affiliated Hosp, Peoples Hosp Lianyungang 1,Dept Gastrointestinal, Tongguan North Rd 182, Lianyungang 222002, Jiangsu, Peoples R China.
EM leonarddav@163.com
OI Yang, Dong/0009-0009-9706-1216
CR Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Du B, 2011, WORLD J GASTROENTERO, V17, P1219, DOI 10.3748/wjg.v17.i9.1219
   He Z, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3121-z
   Jin DJ, 2015, ONCOL REP, V33, P515, DOI 10.3892/or.2014.3638
   Kai L, 2010, INT J CANCER, V126, P1538, DOI 10.1002/ijc.24928
   Lee H, 2009, J GASTROEN HEPATOL, V24, P1445, DOI 10.1111/j.1440-1746.2009.05965.x
   Lee TY, 2016, GENET MOL RES, V15, DOI 10.4238/gmr.15027400
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li DQ, 2012, CANCER RES, V72, P387, DOI 10.1158/0008-5472.CAN-11-2345
   Li SH, 2009, WORLD J SURG, V33, P1876, DOI 10.1007/s00268-009-0119-y
   Liu HY, 2015, INT J CLIN EXP PATHO, V8, P15128
   Liu Q, 2018, J BUON, V23, P29
   Meng DL, 2016, INT J BIOCHEM CELL B, V73, P30, DOI 10.1016/j.biocel.2016.01.018
   Moon WS, 2004, HUM PATHOL, V35, P424, DOI 10.1016/j.humpath.2003.11.007
   Pan YQ, 2016, BIOMED PHARMACOTHER, V83, P1398, DOI 10.1016/j.biopha.2016.08.058
   Sen N, 2014, CANCER METAST REV, V33, P879, DOI 10.1007/s10555-014-9515-3
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Strubberg AM, 2017, DIS MODEL MECH, V10, P197, DOI 10.1242/dmm.027441
   Tariq K, 2016, CANCER BIOL MED, V13, P120, DOI 10.28092/j.issn.2095-3941.2015.0103
   Toh Y, 2009, CLIN EXP METASTAS, V26, P215, DOI 10.1007/s10585-008-9233-8
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Xie ZT, 2015, TUMOR BIOL, V36, P6497, DOI 10.1007/s13277-015-3340-3
   Yoo YG, 2006, EMBO J, V25, P1231, DOI 10.1038/sj.emboj.7601025
   Zhang Z, 2017, CANCER GENE THER, V24, P83, DOI 10.1038/cgt.2017.1
   Zhou SG, 2016, TUMOR BIOL, V37, P9001, DOI 10.1007/s13277-015-4578-5
NR 25
TC 28
Z9 29
U1 0
U2 2
PU IMPRIMATUR PUBLICATIONS
PI ATHENS
PA 30 DEM POLIORKETES ST, ATHENS, 136 76, GREECE
SN 1107-0625
EI 2241-6293
J9 J BUON
JI J. BUON
PD NOV-DEC
PY 2018
VL 23
IS 6
BP 1633
EP 1639
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HB4JC
UT WOS:000451018200010
PM 30610787
DA 2025-01-04
ER

PT J
AU Sharen, G
   Li, XF
   Sun, JX
   Zhang, L
   Xi, W
   Zhao, XD
   Han, F
   Jia, LL
   A, R
   Cheng, HD
   Hou, MX
AF Sharen, Gaowa
   Li, Xiongfeng
   Sun, Jiaxin
   Zhang, Lei
   Xi, Wen
   Zhao, Xiaodong
   Han, Fei
   Jia, Longlong
   A, Rong
   Cheng, Haidong
   Hou, Mingxing
TI Silencing eL31 suppresses the progression of colorectal cancer via
   targeting DEPDC1
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Article
DE Colorectal cancer; eL31; DEPDC1
ID RIBOSOMAL-PROTEIN; INCREASED EXPRESSION; MESSENGER-RNA; GENE;
   IDENTIFICATION
AB Background Colorectal cancer (CRC) is one of the most commonly diagnosed human malignancies. Ribosomal protein L31 (RPL31, aka eL31) is a component of the 60S large ribosomal subunit, and its expression pattern and functional role in CRC have not been reported. Methods Herein, we identified that eL31 protein level was dramatically increased in CRC tissues through using IHC analysis. More notably, elevated eL31 was associated with larger tumor size and shorter overall survival. Besides, we evaluated the effects of eL31 depletion on CRC cell phenotypes in vitro. Results The data indicated that eL31 knockdown restricted CRC cell proliferation, migration and colony formation whilst enhancing cell apoptosis. Importantly, eL31 was also essential for CRC tumor growth in vivo, as demonstrated by impaired tumor growth markers and reduced Ki67 levels in xenografts from eL31-depleted cells. In addition, our evidence indicated that DEP domain containing 1 (DEPDC1) was a potential downstream target of eL31 in regulating CRC. Consistently, DEPDC1 depletion restrained CRC cell proliferation and migration, as well as facilitated cell apoptosis. More interestingly, DEPDC1 depletion could reverse the promotion effects of eL31 elevation on CRC cells. Conclusions Identification of eL31's function in CRC may pave the way for future development of more specific and more effective targeted therapy strategies against CRC.
C1 [Sharen, Gaowa] Inner Mongolia Med Univ, Affiliated Hosp, Dept Pathol, Hohhot 010059, Inner Mongolia, Peoples R China.
   [Sharen, Gaowa] Inner Mongolia Med Univ, Coll Basic Med, Dept Pathol Anat, Hohhot 010059, Inner Mongolia, Peoples R China.
   [Li, Xiongfeng; Zhang, Lei; Xi, Wen; Zhao, Xiaodong; Han, Fei; Jia, Longlong; A, Rong] Inner Mongolia Med Univ, Grad Sch, Hohhot 010063, Inner Mongolia, Peoples R China.
   [Sun, Jiaxin] Inner Mongolia Med Univ, Dept Clin Med Res Ctr, Affiliated Hosp, Hohhot 010059, Inner Mongolia, Peoples R China.
   [Cheng, Haidong; Hou, Mingxing] Inner Mongolia Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Hohhot 010059, Inner Mongolia, Peoples R China.
C3 Inner Mongolia Medical University; Inner Mongolia Medical University;
   Inner Mongolia Medical University; Inner Mongolia Medical University;
   Inner Mongolia Medical University
RP Cheng, HD; Hou, MX (corresponding author), Inner Mongolia Med Univ, Dept Gastrointestinal Surg, Affiliated Hosp, Hohhot 010059, Inner Mongolia, Peoples R China.
EM 763175936@qq.com; hmxnm6412@163.com
RI zhao, xd/HJX-9525-2023; sun, jiaxin/L-2680-2019
FU Joint Project of Inner Mongolia Medical University [YKD2021LH007];
   General Project of Inner Mongolia Medical University [YKD2021MS021];
   Inner Mongolia Grassland Talent Innovative Team Project of methods for
   early screening of digestive tract tumor based on SELDI-TOF-MS; Inner
   Mongolia Natural Science Foundation [2021MS08030]; PhD Initial Funding
   Project of the Affiliated Hospital of Inner Mongolia Medical University
   [NYFYBS202101]
FX This work was financially supported by Joint Project of Inner Mongolia
   Medical University (NO: YKD2021LH007), General Project of Inner Mongolia
   Medical University (NO: YKD2021MS021), the Inner Mongolia Grassland
   Talent Innovative Team Project of methods for early screening of
   digestive tract tumor based on SELDI-TOF-MS, the Inner Mongolia Natural
   Science Foundation (No: 2021MS08030) and PhD Initial Funding Project of
   the Affiliated Hospital of Inner Mongolia Medical University (No:
   NYFYBS202101).
CR Al-Busaidi IS, 2019, ANZ J SURG, V89, P1091, DOI 10.1111/ans.14930
   Allen J, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0621-2
   BARNARD GF, 1992, CANCER RES, V52, P3067
   CHESTER KA, 1989, BIOCHIM BIOPHYS ACTA, V1009, P297, DOI 10.1016/0167-4781(89)90119-X
   CHIAO PJ, 1992, MOL CARCINOGEN, V5, P219, DOI 10.1002/mc.2940050309
   Clark DE, 2005, CANCER RES, V65, P3108
   de la Cruz J, 2015, ANNU REV BIOCHEM, V84, P93, DOI 10.1146/annurev-biochem-060614-033917
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   DENIS MG, 1993, INT J CANCER, V55, P275, DOI 10.1002/ijc.2910550218
   Fan YY, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.899900
   Farrar JE, 2014, AM J HEMATOL, V89, P985, DOI 10.1002/ajh.23807
   Gately L, 2019, FUTURE ONCOL, V15, P2955, DOI 10.2217/fon-2018-0941
   Harada Y, 2010, CANCER RES, V70, P5829, DOI 10.1158/0008-5472.CAN-10-0255
   Haraldsdóttir S, 2014, LAEKNABLADID, V100, P75, DOI 10.17992/lbl.2014.02.531
   Kanehira M, 2007, ONCOGENE, V26, P6448, DOI 10.1038/sj.onc.1210466
   Kassambara A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062752
   MAGER WH, 1988, BIOCHIM BIOPHYS ACTA, V949, P1, DOI 10.1016/0167-4781(88)90048-6
   Maruyama Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108743
   Mi Y, 2015, BMB REP, V48, P413, DOI 10.5483/BMBRep.2015.48.7.036
   Miyata Y, 2015, CANCER BIOMARK, V15, P789, DOI 10.3233/CBM-150521
   Nissen P, 2000, SCIENCE, V289, P920, DOI 10.1126/science.289.5481.920
   OEN H, 1973, P NATL ACAD SCI USA, V70, P2799, DOI 10.1073/pnas.70.10.2799
   Panariello L, 2020, CLIN COLORECTAL CANC, V19, pE235, DOI 10.1016/j.clcc.2020.05.006
   Pecoraro A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115496
   Penzo M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8010055
   Piawah S, 2019, CANCER-AM CANCER SOC, V125, P4139, DOI 10.1002/cncr.32163
   Schreuders EH, 2015, GUT, V64, P1637, DOI 10.1136/gutjnl-2014-309086
   Sendoel A, 2014, NAT CELL BIOL, V16, P812, DOI 10.1038/ncb3010
   Shen XH, 2020, J CLIN LAB ANAL, V34, DOI 10.1002/jcla.23634
   Tanaka A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79049-9
   TANAKA T, 1987, EUR J BIOCHEM, V162, P45, DOI 10.1111/j.1432-1033.1987.tb10539.x
   Thomson E, 2013, J CELL SCI, V126, P4815, DOI 10.1242/jcs.111948
   Wang Q, 2021, CANCER BIOTHER RADIO, V36, P36, DOI 10.1089/cbr.2019.3460
   Wong SH, 2019, NAT REV GASTRO HEPAT, V16, P690, DOI 10.1038/s41575-019-0209-8
   Yang YN, 2016, INT J BIOL MACROMOL, V89, P344, DOI 10.1016/j.ijbiomac.2016.04.048
   Yuan SG, 2014, ASIAN PAC J CANCER P, V15, P10917, DOI 10.7314/APJCP.2014.15.24.10917
NR 36
TC 7
Z9 7
U1 1
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD OCT 29
PY 2022
VL 20
IS 1
AR 493
DI 10.1186/s12967-022-03663-6
PG 12
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 5U5IP
UT WOS:000876580800002
PM 36309731
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Manthalkar, L
   Bhattacharya, S
   Hatware, K
   Sreelaya, P
   Shah, DS
   Jain, A
   Phatak, N
AF Manthalkar, Laxmi
   Bhattacharya, Sankha
   Hatware, Ketan
   Sreelaya, Putrevu
   Shah, Disha
   Jain, Arinjay
   Phatak, Niraj
TI Fabrication of D-α-tocopheryl polyethylene glycol 1000 succinates and
   human serum albumin conjugated chitosan nanoparticles of bosutinib for
   colon targeting application; in vitro-in vivo investigation
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Bosutinib; D-alpha-tocopheryl polyethylene glycol 1000 (TPGS); Chitosan;
   Colorectal cancer; Drug delivery; Human serum albumin; Targeted therapy;
   Cytotoxicity
ID ENHANCED PERMEABILITY; CANCER; IMPROVE
AB For more effective chemotherapy and targeted treatment of colorectal cancer, this study seeks to develop chitosan (CH)-human serum albumin (HAS)-D-alpha-tocopheryl polyethylene glycol 1000 (TPGS) nanoparticles (BOS-CH-HSA-TPGS-NPs) coated with Bosutinib (BOS). Nuclear magnetic resonance (NMR) indicated that chitosan's structure was modified by carbodiimide coupling with HSA. We used a Box-Behnken design to find the ideal region for particle size, zeta potential, and entrapment efficiency, eventually emerging at a formulation with these values: 187.14 +/- 3.2 nm, 76.2 +/- 0.96 %, and 21.1 +/- 2.3 mV. Differential scanning calorimetry (DSC), Transmission electron microscopy (TEM), X-ray diffraction (XRD), Atomic force microscopy (AFM), Fourier transform infrared spectroscopy (FTIR), High-performance liquid chromatography (HPLC) were all used to characterize the sample in detail. At a phosphate buffer pH of 7.4, in vitro drug release tests showed both Higuchi model release (0.954) and Fickian diffusion (n = 0.5). Compared to free BOS, HCT116 cell lines showed considerably higher cytotoxicity in in vitro cytotoxicity assays. In male albino Wistar rats, the BOS-CH-HSA-TPGS-NPs also showed enhanced pharmacokinetics, targeting efficiency, and biocompatibility. When used to the treatment of colorectal cancer, the BOS-CH-HSA-TPGS NPs show promise as a sustained-release therapy with improved therapeutic effects by addressing the challenges of poor solubility, poor permeability, and toxic side effects.
C1 [Manthalkar, Laxmi; Bhattacharya, Sankha; Sreelaya, Putrevu; Shah, Disha; Jain, Arinjay; Phatak, Niraj] SVKMS NMIMS Deemed Univ, Sch Pharm & Technol Management, Dept Pharmaceut, Shirpur 425405, Maharashtra, India.
   [Hatware, Ketan] SVKMS NMIMS Deemed Univ, Sch Pharm & Technol Management, Dept Pharmaceut, Shirpur 425405, Maharashtra, India.
   [Bhattacharya, Sankha] SVKMS NMIMS Deemed Univ, Sch Pharm & Technol Management Shirpur, Shirpur 425405, Maharashtra, India.
C3 SVKM's NMIMS (Deemed to be University); SVKM's NMIMS (Deemed to be
   University); SVKM's NMIMS (Deemed to be University)
RP Bhattacharya, S (corresponding author), SVKMS NMIMS Deemed Univ, Sch Pharm & Technol Management Shirpur, Shirpur 425405, Maharashtra, India.
EM sankhabhatt@gmail.com
RI Hatware, Ketan/LVR-1194-2024; Bhattacharya, Sankha/AAM-5111-2020
OI Jain, Arinjay/0000-0002-6063-7973
CR Abu-Much R, 2021, J CHEM EDUC, V98, P4037, DOI 10.1021/acs.jchemed.1c00777
   Adhikari HS, 2018, INT J BIOMATER, V2018, DOI 10.1155/2018/2952085
   Ahmed R, 2021, ACS OMEGA, V6, P17915, DOI 10.1021/acsomega.1c01490
   Akintimehin E.S., 2021, antioxidative and histology studies, V7, P1
   Alavarse AC, 2022, INT J BIOL MACROMOL, V202, P558, DOI 10.1016/j.ijbiomac.2022.01.029
   Almehmadi MA, 2021, J MOL STRUCT, V1225, DOI 10.1016/j.molstruc.2020.129148
   Bec KB, 2020, ANAL CHIM ACTA, V1133, P150, DOI 10.1016/j.aca.2020.04.015
   Bhattacharya S., 2022, targeting, V31
   Bhattacharya S., 2022, Preparation of Sorafenib tosylate self-emulsified drug delivery system and the effect on combination therapy with Bosutinib against HCT116/SW1417 cells, V4
   Bhattacharya S, 2022, J EXP NANOSCI, V17, P214, DOI 10.1080/17458080.2022.2060501
   Bhattacharya S, 2022, DRUG DELIV, V29, P1060, DOI 10.1080/10717544.2022.2058645
   Bi YG, 2019, MAT SCI ENG C-MATER, V100, P576, DOI 10.1016/j.msec.2019.03.040
   Bishnoi M, 2021, J LIPOSOME RES, V31, P30, DOI 10.1080/08982104.2020.1730400
   Bo T., 2023, Machine learning-assisted data filtering and QSAR models for prediction of chemical acute toxicity on rat and mouse, V452
   Cassimjee H, 2020, CARBOHYD POLYM, V235, DOI 10.1016/j.carbpol.2020.115932
   Chaudhari V.L., 2016, RP-HPLC Method For Estimation of Bosutinib in Bulk Form as per ICH Guidelines
   Chen DM, 2019, PRECIS CLIN MED, V2, P152, DOI 10.1093/pcmedi/pbz016
   Chen JZ, 2014, CLIN COLORECTAL CANC, V13, P5, DOI 10.1016/j.clcc.2013.10.003
   Claesson-Welsh L, 2021, TRENDS MOL MED, V27, P314, DOI 10.1016/j.molmed.2020.11.006
   Dahiya M., 2022, Nano Biomed. Eng., V14, P23
   Daud AI, 2012, CLIN CANCER RES, V18, P1092, DOI 10.1158/1078-0432.CCR-11-2378
   Du Y., 2020, Cytotoxic and optically active pyrisulfoxins from the endophytic Streptomyces albolongus, P248, Patent No. [EA124328, 124328]
   Ejigah V, 2022, POLYMERS-BASEL, V14, DOI 10.3390/polym14132601
   Rodriguez-Garcia ME, 2021, CURR OPIN FOOD SCI, V37, P107, DOI 10.1016/j.cofs.2020.10.002
   Fahmy UA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12100956
   Feyzizadeh M, 2022, EXPERT OPIN DRUG DIS, V17, P1013, DOI 10.1080/17460441.2022.2112666
   Gambacorti-Passerini C, 2020, FUTURE ONCOL, V16, P4395, DOI 10.2217/fon-2019-0555
   Ganesan R, 2022, METABOLITES, V12, DOI 10.3390/metabo12111047
   Garg M, 2021, MED RES REV, V41, P1291, DOI 10.1002/med.21761
   González-González O, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14112324
   Greenshields AL, 2019, EXP MOL PATHOL, V107, P10, DOI 10.1016/j.yexmp.2019.01.006
   Guo JS, 2011, CHEM RES CHINESE U, V27, P329
   Gzil A, 2020, J CANCER RES CLIN, V146, P2547, DOI 10.1007/s00432-020-03314-7
   Hajji S, 2019, BBA-GEN SUBJECTS, V1863, P241, DOI 10.1016/j.bbagen.2018.10.010
   Hegazy H, 2022, INT J PHARMACEUT, V619, DOI 10.1016/j.ijpharm.2022.121717
   Huang KVM, 2020, EXPERT OPIN DRUG MET, V16, P493, DOI 10.1080/17425255.2020.1755253
   Kalyane D, 2019, MAT SCI ENG C-MATER, V98, P1252, DOI 10.1016/j.msec.2019.01.066
   Kilian S, 2021, SMALL, V17, DOI 10.1002/smll.202005443
   Lomis N, 2016, NANOMATERIALS-BASEL, V6, DOI 10.3390/nano6060116
   Luiz MT, 2021, EUR POLYM J, V142, DOI 10.1016/j.eurpolymj.2020.110129
   Lyu Q, 2022, FOOD CHEM, V390, DOI 10.1016/j.foodchem.2022.132954
   Majeed S, 2023, TALANTA, V253, DOI 10.1016/j.talanta.2022.124026
   Mandpe S.R., 2022, Experimental design approach, screening and optimization of system variables, analytical method development of flurbiprofen in nanoparticles and stability-indicating methods for high-pressure liquid chromatography, V8, P1
   Mehata AK, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15030722
   Merlino A.J.C.C.R., 2023, Metallodrug Binding to Serum Albumin: Lessons From Biophysical and Structural Studies, V480
   Mishra AK, 2022, CURR DRUG TARGETS, V23, P1381, DOI 10.2174/1389450123666220906091432
   Mishra S.J.J.O.D.D.S., 2023, Technology
   Mohammadpour R, 2020, J CONTROL RELEASE, V324, P471, DOI 10.1016/j.jconrel.2020.05.027
   Mohassab AM, 2020, PHARMACOL REP, V72, P1101, DOI 10.1007/s43440-020-00156-5
   Montalvao M.M., 2023, Therapies, V23, P1
   Monzer A, 2022, WORLD J GASTROENTERO, V28, P4787, DOI 10.3748/wjg.v28.i33.4787
   Narayani SS, 2019, INT J BIOL MACROMOL, V138, P618, DOI 10.1016/j.ijbiomac.2019.07.127
   Nataj S.M.M., 2023, Post-synthetic Modification of ZrMOFs Using Guanidine for Cyclic Carbonate Formation Catalysis, V422
   Nayek S, 2021, J DRUG DELIV SCI TEC, V61, DOI 10.1016/j.jddst.2020.102073
   Nazeri M, 2020, MOL BIOL REP, V47, P8831, DOI 10.1007/s11033-020-05933-2
   Park J, 2019, THERANOSTICS, V9, P8073, DOI 10.7150/thno.37198
   Pawar A, 2019, BIOMED PHARMACOTHER, V110, P319, DOI 10.1016/j.biopha.2018.11.122
   Peng F, 2019, NAT NANOTECHNOL, V14, P279, DOI 10.1038/s41565-018-0356-z
   Peng SF, 2023, J TRANSL MED, V21, DOI 10.1186/s12967-023-03930-0
   Pessoa B, 2023, MAR DRUGS, V21, DOI 10.3390/md21030179
   Rahman M.M., 2021, Optimum Kinetic Model for gas-solid Physical Adsorption Employing Advanced Statistical Approach
   Rodrigues F.C., 2021, MOL MODELING PILOTED, V11, P1
   Sanati M, 2022, J CONTROL RELEASE, V348, P287, DOI 10.1016/j.jconrel.2022.05.035
   Schuster M, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adg3683
   Senol Y, 2023, J DRUG DELIV SCI TEC, V79, DOI 10.1016/j.jddst.2022.104017
   Serrano-Aroca A, 2022, MATER TODAY BIO, V16, DOI 10.1016/j.mtbio.2022.100412
   Shah AH, 2021, MATER TODAY-PROC, V44, P482, DOI 10.1016/j.matpr.2020.10.199
   Sharma M., 2023, Recent Developments in Anti-Inflammatory Therapy, P245
   Shinde VR, 2022, PHOTODIAGN PHOTODYN, V39, DOI 10.1016/j.pdpdt.2022.102915
   Siddiqui L, 2020, INT J BIOL MACROMOL, V152, P786, DOI 10.1016/j.ijbiomac.2020.02.311
   Siegel J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010312
   Singh G., 2022, A veratraldehyde-appended organosilicon probe and its hybrid silica nanoparticles as a dual chemosensor for colorimetric and fluorimetric detection of Cu2+ and Fe3 + ions, V46, P370
   Singh P, 2022, COLLOID SURFACE B, V218, DOI 10.1016/j.colsurfb.2022.112763
   Singh P, 2023, J LIPOSOME RES, V33, P154, DOI 10.1080/08982104.2022.2108441
   Sonali P., 2016, Transferrin receptor-targeted vitamin E TPGS micelles for brain cancer therapy: preparation, characterization and brain distribution in rats, V23, P1788
   Song C., 2021, Physicochemical aspects of zwitterionic core-shell tecto dendrimers characterized by a thorough NMR investigation, V618
   Sreekumar S, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-23064-4
   Suh MS, 2021, INT J PHARMACEUT, V592, DOI 10.1016/j.ijpharm.2020.120105
   Suresh A.B., 2023, Synthesis of modified tannic acid hydrogel for the transdermal delivery of curcumin, V11
   Taala N., Effect of Initial Particle Size and Surface Charge on the Formation of the Plasma Protein Corona on Chitosan-based Nanoparticles
   Talib WH, 2020, MOLECULES, V25, DOI 10.3390/molecules25225319
   Tao HY, 2021, INT J BIOL MACROMOL, V187, P24, DOI 10.1016/j.ijbiomac.2021.07.080
   Tian L.C., 2023, B. Technology, V2, P25
   Verma, 2018, J NANOMED NANOTECHNO, V9, P2
   Wang PK, 2022, FOOD HYDROCOLLOID, V129, DOI 10.1016/j.foodhyd.2022.107662
   Wu S., 2018, Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells, V17, P1
   Yadav K., 2022, Nano-constructs targeting the primary cellular energy source of cancer cells for modulating tumor progression, V8
   Yang CL, 2018, THERANOSTICS, V8, P464, DOI 10.7150/thno.22711
   Yhee JY, 2015, J CONTROL RELEASE, V198, P1, DOI 10.1016/j.jconrel.2014.11.019
   Zeller J, 2023, EMBO MOL MED, V15, DOI 10.15252/emmm.202216236
   Zhang JX, 2023, DES AUT TEST EUROPE, DOI 10.23919/DATE56975.2023.10136889
   Zhang SL, 2020, AUTOPHAGY, V16, P735, DOI 10.1080/15548627.2019.1632122
   Zheng HW, 2022, COLLOID SURFACE B, V217, DOI 10.1016/j.colsurfb.2022.112705
   Zhong XY, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01358-5
   Zielinska A, 2020, PHARM DEV TECHNOL, V25, P832, DOI 10.1080/10837450.2020.1744008
NR 95
TC 3
Z9 3
U1 3
U2 12
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC 31
PY 2023
VL 253
AR 127531
DI 10.1016/j.ijbiomac.2023.127531
EA OCT 2023
PN 7
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA Y4VL4
UT WOS:001105252600001
PM 37858658
DA 2025-01-04
ER

PT J
AU Crumley, SM
   Pepper, KL
   Phan, AT
   Olsen, RJ
   Schwartz, MR
   Portier, BP
AF Crumley, Suzanne M.
   Pepper, Kristi L.
   Phan, Alexandria T.
   Olsen, Randall J.
   Schwartz, Mary R.
   Portier, Bryce P.
TI Next-Generation Sequencing of Matched Primary and Metastatic Rectal
   Adenocarcinomas Demonstrates Minimal Mutation Gain and Concordance to
   Colonic Adenocarcinomas
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Article
ID COLORECTAL-CANCER; SOMATIC MUTATIONS; STAGE-III; KRAS; PATIENT;
   CHEMOTHERAPY; CHALLENGES; SUBTYPES; CATALOG
AB Context.-Colorectal carcinoma is the third most common cause of cancer death in males and females in the United States. Rectal adenocarcinoma can have distinct therapeutic and surgical management from colonic adenocarcinoma owing to its location and anatomic considerations.
   Objective.-To determine the oncologic driver mutations and better understand the molecular pathogenesis of rectal adenocarcinoma in relation to colon adenocarcinoma.
   Design.-Next-generation sequencing was performed on 20 cases of primary rectal adenocarcinoma with a paired lymph node or solid organ metastasis by using an amplicon-based assay of more than 2800 Catalogue of Somatic Mutations in Cancer (COSMIC)-identified somatic mutations.
   Results.-Next-generation sequencing data were obtained on both the primary tumor and metastasis from 16 patients. Most rectal adenocarcinoma cases demonstrated identical mutations in the primary tumor and metastasis (13 of 16, 81%). The mutations identified, listed in order of frequency, included TP53, KRAS, APC, FBXW7, GNAS, FGFR3, BRAF, NRAS, PIK3CA, and SMAD4.
   Conclusions.-The somatic mutations identified in our rectal adenocarcinoma cohort showed a strong correlation to those previously characterized in colonic adenocarcinoma. In addition, most rectal adenocarcinomas harbored identical somatic mutations in both the primary tumor and metastasis. These findings demonstrate evidence that rectal adenocarcinoma follows a similar molecular pathogenesis as colonic adenocarcinoma and that sampling either the primary or metastatic lesion is valid for initial evaluation of somatic mutations and selection of possible targeted therapy.
C1 [Crumley, Suzanne M.; Pepper, Kristi L.; Olsen, Randall J.; Schwartz, Mary R.; Portier, Bryce P.] Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA.
   [Phan, Alexandria T.] Houston Methodist Hosp, Dept Oncol, Houston, TX 77030 USA.
C3 Houston Methodist; Houston Methodist
RP Portier, BP (corresponding author), Houston Methodist Hosp, Dept Pathol & Genom Med, 6565 Fannin St, Houston, TX 77030 USA.
EM bpportier@houstonmethodist.org
FU Department of Pathology and Genomic Medicine at Houston Methodist
   Hospital
FX Funding was provided for this work by the Department of Pathology and
   Genomic Medicine at Houston Methodist Hospital.
CR [Anonymous], 2015, CANC FACTS FIG
   [Anonymous], CAT SOM MUT CANC COS
   Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Boissière-Michot F, 2012, MODERN PATHOL, V25, P731, DOI 10.1038/modpathol.2011.210
   Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829
   Bosset JF, 2014, LANCET ONCOL, V15, P184, DOI 10.1016/S1470-2045(13)70599-0
   De Caluwé L, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006041.pub3
   Demes M, 2013, J GASTROINTEST ONCOL, V4, P182, DOI 10.3978/j.issn.2078-6891.2013.012
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Dudley J, 2015, ARCH PATHOL LAB MED, V139, P211, DOI 10.5858/arpa.2013-0649-OA
   Edge SB, 2010, AJCC CANC STAGING HD, P173
   Fearon ER, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt444
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Gawlick U, 2013, AM J SURG, V205, P608, DOI 10.1016/j.amjsurg.2013.01.029
   Kosinski L, 2012, CA-CANCER J CLIN, V62, P173, DOI 10.3322/caac.21138
   Liu C., 2004, ROBBINS COTRAN PATHO, P797
   Minoo P, 2010, INT J ONCOL, V37, P707, DOI 10.3892/ijo_00000720
   Minsky BD, 2011, SEMIN ONCOL, V38, P542, DOI 10.1053/j.seminoncol.2011.05.008
   Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nash GM, 2010, ANN SURG ONCOL, V17, P572, DOI 10.1245/s10434-009-0605-3
   National Comprehensive Cancer Network, 2015, RECT CANC VERS 3 201
   Neumann J, 2009, PATHOL RES PRACT, V205, P858, DOI 10.1016/j.prp.2009.07.010
   Phipps AI, 2015, GASTROENTEROLOGY, V148, P77, DOI 10.1053/j.gastro.2014.09.038
   Russo AL, 2014, CANCER-AM CANCER SOC, V120, P1482, DOI 10.1002/cncr.28599
   Singh RR, 2013, J MOL DIAGN, V15, P607, DOI 10.1016/j.jmoldx.2013.05.003
   Sinicrope FA, 2015, GASTROENTEROLOGY, V148, P88, DOI 10.1053/j.gastro.2014.09.041
   Vakiani E, 2012, J CLIN ONCOL, V30, P2956, DOI 10.1200/JCO.2011.38.2994
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yancovitz M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029336
NR 31
TC 15
Z9 16
U1 0
U2 4
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 1543-2165
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD JUN
PY 2016
VL 140
IS 6
BP 529
EP 535
DI 10.5858/arpa.2015-0261-SA
PG 7
WC Medical Laboratory Technology; Medicine, Research & Experimental;
   Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology; Research & Experimental Medicine;
   Pathology
GA DN5JB
UT WOS:000377101500008
PM 26536055
OA Bronze
DA 2025-01-04
ER

PT J
AU Zaporowska-Stachowiak, I
   Springer, M
   Stachowiak, K
   Oduah, M
   Sopata, M
   Wieczorowska-Tobis, K
   Bryl, W
AF Zaporowska-Stachowiak, Iwona
   Springer, Michal
   Stachowiak, Katarzyna
   Oduah, Mary
   Sopata, Maciej
   Wieczorowska-Tobis, Katarzyna
   Bryl, Wieslaw
TI Interleukin-6 Family of Cytokines in Cancers
SO JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
LA English
DT Review
DE cancerogenesis; interleukin-6; cancer progression; gp130;
   cardiotrophin-1
ID CARDIOTROPHIN-LIKE CYTOKINE; ADVANCED PANCREATIC-CANCER; ONCOSTATIN-M;
   INFLAMMATORY CYTOKINES; LYSOPHOSPHATIDIC ACID; CARCINOMA PROGRESSION;
   COLORECTAL-CANCER; SIGNALING PATHWAY; STAT3 ACTIVATION; CELL-GROWTH
AB Nine soluble ligands [interleukin-6 (IL-6), interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OSM), ciliary neurotrophic factor (CNTF), cardiotrophin-1 (CT-1), cardiotrophin-like cytokine, interleukin-27 (IL-27), and interleukin-31] share the ubiquitously expressed transmembrane protein-glycoprotein-130 beta-subunit (gp130) and thus form IL-6 family cytokines. Proteins that may be important for cancerogenesis, CT-1, IL-11, IL-27, LIF, OSM, and CNTF, belong to the superfamily of IL-6. Cytokines such as IL-6, IL-11, and IL-27 are better investigated in comparison with other members of the same family of cytokines, eg, CT-1. Gp130 is one of the main receptors through which these cytokines exert their effects. The clinical implication of understanding the pathways of these cytokines in oncology is that targeted therapy to inhibit or potentiate cytokine activity may lead to remission in some cases.
C1 [Zaporowska-Stachowiak, Iwona; Sopata, Maciej; Wieczorowska-Tobis, Katarzyna] Poznan Univ Med Sci, Dept & Clin Palliat Med, Poznan, Poland.
   [Zaporowska-Stachowiak, Iwona; Sopata, Maciej; Wieczorowska-Tobis, Katarzyna] Poznan Univ Med Sci, Univ Hosp Lords Transfigurat, Palliat Med Inpatient Unit, Poznan, Poland.
   [Springer, Michal; Bryl, Wieslaw] Poznan Univ Med Sci, Dept Internal Dis Metab Disorders & Arterial Hyper, Ul Augustyna Szamarzewskiego 84, PL-60569 Poznan, Poland.
   [Stachowiak, Katarzyna] Univ Warsaw, Inst Appl Linguist, Warsaw, Poland.
   [Oduah, Mary] Poznan Univ Med Sci, English Students Res Assoc, Poznan, Poland.
C3 Poznan University of Medical Sciences; Poznan University of Medical
   Sciences; Poznan University of Medical Sciences; University of Warsaw;
   Poznan University of Medical Sciences
RP Springer, M (corresponding author), Poznan Univ Med Sci, Dept Internal Dis Metab Disorders & Arterial Hyper, Ul Augustyna Szamarzewskiego 84, PL-60569 Poznan, Poland.
EM michal.springer.pl@gmail.com
RI Zaporowska-Stachowiak, Iwona/IQT-0057-2023
OI Springer, Michal/0009-0007-7577-988X
CR Airoldi I, 2015, ONCOTARGET, V6, P3694, DOI 10.18632/oncotarget.2797
   Allegra A, 2014, CANCER INVEST, V32, P470, DOI 10.3109/07357907.2014.958231
   Balic JJ, 2017, CYTOKINE, V92, P118, DOI 10.1016/j.cyto.2017.01.015
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bent EH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-26407-4
   Best M, 2015, PSYCHO-ONCOLOGY, V24, P977, DOI 10.1002/pon.3795
   Bonetto A, 2012, AM J PHYSIOL-ENDOC M, V303, pE410, DOI 10.1152/ajpendo.00039.2012
   Brebner K, 2000, NEUROPSYCHOPHARMACOL, V22, P566, DOI 10.1016/S0893-133X(99)00166-9
   Browning L, 2018, CANCER MANAG RES, V10, P6685, DOI 10.2147/CMAR.S179189
   Brücher BLDM, 2016, CELL PHYSIOL BIOCHEM, V38, P1663, DOI 10.1159/000443106
   Burger R, 2003, BRIT J HAEMATOL, V123, P869, DOI 10.1046/j.1365-2141.2003.04686.x
   Bustos M, 2012, ONCOIMMUNOLOGY, V1, P1527, DOI 10.4161/onci.22504
   Buzzelli JN, 2019, AM J PHYSIOL-GASTR L, V316, pG251, DOI 10.1152/ajpgi.00304.2018
   Cai WL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0746-0
   Campbell CL, 2001, GYNECOL ONCOL, V80, P121, DOI 10.1006/gyno.2000.6064
   Campbell CL, 2001, AM J PATHOL, V158, P25, DOI 10.1016/S0002-9440(10)63940-5
   Canale S, 2011, LEUKEMIA, V25, P1815, DOI 10.1038/leu.2011.158
   Cao JY, 2017, BRAZ J MED BIOL RES, V50, DOI [10.1590/1414-431X20176207, 10.1590/1414-431x20176207]
   Castro CP, 2001, J ENDOCRINOL, V169, P539, DOI 10.1677/joe.0.1690539
   Celik A, 2021, TURK J BIOCHEM, V46, P549, DOI 10.1515/tjb-2020-0508
   Cocco C, 2010, CLIN CANCER RES, V16, P4188, DOI 10.1158/1078-0432.CCR-10-0173
   Dantzer R, 2007, BRAIN BEHAV IMMUN, V21, P153, DOI 10.1016/j.bbi.2006.09.006
   David E, 2012, AM J PATHOL, V181, P1782, DOI 10.1016/j.ajpath.2012.07.023
   David E, 2011, INT J CANCER, V128, P1822, DOI 10.1002/ijc.25776
   Deng GR, 2009, CLIN CANCER RES, V15, P1519, DOI 10.1158/1078-0432.CCR-08-1778
   Di Carlo E, 2014, ONCOTARGET, V5, P10332, DOI 10.18632/oncotarget.1425
   Douglas AM, 1998, INT J CANCER, V75, P64, DOI 10.1002/(SICI)1097-0215(19980105)75:1<64::AID-IJC11>3.0.CO;2-D
   Ellmark P, 2006, MOL CELL PROTEOMICS, V5, P1638, DOI 10.1074/mcp.M600170-MCP200
   Escoté X, 2018, CLIN SCI, V132, P2169, DOI 10.1042/CS20171626
   Fabbi M, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3958069
   Fan K, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-07124-9
   Felger JC, 2013, NEUROSCIENCE, V246, P199, DOI 10.1016/j.neuroscience.2013.04.060
   Feng LY, 2018, J INT MED RES, V46, P5228, DOI 10.1177/0300060518800588
   GEARING DP, 1987, EMBO J, V6, P3995, DOI 10.1002/j.1460-2075.1987.tb02742.x
   Gilabert M, 2014, J CELL PHYSIOL, V229, P1437, DOI 10.1002/jcp.24580
   Gruber S, 2013, CELL REP, V4, P669, DOI 10.1016/j.celrep.2013.07.023
   Grygiel-Górniak B, 2019, PSYCHIAT CLIN NEUROS, V73, P302, DOI 10.1111/pcn.12826
   Hailemichael Y, 2022, CANCER CELL, V40, P509, DOI 10.1016/j.ccell.2022.04.004
   Hanavadi S, 2006, ANN SURG ONCOL, V13, P802, DOI 10.1245/ASO.2006.05.028
   Haroon E, 2012, NEUROPSYCHOPHARMACOL, V37, P137, DOI 10.1038/npp.2011.205
   HART BL, 1988, NEUROSCI BIOBEHAV R, V12, P123, DOI 10.1016/S0149-7634(88)80004-6
   Heichler C, 2020, GUT, V69, P1269, DOI 10.1136/gutjnl-2019-319200
   Hirano T, 2000, ONCOGENE, V19, P2548, DOI 10.1038/sj.onc.1203551
   Hong C, 2022, NATURE, V607, P366, DOI 10.1038/s41586-022-04847-2
   Jaenisch R, 2003, NAT GENET, V33, P245, DOI 10.1038/ng1089
   Jia HY, 2016, J INTERF CYTOK RES, V36, P302, DOI 10.1089/jir.2015.0091
   Jiang Y E, 2018, Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi, V53, P286, DOI 10.3760/cma.j.issn.1673-0860.2018.04.009
   Johnson Christopher, 2012, Transl Gastrointest Cancer, V1, P58
   Kendler KS, 2001, AM J PSYCHIAT, V158, P587, DOI 10.1176/appi.ajp.158.4.587
   Kern L, 2019, CANCERS, V11, DOI 10.3390/cancers11010024
   Kopinski P, 2018, POL ARCH INTERN MED, V128, P105, DOI 10.20452/pamw.4156
   Kraakman MJ, 2015, CELL METAB, V21, P403, DOI 10.1016/j.cmet.2015.02.006
   KUBLERROSS E, 1972, J AMER MED ASSOC, V221, P174, DOI 10.1001/jama.221.2.174
   Kumari N, 2016, TUMOR BIOL, V37, P11553, DOI 10.1007/s13277-016-5098-7
   Lacreusette A, 2007, ONCOGENE, V26, P881, DOI 10.1038/sj.onc.1209844
   LaFemina J, 2013, ANN SURG ONCOL, V20, P66, DOI 10.1245/s10434-012-2573-2
   Leaf DE, 2021, NEW ENGL J MED, V384, P86, DOI 10.1056/NEJMc2032911
   Li YL, 2018, BIOMED PHARMACOTHER, V99, P134, DOI 10.1016/j.biopha.2017.12.108
   Li Y, 2010, GUT, V59, P227, DOI 10.1136/gut.2009.184176
   Lippitz BE, 2013, LANCET ONCOL, V14, pE218, DOI 10.1016/S1470-2045(12)70582-X
   Liu CM, 2022, BMC MED, V20, DOI 10.1186/s12916-022-02356-7
   Liu SC, 2013, J CLIN INVEST, V123, P5269, DOI 10.1172/JCI63428
   López-Yoldi M, 2015, CYTOKINE GROWTH F R, V26, P523, DOI 10.1016/j.cytogfr.2015.07.009
   Lotrich F, 2012, CURR PHARM DESIGN, V18, P5920, DOI 10.2174/138161212803523680
   Lu J, 2012, J NEUROSURG, V117, P1022, DOI 10.3171/2012.9.JNS1212
   Lucas S, 2003, P NATL ACAD SCI USA, V100, P15047, DOI 10.1073/pnas.2536517100
   Ma J, 2019, CANCER RES TREAT, V51, P194, DOI 10.4143/crt.2018.031
   Masi G, 2011, FUTURE ONCOL, V7, P1299, DOI [10.2217/FON.11.108, 10.2217/fon.11.108]
   Matsui M, 2009, CANCER RES, V69, P2523, DOI 10.1158/0008-5472.CAN-08-2793
   McInnis CM, 2014, BRAIN BEHAV IMMUN, V42, P33, DOI 10.1016/j.bbi.2014.07.018
   Meza KS, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.6_suppl.376
   Miller A, 2017, ONCOGENE, V36, P3059, DOI 10.1038/onc.2016.437
   Miller AH, 2009, BIOL PSYCHIAT, V65, P732, DOI 10.1016/j.biopsych.2008.11.029
   Mills GB, 2003, NAT REV CANCER, V3, P582, DOI 10.1038/nrc1143
   Miura T, 2015, PANCREAS, V44, P756, DOI 10.1097/MPA.0000000000000335
   Moses AGW, 2009, ONCOL REP, V21, P1091, DOI 10.3892/or_00000328
   Nam JS, 2018, KOREAN J PHYSIOL PHA, V22, P503, DOI 10.4196/kjpp.2018.22.5.503
   Nishina T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22450-3
   Ouyang LM, 2006, BIOMED RES-TOKYO, V27, P197, DOI 10.2220/biomedres.27.197
   Park EJ, 2010, CELL, V140, P197, DOI 10.1016/j.cell.2009.12.052
   PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915
   PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142
   Petruzzelli M, 2014, CELL METAB, V20, P433, DOI 10.1016/j.cmet.2014.06.011
   Pop VV, 2017, IMMUNOL LETT, V181, P45, DOI 10.1016/j.imlet.2016.11.010
   Radharani NNV, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935-022-02527-9
   Raison CL, 2011, CURR PSYCHIAT REP, V13, P467, DOI 10.1007/s11920-011-0232-0
   Rebouissou S, 2009, NATURE, V457, P200, DOI 10.1038/nature07475
   Robledo O, 1997, J BIOL CHEM, V272, P4855, DOI 10.1074/jbc.272.8.4855
   Rose-John S, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028415
   Rose-John S, 2012, INT J BIOL SCI, V8, P1237, DOI 10.7150/ijbs.4989
   Sabry D, 2018, J INTERF CYTOK RES, V38, P517, DOI 10.1089/jir.2018.0065
   Savarese TM, 2002, CYTOKINE, V17, P324, DOI 10.1006/cyto.2002.1022
   Scoles DR, 2010, GYNECOL ONCOL, V116, P109, DOI 10.1016/j.ygyno.2009.09.034
   Silver JS, 2010, J LEUKOCYTE BIOL, V88, P1145, DOI 10.1189/jlb.0410217
   Simpson RJ, 1997, PROTEIN SCI, V6, P929, DOI 10.1002/pro.5560060501
   Sims NA, 2015, CYTOKINE GROWTH F R, V26, P517, DOI 10.1016/j.cytogfr.2015.07.014
   Sluzewska A, 1999, ADV EXP MED BIOL, V461, P59
   Smythies J, 2015, J CANCER, V6, P604, DOI 10.7150/jca.12372
   Stejskal D, 2008, BIOMED PAP, V152, P9, DOI 10.5507/bp.2008.002
   Stratton JA, 2018, FRONT CELL NEUROSCI, V12, DOI 10.3389/fncel.2018.00356
   Tanaka T, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a016295
   Tang HX, 2018, AUTOIMMUNITY, V51, P399, DOI 10.1080/08916934.2018.1550079
   Timper K, 2017, CELL REP, V19, P267, DOI 10.1016/j.celrep.2017.03.043
   Vecchi L, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11101705
   Vicent S, 2012, CANCER RES, V72, P5744, DOI 10.1158/0008-5472.CAN-12-1097
   Vignali DAA, 2012, NAT IMMUNOL, V13, P722, DOI 10.1038/ni.2366
   Wang HQ, 2019, J CELL PHYSIOL, V234, P13994, DOI 10.1002/jcp.28086
   Wang XX, 2018, EXP CELL RES, V368, P184, DOI 10.1016/j.yexcr.2018.04.028
   Wang YW, 2018, AFR HEALTH SCI, V18, P267, DOI 10.4314/ahs.v18i2.10
   Wang Y, 2012, CYTOKINE, V59, P228, DOI 10.1016/j.cyto.2012.04.020
   Wilde MI, 1998, BIODRUGS, V10, P159, DOI 10.2165/00063030-199810020-00006
   Winship A, 2017, ONCOTARGET, V8, P22716, DOI 10.18632/oncotarget.15187
   Wu JN, 2021, INT J BIOL MARKER, V36, P64, DOI 10.1177/17246008211023515
   Wu LH, 2015, ONCOTARGET, V6, P4406, DOI 10.18632/oncotarget.3017
   Wunderlich CM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03773-0
   Xu GX, 2019, J CELL PHYSIOL, V234, P3613, DOI 10.1002/jcp.27083
   Xu HX, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0467-2
   Yirmiya R, 2000, ANN NY ACAD SCI, V917, P478
   Yoshimoto T, 2008, J IMMUNOL, V180, P6527, DOI 10.4049/jimmunol.180.10.6527
   Zaporowska-Stachowiak I, 2017, BIOMED PHARMACOTHER, V93, P1277, DOI 10.1016/j.biopha.2017.07.023
   Zeng HL, 2016, CANCER CELL, V30, P459, DOI 10.1016/j.ccell.2016.08.001
   Zhang B, 2017, AM J REPROD IMMUNOL, V78, DOI 10.1111/aji.12706
   Zhang RJ, 2022, INT J ONCOL, V60, DOI 10.3892/ijo.2022.5340
   Zhang Z, 2016, MOL IMMUNOL, V78, P155, DOI 10.1016/j.molimm.2016.09.014
   Zheng H, 2016, SCI REP-UK, V6, DOI 10.1038/srep37070
NR 125
TC 4
Z9 4
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1079-9907
EI 1557-7465
J9 J INTERF CYTOK RES
JI J. Interferon Cytokine Res.
PD FEB 1
PY 2024
VL 44
IS 2
BP 45
EP 59
DI 10.1089/jir.2023.0103
EA JAN 2024
PG 15
WC Biochemistry & Molecular Biology; Cell Biology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Immunology
GA IO2B9
UT WOS:001150715300001
PM 38232478
DA 2025-01-04
ER

PT J
AU Jing, XM
   Yang, FM
   Shao, CC
   Wei, K
   Xie, MY
   Shen, H
   Shu, YQ
AF Jing, Xinming
   Yang, Fengming
   Shao, Chuchu
   Wei, Ke
   Xie, Mengyan
   Shen, Hua
   Shu, Yongqian
TI Role of hypoxia in cancer therapy by regulating the tumor
   microenvironment
SO MOLECULAR CANCER
LA English
DT Review
DE Cancer therapy; Chemotherapy; Drug resistance; Hypoxia; Tumor
   microenvironment
ID INDUCIBLE FACTORS; DNA-DAMAGE; COLORECTAL-CANCER; INDUCED RESISTANCE;
   ESOPHAGEAL CANCER; INDUCED APOPTOSIS; DRUG-RESISTANCE; CARCINOMA-CELLS;
   GLYOXALASE I; AUTOPHAGY
AB Aim Clinical resistance is a complex phenomenon in major human cancers involving multifactorial mechanisms, and hypoxia is one of the key components that affect the cellular expression program and lead to therapy resistance. The present study aimed to summarize the role of hypoxia in cancer therapy by regulating the tumor microenvironment (TME) and to highlight the potential of hypoxia-targeted therapy. Methods Relevant published studies were retrieved from PubMed, Web of Science, and Embase using keywords such as hypoxia, cancer therapy, resistance, TME, cancer, apoptosis, DNA damage, autophagy, p53, and other similar terms. Results Recent studies have shown that hypoxia is associated with poor prognosis in patients by regulating the TME. It confers resistance to conventional therapies through a number of signaling pathways in apoptosis, autophagy, DNA damage, mitochondrial activity, p53, and drug efflux. Conclusion Hypoxia targeting might be relevant to overcome hypoxia-associated resistance in cancer treatment.
C1 [Jing, Xinming; Yang, Fengming; Shao, Chuchu; Xie, Mengyan; Shen, Hua; Shu, Yongqian] Nanjing Med Univ, Affiliated Sir Run Run Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Jing, Xinming; Yang, Fengming; Shao, Chuchu; Xie, Mengyan; Shen, Hua; Shu, Yongqian] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
   [Wei, Ke] Nanjing Med Univ, Affiliated Hosp 1, Dept Thorac Surg, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Shen, H; Shu, YQ (corresponding author), Nanjing Med Univ, Affiliated Sir Run Run Hosp, Dept Oncol, Nanjing, Jiangsu, Peoples R China.
EM medshenhua@126.com; shuyongqian1998@163.com
RI 魏, 可/HTS-0838-2023; Shu, Yongqian/ABD-5698-2021; Xie,
   MengYan/LRU-2992-2024; shen, hua/HTM-6972-2023
OI shu, yongqian/0000-0003-2103-0877; wei, ke/0000-0001-5225-1109
FU Natural Science Foundation of Jiangsu Province [BK20171484]; Project of
   Invigorating Health Care through Science, Technology, and Education
   (Jiangsu Provincial Medical Youth Talent) [QNRC2016856]; National
   Natural Science Foundation of China [81672896]; Summit of the Six Top
   Talents Program of Jiangsu Province [2017-WSN-179]; Postgraduate
   Research & Practice Innovation Program of Jiangsu Province [KYCX18_1483,
   KYCX18_1482]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions [JX10231801]; Natural Science Foundation of China
   [81874230]; Jiangsu Social Development Project [BE2018726]
FX This study was supported by grants from the Natural Science Foundation
   of Jiangsu Province (Grants No BK20171484), the Project of Invigorating
   Health Care through Science, Technology, and Education (Jiangsu
   Provincial Medical Youth Talent QNRC2016856), the National Natural
   Science Foundation of China (No. 81672896), the Summit of the Six Top
   Talents Program of Jiangsu Province (2017-WSN-179), the Postgraduate
   Research & Practice Innovation Program of Jiangsu Province
   (KYCX18_1483), the Priority Academic Program Development of Jiangsu
   Higher Education Institutions (JX10231801), Postgraduate Research &
   Practice Innovation Program of Jiangsu Province (No. KYCX18_1482), The
   Natural Science Foundation of China (81874230) and the Jiangsu Social
   Development Project (BE2018726).
CR Achison M, 2003, ONCOGENE, V22, P3431, DOI 10.1038/sj.onc.1206434
   An Y, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.123
   [Anonymous], 2016, OXIDATIVE MED CELLUL
   Barsoum IB, 2014, CANCER RES, V74, P665, DOI 10.1158/0008-5472.CAN-13-0992
   Birner P, 2000, CANCER RES, V60, P4693
   Bridge G, 2014, CANCERS, V6, P1597, DOI 10.3390/cancers6031597
   Bristow RG, 2008, NAT REV CANCER, V8, P180, DOI 10.1038/nrc2344
   Brown JM, 1998, CANCER RES, V58, P1408
   Chen A, 2018, ONCOGENE, V37, P4214, DOI 10.1038/s41388-018-0259-3
   Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7
   Chen JQ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0085161, 10.1371/journal.pone.0101277]
   Chen SN, 2010, BBA-REV CANCER, V1806, P220, DOI 10.1016/j.bbcan.2010.07.003
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Corzo CA, 2010, J EXP MED, V207, P2439, DOI 10.1084/jem.20100587
   Cui XY, 2016, J THROMB HAEMOST, V14, P387, DOI 10.1111/jth.13206
   Daponte A, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-335
   Dean M, 2005, ANNU REV GENOM HUM G, V6, P123, DOI 10.1146/annurev.genom.6.080604.162122
   Denny W A, 2000, Lancet Oncol, V1, P25, DOI 10.1016/S1470-2045(00)00006-1
   Deschoemaeker S, 2015, EMBO MOL MED, V7, P1350, DOI 10.15252/emmm.201505492
   Enari M, 1998, NATURE, V391, P43, DOI 10.1038/34112
   Erler JT, 2004, MOL CELL BIOL, V24, P2875, DOI 10.1128/MCB.24.7.2875-2889.2004
   Fan TT, 2014, CELL BIOSCI, V4, DOI 10.1186/2045-3701-4-49
   Federici C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088193
   Flamant L, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-391
   Fukuda R, 2007, CELL, V129, P111, DOI 10.1016/j.cell.2007.01.047
   Fulda S, 2010, NAT REV DRUG DISCOV, V9, P447, DOI 10.1038/nrd3137
   Gaggioli C, 2007, NAT CELL BIOL, V9, P1392, DOI 10.1038/ncb1658
   Gatti L, 2005, METH MOLEC MED, V111, P127
   Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002
   Gottesman MM, 2002, ANNU REV MED, V53, P615, DOI 10.1146/annurev.med.53.082901.103929
   Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032
   Guzy RD, 2005, CELL METAB, V1, P401, DOI 10.1016/j.cmet.2005.05.001
   Harris AL, 2002, NAT REV CANCER, V2, P38, DOI 10.1038/nrc704
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   Hoffmann AC, 2008, NEOPLASIA, V10, P674, DOI 10.1593/neo.08292
   Hu T, 2015, PHYTOMEDICINE, V22, P536, DOI 10.1016/j.phymed.2015.03.010
   Huang YQ, 2017, SCI CHINA LIFE SCI, V60, P1114, DOI 10.1007/s11427-017-9178-y
   Hunter FW, 2015, CANCER RES, V75, P4211, DOI 10.1158/0008-5472.CAN-15-1107
   Jain RK, 2014, CANCER CELL, V26, P605, DOI 10.1016/j.ccell.2014.10.006
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kim CY, 1997, CANCER RES, V57, P4200
   Kim J, 2011, NAT CELL BIOL, V13, P132, DOI 10.1038/ncb2152
   Koshikawa N, 2006, ONCOGENE, V25, P917, DOI 10.1038/sj.onc.1209128
   Koukourakis MI, 2001, CANCER RES, V61, P1830
   Kozlova N, 2017, ONCOTARGET, V8, P9885, DOI 10.18632/oncotarget.14241
   Kroemer G, 2000, NAT MED, V6, P513, DOI 10.1038/74994
   Lee YY, 2015, ONCOTARGET, V6, P35040, DOI 10.18632/oncotarget.5319
   Li CJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18071566
   Li F, 2005, MOL CELL BIOL, V25, P6225, DOI 10.1128/MCB.25.14.6225-6234.2005
   Li HH, 2017, GASTROENTEROLOGY, V153, P505, DOI 10.1053/j.gastro.2017.04.017
   Li Y, 2017, CHIN J CANC, P36
   Li Yuan, 2015, Zhongguo Yi Xue Ke Xue Yuan Xue Bao, V37, P75, DOI 10.3881/j.issn.1000-503X.2015.01.014
   Lin SH, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx163
   Lin WM, 2015, GENET MOL RES, V14, P16905, DOI 10.4238/2015.December.14.18
   Liu XW, 2010, PHARMACOL RES, V62, P416, DOI 10.1016/j.phrs.2010.07.002
   Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007
   Madan E, 2012, BIOCHEM J, V443, P811, DOI 10.1042/BJ20111627
   Maddika S, 2007, DRUG RESIST UPDATE, V10, P13, DOI 10.1016/j.drup.2007.01.003
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Majmundar AJ, 2010, MOL CELL, V40, P294, DOI 10.1016/j.molcel.2010.09.022
   Mantovani A, 2002, TRENDS IMMUNOL, V23, P549, DOI 10.1016/S1471-4906(02)02302-5
   Maranchie JK, 2002, CANCER CELL, V1, P247, DOI 10.1016/S1535-6108(02)00044-2
   Mayer A, 2008, CANCER RES, V68, P4719, DOI 10.1158/0008-5472.CAN-07-6339
   McKeown SR, 2014, BRIT J RADIOL, V87, DOI 10.1259/bjr.20130676
   Minchinton AI, 2006, NAT REV CANCER, V6, P583, DOI 10.1038/nrc1893
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mow BMF, 2001, CURR OPIN ONCOL, V13, P453, DOI 10.1097/00001622-200111000-00007
   Nardinocchi L, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-1
   Nelson DA, 2004, GENE DEV, V18, P2095, DOI 10.1101/gad.1204904
   Noman MZ, 2014, J EXP MED, V211, P781, DOI 10.1084/jem.20131916
   O'Donovan TR, 2011, AUTOPHAGY, V7, P509, DOI 10.4161/auto.7.5.15066
   Olcina M, 2010, CLIN CANCER RES, V16, P5624, DOI 10.1158/1078-0432.CCR-10-0286
   Pan BZ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-165
   Papandreou I, 2006, CELL METAB, V3, P187, DOI 10.1016/j.cmet.2006.01.012
   Pastorek J, 2015, SEMIN CANCER BIOL, V31, P52, DOI 10.1016/j.semcancer.2014.08.002
   Phillips RM, 2013, BRIT J PHARMACOL, V168, P11, DOI 10.1111/j.1476-5381.2012.01996.x
   Pilon-Thomas S, 2016, CANCER RES, V76, P1381, DOI 10.1158/0008-5472.CAN-15-1743
   Rohwer N, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012038
   Roma-Rodrigues C, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040840
   Rouschop KMA, 2010, J CLIN INVEST, V120, P127, DOI 10.1172/JCI40027
   Saggar JK, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00154
   Sakamoto H, 2000, BLOOD, V95, P3214, DOI 10.1182/blood.V95.10.3214
   Sakamoto H, 2001, CLIN CANCER RES, V7, P2513
   Sasabe E, 2005, CANCER SCI, V96, P394, DOI 10.1111/j.1349-7006.2005.00065.x
   Semenza GL, 2010, ONCOGENE, V29, P625, DOI 10.1038/onc.2009.441
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Semenza GL, 2014, ANNU REV PATHOL-MECH, V9, P47, DOI 10.1146/annurev-pathol-012513-104720
   Semenza GL, 2010, CURR OPIN GENET DEV, V20, P51, DOI 10.1016/j.gde.2009.10.009
   Sendoel A, 2010, NATURE, V465, P577, DOI 10.1038/nature09141
   Sermeus A, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.48
   Sgarbi G, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7070064
   Shao CC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0869-y
   Shen Y, 2015, EXP CELL RES, V334, P207, DOI 10.1016/j.yexcr.2015.04.010
   Shukla SK, 2017, CANCER CELL, V32, P392, DOI 10.1016/j.ccell.2017.08.008
   Siegel RM, 1998, J CELL BIOL, V141, P1243, DOI 10.1083/jcb.141.5.1243
   Silva VL, 2017, J CONTROL RELEASE, V253, P82, DOI 10.1016/j.jconrel.2017.03.013
   Simiantonaki N, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-320
   Smith J, 2010, ADV CANCER RES, V108, P73, DOI 10.1016/S0065.230X(10)08002.4
   Soussi T, 2015, CELL DEATH DIFFER, V22, P1239, DOI 10.1038/cdd.2015.53
   Sullivan R, 2008, MOL CANCER THER, V7, P1961, DOI 10.1158/1535-7163.MCT-08-0198
   Sun HC, 2007, INT J ONCOL, V30, P1359
   Sun Y, 2016, CANCER LETT, V380, P205, DOI 10.1016/j.canlet.2015.07.044
   Syu JP, 2016, ONCOTARGET, V7, P14659, DOI 10.18632/oncotarget.7406
   TEICHER BA, 1987, CANCER RES, V47, P513
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   THORNALLEY PJ, 1990, BIOCHEM J, V269, P1
   Tosatto A, 2016, EMBO MOL MED, V8, P569, DOI 10.15252/emmm.201606255
   Triner D, 2016, J CLIN INVEST, V126, P3689, DOI 10.1172/JCI84430
   Ueda S, 2017, CLIN CANCER RES, V23, P5769, DOI 10.1158/1078-0432.CCR-17-0874
   Unruh A, 2003, ONCOGENE, V22, P3213, DOI 10.1038/sj.onc.1206385
   van Loo G, 2002, CELL DEATH DIFFER, V9, P1031, DOI 10.1038/sj.cdd.4401088
   Wang M, 2014, HORTIC RES-ENGLAND, V1, DOI 10.1038/hortres.2014.16
   Whatcott CJ, 2015, CANCER J, V21, P299, DOI 10.1097/PPO.0000000000000140
   Wiesener MS, 2002, FASEB J, V16, P271, DOI 10.1096/fj.02-0445fje
   Wigerup C, 2016, PHARMACOL THERAPEUT, V164, P152, DOI 10.1016/j.pharmthera.2016.04.009
   Wilson WR, 2011, NAT REV CANCER, V11, P393, DOI 10.1038/nrc3064
   Wirthner R, 2008, CARCINOGENESIS, V29, P2306, DOI 10.1093/carcin/bgn231
   Wohlkoenig C, 2011, CANCER LETT, V308, P134, DOI 10.1016/j.canlet.2011.03.014
   WOZNIAK AJ, 1984, CANCER RES, V44, P626
   Wu HM, 2016, LUNG, V194, P959, DOI 10.1007/s00408-016-9936-6
   Wu T, 2017, CANCER LETT, V387, P61, DOI 10.1016/j.canlet.2016.01.043
   Xia Shu, 2005, J Huazhong Univ Sci Technolog Med Sci, V25, P279
   Xiong GF, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06893-9
   Xu RH, 2005, CANCER RES, V65, P613
   Yan YL, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0303-5
   Yang MH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097242
   Zeller KI, 2006, P NATL ACAD SCI USA, V103, P17834, DOI 10.1073/pnas.0604129103
   Zhang JJ, 2010, WORLD J GASTROENTERO, V16, P2881, DOI 10.3748/wjg.v16.i23.2881
   Zhitomirsky B, 2016, DRUG RESIST UPDATE, V24, P23, DOI 10.1016/j.drup.2015.11.004
   Zhu X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.313
   Zub KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119857
   Zunino F, 1997, PHARMACOL THERAPEUT, V76, P177, DOI 10.1016/S0163-7258(97)00086-7
NR 132
TC 1213
Z9 1290
U1 34
U2 433
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD NOV 11
PY 2019
VL 18
IS 1
AR 157
DI 10.1186/s12943-019-1089-9
PG 15
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA JM8BE
UT WOS:000496432800001
PM 31711497
OA Green Published, gold
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Orlacchio, A
   Mazzone, P
AF Orlacchio, Arturo
   Mazzone, Pellegrino
TI The Role of Toll-like Receptors (TLRs) Mediated Inflammation in
   Pancreatic Cancer Pathophysiology
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE pancreatic cancer; toll-like receptor; inflammation; chemotherapy
ID MACROPHAGE-ACTIVATING LIPOPEPTIDE-2; EPITHELIAL-MESENCHYMAL TRANSITION;
   HEPATOCELLULAR-CARCINOMA CELLS; NF-KAPPA-B; COLON-CANCER; CPG
   OLIGODEOXYNUCLEOTIDE; CYTOKINE PRODUCTION; SIGNALING PATHWAY; RETICULUM
   STRESS; 9 EXPRESSION
AB Pancreatic cancer (PC) is one of the most lethal forms of cancer, characterized by its aggressiveness and metastatic potential. Despite significant improvements in PC treatment and management, the complexity of the molecular pathways underlying its development has severely limited the available therapeutic opportunities. Toll-like receptors (TLRs) play a pivotal role in inflammation and immune response, as they are involved in pathogen-associated molecular patterns (PAMPs) and danger-associated molecular patterns (DAMPs). Activation of TLRs initiates a signaling cascade, which in turn, leads to the transcription of several genes involved in inflammation and anti-microbial defense. TLRs are also deregulated in several cancers and can be used as prognostic markers and potential targets for cancer-targeted therapy. In this review we discuss the current knowledge about the role of TLRs in PC progression, focusing on the available TLRs-targeting compounds and their possible use in PC therapy.
C1 [Orlacchio, Arturo] NYU Langone Hlth, NYU Grossman Sch Med, New York, NY 10016 USA.
   [Mazzone, Pellegrino] Biogem Scarl, Ist Ric Genetiche Gaetano Salvatore, I-83031 Ariano Irpino, Italy.
C3 NYU Langone Medical Center
RP Orlacchio, A (corresponding author), NYU Langone Hlth, NYU Grossman Sch Med, New York, NY 10016 USA.; Mazzone, P (corresponding author), Biogem Scarl, Ist Ric Genetiche Gaetano Salvatore, I-83031 Ariano Irpino, Italy.
EM arturo.orlacchio@nyulangone.org; pellegrino.mazzone@biogem.it
RI Mazzone, Pellegrino/AAC-6576-2020; Orlacchio, Arturo/Q-3110-2019
OI Orlacchio, Arturo/0000-0002-6044-4258; Mazzone,
   Pellegrino/0000-0002-6217-1505
CR Adams S, 2009, IMMUNOTHERAPY-UK, V1, P949, DOI 10.2217/IMT.09.70
   Agrawal S, 2007, BIOCHEM SOC T, V35, P1461, DOI 10.1042/BST0351461
   Huynh AS, 2012, J MED CHEM, V55, P9751, DOI 10.1021/jm301002f
   Anthoney N, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.156018
   Arslan F, 2012, CIRC-CARDIOVASC INTE, V5, P279, DOI 10.1161/CIRCINTERVENTIONS.111.967596
   Awasthi S, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-01187-7
   Awasthi S, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210979
   Awasthi S, 2011, J PHARMACOL EXP THER, V336, P672, DOI 10.1124/jpet.110.173765
   Bai H, 2019, BIOL REPROD, V100, P281, DOI 10.1093/biolre/ioy173
   BAKER PJ, 1992, INFECT IMMUN, V60, P2694, DOI 10.1128/IAI.60.7.2694-2701.1992
   Balducci C, 2017, BRAIN BEHAV IMMUN, V60, P188, DOI 10.1016/j.bbi.2016.10.012
   Basith S, 2012, ARCH PHARM RES, V35, P1297, DOI 10.1007/s12272-012-0802-7
   Bhattacharyya S, 2008, J BIOL CHEM, V283, P10550, DOI 10.1074/jbc.M708833200
   Bhoopathi P, 2014, CANCER RES, V74, P6224, DOI 10.1158/0008-5472.CAN-14-0819
   Blohm-Mangone K, 2018, CANCER PREV RES, V11, P265, DOI 10.1158/1940-6207.CAPR-17-0349
   Botos I, 2011, STRUCTURE, V19, P447, DOI 10.1016/j.str.2011.02.004
   Caballero I, 2017, SCI REP-UK, V7, DOI 10.1038/srep40981
   Calvo-Rodriguez M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01588
   Carbone C, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002876
   Chen XL, 2015, MOL MED REP, V12, P8229, DOI 10.3892/mmr.2015.4479
   Chen XL, 2019, EBIOMEDICINE, V40, P135, DOI 10.1016/j.ebiom.2018.12.016
   Chen XL, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0726-2
   Choi CH, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30582-8
   Chuang YC, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01075
   Ciernikova S, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8120565
   Conroy T, 2018, NEW ENGL J MED, V379, P2395, DOI 10.1056/NEJMoa1809775
   Cooper CL, 2004, J CLIN IMMUNOL, V24, P693, DOI 10.1007/s10875-004-6244-3
   Czeslick E, 2006, INFLAMM RES, V55, P511, DOI 10.1007/s00011-006-6057-3
   Damiano V, 2006, CLIN CANCER RES, V12, P577, DOI 10.1158/1078-0432.CCR-05-1943
   Deguchi A, 2016, ONCOGENE, V35, P1445, DOI 10.1038/onc.2015.211
   Deguine Jacques, 2014, F1000Prime Rep, V6, P97, DOI 10.12703/P6-97
   Didierlaurent AM, 2009, J IMMUNOL, V183, P6186, DOI 10.4049/jimmunol.0901474
   Dowling JK, 2016, METHODS MOL BIOL, V1390, P3, DOI 10.1007/978-1-4939-3335-8_1
   Eremina Natalia V, 2020, Oncotarget, V11, P1273, DOI 10.18632/oncotarget.27549
   Escudero-Paniagua B, 2020, CARCINOGENESIS, V41, P203, DOI 10.1093/carcin/bgz093
   Fan P, 2012, PANCREATOLOGY, V12, P170, DOI 10.1016/j.pan.2012.02.015
   Fang YT, 2013, MED SCI MONITOR, V19, P916, DOI 10.12659/MSM.889636
   Fensterheim BA, 2018, J IMMUNOL, V200, P3777, DOI 10.4049/jimmunol.1800085
   Friess H, 1999, ANN NY ACAD SCI, V880, P110, DOI 10.1111/j.1749-6632.1999.tb09515.x
   Fujisawa M, 2020, ANTICANCER RES, V40, P4445, DOI 10.21873/anticanres.14449
   Gonda TA, 2020, CANCER RES, V80, P4754, DOI 10.1158/0008-5472.CAN-20-0285
   Goral Vedat, 2015, Asian Pac J Cancer Prev, V16, P5619
   Gowayed MA, 2020, LIFE SCI, V259, DOI 10.1016/j.lfs.2020.118250
   Grimmig T, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17122060
   Grimmig T, 2015, INT J ONCOL, V47, P857, DOI 10.3892/ijo.2015.3069
   Güngör C, 2011, CANCER RES, V71, P5009, DOI 10.1158/0008-5472.CAN-11-0036
   Hemmi H, 2000, NATURE, V408, P740, DOI 10.1038/35047123
   Huang HY, 2014, EUR REV MED PHARMACO, V18, P3834
   Huselton E, 2019, BLOOD, V134, DOI 10.1182/blood-2019-132065
   Hussein WM, 2014, EXPERT OPIN THER PAT, V24, P453, DOI 10.1517/13543776.2014.880691
   Ii M, 2006, MOL PHARMACOL, V69, P1288, DOI 10.1124/mol.105.019695
   Iribarren K, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1088631
   Jacobs C, 2011, INT J CANCER, V128, P897, DOI 10.1002/ijc.25399
   Jialal I, 2014, J CLIN ENDOCR METAB, V99, P39, DOI 10.1210/jc.2013-3092
   Jiang NH, 2020, INFECT AGENTS CANCER, V15, DOI 10.1186/s13027-020-0279-9
   Jiang W, 2005, J VIROL, V79, P4109, DOI 10.1128/JVI.79.7.4109-4119.2005
   Jin MS, 2007, CELL, V130, P1071, DOI 10.1016/j.cell.2007.09.008
   Kang TH, 2015, ONCOTARGET, V6, P27751, DOI 10.18632/oncotarget.4859
   Kanzler H, 2007, NAT MED, V13, P552, DOI 10.1038/nm1589
   Kapp K, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.28
   Kashani B, 2019, IMMUNOL RES, V67, P505, DOI 10.1007/s12026-019-09113-8
   Kashani B, 2020, CANCER CHEMOTH PHARM, V85, P47, DOI 10.1007/s00280-019-03988-y
   Kauppila JH, 2015, J ORAL PATHOL MED, V44, P571, DOI 10.1111/jop.12272
   Kauppila JH, 2011, HISTOPATHOLOGY, V59, P643, DOI 10.1111/j.1365-2559.2011.03991.x
   Kaur S, 2012, BIOMARK MED, V6, P597, DOI [10.2217/BMM.12.69, 10.2217/bmm.12.69]
   Kawasaki T, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00461
   Kim J, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00465
   Kim SA, 2009, CANCER SCI, V100, P828, DOI 10.1111/j.1349-7006.2009.01106.x
   Kovacsovics TJ, 2018, BLOOD ADV, V2, P381, DOI 10.1182/bloodadvances.2017013391
   Krieg AM, 2006, NAT REV DRUG DISCOV, V5, P471, DOI 10.1038/nrd2059
   Krock Bryan L, 2011, Genes Cancer, V2, P1117, DOI 10.1177/1947601911423654
   Kumagai Y, 2008, ADV DRUG DELIVER REV, V60, P795, DOI 10.1016/j.addr.2007.12.004
   Kuo WT, 2016, CANCER RES, V76, P4684, DOI 10.1158/0008-5472.CAN-16-0172
   Lambert A, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919875568
   Lamphier M, 2014, MOL PHARMACOL, V85, P429, DOI 10.1124/mol.113.089821
   Lanki M, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0219245
   Lanki Mira A, 2018, Tumour Biol, V40, p1010428318801188, DOI 10.1177/1010428318801188
   Lee Y, 2010, ONCOGENE, V29, P56, DOI 10.1038/onc.2009.298
   Leppänen J, 2018, APMIS, V126, P852, DOI 10.1111/apm.12894
   Leppänen J, 2017, VIRCHOWS ARCH, V470, P401, DOI 10.1007/s00428-017-2087-1
   Letiembre M, 2009, NEUROBIOL AGING, V30, P759, DOI 10.1016/j.neurobiolaging.2007.08.018
   Li JK, 2017, ADV EXP MED BIOL, V1024, P195, DOI 10.1007/978-981-10-5987-2_9
   Li X, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.650283
   Liu CY, 2013, LAB INVEST, V93, P844, DOI 10.1038/labinvest.2013.69
   Liu H, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0845-5
   Lu HL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01438
   Lu YC, 2008, CYTOKINE, V42, P145, DOI 10.1016/j.cyto.2008.01.006
   Ma JX, 2019, AM J TRANSL RES, V11, P3750
   Martins KA, 2015, EXPERT REV VACCINES, V14, P447, DOI 10.1586/14760584.2015.966085
   Mazzone P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249365
   Mazzone P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122365
   Mehla K, 2018, CANCER IMMUNOL IMMUN, V67, P445, DOI 10.1007/s00262-017-2095-7
   Metzger P, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0778-7
   Michaelis KA, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12657-w
   Miranda-Hernandez S, 2013, AM J CLIN EXP IMMUNO, V2, P75
   Mlcochova P, 2020, CELL REP, V30, P3972, DOI 10.1016/j.celrep.2020.03.008
   Mogensen TH, 2009, CLIN MICROBIOL REV, V22, P240, DOI 10.1128/CMR.00046-08
   Monnet E, 2017, CLIN PHARMACOL THER, V101, P200, DOI 10.1002/cpt.522
   Morr M, 2002, EUR J IMMUNOL, V32, P3337, DOI 10.1002/1521-4141(200212)32:12<3337::AID-IMMU3337>3.0.CO;2-#
   Mueller Thomas, 2008, V183, P51
   Murata M, 2008, CANCER SCI, V99, P1435, DOI 10.1111/j.1349-7006.2008.00832.x
   Muzio M, 2000, BIOCHEM SOC T, V28, P563, DOI 10.1042/bst0280563
   Netea MG, 2008, FEMS IMMUNOL MED MIC, V52, P118, DOI 10.1111/j.1574-695X.2007.00353.x
   Noack J, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.60
   Nomi N, 2010, ONCOL REP, V24, P225, DOI 10.3892/or_00000850
   Ochi A, 2012, J CLIN INVEST, V122, P4118, DOI 10.1172/JCI63606
   Onishi H, 2013, CANCER LETT, V335, P289, DOI 10.1016/j.canlet.2013.02.041
   Ou TW, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01188
   Park HD, 2011, ONCOGENE, V30, P201, DOI 10.1038/onc.2010.401
   Patra MC, 2020, SEMIN CANCER BIOL, V64, P61, DOI 10.1016/j.semcancer.2019.05.002
   Petes C, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01075
   Pratesi G, 2005, CANCER RES, V65, P6388, DOI 10.1158/0008-5472.CAN-05-0602
   Premkumar Vummidigiridhar, 2010, BMC Chemical Biology, V10, P3, DOI 10.1186/1472-6769-10-3
   Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134
   Qi XF, 2013, MOL IMMUNOL, V54, P327, DOI 10.1016/j.molimm.2013.01.001
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Raja SG, 2007, CORE EVID, V2, P199
   Rakhesh M, 2012, ONCOIMMUNOLOGY, V1, P1495, DOI 10.4161/onci.22089
   Rebuffini Elena, 2012, Dent Res J (Isfahan), V9, pS192, DOI 10.4103/1735-3327.109752
   Rezaei N, 2006, INT IMMUNOPHARMACOL, V6, P863, DOI 10.1016/j.intimp.2006.02.005
   Ronkainen H, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-84
   Rosa R, 2011, CLIN CANCER RES, V17, P6531, DOI 10.1158/1078-0432.CCR-10-3376
   Rosendahl AH, 2012, PANCREATOLOGY, V12, P467, DOI 10.1016/j.pan.2012.09.004
   Royer CM, 2016, IMMUN INFLAMM DIS, V4, P45, DOI 10.1002/iid3.91
   Rutkowski MR, 2015, CANCER CELL, V27, P27, DOI 10.1016/j.ccell.2014.11.009
   Santoni M, 2015, CANCER TREAT REV, V41, P569, DOI 10.1016/j.ctrv.2015.04.004
   Sato Y, 2009, CANCER MICROENVIRON, V2, pS205, DOI 10.1007/s12307-009-0022-y
   Sawahata R, 2011, MICROBES INFECT, V13, P350, DOI 10.1016/j.micinf.2010.12.003
   Saxena M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00725
   Schmidt J, 2007, BRIT J CANCER, V97, P598, DOI 10.1038/sj.bjc.6603903
   Schneider C, 2004, GUT, V53, P355, DOI 10.1136/gut.2003.026005
   Schulz O, 2005, NATURE, V433, P887, DOI 10.1038/nature03326
   Schwartz AL, 2009, CLIN CANCER RES, V15, P4114, DOI 10.1158/1078-0432.CCR-09-0005
   Scudiero I, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.51
   Sethi V, 2019, GASTROENTEROLOGY, V156, P2097, DOI 10.1053/j.gastro.2018.12.045
   Seya T, 2019, ADV DRUG DELIVER REV, V147, P37, DOI 10.1016/j.addr.2019.07.008
   Shadhu K, 2019, SAUDI J GASTROENTERO, V25, P3, DOI 10.4103/sjg.SJG_390_18
   Shojaei H, 2009, CANCER RES, V69, P8710, DOI 10.1158/0008-5472.CAN-09-1602
   Silva A, 2015, J IMMUNOL, V194, P2199, DOI 10.4049/jimmunol.1402228
   Simons MP, 2008, UROL ONCOL-SEMIN ORI, V26, P341, DOI 10.1016/j.urolonc.2007.11.031
   Smith M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1526250
   Smith RL, 2016, ARCH DERMATOL RES, V308, P201, DOI 10.1007/s00403-016-1620-4
   So EY, 2010, INT J BIOL SCI, V6, P675
   Stöver AG, 2004, J BIOL CHEM, V279, P4440, DOI 10.1074/jbc.M310760200
   Subramanian S, 2006, P NATL ACAD SCI USA, V103, P9970, DOI 10.1073/pnas.0603912103
   Sun LX, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/1824624
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Takeuchi O, 2000, J IMMUNOL, V164, P554, DOI 10.4049/jimmunol.164.2.554
   Tang XY, 2012, ONCOL RES, V20, P15, DOI 10.3727/096504012X13425470196092
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Teague A, 2015, THER ADV MED ONCOL, V7, P68, DOI 10.1177/1758834014564775
   Telesio G, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122581
   Tsai HJ, 2019, J CLIN MED, V8, DOI 10.3390/jcm8091427
   Tuomela J, 2012, BREAST CANCER RES TR, V135, P481, DOI 10.1007/s10549-012-2181-7
   Väisänen MR, 2013, ONCOL LETT, V5, P1659, DOI 10.3892/ol.2013.1204
   van Duijneveldt G, 2020, CLIN SCI, V134, P2091, DOI 10.1042/CS20191211
   Vaz J, 2014, WORLD J GASTROENTERO, V20, P5808, DOI 10.3748/wjg.v20.i19.5808
   Vaz J, 2013, WORLD J GASTROENTERO, V19, P616, DOI 10.3748/wjg.v19.i5.616
   Wang F, 2016, MOL MED REP, V13, P1807, DOI 10.3892/mmr.2015.4730
   Wang XH, 2013, CHEM SOC REV, V42, P4859, DOI 10.1039/c3cs60039d
   Wang YT, 2015, BIOCHEM BIOPH RES CO, V456, P373, DOI 10.1016/j.bbrc.2014.11.090
   Weigt H, 2003, IMMUNOBIOLOGY, V207, P223, DOI 10.1078/0171-2985-00234
   Wittig B, 2015, CRIT REV ONCOL HEMAT, V94, P31, DOI 10.1016/j.critrevonc.2014.12.002
   Wu HQ, 2011, WORLD J GASTROENTERO, V17, P996, DOI 10.3748/wjg.v17.i8.996
   Xia Y, 2012, J MED CHEM, V55, P5642, DOI 10.1021/jm300534u
   Xie X, 2019, CARBOHYD POLYM, V225, DOI 10.1016/j.carbpol.2019.115223
   Yamasaki A, 2016, ANTICANCER RES, V36, P3945
   Yu L, 2010, J CELL MOL MED, V14, P2592, DOI 10.1111/j.1582-4934.2010.01127.x
   Zambirinis CP, 2015, J EXP MED, V212, P2077, DOI 10.1084/jem.20142162
   Zandi Z, 2020, J CELL BIOCHEM, V121, P1623, DOI 10.1002/jcb.29397
   Zandi Z, 2019, EUR J PHARMACOL, V853, P256, DOI 10.1016/j.ejphar.2019.03.046
   Zeng T, 2015, BIOCHEM BIOPH RES CO, V460, P530, DOI 10.1016/j.bbrc.2015.03.064
   Zhang M, 2019, J CELL PHYSIOL, V234, P9457, DOI 10.1002/jcp.27631
   Zhang NL, 2020, EUR REV MED PHARMACO, V24, P461, DOI 10.26355/eurrev_202001_19947
   Zhang XP, 2010, PANCREAS, V39, P819, DOI 10.1097/MPA.0b013e3181ca065c
   Zhou JG, 2020, ACTA HISTOCHEM, V122, DOI 10.1016/j.acthis.2019.151455
   Zou BB, 2015, MOL MED REP, V12, P6079, DOI 10.3892/mmr.2015.4130
NR 177
TC 19
Z9 23
U1 0
U2 15
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2021
VL 22
IS 23
AR 12743
DI 10.3390/ijms222312743
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA XV1XB
UT WOS:000734742400001
PM 34884547
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Mei, LL
   Qiu, YT
   Zhang, B
   Shi, ZZ
AF Mei, Li-Li
   Qiu, Yun-Tan
   Zhang, Bing
   Shi, Zhi-Zhou
TI MicroRNAs in esophageal squamous cell carcinoma: Potential biomarkers
   and therapeutic targets
SO CANCER BIOMARKERS
LA English
DT Review
DE MicroRNA; target gene; biomarker; therapeutic target; esophageal
   squamous cell carcinoma
ID DOWN-REGULATION; COLON-CANCER; TUMOR-SUPPRESSOR; POOR-PROGNOSIS;
   EXPRESSION; INVASION; PROMOTES; PROLIFERATION; MIR-21; GROWTH
AB Esophageal cancer is a common cause of cancer-related deaths worldwide. Squamous cell carcinoma (SCC) is the major histological type of esophageal cancer in developing countries including China, and the prognosis is very poor. Many microRNAs are involved in several important biological and pathologic processes, and promote tumorigenesis. To better understand the prognostic and therapeutic roles of microRNAs in ESCC, we reviewed the diagnosis and prognosis associated oncogenic microRNAs (e.g. miR-21 and miR-17-92 cluster) and tumor suppressor microRNAs (e.g. miR-375, miR-133a and miR-133b), and diagnosis and prognosis associated oncogenic target genes (e.g. PDCD4 and CCND1) and tumor suppressor target genes (e.g. EZH2 and PDK1). We also summarized the prognostic microRNA and target gene pairs (e.g. miR-296 and CCND1, miR214 and EZH2). Taken together, our review highlights the opportunities and challenges for microRNAs in the molecular diagnosis and target therapy of ESCC.
C1 [Mei, Li-Li; Qiu, Yun-Tan; Zhang, Bing; Shi, Zhi-Zhou] Kunming Univ Sci & Technol, Fac Med, 727 Jingming South Rd, Kunming 650500, Yunnan, Peoples R China.
C3 Kunming University of Science & Technology
RP Shi, ZZ (corresponding author), Kunming Univ Sci & Technol, Fac Med, 727 Jingming South Rd, Kunming 650500, Yunnan, Peoples R China.
EM zhizhoushi@126.com
RI qiu, yun-tan/JXX-5965-2024
OI Mei, LiLi/0000-0003-2100-736X; Qiu, Yuntan/0000-0001-5653-7956
FU National Natural Science Foundation of China [81460425]; Yunnan
   Provincial Research Foundation for Basic Research, China [2013FD012];
   Foundation for the Talents of Kunming University of Science and
   Technology [KKSY201226099]
FX This study was supported by the National Natural Science Foundation of
   China (No. 81460425) and the Yunnan Provincial Research Foundation for
   Basic Research, China (No. 2013FD012) and Foundation for the Talents of
   Kunming University of Science and Technology (No. KKSY201226099).
CR Akagi I, 2011, DIS ESOPHAGUS, V24, P523, DOI 10.1111/j.1442-2050.2011.01177.x
   Akanuma N, 2014, BRIT J CANCER, V110, P189, DOI 10.1038/bjc.2013.676
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Cao HH, 2015, ONCOTARGET, V6, P5435, DOI 10.18632/oncotarget.3102
   Chen GM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0263-6
   Chen ML, 2012, CLIN EXP METASTAS, V29, P457, DOI 10.1007/s10585-012-9463-7
   Chen YN, 2015, ANN DIAGN PATHOL, V19, P33, DOI 10.1016/j.anndiagpath.2014.12.004
   Chen Z., 2015, ONCOLOGY LETT, V10
   Chen ZL, 2011, J BIOL CHEM, V286, P10725, DOI 10.1074/jbc.M110.165654
   Danielsona LS, 2015, LEUKEMIA RES, V39, P335, DOI 10.1016/j.leukres.2014.12.002
   Fassan M, 2010, ONCOL REP, V24, P135, DOI 10.3892/or_00000838
   Guo Y, 2008, CANCER RES, V68, P26, DOI 10.1158/0008-5472.CAN-06-4418
   Ha SY, 2012, PATHOL RES PRACT, V208, P462, DOI 10.1016/j.prp.2012.05.012
   Harazono Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062757
   Hezova R, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0280-6
   Hirashima K, 2010, ANN SURG ONCOL, V17, P2486, DOI 10.1245/s10434-010-1040-1
   Hong L, 2010, ANN SURG, V251, P1056, DOI 10.1097/SLA.0b013e3181dd4ea9
   Huang S.D., 2012, MOL CANCER, V11, P756
   Humphreys KJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112288
   Iliopoulos D, 2010, MOL CELL, V39, P493, DOI 10.1016/j.molcel.2010.07.023
   Imsumran A, 2007, CARCINOGENESIS, V28, P947, DOI 10.1093/carcin/bgl247
   Isozaki Y, 2012, INT J ONCOL, V41, P985, DOI 10.3892/ijo.2012.1537
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Jiangchao L., 2013, PLOS ONE, V8
   Kong KL, 2012, GUT, V61, P33, DOI 10.1136/gutjnl-2011-300178
   Kuo YZ, 2014, ORAL DIS, V20, pe65, DOI 10.1111/odi.12133
   Kutanzi KR, 2011, CLIN EPIGENETICS, V2, P171, DOI 10.1007/s13148-011-0040-8
   Li HP, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-196
   Li P, 2013, DIGEST DIS SCI, V58, P3483, DOI 10.1007/s10620-013-2854-z
   Li Q, 2013, CANCER LETT, V335, P168, DOI 10.1016/j.canlet.2013.02.029
   Li Y., 2013, DIAGNOSTIC PATHOLOGY, V8
   Li Y, 2013, DIAGN PATHOL, V8, DOI 10.1186/1746-1596-8-207
   Li Y, 2011, J SURG ONCOL, V104, P617, DOI 10.1002/jso.22018
   Liu FX, 2013, MOL CELL BIOCHEM, V381, P115, DOI 10.1007/s11010-013-1693-8
   Liu K, 2015, CELL PHYSIOL BIOCHEM, V36, P100, DOI 10.1159/000374056
   Liu M, 2011, INT J ONCOL, V38, P1013, DOI 10.3892/ijo.2011.924
   Liu R., 2012, PLOS ONE, V7
   Liu R., 2013, PLOS ONE, V8
   Liu RH, 2015, CLIN CANCER RES, V21, P854, DOI 10.1158/1078-0432.CCR-14-1740
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Matsushima K, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-30
   Mori Y, 2009, MOL MED REP, V2, P235, DOI 10.3892/mmr_00000089
   Murata T, 2010, PROSTATE CANCER P D, V13, P356, DOI 10.1038/pcan.2010.32
   Nohata N, 2012, ONCOTARGET, V3, P9
   Osada H., 2011, CANC SCI, V102
   Qi B, 2015, WORLD J GASTROENTERO, V21, P6884, DOI 10.3748/wjg.v21.i22.6884
   Shen WW, 2013, J MOL MED, V91, P989, DOI 10.1007/s00109-013-1037-x
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Song Y, 2014, ONCOTARGET, V5, P11669, DOI 10.18632/oncotarget.2581
   Sun J., 2013, MED ONCOL, V30, P758
   Sun N., 2014, INT J CLIN EXPT PATH, V7
   Suzuki S, 2012, ONCOL REP, V28, P465, DOI 10.3892/or.2012.1831
   Tanaka K, 2013, ANN SURG ONCOL, V20, pS607, DOI 10.1245/s10434-013-3093-4
   Wang MT, 2012, DIS ESOPHAGUS, V25, P664, DOI 10.1111/j.1442-2050.2011.01291.x
   Wang N, 2013, DIGEST DIS SCI, V58, P1863, DOI 10.1007/s10620-013-2612-2
   Wang XC, 2013, J RADIAT RES, V54, P401, DOI 10.1093/jrr/rrs113
   Wu CY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092292
   Wu CH, 2014, MOL BIOL REP, V41, P1257, DOI 10.1007/s11033-013-2970-z
   Xing X., 2015, ZHONGHUA WEI CHANG W, V18
   Xu M., 2014, MOL THERAPY J AM SOC, V23
   Xu S, 2008, J SURG ONCOL, V97, P44, DOI 10.1002/jso.20892
   Xu XL, 2014, ANN THORAC SURG, V97, P1037, DOI 10.1016/j.athoracsur.2013.10.042
   Xu XH, 2012, BIOCHEM BIOPH RES CO, V421, P640, DOI 10.1016/j.bbrc.2012.03.048
   Yang XZ, 2014, TUMOR BIOL, V35, P11977, DOI 10.1007/s13277-014-2494-8
   Yang ZL, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0337-5
   Yokobori T, 2013, CANCER SCI, V104, P48, DOI 10.1111/cas.12030
   Zhang BJ, 2014, INT J CLIN EXP PATHO, V7, P6213
   Zhang HF, 2014, CARCINOGENESIS, V35, P292, DOI 10.1093/carcin/bgt320
   Zhang HY, 2012, ONCOL REP, V27, P594, DOI 10.3892/or.2011.1530
   Zhang MX, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/1756-9966-33-10
   Zhang MX, 2012, FEBS LETT, V586, P3508, DOI 10.1016/j.febslet.2012.08.007
   Zhao P, 2010, JPN J CLIN ONCOL, V40, P281, DOI 10.1093/jjco/hyp187
   Zhao YQ, 2013, INT J CANCER, V132, P2901, DOI 10.1002/ijc.27954
   Zhou Y, 2013, GENET TEST MOL BIOMA, V17, P470, DOI 10.1089/gtmb.2012.0518
   Zhu HY, 2011, MOL CANCER RES, V9, P960, DOI 10.1158/1541-7786.MCR-10-0531
NR 77
TC 62
Z9 64
U1 0
U2 20
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 1574-0153
EI 1875-8592
J9 CANCER BIOMARK
JI Cancer Biomark.
PY 2017
VL 19
IS 1
BP 1
EP 9
DI 10.3233/CBM-160240
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EU4KR
UT WOS:000400998800001
PM 28269750
DA 2025-01-04
ER

PT J
AU Gan, W
   Zhao, H
   Li, TG
   Liu, KJ
   Huang, JS
AF Gan, Wei
   Zhao, Hua
   Li, Tiegang
   Liu, Kuijie
   Huang, Jiangsheng
TI CDK1 interacts with iASPP to regulate colorectal cancer cell
   proliferation through p53 pathway
SO ONCOTARGET
LA English
DT Article
DE CDK1; iASPP; colorectal cancer; cell proliferation; p53
ID APOPTOSIS-STIMULATING PROTEIN; NONCODING RNAS; ASPP FAMILY; KAPPA-B;
   EXPRESSION; INHIBITOR; CYCLE; PROGNOSIS; SURVIVAL; TARGETS
AB CDK1 (cyclin-dependent kinase 1) is a critical regulator of the G2-M checkpoint. CDK1 is considered a possible target for cancer treatment. In addition to CDK1, iASPP plays essential role in maintaining cancer cell proliferation. In the present study, we monitored the expression of CDK1 and iASPP at mRNA and protein levels in CRC tissues and cell lines; we also predicted that iASPP protein might interact with CDK1 protein. By performing GST pull-down assay and Co-IP assay, we confirmed the interaction of CDK1 and iASPP protein. In CRC cell lines, CDK1 interacted with iASPP to affect CRC cell proliferation and apoptosis; moreover, the p53 apoptosis pathway was involved in this progression. Taken together, we revealed that CDK1 and iASPP was up-regulated in CRC tissues and cell lines; CDK1 protein interacted with iASPP protein to affect CRC cell proliferation and apoptosis through the p53 apoptosis pathway. CDK1 and iASPP might serve as not only promising targets in CRC treatment, but also efficient prognostic markers. From the perspective of protein interactions, we provided a novel theoretical basis for targeted therapy of CRC.
C1 [Gan, Wei; Zhao, Hua; Li, Tiegang; Liu, Kuijie] Cent S Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha 410011, Hunan, Peoples R China.
   [Huang, Jiangsheng] Cent S Univ, Xiangya Hosp 2, Dept Minimally Invas Surg, Changsha 410011, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Liu, KJ (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Gen Surg, Changsha 410011, Hunan, Peoples R China.; Huang, JS (corresponding author), Cent S Univ, Xiangya Hosp 2, Dept Minimally Invas Surg, Changsha 410011, Hunan, Peoples R China.
EM liukuijie228@sohu.com; jiangsheng_huang@163.com
FU National Nature Science Foundation of China [81402536]; Science and
   Technology Plan Fund in Hunan Province, P. R. China [2014WK2016,
   2013FJ6053]
FX This study was supported by the grants from the National Nature Science
   Foundation of China (No. 81402536) and the Science and Technology Plan
   Fund in Hunan Province, P. R. China (2014WK2016, 2013FJ6053).
CR Bostjancic E, 2013, NONCODING RNAS NCRNA
   Dimri GP, 1996, MOL CELL BIOL, V16, P2987
   Dong PX, 2015, ONCOTARGET, V6, P19968, DOI 10.18632/oncotarget.4847
   He Z, 2017, ARCH BIOCH BIOPHYS
   Hermeking H, 2012, NAT REV CANCER, V12, P613, DOI 10.1038/nrc3318
   Hu Y, 2015, ONCOTARGET, V6, P42478, DOI 10.18632/oncotarget.6478
   Huang WW, 2011, INT J ONCOL, V38, P1067, DOI 10.3892/ijo.2011.922
   Kitagawa M, 2012, CURR DRUG TARGETS, V13, P1616, DOI 10.2174/138945012803530026
   Li GL, 2011, MOL CELL BIOCHEM, V350, P193, DOI 10.1007/s11010-010-0698-9
   Li SJ, 2012, ONCOL REP, V28, P133, DOI 10.3892/or.2012.1778
   Lin BL, 2011, NEOPLASMA, V58, P205, DOI 10.4149/neo_2011_03_205
   Liu KJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/867537
   Liu P, 2008, ONCOGENE, V27, P4733, DOI 10.1038/onc.2008.104
   Liu T, 2010, ONCOL RES, V19, P125, DOI 10.3727/096504011X12935427587768
   Lu M, 2013, CANCER CELL, V23, P618, DOI 10.1016/j.ccr.2013.03.013
   Malumbres M, 2009, NAT REV CANCER, V9, P153, DOI 10.1038/nrc2602
   Matsuoka S, 2007, SCIENCE, V316, P1160, DOI 10.1126/science.1140321
   Motwani M, 2003, MOL CANCER THER, V2, P549
   Murray AW, 2004, CELL, V116, P221, DOI 10.1016/S0092-8674(03)01080-8
   Notari M, 2011, P NATL ACAD SCI USA, V108, P16645, DOI 10.1073/pnas.1102292108
   O'Connor DS, 2002, CANCER CELL, V2, P43, DOI 10.1016/S1535-6108(02)00084-3
   Oh You Na, 2016, J Cancer Prev, V21, P249, DOI 10.15430/JCP.2016.21.4.249
   Rahimy E, 2014, CURR DRUG TARGETS, V15, P1247, DOI 10.2174/1389450115666141024113446
   Rinn JL, 2011, TRENDS CELL BIOL, V21, P344, DOI 10.1016/j.tcb.2011.04.002
   Rokavec M, 2014, CLIN EXP GASTROENTER, V7, P395, DOI 10.2147/CEG.S43738
   Santamaría D, 2007, NATURE, V448, P811, DOI 10.1038/nature06046
   Shapiro GI, 2006, J CLIN ONCOL, V24, P1770, DOI 10.1200/JCO.2005.03.7689
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Skene-Arnold TD, 2013, BIOCHEM J, V449, P649, DOI 10.1042/BJ20120506
   Sung WW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-951
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Wolowiec D, 1999, LEUKEMIA LYMPHOMA, V35, P147, DOI 10.3109/10428199909145714
   Wolpin BM, 2007, CA-CANCER J CLIN, V57, P168, DOI 10.3322/canjclin.57.3.168
   Xi QH, 2015, TUMOR BIOL, V36, P4939, DOI 10.1007/s13277-015-3141-8
   Yang JP, 1999, J BIOL CHEM, V274, P15662, DOI 10.1074/jbc.274.22.15662
   Zhang B, 2011, PROSTATE CANCER P D, V14, P219, DOI 10.1038/pcan.2011.25
   Zhang Y, 2015, TUMOR BIOL, V36, P8309, DOI 10.1007/s13277-015-3582-0
NR 37
TC 29
Z9 33
U1 0
U2 5
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD SEP 22
PY 2017
VL 8
IS 42
BP 71618
EP 71629
DI 10.18632/oncotarget.17794
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FH9DW
UT WOS:000411509400021
PM 29069733
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Coppé, JP
   Mori, M
   Pan, B
   Yau, C
   Wolf, DM
   Ruiz-Saenz, A
   Brunen, D
   Prahallad, A
   Cornelissen-Steijger, P
   Kemper, K
   Posch, C
   Wang, CJ
   Dreyer, CA
   Krijgsman, O
   Lee, PRE
   Chen, ZZ
   Peeper, DS
   Moasser, MM
   Bernards, R
   van't Veer, LJ
AF Coppe, Jean-Philippe
   Mori, Miki
   Pan, Bo
   Yau, Christina
   Wolf, Denise M.
   Ruiz-Saenz, Ana
   Brunen, Diede
   Prahallad, Anirudh
   Cornelissen-Steijger, Paulien
   Kemper, Kristel
   Posch, Christian
   Wang, Changjun
   Dreyer, Courtney A.
   Krijgsman, Oscar
   Lee, Pei Rong Evelyn
   Chen, Zhongzhong
   Peeper, Daniel S.
   Moasser, Mark M.
   Bernards, Rene
   van't Veer, Laura J.
TI Mapping phospho-catalytic dependencies of therapy-resistant tumours
   reveals actionable vulnerabilities
SO NATURE CELL BIOLOGY
LA English
DT Article
ID RAF INHIBITION; BRAF(V600E) INHIBITION; QUANTITATIVE-ANALYSIS;
   ACQUIRED-RESISTANCE; DRUG-SENSITIVITY; MELANOMA PATIENT; MEK INHIBITION;
   CANCER; KINOME; VEMURAFENIB
AB Phosphorylation networks intimately regulate mechanisms of response to therapies. Mapping the phospho-catalytic profile of kinases in cells or tissues remains a challenge. Here, we introduce a practical high-throughput system to measure the enzymatic activity of kinases using biological peptide targets as phospho-sensors to reveal kinase dependencies in tumour biopsies and cell lines. A 228-peptide screen was developed to detect the activity of > 60 kinases, including ABLs, AKTs, CDKs and MAPKs. Focusing on BRAF(V600E) tumours, we found mechanisms of intrinsic resistance to BRAF(V600E)-targeted therapy in colorectal cancer, including targetable parallel activation of PDPK1 and PRKCA. Furthermore, mapping the phospho-catalytic signatures of melanoma specimens identifies RPS6KB1 and PIM1 as emerging druggable vulnerabilities predictive of poor outcome in BRAF(V600E) patients. The results show that therapeutic resistance can be caused by the concerted upregulation of interdependent pathways. Our kinase activity-mapping system is a versatile strategy that innovates the exploration of actionable kinases for precision medicine.
C1 [Coppe, Jean-Philippe; Mori, Miki; Pan, Bo; Yau, Christina; Wolf, Denise M.; Ruiz-Saenz, Ana; Posch, Christian; Wang, Changjun; Dreyer, Courtney A.; Lee, Pei Rong Evelyn; Moasser, Mark M.; van't Veer, Laura J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
   [Mori, Miki] Showa Univ, Dept Breast Surg Oncol, Tokyo, Japan.
   [Pan, Bo; Wang, Changjun] Peking Union Med Coll Hosp, Peking Union Med Coll, Dept Breast Surg, Beijing, Peoples R China.
   [Pan, Bo; Wang, Changjun] Chinese Acad Med Sci, Beijing, Peoples R China.
   [Brunen, Diede; Prahallad, Anirudh; Peeper, Daniel S.; Bernards, Rene] Netherlands Canc Inst, Div Mol Carcinogenesis, Amsterdam, Netherlands.
   [Cornelissen-Steijger, Paulien; Kemper, Kristel; Krijgsman, Oscar] Netherlands Canc Inst, Div Mol Oncol & Immunol, Amsterdam, Netherlands.
   [Posch, Christian] Tech Univ Munich, Dept Dermatol & Allergy, Munich, Germany.
   [Posch, Christian] Sigmund Freud Univ, Sch Med, Vienna, Austria.
   [Chen, Zhongzhong] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, State Key Lab Genet Engn, Shanghai, Peoples R China.
   [Chen, Zhongzhong] Fudan Univ, Sch Life Sci, Collaborat Innovat Ctr Genet & Dev, Minist Educ,Key Lab Contemporary Anthropol, Shanghai, Peoples R China.
   [Chen, Zhongzhong] Shanghai Jiao Tong Univ, Shanghai Childrens Hosp, Dept Urol, Shanghai, Peoples R China.
C3 University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; Showa University; Chinese Academy of Medical Sciences - Peking
   Union Medical College; Peking Union Medical College Hospital; Peking
   Union Medical College; Chinese Academy of Medical Sciences - Peking
   Union Medical College; Netherlands Cancer Institute; Netherlands Cancer
   Institute; Technical University of Munich; Fudan University; Fudan
   University; Shanghai Jiao Tong University
RP Coppé, JP (corresponding author), Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
EM Jean-Philippe.Coppe@ucsf.edu
RI Peeper, Daniel/AAA-2430-2020; Chen, Zhongzhong/KBA-7549-2024;
   RUIZ-SAENZ, ANA/U-3220-2017
OI Chen, Zhongzhong/0000-0001-6662-5837; RUIZ-SAENZ,
   ANA/0000-0001-6033-6153
FU US National Institute of Health [NIH U54CA209891, NIH TR000005 T1, NIH
   R01CA122216]; Give Breast Cancer The Boot programme; Friends for an
   Earlier Breast Cancer Test programme; Tri-Valley SOCKs; Natural Science
   Foundation of China [81001183]; Dutch Cancer Society (KWF)
   [NKI-2013-5799]; Breast Cancer Research Foundation; Angela and Shu Kai
   Chan Endowed Chair; National Cancer Institute [U54CA209891] Funding
   Source: NIH RePORTER
FX We thank E. Chow at the Center for Advanced Technologies at UCSF for
   technical support with setting up the liquid assay automation, as well
   as T. Kuwayama, S. OrtizUrda, A. Daud, L. Brown-Swigart, N. Koemans, C.
   van der Borden, J. Zhu, N. Choy and L. Sean for operational support, and
   C. Atreya for constructive feedback. This work was supported by grants
   from the US National Institute of Health (NIH U54CA209891, NIH TR000005
   T1 Catalyst Award to J.-P.C. and NIH R01CA122216 to M.M.M.), Give Breast
   Cancer The Boot programme (to J.-P.C.), Friends for an Earlier Breast
   Cancer Test programme (to J.-P.C.), Tri-Valley SOCKs (to J.-P.C.),
   Natural Science Foundation of China (grant number 81001183 to B. P.),
   Dutch Cancer Society (KWF to R.B., and NKI-2013-5799 to D.S.P. and
   K.K.), Breast Cancer Research Foundation (to L. J.v.tV.), and Angela and
   Shu Kai Chan Endowed Chair (to L.J.v.tV.).
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Akbani R, 2015, CELL, V161, P1681, DOI 10.1016/j.cell.2015.05.044
   Akbani R, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4887
   Anastassiadis T, 2011, NAT BIOTECHNOL, V29, P1039, DOI 10.1038/nbt.2017
   Arao T, 2004, CANCER RES, V64, P9101, DOI 10.1158/0008-5472.CAN-04-2360
   Bantscheff M, 2007, NAT BIOTECHNOL, V25, P1035, DOI 10.1038/nbt1328
   BERENBAUM MC, 1977, CLIN EXP IMMUNOL, V28, P1
   BERENBAUM MC, 1989, PHARMACOL REV, V41, P93
   Bernards R, 2012, CELL, V151, P465, DOI 10.1016/j.cell.2012.10.014
   Bliss W L, 1939, Science, V89, P365, DOI 10.1126/science.89.2312.365-a
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Breitinger H.G., 2012, Drug Synergy-Mechanisms and Methods of Analysis
   Brunen D, 2013, CELL CYCLE, V12, P2960, DOI 10.4161/cc.26034
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   CHOU TC, 1984, ADV ENZYME REGUL, V22, P27, DOI 10.1016/0065-2571(84)90007-4
   Cohen RL, 2014, CELL, V157, P1509, DOI 10.1016/j.cell.2014.05.027
   Coppé JP, 2008, PLOS BIOL, V6, P2853, DOI 10.1371/journal.pbio.0060301
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Daemen A, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-10-r110
   Daub H, 2008, MOL CELL, V31, P438, DOI 10.1016/j.molcel.2008.07.007
   Drake JM, 2016, CELL, V166, P1041, DOI 10.1016/j.cell.2016.07.007
   Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
   Fang C, 2010, CANCER RES, V70, P8299, DOI 10.1158/0008-5472.CAN-10-0851
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Fleuren EDG, 2016, NAT REV CANCER, V16, P83, DOI 10.1038/nrc.2015.18
   Foucquier J, 2015, PHARMACOL RES PERSPE, V3, DOI 10.1002/prp2.149
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hornbeck PV, 2015, NUCLEIC ACIDS RES, V43, pD512, DOI 10.1093/nar/gku1267
   Houseman BT, 2002, NAT BIOTECHNOL, V20, P270, DOI 10.1038/nbt0302-270
   Huttlin EL, 2015, CELL, V162, P425, DOI 10.1016/j.cell.2015.06.043
   Jänne PA, 2009, NAT REV DRUG DISCOV, V8, P709, DOI 10.1038/nrd2871
   Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627
   Johnson SA, 2005, NAT METHODS, V2, P17, DOI 10.1038/NMETH731
   Karaman MW, 2008, NAT BIOTECHNOL, V26, P127, DOI 10.1038/nbt1358
   Kemper K, 2016, CELL REP, V16, P263, DOI 10.1016/j.celrep.2016.05.064
   Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914
   Krogan NJ, 2015, MOL CELL, V58, P690, DOI 10.1016/j.molcel.2015.05.008
   Kubota K, 2009, NAT BIOTECHNOL, V27, P933, DOI 10.1038/nbt.1566
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868
   Li X, 2007, NAT METHODS, V4, P957, DOI 10.1038/NMETH1106
   Moasser MM, 1999, CANCER RES, V59, P6145
   Mori M., 2019, NAT PROTOC EXCH, DOI DOI 10.1038/PROTEX.2019.029
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Nomura DK, 2010, NAT REV CANCER, V10, P630, DOI 10.1038/nrc2901
   Olow A, 2016, CANCER RES, V76, P1733, DOI 10.1158/0008-5472.CAN-15-2325-T
   Petricoin EF, 2002, NAT REV DRUG DISCOV, V1, P683, DOI 10.1038/nrd891
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Ren W, 2016, CHEM COMMUN, V52, P410, DOI 10.1039/c5cc06566f
   Rikova K, 2007, CELL, V131, P1190, DOI 10.1016/j.cell.2007.11.025
   Ruiz-Saenz Ana, 2018, J Clin Oncol, V36, P808, DOI 10.1200/JCO.2017.77.1899
   Sanz A, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018522
   Sharma K, 2014, CELL REP, V8, P1583, DOI 10.1016/j.celrep.2014.07.036
   Sos ML, 2014, CELL REP, V8, P1037, DOI 10.1016/j.celrep.2014.07.010
   Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Ursem Carling, 2018, Gastrointest Cancer, V8, P13, DOI 10.2147/GICTT.S125940
   Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617
   van Geel RMJM, 2015, CURR COLORECT CANC R, V11, P335, DOI 10.1007/s11888-015-0288-z
   Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631
   Wu J, 2006, ASSAY DRUG DEV TECHN, V4, P653, DOI 10.1089/adt.2006.4.653
   Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Yang XP, 2016, CELL, V164, P805, DOI 10.1016/j.cell.2016.01.029
   Yau C., 2019, NAT PROTOC EXCH, DOI [10.1038/protex.2019.030, DOI 10.1038/PROTEX.2019.030]
   Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438
NR 70
TC 30
Z9 31
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1465-7392
EI 1476-4679
J9 NAT CELL BIOL
JI Nat. Cell Biol.
PD JUN
PY 2019
VL 21
IS 6
BP 778
EP +
DI 10.1038/s41556-019-0328-z
PG 21
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA IB2DQ
UT WOS:000470080100014
PM 31160710
OA Green Accepted
DA 2025-01-04
ER

PT J
AU Han, WF
   Liu, JP
AF Han, Weifeng
   Liu, Junpeng
TI LncRNA-p21 inhibited the proliferation of osteosarcoma cells <i>via</i>
   the miR-130b/PTEN/AKT signaling pathway
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE LncRNA-p21; PTEN; AKT; Osteosarcoma; Proliferation
ID LONG NONCODING RNAS; COLORECTAL-CANCER; CHEMOTHERAPY; EXPRESSION; PTEN;
   P21
AB Osteosarcoma (OS) is the most common type of malignant bone tumor in children and adolescents. However, the molecular mechanism underlying OS development is unclear. Here, we investigated the contribution of lncRNA-p21, a novel long non-coding RNA, on OS cell proliferation. Our results demonstrated that the expression of lncRNA-p21 was repressed in OS tissue. Growth curves and the cell colony formation assay showed that lncRNA-p21 significantly inhibited the proliferation of OS cell lines. In addition, the expression of lncRNA-p21 increased the protein levels of proliferation markers, such as Ki-67 and cyclin D1. Subsequently, lncRNA-p21 overexpression up-regulated the protein level of phosphatase and tensin homolog deleted on chromosome ten (PTEN), a well-known inhibitor of AKT signaling. Moreover, our gain and loss function assay showed that the promotion of PTEN by lncRNA-p21 was mediated by miR-130b, an oncogene overexpressed in OS tissue. Our findings may provide a novel lncRNA-targeted therapy for patients with OS.
C1 [Han, Weifeng] Capital Med Univ, Beijing Tian Tan Hosp, Dept Orthopaed, Beijing 100050, Peoples R China.
   [Liu, Junpeng] Peoples Liberat Army, Air Force Gen Hosp, Dept Orthopaed, Beijing 100142, Peoples R China.
C3 Capital Medical University; Air Force General Hospital PLA
RP Liu, JP (corresponding author), Peoples Liberat Army, Air Force Gen Hosp, Dept Orthopaed, Beijing 100142, Peoples R China.
EM louisgoodljp@163.com
RI Han, Weifeng/D-8853-2013
FU National Natural Science Foundation of China (NSFC) [81401831]
FX This work was supported by the grants from the National Natural Science
   Foundation of China (NSFC Nos. 81401831).
CR [Anonymous], 2017, CELL PROLIF
   Cech TR, 2014, CELL, V157, P77, DOI 10.1016/j.cell.2014.03.008
   Del Mare S, 2016, CANCER RES, V76, P6107, DOI 10.1158/0008-5472.CAN-16-0621
   Dimitrova N, 2014, MOL CELL, V54, P777, DOI 10.1016/j.molcel.2014.04.025
   Goorin AM, 2003, J CLIN ONCOL, V21, P1574, DOI 10.1200/JCO.2003.08.165
   He C, 2015, DNA CELL BIOL, V34, P677, DOI 10.1089/dna.2015.2966
   Kempf-Bielack B, 2005, J CLIN ONCOL, V23, P559, DOI 10.1200/JCO.2005.04.063
   Kotake Y, 2017, ANTICANCER RES, V37, P81, DOI 10.21873/anticanres.11292
   Kovac M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9940
   Li Z, 2016, TUMOR BIOL, V37, P2811, DOI 10.1007/s13277-015-4749-4
   Liu CB, 2017, J CELL BIOCHEM, V118, P2250, DOI 10.1002/jcb.25879
   MEYERS PA, 1992, J CLIN ONCOL, V10, P5, DOI 10.1200/JCO.1992.10.1.5
   Miao Y, 2017, SCI REP-UK, V7, DOI 10.1038/srep41942
   Mirabello L, 2009, INT J CANCER, V125, P229, DOI 10.1002/ijc.24320
   Moriarity BS, 2015, NAT GENET, V47, P615, DOI 10.1038/ng.3293
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Schmitt AM, 2013, NATURE, V500, P536, DOI 10.1038/nature12548
   Vanhaesebroeck B, 2012, NAT REV MOL CELL BIO, V13, P195, DOI 10.1038/nrm3290
   Walkley CR, 2008, GENE DEV, V22, P1662, DOI 10.1101/gad.1656808
   Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047
   Wang J, 2015, ONCOTARGET, V6, P37852, DOI 10.18632/oncotarget.5635
   Yang F, 2014, MOL CELL, V53, P88, DOI 10.1016/j.molcel.2013.11.004
   Yang N, 2015, ONCOTARGET, V6, P28151, DOI 10.18632/oncotarget.4661
   Yang W, 2016, ONCOTARGET, V7, P41505, DOI 10.18632/oncotarget.9214
   Yu FJ, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/9856538
   Yu TT, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1031-5
   Zhou DK, 2017, INT J BIOL MARKER, V32, pE108, DOI 10.5301/jbm.5000240
NR 27
TC 38
Z9 41
U1 0
U2 8
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JAN
PY 2018
VL 97
BP 911
EP 918
DI 10.1016/j.biopha.2017.11.014
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA FR4NC
UT WOS:000419041300110
PM 29136769
DA 2025-01-04
ER

PT J
AU Patel, SS
   Schwab, JH
AF Patel, Shalin S.
   Schwab, Joseph H.
TI Immunotherapy as a Potential Treatment for Chordoma: a Review
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Antigen processing; Bone tumors; Carbon-ion; Chordoma; Chimeric antigen
   receptor; CSPG4; CTLA-4; HLA; Immune checkpoint; Immune escape; Immune
   system; Immunotherapy; MHC; PD-1; PD-L1; PD-L2; Proton; Radiation;
   Radiotherapy; Sarcoma; Tumor antigen; Vaccine
ID TUMOR-INFILTRATING LYMPHOCYTES; CELL LUNG-CANCER; CLASS-I ANTIGEN; DOSE
   PHOTON/PROTON RADIOTHERAPY; HUMAN COLORECTAL-CANCER; GROWTH-FACTOR-BETA;
   CD8(+) T-CELLS; OVARIAN-CANCER; IMMUNE ESCAPE; PROGNOSTIC-FACTORS
AB Chordoma is a locally aggressive primary malignancy of the axial skeleton. The gold standard for treatment is en bloc resection, with some centers now advocating for the use of radiation to help mitigate the risk of recurrence. Local recurrence is common, and salvaging local failures is quite difficult. Chemotherapy has been ineffective and small molecule targeted therapy has had only marginal benefits in small subsets of patients with rare tumor phenotypes or refractory disease. Recent successes utilizing immunotherapy in a variety of cancers has led to a resurgence of interest in modifying the host immune system to develop new ways to treat tumors. This review will discuss these studies and will highlight the early studies employing immune strategies for the treatment of chordoma.
C1 [Patel, Shalin S.; Schwab, Joseph H.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St Yawkey Bldg Suite 3A, Boston, MA 02114 USA.
C3 Harvard University; Massachusetts General Hospital; Harvard Medical
   School
RP Schwab, JH (corresponding author), Harvard Med Sch, Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St Yawkey Bldg Suite 3A, Boston, MA 02114 USA.
EM shalin@partners.org; jhschwab@partners.org
OI HUITRON, EFREN/0009-0008-2046-3359
CR Al-Shibli KI, 2008, CLIN CANCER RES, V14, P5220, DOI 10.1158/1078-0432.CCR-08-0133
   Alexe G, 2007, CANCER RES, V67, P10669, DOI 10.1158/0008-5472.CAN-07-0539
   AZZARELLI A, 1988, J SURG ONCOL, V37, P185, DOI 10.1002/jso.2930370311
   Baier PK, 1998, TUMOR BIOL, V19, P205, DOI 10.1159/000030008
   Baker K, 2007, EUR J CANCER, V43, P624, DOI 10.1016/j.ejca.2006.11.012
   Beard RE, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/2051-1426-2-25
   Bordon Y, 2015, NAT REV IMMUNOL, V15, P6, DOI 10.1038/nri3792
   Bordon Y, 2015, NAT REV CANCER, V15, P3, DOI 10.1038/nrc3880
   Boriani S, 2006, SPINE, V31, P493, DOI 10.1097/01.brs.0000200038.30869.27
   Campoli M, 2008, ONCOGENE, V27, P5869, DOI 10.1038/onc.2008.273
   Campoli M, 2008, TISSUE ANTIGENS, V72, P321, DOI 10.1111/j.1399-0039.2008.01106.x
   Campoli M, 2005, CANC TREAT, V123, P61
   Campoli M, 2002, VACCINE, V20, pA40, DOI 10.1016/S0264-410X(02)00386-9
   Campoli M, 2011, SEMIN IMMUNOPATHOL, V33, P321, DOI 10.1007/s00281-011-0270-z
   Campoli M, 2010, CLIN CANCER RES, V16, P11, DOI 10.1158/1078-0432.CCR-09-2345
   Camus M, 2009, CANCER RES, V69, P2685, DOI 10.1158/0008-5472.CAN-08-2654
   Chang CC, 2005, ADV CANCER RES, V93, P189, DOI 10.1016/S0065-230X(05)93006-6
   Chang CC, 2007, CANCER IMMUNOL IMMUN, V56, P227, DOI 10.1007/s00262-006-0183-1
   Chen YL, 2013, SPINE, V38, pE930, DOI 10.1097/BRS.0b013e318296e7d7
   Choi KS, 2008, DEV DYNAM, V237, P3953, DOI 10.1002/dvdy.21805
   Chouaib S, 2013, B CANCER, V100, P569, DOI 10.1684/bdc.2013.1754
   CLARK WH, 1989, JNCI-J NATL CANCER I, V81, P1893, DOI 10.1093/jnci/81.24.1893
   Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO;2-5
   Dahlin AM, 2011, MODERN PATHOL, V24, P671, DOI 10.1038/modpathol.2010.234
   Dalerba P, 2003, CRIT REV ONCOL HEMAT, V46, P33, DOI 10.1016/S1040-8428(02)00159-2
   Delaney TF, 2014, J SURG ONCOL, V110, P115, DOI 10.1002/jso.23617
   DeLaney TF, 2009, INT J RADIAT ONCOL, V74, P732, DOI 10.1016/j.ijrobp.2008.08.058
   Diederichsen ACP, 2003, CANCER IMMUNOL IMMUN, V52, P423, DOI 10.1007/s00262-003-0388-5
   Dieu-Nosjean MC, 2008, J CLIN ONCOL, V26, P4410, DOI 10.1200/JCO.2007.15.0284
   Donahue RN, 2014, J IMMUNOTHER CANC S3, V2, P148
   Feng Y, 2015, ONCOTARGET, V6, P11139, DOI 10.18632/oncotarget.3576
   Ferris RL, 2006, CLIN CANCER RES, V12, P3890, DOI 10.1158/1078-0432.CCR-05-2750
   Ferris RL, 2010, J CLIN ONCOL, V28, P4390, DOI 10.1200/JCO.2009.27.6360
   Ferrone S, 2007, SURG ONCOL CLIN N AM, V16, P755, DOI 10.1016/j.soc.2007.08.004
   Francisco LM, 2010, IMMUNOL REV, V236, P219, DOI 10.1111/j.1600-065X.2010.00923.x
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gameiro SR, 2014, ONCOTARGET, V5, P403, DOI 10.18632/oncotarget.1719
   Halama Niels, 2009, Cancer Immun, V9, P1
   Hamamoto Shinichi, 2014, BMC Res Notes, V7, P765, DOI 10.1186/1756-0500-7-765
   Hamanishi J, 2007, P NATL ACAD SCI USA, V104, P3360, DOI 10.1073/pnas.0611533104
   HARRISON JC, 1994, HUM PATHOL, V25, P498, DOI 10.1016/0046-8177(94)90122-8
   Heery CR, 2015, CANCER IMMUNOL RES, V3, P1248, DOI 10.1158/2326-6066.CIR-15-0119
   HEFFELFINGER MJ, 1973, CANCER-AM CANCER SOC, V32, P410, DOI 10.1002/1097-0142(197308)32:2<410::AID-CNCR2820320219>3.0.CO;2-S
   Hiraoka N, 2006, CLIN CANCER RES, V12, P5423, DOI 10.1158/1078-0432.CCR-06-0369
   Horton R, 2004, NAT REV GENET, V5, P889, DOI 10.1038/nrg1489
   Imai R, 2016, INT J RADIAT ONCOL, V95, P322, DOI 10.1016/j.ijrobp.2016.02.012
   Indelicato DJ, 2016, INT J RADIAT ONCOL, V95, P297, DOI 10.1016/j.ijrobp.2016.01.057
   Ito N, 2005, ANTICANCER RES, V25, P2027
   Kawai O, 2008, CANCER-AM CANCER SOC, V113, P1387, DOI 10.1002/cncr.23712
   Kayani B, 2014, EJSO-EUR J SURG ONC, V40, P1412, DOI 10.1016/j.ejso.2014.04.008
   Lee WS, 2010, CANCER-AM CANCER SOC, V116, P5188, DOI 10.1002/cncr.25293
   Lipowska-Bhalla G, 2012, CANCER IMMUNOL IMMUN, V61, P953, DOI 10.1007/s00262-012-1254-0
   Lugli A, 2009, BRIT J CANCER, V101, P1382, DOI 10.1038/sj.bjc.6605318
   MACKENSEN A, 1993, CANCER RES, V53, P3569
   Mahmoud SMA, 2011, J CLIN ONCOL, V29, P1949, DOI 10.1200/JCO.2010.30.5037
   Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6
   Marrogi AJ, 1997, INT J CANCER, V74, P492, DOI 10.1002/(SICI)1097-0215(19971021)74:5<492::AID-IJC3>3.0.CO;2-Z
   Mathios D, 2015, J NEURO-ONCOL, V121, P251, DOI 10.1007/s11060-014-1637-5
   Menegaz RA, 2008, EUR J GYNAECOL ONCOL, V29, P321
   Menon AG, 2004, LAB INVEST, V84, P493, DOI 10.1038/labinvest.3700055
   Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425
   Nagtegaal ID, 2001, BMC CANCER, V1, DOI 10.1186/1471-2407-1-7
   Naito Y, 1998, CANCER RES, V58, P3491
   Nosho K, 2010, J PATHOL, V222, P350, DOI 10.1002/path.2774
   Pagès F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424
   Pagès F, 2009, J CLIN ONCOL, V27, P5944, DOI 10.1200/JCO.2008.19.6147
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Phukan R, 2016, CLIN ORTHOP RELAT R, V474, P687, DOI 10.1007/s11999-015-4361-3
   Prall F, 2004, HUM PATHOL, V35, P808, DOI 10.1016/j.humpath.2004.01.022
   Pule M, 2003, CYTOTHERAPY, V5, P211, DOI 10.1080/14653240310001488
   Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943
   Robert C, 2014, N ENGL J MED
   Salama P, 2009, J CLIN ONCOL, V27, P186, DOI 10.1200/JCO.2008.18.7229
   Sato E, 2005, P NATL ACAD SCI USA, V102, P18538, DOI 10.1073/pnas.0509182102
   Schoenfeld A. J., 2015, SPINE J
   Schwab JH, 2009, CANCER IMMUNOL IMMUN, V58, P339, DOI 10.1007/s00262-008-0557-7
   Seliger B, 2011, PROTEOMICS, V11, P2528, DOI 10.1002/pmic.201000486
   Senovilla L, 2012, ONCOIMMUNOLOGY, V1, P1323, DOI 10.4161/onci.22009
   Sinicrope FA, 2009, GASTROENTEROLOGY, V137, P1270, DOI 10.1053/j.gastro.2009.06.053
   Stacchiotti S, 2012, J CLIN ONCOL, V30, P914, DOI 10.1200/JCO.2011.35.3656
   Stacchiotti S, 2011, CURR ONCOL REP, V13, P323, DOI 10.1007/s11912-011-0176-x
   TEFANY FJ, 1991, J INVEST DERMATOL, V97, P197, DOI 10.1111/1523-1747.ep12479662
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907
   Travers P., 2007, Janeways immunobiology, V7
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954
   Vujovic S, 2006, J PATHOL, V209, P157, DOI 10.1002/path.1969
   WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X
   Wang X, 2010, CURR MOL MED, V10, P419, DOI 10.2174/156652410791316977
   Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369
   Zhang L, 2003, NEW ENGL J MED, V348, P203, DOI 10.1056/NEJMoa020177
   Zinkernagel R M, 1979, Adv Immunol, V27, P51, DOI 10.1016/S0065-2776(08)60262-X
   Zoccali C., 2016, EUR SPINE J
NR 92
TC 18
Z9 19
U1 0
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD SEP
PY 2016
VL 18
IS 9
AR 55
DI 10.1007/s11912-016-0543-8
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DS3GJ
UT WOS:000380670800003
PM 27475804
DA 2025-01-04
ER

PT J
AU Du, L
   Kim, JJ
   Shen, J
   Chen, B
   Dai, N
AF Du, Lijun
   Kim, John J.
   Shen, Jinhua
   Chen, Binrui
   Dai, Ning
TI KRAS and TP53 mutations in inflammatory bowel disease-associated
   colorectal cancer: a meta-analysis
SO ONCOTARGET
LA English
DT Review
DE KRAS; TP53; mutation; inflammatory bowel disease; colorectal cancer
ID KI-RAS MUTATIONS; ULCERATIVE-COLITIS; GENETIC ALTERATIONS; CROHNS
   COLITIS; P53 MUTATIONS; NEOPLASIA; CARCINOMA; RISK; SUPPRESSOR;
   EXPRESSION
AB Although KRAS and TP53 mutations are common in both inflammatory bowel disease-associated colorectal cancer (IBD-CRC) and sporadic colorectal cancer (S-CRC), molecular events leading to carcinogenesis may be different. Previous studies comparing the frequency of KRAS and TP53 mutations in IBD-CRC and S-CRC were inconsistent. We performed a meta-analysis to compare the presence of KRAS and TP53 mutations among patients with IBD-CRC, S-CRC, and IBD without dysplasia. A total of 19 publications (482 patients with IBD-CRC, 4,222 with S-CRC, 281 with IBD without dysplasia) met the study inclusion criteria. KRAS mutation was less frequent (RR=0.71, 95% CI 0.56-0.90; P=0.004) while TP53 mutation was more common (RR=1.24, 95% CI 1.10-1.39; P<0.001) in patients with IBD-CRC compared to S-CRC. Both KRAS (RR=3.09, 95% CI 1.47-6.51; P=0.003) and TP53 (RR=2.15, 95% CI 1.07-4.31 P=0.03) mutations were more prevalent in patients with IBD-CRC compared to IBD without dysplasia. In conclusion, IBD-CRC and S-CRC appear to have biologically different molecular pathways. TP53 appears to be more important than KRAS in IBD-CRC compared to S-CRC. Our findings suggest possible roles of TP53 and KRAS as biomarkers for cancer and dysplasia screening among patients with IBD and may also provide targeted therapy in patients with IBD-CRC.
C1 [Du, Lijun; Kim, John J.; Shen, Jinhua; Chen, Binrui; Dai, Ning] Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gastroenterol, Hangzhou, Peoples R China.
   [Kim, John J.] Loma Linda Univ, Med Ctr, Div Gastroenterol, Loma Linda, CA 92350 USA.
   [Shen, Jinhua] Shaoxing Univ, Affiliated Hosp, Dept Gastroenterol, Shaoxing, Peoples R China.
C3 Zhejiang University; Loma Linda University; Shaoxing University
RP Dai, N (corresponding author), Zhejiang Univ, Sir Run Run Shaw Hosp, Sch Med, Dept Gastroenterol, Hangzhou, Peoples R China.
EM ndaicn@yahoo.com
CR Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964
   [Anonymous], GASTROENTEROLOGY REP
   AUVINEN A, 1994, BRIT J CANCER, V70, P293, DOI 10.1038/bjc.1994.295
   BAKER SJ, 1989, SCIENCE, V244, P217, DOI 10.1126/science.2649981
   Bell SM, 1991, C KI RAS GENE MUTATI
   Bernstein CN, 2001, CANCER-AM CANCER SOC, V91, P854, DOI 10.1002/1097-0142(20010215)91:4<854::AID-CNCR1073>3.0.CO;2-Z
   Bossard C, 2007, ONCOL REP, V18, P1093
   Bournet B, 2016, EUR J CANCER, V54, P75, DOI 10.1016/j.ejca.2015.11.012
   BURMER GC, 1991, ENVIRON HEALTH PERSP, V93, P27, DOI 10.2307/3431164
   BURMER GC, 1989, P NATL ACAD SCI USA, V86, P2403, DOI 10.1073/pnas.86.7.2403
   BURMER GC, 1992, GASTROENTEROLOGY, V103, P1602, DOI 10.1016/0016-5085(92)91184-6
   BURMER GC, 1990, GASTROENTEROLOGY, V99, P416, DOI 10.1016/0016-5085(90)91024-Z
   Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x
   Castaño-Milla C, 2014, ALIMENT PHARM THER, V39, P645, DOI 10.1111/apt.12651
   CHEN J, 1992, GASTROENTEROLOGY, V102, P1983, DOI 10.1016/0016-5085(92)90323-Q
   Chin L, 2008, NATURE, V455, P1061, DOI 10.1038/nature07385
   Cosnes J, 2011, GASTROENTEROLOGY, V140, P1785, DOI 10.1053/j.gastro.2011.01.055
   COSTA A, 1995, J PATHOL, V176, P45, DOI 10.1002/path.1711760108
   Cox Adrienne D, 2010, Small GTPases, V1, P2
   Di Bartolomeo M, 2014, TARGET ONCOL, V9, P155, DOI 10.1007/s11523-013-0283-8
   Engstrom PF, 2009, J NATL COMPR CANC NE, V7, P778, DOI 10.6004/jnccn.2009.0056
   Engstrom PF, 2009, J NATL COMPR CANC NE, V7, P838, DOI 10.6004/jnccn.2009.0057
   Feagins LA, 2009, NAT REV GASTRO HEPAT, V6, P297, DOI 10.1038/nrgastro.2009.44
   FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531
   Fogt F, 1998, HUM PATHOL, V29, P131, DOI 10.1016/S0046-8177(98)90222-2
   Friis-Ottessen M, 2015, INT J MOL MED, V35, P24, DOI 10.3892/ijmm.2014.1974
   Higgins JPT, 2002, STAT MED, V21, P1539, DOI 10.1002/sim.1186
   Hobbs GA, 2016, J CELL SCI, V129, P1287, DOI 10.1242/jcs.182873
   Itzkowitz SH, 2006, GASTROENTEROL CLIN N, V35, P553, DOI 10.1016/j.gtc.2006.07.002
   Jaiswal M, 2001, AM J PHYSIOL-GASTR L, V281, pG626, DOI 10.1152/ajpgi.2001.281.3.G626
   Jess T, 2012, CLIN GASTROENTEROL H, V10, P639, DOI 10.1016/j.cgh.2012.01.010
   Johnson DH, 2016, INFLAMM BOWEL DIS, V22, P1559, DOI 10.1097/MIB.0000000000000795
   Kisiel JB, 2013, ALIMENT PHARM THER, V37, P546, DOI 10.1111/apt.12218
   Lashner BA, 1999, AM J GASTROENTEROL, V94, P456, DOI 10.1016/S0002-9270(98)00758-8
   Laurent C, 2011, INFLAMM BOWEL DIS, V17, P232, DOI 10.1002/ibd.21451
   Lennerz JK, 2016, INT J COLORECTAL DIS, V31, P973, DOI 10.1007/s00384-016-2574-x
   Leowardi C, 2016, ANN SURG ONCOL, V23, P870, DOI 10.1245/s10434-015-4915-3
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Maia L, 2005, CANCER GENET CYTOGEN, V162, P68, DOI 10.1016/j.cancergencyto.2005.02.017
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Midgley CA, 1997, ONCOGENE, V15, P1179, DOI 10.1038/sj.onc.1201459
   Munro AJ, 2005, BRIT J CANCER, V92, P434, DOI 10.1038/sj.bjc.6602358
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nathanson JW, 2008, DIGEST DIS SCI, V53, P474, DOI 10.1007/s10620-007-9886-1
   Ng SC, 2014, BEST PRACT RES CL GA, V28, P363, DOI 10.1016/j.bpg.2014.04.003
   Olaru AV, 2012, INFLAMM BOWEL DIS, V18, P641, DOI 10.1002/ibd.21826
   Pan W, 2016, ONCOTARGET, V7, P8373, DOI 10.18632/oncotarget.7080
   Pricolo VE, 1996, AM J SURG, V171, P41, DOI 10.1016/S0002-9610(99)80071-3
   Quan S, 2011, GASTROENTEROLOGY, V140, pS730
   Rashid A, 1997, GASTROENTEROLOGY, V113, P127, DOI 10.1016/S0016-5085(97)70087-8
   Reeves HL, 2004, GASTROENTEROLOGY, V126, P1090, DOI 10.1053/j.gastro.2004.01.005
   Sanchez JA, 2011, INFLAMM BOWEL DIS, V17, P1966, DOI 10.1002/ibd.21526
   Scarpa M, 2014, WORLD J GASTROENTERO, V20, P6774, DOI 10.3748/wjg.v20.i22.6774
   Sclafani F, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju121
   Shivakumar BM, 2012, J CROHNS COLITIS, V6, P647, DOI 10.1016/j.crohns.2011.11.013
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171
   TAYLOR HW, 1993, THE BRITISH JOURNAL, V80, P442
   Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057
   Umetani N, 1999, JPN J CANCER RES, V90, P1081, DOI 10.1111/j.1349-7006.1999.tb00681.x
   Vagefi Parsia A, 2005, Clin Colorectal Cancer, V4, P313, DOI 10.3816/CCC.2005.n.003
   van der Woude CJ, 2004, APOPTOSIS, V9, P123, DOI 10.1023/B:APPT.0000018794.26438.22
   Vauthey JN, 2013, ANN SURG, V258, P619, DOI 10.1097/SLA.0b013e3182a5025a
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   WALSH SV, 1999, THE AMERICAN JOURNAL, V23, P963
   Wang Z., 2014, INT J ANTENN PROPAG, V2014, P1
   Yaeger R, 2016, GASTROENTEROLOGY
   YAMAGUCHI A, 1992, CANCER, V70, P2778, DOI 10.1002/1097-0142(19921215)70:12<2778::AID-CNCR2820701209>3.0.CO;2-L
NR 69
TC 49
Z9 51
U1 2
U2 25
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 28
PY 2017
VL 8
IS 13
BP 22175
EP 22186
DI 10.18632/oncotarget.14549
PG 12
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EP8RL
UT WOS:000397642400137
PM 28077799
OA gold, Green Published, Green Submitted
DA 2025-01-04
ER

PT J
AU Mousavi, N
   Truelsen, SLB
   Bernth-Andersen, S
   Koch, A
   Heegaard, S
AF Mousavi, Nabi
   Truelsen, Sarah Line Bring
   Bernth-Andersen, Simon
   Koch, Anders
   Heegaard, Steffen
TI Mutation of <i>KRAS</i> in colorectal adenocarcinoma in Greenland
SO APMIS
LA English
DT Article
DE Colorectal cancer; greenland; inuit; KRAS mutation; population genetics
ID CANCER; PATTERNS; BRAF
AB KRAS mutation is one of the most frequent driver mutations in colorectal cancer (CRC) and is also a prognostic biomarker. The aim of the present study was to determine the frequency of KRAS mutations over time in the Greenlandic population diagnosed with CRC. In total, 578 patients with the diagnosis of adenocarcinoma between 1988 and 2017 were identified. The status of KRAS and the mutational subtypes of KRAS mutations were determined in 102 representative samples by the Idylla (TM) platform in the time periods 1988-1990, 2002-2004, and 2015-2017. The results showed that the frequency of the KRAS mutations increased significantly, from 27% in 1988-1990 to 43% in 2015-2017 (p < 0.001). Furthermore, the most frequent subtypes of KRAS mutations in Greenland were G12D (c.35G > A) with 14%, G12V (c.35G > T) with 7%, and G13D (c.38G > A) with 6%. In conclusion, this study showed that the frequency of KRAS mutations in CRC has been increasing in recent decades in the specific population of Greenland. The results of this study may be used in initiatives related to targeted therapy of CRC in specific ethnicities and in investigations focusing on the environmental factors of cancer-related somatic mutations.
C1 [Mousavi, Nabi; Truelsen, Sarah Line Bring; Heegaard, Steffen] Univ Copenhagen, Rigshosp, Dept Pathol, Copenhagen, Denmark.
   [Bernth-Andersen, Simon] Queen Ingrids Hosp, Dept Surg, Nuuk, Greenland.
   [Koch, Anders] Statens Serum Inst, Copenhagen, Denmark.
   [Koch, Anders] Ilisimatusarfik Univ Greenland, Nuuk, Greenland.
   [Koch, Anders] Univ Copenhagen, Rigshosp, Dept Infect Dis, Copenhagen, Denmark.
   [Heegaard, Steffen] Univ Copenhagen, Rigshosp, Dept Ophthalmol, Copenhagen, Denmark.
C3 Rigshospitalet; University of Copenhagen; Statens Serum Institut;
   University of Copenhagen; Rigshospitalet; University of Copenhagen;
   Rigshospitalet
RP Mousavi, N (corresponding author), Rigshosp, Dept Pathol, Frederik Vs Vej 11, DK-2100 Copenhagen, Denmark.
EM mousavi.nabi7@gmail.com
RI Heegaard, Steffen/LDE-8074-2024; Mousavi, Nabi/JQW-8313-2023
OI Koch, Anders/0000-0001-9205-1048
FU Department of Pathology, Rigshospitalet, Denmark
FX This study was supported by the Department of Pathology, Rigshospitalet,
   Denmark.
CR Abudabous A, 2021, MOL CLIN ONCOL, V15, DOI 10.3892/mco.2021.2359
   [Anonymous], 2020, STATISTIKBANKEN
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Bjerregaard P, 2004, SCAND J PUBLIC HEALT, V32, P390, DOI 10.1080/14034940410028398
   Brink M, 2003, CARCINOGENESIS, V24, P703, DOI 10.1093/carcin/bgg009
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Cannon TL, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0350-8
   Charlton ME, 2017, J NATL COMPR CANC NE, V15, P1484, DOI 10.6004/jnccn.2017.7011
   Chen JQ, 2014, BMC CANCER, V14, DOI [10.1186/1471-2407-14-802, 10.1186/1471-2407-14-15]
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Friborg JT, 2008, LANCET ONCOL, V9, P892, DOI 10.1016/S1470-2045(08)70231-6
   Grady WM, 2015, DIGEST DIS SCI, V60, P762, DOI 10.1007/s10620-014-3444-4
   He K, 2020, ONCOTARGETS THER, V13, P12601, DOI 10.2147/OTT.S279312
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Jayasekara H, 2017, INT J CANCER, V140, P1485, DOI 10.1002/ijc.30568
   Kawada K, 2017, INT J CLIN ONCOL, V22, P651, DOI 10.1007/s10147-017-1156-4
   Li WB, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1345-3
   Li ZZ, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0787-z
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Peng JF, 2021, INT J COLORECTAL DIS, V36, P1781, DOI 10.1007/s00384-021-03911-z
   Rosty C, 2013, MODERN PATHOL, V26, P825, DOI 10.1038/modpathol.2012.240
   Solassol J, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163444
   Staudacher JJ, 2017, CLIN TRANSL GASTROEN, V8, DOI 10.1038/ctg.2017.48
   Sui XK, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5622
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tam IYS, 2006, CLIN CANCER RES, V12, P1647, DOI 10.1158/1078-0432.CCR-05-1981
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Watanabe T, 2013, JPN J CLIN ONCOL, V43, P706, DOI 10.1093/jjco/hyt062
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yoon HH, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv186
   Yousaf U, 2018, ECLINICALMEDICINE, V2-3, P37, DOI 10.1016/j.eclinm.2018.08.003
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhuang RY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182562
NR 34
TC 1
Z9 1
U1 0
U2 1
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0903-4641
EI 1600-0463
J9 APMIS
JI APMIS
PD AUG
PY 2022
VL 130
IS 8
BP 493
EP 497
DI 10.1111/apm.13254
EA JUN 2022
PG 5
WC Immunology; Microbiology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Microbiology; Pathology
GA 2S9HZ
UT WOS:000812951200001
PM 35655437
DA 2025-01-04
ER

PT J
AU Hua, X
   Zhang, HM
   Jia, JF
   Chen, SS
   Sun, Y
   Zhu, XL
AF Hua, Xin
   Zhang, Hongming
   Jia, Jinfang
   Chen, Shanshan
   Sun, Yue
   Zhu, Xiaoli
TI Roles of S100 family members in drug resistance in tumors: Status and
   prospects
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Article
DE S100 protein; Drug resistance; Tumor; Chemotherapy; Biomarker
ID EPITHELIAL-MESENCHYMAL TRANSITION; INVASIVE BLADDER-CANCER; ACUTE
   MYELOID-LEUKEMIA; COLORECTAL-CANCER; IN-VITRO; MESSENGER-RNA;
   CLINICOPATHOLOGICAL SIGNIFICANCE; STAPHYLOCOCCAL NUCLEASE; CISPLATIN
   RESISTANCE; EXPRESSION ANALYSIS
AB Chemotherapy and targeted therapy can significantly improve survival rates in cancer, but multiple drug resistance (MDR) limits the efficacy of these approaches. Understanding the molecular mechanisms underlying MDR is crucial for improving drug efficacy and clinical outcomes of patients with cancer. S100 proteins belong to a family of calcium-binding proteins and have various functions in tumor development. Increasing evidence demonstrates that the dysregulation of various S100 proteins contributes to the development of drug resistance in tumors, providing a basis for the development of predictive and prognostic biomarkers in cancer. Therefore, a combination of biological inhibitors or sensitizers of dysregulated S100 proteins could enhance therapeutic responses. In this review, we provide a detailed overview of the mechanisms by which S100 family members influence resistance of tumors to cancer treatment, with a focus on the development of effective strategies for overcoming MDR.
C1 [Hua, Xin; Jia, Jinfang; Chen, Shanshan; Sun, Yue; Zhu, Xiaoli] Southeast Univ, Med Coll, Nanjing 210009, Peoples R China.
   [Zhang, Hongming] Southeast Univ, Yancheng Peoples Hosp 3, Dept Resp Med, Med Coll, Yancheng 224000, Peoples R China.
   [Zhu, Xiaoli] Southeast Univ, Dept Resp Med, Zhongda Hosp, Med Coll, Dingjiaqiao 87, Nanjing 210009, Peoples R China.
C3 Southeast University - China; Southeast University - China; Southeast
   University - China
RP Zhu, XL (corresponding author), Southeast Univ, Dept Resp Med, Zhongda Hosp, Med Coll, Dingjiaqiao 87, Nanjing 210009, Peoples R China.
EM 13646101567@163.com; hmzhang149252@163.com; 948982762@qq.com;
   1366733480@qq.com; 122592998@qq.com; zhuxiaoli1962@163.com
RI XL, zhu/GQR-1464-2022; Sun, Yue/B-1373-2013; Jia, Jinfang/JQI-2969-2023
OI Chen, Shanshan/0000-0002-9944-6429
CR Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Aleksakhina SN, 2019, BBA-REV CANCER, V1872, DOI 10.1016/j.bbcan.2019.188310
   [Anonymous], 2017, THESIS
   [Anonymous], THESIS
   Arumugam T, 2013, MOL CANCER THER, V12, P654, DOI 10.1158/1535-7163.MCT-12-0771
   Azimi A, 2014, BRIT J CANCER, V110, P2489, DOI 10.1038/bjc.2014.169
   Bachet JB, 2013, EUR J CANCER, V49, P2643, DOI 10.1016/j.ejca.2013.04.017
   Basnet Suyog, 2019, Oncotarget, V10, P2996, DOI 10.18632/oncotarget.26861
   Basu GD, 2008, INT J CANCER, V123, P330, DOI 10.1002/ijc.23447
   Bertram J, 1998, ANTI-CANCER DRUG, V9, P311, DOI 10.1097/00001813-199804000-00004
   Boye K, 2016, CANCER MED-US, V5, P1840, DOI 10.1002/cam4.766
   Brenner AK, 2018, NEOPLASIA, V20, P1175, DOI 10.1016/j.neo.2018.09.007
   Bruheim S, 2009, CLIN CANCER RES, V15, P7161, DOI 10.1158/1078-0432.CCR-08-2816
   Cao CM, 2014, EUR REV MED PHARMACO, V18, P833
   Charmsaz S, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0836-2
   Chen M., 2019, BIOMED PHARMACOTHER, V117, DOI [10.1016/j.biopha.2019, DOI 10.1016/J.BIOPHA.2019]
   Chen SH, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174136
   Chen W, 2014, PLOS ONE, V9
   Cheng CY, 2018, INT J BIOL MACROMOL, V107, P2620, DOI 10.1016/j.ijbiomac.2017.10.154
   Chow KH, 2017, CANCER RES, V77, P5360, DOI 10.1158/0008-5472.CAN-17-1294
   Chuang CK, 2000, J UROLOGY, V163, P1016, DOI 10.1016/S0022-5347(05)67874-3
   Dong XY, 2018, CELL PHYSIOL BIOCHEM, V51, P886, DOI 10.1159/000495387
   Duan L, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0512-2
   Dudás J, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020428
   Fan JJ, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8110557
   Fei F, 2017, ONCOTARGET, V8, P73219, DOI 10.18632/oncotarget.18016
   Feng Po-Hao, 2018, Oncotarget, V9, P7631, DOI 10.18632/oncotarget.24146
   Feng PH, 2012, AM J RESP CRIT CARE, V186, P1025, DOI 10.1164/rccm.201204-0636OC
   Fenouille N, 2012, J PATHOL, V227, P118, DOI 10.1002/path.3034
   Florea AM, 2017, ONCOTARGET, V8, P22876, DOI 10.18632/oncotarget.15283
   Fornecker LM, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-018-37273-4
   Gao JH, 2008, CHINESE MED J-PEKING, V121, P1563, DOI 10.1097/00029330-200808020-00012
   Ge FL, 2013, INT J BIOL MARKER, V28, pE387, DOI [10.5301/JBM.5000034, 10.5301/jbm.5000034]
   Gebhardt C, 2015, CLIN CANCER RES, V21, P5453, DOI 10.1158/1078-0432.CCR-15-0676
   Ghoul A, 2009, CANCER RES, V69, P4260, DOI 10.1158/0008-5472.CAN-08-2837
   Gianni M, 2019, ONCOGENE, V38, P2482, DOI 10.1038/s41388-018-0599-z
   Gibadulinova A, 2016, ONCOTARGET, V7, P22508, DOI 10.18632/oncotarget.7999
   Gollob JA, 2007, CLIN CANCER RES, V13, P5219, DOI 10.1158/1078-0432.CCR-07-0816
   Gonzalez LL, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118677
   Gu YX, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0834-z
   Hamberg AP, 2003, MELANOMA RES, V13, P45, DOI 10.1097/00008390-200302000-00008
   Han MY, 2012, ONCOL REP, V28, P2233, DOI 10.3892/or.2012.2037
   Hano M, 2018, MOLECULES, V23, DOI 10.3390/molecules23020337
   Hatoum D, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169925
   He X, 2017, MOL MED REP, V16, P523, DOI 10.3892/mmr.2017.6636
   He ZJ, 2008, ONCOL REP, V20, P325, DOI 10.3892/or_00000010
   Heizmann CW, 2019, METHODS MOL BIOL, V1929, P157, DOI 10.1007/978-1-4939-9030-6_11
   Hsu YL, 2015, ONCOL REP, V34, P2889, DOI 10.3892/or.2015.4307
   Hua X, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109233
   Huan L, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1122-z
   Humeau J, 2018, CELL CALCIUM, V70, P3, DOI 10.1016/j.ceca.2017.07.006
   Hurtz C, 2019, GENE DEV, V33, P1265, DOI 10.1101/gad.327593.119
   Hwang SH, 2019, GENES GENOM, V41, P1273, DOI 10.1007/s13258-019-00856-0
   Januchowski R, 2017, ONCOTARGET, V8, P49944, DOI 10.18632/oncotarget.18278
   Jariwala N, 2019, HEPATOL COMMUN, V3, P1258, DOI 10.1002/hep4.1400
   Jiao X, 2018, CELL PHYSIOL BIOCHEM, V49, P1184, DOI 10.1159/000493296
   Jin LY, 2012, GYNECOL ONCOL, V126, P140, DOI 10.1016/j.ygyno.2012.04.005
   Johansson HJ, 2015, CLIN PROTEOM, V12, DOI 10.1186/s12014-015-9080-y
   Ju HP, 2018, THORAC CANCER, V9, P353, DOI 10.1111/1759-7714.12584
   Ju W, 2009, ONCOL RES, V18, P47, DOI 10.3727/096504009789954672
   Karjalainen R, 2019, LEUKEMIA, V33, P2548, DOI 10.1038/s41375-019-0504-y
   Kim JH, 2017, CANCER RES TREAT, V49, P947, DOI 10.4143/crt.2016.280
   Kim WT, 2014, ANN ONCOL, V25, P974, DOI 10.1093/annonc/mdu037
   Kim WJ, 2011, MOL MED, V17, P478, DOI 10.2119/molmed.2010.00274
   Kim YJ, 2008, CANCER INVEST, V26, P152, DOI 10.1080/07357900701518909
   Kinoshita R, 2019, INT J CANCER, V145, P569, DOI 10.1002/ijc.31982
   Kiss B, 2019, METHODS MOL BIOL, V1929, P325, DOI 10.1007/978-1-4939-9030-6_21
   Klopper JP, 2010, PPAR RES, V2010, DOI 10.1155/2010/729876
   L'Espérance S, 2006, INT J ONCOL, V29, P5
   Lai E, 2019, CANCER TREAT REV, V81, DOI 10.1016/j.ctrv.2019.101926
   Lang Bin, 2016, Med Sci Monit, V22, P1953
   Lee K, 2012, GENE THER, V19, P967, DOI 10.1038/gt.2011.168
   Li CY, 2020, J CANCER, V11, P826, DOI 10.7150/jca.36203
   Li J, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0329-z
   Li LT, 2018, INT J ONCOL, V53, P1171, DOI 10.3892/ijo.2018.4455
   Li P., 2012, CHIN J CANC PREV TRE, V19, P1317
   Li QC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00388
   Li S, 2020, EXP THER MED, V19, P2360, DOI 10.3892/etm.2020.8459
   Li YH, 2018, HUM PATHOL, V74, P156, DOI 10.1016/j.humpath.2018.01.004
   Li YG, 2017, MOL CANCER RES, V15, P1752, DOI 10.1158/1541-7786.MCR-17-0349
   Liang DP, 2014, EUR REV MED PHARMACO, V18, P3484
   Liang J, 2014, CLIN CANCER RES, V20, P187, DOI 10.1158/1078-0432.CCR-13-1279
   Lin M, 2018, DNA CELL BIOL, V37, P491, DOI 10.1089/dna.2017.3953
   Liu B, 2013, EXP THER MED, V6, P1499, DOI 10.3892/etm.2013.1344
   Liu J, 2020, ONCOL REP, V43, P562, DOI 10.3892/or.2019.7445
   Liu TY, 2013, GLOB CONGRESS INTELL, P200, DOI 10.1109/GCIS.2013.38
   Liu Y., 2017, THESIS
   Liu Y, 2019, AGING-US, V11, P12328, DOI 10.18632/aging.102575
   Luthra MG, 2007, CLIN CANCER RES, V13, P912, DOI 10.1158/1078-0432.CCR-06-1577
   Ma GF, 2015, INT J CLIN EXP PATHO, V8, P13284
   Mahon PC, 2007, CANCER RES, V67, P6786, DOI 10.1158/0008-5472.CAN-07-0440
   Marjaneh RM, 2019, J CELL PHYSIOL, V234, P2306, DOI 10.1002/jcp.27221
   Mencía N, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-250
   Meng M, 2019, ONCOTARGETS THER, V12, P8675, DOI 10.2147/OTT.S225248
   Mersch S, 2016, TUMOR BIOL, V37, P2341, DOI 10.1007/s13277-015-4050-6
   Mohan M, 2020, BRIT J HAEMATOL, V189, P67, DOI 10.1111/bjh.16292
   MOORE BW, 1965, BIOCHEM BIOPH RES CO, V19, P739, DOI 10.1016/0006-291X(65)90320-7
   Mousavian Z, 2019, MOL MED, V25, DOI 10.1186/s10020-019-0106-1
   Mousavian Z, 2017, CELL ONCOL, V40, P33, DOI 10.1007/s13402-016-0303-7
   Mousses S, 2002, CANCER RES, V62, P1256
   Najafi M, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116781
   Nasser MW, 2015, CANCER LETT, V365, P11, DOI 10.1016/j.canlet.2015.05.002
   Nava M, 2019, BMC MED GENOMICS, V12, DOI 10.1186/s12920-019-0477-8
   Noye TM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19124122
   Nymoen DA, 2015, GYNECOL ONCOL, V139, P30, DOI 10.1016/j.ygyno.2015.07.107
   Olszewski U, 2010, LUNG CANCER-TARGETS, V1, P107, DOI 10.2147/LCTT.S12874
   Pan SG, 2020, INT J ONCOL, V56, P101, DOI 10.3892/ijo.2019.4907
   Paulitschke V, 2013, J PROTEOME RES, V12, P3264, DOI 10.1021/pr400124w
   Pedersen KB, 2004, BMC CANCER, V4, DOI 10.1186/1471-2407-4-52
   Prasmickaite L, 2018, MOL ONCOL, V12, P1540, DOI 10.1002/1878-0261.12319
   Prieto D, 2017, BLOOD, V130, P777, DOI 10.1182/blood-2017-02-769851
   Qian JF, 2016, ONCOL LETT, V11, P1113, DOI 10.3892/ol.2015.3984
   Raffat MA, 2018, CLIN CHIM ACTA, V480, P143, DOI 10.1016/j.cca.2018.02.013
   Rocha CRR, 2018, CLINICS, V73
   Ren XF, 2015, EUR REV MED PHARMACO, V19, P1182
   Russi S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20153736
   Saiki Y, 2019, PATHOL INT, V69, P629, DOI 10.1111/pin.12861
   Schenten V, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00447
   Schmidt WM, 2004, INT J CANCER, V112, P200, DOI 10.1002/ijc.20401
   Seubwai W, 2012, ASIAN PAC J CANCER P, V13, P53, DOI 10.7314/APJCP.2012.13.KKSuppl.53
   Shiota M, 2011, BJU INT, V107, P1148, DOI 10.1111/j.1464-410X.2010.09535.x
   Shyu RY, 2003, J BIOMED SCI, V10, P313, DOI 10.1159/000070096
   Simon MA, 2020, FEBS J, V287, P2834, DOI 10.1111/febs.15175
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Song H, 2018, MED SCI MONITOR, V24, P3002, DOI 10.12659/MSM.910084
   Spijkers-Hagelstein JAP, 2013, LEUKEMIA, V27, P1063, DOI 10.1038/leu.2012.372
   Spijkers-Hagelstein JAP, 2012, LEUKEMIA, V26, P1255, DOI 10.1038/leu.2011.388
   Stewart HJS, 2018, BONE MARROW RES, DOI 10.1155/2018/5742954
   Suzuki S, 2014, PROTEOME SCI, V12, DOI 10.1186/1477-5956-12-26
   Suzuki S, 2011, PROTEOME SCI, V9, DOI 10.1186/1477-5956-9-76
   Szczepanek J, 2012, ANTICANCER RES, V32, P503
   Takashima Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111312
   Tamai H, 2017, CANCER RES, V77, P4426, DOI 10.1158/0008-5472.CAN-16-2974
   Tang H, 2007, ANTI-CANCER DRUG, V18, P633, DOI 10.1097/CAD.0b013e3280200428
   Tang Y, 2009, PROSTATE, V69, P1763, DOI 10.1002/pros.21026
   Terai H, 2015, INT J ONCOL, V46, P430, DOI 10.3892/ijo.2014.2733
   Tomiyama N, 2018, ONCOL LETT, V15, P9929, DOI 10.3892/ol.2018.8568
   Tran KB, 2020, CURR PHARM DESIGN, V26, P396, DOI 10.2174/1381612826666200130091318
   Wang CJ, 2019, CANCER MANAG RES, V11, P2449, DOI 10.2147/CMAR.S196450
   Wang LZ, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0592-3
   Wang Q, 2008, CANCER LETT, V272, P277, DOI 10.1016/j.canlet.2008.07.017
   Wang T, 2020, BIOCHEM BIOPH RES CO, V522, P763, DOI 10.1016/j.bbrc.2019.11.162
   Wang T, 2018, CLIN CHIM ACTA, V476, P54, DOI 10.1016/j.cca.2017.11.010
   Wang XJ, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-58534-1
   Wang YY, 2017, ONCOTARGET, V8, P23564, DOI 10.18632/oncotarget.15797
   Wen Z., 2014, THESIS
   Wu W J, 2016, Zhonghua Fu Chan Ke Za Zhi, V51, P515, DOI 10.3760/cma.j.issn.0529-567X.2016.07.007
   Wu YS, 2019, CLIN CHIM ACTA, V495, P417, DOI 10.1016/j.cca.2019.05.015
   Xia C, 2018, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01908
   Xia SJ, 2020, EBIOMEDICINE, V51, DOI 10.1016/j.ebiom.2019.102610
   Xiang QM, 2019, CANCER MANAG RES, V11, P8855, DOI 10.2147/CMAR.S185124
   Xiao X, 2020, CLIN CHIM ACTA, V502, P293, DOI 10.1016/j.cca.2019.11.019
   Xiong TF, 2019, MELANOMA RES, V29, P23, DOI 10.1097/CMR.0000000000000512
   Xu F, 2020, CANCER SCI, V111, P1528, DOI 10.1111/cas.14356
   Xu YZ, 2019, MED SCI MONITOR, V25, P7026, DOI 10.12659/MSM.916260
   Yang LC, 2012, INT J MOL MED, V29, P65, DOI 10.3892/ijmm.2011.806
   Yang L, 2020, ONCOL LETT, V19, P83, DOI 10.3892/ol.2019.11083
   Yang T, 2018, ONCOL REP, V40, P1574, DOI 10.3892/or.2018.6527
   Yang T, 2017, STEM CELLS, V35, P325, DOI 10.1002/stem.2472
   Yang WS, 2012, J PROTEOME RES, V11, P1078, DOI 10.1021/pr2008187
   Yang XY, 2016, ONCOTARGETS THER, V9, P4887, DOI 10.2147/OTT.S101594
   Yuan TM, 2014, ONCOL REP, V32, P2307, DOI 10.3892/or.2014.3540
   Zagryazhskaya A, 2015, ONCOTARGET, V6, P12156, DOI 10.18632/oncotarget.3495
   Zeng SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184504
   Zha H, 2016, ONCOL REP, V36, P279, DOI 10.3892/or.2016.4790
   Zhang HB, 2020, MED SCI MONITOR, V26, DOI 10.12659/MSM.919757
   Zhang YW, 2014, EPIGENETICS-US, V9, P896, DOI 10.4161/epi.28601
   Zhao CC, 2018, CANCER MANAG RES, V10, P3753, DOI 10.2147/CMAR.S168276
   Zhao XM, 2013, CANCER BIOMARK, V13, P1, DOI 10.3233/CBM-130330
   Zheng X, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.264
   Zhou CH, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3144
   Zhou X, 2018, MOL MED REP, V17, P7209, DOI 10.3892/mmr.2018.8790
   Zhou ZY, 2016, SCI REP-UK, V6, DOI 10.1038/srep23695
   Zhu H, 2013, INT J CANCER, V132, P1051, DOI 10.1002/ijc.27764
   Zhu H, 2009, J PROTEOME RES, V8, P3969, DOI 10.1021/pr900287a
   Zhu S, 2019, AGING-US, V11, P12754, DOI 10.18632/aging.102600
NR 176
TC 39
Z9 41
U1 0
U2 9
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD JUL
PY 2020
VL 127
AR 110156
DI 10.1016/j.biopha.2020.110156
PG 14
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA MC7WW
UT WOS:000543493200047
PM 32335300
OA gold
DA 2025-01-04
ER

PT J
AU Yosef, HK
   Mavarani, L
   Maghnouj, A
   Hahn, S
   El-Mashtoly, SF
   Gerwert, K
AF Yosef, Hesham K.
   Mavarani, Laven
   Maghnouj, Abdelouahid
   Hahn, Stephan
   El-Mashtoly, Samir F.
   Gerwert, Klaus
TI In vitro prediction of the efficacy of molecularly targeted cancer
   therapy by Raman spectral imaging
SO ANALYTICAL AND BIOANALYTICAL CHEMISTRY
LA English
DT Article
DE Raman imaging; Erlotinib; Oncogenic mutation; BRAF; KRAS; Colon cancer
ID MEDIATED APOPTOSIS; KINASE INHIBITORS; COLORECTAL-CANCER; MUTATION
   STATUS; LIPID DROPLETS; KRAS MUTATIONS; MOUSE MODELS; LIVE CELLS;
   ERLOTINIB; RAS
AB Mutational acquired resistance is a major challenge in cancer therapy. Somatic tumours harbouring some oncogenic mutations are characterised by a high mortality rate. Surprisingly, preclinical evaluation methods do not show clearly resistance of mutated cancers to some drugs. Here, we implemented Raman spectral imaging to investigate the oncogenic mutation resistance to epidermal growth factor receptor targeting therapy. Colon cancer cells with and without oncogenic mutations such as KRAS and BRAF mutations were treated with erlotinib, an inhibitor of epidermal growth factor receptor, in order to detect the impact of these mutations on Raman spectra of the cells. Clinical studies suggested that oncogenic KRAS and BRAF mutations inhibit the response to erlotinib therapy in patients, but this effect is not observed in vitro. The Raman results indicate that erlotinib induces large spectral changes in SW-48 cells that harbour wild-type KRAS and BRAF. These spectral changes can be used as a marker of response to therapy. HT-29 cells (BRAF mutated) and SW-480 cells (KRAS mutated) display a smaller and no significant response, respectively. However, the erlotinib effect on these cells is not observed when phosphorylation of extracellular-signal-regulated kinase and AKT is monitored by Western blot, where this phosphorylation is the conventional in vitro test. Lipid droplets show a large response to erlotinib only in the case of cells harbouring wild-type KRAS and BRAF, as indicated by Raman difference spectra. This study shows the great potential of Raman spectral imaging as an in vitro tool for detecting mutational drug resistance.
C1 [Yosef, Hesham K.; Mavarani, Laven; El-Mashtoly, Samir F.; Gerwert, Klaus] Ruhr Univ Bochum, Dept Biophys, D-44780 Bochum, Germany.
   [Maghnouj, Abdelouahid; Hahn, Stephan] Ruhr Univ Bochum, Dept Mol GI Oncol, Clin Res Ctr, D-44780 Bochum, Germany.
C3 Ruhr University Bochum; Ruhr University Bochum
RP Gerwert, K (corresponding author), Ruhr Univ Bochum, Dept Biophys, Univ Str 150, D-44780 Bochum, Germany.
EM gerwert@bph.rub.de
RI Yosef, Hesham/AAN-2588-2021; Gerwert, Klaus/G-7311-2015; El-Mashtoly,
   Samir/C-8761-2014; Hahn, Stephan/E-3880-2010
OI El-Mashtoly, Samir/0000-0001-6087-8817; Yosef, Hesham
   K./0000-0002-2385-0046; Hahn, Stephan/0000-0003-0855-9741; Mavarani,
   Laven/0000-0001-7414-0899
FU Protein Research Unit Ruhr Within Europe (PURE); Ministry of Innovation,
   Science and Research (MIWF) of North Rhine-Westphalia, Germany; Center
   for Vibrational Microscopy; European Regional Development Fund; European
   Union; North Rhine-Westphalia, Germany; Deutsche Forschungsgemeinschaft
   [SFB 642]; Konrad Adenauer Foundation
FX We thank Carsten Kotting for helpful discussions. We also thank Dennis
   Petersen for his assistance in the PCA. This study was supported by the
   Protein Research Unit Ruhr Within Europe (PURE), the Ministry of
   Innovation, Science and Research (MIWF) of North Rhine-Westphalia,
   Germany, and the Center for Vibrational Microscopy, European Regional
   Development Fund, the European Union, and North Rhine-Westphalia,
   Germany, and the Deutsche Forschungsgemeinschaft under grant number: SFB
   642. This study was also supported by a fellowship to H.K.Y. from the
   Konrad Adenauer Foundation.
CR Adjei AA, 2001, JNCI-J NATL CANCER I, V93, P1062, DOI 10.1093/jnci/93.14.1062
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Ali S, 2008, MOL CANCER THER, V7, P1708, DOI 10.1158/1535-7163.MCT-08-0354
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], 2014, WORLD CANC REPORT 20
   Arrington AK, 2012, INT J MOL SCI, V13, P12153, DOI 10.3390/ijms131012153
   Bamford S, 2004, BRIT J CANCER, V91, P355, DOI 10.1038/sj.bjc.6601894
   Becher OJ, 2006, CANCER RES, V66, P3355, DOI 10.1158/0008-5472.CAN-05-3827
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0
   Bonnier F, 2010, ANALYST, V135, P3169, DOI 10.1039/c0an00539h
   Borràs E, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-406
   BOS JL, 1989, CANCER RES, V49, P4682
   Brugger W, 2011, J CLIN ONCOL, V29, P4113, DOI 10.1200/JCO.2010.31.8162
   Buck E, 2006, MOL CANCER THER, V5, P2051, DOI 10.1158/1535-7163.MCT-06-0007
   Chong H, 2003, CELL SIGNAL, V15, P463, DOI 10.1016/S0898-6568(02)00139-0
   Citri A, 2006, NAT REV MOL CELL BIO, V7, P505, DOI 10.1038/nrm1962
   Cox Adrienne D, 2010, Small GTPases, V1, P2
   Czejka M, 2013, CASE REP ONCOL, V6, P602, DOI 10.1159/000357211
   Diem M., 2008, VIBRATIONAL SPECTROS
   Doherty KR, 2013, TOXICOL APPL PHARM, V272, P245, DOI 10.1016/j.taap.2013.04.027
   Dorney J, 2012, ANALYST, V137, P1111, DOI 10.1039/c2an15977e
   Dowell J, 2005, NAT REV DRUG DISCOV, V4, P13, DOI 10.1038/nrd1612
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Draux F, 2010, ANAL BIOANAL CHEM, V397, P2727, DOI 10.1007/s00216-010-3759-8
   Duckett DR, 2010, EXPERT OPIN DRUG MET, V6, P1175, DOI 10.1517/17425255.2010.506873
   Eklöf V, 2013, BRIT J CANCER, V108, P2153, DOI 10.1038/bjc.2013.212
   El-Mashtoly SF, 2014, BIOPHYS J, V106, P1910, DOI 10.1016/j.bpj.2014.03.025
   El-Mashtoly SF, 2014, ANALYST, V139, P1155, DOI 10.1039/c3an01993d
   Endres NF, 2013, CELL, V152, P543, DOI 10.1016/j.cell.2012.12.032
   Fujimoto K, 2001, EXP CELL RES, V266, P239, DOI 10.1006/excr.2000.5229
   Goel S, 2007, J EXP THER ONCOL, V6, P305
   Hülsmann HJ, 2014, LUNG CANCER, V86, P151, DOI 10.1016/j.lungcan.2014.09.001
   Huether A, 2005, J HEPATOL, V43, P661, DOI 10.1016/j.jhep.2005.02.040
   Kalady MF, 2012, DIS COLON RECTUM, V55, P128, DOI 10.1097/DCR.0b013e31823c08b3
   Kan ZY, 2010, NATURE, V466, P869, DOI 10.1038/nature09208
   Klein K, 2012, BIOPHYS J, V102, P360, DOI 10.1016/j.bpj.2011.12.027
   Krafft C, 2006, ANAL CHEM, V78, P4424, DOI 10.1021/ac060205b
   Krafft C, 2008, J BIOPHOTONICS, V1, P154, DOI 10.1002/jbio.200710005
   Krauss SD, 2015, ANALYST, V140, P2360, DOI 10.1039/c4an02153c
   Kucherlapati R, 2012, CLIN CANCER RES, V18, P625, DOI 10.1158/1078-0432.CCR-11-2021
   Leicht DT, 2007, BBA-MOL CELL RES, V1773, P1196, DOI 10.1016/j.bbamcr.2007.05.001
   Ling J, 2002, APPL OPTICS, V41, P6006, DOI 10.1364/AO.41.006006
   Ling YH, 2008, MOL PHARMACOL, V74, P793, DOI 10.1124/mol.107.044396
   Marchetti A, 2009, NEOPLASIA, V11, P1084, DOI 10.1593/neo.09814
   Matthäus C, 2007, BIOPHYS J, V93, P668, DOI 10.1529/biophysj.106.102061
   Mavarani L, 2013, ANALYST, V138, P4035, DOI 10.1039/c3an00370a
   Meister K, 2010, ANGEW CHEM INT EDIT, V49, P3310, DOI 10.1002/anie.201000097
   Nawaz H, 2013, ANALYST, V138, P6177, DOI 10.1039/c3an00975k
   Nawaz H, 2011, ANALYST, V136, P2450, DOI 10.1039/c1an15104e
   Nawaz H, 2010, ANALYST, V135, P3070, DOI 10.1039/c0an00541j
   Notingher I, 2004, BIOSENS BIOELECTRON, V20, P780, DOI 10.1016/j.bios.2004.04.008
   Notingher I, 2006, EXPERT REV MED DEVIC, V3, P215, DOI 10.1586/17434440.3.2.215
   Oliveira C, 2007, ONCOGENE, V26, P158, DOI 10.1038/sj.onc.1209758
   Oxnard GR, 2014, CLIN CANCER RES, V20, P1698, DOI 10.1158/1078-0432.CCR-13-2482
   Palonpon AF, 2013, CURR OPIN CHEM BIOL, V17, P708, DOI 10.1016/j.cbpa.2013.05.021
   Parsons BL, 2013, PERS MED, V10, P191, DOI 10.2217/PME.13.1
   Phipps AI, 2013, BRIT J CANCER, V108, P1757, DOI 10.1038/bjc.2013.118
   Popp J, 2011, HDB BIOPHOTONICS, V2
   Qi WT, 2013, J BIOL CHEM, V288, P16274, DOI 10.1074/jbc.M113.470617
   Rak S, 2014, ANALYST, V139, P3407, DOI 10.1039/c4an00412d
   Raponi M, 2008, CURR OPIN PHARMACOL, V8, P413, DOI 10.1016/j.coph.2008.06.006
   Repasky GA, 2004, TRENDS CELL BIOL, V14, P639, DOI 10.1016/j.tcb.2004.09.014
   Salzer R., 2009, Infrared and Raman spectroscopic imaging
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Siegel-Lakhai WS, 2005, ONCOLOGIST, V10, P579, DOI 10.1634/theoncologist.10-8-579
   Singh M, 2006, CLIN CANCER RES, V12, P5312, DOI 10.1158/1078-0432.CCR-06-0437
   Sumimoto H, 2004, ONCOGENE, V23, P6031, DOI 10.1038/sj.onc.1207812
   Tang PA, 2006, EXPERT OPIN PHARMACO, V7, P177, DOI 10.1517/14656566.7.2.177
   Tirinato L, 2015, STEM CELLS, V33, P35, DOI 10.1002/stem.1837
   Townsley CA, 2006, BRIT J CANCER, V94, P1136, DOI 10.1038/sj.bjc.6603055
   Ulivi P, 2015, INT J MOL SCI, V16, P747, DOI 10.3390/ijms16010747
   Vartanian S, 2013, J BIOL CHEM, V288, P2403, DOI 10.1074/jbc.M112.394130
   Welte MA, 2007, TRENDS CELL BIOL, V17, P363, DOI 10.1016/j.tcb.2007.06.004
   Yeh JJ, 2009, MOL CANCER THER, V8, P834, DOI 10.1158/1535-7163.MCT-08-0972
   Zebisch A, 2006, CELL MOL LIFE SCI, V63, P1314, DOI 10.1007/s00018-006-6005-y
   Zhang JM, 2009, NAT REV CANCER, V9, P28, DOI 10.1038/nrc2559
   Zips D, 2005, IN VIVO, V19, P1
NR 78
TC 28
Z9 28
U1 1
U2 38
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 1618-2642
EI 1618-2650
J9 ANAL BIOANAL CHEM
JI Anal. Bioanal. Chem.
PD NOV
PY 2015
VL 407
IS 27
BP 8321
EP 8331
DI 10.1007/s00216-015-8875-z
PG 11
WC Biochemical Research Methods; Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA CT7DN
UT WOS:000362974100018
PM 26168967
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Rudiman, R
   Wijaya, A
   Sribudiani, Y
   Soedjana, HS
   Wiraswati, HL
   Pramaswati, E
   Nugraha, P
   Lukman, K
AF Rudiman, Reno
   Wijaya, Alma
   Sribudiani, Yunia
   Soedjana, Hardi Siswo
   Wiraswati, Hesti Lina
   Pramaswati, Etis
   Nugraha, Prapanca
   Lukman, Kiki
TI Identification of KRAS mutation and HER2 expression in Indonesian
   colorectal cancer population: a cross-sectional study
SO ANNALS OF MEDICINE AND SURGERY
LA English
DT Article
DE colorectal cancer; epidermal growth factor receptor; human epidermal
   growth factor receptor-2; Kirsten rat sarcoma virus
ID COLON
AB Background:In Indonesia, colorectal cancer is the third most common type. In 2008, Indonesia ranked fourth in the Association of Southeast Asian Nations (ASEAN) countries, with an incidence rate of 17.2 per 100 000 population. This figure is predicted to continue to increase from year to year. In 30% of colorectal cancer patients diagnosed after metastases, some patients will develop metastases after undergoing surgical resection of the primary tumor. The survival of metastatic colorectal cancer patients has improved significantly in the last 20 years with the introduction of target-oriented drugs, anti-epidermal growth factor receptor (EGFR), and anti-human epidermal growth factor receptor-2 (HER2). This study aims to assess the relationship between Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation and HER2 expression for targeted therapy implementation. Patients and methods:This research is a cross-sectional study. The research subjects in this study were colorectal cancer patients in the digestive surgery division. There were 58 study subjects. Examination of KRAS mutations was carried out by PCR on fresh tumor tissue obtained from surgery or colonoscopy. Meanwhile, the HER2 examination used the immunohistochemistry method of paraffin blocks for anatomical pathology examination. Results:Examination of KRAS mutations showed 28/58 (43.8%) patients with colorectal cancer, while HER2 overexpression was found in 6/58 (10.3%) patients with colorectal cancer. Univariate analysis of KRAS mutations and HER2 expression showed that four subjects with KRAS mutations had excess HER2 expression (P=0.341). Conclusion:There is no association between KRAS mutations and HER2 overexpression in colorectal cancer patients.
C1 [Rudiman, Reno; Wijaya, Alma; Soedjana, Hardi Siswo; Nugraha, Prapanca; Lukman, Kiki] Padjadjaran State Univ, Dr Hasan Sadikin Gen Hosp, Fac Med, Dept Surg, Bandung, Indonesia.
   [Pramaswati, Etis] Padjadjaran State Univ, Dr Hasan Sadikin Gen Hosp, Fac Med, Dept Pathol Anat, Bandung, Indonesia.
   [Sribudiani, Yunia; Wiraswati, Hesti Lina] Padjadjaran State Univ, Fac Med, Dept Basic Med Sci, Bandung, Indonesia.
   [Lukman, Kiki] Univ Padjadjaran, Dr Hasan Sadikin Gen Hosp, Fac Med, Dept Surg, Bandung, Indonesia.
   [Lukman, Kiki] Univ Padjadjaran, Jalan Pasteur 38, Kota Bandung 40161, Jawa Barat, Indonesia.
C3 Dr Hasan Sadikin General Hospital; Universitas Padjadjaran; Dr Hasan
   Sadikin General Hospital; Universitas Padjadjaran; Universitas
   Padjadjaran; Universitas Padjadjaran; Dr Hasan Sadikin General Hospital;
   Universitas Padjadjaran
RP Lukman, K (corresponding author), Univ Padjadjaran, Dr Hasan Sadikin Gen Hosp, Fac Med, Dept Surg, Bandung, Indonesia.; Lukman, K (corresponding author), Univ Padjadjaran, Jalan Pasteur 38, Kota Bandung 40161, Jawa Barat, Indonesia.
EM rudiman@unpad.ac.id; almawijaya@yahoo.com; y.sribudiani@unpad.ac.id;
   hardisiswo.soedjana5@gmail.com; hesti.lina@unpad.ac.id;
   prapanca18001@mail.unpad.ac.id; kiki.lukman@unpad.ac.id
RI WIRASWATI, HESTI/JHT-2606-2023; Rudiman, Reno/GLU-0014-2022; Lukman,
   Kiki/HRD-3369-2023; Sribudiani, Yunia/I-2972-2019
OI nugraha, prapanca/0000-0001-9701-342X; Sribudiani,
   Yunia/0000-0003-1985-3292; Lukman, Kiki/0000-0002-9551-0972; Rudiman,
   Reno/0000-0001-6826-6313
CR Razzaq EAA, 2021, LIBYAN J MED, V16, DOI 10.1080/19932820.2021.1955462
   Abdullah Murdani, 2012, Gastroenterol Hepatol Bed Bench, V5, P71
   Agha R, 2019, INT J SURG, V72, P156, DOI 10.1016/j.ijsu.2019.11.002
   Ahcene Djaballah Selma, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_351354
   Alghamdi M, 2022, CUREUS J MED SCIENCE, V14, DOI 10.7759/cureus.23656
   [Anonymous], 2020, Cancer Facts Figures 2020, P1
   [Anonymous], 2012, HERED CANCER CLIN PR
   Brand Toni M, 2012, Small GTPases, V3, P34, DOI 10.4161/sgtp.18751
   Bronte G, 2015, ONCOTARGET, V6, P24780, DOI 10.18632/oncotarget.4959
   Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006
   Dai DJ, 2020, PEERJ, V8, DOI 10.7717/peerj.9149
   Dinu D, 2014, J Med Life, V7, P581
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Fleming M, 2012, J GASTROINTEST ONCOL, V3, P153, DOI 10.3978/j.issn.2078-6891.2012.030
   Guarini C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136813
   Isik CB, 2020, ISTANB MED J, V21, P207, DOI 10.4274/imj.galenos.2020.56563
   Kamal LA., 2019, Zanco J Med Sci, V23, P421
   Kaur S., 2020, CUREUS J MED SCIENCE, V14, pe22811
   Kimman M, 2012, ASIAN PAC J CANCER P, V13, P411, DOI 10.7314/APJCP.2012.13.2.411
   Làszló L, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030667
   Lee WS, 2014, CANCER MED-US, V3, P674, DOI 10.1002/cam4.228
   Levi M, 2018, J GASTROINTEST CANC, V49, P124, DOI 10.1007/s12029-016-9901-x
   Martianov AS, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24054868
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   NEWMARK HL, 1984, JNCI-J NATL CANCER I, V72, P1323
   Ottaiano A., 2021, FRONT ONCOL, V11, P1
   Porru M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0719-1
   Purnama A., 2023, VITAMIN D DIAGNOSTIC
   Recio-Boiles A., 2021, StatPearls
   Ross JS, 2018, CANCER-AM CANCER SOC, V124, P1358, DOI 10.1002/cncr.31125
   Sawada K, 2018, CLIN COLORECTAL CANC, V17, P198, DOI 10.1016/j.clcc.2018.05.006
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100
   Sullivan Kevin M, 2011, Patholog Res Int, V2011, P219309, DOI 10.4061/2011/219309
   Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171
   Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98
   Vigil D, 2010, NAT REV CANCER, V10, P842, DOI 10.1038/nrc2960
   Zanatto RM, 2020, ABCD-ARQ BRAS CIR DI, V33, DOI 10.1590/0102-672020200003e1524
NR 38
TC 2
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2049-0801
J9 ANN MED SURG
JI Ann. Med. Surg.
PD MAY
PY 2023
VL 85
IS 5
BP 1761
EP 1768
DI 10.1097/MS9.0000000000000694
PG 8
WC Medicine, General & Internal
WE Emerging Sources Citation Index (ESCI)
SC General & Internal Medicine
GA H1RR2
UT WOS:000993809800067
PM 37228916
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Lwin, TM
   Minnix, M
   Li, L
   Sherman, A
   Hong, TRS
   Wong, JYC
   Olafsen, T
   Poku, E
   Bouvet, M
   Fong, Y
   Shively, JE
   Yazaki, PJ
AF Lwin, Thinzar M.
   Minnix, Megan
   Li, Lin
   Sherman, Anakim
   Hong, Teresa
   Wong, Jeffery Y. C.
   Olafsen, Tove
   Poku, Erasmus
   Bouvet, Michael
   Fong, Yuman
   Shively, John E.
   Yazaki, Paul J.
TI Multimodality PET and Near-Infrared Fluorescence Intraoperative Imaging
   of CEA-Positive Colorectal Cancer
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE Multimodality imaging; Anti-CEA; Antibody-dye conjugate
ID POSITRON-EMISSION-TOMOGRAPHY; GUIDED SURGERY; COLON-CANCER; ANTIBODY
AB PurposeMolecular imaging is a major diagnostic component for cancer management, enabling detection, staging of disease, targeting therapy, and monitoring the therapeutic response. The coordination of multimodality imaging techniques further enhances tumor localization. The development of a single agent for real-time non-invasive targeted positron emission tomography (PET) imaging and fluorescence guided surgery (FGS) will provide the next generation tool in the surgical management of cancer.ProceduresThe humanized anti-CEA M5A-IR800 "sidewinder" (M5A-IR800-SW) antibody-dye conjugate was designed with a NIR 800 nm dye incorporated into a PEGylated linker and conjugated with the metal chelate p-SCN-Bn-deferoxamine (DFO) for zirconium-89 PET imaging (Zr-89, half-life 78.4 h). The dual-labeled Zr-89-DFO-M5A-SW-IR800 was evaluated for near infrared (NIR) fluorescence imaging, PET/MRI imaging, terminal tissue biodistribution, and blood clearance in a human colorectal cancer LS174T xenograft mouse model.ResultsThe Zr-89-DFO-M5A-SW-IR800 NIR fluorescence imaging showed high tumor targeting with normal liver uptake. Serial PET/MRI imaging was performed at 24 h, 48 h, and 72 h and showed tumor localization visible at 24 h that persisted throughout the experiment. However, the PET scans showed higher activity for the liver than the tumor, compared to the NIR fluorescence imaging. This difference is an important finding as it quantifies the expected difference due to the sensitivity and depth of penetration between the 2 modalities.ConclusionsThis study demonstrates the potential of a pegylated anti-CEA M5A-IR800-Sidewinder for NIR fluorescence/PET/MR multimodality imaging for intraoperative fluorescence guided surgery.
C1 [Lwin, Thinzar M.; Fong, Yuman] City Hope Natl Med Ctr, Dept Surg, Natl Med Ctr, Duarte, CA USA.
   [Minnix, Megan; Li, Lin; Sherman, Anakim; Hong, Teresa; Shively, John E.; Yazaki, Paul J.] City Hope Natl Med Ctr, Beckman Res Inst, Dept Immunol & Theranost, 1500 Duarte Rd, Duarte, CA 91010 USA.
   [Wong, Jeffery Y. C.] City Hope Natl Med Ctr, Dept Radiat Oncol, Natl Med Ctr, Duarte, CA 91010 USA.
   [Olafsen, Tove] City Hope Natl Med Ctr, Beckman Res Inst, Small Anim Imaging Core, Duarte, CA 91010 USA.
   [Poku, Erasmus] City Hope Natl Med Ctr, Beckman Res Inst, Radiopharm, Duarte, CA 91010 USA.
   [Bouvet, Michael] Univ Calif San Diego, Dept Surg, La Jolla, CA USA.
   [Bouvet, Michael] VA San Diego Healthcare Syst, La Jolla, CA USA.
C3 City of Hope; City of Hope; Beckman Research Institute of City of Hope;
   City of Hope; City of Hope; Beckman Research Institute of City of Hope;
   City of Hope; Beckman Research Institute of City of Hope; University of
   California System; University of California San Diego; US Department of
   Veterans Affairs; Veterans Health Administration (VHA); VA San Diego
   Healthcare System
RP Yazaki, PJ (corresponding author), City Hope Natl Med Ctr, Beckman Res Inst, Dept Immunol & Theranost, 1500 Duarte Rd, Duarte, CA 91010 USA.
EM pyazaki@coh.org
FU NIH Cancer Center [P30CA033572]
FX Open access funding provided by SCELC, Statewide California Electronic
   Library Consortium This work was partially funded by the NIH Cancer
   Center support grant P30CA033572.
CR An FF, 2016, AM J ROENTGENOL, V207, P266, DOI 10.2214/AJR.16.16181
   Azhdarinia A, 2012, MOL IMAGING BIOL, V14, P261, DOI 10.1007/s11307-011-0528-9
   Bugby SL, 2017, CLIN TRANSL IMAGING, V5, P323, DOI 10.1007/s40336-017-0235-x
   de Valk KS, 2021, ANN SURG ONCOL, V28, P1832, DOI 10.1245/s10434-020-09069-2
   DeLong JC, 2017, J SURG RES, V218, P139, DOI 10.1016/j.jss.2017.05.069
   Eigenmann MJ, 2017, MABS-AUSTIN, V9, P1007, DOI 10.1080/19420862.2017.1337619
   Farnam RW, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.6.066004
   Frangioni JV, 2003, CURR OPIN CHEM BIOL, V7, P626, DOI 10.1016/j.cbpa.2003.08.007
   Galema HA, 2022, EJSO-EUR J SURG ONC, V48, P810, DOI 10.1016/j.ejso.2021.10.005
   Ghosh SC, 2015, CURR MED CHEM, V22, P3390, DOI 10.2174/0929867322666150904111214
   Hague A, 2017, BIOORGAN MED CHEM, V25, P2017, DOI 10.1016/j.bmc.2017.02.061
   Hekman MC, 2018, THERANOSTICS, V8, P2161, DOI 10.7150/thno.23335
   Hollandsworth HM, 2021, SURG ONCOL, V36, P84, DOI 10.1016/j.suronc.2020.11.018
   Hong H, 2012, MOL PHARMACEUT, V9, P2339, DOI 10.1021/mp300277f
   Vaquero JJ, 2015, ANNU REV BIOMED ENG, V17, P385, DOI 10.1146/annurev-bioeng-071114-040723
   Kujawski M, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6056-8
   Li L, 2008, BIOCONJUGATE CHEM, V19, P89, DOI 10.1021/bc700161p
   Loening Andreas Markus, 2003, Mol Imaging, V2, P131, DOI 10.1162/153535003322556877
   Lwin Thinzar M, 2018, Oncotarget, V9, P37333, DOI 10.18632/oncotarget.26484
   Lwin TM, 2018, ANN SURG ONCOL, V25, P1079, DOI 10.1245/s10434-018-6344-6
   Martí-Bonmatí L, 2010, CONTRAST MEDIA MOL I, V5, P180, DOI 10.1002/cmmi.393
   Metildi CA, 2013, J SURG RES, V179, P87, DOI 10.1016/j.jss.2012.08.052
   Rijpkema M, 2015, MOL IMAGING, V14, P348, DOI 10.2310/7290.2015.00015
   Shukla AK, 2006, J MED PHYS, V31, P13, DOI 10.4103/0971-6203.25665
   Vargas SH, 2019, J NUCL MED, V60, P459, DOI 10.2967/jnumed.118.213488
   Yazaki PJ, 2019, J BIOMED OPT, V24, DOI 10.1117/1.JBO.24.6.066012
   Yazaki PJ, 2004, PROTEIN ENG DES SEL, V17, P481, DOI 10.1093/protein/gzh056
NR 27
TC 1
Z9 1
U1 3
U2 11
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1536-1632
EI 1860-2002
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD AUG
PY 2023
VL 25
IS 4
BP 727
EP 734
DI 10.1007/s11307-023-01831-8
EA JUN 2023
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Radiology, Nuclear Medicine & Medical Imaging
GA L2QY7
UT WOS:001013895300001
PM 37341873
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Fan, LQ
   Guo, XY
   Zhang, JY
   Wang, YJ
   Wang, JH
   Li, Y
AF Fan, Leqi
   Guo, Xiangyu
   Zhang, Jiyi
   Wang, Yuji
   Wang, Jinhui
   Li, Ye
TI Relationship between DHX15 expression and survival in colorectal cancer
SO REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS
LA English
DT Article
DE Colorectal cancer; DEAH-box RNA helicase 15; Clinical pathological
   features; Prognosis
AB Objective: to explore the relationship between the expres-sion of DEAH-box RNA helicase 15 (DHX15) in colorectal cancer (CRC), its clinical pathological features and survival.Method: DHX15 expression data with clinical pathological features from the Cancer Gene Atlas (TCGA) and the Clini-cal Proteomic Tumor Analysis Consortium (CPTAC) were sta-tistically analyzed for the association between DHX15 ex-pression and overall survival in CRC. The expression of DHX15 was performed by immunohistochemical staining (IHC) using tumor and the adjacent normal tissue, mounted in tissue microarrays. The significance of DHX15 expression to predict survival and prognosis of CRC were analyzed us-ing the Kaplan-Meier method, univariate and multivariate Cox regression analysis.Results: low expression of DHX15 mRNA and DHX15 protein in CRC were both negative factors for survival. Overall survival of patients with low-expression of DHX15 was significantly lower (x2 = 8.452, p = 0.004) by Kaplan-Meier evaluation. Low expression of DHX15 in CRC tissues correlated with distal lymph node metastasis (x2 = 7.120, p = 0.008), TNM stage (x2 = 3.935, p = 0.047) and disease recurrence (x2 = 9.524, p = 0.002) in CRC. Low expression of DHX15 (HR = 4.012, 95 % CI: 1.462-11.013, p = 0.007), late TNM stage (HR = 0.067, 95 % CI: 0.029-0.156, p < 0.001) and recurrence (HR = 0.008, 95 % CI: 0.002-0.034, p < 0.001) were risk factors related to the prognosis of CRC patients by univariate Cox regression analysis.Conclusion: our findings reveal a key role for DHX15 in the progress of CRC metastasis and recurrence. DHX15 may be a potential biomarker for CRC targeted therapy.
C1 [Fan, Leqi; Li, Ye] Capital Med Univ, Sch Pharmaceut Sci, Dept Pharmacol, Beijing, Peoples R China.
   [Guo, Xiangyu] Capital Med Univ, Sch Pharmaceut Sci, Dept Pharm, Beijing, Peoples R China.
   [Zhang, Jiyi; Wang, Yuji] Capital Med Univ, Sch Pharmaceut Sci, Dept Med Chem, Beijing, Peoples R China.
   [Wang, Jinhui] Harbin Med Univ, Sch Pharmaceut Sci, Harbin, Peoples R China.
C3 Capital Medical University; Capital Medical University; Capital Medical
   University; Harbin Medical University
RP Li, Y (corresponding author), Capital Med Univ, Sch Pharmaceut Sci, Dept Pharmacol, Beijing, Peoples R China.
EM liyer2011@sina.com
RI Tang, Zhicheng/H-2817-2018; Wang, Jinhui/AAS-7317-2021
FU National Science and Tech- nology Major Project of the Ministry of
   Science and Tech- nology of China [2018ZX09735005]; National Natural
   Science Foundation of China [82000807]; Natural Sci- ence Foundation of
   Beijing [7212148]; General Proj- ect of Scientific Research Program of
   Beijing Municipal Ed- ucation Commission [KM2018100250]
FX This study was supported by the National Science and Tech- nology Major
   Project of the Ministry of Science and Tech- nology of China
   (2018ZX09735005) , the National Natural Science Foundation of China
   (82000807) , the Natural Sci- ence Foundation of Beijing (7212148) and
   the General Proj- ect of Scientific Research Program of Beijing
   Municipal Ed- ucation Commission (KM2018100250) .
CR Detanico T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02903
   Hibino S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115421
   Ito S, 2017, BRIT J CANCER, V117, P1349, DOI 10.1038/bjc.2017.273
   Jing Y, 2018, ONCOGENE, V37, P638, DOI 10.1038/onc.2017.371
   Kim J, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.807648
   Mosallanejad K, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004841
   Pan LL, 2017, ONCOTARGET, V8, P89643, DOI 10.18632/oncotarget.20288
   Pellino G, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/2397863
   Ribera J, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02722-w
   Studer MK, 2020, P NATL ACAD SCI USA, V117, P7159, DOI 10.1073/pnas.1913880117
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Wang YL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2017432118
   Xing JJ, 2021, CELL REP, V35, DOI 10.1016/j.celrep.2021.109205
   Yao GD, 2019, MOL THER-NUCL ACIDS, V18, P831, DOI 10.1016/j.omtn.2019.09.028
   Zhao MM, 2021, FRONT MED-LAUSANNE, V7, DOI 10.3389/fmed.2020.591736
   Zong Z, 2020, J GASTROINTEST ONCOL, V11, P685, DOI 10.21037/jgo-20-117
NR 16
TC 2
Z9 2
U1 2
U2 4
PU ARAN EDICIONES, S A
PI MADRID
PA CASTELLO, 128, 28006 MADRID, SPAIN
SN 1130-0108
EI 2340-4167
J9 REV ESP ENFERM DIG
JI Rev. Esp. Enferm. Dig.
PY 2023
VL 115
IS 5
BP 234
EP 240
DI 10.17235/reed.2022.8838/2022
PG 7
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA H4DD6
UT WOS:000995478100004
PM 36177832
OA gold
DA 2025-01-04
ER

PT J
AU Dujardin, PA
   Léger, J
   Lecomte, T
   Patat, F
   Chassagnon, G
   Bleuzen, A
AF Dujardin, Paul-Armand
   Leger, Julie
   Lecomte, Thierry
   Patat, Frederic
   Chassagnon, Guillaume
   Bleuzen, Aurore
TI PERFUSION QUANTIFICATION OF LIVER METASTASES OF COLORECTAL CANCER
   TREATED WITH ANTI-ANGIOGENIC-BASED THERAPY: ASSESSMENT OF INTRA- AND
   INTER-OBSERVER REPRODUCIBILITY OF PARAMETERS IN THREE REGIONS OF
   INTEREST OUTLINING LESIONS
SO ULTRASOUND IN MEDICINE AND BIOLOGY
LA English
DT Article
DE Reproducibility; Colorectal cancer; Ultrasound; Quantification; Liver
   metastases
ID CONTRAST-ENHANCED ULTRASOUND; PREOPERATIVE CHEMOTHERAPY;
   COMPUTED-TOMOGRAPHY; RESPONSE EVALUATION; TARGETED THERAPY; TUMOR
   RESPONSE; BEVACIZUMAB; US; PREDICTION; BIOMARKER
AB This study evaluated the reproducibility of dynamic contrast-enhanced ultrasound (DCEUS) parameters outlining liver metastases of colorectal cancer in 45 patients, before and after anti-angiogenic-based therapy. Tumor enhancement was quantified by drawing three regions of interest (ROIs): (i) outlining the tumor based on portal phase DCEUS images, (ii) in the hypo-enhanced center of the lesion and (iii) outlining the lesion using parametric imaging. Perfusion parameters were extracted from time-intensity curves. Another ROI was drawn in healthy liver parenchyma for normalization. Intra- and inter-observer reproducibility of these parameters was evaluated using intra-class correlation coefficients (ICCs). For the three ROIs, both intra- and inter-observer reproducibility were excellent (ICCs >= 0.9) for 50.8% absolute parameters and were moderate to good (0.7 <= ICC < 0.9) for 26.7% of them. In healthy liver parenchyma and for normalized parameters, reproducibility was moderate to excellent for 59.4% of intensity parameters and was low (ICC <0.7) for almost all temporal parameters. This study indicates that DCEUS is a reproducible tool for evaluating perfusion parameters. (C) 2019 World Federation for Ultrasound in Medicine & Biology. All rights reserved.
C1 [Dujardin, Paul-Armand; Leger, Julie; Patat, Frederic; Chassagnon, Guillaume; Bleuzen, Aurore] CHU Tours, INSERM, CIC 1415, Tours, France.
   [Lecomte, Thierry] CHRU Tours, Dept Hepatogastroenterol & Digest Oncol, F-37044 Tours, France.
   [Lecomte, Thierry] Tours Univ, EA 7501 GICC, Tours, France.
   [Patat, Frederic; Chassagnon, Guillaume; Bleuzen, Aurore] CHRU Tours, Grp Imagerie Med, F-37044 Tours, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm); CHU
   Tours; CHU Tours; CHU Tours
RP Dujardin, PA (corresponding author), CHU Tours, INSERM, CIC 1415, Tours, France.
EM paul-armand.dujardin@chu-tours.fr
RI Chassagnon, Guillaume/HKE-8735-2023; patat, frederic/LRU-5377-2024
OI LECOMTE, Thierry/0000-0001-5093-0212; Dujardin,
   Paul-Armand/0000-0002-4937-7920
CR Atri M, 2016, ULTRASOUND MED BIOL, V42, P763, DOI 10.1016/j.ultrasmedbio.2015.11.005
   Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049
   Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755
   Claudon M, 2013, ULTRASOUND MED BIOL, V39, P187, DOI 10.1016/j.ultrasmedbio.2012.09.002
   Coenegrachts K, 2012, EUR J RADIOL, V81, P3870, DOI 10.1016/j.ejrad.2012.07.022
   De Bruyne S, 2012, BRIT J CANCER, V106, P1926, DOI 10.1038/bjc.2012.184
   Desar IME, 2009, CANCER TREAT REV, V35, P309, DOI 10.1016/j.ctrv.2008.12.001
   Dietrich CF, 2012, ULTRASCHALL MED, V33, P344, DOI 10.1055/s-0032-1313026
   Dietrich CF, 2018, ULTRASOUND INT OPEN, V4, pE2, DOI 10.1055/s-0043-123931
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Gauthier M, 2011, WORLD J RADIOL, V3, P70, DOI 10.4329/wjr.v3.i3.70
   Goh V, 2008, RADIOLOGY, V247, P726, DOI 10.1148/radiol.2473070414
   Goh V, 2007, LANCET ONCOL, V8, P245, DOI 10.1016/S1470-2045(07)70075-X
   Grothey A, 2012, THER ADV MED ONCOL, V4, P301, DOI 10.1177/1758834012454464
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Konerding MA, 2001, BRIT J CANCER, V84, P1354, DOI 10.1054/bjoc.2001.1809
   Krajewski KM, 2011, EUR UROL, V59, P856, DOI 10.1016/j.eururo.2011.01.038
   Lassau N, 2016, ANN ONCOL, V27, P1922, DOI 10.1093/annonc/mdw280
   Lassau N, 2006, AM J ROENTGENOL, V187, P1267, DOI 10.2214/AJR.05.1192
   Lassau N, 2014, INVEST RADIOL, V49, P794, DOI 10.1097/RLI.0000000000000085
   Lassau N, 2011, RADIOLOGY, V258, P291, DOI 10.1148/radiol.10091870
   Lassau N, 2010, CLIN CANCER RES, V16, P1216, DOI 10.1158/1078-0432.CCR-09-2175
   Lyshchik A, 2018, ABDOM RADIOL, V43, P861, DOI 10.1007/s00261-017-1392-0
   Morgan B, 2003, J CLIN ONCOL, V21, P3955, DOI 10.1200/JCO.2003.08.092
   Payen T., 2011, 2011 IEEE International Ultrasonics Symposium (IUS), P1486, DOI 10.1109/ULTSYM.2011.0368
   R Core Team, 2016, R: A Language and Environment for Statistical Computing
   Schirin-Sokhan R, 2012, WORLD J GASTROENTERO, V18, P541, DOI 10.3748/wjg.v18.i6.541
   Shindoh J, 2012, J CLIN ONCOL, V30, P4566, DOI 10.1200/JCO.2012.45.2854
   Tranquart F, 2012, ULTRASCHALL MED, V33, pS31, DOI 10.1055/s-0032-1312894
   Tranquart F, 2018, ULTRASCHALL MED, V39, P544, DOI 10.1055/s-0043-122497
   Williams R, 2011, RADIOLOGY, V260, P581, DOI 10.1148/radiol.11101893
   Wu ZY, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000006731
NR 32
TC 2
Z9 3
U1 1
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 0301-5629
EI 1879-291X
J9 ULTRASOUND MED BIOL
JI Ultrasound Med. Biol.
PD FEB
PY 2020
VL 46
IS 2
BP 286
EP 296
DI 10.1016/j.ultrasmedbio.2019.10.011
PG 11
WC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Acoustics; Radiology, Nuclear Medicine & Medical Imaging
GA JX6GJ
UT WOS:000503830700010
PM 31753600
OA Green Published, Bronze
DA 2025-01-04
ER

PT J
AU Pádua, D
   Figueira, P
   Ribeiro, I
   Almeida, R
   Mesquita, P
AF Padua, Diana
   Figueira, Paula
   Ribeiro, Ines
   Almeida, Raquel
   Mesquita, Patricia
TI The Relevance of Transcription Factors in Gastric and Colorectal Cancer
   Stem Cells Identification and Eradication
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE gastric cancer; colorectal cancer; transcription factors; cancer stem
   cells; signaling pathways; targeted therapy
ID LYMPH-NODE METASTASIS; GAMMA-SECRETASE INHIBITOR; NOTCH SIGNALING
   PATHWAY; CLINICAL-PRACTICE GUIDELINES; KRUPPEL-LIKE FACTOR; P-MTOR
   EXPRESSION; COLON-CANCER; BETA-CATENIN; WNT PATHWAY; PHASE-II
AB Gastric and colorectal cancers have a high incidence and mortality worldwide. The presence of cancer stem cells (CSCs) within the tumor mass has been indicated as the main reason for tumor relapse, metastasis and therapy resistance, leading to poor overall survival. Thus, the elimination of CSCs became a crucial goal for cancer treatment. The identification of these cells has been performed by using cell-surface markers, a reliable approach, however it lacks specificity and usually differs among tumor type and in some cases even within the same type. In theory, the ideal CSC markers are those that are required to maintain their stemness features. The knowledge that CSCs exhibit characteristics comparable to normal stem cells that could be associated with the expression of similar transcription factors (TFs) including SOX2, OCT4, NANOG, KLF4 and c-Myc, and signaling pathways such as the Wnt/beta-catenin, Hedgehog (Hh), Notch and PI3K/AKT/mTOR directed the attention to the use of these similarities to identify and target CSCs in different tumor types. Several studies have demonstrated that the abnormal expression of some TFs and the dysregulation of signaling pathways are associated with tumorigenesis and CSC phenotype. The disclosure of common and appropriate biomarkers for CSCs will provide an incredible tool for cancer prognosis and treatment. Therefore, this review aims to gather the new insights in gastric and colorectal CSC identification specially by using TFs as biomarkers and divulge promising drugs that have been found and tested for targeting these cells.
C1 [Padua, Diana; Figueira, Paula; Ribeiro, Ines; Almeida, Raquel; Mesquita, Patricia] Univ Porto, i3S Inst Res & Innovat Hlth, Porto, Portugal.
   [Padua, Diana; Figueira, Paula; Ribeiro, Ines; Almeida, Raquel; Mesquita, Patricia] Univ Porto, Inst Mol Pathol & Immunol, Porto, Portugal.
   [Almeida, Raquel] Univ Porto, Fac Med, Porto, Portugal.
   [Almeida, Raquel] Univ Porto, Dept Biol, Fac Sci, Porto, Portugal.
C3 Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universidade do Porto; Universidade do
   Porto; Universidade do Porto
RP Mesquita, P (corresponding author), Univ Porto, i3S Inst Res & Innovat Hlth, Porto, Portugal.; Mesquita, P (corresponding author), Univ Porto, Inst Mol Pathol & Immunol, Porto, Portugal.
EM pmesquita@ipatimup.pt
RI ; Almeida, Raquel/B-9647-2012
OI Padua, Diana/0000-0002-5780-9842; Ribeiro, Ines/0000-0003-2647-8638;
   Mesquita, Patricia/0000-0002-4766-9831; Almeida,
   Raquel/0000-0002-5622-1633
FU FEDER - Fundo Europeu de Desenvolvimento Regional funds through the
   COMPETE 2020 - Operacional Programme for Competitiveness and
   Internationalisation (POCI), Portugal 2020; Portuguese funds through the
   FCT - Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia,
   Tecnologia e Inovacao [POCI-01-0145-FEDER-007274]; FCT
   [POCI-01-0145-FEDER-029017, POCI-01-0145-FEDER016390,
   SFRH/BD/146186/2019]; Fundação para a Ciência e a Tecnologia
   [SFRH/BD/146186/2019] Funding Source: FCT
FX This work was supported by the FEDER - Fundo Europeu de Desenvolvimento
   Regional funds through the COMPETE 2020 - Operacional Programme for
   Competitiveness and Internationalisation (POCI), Portugal 2020, and by
   Portuguese funds through the FCT - Fundacao para a Ciencia e a
   Tecnologia/Ministerio da Ciencia, Tecnologia e Inovacao in the framework
   of the project "Institute for Research and Innovation in Health
   Sciences" (POCI-01-0145-FEDER-007274); projects
   POCI-01-0145-FEDER-029017 and POCI-01-0145-FEDER016390 funded by FCT. DP
   acknowledges FCT for financial support through a Ph.D. fellowship
   (SFRH/BD/146186/2019).
CR Abbasian M, 2019, J CELL PHYSIOL, V234, P8192, DOI 10.1002/jcp.27619
   Abetov D, 2015, STEM CELL REV REP, V11, P909, DOI 10.1007/s12015-015-9612-x
   Akbari M, 2020, CELL BIOL INT, V44, P368, DOI 10.1002/cbin.11243
   Al-Batran SE, 2012, INT J CANCER, V130, P491, DOI 10.1002/ijc.26396
   Amini S, 2014, ANAT CELL BIOL, V47, P1, DOI 10.5115/acb.2014.47.1.1
   An JY, 2010, INT J CANCER, V126, P2904, DOI 10.1002/ijc.24872
   Avilion AA, 2003, GENE DEV, V17, P126, DOI 10.1101/gad.224503
   Badrinath N, 2019, CANCERS, V11, DOI 10.3390/cancers11030310
   Barat S, 2017, STEM CELL TRANSL MED, V6, P819, DOI 10.1002/sctm.16-0335
   Basati G, 2020, J GASTROINTEST CANC, V51, P41, DOI 10.1007/s12029-018-00200-x
   Bastide P, 2007, J CELL BIOL, V178, P635, DOI 10.1083/jcb.200704152
   Basu Sayon, 2016, F1000Res, V5, DOI 10.12688/f1000research.7579.1
   Behrens J, 1996, NATURE, V382, P638, DOI 10.1038/382638a0
   Bekaii-Saab T, 2017, CANCER-AM CANCER SOC, V123, P1303, DOI 10.1002/cncr.30538
   Bendel JC, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3529
   Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800
   Boesch M, 2018, STEM CELL TRANSL MED, V7, P495, DOI 10.1002/sctm.17-0289
   Brabletz T, 2005, NAT REV CANCER, V5, P744, DOI 10.1038/nrc1694
   Bretones G, 2015, BBA-GENE REGUL MECH, V1849, P506, DOI 10.1016/j.bbagrm.2014.03.013
   Brungs D, 2016, J GASTROENTEROL, V51, P313, DOI 10.1007/s00535-015-1125-5
   Brunner TB, 2012, SEMIN RADIAT ONCOL, V22, P151, DOI 10.1016/j.semradonc.2011.12.003
   Brzozowa M, 2013, WSPOLCZESNA ONKOL, V17, P1, DOI 10.5114/wo.2013.33765
   Buczek ME, 2018, METHODS MOL BIOL, V1692, P139, DOI 10.1007/978-1-4939-7401-6_13
   Camilo V, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-753
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Carmon KS, 2012, MOL CELL BIOL, V32, P2054, DOI 10.1128/MCB.00272-12
   Carrasco-Garcia E, 2016, AM J CANCER RES, V6, P701
   Chambers I, 2003, CELL, V113, P643, DOI 10.1016/S0092-8674(03)00392-1
   Chaudhry A, 2009, SCIENCE, V326, P986, DOI 10.1126/science.1172702
   Chen K, 2013, ACTA PHARMACOL SIN, V34, P732, DOI 10.1038/aps.2013.27
   Chen T, 2012, CELL RES, V22, P248, DOI 10.1038/cr.2011.109
   Chen ZG, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063854
   Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270
   Chiurillo M.A., 2015, World journal of experimental medicine, V5, P84, DOI DOI 10.5493/WJEM.V5.I2.84
   Cho YG, 2007, APMIS, V115, P802, DOI 10.1111/j.1600-0463.2007.apm_643.x
   Clements WM, 2002, CANCER RES, V62, P3503
   Cohen DJ, 2013, J CLIN ONCOL, V31
   Cui JJ, 2013, CURR CANCER DRUG TAR, V13, P986, DOI 10.2174/15680096113136660104
   Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Dalerba P, 2007, ANNU REV MED, V58, P267, DOI 10.1146/annurev.med.58.062105.204854
   Dang CV, 2013, CSH PERSPECT MED, V3, DOI 10.1101/cshperspect.a014217
   Darido C, 2008, CANCER RES, V68, P4258, DOI 10.1158/0008-5472.CAN-07-5805
   Dasari A, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3563
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Deng JY, 2010, WORLD J GASTROENTERO, V16, P5380, DOI 10.3748/wjg.v16.i42.5380
   Deng JY, 2013, TUMOR BIOL, V34, P2791, DOI 10.1007/s13277-013-0837-5
   Deng Y, 2014, BRIT J CANCER, V110, P430, DOI 10.1038/bjc.2013.767
   Didiasova M, 2018, MOLECULES, V23, DOI 10.3390/molecules23051003
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Dong H, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1776-x
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Du X, 2014, WORLD J GASTROENTERO, V20, P9191, DOI 10.3748/wjg.v20.i27.9191
   Edinger AL, 2002, MOL BIOL CELL, V13, P2276, DOI 10.1091/mbc.01-12-0584
   Espersen MLM, 2015, CLIN COLORECTAL CANC, V14, P63, DOI 10.1016/j.clcc.2014.12.004
   Falchook GS, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.3024
   Fang DD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067258
   Farkona S, 2016, BMC MED, V14, DOI 10.1186/s12916-016-0623-5
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Forghanifard MM, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-6
   Francipane MG, 2013, ONCOTARGET, V4, P1948, DOI 10.18632/oncotarget.1310
   Fujita T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0130808
   Fukamachi H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0072438
   Fukamachi H, 2011, CANCER SCI, V102, P1313, DOI 10.1111/j.1349-7006.2011.01947.x
   Ghanei Z, 2020, J CELL PHYSIOL, V235, P7840, DOI 10.1002/jcp.29437
   Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8
   Gilcrease GW, 2019, INVEST NEW DRUG, V37, P482, DOI 10.1007/s10637-018-0645-2
   Gong X, 2016, MOL CANCER THER, V15, P1580, DOI 10.1158/1535-7163.MCT-16-0114
   Goossens-Beumer IJ, 2014, BRIT J CANCER, V110, P2935, DOI 10.1038/bjc.2014.226
   Grivennikov SI, 2010, CYTOKINE GROWTH F R, V21, P11, DOI 10.1016/j.cytogfr.2009.11.005
   Grothey A, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.TPS3619
   Gullo I, 2018, PATHOBIOLOGY, V85, P50, DOI 10.1159/000473881
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Gupta Sachin, 2010, Ther Adv Med Oncol, V2, P237, DOI 10.1177/1758834010366430
   Hadjimichael C, 2015, WORLD J STEM CELLS, V7, P1150, DOI 10.4252/wjsc.v7.i9.1150
   Hajimoradi M, 2016, CELL J, V17, P617
   Han ME, 2011, CELL MOL LIFE SCI, V68, P3589, DOI 10.1007/s00018-011-0672-z
   Han S, 1999, J KOREAN MED SCI, V14, P526, DOI 10.3346/jkms.1999.14.5.526
   Han SM, 2014, EXP MOL MED, V46, DOI 10.1038/emm.2014.28
   Haraguchi N, 2013, INT J ONCOL, V43, P425, DOI 10.3892/ijo.2013.1955
   Hashimoto I, 2017, ONCOL LETT, V13, P819, DOI 10.3892/ol.2016.5499
   Hashimoto K, 2014, GASTRIC CANCER, V17, P97, DOI 10.1007/s10120-013-0255-9
   Hayakawa Y, 2019, GASTROENTEROLOGY, V156, P1066, DOI 10.1053/j.gastro.2018.11.024
   HORII A, 1992, CANCER RES, V52, P3231
   Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502
   Hsu LS, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0632-6
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Huang R, 2015, MOL MED REP, V12, P2417, DOI 10.3892/mmr.2015.3694
   Huang WS, 2007, WORLD J GASTROENTERO, V13, P6581, DOI 10.3748/wjg.13.6581
   Huch M, 2011, NAT GENET, V43, P9, DOI 10.1038/ng0111-9
   Hütz K, 2014, CARCINOGENESIS, V35, P942, DOI 10.1093/carcin/bgt410
   Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182
   Iida Mari, 2013, Cancer Biol Ther, V14, P481, DOI 10.4161/cbt.24342
   Iseghohi SO, 2016, GENES DIS, V3, P7, DOI 10.1016/j.gendis.2016.01.001
   Ishigami S, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-46
   Ishimoto T, 2014, J GASTROENTEROL, V49, P1111, DOI 10.1007/s00535-014-0952-0
   Jackstadt R, 2019, CANCER CELL, V36, P319, DOI 10.1016/j.ccell.2019.08.003
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Javier BM, 2016, ONCOTARGET, V7, P50875, DOI 10.18632/oncotarget.9682
   Ji K, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0160125
   Jiang J, 2012, ONCOGENE, V31, P671, DOI 10.1038/onc.2011.282
   Jiang R, 2016, ACTA BIOCH BIOPH SIN, V48, P229, DOI 10.1093/abbs/gmv134
   Jiang YX, 2017, ONCOGENE, V36, P1256, DOI 10.1038/onc.2016.291
   Jiang Y, 2012, GASTRIC CANCER, V15, P440, DOI 10.1007/s10120-012-0140-y
   Jiang YY, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1985-3
   Jo A, 2014, GENES DIS, V1, P149, DOI 10.1016/j.gendis.2014.09.004
   Johnson SM, 2010, J AM COLL SURGEONS, V210, P767, DOI 10.1016/j.jamcollsurg.2009.12.008
   Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8
   Kahlert C, 2012, ANN SURG ONCOL, V19, P4193, DOI 10.1245/s10434-012-2518-9
   Kang H, 2012, HISTOPATHOLOGY, V61, P576, DOI 10.1111/j.1365-2559.2012.04274.x
   Kannarkatt J, 2017, J ONCOL PRACT, V13, P233, DOI 10.1200/JOP.2016.017210
   Kanwar SS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-212
   Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233
   Do K, 2015, INVEST NEW DRUG, V33, P720, DOI 10.1007/s10637-015-0212-z
   Kim DY, 2009, J GASTROEN HEPATOL, V24, P646, DOI 10.1111/j.1440-1746.2008.05671.x
   Kim EJ, 2005, J MED FOOD, V8, P431, DOI 10.1089/jmf.2005.8.431
   Kim HB, 2019, ANTICANCER RES, V39, P6097, DOI 10.21873/anticanres.13817
   Kim Yonghyun, 2009, Int J Stem Cells, V2, P109
   Kodama H, 2017, BRIT J CANCER, V116, P186, DOI 10.1038/bjc.2016.401
   Kolligs FT, 2002, DIGESTION, V66, P131, DOI 10.1159/000066755
   Krizhanovsky V, 2009, NATURE, V460, P1085, DOI 10.1038/4601085a
   Kuipers Ernst J, 2015, Nat Rev Dis Primers, V1, P15065, DOI 10.1038/nrdp.2015.65
   Labianca R, 2013, ANN ONCOL, V24, P64, DOI 10.1093/annonc/mdt354
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Lang SA, 2007, INT J CANCER, V120, P1803, DOI 10.1002/ijc.22442
   Lau EYT, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3714190
   Lee HH, 2012, J SURG ONCOL, V106, P999, DOI 10.1002/jso.23178
   Lee KS, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139727
   Leng ZW, 2018, CELL PHYSIOL BIOCHEM, V46, P860, DOI 10.1159/000488743
   Leng ZW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056082
   Li Ming-xue, 2012, Zhonghua Wei Chang Wai Ke Za Zhi, V15, P732
   [李文华 Li Wenhua], 2015, [农业环境科学学报, Journal of Agro-Environment Science], V34, P1
   Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112
   Lin L, 2011, CANCER RES, V71, P7226, DOI 10.1158/0008-5472.CAN-10-4660
   Lin Q, 2005, AM J PATHOL, V167, P969, DOI 10.1016/S0002-9440(10)61187-X
   Lin T, 2012, MED ONCOL, V29, P878, DOI 10.1007/s12032-011-9860-9
   Liu LL, 2008, CANCER SCI, V99, P121, DOI 10.1111/j.1349-7006.2007.00643.x
   Lochhead P, 2008, BRIT MED BULL, V85, P87, DOI 10.1093/bmb/ldn007
   LoConte NK, 2015, INVEST NEW DRUG, V33, P169, DOI 10.1007/s10637-014-0166-6
   Loh YH, 2006, NAT GENET, V38, P431, DOI 10.1038/ng1760
   Low JA, 2010, J CLIN ONCOL, V28, P5321, DOI 10.1200/JCO.2010.27.9943
   Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021
   Lü BJ, 2008, AM J CLIN PATHOL, V130, P897, DOI 10.1309/AJCPW1W8GJBQGCNI
   Lugli A, 2010, BRIT J CANCER, V103, P382, DOI 10.1038/sj.bjc.6605762
   Luistro L, 2009, CANCER RES, V69, P7672, DOI 10.1158/0008-5472.CAN-09-1843
   Lundberg IV, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2509-5
   Lundberg IV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101957
   Ma XL, 2005, CARCINOGENESIS, V26, P1698, DOI 10.1093/carcin/bgi130
   Ma YP, 2006, BLOOD, V108, P2726, DOI 10.1182/blood-2006-02-001594
   Magee JA, 2012, CANCER CELL, V21, P283, DOI 10.1016/j.ccr.2012.03.003
   Malkomes P, 2016, ANN SURG ONCOL, V23, P2849, DOI 10.1245/s10434-016-5218-z
   Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515
   Marjanovic ND, 2013, CLIN CHEM, V59, P168, DOI 10.1373/clinchem.2012.184655
   Matheu A, 2012, CANCER RES, V72, P1301, DOI 10.1158/0008-5472.CAN-11-3660
   Mattiuzzi C, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.91
   Mazumdar J, 2010, NAT CELL BIOL, V12, P1007, DOI 10.1038/ncb2102
   McMillan R, 2012, CLIN CANCER RES, V18, P4883, DOI 10.1158/1078-0432.CCR-11-2509
   Menon S, 2016, CANCERS, V8, DOI 10.3390/cancers8120106
   Mesquita P, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/8267021
   Michl P, 2005, Z GASTROENTEROL, V43, P1133, DOI 10.1055/s-2005-858638
   Miyoshi N, 2018, SURG TODAY, V48, P709, DOI 10.1007/s00595-018-1644-9
   Miyoshi N, 2010, P NATL ACAD SCI USA, V107, P40, DOI 10.1073/pnas.0912407107
   Mohamed SY, 2019, J GASTROINTEST CANC, V50, P824, DOI 10.1007/s12029-018-0156-6
   Müller S, 2017, ISR J CHEM, V57, P239, DOI 10.1002/ijch.201600109
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   Murayama T, 2009, BRIT J CANCER, V100, P782, DOI 10.1038/sj.bjc.6604915
   Myant KB, 2013, CELL STEM CELL, V12, P761, DOI 10.1016/j.stem.2013.04.006
   NAKATSURU S, 1993, HUM MOL GENET, V2, P1463, DOI 10.1093/hmg/2.9.1463
   Narayanankutty A, 2019, CURR DRUG TARGETS, V20, P1217, DOI 10.2174/1389450120666190618123846
   Neri B, 2007, BRIT J CANCER, V96, P1043, DOI 10.1038/sj.bjc.6603644
   Niedzwiecki D, 2011, J CLIN ONCOL, V29, P3146, DOI 10.1200/JCO.2010.32.5357
   Nosrati A, 2014, INT J MOL CELL MED, V3, P279
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ohkuma M, 2012, ANN SURG ONCOL, V19, P1357, DOI 10.1245/s10434-011-1739-7
   Ong CW, 2010, MODERN PATHOL, V23, P450, DOI 10.1038/modpathol.2009.181
   Ooi CH, 2009, PLOS GENET, V5, DOI 10.1371/journal.pgen.1000676
   Pádua D, 2020, CANCERS, V12, DOI 10.3390/cancers12020495
   Pant S, 2016, EUR J CANCER, V56, P1, DOI 10.1016/j.ejca.2015.11.021
   Parizadeh SM, 2019, INT J BIOCHEM CELL B, V110, P75, DOI 10.1016/j.biocel.2019.02.010
   Park JH, 2017, MEDCHEMCOMM, V8, P73, DOI 10.1039/c6md00385k
   Patel S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02872
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Pintova S, 2019, CANCER CHEMOTH PHARM, V84, P591, DOI 10.1007/s00280-019-03886-3
   Prévostel C, 2017, EUR J CANCER, V86, P150, DOI 10.1016/j.ejca.2017.08.037
   Quail DF, 2012, CURR STEM CELL RES T, V7, P197
   Quante M, 2013, GASTROENTEROLOGY, V145, P63, DOI 10.1053/j.gastro.2013.03.052
   Ramanathan RK, 2015, CANCER-AM CANCER SOC, V121, P2193, DOI 10.1002/cncr.29363
   Rassouli FB, 2016, TUMOR BIOL, V37, P7, DOI 10.1007/s13277-015-4155-y
   Rezalotfi A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00226
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Riley RS, 2019, NAT REV DRUG DISCOV, V18, P175, DOI 10.1038/s41573-018-0006-z
   Rimkus TK, 2016, CANCERS, V8, DOI 10.3390/cancers8020022
   Robertson JH, 2009, CLIN EXP METASTAS, V26, P769, DOI 10.1007/s10585-009-9276-5
   Rocco A, 2012, J CELL PHYSIOL, V227, P2686, DOI 10.1002/jcp.23013
   Sahebjam S, 2013, BRIT J CANCER, V109, P943, DOI 10.1038/bjc.2013.380
   Santaliz-Ruiz LEIV, 2014, INT J CANCER, V135, P2741, DOI 10.1002/ijc.28690
   Santos JC, 2016, CANCER RES, V76, P6735, DOI 10.1158/0008-5472.CAN-16-1120
   Sarkar A, 2013, CELL STEM CELL, V12, P15, DOI 10.1016/j.stem.2012.12.007
   Saygin C, 2016, METHODS MOL BIOL, V1516, P319, DOI 10.1007/7651_2016_360
   Schram AM, 2018, BRIT J CANCER, V119, P1471, DOI 10.1038/s41416-018-0322-4
   Shapiro G, 2016, EUR J CANCER, V69, pS148, DOI 10.1016/S0959-8049(16)33039-8
   Shie JL, 2000, AM J PHYSIOL-GASTR L, V279, pG806, DOI 10.1152/ajpgi.2000.279.4.G806
   Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958
   Smyth EC, 2016, ANN ONCOL, V27, pv38, DOI 10.1093/annonc/mdw350
   Sonbol MB, 2019, BIOMEDICINES, V7, DOI 10.3390/biomedicines7010017
   Song ZY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317714626
   Strosberg JR, 2012, EUR J CANCER, V48, P997, DOI 10.1016/j.ejca.2012.02.056
   Su SJ, 2003, NUTR CANCER, V45, P113, DOI 10.1207/S15327914NC4501_13
   Sun MH, 2012, VIRCHOWS ARCH, V460, P271, DOI 10.1007/s00428-012-1201-7
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Takeda K, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-36251-0
   Tang BW, 2015, STEM CELL REP, V4, P155, DOI 10.1016/j.stemcr.2014.11.002
   Tapia O, 2014, VIRCHOWS ARCH, V465, P25, DOI 10.1007/s00428-014-1588-4
   de Souza CRT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064420
   Tian T, 2012, J BIOMED RES, V26, P336, DOI 10.7555/JBR.26.20120045
   Todaro M, 2010, GASTROENTEROLOGY, V138, P2151, DOI 10.1053/j.gastro.2009.12.063
   Tolcher AW, 2012, J CLIN ONCOL, V30, P2348, DOI 10.1200/JCO.2011.36.8282
   Usui T, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041098
   Vadde R, 2017, CRIT REV ONCOL HEMAT, V113, P22, DOI 10.1016/j.critrevonc.2017.02.025
   Vaiopoulos AG, 2012, STEM CELLS, V30, P363, DOI 10.1002/stem.1031
   van der Heijden M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0962-x
   Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039
   Venkatesh Vandana, 2018, Stem Cell Investig, V5, P5, DOI 10.21037/sci.2018.02.02
   Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Voorneveld PW, 2015, BRIT J CANCER, V112, P122, DOI 10.1038/bjc.2014.560
   Wahab SMR, 2017, CLIN COLORECTAL CANC, V16, P93, DOI 10.1016/j.clcc.2017.01.011
   Wakamatsu Y, 2012, PATHOL INT, V62, P112, DOI 10.1111/j.1440-1827.2011.02760.x
   Wang H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040955
   Wang WM, 2017, ONCOL REP, V38, P245, DOI 10.3892/or.2017.5671
   Wang XH, 2016, GASTRIC CANCER, V19, P116, DOI 10.1007/s10120-015-0467-2
   Wang ZW, 2010, BBA-REV CANCER, V1806, P258, DOI 10.1016/j.bbcan.2010.06.001
   Wei DY, 2006, CARCINOGENESIS, V27, P23, DOI 10.1093/carcin/bgi243
   West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896
   Wolpin BM, 2013, ONCOLOGIST, V18, P377, DOI 10.1634/theoncologist.2012-0378
   Woo DK, 2001, INT J CANCER, V95, P108, DOI 10.1002/1097-0215(20010320)95:2<108::AID-IJC1019>3.0.CO;2-#
   Wuebben EL, 2017, ONCOTARGET, V8, P44917, DOI 10.18632/oncotarget.16570
   Xia P, 2015, AM J CANCER RES, V5, P1602
   Xiao L, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-152
   Yang JC, 2008, P NATL ACAD SCI USA, V105, P19756, DOI 10.1073/pnas.0809321105
   Yang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00243-2
   Yang ZT, 2018, EXP CELL RES, V373, P145, DOI 10.1016/j.yexcr.2018.10.006
   Yang ZH, 2019, WORLD J GASTROENTERO, V25, P2863, DOI 10.3748/wjg.v25.i23.2863
   Yao YZ, 2019, BIOMED PHARMACOTHER, V111, P993, DOI 10.1016/j.biopha.2019.01.018
   Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263
   Yeh TS, 2009, CANCER RES, V69, P5039, DOI 10.1158/0008-5472.CAN-08-4021
   Yeung TM, 2011, P NATL ACAD SCI USA, V108, P4382, DOI 10.1073/pnas.1014519107
   Yoon C, 2014, CLIN CANCER RES, V20, P3974, DOI 10.1158/1078-0432.CCR-14-0011
   Young RA, 2011, CELL, V144, P940, DOI 10.1016/j.cell.2011.01.032
   Yu GZ, 2009, CLIN CANCER RES, V15, P1821, DOI 10.1158/1078-0432.CCR-08-2138
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Yuan X, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.69
   Zhang CJ, 2011, J CANCER RES CLIN, V137, P1679, DOI 10.1007/s00432-011-1038-5
   Zhang HF, 2008, HEPATO-GASTROENTEROL, V55, P1126
   Zhang HL, 2019, ONCOL LETT, V17, P4487, DOI 10.3892/ol.2019.10081
   Zhang J, 2013, ONCOGENE, V32, P4397, DOI 10.1038/onc.2012.461
   Zhang JQ, 2006, NAT CELL BIOL, V8, P1114, DOI 10.1038/ncb1481
   Zhang L, 2014, ONCOGENE, V33, P5491, DOI 10.1038/onc.2013.495
   Zhang N, 2012, ONCOL LETT, V3, P1017, DOI 10.3892/ol.2012.619
   Zhang SS, 2016, ONCOL REP, V36, P2252, DOI 10.3892/or.2016.5039
   Zhang XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0176-3
   Zhang XW, 2016, ONCOTARGET, V7, P9815, DOI 10.18632/oncotarget.6890
   Zhang X, 2018, CANCER MANAG RES, V10, P4459, DOI 10.2147/CMAR.S177373
   Zhang X, 2015, CANCER LETT, V357, P55, DOI 10.1016/j.canlet.2014.11.037
   Zhang YM, 2016, CANCER MED-US, V5, P1251, DOI 10.1002/cam4.675
   Zhang YK, 2011, EXP BIOL MED, V236, P714, DOI 10.1258/ebm.2011.010347
   Zhao P, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-218
   Zhao RR, 2020, CANCER MED-US, V9, P2551, DOI 10.1002/cam4.2892
   Zhao Wenxiu, 2017, Cancer Transl Med, V3, P87, DOI 10.4103/ctm.ctm_69_16
   Zhi QM, 2011, BIOMED PHARMACOTHER, V65, P509, DOI 10.1016/j.biopha.2011.06.006
   Zhou Yujuan, 2018, Oncotarget, V9, P33403, DOI 10.18632/oncotarget.23607
NR 278
TC 30
Z9 31
U1 0
U2 14
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD JUN 18
PY 2020
VL 8
AR 442
DI 10.3389/fcell.2020.00442
PG 23
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA MH8NE
UT WOS:000546978200001
PM 32626705
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Wei, L
   Lin, ZX
   Xie, SD
   Ruan, DY
   Jiang, W
   Cui, YL
   Liu, SS
   Wang, TT
   Chen, ZH
   Lin, Q
AF Wei, Li
   Lin, Zexiao
   Xie, Sidong
   Ruan, Danyun
   Jiang, Wen
   Cui, Yueli
   Liu, Sisi
   Wang, Tiantian
   Chen, Zhanhong
   Lin, Qu
TI Complete Response With Cetuximab-Based Treatment of Metastatic
   Colorectal Cancers: Two Case Reports and Literature Review
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE cetuximab; colorectal cancer; liver metastasis; targeted therapy;
   complete response
ID III COLON-CANCER; OPEN-LABEL; CHEMOTHERAPY; FLUOROURACIL; OXALIPLATIN;
   LEUCOVORIN; RAS; PATIENT
AB Metastases typically develop before diagnosis and during the treatment of colorectal cancers, while patients with metastatic colorectal cancers (mCRCs) currently have a poor prognosis. In terms of surgical approaches, adjuvant therapies, and targeted therapies, the treatment of mCRCs has had numerous recent advances. As a targeted agent widely used in mCRCs, cetuximab-based treatment is still under dispute due to its side effects and unstable effect. We present two mCRC cases treated with cetuximab-based therapy, of which two patients achieved complete response and without recurrence for over 22 and 84 months, respectively. To better understand the drug usage, we also reviewed the recent achievements and usage precautions of cetuximab in mCRCs. Present and many previous observations support that cetuximab might be a referred drug in the first-line chemotherapy of mCRCs with wild-type RAS and BRAF and proficient mismatch repair.
C1 [Wei, Li; Lin, Zexiao; Ruan, Danyun; Wang, Tiantian; Chen, Zhanhong; Lin, Qu] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Oncol, Guangzhou, Peoples R China.
   [Xie, Sidong] Sun Yat Sen Univ, Affiliated Hosp 3, Dept Radiol, Guangzhou, Peoples R China.
   [Jiang, Wen; Cui, Yueli; Liu, Sisi] Nanjing Geneseeq Technol Inc, Dept Res & Dev, Nanjing, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University; Geneseeq Technology Inc.
RP Wang, TT; Chen, ZH; Lin, Q (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 3, Dept Oncol, Guangzhou, Peoples R China.
EM wangtt37@mail.sysu.edu.cn; chzhanh3@mail.sysu.edu.cn;
   linqu@mail.sysu.edu.cn
RI Xie, Sidong/AAW-3064-2020; Zhang, Kang/Y-2740-2019; Li,
   Jun/HTN-0647-2023
CR Achermann Yvonne, 2012, BMJ Case Rep, V2012, DOI 10.1136/bcr-03-2012-5973
   Alberts SR, 2012, JAMA-J AM MED ASSOC, V307, P1383, DOI 10.1001/jama.2012.385
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Chang PH, 2014, CHINESE J CANCER RES, V26, pE10, DOI 10.3978/j.issn.1000-9604.2014.02.02
   Cohen R, 2018, J GASTROINTEST ONCOL, V9, pE23, DOI 10.21037/jgo.2018.05.10
   Fukui T, 2019, SURG CASE REP, V5, DOI 10.1186/s40792-019-0707-5
   Grassadonia A, 2019, J CANCER, V10, P5926, DOI 10.7150/jca.34550
   Guerriero C, 2011, EUR J DERMATOL, V21, P277, DOI 10.1684/ejd.2010.1231
   Gurbuz M, 2021, J ONCOL PHARM PRACT, V27, P480, DOI 10.1177/1078155220937751
   Kim TW, 2018, CLIN CANCER RES, V24, P5602, DOI 10.1158/1078-0432.CCR-17-3377
   Li Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.684309
   Lin L, 2016, MOL CLIN ONCOL, V4, P1017, DOI 10.3892/mco.2016.836
   Lu Yen-Man, 2016, J Med Case Rep, V10, P98, DOI 10.1186/s13256-016-0879-6
   Murono K, 2013, INT SURG, V98, P49, DOI 10.9738/CC172.1
   Osumi H, 2015, MOL CLIN ONCOL, V3, P1053, DOI 10.3892/mco.2015.602
   Ottaiano A, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00441
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6
   Qiu CH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.612171
   Reddy TP, 2020, WORLD J CLIN ONCOL, V11, P959, DOI 10.5306/wjco.v11.i11.959
   Rouyer M, 2021, BRIT J CLIN PHARMACO, V87, P1120, DOI 10.1111/bcp.14472
   Schoellhammer HF, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1279-9
   Skelton WP, 2020, J GASTROINTEST ONCOL, V11, P790, DOI 10.21037/jgo-20-184
   Stintzing S, 2016, LANCET ONCOL, V17, P1426, DOI 10.1016/S1470-2045(16)30269-8
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Taieb J, 2014, LANCET ONCOL, V15, P862, DOI 10.1016/S1470-2045(14)70227-X
   Tokumaru Y, 2019, MOL CLIN ONCOL, V10, P571, DOI 10.3892/mco.2019.1836
   Van Bael K, 2015, CASE REP ONCOL MED, V2015, DOI 10.1155/2015/472037
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Yen LC, 2010, ANN SURG, V251, P254, DOI 10.1097/SLA.0b013e3181bc9d96
   Zaanan A, 2020, JCO PRECIS ONCOL, V4, P116, DOI 10.1200/PO.19.00237
   Zhang HY, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06909-y
   Zhang MY, 2020, WORLD J CLIN CASES, V8, P5781, DOI 10.12998/wjcc.v8.i22.5781
NR 33
TC 2
Z9 2
U1 0
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD FEB 16
PY 2022
VL 12
AR 798515
DI 10.3389/fonc.2022.798515
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ZM3SQ
UT WOS:000764282000001
PM 35251973
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Rozpedek-Kaminska, W
   Piotrzkowska, D
   Galita, G
   Pytel, D
   Kucharska, E
   Dziki, L
   Dziki, A
   Majsterek, I
AF Rozpedek-Kaminska, Wioletta
   Piotrzkowska, Danuta
   Galita, Grzegorz
   Pytel, Dariusz
   Kucharska, Ewa
   Dziki, Lukasz
   Dziki, Adam
   Majsterek, Ireneusz
TI Small-molecule inhibitors of the PERK-mediated Unfolded Protein Response
   signaling pathway in targeted therapy for colorectal cancer
SO POLISH JOURNAL OF SURGERY
LA English
DT Article
DE apoptosis; cancer treatment; colorectal cancer; endoplasmic reticulum
   stress; PERK inhibitors; unfolded protein response
ID ENDOPLASMIC-RETICULUM-STRESS; UPR ACTIVATION; GSK2606414; KINASE;
   ADAPTATION; INDUCTION; ANTITUMOR; POTENT; GRP78
AB Introduction: The newest data has reported that endoplasmic reticulum (ER) stress and PERK-dependent Unfolded Protein Response (UPR) signaling pathway may constitute a key factor in colorectal cancer (CRC) pathogenesis on the molecular level. Nowadays used anti-cancer treatment strategies are still insufficient, since patients suffer from various side effects that are directly evoked via therapeutic agents characterized by non-specific action in normal and cancer cells.
   Aim: Thereby, the main aim of the presented research was to analyze the effectiveness of the small-molecule PERK inhibitor NCI 12487 in an in vitro cellular model of CRC.
   Materials and methods: The study was performed on colorectal cancer HT-29 and normal human colon epithelial CCD 841 CoN cell lines. The cytotoxicity was measured by XTT assay, evaluation of apoptosis was performed by caspase-3 assay, whereas cell cycle analysis via the propidium iodide (PI) staining.
   Results: Results obtained have demonstrated that the investigated compound is selective only for HT-29 cancer cells, since at 25 mu M concentration it significantly decreased HT-29 cells viability in a dose- and time-dependent manner, evoked increased caspase-3 activity and arrest in the G2/M phase of the cell cycle. Moreover, NCI 12487 compound markedly decreased HT-29 cells viability, increased caspase-3 activity and percentage of cells in sub-G0/G1, thus promoted apoptosis of cancer HT-29 cells with induced ER stress conditions.
   Conclusion: Thus, based on the results obtained in this study it may be concluded that small-molecule modulators of the PERK-dependent UPR signaling pathway may constitute an innovative, targeted treatment strategy against CRC.
C1 [Rozpedek-Kaminska, Wioletta; Piotrzkowska, Danuta; Galita, Grzegorz; Pytel, Dariusz; Majsterek, Ireneusz] Med Univ Lodz, Dept Clin Chem & Biochem, Lodz, Poland.
   [Kucharska, Ewa] Jesuit Univ Ignatianum, Dept Gerontol Geriatr & Social Work, Krakow, Poland.
   [Dziki, Lukasz] Med Univ Lodz, Dept Gen & Oncol Surg, Lodz, Poland.
   [Dziki, Adam] Med Univ Lodz, Dept Gen & Colorectal Surg, Lodz, Poland.
C3 Medical University Lodz; Medical University Lodz; Medical University
   Lodz
RP Majsterek, I (corresponding author), Med Univ Lodz, Dept Clin Chem & Biochem, Narutowicza St 60, PL-90137 Lodz, Poland.
EM ireneusz.majsterek@umed.lodz.pl
RI Galita, Grzegorz/LKL-6375-2024; Kucharska, Ewa/H-5802-2018
FU Polish National Science Centre [2016/23/B/NZ5/02630,
   2015/19/N/NZ3/00055]
FX This work was supported by grants OPUS no. 2016/23/B/NZ5/02630 and
   PRELUDIUM no. 2015/19/N/NZ3/00055 from the Polish National Science
   Centre.
CR Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Atkins C, 2013, CANCER RES, V73, P1993, DOI 10.1158/0008-5472.CAN-12-3109
   Axten JM, 2012, J MED CHEM, V55, P7193, DOI 10.1021/jm300713s
   Blais JD, 2006, MOL CELL BIOL, V26, P9517, DOI 10.1128/MCB.01145-06
   Chakraborty Sajib, 2012, Ecancermedicalscience, V6, ped16, DOI 10.3332/ecancer.2012.ed16
   Chang MY, 2014, MOLECULES, V19, P6694, DOI 10.3390/molecules19056694
   Cojocari D, 2013, RADIOTHER ONCOL, V108, P541, DOI 10.1016/j.radonc.2013.06.005
   Corazzari M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00078
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Douaiher J, 2017, J SURG ONCOL, V115, P619, DOI 10.1002/jso.24578
   Healy SJM, 2009, EUR J PHARMACOL, V625, P234, DOI 10.1016/j.ejphar.2009.06.064
   Huang JJ, 2021, CELL BIOSCI, V11, DOI 10.1186/s13578-021-00538-z
   Kraskiewicz H, 2012, TRENDS PHARMACOL SCI, V33, P53, DOI 10.1016/j.tips.2011.10.002
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   Lei YP, 2021, BIOCHEM BIOPH RES CO, V557, P316, DOI 10.1016/j.bbrc.2021.03.041
   Limonta P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20040961
   Liu Z, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.183
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   Madden E, 2019, BIOL CELL, V111, P1, DOI 10.1111/boc.201800050
   Martinon F, 2012, ACTA ONCOL, V51, P822, DOI 10.3109/0284186X.2012.689113
   Mercado G, 2018, NEUROBIOL DIS, V112, P136, DOI 10.1016/j.nbd.2018.01.004
   Moreno JA, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006767
   Pytel D, 2014, J BIOMOL SCREEN, V19, P1024, DOI 10.1177/1087057114525853
   Qi JJ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02779-1
   Rojas-Rivera D, 2017, CELL DEATH DIFFER, V24, P1100, DOI 10.1038/cdd.2017.58
   Rouschop KM, 2013, P NATL ACAD SCI USA, V110, P4622, DOI 10.1073/pnas.1210633110
   Rozpedek W, 2020, CURR CANCER DRUG TAR, V20, P223, DOI 10.2174/1568009620666200106114826
   Rozpedek Wioletta, 2015, Pol Merkur Lekarski, V39, P393
   Sawicki T, 2021, CANCERS, V13, DOI 10.3390/cancers13092025
   Senapati S, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-017-0004-3
   Sharma SH, 2018, CHEM-BIOL INTERACT, V291, P16, DOI 10.1016/j.cbi.2018.06.001
   Siwecka N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184354
   Szegezdi E, 2006, EMBO REP, V7, P880, DOI 10.1038/sj.embor.7400779
   Yadav Raj Kumar, 2014, J Cancer Prev, V19, P75
   Yao YF, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00171-w
   Zhao TM, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-01002-0
NR 36
TC 3
Z9 3
U1 0
U2 0
PU INDEX COPERNICUS INT
PI WARSAW
PA Kasprzaka 31A/184 STR, WARSAW, 01-234, POLAND
SN 0032-373X
EI 2299-2847
J9 POL J SURG
JI Pol. J. Surg.
PY 2022
VL 94
IS 6
DI 10.5604/01.3001.0015.7948
PG 9
WC Surgery
WE Emerging Sources Citation Index (ESCI)
SC Surgery
GA E4ZM0
UT WOS:000975638700003
PM 36468513
DA 2025-01-04
ER

PT J
AU Hou, LD
   Zhong, T
   Cheng, P
   Long, BH
   Shi, LL
   Meng, XJ
   Yao, H
AF Hou, Lidan
   Zhong, Ting
   Cheng, Peng
   Long, Bohan
   Shi, Leilei
   Meng, Xiangjun
   Yao, Han
TI Self-assembled peptide-paclitaxel nanoparticles for enhancing
   therapeutic efficacy in colorectal cancer
SO FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
LA English
DT Article
DE peptide; self-assembled; targeted therapy; nanoparticles; colorectal
   cancer
ID DELIVERY; CHALLENGES; CONJUGATE
AB Chemotherapy is one of the main treatments for colorectal cancer, but systemic toxicity severely limits its clinical use. Packaging hydrophobic chemotherapeutic drugs in targeted nanoparticles greatly improve their efficacy and reduce side effects. We previously identified a novel colorectal cancer specific binding peptide P-LPK (LPKTVSSDMSLN) from phage display peptide library. Here we designed a self-assembled paclitaxel (PTX)-loaded nanoparticle (LPK-PTX NPs). LPK-PTX NPs displayed a superior intracellular internalization and improved tumor cytotoxicity in vitro. Cy5.5-labeled LPK-PTX NPs showed much higher tumor accumulation in colorectal cancer-bearing mice. Furthermore, LPK-PTX NPs exhibit enhanced antitumor activity and decreased systemic toxicity in colorectal cancer patient-derived xenografts (PDX) model. The excellent in vitro and in vivo antitumor efficacy proves the improved targeting drug delivery, suggesting that peptide P-LPK has potential to provide a novel approach for enhanced drug delivery with negligible systemic toxicity.
C1 [Hou, Lidan; Zhong, Ting; Cheng, Peng; Long, Bohan; Meng, Xiangjun; Yao, Han] Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Gastroenterol, Shanghai, Peoples R China.
   [Hou, Lidan; Zhong, Ting; Long, Bohan; Meng, Xiangjun; Yao, Han] Shanghai Jiao Tong Univ, Digest Dis Res & Clin Transformat Ctr, Shanghai, Peoples R China.
   [Hou, Lidan; Zhong, Ting; Long, Bohan; Meng, Xiangjun; Yao, Han] Shanghai Key Lab Gut Microecol & Associated Dis, Shanghai, Peoples R China.
   [Cheng, Peng] Hainan West Cent Hosp, Dept Gastroenterol, Hainan, Peoples R China.
   [Shi, Leilei] Sun Yat Sen Univ, Affiliated Hosp 8, Shenzhen, Peoples R China.
C3 Shanghai Jiao Tong University; Shanghai Jiao Tong University; Sun Yat
   Sen University
RP Yao, H (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Shanghai Peoples Hosp 9, Dept Gastroenterol, Shanghai, Peoples R China.; Yao, H (corresponding author), Shanghai Jiao Tong Univ, Digest Dis Res & Clin Transformat Ctr, Shanghai, Peoples R China.; Yao, H (corresponding author), Shanghai Key Lab Gut Microecol & Associated Dis, Shanghai, Peoples R China.
EM hanyao89@163.com
FU National Natural Science Foundation of China [82003167, 81872419,
   32071377]; Interdisciplinary Program of Shanghai Jiao Tong University
   [ZH2018QNA01]; Shanghai Sailing Program [19YF1426900, 20YF1424400];
   Shanghai Ninth People's Hospital, Shanghai Jiao Tong University School
   of Medicine [YBKB201918]; Hainan Provincial Natural Science Foundation
   of China [821RC733]; Hainan Health Industry Scientific research Project
   [20A200397]
FX This work was supported by National Natural Science Foundation of China
   (Grant No. 82003167, 81872419, and 32071377), Interdisciplinary Program
   of Shanghai Jiao Tong University (ZH2018QNA01), Shanghai Sailing Program
   (19YF1426900, 20YF1424400), Project of Biobank from Shanghai Ninth
   People's Hospital, Shanghai Jiao Tong University School of Medicine (No.
   YBKB201918). Hainan Provincial Natural Science Foundation of China
   (No.821RC733) Hainan Health Industry Scientific research Project
   (20A200397).
CR Bernabeu E, 2017, INT J PHARMACEUT, V526, P474, DOI 10.1016/j.ijpharm.2017.05.016
   Chang L, 2021, CANCER CELL, V39, P466, DOI 10.1016/j.ccell.2020.12.008
   Cieslewicz M, 2013, P NATL ACAD SCI USA, V110, P15919, DOI 10.1073/pnas.1312197110
   Deyle K, 2017, ACCOUNTS CHEM RES, V50, P1866, DOI 10.1021/acs.accounts.7b00184
   Fan Z, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04763-y
   Gu WX, 2019, ADV MATER, V31, DOI 10.1002/adma.201904742
   He JY, 2019, ADV MATER, V31, DOI 10.1002/adma.201902409
   Hou LD, 2018, BRIT J CANCER, V118, P79, DOI 10.1038/bjc.2017.366
   Izci M, 2021, CHEM REV, V121, P1746, DOI 10.1021/acs.chemrev.0c00779
   Jiang Y, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01274-8
   Kumthekar P, 2020, CLIN CANCER RES, V26, P2789, DOI 10.1158/1078-0432.CCR-19-3258
   Li K, 2020, ADV DRUG DELIVER REV, V160, P36, DOI 10.1016/j.addr.2020.10.009
   Luo GF, 2021, CHEM SOC REV, V50, P945, DOI 10.1039/d0cs00152j
   Ndinguri MW, 2012, MOLECULES, V17, P14230, DOI 10.3390/molecules171214230
   Pappas CG, 2016, NAT NANOTECHNOL, V11, P960, DOI [10.1038/nnano.2016.169, 10.1038/NNANO.2016.169]
   Qian C, 2020, NANO LETT, V20, P4153, DOI 10.1021/acs.nanolett.0c00152
   Régina A, 2008, BRIT J PHARMACOL, V155, P185, DOI 10.1038/bjp.2008.260
   Saw PE, 2019, PROTEIN CELL, V10, P787, DOI 10.1007/s13238-019-0639-7
   Sofias AM, 2017, ADV DRUG DELIVER REV, V122, P20, DOI 10.1016/j.addr.2017.02.003
   Spicer CD, 2018, CHEM SOC REV, V47, P3574, DOI 10.1039/c7cs00877e
   Thomas FC, 2009, PHARM RES-DORDR, V26, P2486, DOI 10.1007/s11095-009-9964-5
   Wang LY, 2022, BIOMATER SCI-UK, V10, P2263, DOI 10.1039/d2bm00027j
   Wang Y, 2017, ADV DRUG DELIVER REV, V110, P112, DOI 10.1016/j.addr.2016.06.015
   Zhu LJ, 2022, J AM CHEM SOC, V144, P1493, DOI 10.1021/jacs.1c09574
NR 24
TC 9
Z9 9
U1 1
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-4185
J9 FRONT BIOENG BIOTECH
JI Front. Bioeng. Biotechnol.
PD SEP 28
PY 2022
VL 10
AR 938662
DI 10.3389/fbioe.2022.938662
PG 14
WC Biotechnology & Applied Microbiology; Engineering, Biomedical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering
GA 5J5NB
UT WOS:000869087100001
PM 36246349
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Xie, J
   Zhang, Y
   Jiang, LX
AF Xie, Jun
   Zhang, Yu
   Jiang, Luxi
TI Role of Interleukin-1 in the pathogenesis of colorectal cancer: A brief
   look at anakinra therapy
SO INTERNATIONAL IMMUNOPHARMACOLOGY
LA English
DT Article
DE Colorectal cancer; IL-1; Inflammation; Anakinra
ID ULCERATIVE-COLITIS; GROWTH-FACTOR; INFLAMMATORY RESPONSE;
   MONONUCLEAR-CELLS; IL-1 FAMILY; RECEPTOR; IL-1-BETA; RISK; ANTAGONIST;
   GENE
AB Colorectal cancer (CRC) is known as one of the deadliest and most common cancers globally and causes nearly one million cancer deaths yearly. Like many malignancies, the immune system and its components play a crucial role in the pathogenesis of CRC. As multifunction mediators of the immune system, cytokines are involved in several inflammatory and anti-inflammatory responses. Interleukin-1 (IL-1) belongs to a family of 11 members and is involved in inflammatory responses. Beyond its biological role as a mediator of innate immune responses, it is also seen in chronic stress and inflammation and numerous pathological states. The role of IL-1 in malignancies can also be very significant because it has recently been shown that this cytokine can also be secreted from tumor cells and induce the recruitment of myeloid-derived immunosuppressive cells. As a result, the tumor microenvironment (TME) is affected and, despite being inflammatory, causes the onset and progression of tumor cells. Since surgery and chemotherapy are the first choices to treat patients with cancer, especially CRC, it is usually not well-prognosed, particularly in patients with metastatic lesions CRC. Therefore, targeted therapy may prolong the overall survival of CRC patients. Furthermore, evidence shows that anakinra has had satisfactory results in treating CRC. Therefore, this review summarized the role of IL-1 in the pathogenesis of CRC as well as immunotherapy based on inhibition of this cytokine in this type of cancer.
C1 [Xie, Jun] Shaoxing Univ, Dept Colorectal Surg, Affiliated Hosp, Shaoxing 312000, Zhejiang, Peoples R China.
   [Zhang, Yu] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Canc Ctr, Hangzhou 310014, Zhejiang, Peoples R China.
   [Jiang, Luxi] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Lab Med Ctr, Hangzhou 310014, Zhejiang, Peoples R China.
C3 Shaoxing University; Hangzhou Medical College; Zhejiang Provincial
   People's Hospital; Hangzhou Medical College; Zhejiang Provincial
   People's Hospital
RP Jiang, LX (corresponding author), Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Lab Med Ctr, Hangzhou 310014, Zhejiang, Peoples R China.
EM jiangluxi@hmc.edu.cn
FU Zhejiang Medical Technology Plan Project [2019RC124]
FX Funding This work was supported by the Zhejiang Medical Technology Plan
   Project (No. 2019RC124 to LXJ) .
CR Al-Sahaf S, 2019, INT J CANCER, V144, P334, DOI 10.1002/ijc.31852
   Andrei C, 2004, P NATL ACAD SCI USA, V101, P9745, DOI 10.1073/pnas.0308558101
   Apte R.N., 2002, ADV EXPT MED BIOLOGY, P277
   Araghi M, 2019, LANCET GASTROENTEROL, V4, P511, DOI 10.1016/S2468-1253(19)30147-5
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Auron PE, 1998, CYTOKINE GROWTH F R, V9, P221, DOI 10.1016/S1359-6101(98)00018-5
   BankersFulbright JL, 1996, LIFE SCI, V59, P61, DOI 10.1016/0024-3205(96)00135-X
   Becerra C, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.449
   Ben Ahmed A, 2017, CENT EUR J IMMUNOL, V42, P150, DOI 10.5114/ceji.2017.69356
   Bersudsky M, 2014, GUT, V63, P598, DOI 10.1136/gutjnl-2012-303329
   Bhat IA, 2014, META GENE, V2, P123, DOI 10.1016/j.mgene.2013.12.002
   Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261
   Bishayee A, 2014, ADV EXP MED BIOL, V816, P401, DOI 10.1007/978-3-0348-0837-8_16
   Boraschi D, 2018, IMMUNOL REV, V281, P197, DOI 10.1111/imr.12606
   Bou-Dargham MJ, 2017, MED RES REV, V37, P180, DOI 10.1002/med.21406
   Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x
   Cavalli G, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01157
   Center MM, 2009, CA-CANCER J CLIN, V59, P366, DOI 10.3322/caac.20038
   Chen CJ, 2007, NAT MED, V13, P851, DOI 10.1038/nm1603
   Chen MF, 2012, J MOL MED, V90, P89, DOI 10.1007/s00109-011-0809-4
   Chirivi RGS, 1996, INT J CANCER, V67, P856, DOI 10.1002/(SICI)1097-0215(19960917)67:6<856::AID-IJC16>3.0.CO;2-#
   Dinarello C.A., 1996, Biologic basis for interleukin-1 in disease
   DINARELLO CA, 1994, FASEB J, V8, P1314, DOI 10.1096/fasebj.8.15.8001745
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Dinarello CA, 2009, ANNU REV IMMUNOL, V27, P519, DOI 10.1146/annurev.immunol.021908.132612
   Dinarello CA, 2018, CANCER RES, V78, P5200, DOI 10.1158/0008-5472.CAN-18-2225
   Dmitrieva-Posocco O, 2019, IMMUNITY, V50, P166, DOI 10.1016/j.immuni.2018.11.015
   Dranoff G, 2004, NAT REV CANCER, V4, P11, DOI 10.1038/nrc1252
   Dunne Aisling, 2003, Sci STKE, V2003, pre3, DOI 10.1126/stke.2003.171.re3
   Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fei BY, 2014, J GENET, V93, P235, DOI 10.1007/s12041-014-0354-3
   Fields JK, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01412
   Goodarzi E, 2019, WORLD CANCER RES J, V6
   Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076
   GREENFEDER SA, 1995, J BIOL CHEM, V270, P13757, DOI 10.1074/jbc.270.23.13757
   Hamacher R, 2009, CYTOKINE, V46, P182, DOI 10.1016/j.cyto.2009.01.005
   He C, 2017, GASTROENTEROLOGY, V152, P1434, DOI 10.1053/j.gastro.2017.01.049
   Herzig DO, 2015, J SURG ONCOL, V111, P96, DOI 10.1002/jso.23806
   Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289
   Hurmath KF, 2014, CELL BIOL INT, V38, P1415, DOI 10.1002/cbin.10353
   Ibrahimi M, 2019, IMMUNOL RES, V67, P151, DOI 10.1007/s12026-018-9034-3
   Isambert N, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1474319
   Ito H, 2007, ONCOL REP, V18, P473
   Jones GR, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02764
   Kawaguchi Y, 2006, P NATL ACAD SCI USA, V103, P14501, DOI 10.1073/pnas.0603545103
   KOBAYASHI Y, 1990, P NATL ACAD SCI USA, V87, P5548, DOI 10.1073/pnas.87.14.5548
   Konishi N, 2005, ONCOLOGY-BASEL, V68, P138, DOI 10.1159/000086768
   KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475
   Lang D, 1998, J IMMUNOL, V161, P6871
   Lederer J.A., 2020, INTERLEUKIN 1 CYTOKI, P59
   Lee YS, 2010, COLORECTAL DIS, V12, P1208, DOI 10.1111/j.1463-1318.2009.02080.x
   Levin B, 2008, GASTROENTEROLOGY, V134, P1570, DOI 10.1053/j.gastro.2008.02.002
   Li JJ, 2020, INT J BIOL SCI, V16, P2323, DOI 10.7150/ijbs.46651
   LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5
   Lie PPY, 2012, CELL MOL LIFE SCI, V69, P487, DOI 10.1007/s00018-011-0760-0
   Lubberink M, 2015, J NUCL MED, V56, P1144, DOI 10.2967/jnumed.114.151894
   Lurje G, 2009, PHARMACOGENET GENOM, V19, P95, DOI 10.1097/FPC.0b013e32831a9ad1
   Lust J.A., MAYO CLIN
   Lust JA, 2016, AM J HEMATOL, V91, P571, DOI 10.1002/ajh.24352
   Ma JC, 2017, CANCER MANAG RES, V9, P481, DOI 10.2147/CMAR.S147699
   MacKenzie A, 2001, IMMUNITY, V15, P825, DOI 10.1016/S1074-7613(01)00229-1
   MAHIDA YR, 1989, GUT, V30, P835, DOI 10.1136/gut.30.6.835
   Maker AV, 2011, CLIN CANCER RES, V17, P1502, DOI 10.1158/1078-0432.CCR-10-1561
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614
   Mármol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Martinon F, 2002, MOL CELL, V10, P417, DOI 10.1016/S1097-2765(02)00599-3
   Martinon F, 2009, ANNU REV IMMUNOL, V27, P229, DOI 10.1146/annurev.immunol.021908.132715
   McEntee CP, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01266
   Mehtap O, 2014, J POSTGRAD MED, V60, P141, DOI 10.4103/0022-3859.132319
   Mertens M, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005121.pub3
   Miyata-Takata T., 2015, SCI REP-UK, V5, P1
   MOSLEY B, 1987, J BIOL CHEM, V262, P2941
   Ning C, 2015, MUCOSAL IMMUNOL, V8, P1275, DOI 10.1038/mi.2015.18
   Nomura A, 2018, MOL CANCER RES, V16, P162, DOI 10.1158/1541-7786.MCR-17-0221
   Nunberg M, 2018, MSYSTEMS, V3, DOI 10.1128/mSystems.00213-17
   O'Neill LAJ, 2008, IMMUNOL REV, V226, P10, DOI 10.1111/j.1600-065X.2008.00701.x
   ONeill LAJ, 1995, INT J CLIN LAB RES, V25, P169, DOI 10.1007/BF02592694
   OShaughnessy J., 2016, AM SOC CLIN ONCOL
   Ping PH, 2016, ARCH BIOCHEM BIOPHYS, V604, P20, DOI 10.1016/j.abb.2016.06.001
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Ramírez J, 2018, EXPERT OPIN DRUG SAF, V17, P727, DOI 10.1080/14740338.2018.1486819
   Ray AL, 2018, INT J CANCER, V142, P1702, DOI 10.1002/ijc.31191
   REINECKER HC, 1993, CLIN EXP IMMUNOL, V94, P174
   RUBARTELLI A, 1990, EMBO J, V9, P1503, DOI 10.1002/j.1460-2075.1990.tb08268.x
   Sakai K, 2015, J BIOCHEM, V157, P271, DOI 10.1093/jb/mvv027
   Schauer IG, 2013, NEOPLASIA, V15, P409, DOI 10.1593/neo.121228
   Schmitt M., NAT REV IMMUNOL, P1
   Sconocchia G, 2014, NEOPLASIA, V16, P31, DOI 10.1593/neo.131568
   Sengüven B, 2011, MED ORAL PATOL ORAL, V16, pE467, DOI 10.4317/medoral.16.e467
   Seruga B, 2008, NAT REV CANCER, V8, P887, DOI 10.1038/nrc2507
   Stanam A, 2016, ONCOTARGET, V7, P76087, DOI 10.18632/oncotarget.12590
   Stidham RW, 2018, CLIN COLON RECT SURG, V31, P168, DOI 10.1055/s-0037-1602237
   Su B, 2015, HEPATOLOGY, V61, P585, DOI 10.1002/hep.27551
   Sultana Z, 2018, ENVIRON MOL MUTAGEN, V59, P653, DOI 10.1002/em.22208
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Szabo G, 2012, J HEPATOL, V57, P642, DOI 10.1016/j.jhep.2012.03.035
   Tao L, 2018, CANCER LETT, V430, P215, DOI 10.1016/j.canlet.2018.03.045
   Tarassishin L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103432
   THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0
   Upadhyay R, 2008, HUM IMMUNOL, V69, P179, DOI 10.1016/j.humimm.2008.01.012
   Vangsted AJ, 2012, BRIT J HAEMATOL, V158, P515, DOI 10.1111/j.1365-2141.2012.09141.x
   Vikhreva P, 2017, BIOCHEM BIOPH RES CO, V482, P498, DOI 10.1016/j.bbrc.2016.10.085
   Voigt C, 2017, P NATL ACAD SCI USA, V114, P12994, DOI 10.1073/pnas.1705165114
   Wang Y, 2014, MUCOSAL IMMUNOL, V7, P1106, DOI 10.1038/mi.2013.126
   Wang YL, 2018, J CELL BIOCHEM, V119, P2545, DOI 10.1002/jcb.26416
   Waugh J, 2005, BIODRUGS, V19, P189, DOI 10.2165/00063030-200519030-00005
   Whiteley A., 2016, AM SOC CLIN ONCOL
   Wiedemann GM, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1175794
   Willett C.G., 2012, NATURE, V5
   Wu S., 2014, INT J GYNECOL CANCER, V24
   Wu TC, 2018, CANCER RES, V78, P5243, DOI 10.1158/0008-5472.CAN-18-0413
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu H, 2014, ASIAN PAC J CANCER P, V15, P8741, DOI 10.7314/APJCP.2014.15.20.8741
   Xue LP, 2019, ONCOL RES, V27, P557, DOI 10.3727/096504018X15264647024196
   Yang D.-R., J BIOL CHEM, V288
   Yigit M, 2017, MOL CLIN ONCOL, V6, P708, DOI 10.3892/mco.2017.1195
   Yoshimoto S, 2013, NATURE, V499, P97, DOI 10.1038/nature12347
   Yusoff M, 2021, Educ Med J, V13, P43
   Zhou L, 2019, NATURE, V568, P405, DOI 10.1038/s41586-019-1082-x
NR 121
TC 6
Z9 7
U1 1
U2 9
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1567-5769
EI 1878-1705
J9 INT IMMUNOPHARMACOL
JI Int. Immunopharmacol.
PD APR
PY 2022
VL 105
AR 108577
DI 10.1016/j.intimp.2022.108577
EA FEB 2022
PG 10
WC Immunology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Pharmacology & Pharmacy
GA 1F9MJ
UT WOS:000795483500003
PM 35121226
DA 2025-01-04
ER

PT J
AU Hameedat, F
   Pizarroso, NA
   Teixeira, N
   Pinto, S
   Sarmento, B
AF Hameedat, Fatima
   Pizarroso, Nuria A.
   Teixeira, Natalia
   Pinto, Soraia
   Sarmento, Bruno
TI Functionalized FcRn-targeted nanosystems for oral drug delivery: A new
   approach to colorectal cancer treatment
SO EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
LA English
DT Article
DE Colorectal cancer; FcRn; Nanomedicines; Oral delivery; Targeted therapy
ID HISTONE DEACETYLASE INHIBITOR; POROUS SILICON NANOPARTICLES; PHASE-II;
   MONOCLONAL-ANTIBODIES; MECHANISTIC BASIS; IMMUNOGLOBULIN-G; SERUM IGG;
   RECEPTOR; ALBUMIN; NANOMEDICINE
AB Colorectal cancer (CRC) is the second type of cancer with the highest lethality rate. The current chemotherapy to treat CRC causes systemic toxicity, unsatisfying response rate, and low tumor-specific selectivity, which is mainly administered by invasive routes. The chronic and aggressive nature of cancers may require long-term regimens. Thus, the oral route is preferred. However, the orally administered drugs still need to surpass the harsh environment of the gastrointestinal tract and the biological barriers. Nanotechnology is a promising strategy to overcome the oral route limitations. Targeted nanoparticle systems decorated with functional groups can enhance the delivery of anticancer agents to tumor sites. It is described in the literature that the neonatal Fc receptor (FcRn) is expressed in cancer tissue and overexpressed in CRC epithelial cells. However, the impact of FcRn-targeted nanosystems in the treatment of CRC has been poorly investigated. This review article discusses the current knowledge on the involvement of the FcRn in CRC, as well as to critically assess its relevance as a target for further localization of oral nanocarriers in CRC tumor cells. Finally, a brief overview of cancer therapeutics, strategies to design the nanoparticles of anticancer drugs and a review of decorated nanoparticles with FcRn moieties are explored.
C1 [Hameedat, Fatima; Pizarroso, Nuria A.; Teixeira, Natalia; Pinto, Soraia; Sarmento, Bruno] Univ Porto, i3S, Inst Invest & Inovacao Saude, Rua Alfredo Allen 208, P-4200393 Porto, Portugal.
   [Hameedat, Fatima] Univ Angers, Fac Hlth, Pharm Sch, NANOMED EMJMD, Angers, France.
   [Hameedat, Fatima; Teixeira, Natalia; Pinto, Soraia; Sarmento, Bruno] Univ Porto, INEB, Inst Engn Biomed, Rua Alfredo Allen 208, P-4200393 Porto, Portugal.
   [Teixeira, Natalia] Univ Porto, Fac Sci, Dept Chem & Biochem, Rua Campo Alegre, P-4169007 Porto, Portugal.
   [Pinto, Soraia] Univ Porto, ICBAS, Inst Ciencias Biomed Abel Salazar, Rua Jorge Viterbo Ferreira 228, P-4150180 Porto, Portugal.
   [Sarmento, Bruno] IUCS, CESPU, Rua Cent Gandra 1317, P-4585116 Gandra, Portugal.
C3 Universidade do Porto; i3S - Instituto de Investigacao e Inovacao em
   Saude, Universidade do Porto; Universite d'Angers; Universidade do
   Porto; Universidade do Porto; Universidade do Porto
RP Sarmento, B (corresponding author), Univ Porto, i3S, Inst Invest & Inovacao Saude, Rua Alfredo Allen 208, P-4200393 Porto, Portugal.
EM bruno.sarmento@i3s.up.pt
RI Teixeira, Natália/KBD-4547-2024; Sarmento, Bruno/J-6265-2013
OI Pinto, Soraia/0000-0003-3171-8122; Teixeira,
   Natalia/0000-0002-0102-1810; Hameedat, Fatima/0000-0003-2279-6655;
   Sarmento, Bruno/0000-0001-5763-7553
FU FCT -Fundacao para a Ciencia e a Tecnologia/Ministerio da Ciencia,
   Tecnologia e Ensino Superior [PTDC/NAN-MAT/ 1431/2021]; COST (European
   Cooperation in Science and Technology) [CA17140]; FCT
   [SFRH/BD/144719/2019]; Erasmus Mundus Joint master's degree (EMJMD),
   spe-cifically Drug Delivery of Nanomedicine Program; (NANOMED program);
   Fundação para a Ciência e a Tecnologia [SFRH/BD/144719/2019,
   PTDC/NAN-MAT/1431/2021] Funding Source: FCT
FX This work was financed by Portuguese funds through FCT -Fundacao para a
   Ciencia e a Tecnologia/Ministerio da Ciencia, Tecnologia e Ensino
   Superior in the framework of the project PTDC/NAN-MAT/ 1431/2021 and by
   COST Action CA17140 "Cancer Nanomedicine from the Bench to the Bedside"
   supported by COST (European Cooperation in Science and Technology).
   Soraia Pinto would like to acknowledge FCT for the financial support
   through PhD grant SFRH/BD/144719/2019. Fatima Hameedat acknowledges the
   Erasmus Mundus Joint master's degree (EMJMD), spe-cifically Drug
   Delivery of Nanomedicine Program; (NANOMED program) for providing her
   the scholarship.
CR Akilesh S, 2007, J IMMUNOL, V179, P4580, DOI 10.4049/jimmunol.179.7.4580
   Amidon S, 2015, AAPS PHARMSCITECH, V16, P731, DOI 10.1208/s12249-015-0350-9
   [Anonymous], 2016, CURR PROTOC PHARM
   Azevedo C, 2021, ADV DRUG DELIVER REV, V175, DOI 10.1016/j.addr.2021.04.016
   Azevedo C, 2020, J CONTROL RELEASE, V327, P161, DOI 10.1016/j.jconrel.2020.08.005
   Azevedo C, 2018, DRUG DISCOV TODAY, V23, P944, DOI 10.1016/j.drudis.2017.08.011
   Baker K, 2014, FRONT IMMUNOL, V5, DOI [10.3389/fimmu.2014.00408, 10.3389/fimmu.2014.00664]
   Baker K, 2013, IMMUNITY, V39, P1095, DOI 10.1016/j.immuni.2013.11.003
   Baker K, 2009, SEMIN IMMUNOPATHOL, V31, P223, DOI 10.1007/s00281-009-0160-9
   Baldwin J, 2002, J NATL CANCER I, V94, P1191
   Barani M, 2021, J NANOPART RES, V23, DOI 10.1007/s11051-020-05129-6
   Bartczak D, 2011, LANGMUIR, V27, P10119, DOI 10.1021/la2022177
   Bern M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.abb0580
   Oliveira ALCDL, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13081321
   Carrascosa JM, 2013, ACTAS DERMO-SIFILOGR, V104, P471, DOI 10.1016/j.ad.2013.02.005
   Castaneda DC, 2020, CANCER MED-US, V9, P4736, DOI 10.1002/cam4.3067
   Castaneda DC, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02259
   Chaudhury C, 2003, J EXP MED, V197, P315, DOI 10.1084/jem.20021829
   Chawla SP, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11000
   Chawla SP, 2015, JAMA ONCOL, V1, P1272, DOI 10.1001/jamaoncol.2015.3101
   Chia J, 2018, J BIOL CHEM, V293, P6363, DOI 10.1074/jbc.M117.817064
   Cohen MH, 2007, ONCOLOGIST, V12, P356, DOI 10.1634/theoncologist.12-3-356
   CUMMINGS JH, 1987, AM J CLIN NUTR, V45, P1243, DOI 10.1093/ajcn/45.5.1243
   Dinesen A, 2022, BIOCONJUGATE CHEM, V33, P333, DOI 10.1021/acs.bioconjchem.1c00561
   Drago JZ, 2021, NAT REV CLIN ONCOL, V18, P327, DOI 10.1038/s41571-021-00470-8
   Einzig Avi I., 1996, Am J Ther, V3, P750, DOI 10.1097/00045391-199611000-00003
   Ensign LM, 2012, ADV DRUG DELIVER REV, V64, P557, DOI 10.1016/j.addr.2011.12.009
   Essa D, 2020, FRONT BIOENG BIOTECH, V8, DOI 10.3389/fbioe.2020.00048
   EVANS DF, 1988, GUT, V29, P1035, DOI 10.1136/gut.29.8.1035
   Fondevila F, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0308-1
   FRIEND DR, 1985, J MED CHEM, V28, P51, DOI 10.1021/jm00379a012
   FRIEND DR, 1984, J MED CHEM, V27, P261, DOI 10.1021/jm00369a005
   Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234
   Gamboa JM, 2013, ADV DRUG DELIVER REV, V65, P800, DOI 10.1016/j.addr.2013.01.003
   Giusti RM, 2007, ONCOLOGIST, V12, P577, DOI 10.1634/theoncologist.12-5-577
   Graeser R, 2008, INT J CANCER, V122, P1145, DOI 10.1002/ijc.23050
   Hassan MS, 2018, TRANSL ONCOL, V11, P426, DOI 10.1016/j.tranon.2018.01.022
   Hassanin I, 2020, CANCER DRUG RESIST, V3, P930, DOI 10.20517/cdr.2020.68
   Hirsch Bradford R, 2011, Cancer Manag Res, V3, P79, DOI 10.2147/CMR.S11250
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Huang JR, 2019, CANCERS, V11, DOI 10.3390/cancers11030281
   Ignat'eva NV, 2019, B EXP BIOL MED+, V167, P120, DOI 10.1007/s10517-019-04474-4
   Indoria S, 2020, INT J PHARMACEUT, V582, DOI 10.1016/j.ijpharm.2020.119314
   Isaacs JT, 2014, ONCOTARGET, V5, P8093, DOI 10.18632/oncotarget.2378
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Juliano R, 2013, NAT REV DRUG DISCOV, V12, P171, DOI 10.1038/nrd3958
   Kennedy PJ, 2018, ACTA BIOMATER, V81, P208, DOI 10.1016/j.actbio.2018.09.043
   Koo OM, 2005, NANOMED-NANOTECHNOL, V1, P193, DOI 10.1016/j.nano.2005.06.004
   Krauss AC, 2019, CLIN CANCER RES, V25, P2685, DOI 10.1158/1078-0432.CCR-18-2990
   Larsen MT, 2020, J CONTROL RELEASE, V322, P53, DOI 10.1016/j.jconrel.2020.03.004
   Larsen Maja Thim, 2016, Mol Cell Ther, V4, P3
   Li L, 2021, NANOMED-NANOTECHNOL, V34, DOI 10.1016/j.nano.2021.102369
   Lombardi S, 2021, BRIT J HAEMATOL, V194, P453, DOI 10.1111/bjh.17559
   Lu L, 2011, J VIROL, V85, P10542, DOI 10.1128/JVI.05441-11
   Macri C, 2021, MOL IMMUNOL, V139, P193, DOI 10.1016/j.molimm.2021.07.024
   Mansoor S, 2019, POLYMERS-BASEL, V11, DOI 10.3390/polym11091380
   Mantripragada KC, 2016, FUTURE ONCOL, V12, P1125, DOI 10.2217/fon-2015-0006
   Martins JP, 2022, BIOACT MATER, V9, P299, DOI 10.1016/j.bioactmat.2021.08.007
   Martins JP, 2018, ACS APPL MATER INTER, V10, P44354, DOI 10.1021/acsami.8b20821
   Martins JP, 2018, SMALL, V14, DOI 10.1002/smll.201800462
   Martins JP, 2016, PHARMACOL THERAPEUT, V161, P22, DOI 10.1016/j.pharmthera.2016.03.007
   Mei L, 2013, ADV DRUG DELIVER REV, V65, P880, DOI 10.1016/j.addr.2012.11.005
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Miwa M, 1998, EUR J CANCER, V34, P1274, DOI 10.1016/S0959-8049(98)00058-6
   Monnet C, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00039
   Nag OK, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11100543
   Novotny-Diermayr V, 2010, MOL CANCER THER, V9, P642, DOI 10.1158/1535-7163.MCT-09-0689
   Oliveira JP, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50424-5
   Overman MJ, 2018, ANN ONCOL, V29, P139, DOI 10.1093/annonc/mdx688
   Papachristos A, 2016, DRUG DELIV, V23, P1662, DOI 10.3109/10717544.2014.998323
   Philip Anil K, 2010, Oman Med J, V25, P79, DOI 10.5001/omj.2010.24
   Pilati D, 2020, EXPERT OPIN DRUG MET, V16, P783, DOI 10.1080/17425255.2020.1801633
   Pridgen EM, 2015, EXPERT OPIN DRUG DEL, V12, P1459, DOI 10.1517/17425247.2015.1018175
   Pridgen EM, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3007049
   Pyzik M, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01540
   Pyzik M, 2015, J IMMUNOL, V194, P4595, DOI 10.4049/jimmunol.1403014
   Qiao SW, 2008, P NATL ACAD SCI USA, V105, P9337, DOI 10.1073/pnas.0801717105
   Qin JJ, 2016, J CONTROL RELEASE, V237, P101, DOI 10.1016/j.jconrel.2016.07.008
   RAGHAVAN M, 1995, BIOCHEMISTRY-US, V34, P14649, DOI 10.1021/bi00045a005
   Rath T, 2013, J CLIN IMMUNOL, V33, pS9, DOI 10.1007/s10875-012-9768-y
   Ravasco JMJM, 2019, CHEM-EUR J, V25, P43, DOI 10.1002/chem.201803174
   Roos AA, 2008, BIOMACROMOLECULES, V9, P2104, DOI 10.1021/bm701399m
   RUBINSTEIN A, 1990, BIOPHARM DRUG DISPOS, V11, P465, DOI 10.1002/bdd.2510110602
   Rudnik-Jansen I, 2021, J CONTROL RELEASE, V337, P248, DOI 10.1016/j.jconrel.2021.07.007
   Salonen J, 2008, J PHARM SCI-US, V97, P632, DOI 10.1002/jps.20999
   Santhanam S, 2015, J BIOMED MATER RES A, V103, P2300, DOI 10.1002/jbm.a.35366
   Santos HA, 2014, NANOMEDICINE-UK, V9, P535, DOI [10.2217/NNM.13.223, 10.2217/nnm.13.223]
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2020, JAMA ONCOL, V6, P927, DOI 10.1001/jamaoncol.2020.0571
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Saxena A, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00580
   SCHELINE RR, 1973, PHARMACOL REV, V25, P451
   Schlothauer T, 2013, MABS-AUSTIN, V5, P576, DOI 10.4161/mabs.24981
   Shen BQ, 2012, NAT BIOTECHNOL, V30, P184, DOI 10.1038/nbt.2108
   Shi YA, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-19170-y
   Shields AF, 2001, AM J CLIN ONCOL-CANC, V24, P96, DOI 10.1097/00000421-200102000-00019
   SIMISTER NE, 1985, EUR J IMMUNOL, V15, P733, DOI 10.1002/eji.1830150718
   Sinha VR, 2004, INT J PHARMACEUT, V278, P1, DOI 10.1016/j.ijpharm.2004.01.044
   Sleep D, 2015, EXPERT OPIN DRUG DEL, V12, P793, DOI 10.1517/17425247.2015.993313
   Smith JP, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11121766
   Smith KM, 2018, EXPERT REV ANTICANC, V18, P611, DOI 10.1080/14737140.2018.1480942
   Sockolosky JT, 2015, ADV DRUG DELIVER REV, V91, P109, DOI 10.1016/j.addr.2015.02.005
   Sousa AR, 2019, J PHARMACOL EXP THER, V370, P657, DOI 10.1124/jpet.118.254441
   Stern RM, 2019, THER ADV HEMATOL, V10, DOI 10.1177/2040620719874728
   STORY CM, 1994, J EXP MED, V180, P2377, DOI 10.1084/jem.180.6.2377
   Strickler JH, 2012, ONCOLOGIST, V17, P513, DOI 10.1634/theoncologist.2012-0003
   VANCUTSEM E, 2014, ANN ONCOL S3, V25, P1, DOI DOI 10.1093/annonc/mdu260
   Vatandoust S, 2015, WORLD J GASTROENTERO, V21, P11767, DOI 10.3748/wjg.v21.i41.11767
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang HS, 2011, J MED CHEM, V54, P4694, DOI 10.1021/jm2003552
   Wang WR, 2011, DRUG METAB DISPOS, V39, P1469, DOI 10.1124/dmd.111.039453
   Ward ES, 2003, INT IMMUNOL, V15, P187, DOI 10.1093/intimm/dxg018
   Weiner LM, 2010, NAT REV IMMUNOL, V10, P317, DOI 10.1038/nri2744
   Werengowska-Ciecwierz K, 2015, ADV COND MATTER PHYS, V2015, DOI 10.1155/2015/198175
   Wicki A, 2015, J CONTROL RELEASE, V200, P138, DOI 10.1016/j.jconrel.2014.12.030
   Xie XY, 2020, ADV THER, V37, P4233, DOI 10.1007/s12325-020-01447-2
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu B, 2017, MAT SCI ENG C-MATER, V78, P420, DOI 10.1016/j.msec.2017.04.113
   Xu YN, 2020, J CONTROL RELEASE, V322, P486, DOI 10.1016/j.jconrel.2020.04.006
   Ye LL, 2011, NAT BIOTECHNOL, V29, P158, DOI 10.1038/nbt.1742
   Yoshida M, 2004, IMMUNITY, V20, P769, DOI 10.1016/j.immuni.2004.05.007
   Yoshida M, 2006, J CLIN INVEST, V116, P2142, DOI 10.1172/JCI27821
   Yun T, 2016, CANCER RES TREAT, V48, P465, DOI 10.4143/crt.2015.061
   Zhang XY, 2019, J MATER CHEM B, V7, P3537, DOI 10.1039/c9tb00181f
   Zhu XP, 2001, J IMMUNOL, V166, P3266, DOI 10.4049/jimmunol.166.5.3266
NR 125
TC 5
Z9 6
U1 2
U2 18
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0928-0987
EI 1879-0720
J9 EUR J PHARM SCI
JI Eur. J. Pharm. Sci.
PD SEP 1
PY 2022
VL 176
AR 106259
DI 10.1016/j.ejps.2022.106259
EA JUL 2022
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 3R9AB
UT WOS:000839196000005
PM 35842140
OA gold
DA 2025-01-04
ER

PT J
AU Delaye, M
   Ibadioune, S
   Julie, C
   Marin, C
   Lupinacci, R
   Vacher, S
   Ahmanache, L
   Antonio, S
   Schnitzler, A
   Buecher, B
   Mariani, P
   Allory, Y
   Grati, OT
   Emile, JF
   Neuzillet, C
   Bieche, I
AF Delaye, Matthieu
   Ibadioune, Sabrina
   Julie, Catherine
   Marin, Cristi
   Lupinacci, Renato
   Vacher, Sophie
   Ahmanache, Ladidi
   Antonio, Samantha
   Schnitzler, Anne
   Buecher, Bruno
   Mariani, Pascale
   Allory, Yves
   Grati, Olfa T.
   Emile, Jean F.
   Neuzillet, Cindy
   Bieche, Ivan
TI Rational testing for gene fusion in colorectal cancer: MSI and
   <i>RAS</i>-<i>BRAF</i> wild-type metastatic colorectal cancer as target
   population for systematic screening
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Article
DE Gene fusion; Colorectal cancer; Targeted therapy; Medico-economics
ID POSITIVE SOLID TUMORS
AB Gene fusions provide access to new therapeutic opportunities for patients treated for a colorectal cancer (CRC). However, they do not excess 1% of patients. A better identification of patients in whom gene fusions are highly prevalent is a major issue in a therapeutic and medico-economics perspective. This study assesses the rates of gene fusions in CRC patients with MSI/RAS-BRAF (c) in our routine practice detected with a commercially available NGS-based fusion panel. Among the 130 MSI CRC tumors, 43 (33%) were KRASNRAS-BRAF(WT). A gene fusion was detected in 7 ( 25.9%) of the 27 MSI/RAS-BRAF(WT) samples, which had RNA suitable for analysis after quality control. These fusions involved mainly NTRK1/3 (n = 5), as well as ALK (n = 1) and BRAF (n = 1). In the present study, we confirm that patients with MSI/RAS-BRAF(WT) CRCs represent a subpopulation in which targetable gene fusions are overrepresented. Our results support the use of a two-step algorithm for molecular screening, in which metastatic CRC patients would have routine MSI and RAS/BRAF testing, and then only those with MSI/RAS-BRAF(WT) would be screened with dedicated NGS RNA panel for gene fusions. (C) 2022 Elsevier Ltd. All rights reserved.
C1 [Delaye, Matthieu; Neuzillet, Cindy] Paris Saclay Univ, Versailles St Quentin Univ, Curie Inst, Dept Med Oncol, St Cloud, France.
   [Ibadioune, Sabrina; Vacher, Sophie; Ahmanache, Ladidi; Antonio, Samantha; Schnitzler, Anne; Grati, Olfa T.; Bieche, Ivan] Paris Univ, Inst Curie, Dept Genet, Paris, France.
   [Julie, Catherine; Marin, Cristi; Emile, Jean F.] Univ Paris Saclay, Univ Versailles SQY UVSQ, Ambroise Pare Hosp, Assistance Publ Hop Paris AP HP, Saclay, France.
   [Lupinacci, Renato] Paris Saclay Univ, Versailles St Quentin Univ, Ambroise Pare Hosp, Dept Digest & Oncol Surg, Boulogne Billancourt, France.
   [Buecher, Bruno] Paris Univ, Inst Curie, Dept Oncogenet, Paris, France.
   [Mariani, Pascale] Paris Univ, Inst Curie, Dept Surg, Paris, France.
   [Allory, Yves] Versailles St Quentin Univ, Univ Paris Saclay, Hop Foch, Inst Curie, Saclay, France.
   [Bieche, Ivan] Cochin Inst, INSERM U1016, Res Unit, Paris, France.
   [Neuzillet, Cindy] Paris Saclay Univ, Versailles St Quentin Univ, Curie Inst, Dept Med Oncol, 35 Rue Dailly, St Cloud, France.
C3 UNICANCER; Universite PSL; Institut Curie; Universite Paris Saclay;
   UNICANCER; Universite PSL; Institut Curie; Universite Paris Cite;
   Universite Paris Saclay; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Ambroise-Pare - APHP; Universite Paris Saclay;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire
   Ambroise-Pare - APHP; Universite Paris Cite; UNICANCER; Universite PSL;
   Institut Curie; Universite Paris Cite; UNICANCER; Universite PSL;
   Institut Curie; UNICANCER; Universite PSL; Institut Curie; Universite
   Paris Saclay; Hospital Foch; Universite Paris Cite; Institut National de
   la Sante et de la Recherche Medicale (Inserm); UNICANCER; Universite
   PSL; Institut Curie; Universite Paris Saclay
RP Neuzillet, C (corresponding author), Paris Saclay Univ, Versailles St Quentin Univ, Curie Inst, Dept Med Oncol, 35 Rue Dailly, St Cloud, France.
EM cindy.neuzillet@curie.fr
RI ; NEUZILLET, Cindy/K-1378-2017; Bieche, Ivan/O-7399-2017
OI Delaye, Matthieu/0000-0002-2435-4757; VACHER,
   Sophie/0000-0002-0042-6023; NEUZILLET, Cindy/0000-0001-7037-7477;
   Bieche, Ivan/0000-0002-2430-5429
CR Amatu A, 2019, ANN ONCOL, V30, pVIII5, DOI 10.1093/annonc/mdz383
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Bocciarelli C, 2021, HUM PATHOL, V114, P99, DOI 10.1016/j.humpath.2021.05.006
   Cocco E, 2019, CANCER RES, V79, P1047, DOI 10.1158/0008-5472.CAN-18-3126
   Doebele RC, 2020, LANCET ONCOL, V21, P271, DOI 10.1016/S1470-2045(19)30691-6
   Fang MG, 2014, MOL CELL, V55, P904, DOI 10.1016/j.molcel.2014.08.010
   Hechtman JF, 2016, MOL CANCER RES, V14, P296, DOI 10.1158/1541-7786.MCR-15-0392-T
   Hong DS, 2020, LANCET ONCOL, V21, P531, DOI 10.1016/S1470-2045(19)30856-3
   MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0
   Mosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014
   Pietrantonio F, 2018, ANN ONCOL, V29, P1394, DOI 10.1093/annonc/mdy090
   Pietrantonio F, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx089
   Rosas D, 2021, CANCERS, V13, DOI 10.3390/cancers13205038
   Singhi AD, 2019, GASTROENTEROLOGY, V156, P2242, DOI 10.1053/j.gastro.2019.02.037
   Wang J, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-03108-6
   Westphalen CB, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00206-y
NR 16
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD JUL
PY 2022
VL 170
BP 85
EP 90
DI 10.1016/j.ejca.2022.04.024
EA MAY 2022
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 1Y4WC
UT WOS:000808141900009
PM 35598360
OA Green Published, Bronze
DA 2025-01-04
ER

PT J
AU Shaghaghi, Z
   Hosseinimehr, SJ
AF Shaghaghi, Zahra
   Hosseinimehr, Seyed Jalal
TI Synergistic Effect of Epidermal Growth Factor Receptor Inhibitors and
   Ionization Radiation in Cancer Treatment
SO RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY
LA English
DT Review
DE Cancer; EGFR; monoclonal antibodies; radiation therapy; sensitizing;
   tyrosine kinase inhibitors
ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITOR; ADVANCED RECTAL-CANCER;
   RANDOMIZED PHASE-II; EGFR INHIBITORS; MONOCLONAL-ANTIBODY; ESOPHAGEAL
   CANCER; PREOPERATIVE RADIOTHERAPY; CONCURRENT RADIOTHERAPY; INDUCTION
   CHEMOTHERAPY
AB Background: Epidermal Growth Factor Receptor (EGFR) is overexpressed in a variety of cancers and is associated with poor prognosis, low survival rate, and resistance of cancer cells to treatment.
   Objective: This review discusses the combined effect of EGFR inhibitor and radiation therapy in cancer treatment.
   Method: The recent literature and patent applications were considered in which the role of EGFR in cancer and EGFR inhibitors, as well as the preclinical and clinical studies are related to synergistic effects of EGFR inhibitors and ionizing radiation in the treatment of various cancers.
   Results: The specific inhibition has been introduced as targeted therapy for treatment of cancers. Two major pharmacological approaches for inhibition of EGFR are monoclonal antibodies and small-molecule tyrosine kinase inhibitors. The use of these agents in combination with ionizing radiation results in increasing the cytotoxicity on tumors that are rich in expression of EGFR.
   Conclusion: The combination of EGFR inhibitor and ionizing radiation has synergistic effect and resulted in improvement of radiotherapy in patients.
C1 [Shaghaghi, Zahra; Hosseinimehr, Seyed Jalal] Mazandaran Univ Med Sci, Fac Pharm, Dept Radiopharm, Sari, Iran.
C3 Mazandaran University of Medical Sciences
RP Hosseinimehr, SJ (corresponding author), Mazandaran Univ Med Sci, Fac Pharm, Dept Radiopharm, Sari, Iran.
EM sjhosseinim@yahoo.com
RI Hosseinimehr, Seyed/E-5889-2011; Shaghaghi, Zahra/AAY-1294-2021
OI Hosseinimehr, Seyed Jalal/0000-0001-8055-8036; Shaghaghi,
   Zahra/0000-0002-7467-4820
CR Abedi SM, 2016, FUTURE ONCOL, V12, P1165, DOI 10.2217/fon.16.19
   Ahsan A, 2016, ADV EXP MED BIOL, V893, P137, DOI 10.1007/978-3-319-24223-1_7
   Amorino GP, 2002, MOL BIOL CELL, V13, P2233, DOI 10.1091/mbc.01-12-0572
   Ang KK, 2014, J CLIN ONCOL, V32, P2940, DOI 10.1200/JCO.2013.53.5633
   Arora A, 2005, J PHARMACOL EXP THER, V315, P971, DOI 10.1124/jpet.105.084145
   Baskar R, 2012, INT J MED SCI, V9, P193, DOI 10.7150/ijms.3635
   Baumann M, 2004, LUNG CANCER, V45, pS187, DOI 10.1016/j.lungcan.2004.07.975
   Becerra CR, 2013, J THORAC ONCOL, V8, P1425, DOI 10.1097/JTO.0b013e3182a46c3b
   Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007
   Berardi R, 2013, ONCOTARGETS THER, V6, P563, DOI 10.2147/OTT.S28155
   Bianco C, 2002, CLIN CANCER RES, V8, P3250
   Bianco R, 2007, INT J BIOCHEM CELL B, V39, P1416, DOI 10.1016/j.biocel.2007.05.008
   Blumenschein GR, 2011, J CLIN ONCOL, V29, P2312, DOI 10.1200/JCO.2010.31.7875
   Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422
   Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0
   Bradley JD, 2015, LANCET ONCOL, V16, P187, DOI 10.1016/S1470-2045(14)71207-0
   Buchsbaum D. J., 2002, Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody, Patent No. 2002045653
   Buchsbaum D. J., 2005, Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody, Patent No. 20050281814
   Buchsbaum D. J., 2002, Combination radiation therapy and chemotherapy in conjunction with administration of growth factor receptor antibody, Patent No. 20020076408
   Cerniglia GJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006539
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Chen C, 2007, J CLIN ONCOL, V25, P4880, DOI 10.1200/JCO.2007.12.9650
   Chen YM, 2013, J CHIN MED ASSOC, V76, P249, DOI 10.1016/j.jcma.2013.01.010
   Chinnaiyan P, 2005, CANCER RES, V65, P3328, DOI 10.1158/0008-5472.CAN-04-3547
   Crosby T, 2013, LANCET ONCOL, V14, P627, DOI 10.1016/S1470-2045(13)70136-0
   Czito BG, 2006, J CLIN ONCOL, V24, P656, DOI 10.1200/JCO.2005.04.1749
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   Dewdney A, 2012, J CLIN ONCOL, V30, P1620, DOI 10.1200/JCO.2011.39.6036
   Díaz B, 2013, J CELL BIOL, V201, P279, DOI 10.1083/jcb.201209151
   Dittmann K, 2005, RADIOTHER ONCOL, V76, P157, DOI 10.1016/j.radonc.2005.06.022
   Dobelbower MC, 2006, ANTI-CANCER DRUG, V17, P95, DOI 10.1097/01.cad.0000185178.26862.4c
   Duffy A, 2008, ANN ONCOL, V19, P86, DOI 10.1093/annonc/mdm441
   Dutta PR, 2007, CANCER LETT, V254, P165, DOI 10.1016/j.canlet.2007.02.006
   Dziadziuszko R, 2012, ANN ONCOL, V23, P193, DOI 10.1093/annonc/mds351
   Feofanova N, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/461687
   Freeman DJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-47
   Gao L, 2014, ASIAN PAC J CANCER P, V15, P6161, DOI 10.7314/APJCP.2014.15.15.6161
   Gatzemeier U, 2007, J CLIN ONCOL, V25, P1545, DOI 10.1200/JCO.2005.05.1474
   Ghi M, 2013, INT J RADIAT ONCOL, V87, pS2, DOI 10.1016/j.ijrobp.2013.06.014
   Giralt J, 2015, LANCET ONCOL, V16, P221, DOI 10.1016/S1470-2045(14)71200-8
   Govindan R, 2011, J CLIN ONCOL, V29, P3120, DOI 10.1200/JCO.2010.33.4979
   Harari P. M., 2006, Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor, Patent No. 20060084666
   Harari P. M., 2009, Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor, Patent No. 20090253721
   Harari PM, 2004, INT J RADIAT ONCOL, V58, P976, DOI 10.1016/j.ijrobp.2003.09.097
   HARARI PM, 2006, Patent No. 2006110176
   Heath CH, 2013, INT J RADIAT ONCOL, V85, P1275, DOI 10.1016/j.ijrobp.2012.09.030
   Herbst RS, 2002, SEMIN ONCOL, V29, P18, DOI 10.1053/sonc.2002.35644
   Huang SM, 2002, CANCER RES, V62, P4300
   Huang SM, 2000, CLIN CANCER RES, V6, P2166
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Iannitti D, 2005, AM J CLIN ONCOL-CANC, V28, P570, DOI 10.1097/01.coc.0000184682.51193.00
   Jain RK, 2005, SCIENCE, V307, P58, DOI 10.1126/science.1104819
   Javvadi P, 2012, MOL CANCER RES, V10, P1359, DOI 10.1158/1541-7786.MCR-12-0482-T
   Jeggo P, 2009, INT J RADIAT BIOL, V85, P1061, DOI 10.3109/09553000903261263
   Jiang W. D., 2016, Antiepidermal growth factor receptor (EGFR) antibodies, Patent No. 2015184403
   Khoo C, 2015, TRANSL LUNG CANCER R, V4, P126, DOI 10.3978/j.issn.2218-6751.2015.01.10
   Kim SY, 2013, INT J RADIAT ONCOL, V85, P201, DOI 10.1016/j.ijrobp.2012.03.048
   Krause M, 2005, RADIOTHER ONCOL, V74, P109, DOI 10.1016/j.radonc.2004.10.011
   Krause M, 2004, RADIOTHERAPY ONCOLOG
   Kumari R., 2015, Combined treatment for cancer resistant to an epidermal growth factor receptor kinase inhibitor, Patent No. 20150283138
   Lee CC, 2014, EXPERT OPIN INV DRUG, V23, P1333, DOI 10.1517/13543784.2014.928283
   Lee JG, 2015, NEOPLASIA, V17, P190, DOI 10.1016/j.neo.2014.12.008
   Lefebvre JL, 2013, J CLIN ONCOL, V31, P853, DOI 10.1200/JCO.2012.42.3988
   Li CR, 2015, MOL CANCER THER, V14, P2049, DOI 10.1158/1535-7163.MCT-15-0155
   Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008
   Löbrich M, 2007, NAT REV CANCER, V7, P861, DOI 10.1038/nrc2248
   López-Tarruella S, 2012, FUTURE ONCOL, V8, P671, DOI [10.2217/FON.12.66, 10.2217/fon.12.66]
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Magné N, 2008, EUR J CANCER, V44, P2133, DOI 10.1016/j.ejca.2008.06.029
   Martinou M, 2011, CANCER GENOM PROTEOM, V8, P33
   Martins RG, 2013, J CLIN ONCOL, V31, P1415, DOI 10.1200/JCO.2012.46.3299
   Maurel J, 2006, INT J RADIAT ONCOL, V66, P1391, DOI 10.1016/j.ijrobp.2006.07.008
   Mellinghoff IK, 2005, NEW ENGL J MED, V353, P2012, DOI 10.1056/NEJMoa051918
   Mesía R, 2015, LANCET ONCOL, V16, P208, DOI 10.1016/S1470-2045(14)71198-2
   Milas L, 2009, INT J RADIAT BIOL, V79, P539
   Murphy M, 2011, DRUG RESIST UPDATE, V14, P177, DOI 10.1016/j.drup.2011.02.004
   Muthusami S, 2015, J CANCER RES CLIN, V141, P203, DOI 10.1007/s00432-014-1802-4
   Nasu S, 2001, INT J RADIAT ONCOL, V51, P474, DOI 10.1016/S0360-3016(01)01671-6
   Neill T, 2012, J BIOL CHEM, V287, P5492, DOI 10.1074/jbc.M111.283499
   Ng WL, 2013, TRANSL CANCER RES, V2, P442, DOI 10.3978/j.issn.2218-676X.2013.10.03
   Niederst MJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004652
   Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018
   Nyati MK, 2006, NAT REV CANCER, V6, P876, DOI 10.1038/nrc1953
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Peeters M, 2008, ALIMENT PHARM THER, V28, P269, DOI 10.1111/j.1365-2036.2008.03717.x
   Peng XH, 2006, J BIOL CHEM, V281, P25903, DOI 10.1074/jbc.M603414200
   Perez-Torres M, 2006, J BIOL CHEM, V281, P40183, DOI 10.1074/jbc.M607958200
   Pfister DG, 2006, J CLIN ONCOL, V24, P1072, DOI 10.1200/JCO.2004.00.1792
   Pinto C, 2011, ANN ONCOL, V22, P2424, DOI 10.1093/annonc/mdq782
   Pirker R, 2013, TARGET ONCOL, V8, P47, DOI 10.1007/s11523-012-0244-7
   Pore N, 2003, CANCER RES, V63, P236
   Riesterer O, 2009, RADIOTHER ONCOL, V92, P383, DOI 10.1016/j.radonc.2009.07.009
   Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234
   Rouschop KMA, 2009, CURR MOL MED, V9, P417, DOI 10.2174/156652409788167131
   Safran H, 2008, INT J RADIAT ONCOL, V70, P391, DOI 10.1016/j.ijrobp.2007.07.2325
   Salehifar E, 2016, DRUG DISCOV TODAY, V21, P654, DOI 10.1016/j.drudis.2016.02.019
   Sartor CI, 2004, NAT CLIN PRACT ONCOL, V1, P80, DOI 10.1038/ncponc0048
   Schick U, 2012, EXPERT OPIN BIOL TH, V12, P119, DOI 10.1517/14712598.2012.643864
   Selzer E, 2013, EXPERT REV CLIN PHAR, V6, P663, DOI 10.1586/17512433.2013.841540
   Shintani S, 2003, INT J CANCER, V107, P1030, DOI 10.1002/ijc.11437
   Simmons A. D., 2016, Therapeutic combinations for treating cancer, Patent No. 2016164217
   Sirotnak FM, 2000, CLIN CANCER RES, V6, P4885
   Soulieres D, 2004, J CLIN ONCOL, V22, P77, DOI 10.1200/JCO.2004.06.075
   Sridhar SS, 2003, LANCET ONCOL, V4, P397, DOI 10.1016/S1470-2045(03)01137-9
   Stinchcombe TE, 2008, J THORAC ONCOL, V3, P250, DOI 10.1097/JTO.0b013e3181653cf4
   Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404
   Thomas SM, 2004, CANCER TREAT REV, V30, P255, DOI 10.1016/j.ctrv.2003.10.003
   Tomblyn MB, 2012, J THORAC ONCOL, V7, P906, DOI 10.1097/JTO.0b013e31824c7bed
   Toulany M, 2015, SEMIN CANCER BIOL, V35, P180, DOI 10.1016/j.semcancer.2015.07.003
   Valentini V, 2008, INT J RADIAT ONCOL, V72, P644, DOI 10.1016/j.ijrobp.2008.01.046
   Van den Heuvel MM, 2014, RADIOTHER ONCOL, V110, P126, DOI 10.1016/j.radonc.2013.10.009
   Vermorken JB, 2008, NEW ENGL J MED, V359, P1116, DOI 10.1056/NEJMoa0802656
   Wakeling AE, 2002, CURR OPIN PHARMACOL, V2, P382, DOI 10.1016/S1471-4892(02)00183-2
   Waksal H, 2005, Treatment of refractory human tumors with epidermal growth factor receptor antagonists, Patent No. 20050112120
   Waksal H. W., 2009, Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases, Patent No. 20090297509
   Wan J, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0399-7
   Wang H, 2012, FASEB J, V26, P73, DOI 10.1096/fj.11-191064
   Wang Y, 2011, Sensitizer for radiotherapy and chemotherapy of malignant tumor, Patent No. 102145170
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052
   Wheeler D. L., 2015, Her3 inhibitor for modulating radiosensitivity, Patent No. 20150017096
   Williams KJ, 2002, BRIT J CANCER, V86, P1157, DOI 10.1038/sj/bjc/6600182
   Winter SC, 2007, CANCER RES, V67, P3441, DOI 10.1158/0008-5472.CAN-06-3322
   Xu M, 2014, DNA CELL BIOL, V33, P275, DOI 10.1089/dna.2013.2184
   Yang QY, 2015, ONCOTARGETS THER, V8, P819, DOI 10.2147/OTT.S60032
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Yu HA, 2013, J NATL COMPR CANC NE, V11, P161, DOI 10.6004/jnccn.2013.0024
   Zheng DJ, 2013, ASIAN PAC J CANCER P, V14, P4485, DOI 10.7314/APJCP.2013.14.8.4485
   Zhong L, 2008, CANCER RES, V68, P7237, DOI 10.1158/0008-5472.CAN-08-1529
NR 128
TC 3
Z9 3
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1574-8928
EI 2212-3970
J9 RECENT PAT ANTI-CANC
JI Recent Patents Anti-Canc. Drug Discov.
PY 2017
VL 12
IS 4
BP 323
EP 339
DI 10.2174/1574892812666170829150057
PG 17
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA FW5AN
UT WOS:000425328500003
PM 28875828
DA 2025-01-04
ER

PT J
AU McAlpine, JN
   Temkin, SM
   Mackay, HJ
AF McAlpine, Jessica N.
   Temkin, Sarah M.
   Mackay, Helen J.
TI Endometrial cancer: Not your grandmother's cancer
SO CANCER
LA English
DT Review
DE clinical trials; endometrial cancer; genomics; Lynch syndrome; molecular
   classification; obesity and lifestyle factors; DNA polymerase epsilon
   catalytic subunit (POLE) mutations; targeted therapy; The Cancer Genome
   Atlas (TCGA)
ID PHASE-III TRIAL; BODY-MASS INDEX; WHOLE ABDOMINAL RADIOTHERAPY; REVISED
   BETHESDA GUIDELINES; PELVIC RADIATION-THERAPY; MICROSATELLITE
   INSTABILITY; COLORECTAL-CANCER; LYNCH-SYNDROME; SCREENING-STRATEGIES;
   ADJUVANT TREATMENT
AB Worldwide, the incidence of endometrial carcinoma (EC) is rapidly increasing, and the highest disease burden is reported in North America and Western Europe. Although the prognosis remains good for patients with are diagnosed with early stage EC, for those with recurrent or metastatic disease, the options are few, and the median overall survival is short. It is imperative to gain a greater understanding of all aspects of EC, limit its effect on scarce health care resources and, more importantly, prevent this cancer from significantly impacting future generations of women. An exciting new era of endometrial cancer research and clinical management has begun that incorporates biologically and clinically relevant genomic and clinicopathologic parameters. Continued collaborative research efforts and funding are essential if we are to advance our understanding of this disease and improve clinical outcomes. Cancer 2016. (c) 2016 American Cancer Society. Cancer 2016;122:2787-2798. (c) 2016 American Cancer Society
C1 [McAlpine, Jessica N.] Univ British Columbia, Dept Gynecol & Obstet, Div Gynecol Oncol, 2775 Laurel St,Sixth Floor, Vancouver, BC V5Z 1M9, Canada.
   [McAlpine, Jessica N.] British Columbia Canc Agcy, 2775 Laurel St,Sixth Floor, Vancouver, BC V5Z 1M9, Canada.
   [Temkin, Sarah M.] Johns Hopkins Sch Med, Kelly Gynecol Oncol Serv, Baltimore, MD USA.
   [Mackay, Helen J.] Univ Toronto, Sunnybrook Odette Canc Ctr, Fac Med, Div Med Oncol & Hematol, Toronto, ON, Canada.
C3 University of British Columbia; British Columbia Cancer Agency; Johns
   Hopkins University; Johns Hopkins Medicine; University of Toronto;
   Sunnybrook Health Science Center; Sunnybrook Research Institute
RP McAlpine, JN (corresponding author), Univ British Columbia, Dept Gynecol & Obstet, Div Gynecol Oncol, 2775 Laurel St,Sixth Floor, Vancouver, BC V5Z 1M9, Canada.; McAlpine, JN (corresponding author), British Columbia Canc Agcy, 2775 Laurel St,Sixth Floor, Vancouver, BC V5Z 1M9, Canada.
EM jessica.mcalpine@vch.ca
FU Canadian Institute of Health Research; Canadian Cancer Society; British
   Columbia Cancer Foundation
FX Jessica N. McAlpine has recently been awarded funding from the Canadian
   Institute of Health Research, the Canadian Cancer Society, and the
   British Columbia Cancer Foundation for projects that pertain to
   endometrial cancer research. The authors have no conflicts of interest
   to disclose.
CR AALDERS J, 1980, OBSTET GYNECOL, V56, P419
   Aghajanian C, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.5500
   Aghajanian C, 2011, J CLIN ONCOL, V29, P2259, DOI 10.1200/JCO.2010.32.6397
   Alkushi A, 2010, INT J GYNECOL PATHOL, V29, P343, DOI 10.1097/PGP.0b013e3181cd6552
   Alonso DF, 1998, BREAST CANCER RES TR, V50, P83, DOI 10.1023/A:1006058409974
   Anglesio MS, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv428
   [Anonymous], MOD PATHOL S2
   [Anonymous], SGO QUAL MEAS PASS C
   Arnold M, 2015, LANCET ONCOL, V16, P36, DOI 10.1016/S1470-2045(14)71123-4
   BARRETT RJ, 1993, AM J CLIN ONCOL-CANC, V16, P494, DOI 10.1097/00000421-199312000-00007
   Bender D, 2015, GYNECOL ONCOL, V138, P507, DOI 10.1016/j.ygyno.2015.07.018
   Bendifallah S, 2015, BRIT J CANCER, V112, P793, DOI 10.1038/bjc.2015.35
   Beretta Martina, 2015, Advances in Biological Regulation, V58, P1, DOI 10.1016/j.jbior.2014.11.004
   Berg A, 2015, ONCOTARGET, V6, P1327, DOI 10.18632/oncotarget.2675
   BOKHMAN JV, 1983, GYNECOL ONCOL, V15, P10, DOI 10.1016/0090-8258(83)90111-7
   Bouwman F, 2015, GYNECOL ONCOL, V139, P369, DOI 10.1016/j.ygyno.2015.09.020
   Bruegl AS, 2014, CANCER PREV RES, V7, P686, DOI 10.1158/1940-6207.CAPR-13-0359
   Buchanan DD, 2014, J CLIN ONCOL, V32, P90, DOI 10.1200/JCO.2013.51.2129
   Choi M, 2009, RADIOTHER ONCOL, V91, P114, DOI 10.1016/j.radonc.2008.08.002
   Clarke BA, 2010, J CLIN PATHOL, V63, P410, DOI 10.1136/jcp.2009.071225
   Coleman RL, 2012, GYNECOL ONCOL, V127, P538, DOI 10.1016/j.ygyno.2012.08.020
   Colombo N, 2016, ANN ONCOL, V27, P16, DOI 10.1093/annonc/mdv484
   Colombo N, 2013, ANN ONCOL, V24, P33, DOI 10.1093/annonc/mdt353
   CREASMAN WT, 1987, CANCER, V60, P2035, DOI 10.1002/1097-0142(19901015)60:8+<2035::AID-CNCR2820601515>3.0.CO;2-8
   Creutzberg CL, 2000, LANCET, V355, P1404, DOI 10.1016/S0140-6736(00)02139-5
   Crosbie EJ, 2010, CANCER EPIDEM BIOMAR, V19, P3119, DOI 10.1158/1055-9965.EPI-10-0832
   Dandapani S.V., 2015, SCI WORLD J, V2015, P1, DOI 10.1155/2015/483208
   DeLeon MC, 2014, J GYNECOL ONCOL, V25, P136, DOI 10.3802/jgo.2014.25.2.136
   Demaria S, 2007, INT J RADIAT BIOL, V83, P819, DOI 10.1080/09553000701481816
   Dewan MZ, 2009, CLIN CANCER RES, V15, P5379, DOI 10.1158/1078-0432.CCR-09-0265
   Egoavil C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079737
   Ferguson SE, 2014, CANCER-AM CANCER SOC, V120, P3932, DOI 10.1002/cncr.28933
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fiorica JV, 2004, GYNECOL ONCOL, V92, P10, DOI 10.1016/j.ygyno.2003.11.008
   Fleming GF, 2004, J CLIN ONCOL, V22, P2159, DOI 10.1200/JCO.2004.07.184
   Galaal K, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006655.pub2
   Gallego CJ, 2015, J CLIN ONCOL, V33, P2084, DOI 10.1200/JCO.2014.59.3665
   Gallos ID, 2012, AM J OBSTET GYNECOL, V207, DOI 10.1016/j.ajog.2012.08.011
   Getz G, 2013, NATURE, V497, P67, DOI 10.1038/nature12113
   Gilks CB, 2013, AM J SURG PATHOL, V37, P874, DOI 10.1097/PAS.0b013e31827f576a
   Goodfellow PJ, 2015, J CLIN ONCOL, V33, P4301, DOI 10.1200/JCO.2015.63.9518
   GORDON J, 1977, NEW ENGL J MED, V297, P570, DOI 10.1056/NEJM197709152971102
   Hall MJ, 2016, GYNECOL ONCOL, V140, P565, DOI 10.1016/j.ygyno.2016.01.019
   Hawkes AL, 2014, CONTEMP CLIN TRIALS, V39, P14, DOI 10.1016/j.cct.2014.06.014
   Hoang LN, 2013, AM J SURG PATHOL, V37, P1421, DOI 10.1097/PAS.0b013e31828c63ed
   Horowitz NS, 2015, GYNECOL ONCOL, V138, P201, DOI 10.1016/j.ygyno.2015.04.002
   Hubbs JL, 2013, OBSTET GYNECOL, V121, P1172, DOI 10.1097/AOG.0b013e31828d6186
   Janda M, 2010, LANCET ONCOL, V11, P772, DOI 10.1016/S1470-2045(10)70145-5
   Johnson N, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003175.pub2
   Jung KW, 2014, CANCER RES TREAT, V46, P124, DOI 10.4143/crt.2014.46.2.124
   KELLEY RM, 1961, NEW ENGL J MED, V264, P216, DOI 10.1056/NEJM196102022640503
   Keys HM, 2004, GYNECOL ONCOL, V92, P744, DOI 10.1016/j.ygyno.2003.11.048
   Kim YB, 1997, CANCER, V79, P320, DOI 10.1002/(SICI)1097-0142(19970115)79:2<320::AID-CNCR15>3.0.CO;2-2
   Kitchener H, 2009, LANCET, V373, P125, DOI 10.1016/S0140-6736(08)61766-3
   Köbel M, 2008, PLOS MED, V5, P1749, DOI 10.1371/journal.pmed.0050232
   Kokka F, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007926.pub2
   Kong TW, 2015, J GYNECOL ONCOL, V26, P32, DOI 10.3802/jgo.2015.26.1.32
   Kurman RJ, 2013, GYNECOL ONCOL, V129, P271, DOI 10.1016/j.ygyno.2013.03.029
   Kwon JS, 2009, OBSTET GYNECOL, V114, P736, DOI 10.1097/AOG.0b013e3181b96ec6
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le Gallo M, 2012, NAT GENET, V44, P1310, DOI 10.1038/ng.2455
   Lee NK, 2007, OBSTET GYNECOL, V109, P655, DOI 10.1097/01.AOG.0000255980.88205.15
   Lim MC, 2013, J GYNECOL ONCOL, V24, P298, DOI 10.3802/jgo.2013.24.4.298
   Lu KH, 2005, OBSTET GYNECOL, V105, P569, DOI 10.1097/01.AOG.0000154885.44002.ae
   Mandi H, 2015, J MINIM INVAS GYN, V22, P94, DOI 10.1016/j.jmig.2014.07.014
   McConechy MK, 2015, GYNECOL ONCOL, V137, P306, DOI 10.1016/j.ygyno.2015.01.541
   McConechy MK, 2016, CLIN CANCER RES, V22, P2865, DOI 10.1158/1078-0432.CCR-15-2233
   McConechy MK, 2012, J PATHOL, V228, P20, DOI 10.1002/path.4056
   McCourt CK, 2007, GYNECOL ONCOL, V104, P535, DOI 10.1016/j.ygyno.2006.09.019
   McMeekin DS, 2014, GYNECOL ONCOL, V134, P438, DOI 10.1016/j.ygyno.2014.07.078
   McTiernan A, 2008, NAT REV CANCER, V8, P205, DOI 10.1038/nrc2325
   Miller D, 2012, GYNECOL ONCOL, V125, P771, DOI 10.1016/j.ygyno.2012.03.034
   Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0
   Murali R, 2014, LANCET ONCOL, V15, pE268, DOI 10.1016/S1470-2045(13)70591-6
   Oza AM, 2011, J CLIN ONCOL, V29, P3278, DOI 10.1200/JCO.2010.34.1578
   Panici PB, 2008, JNCI-J NATL CANCER I, V100, P1707, DOI 10.1093/jnci/djn397
   Piñol V, 2005, JAMA-J AM MED ASSOC, V293, P1986, DOI 10.1001/jama.293.16.1986
   Rabban JT, 2014, AM J SURG PATHOL, V38, P793, DOI 10.1097/PAS.0000000000000177
   Rahib L, 2014, CANCER RES, V74, P2913, DOI 10.1158/0008-5472.CAN-14-0155
   Randall ME, 2006, J CLIN ONCOL, V24, P36, DOI 10.1200/JCO.2004.00.7617
   Rochet N, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-236
   Rodolakis A, 2015, INT J GYNECOL CANCER, V25, P1258, DOI 10.1097/IGC.0000000000000493
   Ryan P, 2012, CANCER-AM CANCER SOC, V118, P681, DOI 10.1002/cncr.26323
   Salvesen HB, 2012, LANCET ONCOL, V13, pE353, DOI 10.1016/S1470-2045(12)70213-9
   Schmid D, 2015, EUR J EPIDEMIOL, V30, P397, DOI 10.1007/s10654-015-0017-6
   Sheikh MA, 2014, FUTURE ONCOL, V10, P2561, DOI 10.2217/fon.14.192
   SHEPHERD JH, 1989, BRIT J OBSTET GYNAEC, V96, P889, DOI 10.1111/j.1471-0528.1989.tb03341.x
   Shia J, 2008, J MOL DIAGN, V10, P293, DOI 10.2353/jmoldx.2008.080031
   Singh M, 2007, GYNECOL ONCOL, V106, P325, DOI 10.1016/j.ygyno.2007.03.042
   Slomovitz BM, 2015, J CLIN ONCOL, V33, P930, DOI 10.1200/JCO.2014.58.3401
   Smits A, 2015, BMJ OPEN, V5, DOI 10.1136/bmjopen-2015-009291
   Smits A, 2015, GYNECOL ONCOL, V137, P180, DOI 10.1016/j.ygyno.2015.01.540
   Stelloo E, 2015, MODERN PATHOL, V28, P836, DOI 10.1038/modpathol.2015.43
   Stelloo E, 2014, GYNECOL ONCOL, V133, P197, DOI 10.1016/j.ygyno.2014.02.012
   Sutton G, 2005, GYNECOL ONCOL, V97, P755, DOI 10.1016/j.ygyno.2005.03.011
   Talhouk A, 2015, BRIT J CANCER, V113, P299, DOI 10.1038/bjc.2015.190
   THIGPEN JT, 1979, CANCER TREAT REP, V63, P21
   Trovik J, 2011, CLIN CANCER RES, V17, P3368, DOI 10.1158/1078-0432.CCR-10-2412
   Uccella S, 2016, J MINIM INVAS GYN, V23, P53, DOI 10.1016/j.jmig.2015.08.007
   Umar A, 2004, J NATL CANCER I, V96, P261, DOI 10.1093/jnci/djh034
   Vasen HFA, 2013, GUT, V62, P812, DOI 10.1136/gutjnl-2012-304356
   Walker JL, 2009, J CLIN ONCOL, V27, P5331, DOI 10.1200/JCO.2009.22.3248
   Wartko P, 2013, CANCER EPIDEMIOL, V37, P374, DOI 10.1016/j.canep.2013.03.008
   Westin SN, 2015, MOL ONCOL, V9, P1694, DOI 10.1016/j.molonc.2015.04.014
   Whitney CW, 2004, GYNECOL ONCOL, V92, P4, DOI 10.1016/j.ygyno.2003.09.018
   Wrenn DC, 2011, GYNECOL ONCOL, V122, P59, DOI 10.1016/j.ygyno.2011.03.007
   Zeimet AG, 2013, JNCI-J NATL CANCER I, V105, P1142, DOI 10.1093/jnci/djt144
NR 107
TC 127
Z9 137
U1 2
U2 23
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0008-543X
EI 1097-0142
J9 CANCER-AM CANCER SOC
JI Cancer
PD SEP 15
PY 2016
VL 122
IS 18
BP 2787
EP 2798
DI 10.1002/cncr.30094
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DW4OZ
UT WOS:000383624100006
PM 27308732
OA Bronze
DA 2025-01-04
ER

PT J
AU Asghari, M
   Abazari, MF
   Bokharaei, H
   Nouri, M
   Poortahmasebi, V
   Askari, H
   Torabinejad, S
   Ardalan, A
   Negaresh, N
   Ataei, A
   Pazooki, P
   Poorebrahim, M
AF Asghari, Matin
   Abazari, Mohammad Foad
   Bokharaei, Hanieh
   Nouri, Maryam Aleagha
   Poortahmasebi, Vahdat
   Askari, Hassan
   Torabinejad, Sepehr
   Ardalan, Abbas
   Negaresh, Navid
   Ataei, Atousa
   Pazooki, Parisa
   Poorebrahim, Mansour
TI Key genes and regulatory networks involved in the initiation,
   progression and invasion of colorectal cancer
SO FUTURE SCIENCE OA
LA English
DT Article
DE biomarkers; CRC stages; hub genes; PPI networks; signaling pathways
ID PROTEOMIC ANALYSIS; HUMAN COLON; CPG ISLAND; CELLS; METASTASIS;
   EXPRESSION; INHIBITION; ESTROGEN; METHYLATION; ENRICHMENT
AB Aim: Until now, identification of drug targets for treatment of patients with specific stages of colorectal cancer (CRC) has remained a challenging field of research. Herein, we aimed to identify the key genes and regulatory networks involved in each stage of CRC. Results: The results of gene expression profiles were integrated with protein-protein interaction networks, and topologically analyzed. The most important regulatory genes (e.g., CDK1, UBC, ESR1 and ATXN1) and signaling pathways (e.g., Wnt, MAPK and JAK-STAT) in CRC initiation, progression and metastasis were identified. In vitro analysis confirmed some in silico findings. Conclusion: Our study introduces functional hub genes, subnetworks, prioritizes signaling pathways and novel biomarkers in CRC that may guide further development of targeted therapy programs.
   Lay abstract: A comprehensive view of the molecular mechanisms involved in colorectal cancer (CRC) pathogenesis has been demonstrated. Cell cycle and signal transduction genes were contributors to CRC initiation and progression. In contrast to stage IV, the stages I-III of CRC shared a notable number of common genes suggesting their close gene signatures. The efficacy of these predictions has been validated using two colon cancer cell lines in vitro.
C1 [Asghari, Matin] Royan Inst Biotechnol, ACECR, Cell Sci Res Ctr, Dept Mol Biotechnol, Esfahan, Iran.
   [Abazari, Mohammad Foad; Nouri, Maryam Aleagha; Torabinejad, Sepehr] Islamic Azad Univ, Dept Genet, Tehran Med Branch, Tehran, Iran.
   [Bokharaei, Hanieh] Azad Univ, Fac Basic Sci, Dept Genet, Sci & Res Branch, Tehran, Iran.
   [Poortahmasebi, Vahdat] Univ Tehran Med Sci, Sch Publ Hlth, Dept Virol, Hepatitis Mol Lab B, Tehran, Iran.
   [Askari, Hassan] Univ Tehran Med Sci, Fac Med, Dept Physiol, Tehran, Iran.
   [Ardalan, Abbas] Arak Univ, Fac Sci, Dept Biol, Arak, Iran.
   [Negaresh, Navid] Islamic Azad Univ, Fac Med, Dept Med, Qom Branch, Qom, Iran.
   [Ataei, Atousa] Kazan Fed Univ, Inst Fundamental Med & Biol, Kazan, Russia.
   [Pazooki, Parisa] Islamic Azad Univ, Dept Biol Sci, Tehran North Branch, Tehran, Iran.
   [Poorebrahim, Mansour] Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran.
C3 Academic Center for Education, Culture & Research (ACECR); Islamic Azad
   University; Islamic Azad University; Tehran University of Medical
   Sciences; Tehran University of Medical Sciences; Arak University;
   Islamic Azad University; Kazan Federal University; Islamic Azad
   University; Tehran University of Medical Sciences
RP Poorebrahim, M (corresponding author), Univ Tehran Med Sci, Sch Adv Technol Med, Dept Med Biotechnol, Tehran, Iran.
EM mpoorebrahim@razi.tums.ac.ir
RI Poortahmasebi, Vahdat/M-9433-2019; Poorebrahim, Mansour/AAP-4133-2021;
   Torabinejad, Sepehr/AAY-7128-2021; Askari, Hassan/AAO-8945-2021
OI Abazari, Mohammad Foad/0000-0002-3383-8526; Askari,
   Hassan/0000-0002-2285-2592; Poorebrahim, Mansour/0000-0003-0956-3507;
   Torabinejad, Sepehr/0000-0003-0616-8077; Bokharaie,
   Honey/0000-0002-3826-7582
CR Abal M, 2004, ONCOGENE, V23, P1737, DOI 10.1038/sj.onc.1207299
   Ahn J, 2011, BIOINFORMATICS, V27, P1846, DOI 10.1093/bioinformatics/btr283
   Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Bader GD, 2003, NUCLEIC ACIDS RES, V31, P248, DOI 10.1093/nar/gkg056
   Barrett T, 2013, NUCLEIC ACIDS RES, V41, pD991, DOI 10.1093/nar/gks1193
   Beale G, 2016, BRIT J CANCER, V115, P682, DOI 10.1038/bjc.2016.238
   Belshaw NJ, 2005, BIOCHEM SOC T, V33, P709, DOI 10.1042/BST0330709
   Bothos J, 2003, ONCOGENE, V22, P7101, DOI 10.1038/sj.onc.1206831
   Chirica M, 2012, PRESSE MED, V41, P58, DOI 10.1016/j.lpm.2011.10.009
   David Y, 2010, J BIOL CHEM, V285, P8595, DOI 10.1074/jbc.M109.089003
   Duffy MJ, 2015, BIOMARK MED, V9, P337, DOI 10.2217/bmm.15.3
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6
   Hayashida M, 2016, BIOMARK MED, V10, P621, DOI 10.2217/bmm-2015-0047
   Holst F, 2007, NAT GENET, V39, P655, DOI 10.1038/ng2006
   Huang WW, 2011, INT J ONCOL, V38, P1067, DOI 10.3892/ijo.2011.922
   ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536
   Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27
   Kennelly R, 2008, LANCET ONCOL, V9, P385, DOI 10.1016/S1470-2045(08)70100-1
   Kerrien S, 2012, NUCLEIC ACIDS RES, V40, pD841, DOI 10.1093/nar/gkr1088
   Kim HA, 2012, J CLIN INVEST, V122, P3248, DOI 10.1172/JCI61216
   Kitano H, 2002, NATURE, V420, P206, DOI 10.1038/nature01254
   Korzeniewski N, 2012, NEOPLASIA, V14, P799, DOI 10.1593/neo.12580
   Krasilnikov M, 2003, ONCOGENE, V22, P4092, DOI 10.1038/sj.onc.1206598
   Kuleshov MV, 2016, NUCLEIC ACIDS RES, V44, pW90, DOI 10.1093/nar/gkw377
   Lim TG, 2014, CANCER PREV RES, V7, P466, DOI 10.1158/1940-6207.CAPR-13-0387
   Liu YL, 2015, J CANCER RES CLIN, V141, P661, DOI 10.1007/s00432-014-1854-5
   Maere S, 2005, BIOINFORMATICS, V21, P3448, DOI 10.1093/bioinformatics/bti551
   Martin A, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-91
   Maryam I, 2016, RECENT PAT ANTI-CANC, V11, P1
   Novellasdemunt L, 2015, AM J PHYSIOL-CELL PH, V309, pC511, DOI 10.1152/ajpcell.00117.2015
   Oliveros J.C., 2007, VENNY INTERACTIVE TO
   Parikh JR, 2010, NUCLEIC ACIDS RES, V38, pW109, DOI 10.1093/nar/gkq424
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   Poortahmasebi V, 2016, HEPAT MON, V16, DOI 10.5812/hepatmon.36005
   Prasad TSK, 2009, NUCLEIC ACIDS RES, V37, pD767, DOI 10.1093/nar/gkn892
   Riihimäki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Sikandar SS, 2010, CANCER RES, V70, P1469, DOI 10.1158/0008-5472.CAN-09-2557
   Sonoshita M, 2015, CANCER DISCOV, V5, P198, DOI 10.1158/2159-8290.CD-14-0595
   Stark C, 2011, NUCLEIC ACIDS RES, V39, pD698, DOI 10.1093/nar/gkq1116
   Tan HT, 2012, J PROTEOME RES, V11, P1433, DOI 10.1021/pr2010956
   Tong X, 2011, EMBO REP, V12, P428, DOI 10.1038/embor.2011.49
   Vincan E, 2008, CLIN EXP METASTAS, V25, P657, DOI 10.1007/s10585-008-9156-4
   Wu M, 2016, ONCOTARGET, V7, P44534, DOI 10.18632/oncotarget.10003
   Wu Y, 2013, CANCER INVEST, V31, P7, DOI 10.3109/07357907.2012.743556
   Wu-Baer F, 2003, J BIOL CHEM, V278, P34743, DOI 10.1074/jbc.C300249200
   Wu-Baer F, 2010, MOL CELL BIOL, V30, P2787, DOI 10.1128/MCB.01056-09
   Xenarios I, 2002, NUCLEIC ACIDS RES, V30, P303, DOI 10.1093/nar/30.1.303
   Yu H, 2007, NAT REV IMMUNOL, V7, P41, DOI 10.1038/nri1995
   Zanzoni A, 2002, FEBS LETT, V513, P135, DOI 10.1016/S0014-5793(01)03293-8
   Zhang YQ, 2012, BRIT J CANCER, V107, P675, DOI 10.1038/bjc.2012.297
   Zhao L, 2007, J CANCER RES CLIN, V133, P771, DOI 10.1007/s00432-007-0222-0
   Zhou Q, 2017, CANCER INVEST, V35, P367, DOI 10.1080/07357907.2017.1283508
NR 53
TC 11
Z9 12
U1 0
U2 8
PU FUTURE SCI LTD
PI LONDON
PA UNITED HOUSE, 2 ALBERT PL, LONDON, N3 1QB, ENGLAND
SN 2056-5623
J9 FUTUR SCI OA
JI Futur. Sci. OA
PD MAR
PY 2018
VL 4
IS 3
AR FSO278
DI 10.4155/fsoa-2017-0108
PG 15
WC Medicine, Research & Experimental
WE Emerging Sources Citation Index (ESCI)
SC Research & Experimental Medicine
GA GN0CC
UT WOS:000438625200008
PM 29568567
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Arnold, D
   Prager, GW
   Quintela, A
   Stein, A
   Vera, SM
   Mounedji, N
   Taieb, J
AF Arnold, D.
   Prager, G. W.
   Quintela, A.
   Stein, A.
   Vera, S. Moreno
   Mounedji, N.
   Taieb, J.
TI Beyond second-line therapy in patients with metastatic colorectal
   cancer: a systematic review
SO ANNALS OF ONCOLOGY
LA English
DT Review
DE metastatic colorectal cancer; rechallenge; regorafenib; treatment beyond
   the second line; trifluridine/tipiracil
ID MULTICENTER PHASE-II; SUPPORTIVE CARE BSC; NINTEDANIB N PLUS;
   MITOMYCIN-C; OPEN-LABEL; OXALIPLATIN REINTRODUCTION; STANDARD
   CHEMOTHERAPY; 3RD-LINE CHEMOTHERAPY; TAS-102 MONOTHERAPY; PRETREATED
   PATIENTS
AB Background: The optimal chemotherapeutic regimen for use beyond the second line for patients with metastatic colorectal cancer (mCRC) remains unclear.
   Materials and methods: We systematically searched the Cochrane Database of Systematic Reviews, EMBASE and Medline for records published between January 2002 and May 2017, and cancer congress databases for records published between January 2014 and June 2017. Eligible studies evaluated the efficacy, safety and patient-reported outcomes of monotherapies or combination therapies at any dose and number of treatment cycles for use beyond the second line in patients with mCRC. Studies were assessed for design and quality, and a qualitative data synthesis was conducted to understand the impact of treatment on overall survival and other relevant cancer-related outcomes.
   Results: The search yielded 938 references of which 68 were included for qualitative synthesis. There was limited evidence to support rechallenge with chemotherapy, targeted therapy or both. Compared with placebo, an overall survival benefit for trifluridine/tipiracil (also known as TAS-102) or regorafenib has been shown for patients previously treated with conventional chemotherapy and targeted therapy. There was no evidence to suggest a difference in efficacy between these treatments. Patient choice and quality of life at this stage of treatment should also be considered when choosing an appropriate therapy.
   Conclusions: These findings support the introduction of an approved agent such as trifluridine/tipiracil or regorafenib beyond the second line before any rechallenge in patients with mCRC who have failed second-line treatment.
C1 [Arnold, D.; Quintela, A.] Inst CUF Oncol, Lisbon, Portugal.
   [Arnold, D.] Asklepios Tumorzentrum Hamburg, Hamburg, Germany.
   [Prager, G. W.] Med Univ Vienna, Dept Med 1, Vienna, Austria.
   [Prager, G. W.] Med Univ Vienna, Comprehens Canc Ctr Vienna, Vienna, Austria.
   [Stein, A.] Univ Hamburg, Hubertus Wald Tumor Ctr, Hamburg, Germany.
   [Stein, A.] Univ Hamburg, Dept Hematol & Oncol, Hamburg, Germany.
   [Vera, S. Moreno; Mounedji, N.] Serv Global Med Affairs, Oncol, Suresnes, France.
   [Taieb, J.] Paris Descartes Univ, Georges Pompidou European Hosp, Gastroenterol & Digest Oncol, Paris, France.
C3 Medical University of Vienna; Medical University of Vienna; University
   of Hamburg; University Medical Center Hamburg-Eppendorf; University of
   Hamburg; Assistance Publique Hopitaux Paris (APHP); Universite Paris
   Cite; Hopital Universitaire Europeen Georges-Pompidou - APHP
RP Arnold, D (corresponding author), Inst CUF Oncol, Oncol, Trav Castro N3, P-1350070 Lisbon, Portugal.
EM dirk.arnold@jmellosaude.pt
RI Prager, Gerald/AAS-8674-2021
OI taieb, julien/0000-0002-9955-4753; Prager, M.D.,
   Gerald/0000-0002-7854-7781
FU Servier
FX The medical writing assistance and bibliographic searching for this
   manuscript were supported by Servier (no grant number applies). All
   authors had a role in the design of the study, the analysis and
   interpretation of the results, the decision to publish, or the writing
   of the paper.
CR Abrahao ABK, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e15010
   Adenis A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2440-9
   André T, 2013, ANN ONCOL, V24, P412, DOI 10.1093/annonc/mds465
   [Anonymous], 2013, ASSESSING RISK BIAS
   [Anonymous], J CLIN ONCOL S
   [Anonymous], J CLIN ONCOL S
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bitossi R, 2008, ANTICANCER RES, V28, P3055
   Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Calegari MA, 2017, BRIT J CANCER, V116, P1279, DOI 10.1038/bjc.2017.109
   Chaix M, 2014, ONCOLOGY-BASEL, V87, P148, DOI 10.1159/000361031
   Cherny NI, 2015, ANN ONCOL, V26, P1547, DOI 10.1093/annonc/mdv249
   Chong G, 2005, BRIT J CANCER, V93, P510, DOI 10.1038/sj.bjc.6602733
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Dotan Efrat, 2012, J Gastrointest Cancer, V43, P562
   Ferrarotto R, 2012, EUR J CANCER, V48, P820, DOI 10.1016/j.ejca.2012.01.008
   Foubert F, 2014, DIGEST LIVER DIS, V46, P105, DOI 10.1016/j.dld.2013.07.002
   Gebbia V, 2006, CLIN COLORECTAL CANC, V5, P422, DOI 10.3816/CCC.2006.n.013
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guyatt GH, 2011, J CLIN EPIDEMIOL, V64, P1294, DOI 10.1016/j.jclinepi.2011.03.017
   Hartmann JT, 2004, ANTI-CANCER DRUG, V15, P473, DOI 10.1097/01.cad.0000127144.73043.57
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   Hickish T, 2016, ANN ONCOL         S2, V27, pii128
   Hurwitz H, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.676
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Jiménez-Fonseca P, 2015, CLIN TRANSL ONCOL, V17, P384, DOI 10.1007/s12094-014-1243-1
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Kidd MT, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.678
   Kim TW, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw370.14
   Kopetz S, 2017, J CLIN ONCOL, V35
   Kotaka M, 2016, ANN ONCOL         S2, V27
   Kotani D, 2015, EUR J CANCER, V51, pS364, DOI 10.1016/S0959-8049(16)31029-2
   Larsen FO, 2012, ACTA ONCOL, V51, P231, DOI 10.3109/0284186X.2011.614637
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee KW, 2014, CANCER CHEMOTH PHARM, V74, P447, DOI 10.1007/s00280-014-2515-8
   Lenz HJ, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.671
   Lenz HJ, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.660
   Li J, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3508
   Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
   Lièvre A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-347
   Maindrault-Goebel F, 2004, ANN ONCOL, V15, P1210, DOI 10.1093/annonc/mdh305
   Matsuda C, 2016, INT J CLIN ONCOL, V21, P566, DOI 10.1007/s10147-015-0911-7
   Mayer RJ, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3547
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   McLean J, 2016, CLIN COLORECTAL CANC, V15, P135, DOI 10.1016/j.clcc.2015.10.003
   McQuade RM, 2017, CURR MED CHEM, V24, P1537, DOI 10.2174/0929867324666170111152436
   Moriwaki T, 2018, ONCOLOGIST, V23, P7, DOI 10.1634/theoncologist.2017-0275
   Nielsen DL, 2014, CANCER TREAT REV, V40, P701, DOI 10.1016/j.ctrv.2014.02.006
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Park LC, 2012, WORLD J GASTROENTERO, V18, P1104, DOI 10.3748/wjg.v18.i10.1104
   Pietrantonio F, 2014, ANN ONCOL, V25, P404, DOI 10.1093/annonc/mdt547
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Ruzzo A, 2012, ONCOLOGIST, V17, P823, DOI 10.1634/theoncologist.2012-0081
   Saltz L, 2012, CLIN COLORECTAL CANC, V11, P101, DOI 10.1016/j.clcc.2011.05.006
   Saltz LB, 2007, J CLIN ONCOL, V25, P4557, DOI 10.1200/JCO.2007.12.0949
   Santini D, 2012, ANN ONCOL, V23, P2313, DOI 10.1093/annonc/mdr623
   Scartozzi M, 2006, TUMORI J, V92, P384, DOI 10.1177/030089160609200503
   Sclafani F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv258
   Shitara K, 2018, ASCO GASTR CANC S SA
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Siu LL, 2013, J CLIN ONCOL, V31, P2477, DOI 10.1200/JCO.2012.46.0543
   Spindler KLG, 2014, INT J CANCER, V135, P2215, DOI 10.1002/ijc.28863
   Sueda T, 2016, ANTICANCER RES, V36, P4299
   Suenaga M, 2015, DRUG DES DEV THER, V9, P3099, DOI 10.2147/DDDT.S85567
   Tabernero J, 2016, ANN ONCOL         S2, V27
   Tabernero J, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.698
   Takahashi T, 2016, CANCER CHEMOTH PHARM, V78, P585, DOI 10.1007/s00280-016-3109-4
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tonini G, 2013, J EXP CLIN CANC RES, V32, DOI 10.1186/1756-9966-32-92
   Van Cutsem E, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw435.12
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2016, ANN ONCOL, V27, P106
   Van Cutsem E, 2015, EUR J CANCER, V51, pS378, DOI 10.1016/S0959-8049(16)31060-7
   Van Cutsem E, 2015, ANN ONCOL, V26, P149, DOI 10.1093/annonc/mdu496
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P638
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3524
   Vogel A, 2017, CANCER TREAT REV, V59, P54, DOI 10.1016/j.ctrv.2017.04.007
   Vrdoljak E, 2008, J BUON, V13, P513
   Yanai T, 2012, ANTICANCER RES, V32, P5521
   Yoshida M, 2016, ONCOLOGY-BASEL, V91, P24, DOI 10.1159/000446372
   Yoshino T, 2012, LANCET ONCOL, V13, P993, DOI 10.1016/S1470-2045(12)70345-5
NR 83
TC 56
Z9 58
U1 0
U2 9
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD APR
PY 2018
VL 29
IS 4
BP 835
EP 856
DI 10.1093/annonc/mdy038
PG 22
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GE3VJ
UT WOS:000431140700015
PM 29452346
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Feliu, J
   de Corcuera, ID
   Manzano, JL
   Valladares-Ayerbes, M
   Alcaide, J
   García, TG
   Vera, R
   Sastre, J
AF Feliu, J.
   Diez de Corcuera, I.
   Manzano, J. L.
   Valladares-Ayerbes, M.
   Alcaide, J.
   Garcia Garcia, T.
   Vera, R.
   Sastre, J.
TI Effectiveness and safety of aflibercept for metastatic colorectal
   cancer: retrospective review within an early access program in Spain
SO CLINICAL & TRANSLATIONAL ONCOLOGY
LA English
DT Review
DE FOLFIRI; Aflibercept; Metastatic colorectal cancer; Named patient
   programme; Survival analysis
ID OXALIPLATIN-BASED CHEMOTHERAPY; PHASE-III; FLUOROURACIL; LEUCOVORIN;
   IRINOTECAN; BEVACIZUMAB; COMBINATION; TRIAL; SURVIVAL; THERAPY
AB Purpose In the VELOUR study, aflibercept + FOLFIRI regimen resulted in improved survival in metastatic colorectal cancer (mCRC) patients who progressed after oxaliplatin. The use of aflibercept outside the clinical trial framework needs to be further assessed in terms of effectiveness and tolerability.
   Methods Early access to aflibercept through a named patient programme (NPP) was provided to mCRC patients receiving FOLFIRI as second-line treatment in Spain. The effectiveness of aflibercept was assessed as progressionfree survival (PFS) achieved within the NPP population. Post hoc analyses on PFS were done according to certain baseline characteristics (K-RAS mutation, prior targeted therapy) or prognostic factors.
   Results Registries from 71 mCRC patients included in the NPP were reviewed retrospectively. The median age for the NPP population was 64 years (19.7 % aged >= 70 years) and 63.4 % patients had >= 2 metastases. A median PFS of 5.3 months (95 % CI, 3.6-8.5 months) was achieved, which did not depend on K-RAS mutation status or prior targeted therapy received. The risk of progression or death increased in patients with a poor prognosis as per the GERCOR score (performance status [PS] 1-2 and increased baseline lactate dehydrogenase [LDH] level) compared with patients with a good prognosis (PS 0 and normal LDH level) (median PFS: 2.6 vs. 8.3 months, respectively; p = 0.0124). Aflibercept was well tolerated, with a manageable toxicity profile.
   Conclusions Bearing in mind the differences in sample size, the PFS achieved with the aflibercept + FOLFIRI regimen in the real-life practice setting is comparable to that observed in the clinical trial setting.
C1 [Feliu, J.] Hosp Univ La Paz, Dept Med Oncol, Paseo Castellana 261, Madrid 28046, Spain.
   [Diez de Corcuera, I.] Hosp Galdakao Usansolo, Dept Med Oncol, Galdakao, Bizkaia, Spain.
   [Manzano, J. L.] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol, Dept Med Oncol, Barcelona, Spain.
   [Valladares-Ayerbes, M.] H Virgen Rocio, Dept Med Oncol, Seville, Spain.
   [Alcaide, J.] Hosp Costa Sol, Dept Med Oncol, Malaga, Spain.
   [Garcia Garcia, T.] Hosp Gen Univ Morales Meseguer, Dept Med Oncol, Murcia, Spain.
   [Vera, R.] Complejo Hosp Navarra, Dept Med Oncol, Pamplona, Spain.
   [Sastre, J.] H Clin San Carlos, Dept Med Oncol, Madrid, Spain.
   [Sastre, J.] Spanish Minist Sci & Innovat, Inst Carlos III, Ctr Affiliated Red Temat Invest Cooperat RD06 002, Dept Med Oncol, Madrid, Spain.
C3 Hospital Universitario La Paz; Galdakao Hospital; Hospital Germans Trias
   i Pujol; Institut Catala d'Oncologia; Meseguer General University
   Hospital Morales; Servicio Navarro de Salud - Osasunbidea
RP Feliu, J (corresponding author), Hosp Univ La Paz, Dept Med Oncol, Paseo Castellana 261, Madrid 28046, Spain.
EM jaimefeliu@hotmail.com; isabel.diazdecorcuerafrutos@osakidetza.eus;
   jmanzano@iconcologia.net; manuelj.valladares.sspa@juntadeandalucia.es;
   jalcaide@hcs.es; tggarc@gmail.com; ruth.vera.garcia@cfnavarra.es;
   jsastrev@salud.madrid.org
RI Valladares'Ayerbes, MANUEL/LDG-3881-2024
OI Alcaide Garcia, Julia/0000-0002-9301-1387
FU Sanofi
FX This study was supported by Sanofi. A. Del Campo (Pivotal SL) provided
   medical writing services on behalf of Sanofi Pharmaceuticals.
CR Bar J, 2014, CLIN COLORECTAL CANC, V13, P46, DOI 10.1016/j.clcc.2013.11.002
   Chau I, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-605
   Chibaudel B, 2011, ONCOLOGIST, V16, P1228, DOI 10.1634/theoncologist.2011-0039
   De Divitiis C, 2014, WORLD J GASTROENTERO, V20, P15049, DOI 10.3748/wjg.v20.i41.15049
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Hecht JR, 2011, J CLIN ONCOL, V29, P1997, DOI 10.1200/JCO.2010.29.4496
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   KEMENY N, 1983, AM J MED, V74, P786, DOI 10.1016/0002-9343(83)91066-5
   Köhne CH, 2002, ANN ONCOL, V13, P308, DOI 10.1093/annonc/mdf034
   Koukourakis MI, 2005, CLIN EXP METASTAS, V22, P25, DOI 10.1007/s10585-005-2343-7
   Pericay C., 2014, Farm Hosp., V38, P317, DOI [10.7399/fh.2014.38.4.7631, 10.7399/FH.2014.38.4.7631]
   Philipp AB, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-245
   Fernández MS, 2015, EXPERT OPIN DRUG SAF, V14, P1171, DOI 10.1517/14740338.2015.1057495
   Saltz LB, 2000, NEW ENGL J MED, V343, P905, DOI 10.1056/NEJM200009283431302
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Scartozzi M, 2012, BRIT J CANCER, V106, P799, DOI 10.1038/bjc.2012.17
   Tabernero J, 2014, EUR J CANCER, V50, P320, DOI 10.1016/j.ejca.2013.09.013
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Wu XZ, 2010, WORLD J GASTROENTERO, V16, P4084, DOI 10.3748/wjg.v16.i32.4084
NR 22
TC 16
Z9 16
U1 0
U2 6
PU SPRINGER INT PUBL AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 1699-048X
EI 1699-3055
J9 CLIN TRANSL ONCOL
JI Clin. Transl. Oncol.
PD APR
PY 2017
VL 19
IS 4
BP 498
EP 507
DI 10.1007/s12094-016-1556-3
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EO6YR
UT WOS:000396838900013
PM 27718155
DA 2025-01-04
ER

PT S
AU Meurette, O
AF Meurette, Olivier
BE Birbrair, A
TI Shaping of the Tumor Microenvironment by Notch Signaling
SO TUMOR MICROENVIRONMENT: SIGNALING PATHWAYS, PT A
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Cancer; Notch signaling; Microenvironment; Heterotypic interaction;
   Jag1; CAF; Stem cell; Tumor angiogenesis; Targeted therapy
ID BREAST-CANCER CELLS; MESENCHYMAL STEM-CELLS; T-CELLS; COLON-CANCER;
   CROSS-TALK; EXTRACELLULAR-MATRIX; ANTITUMOR IMMUNITY; EPITHELIAL-CELLS;
   TARGETING NOTCH; GAMMA-SECRETASE
AB The tumor microenvironment (TME) has become a major concern of cancer research both from a basic and a therapeutic point of view. Understanding the effect of a signaling pathway-and thus the effect of its targeting-in every aspect of the microenvironment is a prerequisite to predict and analyze the effect of a therapy. The Notch signaling pathway is involved in every component of the TME as well as in the interaction between the different parts of the TME. This review aims at describing how Notch signaling is impacting the TME and the consequences this may have when modulating Notch signaling in a therapeutic perspective.
C1 [Meurette, Olivier] Univ Lyon, Ctr Rech Cancerol Lyon,Ctr Leon Berard, Apoptosis Canc & Dev Lab,INSERM,U1052,UMR5286, Equipe Labellisee La Ligue,LabEx DEVweCAN,CNRS, Lyon, France.
C3 Universite Claude Bernard Lyon 1; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Centre National de la Recherche
   Scientifique (CNRS); CNRS - National Institute for Biology (INSB);
   UNICANCER; Centre Leon Berard
RP Meurette, O (corresponding author), Univ Lyon, Ctr Rech Cancerol Lyon,Ctr Leon Berard, Apoptosis Canc & Dev Lab,INSERM,U1052,UMR5286, Equipe Labellisee La Ligue,LabEx DEVweCAN,CNRS, Lyon, France.
EM olivier.meurette@lyon.unicancer.fr
RI Meurette, Olivier/GVS-8356-2022
CR Ali N, 2017, CELL, V169, P1119, DOI 10.1016/j.cell.2017.05.002
   Aster JC, 2017, ANNU REV PATHOL-MECH, V12, P245, DOI 10.1146/annurev-pathol-052016-100127
   Astudillo L, 2016, CANCER RES, V76, P3593, DOI 10.1158/0008-5472.CAN-16-0061
   Ayyanan A, 2006, P NATL ACAD SCI USA, V103, P3799, DOI 10.1073/pnas.0600065103
   Bassil R, 2011, J IMMUNOL, V187, P2322, DOI 10.4049/jimmunol.1100725
   Bayin NS, 2017, ONCOTARGET, V8, P64932, DOI 10.18632/oncotarget.18117
   Benedito R, 2013, EXP CELL RES, V319, P1281, DOI 10.1016/j.yexcr.2013.01.010
   Benedito R, 2009, CELL, V137, P1124, DOI 10.1016/j.cell.2009.03.025
   Biktasova AK, 2015, CANCER RES, V75, P4728, DOI 10.1158/0008-5472.CAN-14-1154
   Boareto M, 2015, P NATL ACAD SCI USA, V112, pE3836, DOI 10.1073/pnas.1511814112
   Boelens MC, 2014, CELL, V159, P499, DOI 10.1016/j.cell.2014.09.051
   Butcher DT, 2009, NAT REV CANCER, V9, P108, DOI 10.1038/nrc2544
   Cao ZW, 2014, CANCER CELL, V25, P350, DOI 10.1016/j.ccr.2014.02.005
   Chakrabarti R, 2018, SCIENCE, V360, P1421, DOI 10.1126/science.aan4153
   Chandler KB, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060544
   Charbonnier LM, 2015, NAT IMMUNOL, V16, P1162, DOI 10.1038/ni.3288
   Chen HF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5697
   Cho OH, 2009, J IMMUNOL, V182, P3380, DOI 10.4049/jimmunol.0802598
   Choy L, 2017, CANCER RES, V77, P1439, DOI 10.1158/0008-5472.CAN-16-1022
   Collu GM, 2014, CELL MOL LIFE SCI, V71, P3553, DOI 10.1007/s00018-014-1644-x
   Colombo M, 2016, ONCOTARGET, V7, P56013, DOI 10.18632/oncotarget.10820
   Cook N, 2012, J EXP MED, V209, P437, DOI 10.1084/jem.20111923
   Corbet C, 2017, NAT REV CANCER, V17, P577, DOI 10.1038/nrc.2017.77
   Demehri S, 2009, CANCER CELL, V16, P55, DOI 10.1016/j.ccr.2009.05.016
   Denko NC, 2008, NAT REV CANCER, V8, P705, DOI 10.1038/nrc2468
   Franklin RA, 2014, SCIENCE, V344, P921, DOI 10.1126/science.1252510
   Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101
   Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014
   Gama-Norton L, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9510
   Ghajar CM, 2013, NAT CELL BIOL, V15, P807, DOI 10.1038/ncb2767
   Gustafsson MV, 2005, DEV CELL, V9, P617, DOI 10.1016/j.devcel.2005.09.010
   Harisi R, 2015, ONCOTARGETS THER, V8, P1387, DOI 10.2147/OTT.S48883
   Hellström M, 2007, NATURE, V445, P776, DOI 10.1038/nature05571
   Henrique D, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.172148
   Hoare M, 2016, NAT CELL BIOL, V18, P979, DOI 10.1038/ncb3397
   Hossain F, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01288
   Hovinga KE, 2010, STEM CELLS, V28, P1019, DOI 10.1002/stem.429
   Hu B, 2012, CELL, V149, P1207, DOI 10.1016/j.cell.2012.03.048
   Huang YH, 2011, CANCER RES, V71, P6122, DOI 10.1158/0008-5472.CAN-10-4366
   Indraccolo S, 2010, CELL CYCLE, V9, P80, DOI 10.4161/cc.9.1.10346
   Indraccolo S, 2009, CANCER RES, V69, P1314, DOI 10.1158/0008-5472.CAN-08-2791
   Janghorban M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01649
   Kelliher MA, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01718
   Kluk MJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067306
   Kopan R, 2009, CELL, V137, P216, DOI 10.1016/j.cell.2009.03.045
   Kovall RA, 2017, DEV CELL, V41, P228, DOI 10.1016/j.devcel.2017.04.001
   Kuhnert F, 2015, CANCER RES, V75, P4086, DOI 10.1158/0008-5472.CAN-14-3773
   LaFoya B, 2016, DEV BIOL, V418, P227, DOI 10.1016/j.ydbio.2016.08.023
   Langridge PD, 2017, CELL, V171, P1383, DOI 10.1016/j.cell.2017.10.048
   Laplane L, 2018, TRENDS CANCER, V4, P802, DOI 10.1016/j.trecan.2018.10.002
   Li JL, 2007, CANCER CELL, V11, P478, DOI 10.1016/j.ccr.2007.05.004
   Lim JS, 2017, NATURE, V545, P360, DOI 10.1038/nature22323
   Lim R, 2019, SCIENCE, V364, P188, DOI 10.1126/science.aat0778
   Lin JT, 2013, EXP CELL RES, V319, P2216, DOI 10.1016/j.yexcr.2013.06.003
   Lin SH, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms16074
   Liu C., 2017, CANCER RES, V78, P938
   Liu H, 2017, BREAST CANCER RES TR, V166, P95, DOI 10.1007/s10549-017-4394-2
   Lu J, 2013, CANCER CELL, V23, P171, DOI 10.1016/j.ccr.2012.12.021
   Maekawa Y, 2008, NAT IMMUNOL, V9, P1140, DOI 10.1038/ni.1649
   Mamaeva V, 2011, MOL THER, V19, P1538, DOI 10.1038/mt.2011.105
   Maman S, 2018, NAT REV CANCER, V18, P359, DOI 10.1038/s41568-018-0006-7
   Mangolini M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06069-5
   Mao L, 2018, INT J CANCER, V142, P999, DOI 10.1002/ijc.31115
   Meurette O, 2018, CANCER CELL, V34, P536, DOI 10.1016/j.ccell.2018.07.009
   Moellering RE, 2009, NATURE, V462, P182, DOI 10.1038/nature08543
   Multhaupt HAB, 2016, ADV DRUG DELIVER REV, V97, P28, DOI 10.1016/j.addr.2015.10.013
   Nakata T, 2017, BIOCHEM BIOPH RES CO, V482, P1296, DOI 10.1016/j.bbrc.2016.12.031
   Nandagopal N, 2019, ELIFE, V8, DOI 10.7554/eLife.37880
   Nandagopal N, 2018, CELL, V172, P869, DOI 10.1016/j.cell.2018.01.002
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Nolin E, 2019, NAT CHEM BIOL, V15, P179, DOI 10.1038/s41589-018-0200-7
   Ntziachristos P, 2014, CANCER CELL, V25, P318, DOI 10.1016/j.ccr.2014.02.018
   Oskarsson T, 2011, NAT MED, V17, P867, DOI 10.1038/nm.2379
   Pakkiriswami S, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00037
   Patenaude A, 2015, MICROVASC RES, V101, P38, DOI 10.1016/j.mvr.2015.05.004
   Pedrosa AR, 2015, ONCOTARGET, V6, P24404, DOI 10.18632/oncotarget.4380
   Peng DJ, 2016, CANCER RES, V76, P3156, DOI 10.1158/0008-5472.CAN-15-2528
   Peng YN, 2014, BIOCHEM BIOPH RES CO, V451, P68, DOI 10.1016/j.bbrc.2014.07.074
   Procopio MG, 2015, NAT CELL BIOL, V17, P1193, DOI 10.1038/ncb3228
   Radtke F, 2013, NAT REV IMMUNOL, V13, P427, DOI 10.1038/nri3445
   Ranganathan P, 2011, NAT REV CANCER, V11, P338, DOI 10.1038/nrc3035
   Rodilla V, 2009, P NATL ACAD SCI USA, V106, P6315, DOI 10.1073/pnas.0813221106
   Saleem SJ, 2011, INT IMMUNOPHARMACOL, V11, P808, DOI 10.1016/j.intimp.2011.03.010
   Sansone P, 2007, J CLIN INVEST, V117, P3988, DOI 10.1172/JCI32533
   Sarkar S, 2017, CANCER RES, V77, P3231, DOI 10.1158/0008-5472.CAN-16-2171
   Schneider M, 2018, NAT CHEM BIOL, V14, P65, DOI [10.1038/NCHEMBIO.2520, 10.1038/nchembio.2520]
   Sethi N, 2011, CANCER CELL, V19, P192, DOI 10.1016/j.ccr.2010.12.022
   Sierra RA, 2014, CANCER IMMUNOL RES, V2, P800, DOI 10.1158/2326-6066.CIR-14-0021
   Sonoshita M, 2011, CANCER CELL, V19, P125, DOI 10.1016/j.ccr.2010.11.008
   Studebaker AW, 2008, CANCER RES, V68, P9087, DOI 10.1158/0008-5472.CAN-08-0400
   Su Q, 2017, ONCOGENE, V36, P618, DOI 10.1038/onc.2016.232
   Sugimoto K, 2010, J IMMUNOL, V184, P4673, DOI 10.4049/jimmunol.0903661
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Takebe N, 2014, PHARMACOL THERAPEUT, V141, P140, DOI 10.1016/j.pharmthera.2013.09.005
   Teo YV, 2019, CELL REP, V27, P997, DOI 10.1016/j.celrep.2019.03.104
   Tsuyada A, 2012, CANCER RES, V72, P2768, DOI 10.1158/0008-5472.CAN-11-3567
   Villa JC, 2014, CELL REP, V8, P1077, DOI 10.1016/j.celrep.2014.07.028
   Wang QY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00767-2
   Wang YC, 2010, CANCER RES, V70, P4840, DOI 10.1158/0008-5472.CAN-10-0269
   Weng AP, 2004, SCIENCE, V306, P269, DOI 10.1126/science.1102160
   Wieland E, 2017, CANCER CELL, V31, P355, DOI 10.1016/j.ccell.2017.01.007
   Xi Y, 2017, NAT CELL BIOL, V19, P904, DOI 10.1038/ncb3580
   Xing F, 2013, EMBO MOL MED, V5, P384, DOI 10.1002/emmm.201201623
   Xiong S, 2018, AM J CANCER RES, V8, P302
   Yamamoto M, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3299
   Yu WF, 2018, BIOMED PHARMACOTHER, V97, P535, DOI 10.1016/j.biopha.2017.10.143
   Zaman TS, 2017, J IMMUNOL, V199, P1989, DOI 10.4049/jimmunol.1700645
   Zavadil J, 2004, EMBO J, V23, P1155, DOI 10.1038/sj.emboj.7600069
   Zeng QH, 2005, CANCER CELL, V8, P13, DOI 10.1016/j.ccr.2005.06.004
   Zhao JL, 2016, CANCER RES, V76, P1403, DOI 10.1158/0008-5472.CAN-15-2019
   Zhu TS, 2011, CANCER RES, V71, P6061, DOI 10.1158/0008-5472.CAN-10-4269
NR 111
TC 15
Z9 19
U1 1
U2 9
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-030-35582-1; 978-3-030-35581-4
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2020
VL 1223
BP 1
EP 16
DI 10.1007/978-3-030-35582-1_1
D2 10.1007/978-3-030-35582-1
PG 16
WC Biochemistry & Molecular Biology; Oncology; Medicine, Research &
   Experimental
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Research & Experimental
   Medicine
GA BP4XQ
UT WOS:000554915800002
PM 32030682
DA 2025-01-04
ER

PT J
AU Du, FQ
   Xie, YW
   Wu, SZ
   Ji, ML
   Dong, BZ
   Zhu, CZ
AF Du, Fangqian
   Xie, Yuwei
   Wu, Shengze
   Ji, Mengling
   Dong, Bingzi
   Zhu, Chengzhan
TI Expression and Targeted Application of Claudins Family in Hepatobiliary
   and Pancreatic Diseases
SO JOURNAL OF HEPATOCELLULAR CARCINOMA
LA English
DT Review
DE claudins; hepatocellular carcinoma; cholangiocarcinoma; pancreatic
   cancer; targeted therapy
ID CLOSTRIDIUM-PERFRINGENS ENTEROTOXIN; EPITHELIAL-MESENCHYMAL TRANSITION;
   CANCER CELL-PROLIFERATION; TIGHT JUNCTION STRANDS;
   HEPATOCELLULAR-CARCINOMA; MONOCLONAL-ANTIBODY; DOWN-REGULATION;
   SOLID-PSEUDOPAPILLARY; DUCTAL ADENOCARCINOMA; PROGNOSTIC BIOMARKER
AB Hepatobiliary and pancreatic diseases are becoming increasingly common worldwide and associated cancers are prone to recurrence and metastasis. For a more accurate treatment, new therapeutic strategies are urgently needed. The claudins (CLDN) family comprises a class of membrane proteins that are the main components of tight junctions, and are essential for forming intercellular barriers and maintaining cellular polarity. In mammals, the claudin family contains at least 27 transmembrane proteins and plays a major role in mediating cell adhesion and paracellular permeability. Multiple claudin proteins are altered in various cancers, including gastric cancer (GC), esophageal cancer (EC), hepatocellular carcinoma (HCC), pancreatic cancer (PC), colorectal cancer (CRC) and breast cancer (BC). An increasing number of studies have shown that claudins are closely associated with the occurrence and development of hepatobiliary and pancreatic diseases. Interestingly, claudin proteins exhibit different effects on cancer progression in different tumor tissues, including tumor suppression and promotion. In addition, various claudin proteins are currently being studied as potential diagnostic and therapeutic targets, including claudin-3, claudin-4, claudin-18.2, etc. In this article, the functional phenotype, molecular mechanism, and targeted application of the claudin family in hepatobiliary and pancreatic diseases are reviewed, with an emphasis on claudin-1, claudin-4, claudin-7 and claudin-18.2, and the current situation and future prospects are proposed.
C1 [Du, Fangqian; Xie, Yuwei; Wu, Shengze; Zhu, Chengzhan] Qingdao Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp, Qingdao, Peoples R China.
   [Ji, Mengling] Tokushima Univ, Inst Biomed Sci, Dept Surg, Tokushima, Japan.
   [Dong, Bingzi] Qingdao Univ, Affiliated Hosp, Dept Endocrinol & Metab, Qingdao, Peoples R China.
C3 Qingdao University; Tokushima University; Qingdao University
RP Zhu, CZ (corresponding author), Qingdao Univ, Dept Hepatobiliary & Pancreat Surg, Affiliated Hosp, Qingdao, Peoples R China.; Dong, BZ (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Endocrinol & Metab, Qingdao, Peoples R China.
EM dongbingzi@hotmail.com; zhuchengz@qduhospital.cn
RI Dong, Bingzi/KCY-0725-2024
OI Dong, Bingzi/0000-0003-2446-0725
FU Taishan Scholars Program of Shandong Province [2019010668,
   tsqn202312382]; Natural Science Foundation of Shandong Province
   [ZR2021MH171, ZR2023MH243]; Shandong Higher Education Young Science and
   Technology Support Program [2020KJL005, 2023KJ224]
FX The study was supported by Taishan Scholars Program of Shandong Province
   (grant number 2019010668 and NO. tsqn202312382) , Natural Science
   Foundation of Shandong Province (grant number ZR2021MH171, ZR2023MH243)
   , Shandong Higher Education Young Science and Technology Support Program
   (grant number 2020KJL005 and 2023KJ224) .
CR Alikanoglu Arsenal Sezgin, 2015, Asian Pac J Cancer Prev, V16, P4387
   Ashikari D, 2017, CANCER SCI, V108, P1386, DOI 10.1111/cas.13269
   Awsare NS, 2011, ONCOL REP, V25, P1503, DOI 10.3892/or.2011.1244
   Baier FA, 2021, CELL MOL GASTROENTER, V12, P745, DOI 10.1016/j.jcmgh.2021.04.003
   Balda MS, 2023, CURR BIOL, V33, pR1135, DOI 10.1016/j.cub.2023.09.027
   Balda MS, 1996, J CELL BIOL, V134, P1031, DOI 10.1083/jcb.134.4.1031
   Bang C, 2023, BIOMATER RES, V27, DOI 10.1186/s40824-023-00394-7
   Borka K, 2007, VIRCHOWS ARCH, V450, P549, DOI 10.1007/s00428-007-0406-7
   Bouchagier KA, 2014, IN VIVO, V28, P315
   Brokalaki EI, 2012, TRANSPL P, V44, P2737, DOI 10.1016/j.transproceed.2012.09.009
   Caron TJ, 2021, CELL MOL GASTROENTER, V11, P783, DOI 10.1016/j.jcmgh.2020.10.005
   Chao YC, 2009, AM J RESP CRIT CARE, V179, P123, DOI 10.1164/rccm.200803-456OC
   Chen YJ, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061274
   Cheung ST, 2005, CLIN CANCER RES, V11, P551
   Choi E, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-68411-w
   Choi YD, 2007, J KOREAN MED SCI, V22, P305, DOI 10.3346/jkms.2007.22.2.305
   Colegio OR, 2002, AM J PHYSIOL-CELL PH, V283, pC142, DOI 10.1152/ajpcell.00038.2002
   Comper F, 2009, AM J SURG PATHOL, V33, P768, DOI 10.1097/PAS.0b013e3181957bc4
   De Sanctis F, 2024, IMMUNITY, V57, DOI 10.1016/j.immuni.2024.04.021
   Detarya M, 2020, GLYCOBIOLOGY, V30, P312, DOI 10.1093/glycob/cwz098
   Ding Lei, 2013, Cancer Manag Res, V5, P367, DOI 10.2147/CMAR.S38294
   Dottermusch M, 2019, VIRCHOWS ARCH, V475, P563, DOI 10.1007/s00428-019-02624-7
   Elsayed Aya Magdy, 2024, Asian Pac J Cancer Prev, V25, P637, DOI 10.31557/APJCP.2024.25.2.637
   Erramilli SK, 2024, COMMUN BIOL, V7, DOI 10.1038/s42003-024-06437-6
   Evans MJ, 2007, NATURE, V446, P801, DOI 10.1038/nature05654
   Fan LY, 2021, ANAL CHEM, V93, P665, DOI 10.1021/acs.analchem.0c04055
   Feni L, 2017, PHARMACEUTICALS-BASE, V10, DOI 10.3390/ph10040099
   Fink C, 2009, HISTOCHEM CELL BIOL, V131, P755, DOI 10.1007/s00418-009-0576-2
   Foss CA, 2007, MOL IMAGING, V6, P131, DOI 10.2310/7290.2007.00010
   Furuhata A, 2017, PANCREAS, V46, P531, DOI 10.1097/MPA.0000000000000774
   Furuse M, 1998, J CELL BIOL, V143, P391, DOI 10.1083/jcb.143.2.391
   FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777
   Furuse M, 1998, J CELL BIOL, V141, P1539, DOI 10.1083/jcb.141.7.1539
   Furuse M, 2002, J CELL BIOL, V156, P1099, DOI 10.1083/jcb.200110122
   Günzel D, 2013, PHYSIOL REV, V93, P525, DOI 10.1152/physrev.00019.2012
   Günzel D, 2012, COMPR PHYSIOL, V2, P1819, DOI 10.1002/cphy.c110045
   Guo XJ, 2016, CLIN EXP MED, V16, P357, DOI 10.1007/s10238-015-0365-2
   Gurbuz N, 2022, ANTI-CANCER AGENT ME, V22, P2607, DOI 10.2174/1871520622666220117123213
   Gurbuz N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105245
   Gurevich L. E., 2014, Arkhiv Patologii, V76, P44
   Hagen SJ, 2018, GASTROENTEROLOGY, V155, P1852, DOI 10.1053/j.gastro.2018.08.041
   Hagen SJ, 2017, TISSUE BARRIERS, V5, DOI 10.1080/21688370.2017.1327839
   Harris HJ, 2008, J VIROL, V82, P5007, DOI 10.1128/JVI.02286-07
   Harris HJ, 2010, J BIOL CHEM, V285, P21092, DOI 10.1074/jbc.M110.104836
   Hashimoto Y, 2018, EUR J PHARM SCI, V117, P161, DOI 10.1016/j.ejps.2018.02.016
   Hashimoto Y, 2017, PFLUG ARCH EUR J PHY, V469, P45, DOI 10.1007/s00424-016-1878-6
   Hassanzadeh G, 2016, CELL MOL NEUROBIOL, V36, P865, DOI 10.1007/s10571-015-0270-y
   He L, 2024, J DENT RES, V103, P167, DOI 10.1177/00220345231210547
   Heinemann U, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20236020
   Higashi Y, 2007, J SURG RES, V139, P68, DOI 10.1016/j.jss.2006.08.038
   Holczbauer A, 2014, PATHOL ONCOL RES, V20, P493, DOI 10.1007/s12253-013-9683-4
   Holczbauer A, 2013, J HISTOCHEM CYTOCHEM, V61, P294, DOI 10.1369/0022155413479123
   Hong JY, 2020, TRANSL CANCER RES, V9, P3367, DOI 10.21037/tcr-19-1876
   Hu GL, 2022, EUR J NUCL MED MOL I, V49, P2634, DOI 10.1007/s00259-022-05739-3
   Hu R, 2023, BMC GASTROENTEROL, V23, DOI 10.1186/s12876-023-02843-y
   Huang GW, 2011, J CANCER RES CLIN, V137, P1213, DOI 10.1007/s00432-011-0987-z
   Huang LY, 2020, CELL BIOCHEM FUNCT, V38, P541, DOI 10.1002/cbf.3489
   Ikari A, 2014, BBA-MOL CELL RES, V1843, P2079, DOI 10.1016/j.bbamcr.2014.05.017
   Ikeda C, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-81023-y
   Ikenouchi J, 2005, J CELL BIOL, V171, P939, DOI 10.1083/jcb.200510043
   Ip YC, 2007, MOL CANCER THER, V6, P2858, DOI 10.1158/1535-7163.MCT-07-0453
   Ito T, 2011, J CELL BIOCHEM, V112, P1761, DOI 10.1002/jcb.23095
   Jakab C, 2010, HISTOL HISTOPATHOL, V25, P857, DOI 10.14670/HH-25.857
   Jakab C, 2011, ACTA VET HUNG, V59, P87, DOI 10.1556/AVet.59.2011.1.8
   Ji HC, 2024, WORLD J ONCOL, V15, P662, DOI 10.14740/wjon1869
   Ji R, 2021, DIGEST DIS SCI, V66, P3045, DOI 10.1007/s10620-020-06598-4
   Jia KR, 2022, BMC MED, V20, DOI 10.1186/s12916-022-02421-1
   Jiang FR, 2022, PANCREAS, V51, P1201, DOI 10.1097/MPA.0000000000002164
   Jiang L, 2014, ONCOTARGET, V5, P7663, DOI 10.18632/oncotarget.2288
   Kakutani H, 2010, EUR J PHARM BIOPHARM, V75, P213, DOI 10.1016/j.ejpb.2010.03.003
   Karanjawala ZE, 2008, AM J SURG PATHOL, V32, P188, DOI 10.1097/PAS.0b013e31815701f3
   Karnati HK, 2014, CNS NEUROL DISORD-DR, V13, P1413, DOI 10.2174/1871527313666141023121550
   Katoh M, 2020, INT J MOL MED, V45, P279, DOI 10.3892/ijmm.2019.4418
   Kayikcioglu E, 2023, WORLD J GASTRO ONCOL, V15, P343, DOI 10.4251/wjgo.v15.i2.343
   Kayikcioglu E, 2023, MEDICINE, V102, DOI 10.1097/MD.0000000000032882
   Kim JH, 2011, EXP CELL RES, V317, P1108, DOI 10.1016/j.yexcr.2011.02.011
   Kim SO, 2010, J MED FOOD, V13, P31, DOI 10.1089/jmf.2009.1233
   Kind S, 2020, WORLD J UROL, V38, P2185, DOI 10.1007/s00345-019-03017-w
   Kojima T, 2012, ANN NY ACAD SCI, V1257, P85, DOI 10.1111/j.1749-6632.2012.06579.x
   Kondo J, 2008, INT J MOL MED, V22, P645, DOI 10.3892/ijmm_00000067
   Kraiklang R, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089337
   Krause G, 2015, SEMIN CELL DEV BIOL, V42, P3, DOI 10.1016/j.semcdb.2015.04.010
   Krause G, 2009, ANN NY ACAD SCI, V1165, P34, DOI 10.1111/j.1749-6632.2009.04057.x
   Krieger SE, 2010, HEPATOLOGY, V51, P1144, DOI 10.1002/hep.23445
   Kubota Y, 2023, ESMO OPEN, V8, DOI 10.1016/j.esmoop.2022.100762
   Kumar B, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01870-5
   Kumei S, 2009, BIOCHEM BIOPH RES CO, V380, P614, DOI 10.1016/j.bbrc.2009.01.134
   Kuwatsuka S, 2021, J DERMATOL SCI, V104, P132, DOI 10.1016/j.jdermsci.2021.10.002
   Kwon MJ, 2013, INT J MOL SCI, V14, P18148, DOI 10.3390/ijms140918148
   Kyuno D, 2022, TISSUE BARRIERS, V10, DOI 10.1080/21688370.2021.1967080
   Kyuno D, 2019, INT J BIOL SCI, V15, P2224, DOI 10.7150/ijbs.35347
   Kyuno D, 2019, INT J CANCER, V145, P2182, DOI 10.1002/ijc.32312
   Kyuno D, 2014, WORLD J GASTROENTERO, V20, P10813, DOI 10.3748/wjg.v20.i31.10813
   Kyuno D, 2013, CARCINOGENESIS, V34, P1232, DOI 10.1093/carcin/bgt057
   Kyuno D, 2011, CELL TISSUE RES, V346, P369, DOI 10.1007/s00441-011-1287-2
   Ladwein M, 2005, EXP CELL RES, V309, P345, DOI 10.1016/j.yexcr.2005.06.013
   Lee JS, 2019, CLIN EXP DERMATOL, V44, P483, DOI 10.1111/ced.13810
   Lee JH, 2011, ONCOL REP, V25, P971, DOI 10.3892/or.2011.1132
   Lee JH, 2015, J BIOL CHEM, V290, P21421, DOI 10.1074/jbc.M115.654913
   Li CP, 2016, CARCINOGENESIS, V37, P557, DOI 10.1093/carcin/bgw036
   Li J, 2020, AGING-US, V12, P14271, DOI 10.18632/aging.103457
   Li QR, 2024, FRONT MED-PRC, V18, P911, DOI 10.1007/s11684-024-1058-6
   Li WT, 2020, AM J SURG PATHOL, V44, P1643, DOI 10.1097/PAS.0000000000001583
   Li WL, 2018, ONCOGENE, V37, P4903, DOI 10.1038/s41388-018-0341-x
   Liu C, 2019, PANCREAS, V48, P629, DOI 10.1097/MPA.0000000000001321
   Liu HY, 2019, TURK J GASTROENTEROL, V30, P722, DOI 10.5152/tjg.2019.18513
   Liu MY, 2018, CLIN CANCER RES, V24, P3186, DOI 10.1158/1078-0432.CCR-18-0263
   Liu SD, 2024, CELL COMMUN SIGNAL, V22, DOI 10.1186/s12964-023-01406-8
   Liu YF, 2023, J TRANSL MED, V21, DOI 10.1186/s12967-023-04080-z
   Lódi C, 2006, MODERN PATHOL, V19, P460, DOI 10.1038/modpathol.3800549
   Lordick F, 2024, ESMO OPEN, V9, DOI 10.1016/j.esmoop.2024.103663
   Lu Y, 2021, J CANCER, V12, P5454, DOI 10.7150/jca.55727
   Lu Z, 2011, EXP CELL RES, V317, P1935, DOI 10.1016/j.yexcr.2011.05.019
   Lyu SI, 2024, TRANSL ONCOL, V47, DOI 10.1016/j.tranon.2024.102044
   Ma Z, 2024, CANCER IMMUNOL IMMUN, V73, DOI 10.1007/s00262-024-03673-x
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Mahati S, 2017, BIOCHEM BIOPH RES CO, V490, P906, DOI 10.1016/j.bbrc.2017.06.139
   Mahati S, 2017, BIOCHEM BIOPH RES CO, V486, P732, DOI 10.1016/j.bbrc.2017.03.110
   Manole E, 2015, ROM J MORPHOL EMBRYO, V56, P1097
   Matsuishi A, 2024, SCI REP-UK, V14, DOI 10.1038/s41598-024-68970-y
   Matsumoto K, 2014, GASTROENTEROLOGY, V147, P1134, DOI 10.1053/j.gastro.2014.07.033
   McCarthy KM, 1996, J CELL SCI, V109, P2287
   Michl P, 2003, CANCER RES, V63, P6265
   Michl P, 2001, GASTROENTEROLOGY, V121, P678, DOI 10.1053/gast.2001.27124
   Micke P, 2014, INT J CANCER, V135, P2206, DOI 10.1002/ijc.28857
   Mineta K, 2011, FEBS LETT, V585, P606, DOI 10.1016/j.febslet.2011.01.028
   Miskad Upik Anderiani, 2022, Asian Pac J Cancer Prev, V23, P4023, DOI 10.31557/APJCP.2022.23.12.4023
   Morita K, 1999, P NATL ACAD SCI USA, V96, P511, DOI 10.1073/pnas.96.2.511
   Mosley M, 2015, J NUCL MED, V56, P745, DOI 10.2967/jnumed.114.152496
   Nacir M, 2023, POL J PATHOL, V74, P248, DOI [10.5114/PJP.2023.134318, 10.5114/pjp.2023.134318]
   Nakayama F, 2008, PATHOBIOLOGY, V75, P177, DOI 10.1159/000124978
   Nakayama I, 2019, CANCER SCI, V110, P1352, DOI 10.1111/cas.13967
   Narayanan SP, 2022, CLIN GASTROENTEROL H, V20, P1019, DOI 10.1016/j.cgh.2021.09.029
   Neesse A, 2013, GUT, V62, P1034, DOI 10.1136/gutjnl-2012-302577
   Niclauss N, 2021, CANCERS, V13, DOI 10.3390/cancers13225660
   Niimi T, 2001, MOL CELL BIOL, V21, P7380, DOI 10.1128/MCB.21.21.7380-7390.2001
   Nishibata T, 2024, J PHARMACOL SCI, V155, P84, DOI 10.1016/j.jphs.2024.04.004
   Nübel T, 2009, MOL CANCER RES, V7, P285, DOI 10.1158/1541-7786.MCR-08-0200
   Ogawa H, 2024, GASTRIC CANCER, V27, P802, DOI 10.1007/s10120-024-01505-6
   Okui N, 2019, PANCREATOLOGY, V19, P88, DOI 10.1016/j.pan.2018.10.009
   Ono Y, 2016, VIRCHOWS ARCH, V469, P417, DOI 10.1007/s00428-016-1984-z
   Orea MJ, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010803
   Osanai M, 2007, CANCER SCI, V98, P1557, DOI 10.1111/j.1349-7006.2007.00569.x
   Osanai M, 2017, PFLUG ARCH EUR J PHY, V469, P55, DOI 10.1007/s00424-016-1877-7
   Oshima T, 2008, ONCOL REP, V19, P953
   Ouban A, 2023, CANCERS, V15, DOI 10.3390/cancers15164095
   Pahle J, 2021, CANCERS, V13, DOI 10.3390/cancers13174393
   Park JM, 2017, FREE RADICAL BIO MED, V110, P151, DOI 10.1016/j.freeradbiomed.2017.06.003
   Patonai A, 2011, VIRCHOWS ARCH, V458, P679, DOI 10.1007/s00428-011-1077-y
   Pearngam P, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00827
   Pyo JS, 2019, J PATHOL TRANSL MED, V53, P173, DOI 10.4132/jptm.2019.02.03
   Qi CS, 2024, NAT MED, V30, DOI 10.1038/s41591-024-03037-z
   Qi CS, 2024, J NUCL MED, V65, P856, DOI 10.2967/jnumed.123.267110
   Radi DA, 2016, INT J SURG PATHOL, V24, P219, DOI 10.1177/1066896915611488
   Rajasekaran AK, 1996, J CELL BIOL, V132, P451, DOI 10.1083/jcb.132.3.451
   Reynolds GM, 2008, HEPATOLOGY, V47, P418, DOI 10.1002/hep.22028
   Rosenthal R, 2017, ANN NY ACAD SCI, V1397, P100, DOI 10.1111/nyas.13383
   Flores AR, 2014, J COMP PATHOL, V151, P339, DOI 10.1016/j.jcpa.2014.07.006
   Sahin U, 2008, CLIN CANCER RES, V14, P7624, DOI 10.1158/1078-0432.CCR-08-1547
   Sakaguchi T, 2008, J SURG RES, V147, P123, DOI 10.1016/j.jss.2007.07.013
   Sanada Y, 2010, ANTICANCER RES, V30, P2995
   Sasaki T, 2019, CANCER MED-US, V8, P6700, DOI 10.1002/cam4.2547
   Sato M, 2020, CANCER RES, V80, P1279, DOI 10.1158/0008-5472.CAN-18-4099
   Sauer T, 2005, CYTOPATHOLOGY, V16, P193, DOI 10.1111/j.1365-2303.2005.00257.x
   Shah MA, 2023, NAT MED, V29, P2133, DOI 10.1038/s41591-023-02465-7
   Shim MK, 2021, J CONTROL RELEASE, V331, P434, DOI 10.1016/j.jconrel.2021.01.031
   Singh AB, 2010, J ONCOL, V2010, DOI 10.1155/2010/541957
   Soini Y, 2005, HISTOPATHOLOGY, V46, P551, DOI 10.1111/j.1365-2559.2005.02127.x
   Soini Y, 2012, J CLIN PATHOL, V65, P431, DOI 10.1136/jclinpath-2011-200400
   Soini Y, 2014, TUMOR BIOL, V35, P3803, DOI 10.1007/s13277-013-1503-7
   Stadler CR, 2024, SCI TRANSL MED, V16, DOI 10.1126/scitranslmed.adl2720
   Stebbing J, 2013, ONCOGENE, V32, P4871, DOI 10.1038/onc.2012.591
   Suh Y, 2013, ONCOGENE, V32, P4873, DOI 10.1038/onc.2012.505
   Sun LM, 2018, DIAGN PATHOL, V13, DOI 10.1186/s13000-018-0749-1
   Sun ZQ, 2023, MED ONCOL, V40, DOI 10.1007/s12032-023-02136-0
   Suzuki K, 2019, CELL MOL GASTROENTER, V8, P119, DOI 10.1016/j.jcmgh.2019.03.003
   Suzuki M, 2009, CANCER SCI, V100, P1623, DOI 10.1111/j.1349-7006.2009.01239.x
   Sweerus K, 2017, J ALLERGY CLIN IMMUN, V139, P72, DOI 10.1016/j.jaci.2016.02.035
   Tan XD, 2004, INT J ONCOL, V25, P1567
   Tanaka H, 2018, J HEPATOL, V69, P1308, DOI 10.1016/j.jhep.2018.08.025
   Tanaka M, 2011, J HISTOCHEM CYTOCHEM, V59, P942, DOI 10.1369/0022155411420569
   Thuma F, 2013, INT J CANCER, V133, P855, DOI 10.1002/ijc.28085
   Tian XQ, 2019, CANCER MANAG RES, V11, P9339, DOI 10.2147/CMAR.S229441
   Tokumitsu T, 2017, CYTOPATHOLOGY, V28, P116, DOI 10.1111/cyt.12368
   Tomecka P, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25168972
   Torres JB, 2020, J NUCL MED, V61, DOI 10.2967/jnumed.120.243113
   Torres JB, 2018, MOL IMAGING BIOL, V20, P292, DOI 10.1007/s11307-017-1112-8
   Tsukahara M, 2005, PATHOL INT, V55, P63, DOI 10.1111/j.1440-1827.2005.01793.x
   Tsukita S, 2000, J CELL BIOL, V149, P13, DOI 10.1083/jcb.149.1.13
   Tsutsumi K, 2011, MODERN PATHOL, V24, P533, DOI 10.1038/modpathol.2010.218
   Türeci Ö, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1523096
   Vecchio AJ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2024651118
   Wang CM, 2023, BMC GASTROENTEROL, V23, DOI 10.1186/s12876-023-02924-y
   Wang H, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2422-3
   Wang SJ, 2023, EUR J NUCL MED MOL I, V50, P2802, DOI 10.1007/s00259-023-06234-z
   Wang W, 2010, MOL MED REP, V3, P845, DOI 10.3892/mmr.2010.334
   Wang X, 2022, WORLD J GASTRO ONCOL, V14, P1252, DOI 10.4251/wjgo.v14.i7.1252
   Wang ZH, 2019, CLIN RES HEPATOL GAS, V43, P410, DOI 10.1016/j.clinre.2018.11.014
   Williams HL, 2023, CANCER RES, V83, P441, DOI 10.1158/0008-5472.CAN-22-3050
   Wöll S, 2014, INT J CANCER, V134, P731, DOI 10.1002/ijc.28400
   Wu YY, 2012, INT J ONCOL, V41, P1337, DOI 10.3892/ijo.2012.1559
   Xiong L, 2011, AM J MED SCI, V342, P388, DOI 10.1097/MAJ.0b013e31821e12af
   Xu XT, 2023, J ETHNOPHARMACOL, V311, DOI 10.1016/j.jep.2023.116450
   Yamaga K, 2018, J INVEST DERMATOL, V138, P1279, DOI 10.1016/j.jid.2017.11.040
   Yamaguchi H, 2011, CELL MOL BIOL LETT, V16, P385, DOI 10.2478/s11658-011-0014-z
   Yang FL, 2023, AM J CANCER RES, V13, P2530
   Yang JH, 2015, ONCOL REP, V34, P1415, DOI 10.3892/or.2015.4104
   Yang ST, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1370708
   Yang WP, 2022, INT J BIOL SCI, V18, P2329, DOI 10.7150/ijbs.70105
   Yang WP, 2021, EPIGENOMICS-UK, V13, P31, DOI 10.2217/epi-2020-0256
   Yang YJ, 2022, APPL IMMUNOHISTO M M, V30, P8, DOI 10.1097/PAI.0000000000000971
   Yoon CH, 2010, J BIOL CHEM, V285, P226, DOI 10.1074/jbc.M109.054189
   Yue JY, 2024, INVEST NEW DRUG, V42, P106, DOI 10.1007/s10637-024-01417-3
   Zeng ZQ, 2024, EUR J NUCL MED MOL I, V51, P1221, DOI 10.1007/s00259-023-06561-1
   Zhang CY, 2021, FRONT CELL DEV BIOL, V09, DOI 10.3389/fcell.2021.726656
   Zhang FF, 2024, GUT, V73, P1280, DOI 10.1136/gutjnl-2023-329686
   Zhang JW, 2020, CHINESE J CANCER RES, V32, P263, DOI 10.21147/j.issn.1000-9604.2020.02.13
   Zhang LM, 2017, ONCOTARGET, V8, P23033, DOI 10.18632/oncotarget.14974
   Zhang SJ, 2014, DIGEST DIS SCI, V59, P1754, DOI 10.1007/s10620-014-3107-5
   Zhang XW, 2019, J CELL COMMUN SIGNAL, V13, P395, DOI 10.1007/s12079-019-00509-7
   Zhang Y, 2022, RNA BIOL, V19, P548, DOI 10.1080/15476286.2021.1992995
   Zhang ZW, 2022, HISTOL HISTOPATHOL, V37, P1031, DOI 10.14670/HH-18-477
   Zhao CK, 2022, MOL PHARMACEUT, DOI 10.1021/acs.molpharmaceut.1c00947
   Zheng AH, 2007, J VIROL, V81, P12465, DOI 10.1128/JVI.01457-07
   Zheng Hong-yan, 2013, Zhonghua Bing Li Xue Za Zhi, V42, P372, DOI 10.3760/cma.j.issn.0529-5807.2013.06.004
   Zhong WX, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.885424
   Zhou KI, 2024, J HEMATOL ONCOL, V17, DOI 10.1186/s13045-024-01595-w
   Zhou YL, 2018, J CANCER, V9, P4712, DOI 10.7150/jca.28636
   Zhu GY, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-44874-0
   Zhu LX, 2024, CANCER LETT, V586, DOI 10.1016/j.canlet.2024.216611
   Zihni C, 2016, NAT REV MOL CELL BIO, V17, P564, DOI 10.1038/nrm.2016.80
NR 231
TC 0
Z9 0
U1 5
U2 5
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 2253-5969
J9 J HEPATOCELL CARCINO
JI J. HEPATOCELL. CARCINOMA
PY 2024
VL 11
BP 1801
EP 1821
DI 10.2147/JHC.S483861
PG 21
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA H2D0U
UT WOS:001321584900001
PM 39345937
OA gold
DA 2025-01-04
ER

PT J
AU Liu, SS
   Jiang, C
   Yang, L
   Huang, JS
   Peng, RJ
   Wang, XP
   He, WZ
   Bai, L
   Zhou, YX
   Zhang, B
   Xia, LP
AF Liu, Shousheng
   Jiang, Chang
   Yang, Lin
   Huang, Jinsheng
   Peng, Roujun
   Wang, Xiaopai
   He, Wenzhuo
   Bai, Long
   Zhou, Yixin
   Zhang, Bei
   Xia, Liangping
TI First-line cetuximab improves the efficacy of subsequent bevacizumab for
   RAS wild-type left-sided metastatic colorectal cancer: an observational
   retrospective study
SO SCIENTIFIC REPORTS
LA English
DT Article
ID FOLFIRI PLUS CETUXIMAB; PRIMARY TUMOR SITE; ACQUIRED-RESISTANCE;
   RANDOMIZED PHASE-3; 2ND-LINE TREATMENT; COST-EFFECTIVENESS; SALVAGE
   TREATMENT; PROGNOSTIC-FACTOR; OXALIPLATIN; FLUOROURACIL
AB The optimal targeted therapy sequence in patients of RAS wild-type left-sided metastatic colorectal cancer (mCRC) remains controversial, and few studies focus on the impact of first-line targeted agents on second-line ones. We enrolled 101 left-sided mCRC patients with RAS wild-type status, of which 50 cases received bevacizumab plus chemotherapy in both first-line and second-line therapies (Group A) and 51 cases received first-line cetuximab plus chemotherapy followed by second-line bevacizumab-containing regimens (Group B). The progression free survival (PFS) and overall survival (OS) from start of first-line (PFS 1nd and OS 1nd) and second-line (PFS 2nd and OS 2nd) therapy were compared between the two groups. PFS 1nd was comparable (10.0 vs 10.4 months; p=0.402), while PFS 2nd (4.6 vs 7.9 months; p=0.002), OS 1nd (26.8 vs 40.0 months; p=0.011), and OS 2nd (15.2 vs 22.3 months; p=0.006) were all poorer in group A compared with group B. Our study in combination with previous clinical data suggest that first-line application of cetuximab may provide a favorable condition for promoting the effect of subsequent bevacizumab, thus representing the optimal targeted therapy sequence in patients of RAS wild-type left-sided mCRC.
C1 [Liu, Shousheng; Jiang, Chang; Huang, Jinsheng; Peng, Roujun; He, Wenzhuo; Bai, Long; Zhou, Yixin; Zhang, Bei; Xia, Liangping] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China.
   [Liu, Shousheng; Jiang, Chang; Huang, Jinsheng; Peng, Roujun; He, Wenzhuo; Bai, Long; Zhou, Yixin; Zhang, Bei; Xia, Liangping] Sun Yat Sen Univ, Dept Gen Med, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China.
   [Yang, Lin] Southern Med Univ, Nanfang Hosp, Dept Radiat Oncol, 1838 Guangzhou Ave North, Guangzhou 510515, Peoples R China.
   [Wang, Xiaopai] South China Univ Technol, Affiliated Hosp 2, Guangzhou Med Univ, Guangzhou Peoples Hosp 1,Dept Pathol, 1 Panfu Rd, Guangzhou 510080, Peoples R China.
C3 Sun Yat Sen University; State Key Lab Oncology South China; Sun Yat Sen
   University; Southern Medical University - China; Guangzhou Medical
   University; South China University of Technology
RP Zhang, B; Xia, LP (corresponding author), Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China.; Zhang, B; Xia, LP (corresponding author), Sun Yat Sen Univ, Dept Gen Med, Ctr Canc, 651 Dongfeng East Rd, Guangzhou 510060, Peoples R China.
EM zhangbei@sysucc.org.cn; xialp@sysucc.org.cn
RI huang, jinsheng/HPH-7961-2023
OI huang, jinsheng/0000-0002-5859-4994
FU Natural Science Foundation of Guangdong Province [2017A030310337];
   National Natural Science Foundation of China [81572409]; General
   Guidance Project of Health Science and Technology of Guangzhou
   [20191A011010]; Guangdong Medical Science and Technology Research Fund
   [C2018063]
FX The authors thank all the staff in the follow-up room from Sun Yat-sen
   University Cancer Center for their help in the present study. This study
   was funded by Natural Science Foundation of Guangdong Province
   (2017A030310337 to Shousheng Liu), National Natural Science Foundation
   of China (81572409 to Liangping Xia), General Guidance Project of Health
   Science and Technology of Guangzhou (20191A011010 to Xiaopai Wang) and
   Guangdong Medical Science and Technology Research Fund (C2018063 to
   Wenzhuo He).
CR Aljehani MA, 2018, JAMA SURG, V153, P60, DOI 10.1001/jamasurg.2017.3466
   Avallone A, 2016, J CLIN ONCOL, V34, P1564, DOI 10.1200/JCO.2015.66.1512
   Bennouna J, 2019, JAMA ONCOL, V5, P83, DOI 10.1001/jamaoncol.2018.4465
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Capdevila J, 2009, CRIT REV ONCOL HEMAT, V71, P53, DOI 10.1016/j.critrevonc.2008.09.006
   Cascinu S, 2017, EUR J CANCER, V83, P106, DOI 10.1016/j.ejca.2017.06.029
   Chen KH, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2358-2
   Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Hecht JR, 2015, CLIN COLORECTAL CANC, V14, P72, DOI 10.1016/j.clcc.2014.12.009
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Houts AC, 2019, J GASTROINTEST CANC, V50, P69, DOI 10.1007/s12029-017-0027-6
   Hoyle M, 2013, HEALTH TECHNOL ASSES, V17, P1, DOI 10.3310/hta17140
   Kelly H, 2005, J CLIN ONCOL, V23, P4553, DOI 10.1200/JCO.2005.17.749
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Modest DP, 2015, J CLIN ONCOL, V33, P3718, DOI 10.1200/JCO.2015.61.2887
   Moretto R, 2016, ONCOLOGIST, V21, P988, DOI 10.1634/theoncologist.2016-0084
   Peeters M, 2014, ANN ONCOL, V25, P107, DOI 10.1093/annonc/mdt523
   Riesco-Martínez MC, 2016, J ONCOL PRACT, V12, P574, DOI 10.1200/JOP.2015.008730
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Starling N, 2007, BRIT J CANCER, V96, P206, DOI 10.1038/sj.bjc.6603561
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Viloria-Petit A, 2001, CANCER RES, V61, P5090
NR 28
TC 8
Z9 8
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 23
PY 2020
VL 10
IS 1
AR 12336
DI 10.1038/s41598-020-69230-5
PG 12
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA MV9TL
UT WOS:000556690900043
PM 32704062
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Ge, P
   Reyila, A
   Li, XY
   Liu, SY
   Jiang, YX
   Yang, YJ
   Li, XL
   Bian, Y
AF Ge, Pu
   Reyila, Abudurosuli
   Li, Xin-yi
   Liu, Si-yu
   Jiang, Yi-xuan
   Yang, Ya-jie
   Li, Xia-lei
   Bian, Ying
TI Efficacy and safety of aflibercept plus chemotherapy in metastatic
   colorectal cancer: A systematic review and PRISMA-Compliant single-arm
   Meta-Analysis of noncomparative clinical studies and randomized
   controlled trials
SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS
LA English
DT Review
DE aflibercept; chemotherapy; colorectal cancer; meta-analysis; systematic
   review; targeted therapy
ID ENDOTHELIAL GROWTH-FACTOR; 1ST-LINE TREATMENT; 2ND-LINE FOLFIRI;
   VEGF-TRAP; PHASE-II; BEVACIZUMAB; OXALIPLATIN; COMBINATION;
   FLUOROURACIL; IRINOTECAN
AB What is known and Objective Aflibercept, a recombinant protein designed to suppress the vascular endothelial growth factor (VEGF) signalling pathway, has been used in patients with metastatic colorectal cancer (mCRC). We conducted the first meta-analysis to systematically review the efficacy and safety of aflibercept in mCRC. Methods PubMed Central/Medline, Embase and cochrane library were systematically searched for randomized controlled trials and single-arm clinical trials on aflibercept plus chemotherapy for the treatment of mCRC through 9 September 2021. Results Ten studies comprising 2049 patients met the inclusion criteria. The pooled estimate rates were 16.0% for 12mPFS, 64.4% for 12mOS, 32.5% for ORR, 83.5% for DCR, while the rates of III/IV AEs rate were 80.2% respectively. The pooled estimate rates were 16.8% for III/IV diarrhoea, 22.3% for III/IV hypertension, 29.5% for III/IV neutropenia, 7.3% for III/IV proteinuria and 8.6% for III/IV oral mucositis. Conclusions Analysis of data from randomized controlled trials(RCT) and single-arm clinical trials confirmed the good efficacy of aflibercept plus chemotherapy in mCRC, while the safety of the treatment is concerning.
C1 [Ge, Pu; Jiang, Yi-xuan; Bian, Ying] Univ Macau, Inst Chinese Med Sci, Macau, Peoples R China.
   [Ge, Pu; Jiang, Yi-xuan; Bian, Ying] Univ Macau, State Key Lab Qual Res Chinese Med, Macau, Peoples R China.
   [Ge, Pu; Jiang, Yi-xuan; Bian, Ying] Univ Macau, Dept Publ Hlth & Med Adm, Fac Hlth Sci, Macau, Peoples R China.
   [Reyila, Abudurosuli] Air Force Mil Med Univ, Xijing Hosp, Xian, Peoples R China.
   [Li, Xin-yi] Peking Univ, Sch Pharmaceut Sci, Dept Pharm Adm & Clin Pharm, Beijing, Peoples R China.
   [Liu, Si-yu] Shandong Univ, Stomatol Coll, Jinan, Peoples R China.
   [Yang, Ya-jie] Peking Univ, Sch Nursing, Hlth Sci Ctr, Beijing, Peoples R China.
   [Li, Xia-lei] Shandong Univ, Sch Pharmaceut Sci, Jinan, Peoples R China.
C3 University of Macau; University of Macau; University of Macau; Air Force
   Military Medical University; Peking University; Shandong University;
   Peking University; Shandong University
RP Bian, Y (corresponding author), Univ Macau, Inst Chinese Med Sci, Dept Publ Hlth & Med Adm, State Key Lab Qual Res Chinese Med,Fac Hlth Sci, Macau 999078, Peoples R China.
EM bianyingum@163.com
RI li, xinyi/GWZ-8941-2022; Liu, Siyu/GYV-4856-2022; pu, ge/JTV-2070-2023
OI Ge, Pu/0000-0002-9295-6389; Reyila, Abudurousuli/0000-0002-7434-1727
FU University of Macau [MYRG2019--00044-ICMS]
FX This study was supported by the research funds to Ying Bian from the
   University of Macau, which was MYRG2019--00044-ICMS
CR Advani S, 2019, J SURG ONCOL, V119, P642, DOI 10.1002/jso.25441
   Aparicio T, 2020, DIGEST LIVER DIS, V52, P493, DOI 10.1016/j.dld.2019.12.145
   Avolio M, 2021, CANCER DISCOV, V11, P1644, DOI 10.1158/2159-8290.CD-20-1531
   Barendregt JJ, 2013, J EPIDEMIOL COMMUN H, V67, P974, DOI 10.1136/jech-2013-203104
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Benson A, 2021, J NATL COMPR CANC NE, V19, P329, DOI 10.6004/jnccn.2021.0012
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Chibaudel B, 2019, INT J ONCOL, V54, P1433, DOI 10.3892/ijo.2019.4709
   Chiron M, 2014, MOL CANCER THER, V13, P1636, DOI 10.1158/1535-7163.MCT-13-0753
   Denda T, 2019, CANCER SCI, V110, P1032, DOI 10.1111/cas.13943
   Devaux M, 2019, WORLD J CLIN ONCOL, V10, P75, DOI 10.5306/wjco.v10.i2.75
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Ferrara N, 2004, ONCOLOGIST, V9, P2, DOI 10.1634/theoncologist.9-suppl_1-2
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Folprecht G, 2016, ANN ONCOL, V27, P1273, DOI 10.1093/annonc/mdw176
   Hashiguchi Y, 2020, INT J CLIN ONCOL, V25, P1, DOI 10.1007/s10147-019-01485-z
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Higgins Julian P T, 2011, BMJ, V343, pd5928, DOI 10.1136/bmj.d5928
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252
   Lapeyre-Prost A, 2020, CLIN COLORECTAL CANC, V19, P285, DOI 10.1016/j.clcc.2020.06.003
   Li J, 2018, FUTURE ONCOL, V14, P2030, DOI 10.2217/fon-2017-0669
   Matikas A, 2019, TARGET ONCOL, V14, P285, DOI 10.1007/s11523-019-00647-3
   Ottaiano A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00766
   Papadopoulos N, 2012, ANGIOGENESIS, V15, P171, DOI 10.1007/s10456-011-9249-6
   Parisi A, 2020, CANCERS, V12, DOI 10.3390/cancers12051259
   Peeters M, 2014, ANN ONCOL, V25, P107, DOI 10.1093/annonc/mdt523
   Peng L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111839
   Pentheroudakis G, 2018, CLIN COLORECTAL CANC, V17, pE631, DOI 10.1016/j.clcc.2018.06.003
   Qi WX, 2014, CLIN DRUG INVEST, V34, P231, DOI 10.1007/s40261-014-0174-5
   Riechelmann RP, 2019, CLIN COLORECTAL CANC, V18, P183, DOI 10.1016/j.clcc.2019.05.003
   Saif Muhammad Wasif, 2013, Cancer Manag Res, V5, P103, DOI 10.2147/CMAR.S45193
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Slim K, 2003, ANZ J SURG, V73, P712, DOI 10.1046/j.1445-2197.2003.02748.x
   Stewart LA, 2015, JAMA-J AM MED ASSOC, V313, P1657, DOI 10.1001/jama.2015.3656
   Strickler JH, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6234-8
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Trotti A, 2003, SEMIN RADIAT ONCOL, V13, P176, DOI 10.1016/S1053-4296(03)00031-6
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   VANCUTSEM E, 2014, ANN ONCOL, P1, DOI DOI 10.1093/ANNONC/MDU260
   Wang TF, 2012, CLIN MED INSIGHTS-ON, V6, DOI 10.4137/CMO.S7432
   Xie XY, 2020, ADV THER, V37, P4233, DOI 10.1007/s12325-020-01447-2
   Xu Zhili, 2021, Cancer Treat Res Commun, V29, P100455, DOI 10.1016/j.ctarc.2021.100455
   Yamada Y, 2021, ANTICANCER RES, V41, P533, DOI 10.21873/anticanres.14805
NR 48
TC 2
Z9 2
U1 0
U2 14
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0269-4727
EI 1365-2710
J9 J CLIN PHARM THER
JI J. Clin. Pharm. Ther.
PD JUN
PY 2022
VL 47
IS 6
BP 798
EP 808
DI 10.1111/jcpt.13610
EA MAR 2022
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2D2LN
UT WOS:000762411000001
PM 35229901
OA gold
DA 2025-01-04
ER

PT J
AU De Cuyper, A
   Van Den Eynde, M
   Machiels, JP
AF De Cuyper, Astrid
   Van Den Eynde, Marc
   Machiels, Jean-Pascal
TI HER2 as a Predictive Biomarker and Treatment Target in Colorectal Cancer
SO CLINICAL COLORECTAL CANCER
LA English
DT Review
DE Drug resistance; Epidermal growth factor receptor; Human epidermal
   growth factor receptor 2; Gene amplification; Targeted therapy
ID MONOCLONAL-ANTIBODY; BREAST-CANCER; TRASTUZUMAB; MUTATIONS; THERAPY;
   TUMORS; BRAF; OVEREXPRESSION; CHEMOTHERAPY; CETUXIMAB
AB The prognosis of metastatic colorectal cancer (mCRC) is poor. Cetuximab and panitumumab, 2 anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs), improve the overall survival of patients with RAS wild-type mCRC. However, not all patients with RAS wild-type mCRC will respond to anti-EGFR mAbs. Several retrospective trials suggest that human epidermal growth factor receptor 2 (HER2) amplification could be a predictive biomarker of resistance to anti-EGFR mAbs in patients with metastatic RAS and RAF wild-type mCRC. Dual HER2 inhibition with trastuzumab plus lapatinib or pertuzumab has shown promising preliminary anti-tumoral efficacy in RAS wild-type mCRC. Although these findings need to be confirmed in randomized trials, the data strongly support that HER2 is an actionable gene in CRC and provide the scientific rationale to test HER2 status on a routine basis in this disease. In this review, we discuss the predictive value of HER2 activation in CRC as well as its potential role as a treatment target. (C) 2020 Elsevier Inc. All rights reserved.
C1 [De Cuyper, Astrid; Van Den Eynde, Marc; Machiels, Jean-Pascal] Catholic Univ Louvain, Inst Roi Albert II, Clin Univ St Luc, Serv Oncol Med, Ave Hippocrate 10, B-1200 Brussels, Belgium.
   [De Cuyper, Astrid; Van Den Eynde, Marc; Machiels, Jean-Pascal] Catholic Univ Louvain, Inst Rech Clin & Expt POLE MIRO, Brussels, Belgium.
C3 Universite Catholique Louvain; Cliniques Universitaires Saint-Luc;
   Universite Catholique Louvain
RP De Cuyper, A (corresponding author), Catholic Univ Louvain, Inst Roi Albert II, Clin Univ St Luc, Serv Oncol Med, Ave Hippocrate 10, B-1200 Brussels, Belgium.; De Cuyper, A (corresponding author), Catholic Univ Louvain, Inst Rech Clin & Expt, Ave Hippocrate 10, B-1200 Brussels, Belgium.
EM astrid.decuyper@uclouvain.be
CR Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Bang YJ, 2010, LANCET, V376, P1302
   Bekaii-Saab TS, 2009, MOL CANCER THER, V8, P2983, DOI 10.1158/1535-7163.MCT-09-0820
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Clark J.W., 2003, Onkologie, V26, P13
   Cronin KA, 2010, CANCER INVEST, V28, P963, DOI 10.3109/07357907.2010.496759
   De Roock W, 2011, LANCET ONCOL, V12, P594, DOI 10.1016/S1470-2045(10)70209-6
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Doi T, 2017, LANCET ONCOL, V18, P1512, DOI 10.1016/S1470-2045(17)30604-6
   Edenfield WJ, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e14508
   Fujii S, 2020, JCO PRECIS ONCOL, V4, P6, DOI 10.1200/PO.19.00154
   Gharib E, 2019, J CELL PHYSIOL, V234, P13137, DOI 10.1002/jcp.27984
   Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780
   Harbeck N, 2017, LANCET, V389, P1134, DOI [10.1016/s0140-6736(16)31891-8, 10.1016/S0140-6736(16)31891-8]
   Hausman DF, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.TPS215
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Hickinson DM, 2010, CLIN CANCER RES, V16, P1159, DOI 10.1158/1078-0432.CCR-09-2353
   Jeong JH, 2017, CLIN COLORECTAL CANC, V16, pE147, DOI 10.1016/j.clcc.2017.01.005
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Laurent-Puig P, 2019, CLIN CANCER RES, V25, P134, DOI 10.1158/1078-0432.CCR-18-1324
   Lee WS, 2014, CANCER MED-US, V3, P674, DOI 10.1002/cam4.228
   Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
   Martin V, 2013, BRIT J CANCER, V108, P668, DOI 10.1038/bjc.2013.4
   Martinelli E, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2017-000299
   Martins M, 2018, ADV EXP MED BIOL, V1110, P113, DOI 10.1007/978-3-030-02771-1_8
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275
   Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nam SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151865
   Peterson S, 2017, ANN ONCOL, V28
   Raghav K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00226
   Rakha EA, 2015, J CLIN PATHOL, V68, P93, DOI 10.1136/jclinpath-2014-202571
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Rüschoff J, 2012, MODERN PATHOL, V25, P637, DOI 10.1038/modpathol.2011.198
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Sartore-Bianchi A, 2019, ONCOLOGIST, V24, P1395, DOI 10.1634/theoncologist.2018-0785
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sawada K, 2018, CLIN COLORECTAL CANC, V17, P198, DOI 10.1016/j.clcc.2018.05.006
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Sergina NV, 2007, TRENDS MOL MED, V13, P527, DOI 10.1016/j.molmed.2007.10.002
   Shan LN, 2018, J CANCER RES CLIN, V144, P2275, DOI 10.1007/s00432-018-2744-z
   Shimada Y, 2017, HUM PATHOL, V66, P1, DOI 10.1016/j.humpath.2017.02.004
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100
   Siena S, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-CT005
   Siravegna G, 2019, CLIN CANCER RES, V25, P3046, DOI 10.1158/1078-0432.CCR-18-3389
   Siravegna G, 2018, CANCER CELL, V34, P148, DOI 10.1016/j.ccell.2018.06.004
   SLAMON DJ, 1989, SCIENCE, V244, P707, DOI 10.1126/science.2470152
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Strickler JH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.TPS3624
   Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
NR 56
TC 31
Z9 34
U1 0
U2 8
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1533-0028
EI 1938-0674
J9 CLIN COLORECTAL CANC
JI Clin. Colorectal Canc.
PD JUN
PY 2020
VL 19
IS 2
BP 65
EP 72
DI 10.1016/j.clcc.2020.02.007
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LR5LK
UT WOS:000535736200004
PM 32229076
DA 2025-01-04
ER

PT J
AU Yi, Q
   Xie, W
   Sun, W
   Sun, WC
   Liao, Y
AF Yi, Qian
   Xie, Wei
   Sun, Wei
   Sun, Weichao
   Liao, Yi
TI A Concise Review of MicroRNA-383: Exploring the Insights of Its Function
   in Tumorigenesis
SO JOURNAL OF CANCER
LA English
DT Review
DE miR-383; Cancer; Proliferation; Apoptosis; Invasion; Metastasis
ID POTENTIAL PROGNOSTIC BIOMARKER; MESENCHYMAL STEM-CELLS; OVARIAN-CANCER;
   UP-REGULATION; HEPATOCELLULAR-CARCINOMA; INHIBITS PROLIFERATION;
   SPONGING MIR-383-5P; MIRNA EXPRESSION; TUMOR-SUPPRESSOR; PEROXIREDOXIN 3
AB MicroRNAs (miRNAs) are small noncoding RNAs that commonly have 18-22 nucleotides and play important roles in the regulation of gene expression via directly binding to the 3'-UTR of target mRNAs. Approximately 50% of human genes are regulated by miRNAs and they are involved in many human diseases, including various types of cancers. Recently, microRNA-383 (miR-383) has been identified as being aberrantly expressed in multiple cancers, such as malignant melanoma, colorectal cancer, hepatocellular cancer, and glioma. Increasing evidence suggests that miR-383 participates in tumorigenic events including proliferation, apoptosis, invasion, and metastasis as well as drug resistance. Although downstream targets including CCND1, LDHA, VEGF, and IGF are illustrated to be regulated by miR-383, its roles in carcinogenesis are still ambiguous and the underlying mechanisms are still unclear. Herein, we review the latest studies on miR-383 and summarize its functions in human cancers and other diseases. The goal of this review is to provide new strategies for targeted therapy and further investigations.
C1 [Yi, Qian; Sun, Weichao; Liao, Yi] Shenzhen Univ, Cent Lab, Hlth Sci Ctr, Shenzhen Second Peoples Hosp,Affiliated Hosp 1, Shenzhen 518035, Guangdong, Peoples R China.
   [Yi, Qian] Southwest Med Univ, Sch Basic Med Sci, Dept Physiol, Luzhou 646099, Sichuan, Peoples R China.
   [Xie, Wei; Sun, Wei; Sun, Weichao] Shenzhen Univ, Hlth Sci Ctr, Dept Orthoped, Shenzhen Peoples Hosp 2,Affiliated Hosp 1, Shenzhen 518035, Guangdong, Peoples R China.
   [Yi, Qian] Southwest Med Univ, Lab Anesthesia & Organ Protect, Luzhou 646099, Sichuan, Peoples R China.
C3 Second People's Hospital of Shenzhen; Shenzhen University; Southwest
   Medical University; Shenzhen University; Southwest Medical University
RP Sun, WC; Liao, Y (corresponding author), Shenzhen Univ, Cent Lab, Hlth Sci Ctr, Shenzhen Second Peoples Hosp,Affiliated Hosp 1, Shenzhen 518035, Guangdong, Peoples R China.; Sun, W; Sun, WC (corresponding author), Shenzhen Univ, Hlth Sci Ctr, Dept Orthoped, Shenzhen Peoples Hosp 2,Affiliated Hosp 1, Shenzhen 518035, Guangdong, Peoples R China.
EM 414464705@qq.com; weichaosunshine@163.com; science0528@163.com
RI Sun, Weichao/KXR-1734-2024; Liao, Yi/JVM-9413-2024; yi,
   qian/HIR-8841-2022
OI Sun, Weichao/0000-0003-1646-8524
FU National Natural Sciences Foundation of China [82172831, 82003126];
   China Postdoctoral Science Foundation [2019M663106]; Shenzhen Science
   and Technology Projects [JCYJ20190807102601647, JCYJ20210324103604013]
FX This work was supported by funds from the National Natural Sciences
   Foundation of China (No. 82172831 to Yi Liao and No. 82003126 to Weichao
   Sun) ; China Postdoctoral Science Foundation Grant (No. 2019M663106 to
   Yi Liao) ; and Shenzhen Science and Technology Projects (No.
   JCYJ20190807102601647 to Qian Yi and JCYJ20210324103604013 to Weichao
   Sun) .
CR Ameli-Mojarad M, 2021, J ONCOL, V2021, DOI 10.1155/2021/2303946
   Awasthi P, 2016, J CELL SCI, V129, P1285, DOI 10.1242/jcs.188631
   Azarbarzin S, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118939
   Bartel DP, 2018, CELL, V173, P20, DOI 10.1016/j.cell.2018.03.006
   Bi M, 2021, ENVIRON SCI POLLUT R, V28, P56606, DOI 10.1007/s11356-021-13335-5
   Boguslawska J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024541
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Bucay N, 2017, ONCOGENE, V36, P2667, DOI 10.1038/onc.2016.419
   Chakraborty C, 2014, WIRES RNA, V5, P697, DOI 10.1002/wrna.1240
   Chen L, 2016, TUMOR BIOL, V37, P2497, DOI 10.1007/s13277-015-4071-1
   Cheng Y, 2020, MOL GENET GENOM MED, V8, DOI 10.1002/mgg3.1272
   Costa FF, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025114
   Cui Y, 2018, ONCOL LETT, V15, P1184, DOI 10.3892/ol.2017.7409
   Dai RF, 2022, ARCH PHYSIOL BIOCHEM, V128, P637, DOI 10.1080/13813455.2020.1716016
   Derghal A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00172
   Donadeu FX, 2013, DOMEST ANIM ENDOCRIN, V45, P122, DOI 10.1016/j.domaniend.2013.06.006
   Donadeu FX, 2012, J ENDOCRINOL, V215, P323, DOI 10.1530/JOE-12-0252
   Duan DM, 2016, NEUROSCI LETT, V627, P160, DOI 10.1016/j.neulet.2016.05.054
   Elgaaen BV, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-80
   Fan GW, 2016, INFLAMMATION, V39, P375, DOI 10.1007/s10753-015-0259-1
   Fan WX, 2020, ARTIF CELL NANOMED B, V48, P1047, DOI 10.1080/21691401.2020.1773487
   Fang ZX, 2017, IRAN J BASIC MED SCI, V20, P187, DOI 10.22038/ijbms.2017.8246
   Ferretti E, 2009, INT J CANCER, V124, P568, DOI 10.1002/ijc.23948
   Gao CH, 2019, J CELL PHYSIOL, V234, P12809, DOI 10.1002/jcp.27915
   Gao J, 2020, CANCER MANAG RES, V12, P2265, DOI 10.2147/CMAR.S236576
   Gu B, 2018, J CELL BIOL
   Guan CJ, 2021, INFLAMMATION, V44, P923, DOI 10.1007/s10753-020-01387-7
   Guo X, 2021, J CELL MOL MED, V25, P244, DOI 10.1111/jcmm.15953
   Hahne M, 1998, J EXP MED, V188, P1185, DOI 10.1084/jem.188.6.1185
   Han RL, 2017, NEOPLASMA, V64, P244, DOI 10.4149/neo_2017_211
   Han SL, 2015, CANCER LETT, V366, P61, DOI 10.1016/j.canlet.2015.06.004
   He ZW, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0557-0
   Hu Y, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6326-5
   Huang GY, 2021, ANTI-CANCER DRUG, V32, P286, DOI 10.1097/CAD.0000000000000916
   Huang HL, 2014, CELL SIGNAL, V26, P903, DOI 10.1016/j.cellsig.2014.01.016
   Huang SS, 2017, SCI REP-UK, V7, DOI 10.1038/srep45692
   Jiang J, 2019, BIOMED PHARMACOTHER, V109, P595, DOI 10.1016/j.biopha.2018.10.148
   Jiang YY, 2017, AM J TRANSL RES, V9, P2374
   Kang J, 2015, EXP THER MED, V9, P345, DOI 10.3892/etm.2014.2123
   Karshovska E, 2020, ARTERIOSCL THROM VAS, V40, P583, DOI 10.1161/ATVBAHA.119.313290
   Kim JH, 2007, CANCER RES, V67, P8229, DOI 10.1158/0008-5472.CAN-07-1297
   Lai NS, 2017, ARTHRITIS RES THER, V19, DOI 10.1186/s13075-017-1465-z
   Lee CH, 2013, INT J MOL SCI, V14, P11560, DOI 10.3390/ijms140611560
   Li J, 2018, MOL CARCINOGEN, V57, P1408, DOI 10.1002/mc.22866
   Li KKW, 2013, BRAIN PATHOL, V23, P413, DOI 10.1111/bpa.12014
   Li P, 2021, PHARMACOL RES PERSPE, V9, DOI 10.1002/prp2.815
   Li XX, 2020, INT J MOL MED, V46, P397, DOI 10.3892/ijmm.2020.4603
   Li YH, 2020, CANCER MANAG RES, V12, P6795, DOI 10.2147/CMAR.S251952
   Lian J, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.70
   Lian J, 2009, REPROD BIOL ENDOCRIN, V7, DOI 10.1186/1477-7827-7-13
   Lian Z, 2018, J CELL BIOCHEM, V119, P6684, DOI 10.1002/jcb.26854
   Liao XH, 2015, CELL SIGNAL, V27, P2285, DOI 10.1016/j.cellsig.2015.08.005
   Lin J., 2017, MICRORNA, V5, P222
   Liu GY, 2020, CANCER MANAG RES, V12, P12001, DOI 10.2147/CMAR.S282539
   Liu JB, 2016, BIOMED PHARMACOTHER, V83, P1286, DOI 10.1016/j.biopha.2016.07.038
   Lu DD, 2012, CANCER CELL, V21, P92, DOI 10.1016/j.ccr.2011.12.016
   Lu H, 2019, XENOBIOTICA, V49, P740, DOI 10.1080/00498254.2018.1490044
   Lv Q, 2020, BIOSCI BIOTECH BIOCH, V84, P1997, DOI 10.1080/09168451.2020.1780903
   Ma HJ, 2016, CELL BIOCHEM FUNCT, V34, P613, DOI 10.1002/cbf.3237
   Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012
   Mansuri MS, 2016, J DERMATOL SCI, V84, P50, DOI 10.1016/j.jdermsci.2016.07.003
   Mhawech-Fauceglia P, 2008, EUR J CANCER, V44, P2097, DOI 10.1016/j.ejca.2008.07.007
   Mu XQ, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109989
   Mueller DW, 2009, J INVEST DERMATOL, V129, P1740, DOI 10.1038/jid.2008.452
   Nesca V, 2013, DIABETOLOGIA, V56, P2203, DOI 10.1007/s00125-013-2993-y
   Noguchi S, 2013, VET COMP ONCOL, V11, P113, DOI 10.1002/vco.306
   Pei LC, 2016, CELL PHYSIOL BIOCHEM, V39, P1339, DOI 10.1159/000447838
   Piovani G, 2014, MOL CYTOGENET, V7, DOI 10.1186/1755-8166-7-25
   Qie S, 2016, J MOL MED, V94, P1313, DOI 10.1007/s00109-016-1475-3
   Rengaraj D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019524
   Salilew-Wondim D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106795
   Salvador JM, 2013, ADV EXP MED BIOL, V793, P1, DOI 10.1007/978-1-4614-8289-5_1
   Schauer SN, 2013, REPRODUCTION, V146, P273, DOI 10.1530/REP-13-0107
   Shang YH, 2016, BIOMED PHARMACOTHER, V83, P1175, DOI 10.1016/j.biopha.2016.08.006
   Shao BY, 2020, J ORAL PATHOL MED, V49, P21, DOI 10.1111/jop.12946
   Shi Y, 2015, TUMOR BIOL, V36, P8455, DOI 10.1007/s13277-015-3565-1
   Shu SY, 2013, J BIOMED SCI, V20, DOI 10.1186/1423-0127-20-9
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Song Y, 2018, EXP THER MED, V15, P553, DOI 10.3892/etm.2017.5413
   Su QL, 2019, EUR REV MED PHARMACO, V23, P10729, DOI 10.26355/eurrev_201912_19774
   Takahashi RU, 2017, CLIN CHEM LAB MED, V55, P648, DOI 10.1515/cclm-2016-0708
   Takuma A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112335
   Tambyah PA, 2016, ANN CLIN BIOCHEM, V53, P466, DOI 10.1177/0004563215604001
   Tang JF, 2018, BONE, V114, P137, DOI 10.1016/j.bone.2018.06.010
   Taylor BS, 2010, CANCER CELL, V18, P11, DOI 10.1016/j.ccr.2010.05.026
   Teng P, 2018, J CELL BIOCHEM, V119, P5243, DOI 10.1002/jcb.26585
   Tian H, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.138
   Tian YY, 2019, ONCOTARGETS THER, V12, P10569, DOI 10.2147/OTT.S229659
   Tu C., 2019, J CELL MOL MED, P1
   Tugay K, 2016, DIABETOLOGIA, V59, P161, DOI 10.1007/s00125-015-3783-5
   Ushio N, 2019, ONCOL LETT, V17, P1080, DOI 10.3892/ol.2018.9692
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   Wan PQ, 2018, J CELL BIOCHEM, V119, P9720, DOI 10.1002/jcb.27286
   Wang H, 2020, ONCOTARGETS THER, V13, P4305, DOI 10.2147/OTT.S242854
   Wang S, 2021, ONCOL REP, V45, DOI 10.3892/or.2021.8050
   Wang XF, 2020, CANCER MANAG RES, V12, P13415, DOI 10.2147/CMAR.S272753
   Wang XL, 2018, EXP THER MED, V15, P3181, DOI 10.3892/etm.2018.5838
   Wang XY, 2015, FEBS LETT, V589, P3989, DOI 10.1016/j.febslet.2015.11.012
   Wang Y, 2018, KAOHSIUNG J MED SCI, V34, P503, DOI 10.1016/j.kjms.2018.04.006
   Wei GJ, 2018, CELL PHYSIOL BIOCHEM, V47, P129, DOI 10.1159/000489756
   Wei GJ, 2017, CELL PHYSIOL BIOCHEM, V41, P1435, DOI 10.1159/000468057
   Wu SL, 2017, BIOCHEM GENET, V55, P253, DOI 10.1007/s10528-017-9794-9
   Xia SF, 2017, J ENDOCRINOL, V234, P201, DOI [10.1530/JOE-17-0044, 10.1530/joe-17-0044]
   Xu DW, 2015, TUMOR BIOL, V36, P7743, DOI 10.1007/s13277-015-3378-2
   Xu G, 2019, BRAZ J MED BIOL RES, V52, DOI 10.1590/1414-431X20198341
   Xu Z, 2021, ONCOL LETT, V22, DOI 10.3892/ol.2021.12901
   Xu Z, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.9870
   Xu Z, 2014, BIOCHEM BIOPH RES CO, V453, P833, DOI 10.1016/j.bbrc.2014.10.047
   Xue F, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12517
   Yan F, 2018, MOL MED REP, V17, P6893, DOI 10.3892/mmr.2018.8682
   Yao GD, 2010, MOL ENDOCRINOL, V24, P540, DOI 10.1210/me.2009-0432
   Yin MM, 2014, J BIOL CHEM, V289, P18239, DOI 10.1074/jbc.M113.546044
   Yin MM, 2012, MOL ENDOCRINOL, V26, P1129, DOI 10.1210/me.2011-1341
   Yuan YL, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118955
   Yuen CM, 2017, AM J TRANSL RES, V9, P1651
   Zhang JW, 2020, CANCER BIOMARK, V27, P423, DOI 10.3233/CBM-190704
   Zhang X, 2019, ENDOCR J, V66, P1011, DOI 10.1507/endocrj.EJ19-0080
   Zhao L, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110472
   Zhao LN, 2017, CELL SIGNAL, V30, P142, DOI 10.1016/j.cellsig.2016.09.007
   Zhao SS, 2017, ONCOL LETT, V14, P3573, DOI 10.3892/ol.2017.6603
   Zhao X, 2018, GENES-BASEL, V9, DOI 10.3390/genes9090426
   Zhen L, 2017, J THERM BIOL, V66, P114, DOI 10.1016/j.jtherbio.2017.03.005
   Zhou Q, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5936-2
NR 123
TC 12
Z9 13
U1 2
U2 20
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1837-9664
J9 J CANCER
JI J. Cancer
PY 2022
VL 13
IS 1
BP 313
EP 324
DI 10.7150/jca.64846
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA YI2XX
UT WOS:000743717900007
PM 34976192
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Xu, JS
   Guo, JJ
   Jiang, YK
   Liu, YJ
   Liao, KL
   Fu, ZH
   Xiong, ZF
AF Xu, Jiasheng
   Guo, Jingjing
   Jiang, Yangkai
   Liu, Yujun
   Liao, Kaili
   Fu, Zhonghua
   Xiong, Zhenfang
TI Improved characterization of the relationship between long intergenic
   non-coding RNA Linc00152 and the occurrence and development of
   malignancies
SO CANCER MEDICINE
LA English
DT Review
DE linc00152; long non-coding RNA; malignant tumor
ID COMPETING ENDOGENOUS RNA; GASTRIC-CANCER; POOR-PROGNOSIS; EXPRESSION;
   PROGRESSION; REVEALS; CARCINOMA; LNCRNAS; PROLIFERATION; APOPTOSIS
AB Linc00152, located on chromosome 2p11.2, is a long intergenic non-coding RNA molecule with 828 nucleotides that is highly expressed in many types of human tumor tissues, especially in malignant tumors of the digestive system. Linc00152 promotes the occurrence and development of tumors by increasing tumor cell proliferation, invasion, metastasis, and apoptosis. Additionally, linc00152 contributes to the carcinogenesis of several cancers, including gastric cancer, liver cancer, hepatocellular carcinoma, gallbladder cancer, clear cell renal cell carcinoma, and colorectal cancer, by disturbing various signaling pathways (eg PI3K/AKT, mTOR, IL-1, and NOTCH 1 signaling pathways). High linc00152 expression levels are associated with chemoresistance as well as poor prognosis and shorter survival. Continual advances made in the relevant research have indicated that linc00152 may be useful as a new tumor molecular biomarker, applicable for tumor diagnosis, targeted therapy, and prognosis assessment. This review summarizes the progress in the research into the relationship between linc00152 and the occurrence and development of malignancies based on molecular functions, regulatory mechanisms, and clinical applications.
C1 [Xu, Jiasheng; Guo, Jingjing; Jiang, Yangkai; Xiong, Zhenfang] Nanchang Univ, Affiliated Hosp 1, Dept Pathol, 17 Yongwaizheng St, Nanchang 330001, Jiangxi, Peoples R China.
   [Liu, Yujun] Nanchang Univ, Queen Mary Coll, Nanchang, Jiangxi, Peoples R China.
   [Liao, Kaili] Nanchang Univ, Affiliated Hosp 2, Dept Clin Lab, Nanchang, Jiangxi, Peoples R China.
   [Fu, Zhonghua] Nanchang Univ, Affiliated Hosp 1, Dept Burns, 17 Yongwaizheng St, Nanchang 330001, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University; Nanchang University; Nanchang
   University
RP Xiong, ZF (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Pathol, 17 Yongwaizheng St, Nanchang 330001, Jiangxi, Peoples R China.; Fu, ZH (corresponding author), Nanchang Univ, Affiliated Hosp 1, Dept Burns, 17 Yongwaizheng St, Nanchang 330001, Jiangxi, Peoples R China.
EM fzhncuedu@163.com; jesonxudoctor@163.com
RI jiang, yangkai/JAX-2588-2023
CR Bian ZH, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0008-4
   Cabili MN, 2011, GENE DEV, V25, P1915, DOI 10.1101/gad.17446611
   Cai Q, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.160247
   Cai Q, 2016, AM J TRANSL RES, V8, P4068
   Cao WJ, 2013, WORLD J GASTROENTERO, V19, P3658, DOI 10.3748/wjg.v19.i23.3658
   Chen J, 2009, ASIAN J ANDROL, V11, P669, DOI 10.1038/aja.2009.51
   Chen QN, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0581-3
   Chen WM, 2016, ONCOTARGET, V7, P9773, DOI 10.18632/oncotarget.6949
   Chen X, 2018, CELL PHYSIOL BIOCHEM, V46, P1055, DOI 10.1159/000488836
   Chen ZT, 2018, ONCOL LETT, V15, P4177, DOI 10.3892/ol.2018.7833
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Deng X, 2017, BIOMED PHARMACOTHER, V90, P100, DOI 10.1016/j.biopha.2017.03.031
   Derrien T, 2012, GENOME RES, V22, P1775, DOI 10.1101/gr.132159.111
   Dinger ME, 2008, GENOME RES, V18, P1433, DOI 10.1101/gr.078378.108
   Djebali S, 2012, NATURE, V489, P101, DOI 10.1038/nature11233
   Feng SM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-03043-x
   Giannakakis A, 2015, SCI REP-UK, V5, DOI 10.1038/srep09737
   Han L, 2012, INT J ONCOL, V40, P2004, DOI 10.3892/ijo.2012.1413
   Hu HB, 2016, CELL PHYSIOL BIOCHEM, V40, P117, DOI 10.1159/000452529
   Huang Xiaoqing, 2015, Yichuan, V37, P344, DOI 10.16288/j.yczz.14-432
   Huang Y, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20171607
   Hwangbo W, 2013, KOREAN J PATHOL, V47, P107, DOI 10.4132/KoreanJPathol.2013.47.2.107
   Ji J, 2015, ONCOTARGET, V6, P42813, DOI 10.18632/oncotarget.5970
   Kalman B, 2013, NEUROMOL MED, V15, P420, DOI 10.1007/s12017-013-8229-y
   Khalil AM, 2009, P NATL ACAD SCI USA, V106, P11667, DOI 10.1073/pnas.0904715106
   Kim DH, 2015, CELL STEM CELL, V16, P88, DOI 10.1016/j.stem.2014.11.005
   Li J, 2015, CELL PHYSIOL BIOCHEM, V37, P687, DOI 10.1159/000430387
   Li ND, 2017, DIS MARKERS, V2017, DOI 10.1155/2017/7439698
   Li Q, 2015, TUMOR BIOL, V36, P2007, DOI 10.1007/s13277-014-2807-y
   Liu LY, 2017, ONCOTARGET, V8, P93227, DOI 10.18632/oncotarget.21838
   Liu XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-92
   Liu XW, 2016, TUMOR BIOL, V37, P15977, DOI 10.1007/s13277-016-5434-y
   Liu YC, 2014, ARTERIOSCL THROM VAS, V34, P902, DOI 10.1161/ATVBAHA.113.303123
   Ma LN, 2013, RNA BIOL, V10, P925, DOI 10.4161/rna.24604
   Miao CK, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/6010721
   Müller S, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0358-5
   Nötzold L, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02357-0
   Okayama H, 2012, CANCER RES, V72, P100, DOI 10.1158/0008-5472.CAN-11-1403
   Oliveira-Cunha M, 2012, PANCREAS, V41, P428, DOI 10.1097/MPA.0b013e3182327a03
   Pang QQ, 2014, TUMOR BIOL, V35, P5441, DOI 10.1007/s13277-014-1709-3
   Quan FY, 2017, ONCOTARGET, V8, P75427, DOI 10.18632/oncotarget.20130
   Sulsal-Ul Haque, 2018, HEAD NECK-J SCI SPEC, V40, P1555, DOI 10.1002/hed.25136
   Sun KK, 2018, BIOMED PHARMACOTHER, V97, P1296, DOI 10.1016/j.biopha.2017.11.015
   Sun WL, 2016, J CANCER RES CLIN, V142, P2231, DOI 10.1007/s00432-016-2183-7
   Van Grembergen O, 2016, SCI ADV, V2, DOI 10.1126/sciadv.1600220
   Wang LJ, 2015, CELL RES, V25, P335, DOI 10.1038/cr.2015.21
   Wang YJ, 2017, AM J CANCER RES, V7, P312
   Wu JL, 2018, BIOMED PHARMACOTHER, V97, P1275, DOI 10.1016/j.biopha.2017.11.055
   Wu Y, 2016, AM J CANCER RES, V6, P285
   Xia T, 2014, SCI REP-UK, V4, DOI 10.1038/srep06088
   Yang S, 2016, ONCOTARGET, V7, P85728, DOI 10.18632/oncotarget.13828
   Yang T, 2016, CANCER EPIDEMIOL, V44, P147, DOI 10.1016/j.canep.2016.08.015
   Yu JJ, 2017, J CANCER, V8, P523, DOI 10.7150/jca.17510
   Yu MJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0677-9
   Yu X, 2017, CANCER MED-US, V6, P673, DOI 10.1002/cam4.1027
   Yu Y, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12349
   Yuan WD, 2017, CELL PHYSIOL BIOCHEM, V44, P125, DOI 10.1159/000484589
   Yue B, 2018, MOL THER, V26, P1287, DOI 10.1016/j.ymthe.2018.02.024
   Yue B, 2016, MOL THER, V24, P2064, DOI 10.1038/mt.2016.180
   Zhang JM, 2018, CLIN CHIM ACTA, V483, P25, DOI 10.1016/j.cca.2018.03.034
   Zhang PP, 2017, J CANCER, V8, P2042, DOI 10.7150/jca.18852
   Zhang Y, 2017, BIOMED PHARMACOTHER, V94, P644, DOI 10.1016/j.biopha.2017.07.120
   Zhang YH, 2016, AM J TRANSL RES, V8, P5286
   Zhao J, 2015, CELL CYCLE, V14, P3112, DOI 10.1080/15384101.2015.1078034
   Zhao W., 2015, SCI REP-UK, V5, P1, DOI DOI 10.1038/SREP08957
   Zheng J, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0422-2
   Zhou JP, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0262-2
   Zhou JP, 2015, J EXP CLIN CANC RES, V34, DOI 10.1186/s13046-015-0250-6
NR 68
TC 14
Z9 15
U1 1
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD AUG
PY 2019
VL 8
IS 10
BP 4722
EP 4731
DI 10.1002/cam4.2245
EA JUL 2019
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IU7EY
UT WOS:000474109400001
PM 31270960
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Zurloh, M
   Goetz, M
   Herold, T
   Treckmann, J
   Markus, P
   Schumacher, B
   Albers, D
   Rink, A
   Rosery, V
   Zaun, G
   Kostbade, K
   Pogorzelski, M
   Ting, S
   Schmidt, H
   Stiens, R
   Wiesweg, M
   Schuler, M
   Kasper, S
   Virchow, I
AF Zurloh, M.
   Goetz, M.
   Herold, T.
   Treckmann, J.
   Markus, P.
   Schumacher, B.
   Albers, D.
   Rink, A.
   Rosery, V.
   Zaun, G.
   Kostbade, K.
   Pogorzelski, M.
   Ting, S.
   Schmidt, H.
   Stiens, R.
   Wiesweg, M.
   Schuler, M.
   Kasper, Stefan
   Virchow, I.
TI Impact of encorafenib on survival of patients with
   BRAF<SUP>V600E</SUP>-mutant metastatic colorectal cancer in a real-world
   setting
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Metastatic colorectal cancer; BRAFV600E; Chemotherapy; Encorafenib
ID FOLFIRI PLUS BEVACIZUMAB; BRAF-MUTATION; 1ST-LINE TREATMENT;
   PREDICTIVE-VALUE; FOLFOXIRI PLUS; CETUXIMAB; KRAS; CHEMOTHERAPY
AB PurposePatients with BRAF(V600E)-mutant metastatic colorectal cancer (mCRC) have a dismal prognosis. The best strategies in these patients remain elusive. Against this background, we report the clinical course of patients with BRAF(V600E)-mutant mCRC to retrieve the best treatment strategy.Patients and methodsClinico-pathological data were extracted from the electronic health records. Kaplan-Meier method was used to estimate overall (OS) and progression-free survival (PFS). Objective response rate (ORR) was assessed according to RECIST 1.1.ResultsIn total, 51 patients were enrolled. FOLFOXIRI was administered to 12 patients; 29 patients received FOLFOX or FOLFIRI as first-line treatment. Median OS was 17.6 months. Median PFS with FOLFOXIRI (13.0 months) was significantly prolonged (HR 0.325) as compared to FOLFOX/FOLFIRI (4.3 months). However, this failed to translate into an OS benefit (p = 0.433). Interestingly, addition of a monoclonal antibody to chemotherapy associated with superior OS (HR 0.523). A total of 64.7% patients received further-line therapy, which included a BRAF inhibitor in 17 patients. Targeted therapy associated with very favourable OS (25.1 months).ConclusionPatients with BRAF(V600E)-mutated mCRC benefit from the addition of an antibody to first-line chemotherapy. Further-line treatment including a BRAF inhibitor has a dramatic impact on survival.
C1 [Zurloh, M.; Rosery, V.; Zaun, G.; Kostbade, K.; Pogorzelski, M.; Stiens, R.; Wiesweg, M.; Schuler, M.; Kasper, Stefan; Virchow, I.] Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Hufeland Str 55, D-45147 Essen, Germany.
   [Goetz, M.; Herold, T.; Ting, S.] Univ Hosp Essen, Inst Pathol Essen, West German Canc Ctr, Essen, Germany.
   [Treckmann, J.; Rink, A.] Univ Hosp Essen, West German Canc Ctr, Dept Gen Visceral & Transplant Surg, Essen, Germany.
   [Markus, P.] Elisabeth Hosp, Dept Gen Surg & Traumatol, Essen, Germany.
   [Schumacher, B.; Albers, D.] Elisabeth Hosp, Dept Gastroenterol, Essen, Germany.
   [Ting, S.] Inst Pathol Nordhessen, Kassel, Germany.
   [Schmidt, H.] Univ Hosp Essen, Dept Gastroenterol Hepatol & Transplant Med, Essen, Germany.
   [Herold, T.; Wiesweg, M.; Schuler, M.; Kasper, Stefan] Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany.
   [Zurloh, M.; Herold, T.; Treckmann, J.; Rink, A.; Rosery, V.; Zaun, G.; Kostbade, K.; Pogorzelski, M.; Schmidt, H.; Stiens, R.; Wiesweg, M.; Schuler, M.; Kasper, Stefan; Virchow, I.] Univ Duisburg Essen, Med Fac, Essen, Germany.
C3 University of Duisburg Essen; University of Duisburg Essen; University
   of Duisburg Essen; University of Duisburg Essen; Helmholtz Association;
   German Cancer Research Center (DKFZ); University of Duisburg Essen
RP Kasper, S (corresponding author), Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Hufeland Str 55, D-45147 Essen, Germany.; Kasper, S (corresponding author), Partner Site Univ Hosp Essen, German Canc Consortium DKTK, Essen, Germany.; Kasper, S (corresponding author), Univ Duisburg Essen, Med Fac, Essen, Germany.
EM stefan.kasper-virchow@uk-essen.de
RI Schuler, Markus/AAI-6535-2020; Kasper-Virchow, Stefan/KCL-2631-2024;
   Pogorzelski, Michael/JYQ-4594-2024
OI Schuler, Martin/0000-0002-2166-3394; Albers, David/0000-0003-1507-4590
FU Projekt DEAL
FX Open Access funding enabled and organized by Projekt DEAL. This research
   received no specific grant from any funding agency in the public,
   commercial, or not-for-profit sectors
CR Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Benson A, 2021, J NATL COMPR CANC NE, V19, P329, DOI 10.6004/jnccn.2021.0012
   Clancy C, 2013, COLORECTAL DIS, V15, pE711, DOI 10.1111/codi.12427
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Fransén K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Loupakis F, 2016, BRIT J CANCER, V114, P30, DOI 10.1038/bjc.2015.399
   Modest DP, 2016, ANN ONCOL, V27, P1746, DOI 10.1093/annonc/mdw261
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Sinicrope FA, 2015, GASTROENTEROLOGY, V148, P88, DOI 10.1053/j.gastro.2014.09.041
   Souglakos J, 2009, BRIT J CANCER, V101, P465, DOI 10.1038/sj.bjc.6605164
   Stintzing S, 2017, EUR J CANCER, V79, P50, DOI 10.1016/j.ejca.2017.03.023
   Stintzing S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3502
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Wang JH, 2019, J CANCER, V10, P2332, DOI 10.7150/jca.30789
   Yamauchi M, 2012, GUT, V61, P847, DOI 10.1136/gutjnl-2011-300865
   Yokota T, 2011, BRIT J CANCER, V104, P856, DOI 10.1038/bjc.2011.19
   Yoshino T, 2019, ANN ONCOL, V30, P124, DOI 10.1093/annonc/mdy461
NR 24
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD NOV
PY 2023
VL 149
IS 14
BP 12903
EP 12912
DI 10.1007/s00432-023-05141-y
EA JUL 2023
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA U6YH0
UT WOS:001033480900006
PM 37466791
OA hybrid, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU Gouverneur, A
   Salvo, F
   Berdaï, D
   Moore, N
   Fourrier-Réglat, A
   Noize, P
AF Gouverneur, Amandine
   Salvo, Francesco
   Berdai, Driss
   Moore, Nicholas
   Fourrier-Reglat, Annie
   Noize, Pernelle
TI Inclusion of elderly or frail patients in randomized controlled trials
   of targeted therapies for the treatment of metastatic colorectal cancer:
   A systematic review
SO JOURNAL OF GERIATRIC ONCOLOGY
LA English
DT Review
DE Review literature as topic; Molecular targeted therapy; Colorectal
   neoplasm; Neoplasm metastasis; Aged
ID PHASE-III TRIAL; KRAS WILD-TYPE; BEVACIZUMAB PLUS CAPECITABINE; 1ST-LINE
   TREATMENT; OPEN-LABEL; MAINTENANCE THERAPY; PANITUMUMAB PLUS;
   NON-INFERIORITY; OLDER PATIENTS; ONCOLOGY-GROUP
AB Treatment of metastatic colorectal cancer (mCRC) has been modified since the launching of targeted therapies. Colorectal cancer (CRC) is common in elderly patients; their representation in randomized controlled trials (RCTs) is thus crucial. This study aimed to evaluate and quantify the inclusion of elderly/frail patients in RCTs of targeted therapies in mCRC.
   A systematic review using Medline, Scopus, Cochrane Database and ISI Web of Science was performed to identify all phase II/III RCTs of bevacizumab, cetuximab, panitumumab, regorafenib and aflibercept in mCRC until January 2015. Two reviewers independently performed studies selection, and data extraction. The protocol was registered in Prospero (CRD42015016163).
   Among 1369, identified publications, 54 RCTs were selected. Nine RCTs (17%) excluded elderly patients; median age of the included population was <65 years old in 50 RCTs (93%). Twenty RCTs (37%) excluded frail patients, and many RCTs excluded patients with uncontrolled hypertension or heart failure, patients treated with specific drugs (mainly anticoagulants), and patients with inadequate creatinine clearance.
   Elderly/frail patients are underrepresented in RCTs studying targeted therapies in mCRC, and those elderly patients included in RCTs do not reflect well the general elderly population with mCRC because of the exclusion criteria. RCTs results concerning targeted therapies can be inferred only to relatively healthy elderly subjects. (C) 2017 Elsevier Ltd. All rights reserved.
C1 [Gouverneur, Amandine; Salvo, Francesco; Moore, Nicholas; Fourrier-Reglat, Annie; Noize, Pernelle] Univ Bordeaux, INSERM, Bordeaux Populat Hlth Res Ctr, Team Pharmacoepidemiol,UMR 1219, F-33000 Bordeaux, France.
   [Gouverneur, Amandine; Salvo, Francesco; Moore, Nicholas; Fourrier-Reglat, Annie; Noize, Pernelle] INSERM, Bordeaux PharmacoEpi, CIC1401, F-33000 Bordeaux, France.
   [Gouverneur, Amandine; Salvo, Francesco; Berdai, Driss; Moore, Nicholas; Fourrier-Reglat, Annie; Noize, Pernelle] CHU Bordeaux, Pole Sante Publ, Serv Pharmacol Med, F-33000 Bordeaux, France.
C3 Institut National de la Sante et de la Recherche Medicale (Inserm);
   Universite de Bordeaux; Universite de Bordeaux; Institut National de la
   Sante et de la Recherche Medicale (Inserm); Universite de Bordeaux; CHU
   Bordeaux
RP Gouverneur, A (corresponding author), CHU, Serv Pharmacol Med, F-33076 Bordeaux, France.; Gouverneur, A (corresponding author), Univ Bordeaux, Batiment 1A,Case 36,146 Rue Leo Saignat, F-33076 Bordeaux, France.
EM amandine.gouvemeur@u-bordeaux.fr
RI Salvo, Francesco/S-9254-2019; Noize, Pernelle/T-1955-2019; Moore,
   Nicholas/B-2368-2013; Gouverneur, Amandine/O-5332-2018
OI Gouverneur, Amandine/0000-0001-6253-1833; Noize,
   Pernelle/0000-0001-5617-7954; Salvo, Francesco/0000-0003-3210-7171
CR [Anonymous], 2008, J MED SCI
   [Anonymous], STUD SUPP SPEC POP G
   [Anonymous], GUID IND E7 STUD SUP
   Aparicio T, 2016, DIGEST LIVER DIS, V48, P1112, DOI 10.1016/j.dld.2016.05.011
   Asmis TR, 2011, ANN ONCOL, V22, P118, DOI 10.1093/annonc/mdq309
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Borner M, 2008, ANN ONCOL, V19, P1288, DOI 10.1093/annonc/mdn058
   Bray F, 2012, LANCET ONCOL, V13, P790, DOI 10.1016/S1470-2045(12)70211-5
   Brodowicz T, 2013, ANN ONCOL, V24, P1769, DOI 10.1093/annonc/mdt116
   Cassidy J, 2011, BRIT J CANCER, V105, P58, DOI 10.1038/bjc.2011.201
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
   Del Rio M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074599
   Díaz-Rubio E, 2012, ONCOLOGIST, V17, P15, DOI 10.1634/theoncologist.2011-0249
   Dotan Efrat, 2012, J Gastrointest Cancer, V43, P562
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Douillard JY, 2014, CLIN COLORECTAL CANC, V13, P14, DOI 10.1016/j.clcc.2013.11.009
   Ducreux M, 2013, EUR J CANCER, V49, P1236, DOI 10.1016/j.ejca.2012.12.011
   Folprecht G, 2014, ANN ONCOL, V25, P1018, DOI 10.1093/annonc/mdu088
   Fourrier-Réglat A, 2014, TARGET ONCOL, V9, P311, DOI 10.1007/s11523-013-0296-3
   Fuchs CS, 2007, J CLIN ONCOL, V25, P4779, DOI 10.1200/JCO.2007.11.3357
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guan Zhong-Zhen, 2011, Chin J Cancer, V30, P682, DOI 10.5732/cjc.011.10188
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hochster HS, 2008, J CLIN ONCOL, V26, P3523, DOI 10.1200/JCO.2007.15.4138
   Howlader N., 2017, SEER Cancer Statistics Review
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz H, 2012, ONCOLOGIST, V17, P937, DOI 10.1634/theoncologist.2012-0071
   Jackson NA, 2009, CANCER-AM CANCER SOC, V115, P2617, DOI 10.1002/cncr.24305
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
   Jennens RR, 2006, INTERN MED J, V36, P216, DOI 10.1111/j.1445-5994.2006.01033.x
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Kato S, 2012, ONCOLOGY-BASEL, V83, P101, DOI 10.1159/000339541
   Kemeny NE, 2011, J CLIN ONCOL, V29, P884, DOI 10.1200/JCO.2010.32.5977
   Lewis JH, 2003, J CLIN ONCOL, V21, P1383, DOI 10.1200/JCO.2003.08.010
   Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
   Madajewicz S, 2012, INVEST NEW DRUG, V30, P772, DOI 10.1007/s10637-010-9598-9
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Moosmann N, 2011, J CLIN ONCOL, V29, P1050, DOI 10.1200/JCO.2010.31.1936
   Ocvirk J, 2010, WORLD J GASTROENTERO, V16, P3133, DOI 10.3748/wjg.v16.i25.3133
   OKEN MM, 1982, AM J CLIN ONCOL-CANC, V5, P649, DOI 10.1097/00000421-198212000-00014
   Papamichael D, 2015, ANN ONCOL, V26, P463, DOI 10.1093/annonc/mdu253
   Parasuraman S, 2015, J PHARM NEGAT RESULT, V6, P1, DOI 10.4103/0976-9234.157372
   Peeters M, 2014, ANN ONCOL, V25, P107, DOI 10.1093/annonc/mdt523
   Price TJ, 2012, ANN ONCOL, V23, P1531, DOI 10.1093/annonc/mdr488
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6
   Rosati G, 2016, J GERIATR ONCOL, V7, P134, DOI 10.1016/j.jgo.2016.01.006
   Rouyer M, 2016, J GERIATR ONCOL, V7, P187, DOI 10.1016/j.jgo.2016.03.004
   Saltz L, 2012, CLIN COLORECTAL CANC, V11, P101, DOI 10.1016/j.clcc.2011.05.006
   Saltz LB, 2007, J CLIN ONCOL, V25, P4557, DOI 10.1200/JCO.2007.12.0949
   Schmiegel W, 2013, ANN ONCOL, V24, P1580, DOI 10.1093/annonc/mdt028
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Sclafani F, 2014, J GERIATR ONCOL, V5, P78, DOI 10.1016/j.jgo.2013.08.006
   Seruga B, 2016, LANCET ONCOL, V17, pE209, DOI 10.1016/S1470-2045(16)00152-2
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Shankaran V, 2014, ONCOLOGIST, V19, P892, DOI 10.1634/theoncologist.2013-0209
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Sorbye H, 2009, CANCER, V115, P4679, DOI 10.1002/cncr.24527
   Souglakos J, 2012, BRIT J CANCER, V106, P453, DOI 10.1038/bjc.2011.594
   Stathopoulos GP, 2010, ONCOLOGY-BASEL, V78, P376, DOI 10.1159/000320520
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Talarico L, 2004, J CLIN ONCOL, V22, P4626, DOI 10.1200/JCO.2004.02.175
   Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tournigand C, 2015, LANCET ONCOL, V16, P1493, DOI 10.1016/S1470-2045(15)00216-8
   Tsai HT, 2013, ANN ONCOL, V24, P1574, DOI 10.1093/annonc/mdt019
   Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Ward P, 2014, J GERIATR ONCOL, V5, P368, DOI 10.1016/j.jgo.2014.05.002
   Wasan H, 2014, LANCET ONCOL, V15, P631, DOI 10.1016/S1470-2045(14)70106-8
   Winther SB, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000021
   Yalcin S, 2013, ONCOLOGY-BASEL, V85, P328, DOI 10.1159/000355914
   Yamada Y, 2013, LANCET ONCOL, V14, P1278, DOI 10.1016/S1470-2045(13)70490-X
   Ye LC, 2013, J CLIN ONCOL, V31, P1931, DOI 10.1200/JCO.2012.44.8308
NR 84
TC 27
Z9 29
U1 1
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1879-4068
EI 1879-4076
J9 J GERIATR ONCOL
JI J. Geriatr. Oncol.
PD JAN
PY 2018
VL 9
IS 1
BP 15
EP 23
DI 10.1016/j.jgo.2017.08.001
PG 9
WC Oncology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Geriatrics & Gerontology
GA FS8YU
UT WOS:000422701400004
PM 28844343
DA 2025-01-04
ER

PT J
AU Brar, G
   Marshall, JL
   Pishvaian, MJ
AF Brar, Gagandeep
   Marshall, John L.
   Pishvaian, Michael J.
TI Targeted Therapy and the Use of Molecular Profiling in Metastatic
   Colorectal Cancer
SO AMERICAN JOURNAL OF HEMATOLOGY-ONCOLOGY
LA English
DT Article
ID RANDOMIZED PHASE-III; WILD-TYPE KRAS; 1ST-LINE TREATMENT; MICROSATELLITE
   INSTABILITY; OPEN-LABEL; COLON-CANCER; PANITUMUMAB PLUS; SUPPORTIVE
   CARE; RAS MUTATIONS; CETUXIMAB
AB Metastatic colorectal cancer (mCRC) is the third leading cause of cancer-related mortality in the United States, but survival rates for advanced CRC have improved significantly in the past 15 years. This improved survival is due, in large part, to more effective chemotherapy, but improvements have also been attributed to the incorporation of therapies that either target, or are guided by, the multiple aberrant signaling pathways involved in the growth and spread of colorectal cancer cells, including the VEGF, EGFR, RAS/RAF, and HER2 signaling pathways, as well as genetic changes induced by mismatch repair enzyme deficits and the resultant microsatellite instability. Targeted treatments directed toward inhibiting these pathways have improved survival rates beyond those achieved with standard chemotherapy. This review provides an update on targeted agents used in mCRC and the impact that specific, defined predictive biomarkers have on patient selection and, ultimately, patient outcome.
C1 [Brar, Gagandeep; Marshall, John L.; Pishvaian, Michael J.] Georgetown Univ, Div Hematol & Oncol, Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA.
C3 Georgetown University
RP Pishvaian, MJ (corresponding author), Georgetown Univ, Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd NW, Washington, DC 20007 USA.
EM pishvaim@georgetown.edu
CR Al-Shamsi HO, 2015, J GASTROINTEST ONCOL, V6, P314, DOI 10.3978/j.issn.2078-6891.2015.016
   Alexander J, 2001, AM J PATHOL, V158, P527, DOI 10.1016/S0002-9440(10)63994-6
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], J CLIN ONCOL S4S
   [Anonymous], J CLIN ONCOL S15
   [Anonymous], J CLIN ONCOL S4
   [Anonymous], J CLIN ONCOL S4
   [Anonymous], P AM SOC CLIN ONCOL
   [Anonymous], J CLIN ONCOL S4
   [Anonymous], 2014, J CLIN ONCOL S
   [Anonymous], J CLIN ONCOL S15
   [Anonymous], ANN ONCOL S6
   [Anonymous], J CLIN ONCOL
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Dolcetti R, 1999, AM J PATHOL, V154, P1805, DOI 10.1016/S0002-9440(10)65436-3
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Emmanouilides C, 2007, BMC CANCER, V7, DOI 10.1186/1471-2407-7-91
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Fernandez-Medarde Alberto, 2011, Genes Cancer, V2, P344, DOI 10.1177/1947601911411084
   Gajewski TF, 2013, NAT IMMUNOL, V14, P1014, DOI 10.1038/ni.2703
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Goldstein J, 2014, ANN ONCOL, V25, P1032, DOI 10.1093/annonc/mdu100
   Gong J, 2016, J GASTROINTEST ONCOL, V7, P687, DOI 10.21037/jgo.2016.06.12
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Herbst RS, 2014, NATURE, V515, P563, DOI 10.1038/nature14011
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Janakiraman M, 2010, CANCER RES, V70, P5901, DOI 10.1158/0008-5472.CAN-10-0192
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Kim TW, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.642
   Koopman M, 2009, BRIT J CANCER, V100, P266, DOI 10.1038/sj.bjc.6604867
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Martin V, 2013, BRIT J CANCER, V108, P668, DOI 10.1038/bjc.2013.4
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Peeters M, 2014, ANN ONCOL, V25, P107, DOI 10.1093/annonc/mdt523
   Peeters M, 2013, CLIN CANCER RES, V19, P1902, DOI 10.1158/1078-0432.CCR-12-1913
   Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.086
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Smyrk TC, 2001, CANCER, V91, P2417, DOI 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tejpar S, 2012, J CLIN ONCOL, V30, P3570, DOI 10.1200/JCO.2012.42.2592
   Tie J, 2011, INT J CANCER, V128, P2075, DOI 10.1002/ijc.25555
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
   Yan YY, 2015, ONCOTARGETS THER, V8, P2949, DOI 10.2147/OTT.S79145
   Young J, 2001, AM J PATHOL, V159, P2107, DOI 10.1016/S0002-9440(10)63062-3
NR 71
TC 1
Z9 1
U1 0
U2 2
PU ROSSIISKII UNIV
PI NEW YORK
PA 114 W 26TH ST, 4TH FL, NEW YORK, NY 10001 USA
SN 1939-6163
EI 2334-0274
J9 AM J HEMATOL-ONCOL
JI Am. J. Hematol.-Oncol.
PD SEP
PY 2017
VL 13
IS 9
BP 4
EP 12
PG 9
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA FS0MZ
UT WOS:000419469500003
DA 2025-01-04
ER

PT J
AU Guo, M
   Li, XX
   Li, J
   Li, BL
AF Guo, Min
   Li, Xiaxi
   Li, Jiong
   Li, Baolong
TI Identification of the prognostic biomarkers and their correlations with
   immune infiltration in colorectal cancer through bioinformatics analysis
   and<i> in</i><i> vitro</i> experiments
SO HELIYON
LA English
DT Article
DE Colorectal cancer (CRC); Hub gene; Prognosis; Immune infiltration; BIRC5
ID WEB SERVER; SURVIVIN; GENE; PROTEIN; TARGET; TPX2; APOPTOSIS;
   ASSOCIATION; RESISTANCE; TUMOR
AB Colorectal cancer (CRC) is the third most diagnosed malignancy and the second leading cause of cancer death. The objective was to identify novel hub genes that were helpful for prognosis and targeted therapy in CRC. GSE23878, GSE24514, GSE41657, GSE81582 were filtered from the gene expression omnibus (GEO). Differentially expressed genes (DEGs) were identified through GEO2R, which were enriched in the GO term and KEGG pathway in DAVID. PPI network was constructed and analyzed using STRING and hub genes were screened out. The relationships between hub genes and prognoses in CRC were evaluated in GEPIA based on the cancer genome atlas (TCGA) and genotype-tissue expression (GTEx). The transcription factors and miRNA-mRNA interaction networks for hub genes were performed using miRnet and miRTarBase. The relationship between hub genes and tumor-infiltrating lymphocytes were analyzed in TIMER. The protein levels of hub genes were identified in HPA. The expression levels of hub gene in CRC and its effect on the biological effect of CRC cells were identified in vitro. As hub genes, the mRNA levels of BIRC5, CCNB1, KIF20A, NCAPG, and TPX2 were highly expressed in CRC and had excellent prognostic value. The BIRC5, CCNB1, KIF20A, NCAPG, and TPX2 were closely associated with transcription factors, miRNAs, tumor-infiltrating lymphocytes, suggesting their involvement in the regulation of CRC. BIRC5 highly expressed in CRC tissues and cells, and promoted the proliferation, migration, and invasion of CRC cells. BIRC5, CCNB1, KIF20A, NCAPG, and TPX2 are hub genes that serve as promising prognostic biomarkers in CRC. BIRC5 plays an important role in the development and progression of CRC.
C1 [Guo, Min] Southern Med Univ, Affiliated Hosp 5, Dept Oncol, Guangzhou, Guangdong, Peoples R China.
   [Li, Xiaxi] Southern Med Univ, Shenzhen Hosp, Dept Gastroenterol, Shenzhen, Guangdong, Peoples R China.
   [Li, Jiong] Jinan Univ, Med Coll, Dept Anat Neurosci Lab Cognit & Dev Disorders, Guangzhou, Guangdong, Peoples R China.
   [Li, Baolong] Southern Med Univ, Affiliated Hosp 5, Dept Gen Surg, Guangzhou, Guangdong, Peoples R China.
   [Li, Baolong] Southern Med Univ, Affiliated Hosp 5, Dept Gen Surg, Guangzhou 510900, Guangdong, Peoples R China.
C3 Southern Medical University - China; Southern Medical University -
   China; Jinan University; Southern Medical University - China; Southern
   Medical University - China
RP Li, BL (corresponding author), Southern Med Univ, Affiliated Hosp 5, Dept Gen Surg, Guangzhou 510900, Guangdong, Peoples R China.
EM libaolong1457@163.com
RI Li, Xiaxi/F-5009-2013
CR Alhopuro P, 2012, INT J CANCER, V130, P1558, DOI 10.1002/ijc.26167
   Altieri DC, 2015, SEMIN CELL DEV BIOL, V39, P91, DOI 10.1016/j.semcdb.2014.12.007
   Ambrosini G, 1997, NAT MED, V3, P917, DOI 10.1038/nm0897-917
   Anderson AC, 2016, IMMUNITY, V44, P989, DOI 10.1016/j.immuni.2016.05.001
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Asplund A, 2012, PROTEOMICS, V12, P2067, DOI 10.1002/pmic.201100504
   Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Bradley T, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14670-w
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Cesario JM, 2006, J CELL SCI, V119, P4770, DOI 10.1242/jcs.03235
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Ding X, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00045
   Evans PM, 2007, J BIOL CHEM, V282, P33994, DOI 10.1074/jbc.M701847200
   Fan YN, 2016, NUCLEIC ACIDS RES, V44, pW135, DOI 10.1093/nar/gkw288
   Fukuda S, 2006, MOL CANCER THER, V5, P1087, DOI 10.1158/1535-7163.MCT-05-0375
   Grasso CS, 2018, CANCER DISCOV, V8, P730, DOI 10.1158/2159-8290.CD-17-1327
   Gruss OJ, 2002, NAT CELL BIOL, V4, P871, DOI 10.1038/ncb870
   Gruss OJ, 2001, CELL, V104, P83, DOI 10.1016/S0092-8674(01)00193-3
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Huang HY, 2020, NUCLEIC ACIDS RES, V48, pD148, DOI 10.1093/nar/gkz896
   Jasperson KW, 2010, GASTROENTEROLOGY, V138, P2044, DOI 10.1053/j.gastro.2010.01.054
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Kim PJ, 2003, LANCET, V362, P205, DOI 10.1016/S0140-6736(03)13910-4
   Krambeck AE, 2007, CLIN CANCER RES, V13, P1749, DOI 10.1158/1078-0432.CCR-06-2129
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Lammens A, 2004, CURR BIOL, V14, P1778, DOI 10.1016/j.cub.2004.09.044
   Lei XY, 2021, NUTR CANCER, V73, P2568, DOI 10.1080/01635581.2020.1841249
   Li PL, 2015, CARCINOGENESIS, V36, P1484, DOI 10.1093/carcin/bgv145
   Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307
   Lin SC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1303-z
   Liu JH, 2021, MOL THER-NUCL ACIDS, V23, P324, DOI 10.1016/j.omtn.2020.11.010
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   Sayagués JM, 2016, ONCOTARGET, V7, P72908, DOI 10.18632/oncotarget.12140
   Palou R, 2018, PLOS BIOL, V16, DOI 10.1371/journal.pbio.2003980
   Petry S, 2013, CELL, V152, P768, DOI 10.1016/j.cell.2012.12.044
   Sarela AI, 2001, ANN SURG ONCOL, V8, P305
   Satow R, 2010, CLIN CANCER RES, V16, P2518, DOI 10.1158/1078-0432.CCR-09-2214
   Siegel R.L., 2020, CA-CANCER J CLIN, V70, P145
   Singh Neetu, 2018, Oncotarget, V9, P30385, DOI 10.18632/oncotarget.25752
   Slattery ML, 2018, APOPTOSIS, V23, P237, DOI 10.1007/s10495-018-1451-1
   Smith LT, 2006, GENE CHROMOSOME CANC, V45, P957, DOI 10.1002/gcc.20354
   Suzuki H, 2005, CLIN CANCER RES, V11, P1521, DOI 10.1158/1078-0432.CCR-04-0538
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Uddin S, 2011, AM J PATHOL, V178, P537, DOI 10.1016/j.ajpath.2010.10.020
   Vainio P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039801
   Wang HY, 2014, J SURG ONCOL, V109, P574, DOI 10.1002/jso.23526
   Wang N, 2022, PEERJ, V10, DOI 10.7717/peerj.12871
   Wang Y, 2019, BIOCHEM BIOPH RES CO, V511, P685, DOI 10.1016/j.bbrc.2019.02.123
   Wang YX, 2019, JAMA ONCOL, V5, P1118, DOI 10.1001/jamaoncol.2019.0512
   Warner SL, 2009, CLIN CANCER RES, V15, P6519, DOI 10.1158/1078-0432.CCR-09-0077
   Wei P, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-313
   Wittmann T, 2000, J CELL BIOL, V149, P1405, DOI 10.1083/jcb.149.7.1405
   Xie F, 2020, CLIN EXP PHARMACOL P, V47, P135, DOI 10.1111/1440-1681.13183
   Xiong M, 2019, AGING-US, V11, P11905, DOI 10.18632/aging.102505
NR 56
TC 2
Z9 2
U1 1
U2 9
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
EI 2405-8440
J9 HELIYON
JI Heliyon
PD JUN
PY 2023
VL 9
IS 6
AR e17101
DI 10.1016/j.heliyon.2023.e17101
EA JUN 2023
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA O4HX1
UT WOS:001043452500001
PM 37389063
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Jones, LR
   Greene, J
   Chen, KM
   Divine, G
   Chitale, D
   Shah, V
   Datta, I
   Worsham, MJ
AF Jones, Lamont R.
   Greene, Joshua
   Chen, Kang Mei
   Divine, George
   Chitale, Dhananjay
   Shah, Veena
   Datta, Indrani
   Worsham, Maria J.
TI Biological Significance of Genome-Wide DNA Methylation Profiles in
   Keloids
SO LARYNGOSCOPE
LA English
DT Article
DE Methylation; epigenetics; keloid; pathway analysis
ID HYPERTROPHIC SCAR; CELL-DEATH; EXPRESSION; APOPTOSIS; GENE; FIBROBLASTS;
   INSTABILITY; ACTIVATION; HISTAMINE; FAMILY
AB Objectives/Hypothesis: To obtain biological insight into keloid pathogenesis and treatment using pathway analysis of genome-wide differentially methylated gene profiles between keloid and normal skin.
   Study Design: Prospective cohort.
   Methods: Genome-wide profiling was previously done, with institutional review board approval, on six fresh keloid and six fresh normal skin tissue samples, using the Infinium HumanMethylation450 BeadChip kit. Statistically significant differentially methylated cytosine-phosphodiester bond-guanines (CpGs, n = 197) between keloid and normal tissue mapped to 152 genes. These genes were uploaded into Ingenuity Pathway Analysis (IPA) software to identify biological functions or regulatory networks interacting. The pathways (or "network") with an enrichment probability value < .01 were subjected to a heuristic filter of keywords associated with keloid pathogenesis.
   Results: Of the 197 CpGs, 191 were found in the IPA database and mapped to 152 unique genes. The top 10 hypermethylated genes were ACTR3C, LRRC61, PAQR4, Clorf109, SLCO2B1, CMKLR1, AHDC1, FYCO1, CCDC34, and CACNB2. The top 10 hypomethylated genes were GALNT3, SCML4, PPP1R13L, ANKRD11, W1PF1, MX2, 1FF01, DENND1C, CFH, and GHDC. IPA identified nine pathways with enrichment probability values <= .01, of which five (histidine degradation V1, phospholipase C signaling, colorectal cancer metastasis signaling, P2Y purinergic receptor signaling, and G alpha i signaling) were associated with keloid keywords and contained "keloid genes" (P < .05).
   Conclusions: Genes differentially methylated between keloid and normal skin reside in known bionetwork pathways involved in critical biological functioning and signaling events in the cell. This information could he used to refine screening processes for biological significance to better understand keloid pathogenesis and to develop molecular-targeted therapy.
C1 [Jones, Lamont R.; Greene, Joshua; Chen, Kang Mei; Worsham, Maria J.] Henry Ford Hosp, Dept Otolaryngol Head & Neck Surg, 2799 West Grand Blvd, Detroit, MI 48202 USA.
   [Chitale, Dhananjay; Shah, Veena] Henry Ford Hlth Syst, Dept Pathol, Detroit, MI USA.
   [Divine, George] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Detroit, MI USA.
   [Datta, Indrani] Henry Ford Hlth Syst, Dept Publ Hlth Sci, Ctr Bioinformat, Detroit, MI USA.
   Henry Ford Hlth Syst, Detroit, MI USA.
C3 Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System;
   Henry Ford Hospital; Henry Ford Health System; Henry Ford Hospital;
   Henry Ford Health System; Henry Ford Hospital; Henry Ford Health System;
   Henry Ford Hospital
RP Jones, LR (corresponding author), Henry Ford Hosp, Dept Otolaryngol Head & Neck Surg, 2799 West Grand Blvd, Detroit, MI 48202 USA.
EM ljones5@hfhs.org
RI jones, lamont/AAL-6691-2020; Zhou, yin/HGE-2329-2022
OI Chitale, Dhananjay/0000-0002-4421-6431
CR Abbracchio MP, 1998, JPN J PHARMACOL, V78, P113, DOI 10.1254/jjp.78.113
   Ansurudeen I, 2012, AMINO ACIDS, V43, P127, DOI 10.1007/s00726-012-1269-z
   Atiyeh BS, 2005, ANN PLAS SURG, V54, P676, DOI 10.1097/01.sap.0000164538.72375.93
   Bayat A, 2003, BRIT MED J, V326, P88, DOI 10.1136/bmj.326.7380.88
   Bergamaschi D, 2004, MOL CELL BIOL, V24, P1341, DOI 10.1128/MCB.24.3.1341-1350.2004
   Burnstock G, 2012, J INVEST DERMATOL, V132, P526, DOI 10.1038/jid.2011.344
   BURSCH W, 1992, TRENDS PHARMACOL SCI, V13, P245, DOI 10.1016/0165-6147(92)90077-J
   Butler PD, 2008, J AM COLL SURGEONS, V206, P731, DOI 10.1016/j.jamcollsurg.2007.12.001
   Chandrasekar B, 2008, J BIOL CHEM, V283, P24889, DOI 10.1074/jbc.M804236200
   Chao PZ, 2011, J BIOMED SCI, V18, DOI 10.1186/1423-0127-18-86
   Chike-Obi Chuma J, 2009, Semin Plast Surg, V23, P178, DOI 10.1055/s-0029-1224797
   COHEN JJ, 1993, HOSP PRACT, V28, P35, DOI 10.1080/21548331.1993.11442887
   Davis SA, 2013, DERMATOL SURG, V39, P988, DOI 10.1111/dsu.12182
   De Felice B, 2007, DNA CELL BIOL, V26, P541, DOI 10.1089/dna.2007.0591
   Fennell LM, 2014, BIOCHEM BIOPH RES CO, V445, P304, DOI 10.1016/j.bbrc.2014.01.178
   Finnson KW, 2013, ADV WOUND CARE, V2, P195, DOI 10.1089/wound.2013.0429
   Gauglitz GG, 2011, MOL MED, V17, P113, DOI 10.2119/molmed.2009.00153
   Giridharan SSP, 2012, J CELL SCI, V125, P614, DOI 10.1242/jcs.089367
   Grady WM, 2008, GASTROENTEROLOGY, V135, P1079, DOI 10.1053/j.gastro.2008.07.076
   Grady WM, 2000, CURR OPIN GASTROEN, V16, P62, DOI 10.1097/00001574-200001000-00012
   Hong SM, 2015, INT FORUM ALLERGY RH, V5, P923, DOI 10.1002/alr.21555
   Jones LR, 2015, DIS MARKERS, V2015, DOI 10.1155/2015/943176
   Ladin Daniel A., 1995, Wound Repair and Regeneration, V3, P6, DOI 10.1046/j.1524-475X.1995.30106.x
   Lappano R, 2011, NAT REV DRUG DISCOV, V10, P47, DOI 10.1038/nrd3320
   Liu CC, 2010, P NATL ACAD SCI USA, V107, P5136, DOI 10.1073/pnas.0911220107
   Liu SS, 2012, J BIOMED SCI, V19, DOI 10.1186/1423-0127-19-49
   Lum PY, 2006, J NEUROCHEM, V97, P50, DOI 10.1111/j.1471-4159.2006.03661.x
   Nilsson EE, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011637
   Numata Y, 2006, J INVEST DERMATOL, V126, P1403, DOI 10.1038/sj.jid.5700253
   Ogawa R, 2008, PLAST RECONSTR SURG, V122, P993, DOI 10.1097/PRS.0b013e31818120a0
   Penn JW, 2012, INT J BURNS TRAUMA, V2, P18
   Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052
   Ren G, 2015, MED ONCOL, V32, P654
   Sayah DN, 1999, J SURG RES, V87, P209, DOI 10.1006/jsre.1999.5761
   Shih B, 2010, ARCH DERMATOL RES, V302, P319, DOI 10.1007/s00403-009-1014-y
   Shih B, 2010, WOUND REPAIR REGEN, V18, P139, DOI 10.1111/j.1524-475X.2009.00553.x
   Shindo-Okada N, 2003, BIOCHEM BIOPH RES CO, V312, P889, DOI 10.1016/j.bbrc.2003.10.200
   Smith JC, 2008, J INVEST DERMATOL, V128, P1298, DOI 10.1038/sj.jid.5701149
   Ulrich D, 2010, J PLAST RECONSTR AES, V63, P1015, DOI 10.1016/j.bjps.2009.04.021
   Wang Q, 2013, BIOCHEM J, V449, P771, DOI 10.1042/BJ20121170
   Xuan JJ, 2015, BIOMED REP, V3, P395, DOI 10.3892/br.2015.420
   Young WG, 2014, JAMA FACIAL PLAST SU, V16, P379, DOI 10.1001/jamafacial.2014.113
   Zhao J, 2015, TUMOR BIOL, V36, P8609, DOI 10.1007/s13277-015-3558-0
NR 43
TC 19
Z9 23
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD JAN
PY 2017
VL 127
IS 1
BP 70
EP 78
DI 10.1002/lary.26063
PG 9
WC Medicine, Research & Experimental; Otorhinolaryngology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Otorhinolaryngology
GA EL9PB
UT WOS:000394951400025
PM 27312686
DA 2025-01-04
ER

PT J
AU Tintelnot, J
   Stein, A
AF Tintelnot, Joseph
   Stein, Alexander
TI Immunotherapy in colorectal cancer: Available clinical evidence,
   challenges and novel approaches
SO WORLD JOURNAL OF GASTROENTEROLOGY
LA English
DT Review
DE Immunotherapy; Combination; Colorectal cancer; Metastatic; Adjuvant
ID T-CELL THERAPY; MOLECULAR SUBTYPES; PD-1 BLOCKADE; COLON-CANCER; IMMUNE;
   COMBINATION; TUMORS; TRIAL; CHEMOTHERAPY; MUTATIONS
AB In contrast to other tumor types, immunotherapy has not yet become a relevant part of the treatment landscape of unselected colorectal cancer. Beside the small subgroup of deficient mismatch repair or microsatellite instable tumors (about 5%) as a surrogate for high mutational burden and subsequently high neoantigen load and immunogenicity, inhibitors of programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) and/or cytotoxic T lymphocyte-associated antigen-4 were not or only modestly effective in metastatic colorectal cancer. Thus, a variety of combination approaches with chemotherapy, targeted therapy, toll-like receptor agonists, local ablation or oncolytic viruses is currently being evaluated in different disease settings. Despite several encouraging single arm data already presented or published, available randomized data are unimpressive. Adding PD-1/PD-L1 inhibitors to fluoropyrimidines and bevacizumab maintenance showed no beneficial impact on delaying progression. In refractory disease, the combination of PD-1/PD-L1 and MEK inhibitor was not different from regorafenib, whereas a PD-1/PD-L1 and cytotoxic T lymphocyte-associated antigen-4 inhibitor combination demonstrated better overall survival compared to supportive care alone. Clinical trials in all disease settings applying different combination approaches are ongoing and may define the role of immunotherapy in colorectal cancer.
C1 [Tintelnot, Joseph; Stein, Alexander] Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 2, Oncol Ctr, Martinistr 52, D-20246 Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf
RP Stein, A (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Internal Med 2, Oncol Ctr, Martinistr 52, D-20246 Hamburg, Germany.
EM a.stein@uke.de
OI Tintelnot, Joseph/0000-0003-4619-9433
CR Abken H, 2015, IMMUNOTHERAPY-UK, V7, P535, DOI [10.2217/IMT.15.15, 10.2217/imt.15.15]
   [Anonymous], 2017, J CLIN ONCOL S
   [Anonymous], 2015, ASCO M S, DOI DOI 10.1200/jco.2015.33.3_suppl.704
   Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879
   Bendell J., 2018, Annals of Oncology, DOI [10.1093/annonc/mdy208.003, DOI 10.1093/ANNONC/MDY208.003]
   Bendell JC, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3502
   Bourdais R, 2017, CRIT REV ONCOL HEMAT, V113, P242, DOI 10.1016/j.critrevonc.2017.03.027
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Callahan MK, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3069
   Chen EX, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.481
   Chesney J, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw379.4
   Diaz LA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3071
   Dosset M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433981
   Duffy AG, 2016, J CLIN ONCOL S, V34
   Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024
   Fan JQ, 2018, THERANOSTICS, V8, P5784, DOI 10.7150/thno.29035
   Garris CS, 2018, IMMUNITY, V49, P1148, DOI 10.1016/j.immuni.2018.09.024
   Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075
   Gong J, 2017, J NATL COMPR CANC NE, V15, P142, DOI 10.6004/jnccn.2017.0016
   Gubin MM, 2014, NATURE, V515, P577, DOI 10.1038/nature13988
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hegde M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.10508
   Holubec L, 2016, ANTICANCER RES, V36, P4421, DOI 10.21873/anticanres.10985
   Ishikawa T, 2018, INT J CANCER, V142, P2599, DOI 10.1002/ijc.31285
   Iwasaki A, 2010, SCIENCE, V327, P291, DOI 10.1126/science.1183021
   Katz SC, 2015, CLIN CANCER RES, V21, P3149, DOI 10.1158/1078-0432.CCR-14-1421
   Lawler SE, 2017, JAMA ONCOL, V3, P841, DOI 10.1001/jamaoncol.2016.2064
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lenz HJ, 2018, ANN ONCOL, V29
   Lichtenegger FS, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00385
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Mach N, 2000, CANCER RES, V60, P3239
   McCarthy Edward F, 2006, Iowa Orthop J, V26, P154
   MOLE RH, 1953, BRIT J RADIOL, V26, P234, DOI 10.1259/0007-1285-26-305-234
   Morelli MP, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.646
   Newick K, 2016, MOL THER-ONCOLYTICS, V3, DOI 10.1038/mto.2016.6
   Ott PA, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00202
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Park SH, 2015, MOL THER, V23, P1532, DOI 10.1038/mt.2015.109
   Reynders K, 2015, CANCER TREAT REV, V41, P503, DOI 10.1016/j.ctrv.2015.03.011
   Robbins PF, 2013, NAT MED, V19, P747, DOI 10.1038/nm.3161
   Sadelain M, 2013, CANCER DISCOV, V3, P388, DOI 10.1158/2159-8290.CD-12-0548
   Schmoll HJ, 2014, J CANCER RES CLIN, V140, P1615, DOI 10.1007/s00432-014-1682-7
   Seufferlein T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e15545
   Shah M, 2018, ANN ONCOL, V29, P84
   Shahda S., 2017, J Clin Oncol, V35, P3541, DOI [DOI 10.1200/JCO.2017.35.15_SUPPL.3541, DOI 10.1200/JCO.2017.35.15SUPPL.3541]
   Slagter AE, 2018, ANN ONCOL, V29, P233
   Spiotto M, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aag1266
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Thistlethwaite FC, 2017, CANCER IMMUNOL IMMUN, V66, P1425, DOI 10.1007/s00262-017-2034-7
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253
   Troiani T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.TPS731
   Turajlic S, 2017, LANCET ONCOL, V18, P1009, DOI 10.1016/S1470-2045(17)30516-8
   Zhen YH, 2015, CANCER IMMUNOL IMMUN, V64, P1083, DOI 10.1007/s00262-015-1715-3
NR 57
TC 44
Z9 51
U1 1
U2 7
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 8226 REGENCY DR, PLEASANTON, CA 94588 USA
SN 1007-9327
EI 2219-2840
J9 WORLD J GASTROENTERO
JI World J. Gastroenterol.
PD AUG 7
PY 2019
VL 25
IS 29
BP 3920
EP 3928
DI 10.3748/wjg.v25.i29.3920
PG 9
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA IN8XW
UT WOS:000478964100007
PM 31413527
OA Green Submitted, Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Davidson, M
   Cunningham, D
AF Davidson, Michael
   Cunningham, David
TI Molecular Stratification of Colorectal Cancer: Moving from the
   Laboratory to Clinical Practice
SO CURRENT COLORECTAL CANCER REPORTS
LA English
DT Article
DE Colorectal cancer; Molecular stratification; Subtypes; Gene expression
   profiling; Predictive biomarkers; Personalised medicine
ID PROGRESSION-FREE SURVIVAL; FOLFIRI PLUS BEVACIZUMAB; ANTI-EGFR THERAPY;
   III COLON-CANCER; MICROSATELLITE INSTABILITY; BRAF MUTATION; TARGETED
   THERAPY; OPEN-LABEL; ADJUVANT TREATMENT; POOLED ANALYSIS
AB Purpose of Review Colorectal cancer is increasingly recognised as a heterogeneous disease entity, and subtyping is carried out based upon clinical and pathological characteristics, individual somatic gene mutations and, more recently, gene expression profiling. This paper will discuss advances in the molecular stratification of colorectal cancer and the potential challenges and applications for real-world clinical management.
   Recent Findings Beyond the established biomarkers of RAS and BRAF mutational status, a number of rarer genetic mutations have been identified, and trials are ongoing to identify and target these effectively. Differing subtyping systems based on gene expression profiling have also been proposed which have now been integrated into four consensus molecular subtypes, and the prognostic and predictive significance of these subtypes is being investigated. Molecular subtyping is methodologically challenging, and simpler classifier systems based on immunohistochemical correlate markers have been developed which may allow for wider clinical application.
   Summary Emerging genetic biomarkers and gene expression-based molecular subtyping have increased understanding of the underlying biological complexity of colorectal cancer but have not significantly impacted upon clinical decision-making or treatment as yet. Prospective validation is required to establish their role in predicting response to existing and emerging therapies.
C1 [Davidson, Michael; Cunningham, David] Royal Marsden NHS Fdn Trust, London, England.
   [Cunningham, David] Royal Marsden Hosp, Dept Gastrointestinal Res, Downs Rd, Sutton, Surrey, England.
C3 Royal Marsden NHS Foundation Trust; Royal Marsden NHS Foundation Trust
RP Cunningham, D (corresponding author), Royal Marsden NHS Fdn Trust, London, England.; Cunningham, D (corresponding author), Royal Marsden Hosp, Dept Gastrointestinal Res, Downs Rd, Sutton, Surrey, England.
EM David.cunningham@rmh.nhs.uk
RI Cunningham, David/ABT-0193-2022
OI Cunningham, David/0000-0001-5158-1069
FU Amgen; AstraZeneca; Celgene; MedImmune; Merck Serono; Roche; Sanofi;
   Merrimack; Bayer
FX Michael Davidson declares that he has no conflict of interest. David
   Cunningham has received research funding through grants from Amgen,
   AstraZeneca, Celgene, MedImmune, Merck Serono, Roche, Sanofi, Merrimack
   and Bayer.
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Amatu A, 2015, BRIT J CANCER, V113, P1730, DOI 10.1038/bjc.2015.401
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   [Anonymous], ASCO M ABSTRACTS S
   [Anonymous], 2016, J CLIN ONCOL S
   [Anonymous], J CLIN ONCOL S
   Arthur LM, 2014, CANCER RES, V74, P5371, DOI 10.1158/0008-5472.CAN-14-0620
   Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879
   Bendell J, 2016, ANN ONCOL, V27, P140
   Boeckx N, 2016, 89P PRIMARY TUMOR SI, p89P
   Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7
   Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212
   Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225
   Cooper ZA, 2014, CANCER IMMUNOL RES, V2, P643, DOI 10.1158/2326-6066.CIR-13-0215
   Corcoran R, 2016, 455O EFFICACY CIRCUL, p455O
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Dahlin AM, 2011, MODERN PATHOL, V24, P671, DOI 10.1038/modpathol.2010.234
   Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Des Guetz G, 2007, ANTICANCER RES, V27, P2715
   Di Fiore F, 2007, BRIT J CANCER, V96, P1166, DOI 10.1038/sj.bjc.6603685
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Dunne PD, 2016, CLIN CANCER RES, V22, P4095, DOI 10.1158/1078-0432.CCR-16-0032
   Ferlay J, 2014, IARC CANCERBASE, VI to X
   Folprecht G, 2016, 458O FREQUENCY POTEN, p458O
   Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630
   Gajewski TF, 2015, SEMIN ONCOL, V42, P663, DOI 10.1053/j.seminoncol.2015.05.011
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Galon J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3500
   Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287
   Greening DW, 2015, ONCOTARGET, V6, P38166, DOI 10.18632/oncotarget.6241
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hu-Lieskovan S, 2014, J CLIN ONCOL, V32, P2248, DOI 10.1200/JCO.2013.52.1377
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Iorio MV, 2009, J CLIN ONCOL, V27, P5848, DOI 10.1200/JCO.2009.24.0317
   Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6
   Jimeno A, 2009, J CLIN ONCOL, V27, P1130, DOI 10.1200/JCO.2008.19.8168
   Kim JE, 2011, CANCER SCI, V102, P1706, DOI 10.1111/j.1349-7006.2011.02009.x
   Kim R, 2013, CRIT REV ONCOL HEMAT, V88, P416, DOI 10.1016/j.critrevonc.2013.05.007
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kovac E, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.2_suppl.71
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le Tourneau C, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv362
   Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173
   Manceau G, 2014, CLIN CANCER RES, V20, P3338, DOI 10.1158/1078-0432.CCR-13-2750
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Mlcochova J, 2015, ONCOTARGET, V6, P38695, DOI 10.18632/oncotarget.5735
   Mlcochova J, 2013, J CANCER RES CLIN, V139, P1615, DOI 10.1007/s00432-013-1470-9
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nöpel-Dünnebacke S, 2014, Z GASTROENTEROL, V52, P1394, DOI 10.1055/s-0034-1366781
   O'Dwyer Peter J, 2014, Clin Adv Hematol Oncol, V12, P852
   Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396
   Pagès F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424
   Pickup M, 2013, NAT REV CANCER, V13, P788, DOI 10.1038/nrc3603
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Roepman P, 2014, INT J CANCER, V134, P552, DOI 10.1002/ijc.28387
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Schlicker A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-66
   Song N, 2016, JAMA ONCOL, V2, P1162, DOI 10.1001/jamaoncol.2016.2314
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Stintzing S, 2016, LANCET ONCOL, V17, P1426, DOI 10.1016/S1470-2045(16)30269-8
   Suzuki Y, 2017, MOL ONCOL, V11, P124, DOI 10.1002/1878-0261.12012
   Tejpar S, 2016, JAMA ONCOL, V360, P1408
   Tougeron D, 2013, ANN ONCOL, V24, P1267, DOI 10.1093/annonc/mds620
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Trinh A, 2017, CLIN CANCER RES, V23, P387, DOI 10.1158/1078-0432.CCR-16-0680
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2009, J CLIN ONCOL, V27, P3117, DOI 10.1200/JCO.2008.21.6663
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Vassal G, 2015, EUR J CANCER, V51, pS715, DOI 10.1016/S0959-8049(15)30070-8
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Venook AP, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3504
NR 79
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1556-3790
EI 1556-3804
J9 CURR COLORECT CANC R
JI Curr. Colorectal Cancer Rep.
PD FEB
PY 2017
VL 13
IS 1
BP 81
EP 90
DI 10.1007/s11888-017-0347-8
PG 10
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA EP4ZS
UT WOS:000397389200010
DA 2025-01-04
ER

PT J
AU Sultan, AS
   Khalil, MIM
   Sami, BM
   Alkhuriji, AF
   Sadek, O
AF Sultan, Ahmed S.
   Khalil, Mahmoud I. M.
   Sami, Besra M.
   Alkhuriji, Afrah F.
   Sadek, Omayma
TI Quercetin induces apoptosis in triple-negative breast cancer cells via
   inhibiting fatty acid synthase and β-catenin
SO INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE Breast cancer; Quercetin; FASN; beta-catenin; phytochemicals; xenografts
ID TUMOR-GROWTH; COLON-CANCER; PROLIFERATION; EXPRESSION; FLAVONOIDS;
   ESTROGEN; NANOPARTICLES; ACTIVATION; MECHANISMS; RESISTANCE
AB Triple-negative breast cancer (TNBC) is an aggressive malignant neoplasia. The increased research interests in TNBC nowadays are due to the lack of clinically validated and molecular-targeted therapy. Fatty Acid Synthase (FASN) is the major biosynthetic enzyme for the synthesis of fatty acids from small carbon substrates. Elevated expression of FASN is frequent phenotypic alterations in many human cancers. The flavonoid Quercetin is one of the most abundant bioflavonoids in the human diet and a known inducer of apoptosis in several cancer cell lines. We aimed to evaluate the effects of Quercetin on TNBC in vitro and in vivo. Quercetin induced a significant growth-inhibitory effect against TNBC cells and the IC50 were 230 +/- 3 and 415 +/- 4 mu M for the TNBC cells, MDA-MB-231 and MDA-MB-157 respectively. Quercetin treatment induced anticancer/apoptotic effects against TNBC cells as shown by morphological alterations, DNA fragmentation, and caspase-3 activation. When compared to controls, decreased protein expression of FASN, beta-catenin, Bcl-2, and reduced-nuclear accumulation of beta-catenin were detected after Quercetin treatment. Quercetin in vivo-treatment induced significant tumor growth inhibition by 41.7% after 25 days of treatment. Immunohistochemical data showed a clear inhibition of FASN expression in tumor xenografts after Quercetin treatment. Quercetin possibly targets the lipogenic enzyme FASN and beta-catenin in TNBCs. Quercetin-induced apoptosis via targeting the de novo fatty acid synthesis is likely through a caspase-3 dependent mechanism coupled with modulation of FASN and beta-catenin expressions.
C1 [Sultan, Ahmed S.; Sami, Besra M.; Sadek, Omayma] Univ Alexandria, Dept Biochem, Fac Sci, Alexandria, Egypt.
   [Khalil, Mahmoud I. M.] Univ Alexandria, Dept Zool, Mol Biol Unit, Fac Sci, Alexandria, Egypt.
   [Alkhuriji, Afrah F.] King Saud Univ, Dept Zool, Coll Sci, Riyadh, Saudi Arabia.
C3 Egyptian Knowledge Bank (EKB); Alexandria University; Egyptian Knowledge
   Bank (EKB); Alexandria University; King Saud University
RP Sultan, AS (corresponding author), Univ Alexandria, Dept Biochem, Fac Sci, Alexandria, Egypt.
EM dr_asul-tan@alexu.edu.eg
RI Sultan, Prof. Ahmed/AFH-7788-2022; Khalil, Mahmoud/A-1490-2017
OI Khalil, Mahmoud/0000-0001-7629-4357; Sultan, Ahmad/0000-0001-5776-1837
CR Abuetabh Y, 2011, ANN CLIN LAB SCI, V41, P217
   Amado NG, 2009, ANTI-CANCER DRUG, V20, P543, DOI 10.1097/CAD.0b013e32832d1149
   Amin A, 2005, CELL BIOL INT, V29, P687, DOI 10.1016/j.cellbi.2005.04.004
   Anders CK, 2009, CLIN BREAST CANCER, V9, pS73, DOI 10.3816/CBC.2009.s.008
   [Anonymous], EVID BASED COMPLEMEN
   Bauer KR, 2007, CANCER, V109, P1721, DOI 10.1002/cncr.22618
   Bishayee K, 2015, MOL CELLS, V38, P518, DOI 10.14348/molcells.2015.2339
   BISSERY MC, 1991, CANCER RES, V51, P4845
   Brusselmans K, 2005, J BIOL CHEM, V280, P5636, DOI 10.1074/jbc.M408177200
   Bueno MJ, 2015, EBIOMEDICINE, V2, P778, DOI 10.1016/j.ebiom.2015.08.023
   Bui TD, 1997, ONCOGENE, V14, P1249, DOI 10.1038/sj.onc.1200936
   Cai X, 2013, CURR MED CHEM, V20, P2572, DOI 10.2174/09298673113209990120
   Cao HH, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0367-4
   Chan ST, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/580626
   Chan ST, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054255
   Chien SY, 2009, HUM EXP TOXICOL, V28, P493, DOI 10.1177/0960327109107002
   Cosan DT, 2011, MOL BIOL REP, V38, P2463, DOI 10.1007/s11033-010-0382-x
   Daker M, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-34
   Dale TC, 1996, CANCER RES, V56, P4320
   Dechsupa S, 2007, CANCER BIOL THER, V6, P56, DOI 10.4161/cbt.6.1.3548
   Deng XH, 2013, EXP THER MED, V6, P1155, DOI 10.3892/etm.2013.1285
   Dent R, 2007, CLIN CANCER RES, V13, P4429, DOI 10.1158/1078-0432.CCR-06-3045
   Dhumale SS, 2015, IUBMB LIFE, V67, P361, DOI 10.1002/iub.1379
   Douchi D, 2015, CANCER LETT, V365, P132, DOI 10.1016/j.canlet.2015.05.023
   Duo J, 2012, MOL MED REP, V5, P1453, DOI 10.3892/mmr.2012.845
   Duran-Struuck R, 2009, J AM ASSOC LAB ANIM, V48, P11
   Erlund I, 2004, NUTR RES, V24, P851, DOI 10.1016/j.nutres.2004.07.005
   Fiorentino M, 2008, LAB INVEST, V88, P1340, DOI 10.1038/labinvest.2008.97
   Germain M, 1999, J BIOL CHEM, V274, P28379, DOI 10.1074/jbc.274.40.28379
   Giró-Perafita A, 2016, CLIN CANCER RES, V22, P4687, DOI 10.1158/1078-0432.CCR-15-3133
   Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P1516, DOI 10.1002/cncr.25599
   Hwang B, 2011, BIOCHEM BIOPH RES CO, V408, P89, DOI 10.1016/j.bbrc.2011.03.125
   Impheng H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107842
   Jacobson MD, 1997, CELL, V88, P347, DOI 10.1016/S0092-8674(00)81873-5
   Jung CH, 2013, PHYTOTHER RES, V27, P139, DOI 10.1002/ptr.4687
   Kelly GS, 2011, ALTERN MED REV, V16, P263
   Kliem H, 2009, MOL REPROD DEV, V76, P220, DOI 10.1002/mrd.20946
   Kuhajda FP, 2006, CANCER RES, V66, P5977, DOI 10.1158/0008-5472.CAN-05-4673
   Kumar R, 2011, J NUTR BIOCHEM, V22, P723, DOI 10.1016/j.jnutbio.2010.06.003
   Le Du F, 2015, ONCOTARGET, V6, P12890, DOI 10.18632/oncotarget.3849
   Lee MH, 2009, FASEB J, V23, P3874, DOI 10.1096/fj.08-117804
   Li JX, 2013, MOL CARCINOGEN, V52, P134, DOI 10.1002/mc.21839
   Li JQ, 2014, ASIAN PAC J CANCER P, V15, P7617, DOI 10.7314/APJCP.2014.15.18.7617
   Li SZ, 2015, ANTI-CANCER AGENT ME, V15, P1185, DOI 10.2174/1871520615999150121121708
   Loizzo MR, 2009, PLANT FOOD HUM NUTR, V64, P264, DOI 10.1007/s11130-009-0133-0
   Lupu R, 2006, CURR PHARM BIOTECHNO, V7, P483, DOI 10.2174/138920106779116928
   Iglesias JM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077281
   Mason P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033823
   McGill G, 1997, FRONT BIOSCI, V2, P353
   Menendez JA, 2007, NAT REV CANCER, V7, P763, DOI 10.1038/nrc2222
   Do MT, 2013, FOOD CHEM, V141, P2591, DOI 10.1016/j.foodchem.2013.04.125
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Mounier C, 2014, INT J ONCOL, V45, P485, DOI 10.3892/ijo.2014.2441
   Mullen GE, 2015, BIOORG MED CHEM LETT, V25, P4363, DOI 10.1016/j.bmcl.2015.08.087
   Noolu B, 2016, ANTICANCER AGENTS ME
   Notarnicola M, 2012, ANTICANCER RES, V32, P2585
   Pandey PR, 2011, BREAST CANCER RES TR, V130, P387, DOI 10.1007/s10549-010-1300-6
   Park CH, 2005, BIOCHEM BIOPH RES CO, V328, P227, DOI 10.1016/j.bbrc.2004.12.151
   Pizer ES, 2000, CANCER RES, V60, P213
   Polakis P, 2000, GENE DEV, V14, P1837
   Rakha EA, 2007, CANCER-AM CANCER SOC, V109, P25, DOI 10.1002/cncr.22381
   Ranganathan S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141370
   Rivera AR, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157251
   Rosner K, 2006, BIOSCI BIOTECH BIOCH, V70, P2169, DOI 10.1271/bbb.60129
   Sak Katrin, 2014, Pharmacogn Rev, V8, P122, DOI 10.4103/0973-7847.134247
   Sak K, 2014, NUTR CANCER, V66, P177, DOI 10.1080/01635581.2014.864418
   Sanchez-Gonzalez PD, 2011, NEPHROL DIAL TRANSPL, V26, P3484, DOI 10.1093/ndt/gfr195
   Sanderson M, 2014, PHYTOMEDICINE, V21, P109, DOI 10.1016/j.phymed.2013.08.011
   Sarkar A, 2016, BBA-GEN SUBJECTS, V1860, P2065, DOI 10.1016/j.bbagen.2016.07.001
   Schlachterman A, 2008, TRANSL ONCOL, V1, P19, DOI 10.1593/tlo.07100
   Seo HS, 2016, ONCOL REP, V36, P31, DOI 10.3892/or.2016.4786
   Seo YS, 2015, INT J MOL MED, V35, P1779, DOI 10.3892/ijmm.2015.2185
   Shoja MH, 2015, J ETHNOPHARMACOL, V168, P50, DOI 10.1016/j.jep.2015.03.048
   So FV, 1997, CANCER LETT, V112, P127, DOI 10.1016/S0304-3835(96)04557-0
   Song HJ, 2012, PROSTAG LEUKOTR ESS, V87, P197, DOI 10.1016/j.plefa.2012.09.002
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Srinivasan A, 2016, MOL CARCINOGEN, V55, P743, DOI 10.1002/mc.22318
   Srivastava S, 2016, SCI REP-UK, V6, DOI 10.1038/srep24049
   Sultan AS, 2005, ONCOGENE, V24, P746, DOI 10.1038/sj.onc.1208203
   Tan WF, 2003, EUR J PHARMACOL, V459, P255, DOI 10.1016/S0014-2999(02)02848-0
   Tao SF, 2015, MOL CELL BIOCHEM, V402, P93, DOI 10.1007/s11010-014-2317-7
   Tomao F, 2015, ONCOTARGETS THER, V8, P177, DOI 10.2147/OTT.S67673
   Tsuchiya H, 2015, MOLECULES, V20, P18923, DOI 10.3390/molecules201018923
   Vandhana S, 2013, BBA-MOL CELL BIOL L, V1831, P1458, DOI 10.1016/j.bbalip.2013.06.005
   Wang HX, 2015, J BUON, V20, P707
   Wang PW, 2014, J NUTR BIOCHEM, V25, P73, DOI 10.1016/j.jnutbio.2013.09.005
   Wong MY, 2011, NANOMED-NANOTECHNOL, V7, P834, DOI 10.1016/j.nano.2011.02.001
   Wu Xi, 2014, Advances in Biological Regulation, V54, P214, DOI 10.1016/j.jbior.2013.09.004
   Xintaropoulou C, 2015, ONCOTARGET, V6, P25677, DOI 10.18632/oncotarget.4499
   Xu JH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117097
   Zhang Feng, 2012, World J Biol Chem, V3, P167, DOI 10.4331/wjbc.v3.i8.167
   Zhang HS, 2012, FOOD CHEM TOXICOL, V50, P1589, DOI 10.1016/j.fct.2012.01.025
   Zhang X, 2012, CELL PROLIFERAT, V45, P466, DOI 10.1111/j.1365-2184.2012.00833.x
   Zhao P, 2014, ONCOL LETT, V8, P765, DOI 10.3892/ol.2014.2159
   Zhou WB, 2003, CANCER RES, V63, P7330
NR 95
TC 36
Z9 36
U1 0
U2 14
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 1936-2625
J9 INT J CLIN EXP PATHO
JI Int. J. Clin. Exp. Pathol.
PY 2017
VL 10
IS 1
BP 156
EP 172
PG 17
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA EH8DO
UT WOS:000392002100016
DA 2025-01-04
ER

PT J
AU Zhao, YJ
   Adjei, AA
AF Zhao, Yujie
   Adjei, Alex A.
TI Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular
   Endothelial Growth Factor
SO ONCOLOGIST
LA English
DT Article
DE Angiogenesis inhibitors; Antibodies, monoclonal, humanized; Molecular
   targeted therapy; Receptors; Fibroblast growth factor; Platelet-derived
   growth factor; Vascular endothelial growth factor
ID RENAL-CELL CARCINOMA; TYROSINE KINASE INHIBITOR; METASTATIC
   COLORECTAL-CANCER; RANDOMIZED PHASE-III; TRIPLE ANGIOKINASE INHIBITOR;
   LABEL DOSE-ESCALATION; I OPEN-LABEL; DOUBLE-BLIND; BIBF 1120;
   HEPATOCELLULAR-CARCINOMA
AB Angiogenesis, or the formation of new capillary blood vessels, occurs primarily during human development and reproduction; however, aberrant regulation of angiogenesis is also a fundamental process found in several pathologic conditions, including cancer. As a process required for invasion and metastasis, tumor angiogenesis constitutes an important point of control of cancer progression. Although not yet completely understood, the complex process of tumor angiogenesis involves highly regulated orchestration of multiple signaling pathways. The proangiogenic signaling molecule vascular endothelial growth factor (VEGF) and its cognate receptor (VEGF receptor 2 [VEGFR-2]) play a central role in angiogenesis and often are highly expressed in human cancers, and initial clinical efforts to develop antiangiogenic treatments focused largely on inhibiting VEGF/VEGFR signaling. Such approaches, however, often lead to transient responses and further disease progression because angiogenesis is regulated by multiple pathways that are able to compensate for each other when single pathways are inhibited. The platelet-derived growth factor (PDGF) and PDGF receptor (PDGFR) and fibroblast growth factor (FGF) and FGF receptor (FGFR) pathways, for example, provide potential escape mechanisms from anti-VEGF/VEGFR therapy that could facilitate resumption of tumor growth. Accordingly, more recent treatments have focused on inhibiting multiple signaling pathways simultaneously. This comprehensive review discusses the limitations of inhibiting VEGF signaling alone as an antiangiogenic strategy, the importance of other angiogenic pathways including PDGF/PDGFR and FGF/FGFR, and the novel current and emerging agents that target multiple angiogenic pathways for the treatment of advanced solid tumors.
C1 [Zhao, Yujie; Adjei, Alex A.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center
RP Adjei, AA (corresponding author), Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
EM alex.adjei@roswellpark.org
FU Boehringer Ingelheim
FX Medical writing assistance, supported financially by Boehringer
   Ingelheim, was provided by Duncan Campbell of GeoMed and Christopher
   Ontiveros of inVentiv Medical Communications during the preparation of
   the manuscript.
CR Abou-Elkacem L, 2013, MOL CANCER THER, V12, P1322, DOI 10.1158/1535-7163.MCT-12-1162
   Angevin E, 2013, CLIN CANCER RES, V19, P1257, DOI 10.1158/1078-0432.CCR-12-2885
   [Anonymous], 2013, VOTR
   [Anonymous], 2012, COM PACK INS
   [Anonymous], 2013, NEX PACK INS
   [Anonymous], 2013, CAPR
   [Anonymous], 2013, SUT PACK INS
   [Anonymous], 2013, STIV
   [Anonymous], 2014, CYR PACK INS
   [Anonymous], 2013, INL PACK INS
   Aprile G, 2013, DRUGS, V73, P2003, DOI 10.1007/s40265-013-0154-8
   Ballas MS, 2011, ONCOTARGETS THER, V4, P43, DOI 10.2147/OTT.S18155
   Batchelor TT, 2007, CANCER CELL, V11, P83, DOI 10.1016/j.ccr.2006.11.021
   Batchelor TT, 2013, J CLIN ONCOL, V31, P3212, DOI 10.1200/JCO.2012.47.2464
   Beenken A, 2009, NAT REV DRUG DISCOV, V8, P235, DOI 10.1038/nrd2792
   Bergers G, 2003, J CLIN INVEST, V111, P1287, DOI 10.1172/JCI200317929
   Bousquet G, 2011, BRIT J CANCER, V105, P1640, DOI 10.1038/bjc.2011.440
   Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9
   Cai ZW, 2008, J MED CHEM, V51, P1976, DOI 10.1021/jm7013309
   Cainap C, 2015, J CLIN ONCOL, V33, P172, DOI 10.1200/JCO.2013.54.3298
   Cao RH, 2012, P NATL ACAD SCI USA, V109, P15894, DOI 10.1073/pnas.1208324109
   Cao RH, 2004, CANCER CELL, V6, P333, DOI 10.1016/j.ccr.2004.08.034
   Cao YH, 2008, J MOL MED, V86, P785, DOI 10.1007/s00109-008-0337-z
   Cao YH, 2013, TRENDS MOL MED, V19, P460, DOI 10.1016/j.molmed.2013.05.002
   Cao YH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.259re1
   Carmeliet P, 2011, NATURE, V473, P298, DOI 10.1038/nature10144
   Casanovas O, 2005, CANCER CELL, V8, P299, DOI 10.1016/j.ccr.2005.09.005
   Cascone T, 2012, J CLIN ONCOL, V30, P441, DOI 10.1200/JCO.2011.38.7621
   Chang YS, 2007, CANCER CHEMOTH PHARM, V59, P561, DOI 10.1007/s00280-006-0393-4
   Chau NG, 2013, CLIN CANCER RES, V19, P524, DOI 10.1158/1078-0432.CCR-12-2353
   Chen HX, 2009, NAT REV CLIN ONCOL, V6, P465, DOI 10.1038/nrclinonc.2009.94
   Clarke JM, 2013, J GASTROINTEST ONCOL, V4, P253, DOI 10.3978/j.issn.2078-6891.2013.036
   Crinò L, 2014, EUR RESPIR REV, V23, P79, DOI 10.1183/09059180.00008913
   Cyran CC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076009
   De Falco S, 2012, EXP MOL MED, V44, P1, DOI 10.3858/emm.2012.44.1.025
   Demetri GD, 2013, LANCET, V381, P295, DOI 10.1016/S0140-6736(12)61857-1
   Demetri GD, 2012, CLIN CANCER RES, V18, P3170, DOI 10.1158/1078-0432.CCR-11-3005
   Ding W, 2010, BLOOD, V116, P2984, DOI 10.1182/blood-2010-02-269894
   Doebele RC, 2012, ANN ONCOL, V23, P2094, DOI 10.1093/annonc/mdr596
   du Bois A, 2013, INT J GYNECOL CANCER, V23
   du Bois A, 2010, ANN ONCOL, V21, P370, DOI 10.1093/annonc/mdp506
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Ebos JML, 2011, NAT REV CLIN ONCOL, V8, P210, DOI 10.1038/nrclinonc.2011.21
   Eisen T, 2013, INVEST NEW DRUG, V31, P1283, DOI 10.1007/s10637-013-9962-7
   Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
   Ellis PM, 2010, CLIN CANCER RES, V16, P2881, DOI 10.1158/1078-0432.CCR-09-2944
   Erber R, 2004, FASEB J, V18, DOI 10.1096/fj.03-0271fje
   Escudier B, 2009, J CLIN ONCOL, V27, P3312, DOI 10.1200/JCO.2008.19.5511
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Ferrara N, 2010, CYTOKINE GROWTH F R, V21, P21, DOI 10.1016/j.cytogfr.2009.11.003
   Fischer C, 2008, NAT REV CANCER, V8, P942, DOI 10.1038/nrc2524
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Fuchs CS, 2014, LANCET, V383, P31, DOI 10.1016/S0140-6736(13)61719-5
   Garon EB, 2014, LANCET, V384, P665, DOI 10.1016/S0140-6736(14)60845-X
   Genentech, 2014, AV PRESCR INF
   Gerald D, 2013, CANCER RES, V73, P1649, DOI 10.1158/0008-5472.CAN-12-4697
   Giavazzi R, 2003, AM J PATHOL, V162, P1913, DOI 10.1016/S0002-9440(10)64325-8
   Gligorov J, 2014, LANCET ONCOL, V15, P1351, DOI 10.1016/S1470-2045(14)70444-9
   Gomez-Manzano C, 2008, NEURO-ONCOLOGY, V10, P940, DOI 10.1215/15228517-2008-061
   Graveel CR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009209
   Gressett SM, 2009, ANN PHARMACOTHER, V43, P490, DOI 10.1345/aph.1L426
   Griffioen AW, 2012, CLIN CANCER RES, V18, P3961, DOI 10.1158/1078-0432.CCR-12-0002
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hamberg P, 2010, ONCOLOGIST, V15, P539, DOI 10.1634/theoncologist.2009-0274
   Hanna NH, 2013, J CLIN ONCOL, V31
   Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hilberg F, 2008, CANCER RES, V68, P4774, DOI 10.1158/0008-5472.CAN-07-6307
   Hoff PM, 2012, J CLIN ONCOL, V30, P3596, DOI 10.1200/JCO.2012.42.6031
   Holash J, 2002, P NATL ACAD SCI USA, V99, P11393, DOI 10.1073/pnas.172398299
   Huang HH, 2010, NAT REV CANCER, V10, P575, DOI 10.1038/nrc2894
   Ibáñez CF, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009134
   Jahangiri A, 2013, CLIN CANCER RES, V19, P1773, DOI 10.1158/1078-0432.CCR-12-1281
   Javerzat S, 2002, TRENDS MOL MED, V8, P483, DOI 10.1016/S1471-4914(02)02394-8
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Kieran MW, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006593
   Kim ES, 2002, P NATL ACAD SCI USA, V99, P11399, DOI 10.1073/pnas.172398399
   Kim S, 2007, MOL CANCER THER, V6, P1785, DOI 10.1158/1535-7163.MCT-06-0595
   Kodama M, 2010, CANCER SCI, V101, P1984, DOI 10.1111/j.1349-7006.2010.01639.x
   Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252
   Kristensen TB, 2014, INT J MOL SCI, V15, P23024, DOI 10.3390/ijms151223024
   Kudo K, 2011, CLIN CANCER RES, V17, P1373, DOI 10.1158/1078-0432.CCR-09-2755
   Kurzrock R, 2011, J CLIN ONCOL, V29, P2660, DOI 10.1200/JCO.2010.32.4145
   Laurie SA, 2014, EUR J CANCER, V50, P706, DOI 10.1016/j.ejca.2013.11.032
   Ledermann JA, 2013, ECCO ESMO ESTRO EUR
   LEUNG DW, 1989, SCIENCE, V246, P1306, DOI 10.1126/science.2479986
   Levitzki A, 2004, CYTOKINE GROWTH F R, V15, P229, DOI 10.1016/j.cytogfr.2004.03.010
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Liu L, 2006, CANCER RES, V66, P11851, DOI 10.1158/0008-5472.CAN-06-1377
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007
   Loupakis F, 2011, BRIT J CANCER, V104, P1262, DOI 10.1038/bjc.2011.85
   Lu CH, 2010, CANCER BIOL THER, V9, P176, DOI 10.4161/cbt.9.3.10635
   Lu KV, 2012, CANCER CELL, V22, P21, DOI 10.1016/j.ccr.2012.05.037
   Mackey JR, 2015, J CLIN ONCOL, V33, P141, DOI 10.1200/JCO.2014.57.1513
   Majumder S, 2013, EUR J PHARMACOL, V705, P86, DOI 10.1016/j.ejphar.2013.02.026
   Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612
   Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270
   Matsui J, 2008, INT J CANCER, V122, P664, DOI 10.1002/ijc.23131
   Mortimer J, 2012, CANCER CONTROL, V19, P309, DOI 10.1177/107327481201900407
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Motzer RJ, 2014, LANCET ONCOL, V15, P286, DOI 10.1016/S1470-2045(14)70030-0
   Motzer RJ, 2013, LANCET ONCOL, V14, P552, DOI 10.1016/S1470-2045(13)70093-7
   Mross K, 2010, CLIN CANCER RES, V16, P311, DOI 10.1158/1078-0432.CCR-09-0694
   Mulligan LM, 2014, NAT REV CANCER, V14, P173, DOI 10.1038/nrc3680
   Okamoto I, 2010, MOL CANCER THER, V9, P2825, DOI 10.1158/1535-7163.MCT-10-0379
   Olson P, 2011, P NATL ACAD SCI USA, V108, pE1275, DOI 10.1073/pnas.1111079108
   Pàez-Ribes M, 2009, CANCER CELL, V15, P220, DOI 10.1016/j.ccr.2009.01.027
   Pilotto S, 2014, CURR PHARM DESIGN, V20, P3958, DOI 10.2174/13816128113196660757
   Presta M, 2005, CYTOKINE GROWTH F R, V16, P159, DOI 10.1016/j.cytogfr.2005.01.004
   Reck M, 2014, LANCET ONCOL, V15, P143, DOI 10.1016/S1470-2045(13)70586-2
   Reck M, 2010, EXPERT OPIN INV DRUG, V19, P789, DOI 10.1517/13543784.2010.488220
   Rini BI, 2011, LANCET, V378, P1931, DOI 10.1016/S0140-6736(11)61613-9
   Sahade M, 2012, FUTURE ONCOL, V8, P775, DOI [10.2217/FON.12.73, 10.2217/fon.12.73]
   Schlumberger MJ, 2014, J CLIN ONCOL, V32
   Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355
   Shojaei F, 2012, CANCER LETT, V320, P130, DOI 10.1016/j.canlet.2012.03.008
   Sonpavde G, 2014, EXPERT OPIN INV DRUG, V23, P305, DOI 10.1517/13543784.2014.871259
   Spratlin J, 2011, CURR ONCOL REP, V13, P97, DOI 10.1007/s11912-010-0149-5
   Sternberg CN, 2013, EUR J CANCER, V49, P1287, DOI 10.1016/j.ejca.2012.12.010
   Sternberg CN, 2010, J CLIN ONCOL, V28, P1061, DOI 10.1200/JCO.2009.23.9764
   Stopfer P, 2011, XENOBIOTICA, V41, P297, DOI 10.3109/00498254.2010.545452
   Sun H, 2014, WORLD J HEPATOL, V6, P830, DOI 10.4254/wjh.v6.i12.830
   Tait CR, 2004, J PATHOL, V204, P1, DOI 10.1002/path.1618
   Tammela T, 2010, CELL, V140, P460, DOI 10.1016/j.cell.2010.01.045
   Tejada ML, 2006, CLIN CANCER RES, V12, P2676, DOI 10.1158/1078-0432.CCR-05-1770
   TISCHER E, 1989, BIOCHEM BIOPH RES CO, V165, P1198, DOI 10.1016/0006-291X(89)92729-0
   Turner N, 2010, CANCER RES, V70, P2085, DOI 10.1158/0008-5472.CAN-09-3746
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   van der Graaf WTA, 2012, LANCET, V379, P1879, DOI 10.1016/S0140-6736(12)60651-5
   von Minckwitz G, 2014, LANCET ONCOL, V15, P1269, DOI 10.1016/S1470-2045(14)70439-5
   Wedge SR, 2005, CANCER RES, V65, P4389, DOI 10.1158/0008-5472.CAN-04-4409
   Wehland M, 2013, INT J MOL SCI, V14, P9338, DOI 10.3390/ijms14059338
   Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040
   Welti J, 2013, J CLIN INVEST, V123, P3190, DOI 10.1172/JCI70212
   Wilke H, 2014, LANCET ONCOL, V15, P1224, DOI 10.1016/S1470-2045(14)70420-6
   Wilmes LJ, 2007, MAGN RESON IMAGING, V25, P319, DOI 10.1016/j.mri.2006.09.041
   Wojta J, 1999, LAB INVEST, V79, P427
   Wu EX, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003794
   Xue Y, 2012, NAT MED, V18, P100, DOI 10.1038/nm.2575
   You WK, 2008, BMB REP, V41, P833, DOI 10.5483/BMBRep.2008.41.12.833
   Zhou JB, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-33
   Zhu AX, 2013, THER ADV MED ONCOL, V5, P41, DOI 10.1177/1758834012458480
   Zhu AX, 2014, ANN ONCOL, V25
NR 144
TC 437
Z9 477
U1 7
U2 155
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD JUN
PY 2015
VL 20
IS 6
BP 660
EP 673
DI 10.1634/theoncologist.2014-0465
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CL1EC
UT WOS:000356684400018
PM 26001391
OA Green Published, Bronze
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Zheng, Y
   Zeng, JT
   Lin, DJ
   Xia, HY
   Wang, XY
   Chen, LQ
   Chen, HY
   Huang, LX
   Zeng, CQ
AF Zheng, Yu
   Zeng, Jintao
   Lin, Dajia
   Xia, Haoyun
   Wang, Xiangyu
   Chen, Liqi
   Chen, Hongyuan
   Huang, Liangxiang
   Zeng, Changqing
TI Extracellular vesicles derived from cancer-associated fibroblast carries
   miR-224-5p targeting SLC4A4 to promote the proliferation, invasion and
   migration of colorectal cancer cells
SO CARCINOGENESIS
LA English
DT Article
ID MICROVESICLES; BIOLOGY
AB More and more studies indicated that extracellular vesicles (EVs) carrying miRNAs have been potential biomarkers of various cancers including colorectal cancer (CRC). This study aims to explore the function of miR-224-5p carried by EVs derived from cancer-associated fibroblasts (CAFs) in CRC. Here, we found that miR-224-5p was highly expressed while SLC4A4 was lowly expressed in CRC cells. Moreover, dual-luciferase reporter gene assay testified that miR-224-5p targeted SLC4A4. The expression of miR-224-5p in CAFs-derived EVs was found to be elevated. It was also testified that CAFs-derived EVs could transfer miR224-5p into CRC cells. miR-224-5p in CAFs-derived EVs facilitated the proliferation, migration, invasion and anti-apoptosis of CRC cells. Overexpressing miR-224-5p increased the proliferative, migratory and invasive abilities of CRC cells and inhibit CRC cell apoptosis, while overexpressing SLC4A4 caused the opposite result. Research in vitro and in vivo further indicated that miR-224-5p promoted CRC cell progression via binding to its downstream target gene SLC4A4. Rescue assay also demonstrated that overexpressing miR-224-5p reversed the inhibitory effect of overexpressed SLC4A4 on cancer cell growth. In addition, in vivo assay identified that high level of miR-224-5p promoted the growth of cancer cells in mice in vivo. In conclusion, we explored the effect of miR-224-5p in CRC, which helps for further exploration of new methods for CRC targeted therapy.
C1 [Zheng, Yu; Lin, Dajia; Xia, Haoyun; Wang, Xiangyu; Chen, Liqi; Chen, Hongyuan; Huang, Liangxiang; Zeng, Changqing] Fujian Med Univ, Fujian Prov Hosp, Dept Gastrointestinal Surg, Prov Clin Med Coll, Fuzhou 350001, Fujian, Peoples R China.
   [Zeng, Jintao] Chengde Med Univ, Basic Med Coll, Chengde 067000, Hebei, Peoples R China.
C3 Fujian Provincial Hospital; Fujian Medical University; Chengde Medical
   University
RP Huang, LX; Zeng, CQ (corresponding author), Fujian Med Univ, Fujian Prov Hosp, Dept Gastrointestinal Surg, Prov Clin Med Coll, Fuzhou 350001, Fujian, Peoples R China.
EM hlxise0211@163.com; z2_changqing@163.com
RI Zhang, Linhao/AAY-3078-2021; Chen, Hong-Yuan/E-4476-2019; chen,
   yanling/GRE-8287-2022
FU Natural Science Foundation of Fujian Province [2020J011061]
FX This study was supported by the funds from Natural Science Foundation of
   Fujian Province (grant number: 2020J011061). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Abbasian N, 2018, AM J PHYSIOL-RENAL, V315, pF1430, DOI 10.1152/ajprenal.00318.2018
   Allaoui R, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13050
   Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062
   Bhutia YD, 2016, BIOCHEM J, V473, P1113, DOI 10.1042/BJ20150751
   Binefa G, 2014, WORLD J GASTROENTERO, V20, P6786, DOI 10.3748/wjg.v20.i22.6786
   Boesch M, 2019, BBA-REV CANCER, V1872, P111, DOI 10.1016/j.bbcan.2019.06.003
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brennen WN, 2012, JNCI-J NATL CANCER I, V104, P1320, DOI 10.1093/jnci/djs336
   Brody H, 2015, NATURE, V521, pS1, DOI [10.1038/521S1a, 10.1038/526S1a]
   Callier T, 2019, CEREB CORTEX, V29, P4613, DOI 10.1093/cercor/bhy337
   Castellana D, 2009, CANCER RES, V69, P785, DOI 10.1158/0008-5472.CAN-08-1946
   Cheng Y, 2018, BIOCHEM BIOPH RES CO, V506, P793, DOI 10.1016/j.bbrc.2018.10.150
   Curtis M, 2019, CELL METAB, V29, P141, DOI 10.1016/j.cmet.2018.08.007
   Erdogan B, 2017, J CELL BIOL, V216, P3799, DOI 10.1083/jcb.201704053
   Gopal SK, 2017, BIOCHEM J, V474, P21, DOI 10.1042/BCJ20160006
   Hansen HP, 2014, J PATHOL, V232, P405, DOI 10.1002/path.4306
   Josson S, 2015, ONCOGENE, V34, P2690, DOI 10.1038/onc.2014.212
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Ke ZH, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/4759060
   Khan SA, 2017, PATHOL ONCOL RES, V23, P673, DOI 10.1007/s12253-016-0166-2
   Leca J, 2016, J CLIN INVEST, V126, P4140, DOI 10.1172/JCI87734
   Li JC, 2019, J CELL BIOCHEM, V120, P12412, DOI 10.1002/jcb.28507
   Liang HW, 2015, MOL CANCER, V14, DOI 10.1186/s12943-015-0327-z
   Parks SK, 2015, J CELL PHYSIOL, V230, P1954, DOI 10.1002/jcp.24930
   Punt CJA, 2009, NAT REV CLIN ONCOL, V6, P731, DOI 10.1038/nrclinonc.2009.168
   Raposo G, 1996, J EXP MED, V183, P1161, DOI 10.1084/jem.183.3.1161
   Ratajczak J, 2006, LEUKEMIA, V20, P847, DOI 10.1038/sj.leu.2404132
   Sadovska L, 2015, ANTICANCER RES, V35, P6379
   Saigusa S, 2011, INT J ONCOL, V38, P655, DOI 10.3892/ijo.2011.906
   Shimoda M, 2010, SEMIN CELL DEV BIOL, V21, P19, DOI 10.1016/j.semcdb.2009.10.002
   Staudacher JJ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05907-8
   Stec M, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0737-0
   Sun YZ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712592
   Tang D, 2016, TUMOR BIOL, V37, P1889, DOI 10.1007/s13277-015-3942-9
   Tang YY, 2019, J CLIN LAB ANAL, V33, DOI 10.1002/jcla.23004
   Udagawa T, 2010, CURR OPIN PHARMACOL, V10, P369, DOI 10.1016/j.coph.2010.06.010
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Wang X, 2016, BIOMATERIALS, V83, P207, DOI 10.1016/j.biomaterials.2016.01.001
   Yamada NO, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184406
   Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150
   Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023
   Zheng SQ, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00398
NR 42
TC 17
Z9 19
U1 0
U2 3
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0143-3334
EI 1460-2180
J9 CARCINOGENESIS
JI Carcinogenesis
PD SEP
PY 2021
VL 42
IS 9
BP 1143
EP 1153
DI 10.1093/carcin/bgab055
EA JUN 2021
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WJ1FT
UT WOS:000708795400004
PM 34170291
OA Bronze
DA 2025-01-04
ER

PT J
AU Hasanifard, L
   Sheervalilou, R
   Majidinia, M
   Yousefi, B
AF Hasanifard, Leili
   Sheervalilou, Roghayeh
   Majidinia, Maryam
   Yousefi, Bahman
TI New insights into the roles and regulation of SphK2 as a therapeutic
   target in cancer chemoresistance
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
DE apoptosis; chemoresistance; DNA damage; SphK2
ID SPHINGOSINE KINASE 2; LONG NONCODING RNAS; DNA-DAMAGE RESPONSE;
   COLON-CANCER; SPHINGOLIPID METABOLISM; INHIBITOR ABC294640;
   DIHYDROCERAMIDE DESATURASE; PROTEASOMAL DEGRADATION;
   SELECTIVE-INHIBITION; DEPENDENT ACTIVATION
AB Chemoresistance is a complicated process developed by most cancers and accounts for the majority of relapse and metastasis in cancer. The main mechanisms of chemoresistance phenotype include increased expression and/or activated drug efflux pumps, altered DNA repair, altered metabolism of therapeutics as well as impaired apoptotic signaling pathways. Aberrant sphingolipid signaling has also recently received considerable attention in chemoresistance. Sphingolipid metabolites regulate main biological processes such as apoptosis, cell survival, proliferation, and differentiation. Two sphingosine kinases, SphK1 and SphK2, convert sphingosine to sphingosine-1-phosphate, an antiapoptotic bioactive lipid mediator. Numerous evidence has revealed the involvement of activated SphK1 in tumorigenesis and resistance, however, contradictory results have been found for the role of SphK2 in these functions. In some studies, overexpression of SphK2 suppressed cell growth and induced apoptosis. In contrast, some others have shown cell proliferation and tumor promotion effect for SphK2. Our understanding of the role of SphK2 in cancer does not have a sufficient integrity. The main focus of this review will be on the re-evaluation of the role of SphK2 in cell death and chemoresistance in light of our new understanding of molecular targeted therapy. We will also highlight the connections between SphK2 and the DNA damage response. Finally, we will provide our insight into the regulatory mechanisms of SphKs by two main categories, micro and long, noncoding RNAs as the novel players of cancer chemoresistance.
C1 [Hasanifard, Leili] Tabriz Univ Med Sci, Dept Clin Biochem, Fac Med, Tabriz, Iran.
   [Sheervalilou, Roghayeh] Tabriz Univ Med Sci, Mol Med Res Ctr, Tabriz, Iran.
   [Majidinia, Maryam] Urmia Univ Med Sci, Solid Tumor Res Ctr, Orumiyeh, Iran.
   [Yousefi, Bahman] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz 5166614766, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Urmia University of Medical Sciences; Tabriz University of
   Medical Science
RP Yousefi, B (corresponding author), Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz 5166614766, Iran.
EM yousefib@tbzmed.ac.ir
RI Sheervalilou, Roghayeh/KXQ-4449-2024; yousefi, Bahman/AAI-2969-2021;
   majidinia, maryam/V-7187-2019; Hasanifard, Leili/AAX-5785-2021; Yousefi,
   Bahman/AGY-4725-2022
OI Majidinia, Maryam/0000-0001-9776-5816; Hasanifard,
   Leili/0000-0003-1955-5666; Yousefi, Bahman/0000-0002-4220-1527
CR Adams DR, 2016, TRENDS BIOCHEM SCI, V41, P395, DOI 10.1016/j.tibs.2016.02.007
   Alshaker H., 2012, ADV CANC RES, P143
   Alvarez SE, 2010, NATURE, V465, P1084, DOI 10.1038/nature09128
   Antoon JW, 2011, CANCER BIOL THER, V11, P678, DOI 10.4161/cbt.11.7.14903
   Ashkenazi A, 2002, NAT REV CANCER, V2, P420, DOI 10.1038/nrc821
   Askarian-Amiri ME, 2016, METHODS MOL BIOL, V1395, P207, DOI 10.1007/978-1-4939-3347-1_12
   Audic Y, 2004, BIOL CELL, V96, P479, DOI 10.1016/j.biolcel.2004.05.002
   Badalzadeh R, 2015, ADV PHARM BULL, V5, P321, DOI 10.15171/apb.2015.045
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Baxter RC, 2014, NAT REV CANCER, V14, P329, DOI 10.1038/nrc3720
   Carroll Brittany, 2015, Advances in Biological Regulation, V58, P38, DOI 10.1016/j.jbior.2014.11.001
   Cheetham SW, 2013, BRIT J CANCER, V108, P2419, DOI 10.1038/bjc.2013.233
   Chipuk JE, 2012, CELL, V148, P988, DOI 10.1016/j.cell.2012.01.038
   Chua MWY, 2015, J CELL COMMUN SIGNAL, V9, P167, DOI 10.1007/s12079-015-0262-1
   Chumanevich AA, 2010, CARCINOGENESIS, V31, P1787, DOI 10.1093/carcin/bgq158
   Cingolani F, 2014, J LIPID RES, V55, P1711, DOI 10.1194/jlr.M049759
   Congdon MD, 2016, ACS MED CHEM LETT, V7, P229, DOI 10.1021/acsmedchemlett.5b00304
   Congdon MD, 2015, BIOORG MED CHEM LETT, V25, P4956, DOI 10.1016/j.bmcl.2015.03.041
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Ding G, 2007, J BIOL CHEM, V282, P27493, DOI 10.1074/jbc.M701641200
   Ding XW, 2016, ONCOTARGET, V7, P20080, DOI 10.18632/oncotarget.7914
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Etemadi N, 2015, ELIFE, V4, DOI 10.7554/eLife.10592
   Evangelisti C, 2016, LEUKEMIA, V30, P2142, DOI 10.1038/leu.2016.208
   French KJ, 2010, J PHARMACOL EXP THER, V333, P129, DOI 10.1124/jpet.109.163444
   French KJ, 2003, CANCER RES, V63, P5962
   Gao P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0044543
   Gao P, 2011, MOL CANCER RES, V9, P1509, DOI 10.1158/1541-7786.MCR-11-0336
   Gencer S., 2016, BIOCH MOL BIOL
   Giussani P, 2014, INT J MOL SCI, V15, P4356, DOI 10.3390/ijms15034356
   Goldstein DM, 2008, NAT REV DRUG DISCOV, V7, P391, DOI 10.1038/nrd2541
   Granata R, 2004, FASEB J, V18, P1456, DOI 10.1096/fj.04-1618fje
   Hait NC, 2005, J BIOL CHEM, V280, P29462, DOI 10.1074/jbc.M502922200
   Hait NC, 2007, J BIOL CHEM, V282, P12058, DOI 10.1074/jbc.M609559200
   Hait NC, 2006, BBA-BIOMEMBRANES, V1758, P2016, DOI 10.1016/j.bbamem.2006.08.007
   Hait NC, 2009, SCIENCE, V325, P1254, DOI 10.1126/science.1176709
   Hannun YA, 2000, TRENDS CELL BIOL, V10, P73, DOI 10.1016/S0962-8924(99)01694-3
   Hannun YA, 2008, NAT REV MOL CELL BIO, V9, P139, DOI 10.1038/nrm2329
   Hatoum D, 2017, ONCOTARGET, V8, P36898, DOI 10.18632/oncotarget.16370
   Heffernan-Stroud LA, 2012, ONCOGENE, V31, P1166, DOI 10.1038/onc.2011.302
   Heffernan-Stroud LA, 2013, ADV CANCER RES, V117, P201, DOI 10.1016/B978-0-12-394274-6.00007-8
   Hisano Y, 2011, J BIOL CHEM, V286, P1758, DOI 10.1074/jbc.M110.171116
   Igarashi N, 2003, J BIOL CHEM, V278, P46832, DOI 10.1074/jbc.M306577200
   Johnson KR, 2002, J BIOL CHEM, V277, P35257, DOI 10.1074/jbc.M203033200
   Karimaian A, 2017, DNA REPAIR, V51, P14, DOI 10.1016/j.dnarep.2017.01.003
   Khanna A, 2015, CANCER RES, V75, P2133, DOI 10.1158/0008-5472.CAN-14-3247
   Kharel Y, 2012, BIOCHEM J, V447, P149, DOI 10.1042/BJ20120609
   Kreitzburg KM, 2018, CANCER DRUG RESIST, V1, P181, DOI 10.20517/cdr.2018.06
   Krishna R, 2000, EUR J PHARM SCI, V11, P265, DOI 10.1016/S0928-0987(00)00114-7
   Lage H, 2016, RECENT RESULTS CANC, V209, P87, DOI 10.1007/978-3-319-42934-2_6
   Leclercq TM, 2008, J BIOL CHEM, V283, P9606, DOI 10.1074/jbc.M708782200
   Leili H, 2018, DRUG RES, V68, P45, DOI 10.1055/s-0043-117181
   Lewis CS, 2018, ADV CANCER RES, V140, P295, DOI 10.1016/bs.acr.2018.04.015
   Lewis CS, 2016, ONCOTARGET, V7, P60181, DOI 10.18632/oncotarget.11112
   Li XJY, 2017, HEPATOLOGY, V66, P869, DOI 10.1002/hep.29145
   Liang WW, 2017, J CANCER RES CLIN, V143, P601, DOI 10.1007/s00432-016-2315-0
   Lim KG, 2011, CELL SIGNAL, V23, P1590, DOI 10.1016/j.cellsig.2011.05.010
   Liu H, 2003, J BIOL CHEM, V278, P40330, DOI 10.1074/jbc.M304455200
   Liu K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056471
   Liu W, 2016, TUMOR BIOL, V37, P6331, DOI 10.1007/s13277-015-4480-1
   Loveridge C, 2010, J BIOL CHEM, V285, P38841, DOI 10.1074/jbc.M110.127993
   Lu ZP, 2016, ONCOTARGET, V7, P241, DOI 10.18632/oncotarget.6280
   Maceyka M, 2005, J BIOL CHEM, V280, P37118, DOI 10.1074/jbc.M502207200
   Maceyka M, 2012, TRENDS CELL BIOL, V22, P50, DOI 10.1016/j.tcb.2011.09.003
   Majidinia M, 2017, J PINEAL RES, V63, DOI 10.1111/jpi.12416
   Majidinia M, 2017, DNA REPAIR, V54, P22, DOI 10.1016/j.dnarep.2017.03.009
   Mastrandrea LD, 2005, DIABETES, V54, P1429, DOI 10.2337/diabetes.54.5.1429
   Mattick JS, 2006, HUM MOL GENET, V15, pR17, DOI 10.1093/hmg/ddl046
   McCaig C, 2002, J CELL BIOCHEM, V84, P784, DOI 10.1002/jcb.10093
   McNaughton M, 2016, ONCOTARGET, V7, P16663, DOI 10.18632/oncotarget.7693
   Melendez AJ, 2000, GENE, V251, P19, DOI 10.1016/S0378-1119(00)00205-5
   Mercado N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088168
   Mercer TR, 2013, NAT STRUCT MOL BIOL, V20, P300, DOI 10.1038/nsmb.2480
   Micheau O, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030715
   Mitra P, 2006, P NATL ACAD SCI USA, V103, P16394, DOI 10.1073/pnas.0603734103
   Mizutani N, 2015, J CELL BIOCHEM, V116, P2227, DOI 10.1002/jcb.25173
   Mogi A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/583929
   Morad SAF, 2013, NAT REV CANCER, V13, P51, DOI 10.1038/nrc3398
   Mullen TD, 2012, BIOCHEM J, V441, P789, DOI 10.1042/BJ20111626
   Nagahashi M, 2013, FASEB J, V27, P1001, DOI 10.1096/fj.12-219618
   Nemoto S, 2009, J BIOL CHEM, V284, P10422, DOI 10.1074/jbc.M900735200
   Neubauer HA, 2016, ONCOTARGET, V7, P64886, DOI 10.18632/oncotarget.11714
   Neubauer HA, 2013, FEBS J, V280, P5317, DOI 10.1111/febs.12314
   Newton J, 2015, EXP CELL RES, V333, P195, DOI 10.1016/j.yexcr.2015.02.025
   Nicholas SE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182390
   Niederst MJ, 2018, CELL CYCLE, V17, P298, DOI 10.1080/15384101.2016.1221024
   Nonaka M, 2012, INT J GYNECOL CANCER, V22, P922, DOI 10.1097/IGC.0b013e31824f0b13
   Nowsheen S., 2012, Experimental Oncology, V34, P243
   Ogretmen B, 2018, NAT REV CANCER, V18, P33, DOI 10.1038/nrc.2017.96
   Okada T, 2005, J BIOL CHEM, V280, P36318, DOI 10.1074/jbc.M504507200
   Olivera A, 2006, J BIOL CHEM, V281, P2515, DOI 10.1074/jbc.M508931200
   Olivera A, 2007, IMMUNITY, V26, P287, DOI 10.1016/j.immuni.2007.02.008
   Pan MR, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17050685
   Parham KA, 2015, FASEB J, V29, P3638, DOI 10.1096/fj.14-261289
   Patwardhan NN, 2015, J MED CHEM, V58, P1879, DOI 10.1021/jm501760d
   Pitman MR, 2015, ONCOTARGET, V6, P7065, DOI 10.18632/oncotarget.3178
   Pitson SM, 2011, TRENDS BIOCHEM SCI, V36, P97, DOI 10.1016/j.tibs.2010.08.001
   Plano D, 2014, J MED CHEM, V57, P5509, DOI 10.1021/jm4011687
   Postepska-Igielska A, 2015, MOL CELL, V60, P626, DOI 10.1016/j.molcel.2015.10.001
   Pyne NJ, 2012, BIOCHEM SOC T, V40, P94, DOI 10.1042/BST20110602
   Pyne S, 2016, PROG LIPID RES, V62, P93, DOI 10.1016/j.plipres.2016.03.001
   Qin JD, 2018, BIOCHEM BIOPH RES CO, V500, P597, DOI 10.1016/j.bbrc.2018.04.110
   Raje MR, 2012, BIOORGAN MED CHEM, V20, P183, DOI 10.1016/j.bmc.2011.11.011
   Reinhardt HC, 2012, TRENDS GENET, V28, P128, DOI 10.1016/j.tig.2011.12.002
   Reynolds CP, 2004, CANCER LETT, V206, P169, DOI 10.1016/j.canlet.2003.08.034
   Riccitelli E, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068229
   Saliani N, 2013, WORLD J HEPATOL, V5, P220, DOI 10.4254/wjh.v5.i4.220
   Sankala HM, 2007, CANCER RES, V67, P10466, DOI 10.1158/0008-5472.CAN-07-2090
   Santos WL, 2015, ACS CHEM BIOL, V10, P225, DOI 10.1021/cb5008426
   Sathishkumar S, 2005, CANCER BIOL THER, V4, P979, DOI 10.4161/cbt.4.9.1915
   Sato K, 2007, J NEUROCHEM, V103, P2610, DOI 10.1111/j.1471-4159.2007.04958.x
   Schnitzer SE, 2009, MOL CANCER RES, V7, P393, DOI 10.1158/1541-7786.MCR-08-0156
   Selvam SP, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aaa4998
   Sepehr KS, 2014, ADV PHARM BULL, V4, P583, DOI 10.5681/apb.2014.086
   Shen HY, 2014, NAT CELL BIOL, V16, P652, DOI 10.1038/ncb2987
   Song LB, 2011, CLIN CANCER RES, V17, P1839, DOI 10.1158/1078-0432.CCR-10-0720
   Spiegel S, 2003, NAT REV MOL CELL BIO, V4, P397, DOI 10.1038/nrm1103
   Spiegel S, 2000, FEBS LETT, V476, P55, DOI 10.1016/S0014-5793(00)01670-7
   Spiegel S, 2002, J BIOL CHEM, V277, P25851, DOI 10.1074/jbc.R200007200
   Spiegel S, 2011, NAT REV IMMUNOL, V11, P403, DOI 10.1038/nri2974
   St Laurent G, 2015, TRENDS GENET, V31, P239, DOI 10.1016/j.tig.2015.03.007
   Su TT, 2006, ANNU REV GENET, V40, P187, DOI 10.1146/annurev.genet.40.110405.090428
   Taha TA, 2004, J BIOL CHEM, V279, P20546, DOI 10.1074/jbc.M401259200
   Takabe K, 2008, PHARMACOL REV, V60, P181, DOI 10.1124/pr.107.07113
   Takabe K, 2010, J BIOL CHEM, V285, P10477, DOI 10.1074/jbc.M109.064162
   Takasugi N, 2011, J NEUROSCI, V31, P6850, DOI 10.1523/JNEUROSCI.6467-10.2011
   Tehrani SS, 2018, J CELL BIOCHEM, V119, P223, DOI 10.1002/jcb.26217
   Tran TTT, 2016, J BIOL CHEM, V291, P16328, DOI 10.1074/jbc.M115.709626
   Van Brocklyn JR, 2005, J NEUROPATH EXP NEUR, V64, P695, DOI 10.1097/01.jnen.0000175329.59092.2c
   Venant H, 2015, MOL CANCER THER, V14, P2744, DOI 10.1158/1535-7163.MCT-15-0279
   Venkata JK, 2014, BLOOD, V124, P1915, DOI 10.1182/blood-2014-03559385
   Wacker BK, 2009, STROKE, V40, P3342, DOI 10.1161/STROKEAHA.109.560714
   Wallington-Beddoe CT, 2014, CANCER RES, V74, P2803, DOI 10.1158/0008-5472.CAN-13-2732
   Wang KC, 2011, MOL CELL, V43, P904, DOI 10.1016/j.molcel.2011.08.018
   Wang L, 2009, J INT MED RES, V37, P803, DOI 10.1177/147323000903700323
   Wang QS, 2014, TUMOR BIOL, V35, P363, DOI 10.1007/s13277-013-1051-1
   White C, 2016, ONCOTARGET, V7, P23106, DOI 10.18632/oncotarget.7145
   White MD, 2013, ANTICANCER RES, V33, P3573
   Xia P, 2000, CURR BIOL, V10, P1527, DOI 10.1016/S0960-9822(00)00834-4
   Xiao M, 2014, BIOMED ENVIRON SCI, V27, P197, DOI 10.3967/bes2014.040
   Xiao M, 2012, EXP CELL RES, V318, P43, DOI 10.1016/j.yexcr.2011.10.006
   Xiong YQ, 2013, J BIOL CHEM, V288, P32563, DOI 10.1074/jbc.M113.483750
   Yang J, 2015, CANCER BIOL THER, V16, P1194, DOI 10.1080/15384047.2015.1056944
   Yauch RL, 2018, METHODS TREATING PRE
   Yoshimoto T, 2003, J IMMUNOL, V171, P1352, DOI 10.4049/jimmunol.171.3.1352
   Young MM, 2013, J LIPID RES, V54, P5, DOI 10.1194/jlr.R031278
   Yousefi B, 2015, CELL MOL BIOL, V61, P118
   Yousefi B, 2012, BIOIMPACTS, V2, P145, DOI 10.5681/bi.2012.019
   Zemann B, 2006, BLOOD, V107, P1454, DOI 10.1182/blood-2005-07-2628
   Zhang H, 2012, CELL PROLIFERAT, V45, P167, DOI 10.1111/j.1365-2184.2012.00807.x
NR 150
TC 31
Z9 33
U1 1
U2 37
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD JUN
PY 2019
VL 234
IS 6
BP 8162
EP 8181
DI 10.1002/jcp.27612
PG 20
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA HM2QU
UT WOS:000459314500045
PM 30456838
DA 2025-01-04
ER

PT J
AU Mevizou, R
   Sirvent, A
   Roche, S
AF Mevizou, Rudy
   Sirvent, Audrey
   Roche, Serge
TI Control of Tyrosine Kinase Signalling by Small Adaptors in Colorectal
   Cancer
SO CANCERS
LA English
DT Review
DE cell signalling; tyrosine kinase; small adaptor proteins; colorectal
   cancer; targeted therapy
ID SRC FAMILY KINASES; COLON-CANCER; CELL-PROLIFERATION; C-SRC;
   MYELOPROLIFERATIVE NEOPLASM; ABERRANT METHYLATION; HEMATOPOIETIC STEM;
   NEGATIVE REGULATOR; TUMOR PROGRESSION; PROTEIN SLAP
AB Tyrosine kinases (TKs) phosphorylate proteins on tyrosine residues as an intracellular signalling mechanism to coordinate intestinal epithelial cell communication and fate decision. Deregulation of their activity is ultimately connected with carcinogenesis. In colorectal cancer (CRC), it is still unclear how aberrant TK activities contribute to tumour formation because TK-encoding genes are not frequently mutated in this cancer. In vertebrates, several TKs are under the control of small adaptor proteins with potential important physiopathological roles. For instance, they can exert tumour suppressor functions in human cancer by targeting several components of the oncogenic TK signalling cascades. Here, we review how the Src-like adaptor protein (SLAP) and the suppressor of cytokine signalling (SOCS) adaptor proteins regulate the SRC and the Janus kinase (JAK) oncogenic pathways, respectively, and how their loss of function in the intestinal epithelium may influence tumour formation. We also discuss the potential therapeutic value of these adaptors in CRC.
C1 [Mevizou, Rudy; Sirvent, Audrey; Roche, Serge] Univ Montpellier, Equipe Labellisee Ligue Canc, CNRS, CRBM, F-34000 Montpellier, France.
C3 Centre National de la Recherche Scientifique (CNRS); Universite de
   Montpellier
RP Roche, S (corresponding author), Univ Montpellier, Equipe Labellisee Ligue Canc, CNRS, CRBM, F-34000 Montpellier, France.
EM rudy.mevizou@crbm.cnrs.fr; audrey.sirvent@crbm.cnrs.fr;
   serge.roche@crbm.cnrs.fr
OI Sirvent, Audrey/0000-0003-4555-6312; roche, serge/0000-0003-3413-3859
FU La Ligue Contre le Cancer (Equipe Labellisee LIGUE 2017); Montpellier
   SIRIC Grant "INCa-DGOS-Inserm 6045"; CNRS; University of Montpellier;
   Ligue contre le Cancer
FX This work was supported by La Ligue Contre le Cancer (Equipe Labellisee
   LIGUE 2017), Montpellier SIRIC Grant "INCa-DGOS-Inserm 6045", CNRS and
   the University of Montpellier. R.M. was supported by la Ligue contre le
   Cancer, and SR is an INSERM investigator.
CR Ahler E, 2019, MOL CELL, V74, P393, DOI 10.1016/j.molcel.2019.02.003
   Akada H, 2010, BLOOD, V115, P3589, DOI 10.1182/blood-2009-04-215848
   Allgayer H, 2002, CANCER, V94, P344, DOI 10.1002/cncr.10221
   Aringer M, 1999, LIFE SCI, V64, P2173, DOI 10.1016/S0024-3205(98)00538-4
   Baird AM, 1998, J LEUKOCYTE BIOL, V63, P669, DOI 10.1002/jlb.63.6.669
   Bardelli A, 2003, SCIENCE, V300, P949, DOI 10.1126/science.1082596
   Beebe K, 2010, DEV BIOL, V338, P28, DOI 10.1016/j.ydbio.2009.10.045
   Bénistant C, 2001, CANCER RES, V61, P1415
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Boggon TJ, 2004, ONCOGENE, V23, P7918, DOI 10.1038/sj.onc.1208081
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Buchert M, 2016, ONCOGENE, V35, P939, DOI 10.1038/onc.2015.150
   Buchon N, 2009, CELL HOST MICROBE, V5, P200, DOI 10.1016/j.chom.2009.01.003
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Chen JZ, 2014, CLIN COLORECTAL CANC, V13, P5, DOI 10.1016/j.clcc.2013.10.003
   Chu QJ, 2017, GENE, V627, P114, DOI 10.1016/j.gene.2017.06.013
   Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006
   Cordero JB, 2014, EMBO J, V33, P1474, DOI 10.1002/embj.201387454
   Cordero JB, 2012, DEVELOPMENT, V139, P4524, DOI 10.1242/dev.078261
   Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571
   DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455
   David M, 2014, MOL ONCOL, V8, P942, DOI 10.1016/j.molonc.2014.03.014
   Dong Xing, 2018, Oncotarget, V9, P15984, DOI 10.18632/oncotarget.23477
   Dragone LL, 2009, IMMUNOL REV, V232, P218, DOI 10.1111/j.1600-065X.2009.00827.x
   Dubois F, 2015, AM J CANCER RES, V5, P1972
   Endo TA, 1997, NATURE, V387, P921, DOI 10.1038/43213
   Ernst M, 2013, CYTOKINE, V63, P261, DOI 10.1016/j.cyto.2013.06.081
   Fang YT, 2015, CELL PHYSIOL BIOCHEM, V35, P227, DOI 10.1159/000369690
   FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329
   Frame MC, 2004, J CELL SCI, V117, P989, DOI 10.1242/jcs.01111
   Fujitake S, 2004, J GASTROENTEROL, V39, P120, DOI 10.1007/s00535-003-1262-0
   García-Aranda M, 2019, CANCERS, V11, DOI 10.3390/cancers11040433
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Grivennikov SI, 2012, NATURE, V491, P254, DOI 10.1038/nature11465
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hainzl E, 2015, J IMMUNOL, V195, P5011, DOI 10.4049/jimmunol.1402565
   Hanada T, 2006, J EXP MED, V203, P1391, DOI 10.1084/jem.20060436
   Hashimoto M, 2009, CANCER SCI, V100, P730, DOI 10.1111/j.1349-7006.2009.01098.x
   Hibi K, 2005, DIS COLON RECTUM, V48, P1282, DOI 10.1007/s10350-004-0947-7
   Imada S, 2016, MOL CELL BIOL, V36, P2811, DOI 10.1128/MCB.00311-16
   Inagaki-Ohara Kyoko, 2013, JAKSTAT, V2, pe24053, DOI 10.4161/jkst.24053
   Jeitany M, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201707918
   Jeong EG, 2008, CLIN CANCER RES, V14, P3716, DOI 10.1158/1078-0432.CCR-07-4839
   Jiang HQ, 2009, CELL, V137, P1343, DOI 10.1016/j.cell.2009.05.014
   Jin J, 2012, PHILOS T R SOC B, V367, P2540, DOI 10.1098/rstb.2012.0106
   Kang XC, 2016, BIOMED PHARMACOTHER, V80, P23, DOI 10.1016/j.biopha.2016.02.011
   Karpowicz P, 2010, DEVELOPMENT, V137, P4135, DOI 10.1242/dev.060483
   KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374
   Kazi JU, 2014, J CELL SCI, V127, P653, DOI 10.1242/jcs.140590
   Kazi JU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0053509
   Kim JH, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-017-0001-1
   Kohlmaier A, 2015, ONCOGENE, V34, P2371, DOI 10.1038/onc.2014.163
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   Kusaba T, 2005, J CLIN PATHOL, V58, P833, DOI 10.1136/jcp.2004.023416
   Lacout C, 2006, BLOOD, V108, P1652, DOI 10.1182/blood-2006-02-002030
   Lai RH, 2009, GENE, V448, P64, DOI 10.1016/j.gene.2009.07.022
   Le Roux AL, 2016, COLLOID SURFACE B, V138, P17, DOI 10.1016/j.colsurfb.2015.11.013
   Lee J, 2012, J BIOL CHEM, V287, P18182, DOI 10.1074/jbc.M111.328831
   Lee S, 2008, ARCH PATHOL LAB MED, V132, P1657, DOI 10.1043/1543-2165(2008)132[1657:CIMPIC]2.0.CO;2
   Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293
   Leroy C, 2009, CANCER RES, V69, P2279, DOI 10.1158/0008-5472.CAN-08-2354
   Letellier E, 2014, BRIT J CANCER, V111, P726, DOI 10.1038/bjc.2014.377
   Li JA, 2010, BLOOD, V116, P1528, DOI 10.1182/blood-2009-12-259747
   Li Y, 2012, CARCINOGENESIS, V33, P1889, DOI 10.1093/carcin/bgs214
   Lièvre A, 2009, NAT REV CLIN ONCOL, V6, P306, DOI 10.1038/nrclinonc.2009.69
   Lim WA, 2010, CELL, V142, P661, DOI 10.1016/j.cell.2010.08.023
   Lin SY, 2004, ONCOL REP, V11, P341
   Liu BA, 2012, PHILOS T R SOC B, V367, P2556, DOI 10.1098/rstb.2012.0107
   Liu JK, 2011, BIOCHEM BIOPH RES CO, V407, P348, DOI 10.1016/j.bbrc.2011.03.021
   Liu XH, 2009, J INTERF CYTOK RES, V29, P809, DOI 10.1089/jir.2009.0004
   Manes G, 2000, MOL CELL BIOL, V20, P3396, DOI 10.1128/MCB.20.10.3396-3406.2000
   Marty C, 2010, BLOOD, V116, P783, DOI 10.1182/blood-2009-12-257063
   Metcalf D, 2000, NATURE, V405, P1069, DOI 10.1038/35016611
   Mullally A, 2010, CANCER CELL, V17, P584, DOI 10.1016/j.ccr.2010.05.015
   Musteanu M, 2010, GASTROENTEROLOGY, V138, P1003, DOI 10.1053/j.gastro.2009.11.049
   Myers MD, 2006, NAT IMMUNOL, V7, P57, DOI 10.1038/ni1291
   Naka T, 1997, NATURE, V387, P924, DOI 10.1038/43219
   Naudin C, 2016, ONCOTARGET, V7, P11033, DOI 10.18632/oncotarget.6929
   Naudin C, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4159
   Neubauer H, 1998, CELL, V93, P397, DOI 10.1016/S0092-8674(00)81168-X
   Newton VA, 2010, AM J PATHOL, V176, P2320, DOI 10.2353/ajpath.2010.090684
   Oneyama C, 2008, MOL CELL, V30, P426, DOI 10.1016/j.molcel.2008.03.026
   Pakuts B, 2007, J BIOL CHEM, V282, P17953, DOI 10.1074/jbc.M701182200
   Parganas E, 1998, CELL, V93, P385, DOI 10.1016/S0092-8674(00)81167-8
   Parseghian CM, 2017, CLIN CANCER RES, V23, P4146, DOI 10.1158/1078-0432.CCR-16-3138
   Perez M, 2016, ONCOTARGET, V7, P33111, DOI 10.18632/oncotarget.8880
   Phesse TJ, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005411
   Pilling C, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11040-3
   Poh AR, 2017, CANCER CELL, V31, P563, DOI 10.1016/j.ccell.2017.03.006
   Pohl M, 2016, DIGEST DIS, V34, P574, DOI 10.1159/000445267
   Ragusa M, 2012, J MOL MED, V90, P1421, DOI 10.1007/s00109-012-0918-8
   Reddy SM, 2015, INVEST NEW DRUG, V33, P977, DOI 10.1007/s10637-015-0257-z
   Ren D, 2017, ONCOTARGET, V8, P49807, DOI 10.18632/oncotarget.17971
   Rigby RJ, 2007, ONCOGENE, V26, P4833, DOI 10.1038/sj.onc.1210286
   Roche S, 1998, CURR BIOL, V8, P975, DOI 10.1016/S0960-9822(98)70400-2
   Rodig SJ, 1998, CELL, V93, P373, DOI 10.1016/S0092-8674(00)81166-6
   Rosenbluh J, 2012, CELL, V151, P1457, DOI 10.1016/j.cell.2012.11.026
   Roseweir AK, 2019, CELL SIGNAL, V56, P15, DOI 10.1016/j.cellsig.2019.01.007
   Sakiyarna T, 2008, INFLAMM BOWEL DIS, V14, P310, DOI 10.1002/ibd.20328
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Sancier F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017237
   Savage DG, 2002, NEW ENGL J MED, V346, P683, DOI 10.1056/NEJMra013339
   Schetter AJ, 2009, CLIN CANCER RES, V15, P5878, DOI 10.1158/1078-0432.CCR-09-0627
   Shimoda K, 2002, J IMMUNOL, V169, P4707, DOI 10.4049/jimmunol.169.9.4707
   Shimoda K, 2000, IMMUNITY, V13, P561, DOI 10.1016/S1074-7613(00)00055-8
   Shimoda K, 2002, BLOOD, V99, P2094, DOI 10.1182/blood.V99.6.2094
   Shin DS, 2017, CANCER DISCOV, V7, P188, DOI 10.1158/2159-8290.CD-16-1223
   Sirvent A, 2008, ONCOGENE, V27, P3494, DOI 10.1038/sj.onc.1211011
   Sirvent A, 2010, ONCOGENE, V29, P1303, DOI 10.1038/onc.2009.450
   Sirvent A, 2012, MOL CELL PROTEOMICS, V11, P1937, DOI 10.1074/mcp.M112.018168
   Sirvent A, 2012, AM J CANCER RES, V2, P357
   Slattery ML, 2013, MOL CARCINOGEN, V52, P155, DOI 10.1002/mc.21841
   Sosinowski T, 2001, IMMUNITY, V15, P457, DOI 10.1016/S1074-7613(01)00195-9
   Spassov DS, 2018, CELL REP, V25, P449, DOI 10.1016/j.celrep.2018.09.035
   Starr R, 1997, NATURE, V387, P917, DOI 10.1038/43206
   Storojeva I, 2005, ONCOLOGY-BASEL, V68, P246, DOI 10.1159/000086781
   Su M, 2018, ONCOL LETT, V16, P65, DOI 10.3892/ol.2018.8645
   Summy JM, 2003, CANCER METAST REV, V22, P337, DOI 10.1023/A:1023772912750
   Suzuki K, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.195362
   Sveen A, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0434-0
   Taniguchi K, 2017, P NATL ACAD SCI USA, V114, P1643, DOI 10.1073/pnas.1620290114
   Taniguchi K, 2015, NATURE, V519, P57, DOI 10.1038/nature14228
   Thomas SM, 1997, ANNU REV CELL DEV BI, V13, P513, DOI 10.1146/annurev.cellbio.13.1.513
   Tiedt R, 2008, BLOOD, V111, P3931, DOI 10.1182/blood-2007-08-107748
   Tobelaim WS, 2015, SCI REP-UK, V5, DOI 10.1038/srep14301
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907
   Trengove MC, 2013, AM J CLIN EXP IMMUNO, V2, P1
   Tsareva SA, 2007, NEOPLASIA, V9, P279, DOI 10.1593/neo.06820
   Vainchenker W, 2013, ONCOGENE, V32, P2601, DOI 10.1038/onc.2012.347
   Vanharanta S, 2013, CANCER CELL, V24, P410, DOI 10.1016/j.ccr.2013.09.007
   Villarino AV, 2017, NAT IMMUNOL, V18, P374, DOI 10.1038/ni.3691
   Wang SW, 2016, TUMOR BIOL, V37, P6561, DOI 10.1007/s13277-015-4529-1
   Wernig G, 2008, BLOOD, V111, P3751, DOI 10.1182/blood-2007-07-102186
   WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057
   Wybenga-Groot LE, 2015, CELL SIGNAL, V27, P267, DOI 10.1016/j.cellsig.2014.11.010
   Xiong H, 2008, NEOPLASIA, V10, P287, DOI 10.1593/neo.07971
   Xu SB, 2009, J CANCER RES CLIN, V135, P1791, DOI 10.1007/s00432-009-0627-z
   Zhang B, 2014, NATURE, V513, P382, DOI 10.1038/nature13438
   Zhang L, 2014, CARCINOGENESIS, V35, P1330, DOI 10.1093/carcin/bgu017
   Zhang Y, 2000, J BIOL CHEM, V275, P24935, DOI 10.1074/jbc.M002383200
NR 141
TC 6
Z9 6
U1 0
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2019
VL 11
IS 5
AR 669
DI 10.3390/cancers11050669
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IF0AP
UT WOS:000472738300082
PM 31091767
OA Green Published, gold, Green Submitted
DA 2025-01-04
ER

PT J
AU Wu, T
   Dai, Y
   Wang, WH
   Teng, GG
   Jiao, HM
   Shuai, XW
   Zhang, RX
   Zhao, P
   Qiao, L
AF Wu, Ting
   Dai, Yun
   Wang, Weihong
   Teng, Guigen
   Jiao, Hongmei
   Shuai, Xiaowei
   Zhang, Rongxin
   Zhao, Peng
   Qiao, Liang
TI Macrophage targeting contributes to the inhibitory effects of embelin on
   colitis-associated cancer
SO ONCOTARGET
LA English
DT Article
DE embelin; colitis-associated cancer; macrophage; target therapy
ID TUMOR-ASSOCIATED MACROPHAGES; COLORECTAL-CANCER; INFLAMMATION; CELLS;
   RISK; TUMORIGENESIS; POLARIZATION; METAANALYSIS; PROGRESSION; ALPHA
AB Macrophages are a major component of inflammatory and tumor microenvironment. We previously reported that embelin suppresses colitis-associated tumorigenesis. Here, the role of macrophage targeting in the anti-inflammatory and anti-tumor properties of embelin was investigated. By using colitis-associated cancer (CAC) model, we demonstrated that embelin significantly depleted colon macrophages by blocking their recruitment. Moreover, embelin attenuated M2-like polarization of macrophages within the tumor microenvironment and eliminated their tumor-promoting functions during the development of CAC. Embelin potently inhibited NF-kappa B signaling in macrophages and decreased the production of key pro-inflammatory cytokines and tumorigenic factors involved in CAC, such as TNF alpha, IL-6 and COX-2. In addition, embelin directly reduced the polarization of M2 macrophages in vitro even in the presence of Th2 cytokines. These results suggested that targeting macrophages is, at least in part, responsible for the anti-tumor activity of embelin in CAC. Our observations strengthen the rationale for future validation of embelin in the prevention and treatment of CAC
C1 [Wu, Ting; Dai, Yun; Wang, Weihong; Teng, Guigen; Shuai, Xiaowei] Peking Univ, Hosp 1, Dept Gastroenterol, Beijing 100034, Peoples R China.
   [Jiao, Hongmei] Peking Univ, Hosp 1, Dept Gerontol, Beijing 100034, Peoples R China.
   [Zhang, Rongxin] Tianjin Med Univ, Res Ctr Basic Med Sci, Tianjin 300070, Peoples R China.
   [Zhang, Rongxin] Tianjin Med Univ, Dept Immunol, Educ Minist China, Key Lab Immune Microenvironm & Dis, Tianjin 300070, Peoples R China.
   [Zhao, Peng] Tianjin Med Univ, Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Colorectal Canc,Key Lab Canc Prevent & Thera, Tianjin 300060, Peoples R China.
   [Qiao, Liang] Univ Sydney, Westmead Hosp, Storr Liver Ctr, Westmead Inst Med Res, Westmead, NSW 2145, Australia.
C3 Peking University; Peking University; Tianjin Medical University;
   Tianjin Medical University; Tianjin Medical University; University of
   Sydney; Westmead Institute for Medical Research; NSW Health; Westmead
   Hospital
RP Dai, Y (corresponding author), Peking Univ, Hosp 1, Dept Gastroenterol, Beijing 100034, Peoples R China.; Qiao, L (corresponding author), Univ Sydney, Westmead Hosp, Storr Liver Ctr, Westmead Inst Med Res, Westmead, NSW 2145, Australia.
EM daiyun1@medmail.com.cn; liang.qiao@sydney.edu.au
RI Zhang, Rongxin/ABG-3679-2021
OI Zhang, Rongxin/0000-0002-4083-374X; Dai, Yun/0000-0002-8854-631X
FU Natural Science Foundation of China (NSFC) [81472267, 81072019]; Natural
   Science Foundation of Beijing [7122189]; NSFC [81172271, 81272317];
   NHMRC Project Grant [APP1047417]; NSW Cancer Council Grant [APP1070076]
FX This work was supported by the Natural Science Foundation of China (NSFC
   #81472267 and #81072019) and the Natural Science Foundation of Beijing
   (7122189) awarded to Y. Dai. WH. Wang was partially supported by NSFC
   #81172271. RX. Zhang was partially supported by NSFC #81272317. L.
   Qiao's work was supported by the NHMRC Project Grant (ID: APP1047417)
   and NSW Cancer Council Grant (ID: APP1070076).
CR Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Canavan C, 2006, ALIMENT PHARM THER, V23, P1097, DOI 10.1111/j.1365-2036.2006.02854.x
   Chapple KS, 2000, AM J PATHOL, V156, P545, DOI 10.1016/S0002-9440(10)64759-1
   Chow JC, 1999, J BIOL CHEM, V274, P10689, DOI 10.1074/jbc.274.16.10689
   Dai Y, 2014, MOL CANCER THER, V13, P1206, DOI 10.1158/1535-7163.MCT-13-0378
   Dai Y, 2009, CANCER RES, V69, P4776, DOI 10.1158/0008-5472.CAN-08-4754
   DeNardo DG, 2009, CANCER CELL, V16, P91, DOI 10.1016/j.ccr.2009.06.018
   Duluc D, 2009, INT J CANCER, V125, P367, DOI 10.1002/ijc.24401
   Eaden JA, 2001, GUT, V48, P526, DOI 10.1136/gut.48.4.526
   ELSON CO, 1995, GASTROENTEROLOGY, V109, P1344, DOI 10.1016/0016-5085(95)90599-5
   Engel MA, 2010, CURR MED CHEM, V17, P3303
   Fukata M, 2007, GASTROENTEROLOGY, V133, P1869, DOI 10.1053/j.gastro.2007.09.008
   Germano G, 2013, CANCER CELL, V23, P249, DOI 10.1016/j.ccr.2013.01.008
   Grenz S, 2013, AM J PATHOL, V183, P1897, DOI 10.1016/j.ajpath.2013.08.025
   Greten FR, 2004, CELL, V118, P285, DOI 10.1016/j.cell.2004.07.013
   Grivennikov S, 2009, CANCER CELL, V15, P103, DOI 10.1016/j.ccr.2009.01.001
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108
   Hajjar AM, 2002, NAT IMMUNOL, V3, P354, DOI 10.1038/ni777
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hull MA, 1999, BRIT J CANCER, V79, P1399, DOI 10.1038/sj.bjc.6690224
   Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997
   Mahida YR, 2000, INFLAMM BOWEL DIS, V6, P21, DOI 10.1097/00054725-200002000-00004
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Matsunaga N, 2011, MOL PHARMACOL, V79, P34, DOI 10.1124/mol.110.068064
   Nikolovska-Coleska Z, 2004, J MED CHEM, V47, P2430, DOI 10.1021/jm030420+
   Ostuni R, 2015, TRENDS IMMUNOL, V36, P229, DOI 10.1016/j.it.2015.02.004
   Pollard JW, 2004, NAT REV CANCER, V4, P71, DOI 10.1038/nrc1256
   Popivanova BK, 2008, J CLIN INVEST, V118, P560, DOI [10.1172/JC132453, 10.1172/JCI32453]
   Popivanova BK, 2009, CANCER RES, V69, P7884, DOI 10.1158/0008-5472.CAN-09-1451
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016
   Sica A, 2008, SEMIN CANCER BIOL, V18, P349, DOI 10.1016/j.semcancer.2008.03.004
   Sica A, 2012, J CLIN INVEST, V122, P787, DOI 10.1172/JCI59643
   Sturlan S, 2001, CARCINOGENESIS, V22, P665, DOI 10.1093/carcin/22.4.665
   Ullman TA, 2011, GASTROENTEROLOGY, V140, P1807, DOI 10.1053/j.gastro.2011.01.057
   Velayos FS, 2005, AM J GASTROENTEROL, V100, P1345, DOI 10.1111/j.1572-0241.2005.41442.x
   Zaki MH, 2011, CANCER CELL, V20, P649, DOI 10.1016/j.ccr.2011.10.022
NR 40
TC 23
Z9 26
U1 1
U2 18
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD APR 12
PY 2016
VL 7
IS 15
BP 19548
EP 19558
DI 10.18632/oncotarget.6969
PG 11
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DL7ES
UT WOS:000375804000035
PM 26799669
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Li, HZ
   Jing, CW
   Wu, JZ
   Ni, J
   Sha, HH
   Xu, XY
   Du, YY
   Lou, R
   Dong, SC
   Feng, JF
AF Li, Huizi
   Jing, Changwen
   Wu, Jianzhong
   Ni, Jie
   Sha, Huanhuan
   Xu, Xiaoyue
   Du, Yuanyuan
   Lou, Rui
   Dong, Shuchen
   Feng, Jifeng
TI Circulating tumor DNA detection: A potential tool for colorectal cancer
   management
SO ONCOLOGY LETTERS
LA English
DT Review
DE circulating tumor DNA; colorectal cancer; detection methods; clinical
   applications; biomarkers
ID WHOLE-GENOME; LIQUID BIOPSY; TARGETED THERAPY; RECTAL-CANCER; DIGITAL
   PCR; CELLS; MARKER; METHYLATION; RECURRENCE; RESISTANCE
AB Colorectal cancer (CRC) is frequently diagnosed at an advanced stage of the disease, the pathogenesis of which is influenced by genetic and epigenetic events. Circulating tumor DNA (ctDNA) is extracellular DNA that is present in a number of bodily fluids, including blood, synovial fluid and cerebrospinal fluid. Compared with performing a tissue biopsy, ctDNA examination presents the advantages of minimal invasion and greater convenience. ctDNA is commonly used to identify actionable genomic alterations, monitor treatment responses, unravel therapeutic resistance and potentially detect disease progression prior to clinical and radiological confirmation. The technique can potentially serve as a non-invasive diagnostic tool in personalized medicine, as it demonstrates prognostic value in the management of patients with CRC. ctDNA detection continues to demonstrate inherent advantages compared with other methods, thus serving an increasingly important role in tumor monitoring and oncotherapy. The aim of the current review was to explore the clinical applications of ctDNA in patients with CRC, including early detection and screening, medication guidance, resistance prediction, and residual lesion and recurrence monitoring. Furthermore, several technical methods for ctDNA detection and analysis are explored, as well as other potential biomarkers.
C1 [Li, Huizi; Ni, Jie; Sha, Huanhuan; Xu, Xiaoyue; Du, Yuanyuan; Lou, Rui; Dong, Shuchen; Feng, Jifeng] Nanjing Med Univ, Affiliated Canc Hosp, Dept Oncol, Bldg 7,42 Baiziting St, Nanjing 210009, Jiangsu, Peoples R China.
   [Li, Huizi; Jing, Changwen; Wu, Jianzhong; Ni, Jie; Sha, Huanhuan; Xu, Xiaoyue; Du, Yuanyuan; Lou, Rui; Dong, Shuchen; Feng, Jifeng] Jiangsu Canc Hosp, Dept Oncol, Nanjing 210009, Jiangsu, Peoples R China.
   [Li, Huizi; Jing, Changwen; Wu, Jianzhong; Ni, Jie; Sha, Huanhuan; Xu, Xiaoyue; Du, Yuanyuan; Lou, Rui; Dong, Shuchen; Feng, Jifeng] Jiangsu Inst Canc Res, Dept Oncol, Nanjing 210009, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Feng, JF (corresponding author), Nanjing Med Univ, Affiliated Canc Hosp, Dept Oncol, Bldg 7,42 Baiziting St, Nanjing 210009, Jiangsu, Peoples R China.
EM jifeng_feng@163.com
RI Feng, Jifeng/KMA-1502-2024
FU Science Foundation of Jiangsu Province [BE2016795]
FX The present study was supported by the Science Foundation of Jiangsu
   Province (grant no. BE2016795).
CR Berger AW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174308
   Boni L, 2007, SURG ONCOL, V16, pS29, DOI 10.1016/j.suronc.2007.10.004
   Bratman SV, 2015, EXPERT REV MOL DIAGN, V15, P715, DOI 10.1586/14737159.2015.1019476
   Cabel L, 2017, ANN ONCOL, V28, P1996, DOI 10.1093/annonc/mdx212
   Carpinetti P, 2015, ONCOTARGET, V6, P38360, DOI 10.18632/oncotarget.5256
   Casuscelli J, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.92688
   Chen KZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep31985
   Cheng FF, 2016, ONCOTARGET, V7, P48832, DOI 10.18632/oncotarget.9453
   Church TR, 2014, GUT, V63, P317, DOI 10.1136/gutjnl-2012-304149
   Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Dolzhenko E, 2017, GENOME RES, V27, P1895, DOI 10.1101/gr.225672.117
   Dressman D, 2003, P NATL ACAD SCI USA, V100, P8817, DOI 10.1073/pnas.1133470100
   Fackler MJ, 2014, CANCER RES, V74, P2160, DOI 10.1158/0008-5472.CAN-13-3392
   Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726
   Gao YH, 2017, ONCOTARGET, V8, P6330, DOI 10.18632/oncotarget.14064
   García-Foncillas J, 2017, ANN ONCOL, V28, P2943, DOI 10.1093/annonc/mdx501
   Garrigou S, 2016, CLIN CHEM, V62, P1129, DOI 10.1373/clinchem.2015.253609
   Grasselli J, 2017, ANN ONCOL, V28, P1294, DOI 10.1093/annonc/mdx112
   Haber DA, 2014, CANCER DISCOV, V4, P650, DOI 10.1158/2159-8290.CD-13-1014
   Habr-Gama A, 2014, INT J RADIAT ONCOL, V88, P822, DOI 10.1016/j.ijrobp.2013.12.012
   Harouaka R, 2014, PHARMACOL THERAPEUT, V141, P209, DOI 10.1016/j.pharmthera.2013.10.004
   Heitzer E, 2013, GENOME MED, V5, DOI 10.1186/gm434
   Hindson CM, 2013, NAT METHODS, V10, P1003, DOI 10.1038/nmeth.2633
   Hintzsche JD, 2016, INT J GENOMICS, V2016, DOI 10.1155/2016/7983236
   Hon GC, 2012, GENOME RES, V22, P246, DOI 10.1101/gr.125872.111
   Hrebien S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165023
   Husain H, 2017, CLIN CANCER RES, V23, P4716, DOI 10.1158/1078-0432.CCR-17-0454
   Isobe K, 2015, CANCER GENOM PROTEOM, V12, P31
   Kadiyska T, 2015, WORLD J GASTROENTERO, V21, P10057, DOI 10.3748/wjg.v21.i35.10057
   Kakizawa N, 2017, ONCOL REP, V37, P2506, DOI 10.3892/or.2017.5456
   Kim H, 2015, GENOME RES, V25, P316, DOI 10.1101/gr.180612.114
   Kitahara M, 2016, CANCER SCI, V107, P1825, DOI 10.1111/cas.13085
   Krebs MG, 2015, CLIN COLORECTAL CANC, V14, P115, DOI 10.1016/j.clcc.2014.12.006
   Kuo CC, 2015, WORLD J GASTROENTERO, V21, P3960, DOI 10.3748/wjg.v21.i13.3960
   Lan YT, 2017, ONCOTARGET, V8, P3009, DOI 10.18632/oncotarget.13821
   Lecomte T, 2002, INT J CANCER, V100, P542, DOI 10.1002/ijc.10526
   LEON SA, 1977, CANCER RES, V37, P646
   Lin JK, 2014, ANN SURG ONCOL, V21, pS680, DOI 10.1245/s10434-014-3804-5
   Link-Lenczowska D, 2018, ANN HEMATOL, V97, P2299, DOI 10.1007/s00277-018-3451-1
   Lu CY, 2013, BRIT J CANCER, V108, P791, DOI 10.1038/bjc.2012.595
   McGuire AL, 2008, NAT REV GENET, V9, P152, DOI 10.1038/nrg2302
   Mitchell SM, 2016, GENES-BASEL, V7, DOI 10.3390/genes7120125
   Moore LD, 2013, NEUROPSYCHOPHARMACOL, V38, P23, DOI 10.1038/npp.2012.112
   Mouliere F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023418
   Myint NNM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0934-x
   Nakamura Kenichi, 2016, Rinsho Byori, V64, P400
   Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519
   Ng SB, 2017, SCI REP-UK, V7, DOI 10.1038/srep40737
   Oke S, 2017, THER ADV GASTROENTER, V10, P417, DOI 10.1177/1756283X17694832
   Pailler E, 2013, J CLIN ONCOL, V31, P2273, DOI 10.1200/JCO.2012.44.5932
   Pal SK, 2017, EUR UROL, V72, P557, DOI 10.1016/j.eururo.2017.03.046
   Pantel K, 2016, MOL ONCOL, V10, P371, DOI 10.1016/j.molonc.2016.01.009
   Parkinson CA, 2016, PLOS MED, V13, DOI 10.1371/journal.pmed.1002198
   Przybyl J, 2018, CLIN CANCER RES, V24, P2688, DOI 10.1158/1078-0432.CCR-17-3704
   Racila E, 1998, P NATL ACAD SCI USA, V95, P4589, DOI 10.1073/pnas.95.8.4589
   Reinert T, 2016, GUT, V65, P625, DOI 10.1136/gutjnl-2014-308859
   Riva F, 2017, CLIN CHEM, V63, P691, DOI 10.1373/clinchem.2016.262337
   Sameen S, 2016, J THEOR BIOL, V389, P263, DOI 10.1016/j.jtbi.2015.10.019
   Schmiegel W, 2017, MOL ONCOL, V11, P208, DOI 10.1002/1878-0261.12023
   Scholefield JH, 2002, GUT, V51, pV3, DOI 10.1136/gut.51.suppl_5.v3
   Seidman AD, 2001, J CLIN ONCOL, V19, P2587, DOI 10.1200/JCO.2001.19.10.2587
   Seifert L, 2016, NATURE, V532, P245, DOI 10.1038/nature17403
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Takai Daiya, 2010, Gan To Kagaku Ryoho, V37, P189
   Takayama Yuji, 2018, Oncotarget, V9, P24398, DOI 10.18632/oncotarget.25309
   Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177
   Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219
   Underhill HR, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006162
   van der Vaart M, 2007, CLIN CHEM, V53, P2215, DOI 10.1373/clinchem.2007.092734
   van Ginkel JH, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3424-0
   Vidal J, 2017, ANN ONCOL, V28, P1325, DOI 10.1093/annonc/mdx125
   Villaflor V, 2016, ONCOTARGET, V7, P66880, DOI 10.18632/oncotarget.11801
   Wardenaar R, 2013, METHODS MOL BIOL, V1067, P203, DOI 10.1007/978-1-62703-607-8_13
   Xu JM, 2017, CLIN CANCER RES, V23, P4602, DOI 10.1158/1078-0432.CCR-16-2738
   Yu D, 2016, CLIN LAB, V62, P1947, DOI 10.7754/Clin.Lab.2016.160215
   Zhai ZH, 2017, SEMIN CELL DEV BIOL, V64, P107, DOI 10.1016/j.semcdb.2016.08.033
   Zhang B, 2015, EXP THER MED, V9, P1383, DOI 10.3892/etm.2015.2221
   Zhao HJ, 2017, CANCER BIOL THER, V18, P863, DOI 10.1080/15384047.2016.1219816
   Zhou JL, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159708
   Zippi M, 2017, SAUDI J GASTROENTERO, V23, P39, DOI 10.4103/1319-3767.199114
NR 81
TC 49
Z9 54
U1 2
U2 13
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD FEB
PY 2019
VL 17
IS 2
BP 1409
EP 1416
DI 10.3892/ol.2018.9794
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HM5YS
UT WOS:000459551800002
PM 30675194
OA gold, Green Published, Green Submitted
DA 2025-01-04
ER

PT J
AU Bronte, F
   Bronte, G
   Fanale, D
   Caruso, S
   Bronte, E
   Bavett, MG
   Fiorentino, E
   Rolfo, C
   Bazan, V
   Di Marco, V
   Russo, A
AF Bronte, Fabrizio
   Bronte, Giuseppe
   Fanale, Daniele
   Caruso, Stefano
   Bronte, Enrico
   Bavett, Maria Grazia
   Fiorentino, Eugenio
   Rolfo, Christian
   Bazan, Viviana
   Di Marco, Vito
   Russo, Antonio
TI HepatomiRNoma: The proposal of a new network of targets for diagnosis,
   prognosis and therapy in hepatocellular carcinoma
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Review
DE Hepatocellular carcinoma; MicroRNA; Diagnosis; Targeted therapy; Serum;
   Prognosis
ID MICRORNA-224 UP-REGULATION; VIRUS X PROTEIN; TUMOR-SUPPRESSOR;
   DOWN-REGULATION; CANCER-CELLS; ANTI-EGFR; DOXORUBICIN SENSITIVITY;
   MONOCLONAL-ANTIBODIES; REGULATES EXPRESSION; COLORECTAL-CANCER
AB The diagnosis and treatment of hepatocellular carcinoma (HCC) underwent a huge advancement in the last years. Recently, microRNAs (miRNAs) have been also studied to provide a new tool for early diagnosis of high risk patients, for prognostic classification to identify those patients who benefit cancer treatment and for predictive definition to select the right targeted drug.
   In this review we revised all the available data obtained to explore the role of miRNAs in HCC. This analysis led to identification of miRNAs which could gain a diagnostic, prognostic or predictive role.
   The results of studies on miRNAs involved in HCC are initial and far from providing scientific evidences to translate into clinical practice. We propose a classification of these miRNAs, that we could name HepatomiRNoma as a whole. Anyway prospective studies have to be designed to clarify the real clinical impact of this new tool. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
C1 [Bronte, Fabrizio; Bavett, Maria Grazia; Di Marco, Vito] Univ Palermo, DiBiMIS, Gastroenterol Sect, Palermo, Italy.
   [Bronte, Giuseppe; Fanale, Daniele; Caruso, Stefano; Bronte, Enrico; Fiorentino, Eugenio; Bazan, Viviana; Russo, Antonio] Univ Palermo, Dept Surg Oncol & Oral Sci, Palermo, Italy.
   [Rolfo, Christian] Univ Antwerp Hosp, Dept Oncol, Edegem, Belgium.
C3 University of Palermo; University of Palermo; University of Antwerp
RP Russo, A (corresponding author), Univ Palermo, Sect Med Oncol, Dept Surg Oncol & Oral Sci, Via Vespro 129, I-90127 Palermo, Italy.
EM antonio.russo@usa.net
RI Fanale, Daniele/K-8630-2016; Rolfo, Christian/AAW-5173-2021; Di Marco,
   Vito/AAC-4612-2022; Caruso, Stefano/AAA-9564-2020; Bronte,
   Fabrizio/L-6365-2015
OI Rolfo, Christian/0000-0002-7860-8417; Bronte,
   Fabrizio/0000-0003-0896-830X; Caruso, Stefano/0000-0002-6319-3642;
   Bronte, Giuseppe/0000-0002-2306-2445
CR Amodeo V, 2013, EXPERT OPIN THER TAR, V17, P1249, DOI 10.1517/14728222.2013.832206
   Bai SM, 2009, J BIOL CHEM, V284, P32015, DOI 10.1074/jbc.M109.016774
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bihrer V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026971
   Borchert GM, 2006, NAT STRUCT MOL BIOL, V13, P1097, DOI 10.1038/nsmb1167
   Bronte F, 2014, CURR MED CHEM, V21, P966, DOI 10.2174/09298673113209990234
   Bronte G, 2013, EXPERT OPIN BIOL TH, V13, P889, DOI 10.1517/14712598.2013.774367
   Bronte Giuseppe, 2011, Front Biosci (Elite Ed), V3, P879
   Bronte G, 2010, CANCER TREAT REV, V36, pS21, DOI 10.1016/S0305-7372(10)70016-5
   Cai L, 2014, DIAGN PATHOL, V9, DOI 10.1186/s13000-014-0228-2
   Callegari E, 2012, HEPATOLOGY, V56, P1025, DOI 10.1002/hep.25747
   Caraglia M, 2011, CURR DRUG METAB, V12, P944, DOI 10.2174/138920011798062346
   Caruso S, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.33
   Cermelli S, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023937
   Chang Y, 2012, GASTROENTEROLOGY, V143, P177, DOI 10.1053/j.gastro.2012.04.009
   Chen XM, 2013, LIVER INT, V33, P476, DOI 10.1111/liv.12097
   Cheng J, 2010, PROTEOMICS, V10, P1557, DOI 10.1002/pmic.200900646
   Chung GE, 2010, ONCOL REP, V23, P113, DOI 10.3892/or_00000612
   Connolly E, 2008, AM J PATHOL, V173, P856, DOI 10.2353/ajpath.2008.080096
   Connolly EC, 2010, MOL CANCER RES, V8, P691, DOI 10.1158/1541-7786.MCR-09-0465
   Corsini LR, 2012, EXPERT OPIN THER TAR, V16, pS103, DOI 10.1517/14728222.2011.650632
   Cummins JM, 2006, ONCOGENE, V25, P6220, DOI 10.1038/sj.onc.1209914
   Dai RY, 2010, BIOL CHEM, V391, P791, DOI 10.1515/BC.2010.072
   Datta J, 2008, CANCER RES, V68, P5049, DOI 10.1158/0008-5472.CAN-07-6655
   Di Fede G, 2011, EXPERT OPIN BIOL TH, V11, P1433, DOI 10.1517/14712598.2011.594436
   Fan CG, 2011, ONCOL REP, V26, P1281, DOI 10.3892/or.2011.1375
   Fornari F, 2008, ONCOGENE, V27, P5651, DOI 10.1038/onc.2008.178
   Fornari F, 2010, CANCER RES, V70, P5184, DOI 10.1158/0008-5472.CAN-10-0145
   Fornari F, 2009, CANCER RES, V69, P5761, DOI 10.1158/0008-5472.CAN-08-4797
   Franchina T, 2014, J CELL PHYSIOL, V229, P97, DOI 10.1002/jcp.24422
   Fu XH, 2011, MOL BIOL REP, V38, P3029, DOI 10.1007/s11033-010-9969-5
   Fu Y, 2013, ONCOL LETT, V6, P1811, DOI 10.3892/ol.2013.1638
   Ge W, 2014, CLIN LAB, V60, P427, DOI 10.7754/Clin.Lab.2013.130133
   Giray BG, 2014, MOL BIOL REP, V41, P4513, DOI 10.1007/s11033-014-3322-3
   Gramantieri L, 2009, CLIN CANCER RES, V15, P5073, DOI 10.1158/1078-0432.CCR-09-0092
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Griffiths-Jones S, 2008, NUCLEIC ACIDS RES, V36, pD154, DOI 10.1093/nar/gkm952
   Gui JH, 2011, CLIN SCI, V120, P183, DOI 10.1042/CS20100297
   Guo YJ, 2011, MOL CELL BIOCHEM, V354, P275, DOI 10.1007/s11010-011-0827-0
   Henry JC, 2010, BIOCHEM BIOPH RES CO, V403, P120, DOI 10.1016/j.bbrc.2010.10.130
   Hernandez JM, 2013, ANN SURG ONCOL, V20, pS625, DOI 10.1245/s10434-013-3106-3
   Ho CM, 2011, HEPATOLOGY, V54, P1105, DOI 10.1002/hep.24521
   Hou J, 2011, CANCER CELL, V19, P232, DOI 10.1016/j.ccr.2011.01.001
   Huang Zenghong, 2009, Sheng Wu Gong Cheng Xue Bao, V25, P587
   Karakatsanis A, 2013, MOL CARCINOGEN, V52, P297, DOI 10.1002/mc.21864
   Kim VN, 2005, NAT REV MOL CELL BIO, V6, P376, DOI 10.1038/nrm1644
   Köberle V, 2013, EUR J CANCER, V49, P3442, DOI 10.1016/j.ejca.2013.06.002
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Li CF, 2013, J VIROL, V87, P2193, DOI 10.1128/JVI.02831-12
   Li CL, 2015, INT J CANCER, V136, P761, DOI 10.1002/ijc.29052
   Li D, 2012, LIFE SCI, V91, P440, DOI 10.1016/j.lfs.2012.08.015
   Li JP, 2011, BIOCHEM BIOPH RES CO, V406, P70, DOI 10.1016/j.bbrc.2011.01.111
   Li LM, 2011, CANCER RES, V71, P2022, DOI 10.1158/0008-5472.CAN-11-0110
   Li LM, 2010, CANCER RES, V70, P9798, DOI 10.1158/0008-5472.CAN-10-1001
   Li LH, 2012, DIGEST DIS SCI, V57, P2910, DOI 10.1007/s10620-012-2317-y
   Li M, 2009, WORLD J SURG, V33, P667, DOI 10.1007/s00268-008-9836-x
   Li N, 2009, CANCER LETT, V275, P44, DOI 10.1016/j.canlet.2008.09.035
   Li Q, 2010, J GASTROEN HEPATOL, V25, P164, DOI 10.1111/j.1440-1746.2009.05971.x
   Lin CJF, 2008, BIOCHEM BIOPH RES CO, V375, P315, DOI 10.1016/j.bbrc.2008.07.154
   Liu AM, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2012-000825
   Liu AM, 2010, BIOCHEM BIOPH RES CO, V394, P623, DOI 10.1016/j.bbrc.2010.03.036
   Liu WH, 2009, GASTROENTEROLOGY, V136, P683, DOI 10.1053/j.gastro.2008.10.029
   Liu Zhuo-ran, 2009, Nan Fang Yi Ke Da Xue Xue Bao, V29, P751
   Lou WJ, 2013, J MOL MED, V91, P715, DOI 10.1007/s00109-012-0985-x
   Lu CY, 2013, GENE CHROMOSOME CANC, V52, P636, DOI 10.1002/gcc.22059
   Marquez RT, 2010, LAB INVEST, V90, P1727, DOI 10.1038/labinvest.2010.126
   Meng FY, 2007, GASTROENTEROLOGY, V133, P647, DOI 10.1053/j.gastro.2007.05.022
   Moshiri Farzaneh, 2014, Gastroenterol Hepatol Bed Bench, V7, P43
   Park JK, 2011, CANCER RES, V71, P7608, DOI 10.1158/0008-5472.CAN-11-1144
   Petrini E, 2015, PANMINERVA MED, V57, P201
   Pineau P, 2010, P NATL ACAD SCI USA, V107, P264, DOI 10.1073/pnas.0907904107
   Qu KZ, 2011, J CLIN GASTROENTEROL, V45, P355, DOI 10.1097/MCG.0b013e3181f18ac2
   Rizzo S, 2010, CANCER TREAT REV, V36, pS56, DOI 10.1016/S0305-7372(10)70021-9
   Rong MH, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-21
   Russo A, 2013, CRIT REV ONCOL HEMAT, V86, P278, DOI 10.1016/j.critrevonc.2012.12.001
   Russo A, 2009, ONCOLOGY-BASEL, V77, P57, DOI 10.1159/000258497
   Santhekadur PK, 2012, J BIOL CHEM, V287, P13952, DOI 10.1074/jbc.M111.321646
   Shen J, 2015, GASTROENT RES PRACT, V2015, DOI 10.1155/2015/230642
   Shen QL, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-227
   Shigoka M, 2010, PATHOL INT, V60, P351, DOI 10.1111/j.1440-1827.2010.02526.x
   Siegel R, 2014, CA-CANCER J CLIN, V64, P9, DOI 10.3322/caac.21208
   Song JG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0110074
   Sun Z, 2013, MOL ONCOL, V7, P884, DOI 10.1016/j.molonc.2013.04.007
   Tan HX, 2010, MED ONCOL, V27, P654, DOI 10.1007/s12032-009-9264-2
   Thakral S, 2015, CURR GENE THER, V15, P142, DOI 10.2174/1566523214666141224095610
   Tomimaru Y, 2010, BRIT J CANCER, V103, P1617, DOI 10.1038/sj.bjc.6605958
   Tsai WC, 2012, J CLIN INVEST, V122, P2884, DOI 10.1172/JCI63455
   Tsai WC, 2009, HEPATOLOGY, V49, P1571, DOI 10.1002/hep.22806
   Tsang WP, 2010, J NUTR BIOCHEM, V21, P140, DOI 10.1016/j.jnutbio.2008.12.003
   Tu KS, 2014, INT J MOL SCI, V15, P20486, DOI 10.3390/ijms151120486
   Visone R, 2009, AM J PATHOL, V174, P1131, DOI 10.2353/ajpath.2009.080794
   Wang HW, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/864894
   Wang HJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038885
   Wang Y, 2008, J BIOL CHEM, V283, P13205, DOI 10.1074/jbc.M707629200
   Wang Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068744
   Wei W, 2012, ONCOL REP, V28, P701, DOI 10.3892/or.2012.1850
   Wei XF, 2013, CELL SIGNAL, V25, P1037, DOI 10.1016/j.cellsig.2013.01.019
   Wen Y, 2015, INT J CANCER, V137, P1679, DOI 10.1002/ijc.29544
   Wong QWL, 2008, GASTROENTEROLOGY, V135, P257, DOI 10.1053/j.gastro.2008.04.003
   Wong QWL, 2010, CLIN CANCER RES, V16, P867, DOI 10.1158/1078-0432.CCR-09-1840
   Wu CS, 2014, INT J CANCER, V134, P1638, DOI 10.1002/ijc.28501
   Wu G, 2011, BRIT J CANCER, V105, P146, DOI 10.1038/bjc.2011.190
   Xie Y, 2014, CANCER BIOL THER, V15, P1248, DOI 10.4161/cbt.29688
   Xu JA, 2011, MOL CARCINOGEN, V50, P136, DOI 10.1002/mc.20712
   Xu LB, 2014, J HEPATOL, V60, P590, DOI 10.1016/j.jhep.2013.10.028
   Xu T, 2009, HEPATOLOGY, V50, P113, DOI 10.1002/hep.22919
   Xu XS, 2015, ONCOTARGET, V6, P3988, DOI 10.18632/oncotarget.2905
   Xu YM, 2011, CANCER LETT, V310, P160, DOI 10.1016/j.canlet.2011.06.027
   Yamamoto Y, 2009, BIOMARKERS, V14, P529, DOI 10.3109/13547500903150771
   Yan H, 2013, PHARMACOLOGY, V92, P167, DOI 10.1159/000354585
   Yang PY, 2012, CANCER CELL, V22, P291, DOI 10.1016/j.ccr.2012.07.023
   Yang T, 2013, EXP BIOL MED, V238, P1024, DOI 10.1177/1535370213497321
   Yang XY, 2012, ONCOL REP, V27, P250, DOI 10.3892/or.2011.1472
   Yang Y, 2014, MOL MED REP, V10, P2643, DOI 10.3892/mmr.2014.2526
   Yang YF, 2014, INT J CLIN EXP MED, V7, P893
   Yin J, 2015, TUMOR BIOL, V36, P4501, DOI 10.1007/s13277-015-3092-0
   Young DD, 2010, J AM CHEM SOC, V132, P7976, DOI 10.1021/ja910275u
   Yu LX, 2014, CANCER EPIDEMIOL, V38, P408, DOI 10.1016/j.canep.2014.05.001
   Yuan QG, 2013, HEPATOLOGY, V57, P299, DOI 10.1002/hep.25984
   Zhao Wen-Yue, 2011, Zhonghua Gan Zang Bing Za Zhi, V19, P114, DOI 10.3760/cma.j.issn.1007-3418.2011.02.010
   Zheng CL, 2015, ONCOL REP, V33, P1115, DOI 10.3892/or.2015.3734
   Zheng F, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1004873
   Zhou CC, 2011, FEBS LETT, V585, P1828, DOI 10.1016/j.febslet.2011.04.040
   Zhu MF, 2011, EXP THER MED, V2, P27, DOI 10.3892/etm.2010.164
   Zhu Q, 2012, ONCOL REP, V27, P1660, DOI 10.3892/or.2012.1682
   Zhuang LP, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/731781
NR 128
TC 28
Z9 29
U1 0
U2 15
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD JAN
PY 2016
VL 97
BP 312
EP 321
DI 10.1016/j.critrevonc.2015.09.007
PG 10
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA DB8CI
UT WOS:000368744100029
PM 26603462
DA 2025-01-04
ER

PT J
AU Shida, D
   Boku, N
   Tanabe, T
   Yoshida, T
   Tsukamoto, S
   Takashima, A
   Kanemitsu, Y
AF Shida, Dai
   Boku, Narikazu
   Tanabe, Taro
   Yoshida, Takefumi
   Tsukamoto, Shunsuke
   Takashima, Atsuo
   Kanemitsu, Yukihide
TI Primary Tumor Resection for Stage IV Colorectal Cancer in the Era of
   Targeted Chemotherapy
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article
DE Unresectable colorectal cancer; Targeted therapy; Palliative resection;
   Stage IV; Propensity score
ID PROGNOSTIC IMPACT; SURVIVAL; SURGERY; MULTICENTER; METASTASIS; BENEFIT
AB BackgroundIn the current era of targeted therapies, the benefits of resection of primary tumors in patients with unresectable stage IV colorectal cancer, specifically with regard to overall survival, are unknown.MethodsOur study population comprised 208 consecutive patients with unresectable stage IV colorectal cancer who received chemotherapy containing at least one molecular target agent, bevacizumab, cetuximab, and panitumumab, at the National Cancer Center Hospital from 2006 to 2013. To lessen the effects of confounding factors between two treatment groups (resection versus non-resection) such as performance status, presence of severe symptoms, M subcategories (M1a versus M1b, M1c) according to the TNM classification, primary tumor site, and CEA value, we conducted three different propensity score analyses (regression adjustment, stratification, and matching).ResultsOf the 208 patients, 108 (52%) underwent resection of the primary tumor, while 100 (48%) did not. Regression adjustment revealed that resection was not associated with longer overall survival (hazard ratio of 0.70 (95% CI [0.49-1.00]; p=0.051)). Stratification analysis of five strata revealed inconsistent results (hazard ratios ranged from 0.50 to 1.58); specifically, resection was associated with longer overall survival in four strata, but with shorter survival in one stratum. The propensity score-matched cohort (64 matched pairs) yielded a hazard ratio of 0.76 (95% CI [0.51-1.15]; p=0.197).ConclusionsAll three analyses revealed that, in the current era of chemotherapy with target agents, primary tumor resection was only marginally influential and did not significantly improve overall survival over chemotherapy alone.
C1 [Shida, Dai; Tanabe, Taro; Yoshida, Takefumi; Tsukamoto, Shunsuke; Kanemitsu, Yukihide] Natl Canc Ctr, Colorectal Surg Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
   [Boku, Narikazu; Takashima, Atsuo] Natl Canc Ctr, Gastrointestinal Med Oncol Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
C3 National Cancer Center - Japan; National Cancer Center - Japan
RP Shida, D (corresponding author), Natl Canc Ctr, Colorectal Surg Div, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
EM dshida@ncc.go.jp
OI Shida, Dai/0000-0003-3294-1924
CR AJCC/UICC, 2017, TNM classification of malignant tumours, V8th
   Anwar S, 2012, COLORECTAL DIS, V14, P920, DOI 10.1111/j.1463-1318.2011.02817.x
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   D'Agostino RB, 2007, CIRCULATION, V115, P2340, DOI 10.1161/CIRCULATIONAHA.105.594952
   Eisenberger A, 2008, INT J COLORECTAL DIS, V23, P559, DOI 10.1007/s00384-008-0456-6
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Ferrand F, 2013, EUR J CANCER, V49, P90, DOI 10.1016/j.ejca.2012.07.006
   Franko J, 2016, LANCET ONCOL, V17, P1709, DOI 10.1016/S1470-2045(16)30500-9
   Gresham G, 2014, ANN SURG ONCOL, V21, P3917, DOI 10.1245/s10434-014-3797-0
   Hu CY, 2015, JAMA SURG, V150, P245, DOI 10.1001/jamasurg.2014.2253
   Ishihara S, 2014, ANN SURG ONCOL, V21, P2949, DOI 10.1245/s10434-014-3719-1
   Lam-Boer J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-741
   Loupakis F, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/dju427
   Shida D, 2018, ANN SURG ONCOL, V25, P1646, DOI 10.1245/s10434-018-6436-3
   Shida D, 2018, ANN SURG ONCOL, V25, P173, DOI 10.1245/s10434-017-6133-7
   Shida D, 2016, ANN SURG ONCOL, V23, P3602, DOI 10.1245/s10434-016-5299-8
   Stillwell AP, 2010, WORLD J SURG, V34, P797, DOI 10.1007/s00268-009-0366-y
   Tarantino I, 2015, ANN SURG, V262, P112, DOI 10.1097/SLA.0000000000000860
   Tebbutt NC, 2003, GUT, V52, P568, DOI 10.1136/gut.52.4.568
   Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797
   Watanabe T, 2018, INT J CLIN ONCOL, V23, P1, DOI 10.1007/s10147-017-1101-6
   Zhu JY, 2012, JAMA-J AM MED ASSOC, V307, P1593, DOI 10.1001/jama.2012.454
NR 22
TC 15
Z9 15
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
EI 1873-4626
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD NOV
PY 2019
VL 23
IS 11
BP 2144
EP 2150
DI 10.1007/s11605-018-4044-y
PG 7
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA JK2PO
UT WOS:000494689100003
PM 30484063
DA 2025-01-04
ER

PT J
AU Bahrami, A
   Hesari, A
   Khazaei, M
   Hassanian, SM
   Ferns, GA
   Avan, A
AF Bahrami, Afsane
   Hesari, AmirReza
   Khazaei, Majid
   Hassanian, Seyed Mahdi
   Ferns, Gordon A.
   Avan, Amir
TI The therapeutic potential of targeting the BRAF mutation in patients
   with colorectal cancer
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Review
DE BRAF mutation; colorectal cancer; RAS/RAF/MEK/ERK pathway; target
   therapy
ID ISLAND METHYLATOR PHENOTYPE; DOSE-ESCALATION TRIAL; COLON-CANCER;
   ACQUIRED-RESISTANCE; RAF INHIBITION; V600E MUTATION; VEMURAFENIB;
   BRAF(V600E); MELANOMA; KINASE
AB Colorectal cancer is among the most lethal malignancies globally. BRAF is a member of the RAS/RAF/MEK/ERK signaling pathway. Its constitutive activation can result in increased cellular growth, development, invasion, and resistance to therapy. A mutation of the BRAF gene is present in 5-10% of metastatic colorectal cancers. BRAF mutations have been found to predict a lack of benefit to anti-EGFR therapy in metastatic CRC. Furthermore, CRC containing the BRAF V600E mutation display an innate resistance to BRAF inhibitors. The mechanisms of cell resistance can be explained at least in part by ERK dependent and ERK in-dependent pathway. Clinical trials evaluating the combinations of BRAF, PI3K, EGFR, and/or MEK inhibitors have revealed promising activity in BRAF mutant containing CRCs. There may be some benefit from future studies that focus on improving the efficacy of combined therapy in CRC with respect to the sustained effects. The aim of current review is to give an overview about the current status and prospective regarding the therapeutic potential of targeting BRAF mutant colorectal cancer.
C1 [Bahrami, Afsane] Mashhad Univ Med Sci, Fac Med, Dept Modern Sci & Technol, Mashhad, Iran.
   [Bahrami, Afsane] Mashhad Univ Med Sci, Fac Med, Student Res Comm, Mashhad, Iran.
   [Hesari, AmirReza] Islamic Azad Univ, Damghan Branch, Dept Biol, Damghan, Iran.
   [Khazaei, Majid] Mashhad Univ Med Sci, Fac Med, Dept Physiol, Mashhad, Iran.
   [Hassanian, Seyed Mahdi; Avan, Amir] Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran.
   [Hassanian, Seyed Mahdi] Mashhad Univ Med Sci, Fac Med, Dept Med Biochem, Mashhad, Iran.
   [Ferns, Gordon A.] Brighton & Sussex Med Sch, Div Med Educ, Brighton, E Sussex, England.
   [Avan, Amir] Mashhad Univ Med Sci, Canc Res Ctr, Mashhad, Iran.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; Islamic Azad University; Mashhad University of Medical
   Sciences; Mashhad University of Medical Sciences; Mashhad University of
   Medical Sciences; University of Brighton; University of Sussex; Mashhad
   University of Medical Sciences
RP Avan, A (corresponding author), Mashhad Univ Med Sci, Metab Syndrome Res Ctr, Mashhad, Iran.
EM avana@mums.ac.ir
RI shahidsales, soudabe/AAY-2920-2020; bahrami, afsaneh/Q-3369-2018;
   Hassanian, Seyed Mahdi/KAL-9917-2024; Khazaei, Majid/A-6143-2018
OI naseri, shahrokh/0000-0001-8974-2120; Khazaei,
   Majid/0000-0002-7979-5699; Bahrami, Afsane/0000-0002-4563-6112
FU National Institute for Medical research Development [958349]; Mashhad
   University of Medical Sciences
FX National Institute for Medical research Development, Grant number:
   958349; Mashhad University of Medical Sciences
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   [Anonymous], J CLIN ONCOLOGY S
   ATREYA CE, 2015, J CLIN ONCOLOGY S, V33
   Bahrami A., 2017, J CELLULAR PHYSL, DOI [10.1002/jcp.25897, DOI 10.1002/JCP.25897]
   Bahrami A., 2017, J CELL BIOCHEM, DOI [10.1002/jcp.25950, DOI 10.1002/JCP.25950]
   Bahrami A, 2018, J CELL PHYSIOL, V233, P2058, DOI 10.1002/jcp.25890
   Bahrami A, 2018, J CELL PHYSIOL, V233, P2193, DOI 10.1002/jcp.25966
   Bahrami A, 2017, J CELL PHYSIOL, V232, P2657, DOI 10.1002/jcp.25794
   Benson AB III, 2013, J NATL COMPR CANC NE, V11, P519, DOI 10.6004/jnccn.2013.0069
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Coffee EM, 2013, CLIN CANCER RES, V19, P2688, DOI 10.1158/1078-0432.CCR-12-2556
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Corcoran RB, 2011, ONCOTARGET, V2, P336
   Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Donehower LA, 2013, J PATHOL, V229, P99, DOI 10.1002/path.4087
   Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Girotti MR, 2015, CANCER CELL, V27, P85, DOI 10.1016/j.ccell.2014.11.006
   Han SW, 2013, INT J CANCER, V132, P2209, DOI 10.1002/ijc.27888
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Hoeflich KP, 2009, CANCER RES, V69, P3042, DOI 10.1158/0008-5472.CAN-08-3563
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Iacopetta B, 2008, INT J CLIN ONCOL, V13, P498, DOI 10.1007/s10147-008-0854-3
   Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X
   Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627
   Jover R, 2011, GASTROENTEROLOGY, V140, P1174, DOI 10.1053/j.gastro.2010.12.035
   Juo YY, 2014, ANN ONCOL, V25, P2314, DOI 10.1093/annonc/mdu149
   Kim JY, 2013, J KOREAN SURG SOC, V85, P154, DOI 10.4174/jkss.2013.85.4.154
   Kopetz S., 2015, J CLIN ONCOLOGY S3, V33
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392
   Lo RS, 2012, CELL RES, V22, P945, DOI 10.1038/cr.2012.78
   Loupakis F, 2014, EUR J CANCER, V50, P57, DOI 10.1016/j.ejca.2013.08.024
   Martinelli E, 2010, CLIN CANCER RES, V16, P4990, DOI 10.1158/1078-0432.CCR-10-0923
   Masi G, 2010, LANCET ONCOL, V11, P845, DOI 10.1016/S1470-2045(10)70175-3
   Min BH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-344
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Paraiso KHT, 2011, CANCER RES, V71, P2750, DOI 10.1158/0008-5472.CAN-10-2954
   Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297
   Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Rad R, 2013, CANCER CELL, V24, P15, DOI 10.1016/j.ccr.2013.05.014
   Rahmani F, 2018, J CELL PHYSIOL, V233, P811, DOI 10.1002/jcp.25897
   Romano E, 2013, CLIN CANCER RES, V19, P5749, DOI 10.1158/1078-0432.CCR-13-0661
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Saridaki Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084604
   Schellens JHM, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-CT136
   Shiovitz S, 2014, GASTROENTEROLOGY, V147, P637, DOI 10.1053/j.gastro.2014.05.009
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Tabernero J., 2014, J CLIN ONCOLOGY S, V32
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Tsai J, 2008, P NATL ACAD SCI USA, V105, P3041, DOI 10.1073/pnas.0711741105
   Vatandoost N, 2016, J CANCER RES CLIN, V142, P341, DOI 10.1007/s00432-015-1928-z
   Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023
   Wang YW, 2014, GASTROENT RES PRACT, V2014, DOI 10.1155/2014/418148
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
NR 65
TC 45
Z9 45
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAR
PY 2018
VL 233
IS 3
BP 2162
EP 2169
DI 10.1002/jcp.25952
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA GH5ZZ
UT WOS:000433519300034
PM 28407239
DA 2025-01-04
ER

PT J
AU Zarghampoor, F
   Valibeigi, B
   Behzad-Behbahani, A
AF Zarghampoor, Farzaneh
   Valibeigi, Behnaz
   Behzad-Behbahani, Abbas
TI The molecular characteristics of colorectal cancer: Impact of Ibuprofen
   and hyperthermia
SO MOLECULAR BIOLOGY RESEARCH COMMUNICATIONS
LA English
DT Article
DE Colorectal cancer; Hyperthermia; HT29 Cells; Ibuprofen; Wnt Signaling
   Pathway
ID NONSTEROIDAL ANTIINFLAMMATORY DRUGS; KLF4 EXPRESSION; APOPTOSIS; RISK;
   RESISTANCE; CELLS
AB Despite various treatment options available for colorectal cancer, the survival rates for patients remain low. This study investigated the effects of hyperthermia and Ibuprofen on human colorectal adenocarcinoma cells (HT-29) viability, proliferation, and gene expression related to tumor suppression, Wnt signaling pathways, proliferation, and apoptosis The cells were exposed to hyperthermia at 42 or 43 degrees C for 3 hours or Ibuprofen at different concentrations (700-1500 mu M), and the effects were analyzed through MTT assay, trypan blue staining, and quantitative Real-time PCR. The study used quantitative Real-time PCR (qRT-PCR) to evaluate the effect of hyperthermia and Ibuprofen on the expression of various genes associated with tumor suppression, proliferation, Wnt signaling pathway, and apoptosis. The results revealed that hyperthermia caused a minor reduction in the viability and proliferation of HT-29 cells, but the decrease was not statistically significant (P<0.05). On the other hand, Ibuprofen caused a concentration-dependent decrease in the viability and proliferation of HT-29 cells. Both hyperthermia and Ibuprofen reduced the expression of WNT1, CTNNB1, BCL2, and PCNA genes, and increased the expression of KLF4, P53, and BAX genes. However, the changes in gene expression were not statistically significant in cells treated with hyperthermia. The findings suggest that Ibuprofen is more effective in reducing cancer cell proliferation by promoting apoptosis and inhibiting the Wnt signaling pathway than hyperthermia, which had some impact but was not statistically significant. The study highlights the potential of Ibuprofen as a targeted therapy for colorectal cancer.
C1 [Zarghampoor, Farzaneh; Behzad-Behbahani, Abbas] Shiraz Univ Med Sci, Sch Paramed Sci, Diagnost Lab Sci, Shiraz, Iran.
   [Zarghampoor, Farzaneh; Behzad-Behbahani, Abbas] Shiraz Univ Med Sci, Technol Res Ctr, Sch Paramed Sci, Shiraz, Iran.
   [Valibeigi, Behnaz] Islamic Azad Univ, Dept Biol, Marvdasht Branch, Marvdasht, Iran.
C3 Shiraz University of Medical Science; Shiraz University of Medical
   Science; Islamic Azad University
RP Zarghampoor, F; Behzad-Behbahani, A (corresponding author), Shiraz Univ Med Sci, Sch Paramed Sci, Diagnost Lab Sci, Shiraz, Iran.; Zarghampoor, F; Behzad-Behbahani, A (corresponding author), Shiraz Univ Med Sci, Technol Res Ctr, Sch Paramed Sci, Shiraz, Iran.
EM behzadba@sums.ac.ir
RI Behzad-Behbahani, Abbas/Q-6128-2017
OI Zarghampoor, Farzaneh/0000-0002-7266-8312
FU Department of Biology, Marvdasht Branch, Islamic Azad University,
   Marvdasht, Iran; Department of Medical Physics, School of Medicine,
   Shiraz University of Medical Sciences, Shiraz, Iran
FX The present article was extracted from a Ph.D. thesis and supported by
   the Department of Biology, Marvdasht Branch, Islamic Azad University,
   Marvdasht, Iran, and Department of Medical Physics, School of Medicine,
   Shiraz University of Medical Sciences, Shiraz, Iran. The study team
   would like to gratefully acknowledge the staff of these centers for
   their sincere cooperation.
CR Abbas Z., 2018, Neoplasm, V1, P139, DOI 10.5772/intechopen.76558
   Bonelli P, 2011, PHARMACOGENOMICS J, V11, P412, DOI 10.1038/tpj.2010.55
   BUSSON M, 1986, J INT MED RES, V14, P53, DOI 10.1177/030006058601400201
   Cheng XF, 2019, BIOMED PHARMACOTHER, V110, P473, DOI 10.1016/j.biopha.2018.11.082
   Cheraghzadeh M, 2018, HLTH BIOTECH BIOPHAR, V2, P56
   Cherukuri P, 2010, ADV DRUG DELIVER REV, V62, P339, DOI 10.1016/j.addr.2009.11.006
   Datta NR, 2015, CANCER TREAT REV, V41, P742, DOI 10.1016/j.ctrv.2015.05.009
   Doat S, 2017, CANCER MED-US, V6, P2461, DOI 10.1002/cam4.1186
   Douaiher J, 2017, J SURG ONCOL, V115, P619, DOI 10.1002/jso.24578
   Elming PB, 2019, CANCERS, V11, DOI 10.3390/cancers11010060
   Friis S, 2015, ANN INTERN MED, V163, P347, DOI 10.7326/M15-0039
   Ghanbarei S, 2021, BIOTECHNOL LETT, V43, P1659, DOI 10.1007/s10529-021-03134-w
   Gottesman MM, 2002, NAT REV CANCER, V2, P48, DOI 10.1038/nrc706
   Gunaydin C, 2018, EURASIAN J MED, V50, P116, DOI 10.5152/eurasianjmed.2018.0010
   Hamoya T, 2016, GENES ENVIRON, V38, DOI 10.1186/s41021-016-0033-0
   Harris RE, 2003, CANCER RES, V63, P6096
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Jacopin E, 2020, J R SOC INTERFACE, V17, DOI 10.1098/rsif.2020.0105
   Jaktaji RP, 2017, IRAN J PHARM RES, V16, P1185
   Johnson CM, 2013, CANCER CAUSE CONTROL, V24, P1207, DOI 10.1007/s10552-013-0201-5
   Krstic M, 2013, J BUON, V18, P695
   Leksomboon R, 2022, J TAIBAH UNIV MED SC, V17, P869, DOI 10.1016/j.jtumed.2022.02.012
   Li ZD, 2010, CELL STRESS CHAPERON, V15, P905, DOI 10.1007/s12192-010-0199-5
   Ma YZ, 2017, ONCOL REP, V38, P975, DOI 10.3892/or.2017.5736
   Milleron RS, 2007, CELL MOL LIFE SCI, V64, P2329, DOI 10.1007/s00018-007-7135-6
   Munteanu I, 2014, J Med Life, V7, P507
   Oei AL, 2020, ADV DRUG DELIVER REV, V163, P84, DOI 10.1016/j.addr.2020.01.003
   Rowland BD, 2005, NAT CELL BIOL, V7, P1074, DOI 10.1038/ncb1314
   Sawicki T, 2021, CANCERS, V13, DOI 10.3390/cancers13092025
   Shi J, 2017, ONCOTARGET, V8, P99066, DOI 10.18632/oncotarget.21524
   Shie JL, 2000, NUCLEIC ACIDS RES, V28, P2969, DOI 10.1093/nar/28.15.2969
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Tetreault MP, 2013, NAT REV CANCER, V13, P701, DOI 10.1038/nrc3582
   Thun MJ, 2002, JNCI-J NATL CANCER I, V94, P252, DOI 10.1093/jnci/94.4.252
   Trabert B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt431
   Upadhyay A, 2016, MOL NEUROBIOL, V53, P6968, DOI 10.1007/s12035-015-9603-6
   Wang BJ, 2017, BIOCHEM BIOPH RES CO, V484, P486, DOI 10.1016/j.bbrc.2017.01.062
   Wong RSY, 2019, ADV PHARMACOL SCI, V2019, DOI 10.1155/2019/3418975
   Yuan SL, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/9390878
   Zhang W, 2006, MOL CELL BIOL, V26, P2055, DOI 10.1128/MCB.26.6.2055-2064.2006
   Zhong Z, 2020, MOL PHARMACOL, V97, P72, DOI 10.1124/mol.119.117978
   Zhou XM, 2001, CARCINOGENESIS, V22, P1393, DOI 10.1093/carcin/22.9.1393
NR 42
TC 3
Z9 3
U1 0
U2 1
PU SHIRAZ UNIV
PI SHIRAZ
PA SCHOOL VETERINARY MEDICINE, SHIRAZ, 71344, IRAN
SN 2322-181X
EI 2345-2005
J9 MOL BIOL RES COMMUN
JI Mol. Biol. Res. Commun.
PD MAR
PY 2023
VL 12
IS 1
BP 17
EP 25
DI 10.22099/mbrc.2023.45296.1802
PG 9
WC Biochemistry & Molecular Biology
WE Emerging Sources Citation Index (ESCI)
SC Biochemistry & Molecular Biology
GA G0LE8
UT WOS:000986163500002
PM 37201032
DA 2025-01-04
ER

PT J
AU Gong, L
   Yang, SX
   Huang, JL
   Li, YS
AF Gong, Li
   Yang, Shixue
   Huang, Junli
   Li, Yongsheng
TI Modulation of gut microbiota in targeted cancer therapy: insights on the
   EGFR/VEGF/KRAS pathways
SO CANCER BIOLOGY & MEDICINE
LA English
DT Review; Early Access
DE Gut microbiota; metabolites; targeted therapy; tumorigenesis pathway;
   EGFR; VEGF; KRAS
ID ENDOTHELIAL GROWTH-FACTOR; RENAL-CELL CARCINOMA; COLON-CANCER;
   METABOLISM; LIPOPOLYSACCHARIDE; ANGIOGENESIS; CHEMOTHERAPY; AUTOPHAGY;
   PROTEINS; BUTYRATE
AB The rise in the incidence of cancer globally has led to a heightened interest in targeted therapies as a form of anticancer treatment. Key oncogenic targets, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and kirsten rat sarcoma viral oncogene homologue (KRAS), have emerged as focal points in the development of targeted agents. Research has investigated the impact of gut microbiota on the efficacy of various anticancer therapies, such as immunotherapy, chemotherapy, and radiotherapy. However, anotablegap exists in the literature regardingthe relationship between gut microbiota and targeted agents. This review emphasizes how specific gut microbiota and gut microbiota metabolites, including butyrate, propionate, and ursodeoxycholic acid, interact with oncogenic pathways to modulate anti-tumor effects. Conversely, deoxycholic acid, lipopolysaccharide, and trimethylamine n-oxide may exert pro-tumor effects. Furthermore, modulation of the gut microbiota influences glucose and lipid metabolism, thereby enhancing the response to anti-KRAS agents and addressing diarrhea induced by tyrosine kinase inhibitors. By elucidating the connection between gut microbiota and the EGFR/VEGF/KRAS pathways, this review provides valuable insights for advancing targeted cancer therapy and optimizing treatment outcomes in clinical settings.
C1 [Gong, Li; Li, Yongsheng] Chongqing Univ, Canc Hosp, Dept Phase Clin Trial Ward 1, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing 400030, Peoples R China.
   [Gong, Li; Huang, Junli] Chongqing Univ, Bioengn Coll, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400044, Peoples R China.
   [Yang, Shixue] Chongqing Univ, Dept Med Oncol, Chongqing Key Lab Translat Res Canc Metastasis & I, Canc Hosp, Chongqing 400030, Peoples R China.
C3 Chongqing University; Chongqing University; Chongqing University
RP Li, YS (corresponding author), Chongqing Univ, Canc Hosp, Dept Phase Clin Trial Ward 1, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing 400030, Peoples R China.; Huang, JL (corresponding author), Chongqing Univ, Bioengn Coll, Key Lab Biorheol Sci & Technol, Minist Educ, Chongqing 400044, Peoples R China.
EM huangjunli@cqu.edu.cn; lys@cqu.edu.cn
RI SHIXUE, YANG/KQU-8434-2024
OI Li, Yongsheng/0000-0003-2175-9449
FU Major International (Regional) Joint Research Program of the National
   Natural Science Foundation of China [81920108027]; National Outstanding
   Youth Reserve Talent Training Project, Research Capacity Enhancement
   Project of Chongqing University Cancer Hospital [Y121]; Funding for
   Chongqing Young and Middle-Aged Medical Excellence Team
FX This work was supported by the Major International (Regional) Joint
   Research Program of the National Natural Science Foundation of China
   (Grant No. 81920108027) , National Outstanding Youth Reserve Talent
   Training Project, Research Capacity Enhancement Project of Chongqing
   University Cancer Hospital (Grant No. Y121) , and Funding for Chongqing
   Young and Middle-Aged Medical Excellence Team.
CR Abdullah ST, 2024, NON-CODING RNA RES, V9, P236, DOI 10.1016/j.ncrna.2023.12.002
   Alexander JL, 2017, NAT REV GASTRO HEPAT, V14, P356, DOI 10.1038/nrgastro.2017.20
   Belcheva A, 2015, BIOESSAYS, V37, P403, DOI 10.1002/bies.201400204
   Borrego-Ruiz A, 2024, PROG NEURO-PSYCHOPH, V128, DOI 10.1016/j.pnpbp.2023.110861
   Brown JM, 2003, J LIPID RES, V44, P1287, DOI 10.1194/jlr.M300001-JLR200
   Budden KF, 2017, NAT REV MICROBIOL, V15, P55, DOI 10.1038/nrmicro.2016.142
   Burnat G, 2007, SCAND J GASTROENTERO, V42, P1460, DOI 10.1080/00365520701452209
   Canani RB, 2011, WORLD J GASTROENTERO, V17, P1519, DOI [10.3748/wjg.v17.i12. 1519, 10.3748/wjg.v17.i12.1519]
   Chen JW, 2024, P NATL ACAD SCI USA, V121, DOI 10.1073/pnas.2306776121
   Chrysostomou D, 2023, GASTROENTEROLOGY, V164, P198, DOI 10.1053/j.gastro.2022.10.018
   Chung SY, 2005, J LIPID RES, V46, P885, DOI 10.1194/jlr.M400476-JLR200
   Cicuéndez B, 2020, MOL METAB, V50, DOI 10.1016/j.molmet.2021.101190
   Dai MQ, 2021, PHYTOMEDICINE, V87, DOI 10.1016/j.phymed.2021.153580
   de Vos WM, 2022, GUT, V71, P1020, DOI 10.1136/gutjnl-2021-326789
   de Waal GM, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65324-2
   Deng Handan, 2022, Sheng Wu Gong Cheng Xue Bao, V38, P2105, DOI 10.13345/j.cjb.210711
   Dizman N, 2021, CANCER MED-US, V10, P79, DOI 10.1002/cam4.3569
   Druart C, 2013, BRIT J NUTR, V110, P998, DOI 10.1017/S0007114513000123
   Fernández MF, 2018, INT J ENV RES PUB HE, V15, DOI 10.3390/ijerph15081747
   Ferrín G, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21041266
   Fiorucci S, 2022, TRENDS MOL MED, V28, P51, DOI 10.1016/j.molmed.2021.10.005
   Gagnière J, 2016, WORLD J GASTROENTERO, V22, P501, DOI 10.3748/wjg.v22.i2.501
   Gao P, 2023, ANN HEPATOL, V28, DOI 10.1016/j.aohep.2023.101124
   Guo Q, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392-024-01757-9
   Guo W, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02557-5
   Gupta Arjun, 2017, JAMA, V318, P102, DOI 10.1001/jama.2017.6466
   Gwang-woong G, 2013, J MICROBIOL BIOTECHN, V23, P1569, DOI 10.4014/jmb.1308.08008
   Hahn AW, 2018, CLIN GENITOURIN CANC, V16, P365, DOI 10.1016/j.clgc.2018.05.001
   Hsiao YP, 2021, NUTRIENTS, V13, DOI 10.3390/nu13082792
   Hu CP, 2023, HEPATOLOGY, V77, P48, DOI 10.1002/hep.32449
   Huang JY, 2022, EBIOMEDICINE, V83, DOI 10.1016/j.ebiom.2022.104197
   Ianiro G, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18127-y
   Im E, 2004, J NUTR, V134, P483, DOI 10.1093/jn/134.2.483
   Jia W, 2018, NAT REV GASTRO HEPAT, V15, P111, DOI 10.1038/nrgastro.2017.119
   Ke X., 2017, Frontiers in Laboratory Medicine, V1, P69
   Kim EJ, 2002, AM J PHYSIOL-GASTR L, V283, pG357, DOI 10.1152/ajpgi.00495.2001
   Kovatcheva-Datchary P, 2015, CELL METAB, V22, P971, DOI 10.1016/j.cmet.2015.10.001
   Lee J, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13568
   Lee J, 2021, MOL BIOL REP, V48, P6231, DOI 10.1007/s11033-021-06331-y
   Lehouritis P, 2015, SCI REP-UK, V5, DOI 10.1038/srep14554
   Leigh SJ, 2022, EXPERT OPIN DRUG MET, V18, P5, DOI 10.1080/17425255.2022.2043849
   Lin H, 2019, J AGR FOOD CHEM, V67, P3624, DOI 10.1021/acs.jafc.9b00249
   Liu XY, 2024, NEURAL REGEN RES, V19, P833, DOI 10.4103/1673-5374.382223
   Liu XJ, 2023, BIOORG CHEM, V133, DOI 10.1016/j.bioorg.2023.106425
   Lu JW, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10010095
   Lu JW, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9080974
   Lu Y, 2017, ACTA BIOCH BIOPH SIN, V49, P1029, DOI 10.1093/abbs/gmx100
   Massoumi RL, 2021, PANCREAS, V50, P524, DOI 10.1097/MPA.0000000000001790
   Mizukami Y, 2006, J BIOL CHEM, V281, P13957, DOI 10.1074/jbc.M511763200
   Montoya S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9111591
   Natividad JMM, 2013, PHARMACOL RES, V69, P42, DOI 10.1016/j.phrs.2012.10.007
   Noureldein MH, 2018, MICROB PATHOGENESIS, V118, P98, DOI 10.1016/j.micpath.2018.03.021
   Pal SK, 2015, CLIN CANCER RES, V21, P5286, DOI 10.1158/1078-0432.CCR-15-0724
   Pant K, 2017, CHEM-BIOL INTERACT, V273, P99, DOI 10.1016/j.cbi.2017.06.001
   Park EM, 2022, NAT MED, V28, P690, DOI 10.1038/s41591-022-01779-2
   Patel SA, 2023, CLIN CANCER RES, V29, P30, DOI 10.1158/1078-0432.CCR-22-1366
   Qu RZ, 2023, ADV SCI, V10, DOI 10.1002/advs.202205563
   Saifon W, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-10050-3
   Salmerón AM, 2024, TOXICOLOGY, V506, DOI 10.1016/j.tox.2024.153871
   Secombe KR, 2022, NEOPLASIA, V30, DOI 10.1016/j.neo.2022.100806
   Selle K, 2020, MBIO, V11, DOI 10.1128/mBio.00019-20
   Serfaty L, 2010, GASTROEN CLIN BIOL, V34, P516, DOI 10.1016/j.gcb.2010.05.005
   Shen YY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-31141-6
   Silveira MAD, 2022, TRENDS CANCER, V8, P583, DOI 10.1016/j.trecan.2022.02.009
   Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009
   Su ZM, 2021, CANCER MANAG RES, V13, P8663, DOI 10.2147/CMAR.S328451
   Tang Y, 2011, CELL DEATH DIFFER, V18, P602, DOI 10.1038/cdd.2010.117
   Ternet C, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-021-00712-3
   Thursby E, 2017, BIOCHEM J, V474, P1823, DOI 10.1042/BCJ20160510
   Tinsley N, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100430
   Uribe ML, 2021, CANCERS, V13, DOI 10.3390/cancers13112748
   Diéguez MCV, 2015, LWT-FOOD SCI TECHNOL, V61, P70, DOI 10.1016/j.lwt.2014.11.017
   Wang H, 2022, CELL METAB, V34, P581, DOI 10.1016/j.cmet.2022.02.010
   Wang JP, 2024, ONCOGENE, V43, P1386, DOI 10.1038/s41388-024-03003-6
   Wang TT, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01235
   Wang Z, 2019, BBA-MOL CELL RES, V1866, P566, DOI 10.1016/j.bbamcr.2018.11.016
   Wei J, 2024, J ETHNOPHARMACOL, V318, DOI 10.1016/j.jep.2023.116866
   Wong CC, 2023, NAT REV CLIN ONCOL, V20, P429, DOI 10.1038/s41571-023-00766-x
   Xie JD, 2024, IMETA, V3, DOI 10.1002/imt2.156
   Xie TT, 2019, LAB INVEST, V99, P625, DOI 10.1038/s41374-018-0160-2
   Yang SY, 2022, J IMMUNOL RES, V2022, DOI 10.1155/2022/7043856
   Yin BB, 2022, FRONT MICROBIOL, V13, DOI 10.3389/fmicb.2022.899111
   Yu DCW, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-27
   Yu DCW, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-276
   Yu MR, 2020, CANCERS, V12, DOI 10.3390/cancers12102728
   Yun JY, 2009, SCIENCE, V325, P1555, DOI 10.1126/science.1174229
   Zhang WQ, 2018, AM J TRANSL RES, V10, P3171
   Zhong L, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00572-w
   Zhu GW, 2016, CELL PHYSIOL BIOCHEM, V39, P1665, DOI 10.1159/000447868
   Zou SM, 2018, GASTROENTEROL REP, V6, P1, DOI 10.1093/gastro/gox031
NR 90
TC 0
Z9 0
U1 3
U2 3
PU CHINA ANTI-CANCER ASSOC
PI TIANJIN
PA TIANJIN MEDICAL UNIV, CANCER INST & HOSPITAL  TI-YUAN-BEI, HUANHU XI LU,
   HEXIQU, TIANJIN, 300060, PEOPLES R CHINA
SN 2095-3941
J9 CANCER BIOL MED
JI Cancer Biol. Med.
PD 2024 NOV 25
PY 2024
DI 10.20892/j.issn.2095-3941.2024.0320
EA NOV 2024
PG 15
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA N2T4E
UT WOS:001362920900001
PM 39593276
OA gold
DA 2025-01-04
ER

PT J
AU Zafari, V
   Hashemzadeh, S
   Feizi, MH
   Pouladi, N
   Zadeh, LR
   Sakhinia, E
AF Zafari, Venus
   Hashemzadeh, Shahryar
   Feizi, Mohammadali Hosseinpour
   Pouladi, Nasser
   Zadeh, Leila Rostami
   Sakhinia, Ebrahim
TI mRNA expression of nuclear factor of activated T-cells, cytoplasmic 2
   (NFATc2) and peroxisome proliferator-activated receptor gamma (PPARG)
   transcription factors in colorectal carcinoma
SO BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE NFATc2; PPARG; colorectal cancer; gene expression; biomarker; CRC;
   targeted therapy
ID BETA-CATENIN; GENE-EXPRESSION; WNT PATHWAY; CANCER; CALCINEURIN;
   MUTATIONS; INVASION; LIGANDS; GROWTH; DELTA
AB Transcription factors are involved in cell cycle and apoptosis regulation and thus have a key role in the carcinogenesis of different tumors. Nuclear factor of activated T-cells, cytoplasmic 2 (NFATc2) and peroxisome proliferator-activated receptor gamma (PPARG) transcription factors are important in the carcinogenesis of colorectal cancer (CRC). In this study, we examined whether the expression of NFATc2 and PPARG genes is significantly altered during the carcinogenesis of CRC. A total of 47 tumor samples and matched normal tissue margins were collected during surgery from patients with CRC. In addition, three CRC cell lines (HCT119, SW480, and HT29) and healthy cell line were used. After total RNA extraction and cDNA synthesis, mRNA expression levels of NFATc2 and PPARG were examined by real-time polymerase chain reaction. The results showed that NFATc2 is overexpressed in the tumor tissues compared with normal tissue margins (p = 0.05). However, the mRNA expression levels of PPARG were not significantly different between the tumor tissues and tissue margins. Our results indicate that NFATc2 may be used as an early diagnostic or predictive biomarker for CRC as well as a therapeutic target, providing that upcoming studies confirm these results. S
C1 [Zafari, Venus; Zadeh, Leila Rostami; Sakhinia, Ebrahim] Tabriz Univ Med Sci, Fac Med, Div Med Genet, Dept Biochem & Clin Labs, Tabriz, Iran.
   [Zafari, Venus; Hashemzadeh, Shahryar; Sakhinia, Ebrahim] Tabriz Univ Med Sci, TB & Lung Dis Res Ctr, Tabriz, Iran.
   [Hashemzadeh, Shahryar] Tabriz Univ Med Sci, General & Vasc Surg Dept, Tabriz, Iran.
   [Feizi, Mohammadali Hosseinpour] Univ Tabriz, Dept Anim Biol, Tabriz, Iran.
   [Pouladi, Nasser] Azarbaijan Shahid Madani Univ, Dept Biol, Tabriz, Iran.
   [Sakhinia, Ebrahim] Tabriz Univ Med Sci, TGAC, Tabriz, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science; University of Tabriz;
   Azarbaijan Shahid Madani University; Tabriz University of Medical
   Science
RP Sakhinia, E (corresponding author), Tabriz Univ Med Sci, Fac Med, Tabriz Genet Anal Ctr, Dept Biochem & Clin Labs,Div Med Genet, Golgasht St, Tabriz 516615731, Iran.
EM ebrahim666saxi@gmail.com
RI Pouladi, Nasser/AAP-4036-2021; sakhinia, ebrahim/AAA-8636-2021
OI Pouladi, Nasser/0000-0001-8125-5352
CR Adesina AM, 2009, HUM PATHOL, V40, P843, DOI 10.1016/j.humpath.2008.10.022
   Baumgart S, 2012, GASTROENTEROLOGY, V142
   Buchholz M, 2006, EMBO J, V25, P3714, DOI 10.1038/sj.emboj.7601246
   Chen LC, 2004, CANCER RES, V64, P3694, DOI 10.1158/0008-5472.CAN-03-3264
   CLIPSTONE NA, 1992, NATURE, V357, P695, DOI 10.1038/357695a0
   Dai Y, 2009, CANCER RES, V69, P4776, DOI 10.1158/0008-5472.CAN-08-4754
   Daniel C, 2014, INT J CANCER, V134, P1767, DOI 10.1002/ijc.28329
   de La Coste A, 1998, P NATL ACAD SCI USA, V95, P8847
   Duque J, 2005, J BIOL CHEM, V280, P8686, DOI 10.1074/jbc.M413076200
   Fajas L, 1997, J BIOL CHEM, V272, P18779, DOI 10.1074/jbc.272.30.18779
   Gerlach K, 2012, CANCER RES, V72, P4340, DOI 10.1158/0008-5472.CAN-11-4155
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hashemzadeh S, 2014, MED ONCOL, V31, P1
   Houseknecht KL, 2002, DOMEST ANIM ENDOCRIN, V22, P1, DOI 10.1016/S0739-7240(01)00117-5
   Jauliac S, 2002, NAT CELL BIOL, V4, P540, DOI 10.1038/ncb816
   Kim MS, 2009, HUM PATHOL, V40, P58, DOI 10.1016/j.humpath.2008.06.006
   Köenig A, 2010, GASTROENTEROLOGY, V138, P1189, DOI 10.1053/j.gastro.2009.10.045
   Koesters R, 1999, CANCER RES, V59, P3880
   Lehrke M, 2005, CELL, V123, P993, DOI 10.1016/j.cell.2005.11.026
   Macian F, 2005, NAT REV IMMUNOL, V5, P472, DOI 10.1038/nri1632
   Martín V, 2010, CANCER SCI, V101, P425, DOI 10.1111/j.1349-7006.2009.01413.x
   Maxeiner JH, 2009, CANCER RES, V69, P3069, DOI 10.1158/0008-5472.CAN-08-1678
   Menendez JA, 2010, BBA-MOL CELL BIOL L, V1801, P381, DOI 10.1016/j.bbalip.2009.09.005
   Michalik L, 2004, NAT REV CANCER, V4, P61, DOI 10.1038/nrc1254
   Ogino S, 2009, GASTROENTEROLOGY, V136, P1242, DOI 10.1053/j.gastro.2008.12.048
   Orang AV, 2014, ASIAN PAC J CANCER P, V15, P6685, DOI 10.7314/APJCP.2014.15.16.6685
   Panza A, 2013, BBA-MOL CELL RES, V1833, P1853, DOI 10.1016/j.bbamcr.2013.04.004
   Papi A, 2010, CANCER LETT, V297, P65, DOI 10.1016/j.canlet.2010.04.026
   Peri A, 2008, PPAR RES, V2008, DOI 10.1155/2008/917815
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Qin LL, 2006, MOL CANCER RES, V4, P811, DOI 10.1158/1541-7786.MCR-06-0126
   Rao TP, 2010, CIRC RES, V106, P1798, DOI 10.1161/CIRCRESAHA.110.219840
   Robbs BK, 2008, MOL CELL BIOL, V28, P7168, DOI 10.1128/MCB.00256-08
   Sabatino L, 2014, WORLD J GASTROENTERO, V20, P7137, DOI 10.3748/wjg.v20.i23.7137
   Sabatino L, 2012, PPAR RES, V2012, DOI 10.1155/2012/687492
   Schweitzer A, 2010, INT J CANCER, V126, P801, DOI 10.1002/ijc.24968
   Shibasaki F, 1996, NATURE, V382, P370, DOI 10.1038/382370a0
   Siegel RL, 2020, ANTI-CANCER DRUG, V70, P7, DOI [DOI 10.3322/CAAC.21590, DOI 10.1097/CAD.0000000000000617]
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Takebe N, 2010, CLIN CANCER RES, V16, P3106, DOI 10.1158/1078-0432.CCR-09-2934
   Tie XX, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066008
   Viola JPB, 2005, BRAZ J MED BIOL RES, V38, P335, DOI 10.1590/S0100-879X2005000300003
   Welch JS, 2003, P NATL ACAD SCI USA, V100, P6712, DOI 10.1073/pnas.1031789100
   Yang L, 2011, CLIN CANCER RES, V17, P3760, DOI 10.1158/1078-0432.CCR-10-2779
   Yiu GK, 2006, J BIOL CHEM, V281, P12210, DOI 10.1074/jbc.M600184200
   Yoeli-Lerner M, 2005, MOL CELL, V20, P539, DOI 10.1016/j.molcel.2005.10.033
NR 46
TC 10
Z9 10
U1 0
U2 3
PU ASSOC BASIC MEDICAL SCI FEDERATION BOSNIA & HERZEGOVINA SARAJEVO
PI CEKALUSA
PA UNIV SARAJEVO, MEDICAL FAC, CEKALUSA, SARAJEVO 90, BOSNIA & HERCEG
SN 1512-8601
EI 1840-4812
J9 BOSNIAN J BASIC MED
JI Bosnian J. Basic Med. Sci.
PY 2017
VL 17
IS 3
BP 255
EP 261
DI 10.17305/bjbms.2017.1886
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FG7IS
UT WOS:000410590500011
PM 28504924
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Fiori, E
   Lamazza, A
   Sterpetti, AV
   Crocetti, D
   De Felice, F
   Di Muzio, M
   Mingoli, A
   Sapienza, P
   De Toma, G
AF Fiori, Enrico
   Lamazza, Antonietta
   Sterpetti, Antonio, V
   Crocetti, Daniele
   De Felice, Francesca
   Di Muzio, Marco
   Mingoli, Andrea
   Sapienza, Paolo
   De Toma, Giorgio
TI Quality of Life for Patients With Incurable Stage IV Colorectal Cancer:
   Randomized Controlled Trial Comparing Resection Versus Endoscopic
   Stenting
SO IN VIVO
LA English
DT Article
DE Advanced colorectal cancer; surgical resection; endoscopic stent
   positioning; targeted therapy
ID PLUS SUPPORTIVE CARE; PRIMARY TUMOR; COMBINATION CHEMOTHERAPY;
   COLON-CANCER; SURGERY; FLUOROURACIL; BEVACIZUMAB; CETUXIMAB;
   OBSTRUCTION; LEUCOVORIN
AB Background/Aim: A prospective randomized open label parallel trial, comparing the quality of life (QoL) after endoscopic placement of a self-expandable metal stent or primary tumor resection, in patients with stage IV colorectal cancer was performed. Patients and Methods: Thirty-three patients affected with stage IV colorectal cancer and unresectable metastases were randomly assigned into two groups: Group 1 (16 patients), that underwent self-expandable metal stent positioning and Group 2 (17 patients), in which primary tumor resection was performed. Karnofsky performance scale and QoL assessment using the EQ-5D5LT questionnaire was administered before treatment and thereafter at 1, 3 and 6 months. Results: At 1 month, index values showed a statistically significant deterioration of the QoL in patients of Group 2 when compared to those of Group 1 (p=0.001; 95%CI=0.065-0.211) whereas, at 6 months, index values showed a statistically significant deterioration of the QoL in patients of Group 1 (p<0.025; 95%CI=0.0170.238). Conclusion: QoL in patients affected with stage IV colorectal cancer has a bimodal fluctuation pattern: at 1-month it was better in patients that received stent, but at 6months it was significantly better in patients submitted to surgical resection.
C1 [Fiori, Enrico; Lamazza, Antonietta; Sterpetti, Antonio, V; Crocetti, Daniele; Mingoli, Andrea; Sapienza, Paolo; De Toma, Giorgio] Sapienza Univ Rome, Dept Surg Pietro Valdoni, Viale Policlin 155, I-00166 Rome, Italy.
   [De Felice, Francesca] Sapienza Univ Rome, Dept Radiol Radiotherapy Oncol & Anatomopathol, Rome, Italy.
   [Di Muzio, Marco] Sapienza Univ Rome, Dept Clin & Mol Med, Rome, Italy.
C3 Sapienza University Rome; Sapienza University Rome; Sapienza University
   Rome
RP Crocetti, D (corresponding author), Sapienza Univ Rome, Dept Surg Pietro Valdoni, Viale Policlin 155, I-00166 Rome, Italy.
EM danielecrocetti@hotmail.it
RI Sapienza, Paolo/AAL-7381-2020; Mingoli, Andrea/A-2889-2010; Crocetti,
   Daniele/G-8694-2014; De Felice, Francesca/I-2075-2017
OI Di Muzio, Marco/0000-0003-2641-4044; Crocetti,
   Daniele/0000-0001-9950-3553; De Felice, Francesca/0000-0002-5119-8358;
   Sapienza, Paolo/0000-0002-0198-7930
CR Ahmed S, 2013, CURR ONCOL, V20, pE420, DOI 10.3747/co.20.1469
   [Anonymous], 1949, CLIN EVALUATION CHEM
   Benson AB, 2011, J NATL COMPR CANC NE, V9, P1238, DOI 10.6004/jnccn.2011.0104
   Cisano C, 2016, ANN ROY COLL SURG, V98, P340, DOI 10.1308/rcsann.2016.0114
   Crocetti D, 2019, CLIN TER, V170, pE124, DOI 10.7417/CT.2019.2121
   Crocetti D, 2014, ANN ROY COLL SURG, V96, P558, DOI 10.1308/rcsann.2014.96.7.558
   Crocetti D, 2014, ANTICANCER RES, V34, P6271
   Cunningham D, 1998, LANCET, V352, P1413, DOI 10.1016/S0140-6736(98)02309-5
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Faiz Kashif Waqar, 2014, Tidsskr Nor Laegeforen, V134, P323, DOI 10.4045/tidsskr.13.1145
   Fiori E, 2004, ANTICANCER RES, V24, P265
   Fiori E, 2015, ANTICANCER RES, V35, P2211
   Hu CY, 2015, JAMA SURG, V150, P245, DOI 10.1001/jamasurg.2014.2253
   김정연, 2009, Annals of Coloproctolgy, V25, P81
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kim JH, 2005, SURG ENDOSC, V19, P1381, DOI 10.1007/s00464-004-8232-3
   Laghousi D, 2019, J GASTROINTEST ONCOL, V10, P453, DOI 10.21037/jgo.2019.02.04
   Lamazza A, 2014, COLORECTAL DIS, V16, pO150, DOI 10.1111/codi.12488
   Lamazza A, 2015, ENDOSCOPY, V47, P270, DOI 10.1055/s-0034-1391403
   Lamazza A, 2013, SURG ENDOSC, V27, P1045, DOI 10.1007/s00464-012-2522-y
   Marques RP, 2019, J CANCER RES CLIN, V145, P1719, DOI 10.1007/s00432-019-02924-0
   McCahill LE, 2012, J CLIN ONCOL, V30, P3223, DOI 10.1200/JCO.2012.42.4044
   Pattamatta M, 2020, EXPERT REV PHARM OUT, V20, P193, DOI 10.1080/14737167.2019.1628641
   Polistena A, 2013, MINERVA CHIR, V68, P281
   Polistena A, 2014, IN VIVO, V28, P105
   Poultsides GA, 2009, J CLIN ONCOL, V27, P3379, DOI 10.1200/JCO.2008.20.9817
   Ruo L, 2003, J AM COLL SURGEONS, V196, P722, DOI 10.1016/S1072-7515(03)00136-4
   Scalone L, 2013, VALUE HEALTH, V16, P814, DOI 10.1016/j.jval.2013.04.008
   SCHAG CC, 1984, J CLIN ONCOL, V2, P187, DOI 10.1200/JCO.1984.2.3.187
   SCHEITHAUER W, 1993, BRIT MED J, V306, P752, DOI 10.1136/bmj.306.6880.752
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Tebala GD, 2018, CANCER MANAG RES, V10, P827, DOI 10.2147/CMAR.S158335
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Whitley E, 2002, CRIT CARE, V6, P66
NR 36
TC 12
Z9 12
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0258-851X
EI 1791-7549
J9 IN VIVO
JI In Vivo
PD NOV-DEC
PY 2019
VL 33
IS 6
BP 2065
EP 2070
DI 10.21873/invivo.11705
PG 6
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA JI6FW
UT WOS:000493564200045
PM 31662539
OA gold, Green Published, Green Submitted
DA 2025-01-04
ER

PT J
AU Wu, XY
   Tao, P
   Zhou, Q
   Li, J
   Yu, ZJ
   Wang, XF
   Li, JF
   Li, C
   Yan, M
   Zhu, ZG
   Liu, BY
   Su, LP
AF Wu, Xiongyan
   Tao, Pan
   Zhou, Quan
   Li, Jie
   Yu, Zhenjia
   Wang, Xiaofeng
   Li, Jiaanfang
   Li, Chen
   Yan, Min
   Zhu, Zhenggang
   Liu, Bingya
   Su, Liping
TI IL-6 secreted by cancer-associated fibroblasts promotes
   epithelial-mesenchymal transition and metastasis of gastric cancer via
   JAK2/STAT3 signaling pathway
SO ONCOTARGET
LA English
DT Article
DE cancer-associated fibroblasts; interleukin-6; JAK/STAT3; gastric cancer
ID GROWTH-FACTOR; STROMAL FIBROBLASTS; COLORECTAL-CANCER; TGF-BETA; STAT3;
   ANGIOGENESIS; ACTIVATION; INTERLEUKIN-6; INFLAMMATION; EXPRESSION
AB Cancer-associated fibroblasts (CAFs), as the activated fibroblasts in tumor stroma, are important modifiers of tumor progression. However, the molecular mechanisms underlying the tumor-promoting properties of CAFs in gastric cancer remain unclear. Here, we show that CAFs isolated from gastric cancer produce significant amounts of interleukin-6 (IL-6). CAFs enhances the migration and EMT of gastric cancer cells through the secretion of IL-6 that activates Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT3) pathway in gastric cancer cells, while deprivation of IL-6 using a neutralizing antibody or inhibition of JAK/STAT3 pathway with specific inhibitor AG490 markedly attenuates these phenotypes in gastric cancer cells induced by CAFs. Moreover, silencing IL-6 expression in CAFs or inhibiting JAK2/STAT3 pathway in gastric cancer cells impairs tumor peritoneal metastasis induced by CAFs in vivo. Taken together, these results suggest that CAFs in the tumor microenvironment promote the progression of gastric cancer through IL-6/JAK2/STAT3 signaling, and IL-6 targeted therapy could be a complementary approach against gastric cancer by exerting their action on stromal fibroblasts.
C1 [Wu, Xiongyan; Tao, Pan; Zhou, Quan; Li, Jie; Yu, Zhenjia; Wang, Xiaofeng; Li, Jiaanfang; Li, Chen; Yan, Min; Zhu, Zhenggang; Liu, Bingya; Su, Liping] Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.
C3 Shanghai Jiao Tong University
RP Su, LP (corresponding author), Shanghai Jiao Tong Univ, Shanghai Key Lab Gastr Neoplasms, Shanghai Inst Digest Surg, Dept Surg,Ruijin Hosp,Sch Med, Shanghai 200025, Peoples R China.
EM suliping@shsmu.edu.cn
RI Li, jie/GXG-4583-2022; Liu, Bingya/GMW-5655-2022
OI Liu, Bingya/0000-0002-4406-3762
FU National Natural Science Foundation of China [81272749, 81572798,
   91529302]; Shanghai Municipal Education Commission-Gaofeng Clinical
   Medicine Grant Support [20152505]
FX This study was supported by grants from National Natural Science
   Foundation of China (No. 81272749, No. 81572798 and No. 91529302), and
   Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant
   Support (20152505).
CR Augsten M, 2009, P NATL ACAD SCI USA, V106, P3414, DOI 10.1073/pnas.0813144106
   Bae YK, 2015, J BREAST CANCER, V18, P256, DOI 10.4048/jbc.2015.18.3.256
   Banerjee K, 2016, INT J CANCER, V138, P2570, DOI 10.1002/ijc.29923
   Benwell RK, 2010, CLIN IMMUNOL, V134, P178, DOI 10.1016/j.clim.2009.09.013
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009
   Cirri P, 2011, AM J CANCER RES, V1, P482
   Culig Z, 2012, MOL CELL ENDOCRINOL, V360, P52, DOI 10.1016/j.mce.2011.05.033
   De Vlieghere E, 2015, VIRCHOWS ARCH, V467, P367, DOI 10.1007/s00428-015-1818-4
   Du R, 2014, MOL BIOL CELL, V25, P2650, DOI 10.1091/mbc.E14-01-0044
   Elliott BE, 2002, CAN J PHYSIOL PHARM, V80, P91, DOI 10.1139/y02-010
   Erez N, 2010, CANCER CELL, V17, P135, DOI 10.1016/j.ccr.2009.12.041
   Galdiero M, 2006, CYTOKINE, V36, P218, DOI 10.1016/j.cyto.2006.12.003
   Grivennikov SI, 2010, CELL, V140, P883, DOI 10.1016/j.cell.2010.01.025
   Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012
   Jackson CB, 2007, J PATHOL, V213, P140, DOI 10.1002/path.2218
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kim MS, 2015, ONCOTARGET, V6, P40158, DOI 10.18632/oncotarget.5522
   Kinoshita H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060914
   Li P, 2015, CELL RES, V25, P588, DOI 10.1038/cr.2015.51
   Liu RY, 2014, INT J ONCOL, V44, P1643, DOI 10.3892/ijo.2014.2310
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Moon YW, 2007, ANN SURG ONCOL, V14, P2730, DOI 10.1245/s10434-007-9479-4
   Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Semerano L, 2014, EXPERT OPIN INV DRUG, V23, P979, DOI 10.1517/13543784.2014.912276
   Shiga K, 2015, CANCERS, V7, P2443, DOI 10.3390/cancers7040902
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Waldner MJ, 2012, INT J BIOL SCI, V8, P1248, DOI 10.7150/ijbs.4614
   Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259
   Wu XY, 2013, CANCER LETT, V335, P128, DOI 10.1016/j.canlet.2013.02.002
   Yadav A, 2011, MOL CANCER RES, V9, P1658, DOI 10.1158/1541-7786.MCR-11-0271
   Yang F, 2005, CANCER RES, V65, P8887, DOI 10.1158/0008-5472.CAN-05-1702
   Yang J, 2008, DEV CELL, V14, P818, DOI 10.1016/j.devcel.2008.05.009
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zhang XM, 2014, INT J CLIN EXP PATHO, V7, P5902
   Zheng XF, 2015, NATURE, V527, P525, DOI 10.1038/nature16064
NR 38
TC 257
Z9 289
U1 1
U2 32
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD MAR 28
PY 2017
VL 8
IS 13
BP 20741
EP 20750
DI 10.18632/oncotarget.15119
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EP8RL
UT WOS:000397642400022
PM 28186964
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Majumder, A
AF Majumder, Avisek
TI Targeting Homocysteine and Hydrogen Sulfide Balance as Future
   Therapeutics in Cancer Treatment
SO ANTIOXIDANTS
LA English
DT Review
DE targeted therapy; cancer biology; hyperhomocysteinemia; gene-environment
   interaction; epigenetics; stress response
ID CYSTATHIONINE-BETA-SYNTHASE; METHYLENETETRAHYDROFOLATE REDUCTASE GENE;
   MTHFR C677T POLYMORPHISM; SQUAMOUS-CELL CARCINOMA; ONE-CARBON
   METABOLISM; INDUCED OXIDATIVE STRESS; MTRR A66G POLYMORPHISM;
   COLORECTAL-CANCER; GAMMA-LYASE; COLON-CANCER
AB A high level of homocysteine (Hcy) is associated with oxidative/ER stress, apoptosis, and impairment of angiogenesis, whereas hydrogen sulfide (H2S) has been found to reverse this condition. Recent studies have shown that cancer cells need to produce a high level of endogenous H2S to maintain cell proliferation, growth, viability, and migration. However, any novel mechanism that targets this balance of Hcy and H2S production has yet to be discovered or exploited. Cells require homocysteine metabolism via the methionine cycle for nucleotide synthesis, methylation, and reductive metabolism, and this pathway supports the high proliferative rate of cancer cells. Although the methionine cycle favors cancer cells for their survival and growth, this metabolism produces a massive amount of toxic Hcy that somehow cancer cells handle very well. Recently, research showed specific pathways important for balancing the antioxidative defense through H2S production in cancer cells. This review discusses the relationship between Hcy metabolism and the antiapoptotic, antioxidative, anti-inflammatory, and angiogenic effects of H2S in different cancer types. It also summarizes the historical understanding of targeting antioxidative defense systems, angiogenesis, and other protective mechanisms of cancer cells and the role of H2S production in the genesis, progression, and metastasis of cancer. This review defines a nexus of diet and precision medicine in targeting the delicate antioxidative system of cancer and explores possible future therapeutics that could exploit the Hcy and H2S balance.
C1 [Majumder, Avisek] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
C3 University of California System; University of California San Francisco
RP Majumder, A (corresponding author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
EM avisek.biochem@gmail.com
RI Majumder, Avisek/AAO-9296-2020
OI Majumder, Avisek/0000-0002-6761-2242
CR Al-Magableh MR, 2014, N-S ARCH PHARMACOL, V387, P67, DOI 10.1007/s00210-013-0920-x
   Al-Rubeaan K, 2013, GENE, V520, P166, DOI 10.1016/j.gene.2013.02.017
   Altea-Manzano P, 2020, EMBO REP, V21, DOI 10.15252/embr.202050635
   Arfin S, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10050642
   Ascencao K, 2022, REDOX BIOL, V53, DOI 10.1016/j.redox.2022.102331
   Ascençao K, 2021, PHARMACOL RES, V165, DOI 10.1016/j.phrs.2020.105393
   Asimakopoulou A, 2013, BRIT J PHARMACOL, V169, P922, DOI 10.1111/bph.12171
   Augsburger F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10030447
   Banerjee I, 2007, J HUM GENET, V52, P205, DOI 10.1007/s10038-006-0098-x
   Bantzi M, 2021, J MED CHEM, V64, P6221, DOI 10.1021/acs.jmedchem.1c00260
   Beltowski Jerzy, 2005, Postepy Hig Med Dosw (Online), V59, P392
   Benetti LR, 2013, EUR J PHARMACOL, V698, P463, DOI 10.1016/j.ejphar.2012.11.025
   Berchuck JE, 2022, CLIN CANCER RES, V28, P928, DOI 10.1158/1078-0432.CCR-21-3762
   Bhattacharyya S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079167
   Bianca RDD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136859
   Bravatà V, 2015, INT J FOOD SCI NUTR, V66, P43, DOI 10.3109/09637486.2014.959896
   Breza J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4508-1
   BURNETT G, 1980, J BIOL CHEM, V255, P3487
   Burns KH, 2017, NAT REV CANCER, V17, P415, DOI 10.1038/nrc.2017.35
   Cahill N, 2013, EPIGENETICS-US, V8, P138, DOI 10.4161/epi.23439
   Cai WJ, 2014, BIOMED REP, V2, P861, DOI 10.3892/br.2014.357
   Cai WJ, 2010, CELL BIOL INT, V34, P565, DOI 10.1042/CBI20090368
   Cao X, 2019, ANTIOXID REDOX SIGN, V31, P1, DOI 10.1089/ars.2017.7058
   Cascella M, 2015, J Med Case Rep, V9, P218, DOI 10.1186/s13256-015-0706-5
   Castro R, 2006, J INHERIT METAB DIS, V29, P3, DOI 10.1007/s10545-006-0106-5
   Cellarier E, 2003, CANCER TREAT REV, V29, P489, DOI 10.1016/S0305-7372(03)00118-X
   Chang WW, 2013, RENAL FAILURE, V35, P1038, DOI 10.3109/0886022X.2013.810542
   Chaturvedi P, 2014, PHYSIOL GENOMICS, V46, P245, DOI 10.1152/physiolgenomics.00168.2013
   Chaudhuri AR, 2017, NAT REV MOL CELL BIO, V18, P610, DOI 10.1038/nrm.2017.53
   Chen J, 1998, CARCINOGENESIS, V19, P2129, DOI 10.1093/carcin/19.12.2129
   Chen J, 1996, CANCER RES, V56, P4862
   Chen Kun, 2006, Zhonghua Zhongliu Zazhi, V28, P429
   Chen SM, 2022, CURR NEUROPHARMACOL, V20, P1726, DOI 10.2174/1570159X20666211223125448
   Combs JA, 2019, CANCERS, V11, DOI 10.3390/cancers11050678
   Corona G, 1997, EUR J CANCER, V33, P1284, DOI 10.1016/S0959-8049(97)00121-4
   Cui J, 2013, EXP THER MED, V5, P689, DOI 10.3892/etm.2012.870
   Cui LH, 2012, MED ONCOL, V29, P1837, DOI 10.1007/s12032-011-0066-y
   de Franchis R, 2000, THROMB HAEMOSTASIS, V84, P576, DOI 10.1055/s-0037-1614070
   de Jong MM, 2002, CANCER EPIDEM BIOMAR, V11, P1332
   de la Vega MR, 2018, CANCER CELL, V34, P21, DOI 10.1016/j.ccell.2018.03.022
   Devlin AM, 2004, BLOOD, V103, P2624, DOI 10.1182/blood-2003-09-3078
   Diakoumopoulou E, 2005, NUTR METAB CARDIOVAS, V15, P109, DOI 10.1016/j.numecd.2004.01.001
   Dick DM, 2011, ANNU REV CLIN PSYCHO, V7, P383, DOI 10.1146/annurev-clinpsy-032210-104518
   Dicks N, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00011
   DIDDENS H, 1983, CANCER RES, V43, P5286
   Ding R, 2012, J NEUROL SCI, V312, P26, DOI 10.1016/j.jns.2011.08.029
   Ducker GS, 2016, CELL METAB, V23, P1140, DOI 10.1016/j.cmet.2016.04.016
   DUNN R, 1981, P NATL ACAD SCI-BIOL, V78, P6744, DOI 10.1073/pnas.78.11.6744
   Ehrlich M, 2002, J NUTR, V132, p2424S, DOI 10.1093/jn/132.8.2424S
   Ehrlich M, 2009, EPIGENOMICS-UK, V1, P239, DOI [10.2217/epi.09.33, 10.2217/EPI.09.33]
   ELORANTA TO, 1990, P SOC EXP BIOL MED, V194, P364, DOI 10.3181/00379727-194-43110
   Epner DE, 2002, NUTR CANCER, V42, P158, DOI 10.1207/S15327914NC422_2
   Esteller M, 1997, CARCINOGENESIS, V18, P2307, DOI 10.1093/carcin/18.12.2307
   Fan K, 2014, CELL SIGNAL, V26, P2801, DOI 10.1016/j.cellsig.2014.08.023
   Fang DH, 2014, LEUKEMIA LYMPHOMA, V55, P1910, DOI 10.3109/10428194.2013.867492
   FINKELSTEIN JD, 1984, J BIOL CHEM, V259, P9508
   FINKELSTEIN JD, 1975, BIOCHEM BIOPH RES CO, V66, P81, DOI 10.1016/S0006-291X(75)80297-X
   Folkman J, 2007, NAT REV DRUG DISCOV, V6, P273, DOI 10.1038/nrd2115
   Fu ZF, 2008, LIFE SCI, V82, P1196, DOI 10.1016/j.lfs.2008.04.005
   Gai JW, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2015.06.020
   Gao Chang-Ming, 2004, Asian Pac J Cancer Prev, V5, P133
   Gao S, 2012, J NEUROL SCI, V323, P40, DOI 10.1016/j.jns.2012.07.038
   Gao X, 2019, NATURE, V572, P397, DOI 10.1038/s41586-019-1437-3
   Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002
   Gatt A, 2007, INT J LAB HEMATOL, V29, P421, DOI 10.1111/j.1751-553X.2007.00907.x
   Geng B, 2004, BIOCHEM BIOPH RES CO, V318, P756, DOI 10.1016/j.bbrc.2004.04.094
   George AK, 2019, PHYSIOL GENOMICS, V51, P613, DOI 10.1152/physiolgenomics.00041.2019
   George AK, 2019, INT J OPHTHALMOL-CHI, V12, P754, DOI 10.18240/ijo.2019.05.09
   George AK, 2019, CAN J PHYSIOL PHARM, V97, P463, DOI 10.1139/cjpp-2018-0505
   George AK, 2018, INT J OPHTHALMOL-CHI, V11, P881, DOI 10.18240/ijo.2018.05.26
   GIOVANNUCCI E, 1995, JNCI-J NATL CANCER I, V87, P265, DOI 10.1093/jnci/87.4.265
   Giuffrè A, 2020, ADV EXP MED BIOL, V1219, P335, DOI 10.1007/978-3-030-34025-4_17
   Gouveia LO, 2010, THROMB RES, V125, pE153, DOI 10.1016/j.thromres.2009.10.019
   GOYETTE P, 1995, AM J HUM GENET, V56, P1052
   GOYETTE P, 1994, NAT GENET, V7, P195, DOI 10.1038/ng0694-195
   Greiner R, 2013, ANTIOXID REDOX SIGN, V19, P1749, DOI 10.1089/ars.2012.5041
   Guo C, 2014, EUR J PHARMACOL, V725, P70, DOI 10.1016/j.ejphar.2014.01.009
   Guo H, 2012, UROLOGY, V79, DOI 10.1016/j.urology.2011.10.013
   GUO HY, 1993, CANCER RES, V53, P5676
   Halsall JA, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-82539-z
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanaoka K, 2017, SCI REP-UK, V7, DOI 10.1038/srep40227
   Handy DE, 2011, CIRCULATION, V123, P2145, DOI 10.1161/CIRCULATIONAHA.110.956839
   Hankey GJ, 1999, LANCET, V354, P407, DOI 10.1016/S0140-6736(98)11058-9
   Hasan T, 2019, EXP MOL MED, V51, DOI 10.1038/s12276-019-0216-4
   Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001
   Hazra A, 2007, CARCINOGENESIS, V28, P1510, DOI 10.1093/carcin/bgm062
   He LL, 2017, ONCOTARGETS THER, V10, P227, DOI 10.2147/OTT.S121472
   Heifetz EM, 2015, AM J HYPERTENS, V28, P387, DOI 10.1093/ajh/hpu152
   Helin K, 2013, NATURE, V502, P480, DOI 10.1038/nature12751
   Hellmich MR, 2015, HANDB EXP PHARMACOL, V230, P233, DOI 10.1007/978-3-319-18144-8_12
   Hellmich MR, 2015, ANTIOXID REDOX SIGN, V22, P424, DOI 10.1089/ars.2014.5933
   Hoesel B, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-86
   Homme RP, 2018, FRONT PHYSIOL, V9, DOI 10.3389/fphys.2018.01268
   Hourihan JM, 2013, ANTIOXID REDOX SIGN, V19, P465, DOI 10.1089/ars.2012.4944
   Hua Y, 2011, INT J NEUROSCI, V121, P462, DOI 10.3109/00207454.2011.578778
   Huang CR, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069205
   Ibrahim H, 2021, J ADV RES, V27, P137, DOI 10.1016/j.jare.2020.05.018
   Ibrahim S, 2018, MOL BIOL REP, V45, P353, DOI 10.1007/s11033-018-4169-9
   Ishii I, 2010, J BIOL CHEM, V285, P26358, DOI 10.1074/jbc.M110.147439
   Izadi P, 2012, CELL J, V14, P102
   Jiang L, 2008, CANCER RES, V68, P9900, DOI 10.1158/0008-5472.CAN-08-1319
   Kai S, 2012, ANTIOXID REDOX SIGN, V16, P203, DOI 10.1089/ars.2011.3882
   Kaiser P, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10040568
   Kalani A, 2013, MOL NEUROBIOL, V48, P157, DOI 10.1007/s12035-013-8421-y
   Kang S, 2013, GENET TEST MOL BIOMA, V17, P412, DOI 10.1089/gtmb.2012.0295
   Kato I, 1999, BRIT J CANCER, V79, P1917, DOI 10.1038/sj.bjc.6690305
   Kesherwani V, 2013, BRAIN RES, V1527, P222, DOI 10.1016/j.brainres.2013.06.023
   Khairan P, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08721-8
   Kim J, 2009, ONCOL REP, V21, P1449, DOI 10.3892/or_00000373
   Kimura H, 2002, MOL NEUROBIOL, V26, P13, DOI 10.1385/MN:26:1:013
   Kimura Y, 2004, FASEB J, V18, P1165, DOI 10.1096/fj.04-1815fje
   Kimura Y, 2015, SCI REP-UK, V5, DOI 10.1038/srep14774
   Kluijtmans LAJ, 1998, EUR J HUM GENET, V6, P257, DOI 10.1038/sj.ejhg.5200182
   Krajinovic M, 2004, PHARMACOGENOMICS J, V4, P66, DOI 10.1038/sj.tpj.6500224
   Krajinovic M, 2004, BLOOD, V103, P252, DOI 10.1182/blood-2003-06-1794
   Kurzwelly D, 2010, J NEURO-ONCOL, V100, P187, DOI 10.1007/s11060-010-0154-4
   Laha A, 2018, CAN J PHYSIOL PHARM, V96, P971, DOI 10.1139/cjpp-2018-0037
   Lahiri KD, 2014, INDIAN J CLIN BIOCHE, V29, P74, DOI 10.1007/s12291-013-0304-5
   LASTER L, 1965, J CLIN INVEST, V44, P1708, DOI 10.1172/JCI105278
   Predmore BL, 2012, ANTIOXID REDOX SIGN, V17, P119, DOI 10.1089/ars.2012.4612
   Lee ZW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021077
   Lehotsky J, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00538
   Li CY, 2015, INT J CLIN EXP PATHO, V8, P7740
   Li DQ, 2020, APPL IMMUNOHISTO M M, V28, P103, DOI 10.1097/PAI.0000000000000705
   Li S, 2019, ANGIOGENESIS, V22, P15, DOI 10.1007/s10456-018-9645-2
   Li XL, 2012, PROSTATE CANCER P D, V15, P244, DOI 10.1038/pcan.2012.5
   Li X, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0099697, 10.1371/journal.pone.0095004, 10.1371/journal.pone.0098139, 10.1371/journal.pone.0110546, 10.1371/journal.pone.0089856]
   Liang Ruilian, 2014, Nan Fang Yi Ke Da Xue Xue Bao, V34, P1195
   Lister R, 2009, NATURE, V462, P315, DOI 10.1038/nature08514
   Liu X, 2021, MOL THER NUCL ACIDS, V26, P1130, DOI 10.1016/j.omtn.2021.10.017
   Liu YY, 2013, NEUROCHEM INT, V62, P603, DOI 10.1016/j.neuint.2012.12.010
   Lu M, 2008, FREE RADICAL BIO MED, V45, P1705, DOI 10.1016/j.freeradbiomed.2008.09.014
   Lu S, 2014, INT J ONCOL, V44, P1259, DOI 10.3892/ijo.2014.2305
   Lu ZM, 2006, IUBMB LIFE, V58, P621, DOI 10.1080/15216540600957438
   Lund G, 2004, J BIOL CHEM, V279, P29147, DOI 10.1074/jbc.M403618200
   Ma E, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-122
   Ma J, 1999, CANCER EPIDEM BIOMAR, V8, P825
   Ma J, 1997, CANCER RES, V57, P1098
   Maddocks ODK, 2016, MOL CELL, V61, P210, DOI 10.1016/j.molcel.2015.12.014
   Majumder A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-88683-w
   Majumder A, 2019, CAN J PHYSIOL PHARM, V97, P441, DOI 10.1139/cjpp-2018-0501
   Majumder A, 2019, J CELL BIOCHEM, V120, P77, DOI 10.1002/jcb.27603
   Majumder A, 2018, PHYSIOL REP, V6, DOI 10.14814/phy2.13858
   Majumder A, 2018, AM J PHYSIOL-CELL PH, V315, pC609, DOI 10.1152/ajpcell.00147.2018
   Majumder A, 2017, ONCOTARGET, V8, P102739, DOI 10.18632/oncotarget.22156
   Majumder A, 2017, J CELL BIOCHEM, V118, P2108, DOI 10.1002/jcb.25841
   Mariño-Ramírez L, 2005, EXPERT REV PROTEOMIC, V2, P719, DOI 10.1586/14789450.2.5.719
   Martin C, 2005, NAT REV MOL CELL BIO, V6, P838, DOI 10.1038/nrm1761
   Marugame T, 2000, CANCER LETT, V151, P181, DOI 10.1016/S0304-3835(99)00412-7
   Matsuo K, 2005, CARCINOGENESIS, V26, P2164, DOI 10.1093/carcin/bgi196
   Matsuo Keitaro, 2002, Asian Pac J Cancer Prev, V3, P353
   Mbemi A, 2020, INT J ENV RES PUB HE, V17, DOI 10.3390/ijerph17218089
   McGimpsey SJ, 2009, OPHTHALMOLOGY, V116, P1778, DOI 10.1016/j.ophtha.2009.02.033
   Millán-Zambrano G, 2022, NAT REV GENET, V23, P563, DOI 10.1038/s41576-022-00468-7
   Mitra J, 2013, FEBS OPEN BIO, V3, P135, DOI 10.1016/j.fob.2013.01.010
   Mitsuboshi S, 2022, ANN PHARMACOTHER, V56, P910, DOI 10.1177/10600280211055794
   Módis K, 2016, PHARMACOL RES, V113, P116, DOI 10.1016/j.phrs.2016.08.023
   Modis K, 2014, NITRIC OXIDE-BIOL CH, V41, P146, DOI 10.1016/j.niox.2014.03.001
   Mortality GBD., 2016, LANCET, V388, P1459, DOI [10.1016/S0140-6736(16)31012-1, DOI 10.1016/S0140-6736(16)31012-1]
   Mostowska A, 2011, CLIN BIOCHEM, V44, P596, DOI 10.1016/j.clinbiochem.2011.02.007
   Mullarky E, 2016, P NATL ACAD SCI USA, V113, P1778, DOI 10.1073/pnas.1521548113
   Murphy B, 2019, FASEB J, V33, P13098, DOI 10.1096/fj.201901304R
   Mustafa AK, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000464
   Nagahara N, 2005, J BIOL CHEM, V280, P34569, DOI 10.1074/jbc.M505643200
   Navik U, 2021, AGEING RES REV, V72, DOI 10.1016/j.arr.2021.101500
   Newman AC, 2017, BRIT J CANCER, V116, P1499, DOI 10.1038/bjc.2017.118
   Niu WN, 2018, J BIOL CHEM, V293, P2523, DOI 10.1074/jbc.RA117.000103
   Oláh G, 2018, BIOCHEM PHARMACOL, V149, P186, DOI 10.1016/j.bcp.2017.10.011
   Orendác M, 1999, J INHERIT METAB DIS, V22, P674, DOI 10.1023/A:1005554702861
   Ott N, 2008, J CANCER RES CLIN, V134, P405, DOI 10.1007/s00432-007-0301-2
   Ouyang Y, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12891
   Pacold ME, 2016, NAT CHEM BIOL, V12, P452, DOI [10.1038/NCHEMBIO.2070, 10.1038/nchembio.2070]
   Pan Y, 2014, MUTAT RES-FUND MOL M, V763, P10, DOI 10.1016/j.mrfmmm.2014.03.002
   Pappalardo XG, 2021, EPIGENET CHROMATIN, V14, DOI 10.1186/s13072-021-00400-z
   Pawlik P, 2012, MOL BIOL REP, V39, P5553, DOI 10.1007/s11033-011-1359-0
   Paynter RA, 2004, CANCER EPIDEM BIOMAR, V13, P1088
   Pei YX, 2011, TOXICOL APPL PHARM, V257, P420, DOI 10.1016/j.taap.2011.09.026
   Peng H, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419-023-05860-7
   Phillips CM, 2017, CANCER RES, V77, P5741, DOI 10.1158/0008-5472.CAN-16-3480
   Ratti M, 2020, TARGET ONCOL, V15, P261, DOI 10.1007/s11523-020-00717-x
   Ray JG, 2002, PATHOPHYSIOL HAEMO T, V32, P51, DOI 10.1159/000065076
   da Silva LMB, 2012, MOL BIOL REP, V39, P887, DOI 10.1007/s11033-011-0813-3
   Refsum H, 2006, J NUTR, V136, p1731S, DOI 10.1093/jn/136.6.1731S
   Robien K, 2003, AM J EPIDEMIOL, V157, P571, DOI 10.1093/aje/kwg024
   Rose P, 2005, WORLD J GASTROENTERO, V11, P3990, DOI 10.3748/wjg.v11.i26.3990
   Safarinejad MR, 2010, PROSTATE, V70, P1645, DOI 10.1002/pros.21200
   Sakuma S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02244
   Santos-Rebouças CB, 2007, EUR J HUM GENET, V15, P10, DOI 10.1038/sj.ejhg.5201727
   Santotoribio JD, 2015, TUMOR BIOL, V36, P7941, DOI 10.1007/s13277-015-3517-9
   Sbodio JI, 2019, BRIT J PHARMACOL, V176, P583, DOI 10.1111/bph.14446
   Selhub J, 1999, ANNU REV NUTR, V19, P217, DOI 10.1146/annurev.nutr.19.1.217
   Selhub J, 1999, ANN INTERN MED, V131, P331, DOI 10.7326/0003-4819-131-5-199909070-00003
   Semmler A, 2006, CANCER EPIDEM BIOMAR, V15, P2314, DOI 10.1158/1055-9965.EPI-05-0979
   Sen N, 2012, MOL CELL, V45, P13, DOI 10.1016/j.molcel.2011.10.021
   Sen S, 2015, FREE RADICAL BIO MED, V86, P228, DOI 10.1016/j.freeradbiomed.2015.05.024
   Sen U, 2010, CELL BIOCHEM BIOPHYS, V57, P49, DOI 10.1007/s12013-010-9079-y
   Sen U, 2009, AM J PHYSIOL-RENAL, V297, pF410, DOI 10.1152/ajprenal.00145.2009
   Shackelford RE, 2021, PATHOPHYSIOLOGY-BASE, V28, P437, DOI 10.3390/pathophysiology28030028
   Shibuya N, 2009, J BIOCHEM, V146, P623, DOI 10.1093/jb/mvp111
   Shujuan Yang, 2013, Pak J Med Sci, V29, P693
   Sibani S, 2000, HUM MUTAT, V15, P280, DOI 10.1002/(SICI)1098-1004(200003)15:3<280::AID-HUMU9>3.3.CO;2-9
   Singal R, 2004, INT J ONCOL, V25, P1465
   Singh M, 2019, CURR EYE RES, V44, P287, DOI 10.1080/02713683.2018.1542005
   Singh M, 2018, EXP EYE RES, V174, P80, DOI 10.1016/j.exer.2018.05.026
   Skibola CF, 1999, P NATL ACAD SCI USA, V96, P12810, DOI 10.1073/pnas.96.22.12810
   Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017
   Song CY, 2001, CANCER RES, V61, P3272
   Stabler SP, 2002, METABOLISM, V51, P981, DOI 10.1053/meta.2002.34017
   Stathopoulou A, 2002, J CLIN ONCOL, V20, P3404, DOI 10.1200/JCO.2002.08.135
   Stipanuk MH, 2011, J INHERIT METAB DIS, V34, P17, DOI 10.1007/s10545-009-9006-9
   Stolzenberg-Solomon RZ, 1999, AM J CLIN NUTR, V69, P467
   Su YW, 2009, CIRC J, V73, P741, DOI 10.1253/circj.CJ-08-0636
   Suzuki T, 2008, CANCER EPIDEM BIOMAR, V17, P2742, DOI 10.1158/1055-9965.EPI-08-0470
   Szabó C, 2007, NAT REV DRUG DISCOV, V6, P917, DOI 10.1038/nrd2425
   Szabo C, 2013, P NATL ACAD SCI USA, V110, P12474, DOI 10.1073/pnas.1306241110
   Szabó C, 2011, BRIT J PHARMACOL, V164, P853, DOI 10.1111/j.1476-5381.2010.01191.x
   Szczesny B, 2016, SCI REP-UK, V6, DOI 10.1038/srep36125
   Takano N, 2014, MOL CANCER RES, V12, P1398, DOI 10.1158/1541-7786.MCR-14-0184
   TANASE S, 1976, BIOCHEM BIOPH RES CO, V68, P1301, DOI 10.1016/0006-291X(76)90338-7
   Tao MH, 2009, CANCER EPIDEM BIOMAR, V18, P998, DOI 10.1158/1055-9965.EPI-08-0916
   Tiahou G, 2009, INT J VITAM NUTR RES, V79, P319, DOI 10.1024/0300-9831.79.56.319
   Tiong CX, 2010, BRIT J PHARMACOL, V161, P467, DOI 10.1111/j.1476-5381.2010.00887.x
   Tonetti C, 2001, J INHERIT METAB DIS, V24, P833, DOI 10.1023/A:1013988123902
   Tu Xiao-huang, 2013, Zhonghua Zhong Liu Za Zhi, V35, P351, DOI 10.3760/cma.j.issn.0253-3766.2013.05.007
   Turbat-Herrera EA, 2018, ANTICANCER RES, V38, P6085, DOI 10.21873/anticanres.12958
   Tyagi N, 2009, ANTIOXID REDOX SIGN, V11, P25, DOI 10.1089/ars.2008.2073
   UELAND PM, 1989, J LAB CLIN MED, V114, P473
   Untereiner AA, 2018, BIOCHEM PHARMACOL, V149, P174, DOI 10.1016/j.bcp.2017.10.007
   Veeranki S, 2015, BBA-MOL BASIS DIS, V1852, P732, DOI 10.1016/j.bbadis.2015.01.008
   Veeranki S, 2015, INT J MOL SCI, V16, P1252, DOI 10.3390/ijms16011252
   Veeranki S, 2013, INT J MOL SCI, V14, P15074, DOI 10.3390/ijms140715074
   Volovat SR, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.526850
   Wanders D, 2020, NUTRIENTS, V12, DOI 10.3390/nu12030684
   Wang C, 2011, CHINESE MED J-PEKING, V124, P3476, DOI 10.3760/cma.j.issn.0366-6999.2011.21.007
   Wang D, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00410-5
   Wang LN, 2007, CLIN CANCER RES, V13, P2526, DOI 10.1158/1078-0432.CCR-06-2293
   Wang MX, 2014, BIOCHEM GENET, V52, P29, DOI 10.1007/s10528-013-9624-7
   Wang MQ, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113775
   Wang P, 2017, J CANCER, V8, P266, DOI 10.7150/jca.17379
   Wang YH, 2019, EMBO REP, V20, DOI 10.15252/embr.201845986
   Wei HL, 2010, ANTIOXID REDOX SIGN, V12, P1079, DOI 10.1089/ars.2009.2898
   Weisberg I, 1998, MOL GENET METAB, V64, P169, DOI 10.1006/mgme.1998.2714
   Wen YD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053147
   White RH, 2003, CIRCULATION, V107, pI4, DOI 10.1161/01.CIR.0000078468.11849.66
   Whiteman M, 2006, BIOCHEM BIOPH RES CO, V343, P303, DOI 10.1016/j.bbrc.2006.02.154
   Whiteman M, 2005, BIOCHEM BIOPH RES CO, V326, P794, DOI 10.1016/j.bbrc.2004.11.110
   Whiteman M, 2004, J NEUROCHEM, V90, P765, DOI 10.1111/j.1471-4159.2004.02617.x
   Winchester L, 2014, CAN J PHYSIOL PHARM, V92, P575, DOI [10.1139/cjpp-2014-0059, 10.1139/cjpp-2014-0060]
   Wong RSY, 2011, J EXP CLIN CANC RES, V30, DOI 10.1186/1756-9966-30-87
   Wróbel M, 2014, MOLECULES, V19, P21350, DOI 10.3390/molecules191221350
   Wu CY, 2013, ARCH GYNECOL OBSTET, V288, P595, DOI 10.1007/s00404-013-2721-3
   Wu LL, 2002, CLIN CHIM ACTA, V322, P21, DOI 10.1016/S0009-8981(02)00174-2
   Wu PP, 2015, J BUON, V20, P918
   Wu XY, 2014, HERED CANCER CLIN PR, V12, DOI 10.1186/1897-4287-12-2
   Wu YL, 2013, J NEUROL SCI, V335, P14, DOI 10.1016/j.jns.2013.09.006
   Xu XR, 2008, FASEB J, V22, P2045, DOI 10.1096/fj.07-101279
   Yadav PK, 2013, J BIOL CHEM, V288, P20002, DOI 10.1074/jbc.M113.466177
   Yan SK, 2006, BIOCHEM BIOPH RES CO, V351, P485, DOI 10.1016/j.bbrc.2006.10.058
   Yang GD, 2013, ANTIOXID REDOX SIGN, V18, P1906, DOI 10.1089/ars.2012.4645
   Yang GD, 2011, J BIOL CHEM, V286, P26450, DOI 10.1074/jbc.M111.266643
   Yang JX, 2016, ADV EXP MED BIOL, V886, P13, DOI 10.1007/978-94-017-7417-8_2
   Yang KM, 2014, BIOMED REP, V2, P699, DOI 10.3892/br.2014.302
   Yang S, 2013, METABOLISM, V62, P586, DOI 10.1016/j.metabol.2012.10.004
   Yano H, 2004, NEUROGENETICS, V5, P135, DOI 10.1007/s10048-004-0177-0
   Yoo Jae-Young, 2012, Genomics & Informatics, V10, P184, DOI 10.5808/GI.2012.10.3.184
   You J, 2017, ONCOTARGET, V8, P65677, DOI 10.18632/oncotarget.20057
   Yu Hui-hui, 2011, Zhonghua Yi Xue Za Zhi, V91, P2060
   Yuan C, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.868830
   Zhang D, 2014, ENDOCR J, V61, P717, DOI 10.1507/endocrj.EJ14-0071
   Zhang HT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069366
   Zhang JG, 2007, CHINESE MED J-PEKING, V120, P2132, DOI 10.1097/00029330-200712010-00013
   Zhang L, 2015, OXID MED CELL LONGEV, V2015, DOI 10.1155/2015/636410
   Zhang NF, 2018, ANIM NUTR, V4, P11, DOI 10.1016/j.aninu.2017.08.009
   Zhang XD, 2013, BIOMED REP, V1, P440, DOI 10.3892/br.2013.68
   Zhao H, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049683
   Zhao KX, 2014, EMBO REP, V15, P792, DOI 10.1002/embr.201338213
   Zhao P, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.677926
   Zhao Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061511
   Zhen YL, 2015, INT J ONCOL, V46, P2194, DOI 10.3892/ijo.2015.2914
   Zheng D, 2016, ONCOL REP, V36, P1909, DOI 10.3892/or.2016.5014
   Zhou SY, 2014, LIPIDS HEALTH DIS, V13, DOI 10.1186/1476-511X-13-134
   Zhou Y, 2016, AM J PHYSIOL-CELL PH, V310, pC305, DOI 10.1152/ajpcell.00230.2015
   Zhu XY, 2013, MENOPAUSE, V20, P1084, DOI [10.1097/GME.0b013e3182874732, 10.1097/gme.0b013e3182874732]
   Zuhra K, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10050697
NR 285
TC 11
Z9 12
U1 3
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3921
J9 ANTIOXIDANTS-BASEL
JI Antioxidants
PD AUG
PY 2023
VL 12
IS 8
AR 1520
DI 10.3390/antiox12081520
PG 28
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Food Science &
   Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy; Food Science
   & Technology
GA Q2ZO3
UT WOS:001056250000001
PM 37627515
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Xiong, F
   Zhou, YW
   Hao, YT
   Wei, GX
   Chen, XR
   Qiu, M
AF Xiong, Feng
   Zhou, Yu-Wen
   Hao, Ya-Ting
   Wei, Gui-Xia
   Chen, Xiao-Rong
   Qiu, Meng
TI Combining Anti-epidermal Growth Factor Receptor (EGFR) Therapy with
   Immunotherapy in Metastatic Colorectal Cancer (mCRC)
SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
DE Anti-EGFR therapy; combination therapy; immune checkpoint inhibitors;
   immunomodulation; metastatic colorectal cancer
ID IMMUNOGENIC CELL-DEATH; 1ST-LINE TREATMENT; NATURAL-KILLER; OPEN-LABEL;
   MICROSATELLITE INSTABILITY; MEDIATED CYTOTOXICITY; COMBINED BRAF;
   COLON-CANCER; CETUXIMAB; ANTIBODY
AB IntroductionMonoclonal antibodies binding the EGFR, such as cetuximab and panitumumab, have been extensively used as targeted therapy for the treatment of mCRC. However, in clinical practice, it has been found that these treatment options have some limitations and fail to fully exploit their immunoregulatory activities. Meanwhile, because of the limited effects of current treatments, immunotherapy is being widely studied for patients with mCRC. However, previous immunotherapy trials in mCRC patients have had unsatisfactory outcomes as monotherapy. Thus, combinatorial treatment strategies are being researched.Areas coveredThe authors retrieved relevant documents of combination therapy for mCRC from PubMed and Medline. This review elaborates on the knowledge of immunomodulatory effects of anti-EGFR therapy alone and in combination with immunotherapy for mCRC.Expert opinionAlthough current treatment options have improved median overall survival (OS) for advanced disease to 30 months, the prognosis remains challenging for those with metastatic disease. More recently, the combination of anti-EGFR therapy with immunotherapy has been shown activity with complementary mechanisms. Hence, anti-EGFR therapy in combination with immunotherapy may hold the key to improving the therapeutic effect of refractory mCRC.
C1 [Xiong, Feng; Zhou, Yu-Wen; Wei, Gui-Xia; Chen, Xiao-Rong; Qiu, Meng] Sichuan Univ, Dept Colorectal Canc Ctr, West China Hosp, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China.
   [Hao, Ya-Ting] Ningxia Med Univ, Sch Clin Med, Yinchuan, Peoples R China.
C3 Sichuan University; Ningxia Medical University
RP Qiu, M (corresponding author), Sichuan Univ, Dept Colorectal Canc Ctr, West China Hosp, 37 Guoxue Alley, Chengdu 610041, Sichuan, Peoples R China.
EM qiumeng@wchscu.cn
RI Zhou, Yuwen/IQR-6924-2023
FU Sichuan Science and Technology Department Key Research and Development
   Project [2022YFS0209]; 1.3.5 Project for Disciplines of Excellence, West
   China Hospital, Sichuan University [ZYJC21017]
FX This paper was funded by the Sichuan Science and Technology Department
   Key Research and Development Project (grant no. 2022YFS0209) and 1.3.5
   Project for Disciplines of Excellence, West China Hospital, Sichuan
   University (grant no. ZYJC21017).
CR Akiyama Y, 2016, INT J ONCOL, V49, P1099, DOI 10.3892/ijo.2016.3586
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Barrueto L, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2019.12.010
   Bellucci R, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1008824
   Bhat R, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000326
   Bourhis J, 2021, CANCER TREAT REV, V97, DOI 10.1016/j.ctrv.2021.102172
   Boyerinas B, 2015, CANCER IMMUNOL RES, V3, P1148, DOI 10.1158/2326-6066.CIR-15-0059
   Chen SS, 2016, ONCOL LETT, V12, P1868, DOI 10.3892/ol.2016.4835
   Chowdhury PS, 2018, J INTERN MED, V283, P110, DOI 10.1111/joim.12708
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016
   Concha-Benavente F, 2016, CANCER RES, V76, P1031, DOI 10.1158/0008-5472.CAN-15-2001
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Elbers JBW, 2020, RADIOTHER ONCOL, V142, P79, DOI 10.1016/j.radonc.2019.08.007
   Fasano M, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835920949418
   Fasano M, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000753
   Ferris RL, 2018, CANCER TREAT REV, V63, P48, DOI 10.1016/j.ctrv.2017.11.008
   Florescu-Tenea R M, 2019, Curr Health Sci J, V45, P134, DOI 10.12865/CHSJ.45.02.02
   Fountzilas C, 2021, CLIN CANCER RES, V27, P6726, DOI 10.1158/1078-0432.CCR-21-1650
   Fujii R, 2016, ONCOTARGET, V7, P33498, DOI 10.18632/oncotarget.9256
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Garcia-Foncillas J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00849
   Ghiringhelli F, 2005, J EXP MED, V202, P1075, DOI 10.1084/jem.20051511
   Groom JR, 2011, IMMUNOL CELL BIOL, V89, P207, DOI 10.1038/icb.2010.158
   Grothey A, 2020, NEW ENGL J MED, V383, P2283, DOI 10.1056/NEJMe2031294
   Guerrero RM, 2022, ECANCERMEDICALSCIENC, V16, DOI 10.3332/ecancer.2022.1489
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Holubec L, 2016, ANTICANCER RES, V36, P4421, DOI 10.21873/anticanres.10985
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913
   Inoue Y, 2017, CANCER SCI, V108, P455, DOI 10.1111/cas.13162
   Jie HB, 2013, BRIT J CANCER, V109, P2629, DOI 10.1038/bjc.2013.645
   Jie HB, 2015, CANCER RES, V75, P2200, DOI 10.1158/0008-5472.CAN-14-2788
   Kishore C, 2021, EUR J PHARMACOL, V893, DOI 10.1016/j.ejphar.2020.173819
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Kubach J, 2015, INT J CANCER, V136, P821, DOI 10.1002/ijc.29037
   Lazzari C, 2018, THER ADV MED ONCOL, V10, P1, DOI 10.1177/1758835918762094
   Lee MS, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.7
   Lee SC, 2011, IMMUNOL RES, V50, P248, DOI 10.1007/s12026-011-8231-0
   Lieberman J, 2003, NAT REV IMMUNOL, V3, P361, DOI 10.1038/nri1083
   Lonardi S, 2020, ANN ONCOL, V31, pS412, DOI 10.1016/j.annonc.2020.08.513
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007
   Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915
   Meric-Bernstam F, 2021, LANCET, V397, P1010, DOI 10.1016/S0140-6736(20)32598-8
   Ott PA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0218-5
   Overman Michael J, 2018, Am Soc Clin Oncol Educ Book, V38, P239, DOI 10.1200/EDBK_200821
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Qiao GL, 2012, CLIN IMMUNOL, V143, P128, DOI 10.1016/j.clim.2012.02.006
   Schmoll HJ, 2018, J CANCER RES CLIN, V144, P1197, DOI 10.1007/s00432-018-2632-6
   Schoppy DW, 2015, HEMATOL ONCOL CLIN N, V29, P1033, DOI 10.1016/j.hoc.2015.07.009
   Sebastian S., 2019, FORUM, V34, P371, DOI [10.1007/s12312-019-0657-7, DOI 10.1007/S12312-019-0657-7]
   Simpson TR, 2013, J EXP MED, V210, P1695, DOI 10.1084/jem.20130579
   Sotelo MJ, 2014, WORLD J GASTROENTERO, V20, P4208, DOI 10.3748/wjg.v20.i15.4208
   Srivastava RM, 2013, CLIN CANCER RES, V19, P1858, DOI 10.1158/1078-0432.CCR-12-2426
   Stein A, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002844
   Strauss L, 2007, CLIN CANCER RES, V13, P4345, DOI 10.1158/1078-0432.CCR-07-0472
   Tang QZ, 2004, EUR J IMMUNOL, V34, P2996, DOI 10.1002/eji.200425143
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Trivedi S, 2015, ANN ONCOL, V26, P40, DOI 10.1093/annonc/mdu156
   Trivedi S, 2016, CLIN CANCER RES, V22, P5229, DOI 10.1158/1078-0432.CCR-15-2971
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2009, ANN ONCOL, V20, P61, DOI 10.1093/annonc/mdp130
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Van den Eynde M, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.80
   Van den Eynde M, 2018, CANCER CELL, V34, P1012, DOI 10.1016/j.ccell.2018.11.003
   Veluchamy JP, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157830
   Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
NR 79
TC 3
Z9 3
U1 0
U2 2
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-4124
EI 1747-4132
J9 EXPERT REV GASTROENT
JI Expert Rev. Gastroenterol. Hepatol.
PD MAY 3
PY 2024
VL 18
IS 4-5
BP 185
EP 192
DI 10.1080/17474124.2023.2232718
EA SEP 2023
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA RW3K7
UT WOS:001065892100001
PM 37705376
DA 2025-01-04
ER

PT S
AU Sartore-Bianchi, A
   Siena, S
AF Sartore-Bianchi, Andrea
   Siena, Salvatore
BE Mandala, M
   Romano, E
TI Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor
   Receptor Inhibitors in Metastatic Colorectal Cancer
SO MECHANISMS OF DRUG RESISTANCE IN CANCER THERAPY
SE Handbook of Experimental Pharmacology
LA English
DT Article; Book Chapter
DE Cetuximab; Colorectal cancer; EGFR; Liquid biopsy; Panitumumab; RAS
ID GENE COPY NUMBER; EGFR MONOCLONAL-ANTIBODIES; CETUXIMAB PLUS IRINOTECAN;
   WILD-TYPE KRAS; RAS MUTATIONS; ACQUIRED-RESISTANCE; EXTRACELLULAR
   DOMAIN; TARGETED THERAPIES; 1ST-LINE TREATMENT; BRAF MUTATION
AB Colorectal cancer (CRC) is one of the most prevalent cancers and the second leading cause of cancer mortality worldwide. Survival in the metastatic setting has been gradually improved by the addition to cytotoxic chemotherapy of agents targeting the vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR). Considerable heterogeneity exists within CRC due to the varied genetic and epigenetic mechanisms involved in differing pathways of carcinogenesis. The knowledge of molecular abnormalities underlying colorectal tumourigenesis and the progression of dysplastic precursors to invasive and ultimately metastatic lesions has advanced in recent years by comprehensive sequencing studies. From these genome-scale analyses, we know that a handful of genes are commonly affected by somatic mutations, whereas recurrent copy-number alterations and chromosomal translocations are rarer in this disease. Even though some of these molecular abnormalities make genes acting as drivers of cancer progression, translation of this recognition for therapeutic purposes is still limited, encompassing only as standard of care the exclusion of RAS-mutated cancers for better selecting patients to candidate to EGFR-targeted therapy with monoclonal antibodies. However, the effort of ameliorating molecular selection should not be considered exhausted by demonstration of RAS and BRAF-induced resistance, as the genomic landscape of response to EGFR blockade has been demonstrated to be wider and dynamically multifaceted. In this chapter we will review main molecular biomarkers of de novo (primary) and acquired (secondary) resistance to EGFR-targeted monoclonal antibodies in metastatic CRC and discuss therapeutic implications.
C1 [Sartore-Bianchi, Andrea; Siena, Salvatore] Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
   [Siena, Salvatore] Univ Milan, Dipartimento Oncol & Ematooncol, Milan, Italy.
C3 University of Milan
RP Sartore-Bianchi, A (corresponding author), Grande Osped Metropolitano Niguarda, Niguarda Canc Ctr, Piazza Osped Maggiore 3, I-20162 Milan, Italy.
EM andrea.sartorebianchi@ospedaleniguarda.it
RI Sartore-Bianchi, Andrea/AAB-9848-2019; SIENA, SALVATORE/AAC-5806-2019
OI Sartore-Bianchi, Andrea/0000-0003-0780-0409; SIENA,
   SALVATORE/0000-0002-2681-2846
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037
   Ciombor KK, 2015, ANNU REV MED, V66, P83, DOI 10.1146/annurev-med-051513-102539
   Corcoran RB, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3517
   Cremolini C, 2015, ANN ONCOL, V26, P2092, DOI 10.1093/annonc/mdv290
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Day E, 2013, INT J EXP PATHOL, V94, P203, DOI 10.1111/iep.12021
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   DIRENZO MF, 1995, CLIN CANCER RES, V1, P147
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Esposito C, 2013, CANCER BIOL THER, V14, P1143, DOI 10.4161/cbt.26340
   Fisher R, 2013, BRIT J CANCER, V108, P479, DOI 10.1038/bjc.2012.581
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Leto SM, 2014, J MOL MED, V92, P709, DOI 10.1007/s00109-014-1161-2
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568
   Martin V, 2013, BRIT J CANCER, V108, P668, DOI 10.1038/bjc.2013.4
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Moroni M, 2005, LANCET ONCOL, V6, P279, DOI 10.1016/S1470-2045(05)70102-9
   Moroni M, 2008, TARGET ONCOL, V3, P127, DOI 10.1007/s11523-008-0073-x
   Newhall K, 2014, ANN ONCOL, V25, pii109, DOI DOI 10.1093/ANNONC/MDU193.11
   Nunes M, 2015, CANCER RES, V75, P1560, DOI 10.1158/0008-5472.CAN-14-1590
   Oh MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047846
   Park DI, 2007, INT J COLORECTAL DIS, V22, P491, DOI 10.1007/s00384-006-0192-8
   Peeters M, 2015, EUR J CANCER, V51, P1704, DOI 10.1016/j.ejca.2015.05.017
   Personeni N, 2008, CLIN CANCER RES, V14, P5869, DOI 10.1158/1078-0432.CCR-08-0449
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612
   Raghav K, 2016, ONCOTARGET, V7, P54627, DOI 10.18632/oncotarget.10559
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Sánchez-Martín FJ, 2016, CLIN CANCER RES, V22, P3260, DOI 10.1158/1078-0432.CCR-15-2400
   Sartore-Bianchi A, 2016, ANN ONCOL, V27, P1456, DOI 10.1093/annonc/mdw191
   Sartore-Bianchi A, 2007, J CLIN ONCOL, V25, P3238, DOI 10.1200/JCO.2007.11.5956
   Sartore-Bianchi A, 2016, CANCER TREAT REV, V51, P54, DOI 10.1016/j.ctrv.2016.10.006
   Sartore-Bianchi A, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2016-000079
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sartore-Bianchi A, 2012, J CLIN PATHOL, V65, P218, DOI 10.1136/jclinpath-2011-200353
   Scartozzi M, 2011, ONCOLOGIST, V16, P53, DOI 10.1634/theoncologist.2010-0119
   Scartozzi M, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-303
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Tannock IF, 2016, NEW ENGL J MED, V375, P1289, DOI 10.1056/NEJMsb1607705
   Thierry AR, 2014, NAT MED, V20, P430, DOI 10.1038/nm.3511
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   Ushijima T, 2016, CANCER RES, V76, P6443, DOI 10.1158/0008-5472.CAN-16-2867
   Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98
   Valtorta E, 2013, INT J CANCER, V133, P1259, DOI 10.1002/ijc.28106
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
   Van Emburgh BO, 2014, MOL ONCOL, V8, P1084, DOI 10.1016/j.molonc.2014.05.003
   Venook AP., 2014, J Clin Oncol., V32, pLBA3, DOI [10.1200/jco.2014.32.18_suppl.lba3, DOI 10.1200/JCO.2014.32.15_SUPPL.LBA3]
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Yuan ZJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058685
   Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049
NR 77
TC 1
Z9 1
U1 0
U2 0
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0171-2004
BN 978-3-030-10507-5; 978-3-030-10506-8
J9 HANDB EXP PHARMACOL
JI Handb. Exp. Pharmacol.
PY 2018
VL 249
BP 145
EP 159
DI 10.1007/164_2017_19
D2 10.1007/978-3-030-10507-5
PG 15
WC Oncology; Pharmacology & Pharmacy
WE Book Citation Index – Science (BKCI-S)
SC Oncology; Pharmacology & Pharmacy
GA BQ3LL
UT WOS:000585703200009
PM 28382467
DA 2025-01-04
ER

PT J
AU Damato, A
   Ghidini, M
   Dottorini, L
   Tomasello, G
   Iaculli, A
   Ghidini, A
   Luciani, A
   Petrelli, F
AF Damato, Angela
   Ghidini, Michele
   Dottorini, Lorenzo
   Tomasello, Gianluca
   Iaculli, Alessandro
   Ghidini, Antonio
   Luciani, Andrea
   Petrelli, Fausto
TI Chemotherapy Duration for Various Indications in Colorectal Cancer: a
   Review
SO CURRENT ONCOLOGY REPORTS
LA English
DT Review
DE Colorectal cancer; Chemotherapy; Duration; Review
ID ADVANCED RECTAL-CANCER; III COLON-CANCER; RESECTABLE LIVER METASTASES;
   TOTAL MESORECTAL EXCISION; ADJUVANT CHEMOTHERAPY; STAGE-II; 1ST-LINE
   TREATMENT; PLUS BEVACIZUMAB; OPEN-LABEL; PREOPERATIVE CHEMORADIOTHERAPY
AB Purpose of ReviewThe treatment of colorectal cancer (CRC) has evolved and become more personalized during the past several years. For example, depotentiation/reduced duration of systemic therapies has proven to be beneficial in both advanced and early stages of the disease.Recent FindingsIn particular, recent randomized studies of stage III and high-risk stage II CRC showed that a shorter duration (3 months), when compared to the historical 6-month comparator, provides nearly similar overall survival (OS) and disease-free survival (DFS). In the setting of advanced, inoperable CRC, a relatively short induction phase (six to eight cycles) followed by biological agents is the current standard of care in RAS wild-type (wt). versus RAS mutated cases. With regard to potentially operable stage IV disease (with the aim of converting liver metastases to operability), a relatively short number of cycles (four to six cycles) should be offered with re-staging and re-evaluation for surgery as soon as possible in most cases. For inoperable liver metastases, a relatively intensive triplet or doublet plus targeted therapy may attain conversion in some cases and may even result in cure. Rectal cancer treatment continues to be a complex disease in terms of treatment and oncological results. Recent data seem to showcase the benefits of more prolonged sequential strategies (total neoadjuvant therapy, all treatment delivered before surgery, to reduce the risk of distant metastases and local control).In recent years, different strategies regarding treatment intensity have been employed in CRC in adjuvant and metastatic setting. Introduction of triplets as first-line therapy for colon cancer and as induction phase for rectal cancer are now therapeutic options. Conversely in stage II disease or low-risk stage III resected CRC, a reduced chemotherapy length is a new standard of care.
C1 [Damato, Angela] Azienda USL Un Sanit Locale IRCCS Ist Ricovero & C, Med Oncol Unit, Reggio Emilia, Italy.
   [Ghidini, Michele; Tomasello, Gianluca] Fdn IRCCs Osped Maggiore Policlin, Oncol Unit, Milan, Italy.
   [Dottorini, Lorenzo; Iaculli, Alessandro] ASST Bergamo Est, Oncol Unit, Seriate, BG, Italy.
   [Ghidini, Antonio] Casa Cura Igea, Oncol Unit, Milan, Italy.
   [Luciani, Andrea; Petrelli, Fausto] ASST Bergamo Ovest, Med Sci Dept, Oncol Unit, Piazzale Osped 1, I-24047 Treviglio, BG, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico
RP Petrelli, F (corresponding author), ASST Bergamo Ovest, Med Sci Dept, Oncol Unit, Piazzale Osped 1, I-24047 Treviglio, BG, Italy.
EM faupe@libero.it
RI Luciani, Andrea/KSM-8704-2024; Damato, Angela/AAC-1343-2019; Ghidini,
   Antonio/ABH-8831-2020
OI Tomasello, Gianluca/0009-0005-0941-8547; Luciani,
   Andrea/0000-0002-9118-2051; Ghidini, Antonio/0000-0002-6142-2018
CR Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4
   Aldo S, 2014, RADIOTHER ONCOL, V113, P223, DOI 10.1016/j.radonc.2014.10.006
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   André T, 2020, LANCET ONCOL, V21, P1620, DOI 10.1016/S1470-2045(20)30527-1
   André T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   [Anonymous], NCCN CLIN PRACTICE G
   Aparicio T, 2018, J CLIN ONCOL, V36, P674, DOI 10.1200/JCO.2017.75.2931
   Aranda E, 2018, EUR J CANCER, V101, P263, DOI 10.1016/j.ejca.2018.06.024
   Bahadoer RR, 2021, LANCET ONCOL, V22, P29, DOI 10.1016/S1470-2045(20)30555-6
   Berry SR, 2015, ANN ONCOL, V26, P477, DOI 10.1093/annonc/mdu272
   Bilchik AJ, 2005, J CLIN ONCOL, V23, P9073, DOI 10.1200/JCO.2005.03.2334
   Bosset JF, 2014, LANCET ONCOL, V15, P184, DOI 10.1016/S1470-2045(13)70599-0
   Boustani J, 2016, CLIN ONCOL-UK, V28, P140, DOI 10.1016/j.clon.2015.11.004
   Bregni G, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0600-2
   Breugom AJ, 2015, ANN ONCOL, V26, P696, DOI 10.1093/annonc/mdu560
   Bujko K, 2010, ANN ONCOL, V21, P1743, DOI 10.1093/annonc/mdq054
   Casadaban L, 2016, CANCER-AM CANCER SOC, V122, P3277, DOI 10.1002/cncr.30181
   Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344
   Conroy T, 2021, LANCET ONCOL, V22, P702, DOI 10.1016/S1470-2045(21)00079-6
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   de Campos-Lobato LF, 2011, ANN SURG ONCOL, V18, P1590, DOI 10.1245/s10434-010-1506-1
   Díaz-Rubio E, 2012, ONCOLOGIST, V17, P15, DOI 10.1634/theoncologist.2011-0249
   European Society of Medical Oncology, 2017, ANN ONCOL
   Fokas Emmanouil, 2019, J Clin Oncol, V37, P3212, DOI 10.1200/JCO.19.00308
   Folprecht G, 2010, LANCET ONCOL, V11, P38, DOI 10.1016/S1470-2045(09)70330-4
   Fontana E, 2021, J CLIN ONCOL, V39, P4009, DOI 10.1200/JCO.21.02008
   Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059
   Glynne-Jones R, 2014, ANN ONCOL, V25, P1356, DOI 10.1093/annonc/mdu147
   Goey KKH, 2017, BRIT J CANCER, V117, P1768, DOI 10.1038/bjc.2017.382
   Govindarajan A, 2011, ANN SURG ONCOL, V18, P3666, DOI 10.1245/s10434-011-1788-y
   Gray R, 2007, LANCET, V370, P2020, DOI 10.1016/s0140-6736(07)61866-2
   Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709
   Hayashi M, 2010, BMC SURG, V10, DOI 10.1186/1471-2482-10-27
   Hegewisch-Becker S, 2015, LANCET ONCOL, V16, P1355, DOI 10.1016/S1470-2045(15)00042-X
   Hong TS, 2015, J CLIN ONCOL, V33, P1878, DOI 10.1200/JCO.2015.60.8554
   Huh JW, 2009, J SURG ONCOL, V100, P387, DOI 10.1002/jso.21342
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iveson TJ, 2021, J CLIN ONCOL, V39, P631, DOI 10.1200/JCO.20.01330
   Jeon YW, 2021, WORLD J GASTRO SURG, V13, DOI 10.4240/wjgs.v13.i9.1000
   Kiran RP, 2012, ANN SURG ONCOL, V19, P1206, DOI 10.1245/s10434-011-2044-1
   Koeberle D, 2015, ANN ONCOL, V26, P709, DOI 10.1093/annonc/mdv011
   Labianca R, 2011, ANN ONCOL, V22, P1236, DOI 10.1093/annonc/mdq580
   Li JY, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/8852699
   Pereira AAL, 2015, ACTA ONCOL, V54, P1737, DOI 10.3109/0284186X.2015.1044022
   Masi G, 2010, LANCET ONCOL, V11, P845, DOI 10.1016/S1470-2045(10)70175-3
   Maughan TS, 2003, LANCET, V361, P457, DOI 10.1016/S0140-6736(03)12461-0
   Milinis K, 2015, WORLD J CLIN ONCOL, V6, P225, DOI 10.5306/wjco.v6.i6.225
   Morano F, 2018, CRIT REV ONCOL HEMAT, V131, P53, DOI 10.1016/j.critrevonc.2018.08.006
   Muratore A, 2007, ANN SURG ONCOL, V14, P766, DOI 10.1245/s10434-006-9146-1
   NCCN, 2021, NCCN Clinical Practice Guidelines in Oncology. Vulvar Cancer Version 1.2022
   Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9
   Nordlinger B, 2013, LANCET ONCOL, V14, P1208, DOI 10.1016/S1470-2045(13)70447-9
   Park IJ, 2012, J CLIN ONCOL, V30, P1770, DOI 10.1200/JCO.2011.39.7901
   Petersen SH, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004078.pub2
   Petrelli F, 2021, ANN ONCOL, V32, P66, DOI 10.1016/j.annonc.2020.10.477
   Petrelli F, 2012, INT J COLORECTAL DIS, V27, P997, DOI 10.1007/s00384-012-1438-2
   Pietrantonio F, 2019, JAMA ONCOL, V5, P1268, DOI 10.1001/jamaoncol.2019.1467
   Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6
   Quidde J, 2016, ANN ONCOL, V27, P2203, DOI 10.1093/annonc/mdw425
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Sobrero AF, 2020, EUR J CANCER, V138, P182, DOI 10.1016/j.ejca.2020.07.031
   Stein A, 2016, CLIN COLORECTAL CANC, V15, pE29, DOI 10.1016/j.clcc.2015.12.005
   Tamburini E, 2016, CRIT REV ONCOL HEMAT, V104, P115, DOI 10.1016/j.critrevonc.2016.05.016
   Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106
   Tournigand C, 2012, J CLIN ONCOL, V30, P3353, DOI 10.1200/JCO.2012.42.5645
   Tveit KM, 2012, J CLIN ONCOL, V30, P1755, DOI 10.1200/JCO.2011.38.0915
   Ye LC, 2013, J CLIN ONCOL, V31, P1931, DOI 10.1200/JCO.2012.44.8308
   Yothers G, 2011, J CLIN ONCOL, V29, P3768, DOI 10.1200/JCO.2011.36.4539
   Zhao L, 2016, ONCOTARGET, V7, P33418, DOI 10.18632/oncotarget.8644
NR 73
TC 6
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1523-3790
EI 1534-6269
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD APR
PY 2023
VL 25
IS 4
BP 341
EP 352
DI 10.1007/s11912-023-01378-5
EA FEB 2023
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA C1FB6
UT WOS:000930477500001
PM 36781622
DA 2025-01-04
ER

PT J
AU Ouchi, K
   Takahashi, S
   Yamada, Y
   Tsuji, S
   Tatsuno, K
   Takahashi, H
   Takahashi, N
   Takahashi, M
   Shimodaira, H
   Aburatani, H
   Ishioka, C
AF Ouchi, Kota
   Takahashi, Shin
   Yamada, Yasuhide
   Tsuji, Shingo
   Tatsuno, Kenji
   Takahashi, Hidekazu
   Takahashi, Naoki
   Takahashi, Masanobu
   Shimodaira, Hideki
   Aburatani, Hiroyuki
   Ishioka, Chikashi
TI DNA methylation status as a biomarker of anti-epidermal growth factor
   receptor treatment for metastatic colorectal cancer
SO CANCER SCIENCE
LA English
DT Article
DE Anti-EGFR treatment; biomarker; colorectal cancer; DNA methylation;
   molecular targeted therapy
ID WILD-TYPE KRAS; 1ST-LINE TREATMENT; PLUS IRINOTECAN; PANITUMUMAB PLUS;
   RAS MUTATIONS; OPEN-LABEL; PHASE-III; FLUOROURACIL; OXALIPLATIN;
   LEUCOVORIN
AB Anti-epidermal growth factor receptor (EGFR) treatment is an effective option for metastatic colorectal cancer (CRC) treatment. However, there are few reliable biomarkers to predict the clinical response to anti-EGFR treatment. We investigated the genome-wide DNA methylation status in metastatic colorectal cancer to identify associations between the methylation status and clinical response to anti-EGFR antibody. We retrospectively reviewed the medical records of 97 patients (45 patients for the first cohort and 52 patients for the second cohort) who received anti-EGFR treatment for KRAS wild-type metastatic CRC. Then we analyzed the associations between genome-wide DNA methylation status and clinical response to anti-EGFR treatment, and evaluated the predictive power and value of the methylation status statistically. As a result, each cohort was classified into highly methylated CRC and low methylated CRC subgroups by unsupervised clustering analyses. In the first cohort, clinical outcomes were significantly better in the low methylated CRC subgroup than in the highly methylated CRC subgroup (response rate, 35.7% vs 6.3%, P = 0.03; disease control rate, 75% vs 31.3%, P = 0.005; hazard ratio for progression-free survival, 0.27; 95% confidence interval, 0.13-0.57, P < 0.001; overall survival, 0.19; 95% confidence interval, 0.06-0.54, P < 0.001). These results were reproducible in the second cohort. The genome-wide methylation status was a predictive factor of progression-free survival and overall survival independently of RAS mutation status. In conclusion, we found that the genome-wide DNA methylation status is a powerful epigenetic predictor of anti-EGFR treatment in patients with KRAS wild-type metastatic colorectal cancer (UMIN000005490).
C1 [Ouchi, Kota; Takahashi, Shin; Takahashi, Hidekazu; Takahashi, Masanobu; Shimodaira, Hideki; Ishioka, Chikashi] Inst Dev Aging & Canc, Dept Clin Oncol, Sendai, Miyagi 9808575, Japan.
   [Ouchi, Kota; Takahashi, Shin; Takahashi, Hidekazu; Takahashi, Masanobu; Shimodaira, Hideki; Ishioka, Chikashi] Tohoku Univ Hosp, Dept Med Oncol, Sendai, Miyagi, Japan.
   [Yamada, Yasuhide; Takahashi, Naoki] Natl Canc Ctr, Gastrointestinal Oncol Div, Tokyo, Japan.
   [Tsuji, Shingo; Tatsuno, Kenji; Aburatani, Hiroyuki] Univ Tokyo, Adv Sci & Technol Res Ctr, Genome Sci Div, Tokyo, Japan.
C3 Tohoku University; National Cancer Center - Japan; University of Tokyo
RP Ishioka, C (corresponding author), Inst Dev Aging & Canc, Dept Clin Oncol, Aoba Ku, 4-1 Seiryo Machi, Sendai, Miyagi 9808575, Japan.
EM chikashi@idac.tohoku.ac.jp
RI Ishioka, Chikashi/AFC-8795-2022; Takahashi, Shin/AAE-5011-2019; 雅信,
   高橋/ITW-2433-2023; Tatsuno, Kenji/B-1765-2008; Yamada,
   Yasuhide/AAH-9124-2020
OI Ouchi, Kota/0000-0002-5572-1337; Ishioka, Chikashi/0000-0002-3023-1227;
   Takahashi, Shin/0000-0001-6695-3099
FU Ministry of Education, Culture, Sports, Science and Technology of Japan;
   Grants-in-Aid for Scientific Research [15H04307, 26460958, 15K08962]
   Funding Source: KAKEN
FX Ministry of Education, Culture, Sports, Science and Technology of Japan.
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Dahlin AM, 2010, CLIN CANCER RES, V16, P1845, DOI 10.1158/1078-0432.CCR-09-2594
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Garrido-Laguna I, 2013, INVEST NEW DRUG, V31, P1257, DOI 10.1007/s10637-013-9947-6
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kim JC, 2011, J CANCER RES CLIN, V137, P1571, DOI 10.1007/s00432-011-1036-7
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Ogino S, 2006, GUT, V55, P1000, DOI 10.1136/gut.2005.082933
   Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Samowitz WS, 2006, J NATL CANCER I, V98, P1731, DOI 10.1093/jnci/djj468
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Siegel RL, 2020, ANTI-CANCER DRUG, V70, P7, DOI [DOI 10.3322/CAAC.21590, DOI 10.1097/CAD.0000000000000617]
   Soeda H, 2014, ONCOLOGY-BASEL, V87, P7, DOI 10.1159/000360989
   Torlakovic EE, 2008, AM J SURG PATHOL, V32, P21, DOI 10.1097/PAS.0b013e318157f002
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Van Cutsem E, 2009, ANN ONCOL, V20, P61, DOI 10.1093/annonc/mdp130
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Weisenberger DJ, 2008, NUCLEIC ACIDS RES, V36, P4689, DOI 10.1093/nar/gkn455
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yagi K, 2010, CLIN CANCER RES, V16, P21, DOI 10.1158/1078-0432.CCR-09-2006
NR 32
TC 24
Z9 26
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1347-9032
EI 1349-7006
J9 CANCER SCI
JI Cancer Sci.
PD DEC
PY 2015
VL 106
IS 12
BP 1722
EP 1729
DI 10.1111/cas.12827
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DB1DY
UT WOS:000368249400009
PM 26426205
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Tsai, HL
   Chen, YC
   Yin, TC
   Su, WC
   Chen, PJ
   Chang, TK
   Li, CC
   Huang, CW
   Wang, JY
AF Tsai, Hsiang-Lin
   Chen, Yen-Cheng
   Yin, Tzu-Chieh
   Su, Wei-Chih
   Chen, Po-Jung
   Chang, Tsung-Kun
   Li, Ching-Chun
   Huang, Ching-Wen
   Wang, Jaw-Yuan
TI Comparison of <i>UGT1A1</i> Polymorphism as Guidance of Irinotecan Dose
   Escalation in <i>RAS</i> Wild-Type Metastatic Colorectal Cancer Patients
   Treated With Cetuximab or Bevacizumab Plus FOLFIRI as the First-Line
   Therapy
SO ONCOLOGY RESEARCH
LA English
DT Article
DE Metastatic colorectal cancer (mCRC); Irinotecan dose escalation;
   Biologics; Efficacy; Safety
ID GENOTYPING REDUCE MORBIDITY; UGT1A1-ASTERISK-28 GENOTYPE;
   ACQUIRED-RESISTANCE; INDUCED NEUTROPENIA; PRIMARY TUMOR; PHASE-II;
   FLUOROURACIL; LEUCOVORIN; CHEMOTHERAPY; TRIAL
AB Uridine diphosphate glucuronosyltransferase 1A1 (UGT1A1) polymorphism plays a crucial role in the increased susceptibility and toxicity of patients to irinotecan. This retrospective, observational study compared the clinical outcomes and adverse events (AEs) in RAS wild-type metastatic colorectal cancer (mCRC) patients treated with cetuximab or bevacizumab plus FOLFIRI with UGT1A1 genotyping and irinotecan dose escalation as the first-line therapy. In total, 173 patients with mCRC with RAS wild-type were enrolled. Among them, 98 patients were treated with cetuximab, whereas 75 patients were treated with bevacizumab. All patients received irinotecan dose escalation based on UGT1A1 genotyping. We compared the progression-free survival (PFS), overall survival (OS), objective response rates (ORRs), disease control rates (DCRs), metastatectomy, and severe adverse events (SAEs) between the two groups. The clinical effects of primary tumor sidedness and target therapy crossover were further analyzed. Over a median follow-up of 23.0 months [interquartile range (IQR), 15.0???32.5 months], no significant differences were observed between the cetuximab and bevacizumab groups in PFS [18.0 months vs. 14.0 months; 95% confidence interval (CI), 0.517???1.027; hazard ratio (HR), 0.729; p = 0.071], OS (40.0 months vs. 30.0 months; 95% CI, 0.410???1.008; HR, 0.643; p = 0.054), ORR (65.3% vs. 62.7%; p = 0.720), DCR (92.8% vs. 86.7%; p = 0.175), metastatectomy (36.7% vs. 29.3%; p = 0.307), and SAEs (p = 0.685). Regardless of primary tumor sidedness and target therapy crossover, no significant differences were noted in efficacy and safety between the two groups (all p > 0.05). Our results revealed that patients with wild-type RAS mCRC, regardless of biologics, with UGT1A1 genotyping can tolerate escalated doses of irinotecan and potentially achieve a more favorable clinical outcome without significantly increased toxicity.
C1 [Tsai, Hsiang-Lin; Chen, Yen-Cheng; Yin, Tzu-Chieh; Su, Wei-Chih; Chen, Po-Jung; Chang, Tsung-Kun; Li, Ching-Chun; Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, 100 Tzyou 1st Rd, Kaohsiung 807, Taiwan.
   [Tsai, Hsiang-Lin; Chang, Tsung-Kun; Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Dept Surg, Coll Med, Fac Med, Kaohsiung, Taiwan.
   [Chen, Yen-Cheng; Su, Wei-Chih; Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung, Taiwan.
   [Yin, Tzu-Chieh] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Div Gen & Digest Surg, Dept Surg, Kaohsiung, Taiwan.
   [Yin, Tzu-Chieh] Kaohsiung Med Univ, Kaohsiung Municipal Tatung Hosp, Dept Surg, Kaohsiung, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Ctr Liquid Biopsy & Cohort Res, Kaohsiung, Taiwan.
   [Wang, Jaw-Yuan] Pingtung Hosp, Minist Hlth & Welf, Pingtung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University Hospital; Kaohsiung
   Medical University; Kaohsiung Municipal Ta-Tung Hospital; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University
RP Wang, JY (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, 100 Tzyou 1st Rd, Kaohsiung 807, Taiwan.
EM cy614112@ms14.hinet.net
RI Jaw-Yuan, Wang/AFS-8845-2022
OI Wang, Jaw-Yuan/0000-0002-7705-2621
FU Ministry of Science and Technology [MOST 109-2314-B-037-035, MOST
   109-2314-B-037-040, MOST 109-2314-B-037-046-MY3, MOST110-2314-B037-097];
   Ministry of Health and Welfare [MOHW109TDU-B-212-134026,
   MOHW109-TDU-B-212-114006, MOHW110-TDU-B-212-1140026]; Kaohsiung Medical
   University Hospital [KMUH109-9R33, KMUH1100R37, KMUH110-0R38,
   KMUH110-0M34, KMUH110-0M35, KMUH110-0M36, KMUHSA11013, 110010]; KMU
   Center for Cancer Research [KMU-TC111A04-1]; KMU Center for Liquid
   Biopsy [KMU-TC109B05]; KMU Office for Industry-Academic Collaboration
   [S109036]; Kaohsiung Medical University; Grant of Taiwan Precision
   Medicine Initiative, Academia Sinica, Taiwan, ROC
FX This work was supported by grants through funding from the Ministry of
   Science and Technology (MOST 109-2314-B-037-035, MOST
   109-2314-B-037-040, MOST 109-2314-B-037-046-MY3, and
   MOST110-2314-B037-097) and the Ministry of Health and Welfare
   (MOHW109TDU-B-212-134026, MOHW109-TDU-B-212-114006, and
   MOHW110-TDU-B-212-1140026), and funded by the health and welfare
   surcharge of on tobacco products and the Kaohsiung Medical University
   Hospital (KMUH109-9R33, KMUH1100R37, KMUH110-0R38, KMUH110-0M34,
   KMUH110-0M35, KMUH110-0M36, KMUHSA11013, KMUH-DK(C)110010, and
   KMUH-DK(B)110004-3), KMU Center for Cancer Research (KMU-TC111A04-1),
   KMU Center for Liquid Biopsy and Cohort Research Center Grant
   (KMU-TC109B05), and KMU Office for Industry-Academic Collaboration
   (S109036), Kaohsiung Medical University. In addition, this study was
   supported by the Grant of Taiwan Precision Medicine Initiative, Academia
   Sinica, Taiwan, ROC. The authors declare no conflicts of interest.
CR Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Berg AO, 2009, GENET MED, V11, P15, DOI 10.1097/GIM.0b013e31818efd9d
   Chen ZW, 2014, GENE, V552, P32, DOI 10.1016/j.gene.2014.09.009
   Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03
   De Mattia E, 2015, DRUG RESIST UPDATE, V20, P39, DOI 10.1016/j.drup.2015.05.003
   Folprecht G, 2010, LANCET ONCOL, V11, P38, DOI 10.1016/S1470-2045(09)70330-4
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Goel G, 2018, CANCER MANAG RES, V10, P425, DOI 10.2147/CMAR.S88825
   Heinemann V, 2021, BRIT J CANCER, V124, P587, DOI 10.1038/s41416-020-01140-9
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hoskins JM, 2007, J NATL CANCER I, V99, P1290, DOI 10.1093/jnci/djm115
   Hsieh YC, 2021, J ONCOL, V2021, DOI 10.1155/2021/6686517
   Hu ZY, 2010, CLIN CANCER RES, V16, P3832, DOI 10.1158/1078-0432.CCR-10-1122
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Lu CY, 2015, TRANSL ONCOL, V8, P474, DOI 10.1016/j.tranon.2015.11.002
   Ma CJ, 2017, ONCOL RES, V25, P673, DOI 10.3727/97818823455816X14786040691928
   Marcuello E, 2011, BRIT J CANCER, V105, P53, DOI 10.1038/bjc.2011.206
   McLeod HL, 2010, J CLIN ONCOL, V28, P3227, DOI 10.1200/JCO.2009.21.7943
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Moretto R, 2016, ONCOLOGIST, V21, P988, DOI 10.1634/theoncologist.2016-0084
   O'Dwyer PJ, 2001, J CLIN ONCOL, V19, P2413, DOI 10.1200/JCO.2001.19.9.2413
   Páez D, 2019, BRIT J CANCER, V120, P190, DOI 10.1038/s41416-018-0348-7
   Palomaki GE, 2009, GENET MED, V11, P21, DOI 10.1097/GIM.0b013e31818efd77
   Peeters M, 2012, CANCER TREAT REV, V38, P397, DOI 10.1016/j.ctrv.2011.08.002
   Petrelli F, 2017, ANN SURG ONCOL, V24, P2655, DOI 10.1245/s10434-017-5832-4
   Phelip JM, 2016, ANN SURG ONCOL, V23, P2161, DOI 10.1245/s10434-015-5072-4
   Shulman K, 2011, CANCER-AM CANCER SOC, V117, P3156, DOI 10.1002/cncr.25735
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Toffoli G, 2010, J CLIN ONCOL, V28, P866, DOI 10.1200/JCO.2009.23.6125
   Tsai HL, 2009, OPEN COLORECTAL CANC, V2, P21
   Tsai HL, 2020, EUR J CANCER, V138, P19, DOI 10.1016/j.ejca.2020.05.031
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Viloria-Petit A, 2001, CANCER RES, V61, P5090
   Yahagi M, 2016, J GASTROINTEST SURG, V20, P648, DOI 10.1007/s11605-015-3026-6
   Yan W, 2013, GENET MOL RES, V12, P6454, DOI 10.4238/2013.December.10.6
   Yeh YS, 2016, TRIALS, V17, DOI 10.1186/s13063-016-1153-3
   Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738
NR 40
TC 11
Z9 11
U1 0
U2 2
PU COGNIZANT COMMUNICATION CORP
PI PUTNAM VALLEY
PA 18 PEEKSKILL HOLLOW RD, PO BOX 37, PUTNAM VALLEY, NY 10579 USA
SN 0965-0407
EI 1555-3906
J9 ONCOL RES
JI Oncol. Res.
PY 2021
VL 29
IS 1
BP 47
EP 61
DI 10.3727/096504022X16451187313084
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 1L3MO
UT WOS:000799195900005
PM 35177165
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Jacome, AA
   Peixoto, RD
   Gil, M
   Ominelli, J
   Prolla, G
   Dienstmann, R
   Eng, C
AF Jacome, Alexandre A.
   Peixoto, Renata D'Alpino
   Gil, Mariana, V
   Ominelli, Juliana
   Prolla, Gabriel
   Dienstmann, Rodrigo
   Eng, Cathy
TI Biologics in rectal cancer
SO EXPERT OPINION ON BIOLOGICAL THERAPY
LA English
DT Review
DE Antineoplastic agents; angiogenesis inhibitors; monoclonal antibodies;
   immune checkpoint inhibitors; immunoconjugates; bispecific antibodies;
   genic therapy; precision medicine
ID METASTATIC COLORECTAL-CANCER; CETUXIMAB PLUS IRINOTECAN; HEPATIC
   ARTERIAL INFUSION; TOTAL MESORECTAL EXCISION; PHASE-III TRIAL; WILD-TYPE
   KRAS; MICROSATELLITE INSTABILITY; COLON-CANCER; OPEN-LABEL; PREOPERATIVE
   CHEMORADIOTHERAPY
AB Introduction Despite the use of multimodality therapy, locally advanced rectal cancer (LARC) still presents high rates of disease recurrence. Fluoropyrimidine-based chemotherapy concurrently with radiation therapy (RT) remains the cornerstone of neoadjuvant therapy of LARC, and novel therapies are urgently needed in order to improve the clinical outcomes. Areas covered We aim to summarize data from completed and ongoing clinical trials addressing the role of biological therapies, including monoclonal antibodies, immune checkpoint inhibitors (ICIs), antibody-drug conjugates, bispecific antibodies, and gene therapies in the systemic therapy of rectal cancer. Expert opinion Deeper understanding of the molecular biology of colorectal cancer (CRC) has allowed meaningful advances in the systemic therapy of metastatic disease in the past few years. The larger applicability of biological therapy in CRC, including genome-guided targeted therapy, antiangiogenics, and immunotherapy, gives us optimism for the personalized management of rectal cancer. Microsatellite instability (MSI) tumors have demonstrated high sensitivity to ICIs, and preliminary findings in the neoadjuvant setting of rectal cancer are promising. To date, antiangiogenic and anti-EGFR therapies in LARC have not demonstrated the same benefit seen in metastatic disease. The outstanding results accomplished by biomarker-guided therapy in metastatic CRC will guide future developments of biological therapy in LARC.
C1 [Jacome, Alexandre A.] Oncoclin, Dept Gastrointestinal Med Oncol, Rua Roma 561, BR-30360680 Belo Horizonte, MG, Brazil.
   [Peixoto, Renata D'Alpino] Oncoclin, Dept Gastrointestinal Med Oncol, Sao Paulo, Brazil.
   [Gil, Mariana, V; Ominelli, Juliana] Oncoclin, Dept Gastrointestinal Med Oncol, Rio De Janeiro, Brazil.
   [Prolla, Gabriel] Oncoclin, Dept Gastrointestinal Med Oncol, Porto Alegre, RS, Brazil.
   [Dienstmann, Rodrigo] Oncoclin Precis Med, Sao Paulo, Brazil.
   [Eng, Cathy] Vanderbilt Ingram Canc Ctr, Div Hematol & Oncol, Dept Med, Nashville, TN USA.
C3 Vanderbilt University
RP Jacome, AA (corresponding author), Oncoclin, Dept Gastrointestinal Med Oncol, Rua Roma 561, BR-30360680 Belo Horizonte, MG, Brazil.
EM alexandre.jacome@medicos.oncoclinicas.com
RI Jácome, Alexandre/AAW-7749-2020; PROLLA, GABRIEL/T-3669-2018
OI Jacome, Alexandre/0000-0001-9070-4383
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   ANONYMOUS, 2021, J CLIN ONCOL, V39
   [Anonymous], 2020, KEYTR PEMBR PACK INS
   [Anonymous], 2017, J CLIN ONCOL
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Atencio IA, 2006, CANCER GENE THER, V13, P169, DOI 10.1038/sj.cgt.7700870
   Avallone A, 2015, ONCOTARGET, V6, P30394, DOI 10.18632/oncotarget.4724
   Bahadoer RR, 2021, LANCET ONCOL, V22, P29, DOI 10.1016/S1470-2045(20)30555-6
   Bando H, 2022, CLIN CANCER RES, V28, P1136, DOI 10.1158/1078-0432.CCR-21-3213
   Barzi A, 2020, ONCOLOGIST, V25, pE1879, DOI 10.1634/theoncologist.2020-0642
   Bendell JC, 2017, CANCER INVEST, V35, P535, DOI 10.1080/07357907.2017.1344700
   Bertolini F, 2009, INT J RADIAT ONCOL, V73, P466, DOI 10.1016/j.ijrobp.2008.04.065
   Bonner JA, 2010, LANCET ONCOL, V11, P21, DOI 10.1016/S1470-2045(09)70311-0
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Capirci C, 2008, INT J RADIAT ONCOL, V72, P99, DOI 10.1016/j.ijrobp.2007.12.019
   Cercek A, 2022, NEW ENGL J MED, V386, P2363, DOI 10.1056/NEJMoa2201445
   Chau CH, 2019, LANCET, V394, P793, DOI 10.1016/S0140-6736(19)31774-X
   Chen G, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.e15602
   Chen Y, 2002, INT J COLORECTAL DIS, V17, P388, DOI 10.1007/s00384-002-0400-0
   Conradi LC, 2013, AM J SURG PATHOL, V37, P522, DOI 10.1097/PAS.0b013e318272ff4d
   Conroy T, 2021, LANCET ONCOL, V22, P702, DOI 10.1016/S1470-2045(21)00079-6
   Cross D, 2006, CLIN MED RES, V4, P218, DOI 10.3121/cmr.4.3.218
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Dallas MR, 2012, FASEB J, V26, P2648, DOI 10.1096/fj.12-203786
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Dellas K, 2013, RADIAT ONCOL, V8, DOI 10.1186/1748-717X-8-90
   Dewdney A, 2012, J CLIN ONCOL, V30, P1620, DOI 10.1200/JCO.2011.39.6036
   do Pazo C, 2021, NAT REV DRUG DISCOV, V20, P583, DOI 10.1038/d41573-021-00054-2
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Eisterer WM, 2009, J CLIN ONCOL, V27
   Erlandsson J, 2017, LANCET ONCOL, V18, P336, DOI 10.1016/S1470-2045(17)30086-4
   Fernandez-Martos C, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3512
   Fernández-Martos C, 2019, JAMA ONCOL, V5, P1566, DOI 10.1001/jamaoncol.2019.2294
   Fernandez-Martos C, 2014, ONCOLOGIST, V19, P1042, DOI 10.1634/theoncologist.2014-0233
   Fokas Emmanouil, 2019, J Clin Oncol, V37, P3212, DOI 10.1200/JCO.19.00308
   García M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1052-0
   George TJ, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.099
   Goéré D, 2013, CANCER RES, V73, P4663, DOI 10.1158/0008-5472.CAN-12-4460
   Haas C, 2009, IMMUNOBIOLOGY, V214, P441, DOI 10.1016/j.imbio.2008.11.014
   Hammarström S, 1999, SEMIN CANCER BIOL, V9, P67, DOI 10.1006/scbi.1998.0119
   Hasan S, 2020, ANN SURG, V271, P716, DOI 10.1097/SLA.0000000000003051
   Hasegawa J, 2014, CANCER CHEMOTH PHARM, V73, P1079, DOI 10.1007/s00280-014-2417-9
   Heiss MM, 2010, INT J CANCER, V127, P2209, DOI 10.1002/ijc.25423
   Helbling D, 2013, ANN ONCOL, V24, P718, DOI 10.1093/annonc/mds519
   Herrmann I, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013474
   Higashijima J, 2021, INT J CLIN ONCOL, V26, P875, DOI 10.1007/s10147-021-01868-1
   Hoffmann P, 2005, INT J CANCER, V115, P98, DOI 10.1002/ijc.20908
   Hong SP, 2012, EUR J CANCER, V48, P1235, DOI 10.1016/j.ejca.2011.10.005
   Horisberger K, 2009, INT J RADIAT ONCOL, V74, P1487, DOI 10.1016/j.ijrobp.2008.10.014
   Kennecke H, 2012, EUR J CANCER, V48, P37, DOI 10.1016/j.ejca.2011.05.016
   Kim SY, 2011, INT J RADIAT ONCOL, V81, P677, DOI 10.1016/j.ijrobp.2010.06.035
   Kolodkin-Gal D, 2009, GENE THER, V16, P905, DOI 10.1038/gt.2009.44
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Leichman CG, 2018, CLIN COLORECTAL CANC, V17, pE121, DOI 10.1016/j.clcc.2017.10.008
   Li SY, 2005, CLIN CANCER RES, V11, P3574, DOI 10.1158/1078-0432.CCR-04-2077
   Lin ZY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003554
   LITVINOV SV, 1994, J CELL BIOL, V125, P437, DOI 10.1083/jcb.125.2.437
   Lumish MA, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.016
   Ma JB, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.626616
   Maetzel D, 2009, NAT CELL BIOL, V11, P162, DOI 10.1038/ncb1824
   Mardjuadi FI, 2015, TARGET ONCOL, V10, P375, DOI 10.1007/s11523-014-0342-9
   Mau-Sorensen M, 2015, CANCER CHEMOTH PHARM, V75, P1065, DOI 10.1007/s00280-015-2728-5
   May C, 2012, BIOCHEM PHARMACOL, V84, P1105, DOI 10.1016/j.bcp.2012.07.011
   McCollum AD, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.3_suppl.537
   Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Merx K, 2017, INT J RADIAT ONCOL, V99, P867, DOI 10.1016/j.ijrobp.2017.06.2460
   Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275
   Nguyen TH., 2020, CURR GASTROENTEROL R, V22, P1
   Noepel-Duennebacke S, 2020, Z GASTROENTEROL, V58, P533, DOI 10.1055/a-1156-4433
   O'Connell E, 2020, SURG ONCOL, V34, P57, DOI 10.1016/j.suronc.2020.03.009
   Oberst MD, 2014, MABS-AUSTIN, V6, P1571, DOI 10.4161/19420862.2014.975660
   Oh CR, 2018, CLIN COLORECTAL CANC, V17, pE679, DOI 10.1016/j.clcc.2018.07.003
   Peeters M, 2018, BRIT J CANCER, V119, P303, DOI 10.1038/s41416-018-0165-z
   Phipps AI, 2013, DIS COLON RECTUM, V56, P937, DOI 10.1097/DCR.0b013e31828f9a57
   Pinto C, 2011, ANN ONCOL, V22, P2424, DOI 10.1093/annonc/mdq782
   Pinto C, 2018, ONCOLOGIST, V23, P912, DOI 10.1634/theoncologist.2017-0484
   Pishvaian M, 2016, CLIN COLORECTAL CANC, V15, P345, DOI 10.1016/j.clcc.2016.07.009
   Rahma OE, 2021, JAMA ONCOL, V7, P1225, DOI 10.1001/jamaoncol.2021.1683
   Reid T, 2002, CANCER RES, V62, P6070
   Rödel C, 2008, INT J RADIAT ONCOL, V70, P1081, DOI 10.1016/j.ijrobp.2007.07.2356
   Sadahiro S, 2015, ONCOLOGY-BASEL, V88, P49, DOI 10.1159/000367972
   Salazar R, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1053-z
   Salazar R, 2011, J CLIN ONCOL, V29, P17, DOI 10.1200/JCO.2010.30.1077
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sauer R, 2004, NEW ENGL J MED, V351, P1731, DOI 10.1056/NEJMoa040694
   Schlereth B, 2005, CANCER RES, V65, P2882, DOI 10.1158/0008-5472.CAN-04-2637
   Schrag D, 2014, J CLIN ONCOL, V32, P513, DOI 10.1200/JCO.2013.51.7904
   Seeber A, 2018, ONCOL RES TREAT, V41, P188, DOI 10.1159/000488301
   Seimetz D, 2010, CANCER TREAT REV, V36, P458, DOI 10.1016/j.ctrv.2010.03.001
   Shamseddine A, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01673-6
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Siena S, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.tps774
   Sun PL, 2012, INT J COLORECTAL DIS, V27, P1325, DOI 10.1007/s00384-012-1446-2
   Sung MW, 2001, MOL THER, V4, P182, DOI 10.1006/mthe.2001.0444
   Tamberi S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3607
   Tejpar S, 2017, JAMA ONCOL, V3, P194, DOI 10.1001/jamaoncol.2016.3797
   Tomida A, 2019, INT J CLIN ONCOL, V24, P403, DOI 10.1007/s10147-018-1372-6
   Toritani K, 2020, INT J COLORECTAL DIS, V35, P2197, DOI 10.1007/s00384-020-03693-w
   Uehara K, 2013, JPN J CLIN ONCOL, V43, P964, DOI 10.1093/jjco/hyt115
   Uhlig J, 2021, J NATL COMPR CANC NE, V19, P307, DOI 10.6004/jnccn.2020.7619
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   van der Valk MJM, 2018, LANCET, V391, P2537, DOI 10.1016/S0140-6736(18)31078-X
   Velenik V, 2010, EJSO-EUR J SURG ONC, V36, P244, DOI 10.1016/j.ejso.2009.12.002
   Velenik V, 2020, RADIOL ONCOL, V54, P461, DOI 10.2478/raon-2020-0043
   Velenik V, 2011, RADIAT ONCOL, V6, DOI 10.1186/1748-717X-6-105
   Weiss J, 2021, ANN ONCOL, V32, pS1294, DOI 10.1016/j.annonc.2021.08.2093
   Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yu X, 2018, CANCER COMMUN, V38, DOI 10.1186/s40880-018-0294-z
   Zhong X, 2018, CANCER MED-US, V7, P565, DOI 10.1002/cam4.1298
NR 118
TC 0
Z9 0
U1 1
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1471-2598
EI 1744-7682
J9 EXPERT OPIN BIOL TH
JI Expert Opin. Biol. Ther.
PD OCT 3
PY 2022
VL 22
IS 10
BP 1245
EP 1257
DI 10.1080/14712598.2022.2108700
EA AUG 2022
PG 13
WC Biotechnology & Applied Microbiology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Research & Experimental Medicine
GA 5L6BS
UT WOS:000836054100001
PM 35912589
DA 2025-01-04
ER

PT J
AU Cheshomi, H
   Gholami, O
   Peyroshabani, B
   Rad, A
AF Cheshomi, Hamid
   Gholami, Omid
   Peyroshabani, Babak
   Rad, Abolfazl
TI Impact of OCT4 and Its Related Signaling Pathways on Gastrointestinal
   Cancers: Focusing on Targeted Therapy
SO IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY
LA English
DT Review
DE Colorectal cancer; Esophageal neoplasms; Stomach neoplasms
ID STEM-CELL MARKERS; HUMAN EMBRYONIC STEM; COLORECTAL-CANCER;
   GASTRIC-CANCER; COLON-CANCER; GENE-EXPRESSION; ESOPHAGEAL CANCER;
   MESENCHYMAL TRANSITION; PROGNOSTIC VALUE; PROSTATE-CANCER
AB There are many pieces of evidence support the effect of cancer stem cells on the initiation and progression of cancer. However, related mechanisms involved in these phenomena are far more complicated to understand. The function of different stemness factorsin cancer stem cells (CSCs) and their complex associations at different levels of cancer have been reported. Therefore, it seems that focusing on one master factor would be more helpful to complete the puzzle of singling pathways in these cells. Octamer-binding transcription factor 4 (OCT4) also known as POU domain, class 5, transcription factor 1(POU5F1), one of these key pluripotency factors, has important roles in both embryogenesis and tumorigenesis.
   In this review, we gathered information about the association of different markers with OCT4 expression in three types of gastrointestinal cancers including esophageal, gastric and colorectal cancers.
   OCT4 through different signaling pathways has an impact on different processes of gastrointestinal cancers such as proliferation, invasion, and metastasis.
   Based on the literature, OCT4 has great effects on cancer progression at different stages, therefore we suggested it has potential implications in therapeutic options.
C1 [Cheshomi, Hamid; Gholami, Omid; Rad, Abolfazl] Sabzevar Univ Med Sci, Cellular & Mol Res Ctr, POB 9816745639, Sabzevar, Iran.
   [Peyroshabani, Babak] Sabzevar Univ Med Sci, Clin Res Dev Unit, Sabzevar, Iran.
RP Rad, A (corresponding author), Sabzevar Univ Med Sci, Cellular & Mol Res Ctr, POB 9816745639, Sabzevar, Iran.
EM rad6790@yahoo.com
RI Rad, Aboulfazl/JAX-9178-2023; Cheshomi, Hamid/G-1125-2016; gholami,
   omid/H-5938-2017
OI Rad, Abolfazl/0000-0001-8627-8828
CR Al-Marzoqee FY, 2012, INT J ONCOL, V41, P1733, DOI 10.3892/ijo.2012.1608
   Amini S, 2014, ANAT CELL BIOL, V47, P1, DOI 10.5115/acb.2014.47.1.1
   Amsterdam A, 2013, ACTA HISTOCHEM, V115, P320, DOI 10.1016/j.acthis.2012.09.003
   An Y, 2017, J CELL MOL MED, V21, P185, DOI 10.1111/jcmm.12952
   [Anonymous], CLIN CANC RES
   Asadi MH, 2011, INT J CANCER, V128, P2645, DOI 10.1002/ijc.25643
   Atlasi Y, 2008, STEM CELLS, V26, P3068, DOI 10.1634/stemcells.2008-0530
   Batsaikhan BE, 2014, ANTICANCER RES, V34, P6339
   Bedard PL, 2013, NATURE, V501, P355, DOI 10.1038/nature12627
   Bornschein J, 2013, J CLIN PATHOL, V66, P819, DOI 10.1136/jclinpath-2013-201448
   Brehm A, 1997, MOL CELL BIOL, V17, P154, DOI 10.1128/MCB.17.1.154
   Cantz T, 2008, STEM CELLS, V26, P692, DOI 10.1634/stemcells.2007-0657
   Cauffman G, 2006, STEM CELLS, V24, P2685, DOI 10.1634/stemcells.2005-0611
   Chang CJ, 2011, BIOCHEM BIOPH RES CO, V415, P245, DOI 10.1016/j.bbrc.2011.10.024
   Chen BR, 2019, ONCOTARGETS THER, V12, P4667, DOI 10.2147/OTT.S209734
   Chen J, 2015, INT J ONCOL, V47, P1476, DOI 10.3892/ijo.2015.3138
   Chen SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056380
   Chen SS, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0049275, 10.1371/journal.pone.0036784, 10.1371/journal.pone.0050456, 10.1371/journal.pone.0045763]
   Chen XL, 2016, ONCOTARGET, V7, P62049, DOI 10.18632/oncotarget.11384
   Chen Z, 2009, J SURG ONCOL, V99, P414, DOI 10.1002/jso.21270
   Cheng L, 2004, CANCER-AM CANCER SOC, V101, P2006, DOI 10.1002/cncr.20566
   Costabile V, 2015, INT J ONCOL, V46, P1913, DOI 10.3892/ijo.2015.2911
   Dai XZ, 2013, ONCOL REP, V29, P155, DOI 10.3892/or.2012.2086
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Deb-Rinker P, 2005, J BIOL CHEM, V280, P6257, DOI 10.1074/jbc.C400479200
   Dewi DL, 2012, INT J MOL MED, V29, P1060, DOI 10.3892/ijmm.2012.945
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Fidalgo M, 2012, P NATL ACAD SCI USA, V109, P16202, DOI 10.1073/pnas.1208533109
   Fukuda K, 2009, INT J ONCOL, V34, P1201, DOI 10.3892/ijo_00000248
   Gazouli M, 2012, MOL CARCINOGEN, V51, P165, DOI 10.1002/mc.20773
   Ghodsi M, 2015, INT J SURG, V13, P193, DOI 10.1016/j.ijsu.2014.11.036
   Gidekel S, 2003, CANCER CELL, V4, P361, DOI 10.1016/S1535-6108(03)00270-8
   Grander D, 2015, LONG NONCODING RNAS, P111
   Guo JB, 2016, TECHNOL CANCER RES T, V15, P60, DOI 10.1177/1533034614566413
   Guo XP, 2012, CLIN EXP MED, V12, P207, DOI 10.1007/s10238-011-0163-4
   Hayashi H, 2015, ONCOGENE, V34, P199, DOI 10.1038/onc.2013.547
   He W, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-426
   Hong KJ, 2014, J CELL PHYSIOL, V229, P191, DOI 10.1002/jcp.24434
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182
   Izadpanah MH, 2017, CELL MOL BIOL LETT, V22, DOI 10.1186/s11658-017-0065-x
   Ji W, 2013, ONCOL LETT, V6, P367, DOI 10.3892/ol.2013.1394
   Jung P, 2011, NAT MED, V17, P1225, DOI 10.1038/nm.2470
   Kemper K, 2012, STEM CELLS, V30, P2378, DOI 10.1002/stem.1233
   Khorrami S, 2015, IRAN J CANCER PREV, V8, DOI 10.17795/ijcp-3446
   Kim Ran-Ju, 2011, Lab Anim Res, V27, P147, DOI 10.5625/lar.2011.27.2.147
   Kong DQ, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0130-5
   Koren A, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/9714315
   Koshkin S, 2016, TUMOR BIOL, V37, P12833, DOI 10.1007/s13277-016-5214-8
   Lee J.W.M., 2006, J BIOL CHEM
   Lengerke C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-42
   Li CG, 2017, ONCOTARGET, V8, P71933, DOI 10.18632/oncotarget.18035
   Li CG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049693
   Li N, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0433-6
   Li ZG, 2014, CANCER LETT, V354, P77, DOI 10.1016/j.canlet.2014.07.049
   Liang K, 2014, SAUDI J GASTROENTERO, V20, P188, DOI 10.4103/1319-3767.133025
   Lin T, 2012, MED ONCOL, V29, P878, DOI 10.1007/s12032-011-9860-9
   Litwin M, 2015, ANTICANCER RES, V35, P3317
   Liu JM, 2013, INT J ONCOL, V42, P453, DOI 10.3892/ijo.2012.1720
   Liu RL, 2008, CHINESE MED J-PEKING, V121, P299, DOI 10.1097/00029330-200802020-00004
   Liu X, 2017, CLIN TRANSL ONCOL, V19, P587, DOI 10.1007/s12094-016-1569-y
   Liu YH, 2013, MED ONCOL, V30, DOI 10.1007/s12032-012-0426-2
   Long WY, 2018, J MOL CELL BIOL, V10, P147, DOI 10.1093/jmcb/mjy007
   Lönnroth C, 2014, INT J ONCOL, V45, P2208, DOI 10.3892/ijo.2014.2686
   Lu X, 2014, ONCOGENE, V33, P2655, DOI 10.1038/onc.2013.209
   Lu Y, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011022
   Madani GK, 2018, J GASTROINTEST CANC, V49, P437, DOI 10.1007/s12029-017-9985-y
   Mao J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2013.515
   Mao JH, 2017, STEM CELLS, V35, P2267, DOI 10.1002/stem.2702
   Miranda PV, 2009, BIOL REPROD, V80, P897, DOI 10.1095/biolreprod.108.075242
   Monk M, 2001, ONCOGENE, V20, P8085, DOI 10.1038/sj.onc.1205088
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Müller M, 2016, STEM CELL RES, V16, P349, DOI 10.1016/j.scr.2016.02.005
   Munro MJ, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0221963
   Nagaraja V, 2014, J GASTROINTEST ONCOL, V5, P67, DOI 10.3978/j.issn.2078-6891.2013.054
   Napier KJ, 2014, WORLD J GASTRO ONCOL, V6, P112, DOI 10.4251/wjgo.v6.i5.112
   Nishii T, 2009, CANCER SCI, V100, P1397, DOI 10.1111/j.1349-7006.2009.01211.x
   Niwa H, 2000, NAT GENET, V24, P372, DOI 10.1038/74199
   Niwa H, 2001, CELL STRUCT FUNCT, V26, P137, DOI 10.1247/csf.26.137
   Nosrati A, 2014, INT J MOL CELL MED, V3, P279
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ong CW, 2015, ONCOTARGET, V6, P12763
   Padín-Iruegas ME, 2013, ONCOL REP, V29, P2467, DOI 10.3892/or.2013.2368
   Pain D, 2005, J BIOL CHEM, V280, P6265, DOI 10.1074/jbc.C400587200
   Pan GJ, 2002, CELL RES, V12, P321, DOI 10.1038/sj.cr.7290134
   Pesce M, 2001, STEM CELLS, V19, P271, DOI 10.1634/stemcells.19-4-271
   Poursani EM, 2017, GENE, V627, P369, DOI 10.1016/j.gene.2017.06.032
   Poursani EM, 2016, CELL J, V18, P28
   Qiao XTT, 2011, J GASTROENTEROL, V46, P855, DOI 10.1007/s00535-011-0413-y
   Rad A, 2016, TUMOR BIOL, V37, P1715, DOI 10.1007/s13277-015-3780-9
   Raghoebir L, 2012, J MOL CELL BIOL, V4, P377, DOI 10.1093/jmcb/mjs030
   Rassouli FB, 2015, INT J BIOL MARKER, V30, pE315, DOI 10.5301/jbm.5000137
   Rassouli FB, 2013, TUMOR BIOL, V34, P2909, DOI 10.1007/s13277-013-0853-5
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z
   Saiki Y, 2009, ANN SURG ONCOL, V16, P2638, DOI 10.1245/s10434-009-0567-5
   Santagata S, 2007, AM J SURG PATHOL, V31, P836, DOI 10.1097/PAS.0b013e31802e708a
   SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M
   SCHOLER HR, 1990, EMBO J, V9, P2185, DOI 10.1002/j.1460-2075.1990.tb07388.x
   Sedlar IT, 2016, ACTA HISTOCHEM, V118, P693, DOI 10.1016/j.acthis.2016.08.004
   Shi Z, 2012, J ZHEJIANG UNIV-SC B, V13, P11, DOI 10.1631/jzus.B1100154
   Shirzadeh E, 2018, CRITICAL REV EUKARYO, V28
   Sitarz R, 2018, CANCER MANAG RES, V10, P239, DOI 10.2147/CMAR.S149619
   Stock M, 2005, GENE, V360, P1, DOI 10.1016/j.gene.2005.06.026
   Suo GL, 2005, BIOCHEM BIOPH RES CO, V337, P1047, DOI 10.1016/j.bbrc.2005.09.157
   Tai MH, 2005, CARCINOGENESIS, V26, P495, DOI 10.1093/carcin/bgh321
   Takahashi K, 2007, CELL, V131, P861, DOI 10.1016/j.cell.2007.11.019
   Takaishi S, 2009, STEM CELLS, V27, P1006, DOI 10.1002/stem.30
   Takeuchi A, 2003, NAT GENET, V33, P172, DOI 10.1038/ng1072
   Talebi A, 2015, ADV BIOMEDICAL RES, V4
   Thrift AP, 2016, CANCER EPIDEMIOL, V41, P88, DOI 10.1016/j.canep.2016.01.013
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Tsukamoto T, 2005, HISTOPATHOLOGY, V46, P649, DOI 10.1111/j.1365-2559.2005.02170.x
   Vaiphei K, 2014, ASIAN PAC J CANCER P, V15, P3519, DOI 10.7314/APJCP.2014.15.8.3519
   Villodre ES, 2016, CANCER TREAT REV, V51, P1, DOI 10.1016/j.ctrv.2016.10.003
   Voutsadakis IA, 2015, BIOMARK MED, V9, P349, DOI [10.2217/BMM.15.4, 10.2217/bmm.15.4]
   Wang JL, 2006, NATURE, V444, P364, DOI 10.1038/nature05284
   Wang L, 2013, CARCINOGENESIS, V34, P1773, DOI 10.1093/carcin/bgt139
   Wang R, 2017, MOL ONCOL, V11, P1023, DOI 10.1002/1878-0261.12071
   Wang S, 2016, CELL REPROGRAM, V18, P319, DOI 10.1089/cell.2016.0001
   Wang X, 2010, STEM CELLS, V28, P885, DOI 10.1002/stem.419
   Wang XF, 2016, ONCOTARGET, V7, P63352, DOI 10.18632/oncotarget.11221
   Wang ZX, 2008, STEM CELLS, V26, P2791, DOI 10.1634/stemcells.2008-0443
   Wen KM, 2013, CANCER LETT, V333, P56, DOI 10.1016/j.canlet.2013.01.009
   Williamson JML, 2010, SCAND J GASTROENTERO, V45, P1472, DOI 10.3109/00365521.2010.501523
   Xi Z, 2011, MOL CELLS, V32, P39, DOI 10.1007/s10059-011-2315-5
   Xu GZ, 2015, STEM CELLS DEV, V24, P1546, DOI 10.1089/scd.2014.0552
   Yang L, 2011, CANCER LETT, V310, P46, DOI 10.1016/j.canlet.2011.06.003
   Yasuda H, 2011, ONCOL LETT, V2, P1065, DOI 10.3892/ol.2011.415
   Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012
   Zhan YY, 2013, CANCER LETT, V329, P37, DOI 10.1016/j.canlet.2012.09.022
   Zhang G, 2012, MOL MED REP, V6, P519, DOI 10.3892/mmr.2012.939
   Zhang XW, 2016, ONCOTARGET, V7, P9815, DOI 10.18632/oncotarget.6890
   Zhang YJ, 2012, CANCER LETT, V321, P45, DOI 10.1016/j.canlet.2012.03.013
   Zhou GX, 2013, ASIAN PAC J CANCER P, V14, P5199, DOI 10.7314/APJCP.2013.14.9.5199
   Zhu R, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032170
   Zou GM, 2008, J CELL PHYSIOL, V217, P598, DOI 10.1002/jcp.21541
NR 137
TC 6
Z9 6
U1 0
U2 1
PU TEHRAN UNIV MEDICAL SCIENCES
PI TEHRAN
PA CTR ELECTR RES PROVISION & J IMPROVEMENT, #7, POURSINA AVE, QODS AVE, PO
   1417653911, TEHRAN, 11498, IRAN
SN 1735-1502
EI 1735-5249
J9 IRAN J ALLERGY ASTHM
JI Iran. J. Allergy Asthma Immunol.
PD JUN
PY 2020
VL 19
IS 3
BP 229
EP 242
DI 10.18502/ijaai.v19i3.3451
PG 14
WC Allergy; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Allergy; Immunology
GA MG5CE
UT WOS:000546049000002
PM 32615657
OA gold
DA 2025-01-04
ER

PT J
AU Wang, BC
   Li, YX
   Tan, FB
   Xiao, ZX
AF Wang, Baochun
   Li, Yixiong
   Tan, Fengbo
   Xiao, Zhanxiang
TI Increased expression of SOX4 is associated with colorectal cancer
   progression
SO TUMOR BIOLOGY
LA English
DT Article
DE Colorectal cancer; SOX4; Proliferation; Invasion; EMT; Targeted therapy
ID EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR 4; METASTASIS;
   TUMORIGENESIS; GENE
AB Sex-determining region Y-related high-mobility group box 4 (SOX4) has been proven to serve as a critical role in cancer progression. However, the pathological role of SOX4 in colorectal cancer (CRC) remains unknown. The aim of this study was to investigate the role of SOX4 in CRC. In this study, we investigated the expression of SOX4 in CRC tissues by immunohistochemistry, quantitative reverse transcription polymerase chain reaction (qRT-PCR), and Western blot. We also evaluated the effect of SOX4 on cell proliferation and invasion by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) and transwell assay. The SOX4 messenger RNA (mRNA) and protein expression were markedly higher in CRC tissues compared with adjacent normal mucosa tissues. Inhibition of SOX4 could suppress CRC cell proliferation, and invasion in vitro. Our findings indicate that targeting SOX4 might provide a new therapeutic modality for the treatment of CRC patients.
C1 [Wang, Baochun; Li, Yixiong; Tan, Fengbo] Cent S Univ, Xiangya Hosp, Dept Gen Surg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
   [Wang, Baochun; Xiao, Zhanxiang] Hainan Prov Peoples Hosp, Dept Gen Surg, Haikou 570311, Peoples R China.
C3 Central South University
RP Li, YX (corresponding author), Cent S Univ, Xiangya Hosp, Dept Gen Surg, 87 Xiangya Rd, Changsha 410008, Hunan, Peoples R China.
EM liyixong@126.com
FU National Natural Science Foundation of Hainan [814309]
FX This study was supported by the National Natural Science Foundation of
   Hainan (no. 814309)
CR Andersen CL, 2009, BRIT J CANCER, V100, P511, DOI 10.1038/sj.bjc.6604884
   Castillo SD, 2012, CANCER RES, V72, P176, DOI 10.1158/0008-5472.CAN-11-3506
   Iqbal MS, 2010, INT J HEMATOL, V91, P267, DOI 10.1007/s12185-009-0474-3
   Jafarnejad SM, 2013, CELL MOL LIFE SCI, V70, P2677, DOI 10.1007/s00018-012-1187-y
   Lee AK, 2011, ONCOL REP, V25, P559, DOI 10.3892/or.2010.1091
   Liao YL, 2008, ONCOGENE, V27, P5578, DOI 10.1038/onc.2008.168
   Lieberman DA, 2012, GASTROENTEROLOGY, V143, P844, DOI 10.1053/j.gastro.2012.06.001
   Lin BY, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010210
   Penzo-Méndez AI, 2010, INT J BIOCHEM CELL B, V42, P425, DOI 10.1016/j.biocel.2009.07.018
   Perencevich Molly, 2011, Gastroenterol Hepatol (N Y), V7, P420
   Saegusa M, 2012, LAB INVEST, V92, P511, DOI 10.1038/labinvest.2011.196
   Schepers GE, 2002, DEV CELL, V3, P167, DOI 10.1016/S1534-5807(02)00223-X
   Schilham MW, 1996, NATURE, V380, P711, DOI 10.1038/380711a0
   Schoen RE, 2012, NEW ENGL J MED, V366, P2345, DOI 10.1056/NEJMoa1114635
   Shimada H, 2009, LANGENBECK ARCH SURG, V394, P973, DOI 10.1007/s00423-009-0530-8
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Tavazoie SF, 2008, NATURE, V451, P147, DOI 10.1038/nature06487
   Thiery JP, 2002, NAT REV CANCER, V2, P442, DOI 10.1038/nrc822
   Toiyama Y, 2014, ANN SURG, V259, P735, DOI 10.1097/SLA.0b013e3182a6909d
   Tsuji T, 2009, CANCER RES, V69, P7135, DOI 10.1158/0008-5472.CAN-09-1618
   Vervoort SJ, 2013, ONCOGENE, V32, P3397, DOI 10.1038/onc.2012.506
   Wang L, 2013, PROSTATE CANCER P D, V16, P301, DOI 10.1038/pcan.2013.25
   Wilson M, 2002, CURR OPIN GENET DEV, V12, P441, DOI 10.1016/S0959-437X(02)00323-4
   Zhang JC, 2012, CANCER RES, V72, P4597, DOI 10.1158/0008-5472.CAN-12-1045
NR 24
TC 40
Z9 42
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1010-4283
EI 1423-0380
J9 TUMOR BIOL
JI Tumor Biol.
PD JUL
PY 2016
VL 37
IS 7
BP 9131
EP 9137
DI 10.1007/s13277-015-4756-5
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DU4HU
UT WOS:000382174500064
PM 26768610
DA 2025-01-04
ER

PT J
AU Cao, J
   Tao, X
   Shi, B
   Wang, J
   Ma, R
   Zhao, JF
   Tian, JH
   Huang, Q
   Yu, JJ
   Wang, LB
AF Cao, Jia
   Tao, Xiang
   Shi, Bin
   Wang, Jia
   Ma, Rong
   Zhao, Jufen
   Tian, Jinhai
   Huang, Qi
   Yu, Jingjing
   Wang, Libin
TI NKD1 targeting PCM1 regulates the therapeutic effects of
   homoharringtonine on colorectal cancer
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Article
DE Colorectal cancer; NKD1; Homoharringtonine; Cell cycle; Apoptosis
ID EXPRESSION; GROWTH
AB BackgroundColorectal cancer (CRC) is the most common primary malignancy. Recently, antineoplastic attributes of homoharringtonine (HHT) have attracted lots of attention. This study investigated the molecular target and underlying mechanism of HHT in the CRC process by using a cellular and animal models.MethodsThis study first detected the effects of HHT on the proliferation, cell cycle and apoptosis ability of CRC cells using CCK-8, Edu staining, flow cytometry and Western blotting assay. In vitro recovery experiment and in vivo tumorigenesis experiment were used to detect the targeted interaction between HHT and NKD1. After that, the downstream target and mechanism of action of HHT targeting NKD1 was determined using quantitative proteomics combined with co-immunoprecipitation/immunofluorescence assay.ResultsHHT suppressed CRC cells proliferation by inducing cell cycle arrest and apoptosis in vitro and vivo. HHT inhibited NKD1 expression in a concentration and time dependent manner. NKD1 was overexpressed in CRC and its depletion enhanced the therapeutic sensitivity of HHT on CRC, which indicating that NKD1 plays an important role in the development of CRC as the drug delivery target of HHT. Furthermore, proteomic analysis revealed that PCM1 participated the process of NKD1-regulated cell proliferation and cell cycle. NKD1 interacted with PCM1 and promoted PCM1 degradation through the ubiquitin-proteasome pathway. The overexpression of PCM1 effectively reversed the inhibition of siNKD1 on cell cycle.ConclusionsThe present findings revealed that HHT blocked NKD1 expression to participate in inhibiting cell proliferation and inducing cell apoptosis, ultimately leading to obstruction of CRC development through NKD1/PCM1 dependent mechanism. Our research provide evidence for clinical application of NKD1-targeted therapy in improving HHT sensitivity for CRC treatment.
C1 [Cao, Jia; Wang, Jia; Ma, Rong; Tian, Jinhai; Huang, Qi; Yu, Jingjing; Wang, Libin] Ningxia Med Univ, Gen Hosp, Dept Beijing Natl Biochip Res Ctr Sub, Ctr Ningxia, Yinchuan, Ningxia, Peoples R China.
   [Cao, Jia; Wang, Jia; Ma, Rong; Huang, Qi; Yu, Jingjing] Ningxia Med Univ, Gen Hosp, Inst Med Sci, Yinchuan, Ningxia, Peoples R China.
   [Tao, Xiang; Zhao, Jufen; Wang, Libin] Ningxia Med Univ, Coll Clin Med, Yinchuan, Ningxia, Peoples R China.
   [Shi, Bin] Ningxia Med Univ, Gen Hosp, Dept Emergency, Yinchuan, Ningxia, Peoples R China.
C3 Ningxia Medical University; Ningxia Medical University; Ningxia Medical
   University; Ningxia Medical University
RP Wang, LB (corresponding author), Ningxia Med Univ, Gen Hosp, Dept Beijing Natl Biochip Res Ctr Sub, Ctr Ningxia, Yinchuan, Ningxia, Peoples R China.; Wang, LB (corresponding author), Ningxia Med Univ, Coll Clin Med, Yinchuan, Ningxia, Peoples R China.
EM wanglibin007@126.com
FU First-Class Discipline Construction Founded Project of Ningxia Medical
   University and the School of Clinical Medicine [NXYLXK3020071]; Ningxia
   Natural Science Foundation [2021AAC03350]; Special Talent Introduction
   Project of Ningxia Autonomous Region Key Ramp;D Programs [2021BEB04046];
   sixth group of Ningxia Autonomous Region Young Scientific and
   Technological Talent Lifting Project [NXKJTJ2021119]; Special Project
   for Discipline Construction of the General Hospital of Ningxia Medical
   University [2020 - 149]; Ningxia high level science and technology
   innovation leading talent project [KJT2019003]
FX This study was funded by First-Class Discipline Construction Founded
   Project of Ningxia Medical University and the School of Clinical
   Medicine (No. NXYLXK3020071). Ningxia Natural Science Foundation (No.
   2021AAC03350). Special Talent Introduc-tion Project of Ningxia
   Autonomous Region Key R & D Programs (No. 2021BEB04046). The sixth group
   of Ningxia Autonomous Region Young Scientific and Technological Talent
   Lifting Project (No. NXKJTJ2021119). Special Project for Discipline
   Construction of the General Hospital of Ningxia Medical University (No.
   2020 - 149). Ningxia high level science and technology innovation
   leading talent project (Grant No. KJT2019003)
CR BALCZON R, 1994, J CELL BIOL, V124, P783, DOI 10.1083/jcb.124.5.783
   Cao J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0810-5
   Chen XJ, 2019, P NATL ACAD SCI USA, V116, P2220, DOI 10.1073/pnas.1818539116
   D'Arcy MS, 2019, CELL BIOL INT, V43, P582, DOI 10.1002/cbin.11137
   Durinikova E, 2022, CLIN CANCER RES, V28, P3874, DOI 10.1158/1078-0432.CCR-22-0875
   Fu MS, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.899837
   Gandhi V, 2014, CLIN CANCER RES, V20, P1735, DOI 10.1158/1078-0432.CCR-13-1283
   Guo S, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222010930
   Haider M, 2022, J ADV RES, V39, P237, DOI 10.1016/j.jare.2021.11.008
   Hoang-Minh LB, 2016, TRANSL ONCOL, V9, P392, DOI 10.1016/j.tranon.2016.08.006
   Huang JY, 2019, ACTA BIOCH BIOPH SIN, V51, P900, DOI 10.1093/abbs/gmz077
   Joachim J, 2017, CURR BIOL, V27, P2123, DOI 10.1016/j.cub.2017.06.021
   Katoh M, 2001, INT J ONCOL, V19, P963
   Kleeman SO, 2020, GUT, V69, P1092, DOI 10.1136/gutjnl-2019-319126
   Li CY, 2020, HAEMATOLOGICA, V105, P148, DOI 10.3324/haematol.2018.208835
   Lv ZD, 2015, INT J CLIN EXP PATHO, V8, P4015
   Micu BV, 2020, ANN ITAL CHIR, V91, P41
   Porcu E, 2022, TRANSL RES, P151
   Qu MW, 2021, BIOENGINEERED, V12, P12940, DOI 10.1080/21655979.2021.2012626
   Shi XP, 2020, FOOD CHEM TOXICOL, V136, DOI 10.1016/j.fct.2019.110960
   Sun Y, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136923
   Wang C, 2017, BIOMED PHARMACOTHER, V89, P926, DOI 10.1016/j.biopha.2017.01.031
   Wang LL, 2018, J CELL BIOCHEM, V119, P6644, DOI 10.1002/jcb.26847
   Wang LB, 2021, INT J BIOL SCI, V17, P995, DOI 10.7150/ijbs.44907
   Wang Y, 2021, CANCER MED-US, V10, P7383, DOI 10.1002/cam4.4224
   Wei WW, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03497-2
   Wouters Y, 2021, BRIT J HAEMATOL, V192, pe112, DOI 10.1111/bjh.17340
   Xu M, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1063-6
   Yakhni M, 2019, AM J CANCER RES, V9, P1043
   Yuan FF, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-22-1459
   Zhang JW, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-30264-0
   Zhang S, 2015, APMIS, V123, P315, DOI 10.1111/apm.12360
   Zhang S, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-186
   Zhu M, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02902-2
NR 34
TC 0
Z9 0
U1 0
U2 5
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD AUG
PY 2023
VL 50
IS 8
BP 6543
EP 6556
DI 10.1007/s11033-023-08572-5
EA JUN 2023
PG 14
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA M9TB9
UT WOS:001011693700002
PM 37338734
OA Green Submitted
DA 2025-01-04
ER

PT J
AU Pemmaraju, N
   Sweet, KL
   Stein, AS
   Wang, ES
   Rizzieri, DA
   Vasu, S
   Rosenblat, TL
   Brooks, CL
   Habboubi, N
   Mughal, TI
   Kantarjian, H
   Konopleva, M
   Lane, AA
AF Pemmaraju, Naveen
   Sweet, Kendra L.
   Stein, Anthony S.
   Wang, Eunice S.
   Rizzieri, David A.
   Vasu, Sumithira
   Rosenblat, Todd L.
   Brooks, Christopher L.
   Habboubi, Nassir
   Mughal, Tariq, I
   Kantarjian, Hagop
   Konopleva, Marina
   Lane, Andrew A.
TI Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid
   Dendritic Cell Neoplasm
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
ID TRANSPLANTATION
AB Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is an aggressive myeloid malignancy. We report long-term results, including data from the continued access phase, of the largest prospective BPDCN trial evaluating the CD123-targeted therapy tagraxofusp (TAG) in adults with treatment-naive and relapsed/refractory BPDCN. The primary outcome was complete response (CR) + clinical CR (CRc: CR with residual skin abnormality not indicative of active disease). Eighty-four (65 treatment-naive and 19 relapsed/refractory) of 89 patients received TAG 12 mu g/kg once daily; the median follow-up was 34.0 months. For treatment-naive patients, the overall response rate was 75%; 57% achieved CR + CRc. The median time to remission was 39 (range, 14-131) days, and the median CR + CRc duration was 24.9 (95% CI, 3.8 to not reached) months. Nineteen patients (51%) with CR + CRc were bridged to stem-cell transplant, with a median CR + CRc duration of 22.2 (range, 1.5-57.4) months. Most common adverse events were increased alanine (64%) or aspartate (60%) aminotransferase and hypoalbuminemia (51%); most occurred in cycle 1 and were transient. Capillary leak syndrome occurred in 21% of patients (grade >= 3: 7%). In first-line patients with BPDCN, TAG monotherapy resulted in high and durable responses, allowing many to bridge to stem-cell transplant. TAG was generally well-tolerated with a predictable and manageable safety profile.
C1 [Pemmaraju, Naveen; Kantarjian, Hagop; Konopleva, Marina] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Sweet, Kendra L.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
   [Stein, Anthony S.] City Hope Natl Med Ctr, 1500 E Duarte Rd, Duarte, CA 91010 USA.
   [Wang, Eunice S.] Roswell Pk Comprehens Canc Ctr, Buffalo, NY USA.
   [Rizzieri, David A.] Duke Univ, Med Ctr, Durham, NC USA.
   [Vasu, Sumithira] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA.
   [Rosenblat, Todd L.] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA.
   [Brooks, Christopher L.; Habboubi, Nassir; Mughal, Tariq, I] Stemline Therapeut, New York, NY USA.
   [Mughal, Tariq, I] Tufts Univ, Sch Med, Boston, MA 02111 USA.
   [Lane, Andrew A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; H Lee Moffitt
   Cancer Center & Research Institute; City of Hope; Roswell Park
   Comprehensive Cancer Center; Duke University; University System of Ohio;
   Ohio State University; James Cancer Hospital & Solove Research
   Institute; Columbia University; Tufts University; Harvard University;
   Dana-Farber Cancer Institute
RP Pemmaraju, N (corresponding author), MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
EM npemmaraju@mdanderson.org
RI Kantarjian, Hagop/B-4264-2015
OI Lane, Andrew/0000-0001-7380-0226; mughal, tariq/0000-0003-1005-7724;
   Wang, Eunice/0000-0002-8644-0968
FU Stemline Therapeutics, Inc.
FX We thank the patients and their families, as well as the participating
   study teams, for making this study possible. Editorial and medical
   writing assistance was provided by Joanne Franklin, PhD, CMPP, from
   Aptitude Health, The Hague, the Netherlands and funding of this was
   supported by Stemline Therapeutics, Inc. The authors are fully
   responsible for all content and editorial decisions for this manuscript.
CR Alfayez M, 2020, EXPERT OPIN BIOL TH, V20, P115, DOI 10.1080/14712598.2020.1701651
   [Anonymous], 2018, ELZONRIS (tagraxofusp-erzs)
   Beziat G, 2020, ONCOTARGETS THER, V13, P5199, DOI 10.2147/OTT.S228342
   Dalle S, 2010, BRIT J DERMATOL, V162, P74, DOI 10.1111/j.1365-2133.2009.09373.x
   Dietrich S, 2011, BIOL BLOOD MARROW TR, V17, P1250, DOI 10.1016/j.bbmt.2010.12.706
   Fanny D., 2013, BLOOD, V122, P21
   Frankel A, 2008, LEUKEMIA LYMPHOMA, V49, P543, DOI 10.1080/10428190701799035
   Frankel AE, 2014, BLOOD, V124, P385, DOI 10.1182/blood-2014-04-566737
   Han LN, 2015, CYTOM PART A, V87A, P346, DOI 10.1002/cyto.a.22628
   Jen EY, 2020, CLIN CANCER RES, V26, P532, DOI 10.1158/1078-0432.CCR-19-2329
   Kharfan-Dabaja MA, 2013, BIOL BLOOD MARROW TR, V19, P1006, DOI 10.1016/j.bbmt.2013.01.027
   Lee SS, 2020, EXPERT REV ANTICANC, V20, P543, DOI 10.1080/14737140.2020.1776120
   Martín-Martín L, 2015, ONCOTARGET, V6, P19204, DOI 10.18632/oncotarget.4146
   Pagano L, 2016, BRIT J HAEMATOL, V174, P188, DOI 10.1111/bjh.14146
   Pagano L, 2013, HAEMATOLOGICA, V98, P239, DOI 10.3324/haematol.2012.072645
   Pemmaraju N, 2019, NEW ENGL J MED, V380, P1628, DOI 10.1056/NEJMoa1815105
   PMDA, 2020, JanssenCilag International NV
   Taylor J, 2019, BLOOD, V134, P678, DOI 10.1182/blood.2019001144
NR 18
TC 27
Z9 27
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD SEP 10
PY 2022
VL 40
IS 26
BP 3032
EP +
DI 10.1200/JCO.22.00034
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 4K9FT
UT WOS:000852246600006
PM 35820082
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Li, JJ
   Xu, XF
AF Li, Jingjing
   Xu, Xuanfu
TI Immune Checkpoint Inhibitor-Based Combination Therapy for Colorectal
   Cancer: An Overview
SO INTERNATIONAL JOURNAL OF GENERAL MEDICINE
LA English
DT Review
DE immune checkpoint inhibitors; colorectal cancer; PD-1; PD-L1;
   combination therapy; DNA mismatch repair
ID MISMATCH REPAIR-DEFICIENT; CORNEAL EPITHELIAL-CELLS; PHASE-II; T-CELL;
   MAINTENANCE THERAPY; ANTITUMOR-ACTIVITY; DOSE-ESCALATION; INNATE
   IMMUNITY; PLUS AVELUMAB; SOLID TUMORS
AB Colorectal cancer (CRC) is one of the most common diseases in the world. Tumor immunotherapy is an innovative cancer treatment that acts by activating the human body's autoimmune system. Immune checkpoint block has been shown to be effective in DNA deficient mismatch repair/microsatellite instability-high CRC. However, the therapeutic effect for proficient mismatch repair/ microsatellite stability patients still requires further study and optimization. At present, the main CRC strategy is to combine other therapeutic methods, such as chemotherapy, targeted therapy, and radiotherapy. Here, we review the current status and the latest progress of immune checkpoint inhibitors in the treatment of CRC. At the same time, we consider therapeutic opportunities for transforming cold to hot, as well as perspectives on possible future therapies, which may be in great demand for drug-resistant patients.
C1 [Li, Jingjing; Xu, Xuanfu] Shidong Hosp Shanghai, Dept Gastroenterol, Shanghai, Peoples R China.
RP Xu, XF (corresponding author), Shidong Hosp Shanghai, Dept Gastroenterol, Shanghai, Peoples R China.
EM shuanfusky@163.com
CR Abdullaev S, 2020, J CLIN ONCOL, V38
   Abunasser AAA, 2021, J ONCOL, V2021, DOI 10.1155/2021/6662344
   Amodio V, 2023, CANCER CELL, V41, P196, DOI 10.1016/j.ccell.2022.12.003
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Andre T, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.9
   Andrews LP, 2019, NAT IMMUNOL, V20, P1425, DOI 10.1038/s41590-019-0512-0
   Antonia S, 2016, LANCET ONCOL, V17, P299, DOI 10.1016/S1470-2045(15)00544-6
   Bai YX, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.e15551
   Bailey SR, 2023, EUR J IMMUNOL, DOI 10.1002/eji.202250039
   Baraibar I, 2021, CANCERS, V13, DOI 10.3390/cancers13246311
   Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004
   Bendell JC, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.TPS870
   Benson AB., 2021, J. Natl. Compr. Canc. Netw., V19, P329, DOI DOI 10.6004/JNCCN.2021.0012
   Berezhnoy A, 2020, CELL REP MED, V1, DOI 10.1016/j.xcrm.2020.100163
   Bhamidipati D, 2022, J CLIN ONCOL, V40
   Boland PM, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.834
   Borelli B, 2022, CANCERS, V14, DOI 10.3390/cancers14204974
   Brauneck F, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-004794
   Bredin P, 2022, CANCER METAST REV, V41, P347, DOI 10.1007/s10555-022-10039-1
   Buhle Anna, 2022, Dermatol Online J, V28, DOI 10.5070/D328157062
   Çaglayan M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06700-5
   Cao MY, 2022, CURR ISSUES MOL BIOL, V44, P4447, DOI 10.3390/cimb44100305
   Cercek A, 2022, NEW ENGL J MED, V386, P2363, DOI 10.1056/NEJMoa2201445
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Cheever MA, 2011, CLIN CANCER RES, V17, P3520, DOI 10.1158/1078-0432.CCR-10-3126
   Chen L, 2022, CLIN IMMUNOL, V237, DOI 10.1016/j.clim.2022.108962
   Chen YT, 2023, ACS NANO, V17, P760, DOI 10.1021/acsnano.2c10797
   Chu JJ, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.801319
   Cooper ZA, 2015, CLIN CANCER RES, V21, P3102, DOI 10.1158/1078-0432.CCR-15-0363
   Corcoran R, 2020, ANN ONCOL, V31, pS226, DOI 10.1016/j.annonc.2020.04.041
   Cousin S, 2022, EUR J CANCER, V162, P161, DOI 10.1016/j.ejca.2021.11.012
   Cousin Sophie, 2021, Clin Cancer Res, V27, P2139, DOI 10.1158/1078-0432.CCR-20-3416
   Cousin S, 2020, J CLIN ONCOL, V38
   Cremolini C, 2021, ANN ONCOL, V32, pS1294, DOI 10.1016/j.annonc.2021.08.2094
   Crupi MJF, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1029269
   Cui J, 2022, J CLIN ONCOL, V40, P3582, DOI DOI 10.1200/JCO.2022.40.16_SUPPL.3582
   Dai WQ, 2023, CANCER SCI, V114, P1309, DOI 10.1111/cas.15540
   Dai WQ, 2020, J HEPATOL, V72, P909, DOI 10.1016/j.jhep.2019.12.015
   de Weger VA, 2012, CLIN CANCER RES, V18, P882, DOI 10.1158/1078-0432.CCR-11-1716
   Aquila ED, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100606
   Ding S, 2022, PEDIATR INVEST, V6, P291, DOI 10.1002/ped4.12343
   Doleschal B, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1048166
   Fox TA, 2022, SCI TRANSL MED, V14, DOI 10.1126/scitranslmed.abn5811
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Garralda E, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3584
   Gemelli M, 2022, CANCERS, V14, DOI 10.3390/cancers14246063
   Gessani S, 2019, CANCERS, V11, P1491, DOI DOI 10.3390/cancers11101491
   Geuijen C, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24767-5
   Ghazi B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.978195
   Ghidini M, 2021, CURR DRUG TARGETS, V22, P1021, DOI 10.2174/1389450122666210204204415
   Goldman C, 2017, ONCOLOGY-BASEL, V93, P164, DOI 10.1159/000475715
   GOLSTEIN P, 1987, NATURE, V327, P12, DOI 10.1038/327012a0
   Gomez-Roca CA, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3564
   Guo Y, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2514
   Hernaez R, 2023, GUT, V72, P7, DOI 10.1136/gutjnl-2022-327132
   Horzum U, 2022, IMMUNOLOGY, V167, P640, DOI 10.1111/imm.13560
   Hoxha M, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1032806
   Huang KM, 2022, BIOINFORMATICS, V38, P5108, DOI 10.1093/bioinformatics/btac641
   Huang SX, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1014904
   Hubbard JM, 2020, J CLIN ONCOL, V38
   Hubbard JM, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3557
   ISHIDA Y, 1992, EMBO J, V11, P3887, DOI 10.1002/j.1460-2075.1992.tb05481.x
   Jacoberger-Foissac Celia, 2023, Methods Mol Biol, V2614, P151, DOI 10.1007/978-1-0716-2914-7_11
   Janani B, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10040499
   Janman D, 2021, IMMUNOLOGY, V164, P106, DOI 10.1111/imm.13343
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Katz SC, 2015, CLIN CANCER RES, V21, P3149, DOI 10.1158/1078-0432.CCR-14-1421
   Keck JG, 2022, J CLIN ONCOL, V40
   Kiasari BA, 2022, INT IMMUNOPHARMACOL, V113, DOI 10.1016/j.intimp.2022.109365
   Kim CW, 2021, CANCERS, V13, DOI 10.3390/cancers13194906
   Koyel B, 2017, INDIA J SURG ONCOL, V8, P462, DOI 10.1007/s13193-017-0651-4
   Lai E, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.637823
   Lau D, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS3615
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lee MS, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.7
   Lentz RW, 2021, MOL CANCER THER, V20, P961, DOI 10.1158/1535-7163.MCT-21-0041
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Li JS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.594125
   Li Y, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.751407
   MAK TW, 1995, J INFLAMM, V45, P79
   Makaremi S, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091075
   Mettu NB, 2019, ANN ONCOL, V30
   Michael M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS3622
   Michelson DA, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2215474119
   Monge MC, 2020, J CLIN ONCOL, V38
   Moretto R, 2022, JNCI-J NATL CANCER I, V114, P271, DOI 10.1093/jnci/djab169
   Morse MA, 2020, ONCOLOGIST, V25, P33, DOI 10.1634/theoncologist.2019-0176
   Nelson A, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003923
   O'Leary K, 2022, NAT MED, V28, P2450, DOI 10.1038/s41591-022-02150-1
   O'Neil BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189848
   Oaknin A, 2020, JAMA ONCOL, V6, P1766, DOI 10.1001/jamaoncol.2020.4515
   Olave MC, 2022, GENE CHROMOSOME CANC, V61, P314, DOI 10.1002/gcc.23015
   Ott PA, 2017, ANN ONCOL, V28, P1036, DOI 10.1093/annonc/mdx029
   Ou SHI, 2022, J CLIN ONCOL, V40, P2530, DOI 10.1200/JCO.21.02752
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Parikh AR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3514
   Park YL, 2022, ONCOGENE, V41, P2026, DOI 10.1038/s41388-021-01920-4
   Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272
   Peng XD, 2015, INT J OPHTHALMOL-CHI, V8, P441, DOI 10.3980/j.issn.2222-3959.2015.03.02
   Peng XD, 2018, INT IMMUNOPHARMACOL, V63, P161, DOI 10.1016/j.intimp.2018.08.003
   Peng XD, 2018, BMC OPHTHALMOL, V18, DOI 10.1186/s12886-018-0847-6
   Prenen H, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.74
   Ree AH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3556
   Ren BX, 2023, NUTR CANCER, V75, P685, DOI 10.1080/01635581.2022.2153879
   Ribas A, 2018, CELL, V174, P1031, DOI 10.1016/j.cell.2018.07.035
   Roccuzzo G, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.733770
   Salvatore L, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3511
   Schröder C, 2021, JCO CLIN CANCER INFO, V5, P450, DOI 10.1200/CCI.20.00149
   Schuch Gunter, 2009, Cancer Manag Res, V1, P79
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Sinicrope FA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e15169
   Sobhani N, 2021, CANCERS, V13, DOI 10.3390/cancers13061440
   Stein A, 2020, J CLIN ONCOL, V38
   Strickler JH, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.TPS153
   Sturrock M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29318-5
   Suh K, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.040
   Svensson-Arvelund J, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-34791-8
   Tabernero J, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3570
   Tamberi S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3607
   Telli TA, 2022, CANCER TREAT REV, V110, DOI 10.1016/j.ctrv.2022.102460
   Uyl-de Groot CA, 2005, VACCINE, V23, P2379, DOI 10.1016/j.vaccine.2005.01.015
   Verschoor YL, 2022, J CLIN ONCOL, V40
   Voronova V, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1035884
   Waissengrin B, 2023, EUR J CANCER, V180, P52, DOI 10.1016/j.ejca.2022.11.022
   Wang DY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.762341
   Wang F, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100383
   Wang FH, 2021, CHINESE J CANCER RES, V33, P490, DOI 10.21147/j.issn.1000-9604.2021.04.06
   Wang LJ, 2022, APPL BIONICS BIOMECH, V2022, DOI 10.1155/2022/8666724
   Wiede F, 2022, CANCER DISCOV, V12, P752, DOI 10.1158/2159-8290.CD-21-0694
   Wu QY, 2022, THERANOSTICS, V12, P7371, DOI 10.7150/thno.74075
   Xu T, 2023, CANCER RES TREAT, V55, P626, DOI 10.4143/crt.2022.1058
   Xu YP, 2021, J CANCER, V12, P4655, DOI 10.7150/jca.51038
   Xue ML, 2022, BIOMED PHARMACOTHER, V153, DOI 10.1016/j.biopha.2022.113402
   Yamada N, 2020, AM J TRANSPLANT, V20, P1606, DOI 10.1111/ajt.15773
   Yorita N, 2021, CANCER LETT, V498, P111, DOI 10.1016/j.canlet.2020.10.041
   Yuki S, 2020, J CLIN ONCOL, V38
   Zhang Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.663986
   Zhang RR, 2021, INVEST OPHTH VIS SCI, V62, DOI 10.1167/iovs.62.9.12
   Zhang W, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-10147-9
   Zheng YY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02030-5
   Zhou LN, 2022, J GASTROINTEST ONCOL, V13, P1086, DOI 10.21037/jgo-22-207
NR 145
TC 6
Z9 7
U1 0
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
EI 1178-7074
J9 INT J GEN MED
JI Int. J. Gen. Med.
PY 2023
VL 16
BP 1527
EP 1540
DI 10.2147/IJGM.S408349
PG 14
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA F3LD0
UT WOS:000981383200001
PM 37131870
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Karthikeyan, M
   Kolandasamy, C
   Babu, OLN
AF Karthikeyan, Mohan
   Kolandasamy, Chinnusamy
   Babu, Obla L. Naganath
TI Malignant Gastrointestinal Stromal Tumor of Rectum: A Case Report and
   Review of Literature
SO SURGERY JOURNAL
LA English
DT Review
DE gastrointestinal stromal tumor; rectum; laparoscopic resection;
   immunohistochemistry; high risk; imatinib
ID ADJUVANT IMATINIB; DIFFERENTIAL-DIAGNOSIS; HIGH-RISK; MANAGEMENT; GIST;
   RECURRENCE; MESYLATE
AB Gastrointestinal stromal tumors (GISTs) are rare tumors of the gastrointestinal tract accounting for less than 1% of all gut tumors. GISTs occurring in the rectum are extremely rare and these usually present at an advanced stage compared with other sites.
   We report a case of a middle-aged female who presented with features of anemia and subacute obstruction due to a large rectal tumor and underwent abdominoperineal resection. The histopathological examination confirmed the diagnosis of high-grade malignant GIST with multiple lymph nodal metastasis. She was started on adjuvant imatinib therapy and is on follow-up without any evidence of recurrence.
   The authors conclude that GIST must be included in the differential diagnosis of a rectal tumor. Diagnosis is established by biopsy and immunohistochemistry studies. Surgical resection with histological negative margins is the standard curative treatment. Adjuvant targeted therapy can reduce long-term recurrence in high-risk cases.
C1 [Karthikeyan, Mohan; Kolandasamy, Chinnusamy; Babu, Obla L. Naganath] Madras Med Coll & Govt Gen Hosp, Inst Surg Gastroenterol, Chennai 600003, Tamil Nadu, India.
   [Karthikeyan, Mohan; Kolandasamy, Chinnusamy; Babu, Obla L. Naganath] Rajiv Gandhi Govt Gen Hosp, Chennai 600003, Tamil Nadu, India.
C3 Madras Medical College & General Hospital; Madras Medical College &
   General Hospital
RP Babu, OLN (corresponding author), Madras Med Coll & Govt Gen Hosp, Inst Surg Gastroenterol, Chennai 600003, Tamil Nadu, India.; Babu, OLN (corresponding author), Rajiv Gandhi Govt Gen Hosp, Chennai 600003, Tamil Nadu, India.
EM naganathbabu@gmail.com
RI Obla, Naganath/AAA-9077-2020
OI Mohan, Karthikeyan/0000-0002-6942-2346
CR [Anonymous], NCCN CLIN PRACTICE G
   Chen CW, 2008, Z GASTROENTEROL, V46, P760, DOI 10.1055/s-2008-1027243
   Choi H, 2004, AM J ROENTGENOL, V183, P1619, DOI 10.2214/ajr.183.6.01831619
   DeMatteo RP, 2013, ANN SURG, V258, P422, DOI 10.1097/SLA.0b013e3182a15eb7
   DeMatteo RP, 2000, ANN SURG, V231, P51, DOI 10.1097/00000658-200001000-00008
   Demetri GD, 2010, J NATL COMPR CANC NE, V8, pS1
   Fletcher CDM, 2002, HUM PATHOL, V33, P459, DOI 10.1053/hupa.2002.123545
   Grassi N, 2008, WORLD J GASTROENTERO, V14, P1302, DOI 10.3748/wjg.14.1302
   Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190
   Joensuu H, 2016, J CLIN ONCOL, V34, P244, DOI 10.1200/JCO.2015.62.9170
   Joensuu H, 2014, CANCER-AM CANCER SOC, V120, P2325, DOI 10.1002/cncr.28669
   Joensuu H, 2012, JAMA-J AM MED ASSOC, V307, P1265, DOI 10.1001/jama.2012.347
   Joshi Arbin, 2018, J Nepal Health Res Counc, V16, P99
   Kalkmann J, 2012, CANCER IMAGING, V12, P126, DOI 10.1102/1470-7330.2012.0013
   Kameyama H, 2018, TRANSL GASTROENT HEP, V3, DOI 10.21037/tgh.2018.01.08
   Miettinen M, 2000, MODERN PATHOL, V13, P1134, DOI 10.1038/modpathol.3880210
   Miettinen M, 2001, VIRCHOWS ARCH, V438, P1, DOI 10.1007/s004280000338
   Miettinen M, 2006, SEMIN DIAGN PATHOL, V23, P70, DOI 10.1053/j.semdp.2006.09.001
   Miettinen M, 2009, AM J SURG PATHOL, V33, P1401, DOI 10.1097/PAS.0b013e3181a90e1a
   Nepal P, 2018, WORLD J SURG ONCOL, V16, DOI 10.1186/s12957-018-1463-x
   Shafizad A, 2014, IRAN J CANCER PREV, V7, P171
   Singhal S, 2013, CASE REP GASTROINTES, V2013, DOI 10.1155/2013/934875
   Somu K, 2016, J MINIM ACCESS SURG, V12, P283, DOI 10.4103/0972-9941.181311
   Stupp R, 2014, ANN ONCOL, V25, P93, DOI 10.1093/annonc/mdu050
   Tran T, 2005, AM J GASTROENTEROL, V100, P162, DOI [10.1111/j.1572-0241.2005.40709.x, 10.1111/j.1572-0241.2005.41007.x]
   Rivera AKU, 2020, ECANCERMEDICALSCIENC, V14, DOI 10.3332/ecancer.2020.1139
   Wong HH., 2013, J CLIN ONCOL, V31, pe21503
NR 27
TC 5
Z9 5
U1 0
U2 0
PU THIEME MEDICAL PUBL INC
PI NEW YORK
PA 333 SEVENTH AVE, NEW YORK, NY 10001 USA
SN 2378-5128
EI 2378-5136
J9 SURG J-NY
JI Surg. J.
PD JAN
PY 2022
VL 08
IS 01
BP E60
EP E64
DI 10.1055/s-0042-1742778
PG 5
WC Surgery
WE Emerging Sources Citation Index (ESCI)
SC Surgery
GA ZA2GK
UT WOS:000755985300001
PM 35187230
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Pazarentzos, E
   Bivona, TG
AF Pazarentzos, E.
   Bivona, T. G.
TI Adaptive stress signaling in targeted cancer therapy resistance
SO ONCOGENE
LA English
DT Review
ID CELL LUNG-CANCER; TYROSINE KINASE INHIBITORS; ANTI-EGFR THERAPY;
   ACQUIRED-RESISTANCE; MEK INHIBITION; ANDROGEN RECEPTOR; BRAF(V600E)
   INHIBITION; FEEDBACK ACTIVATION; COLORECTAL-CANCER; NEGATIVE FEEDBACK
AB The identification of specific genetic alterations that drive the initiation and progression of cancer and the development of targeted drugs that act against these driver alterations has revolutionized the treatment of many human cancers. Although substantial progress has been achieved with the use of such targeted cancer therapies, resistance remains a major challenge that limits the overall clinical impact. Hence, despite progress, new strategies are needed to enhance response and eliminate resistance to targeted cancer therapies in order to achieve durable or curative responses in patients. To date, efforts to characterize mechanisms of resistance have primarily focused on molecular events that mediate primary or secondary resistance in patients. Less is known about the initial molecular response and adaptation that may occur in tumor cells early upon exposure to a targeted agent. Although understudied, emerging evidence indicates that the early adaptive changes by which tumor cells respond to the stress of a targeted therapy may be crucial for tumo r cell survival during treatment and the development of resistance. Here we review recent data illuminating the molecular architecture underlying adaptive stress signaling in tumor cells. We highlight how leveraging this knowledge could catalyze novel strategies to minimize or eliminate targeted therapy resistance, thereby unleashing the full potential of targeted therapies to transform many cancers from lethal to chronic or curable conditions.
C1 [Pazarentzos, E.; Bivona, T. G.] Univ Calif San Francisco, Div Hematol Oncol, Dept Med, San Francisco, CA 94158 USA.
   [Pazarentzos, E.; Bivona, T. G.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94158 USA.
C3 University of California System; University of California San Francisco;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center
RP Bivona, TG (corresponding author), Univ Calif San Francisco, Div Hematol Oncol, Dept Med, 600 16th St Genentech Hall,N212D, San Francisco, CA 94158 USA.
EM Trever.Bivona@ucsf.edu
OI Pazarentzos, Evangelos/0000-0002-5453-1646
FU NIH [NIH R01 CA169338]; Howard Hughes Medical Institute; Doris Duke
   Charitable Foundation; Searle Scholars Program; California Institute for
   Quantitative Biosciences; QB3@UCSF; National Cancer Institute
   [R01CA169338] Funding Source: NIH RePORTER
FX We thank members of the Bivona lab for critical review and thoughtful
   comments on the manuscript. We are grateful to the following funding
   sources: NIH Director's New Innovator Award, NIH R01 CA169338, Howard
   Hughes Medical Institute, Doris Duke Charitable Foundation, Searle
   Scholars Program, California Institute for Quantitative Biosciences,
   QB3@UCSF (to TGB).
CR Ahmed KM, 2008, ONCOGENE, V27, P6738, DOI 10.1038/onc.2008.265
   Akhavan D, 2013, CANCER DISCOV, V3, P534, DOI 10.1158/2159-8290.CD-12-0502
   Aparicio A, 2011, CANCER DISCOV, V1, P466, DOI 10.1158/2159-8290.CD-11-0259
   Arora VK, 2013, CELL, V155, P1309, DOI 10.1016/j.cell.2013.11.012
   Bailey ST, 2014, MOL CANCER RES, V12, P408, DOI 10.1158/1541-7786.MCR-13-0206-T
   Baker NM, 2013, NATURE, V497, P577, DOI 10.1038/nature12248
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104
   Blume-Jensen P, 2001, NATURE, V411, P355, DOI 10.1038/35077225
   Carreira S, 2006, GENE DEV, V20, P3426, DOI 10.1101/gad.406406
   Carver BS, 2011, CANCER CELL, V19, P575, DOI 10.1016/j.ccr.2011.04.008
   Chandarlapaty S, 2012, CANCER DISCOV, V2, P311, DOI 10.1158/2159-8290.CD-12-0018
   Chandarlapaty S, 2011, CANCER CELL, V19, P58, DOI 10.1016/j.ccr.2010.10.031
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Cheli Y, 2011, ONCOGENE, V30, P2307, DOI 10.1038/onc.2010.598
   Chen XF, 2002, CANCER RES, V62, P1213
   Chen YJ, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3575
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92
   Duncan JS, 2012, CELL, V149, P307, DOI 10.1016/j.cell.2012.02.053
   Duru N, 2014, J CANCER RES CLIN, V140, P1, DOI 10.1007/s00432-013-1494-1
   Duru N, 2012, CLIN CANCER RES, V18, P6634, DOI 10.1158/1078-0432.CCR-12-1436
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Flanigan SA, 2013, CLIN CANCER RES, V19, P6219, DOI 10.1158/1078-0432.CCR-13-0145
   Fox EM, 2011, CANCER RES, V71, P6773, DOI 10.1158/0008-5472.CAN-11-1295
   Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012
   Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108
   Glickman MS, 2012, CELL, V148, P1089, DOI 10.1016/j.cell.2012.02.015
   Godin-Heymann N, 2008, MOL CANCER THER, V7, P874, DOI 10.1158/1535-7163.MCT-07-2387
   Goltsov A, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00013
   Haber DA, 2011, CELL, V145, P19, DOI 10.1016/j.cell.2011.03.026
   Haq R, 2013, CANCER CELL, V23, P302, DOI 10.1016/j.ccr.2013.02.003
   Haruta T, 2000, MOL ENDOCRINOL, V14, P783, DOI 10.1210/me.14.6.783
   Huang PH, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.287re6
   Ishiguro Y, 2013, ONCOTARGET, V4, P550, DOI 10.18632/oncotarget.939
   Kaplon J, 2013, NATURE, V498, P109, DOI 10.1038/nature12154
   Kirouac DC, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004008
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019
   Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006
   Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011
   Lovly CM, 2014, CLIN CANCER RES, V20, P2249, DOI 10.1158/1078-0432.CCR-13-1610
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Maemondo M, 2010, NEW ENGL J MED, V362, P2380, DOI 10.1056/NEJMoa0909530
   McDonagh CF, 2012, MOL CANCER THER, V11, P582, DOI 10.1158/1535-7163.MCT-11-0820
   Miller TW, 2011, J CLIN ONCOL, V29, P4452, DOI 10.1200/JCO.2010.34.4879
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Moreno-Sánchez R, 2007, FEBS J, V274, P1393, DOI 10.1111/j.1742-4658.2007.05686.x
   Muranen T, 2012, CANCER CELL, V21, P227, DOI 10.1016/j.ccr.2011.12.024
   O'Reilly KE, 2006, CANCER RES, V66, P1500, DOI 10.1158/0008-5472.CAN-05-2925
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Papa S, 2012, ADV EXP MED BIOL, V942, P3, DOI 10.1007/978-94-007-2869-1_1
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Rodrik-Outmezguine VS, 2011, CANCER DISCOV, V1, P248, DOI 10.1158/2159-8290.CD-11-0085
   Rosell R, 2012, LANCET ONCOL, V13, P239, DOI 10.1016/S1470-2045(11)70393-X
   Sáez-Ayala M, 2013, CANCER CELL, V24, P105, DOI 10.1016/j.ccr.2013.05.009
   Scaltriti M, 2009, ONCOGENE, V28, P803, DOI 10.1038/onc.2008.432
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Schweizer L, 2008, BMC CELL BIOL, V9, DOI 10.1186/1471-2121-9-4
   Sequist LV, 2013, J CLIN ONCOL, V31, P3327, DOI 10.1200/JCO.2012.44.2806
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Serra V, 2011, ONCOGENE, V30, P2547, DOI 10.1038/onc.2010.626
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shaw AT, 2013, NEW ENGL J MED, V368, P2385, DOI 10.1056/NEJMoa1214886
   Shi Y, 2005, INT J INF TECH DECIS, V4, P1
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Sun C, 2014, NATURE, V508, P118, DOI 10.1038/nature13121
   Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747
   WARBURG O, 1956, SCIENCE, V123, P309, DOI 10.1126/science.123.3191.309
   Watanabe S, 2013, LUNG CANCER, V82, P370, DOI 10.1016/j.lungcan.2013.06.003
   Weinstein IB, 2002, SCIENCE, V297, P63, DOI 10.1126/science.1073096
   Wetterskog D, 2014, ONCOGENE, V33, P966, DOI 10.1038/onc.2013.41
   Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330
   Zhao YJ, 2014, NAT REV CLIN ONCOL, V11, P385, DOI 10.1038/nrclinonc.2014.83
   Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205
NR 81
TC 41
Z9 42
U1 0
U2 9
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD NOV 5
PY 2015
VL 34
IS 45
BP 5599
EP 5606
DI 10.1038/onc.2015.26
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA CV9GA
UT WOS:000364594300001
PM 25703329
OA Green Accepted, Bronze
DA 2025-01-04
ER

PT J
AU Shi, WK
   Li, YH
   Bai, XS
   Lin, GL
AF Shi, Wei-Kun
   Li, Yun-Hao
   Bai, Xue-Shan
   Lin, Guo-Le
TI The Cell Cycle-Associated Protein CDKN2A May Promotes Colorectal Cancer
   Cell Metastasis by Inducing Epithelial-Mesenchymal Transition
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE CDKN2A; colorectal cancer; epithelial-mesenchymal transition; cancer
   metastasis; cell proliferation and migration
ID EMT; PROLIFERATION; INVASION
AB Colorectal cancer (CRC) is a common gastrointestinal malignancy, and recurrence and metastasis contribute considerably to its high mortality. It is well known that the epithelial-mesenchymal transition (EMT) accelerates the rate of cancer cell dissemination and migration, thus promoting cancer metastasis. Targeted therapy is a common modality for cancer treatment, and it can play a role in inhibiting cancer progression. In this study, bioinformatics was used to search for genes associated with the prognosis of CRC. First, differential analysis was performed on colon and rectal cancer samples to obtain 2,840 and 3,177 differentially expressed genes (DEGs), respectively. A Venn diagram was then used to identify 262 overlapping genes from the two groups of DEGs and EMT-related genes. The overlapping genes were subjected to batch survival analysis and batch expression analysis successively, and nine genes were obtained whose high expression in CRC led to a poor prognosis. The least absolute shrinkage and selection operator (LASSO) prognostic model was then constructed to obtain the risk score formula. A nomogram was constructed to seek prognostic independent factors to obtain CDKN2A. Finally, CCK-8 assay, flow cytometry and western blotting assays were performed to analyze the cellular biological function of CDKN2A. The results showed that knockdown of CDKN2A expression inhibited HT-29 cell proliferation, promoted apoptosis and cell cycle progression, and affected the EMT process in CRC.
C1 [Shi, Wei-Kun; Li, Yun-Hao; Lin, Guo-Le] Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China.
   [Bai, Xue-Shan] Chinese Acad Med Sci, Plast Surg Hosp, Beijing, Peoples R China.
   [Bai, Xue-Shan] Peking Union Med Coll, Beijing, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College Hospital; Peking Union Medical College;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Plastic Surgery Hospital - CAMS; Chinese Academy of Medical Sciences -
   Peking Union Medical College; Peking Union Medical College
RP Lin, GL (corresponding author), Peking Union Med Coll & Chinese Acad Med Sci, Peking Union Med Coll Hosp, Dept Gen Surg, Beijing, Peoples R China.
EM linguole@126.com
RI Shi, Weikun/HGV-2450-2022; LI, YUNHAO/IAQ-8876-2023
FU Beijing Major Science and Technology Projects [D171100002617003]
FX Funding This work was supported by Beijing Major Science and Technology
   Projects under grant No. D171100002617003.
CR Aiello NM, 2019, J EXP MED, V216, P1016, DOI 10.1084/jem.20181827
   Boulding T, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-17913-x
   Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118
   Bui NQ, 2019, CLIN SARCOMA RES, V9, DOI 10.1186/s13569-019-0122-5
   Chen WS, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00095
   Derynck R, 2019, DEV CELL, V49, P313, DOI 10.1016/j.devcel.2019.04.026
   Georgakopoulos-Soares I, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00499
   Hampel H, 2011, CANCER PREV RES, V4, P1, DOI 10.1158/1940-6207.CAPR-10-0345
   Hibi K, 2002, JPN J CANCER RES, V93, P883, DOI 10.1111/j.1349-7006.2002.tb01333.x
   Hong S, 2021, MOL THER NUCL ACIDS, V24, P1012, DOI 10.1016/j.omtn.2021.04.007
   Inoue Kazushi, 2018, Tumor Microenviron, V1, P37, DOI 10.4103/tme.tme_24_17
   Jeong EH, 2018, CELL ONCOL, V41, P663, DOI 10.1007/s13402-018-0404-6
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Li QY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1330-9
   Li T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1038-7
   Lim SHS, 2014, J CLIN PATHOL, V67, P848, DOI 10.1136/jclinpath-2014-202499
   Lin JG, 2018, BIOMED PHARMACOTHER, V98, P433, DOI 10.1016/j.biopha.2017.12.058
   Loh CY, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8101118
   Mattiuzzi C, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.07.91
   Merkle J, 2021, CANCERS, V13, DOI 10.3390/cancers13205139
   Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001
   Pfeifer H, 2018, BLOOD, V131, P1464, DOI 10.1182/blood-2017-07-796862
   Shintani Y, 2011, ANN THORAC SURG, V92, P1794, DOI 10.1016/j.athoracsur.2011.07.032
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sommariva M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9041040
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tu Q, 2018, ONCOGENE, V37, P128, DOI 10.1038/onc.2017.316
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   Wang K, 2020, BRIT J CANCER, V123, P410, DOI 10.1038/s41416-020-0902-y
   Wang XK, 2019, INT J MED SCI, V16, P51, DOI 10.7150/ijms.27359
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xing X, 2013, BRIT J CANCER, V108, P2542, DOI 10.1038/bjc.2013.251
   Yang C, 2021, MODERN PATHOL, V34, P445, DOI 10.1038/s41379-020-00667-9
   Zeng HL, 2018, CANCER CELL, V34, P56, DOI 10.1016/j.ccell.2018.05.014
   Zeng QY, 2020, MOL MED REP, V21, P2544, DOI 10.3892/mmr.2020.11051
NR 35
TC 17
Z9 17
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAR 3
PY 2022
VL 12
AR 834235
DI 10.3389/fonc.2022.834235
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ZX8LY
UT WOS:000772145700001
PM 35311137
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Yousef, PG
   Gabril, MY
AF Yousef, Peter G.
   Gabril, Manal Y.
TI An update on the molecular pathology of urinary bladder tumors
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Review
DE Urothelial carcinoma; Molecular biomarkers; Molecular pathways
ID TRANSITIONAL-CELL CARCINOMA; IN-SITU; UROTHELIAL CARCINOMA; PROSPECTIVE
   MULTICENTER; PROSTATE-CANCER; STEM-CELLS; MARKERS; VALIDATION;
   RECURRENCE; CYTOLOGY
AB Urothelial carcinoma is the fourth most common tumors after prostate cancer, lung, and colorectal carcinoma but the second most common urologic malignancy. Urothelial carcinoma composed more than 90% of bladder tumors while squamous cell carcinoma and adenocarcinomas composed 5% and 2% respectively. The intense research involving the different molecular aspects of bladder cancer has provided a great insight into identifying more about molecular profiling and pathways of bladder cancer.
   In this review, we will highlight the general concepts of the molecular features; profiling and classification as well as the molecular pathways for bladder carcinomas, especially urothelial carcinoma. Also, we will discuss the advances of molecular biomarkers for screening, early diagnosis, surveillance and potential prognosis of urothelial carcinoma of the bladder. Studies showed that accumulation of genetic alterations involving the clonal expansion of altered cells with growth advantages through sequential multi-step pathways results in progression of bladder tumors.
   The accumulated research data from literature has revealed that the genomic signatures of urothelial carcinoma are required to subclassify bladder cancer into genetically distinct subgroups. These findings could improve the understating of pathogenesis as well as will provide new therapeutic modules e.g. targeted therapy.
C1 [Yousef, Peter G.; Gabril, Manal Y.] Western Univ, London Hlth Sci Ctr, Pathol & Lab Med, London, ON, Canada.
C3 Western University (University of Western Ontario); London Health
   Sciences Centre
RP Gabril, MY (corresponding author), Western Univ, London Hlth Sci Ctr, Pathol & Lab Med, Univ Hosp, 339 Windermere Rd, London, ON N6A 5A5, Canada.
EM manal.gabril@lhsc.on.ca
CR Adams J, 2005, CANCER LETT, V220, P137, DOI 10.1016/j.canlet.2004.06.052
   Alva A, 2015, J UROLOGY, V194, P790, DOI 10.1016/j.juro.2015.02.2951
   [Anonymous], CAN UROL ASS J
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Chan MWY, 2002, CLIN CANCER RES, V8, P464
   Cheng LA, 2011, HUM PATHOL, V42, P455, DOI 10.1016/j.humpath.2010.07.007
   Cronin M, 2007, CLIN CHEM, V53, P1084, DOI 10.1373/clinchem.2006.076497
   Dyrskjot L, 2017, EUR UROL, V72, P461, DOI 10.1016/j.eururo.2017.05.040
   Fendler A, 2011, CLIN CHEM, V57, P954, DOI 10.1373/clinchem.2010.157727
   Friedrich MG, 2004, CLIN CANCER RES, V10, P7457, DOI 10.1158/1078-0432.CCR-04-0930
   Hafner C, 2002, INT J CANCER, V101, P1, DOI 10.1002/ijc.10544
   Hanke M, 2010, UROL ONCOL-SEMIN ORI, V28, P655, DOI 10.1016/j.urolonc.2009.01.027
   Hartmann A, 2002, CANCER RES, V62, P809
   Hausladen DA, 2003, J UROLOGY, V170, P230, DOI 10.1097/01.ju.0000063685.29339.24
   Hautmann S, 2004, EUR UROL, V46, P466, DOI 10.1016/j.eururo.2004.06.006
   Ho PL, 2012, NAT REV UROL, V9, P583, DOI 10.1038/nrurol.2012.142
   Hurst CD, 2012, CLIN CANCER RES, V18, P5865, DOI 10.1158/1078-0432.CCR-12-1807
   Kattan MW, 2006, J UROLOGY, V175, P2103, DOI 10.1016/S0022-5347(06)00313-2
   Kattan MW, 1998, JNCI-J NATL CANCER I, V90, P766, DOI 10.1093/jnci/90.10.766
   Kattan MW, 2006, J UROLOGY, V175, P2108
   Knowles MA, 2005, CANCER LETT, V225, P121, DOI 10.1016/j.canlet.2004.10.047
   Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821
   Konety BR, 2001, J UROLOGY, V165, P600, DOI 10.1097/00005392-200102000-00081
   Lokeshwar VB, 2005, UROLOGY, V66, P35, DOI 10.1016/j.urology.2005.08.064
   Lokeshwar VB, 2001, J UROLOGY, V165, P1067, DOI 10.1016/S0022-5347(05)66428-2
   Mallmann P, 1991, ACTA OBSTET GYN SCAN, V70, P35, DOI 10.3109/00016349109006175
   Matsushita K, 2011, INT J UROL, V18, P616, DOI 10.1111/j.1442-2042.2011.02809.x
   McConkey DJ, 2010, UROL ONCOL-SEMIN ORI, V28, P429, DOI 10.1016/j.urolonc.2010.04.008
   McKenney JK, 2001, AM J SURG PATHOL, V25, P1074, DOI 10.1097/00000478-200108000-00013
   Mian C, 2006, CANCER CYTOPATHOL, V108, P60, DOI 10.1002/cncr.21712
   Mian C, 2005, ANTICANCER RES, V25, P3641
   Moonen PMJ, 2007, EUR UROL, V51, P1275, DOI 10.1016/j.eururo.2006.10.044
   Moussa O, 2006, J UROLOGY, V175, P2312, DOI 10.1016/S0022-5347(06)00254-0
   Nezos A, 2011, CANCER TREAT REV, V37, P284, DOI 10.1016/j.ctrv.2010.10.002
   Piaton E, 2003, LAB INVEST, V83, P845, DOI 10.1097/01.LAB.0000074893.70675.2E
   Reinert T, 2012, ADV UROL, V2012, DOI 10.1155/2012/503271
   Reinert T, 2011, CLIN CANCER RES, V17, P5582, DOI 10.1158/1078-0432.CCR-10-2659
   Retz M, 2003, J UROLOGY, V169, P86, DOI 10.1016/S0022-5347(05)64042-6
   Schaefer A, 2010, NAT REV UROL, V7, P286, DOI 10.1038/nrurol.2010.45
   Sethi S, 2013, AM J TRANSL RES, V5, P200
   Shariat SF, 2008, CANCER-AM CANCER SOC, V112, P315, DOI 10.1002/cncr.23162
   Shariat SF, 2006, J UROLOGY, V176, P2414, DOI 10.1016/j.juro.2006.08.004
   Shariat SF, 2006, J UROLOGY, V176, P919, DOI 10.1016/j.juro.2006.04.017
   Simon R, 2001, CANCER RES, V61, P355
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Steiner G, 1997, NAT MED, V3, P621, DOI 10.1038/nm0697-621
   Takihana Y, 2006, INT J UROL, V13, P401, DOI 10.1111/j.1442-2042.2006.01300.x
   Tomlinson DC, 2007, J PATHOL, V213, P91, DOI 10.1002/path.2207
   van Rhijn BSW, 2004, CANCER RES, V64, P1911, DOI 10.1158/0008-5472.CAN-03-2421
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Wu XR, 2005, NAT REV CANCER, V5, P713, DOI 10.1038/nrc1697
   Yoder BJ, 2007, AM J CLIN PATHOL, V127, P295, DOI 10.1309/ADJL7E810U1H42BJ
   Zellweger T, 2006, INT J CANCER, V119, P1660, DOI 10.1002/ijc.21704
   Zuiverloon TCM, 2012, BJU INT, V109, P941, DOI 10.1111/j.1464-410X.2011.10428.x
   Zuiverloon TCM, 2010, CLIN CANCER RES, V16, P3011, DOI 10.1158/1078-0432.CCR-09-3013
NR 55
TC 28
Z9 33
U1 0
U2 5
PU ELSEVIER GMBH, URBAN & FISCHER VERLAG
PI JENA
PA OFFICE JENA, P O BOX 100537, 07705 JENA, GERMANY
SN 0344-0338
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD JAN
PY 2018
VL 214
IS 1
BP 1
EP 6
DI 10.1016/j.prp.2017.11.00:3
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA GB5EN
UT WOS:000429086000001
PM 29254798
DA 2025-01-04
ER

PT J
AU Ruffinelli, JC
   Vivas, CS
   Sanz-Pamplona, R
   Moreno, V
AF Carlos Ruffinelli, Jose
   Santos Vivas, Cristina
   Sanz-Pamplona, Rebeca
   Moreno, Victor
TI New advances in the clinical management of RAS and BRAF mutant
   colorectal cancer patients
SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
DE Colorectal cancer; mapk; ras; braf; targeted therapy; egfr; mek
ID ORAL MEK INHIBITOR; III COLON-CANCER; PHASE-1 DOSE-ESCALATION; FOLFIRI
   PLUS BEVACIZUMAB; KRAS CODON 12; WILD-TYPE; MICROSATELLITE INSTABILITY;
   SOLID TUMORS; STAGE-II; ANTITUMOR-ACTIVITY
AB Introduction In colorectal carcinogenesis, genetic alterations in RAS and BRAF oncogenes play an important role for cancer initiation and/or progression and represent a key focus in the search for targeted therapies. Despite many years of research and a great amount of studies, until very recently this pathway was considered extremely hard to downregulate to obtain a significant clinical impact in colorectal cancer patients. But better times are coming with the advent of new promising drugs and combinations strategies. Areas covered In this review, we go over the biological characteristics of the MAPK pathway in colorectal tumors, while illustrating the clinical correlation of RAS and BRAF mutations, particularly its prognostic and predictive value. We also present newly data about recent improvements in the treatment strategy for patients harboring these types of tumors. Expert commentary With great advances in the knowledge of molecular basis of RAS and BRAF mutant colorectal cancer in conjunction with biotechnology development and the constant effort for improvement, in the near future many new therapeutic options would be available for the management of this group of patient with dismal prognosis.
C1 [Carlos Ruffinelli, Jose; Santos Vivas, Cristina] Catalan Inst Oncol ICO, Dept Med Oncol, Barcelona, Spain.
   [Carlos Ruffinelli, Jose; Santos Vivas, Cristina; Sanz-Pamplona, Rebeca; Moreno, Victor] Inst Recerca Biomed Bellvitge IDIBELL, Colorectal Canc Grp, ONCOBELL Program, Barcelona, Spain.
   [Santos Vivas, Cristina] Consortium Biomed Res Oncol CIBERONC, Barcelona, Spain.
   [Santos Vivas, Cristina; Moreno, Victor] Univ Barcelona, Fac Med & Hlth Sci, Dept Clin Sci, Barcelona, Spain.
   [Sanz-Pamplona, Rebeca; Moreno, Victor] Catalan Inst Oncol ICO, Oncol Data Analyt Program ODAP, Unit Biomarkers & Susceptibil, Barcelona, Spain.
   [Sanz-Pamplona, Rebeca; Moreno, Victor] Consortium Biomed Res Epidemiol & Publ Hlth CIBER, Barcelona, Spain.
C3 Institut Catala d'Oncologia; Institut d'Investigacio Biomedica de
   Bellvitge (IDIBELL); University of Barcelona; Institut Catala
   d'Oncologia; CIBER - Centro de Investigacion Biomedica en Red; CIBERESP
RP Moreno, V (corresponding author), Catalan Inst Oncol ICO, Oncol Data Analyt Program ODAP, Unit Biomarkers & Susceptibil, Barcelona, Spain.
EM v.moreno@iconcologia.net
RI ; Moreno, Victor/A-1697-2010
OI Sanz-Pamplona, Rebeca/0000-0002-2187-3527; Moreno,
   Victor/0000-0002-2818-5487; Ruffinelli, Jose Carlos/0000-0003-2947-320X
FU Agency for Management of University and Research Grants (AGAUR) of the
   Catalan Government [2017SGR723]; Instituto de Salud Carlos III; FEDER
   funds -a way to build Europe-grant [PI17-00092]; Spanish Association
   Against Cancer (AECC) Scientific Foundation
FX This paper was funded by the Agency for Management of University and
   Research Grants (AGAUR) of the Catalan Government grant 2017SGR723; the
   Instituto de Salud Carlos III, co-funded by FEDER funds -a way to build
   Europe-grant PI17-00092 and the Spanish Association Against Cancer
   (AECC) Scientific Foundation.
CR Adjei AA, 2017, INVEST NEW DRUG, V35, P47, DOI 10.1007/s10637-016-0391-2
   Adjei AA, 2016, CLIN CANCER RES, V22, P2368, DOI 10.1158/1078-0432.CCR-15-1681
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Andre T, 2020, J CLIN ONCOL, V38, pLBA4
   Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964
   Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675
   [Anonymous], 2020, J CLIN ONCOL S
   [Anonymous], 2014, J NATL CANC I
   [Anonymous], 2013, ANN ONCOL S6
   [Anonymous], 2014, J CLIN ONCOL S
   Awada A, 2012, 24 EORTC NCI AACR S
   Bardia A, 2020, ONCOLOGIST, V25, pE160, DOI 10.1634/theoncologist.2019-0297
   Bedard PL, 2015, CLIN CANCER RES, V21, P730, DOI 10.1158/1078-0432.CCR-14-1814
   Bendell JC, 2017, BRIT J CANCER, V116, P575, DOI 10.1038/bjc.2017.10
   Bennouna J, 2011, INVEST NEW DRUG, V29, P1021, DOI 10.1007/s10637-010-9392-8
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bond CE, 2018, GASTROENT RES PRACT, V2018, DOI 10.1155/2018/9250757
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Cho M, 2017, ONCOTARGET, V8, P79750, DOI 10.18632/oncotarget.19336
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Coffee EM, 2013, CLIN CANCER RES, V19, P4018, DOI 10.1158/1078-0432.CCR-13-1433
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J GASTROINTEST ONCOL, V6, P650, DOI 10.3978/j.issn.2078-6891.2015.076
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148
   Cremolini C, 2015, ANN ONCOL, V26, P2092, DOI 10.1093/annonc/mdv290
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Deming DA, 2016, INVEST NEW DRUG, V34, P168, DOI 10.1007/s10637-015-0314-7
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Dienstmann R, 2017, ANN ONCOL, V28, P1023, DOI 10.1093/annonc/mdx052
   Domingo E, 2013, J PATHOL, V229, P441, DOI 10.1002/path.4139
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Etienne-Grimaldi MC, 2008, CLIN CANCER RES, V14, P4830, DOI 10.1158/1078-0432.CCR-07-4906
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Fariña-Sarasqueta A, 2010, ANN ONCOL, V21, P2396, DOI 10.1093/annonc/mdq258
   Fell JB, 2020, J MED CHEM, V63, P6679, DOI 10.1021/acs.jmedchem.9b02052
   Ferlay J, 2013, EUR J CANCER, V49, P6
   Fritsche-Guenther R, 2011, MOL SYST BIOL, V7, P1
   Gavin PG, 2012, CLIN CANCER RES, V18, P6531, DOI 10.1158/1078-0432.CCR-12-0605
   Gomez-Roca C A, 2014, ANN ONCOL, V25, p535P
   Grasselli J, 2017, ANN ONCOL, V28, P1294, DOI 10.1093/annonc/mdx112
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167
   Hellmann MD, 2019, ANN ONCOL, V30, P1134, DOI 10.1093/annonc/mdz113
   Hochster HS, 2015, CANCER CHEMOTH PHARM, V75, P17, DOI 10.1007/s00280-014-2609-3
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X
   Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006
   Janne P., 2019, P AACR NCI EORTC INT
   Kasi PM, 2020, ANN ONCOL, V31, P15, DOI 10.1016/j.annonc.2019.11.001
   Kefford R, 2014, J TRANSLAT MED S1, V12, pP5
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3505
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Korphaisarn K, 2016, CANCER J, V22, P175, DOI 10.1097/PPO.0000000000000189
   Krishnamurthy A, 2018, CANCER RES, V78, P5398, DOI 10.1158/0008-5472.CAN-18-0316
   Laquerre S, 2009, MOL CANCER THER, V8, DOI 10.1158/1535-7163.TARG-09-B88
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Leijen S, 2012, CLIN CANCER RES, V18, P4794, DOI 10.1158/1078-0432.CCR-12-0868
   Li SQ, 2018, NAT REV CANCER, V18, P767, DOI 10.1038/s41568-018-0076-6
   Li X, 2008, CELL SIGNAL, V20, P2145, DOI 10.1016/j.cellsig.2008.08.006
   Lieu CH, 2017, ONCOLOGIST, V22, P1024, DOI 10.1634/theoncologist.2017-0175
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lipsyc M, 2015, J GASTROINTEST ONCOL, V6, P645, DOI 10.3978/j.issn.2078-6891.2015.045
   Lito P, 2013, NAT MED, V19, P1401, DOI 10.1038/nm.3392
   Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173
   LoRusso PM, 2010, CLIN CANCER RES, V16, P1924, DOI 10.1158/1078-0432.CCR-09-1883
   LoRusso PM, 2005, J CLIN ONCOL, V23, P5281, DOI 10.1200/JCO.2005.14.415
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Macarulla T, 2015, BRIT J CANCER, V112, P1874, DOI 10.1038/bjc.2015.144
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   McCormick F, 2020, CANCER CELL, V37, P3, DOI 10.1016/j.ccell.2019.12.009
   Mita M, 2017, INVEST NEW DRUG, V35, P616, DOI 10.1007/s10637-017-0442-3
   Modest DP, 2016, ANN ONCOL, V27, P1746, DOI 10.1093/annonc/mdw261
   Montagut C, 2018, ANN ONCOL, V29, P1083, DOI 10.1093/annonc/mdy091
   Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   Morris Van, 2013, Clin Adv Hematol Oncol, V11, P768
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   National Comprehensive Cancer Network, COL CANC VERS 3 0
   O'Bryan JP, 2019, PHARMACOL RES, V139, P503, DOI 10.1016/j.phrs.2018.10.021
   Ogino S, 2009, CLIN CANCER RES, V15, P7322, DOI 10.1158/1078-0432.CCR-09-1570
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Owonikoko TK, 2019, ANN ONCOL, V30, P77, DOI 10.1093/annonc/mdz094
   Papke B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11360
   Peeters M, 2015, CLIN CANCER RES, V21, P5469, DOI 10.1158/1078-0432.CCR-15-0526
   Petrelli F, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0650-4
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prewett MC, 2002, CLIN CANCER RES, V8, P994
   Qiu LX, 2010, EUR J CANCER, V46, P2781, DOI 10.1016/j.ejca.2010.05.022
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Ramanathan RK, 2020, TARGET ONCOL, V15, P163, DOI 10.1007/s11523-020-00714-0
   Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295
   Rimbert J, 2018, MODERN PATHOL, V31, P517, DOI 10.1038/modpathol.2017.119
   Rinehart J, 2004, J CLIN ONCOL, V22, P4456, DOI 10.1200/JCO.2004.01.185
   Rosen LS, 2016, INVEST NEW DRUG, V34, P604, DOI 10.1007/s10637-016-0374-3
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Ryan MB, 2018, NAT REV CLIN ONCOL, V15, P709, DOI 10.1038/s41571-018-0105-0
   Schirripa M, 2020, CLIN COLORECTAL CANC, VS1533-0028
   Schram AM, 2018, BRIT J CANCER, V119, P1471, DOI 10.1038/s41416-018-0322-4
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Shimada Y, 2018, J SURG RES, V232, P72, DOI 10.1016/j.jss.2018.06.020
   Stintzing S, 2017, EUR J CANCER, V79, P50, DOI 10.1016/j.ejca.2017.03.023
   Stuart DD, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3790
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Taieb J, 2017, ANN ONCOL, V28, P824, DOI 10.1093/annonc/mdw687
   Taieb J, 2019, BRIT J CANCER, V121, P434, DOI 10.1038/s41416-019-0526-2
   Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272
   Taieb J, 2016, JAMA ONCOL, V2, P643, DOI 10.1001/jamaoncol.2015.5225
   Thierry AR, 2014, NAT MED, V20, P430, DOI 10.1038/nm.3511
   Tolcher AW, 2020, CANCER CHEMOTH PHARM, V85, P673, DOI 10.1007/s00280-020-04038-8
   Tolcher AW, 2015, CLIN CANCER RES, V21, P739, DOI 10.1158/1078-0432.CCR-14-1901
   Tolcher AW, 2015, CANCER CHEMOTH PHARM, V75, P183, DOI 10.1007/s00280-014-2615-5
   Tosi F, 2017, CLIN COLORECTAL CANC, V16, pE153, DOI 10.1016/j.clcc.2017.01.004
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Tsilimigras DI, 2018, SURG ONCOL, V27, P280, DOI 10.1016/j.suronc.2018.05.012
   Vacante M, 2018, WORLD J CLIN CASES, V6, P869, DOI 10.12998/wjcc.v6.i15.869
   Van Cutsem E, 2016, ANN ONCOL S2, V27, pii106
   Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   van Geel RMJM, 2020, BRIT J CANCER, V122, P1166, DOI 10.1038/s41416-020-0776-z
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   Vidal J, 2017, ANN ONCOL, V28, P1325, DOI 10.1093/annonc/mdx125
   Wainberg ZA, 2017, TARGET ONCOL, V12, P775, DOI 10.1007/s11523-017-0530-5
   Weekes CD, 2013, CLIN CANCER RES, V19, P1232, DOI 10.1158/1078-0432.CCR-12-3529
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941
   Yoon HH, 2014, CLIN CANCER RES, V20, P3033, DOI 10.1158/1078-0432.CCR-13-3140
   Zimmer L, 2014, CLIN CANCER RES, V20, P4251, DOI 10.1158/1078-0432.CCR-14-0341
   Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205
NR 142
TC 2
Z9 2
U1 0
U2 4
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-4124
EI 1747-4132
J9 EXPERT REV GASTROENT
JI Expert Rev. Gastroenterol. Hepatol.
PD JAN 2
PY 2021
VL 15
IS 1
BP 65
EP 79
DI 10.1080/17474124.2021.1826305
EA OCT 2020
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA PR0BQ
UT WOS:000579061600001
PM 32946312
DA 2025-01-04
ER

PT J
AU Qi, LN
   Chen, JN
   Yang, YM
   Hu, WX
AF Qi, Lina
   Chen, Jiani
   Yang, Yanmei
   Hu, Wangxiong
TI Hypoxia Correlates With Poor Survival and M2 Macrophage Infiltration in
   Colorectal Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; HIF-1; hypoxia; KRAS mutation; M2 macrophages
ID TUMOR-ASSOCIATED MACROPHAGES; GENE-EXPRESSION; R PACKAGE; RADIOTHERAPY;
   METASTASIS; CELLS; HEAD; ETS1
AB Background
   It is widely accepted that the oxygen level in tumor tissue is significantly lower than the adjacent normal tissue, thus termed hypoxia. Intratumoral hypoxia represents a major driving force in cancer progression, recurrence, metastasis, and decreased survival. Though multiple gene signatures reflect the complex cellular response to hypoxia have been established in several cancer types such as head and neck, breast, and lung cancers, the hypoxic panorama in colorectal cancer (CRC) remains poorly understood.
   Methods
   A hypoxic signature constituted by a total of 356 genes, including canonical hypoxia-responsive ADM, ANGPTL4, CA9, and VEGFA, was established based on systemic literature search. A total of 1,730 CRC samples across four independent cohorts were used for nonnegative matrix factorization clustering and subtyping. Prognosis, molecular signatures, pathways, and tumor-infiltrating lymphocytes were compared between the subtypes.
   Results
   CRCs mainly fell into two subgroups, one indicated as hypoxia and the other one designated as normoxia. Hypoxia was correlated with poor outcomes in CRC and will increase the risk of a subset of stage II patients to the level of normoxic stage III. Additionally, hypoxia was closely associated with activation of RAS signaling pathway independent of KRAS mutation. More M2 macrophage infiltration was another hypoxic marker indicated that subsets of patients with high M2 macrophages may benefit from macrophage-targeting therapy.
   Conclusions
   These findings will facilitate the development of a hypoxia-oriented therapy strategy to enhance the treatment effect in the near future.
C1 [Qi, Lina; Chen, Jiani; Hu, Wangxiong] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst,Key Lab Canc Prevent & Intervent,China, Hangzhou, Peoples R China.
   [Yang, Yanmei] Zhejiang Univ, Sch Med, Womens Hosp, Minist Educ,Key Lab Reprod & Genet, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Hu, WX (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Canc Inst,Key Lab Canc Prevent & Intervent,China, Hangzhou, Peoples R China.; Yang, YM (corresponding author), Zhejiang Univ, Sch Med, Womens Hosp, Minist Educ,Key Lab Reprod & Genet, Hangzhou, Peoples R China.
EM yangyanmei@zju.edu.cn; wxhu@zju.edu.cn
FU National Natural Science Foundation of China [81802883]; Fundamental
   Research Funds for the Central Universities [2018FZA7012]
FX This work was supported by the National Natural Science Foundation of
   China (grant number 81802883) and the Fundamental Research Funds for the
   Central Universities (grant number 2018FZA7012) to WH.
CR [Anonymous], 2000, STAT BIOL HEALTH, DOI 10.1007/978-1-4757-3294-8_3
   Ascierto PA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000878
   Barkal AA, 2019, NATURE, V572, P392, DOI 10.1038/s41586-019-1456-0
   Barkal AA, 2018, NAT IMMUNOL, V19, P76, DOI 10.1038/s41590-017-0004-z
   Bhandari V, 2019, NAT GENET, V51, P308, DOI 10.1038/s41588-018-0318-2
   Buffa FM, 2010, BRIT J CANCER, V102, P428, DOI 10.1038/sj.bjc.6605450
   Elvidge GP, 2006, J BIOL CHEM, V281, P15215, DOI 10.1074/jbc.M511408200
   Eustace A, 2013, CLIN CANCER RES, V19, P4879, DOI 10.1158/1078-0432.CCR-13-0542
   Gaujoux R, 2010, BMC BIOINFORMATICS, V11, DOI 10.1186/1471-2105-11-367
   Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405
   Hu WX, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0397-4
   Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046
   Jeong H, 2019, CANCER RES, V79, P795, DOI 10.1158/0008-5472.CAN-18-2545
   Jing XM, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1089-9
   Kannarkatt J, 2017, J ONCOL PRACT, V13, P233, DOI 10.1200/JOP.2016.017210
   Kessenbrock K, 2010, CELL, V141, P52, DOI 10.1016/j.cell.2010.03.015
   Khong TL, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-518
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3
   Mantovani A, 2015, J EXP MED, V212, P435, DOI 10.1084/jem.20150295
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Morrison C, 2016, NAT REV DRUG DISCOV, V15, P373, DOI 10.1038/nrd.2016.111
   Muz B, 2015, HYPOXIA, V3, P83, DOI 10.2147/HP.S93413
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Noman MZ, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091083
   Plotnik JP, 2014, NUCLEIC ACIDS RES, V42, P11928, DOI 10.1093/nar/gku929
   Salnikow K, 2008, CARCINOGENESIS, V29, P1493, DOI 10.1093/carcin/bgn088
   Sorensen BS, 2010, ACTA ONCOL, V49, P895, DOI 10.3109/02841861003614343
   Toustrup K, 2011, CANCER RES, V71, P5923, DOI 10.1158/0008-5472.CAN-11-1182
   Vito A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040992
   Wang LK, 2010, BIOINFORMATICS, V26, P136, DOI 10.1093/bioinformatics/btp612
   Wei C, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0976-4
   Wilson PM, 2010, CANCER J, V16, P262, DOI 10.1097/PPO.0b013e3181e07738
   Winter SC, 2007, CANCER RES, V67, P3441, DOI 10.1158/0008-5472.CAN-06-3322
   Wu DW, 2017, THERANOSTICS, V7, P1114, DOI 10.7150/thno.18175
   Yang LJ, 2018, EBIOMEDICINE, V31, P182, DOI 10.1016/j.ebiom.2018.04.019
   Yang LJ, 2017, CLIN CANCER RES, V23, P4761, DOI 10.1158/1078-0432.CCR-17-0038
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
NR 38
TC 35
Z9 37
U1 0
U2 8
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 20
PY 2020
VL 10
AR 566430
DI 10.3389/fonc.2020.566430
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PA1VH
UT WOS:000595418900001
PM 33330037
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Qiang, LM
   Li, HP
   Wang, ZH
   Wan, L
   Jiang, GF
AF Qiang, Liming
   Li, Hongpeng
   Wang, Zhaohui
   Wan, Lin
   Jiang, Guangfu
TI Deconvoluting the complexity of autophagy in colorectal cancer: From
   crucial pathways to targeted therapies
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE colorectal cancer (CRC); autophagy; crucial pathway; therapeutic
   strategy; targeted therapy
AB Colorectal cancer (CRC) is a common gastrointestinal tumor with a high degree of malignancy, and most clinical cases are diagnosed at an advanced stage, which has unfortunately missed an opportunity for surgery; therefore, elucidation of the crucial pathways of CRC development and discovery of targeted therapeutic strategies should be anticipated. Autophagy, which is an evolutionarily highly conserved catabolic process, may promote tumorigenesis and development of CRC. On the contrary, autophagy can trigger programmed cell death to inhibit CRC progression. Correspondingly, several targeted therapeutic strategies have been reported in CRC, including small-molecule compounds, polypeptides, non-coding RNAs, photodynamic, and adjuvant therapies. Thus, in this review, we focus on summarizing the crucial pathways of autophagy in CRC, and further discuss the current therapeutic strategies targeting autophagy. Together, these findings may shed light on the key regulatory mechanisms of autophagy and provide more promising therapeutic approaches for the future CRC therapies.
C1 [Qiang, Liming] Guangan Peoples Hosp, Dept Gastroenterol Ward, Guangan, Peoples R China.
   [Li, Hongpeng; Wang, Zhaohui; Wan, Lin; Jiang, Guangfu] Guangan Peoples Hosp, Dept Gastrointestinal Surg, Guangan, Peoples R China.
RP Jiang, GF (corresponding author), Guangan Peoples Hosp, Dept Gastrointestinal Surg, Guangan, Peoples R China.
EM huaxi_jgf@outlook.com
FU fund of the high-quality development of Guang 'an People's Hospital
   [21FZ008]
FX This work was supported by grants from the fund of the high-quality
   development of Guang 'an People's Hospital (Grant No. 21FZ008).
CR Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Bhinder B, 2021, CANCER DISCOV, V11, P900, DOI 10.1158/2159-8290.CD-21-0090
   Bijelic L, 2021, ANN SURG ONCOL, V28, P4140, DOI 10.1245/s10434-021-10049-3
   Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532
   Chen J, 2021, ONCOGENE, V40, P3974, DOI 10.1038/s41388-021-01815-4
   Chu CA, 2019, EBIOMEDICINE, V43, P270, DOI 10.1016/j.ebiom.2019.04.010
   Dang YQ, 2020, CLIN TRANSL MED, V10, DOI 10.1002/ctm2.125
   Luu LDW, 2022, AUTOPHAGY, V18, P2537, DOI 10.1080/15548627.2022.2042783
   Foerster EG, 2022, AUTOPHAGY, V18, P86, DOI 10.1080/15548627.2021.1909406
   Galluzzi L, 2019, CELL, V177, P1682, DOI 10.1016/j.cell.2019.05.026
   Galluzzi L, 2017, NAT REV DRUG DISCOV, V16, P487, DOI 10.1038/nrd.2017.22
   Gholizadeh M, 2021, MOLECULES, V26, DOI 10.3390/molecules26226877
   Han Y, 2020, BIOMED PHARMACOTHER, V121, DOI 10.1016/j.biopha.2019.109580
   Hu FQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23923-1
   Hu S, 2021, BIOORG CHEM, V109, DOI 10.1016/j.bioorg.2021.104693
   Hu WH, 2021, DIAGNOSTICS, V11, DOI 10.3390/diagnostics11050782
   Hu YT, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.752825
   Khan MZI, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.627022
   Kumar B, 2021, CANCERS, V13, DOI 10.3390/cancers13092168
   Kwiatkowski S, 2018, BIOMED PHARMACOTHER, V106, P1098, DOI 10.1016/j.biopha.2018.07.049
   Levy JMM, 2020, CELL DEATH DIFFER, V27, P843, DOI [10.1038/s41418-019-0474, 10.1038/s41418-019-0474-7]
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li CH, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01915-9
   Li C, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.01175
   Li N, 2021, CANCER LETT, V522, P255, DOI 10.1016/j.canlet.2021.09.034
   Liang JQ, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188642
   Lin SC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1303-z
   Liu PF, 2014, AUTOPHAGY, V10, P1454, DOI 10.4161/auto.29556
   Liu YQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2268-8
   Lystad AH, 2019, AUTOPHAGY, V15, P1485, DOI 10.1080/15548627.2019.1618100
   Ma Z, 2020, AGING-US, V12, P7985, DOI 10.18632/aging.103117
   Martins WK, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.610472
   Pan ZP, 2020, J MED CHEM, V63, P3678, DOI 10.1021/acs.jmedchem.9b02178
   Peng Y, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.819128
   Porter RJ, 2021, J PATHOL CLIN RES, V7, P495, DOI 10.1002/cjp2.222
   Scherr AL, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21031099
   Shi XF, 2019, J PHOTOCH PHOTOBIO B, V198, DOI 10.1016/j.jphotobiol.2019.111586
   Si YR, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0175-8
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017
   Song CF, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03136-y
   Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Wang XK, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0951-6
   Wang YJ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04509-1
   Wei R, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1043-0
   Xia HJ, 2021, NAT REV CANCER, V21, P281, DOI 10.1038/s41568-021-00344-2
   Xiang XC, 2021, BIOCHEM PHARMACOL, V186, DOI 10.1016/j.bcp.2021.114475
   Yang BL, 2022, AGING-US, V14, P497, DOI 10.18632/aging.203827
   Yu HY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0660-4
   Yuan JM, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00949-4
   Yun CW, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010179
   Zachari M, 2017, ESSAYS BIOCHEM, V61, P585, DOI 10.1042/EBC20170021
   Zhang N, 2019, J CONTROL RELEASE, V309, P48, DOI 10.1016/j.jconrel.2019.07.012
   Zhang P, 2019, DEV CELL, V49, P574, DOI 10.1016/j.devcel.2019.03.029
   Zhang SL, 2020, AUTOPHAGY, V16, P735, DOI 10.1080/15548627.2019.1632122
   Zhang WX, 2022, PHYTOMEDICINE, V104, DOI 10.1016/j.phymed.2022.154280
   Zhang YL, 2019, EBIOMEDICINE, V48, P277, DOI 10.1016/j.ebiom.2019.09.051
   Zhao C, 2020, CANCER LETT, V481, P15, DOI 10.1016/j.canlet.2020.03.010
   Zhou JM, 2021, CARCINOGENESIS, V42, P1370, DOI 10.1093/carcin/bgab069
   Zhu Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03733-5
   Zuo Q, 2021, CANCER LETT, V521, P281, DOI 10.1016/j.canlet.2021.09.010
NR 62
TC 1
Z9 1
U1 2
U2 10
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD SEP 12
PY 2022
VL 12
AR 1007509
DI 10.3389/fonc.2022.1007509
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 4W9JZ
UT WOS:000860472300001
PM 36172152
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Amirmahani, F
   Asadi, MH
   Alipoor, FJ
AF Amirmahani, Farzane
   Asadi, Malek Hossein
   Alipoor, Firooz Jannat
TI LncRNA MIAT Promotes the Proliferation and Invasion of Colorectal Cancer
   via Suppressing Apoptosis and Senescence
SO MIDDLE EAST JOURNAL OF CANCER
LA English
DT Article
DE MIAT long non-coding RNA; Colorectal neoplasms; Cellular senescence; DNA
   damage
ID NONCODING RNA; BREAST-CANCER; PROGRESSION; EXPRESSION; RISK
AB Background: Myocardial infarction-associated transcript (MIAT) is a long non -coding RNA (lncRNA), which functions in a variety of disorders, like myocardial infarction and diabetic retinopathy. Moreover, recent reports have established that MIAT is upregulated in several types of malignancies and plays a crucial role in tumorigenesis. Therefore, this research aimed to investigate the expression of MIAT in colorectal cancer (CRC) and further evaluate the impact of its knocking-down on the proliferation and migration of the CRC cell.Method: In this case-control experimental study, we evaluated the expression level of MIAT in a series of CRC and marginal tissues using RT-qPCR. Furthermore, the role of MIAT was assessed employing RNA interference (RNAi)-mediated suppressing strategy in CRC-derived cells. Subsequently, colony formation, cell cycle analysis, migration, apoptosis, and senescence assays were done to decipher the influence of MIAT on initiation and progression of CRC.Results: Our findings revealed that MIAT expression is significantly upregulated in high-grade and vascular invasion tumor tissues. Furthermore, MIAT silencing led to G1 arrest in SW116 and SW48 CRC-derived cells. We also found that MIAT inhibition contributed to the induction of apoptosis/cellular senescence as well as the limitation of colony formation capability and cell migration in CRC cells. The obtained findings also showed that MIAT silencing dysregulated the expression of ATM and CHK2 genes known as DNA damage responsive genes.Conclusion: The results of the present study demonstrated that lncRNA MIAT may control CRC cell proliferation and metastasis through regulating DNA damage -responsive pathway and can be noticed as a potential marker for diagnosis, prognosis, and targeted-therapy of high-grade CRC.
C1 [Amirmahani, Farzane] Univ Isfahan, Fac Sci & Technol, Dept Cell & Mol Biol & Microbiol, Esfahan, Iran.
   [Asadi, Malek Hossein; Alipoor, Firooz Jannat] Grad Univ Adv Technol, Inst Sci & High Technol & Environm Sci, Dept Biotechnol, Kerman, Iran.
C3 University of Isfahan; Graduate University of Advanced Technology
RP Asadi, MH (corresponding author), Grad Univ Adv Technol, Inst Sci & High Technol & Environm Sci, Dept Biotechnol, Kerman, Iran.
EM mh.asadi@kgut.ac.ir
RI Asadi, M.H./AAB-7598-2022; Amirmahani, Farzane/AAG-1678-2019
FU Graduate University of Advanced Technology, Kerman, Iran
FX This study was supported in part by Graduate University of Advanced
   Technology, Kerman, Iran. All the biological materials were provided by
   the Iran National Tumor Bank founded by Cancer Institute of Tehran
   University of Medical Sciences, for Cancer Research.
CR Alipoor FJ, 2018, J CELL BIOCHEM, V119, P6470, DOI 10.1002/jcb.26678
   Bazi Z, 2018, J CELL BIOCHEM, V119, P3174, DOI 10.1002/jcb.26472
   Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118
   Castro-Oropeza R, 2018, CELL ONCOL, V41, P585, DOI 10.1007/s13402-018-0406-4
   Chen S, 2020, J CELL MOL MED, V24, P1804, DOI 10.1111/jcmm.14878
   Ellis BC, 2014, BBA-MOL CELL RES, V1843, P372, DOI 10.1016/j.bbamcr.2013.10.016
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Ishii N, 2006, J HUM GENET, V51, P1087, DOI 10.1007/s10038-006-0070-9
   Jafari-Oliayi A, 2019, CELL ONCOL, V42, P211, DOI 10.1007/s13402-019-00422-6
   Jiang HJ, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.258
   Jin H, 2019, ONCOL LETT, V17, P1229, DOI 10.3892/ol.2018.9671
   Keshavarz M, 2019, FEBS J, V286, P2611, DOI 10.1111/febs.14825
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Kita Y, 2017, J HUM GENET, V62, P41, DOI 10.1038/jhg.2016.66
   Kong S, 2020, CANCER LETT, V483, P59, DOI 10.1016/j.canlet.2020.04.006
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Liu ZX, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-017-0477-8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Luan T, 2017, ONCOTARGET, V8, P76153, DOI 10.18632/oncotarget.19190
   Maillet H, 2021, THESIS DALHOUSIE U H
   Manic G, 2015, MOL CELL ONCOL, V2, DOI 10.1080/23723556.2015.1012976
   Molinaro C, 2021, CANCERS, V13, DOI 10.3390/cancers13153819
   Peng LR, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107071
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rafiee A, 2018, BIOTECHNOL GENET ENG, V34, P153, DOI 10.1080/02648725.2018.1471566
   Rao SQ, 2015, SCHIZOPHR RES, V166, P125, DOI 10.1016/j.schres.2015.04.032
   Rokavec M, 2017, CANCER RES, V77, P1854, DOI 10.1158/0008-5472.CAN-16-3236
   Sattari A, 2016, ONCOTARGET, V7, P54174, DOI 10.18632/oncotarget.11099
   Sharma S, 2020, MBIO, V11, DOI 10.1128/mBio.01190-20
   Sun C, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0427-3
   Yan BA, 2015, CIRC RES, V116, P1143, DOI 10.1161/CIRCRESAHA.116.305510
   Yu SJ, 2019, AGING-US, V11, P1389, DOI 10.18632/aging.101839
   Zhang L, 2020, J BIOCHEM, V168, P183, DOI 10.1093/jb/mvaa037
   Zhang MJ, 2021, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.601468
   Zhang ZL, 2018, BIOCHEM BIOPH RES CO, V503, P1530, DOI 10.1016/j.bbrc.2018.07.075
   Zhou SY, 2020, CANCER BIOTHER RADIO, V35, P650, DOI 10.1089/cbr.2019.3259
   Zhu LF, 2020, HUM CELL, V33, P819, DOI 10.1007/s13577-020-00340-y
NR 37
TC 4
Z9 4
U1 1
U2 2
PU SHIRAZ UNIV MEDICAL SCIENCES
PI SHIRAZ
PA NEMAZEE HOSPITAL, SHIRAZ, 71934, IRAN
SN 2008-6709
EI 2008-6687
J9 MIDDLE EAST J CANCER
JI Middle East J. Cancer
PD APR
PY 2023
VL 14
IS 2
BP 219
EP 229
DI 10.30476/mejc.2022.92233.1651
PG 11
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA E4ES6
UT WOS:000975097200003
DA 2025-01-04
ER

PT J
AU Manic, G
   Signore, M
   Sistigu, A
   Russo, G
   Corradi, F
   Siteni, S
   Musella, M
   Vitale, S
   De Angelis, ML
   Pallocca, M
   Amoreo, CA
   Sperati, F
   Di Franco, S
   Barresi, S
   Policicchio, E
   De Luca, G
   De Nicola, F
   Mottolese, M
   Zeuner, A
   Fanciulli, M
   Stassi, G
   Maugeri-Saccà, M
   Baiocchi, M
   Tartaglia, M
   Vitale, I
   De Maria, R
AF Manic, Gwenola
   Signore, Michele
   Sistigu, Antonella
   Russo, Giorgio
   Corradi, Francesca
   Siteni, Silvia
   Musella, Martina
   Vitale, Sara
   De Angelis, Maria Laura
   Pallocca, Matteo
   Amoreo, Carla Azzurra
   Sperati, Francesca
   Di Franco, Simone
   Barresi, Sabina
   Policicchio, Eleonora
   De Luca, Gabriele
   De Nicola, Francesca
   Mottolese, Marcella
   Zeuner, Ann
   Fanciulli, Maurizio
   Stassi, Giorgio
   Maugeri-Sacca, Marcello
   Baiocchi, Marta
   Tartaglia, Marco
   Vitale, Ilio
   De Maria, Ruggero
TI CHK1-targeted therapy to deplete DNA replication-stressed,
   p53-deficient, hyperdiploid colorectal cancer stem cells
SO GUT
LA English
DT Article
ID HUMAN COLON; CHK1; RESISTANCE; HETEROGENEITY; CATASTROPHE; STATE; ATM
AB Objective Cancer stem cells (CSCs) are responsible for tumour formation and spreading, and their targeting is required for tumour eradication. There are limited therapeutic options for advanced colorectal cancer (CRC), particularly for tumours carrying RAS-activating mutations. The aim of this study was to identify novel CSC-targeting strategies.
   Design To discover potential therapeutics to be clinically investigated as single agent, we performed a screening with a panel of FDA-approved or investigational drugs on primary CRC cells enriched for CSCs (CRC-SCs) isolated from 27 patients. Candidate predictive biomarkers of efficacy were identified by integrating genomic, reverse-phase protein microarray (RPPA) and cytogenetic analyses, and validated by immunostainings. DNA replication stress (RS) was increased by employing DNA replication-perturbing or polyploidising agents.
   Results The drug-library screening led to the identification of LY2606368 as a potent anti-CSC agent acting in vitro and in vivo in tumour cells from a considerable number of patients (similar to 36%). By inhibiting checkpoint kinase (CHK) 1, LY2606368 affected DNA replication in most CRC-SCs, including RAS-mutated ones, forcing them into premature, lethal mitoses. Parallel genomic, RPPA and cytogenetic analyses indicated that CRC-SCs sensitive to LY2606368 displayed signs of ongoing RS response, including the phosphorylation of RPA32 and ataxia telangiectasia mutated serine/threonine kinase (ATM). This was associated with mutation(s) in TP53 and hyperdiploidy, and made these CRC-SCs exquisitely dependent on CHK1 function. Accordingly, experimental increase of RS sensitised resistant CRC-SCs to LY2606368.
   Conclusions LY2606368 selectively eliminates replication-stressed, p53-deficient and hyperdiploid CRC-SCs independently of RAS mutational status. These results provide a strong rationale for biomarker-driven clinical trials with LY2606368 in patients with CRC.
C1 [Manic, Gwenola; Corradi, Francesca; Vitale, Ilio] Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy.
   [Signore, Michele; De Angelis, Maria Laura; De Luca, Gabriele; Zeuner, Ann; Baiocchi, Marta] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy.
   [Sistigu, Antonella; Russo, Giorgio; Siteni, Silvia; Musella, Martina; Vitale, Ilio] Regina Elena Inst Canc Res, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy.
   [Russo, Giorgio; Vitale, Sara; De Maria, Ruggero] Catholic Univ, Inst Gen Pathol, Rome, Italy.
   [Russo, Giorgio; Vitale, Sara; De Maria, Ruggero] A Gemelli Polyclin, Rome, Italy.
   [Siteni, Silvia] Univ Roma Tre, Dept Sci, Rome, Italy.
   [Musella, Martina] Univ Roma La Sapienza, Dept Mol Med, Rome, Italy.
   [Pallocca, Matteo; De Nicola, Francesca; Fanciulli, Maurizio] Regina Elena Inst Canc Res, SAFU, Translat Res Area, Dept Res Adv Diagnost & Technol Innovat, Rome, Italy.
   [Amoreo, Carla Azzurra; Mottolese, Marcella] Regina Elena Inst Canc Res, Dept Pathol, Rome, Italy.
   [Sperati, Francesca] Regina Elena Inst Canc Res, Biostat Unit, Rome, Italy.
   [Di Franco, Simone; Stassi, Giorgio] Univ Palermo, Dept Surg Oncol & Stomatol Sci, Palermo, Italy.
   [Barresi, Sabina; Tartaglia, Marco] Osped Pediat Bambino Gesu, Genet & Rare Dis Res Div, Rome, Italy.
   [Policicchio, Eleonora] Univ Roma La Sapienza, Dept Expt Med, Rome, Italy.
   [Maugeri-Sacca, Marcello] Regina Elena Inst Canc Res, Div Med Oncol 2, Rome, Italy.
C3 University of Rome Tor Vergata; Istituto Superiore di Sanita (ISS);
   IRCCS Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Italfarmaco; Roma Tre University; Sapienza University Rome; IRCCS
   Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS
   Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; IRCCS
   Istituti Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena; University
   of Palermo; IRCCS Bambino Gesu; Sapienza University Rome; IRCCS Istituti
   Fisioterapici Ospitalieri (IFO); IRCCS Regina Elena
RP Vitale, I (corresponding author), Univ Roma Tor Vergata, Dept Biol, Via Ric Sci 1, I-00133 Rome, Italy.; De Maria, R (corresponding author), Catholic Univ, Inst Gen Pathol, Rome, Italy.
EM iliovit@gmail.com; ruggero.demaria@unicatt.it
RI De Maria, Ruggero/S-6385-2019; Manic, Gwenola/J-8496-2018; Di Franco,
   Simone/AAD-4391-2019; Vitale, Ilio/M-3960-2017; Zeuner, Ann/K-8607-2016;
   Vitale, Sara/AAB-9588-2019; fanciulli, maurizio/ABH-6745-2020; De
   Angelis, Maria Laura/Y-4004-2019; Russo, Giorgio/I-3347-2019; Tartaglia,
   Marco/K-2955-2018; De Nicola, Francesca/AAC-6887-2022; Sistigu,
   Antonella/J-8934-2018; Stassi, Giorgio/JAZ-0703-2023; Musella,
   Martina/JMA-9073-2023; Pallocca, Matteo/K-9259-2016; Zeuner,
   Ann/A-8529-2010; de luca, gabriele/J-6655-2018; di franco,
   simone/M-3714-2019; Amoreo, Carla Azzurra/K-5375-2018; Maugeri-Sacca,
   Marcello/K-2350-2014; Signore, Michele/J-8563-2016; sperati,
   francesca/K-5843-2016
OI Musella, Martina/0000-0002-8021-9488; Pallocca,
   Matteo/0000-0002-7756-3579; Tartaglia, Marco/0000-0001-7736-9672;
   Zeuner, Ann/0000-0002-8295-3715; De Maria, Ruggero/0000-0003-2255-0583;
   de luca, gabriele/0000-0003-2918-0124; di franco,
   simone/0000-0002-6217-2161; Amoreo, Carla Azzurra/0000-0003-3817-1967;
   De Angelis, Maria Laura/0000-0003-4220-8822; Maugeri-Sacca,
   Marcello/0000-0003-2287-9581; Sistigu, Antonella/0000-0002-2528-1238;
   Signore, Michele/0000-0002-0262-842X; Manic,
   Gwenola/0000-0003-3759-8029; vitale, sara/0000-0002-9011-9042; De
   Nicola, FRANCESCA/0000-0002-2187-7544; Stassi,
   Giorgio/0000-0002-1016-9059; Baiocchi, Marta/0000-0003-0976-0690;
   sperati, francesca/0000-0002-6038-2798
FU Associazione Italiana per la Ricerca sul Cancro (AIRC, MFAG) [14641,
   9979]; Ministero Italiano della Salute [RF_GR-2011-02351355]; Ministero
   Italiano dell'Istruzione, dell'Universita e della Ricerca (MIUR)
   [RBAP11WCRZ-005 U54]; AIRC [18418, 15749]; AIRC fellowship
FX This work was supported by the Associazione Italiana per la Ricerca sul
   Cancro (AIRC, MFAG 2013 grant number 14641 to IV, 5 per Mille grant
   number 9979 to GS, MT and RDM), Ministero Italiano della Salute (grant
   number RF_GR-2011-02351355 to IV), Ministero Italiano dell'Istruzione,
   dell'Universita e della Ricerca (MIUR, Programma per i Giovani
   Ricercatori 'Rita Levi Montalcini' 2010 to IV and Fondo per gli
   Investimenti della Ricerca di Base, FIRB, grant number RBAP11WCRZ-005
   U54 2010 to RDM). AS is supported by AIRC (Start-Up 2016 #18418). GM is
   supported by AIRC (Triennial Fellowship 'Antonietta Latronico' 2014). AZ
   is supported by AIRC (grant number 15749). SDF is an AIRC fellowship
   recipient for 2016.
CR Aguilera A, 2013, ANNU REV GENET, V47, P1, DOI 10.1146/annurev-genet-111212-133232
   Al-Ahmadie H, 2014, CANCER DISCOV, V4, P1014, DOI 10.1158/2159-8290.CD-14-0380
   Bao SD, 2006, NATURE, V444, P756, DOI 10.1038/nature05236
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bartucci M, 2012, CELL DEATH DIFFER, V19, P768, DOI 10.1038/cdd.2011.170
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bouwman P, 2010, NAT STRUCT MOL BIOL, V17, P688, DOI 10.1038/nsmb.1831
   Brooks K, 2013, ONCOGENE, V32, P788, DOI 10.1038/onc.2012.72
   Burrell RA, 2013, NATURE, V494, P492, DOI 10.1038/nature11935
   Castedo M, 2006, EMBO J, V25, P2584, DOI 10.1038/sj.emboj.7601127
   Dalerba P, 2016, NEW ENGL J MED, V374, P211, DOI 10.1056/NEJMoa1506597
   Dalerba P, 2011, NAT BIOTECHNOL, V29, P1120, DOI 10.1038/nbt.2038
   De Angelis ML, 2016, STEM CELL TRANSL MED, V5, P511, DOI 10.5966/sctm.2015-0214
   de Sousa e Melo F, 2011, CELL STEM CELL, V9, P476, DOI 10.1016/j.stem.2011.10.008
   Francescangeli F, 2012, STEM CELLS, V30, P1819, DOI 10.1002/stem.1163
   Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891
   Gorgoulis VG, 2005, NATURE, V434, P907, DOI 10.1038/nature03485
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Hong D, 2016, J CLIN ONCOL, V34, P1764, DOI 10.1200/JCO.2015.64.5788
   King C, 2015, MOL CANCER THER, V14, P2004, DOI 10.1158/1535-7163.MCT-14-1037
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Kreso A, 2013, SCIENCE, V339, P543, DOI 10.1126/science.1227670
   Kwok Marwan, 2015, Lancet, V385 Suppl 1, pS58, DOI 10.1016/S0140-6736(15)60373-7
   Lam MH, 2004, CANCER CELL, V6, P45, DOI 10.1016/j.ccr.2004.06.015
   Ma CX, 2012, J CLIN INVEST, V122, P1541, DOI 10.1172/JCI58765
   Manic G, 2018, GUT, V67, P903, DOI 10.1136/gutjnl-2016-312623
   Maréchal A, 2015, CELL RES, V25, P9, DOI 10.1038/cr.2014.147
   Marziali G, 2016, SCI REP-UK, V6, DOI 10.1038/srep21557
   McNeely S, 2010, CELL CYCLE, V9, P995, DOI 10.4161/cc.9.5.10935
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Merlos-Suárez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Murga M, 2011, NAT STRUCT MOL BIOL, V18, P1331, DOI 10.1038/nsmb.2189
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980
   Pearl LH, 2015, NAT REV CANCER, V15, P166, DOI 10.1038/nrc3891
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Ricci-Vitiani L, 2010, NATURE, V468, P824, DOI 10.1038/nature09557
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Sottoriva A, 2015, NAT GENET, V47, P209, DOI 10.1038/ng.3214
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Toledo LI, 2011, NAT STRUCT MOL BIOL, V18, P721, DOI 10.1038/nsmb.2076
   Toledo LI, 2013, CELL, V155, P1088, DOI 10.1016/j.cell.2013.10.043
   van de Wetering M, 2015, CELL, V161, P933, DOI 10.1016/j.cell.2015.03.053
   Vitale I, 2011, CELL DEATH DIFFER, V18, P1403, DOI 10.1038/cdd.2010.145
   Vitale I, 2015, TRENDS CANCER, V1, P124, DOI 10.1016/j.trecan.2015.08.001
   Zeman MK, 2014, NAT CELL BIOL, V16, P2, DOI 10.1038/ncb2897
   Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012
   Zhang YW, 2014, INT J CANCER, V134, P1013, DOI 10.1002/ijc.28226
NR 51
TC 63
Z9 67
U1 0
U2 22
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD MAY
PY 2018
VL 67
IS 5
BP 903
EP 917
DI 10.1136/gutjnl-2016-312623
PG 15
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA GC4DL
UT WOS:000429733600015
PM 28389531
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Silva, VR
   Santos, LD
   Dias, RB
   Quadros, CA
   Bezerra, DP
AF Silva, Valdenizia R.
   Santos, Luciano de S.
   Dias, Rosane B.
   Quadros, Claudio A.
   Bezerra, Daniel P.
TI Emerging agents that target signaling pathways to eradicate colorectal
   cancer stem cells
SO CANCER COMMUNICATIONS
LA English
DT Review
DE colorectal; cancer stem cells; cell signaling; Wnt/beta-catenin pathway;
   Notch; Hedgehog; NF-kappa B; JAK/STAT signaling; PI3K/Akt/mTOR
   signaling; targeted therapy
ID NF-KAPPA-B; COLON-CANCER; WNT/BETA-CATENIN; TUMOR-GROWTH; SELF-RENEWAL;
   WNT PATHWAY; PHENETHYL ISOTHIOCYANATE; PI3K/AKT/MTOR PATHWAY; OXIDATIVE
   STRESS; PROGNOSTIC VALUE
AB Colorectal cancer (CRC) represents the third most commonly diagnosed cancer and the second leading cause of cancer death worldwide. The modern concept of cancer biology indicates that cancer is formed of a small population of cells called cancer stem cells (CSCs), which present both pluripotency and self-renewal properties. These cells are considered responsible for the progression of the disease, recurrence and tumor resistance. Interestingly, some cell signaling pathways participate in CRC survival, proliferation, and self-renewal properties, and most of them are dysregulated in CSCs, including the Wingless (Wnt)/beta-catenin, Notch, Hedgehog, nuclear factor kappa B (NF-kappa B), Janus kinase/signal transducer and activator of transcription (JAK/STAT), peroxisome proliferator-activated receptor (PPAR), phosphatidyl-inositol-3-kinase/Akt/mechanistic target of rapamycin (PI3K/Akt/mTOR), and transforming growth factor-beta (TGF-beta)/Smad pathways. In this review, we summarize the strategies for eradicating CRC stem cells by modulating these dysregulated pathways, which will contribute to the study of potential therapeutic schemes, combining conventional drugs with CSC-targeting drugs, and allowing better cure rates in anti-CRC therapy.
C1 [Silva, Valdenizia R.; Santos, Luciano de S.; Dias, Rosane B.; Bezerra, Daniel P.] Oswaldo Cruz Fdn IGM FIOCRUZ BA, Goncalo Moniz Inst, BR-40296710 Salvador, BA, Brazil.
   [Quadros, Claudio A.] Rede DOr Sao Luiz, Sao Rafael Hosp, Salvador, BA, Brazil.
   [Quadros, Claudio A.] Bahia State Univ, Salvador, BA, Brazil.
C3 Universidade do Estado Bahia
RP Bezerra, DP (corresponding author), Oswaldo Cruz Fdn IGM FIOCRUZ BA, Goncalo Moniz Inst, BR-40296710 Salvador, BA, Brazil.
EM danielpbezerra@gmail.com
RI Silva, Valdenizia/AAD-3061-2022; SANTOS, LUCIANO/AAD-5969-2022; Bezerra,
   Daniel/K-7889-2017
OI Santos, Luciano/0000-0002-1381-1342; Bezerra, Daniel/0000-0002-6774-2063
FU Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES,
   Brazil); Conselho Nacional de Desenvolvimento Cientifico e Tecnologico
   (CNPq, Brazil)
FX VRS, LSS and RBD receive personal scholarship from Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES, Brazil), and DPB
   receives personal scholarship from Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq, Brazil).
CR Adams DJ, 2012, P NATL ACAD SCI USA, V109, P15115, DOI 10.1073/pnas.1212802109
   Núñez-Sánchez MA, 2016, FOOD CHEM TOXICOL, V92, P8, DOI 10.1016/j.fct.2016.03.011
   Ayadi M, 2015, ONCOTARGET, V6, P18518, DOI 10.18632/oncotarget.3934
   Baliza IRS, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00582
   Bamodu OA, 2018, CANCERS, V10, DOI 10.3390/cancers10080269
   Batsaikhan BE, 2014, ANTICANCER RES, V34, P6339
   Berlin J, 2013, CLIN CANCER RES, V19, P258, DOI 10.1158/1078-0432.CCR-12-1800
   Bezerra DP, 2013, EUR J PHARM SCI, V48, P453, DOI 10.1016/j.ejps.2012.12.003
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Bin Hafeez B, 2014, ANTIOXID REDOX SIGN, V21, P682, DOI 10.1089/ars.2013.5212
   Boinpelly VC, 2020, J CELL MOL MED, V24, P11343, DOI 10.1111/jcmm.15731
   Boman BM, 2008, J CLIN ONCOL, V26, P2828, DOI 10.1200/JCO.2008.17.6941
   Boman BM, 2008, J CLIN ONCOL, V26, P2795, DOI 10.1200/JCO.2008.17.7436
   Boothello RS, 2019, MOL CANCER THER, V18, P51, DOI 10.1158/1535-7163.MCT-18-0104
   Boumahdi S, 2014, NATURE, V511, P246, DOI 10.1038/nature13305
   Bray SJ, 2016, NAT REV MOL CELL BIO, V17, P722, DOI 10.1038/nrm.2016.94
   Brooks AJ, 2020, CANCERS, V12, DOI 10.3390/cancers12071971
   Cai S, 2017, CELL STEM CELL, V20, P247, DOI 10.1016/j.stem.2016.11.007
   Cai ZR, 2014, ANN SURG ONCOL, V21, P179, DOI 10.1245/s10434-013-3146-8
   Chaffer CL, 2011, P NATL ACAD SCI USA, V108, P7950, DOI 10.1073/pnas.1102454108
   Chang TC, 2015, TOXICOL APPL PHARM, V288, P258, DOI 10.1016/j.taap.2015.07.025
   Chapouton P, 2010, J NEUROSCI, V30, P7961, DOI 10.1523/JNEUROSCI.6170-09.2010
   Chen BH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317715155
   Chen JY, 2016, NATURE, V530, P223, DOI 10.1038/nature16943
   Chen JZ, 2015, CLIN EXP PHARMACOL P, V42, P1317, DOI 10.1111/1440-1681.12493
   Chen JZ, 2013, CURR CANCER DRUG TAR, V13, P117, DOI 10.2174/1568009611313020001
   Chen JK, 2002, GENE DEV, V16, P2743, DOI 10.1101/gad.1025302
   Chen Q, 2018, J PHARMACOL SCI, V137, P256, DOI 10.1016/j.jphs.2018.07.001
   Chen Q, 2019, INT J BIOL SCI, V15, P430, DOI 10.7150/ijbs.27050
   Chen SG, 2017, ONCOTARGET, V8, P50476, DOI 10.18632/oncotarget.9919
   Chen YY, 2017, J CANCER, V8, P3142, DOI 10.7150/jca.19273
   Chen YW, 2010, MOL CANCER THER, V9, P2879, DOI 10.1158/1535-7163.MCT-10-0504
   Chen YJ, 2018, ONCOL LETT, V15, P1789, DOI 10.3892/ol.2017.7486
   Chen Y, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00273-z
   Chen Y, 2018, PHYTOTHER RES, V32, P2447, DOI 10.1002/ptr.6183
   Chen Y, 2017, NUTRIENTS, V9, DOI 10.3390/nu9060572
   Cheng DT, 2016, ONCOTARGET, V7, P45199, DOI 10.18632/oncotarget.9900
   Cho YH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19173-2
   Chung SY, 2018, CELL DEATH DISCOV, V4, DOI 10.1038/s41420-018-0084-z
   Clarke MF, 2019, NEW ENGL J MED, V380, P2237, DOI 10.1056/NEJMra1804280
   Cooks T, 2013, CANCER CELL, V23, P634, DOI 10.1016/j.ccr.2013.03.022
   Corvinus FM, 2005, NEOPLASIA, V7, P545, DOI 10.1593/neo.04571
   Costa COD, 2017, ONCOTARGET, V8, P104367, DOI 10.18632/oncotarget.22248
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Dandawate P, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-57940-9
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   Dermani FK, 2018, J CELL PHYSIOL, V233, P9538, DOI 10.1002/jcp.26874
   Dixon SW, 2021, BRIT J CANCER, V124, P1959, DOI 10.1038/s41416-021-01354-5
   Dong TT, 2011, ANN SURG ONCOL, V18, P1797, DOI 10.1245/s10434-011-1561-2
   Espinosa-Sánchez A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01533
   Fan YP, 2019, CANCERS, V11, DOI 10.3390/cancers11010022
   Fiore D, 2018, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00949
   Fischer M, 2011, CANCER RES, V71, P1520, DOI 10.1158/0008-5472.CAN-10-2817
   Fiúza UM, 2007, J ENDOCRINOL, V194, P459, DOI 10.1677/JOE-07-0242
   Francipane MG, 2013, ONCOTARGET, V4, P1948, DOI 10.18632/oncotarget.1310
   Fre S, 2009, P NATL ACAD SCI USA, V106, P6309, DOI 10.1073/pnas.0900427106
   Galardi S, 2016, EMBO REP, V17, P1872, DOI 10.15252/embr.201541489
   Gamet-Payrastre L, 2000, CANCER RES, V60, P1426
   Gao ZH, 2001, PHARMACOL RES, V43, P173, DOI 10.1006/phrs.2000.0761
   Gheytanchi E, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-01898-9
   Giacchetti S, 2000, J CLIN ONCOL, V18, P136, DOI 10.1200/JCO.2000.18.1.136
   Giraud J, 2016, CANCER RES, V76, P3618, DOI 10.1158/0008-5472.CAN-15-1497
   Goodwin R, 2020, INVEST NEW DRUG, V38, P1077, DOI 10.1007/s10637-019-00814-3
   Gu HF, 2020, CRIT REV FOOD SCI, V60, P810, DOI 10.1080/10408398.2018.1551778
   Gupta P, 2014, BBA-REV CANCER, V1846, P405, DOI 10.1016/j.bbcan.2014.08.003
   Gupta PB, 2009, CELL, V138, P645, DOI 10.1016/j.cell.2009.06.034
   Gupta SC, 2010, BBA-GENE REGUL MECH, V1799, P775, DOI 10.1016/j.bbagrm.2010.05.004
   Handeli S, 2008, MOL CANCER THER, V7, P521, DOI 10.1158/1535-7163.MCT-07-2063
   Haraguchi N, 2008, ANN SURG ONCOL, V15, P2927, DOI 10.1245/s10434-008-0074-0
   Harrington BS, 2020, CANCERS, V12, DOI 10.3390/cancers12061645
   Hirata A, 2019, ADV EXP MED BIOL, V1139, P115, DOI 10.1007/978-3-030-14366-4_7
   Hirsch HA, 2009, CANCER RES, V69, P7507, DOI 10.1158/0008-5472.CAN-09-2994
   Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019
   Hou YZ, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2270
   Hrabe JE, 2015, REDOX BIOL, V5, P319, DOI 10.1016/j.redox.2015.06.004
   Hsu HS, 2011, CANCER-AM CANCER SOC, V117, P2970, DOI 10.1002/cncr.25869
   Hsu HC, 2015, J CANCER RES CLIN, V141, P11, DOI 10.1007/s00432-014-1782-4
   Hu F, 2015, J PHARMACOL SCI, V128, P27, DOI 10.1016/j.jphs.2015.04.003
   Hu Y, 2016, BRIT J NUTR, V116, P1901, DOI 10.1017/S0007114516003937
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   Huang J, 2015, ONCOL REP, V34, P3203, DOI 10.3892/or.2015.4309
   Huang R, 2015, MOL MED REP, V12, P2417, DOI 10.3892/mmr.2015.3694
   Husain K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80911-z
   Ibrahim EE, 2012, STEM CELLS, V30, P2076, DOI 10.1002/stem.1182
   Inamoto S, 2016, CLIN CANCER RES, V22, P492, DOI 10.1158/1078-0432.CCR-15-0726
   Iranshahy M, 2017, J ETHNOPHARMACOL, V205, P158, DOI 10.1016/j.jep.2017.05.004
   Itatani Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235822
   Itatani Y, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19041232
   Jenkins D, 2009, CELL SIGNAL, V21, P1023, DOI 10.1016/j.cellsig.2009.01.033
   Jiang P, 2020, INT J MOL MED, V46, P2216, DOI 10.3892/ijmm.2020.4758
   Jiang SX, 2019, J CELL MOL MED, V23, P630, DOI 10.1111/jcmm.13968
   Jin HY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317708699
   Jin MZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00280-x
   Jin W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010217
   Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8
   Ju SY, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.155
   Kallifatidis G, 2009, GUT, V58, P949, DOI 10.1136/gut.2008.149039
   Kaltschmidt C, 2019, CANCERS, V11, DOI 10.3390/cancers11050655
   Kannappan R, 2012, GENES NUTR, V7, P43, DOI 10.1007/s12263-011-0220-3
   Kaushik G, 2015, MOL CARCINOGEN, V54, P1710, DOI 10.1002/mc.22242
   Kemper K, 2012, CLIN CANCER RES, V18, P3132, DOI 10.1158/1078-0432.CCR-11-3066
   Kemper K, 2010, CANCER RES, V70, P719, DOI 10.1158/0008-5472.CAN-09-1820
   Kim H, 2019, MOLECULES, V24, DOI 10.3390/molecules24244520
   Kim J, 2013, CANCER CELL, V23, P23, DOI 10.1016/j.ccr.2012.11.017
   Kim MS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-24903-0
   Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997
   Klose J, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0211916
   Kolterud Å, 2009, GASTROENTEROLOGY, V137, P618, DOI 10.1053/j.gastro.2009.05.002
   Koschorke A, 2019, CELL ONCOL, V42, P815, DOI 10.1007/s13402-019-00464-w
   Krausova M, 2014, CELL SIGNAL, V26, P570, DOI 10.1016/j.cellsig.2013.11.032
   Kuipers Ernst J, 2015, Nat Rev Dis Primers, V1, P15065, DOI 10.1038/nrdp.2015.65
   Kumar B, 2021, CANCERS, V13, DOI 10.3390/cancers13092168
   Kumar Gaurav, 2018, Curr Pharmacol Rep, V4, P326, DOI 10.1007/s40495-018-0145-2
   Kumar S, 2019, BIOMED PHARMACOTHER, V109, P1462, DOI 10.1016/j.biopha.2018.10.182
   Kumar S, 2014, ONCOTARGET, V5, P4972, DOI 10.18632/oncotarget.2068
   Kuramoto K, 2021, GENES-BASEL, V12, DOI 10.3390/genes12010099
   Lee LH, 2016, MODERN PATHOL, V29, P1433, DOI 10.1038/modpathol.2016.139
   Levy DE, 2002, NAT REV MOL CELL BIO, V3, P651, DOI 10.1038/nrm909
   Li CY, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-56
   Li L, 2017, MED ONCOL, V34, DOI 10.1007/s12032-017-1039-6
   Li SH, 2013, MOL CELL BIOCHEM, V373, P217, DOI 10.1007/s11010-012-1493-6
   Li Y, 2020, BIOCHEM BIOPH RES CO, V523, P947, DOI 10.1016/j.bbrc.2020.01.048
   Li YZ, 2015, P NATL ACAD SCI USA, V112, P1839, DOI 10.1073/pnas.1424171112
   Lim YC, 2012, EUR J CANCER, V48, P3310, DOI 10.1016/j.ejca.2012.04.013
   Lin L, 2011, BRIT J CANCER, V105, P212, DOI 10.1038/bjc.2011.200
   Lin LC, 2012, J AGR FOOD CHEM, V60, P7031, DOI 10.1021/jf301981n
   Liu D, 2014, ONCOL LETT, V7, P1544, DOI 10.3892/ol.2014.1907
   Lobo NA, 2007, ANNU REV CELL DEV BI, V23, P675, DOI 10.1146/annurev.cellbio.22.010305.104154
   Lokau J, 2019, CANCERS, V11, DOI 10.3390/cancers11111704
   MACKAY CR, 1994, J CELL BIOL, V124, P71, DOI 10.1083/jcb.124.1.71
   Maenhaut C, 2010, CARCINOGENESIS, V31, P149, DOI 10.1093/carcin/bgp259
   Magrath J, 2020, ONCOL REP, V44, P777, DOI 10.3892/or.2020.7642
   Mah AT, 2016, J PHYSIOL-LONDON, V594, P4837, DOI 10.1113/JP271754
   Mahmoudi T, 2009, EMBO J, V28, P3329, DOI 10.1038/emboj.2009.285
   Maitland NJ, 2008, J CLIN ONCOL, V26, P2862, DOI 10.1200/JCO.2007.15.1472
   Malkomes P, 2016, ANN SURG ONCOL, V23, P2849, DOI 10.1245/s10434-016-5218-z
   Mangiapane LR, 2022, GUT, V71, P119, DOI 10.1136/gutjnl-2020-323553
   Marzano C, 2007, FREE RADICAL BIO MED, V42, P872, DOI 10.1016/j.freeradbiomed.2006.12.021
   Masuda M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12586
   Mayo MW, 1997, SCIENCE, V278, P1812, DOI 10.1126/science.278.5344.1812
   Mineo PG, 2020, ANAL BIOANAL CHEM, V412, P4681, DOI 10.1007/s00216-020-02721-6
   Morgensztern D, 2005, ANTI-CANCER DRUG, V16, P797, DOI 10.1097/01.cad.0000173476.67239.3b
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   Murakami S, 2015, STEM CELLS, V33, P2652, DOI 10.1002/stem.2059
   Nag D, 2019, CLIN CANCER RES, V25, P4791, DOI 10.1158/1078-0432.CCR-18-2751
   Narayan S, 2019, EUR J MED CHEM, V161, P456, DOI 10.1016/j.ejmech.2018.10.052
   Narayan S, 2017, ONCOTARGET, V8, P57246, DOI 10.18632/oncotarget.19778
   Nguyen YTK, 2020, CANCERS, V12, DOI 10.3390/cancers12020268
   Ning K, 2018, ONCOL LETT, V16, P4008, DOI 10.3892/ol.2018.9110
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Oliveira MD, 2019, REDOX BIOL, V20, P182, DOI 10.1016/j.redox.2018.10.006
   Ong CP, 2020, CANCERS, V12, DOI 10.3390/cancers12010048
   Ordóñez-Morán P, 2015, CANCER CELL, V28, P815, DOI 10.1016/j.ccell.2015.11.001
   Padgaonkar A, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-4453
   Pang R, 2010, CELL STEM CELL, V6, P603, DOI 10.1016/j.stem.2010.04.001
   Pannequin J, 2007, GASTROENTEROLOGY, V133, P1554, DOI 10.1053/j.gastro.2007.08.023
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Patel N, 2015, METHODS MOL BIOL, V1229, P529, DOI 10.1007/978-1-4939-1714-3_41
   Patel NJ, 2016, ONCOTARGET, V7, P84608, DOI 10.18632/oncotarget.12358
   Patel NJ, 2014, ACS CHEM BIOL, V9, P1826, DOI 10.1021/cb500402f
   Patel SS, 2022, J FOOD SCI TECH MYS, V59, P1326, DOI 10.1007/s13197-021-05142-0
   Pei SS, 2013, J BIOL CHEM, V288, P33542, DOI 10.1074/jbc.M113.511170
   Perekatt AO, 2018, CANCER RES, V78, P4878, DOI 10.1158/0008-5472.CAN-18-0043
   Pilati P, 2012, ANN SURG ONCOL, V19, P402, DOI 10.1245/s10434-011-2132-2
   Polivka J, 2014, PHARMACOL THERAPEUT, V142, P164, DOI 10.1016/j.pharmthera.2013.12.004
   Ponnurangam S, 2012, MOL CANCER THER, V11, P963, DOI 10.1158/1535-7163.MCT-11-0999
   Prieur A, 2017, CLIN CANCER RES, V23, P5267, DOI 10.1158/1078-0432.CCR-17-0533
   Prossomariti A, 2020, CELL MOL GASTROENTER, V10, P491, DOI 10.1016/j.jcmgh.2020.04.007
   Proto MC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-11688-x
   Qi F, 2016, ONCOL REP, V35, P511, DOI 10.3892/or.2015.4378
   Quarni W, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-50917-3
   Quintás-Cardama A, 2013, CLIN CANCER RES, V19, P1933, DOI 10.1158/1078-0432.CCR-12-0284
   Rattan R, 2011, NEOPLASIA, V13, P483, DOI 10.1593/neo.11148
   Regan JL, 2017, CELL REP, V21, P2813, DOI 10.1016/j.celrep.2017.11.025
   Ricci-Vitiani L, 2009, J MOL MED, V87, P1097, DOI 10.1007/s00109-009-0518-4
   Rinkenbaugh AL, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020016
   Robarge KD, 2009, BIOORG MED CHEM LETT, V19, P5576, DOI 10.1016/j.bmcl.2009.08.049
   Rodrigues ACBD, 2021, CRIT REV ONCOL HEMAT, V160, DOI 10.1016/j.critrevonc.2021.103277
   Saif Muhammad Wasif, 2021, Cancer Med J, V4, P1
   Saigusa S, 2011, CLIN ONCOL-UK, V23, P323, DOI 10.1016/j.clon.2010.09.012
   Sari IN, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7110208
   Sato T, 2011, NATURE, V469, P415, DOI 10.1038/nature09637
   Sato-Dahlman M, 2017, ONCOTARGET, V8, P76044, DOI 10.18632/oncotarget.18340
   Sengupta S, 2017, ONCOGENE, V36, P5709, DOI 10.1038/onc.2017.164
   Seo Y, 2020, CANCERS, V12, DOI 10.3390/cancers12092554
   Seto K, 2017, ANTICANCER RES, V37, P3569, DOI 10.21873/anticanres.11727
   Shang Y, 2014, SCIENCE, V346, P1084, DOI 10.1126/science.1259215
   Shenoy AK, 2012, CANCER RES, V72, P5091, DOI 10.1158/0008-5472.CAN-12-1806
   Shi L, 2019, BIOMED PHARMACOTHER, V109, P902, DOI 10.1016/j.biopha.2018.10.080
   Shimada M, 2010, J GASTROENTEROL, V45, P896, DOI 10.1007/s00535-010-0235-3
   Shimizu M, 2008, CANCER EPIDEM BIOMAR, V17, P3020, DOI 10.1158/1055-9965.EPI-08-0528
   Shin JM, 2021, PHYTOMEDICINE, V84, DOI 10.1016/j.phymed.2021.153493
   Siebel C, 2017, PHYSIOL REV, V97, P1235, DOI 10.1152/physrev.00005.2017
   Signore M, 2016, ONCOTARGET, V7, P44113, DOI 10.18632/oncotarget.9859
   Singh AK, 2021, EPIGENETICS-US, V16, P144, DOI 10.1080/15592294.2020.1789270
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Song CW, 2012, SCI REP-UK, V2, DOI 10.1038/srep00362
   Song L, 2015, CANCER BIOL THER, V16, P1, DOI 10.4161/15384047.2014.972215
   Sprenger T, 2013, CANCER-AM CANCER SOC, V119, P26, DOI 10.1002/cncr.27703
   Stechishin OD, 2013, NEURO-ONCOLOGY, V15, P198, DOI 10.1093/neuonc/nos302
   Subramaniam D, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10071607
   Sun SC, 2017, NAT REV IMMUNOL, V17, P545, DOI 10.1038/nri.2017.52
   Sun XC, 2019, ONCOL REP, V42, P425, DOI 10.3892/or.2019.7170
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Takaku K, 1998, CELL, V92, P645, DOI 10.1016/S0092-8674(00)81132-0
   Takebe N, 2015, NAT REV CLIN ONCOL, V12, P445, DOI 10.1038/nrclinonc.2015.61
   Tan Z, 2016, SCI REP-UK, V6, DOI 10.1038/srep33534
   Tanaka G, 2016, CANCER MED-US, V5, P2544, DOI 10.1002/cam4.844
   Tang YC, 2018, INT J ONCOL, V52, P127, DOI 10.3892/ijo.2017.4183
   Taniguchi H, 2021, INT J CLIN ONCOL, V26, P2017, DOI 10.1007/s10147-021-01987-9
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Toden S, 2016, ONCOTARGET, V7, P16158, DOI 10.18632/oncotarget.7567
   Tsakiris N, 2020, J CONTROL RELEASE, V326, P387, DOI 10.1016/j.jconrel.2020.07.025
   Upadhyaya B, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051027
   Urushibara S, 2017, ANTICANCER RES, V37, P4085, DOI 10.21873/anticanres.11795
   van den Brink GR, 2006, GUT, V55, P912, DOI 10.1136/gut.2005.085902
   Varjosalo M, 2008, GENE DEV, V22, P2454, DOI 10.1101/gad.1693608
   Varnat F, 2009, EMBO MOL MED, V1, P338, DOI 10.1002/emmm.200900039
   Vermeulen L, 2008, P NATL ACAD SCI USA, V105, P13427, DOI 10.1073/pnas.0805706105
   Wang D, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-591
   Wang H, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.654428
   Wang JG, 2020, INT J NANOMED, V15, P6839, DOI 10.2147/IJN.S236928
   Wang JK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.272
   Wang KL, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2020.153191
   Wang L, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3035
   Wang LG, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01704-w
   Wang M, 2012, CHINESE J PHYSIOL, V55, P134, DOI 10.4077/CJP.2012.BAA085
   Wang XL, 2021, ANTI-CANCER DRUG, V32, P548, DOI 10.1097/CAD.0000000000001062
   Wang Y, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1440169
   Wang ZP, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00309
   Wang ZY, 2020, NANOSCALE, V12, P19931, DOI 10.1039/d0nr04552g
   Wang ZY, 2019, BRIT J PHARMACOL, V176, P3390, DOI 10.1111/bph.14770
   Watanabe D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-72245-7
   Wei F, 2018, CELL PHYSIOL BIOCHEM, V46, P829, DOI 10.1159/000488740
   Wielenga VJM, 1999, AM J PATHOL, V154, P515, DOI 10.1016/S0002-9440(10)65297-2
   Williamson T, 2016, ONCOTARGET, V7, P68571, DOI 10.18632/oncotarget.11851
   Wright M, 2017, SURG CLIN N AM, V97, P683, DOI 10.1016/j.suc.2017.01.014
   Wu CQ, 2017, ONCOTARGETS THER, V10, P3249, DOI 10.2147/OTT.S139639
   Wu CQ, 2017, EXP THER MED, V13, P2529, DOI 10.3892/etm.2017.4282
   Wu SM, 2010, STEM CELL RES, V4, P38, DOI 10.1016/j.scr.2009.09.002
   Wu ZH, 2018, ACTA BIOCH BIOPH SIN, V50, P355, DOI 10.1093/abbs/gmy018
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu JX, 2020, ARCH BIOCHEM BIOPHYS, V684, DOI 10.1016/j.abb.2020.108314
   Yang BL, 2020, J CANCER, V11, P2303, DOI 10.7150/jca.37242
   Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5
   Yao CJ, 2013, EVID-BASED COMPL ALT, V2013, DOI 10.1155/2013/146136
   Ye J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01251
   Ying HQ, 2011, CANCER DISCOV, V1, P158, DOI 10.1158/2159-8290.CD-11-0031
   Yokogi S, 2016, YONAGO ACTA MED, V59, P93
   You ML, 2017, J CELL BIOCHEM, V118, P1556, DOI 10.1002/jcb.25817
   Yu XZ, 2011, CURR COLORECT CANC R, V7, P253, DOI 10.1007/s11888-011-0106-1
   Yuan RX, 2015, CLIN EXP METASTAS, V32, P169, DOI 10.1007/s10585-015-9700-y
   Yun JH, 2017, PHYTOMEDICINE, V30, P42, DOI 10.1016/j.phymed.2017.01.015
   Zeilstra J, 2014, ONCOGENE, V33, P665, DOI 10.1038/onc.2012.611
   Zeilstra J, 2008, CANCER RES, V68, P3655, DOI 10.1158/0008-5472.CAN-07-2940
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhan T, 2019, NAT COMMUN, V10, DOI [10.1038/s41467-019-09898-0, 10.1038/s41467-019-11921-3]
   Zhang C, 2015, ONCOL REP, V34, P2469, DOI 10.3892/or.2015.4253
   Zhang C, 2010, ANTI-CANCER DRUG, V21, P766, DOI 10.1097/CAD.0b013e32833d26a9
   Zhang GJ, 2017, ONCOTARGET, V8, P101760, DOI 10.18632/oncotarget.21667
   Zhang M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0656-7
   Zhang Q, 2018, CANCER CHEMOTH PHARM, V81, P969, DOI 10.1007/s00280-018-3565-0
   Zhang SH, 2021, BIOCHEM BIOPH RES CO, V562, P21, DOI 10.1016/j.bbrc.2021.05.017
   Zhang WB, 2017, CARCINOGENESIS, V38, P748, DOI 10.1093/carcin/bgx035
   Zhang X, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.104794
   Zhang Y, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00990-3
   Zhang YM, 2016, CURR STEM CELL RES T, V11, P226, DOI 10.2174/1574888X10666150728122921
   ZHANG YS, 1992, P NATL ACAD SCI USA, V89, P2399, DOI 10.1073/pnas.89.6.2399
   Zhao L, 2015, J IMMUNOTHER, V38, P217, DOI 10.1097/CJI.0000000000000086
   Zhou H, 2020, J CELL BIOCHEM, V121, P2510, DOI 10.1002/jcb.29473
   Zhou HM, 2012, WORLD J GASTROENTERO, V18, P2640, DOI 10.3748/wjg.v18.i21.2640
   Zhou JF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1068-1
   Zonneville J, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4587-z
NR 274
TC 61
Z9 63
U1 7
U2 29
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2523-3548
J9 CANCER COMMUN
JI Cancer Commun.
PD DEC
PY 2021
VL 41
IS 12
BP 1275
EP 1313
DI 10.1002/cac2.12235
EA NOV 2021
PG 39
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XT0WI
UT WOS:000719796500001
PM 34791817
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Lei, XY
   Jing, J
   Zhang, M
   Guan, BS
   Dong, ZY
   Wang, CN
AF Lei, Xinyi
   Jing, Jing
   Zhang, Miao
   Guan, Bingsheng
   Dong, Zhiyong
   Wang, Cunchuan
TI Bioinformatic Identification of Hub Genes and Analysis of Prognostic
   Values in Colorectal Cancer
SO NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL
LA English
DT Article
ID CELL LUNG-CANCER; CYCLIN B1; GASTRIC-CANCER; COLON-CANCER; EXPRESSION;
   OVEREXPRESSION; BIOMARKER; TUMOR; PROLIFERATION; SURVIVAL
AB The purpose of this study is to discover novel hub genes which are helpful for diagnosis, prognosis, and targeted therapy in colorectal cancer (CRC) by using bioinformatics analysis. GSE74602, GSE110225, and GSE113513 were extracted from the gene expression omnibus (GEO). Differentially expressed genes (DEGs) in expression profiles were identified by GEO2R. Gene ontology and Kyoto Encyclopedia of Genes and Genomes analyses of the DEGs were carried out in the Database for Annotation, Visualization, and Integrated Discovery (DAVID). String database and cytoscape were used for building protein-protein interaction (PPI) network and module analysis. The UALCAN was used for in-depth analysis of data of CRC patients from The Cancer Genome Atlas (TCGA) to identify expression levels and overall survival rates of hub genes. The DEGs included 107 up-regulation genes and 232 down-regulation genes. Twenty-nine (29) hub genes and two significant modules were screened from PPI network. The expression levels of hub genes in TCGA were verified. Survival analysis curve indicated high expression of CCNA2, CCNB1, DLGAP5, were related to high survival rates, and low expression of TIMP1 were associated with high survival rates. These results suggest that DEGs may be the hub genes of CRC, and CCNA2, CCNB1, DLGAP5, TIMP1 may be the potential prognostic markers of CRC.
C1 [Lei, Xinyi; Guan, Bingsheng; Dong, Zhiyong; Wang, Cunchuan] Jinan Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, 613 Huangpu Rd West, Guangzhou 510630, Peoples R China.
   [Jing, Jing] Municipal Hosp, Dept Endocrinol, Qingdao, Peoples R China.
   [Zhang, Miao] Jinan Univ, Affiliated Hosp 1, Dept Resp, Guangzhou, Peoples R China.
C3 Jinan University; Jinan University
RP Dong, ZY; Wang, CN (corresponding author), Jinan Univ, Dept Gastrointestinal Surg, Affiliated Hosp 1, 613 Huangpu Rd West, Guangzhou 510630, Peoples R China.
EM dongzy2008@jnu.edu.cn; twcc2015@163.com
RI 关, 炳生/HHM-3336-2022; lei, xinyi/AAS-9133-2021
OI Guan, Bingsheng/0000-0001-8583-8045
CR Bader GD, 2003, BMC BIOINFORMATICS, V4, DOI 10.1186/1471-2105-4-2
   Batra J, 2012, J BIOL CHEM, V287, P15935, DOI 10.1074/jbc.M112.341156
   Begnami MD, 2010, HUM PATHOL, V41, P1120, DOI 10.1016/j.humpath.2010.01.007
   Branchi V, 2019, INT J COLORECTAL DIS, V34, P1455, DOI 10.1007/s00384-019-03339-6
   Brandeis M, 1998, P NATL ACAD SCI USA, V95, P4344, DOI 10.1073/pnas.95.8.4344
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brcic L, 2019, PATHOLOGY, V51, P481, DOI 10.1016/j.pathol.2019.03.011
   Brien TP, 1998, MODERN PATHOL, V11, P870
   Bukholm IRK, 2001, INT J CANCER, V93, P283, DOI 10.1002/ijc.1311
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Chen ZH, 2019, ONCOL LETT, V18, P6583, DOI 10.3892/ol.2019.10996
   Dechaphunkul A, 2012, INT J BREAST CANCER, V2012, DOI 10.1155/2012/290854
   Fang YF, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126875
   Fang YF, 2014, CANCER BIOL THER, V15, P1268, DOI 10.4161/cbt.29691
   Gan YQ, 2018, CANCER MANAG RES, V10, P5113, DOI 10.2147/CMAR.S176833
   Gao P, 2018, GENE, V654, P95, DOI 10.1016/j.gene.2018.02.007
   Grunnet M, 2013, SCAND J GASTROENTERO, V48, P899, DOI 10.3109/00365521.2013.812235
   Hong BS, 2009, BMC GENOMICS, V10, DOI 10.1186/1471-2164-10-556
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang DW, 2009, NUCLEIC ACIDS RES, V37, P1, DOI 10.1093/nar/gkn923
   Jansson EÅ, 2005, P NATL ACAD SCI USA, V102, P1460, DOI 10.1073/pnas.0405928102
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jia W, 2018, NAT REV GASTRO HEPAT, V15, P111, DOI 10.1038/nrgastro.2017.119
   Kanai M, 1998, CANCER, V82, P1709, DOI 10.1002/(SICI)1097-0142(19980501)82:9<1709::AID-CNCR18>3.0.CO;2-8
   Kasprzak A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194915
   Li P, 2011, BIOCHEM BIOPH RES CO, V409, P344, DOI 10.1016/j.bbrc.2011.05.021
   Li X, 2019, AM J REPROD IMMUNOL, V82, DOI 10.1111/aji.13144
   Lichtenstein P, 2000, NEW ENGL J MED, V343, P78, DOI 10.1056/NEJM200007133430201
   Liu D, 1998, NAT GENET, V20, P377, DOI 10.1038/3855
   Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477
   Murakami H, 1999, VIRCHOWS ARCH, V434, P153, DOI 10.1007/s004280050319
   Murphy M, 1997, NAT GENET, V15, P83, DOI 10.1038/ng0197-83
   Niméus-Malmström E, 2010, INT J CANCER, V127, P961, DOI 10.1002/ijc.25091
   Ohashi R, 2001, ANTICANCER RES, V21, P657
   PAGANO M, 1992, EMBO J, V11, P961, DOI 10.1002/j.1460-2075.1992.tb05135.x
   Smith FM, 2005, BRIT J CANCER, V92, P1813, DOI 10.1038/sj.bjc.6602589
   Song GH, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0427-7
   Soria JC, 2000, CANCER RES, V60, P4000
   Strauss B, 2018, J CELL BIOL, V217, P179, DOI 10.1083/jcb.201612147
   Szklarczyk D, 2017, NUCLEIC ACIDS RES, V45, pD362, DOI 10.1093/nar/gkw937
   Tenbaum SP, 2012, NAT MED, V18, P892, DOI 10.1038/nm.2772
   Tie J, 2019, JAMA ONCOL, V5, P1710, DOI 10.1001/jamaoncol.2019.3616
   Vlachavas EI, 2019, COMPUT STRUCT BIOTEC, V17, P177, DOI 10.1016/j.csbj.2019.01.007
   Volm M, 2000, BRIT J CANCER, V82, P1747
   Wang Y., 2013, P 2013 IEEE ELECT PO, P1, DOI DOI 10.1109/EPEC.2013.6802933
   Weng L, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-39
   Xiao Z, 2008, BIOMARKERS, V13, P579, DOI [10.1080/13547500802063240, 10.1080/13547500802063240 ]
   Yam CH, 2002, CELL MOL LIFE SCI, V59, P1317, DOI 10.1007/s00018-002-8510-y
   Yamamoto S, 2019, CANCER SCI, V110, P3476, DOI 10.1111/cas.14183
   Yang L, 2019, AGING-US, V11, P8998, DOI 10.18632/aging.102366
   Yuan WL, 2019, PEERJ, V7, DOI 10.7717/peerj.7602
   Zhang GL, 2019, J CANCER, V10, P5883, DOI 10.7150/jca.32267
   Zhu CX, 2017, ADV EXP MED BIOL, V1018, P181, DOI 10.1007/978-981-10-5765-6_11
NR 53
TC 7
Z9 8
U1 1
U2 20
PU ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND
SN 0163-5581
EI 1532-7914
J9 NUTR CANCER
JI Nutr. Cancer
PD DEC 31
PY 2021
VL 73
IS 11-12
BP 2568
EP 2578
DI 10.1080/01635581.2020.1841249
EA NOV 2020
PG 11
WC Oncology; Nutrition & Dietetics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Nutrition & Dietetics
GA XY2UY
UT WOS:000586068100001
PM 33153324
DA 2025-01-04
ER

PT J
AU Song, XH
   Lan, Y
   Zheng, XL
   Zhu, QY
   Liao, XL
   Liu, K
   Zhang, WH
   Peng, QB
   Zhu, YF
   Zhao, LY
   Chen, XL
   Shu, Y
   Yang, K
   Hu, JK
AF Song, Xiaohai
   Lan, Yang
   Zheng, Xiuli
   Zhu, Qianyu
   Liao, Xuliang
   Liu, Kai
   Zhang, Weihan
   Peng, Qiangbo
   Zhu, Yunfeng
   Zhao, Linyong
   Chen, Xiaolong
   Shu, Yang
   Yang, Kun
   Hu, Jiankun
TI Targeting drug-tolerant cells: A promising strategy for overcoming
   acquired drug resistance in cancer cells
SO MEDCOMM
LA English
DT Review
DE acquired drug resistance; drug-tolerant cells; phenotype plasticity;
   translational remodeling
ID EPITHELIAL-MESENCHYMAL TRANSITION; LUNG-CANCER; BREAST-CANCER;
   THERAPEUTIC TARGET; TUMOR MICROENVIRONMENT; MET AMPLIFICATION;
   STEM-CELLS; COLORECTAL-CANCER; ANTICANCER DRUGS; EGFR INHIBITORS
AB Drug resistance remains the greatest challenge in improving outcomes for cancer patients who receive chemotherapy and targeted therapy. Surmounting evidence suggests that a subpopulation of cancer cells could escape intense selective drug treatment by entering a drug-tolerant state without genetic variations. These drug-tolerant cells (DTCs) are characterized with a slow proliferation rate and a reversible phenotype. They reside in the tumor region and may serve as a reservoir for resistant phenotypes. The survival of DTCs is regulated by epigenetic modifications, transcriptional regulation, mRNA translation remodeling, metabolic changes, antiapoptosis, interactions with the tumor microenvironment, and activation of signaling pathways. Thus, targeting the regulators of DTCs opens a new avenue for the treatment of therapy-resistant tumors. In this review, we first provide an overview of common characteristics of DTCs and the regulating networks in DTCs development. We also discuss the potential therapeutic opportunities to target DTCs. Last, we discuss the current challenges and prospects of the DTC-targeting approach to overcome acquired drug resistance. Reviewing the latest developments in DTC research could be essential in discovering of methods to eliminate DTCs, which may represent a novel therapeutic strategy for preventing drug resistance in the future.
C1 [Song, Xiaohai; Lan, Yang; Zhu, Qianyu; Liao, Xuliang; Liu, Kai; Zhang, Weihan; Peng, Qiangbo; Zhu, Yunfeng; Zhao, Linyong; Chen, Xiaolong; Shu, Yang; Yang, Kun; Hu, Jiankun] Sichuan Univ, Lab Gastr Canc, West China Hosp, State Key Lab Biotherapy,Dept Gen Surg,Lab Gastr C, Chengdu, Peoples R China.
   [Zheng, Xiuli] Sichuan Univ, Huaxi MR Res Ctr HMRRC, Dept Radiol, Chengdu, Peoples R China.
   [Zheng, Xiuli] Sichuan Univ, West China Hosp, Precis Med Ctr, Frontiers Sci Ctr Dis Related Mol Network, Chengdu, Peoples R China.
   [Hu, Jiankun] Sichuan Univ, West China Hosp, Gastr Canc Ctr, Dept Gen Surg,Lab Gastr Canc,State Key Lab Biother, 37 Guoxue Alley, Chengdu 610041, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University; Sichuan
   University
RP Hu, JK (corresponding author), Sichuan Univ, West China Hosp, Gastr Canc Ctr, Dept Gen Surg,Lab Gastr Canc,State Key Lab Biother, 37 Guoxue Alley, Chengdu 610041, Peoples R China.
EM hujkwch@126.com
RI Hu, Jiankun/D-9856-2012
OI zheng, xiuli/0000-0001-7671-2395
FU West China Hospital, Sichuan University [ZYJC21006]; Sichuan Province
   Science and Technology Support Program [2020YJ0212]; National Natural
   Science Foundation of China [32000432]
FX West China Hospital, Sichuan University, Grant/Award Number: ZYJC21006;
   Sichuan Province Science and Technology Support Program, Grant/Award
   Number: 2020YJ0212; National Natural Science Foundation of China,
   Grant/Award Number: 32000432
CR Abel EV, 2013, J CLIN INVEST, V123, P2155, DOI 10.1172/JCI65780
   Acharyya S, 2012, CELL, V150, P165, DOI 10.1016/j.cell.2012.04.042
   Adesso L, 2013, ONCOGENE, V32, P2848, DOI 10.1038/onc.2012.306
   Ahn A, 2017, MOL CANCER THER, V16, P1002, DOI 10.1158/1535-7163.MCT-16-0535
   Akbarzadeh M, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.153158
   Al-Odat OS, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24010644
   Aldonza MBD, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aav7416
   Aloia A, 2019, CLIN CANCER RES, V25, P6852, DOI 10.1158/1078-0432.CCR-19-0253
   Alsayed RKME, 2023, SEMIN CANCER BIOL, V92, P74, DOI 10.1016/j.semcancer.2023.04.005
   Arasada RR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05626-2
   Asano T, 2020, J NIPPON MED SCH, V87, P244, DOI 10.1272/jnms.JNMS.2020_87-508
   Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741
   Bahadoer RR, 2021, LANCET ONCOL, V22, P29, DOI 10.1016/S1470-2045(20)30555-6
   Balaban NQ, 2013, NAT REV MICROBIOL, V11, P587, DOI 10.1038/nrmicro3076
   Balaban NQ, 2004, SCIENCE, V305, P1622, DOI 10.1126/science.1099390
   Banelli B, 2015, CELL CYCLE, V14, P3418, DOI 10.1080/15384101.2015.1090063
   Bansal A, 2018, J CELL BIOL, V217, P2291, DOI 10.1083/jcb.201804161
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bejjani AC, 2022, J CLIN ONCOL, V40, P2763, DOI 10.1200/JCO.21.02605
   Bell CC, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10652-9
   BeLow M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9102204
   Biehs B, 2018, NATURE, V562, P429, DOI 10.1038/s41586-018-0596-y
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Blakely CM, 2015, CELL REP, V11, P98, DOI 10.1016/j.celrep.2015.03.012
   Boila LD, 2023, LEUKEMIA, V37, P751, DOI 10.1038/s41375-023-01833-z
   Bosc C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17882-2
   Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1
   Boussemart L, 2014, NATURE, V513, P105, DOI 10.1038/nature13572
   Boyd AL, 2018, CANCER CELL, V34, P483, DOI 10.1016/j.ccell.2018.08.007
   Bradner JE, 2017, CELL, V168, P629, DOI 10.1016/j.cell.2016.12.013
   BRAY F, 2018, CA-CANCER J CLIN, V68, P394, DOI [DOI 10.3322/CANJCLIN.49.1.33, DOI 10.3322/CAAC.21492]
   Butti R, 2023, CANCER DRUG RESIST, V6, P182, DOI 10.20517/cdr.2022.72
   Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558
   Cabanos HF, 2021, CANCERS, V13, DOI 10.3390/cancers13112666
   Cai WP, 2023, BMC CANCER, V23, DOI 10.1186/s12885-023-10561-7
   Camero S, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10112956
   Carneiro BA, 2020, NAT REV CLIN ONCOL, V17, P395, DOI 10.1038/s41571-020-0341-y
   Cassetta L, 2023, NAT REV CANCER, V23, P238, DOI 10.1038/s41568-022-00547-1
   Ceol CJ, 2011, NATURE, V471, P513, DOI 10.1038/nature09806
   Chang CA, 2022, CANCER DISCOV, V12, P1022, DOI 10.1158/2159-8290.CD-20-1265
   Chatterjee N, 2019, TRENDS CANCER, V5, P170, DOI 10.1016/j.trecan.2019.02.003
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Chen YJC, 2022, MOL CELL, V82, P716, DOI 10.1016/j.molcel.2021.12.004
   Chhabra Y, 2023, CELL, V186, P1580, DOI 10.1016/j.cell.2023.03.016
   Choi HJ, 2018, JNCI-J NATL CANCER I, V110, P400, DOI 10.1093/jnci/djx207
   Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388
   Cierlitza M, 2015, EXP DERMATOL, V24, P155, DOI 10.1111/exd.12613
   Cooper AJ, 2022, NAT REV CLIN ONCOL, V19, P499, DOI 10.1038/s41571-022-00639-9
   Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007
   Correia C, 2022, FRONT CELL DEV BIOL, V10, DOI 10.3389/fcell.2022.752326
   Cortés J, 2022, NEW ENGL J MED, V386, P1143, DOI 10.1056/NEJMoa2115022
   Cragg MS, 2008, J CLIN INVEST, V118, P3651, DOI 10.1172/JCI35437
   Cragg MS, 2007, PLOS MED, V4, P1681, DOI 10.1371/journal.pmed.0040316
   D'Oto A, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27502-2
   Dai JM, 2023, CLIN TRANSL ONCOL, V25, P1606, DOI 10.1007/s12094-022-03054-9
   Dawson MA, 2012, CELL, V150, P12, DOI 10.1016/j.cell.2012.06.013
   Dean M, 2005, NAT REV CANCER, V5, P275, DOI 10.1038/nrc1590
   Debaugnies M, 2023, NATURE, V616, P168, DOI 10.1038/s41586-023-05838-7
   Dhimolea E, 2021, CANCER CELL, V39, P240, DOI 10.1016/j.ccell.2020.12.002
   Dörr JR, 2013, NATURE, V501, P421, DOI 10.1038/nature12437
   Duy C, 2021, CANCER DISCOV, V11, P1542, DOI 10.1158/2159-8290.CD-20-1375
   Eberl M, 2018, CANCER CELL, V33, P229, DOI 10.1016/j.ccell.2017.12.015
   Echeverria GV, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aav0936
   Eggermont C, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04994-4
   Emran Abdullah Al, 2018, Oncotarget, V9, P8206, DOI 10.18632/oncotarget.23654
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Eptaminitaki GC, 2022, DRUG RESIST UPDATE, V65, DOI 10.1016/j.drup.2022.100866
   Erin N, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100715
   Fabbri L, 2021, NAT REV CANCER, V21, P558, DOI 10.1038/s41568-021-00380-y
   Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106
   Facompre ND, 2016, CANCER RES, V76, P5538, DOI 10.1158/0008-5472.CAN-15-3377
   Farge T, 2017, CANCER DISCOV, V7, P716, DOI 10.1158/2159-8290.CD-16-0441
   Fischer KR, 2015, NATURE, V527, P472, DOI 10.1038/nature15748
   Forloni M, 2016, CELL REP, V16, P457, DOI 10.1016/j.celrep.2016.05.087
   Fox DB, 2020, NAT METAB, V2, P318, DOI 10.1038/s42255-020-0191-z
   Friedlaender A, 2022, NAT REV CLIN ONCOL, V19, P51, DOI 10.1038/s41571-021-00558-1
   Gaiti F, 2019, NATURE, V569, P576, DOI 10.1038/s41586-019-1198-z
   Garcia TB, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00296
   Garcia-Martinez L, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22024-3
   Ghahhari NM, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29723-5
   Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465
   Goldman A, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aas8779
   Gu BN, 2013, CELL BIOSCI, V3, DOI 10.1186/2045-3701-3-39
   Guan TM, 2023, ADV SCI, V10, DOI 10.1002/advs.202205873
   Guler GD, 2017, CANCER CELL, V32, P221, DOI 10.1016/j.ccell.2017.07.002
   Guo JY, 2016, GENE DEV, V30, P1704, DOI 10.1101/gad.283416.116
   Guo ZZ, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420-023-01306-3
   Ha M, 2014, NAT REV MOL CELL BIO, V15, P509, DOI 10.1038/nrm3838
   Hammerlindl H, 2018, J CELL COMMUN SIGNAL, V12, P133, DOI 10.1007/s12079-017-0435-1
   Han J, 2020, CHEM SOC REV, V49, P7856, DOI 10.1039/d0cs00379d
   Hanahan D, 2014, LANCET, V383, P558, DOI 10.1016/S0140-6736(13)62226-6
   Hangauer MJ, 2017, NATURE, V551, P247, DOI 10.1038/nature24297
   Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040
   Hirata E, 2015, CANCER CELL, V27, P574, DOI 10.1016/j.ccell.2015.03.008
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Hong SH, 2007, P NATL ACAD SCI USA, V104, P18439, DOI 10.1073/pnas.0707292104
   Huang YH, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01347-8
   Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061
   Huo KG, 2020, TRANSL LUNG CANCER R, V9, P2214, DOI 10.21037/tlcr-20-154
   Jänne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817
   Ji GY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03914-2
   Jin Bilian, 2011, Genes Cancer, V2, P607, DOI 10.1177/1947601910393957
   Joshi SS, 2021, CA-CANCER J CLIN, V71, P264, DOI 10.3322/caac.21657
   Jurj A, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02484-1
   Kaldalu N, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aay1167
   Kalkavan H, 2022, CELL, V185, P3356, DOI 10.1016/j.cell.2022.07.025
   Kashani E, 2023, NEURO-ONCOLOGY, V25, P662, DOI 10.1093/neuonc/noac220
   Kasinski AL, 2011, NAT REV CANCER, V11, P849, DOI 10.1038/nrc3166
   Kawakami R, 2020, CANCER SCI, V111, P962, DOI 10.1111/cas.14316
   Keeratichamroen S, 2018, ONCOL REP, V39, P1765, DOI 10.3892/or.2018.6258
   Kemper K, 2014, CANCER RES, V74, P5937, DOI 10.1158/0008-5472.CAN-14-1174
   Kim MR, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18129-w
   Kloosterman DJ, 2023, CELL, V186, P1627, DOI 10.1016/j.cell.2023.02.020
   Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Korman AJ, 2022, NAT REV DRUG DISCOV, V21, P509, DOI 10.1038/s41573-021-00345-8
   Kruger DT, 2020, INT J CANCER, V146, P2348, DOI 10.1002/ijc.32668
   Kunimasa K, 2017, CANCER SCI, V108, P1368, DOI 10.1111/cas.13266
   Kuo KT, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0533-9
   Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006
   Kusienicka A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073596
   Lai GG, 2019, J CLIN ONCOL, V37, P876, DOI 10.1200/JCO.18.00177
   Lee JH, 2022, SEMIN CANCER BIOL, V86, P136, DOI 10.1016/j.semcancer.2022.09.004
   Lee MCW, 2014, P NATL ACAD SCI USA, V111, pE4726, DOI 10.1073/pnas.1404656111
   Lee TKW, 2022, NAT REV GASTRO HEPAT, V19, P26, DOI 10.1038/s41575-021-00508-3
   Lee WK, 2022, ONCOGENE, V41, P2315, DOI 10.1038/s41388-022-02242-9
   Leonce C, 2022, MOL CANCER RES, V20, P11, DOI 10.1158/1541-7786.MCR-21-0038
   Leonetti A, 2019, BRIT J CANCER, V121, P725, DOI 10.1038/s41416-019-0573-8
   Li LJ, 2019, GENE, V694, P76, DOI 10.1016/j.gene.2018.12.076
   Li XR, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05086-6
   Li Y, 2023, CANCER RES, V83, P398, DOI 10.1158/0008-5472.CAN-22-2370
   Li ZQ, 2017, ONCOTARGET, V8, P2906, DOI 10.18632/oncotarget.13772
   Liau BB, 2017, CELL STEM CELL, V20, P233, DOI 10.1016/j.stem.2016.11.003
   Liu MY, 2021, GASTROENTEROLOGY, V160, P1771, DOI 10.1053/j.gastro.2020.12.077
   Liu X., 2022, Cancers, V14
   Liu XN, 2019, MOL CANCER THER, V18, P706, DOI 10.1158/1535-7163.MCT-18-0395
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   Loibl S, 2021, LANCET, V397, P1750, DOI 10.1016/S0140-6736(20)32381-3
   Lotsberg ML, 2020, J THORAC ONCOL, V15, P973, DOI 10.1016/j.jtho.2020.01.015
   Lovly CM, 2014, NAT MED, V20, P1027, DOI 10.1038/nm.3667
   Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888
   Lytle NK, 2018, NAT REV CANCER, V18, P669, DOI 10.1038/s41568-018-0056-x
   Ma Y, 2020, PHARMACOL RES, V160, DOI 10.1016/j.phrs.2020.105071
   Macedo-Silva C, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-03279-y
   Magtanong L, 2016, CELL DEATH DIFFER, V23, P1099, DOI 10.1038/cdd.2016.25
   Magtanong L, 2019, CELL CHEM BIOL, V26, P420, DOI 10.1016/j.chembiol.2018.11.016
   Mani N, 2023, ADV CANCER RES, V158, P293, DOI 10.1016/bs.acr.2022.12.006
   Mao Y, 2015, MOL BIOSYST, V11, P1029, DOI 10.1039/c4mb00710g
   Marin-Bejar O, 2021, CANCER CELL, V39, P1135, DOI 10.1016/j.ccell.2021.05.015
   Marsolier J, 2022, NAT GENET, V54, P459, DOI 10.1038/s41588-022-01047-6
   Martori C, 2022, CANCERS, V14, DOI 10.3390/cancers14020440
   Mathur R, 2017, HAEMATOLOGICA, V102, P373, DOI 10.3324/haematol.2016.144964
   MAYR E, 1972, Journal of the History of Biology, V5, P55, DOI 10.1007/BF02113486
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Mehraj U, 2021, CANCER CHEMOTH PHARM, V87, P147, DOI 10.1007/s00280-020-04222-w
   Menon DR, 2015, ONCOGENE, V34, P4448, DOI 10.1038/onc.2014.372
   Menon DR, 2020, THERANOSTICS, V10, P6261, DOI 10.7150/thno.42523
   Miao YX, 2019, CELL, V177, P1172, DOI 10.1016/j.cell.2019.03.025
   Migliore C, 2013, TRENDS MOL MED, V19, P633, DOI 10.1016/j.molmed.2013.08.002
   Mikubo M, 2021, J THORAC ONCOL, V16, P1798, DOI 10.1016/j.jtho.2021.07.017
   Mitsui E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46346-x
   Moghal N, 2023, J THORAC ONCOL, V18, P499, DOI 10.1016/j.jtho.2022.12.003
   Monk BJ, 2023, LANCET ONCOL, V24, P392, DOI 10.1016/S1470-2045(23)00052-9
   Mueller KL, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3224
   Nallasamy P, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01682-x
   Nechushtan H, 2015, ONCOLOGIST, V20, P366, DOI 10.1634/theoncologist.2014-0424
   Neel DS, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0007-0
   Nie M, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI160152
   Niederst MJ, 2015, CLIN CANCER RES, V21, P3924, DOI 10.1158/1078-0432.CCR-15-0560
   Nik-Zainal S, 2016, NATURE, V534, P47, DOI 10.1038/nature17676
   Nilsson MB, 2023, CANCER CELL, V41, P340, DOI 10.1016/j.ccell.2023.01.007
   Niu BY, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121110
   Niveditha D, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6300-2
   Niveditha D, 2019, CANCER INFORM, V18, DOI 10.1177/1176935119881633
   Noronha A, 2022, CANCER DISCOV, V12, P2666, DOI 10.1158/2159-8290.CD-22-0111
   O'Donnell JS, 2019, NAT REV CLIN ONCOL, V16, P151, DOI 10.1038/s41571-018-0142-8
   Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3
   Oren Y, 2021, NATURE, V596, P576, DOI 10.1038/s41586-021-03796-6
   Oser MG, 2015, LANCET ONCOL, V16, pE165, DOI 10.1016/S1470-2045(14)71180-5
   Ozyurt R., 2023, MOL CANCER THER
   Pan GJ, 2007, CELL STEM CELL, V1, P299, DOI 10.1016/j.stem.2007.08.003
   Pantelaiou-Prokaki G, 2023, INT J CANCER, V152, P1916, DOI 10.1002/ijc.34429
   Park SY, 2015, BREAST CANCER RES TR, V149, P727, DOI 10.1007/s10549-015-3291-9
   Paschall AV, 2015, J IMMUNOL, V195, P1868, DOI 10.4049/jimmunol.1402243
   Passaro A, 2022, J CLIN ONCOL, V40, P598, DOI 10.1200/JCO.21.01845
   Patel SA, 2010, J IMMUNOL, V184, P5885, DOI 10.4049/jimmunol.0903143
   Paul MC, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-36505-0
   Perego M, 2018, ONCOGENE, V37, P302, DOI 10.1038/onc.2017.341
   Pham V, 2020, J PROTEOME RES, V19, P1533, DOI 10.1021/acs.jproteome.9b00773
   Pi MF, 2022, DRUG RESIST UPDATE, V61, DOI 10.1016/j.drup.2022.100822
   Pontiggia O, 2012, BREAST CANCER RES TR, V133, P459, DOI 10.1007/s10549-011-1766-x
   Puig-Saus C, 2023, NATURE, V615, P697, DOI 10.1038/s41586-023-05787-1
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Quagliano A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00992
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Rafii A, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003894
   Raha D, 2014, CANCER RES, V74, P3579, DOI 10.1158/0008-5472.CAN-13-3456
   Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025
   Ramirez M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10690
   Raoof S, 2019, ONCOGENE, V38, P6399, DOI 10.1038/s41388-019-0887-2
   Reckamp KL, 2022, J CLIN ONCOL, V40, P2295, DOI 10.1200/JCO.22.00912
   Rehman SK, 2021, CELL, V184, P226, DOI 10.1016/j.cell.2020.11.018
   Richard G, 2016, EMBO MOL MED, V8, P1143, DOI 10.15252/emmm.201505971
   Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w
   Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Ruffell B, 2015, CANCER CELL, V27, P462, DOI 10.1016/j.ccell.2015.02.015
   Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461
   Sahu N, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12351
   Sánchez-Danés A, 2018, NATURE, V562, P434, DOI 10.1038/s41586-018-0603-3
   Sanduja S, 2016, ONCOGENE, V35, P5295, DOI 10.1038/onc.2016.70
   Sansone P, 2017, CANCER RES, V77, P1927, DOI 10.1158/0008-5472.CAN-16-2129
   Sarkar M, 2023, FRONT CELL DEV BIOL, V11, DOI 10.3389/fcell.2023.1089068
   Scherschinski L, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020982
   Schoenfeld AJ, 2020, CLIN CANCER RES, V26, P2654, DOI [10.1158/10780432.CCR-19-3563, 10.1158/1078-0432.CCR-19-3563]
   Schuettengruber B, 2017, CELL, V171, P34, DOI 10.1016/j.cell.2017.08.002
   Seligson DB, 2009, AM J PATHOL, V174, P1619, DOI 10.2353/ajpath.2009.080874
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794
   Shah KN, 2019, NAT MED, V25, P111, DOI 10.1038/s41591-018-0264-7
   Shannan B, 2019, EUR J CANCER, V109, P137, DOI 10.1016/j.ejca.2018.12.024
   Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shen SS, 2020, CELL, V183, P860, DOI 10.1016/j.cell.2020.10.027
   Shen S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-13360-6
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Shiozawa Y, 2010, NEOPLASIA, V12, P116, DOI 10.1593/neo.91384
   Singh M, 2022, SEMIN CANCER BIOL, V83, P422, DOI 10.1016/j.semcancer.2021.03.013
   Singh M, 2018, PHARMACOL THERAPEUT, V182, P80, DOI 10.1016/j.pharmthera.2017.08.009
   Slack FJ, 2019, CELL, V179, P1033, DOI 10.1016/j.cell.2019.10.017
   Smith MP, 2016, CLIN CANCER RES, V22, P5966, DOI 10.1158/1078-0432.CCR-16-0954
   Smith MP, 2016, CANCER CELL, V29, P270, DOI 10.1016/j.ccell.2016.02.003
   Song CY, 2017, CANCER DISCOV, V7, P1248, DOI 10.1158/2159-8290.CD-17-0401
   Song KA, 2018, CLIN CANCER RES, V24, P5658, DOI 10.1158/1078-0432.CCR-18-0304
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Springfeld C, 2023, NAT REV CLIN ONCOL, V20, P318, DOI 10.1038/s41571-023-00746-1
   Sridharan S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01311
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Su YP, 2017, P NATL ACAD SCI USA, V114, P13679, DOI 10.1073/pnas.1712064115
   Sun YZ, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317712592
   Swain SM, 2023, NAT REV DRUG DISCOV, V22, P101, DOI 10.1038/s41573-022-00579-0
   Swayden M, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122601
   Taki M, 2021, CLIN CANCER RES, V27, P4669, DOI [10.1158/1078-0432.CCR-20-4459, DOI 10.1158/1078-0432.CCR-20-4459]
   Tang XL, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-05299-2
   Taniguchi H, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08074-0
   Tanimura K, 2022, NPJ PRECIS ONCOL, V6, DOI 10.1038/s41698-021-00250-8
   Terai H, 2018, CANCER RES, V78, P1044, DOI 10.1158/0008-5472.CAN-17-1904
   Tetsu O, 2015, PHARMACOL RES, V102, P132, DOI 10.1016/j.phrs.2015.09.022
   Thankamony AP, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00079
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Torrano J, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0644-y
   Tran J, 2002, P NATL ACAD SCI USA, V99, P4349, DOI 10.1073/pnas.072586399
   Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017
   Tsukamoto S, 2023, MOL CANCER THER, V22, DOI 10.1158/1535-7163.MCT-21-0879
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Vallette FM, 2019, BIOCHEM PHARMACOL, V162, P169, DOI 10.1016/j.bcp.2018.11.004
   Van Allen EM, 2014, CANCER DISCOV, V4, P94, DOI 10.1158/2159-8290.CD-13-0617
   van Hooren L, 2023, NAT CANCER, V4, P665, DOI 10.1038/s43018-023-00547-6
   Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Vinogradova M, 2016, NAT CHEM BIOL, V12, P531, DOI 10.1038/nchembio.2085
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Viswanathan VS, 2017, NATURE, V547, P453, DOI 10.1038/nature23007
   Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631
   Wang K, 2023, ONCOGENE, V42, P1072, DOI 10.1038/s41388-023-02619-4
   Wang K, 2021, CA-CANCER J CLIN, V71, P437, DOI 10.3322/caac.21689
   Wang LQ, 2017, CELL REP, V21, P773, DOI 10.1016/j.celrep.2017.09.085
   Wang MN, 2021, NAT MED, V27, P1345, DOI 10.1038/s41591-021-01450-2
   Wang Q, 2021, J HEPATOL, V75, P1142, DOI 10.1016/j.jhep.2021.06.025
   Wang W, 2009, CLIN CANCER RES, V15, P6630, DOI 10.1158/1078-0432.CCR-09-1001
   Wang WY, 2018, MOL CANCER THER, V17, P1973, DOI 10.1158/1535-7163.MCT-17-0802
   Webster MR, 2015, PIGM CELL MELANOMA R, V28, P184, DOI 10.1111/pcmr.12330
   Wei YY, 2022, ADV SCI, V9, DOI 10.1002/advs.202202216
   Westermarck J, 2023, MOL ONCOL, V17, P537, DOI 10.1002/1878-0261.13406
   Wu B, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01748-4
   Xia RH, 2013, ARCH PATHOL LAB MED, V137, P1761, DOI 10.5858/arpa.2012-0704-OA
   Xu MS, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01670-1
   Xu WX, 2018, INT J BIOL SCI, V14, P1122, DOI 10.7150/ijbs.25881
   Yang CX, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0352-6
   Ye X, 2013, J THORAC ONCOL, V8, P1118, DOI 10.1097/JTO.0b013e31829f691f
   Yi YM, 2018, BBA-MOL BASIS DIS, V1864, P793, DOI 10.1016/j.bbadis.2017.12.021
   Yoda S, 2019, PHARMACOL THERAPEUT, V193, P20, DOI 10.1016/j.pharmthera.2018.08.007
   Zampieri C, 2022, MOL ONCOL, V16, P1259, DOI 10.1002/1878-0261.13161
   Zawistowski JS, 2017, CANCER DISCOV, V7, P302, DOI 10.1158/2159-8290.CD-16-0653
   Zhang AP, 2022, INT J BIOL SCI, V18, P3019, DOI 10.7150/ijbs.72534
   Zhang C, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01530-y
   Zhang CW, 2021, THERANOSTICS, V11, P2691, DOI 10.7150/thno.50571
   Zhang G, 2016, J CLIN INVEST, V126, P1834, DOI 10.1172/JCI82661
   Zhang M, 2019, J CELL PHYSIOL, V234, P6361, DOI 10.1002/jcp.27369
   Zhang N, 2021, LANCET ONCOL, V22, pE358, DOI 10.1016/S1470-2045(21)00343-0
   Zhang WC, 2019, NAT METAB, V1, P460, DOI 10.1038/s42255-019-0052-9
   Zhang Z, 2023, EBIOMEDICINE, V89, DOI 10.1016/j.ebiom.2023.104483
   Zhang Z, 2022, EMBO MOL MED, V14, DOI 10.15252/emmm.202114903
   Zhao H, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01616-7
   Zhao XL, 2017, J PATHOL, V243, P376, DOI 10.1002/path.4958
   Zhu MX, 2023, SEMIN CANCER BIOL, V88, P18, DOI 10.1016/j.semcancer.2022.11.011
   Zhuang JL, 2023, CANCER RES, V83, P1611, DOI 10.1158/0008-5472.CAN-22-2213
   Zindy P, 2011, CANCER RES, V71, P4068, DOI 10.1158/0008-5472.CAN-11-0420
NR 300
TC 7
Z9 8
U1 1
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2688-2663
J9 MEDCOMM
JI MedComm
PD OCT
PY 2023
VL 4
IS 5
AR e342
DI 10.1002/mco2.342
PG 28
WC Medicine, Research & Experimental
WE Emerging Sources Citation Index (ESCI)
SC Research & Experimental Medicine
GA P9NB2
UT WOS:001053861400001
PM 37638338
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Luo, ZK
   Chen, QF
   Qu, XQ
   Zhou, XY
AF Luo, Zi-Kang
   Chen, Qiong-Feng
   Qu, Xiaoqin
   Zhou, Xiao-Yan
TI The Roles And Signaling Pathways Of Phosphatidylethanolamine-Binding
   Protein 4 In Tumors
SO ONCOTARGETS AND THERAPY
LA English
DT Review
DE PEBP4; signaling pathway; targeted therapy
ID TRAIL-INDUCED APOPTOSIS; ALPHA-INDUCED APOPTOSIS; CANCER-CELLS;
   LUNG-CANCER; DOWN-REGULATION; KINASE PATHWAY; RECTAL-CANCER; PEBP4;
   MIGRATION; PROMOTES
AB Phosphatidylethanolamine-binding protein 4 (PEBP4) has been found to be highly expressed in many tumors and to be closely related to the proliferation, differentiation, and metastasis of tumors. PEBP4 has also been found to be involved in many cancer-activated signaling pathways and to cause therapeutic resistance. In this study, we first reviewed the morphological structure and expression of PEBP4, then discussed the roles of PEBP4 in individualized treatment of some cancers, and finally explored the possibilities of cultivating PEBP4 as a therapeutic target.We also identified the main signaling pathways in which PEBP4 affects different cancers. It is here concluded that over-expression of PEBP4 can enhance the proliferation and metastasis of the cancer cells and the resistance to radiotherapy/chemotherapy in cancers.
C1 [Luo, Zi-Kang] Nanchang Univ, Clin Med Coll 2, Dept Clin Med, Nanchang 330006, Jiangxi, Peoples R China.
   [Chen, Qiong-Feng; Qu, Xiaoqin; Zhou, Xiao-Yan] Nanchang Univ, Dept Pathophysiol, Med Coll, 461 BaYi Rd, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhou, Xiao-Yan] Jiangxi Prov Key Lab Tumor Pathogenesis & Mol Pat, Nanchang 330006, Jiangxi, Peoples R China.
C3 Nanchang University; Nanchang University
RP Zhou, XY (corresponding author), Nanchang Univ, Dept Pathophysiol, Med Coll, 461 BaYi Rd, Nanchang 330006, Jiangxi, Peoples R China.
EM zhouxiaoyan@ncu.edu.cn
FU National Natural Science Foundation of China [81760117, 81460126];
   Natural Science Foundation of Jiangxi Province [20181BAB205012]
FX This work was supported by the National Natural Science Foundation of
   China (Nos. 81760117 and 81460126) and the Natural Science Foundation of
   Jiangxi Province (No. 20181BAB205012).
CR Al-Mulla F, 2013, J CELL PHYSIOL, V228, P1688, DOI 10.1002/jcp.24335
   Aribike O, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2355
   Batra Ranmeet, 2014, Indian J Dent, V5, P225, DOI 10.4103/0975-962X.144742
   Berghoff AS, 2017, NEURO-ONCOLOGY, V19, P1460, DOI 10.1093/neuonc/nox054
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brown JS, 2017, PHARMACOL THERAPEUT, V172, P101, DOI 10.1016/j.pharmthera.2016.12.001
   Burkhard K, 2009, CURR TOP MED CHEM, V9, P678, DOI 10.2174/156802609789044416
   Caunt CJ, 2015, NAT REV CANCER, V15, P577, DOI 10.1038/nrc4000
   CHEN RH, 1992, MOL CELL BIOL, V12, P915, DOI 10.1128/MCB.12.3.915
   Del Vescovo V, 2015, ADV EXP MED BIOL, V889, P153, DOI 10.1007/978-3-319-23730-5_9
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Garcia R, 2009, EMBO REP, V10, P278, DOI 10.1038/embor.2009.4
   He H, 2016, BBA-MOL CELL RES, V1863, P1682, DOI 10.1016/j.bbamcr.2016.03.022
   Huang RQ, 2019, MOL CARCINOGEN, V58, P135, DOI 10.1002/mc.22915
   Huang RQ, 2016, J NEURO-ONCOL, V127, P235, DOI 10.1007/s11060-015-2040-6
   Jacquemin G, 2012, HAEMATOL-HEMATOL J, V97, P38, DOI 10.3324/haematol.2011.046466
   Jian W, 2019, J CELL BIOCHEM, V120, P5386, DOI 10.1002/jcb.27817
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Lelli D, 2017, CURR PHARM DESIGN, V23, P3440, DOI 10.2174/1381612823666170109144818
   Li HZ, 2007, J BIOL CHEM, V282, P4943, DOI 10.1074/jbc.M609494200
   Li WP, 2016, BIOMED PHARMACOTHER, V81, P1, DOI 10.1016/j.biopha.2016.03.030
   Lien EC, 2017, CURR OPIN CELL BIOL, V45, P62, DOI 10.1016/j.ceb.2017.02.007
   Liu HB, 2010, J BIOL CHEM, V285, P21934, DOI 10.1074/jbc.M110.109876
   Liu HY, 2012, TUMOR BIOL, V33, P267, DOI 10.1007/s13277-011-0279-x
   Ma ZM, 2016, INT J CLIN EXP MED, V9, P12687
   Olow A, 2016, CLIN CANCER RES, V22, P5312, DOI 10.1158/1078-0432.CCR-15-1101
   Qiu JM, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-0977-3
   Qiu JM, 2013, INT J COLORECTAL DIS, V28, P241, DOI 10.1007/s00384-012-1534-3
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Stolz C, 2009, LEUKEMIA LYMPHOMA, V50, P873, DOI 10.1080/10428190902878471
   Tanimura S, 2017, J BIOCHEM, V162, P145, DOI 10.1093/jb/mvx048
   Wang K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056829
   Wang Q, 2017, BRIT J CANCER, V117, P159, DOI 10.1038/bjc.2017.153
   Wang SC, 2017, BIOMED PHARMACOTHER, V90, P659, DOI 10.1016/j.biopha.2017.03.098
   Wang XJ, 2005, CLIN CANCER RES, V11, P7545, DOI 10.1158/1078-0432.CCR-05-0879
   Wang XJ, 2004, J BIOL CHEM, V279, P45855, DOI 10.1074/jbc.M405147200
   Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498
   Wu ZJ, 2017, ONCOTARGET, V8, P18177, DOI 10.18632/oncotarget.15255
   Yang Y, 2017, ONCOTARGET, V8, P30621, DOI 10.18632/oncotarget.15695
   Yeung K, 2000, MOL CELL BIOL, V20, P3079, DOI 10.1128/MCB.20.9.3079-3085.2000
   Yu GP, 2015, J THORAC DIS, V7, P1806, DOI 10.3978/j.issn.2072-1439.2015.10.17
   Yu GP, 2014, TUMOR BIOL, V35, P10341, DOI 10.1007/s13277-014-2284-3
   Yu GP, 2013, TUMOR BIOL, V34, P91, DOI 10.1007/s13277-012-0514-0
   Zhang DX, 2016, TUMOR BIOL, V37, P1699, DOI 10.1007/s13277-015-3906-0
   Zhang YL, 2014, CANCER CHEMOTH PHARM, V74, P1105, DOI 10.1007/s00280-014-2559-9
   Zhao Y, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0648-1
   Zhao Z, 2015, CANCER GENE THER, V22, P108, DOI 10.1038/cgt.2014.73
NR 47
TC 7
Z9 7
U1 1
U2 14
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2019
VL 12
BP 7685
EP 7690
DI 10.2147/OTT.S216161
PG 6
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA IZ9LN
UT WOS:000487428100005
PM 31571919
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Babaei, M
   Abrishami, A
   Iranpour, S
   Saljooghi, AS
   Matin, MM
AF Babaei, Maryam
   Abrishami, Amir
   Iranpour, Sonia
   Saljooghi, Amir Sh.
   Matin, Maryam M.
TI Harnessing curcumin in a multifunctional biodegradable metal-organic
   framework (bio-MOF) for targeted colorectal cancer theranostics
SO DRUG DELIVERY AND TRANSLATIONAL RESEARCH
LA English
DT Article; Early Access
DE Colorectal cancer; Drug delivery system; Curcumin; Metal-organic
   framework
ID DRUG-DELIVERY; HYDROTHERMAL SYNTHESIS; NANOPARTICLES; CHEMOTHERAPY;
   DOXORUBICIN; STABILITY; TOXICITY; APTAMERS; RELEASE; GAS
AB Despite significant advancements in managing colorectal cancer (CRC), the issues of efficient diagnosis and targeted therapy remain demanding. To address these challenges and improve treatment outcomes while reducing the cost and side effects, there is a need for more effective theranostic systems that combine diagnostic techniques with therapeutic modalities. This study introduces a pioneering approach for the synthesis of a porous bio-MOF (biodegradable metal-organic framework) using iron as the metal component and curcumin as the pharmaceutical ingredient. Subsequently, the developed drug delivery system was equipped with the anticancer drug doxorubicin (DOX), coated with biocompatible polyethylene glycol (PEG), and targeted with a CRC-specific aptamer (EpCAM). The physicochemical characterization confirmed the successful synthesis of the bio-MOF, demonstrating high encapsulation efficiency and pH-dependent release of DOX. In vitro studies for anticancer activity, cellular uptake, and mechanism of cell death demonstrated that in the case of positive EpCAM HT-29 cells, Apt-PEG-MOF@DOX had enhanced internalization that resulted in massive apoptosis. In vivo studies of the nanoparticles were then conducted in immunocompromised C57BL/6 mice bearing HT-29 tumors. These studies showed that the targeted platform could induce efficient tumor regression with reduced systemic toxicity. The targeted bio-MOF also exhibited MRI imaging properties useful for monitoring tumors. Significantly, the biocompatibility of the introduced bio-MOF was enhanced by pursuing the green synthesis method, which does not engage toxic solvents and strong acids. Overall, this multimodal system acts diversely as a tumor imaging agent and a therapeutic delivery platform suitable for CRC theranostics.
C1 [Babaei, Maryam; Abrishami, Amir; Iranpour, Sonia; Matin, Maryam M.] Ferdowsi Univ Mashhad, Fac Sci, Dept Biol, Mashhad, Iran.
   [Saljooghi, Amir Sh.] Ferdowsi Univ Mashhad, Fac Sci, Dept Chem, Mashhad, Iran.
   [Saljooghi, Amir Sh.; Matin, Maryam M.] Ferdowsi Univ Mashhad, Inst Biotechnol, Novel Diagnost & Therapeut Res Grp, Mashhad, Iran.
C3 Ferdowsi University Mashhad; Ferdowsi University Mashhad; Ferdowsi
   University Mashhad
RP Matin, MM (corresponding author), Ferdowsi Univ Mashhad, Fac Sci, Dept Biol, Mashhad, Iran.; Saljooghi, AS (corresponding author), Ferdowsi Univ Mashhad, Fac Sci, Dept Chem, Mashhad, Iran.; Saljooghi, AS; Matin, MM (corresponding author), Ferdowsi Univ Mashhad, Inst Biotechnol, Novel Diagnost & Therapeut Res Grp, Mashhad, Iran.
EM saljooghi@um.ac.ir; matin@um.ac.ir
RI Saljooghi, Amir/AAB-6042-2021; M. Matin, Maryam/W-1884-2017
OI M. Matin, Maryam/0000-0002-7949-7712
FU Ministry of Science, Research and Technology of Iran, at Ferdowsi
   University of Mashhad (FUM) [UR26N6Q6FE, MI26NLW00W]
FX The authors thank Prof. Mashreghi, Mr. Malaekeh, Dr. Noroozpour, and Dr.
   Shaterzade for their excellent support and technical assistance. The
   schematic figures were created with BioRender.com (Agreement numbers:
   UR26N6Q6FE and MI26NLW00W).
CR Abrishami A, 2024, COMMUN BIOL, V7, DOI 10.1038/s42003-024-06043-6
   Abrishami A, 2024, NANOSCALE, V16, P6215, DOI 10.1039/d3nr06642h
   Adiwidjaja J, 2017, EXPERT OPIN DRUG MET, V13, P953, DOI 10.1080/17425255.2017.1360279
   Afshari AR, 2023, J FUNCT BIOMATER, V14, DOI 10.3390/jfb14080408
   Aghasizadeh M, 2022, LIFE SCI, V293, DOI 10.1016/j.lfs.2021.120272
   Ahmadi M, 2021, HELIYON, V7, DOI 10.1016/j.heliyon.2021.e06914
   Ahmed N, 2012, DRUG DISCOV TODAY, V17, P928, DOI 10.1016/j.drudis.2012.03.010
   Paz FAA, 2012, CHEM SOC REV, V41, P1088, DOI 10.1039/c1cs15055c
   Anderson SL, 2017, COORDIN CHEM REV, V349, P102, DOI 10.1016/j.ccr.2017.07.012
   Ashrafizadeh M, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12111084
   Bakhshi S, 2024, J DRUG DELIV SCI TEC, V91, DOI 10.1016/j.jddst.2023.105270
   Binaeian E, 2023, J MATER CHEM B, V11, P11426, DOI 10.1039/d3tb01959d
   Cai H, 2019, COORDIN CHEM REV, V378, P207, DOI 10.1016/j.ccr.2017.12.003
   Cai MR, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12030232
   Canivet J, 2014, CHEM SOC REV, V43, P5594, DOI 10.1039/c4cs00078a
   Chen C, 2017, NPJ PRECIS ONCOL, V1, DOI 10.1038/s41698-017-0041-y
   Chowdhury MA, 2017, CHEMBIOENG REV, V4, P225, DOI 10.1002/cben.201600027
   Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166
   Davodabadi F, 2024, NANOSCALE, V16, P3881, DOI 10.1039/d3nr05656b
   Dybtsev D.N., 2006, Angew. Chem., V118, P930, DOI [DOI 10.1002/ANGE.200503023, 10.1002/ange.200503023]
   Dybtsev DN, 2004, J AM CHEM SOC, V126, P32, DOI 10.1021/ja038678c
   Elmehrath S., 2023, BioMOF-Based Anti-Cancer Drug Delivery Syst Nanomaterials, V13, P953
   Far BF, 2024, J MATER CHEM B, V12, P609, DOI 10.1039/d3tb01786a
   Fathi-karkan S, 2023, J DRUG DELIV SCI TEC, V87, DOI 10.1016/j.jddst.2023.104805
   Fathi-Karkan S, 2023, INT J BIOL MACROMOL, V243, DOI 10.1016/j.ijbiomac.2023.125232
   Fatima I, 2024, J Drug Deliv Sci Technol
   Feng HT, 2020, J AM CHEM SOC, V142, P11442, DOI 10.1021/jacs.0c02434
   Fu ZY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21239123
   Guo W, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-64828-1
   Gupta SC, 2013, MOL NUTR FOOD RES, V57, P1510, DOI 10.1002/mnfr.201100741
   He YB, 2014, CHEM SOC REV, V43, P5657, DOI 10.1039/c4cs00032c
   Iranpour S, 2024, J MATER CHEM B, V12, P1096, DOI 10.1039/d3tb02571c
   Iranpour S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-01056-3
   Iranpour S, 2021, COORDIN CHEM REV, V442, DOI 10.1016/j.ccr.2021.213949
   Iranpour S, 2021, J BIOL RES-THESSALON, V28, DOI 10.1186/s40709-021-00141-w
   Jain P, 2020, ACS APPL BIO MATER, V3, P6852, DOI 10.1021/acsabm.0c00780
   Jain P, 2009, J AM CHEM SOC, V131, P13625, DOI 10.1021/ja904156s
   Jalaladdiny SS, 2022, J IRAN CHEM SOC, V19, P4287, DOI 10.1007/s13738-022-02604-w
   Javid-Naderi MJ, 2023, INORG CHEM COMMUN, V157, DOI 10.1016/j.inoche.2023.111423
   Jiang N, 2016, KOREAN J CHEM ENG, V33, P2747, DOI 10.1007/s11814-016-0092-8
   Al-Mosawi AKM, 2023, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1095837
   Khameneh ZR., 2018, Asian Pac J Cancer Biology, V3, P89, DOI [10.31557/apjcb.2018.3.4.89-92, DOI 10.31557/APJCB.2018.3.4.89-92]
   Lajunen T, 2015, J CONTROL RELEASE, V203, P85, DOI 10.1016/j.jconrel.2015.02.028
   Lan SK, 2022, NANOMATERIALS-BASEL, V12, DOI 10.3390/nano12193398
   Li MQ, 2013, ACS APPL MATER INTER, V5, P1781, DOI 10.1021/am303073u
   Li YN, 2020, CANCER BIOL MED, V17, P307, DOI 10.20892/j.issn.2095-3941.2020.0072
   Lin ZT, 2021, REACT FUNCT POLYM, V169, DOI 10.1016/j.reactfunctpolym.2021.105072
   Lin ZJ, 2014, CHEM SOC REV, V43, P5867, DOI 10.1039/c3cs60483g
   Liu J, 2022, SUSTAINABILITY-BASEL, V14, DOI 10.3390/su14105768
   MATSUMURA Y, 1986, CANCER RES, V46, P6387
   Miller SR, 2013, CHEM COMMUN, V49, P7773, DOI 10.1039/c3cc41987h
   Morita Y, 2018, CANCERS, V10, DOI 10.3390/cancers10030080
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Movaheditabar P, 2022, APPL ORGANOMET CHEM, V36, DOI 10.1002/aoc.6602
   Mustafa G, 2023, J DRUG DELIV SCI TEC, V87, DOI 10.1016/j.jddst.2023.104774
   Namkaew J, 2018, IN VITRO CELL DEV-AN, V54, P629, DOI 10.1007/s11626-018-0288-9
   Ojo OA, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.881641
   Peller M, 2018, INORG CHEM FRONT, V5, P1760, DOI 10.1039/c8qi00149a
   Pignatello R, 2001, DRUG DELIV, V8, P35
   Pourmadadi M., 2024, HYBRID ADV, V6, P100210, DOI [10.1016/j.hybadv.2024.100210, DOI 10.1016/J.HYBADV.2024.100210]
   Pourmadadi M, 2023, INORG CHEM COMMUN, V155, DOI 10.1016/j.inoche.2023.110999
   Prajakta D, 2009, J BIOMED NANOTECHNOL, V5, P445, DOI 10.1166/jbn.2009.1038
   Roostaee M, 2024, NANOSCALE, V16, P2713, DOI 10.1039/d3nr03495j
   Saebo IP, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032914
   Saeinasab M, 2024, INT J BIOL MACROMOL, V259, DOI 10.1016/j.ijbiomac.2024.129233
   Schlossbauer A, 2010, ANGEW CHEM INT EDIT, V49, P4734, DOI 10.1002/anie.201000827
   Shahriari M, 2021, J CONTROL RELEASE, V335, P369, DOI 10.1016/j.jconrel.2021.05.039
   Shaukat A, 2022, NAT REV GASTRO HEPAT, V19, P521, DOI 10.1038/s41575-022-00612-y
   Shen K, 2015, CRYSTENGCOMM, V17, P981, DOI 10.1039/c4ce02150a
   Shi LW, 2021, NANOSCALE, V13, P10748, DOI 10.1039/d1nr02065j
   Si G, 2024, Natl Sci Rev, V11
   SIEGEL RL, 2017, CA-CANCER J CLIN, V67, P7, DOI [DOI 10.3322/CAAC.21387, DOI 10.3322/caac.21772]
   Song YL, 2013, ANAL CHEM, V85, P4141, DOI 10.1021/ac400366b
   Su HM, 2015, CHEM COMMUN, V51, P5774, DOI 10.1039/c4cc10159f
   Subramanian N, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-014-0108-9
   Suk JS, 2016, ADV DRUG DELIVER REV, V99, P28, DOI 10.1016/j.addr.2015.09.012
   Sumer B, 2008, NANOMEDICINE-UK, V3, P137, DOI 10.2217/17435889.3.2.137
   Sun BT, 2019, KOREAN J CHEM ENG, V36, P1949, DOI 10.1007/s11814-019-0394-8
   Tacar O, 2013, J PHARM PHARMACOL, V65, P157, DOI 10.1111/j.2042-7158.2012.01567.x
   Tarin M, 2024, TALANTA, V270, DOI 10.1016/j.talanta.2023.125539
   Taylor KML, 2008, J AM CHEM SOC, V130, P2154, DOI 10.1021/ja710193c
   Thi TTH, 2020, POLYMERS-BASEL, V12, DOI 10.3390/polym12020298
   Thushari S, 2005, CHEM COMMUN, P5515, DOI 10.1039/b508574h
   van Driel WJ, 2018, NEW ENGL J MED, V378, P230, DOI 10.1056/NEJMoa1708618
   Velásquez-Hernández MD, 2020, CHEM SCI, V11, P10835, DOI 10.1039/d0sc01204a
   Xiao YD, 2016, INT J MOL MED, V38, P1319, DOI 10.3892/ijmm.2016.2744
   Xie XD, 2016, EUR J PHARM SCI, V83, P28, DOI 10.1016/j.ejps.2015.12.014
   YAGHI OM, 1995, J AM CHEM SOC, V117, P10401, DOI 10.1021/ja00146a033
   Zhang CL, 2010, J INVEST DERMATOL, V130, P2110, DOI 10.1038/jid.2010.86
   Zhang X, 2023, PART PART SYST CHAR, V40, DOI 10.1002/ppsc.202300047
   Zheng HQ, 2016, J AM CHEM SOC, V138, P962, DOI 10.1021/jacs.5b11720
   Zhou G, 2016, ONCOTARGET, V7, P13446, DOI 10.18632/oncotarget.7178
   Zhou HC, 2012, CHEM REV, V112, P673, DOI 10.1021/cr300014x
   Zhou HC, 2014, CHEM SOC REV, V43, P5415, DOI 10.1039/c4cs90059f
   Zhu RY, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15061599
   Zhuang DP, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951-022-01479-6
   Zimpel A, 2016, CHEM MATER, V28, P3318, DOI 10.1021/acs.chemmater.6b00180
NR 97
TC 0
Z9 0
U1 23
U2 23
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 2190-393X
EI 2190-3948
J9 DRUG DELIV TRANSL RE
JI Drug Deliv. Transl. Res.
PD 2024 SEP 20
PY 2024
DI 10.1007/s13346-024-01707-6
EA SEP 2024
PG 20
WC Instruments & Instrumentation; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Instruments & Instrumentation; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA G4J4J
UT WOS:001316319100001
PM 39302530
DA 2025-01-04
ER

PT J
AU Li, ZM
   Xu, WG
   Yang, JZ
   Wang, J
   Wang, JL
   Zhu, G
   Li, D
   Ding, JX
   Sun, TM
AF Li, Zhongmin
   Xu, Weiguo
   Yang, Jiazhen
   Wang, Juan
   Wang, Jialiang
   Zhu, Ge
   Li, Di
   Ding, Jianxun
   Sun, Tianmeng
TI A Tumor Microenvironments-Adapted Polypeptide Hydrogel/Nanogel Composite
   Boosts Antitumor Molecularly Targeted Inhibition and Immunoactivation
SO ADVANCED MATERIALS
LA English
DT Article
DE polypeptides; reactive oxygen species responsive nanogels; sequential
   drug delivery; synergistic cancer therapy; thermosensitive hydrogel
ID CANCER; COMBINATION; ROBUST; CELLS
AB Various macro/microscopic biomaterials have been developed for controlled drug delivery in the combination therapy of malignancies. However, uncertain loading ratio, release sequence, and spatiotemporal distribution of drugs hinder their synergistic therapeutic effects and clinical applications. In this work, a tumor microenvironments-adapted composite consisting of a thermosensitive hydrogel and a reactive oxygen species (ROS)-responsive nanogel is developed for precisely sequential drug release to enhance molecularly targeted therapy and amplify immune activation. LY3200882 (LY), a selective transforming growth factor-beta (TGF-beta) inhibitor, is encapsulated in the ROS-responsive nanogel and dispersed uniformly with regorafenib (REG) in a thermosensitive hydrogel (Gel/(REG+NG/LY)). After in situ administration, REG is preferentially released from the hydrogel to inhibit tumor growth and promote ROS generation, which triggers the subsequent on-demand release of LY from the nanogel. LY contributes to preventing the epithelial-mesenchymal transition and immune escape of tumor cells induced by elevated TGF-beta. In subcutaneous and orthotopic colorectal tumor bearing mouse models, Gel/(REG+NG/LY) effectively inhibits tumor growth and liver metastases by increasing the tumor infiltration of CD8(+) T cells, reducing the recruitment of tumor-associated macrophages and myeloid-derived suppressor cells, and promoting the polarization of macrophages from M2 to M1 type, indicating the significant potential in improving the prognosis of advanced cancer patients.
C1 [Li, Zhongmin; Wang, Juan; Wang, Jialiang; Zhu, Ge; Sun, Tianmeng] Jilin Univ, Key Lab Organ Regenerat & Transplantat, Minist Educ, Natl Local Joint Engn Lab Anim Models Human Dis, 1 Xinmin St, Changchun 130061, Peoples R China.
   [Li, Zhongmin; Xu, Weiguo; Yang, Jiazhen; Li, Di; Ding, Jianxun] Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, 5625 Renmin St, Changchun 130022, Peoples R China.
   [Li, Zhongmin] Jilin Univ, China Japan Union Hosp, Dept Gastrointestinal Colorectal & Anal Surg, 126 Xiantai St, Changchun 130033, Peoples R China.
   [Li, Di] First Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, 1 Xinmin St, Changchun 130061, Peoples R China.
   [Sun, Tianmeng] Jilin Univ, Int Ctr Future Sci, 2699 Qianjin St, Changchun 130015, Peoples R China.
C3 Jilin University; Chinese Academy of Sciences; Changchun Institute of
   Applied Chemistry, CAS; Jilin University; Jilin University; Jilin
   University
RP Sun, TM (corresponding author), Jilin Univ, Key Lab Organ Regenerat & Transplantat, Minist Educ, Natl Local Joint Engn Lab Anim Models Human Dis, 1 Xinmin St, Changchun 130061, Peoples R China.; Li, D; Ding, JX (corresponding author), Chinese Acad Sci, Changchun Inst Appl Chem, Key Lab Polymer Ecomat, 5625 Renmin St, Changchun 130022, Peoples R China.; Li, D (corresponding author), First Hosp Jilin Univ, Dept Hepatobiliary & Pancreat Surg, 1 Xinmin St, Changchun 130061, Peoples R China.; Sun, TM (corresponding author), Jilin Univ, Int Ctr Future Sci, 2699 Qianjin St, Changchun 130015, Peoples R China.
EM dili_@jlu.edu.cn; jxding@ciac.ac.cn; tsun41@jlu.edu.cn
RI Wang, Jun/F-9033-2011; Ding, Jianxun/A-6155-2013; Xu,
   Weiguo/H-1489-2014; Sun, Tianmeng/C-7853-2014; Li, Di/ADN-4545-2022
OI Sun, Tianmeng/0000-0003-2261-4532; Li, Zhongmin/0000-0002-0865-4864; Li,
   Di/0000-0001-6783-4542; Wang, Jialiang/0000-0003-3228-7336
FU National Key Research and Development Program of China [2021YFC2400600,
   2017YFA0208100]; National Natural Science Foundation of China [U21A2099,
   52022095, 52073280, 51973216, 51873207, 81871478, 51803006, 51833010];
   Science and Technology Development Program of Jilin Province
   [20210509005RQ, 20200404182YY, 20200301007RQ]; Youth Innovation
   Promotion Association of Chinese Academy of Sciences [2019230]; Health
   Science and Technology Capacity Improvement Project of Jilin Province
   [2021JC026]; Fundamental Research Funds for the Central Universities
FX This study was financially supported by the National Key Research and
   Development Program of China (Grant Nos. 2021YFC2400600 and
   2017YFA0208100), the National Natural Science Foundation of China (Grant
   Nos. U21A2099, 52022095, 52073280, 51973216, 51873207, 81871478,
   51803006, and 51833010), the Science and Technology Development Program
   of Jilin Province (Grant Nos. 20210509005RQ, 20200404182YY, and
   20200301007RQ), the Youth Innovation Promotion Association of Chinese
   Academy of Sciences (Grant No. 2019230), the Health Science and
   Technology Capacity Improvement Project of Jilin Province (Grant No.
   2021JC026), and the Fundamental Research Funds for the Central
   Universities, JLU. CT26 cells and stable luciferase-expressing CT26
   (CT26-luc) cells were purchased from Changchun Golden Transfer Science
   and Technology Co., Ltd. (Changchun, P. R. China). Protocols involved in
   the use of animals were reviewed and approved by the Institutional
   Review Board and Institutional Animal Care and Use Committee of the
   First Hospital of Jilin University, and all experiments were performed
   following the protocols.
CR Ao Q, 2020, ACS APPL MATER INTER, V12, P13400, DOI 10.1021/acsami.0c01371
   Arai H, 2019, CANCER TREAT REV, V81, DOI 10.1016/j.ctrv.2019.101912
   Bridgewater JA, 2020, LANCET ONCOL, V21, P398, DOI [10.1016/S1470-2045(19)30798-3, 10.1016/51470-2045(19)30798-3]
   Chen JJ, 2020, NANO LETT, V20, P6191, DOI 10.1021/acs.nanolett.0c02515
   Chen JJ, 2017, ADV MATER, V29, DOI 10.1002/adma.201701170
   Cheng YL, 2012, BIOMACROMOLECULES, V13, P2053, DOI 10.1021/bm3004308
   Cong ZQ, 2020, ACS NANO, V14, P1958, DOI 10.1021/acsnano.9b08434
   de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51
   Deng C, 2020, ADV DRUG DELIVER REV, V160, P199, DOI 10.1016/j.addr.2020.10.019
   Derynck R, 2021, NAT REV CLIN ONCOL, V18, P9, DOI 10.1038/s41571-020-0403-1
   Huang DC, 2018, EXPERT OPIN DRUG DEL, V15, P703, DOI 10.1080/17425247.2018.1497607
   Klichinsky M, 2020, NAT BIOTECHNOL, V38, P947, DOI 10.1038/s41587-020-0462-y
   Kwon M, 2021, J CONTROL RELEASE, V331, P321, DOI 10.1016/j.jconrel.2021.01.009
   Lacy P, 2011, BLOOD, V118, P9, DOI 10.1182/blood-2010-08-265892
   Lang TQ, 2019, ADV MATER, V31, DOI 10.1002/adma.201806202
   Li S, 2020, NATURE, V587, P121, DOI 10.1038/s41586-020-2850-3
   Liu B, 2020, ADV MATER, V32, DOI 10.1002/adma.202004460
   Liu Y, 2020, CHINESE CHEM LETT, V31, P3001, DOI 10.1016/j.cclet.2020.04.029
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mao KR, 2019, BIOMATER SCI-UK, V7, P2769, DOI 10.1039/c9bm00226j
   Peng SJ, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202001832
   Raza-Karimi A, 2016, ACS APPL MATER INTER, V8, P27254, DOI 10.1021/acsami.6b10375
   Sang W, 2019, CHEM SOC REV, V48, P3771, DOI 10.1039/c8cs00896e
   Showalter A, 2017, CYTOKINE, V97, P123, DOI 10.1016/j.cyto.2017.05.024
   Song B, 2019, J CLIN INVEST, V129, P569, DOI 10.1172/JCI122367
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Tomida C, 2015, J MED INVESTIG, V62, P195, DOI 10.2152/jmi.62.195
   Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1
   Wang HX, 2016, NANO TODAY, V11, P133, DOI 10.1016/j.nantod.2016.04.008
   Wang HZ, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-00258-y
   Wang JX, 2021, ACS NANO, V15, P4636, DOI 10.1021/acsnano.0c08996
   Wang M, 2020, BIOMATERIALS, V261, DOI 10.1016/j.biomaterials.2020.120301
   Wang Y, 2019, ACS APPL MATER INTER, V11, P8725, DOI 10.1021/acsami.9b01872
   Zhang F, 2019, ACS NANO, V13, P5662, DOI 10.1021/acsnano.9b00892
   Zhang XL, 2020, CANCER BIOL MED, V17, P418, DOI 10.20892/j.issn.2095-3941.2019.0215
   Zhang ZZ, 2021, ADV MATER, V33, DOI 10.1002/adma.202007719
   Zhao H, 2019, ACS NANO, V13, P6647, DOI 10.1021/acsnano.9b00972
   Zheng P, 2021, ADV MATER, V33, DOI 10.1002/adma.202007426
NR 39
TC 103
Z9 108
U1 84
U2 598
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 0935-9648
EI 1521-4095
J9 ADV MATER
JI Adv. Mater.
PD MAY
PY 2022
VL 34
IS 21
AR 2200449
DI 10.1002/adma.202200449
EA APR 2022
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
   Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
   Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science;
   Physics
GA 1M8UD
UT WOS:000783063700001
PM 35291052
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Marolleau, P
   Tougeron, D
   Allignet, B
   Cohen, R
   Sefrioui, D
   Gallet, B
   Dumont, F
   Guimbaud, R
   Alouani, E
   Passot, G
   Desolneux, G
   Ghiringhelli, F
   Marchal, F
   Mourthadhoi, F
   Coriat, R
   Desgrippes, R
   Locher, C
   Goujon, G
   Des Guetz, G
   Aparicio, T
   Paubelle, E
   Dupré, A
   de la Fouchardiere, C
AF Marolleau, Pauline
   Tougeron, David
   Allignet, Benoit
   Cohen, Romain
   Sefrioui, David
   Gallet, Blandine
   Dumont, Frederic
   Guimbaud, Rosine
   Alouani, Emily
   Passot, Guillaume
   Desolneux, Gregoire
   Ghiringhelli, Francois
   Marchal, Frederic
   Mourthadhoi, Farouk
   Coriat, Romain
   Desgrippes, Romain
   Locher, Christophe
   Goujon, Gael
   Des Guetz, Gaetan
   Aparicio, Thomas
   Paubelle, Etienne
   Dupre, Aurelien
   de la Fouchardiere, Christelle
TI Complete pathological response after chemotherapy or immune checkpoint
   inhibitors in deficient MMR metastatic colorectal cancer: Results of a
   retrospective multicenter study
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE deficient mismatch repair system; immune checkpoint inhibitors;
   metastatic colorectal cancer; microsatellite instability; neoadjuvant
   treatment; pathological complete response
ID MISMATCH REPAIR-DEFICIENT; MICROSATELLITE INSTABILITY; LIVER METASTASES;
   OPEN-LABEL; PREOPERATIVE CHEMOTHERAPY; NEOADJUVANT CHEMOTHERAPY; POOLED
   ANALYSIS; TUMOR RESPONSE; EFFICACY; PEMBROLIZUMAB
AB About 5% of the patients with metastatic colorectal cancers (mCRC) present microsatellite instability (MSI)/deficient mismatch repair system (dMMR). While metastasectomy is known to improve overall and progression-free survival in mCRC, specific results in selected patients with dMMR/MSI mCRC are lacking. Our study aimed to describe metastasectomy results, characterize histological response and evaluate pathological complete response (pCR) rate in patients with dMMR/MSI mCRC. We retrospectively reviewed data from all consecutive patients with dMMR/MSI mCRC who underwent surgical metastasectomy between January 2010 and June 2021 in 17 French centers. Primary outcome was to assess the pCR rate defined by tumor regression grade (TRG) 0. Secondary endpoints included relapse-free survival (RFS) and overall survival (OS), and explored TRG as predictive factor for RFS and OS. Among the 88 patients operated, 109 metastasectomies were performed in 81 patients after neoadjuvant treatment [chemotherapy & PLUSMN; targeted therapy (CTT): 69, 85.2%; immunotherapy (ICI): 12, 14.8%], and pCR was achieved in 13 (16.1%) patients. Among the latter, pCR rate were 10.2% in the patients having received CTT (N = 7) and 50.0% in the patients treated with ICI (N = 6). Radiological response did not predict TRG. With a median follow-up of 57.9 (IQR 34.2-81.6) months, median RFS was 20.2 (15.4-not reached) months, median OS was not reached. Major pathological responses (TRG0 + TRG1) were significantly associated with longer RFS (HR 0.12, 95% CI 0.03-0.55; P = .006). The pCR rate of 16.1% achieved with neoadjuvant treatment in patients with dMMR/MSI mCRC is consistent with previously reported rates in pMMR/MSS mCRC. Immunotherapy showed better pCR rate than chemotherapy & PLUSMN; targeted therapy. Further prospective trials are needed to validate immunotherapy as neoadjuvant treatment in resectable/potentially resectable dMMR/MSI mCRC and identify predictive factors for pCR.
C1 [Marolleau, Pauline; de la Fouchardiere, Christelle] Leon Berard Ctr, Med Oncol Dept, Lyon, France.
   [Tougeron, David] Univ Poitiers, Poitiers Univ Hosp, Gastroenterol & Hepatol Dept, Poitiers, France.
   [Allignet, Benoit] Leon Berard Ctr, Dept Radiat Oncol, Lyon, France.
   [Cohen, Romain] Sorbonne Univ, St Antoine Hosp, AP HP, Dept Med Oncol,Ctr Rech St Antoine, Paris, France.
   [Cohen, Romain] Ctr Rech St Antoine, Unite Mixte Rech Sci 938, Equipe Instabil Microsatell & Canc, Equipe labellisee Ligue Natl Canc,INSERM, Paris, France.
   [Sefrioui, David] Normandie Univ, Rouen Univ Hosp, Normandy Ctr Genom & Personalized Med, UNIROUEN,Inserm U1245,IRON Grp, Rouen, France.
   [Sefrioui, David] Normandie Univ, Rouen Univ Hosp, Dept Hepatogastroenterol, UNIROUEN,Inserm U1245,IRON Grp, Rouen, France.
   [Gallet, Blandine] Val Aurelle Ctr, Dept Med Oncol, Montpellier, France.
   [Dumont, Frederic] Inst Cancerol Ouest, Comprehens Canc Ctr, Dept Surg Oncol, Angers, France.
   [Alouani, Emily] Univ Hosp Toulouse, Rangueil Hosp, Digest Oncol Dept, Toulouse, France.
   [Passot, Guillaume] Hosp Civils Lyon, Ctr Hosp Lyon Sud, Dept Gen Surg & Surg Oncol, Pierre Benite, France.
   [Desolneux, Gregoire] Bergonie Inst, Dept Surg Oncol, Bordeaux, France.
   [Ghiringhelli, Francois] GF Leclerc Ctr, Dept Med Oncol, Dijon, France.
   [Marchal, Frederic] Lorraine Canc Ctr, Dept Surg Oncol, Vandoeuvre Les Nancy, France.
   [Mourthadhoi, Farouk] Jean Monnet Univ, St Etienne Univ Hosp, Dept Gen Surg, St Etienne, France.
   [Desgrippes, Romain] Univ Paris, Cochin Univ Hosp, APHP, Gastroenterol Dept, Paris, France.
   [Desgrippes, Romain] St Malo Gen Hosp, Gastroenterol Dept, St Malo, France.
   [Locher, Christophe] Meaux Hosp, Gastroenterol & Digest Oncol Dept, Meaux, France.
   [Goujon, Gael; Des Guetz, Gaetan] Hop Xavier Bichat, Gastroenterol Dept, Paris, France.
   [Aparicio, Thomas] St Louis Hosp, Gastroenterol Dept, Paris, France.
   [Paubelle, Etienne] Amiens Univ Hosp, Hematol Dept, Amiens, France.
   [Dupre, Aurelien] Ctr Leon Berard, Surg Dept, Lyon, France.
   [Dupre, Aurelien] Inst Paoli Calmettes, Med Oncol Dept, Marseille, France.
   [de la Fouchardiere, Christelle] Ctr Leon Berard, Med Oncol Dept, 28,rue Laennec, F-69373 Lyon 08, France.
C3 UNICANCER; Centre Leon Berard; CHU Poitiers; Universite de Poitiers;
   UNICANCER; Centre Leon Berard; Institut National de la Sante et de la
   Recherche Medicale (Inserm); Assistance Publique Hopitaux Paris (APHP);
   Sorbonne Universite; Hopital Universitaire Saint-Antoine - APHP;
   Institut National de la Sante et de la Recherche Medicale (Inserm);
   Sorbonne Universite; Institut National de la Sante et de la Recherche
   Medicale (Inserm); Universite de Rouen Normandie; CHU de Rouen; Institut
   National de la Sante et de la Recherche Medicale (Inserm); Universite de
   Rouen Normandie; CHU de Rouen; UNICANCER; Universite de Montpellier;
   Institut Regional du Cancer Montpellier / Val d'Aurelle (ICM); CHU de
   Toulouse; CHU Lyon; UNICANCER; Institut Bergonie; CHU de St Etienne;
   Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Hotel-Dieu - APHP; Hopital Universitaire Cochin -
   APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Bichat-Claude Bernard - APHP; Assistance Publique
   Hopitaux Paris (APHP); Universite Paris Cite; Hopital Universitaire
   Saint-Louis - APHP; Universite de Picardie Jules Verne (UPJV); CHU
   Amiens; UNICANCER; Centre Leon Berard; UNICANCER; Institut
   Paoli-Calmette (IPC); UNICANCER; Centre Leon Berard
RP de la Fouchardiere, C (corresponding author), Ctr Leon Berard, Med Oncol Dept, 28,rue Laennec, F-69373 Lyon 08, France.
EM christelle.delafouchardiere@lyon.unicancer.fr
RI Cohen, Romain/AAC-9089-2019; tougeron, david/ABF-3217-2020; ALLIGNET,
   Benoît/AFR-0990-2022; Passot, Guillaume/K-6271-2012; de la Fouchardiere,
   Christelle/AAW-7887-2021
OI tougeron, david/0000-0002-8065-9635; , Emily/0000-0002-2303-118X; DE LA
   FOUCHARDIERE, CHRISTELLE/0000-0003-2291-5693
CR Adam R, 2008, J CLIN ONCOL, V26, P1635, DOI 10.1200/JCO.2007.13.7471
   Al-Kaabi A, 2021, ACTA ONCOL, V60, P497, DOI 10.1080/0284186X.2020.1870246
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Andre T, 2021, LANCET ONCOL, V22, P665, DOI 10.1016/S1470-2045(21)00064-4
   Bartlett DL, 2012, ONCOLOGY-NY, V26, P266
   Basnet S, 2016, J CANCER, V7, P1105, DOI 10.7150/jca.14801
   Benoist S, 2006, J CLIN ONCOL, V24, P3939, DOI 10.1200/JCO.2006.05.8727
   Blazer DG, 2008, J CLIN ONCOL, V26, P5344, DOI 10.1200/JCO.2008.17.5299
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Brouquet A, 2020, ANN SURG ONCOL, V27, P2877, DOI 10.1245/s10434-020-08284-1
   Cercek A, 2022, NEW ENGL J MED, V386, P2363, DOI 10.1056/NEJMoa2201445
   Cercek A, 2020, CLIN CANCER RES, V26, P3271, DOI 10.1158/1078-0432.CCR-19-3728
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Cohen R, 2017, EUR J CANCER, V86, P266, DOI 10.1016/j.ejca.2017.09.022
   Cohen R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001499
   Cremolini C, 2017, EUR J CANCER, V73, P74, DOI 10.1016/j.ejca.2016.10.028
   Des Guetz G, 2009, EUR J CANCER, V45, P1890, DOI 10.1016/j.ejca.2009.04.018
   Diaz LA, 2022, LANCET ONCOL, V23, P659, DOI 10.1016/S1470-2045(22)00197-8
   Gallagher DJ, 2009, ANN SURG ONCOL, V16, P1844, DOI 10.1245/s10434-009-0348-1
   Garlan F, 2017, CLIN CANCER RES, V23, P5416, DOI 10.1158/1078-0432.CCR-16-3155
   He J, 2018, ANN SURG, V268, P1, DOI 10.1097/SLA.0000000000002672
   Jin ZH, 2018, ONCOLOGIST, V23, P1083, DOI 10.1634/theoncologist.2017-0289
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Liu X Z, 2022, Zhonghua Wei Chang Wai Ke Za Zhi, V25, P219, DOI 10.3760/cma.j.cn441530-20220228-00070
   Ludford K, 2021, JNCI-J NATL CANCER I, V113, P208, DOI 10.1093/jnci/djaa052
   Maas M, 2010, LANCET ONCOL, V11, P835, DOI 10.1016/S1470-2045(10)70172-8
   Mace AG, 2015, DIS COLON RECTUM, V58, P32, DOI 10.1097/DCR.0000000000000266
   Morton UKD, 2012, LANCET ONCOL, V13, P1152, DOI 10.1016/S1470-2045(12)70348-0
   Osumi H, 2019, CANCER MED-US, V8, P408, DOI 10.1002/cam4.1913
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Phelip JM, 2019, DIGEST LIVER DIS, V51, P1357, DOI 10.1016/j.dld.2019.05.035
   Pons-Tostivint E, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00114
   Pudlarz T, 2020, ANN ONCOL, V31, pS1434, DOI 10.1016/j.annonc.2020.10.533
   Rubbia-Brandt L, 2007, ANN ONCOL, V18, P299, DOI 10.1093/annonc/mdl386
   Sargent DJ, 2010, J CLIN ONCOL, V28, P3219, DOI 10.1200/JCO.2009.27.1825
   Sefrioui D, 2021, BRIT J CANCER, V125, P725, DOI 10.1038/s41416-021-01431-9
   SHUSTER JJ, 1991, J CLIN ONCOL, V9, P191, DOI 10.1200/JCO.1991.9.1.191
   Tan AC, 2018, ANN ONCOL, V29, P2115, DOI 10.1093/annonc/mdy330
   Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219
   Tougeron D, 2020, INT J CANCER, V147, P285, DOI 10.1002/ijc.32879
   Tougeron D, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv438
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
NR 43
TC 2
Z9 2
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD OCT 1
PY 2023
VL 153
IS 7
BP 1376
EP 1385
DI 10.1002/ijc.34636
EA JUL 2023
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FO9B1
UT WOS:001024159600001
PM 37403609
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Santini, D
   Botticelli, A
   Galvano, A
   Iuliani, M
   Incorvaia, L
   Gristina, V
   Taffon, C
   Foderaro, S
   Paccagnella, E
   Simonetti, S
   Fazio, F
   Scagnoli, S
   Pomati, G
   Pantano, F
   Perrone, G
   De Falco, E
   Russo, A
   Spinelli, GP
AF Santini, Daniele
   Botticelli, Andrea
   Galvano, Antonio
   Iuliani, Michele
   Incorvaia, Lorena
   Gristina, Valerio
   Taffon, Chiara
   Foderaro, Simone
   Paccagnella, Elisa
   Simonetti, Sonia
   Fazio, Federico
   Scagnoli, Simone
   Pomati, Giulia
   Pantano, Francesco
   Perrone, Giuseppe
   De Falco, Elena
   Russo, Antonio
   Spinelli, Gian Paolo
TI Network approach in liquidomics landscape
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Review
DE Liquid biopsy; CTC; ctDNA; MRD; Targeted therapy; Liquidomics
ID CIRCULATING-TUMOR DNA; CELL LUNG-CANCER; ADVANCED BREAST-CANCER;
   MOLECULAR TESTING GUIDELINE; DABRAFENIB PLUS TRAMETINIB;
   OF-AMERICAN-PATHOLOGISTS; PIWI-INTERACTING RNA; FECAL OCCULT BLOOD;
   PHASE-II TRIAL; COLORECTAL-CANCER
AB Tissue-based biopsy is the present main tool to explore the molecular landscape of cancer, but it also has many limits to be frequently executed, being too invasive with the risk of side effects. These limits and the ability of cancer to constantly evolve its genomic profile, have recently led to the need of a less invasive and more accurate alternative, such as liquid biopsy. By searching Circulating Tumor Cells and residues of their nucleic acids or other tumor products in body fluids, especially in blood, but also in urine, stools and saliva, liquid biopsy is becoming the future of clinical oncology. Despite the current lack of a standardization for its workflows, that makes it hard to be reproduced, liquid biopsy has already obtained promising results for cancer screening, diagnosis, prognosis, and risk of recurrence.Through a more accessible molecular profiling of tumors, it could become easier to identify biomarkers predictive of response to treatment, such as EGFR mutations in non-small cell lung cancer and KRAS mutations in colorectal cancer, or Microsatellite Instability and Mismatch Repair as predictive markers of pembrolizumab response.By monitoring circulating tumor DNA in longitudinal repeated sampling of blood we could also predict Minimal Residual Disease and the risk of recurrence in already radically resected patients.In this review we will discuss about the current knowledge of limitations and strengths of the different forms of liquid biopsies for its inclusion in normal cancer management, with a brief nod to their newest biomarkers and its future implications.
C1 [Santini, Daniele; Botticelli, Andrea; Scagnoli, Simone] Univ Roma La Sapienza, Oncol Med A, Policlin Umberto 1, Rome, Italy.
   [Galvano, Antonio; Incorvaia, Lorena; Gristina, Valerio; Russo, Antonio] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy.
   [Iuliani, Michele; Foderaro, Simone; Simonetti, Sonia; Pantano, Francesco] Univ Campus Biomed Roma, Fdn Policlin Univ Campus Biomed, Dept Med & Surg, Med Oncol, Selcetta, Italy.
   [Taffon, Chiara; Perrone, Giuseppe] Fdn Policlin Univ Campus Biomed, Anat Pathol Operat Res Unit, Rome, Italy.
   [Taffon, Chiara; Perrone, Giuseppe] Univ Campus Biomed Roma, Dept Med & Surg, Res Unit Anat Pathol, Rome, Italy.
   [Paccagnella, Elisa; De Falco, Elena] Sapienza Univ Rome, Dept Med Surg Sci & Biotechnol, C So Repubbl 79, I-04100 Latina, Italy.
   [Fazio, Federico; Spinelli, Gian Paolo] Univ Roma La Sapienza, UOC Oncol Terr, Polo Pontino, Latina, Italy.
   [Pomati, Giulia] INI Casa Cura, Grottaferrata, Italy.
   [De Falco, Elena] Mediterranea Cardioctr, I-80122 Naples, Italy.
C3 Sapienza University Rome; University Hospital Sapienza Rome; University
   of Palermo; Fondazione Policlinico Universitario Campus Bio-Medico;
   Fondazione Policlinico Universitario Campus Bio-Medico; University
   Campus Bio-Medico - Rome Italy; Sapienza University Rome; Sapienza
   University Rome
RP Fazio, F (corresponding author), Univ Roma La Sapienza, UOC Oncol Terr, Polo Pontino, Latina, Italy.
EM Federico_fazio@outlook.it
RI Perrone, Giuseppe/GLR-7098-2022; Galvano, Antonio/K-7810-2016; taffon,
   chiara/AAC-1838-2022; Pomati, Giulia/HMV-9476-2023; GRISTINA,
   VALERIO/AAC-1601-2019; Botticelli, Andrea/J-9926-2018; Scagnoli,
   Simone/ADZ-8234-2022; Perrone, Giuseppe/E-7062-2011
OI Perrone, Giuseppe/0000-0002-9538-5729; Pomati,
   Giulia/0000-0001-6715-5443; scagnoli, simone/0000-0003-4943-5622;
   Paccagnella, Elisa/0000-0002-1240-6513
CR Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364
   Abrahamsson J, 2017, UROL ONCOL-SEMIN ORI, V35, DOI 10.1016/j.urolonc.2017.05.021
   Ahmad P, 2019, CANCER GENOM PROTEOM, V16, P139, DOI 10.21873/cgp.20119
   Ahn HS, 2021, CANCERS, V13, DOI 10.3390/cancers13102300
   Ahn SM, 2014, JAMA OTOLARYNGOL, V140, P846, DOI 10.1001/jamaoto.2014.1338
   Allen-Vercoe E, 2020, CANCER CELL, V38, P452, DOI 10.1016/j.ccell.2020.09.005
   Amatu A, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000023
   Amintas S, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.622048
   André F, 2021, ANN ONCOL, V32, P208, DOI 10.1016/j.annonc.2020.11.011
   André F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904
   Angelini F, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2712751
   [Anonymous], Detection, Prevention, and Risk Reduction
   [Anonymous], 2022, NATURE
   Arechederra M, 2020, ADV LAB MED, V1, DOI 10.1515/almed-2020-0009
   Augustus E, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0231058
   Bachet JB, 2018, ANN ONCOL, V29, P1211, DOI 10.1093/annonc/mdy061
   Bachet JB, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.11509
   Bahn JH, 2015, CLIN CHEM, V61, P221, DOI 10.1373/clinchem.2014.230433
   Baruch EN, 2021, SCIENCE, V371, P602, DOI 10.1126/science.abb5920
   Bastaminejad Saiyad, 2017, Iranian Biomedical Journal, V21, P106, DOI 10.18869/acadpub.ibj.21.2.106
   Beije N, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100416
   Bellmunt J, 2021, LANCET ONCOL, V22, P525, DOI 10.1016/S1470-2045(21)00004-8
   Bernard V, 2019, GASTROENTEROLOGY, V156, P108, DOI 10.1053/j.gastro.2018.09.022
   Bernocchi O, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14020159
   Berz D, 2016, EXP HEMATOL ONCOL, V5, DOI 10.1186/s40164-016-0052-3
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Bian B, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1561120
   Bidard FC, 2010, ANN ONCOL, V21, P729, DOI 10.1093/annonc/mdp391
   Bidard FC, 2021, JAMA ONCOL, V7, P34, DOI 10.1001/jamaoncol.2020.5660
   Bidard FC, 2018, JNCI-J NATL CANCER I, V110, P560, DOI 10.1093/jnci/djy018
   Bidard FC, 2014, INT J CANCER, V134, P1207, DOI 10.1002/ijc.28436
   Bordin A, 2022, CELL PROLIFERAT, V55, DOI 10.1111/cpr.13312
   Bratman SV, 2020, NAT CANCER, V1, P873, DOI 10.1038/s43018-020-0096-5
   Bu JQ, 2015, MED SCI MONITOR, V21, P2275, DOI 10.12659/MSM.893925
   Buglyó G, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23084284
   Busetto GM, 2017, CLIN GENITOURIN CANC, V15, pE661, DOI 10.1016/j.clgc.2017.01.011
   Cai X, 2015, TRENDS GENET, V31, P564, DOI 10.1016/j.tig.2015.06.001
   CALDAS C, 1994, CANCER RES, V54, P3568
   Cammarata G, 2022, CANCERS, V14, DOI 10.3390/cancers14143404
   Cardinali B, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116320
   Casadio V, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/270457
   Castellanos-Rizaldos E, 2018, CLIN CANCER RES, V24, P2944, DOI 10.1158/1078-0432.CCR-17-3369
   Ceccon C, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.930108
   Cescon DW, 2020, NAT CANCER, V1, P276, DOI 10.1038/s43018-020-0043-5
   Chabon JJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11815
   Chai RC, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2217-1
   Chan HT, 2022, CANCERS, V14, DOI 10.3390/cancers14133275
   Chan HT, 2020, CANCERS, V12, DOI 10.3390/cancers12082277
   Chan KCA, 2005, CLIN CHEM, V51, P781, DOI 10.1373/clinchem.2004.046219
   Chaudhuri AA, 2017, CANCER DISCOV, V7, P1394, DOI 10.1158/2159-8290.CD-17-0716
   Chen I, 2017, ONCOTARGET, V8, P97769, DOI 10.18632/oncotarget.22080
   Chen KZ, 2019, CLIN CANCER RES, V25, P7058, DOI 10.1158/1078-0432.CCR-19-1213
   Chen M, 2019, HUM GENOMICS, V13, DOI 10.1186/s40246-019-0220-8
   Chen W, 2019, BIOMARKERS, V24, P524, DOI 10.1080/1354750X.2019.1593507
   Chen X, 2018, CLIN CANCER RES, V24, P6319, DOI 10.1158/1078-0432.CCR-18-1270
   Chen YH, 2017, NPJ BREAST CANCER, V3, DOI 10.1038/s41523-017-0028-4
   Chinniah C, 2019, CLIN LUNG CANCER, V20, P384, DOI 10.1016/j.cllc.2019.04.011
   Ciardiello F, 2016, ANN ONCOL, V27, P1055, DOI 10.1093/annonc/mdw136
   Clark TA, 2018, J MOL DIAGN, V20, P686, DOI 10.1016/j.jmoldx.2018.05.004
   Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0
   Cocucci E, 2009, TRENDS CELL BIOL, V19, P43, DOI 10.1016/j.tcb.2008.11.003
   Cohn AL, 2017, ONCOTARGETS THER, V10, P965, DOI 10.2147/OTT.S120440
   Coombes RC, 2019, CLIN CANCER RES, V25, P4255, DOI 10.1158/1078-0432.CCR-18-3663
   Corcoran C, 2014, PROSTATE, V74, P1320, DOI 10.1002/pros.22848
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166
   Davar D, 2021, SCIENCE, V371, P595, DOI 10.1126/science.abf3363
   de Castro G Jr, 2023, J THORAC ONCOL, V18, P106, DOI 10.1016/j.jtho.2022.09.223
   de Miguel-Perez D, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02379-1
   De Rubis G, 2019, TRENDS PHARMACOL SCI, V40, P172, DOI 10.1016/j.tips.2019.01.006
   Delgado PO, 2013, TUMOR BIOL, V34, P983, DOI 10.1007/s13277-012-0634-6
   Deo Priya Nimish, 2020, J Oral Maxillofac Pathol, V24, P361, DOI 10.4103/jomfp.JOMFP_20_20
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Diehl F, 2008, GASTROENTEROLOGY, V135, P489, DOI 10.1053/j.gastro.2008.05.039
   Ding SS, 2019, THORAC CANCER, V10, P1973, DOI 10.1111/1759-7714.13178
   Dizdar L, 2019, MOL ONCOL, V13, P1548, DOI 10.1002/1878-0261.12507
   Doebele RC, 2020, LANCET ONCOL, V21, P271, DOI 10.1016/S1470-2045(19)30691-6
   Dorsey JF, 2015, CANCER-AM CANCER SOC, V121, P139, DOI 10.1002/cncr.28975
   Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448
   Dudley JC, 2019, CANCER DISCOV, V9, P500, DOI 10.1158/2159-8290.CD-18-0825
   Duran-Sanchon S, 2021, CLIN GASTROENTEROL H, V19, P323, DOI 10.1016/j.cgh.2020.02.043
   Duran-Sanchon S, 2020, GASTROENTEROLOGY, V158, P947, DOI 10.1053/j.gastro.2019.10.005
   El Messaoudi S, 2016, CLIN CANCER RES, V22, P3067, DOI 10.1158/1078-0432.CCR-15-0297
   El Messaoudi S, 2013, CLIN CHIM ACTA, V424, P222, DOI 10.1016/j.cca.2013.05.022
   Elashoff D, 2012, CANCER EPIDEM BIOMAR, V21, P664, DOI 10.1158/1055-9965.EPI-11-1093
   Esagian SM, 2020, J CANCER RES CLIN, V146, P2051, DOI 10.1007/s00432-020-03267-x
   Fanale D, 2021, CANCERS, V13, DOI 10.3390/cancers13092118
   Fenizia F, 2015, FUTURE ONCOL, V11, P1611, DOI 10.2217/fon.15.23
   Forde PM, 2022, NEW ENGL J MED, V386, P1973, DOI 10.1056/NEJMoa2202170
   Frick MA, 2020, CLIN CANCER RES, V26, P2372, DOI 10.1158/1078-0432.CCR-19-2158
   Gale D, 2022, ANN ONCOL, V33, P500, DOI 10.1016/j.annonc.2022.02.007
   Galvano A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100124
   Galvano A, 2022, THER ADV MED ONCOL, V14, DOI 10.1177/17588359221110162
   Gandara DR, 2018, NAT MED, V24, P1441, DOI 10.1038/s41591-018-0134-3
   Garber JE, 2005, J CLIN ONCOL, V23, P276, DOI 10.1200/JCO.2005.10.042
   García-Foncillas J, 2017, ANN ONCOL, V28, P2943, DOI 10.1093/annonc/mdx501
   Garcia-Murillas I, 2019, JAMA ONCOL, V5, P1473, DOI 10.1001/jamaoncol.2019.1838
   Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021
   Gazzaniga P, 2012, ANN ONCOL, V23, P2352, DOI 10.1093/annonc/mdr619
   Gazzaniga P, 2014, INT J CANCER, V135, P1978, DOI 10.1002/ijc.28830
   Geeurickx E, 2020, MOL ASPECTS MED, V72, DOI 10.1016/j.mam.2019.10.005
   Georgiadis A, 2019, CLIN CANCER RES, V25, P7024, DOI 10.1158/1078-0432.CCR-19-1372
   Gharib E, 2021, J CLIN LAB ANAL, V35, DOI 10.1002/jcla.23601
   Goldberg SB, 2018, CLIN CANCER RES, V24, P1872, DOI 10.1158/1078-0432.CCR-17-1341
   Gonzalez-Cao M, 2015, MELANOMA RES, V25, P486, DOI 10.1097/CMR.0000000000000187
   Goodman CR, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0163
   Green EA, 2021, EUR UROL ONCOL, V4, P893, DOI 10.1016/j.euo.2021.04.005
   Green SF, 2013, CLIN BIOCHEM, V46, P1175, DOI 10.1016/j.clinbiochem.2013.06.001
   Greither T, 2017, ONCOL REP, V38, P1268, DOI 10.3892/or.2017.5764
   Gristina V, 2022, CANCERS, V14, DOI 10.3390/cancers14236013
   Gristina V, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/17588359211018018
   Gristina V, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13120474
   Grölz D, 2018, CURR PATHOBIOL REP, V6, P275, DOI 10.1007/s40139-018-0180-z
   Gros A, 2016, NAT MED, V22, P433, DOI 10.1038/nm.4051
   Groskopf J, 2006, CLIN CHEM, V52, P1089, DOI 10.1373/clinchem.2005.063289
   Guibert N, 2019, LUNG CANCER, V137, P1, DOI 10.1016/j.lungcan.2019.09.005
   Guibert N, 2018, LUNG CANCER, V120, P108, DOI 10.1016/j.lungcan.2018.04.001
   Guttery DS, 2015, CLIN CHEM, V61, P974, DOI 10.1373/clinchem.2015.238717
   Han B, 2018, PHARMACOL THERAPEUT, V187, P31, DOI 10.1016/j.pharmthera.2018.01.010
   Hann Hie-Won, 2017, Hepatoma Res, V3, P105, DOI 10.20517/2394-5079.2017.15
   Hanna GJ, 2019, ORAL ONCOL, V95, P120, DOI 10.1016/j.oraloncology.2019.06.019
   Hashad D, 2012, J CLIN LAB ANAL, V26, P467, DOI 10.1002/jcla.21548
   Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535
   He J, 2022, CANCER RES, V82
   He YJ, 2023, J TRANSL MED, V21, DOI 10.1186/s12967-023-03879-0
   Heitzer E, 2019, NAT REV GENET, V20, P71, DOI 10.1038/s41576-018-0071-5
   Hendriks RJ, 2021, PROSTATE CANCER P D, V24, P1110, DOI 10.1038/s41391-021-00367-8
   Henriksen TV, 2022, CLIN CANCER RES, V28, P507, DOI 10.1158/1078-0432.CCR-21-2404
   Herrera LJ, 2005, CLIN CHEM, V51, P113, DOI 10.1373/clinchem.2004.039263
   Hinz S, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-3035-1
   Hofman P, 2019, ANN ONCOL, V30, P1448, DOI 10.1093/annonc/mdz196
   Hogan SA, 2019, CANCER IMMUNOL RES, V7, P77, DOI 10.1158/2326-6066.CIR-18-0136
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Hosseini K, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03231-y
   Hou JM, 2012, J CLIN ONCOL, V30, P525, DOI 10.1200/JCO.2010.33.3716
   Hou J, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01309-7
   Hrebien S, 2019, ANN ONCOL, V30, P945, DOI 10.1093/annonc/mdz085
   Huang AC, 2017, NATURE, V545, P60, DOI 10.1038/nature22079
   Ignatiadis M, 2021, NAT REV CLIN ONCOL, V18, P297, DOI 10.1038/s41571-020-00457-x
   Ilié M, 2018, ANN ONCOL, V29, P193, DOI 10.1093/annonc/mdx636
   Iliev R, 2016, ANTICANCER RES, V36, P6419, DOI 10.21873/anticanres.11239
   Imperiale TF, 2004, NEW ENGL J MED, V351, P2704, DOI 10.1056/NEJMoa033403
   Incorvaia L, 2023, THER ADV MED ONCOL, V15, DOI 10.1177/17588359231151845
   Incorvaia L, 2020, CANCERS, V12, DOI 10.3390/cancers12113396
   Incorvaia L, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1832348
   Incorvaia L, 2019, ADV THER, V36, P2600, DOI 10.1007/s12325-019-01057-7
   Incorvaia L, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919848872
   Ishiba T, 2018, BIOCHEM BIOPH RES CO, V500, P621, DOI 10.1016/j.bbrc.2018.04.120
   Israeli E, 2022, ISR MED ASSOC J, V24, P481, DOI 10.1056/NEJMoa2200075
   Iwata H, 2017, J GLOB ONCOL, V3, P289, DOI 10.1200/JGO.2016.008318
   Jacobs B, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e15127
   Jacobs MT, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.17.00318
   Janni WJ, 2016, CLIN CANCER RES, V22, P2583, DOI 10.1158/1078-0432.CCR-15-1603
   Jenkins S, 2017, J THORAC ONCOL, V12, P1061, DOI 10.1016/j.jtho.2017.04.003
   Juric D, 2018, J CLIN ONCOL, V36, P1291, DOI 10.1200/JCO.2017.72.7107
   Kaczor-Urbanowicz KE, 2019, BBA-REV CANCER, V1872, P49, DOI 10.1016/j.bbcan.2019.05.007
   Kalemkerian GP, 2018, J CLIN ONCOL, V36, P911, DOI 10.1200/JCO.2017.76.7293
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kang KKM, 2021, CANCERS, V13, DOI 10.3390/cancers13061227
   Kang Taeyoung, 2021, Subcell Biochem, V97, P19, DOI 10.1007/978-3-030-67171-6_2
   Kanikarla-Marie P, 2017, CANCER METAST REV, V36, P235, DOI 10.1007/s10555-017-9681-1
   Keller L, 2021, BRIT J CANCER, V124, P345, DOI 10.1038/s41416-020-01047-5
   Kerachian MA, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01182-7
   Khagi Y, 2017, CLIN CANCER RES, V23, P5729, DOI 10.1158/1078-0432.CCR-17-1439
   Kim ES, 2022, NAT MED, V28, P939, DOI 10.1038/s41591-022-01754-x
   Kim MY, 2009, CELL, V139, P1315, DOI 10.1016/j.cell.2009.11.025
   Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z
   Kim Won Tae, 2018, Oncotarget, V9, P14354, DOI 10.18632/oncotarget.24436
   Kim WT, 2016, ONCOTARGET, V7, P58193, DOI 10.18632/oncotarget.11277
   Kimura H, 2006, CLIN CANCER RES, V12, P3915, DOI 10.1158/1078-0432.CCR-05-2324
   Kingston B, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22605-2
   Klaassen CHW, 2003, CLIN CHEM, V49, P1185, DOI 10.1373/49.7.1185
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Krebs MG, 2011, J CLIN ONCOL, V29, P1556, DOI 10.1200/JCO.2010.28.7045
   Kuang Y, 2009, CLIN CANCER RES, V15, P2630, DOI 10.1158/1078-0432.CCR-08-2592
   Kuskel A, 2016, SCI REP-UK, V6, DOI 10.1038/srep39736
   Kwapisz D, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.01.32
   Lane RE, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0192-7
   Lau E, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00770-1
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Leetanaporn K, 2021, ONCOL REV, V15, DOI 10.4081/oncol.2021.542
   Leicht DT, 2007, BBA-MOL CELL RES, V1773, P1196, DOI 10.1016/j.bbamcr.2007.05.001
   Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968
   LEON SA, 1977, CANCER RES, V37, P646
   Li F, 2020, CANCERS, V12, DOI 10.3390/cancers12082041
   Li F, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e24062
   Li K, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01499-8
   Li W, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01505-z
   Li XS, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.923232
   Li Y, 2004, CLIN CANCER RES, V10, P8442, DOI 10.1158/1078-0432.CCR-04-1167
   Lindeman NI, 2018, J MOL DIAGN, V20, P129, DOI [10.1016/j.jmoldx.2017.11.004, 10.5858/arpa.2017-0388-CP, 10.1016/j.jtho.2017.12.001]
   Lipsyc-Sharf M, 2022, J CLIN ONCOL, V40, P2408, DOI 10.1200/JCO.22.00908
   Listì A, 2019, TRANSL CANCER RES, V8, pS55, DOI 10.21037/tcr.2018.10.04
   Liu H, 2016, INT J CLIN EXP MED, V9, P16441
   Liu MC, 2020, ANN ONCOL, V31, P745, DOI 10.1016/j.annonc.2020.02.011
   Liu SY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.705791
   Liu Y, 2022, J CHROMATOGR B, V1199, DOI 10.1016/j.jchromb.2022.123236
   Ma CY, 2019, DOSE-RESPONSE, V17, DOI 10.1177/1559325819891004
   Mack PC, 2022, CLIN CANCER RES, V28, P3752, DOI 10.1158/1078-0432.CCR-22-0741
   Magbanua MJM, 2021, ANN ONCOL, V32, P229, DOI 10.1016/j.annonc.2020.11.007
   Majem M, 2019, CLIN TRANSL ONCOL, V21, P3, DOI 10.1007/s12094-018-1978-1
   Majood M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.966661
   Malone ER, 2020, GENOME MED, V12, DOI 10.1186/s13073-019-0703-1
   MANDEL P, 1948, CR SOC BIOL, V142, P241
   Mandelker D, 2019, ANN ONCOL, V30, P1221, DOI 10.1093/annonc/mdz136
   Marcus Leigh, 2021, Clin Cancer Res, V27, P4685, DOI 10.1158/1078-0432.CCR-21-0327
   Marcus L, 2019, CLIN CANCER RES, V25, P3753, DOI 10.1158/1078-0432.CCR-18-4070
   Markus H, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-25810-0
   MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0
   Mateo J, 2018, ANN ONCOL, V29, P1895, DOI 10.1093/annonc/mdy263
   Mathew M, 2020, CANCERS, V12, DOI 10.3390/cancers12102825
   Matikas A, 2022, BRIT J CANCER, V126, P1563, DOI 10.1038/s41416-022-01699-5
   McDonald BR, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax7392
   McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018
   McKiernan J, 2016, JAMA ONCOL, V2, P882, DOI 10.1001/jamaoncol.2016.0097
   Melo SA, 2015, NATURE, V523, P177, DOI 10.1038/nature14581
   Meric-Bernstam F, 2016, ANN ONCOL, V27, P795, DOI 10.1093/annonc/mdw018
   Merker JD, 2018, J CLIN ONCOL, V36, P1631, DOI 10.1200/JCO.2017.76.8671
   Mizuno K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-51459-4
   Moding EJ, 2021, CANCER DISCOV, V11, P2968, DOI 10.1158/2159-8290.CD-21-0634
   Mok T, 2020, ANN ONCOL, V31, P1056, DOI 10.1016/j.annonc.2020.04.478
   Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674
   Morbelli S, 2017, J NUCL MED, V58, P1764, DOI 10.2967/jnumed.117.193201
   Mosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014
   Mullard A, 2022, NAT REV DRUG DISCOV, V21, P548, DOI 10.1038/d41573-022-00117-y
   Naber SK, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0220234
   Neumann MHD, 2018, COMPUT STRUCT BIOTEC, V16, P190, DOI 10.1016/j.csbj.2018.05.002
   Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519
   Ng SB, 2017, SCI REP-UK, V7, DOI 10.1038/srep40737
   Nicolazzo C, 2019, ONCOLOGIST, V24, P612, DOI 10.1634/theoncologist.2018-0784
   Nicolazzo C, 2016, SCI REP-UK, V6, DOI 10.1038/srep31726
   Normanno N, 2018, ANN ONCOL, V29, P112, DOI 10.1093/annonc/mdx417
   Nors J, 2020, ACTA ONCOL, V59, P336, DOI 10.1080/0284186X.2019.1711170
   Nuzzo PV, 2020, NAT MED, V26, P1041, DOI 10.1038/s41591-020-0933-1
   O'Leary B, 2018, CANCER DISCOV, V8, P1390, DOI 10.1158/2159-8290.CD-18-0264
   Odegaard JI, 2018, CLIN CANCER RES, V24, P3539, DOI 10.1158/1078-0432.CCR-17-3831
   Okada Tetsuhiro, 2018, Endosc Int Open, V6, pE1454, DOI 10.1055/a-0721-1747
   Olsson E, 2015, EMBO MOL MED, V7, P1034, DOI 10.15252/emmm.201404913
   Oneal PA, 2018, ONCOLOGIST, V23, P1520, DOI 10.1634/theoncologist.2018-0295
   Onidani K, 2019, CANCER SCI, V110, P2590, DOI 10.1111/cas.14092
   Osborne JM, 2018, PATIENT PREFER ADHER, V12, P1825, DOI 10.2147/PPA.S172143
   Oshi M, 2021, CANCERS, V13, DOI 10.3390/cancers13112652
   Osumi H, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53711-3
   Oto J., 2019, J UROLOGY, V201, pe296
   Page RD, 2022, CLIN LUNG CANCER, V23, P72, DOI 10.1016/j.cllc.2021.10.001
   Palviainen M, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0236439
   Pantel K, 2004, NAT REV CANCER, V4, P448, DOI 10.1038/nrc1370
   Pantel K, 2019, NAT REV CLIN ONCOL, V16, P409, DOI 10.1038/s41571-019-0187-3
   Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030
   Paramathas S, 2020, PEDIATR BLOOD CANCER, V67, DOI 10.1002/pbc.28758
   Parikh A R., 2021, CLIN CANCER RES, V27, pOF1, DOI DOI 10.1158/1078-0432.CCR-21-0410
   Parsons HA, 2020, CLIN CANCER RES, V26, P2556, DOI 10.1158/1078-0432.CCR-19-3005
   Pascual J, 2022, ANN ONCOL, V33, P750, DOI 10.1016/j.annonc.2022.05.520
   Passaro A, 2021, NAT CANCER, V2, P377, DOI 10.1038/s43018-021-00195-8
   Passiglia F, 2021, TRANSL LUNG CANCER R, V10, P3106, DOI 10.21037/tlcr-21-52
   Patel A, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.828434
   Patel A, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100420
   Pepe F, 2021, CANCER CYTOPATHOL, V129, P460, DOI 10.1002/cncy.22400
   Peters S, 2022, NAT MED, V28, P1831, DOI 10.1038/s41591-022-01933-w
   Phua LC, 2014, ONCOL REP, V32, P97, DOI 10.3892/or.2014.3193
   Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863
   Poulet G, 2019, ACTA CYTOL, V63, P449, DOI 10.1159/000499337
   Powles T, 2021, NATURE, V595, P432, DOI 10.1038/s41586-021-03642-9
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Prince M, 2017, WORLD J GASTROENTERO, V23, P464, DOI 10.3748/wjg.v23.i3.464
   Pu D, 2016, THORAC CANCER, V7, P428, DOI 10.1111/1759-7714.12350
   Qian X, 2016, ONCOTARGET, V7, P29154, DOI 10.18632/oncotarget.8684
   Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004
   Rack B, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju066
   Raut JR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-25067-8
   Rawla P, 2019, WORLD J ONCOL, V10, P63, DOI 10.14740/wjon1191
   Razavi P, 2019, NAT MED, V25, P1928, DOI 10.1038/s41591-019-0652-7
   Reckamp KL, 2016, J THORAC ONCOL, V11, P1690, DOI 10.1016/j.jtho.2016.05.035
   Redwood DG, 2016, MAYO CLIN PROC, V91, P61, DOI 10.1016/j.mayocp.2015.10.008
   Reinert T, 2019, JAMA ONCOL, V5, P1124, DOI 10.1001/jamaoncol.2019.0528
   Riethdorf S, 2017, CLIN CANCER RES, V23, P5384, DOI 10.1158/1078-0432.CCR-17-0255
   Rink M, 2012, EUR UROL, V61, P810, DOI 10.1016/j.eururo.2012.01.017
   Riva F, 2017, CLIN CHEM, V63, P691, DOI 10.1373/clinchem.2016.262337
   Rodon Jordi, 2018, Oncotarget, V9, P31709, DOI 10.18632/oncotarget.25854
   Rodríguez N, 2020, CLIN TRANSL ONCOL, V22, P1430, DOI 10.1007/s12094-020-02296-9
   Rolfo C, 2022, BRIT J CANCER, V126, P514, DOI 10.1038/s41416-021-01536-1
   Rolfo C, 2020, CRIT REV ONCOL HEMAT, V151, DOI 10.1016/j.critrevonc.2020.102978
   Rolfo C, 2020, LANCET ONCOL, V21, P472, DOI 10.1016/S1470-2045(20)30026-7
   Rolfo C, 2018, J THORAC ONCOL, V13, P1248, DOI 10.1016/j.jtho.2018.05.030
   Rushton AJ, 2021, CANCERS, V13, DOI 10.3390/cancers13050970
   Russo A, 2020, PRECIS CANC MED, V3
   Salami SS, 2019, JCO PRECIS ONCOL, V3, DOI [10.1200/po.18.00352, 10.1200/PO.18.00352]
   Salvianti F, 2020, NEW BIOTECHNOL, V55, P19, DOI 10.1016/j.nbt.2019.09.006
   Sanguedolce F, 2016, CLIN GENITOURIN CANC, V14, P117, DOI 10.1016/j.clgc.2015.12.001
   Sartore-Bianchi A, 2022, NAT MED, V28, P1612, DOI 10.1038/s41591-022-01886-0
   Sausen M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8686
   Schenker M, 2022, CANCER RES, V82
   Scherer F, 2020, RECENT RESULTS CANC, V215, P213, DOI 10.1007/978-3-030-26439-0_11
   Schmiegel W, 2017, MOL ONCOL, V11, P208, DOI 10.1002/1878-0261.12023
   Scholer LV, 2017, CLIN CANCER RES, V23, P5437, DOI 10.1158/1078-0432.CCR-17-0510
   Schrock AB, 2018, CLIN CANCER RES, V24, P1881, DOI 10.1158/1078-0432.CCR-17-3103
   Sethi S, 2009, DIAGN MOL PATHOL, V18, P81, DOI 10.1097/PDM.0b013e3181804b82
   Shaw AT, 2019, J CLIN ONCOL, V37, P1370, DOI 10.1200/JCO.18.02236
   Si H, 2021, CLIN CANCER RES, V27, P1631, DOI 10.1158/1078-0432.CCR-20-3771
   Siena S, 2018, ANN ONCOL, V29, P119, DOI 10.1093/annonc/mdx504
   Silva R, 2020, EPIGENETICS-US, V15, P715, DOI 10.1080/15592294.2020.1712876
   Siravegna G, 2019, CLIN CANCER RES, V25, P3046, DOI 10.1158/1078-0432.CCR-18-3389
   Siravegna G, 2018, CANCER CELL, V34, P148, DOI 10.1016/j.ccell.2018.06.004
   Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255
   Sivapalan L, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2022-005924
   Smith CG, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00723-8
   Soave A, 2017, INT J CANCER, V140, P381, DOI 10.1002/ijc.30445
   Soekmadji C, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1809766
   Sorber L, 2017, LUNG CANCER, V107, P100, DOI 10.1016/j.lungcan.2016.04.026
   Sorber L, 2020, MOL DIAGN THER, V24, P113, DOI 10.1007/s40291-019-00442-w
   Sorber L, 2017, J MOL DIAGN, V19, P162, DOI 10.1016/j.jmoldx.2016.09.009
   SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67
   Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137
   Sozzi G, 1999, CLIN CANCER RES, V5, P2689
   Sparano JA, 2018, NEW ENGL J MED, V379, P111, DOI 10.1056/NEJMoa1804710
   Springer SU, 2018, ELIFE, V7, DOI 10.7554/eLife.32143
   Srivastava AK, 2014, TUMOR BIOL, V35, P11435, DOI 10.1007/s13277-014-2474-z
   Stevens GL, 1996, CANCER EPIDEM BIOMAR, V5, P293
   Subbiah V, 2020, LANCET ONCOL, V21, P1234, DOI 10.1016/S1470-2045(20)30321-1
   Svedman FC, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0206942
   Swinkels DW, 2003, CLIN CHEM, V49, P525, DOI 10.1373/49.3.525
   Swisher EM, 2005, AM J OBSTET GYNECOL, V193, P662, DOI 10.1016/j.ajog.2005.01.054
   Taieb J, 2019, ANN ONCOL, V30, P867
   Tang HK, 2013, MOL MED REP, V7, P761, DOI 10.3892/mmr.2012.1254
   Tarazona N, 2019, ANN ONCOL, V30, P1804, DOI 10.1093/annonc/mdz390
   Taylor DD, 2008, GYNECOL ONCOL, V110, P13, DOI 10.1016/j.ygyno.2008.04.033
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Thierry AR, 2017, ANN ONCOL, V28, P2149, DOI 10.1093/annonc/mdx330
   Tian F, 2017, INT J BIOL MARKER, V32, pE434, DOI 10.5301/ijbm.5000288
   Tie J, 2021, INT J CANCER, V148, P1014, DOI 10.1002/ijc.33312
   Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219
   Tito C, 2021, GENES-BASEL, V12, DOI 10.3390/genes12081154
   Tivey A, 2022, NAT REV CLIN ONCOL, V19, P600, DOI 10.1038/s41571-022-00660-y
   Trapp E, 2019, JNCI-J NATL CANCER I, V111, P380, DOI 10.1093/jnci/djy152
   Tsao SCH, 2015, SCI REP-UK, V5, DOI 10.1038/srep11198
   Tsui MDWY, 2020, CLIN CHEM, V66, P408, DOI 10.1093/clinchem/hvaa010
   Turner NC, 2020, LANCET ONCOL, V21, P1296, DOI [10.11016/S1470-2045(20)30444-7, 10.1016/S1470-2045(20)30444-7]
   Tutrone R, 2020, PROSTATE CANCER P D, V23, P607, DOI 10.1038/s41391-020-0237-z
   Maheswari TNU, 2020, BRAZ ORAL RES, V34, DOI 10.1590/1807-3107bor-2020.vol34.0002
   Umetani N, 2006, CLIN CHEM, V52, P1062, DOI 10.1373/clinchem.2006.068577
   Van Dalum G, 2015, INT J ONCOL, V46, P1361, DOI 10.3892/ijo.2015.2824
   van Dam L, 2013, EUR J CANCER, V49, P2321, DOI 10.1016/j.ejca.2013.03.007
   van der Pol Y, 2019, CANCER CELL, V36, P350, DOI 10.1016/j.ccell.2019.09.003
   Váraljai R, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00229
   Vétizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329
   Vidal J, 2017, ANN ONCOL, V28, P1325, DOI 10.1093/annonc/mdx125
   Vidal J, 2021, CLIN CANCER RES, V27, P2890, DOI 10.1158/1078-0432.CCR-20-4769
   Vinik Y, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aba5714
   Wan JCM, 2017, NAT REV CANCER, V17, P223, DOI 10.1038/nrc.2017.7
   Wang XJ, 2017, BIOMARKERS, V22, P654, DOI 10.1080/1354750X.2016.1269202
   Wang XS, 2019, BMC IMMUNOL, V20, DOI 10.1186/s12865-018-0285-5
   Wang YX, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aap8793
   Wang YX, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa8507
   Wang ZC, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317709990
   Wei F, 2014, AM J RESP CRIT CARE, V190, P1117, DOI 10.1164/rccm.201406-1003OC
   Wen PY, 2022, LANCET ONCOL, V23, P53, DOI 10.1016/S1470-2045(21)00578-7
   Whitman EJ, 2008, J UROLOGY, V180, P1975, DOI 10.1016/j.juro.2008.07.060
   Willis J, 2019, CLIN CANCER RES, V25, P7035, DOI 10.1158/1078-0432.CCR-19-1324
   Witwer KW, 2013, J EXTRACELL VESICLES, V2, DOI 10.3402/jev.v2i0.20360
   WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x
   Wu CW, 2012, GUT, V61, P739, DOI 10.1136/gut.2011.239236
   Wu LR, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6037-y
   Wu W, 2017, CANCERS, V9, DOI 10.3390/cancers9120164
   Xia L, 2022, CLIN CANCER RES, V28, P3308, DOI 10.1158/1078-0432.CCR-21-3044
   Xie F, 2018, CLIN TRANSL ONCOL, V20, P591, DOI 10.1007/s12094-017-1754-7
   Xu XJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.00814
   Yang JS, 2021, CANCER COMMUN, V41, P1257, DOI 10.1002/cac2.12204
   Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444
   Youssef O, 2017, WORLD J GASTROENTERO, V23, P8291, DOI 10.3748/wjg.v23.i47.8291
   Yu FY, 2021, COMPUT STRUCT BIOTEC, V19, P4931, DOI 10.1016/j.csbj.2021.08.037
   Yu HY, 2020, CANCER BIOMARK, V27, P29, DOI 10.3233/CBM-182344
   Yuvaraj M, 2014, J PHOTOCH PHOTOBIO B, V130, P153, DOI 10.1016/j.jphotobiol.2013.11.006
   Zahran F, 2015, ORAL DIS, V21, P739, DOI 10.1111/odi.12340
   Zaman A, 2019, CANCERS, V11, DOI 10.3390/cancers11081197
   Zapico A, 2005, EUR J OBSTET GYN R B, V119, P114, DOI 10.1016/j.ejogrb.2004.07.017
   Zhang RY, 2021, J UROLOGY, V206, P873, DOI 10.1097/JU.0000000000001878
   Zhao SY, 2018, CELL PHYSIOL BIOCHEM, V47, P2511, DOI 10.1159/000491624
   Zhao ZT, 2022, CANCERS, V14, DOI 10.3390/cancers14010065
   Zhong YM, 2021, ANN LAB MED, V41, P25, DOI 10.3343/alm.2021.41.1.25
   Zhu JW, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01588-8
   Zimmermann BG, 2007, ANN NY ACAD SCI, V1098, P184, DOI 10.1196/annals.1384.002
   Zuo ZG, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20194306
NR 384
TC 14
Z9 13
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD AUG 4
PY 2023
VL 42
IS 1
AR 193
DI 10.1186/s13046-023-02743-9
PG 43
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA O2YT8
UT WOS:001042534000001
PM 37542343
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Xu, N
   Zhang, ZH
   Zhu, J
   Xu, L
   Li, YH
   Duan, L
   Mao, Y
   Li, HX
AF Xu, Ning
   Zhang, Zhihong
   Zhu, Jin
   Xu, Lu
   Li, Yuhua
   Duan, Lei
   Mao, Yuan
   Li, Hongxia
TI Overexpression of trophoblast cell surface antigen 2 as an independent
   marker for a poor prognosis and as a potential therapeutic target in
   epithelial ovarian carcinoma
SO INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY
LA English
DT Article
DE biomarker targeted therapy; epithelial ovarian cancer;
   immunohistochemistry; independent prognostic marker; TROP2
ID SACITUZUMAB GOVITECAN IMMU-132; COLORECTAL-CANCER; PANCREATIC-CANCER;
   TROP2 EXPRESSION; CONJUGATE; ANTIBODY; RESISTANCE; TRIAL; RNA
AB Most patients with epithelial ovarian cancer (EOC) are diagnosed at an advanced stage, and therapeutic options for these patients are limited. The identification of suitable biomarkers could be helpful for patients with EOC, who might benefit from targeted therapies even in advanced stages of the disease. Trophoblast cell surface antigen 2 (TROP2) is highly expressed in various human malignant tumours; however, this has not been demonstrated clearly in EOC. In this study, we further evaluated whether TROP2 is a promising marker for EOC, and thus also a potential target for EOC immunotherapy. Quantitative real-time polymerase chain reaction (qPCR) and fluorescence-activated cell sorting (FACS) analysis were employed to determine TROP2 mRNA and protein expression in both human EOC and normal ovarian cell lines. Additionally, TROP2 protein expression was measured by immunohistochemistry in 128 EOC tissue samples, 21 normal ovarian tissues and 18 normal fallopiantubes. The correlations between TROP2 protein expression and patients' clinicopathological features were investigated, and survival outcomes were analysed. TROP2 mRNA and protein levels were upregulated significantly in EOC cell lines compared with normal cell lines. The protein of TROP2 was expressed in the majority of EOC tissue samples (90.6%) and overexpressed in 75 (58.6%) of the 128 tumour samples. TROP2 overexpression was correlated with relevant clinicopathological characteristics and was associated with significantly shortened overall survival and disease-free survival. Furthermore, TROP2 was an independent prognostic marker for EOCs as analysed by Cox regression. TROP2 was a potential biomarker for targeted therapy in patients with TROP2-overexpressing EOC.
C1 [Xu, Ning; Xu, Lu; Li, Yuhua; Duan, Lei] Nanjing Med Univ, Nanjing, Jiangsu, Peoples R China.
   [Zhang, Zhihong; Li, Hongxia] Nanjing Med Univ, Affiliated Hosp 1, Nanjing, Jiangsu, Peoples R China.
   [Zhu, Jin] Huadong Med Insitute Biotech, Nanjing, Jiangsu, Peoples R China.
   [Mao, Yuan] Jiangsu Prov Hosp, Nanjing, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University
RP Xu, N (corresponding author), Nanjing Med Univ, Pathol, 140 Hanzhong Rd, Nanjing 210029, Jiangsu, Peoples R China.; Li, HX (corresponding author), Nanjing Med Univ, Pathol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Jiangsu, Peoples R China.
EM xuning@njmu.edu.cn; susangsq2011@hotmail.com
FU Natural Science Foundation of Jiangsu Province [BK20130895]; Natural
   Science Research Program for Colleges and Universities in Jiangsu
   Province [11KJB320006]; National Natural Science Foundation of China
   [NSFC 81201703]; Priority Academic Program Development of Jiangsu Higher
   Education Institutions [JX10231801]
FX This work was supported by the Grant of Natural Science Foundation of
   Jiangsu Province (BK20130895), the Natural Science Research Program for
   Colleges and Universities in Jiangsu Province (11KJB320006) as well as
   the National Natural Science Foundation of China (NSFC 81201703); also
   the project was funded by the Priority Academic Program Development of
   Jiangsu Higher Education Institutions (JX10231801).
CR Auersperg N, 2001, ENDOCR REV, V22, P255, DOI 10.1210/er.22.2.255
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Ben-Neriah Y, 2011, NAT IMMUNOL, V12, P715, DOI 10.1038/ni.2060
   Bignotti E, 2010, EUR J CANCER, V46, P944, DOI 10.1016/j.ejca.2009.12.019
   Cannistra SA, 2004, NEW ENGL J MED, V351, P2519, DOI 10.1056/NEJMra041842
   Cardillo TM, 2015, BIOCONJUGATE CHEM, V26, P919, DOI 10.1021/acs.bioconjchem.5b00223
   Carlson JW, 2008, J CLIN ONCOL, V26, P4160, DOI 10.1200/JCO.2008.16.4814
   Coleman RL, 2013, NAT REV CLIN ONCOL, V10, P211, DOI 10.1038/nrclinonc.2013.5
   Crum CP, 2009, MOL ONCOL, V3, P165, DOI 10.1016/j.molonc.2009.01.004
   Cubas R, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-253
   Cubas R, 2009, BBA-REV CANCER, V1796, P309, DOI 10.1016/j.bbcan.2009.08.001
   Fang YJ, 2009, INT J COLORECTAL DIS, V24, P875, DOI 10.1007/s00384-009-0725-z
   Foley OW, 2013, ONCOLOGY-NY, V27, P288
   Fong D, 2008, BRIT J CANCER, V99, P1290, DOI 10.1038/sj.bjc.6604677
   Fong D, 2008, MODERN PATHOL, V21, P186, DOI 10.1038/modpathol.3801001
   FORNARO M, 1995, INT J CANCER, V62, P610, DOI 10.1002/ijc.2910620520
   Goldenberg DM, 2015, ONCOTARGET, V6, P22496, DOI 10.18632/oncotarget.4318
   Govindan SV, 2004, BREAST CANCER RES TR, V84, P173, DOI 10.1023/B:BREA.0000018417.02580.ef
   Iacobuzio-Donahue CA, 2002, AM J PATHOL, V160, P1239, DOI 10.1016/S0002-9440(10)62551-5
   KARLAN BY, 1994, GYNECOL ONCOL, V53, P70
   Lage Hermann, 2007, V176, P51
   Lin H, 2013, EXP MOL PATHOL, V94, P73, DOI 10.1016/j.yexmp.2012.08.004
   LIPINSKI M, 1981, P NATL ACAD SCI-BIOL, V78, P5147, DOI 10.1073/pnas.78.8.5147
   MAINESBANDIERA SL, 1992, AM J OBSTET GYNECOL, V167, P729, DOI 10.1016/S0002-9378(11)91579-8
   Materna V, 2005, INT J CANCER, V115, P393, DOI 10.1002/ijc.20899
   Ng JS, 2012, BEST PRACT RES CL OB, V26, P337, DOI 10.1016/j.bpobgyn.2011.12.005
   Ohmachi T, 2006, CLIN CANCER RES, V12, P3057, DOI 10.1158/1078-0432.CCR-05-1961
   Ripani E, 1998, INT J CANCER, V76, P671
   Siegel R, 2011, CA-CANCER J CLIN, V61, P212, DOI 10.3322/caac.20121
   Starodub AN, 2015, CLIN CANCER RES, V21, P3870, DOI 10.1158/1078-0432.CCR-14-3321
   Sukhthankar M, 2010, ANTICANCER RES, V30, P2497
   Tang ZY, 2015, ONCOL REP, V33, P1411, DOI 10.3892/or.2015.3742
   Varughese J, 2011, CANCER-AM CANCER SOC, V117, P3163, DOI 10.1002/cncr.25891
   Vincenzi B, 2006, BRIT J CANCER, V94, P792, DOI 10.1038/sj.bjc.6603018
   Wang JB, 2008, MOL CANCER THER, V7, P280, DOI 10.1158/1535-7163.MCT-07-2003
   Wu H, 2013, HEAD NECK-J SCI SPEC, V35, P1373, DOI 10.1002/hed.23138
NR 36
TC 25
Z9 27
U1 2
U2 15
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0959-9673
EI 1365-2613
J9 INT J EXP PATHOL
JI Int. J. Exp. Pathol.
PD APR
PY 2016
VL 97
IS 2
BP 150
EP 158
DI 10.1111/iep.12174
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA DR2ZY
UT WOS:000379773600007
PM 27127000
OA Green Published
DA 2025-01-04
ER

PT J
AU Meng, WJ
   Pan, L
   Huang, L
   Li, Q
   Sun, Y
AF Meng, Wenjun
   Pan, Lu
   Huang, Li
   Li, Qing
   Sun, Yi
TI Applications of image-guided locoregional transarterial chemotherapy in
   patients with inoperable colorectal cancer: a review
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE transarterial chemotherapy; chemoembolization; colorectal cancer;
   neoadjuvant therapy; comprehensive treatment
ID HEPATIC ARTERIAL INFUSION; PLUS SYSTEMIC CHEMOTHERAPY; QUALITY-OF-LIFE;
   LIVER METASTASES; HEPATOCELLULAR-CARCINOMA; PUMP CHEMOTHERAPY; TARGETED
   THERAPY; PRIMARY TUMOR; CHEMOEMBOLIZATION; RESECTION
AB With the development of comprehensive treatment, locoregional transarterial chemotherapy has become an alternative conversion therapy, palliative therapy, and neoadjuvant therapy for many solid malignant tumors. Locoregional transarterial chemotherapy, which is most frequently used for treating liver cancer, has the characteristics of high regional efficacy and few systemic adverse reactions. In recent years, the number of relevant reports of locoregional chemotherapy for treating initially inoperable colorectal cancer (CRC), including non-metastatic and metastatic CRC, has gradually increased. However, the specific treatment options for such locoregional therapy are not the same, and its indications, medication regimens and combined treatments have not reached any consensus. In this review, the application status of locoregional transarterial chemotherapy in primary and metastatic CRC patients has been reviewed and summarized to provide a reference for future clinical work and scientific research.
C1 [Meng, Wenjun; Pan, Lu; Huang, Li; Li, Qing] Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Peoples R China.
   [Meng, Wenjun] Sichuan Univ, West China Sch Med, Chengdu, Peoples R China.
   [Pan, Lu; Huang, Li] Sichuan Univ, West China Sch Nursing, Chengdu, Peoples R China.
   [Sun, Yi] Air Force Hosp Western Theater Command, Dept Oncol & Hematol, Chengdu, Peoples R China.
C3 Sichuan University; Sichuan University; Sichuan University
RP Li, Q (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Biotherapy, Chengdu, Peoples R China.; Sun, Y (corresponding author), Air Force Hosp Western Theater Command, Dept Oncol & Hematol, Chengdu, Peoples R China.
EM yi_sun307@163.com; liqing@scu.edu.cn
RI Meng, Wenjun/AFV-4993-2022
OI Meng, Wenjun/0000-0002-6780-8720
FU National Natural Science Foundation of China [82203033]; Sichuan Science
   and Technology Program [2023YFS0166, 2022YFQ0095]; National Clinical
   Research Center for Geriatrics, West China Hospital, Sichuan University
   [Z2023JC002]
FX The author(s) declare financial support was received for the research,
   authorship, and/or publication of this article. This work was supported
   by (1) the National Natural Science Foundation of China (82203033); (2)
   the Sichuan Science and Technology Program (2023YFS0166; 2022YFQ0095);
   and (3) the National Clinical Research Center for Geriatrics, West China
   Hospital, Sichuan University (Z2023JC002).r The author(s) declare
   financial support was received for the research, authorship, and/or
   publication of this article. This work was supported by (1) the National
   Natural Science Foundation of China (82203033); (2) the Sichuan Science
   and Technology Program (2023YFS0166; 2022YFQ0095); and (3) the National
   Clinical Research Center for Geriatrics, West China Hospital, Sichuan
   University (Z2023JC002).
CR Adam R, 2009, J CLIN ONCOL, V27, P1829, DOI 10.1200/JCO.2008.19.9273
   Aigner K, 2021, J CLIN MED, V10, DOI 10.3390/jcm10225322
   ALLENMERSH TG, 1994, LANCET, V344, P1255, DOI 10.1016/S0140-6736(94)90750-1
   Ammon JB, 2010, SEMIN ONCOL, V37, P139, DOI 10.1053/j.seminoncol.2010.03.003
   Barault L, 2018, GUT, V67, P1995, DOI 10.1136/gutjnl-2016-313372
   Basra M, 2024, CUREUS J MED SCIENCE, V16, DOI 10.7759/cureus.60696
   Bedri S, 2019, HUM VACC IMMUNOTHER, V15, P603, DOI 10.1080/21645515.2018.1543525
   Bi YH, 2022, WORLD J SURG ONCOL, V20, DOI 10.1186/s12957-022-02696-x
   Bi YH, 2021, ABDOM RADIOL, V46, P2833, DOI 10.1007/s00261-020-02877-w
   Bini R, 2016, ONCOTARGET, V7, P45275, DOI 10.18632/oncotarget.9940
   Bini R, 2015, TUMORI J, V101, pE82, DOI 10.5301/tj.5000270
   Boilève A, 2020, EUR J CANCER, V138, P89, DOI 10.1016/j.ejca.2020.07.022
   Bouchahda M, 2011, EUR J CANCER, V47, P2681, DOI 10.1016/j.ejca.2011.06.037
   Braun EM, 1997, EUR J SURG ONCOL, V23, P228, DOI 10.1016/S0748-7983(97)92412-4
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   BREEDIS C, 1954, AM J PATHOL, V30, P969
   Brown DB, 2007, J VASC INTERV RADIOL, V18, P1469, DOI 10.1016/j.jvir.2007.08.027
   Cao F, 2021, J CANCER RES CLIN, V147, P2993, DOI 10.1007/s00432-021-03708-1
   Chang Y, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218165
   Chen C, 2023, EUR REV MED PHARMACO, V27, P4135, DOI 10.26355/eurrev_202305_32322
   Chennavasin P, 2023, INT J SURG CASE REP, V104, DOI 10.1016/j.ijscr.2023.107965
   Chevallier O, 2023, CHIN CLIN ONCOL, V12, DOI 10.21037/cco-22-119
   Chinese College of Surgeons, 2023, Zhonghua Wei Chang Wai Ke Za Zhi, V26, P1, DOI 10.3760/cma.j.cn441530-20221229-00542
   Clark Timothy W I, 2006, Semin Intervent Radiol, V23, P119, DOI 10.1055/s-2006-941442
   Deschamps F, 2011, CARDIOVASC INTER RAD, V34, P973, DOI 10.1007/s00270-010-9996-6
   Dhir M, 2017, ANN SURG ONCOL, V24, P150, DOI 10.1245/s10434-016-5418-6
   Ding XL, 2024, FRONT ONCOL, V14, DOI 10.3389/fonc.2024.1369829
   Ducreux M, 2005, J CLIN ONCOL, V23, P4881, DOI 10.1200/JCO.2005.05.120
   Ensminger WD, 2002, SEMIN ONCOL, V29, P119, DOI 10.1053/sonc.2002.31679
   European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
   Fan YQ, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen-2022-069401
   Feng AW, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.913017
   Ferretti S, 2015, WORLD J SURG, V39, P2052, DOI 10.1007/s00268-015-3034-4
   Fiorentini G, 2020, HEPAT ONCOL, V7, DOI 10.2217/hep-2019-0010
   Fiorentini G, 2012, ANTICANCER RES, V32, P1387
   Gaba RC, 2017, J VASC INTERV RADIOL, V28, P1210, DOI 10.1016/j.jvir.2017.04.025
   Gao L, 2019, DRUG DELIV, V26, P1049, DOI 10.1080/10717544.2019.1676842
   Gao L, 2019, DRUG DELIV, V26, P208, DOI 10.1080/10717544.2019.1574938
   Gao YS., 2013, Shijie Huaren Xiaohua Zazhi, V21, P367, DOI [10.11569/wcjd.v21.i4.367, DOI 10.11569/WCJD.V21.I4.367]
   Georgilis E, 2023, J CLIN MED, V12, DOI 10.3390/jcm12062401
   Gholami S, 2020, ANN SURG, V272, P352, DOI 10.1097/SLA.0000000000003248
   Guan Yong-Song, 2012, ISRN Gastroenterol, V2012, P480650, DOI 10.5402/2012/480650
   Guo JH, 2017, WORLD J GASTROENTERO, V23, P1406, DOI 10.3748/wjg.v23.i8.1406
   He MK, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0251-2
   Helmberger T, 2022, J CLIN MED, V11, DOI 10.3390/jcm11206178
   Hu C, 2023, SCI BULL, V68, P653, DOI 10.1016/j.scib.2023.03.011
   Huang WP, 2023, BMJ OPEN, V13, DOI 10.1136/bmjopen-2023-075023
   Huang WP, 2019, ONCOL RES TREAT, V42, P678, DOI 10.1159/000502802
   Irizato M, 2023, INTERV RADIOL, V8, P92, DOI 10.22575/interventionalradiology.2022-0026
   Ito K, 2012, ANN SURG ONCOL, V19, P1609, DOI 10.1245/s10434-011-2102-8
   Ji Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14869-x
   Jiang HL, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.986728
   Johnson D, 2024, CANCER TREAT REV, V125, DOI 10.1016/j.ctrv.2024.102700
   Kanat O, 2012, J GASTROINTEST ONCOL, V3, P130, DOI 10.3978/j.issn.2078-6891.2011.025
   Kemeny NE, 2009, J CLIN ONCOL, V27, P3465, DOI 10.1200/JCO.2008.20.1301
   Kemeny NE, 2006, J CLIN ONCOL, V24, P1395, DOI 10.1200/JCO.2005.03.8166
   Khorsandi K, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1100-y
   Kim JS, 2023, BMC CANCER, V23, DOI 10.1186/s12885-023-11085-w
   Kim SI, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003987
   Kimura H, 2003, HEPATO-GASTROENTEROL, V50, P1393
   Kobayashi S, 2020, CANCERS, V12, DOI 10.3390/cancers12092596
   Koerkamp BG, 2017, J CLIN ONCOL, V35, P1938, DOI 10.1200/JCO.2016.71.8346
   Lewandowski RJ, 2011, RADIOLOGY, V259, P641, DOI 10.1148/radiol.11081489
   Lewis AL, 2011, EXPERT OPIN DRUG DEL, V8, P153, DOI 10.1517/17425247.2011.545388
   Li HT, 2023, BMC CANCER, V23, DOI 10.1186/s12885-023-11350-y
   Li JN, 2020, WORLD J GASTRO ONCOL, V12, DOI 10.4251/wjgo.v12.i4.365
   Li YR, 2022, BIOENGINEERED, V13, P10827, DOI 10.1080/21655979.2022.2065800
   Li ZY, 2020, WORLD J GASTROENTERO, V26, P2388, DOI 10.3748/wjg.v26.i19.2388
   Lin HQ, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957-021-02251-0
   Liu HY, 2024, CHINESE J CANCER RES, V36, DOI 10.21147/j.issn.1000-9604.2024.02.06
   Liu YW, 2024, VIS COMPUT IND BIOME, V7, DOI 10.1186/s42492-024-00167-6
   Long GB, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000020745
   Malagari K, 2023, CARDIOVASC INTER RAD, V46, P880, DOI 10.1007/s00270-023-03446-6
   Malka D, 2023, EUR J CANCER, V195, DOI 10.1016/j.ejca.2023.113400
   Maraj T, 2023, J VASC INTERV RADIOL, V34, DOI 10.1016/j.jvir.2023.02.005
   Mauri G, 2018, CARDIOVASC INTER RAD, V41, P1708, DOI 10.1007/s00270-018-2017-x
   Meng WJ, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1201544
   Meng WJ, 2021, J SURG ONCOL, V124, P1451, DOI 10.1002/jso.26673
   Meng WJ, 2021, ANN PALLIAT MED, V10, P9281, DOI 10.21037/apm-21-1881
   Mikhail AS, 2021, EXPERT OPIN DRUG DEL, V18, P383, DOI 10.1080/17425247.2021.1835858
   Ouyang HQ, 2023, CLIN COLORECTAL CANC, V22, P111, DOI 10.1016/j.clcc.2022.10.007
   Owen M, 2023, CANCERS, V15, DOI 10.3390/cancers15082384
   Peng D, 2022, FRONT SURG, V9, DOI 10.3389/fsurg.2022.1004064
   Pinato DJ, 2024, CLIN CANCER RES, V30, P2433, DOI 10.1158/1078-0432.CCR-24-0177
   Poon RTP, 2002, ANN SURG, V235, P466, DOI 10.1097/00000658-200204000-00004
   Przystupski D, 2019, NUTRIENTS, V11, DOI 10.3390/nu11061426
   Qi XS, 2016, ONCOTARGET, V7, P34703, DOI 10.18632/oncotarget.9157
   Randrian V, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.830595
   Ren YQ, 2020, ABDOM RADIOL, V45, P2862, DOI 10.1007/s00261-020-02584-6
   Rigaulta E, 2023, CANCER TREAT RES COM, V34, DOI 10.1016/j.ctarc.2022.100674
   Rouyer M, 2018, CLIN COLORECTAL CANC, V17, P129, DOI 10.1016/j.clcc.2018.01.007
   Sakai H, 2001, CATHETER CARDIO INTE, V54, P204, DOI 10.1002/ccd.1268.abs
   Scherman P, 2021, EJSO-EUR J SURG ONC, V47, P375, DOI 10.1016/j.ejso.2020.07.030
   Shirono T, 2022, HEPATOL COMMUN, V6, P2594, DOI 10.1002/hep4.2016
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7, DOI 10.3322/caac.21332
   Sperling J, 2013, CLIN EXP METASTAS, V30, P447, DOI 10.1007/s10585-012-9550-9
   Sperling J, 2012, CLIN EXP METASTAS, V29, P91, DOI 10.1007/s10585-011-9432-6
   Sun Y, 2022, WORLD J SURG ONCOL, V20, DOI 10.1186/s12957-022-02859-w
   Szemitko M, 2021, J CLIN MED, V10, DOI 10.3390/jcm10010121
   Tellez C, 1998, CANCER, V82, P1250, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1250::AID-CNCR7>3.0.CO;2-J
   Valderrama-Trevino Alan I, 2017, Euroasian J Hepatogastroenterol, V7, P166, DOI 10.5005/jp-journals-10018-1241
   Voizard N, 2022, CURR ONCOL, V29, P209, DOI 10.3390/curroncol29010020
   Walker BS, 2022, J SURG ONCOL, V126, P513, DOI 10.1002/jso.26911
   Wang L, 2020, ONCOTARGETS THER, V13, P8451, DOI 10.2147/OTT.S263858
   Wei N, 2019, CLIN TRANSL ONCOL, V21, P443, DOI 10.1007/s12094-018-1942-0
   Wieners G, 2009, CARDIOVASC INTER RAD, V32, P937, DOI 10.1007/s00270-009-9597-4
   Winner M, 2013, JAMA SURG, V148, P715, DOI 10.1001/jamasurg.2013.1
   Xiang XS, 2023, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1015962
   Xu J, 2007, ANN SURG, V245, P583, DOI 10.1097/01.sla.0000250453.34507.d3
   Xu JM, 2019, J CANCER RES CLIN, V145, P725, DOI 10.1007/s00432-018-2795-1
   Yang B, 2020, RADIAT ONCOL, V15, DOI 10.1186/s13014-020-01540-4
   Yang W, 2024, CLIN ONCOL-UK, V36, P233, DOI 10.1016/j.clon.2024.01.015
   Yasuno M, 2019, INT J CLIN ONCOL, V24, P516, DOI 10.1007/s10147-018-01393-8
   Zhang HY, 2017, CHINESE J CANCER RES, V29, P36, DOI 10.21147/j.issn.1000-9604.2017.01.05
   Zhang Q, 2023, INT J CANCER, V153, P1885, DOI 10.1002/ijc.34543
   Zhang SW, 2021, J NATL CANCER CTR, V1, P2, DOI 10.1016/j.jncc.2020.12.001
   Zhang Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.628558
   Zhu DX, 2021, ANN SURG, V273, P1066, DOI 10.1097/SLA.0000000000004558
NR 118
TC 0
Z9 0
U1 4
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD AUG 23
PY 2024
VL 14
AR 1464242
DI 10.3389/fonc.2024.1464242
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA E9I6S
UT WOS:001306068100001
PM 39246324
OA gold
DA 2025-01-04
ER

PT J
AU Yang, J
   Ding, SG
AF Yang, Jiong
   Ding, Shigang
TI Engineering L7Ae for RNA-Only Delivery Kill Switch Targeting CMS2 Type
   Colorectal Cancer Cells
SO ACS SYNTHETIC BIOLOGY
LA English
DT Article
DE synthetic circuit; RNA binding protein; MYC; WNT; CRC
ID BETA-CATENIN; C-MYC; CIRCUITS; INHIBITION; CLEAVAGE
AB The lack of specific-targeting therapy to precisely identify and kill malignant cells while sparing others is a great challenge in colorectal cancer (CRC) treatment. In the era of molecular classification of tumors, CRC has been grouped into four Consensus Molecular Subtypes. Accounting for 37% of all types, the CMS2 group (canonical type) shows distinguishing features: WNT and MYC signaling activation. In this study, we designed an RNA-only delivery kill switch to specifically eliminate CMS2 type CRC cells. The sensing and logic processing functions are integrated by the newly engineered L7Ae, which can not only detect the stability of beta-catenin protein and the presence of cytoplasm located Myc/Myc-nick, but also do logic computation. The circuit specifically eliminated HCT-116 cells while sparing other kinds of cells, showing a proof-of-principle approach to precisely target CMS2 type CRC.
C1 [Yang, Jiong; Ding, Shigang] Peking Univ Third Hosp, Dept Gastroenterol, Beijing 100191, Peoples R China.
   [Yang, Jiong; Ding, Shigang] Beijing Key Lab Helicobacter Pylori Infect & Uppe, Beijing 100191, Peoples R China.
C3 Peking University
RP Yang, J; Ding, SG (corresponding author), Peking Univ Third Hosp, Dept Gastroenterol, Beijing 100191, Peoples R China.; Yang, J; Ding, SG (corresponding author), Beijing Key Lab Helicobacter Pylori Infect & Uppe, Beijing 100191, Peoples R China.
EM yangjiong@bjmu.edu.cn; dingshigang222@163.com
OI , Jiong/0000-0001-9698-0338
FU National Natural Science Foundation of China [82003254]
FX This work was supported by the National Natural Science Foundation of
   China (82003254). The authors would like to thank Kaiyu Liu for
   providing technical support in plasmid construction.
CR Ausländer S, 2012, NATURE, V487, P123, DOI 10.1038/nature11149
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brody H, 2015, NATURE, V521, pS1, DOI [10.1038/521S1a, 10.1038/526S1a]
   Carabet LA, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20010120
   Cella F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06825-7
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Conacci-Sorrell M, 2014, GENE DEV, V28, P689, DOI 10.1101/gad.231894.113
   Conacci-Sorrell M, 2010, CELL, V142, P480, DOI 10.1016/j.cell.2010.06.037
   Das S, 2012, CELL REP, V1, P110, DOI 10.1016/j.celrep.2011.12.001
   Dastor M, 2018, ACS SYNTH BIOL, V7, P474, DOI 10.1021/acssynbio.7b00303
   Elzi DJ, 2012, MOL CELL BIOL, V32, P4388, DOI 10.1128/MCB.06023-11
   Gao XJ, 2018, SCIENCE, V361, P1252, DOI 10.1126/science.aat5062
   Grossmann TN, 2012, P NATL ACAD SCI USA, V109, P17942, DOI 10.1073/pnas.1208396109
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Huang L, 2016, J MOL BIOL, V428, P790, DOI 10.1016/j.jmb.2015.09.026
   Iwamoto M, 2010, CHEM BIOL, V17, P981, DOI 10.1016/j.chembiol.2010.07.009
   Kobayashi H, 2004, P NATL ACAD SCI USA, V101, P8414, DOI 10.1073/pnas.0402940101
   Korinek V, 1997, SCIENCE, V275, P1784, DOI 10.1126/science.275.5307.1784
   Kyo S, 2000, NUCLEIC ACIDS RES, V28, P669, DOI 10.1093/nar/28.3.669
   Lee HK, 2007, CANCER RES, V67, P9315, DOI 10.1158/0008-5472.CAN-07-1128
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Lin MW, 2018, NUCLEIC ACIDS RES, V46, DOI 10.1093/nar/gky447
   Liu KY, 2020, ACS SYNTH BIOL, V9, P269, DOI 10.1021/acssynbio.9b00313
   Liu YC, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6393
   Matsuura S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07181-2
   Miller JR, 1997, J CELL BIOL, V139, P229, DOI 10.1083/jcb.139.1.229
   Mircetic J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01688-w
   Mohammadi P, 2017, CELL SYST, V4, P207, DOI 10.1016/j.cels.2017.01.003
   Nan JN, 2019, KOREAN J INTERN MED, V34, P618, DOI 10.3904/kjim.2017.155
   Nolivos S, 2005, NUCLEIC ACIDS RES, V33, P6507, DOI 10.1093/nar/gki962
   Oda K, 2016, RESP RES, V17, DOI 10.1186/s12931-016-0357-0
   Okuyama H, 2010, CANCER RES, V70, P10213, DOI 10.1158/0008-5472.CAN-10-2720
   Ono H, 2020, ACS SYNTH BIOL, V9, P169, DOI 10.1021/acssynbio.9b00343
   Pineda-Lucena A, 2005, J MOL BIOL, V351, P182, DOI 10.1016/j.jmb.2005.05.046
   Polakis P, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a008052
   Satoh K, 2017, P NATL ACAD SCI USA, V114, pE7697, DOI 10.1073/pnas.1710366114
   Scola PM, 2014, J MED CHEM, V57, P1708, DOI 10.1021/jm401840s
   Sedlmayer F, 2018, NAT BIOMED ENG, V2, P399, DOI 10.1038/s41551-018-0215-0
   Shekhawat SS, 2011, CURR OPIN CHEM BIOL, V15, P789, DOI 10.1016/j.cbpa.2011.10.014
   Taxis C, 2009, MOL SYST BIOL, V5, DOI 10.1038/msb.2009.25
   Thomas LR, 2015, MOL CELL, V58, P440, DOI 10.1016/j.molcel.2015.02.028
   Varshavsky A, 1996, P NATL ACAD SCI USA, V93, P12142, DOI 10.1073/pnas.93.22.12142
   Wagner TE, 2018, NAT CHEM BIOL, V14, P1043, DOI 10.1038/s41589-018-0146-9
   Wang J, 1998, GENE DEV, V12, P1769, DOI 10.1101/gad.12.12.1769
   Wei Y, 2019, NAT STRUCT MOL BIOL, V26, P1035, DOI 10.1038/s41594-019-0321-z
   Wroblewska L, 2015, NAT BIOTECHNOL, V33, P839, DOI 10.1038/nbt.3301
   Zhan HJ, 2018, ACS SYNTH BIOL, V7, P1798, DOI 10.1021/acssynbio.8b00202
   Zhan T, 2017, ONCOGENE, V36, P1461, DOI 10.1038/onc.2016.304
   Zhang Q, 2016, AM J TRANSL RES, V8, P4490
NR 49
TC 8
Z9 9
U1 2
U2 9
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 2161-5063
J9 ACS SYNTH BIOL
JI ACS Synth. Biol.
PD MAY 21
PY 2021
VL 10
IS 5
BP 1095
EP 1105
DI 10.1021/acssynbio.0c00612
EA MAY 2021
PG 11
WC Biochemical Research Methods
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA SK2NV
UT WOS:000656057600019
PM 33939419
DA 2025-01-04
ER

PT J
AU An, YC
   Li, XD
   Yao, FJ
   Duan, JH
   Yang, XD
AF An, Yacong
   Li, Xundou
   Yao, Fengjiao
   Duan, Jinhong
   Yang, Xian-Da
TI Novel Complex of PD-L1 Aptamer and Albumin Enhances Antitumor Efficacy
   In Vivo
SO MOLECULES
LA English
DT Article
DE PD-L1; aptamer; albumin; BSA-Apt; cancer; immunotherapy
ID TARGETED-THERAPY; DRUG-DELIVERY; COLON-CANCER; PEMBROLIZUMAB; ANTIBODY;
   NANOPARTICLES; CELLS; DENDRIMERS; SELECTION
AB The PD-1/PD-L1 pathway blockade can generate a good clinical response by reducing immunosuppression and provoking durable antitumor immunity. In addition to antibodies, aptamers can also block the interaction between PD-1 and PD-L1. For the in vivo application, however, free aptamers are usually too small in size and quickly removed from blood via glomerular filtration. To avoid renal clearance of aptamer, we conjugated the PD-L1 aptamer to albumin to form a larger complex (BSA-Apt) and evaluated whether BSA-Apt would enhance the in vivo antitumor efficacy. The PD-L1 aptamer was thiol-modified and conjugated to the amino group of BSA via a SMCC linker. The average size of BSA-Apt was 11.65 nm, which was above the threshold for renal clearance. Functionally, BSA-Apt retained the capability of the PD-L1 aptamer to bind with PDL1-expressing tumor cells. Moreover, both the free aptamer and BSA-Apt augmented the PBMC-induced antitumor cytotoxicity in vitro. Furthermore, BSA-Apt generated a significantly stronger antitumor efficacy than the free PD-L1 aptamer in vivo without raising systemic toxicity. The results indicate that conjugating the PD-L1 aptamer to albumin may serve as a promising strategy to improve the in vivo functionality of the aptamer and that BSA-Apt may have application potential in cancer immunotherapy.
C1 [An, Yacong; Li, Xundou; Yao, Fengjiao; Duan, Jinhong; Yang, Xian-Da] Chinese Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, Beijing 100005, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College
RP Yang, XD (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Inst Basic Med Sci, Beijing 100005, Peoples R China.
EM anyacong@ibms.pumc.edu.cn; lixd1012@163.com; fjyao_1103@126.com;
   jinhong_duan@aliyun.com; ayangmd@hotmail.com
RI Yang, Xianda/G-5132-2018
FU Ministry of Science and Technology [2017YFA0205504]
FX FundingThis research was funded by the Ministry of Science and
   Technology (2017YFA0205504).
CR Ahmadzadeh M, 2009, BLOOD, V114, P1537, DOI 10.1182/blood-2008-12-195792
   An YC, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-43910-3
   Armstrong JK, 2007, CANCER-AM CANCER SOC, V110, P103, DOI 10.1002/cncr.22739
   Bäumer N, 2016, NAT PROTOC, V11, P22, DOI 10.1038/nprot.2015.137
   Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741
   Bellmunt J, 2017, NEW ENGL J MED, V376, P1015, DOI 10.1056/NEJMoa1613683
   Birn H, 2006, KIDNEY INT, V69, P440, DOI 10.1038/sj.ki.5000141
   Burmeister PE, 2005, CHEM BIOL, V12, P25, DOI 10.1016/j.chembiol.2004.10.017
   Callahan MK, 2013, J LEUKOCYTE BIOL, V94, P41, DOI 10.1189/jlb.1212631
   Chatterjee S, 2016, ONCOTARGET, V7, P10215, DOI 10.18632/oncotarget.7143
   Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500
   Chow LQM, 2016, J CLIN ONCOL, V34, P3838, DOI 10.1200/JCO.2016.68.1478
   Daassi D, 2020, NAT REV IMMUNOL, V20, P209, DOI 10.1038/s41577-019-0264-y
   Dias AP, 2020, INT J PHARMACEUT, V573, DOI 10.1016/j.ijpharm.2019.118814
   Dougan H, 2000, NUCL MED BIOL, V27, P289, DOI 10.1016/S0969-8051(99)00103-1
   Eilers A, 2020, ADV BIOCHEM ENG BIOT, V174, P161, DOI 10.1007/10_2020_124
   El-Khoueiry AB, 2017, LANCET, V389, P2492, DOI 10.1016/S0140-6736(17)31046-2
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   Farrugia A, 2010, TRANSFUS MED REV, V24, P53, DOI 10.1016/j.tmrv.2009.09.005
   Ganson NJ, 2006, ARTHRITIS RES THER, V8, DOI 10.1186/ar1861
   Grubczak K, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10082044
   Haruta K, 2017, NUCLEIC ACID THER, V27, P36, DOI 10.1089/nat.2016.0627
   Hershfield MS, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4500
   Hu ZX, 2018, J BIOMED NANOTECHNOL, V14, P1645, DOI 10.1166/jbn.2018.2619
   Ivens IA, 2015, TOXICOL PATHOL, V43, P959, DOI 10.1177/0192623315591171
   Iyer AK, 2006, DRUG DISCOV TODAY, V11, P812, DOI 10.1016/j.drudis.2006.07.005
   Jaffe GJ, 2021, OPHTHALMOLOGY, V128, P576, DOI 10.1016/j.ophtha.2020.08.027
   Jaffe GJ, 2017, OPHTHALMOLOGY, V124, P224, DOI 10.1016/j.ophtha.2016.10.010
   Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596
   Kulabhusan PK, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070646
   Lai WY, 2016, MOL THER-NUCL ACIDS, V5, DOI 10.1038/mtna.2016.102
   Lakhin AV, 2013, ACTA NATURAE, V5, P34, DOI 10.32607/20758251-2013-5-4-34-43
   Lee CH, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.30
   Li T, 2021, MOLECULES, V26, DOI 10.3390/molecules26041067
   Liang JY, 2020, CANCER IMMUNOL RES, V8, P952, DOI 10.1158/2326-6066.CIR-19-0159
   Liang ZD, 2019, CANCER LETT, V447, P164, DOI 10.1016/j.canlet.2019.01.016
   Liu J, 2011, CURR MED CHEM, V18, P4117, DOI 10.2174/092986711797189619
   Mignani S, 2020, DRUG DISCOV TODAY, V25, P1065, DOI 10.1016/j.drudis.2020.03.009
   Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665
   Nasser NJ, 2020, PHARMACEUTICALS-BASE, V13, DOI 10.3390/ph13110373
   Nimjee SM, 2017, ANNU REV PHARMACOL, V57, P61, DOI 10.1146/annurev-pharmtox-010716-104558
   Ohaegbulam KC, 2015, TRENDS MOL MED, V21, P24, DOI 10.1016/j.molmed.2014.10.009
   Prodeus A, 2015, MOL THER-NUCL ACIDS, V4, DOI 10.1038/mtna.2015.11
   Qin L, 2013, J CONTROL RELEASE, V171, P133, DOI 10.1016/j.jconrel.2013.07.005
   Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774
   Rinnerthaler G, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051115
   Robert C, 2018, J CLIN ONCOL, V36, P1668, DOI 10.1200/JCO.2017.75.6270
   Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093
   Rusconi CP, 2004, NAT BIOTECHNOL, V22, P1423, DOI 10.1038/nbt1023
   Shubayev VI, 2009, ADV DRUG DELIVER REV, V61, P467, DOI 10.1016/j.addr.2009.03.007
   Stein CA, 2017, MOL THER, V25, P1069, DOI 10.1016/j.ymthe.2017.03.023
   Steurer M, 2019, HAEMATOLOGICA, V104, P2053, DOI 10.3324/haematol.2018.205930
   Stewart R, 2015, CANCER IMMUNOL RES, V3, P1052, DOI 10.1158/2326-6066.CIR-14-0191
   Svenson S, 2009, EUR J PHARM BIOPHARM, V71, P445, DOI 10.1016/j.ejpb.2008.09.023
   TUERK C, 1990, SCIENCE, V249, P505, DOI 10.1126/science.2200121
   Upadhaya S, 2021, NAT REV DRUG DISCOV, V20, P168, DOI 10.1038/d41573-020-00204-y
   Vaisman-Mentesh A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01951
   van den Bulk J, 2018, OPEN BIOL, V8, DOI 10.1098/rsob.180037
   Willis MC, 1998, BIOCONJUGATE CHEM, V9, P573, DOI 10.1021/bc980002x
   Wrobel D, 2015, BBA-BIOMEMBRANES, V1848, P1490, DOI 10.1016/j.bbamem.2015.03.033
   Yao FJ, 2020, INT J NANOMED, V15, P2119, DOI 10.2147/IJN.S240083
   Yu Z, 2020, INT J NANOMED, V15, P6737, DOI 10.2147/IJN.S267177
   Zamay GS, 2015, MOL THER, V23, P1486, DOI 10.1038/mt.2015.108
   Zhao NX, 2015, BIOMATERIALS, V67, P42, DOI 10.1016/j.biomaterials.2015.07.025
   Zhou G, 2018, ADV DRUG DELIVER REV, V134, P107, DOI 10.1016/j.addr.2018.04.005
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
NR 66
TC 9
Z9 9
U1 10
U2 76
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD MAR
PY 2022
VL 27
IS 5
AR 1482
DI 10.3390/molecules27051482
PG 13
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA ZS0AN
UT WOS:000768136100001
PM 35268583
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Senapati, D
   Patra, BC
   Kar, A
   Chini, DS
   Ghosh, S
   Patra, S
   Bhattacharya, M
AF Senapati, Debabrata
   Patra, Bidhan Chandra
   Kar, Avijit
   Chini, Deep Sankar
   Ghosh, Souniendu
   Patra, Shinjan
   Bhattacharya, Manojit
TI Promising approaches of small interfering RNAs (siRNAs) mediated cancer
   gene therapy
SO GENE
LA English
DT Review
DE RNA interference; siRNA; Gene silencing; Cancer therapy
ID INHIBITS TUMOR-GROWTH; DELIVERY IN-VITRO; OVARIAN-CANCER; COLON-CANCER;
   SYSTEMIC DELIVERY; CRYSTAL-STRUCTURE; ANTICANCER DRUG; HEPATITIS-B;
   MOUSE MODEL; CO-DELIVERY
AB RNA interference (RNAi) has extensive potential to revolutionize every aspect of clinical application in biomedical research. One of the promising tools is the Small interfering RNA (siRNA) molecules within a cellular component. Principally, siRNA mediated innovative advances are increasing rapidly in support of cancer diagnosis and therapeutic purposes. Conversely, it has some delivery challenges to the site of action within the cells of a target organ, due to the progress of nucleic acids engineering and advance material science research contributing to the exceptional organ-specific targeted therapy. This siRNA based therapeutic technique definitely favors a unique and effective prospect to cancer patients. Herein, the significant drive also takes to review and summarize the major organ specific targets of diverse siRNAs based gene silencing mechanism. This machinery promisingly served as the inhibitor components for cancer development in the human model. Furthermore, the focus is also given to current applications on siRNA based quantifiable therapy leading to the silencing of cancer related gene expression in a sequence dependent and selective manner for cancer treatment. That might be a potent tool against the traditional chemotherapy techniques. Therefore, the siRNA mediated cancer gene therapy definitely require sharp attention like future weapons in opposition to cancer by the method of non-invasive siRNA delivery and effective gene silencing approaches.
C1 [Senapati, Debabrata; Patra, Bidhan Chandra; Kar, Avijit; Chini, Deep Sankar; Ghosh, Souniendu; Bhattacharya, Manojit] Vidyasagar Univ, Dept Zool, Midnapore 721102, W Bengal, India.
   [Patra, Shinjan] Midnapore Med Coll & Hosp, Dept Gen Med, Midnapore 721101, W Bengal, India.
C3 Vidyasagar University; Midnapore Medical College
RP Bhattacharya, M (corresponding author), Vidyasagar Univ, Dept Zool, Midnapore 721102, W Bengal, India.
EM pfzf_manojit@mail.vidyasagar.ac.in
RI Patra, Shinjan/JLL-4064-2023; Bhattacharya, Manojit/A-2027-2012
OI CHINI, DEEP SANKAR/0000-0003-3289-0506; Bhattacharya,
   Manojit/0000-0001-9669-1835; Patra, Shinjan/0000-0003-1527-2722
FU Department of Science and Technology, Govt. of India
   [SEED/WTP/059/2014/G]
FX This research work is supported by the Department of Science and
   Technology, Govt. of India under the SEED sponsored project (Ref:
   SEED/WTP/059/2014/G).
CR Aagaard L, 2007, ADV DRUG DELIVER REV, V59, P75, DOI 10.1016/j.addr.2007.03.005
   Arbuthnot P, 2007, J VIRAL HEPATITIS, V14, P447, DOI 10.1111/j.1365-2893.2006.00818.x
   Birmingham A, 2006, NAT METHODS, V3, P199, DOI 10.1038/NMETH854
   Bisanz K, 2005, MOL THER, V12, P634, DOI 10.1016/j.ymthe.2005.05.012
   Bumcrot D, 2006, NAT CHEM BIOL, V2, P711, DOI 10.1038/nchembio839
   Chien PY, 2005, CANCER GENE THER, V12, P321, DOI 10.1038/sj.cgt.7700793
   Dallas A, 2006, MED SCI MONITOR, V12, pRA67
   Deng ZJ, 2013, ACS NANO, V7, P9571, DOI 10.1021/nn4047925
   Doi N, 2003, CURR BIOL, V13, P41, DOI 10.1016/S0960-9822(02)01394-5
   Elbashir SM, 2001, GENE DEV, V15, P188, DOI 10.1101/gad.862301
   Fedorov Y, 2006, RNA, V12, P1188, DOI 10.1261/rna.28106
   Filleur S, 2003, CANCER RES, V63, P3919
   Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888
   Fujii T, 2006, INT J ONCOL, V29, P541
   Goldberg MS, 2011, P NATL ACAD SCI USA, V108, P745, DOI 10.1073/pnas.1016538108
   Golzio M, 2007, GENE THER, V14, P752, DOI 10.1038/sj.gt.3302920
   Grzelinski M, 2006, HUM GENE THER, V17, P751, DOI 10.1089/hum.2006.17.751
   Halder J, 2006, CLIN CANCER RES, V12, P4916, DOI 10.1158/1078-0432.CCR-06-0021
   Hammond SM, 2000, NATURE, V404, P293, DOI 10.1038/35005107
   He CB, 2014, J AM CHEM SOC, V136, P5181, DOI 10.1021/ja4098862
   He XW, 2008, CANCER GENE THER, V15, P193, DOI 10.1038/sj.cgt.7701122
   Heidel JD, 2007, P NATL ACAD SCI USA, V104, P5715, DOI 10.1073/pnas.0701458104
   Hogrefe RI, 2006, NUCLEOS NUCLEOT NUCL, V25, P889, DOI 10.1080/15257770600793885
   Hornung V, 2005, NAT MED, V11, P263, DOI 10.1038/nm1191
   Hu-Lieskovan S, 2005, CANCER RES, V65, P8984, DOI 10.1158/0008-5472.CAN-05-0565
   Jackson AL, 2006, RNA, V12, P1179, DOI 10.1261/rna.25706
   Jackson AL, 2003, NAT BIOTECHNOL, V21, P635, DOI 10.1038/nbt831
   Jemal A, 2004, CANCER-AM CANCER SOC, V101, P3, DOI 10.1002/cncr.20288
   Jiang JA, 2010, EUR J PHARM BIOPHARM, V76, P170, DOI 10.1016/j.ejpb.2010.06.011
   John M, 2007, NATURE, V449, P745, DOI 10.1038/nature06179
   Judge AD, 2005, NAT BIOTECHNOL, V23, P457, DOI 10.1038/nbt1081
   Jung JJ, 2010, ANGEW CHEM INT EDIT, V49, P103, DOI 10.1002/anie.200905126
   Kenny HA, 2009, CELL CYCLE, V8, P683, DOI 10.4161/cc.8.5.7703
   Kim B, 2004, AM J PATHOL, V165, P2177, DOI 10.1016/S0002-9440(10)63267-1
   Kim DH, 2007, NAT REV GENET, V8, P173, DOI 10.1038/nrg2006
   Kleinman ME, 2008, NATURE, V452, P591, DOI 10.1038/nature06765
   Landen CN, 2006, CANCER BIOL THER, V5, P1708, DOI 10.4161/cbt.5.12.3468
   Landen CN, 2005, CANCER RES, V65, P6910, DOI 10.1158/0008-5472.CAN-05-0530
   Lavigne C, 2007, BIOCHIMIE, V89, P1245, DOI 10.1016/j.biochi.2007.05.002
   Leng QX, 2005, J GENE MED, V7, P977, DOI 10.1002/jgm.748
   Li SD, 2008, MOL THER, V16, P163, DOI 10.1038/sj.mt.6300323
   Li SD, 2006, MOL PHARMACEUT, V3, P579, DOI 10.1021/mp060039w
   Lima RT, 2004, CANCER GENE THER, V11, P309, DOI 10.1038/sj.cgt.7700706
   Lin XY, 2005, NUCLEIC ACIDS RES, V33, P4527, DOI 10.1093/nar/gki762
   Liu CX, 2009, J CONTROL RELEASE, V140, P277, DOI 10.1016/j.jconrel.2009.08.013
   Liu DX, 2007, J CLIN ENDOCR METAB, V92, P2264, DOI 10.1210/jc.2006-1613
   Liu JD, 2004, SCIENCE, V305, P1437, DOI 10.1126/science.1102513
   Loveday C, 2011, NAT GENET, V43, P879, DOI 10.1038/ng.893
   Ma JB, 2005, NATURE, V434, P666, DOI 10.1038/nature03514
   Marques JT, 2005, NAT BIOTECHNOL, V23, P1399, DOI 10.1038/nbt1161
   MCMICHAEL AJ, 1980, J NATL CANCER I, V65, P1201
   Merritt WM, 2008, J NATL CANCER I, V100, P359, DOI 10.1093/jnci/djn024
   Meryet-Figuières M, 2007, BIOCHIMIE, V89, P1228, DOI 10.1016/j.biochi.2007.03.017
   Morrissey DV, 2005, NAT BIOTECHNOL, V23, P1002, DOI 10.1038/nbt1122
   Morrissey DV, 2005, HEPATOLOGY, V41, P1349, DOI 10.1002/hep.20702
   Nakayama N, 2010, CANCER-AM CANCER SOC, V116, P2621, DOI 10.1002/cncr.24987
   Nam NH, 2003, CURR DRUG TARGETS, V4, P159, DOI 10.2174/1389450033346966
   Nishimura M, 2013, CANCER DISCOV, V3, P1302, DOI 10.1158/2159-8290.CD-13-0159
   Pal A, 2005, INT J ONCOL, V26, P1087
   Park YK, 2008, NUCLEIC ACIDS RES, V36, pW97, DOI 10.1093/nar/gkn280
   Parker JS, 2004, EMBO J, V23, P4727, DOI 10.1038/sj.emboj.7600488
   Peng S, 2010, ONCOGENE, V29, P2153, DOI 10.1038/onc.2009.500
   Pine J. Y., 2005, MOL THER J AM SOC GE, V11, P267
   Ren Y., 2012, SCI TRANSL MED, V4, P1
   Rubin MA, 2008, MODERN PATHOL, V21, pS44, DOI 10.1038/modpathol.2008.11
   Santel A, 2006, GENE THER, V13, P1222, DOI 10.1038/sj.gt.3302777
   Schiffelers RM, 2004, NUCLEIC ACIDS RES, V32, DOI 10.1093/nar/gnh140
   Schiffman M, 2007, LANCET, V370, P890, DOI [10.1016/S0140-6736(07)61416-0, 10.1016/S0140-6736(13)60022-7]
   Shah V, 2013, CLIN CANCER RES, V19, P6193, DOI 10.1158/1078-0432.CCR-13-1536
   Shahzad MMK, 2009, CANCER BIOL THER, V8, P1027, DOI 10.4161/cbt.8.11.8523
   Song EW, 2005, NAT BIOTECHNOL, V23, P709, DOI 10.1038/nbt1101
   Song JJ, 2004, SCIENCE, V305, P1434, DOI 10.1126/science.1102514
   Sorensen DR, 2003, J MOL BIOL, V327, P761, DOI 10.1016/S0022-2836(03)00181-5
   Stein Ulrike, 2007, V176, P61
   Stein U, 2009, NAT MED, V15, P59, DOI 10.1038/nm.1889
   Subramaniam V, 2007, EXP MOL PATHOL, V83, P332, DOI 10.1016/j.yexmp.2007.08.013
   Sunters A, 2003, J BIOL CHEM, V278, P49795, DOI 10.1074/jbc.M309523200
   Sutton D, 2006, INT J NANOMED, V1, P155, DOI 10.2147/nano.2006.1.2.155
   Tan WB, 2007, BIOMATERIALS, V28, P1565, DOI 10.1016/j.biomaterials.2006.11.018
   Thaker PH, 2006, NAT MED, V12, P939, DOI 10.1038/nm1447
   Urban-Klein B, 2005, GENE THER, V12, P461, DOI 10.1038/sj.gt.3302425
   Verma UN, 2003, CLIN CANCER RES, V9, P1291
   Wang Y, 2006, NAT MATER, V5, P791, DOI 10.1038/nmat1737
   Xia CF, 2007, PHARM RES, V24, P2309, DOI 10.1007/s11095-007-9460-8
   Xie FY, 2006, DRUG DISCOV TODAY, V11, P67, DOI 10.1016/S1359-6446(05)03668-8
   Yang G, 2003, ONCOGENE, V22, P5694, DOI 10.1038/sj.onc.1206858
   Yano J, 2004, CLIN CANCER RES, V10, P7721, DOI 10.1158/1078-0432.CCR-04-1049
   Yoshizawa T, 2008, EUR J PHARM BIOPHARM, V70, P718, DOI 10.1016/j.ejpb.2008.06.026
   Zhang CL, 2006, J CONTROL RELEASE, V112, P229, DOI 10.1016/j.jconrel.2006.01.022
   Zhang Y, 2004, CLIN CANCER RES, V10, P3667, DOI 10.1158/1078-0432.CCR-03-0740
   Zhang ZH, 2006, CLIN CANCER RES, V12, P4933, DOI 10.1158/1078-0432.CCR-05-2831
   Zimmermann TS, 2006, NATURE, V441, P111, DOI 10.1038/nature04688
NR 92
TC 40
Z9 43
U1 0
U2 81
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD NOV 30
PY 2019
VL 719
AR 144071
DI 10.1016/j.gene.2019.144071
PG 12
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA JB1PG
UT WOS:000488332100001
PM 31454539
DA 2025-01-04
ER

PT J
AU Wrana, F
   Dötzer, K
   Prüfer, M
   Werner, J
   Mayer, B
AF Wrana, Friederike
   Doetzer, Katharina
   Pruefer, Martin
   Werner, Jens
   Mayer, Barbara
TI High Dual Expression of the Biomarkers CD44v6/α2β1 and CD44v6/PD-L1
   Indicate Early Recurrence after Colorectal Hepatic Metastasectomy
SO CANCERS
LA English
DT Article
DE colorectal cancer; liver metastases; lung metastases; protein biomarker;
   dual expression; early recurrence; poor prognosis
ID LIVER METASTASES; COLON-CANCER; PERIOPERATIVE CHEMOTHERAPY; MOLECULAR
   DIFFERENCES; LUNG METASTASES; CELL-ADHESION; PROGNOSIS; SURVIVAL;
   CETUXIMAB; RESECTION
AB Simple Summary Distant metastasis in colorectal cancer still correlates with poor prognosis, emphasizing the high need for new diagnostic and therapeutic strategies. In the present study, liver and lung metastases revealed profound differences in the expression pattern of metastasis-driving protein biomarkers. This suggests the adaption of the therapy to the biology of the metastatic organ site. High expression of the cell adhesion molecule CD44v6 and high dual expression of CD44v6, combined with the cell adhesion molecules integrin alpha 2 beta 1, as well as the checkpoint inhibitor molecule PD-L1, correlated significantly with early recurrence after hepatectomy, in a substantial number of liver metastatic patients. These findings suggest the need for the implementation of biological risk factors into clinical risk scores, aiming to make the prognosis of the individual patient more precise. Further, dual expression of protein biomarkers that are druggable, such as CD44v6/alpha 2 beta 1 and CD44v6/PD-L1, can identify high-risk patients for targeted therapy that might provide a survival benefit. Considering the biology of CRC, distant metastases might support the identification of high-risk patients for early recurrence and targeted therapy. Expression of a panel of druggable, metastasis-related biomarkers was immunohistochemically analyzed in 53 liver (LM) and 15 lung metastases (LuM) and correlated with survival. Differential expression between LM and LuM was observed for the growth factor receptors IGF1R (LuM 92.3% vs. LM 75.8%, p = 0.013), EGFR (LuM 68% vs. LM 41.5%, p = 0.004), the cell adhesion molecules CD44v6 (LuM 55.7% vs. LM 34.9%, p = 0.019) and alpha 2 beta 1 (LuM 88.3% vs. LM 58.5%, p = 0.001) and the check point molecule PD-L1 (LuM 6.1% vs. LM 3.3%, p = 0.005). Contrary, expression of HGFR, Hsp90, Muc1, Her2/neu, ER alpha and PR was comparable in LuM and LM. In the LM cohort (n = 52), a high CD44v6 expression was identified as an independent factor of poor prognosis (PFS: HR 2.37, 95% CI 1.18-4.78, p = 0.016). High co-expression of CD44v6/alpha 2 beta 1 (HR 4.14, 95% CI 1.65-10.38, p = 0.002) and CD44v6/PD-L1 (HR 2.88, 95% CI 1.21-6.85, p = 0.017) indicated early recurrence after hepatectomy, in a substantial number of patients (CD44v6/alpha 2 beta 1: 11 (21.15%) patients; CD44v6/PD-L1: 12 (23.1%) patients). Dual expression of druggable protein biomarkers may refine prognostic prediction and stratify high-risk patients for new therapeutic concepts, depending on the metastatic location.
C1 [Wrana, Friederike; Doetzer, Katharina; Pruefer, Martin; Werner, Jens; Mayer, Barbara] Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplant Surg, Marchioninistr 15, D-81377 Munich, Germany.
   [Werner, Jens; Mayer, Barbara] German Canc Consortium DKTK, Partner Site Munich, Pettenkoferstr 8a, D-80336 Munich, Germany.
C3 University of Munich; Helmholtz Association; German Cancer Research
   Center (DKFZ)
RP Mayer, B (corresponding author), Ludwig Maximilians Univ Munchen, Dept Gen Visceral & Transplant Surg, Marchioninistr 15, D-81377 Munich, Germany.; Mayer, B (corresponding author), German Canc Consortium DKTK, Partner Site Munich, Pettenkoferstr 8a, D-80336 Munich, Germany.
EM friederike.schlueter@med.uni.muenchen.de;
   katharina.doetzer@muenchen-klinik.de; martin.pruefer@dritter-orden.de;
   jens.werner@med.uni-muenchen.de; barbara.mayer@med.uni-muenchen.de
FU German Federal Ministry of Education and Research, Leading Edge Cluster
   m4 [FKZ 16EX1021N]
FX This research was funded by the German Federal Ministry of Education and
   Research, Leading Edge Cluster m4 (B.M.) under Grant FKZ 16EX1021N.
CR Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9
   [Anonymous], 2020, 2020 Exceptional Surveillance of Neutropenic Sepsis: Prevention and Management in People with Cancer (NICE guideline CG151)
   Baran B, 2018, GASTROENTEROL RES, V11, P264, DOI 10.14740/gr1062w
   Benson AB., 2021, J. Natl. Compr. Canc. Netw., V19, P329, DOI DOI 10.6004/JNCCN.2021.0012
   Bhullar DS, 2019, EBIOMEDICINE, V40, P363, DOI 10.1016/j.ebiom.2019.01.050
   Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Chandra R, 2021, CANCERS, V13, DOI 10.3390/cancers13246206
   Chen K, 2014, ONCOL REP, V32, P755, DOI 10.3892/or.2014.3245
   Chen YJ, 2020, ONCOLOGIST, V25, pE1031, DOI 10.1634/theoncologist.2019-0797
   Dai SQ, 2021, GASTROENTEROL REP, V9, P241, DOI 10.1093/gastro/goaa092
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Diener MK, 2021, ANN GASTROENT SURG, V5, P477, DOI 10.1002/ags3.12454
   Dmello RS, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042067
   Dötzer K, 2019, CANCERS, V11, DOI 10.3390/cancers11091250
   Eide PW, 2021, NPJ GENOM MED, V6, DOI 10.1038/s41525-021-00223-7
   Fahrner M, 2021, NEOPLASIA, V23, P1240, DOI 10.1016/j.neo.2021.10.005
   Filip S, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155255
   Gao CJ, 2003, CARCINOGENESIS, V24, P1871, DOI 10.1093/carcin/bgg139
   Gao Y, 2019, DEV CELL, V49, P375, DOI 10.1016/j.devcel.2019.04.012
   García-Mulero S, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000491
   Gonzalez-Zubeldia I, 2015, CELL TISSUE RES, V359, P829, DOI 10.1007/s00441-014-2075-6
   Guerrera F, 2017, INTERACT CARDIOV TH, V24, P789, DOI 10.1093/icvts/ivw389
   Hou SC, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.708779
   Huang JJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047901
   Imyanitov E, 2021, WORLD J GASTRO ONCOL, V13, P1288, DOI 10.4251/wjgo.v13.i10.1288
   Jiang BB, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-27017-w
   Jung T, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.208421
   Kamphues C, 2022, CANCERS, V14, DOI 10.3390/cancers14010088
   Kanemitsu Y, 2021, J CLIN ONCOL, V39, P3789, DOI 10.1200/JCO.21.01032
   Kong J, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1101-4
   Korehisa S, 2018, INT J CANCER, V142, P822, DOI 10.1002/ijc.31107
   Lang HK, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-292
   Lee Y, 2016, CLIN CANCER RES, V22, P3571, DOI 10.1158/1078-0432.CCR-15-2665
   Li C, 2019, GASTROENT RES PRACT, V2019, DOI 10.1155/2019/2391670
   Li YT, 2020, J CANCER RES CLIN, V146, P545, DOI 10.1007/s00432-020-03142-9
   Liang R, 2018, ONCOL LETT, V15, P5933, DOI 10.3892/ol.2018.8011
   Lin CC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.588542
   Lourenco BN, 2021, NANOMATERIALS-BASEL, V11, DOI 10.3390/nano11020295
   Ma LX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1265-7
   Margonis GA, 2018, BRIT J SURG, V105, P1210, DOI 10.1002/bjs.10838
   Martin J, 2020, WORLD J CLIN ONCOL, V11, P761, DOI 10.5306/wjco.v11.i10.761
   Mayer B, 1995, INT J CANCER, V64, P415, DOI 10.1002/ijc.2910640611
   Naba A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-518
   Naci D, 2015, SEMIN CANCER BIOL, V35, P145, DOI 10.1016/j.semcancer.2015.08.004
   Nagai S, 2006, J THORAC ONCOL, V1, P46, DOI 10.1097/01243894-200601000-00010
   Nordlinger B, 2013, LANCET ONCOL, V14, P1208, DOI 10.1016/S1470-2045(13)70447-9
   Oliveira AF, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00396
   Oliveres H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22095019
   Ooki A, 2021, J ANUS RECTUM COLON, V5, P11, DOI 10.23922/jarc.2020-064
   Passot G, 2018, ANN SURG ONCOL, V25, P179, DOI 10.1245/s10434-017-6141-7
   Peinado H, 2017, NAT REV CANCER, V17, P302, DOI 10.1038/nrc.2017.6
   Pereira C, 2020, CANCERS, V12, DOI 10.3390/cancers12040858
   Porcellini S, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00099
   Pretzsch E, 2019, J ONCOL, V2019, DOI 10.1155/2019/7407190
   Puccini A, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00230-y
   Riihimäki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Rüschoff J, 2010, VIRCHOWS ARCH, V457, P299, DOI 10.1007/s00428-010-0952-2
   Schlueter F., 2021, J CANC SCI CLIN THER, V5, P49, DOI [10.26502/jcsct.5079100, DOI 10.26502/JCSCT.5079100]
   Shek D, 2021, CANCERS, V13, DOI 10.3390/cancers13174345
   Sieh W, 2013, LANCET ONCOL, V14, P853, DOI 10.1016/S1470-2045(13)70253-5
   Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100
   Strickler JH, 2021, ONCOLOGIST, V26, P465, DOI 10.1002/onco.13678
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Takahashi Y, 2016, INT J CANCER, V139, P2493, DOI 10.1002/ijc.30377
   Testa U, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8100414
   Ueda A, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0184123
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Vigano L, 2021, CANCERS, V13, DOI 10.3390/cancers13030464
   Viganò L, 2014, ANN SURG ONCOL, V21, P1276, DOI 10.1245/s10434-013-3421-8
   Wang JL, 2017, ONCOTARGET, V8, P12866, DOI 10.18632/oncotarget.14163
   Wang ZH, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-21-2221
   Welch DR, 2019, CANCER RES, V79, P3011, DOI 10.1158/0008-5472.CAN-19-0458
   Wolff AC, 2018, ARCH PATHOL LAB MED, V142, P1364, DOI 10.5858/arpa.2018-0902-SA
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xue XL, 2017, INT J CLIN EXP PATHO, V10, P11353
   Ye SB, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5918-4
   Yong ZZH, 2020, J SURG RES, V246, P325, DOI 10.1016/j.jss.2018.11.025
   Zeng YH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138049
   Zhang SM, 2019, PEERJ, V7, DOI 10.7717/peerj.7946
NR 79
TC 7
Z9 7
U1 1
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD APR
PY 2022
VL 14
IS 8
AR 1939
DI 10.3390/cancers14081939
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 0R1MF
UT WOS:000785367700001
PM 35454846
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Ma, YS
   Liu, JB
   Yang, XL
   Xin, R
   Shi, Y
   Zhang, DD
   Wang, HM
   Wang, PY
   Lin, QL
   Li, W
   Fu, D
AF Ma, Yu-Shui
   Liu, Ji-Bin
   Yang, Xiao-Li
   Xin, Rui
   Shi, Yi
   Zhang, Dan-Dan
   Wang, Hui-Min
   Wang, Pei-Yao
   Lin, Qin-Lu
   Li, Wen
   Fu, Da
TI Basic approaches, challenges and opportunities for the discovery of
   small molecule anti-tumor drugs
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Review
DE Drug therapy; cancer; inhibitor; comprehensive utilization
ID COLORECTAL-CANCER PROGRESSION; LONG NONCODING RNA; PROMOTES
   CELL-PROLIFERATION; TARGETED THERAPY; STEM-CELLS; RESISTANCE;
   EXPRESSION; GENE; OSTEOSARCOMA; ACTIVATION
AB Chemotherapy is one of the main treatments for cancer, especially for advanced cancer patients. In the past decade, significant progress has been made with the research into the molecular mechanisms of cancer cells and the precision medicine. The treatment on cancer patients has gradually changed from cytotoxic chemotherapy to precise treatment strategy. Research into anticancer drugs has also changed from killing effects on all cells to targeting drugs for target genes. Besides, researchers have developed the understanding of the abnormal physiological function, related genomics, epigenetics, and proteomics of cancer cells with cancer genome sequencing, epigenetic research, and proteomic research. These technologies and related research have accelerated the development of related cancer drugs. In this review, we summarize the research progress of anticancer drugs, the current challenges, and future opportunities.
C1 [Ma, Yu-Shui; Shi, Yi; Lin, Qin-Lu; Li, Wen; Fu, Da] Cent South Univ Forestry & Technol, Natl Engn Lab Deep Proc Rice & Byprod, Coll Food Sci & Engn, Changsha 410004, Hunan, Peoples R China.
   [Ma, Yu-Shui; Liu, Ji-Bin; Shi, Yi] Nantong Tumor Hosp, Canc Inst, Nantong 226631, Peoples R China.
   [Ma, Yu-Shui; Yang, Xiao-Li; Xin, Rui; Zhang, Dan-Dan; Wang, Hui-Min; Wang, Pei-Yao; Fu, Da] Tongji Univ, Shanghai Peoples Hosp 10, Cent Lab Med Res, Sch Med, 36 Yunxin Rd, Shanghai 200072, Peoples R China.
C3 Central South University of Forestry & Technology; Tongji University
RP Li, W (corresponding author), Cent South Univ Forestry & Technol, Natl Engn Lab Deep Proc Rice & Byprod, Coll Food Sci & Engn, Changsha 410004, Hunan, Peoples R China.; Fu, D (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Cent Lab Med Res, Sch Med, 36 Yunxin Rd, Shanghai 200072, Peoples R China.
EM liwendream@163.com; fu800da900@126.com
RI Wang, Peiyao/AAW-7758-2021; liu, James/E-9699-2014; ma,
   yushui/HGC-6206-2022; Fu, Da/GXF-2656-2022; wang, huimin/HDM-8421-2022;
   Zhang, Dandan/AAB-9353-2020; Lin, Qinlu/B-1732-2019
OI Li, Wen/0000-0002-6807-479X; Lin, Qinlu/0000-0003-2043-4220
FU National Natural Science Foundation of China [81772932, 81972214,
   81472202, 81302065]; Shanghai Natural Science Foundation [20ZR1472400];
   Natural Science Foundation of Hunan Province of China [2018JJ4-061,
   2020JJ4278, 2020JJ5127]; Key Program of Hunan Provincial Department of
   Science and Technology [2020WK2020, 2019NK2111]; Scientific Research
   Fund of Hunan Provincial Education Department [18B290]; Zhuzou Key
   Science & Technology Program of Hunan Province (2017); Construction of
   Clinical Medical Centre for Tumor Biological Samples in Nantong
   [HS2016-004]; Jiangsu 333 Program [BRA2017205]; Zhuzou Key Science &
   Technology Program of Hunan Province (2019)
FX This study was supported partly by grants from the National Natural
   Science Foundation of China (81772932, 81972214, 81472202 and 81302065)
   , Shanghai Natural Science Foundation (20ZR1472400) , Natural Science
   Foundation of Hunan Province of China (2018JJ4-061, 2020JJ4278 and
   2020JJ5127) , the Key Program of Hunan Provincial Department of Science
   and Technology (2020WK2020 and 2019NK2111) , the Scientific Research
   Fund of Hunan Provincial Education Department (18B290) , Zhuzou Key
   Science & Technology Program of Hunan Province (2017 and 2019) ,
   Construction of Clinical Medical Centre for Tumor Biological Samples in
   Nantong (HS2016-004) and Jian gsu 333 Program (BRA2017205) .
CR Abou-El-Enein M, 2018, MOL THER, V26, P1172, DOI 10.1016/j.ymthe.2018.04.007
   Al-Bari MAA, 2020, J CELL MOL MED, V24, P11667, DOI 10.1111/jcmm.15879
   Andrzejewska A, 2020, THERANOSTICS, V10, P6615, DOI 10.7150/thno.43169
   Aulova KS, 2021, J CELL MOL MED, V25, P2493, DOI 10.1111/jcmm.16183
   Bae SD, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188516
   Bao ZY, 2021, AM J TRANSL RES, V13, P757
   Belhadj S, 2019, CANCER LETT, V447, P86, DOI 10.1016/j.canlet.2019.01.019
   Besnier M, 2018, MOL THER, V26, P1694, DOI 10.1016/j.ymthe.2018.06.003
   Bhatta B, 2020, CARCINOGENESIS, V41, P1461, DOI 10.1093/carcin/bgaa107
   Bouclier C, 2020, THERANOSTICS, V10, P2008, DOI 10.7150/thno.40971
   Burton C, 2019, MOL THER-ONCOLYTICS, V15, P131, DOI 10.1016/j.omto.2019.09.006
   Cao T, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.612083
   Chen FL, 2020, J CELL MOL MED, V24, P7378, DOI 10.1111/jcmm.15339
   Chen L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16084-0
   Chen WQ, 2017, CANCER LETT, V401, P63, DOI 10.1016/j.canlet.2017.04.024
   Chen Z, 2020, THERANOSTICS, V10, P6448, DOI 10.7150/thno.43577
   Cristóbal I, 2018, MOL THER, V26, P1399, DOI 10.1016/j.ymthe.2018.05.008
   Cullis PR, 2017, MOL THER, V25, P1467, DOI 10.1016/j.ymthe.2017.03.013
   de Bruijn HS, 2020, THERANOSTICS, V10, P2436, DOI 10.7150/thno.37949
   De Robertis M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0912-z
   Deng SR, 2019, CANCER LETT, V443, P1, DOI 10.1016/j.canlet.2018.11.017
   Deng SM, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0932-y
   Di L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1130-2
   Dong R, 2017, CANCER LETT, V388, P43, DOI 10.1016/j.canlet.2016.11.029
   Du HQ, 2021, AM J TRANSL RES, V13, P803
   Duan SY, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0980-3
   Elsedawy NB, 2020, MOL THER-ONCOLYTICS, V17, P484, DOI 10.1016/j.omto.2020.05.003
   Escobar G, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05315-0
   Fan HJ, 2019, CARCINOGENESIS, V40, P669, DOI 10.1093/carcin/bgy160
   Fassunke J, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07078-0
   Gambera S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06401-z
   Gao TT, 2019, CANCER LETT, V445, P11, DOI 10.1016/j.canlet.2018.12.016
   Giordano G, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-1019-5
   González-Fernández Y, 2018, CANCER LETT, V430, P193, DOI 10.1016/j.canlet.2018.05.030
   Gushchina LV, 2017, MOL THER, V25, P2360, DOI 10.1016/j.ymthe.2017.06.025
   Han X, 2020, MOL THER-ONCOLYTICS, V17, P70, DOI 10.1016/j.omto.2020.03.008
   He YW, 2020, MOL THER-ONCOLYTICS, V17, P448, DOI 10.1016/j.omto.2020.05.001
   Herrera M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0863-4
   Holmes TR, 2021, CARCINOGENESIS, V42, P232, DOI 10.1093/carcin/bgaa091
   Hu FQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0861-6
   Hu YN, 2020, MOL THER-ONCOLYTICS, V16, P272, DOI 10.1016/j.omto.2020.01.010
   Hu ZM, 2020, MOL THER-ONCOLYTICS, V17, P361, DOI 10.1016/j.omto.2020.04.008
   Huang XY, 2021, J CELL MOL MED, V25, P3103, DOI 10.1111/jcmm.16370
   Jeong S, 2019, CANCER LETT, V447, P12, DOI 10.1016/j.canlet.2019.01.011
   Jin FF, 2019, CANCER LETT, V440, P211, DOI 10.1016/j.canlet.2018.10.025
   Jin J, 2020, THERANOSTICS, V10, P6231, DOI 10.7150/thno.45219
   Ke WF, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16220-w
   Koujima T, 2020, MOL THER ONCOLYTICS, V17, P107, DOI 10.1016/j.omto.2020.03.016
   Li HZ, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01893-y
   Li JQ, 2018, MOL THER, V26, P1828, DOI 10.1016/j.ymthe.2018.04.014
   Li TT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0879-z
   Li XN, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-1006-x
   Li Y, 2020, MOL THER-NUCL ACIDS, V21, P86, DOI 10.1016/j.omtn.2020.05.021
   Lin J, 2020, MOL THER NUCL ACIDS, V21, P121, DOI 10.1016/j.omtn.2020.05.007
   Liu K, 2020, MOL THER-ONCOLYTICS, V16, P86, DOI 10.1016/j.omto.2019.12.005
   Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329
   Lou XL, 2021, J CELL MOL MED, V25, P2786, DOI 10.1111/jcmm.16372
   Luo Y, 2019, CANCER LETT, V440, P11, DOI 10.1016/j.canlet.2018.10.002
   Luo YL, 2020, THERANOSTICS, V10, P6987, DOI 10.7150/thno.44569
   Ma J, 2018, MOL THER, V26, P70, DOI 10.1016/j.ymthe.2017.11.006
   Ma YS, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0927-8
   Ma YS, 2018, MOL THER, V26, P2751, DOI 10.1016/j.ymthe.2018.09.006
   Ma YS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0890-1
   Martin-Tellez KS, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102058
   Matsuyama T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0945-y
   Miao YM, 2021, THERANOSTICS, V11, P4531, DOI 10.7150/thno.54803
   Murad JP, 2021, MOL THER, V29, P2335, DOI 10.1016/j.ymthe.2021.02.024
   Murillo-Garzón V, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04042-w
   Oddone N, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00574
   Oshima G, 2017, MOL THER, V25, P1588, DOI 10.1016/j.ymthe.2017.04.005
   Panda M, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188517
   Park GB, 2020, CARCINOGENESIS, V41, P1329, DOI 10.1093/carcin/bgaa074
   Parry AJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04283-9
   Patel J, 2020, CARCINOGENESIS, V41, P1625, DOI 10.1093/carcin/bgaa114
   Peng Y, 2019, CANCER LETT, V442, P181, DOI 10.1016/j.canlet.2018.10.027
   Petersen LM, 2020, CURR PROB CANCER, V44, DOI 10.1016/j.currproblcancer.2020.100605
   Piramoon M, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188529
   Ratnayake G, 2018, CANCER LETT, V439, P14, DOI 10.1016/j.canlet.2018.09.011
   Rauth S, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2021.188527
   Rezvani K, 2017, MOL THER, V25, P1769, DOI 10.1016/j.ymthe.2017.06.012
   Rizzo M, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188481
   Rodríguez MM, 2018, MOL THER, V26, P2738, DOI 10.1016/j.ymthe.2018.09.012
   Sadremomtaz A, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0177-z
   Salem A, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188499
   Samet JM, 2020, CARCINOGENESIS, V41, P1471, DOI 10.1093/carcin/bgaa104
   Shan GY, 2020, MOL THER-NUCL ACIDS, V21, P133, DOI 10.1016/j.omtn.2020.05.008
   Shastri A, 2018, J CLIN INVEST, V128, P5479, DOI 10.1172/JCI120156
   Su R, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0737-1
   Sun JH, 2018, CANCER LETT, V427, P1, DOI 10.1016/j.canlet.2018.04.015
   Sun Q, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0096-z
   Terasaki M, 2021, CARCINOGENESIS, V42, P210, DOI 10.1093/carcin/bgaa100
   Thomas D, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188464
   Toden S, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188491
   Tsai KW, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0821-1
   Tsai YC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0785-1
   Tzchori I, 2018, MOL THER, V26, P1660, DOI 10.1016/j.ymthe.2018.04.003
   Tzelepis K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07620-0
   Vitiello PP, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1035-0
   Wang DJ, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0491-7
   Wang JJ, 2020, MOL THER-ONCOLYTICS, V17, P130, DOI 10.1016/j.omto.2020.03.011
   Wang L, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0113-2
   Wang LH, 2017, CANCER LETT, V391, P28, DOI 10.1016/j.canlet.2017.01.013
   Wang M, 2020, MOL THER NUCL ACIDS, V21, P13, DOI 10.1016/j.omtn.2020.05.011
   Wang X, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0860-7
   Wang XY, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01840-x
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0922-0
   Wang Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0970-5
   Wang YA, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0913-y
   Wang ZF, 2020, THERANOSTICS, V10, P7178, DOI 10.7150/thno.43093
   Wei F, 2019, CANCER LETT
   Wei F, 2019, CANCER LETT, V450, P1, DOI 10.1016/j.canlet.2019.02.022
   Weng HQ, 2021, MOL THER-NUCL ACIDS, V23, P811, DOI 10.1016/j.omtn.2020.12.019
   Wu X, 2020, MOL THER NUCL ACIDS, V21, P108, DOI 10.1016/j.omtn.2020.05.023
   Xing LN, 2020, J CELL MOL MED, V24, P9839, DOI 10.1111/jcmm.15567
   Xu LJ, 2020, MOL THER-ONCOLYTICS, V16, P100, DOI 10.1016/j.omto.2019.12.007
   Yan CY, 2017, MOL PHARMACEUT, V14, P1898, DOI 10.1021/acs.molpharmaceut.6b01167
   Ylä-Herttuala S, 2017, MOL THER, V25, P1731, DOI 10.1016/j.ymthe.2017.07.007
   You JH, 2021, CANCER LETT, V507, P40, DOI 10.1016/j.canlet.2021.03.013
   Yu F, 2018, CANCER LETT, V427, P74, DOI 10.1016/j.canlet.2018.04.022
   Yu JT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0896-y
   Yu TJ, 2021, MOL THER, V29, P2350, DOI 10.1016/j.ymthe.2021.03.003
   Yue B, 2018, MOL THER, V26, P1287, DOI 10.1016/j.ymthe.2018.02.024
   Yuki R, 2021, J CELL MOL MED, V25, P1677, DOI 10.1111/jcmm.16270
   Zhang F, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0791-6
   Zhang JY, 2019, CANCER LETT, V440, P106, DOI 10.1016/j.canlet.2018.10.010
   Zhang JF, 2020, THERANOSTICS, V10, P7245, DOI 10.7150/thno.44427
   Zhang S, 2020, MOL THER-NUCL ACIDS, V20, P881, DOI 10.1016/j.omtn.2020.05.017
   Zheng MJ, 2019, MOL THER-ONCOLYTICS, V15, P234, DOI 10.1016/j.omto.2019.10.007
   Zhu Y, 2018, MOL THER, V26, P744, DOI 10.1016/j.ymthe.2017.12.023
   Zuo DQ, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0914-0
NR 130
TC 5
Z9 6
U1 3
U2 16
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2021
VL 11
IS 6
BP 2386
EP 2400
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TA4HL
UT WOS:000667209700002
PM 34249406
DA 2025-01-04
ER

PT J
AU Takahashi, H
   Yoshimatsu, G
   Faustman, DL
AF Takahashi, Hiroyuki
   Yoshimatsu, Gumpei
   Faustman, Denise Louise
TI The Roles of TNFR2 Signaling in Cancer Cells and the Tumor
   Microenvironment and the Potency of TNFR2 Targeted Therapy
SO CELLS
LA English
DT Review
DE TNFR2; tumor microenvironment; immune checkpoint inhibitor; Tregs;
   immunotherapy; anti-TNFR2 antibody
ID NECROSIS-FACTOR-ALPHA; REGULATORY T-CELLS; FACTOR RECEPTOR 2;
   NF-KAPPA-B; COLORECTAL-CANCER; SUPPRESSOR-CELLS; SERUM-LEVELS; PROMOTES;
   EXPRESSION; BREAST
AB The appreciation that cancer growth is promoted by a dynamic tumor microenvironment (TME) has spawned novel approaches to cancer treatment. New therapies include agents that activate quiescent T effector cells and agents that interfere with abnormal neovascularity. Although promising, many experimental therapies targeted at the TME have systemic toxicity. Another approach is to target the TME with greater specificity by taking aim at the tumor necrosis factor receptor 2 (TNFR2) signaling pathway. TNFR2 is an attractive molecular target because it is rarely expressed in normal tissues (thus, has low potential for systemic toxicity) and because it is overexpressed on many types of cancer cells as well as on associated TME components, such as T regulatory cells (Tregs), tumor-associated macrophages, and other cells that facilitate tumor progression and spread. Novel therapies that block TNFR2 signaling show promise in cell culture studies, animal models, and human studies. Novel antibodies have been developed that expressly kill only rapidly proliferating cells expressing newly synthesized TNFR2 protein. This review traces the origins of our understanding of TNFR2's multifaceted roles in the TME and discusses the therapeutic potential of agents designed to block TNFR2 as the cornerstone of a TME-specific strategy.
C1 [Takahashi, Hiroyuki; Yoshimatsu, Gumpei] Fukuoka Univ Hosp, Dept Surg Gastroenterol, Fukuoka 8140180, Japan.
   [Takahashi, Hiroyuki; Faustman, Denise Louise] Massachusetts Gen Hosp, Dept Immunobiol, Charlestown, MA 02129 USA.
   [Takahashi, Hiroyuki; Faustman, Denise Louise] Harvard Med Sch, Charlestown, MA 02129 USA.
C3 Fukuoka University; Harvard University; Massachusetts General Hospital
RP Faustman, DL (corresponding author), Massachusetts Gen Hosp, Dept Immunobiol, Charlestown, MA 02129 USA.; Faustman, DL (corresponding author), Harvard Med Sch, Charlestown, MA 02129 USA.
EM htakahashi3@mgh.harvard.edu;
   gumpei.ysohimatsu@fukuokauniversityhospital.org;
   dfaustman@mgh.harvard.edu
FU Iacocca Foundation
FX This study was supported by The Iacocca Foundation.
CR ADERKA D, 1992, LYMPHOKINE CYTOK RES, V11, P157
   Ahluwalia MS, 2017, J NEURO-ONCOL, V131, P449, DOI 10.1007/s11060-016-2319-2
   Al-Hatamleh MAI, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010033
   Al-Lamki RS, 2016, ONCOTARGET, V7, P24111, DOI 10.18632/oncotarget.8125
   Al-Lamki RS, 2010, AM J PATHOL, V177, P943, DOI 10.2353/ajpath.2010.091218
   [Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210
   ANSLOW WP, 1947, J PHARMACOL EXP THER, V91, P224
   Arnott CH, 2004, ONCOGENE, V23, P1902, DOI 10.1038/sj.onc.1207317
   Ba HP, 2017, INT IMMUNOPHARMACOL, V44, P143, DOI 10.1016/j.intimp.2016.12.028
   Babic A, 2016, BRIT J CANCER, V114, P995, DOI 10.1038/bjc.2016.85
   Baluk P, 2009, J CLIN INVEST, V119, P2954, DOI 10.1172/JCI37626
   Bayik D, 2021, NAT REV CANCER, V21, P526, DOI 10.1038/s41568-021-00366-w
   Black RA, 1997, NATURE, V385, P729, DOI 10.1038/385729a0
   Bowers E, 2018, NAT MED, V24, P95, DOI 10.1038/nm.4448
   Bradley JR, 2020, FASEB BIOADV, V2, P126, DOI 10.1096/fba.2019-00071
   Brenner D, 2015, NAT REV IMMUNOL, V15, P362, DOI 10.1038/nri3834
   Cabal-Hierro L, 2014, CELL SIGNAL, V26, P2658, DOI 10.1016/j.cellsig.2014.08.011
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   Case K, 2020, J LEUKOCYTE BIOL, V107, P981, DOI 10.1002/JLB.5MA0420-375RRRRR
   Chang LY, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1040215
   Chen X, 2008, J IMMUNOL, V180, P6467, DOI 10.4049/jimmunol.180.10.6467
   Chen X, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aal2328
   Chen X, 2013, J IMMUNOL, V190, P1076, DOI 10.4049/jimmunol.1202659
   Chen X, 2010, J IMMUNOL, V185, P174, DOI 10.4049/jimmunol.0903548
   Chopra M, 2013, CARCINOGENESIS, V34, P1296, DOI 10.1093/carcin/bgt038
   Collette Y, 2003, TRENDS IMMUNOL, V24, P387, DOI 10.1016/S1471-4906(03)00166-2
   Cui LF, 2008, HISTOPATHOLOGY, V53, P381, DOI 10.1111/j.1365-2559.2008.03128.x
   Almeida ACD, 2015, NAT GENET, V47, P1465, DOI 10.1038/ng.3442
   Deb S, 2004, J CLIN ENDOCR METAB, V89, P4018, DOI 10.1210/jc.2004-0127
   DeRogatis JM, 2022, CANCER IMMUNOL RES, V10, P612, DOI 10.1158/2326-6066.CIR-21-0690
   DESILVA DGH, 1992, LANCET, V340, P372, DOI 10.1016/0140-6736(92)91446-F
   DeVita VT, 2008, CANCER RES, V68, P8643, DOI 10.1158/0008-5472.CAN-07-6611
   Dobrzycka B, 2009, FOLIA HISTOCHEM CYTO, V47, P609, DOI 10.2478/v10042-008-0117-1
   Dollt C, 2017, ONCOTARGET, V8, P103682, DOI 10.18632/oncotarget.21771
   Dossus L, 2011, INT J CANCER, V129, P2032, DOI 10.1002/ijc.25840
   Facciabene A, 2012, CANCER RES, V72, P2162, DOI 10.1158/0008-5472.CAN-11-3687
   Faustman D, 2010, NAT REV DRUG DISCOV, V9, P482, DOI 10.1038/nrd3030
   Faustman DL, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00478
   Feng TT, 2016, ONCOTARGET, V7, P58381, DOI 10.18632/oncotarget.11126
   Frankenberger C, 2015, CANCER RES, V75, P4063, DOI 10.1158/0008-5472.CAN-14-3394
   Gadducci A, 1996, ANTICANCER RES, V16, P3125
   Ghods A, 2019, IMMUNOL LETT, V209, P36, DOI 10.1016/j.imlet.2019.03.013
   Gobbini E, 2019, CRIT REV ONCOL HEMAT, V144, DOI 10.1016/j.critrevonc.2019.102816
   Goo K, 2019, J ONCOL PHARM PRACT, V25, P1248, DOI 10.1177/1078155218784762
   Govindaraj C, 2014, AM J HEMATOL, V89, P795, DOI 10.1002/ajh.23746
   Govindaraj C, 2014, CLIN CANCER RES, V20, P724, DOI 10.1158/1078-0432.CCR-13-1576
   Govindaraj C, 2013, CLIN IMMUNOL, V149, P97, DOI 10.1016/j.clim.2013.07.003
   GRELL M, 1995, CELL, V83, P793, DOI 10.1016/0092-8674(95)90192-2
   Grote VA, 2012, BRIT J CANCER, V106, P1866, DOI 10.1038/bjc.2012.172
   Gu YA, 2010, CANCER CAUSE CONTROL, V21, P1323, DOI 10.1007/s10552-010-9560-3
   Hagemann T, 2005, J IMMUNOL, V175, P1197, DOI 10.4049/jimmunol.175.2.1197
   Ham B, 2015, CANCER RES, V75, P5235, DOI 10.1158/0008-5472.CAN-14-3173
   Hamaguchi T, 2019, CANCER SCI, V110, P3565, DOI 10.1111/cas.14198
   Hamilton KE, 2011, MOL CANCER RES, V9, P1718, DOI 10.1158/1541-7786.MCR-10-0210
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hasegawa S, 2004, MICROB PATHOGENESIS, V37, P119, DOI 10.1016/j.micpath.2004.06.004
   He L, 2021, NEOPLASIA, V23, P197, DOI 10.1016/j.neo.2020.12.007
   Hu X, 2014, J IMMUNOL, V192, P1320, DOI 10.4049/jimmunol.1203195
   Huang J, 2015, APOPTOSIS, V20, P210, DOI 10.1007/s10495-014-1061-5
   Ieda T, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52816-z
   Iwai Y, 2017, J BIOMED SCI, V24, DOI 10.1186/s12929-017-0329-9
   Jing YY, 2018, CANCER LETT, V434, P22, DOI 10.1016/j.canlet.2018.07.001
   Johnson DB, 2022, NAT REV CLIN ONCOL, V19, P254, DOI 10.1038/s41571-022-00600-w
   Jöhrer K, 2004, CLIN CANCER RES, V10, P1901, DOI 10.1158/1078-0432.CCR-1053-03
   Kim EY, 2009, J IMMUNOL, V183, P6051, DOI 10.4049/jimmunol.0803482
   Komohara Y, 2017, J PATHOL, V241, P313, DOI 10.1002/path.4824
   Kowal J, 2019, IMMUNOTHERAPY-UK, V11, P677, DOI 10.2217/imt-2018-0156
   Lan XB, 2018, GENE, V646, P98, DOI 10.1016/j.gene.2017.12.051
   Lauenborg B, 2015, ONCOTARGET, V6, P15235, DOI 10.18632/oncotarget.3837
   Liu J, 2018, BIOMATERIALS, V152, P24, DOI 10.1016/j.biomaterials.2017.10.027
   Liu ZF, 2018, HUM PATHOL, V80, P179, DOI 10.1016/j.humpath.2018.03.027
   Madsen PM, 2016, J NEUROSCI, V36, P5128, DOI 10.1523/JNEUROSCI.0211-16.2016
   Mahmud SA, 2014, NAT IMMUNOL, V15, P473, DOI 10.1038/ni.2849
   Mayer LS, 2020, J IMMUNOL, V204
   McAllister SS, 2014, NAT CELL BIOL, V16, P717, DOI 10.1038/ncb3015
   Meng Y, 2021, CANCER RES, V81, P3036, DOI 10.1158/0008-5472.CAN-20-3175
   Murciano-Goroff YR, 2020, CELL RES, V30, P507, DOI 10.1038/s41422-020-0337-2
   Nagaraj S, 2012, SEMIN CANCER BIOL, V22, P282, DOI 10.1016/j.semcancer.2012.01.010
   Naudé PJW, 2011, FEBS J, V278, P888, DOI 10.1111/j.1742-4658.2011.08017.x
   Nie Y, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aan0790
   Okubo Y, 2013, SCI REP-UK, V3, DOI 10.1038/srep03153
   Onizawa M, 2009, AM J PHYSIOL-GASTR L, V296, pG850, DOI 10.1152/ajpgi.00071.2008
   Paris J, 2019, CELL STEM CELL, V25, P137, DOI 10.1016/j.stem.2019.03.021
   Purdue MP, 2013, BLOOD, V122, P951, DOI 10.1182/blood-2013-01-481077
   Rivas MA, 2008, EXP CELL RES, V314, P509, DOI 10.1016/j.yexcr.2007.10.005
   ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915
   Sade-Feldman M, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01062-w
   Sakaguchi S, 2005, NAT IMMUNOL, V6, P345, DOI 10.1038/ni1178
   Sasi SP, 2012, ONCOGENE, V31, P4117, DOI 10.1038/onc.2011.567
   Sasi SP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092373
   Sheng YQ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01170
   Sprowl JA, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3083
   Suzuki M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088369
   Tai SK, 2012, J IMMUNOL, V188, P2464, DOI 10.4049/jimmunol.1101101
   Takahashi E, 2010, J BIOL CHEM, V285, P4060, DOI 10.1074/jbc.M109.056523
   Tam EM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aax0720
   Tanimura Y, 2005, CANCER LETT, V219, P205, DOI 10.1016/j.canlet.2004.07.027
   Tirosh I, 2016, SCIENCE, V352, P189, DOI 10.1126/science.aad0501
   Torrey H, 2019, LEUKEMIA, V33, P1206, DOI 10.1038/s41375-018-0292-9
   Torrey H, 2017, SCI SIGNAL, V10, DOI 10.1126/scisignal.aaf8608
   Ungewickell A, 2015, NAT GENET, V47, P1056, DOI 10.1038/ng.3370
   Urbano PCM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00573
   Vanamee ÉS, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao4910
   Vanamee ES, 2017, TRENDS MOL MED, V23, P1037, DOI 10.1016/j.molmed.2017.09.007
   Varricchi G, 2018, LANCET ONCOL, V19, P1545, DOI 10.1016/S1470-2045(18)30622-3
   Wajant H, 2015, CELL DEATH DIFFER, V22, P1727, DOI 10.1038/cdd.2015.109
   Wajant H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02040
   Wang LL, 2017, ONCOTARGET, V8, P26323, DOI 10.18632/oncotarget.15461
   Xian QL, 2019, J CELL MOL MED, V23, P2943, DOI 10.1111/jcmm.14202
   Xiao CH, 2018, CANCER-AM CANCER SOC, V124, P3163, DOI 10.1002/cncr.31537
   Xu J, 2007, BLOOD, V109, P3333, DOI 10.1182/blood-2006-06-026385
   Yan F, 2015, CANCER IMMUNOL IMMUN, V64, P1475, DOI 10.1007/s00262-015-1751-z
   Yang D, 2015, AM J CANCER RES, V5, P3085
   Yang FQ, 2017, ONCOL LETT, V14, P2393, DOI 10.3892/ol.2017.6410
   Yang FQ, 2017, MOL MED REP, V16, P2962, DOI 10.3892/mmr.2017.6898
   Yang M, 2020, J LEUKOCYTE BIOL, V107, P971, DOI 10.1002/JLB.5AB0320-415RRRRR
   Yang SJ, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00784
   Zhang T, 2018, ONCOTARGET, V9, P5073, DOI 10.18632/oncotarget.23581
   Zhang W, 2003, CANCER BIOL THER, V2, P572, DOI 10.4161/cbt.2.5.532
   Zhao T, 2017, ONCOL LETT, V13, P342, DOI 10.3892/ol.2016.5403
   Zhao XQ, 2012, J CLIN INVEST, V122, P4094, DOI 10.1172/JCI64115
   Zhou Q, 2020, ONCOGENE, V39, P1414, DOI 10.1038/s41388-019-1078-x
NR 122
TC 20
Z9 20
U1 4
U2 12
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JUN
PY 2022
VL 11
IS 12
AR 1952
DI 10.3390/cells11121952
PG 22
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 2L9KX
UT WOS:000817333400001
PM 35741080
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Pfeifer, RJD
   Loberg, R
   Lofton-Day, C
   Zehnbauer, BA
AF Pfeifer, John D. r
   Loberg, Robert
   Lofton-Day, Catherine
   Zehnbauer, Barbara A.
TI Reference Samples to Compare Next-Generation Sequencing Test Performance
   for Oncology Therapeutics and Diagnostics
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE Precision medicine; Companion diagnostic; Next-generation sequencing;
   Reference materials; Test performance
ID RAS MUTATIONS; LABORATORY STANDARDS; GUIDELINES; CANCER; BIOINFORMATICS;
   HETEROGENEITY; CONTAMINATION; VALIDATION; EGFR
AB Objectives Diversity of laboratory-developed tests (LDTs) using next-generation sequencing (NGS) raises concerns about their accuracy for selection of targeted therapies. A working group developed a pilot study of traceable reference samples to measure NGS LDT performance among a cohort of clinical laboratories. Methods Human cell lines were engineered via CRISPR/Cas9 and prepared as formalin-fixed, paraffin-embedded cell pellets ("wet" samples) to assess the entire NGS test cycle. In silico mutagenized NGS sequence files ("dry" samples) were used to assess the bioinformatics component of the NGS test cycle. Single and multinucleotide variants (n = 36) of KRAS and NRAS were tested at 5% or 15% variant allele fraction to determine eligibility for therapy with the EGFR inhibitor panitumumab in the setting of metastatic colorectal cancer. Results Twenty-one (21/21) laboratories tested wet samples; 19 of 21 analyzed dry samples. Of the laboratories that tested both the wet and dry samples, 7 (37%) of 19 laboratories correctly reported all variants, 3 (16%) of 19 had fewer than five errors, and 9 (47%) of 19 had five or more errors. Most errors were false negatives. Conclusions Genetically engineered cell lines and mutagenized sequence files are complementary reference samples for evaluating NGS test performance among clinical laboratories using LDTs. Variable accuracy in detection of genetic variants among some LDTs may identify different patient populations for targeted therapy.
C1 [Pfeifer, John D. r] Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.
   [Loberg, Robert] Clin Biomarkers & Diagnost, Thousand Oaks, CA USA.
   [Lofton-Day, Catherine] Amgen Inc, In Vitro Diagnost, Thousand Oaks, CA USA.
   [Zehnbauer, Barbara A.] Emory Univ, Sch Med, Dept Pathol, Atlanta, GA 30322 USA.
C3 Washington University (WUSTL); Amgen; Emory University
RP Pfeifer, RJD (corresponding author), Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA.
EM jdpfeifer@wustl.edu
CR [Anonymous], 2018, Clinical laboratory improvement amendments-Test complexities: Test complexity categorization
   Aziz N, 2015, ARCH PATHOL LAB MED, V139, P481, DOI 10.5858/arpa.2014-0250-CP
   Baum PD, 2011, ANAL BIOCHEM, V411, P106, DOI 10.1016/j.ab.2010.11.035
   Benson A, 2021, J NATL COMPR CANC NE, V19, P329, DOI 10.6004/jnccn.2021.0012
   Berger MF, 2018, NAT REV CLIN ONCOL, V15, P353, DOI 10.1038/s41571-018-0002-6
   Blackburn J, 2019, NAT PROTOC, V14, P2119, DOI 10.1038/s41596-019-0175-1
   Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007
   Cibulskis K, 2011, BIOINFORMATICS, V27, P2601, DOI 10.1093/bioinformatics/btr446
   Coriell Institute for Medical Research, NATL I STANDARDS TEC
   Davies KD, 2016, J MOL DIAGN, V18, P572, DOI 10.1016/j.jmoldx.2016.03.002
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Duncavage EJ, 2021, NEW ENGL J MED, V384, P924, DOI 10.1056/NEJMoa2024534
   Duncavage EJ, 2017, J MOL DIAGN, V19, P35, DOI 10.1016/j.jmoldx.2016.09.005
   Duncavage EJ, 2016, ARCH PATHOL LAB MED, V140, P1085, DOI 10.5858/arpa.2016-0194-CP
   Escalona M, 2016, NAT REV GENET, V17, P459, DOI 10.1038/nrg.2016.57
   Essletzbichler P, 2014, GENOME RES, V24, P2059, DOI 10.1101/gr.177220.114
   Fiévet A, 2019, EUR J HUM GENET, V27, P792, DOI 10.1038/s41431-018-0317-x
   Ghoneim Dalia H, 2014, BMC Res Notes, V7, P864, DOI 10.1186/1756-0500-7-864
   Gullapalli RR, 2020, J MOL DIAGN, V22, P147, DOI 10.1016/j.jmoldx.2019.09.007
   Gutowska-Ding MW, 2020, EUR J HUM GENET, V28, P202, DOI 10.1038/s41431-019-0515-1
   Haigis KM, 2017, TRENDS CANCER, V3, P686, DOI 10.1016/j.trecan.2017.08.006
   Hardwick SA, 2017, NAT REV GENET, V18, P473, DOI 10.1038/nrg.2017.44
   Hume S, 2019, J MED GENET, V56, P792, DOI 10.1136/jmedgenet-2019-106152
   Illumina, PRAXIS EXTENDED RAS
   Jennings LJ, 2017, J MOL DIAGN, V19, P341, DOI 10.1016/j.jmoldx.2017.01.011
   Keegan A, 2020, ARCH PATHOL LAB MED, V144, P959, DOI 10.5858/arpa.2019-0352-CP
   Kim AS, 2018, JAMA ONCOL, V4, P838, DOI 10.1001/jamaoncol.2017.4021
   Kudalkar EM, 2016, J MOL DIAGN, V18, P882, DOI 10.1016/j.jmoldx.2016.07.005
   Matthijs G, 2016, EUR J HUM GENET, V24, P2, DOI 10.1038/ejhg.2015.226
   McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018
   Medical Device Innovation Consortium, CANC GENOMIC SOMATIC
   Merker JD, 2019, ARCH PATHOL LAB MED, V143, P463, DOI 10.5858/arpa.2018-0336-CP
   Moncur JT, 2019, ARCH PATHOL LAB MED, V143, P1203, DOI 10.5858/arpa.2018-0396-CP
   Nagarajan R, 2017, ARCH PATHOL LAB MED, V141, P1679, DOI 10.5858/arpa.2016-0542-CP
   National Institute of Standards and Technology, NATL MEASUREMENT LAB
   New York Department of Health, NEXT GENERATION SEQU
   Patil SA, 2019, J MOL DIAGN, V21, P19, DOI 10.1016/j.jmoldx.2018.08.001
   Rehm HL, 2013, GENET MED, V15, P733, DOI 10.1038/gim.2013.92
   Roy S, 2018, J MOL DIAGN, V20, P4, DOI 10.1016/j.jmoldx.2017.11.003
   Santani A, 2019, J MOL DIAGN, V21, P369, DOI 10.1016/j.jmoldx.2018.11.004
   Sehn JK, 2015, AM J CLIN PATHOL, V144, P667, DOI 10.1309/AJCPR88WDJJLDMBN
   Sims DJ, 2016, J MOL DIAGN, V18, P336, DOI 10.1016/j.jmoldx.2015.11.008
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Surrey LF, 2019, ARCH PATHOL LAB MED, V143, P980, DOI 10.5858/arpa.2018-0394-CP
   Suzuki T, 2020, GENES ENVIRON, V42, DOI 10.1186/s41021-020-0147-2
   Tapestry Networks, HEALTHCARE
   Tapestry Networks, SPOT/Dx Working Group project
   Tapestry Networks, DIAGNOSTIC QUALITY A
   US Food and Drug Administration, CONSIDERATIONS DESIG
   Viray H, 2013, ARCH PATHOL LAB MED, V137, P1545, DOI 10.5858/arpa.2012-0561-CP
   Vitale I, 2021, NAT MED, V27, P212, DOI 10.1038/s41591-021-01233-9
   Wakeling Matthew N, 2019, Wellcome Open Res, V4, P145, DOI 10.12688/wellcomeopenres.15420.2
   Wellcome Sanger Institute, CATALOG SOMATIC MUTA
   Zehnbauer B, 2017, J MOL DIAGN, V19, P1, DOI 10.1016/j.jmoldx.2016.10.001
   Zook JM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041356
NR 55
TC 8
Z9 8
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD APR 1
PY 2022
VL 157
IS 4
BP 628
EP 638
DI 10.1093/ajcp/aqab164
EA DEC 2021
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 0E6CR
UT WOS:000776768000024
PM 34871357
OA Bronze
DA 2025-01-04
ER

PT J
AU Johnson, B
   Kopetz, S
AF Johnson, Benny
   Kopetz, Scott
TI Applying Precision to the Management of BRAF-Mutant Metastatic
   Colorectal Cancer
SO TARGETED ONCOLOGY
LA English
DT Review
ID CONSENSUS MOLECULAR SUBTYPES; COLON-CANCER; OPEN-LABEL; WILD-TYPE;
   MICROSATELLITE INSTABILITY; IMPROVED SURVIVAL; SERRATED PATHWAY;
   DOSE-ESCALATION; MEK INHIBITION; PHASE IB
AB Identifying the presence or absence of aBRAF(V600E)mutation is paramount for the management of patients with metastatic colorectal cancer (mCRC) as there are distinct predictive and prognostic implications, as well as unique therapeutic approaches for this molecular subtype. Traditional cytotoxic doublet chemotherapy has historically been ineffective for this poor prognostic group, thereby highlighting the critical need for novel targeted therapies to drive management. Unlike the early success achieved with BRAF-inhibitor monotherapy for patients withBRAF(V600E)-mutated metastatic melanoma, response rates were found to only be 5% in early-phase clinical trials for patients withBRAF(V600E)mCRC. A deeper understanding of predominant resistance mechanisms inBRAF(V600E)mCRC after exposure to BRAF inhibition has resulted in innovative combinatorial approaches targeting the mitogen-activated protein kinase (MAPK) pathway, revitalizing the treatment portfolio for these patients. Of note, in recent years non-V600 BRAF mutations have been appreciated as a distinct molecular subset in mCRC, representing 2-4% of patients with a unique clinical presentation and complex signaling biology. These mutations, referred to as "atypical" BRAF mutations, warrant individual clinical investigation and demand innovative drug development that leverages known signaling class biology. Here, we summarize the current molecular and clinicopathologic understanding ofBRAF(V600E)mCRC, as well as the landmark clinical trials that have led to successful targeted therapy for this historically aggressive subtype of colorectal cancer. Additionally, we briefly describe the current understanding of patients with atypical BRAF mutations, highlighting the importance of continued research efforts to appropriately treat this evolving subset of BRAF mutations.
C1 [Johnson, Benny; Kopetz, Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd,Unit 426, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Kopetz, S (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, 1515 Holcombe Blvd,Unit 426, Houston, TX 77030 USA.
EM skopetz@mdanderson.org
RI Kopetz, Scott/AAC-1387-2019
OI Kopetz, Scott/0000-0001-9647-3416
FU Cancer Center Support Grant (CCSG) [CA016672]; National Institutes of
   Health/National Cancer Institute (NIH/NCI) [R01 CA187238, R01 CA184843];
   MD Anderson Moon Shots
FX Cancer Center Support Grant (CCSG) CA016672; National Institutes of
   Health/National Cancer Institute (NIH/NCI) R01 CA187238, R01 CA184843
   and MD Anderson Moon Shots.
CR Andre T, 2020, J CLIN ONCOL, V38, pLBA4
   [Anonymous], 2019, JCO PRECIS ONCOL
   [Anonymous], 2019, NCCN GUIDELINES VERS
   [Anonymous], 2018, J CLIN ONCOL S
   Bettington M, 2013, HISTOPATHOLOGY, V62, P367, DOI 10.1111/his.12055
   Brose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chu JE, 2020, CLIN CANCER RES, V26, P4599, DOI 10.1158/1078-0432.CCR-20-1024
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Corcoran N, 2020, J CLIN ONCOL, V38
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2015, ANN ONCOL, V26, P2092, DOI 10.1093/annonc/mdv290
   Cremolini C, 2020, J CLIN ONCOL, V38
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Delord JP, 2017, CLIN CANCER RES, V23, P5339, DOI 10.1158/1078-0432.CCR-16-2923
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Forbes SA, 2017, NUCLEIC ACIDS RES, V45, pD777, DOI 10.1093/nar/gkw1121
   Gomez-Roca C. A., 2014, Ann Oncol, DOI [10.1093/annonc/mdu333.38, DOI 10.1093/ANNONC/MDU333.38]
   Greene C, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.554
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Howlader N, 2019, SEER CANC STAT REV
   Jass JR, 2007, HISTOPATHOLOGY, V50, P1, DOI 10.1111/j.1365-2559.2006.02568.x
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79
   Kasi PM, 2020, ANN ONCOL, V31, P15, DOI 10.1016/j.annonc.2019.11.001
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2020, J CLIN ONCOL, V38
   Kopetz S, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.688
   Kopetz S, 2017, J CLIN ONCOL, V35
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kotani D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2019-000624
   Lai E, 2018, EXPERT REV MOL DIAGN, V18, P499, DOI 10.1080/14737159.2018.1470928
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   McArthur GA, 2014, LANCET ONCOL, V15, P323, DOI 10.1016/S1470-2045(14)70012-9
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   Network NCC, 2019, NCCN CLIN PRACT GUID
   Nikolouzakis TK, 2018, ONCOL REP, V39, P2455, DOI 10.3892/or.2018.6330
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805
   Saridaki Z, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084604
   Schirripa M, 2016, CANCER J, V22, P156, DOI 10.1097/PPO.0000000000000190
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Shui L, 2018, CELL PHYSIOL BIOCHEM, V48, P1870, DOI 10.1159/000492508
   Sinicrope FA, 2015, GASTROENTEROLOGY, V148, P88, DOI 10.1053/j.gastro.2014.09.041
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Thomsen M, 2017, EUR J CANCER, V81, P26, DOI 10.1016/j.ejca.2017.04.026
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Tsai JH, 2014, MODERN PATHOL, V27, P1375, DOI 10.1038/modpathol.2014.35
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Wang Y, 2019, ANN ONCOL, V30, P147, DOI 10.1093/annonc/mdy477
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yaeger R, 2019, CLIN CANCER RES, V25, P7089, DOI 10.1158/1078-0432.CCR-19-2004
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yao Z, 2019, NAT MED, V25, P284, DOI 10.1038/s41591-018-0274-5
   Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291
   Yokota T, 2011, BRIT J CANCER, V104, P856, DOI 10.1038/bjc.2011.19
   Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012
   Zoratto F, 2014, TUMOR BIOL, V35, P6195, DOI 10.1007/s13277-014-1845-9
NR 78
TC 10
Z9 12
U1 0
U2 1
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1776-2596
EI 1776-260X
J9 TARGET ONCOL
JI Target. Oncol.
PD OCT
PY 2020
VL 15
IS 5
BP 567
EP 577
DI 10.1007/s11523-020-00747-5
EA SEP 2020
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OB4SG
UT WOS:000566324200001
PM 32889679
OA Green Accepted
DA 2025-01-04
ER

PT J
AU Tsui, YW
   Tsai, CY
   Chen, HC
AF Tsui, Yu-Wen
   Tsai, Chia-Yu
   Chen, Hung-Chi
TI An unusual case of long-term survival with excellent quality of life
   after surgery of rectal cancer with metastasis to the liver, lung, and
   scalp
SO FORMOSAN JOURNAL OF SURGERY
LA English
DT Article
DE metastatic colorectal cancer; chemotherapy; quality of life; wide
   excision
ID COLORECTAL-CANCER
AB With improvements in therapies for colorectal cancer, patient survival can be extended remarkably. Multiple treatment modalities can be combined, and collaboration among different departments is important. A patient presented with rectal cancer with metastases to the liver, lungs, and scalp, which were excised completely. The scalp lesion recurred twice, and the final procedure was a free flap reconstruction after wide excision. Since then, there has been no recurrence, and the patient has had an excellent quality of life after 8 years of follow-up. The overall survival of colorectal cancer is increasing owing to improvements in surgery, chemotherapy, and targeted therapy. Aggressive treatment is helpful in patients with metastatic colorectal cancer.
C1 [Tsui, Yu-Wen; Tsai, Chia-Yu; Chen, Hung-Chi] China Med Univ Hosp, Dept Surg, Taichung, Taiwan.
   [Chen, Hung-Chi] China Med Univ Hosp, Dept Surg, 2 Yuh Der Rd, Taichung, Taiwan.
C3 China Medical University Taiwan; China Medical University Hospital -
   Taiwan; China Medical University Taiwan; China Medical University
   Hospital - Taiwan
RP Chen, HC (corresponding author), China Med Univ Hosp, Dept Surg, 2 Yuh Der Rd, Taichung, Taiwan.
EM u103001409@gmail.com; p6782002@hotmail.com; d19722@mail.cmuh.org.tw
RI chen, hongyu/HHS-4314-2022
OI Tsai, Chia Yu/0000-0002-9771-5445; Chen, Hung-Chi/0000-0002-2749-1909
FU There are no conflicts of interest.
FX There are no conflicts of interest.
CR Akhondi-Meybodi M, 2016, ARAB J GASTROENTEROL, V17, P127, DOI 10.1016/j.ajg.2016.06.001
   Balta AZ, 2013, TURK J SURG, V29, P197, DOI 10.5152/UCD.2013.16
   Cecil TD, 2004, DIS COLON RECTUM, V47, P1145, DOI 10.1007/s10350-004-0086-6
   Fragulidis Georgios P, 2015, World J Oncol, V6, P304, DOI 10.14740/wjon862w
   Hashimi Yasmin, 2013, BMJ Case Rep, V2013, DOI 10.1136/bcr-2013-009875
   Lee YC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078709
   Parente P, 2021, LIFE-BASEL, V11, DOI 10.3390/life11090954
   Piawah S, 2019, CANCER-AM CANCER SOC, V125, P4139, DOI 10.1002/cncr.32163
   Qiu MZ, 2015, ONCOTARGET, V6, P38658, DOI 10.18632/oncotarget.6130
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(19)32319-0
NR 11
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1682-606X
EI 2213-5413
J9 FORMOS J SURG
JI Formos. J. Surg.
PD MAR-APR
PY 2023
VL 56
IS 2
BP 62
EP 64
DI 10.1097/FS9.0000000000000034
PG 3
WC Surgery
WE Emerging Sources Citation Index (ESCI)
SC Surgery
GA R0AM1
UT WOS:001061051200006
OA gold
DA 2025-01-04
ER

PT J
AU Wang, WW
   Tao, ZY
   Tu, LL
   Huang, WK
   Ye, YP
   Gao, LJ
   Li, XY
AF Wang, Wenwen
   Tao, Zhongyi
   Tu, Linglan
   Huang, Wenkang
   Ye, Yiping
   Gao, Lijuan
   Li, Xiaoyu
TI Diterpenoids from <i>Scutellaria barbata</i> D. Don Exert the
   Antiproliferative Effect on Colorectal Cancer Cells Via Hedgehog
   Signaling Pathway
SO PHARMACOGNOSY MAGAZINE
LA English
DT Article
DE Scutellaria barbata D. Don; diterpenoids; colorectal cancer; Hedgehog
   pathway; SHH
ID NEOCLERODANE DITERPENOIDS; COLON-CANCER; CHLOROFORM FRACTION; ALKALOIDS;
   APOPTOSIS; GROWTH; PROLIFERATION; SUPPRESSION; INDUCTION; PROMOTES
AB Background: Scutellaria barbata D. Don, also known as "Banzhilian" in China, the diterpenes of Banzhilian (Bzl-D) is a commonly used herbal medicine for treating various tumors including colorectal cancer (CRC). Objectives: This study aimed to examine the function of Bzl-D in inhibiting CRC development and explore its potential targets and mechanisms involving the Hedgehog (HH) pathway. Materials and methods: To determine the major components in Bzl-D, we performed ultra-performance liquid chromatography-quadrupole time-of-flight mass spectrometry (UPLC-qTOF-MS) analysis. The proliferation, migration, invasion, and apoptosis abilities of the CRC HT-29 cell line were examined, and the related protein expression was tested. Tumorigenesis after treatment was detected by in vivo experiments. Results: Nineteen diterpenoids were detected, Bzl-D significantly inhibited the cell proliferation and metastasis and induced the apoptosis of HT-29 cells through binding to Sonic HH (SHH) and down-regulating the key proteins (SHH, patched, smoothened, and glioma-associated oncogene) of the HH pathway, thus. Of note, Bzl-D remarkably suppressed the growth of HT-29 xenografts in nude mice. Conclusion: This research demonstrates that Bzl-D is a promising anti-rectal cancer drug, providing a new entry point for targeted therapy of CRC.
C1 [Wang, Wenwen; Tao, Zhongyi; Tu, Linglan; Huang, Wenkang; Ye, Yiping; Gao, Lijuan; Li, Xiaoyu] Hangzhou Med Coll, Sch Pharm, Hangzhou, Zhejiang, Peoples R China.
   [Li, Xiaoyu] First Peoples Hosp Xiaoshan Dist, Dept Pathol, Hangzhou, Zhejiang, Peoples R China.
   [Wang, Wenwen; Tao, Zhongyi; Tu, Linglan; Huang, Wenkang; Ye, Yiping; Gao, Lijuan; Li, Xiaoyu] Hangzhou Med Coll, Sch Pharm, Key Lab Neuropsychiat Drug Res Zhejiang Prov, Hangzhou, Zhejiang, Peoples R China.
   [Li, Xiaoyu] Hangzhou Med Coll, Sch Pharm, Hangzhou 310013, Zhejiang, Peoples R China.
C3 Hangzhou Medical College; Hangzhou Medical College; Hangzhou Medical
   College
RP Li, XY (corresponding author), Hangzhou Med Coll, Sch Pharm, Hangzhou 310013, Zhejiang, Peoples R China.
EM 775423305@qq.com
RI Li, Xiaoyu/R-4413-2016
FU Medical Health Science and Technology Project of Zhejiang Provincial
   Health Commission [2021KY638, 2021KY644]
FX This research was funded by the Medical Health Science and Technology
   Project of Zhejiang Provincial Health Commission (2021KY638 and
   2021KY644).
CR Bian YH, 2007, WORLD J GASTROENTERO, V13, P1659, DOI 10.3748/wjg.v13.i11.1659
   Bissey PA, 2020, CANCER RES, V80, P1970, DOI 10.1158/0008-5472.CAN-19-1340
   BRAY F, 2018, CA-CANCER J CLIN, V68, P394, DOI [DOI 10.3322/CANJCLIN.49.1.33, DOI 10.3322/CAAC.21492]
   Briscoe J, 2013, NAT REV MOL CELL BIO, V14, P416, DOI 10.1038/nrm3598
   Chang GJ, 2007, J NATL CANCER I, V99, P433, DOI 10.1093/jnci/djk092
   Chen CC, 2017, ONCOTARGET, V8, P109340, DOI 10.18632/oncotarget.22677
   Dai SJ, 2008, CHEM PHARM BULL, V56, P207, DOI 10.1248/cpb.56.207
   Dai SJ, 2007, CHEM PHARM BULL, V55, P1218, DOI 10.1248/cpb.55.1218
   Dai SJ, 2006, PHYTOCHEMISTRY, V67, P1326, DOI 10.1016/j.phytochem.2006.04.024
   Dai SJ, 2006, CHEM PHARM BULL, V54, P869, DOI 10.1248/cpb.54.869
   Dai SJ, 2010, FITOTERAPIA, V81, P737, DOI 10.1016/j.fitote.2010.01.001
   Dai SJ, 2009, J ASIAN NAT PROD RES, V11, P451, DOI 10.1080/10286020902845652
   Douard R, 2006, SURGERY, V139, P665, DOI 10.1016/j.surg.2005.10.012
   Feng PP, 2021, J BIOCHEM MOL TOXIC, V35, DOI 10.1002/jbt.22731
   Gao J, 2014, TUMOR BIOL, V35, P2549, DOI 10.1007/s13277-013-1336-4
   Gulino A, 2012, VITAM HORM, V88, P211, DOI 10.1016/B978-0-12-394622-5.00009-2
   [郝晓杉 Hao Xiaoshan], 2022, [中国病理生理杂志, Chinese Journal of Pathophysiology], V38, P1001
   Haycraft CJ, 2005, PLOS GENET, V1, P480, DOI 10.1371/journal.pgen.0010053
   Hung JS, 2014, ONCOTARGET, V5, P2096, DOI 10.18632/oncotarget.1815
   Jiang J, 2022, SEMIN CANCER BIOL, V85, P107, DOI 10.1016/j.semcancer.2021.04.003
   Li HY, 2020, PHYTOCHEMISTRY, V171, DOI 10.1016/j.phytochem.2019.112230
   Li YY, 2013, J ASIAN NAT PROD RES, V15, P941, DOI 10.1080/10286020.2013.821983
   Lin JM, 2014, INTEGR CANCER THER, V13, P240, DOI 10.1177/1534735413508811
   Liu YM, 2018, CANCER MED-US, V7, P5704, DOI 10.1002/cam4.1827
   Nguyen VH, 2009, EUR J ORG CHEM, V2009, P5810, DOI 10.1002/ejoc.200900431
   Niewiadomski P, 2014, CELL REP, V6, P168, DOI 10.1016/j.celrep.2013.12.003
   Qu GW, 2010, J ASIAN NAT PROD RES, V12, P859, DOI 10.1080/10286020.2010.507546
   Skoda AM, 2018, BOSNIAN J BASIC MED, V18, P8, DOI 10.17305/bjbms.2018.2756
   Sustic T, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0600-z
   Tiwari A, 2018, WORLD J GASTROENTERO, V24, P4428, DOI 10.3748/wjg.v24.i39.4428
   Hanh TTH, 2019, PHYTOCHEM LETT, V29, P65, DOI 10.1016/j.phytol.2018.11.008
   Wang F, 2010, CHEM PHARM BULL, V58, P1267, DOI 10.1248/cpb.58.1267
   Wang ML, 2019, CHEM BIODIVERS, V16, DOI 10.1002/cbdv.201800499
   Wang ML, 2020, NAT PROD RES, V34, P1345, DOI 10.1080/14786419.2018.1514399
   Wang TP, 2012, CARCINOGENESIS, V33, P1158, DOI 10.1093/carcin/bgs138
   Wei LH, 2012, INT J MOL SCI, V13, P9419, DOI 10.3390/ijms13089419
   Xiao Kai, 2016, Zhongguo Zhong Yao Za Zhi, V41, P3366, DOI 10.4268/cjcmm20161810
   Xu HL, 2013, PHYTOMEDICINE, V20, P897, DOI 10.1016/j.phymed.2013.03.025
   Yang XK, 2014, MOLECULES, V19, P8740, DOI 10.3390/molecules19078740
   Zhang L, 2017, ONCOL REP, V37, P3695, DOI 10.3892/or.2017.5625
   Zhang L, 2014, MOL MED REP, V9, P701, DOI 10.3892/mmr.2013.1864
   Zhang M, 2022, DRUG DEVELOP RES, V83, P1201, DOI 10.1002/ddr.21951
   Zhu F, 2011, PLANTA MED, V77, P1536, DOI 10.1055/s-0030-1270797
   Zhu F, 2010, J NAT PROD, V73, P233, DOI 10.1021/np900309p
NR 44
TC 0
Z9 0
U1 5
U2 6
PU SAGE PUBLICATIONS INDIA  PVT LTD
PI NEW DELHI
PA B-1-I-1 MOHAN CO-OPERATIVE INDUSTRIAL AREA, MATHURA RD, POST BAG NO 7,
   NEW DELHI 110 044, INDIA
SN 0973-1296
EI 0976-4062
J9 PHARMACOGN MAG
JI Pharmacogn. Mag.
PD SEP
PY 2024
VL 20
IS 3
BP 877
EP 886
DI 10.1177/09731296241234714
EA MAR 2024
PG 10
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA A5G1B
UT WOS:001186622400001
OA hybrid
DA 2025-01-04
ER

PT J
AU Yuan, MQ
   Wang, Z
   Zhao, YZ
   Feng, TT
   Lv, WX
   Zhong, HJ
AF Yuan, Meiqin
   Wang, Zeng
   Zhao, Yazhen
   Feng, Tingting
   Lv, Wangxia
   Zhong, Haijun
TI Cetuximab Can Be an Effective and Low-Toxicity Maintenance Treatment
   Drug in Patients With Metastatic Colorectal Cancer: A Real-World Study
   of Zhejiang Cancer Hospital
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Article
DE cetuximab; mCRC; maintenance treatment; survival; safety
ID FLUOROURACIL PLUS LEUCOVORIN; RANDOMIZED CONTROLLED-TRIAL; 1ST-LINE
   TREATMENT; OXALIPLATIN; IRINOTECAN
AB After initial treatment, maintenance therapy is now commonly used in mCRC patients, which can help patients live longer, have lower side effects, and higher quality of life. The maintenance treatment may include chemotherapy, targeted therapy, or combined with chemotherapy and targeted therapy. But the evidence of cetuximab maintenance is still scant.
   Methods: We collected real-world data of wild-type RAS unresectable mCRC patients who were treated with cetuximab-based chemotherapy as the first-line therapy between January 2013 and December 2018 at the Zhejiang Cancer Hospital (Hangzhou, China).
   Results: A total of 177 patients were ultimately included in the study, and 107 patients had progression information in medical records; all patients had survival data. The median OS was 40.9 ms, ORR was 14.7%, and DCR was 73.5%. The subgroup analysis showed that the mOS was better in maintenance patients than in non-maintenance patients (47.1 vs. 28.6 ms, p = 0.001), patients with primary tumor resection had better mOS than who did not (47.1 vs. 35.4 ms, p = 0.038). In those 107 patients who had progression information, the median PFS was 9 ms, the median OS was 42.6 ms, ORR was 18.7%, and DCR was 84.1%. The subgroup analysis showed that the mPFS and mOS were 11.6 and 47.1 ms, respectively, in the maintenance group, which were significantly better than 6.1 ms and 28.7 ms in the non-maintenance group (p = 0.025 and 0.017, respectively). The mPFS and mOS in patients with efficacy evaluation of CR + PR + SD were 10.3 and 47.1 ms, respectively, which is significantly better than 2.8 and 13.5 ms in the PD patients (p = 0.012 and <0.001, respectively). The mOS was best in only lung metastases patients (60.9 ms), then only liver metastases patients (47.1 ms), and then in both liver and lung metastases (42.6 ms); the mOS in patients with other organs metastases was the worst (22.4 ms), p = 0.022. The mOS in male individuals is better than that in female individuals, 60.99 vs. 29.1 ms, respectively, p = 0.042. The primary tumor site and primary tumor resection also affect the OS, primary tumor resection better than did not (not reach the end vs. 35.7 ms, p = 0.048), left side better than right side (47.1 vs. 16.6 ms, p < 0.001), which is consistent with the literature report. There was no statistical difference in other subgroups.
   Conclusion: For patients with all RAS wild-type and initially unresectable mCRC who experienced standard first-line cetuximab-based treatment and maintenance treatment that contained cetuximab can significantly improve the mPFS and mOS, and the observed toxicity was mostly mild too. So, we consider that cetuximab can be an effective and safety maintenance drug in mCRC patients.
C1 [Yuan, Meiqin; Zhao, Yazhen; Feng, Tingting; Lv, Wangxia; Zhong, Haijun] Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Dept Colorectal Med,Zhejiang Canc Hosp,Canc Hosp, Hangzhou, Peoples R China.
   [Wang, Zeng] Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Dept Pharm,Canc Hosp,Zhejiang Canc Hosp, Hangzho, Peoples R China.
C3 Chinese Academy of Sciences; University of Chinese Academy of Sciences,
   CAS; Zhejiang Cancer Hospital; Chinese Academy of Sciences; University
   of Chinese Academy of Sciences, CAS; Zhejiang Cancer Hospital
RP Lv, WX; Zhong, HJ (corresponding author), Chinese Acad Sci, Univ Chinese Acad Sci, Inst Basic Med & Canc IBMC, Dept Colorectal Med,Zhejiang Canc Hosp,Canc Hosp, Hangzhou, Peoples R China.
EM Lvwx@zjcc.org.cn; Zhonghj@zjcc.org.cn
FU 1022 Talent Training Program of Zhejiang Cancer Hospital, Zhejiang
   Provincial National Science Foundation of China [LQ18H290002]; Zhejiang
   Medical and Health Science and Technology Project [2020KY477]; Zhejiang
   Science and technology project of traditional Chinese medicine
   [2021ZB036]
FX This work was supported by the 1022 Talent Training Program of Zhejiang
   Cancer Hospital, Zhejiang Provincial National Science Foundation of
   China (No. LQ18H290002), Zhejiang Medical and Health Science and
   Technology Project (No. 2020KY477), Zhejiang Science and technology
   project of traditional Chinese medicine (No. 2021ZB036).
CR Aranda E, 2018, EUR J CANCER, V101, P263, DOI 10.1016/j.ejca.2018.06.024
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Cassidy J, 2008, J CLIN ONCOL, V26, P2006, DOI 10.1200/JCO.2007.14.9898
   Chibaudel B, 2009, J CLIN ONCOL, V27, P5727, DOI 10.1200/JCO.2009.23.4344
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Goldberg RM, 2006, J CLIN ONCOL, V24, P3347, DOI 10.1200/JCO.2006.06.1317
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Tournigand C, 2006, J CLIN ONCOL, V24, P394, DOI 10.1200/JCO.2005.03.0106
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Waddell T, 2011, CANCER CHEMOTH PHARM, V67, P1111, DOI 10.1007/s00280-010-1322-0
   Yalcin S., 2013, J CLIN ONCOL, V30, P2012, DOI [10.1159/000355914, DOI 10.1159/000355914]
NR 14
TC 5
Z9 5
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD MAY 28
PY 2021
VL 12
AR 632076
DI 10.3389/fphar.2021.632076
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA SQ0NS
UT WOS:000660058700001
PM 34122063
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Tu, LF
   Sheng, LY
   Zhou, JY
   Wang, XF
   Wang, YH
   Shen, Q
   Shen, YH
AF Tu, Ling-Fang
   Sheng, Ling-Yan
   Zhou, Jian-Ying
   Wang, Xue-Fen
   Wang, Yue-Hong
   Shen, Qian
   Shen, Yi-Hong
TI Diagnosis and treatment of primary pulmonary enteric adenocarcinoma:
   Report of Six cases
SO WORLD JOURNAL OF CLINICAL CASES
LA English
DT Article
DE Pulmonary enteric adenocarcinoma; Immunohistochemistry; Diagnosis;
   Treatment; KRAS; Case report
ID DIFFERENTIATION
AB BACKGROUND
   Primary pulmonary enteric adenocarcinoma (PEAC) is a very rare subtype of invasive adenocarcinoma, and there have been no large studies on PEAC to date. Therefore, it is necessary to obtain much more information about the clinical and pathological features, diagnosis, differential diagnosis, and treatment of PEAC.
   CASE SUMMARY
   All clinical data of six patients with confirmed PEAC from 2013 to 2018 were collected, and data on diagnosis, differential diagnosis, and treatment of PEAC are discussed combined with all the associated literature. The mean age of six patients was 64.0 +/- 5.6 (59-73) years old. Their clinical manifestations were heterogeneous, and during their disease course, there were no gastrointestinal symptoms. There was no evidence from colonoscopy or imaging studies to suggest digestive tract tumors or new metastases. The most commonly mutated gene was KRAS (50.0%), and the pathological features of the six cases were similar to those of colorectal cancer. CDX2 (83.3%) and CK7 (66.7%) had the highest positive rates upon immunohistochemical examination. In the associated literature, 252 cases were identified, and the most commonly mutated gene was KRAS (42.9%). Additionally, CDX2 (68.3%) and CK7 (85.8%) had the highest positive rates. Patients mainly received surgery, chemotherapy, and radiotherapy, immunotherapy was not included.
   CONCLUSION
   Positive results for CDX2 and CK7 play an important role in the diagnosis and differential diagnosis of PEAC, and immunotherapy or targeted therapy focused on KRAS needs to be further studied for the treatment of PEAC.
C1 [Tu, Ling-Fang; Sheng, Ling-Yan; Zhou, Jian-Ying; Wang, Xue-Fen; Wang, Yue-Hong; Shen, Qian; Shen, Yi-Hong] Zhejiang Univ, Affiliated Hosp 1, Dept Resp Med, Sch Med, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
C3 Zhejiang University
RP Shen, YH (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Resp Med, Sch Med, 79 Qingchun Rd, Hangzhou 310003, Zhejiang, Peoples R China.
EM drsyh@zju.edu.cn
FU Medicine and Health Project of Zhejiang Province, China [2018KY049]
FX Medicine and Health Project of Zhejiang Province, China, No. 2018KY049.
CR Chen M, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1449-z
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Feng C, 2019, APPL IMMUNOHISTO M M, V27, P364, DOI 10.1097/PAI.0000000000000632
   Handa Y, 2016, GEN THORAC CARDIOVAS, V64, P749, DOI 10.1007/s11748-015-0569-0
   Hatanaka K, 2011, PATHOL RES PRACT, V207, P188, DOI 10.1016/j.prp.2010.07.005
   Inamura K, 2005, AM J SURG PATHOL, V29, P660, DOI 10.1097/01.pas.0000160438.00652.8b
   Kazama Shinsuke, 2014, Nihon Rinsho, V72, P71
   László T, 2014, HISTOPATHOLOGY, V65, P283, DOI 10.1111/his.12403
   Lin L, 2016, EXP THER MED, V11, P201, DOI 10.3892/etm.2015.2864
   Matsushima J, 2017, HUM PATHOL, V64, P179, DOI 10.1016/j.humpath.2017.04.006
   Miyaoka M, 2018, INT J SURG PATHOL, V26, P464, DOI 10.1177/1066896918756737
   Nottegar A, 2017, EXP MOL PATHOL, V102, P276, DOI 10.1016/j.yexmp.2017.02.014
   Ou SHI, 2011, EXPERT REV ANTICANC, V11, P1535, DOI [10.1586/era.11.99, 10.1586/ERA.11.99]
   Perkins GL, 2003, AM FAM PHYSICIAN, V68, P1075
   Sato Y, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2897-6
   TSAO MS, 1991, CANCER-AM CANCER SOC, V68, P1754, DOI 10.1002/1097-0142(19911015)68:8<1754::AID-CNCR2820680818>3.0.CO;2-E
   Wang CX, 2014, INT J CLIN EXP PATHO, V7, P1266
   Yin ZH, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-439
   Yousem SA, 2005, MODERN PATHOL, V18, P816, DOI 10.1038/modpathol.3800358
   Zhao L, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008153
NR 20
TC 7
Z9 7
U1 0
U2 7
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 2307-8960
J9 WORLD J CLIN CASES
JI World J. Clin. Cases
PD OCT 26
PY 2021
VL 9
IS 30
BP 9236
EP 9243
DI 10.12998/wjcc.v9.i30.9236
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA YN4HT
UT WOS:000747221600032
PM 34786410
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Iyer, P
   Shrikhande, SV
   Ranjan, M
   Joshi, A
   Gardi, N
   Prasad, R
   Dharavath, B
   Thorat, R
   Salunkhe, S
   Sahoo, B
   Chandrani, P
   Kore, H
   Mohanty, B
   Chaudhari, V
   Choughule, A
   Kawle, D
   Chaudhari, P
   Ingle, A
   Banavali, S
   Gera, P
   Ramadwar, MR
   Prabhash, K
   Barreto, SG
   Dutt, S
   Dutt, A
AF Iyer, Prajish
   Shrikhande, Shailesh V.
   Ranjan, Malika
   Joshi, Asim
   Gardi, Nilesh
   Prasad, Ratnam
   Dharavath, Bhasker
   Thorat, Rahul
   Salunkhe, Sameer
   Sahoo, Bikram
   Chandrani, Pratik
   Kore, Hitesh
   Mohanty, Bhabani
   Chaudhari, Vikram
   Choughule, Anuradha
   Kawle, Dhananjay
   Chaudhari, Pradip
   Ingle, Arvind
   Banavali, Shripad
   Gera, Poonam
   Ramadwar, Mukta R.
   Prabhash, Kumar
   Barreto, Savio George
   Dutt, Shilpee
   Dutt, Amit
TI ERBB2 and KRAS alterations mediate response to EGFR inhibitors in early
   stage gallbladder cancer
SO INTERNATIONAL JOURNAL OF CANCER
LA English
DT Article
DE gallbladder cancer; whole exome sequencing; ErbB pathway; KRAS mutation;
   targeted therapy
ID TYROSINE-KINASE; LUNG-CANCER; CODON 12; MUTATIONS; THERAPY;
   HETEROGENEITY; ALIGNMENT; IMPACT; GROWTH; EXOME
AB The uncommonness of gallbladder cancer in the developed world has contributed to the generally poor understanding of the disease. Our integrated analysis of whole exome sequencing, copy number alterations, immunohistochemical, and phospho-proteome array profiling indicates ERBB2 alterations in 40% early-stage rare gallbladder tumors, among an ethnically distinct population not studied before, that occurs through overexpression in 24% (n = 25) and recurrent mutations in 14% tumors (n = 44); along with co-occurring KRAS mutation in 7% tumors (n = 44). We demonstrate that ERBB2 heterodimerizes with EGFR to constitutively activate the ErbB signaling pathway in gallbladder cells. Consistent with this, treatment with ERBB2-specific, EGFR-specific shRNA or with a covalent EGFR family inhibitor Afatinib inhibits tumor-associated characteristics of the gallbladder cancer cells. Furthermore, we observe an in vivo reduction in tumor size of gallbladder xenografts in response to Afatinib is paralleled by a reduction in the amounts of phospho-ERK, in tumors harboring KRAS (G13D) mutation but not in KRAS (G12V) mutation, supporting an essential role of the ErbB pathway. In overall, besides implicating ERBB2 as an important therapeutic target under neo-adjuvant or adjuvant settings, we present the first evidence that the presence of KRAS mutations may preclude gallbladder cancer patients to respond to anti-EGFR treatment, similar to a clinical algorithm commonly practiced to opt for anti-EGFR treatment in colorectal cancer.
C1 [Iyer, Prajish; Ranjan, Malika; Joshi, Asim; Gardi, Nilesh; Prasad, Ratnam; Dharavath, Bhasker; Sahoo, Bikram; Chandrani, Pratik; Kore, Hitesh; Kawle, Dhananjay; Dutt, Amit] Tata Mem Hosp, ACTREC, Integrated Canc Genom Lab, Navi Mumbai, Maharashtra, India.
   [Iyer, Prajish; Shrikhande, Shailesh V.; Joshi, Asim; Dharavath, Bhasker; Salunkhe, Sameer; Banavali, Shripad; Ramadwar, Mukta R.; Prabhash, Kumar; Dutt, Shilpee; Dutt, Amit] Homi Bhabha Natl Inst, Mumbai, Maharashtra, India.
   [Shrikhande, Shailesh V.; Chaudhari, Vikram; Barreto, Savio George] Tata Mem Hosp, Dept Gastrointestinal & Hepatopancreatobiliary Su, Ernest Borges Marg, Mumbai, Maharashtra, India.
   [Thorat, Rahul; Ingle, Arvind] Tata Mem Hosp, Adv Ctr Treatment Res & Educ Canc, Lab Anim Facil, Navi Mumbai, Maharashtra, India.
   [Salunkhe, Sameer; Dutt, Shilpee] Tata Mem Hosp, ACTREC, Shilpee Lab, Navi Mumbai, Maharashtra, India.
   [Mohanty, Bhabani; Chaudhari, Pradip] Tata Mem Hosp, ACTREC, Small Anim Imaging Facil, Navi Mumbai, Maharashtra, India.
   [Choughule, Anuradha; Banavali, Shripad; Prabhash, Kumar] Tata Mem Hosp, Dept Med Oncol, Ernest Borges Marg, Mumbai, Maharashtra, India.
   [Gera, Poonam] Tata Mem Hosp, ACTREC, Tissue Biorepository, Navi Mumbai, Maharashtra, India.
   [Ramadwar, Mukta R.] Tata Mem Hosp, Dept Pathol, Ernest Borges Marg, Mumbai, Maharashtra, India.
C3 Tata Memorial Centre (TMC); Tata Memorial Hospital; Advance Centre for
   Treatment, Research & Education in Cancer (ACTREC); Homi Bhabha National
   Institute; Tata Memorial Centre (TMC); Tata Memorial Hospital; Tata
   Memorial Centre (TMC); Tata Memorial Hospital; Advance Centre for
   Treatment, Research & Education in Cancer (ACTREC); Tata Memorial Centre
   (TMC); Advance Centre for Treatment, Research & Education in Cancer
   (ACTREC); Tata Memorial Hospital; Tata Memorial Centre (TMC); Advance
   Centre for Treatment, Research & Education in Cancer (ACTREC); Tata
   Memorial Hospital; Tata Memorial Centre (TMC); Tata Memorial Hospital;
   Tata Memorial Centre (TMC); Advance Centre for Treatment, Research &
   Education in Cancer (ACTREC); Tata Memorial Hospital; Tata Memorial
   Centre (TMC); Tata Memorial Hospital
RP Dutt, A (corresponding author), Tata Mem Hosp, ACTREC, Navi Mumbai 410210, India.
EM adutt@actrec.gov.in
RI Chaudhari, Pradip/H-6488-2013; Sundaram, Prajish/AAX-6691-2020;
   Salunkhe, Sameer/LBI-5928-2024; Chandrani, Pratik/AAV-9081-2021; Dutt,
   Amit/I-1911-2013; Chandrani, Pratik/K-2654-2014
OI Dutt, Amit/0000-0002-1119-4774; Chandrani, Pratik/0000-0003-2572-0189;
   Iyer, Prajish/0000-0001-6982-6343; Barreto, Savio
   George/0000-0002-4999-5657
FU Wellcome Trust/DBT India Alliance [IA/I/11/2500278]
FX Wellcome Trust/DBT India Alliance; Grant numbers: IA/I/11/2500278
CR Barreto SG, 2014, ANN ONCOL, V25, P1086, DOI 10.1093/annonc/mdu006
   Boeva V, 2012, BIOINFORMATICS, V28, P423, DOI 10.1093/bioinformatics/btr670
   Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349
   Carpenter AE, 2006, GENOME BIOL, V7, DOI 10.1186/gb-2006-7-10-r100
   Chandrani P, 2017, ANN ONCOL, V28, P597, DOI 10.1093/annonc/mdw636
   Chandrani P, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-2138-4
   Choughule A, 2014, BRIT J CANCER, V111, P2203, DOI 10.1038/bjc.2014.401
   Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Do K, 2015, CHIN CLIN ONCOL, V4, DOI 10.3978/j.issn.2304-3865.2015.08.01
   Doval Dinesh Chandra, 2014, J Carcinog, V13, P10, DOI 10.4103/1477-3163.139450
   Druker BJ, 2001, NEW ENGL J MED, V344, P1038, DOI 10.1056/NEJM200104053441402
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Forbes S A, 2008, Curr Protoc Hum Genet, VChapter 10, DOI 10.1002/0471142905.hg1011s57
   García-Alcalde F, 2012, BIOINFORMATICS, V28, P2678, DOI 10.1093/bioinformatics/bts503
   Garner AP, 2013, CANCER RES, V73, P6024, DOI 10.1158/0008-5472.CAN-13-1198
   Godbole M, 2017, CELL ONCOL, V40, P411, DOI 10.1007/s13402-017-0330-z
   Gonzalez-Perez A, 2013, NAT METHODS, V10, P1081, DOI [10.1038/nmeth.2642, 10.1038/NMETH.2642]
   Iyer P, 2016, INFECT AGENTS CANCER, V11, DOI 10.1186/s13027-016-0057-x
   Javle M, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0155-z
   Jiao YC, 2013, NAT GENET, V45, P1470, DOI 10.1038/ng.2813
   Krause DS, 2005, NEW ENGL J MED, V353, P172, DOI 10.1056/NEJMra044389
   Kumar Shalini Sree, 2014, Gastrointest Cancer Res, V7, P23
   Lawrence MS, 2013, NATURE, V499, P214, DOI 10.1038/nature12213
   Le Tourneau C, 2014, BRIT J CANCER, V111, P17, DOI 10.1038/bjc.2014.211
   Li D, 2008, ONCOGENE, V27, P4702, DOI 10.1038/onc.2008.109
   Li H, 2009, BIOINFORMATICS, V25, P1754, DOI 10.1093/bioinformatics/btp324
   Li ML, 2019, GUT, V68, P1024, DOI 10.1136/gutjnl-2018-316039
   Li ML, 2014, NAT GENET, V46, P872, DOI 10.1038/ng.3030
   Li WB, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1345-3
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Linggi B, 2006, TRENDS CELL BIOL, V16, P649, DOI 10.1016/j.tcb.2006.10.008
   McGranahan N, 2015, CANCER CELL, V27, P15, DOI 10.1016/j.ccell.2014.12.001
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   Miller G, 2008, EJSO-EUR J SURG ONC, V34, P306, DOI 10.1016/j.ejso.2007.07.206
   Muller Bettina G, 2014, Am Soc Clin Oncol Educ Book, pe165, DOI 10.14694/EdBook_AM.2014.34.e165
   Nakamura H, 2015, NAT GENET, V47, P1003, DOI 10.1038/ng.3375
   Osumi H, 2015, MOL CLIN ONCOL, V3, P1053, DOI 10.3892/mco.2015.602
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Petitjean A, 2007, ONCOGENE, V26, P2157, DOI 10.1038/sj.onc.1210302
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612
   Rakic Mislav, 2014, Hepatobiliary Surg Nutr, V3, P221, DOI 10.3978/j.issn.2304-3881.2014.09.03
   Ramos AH, 2015, HUM MUTAT, V36, pE2423, DOI 10.1002/humu.22771
   Rusnak DW, 2001, MOL CANCER THER, V1, P85
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   SPIVAKKROIZMAN T, 1992, J BIOL CHEM, V267, P8056
   Tebbutt N, 2013, NAT REV CANCER, V13, P663, DOI 10.1038/nrc3559
   Upadhyay P, 2016, DATABASE, P1
   Upadhyay P, 2016, ONCOTARGET, V7, P50437, DOI 10.18632/oncotarget.10419
   Yanagisawa N, 2010, ANTICANCER RES, V30, P4443
   Yaziji H, 2004, JAMA-J AM MED ASSOC, V291, P1972, DOI 10.1001/jama.291.16.1972
   Yoon HH, 2014, CLIN CANCER RES, V20, P3033, DOI 10.1158/1078-0432.CCR-13-3140
   Yoshida K, 2014, WIRES RNA, V5, P445, DOI 10.1002/wrna.1222
   Zhou XD, 2012, CELL SIGNAL, V24, P140, DOI 10.1016/j.cellsig.2011.08.015
   Zhu AX, 2010, ONCOLOGIST, V15, P168, DOI 10.1634/theoncologist.2009-0302
NR 56
TC 32
Z9 34
U1 0
U2 21
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0020-7136
EI 1097-0215
J9 INT J CANCER
JI Int. J. Cancer
PD APR 15
PY 2019
VL 144
IS 8
BP 2008
EP 2019
DI 10.1002/ijc.31916
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HL6DP
UT WOS:000458824300022
PM 30304546
OA hybrid, Green Submitted, Green Accepted, Green Published
DA 2025-01-04
ER

PT J
AU Moradi, A
   Pourseif, MM
   Jafari, B
   Parvizpour, S
   Omidi, Y
AF Moradi, Azita
   Pourseif, Mohammad M.
   Jafari, Behzad
   Parvizpour, Sepideh
   Omidi, Yadollah
TI Nanobody-based therapeutics against colorectal cancer: Precision
   therapies based on the personal mutanome profile and tumor neoantigens
SO PHARMACOLOGICAL RESEARCH
LA English
DT Review
DE Camelid heavy chain; Colorectal cancer; Nanobody; Neoantigen
   vaccination; Precision immunotherapy; Targeted therapy
ID GROWTH-FACTOR RECEPTOR; SINGLE-DOMAIN ANTIBODIES; GENE MUTATION STATUS;
   EFFICIENT INHIBITION; BREAST-CANCER; HUMAN COLON; STEM-CELLS; EGFR;
   ANGIOGENESIS; NANOPARTICLES
AB Monoclonal antibodies and vaccines have widely been studied for the immunotherapy of cancer, while their large size appears to limit their functionality in solid tumors, in large part due to unique properties of tumor microenvironment such as high pressure of tumor interstitial fluid. To tackle such limitations, smaller formats of antibodies have been developed, including antigen-binding fragments, single-chain variable fragments, single variable domain of camelid antibody (so-called nanobody (Nb) or VHH). Of these, Nbs offer great immunotherapy potentials because of their advantageous physicochemical and pharmacological features, including small size, high stability, and excellent tissue penetration. Besides, the therapeutic impacts of Nbs can be improved by their modifications and functionalizations (e.g., PEGylation and conjugation to the Fc domain, peptide tags, drugs, toxins, aptamers, and radionuclides). This review aims to provide comprehensive insights into key signaling networks of colorectal cancer and discuss Nb-based precision immunotherapy of colorectal cancer.
C1 [Moradi, Azita; Pourseif, Mohammad M.; Jafari, Behzad; Parvizpour, Sepideh; Omidi, Yadollah] Tabriz Univ Med Sci, Biomed Inst, Res Ctr Pharmaceut Nanotechnol, Tabriz, Iran.
   [Jafari, Behzad] Urmia Univ Med Sci, Fac Pharm, Dept Med Chem, Orumiyeh, Iran.
   [Omidi, Yadollah] Tabriz Univ Med Sci, Fac Pharm, Dept Pharmaceut, Tabriz, Iran.
C3 Tabriz University of Medical Science; Urmia University of Medical
   Sciences; Tabriz University of Medical Science
RP Omidi, Y (corresponding author), Tabriz Univ Med Sci, Fac Pharm, Res Ctr Pharmaceut Nanotechnol, Tabriz 5165665811, Iran.
EM yomidi@tbzmed.ac.ir
RI Jafari, Behzad/P-7365-2019; Pourseif, Mohammad mostafa/IUO-0629-2023;
   Parvizpour, Sepideh/AAK-7331-2021; Omidi, Yadollah/U-2397-2019
OI Pourseif, Mohammad Mostafa/0000-0001-8314-2853
FU Research Center for Pharmaceutical Nanotechnology (RCPN), Tabriz
   University of Medical Sciences
FX The authors are grateful for the financial support provided by the
   Research Center for Pharmaceutical Nanotechnology (RCPN), Tabriz
   University of Medical Sciences. The authors also like to thank Ms.
   Nastaran Mohammadi Ghahhari for assisting in English editing.
CR Abdullah SE, 2012, CANCER-AM CANCER SOC, V118, P3455, DOI 10.1002/cncr.26540
   Ainscough BJ, 2016, NAT METHODS, V13, P806, DOI 10.1038/nmeth.4000
   Albert Susann, 2018, Oncotarget, V9, P25597, DOI 10.18632/oncotarget.25390
   Alibakhshi A, 2017, J CONTROL RELEASE, V268, P323, DOI 10.1016/j.jconrel.2017.10.036
   Alizadeh S, 2020, J DRUG TARGET, V28, P700, DOI 10.1080/1061186X.2020.1737087
   Allen J, 2004, HEMATOL ONCOL CLIN N, V18, P1087, DOI 10.1016/j.hoc.2004.05.002
   Altintas I, 2013, J CONTROL RELEASE, V165, P110, DOI 10.1016/j.jconrel.2012.11.007
   Antonacopoulou AG, 2008, HISTOPATHOLOGY, V53, P698, DOI 10.1111/j.1365-2559.2008.03165.x
   Appert-Collin A, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00283
   Arezumand R, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01746
   Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Asgharzadeh MR, 2019, BIOIMPACTS, V9, P145, DOI 10.15171/bi.2019.19
   Bannas P, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01603
   Bannas P, 2015, JOVE-J VIS EXP, DOI 10.3791/52462
   Behdani M, 2013, NEW BIOTECHNOL, V30, P205, DOI 10.1016/j.nbt.2012.09.002
   Behdani M, 2012, MOL IMMUNOL, V50, P35, DOI 10.1016/j.molimm.2011.11.013
   Bell A, 2010, CANCER LETT, V289, P81, DOI 10.1016/j.canlet.2009.08.003
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Béroud C, 2003, HUM MUTAT, V21, P176, DOI 10.1002/humu.10187
   Bethuyne J, 2014, NUCLEIC ACIDS RES, V42, P12928, DOI 10.1093/nar/gku962
   Bian XY, 2016, ONCOTARGETS THER, V9, P3153, DOI 10.2147/OTT.S100678
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Caspi R, 2020, NUCLEIC ACIDS RES, V48, pD445, DOI 10.1093/nar/gkz862
   CHUNG TP, 2004, SEMIN COLON RECTAL S, P128
   Conradi LC, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6051-0
   Conrath KE, 2001, J BIOL CHEM, V276, P7346, DOI 10.1074/jbc.M007734200
   Cortez-Retamozo V, 2004, CANCER RES, V64, P2853, DOI 10.1158/0008-5472.CAN-03-3935
   Croft D, 2011, NUCLEIC ACIDS RES, V39, pD691, DOI 10.1093/nar/gkq1018
   De Buck S, 2013, PLANT BIOTECHNOL J, V11, P1006, DOI 10.1111/pbi.12094
   Ding L, 2015, THERANOSTICS, V5, P378, DOI 10.7150/thno.10084
   Dobre M, 2013, ROM J MORPHOL EMBRYO, V54, P567
   Dotan E, 2017, J CLIN ONCOL, V35, P3338, DOI 10.1200/JCO.2017.73.9011
   Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033
   Ebrahimizadeh W, 2015, APPL BIOCHEM BIOTECH, V176, P1985, DOI 10.1007/s12010-015-1695-y
   Ellis LM, 2004, HEMATOL ONCOL CLIN N, V18, P1007, DOI 10.1016/j.hoc.2004.06.002
   Farajpour Z, 2014, BIOCHEM BIOPH RES CO, V446, P132, DOI 10.1016/j.bbrc.2014.02.069
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Fernandes CFC, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00653
   Friedl P, 2003, NAT REV CANCER, V3, P362, DOI 10.1038/nrc1075
   Gainkam LOT, 2008, J NUCL MED, V49, P788, DOI 10.2967/jnumed.107.048538
   Gertig DM, 1998, SEMIN CANCER BIOL, V8, P285, DOI 10.1006/scbi.1998.0078
   Giordano TJ, 2014, ENDOCR PATHOL, V25, P362, DOI 10.1007/s12022-014-9345-4
   Gong Rui, 2012, Methods Mol Biol, V899, P85, DOI 10.1007/978-1-61779-921-1_6
   Gonzalez-Perez A, 2013, NAT METHODS, V10, P1081, DOI [10.1038/nmeth.2642, 10.1038/NMETH.2642]
   HAMERSCASTERMAN C, 1993, NATURE, V363, P446, DOI 10.1038/363446a0
   Hampel H, 2008, J CLIN ONCOL, V26, P5783, DOI 10.1200/JCO.2008.17.5950
   Harmsen MM, 2007, APPL MICROBIOL BIOT, V77, P13, DOI 10.1007/s00253-007-1142-2
   Harmsen MM, 2005, VACCINE, V23, P4926, DOI 10.1016/j.vaccine.2005.05.017
   Hassink J, 2017, ANIMALS-BASEL, V7, DOI 10.3390/ani7060045
   Hemminki K, 2004, CANCER EPIDEM BIOMAR, V13, P1253
   Holliger P, 2005, NAT BIOTECHNOL, V23, P1126, DOI 10.1038/nbt1142
   Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang L, 2008, MOL IMAGING BIOL, V10, P167, DOI 10.1007/s11307-008-0133-8
   Huber PE, 2005, CANCER RES, V65, P3643, DOI 10.1158/0008-5472.CAN-04-1668
   Iranzo J, 2018, P NATL ACAD SCI USA, V115, pE6010, DOI 10.1073/pnas.1803155115
   Jafari B, 2019, EXPERT OPIN DRUG DEL, V16, P583, DOI 10.1080/17425247.2019.1614911
   Janmaat ML, 2003, DRUG TODAY, V39, P61
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kanehisa M, 2012, NUCLEIC ACIDS RES, V40, pD109, DOI 10.1093/nar/gkr988
   Kavousipour S, 2017, BIOTECHNOL LETT, V39, P785, DOI 10.1007/s10529-017-2303-8
   Kazemi-Lomedasht F, 2015, MOL IMMUNOL, V65, P58, DOI 10.1016/j.molimm.2015.01.010
   Keyaerts M, 2016, J NUCL MED, V57, P27, DOI 10.2967/jnumed.115.162024
   Khiavi MA, 2020, BIOIMPACTS, V10, P27, DOI 10.15171/bi.2020.04
   Khiavi MA, 2020, CELL MOL LIFE SCI, V77, P997, DOI 10.1007/s00018-019-03305-z
   Kijanka M, 2015, NANOMEDICINE-UK, V10, P161, DOI 10.2217/nnm.14.178
   Klebanov N, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41015-5
   Koch-Nolte F, 2007, FASEB J, V21, P3490, DOI 10.1096/fj.07-8661com
   Koganemaru S, 2019, MOL CANCER THER, V18, P2043, DOI 10.1158/1535-7163.MCT-19-0452
   Kreiter S, 2015, NATURE, V523, DOI 10.1038/nature14567
   Krishna M, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00021
   Krüwel T, 2016, SCI REP-UK, V6, DOI 10.1038/srep21834
   Laskowski RA, 2011, J CHEM INF MODEL, V51, P2778, DOI 10.1021/ci200227u
   Lengauer C, 1998, NATURE, V396, P643, DOI 10.1038/25292
   Leslie A, 2002, BRIT J SURG, V89, P845, DOI 10.1046/j.1365-2168.2002.02120.x
   Lu X, 2005, CURR OPIN GENET DEV, V15, P27, DOI 10.1016/j.gde.2004.12.008
   Ma L, 2016, ACTA PHARMACOL SIN, V37, P857, DOI 10.1038/aps.2016.2
   Macaron C, 2015, J SURG ONCOL, V111, P103, DOI 10.1002/jso.23706
   Mallini P, 2014, CANCER TREAT REV, V40, P341, DOI 10.1016/j.ctrv.2013.09.008
   Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373
   Muller BG, 1996, PHARMACEUT RES, V13, P32, DOI 10.1023/A:1016064930502
   Mundade Rasika, 2014, Oncoscience, V1, P400
   Muyldermans S, 2013, ANNU REV BIOCHEM, V82, P775, DOI 10.1146/annurev-biochem-063011-092449
   Nersisyan Lilit, 2014, F1000Res, V3, P145, DOI 10.12688/f1000research.4410.2
   Newnham LE, 2015, MABS-AUSTIN, V7, P180, DOI 10.4161/19420862.2015.989023
   Oliveira S, 2013, J CONTROL RELEASE, V172, P607, DOI 10.1016/j.jconrel.2013.08.298
   Ong BA, 2014, WORLD J GASTROENTERO, V20, P1898, DOI 10.3748/wjg.v20.i8.1898
   Ozturk K, 2018, J MOL BIOL, V430, P2875, DOI 10.1016/j.jmb.2018.06.016
   Pérez JMJ, 2001, BIOCHEMISTRY-US, V40, P74, DOI 10.1021/bi0009082
   Peyvandi F, 2016, NEW ENGL J MED, V374, P511, DOI 10.1056/NEJMoa1505533
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Polonelli L, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002371
   Price TJ, 2015, BRIT J CANCER, V112, P963, DOI 10.1038/bjc.2015.37
   Pruitt K, 2001, CANCER LETT, V171, P1, DOI 10.1016/S0304-3835(01)00528-6
   Qasemi M, 2016, PROTEIN EXPRES PURIF, V123, P19, DOI 10.1016/j.pep.2016.03.004
   RADINSKY R, 1995, CLIN CANCER RES, V1, P19
   Rahbarizadeh F, 2011, IMMUNOL INVEST, V40, P299, DOI 10.3109/08820139.2010.542228
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Ritchie DW, 2010, BIOINFORMATICS, V26, P2398, DOI 10.1093/bioinformatics/btq444
   Roovers RC, 2007, CANCER IMMUNOL IMMUN, V56, P303, DOI 10.1007/s00262-006-0180-4
   Roovers RC, 2011, INT J CANCER, V129, P2013, DOI 10.1002/ijc.26145
   Salema V, 2017, MICROB BIOTECHNOL, V10, P1468, DOI 10.1111/1751-7915.12819
   Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8
   Schmitz KR, 2013, STRUCTURE, V21, P1214, DOI 10.1016/j.str.2013.05.008
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Segditsas S, 2006, ONCOGENE, V25, P7531, DOI 10.1038/sj.onc.1210059
   STEELS A, 2018, INTRACELLULAR DISPLA, P1045
   Sundberg EJ, 2003, ADV PROTEIN CHEM, V61, P119
   Talelli M, 2013, BIOMATERIALS, V34, P1255, DOI 10.1016/j.biomaterials.2012.09.064
   Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171
   Tate JG, 2019, NUCLEIC ACIDS RES, V47, pD941, DOI 10.1093/nar/gky1015
   Tijink BM, 2008, MOL CANCER THER, V7, P2288, DOI 10.1158/1535-7163.MCT-07-2384
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160
   Vahed SZ, 2017, BIOMED PHARMACOTHER, V94, P1094, DOI 10.1016/j.biopha.2017.08.033
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P2861, DOI 10.1200/JCO.2011.40.9243
   van der Meel R, 2012, J CONTROL RELEASE, V159, P281, DOI 10.1016/j.jconrel.2011.12.027
   van Driel PBAA, 2016, J CONTROL RELEASE, V229, P93, DOI 10.1016/j.jconrel.2016.03.014
   Vormehr M, 2016, CURR OPIN IMMUNOL, V39, P14, DOI 10.1016/j.coi.2015.12.001
   Wang QJ, 2016, CANCER IMMUNOL RES, V4, P204, DOI 10.1158/2326-6066.CIR-15-0188
   Wang SY, 2008, EXPERT OPIN BIOL TH, V8, P759, DOI [10.1517/14712598.8.6.759, 10.1517/14712598.8.6.759 ]
   Waterhouse A, 2018, NUCLEIC ACIDS RES, V46, pW296, DOI 10.1093/nar/gky427
   Wesolowski J, 2009, MED MICROBIOL IMMUN, V198, P157, DOI 10.1007/s00430-009-0116-7
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Yarchoan M, 2017, NAT REV CANCER, V17, DOI [10.1038/nrc.2017.74, 10.1038/nrc.2016.154]
   Yeang CH, 2016, BIOL DIRECT, V11, DOI 10.1186/s13062-016-0153-2
   Yen LC, 2010, ANN SURG, V251, P254, DOI 10.1097/SLA.0b013e3181bc9d96
   Yokota T, 2012, ANTI-CANCER AGENT ME, V12, P163, DOI 10.2174/187152012799014968
   Yue P, 2012, ONCOGENE, V31, P2309, DOI 10.1038/onc.2011.409
   Zhou J, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/8103142
   ZHU YN, 2017, SCI REP UK, V7
NR 133
TC 24
Z9 29
U1 1
U2 42
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1043-6618
EI 1096-1186
J9 PHARMACOL RES
JI Pharmacol. Res.
PD JUN
PY 2020
VL 156
AR 104790
DI 10.1016/j.phrs.2020.104790
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA LP3UP
UT WOS:000534244400026
PM 32278043
DA 2025-01-04
ER

PT J
AU Morris, VK
AF Morris, Van K.
TI Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer:
   Recent Advances and Future Strategies
SO CURRENT COLORECTAL CANCER REPORTS
LA English
DT Article
DE Colorectal cancer; BRAF; Immunotherapy; Targeted therapy; Clinical
   trial; Biomarker
ID ISLAND METHYLATOR PHENOTYPE; CETUXIMAB PLUS IRINOTECAN; MICROSATELLITE
   INSTABILITY; OPEN-LABEL; WILD-TYPE; SERRATED POLYPS; COLON-CANCER;
   1ST-LINE TREATMENT; DOSE-ESCALATION; RAS MUTATIONS
AB Purpose of Review This review seeks to detail the clinical and pathologic features specific to BRAF(V600E) colorectal cancer. Application of novel preclinical findings translated into the clinic for the development of new therapeutic options for patients with BRAF(V600E) metastatic colorectal cancer will be detailed.
   Recent Findings While BRAF inhibitors as monotherapy do not have the same clinical activity for colorectal cancer relative to other solid tumors harboring an oncogenic BRAF(V600E) mutation, combination approaches targeting BRAF + MEK + EGFR hold promise for patients with BRAF(V600E) colorectal cancer.
   Summary Simultaneous targeting of multiple drivers along the MAPK pathway improves clinical outcomes for patients with BRAF(V600E) colorectal cancer. Targeted therapies and immunotherapy hold great promise in the years to come for patients with this subtype of colorectal cancer.
C1 [Morris, Van K.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center
RP Morris, VK (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
EM vkmorris@mdanderson.org
RI Morris, Van/KIE-0809-2024
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Hyman David M, 2015, N Engl J Med, V373, P726, DOI 10.1056/NEJMoa1502309
   [Anonymous], J CLIN ONCOL S
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Brose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8
   Campisi J, 2005, SCIENCE, V309, P886, DOI 10.1126/science.1116801
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Dietrich S, 2012, NEW ENGL J MED, V366, P2038, DOI 10.1056/NEJMc1202124
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Dummer R, 2018, LANCET ONCOL, V19, P603, DOI 10.1016/S1470-2045(18)30142-6
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Gervais R, 2005, ANN ONCOL, V16, P90, DOI 10.1093/annonc/mdi018
   Gonsalves WI, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju106
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Hazar-Rethinam M, 2018, CANCER DISCOV, V8, P417, DOI 10.1158/2159-8290.CD-17-1227
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Kalady MF, 2012, DIS COLON RECTUM, V55, P128, DOI 10.1097/DCR.0b013e31823c08b3
   Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   Kane MF, 1997, CANCER RES, V57, P808
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868
   Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Li WQ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-2
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   *NCC NETW, 2018, NCCN GUID COL CANC V
   O'Brien MJ, 2006, AM J SURG PATHOL, V30, P1491, DOI 10.1097/01.pas.0000213313.36306.85
   O'Brien MJ, 2004, AM J SURG PATHOL, V28, P423, DOI 10.1097/00000478-200404000-00001
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Oh MC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047846
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Price TJ, 2011, J CLIN ONCOL, V29, P2675, DOI 10.1200/JCO.2010.34.5520
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Robert C, 2015, NEW ENGL J MED, V372, P30, DOI 10.1056/NEJMoa1412690
   Rosove MH, 2013, NEW ENGL J MED, V368, P684, DOI 10.1056/NEJMc1215697
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Saridaki Z, 2010, BRIT J CANCER, V102, P1762, DOI 10.1038/sj.bjc.6605694
   Serrano M, 1997, CELL, V88, P593, DOI 10.1016/S0092-8674(00)81902-9
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Shen LL, 2007, P NATL ACAD SCI USA, V104, P18654, DOI 10.1073/pnas.0704652104
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sosman JA, 2012, NEW ENGL J MED, V366, P707, DOI 10.1056/NEJMoa1112302
   Subbiah V, 2018, J CLIN ONCOL, V36, P7, DOI 10.1200/JCO.2017.73.6785
   Tang Y, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0091571, 10.1371/journal.pone.0073402]
   Tie J, 2011, INT J CANCER, V128, P2075, DOI 10.1002/ijc.25555
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   VANCUTSEM E, 1926, ANN ONCOL, V29
   Wajapeyee N, 2008, CELL, V132, P363, DOI 10.1016/j.cell.2007.12.032
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yang S, 2004, AM J SURG PATHOL, V28, P1452, DOI 10.1097/01.pas.0000141404.56839.6a
   2014, ANN ONCOL S4, V25, P167
NR 77
TC 4
Z9 7
U1 2
U2 8
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1556-3790
EI 1556-3804
J9 CURR COLORECT CANC R
JI Curr. Colorectal Cancer Rep.
PD APR
PY 2019
VL 15
IS 2
BP 53
EP 60
DI 10.1007/s11888-019-00429-z
PG 8
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA HT9JD
UT WOS:000464884500002
PM 31762713
OA Green Accepted
DA 2025-01-04
ER

PT J
AU Wu, YX
   Mou, J
   Zhou, G
   Yuan, CF
AF Wu, Yinxin
   Mou, Jie
   Zhou, Gang
   Yuan, Chengfu
TI CASC19: An Oncogenic Long Non-coding RNA in Different Cancers
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE LncRNA; CASC19; tumors; mechanisms; biomarkers; radiation resistance
ID COLORECTAL-CANCER; PROGRESSION; CARCINOMA; OSTEOARTHRITIS;
   IMMUNOTHERAPY; EPIDEMIOLOGY; EXPRESSION; APOPTOSIS; AUTOPHAGY; CELLS
AB A 324 bp lncRNA called CASC19 is found on chromosome 8q24.21. Recent research works have revealed that CASC19 is involved in the prognosis of tumors and related to the regulation of the radiation tolerance mechanisms during tumor radiotherapy (RT). This review sheds light on the changes and roles that CASC19 plays in many tumors and diseases, such as nasopharyngeal carcinoma (NPC), cervical cancer, colorectal cancer (CRC), non-small cell lung cancer (NSCLC), clear cell renal cell carcinoma (ccRCC), gastric cancer (GC), pancreatic cancer (PC), hepatocellular carcinoma (HCC), glioma, and osteoarthritis (OA). CASC19 provides a new strategy for targeted therapy, and the regulatory networks of CASC19 expression levels play a key role in the occurrence and development of tumors and diseases. In addition, the expression level of CASC19 has predictive roles in the prognosis of some tumors and diseases, which has major implications for clinical diagnoses and treatments. CASC19 is also unique in that it is a key gene affecting the efficacy of RT in many tumors, and its expression level plays a decisive role in improving the success rate of treatments. Further research is required to determine the precise process by which CASC19 causes changes in diseased cells in some tumors and diseases.
C1 [Wu, Yinxin; Mou, Jie; Yuan, Chengfu] China Three Gorges Univ, Hubei Key Lab Tumor Microenvironm & Immunotherapy, Yichang 443002, Peoples R China.
   [Wu, Yinxin; Mou, Jie; Yuan, Chengfu] China Three Gorges Univ, Coll Basic Med Sci, Yichang 443002, Peoples R China.
   [Wu, Yinxin; Mou, Jie; Yuan, Chengfu] China Three Gorges Univ, Third Grade Pharmacol Lab Tradit Chinese Med, State Adm Tradit Chinese Med, Yichang 443002, Peoples R China.
   [Zhou, Gang] China Three Gorges Univ, Coll Tradit Chinese Med, Yichang 443002, Peoples R China.
   [Zhou, Gang] Yichang Hosp Tradit Chinese Med, Yichang 443002, Peoples R China.
C3 China Three Gorges University; China Three Gorges University; China
   Three Gorges University; China Three Gorges University
RP Yuan, CF (corresponding author), China Three Gorges Univ, Hubei Key Lab Tumor Microenvironm & Immunotherapy, Yichang 443002, Peoples R China.; Yuan, CF (corresponding author), China Three Gorges Univ, Coll Basic Med Sci, Yichang 443002, Peoples R China.; Yuan, CF (corresponding author), China Three Gorges Univ, Third Grade Pharmacol Lab Tradit Chinese Med, State Adm Tradit Chinese Med, Yichang 443002, Peoples R China.; Zhou, G (corresponding author), China Three Gorges Univ, Coll Tradit Chinese Med, Yichang 443002, Peoples R China.; Zhou, G (corresponding author), Yichang Hosp Tradit Chinese Med, Yichang 443002, Peoples R China.
EM yuancf46@ctgu.edu.cn; 13661880@qq.com
FU National Natural Science Foundation of China [82174035, 82374107,
   81974528, 81773959]; Hubei Province Natural Science Foundation in China
   [2021C-FA015]; Open Foundation for Tumor Micro environment and
   Immunotherapy Key Laboratory of Hubei province in China [2023KZL01]
FX The work was supported by grants from the National Natural Science
   Foundation of China (No. 82174035 to C.F. Yuan, No.82374107 to C.F.
   Yuan, Grant No. 81974528 to C.F. Yuan and No.81773959 to C.F. Yuan), the
   innovational group project of Hubei Province Natural Science Foundation
   in China (Grant No. 2021C-FA015 to C.F. Yuan), and Open Foundation for
   Tumor Micro environment and Immunotherapy Key Laboratory of Hubei
   province in China (Grant No. 2023KZL01 to C.F. Yuan).
CR Ang TL, 2014, SINGAP MED J, V55, P621, DOI 10.11622/smedj.2014174
   Bartonicek N, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0530-6
   Chen CX, 2018, BRAZ J MED BIOL RES, V51, DOI [10.1590/1414-431x20187080, 10.1590/1414-431X20187080]
   Chen H, 2018, BIOMED PHARMACOTHER, V108, P1201, DOI 10.1016/j.biopha.2018.09.140
   Cheng HJ, 2019, AM J CANCER RES, V9, P1536
   Chow WH, 2010, NAT REV UROL, V7, P245, DOI 10.1038/nrurol.2010.46
   Correa P, 2013, GASTROENTEROL CLIN N, V42, P211, DOI 10.1016/j.gtc.2013.01.002
   Diamantopoulos PT, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/106713
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Gallagher DJ, 2010, ONCOLOGY-BASEL, V78, P237, DOI 10.1159/000315730
   Hähle A, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9010035
   Hou Y, 2023, DIGEST LIVER DIS, V55, P799, DOI 10.1016/j.dld.2022.12.001
   Huang BW, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.812785
   Imyanitov EN, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103194
   Johnson CA, 2019, SEMIN ONCOL NURS, V35, P166, DOI 10.1016/j.soncn.2019.02.003
   Kalmár A, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-6180-5
   Katz JN, 2021, JAMA-J AM MED ASSOC, V325, P568, DOI 10.1001/jama.2020.22171
   Kim T, 2014, P NATL ACAD SCI USA, V111, P4173, DOI 10.1073/pnas.1400350111
   Ko EC, 2018, CLIN CANCER RES, V24, P5792, DOI 10.1158/1078-0432.CCR-17-3620
   Kopp F, 2018, CELL, V172, P393, DOI 10.1016/j.cell.2018.01.011
   Li DG, 2018, ONCOL RES, V26, P537, DOI 10.3727/096504017X15009792179602
   Li FJ, 2022, J CANCER, V13, P2540, DOI 10.7150/jca.72161
   Liu HX, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24033047
   Liu HX, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031407
   Liu JKH, 2022, CANCER MED-US, V11, P571, DOI 10.1002/cam4.4468
   Liu Y J, 2020, Zhonghua Fu Chan Ke Za Zhi, V55, P36, DOI 10.3760/cma.j.issn.0529-567X.2020.01.007
   Lu T, 2020, EUR REV MED PHARMACO, V24, P10462, DOI 10.26355/eurrev_202010_23399
   Luo T, 2019, ONCOTARGETS THER, V12, P6203, DOI 10.2147/OTT.S213833
   Luo Y, 2020, CANCER MANAG RES, V12, P2195, DOI 10.2147/CMAR.S242472
   Nagelkerke A, 2016, ADV EXP MED BIOL, V899, P1, DOI 10.1007/978-3-319-26666-4_1
   Olusola P, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060622
   Pelletier J, 2012, FRONT ONCOL, V2, DOI 10.3389/fonc.2012.00018
   Pereira D, 2015, ACTA MEDICA PORT, V28, P99
   Song JH, 2021, J ONCOL, V2021, DOI 10.1155/2021/4338838
   Song ZY, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317714626
   Sun QQ, 2015, INT J CANCER, V136, P1003, DOI 10.1002/ijc.29065
   Swatek KN, 2016, CELL RES, V26, P399, DOI 10.1038/cr.2016.39
   Terashima M, 2014, ONCOTARGET, V5, P7040, DOI 10.18632/oncotarget.2220
   Tom MC, 2019, INT J RADIAT ONCOL, V105, P1106, DOI 10.1016/j.ijrobp.2019.08.025
   Wang LJ, 2020, J GENE MED, V22, DOI 10.1002/jgm.3254
   Wang SD, 2023, CARCINOGENESIS, V44, P209, DOI 10.1093/carcin/bgad001
   Wang WJ, 2019, AGING-US, V11, P5829, DOI 10.18632/aging.102190
   Wang XD, 2019, WORLD J GASTROENTERO, V25, P1697, DOI 10.3748/wjg.v25.i14.1697
   Wang Y, 2020, CELL DEATH DIFFER, V27, P695, DOI 10.1038/s41418-019-0381-y
   Wirsching Hans-Georg, 2016, Handb Clin Neurol, V134, P381, DOI 10.1016/B978-0-12-802997-8.00023-2
   Wolf MM, 2020, ONCOGENE, V39, P3413, DOI 10.1038/s41388-020-1234-3
   Wu YJ, 2021, ONCOL REP, V45, P728, DOI 10.3892/or.2020.7876
   Xiao JN, 2017, J CANCER RES CLIN, V143, P981, DOI 10.1007/s00432-017-2370-1
   Xu F, 2023, TRANSL ANDROL UROL, V12, P33, DOI 10.21037/tau-22-663
   Xu QH, 2021, INT IMMUNOPHARMACOL, V92, DOI 10.1016/j.intimp.2020.107333
   Xu SC, 2020, CANCER LETT, V476, P1, DOI 10.1016/j.canlet.2020.02.002
   Zhang YJ, 2018, CANCER SCI, V109, P3865, DOI 10.1111/cas.13808
   Zhao XP, 2022, J THORAC DIS, V14, P1243, DOI 10.21037/jtd-22-343
   Zhou C, 2021, J ORTHOP SURG RES, V16, DOI 10.1186/s13018-021-02543-x
NR 54
TC 2
Z9 2
U1 1
U2 3
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2024
VL 30
IS 15
BP 1157
EP 1166
DI 10.2174/0113816128300061240319034243
EA MAR 2024
PG 10
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA RW7R4
UT WOS:001198575300001
PM 38544395
DA 2025-01-04
ER

PT J
AU Cheng, FF
   Su, L
   Yao, C
   Liu, LM
   Shen, JJ
   Liu, CG
   Chen, XJ
   Luo, YL
   Jiang, LP
   Shan, JJ
   Chen, J
   Zhu, W
   Shao, JM
   Qian, C
AF Cheng, Feifei
   Su, Li
   Yao, Chao
   Liu, Limei
   Shen, Junjie
   Liu, Chungang
   Chen, Xuejiao
   Luo, Yongli
   Jiang, Lupin
   Shan, Juanjuan
   Chen, Jun
   Zhu, Wei
   Shao, Jimin
   Qian, Cheng
TI SIRT1 promotes epithelial-mesenchymal transition and metastasis in
   colorectal cancer by regulating Fra-1 expression
SO CANCER LETTERS
LA English
DT Article
DE Colorectal cancer; Metastasis; SIRT1; Epithelial-mesenchymal transition;
   Fra-1
ID MALIGNANT-TRANSFORMATION; EMT; CELLS; SUPPRESSES; INITIATION; PROTEINS
AB Understanding molecular mechanisms of colorectal cancer (CRC) metastasis is urgently required for targeted therapy and prognosis of metastatic CRC In this study, we explored potential effects of silent mating type information regulation 2 homolog 1 (SIRT1) on CRC metastasis. Our data showed that ectopic expression of SIRT1 markedly increased the migration and invasion of CRC cells. In contrast, silencing SIRT1 repressed this behavior in aggressive CRC cells. Tumor xenograft experiments revealed that knockdown of SIRT1 impaired CRC metastasis in vivo. Silencing SIRT1 in CRC cells induced mesenchymal-epithelial transition (MET), which is the reverse process of epithelial-mesenchymal transition (EMT) and characterized by a gain of epithelial and loss of mesenchymal markers. We provided a mechanistic insight toward regulation of Fra-1 by SIRT1 and demonstrated a direct link between the SIRT1-Fra-1 axis and EMT. Moreover, SIRT1 expression correlated positively with Fra-1 expression, metastasis and overall survival in patients with,CRC. Taken together, our data provide a novel mechanistic role of SIRT1 in CRC metastasis, suggesting that SIRT1 may serve as a potential therapeutic target for metastatic CRC. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
C1 [Cheng, Feifei; Qian, Cheng] Zhejiang Sci Tech Univ, Sch Life Sci, Hangzhou 310018, Peoples R China.
   [Su, Li; Yao, Chao; Liu, Limei; Shen, Junjie; Liu, Chungang; Chen, Xuejiao; Luo, Yongli; Jiang, Lupin; Shan, Juanjuan; Chen, Jun; Zhu, Wei; Qian, Cheng] Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Su, Li; Yao, Chao; Liu, Limei; Shen, Junjie; Liu, Chungang; Chen, Xuejiao; Luo, Yongli; Jiang, Lupin; Shan, Juanjuan; Chen, Jun; Zhu, Wei; Qian, Cheng] Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing 400038, Peoples R China.
   [Shao, Jimin] Zhejiang Univ, Zhejiang Key Lab Dis Prote, Dept Pathol & Pathophysiol, Sch Med, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Zhejiang Sci-Tech University; Army Medical University; Army Medical
   University; Zhejiang University
RP Qian, C (corresponding author), Zhejiang Sci Tech Univ, Sch Life Sci, Hangzhou 310018, Peoples R China.; Qian, C (corresponding author), Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing 400038, Peoples R China.; Qian, C (corresponding author), Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing 400038, Peoples R China.
EM cqian8634@gmail.com
RI Jin, Min/AAU-6731-2021; cheng, qian/KFB-6227-2024; Cheng,
   Feifei/GXG-8734-2022; Jin, Min/KFT-2653-2024
OI Qian, Cheng/0000-0003-1500-9991; Cheng, Feifei/0000-0002-3234-513X
FU National Natural Science Foundation of China [81330048, 81520108025]
FX This work was supported by funds from the National Natural Science
   Foundation of China(Nos. 81330048 and 81520108025).
CR Andre N, 2005, GUT, V54, P1194, DOI 10.1136/gut.2004.062745
   Ang PW, 2009, CANCER LETT, V273, P221, DOI 10.1016/j.canlet.2008.08.001
   Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157
   Brabletz T, 2012, CANCER CELL, V22, P699, DOI 10.1016/j.ccr.2012.11.009
   Byles V, 2012, ONCOGENE, V31, P4619, DOI 10.1038/onc.2011.612
   Caramel J, 2013, CANCER CELL, V24, P466, DOI 10.1016/j.ccr.2013.08.018
   Chang HC, 2013, CELL, V153, P1448, DOI 10.1016/j.cell.2013.05.027
   Chen J, 2011, CANCER RES, V71, P4138, DOI 10.1158/0008-5472.CAN-10-4274
   Dave N, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.168625
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Diesch J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088950
   Fang YJ, 2011, CANCER LETT, V306, P10, DOI 10.1016/j.canlet.2011.02.019
   Ford J, 2005, CANCER RES, V65, P10457, DOI 10.1158/0008-5472.CAN-05-1923
   Hao C, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-978
   Holloway KR, 2010, P NATL ACAD SCI USA, V107, P9216, DOI 10.1073/pnas.0911325107
   Huffman DM, 2007, CANCER RES, V67, P6612, DOI 10.1158/0008-5472.CAN-07-0085
   Kabra N, 2009, J BIOL CHEM, V284, P18210, DOI 10.1074/jbc.M109.000034
   Knight JRP, 2012, CURR OPIN ONCOL, V24, P68, DOI 10.1097/CCO.0b013e32834d813b
   Kraus S, 2014, CANCER LETT, V347, P15, DOI 10.1016/j.canlet.2014.01.025
   Kriegl L, 2012, ONCOTARGET, V3, P1182
   Kustikova O, 1998, MOL CELL BIOL, V18, P7095, DOI 10.1128/MCB.18.12.7095
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee SH, 2013, CANCER LETT, V335, P397, DOI 10.1016/j.canlet.2013.02.051
   Leko V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0066283
   Li C, 2015, ONCOTARGETS THER, V8, P977, DOI 10.2147/OTT.S82378
   Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673
   Liu H, 2015, CARCINOGENESIS, V36, P459, DOI 10.1093/carcin/bgv017
   Liu T, 2009, CANCER RES, V69, P1702, DOI 10.1158/0008-5472.CAN-08-3365
   Lv L, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0965-9
   Ou X, 2014, STEM CELLS, V32, P1183, DOI 10.1002/stem.1641
   Siegel RL, 2020, ANTI-CANCER DRUG, V70, P7, DOI [DOI 10.3322/CAAC.21590, DOI 10.1097/CAD.0000000000000617]
   Simic P, 2013, CELL REP, V3, P1175, DOI 10.1016/j.celrep.2013.03.019
   Steder M, 2013, CANCER CELL, V24, P512, DOI 10.1016/j.ccr.2013.08.023
   Thiery JP, 2006, NAT REV MOL CELL BIO, V7, P131, DOI 10.1038/nrm1835
   Wang YS, 2014, CANCER RES, V74, P520, DOI 10.1158/0008-5472.CAN-13-2182
   Xiong H, 2012, J BIOL CHEM, V287, P5819, DOI 10.1074/jbc.M111.295964
   Young MR, 2006, GENE, V379, P1, DOI 10.1016/j.gene.2006.05.001
   Zhang XZ, 2015, INT J CLIN EXP MED, V8, P809
   Zhang Y, 2009, ONCOGENE, V28, P445, DOI 10.1038/onc.2008.388
NR 40
TC 80
Z9 87
U1 1
U2 32
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD JUN 1
PY 2016
VL 375
IS 2
BP 274
EP 283
DI 10.1016/j.canlet.2016.03.010
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DL4TT
UT WOS:000375630800009
PM 26975631
DA 2025-01-04
ER

PT J
AU de Porras, VR
   Layos, L
   Martínez-Balibrea, E
AF de Porras, Vicenc Ruiz
   Layos, Laura
   Martinez-Balibrea, Eva
TI Curcumin: A therapeutic strategy for colorectal cancer?
SO SEMINARS IN CANCER BIOLOGY
LA English
DT Article
DE Curcumin; Colorectal cancer; Chemotherapy; Targeted therapy;
   Immunotherapy
ID HUMAN COLON-CANCER; EPITHELIAL-MESENCHYMAL TRANSITION; KAPPA-B
   ACTIVATION; REGULATORY T-CELLS; CHEMOPREVENTIVE AGENT CURCUMIN; PLUS
   CETUXIMAB TREATMENT; RANDOMIZED PHASE-III; DRUG-RESISTANCE;
   DOWN-REGULATION; RAS MUTATIONS
AB Colorectal cancer (CRC) is the second cause of cancer death worldwide. The metastatic disease is mainly treated with aggressive therapies consisting on combinations of cytotoxic chemotherapy plus anti-EGFR or anti-VEGF drugs. In spite of the improvements in clinical outcomes achieved in the last decade, these are the result of multiple new combinations using the existing therapeutic options and the introduction of regorafenib and TAS102 in second or later lines of treatment. As immunotherapies are limited to less than 5% of CRC patients harboring tumors with deficient mismatch repair, there is an urgent need of finding new drugs to increase our patients' survival opportunities. Among all the natural products that are candidates to be used for the treatment of CRC cancer, curcumin (the golden spice) is in the spotlight. Used for centuries in the Ayurveda medicine, its demonstrated anticancer properties and low toxicity profile made it the focus of hundreds of preclinical and clinical investigations. So far we know that it can be combined with most of the aforementioned drugs in a safe and synergistic way. Regretfully, its poor bioavailability has been one of the main issues for its successful introduction in the clinic. Nevertheless, a plethora of new formulations with a huge increase in bioavailability are under study with promising results. In this review we discuss the possibility of incorporating curcumin in the treatment of CRC; specifically, we review preclinical and clinical data supporting its possible combination with current therapies as well as new formulations under clinical study. It is time for the golden spice revolution.
C1 [de Porras, Vicenc Ruiz; Layos, Laura] Catalan Inst Oncol, Med Oncol Serv, B ARGO Grp, Ctra Canyet S-N, Badalona 08916, Spain.
   [de Porras, Vicenc Ruiz; Layos, Laura; Martinez-Balibrea, Eva] Germans Trias & Pujol Res Inst IGTP, Cami Escoles S-N, Badalona 08916, Spain.
   [Layos, Laura; Martinez-Balibrea, Eva] Catalan Inst Oncol, Program Canc Therapeut Resistance ProCURE, Cami Escoles S-N, Badalona 08916, Spain.
   [Martinez-Balibrea, Eva] IGTP, Program Predict & Personalized Canc Med PMPPC, Cami Escoles S-N, Badalona 08916, Spain.
C3 Institut Catala d'Oncologia; Fundacio Institut d'Investigacio en
   Ciencies de la Salut Germans Trias i Pujol (IGTP); Institut Catala
   d'Oncologia; Fundacio Institut d'Investigacio en Ciencies de la Salut
   Germans Trias i Pujol (IGTP)
RP Martínez-Balibrea, E (corresponding author), Germans Trias & Pujol Res Inst IGTP, Cami Escoles S-N, Badalona 08916, Spain.
EM vruiz@igtp.cat; llayos@iconcologia.net; embalibrea@iconcologia.net
RI Martinez-Balibrea, Eva/HHS-5710-2022
OI Layos Romero, Laura/0000-0002-0537-6061; Martinez-Balibrea,
   Eva/0000-0002-4501-7100
FU Departament d'Innovacio, Universitats i Empresa, Generalitat de
   Catalunya [2014-SGR-1494, 2017-SGR-1705]; Instituto de Salud Carlos III,
   Spanish Government [PI16/01800, PIE16/00011]
FX The group from Dr. Eva MartinezBalibrea is currently funded by the
   Departament d'Innovacio, Universitats i Empresa, Generalitat de
   Catalunya, project number 2014-SGR-1494 and 2017-SGR-1705 and by grants
   from the Instituto de Salud Carlos III, Spanish Government, with project
   numbers PI16/01800 and PIE16/00011. We want to acknoledge miss Sara
   Bystrup for critical reading and language corrections.
CR Agarwal A, 2018, NUTR RES, V51, P67, DOI 10.1016/j.nutres.2017.12.011
   Al Moundhri MS, 2013, J MED TOXICOL, V9, P25, DOI 10.1007/s13181-012-0239-x
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   [Anonymous], 2019, NUTRIENTS
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Asangani IA, 2008, ONCOGENE, V27, P2128, DOI 10.1038/sj.onc.1210856
   Bae MK, 2006, ONCOL REP, V15, P1557
   Binion DG, 2008, GUT, V57, P1509, DOI 10.1136/gut.2008.152496
   Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Buhrmann C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107514
   Cao H, 2015, PATHOL RES PRACT, V211, P557, DOI 10.1016/j.prp.2015.05.010
   Carroll RE, 2011, CANCER PREV RES, V4, P354, DOI 10.1158/1940-6207.CAPR-10-0098
   Chen A, 2006, ONCOGENE, V25, P278, DOI [10.1038/sj.onc.1209019, 10.1038/sj.onc.1209573]
   Chen XM, 2000, BIOCHEM BIOPH RES CO, V277, P757, DOI 10.1006/bbrc.2000.3731
   Choudhuri T, 2005, J BIOL CHEM, V280, P20059, DOI 10.1074/jbc.M410670200
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Codony-Servat J, 2017, BRIT J CANCER, V117, P1777, DOI 10.1038/bjc.2017.279
   Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006
   Collett GP, 2004, CARCINOGENESIS, V25, P2183, DOI 10.1093/carcin/bgh233
   Cruz-Correa M, 2006, CLIN GASTROENTEROL H, V4, P1035, DOI 10.1016/j.cgh.2006.03.020
   Dallas NA, 2009, CANCER RES, V69, P1951, DOI 10.1158/0008-5472.CAN-08-2023
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   Dasiram JD, 2017, BIOMED PHARMACOTHER, V86, P373, DOI 10.1016/j.biopha.2016.12.034
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Dent P., 2020, J CELL PHYSIOL
   Dou HQ, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00877
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Garcea G, 2005, CANCER EPIDEM BIOMAR, V14, P120
   Giordano A, 2019, NUTRIENTS, V11, DOI 10.3390/nu11102376
   Girardi B, 2020, WORLD J GASTROENTERO, V26, P1601, DOI 10.3748/wjg.v26.i14.1601
   Girardi B, 2018, CARCINOGENESIS, V39, P1274, DOI 10.1093/carcin/bgy104
   Goel A, 2001, CANCER LETT, V172, P111, DOI 10.1016/S0304-3835(01)00655-3
   Goel A, 2004, CANCER RES, V64, P3014, DOI 10.1158/0008-5472.CAN-2401-2
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Güçlü O, 2020, CARDIOVASC TOXICOL, V20, P139, DOI 10.1007/s12012-019-09541-w
   Guo LD, 2013, PHYTOTHER RES, V27, P422, DOI 10.1002/ptr.4731
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Haller DG, 2011, J CLIN ONCOL, V29, P1465, DOI 10.1200/JCO.2010.33.6297
   He WT, 2019, CHIN J INTEGR MED, V25, P416, DOI 10.1007/s11655-018-2997-z
   He ZY, 2011, CANCER INVEST, V29, P208, DOI 10.3109/07357907.2010.550592
   Hoos A, 2016, NAT REV DRUG DISCOV, V15, P235, DOI 10.1038/nrd.2015.35
   Howells LM, 2007, INT J CANCER, V121, P175, DOI 10.1002/ijc.22645
   Howells LM, 2019, J NUTR, V149, P1133, DOI 10.1093/jn/nxz029
   Howells LM, 2011, INT J CANCER, V129, P476, DOI 10.1002/ijc.25670
   Irving GRB, 2013, CANCER PREV RES, V6, P119, DOI 10.1158/1940-6207.CAPR-12-0281
   Ismail NI, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20102454
   James MI, 2015, CANCER LETT, V364, P135, DOI 10.1016/j.canlet.2015.05.005
   Jiang QG, 2014, MOL BIOL REP, V41, P3359, DOI 10.1007/s11033-014-3198-2
   Jin G, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.84
   Jobin C, 1999, J IMMUNOL, V163, P3474
   Kanwar SS, 2011, PHARM RES-DORDR, V28, P827, DOI 10.1007/s11095-010-0336-y
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Kuebler JP, 2007, J CLIN ONCOL, V25, P2198, DOI 10.1200/JCO.2006.08.2974
   Kukcinaviciute E, 2018, J CELL BIOCHEM, V119, P5913, DOI 10.1002/jcb.26783
   Kunnumakkara AB, 2008, CLIN CANCER RES, V14, P2128, DOI 10.1158/1078-0432.CCR-07-4722
   Kunnumakkara AB, 2009, INT J CANCER, V125, P2187, DOI 10.1002/ijc.24593
   Lai HW, 2012, EVID-BASED COMPL ALT, V2012, DOI 10.1155/2012/486568
   Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee YK, 2009, ANN NY ACAD SCI, V1171, P489, DOI 10.1111/j.1749-6632.2009.04699.x
   Li JP, 2015, MOL MED REP, V12, P192, DOI 10.3892/mmr.2015.3356
   Li YR, 2017, BIOMED PHARMACOTHER, V92, P140, DOI 10.1016/j.biopha.2017.05.058
   Lien JC, 2015, CHEM-BIOL INTERACT, V235, P17, DOI 10.1016/j.cbi.2015.04.005
   Lim TG, 2014, CANCER PREV RES, V7, P466, DOI 10.1158/1940-6207.CAPR-13-0387
   Lu W, 2019, DEV CELL, V49, P361, DOI 10.1016/j.devcel.2019.04.010
   Lu YL, 2020, DRUG DES DEV THER, V14, P73, DOI 10.2147/DDDT.S224318
   Luo J, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00189
   Mani SA, 2008, CELL, V133, P704, DOI 10.1016/j.cell.2008.03.027
   Martinez-Balibrea E, 2015, MOL CANCER THER, V14, P1767, DOI 10.1158/1535-7163.MCT-14-0636
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683
   Momtazi AA, 2016, CURR PHARM DESIGN, V22, P4386, DOI 10.2174/1381612822666160527113501
   Moragoda L, 2001, ANTICANCER RES, V21, P873
   Mosieniak G, 2012, MECH AGEING DEV, V133, P444, DOI 10.1016/j.mad.2012.05.004
   Mudduluru G, 2011, BIOSCIENCE REP, V31, P185, DOI 10.1042/BSR20100065
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Najafi M, 2019, LIFE SCI, V234, DOI 10.1016/j.lfs.2019.116781
   Nosho K, 2008, NEOPLASIA, V10, P534, DOI 10.1593/neo.08336
   Ouyang MZ, 2019, INT J ONCOL, V54, P1376, DOI 10.3892/ijo.2019.4714
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Pagano E, 2018, PHARMACOL RES, V134, P79, DOI 10.1016/j.phrs.2018.06.007
   Patel BB, 2008, INT J CANCER, V122, P267, DOI 10.1002/ijc.23097
   Patel BB, 2010, ANTICANCER RES, V30, P319
   Patel M, 2018, TRANSL RES, V197, P43, DOI 10.1016/j.trsl.2018.02.002
   Plummer SM, 1999, ONCOGENE, V18, P6013, DOI 10.1038/sj.onc.1202980
   Prasad S, 2014, CANCER RES TREAT, V46, P2, DOI 10.4143/crt.2014.46.1.2
   Pricci M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21072364
   Rahimi K, 2019, AUTOIMMUN REV, V18, P738, DOI 10.1016/j.autrev.2019.05.012
   Rajitha B, 2017, MOL CARCINOGEN, V56, P288, DOI 10.1002/mc.22492
   Rajitha B, 2016, CANCER LETT, V373, P227, DOI 10.1016/j.canlet.2016.01.052
   Rana C, 2015, MOL CELL BIOCHEM, V402, P225, DOI 10.1007/s11010-015-2330-5
   Reddy S, 2006, NUTR CANCER, V55, P185, DOI 10.1207/s15327914nc5502_10
   Rodrigues FC, 2019, EUR J MED CHEM, V177, P76, DOI 10.1016/j.ejmech.2019.04.058
   Roh MS, 2009, J CLIN ONCOL, V27, P5124, DOI 10.1200/JCO.2009.22.0467
   Roy S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068543
   de Porras VR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24675
   Sabet N.S., 2020, NAUNYN SCHMIEDEBERGS
   Sabra R, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118775
   Sakaguchi S, 2008, CELL, V133, P775, DOI 10.1016/j.cell.2008.05.009
   Sandur SK, 2009, INT J RADIAT ONCOL, V75, P534, DOI 10.1016/j.ijrobp.2009.06.034
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sauer R, 2012, J CLIN ONCOL, V30, P1926, DOI 10.1200/JCO.2011.40.1836
   Scontre Vanessa Armenio, 2018, Journal of Dietary Supplements, V15, P606, DOI 10.1080/19390211.2017.1366387
   Selvam C, 2019, LIFE SCI, V239, DOI 10.1016/j.lfs.2019.117032
   Shafabakhsh R, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104353
   Shakibaei M, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1291-0
   Shakibaei M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085397
   Shakibaei M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057218
   Shanmugam MK, 2015, MOLECULES, V20, P2728, DOI 10.3390/molecules20022728
   Sharma RA, 2001, CLIN CANCER RES, V7, P1894
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Shehzad A, 2013, MOL CELLS, V35, P526, DOI 10.1007/s10059-013-0038-5
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Shoba G, 1998, PLANTA MED, V64, P353, DOI 10.1055/s-2006-957450
   Song G, 2005, BRAZ J MED BIOL RES, V38, P1791, DOI 10.1590/S0100-879X2005001200007
   Song Yihuan, 2016, Zhonghua Wei Chang Wai Ke Za Zhi, V19, P1395
   Stohs SJ, 2020, MOLECULES, V25, DOI 10.3390/molecules25061397
   Storka A, 2015, INT J CLIN PHARM TH, V53, P54, DOI 10.5414/CP202076
   Su PF, 2018, INT J ONCOL, V53, P1343, DOI 10.3892/ijo.2018.4461
   Sun WJ, 2012, J HEMATOL ONCOL, V5, DOI 10.1186/1756-8722-5-63
   Takebe N, 2011, NAT REV CLIN ONCOL, V8, P97, DOI 10.1038/nrclinonc.2010.196
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Toden S, 2015, CARCINOGENESIS, V36, P355, DOI 10.1093/carcin/bgv006
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160
   Tsubaki M., 2019, CANC BASEL, V11
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Väyrynen JP, 2013, BRIT J CANCER, V109, P1839, DOI 10.1038/bjc.2013.508
   Vazquez A, 2008, NAT REV DRUG DISCOV, V7, P979, DOI 10.1038/nrd2656
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Voboril R, 2006, NEOPLASMA, V53, P518
   Wang SW, 2014, INT J ONCOL, V44, P1032, DOI 10.3892/ijo.2014.2259
   Wang SL, 2009, CELL MOL IMMUNOL, V6, P327, DOI 10.1038/cmi.2009.43
   Waseem M, 2017, ARCH MED RES, V48, P55, DOI 10.1016/j.arcmed.2017.01.010
   Waseem M, 2016, PROTOPLASMA, V253, P417, DOI 10.1007/s00709-015-0821-6
   Wilson C, 2008, J PHARMACOL EXP THER, V327, P746, DOI 10.1124/jpet.108.143826
   Wu CS, 2019, J NUTR BIOCHEM, V74, DOI 10.1016/j.jnutbio.2019.108227
   Xia H, 2012, CANCER GENE THER, V19, P723, DOI 10.1038/cgt.2012.58
   Xiao ZC, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay7785
   Xu B, 2017, AM J TRANSL RES, V9, P1866
   Yang AD, 2006, CLIN CANCER RES, V12, P4147, DOI 10.1158/1078-0432.CCR-06-0038
   Yang GG, 2018, ANTICANCER RES, V38, P131, DOI 10.21873/anticanres.12200
   Yang Y, 2017, INT J ONCOL, V51, P515, DOI 10.3892/ijo.2017.4044
   Yin JH, 2019, ONCOTARGETS THER, V12, P3893, DOI 10.2147/OTT.S199601
   Yu YJ, 2013, TRANSL ONCOL, V6, P180, DOI 10.1593/tlo.12397
   Yu YJ, 2012, CARCINOGENESIS, V33, P68, DOI 10.1093/carcin/bgr246
   Yu YJ, 2009, TRANSL ONCOL, V2, P321, DOI 10.1593/tlo.09193
   Yue GGL, 2016, PHARMACOL RES, V111, P43, DOI 10.1016/j.phrs.2016.05.025
   Zhang CH, 2018, ANTI-CANCER DRUG, V29, P334, DOI 10.1097/CAD.0000000000000599
   Zhang JR, 2017, AM J CANCER RES, V7, P275
   Zhao GJ, 2012, INT IMMUNOPHARMACOL, V14, P99, DOI 10.1016/j.intimp.2012.06.016
   Zhu J, 2018, MED SCI MONITOR, V24, P7035, DOI 10.12659/MSM.910650
   Zou JY, 2018, J CELL BIOCHEM, V119, P1420, DOI 10.1002/jcb.26302
   Zou WP, 2006, NAT REV IMMUNOL, V6, P295, DOI 10.1038/nri1806
NR 162
TC 37
Z9 38
U1 4
U2 45
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 1044-579X
EI 1096-3650
J9 SEMIN CANCER BIOL
JI Semin. Cancer Biol.
PD AUG
PY 2021
VL 73
BP 321
EP 330
DI 10.1016/j.semcancer.2020.09.004
EA JUN 2021
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SR7PW
UT WOS:000661238700006
PM 32942023
DA 2025-01-04
ER

PT J
AU Fujii, S
   Kotani, D
   Hattori, M
   Nishihara, M
   Shikanai, T
   Hashimoto, J
   Hama, Y
   Nishino, T
   Suzuki, M
   Yoshidumi, A
   Ueno, M
   Komatsu, Y
   Masuishi, T
   Hara, H
   Esaki, T
   Nakamura, Y
   Bando, H
   Yamada, T
   Yoshino, T
AF Fujii, Satoshi
   Kotani, Daisuke
   Hattori, Masahiro
   Nishihara, Masato
   Shikanai, Toshihide
   Hashimoto, Junji
   Hama, Yuki
   Nishino, Takuya
   Suzuki, Mizuto
   Yoshidumi, Ayatoshi
   Ueno, Makoto
   Komatsu, Yoshito
   Masuishi, Toshiki
   Hara, Hiroki
   Esaki, Taito
   Nakamura, Yoshiaki
   Bando, Hideaki
   Yamada, Tomoyuki
   Yoshino, Takayuki
TI Rapid Screening Using Pathomorphologic Interpretation to Detect
   <i>BRAF</i><SUP>V600E</SUP> Mutation and Microsatellite Instability in
   Colorectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
AB Purpose: Rapid decision-making is essential in precision med-icine for initiating molecular targeted therapy for patients with cancer. This study aimed to extract pathomorphologic features that enable the accurate prediction of genetic abnormalities in cancer from hematoxylin and eosin images using deep learning (DL).
   Experimental Design: A total of 1,657 images (one representa-tive image per patient) of thin formalin-fixed, paraffin-embedded tissue sections from either primary or metastatic tumors with next-generation sequencing-confirmed genetic abnormalities- including BRAF(V600E) and KRAS mutations, and microsatellite instability high (MSI-H)-that are directly relevant to therapeu-tic strategies for advanced colorectal cancer were obtained from the nationwide SCRUM-Japan GI-SCREEN project. The images were divided into three groups of 986, 248, and 423 images to create one training and two validation cohorts, respectively. Pathomorphologic feature-prediction DL models were first devel-oped on the basis of pathomorphologic features. Subsequently, gene-prediction DL models were constructed for all possible com-binations of pathomorphologic features that enabled the prediction of gene abnormalities based on images filtered by the combination of pathomorphologic feature-prediction models.
   Results: High accuracies were achieved, with AUCs > 0.90 and 0.80 for 12 and 27, respectively, of 33 analyzed pathomorphologic features, with high AUCs being yielded for both BRAF(V600E) (0.851 and 0.859) and MSI-H (0.923 and 0.862).
   Conclusions: These findings show that novel next-generation pathology methods can predict genetic abnormalities without the need for standard-of-care gene tests, and this novel next-generation pathology method can be applied for colorectal cancer treatment planning in the near future.
C1 [Fujii, Satoshi] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Div Pathol, Kashiwa, Chiba, Japan.
   [Fujii, Satoshi] Yokohama City Univ, Dept Mol Pathol, Grad Sch Med, Yokohama, Kanagawa, Japan.
   [Kotani, Daisuke; Nakamura, Yoshiaki; Bando, Hideaki; Yoshino, Takayuki] Hosp East, Natl Canc Ctr, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan.
   [Hattori, Masahiro; Nishihara, Masato; Shikanai, Toshihide; Hashimoto, Junji; Yamada, Tomoyuki] Genomedia Inc, Tokyo, Japan.
   [Hama, Yuki; Nishino, Takuya; Suzuki, Mizuto] PAPPARE Corp, Tokyo, Japan.
   [Yoshidumi, Ayatoshi] Cloud Ace Inc, Tokyo, Japan.
   [Ueno, Makoto] Kanagawa Canc Ctr, Dept Gastroenterol, Hepatobiliary & Pancreat Med Oncol Div, Yokohama, Kanagawa, Japan.
   [Komatsu, Yoshito] Hokkaido Univ Hosp, Dept Canc Ctr, Sapporo, Hokkaido, Japan.
   [Masuishi, Toshiki] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan.
   [Hara, Hiroki] Saitama Canc Ctr, Dept Gastroenterol, Saitama, Japan.
   [Esaki, Taito] Kyushu Canc Ctr, Natl Hosp Org, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan.
C3 National Cancer Center - Japan; Yokohama City University; National
   Cancer Center - Japan; Kanagawa Prefectural Cancer Center; Hokkaido
   University; Aichi Cancer Center; Kyushu Cancer Center
RP Fujii, S (corresponding author), Yokohama City Univ, Dept Mol Pathol, Yokohama, Kanagawa 2360004, Japan.
EM sfujii@yokohama-cu.ac.jp
OI Kotani, Daisuke/0000-0002-4196-555X
CR [Anonymous], 2017, Robbins Basic Pathology E
   Bando H, 2018, CANCER SCI, V109, P3411, DOI 10.1111/cas.13774
   Bejnordi BE, 2018, MODERN PATHOL, V31, P1502, DOI 10.1038/s41379-018-0073-z
   Bilal M, 2021, LANCET DIGIT HEALTH, V3, pE763, DOI 10.1016/S2589-7500(21)00180-1
   Chang HY, 2019, J PATHOL TRANSL MED, V53, P1, DOI 10.4132/jptm.2018.12.16
   Chang P, 2018, AM J NEURORADIOL, V39, P1201, DOI 10.3174/ajnr.A5667
   Chen MY, 2020, NPJ PRECIS ONCOL, V4, DOI 10.1038/s41698-020-0120-3
   Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5
   Diao J.A., 2020, bioRxiv
   Dolezal JM, 2021, MODERN PATHOL, V34, P862, DOI 10.1038/s41379-020-00724-3
   Echle A, 2020, GASTROENTEROLOGY, V159, P1406, DOI 10.1053/j.gastro.2020.06.021
   Fu Y, 2020, NAT CANCER, V1, P800, DOI 10.1038/s43018-020-0085-8
   Goode Adam, 2013, J Pathol Inform, V4, P27, DOI 10.4103/2153-3539.119005
   Greenson JK, 2009, AM J SURG PATHOL, V33, P126, DOI 10.1097/PAS.0b013e31817ec2b1
   He KM, 2016, PROC CVPR IEEE, P770, DOI 10.1109/CVPR.2016.90
   Howard F.M., 2020, bioRxiv
   Howard FM, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24698-1
   Howard J, 2020, INFORMATION, V11, DOI 10.3390/info11020108
   Jain MS, 2020, NAT MACH INTELL, V2, P356, DOI 10.1038/s42256-020-0190-5
   Kather J.N., 2019, BIORXIV
   Kather JN, 2019, NAT MED, V25, P1054, DOI 10.1038/s41591-019-0462-y
   Kuwata T, 2020, PATHOL INT, V70, P932, DOI 10.1111/pin.13029
   Nakamura Y, 2020, NAT MED, V26, DOI 10.1038/s41591-020-1063-5
   Nakayama M, 2017, ONCOGENE, V36, P5885, DOI 10.1038/onc.2017.194
   Norgeot B, 2019, NAT MED, V25, P14, DOI 10.1038/s41591-018-0320-3
   Sakai E, 2018, CANCER RES, V78, P1334, DOI 10.1158/0008-5472.CAN-17-3303
   Schaumberg A.J., 2018, BIORXIV
   Skrede OJ, 2020, LANCET, V395, P350, DOI 10.1016/S0140-6736(19)32998-8
   Srinidhi CL, 2021, MED IMAGE ANAL, V67, DOI 10.1016/j.media.2020.101813
   Takeda M, 2021, ONCOLOGIST, V26, pE588, DOI 10.1002/onco.13639
   Yousem SA, 2008, AM J SURG PATHOL, V32, P1317, DOI 10.1097/PAS.0b013e31816597ca
NR 31
TC 9
Z9 10
U1 4
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 15
PY 2022
VL 28
IS 12
BP 2623
EP 2632
DI 10.1158/1078-0432.CCR-21-4391
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 2F8ZN
UT WOS:000813192700001
PM 35363302
OA Green Submitted, Bronze
DA 2025-01-04
ER

PT J
AU Hosoya, K
   Matsusaka, S
   Kashiwada, T
   Suzuki, K
   Ureshino, N
   Sato, A
   Miki, Y
   Kitera, K
   Hirai, M
   Hatake, K
   Kimura, S
   Sueoka-Aragane, N
AF Hosoya, Kazuhisa
   Matsusaka, Satoshi
   Kashiwada, Tomomi
   Suzuki, Koichi
   Ureshino, Norio
   Sato, Akemi
   Miki, Yoshio
   Kitera, Kazuki
   Hirai, Mitsuharu
   Hatake, Kiyohiko
   Kimura, Shinya
   Sueoka-Aragane, Naoko
TI Detection of <i>KRAS</i> Mutations in Plasma DNA Using a fully Automated
   Rapid Detection System in Colorectal Cancer Patients
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Plasma DNA; KRAS mutation; Colorectal neoplasms; Molecular targeted
   therapy
ID ANTI-EGFR THERAPY; ACQUIRED-RESISTANCE; RAS MUTATIONS; INTRATUMOR
   HETEROGENEITY; CLINICAL VALIDATION; BRAF MUTATIONS; CETUXIMAB;
   EVOLUTION; ACTIVATION; EMERGENCE
AB KRAS mutations have been recognized as predictive markers of primary resistance to anti-EGFR-antibodies in colorectal cancer patients. In addition, newly detected KRAS mutations have been reported to be related with acquired resistance to chemotherapy containing anti-EGFR antibody. Considering this evidence, monitoring of KRAS mutations is indispensable for making treatment decisions, and the method should be non-invasive allowing repeated examinations. Recently, we established a novel automated sensitive detection system for KRAS mutations, named mutation-biased PCR quenching probe system (MBP-QP). The goal of our study was to investigate the potential for monitoring KRAS mutations during treatment with anti-EGFR antibodies. The detection limit of MBP-QP using a control plasmid containing KRAS mutations was 1-9 copies, and 0.05-0.3% mutant plasmid was detectable in a mixture of wild type and mutants. One-hundred twenty colorectal cancer patients were genotyped for KRAS mutations with MBP-QP as well as polymerase chain reaction reverse sequence-specific oligonucleotide (PCR-rSSO), which has already been applied to cancer tissue samples in the clinical setting. Concordance rates between plasma DNA and cancer tissues were 68% with MBP-QP and 66% with PCR-rSSO, indicating that these systems are equivalent in terms of detecting KRAS mutations with plasma DNA. KRAS mutations in plasma DNA were frequently observed in systemic metastatic cancer patients, and in three patients KRAS mutations appeared after chemotherapy containing anti-EGFR antibody. A prospective study is needed for clarifying whether KRAS mutations detected in plasma DNA are predictive markers of treatment efficacy with anti-EGFR antibody.
C1 [Hosoya, Kazuhisa; Kashiwada, Tomomi; Sato, Akemi; Kimura, Shinya; Sueoka-Aragane, Naoko] Saga Univ, Fac Med, Dept Internal Med, Div Hematol Resp Med & Oncol, 5-1-1 Nabeshima, Saga 8498501, Japan.
   [Matsusaka, Satoshi] Japanese Fdn Canc Res, Canc Inst Hosp, Gastroenterol Ctr, Tokyo, Japan.
   [Suzuki, Koichi] Jichi Med Univ, Saitama Med Ctr, Dept Surg, Saitama, Japan.
   [Ureshino, Norio] Saga Prefectural Hosp, Dept Med Oncol, Saga, Japan.
   [Miki, Yoshio] Japanese Fdn Canc Res, Inst Canc, Dept Genet Diag, Tokyo, Japan.
   [Kitera, Kazuki; Hirai, Mitsuharu] ARKRAY Inc, Div Res & Dev, Kyoto, Japan.
   [Hatake, Kiyohiko] Japanese Fdn Canc Res, Clin Chemotherapy, Ctr Canc Chemotherapy, Tokyo, Japan.
C3 Saga University; Japanese Foundation for Cancer Research; Jichi Medical
   University; Japanese Foundation for Cancer Research; Japanese Foundation
   for Cancer Research
RP Sueoka-Aragane, N (corresponding author), Saga Univ, Fac Med, Dept Internal Med, Div Hematol Resp Med & Oncol, 5-1-1 Nabeshima, Saga 8498501, Japan.
EM sueokan@cc.saga-u.ac.jp
OI Hirai, Mitsuharu/0000-0002-7633-9161
CR Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Bouchahda M, 2010, CANCER CHEMOTH PHARM, V66, P605, DOI 10.1007/s00280-010-1298-9
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Lech G, 2016, WORLD J GASTROENTERO, V22, P1745, DOI 10.3748/wjg.v22.i5.1745
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Misale S, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9305
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Nakamura T, 2012, J THORAC ONCOL, V7, P1369, DOI 10.1097/JTO.0b013e31825f2821
   Nakamura T, 2011, J THORAC ONCOL, V6, P1639, DOI 10.1097/JTO.0b013e31822956e8
   Schrag D, 2016, ASCO ANN M
   Spindler KLG, 2012, CLIN CANCER RES, V18, P1177, DOI 10.1158/1078-0432.CCR-11-0564
   Sueoka-Aragane N, 2016, CANCER SCI, V107, P162, DOI 10.1111/cas.12847
   Sueoka-Aragane N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111881
   Swanton C, 2012, CANCER RES, V72, P4875, DOI 10.1158/0008-5472.CAN-12-2217
   Tabernero J, 2015, LANCET ONCOL, V16, P937, DOI 10.1016/S1470-2045(15)00138-2
   Thierry AR, 2014, NAT MED, V20, P430, DOI 10.1038/nm.3511
   Tol J, 2010, CLIN THER, V32, P437, DOI 10.1016/j.clinthera.2010.03.012
   Troiani T, 2013, CLIN CANCER RES, V19, P6751, DOI 10.1158/1078-0432.CCR-13-0423
   Yoshino T, 2015, EBIOMEDICINE, V2, P317, DOI 10.1016/j.ebiom.2015.02.007
NR 27
TC 2
Z9 2
U1 0
U2 6
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD OCT
PY 2017
VL 23
IS 4
BP 737
EP 744
DI 10.1007/s12253-016-0175-1
PG 8
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA FE8ZN
UT WOS:000408494100005
PM 28058585
DA 2025-01-04
ER

PT J
AU Akbari, M
   Shomali, N
   Faraji, A
   Shanehbandi, D
   Asadi, M
   Mokhtarzadeh, A
   Shabani, A
   Baradaran, B
AF Akbari, Morteza
   Shomali, Navid
   Faraji, Afsaneh
   Shanehbandi, Dariush
   Asadi, Milad
   Mokhtarzadeh, Ahad
   Shabani, Aliakbar
   Baradaran, Behzad
TI CD133: An emerging prognostic factor and therapeutic target in
   colorectal cancer
SO CELL BIOLOGY INTERNATIONAL
LA English
DT Review
DE colorectal cancer; cancer stem cells; chemoresistance; CD133; targeted
   therapy
ID EPITHELIAL-MESENCHYMAL TRANSITION; CELL MARKER CD133; STEM-LIKE CELLS;
   POOR-PROGNOSIS; CLINICAL-SIGNIFICANCE; SELF-RENEWAL; TUMOR-GROWTH;
   LUNG-CANCER; IN-VITRO; EXPRESSION
AB Colorectal cancer (CRC) is one of the leading causes of death worldwide. Recently, the role of cancer stem cells (CSCs) has been highlighted as a crucial emerging factor in chemoresistance, cancer relapse, and metastasis. CD133 is a surface marker of CSCs and has been argued to have prognostic and therapeutic values in CRC along with its related pathways such as Wnt, Notch, and hedgehog. Several studies have successfully applied targeted therapies against CD133 in CRC models namely bispecific antibodies (BiAbs) and anti-Wnt and notch pathways agents. These studies have yielded initial promising results in this regard. However, none of the therapeutics have been used in the clinical setting and their efficacy and adverse effects profile are yet to be elucidated. This review aims to gather the old and most recent data on the prognostic and therapeutic values of CD133 and CD133-targeted therapies in CRC.
C1 [Akbari, Morteza] Semnan Univ Med Sci, Dept Biotechnol, Fac Med, Semnan 3514799422, Iran.
   [Akbari, Morteza; Shomali, Navid; Faraji, Afsaneh; Shanehbandi, Dariush; Asadi, Milad; Mokhtarzadeh, Ahad; Baradaran, Behzad] Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz 5166614766, Iran.
   [Akbari, Morteza; Shabani, Aliakbar] Semnan Univ Med Sci, Semnan Biotechnol Res Ctr, Semnan 3514799422, Iran.
   [Shomali, Navid] Tabriz Univ Med Sci, Student Res Comm, Tabriz 5166614766, Iran.
   [Shomali, Navid] Tabriz Univ Med Sci, Dept Immunol, Fac Med, Tabriz 5166614766, Iran.
C3 Semnan University of Medical Sciences; Tabriz University of Medical
   Science; Semnan University of Medical Sciences; Tabriz University of
   Medical Science; Tabriz University of Medical Science
RP Baradaran, B (corresponding author), Tabriz Univ Med Sci, Immunol Res Ctr, Tabriz 5166614766, Iran.; Shabani, A (corresponding author), Semnan Univ Med Sci, Semnan Biotechnol Res Ctr, Semnan 3514799422, Iran.
EM shabanialiakbar48@yahoo.com; baradaranb@tbzmed.ac.ir
RI Mokhtarzadeh, Ahad/V-3748-2017; Akbari, Morteza/AGY-1268-2022; Shomali,
   Navid/AAM-4488-2021; Baradaran, Behzad/AAQ-5177-2020; Shanehbandi,
   Dariush/H-2502-2013
OI Shomali, Navid/0000-0003-4679-9658; baradaran,
   behzad/0000-0002-8642-6795; mokhtarzadeh, Amir Ali/0000-0002-4515-8675;
   Shanehbandi, Dariush/0000-0002-9449-0607
FU Immunology Research Center, Tabriz University of Medical Sciences,
   Tabriz, Iran
FX The authors thank the Immunology Research Center, Tabriz University of
   Medical Sciences, Tabriz, Iran for supporting this study.
CR [Anonymous], SCAND J GASTROENTERO
   Aran V, 2016, CLIN COLORECTAL CANC, V15, P195, DOI 10.1016/j.clcc.2016.02.008
   Arne G, 2011, INT J CANCER, V129, P1149, DOI 10.1002/ijc.25755
   Artells R, 2010, EUR J CANCER, V46, P642, DOI 10.1016/j.ejca.2009.11.003
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Bellacosa A, 2005, ADV CANCER RES, V94, P29, DOI 10.1016/S0065-230X(05)94002-5
   Bostad M, 2015, J CONTROL RELEASE, V206, P37, DOI 10.1016/j.jconrel.2015.03.008
   Chen KH, 2010, CHILD NERV SYST, V26, P1605, DOI 10.1007/s00381-010-1190-2
   Chen SC, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056380
   Chen YL, 2011, PLOS ONE, V6, DOI [10.1371/journal.pone.0023237, 10.1371/journal.pone.0017876]
   Choi D, 2009, WORLD J GASTROENTERO, V15, P2258, DOI 10.3748/wjg.15.2258
   Clement V, 2007, CURR BIOL, V17, P165, DOI 10.1016/j.cub.2006.11.033
   Colman H, 2010, NEURO-ONCOLOGY, V12, P49, DOI 10.1093/neuonc/nop007
   Corbeil D, 2001, TRAFFIC, V2, P82, DOI 10.1034/j.1600-0854.2001.020202.x
   Corbo C, 2012, PROTEOMICS, V12, P2045, DOI 10.1002/pmic.201100370
   Dalerba P, 2007, P NATL ACAD SCI USA, V104, P10158, DOI 10.1073/pnas.0703478104
   Damek-Poprawa M, 2011, J DENT RES, V90, P638, DOI 10.1177/0022034510393511
   de Sousa EMF, 2011, CLIN CANCER RES, V17, P647, DOI 10.1158/1078-0432.CCR-10-1204
   Deng Y, 2009, J CLIN ONCOL, V27
   Deng Yan-Hong, 2010, Chin J Cancer, V29, P810
   Ding Q, 2012, HUM CELL, V25, P1, DOI 10.1007/s13577-011-0037-9
   Fang YT, 2012, ONCOL REP, V28, P2115, DOI 10.3892/or.2012.2054
   Ferrand A, 2009, BBA-MOL CELL RES, V1793, P477, DOI 10.1016/j.bbamcr.2009.01.004
   Georgia S, 2006, DEV BIOL, V298, P22, DOI 10.1016/j.ydbio.2006.05.036
   Ghasabi M, 2019, J CELL PHYSIOL, V234, P2152, DOI 10.1002/jcp.26810
   Grosse-Gehling P, 2013, J PATHOL, V229, P355, DOI 10.1002/path.4086
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   Horst D, 2009, J PATHOL, V219, P427, DOI 10.1002/path.2597
   Horst D, 2009, EUR J CANCER, V45, P2034, DOI 10.1016/j.ejca.2009.04.004
   HUANG R, 2018, MEDICINE, V97, DOI [10.1097/MD.0000000000010446, DOI 10.1097/MD.0000000000010446]
   Huang R, 2015, MOL MED REP, V12, P2417, DOI 10.3892/mmr.2015.3694
   Jao SW, 2012, ANN SURG ONCOL, V19, P3432, DOI 10.1245/s10434-012-2394-3
   Karbanova J, 2008, J HISTOCHEM CYTOCHEM, V56, P977, DOI 10.1369/jhc.2008.951897
   Karimi L, 2017, BIOMED PHARMACOTHER, V91, P121, DOI 10.1016/j.biopha.2017.04.060
   Kashihara H, 2014, HEPATO-GASTROENTEROL, V61, P1563, DOI 10.5754/hge13657
   Kawamoto H, 2010, CELL TRANSPLANT, V19, P857, DOI 10.3727/096368910X508988
   Kazama S, 2018, ASIAN J SURG, V41, P274, DOI 10.1016/j.asjsur.2016.12.002
   Kemper K, 2012, CLIN CANCER RES, V18, P3132, DOI 10.1158/1078-0432.CCR-11-3066
   Khelwatty Said Abdullah, 2019, Oncotarget, V10, P1704, DOI 10.18632/oncotarget.26722
   Kishikawa J, 2016, ANN SURG ONCOL, V23, P1916, DOI 10.1245/s10434-016-5099-1
   Kojima M, 2008, CANCER SCI, V99, P1578, DOI 10.1111/j.1349-7006.2008.00849.x
   Kong Dejuan, 2011, Cancers (Basel), V3, P716, DOI 10.3390/cancers30100716
   LaBarge MA, 2008, J CLIN INVEST, V118, P2021, DOI 10.1172/JCI36046
   Li CY, 2009, J TRANSL MED, V7, DOI 10.1186/1479-5876-7-56
   Liao YQ, 2010, BIOL PHARM BULL, V33, P738, DOI 10.1248/bpb.33.738
   Lin L, 2011, BRIT J CANCER, V105, P212, DOI 10.1038/bjc.2011.200
   Lönnroth C, 2012, INT J ONCOL, V41, P15, DOI 10.3892/ijo.2012.1460
   Ma YH, 2008, J NEURO-ONCOL, V86, P31, DOI 10.1007/s11060-007-9439-7
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Montazami N, 2015, CELL MOL BIOL, V61, P98
   Nagaharu K, 2011, AM J PATHOL, V178, P754, DOI 10.1016/j.ajpath.2010.10.015
   Ning ST, 2016, ACS APPL MATER INTER, V8, P17793, DOI 10.1021/acsami.6b04403
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Ong CW, 2010, MODERN PATHOL, V23, P450, DOI 10.1038/modpathol.2009.181
   Qi LS, 2012, CANCER SCI, V103, P828, DOI 10.1111/j.1349-7006.2012.02222.x
   Ren F, 2013, WORLD J GASTROENTERO, V19, P2603, DOI 10.3748/wjg.v19.i17.2603
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Ricci-Vitiani L, 2009, J MOL MED, V87, P1097, DOI 10.1007/s00109-009-0518-4
   Sadreddini S, 2017, IMMUNOL LETT, V181, P79, DOI 10.1016/j.imlet.2016.11.013
   Sahlberg SH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094621
   Saigusa S, 2011, CLIN ONCOL-UK, V23, P323, DOI 10.1016/j.clon.2010.09.012
   Saigusa S, 2009, ANN SURG ONCOL, V16, P3488, DOI 10.1245/s10434-009-0617-z
   Salnikov AV, 2010, INT J CANCER, V126, P950, DOI 10.1002/ijc.24822
   Sato-Dahlman M, 2017, ONCOTARGET, V8, P76044, DOI 10.18632/oncotarget.18340
   Scheel C, 2011, INT J CANCER, V129, P2310, DOI 10.1002/ijc.26311
   Shen WW, 2013, J MOL MED, V91, P989, DOI 10.1007/s00109-013-1037-x
   Shirafkan N, 2018, BIOMED PHARMACOTHER, V97, P1319, DOI 10.1016/j.biopha.2017.11.046
   Shmelkov SV, 2008, J CLIN INVEST, V118, P2111, DOI 10.1172/JCI34401
   Shmelkov SV, 2004, BLOOD, V103, P2055, DOI 10.1182/blood-2003-06-1881
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Smith LM, 2008, BRIT J CANCER, V99, P100, DOI 10.1038/sj.bjc.6604437
   Stanisavljevic L, 2016, ACTA ONCOL, V55, P1425, DOI 10.1080/0284186X.2016.1201215
   Swaminathan SK, 2013, J CONTROL RELEASE, V171, P280, DOI 10.1016/j.jconrel.2013.07.014
   Tabu K, 2008, CELL RES, V18, P1037, DOI 10.1038/cr.2008.270
   Tabu K, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-39
   Tirino V, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003469
   Todaro M, 2007, CELL STEM CELL, V1, P389, DOI 10.1016/j.stem.2007.08.001
   Van Orden K., 2007, CANCER RES, V67, P1324
   Wang BB, 2016, HISTOL HISTOPATHOL, V31, P299, DOI 10.14670/HH-11-676
   Wang CH, 2011, NANOMED-NANOTECHNOL, V7, P69, DOI 10.1016/j.nano.2010.06.010
   Wang K, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-573
   Wang YK, 2010, CARCINOGENESIS, V31, P1376, DOI 10.1093/carcin/bgq120
   Wu N, 2012, FEBS LETT, V586, P3831, DOI 10.1016/j.febslet.2012.08.023
   Wu SW, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-535
   Yamamoto S, 2014, ANN SURG ONCOL, V21, P1853, DOI 10.1245/s10434-014-3549-1
   Yanagisawa S, 2009, CLIN CANCER RES, V15, P3014, DOI 10.1158/1078-0432.CCR-08-2237
   Yao J, 2009, ONCOL REP, V22, P781, DOI 10.3892/or_00000500
   Yasuda H, 2009, ONCOL REP, V22, P709, DOI 10.3892/or_00000491
   Yi JM, 2008, CANCER RES, V68, P8094, DOI 10.1158/0008-5472.CAN-07-6208
   Zhao L, 2015, J IMMUNOTHER, V38, P217, DOI 10.1097/CJI.0000000000000086
   Zhao P, 2011, CANCER SCI, V102, P1107, DOI 10.1111/j.1349-7006.2011.01894.x
   Zhao Y, 2016, ONCOTARGET, V7, P10023, DOI 10.18632/oncotarget.7054
NR 92
TC 42
Z9 43
U1 1
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-6995
EI 1095-8355
J9 CELL BIOL INT
JI Cell Biol. Int.
PD FEB
PY 2020
VL 44
IS 2
BP 368
EP 380
DI 10.1002/cbin.11243
EA OCT 2019
PG 13
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA KF9OC
UT WOS:000490855600001
PM 31579983
DA 2025-01-04
ER

PT J
AU Kim, MJ
   Huang, YJ
   Park, JI
AF Kim, Moon Jong
   Huang, Yuanjian
   Park, Jae-Il
TI Targeting Wnt Signaling for Gastrointestinal Cancer Therapy: Present and
   Evolving Views
SO CANCERS
LA English
DT Review
DE Wnt signaling; &#946; -catenin; cancer; gastrointestinal cancers;
   therapeutic targeting of Wnt signaling; &#946; -catenin paradox;
   molecular targeting
ID SMALL-MOLECULE INHIBITOR; BETA-CATENIN DEGRADATION; WNT/BETA-CATENIN;
   COLORECTAL-CANCER; STEM-CELLS; PHASE-I; AUTOPHAGY INHIBITION; TANKYRASE
   INHIBITOR; FRIZZLED HOMOLOGS; BREAST-CANCER
AB Simple Summary
   Therapeutic targeting of Wnt has long been suggested for gastrointestinal (GI) cancer treatment because deregulation of Wnt signaling is associated with GI cancers. However, therapeutic targeting of Wnt is still challenging because of the pleiotropic roles of Wnt signaling in the human body. Thus, targeting strategies of Wnt signaling are continuously evolving. The current flows of targeting Wnt signaling for cancer treatment are focused on increasing the specificity of drugs and combinatory treatment with other cancer drugs that minimize side effects and increase efficacy. Additionally, increased knowledge about the beta-catenin paradox has expanded the cases that can be treated with Wnt targeting therapy, not strictly considering Wnt upstream and downstream mutations. Here, we discuss these evolving views of targeting Wnt signaling and describe examples of current clinical trials.
   Wnt signaling governs tissue development, homeostasis, and regeneration. However, aberrant activation of Wnt promotes tumorigenesis. Despite the ongoing efforts to manipulate Wnt signaling, therapeutic targeting of Wnt signaling remains challenging. In this review, we provide an overview of current clinical trials to target Wnt signaling, with a major focus on gastrointestinal cancers. In addition, we discuss the caveats and alternative strategies for therapeutically targeting Wnt signaling for cancer treatment.
C1 [Kim, Moon Jong; Huang, Yuanjian; Park, Jae-Il] Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.
   [Park, Jae-Il] Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.
   [Park, Jae-Il] Hlth Sci Ctr, Houston, TX 77030 USA.
   [Park, Jae-Il] Univ Texas MD Anderson Canc Ctr, Program Genet & Epigenet, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center; University of Texas System;
   University of Texas Health Science Center Houston; University of Texas
   System; UTMD Anderson Cancer Center
RP Park, JI (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Expt Radiat Oncol, Houston, TX 77030 USA.; Park, JI (corresponding author), Univ Texas MD Anderson Canc Ctr, Grad Sch Biomed Sci, Houston, TX 77030 USA.; Park, JI (corresponding author), Hlth Sci Ctr, Houston, TX 77030 USA.; Park, JI (corresponding author), Univ Texas MD Anderson Canc Ctr, Program Genet & Epigenet, Houston, TX 77030 USA.
EM mkim312@mdanderson.org; yhuang14@mdanderson.org; jaeil@mdanderson.org
RI park, jaeil/AAS-5894-2021; Kim, Moon/AAK-7406-2021
OI Huang, Yuanjian/0000-0002-1611-8252; Kim, Moon Jong/0000-0002-7876-4639;
   PARK, JAE-IL/0000-0002-0737-2654
FU National Institutes of Health [2R01 CA193297]; Department of Defense
   Peer Reviewed Cancer Research Program [CA140572]; Specialized Program of
   Research Excellence (SPORE) grant in endometrial cancer [P50 CA83639];
   ROSI Seed Award [00057597]; Institutional Research Grant (MD Anderson); 
   [RP140563];  [RP200315]
FX This work was supported by grants to the Cancer Prevention and Research
   Institute of Texas (RP140563 and RP200315 to J.-I.P.), the National
   Institutes of Health (2R01 CA193297 to J.-I.P.), the Department of
   Defense Peer Reviewed Cancer Research Program (CA140572 to J.-I.P.), an
   Institutional Research Grant (MD Anderson to J.-I.P.), a Specialized
   Program of Research Excellence (SPORE) grant in endometrial cancer (P50
   CA83639), and an ROSI Seed Award (00057597 to M.J.K.).
CR Agostino M, 2017, J BIOL CHEM, V292, P11218, DOI 10.1074/jbc.M117.786269
   Anastas JN, 2013, NAT REV CANCER, V13, P11, DOI 10.1038/nrc3419
   [Anonymous], 2019, NAT COMMUN
   [Anonymous], 2016, J CLIN ONCOL S
   Arora SP, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3551
   Barker N, 2013, DEVELOPMENT, V140, P2484, DOI 10.1242/dev.083113
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Bendell J, 2016, EUR J CANCER, V69, pS29, DOI 10.1016/S0959-8049(16)32668-5
   Boone BA, 2015, ANN SURG ONCOL, V22, P4402, DOI 10.1245/s10434-015-4566-4
   Bossard C, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.PANCA19-A02
   Bossard C, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.e15185
   Brabletz T, 2001, P NATL ACAD SCI USA, V98, P10356, DOI 10.1073/pnas.171610498
   Brunner E, 1997, NATURE, V385, P829, DOI 10.1038/385829a0
   Bu QX, 2017, J BIOL CHEM, V292, P16055, DOI 10.1074/jbc.M117.791756
   Buchert M, 2010, PLOS GENET, V6, DOI 10.1371/journal.pgen.1000816
   Burock S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.e14536
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Caneparo L, 2007, GENE DEV, V21, P465, DOI 10.1101/gad.406007
   Cha SW, 2008, DEVELOPMENT, V135, P3719, DOI 10.1242/dev.029025
   Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677
   Chen W, 2016, MOL MED REP, V13, P3466, DOI 10.3892/mmr.2016.4986
   Chou CT, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0107869, 10.1371/journal.pone.0104899, 10.1371/journal.pone.0105414]
   Clevers H, 2016, CELL, V165, P1586, DOI 10.1016/j.cell.2016.05.082
   Clevers H, 2014, SCIENCE, V346, P54, DOI 10.1126/science.1248012
   Davis SL, 2020, INVEST NEW DRUG, V38, P821, DOI [10.1038/s41564-019-0492-8, 10.1007/s10637-019-00824-1]
   De A, 2011, ACTA BIOCH BIOPH SIN, V43, P745, DOI 10.1093/abbs/gmr079
   de la Roche M, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1680
   de Lau W, 2014, GENE DEV, V28, P305, DOI 10.1101/gad.235473.113
   Melo FDE, 2017, NATURE, V543, P676, DOI 10.1038/nature21713
   Deka J, 2010, CANCER RES, V70, P6619, DOI 10.1158/0008-5472.CAN-10-0148
   Diamond JR, 2020, BREAST CANCER RES TR, V184, P53, DOI 10.1007/s10549-020-05817-w
   Dotan E, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.369
   Duncan AW, 2005, NAT IMMUNOL, V6, P314, DOI 10.1038/ni1164
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   El-Khoueiry AB, 2013, J CLIN ONCOL, V31
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Feng M, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aau5240
   Fevr T, 2007, MOL CELL BIOL, V27, P7551, DOI 10.1128/MCB.01034-07
   Fiedler M, 2011, P NATL ACAD SCI USA, V108, P1937, DOI 10.1073/pnas.1017063108
   Fischer MM, 2017, SCI ADV, V3, DOI 10.1126/sciadv.1700090
   Flanagan DJ, 2019, CANCER RES, V79, P970, DOI 10.1158/0008-5472.CAN-18-2095
   Flanagan DJ, 2017, DIS MODEL MECH, V10, P971, DOI 10.1242/dmm.029876
   Flanagan DJ, 2015, STEM CELL REP, V4, P759, DOI 10.1016/j.stemcr.2015.03.003
   Fodde R, 2010, J PATHOL, V221, P239, DOI 10.1002/path.2718
   Fujii N, 2007, CANCER RES, V67, P573, DOI 10.1158/0008-5472.CAN-06-2726
   Gao ZH, 2002, P NATL ACAD SCI USA, V99, P1182, DOI 10.1073/pnas.032468199
   Glinka A, 1998, NATURE, V391, P357, DOI 10.1038/34848
   Goentoro L, 2009, MOL CELL, V36, P872, DOI 10.1016/j.molcel.2009.11.017
   Gong X, 2016, MOL CANCER THER, V15, P1580, DOI 10.1158/1535-7163.MCT-16-0114
   Gonsalves FC, 2011, P NATL ACAD SCI USA, V108, P5954, DOI 10.1073/pnas.1017496108
   Grandy D, 2009, J BIOL CHEM, V284, P16256, DOI 10.1074/jbc.M109.009647
   Grumolato L, 2010, GENE DEV, V24, P2517, DOI 10.1101/gad.1957710
   Gurney A, 2012, P NATL ACAD SCI USA, V109, P11717, DOI 10.1073/pnas.1120068109
   Ha NC, 2004, MOL CELL, V15, P511, DOI 10.1016/j.molcel.2004.08.010
   Hao HX, 2012, NATURE, V485, P195, DOI 10.1038/nature11019
   He X, 2004, DEVELOPMENT, V131, P1663, DOI 10.1242/dev.01117
   Hecht A, 2000, EMBO J, V19, P1839, DOI 10.1093/emboj/19.8.1839
   Hikasa H, 2011, J BIOL CHEM, V286, DOI 10.1074/jbc.M110.185280
   Hikasa H, 2010, DEV CELL, V19, P521, DOI 10.1016/j.devcel.2010.09.005
   Hong TS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4118
   Horst D, 2012, CANCER RES, V72, P1547, DOI 10.1158/0008-5472.CAN-11-3222
   Hou PP, 2019, GENE DEV, V33, P1361, DOI 10.1101/gad.326314.119
   Huang J, 2014, ONCOGENE, V33, P2737, DOI 10.1038/onc.2013.238
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hwang SY, 2016, CELL REP, V16, P28, DOI 10.1016/j.celrep.2016.05.071
   Inglis DJ, 2018, CANCER RES, V78, DOI 10.1158/1538-7445.AM2018-3910
   Ishitani T, 1999, NATURE, V399, P798, DOI 10.1038/21674
   Ishitani T, 2003, MOL CELL BIOL, V23, P131, DOI 10.1128/MCB.23.1.131-139.2003
   Itasaki N, 2003, DEVELOPMENT, V130, P4295, DOI 10.1242/dev.00674
   Ito M, 2007, NATURE, V447, P316, DOI 10.1038/nature05766
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Jansson M, 2001, J CELL SCI, V114, P2043
   Ji L, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12143-3
   Ji L, 2017, GENE DEV, V31, P904, DOI 10.1101/gad.300053.117
   Jimeno A, 2017, CLIN CANCER RES, V23, P7490, DOI 10.1158/1078-0432.CCR-17-2157
   Jung HY, 2013, MOL CELL, V52, P193, DOI 10.1016/j.molcel.2013.08.028
   Jung YS, 2021, HEPATOLOGY, V73, P776, DOI 10.1002/hep.31305
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6
   Jung YS, 2018, NAT CELL BIOL, V20, P1421, DOI 10.1038/s41556-018-0219-8
   Jung YS, 2015, ONCOTARGET, V6, P37257, DOI 10.18632/oncotarget.6133
   Junttila MR, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac7433
   Kahn M, 2014, NAT REV DRUG DISCOV, V13, P513, DOI 10.1038/nrd4233
   Karasic TB, 2019, JAMA ONCOL, V5, P993, DOI 10.1001/jamaoncol.2019.0684
   Khalaf AM, 2018, J HEPATOCELL CARCINO, V5, P61, DOI 10.2147/JHC.S156701
   Kikuchi A, 2011, INT REV CEL MOL BIO, V291, P21, DOI 10.1016/B978-0-12-386035-4.00002-1
   Kim MJ, 2018, DEV CELL, V44, P582, DOI 10.1016/j.devcel.2018.02.010
   Kishida S, 1999, MOL CELL BIOL, V19, P4414
   Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308
   Kühl M, 2000, J BIOL CHEM, V275, P12701, DOI 10.1074/jbc.275.17.12701
   Lau T, 2013, CANCER RES, V73, P3132, DOI 10.1158/0008-5472.CAN-12-4562
   Lee Y, 2017, ONCOTARGET, V8, P41091, DOI 10.18632/oncotarget.17056
   Lenz HJ, 2014, CANCER SCI, V105, P1087, DOI 10.1111/cas.12471
   Li VSW, 2012, CELL, V149, P1245, DOI 10.1016/j.cell.2012.05.002
   Liang CJ, 2019, CELL REP, V28, P1511, DOI 10.1016/j.celrep.2019.07.023
   Liu CM, 2002, CELL, V108, P837, DOI 10.1016/S0092-8674(02)00685-2
   Liu L, 2018, CANCER RES, V78, P1958, DOI 10.1158/0008-5472.CAN-17-2683
   Loaiza-Bonilla A, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.3614
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Lopez-Rios J, 2008, NEURAL DEV, V3, DOI 10.1186/1749-8104-3-19
   Lu WY, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029290
   Mahalingam D, 2014, AUTOPHAGY, V10, P1403, DOI 10.4161/auto.29231
   Mahmoudi T, 2009, EMBO J, V28, P3329, DOI 10.1038/emboj.2009.285
   Malinauskas T, 2011, NAT STRUCT MOL BIOL, V18, P886, DOI 10.1038/nsmb.2081
   Martins-Neves SR, 2018, CANCER LETT, V414, P1, DOI 10.1016/j.canlet.2017.11.004
   Masuda M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12586
   Merle P, 2004, GASTROENTEROLOGY, V127, P1110, DOI 10.1053/j.gastro.2004.07.009
   Mikels AJ, 2006, PLOS BIOL, V4, P570, DOI 10.1371/journal.pbio.0040115
   Miyabayashi T, 2007, P NATL ACAD SCI USA, V104, P5668, DOI 10.1073/pnas.0701331104
   Molenaar RJ, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2016-014961
   Movérare-Skrtic S, 2019, FASEB J, V33, P11163, DOI 10.1096/fj.201900707R
   Murphy LLS, 2002, J IMMUNOL, V169, P3717, DOI 10.4049/jimmunol.169.7.3717
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Mzoughi S, 2017, NAT GENET, V49, P1354, DOI 10.1038/ng.3922
   Nagle PW, 2018, SEMIN CANCER BIOL, V53, P258, DOI 10.1016/j.semcancer.2018.06.005
   Ng M, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.2584
   Niehrs C, 2006, ONCOGENE, V25, P7469, DOI 10.1038/sj.onc.1210054
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Novellasdemunt L, 2017, CELL REP, V21, P612, DOI 10.1016/j.celrep.2017.09.072
   Nusse R, 2005, CELL RES, V15, P28, DOI 10.1038/sj.cr.7290260
   NUSSE R, 1982, CELL, V31, P99, DOI 10.1016/0092-8674(82)90409-3
   Nusse R, 2017, CELL, V169, P985, DOI 10.1016/j.cell.2017.05.016
   NUSSLEINVOLHARD C, 1980, NATURE, V287, P795, DOI 10.1038/287795a0
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008-5472.CAN-10-3978
   PAPKOFF J, 1987, MOL CELL BIOL, V7, P3978, DOI 10.1128/MCB.7.11.3978
   Patel A, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.88
   Phelps RA, 2009, CELL, V137, P623, DOI 10.1016/j.cell.2009.02.037
   Piccolo S, 1999, NATURE, V397, P707, DOI 10.1038/17820
   Pinto D, 2003, GENE DEV, V17, P1709, DOI 10.1101/gad.267103
   Pintova S, 2019, CANCER CHEMOTH PHARM, V84, P591, DOI 10.1007/s00280-019-03886-3
   Prossomariti A, 2020, CELL MOL GASTROENTER, V10, P491, DOI 10.1016/j.jcmgh.2020.04.007
   Riffell JL, 2012, NAT REV DRUG DISCOV, V11, P923, DOI 10.1038/nrd3868
   Rios-Esteves J, 2014, J BIOL CHEM, V289, P17009, DOI 10.1074/jbc.M114.561209
   Rowan AJ, 2000, P NATL ACAD SCI USA, V97, P3352, DOI 10.1073/pnas.97.7.3352
   Russell JO, 2018, ANNU REV PATHOL-MECH, V13, P351, DOI 10.1146/annurev-pathol-020117-044010
   Ryan DP, 2016, ANN ONCOL, V27, P108
   Säfholm A, 2006, J BIOL CHEM, V281, P2740, DOI 10.1074/jbc.M508386200
   Säfholm A, 2008, CLIN CANCER RES, V14, P6556, DOI 10.1158/1078-0432.CCR-08-0711
   Salik B, 2020, CANCER CELL, V38, P263, DOI 10.1016/j.ccell.2020.05.014
   Sato A, 2010, EMBO J, V29, P41, DOI 10.1038/emboj.2009.322
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Scarborough HA, 2017, CLIN CANCER RES, V23, P1531, DOI 10.1158/1078-0432.CCR-16-1179
   Schepers A, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007989
   Schutgens F, 2020, ANNU REV PATHOL-MECH, V15, P211, DOI 10.1146/annurev-pathmechdis-012419-032611
   Seino T, 2018, CELL STEM CELL, V22, P454, DOI 10.1016/j.stem.2017.12.009
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shan JF, 2005, BIOCHEMISTRY-US, V44, P15495, DOI 10.1021/bi0512602
   Sheldahl LC, 1999, CURR BIOL, V9, P695, DOI 10.1016/S0960-9822(99)80310-8
   Shi RY, 2013, CANCER-AM CANCER SOC, V119, P993, DOI 10.1002/cncr.27788
   Shi Y, 2014, ACTA OTO-LARYNGOL, V134, P753, DOI 10.3109/00016489.2014.894251
   Shimokawa M, 2017, NATURE, V545, P187, DOI 10.1038/nature22081
   Shitashige M, 2010, CANCER RES, V70, P5024, DOI 10.1158/0008-5472.CAN-10-0306
   Shorning BY, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21124507
   Simonetta KR, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09358-9
   Simons M, 2008, ANNU REV GENET, V42, P517, DOI 10.1146/annurev.genet.42.110807.091432
   Slusarski DC, 1997, DEV BIOL, V182, P114, DOI 10.1006/dbio.1996.8463
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Steinhart Z, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.146589
   Steinhart Z, 2017, NAT MED, V23, P60, DOI 10.1038/nm.4219
   Suciu RM, 2018, ACS MED CHEM LETT, V9, P563, DOI 10.1021/acsmedchemlett.8b00191
   Sukhdeo K, 2007, P NATL ACAD SCI USA, V104, P7516, DOI 10.1073/pnas.0610299104
   Takemaru KI, 2000, J CELL BIOL, V149, P249, DOI 10.1083/jcb.149.2.249
   Tam BY, 2020, CANCER LETT, V473, P186, DOI 10.1016/j.canlet.2019.09.009
   Tammela T, 2017, NATURE, V545, P355, DOI 10.1038/nature22334
   Thorne CA, 2010, NAT CHEM BIOL, V6, P829, DOI 10.1038/NCHEMBIO.453
   Tian W, 2012, BIOCHEMISTRY-US, V51, P724, DOI 10.1021/bi201428h
   Tomar VS, 2020, CELL BIOL TOXICOL, V36, P273, DOI 10.1007/s10565-019-09502-7
   vandeWetering M, 1997, CELL, V88, P789, DOI 10.1016/S0092-8674(00)81925-X
   Vermorken J, 2019, ANN ONCOL, V30, P36
   Vlachogiannis G, 2018, SCIENCE, V359, P920, DOI 10.1126/science.aao2774
   Voloshanenko O, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3610
   Waaler J, 2012, CANCER RES, V72, P2822, DOI 10.1158/0008-5472.CAN-11-3336
   Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wong HC, 2003, MOL CELL, V12, P1251, DOI 10.1016/S1097-2765(03)00427-1
   Xavier CP, 2014, CELL SIGNAL, V26, P94, DOI 10.1016/j.cellsig.2013.09.016
   Xu WH, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0037624
   Yanagita M, 2004, BIOCHEM BIOPH RES CO, V316, P490, DOI 10.1016/j.bbrc.2004.02.075
   Yao Y, 2020, CELL STEM CELL, V26, P17, DOI 10.1016/j.stem.2019.10.010
   Yu B, 2009, J HEPATOL, V50, P948, DOI 10.1016/j.jhep.2008.11.020
   Yu J, 2014, DEV CELL, V29, P277, DOI 10.1016/j.devcel.2014.03.016
   Zhang XJ, 2016, J BIOL CHEM, V291, P2435, DOI 10.1074/jbc.M115.677807
   Zhang XJ, 2012, CELL, V149, P1565, DOI 10.1016/j.cell.2012.04.039
   Zhang YN, 2009, NAT CHEM BIOL, V5, P217, DOI 10.1038/nchembio.152
   Zhong Z, 2019, ONCOGENE, V38, P6662, DOI 10.1038/s41388-019-0908-1
   Zhuang XQ, 2017, NAT CELL BIOL, V19, P1274, DOI 10.1038/ncb3613
NR 185
TC 24
Z9 25
U1 3
U2 31
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD DEC
PY 2020
VL 12
IS 12
AR 3638
DI 10.3390/cancers12123638
PG 27
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PJ5VP
UT WOS:000601835300001
PM 33291655
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Zhou, JW
   Dong, CT
   Tan, J
   Wang, GJ
   Li, Z
   Li, S
   He, ZQ
AF Zhou, Jiawei
   Dong, Caitao
   Tan, Jing
   Wang, Guijun
   Li, Zhen
   Li, Sheng
   He, Ziqi
TI Promoting effect and immunologic role of secretogranin II on bladder
   cancer progression via regulating MAPK and NF-κB pathways
SO APOPTOSIS
LA English
DT Article
DE Bladder cancer; Secretogranin II; Apoptosis; MAPK; NF-kappa B;
   Macrophage
ID RISK-FACTORS; ASSOCIATION; STATISTICS; MORTALITY; SMOKING
AB Bladder cancer (BLCA) is ranked among the top ten most prevalent cancers worldwide and is the second most common malignant tumor within the field of urology. The limited effectiveness of immune targeted therapy in treating BLCA, due to its high metastasis and recurrence rates, necessitates the identification of new therapeutic targets. Secretogranin II (SCG2), a member of the chromaffin granin/secreted granin family, plays a crucial role in the regulated release of peptides and hormones. The role of SCG2 in the tumor microenvironment (TME) of lung adenocarcinoma and colon cancer has been established, but its functional significance in BLCA remains uncertain. This study aimed to investigate SCG2 expression in 15 bladder cancer tissue samples and their corresponding adjacent control tissues. The potential involvement of SCG2 in BLCA progression was assessed using various techniques, including analysis of public databases, immunohistochemistry, Western Blotting, immunofluorescence, wound-healing assay, Transwell assay, and xenograft tumor formation experiments in nude mice. This study provided novel evidence indicating that SCG2 plays a pivotal role in facilitating the proliferation, migration, and invasion of BLCA by activating the MEK/Erk and MEK/IKK/NF-kappa B signaling pathways, as well as by promoting M2 macrophage polarization. These findings propose the potential of SCG2 as a molecular target for immunotherapy in human BLCA.
C1 [Zhou, Jiawei; Dong, Caitao; He, Ziqi] Wuhan Univ, Renmin Hosp, Dept Urol, Wuhan 430060, Hubei, Peoples R China.
   [Tan, Jing] Wuhan Univ, Coll Life Sci, Hubei Key Lab Homeostasis, Wuhan, Peoples R China.
   [Wang, Guijun; Li, Zhen] Wuhan Univ, Renmin Hosp, Wuhan 430060, Hubei, Peoples R China.
   [Li, Sheng] Wuhan Univ, Dept Urol, Zhongnan Hosp, Wuhan, Hubei, Peoples R China.
   [Li, Sheng] Wuhan Univ, Zhongnan Hosp, Hubei Engn Res Ctr, Canc Precis Diag & Treatment & Translat Med,Dept B, Wuhan 430071, Peoples R China.
C3 Wuhan University; Wuhan University; Wuhan University; Wuhan University;
   Wuhan University
RP He, ZQ (corresponding author), Wuhan Univ, Renmin Hosp, Dept Urol, Wuhan 430060, Hubei, Peoples R China.
EM ziqihe1990@163.com
CR Ang HL, 2023, MED RES REV, V43, P1141, DOI 10.1002/med.21948
   Antoni S, 2017, EUR UROL, V71, P96, DOI 10.1016/j.eururo.2016.06.010
   Asl ER, 2021, LIFE SCI, V278, DOI 10.1016/j.lfs.2021.119499
   Babjuk M, 2022, EUR UROL, V81, P75, DOI 10.1016/j.eururo.2021.08.010
   Bertheloot D, 2021, CELL MOL IMMUNOL, V18, P1106, DOI 10.1038/s41423-020-00630-3
   Bock FJ, 2020, NAT REV MOL CELL BIO, V21, P85, DOI 10.1038/s41580-019-0173-8
   Burger M, 2013, EUR UROL, V63, P234, DOI 10.1016/j.eururo.2012.07.033
   Cheng X, 2023, INT IMMUNOPHARMACOL, V118, DOI 10.1016/j.intimp.2023.110025
   Compérat E, 2015, VIRCHOWS ARCH, V466, P589, DOI 10.1007/s00428-015-1739-2
   Daugherty SE, 2013, INT J CANCER, V133, P462, DOI 10.1002/ijc.28022
   Freedman ND, 2011, JAMA-J AM MED ASSOC, V306, P737, DOI 10.1001/jama.2011.1142
   Gaffney CD, 2023, EUR UROL FOCUS, V9, P575, DOI 10.1016/j.euf.2023.03.017
   Jain P, 2021, PHARMACOL THERAPEUT, V226, DOI 10.1016/j.pharmthera.2021.107871
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jemal A, 2010, CA-CANCER J CLIN, V60, P277, DOI [10.3322/caac.21254, 10.3322/caac.20073]
   Li DD, 2023, CELL PROLIFERAT, V56, DOI 10.1111/cpr.13423
   Lin HC, 2021, MOL THER ONCOLYTICS, V21, P23, DOI 10.1016/j.omto.2021.02.015
   Liu J, 2023, TRENDS CELL BIOL, V33, P967, DOI 10.1016/j.tcb.2023.03.008
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mitchell S, 2016, WIRES SYST BIOL MED, V8, P227, DOI 10.1002/wsbm.1331
   ncbi, TIMELINE TUMOUR ASS
   ncbi, NUCL FACTOR KAPPA B
   ncbi, SCG2 IS PROGNOSTIC B
   ncbi, PROGNOSTIC VALUE SEC
   ncbi, METABOLIC REGULATION
   ncbi, TARGETING ABERRANT R
   .ncbi, TALE EXOSOMES THEIR
   ncbi, NF KB DEV PROGR HUMA
   ncbi, ANTICANCER NATURAL P
   ncbi, APOPTOSIS CANC PATHO
   ncbi, EMT TRANSITION STATE
   ncbi, EMT MET PLASTICITY C
   ncbi, ANGIOGENIC FACTOR SE
   ncbi, TUMOR ASS MACROPHAGE
   ncbi, CELL DEATH THERAPEUT
   ncbi, APOBEC MEDIATED MUTA
   Patel VG, 2020, CA-CANCER J CLIN, V70, P404, DOI 10.3322/caac.21631
   Pfail JL, 2021, WORLD J UROL, V39, P1319, DOI 10.1007/s00345-020-03474-8
   Reulen RC, 2008, SCAND J UROL NEPHROL, V42, P64, DOI 10.1080/03008880802325192
   Scosyrev E, 2009, CANCER-AM CANCER SOC, V115, P68, DOI 10.1002/cncr.23986
   Shapouri-Moghaddam A, 2018, J CELL PHYSIOL, V233, P6425, DOI 10.1002/jcp.26429
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Smith AB, 2014, BJU INT, V114, P719, DOI 10.1111/bju.12601
   Soloway MS, 2013, NAT REV UROL, V10, P5, DOI 10.1038/nrurol.2012.219
   Steinfass T, 2023, EXP HEMATOL ONCOL, V12, DOI 10.1186/s40164-023-00387-1
   Strope SA, 2008, J UROLOGY, V180, P31, DOI 10.1016/j.juro.2008.03.045
   Sun QH, 2022, CELL BIOCHEM FUNCT, V40, P79, DOI 10.1002/cbf.3677
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tan JS, 2023, DISCOV ONCOL, V14, DOI 10.1007/s12672-023-00737-9
   Ullah R, 2022, SEMIN CANCER BIOL, V85, P123, DOI 10.1016/j.semcancer.2021.05.010
   Weng SY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.873871
   Yap EL, 2020, NATURE, DOI 10.1038/s41586-020-3031-0
   Zeegers MPA, 2001, OCCUP ENVIRON MED, V58, P590, DOI 10.1136/oem.58.9.590
   Zhang X, 2023, IMMUNITY, V56, P14, DOI 10.1016/j.immuni.2022.12.003
NR 54
TC 1
Z9 1
U1 3
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 1360-8185
EI 1573-675X
J9 APOPTOSIS
JI Apoptosis
PD FEB
PY 2024
VL 29
IS 1-2
BP 121
EP 141
DI 10.1007/s10495-023-01898-2
EA OCT 2023
PG 21
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA GH3M6
UT WOS:001084811300001
PM 37848672
DA 2025-01-04
ER

PT J
AU Park, J
   Cho, YH
   Shin, WJ
   Lee, SK
   Lee, J
   Kim, T
   Cha, PH
   Yang, JS
   Cho, J
   Min, DS
   Han, G
   Lee, HY
   Choi, KY
AF Park, Jieun
   Cho, Yong-Hee
   Shin, Wook-Jin
   Lee, Sang-Kyu
   Lee, JaeHeon
   Kim, Taehyung
   Cha, Pu-Hyeon
   Yang, Jee Sun
   Cho, Jaebeom
   Min, Do Sik
   Han, Gyoonhee
   Lee, Ho-Young
   Choi, Kang-Yell
TI A Ras destabilizer KYA1797K overcomes the resistance of EGFR tyrosine
   kinase inhibitor in <i>KRAS</i>-mutated non-small cell lung cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID WNT/BETA-CATENIN PATHWAY; GROWTH-FACTOR RECEPTOR; CANONICAL WNT PATHWAY;
   BETA-CATENIN; CONSTITUTIVE ACTIVATION; SIGNALING PATHWAYS; K-RAS;
   MUTATIONS; TARGET; PROLIFERATION
AB The epidermal growth factor receptor (EGFR) inhibitors such as erlotinib and gefitinib are widely used for treatment of non-small cell lung cancer (NSCLC), but they have shown limited efficacy in an unselected population of patients. The KRAS mutations, which are identified in approximately 20% of NSCLC patients, have shown to be associated with the resistance to the EGFR tyrosine kinase inhibitors (TKIs). Currently, there is no clinically available targeted therapy which can effectively inhibit NSCLC tumors harboring KRAS mutations. This study aims to show the effectiveness of KYA1797K, a small molecule which revealed anti-cancer effect in colorectal cancer by destabilizing Ras via inhibiting the Wnt/beta-catenin pathway, for the treatment of KRAS-mutated NSCLC. While erlotinib fail to have anti-transforming effect in NSCLC cell lines harboring KRAS mutations, KYA1797K effectively inhibited the Ras-ERK pathway in KRAS-mutant NSCLC cell lines. As a result, KYA1797K treatment suppressed the growth and transformation of KRAS mutant NSCLC cells and also induced apoptosis. Furthermore, KYA1797K effectively inhibited Kras-driven tumorigenesis in the KrasLA2 mouse model by suppressing the Ras-ERK pathway. The destabilization of Ras via inhibition of the Wnt/beta-catenin pathway is a potential therapeutic strategy for KRAS-mutated NSCLC that is resistant to EGFR TKI.
C1 [Park, Jieun; Cho, Yong-Hee; Shin, Wook-Jin; Lee, Sang-Kyu; Lee, JaeHeon; Kim, Taehyung; Cha, Pu-Hyeon; Yang, Jee Sun; Min, Do Sik; Han, Gyoonhee; Choi, Kang-Yell] Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul, South Korea.
   [Park, Jieun; Cho, Yong-Hee; Shin, Wook-Jin; Lee, Sang-Kyu; Lee, JaeHeon; Kim, Taehyung; Cha, Pu-Hyeon; Yang, Jee Sun; Min, Do Sik; Han, Gyoonhee; Choi, Kang-Yell] Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul, South Korea.
   [Min, Do Sik] Pusan Natl Univ, Dept Mol Biol, Coll Nat Sci, Pusan, South Korea.
   [Cho, Jaebeom; Lee, Ho-Young] Seoul Natl Univ, Coll Pharm, Seoul, South Korea.
   [Cho, Jaebeom; Lee, Ho-Young] Seoul Natl Univ, Res Inst Pharmaceut Sci, Seoul, South Korea.
C3 Yonsei University; Yonsei University; Pusan National University; Seoul
   National University (SNU); Seoul National University (SNU)
RP Choi, KY (corresponding author), Yonsei Univ, Translat Res Ctr Prot Funct Control, Seoul, South Korea.; Choi, KY (corresponding author), Yonsei Univ, Dept Biotechnol, Coll Life Sci & Biotechnol, Seoul, South Korea.
EM kychoi@yonsei.ac.kr
RI Kim, Jong/M-5732-2019; cha, puhyeon/ABA-7719-2020; Lee,
   Sun-Ho/AAD-6712-2022
OI Lee, Ho-Young/0000-0001-7556-9312; Park, Jieun/0000-0003-4927-0135; Kim,
   Taehyung/0000-0002-3024-6031; Cho, Yong-Hee/0000-0003-3333-7016
FU National Research Foundation of Korea (NRF) - Korea government (MSIP)
   [2016R1A5A1004694, 2015R1A2A1A05001873]; Brain Korea 21(BK21) PLUS
   program; BK21 PLUS program; National Research Foundation of Korea
   [2016R1A5A1004694] Funding Source: Korea Institute of Science &
   Technology Information (KISTI), National Science & Technology
   Information Service (NTIS)
FX The authors thank Dr. Keun Chil Park and Dr. Jong Soon Kang for
   providing cell lines. This work was supported by National Research
   Foundation of Korea (NRF) grants funded by the Korea government (MSIP)
   (2016R1A5A1004694 and (2015R1A2A1A05001873). This work was supported in
   part by the Brain Korea 21(BK21) PLUS program. J.P., W.S. and T.H.K. are
   fellowship awardee by BK21 PLUS program.
CR Adjei AA, 2008, J THORAC ONCOL, V3, pS160, DOI 10.1097/JTO.0b013e318174dbf9
   Casás-Selves M, 2012, CANCER RES, V72, P4154, DOI 10.1158/0008-5472.CAN-11-2848
   Cha PH, 2016, NAT CHEM BIOL, V12, P593, DOI [10.1038/NCHEMBIO.2103, 10.1038/nchembio.2103]
   Cho YH, 2016, ONCOTARGET, V7, P81727, DOI 10.18632/oncotarget.13172
   Crunkhorn S, 2015, NAT REV DRUG DISCOV, V14, P460, DOI 10.1038/nrd4670
   Downward J, 2003, NAT REV CANCER, V3, P11, DOI 10.1038/nrc969
   Ferlay J, 2010, INT J CANCER, V127, P2893, DOI 10.1002/ijc.25516
   Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871
   Herbst RS, 2008, NEW ENGL J MED, V359, P1367, DOI 10.1056/NEJMra0802714
   Janku F, 2010, NAT REV CLIN ONCOL, V7, P401, DOI 10.1038/nrclinonc.2010.64
   Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200
   Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242
   Johnson L, 2001, NATURE, V410, P1111, DOI 10.1038/35074129
   Kaiser J, 2013, SCIENCE, V342, P416, DOI 10.1126/science.342.6157.416
   Kim SE, 2009, J CELL SCI, V122, P842, DOI 10.1242/jcs.040493
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Ledford H, 2015, NATURE, V520, P278, DOI 10.1038/520278a
   Lim JH, 2006, CANCER RES, V66, P10677, DOI 10.1158/0008-5472.CAN-06-3171
   Ma Chunyan, 2011, J Thorac Dis, V3, P10, DOI 10.3978/j.issn.2072-1439.2010.12.02
   Ma Patrick C, 2012, Cleve Clin J Med, V79 Electronic Suppl 1, peS56, DOI 10.3949/ccjm.79.s2.12
   McCubrey JA, 2007, BBA-MOL CELL RES, V1773, P1263, DOI 10.1016/j.bbamcr.2006.10.001
   Moon BS, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt373
   Nakayama S, 2014, CANCER RES, V74, P5891, DOI 10.1158/0008-5472.CAN-14-0184
   Ohgaki H, 2004, CANCER LETT, V207, P197, DOI 10.1016/j.canlet.2003.10.020
   Okabe T, 2007, CANCER RES, V67, P2046, DOI 10.1158/0008-5472.CAN-06-3339
   Pao W, 2005, PLOS MED, V2, P57, DOI 10.1371/journal.pmed.0020017
   Pao W, 2011, LANCET ONCOL, V12, P175, DOI 10.1016/S1470-2045(10)70087-5
   Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779
   Sakai K, 2006, BIOCHEM J, V397, P537, DOI 10.1042/BJ20051962
   Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375
   Scarborough HA, 2017, CLIN CANCER RES, V23, P1531, DOI 10.1158/1078-0432.CCR-16-1179
   Seto T, 2013, LANCET ONCOL, V14, P590, DOI 10.1016/S1470-2045(13)70142-6
   Shapiro P, 2002, CRIT REV CL LAB SCI, V39, P285, DOI 10.1080/10408360290795538
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Shigemitsu K, 2001, ONCOGENE, V20, P4249, DOI 10.1038/sj.onc.1204557
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Sordella R, 2004, SCIENCE, V305, P1163, DOI 10.1126/science.1101637
   Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055
   Sunaga N, 2001, GENE CHROMOSOME CANC, V30, P316, DOI 10.1002/1098-2264(2000)9999:9999<::AID-GCC1097>3.0.CO;2-9
   TAKAHASHI T, 1989, SCIENCE, V246, P491, DOI 10.1126/science.2554494
   Tan XP, 2005, GASTROENTEROLOGY, V129, P285, DOI 10.1053/j.gastro.2005.04.013
   Thompson H, 2013, NAT MED, V19, P949, DOI 10.1038/nm0813-949
   Uematsu K, 2003, ONCOGENE, V22, P7218, DOI 10.1038/sj.onc.1206817
   Wissmann C, 2003, J PATHOL, V201, P204, DOI 10.1002/path.1449
   Yeo WL, 2010, J THORAC ONCOL, V5, P1048, DOI 10.1097/JTO.0b013e3181dd1386
   You L, 2004, ONCOGENE, V23, P6170, DOI 10.1038/sj.onc.1207844
   Yue W, 2008, CARCINOGENESIS, V29, P84, DOI 10.1093/carcin/bgm267
NR 47
TC 22
Z9 23
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JAN 24
PY 2019
VL 9
AR 648
DI 10.1038/s41598-018-37059-8
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HI6HI
UT WOS:000456554600087
PM 30679620
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Ansell, A
   Jedlinski, A
   Johansson, AC
   Roberg, K
AF Ansell, Anna
   Jedlinski, Adam
   Johansson, Ann-Charlotte
   Roberg, Karin
TI Epidermal growth factor is a potential biomarker for poor cetuximab
   response in tongue cancer cells
SO JOURNAL OF ORAL PATHOLOGY & MEDICINE
LA English
DT Article
DE epidermal growth factor receptor ligands; erbitux; head and neck cancer;
   tongue cancer; treatment response
ID NECK SQUAMOUS CARCINOMA; FACTOR RECEPTOR; EGF RECEPTOR;
   COLORECTAL-CANCER; CHIMERIC ANTIBODY; MUTATION STATUS; PLUS CETUXIMAB;
   PHASE-I; HEAD; AMPHIREGULIN
AB BACKGROUND: Head and neck squamous cell carcinoma is frequently associated with aberrant epidermal growth factor receptor (EGFR) signaling, which contributes to tumor growth. Here, the functional importance of EGFR ligands in relation to proliferation and sensitivity to the EGFR-targeted therapy cetuximab was investigated in three tongue cancer cell lines.
   METHODS: The influence of epidermal growth factor (EGF), amphiregulin (AR), and epiregulin (EPR) on tumor cell proliferation and cetuximab response was evaluated by the addition of recombinant human (rh) proteins or by siRNA-mediated downregulation of the endogenous ligand production. The expression, activation and cellular distribution of EGFR were assessed by Western blot analysis and immunocytochemistry.
   RESULTS: EGF downregulation suppressed the proliferation of all investigated tumor cell lines, whereas the response to an increased level of EGF differed between EGFR-overexpressing and EGFR-non-overexpressing cell lines. Furthermore, tumor cells consistently displayed increased cetuximab resistance upon the addition of rhEGF, whereas EGF silencing was associated with an improved cetuximab response. The data regarding AR and EPR were inconclusive.
   CONCLUSIONS: Our data suggest that the amount of EGF is a determinant of the tumor cell proliferation rate and the response to cetuximab treatment in tongue cancer. Thus, EGF is a potential predictive biomarker of poor cetuximab response and a possible treatment target.
C1 [Ansell, Anna; Jedlinski, Adam; Johansson, Ann-Charlotte; Roberg, Karin] Linkoping Univ, Fac Hlth Sci, Dept Clin & Expt Med, Div Otorhinolaryngol & Head & Neck Surg, Linkoping, Sweden.
   [Jedlinski, Adam; Roberg, Karin] Cty Council Ostergotland, Dept ENT Head & Neck Surg UHL, SE-58185 Linkoping, Sweden.
C3 Linkoping University; City Council Ostergotland
RP Jedlinski, A (corresponding author), Cty Council Ostergotland, Dept ENT Head & Neck Surg UHL, SE-58185 Linkoping, Sweden.
EM adam.jedlinski@lio.se
FU Foundation of Ake Wiberg; Swedish Cancer Society [2008/552, 2010/545];
   County Council of Ostergotland; Linkoping University Hospital;
   Foundation of Magnus Bergvall; Cancer Foundation of Ostergotland
FX The authors wish to thank Camilla Janefjord for technical assistance.
   This study was supported by the Foundation of Ake Wiberg, the Swedish
   Cancer Society (2008/552, 2010/545), the County Council of Ostergotland,
   the Research Funds of Linkoping University Hospital, the Foundation of
   Magnus Bergvall, and the Cancer Foundation of Ostergotland.
CR Argiris A, 2003, CANC TREAT, V114, P15
   Argiris A, 2008, LANCET, V371, P1695, DOI 10.1016/S0140-6736(08)60728-X
   Baselga J, 2000, J CLIN ONCOL, V18, P904, DOI 10.1200/JCO.2000.18.4.904
   Bonner JA, 2006, NEW ENGL J MED, V354, P567, DOI 10.1056/NEJMoa053422
   Busser B, 2010, MOL THER, V18, P536, DOI 10.1038/mt.2009.227
   Busser B, 2010, MOL THER, V18, P528, DOI 10.1038/mt.2009.226
   De Luca A, 2011, J CELL PHYSIOL, V226, P2131, DOI 10.1002/jcp.22548
   Farnebo L, 2008, ONCOL REP, V20, P453, DOI 10.3892/or_00000028
   GILL GN, 1984, J BIOL CHEM, V259, P7755
   Goldstein NI, 1995, CLIN CANCER RES, V1, P1311
   Grandis JR, 1998, J CELL BIOCHEM, V69, P55, DOI 10.1002/(SICI)1097-4644(19980401)69:1<55::AID-JCB6>3.3.CO;2-4
   Harris RC, 2003, EXP CELL RES, V284, P2, DOI 10.1016/S0014-4827(02)00105-2
   Hatakeyama H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012702
   Jacobs B, 2009, J CLIN ONCOL, V27, P5068, DOI 10.1200/JCO.2008.21.3744
   Jedlinski A, 2013, J ORAL PATHOL MED, V42, P26, DOI 10.1111/j.1600-0714.2012.01177.x
   Johansson AC, 2012, MOL CANCER RES, V10, P1158, DOI 10.1158/1541-7786.MCR-12-0030
   Jones JT, 1999, FEBS LETT, V447, P227, DOI 10.1016/S0014-5793(99)00283-5
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   KIARIS H, 1995, BRIT J CANCER, V72, P123, DOI 10.1038/bjc.1995.287
   Kuan CT, 2001, ENDOCR-RELAT CANCER, V8, P83, DOI 10.1677/erc.0.0080083
   Leutenegger CM, 1999, VET IMMUNOL IMMUNOP, V71, P291, DOI 10.1016/S0165-2427(99)00100-2
   Li SQ, 2005, CANCER CELL, V7, P301, DOI 10.1016/j.ccr.2005.03.003
   Licitra L, 2013, EUR J CANCER, V49, P1161, DOI 10.1016/j.ejca.2012.11.018
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Mendelsohn J, 2000, ONCOGENE, V19, P6550, DOI 10.1038/sj.onc.1204082
   MODJTAHEDI H, 1993, INT J ONCOL, V3, P237
   O-charoenrat P, 2000, CANCER RES, V60, P1121
   Oda K, 2005, MOL SYST BIOL, V1, DOI 10.1038/msb4100014
   Oliveras-Ferraros C, 2012, BRIT J CANCER, V106, P1406, DOI 10.1038/bjc.2012.103
   Ono M, 2006, CLIN CANCER RES, V12, P7242, DOI 10.1158/1078-0432.CCR-06-0646
   Oshima G, 2012, J CANCER RES CLIN, V138, P491, DOI 10.1007/s00432-011-1127-5
   Rebucci M, 2011, INT J ONCOL, V38, P189, DOI 10.3892/ijo_00000838
   Robert F, 2001, J CLIN ONCOL, V19, P3234, DOI 10.1200/JCO.2001.19.13.3234
   Roepstorff K, 2009, TRAFFIC, V10, P1115, DOI 10.1111/j.1600-0854.2009.00943.x
   Saridaki Z, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015980
   Sato J D, 1983, Mol Biol Med, V1, P511
   Shin DM, 2001, CLIN CANCER RES, V7, P1204
   SHIRASUNA K, 1991, VIRCHOWS ARCH A, V418, P349, DOI 10.1007/BF01600165
   Tinhofer I, 2011, CLIN CANCER RES, V17, P5197, DOI 10.1158/1078-0432.CCR-10-3338
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yonesaka K, 2008, CLIN CANCER RES, V14, P6963, DOI 10.1158/1078-0432.CCR-08-0957
NR 41
TC 15
Z9 17
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0904-2512
EI 1600-0714
J9 J ORAL PATHOL MED
JI J. Oral Pathol. Med.
PD JAN
PY 2016
VL 45
IS 1
BP 9
EP 16
DI 10.1111/jop.12310
PG 8
WC Dentistry, Oral Surgery & Medicine; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dentistry, Oral Surgery & Medicine; Pathology
GA DD5UN
UT WOS:000369990100003
PM 25677871
DA 2025-01-04
ER

PT J
AU Adem, BF
   Bastos, NRA
   Dias, F
   Teixeira, AL
   Medeiros, R
AF Adem, Barbara Filipa
   Alves Bastos, Nuno Ricardo
   Dias, Francisca
   Teixeira, Ana Luisa
   Medeiros, Rui
TI miRNAs: mediators of ErbB family targeted therapy resistance
SO PHARMACOGENOMICS
LA English
DT Review
DE acquired resistance; ErbB family; exosomes; miRNAs; targeted therapies
ID BREAST-CANCER; TRASTUZUMAB-RESISTANCE; GEFITINIB RESISTANCE;
   ACQUIRED-RESISTANCE; LUNG-CANCER; COLORECTAL-CARCINOMA; SIGNALING
   PATHWAY; DRUG-RESISTANCE; DOWN-REGULATION; UP-REGULATION
AB The ErbB/HER tyrosine kinase receptors family plays a key regulatory role in different cellular processes by activating several signaling pathways. In different tumor types, mutations or overexpression of the ErbB family members are a common feature, which led to the development of targeted therapies against this receptors. Although with this kind of treatment we are heading to a more personalized medicine, the development of acquired resistance is still an issue, therefore, several studies focused on discovering the mechanisms behind it. More recently, miRNAs have been described as important mediators of acquired resistance, specifically, acquired resistance to ErbB family targeted therapies. Ultimately, miRNA-based therapeutics using exosomes as a drug delivery model can revolutionize today's approach of cancer treatment.
C1 [Adem, Barbara Filipa; Alves Bastos, Nuno Ricardo; Dias, Francisca; Teixeira, Ana Luisa; Medeiros, Rui] Portuguese Oncol Inst Porto IPO Porto, IPO Porto Res Ctr CI IPOP, Mol Oncol & Viral Pathol Grp, Rua Dr Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
   [Adem, Barbara Filipa; Alves Bastos, Nuno Ricardo] Univ Porto, Fac Med, FMUP, Alameda Prof Hernani Monteiro, P-4200319 Oporto, Portugal.
   [Dias, Francisca; Medeiros, Rui] Univ Porto, Abel Salazar Biomed Sci Inst, ICBAS, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal.
   [Dias, Francisca; Teixeira, Ana Luisa; Medeiros, Rui] Res Dept Portuguese League Canc NRNorte, LPCC, Estr Interior Circunvalacao 6657, P-4200 Oporto, Portugal.
   [Medeiros, Rui] Fernando Pessoa Univ, Hlth Sci, CEBIMED, Rua Carlos da Maia 296, P-4200150 Oporto, Portugal.
C3 Portuguese Institute of Oncology; Universidade do Porto; Universidade do
   Porto; Universidade Fernando Pessoa
RP Medeiros, R (corresponding author), Portuguese Oncol Inst Porto IPO Porto, IPO Porto Res Ctr CI IPOP, Mol Oncol & Viral Pathol Grp, Rua Dr Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.; Medeiros, R (corresponding author), Univ Porto, Abel Salazar Biomed Sci Inst, ICBAS, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal.; Medeiros, R (corresponding author), Res Dept Portuguese League Canc NRNorte, LPCC, Estr Interior Circunvalacao 6657, P-4200 Oporto, Portugal.; Medeiros, R (corresponding author), Fernando Pessoa Univ, Hlth Sci, CEBIMED, Rua Carlos da Maia 296, P-4200150 Oporto, Portugal.
EM ruimedei@ipoporto.min-saude.pt
RI Dias, Francisca/AAH-4148-2021; Teixeira, Ana Luísa/ABB-3437-2020;
   Medeiros, Rui/C-7938-2009; Dias, Francisca/P-1272-2018
OI Teixeira, Ana L/0000-0002-7489-2211; Medeiros, Rui/0000-0003-3010-8373;
   Dias, Francisca/0000-0002-4993-4467; Bastos, Nuno/0000-0002-5745-3890;
   Adem, Barbara/0000-0003-0398-1185
FU LPCC-NRN; FCT [PCT: PEst- UID/DTP/00776/2013, COMPETE:
   POCI-01-0145-FEDER-006868]
FX The authors would like to thank the Liga Portuguesa Contra o Cancro -
   Nucleo Regional do Norte- LPCC-NRN (Portuguese League Against Cancer)
   and Fundacao para a Ciencia e Tecnologia- FCT (Portuguese Foundation for
   Science and Technology). F Dias is recipient of research scholarship
   awarded by LPCC-NRN. AL Teixeira is a research fellow from the strategic
   funding of the FCT (PCT: PEst- UID/DTP/00776/2013 and COMPETE:
   POCI-01-0145-FEDER-006868). The authors have no other relevant
   affiliations or financial involvement with any organization or entity
   with a financial interest in or financial conflict with the subject
   matter or materials discussed in the manuscript apart from those
   disclosed.
CR Bang YJ, 2010, LANCET, V376, P1302
   Bao LL, 2013, CANCER LETT, V337, P226, DOI 10.1016/j.canlet.2013.05.007
   Benedettini E, 2010, AM J PATHOL, V177, P415, DOI 10.2353/ajpath.2010.090863
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Cho WCS, 2010, INT J BIOCHEM CELL B, V42, P1273, DOI 10.1016/j.biocel.2009.12.014
   Corcoran C, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-71
   Croce CM, 2009, NAT REV GENET, V10, P704, DOI 10.1038/nrg2634
   Dean M, 2001, GENOME RES, V11, P1156, DOI 10.1101/gr.GR-1649R
   Dias F, 2013, PHARMACOGENOMICS, V14, P1793, DOI 10.2217/pgs.13.184
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   El-Awady RA, 2015, CANCER BIOL THER, V16, P1056, DOI 10.1080/15384047.2015.1046023
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Eto K, 2014, ANN SURG ONCOL, V21, P343, DOI 10.1245/s10434-013-3325-7
   Gao W, 2012, CANCER BIOL THER, V13, P330, DOI 10.4161/cbt.19073
   Garofalo M, 2013, DRUG RESIST UPDATE, V16, P47, DOI 10.1016/j.drup.2013.05.001
   Garofalo M, 2012, NAT MED, V18, P74, DOI 10.1038/nm.2577
   Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012
   Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311
   Gong C, 2011, J BIOL CHEM, V286, P19127, DOI 10.1074/jbc.M110.216887
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hatakeyama H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012702
   He L, 2005, NATURE, V435, P828, DOI 10.1038/nature03552
   Hoelder S, 2012, MOL ONCOL, V6, P155, DOI 10.1016/j.molonc.2012.02.004
   Horikawa Y, 2008, CLIN CANCER RES, V14, P7956, DOI 10.1158/1078-0432.CCR-08-1199
   Hossain A, 2006, MOL CELL BIOL, V26, P8191, DOI 10.1128/MCB.00242-06
   Huang LH, 2015, ACTA PHARM SIN B, V5, P390, DOI 10.1016/j.apsb.2015.07.001
   HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567
   Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027
   Izumchenko E, 2014, CANCER RES, V74, P3995, DOI 10.1158/0008-5472.CAN-14-0110
   Jansson MD, 2012, MOL ONCOL, V6, P590, DOI 10.1016/j.molonc.2012.09.006
   Johansson AC, 2012, MOL CANCER RES, V10, P1158, DOI 10.1158/1541-7786.MCR-12-0030
   Johnson SM, 2009, ANTICANCER RES, V29, P3185
   Kalra H, 2013, PROTEOMICS, V13, P3354, DOI 10.1002/pmic.201300282
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Kaptain S, 2001, DIAGN MOL PATHOL, V10, P139, DOI 10.1097/00019606-200109000-00001
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Khoshnaw SM, 2013, BREAST CANCER RES TR, V137, P139, DOI 10.1007/s10549-012-2358-0
   Khoshnaw SM, 2012, BREAST CANCER RES TR, V135, P403, DOI 10.1007/s10549-012-2169-3
   Lee JY, 2015, SCI REP-UK, V5, DOI 10.1038/srep09289
   Li HR, 2013, ACTA PHARMACOL SIN, V34, P870, DOI 10.1038/aps.2013.35
   Liu K, 2015, INT J ONCOL, V46, P2526, DOI 10.3892/ijo.2015.2949
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   Mathivanan S, 2010, J PROTEOMICS, V73, P1907, DOI 10.1016/j.jprot.2010.06.006
   Mellinghoff IK, 2007, CLIN CANCER RES, V13, P378, DOI 10.1158/1078-0432.CCR-06-1992
   Estal RM, 2013, BREAST CANCER RES TR, V142, P19, DOI 10.1007/s10549-013-2723-7
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Nahta R, 2005, CANCER RES, V65, P11118, DOI 10.1158/0008-5472.CAN-04-3841
   Nakamura K, 2001, ONCOGENE, V20, P2626, DOI 10.1038/sj.onc.1204359
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Normanno N, 2003, ENDOCR-RELAT CANCER, V10, P1, DOI 10.1677/erc.0.0100001
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   Ohno S, 2013, MOL THER, V21, P185, DOI 10.1038/mt.2012.180
   Pereira DM, 2013, DRUG DISCOV TODAY, V18, P282, DOI 10.1016/j.drudis.2012.10.002
   Price KAR, 2012, CURR TREAT OPTION ON, V13, P35, DOI 10.1007/s11864-011-0176-y
   Rabinowits G, 2009, CLIN LUNG CANCER, V10, P42, DOI 10.3816/CLC.2009.n.006
   Ragusa M, 2010, MOL CANCER THER, V9, P3396, DOI 10.1158/1535-7163.MCT-10-0137
   Ren JH, 2016, BIOMATER SCI-UK, V4, P910, DOI 10.1039/c5bm00583c
   Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002
   Ross, 1998, Oncologist, V3, P237
   Ross JS, 2004, MOL CELL PROTEOMICS, V3, P379, DOI 10.1074/mcp.R400001-MCP200
   Salido-Guadarrama I, 2014, ONCOTARGETS THER, V7, P1327, DOI 10.2147/OTT.S61562
   Sato-Kuwabara Y, 2015, INT J ONCOL, V46, P17, DOI 10.3892/ijo.2014.2712
   SCHECHTER AL, 1984, NATURE, V312, P513, DOI 10.1038/312513a0
   Shen H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103305
   Shi XB, 2008, CELL CYCLE, V7, P1529, DOI 10.4161/cc.7.11.5977
   Shi Z, 2011, CANCER RES, V71, P3029, DOI 10.1158/0008-5472.CAN-10-3820
   Siegel RL, 2020, ANTI-CANCER DRUG, V70, P7, DOI [DOI 10.3322/CAAC.21590, DOI 10.1097/CAD.0000000000000617]
   Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280
   Simons M, 2009, CURR OPIN CELL BIOL, V21, P575, DOI 10.1016/j.ceb.2009.03.007
   Simpson RJ, 2008, PROTEOMICS, V8, P4083, DOI 10.1002/pmic.200800109
   Skog J, 2008, NAT CELL BIOL, V10, P1470, DOI 10.1038/ncb1800
   Slezak-Prochazka I, 2010, RNA, V16, P1087, DOI 10.1261/rna.1804410
   Smith JP, 2009, AM J PHYSIOL-RENAL, V296, pF957, DOI 10.1152/ajprenal.90490.2008
   Suntres Z.E., 2013, J. Circ. Biomark., V1, DOI [10.5772/56522, DOI 10.5772/56522]
   Teixeira AL, 2014, TUMOR BIOL, V35, P4057, DOI 10.1007/s13277-013-1531-3
   Teixeira Ana L., 2012, Frontiers in Genetics, V3, P286, DOI 10.3389/fgene.2012.00286
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Wang F, 2007, ONCOGENE, V26, P2006, DOI 10.1038/sj.onc.1209999
   Wang Y, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.186
   Wang YS, 2012, ASIAN PAC J CANCER P, V13, P255, DOI 10.7314/APJCP.2012.13.1.255
   Wen YH, 2015, EXPERT OPIN EMERG DR, V20, P313, DOI 10.1517/14728214.2015.1031653
   Wozniak MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125026
   Yagi H, 2008, MOL CANCER THER, V7, P3441, DOI 10.1158/1535-7163.MCT-08-0417
   Yamasaki F, 2007, CANCER RES, V67, P5779, DOI 10.1158/0008-5472.CAN-06-3020
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309
   Ye XM, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-134
   Ye XM, 2014, BMB REP, V47, P268, DOI 10.5483/BMBRep.2014.47.5.165
   Yip PY, 2015, TRANSL LUNG CANCER R, V4, P165, DOI 10.3978/j.issn.2218-6751.2015.01.04
   Yu HA, 2013, CLIN CANCER RES, V19, P2240, DOI 10.1158/1078-0432.CCR-12-2246
   Zhang J, 2012, BBA-REV CANCER, V1826, P32, DOI 10.1016/j.bbcan.2012.03.001
   Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330
NR 92
TC 7
Z9 7
U1 1
U2 12
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD JUL
PY 2016
VL 17
IS 10
BP 1175
EP 1187
DI 10.2217/pgs-2016-0038
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA DR3XC
UT WOS:000379835000007
PM 27359187
DA 2025-01-04
ER

PT J
AU Wu, YW
   Wei, LJ
   Yang, X
   Liang, HY
   Cai, MY
   Luo, RZ
   Liu, LL
AF Wu, Ying-Wen
   Wei, Li-Jun
   Yang, Xia
   Liang, Hao-Yu
   Cai, Mu-Yan
   Luo, Rong-Zhen
   Liu, Li-Li
TI Clinicopathological and immune characterization of mismatch repair
   deficient endocervical adenocarcinoma
SO ONCOLOGIST
LA English
DT Article
DE endocervical adenocarcinoma; mismatch repair deficiency; immune
   microenvironment; morphological characteristics; programmed cell death
   ligand 1
ID TUMOR-INFILTRATING LYMPHOCYTES; MICROSATELLITE INSTABILITY;
   COLORECTAL-CANCER; CELL CARCINOMA; EXPRESSION; CLASSIFICATION; FEATURES;
   CERVIX; ASSOCIATIONS; CRITERIA
AB Endocervical adenocarcinoma (ECA) is reported increasingly often in young women, and this aggressive disease lacks effective methods of targeted therapy. Since mismatch repair deficiency (dMMR) is an important biomarker for predicting response to immune checkpoint inhibitors, it is important to investigate the clinicopathological features and immune microenvironment of dMMR ECAs. We assessed 617 ECAs from representative tissue microarray sections, gathered clinicopathologic information, reviewed histological characteristics, and performed immunohistochemical staining for MMR, programmed cell death 1 (PD-L1), and other immune markers. Of 617 ECA samples, 20 (3.2%) cases had dMMR. Among them, loss of MMR-related proteins expression was observed in 17/562 (3.0%) human papilloma virus-associated (HPVA) adenocarcinoma and 3/55 (5.5%) non-HPV-associated (NHPVA) adenocarcinoma. In NHPVA cohort, dMMR status was observed in 3 (3/14, 15.0%) patients with clear cells. dMMR ECAs had a higher tendency to have a family history of cancer, larger tumor size, p16 negative, HPV E6/E7 mRNA in situ hybridization (HPV E6/E7 RNAscope) negative, and lower ki-67 index. Among the morphological variables evaluated, poor differentiation, necrosis, stromal tumor-infiltrating lymphocytes, peritumoral lymphocytes, and lymphoid follicles were easily recognized in the dMMR ECAs. In addition, dMMR ECAs had higher CD3+, CD8+, CD38+, CD68+ and PD-1+ immune cells. A relatively high prevalence of PD-L1 expression was observed in dMMR ECAs. dMMR ECAs were significantly more likely to present with a tumor-infiltrating lymphocytes -high/PD-L1-positive status. In conclusion, dMMR ECAs have some specific morphological features and a critical impact on the immune microenvironment, which may provide insights into improving responses to immunotherapy-included comprehensive treatment for ECAs in the future.
   Endocervical adenocarcinoma (ECA) is reported increasingly often in young women, and this aggressive disease lacks effective methods of targeted therapy. This article focuses on mismatch repair deficiency to possibly improve responses to immunotherapy-included comprehensive treatment for ECAs in the future.
C1 [Wu, Ying-Wen; Wei, Li-Jun; Yang, Xia; Liang, Hao-Yu; Cai, Mu-Yan; Luo, Rong-Zhen; Liu, Li-Li] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, State Key Lab Oncol South China, Guangzhou 510060, Peoples R China.
   [Wu, Ying-Wen; Wei, Li-Jun; Yang, Xia; Liang, Hao-Yu; Cai, Mu-Yan; Luo, Rong-Zhen; Liu, Li-Li] Sun Yat Sen Univ, Dept Pathol, Ctr Canc, 651 Dong Feng Rd East, Guangzhou 510060, Peoples R China.
   [Wu, Ying-Wen] Guangdong Sanjiu Brain Hosp, Dept Pathol, Guangzhou, Peoples R China.
C3 State Key Lab Oncology South China; Sun Yat Sen University; Sun Yat Sen
   University
RP Luo, RZ; Liu, LL (corresponding author), Sun Yat Sen Univ, Dept Pathol, Ctr Canc, 651 Dong Feng Rd East, Guangzhou 510060, Peoples R China.
EM luorzh@sysucc.org.cn; liulil@sysucc.org.cn
RI wei, li/AAO-8369-2020; Cai, mu-yan/K-3230-2015; wu,
   yingwen/KIB-9748-2024
FU National Natural Science Foundation of China [82072853]
FX This work was supported by grants from The National Natural Science
   Foundation of China (No. 82072853)
CR Baretti M, 2018, PHARMACOL THERAPEUT, V189, P45, DOI 10.1016/j.pharmthera.2018.04.004
   Black D, 2006, J CLIN ONCOL, V24, P1745, DOI 10.1200/JCO.2005.04.1574
   Bonneville R, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00073
   Boyd J, 1996, CANCER-AM CANCER SOC, V77, P507, DOI 10.1002/(SICI)1097-0142(19960201)77:3<507::AID-CNCR12>3.0.CO;2-8
   Broaddus RR, 2006, CANCER, V106, P87, DOI 10.1002/cncr.21560
   Carleton C, 2016, AM J SURG PATHOL, V40, P636, DOI 10.1097/PAS.0000000000000578
   Chiba T, 2004, BRIT J CANCER, V91, P1711, DOI 10.1038/sj.bjc.6602201
   De Smedt L, 2015, BRIT J CANCER, V113, P500, DOI 10.1038/bjc.2015.213
   Dong DD, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.640018
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Holloway SB, 2021, AM J CLIN ONCOL-CANC, V44, P162, DOI 10.1097/COC.0000000000000798
   Howitt BE, 2015, JAMA ONCOL, V1, P1319, DOI 10.1001/jamaoncol.2015.2151
   Hussein MR, 2006, J CLIN PATHOL, V59, P316, DOI 10.1136/jcp.2005.028860
   Jenkins MA, 2007, GASTROENTEROLOGY, V133, P48, DOI 10.1053/j.gastro.2007.04.044
   Jesinghaus M, 2021, AM J SURG PATHOL, V45, P969, DOI 10.1097/PAS.0000000000001692
   Jiricny J, 2006, NAT REV MOL CELL BIO, V7, P335, DOI 10.1038/nrm1907
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le Flahec G, 2018, HUM PATHOL, V72, P135, DOI 10.1016/j.humpath.2017.09.019
   Luo RZ, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02349-1
   Mills AM, 2012, INT J GYNECOL PATHOL, V31, P463, DOI 10.1097/PGP.0b013e31824a1dad
   Monk BJ, 2009, J CLIN ONCOL, V27, P4649, DOI 10.1200/JCO.2009.21.8909
   Park JH, 2016, BRIT J CANCER, V114, P562, DOI 10.1038/bjc.2016.17
   Peiró G, 2002, HUM PATHOL, V33, P347, DOI 10.1053/hupa.2002.32220
   Quist E, 2014, AM J CLIN PATHOL, V142, P670, DOI 10.1309/AJCPSUQVIGA8S1AH
   Rivera-Colon G, 2021, AM J SURG PATHOL, V45, P742, DOI 10.1097/PAS.0000000000001633
   Roma AA, 2015, AM J SURG PATHOL, V39, P667, DOI 10.1097/PAS.0000000000000402
   Rotte A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1259-z
   Schildhaus HU, 2018, PATHOLOGE, V39, P498, DOI 10.1007/s00292-018-0507-x
   Serebriiskii IG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11530-0
   Shia J, 2003, AM J SURG PATHOL, V27, P1407, DOI 10.1097/00000478-200311000-00002
   Shia J, 2008, HUM PATHOL, V39, P116, DOI 10.1016/j.humpath.2007.05.022
   Shia J, 2017, MODERN PATHOL, V30, P599, DOI 10.1038/modpathol.2016.198
   Smith HO, 2000, GYNECOL ONCOL, V78, P97, DOI 10.1006/gyno.2000.5826
   Smyrk TC, 2001, CANCER, V91, P2417, DOI 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U
   Song FQ, 2021, HISTOPATHOLOGY, V79, P861, DOI 10.1111/his.14435
   Stolnicu S, 2022, AM J SURG PATHOL, V46, P765, DOI 10.1097/PAS.0000000000001863
   Stolnicu S, 2018, AM J SURG PATHOL, V42, P214, DOI 10.1097/PAS.0000000000000986
   van den Bos M, 2004, AM J SURG PATHOL, V28, P706, DOI 10.1097/01.pas.0000126720.49083.11
   Willis JA, 2020, CLIN CANCER RES, V26, P11, DOI 10.1158/1078-0432.CCR-18-0856
   World Health Organization classification of tumours, 2020, FEMALE GENITAL TUMOU
   Zhang YY, 2017, ONCOTARGET, V8, P85526, DOI 10.18632/oncotarget.20241
   Zhou F, 2022, AM J SURG PATHOL, V46, P300, DOI 10.1097/PAS.0000000000001800
NR 42
TC 0
Z9 0
U1 1
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1083-7159
EI 1549-490X
J9 ONCOLOGIST
JI Oncologist
PD AUG 7
PY 2024
VL 29
IS 10
BP e1302
EP e1314
DI 10.1093/oncolo/oyae192
EA AUG 2024
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA H7Z0G
UT WOS:001285192500001
PM 39110901
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Prete, A
   Lo, AS
   Sadow, PM
   Bhasin, SS
   Antonello, ZA
   Vodopivec, DM
   Ullas, S
   Sims, JN
   Clohessy, J
   Dvorak, AM
   Sciuto, T
   Bhasin, M
   Murphy-Ullrich, JE
   Lawler, J
   Karumanchi, SA
   Nucera, C
AF Prete, Alessandro
   Lo, Agnes S.
   Sadow, Peter M.
   Bhasin, Swati S.
   Antonello, Zeus A.
   Vodopivec, Danica M.
   Ullas, Soumya
   Sims, Jennifer N.
   Clohessy, John
   Dvorak, Ann M.
   Sciuto, Tracey
   Bhasin, Manoj
   Murphy-Ullrich, Joanne E.
   Lawler, Jack
   Karumanchi, S. Ananth
   Nucera, Carmelo
TI Pericytes Elicit Resistance to Vemur1afenib and Sorafenib Therapy in
   Thyroid Carcinoma via the TSP-1/TGFβ1 Axis
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID BRAF V600E MUTATION; MESENCHYMAL TRANSITION; RADIOACTIVE IODINE;
   COLORECTAL-CANCER; BLOOD-VESSELS; TUMOR-GROWTH; VEMURAFENIB;
   THROMBOSPONDIN-1; INHIBITION; EXPRESSION
AB Purpose: The BRAF(V600E) oncogene modulates the papillary thyroid carcinoma (PTC) microenvironment, in which pericytes are critical regulators of tyrosine-kinase (TK)-dependent signaling pathways. Although BRAF(V600E) and TK inhibitors are available, their efficacy as bimodal therapeutic agents in BRAF(V600E)-PTC is still unknown.
   Experimental Design: We assessed the effects of vemurafenib (BRAF(V600E) inhibitor) and sorafenib (TKI) as single agents or in combination in BRAF(WT/V600E)-PTC and BRAFWT/WT cells using cell-autonomous, pericyte coculture, and an orthotopic mouse model. We also used BRAF(WT/V600E)-PTC and BRAF(WT/WT)-PTC clinical samples to identify differentially expressed genes fundamental to tumor microenvironment.
   Results: Combined therapy blocks tumor cell proliferation, increases cell death, and decreases motility via BRAF(V600E) inhibition in thyroid tumor cells in vitro. Vemurafenib produces cytostatic effects in orthotopic tumors, whereas combined therapy (likely reflecting sorafenib activity) generates biological fluctuations with tumor inhibition alternating with tumor growth. We demonstrate that pericytes secrete TSP-1 and TGF beta 1, and induce the rebound of pERK1/2, pAKT and pSMAD3 levels to overcome the inhibitory effects of the targeted therapy in PTC cells. This leads to increased BRAF(V600E)-PTC cell survival and cell death refractoriness. We find that BRAF(WT/V600E)-PTC clinical samples are enriched in pericytes, and TSP1 and TGF beta 1 expression evoke generegulatory networks and pathways (TGF beta signaling, metastasis, tumor growth, tumor microenvironment/ECM remodeling functions, inflammation, VEGF ligand-VEGF receptor interactions, immune modulation, etc.) in the microenvironment essential for BRAF(WT/V600E)-PTC cell survival. Critically, antagonism of the TSP-1/TGF beta 1 axis reduces tumor cell growth and overcomes drug resistance.
   Conclusions: Pericytes shield BRAF(V600E)-PTC cells from targeted therapy via TSP-1 and TGF beta 1, suggesting this axis as a new therapeutic target for overcoming resistance to BRAF(V600E) and TK inhibitors.
C1 [Prete, Alessandro; Antonello, Zeus A.; Vodopivec, Danica M.; Sims, Jennifer N.; Nucera, Carmelo] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Lab Human Thyroid Canc Preclin & Translat Res, Div Expt Pathol,Canc Res Inst,Canc Ctr,Dept Patho, Boston, MA USA.
   [Prete, Alessandro; Antonello, Zeus A.; Vodopivec, Danica M.; Sims, Jennifer N.; Dvorak, Ann M.; Sciuto, Tracey; Lawler, Jack; Nucera, Carmelo] Harvard Med Sch, Dept Pathol, Ctr Vasc Biol Res, Beth Israel Deaconess Med Ctr, Boston, MA USA.
   [Lo, Agnes S.; Karumanchi, S. Ananth] Harvard Med Sch, Dept Med, Ctr Vasc Biol Res, Beth Israel Deaconess Med Ctr, Boston, MA USA.
   [Sadow, Peter M.] Harvard Med Sch, Massachusetts Gen Hosp, Dept Pathol, Boston, MA USA.
   [Bhasin, Swati S.; Bhasin, Manoj] Harvard Med Sch, Dept Med, Bioinformat & Syst Biol Unit, Beth Israel Deaconess Med Ctr, Boston, MA USA.
   [Ullas, Soumya] Harvard Med Sch, Dept Radiol, Beth Israel Deaconess Med Ctr, Longwood Small Anim Imaging Facil, Boston, MA USA.
   [Clohessy, John] Harvard Med Sch, Beth Israel Deaconess Med Sch, Div Canc Genet, Dept Med, Boston, MA USA.
   [Murphy-Ullrich, Joanne E.] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA.
   [Murphy-Ullrich, Joanne E.] Univ Alabama Birmingham, Dept Cell Dev & Integrat Biol, Birmingham, AL USA.
   [Murphy-Ullrich, Joanne E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA.
   [Nucera, Carmelo] Broad Inst MIT & Harvard, Cambridge, MA USA.
C3 Harvard University; Harvard Medical School; Beth Israel Deaconess
   Medical Center; Harvard University; Harvard Medical School; Beth Israel
   Deaconess Medical Center; Harvard University; Beth Israel Deaconess
   Medical Center; Harvard Medical School; Harvard University; Harvard
   Medical School; Massachusetts General Hospital; Harvard University; Beth
   Israel Deaconess Medical Center; Harvard Medical School; Harvard
   University; Harvard Medical School; Beth Israel Deaconess Medical
   Center; Harvard University; Harvard Medical School; Beth Israel
   Deaconess Medical Center; University of Alabama System; University of
   Alabama Birmingham; University of Alabama System; University of Alabama
   Birmingham; University of Alabama System; University of Alabama
   Birmingham; Harvard University; Massachusetts Institute of Technology
   (MIT); Broad Institute
RP Nucera, C (corresponding author), Harvard Med Sch, Beth Israel Deaconess Med Ctr, Broad Inst MIT & Harvard, Cambridge, MA 02215 USA.
EM cnucera@bidmc.harvard.edu
RI Lawler, Jack/AAJ-1379-2020; Prete, Alessandro/JXM-9883-2024; Bhasin,
   Manoj/B-3018-2009; Sadow, Peter/E-7691-2015
OI Sadow, Peter/0000-0003-1036-6367; Karumanchi,
   Subbian/0000-0002-2281-6831; Prete, Alessandro/0000-0003-3633-6916;
   Bhasin, Swati/0000-0001-8661-1459
FU National Cancer Institute/NIH [1R21CA165039-01A1, 1R01CA181183-01A1];
   American Thyroid Association (ATA); ThyCa: Thyroid Cancer Survivors
   Association Inc.; Guido Berlucchi "Young Investigator" research award
   2013 (Brescia, Italy); BIDMC/CAO Grants; NIH [1R01CA175012]
FX C. Nucera (Principal Investigator, Human Thyroid Cancers Preclinical and
   Translational Research at the Beth Israel Deaconess Medical Center
   (BIDMC)/Harvard Medical School) was awarded grants by the National
   Cancer Institute/NIH (1R21CA165039-01A1 and 1R01CA181183-01A1), the
   American Thyroid Association (ATA), and ThyCa: Thyroid Cancer Survivors
   Association Inc. for Thyroid Cancer Research. C. Nucera was also a
   recipient of the Guido Berlucchi "Young Investigator" research award
   2013 (Brescia, Italy) and BIDMC/CAO Grants. SRI31277 production and J.E.
   Murphy-Ullrich's contributions were supported by NIH grant 1R01CA175012.
   We are grateful to Prof. Harold F. Dvorak and Miss Elizabeth McGonagle
   (BIDMC/HMS) for critical reading of our manuscript. We are grateful to
   Dr. Andrew L. Kung (Memorial Sloan Kettering Cancer Center, NYC, USA)
   for kindly providing the FUW-LucmCherry-puro (luciferase/cherry)
   plasmid, and to Prof. Judy Lieberman and Dr. Minh T.N. Le (Children's
   Hospital, HarvardMedical School, Boston, MA) for kindly providing
   packaging plasmids (psPAX2, pMD2-G, and RTR2). We also thank Miss Nicole
   Pandell for the technical support for the oral gavages in the mice.
CR Agrawal N, 2014, CELL, V159, P676, DOI 10.1016/j.cell.2014.09.050
   [Anonymous], 2016, JAMA ONCOL
   Antonello ZA, 2017, ONCOTARGET, V8, P84743, DOI 10.18632/oncotarget.21262
   Azimi A, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.406
   Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847
   Brose MS, 2016, LANCET ONCOL, V17, P1272, DOI 10.1016/S1470-2045(16)30166-8
   Brose MS, 2014, LANCET, V384, P319, DOI 10.1016/S0140-6736(14)60421-9
   Bunone G, 1999, AM J PATHOL, V155, P1967, DOI 10.1016/S0002-9440(10)65515-0
   Cabanillas ME, 2015, HEMATOL ONCOL CLIN N, V29, P1123, DOI 10.1016/j.hoc.2015.07.011
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Caspani EM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0101402
   Chakravarty D, 2011, J CLIN INVEST, V121, P4700, DOI 10.1172/JCI46382
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Cooke VG, 2012, CANCER CELL, V21, P66, DOI 10.1016/j.ccr.2011.11.024
   Crawford SE, 1998, CELL, V93, P1159, DOI 10.1016/S0092-8674(00)81460-9
   Dadu R, 2014, J CLIN ENDOCR METAB, V99, P2086, DOI 10.1210/jc.2013-3588
   Danysh BP, 2016, ONCOTARGET, V7, P30907, DOI 10.18632/oncotarget.9023
   David CJ, 2016, CELL, V164, P1015, DOI 10.1016/j.cell.2016.01.009
   Duquette M, 2015, ONCOTARGET, V6, P42445, DOI 10.18632/oncotarget.6442
   Dvorak HF, 2015, CANCER J, V21, P237, DOI 10.1097/PPO.0000000000000124
   Fendrich V, 2012, SCI WORLD J, DOI 10.1100/2012/529151
   Franco M, 2011, BLOOD, V118, P2906, DOI 10.1182/blood-2011-01-331694
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Jain RK, 2003, J CLIN INVEST, V112, P1134, DOI 10.1172/JCI200320087
   Kazerounian S, 2008, CELL MOL LIFE SCI, V65, P700, DOI 10.1007/s00018-007-7486-z
   Kloos RT, 2009, J CLIN ONCOL, V27, P1675, DOI 10.1200/JCO.2008.18.2717
   Knauf JA, 2011, ONCOGENE, V30, P3153, DOI 10.1038/onc.2011.44
   Kurebayashi J, 2000, J CLIN ENDOCR METAB, V85, P2889, DOI 10.1210/jc.85.8.2889
   Lim H, 2017, JAMA-J AM MED ASSOC, V317, P1338, DOI 10.1001/jama.2017.2719
   Lu AL, 2016, AM J PATHOL, V186, P678, DOI 10.1016/j.ajpath.2015.11.003
   Lynch JM, 2012, CELL, V149, P1257, DOI 10.1016/j.cell.2012.03.050
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531
   Nagy JA, 2006, LAB INVEST, V86, P767, DOI 10.1038/labinvest.3700436
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Nucera C, 2016, AGING-US, V8, P1576, DOI 10.18632/aging.101030
   Nucera C, 2011, CANCER RES, V71, P2417, DOI 10.1158/0008-5472.CAN-10-3844
   Nucera C, 2011, ONCOLOGIST, V16, P296, DOI 10.1634/theoncologist.2010-0317
   Nucera C, 2010, P NATL ACAD SCI USA, V107, P10649, DOI 10.1073/pnas.1004934107
   Pitoia F, 2016, DRUG DES DEV THER, V10, P1119, DOI 10.2147/DDDT.S82972
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Sadow PM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju182
   Sherman EJ, 2017, CANCER-AM CANCER SOC, V123, P4114, DOI 10.1002/cncr.30861
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Song S, 2005, NAT CELL BIOL, V7, P870, DOI 10.1038/ncb1288
   Su F, 2012, CANCER RES, V72, P969, DOI 10.1158/0008-5472.CAN-11-1875
   Sweetwyne MT, 2010, AM J PATHOL, V177, P1710, DOI 10.2353/ajpath.2010.090903
   Tallarida Ronald J, 2011, Genes Cancer, V2, P1003, DOI 10.1177/1947601912440575
   Taverna D, 2001, CANCER RES, V61, P5255
   Xing MZ, 2015, J CLIN ONCOL, V33, P42, DOI 10.1200/JCO.2014.56.8253
   Xing MZ, 2013, JAMA-J AM MED ASSOC, V309, P1493, DOI 10.1001/jama.2013.3190
   Yee KO, 2004, AM J PATHOL, V165, P541, DOI 10.1016/S0002-9440(10)63319-6
   Young GD, 2004, J BIOL CHEM, V279, P38032, DOI 10.1074/jbc.M405658200
   Zhang XF, 2009, FASEB J, V23, P3368, DOI 10.1096/fj.09-131649
   Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30
NR 55
TC 42
Z9 50
U1 0
U2 11
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD DEC 1
PY 2018
VL 24
IS 23
BP 6078
EP 6097
DI 10.1158/1078-0432.CCR-18-0693
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HD2XG
UT WOS:000452374700029
PM 30076136
OA Green Submitted, Green Accepted, Bronze
DA 2025-01-04
ER

PT J
AU Liu, ZG
   Wang, XL
   Cao, LQ
   Yin, XW
   Zhang, Q
   Wang, L
AF Liu, Zhiguang
   Wang, Xinlian
   Cao, Liqiang
   Yin, Xiaowei
   Zhang, Qian
   Wang, Lan
TI MicroRNA-877-5p Inhibits Cell Progression by Targeting FOXM1 in Lung
   Cancer
SO CANADIAN RESPIRATORY JOURNAL
LA English
DT Article
ID MESENCHYMAL TRANSITION; COLORECTAL-CANCER; PROLIFERATION; INVASION;
   METASTASIS; BIOGENESIS; CARCINOMA; MIGRATION; PROMOTES; GROWTH
AB Background. Many researches revealed that microRNAs (miRNAs) function as potential oncogene or tumor suppressor gene. As an antioncogene, miR-877-5p was reduced in many tumors. Objective. This research aimed to explore the biological role and mechanisms of miR-877-5p, which may help patients with non-small-cell lung cancer (NSCLC) find effective therapeutic targets. Methods. The downstream targets of miR-877-5p were predicted by Bioinformatics software. RT-qPCR and western blot were employed to analyze the gene levels. The impacts of miR-877-5p and FOXM1 were assessed by cell function experiments. Results. The miR-877-5p was reduced in NSCLC. In addition to this, it also inhibited cell progression of NSCLC cells in vitro. Moreover, the upregulation of FOXM1 expression restored the inhibitory effect of enhancement of miR-877-5p. Conclusions. Taken together, miR-877-5p inhibited cell progression by directly targeting FOXM1, which may provide potential biomarkers for targeted therapy of NSCLC.
C1 [Liu, Zhiguang; Yin, Xiaowei; Zhang, Qian] Nanjing Med Univ, Dept Resp & Crit Care Med, Changzhou Peoples Hosp 2, Changzhou 213164, Jiangsu, Peoples R China.
   [Wang, Xinlian] Southeast Univ, Dept Thorac Surg, Zhongda Hosp, Wuxi Branch, Wuxi 214105, Jiangsu, Peoples R China.
   [Cao, Liqiang; Wang, Lan] Xuzhou Med Univ, Dept Resp & Crit Care Med, Jiangyin Clin Coll, Jiangyin 214400, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Southeast University - China; Xuzhou Medical
   University
RP Yin, XW; Zhang, Q (corresponding author), Nanjing Med Univ, Dept Resp & Crit Care Med, Changzhou Peoples Hosp 2, Changzhou 213164, Jiangsu, Peoples R China.; Wang, L (corresponding author), Xuzhou Med Univ, Dept Resp & Crit Care Med, Jiangyin Clin Coll, Jiangyin 214400, Jiangsu, Peoples R China.
EM liuzhiguang5555@163.com; wxlgs993@163.com; 19109327@qq.com;
   yingxiaoweicz@163.com; zhangqian2021888@126.com; jywanglan8888@163.com
RI Zhang, Qian/E-4260-2012
OI Zhang, Qian/0000-0003-4928-3366
FU Open Research Fund of Jiangsu Key Laboratory of New Drug Research and
   Clinical Pharmacy [XZSYSKF 2020021]
FX AcknowledgmentsThis study was supported by the Open Research Fund of
   Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy (No.
   XZSYSKF 2020021).
CR Ai C, 2020, J CANCER, V11, P788, DOI 10.7150/jca.37323
   Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9
   Ba S, 2017, CELL PHYSIOL BIOCHEM, V42, P1920, DOI 10.1159/000479610
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Chen H, 2020, ONCOTARGETS THER, V13, P5939, DOI 10.2147/OTT.S253468
   Cong JC, 2020, CANCER MANAG RES, V12, P5419, DOI 10.2147/CMAR.S255125
   Du YQ, 2020, AMB EXPRESS, V10, DOI 10.1186/s13568-020-01072-w
   Hayes J, 2014, TRENDS MOL MED, V20, P460, DOI 10.1016/j.molmed.2014.06.005
   He JT, 2020, CELL SIGNAL, V74, DOI 10.1016/j.cellsig.2020.109720
   He SY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3650-5
   Huang XL, 2015, INT J CLIN EXP PATHO, V8, P1515
   Iorio MV, 2012, EMBO MOL MED, V4, P143, DOI 10.1002/emmm.201100209
   Iqbal MA, 2019, MOL ASPECTS MED, V70, P3, DOI 10.1016/j.mam.2018.07.003
   Kang K, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21176141
   Knight SB, 2017, OPEN BIOL, V7, DOI 10.1098/rsob.170070
   Kong QL, 2018, ONCOL RES, V26, P735, DOI 10.3727/096504017X15021536183490
   Krol J, 2010, NAT REV GENET, V11, P597, DOI 10.1038/nrg2843
   Li JP, 2012, FEBS LETT, V586, P3761, DOI 10.1016/j.febslet.2012.09.016
   Li SQ, 2016, ONCOTARGET, V7, P51773, DOI 10.18632/oncotarget.10575
   Liang J, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20192061
   Liang L, 2020, CANCER MANAG RES, V12, P5301, DOI 10.2147/CMAR.S244167
   Meng FX, 2019, EXP THER MED, V18, P3650, DOI 10.3892/etm.2019.7989
   Myatt SS, 2007, NAT REV CANCER, V7, P847, DOI 10.1038/nrc2223
   Petrek H, 2019, PHARMACOL RES PERSPE, V7, DOI 10.1002/prp2.528
   Politi K, 2015, CLIN CANCER RES, V21, P2213, DOI 10.1158/1078-0432.CCR-14-2748
   Qin Q, 2016, J CELL MOL MED, V20, P1974, DOI 10.1111/jcmm.12889
   Rinaldetti S, 2018, J CANCER RES CLIN, V144, P1701, DOI 10.1007/s00432-018-2694-5
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Song NN, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00540
   Tian JW, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0382-3
   Tian QQ, 2020, CANCER MANAG RES, V12, P5749, DOI 10.2147/CMAR.S249686
   Wan LY, 2015, BIOCHEM BIOPH RES CO, V457, P125, DOI 10.1016/j.bbrc.2014.11.039
   Wang F, 2020, ONCOL REP, V44, P1282, DOI 10.3892/or.2020.7682
   Wang XL, 2020, ONCOTARGETS THER, V13, P4569, DOI 10.2147/OTT.S250752
   Wei YP, 2020, BIOMED PHARMACOTHER, V125, DOI 10.1016/j.biopha.2020.109890
   Wu K, 2020, ONCOTARGETS THER, V13, P4731, DOI 10.2147/OTT.S251916
   Yan TH, 2018, EUR REV MED PHARMACO, V22, P3038, DOI 10.26355/eurrev_201805_15061
   Yuan M, 2019, SIGNAL TRANSDUCT TAR, V4, DOI 10.1038/s41392-019-0099-9
   Zhai SP, 2019, J CELL BIOCHEM, V120, P6651, DOI 10.1002/jcb.27961
   Zhou GH, 2019, EXP THER MED, V18, P1449, DOI 10.3892/etm.2019.7676
   Zhou Z, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01432-3
   Zhu HY, 2020, J INT MED RES, V48, DOI 10.1177/0300060520903661
   Zhu KG, 2016, ONCOTARGET, V7, P28075, DOI 10.18632/oncotarget.8576
NR 44
TC 5
Z9 6
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1198-2241
EI 1916-7245
J9 CAN RESPIR J
JI Can. Respir. J.
PD JUN 15
PY 2022
VL 2022
AR 4256172
DI 10.1155/2022/4256172
PG 11
WC Respiratory System
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Respiratory System
GA 2L7HG
UT WOS:000817188400001
PM 35756697
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Huang, LP
   Chen, S
   Fan, HJ
   Ai, F
   Sheng, WW
AF Huang, Longping
   Chen, Si
   Fan, Haijun
   Ai, Fan
   Sheng, Weiwei
TI BZW2 promotes the malignant progression of colorectal cancer via
   activating the ERK/MAPK pathway
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
DE basic leucine zipper and W2 domains 2; colorectal cancer; ERK
ID STAG2; EXPRESSION; PROTEIN; CELLS
AB Colorectal cancer (CRC) is one of the most prevalent malignant solid cancers worldwide involving the dysregulation of multiple signaling molecules. However, the role and corresponding mechanism of basic leucine zipper and W2 domains 2 (BZW2) in CRC development, to our knowledge, has not been reported. We found BZW2 was overexpressed in human CRC tissues compared with that in paired adjacent colorectal samples. BZW2 overexpression was closely associated with tumor T stage (p = .030), metastatic lymph nodes (p = .037), TNM stage (p = .018) and the worse prognosis of CRC patients (p = .009). Moreover, BZW2 was an independent disadvantage prognostic factor (p = .031). BZW2 also showed an increased expression in different invasive CRC cell lines. Its silencing and overexpression diminished and increased cell proliferation, invasion, and migration in Colo205 and HCT116 cells via specifically activating of extracellular-signal-regulated kinase (ERK)/mitogen-activated protein kinase (MAPK) signaling. Moreover, ERK/MAPK inhibitor PD98059 reverse the enhancement of cell proliferation, invasion, and migration in BZW2 overexpressing HCT116 cells. BZW2 silencing also inhibited subcutaneous tumors growth and p-ERK expression in vivo. BZW2 promotes the malignant progression of CRC via activating ERK/MAPK signaling, which provided a promising gene target therapy for CRC.
C1 [Huang, Longping; Fan, Haijun; Ai, Fan] Fourth Peoples Hosp Shenyang City, Dept Gen & Hepatobiliary Surg, Shenyang, Liaoning, Peoples R China.
   [Chen, Si] Fourth Peoples Hosp Shenyang City, Dept Anesthesiol, Shenyang, Liaoning, Peoples R China.
   [Sheng, Weiwei] China Med Univ, Hosp 1, Dept Gastrointestinal Surg, Shenyang 110001, Liaoning, Peoples R China.
C3 China Medical University
RP Sheng, WW (corresponding author), China Med Univ, Hosp 1, Dept Gastrointestinal Surg, Shenyang 110001, Liaoning, Peoples R China.
EM cmu_wwsheng@sina.com
CR Aquila L, 2018, PHARMACOL RES, V131, P143, DOI 10.1016/j.phrs.2018.02.025
   Bénard F, 2018, WORLD J GASTROENTERO, V24, P124, DOI 10.3748/wjg.v24.i1.124
   Buonato JM, 2014, CANCER RES, V74, P309, DOI 10.1158/0008-5472.CAN-12-4721
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cheng DD, 2017, ONCOL REP, V38, P2116, DOI 10.3892/or.2017.5890
   Evers L, 2014, GENOME MED, V6, DOI 10.1186/gm526
   Fan HJ, 2019, CYTOTECHNOLOGY, V71, P35, DOI 10.1007/s10616-018-0259-8
   França JA, 2017, J ORAL PATHOL MED, V46, P188, DOI 10.1111/jop.12474
   Gao HF, 2019, J CELL MOL MED, V23, P3905, DOI 10.1111/jcmm.14266
   Gomes CC, 2014, J ORAL PATHOL MED, V43, P273, DOI 10.1111/jop.12127
   Guo ZH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005473
   Hiraishi H, 2014, NUCLEIC ACIDS RES, V42, P10321, DOI 10.1093/nar/gku670
   Jin X, 2019, J CELL PHYSIOL, V234, P16592, DOI 10.1002/jcp.28331
   Kozel C, 2016, NUCLEIC ACIDS RES, V44, P8704, DOI 10.1093/nar/gkw559
   Li X, 2015, GENET MOL RES, V14, P2638, DOI 10.4238/2015.March.30.24
   McFerran E, 2017, EPIDEMIOL REV, V39, P148, DOI 10.1093/epirev/mxx002
   Montagut C, 2009, CANCER LETT, V283, P125, DOI 10.1016/j.canlet.2009.01.022
   Ouakrim DA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4970
   Shen CH, 2016, NAT MED, V22, P1056, DOI 10.1038/nm.4155
   Sheng WW, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.547
   Sheng WW, 2014, HISTOPATHOLOGY, V64, P523, DOI 10.1111/his.12273
   Singh CR, 2011, NUCLEIC ACIDS RES, V39, P8314, DOI 10.1093/nar/gkr339
   Yu ZT, 2015, FUTURE MED CHEM, V7, P269, DOI [10.4155/fmc.14.143, 10.4155/FMC.14.143]
NR 23
TC 29
Z9 32
U1 1
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD MAY
PY 2020
VL 235
IS 5
BP 4834
EP 4842
DI 10.1002/jcp.29361
EA OCT 2019
PG 9
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA KK6JH
UT WOS:000491559500001
PM 31643092
DA 2025-01-04
ER

PT J
AU Qu, W
   Sun, YK
   Zhang, W
   Jiang, ZC
   Han, Y
   Jin, J
   Xue, Q
   Zhou, AP
AF Qu, Wang
   Sun, Yongkun
   Zhang, Wen
   Jiang, Zhichao
   Han, Yue
   Jin, Jing
   Xue, Qi
   Zhou, Aiping
TI Less aggressive treatment for less aggressive disease? A retrospective
   single-center study of pulmonary-limited metastases associated with
   colorectal cancer
SO ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Article
DE colorectal cancer; prognosis; pulmonary-limited metastases; survival;
   treatment modality
ID FOLFIRI PLUS BEVACIZUMAB; LUNG METASTASIS; INFUSIONAL FLUOROURACIL;
   1ST-LINE TREATMENT; PROGNOSTIC-FACTORS; COLON-CANCER; OPEN-LABEL;
   RESECTION; RECURRENCE; CHEMOTHERAPY
AB ObjectiveTo explore the appropriate treatment strategies, clinical outcomes, and prognostic factors of patients with pulmonary-limited metastases derived from colorectal cancer (CRC), usually manifested as a less aggressive course. MethodsA retrospective review was conducted in 331 CRC patients diagnosed with pulmonary-limited metastases at a single institution between January 2011 and November 2017. The Kaplan-Meier method was used to calculate the overall survival (OS). Further analysis was conducted according to treatment modalities. Univariate and multivariate analyses were used to determine potential prognostic factors influencing OS. ResultsWith a median follow-up time of 38.6 months, the median OS in all patients was 45.2 months. A total of 163 patients received intensive local treatment with a median OS of 76.4 months, whereas 168 patients received palliative systemic treatment with a median OS of 29.7 months. The median OS was 68.9 months for patients treated with radiotherapy/radiofrequency ablation, with similar efficacy compared to surgery group, whose OS had not reached yet. No survival benefits were observed from the additional targeted therapy in systemic treatment group. The prognostic analysis demonstrated unilateral/bilateral lesions, synchronous/metachronous metastases, intensive local treatment, and resection of primary lesion that were significantly associated with survival of patients. ConclusionsIntensive local treatment alone for pulmonary lesions was associated with excellent survival in certain patients with CRC presented with metastases confined to lungs. Doublet systemic chemotherapy as the first-line treatment also revealed satisfied efficacy and safety.
C1 [Qu, Wang; Sun, Yongkun; Zhang, Wen; Jiang, Zhichao; Zhou, Aiping] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol,Nat Clin Res Ctr Canc, Beijing, Peoples R China.
   [Han, Yue] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Intervent Radiog,Nat Clin Res Ctr Canc, Beijing, Peoples R China.
   [Jin, Jing] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Radiotherapy,Nat Clin Res Ctr Canc, Beijing, Peoples R China.
   [Xue, Qi] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Thorac Surg,Nat Clin Res Ctr Canc, Beijing, Peoples R China.
   [Xue, Qi; Zhou, Aiping] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China.
C3 Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Cancer Institute & Hospital - CAMS;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Cancer Institute & Hospital - CAMS;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Cancer Institute & Hospital - CAMS; Peking Union Medical College;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Cancer Institute & Hospital - CAMS; Peking Union Medical College;
   Chinese Academy of Medical Sciences - Peking Union Medical College;
   Peking Union Medical College; Cancer Institute & Hospital - CAMS
RP Xue, Q; Zhou, AP (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Natl Clin Res Ctr Canc, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China.
EM xueqi@cicams.ac.cn; zhouap1825@126.com
OI Qu, Wang/0000-0002-5997-4761
CR Akasu T, 2007, ANN SURG ONCOL, V14, P74, DOI 10.1245/s10434-006-9082-0
   Balhareth AS, 2022, ANN MED SURG, V77, DOI 10.1016/j.amsu.2022.103559
   BUO L, 1995, HUM PATHOL, V26, P1133, DOI 10.1016/0046-8177(95)90276-7
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cho S, 2013, INTERACT CARDIOV TH, V17, P303, DOI 10.1093/icvts/ivt164
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Falcone A, 2002, J CLIN ONCOL, V20, P4006, DOI 10.1200/JCO.2002.12.075
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   FOSTER JH, 1984, SEMIN LIVER DIS, V4, P170, DOI 10.1055/s-2008-1040656
   Gonzalez M, 2012, EXPERT REV ANTICANC, V12, P495, DOI [10.1586/ERA.12.21, 10.1586/era.12.21]
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Li WH, 2010, WORLD J GASTROENTERO, V16, P3318, DOI 10.3748/wjg.v16.i26.3318
   Li YT, 2020, J CANCER RES CLIN, V146, P545, DOI 10.1007/s00432-020-03142-9
   Luo DK, 2018, INT J COLORECTAL DIS, V33, P1241, DOI 10.1007/s00384-018-3091-x
   Margalit O, 2019, CLIN COLORECTAL CANC, V18, pE300, DOI 10.1016/j.clcc.2019.06.001
   MCCORMACK PM, 1979, DIS COLON RECTUM, V22, P553, DOI 10.1007/BF02587003
   Merrie AEH, 2001, SURGERY, V129, P684, DOI 10.1067/msy.2001.113887
   Milosevic M, 2020, COLORECTAL DIS, V22, P1314, DOI 10.1111/codi.15113
   Mitry E, 2010, GUT, V59, P1383, DOI 10.1136/gut.2010.211557
   Modest DP, 2011, ANTI-CANCER DRUG, V22, P913, DOI 10.1097/CAD.0b013e3283493160
   Pan HD, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-019614
   Pennathur A, 2009, ANN THORAC SURG, V87, P1030, DOI 10.1016/j.athoracsur.2008.12.061
   Pereira AAL, 2015, BRIT J CANCER, V112, P424, DOI 10.1038/bjc.2014.619
   Pfannschmidt J, 2007, ANN THORAC SURG, V84, P324, DOI 10.1016/j.athoracsur.2007.02.093
   PIHL E, 1987, DIS COLON RECTUM, V30, P417, DOI 10.1007/BF02556487
   Rusthoven KE, 2009, J CLIN ONCOL, V27, P1579, DOI 10.1200/JCO.2008.19.6386
   Sadahiro S, 2003, HEPATO-GASTROENTEROL, V50, P1362
   Salah S, 2012, ANN ONCOL, V23, P2649, DOI 10.1093/annonc/mds100
   SCHEELE J, 1990, DIS COLON RECTUM, V33, P745, DOI 10.1007/BF02052319
   Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011
   Tampellini M, 2012, ONCOLOGIST, V17, P1430, DOI 10.1634/theoncologist.2012-0142
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2006, EUR J CANCER, V42, P2212, DOI 10.1016/j.ejca.2006.04.012
   van der Geest LGM, 2015, CLIN EXP METASTAS, V32, P457, DOI 10.1007/s10585-015-9719-0
   Venook AP, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3504
   Wang CK, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.18416
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   YAMAMOTO H, 1995, J CLIN LAB ANAL, V9, P297, DOI 10.1002/jcla.1860090504
NR 38
TC 0
Z9 0
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1743-7555
EI 1743-7563
J9 ASIA-PAC J CLIN ONCO
JI Asia-Pac. J. Clin. Oncol.
PD DEC
PY 2023
VL 19
IS 6
BP 664
EP 671
DI 10.1111/ajco.13918
EA JAN 2023
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA Y4WY5
UT WOS:000919908900001
PM 36693818
DA 2025-01-04
ER

PT J
AU Huang, TZ
   Lin, YY
   Chen, JG
   Hu, JC
   Chen, H
   Zhang, YH
   Zhang, B
   He, XS
AF Huang, Tianze
   Lin, Yanyun
   Chen, Junguo
   Hu, Jiancong
   Chen, Hao
   Zhang, Yanhong
   Zhang, Bin
   He, Xiaosheng
TI CD51 Intracellular Domain Promotes Cancer Cell Neurotropism through
   Interacting with Transcription Factor NR4A3 in Colorectal Cancer
SO CANCERS
LA English
DT Article
DE CD51; colorectal cancer; intracellular domain; perineural invasion
ID GAMMA-SECRETASE INHIBITORS; PERINEURAL INVASION; INTEGRIN ADHESOME;
   CLEAVAGE; ADHESION; RECEPTOR; TRAFFICKING; PROGRESSION; PATHWAY; DISEASE
AB Perineural invasion is an important cause of postoperative recurrence andmetastasis of colorectal cancer, but the mechanisms of perineural invasion are not well characterized. Meanwhile, there is no targeted therapy for perineural invasion in the current treatment of colorectal cancer. In this study, we first show that CD51 can be cleaved by gamma-secretase to generate an intracellular domain that promotes perineural invasion. More importantly, we have demonstrated for the first time that pharmacological inhibition of gamma-secretase can help prevent perineural invasion in colorectal cancer.
   The abundant nervous system in intestine provides the basis for perineural invasion (PNI) of colorectal cancer (CRC). PNI is defined as the invasion of the nerves by cancer cells. Although PNI is already known to be an independent prognostic factor in CRC, the molecular mechanism underlying PNI remains obscure. In this study, we first demonstrated that CD51 could promote the neurotropism of tumor cells through cleavage with gamma-secretase to generate an intracellular domain (ICD). Mechanistically, ICD of CD51 could bind to the transcription factor NR4A3, and act as a coactivator to promote the expression of downstream effectors, such as NTRK1, NTRK3, and SEMA3E. Pharmacological inhibition of gamma-secretase impedes PNI mediated by CD51 in CRC both in vitro and in vivo and may become a potential therapeutic target for PNI in CRC.
C1 [Huang, Tianze; Lin, Yanyun; Chen, Junguo; Chen, Hao; Zhang, Yanhong; Zhang, Bin; He, Xiaosheng] Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510655, Peoples R China.
   [Huang, Tianze; Lin, Yanyun; Chen, Junguo; Hu, Jiancong; Chen, Hao; Zhang, Yanhong; Zhang, Bin; He, Xiaosheng] Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, Guangzhou 510655, Peoples R China.
C3 Sun Yat Sen University; Sun Yat Sen University
RP Zhang, B; He, XS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Dept Colorectal Surg, Guangzhou 510655, Peoples R China.; Zhang, B; He, XS (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, Guangzhou 510655, Peoples R China.
EM zhangb278@mail.sysu.edu.cn; hexsheng@mail.sysu.edu.cn
RI lin, yanyun/GRX-9892-2022
OI lin, yanyun/0000-0003-4298-6683; Zhang, Bin/0000-0003-4531-4946; huang,
   tianze/0000-0003-2915-3687; He, Xiaosheng/0000-0002-8346-4972
FU Natural Science Foundation of China [82172561, 81970482, 32000555];
   Natural Science Foundation of Guangdong [2021A1515110987,
   2019A1515011313]; Guangdong Special Young Talent Plan of Scientific and
   Technological Innovation [2022B1515020022]; China Postdoctoral Science
   Foundation [2019M663250]; Complete Period Talent Project of The Sixth
   Affiliated Hospital of Sun Yat-sen University [R20210217202501976]
FX This research was supported by grants from the Natural Science
   Foundation of China (82172561, 81970482, 32000555), Natural Science
   Foundation of Guangdong (2021A1515110987, 2019A1515011313), Guangdong
   Special Young Talent Plan of Scientific and Technological Innovation
   (2022B1515020022), China Postdoctoral Science Foundation (2019M663250),
   and Complete Period Talent Project of The Sixth Affiliated Hospital of
   Sun Yat-sen University (R20210217202501976).
CR Al-Sukhni E, 2017, INT J SURG, V37, P42, DOI 10.1016/j.ijsu.2016.08.528
   Amit M, 2016, NAT REV CANCER, V16, P399, DOI 10.1038/nrc.2016.38
   Bateman RJ, 2009, ANN NEUROL, V66, P48, DOI 10.1002/ana.21623
   Baxter NN, 2022, J CLIN ONCOL, V40, P892, DOI 10.1200/JCO.21.02538
   Beel AJ, 2008, CELL MOL LIFE SCI, V65, P1311, DOI 10.1007/s00018-008-7462-2
   Blobel CP, 1997, CELL, V90, P589, DOI 10.1016/S0092-8674(00)80519-X
   Collingwood TN, 1999, J MOL ENDOCRINOL, V23, P255, DOI 10.1677/jme.0.0230255
   Coric V, 2015, JAMA NEUROL, V72, P1324, DOI 10.1001/jamaneurol.2015.0607
   Crippa S, 2022, ANN SURG, V276, P378, DOI 10.1097/SLA.0000000000004464
   Cui Y, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02381-y
   De Strooper B, 2003, NEURON, V38, P9, DOI 10.1016/S0896-6273(03)00205-8
   De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083
   De Strooper B, 2014, CELL, V159, P721, DOI 10.1016/j.cell.2014.10.016
   Doan C, 2022, ADV BIOL-GER, V6, DOI 10.1002/adbi.202200190
   Doody RS, 2013, NEW ENGL J MED, V369, P341, DOI 10.1056/NEJMoa1210951
   Fryer CJ, 2004, MOL CELL, V16, P509, DOI 10.1016/j.molcel.2004.10.014
   Gil Z, 2010, J NATL CANCER I, V102, P107, DOI 10.1093/jnci/djp456
   Haapasalo A, 2011, J ALZHEIMERS DIS, V25, P3, DOI 10.3233/JAD-2011-101065
   Hamidi H, 2018, NAT REV CANCER, V18, P532, DOI 10.1038/s41568-018-0038-z
   Horton ER, 2015, NAT CELL BIOL, V17, P1577, DOI 10.1038/ncb3257
   Hülsbusch N, 2015, EUR J CELL BIOL, V94, P531, DOI 10.1016/j.ejcb.2015.07.003
   Hur JY, 2022, EXP MOL MED, V54, P433, DOI 10.1038/s12276-022-00754-8
   Hynes RO, 2002, CELL, V110, P673, DOI 10.1016/S0092-8674(02)00971-6
   Kechagia JZ, 2019, NAT REV MOL CELL BIO, V20, P457, DOI 10.1038/s41580-019-0134-2
   Kummar S, 2017, J CLIN ONCOL, V35, P1561, DOI 10.1200/JCO.2016.71.1994
   Lal M, 2011, PHYSIOLOGY, V26, P34, DOI 10.1152/physiol.00028.2010
   Li GM, 2018, INT J BIOL SCI, V14, P280, DOI 10.7150/ijbs.23756
   Liebig C, 2009, J CLIN ONCOL, V27, P5131, DOI 10.1200/JCO.2009.22.4949
   Liebig C, 2009, CANCER-AM CANCER SOC, V115, P3379, DOI 10.1002/cncr.24396
   Mashour GA, 2001, EXP NEUROL, V169, P64, DOI 10.1006/exnr.2001.7641
   Mayo E, 2016, HISTOPATHOLOGY, V69, P230, DOI 10.1111/his.12936
   Merilahti JAM, 2017, MOL BIOL CELL, V28, P3123, DOI 10.1091/mbc.E17-04-0261
   Messersmith WA, 2015, CLIN CANCER RES, V21, P60, DOI 10.1158/1078-0432.CCR-14-0607
   Moreno-Layseca P, 2019, NAT CELL BIOL, V21, P122, DOI 10.1038/s41556-018-0223-z
   Muller PAJ, 2009, CELL, V139, P1327, DOI 10.1016/j.cell.2009.11.026
   Mygind KJ, 2018, J CELL SCI, V131, DOI 10.1242/jcs.205393
   Ni CY, 2001, SCIENCE, V294, P2179, DOI 10.1126/science.1065412
   Nie PJ, 2020, SEMIN CELL DEV BIOL, V105, P43, DOI 10.1016/j.semcdb.2020.03.002
   Oh WJ, 2013, SEMIN CELL DEV BIOL, V24, P156, DOI 10.1016/j.semcdb.2012.12.001
   Paul NR, 2015, CURR BIOL, V25, pR1092, DOI 10.1016/j.cub.2015.09.049
   Penninkilampi R, 2016, J ALZHEIMERS DIS, V53, P1395, DOI 10.3233/JAD-160275
   Qin T, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.728583
   Saalbach A, 2005, ONCOGENE, V24, P4710, DOI 10.1038/sj.onc.1208559
   Safe S, 2021, MOL CANCER RES, V19, P180, DOI 10.1158/1541-7786.MCR-20-0707
   Schott AF, 2013, CLIN CANCER RES, V19, P1512, DOI 10.1158/1078-0432.CCR-11-3326
   Senbanjo LT, 2019, CELL COMMUN SIGNAL, V17, DOI 10.1186/s12964-019-0395-6
   Shih IM, 2007, CANCER RES, V67, P1879, DOI 10.1158/0008-5472.CAN-06-3958
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Spencer NJ, 2020, NAT REV GASTRO HEPAT, V17, P338, DOI 10.1038/s41575-020-0271-2
   Sui X, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0541-x
   Sykes AM, 2012, J BIOL CHEM, V287, P43810, DOI 10.1074/jbc.M112.382903
   van Wyk HC, 2017, CRIT REV ONCOL HEMAT, V112, P11, DOI 10.1016/j.critrevonc.2017.02.005
   Viana LD, 2013, ONCOLOGY-BASEL, V84, P81, DOI 10.1159/000343436
   Waisberg J, 2014, ANTICANCER RES, V34, P5599
   Wang J, 2017, ONCOGENE, V36, P1351, DOI 10.1038/onc.2016.299
   Wang J, 2016, ONCOGENE, V35, P3139, DOI 10.1038/onc.2015.370
   Winograd-Katz SE, 2014, NAT REV MOL CELL BIO, V15, P273, DOI 10.1038/nrm3769
   Xie YM, 2021, GASTROENTEROL REP, V9, P91, DOI 10.1093/gastro/goab010
   Xu L, 2020, CANCER LETT, V482, P74, DOI 10.1016/j.canlet.2020.04.002
   Zhang B, 2019, CANCER LETT, V459, P204, DOI 10.1016/j.canlet.2019.06.005
   Zhang JF, 2021, CANCER LETT, V508, P47, DOI 10.1016/j.canlet.2021.03.016
   Zhou BH, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00934-y
   Zhou Y, 2015, PATHOL RES PRACT, V211, P839, DOI 10.1016/j.prp.2015.09.001
NR 63
TC 3
Z9 3
U1 0
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY 5
PY 2023
VL 15
IS 9
AR 2623
DI 10.3390/cancers15092623
PG 18
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA G1WF4
UT WOS:000987137500001
PM 37174090
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Xu, J
   Meng, QT
   Sun, H
   Zhang, XW
   Yun, J
   Li, B
   Wu, SS
   Li, XB
   Yang, HB
   Zhu, HT
   Aschner, M
   Relucenti, M
   Familiari, G
   Chen, R
AF Xu, Jie
   Meng, Qingtao
   Sun, Hao
   Zhang, Xinwei
   Yun, Jun
   Li, Bin
   Wu, Shenshen
   Li, Xiaobo
   Yang, Hongbao
   Zhu, Haitao
   Aschner, Michael
   Relucenti, Michela
   Familiari, Giuseppe
   Chen, Rui
TI HER2-specific chimeric antigen receptor-T cells for targeted therapy of
   metastatic colorectal cancer
SO CELL DEATH & DISEASE
LA English
DT Article
ID BREAST-CANCER; IMMUNOTHERAPY; EXPRESSION; HER2
AB Chimeric antigen receptor (CAR) - T cell therapy is a new class of cellular immunotherapies, which has made great achievements in the treatment of malignant tumors. Despite improvements in colorectal cancer (CRC) therapy, treatment of many patients fails because of metastasis and recurrence. The human epidermal growth factor receptor 2 (HER2) is a substantiated target for CAR-T therapy, and has been reported recently to be over-expressed in CRC, which may provide a potential therapeutic target for CRC treatment. Herein, HER2 was a promising target of metastatic colorectal cancer (mCRC) in CAR-T therapy as assessed by flow cytometry and tissue microarray (TMA) with 9-year survival follow-up data. Furthermore, HER2-specific CAR-T cells exhibited strong cytotoxicity and cytokine-secreting ability against CRC cells in vitro. Moreover, through the tumor-bearing model of the NOD-Prkdc(em26cd52)Il2rg(em26Cd22)/Nju (NCG) mice, HER2 CAR-T cells showed signs of effectively preventing CRC progression in three different xenograft models. Notably, HER2 CAR-T cells displayed greater aggressiveness in HER2(+) CRC in the patient-derived tumor xenograft (PDX) models and had potent immunotherapeutic capacity for mCRC in the metastatic xenograft mouse models. In conclusion, our studies provide scientific evidence that HER2 CAR-T cells represent an emerging immunotherapy for the treatment of mCRC.
C1 [Xu, Jie] Kunming Med Univ, Sch Publ Hlth, Kunming 650500, Yunnan, Peoples R China.
   [Xu, Jie; Sun, Hao; Yun, Jun; Li, Bin; Li, Xiaobo; Chen, Rui] Southeast Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Med Engn, Nanjing 210009, Peoples R China.
   [Meng, Qingtao; Wu, Shenshen; Li, Xiaobo; Chen, Rui] Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Sch Publ Hlth, Beijing 100069, Peoples R China.
   [Meng, Qingtao; Wu, Shenshen; Li, Xiaobo; Chen, Rui] Capital Med Univ, Beijing Key Lab Environm Toxicol, Beijing 100069, Peoples R China.
   [Zhang, Xinwei] Nanjing Municipal Ctr Dis Control & Prevent, Nanjing 210003, Peoples R China.
   [Yang, Hongbao] China Pharmaceut Univ, Ctr Drug Safety Evaluat & Res, Nanjing 211198, Peoples R China.
   [Zhu, Haitao] Nanjing Med Univ, Canc Hosp, Jiangsu Canc Hosp, Colorectal Canc Ctr,Dept Gen Surg,Canc Res Inst, Nanjing 210009, Peoples R China.
   [Aschner, Michael] Albert Einstein Coll Med, Dept Mol Pharmacol, Bronx, NY 10461 USA.
   [Relucenti, Michela] Sapienza Univ Rome, Dept Anat Histol Forens Med & Orthoped Sci, I-5000161 Rome, Italy.
   [Familiari, Giuseppe] Sapienza Univ Rome, Sect Human Anat, Dept Anat Histol Med & Legal Locomot Apparat, Via Alfonso Borelli, I-5000161 Rome, Italy.
   [Chen, Rui] Guangzhou Med Univ, Inst Chem Carcinogenesis, Guangzhou 511436, Peoples R China.
C3 Kunming Medical University; Southeast University - China; Capital
   Medical University; Capital Medical University; China Pharmaceutical
   University; Nanjing Medical University; Montefiore Medical Center;
   Albert Einstein College of Medicine; Yeshiva University; Sapienza
   University Rome; Sapienza University Rome; Guangzhou Medical University
RP Chen, R (corresponding author), Southeast Univ, Sch Publ Hlth, Minist Educ, Key Lab Environm Med Engn, Nanjing 210009, Peoples R China.; Chen, R (corresponding author), Capital Med Univ, Adv Innovat Ctr Human Brain Protect, Sch Publ Hlth, Beijing 100069, Peoples R China.; Chen, R (corresponding author), Capital Med Univ, Beijing Key Lab Environm Toxicol, Beijing 100069, Peoples R China.; Chen, R (corresponding author), Guangzhou Med Univ, Inst Chem Carcinogenesis, Guangzhou 511436, Peoples R China.
EM 101011816@seu.edu.cn
RI Aschner, Michael/ACO-6461-2022; Relucenti, Michela/I-2377-2012; zhu,
   HAITAO/GVL-0589-2022
OI Familiari, Giuseppe/0000-0002-3456-1434
FU National Science Fund for Distinguished Young Scholars [82025031]; State
   Key Program of the National Natural Science Foundation of China
   [81730088]; National Natural Science Foundation of China [82003498];
   Fund of International Cooperation and Exchange of the National Natural
   Science Foundation of China [81861138017]; Ministry of Foreign Affairs
   and International Cooperation of Italy (MAECI) [CN18GR10]; National
   Institute of Environmental Health Sciences (NIEHS) [R01ES10563,
   R01ES07331]
FX This work was financially supported by the National Science Fund for
   Distinguished Young Scholars (82025031), the State Key Program of the
   National Natural Science Foundation of China (81730088), the National
   Natural Science Foundation of China (82003498), Fund of International
   Cooperation and Exchange of the National Natural Science Foundation of
   China (81861138017), funding from the Ministry of Foreign Affairs and
   International Cooperation of Italy (MAECI) CN18GR10, MA was supported in
   part by grants from the National Institute of Environmental Health
   Sciences (NIEHS) R01ES10563 and R01ES07331.
CR Abdelwahab MG, 2011, JOVE-J VIS EXP, DOI 10.3791/3403
   Ahmed N, 2015, J CLIN ONCOL, V33, P1688, DOI 10.1200/JCO.2014.58.0225
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Beatty GL, 2014, CANCER IMMUNOL RES, V2, P112, DOI 10.1158/2326-6066.CIR-13-0170
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Cartellieri M, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/956304
   Chand M, 2018, WORLD J GASTRO ONCOL, V10, P145, DOI 10.4251/wjgo.v10.i7.145
   Chen N, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1273302
   D'Aloia MM, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0278-6
   Du HW, 2019, CANCER CELL, V35, P221, DOI 10.1016/j.ccell.2019.01.002
   Ferreri AJM, 2010, NAT REV CLIN ONCOL, V7, DOI 10.1038/nrclinonc.2010.9-c1
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Garcia PL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0078183
   Ghosh A, 2017, NAT MED, V23, P242, DOI 10.1038/nm.4258
   Greally M, 2018, CURR PROB CANCER, V42, P560, DOI 10.1016/j.currproblcancer.2018.07.001
   Haso W, 2013, BLOOD, V121, P1165, DOI 10.1182/blood-2012-06-438002
   Hiramatsu Hidefumi, 2018, Rinsho Ketsueki, V59, P1948, DOI 10.11406/rinketsu.59.1948
   Hu ZM, 2020, MOL THER-ONCOLYTICS, V17, P361, DOI 10.1016/j.omto.2020.04.008
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Jackson HJ, 2016, NAT REV CLIN ONCOL, V13, P370, DOI 10.1038/nrclinonc.2016.36
   Johnson LA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4963
   Kasakovski D, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0629-x
   Kershaw MH, 2014, CLIN TRANSL IMMUNOL, V3, DOI 10.1038/cti.2014.7
   La Salvia A, 2019, EXPERT OPIN INV DRUG, V28, P29, DOI 10.1080/13543784.2019.1555583
   Li J, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0568-6
   Li KS, 2016, ONCOTARGET, V7, P2496, DOI 10.18632/oncotarget.6595
   Li XB, 2016, ONCOTARGET, V7, P35026, DOI 10.18632/oncotarget.9019
   Liu F, 2018, ONCOL LETT, V15, P3362, DOI 10.3892/ol.2017.7684
   Luo MN, 2017, ONCOL LETT, V13, P1745, DOI 10.3892/ol.2017.5601
   Maus MV, 2013, CANCER IMMUNOL RES, V1, P26, DOI 10.1158/2326-6066.CIR-13-0006
   Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24
   O'Rourke DM, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aaa0984
   Qu L, 2016, CANCER CELL, V29, P653, DOI 10.1016/j.ccell.2016.03.004
   Raj D, 2019, GUT, V68, P1052, DOI 10.1136/gutjnl-2018-316595
   Ramello MC, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aap9777
   Ramos CA, 2020, J CLIN ONCOL, V38, P3794, DOI 10.1200/JCO.20.01342
   Shang YL, 2014, ARCH PATHOL LAB MED, V138, P910, DOI 10.5858/arpa.2013-0064-OA
   Shi DH, 2020, CLIN CANCER RES, V26, P3979, DOI 10.1158/1078-0432.CCR-19-3259
   Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Song YJ, 2018, PROTEIN CELL, V9, P867, DOI 10.1007/s13238-017-0384-8
   Staedtke V, 2018, NATURE, V564, P273, DOI 10.1038/s41586-018-0774-y
   Taieb J, 2019, DRUGS, V79, P1375, DOI 10.1007/s40265-019-01165-2
   Teng RD, 2019, J IMMUNOTHER, V42, P33, DOI 10.1097/CJI.0000000000000251
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Wang JH, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-017-0553-5
   Wang SY, 2012, ONCOL REP, V28, P91, DOI 10.3892/or.2012.1756
   Yu SN, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0444-9
   Zhang Xiaomei, 2013, Curr Protoc Mouse Biol, V3, P21, DOI 10.1002/9780470942390.mo120140
   Zhou S, 2021, LEUKEMIA, V35, P119, DOI 10.1038/s41375-020-0824-y
NR 51
TC 32
Z9 36
U1 1
U2 23
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD NOV 27
PY 2021
VL 12
IS 12
AR 1109
DI 10.1038/s41419-021-04100-0
PG 11
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA XD9DZ
UT WOS:000723001800006
PM 34839348
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Wojas-Krawczyk, K
   Kalinka-Warzocha, E
   Reszka, K
   Nicos, M
   Szumilo, J
   Mandziuk, S
   Szczepaniak, K
   Kupnicka, D
   Lewandowski, R
   Milanowski, J
   Krawczyk, P
AF Wojas-Krawczyk, Kamila
   Kalinka-Warzocha, Ewa
   Reszka, Katarzyna
   Nicos, Marcin
   Szumilo, Justyna
   Mandziuk, Slawomir
   Szczepaniak, Katarzyna
   Kupnicka, Dorota
   Lewandowski, Remigiusz
   Milanowski, Janusz
   Krawczyk, Pawel
TI Analysis of <i>KRAS, NRAS, BRAF</i>, and <i>PIK3CA</i> mutations could
   predict metastases in colorectal cancer: A preliminary study
SO ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE
LA English
DT Article
DE colorectal cancer; PIK3CA; BRAF; molecularly targeted therapy; RAS
   mutation
ID FLUOROURACIL; BEVACIZUMAB; LEUCOVORIN; IRINOTECAN; PROGNOSIS; COLON
AB Background. Colorectal cancer (CRC) is usually diagnosed in the metastatic stage, when chemotherapy and molecularly-targeted therapies, instead of surgery, play the most important therapeutic role. Application of anti-epidermal growth factor receptor (EGFR) therapy requires the analysis of RAS mutation status and only RAS wild-type (wt) patients are qualified for the therapy.
   Objectives. The objective of this study was to analyze driver mutations in KRAS, NRAS, BRAF, and PIK3G4 genes in CRC patients.
   Material and methods. We assessed the KRAS, NRAS, BRAF, and PIK3CA genes in 102 inoperable, locally advanced and advanced CRC patients. Real-time polymerase chain reaction (RT-PCR) and high resolution melt PCR (HRM-PCR) techniques with DNA intercalating dye were applied in the study.
   Results. Forty-six patients demonstrated the presence of examined mutations (45.1%). No significant differences in driver mutation occurrence between men and women, as well as between younger (<65 years) and older (>= 65 years) patients were found. The mutations were present significantly more frequently in metastatic than in primary tumors (p = 0.039) due to the high incidence of KRAS gene mutations in metastatic tissue. BRAF and PIK3CA mutations were found only in primary tumors. The incidence of PIK3CA mutations was significantly higher (11.77%) in early than in advanced stages of the disease (1.96%; p = 0.05); NRAS mutations were found only in metastatic cancer (7.85%; p = 0.041). Only a single mutation of the PIK3CA and no mutations of NRAS were found in rectal cancer.
   Conclusions. Our results have shown low occurrence of driver mutations in Polish CRC patients, involving also mutations in rarely tested genes. The extent of the research panel of additional mutations could contribute to creating a better method of qualifying patients for molecularly targeted therapies and obtaining a better outcome for these therapeutic strategies.
C1 [Wojas-Krawczyk, Kamila; Nicos, Marcin; Milanowski, Janusz; Krawczyk, Pawel] Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland.
   [Kalinka-Warzocha, Ewa] Polish Mothers Mem Hosp Res Inst, Lodz, Poland.
   [Reszka, Katarzyna] Genet & Immunol Inst GENIM Ltd, Lublin, Poland.
   [Szumilo, Justyna] Med Univ Lublin, Dept Clin Patomorphol, Lublin, Poland.
   [Mandziuk, Slawomir] Med Univ Lublin, Oncol & Chemotherapy vUnit, Lublin, Poland.
   [Szczepaniak, Katarzyna] Nicolaus Copernicus Prov Specialist Hosp, Reg Ctr Oncol, Chemotherapy Dept, Lodz, Poland.
   [Kupnicka, Dorota] Pathol Lab Synevo, Lodz, Poland.
   [Lewandowski, Remigiusz] MolGenDia Ltd, Bydgoszcz, Poland.
C3 Medical University of Lublin; Polish Mother's Memorial Hospital -
   Research Institute; Medical University of Lublin; Medical University of
   Lublin
RP Wojas-Krawczyk, K (corresponding author), Med Univ Lublin, Dept Pneumonol Oncol & Allergol, Lublin, Poland.
EM kamilawojas@wp.pl
RI Wojas-Krawczyk, Kamila/GZK-4332-2022
OI Kalinka, Ewa/0000-0003-4791-8372; Mandziuk,
   Slawomir/0000-0002-9812-0777; MILANOWSKI, JANUSZ/0000-0002-8616-596X;
   Krawczyk, Pawel/0000-0001-8400-4452; Nicos, Marcin/0000-0002-9566-113X;
   Wojas-Krawczyk, Kamila/0000-0001-9947-5169
CR Akkad J, 2015, LANGENBECK ARCH SURG, V400, P129, DOI 10.1007/s00423-015-1276-0
   [Anonymous], 2014, P AM SOC CLIN ONCO S
   [Anonymous], J CLIN ONCOL S
   Cathomas G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00035
   Coppedè F, 2014, WORLD J GASTROENTERO, V20, P943, DOI 10.3748/wjg.v20.i4.943
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Kim TM, 2013, WORLD J GASTROENTERO, V19, P6784, DOI 10.3748/wjg.v19.i40.6784
   Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240
   Lipsyc M, 2015, J GASTROINTEST ONCOL, V6, P645, DOI 10.3978/j.issn.2078-6891.2015.045
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Nagtegaal ID, 2013, NAT REV GASTRO HEPAT, V10, P391, DOI 10.1038/nrgastro.2013.90
   Nakayama I, 2017, BMC CANCER, V17, DOI 10.1186/s12885-016-2994-6
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Slattery ML, 2009, DIS COLON RECTUM, V52, P1304, DOI 10.1007/DCR.0b013e3181a0e5df
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
NR 19
TC 8
Z9 8
U1 0
U2 2
PU WROCLAW MEDICAL UNIV
PI WROCLAW
PA UL K MARCINKOWSKIEGO 2-6, WROCLAW, 50-368, POLAND
SN 1899-5276
EI 2451-2680
J9 ADV CLIN EXP MED
JI Adv. Clin. Exp. Med.
PD JAN
PY 2019
VL 28
IS 1
BP 67
EP 73
DI 10.17219/acem/76162
PG 7
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA HJ5BS
UT WOS:000457193900009
PM 30085422
OA gold, Green Submitted
DA 2025-01-04
ER

PT J
AU Clarke, CN
   Kopetz, ES
AF Clarke, Callisia N.
   Kopetz, E. Scott
TI BRAF mutant colorectal cancer as a distinct subset of colorectal cancer:
   clinical characteristics, clinical behavior, and response to targeted
   therapies
SO JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Review
DE Colorectal cancer (CRC); BRAF; prognostic biomarker; targeted therapy
ID ISLAND METHYLATOR PHENOTYPE; K-RAS MUTATIONS; MICROSATELLITE
   INSTABILITY; COLON-CANCER; MISMATCH-REPAIR; STAGE-II; THERAPEUTIC
   DEVELOPMENT; MOLECULAR-FEATURES; V600E MUTATION; KRAS
AB Despite new and more effective cytotoxic chemotherapy, limitations to conventional agents have been reached in a subset of patients with advanced colorectal cancer (CRC). The identification of novel prognostic and predictive biomarkers to guide individualized treatment plans is critical to overcoming therapeutic resistance. Mutation of the BRAF proto-oncogene is linked to a variety of cancers and is increasingly being used as a prognostic tool and therapeutic target. This paper is a comprehensive review of the literature that summarizes the clinical, pathologic, and molecular features of BRAF mutated CRC that support the hypothesis that BRAF mutant cancers represent a distinct subset of CRC with its own clinical implications with regard to prognosis, treatments and emerging therapeutic strategies.
C1 [Clarke, Callisia N.] Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, Houston, TX 77030 USA.
   [Kopetz, E. Scott] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; University of
   Texas System; UTMD Anderson Cancer Center
RP Clarke, CN (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Surg Oncol, 1400 Pressler St,Unit 1484, Houston, TX 77030 USA.
EM cnclarke@mdanderson.org
RI Kopetz, Scott/AAC-1387-2019
OI Kopetz, Scott/0000-0001-9647-3416
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], 2014, J NATL CANC I
   [Anonymous], J CLIN ONCOL
   Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171
   Beeram M, 2005, J CLIN ONCOL, V23, P6771, DOI 10.1200/JCO.2005.08.036
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   Chang DZ, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-18
   Cohen SJ, 2005, J CLIN ONCOL, V23, P5374, DOI 10.1200/JCO.2005.02.194
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Corcoran RB, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3517
   Cunningham JM, 1998, CANCER RES, V58, P3455
   Dahlin AM, 2010, CLIN CANCER RES, V16, P1845, DOI 10.1158/1078-0432.CCR-09-2594
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Fariña-Sarasqueta A, 2010, ANN ONCOL, V21, P2396, DOI 10.1093/annonc/mdq258
   Fransén K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049
   French AJ, 2008, CLIN CANCER RES, V14, P3408, DOI 10.1158/1078-0432.CCR-07-1489
   Issa JP, 2004, NAT REV CANCER, V4, P988, DOI 10.1038/nrc1507
   Joneson T, 1997, J MOL MED-JMM, V75, P587, DOI 10.1007/s001090050143
   Jover R, 2011, GASTROENTEROLOGY, V140, P1174, DOI 10.1053/j.gastro.2010.12.035
   Kalady MF, 2012, DIS COLON RECTUM, V55, P128, DOI 10.1097/DCR.0b013e31823c08b3
   Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534
   Lee S, 2008, PATHOL INT, V58, P104, DOI 10.1111/j.1440-1827.2007.02197.x
   Li WQ, 2006, MOL CANCER, V5, DOI 10.1186/1476-4598-5-2
   Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704
   Min BH, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-344
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   Naguib A, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-99
   Ogino S, 2006, MODERN PATHOL, V19, P59, DOI 10.1038/modpathol.3800482
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Oliveira C, 2003, ONCOGENE, V22, P9192, DOI 10.1038/sj.onc.1207061
   Popat S, 2005, J CLIN ONCOL, V23, P609, DOI 10.1200/JCO.2005.01.086
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Rajagopalan H, 2002, NATURE, V418, P934, DOI 10.1038/418934a
   Richman SD, 2009, J CLIN ONCOL, V27, P5931, DOI 10.1200/JCO.2009.22.4295
   Roberts PJ, 2007, ONCOGENE, V26, P3291, DOI 10.1038/sj.onc.1210422
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Sinicrope FA, 2015, GASTROENTEROLOGY, V148, P88, DOI 10.1053/j.gastro.2014.09.041
   Soulières D, 2010, CURR ONCOL, V17, pS31
   Thibodeau SN, 1998, CANCER RES, V58, P1713
   THIBODEAU SN, 1993, SCIENCE, V260, P816, DOI 10.1126/science.8484122
   Tie J, 2011, INT J CANCER, V128, P2075, DOI 10.1002/ijc.25555
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Veigl ML, 1998, P NATL ACAD SCI USA, V95, P8698, DOI 10.1073/pnas.95.15.8698
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wang L, CANC RES
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yaeger R, 2014, CANCER-AM CANCER SOC, V120, P2316, DOI 10.1002/cncr.28729
   Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941
NR 59
TC 164
Z9 174
U1 0
U2 8
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2078-6891
EI 2219-679X
J9 J GASTROINTEST ONCOL
JI J. Gastrointest. Oncol.
PD DEC
PY 2015
VL 6
IS 6
BP 660
EP 667
DI 10.3978/j.issn.2078-6891.2015.077
PG 8
WC Oncology; Gastroenterology & Hepatology
WE Emerging Sources Citation Index (ESCI)
SC Oncology; Gastroenterology & Hepatology
GA CZ2AW
UT WOS:000366908400012
PM 26697199
DA 2025-01-04
ER

PT J
AU Rogers, JT
   Brown, RE
   Buryanek, JJ
   Weerasinghe, P
AF Rogers, John Thomas
   Brown, Robert E.
   Buryanek, Jamie Jay
   Weerasinghe, Priya
TI Morphoproteomic-Guided Treatment of Chemotherapy Resistant Colon Cancer
   using Natural Based Therapies: A Case Study
SO ANNALS OF CLINICAL AND LABORATORY SCIENCE
LA English
DT Article
ID EXPRESSION; CURCUMIN; TUMORS
AB Colorectal cancer was estimated to have the fourth newest incident rate and to have the second highest death rate in 2015 according to the American Cancer Society. There were an estimated 132,700 new diagnoses of colorectal cancer made and approximately 69,000 deaths in 2015 attributing to this form of cancer. 5-fluorouracil (5-FU) or 5-FU with oxaliplatin (FOLFOX) continues to be the standard treatment protocol for patients presenting with colorectal cancer. However, treatment with FOLFOX and conventional chemotherapy has shown to lead to cancer recurrence and a number of toxic side effects. Alternative therapies based on natural ingredients show promise in combating cancer by inhibiting tumorigenic pathways, such as mTORC (mammalian target of rapamycin complex), c-MYC oncogene, and the COX-2 pathway. Using natural based agents and morphoproteomic-guided targeted therapy, the goal of this study was to evaluate the effectiveness of such an approach in a chemotherapy resistant, colon cancer patient. This case report describes a 46-year old woman with a non-metastasizing colorectal cancer that showed "minimal treatment effect" with chemotherapy despite being compliant. As of May 2016, CT scans and colonoscopy confirmed that the cancer was in remission after that patient had been compliant with morphoproteomic-guided, natural therapies for nine months.
C1 [Rogers, John Thomas; Brown, Robert E.; Buryanek, Jamie Jay; Weerasinghe, Priya] UTHlth McGovern Med Sch, Dept Pathol & Lab Med, Houston, TX USA.
RP Weerasinghe, P (corresponding author), Univ Texas Houston, McGovern Med Sch, Dept Pathol & Lab Med, 6431 Fannin St,MSB 2-126, Houston, TX 77030 USA.
EM Priya.Weerasinghe@uth.tmc.edu
CR Algire C, 2010, ENDOCR-RELAT CANCER, V17, P351, DOI 10.1677/ERC-09-0252
   Anisimov VN, 2000, EXP TOXICOL PATHOL, V52, P71, DOI 10.1016/S0940-2993(00)80022-6
   [Anonymous], 2015, CANC FACTS FIG 2015
   Aviello G, 2010, J CELL MOL MED, V14, P2006, DOI 10.1111/j.1582-4934.2009.00815.x
   Brown RE, 2005, EXPERT REV PROTEOMIC, V2, P337, DOI 10.1586/14789450.2.3.337
   Brown RE, 2009, ARCH PATHOL LAB MED, V133, P568, DOI 10.1043/1543-2165-133.4.568
   Chen MJ, 2012, EVID-BASED COMPL ALT, V2012, P1, DOI 10.1155/2012/415231
   Jia BX, 2012, J NANOMATER, V2012, DOI 10.1155/2012/796815
   Karnevi E, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-235
   Klampfer L, 2014, WORLD J GASTRO ONCOL, V6, P430, DOI 10.4251/wjgo.v6.i11.430
   Kunnumakkara AB, 2009, INT J CANCER, V125, P2187, DOI 10.1002/ijc.24593
   Sharma RA, 2004, CLIN CANCER RES, V10, P6847, DOI 10.1158/1078-0432.CCR-04-0744
   Shi XJ, 2015, INT J MOL MED, V35, P31, DOI 10.3892/ijmm.2014.1997
   Wang YM, 2012, CANCER CHEMOTH PHARM, V69, P1213, DOI 10.1007/s00280-012-1828-8
NR 14
TC 0
Z9 0
U1 0
U2 3
PU ASSOC CLINICAL SCIENTISTS
PI MIDDLEBURY
PA PO BOX 1287, MIDDLEBURY, VT 05753 USA
SN 0091-7370
EI 1550-8080
J9 ANN CLIN LAB SCI
JI Ann. Clin. Lab. Sci.
PD MAR-APR
PY 2017
VL 47
IS 2
BP 217
EP 220
PG 4
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA ET1EY
UT WOS:000400010900016
PM 28442526
DA 2025-01-04
ER

PT J
AU Razenberg, LGEM
   van Gestel, YRBM
   de Hingh, IHJT
   Loosveld, OJL
   Vreugdenhil, G
   Beerepoot, LV
   Creemers, GJ
   Lemmens, VEPP
AF Razenberg, L. G. E. M.
   van Gestel, Y. R. B. M.
   de Hingh, I. H. J. T.
   Loosveld, O. J. L.
   Vreugdenhil, G.
   Beerepoot, L. V.
   Creemers, G. J.
   Lemmens, V. E. P. P.
TI Bevacizumab for metachronous metastatic colorectal cancer: a reflection
   of community based practice
SO BMC CANCER
LA English
DT Article
DE Colorectal cancer; Metachronous metastases; Palliative; Chemotherapy;
   Targeted therapy; Bevacizumab
ID RANDOMIZED PHASE-III; COLON-CANCER; COMBINATION CHEMOTHERAPY; PLUS
   IRINOTECAN; FLUOROURACIL; OXALIPLATIN; LEUCOVORIN; CAPECITABINE;
   NETHERLANDS; SURVIVAL
AB Background: Although the efficacy of bevacizumab has been established in patients with metastatic colorectal cancer (mCRC), population-based studies are needed to gain insight into the actual implementation of bevacizumab in daily practice. Since these studies are lacking for patients with metachronous metastases, the aim of this study is to evaluate the current role of bevacizumab in the treatment of metachronous metastases of CRC.
   Methods: Data on the use of bevacizumab as palliative treatment of metachronous metastases were collected for patients diagnosed with M0 CRC between 2003 and 2008 in the Eindhoven Cancer Registry (n = 361). Median follow up was 5.3 years.
   Results: One hundred eighty-five patients received bevacizumab in addition to first-line palliative chemotherapy (51 %), ranging from 36 % to 80 % between hospitals of diagnosis (p < 0.0001). Combined cytostatic regimens (CAPOX/FOLFOX in 97 %) were prescribed in the majority of patients (63 %) and were associated with a higher odds for additional treatment with bevacizumab than single-agent cytostatic regimens (OR 9.9, 95 % CI 5.51-18.00). Median overall survival (OS) rates were 21.6 and 13.9 months with and without the addition of bevacizumab to palliative systemic treatment respectively (p < 0.0001). The addition of bevacizumab to palliative chemotherapy was associated with a reduced hazard ratio for death (HR 0.6, 95 % CI 0.45-0.73) after adjustment for patient- and tumor characteristics and the prescribed chemotherapeutic regimen.
   Conclusion: Bevacizumab is adopted as a therapeutic option for metachronous metastasized CRC mainly in addition to first-line oxaliplatin-based regimens, and was associated with a reduced risk of death. The presence of inter-hospital differences in the prescription of bevacizumab reflected important differences in attitude and policies in clinical practice. Ongoing efforts should be made to further define the position of targeted agents in the treatment of metastatic colorectal cancer.
C1 [Razenberg, L. G. E. M.; Creemers, G. J.] Catharina Hosp, Dept Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands.
   [Razenberg, L. G. E. M.; van Gestel, Y. R. B. M.; Lemmens, V. E. P. P.] Netherlands Comprehens Canc Org IKNL, Godebaldkwartier 419, NL-3511 DT Utrecht, Netherlands.
   [de Hingh, I. H. J. T.] Catharina Hosp, Dept Surg, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands.
   [Loosveld, O. J. L.] Amphia Hosp, Dept Oncol, Langendijk 75, NL-4819 EV Breda, Netherlands.
   [Vreugdenhil, G.] Maxima Med Ctr, Dept Oncol, De Run 4600, NL-5504 DB Veldhoven, Netherlands.
   [Beerepoot, L. V.] Elisabeth TweeSteden Hosp, Dept Oncol, Hilvarenbeekse Weg 60, NL-5022 GC Tilburg, Netherlands.
   [Lemmens, V. E. P. P.] Erasmus MC Univ, Med Ctr, Dept Publ Hlth, Wytemaweg 8, NL-3015 CN Rotterdam, Netherlands.
C3 Catharina Hospital; Catharina Hospital; Amphia Hospital; Maxima Medical
   Center; Elisabeth-TweeSteden Ziekenhuis (ETZ); Erasmus University
   Rotterdam; Erasmus MC
RP Razenberg, LGEM (corresponding author), Catharina Hosp, Dept Oncol, Michelangelolaan 2, NL-5623 EJ Eindhoven, Netherlands.; Razenberg, LGEM (corresponding author), Netherlands Comprehens Canc Org IKNL, Godebaldkwartier 419, NL-3511 DT Utrecht, Netherlands.
EM lieke.razenberg@catharinaziekenhuis.nl
OI De Hingh, Ignace/0000-0003-3491-4268; Beerepoot, Laurens
   Victor/0000-0002-3040-4626
FU Netherlands Organisation for Health Research and Development (ZonMw)
   [152002012, 152001022]; Roche Pharameuticals
FX The study was financed by a grand from the Netherlands Organisation for
   Health Research and Development (ZonMw), project numbers 152002012 and
   152001022 and was supported by an unrestricted grant from Roche
   Pharameuticals. Both funders did not have any involvement in the study
   design, data collection, data analysis, data interpretation and writing
   of the report. Moreover, the decision to submit for publication was made
   independently by the authors.
CR Alves A, 2005, ARCH SURG-CHICAGO, V140, P278, DOI 10.1001/archsurg.140.3.278
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   BOM C, 2005, MED ONCOLOGIE, V2, P43
   BOM C, 2004, MED ONCOLOGIE, V4, P45
   BOM C, 2001, MED ONCOLOGIE, V1, P30
   BOM C, 2011, MED ONCOLOGIE, V5, P29
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Khattak MA, 2012, EUR J CANCER, V48, P1293, DOI 10.1016/j.ejca.2011.09.029
   Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1
   Kozloff M, 2009, ONCOLOGIST, V14, P862, DOI 10.1634/theoncologist.2009-0071
   Kozloff MF, 2010, ONCOLOGY-BASEL, V78, P329, DOI 10.1159/000320222
   Kumar R, 2014, CLIN COLORECTAL CANC, V13, P87, DOI 10.1016/j.clcc.2013.11.008
   Lemmens V, 2010, ACTA ONCOL, V49, P784, DOI 10.3109/02841861003733713
   lves A, 2005, ARCH SURG-CHICAGO, V140, P84
   Macedo LT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-89
   McArdle C, 2000, BRIT MED J, V321, P1332, DOI 10.1136/bmj.321.7272.1332
   McKibbin T, 2008, ONCOLOGIST, V13, P876, DOI 10.1634/theoncologist.2008-0061
   Mekenkamp LJM, 2010, BRIT J CANCER, V103, P159, DOI 10.1038/sj.bjc.6605737
   Meulenbeld HJ, 2008, ANN ONCOL, V19, P1600, DOI 10.1093/annonc/mdn176
   Meyerhardt JA, 2012, J CLIN ONCOL, V30, P608, DOI 10.1200/JCO.2011.38.9650
   Mols F, 2013, J CLIN ONCOL, V31, P2699, DOI 10.1200/JCO.2013.49.1514
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Sclafani F, 2014, J GERIATR ONCOL, V5, P78, DOI 10.1016/j.jgo.2013.08.006
   Slesser AAP, 2013, CLIN EXP METASTAS, V30, P457, DOI 10.1007/s10585-012-9551-8
   Tebbutt NC, 2010, J CLIN ONCOL, V28, P3191, DOI 10.1200/JCO.2009.27.7723
   UICC, 2009, TNM CLASSIFICATION M
   Van Cutsem E, 2009, ANN ONCOL, V20, P1842, DOI 10.1093/annonc/mdp233
   van der Pool AEM, 2012, COLORECTAL DIS, V14, P56, DOI 10.1111/j.1463-1318.2010.02539.x
NR 31
TC 8
Z9 8
U1 0
U2 3
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD FEB 16
PY 2016
VL 16
AR 110
DI 10.1186/s12885-016-2158-8
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DD9EL
UT WOS:000370228400004
PM 26882902
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Sun, J
   Tian, Y
   Yang, CQ
AF Sun, Jing
   Tian, Yan
   Yang, Changqing
TI Target therapy of TIGIT; a novel approach of immunotherapy for the
   treatment of colorectal cancer
SO NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY
LA English
DT Review; Early Access
DE Immune checkpoint; TIGIT; Colorectal cancer; Cancer immunotherapy;
   Clinical trial
ID T-CELL IMMUNOGLOBULIN; IMMUNE MICROENVIRONMENT; ITIM DOMAIN; ADHESION;
   NECTINS; OVEREXPRESSION; CYTOTOXICITY; COMBINATION; EXHAUSTION;
   RECEPTORS
AB The T cell immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domain (TIGIT), a newly discovered checkpoint, is characterized by its elevated expression on CD4 + T cells, CD8 + T cells, natural killer (NK) cells, regulatory T cells (Tregs), and tumor-infiltrating lymphocytes (TILs). Research to date has been shown that TIGIT has been linked to exhaustion of NK cell both and T cells in numerous cancers. CD155, being the specific ligand of TIGIT in humans, emerges as a key target for immunotherapy owing to its crucial interaction with TIGIT. Furthermore, numerous studies have demonstrated that the combination of TIGIT with other immune checkpoint inhibitors (ICIs) and/or traditional treatments elicits a potent antitumor response in colorectal cancer (CRC). This review provides an overview of the structure, function, and signaling pathways associated with TIGIT across multiple immune system cell types. Additionally, focusing on the role of TIGIT in the progression of CRC, this study reviewed various studies exploring TIGIT-based immunotherapy in CRC.
C1 [Sun, Jing; Tian, Yan; Yang, Changqing] Changzhi Med Coll, Heping Hosp, Dept Gastroenterol, Changzhi 046000, Peoples R China.
C3 Changzhi Medical College
RP Yang, CQ (corresponding author), Changzhi Med Coll, Heping Hosp, Dept Gastroenterol, Changzhi 046000, Peoples R China.
EM ycq1234562024@126.com
CR Annese T, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.871085
   Bevelacqua V, 2012, ONCOTARGET, V3, P879
   Bi JC, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01999
   Blackburn SD, 2009, NAT IMMUNOL, V10, P29, DOI 10.1038/ni.1679
   Blessin NC, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/5160565
   Boles KS, 2009, EUR J IMMUNOL, V39, P695, DOI 10.1002/eji.200839116
   Cai HZ, 2022, BIOMARK RES, V10, DOI 10.1186/s40364-022-00413-0
   Chauvin JM, 2020, CLIN CANCER RES, V26, P5520, DOI 10.1158/1078-0432.CCR-20-0575
   Chauvin JM, 2015, J CLIN INVEST, V125, P2046, DOI 10.1172/JCI80445
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen FZ, 2020, CANCER MED-US, V9, P3584, DOI 10.1002/cam4.2976
   Chen X, 2016, IMMUNOBIOLOGY, V221, P48, DOI 10.1016/j.imbio.2015.08.003
   Chen X, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.828319
   Chiang EY, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-004711
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Eso Y, 2020, J GASTROENTEROL, V55, P15, DOI 10.1007/s00535-019-01620-7
   Fathi M, 2021, IUBMB LIFE, V73, P726, DOI 10.1002/iub.2461
   Fuchs A, 2006, SEMIN CANCER BIOL, V16, P359, DOI 10.1016/j.semcancer.2006.07.002
   Fuhrman CA, 2015, J IMMUNOL, V195, P145, DOI 10.4049/jimmunol.1402381
   Galletti G, 2020, NAT IMMUNOL, V21, P1552, DOI 10.1038/s41590-020-0791-5
   Gattinoni L, 2011, NAT MED, V17, P1290, DOI 10.1038/nm.2446
   Ge ZH, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.699895
   Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075
   Grapin M, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0634-9
   Gu-Trantien C, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.91487
   Gu-Trantien C, 2013, J CLIN INVEST, V123, P2873, DOI 10.1172/JCI67428
   Guillerey C, 2018, BLOOD, V132, P1689, DOI 10.1182/blood-2018-01-825265
   Hansen K, 2021, CANCER IMMUNOL IMMUN, V70, P3525, DOI 10.1007/s00262-021-02921-8
   Harjunpää H, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1445949
   Hassandokht Mashhadi Morteza, 2024, Iran J Pathol, V19, P1, DOI 10.30699/IJP.2023.1999459.3093
   He WL, 2017, CANCER RES, V77, P6375, DOI 10.1158/0008-5472.CAN-17-0381
   Hutloff A, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01707
   Irie K, 2004, HANDB EXP PHARM, V165, P343, DOI 10.1007/978-3-540-68170-0_11
   Irie K, 2004, SEMIN CELL DEV BIOL, V15, P643, DOI 10.1016/j.semcdb.2004.09.002
   Jameson SC, 2018, IMMUNITY, V48, P214, DOI 10.1016/j.immuni.2018.02.010
   Javid H, 2023, FUTURE MICROBIOL, V18, P1197, DOI 10.2217/fmb-2023-0076
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Johnston RJ, 2014, CANCER CELL, V26, P923, DOI 10.1016/j.ccell.2014.10.018
   Joller N, 2017, CURR TOP MICROBIOL, V410, P127, DOI 10.1007/82_2017_62
   Joller N, 2014, IMMUNITY, V40, P569, DOI 10.1016/j.immuni.2014.02.012
   Joller N, 2011, J IMMUNOL, V186, P1338, DOI 10.4049/jimmunol.1003081
   Judge SJ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001355
   Kallies A, 2020, NAT REV IMMUNOL, V20, P128, DOI 10.1038/s41577-019-0223-7
   Kawashima S, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003134
   Kloor M, 2010, INT J CANCER, V127, P1001, DOI 10.1002/ijc.25283
   Koi M, 2017, FUTURE ONCOL, V13, P1633, DOI 10.2217/fon-2017-0145
   Kurtulus S, 2015, J CLIN INVEST, V125, P4053, DOI 10.1172/JCI81187
   Levin SD, 2011, EUR J IMMUNOL, V41, P902, DOI 10.1002/eji.201041136
   Li M, 2014, J BIOL CHEM, V289, P17647, DOI 10.1074/jbc.M114.572420
   Li SS, 2022, J GASTROEN HEPATOL, V37, P154, DOI 10.1111/jgh.15730
   Li X, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01066
   Liu L, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03480-x
   Liu S, 2013, CELL DEATH DIFFER, V20, P456, DOI 10.1038/cdd.2012.141
   Liu XL, 2019, CANCER IMMUNOL IMMUN, V68, P2041, DOI 10.1007/s00262-019-02426-5
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Lozano E, 2012, J IMMUNOL, V188, P3869, DOI 10.4049/jimmunol.1103627
   Lucca LE, 2020, NAT REV IMMUNOL, V20, P680, DOI 10.1038/s41577-020-0296-3
   Lucca LE, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.124427
   Ma B, 2019, J CELL MOL MED, V23, P4514, DOI 10.1111/jcmm.14332
   Mao L, 2021, ORAL ONCOL, V121, DOI 10.1016/j.oraloncology.2021.105472
   Masson D, 2001, GUT, V49, P236, DOI 10.1136/gut.49.2.236
   Mettu NB, 2022, CLIN CANCER RES, V28, P882, DOI 10.1158/1078-0432.CCR-21-2780
   Michel S, 2010, INT J CANCER, V127, P889, DOI 10.1002/ijc.25106
   Mueller SN, 2013, ANNU REV IMMUNOL, V31, P137, DOI 10.1146/annurev-immunol-032712-095954
   Nair VS, 2017, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0539-3
   Niu J, 2022, ANN ONCOL, V33, P169, DOI 10.1016/j.annonc.2021.11.002
   Oshima T, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-60
   Pompura SL, 2018, J LEUKOCYTE BIOL, V103, P1065, DOI 10.1002/JLB.2MIR0817-349R
   Rastin F, 2024, J MATER CHEM B, V12, P872, DOI 10.1039/d3tb02471g
   Rastin F, 2024, INT IMMUNOPHARMACOL, V126, DOI 10.1016/j.intimp.2023.111055
   Reches A, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000266
   Rotte A, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091277
   Safran M, 2010, DATABASE-OXFORD, DOI 10.1093/database/baq020
   Sakisaka T, 2004, CURR OPIN CELL BIOL, V16, P513, DOI 10.1016/j.ceb.2004.07.007
   Seth S, 2009, EUR J IMMUNOL, V39, P3160, DOI 10.1002/eji.200939470
   Seyedzade SA, 2024, BIONANOSCIENCE, V14, P485, DOI 10.1007/s12668-023-01270-3
   Shao Q, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.688961
   Stamm H, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1674605
   Stanietsky N, 2013, EUR J IMMUNOL, V43, P2138, DOI 10.1002/eji.201243072
   Stanietsky N, 2009, P NATL ACAD SCI USA, V106, P17858, DOI 10.1073/pnas.0903474106
   Stengel KF, 2012, P NATL ACAD SCI USA, V109, P5399, DOI 10.1073/pnas.1120606109
   Svrcek M, 2019, B CANCER, V106, P119, DOI 10.1016/j.bulcan.2018.12.008
   Teillaud JL, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.00830
   Türeci Ö, 2016, CLIN CANCER RES, V22, P1885, DOI 10.1158/1078-0432.CCR-15-1509
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van den Mooter TFA, 2021, CANCER RES, V81
   Walsh SR, 2019, J CLIN INVEST, V129, P5400, DOI 10.1172/JCI126199
   Wang YC, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01325-0
   Wen J, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-01933-9
   Wherry EJ, 2015, NAT REV IMMUNOL, V15, P486, DOI 10.1038/nri3862
   Xu LL, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01307-2
   Xu MX, 2020, ADV EXP MED BIOL, V1244, P37, DOI 10.1007/978-3-030-41008-7_2
   Xu XZ, 2021, ELIFE, V10, DOI [10.7554/eLife.74276, 10.7554/eLife.74276.sa0, 10.7554/eLife.74276.sa1, 10.7554/eLife.74276.sa2]
   Yin XX, 2020, AM J TRANSL RES, V12, P5416
   Yoo KJ, 2022, J IMMUNOL, V209, P510, DOI 10.4049/jimmunol.2101175
   Yu X, 2009, NAT IMMUNOL, V10, P48, DOI 10.1038/ni.1674
   Zappasodi R, 2018, CANCER CELL, V33, P581, DOI 10.1016/j.ccell.2018.03.005
   Zaravinos A, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1372-z
   Zarour HM, 2016, CLIN CANCER RES, V22, P1856, DOI 10.1158/1078-0432.CCR-15-1849
   Zhang P, 2024, BIOMARK RES, V12, DOI 10.1186/s40364-023-00543-z
   Zhang Q, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20204340
   Zhang Q, 2018, NAT IMMUNOL, V19, P723, DOI 10.1038/s41590-018-0132-0
   Zhang Y, 2020, CANCERS, V12, DOI 10.3390/cancers12092471
   Zhou XW, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-020-00701-y
   Zhou XM, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.02821
   Zhou XM, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11050706
   Zuo SG, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002843
NR 108
TC 0
Z9 0
U1 4
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0028-1298
EI 1432-1912
J9 N-S ARCH PHARMACOL
JI Naunyn-Schmiedebergs Arch. Pharmacol.
PD 2024 AUG 19
PY 2024
DI 10.1007/s00210-024-03346-7
EA AUG 2024
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA D0X3B
UT WOS:001293495300002
PM 39158733
DA 2025-01-04
ER

PT J
AU Crimini, E
   Bielo, LB
   Giachetti, PPMB
   Pellizzari, G
   Antonarelli, G
   Salimbeni, BT
   Repetto, M
   Belli, C
   Curigliano, G
AF Crimini, Edoardo
   Bielo, Luca Boscolo
   Giachetti, Pier Paolo Maria Berton
   Pellizzari, Gloria
   Antonarelli, Gabriele
   Salimbeni, Beatrice Taurelli
   Repetto, Matteo
   Belli, Carmen
   Curigliano, Giuseppe
TI Beyond PD(L)-1 Blockade in Microsatellite-Instable Cancers: Current
   Landscape of Immune Co-Inhibitory Receptor Targeting
SO CANCERS
LA English
DT Review
DE cancer; microsatellite instability; immunotherapy; PD-L1; precision
   oncology; drug development; target therapy; combination treatment;
   biomarkers; agnostic
ID MISMATCH REPAIR-DEFICIENT; SOLID TUMORS; INSTABILITY; REGULATOR;
   NIVOLUMAB; RESPONSES; EFFICACY; PKM2; IG; EXPRESSION
AB High microsatellite instability (MSI-H) derives from genomic hypermutability due to deficient mismatch repair function. Colorectal (CRC) and endometrial cancers (EC) are the tumor types that more often present MSI-H. Anti-PD(L)-1 antibodies have been demonstrated to be agnostically effective in patients with MSI-H cancer, but 50-60% of them do not respond to single-agent treatment, highlighting the necessity of expanding their treatment opportunities. Ipilimumab (anti-CTLA4) is the only immune checkpoint inhibitor (ICI) non-targeting PD(L)-1 that has been approved so far by the FDA for MSI-H cancer, namely, CRC in combination with nivolumab. Anti-TIM3 antibody LY3321367 showed interesting clinical activity in combination with anti-PDL-1 antibody in patients with MSI-H cancer not previously treated with anti-PD(L)-1. In contrast, no clinical evidence is available for anti-LAG3, anti-TIGIT, anti-BTLA, anti-ICOS and anti-IDO1 antibodies in MSI-H cancers, but clinical trials are ongoing. Other immunotherapeutic strategies under study for MSI-H cancers include vaccines, systemic immunomodulators, STING agonists, PKM2 activators, T-cell immunotherapy, LAIR-1 immunosuppression reversal, IL5 superagonists, oncolytic viruses and IL12 partial agonists. In conclusion, several combination therapies of ICIs and novel strategies are emerging and may revolutionize the treatment paradigm of MSI-H patients in the future. A huge effort will be necessary to find reliable immune biomarkers to personalize therapeutical decisions.
C1 [Crimini, Edoardo; Bielo, Luca Boscolo; Giachetti, Pier Paolo Maria Berton; Pellizzari, Gloria; Antonarelli, Gabriele; Salimbeni, Beatrice Taurelli; Belli, Carmen; Curigliano, Giuseppe] European Inst Oncol, Div Early Drug Dev, IRCCS, Via Giuseppe Ripamonti 435, I-20141 Milan, Italy.
   [Crimini, Edoardo; Bielo, Luca Boscolo; Giachetti, Pier Paolo Maria Berton; Pellizzari, Gloria; Antonarelli, Gabriele; Curigliano, Giuseppe] Univ Milan, Dept Oncol & Hemato Oncol, I-20122 Milan, Italy.
   [Repetto, Matteo] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
C3 IRCCS European Institute of Oncology (IEO); University of Milan;
   Memorial Sloan Kettering Cancer Center
RP Crimini, E; Curigliano, G (corresponding author), European Inst Oncol, Div Early Drug Dev, IRCCS, Via Giuseppe Ripamonti 435, I-20141 Milan, Italy.; Crimini, E; Curigliano, G (corresponding author), Univ Milan, Dept Oncol & Hemato Oncol, I-20122 Milan, Italy.
EM edoardo.crimini@ieo.it; gloria.pellizzari@ieo.it;
   gabriele.antonarelli@ieo.it; giuseppe.curigliano@ieo.it
RI Repetto, Matteo/AAB-2012-2021; Crimini, Edoardo/AAB-3610-2021; Belli,
   Carmen/LQK-0686-2024; Curigliano, Giuseppe/D-3371-2018
OI Taurelli Salimbeni, Beatrice/0000-0002-7345-4148; Pellizzari,
   Gloria/0009-0002-5733-2316; Berton Giachetti, Pier Paolo
   Maria/0000-0001-5559-7279; Belli, Carmen/0000-0001-7067-7496;
   Curigliano, Giuseppe/0000-0003-1781-2518; Crimini,
   Edoardo/0000-0002-1869-0607
CR Amato M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23158726
   AndrT T, 2022, ANN ONCOL, V33, P1052, DOI 10.1016/j.annonc.2022.06.008
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Andre T, 2023, FUTURE ONCOL, V19, P2445, DOI 10.2217/fon-2022-1105
   Andre T, 2022, J CLIN ONCOL, V40
   Andre T, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.9
   Antosova Z, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.989895
   Azadi A, 2021, BIOL PROCED ONLINE, V23, DOI 10.1186/s12575-021-00147-7
   Ballhausen A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18514-5
   Banerjee Hridesh, 2018, F1000Res, V7, P316, DOI 10.12688/f1000research.13446.1
   Bartley AN, 2022, ARCH PATHOL LAB MED, V146, P1194, DOI 10.5858/arpa.2021-0632-CP
   Belli C, 2022, CANCERS, V14, DOI 10.3390/cancers14174278
   Berraondo P, 2019, BRIT J CANCER, V120, P6, DOI 10.1038/s41416-018-0328-y
   Bever K, 2022, J IMMUNOTHER CANCER, V10, pA744, DOI 10.1136/jitc-2022-SITC2022.0711
   Blake SJ, 2016, CLIN CANCER RES, V22, P5183, DOI 10.1158/1078-0432.CCR-16-0933
   Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6
   Buchbinder EI, 2016, AM J CLIN ONCOL-CANC, V39, P98, DOI 10.1097/COC.0000000000000239
   Cai DL, 2020, CELL MOL IMMUNOL, V17, P227, DOI 10.1038/s41423-019-0305-2
   Chakravarti S, 2005, J EXP MED, V202, P437, DOI 10.1084/jem.20050308
   Chamie K, 2022, J CLIN ONCOL, V40
   Champiat S, 2022, J IMMUNOTHER CANCER, V10, pA749, DOI 10.1136/jitc-2022-SITC2022.0716
   Champiat S, 2022, CANCER RES, V82
   Chang CC, 2002, NAT IMMUNOL, V3, P237, DOI 10.1038/ni760
   Chauvin JM, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000957
   Chen MX, 2021, J CANCER, V12, P3566, DOI 10.7150/jca.54430
   Chhipa A, 2021, LIFE SCI, V280, DOI 10.1016/j.lfs.2021.119694
   Corrales L, 2016, J CLIN INVEST, V126, P2404, DOI 10.1172/JCI86892
   de Goeje PL, 2015, ONCOIMMUNOLOGY, V4, DOI 10.1080/2162402X.2015.1014242
   de Gruijl TD, 2015, EXPERT OPIN BIOL TH, V15, P959, DOI 10.1517/14712598.2015.1044433
   Deng Mi, 2021, Antib Ther, V4, P16, DOI 10.1093/abt/tbab002
   Dorigo O, 2020, J CLIN ONCOL, V38
   Eckert KA, 2009, MOL CARCINOGEN, V48, P379, DOI 10.1002/mc.20499
   Fakih M, 2022, J CLIN ONCOL, V40
   Fourcade J, 2010, J EXP MED, V207, P2175, DOI 10.1084/jem.20100637
   Fousek K, 2023, J THORAC ONCOL, V18, P350, DOI 10.1016/j.jtho.2022.11.008
   Fu J, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4306
   Garralda E, 2022, J CLIN ONCOL, V40
   Graydon CG, 2021, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.615317
   Han GC, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00449
   Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191
   Hemminki O, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00922-1
   Hernandez-Sanchez A, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-004416
   Hollebecque A, 2021, CLIN CANCER RES, V27, P6393, DOI 10.1158/1078-0432.CCR-21-0261
   Horn LA, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI155148
   Hosseinkhani N, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.676181
   Hsu MC, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0791-3
   Huo JL, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.956090
   Jafari M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1012806
   Kane LP, 2010, J IMMUNOL, V184, P2743, DOI 10.4049/jimmunol.0902937
   Kim TW, 2023, JAMA ONCOL, V9, P1574, DOI 10.1001/jamaoncol.2023.3867
   Klein C, 2016, MABS-AUSTIN, V8, P1010, DOI 10.1080/19420862.2016.1197457
   Kloor M, 2020, CLIN CANCER RES, V26, P4503, DOI 10.1158/1078-0432.CCR-19-3517
   Kloor M, 2016, TRENDS CANCER, V2, P121, DOI 10.1016/j.trecan.2016.02.004
   Knudson KM, 2020, EXPERT OPIN BIOL TH, V20, P705, DOI 10.1080/14712598.2020.1738379
   Kobayashi N, 2007, IMMUNITY, V27, P927, DOI 10.1016/j.immuni.2007.11.011
   Koyama S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10501
   Kunac N, 2023, CANCERS, V15, DOI 10.3390/cancers15010221
   Lan QS, 2020, FRONT MED-PRC, V14, P160, DOI 10.1007/s11684-020-0750-4
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lebbink RJ, 2008, J IMMUNOL, V180, P1662, DOI 10.4049/jimmunol.180.3.1662
   Lemery S, 2017, NEW ENGL J MED, V377, P1409, DOI 10.1056/NEJMp1709968
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Linsley PS, 1996, IMMUNITY, V4, P535, DOI 10.1016/S1074-7613(00)80480-X
   Liu S, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/1202797
   Liu YJ, 2021, EUR J MED CHEM, V211, DOI 10.1016/j.ejmech.2020.113113
   LOEB LA, 1994, CANCER RES, V54, P5059
   Malogolovkin A, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071271
   Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105
   Marcus VA, 1999, AM J SURG PATHOL, V23, P1248, DOI 10.1097/00000478-199910000-00010
   Maruhashi T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001014
   Mehta N, 2019, CELL REP, V28, P2509, DOI 10.1016/j.celrep.2019.07.073
   Murphy KM, 2006, NAT REV IMMUNOL, V6, P671, DOI 10.1038/nri1917
   Neoadjuvant, Immune Checkpoint Inhibition in Locally Advanced MMR-Deficient Colon Cancer: The NICHE-2 Study|OncologyPRO
   Ng KW, 2018, TRENDS IMMUNOL, V39, P44, DOI 10.1016/j.it.2017.07.013
   Ning ZC, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.654960
   Oaknin A, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003777
   Olave MC, 2022, GENE CHROMOSOME CANC, V61, P314, DOI 10.1002/gcc.23015
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Oyewole-Said D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.608024
   Pietrantonio F, 2023, J CLIN ONCOL, V41, P358
   Prasad DVR, 2004, J IMMUNOL, V173, P2500, DOI 10.4049/jimmunol.173.4.2500
   Pu FF, 2021, ONCOTARGETS THER, V14, P1501, DOI 10.2147/OTT.S298958
   Ren Y, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.961796
   Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027
   Rosser CJ, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.6_suppl.510
   Roudko V, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.757804
   Shayan G, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1261779
   Sommakia S, 2022, EUR J CANCER, V174, pS47
   Subramanian S, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-r13
   Svrcek M, 2019, B CANCER, V106, P119, DOI 10.1016/j.bulcan.2018.12.008
   Van der Meer JMR, 2021, CANCER IMMUNOL IMMUN, V70, P1305, DOI 10.1007/s00262-020-02749-8
   Verschoor YL, 2022, J CLIN ONCOL, V40
   Vikas P, 2023, J CLIN ONCOL, V41, P1943, DOI 10.1200/JCO.22.02462
   Vlad G, 2009, HUM IMMUNOL, V70, P340, DOI 10.1016/j.humimm.2009.03.004
   Waldmann TA, 2015, CANCER IMMUNOL RES, V3, P219, DOI 10.1158/2326-6066.CIR-15-0009
   Walker LSK, 2011, NAT REV IMMUNOL, V11, P852, DOI 10.1038/nri3108
   Warner SL, 2014, FUTURE MED CHEM, V6, P1167, DOI [10.4155/FMC.14.70, 10.4155/fmc.14.70]
   Wolfson B, 2021, VACCINES-BASEL, V9, DOI 10.3390/vaccines9050509
   Wong HL, 2018, FUTURE ONCOL, V14, P2725, DOI 10.2217/fon-2018-0319
   Woo SR, 2014, IMMUNITY, V41, P830, DOI 10.1016/j.immuni.2014.10.017
   Wrangle JM, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.2596
   Wu Z., 2022, Medicine in Drug Discovery, V16, DOI [10.1016/j.medidd.2022.100144, DOI 10.1016/J.MEDIDD.2022.100144]
   Xiang Z, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.883655
   Xu LJ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1740477
   Yang F, 2022, CANCERS, V14, DOI 10.3390/cancers14010109
   Yang S, 2020, INT J BIOL SCI, V16, P1767, DOI 10.7150/ijbs.41105
   Yang Y, 2020, CANCERS, V12, DOI 10.3390/cancers12123586
   Zhang Y, 2012, MOL MED REP, V5, P910, DOI 10.3892/mmr.2012.744
   Zhou WT, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.701006
NR 110
TC 0
Z9 0
U1 1
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JAN
PY 2024
VL 16
IS 2
AR 281
DI 10.3390/cancers16020281
PG 20
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FY0S8
UT WOS:001149301700001
PM 38254772
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Baur, F
   Nietzer, SL
   Kunz, M
   Saal, F
   Jeromin, J
   Matschos, S
   Linnebacher, M
   Walles, H
   Dandekar, T
   Dandekar, G
AF Baur, Florentin
   Nietzer, Sarah L.
   Kunz, Meik
   Saal, Fabian
   Jeromin, Julian
   Matschos, Stephanie
   Linnebacher, Michael
   Walles, Heike
   Dandekar, Thomas
   Dandekar, Gudrun
TI Connecting Cancer Pathways to Tumor Engines: A Stratification Tool for
   Colorectal Cancer Combining Human In Vitro Tissue Models with Boolean In
   Silico Models
SO CANCERS
LA English
DT Article
DE in silico simulation; 3D tissue models; colorectal cancer; BRAF
   mutation; targeted therapy; stratification
ID COLON-CANCER; PROTEIN EXPRESSION; RAF INHIBITORS; BRAF MUTATION; GROWTH;
   VEMURAFENIB; THERAPY; ESTABLISHMENT; INSTABILITY; ACTIVATION
AB To improve and focus preclinical testing, we combine tumor models based on a decellularized tissue matrix with bioinformatics to stratify tumors according to stage-specific mutations that are linked to central cancer pathways. We generated tissue models with BRAF-mutant colorectal cancer (CRC) cells (HROC24 and HROC87) and compared treatment responses to two-dimensional (2D) cultures and xenografts. As the BRAF inhibitor vemurafenib is-in contrast to melanoma-not effective in CRC, we combined it with the EGFR inhibitor gefitinib. In general, our 3D models showed higher chemoresistance and in contrast to 2D a more active HGFR after gefitinib and combination-therapy. In xenograft models murine HGF could not activate the human HGFR, stressing the importance of the human microenvironment. In order to stratify patient groups for targeted treatment options in CRC, an in silico topology with different stages including mutations and changes in common signaling pathways was developed. We applied the established topology for in silico simulations to predict new therapeutic options for BRAF-mutated CRC patients in advanced stages. Our in silico tool connects genome information with a deeper understanding of tumor engines in clinically relevant signaling networks which goes beyond the consideration of single drivers to improve CRC patient stratification.
C1 [Baur, Florentin; Nietzer, Sarah L.; Walles, Heike; Dandekar, Gudrun] Univ Hosp Wurzburg, Chair Tissue Engn & Regenerat Med, Rontgenring 11, D-97070 Wurzburg, Germany.
   [Nietzer, Sarah L.; Walles, Heike; Dandekar, Gudrun] Fraunhofer Inst Silicate Res ISC, Translat Ctr Regenerat Therapies, Rontgenring 11, D-97070 Wurzburg, Germany.
   [Kunz, Meik] Friedrich Alexander Univ Erlangen Nurnberg, Chair Med Informat, D-91058 Erlangen, Germany.
   [Kunz, Meik; Saal, Fabian; Jeromin, Julian; Dandekar, Thomas] Univ Wurzburg, Dept Bioinformat, Bioctr, D-97074 Wurzburg, Germany.
   [Matschos, Stephanie; Linnebacher, Michael] Univ Med Ctr Rostock, Dept Surg Mol Oncol & Immunotherapy, Schillingallee 35, D-18057 Rostock, Germany.
   [Dandekar, Thomas] EMBL Heidelberg, Struct & Computat Biol, Meyerhofstr 1, D-69117 Heidelberg, Germany.
C3 University of Wurzburg; Fraunhofer Gesellschaft; University of Erlangen
   Nuremberg; University of Wurzburg; University of Rostock; European
   Molecular Biology Laboratory (EMBL)
RP Dandekar, G (corresponding author), Univ Hosp Wurzburg, Chair Tissue Engn & Regenerat Med, Rontgenring 11, D-97070 Wurzburg, Germany.; Dandekar, G (corresponding author), Fraunhofer Inst Silicate Res ISC, Translat Ctr Regenerat Therapies, Rontgenring 11, D-97070 Wurzburg, Germany.; Dandekar, T (corresponding author), Univ Wurzburg, Dept Bioinformat, Bioctr, D-97074 Wurzburg, Germany.; Dandekar, T (corresponding author), EMBL Heidelberg, Struct & Computat Biol, Meyerhofstr 1, D-69117 Heidelberg, Germany.
EM baur@em.uni-frankfurt.de; sarah.nietzer@uni-wuerzburg.de;
   meik.kunz@fau.de; fabian.saal@googlemail.com;
   julian.jeromin@stud-mail.uni-wuerzburg.de;
   stephanie.matschos@med.uni-rostock.de;
   michael.linnebacher@med.uni-rostock.de; heike.walles@ovgu.de;
   dandekar@biozentrum.uni-wuerzburg.de; gudrun.dandekar@uni-wuerzburg.de
RI Walles, Heike/M-1289-2015; Linnebacher, Michael/AAT-3763-2021; Dandekar,
   Thomas/A-4431-2017
OI Dandekar, Thomas/0000-0003-1886-7625; Linnebacher,
   Michael/0000-0001-8054-1402
FU Bayern-Fit program until 2019; Federal Ministry of Education and
   Research Era-Net grant [01KT1801]; University of Wurzburg; German
   Research Foundation (DFG)
FX This work was supported by the Bayern-Fit program until 2019 (F.B.,
   S.L.N.) and the Federal Ministry of Education and Research Era-Net grant
   01KT1801 (M.K., T.D.). Furthermore, this publication was funded by the
   German Research Foundation (DFG) and the University of Wurzburg in the
   funding program Open Access Publishing.
CR [Anonymous], 2007, BIOL CANC
   Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Bendell JC, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3515
   Bissell MJ, 2001, NAT REV CANCER, V1, P46, DOI 10.1038/35094059
   Bocsi J, 1999, J CANCER RES CLIN, V125, P9, DOI 10.1007/s004320050236
   Bonine-Summers AR, 2007, CANCER BIOL THER, V6, P561, DOI 10.4161/cbt.6.4.3851
   Buiga P, 2018, BMC SYST BIOL, V12, DOI 10.1186/s12918-018-0534-5
   Capalbo C, 2014, CANCER BIOL THER, V15, P826, DOI 10.4161/cbt.28878
   Chang YC, 2016, WORLD J GASTROENTERO, V22, P2314, DOI 10.3748/wjg.v22.i7.2314
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chubb D, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11883
   Connolly K, 2014, CURR ONCOL, V21, pE151, DOI 10.3747/co.21.1661
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   DANES BS, 1988, SCAND J GASTROENTERO, V23, P840, DOI 10.3109/00365528809090770
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Di Cara A, 2007, BMC BIOINFORMATICS, V8, DOI 10.1186/1471-2105-8-462
   Engelman JA, 2007, CANCER RES, V67, P11924, DOI 10.1158/0008-5472.CAN-07-1885
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Fischbach C, 2007, NAT METHODS, V4, P855, DOI 10.1038/NMETH1085
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Fodde R, 2001, NAT REV CANCER, V1, P55, DOI 10.1038/35094067
   Francone TD, 2007, MOL CANCER THER, V6, P1460, DOI 10.1158/1535-7163.MCT-06-0466
   Fritsche-Guenther R, 2016, ONCOTARGET, V7, P7960, DOI 10.18632/oncotarget.6959
   Göttlich C, 2018, MOL ONCOL, V12, P1264, DOI 10.1002/1878-0261.12323
   Göttlich C, 2016, JOVE-J VIS EXP, DOI 10.3791/53885
   Groeber F, 2016, ALTEX-ALTERN ANIM EX, V33, P415, DOI 10.14573/altex.1604041
   Hata AN, 2015, CANCER DISCOV, V5, P475, DOI 10.1158/2159-8290.CD-15-0011
   Hirschi B, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-122
   Jeffers M, 1996, J MOL MED-JMM, V74, P505, DOI 10.1007/BF00204976
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Komoto C., 2007, KOBE J MED SCI, V53, P335
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534
   Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013
   Lee JM, 2013, LAB INVEST, V93, P528, DOI 10.1038/labinvest.2013.41
   Linke K, 2007, TISSUE ENG, V13, P2699, DOI 10.1089/ten.2006.0388
   Lübtow MM, 2019, J CONTROL RELEASE, V303, P162, DOI 10.1016/j.jconrel.2019.04.014
   Maletzki C, 2014, ONCOTARGET, V5, P4467, DOI 10.18632/oncotarget.2039
   Maletzki C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052485
   Meli L, 2012, BIOMATERIALS, V33, P9087, DOI 10.1016/j.biomaterials.2012.08.065
   Moll C, 2013, JOVE-J VIS EXP, DOI 10.3791/50460
   Mullins CS, 2019, CANCERS, V11, DOI 10.3390/cancers11101520
   Nagaraja AK, 2015, J CLIN ONCOL, V33, P3990, DOI 10.1200/JCO.2015.63.7793
   Nehls O, 2007, BRIT J CANCER, V96, P1409, DOI 10.1038/sj.bjc.6603728
   Nietzer S, 2016, TISSUE ENG PART C-ME, V22, P621, DOI [10.1089/ten.TEC.2015.0557, 10.1089/ten.tec.2015.0557]
   Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396
   Philippi N, 2009, BMC SYST BIOL, V3, DOI 10.1186/1752-0509-3-97
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Pinto D, 2005, BIOL CELL, V97, P185
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Provençal M, 2010, J NEURO-ONCOL, V97, P365, DOI 10.1007/s11060-009-0041-z
   Puri Neelu, 2008, J Carcinog, V7, P9
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Schanz J, 2010, J BIOTECHNOL, V148, P56, DOI 10.1016/j.jbiotec.2010.03.015
   Scheller K, 2013, TISSUE ENG PART C-ME, V19, DOI [10.1089/ten.tec.2011.0723, 10.1089/ten.TEC.2011.0723]
   Schlatter R, 2012, BRIEF BIOINFORM, V13, P365, DOI 10.1093/bib/bbr065
   Song G, 2005, J CELL MOL MED, V9, P59, DOI 10.1111/j.1582-4934.2005.tb00337.x
   Souers AJ, 2013, NAT MED, V19, P202, DOI 10.1038/nm.3048
   Spix JK, 2007, EXP CELL RES, V313, P3319, DOI 10.1016/j.yexcr.2007.06.006
   Stratmann AT, 2014, MOL ONCOL, V8, P351, DOI 10.1016/j.molonc.2013.11.009
   Straussman R, 2012, NATURE, V487, P500, DOI 10.1038/nature11183
   Sun Q, 2012, MOL BIOL REP, V39, P6753, DOI 10.1007/s11033-012-1500-8
   Thiel A, 2013, VIRCHOWS ARCH, V463, P613, DOI 10.1007/s00428-013-1470-9
   van Es Johan H, 2015, Methods Mol Biol, V1267, P125, DOI 10.1007/978-1-4939-2297-0_6
   Wallstabe L, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.126345
   Wang D, 2010, ONCOGENE, V29, P781, DOI 10.1038/onc.2009.421
   WESSEL D, 1984, ANAL BIOCHEM, V138, P141, DOI 10.1016/0003-2697(84)90782-6
   World Health Organization, GLOBOCAN 2012 ESTIMA
   Yaeger RD, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.611
   Yokota T, 2011, BRIT J CANCER, V104, P856, DOI 10.1038/bjc.2011.19
   Zschenker O, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034279
NR 73
TC 9
Z9 9
U1 1
U2 3
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JAN
PY 2020
VL 12
IS 1
AR 28
DI 10.3390/cancers12010028
PG 27
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KQ3KZ
UT WOS:000516826700028
PM 31861874
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Li, DD
   Tang, YL
   Wang, X
AF Li, Dan-Dan
   Tang, Yuan-Ling
   Wang, Xin
TI Challenges and exploration for immunotherapies targeting cold colorectal
   cancer
SO WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Review
DE Colorectal cancer; Immune checkpoint inhibitors; Cold tumors;
   Immunotherapy mechanism; Combination therapy; Effector T cells
ID TUMOR MICROENVIRONMENT; GUT MICROBIOME; CHECKPOINT INHIBITORS; PD-1
   BLOCKADE; RADIOTHERAPY; CELLS; EXPRESSION; IMMUNITY; OPPORTUNITIES;
   ONCOLOGY
AB In recent years, immune checkpoint inhibitors (ICIs) have made significant breakthroughs in the treatment of various tumors, greatly improving clinical efficacy. As the fifth most common antitumor treatment strategy for patients with solid tumors after surgery, chemotherapy, radiotherapy and targeted therapy, the therapeutic response to ICIs largely depends on the number and spatial distribution of effector T cells that can effectively identify and kill tumor cells, features that are also important when distinguishing malignant tumors from "cold tumors" or "hot tumors". At present, only a small proportion of colorectal cancer (CRC) patients with deficient mismatch repair (dMMR) or who are microsatellite instability-high (MSI-H) can benefit from ICI treatments because these patients have the characteristics of a "hot tumor", with a high tumor mutational burden (TMB) and massive immune cell infiltration, making the tumor more easily recognized by the immune system. In contrast, a majority of CRC patients with proficient MMR (pMMR) or who are microsatellite stable (MSS) have a low TMB, lack immune cell infiltration, and have almost no response to immune monotherapy; thus, these tumors are "cold". The greatest challenge today is how to improve the immunotherapy response of "cold tumor" patients. With the development of clinical research, immunotherapies combined with other treatment strategies (such as targeted therapy, chemotherapy, and radiotherapy) have now become potentially effective clinical strategies and research hotspots. Therefore, the question of how to promote the transformation of "cold tumors" to "hot tumors" and break through the bottleneck of immunotherapy for cold tumors in CRC patients urgently requires consideration. Only by developing an in-depth understanding of the immunotherapy mechanisms of cold CRCs can we screen out the immunotherapy-dominant groups and explore the most suitable treatment options for individuals to improve therapeutic efficacy.
C1 [Li, Dan-Dan; Tang, Yuan-Ling; Wang, Xin] Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Oncol Radiat Oncol, 37 Wainan Guoxue Lane, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University
RP Wang, X (corresponding author), Sichuan Univ, West China Hosp, Canc Ctr, Dept Abdominal Oncol Radiat Oncol, 37 Wainan Guoxue Lane, Chengdu 610041, Sichuan, Peoples R China.
EM wangxin213@sina.com
RI Wang, Xin/N-8865-2018; Li, Dandan/HPH-9109-2023
FU National Natural Science Foundation of China [82073338]; Sichuan Science
   and Technology Support Project [2021YFSY0039, 22ZDYF0499]; 1.3.5 Project
   for Disciplines of Excellence-Clinical Research Incubation Project West
   China Hospital, Sichuan University [2020HXFH002]; 1.3.5 Project for
   Disciplines of Excellence, West China Hospital, Sichuan University
   [ZYJC21059]
FX Supported by National Natural Science Foundation of China, No. 82073338;
   Sichuan Science and Technology Support Project, No. 2021YFSY0039 and No.
   22ZDYF0499; The 1 center dot 3 center dot 5 Project for Disciplines of
   Excellence-Clinical Research Incubation Project West China Hospital,
   Sichuan University, No. 2020HXFH002; and The 1.3.5 Project for
   Disciplines of Excellence, West China Hospital, Sichuan University, No.
   ZYJC21059.
CR Ahn J, 2013, JNCI-J NATL CANCER I, V105, P1907, DOI 10.1093/jnci/djt300
   Anne H., 2022, METIMMOX COLORECTAL
   Badgeley A, 2021, BBA-REV CANCER, V1875, DOI 10.1016/j.bbcan.2020.188494
   Bando H., 2021, STUDY NIVOLUMAB FOLL
   Baumgaertner P, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1216290
   Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808
   Bernier J, 2016, CRIT REV ONCOL HEMAT, V108, P97, DOI 10.1016/j.critrevonc.2016.11.001
   Bertolini F, 2011, DRUG DISCOV TODAY, V16, P1052, DOI 10.1016/j.drudis.2011.08.007
   Blank CU, 2018, NAT MED, V24, P1655, DOI 10.1038/s41591-018-0198-0
   Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6
   Bonaventura P, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00168
   Buchbinder E, 2015, J CLIN INVEST, V125, P3377, DOI 10.1172/JCI80012
   Butterfield LH, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h988
   Chajon E, 2017, CRIT REV ONCOL HEMAT, V111, P124, DOI 10.1016/j.critrevonc.2017.01.017
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012
   Chen EX, 2020, JAMA ONCOL, V6, P831, DOI 10.1001/jamaoncol.2020.0910
   Chen YX, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.524
   Clavreul A, 2018, DRUG DELIV, V25, P1756, DOI 10.1080/10717544.2018.1507061
   Cousin Sophie, 2021, Clin Cancer Res, V27, P2139, DOI 10.1158/1078-0432.CCR-20-3416
   Cremolini C., 2021, FOLFOXIRI BEV ATEZO
   Cresci GA, 2015, NUTR CLIN PRACT, V30, P734, DOI 10.1177/0884533615609899
   Damgaci S, 2018, IMMUNOLOGY, V154, P354, DOI 10.1111/imm.12917
   Dangaj D, 2019, CANCER CELL, V35, P885, DOI 10.1016/j.ccell.2019.05.004
   Demaria S, 2016, TRENDS CANCER, V2, P286, DOI 10.1016/j.trecan.2016.05.002
   Díaz-Gay M, 2021, ADV CANCER RES, V151, P385, DOI 10.1016/bs.acr.2021.03.003
   Dirkx AEM, 2003, CANCER RES, V63, P2322
   Donlon NE, 2021, CANCER LETT, V502, P84, DOI 10.1016/j.canlet.2020.12.045
   Dubin K, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10391
   Dudal S, 2016, J IMMUNOTHER, V39, P279, DOI 10.1097/CJI.0000000000000132
   Egeblad M, 2010, DEV CELL, V18, P884, DOI 10.1016/j.devcel.2010.05.012
   Fakih M., 2022, SAFETY EFFICACY PEMB
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Fukurnura D, 2018, NAT REV CLIN ONCOL, V15, P325, DOI 10.1038/nrclinonc.2018.29
   Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z
   Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y
   Garg AD, 2015, INT J DEV BIOL, V59, P131, DOI 10.1387/ijdb.150061pa
   GeurtsvanKessel CH, 2008, J EXP MED, V205, P1621, DOI 10.1084/jem.20071365
   Ghiringhelli F, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01816
   Golden EB, 2015, SEMIN RADIAT ONCOL, V25, P11, DOI 10.1016/j.semradonc.2014.07.005
   Gong J, 2017, J NATL COMPR CANC NE, V15, P142, DOI 10.6004/jnccn.2017.0016
   Goodman AM, 2019, CANCER IMMUNOL RES, V7, P1570, DOI 10.1158/2326-6066.CIR-19-0149
   Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236
   Greer CB, 2015, CELL REP, V13, P1444, DOI 10.1016/j.celrep.2015.10.013
   Gubin MM, 2015, J CLIN INVEST, V125, P3413, DOI 10.1172/JCI80008
   Haanen JBAG, 2017, CELL, V170, P1055, DOI 10.1016/j.cell.2017.08.031
   Hakozaki T, 2020, CANCER IMMUNOL RES, V8, P1243, DOI 10.1158/2326-6066.CIR-20-0196
   Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7
   Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x
   Hazama S, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-108
   He JJ, 2021, ANN TRANSL MED, V9, DOI 10.21037/atm-20-7553
   He RZ, 2022, MEDICINE, V101, DOI 10.1097/MD.0000000000030561
   Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011
   Hegde PS, 2016, CLIN CANCER RES, V22, P1865, DOI 10.1158/1078-0432.CCR-15-1507
   Herrera FG, 2017, CA-CANCER J CLIN, V67, P65, DOI 10.3322/caac.21358
   Higano CS, 2009, CANCER-AM CANCER SOC, V115, P3670, DOI 10.1002/cncr.24429
   Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109
   Hyun YM, 2012, J EXP MED, V209, P1349, DOI 10.1084/jem.20111426
   Kelderman S, 2016, BBA-REV CANCER, V1865, P83, DOI 10.1016/j.bbcan.2015.10.004
   Kershaw MH, 2006, CLIN CANCER RES, V12, P6106, DOI 10.1158/1078-0432.CCR-06-1183
   Kim JM, 2016, ANN ONCOL, V27, P1492, DOI 10.1093/annonc/mdw217
   Kuehlbach C, 2021, BIOENGINEERING-BASEL, V8, DOI 10.3390/bioengineering8110186
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Li YG, 2022, BMC GASTROENTEROL, V22, DOI 10.1186/s12876-022-02511-7
   Liu C, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.783527
   Lizardo DY, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188447
   Long YY, 2014, EXP THER MED, V8, P1279, DOI 10.3892/etm.2014.1913
   Luqmani YA, 2005, MED PRIN PRACT, V14, P35, DOI 10.1159/000086183
   MacDonald F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00575
   Maimela NR, 2019, COMPUT STRUCT BIOTEC, V17, P1, DOI 10.1016/j.csbj.2018.11.004
   Malogolovkin A, 2021, VIRUSES-BASEL, V13, DOI 10.3390/v13071271
   Martin JD, 2019, ANNU REV PHYSIOL, V81, P505, DOI 10.1146/annurev-physiol-020518-114700
   Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290
   McNabney SM, 2017, NUTRIENTS, V9, DOI 10.3390/nu9121348
   Mettu NB., 2022, METASTATIC COLORECTA
   Mortezaee K, 2020, LIFE SCI, V249, DOI 10.1016/j.lfs.2020.117534
   Mouw KW, 2017, CANCER DISCOV, V7, P675, DOI 10.1158/2159-8290.CD-17-0226
   Okuno K, 2014, ANTICANCER RES, V34, P3045
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Peddareddigari VG, 2010, CANCER MICROENVIRON, V3, P149, DOI 10.1007/s12307-010-0038-3
   Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520
   Rayner E, 2016, NAT REV CANCER, V16, P71, DOI 10.1038/nrc.2015.12
   Reits EA, 2006, J EXP MED, V203, P1259, DOI 10.1084/jem.20052494
   Ribas A, 2017, CELL, V170, P1109, DOI 10.1016/j.cell.2017.08.027
   Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943
   Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706
   Russell L, 2019, BIODRUGS, V33, P485, DOI 10.1007/s40259-019-00367-0
   Russell SJ, 2018, CANCER CELL, V33, P599, DOI 10.1016/j.ccell.2018.03.011
   Saito T, 2014, VACCINE, V32, P5901, DOI 10.1016/j.vaccine.2014.09.002
   Salvatore L., 2022, IMMUNOTHERAPY LOCALL
   Santin AD, 1998, GYNECOL ONCOL, V70, P195, DOI 10.1006/gyno.1998.5060
   Scanlan Matthew J, 2004, Cancer Immun, V4, P1
   Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002
   Schulze T, 2009, CANCER IMMUNOL IMMUN, V58, P61, DOI 10.1007/s00262-008-0526-1
   Simonelli M, 2018, CANCER TREAT REV, V69, P121, DOI 10.1016/j.ctrv.2018.06.016
   Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabernero J, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100559
   Telli TA, 2022, CANCER TREAT REV, V110, DOI 10.1016/j.ctrv.2022.102460
   Topper MJ, 2017, CELL, V171, P1284, DOI 10.1016/j.cell.2017.10.022
   Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1
   van der Bruggen P, 2002, IMMUNOL REV, V188, P51, DOI 10.1034/j.1600-065X.2002.18806.x
   van der Woude LL, 2017, TRENDS CANCER, V3, P797, DOI 10.1016/j.trecan.2017.09.006
   Vargas FA, 2018, CANCER CELL, V33, P649, DOI 10.1016/j.ccell.2018.02.010
   Walle T, 2018, THER ADV MED ONCOL, V10, DOI 10.1177/1758834017742575
   Wang F., 2020, JS001 COMBINED REGOR
   Wang Q, 2018, CANCER LETT, V438, P17, DOI 10.1016/j.canlet.2018.08.028
   Weiden J, 2018, NAT REV IMMUNOL, V18, P212, DOI 10.1038/nri.2017.89
   Wong KK, 2016, ADV IMMUNOL, V130, P191, DOI 10.1016/bs.ai.2015.12.001
   Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397
   Yachida S, 2019, NAT MED, V25, P968, DOI 10.1038/s41591-019-0458-7
   Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00978
   Yang WJ, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18262-6
   Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444
   Yarchoan M, 2017, NAT REV CANCER, V17, P209, DOI 10.1038/nrc.2016.154
   Yin GF, 2022, MELANOMA RES, V32, P71, DOI 10.1097/CMR.0000000000000800
   Zeng HW, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051214
   Zhang CX, 2019, BIOMED RES INT-UK, V2019, DOI 10.1155/2019/6764919
   Zhang FS, 2022, CANCER LETT, V526, P29, DOI 10.1016/j.canlet.2021.11.015
   Zhao Y, 2020, ACTA PHARMACOL SIN B, V10, P2018, DOI 10.1016/j.apsb.2020.09.014
   Zhao YB, 2003, BLOOD, V102, P4137, DOI 10.1182/blood-2003-06-1867
NR 122
TC 11
Z9 11
U1 0
U2 8
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1948-5204
J9 WORLD J GASTRO ONCOL
JI World J. Gastrointest. Oncol.
PD JAN 15
PY 2023
VL 15
IS 1
BP 55
EP 68
DI 10.4251/wjgo.v15.i1.55
PG 14
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA 8R8ZO
UT WOS:000928176700004
PM 36684057
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Petrelli, F
   Perego, G
   Ghidini, A
   Ghidini, M
   Borgonovo, K
   Scolari, C
   Nozza, R
   Rampulla, V
   Costanzo, A
   Varricchio, A
   Rausa, E
   Pietrantonio, F
   Zaniboni, A
AF Petrelli, Fausto
   Perego, Gianluca
   Ghidini, Antonio
   Ghidini, Michele
   Borgonovo, Karen
   Scolari, Cinzia
   Nozza, Renata
   Rampulla, Valentina
   Costanzo, Antonio
   Varricchio, Antonio
   Rausa, Emanuele
   Pietrantonio, Filippo
   Zaniboni, Alberto
TI A systematic review of salvage therapies in refractory metastatic
   colorectal cancer
SO INTERNATIONAL JOURNAL OF COLORECTAL DISEASE
LA English
DT Review
DE Colorectal cancer; Chemotherapy; Refractory; Third line; Review
ID PHASE-II TRIAL; PLUS IRINOTECAN; DOUBLE-BLIND; OPEN-LABEL; PANITUMUMAB
   MONOTHERAPY; MONOCLONAL-ANTIBODY; 3RD-LINE TREATMENT; RANDOMIZED-TRIAL;
   TREATED PATIENTS; ORAL LEUCOVORIN
AB Purpose Established that the only approved agents in previously treated metastatic colorectal cancer (CRC) are trifluoridine/tipiracil and regorafenib, we conducted a systematic review of all the published phase 2-3 trials, with the scope to evaluate the benefit of any later-line regimens in refractory metastatic CRC. Methods Phase 2-3 studies that enrolled patients with stage IV disease receiving salvage therapies for refractory CRC were identified using electronic databases (Pubmed, EMBASE, and Cochrane Library). Clinical outcomes were pooled using a point estimates for the weighted values of median overall survival (OS), progression-free survival (PFS), response rate (ORR), stable disease rate (SD), and 6-month and 1-year OS. Results Overall, 7556 patients were included from 67 studies (n = 70 arms). Overall, the pooled ORR and SD were 15.4% (95% CI 13-18%) and 36.9% (95% CI 33.5-40.6%). Median PFS, 6-month and 1-year OS, and median OS were 3.2 (95% CI 2.9-3.3) months, 65.4% (95% CI 61.9-68.8%), 36% (95% CI 32.3-39.9%) and 8.8 (95% CI 8.3-9.2) months. Overall survival was different in the monochemotherapy, polychemotherapy, chemotherapy + targeted therapy, and targeted therapy alone arms (7.6, 9.5, 10.3, and 7.9 months, respectively, P for difference = 0.01). Median PFS were respectively 2.3, 3.9, 3.8, and 2.6, respectively (P for difference < 0.01). Conclusions Overall, combination therapy (polychemotherapy with or without targeted agents) is associated with a higher control of disease and better outcome than approved agents. Treatment, if possible, should be personalized according to the patients' conditions, physician preference and molecular profile of disease.
C1 [Petrelli, Fausto; Borgonovo, Karen] ASST Bergamo Ovest, Med Sci Dept, Oncol Unit, Piazzale Osped 1, I-24047 Treviglio, BG, Italy.
   [Perego, Gianluca] Osped San Raffaele, Pharm Unit, Milan, Italy.
   [Ghidini, Antonio] Casa Cura Igea, Oncol Unit, Milan, Italy.
   [Ghidini, Michele] Osped Maggiore Policlin, Fdn IRCCS Ca Granda, Oncol Unit, Milan, Italy.
   [Scolari, Cinzia; Nozza, Renata] ASST Bergamo Ovest, Pharm Unit, Treviglio, BG, Italy.
   [Rampulla, Valentina; Costanzo, Antonio; Varricchio, Antonio] ASST Bergamo Ovest, Surg Oncol Unit, Treviglio, BG, Italy.
   [Rausa, Emanuele] ASST Papa Giovanni XXIII, Surg Unit, Bergamo, Italy.
   [Pietrantonio, Filippo] Fdn IRCCS Ist Nazl Tumori Milano, Oncol Unit, Milan, Italy.
   [Zaniboni, Alberto] Fdn Poliambulanza, Oncol Unit, Brescia, Italy.
C3 Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; IRCCS
   Ca Granda Ospedale Maggiore Policlinico; ASST Papa Giovanni XXIII;
   Fondazione IRCCS Istituto Nazionale Tumori Milan
RP Petrelli, F (corresponding author), ASST Bergamo Ovest, Med Sci Dept, Oncol Unit, Piazzale Osped 1, I-24047 Treviglio, BG, Italy.
EM faupe@libero.it
RI Costanzo, Antonio/GZG-2433-2022; Ghidini, Michele/I-7362-2018; Ghidini,
   Antonio/ABH-8831-2020; Pietrantonio, Filippo/C-2180-2017
OI Ghidini, Michele/0000-0001-5435-1218; Ghidini,
   Antonio/0000-0002-6142-2018; Rausa, Emanuele/0000-0001-6780-1783;
   Pietrantonio, Filippo/0000-0002-8530-8420; Costanzo,
   Antonio/0000-0001-9697-2557; Costanzo, Antonio/0000-0002-1048-6089
CR Altomare I, 2011, ONCOLOGIST, V16, P1131, DOI 10.1634/theoncologist.2011-0078
   André T, 1999, EUR J CANCER, V35, P1343, DOI 10.1016/S0959-8049(99)00150-1
   André T, 2013, ANN ONCOL, V24, P412, DOI 10.1093/annonc/mds465
   [Anonymous], CA CANC J CLIN
   [Anonymous], NUM CANCR IT
   [Anonymous], 2019, Lancet Oncol, DOI DOI 10.1016/S1470-2045(18)30742-3
   Baratelli C, 2018, INT J CLIN ONCOL, V23, P281, DOI 10.1007/s10147-017-1195-x
   Becerra CR, 2014, CANCER CHEMOTH PHARM, V73, P695, DOI 10.1007/s00280-014-2391-2
   Benson AB III, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/jnccn.2018.0021
   Bouche O, 2011, ANTICANCER RES, V31, P2271
   Calegari MA, 2017, BRIT J CANCER, V116, P1279, DOI 10.1038/bjc.2017.109
   Cascinu S, 2017, EUR J CANCER, V83, P106, DOI 10.1016/j.ejca.2017.06.029
   Chen XF, 2019, ONCOLOGIST, V24, P883, DOI 10.1634/theoncologist.2019-0164
   Chen Y, 2019, ONCOLOGIST, V24, P591, DOI 10.1634/theoncologist.2018-0901
   Choi DR, 2015, CANCER CHEMOTH PHARM, V75, P639, DOI 10.1007/s00280-015-2688-9
   Chong G, 2005, BRIT J CANCER, V93, P510, DOI 10.1038/sj.bjc.6602733
   Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Ducreux M, 2017, CANCER CHEMOTH PHARM, V79, P9, DOI 10.1007/s00280-016-3193-5
   Fakih MG, 2012, CANCER CHEMOTH PHARM, V69, P743, DOI 10.1007/s00280-011-1762-1
   Foubert F, 2014, DIGEST LIVER DIS, V46, P105, DOI 10.1016/j.dld.2013.07.002
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hecht JR, 2007, CANCER-AM CANCER SOC, V110, P980, DOI 10.1002/cncr.22915
   Hickish T, 2017, LANCET ONCOL, V18, P192, DOI 10.1016/S1470-2045(17)30006-2
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2016, COCHRANE DB SYST REV, V10, P29
   Hsu HC, 2018, CANCER MANAG RES, V10, P6061, DOI 10.2147/CMAR.S179345
   Huang WT, 2013, J INVEST MED, V61, P1108, DOI 10.2310/JIM.0b013e3182a6799d
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8
   Kemeny N, 2004, J CLIN ONCOL, V22, P4753, DOI 10.1200/JCO.2004.03.119
   Kim SY, 2009, INVEST NEW DRUG, V27, P269, DOI 10.1007/s10637-008-9177-5
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Lee KW, 2014, CANCER CHEMOTH PHARM, V74, P447, DOI 10.1007/s00280-014-2515-8
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
   Manley Gerard., 2017, PLoS ONE, V32, P736
   Matsuda C, 2016, INT J CLIN ONCOL, V21, P566, DOI 10.1007/s10147-015-0911-7
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Milione M, 2017, ONCOTARGET, V8, P55353, DOI 10.18632/oncotarget.19512
   Miranda VC, 2016, CLIN COLORECTAL CANC, V15, P321, DOI 10.1016/j.clcc.2016.04.011
   Moher D, 2010, INT J SURG, V8, P658, DOI [10.1136/bmj.i4086, 10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1186/2046-4053-4-1]
   Moorcraft SY, 2013, INVEST NEW DRUG, V31, P1339, DOI 10.1007/s10637-013-9990-3
   Morano F, 2018, ANN ONCOL, V29, P1800, DOI 10.1093/annonc/mdy197
   Muro K, 2009, JPN J CLIN ONCOL, V39, P321, DOI 10.1093/jjco/hyp016
   Osumi H, 2018, CANCER SCI, V109, P2567, DOI 10.1111/cas.13698
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pietrantonio F, 2018, ANN ONCOL, V29, P1394, DOI 10.1093/annonc/mdy090
   Pietrantonio F, 2017, ANN ONCOL, V28, P555, DOI 10.1093/annonc/mdw627
   Pietrantonio F, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx089
   Pishvaian MJ, 2018, CANCER-AM CANCER SOC, V124, P2337, DOI 10.1002/cncr.31309
   Ramanathan RK, 2008, CANCER CHEMOTH PHARM, V61, P453, DOI 10.1007/s00280-007-0489-5
   Reidy DL, 2010, J CLIN ONCOL, V28, P4240, DOI 10.1200/JCO.2010.30.4154
   Riaz N, 2016, WIRES DEV BIOL, V118, P6072, DOI DOI 10.1002/CNCR.27633.PERCUTANE0US
   Santoro A, 2010, EUR J CANCER, V46, P2746, DOI 10.1016/j.ejca.2010.07.012
   Sartore-Bianchi A, 2016, CANCER TREAT REV, V51, P54, DOI 10.1016/j.ctrv.2016.10.006
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sartore-Bianchi A, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv306
   Shitara K, 2011, INVEST NEW DRUG, V29, P688, DOI 10.1007/s10637-009-9382-x
   Siu LL, 2013, J CLIN ONCOL, V31, P2477, DOI 10.1200/JCO.2012.46.0543
   Skougaard K, 2016, ACTA ONCOL, V55, P1175, DOI 10.3109/0284186X.2016.1170197
   Soeda H, 2014, ONCOLOGY-BASEL, V87, P7, DOI 10.1159/000360989
   Spindler KLG, 2014, ANTICANCER RES, V34, P845
   Spindler KLG, 2015, TUMOR BIOL, V36, P4301, DOI 10.1007/s13277-015-3069-z
   Stec R, 2014, ONCOLOGIST, V19, P356, DOI 10.1634/theoncologist.2014-0029
   Sterne JAC, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i4919
   Stroup DF, 2000, JAMA-J AM MED ASSOC, V283, P2008, DOI 10.1001/jama.283.15.2008
   Subbiah V, 2018, CANCER DISCOV, V8, P836, DOI 10.1158/2159-8290.CD-18-0338
   Tahara M, 2008, JPN J CLIN ONCOL, V38, P762, DOI 10.1093/jjco/hyn102
   Takahashi T, 2016, CANCER CHEMOTH PHARM, V78, P585, DOI 10.1007/s00280-016-3109-4
   Tanioka H, 2019, INT J CLIN ONCOL, V24, P836, DOI 10.1007/s10147-019-01414-0
   Trarbach T, 2010, BRIT J CANCER, V102, P506, DOI 10.1038/sj.bjc.6605507
   Valeri N, 2019, CANCER RES, V79, P1041, DOI 10.1158/0008-5472.CAN-19-0305
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Vincenzi B, 2009, CANCER-AM CANCER SOC, V115, P4849, DOI 10.1002/cncr.24540
   Wilke H, 2008, J CLIN ONCOL, V26, P5335, DOI 10.1200/JCO.2008.16.3758
   Wolpin BM, 2013, ONCOLOGIST, V18, P377, DOI 10.1634/theoncologist.2012-0378
   Wu XY, 2013, ASIAN PAC J CANCER P, V14, P2019, DOI 10.7314/APJCP.2013.14.3.2019
   Xu RH, 2017, CHIN J CANCER, V36, DOI 10.1186/s40880-017-0263-y
   Xu RH, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-016-0384-9
   Yamaguchi K, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1606-1
   Yoshida M, 2016, ONCOLOGY-BASEL, V91, P24, DOI 10.1159/000446372
   Yoshino T, 2012, LANCET ONCOL, V13, P993, DOI 10.1016/S1470-2045(12)70345-5
NR 85
TC 6
Z9 6
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 0179-1958
EI 1432-1262
J9 INT J COLORECTAL DIS
JI Int. J. Colorectal Dis.
PD MAY
PY 2020
VL 35
IS 5
BP 783
EP 794
DI 10.1007/s00384-020-03571-5
EA MAR 2020
PG 12
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA LJ0YM
UT WOS:000521881400001
PM 32219509
DA 2025-01-04
ER

PT J
AU de Bono, JS
   Harris, JR
   Burm, SM
   Vanderstichele, A
   Houtkamp, MA
   Aarass, S
   Riisnaes, R
   Figueiredo, I
   Rodrigues, DN
   Christova, R
   Olbrecht, S
   Niessen, HWM
   Ruuls, SR
   Schuurhuis, DH
   van Bueren, JJL
   Breij, ECW
   Vergote, I
AF de Bono, Johann S.
   Harris, Jeffrey R.
   Burm, Saskia M.
   Vanderstichele, Adriaan
   Houtkamp, Mischa A.
   Aarass, Saida
   Riisnaes, Ruth
   Figueiredo, Ines
   Rodrigues, Daniel Nava
   Christova, Rossitza
   Olbrecht, Siel
   Niessen, Hans W. M.
   Ruuls, Sigrid R.
   Schuurhuis, Danita H.
   van Bueren, Jeroen J. Lammerts
   Breij, Esther C. W.
   Vergote, Ignace
TI Systematic study of tissue factor expression in solid tumors
SO CANCER REPORTS
LA English
DT Article
DE biopsies expression; immunohistochemistry; solid tumor; targeted
   therapy; tissue factor
ID CANCER; PROGRESSION; HEMOSTASIS; SURVIVAL; GROWTH; TF
AB Background Elevated tissue factor (TF) expression, although restricted in normal tissue, has been reported in multiple solid cancers, and expression has been associated with poor prognosis. This manuscript compares TF expression across various solid tumor types via immunohistochemistry in a single study, which has not been performed previously. Aims To increase insight in the prevalence and cellular localization of TF expression across solid cancer types, we performed a detailed and systematic analysis of TF expression in tumor tissue obtained from patients with ovarian, esophageal, bladder, cervical, endometrial, pancreatic, prostate, colon, breast, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and glioblastoma. The spatial and temporal variation of TF expression was analyzed over time and upon disease progression in patient-matched biopsies taken at different timepoints. In addition, TF expression in patient-matched primary tumor and metastatic lesions was also analyzed. Methods and Results TF expression was detected via immunohistochemistry (IHC) using a validated TF-specific antibody. TF was expressed in all cancer types tested, with highest prevalence in pancreatic cancer, cervical cancer, colon cancer, glioblastoma, HNSCC, and NSCLC, and lowest in breast cancer. Staining was predominantly membranous in pancreatic, cervical, and HNSCC, and cytoplasmic in glioblastoma and bladder cancer. In general, expression was consistent between biopsies obtained from the same patient over time, although variability was observed for individual patients. NSCLC biopsies of primary tumor and matched lymph node metastases showed no clear difference in TF expression overall, although individual patient changes were observed. Conclusion This study shows that TF is expressed across a broad range of solid cancer types, and expression is present upon tumor dissemination and over the course of treatment.
C1 [de Bono, Johann S.; Riisnaes, Ruth; Figueiredo, Ines; Rodrigues, Daniel Nava; Christova, Rossitza] Royal Canc Hosp, Inst Canc Res, London, England.
   [Harris, Jeffrey R.; Aarass, Saida] Genmab, Plainsboro, NJ USA.
   [Burm, Saskia M.; Houtkamp, Mischa A.; Aarass, Saida; Schuurhuis, Danita H.; Breij, Esther C. W.] Genmab, Utrecht, Netherlands.
   [Vanderstichele, Adriaan; Olbrecht, Siel; Vergote, Ignace] Univ Hosp Leuven, Leuven Canc Inst, Dept Gynaecol & Obstet, Div Gynaecol Oncol, Leuven, Belgium.
   [Niessen, Hans W. M.] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands.
   [Ruuls, Sigrid R.] Lava Therapeut, Utrecht, Netherlands.
   [van Bueren, Jeroen J. Lammerts] Merus, Utrecht, Netherlands.
C3 University of London; Institute of Cancer Research - UK; Royal Marsden
   NHS Foundation Trust; Genmab; Genmab; KU Leuven; University Hospital
   Leuven; Vrije Universiteit Amsterdam; VU UNIVERSITY MEDICAL CENTER
RP de Bono, JS (corresponding author), Inst Canc Res & Royal Marsden, Downs Rd, London SM1 2DL, England.; Vergote, I (corresponding author), Univ Hosp Leuven, Dept Gynaecol & Obstet, Leuven, Belgium.
EM Johann.DeBono@icr.ac.uk; ignace.vergote@uzleuven.be
RI Rodrigues, Daniel/D-3533-2014
OI Nava Rodrigues, Daniel/0009-0003-9872-1008; Olbrecht,
   Siel/0000-0001-9452-5905; de Bono, Johann S/0000-0002-2034-595X
CR Breij ECW, 2014, CANCER RES, V74, P1214, DOI 10.1158/0008-5472.CAN-13-2440
   Chu AJ, 2011, INT J INFLAMM, V2011, DOI 10.4061/2011/367284
   Cocco E, 2011, CLIN EXP METASTAS, V28, P689, DOI 10.1007/s10585-011-9401-0
   Cole M, 2013, ONCOLOGIST, V18, P14, DOI 10.1634/theoncologist.2012-0322
   de Goeij BECG, 2015, MOL CANCER THER, V14, P1130, DOI 10.1158/1535-7163.MCT-14-0798
   DRAKE TA, 1989, AM J PATHOL, V134, P1087
   FLOSSEL C, 1994, HISTOCHEMISTRY, V101, P449, DOI 10.1007/BF00269495
   GOUAULTHEILMANN M, 1975, BRIT J HAEMATOL, V30, P151, DOI 10.1111/j.1365-2141.1975.tb00529.x
   Helft PR, 2006, J CLIN ONCOL, V24, P4793, DOI 10.1200/JCO.2006.05.7125
   Hisada Y, 2019, SEMIN THROMB HEMOST, V45, P385, DOI 10.1055/s-0039-1687894
   Kasthuri RS, 2009, J CLIN ONCOL, V27, P4834, DOI 10.1200/JCO.2009.22.6324
   Kocatürk B, 2013, P NATL ACAD SCI USA, V110, P11517, DOI 10.1073/pnas.1307100110
   Lwaleed BA, 2001, J PATHOL, V193, P3
   Olson EM, 2011, NAT REV CLIN ONCOL, V8, P620, DOI 10.1038/nrclinonc.2011.114
   Patry G, 2008, INT J CANCER, V122, P1592, DOI 10.1002/ijc.23240
   Pedersen B, 2005, BLOOD, V105, P2777, DOI 10.1182/blood-2004-09-3724
   Rondon AMR, 2019, SEMIN THROMB HEMOST, V45, P396, DOI 10.1055/s-0039-1687895
   Ruf W, 1996, Curr Opin Hematol, V3, P379
   Ruf W, 2010, THROMB RES, V125, pS36, DOI 10.1016/S0049-3848(10)70010-4
   Sharp A, 2019, J CLIN INVEST, V129, P192, DOI 10.1172/JCI122819
   Smith SA, 2015, CRIT REV BIOCHEM MOL, V50, P326, DOI 10.3109/10409238.2015.1050550
   Ten Cate H, 2007, PATHOPHYSIOL HAEMO T, V36, P122, DOI 10.1159/000175150
   Unruh D, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00932-z
   Versteeg HH, 2015, SEMIN THROMB HEMOST, V41, P747, DOI 10.1055/s-0035-1556048
   Versteeg HH, 2004, CIRC RES, V94, P1032, DOI 10.1161/01.RES.0000125625.18597.AD
   Vrana JA, 1996, CANCER RES, V56, P5063
NR 26
TC 11
Z9 11
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2573-8348
J9 CANCER REP-US
JI Cancer Rep.-US
PD FEB
PY 2023
VL 6
IS 2
AR e1699
DI 10.1002/cnr2.1699
EA AUG 2022
PG 11
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA 9W4RX
UT WOS:000851509900001
PM 36806722
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Liang, D
   Khoonkari, M
   Avril, T
   Chevet, E
   Kruyt, FAE
AF Liang, Dong
   Khoonkari, Mohammad
   Avril, Tony
   Chevet, Eric
   Kruyt, Frank A. E.
TI The unfolded protein response as regulator of cancer stemness and
   differentiation: Mechanisms and implications for cancer therapy
SO BIOCHEMICAL PHARMACOLOGY
LA English
DT Review
DE Unfolded protein response; Cancer stem cells; Tumor formation; Therapy;
   PERK; IRE1
ID ENDOPLASMIC-RETICULUM STRESS; BREAST-CANCER; BONE-MARROW; CELLS;
   ACTIVATION; GSK2606414; DISCOVERY; AUTOPHAGY; SURVIVAL; TARGET
AB The unfolded protein response (UPR) is an adaptive mechanism that regulates protein and cellular homeostasis. Three endoplasmic reticulum (ER) membrane localized stress sensors, IRE1, PERK and ATF6, coordinate the UPR in order to maintain ER proteostasis and cell survival, or induce cell death when homeostasis cannot be restored. However, recent studies have identified alternative functions for the UPR in developmental biology processes and cell fate decisions under both normal and cancerous conditions. In cancer, increasing evidence points to-wards the involvement of the three UPR sensors in oncogenic reprogramming and the regulation of tumor cells endowed with stem cell properties, named cancer stem cells (CSCs), that are considered to be the most malignant cells in tumors. Here we review the reported roles and underlying molecular mechanisms of the three UPR sensors in regulating stemness and differentiation, particularly in solid tumor cells, processes that have a major impact on tumor aggressiveness. Mainly PERK and IRE1 branches of the UPR were found to regulate CSCs and tumor development and examples are provided for breast cancer, colon cancer and aggressive brain tumors, glioblastoma. Although the underlying mechanisms and interactions between the different UPR branches in regulating stemness in cancer need to be further elucidated, we propose that PERK and IRE1 targeted therapy could inhibit self-renewal of CSCs or induce differentiation that is predicted to have therapeutic benefit. For this, more specific UPR modulators need to be developed with favorable pharmacological properties that together with patient stratification will allow optimal evaluation in clinical studies.
C1 [Liang, Dong; Khoonkari, Mohammad; Kruyt, Frank A. E.] Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
   [Avril, Tony; Chevet, Eric] Univ Rennes, INSERM U1242, Rennes, France.
   [Avril, Tony; Chevet, Eric] Ctr Lutte Canc Eugene Marquis, Rennes, France.
C3 University of Groningen; Universite de Rennes; Institut National de la
   Sante et de la Recherche Medicale (Inserm); UNICANCER; Centre Eugene
   Marquis; Universite de Rennes
RP Kruyt, FAE (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Med Oncol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands.
EM f.a.e.kruyt@umcg.nl
RI Avril, Tony/ABG-7611-2020; Chevet, Eric/E-4992-2016
OI AVRIL, TONY/0000-0002-1129-8514; Chevet, Eric/0000-0001-5855-4522;
   Kruyt, Frank A.E./0000-0002-2445-9380; Liang, Dong/0000-0002-7145-5569
FU China Scholarship Council; University of Groningen; Zernike Institute
   for Advanced Materials at the University of Groningen; Bonus Incentive
   Scheme (Dutch Ministry for Education, Culture and Science (OCW)); La
   Ligue contre le cancer (comite 35); l'Institut des Neurosciences
   Cliniques de Rennes (AAP 2020); Fondation pour la Recherche Medicale
   (FRM equipe labellisee 2018); Institut National du Cancer (INCa; PLBIO);
   Agence Nationale de la Recherche (ANR; ERAAT); La Ligue contre le cancer
   (comite 56); La Ligue contre le cancer (comite 85)
FX DL was supported by the China Scholarship Council and the University of
   Groningen. MK was financially supported by the Zernike Institute for
   Advanced Materials at the University of Groningen, including funding
   from the Bonus Incentive Scheme (of the Dutch Ministry for Education,
   Culture and Science (OCW)). T. Avril was supported by La Ligue contre le
   cancer (comites 35, 56 and 85) and by l'Institut des Neurosciences
   Cliniques de Rennes (AAP 2020). EC was funded by Grants from Fondation
   pour la Recherche Medicale (FRM equipe labellisee 2018), Institut
   National du Cancer (INCa; PLBIO), Agence Nationale de la Recherche (ANR;
   ERAAT).
CR Almanza A, 2019, FEBS J, V286, P241, DOI 10.1111/febs.14608
   Avivar-Valderas A, 2013, ONCOGENE, V32, P4932, DOI 10.1038/onc.2012.512
   Avivar-Valderas A, 2011, MOL CELL BIOL, V31, P3616, DOI 10.1128/MCB.05164-11
   Axten JM, 2013, ACS MED CHEM LETT, V4, P964, DOI 10.1021/ml400228e
   Bartkowiak K, 2015, CANCER RES, V75, P5367, DOI 10.1158/0008-5472.CAN-14-3728
   Bartkowiak K, 2010, J PROTEOME RES, V9, P3158, DOI 10.1021/pr100039d
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Bertolotti A, 2000, NAT CELL BIOL, V2, P326, DOI 10.1038/35014014
   Bobrovnikova-Marjon E, 2010, ONCOGENE, V29, P3881, DOI 10.1038/onc.2010.153
   Briggs Michael D, 2020, F1000Res, V9, DOI 10.12688/f1000research.22275.1
   Caras IW, 2020, STEM CELL TRANSL MED, V9, P821, DOI 10.1002/sctm.19-0424
   Chen B, 2011, CSH PERSPECT BIOL, V3, DOI 10.1101/cshperspect.a004374
   Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119
   Chevet E, 2015, CANCER DISCOV, V5, P586, DOI 10.1158/2159-8290.CD-14-1490
   Cho YM, 2009, EXP MOL MED, V41, P440, DOI 10.3858/emm.2009.41.6.049
   Cullinan SB, 2004, J BIOL CHEM, V279, P20108, DOI 10.1074/jbc.M314219200
   de Jeude JFV, 2017, ONCOGENE, V36, P3397, DOI 10.1038/onc.2016.326
   Fajardo NMP, 2016, BIOCHEM PHARMACOL, V118, P1, DOI 10.1016/j.bcp.2016.04.008
   Frakes AE, 2017, MOL CELL, V66, P761, DOI 10.1016/j.molcel.2017.05.031
   Fusakio ME, 2016, MOL BIOL CELL, V27, P1536, DOI 10.1091/mbc.E16-01-0039
   Ganz J, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-63899-4
   Han J, 2017, GENE DEV, V31, P1417, DOI 10.1101/gad.297374.117
   Harding HP, 2001, MOL CELL, V7, P1153, DOI 10.1016/S1097-2765(01)00264-7
   Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031
   Hetz C, 2018, MOL CELL, V69, P169, DOI 10.1016/j.molcel.2017.06.017
   Hetz C, 2012, NAT REV MOL CELL BIO, V13, P89, DOI 10.1038/nrm3270
   Horiuchi K, 2016, CELL MOL LIFE SCI, V73, P2851, DOI 10.1007/s00018-016-2178-1
   Cornejo VH, 2013, IUBMB LIFE, V65, P962, DOI 10.1002/iub.1224
   Iwawaki T, 2009, P NATL ACAD SCI USA, V106, P16657, DOI 10.1073/pnas.0903775106
   Jurkin J, 2014, EMBO J, V33, P2922, DOI 10.15252/embj.201490332
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Le Reste P.-J., 2019, CONTROL GLIOBLAS
   Lhomond S, 2018, EMBO MOL MED, V10, DOI 10.15252/emmm.201707929
   Li C, 2018, EXP CELL RES, V367, P170, DOI 10.1016/j.yexcr.2018.03.033
   Liu L, 2019, NAT CELL BIOL, V21, P328, DOI 10.1038/s41556-019-0285-6
   Lujan P, 2021, CURR OPIN CELL BIOL, V71, P95, DOI 10.1016/j.ceb.2021.01.010
   Ma YJ, 2004, NAT REV CANCER, V4, P966, DOI 10.1038/nrc1505
   Madden E, 2019, BIOL CELL, V111, P1, DOI 10.1111/boc.201800050
   Mahameed M, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1523-3
   Maly DJ, 2014, NAT CHEM BIOL, V10, P892, DOI 10.1038/nchembio.1664
   Maurel M, 2014, TRENDS BIOCHEM SCI, V39, P245, DOI 10.1016/j.tibs.2014.02.008
   McGrath EP, 2021, BBA-MOL CELL RES, V1868, DOI 10.1016/j.bbamcr.2021.119001
   Mitra S, 2019, J CELL SCI, V132, DOI 10.1242/jcs.217216
   Muncan V, 2018, MOL CELL BIOL, V38, DOI 10.1128/MCB.00482-18
   Murao N, 2017, J BIOCHEM, V162, P155, DOI 10.1093/jb/mvx047
   Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341
   Passier R, 2003, CARDIOVASC RES, V58, P324, DOI 10.1016/S0008-6363(02)00770-8
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Peñaranda-Fajardo NM, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1934-1
   Pérez-Arancibia R, 2018, EXPERT OPIN THER TAR, V22, P97, DOI 10.1080/14728222.2018.1420169
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Rojas-Rivera D, 2017, CELL DEATH DIFFER, V24, P1100, DOI 10.1038/cdd.2017.58
   Rutkowski DT, 2010, J CELL BIOL, V189, P783, DOI 10.1083/jcb.201003138
   Saito A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103215
   Schneider K, 2015, J CELL SCI, V128, P3861, DOI 10.1242/jcs.173047
   Sequeira SJ, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000615
   Shen JS, 2002, DEV CELL, V3, P99, DOI 10.1016/S1534-5807(02)00203-4
   Sigurdsson V, 2018, INT J HEMATOL, V107, P627, DOI 10.1007/s12185-018-2458-7
   Simic MS, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aaw0025
   Siwecka N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184354
   Spaan CN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1729-4
   Stockwell SR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0028568
   Urra H, 2016, TRENDS CANCER, V2, P252, DOI 10.1016/j.trecan.2016.03.007
   Visvader JE, 2012, CELL STEM CELL, V10, P717, DOI 10.1016/j.stem.2012.05.007
   Walter P, 2011, SCIENCE, V334, P1081, DOI 10.1126/science.1209038
   Wang LF, 2015, PLOS GENET, V11, DOI 10.1371/journal.pgen.1005220
   Wang MX, 2018, CRIT REV ONCOL HEMAT, V127, P66, DOI 10.1016/j.critrevonc.2018.05.003
   Wang M, 2016, NATURE, V529, P326, DOI 10.1038/nature17041
   Wang SY, 2012, J CELL BIOL, V197, P857, DOI 10.1083/jcb.201110131
   Wey S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039047
   Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016
   Xing Y, 2016, ONCOTARGET, V7, P36395, DOI 10.18632/oncotarget.8954
   Yan Pengze, 2020, Cell Regen, V9, P22, DOI 10.1186/s13619-020-00064-2
NR 73
TC 28
Z9 32
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0006-2952
EI 1873-2968
J9 BIOCHEM PHARMACOL
JI Biochem. Pharmacol.
PD OCT
PY 2021
VL 192
AR 114737
DI 10.1016/j.bcp.2021.114737
EA AUG 2021
PG 7
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA US9US
UT WOS:000697771600011
PM 34411568
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Barnestein, R
   Galland, L
   Kalfeist, L
   Ghiringhelli, F
   Ladoire, S
   Limagne, E
AF Barnestein, Robby
   Galland, Loick
   Kalfeist, Laura
   Ghiringhelli, Francois
   Ladoire, Sylvain
   Limagne, Emeric
TI Immunosuppressive tumor microenvironment modulation by chemotherapies
   and targeted therapies to enhance immunotherapy effectiveness
SO ONCOIMMUNOLOGY
LA English
DT Review
DE Cancer; chemotherapy; immunotherapy; targeted therapy; immunosuppressive
   cells; tumor microenvironment
ID REGULATORY T-CELLS; METASTATIC COLORECTAL-CANCER; ENDOTHELIAL
   GROWTH-FACTOR; BREAST-CANCER; SUPPRESSOR-CELLS; PD-L1 EXPRESSION;
   ANTITUMOR IMMUNITY; TYROSINE KINASE; INFILTRATING LYMPHOCYTES;
   PANCREATIC-CANCER
AB With the rapid clinical development of immune checkpoint inhibitors (ICIs), the standard of care in cancer management has evolved rapidly. However, immunotherapy is not currently beneficial for all patients. In addition to intrinsic tumor factors, other etiologies of resistance to ICIs arise from the complex interplay between cancer and its microenvironment. Recognition of the essential role of the tumor microenvironment (TME) in cancer progression has led to a shift from a tumor-cell-centered view of cancer development, to the concept of a complex tumor ecosystem that supports tumor growth and metastatic dissemination. The expansion of immunosuppressive cells represents a cardinal strategy deployed by tumor cells to escape detection and elimination by the immune system. Regulatory T lymphocytes (Treg), myeloid-derived suppressor cells (MDSCs), and type-2 tumor-associated macrophages (TAM2) are major components of these inhibitory cellular networks, with the ability to suppress innate and adaptive anticancer immunity. They therefore represent major impediments to anticancer therapies, particularly immune-based interventions. Recent work has provided evidence that, beyond their direct cytotoxic effects on cancer cells, several conventional chemotherapeutic (CT) drugs and agents used in targeted therapies (TT) can promote the elimination or inactivation of suppressive immune cells, resulting in enhanced antitumor immunity. In this review, we will analyze findings pertaining to this concept, discuss the possible molecular bases underlying the selective targeting of these immunosuppressive cells by antineoplastic agents (CT and/or TT), and consider current challenges and future prospects related to the integration of these molecules into more efficient anticancer strategies, in the era of immunotherapy.
C1 [Barnestein, Robby; Galland, Loick; Kalfeist, Laura; Ghiringhelli, Francois; Ladoire, Sylvain; Limagne, Emeric] Univ Burgundy, Dijon, France.
   [Barnestein, Robby; Galland, Loick; Kalfeist, Laura; Ghiringhelli, Francois; Ladoire, Sylvain; Limagne, Emeric] Georges Francois Leclerc Canc Ctr, Platform Transfer Canc Biol, Dijon, France.
   [Galland, Loick; Ghiringhelli, Francois; Ladoire, Sylvain; Limagne, Emeric] Georges Francois Leclerc Ctr, Dept Med Oncol, Dijon, France.
   [Kalfeist, Laura; Ghiringhelli, Francois; Ladoire, Sylvain; Limagne, Emeric] Ctr Rech INSERM LNC UMR1231, Dijon, France.
   [Kalfeist, Laura; Ghiringhelli, Francois; Ladoire, Sylvain; Limagne, Emeric] Dijon Univ Hosp, Genom & Immunotherapy Med Inst, Dijon, France.
C3 Universite de Bourgogne; Institut Agro; AgroSup Dijon; UNICANCER; Centre
   Georges-Francois Leclerc; Universite de Bourgogne; UNICANCER; Centre
   Georges-Francois Leclerc; Universite de Bourgogne; Institut National de
   la Sante et de la Recherche Medicale (Inserm); Institut Agro; AgroSup
   Dijon; CHU Dijon Bourgogne
RP Limagne, E (corresponding author), UNICANCER, Platform Transfer Canc Biol, Georges Francois Leclerc Canc Ctr, 1 Rue Prof Marion, F-21000 Dijon, France.
EM elimagne@cgfl.fr
OI Emeric, Limagne/0000-0002-1098-8441
FU Ligue Nationale contre le Cancer; Ligue Nationale contre le Cancer
   Grand-Est; Institut National du Cancer (INCa); Association pour la
   Recherche sur le Cancer (ARC); Fondation AMGEN; LabEx LipSTIC; Region
   Bourgogne-Franche-Comte (BFC); I-Site-BFC program; GeorgesFrancois
   Leclerc Cancer Center
FX R.B., L.G., L.K., F.G, S.L. and E.L. are supported by the "Ligue
   Nationale contre le Cancer (Labelled teams)", the "Ligue Nationale
   contre le Cancer Grand-Est", the "Institut National du Cancer (INCa)",
   the "Association pour la Recherche sur le Cancer (ARC)", the "Fondation
   AMGEN", the "LabEx LipSTIC", the "Region Bourgogne-Franche-Comte (BFC)",
   and the "I-Site-BFC program". This study was also supported by the
   GeorgesFrancois Leclerc Cancer Center.
CR Abu-Eid R, 2014, CANCER IMMUNOL RES, V2, P1080, DOI 10.1158/2326-6066.CIR-14-0095
   Agata Y, 1996, INT IMMUNOL, V8, P765, DOI 10.1093/intimm/8.5.765
   Ali K, 2014, NATURE, V510, P407, DOI 10.1038/nature13444
   Allard B, 2017, IMMUNOL REV, V276, P121, DOI 10.1111/imr.12528
   Allegrezza MJ, 2016, CANCER RES, V76, P6253, DOI 10.1158/0008-5472.CAN-16-1308
   Apetoh L, 2007, NAT MED, V13, P1050, DOI 10.1038/nm1622
   Arnould L, 2006, BRIT J CANCER, V94, P259, DOI 10.1038/sj.bjc.6602930
   Balan M, 2015, J BIOL CHEM, V290, P8110, DOI 10.1074/jbc.M114.612689
   Barta JA, 2019, ANN GLOB HEALTH, V85, DOI 10.5334/aogh.2419
   Baumann D, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15979-2
   Beavis PA, 2013, P NATL ACAD SCI USA, V110, P14711, DOI 10.1073/pnas.1308209110
   Behjati S, 2009, CURR MED CHEM, V16, P3076, DOI 10.2174/092986709788803042
   Ben Baruch B, 2020, LAB INVEST, V100, P1517, DOI 10.1038/s41374-020-0458-8
   Ben-Shmuel A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00275
   Bloom MJ, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06868-4
   Bonavita E, 2020, IMMUNITY, V53, P1215, DOI 10.1016/j.immuni.2020.10.020
   Boustani J, 2021, CANCERS, V13, DOI 10.3390/cancers13194893
   Briere DM, 2021, MOL CANCER THER, V20, P975, DOI 10.1158/1535-7163.MCT-20-0462
   Brlic PK, 2019, CELL MOL IMMUNOL, V16, P40, DOI 10.1038/s41423-018-0168-y
   Buehler M, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/238284
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Cao MD, 2011, LAB INVEST, V91, P598, DOI 10.1038/labinvest.2010.205
   Carson WE, 2004, CLIN CANCER RES, V10, P3401, DOI 10.1158/1078-0432.CCR-1016-03
   Chan MSM, 2012, INT J BIOL MARKER, V27, pE295, DOI 10.5301/JBM.2012.10439
   Chang CJ, 2018, INT J CANCER, V142, P1878, DOI 10.1002/ijc.31216
   Chen C, 2015, J INT MED RES, V43, P180, DOI 10.1177/0300060514561504
   Chen JJW, 2005, J CLIN ONCOL, V23, P953, DOI 10.1200/JCO.2005.12.172
   Chen ML, 2014, INT J CANCER, V134, P319, DOI 10.1002/ijc.28362
   Chen XZ, 2021, THERANOSTICS, V11, P3392, DOI 10.7150/thno.52435
   Chen YC, 2015, HEPATOLOGY, V61, P1591, DOI 10.1002/hep.27665
   Chiu KC, 2015, ORAL ONCOL, V51, P683, DOI 10.1016/j.oraloncology.2015.04.004
   D'Amico L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-018-0464-1
   de Almeida PE, 2020, CANCER IMMUNOL RES, V8, P806, DOI 10.1158/2326-6066.CIR-19-0360
   de Andrade LF, 2014, CANCER RES, V74, P7298, DOI 10.1158/0008-5472.CAN-14-1339
   Demaria S, 2001, CLIN CANCER RES, V7, P3025
   DeNardo DG, 2011, CANCER DISCOV, V1, P54, DOI 10.1158/2159-8274.CD-10-0028
   Dent R, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS1117
   Desai J, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw370.19
   Ding LY, 2018, CELL REP, V25, P2972, DOI 10.1016/j.celrep.2018.11.054
   Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265
   Domchek SM, 2020, LANCET ONCOL, V21, P1155, DOI 10.1016/S1470-2045(20)30324-7
   Dominguez GA, 2017, CLIN CANCER RES, V23, P2942, DOI 10.1158/1078-0432.CCR-16-1784
   Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145
   Dosset M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1433981
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Du X, 2005, EUR J IMMUNOL, V35, P3414, DOI 10.1002/eji.200535366
   Dubovsky JA, 2013, BLOOD, V122, P2539, DOI 10.1182/blood-2013-06-507947
   Duffy AG, 2014, ANN ONCOL, V25, P24, DOI 10.1093/annonc/mdt349
   Emami F, 2021, J CONTROL RELEASE, V329, P645, DOI 10.1016/j.jconrel.2020.10.001
   Emens L, 2020, J IMMUNOTHER CANCER, V8, pA195, DOI 10.1136/jitc-2020-SITC2020.0317
   Eruslanov E, 2010, J LEUKOCYTE BIOL, V88, P839, DOI 10.1189/jlb.1209821
   Fakih M, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3560
   Fang DD, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0750-6
   Feng PH, 2014, AM J TRANSL RES, V6, P593
   Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745
   Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Flood BA, 2019, IMMUNOL REV, V290, P24, DOI 10.1111/imr.12765
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Gadgeel S, 2020, J CLIN ONCOL, V38, P1505, DOI 10.1200/JCO.19.03136
   Galetto Alessandra, 2003, Anticancer Drugs, V14, P833
   Galluzzi L, 2020, NAT REV CLIN ONCOL, V17, P725, DOI 10.1038/s41571-020-0413-z
   Galluzzi L, 2018, CELL DEATH DIFFER, V25, P486, DOI 10.1038/s41418-017-0012-4
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gameiro SR, 2011, CANCER IMMUNOL IMMUN, V60, P1227, DOI 10.1007/s00262-011-1020-8
   Ganten TM, 2006, CLIN CANCER RES, V12, P2640, DOI 10.1158/1078-0432.CCR-05-2635
   Generali D, 2009, CLIN CANCER RES, V15, P1046, DOI 10.1158/1078-0432.CCR-08-1507
   Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225
   Ghiringhelli F, 2004, EUR J IMMUNOL, V34, P336, DOI 10.1002/eji.200324181
   Ghiringhelli F, 2007, CANCER IMMUNOL IMMUN, V56, P641, DOI 10.1007/s00262-006-0225-8
   Ghiringhelli F, 2020, J CLIN ONCOL, V38
   Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465
   Gonzalez-Aparicio M, 2011, GUT, V60, P341, DOI 10.1136/gut.2010.211722
   Grabinski N, 2014, INVEST NEW DRUG, V32, P1096, DOI 10.1007/s10637-014-0141-2
   Griguolo G, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00163-6
   Haag GM, 2022, EUR J CANCER, V167, P112, DOI 10.1016/j.ejca.2022.03.017
   Halama N, 2016, CANCER CELL, V29, P587, DOI 10.1016/j.ccell.2016.03.005
   Hegde PS, 2018, SEMIN CANCER BIOL, V52, P117, DOI 10.1016/j.semcancer.2017.12.002
   Hervieu A, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.23714
   Hervieu A, 2013, J INVEST DERMATOL, V133, P499, DOI 10.1038/jid.2012.273
   Homma Y, 2014, CLIN TRANSL ONCOL, V16, P330, DOI 10.1007/s12094-013-1079-0
   Hong D, 2019, ONCOLOGY-BASEL, V97, P102, DOI 10.1159/000500571
   Horlock C, 2009, BRIT J CANCER, V100, P1061, DOI 10.1038/sj.bjc.6604963
   Hu XL, 2013, J BIOL CHEM, V288, P19103, DOI 10.1074/jbc.M112.434530
   Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691
   Huang H, 2015, FASEB J, V29, P227, DOI 10.1096/fj.14-250985
   Huang HH, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-020-01788-4
   Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109
   Ilangumaran S, 2016, CYTOKINE, V82, P125, DOI 10.1016/j.cyto.2015.12.013
   Iwamoto M, 2003, INT J CANCER, V104, P92, DOI 10.1002/ijc.10915
   Jain J, 2020, J IMMUNOTHER CANCER, V8, pA260, DOI 10.1136/jitc-2020-SITC2020.0427
   Jia YJ, 2019, INT J CANCER, V145, P1432, DOI 10.1002/ijc.32191
   Johnson B, 2009, CURR MOL MED, V9, P702, DOI 10.2174/156652409788970634
   Julía EP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9071573
   Kakavand H, 2015, CLIN CANCER RES, V21, P3140, DOI 10.1158/1078-0432.CCR-14-2023
   Kalathil SG, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1824863
   Kalathil SG, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.86182
   Kalfeist L, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11050770
   Kanterman J, 2014, CANCER RES, V74, P6022, DOI 10.1158/0008-5472.CAN-14-0657
   Kawaguchi N, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8020185
   Kawashima S, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003134
   Khallouf H, 2012, J IMMUNOTHER, V35, P245, DOI 10.1097/CJI.0b013e31824b3a76
   Kitamura H, 2017, CANCER SCI, V108, P1947, DOI 10.1111/cas.13332
   Kohlhapp FJ, 2021, CANCER DISCOV, V11, P68, DOI 10.1158/2159-8290.CD-19-0759
   Kwon M, 2021, J CONTROL RELEASE, V331, P321, DOI 10.1016/j.jconrel.2021.01.009
   Ladoire S, 2008, CLIN CANCER RES, V14, P2413, DOI 10.1158/1078-0432.CCR-07-4491
   Lapeyre-Prost A, 2017, INT REV CEL MOL BIO, V330, P295, DOI 10.1016/bs.ircmb.2016.09.007
   Le HK, 2009, INT IMMUNOPHARMACOL, V9, P900, DOI 10.1016/j.intimp.2009.03.015
   Lebbé C, 2019, J CLIN ONCOL, V37, P867, DOI 10.1200/JCO.18.01998
   Ledys F, 2021, CANCERS, V13, DOI 10.3390/cancers13235999
   Lee JW, 2019, J THORAC ONCOL, V14, P1046, DOI 10.1016/j.jtho.2019.02.004
   Li AL, 2018, CANCER LETT, V431, P54, DOI 10.1016/j.canlet.2018.05.005
   Li HQ, 2009, J IMMUNOL, V182, P240, DOI 10.4049/jimmunol.182.1.240
   Li JY, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/286170
   Li T, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188439
   Lian GH, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819849068
   Lim SH, 2014, ANTICANCER RES, V34, P6505
   Limagne E, 2022, CANCER CELL, V40, P136, DOI 10.1016/j.ccell.2021.12.009
   Limagne E, 2019, CANCER IMMUNOL RES, V7, P1958, DOI 10.1158/2326-6066.CIR-19-0228
   Limagne E, 2016, CANCER RES, V76, P5241, DOI 10.1158/0008-5472.CAN-15-3164
   Liu C, 2021, CLIN CANCER RES, V27, P342, DOI 10.1158/1078-0432.CCR-20-2718
   Liu D, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1372079
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Liu P, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09415-3
   Liu SC, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2511-3
   Liu SH, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-020-01724-8
   Long GV, 2019, LANCET ONCOL, V20, P1083, DOI 10.1016/S1470-2045(19)30274-8
   Manzoni M, 2010, ONCOLOGY-BASEL, V79, P187, DOI 10.1159/000320609
   Marciscano AE, 2021, SEMIN IMMUNOL, V52, DOI 10.1016/j.smim.2021.101481
   Mascia F, 2016, INT J CANCER, V139, P2593, DOI 10.1002/ijc.30376
   Mehta AK, 2021, NAT CANCER, V2, P66, DOI 10.1038/s43018-020-00148-7
   Miles D, 2021, ANN ONCOL, V32, P994, DOI 10.1016/j.annonc.2021.05.801
   Mills CD, 2012, CRIT REV IMMUNOL, V32, P463, DOI 10.1615/CritRevImmunol.v32.i6.10
   Min AKT, 2021, CANCER IMMUNOL IMMUN, V70, P289, DOI 10.1007/s00262-020-02676-8
   Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731
   Mittendorf EA, 2014, CANCER IMMUNOL RES, V2, P361, DOI 10.1158/2326-6066.CIR-13-0127
   Modi S, 2021, FUTURE ONCOL, V17, P3415, DOI 10.2217/fon-2021-0427
   Moerland JA, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-79260-8
   Mohrherr J, 2019, INT J CANCER, V145, P3376, DOI 10.1002/ijc.32624
   Moon YW, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0094-9
   Morse MA, 2019, CLIN CANCER RES, V25, P912, DOI 10.1158/1078-0432.CCR-18-1254
   Motz GT, 2014, NAT MED, V20, P607, DOI 10.1038/nm.3541
   Mundy-Bosse BL, 2011, CANCER RES, V71, P5101, DOI 10.1158/0008-5472.CAN-10-2670
   Nalbandian G, 2005, J IMMUNOL, V175, P2666, DOI 10.4049/jimmunol.175.4.2666
   Nowak AK, 2003, J IMMUNOL, V170, P4905, DOI 10.4049/jimmunol.170.10.4905
   Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4
   Ohm JE, 2001, IMMUNOL RES, V23, P263, DOI 10.1385/IR:23:2-3:263
   Ohue Y, 2019, CANCER SCI, V110, P2080, DOI 10.1111/cas.14069
   Ono M, 2012, BREAST CANCER RES TR, V132, P793, DOI 10.1007/s10549-011-1554-7
   Orecchioni S, 2018, BRIT J CANCER, V118, P1329, DOI 10.1038/s41416-018-0076-z
   Oyama R, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2022.13286
   Park SJ, 2004, J IMMUNOL, V173, P3844, DOI 10.4049/jimmunol.173.6.3844
   Park YH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19933-0
   Parkes EE, 2022, BRIT J CANCER, V126, P247, DOI 10.1038/s41416-021-01599-0
   Parra ER, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0368-0
   Patel KR, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442168
   Patel SP, 2015, MOL CANCER THER, V14, P847, DOI 10.1158/1535-7163.MCT-14-0983
   Peng HG, 2017, NANO LETT, V17, P7684, DOI 10.1021/acs.nanolett.7b03756
   Petroni G, 2021, CANCER CELL, V39, P310, DOI 10.1016/j.ccell.2020.11.009
   Pfirschke C, 2016, IMMUNITY, V44, P343, DOI 10.1016/j.immuni.2015.11.024
   Poon E, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0268-8
   Prendergast GC, 2018, INT REV CEL MOL BIO, V336, P175, DOI 10.1016/bs.ircmb.2017.07.004
   Prima V, 2017, P NATL ACAD SCI USA, V114, P1117, DOI 10.1073/pnas.1612920114
   Qu XY, 2013, INT IMMUNOPHARMACOL, V17, P1141, DOI 10.1016/j.intimp.2013.10.019
   Quintela-Fandino M, 2020, BREAST CANCER RES, V22, DOI 10.1186/s13058-020-01362-y
   Ramalingam SS, 2020, NEW ENGL J MED, V382, P41, DOI 10.1056/NEJMoa1913662
   Ramjiawan RR, 2017, ANGIOGENESIS, V20, P185, DOI 10.1007/s10456-017-9552-y
   Raskov H, 2021, BRIT J CANCER, V124, P359, DOI 10.1038/s41416-020-01048-4
   Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774
   Reguera-Nuñez E, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0999-5
   Ribas A, 2018, SCIENCE, V359, P1350, DOI 10.1126/science.aar4060
   Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016
   Robson M, 2017, NEW ENGL J MED, V377, P523, DOI 10.1056/NEJMoa1706450
   Roland CL, 2009, MOL CANCER THER, V8, P1761, DOI 10.1158/1535-7163.MCT-09-0280
   Roselli M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27025
   Sagiv-Barfi I, 2015, P NATL ACAD SCI USA, V112, pE966, DOI 10.1073/pnas.1500712112
   Salvagno C, 2019, NAT CELL BIOL, V21, P511, DOI 10.1038/s41556-019-0298-1
   Sawant A, 2013, CANCER RES, V73, P6609, DOI 10.1158/0008-5472.CAN-13-0987
   Schirripa M, 2019, PHARMACOGENOMICS J, V19, P455, DOI 10.1038/s41397-019-0075-3
   Schmid P, 2020, NEW ENGL J MED, V382, P810, DOI [10.1056/NEJMoa1910549, 10.1056/NEJMc2006684]
   Schmid P, 2020, LANCET ONCOL, V21, P44, DOI 10.1016/S1470-2045(19)30689-8
   Schneider BP, 2005, J CLIN ONCOL, V23, P1782, DOI 10.1200/JCO.2005.12.017
   Sciarra A, 2019, CANCER IMMUNOL IMMUN, V68, P467, DOI 10.1007/s00262-018-2290-1
   Serafini P, 2006, J EXP MED, V203, P2691, DOI 10.1084/jem.20061104
   Shafiekhani S, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08770-z
   Shimizu K, 2017, CANCER MANAG RES, V9, P741, DOI 10.2147/CMAR.S146897
   Sinha P, 2007, J IMMUNOL, V179, P977, DOI 10.4049/jimmunol.179.2.977
   Soria JC, 2018, NEW ENGL J MED, V378, P113, DOI 10.1056/NEJMoa1713137
   Stanley ER, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a021857
   Stiff A, 2016, CANCER RES, V76, P2125, DOI 10.1158/0008-5472.CAN-15-1490
   Svensson S, 2015, CLIN CANCER RES, V21, P3794, DOI 10.1158/1078-0432.CCR-15-0204
   Szebeni GJ, 2016, INT J MOL SCI, V17, DOI 10.3390/ijms17111958
   Takahashi K, 2014, CANCER CHEMOTH PHARM, V74, P721, DOI 10.1007/s00280-014-2548-z
   Takigawa H, 2016, CANCER SCI, V107, P601, DOI 10.1111/cas.12907
   Tang HL, 2019, J PHARMACOL EXP THER, V368, P401, DOI 10.1124/jpet.118.254359
   Tang KH, 2022, CANCER DISCOV, V12, P47, DOI 10.1158/2159-8290.CD-21-0369
   Teo ZL, 2017, CANCER RES, V77, P6340, DOI 10.1158/0008-5472.CAN-17-2210
   Tiu C, 2021, CANCER RES, V81, pCT120, DOI [10.1158/1538-7445.AM2021-CT120, DOI 10.1158/1538-7445.AM2021-CT120]
   Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7
   Tomasini P, 2019, THER ADV RESPIR DIS, V13, DOI 10.1177/1753466619831906
   Travis WD, 2011, J THORAC ONCOL, V6, P244, DOI 10.1097/JTO.0b013e318206a221
   Tsavaris N, 2002, BRIT J CANCER, V87, P21, DOI 10.1038/sj.bjc.6600347
   Tutt ANJ, 2021, NEW ENGL J MED, V384, P2394, DOI 10.1056/NEJMoa2105215
   Varikuti S, 2020, BRIT J CANCER, V122, P1005, DOI 10.1038/s41416-020-0743-8
   Viaud S, 2015, CELL DEATH DIFFER, V22, P199, DOI 10.1038/cdd.2014.56
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Vilain RE, 2017, CLIN CANCER RES, V23, P5024, DOI 10.1158/1078-0432.CCR-16-0698
   Vinayak S, 2019, JAMA ONCOL, V5, P1132, DOI 10.1001/jamaoncol.2019.1029
   Vincent J, 2010, CANCER RES, V70, P3052, DOI 10.1158/0008-5472.CAN-09-3690
   Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559
   WALUNAS TL, 1994, IMMUNITY, V1, P405, DOI 10.1016/1074-7613(94)90071-X
   Wang DZ, 2016, TRENDS MOL MED, V22, P1, DOI 10.1016/j.molmed.2015.11.003
   Wang LL, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax2282
   Wang QH, 2020, CANCER IMMUNOL IMMUN, V69, P1781, DOI 10.1007/s00262-020-02576-x
   Wang SH, 2016, J BIOL CHEM, V291, P21085, DOI 10.1074/jbc.M116.717892
   Wang ZB, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-38534-6
   Wang ZB, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1331807
   Weinlich G, 2007, DERMATOLOGY, V214, P8, DOI 10.1159/000096906
   Weiss EM, 2011, J IMMUNOL, V187, P1684, DOI 10.4049/jimmunol.1002321
   Weisser Shelley B, 2013, Methods Mol Biol, V946, P225, DOI 10.1007/978-1-62703-128-8_14
   Whittle JR, 2020, CLIN CANCER RES, V26, P4120, DOI 10.1158/1078-0432.CCR-19-1872
   Wrzesinski SH, 2007, CLIN CANCER RES, V13, P5262, DOI 10.1158/1078-0432.CCR-07-1157
   Xu M, 2015, J IMMUNOL, V194, P4997, DOI 10.4049/jimmunol.1402603
   Yang J, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00978
   Yang R, 2018, IMMUNOLOGY, V155, P263, DOI 10.1111/imm.12949
   Yin TT, 2019, CANCER RES, V79, P3431, DOI 10.1158/0008-5472.CAN-18-3397
   Young A, 2017, CANCER RES, V77, P4684, DOI 10.1158/0008-5472.CAN-17-0393
   Young A, 2014, CANCER DISCOV, V4, P879, DOI 10.1158/2159-8290.CD-14-0341
   Yu SJ, 2019, J HEPATOL, V70, P449, DOI 10.1016/j.jhep.2018.10.040
   Yuan CH, 2015, ONCOTARGET, V6, P32138, DOI 10.18632/oncotarget.5171
   Yuan M, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.683502
   Yuan X, 2018, CANCER METAST REV, V37, P733, DOI 10.1007/s10555-018-9728-y
   Zelenay S, 2015, CELL, V162, P1257, DOI 10.1016/j.cell.2015.08.015
   Zhang D, 2019, THERANOSTICS, V9, P6224, DOI 10.7150/thno.36281
   Zhang L, 2008, CLIN IMMUNOL, V129, P219, DOI 10.1016/j.clim.2008.07.013
   Zhang QW, 2019, CLIN CANCER RES, V25, P3630, DOI 10.1158/1078-0432.CCR-18-2548
   Zhang XH, 2014, ANTI-CANCER DRUG, V25, P204, DOI 10.1097/CAD.0000000000000033
   Zhang ZG, 2015, CANCER LETT, V369, P331, DOI 10.1016/j.canlet.2015.10.002
   Zhao F, 2018, CANCER IMMUNOL RES, V6, P1459, DOI 10.1158/2326-6066.CIR-18-0086
   Zhao YH, 2021, LIFE SCI, V267, DOI 10.1016/j.lfs.2020.118953
   Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30
   Zhu HZ, 2020, CELL ONCOL, V43, P1203, DOI 10.1007/s13402-020-00552-2
   Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646
NR 243
TC 44
Z9 44
U1 2
U2 55
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD DEC 31
PY 2022
VL 11
IS 1
AR 2120676
DI 10.1080/2162402X.2022.2120676
PG 29
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA 4M5HF
UT WOS:000853353800001
PM 36117524
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Brunsell, TH
   Cengija, V
   Sveen, A
   Bjornbeth, BA
   Rosok, BI
   Brudvik, KW
   Guren, MG
   Lothe, RA
   Abildgaard, A
   Nesbakken, A
AF Brunsell, Tuva Host
   Cengija, Vanja
   Sveen, Anita
   Bjornbeth, Bjorn Atle
   Rosok, Bard, I
   Brudvik, Kristoffer Watten
   Guren, Marianne Gronlie
   Lothe, Ragnhild A.
   Abildgaard, Andreas
   Nesbakken, Arild
TI Heterogeneous radiological response to neoadjuvant therapy is associated
   with poor prognosis after resection of colorectal liver metastases
SO EJSO
LA English
DT Article
DE Colorectal cancer; Liver metastases; Surgery; Neoadjuvant chemotherapy;
   Response; Prognosis
ID POSITRON-EMISSION-TOMOGRAPHY; COMPUTED-TOMOGRAPHY; PREOPERATIVE
   CHEMOTHERAPY; SYSTEMIC THERAPY; TARGETED THERAPY; CANCER; SURVIVAL;
   RECIST; PROGRESSION; CRITERIA
AB Introduction: Surgery combined with perioperative chemotherapy has become standard of care in patients with resectable colorectal liver metastases. However, poor outcome is expected for a significant subgroup. The clinical implications of inter-metastatic heterogeneity remain largely unknown. In a prospective, population-based series of patients undergoing resection of multiple colorectal liver metastases, the aim was to investigate the prevalence and prognostic impact of heterogeneous response to neoadjuvant chemotherapy.
   Materials and Methods: Radiological response to treatment was evaluated in a lesion-specific manner in 2-5 metastases per patient. Change of lesion diameter was evaluated and response/progression was classified according to three different size thresholds; 3, 4 and 5 mm. A heterogeneous response was defined as progression and response of different metastases in the same patient.
   Results: In total, 142 patients with 585 liver metastases were examined with the same radiological method (MRI or CT) before and after neoadjuvant treatment. Heterogeneous response to treatment was seen in 16 patients (11%) using the 3 mm size change threshold, and this group had a 5-year cancer-specific survival of 19% compared to 49% for patients with response in all lesions (p = 0.003). Cut-off values of 4-5 mm were less sensitive for detecting a heterogeneous response, but the survival difference was similar and significant.
   Conclusion: A subgroup of patients with multiple colorectal liver metastases had heterogeneous radiological response to neoadjuvant chemotherapy and poor prognosis. The evaluation of response pattern is easy to perform, feasible in clinical practice and, if validated, a promising biomarker for treatment decisions. (C) 2019 The Authors. Published by Elsevier Ltd.
C1 [Brunsell, Tuva Host; Sveen, Anita; Lothe, Ragnhild A.] Oslo Univ Hosp, Inst Canc Res, Dept Mol Oncol, POB 4950 Nydalen, N-0424 Oslo, Norway.
   [Brunsell, Tuva Host; Cengija, Vanja; Sveen, Anita; Bjornbeth, Bjorn Atle; Rosok, Bard, I; Brudvik, Kristoffer Watten; Guren, Marianne Gronlie; Lothe, Ragnhild A.; Abildgaard, Andreas; Nesbakken, Arild] Oslo Univ Hosp, KG Jebsen Colorectal Canc Res Ctr, POB 4950 Nydalen, N-0424 Oslo, Norway.
   [Brunsell, Tuva Host; Sveen, Anita; Lothe, Ragnhild A.; Nesbakken, Arild] Univ Oslo, Inst Clin Med, POB 1171 Blindern, N-0318 Oslo, Norway.
   [Cengija, Vanja; Abildgaard, Andreas] Oslo Univ Hosp, Dept Radiol & Nucl Med, POB 4950 Nydalen, N-0424 Oslo, Norway.
   [Bjornbeth, Bjorn Atle; Rosok, Bard, I; Brudvik, Kristoffer Watten; Nesbakken, Arild] Oslo Univ Hosp, Dept Gastrointestinal Surg, POB 4950 Nydalen, N-0424 Oslo, Norway.
   [Guren, Marianne Gronlie] Oslo Univ Hosp, Dept Oncol, POB 4956 Nydalen, N-0424 Oslo, Norway.
C3 University of Oslo; University of Oslo; University of Oslo; University
   of Oslo; University of Oslo; University of Oslo
RP Nesbakken, A (corresponding author), POB 4956 Nydalen, N-0424 Oslo, Norway.
EM t.h.brunsell@medisin.uio.no; vancen@ous-hf.no;
   anita.sveen@rr-research.no; bbjoer@ous-hf.no; brosok@ous-hf.no;
   krbrud@ous-hf.no; marianne.gronlie.guren@ous-hf.no;
   ragnhild.a.lothe@rr-research.no; aabildga@ous-hf.no;
   Arild.Nesbakken@medisin.uio.no
RI Guren, Marianne/A-4119-2008
OI Lothe, Ragnhild A./0000-0002-1693-1032; Sveen,
   Anita/0000-0001-8219-6251; Guren, Marianne/0000-0003-0593-0218
FU Stiftelsen Kristian Gerhard Jebsen; Southern and Eastern Norway Regional
   Health Authority; Norwegian Cancer Society [6824048-2016, 182759-2016];
   University of Oslo/the Research Council of Norway (FRIPRO Toppforsk)
   [250993]
FX The authors thank Magdalena Kowalewska-Harbiyeli and Gyda G.
   Christiansen for assistance in patient inclusion, biobanking and
   clinical data registration. This study was supported by Stiftelsen
   Kristian Gerhard Jebsen, the Southern and Eastern Norway Regional Health
   Authority, the Norwegian Cancer Society (project number 6824048-2016 to
   A. S. and project number 182759-2016 to R.A. L.) and the University of
   Oslo/the Research Council of Norway (FRIPRO Toppforsk, project number
   250993 to R.A.L.).
CR Adam R, 2004, ANN SURG, V240, P1052, DOI 10.1097/01.sla.0000145964.08365.01
   Adam R, 2015, CANCER TREAT REV, V41, P729, DOI 10.1016/j.ctrv.2015.06.006
   Benjamin RS, 2007, J CLIN ONCOL, V25, P1760, DOI 10.1200/JCO.2006.07.3411
   Brudvik Kristoffer Watten, 2013, HPB Surg, V2013, P727095, DOI 10.1155/2013/727095
   Chiappa A, 2009, HEPATO-GASTROENTEROL, V56, P829
   Chiu KWH, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4687-9
   Choi H, 2007, J CLIN ONCOL, V25, P1753, DOI 10.1200/JCO.2006.07.3049
   Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755
   Chung WS, 2012, AM J ROENTGENOL, V199, P809, DOI 10.2214/AJR.11.7910
   Formiga MND, 2016, J GASTROINTEST ONCOL, V7, P365, DOI 10.21037/jgo.2016.02.04
   de Geus-Oei LF, 2009, J NUCL MED, V50, p43S, DOI 10.2967/jnumed.108.057224
   de Ridder JAM, 2016, EUR J CANCER, V59, P13, DOI 10.1016/j.ejca.2016.02.003
   Dong ZY, 2017, ONCOLOGIST, V22, P61, DOI 10.1634/theoncologist.2016-0150
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Elias D, 2017, LIVER CANCER, V6, P90, DOI 10.1159/000449492
   Fiorentini G, 2017, WORLD J CLIN ONCOL, V8, P190, DOI 10.5306/wjco.v8.i3.190
   Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004
   Fretland ÅA, 2018, ANN SURG, V267, P199, DOI 10.1097/SLA.0000000000002353
   Gallagher DJ, 2009, ANN SURG ONCOL, V16, P1844, DOI 10.1245/s10434-009-0348-1
   Grothey A, 2008, J CLIN ONCOL, V26, P183, DOI 10.1200/JCO.2007.13.8099
   Hendlisz A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138341
   Jaffe CC, 2006, J CLIN ONCOL, V24, P3245, DOI 10.1200/JCO.2006.06.5599
   Jain RK, 2012, J CLIN ONCOL, V30, P2684, DOI 10.1200/JCO.2011.36.4752
   Khoo E, 2016, HPB, V18, P485, DOI 10.1016/j.hpb.2016.03.001
   Ma B, 2017, ANN ONCOL, V28, P1576, DOI 10.1093/annonc/mdx149
   Mao R, 2017, ONCOTARGET, V8, P75151, DOI 10.18632/oncotarget.20647
   Menzies AM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085004
   Neumann UP, 2009, SURGERY, V146, P52, DOI 10.1016/j.surg.2009.02.004
   Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.3.CO;2-R
   Nordlinger B, 2013, LANCET ONCOL, V14, P1208, DOI 10.1016/S1470-2045(13)70447-9
   Punt CJA, 2007, JNCI-J NATL CANCER I, V99, P998, DOI 10.1093/jnci/djm024
   Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283
   Shindoh J, 2012, J CLIN ONCOL, V30, P4566, DOI 10.1200/JCO.2012.45.2854
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   van Kessel CS, 2013, EUR J CANCER, V49, P2486, DOI 10.1016/j.ejca.2013.03.027
   Viganò L, 2012, ANN SURG ONCOL, V19, P2786, DOI 10.1245/s10434-012-2382-7
   Wahl RL, 2009, J NUCL MED, V50, p122S, DOI 10.2967/jnumed.108.057307
   Wilkerson J, 2009, CANCER J, V15, P379, DOI 10.1097/PPO.0b013e3181bef8cd
   Winter KS, 2018, EUR RADIOL, V28, P4839, DOI 10.1007/s00330-018-5424-0
   Woff E, 2016, EUR J NUCL MED MOL I, V43, P1792, DOI 10.1007/s00259-016-3365-x
   Zhao BS, 2014, CLIN CANCER RES, V20, P3560, DOI 10.1158/1078-0432.CCR-14-0245
NR 41
TC 14
Z9 14
U1 1
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0748-7983
EI 1532-2157
J9 EJSO-EUR J SURG ONC
JI EJSO
PD DEC
PY 2019
VL 45
IS 12
BP 2340
EP 2346
DI 10.1016/j.ejso.2019.07.017
PG 7
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA JU4KL
UT WOS:000501646400016
PM 31350075
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Zhu, Y
   Zhang, XC
   Lou, XE
   Chen, M
   Luo, PH
   He, QJ
AF Zhu, Yi
   Zhang, Xiaochen
   Lou, Xiaoe
   Chen, Min
   Luo, Peihua
   He, Qiaojun
TI Vascular endothelial growth factor (VEGF) antibody significantly
   increases the risk of hand-foot skin reaction to multikinase inhibitors
   (MKIs): A systematic literature review and meta-analysis
SO CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
LA English
DT Review
DE antivascular endothelial growth factor antibody; hand-foot skin reaction
   (HFSR); HFSR risk; meta-analysis; multikinase inhibitors (MKIs)
ID INDUCED ACRAL ERYTHEMA; COMBINATION TARGETED THERAPY; RENAL-CELL;
   PHASE-II; COLORECTAL-CANCER; SORAFENIB; BEVACIZUMAB; CHEMOTHERAPY;
   SUNITINIB; 5-FLUOROURACIL
AB With the use of multikinase inhibitors (MKIs) having emerged in recent years, skin toxicities such as hand-foot skin reaction (HFSR) are primary side effects, and they lack effective prediction methods. Here, we updated a previous systematic review by establishing a meta-analysis of the risk of developing HFSR among patients receiving MKIs and antivascular endothelial growth factor antibody. Publications from PubMed and abstracts presented at the American Society of Clinical Oncology Annual Meeting up to February 5, 2015, were searched to identify relevant studies, and a total of 236 patients with metastatic tumours in nine trials were included for analysis. In the meta-analysis, the pooled incidence rates of all-grade and high-grade HFSR among patients who received the combination therapy were 56.9% [95% confidence interval (CI), 45%-71.1%] and 14.3% (95%CI, 9%-24.2%), respectively, with significant differences observed with MKI monotherapy (P < .05). Further subgroup analysis demonstrated that increasing the dosages of bevacizumab (77.8% vs 51.1%, P = .04) and MKIs (64.3% vs 52.6%, P = .02) significantly increased HFSR incidence. Moreover, combination with chemotherapy exerted a minimal effect on HFSR risk (61% vs 55.3%, P = .5). This updated review and meta-analysis confirm the increased risk of HFSR incidence due to the use of MKIs and antivascular endothelial growth factor antibody. Thus, using these therapies requires safety standards.
C1 [Zhu, Yi; Lou, Xiaoe; Luo, Peihua; He, Qiaojun] Zhejiang Univ, Zhejiang Prov Key Lab Anticanc Drug Res, Inst Pharmacol & Toxicol, Coll Pharmaceut Sci, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Xiaochen] Zhejiang Univ, Affiliated Hosp 1, Dept Med Oncol, Coll Med, Hangzhou, Zhejiang, Peoples R China.
   [Chen, Min] Zhejiang Hosp, Dept Pharm, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Luo, PH; He, QJ (corresponding author), Zhejiang Univ, Hangzhou, Zhejiang, Peoples R China.
EM peihualuo@zju.edu.cn; qiaojunhe@zju.edu.cn
RI Zhu, Yi/JDM-1998-2023; Zhang, Xiaochen/HHS-9663-2022
OI Luo, Peihua/0000-0002-6576-2052
FU Public Projects of Zhejiang Province [2016C31005]; Zhejiang Province
   Joint Construction Project [WSK2014-2-007]; National Natural Science
   Foundation of China [81473288, 81673522]
FX Public Projects of Zhejiang Province, Grant/Award Number: No.
   2016C31005; Zhejiang Province Joint Construction Project, Grant/Award
   Number: No. WSK2014-2-007; National Natural Science Foundation of China,
   Grant/Award Number: Nos. 81473288 and Nos. 81673522
CR Abushullaih S, 2002, CANCER INVEST, V20, P3, DOI 10.1081/CNV-120000360
   [Anonymous], 2009, COMM TOX CRIT V
   Autier J, 2008, ARCH DERMATOL, V144, P886, DOI 10.1001/archderm.144.7.886
   Azad NS, 2008, J CLIN ONCOL, V26, P3709, DOI 10.1200/JCO.2007.10.8332
   Balagula Y, 2012, INVEST NEW DRUG, V30, P1773, DOI 10.1007/s10637-011-9652-2
   BEARD JS, 1993, J AM ACAD DERMATOL, V29, P325, DOI 10.1016/0190-9622(93)70187-X
   Breccia M, 2005, EUR J HAEMATOL, V74, P121, DOI 10.1111/j.1600-0609.2004.00351.x
   Castellano D, 2013, EUR J CANCER, V49, P3780, DOI 10.1016/j.ejca.2013.06.042
   Chu D, 2008, ACTA ONCOL, V47, P176, DOI 10.1080/02841860701765675
   Chu D, 2009, CLIN GENITOURIN CANC, V7, P11, DOI 10.3816/CGC.2009.n.002
   CRIDER MK, 1986, ARCH DERMATOL, V122, P1023, DOI 10.1001/archderm.122.9.1023
   Demetri GD, 2006, LANCET, V368, P1329, DOI 10.1016/S0140-6736(06)69446-4
   Demircay Z, 1997, INT J DERMATOL, V36, P593, DOI 10.1046/j.1365-4362.1997.00040.x
   DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2
   Drake RD, 2004, GYNECOL ONCOL, V94, P320, DOI 10.1016/j.ygyno.2004.05.027
   Ehnman M, 2014, EXPERT OPIN INV DRUG, V23, P211, DOI 10.1517/13543784.2014.847086
   Escudier B, 2007, NEW ENGL J MED, V356, P125, DOI 10.1056/NEJMoa060655
   FABIAN CJ, 1990, INVEST NEW DRUG, V8, P57
   Fischer A, 2013, INVEST NEW DRUG, V31, P787, DOI 10.1007/s10637-013-9927-x
   Galanis E, 2013, CLIN CANCER RES, V19, P4816, DOI 10.1158/1078-0432.CCR-13-0708
   Gomez P, 2011, ONCOLOGIST, V16, P1508, DOI 10.1634/theoncologist.2011-0115
   GORDON KB, 1995, CANCER, V75, P2169, DOI 10.1002/1097-0142(19950415)75:8<2169::AID-CNCR2820750822>3.0.CO;2-H
   Grandinetti CA, 2007, PHARMACOTHERAPY, V27, P1125, DOI 10.1592/phco.27.8.1125
   Gridelli C, 2007, ONCOLOGIST, V12, P191, DOI 10.1634/theoncologist.12-2-191
   Hipp MM, 2008, BLOOD, V111, P5610, DOI 10.1182/blood-2007-02-075945
   KROLL SS, 1989, ANN PLAS SURG, V23, P263, DOI 10.1097/00000637-198909000-00012
   Lau J, 1997, ANN INTERN MED, V127, P820, DOI 10.7326/0003-4819-127-9-199711010-00008
   Lee JM, 2010, BRIT J CANCER, V102, P495, DOI 10.1038/sj.bjc.6605514
   Mahalingam D, 2014, CANCER CHEMOTH PHARM, V74, P77, DOI 10.1007/s00280-014-2479-8
   Mina LA, 2013, INVEST NEW DRUG, V31, P1307, DOI 10.1007/s10637-013-9976-1
   Motzer RJ, 2007, NEW ENGL J MED, V356, P115, DOI 10.1056/NEJMoa065044
   Nagore E, 2000, Am J Clin Dermatol, V1, P225, DOI 10.2165/00128071-200001040-00004
   Navid F, 2013, CLIN CANCER RES, V19, P236, DOI 10.1158/1078-0432.CCR-12-1897
   Robert C, 2005, LANCET ONCOL, V6, P491, DOI 10.1016/S1470-2045(05)70243-6
   Schenone S, 2007, CURR MED CHEM, V14, P2495, DOI 10.2174/092986707782023622
   Schultheis B, 2012, INT J CLIN PHARM TH, V50, P72, DOI 10.5414/CPP50072
   SHALL L, 1988, BRIT J DERMATOL, V119, P249, DOI 10.1111/j.1365-2133.1988.tb03208.x
   Sharma S, 2010, ANN ONCOL, V21, P297, DOI 10.1093/annonc/mdp489
   Tsai KY, 2006, J CLIN ONCOL, V24, P5786, DOI 10.1200/JCO.2006.08.6868
   Vargas-Díez E, 1999, ACTA DERM-VENEREOL, V79, P173
   Virakul S, 2014, EUR THYROID J, V3, P217, DOI 10.1159/000367968
   Yang CH, 2008, BRIT J DERMATOL, V158, P592, DOI 10.1111/j.1365-2133.2007.08357.x
   Zeng Xiantao, 2015, J Evid Based Med, V8, P2, DOI 10.1111/jebm.12141
   Zhang RX, 2012, ANN ONCOL, V23, P1348, DOI 10.1093/annonc/mdr400
   ZIMMERMAN GC, 1995, ARCH DERMATOL, V131, P202, DOI 10.1001/archderm.131.2.202
NR 45
TC 7
Z9 7
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1870
EI 1440-1681
J9 CLIN EXP PHARMACOL P
JI Clin. Exp. Pharmacol. Physiol.
PD JUL
PY 2018
VL 45
IS 7
BP 659
EP 667
DI 10.1111/1440-1681.12935
PG 9
WC Pharmacology & Pharmacy; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy; Physiology
GA GK4DX
UT WOS:000436106900006
PM 29543385
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Cheng, LX
   Zhou, RX
   Chen, M
   Feng, LN
   Li, HY
AF Cheng, Lixia
   Zhou, Ruixiu
   Chen, Min
   Feng, Linan
   Li, Hongyan
TI MicroRNA-150 targets Rho-associated protein kinase 1 to inhibit cell
   proliferation, migration and invasion in papillary thyroid carcinoma
SO MOLECULAR MEDICINE REPORTS
LA English
DT Article
DE microRNA-150; papillary thyroid carcinoma; growth; metastasis;
   Rho-associated protein kinase 1
ID HUMAN COLORECTAL-CANCER; TUMOR-SUPPRESSOR; POOR-PROGNOSIS; METASTASIS;
   EXPRESSION; MIR-150; GROWTH; REGULATORS; APOPTOSIS
AB Thyroid cancer is the most prevalent malignant tumor of the endocrine organs and accounts for one third of all head and neck tumors. Dysregulation of microRNAs is well-known to contribute to the development of various cancers, including papillary thyroid carcinoma (PTC), which accounts for 80-90% of all thyroid cancer cases. The present study aimed to investigate the expression, functional roles of microRNA-150 (miR-150) and its direct target gene in PTC. miR-150 expression in PTC tissues and cell lines was analyzed by reverse transcription-quantitative polymerase chain reaction (RT-qPCR). After transfection with miR-150 mimics, cell proliferation, migration and invasion was analyzed by MTT and Transwell assays, respectively. Bioinformatics analysis was performed to investigate the potential target genes of miR-150, which were then confirmed by luciferase reporter assay, RT-qPCR and western blotting. Functional assays were also applied to investigate the effects of endogenous Rho-associated protein kinase 1 (ROCK1) in PTC. miR-150 was demonstrated to be significantly downregulated in PTC tissues and cell lines. In addition, reduced miR-150 expression was obviously correlated with TNM stage and lymph node metastasis in PTC patients. Restoration of miR-150 expression significantly inhibited PTC cell proliferation, migration and invasion in vitro. Furthermore, ROCK1 was identified as a direct target gene of miR-150. Therefore, ROCK1 knockdown may serve tumor suppressive functions in PTC, induced by miR-150 overexpression. In conclusion, miR-150 overexpression in PTC may inhibit growth and metastasis of PTC cells. miR-150/ROCK1-based targeted therapy may be a potential strategy for the treatment of PTC.
C1 [Cheng, Lixia; Chen, Min; Feng, Linan; Li, Hongyan] Weifang Med Univ, Dept Endocrine, Weifang Peoples Hosp, 151 Guangwen Rd, Weifang 261000, Shandong, Peoples R China.
   [Zhou, Ruixiu] Weifang Med Univ, Dept Endocrine, Gaomi Peoples Hosp, Weifang 261000, Shandong, Peoples R China.
C3 Shandong Second Medical University; Shandong Second Medical University
RP Li, HY (corresponding author), Weifang Med Univ, Dept Endocrine, Weifang Peoples Hosp, 151 Guangwen Rd, Weifang 261000, Shandong, Peoples R China.
EM hongyan_li151@163.com
RI Liu, You-Nian/G-2697-2013
CR Ambros V, 2001, CELL, V107, P823, DOI 10.1016/S0092-8674(01)00616-X
   Chen W, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0357-4
   Cho BY, 2013, THYROID, V23, P797, DOI 10.1089/thy.2012.0329
   Davies L, 2015, ENDOCR PRACT, V21, P686, DOI 10.4158/EP14466.DSCR
   Feng JL, 2014, J CELL MOL MED, V18, P2125, DOI 10.1111/jcmm.12398
   Fernandez S, 2015, ONCOGENE, V34, P3240, DOI 10.1038/onc.2014.267
   Geraldo MV, 2012, ARQ BRAS ENDOCRINOL, V56, P552, DOI 10.1590/S0004-27302012000800015
   Gu XY, 2014, TUMOR BIOL, V35, P5287, DOI 10.1007/s13277-014-1688-4
   Hodge LS, 2011, BLOOD CANCER J, V1, DOI 10.1038/bcj.2011.25
   Huang SY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080707
   Ito M, 2014, BLOOD, V123, P1499, DOI 10.1182/blood-2013-09-527739
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Jin MF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103965
   Li J, 2015, BMC MOL BIOL, V16, DOI 10.1186/s12867-015-0052-6
   Li X, 2015, CYTOGENET GENOME RES, V146, P124, DOI 10.1159/000437379
   Liao WT, 2014, J PATHOL, V232, P415, DOI 10.1002/path.4309
   Lima CR, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2146-z
   Liu DZ, 2015, J BUON, V20, P173
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lochhead PA, 2010, ONCOGENE, V29, P2591, DOI 10.1038/onc.2010.3
   Lock FE, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031423
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Oellers P, 2009, GLIA, V57, P499, DOI 10.1002/glia.20777
   Pizzini S, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-589
   Schneider AB, 2005, NAT CLIN PRACT ENDOC, V1, P82, DOI 10.1038/ncpendmet0022
   Shah NR, 2014, WORLD J CLIN ONCOL, V5, P48, DOI 10.5306/wjco.v5.i2.48
   Sherman SI, 2003, LANCET, V361, P501, DOI 10.1016/S0140-6736(03)12488-9
   Srivastava A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076994
   Srivastava SK, 2011, CARCINOGENESIS, V32, P1832, DOI 10.1093/carcin/bgr223
   Sun W, 2016, ONCOTARGET, V7, P11595, DOI 10.18632/oncotarget.7292
   Vasko VV, 2007, CURR OPIN ONCOL, V19, P11, DOI 10.1097/CCO.0b013e328011ab86
   Wang WH, 2014, ASIAN PAC J CANCER P, V15, P6269, DOI 10.7314/APJCP.2014.15.15.6269
   Watanabe A, 2011, LEUKEMIA, V25, P1324, DOI 10.1038/leu.2011.81
   Wu Q, 2010, BIOCHEM BIOPH RES CO, V392, P340, DOI 10.1016/j.bbrc.2009.12.182
   Yang Q, 2013, J CLIN ENDOCR METAB, V98, pE1909, DOI 10.1210/jc.2013-2583
   Yin QW, 2015, INT J CLIN EXP PATHO, V8, P842
   Yokobori T, 2013, CANCER SCI, V104, P48, DOI 10.1111/cas.12030
   Yu FJ, 2015, DIAGN PATHOL, V10, DOI 10.1186/s13000-015-0369-y
   Zheng HT, 2016, CANCER RES TREAT, V48, P698, DOI 10.4143/crt.2015.118
   Zhou X, 2013, BIOCHEM BIOPH RES CO, V437, P653, DOI 10.1016/j.bbrc.2013.07.033
NR 40
TC 21
Z9 21
U1 0
U2 4
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1791-2997
EI 1791-3004
J9 MOL MED REP
JI Mol. Med. Rep.
PD AUG
PY 2017
VL 16
IS 2
BP 2217
EP 2224
DI 10.3892/mmr.2017.6842
PG 8
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA EZ9VX
UT WOS:000405079300160
PM 28656254
OA Bronze
DA 2025-01-04
ER

PT J
AU Leichsenring, J
   Volckmar, AL
   Magios, N
   de Oliveira, CMM
   Penzel, R
   Brandt, R
   Kirchner, M
   Bozorgmehr, F
   Thomas, M
   Schirmacher, P
   Warth, A
   Endris, V
   Stenzinger, A
AF Leichsenring, Jonas
   Volckmar, Anna-Lena
   Magios, Nikolaus
   de Oliveira, Cristiano Manuel Morais
   Penzel, Roland
   Brandt, Regine
   Kirchner, Martina
   Bozorgmehr, Farastuk
   Thomas, Michael
   Schirmacher, Peter
   Warth, Arne
   Endris, Volker
   Stenzinger, Albrecht
TI Synonymous EGFR Variant p.Q787Q is Neither Prognostic Nor Predictive in
   Patients with Lung Adenocarcinoma
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID TARGETED THERAPY; GENE FUSIONS; COPY NUMBER; CANCER; MUTATIONS;
   RESISTANCE; RET; EFFICACY; GENOME; HEAD
AB Patients with non-small cell lung cancer (NSCLC) harboring activating mutations in the Epidermal Growth Factor Receptor (EGFR) benefit from targeted therapies. A synonymous polymorphism (rs1050171, p.Q787Q) was shown to be associated with improved overall survival (OS) in colorectal cancer patients. As data in NSCLC are limited, we retrospectively analyzed associations of p.Q787Q with clinicopathological parameters including clinical response and outcome in patients with lung adenocarcinoma (ADC) who received tyrosine kinase inhibitor (TKI) therapy. Of 642 ADC patients whose tumors were profiled by next generation sequencing, 102 (15.9%) carried EGFR mutations targetable by TKIs (30.4% male patients, median age 65.1 y, 19.6% smokers with 12.8 median pack years). Seventy-nine patients (77.5%) received TKI therapy either as a first-or second-line therapy. Of the 102 EGFR-mutant tumors, 72 (70.6%) exhibited the p.Q787Q polymorphism and another 12 (11.8%) cases with p.Q787Q harbored an additional TKI insensitive mutation (p.T790M). The polymorphism was neither associated with classic clinicopathological parameters nor with overall survival (21.1 months vs. 20.1 months; P-value = 0.91) or clinical response (P-value = 0.122). The patients with p.T790M had worse survival compared to EGFR activating mutation carriers with and without p.Q787Q when analyzed as a separate group (27.5 months, P-value = 0.02). In conclusion, p.Q787Q is neither a suitable prognostic nor predictive biomarker for ADC patients receiving anti-EGFR therapy in first-or second-line of therapy. (C) 2016 Wiley Periodicals, Inc.
C1 [Leichsenring, Jonas; Volckmar, Anna-Lena; de Oliveira, Cristiano Manuel Morais; Penzel, Roland; Brandt, Regine; Kirchner, Martina; Schirmacher, Peter; Warth, Arne; Endris, Volker; Stenzinger, Albrecht] Univ Heidelberg Hosp, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
   [Magios, Nikolaus; Bozorgmehr, Farastuk; Thomas, Michael] Heidelberg Univ, Translat Lung Res Ctr, Thoraxklin, Thorac Oncol, Heidelberg, Germany.
   [Thomas, Michael; Warth, Arne] German Ctr Lung Res DZL, Heidelberg, Germany.
   [Stenzinger, Albrecht] Nat Ctr Tumor Dis NCT, Heidelberg, Germany.
   [Schirmacher, Peter; Stenzinger, Albrecht] German Canc Consortium DKTK, Heidelberg, Germany.
C3 Ruprecht Karls University Heidelberg; Ruprecht Karls University
   Heidelberg; Helmholtz Association; German Cancer Research Center (DKFZ)
RP Stenzinger, A (corresponding author), Univ Heidelberg Hosp, Inst Pathol, Neuenheimer Feld 224, D-69120 Heidelberg, Germany.
EM albrecht.stenzinger@med.uni-heidelberg.de
RI Bozorgmehr, Farastuk/KYR-8189-2024; Volckmar, Anna-Lena/ABE-3676-2021
FU German Cancer Consortium (DKTK); German Center for Lung Research (DZL)
FX Funded by the German Cancer Consortium (DKTK; to PS and AS) and German
   Center for Lung Research (DZL; to MT and AW).
CR Betel D, 2008, NUCLEIC ACIDS RES, V36, pD149, DOI 10.1093/nar/gkm995
   Bonin S, 2016, TUMOR BIOL, V37, P7295, DOI 10.1007/s13277-015-4543-3
   Cheng XH, 2014, ONCOTARGETS THER, V7, P1689, DOI 10.2147/OTT.S66502
   Daily K, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-495
   de Biase D, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083607
   Endris V, 2013, J MOL DIAGN, V15, P765, DOI 10.1016/j.jmoldx.2013.06.002
   Fåhraeus R, 2016, ONCOGENE, V35, P3753, DOI 10.1038/onc.2015.454
   Fukushima T, 2006, J NEUROPATH EXP NEUR, V65, P12, DOI 10.1097/01.jnen.0000196132.66464.96
   Gao X, 2016, EXPERT REV ANTICANC, V16, P383, DOI 10.1586/14737140.2016.1162103
   Griffiths-Jones Sam, 2010, Curr Protoc Bioinformatics, VChapter 12, DOI 10.1002/0471250953.bi1209s29
   Ju YS, 2012, GENOME RES, V22, P436, DOI 10.1101/gr.133645.111
   Koh YW, 2016, ONCOLOGY-BASEL, V90, P289, DOI 10.1159/000444495
   Kohno T, 2012, NAT MED, V18, P375, DOI 10.1038/nm.2644
   Kwak EL, 2010, NEW ENGL J MED, V363, P1693, DOI 10.1056/NEJMoa1006448
   Lee J, 2007, CANCER-AM CANCER SOC, V109, P1561, DOI 10.1002/cncr.22559
   Lin YX, 2014, AM J CANCER RES, V4, P411
   Lipson D, 2012, NAT MED, V18, P382, DOI 10.1038/nm.2673
   Longatto A, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-212
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Mathelier A, 2016, NUCLEIC ACIDS RES, V44, pD110, DOI 10.1093/nar/gkv1176
   Metzger B, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-144
   Nakazaki K, 2010, ONCOL LETT, V1, P1017, DOI 10.3892/ol.2010.188
   Ohgaki H, 2004, CANCER RES, V64, P6892, DOI 10.1158/0008-5472.CAN-04-1337
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2005, J CLIN ONCOL, V23, P2556, DOI 10.1200/JCO.2005.07.799
   Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P821, DOI 10.1002/gcc.22378
   Pfarr N, 2016, GENE CHROMOSOME CANC, V55, P30, DOI 10.1002/gcc.22297
   Spaans JN, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00190
   Su MC, 2005, CANCER LETT, V224, P117, DOI 10.1016/j.canlet.2004.10.010
   Supek F, 2016, J MOL EVOL, V82, P65, DOI 10.1007/s00239-015-9714-8
   Taguchi T, 2008, ONCOL REP, V19, P65
   Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658
   Therneau T.M., 2020, Modeling Survival Data: Extending the Cox Model, DOI 10.1007/978-1-4757-3294-8
   Wang DD, 2016, MOL BIOSYST, V12, P1552, DOI 10.1039/c6mb00038j
   Warth A, 2012, VIRCHOWS ARCH, V460, P407, DOI 10.1007/s00428-012-1219-x
   Young-Chul K, 2012, CLIN CANCER RES, V18, DOI 10.1158/1078-0432.12AACRIASLC-B43
   Zhang WP, 2006, J THORAC ONCOL, V1, P635
NR 37
TC 7
Z9 7
U1 0
U2 6
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD MAR
PY 2017
VL 56
IS 3
BP 214
EP 220
DI 10.1002/gcc.22427
PG 7
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA EL2CE
UT WOS:000394426900004
PM 27750395
DA 2025-01-04
ER

PT J
AU Zhou, FY
   Ding, JX
AF Zhou, Fangyue
   Ding, Jingxin
TI Prognosis and factors affecting colorectal cancer with ovarian
   metastasis
SO UPDATES IN SURGERY
LA English
DT Review
DE Colorectal cancer; Ovarian metastasis; Prognosis; Clinical pathological
   features; Genetic features; Treatments
ID HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; CYTOREDUCTIVE SURGERY;
   SURGICAL-TREATMENT; PROPHYLACTIC OOPHORECTOMY; PULMONARY METASTASES;
   KRUKENBERG TUMORS; COLON-CANCER; APPENDICEAL; IMPACT; SURVIVAL
AB Colorectal cancer is one of the most common malignant tumors. Its incidence has been increasing in recent years, as has the number of cases of ovarian metastasis of colorectal cancer. The prognosis of colorectal cancer with ovarian metastasis is poor, and it is an important cause of death in female patients. A variety of clinicopathological factors were found to be related to the prognosis of patients with colorectal cancer with ovarian metastasis, such as menopausal status, metastasis limited to the pelvis, and tumor differentiation. Tumor genetic characteristics also provide a new perspective for the prognostic evaluation of colorectal cancer with ovarian metastasis. The prognosis of ovarian metastasis is also closely associated with treatment. The major treatment methods are prophylactic oophorectomy, surgical resection of the primary and metastatic lesions, cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy and systematic therapy. If feasible, complete surgical resection of the primary and ovarian metastatic macroscopic lesions combined with postoperative chemotherapy might currently be the most effective treatment for improving the prognosis of patients with colorectal cancer with ovarian metastasis. Genetic analysis also provides a theoretical basis for potential targeted therapy and immunotherapy.
C1 [Zhou, Fangyue; Ding, Jingxin] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, 419 Fang Xie Rd, Shanghai 200011, Peoples R China.
C3 Fudan University
RP Ding, JX (corresponding author), Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol, 419 Fang Xie Rd, Shanghai 200011, Peoples R China.
EM djxdd@sina.com
CR Al-Busaidi IS, 2019, ANZ J SURG, V89, P1091, DOI 10.1111/ans.14930
   [Anonymous], 2020, NCCN Clinical Practice Guidelines in Oncology: Survivorship
   Bakkers C, 2020, INT J COLORECTAL DIS, V35, P1035, DOI 10.1007/s00384-020-03555-5
   BALLANTYNE GH, 1993, CANCER, V71, P4252, DOI 10.1002/1097-0142(19930615)71:12+<4252::AID-CNCR2820711815>3.0.CO;2-6
   Banerjee S, 2005, COLORECTAL DIS, V7, P214, DOI 10.1111/j.1463-1318.2005.00770.x
   Bignell MB, 2018, COLORECTAL DIS, V20, P704, DOI 10.1111/codi.14057
   BIRNKRANT A, 1986, DIS COLON RECTUM, V29, P767, DOI 10.1007/BF02555331
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Byun JH, 2019, KOREAN J INTERN MED, V34, P165, DOI 10.3904/kjim.2016.348
   Cano, 2014, J CLIN ONCOL, DOI [10.5772/57487, DOI 10.5772/57487]
   Christensen TD, 2018, ACTA ONCOL, V57, P1057, DOI 10.1080/0284186X.2018.1433322
   Chung TS, 2009, J SURG ONCOL, V100, P570, DOI 10.1002/jso.21382
   Colorectal Cancer Committee CMDA, 2020, CHIN J COLOREC DIS, V9, P115, DOI DOI 10.3877/CMA.J.ISSN.2095-3224.2020.02.002
   Erroi F, 2007, J SURG ONCOL, V96, P113, DOI 10.1002/jso.20803
   Eveno C, 2013, ANN SURG ONCOL, V20, P491, DOI 10.1245/s10434-012-2623-9
   Fujiwara A, 2010, J SURG ONCOL, V102, P582, DOI 10.1002/jso.21675
   FUJIWARA K, 1995, GYNECOL ONCOL, V59, P124, DOI 10.1006/gyno.1995.1278
   Ganesh K, 2017, CANCER-AM CANCER SOC, V123, P1134, DOI 10.1002/cncr.30424
   Goéré D, 2008, EJSO-EUR J SURG ONC, V34, P1335, DOI 10.1016/j.ejso.2008.03.010
   GRAFFNER HOL, 1983, AM J SURG, V146, P233, DOI 10.1016/0002-9610(83)90380-X
   Hanna Nader N, 2004, Clin Colorectal Cancer, V3, P215, DOI 10.3816/CCC.2004.n.002
   He WZ, 2019, J NATL COMPR CANC NE, V17, P1173, DOI 10.6004/jnccn.2019.7308
   Headrick JR, 2001, ANN THORAC SURG, V71, P975, DOI 10.1016/S0003-4975(00)02522-4
   Iavazzo C, 2020, INT J COLORECTAL DIS, V35, P1335, DOI 10.1007/s00384-020-03613-y
   Jeung Yi Jo, 2015, Obstet Gynecol Sci, V58, P32, DOI 10.5468/ogs.2015.58.1.32
   Jiang R, 2009, EJSO-EUR J SURG ONC, V35, P92, DOI 10.1016/j.ejso.2008.05.006
   Kammar PS, 2017, INDIA J SURG ONCOL, V8, P519, DOI 10.1007/s13193-017-0667-9
   KARSH J, 1951, AM J OBSTET GYNECOL, V61, P154, DOI 10.1016/0002-9378(51)90018-X
   Kato MK, 2020, INT J CLIN ONCOL, V25, P1663, DOI 10.1007/s10147-020-01717-7
   Kim DD, 2009, COLORECTAL DIS, V11, P32, DOI 10.1111/j.1463-1318.2008.01543.x
   Kir G, 2010, WORLD J GASTRO SURG, V2, P109, DOI 10.4240/wjgs.v2.i4.109
   Lee SJ, 2010, CANCER CHEMOTH PHARM, V66, P229, DOI 10.1007/s00280-009-1150-2
   Lee SJ, 2009, J KOREAN MED SCI, V24, P114, DOI 10.3346/jkms.2009.24.1.114
   Li JL, 2019, BMC CLIN PATHOL, V19, DOI 10.1186/s12907-019-0085-8
   Li XF, 2020, CANCER MANAG RES, V12, P4493, DOI 10.2147/CMAR.S254876
   Liang JT, 2007, ANN SURG ONCOL, V14, P1991, DOI 10.1245/s10434-007-9346-3
   McCormick CC, 2007, GYNECOL ONCOL, V105, P791, DOI 10.1016/j.ygyno.2007.02.025
   Mehta AM, 2017, DIS COLON RECTUM, V60, P691, DOI 10.1097/DCR.0000000000000791
   Miller BE, 1997, GYNECOL ONCOL, V66, P368, DOI 10.1006/gyno.1997.4811
   Milovanov V, 2016, ANN SURG ONCOL, V23, P1928, DOI 10.1245/s10434-015-5047-5
   Moore RG, 2004, GYNECOL ONCOL, V93, P87, DOI 10.1016/j.ygyno.2003.12.039
   Mori Yoshiko, 2018, Oncotarget, V9, P16477, DOI 10.18632/oncotarget.24735
   Omranipour R, 2009, INT J GYNECOL CANCER, V19, P1524, DOI 10.1111/IGC.0b013e3181a84011
   Rayson D, 2000, J SURG ONCOL, V75, P186, DOI 10.1002/1096-9098(200011)75:3<186::AID-JSO6>3.0.CO;2-S
   Regnard JF, 1998, ANN THORAC SURG, V66, P214, DOI 10.1016/S0003-4975(98)00269-0
   Gomes JR, 2017, EJSO-EUR J SURG ONC, V43, P15, DOI 10.1016/j.ejso.2016.05.019
   Segelman J, 2010, BRIT J SURG, V97, P1704, DOI 10.1002/bjs.7196
   Sekine K, 2018, ONCOLOGY-BASEL, V95, P220, DOI 10.1159/000489665
   Stukan M, 2019, DIAGNOSTICS, V9, DOI 10.3390/diagnostics9040210
   Tai HY, 2018, J IMMUNOL RES, V2018, DOI 10.1155/2018/9485285
   Tan KL, 2010, INT J COLORECTAL DIS, V25, P233, DOI 10.1007/s00384-009-0796-x
   Ursem C, 2020, ONCOLOGIST, V25, P564, DOI 10.1634/theoncologist.2019-0282
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   van Oudheusden TR, 2015, J SURG ONCOL, V111, P237, DOI 10.1002/jso.23784
   Wright JD, 2004, GYNECOL ONCOL, V92, P851, DOI 10.1016/j.ygyno.2003.12.017
   Xu KY, 2017, WORLD J SURG ONCOL, V15, DOI 10.1186/s12957-016-1087-y
   Young-Fadok TM, 1998, DIS COLON RECTUM, V41, P277, DOI 10.1007/BF02237479
   Zhou R, 2020, INT J CLIN ONCOL, V25, P1822, DOI 10.1007/s10147-020-01730-w
NR 58
TC 7
Z9 8
U1 0
U2 8
PU SPRINGER-VERLAG ITALIA SRL
PI MILAN
PA VIA DECEMBRIO, 28, MILAN, 20137, ITALY
SN 2038-131X
EI 2038-3312
J9 UPDATES SURG
JI Updates Surg.
PD APR
PY 2021
VL 73
IS 2
BP 391
EP 398
DI 10.1007/s13304-021-00978-9
EA FEB 2021
PG 8
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA RE7RT
UT WOS:000613580400001
PM 33523414
DA 2025-01-04
ER

PT J
AU Möller, Y
   Morkel, M
   Schmid, J
   Beyes, S
   Hendrick, J
   Strotbek, M
   Riemer, P
   Schmid, S
   Schmitt, LC
   Kontermann, R
   Mürdter, T
   Schwab, M
   Sers, C
   Olayioye, MA
AF Moeller, Yvonne
   Morkel, Markus
   Schmid, Jens
   Beyes, Sven
   Hendrick, Janina
   Strotbek, Michaela
   Riemer, Pamela
   Schmid, Simone
   Schmitt, Lisa C.
   Kontermann, Roland
   Muerdter, Thomas
   Schwab, Matthias
   Sers, Christine
   Olayioye, Monilola A.
TI Oncogenic Ras triggers hyperproliferation and impairs polarized colonic
   morphogenesis by autocrine ErbB3 signaling
SO ONCOTARGET
LA English
DT Article
DE oncogenic Ras; ErbB3/HER3; 3D culture; intestinal organoids;
   apical-basolateral polarity
ID GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; K-RAS; COLORECTAL-CANCER;
   TARGETED THERAPY; EPITHELIAL-CELLS; MEK INHIBITION; UP-REGULATION; HER3;
   RESISTANCE
AB Here we study the effects of inducible oncogenic K-Ras (G12V) expression on the polarized morphogenesis of colonic epithelial cells. We provide evidence that the autocrine production of heregulins, ligands for the ErbB3 receptor tyrosine kinase, is responsible for the hyperproliferation and aberrant 3D morphogenesis upon oncogenic K-Ras expression. This is in line with results obtained in primary intestinal organoid cultures, in which exogenous heregulin is shown to interfere with normal tissue architecture. Importantly, ErbB3 inhibition and heregulin gene silencing rescued K-Ras(G12V)-induced features of cell transformation. Together with the increased ErbB3 positivity detected in human high-grade primary colorectal cancers, our findings provide support for an autocrine signaling loop engaged by oncogenic K-Ras involving ErbB3 that contributes to the dedifferentiation of the intestinal epithelium during tumor initiation and progression.
C1 [Moeller, Yvonne; Beyes, Sven; Hendrick, Janina; Strotbek, Michaela; Schmid, Simone; Schmitt, Lisa C.; Kontermann, Roland; Olayioye, Monilola A.] Univ Stuttgart, Inst Cell Biol & Immunol, Stuttgart, Germany.
   [Morkel, Markus; Riemer, Pamela; Sers, Christine] Charite Univ Med Berlin, Inst Pathol, Lab Mol Tumor Pathol & Syst Biol, Berlin, Germany.
   [Schmid, Jens; Muerdter, Thomas; Schwab, Matthias] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany.
   [Schmid, Jens; Muerdter, Thomas; Schwab, Matthias] Univ Tubingen, Stuttgart, Germany.
   [Riemer, Pamela; Sers, Christine] German Canc Consortium, DKTK, Partner Site Charite, Berlin, Germany.
   [Kontermann, Roland; Olayioye, Monilola A.] Univ Stuttgart, Stuttgart Res Ctr Syst Biol SRCSB, Stuttgart, Germany.
   [Schwab, Matthias] Univ Hosp, Dept Clin Pharmacol, Tubingen, Germany.
   [Schwab, Matthias] Univ Tubingen, Dept Biochem & Pharm, Tubingen, Germany.
   [Beyes, Sven] Univ Freiburg, Inst Mol Med & Cell Res, Fac Biol, Freiburg, Germany.
C3 University of Stuttgart; Berlin Institute of Health; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Eberhard Karls University of Tubingen; Eberhard Karls University
   Hospital; Eberhard Karls University of Tubingen; Helmholtz Association;
   German Cancer Research Center (DKFZ); University of Stuttgart; Eberhard
   Karls University of Tubingen; Eberhard Karls University Hospital;
   Eberhard Karls University of Tubingen; University of Freiburg
RP Olayioye, MA (corresponding author), Univ Stuttgart, Inst Cell Biol & Immunol, Stuttgart, Germany.; Olayioye, MA (corresponding author), Univ Stuttgart, Stuttgart Res Ctr Syst Biol SRCSB, Stuttgart, Germany.
EM monilola.olayioye@izi.uni-stuttgart.de
RI Schmid, Simone/ABD-5209-2021; Sers, Christine/B-5438-2010; Morkel,
   Markus/HLQ-0079-2023; Schwab, Matthias/ABH-7449-2020
OI Schwab, Matthias/0000-0002-9984-075X; Riemer,
   Pamela/0000-0003-3231-7056; Beyes, Sven/0000-0002-7665-6829; Sers,
   christine/0000-0002-6219-1514; Morkel, Markus/0000-0002-2553-9999;
   Schmitt, Lisa/0000-0003-2593-1285
FU Bundesministerium fur Bildung und Forschung (BMBF) e:Bio grant
   'PREDICT'; OncoPATH; German Cancer Consortium DKTK; Robert Bosch
   Foundation (Stuttgart, Germany); Heisenberg program of the Deutsche
   Forschungsgemeinschaft (DFG)
FX This work was funded by the Bundesministerium fur Bildung und Forschung
   (BMBF) e:Bio grant 'PREDICT' (MAO, RK, MS) and OncoPATH (CS, MM), the
   German Cancer Consortium DKTK (CS) and the Robert Bosch Foundation
   (Stuttgart, Germany). MAO is funded by the Heisenberg program of the
   Deutsche Forschungsgemeinschaft (DFG).
CR Amin DN, 2010, SEMIN CELL DEV BIOL, V21, P944, DOI 10.1016/j.semcdb.2010.08.007
   Aranda V, 2006, NAT CELL BIOL, V8, P1235, DOI 10.1038/ncb1485
   Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023
   Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656
   Beji A, 2012, CLIN CANCER RES, V18, P956, DOI 10.1158/1078-0432.CCR-11-1186
   Brand Toni M, 2012, Small GTPases, V3, P34, DOI 10.4161/sgtp.18751
   Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050
   Breuleux M, 2007, CELL MOL LIFE SCI, V64, P2358, DOI 10.1007/s00018-007-7120-0
   Debnath J, 2005, NAT REV CANCER, V5, P675, DOI 10.1038/nrc1695
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Fisel P, 2015, ONCOTARGET, V6, P30615, DOI 10.18632/oncotarget.5593
   Fux R, 2005, CLIN CANCER RES, V11, P4754, DOI 10.1158/1078-0432.CCR-04-2586
   Gala K, 2014, CLIN CANCER RES, V20, P1410, DOI 10.1158/1078-0432.CCR-13-1549
   Gangarosa LM, 1997, J BIOL CHEM, V272, P18926, DOI 10.1074/jbc.272.30.18926
   Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108
   Garrett TPJ, 2003, MOL CELL, V11, P495, DOI 10.1016/S1097-2765(03)00048-0
   Gespach C, 2012, CLIN CANCER RES, V18, P917, DOI 10.1158/1078-0432.CCR-11-3143
   GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132
   Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100
   Hothorn T., 2006, LEGO SYSTEM CONDITIO
   Jaffe AB, 2008, J CELL BIOL, V183, P625, DOI 10.1083/jcb.200807121
   Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012
   Lee D, 2009, J CLIN INVEST, V119, P2702, DOI 10.1172/JCI36435
   Lee GY, 2007, NAT METHODS, V4, P359, DOI 10.1038/NMETH1015
   Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380
   Linch M, 2014, CARCINOGENESIS, V35, P396, DOI 10.1093/carcin/bgt313
   Magudia K, 2012, J CELL BIOL, V198, P185, DOI 10.1083/jcb.201202108
   Möller Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0107165
   Montero JC, 2008, CLIN CANCER RES, V14, P3237, DOI 10.1158/1078-0432.CCR-07-5133
   Navas C, 2012, CANCER CELL, V22, P318, DOI 10.1016/j.ccr.2012.08.001
   Normanno N, 2009, NAT REV CLIN ONCOL, V6, P519, DOI 10.1038/nrclinonc.2009.111
   Ootani A, 2009, NAT MED, V15, P1, DOI 10.1038/nm.1951
   Röring M, 2012, EMBO J, V31, P2629, DOI 10.1038/emboj.2012.100
   Sato T, 2013, SCIENCE, V340, P1190, DOI 10.1126/science.1234852
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Sergina NV, 2007, NATURE, V445, P437, DOI 10.1038/nature05474
   Steinkamp MP, 2014, MOL CELL BIOL, V34, P965, DOI 10.1128/MCB.01605-13
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Toulany M, 2007, MOL CANCER RES, V5, P863, DOI 10.1158/1541-7786.MCR-06-0297
   Turke AB, 2012, CANCER RES, V72, P3228, DOI 10.1158/0008-5472.CAN-11-3747
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   Van Schaeybroeck S, 2011, CANCER RES, V71, P1071, DOI 10.1158/0008-5472.CAN-10-0714
   Vaught DB, 2012, CANCER RES, V72, P2672, DOI 10.1158/0008-5472.CAN-11-3594
   Vermeer PD, 2003, NATURE, V422, P322, DOI 10.1038/nature01440
   Walther A, 2009, NAT REV CANCER, V9, P489, DOI 10.1038/nrc2645
   Wang S, 2013, BREAST CANC RES
   Wheeler DL, 2008, ONCOGENE, V27, P3944, DOI 10.1038/onc.2008.19
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
NR 50
TC 10
Z9 10
U1 0
U2 3
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD AUG 16
PY 2016
VL 7
IS 33
BP 53526
EP 53539
DI 10.18632/oncotarget.10658
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY9DG
UT WOS:000385433000069
PM 27447549
OA Green Published, gold, Green Submitted
DA 2025-01-04
ER

PT J
AU Oytun, MG
   Bulut, G
   Gökmen, E
   Dogu, BB
   Karabulut, B
AF Oytun, Merve Guner
   Bulut, Gulcan
   Gokmen, Erhan
   Dogu, Burcu B.
   Karabulut, Bulent
TI Older adults with colon cancer are not different from younger ones, but
   treated differently: Retrospective analysis from single centre
SO JOURNAL OF ONCOLOGY PHARMACY PRACTICE
LA English
DT Article
DE Cancer treatment; colon cancer; age difference; decision-making
ID METASTATIC COLORECTAL-CANCER; ELDERLY-PATIENTS; ADJUVANT CHEMOTHERAPY;
   COMBINATION CHEMOTHERAPY; POOLED ANALYSIS; STAGE-II; THERAPY; AGE;
   OXALIPLATIN; SURVIVAL
AB Aim
   Decision- making of the treatment of colon cancer for the older patients becomes more complicated in consequence of comorbidities and geriatric syndromes, most importantly frailty. In the present study, we aimed to investigate whether there is a difference between tumour characteristics, treatment choices, and outcomes between the younger and older adults.
   Method
   The patients who were diagnosed with colorectal carcinoma in our centre between 2010 and 2015 included. Clinicopathological features of tumour, treatment choices and survivals of the patients were recorded. Patients were separated into two groups according to their chronological age.
   Results
   The present study included 465 patients, there were 173 patients aged 65 years and older. Clinicopathological features were similar in both groups. Adjuvant chemotherapy was given in similar rates. Whereas combination chemotherapies were preferred in younger patients as first-line therapy, single agents were given to the older group(p-value < 0.001). No significant differences were observed between combination therapy and monotherapy as progression-free and overall survival in older adults(p value > 0.05). It was observed that 53.2% of the older patients was not treated with any biological treatment (p-value < 0.001).
   Discussion
   Geriatric people are underrepresented in clinical trials,because of the presence of the limitations in the older patients. The results of our study revealed older patients with colon cancer patients underwent surgery less than the younger ones, they recieved monotherapy more frequently as first-line chemotherapy, and less frequently targeted therapy. Their mortality was higher. It was shown that decision-making of colon cancer therapy is influenced by age according to our results.
C1 [Oytun, Merve Guner; Dogu, Burcu B.] Hacettepe Univ, Dept Internal Med, Div Geriatr Med, Sch Med, Ankara, Turkey.
   [Bulut, Gulcan; Gokmen, Erhan; Karabulut, Bulent] Ege Univ, Dept Internal Med, Div Med Oncol, Sch Med, Izmir, Turkey.
C3 Hacettepe University; Ege University
RP Oytun, MG (corresponding author), Hacettepe Univ Hosp, Div Geriatr Med, Dept Internal Med, Ankara, Turkey.
EM mguner54@gmail.com
RI Bulut, Gülcan/AAH-8257-2021; Gokmen, Erhan/HKM-3785-2023; Guner,
   Merve/ISA-1949-2023
OI Guner, Merve/0000-0002-7417-5415; Bulut, Gulcan/0000-0001-7382-0972
CR André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Antonio M, 2017, ONCOLOGIST, V22, P934, DOI 10.1634/theoncologist.2016-0462
   Argyriou AA, 2012, ANN ONCOL, V23, P3116, DOI 10.1093/annonc/mds208
   Benson AB III, 2018, J NATL COMPR CANC NE, V16, P359, DOI 10.6004/jnccn.2018.0021
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bouché O, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2005.04.7118
   De Angelis R, 2014, LANCET ONCOL, V15, P23, DOI 10.1016/S1470-2045(13)70546-1
   Dekker JWT, 2011, ANN SURG ONCOL, V18, P1533, DOI 10.1245/s10434-011-1671-x
   Folprecht G, 2004, ANN ONCOL, V15, P1330, DOI 10.1093/annonc/mdh344
   Jemal A, 2009, CA-CANCER J CLIN, V59, P225, DOI 10.3322/caac.20006
   Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1
   Kozloff MF, 2010, ONCOLOGY-BASEL, V78, P329, DOI 10.1159/000320222
   Lawler M, 2014, BMJ-BRIT MED J, V348, DOI 10.1136/bmj.g1614
   McCleary NAJ, 2009, J CLIN ONCOL, V27
   Pal SK, 2010, J CLIN ONCOL, V28, P4086, DOI 10.1200/JCO.2009.27.0579
   Papamichael D, 2015, ANN ONCOL, V26, P463, DOI 10.1093/annonc/mdu253
   Potosky AL, 2002, J CLIN ONCOL, V20, P1192, DOI 10.1200/JCO.20.5.1192
   Sanoff HK, 2012, J CLIN ONCOL, V30, P2624, DOI 10.1200/JCO.2011.41.1140
   Sargent DJ, 2001, NEW ENGL J MED, V345, P1091, DOI 10.1056/NEJMoa010957
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Schrag D, 2001, J NATL CANCER I, V93, P850, DOI 10.1093/jnci/93.11.850
   Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3
   Simmonds P, 2000, LANCET, V356, P968, DOI 10.1016/S0140-6736(00)02713-6
   Tournigand C, 2012, J CLIN ONCOL, V30, P3353, DOI 10.1200/JCO.2012.42.5645
   Townsley CA, 2005, J CLIN ONCOL, V23, P3112, DOI 10.1200/JCO.2005.00.141
   Twelves CJ, 2006, CLIN COLORECTAL CANC, V6, P278, DOI 10.3816/CCC.2006.n.046
   Van Cutsem E, 2009, EJC SUPPL, V7, P349, DOI 10.1016/S1359-6349(09)71183-8
NR 28
TC 0
Z9 0
U1 2
U2 7
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1078-1552
EI 1477-092X
J9 J ONCOL PHARM PRACT
JI J. Oncol. Pharm. Pract.
PD APR
PY 2022
VL 28
IS 3
BP 569
EP 576
AR 10781552211002912
DI 10.1177/10781552211002912
EA MAR 2021
PG 8
WC Oncology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pharmacology & Pharmacy
GA 0U0CA
UT WOS:000634465200001
PM 33752476
DA 2025-01-04
ER

PT J
AU Hecht, JR
   Reid, TR
   Garrett, CR
   Beck, JT
   Davidson, SJ
   Mackenzie, MJ
   Brandt, U
   Rizvi, S
   Sharma, S
AF Hecht, J. Randolph
   Reid, Tony R.
   Garrett, Christopher R.
   Beck, J. Thaddeus
   Davidson, Sheldon J.
   Mackenzie, Mary J.
   Brandt, Ulrike
   Rizvi, Syed
   Sharma, Sunil
TI Phase I Study of Everolimus, Cetuximab and Irinotecan as Second-line
   Therapy in Metastatic Colorectal Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Dose determination; EGFR monoclonal antibody; mTOR inhibitor;
   targeted-therapy
ID PLUS IRINOTECAN; MAMMALIAN TARGET; 1ST-LINE TREATMENT; III TRIAL;
   FLUOROURACIL; LEUCOVORIN; KRAS; OXALIPLATIN; MONOTHERAPY; INHIBITION
AB Aim: To evaluate feasible doses of weekly everolimus and irinotecan given with cetuximab for previously treated metastatic colorectal cancer (mCRC). Patients and Methods: Adults with in mCRC that progressed after 5-fluorouracil or capecitabine-plus-oxaliplatin were treated using a sequential dose escalation scheme. Dosing decisions were based on the probability of experiencing a dose-limiting toxicity (DLT) during the,first two 21-day treatment cycles. Results: Patients received everolimus 30 mg/week plus irinotecan 350 mg/m(2) q3w (n=5; dose A1) or everolimus 30 mg/week plus irinotecan 250 mg/m(2) q3w (n=14; dose B1). Among patients evaluable for the maximum tolerated dose, two out of four in A1 and one out of eight in B1 experienced four DLTs. The trial was terminated early based on changes in clinical practice and emerging data on everolimus dosing. Conclusion: The feasible doses of everolimus and irinotecan administered with cetuximab as second-line therapy in mCRC were 30 mg/week and 250 mg/m(2), respectively.
C1 [Hecht, J. Randolph] Univ Calif Los Angeles, David Geffen Sch Med, Santa Monica, CA 90404 USA.
   [Reid, Tony R.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
   [Garrett, Christopher R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
   [Beck, J. Thaddeus] Highlands Oncol Grp, Fayetteville, AR USA.
   [Davidson, Sheldon J.] Leavey Canc Ctr, Northridge, CA USA.
   [Mackenzie, Mary J.] London Reg Canc Ctr, London, ON N6A 4L6, Canada.
   [Brandt, Ulrike] Novartis Pharma AG, Basel, Switzerland.
   [Rizvi, Syed] Novartis Pharmaceut, E Hanover, NJ USA.
   [Sharma, Sunil] Huntsman Canc Inst, Salt Lake City, UT USA.
C3 University of California System; University of California Los Angeles;
   University of California Los Angeles Medical Center; David Geffen School
   of Medicine at UCLA; University of California System; University of
   California San Diego; University of Texas System; UTMD Anderson Cancer
   Center; Highlands Oncology Group; Western University (University of
   Western Ontario); Novartis; Novartis; Novartis USA; Utah System of
   Higher Education; University of Utah; Huntsman Cancer Institute
RP Hecht, JR (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, 2825 Santa Monica Blvd,Suite 221, Santa Monica, CA 90404 USA.
EM jrhecht@mednet.ucla.edu
FU Novartis Pharmaceuticals Corporation
FX This study and editorial support in preparation of this manuscript
   [provided by Melanie Leiby, Ph.D. (ApotheCom, Yardley, PA. U.S.A.)] was
   funded by Novartis Pharmaceuticals Corporation.
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   André T, 1999, J CLIN ONCOL, V17, P3560, DOI 10.1200/JCO.1999.17.11.3560
   [Anonymous], 2014, NCCN Clinical Practice Guidelines in Oncology: Survivorship
   [Anonymous], P AM ASS CANC RES
   [Anonymous], 2006, COMMON TERMINOLOGY C
   Baselga J, 2012, NEW ENGL J MED, V366, P520, DOI 10.1056/NEJMoa1109653
   Bianco R, 2008, BRIT J CANCER, V98, P923, DOI 10.1038/sj.bjc.6604269
   Chua W, 2009, CLIN COLORECTAL CANC, V8, P118, DOI 10.3816/CCC.2009.n.019
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Frattini M, 2005, CANCER RES, V65, P11227, DOI 10.1158/0008-5472.CAN-05-2780
   Fuchs CS, 2003, J CLIN ONCOL, V21, P807, DOI 10.1200/JCO.2003.08.058
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Hecht JR, 2007, CANCER-AM CANCER SOC, V110, P980, DOI 10.1002/cncr.22915
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Manegold PC, 2008, CLIN CANCER RES, V14, P892, DOI 10.1158/1078-0432.CCR-07-0955
   Motzer RJ, 2010, CANCER-AM CANCER SOC, V116, P4256, DOI 10.1002/cncr.25219
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   O'Donnell A, 2008, J CLIN ONCOL, V26, P1588, DOI 10.1200/JCO.2007.14.0988
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Shahda S, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.3587
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   Tanaka Chiaki, 2008, J Clin Oncol, V26, P1596, DOI 10.1200/JCO.2007.14.1127
   Therasse P, 2000, J NATL CANCER I, V92, P205, DOI 10.1093/jnci/92.3.205
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022
   Yao JC, 2011, NEW ENGL J MED, V364, P514, DOI 10.1056/NEJMoa1009290
NR 31
TC 12
Z9 12
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD MAR
PY 2015
VL 35
IS 3
BP 1567
EP 1573
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CF3QF
UT WOS:000352462900044
PM 25750312
DA 2025-01-04
ER

PT J
AU Geva, R
   Tulchinsky, H
AF Geva, Ravit
   Tulchinsky, Hagit
TI The Role of Primary Tumor Resection (PTR) in Metastatic Colorectal
   Cancer
SO CURRENT COLORECTAL CANCER REPORTS
LA English
DT Article
DE Metastatic colorectal cancer; Primary tumor resection; Palliation;
   Overall survival
ID SYNCHRONOUS UNRESECTABLE METASTASES; ADVANCED RECTAL-CANCER; PALLIATIVE
   RESECTION; METALLIC STENTS; BREAST-CANCER; PHASE-II; SURGERY;
   CHEMOTHERAPY; OBSTRUCTION; OXALIPLATIN
AB Patients with unresectable metastatic colorectal cancer can either receive systemic chemotherapy as first treatment or have a palliative resection of the primary tumor or endoscopic placement of a self-expanding metallic stent if they present with colonic obstruction. The ongoing dilemma is whether resection of the primary tumor in asymptomatic patients is beneficial. The effectiveness of current systemic treatment regimens on the primary tumor as well as the survival benefit of primary tumor resection in the era of new chemotherapy agents, biologics, and targeted therapy is underreported. No prospective randomized studies have yet been published; nevertheless, based on the available literature, it seems that primary tumor (PTR) can possibly improve short-and long-term outcome in highly selected patients with favorable characteristics, specifically low tumor burden and good performance status.
C1 [Geva, Ravit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Div Oncol, Tel Aviv, Israel.
   [Tulchinsky, Hagit] Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Div Surg, Tel Aviv, Israel.
C3 Tel Aviv University; Tel Aviv University
RP Geva, R (corresponding author), Tel Aviv Univ, Sackler Fac Med, Tel Aviv Med Ctr, Div Oncol, Tel Aviv, Israel.
EM ravitg@tlvmc.gov.il
CR Ahmed S, 2014, CANCER-AM CANCER SOC, V120, P683, DOI 10.1002/cncr.28464
   Al-Sanea N, 2004, ANZ J SURG, V74, P229, DOI 10.1111/j.1445-2197.2004.02946.x
   [Anonymous], 2011 ASCO ANN M
   [Anonymous], 2012 ASCO ANN M
   [Anonymous], WORLD J SURG
   [Anonymous], RADIOTHER ONCOL
   [Anonymous], 2010 GASTR CANC S
   [Anonymous], 2015 GASTR CANC S SU
   [Anonymous], LANCET ONCOLOGY
   [Anonymous], 2015 GASTR CANC S LA
   [Anonymous], 2010 ASCO ANN M
   [Anonymous], 2015 GASTR CANC S SU
   [Anonymous], 14 ASCO ANN M
   [Anonymous], NCCN GUIDELINES COLO
   Anwar S, 2012, COLORECTAL DIS, V14, P920, DOI 10.1111/j.1463-1318.2011.02817.x
   Camúñez F, 2000, RADIOLOGY, V216, P492, DOI 10.1148/radiology.216.2.r00au12492
   Chua YJ, 2010, LANCET ONCOL, V11, P241, DOI 10.1016/S1470-2045(09)70381-X
   Cirocchi R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008997.pub2
   Costi R, 2007, ANN SURG ONCOL, V14, P2567, DOI 10.1245/s10434-007-9444-2
   De Gregorio MA, 1998, RADIOLOGY, V209, P117, DOI 10.1148/radiology.209.1.9769821
   DEANS GT, 1994, BRIT J SURG, V81, P1270, DOI 10.1002/bjs.1800810905
   DOHMOTO M, 1990, DEUT MED WOCHENSCHR, V115, P915
   Fernández-Martos C, 2010, J CLIN ONCOL, V28, P859, DOI 10.1200/JCO.2009.25.8541
   Flanigan RC, 2001, NEW ENGL J MED, V345, P1655, DOI 10.1056/NEJMoa003013
   Folprecht G, 2010, LANCET ONCOL, V11, P38, DOI 10.1016/S1470-2045(09)70330-4
   Kulig P, 2012, EJSO-EUR J SURG ONC, V38, P490, DOI 10.1016/j.ejso.2012.01.013
   Kuo LJ, 2003, DIS COLON RECTUM, V46, P1646, DOI 10.1007/BF02660770
   Lam-Boer J, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-741
   Mickisch GHJ, 2001, LANCET, V358, P966, DOI 10.1016/S0140-6736(01)06103-7
   Mohri Y, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-409
   Poultsides GA, 2009, J CLIN ONCOL, V27, P3379, DOI 10.1200/JCO.2008.20.9817
   Rahbari NN, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-142
   Rapiti E, 2006, J CLIN ONCOL, V24, P2743, DOI 10.1200/JCO.2005.04.2226
   Ruo L, 2003, J AM COLL SURGEONS, V196, P722, DOI 10.1016/S1072-7515(03)00136-4
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Samiee S, 2012, CURR ONCOL, V19, pE270, DOI 10.3747/co.19.974
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Sorbye H, 2007, ANN ONCOL, V18, P1666, DOI 10.1093/annonc/mdm267
   Souglakos J, 2006, BRIT J CANCER, V94, P798, DOI 10.1038/sj.bjc.6603011
   Tack J, 1998, GASTROINTEST ENDOSC, V48, P267, DOI 10.1016/S0016-5107(98)70189-0
   Tebbutt NC, 2003, GUT, V52, P568, DOI 10.1136/gut.52.4.568
   Uehara K, 2013, JPN J CLIN ONCOL, V43, P964, DOI 10.1093/jjco/hyt115
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Vibert E, 2007, DIS COLON RECTUM, V50, P1776, DOI 10.1007/s10350-007-9025-2
NR 45
TC 0
Z9 0
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1556-3790
EI 1556-3804
J9 CURR COLORECT CANC R
JI Curr. Colorectal Cancer Rep.
PD OCT
PY 2015
VL 11
IS 5
BP 225
EP 230
DI 10.1007/s11888-015-0281-6
PG 6
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA V2G9F
UT WOS:000217569400002
DA 2025-01-04
ER

PT J
AU Chen, YX
   Han, LL
   Qiu, XY
   Wang, G
   Zheng, JN
AF Chen, Yuxin
   Han, Lulu
   Qiu, Xiaoyan
   Wang, Gang
   Zheng, Junnian
TI Neutrophil Extracellular Traps in Digestive Cancers: Warrior or
   Accomplice
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE neutrophil extracellular trap; cancer; digestive system; immunity;
   targeted therapy
ID CIRCULATING TUMOR-CELLS; PANCREATIC-CANCER; PROCOAGULANT ACTIVITY;
   ELASTASE INHIBITOR; COLORECTAL-CANCER; VENOUS THROMBOEMBOLISM; CARCINOMA
   METASTASIS; THERAPEUTIC TARGET; ULCERATIVE-COLITIS; CROHNS-DISEASE
AB Characterized as a complex of extracellular DNA fibers and granule proteins, neutrophil extracellular traps (NETs) are generated specifically by neutrophils which play a critical role in host defense and immune regulation. NETs have been initially found crucial for neutrophil anti-microbial function. Recent studies suggest that NETs are involved in tumorigenesis and cancer progression. However, the function of NETs in cancer remains unclear, which might be due to the variation of research models and the heterogeneity of cancers. Although most of malignant tumors have similar biological behaviors, significant differences indeed exist in various systems. Malignant tumors of the digestive system cause the most incidence and mortality of cancer worldwide. In this review, we would focus on research developments on NETs in digestive cancers to provide insights on their role in digestive cancer progression and future research directions.
C1 [Chen, Yuxin; Han, Lulu; Qiu, Xiaoyan; Wang, Gang] Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China.
   [Chen, Yuxin; Han, Lulu; Qiu, Xiaoyan; Wang, Gang; Zheng, Junnian] Xuzhou Med Univ, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Canc Inst, Xuzhou, Jiangsu, Peoples R China.
   [Han, Lulu; Wang, Gang; Zheng, Junnian] Affiliated Hosp Xuzhou Med Univ, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China.
C3 Xuzhou Medical University; Xuzhou Medical University
RP Wang, G (corresponding author), Xuzhou Med Univ, Canc Inst, Xuzhou, Jiangsu, Peoples R China.; Wang, G; Zheng, JN (corresponding author), Xuzhou Med Univ, Jiangsu Ctr Collaborat & Innovat Canc Biotherapy, Canc Inst, Xuzhou, Jiangsu, Peoples R China.; Wang, G; Zheng, JN (corresponding author), Affiliated Hosp Xuzhou Med Univ, Ctr Clin Oncol, Xuzhou, Jiangsu, Peoples R China.
EM wangg@xzhmu.edu.cn; jnzheng@xzhmu.edu.cn
RI Chen, Yuxin/HOH-1234-2023
OI wang, Gang/0000-0001-6020-7263
FU National Natural Science Foundation of China [81871869, 82072814];
   Jiangsu Province Social Development Key Projects [BE2020641, BE2020640];
   Key Research Development project of Xuzhou [KC19082]; Natural Science
   Key Project of Jiangsu Provincial Education Department [19KJA470001];
   Youth Technology Innovation Team of Xuzhou Medical University
   [TD202003]; Jiangsu Provincial Key Medical Discipline, The Project of
   Invigorating Health Care through Science, Technology and Education
   [ZDXKA2016014, CXTDA2017034]; Postgraduate Research & Practice
   Innovation Program of Jiangsu Province [KYCX20_2458]; Qing Lan Project
   of Jiangsu Province
FX This work was supported by the National Natural Science Foundation of
   China (81871869 and 82072814); Jiangsu Province Social Development Key
   Projects (BE2020641 and BE2020640); Key Research Development project of
   Xuzhou (KC19082); the Natural Science Key Project of Jiangsu Provincial
   Education Department (19KJA470001); Youth Technology Innovation Team of
   Xuzhou Medical University (TD202003); Jiangsu Provincial Key Medical
   Discipline, The~Project of Invigorating Health Care through Science,
   Technology and Education (ZDXKA2016014 and CXTDA2017034); Postgraduate
   Research & Practice Innovation Program of Jiangsu Province (KYCX20_2458)
   and the Qing Lan Project of Jiangsu Province.
CR Abdallah DSA, 2012, INFECT IMMUN, V80, P768, DOI 10.1128/IAI.05730-11
   Adrover JM, 2016, TRENDS IMMUNOL, V37, P334, DOI 10.1016/j.it.2016.03.005
   Agarwal S, 2015, CANCER RES, V75, P2566, DOI 10.1158/0008-5472.CAN-14-2946
   Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227
   Alfaro C, 2016, CLIN CANCER RES, V22, P3924, DOI 10.1158/1078-0432.CCR-15-2463
   Ansari D, 2015, HEPATOBIL SURG NUTR, V4, P325, DOI 10.3978/j.issn.2304-3881.2015.06.08
   Arelaki S, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193089
   Arelaki S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154484
   Arigami T, 2015, MEDICINE, V94, DOI 10.1097/MD.0000000000001702
   Arneth B, 2020, MEDICINA-LITHUANIA, V56, DOI 10.3390/medicina56010015
   Bang OY, 2019, STROKE, V50, P2944, DOI 10.1161/STROKEAHA.119.026373
   Barnes BJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20200652
   Bawadekar M, 2017, J AUTOIMMUN, V80, P39, DOI 10.1016/j.jaut.2017.01.006
   Bennike TB, 2015, INFLAMM BOWEL DIS, V21, P2052, DOI 10.1097/MIB.0000000000000460
   Berger-Achituv S, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00048
   Boone BA, 2015, CANCER GENE THER, V22, P326, DOI 10.1038/cgt.2015.21
   Boone BA, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4584-2
   Branzk N, 2014, NAT IMMUNOL, V15, P1017, DOI 10.1038/ni.2987
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brinkmann V, 2004, SCIENCE, V303, P1532, DOI 10.1126/science.1092385
   Cai ZY, 2020, GENE, V754, DOI 10.1016/j.gene.2020.144902
   Cedervall J, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1320009
   Cedervall J, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1098803
   Cedervall J, 2015, CANCER RES, V75, P2653, DOI 10.1158/0008-5472.CAN-14-3299
   Chen MF, 2019, ANN SURG ONCOL, V26, P190, DOI 10.1245/s10434-018-6944-1
   Cheng FJ, 2015, INT J RHEUM DIS, V18, P533, DOI 10.1111/1756-185X.12433
   Chrysanthopoulou A, 2017, J PATHOL, V243, P111, DOI 10.1002/path.4935
   Chu ZQ, 2021, WORLD J GASTROENTERO, V27, P5474, DOI 10.3748/wjg.v27.i33.5474
   Coffelt SB, 2016, NAT REV CANCER, V16, P431, DOI 10.1038/nrc.2016.52
   Cools-Lartigue J, 2013, J CLIN INVEST, V123, P3446, DOI 10.1172/JCI67484
   Decker AS, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8090946
   Demers M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1134073
   Demers M, 2012, P NATL ACAD SCI USA, V109, P13076, DOI 10.1073/pnas.1200419109
   Deng JY, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.146133
   Dinallo V, 2019, J CROHNS COLITIS, V13, P772, DOI 10.1093/ecco-jcc/jjy215
   Donis-Maturano L, 2015, SPRINGERPLUS, V4, DOI 10.1186/s40064-015-0932-8
   Douda DN, 2015, P NATL ACAD SCI USA, V112, P2817, DOI 10.1073/pnas.1414055112
   Dulai PS, 2016, CANCER PREV RES, V9, P887, DOI 10.1158/1940-6207.CAPR-16-0124
   Farrera C, 2013, J IMMUNOL, V191, P2647, DOI 10.4049/jimmunol.1300436
   Fuchs TA, 2007, J CELL BIOL, V176, P231, DOI 10.1083/jcb.200606027
   Fukunaga S, 2018, INT J MOL MED, V41, P107, DOI 10.3892/ijmm.2017.3244
   Garley M, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820960473
   Garley M, 2018, J CANCER, V9, P1958, DOI 10.7150/jca.24238
   Garley M, 2016, TUMOR BIOL, V37, P14355, DOI 10.1007/s13277-016-5328-z
   Germann M, 2020, EMBO MOL MED, V12, DOI 10.15252/emmm.201910681
   Glogauer JE, 2015, CANCER IMMUNOL RES, V3, P1218, DOI 10.1158/2326-6066.CIR-15-0017
   Gomes T, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02088
   Gong J, 2018, J MED VIROL, V90, P730, DOI 10.1002/jmv.25015
   Gonzalez-Aparicio M, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/6252138
   Gottlieb Y, 2018, PATHOL INT, V68, P517, DOI 10.1111/pin.12715
   Groeneveld DJ, 2019, J THROMB HAEMOST, V17, P1201, DOI 10.1111/jth.14530
   Gu FM, 2012, ANN SURG ONCOL, V19, P2506, DOI 10.1245/s10434-012-2268-8
   Guan XQ, 2021, J HEPATOCELL CARCINO, V8, P451, DOI 10.2147/JHC.S303588
   Guglietta S, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11037
   Hakkim A, 2011, NAT CHEM BIOL, V7, P75, DOI 10.1038/NCHEMBIO.496
   Hakkim A, 2010, P NATL ACAD SCI USA, V107, P9813, DOI 10.1073/pnas.0909927107
   Hassanabad AF, 2020, CELL ONCOL, V43, P195, DOI 10.1007/s13402-019-00488-2
   Hedrick CC, 2022, NAT REV IMMUNOL, V22, P173, DOI 10.1038/s41577-021-00571-6
   Hell L, 2016, THROMB RES, V140, pS174, DOI 10.1016/S0049-3848(16)30133-5
   Hilscher MB, 2020, SEMIN LIVER DIS, V40, P171, DOI 10.1055/s-0039-3399562
   Hilscher MB, 2019, GASTROENTEROLOGY, V157, P193, DOI 10.1053/j.gastro.2019.03.013
   Hisada Y, 2020, HAEMATOLOGICA, V105, P218, DOI 10.3324/haematol.2019.217083
   Hisada Y, 2019, HEMATOL-AM SOC HEMAT, P182, DOI 10.1182/hematology.2019000025
   Ho AS, 2014, ONCOTARGET, V5, P473, DOI 10.18632/oncotarget.1631
   Hosseinzadeh A, 2016, J LEUKOCYTE BIOL, V100, P1105, DOI 10.1189/jlb.3AB0815-379RR
   Hu N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099671
   Hu SN, 2019, J IMMUNOL, V202, P805, DOI 10.4049/jimmunol.1800871
   Inoue M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07550-x
   Jablonska E, 2020, IMMUNOBIOLOGY, V225, DOI 10.1016/j.imbio.2019.151901
   Jiang C, 2016, ONCOTARGETS THER, V9, P877, DOI 10.2147/OTT.S90569
   Jin W, 2021, J CELL MOL MED, V25, P5443, DOI 10.1111/jcmm.16555
   Jin W, 2019, ANN SURG ONCOL, V26, P635, DOI 10.1245/s10434-018-6941-4
   Ju CY, 2019, SMALL, V15, DOI 10.1002/smll.201804191
   Jung HS, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0216055
   Kajioka H, 2021, CANCER LETT, V497, P1, DOI 10.1016/j.canlet.2020.10.015
   Kaltenmeier CT, 2021, HPB, V23, P309, DOI 10.1016/j.hpb.2020.06.012
   Kanamaru R, 2018, JOVE-J VIS EXP, DOI 10.3791/58201
   Kanamaru R, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-19091-2
   Kawahara Y, 2010, DIS ESOPHAGUS, V23, P329, DOI 10.1111/j.1442-2050.2009.01010.x
   Kitagawa Y, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06864-8
   Kolaczkowska E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7673
   Kruger S, 2017, THROMB RES, V157, P9, DOI 10.1016/j.thromres.2017.06.021
   Krzystek-Korpacka M, 2008, CYTOKINE, V41, P232, DOI 10.1016/j.cyto.2007.11.011
   Kumagai Y, 2020, J SURG RES, V246, P52, DOI 10.1016/j.jss.2019.08.022
   Kwon HC, 2008, JPN J CLIN ONCOL, V38, P2, DOI 10.1093/jjco/hym157
   Lazaar AL, 2018, EUR RESPIR J, V52, DOI 10.1183/13993003.01020-2018
   Lazzaretto B, 2019, J IMMUNOL, V203, P2276, DOI 10.4049/jimmunol.1800159
   Leal AC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-06893-7
   Lehmann T, 2019, J PROTEOMICS, V201, P93, DOI 10.1016/j.jprot.2019.04.009
   Li BR, 2019, J CANCER RES CLIN, V145, P1695, DOI 10.1007/s00432-019-02922-2
   Li M, 2020, MOL CANCER THER, V19, P1530, DOI 10.1158/1535-7163.MCT-19-1020
   Li R, 2020, ONCOTARGETS THER, V13, P5271, DOI 10.2147/OTT.S227331
   Li Y, 2019, INT J ONCOL, V55, P69, DOI 10.3892/ijo.2019.4808
   Li Y, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-020-03286-z
   Liu KK, 2019, CLIN IMMUNOL, V201, P4, DOI 10.1016/j.clim.2019.02.005
   Liu L, 2020, J MOL CELL BIOL, V12, P723, DOI 10.1093/jmcb/mjaa016
   Llovet JM, 2016, NAT REV DIS PRIMERS, V2, DOI [10.1038/nrdp.2016.18, 10.1038/nrdp.2016.19]
   Lood C, 2016, NAT MED, V22, P146, DOI 10.1038/nm.4027
   Lu HB, 2017, AM J TRANSL RES, V9, P5361
   Luley K, 2011, INT J COLORECTAL DIS, V26, P603, DOI 10.1007/s00384-011-1165-0
   Mady M, 2020, HPB, V22, P1490, DOI 10.1016/j.hpb.2020.02.002
   Makino H, 2011, BRIT J SURG, V98, P975, DOI 10.1002/bjs.7499
   Mandalà M, 2007, ANN ONCOL, V18, P1660, DOI 10.1093/annonc/mdm284
   McKeown STW, 2006, ORAL ONCOL, V42, P685, DOI 10.1016/j.oraloncology.2005.11.005
   Middleton EA, 2020, BLOOD, V136, P1169, DOI 10.1182/blood.2020007008
   Miller-Ocuin JL, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2019.1605822
   Millrud CR, 2017, INT J CANCER, V140, P2557, DOI 10.1002/ijc.30671
   Mishalian I, 2017, IMMUNOBIOLOGY, V222, P82, DOI 10.1016/j.imbio.2016.02.001
   Monti M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082350
   Mor-Vaknin N, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14252
   Munir H, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-20982-2
   Muqaku B, 2020, CANCERS, V12, DOI 10.3390/cancers12020505
   Najmeh S, 2017, INT J CANCER, V140, P2321, DOI 10.1002/ijc.30635
   Nathan C, 2006, NAT REV IMMUNOL, V6, P173, DOI 10.1038/nri1785
   Németh T, 2020, NAT REV DRUG DISCOV, V19, P253, DOI 10.1038/s41573-019-0054-z
   Ng H, 2021, ARTERIOSCL THROM VAS, V41, P988, DOI 10.1161/ATVBAHA.120.315267
   Nicoud IB, 2007, CANCER RES, V67, P2720, DOI 10.1158/0008-5472.CAN-06-3923
   Nie M, 2019, CLIN CANCER RES, V25, P1867, DOI 10.1158/1078-0432.CCR-18-1226
   Nishiyama J, 2012, SURG TODAY, V42, P659, DOI 10.1007/s00595-011-0105-5
   Oklu R, 2017, CARDIOVASC DIAGN THE, V7, pS140, DOI 10.21037/cdt.2017.08.01
   Olén O, 2020, LANCET GASTROENTEROL, V5, P475, DOI 10.1016/S2468-1253(20)30005-4
   Olén O, 2020, LANCET, V395, P123, DOI 10.1016/S0140-6736(19)32545-0
   OLYAEE M, 1995, GUT, V37, P168, DOI 10.1136/gut.37.2.168
   Oto J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21030840
   Paillet J, 2020, CURR OPIN GASTROEN, V36, P70, DOI 10.1097/MOG.0000000000000613
   Papayannopoulos V, 2018, NAT REV IMMUNOL, V18, P134, DOI 10.1038/nri.2017.105
   Papayannopoulos V, 2010, J CELL BIOL, V191, P677, DOI 10.1083/jcb.201006052
   Park J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aag1711
   Phulari Rashmi G S, 2019, J Oral Maxillofac Pathol, V23, P78, DOI 10.4103/jomfp.JOMFP_160_17
   Pilsczek FH, 2010, J IMMUNOL, V185, P7413, DOI 10.4049/jimmunol.1000675
   Podaza E, 2017, CANCER IMMUNOL IMMUN, V66, P77, DOI 10.1007/s00262-016-1921-7
   Rayes RF, 2020, J IMMUNOL, V204, P2285, DOI 10.4049/jimmunol.1900240
   Rayes RF, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.128008
   Razak NA, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030487
   Ren JH, 2021, CANCER RES, V81, P2373, DOI 10.1158/0008-5472.CAN-20-3222
   Richardson JJR, 2017, INT J INFLAMM, V2017, DOI 10.1155/2017/4915062
   Rohrbach AS, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00360
   Rosales C, 2020, J LEUKOCYTE BIOL, V108, P377, DOI 10.1002/JLB.4MIR0220-574RR
   Saitoh T, 2012, CELL HOST MICROBE, V12, P109, DOI 10.1016/j.chom.2012.05.015
   Sanmamed MF, 2014, CLIN CANCER RES, V20, P5697, DOI 10.1158/1078-0432.CCR-13-3203
   Schedel F, 2020, PIGM CELL MELANOMA R, V33, P63, DOI 10.1111/pcmr.12818
   Schlesinger M, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0669-2
   Schoeps B, 2021, CANCER RES, V81, P3568, DOI 10.1158/0008-5472.CAN-20-4125
   Seo JD, 2019, CLIN APPL THROMB-HEM, V25, DOI 10.1177/1076029618825310
   Shang AQ, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0517-1
   Shinde-Jadhav S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23086-z
   Shrestha S, 2017, IMMUNOL LETT, V182, P24, DOI 10.1016/j.imlet.2017.01.001
   Singel KL, 2019, BRIT J CANCER, V120, P207, DOI 10.1038/s41416-018-0339-8
   Sorvillo N, 2019, CIRC RES, V125, P470, DOI 10.1161/CIRCRESAHA.119.314581
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Stillie R, 2009, J LEUKOCYTE BIOL, V86, P529, DOI 10.1189/jlb.0208125
   Takesue S, 2020, INT J ONCOL, V56, P596, DOI 10.3892/ijo.2019.4951
   Teijeira A, 2020, IMMUNITY, V52, P856, DOI 10.1016/j.immuni.2020.03.001
   Thomas GM, 2015, J THROMB HAEMOST, V13, P1310, DOI 10.1111/jth.13002
   Tohme S, 2016, CANCER RES, V76, P1367, DOI 10.1158/0008-5472.CAN-15-1591
   Tomochika S, 2010, EXP THER MED, V1, P89, DOI 10.3892/etm_00000016
   Tuveson DA, 2012, CELL, V148, P21, DOI 10.1016/j.cell.2011.12.021
   Urban CF, 2006, CELL MICROBIOL, V8, P668, DOI 10.1111/j.1462-5822.2005.00659.x
   Valero C, 2020, CANCER-AM CANCER SOC, V126, P994, DOI 10.1002/cncr.32591
   van der Windt DJ, 2018, HEPATOLOGY, V68, P1347, DOI 10.1002/hep.29914
   Vito A, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040992
   Wada Y, 2007, ONCOL REP, V17, P161
   Wang H, 2021, J HEPATOL, V75, P1271, DOI 10.1016/j.jhep.2021.07.032
   Wang N, 2019, CANCER SCI, V110, P519, DOI 10.1111/cas.13909
   Wang WW, 2021, J CANCER RES CLIN, V147, P2609, DOI 10.1007/s00432-021-03682-8
   Wang Y, 2004, SCIENCE, V306, P279, DOI 10.1126/science.1101400
   Whittall-García LP, 2019, LUPUS, V28, P1549, DOI 10.1177/0961203319883936
   Wolpin BM, 2008, GASTROENTEROLOGY, V134, P1296, DOI 10.1053/j.gastro.2008.02.098
   Xia YJ, 2020, MOL ONCOL, V14, P2920, DOI 10.1002/1878-0261.12787
   Xiao YS, 2021, CANCER CELL, V39, P423, DOI 10.1016/j.ccell.2020.12.012
   Yang CF, 2015, INT J CLIN EXP PATHO, V8, P14075
   Yang LB, 2020, NATURE, V583, P133, DOI 10.1038/s41586-020-2394-6
   Yang LY, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-019-0836-0
   Yang LY, 2020, J CANCER, V11, P4384, DOI 10.7150/jca.44215
   Yazdani HO, 2019, CANCER RES, V79, P5626, DOI 10.1158/0008-5472.CAN-19-0800
   Yu MX, 2020, THROMB RES, V188, P5, DOI 10.1016/j.thromres.2020.01.025
   Yuan X, 2020, CANCERS, V12, DOI 10.3390/cancers12030770
   Zha CJ, 2020, CANCER BIOL MED, V17, P154, DOI 10.20892/j.issn.2095-3941.2019.0353
   Zhang H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm.2020.03.190
   Zhang Y, 2019, THROMB RES, V180, P87, DOI 10.1016/j.thromres.2019.06.005
   Zhang YY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01036
   Zhang Y, 2020, J EXP MED, V217, DOI 10.1084/jem.20190354
   Zhou GX, 2018, GUT, V67, P1052, DOI 10.1136/gutjnl-2016-313535
   Zhou JW, 2019, ONCOL LETT, V18, P181, DOI 10.3892/ol.2019.10290
   Zhou SL, 2014, CARCINOGENESIS, V35, P597, DOI 10.1093/carcin/bgt397
   Zhu T, 2021, INT J MOL MED, V48, DOI 10.3892/ijmm.2021.4960
   Zuo Y, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.138999
NR 187
TC 8
Z9 8
U1 0
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 19
PY 2021
VL 11
AR 766636
DI 10.3389/fonc.2021.766636
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XI8QJ
UT WOS:000726368500001
PM 34868992
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Hu, ZJ
   Wu, JR
   Tan, SL
   Yang, LJ
   Huang, JH
   Mo, CJ
   Chen, HP
   Ruan, XL
   Qin, X
AF Hu, Zuojian
   Wu, Junrong
   Tan, Shaolin
   Yang, Lujie
   Huang, Junhui
   Mo, Cuiju
   Chen, Huaping
   Ruan, Xuelian
   Qin, Xue
TI Diagnostic value of long noncoding RNA LINC01485 in patients with
   colorectal cancer
SO CLINICAL BIOCHEMISTRY
LA English
DT Article
DE Colorectal cancer; LINC01485; Diagnostic; Whole blood sample; Clinical
   characteristics
ID IDENTIFICATION; BIOMARKERS; PROGNOSIS; CHINA
AB Background: Long noncoding RNAs (lncRNAs) were considered as transcription noise without biological functions. However, accumulated evidence shows that lncRNAs are expressed heterogeneously in tumor tissues. This study aims to identify the specific expression of lncRNAs in colorectal cancer patients and to perform verification analysis.
   Methods: The differentially expressed lncRNAs and mRNAs in colorectal cancer and normal tissues were screened by bioinformatics methods. Subsequently, the qRT-PCR method was used to verify the expression of differential lncRNAs in tumor tissues and blood samples. Concurrently ROC curves were used to analyze the diagnostic efficacy of lncRNAs. Moreover, the correlation between lncRNAs and clinicopathological features was also analyzed. Finally, functional annotation analysis was performed for lncRNAs.
   Results: Eleven lncRNAs differentially expressed in colorectal cancer tissues and normal tissues were screened. In the validation tissue sample set, FOXD3-AS1 was down-regulated in colorectal cancer tissues (P < 0.001), while LINC01485 was up-regulated in colorectal cancer tissues compared with the adjacent tissues (P < 0.05). In a further verification of the whole blood sample set, LINC01485 showed high sensitivity and specificity (sensitivity = 98.33%, specificity = 84.00%) in differentiating colorectal cancer patients from healthy controls (P < 0.001). Simultaneously, there was no difference in the expression of LINC01485 in other gastrointestinal tumors (hepatocellular carcinoma, esophageal cancer, gastric cancer, and pancreatic cancer) and healthy controls. LINC01485 is significantly related to the clinical staging, lymph node metastasis, and distant metastasis of colorectal cancer.
   Conclusions: The expression, diagnostic efficiency, and functional analysis of the lncRNA file of colorectal cancer reveals the important role of LINC01485 in colorectal cancer and provides an important clinical reference value for the early diagnosis and targeted therapy of colorectal cancer.
C1 [Hu, Zuojian; Huang, Junhui; Mo, Cuiju; Chen, Huaping; Ruan, Xuelian; Qin, Xue] Guangxi Med Univ, Dept Lab Med, Affiliated Hosp 1, Nanning 530021, Guangxi, Peoples R China.
   [Wu, Junrong] Guangxi Med Univ, Dept Lab Med, Affiliated Tumor Hosp, Nanning 530021, Guangxi, Peoples R China.
   [Tan, Shaolin] Guangxi Med Univ, Dept Orthopaed, Affiliated Hosp 2, Nanning 530021, Guangxi, Peoples R China.
   [Yang, Lujie] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University; Guangxi Medical
   University; Fudan University
RP Qin, X (corresponding author), Guangxi Med Univ, Dept Lab Med, Affiliated Hosp 1, Nanning 530021, Guangxi, Peoples R China.
EM qinxue@gxmu.edu.cn
RI huang, junhui/HKO-6659-2023; Ruan, Xuelian/GQO-8550-2022
FU National Natural Science Foundation of Guangxi [2018GXNSFBA281160]; Key
   laboratory of early prevention and treatment of regional high-incidence
   tumors, ministry of education [GKE2019-05]
FX This work was supported by the National Natural Science Foundation of
   Guangxi (2018JJA140407), the Key laboratory of early prevention and
   treatment of regional high-incidence tumors, ministry of education
   (GKE2019-05) and the National Natural Science Foundation of Guangxi
   (2018GXNSFBA281160).
CR Altman R, 2016, BRIEF BIOINFORM, V17, P1, DOI 10.1093/bib/bbv105
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen XG, 2019, BIOMED PHARMACOTHER, V120, DOI 10.1016/j.biopha.2019.109438
   Chen X, 2013, BIOINFORMATICS, V29, P2617, DOI 10.1093/bioinformatics/btt426
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Gong YM, 2018, ONCOLOGIST, V23, P928, DOI 10.1634/theoncologist.2017-0451
   Huang X, 2020, INT J CLIN EXP PATHO, V13, P675
   Jiang N, 2018, CLIN CHIM ACTA, V486, P26, DOI 10.1016/j.cca.2018.07.026
   Jin M, 2018, SURG ONCOL CLIN N AM, V27, P401, DOI 10.1016/j.soc.2017.11.011
   Liang Y, 2018, CELL DEATH DIFFER, V25, P1980, DOI 10.1038/s41418-018-0084-9
   Liu HS, 2019, CLIN CHEM LAB MED, V57, P1073, DOI 10.1515/cclm-2019-0052
   Mahasneh A, 2017, EXP MOL PATHOL, V102, P475, DOI 10.1016/j.yexmp.2017.05.005
   Moreno CC, 2016, CLIN COLORECTAL CANC, V15, P67, DOI 10.1016/j.clcc.2015.07.004
   Pardini B, 2019, CANCERS, V11, DOI 10.3390/cancers11081170
   Ponting CP, 2009, CELL, V136, P629, DOI 10.1016/j.cell.2009.02.006
   Quinn JJ, 2016, NAT REV GENET, V17, P47, DOI 10.1038/nrg.2015.10
   Rao H, 2021, CLIN LAB, V67, P1079, DOI 10.7754/Clin.Lab.2020.200828
   Rönnau CGH, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/591703
   Sung H., CA: A Cancer Journal for Clinicians, V2021, P209
   Tong YS, 2015, MOL CANCER, V14, DOI 10.1186/1476-4598-14-3
   Wang R, 2016, J CANCER RES CLIN, V142, P2291, DOI 10.1007/s00432-016-2238-9
   Wei WQ, 2020, LANCET ONCOL, V21, pE342, DOI 10.1016/S1470-2045(20)30073-5
   Wu Q, 2019, J CELL PHYSIOL, V234, P21889, DOI 10.1002/jcp.28752
   Xu W, 2020, INT J CANCER, V146, P2901, DOI 10.1002/ijc.32747
   Yang X, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01159-9
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zeng ZL, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01402-9
   Zhang X, 2015, WORLD J GASTROENTERO, V21, P2629, DOI 10.3748/wjg.v21.i9.2629
   Zhang YJ, 2018, NAT GENET, V50, P814, DOI 10.1038/s41588-018-0120-1
   Zhang YJ, 2018, CANCER BIOMARK, V21, P89, DOI 10.3233/CBM-170286
   Zhao X, 2018, MOL THER, V26, P755, DOI 10.1016/j.ymthe.2017.12.017
   Zhou JP, 2020, ONCOTARGETS THER, V13, P8413, DOI 10.2147/OTT.S257151
NR 34
TC 3
Z9 3
U1 0
U2 9
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0009-9120
EI 1873-2933
J9 CLIN BIOCHEM
JI Clin. Biochem.
PD FEB
PY 2022
VL 102
BP 34
EP 43
DI 10.1016/j.clinbiochem.2022.01.003
PG 10
WC Medical Laboratory Technology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Medical Laboratory Technology
GA 2P6TW
UT WOS:000819871800005
PM 35033545
DA 2025-01-04
ER

PT J
AU Al-Hajeili, M
   Shields, AE
   Hwang, JJ
   Wadlow, RC
   Marshall, JL
AF Al-Hajeili, Marwan
   Shields, Anthony E.
   Hwang, Jimmy J.
   Wadlow, Raymond C.
   Marshall, John L.
TI Molecular Testing to Optimize and Personalize Decision Making in the
   Management of Colorectal Cancer
SO ONCOLOGY-NEW YORK
LA English
DT Article
ID ANTI-EGFR THERAPY; THYMIDYLATE SYNTHASE EXPRESSION; GROWTH-FACTOR
   RECEPTOR; MICROSATELLITE-INSTABILITY; COLON-CANCER; DIHYDROPYRIMIDINE
   DEHYDROGENASE; ADJUVANT CHEMOTHERAPY; PREDICTIVE-VALUE; SEVERE TOXICITY;
   KRAS MUTATIONS
AB Recent improvements in our understanding of the biology of colorectal cancer have led to the identification of several important prognostic and predictive markers of disease-associated risk and treatment response for the individual patient. Proper utilization of these biomarkers can enable physicians to tailor therapeutic strategies to maximize the likelihood of response and minimize treatment toxicity. In the management of colorectal cancer, tremendous progress has been made in the development of strategies for immune checkpoint inhibition; in refinement Df agents and approaches used in targeted therapy; and in techniques for molecular subtyping of tumor samples that lave identified patient subgroups with clinically relevant cellular differences potentially affecting clinical management and treatment outcome. In this article, we discuss several of the commonly tested markers in colorectal cancer includng microsatellite instability, RAS/RAF, DPD, HER2, UTG1A1, TS, and Immunoscore-and highlight their prevalence, prognostic and predictive value, and current role in the overall treatment paradigm.
C1 King Abdulaziz Univ Hosp, Dept Internal Med, Jeddah, Saudi Arabia.
   Barbara Ann Karmanos Canc Inst, Clin Sci, Detroit, MI USA.
   Wayne State Univ, Sch Med, Med & Oncol, Detroit, MI USA.
   Carolinas HealthCare Syst, Gastrointestinal Med Oncol, Levine Canc Inst, Charlotte, NC USA.
   US Oncol Network, VCS Res Inst, Virginia Canc Specialists, Fairfax, VA USA.
   Medstar Georgetown Univ Hosp, Div Hematol Oncol, Washington, DC USA.
   Georgetown Univ, Med Ctr, Otto J Ruesch Ctr Cure Gastrointestinal Canc, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
C3 King Abdulaziz University; King Abdulaziz University Hospital - Jeddah;
   Barbara Ann Karmanos Cancer Institute; Wayne State University; Carolinas
   HealthCare System; Georgetown University; Georgetown University
RP Marshall, JL (corresponding author), Lombardi Comprehens Canc Ctr, 3800 Reservoir Rd, Washington, DC 20007 USA.
EM marshalj@georgetown.edu
RI ; Al-Hajeili, Marwan/D-9009-2018
OI Wadlow, Raymond/0000-0003-1959-5406; Al-Hajeili,
   Marwan/0000-0001-5486-8057
FU Caris Life Sciences
FX Dr. Marshall has relationships with the following companies, for which
   he has served as an advisor, consultant, researcher, and speaker: Amgen,
   Bayer, Caris Life Sciences, Celgene, Genentech, and Taiho. Dr. Shields
   has received funding for research and travel from Caris Life Sciences.
   The other authors have no significant interest in or other relationship
   with the manufacturer of any product or provider of any service
   mentioned in this article.
CR [Anonymous], J CLIN ONCOL S
   [Anonymous], J CLIN ONCOL S
   [Anonymous], 2003, P AM SOC CLIN ONCOL
   Atkin GK, 2006, BRIT J CANCER, V95, P928, DOI 10.1038/sj.bjc.6603362
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Beutler E, 1998, P NATL ACAD SCI USA, V95, P8170, DOI 10.1073/pnas.95.14.8170
   Boland CR, 2008, FAM CANCER, V7, P41, DOI 10.1007/s10689-007-9145-9
   Butzke B, 2016, ACTA ONCOL, V55, P318, DOI 10.3109/0284186X.2015.1053983
   Chen S, 2015, PHARMACOGENOMICS J, V15, P513, DOI 10.1038/tpj.2015.12
   Choueiri MB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126898
   Chu E, 2003, CANCER CHEMOTH PHARM, V52, pS80, DOI 10.1007/s00280-003-0625-9
   Cicek MS, 2011, J MOL DIAGN, V13, P271, DOI 10.1016/j.jmoldx.2010.12.004
   Cohen R, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0453-5
   Deenen MJ, 2016, J CLIN ONCOL, V34, P227, DOI 10.1200/JCO.2015.63.1325
   Des Guetz G, 2009, EUR J CANCER, V45, P1890, DOI 10.1016/j.ejca.2009.04.018
   Des Guetz G, 2009, ANTICANCER RES, V29, P1615
   Dias MM, 2012, PHARMACOGENOMICS, V13, P889, DOI [10.2217/PGS.12.68, 10.2217/pgs.12.68]
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Etienne-Grimaldi MC, 2015, FUND CLIN PHARMACOL, V29, P219, DOI 10.1111/fcp.12117
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Galon J, 2014, J PATHOL, V232, P199, DOI 10.1002/path.4287
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hagemann IS, 2016, ARCH PATHOL LAB MED, V140, P815, DOI 10.5858/arpa.2016-0051-RA
   Jason TLH, 2007, GENE EXPRESSION, V13, P227
   Kassouf E, 2016, BIODRUGS, V30, P95, DOI 10.1007/s40259-016-0166-5
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee AM, 2016, PHARMACOGENET GENOM, V26, P133, DOI 10.1097/FPC.0000000000000197
   Lee MS, 2015, CLIN COLORECTAL CANC, V14, P203, DOI 10.1016/j.clcc.2015.05.006
   Leto SM, 2015, CLIN CANCER RES, V21, P5519, DOI 10.1158/1078-0432.CCR-14-3066
   Liu J, 2002, BBA-MOL BASIS DIS, V1587, P174, DOI 10.1016/S0925-4439(02)00080-7
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Loughrey MB, 2007, FAM CANCER, V6, P301, DOI 10.1007/s10689-007-9124-1
   Lunenburg CATC, 2016, EUR J CANCER, V54, P40, DOI 10.1016/j.ejca.2015.11.008
   Mercier C, 2006, CLIN COLORECTAL CANC, V6, P288, DOI 10.3816/CCC.2006.n.047
   Meulendijks D, 2015, LANCET ONCOL, V16, P1639, DOI 10.1016/S1470-2045(15)00286-7
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mlecnik B, 2016, IMMUNITY, V44, P698, DOI 10.1016/j.immuni.2016.02.025
   Mlecnik B, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad6352
   PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8
   Perkins G, 2014, PHARMACOGENOMICS, V15, P1043, DOI 10.2217/pgs.14.66
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Qiu LX, 2008, INT J CANCER, V123, P2384, DOI 10.1002/ijc.23822
   Raghav KPS, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3517
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Ribic CM, 2003, NEW ENGL J MED, V349, P247, DOI 10.1056/NEJMoa022289
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Rosenberg JE, 2016, LANCET, V387, P1909, DOI 10.1016/S0140-6736(16)00561-4
   Rosmarin D, 2014, J CLIN ONCOL, V32, P1031, DOI 10.1200/JCO.2013.51.1857
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Rui YY, 2015, HEPATO-GASTROENTEROL, V62, P19
   Santini D, 2008, ONCOLOGIST, V13, P1270, DOI 10.1634/theoncologist.2008-0181
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Setaffy L, 2015, POL J PATHOL, V66, P203, DOI 10.5114/PJP.2015.54953
   Shulman K, 2011, CANCER-AM CANCER SOC, V117, P3156, DOI 10.1002/cncr.25735
   Siegel RL, 2016, CA-CANCER J CLIN, V66, P7
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Smyrk TC, 2001, CANCER, V91, P2417, DOI 10.1002/1097-0142(20010615)91:12<2417::AID-CNCR1276>3.0.CO;2-U
   Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498
   Stadler ZK, 2016, J CLIN ONCOL, V34, P2141, DOI 10.1200/JCO.2015.65.1067
   Strassburg CP, 2008, PHARMACOGENOMICS, V9, P703, DOI 10.2217/14622416.9.6.703
   Swen JJ, 2011, CLIN PHARMACOL THER, V89, P662, DOI 10.1038/clpt.2011.34
   Taly V, 2013, CLIN CHEM, V59, P1722, DOI 10.1373/clinchem.2013.206359
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   van Kuilenburg ABP, 2004, EUR J CANCER, V40, P939, DOI 10.1016/j.ejca.2003.12.004
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
   Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237
   Vincenzi B, 2005, J CLIN ONCOL, V23, P2108, DOI 10.1200/JCO.2005.05.178
   Yiu AJ, 2016, ANTICANCER RES, V36, P1093
   Yu QQ, 2016, WORLD J GASTROENTERO, V22, P4250, DOI 10.3748/wjg.v22.i16.4250
   Zhang CM, 2016, INT J ENV RES PUB HE, V13, DOI 10.3390/ijerph13090892
NR 72
TC 3
Z9 3
U1 0
U2 2
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
EI 2767-7389
J9 ONCOLOGY-NY
JI Oncology-NY
PD APR
PY 2017
VL 31
IS 4
BP 301
EP 312
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ET0NX
UT WOS:000399960200009
PM 28412781
DA 2025-01-04
ER

PT J
AU De Angelis, ML
   Francescangeli, F
   La Torre, F
   Zeuner, A
AF De Angelis, Maria Laura
   Francescangeli, Federica
   La Torre, Filippo
   Zeuner, Ann
TI Stem Cell Plasticity and Dormancy in the Development of Cancer Therapy
   Resistance
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE cancer stem cells; chemoresistance; dormancy; quiescence; plasticity;
   drug resistance; target therapies
ID DISSEMINATED TUMOR-CELLS; BREAST-CANCER; COLON-CANCER; TARGETED THERAPY;
   OXIDATIVE-PHOSPHORYLATION; EARLY DISSEMINATION; DRUG-RESISTANCE;
   OVARIAN-CANCER; METASTASIS; INHIBITION
AB Cancer treatment with either standard chemotherapy or targeted agents often results in the emergence of drug-refractory cell populations, ultimately leading to therapy failure. The biological features of drug resistant cells are largely overlapping with those of cancer stem cells and include heterogeneity, plasticity, self-renewal ability, and tumor-initiating capacity. Moreover, drug resistance is usually characterized by a suppression of proliferation that can manifest as quiescence, dormancy, senescence, or proliferative slowdown. Alterations in key cellular pathways such as autophagy, unfolded protein response or redox signaling, as well as metabolic adaptations also contribute to the establishment of drug resistance, thus representing attractive therapeutic targets. Moreover, a complex interplay of drug resistant cells with the micro/macroenvironment and with the immune system plays a key role in dictating and maintaining the resistant phenotype. Recent studies have challenged traditional views of cancer drug resistance providing innovative perspectives, establishing new connections between drug resistant cells and their environment and indicating unexpected therapeutic strategies. In this review we discuss recent advancements in understanding the mechanisms underlying drug resistance and we report novel targeting agents able to overcome the drug resistant status, with particular focus on strategies directed against dormant cells. Research on drug resistant cancer cells will take us one step forward toward the development of novel treatment approaches iand the improvement of relapse-free survival in solid and hematological cancer patients.
C1 [De Angelis, Maria Laura; Francescangeli, Federica; Zeuner, Ann] Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy.
   [La Torre, Filippo] Sapienza Univ Rome, Policlin Umberto I, Dept Surg Sci, Rome, Italy.
C3 Istituto Superiore di Sanita (ISS); Sapienza University Rome; University
   Hospital Sapienza Rome
RP Zeuner, A (corresponding author), Ist Super Sanita, Dept Oncol & Mol Med, Rome, Italy.
EM ann.zeuner@iss.it
RI De Angelis, Maria Laura/Y-4004-2019; Zeuner, Ann/K-8607-2016; La Torre,
   Filippo/AAI-7284-2020; Francescangeli, Federica/K-6500-2016; Zeuner,
   Ann/A-8529-2010
OI La Torre, Filippo/0000-0002-0787-8794; Francescangeli,
   Federica/0000-0002-1086-5265; Zeuner, Ann/0000-0002-8295-3715; De
   Angelis, Maria Laura/0000-0003-4220-8822
FU ERA-NET TRANSCAN grant [TRS-2015-00000096]; Italian Association for
   Cancer Research (AIRC) Investigator Grant [20744]; Awards Sapienza
   University of Rome grant [C26H15ZKWL]
FX This work was supported by an ERA-NET TRANSCAN grant TRS-2015-00000096
   to AZ, by Italian Association for Cancer Research (AIRC) Investigator
   Grant 20744 to AZ, and by Awards Sapienza University of Rome grant
   C26H15ZKWL to FL.
CR Abderrahman B, 2018, JAMA ONCOL, V4, P15, DOI 10.1001/jamaoncol.2017.3510
   Aguirre-Ghiso JA, 2001, MOL BIOL CELL, V12, P863, DOI 10.1091/mbc.12.4.863
   Aguirre-Ghiso JA, 2003, CANCER RES, V63, P1684
   Aguirre-Ghiso JA, 2018, ANNU REV CANC BIOL, V2, P377, DOI 10.1146/annurev-cancerbio-030617-050446
   Aguirre-Ghiso JA, 2018, SCIENCE, V361, P1314, DOI 10.1126/science.aav0191
   Albrengues J, 2018, SCIENCE, V361, P1353, DOI 10.1126/science.aao4227
   Aqbi HF, 2018, J LEUKOCYTE BIOL, V103, P1219, DOI 10.1002/JLB.5MIR0917-351R
   Bacci M, 2016, CANCER RES, V76, P1615, DOI 10.1158/0008-5472.CAN-15-2038
   Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432
   Ben-Porath I, 2008, NAT GENET, V40, P499, DOI 10.1038/ng.127
   Bhang HEC, 2015, NAT MED, V21, P440, DOI 10.1038/nm.3841
   Borgen E, 2018, BREAST CANCER RES, V20, DOI 10.1186/s13058-018-1049-0
   Botzer LE, 2016, BRIT J CANCER, V114, P759, DOI 10.1038/bjc.2016.26
   Bovenzi CD, 2015, BIOMED RES INT-UK, V2015, DOI 10.1155/2015/242437
   Bragado P, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029974
   Buczacki SJA, 2018, J EXP MED, V215, P1891, DOI 10.1084/jem.20171385
   Budhwani M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00322
   Calabrese C, 2007, CANCER CELL, V11, P69, DOI 10.1016/j.ccr.2006.11.020
   Carlson P, 2019, NAT CELL BIOL, V21, P238, DOI 10.1038/s41556-018-0267-0
   Carreau N, 2022, SURG ONCOL, V42, DOI 10.1016/j.suronc.2019.01.002
   Charles N, 2010, CELL STEM CELL, V6, P141, DOI 10.1016/j.stem.2010.01.001
   Chen JY, 2013, MOL CELL, V52, P87, DOI 10.1016/j.molcel.2013.09.009
   Chen J, 2012, NATURE, V488, P522, DOI 10.1038/nature11287
   Chen Q, 2016, NATURE, V533, P493, DOI 10.1038/nature18268
   Cheng N, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.120638
   Cooper J, 2019, CANCER CELL, V35, P347, DOI 10.1016/j.ccell.2019.01.007
   Corre S, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06951-2
   Crespo J, 2013, CURR OPIN IMMUNOL, V25, P214, DOI 10.1016/j.coi.2012.12.003
   Dalvi MP, 2017, CELL REP, V19, P1669, DOI 10.1016/j.celrep.2017.04.077
   Dauer P, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1408-5
   De Cock JM, 2016, CANCER RES, V76, P6778, DOI 10.1158/0008-5472.CAN-16-0608
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Dembinski JL, 2009, CLIN EXP METASTAS, V26, P611, DOI 10.1007/s10585-009-9260-0
   Domenici G, 2019, ONCOGENE, V38, P3151, DOI 10.1038/s41388-018-0656-7
   Doyen J, 2014, BIOCHEM BIOPH RES CO, V451, P54, DOI 10.1016/j.bbrc.2014.07.050
   Ebinger S, 2016, CANCER CELL, V30, P849, DOI 10.1016/j.ccell.2016.11.002
   El Rayes T, 2015, P NATL ACAD SCI USA, V112, P16000, DOI 10.1073/pnas.1507294112
   El Touny LH, 2014, J CLIN INVEST, V124, P156, DOI 10.1172/JCI70259
   Elgendy M, 2019, CANCER CELL, V35, P798, DOI 10.1016/j.ccell.2019.03.007
   Endo H, 2017, ONCOGENE, V36, P2824, DOI 10.1038/onc.2016.431
   Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415
   Essers MAG, 2010, MOL ONCOL, V4, P443, DOI 10.1016/j.molonc.2010.06.001
   Esteva FJ, 2019, LANCET ONCOL, V20, pE175, DOI 10.1016/S1470-2045(19)30026-9
   Flavahan WA, 2017, SCIENCE, V357, DOI 10.1126/science.aal2380
   Fluegen G, 2017, NAT CELL BIOL, V19, P120, DOI 10.1038/ncb3465
   Francescangeli F, 2015, CELL DEATH DIFFER, V22, P1700, DOI 10.1038/cdd.2015.19
   Francica P, 2017, BIOCHEM PHARMACOL, V126, P1, DOI 10.1016/j.bcp.2016.08.022
   Gan BY, 2010, NATURE, V468, P701, DOI 10.1038/nature09595
   Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35
   Giannoni E, 2015, ONCOTARGET, V6, P24061, DOI 10.18632/oncotarget.4448
   Giessler KM, 2017, J EXP MED, V214, P2073, DOI 10.1084/jem.20162017
   Gifford JB, 2016, MOL CANCER THER, V15, P1043, DOI 10.1158/1535-7163.MCT-15-0774
   Goddard ET, 2018, NAT CELL BIOL, V20, P1240, DOI 10.1038/s41556-018-0214-0
   Goel S, 2017, NATURE, V548, P471, DOI 10.1038/nature23465
   Goff DJ, 2013, CELL STEM CELL, V12, P316, DOI 10.1016/j.stem.2012.12.011
   Gonzalez H, 2018, GENE DEV, V32, P1267, DOI 10.1101/gad.314617.118
   Grzelak CA, 2017, CURR OPIN CELL BIOL, V48, P79, DOI 10.1016/j.ceb.2017.06.002
   Gui X, 2019, NATURE, V567, P262, DOI 10.1038/s41586-019-1006-9
   Guler GD, 2017, CANCER CELL, V32, P221, DOI 10.1016/j.ccell.2017.07.002
   Gupta A, 2010, P NATL ACAD SCI USA, V107, P14333, DOI 10.1073/pnas.1000248107
   Gupta PB, 2011, CELL, V146, P633, DOI 10.1016/j.cell.2011.07.026
   Hangauer MJ, 2017, NATURE, V551, P247, DOI 10.1038/nature24297
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Hinohara K, 2018, CANCER CELL, V34, P939, DOI 10.1016/j.ccell.2018.10.014
   Holohan C, 2013, NAT REV CANCER, V13, P714, DOI 10.1038/nrc3599
   Holtz MS, 2005, LEUKEMIA, V19, P1034, DOI 10.1038/sj.leu.2403724
   Hopkins BD, 2018, NATURE, V560, P499, DOI 10.1038/s41586-018-0343-4
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   Hou YZ, 2018, IMMUNITY, V49, P490, DOI 10.1016/j.immuni.2018.07.008
   Huang X, 2019, AUTOPHAGY, V15, P1258, DOI 10.1080/15548627.2019.1580105
   Iniguez AB, 2018, CANCER CELL, V34, P922, DOI 10.1016/j.ccell.2018.11.005
   Ippolito L, 2016, ONCOTARGET, V7, P61890, DOI 10.18632/oncotarget.11301
   Ishak CA, 2018, TRENDS CANCER, V4, P583, DOI 10.1016/j.trecan.2018.05.008
   Kabraji S, 2017, BREAST CANCER RES, V19, DOI 10.1186/s13058-017-0877-7
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Kitapma S, 2019, CANCER DISCOV, V9, P34, DOI 10.1158/2159-8290.CD-18-0689
   Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Kuang R, 2017, JCI INSIGHT, V2, DOI 10.1172/jci.insight.88815
   Kuntz EM, 2017, NAT MED, V23, P1234, DOI 10.1038/nm.4399
   Lagadinou ED, 2013, CELL STEM CELL, V12, P329, DOI 10.1016/j.stem.2012.12.013
   Lan XY, 2017, NATURE, V549, P227, DOI 10.1038/nature23666
   Lawson DA, 2015, NATURE, V526, P131, DOI 10.1038/nature15260
   Leadem BR, 2018, CANCER RES, V78, P1127, DOI 10.1158/0008-5472.CAN-17-1453
   Li S, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09634-8
   Liau BB, 2017, CELL STEM CELL, V20, P233, DOI 10.1016/j.stem.2016.11.003
   Lin WC, 2013, CANCER RES, V73, P1821, DOI 10.1158/0008-5472.CAN-12-2067
   Linde N, 2016, ADV CANCER RES, V132, P45, DOI 10.1016/bs.acr.2016.07.002
   Liu YY, 2018, J CLIN INVEST, V128, P1057, DOI 10.1172/JCI96329
   Liu YY, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15207
   Lu HH, 2014, NAT CELL BIOL, V16, P1105, DOI 10.1038/ncb3041
   Lu HQ, 2017, CELL REP, V18, P1946, DOI 10.1016/j.celrep.2017.02.001
   Lu Z, 2008, J CLIN INVEST, V118, P3917, DOI 10.1172/JCI35512
   Lytle NK, 2019, CELL, V177, P572, DOI 10.1016/j.cell.2019.03.010
   Maccalli C, 2018, SEMIN CANCER BIOL, V53, P189, DOI 10.1016/j.semcancer.2018.09.006
   Madden E, 2019, BIOL CELL, V111, P1, DOI 10.1111/boc.201800050
   Makena MR, 2020, BBA-MOL BASIS DIS, V1866, DOI 10.1016/j.bbadis.2018.11.015
   Malladi S, 2016, CELL, V165, P45, DOI 10.1016/j.cell.2016.02.025
   Manzotti G, 2019, CANCERS, V11, DOI 10.3390/cancers11030304
   Martins-Neves SR, 2018, PHARMACOL RES, V137, P193, DOI 10.1016/j.phrs.2018.10.011
   Matassa DS, 2016, CELL DEATH DIFFER, V23, P1542, DOI 10.1038/cdd.2016.39
   Merlos-Suárez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Miao YX, 2019, CELL, V177, P1172, DOI 10.1016/j.cell.2019.03.025
   Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167
   Moeckel Sylvia, 2019, Oncotarget, V10, P368, DOI 10.18632/oncotarget.26569
   Mohammad HP, 2019, NAT MED, V25, P403, DOI 10.1038/s41591-019-0376-8
   Mohme M, 2017, NAT REV CLIN ONCOL, V14, P155, DOI 10.1038/nrclinonc.2016.144
   Morandi A, 2017, BBA-REV CANCER, V1868, P1, DOI 10.1016/j.bbcan.2016.12.004
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   Nencioni A, 2018, NAT REV CANCER, V18, P707, DOI 10.1038/s41568-018-0061-0
   O'Leary B, 2016, NAT REV CLIN ONCOL, V13, P417, DOI 10.1038/nrclinonc.2016.26
   Ogba N, 2014, BREAST CANCER RES, V16, DOI 10.1186/s13058-014-0489-4
   Ojha R, 2019, CANCER DISCOV, V9, P396, DOI 10.1158/2159-8290.CD-18-0348
   Orienti I, CELL DEATH DIS
   Ou JJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-08902-x
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Payne KK, 2016, J LEUKOCYTE BIOL, V100, P625, DOI 10.1189/jlb.5A1215-580R
   Pece S, 2010, CELL, V140, P62, DOI 10.1016/j.cell.2009.12.007
   Pfister SX, 2017, NAT REV DRUG DISCOV, V16, P241, DOI 10.1038/nrd.2016.256
   Polzer B, 2013, NAT MED, V19, P274, DOI 10.1038/nm.3121
   Pommier A, 2018, SCIENCE, V360, P1202, DOI 10.1126/science.aao4908
   Puig I, 2018, J CLIN INVEST, V128, P3887, DOI 10.1172/JCI96393
   Rabinowitz JD, 2010, SCIENCE, V330, P1344, DOI 10.1126/science.1193497
   Rahmanto AS, 2016, EMBO J, V35, P2192, DOI 10.15252/embj.201693889
   Rajbhandari N, 2017, CELL REP, V18, P2243, DOI 10.1016/j.celrep.2017.02.013
   Ramirez M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10690
   Ranganathan AC, 2006, CANCER RES, V66, P1702, DOI 10.1158/0008-5472.CAN-05-3092
   Ranoa DRE, 2019, CANCER RES, V79, P1465, DOI 10.1158/0008-5472.CAN-18-1972
   Rapisarda A, 2009, DRUG RESIST UPDATE, V12, P74, DOI 10.1016/j.drup.2009.03.002
   Ren D, 2019, J EXP MED, V216, P428, DOI 10.1084/jem.20180661
   Retsky M, 2013, CURR MED CHEM, V20, P4163
   Risom T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05729-w
   Roberson RS, 2005, CANCER RES, V65, P2795, DOI 10.1158/0008-5472.CAN-04-1270
   Roche B, 2017, RNA BIOL, V14, P843, DOI 10.1080/15476286.2017.1327510
   Roesch A, 2013, CANCER CELL, V23, P811, DOI 10.1016/j.ccr.2013.05.003
   Roesch A, 2010, CELL, V141, P583, DOI 10.1016/j.cell.2010.04.020
   Rothwell PM, 2012, LANCET, V379, P1591, DOI 10.1016/S0140-6736(12)60209-8
   Sakai W, 2008, NATURE, V451, P1116, DOI 10.1038/nature06633
   Saleh T, 2019, CANCER RES, V79, P1044, DOI 10.1158/0008-5472.CAN-18-3437
   Saleh T, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00164
   Sansone P, 2017, CANCER RES, V77, P1927, DOI 10.1158/0008-5472.CAN-16-2129
   Sansone P, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10442
   Senft D, 2018, NAT REV CANCER, V18, P69, DOI 10.1038/nrc.2017.105
   Shaffer SM, 2017, NATURE, V546, P431, DOI 10.1038/nature22794
   Sharma P, 2017, CELL, V168, P707, DOI 10.1016/j.cell.2017.01.017
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shimizu H, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.125138
   Song MY, 2018, GASTROENTEROLOGY, V155, P596, DOI 10.1053/j.gastro.2018.07.038
   Soppa U, 2014, CELL CYCLE, V13, P2084, DOI 10.4161/cc.29104
   Sosa MS, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7170
   Sosa MS, 2014, NAT REV CANCER, V14, P611, DOI 10.1038/nrc3793
   Staberg M, 2018, MOL ONCOL, V12, P406, DOI 10.1002/1878-0261.12174
   Stevanovic S, 2017, SCIENCE, V356, P200, DOI 10.1126/science.aak9510
   Terai H, 2018, CANCER RES, V78, P1044, DOI 10.1158/0008-5472.CAN-17-1904
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Tran E, 2015, SCIENCE, V350, P1387, DOI 10.1126/science.aad1253
   Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Vallette FM, 2019, BIOCHEM PHARMACOL, V162, P169, DOI 10.1016/j.bcp.2018.11.004
   van der Heijden M, 2019, P NATL ACAD SCI USA, V116, P6140, DOI 10.1073/pnas.1813417116
   Vanner RJ, 2014, CANCER CELL, V26, P33, DOI 10.1016/j.ccr.2014.05.005
   Vera-Ramirez Laura, 2017, F1000Res, V6, P2134, DOI 10.12688/f1000research.12174.1
   Vermeulen L, 2010, NAT CELL BIOL, V12, P468, DOI 10.1038/ncb2048
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Vinogradova M, 2016, NAT CHEM BIOL, V12, P531, DOI 10.1038/nchembio.2085
   Wang LH, 2019, ONCOGENE, V38, P2042, DOI 10.1038/s41388-018-0476-9
   Wang XH, 2017, CANCER RES, V77, P839, DOI 10.1158/0008-5472.CAN-15-3142
   Wawruszak A, 2019, CANCERS, V11, DOI 10.3390/cancers11020148
   Werner-Klein M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02674-y
   Yan MM, 2015, ONCOL LETT, V10, P1959, DOI 10.3892/ol.2015.3508
   Yan W, 2018, NAT CELL BIOL, V20, P597, DOI 10.1038/s41556-018-0083-6
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yuan XD, 2018, BRIT J CANCER, V119, P1358, DOI 10.1038/s41416-018-0338-9
   Zacharakis N, 2018, NAT MED, V24, P724, DOI 10.1038/s41591-018-0040-8
   Zanconato F, 2018, NAT MED, V24, P1599, DOI 10.1038/s41591-018-0158-8
   Zeuner A, 2014, CELL DEATH DIFFER, V21, P1877, DOI 10.1038/cdd.2014.105
   Zeuner A, 2015, MOL CELL ONCOL, V2, DOI 10.4161/23723548.2014.968067
   Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012
   Zhang XJ, 2019, CANCER RES, V79, P2447, DOI 10.1158/0008-5472.CAN-18-2468
   Zhang XN, 2016, TRENDS CANCER, V2, P657, DOI 10.1016/j.trecan.2016.10.009
   Zhou WC, 2015, NAT CELL BIOL, V17, P170, DOI 10.1038/ncb3090
   Zhou YF, 2012, CANCER RES, V72, P304, DOI 10.1158/0008-5472.CAN-11-1674
NR 183
TC 146
Z9 151
U1 0
U2 36
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JUL 10
PY 2019
VL 9
AR 626
DI 10.3389/fonc.2019.00626
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IH8AE
UT WOS:000474725600004
PM 31355143
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Baranyi, M
   Rittler, D
   Molnár, E
   Shirasawa, S
   Jalsovszky, I
   Varga, IK
   Hegedus, L
   Németh, A
   Dank, M
   Aigner, C
   Tóvári, J
   Tímár, J
   Hegedus, B
   Garay, T
AF Baranyi, Marcell
   Rittler, Dominika
   Molnar, Eszter
   Shirasawa, Senji
   Jalsovszky, Istvan
   Varga, Imre Karoly
   Hegedus, Luca
   Nemeth, Afrodite
   Dank, Magdolna
   Aigner, Clemens
   Tovari, Jozsef
   Timar, Jozsef
   Hegedus, Balazs
   Garay, Tamas
TI Next Generation Lipophilic Bisphosphonate Shows Antitumor Effect in
   Colorectal Cancer In Vitro and In Vivo
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Lipophilic bisphosphonate; Zoledronic acid; Colorectal cancer; In vitro;
   In vivo
ID NITROGEN-CONTAINING BISPHOSPHONATES; ZOLEDRONIC ACID; HUMAN BREAST; ORAL
   BISPHOSPHONATES; CELL-LINES; GROWTH; APOPTOSIS; THERAPY; RISK; KRAS
AB Bisphosphonates, despite proven antitumor effect in vitro in many tumor types, are currently used only for treatment of osteoporosis and bone metastasis. Colorectal cancer is the third most commonly diagnosed type of cancer and lacks targeted therapy for RAS or RAF mutation carrying cases. A new lipophilic bisphosphonate showed promising results in lung cancer models, but their effect on colorectal cancer cells was not investigated excessively. Antitumor effects and impact on RAS-related signalization of zoledronic acid (ZA) and a lipophilic bisphosphonate (BPH1222) were investigated on 7 human colorectal cancer cell lines in vitro and in vivo. Furthermore, mutant KRAS dependent effect of prenylation inhibition was investigated using isogeneic cell lines. Both bisphosphonates reduced cell viability in vitro in a dose-dependent manner. Both compounds changed cell cycle distribution similarly by increasing the proportion of cells either in the S or in the subG1 phase or both. However, BPH1222 exerted higher inhibitory effect on spheroid growth than ZA. Interestingly, we found profound alterations in phosphorylation level of Erk and S6 proteins upon ZA or BPH1222 treatment. Furthermore, investigation of a mutant KRAS isogeneic model system suggests that the drugs interfere also with the mutant KRAS proteins. In vivo experiments with KRAS mutant xenograft model also revealed growth inhibitory potential of bisphosphonate treatment. Our results show that lipophilic bisphosphonates might extend the therapeutic spectrum of bisphosphonate drugs and could be considered as additional treatment approaches in colorectal cancer.
C1 [Baranyi, Marcell; Rittler, Dominika; Molnar, Eszter; Timar, Jozsef; Hegedus, Balazs; Garay, Tamas] Semmelweis Univ, Dept Pathol 2, H-1091 Budapest, Hungary.
   [Shirasawa, Senji] Fukuoka Univ, Fac Med, Dept Cell Biol, Fukuoka, Fukuoka, Japan.
   [Jalsovszky, Istvan; Varga, Imre Karoly] Eotvos Lorand Univ, Fac Sci, Inst Chem, Dept Organ Chem, H-1117 Budapest, Hungary.
   [Hegedus, Luca; Aigner, Clemens; Hegedus, Balazs] Univ Duisburg Essen, Dept Thorac Surg, Ruhrlandklin, D-45239 Essen, Germany.
   [Nemeth, Afrodite; Dank, Magdolna] Semmelweis Univ, Oncol Ctr, H-1091 Budapest, Hungary.
   [Tovari, Jozsef; Garay, Tamas] Natl Inst Oncol, Dept Expt Pharmacol, H-1122 Budapest, Hungary.
   [Garay, Tamas] Pazmany Peter Catholic Univ, Fac Informat Technol, H-1083 Budapest, Hungary.
   [Garay, Tamas] Hungarian Acad Sci, Postdoctoral Fellowship Program, H-1051 Budapest, Hungary.
C3 Semmelweis University; Fukuoka University; Hungarian Academy of
   Sciences; Eotvos Lorand University; University of Duisburg Essen;
   Semmelweis University; National Institute of Oncology Hungary; Pazmany
   Peter Catholic University; Hungarian Academy of Sciences
RP Hegedus, B (corresponding author), Semmelweis Univ, Dept Pathol 2, H-1091 Budapest, Hungary.
EM baranyi2marci@gmail.com; rittler.dominika@med.semmelweis-univ.hu;
   molnar.eszter@med.semmelweis-univ.hu; sshirasa@fukuoka-u.ac.jp;
   jalso@caesar.elte.hu; vukracs@caesar.elte.hu;
   luca.hegedues@rlk.uk-essen.de; afrodite.nemeth@gmail.com;
   dank.magdolna@med.semmelweis-univ.hu;
   clemens.aigner@ruhrlandklinik.uk-essen.de; jtovari@yahoo.com;
   jtimar@gmail.com; balazs.hegedues@rlk.uk-essen.de; garayt@gmail.com
RI Eszter, Molnar/F-1894-2014; Hegedűs, Luca/AFL-9911-2022; Aigner,
   Clemens/A-7284-2019; Hegedus, Balazs/HKE-7559-2023; Hegedus,
   Balazs/B-6076-2008
OI Hegedus, Balazs/0000-0002-4341-4153; Nemeth,
   Afrodite/0000-0002-8687-5523; Dank, Magdolna/0000-0002-4694-3624;
   Aigner, Clemens/0000-0002-7787-991X
FU Hungarian National Research, Development and Innovation Office
   [MOB80325, NVKP-16-1-2016-0020]; Hungarian Scientific Research Fund -
   OTKA [K116151]; HAS Postdoctoral Fellowship Program [450,071]
FX This work was supported by the Hungarian National Research, Development
   and Innovation Office (MOB80325 to BH and NVKP-16-1-2016-0020 to
   JTimar), Hungarian Scientific Research Fund - OTKA (K116151 to JTimar)
   and by the HAS Postdoctoral Fellowship Program (450,071 to TG). The
   funding bodies did not play a role in the design of the study, the
   collection, analysis and interpretation of data or in the preparation of
   the manuscript.
CR Baldus SE, 2010, CLIN CANCER RES, V16, P790, DOI 10.1158/1078-0432.CCR-09-2446
   Bonovas S, 2013, BRIT J CLIN PHARMACO, V76, P329, DOI 10.1111/bcp.12135
   Cohen R, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0453-5
   Coleman R, 2014, LANCET ONCOL, V15, P997, DOI 10.1016/S1470-2045(14)70302-X
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Salvatore M, 2011, CELL PROLIFERAT, V44, P139, DOI 10.1111/j.1365-2184.2011.00745.x
   Fearon ER, 2011, ANNU REV PATHOL-MECH, V6, P479, DOI 10.1146/annurev-pathol-011110-130235
   Forsea AM, 2004, BRIT J CANCER, V91, P803, DOI 10.1038/sj.bjc.6602052
   Fragni M, 2016, N-S ARCH PHARMACOL, V389, P529, DOI 10.1007/s00210-016-1224-8
   Gao X, 2015, TUMOR BIOL, V36, P5315, DOI 10.1007/s13277-015-3192-x
   Garay T, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0117021
   Hack S, 2011, EUR J MED CHEM, V46, P1483, DOI 10.1016/j.ejmech.2011.01.042
   Hegedüs L, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00095
   Ibrahim T, 2012, CANCER CELL INT, V12, DOI 10.1186/1475-2867-12-48
   Ivanov DP, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103817
   James ND, 2016, LANCET, V387, P1163, DOI 10.1016/S0140-6736(15)01037-5
   Kato J, 2016, INT J CANCER, V138, P1516, DOI 10.1002/ijc.29881
   Kelsey I, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004632
   Kenessey I, 2016, ONCOTARGET, V7, P79489, DOI 10.18632/oncotarget.12806
   Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kuroda J, 2004, CANCER SCI, V95, P186, DOI 10.1111/j.1349-7006.2004.tb03202.x
   Lau KS, 2009, MOL CELLS, V28, P315, DOI 10.1007/s10059-009-0143-7
   Mansouri M, 2014, BIOCHIMIE, V99, P71, DOI 10.1016/j.biochi.2013.11.010
   McGuire S, 2016, ADV NUTR, V7, P418, DOI 10.3945/an.116.012211
   Michailidou M, 2010, J VASC RES, V47, P481, DOI 10.1159/000313876
   Morgan GJ, 2010, LANCET, V376, P1989, DOI 10.1016/S0140-6736(10)62051-X
   Mouradov D, 2014, CANCER RES, V74, P3238, DOI 10.1158/0008-5472.CAN-14-0013
   Nath S, 2016, PHARMACOL THERAPEUT, V163, P94, DOI 10.1016/j.pharmthera.2016.03.013
   Räkel A, 2011, CLIN INTERV AGING, V6, P89, DOI 10.2147/CIA.S7282
   Rennert G, 2011, J CLIN ONCOL, V29, P1146, DOI 10.1200/JCO.2010.33.7485
   Senaratne SG, 2000, BRIT J CANCER, V82, P1459, DOI 10.1054/bjoc.1999.1131
   Sewing L, 2008, APOPTOSIS, V13, P782, DOI 10.1007/s10495-008-0211-z
   SHIRASAWA S, 1993, SCIENCE, V260, P85, DOI 10.1126/science.8465203
   Stachnik A, 2014, P NATL ACAD SCI USA, V111, P17995, DOI 10.1073/pnas.1421422111
   Sundar R, 2017, CANCER DISCOV, V7, P558, DOI 10.1158/2159-8290.CD-17-0087
   Tamura T, 2011, ONCOL REP, V25, P1139, DOI 10.3892/or.2011.1152
   Tassone P, 2003, BRIT J CANCER, V88, P1971, DOI 10.1038/sj.bjc.6600986
   Thosani N, 2013, J CLIN ONCOL, V31, P623, DOI 10.1200/JCO.2012.42.9530
   Tímár J, 2010, CURR CANCER DRUG TAR, V10, P813, DOI 10.2174/156800910793357989
   van Beek E, 1999, BIOCHEM BIOPH RES CO, V264, P108, DOI 10.1006/bbrc.1999.1499
   Vaughn CP, 2011, GENE CHROMOSOME CANC, V50, P307, DOI 10.1002/gcc.20854
   Wang M, 2016, NAT REV MOL CELL BIO, V17, P110, DOI 10.1038/nrm.2015.11
   Weiss HM, 2008, DRUG METAB DISPOS, V36, P2043, DOI 10.1124/dmd.108.021071
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Xia YF, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3010382
   Yang GR, 2013, J CLIN GASTROENTEROL, V47, P741, DOI 10.1097/MCG.0b013e31829e446b
   Zhang YH, 2013, ACS MED CHEM LETT, V4, P423, DOI 10.1021/ml4000436
   Zhang YH, 2009, J AM CHEM SOC, V131, P5153, DOI 10.1021/ja808285e
NR 50
TC 11
Z9 12
U1 0
U2 9
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD JUL
PY 2020
VL 26
IS 3
BP 1957
EP 1969
DI 10.1007/s12253-019-00789-9
EA JAN 2020
PG 13
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA LY6CR
UT WOS:000505406600002
PM 31902117
DA 2025-01-04
ER

PT J
AU Bensberg, M
   Rundquist, O
   Selimovic, A
   Lagerwall, C
   Benson, M
   Gustafsson, M
   Vogt, H
   Lentini, A
   Nestor, CE
AF Bensberg, Maike
   Rundquist, Olof
   Selimovic, Aida
   Lagerwall, Cathrine
   Benson, Mikael
   Gustafsson, Mika
   Vogt, Hartmut
   Lentini, Antonio
   Nestor, Colm E.
TI TET2 as a tumor suppressor and therapeutic target in T-cell acute
   lymphoblastic leukemia
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE TET2; T-ALL; &nbsp; 5-azacytidine; &nbsp; HERV; &nbsp; vitamin C
ID CONVENTIONAL CARE REGIMENS; COLORECTAL-CANCER CELLS; DEMETHYLATING
   AGENTS; VIRAL MIMICRY; SELF-RENEWAL; DNA; METHYLATION;
   5-HYDROXYMETHYLCYTOSINE; 5-METHYLCYTOSINE; MUTATIONS
AB Pediatric T-cell acute lymphoblastic leukemia (T-ALL) is an aggres-sive malignancy resulting from overproduction of immature T-cells in the thymus and is typified by widespread alterations in DNA methyl-ation. As survival rates for relapsed T-ALL remain dismal (10 to 25%), development of targeted therapies to prevent relapse is key to improv-ing prognosis. Whereas mutations in the DNA demethylating enzyme TET2 are frequent in adult T-cell malignancies, TET2 mutations in T-ALL are rare. Here, we analyzed RNA-sequencing data of 321 primary T-ALLs, 20 T-ALL cell lines, and 25 normal human tissues, revealing that TET2 is transcriptionally repressed or silenced in 71% and 17% of T-ALL, respec-tively. Furthermore, we show that TET2 silencing is often associated with hypermethylation of the TET2 promoter in primary T-ALL. Impor-tantly, treatment with the DNA demethylating agent, 5-azacytidine (5-aza), was significantly more toxic to TET2-silenced T-ALL cells and resulted in stable re-expression of the TET2 gene. Additionally, 5-aza led to up-regulation of methylated genes and human endogenous ret-roviruses (HERVs), which was further enhanced by the addition of phys-iological levels of vitamin C, a potent enhancer of TET activity. Together, our results clearly identify 5-aza as a potential targeted therapy for TET2-silenced T-ALL.
C1 [Bensberg, Maike; Rundquist, Olof; Selimovic, Aida; Lagerwall, Cathrine; Benson, Mikael; Vogt, Hartmut; Nestor, Colm E.] Linkoping Univ, Crown Princess Victoria Childrens Hosp, Dept Biomed & Clin Sci, S-58183 Linkoping, Sweden.
   [Rundquist, Olof; Gustafsson, Mika] Linkoping Univ, Dept Phys Chem & Biol, Bioinformat, S-58183 Linkoping, Sweden.
   [Lentini, Antonio] Karolinska Inst, Dept Med Biochem & Biophys, S-17177 Stockholm, Sweden.
C3 Linkoping University; Linkoping University; Karolinska Institutet
RP Nestor, CE (corresponding author), Linkoping Univ, Crown Princess Victoria Childrens Hosp, Dept Biomed & Clin Sci, S-58183 Linkoping, Sweden.
EM colm.nestor@liu.se
RI ; Lentini, Antonio/N-5684-2015
OI Lagerwall, Cathrine/0000-0002-3605-1470; Lentini,
   Antonio/0000-0003-1239-5495; Bensberg, Maike/0000-0003-2395-6083;
   Nestor, Colm/0000-0001-5853-1769; Selimovic-Pasic,
   Aida/0000-0001-9580-4455; Rundquist, Olof/0000-0002-1424-3658
CR Agathocleous M, 2017, NATURE, V549, P476, DOI 10.1038/nature23876
   Almeida LG, 2009, NUCLEIC ACIDS RES, V37, pD816, DOI 10.1093/nar/gkn673
   An J, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms10071
   Aryee MJ, 2014, BIOINFORMATICS, V30, P1363, DOI 10.1093/bioinformatics/btu049
   Bamezai S, 2021, LEUKEMIA, V35, P389, DOI 10.1038/s41375-020-0864-3
   Bechtel S, 2007, BMC GENOMICS, V8, DOI 10.1186/1471-2164-8-399
   Bensberg M., EMB EBI ARRAYEXPRESS
   Campbell PJ, 2020, NATURE, V578, P82, DOI 10.1038/s41586-020-1969-6
   Chen H, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-35
   Chen Q, 2005, P NATL ACAD SCI USA, V102, P13604, DOI 10.1073/pnas.0506390102
   Chen Q, 2008, P NATL ACAD SCI USA, V105, P11105, DOI 10.1073/pnas.0804226105
   Chiappinelli KB, 2015, CELL, V162, P974, DOI 10.1016/j.cell.2015.07.011
   Choi Y, 2015, BIOINFORMATICS, V31, P2745, DOI 10.1093/bioinformatics/btv195
   Chong TL, 2019, FRONT CELL DEV BIOL, V7, DOI 10.3389/fcell.2019.00128
   Cimmino L, 2017, CELL, V170, P1079, DOI 10.1016/j.cell.2017.07.032
   Conway JR, 2017, BIOINFORMATICS, V33, P2938, DOI 10.1093/bioinformatics/btx364
   Couronné L, 2012, NEW ENGL J MED, V366, P95, DOI 10.1056/NEJMc1111708
   Dang L, 2009, NATURE, V462, P739, DOI 10.1038/nature08617
   Dickson KM, 2013, BIOCHEM BIOPH RES CO, V439, P522, DOI 10.1016/j.bbrc.2013.09.010
   Dobin A, 2013, BIOINFORMATICS, V29, P15, DOI 10.1093/bioinformatics/bts635
   Dunwell TL, 2009, EPIGENETICS-US, V4, P185, DOI 10.4161/epi.4.3.8752
   Esteller M, 2008, NEW ENGL J MED, V358, P1148, DOI [10.1056/NEJMra072067, 10.1093/carcin/bgp220]
   Fenaux P, 2010, J CLIN ONCOL, V28, P562, DOI 10.1200/JCO.2009.23.8329
   Fenaux P, 2009, LANCET ONCOL, V10, P223, DOI 10.1016/S1470-2045(09)70003-8
   Fortin JP, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0503-2
   Ghandi M, 2019, NATURE, V569, P503, DOI 10.1038/s41586-019-1186-3
   Gustafson CB, 2015, CLIN EPIGENETICS, V7, DOI 10.1186/s13148-015-0087-z
   Hackett JA, 2012, DEVELOPMENT, V139, P3623, DOI 10.1242/dev.081661
   Hahne F, 2016, METHODS MOL BIOL, V1418, P335, DOI 10.1007/978-1-4939-3578-9_16
   Hu YH, 2019, ONCOTARGETS THER, V12, P8105, DOI 10.2147/OTT.S223423
   Im JY, 2016, BBA-MOL CELL RES, V1863, P40, DOI 10.1016/j.bbamcr.2015.10.011
   Issa JPJ, 2015, LANCET ONCOL, V16, P1099, DOI 10.1016/S1470-2045(15)00038-8
   Ito S, 2011, SCIENCE, V333, P1300, DOI 10.1126/science.1210597
   Jaiswal S, 2014, NEW ENGL J MED, V371, P2488, DOI 10.1056/NEJMoa1408617
   Kuiper C, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00359
   Lasa A, 2004, LEUKEMIA, V18, P1231, DOI 10.1038/sj.leu.2403377
   Lemonnier F, 2012, BLOOD, V120, P1466, DOI 10.1182/blood-2012-02-408542
   Lio CWJ, 2019, BLOOD, V134, P1487, DOI 10.1182/blood.2019791475
   Liu MM, 2016, P NATL ACAD SCI USA, V113, P10238, DOI 10.1073/pnas.1612262113
   Liu Y, 2017, NAT GENET, V49, P1211, DOI 10.1038/ng.3909
   Losman JA, 2013, SCIENCE, V339, P1621, DOI 10.1126/science.1231677
   Lu YX, 2018, THERANOSTICS, V8, P1312, DOI 10.7150/thno.21745
   Luchtel RA, 2020, P NATL ACAD SCI USA, V117, P1666, DOI 10.1073/pnas.1908158117
   Ma XT, 2018, NATURE, V555, P371, DOI 10.1038/nature25795
   Ma Y, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007154
   Magrì A, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aay8707
   Marçais A, 2017, ONCOTARGET, V8, P52256, DOI 10.18632/oncotarget.13665
   May JM, 2011, BRIT J PHARMACOL, V164, P1793, DOI 10.1111/j.1476-5381.2011.01350.x
   Moran-Crusio K, 2011, CANCER CELL, V20, P11, DOI 10.1016/j.ccr.2011.06.001
   Navada SC, 2014, J CLIN INVEST, V124, P40, DOI 10.1172/JCI69739
   Ness KK, 2011, EXPERT REV HEMATOL, V4, P185, DOI [10.1586/ehm.11.8, 10.1586/EHM.11.8]
   Nordlund J, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-9-r105
   Odejide O, 2014, BLOOD, V123, P1293, DOI 10.1182/blood-2013-10-531509
   Ohtani H, 2020, CANCER RES, V80, P2441, DOI 10.1158/0008-5472.CAN-19-1696
   Patro R, 2017, NAT METHODS, V14, P417, DOI 10.1038/nmeth.4197
   Peng D, 2018, CLIN EPIGENETICS, V10, DOI 10.1186/s13148-018-0527-7
   Pimentel H, 2017, NAT METHODS, V14, P687, DOI 10.1038/nmeth.4324
   Pronier E, 2011, BLOOD, V118, P2551, DOI 10.1182/blood-2010-12-324707
   Qiu XN, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012994
   Quist-Paulsen P, 2020, LEUKEMIA, V34, P347, DOI 10.1038/s41375-019-0598-2
   Quivoron C, 2011, CANCER CELL, V20, P25, DOI 10.1016/j.ccr.2011.06.003
   Repana D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1612-0
   Reva B, 2011, NUCLEIC ACIDS RES, V39, pE118, DOI 10.1093/nar/gkr407
   Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Roels J, 2020, NAT IMMUNOL, V21, P1280, DOI 10.1038/s41590-020-0747-9
   Roulois D, 2015, CELL, V162, P961, DOI 10.1016/j.cell.2015.07.056
   Saini SK, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19464-8
   Schmiegelow K, 2010, LEUKEMIA, V24, P345, DOI 10.1038/leu.2009.251
   Spegarova JS, 2020, BLOOD, V136, P1055, DOI 10.1182/blood.2020005844
   Sproul D, 2012, GENOME BIOL, V13, DOI [10.1186/gb-2012-13-10-R84, 10.1186/gb-2012-13-10-r84]
   Sproul D, 2011, P NATL ACAD SCI USA, V108, P4364, DOI 10.1073/pnas.1013224108
   Szarzynska-Zawadzka B, 2019, AM J HEMATOL, V94, pE93, DOI 10.1002/ajh.25396
   Tahiliani M, 2009, SCIENCE, V324, P930, DOI 10.1126/science.1170116
   Takane K, 2014, CANCER MED-US, V3, P1235, DOI 10.1002/cam4.273
   Toft N, 2018, LEUKEMIA, V32, P606, DOI 10.1038/leu.2017.265
   Tsagaratou A, 2017, NAT IMMUNOL, V18, P45, DOI 10.1038/ni.3630
   Tsukaguchi H, 1999, NATURE, V399, P70, DOI 10.1038/19986
   Uhlen M, 2015, SCIENCE, V347, DOI 10.1126/science.1260419
   Verboom K, 2018, HAEMATOLOGICA, V103, pE585, DOI 10.3324/haematol.2018.190587
   Ward AK, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-016-0672-x
   Wilson KD, 2020, DEV CELL, V54, P694, DOI 10.1016/j.devcel.2020.07.006
   Wu XJ, 2017, NAT REV GENET, V18, P517, DOI 10.1038/nrg.2017.33
   Yi L, 2018, GENOME BIOL, V19, DOI 10.1186/s13059-018-1419-z
   Young JI, 2015, ANNU REV NUTR, V35, P545, DOI 10.1146/annurev-nutr-071714-034228
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
   Zhou WD, 2017, NUCLEIC ACIDS RES, V45, DOI 10.1093/nar/gkw967
NR 87
TC 32
Z9 35
U1 0
U2 10
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD AUG 24
PY 2021
VL 118
IS 34
AR e2110758118
DI 10.1073/pnas.2110758118
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA UH1VO
UT WOS:000689727900026
PM 34413196
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Zhang, LN
   Qian, YC
AF Zhang, Lina
   Qian, Yucheng
TI An epithelial-mesenchymal transition-related prognostic model for
   colorectal cancer based on weighted gene co-expression network analysis
SO JOURNAL OF INTERNATIONAL MEDICAL RESEARCH
LA English
DT Article
DE Colorectal cancer; weighted gene co-expression network; consensus
   clustering; epithelial-mesenchymal transition; biomarker; prognosis
ID R PACKAGE; BIOINFORMATICS; METASTASIS; FYN; MECHANISM; EXPRESSION;
   DISCOVERY; TARGET; L1CAM
AB Objective: To identify susceptibility modules and genes for colorectal cancer (CRC) using weighted gene co-expression network analysis (WGCNA).
   Methods: Four microarray datasets were downloaded from the Gene Expression Omnibus database. We divided the tumor samples into three subgroups based on consensus clustering of gene expression, and analyzed the correlations between the subgroups and clinical features. The genetic features of the subgroups were investigated by gene set enrichment analysis (GSEA). A gene expression network was constructed using WGCNA, and a protein-protein interaction (PPI) network was used to identify the key genes. Gene modules were annotated by Gene Ontology and Kyoto Encyclopedia of Genes and Genomes enrichment analyses.
   Results: We divided the cancer cases into three subgroups based on consensus clustering (subgroups I, II, III). The green module identified by WGCNA was correlated with clinical characteristics. Ten key genes were identified according to their degree of connectivity in the protein-protein interaction network: FYN, SEMA3A, AP2M1, L1CAM, NRP1, TLN1, VWF, ITGB3, ILK, and ACTN1.
   Conclusion: We identified 10 hub genes as candidate biomarkers for CRC. These key genes may provide a theoretical basis for targeted therapy against CRC.
C1 [Zhang, Lina] Zhejiang Univ, Ningbo Hosp, Ningbo Hosp 1, Dept Gen Surg, 59 Liuting St, Ningbo 315010, Zhejiang, Peoples R China.
   [Qian, Yucheng] Zhejiang Univ, Affiliated Hosp 2, Sch Med,Lab Canc Prevent & Intervent, Dept Colorectal Surg & Oncol,Minist Educ, Hangzhou, Zhejiang, Peoples R China.
   [Qian, Yucheng] Zhejiang Univ, Canc Ctr, Hangzhou 310058, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University
RP Zhang, LN (corresponding author), Zhejiang Univ, Ningbo Hosp, Ningbo Hosp 1, Dept Gen Surg, 59 Liuting St, Ningbo 315010, Zhejiang, Peoples R China.
EM 21818312@zju.edu.cn.com
OI Zhang, Lina/0000-0002-4147-0442
CR André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Ashizawa N, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5243
   Barbazán J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040476
   Basak D, 2020, CANCERS, V12, DOI 10.3390/cancers12113336
   Boesch M, 2018, STEM CELL TRANSL MED, V7, P495, DOI 10.1002/sctm.17-0289
   Celià-Terrassa T, 2016, GENE DEV, V30, P892, DOI 10.1101/gad.277681.116
   Chen ZP, 2018, INT J ONCOL, V53, P1227, DOI 10.3892/ijo.2018.4451
   Elias D, 2015, PHARMACOL RES, V100, P250, DOI 10.1016/j.phrs.2015.08.010
   Er EE, 2018, NAT CELL BIOL, V20, P966, DOI 10.1038/s41556-018-0138-8
   Fang QX, 2020, AM J TRANSL RES, V12, P837
   Fukumoto M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120616
   Ganesh K, 2020, NAT CANCER, V1, P28, DOI 10.1038/s43018-019-0006-x
   Gaur P, 2009, CLIN CANCER RES, V15, P6763, DOI 10.1158/1078-0432.CCR-09-1810
   Giuliani A, 2017, DRUG DISCOV TODAY, V22, P1069, DOI 10.1016/j.drudis.2017.01.005
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032
   Hänzelmann S, 2013, BMC BIOINFORMATICS, V14, DOI 10.1186/1471-2105-14-7
   Hogan J, 2014, ANN SURG, V260, P94, DOI 10.1097/SLA.0000000000000289
   Huang MD, 2015, PLANT PHYSIOL, V169, P453, DOI 10.1104/pp.15.00634
   Janiszewska M, 2020, J BIOL CHEM, V295, P2495, DOI 10.1074/jbc.REV119.007759
   Jiang H, 2018, INT J MOL MED, V42, P368, DOI 10.3892/ijmm.2018.3631
   Lackner C, 2004, VIRCHOWS ARCH, V445, P160, DOI 10.1007/s00428-004-1051-z
   Langfelder P, 2008, BMC BIOINFORMATICS, V9, DOI 10.1186/1471-2105-9-559
   Le CC, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00527
   Le Duff M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0209-y
   Lee GH, 2018, ONCOGENE, V37, P1857, DOI 10.1038/s41388-017-0114-y
   Lei YL, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.005397
   Lepelletier Y, 2006, EUR J IMMUNOL, V36, P1782, DOI 10.1002/eji.200535601
   Liang YQ, 2020, ONCOL REP, V44, P1671, DOI 10.3892/or.2020.7729
   Liu XS, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03672-1
   Lu JM, 2020, PLOS ONE, V15, DOI 10.1371/journal.pone.0233208
   Ma LL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2370-y
   Maida M, 2017, EXPERT REV ANTICANC, V17, P1131, DOI 10.1080/14737140.2017.1392243
   McMahon HT, 2011, NAT REV MOL CELL BIO, V12, P517, DOI 10.1038/nrm3151
   Powner D, 2011, BIOCHEM SOC T, V39, P563, DOI 10.1042/BST0390563
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Reinmuth N, 2003, CANCER RES, V63, P2079
   Ren JJ, 2017, PSYCHONEUROENDOCRINO, V86, P17, DOI 10.1016/j.psyneuen.2017.09.005
   Resh MD, 1998, INT J BIOCHEM CELL B, V30, P1159, DOI 10.1016/S1357-2725(98)00089-2
   Rong L, 2018, PATHOL ONCOL RES, V24, P129, DOI 10.1007/s12253-017-0223-5
   Saito YD, 2010, CANCER-AM CANCER SOC, V116, P1629, DOI 10.1002/cncr.24879
   Song EL, 2018, J CELL BIOCHEM, V119, P5163, DOI 10.1002/jcb.26543
   Staton CA, 2011, BIOCHEM SOC T, V39, P1565, DOI 10.1042/BST20110654
   Sumi C, 2018, MEDIAT INFLAMM, V2018, DOI 10.1155/2018/5703651
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tampakis A, 2020, ACTA ONCOL, V59, P55, DOI 10.1080/0284186X.2019.1667022
   Tsoumas D, 2018, CANCER GENOM PROTEOM, V15, P127, DOI 10.21873/cgp.20071
   Türei D, 2015, AUTOPHAGY, V11, P155, DOI 10.4161/15548627.2014.994346
   Vivekanandhan S, 2019, SEMIN CANCER BIOL, V54, P72, DOI 10.1016/j.semcancer.2018.01.014
   Walter W, 2015, BIOINFORMATICS, V31, P2912, DOI 10.1093/bioinformatics/btv300
   Wilkerson MD, 2010, BIOINFORMATICS, V26, P1572, DOI 10.1093/bioinformatics/btq170
   Yu B, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02830-1
   Yu GC, 2012, OMICS, V16, P284, DOI 10.1089/omi.2011.0118
   Zhang CG, 2015, PROTEIN CELL, V6, P88, DOI 10.1007/s13238-014-0119-z
   Zhang S, 2016, CELL DEATH DIFFER, V23, P52, DOI 10.1038/cdd.2015.66
   Zhang YM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000008242
   Zhu C, 2019, AM J TRANSL RES, V11, P7195
   Zhu HQ, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02896-x
   Zhu QN, 2018, HEREDITAS, V155, DOI 10.1186/s41065-018-0055-7
NR 59
TC 2
Z9 2
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0300-0605
EI 1473-2300
J9 J INT MED RES
JI J. Int. Med. Res.
PD DEC
PY 2022
VL 50
IS 12
DI 10.1177/03000605221140683
PG 15
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA 8J7IW
UT WOS:000922585700001
PM 36510452
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Peng, LP
   Zhu, HQ
   Wang, JS
   Sui, HN
   Zhang, HL
   Jin, CQ
   Li, LP
   Xu, T
   Miao, RZ
AF Peng, Lipan
   Zhu, Huaqiang
   Wang, Jinshen
   Sui, Haina
   Zhang, Honglai
   Jin, Changqing
   Li, Leping
   Xu, Tao
   Miao, Ruizheng
TI MiR-492 is functionally involved in Oxaliplatin resistance in colon
   cancer cells LS174T via its regulating the expression of CD147
SO MOLECULAR AND CELLULAR BIOCHEMISTRY
LA English
DT Article
DE MiR-492; Oxaliplatin; LS174T; CD147
ID GENE-EXPRESSION; INVASION
AB Chemotherapy remains the core of anticancer treatment. However, despite the tremendous strides made in the development of targeted anticancer therapies, emergence of resistance to chemotherapeutic drugs is still a major obstacle in the successful management of resistant tumors. Therefore, profound investigation into the in-depth molecular mechanisms of drug resistance is essential and may hopefully translate into effective therapies that can flip the switch from drug resistance to susceptibility. To develop novel-targeted therapy holds promise for conquering chemotherapy resistance, one of the major hurdles in current colon cancer treatment. Previous studies indicate that CD147 is involved in the progression of chemotherapy resistance in breast cancer and ovarian cancer cells and its expression is negative regulated by miR-492 in muscles cells. In the present study, we found that lower level of miR-492 is accompanied with increased expression of CD147 in Oxaliplatin-resistant colon cancer cell line LS174T/L-OHP as compared with its parental cell line LS174T. Exogenous expression of miR-492 in LS174T/L-OHP could sensitize its reaction on the treatment of Oxaliplatin, which is coincided with its directly reducing the expression of CD147. Furthermore, we found that knockdown of CD147 in LS174T/L-OHP could also sensitize its reaction of the treatment with Oxaliplatin. Besides, intra-tumoral delivering of miR-492 could also restore Oxaliplatin treatment response in Oxaliplatin-resistant xenografts in vivo. These findings provide direct evidences that the miR-492/CD147 axis might play an essential role in the Oxaliplatin resistance of colon cancer cells, suggesting that the miR-492/CD147 signaling cohort could be served as a novel therapeutic target for the treatment of chemotherapy resistant in colon cancer.
C1 [Peng, Lipan; Wang, Jinshen; Zhang, Honglai; Jin, Changqing; Li, Leping; Xu, Tao; Miao, Ruizheng] Shandong Univ, Dept Gastrointestinal Surg, Shandong Prov Hosp, Jinan 250100, Peoples R China.
   [Zhu, Huaqiang] Qingdao Municipal Hosp, Dept Breast Surg, Qingdao, Peoples R China.
   [Sui, Haina] Shandong Canc Hosp, Dept Radiotherapy, Jinan, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical
   Sciences; Shandong University; Qingdao Municipal Hospital; Shandong
   First Medical University & Shandong Academy of Medical Sciences
RP Miao, RZ (corresponding author), Shandong Univ, Dept Gastrointestinal Surg, Shandong Prov Hosp, Jinan 250100, Peoples R China.
EM lpp408@126.com; mrz1983@126.com
OI Li, Leping/0000-0003-2329-6791; Jin, Chongqiang/0009-0008-4537-3544
FU Shandong Provincial Foundation for Natural Sciences [ZR2011HM07]
FX This work was funded by the Shandong Provincial Foundation for Natural
   Sciences (ZR2011HM07).
CR Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Calin GA, 2006, NAT REV CANCER, V6, P857, DOI 10.1038/nrc1997
   Chen PN, 2006, CANCER LETT, V235, P248, DOI 10.1016/j.canlet.2005.04.033
   Chen X, 2006, CANCER RES, V66, P11323, DOI 10.1158/0008-5472.CAN-06-1536
   Chu K, 2008, DNA CELL BIOL, V27, P315, DOI 10.1089/dna.2007.0656
   Hao JL, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040716
   Iacono KT, 2007, EXP MOL PATHOL, V83, P283, DOI 10.1016/j.yexmp.2007.08.014
   Ieta K, 2008, ANN SURG ONCOL, V15, P638, DOI 10.1245/s10434-007-9605-3
   Jemal A, 2010, CANCER EPIDEM BIOMAR, V19, P1893, DOI 10.1158/1055-9965.EPI-10-0437
   Kupcinskas J, 2014, SCI REP, V4, P1
   L'Espérance S, 2006, INT J ONCOL, V29, P5
   Lu RJ, 2014, J CANCER RES CLIN, V140, P387, DOI 10.1007/s00432-013-1577-z
   Montero J, 2008, CANCER RES, V68, P5246, DOI 10.1158/0008-5472.CAN-07-6161
   Nabeshima K, 2006, PATHOL INT, V56, P359, DOI 10.1111/j.1440-1827.2006.01972.x
   Stordal B, 2010, CANC TREAT REV, V33, P347
   Sun JX, 2001, CANCER RES, V61, P2276
   von Frowein J, 2011, HEPATOLOGY, V53, P833, DOI 10.1002/hep.24125
   Wu LS, 2011, HUM GENET, V130, P749, DOI 10.1007/s00439-011-1026-5
   Wu LS, 2012, P 2 E AS DERM C EADC, V125, P3
   Xia L, 2008, INT J CANCER, V123, P372, DOI 10.1002/ijc.23501
   Xiong LJ, 2014, INT J MOL SCI, V15, P17411, DOI 10.3390/ijms151017411
   Zheng HC, 2006, BRIT J CANCER, V95, P1371, DOI 10.1038/sj.bjc.6603425
   Zou W, 2007, CANCER LETT, V248, P211, DOI 10.1016/j.canlet.2006.07.005
NR 23
TC 41
Z9 42
U1 1
U2 11
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0300-8177
EI 1573-4919
J9 MOL CELL BIOCHEM
JI Mol. Cell. Biochem.
PD JUL
PY 2015
VL 405
IS 1-2
BP 73
EP 79
DI 10.1007/s11010-015-2397-z
PG 7
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA CN1XB
UT WOS:000358212900008
PM 25862460
DA 2025-01-04
ER

PT J
AU Lucifero, AG
   Elbabaa, SK
   Baldoncini, M
   Bruno, N
   Savasta, S
   Marseglia, GL
   Luzzi, S
AF Lucifero, Alice Giotta
   Elbabaa, Samer K.
   Baldoncini, Matias
   Bruno, Nunzio
   Savasta, Salvatore
   Marseglia, Gian Luigi
   Luzzi, Sabino
TI Novel "T-Dimension" Therapies for Pediatric Optic Pathway Glioma: A
   Timely, Targeted, and Tailored Treatment Trend
SO PEDIATRIC NEUROSURGERY
LA English
DT Review
DE Bevacizumab; MEK inhibitors; mTOR inhibitors; Optic pathway glioma;
   Proton beam radiotherapy; Stereotactic radiosurgery; Target therapy
ID LOW-GRADE GLIOMAS; BEVACIZUMAB PLUS IRINOTECAN; 2 CHEMOTHERAPY REGIMENS;
   NEUROFIBROMATOSIS TYPE-1; RADIATION-THERAPY; BRAIN-TUMORS; PHASE-II;
   RETROSPECTIVE ANALYSIS; HYPOTHALAMIC GLIOMAS; COLORECTAL-CANCER
AB Introduction: Novel targeted and tailored therapies can substantially improve the prognosis for optic pathway glioma (OPG), especially when implemented in a timely manner. However, their tremendous potential remains underestimated. Therefore, in this study, we provide an updated overview of the clinical trials, current trends, and future perspectives for OPG's novel therapeutic strategies. Methods: We completed an extensive literature review using the PubMed, MEDLINE, and ClinicalTrials.gov databases. We analyzed and reported the data following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines. Results: Thioguanine, procarbazine, lomustine, and vincristine/vinblastine, as well as cisplatin-etoposide, provided excellent results in advanced-phase trials. Selumetinib and trametinib, two oral MEK inhibitors, have been approved for recurrent or refractory OPGs in association with the angiogenetic inhibitor bevacizumab. Among the mTOR inhibitors, everolimus and sirolimus showed the best results. Stereotactic radiosurgery and proton beam radiation therapy have advantages over conventional radiotherapy regimens. Timely treatment is imperative for acute visual symptoms with evidence of tumor progression. This latest evidence can help define a novel "T-Dimension" for pediatric OPG therapies. Conclusion: The novel "T-Dimension" for pediatric OPGs is based on recent evidence-based treatments, including combination chemotherapy regimens, molecular targeted therapies, stereotactic radiosurgery, and proton beam radiation therapy. Additional clinical trials are essential for validating each of these new therapies. (C) 2022 S. Karger AG, Basel
C1 [Lucifero, Alice Giotta; Luzzi, Sabino] Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Neurosurg Unit, Pavia, Italy.
   [Elbabaa, Samer K.] Arnold Palmer Hosp Children, Leon Pediat Neurosci Ctr Excellence, Dept Pediat Neurosurg, Orlando, FL USA.
   [Baldoncini, Matias] Univ Buenos Aires, Sch Med, Lab Neuroanat Microsurg LaNeMic 2, Div Anat, Buenos Aires, DF, Argentina.
   [Bruno, Nunzio] Azienda Osped Univ Consorziale Policlin Bari, Div Neurosurg, Bari, Italy.
   [Savasta, Salvatore; Marseglia, Gian Luigi] Univ Pavia, Fdn IRCCS Policlin San Matteo, Dept Pediat, Pediat Clin, Pavia, Italy.
C3 University of Pavia; University of Buenos Aires; Universita degli Studi
   di Bari Aldo Moro; University of Pavia; IRCCS Fondazione San Matteo
RP Luzzi, S (corresponding author), Univ Pavia, Dept Clin Surg Diagnost & Pediat Sci, Neurosurg Unit, Pavia, Italy.
EM sabino.luzzi@unipv.it
RI Giotta Lucifero, Alice/HJZ-2816-2023; Luzzi, Prof. Sabino/HKW-3215-2023;
   Elbabaa, Samer/X-4709-2019
OI Luzzi, Sabino/0000-0002-1381-8528; Baldoncini,
   Matias/0000-0001-9323-8306; Elbabaa, Samer/0000-0003-1733-1941
CR Ahn Y, 2006, CHILD NERV SYST, V22, P1136, DOI 10.1007/s00381-006-0086-7
   Allen JC, 2000, PEDIATR NEUROSURG, V32, P154, DOI 10.1159/000028922
   Aquilina K, 2015, CHILD NERV SYST, V31, P2041, DOI 10.1007/s00381-015-2855-7
   Astrup J, 2003, BRIT J NEUROSURG, V17, P327, DOI 10.1080/02688690310001601216
   Ater J, 2008, NEURO-ONCOLOGY, V10, P451
   Ater JL, 2012, J CLIN ONCOL, V30, P2641, DOI 10.1200/JCO.2011.36.6054
   Avery RA, 2016, J AAPOS, V20, P268, DOI 10.1016/j.jaapos.2016.01.012
   Avery RA, 2014, JAMA OPHTHALMOL, V132, P111, DOI 10.1001/jamaophthalmol.2013.5819
   Avery RA, 2011, J NEURO-OPHTHALMOL, V31, P269, DOI 10.1097/WNO.0b013e31822aef82
   Awdeh RM, 2012, INT J RADIAT ONCOL, V84, P46, DOI 10.1016/j.ijrobp.2011.10.067
   Banerjee A, 2017, NEURO-ONCOLOGY, V19, P1135, DOI 10.1093/neuonc/now282
   Bartels U, 2006, J NEUROSURG, V104, P314, DOI 10.3171/ped.2006.104.5.314
   Beres SJ, 2017, SEMIN PEDIATR NEUROL, V24, P92, DOI 10.1016/j.spen.2017.04.006
   Bianchi-Marzoli S, 1994, Curr Opin Ophthalmol, V5, P11
   Binning Mandy J, 2007, Neurosurg Focus, V23, pE2
   Blanchard G, 2016, EUR J PAEDIATR NEURO, V20, P275, DOI 10.1016/j.ejpn.2015.12.002
   Bouffet E, 2012, J CLIN ONCOL, V30, P1358, DOI 10.1200/JCO.2011.34.5843
   Calixto NC, 2019, CHILD NERV SYST, V35, P63, DOI 10.1007/s00381-018-3904-9
   Campanella R, 2020, J NEUROL SCI, V417, DOI 10.1016/j.jns.2020.117083
   Campanella R, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020294
   Cardellicchio S, 2014, NEUROPEDIATRICS, V45, P42, DOI 10.1055/s-0033-1360482
   Combs SE, 2005, INT J RADIAT ONCOL, V62, P814, DOI 10.1016/j.ijrobp.2004.12.081
   Couec ML, 2012, PEDIATR BLOOD CANCER, V59, P34, DOI 10.1002/pbc.24066
   Czyzyk E, 2003, J CHILD NEUROL, V18, P471, DOI 10.1177/08830738030180070401
   de Blank PMK, 2017, J NEURO-OPHTHALMOL, V37, pS23, DOI 10.1097/WNO.0000000000000550
   Dehcordi SR, 2017, WORLD NEUROSURG, V105, P895, DOI 10.1016/j.wneu.2017.05.099
   Del Bufalo F, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00526
   Dombi E, 2016, NEW ENGL J MED, V375, P2550, DOI 10.1056/NEJMoa1605943
   DUTTON JJ, 1994, SURV OPHTHALMOL, V38, P427, DOI 10.1016/0039-6257(94)90173-2
   Erkal HS, 1997, RADIOTHER ONCOL, V45, P11, DOI 10.1016/S0167-8140(97)00102-3
   Fangusaro J, 2019, LANCET ONCOL, V20, P1011, DOI 10.1016/S1470-2045(19)30277-3
   Fangusaro JR, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.10035
   Farazdaghi MK, 2019, CURR OPIN OPHTHALMOL, V30, P356, DOI 10.1097/ICU.0000000000000587
   Fisher BJ, 1998, J NEUROSURG, V88, P969, DOI 10.3171/jns.1998.88.6.0969
   Fisher MJ, 2012, NEURO-ONCOLOGY, V14, P790, DOI 10.1093/neuonc/nos076
   Foiadelli Thomas, 2020, Acta Biomed, V91, P101, DOI 10.23750/abm.v91i7-S.9961
   Fried Iris, 2013, CNS Oncol, V2, P143, DOI 10.2217/cns.12.47
   Lucifero AG, 2021, BRAIN SCI, V11, DOI 10.3390/brainsci11030386
   Giotta Lucifero Alice, 2020, Acta Biomed, V91, P32, DOI 10.23750/abm.v91i7-S.9953
   Giotta Lucifero Alice, 2020, Acta Biomed, V91, P5, DOI 10.23750/abm.v91i7-S.9951
   Giotta Lucifero Alice, 2020, Acta Biomed, V91, P61, DOI 10.23750/abm.v91i7-S.9956
   Gnekow AK, 2004, KLIN PADIATR, V216, P331, DOI 10.1055/s-2004-832355
   Goodden J, 2014, J NEUROSURG-PEDIATR, V13, P1, DOI 10.3171/2013.8.PEDS12546
   Gorsi HS, 2018, PEDIATR BLOOD CANCER, V65, DOI 10.1002/pbc.27234
   Grill J, 1999, ANN NEUROL, V45, P393, DOI 10.1002/1531-8249(199903)45:3<393::AID-ANA17>3.0.CO;2-B
   Gururangan S, 2007, NEURO-ONCOLOGY, V9, P161, DOI 10.1215/15228517-2006-030
   Gururangan S, 2014, NEURO-ONCOLOGY, V16, P310, DOI 10.1093/neuonc/not154
   Helfferich J, 2016, CRIT REV ONCOL HEMAT, V104, P30, DOI 10.1016/j.critrevonc.2016.05.008
   Hill CS, 2021, CHILD NERV SYST, V37, P1917, DOI 10.1007/s00381-021-05060-8
   Hill CS, 2020, CHILD NERV SYST, V36, P1869, DOI 10.1007/s00381-020-04724-1
   HOFFMAN HJ, 1993, PEDIATR NEUROSURG, V19, P186, DOI 10.1159/000120729
   HOFFMAN HJ, 1993, NEUROSURGERY, V33, P964
   Hug EB, 2002, STRAHLENTHER ONKOL, V178, P10, DOI 10.1007/s00066-002-0874-2
   Hwang EI, 2013, PEDIATR BLOOD CANCER, V60, P776, DOI 10.1002/pbc.24297
   Jahraus CD, 2006, PEDIATR BLOOD CANCER, V46, P586, DOI 10.1002/pbc.20655
   Kalin-Hajdu E, 2014, PEDIATR BLOOD CANCER, V61, P223, DOI 10.1002/pbc.24726
   Kalra M, 2015, J PEDIAT HEMATOL ONC, V37, pe341, DOI 10.1097/MPH.0000000000000371
   Kaul A, 2015, NEURO-ONCOLOGY, V17, P843, DOI 10.1093/neuonc/nou329
   Khafaga Y, 2003, INT J RADIAT ONCOL, V56, P807, DOI 10.1016/S0360-3016(02)04512-1
   Komotar RJ, 2004, NEUROSURGERY, V54, P72, DOI 10.1227/01.NEU.0000097266.89676.25
   Lafay-Cousin L, 2008, CANCER, V112, P892, DOI 10.1002/cncr.23249
   Lassaletta A, 2016, J CLIN ONCOL, V34, P3537, DOI 10.1200/JCO.2016.68.1585
   Liberati A., 2009, BMJ, V62, pe1, DOI [DOI 10.1016/j.ijsu.2010.02.007, DOI 10.1016/J.IJSU.2010.02.007, 10.1016/j.jclinepi.2009.06.006, DOI 10.1136/BMJ.B2700]
   Listernick R, 2007, ANN NEUROL, V61, P189, DOI 10.1002/ana.21107
   Liu GT, 2006, CURR OPIN OPHTHALMOL, V17, P427, DOI 10.1097/01.icu.0000243016.90004.12
   Liu HB, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.789856
   Luzzi Sabino, 2020, Acta Biomed, V91, P18, DOI 10.23750/abm.v91i7-S.9952
   Luzzi Sabino, 2020, Acta Biomed, V91, P79, DOI 10.23750/abm.v91i7-S.9958
   Luzzi Sabino, 2020, Acta Biomed, V91, P51, DOI 10.23750/abm.v91i7-S.9955
   Luzzi S, 2019, HELIYON, V5, DOI 10.1016/j.heliyon.2019.e02818
   Machein MR, 2000, J NEURO-ONCOL, V50, P109, DOI 10.1023/A:1006416003964
   Massimino M, 2002, J CLIN ONCOL, V20, P4209, DOI 10.1200/JCO.2002.08.087
   Maubon L, 2016, EYE, V30, P330, DOI 10.1038/eye.2015.243
   McCannel TA, 2014, JAMA OPHTHALMOL, V132, P1005, DOI 10.1001/jamaophthalmol.2014.976
   Méndez-Martínez S, 2019, RETINA-J RET VIT DIS, V39, P1435, DOI 10.1097/IAE.0000000000002451
   Merchant TE, 2008, PEDIATR BLOOD CANCER, V51, P110, DOI 10.1002/pbc.21530
   Merchant TE, 2009, J CLIN ONCOL, V27, P3598, DOI 10.1200/JCO.2008.20.9494
   Nakaya A, 2016, CANCER MED-US, V5, P1381, DOI 10.1002/cam4.701
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Nicolin G, 2009, PEDIATR BLOOD CANCER, V53, P1231, DOI 10.1002/pbc.22198
   Nolan Daniel P, 2016, Ophthalmic Surg Lasers Imaging Retina, V47, P398, DOI 10.3928/23258160-20160419-01
   Österlund P, 2011, BRIT J CANCER, V104, P599, DOI 10.1038/bjc.2011.2
   Okada K, 2013, JPN J CLIN ONCOL, V43, P1073, DOI 10.1093/jjco/hyt124
   Orts Alborch M, 2000, Acta Otorrinolaringol Esp, V51, P469
   Packer R J, 1988, Neurofibromatosis, V1, P212
   PACKER RJ, 1983, CHILD BRAIN, V10, P393
   PACKER RJ, 1993, J CLIN ONCOL, V11, P850, DOI 10.1200/JCO.1993.11.5.850
   Packer RJ, 1997, J NEUROSURG, V86, P747, DOI 10.3171/jns.1997.86.5.0747
   Packer RJ, 2017, NEURO-ONCOLOGY, V19, P750, DOI 10.1093/neuonc/now209
   Palumbo P, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20123010
   Pfister S, 2008, J CLIN INVEST, V118, P1739, DOI 10.1172/JCI33656
   Presta LG, 1997, CANCER RES, V57, P4593
   Revere KE, 2017, OPHTHAL PLAST RECONS, V33, pS107, DOI 10.1097/IOP.0000000000000687
   Sanchez JN, 2018, DRUGS, V78, P549, DOI 10.1007/s40265-018-0884-8
   Sawamura Y, 2008, NEURO-ONCOLOGY, V10, P725, DOI 10.1215/15228517-2008-033
   Schreck KC, 2019, CANCERS, V11, DOI 10.3390/cancers11091262
   Suárez JC, 2006, CHILD NERV SYST, V22, P679, DOI 10.1007/s00381-005-0021-3
   SUTTON LN, 1995, J NEUROSURG, V83, P583, DOI 10.3171/jns.1995.83.4.0583
   Sylvester CL, 2006, CURR OPIN OPHTHALMOL, V17, P7, DOI 10.1097/01.icu.0000193070.32369.37
   TAVERAS JM, 1956, RADIOLOGY, V66, P518, DOI 10.1148/66.4.518
   Thiagalingam S, 2004, OPHTHALMOLOGY, V111, P568, DOI 10.1016/j.ophtha.2003.06.008
   Thomas RP, 2015, CURR TREAT OPTION NE, V17, DOI 10.1007/s11940-014-0333-2
   Tow SL, 2003, PEDIATR NEUROL, V28, P262, DOI 10.1016/S0887-8994(02)00628-8
   Tsang DS, 2017, INT J RADIAT ONCOL, V99, P642, DOI 10.1016/j.ijrobp.2017.07.023
   Ullrich NJ, 2007, NEUROLOGY, V68, P932, DOI 10.1212/01.wnl.0000257095.33125.48
   VALDUEZA JM, 1994, ACTA NEUROCHIR, V126, P44, DOI 10.1007/BF01476493
   Warren KE, 2011, J CLIN ONCOL, V29, P324, DOI 10.1200/JCO.2010.31.3601
   Warrington NM, 2015, CANCER RES, V75, P16, DOI 10.1158/0008-5472.CAN-14-1891
   Wisoff J H, 1992, Neurosurg Clin N Am, V3, P791
   Wu Wan-Shui, 2019, Zhongguo Dang Dai Er Ke Za Zhi, V21, P1193
   Yamasaki F, 2020, CHILD NERV SYST, V36, P635, DOI 10.1007/s00381-019-04407-6
   Yu DY, 2001, J PEDIAT HEMATOL ONC, V23, P349, DOI 10.1097/00043426-200108000-00005
   Yu J, 2009, NEUROLOGY, V73, P1526, DOI 10.1212/WNL.0b013e3181c0664a
   Zhukova N, 2019, CANCER MED-US, V8, P40, DOI 10.1002/cam4.1799
NR 114
TC 0
Z9 0
U1 1
U2 4
PU KARGER
PI BASEL
PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND
SN 1016-2291
EI 1423-0305
J9 PEDIATR NEUROSURG
JI Pediatr. Neurosurg.
PY 2022
VL 57
IS 3
BP 161
EP 174
DI 10.1159/000524873
PG 14
WC Clinical Neurology; Pediatrics; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Neurosciences & Neurology; Pediatrics; Surgery
GA 5V8PR
UT WOS:000877486900003
PM 35588700
DA 2025-01-04
ER

PT J
AU Fontanges, Q
   De Mendonca, R
   Salmon, I
   Le Mercier, M
   D'Haene, N
AF Fontanges, Quitterie
   De Mendonca, Ricardo
   Salmon, Isabelle
   Le Mercier, Marie
   D'Haene, Nicky
TI Clinical Application of Targeted Next Generation Sequencing for
   Colorectal Cancers
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE targeted next generation sequencing; colorectal cancer; clinical
   application
ID MUTATION; LUNG; VALIDATION; THERAPY; GENES; COLON
AB Promising targeted therapy and personalized medicine are making molecular profiling of tumours a priority. For colorectal cancer (CRC) patients, international guidelines made RAS (KRAS and NRAS) status a prerequisite for the use of anti-epidermal growth factor receptor agents (anti-EGFR). Daily, new data emerge on the theranostic and prognostic role of molecular biomarkers, which is a strong incentive for a validated, sensitive and broadly available molecular screening test in order to implement and improve multi-modal therapy strategy and clinical trials. Next generation sequencing (NGS) has begun to supplant other technologies for genomic profiling. Targeted NGS is a method that allows parallel sequencing of thousands of short DNA sequences in a single test offering a cost-effective approach for detecting multiple genetic alterations with a minimum amount of DNA. In the present review, we collected data concerning the clinical application of NGS technology in the setting of colorectal cancer.
C1 [Fontanges, Quitterie; De Mendonca, Ricardo; Salmon, Isabelle; Le Mercier, Marie; D'Haene, Nicky] Univ Libre Bruxelles, Erasme Hosp, Dept Pathol, B-1070 Brussels, Belgium.
C3 Universite Catholique Louvain; Cliniques Universitaires Saint-Luc;
   Universite Libre de Bruxelles
RP D'Haene, N (corresponding author), Univ Libre Bruxelles, Erasme Hosp, Dept Pathol, B-1070 Brussels, Belgium.
EM quitterie.fontanges@erasme.ulb.ac.be;
   ricardo.de.mendonca@erasme.ulb.ac.be; isabelle.salmon@erasme.ulb.ac.be;
   marie.le.mercier@erasme.ulb.ac.be; nicky.d.haene@erasme.ulb.ac.be
RI Le Mercier, Marie/JJE-0148-2023
OI D'Haene, Nicky/0000-0001-8100-377X
FU "Fonds Yvonne Boel" (Brussels, Belgium)
FX This work was supported by funding from the "Fonds Yvonne Boel"
   (Brussels, Belgium).
CR [Anonymous], COMMUNICATION
   Belardinilli F, 2015, CLIN BIOCHEM, V48, P908, DOI 10.1016/j.clinbiochem.2015.04.003
   Chevrier S, 2014, INT J ONCOL, V45, P1167, DOI 10.3892/ijo.2014.2528
   Cottrell CE, 2014, J MOL DIAGN, V16, P89, DOI 10.1016/j.jmoldx.2013.10.002
   D'Haene N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138245
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Fontanges Q, 2016, ANN ONCOL, V27, P124
   Froyen G, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154038
   Gao J, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009532
   Hadd AG, 2013, J MOL DIAGN, V15, P234, DOI 10.1016/j.jmoldx.2012.11.006
   Haley L, 2015, MODERN PATHOL, V28, P1390, DOI 10.1038/modpathol.2015.86
   Han SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064271
   Jesinghaus M, 2016, GENE CHROMOSOME CANC, V55, P505, DOI 10.1002/gcc.22352
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Malapelle U, 2016, J CLIN PATHOL, V69, P767, DOI 10.1136/jclinpath-2015-203403
   Malapelle U, 2015, J CLIN PATHOL, V68, P64, DOI 10.1136/jclinpath-2014-202691
   Meldrum Cliff, 2011, Clin Biochem Rev, V32, P177
   Meric-Bernstam F, 2015, J CLIN ONCOL, V33, P2753, DOI 10.1200/JCO.2014.60.4165
   Moorcraft SY, 2015, CRIT REV ONCOL HEMAT, V96, P463, DOI 10.1016/j.critrevonc.2015.06.007
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Ohhara Y, 2016, WORLD J GASTRO ONCOL, V8, P642, DOI 10.4251/wjgo.v8.i9.642
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   Tops BBJ, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1015-5
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   VEALE D, 1987, BRIT J CANCER, V55, P513, DOI 10.1038/bjc.1987.104
   Wong NACS, 2014, J CLIN PATHOL, V67, P751, DOI 10.1136/jclinpath-2014-202467
   Wong SQ, 2015, BRIT J CANCER, V112, P1411, DOI 10.1038/bjc.2015.80
   Zhang LX, 2014, ONCOLOGIST, V19, P336, DOI 10.1634/theoncologist.2013-0180
NR 32
TC 15
Z9 17
U1 0
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD DEC
PY 2016
VL 17
IS 12
AR 2117
DI 10.3390/ijms17122117
PG 10
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA EI1XR
UT WOS:000392280500161
PM 27999270
OA Green Submitted, gold, Green Published
DA 2025-01-04
ER

PT J
AU Qu, FJ
   Wu, S
   Kong, Y
AF Qu, Fan-Jie
   Wu, Shuang
   Kong, Yan
TI Oral fruquintinib combined with tegafur-gimeracil-oteracil potassium for
   advanced colorectal cancer to obtain longer progression-free survival: A
   case report
SO WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY
LA English
DT Article
DE Fruquintinib; Tegafur-gimeracil-oteracil potassium (S-1); Advanced
   colorectal cancer; Progression-free survival; Case report
ID 1ST-LINE TREATMENT; CHINESE PATIENTS; OPEN-LABEL; PHASE-II; BEVACIZUMAB;
   S-1; OXALIPLATIN; COLON; CAPECITABINE; CHEMOTHERAPY
AB BACKGROUNDAfter the failure of second-line standard therapy, effective treatment options for metastatic colorectal cancer are limited, and the duration of remission cannot meet clinical needs. In addition, associated drug toxicity may lead to treatment interruption that may affect patient outcomes. Therefore, more safe, effective and convenient treatments are urgently needed.CASE SUMMARYHere, we describe a patient with advanced colorectal cancer with multiple metastases in both lungs. Oxaliplatin combined with 5-fluorouracil or capecitabine was given as the first-line treatment, and bevacizumab combined with irinotecan was given as the second-line treatment after disease progression. However, treatment was interrupted due to recurrent grade 2 nausea and grade 1 diarrhea. He received targeted therapy with fruquintinib starting on August 26, 2020 and responded well for 12 mo. After slow progression of the lung metastases, progression-free survival was again achieved over 13.5 mo by continued treatment of fruquintinib in combination with tegafur-gimeracil-oteracil potassium chemotherapy. Overall treatment duration was more than 25.5 mo. The treatments delayed tumor progression, reduced drug side effects, maintained a good quality of life, and further extended overall survival.CONCLUSIONThis case report detailed preliminary evidence showing that the combination of fruquintinib with tegafur-gimeracil-oteracil potassium chemotherapy double oral therapy may result in longer progression-free survival in patients with advanced colorectal cancer.
C1 [Qu, Fan-Jie; Wu, Shuang; Kong, Yan] Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, Dalian 116033, Liaoning, Peoples R China.
   [Kong, Yan] Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, 40 Qianshan Rd, Dalian 116033, Liaoning, Peoples R China.
C3 Dalian Medical University; Dalian Medical University
RP Kong, Y (corresponding author), Dalian Med Univ, Affiliated Dalian Peoples Hosp 3, Dept Oncol, 40 Qianshan Rd, Dalian 116033, Liaoning, Peoples R China.
EM kongkongyan2022@163.com
CR Cao RH, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0325-9
   Dvorak HF, 2002, J CLIN ONCOL, V20, P4368, DOI 10.1200/JCO.2002.10.088
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guan X, 2021, J MED ECON, V24, P339, DOI 10.1080/13696998.2021.1888743
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hong YS, 2012, LANCET ONCOL, V13, P1125, DOI 10.1016/S1470-2045(12)70363-7
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Li J, 2020, ADV THER, V37, P4585, DOI 10.1007/s12325-020-01477-w
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Liu HQ, 2015, J CANCER RES THER, V11, P331, DOI 10.4103/0973-1482.157339
   Marcus L, 2017, CLIN CANCER RES, V23, P2924, DOI 10.1158/1078-0432.CCR-16-2157
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Moehler M, 2009, WORLD J GASTROENTERO, V15, P449, DOI 10.3748/wjg.15.449
   Pfeiffer P, 2020, LANCET ONCOL, V21, P412, DOI 10.1016/S1470-2045(19)30827-7
   Schmoll HJ, 2012, ANN ONCOL, V23, P2479, DOI 10.1093/annonc/mds236
   Shah MA, 2016, J CLIN ONCOL, V34, P843, DOI 10.1200/JCO.2015.63.0558
   Shin SJ, 2011, INVEST NEW DRUG, V29, P1073, DOI 10.1007/s10637-010-9418-2
   Shirao K, 2004, CANCER, V100, P2355, DOI 10.1002/cncr.20277
   Shirasaka T, 1996, CANCER RES, V56, P2602
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sun QL, 2014, CANCER BIOL THER, V15, P1635, DOI 10.4161/15384047.2014.964087
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tampellini M, 2016, EXPERT OPIN INV DRUG, V25, P507, DOI 10.1517/13543784.2016.1161754
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Xu RH, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-6557-5
NR 25
TC 1
Z9 1
U1 2
U2 4
PU BAISHIDENG PUBLISHING GROUP INC
PI PLEASANTON
PA 7041 Koll Center Parkway, Suite 160, PLEASANTON, CA, UNITED STATES
SN 1948-5204
J9 WORLD J GASTRO ONCOL
JI World J. Gastrointest. Oncol.
PD MAY 15
PY 2023
VL 15
IS 5
BP 902
EP 910
DI 10.4251/wjgo.v15.i5.902
PG 9
WC Oncology; Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology
GA I6IW0
UT WOS:001003811100013
PM 37275454
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Yang, Y
   Meng, WJ
   Wang, ZQ
AF Yang, Ying
   Meng, Wen-Jian
   Wang, Zi-Qiang
TI Immunotherapy with Immune Checkpoint Inhibitors for Advanced Colorectal
   Cancer: A Promising Individualized Treatment Strategy
SO FRONTIERS IN BIOSCIENCE-LANDMARK
LA English
DT Review
DE colorectal cancer; immunotherapy; immune checkpoint inhibitors;
   microsatellite instability; deficient mismatch repair
ID MISMATCH REPAIR-DEFICIENT; TUMOR MUTATIONAL BURDEN; NIVOLUMAB PLUS
   IPILIMUMAB; MICROSATELLITE INSTABILITY; OPEN-LABEL; PHASE-II; ANTI-PD-1
   IMMUNOTHERAPY; RESPONSE EVALUATION; CLINICAL BENEFIT; PD-1 BLOCKADE
AB Colorectal cancer (CRC) is one of the high incident and lethal malignant tumors, and most of the patients are diagnosed at an advanced stage. The treatment of CRC mainly includes surgery, chemotherapy, radiotherapy and molecular targeted therapy. Despite these ap-proaches have increased overall survival (OS) of CRC patients, the prognosis of advanced CRC remains poor. In recent years, remarkable breakthroughs have been made in tumor immunotherapy, especially immune checkpoint inhibitors (ICIs) therapy, bringing long-term survival benefits to tumor patients. With the increasing wealth of clinical data, ICIs have achieved significant efficacy in the treatment of high microsatellite instability/deficient mismatch repair (MSI-H/dMMR) advanced CRC, but the therapeutic effects of ICIs on mi-crosatellite stable (MSS) advanced CRC patients is currently unsatisfactory. As increasing numbers of large clinical trials are performed globally, patients treated with ICIs therapy also have immunotherapy-related adverse events and treatment resistance. Therefore, a large number of clinical trials are still needed to evaluate the therapeutic effect and safety of ICIs therapy in advanced CRC. This article will focus on the current research status of ICIs in advanced CRC and discuss the current predicament of ICIs treatment.
C1 [Yang, Ying; Meng, Wen-Jian; Wang, Zi-Qiang] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University
RP Meng, WJ (corresponding author), Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, Chengdu 610041, Sichuan, Peoples R China.
EM mengwenjian@126.com
RI wang, ziqiang/E-5993-2016
CR Anderson R, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02254
   AndrT T, 2022, ANN ONCOL, V33, P1052, DOI 10.1016/j.annonc.2022.06.008
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Andre T, 2021, LANCET ONCOL, V22, P665, DOI 10.1016/S1470-2045(21)00064-4
   [Anonymous], 2020, National comprehensive cancer network Survivorship Care for Cancer-Related Late and Long-Term Effects
   Antoniotti C, 2022, LANCET ONCOL, V23, P876, DOI 10.1016/S1470-2045(22)00274-1
   Antoniotti C, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07169-6
   Bagchi S, 2021, ANNU REV PATHOL-MECH, V16, P223, DOI 10.1146/annurev-pathol-042020-042741
   Ballhausen A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18514-5
   Bellone M, 2017, CYTOKINE GROWTH F R, V36, P17, DOI 10.1016/j.cytogfr.2017.06.002
   Brahmer JR, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002435
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7
   Carlino MS, 2021, LANCET, V398, P1002, DOI 10.1016/S0140-6736(21)01206-X
   Cercek A, 2022, NEW ENGL J MED, V386, P2363, DOI 10.1056/NEJMoa2201445
   Cercek A, 2020, CLIN CANCER RES, V26, P3271, DOI 10.1158/1078-0432.CCR-19-3728
   Chakrabarti S, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.19.00055
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chen B, 2022, BMC Cancer, V22, P1
   Chen DS, 2013, IMMUNITY, V39, P1, DOI 10.1016/j.immuni.2013.07.012
   Cheng WY, 2020, GUT, V69, P1867, DOI 10.1136/gutjnl-2020-321153
   Cho YH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19173-2
   Choucair K, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5254
   Chu JN, 2019, CANCER-AM CANCER SOC, V125, P278, DOI 10.1002/cncr.31795
   Chung KY, 2010, J CLIN ONCOL, V28, P3485, DOI 10.1200/JCO.2010.28.3994
   Cohen R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001499
   Corrò C, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09820-w
   Couey MA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0645-6
   Dagenborg VJ, 2020, CANCER BIOL THER, V21, P432, DOI 10.1080/15384047.2020.1721252
   Damato A, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.766500
   Damato A, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07268-4
   de la Chapelle A, 2003, NEW ENGL J MED, V349, P209, DOI 10.1056/NEJMp038099
   de Rosa N, 2016, J CLIN ONCOL, V34, P3039, DOI 10.1200/JCO.2016.66.6826
   Diaz LA, 2022, LANCET ONCOL, V23, P659, DOI 10.1016/S1470-2045(22)00197-8
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Finotello F, 2019, GENOME MED, V11, DOI 10.1186/s13073-019-0638-6
   Formenti SC, 2018, NAT MED, V24, P1845, DOI 10.1038/s41591-018-0232-2
   Fu YL, 2019, BMC GENOMICS, V20, DOI 10.1186/s12864-019-6129-8
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Galon J, 2007, CANCER RES, V67, P1883, DOI 10.1158/0008-5472.CAN-06-4806
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Goodman AM, 2017, MOL CANCER THER, V16, P2598, DOI 10.1158/1535-7163.MCT-17-0386
   Grothey A, 2021, ANN ONCOL, V32, P959, DOI 10.1016/j.annonc.2021.03.206
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201
   Hamada T, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1442999
   Hasan S, 2020, ANN SURG, V271, P716, DOI 10.1097/SLA.0000000000003051
   Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x
   Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011
   Hodi FS, 2018, J CLIN ONCOL, V36, P850, DOI 10.1200/JCO.2017.75.1644
   Huang BZ, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1684127
   Iams WT, 2020, NAT REV CLIN ONCOL, V17, P300, DOI 10.1038/s41571-019-0316-z
   Johdi NA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01624
   Kalbasi A, 2020, NAT REV IMMUNOL, V20, P25, DOI 10.1038/s41577-019-0218-4
   Kim JY, 2019, CANCERS, V11, DOI 10.3390/cancers11111798
   Kim JH, 2020, CANCER RES TREAT, V52, P1135, DOI 10.4143/crt.2020.218
   Kim RD, 2022, EUR J CANCER, V169, P93, DOI 10.1016/j.ejca.2022.03.026
   Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Lin ZY, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-003554
   Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625
   Lu HY, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00315-3
   Luo MC, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188623
   Mandal R, 2019, SCIENCE, V364, P485, DOI 10.1126/science.aau0447
   Mayoux M, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aav7431
   McGrail DJ, 2021, ANN ONCOL, V32, P661, DOI 10.1016/j.annonc.2021.02.006
   Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425
   Morse MA, 2019, ONCOLOGIST, V24, P1453, DOI 10.1634/theoncologist.2019-0129
   Na HY, 2021, CANCER SCI, V112, P91, DOI 10.1111/cas.14723
   National Comprehensive Cancer Network, 2020, NCCN Clinical Practice Guidelines in Oncology Colon Cancer Version 1
   Ngwa W, 2018, NAT REV CANCER, V18, P313, DOI 10.1038/nrc.2018.6
   Ni KY, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04703-w
   Nishino M, 2017, NAT REV CLIN ONCOL, V14, P655, DOI 10.1038/nrclinonc.2017.88
   Ogura A, 2018, EUR J CANCER, V91, P11, DOI 10.1016/j.ejca.2017.12.005
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pagès F, 2005, NEW ENGL J MED, V353, P2654, DOI 10.1056/NEJMoa051424
   Pagès F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X
   Parikh AR, 2021, NAT CANCER, V2, P1124, DOI 10.1038/s43018-021-00269-7
   Patel MR, 2021, CANCER MED-US, V10, P1183, DOI 10.1002/cam4.3630
   Pietrantonio F, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx089
   Rahman R, 2019, CLIN CANCER RES, V25, P6339, DOI 10.1158/1078-0432.CCR-18-3999
   Razavi P, 2019, NAT MED, V25, P1928, DOI 10.1038/s41591-019-0652-7
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8
   Schrock AB, 2019, ANN ONCOL, V30, P1096, DOI 10.1093/annonc/mdz134
   Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Strauss L, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aay1863
   Subbiah V, 2020, ANN ONCOL, V31, P1115, DOI 10.1016/j.annonc.2020.07.002
   Subrahmanyam PB, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0328-8
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tang JM, 2018, AM J CANCER RES, V8, P892
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954
   U.S. Food and Drug Administration, 2017, FDA APPROVES 1 CANC
   Ukai S, 2021, CANCER SCI, V112, P1196, DOI 10.1111/cas.14805
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Vareki SM, 2017, CRIT REV ONCOL HEMAT, V116, P116, DOI 10.1016/j.critrevonc.2017.06.001
   Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369
   Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624
   Wu TD, 2020, NATURE, V579, P274, DOI 10.1038/s41586-020-2056-8
   Wu YC, 2017, INT J CANCER, V141, P2562, DOI 10.1002/ijc.31012
   Xiao W, 2019, MOL CANCER RES, V17, P420, DOI 10.1158/1541-7786.MCR-18-0455
   Xu K, 2019, MOL THER, V27, P1810, DOI 10.1016/j.ymthe.2019.05.017
   Xu WX, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.605097
   Xu YY, 2019, TRANSL LUNG CANCER R, V8, P413, DOI 10.21037/tlcr.2019.08.09
   Yang Y, 2022, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.803974
   Yoon HH, 2019, CLIN CANCER RES, V25, P125, DOI 10.1158/1078-0432.CCR-18-1984
   Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738
   Yost KE, 2019, NAT MED, V25, P1251, DOI 10.1038/s41591-019-0522-3
   Zhang JF, 2018, TRENDS BIOCHEM SCI, V43, P1014, DOI 10.1016/j.tibs.2018.09.004
   Zheng YX, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-20019-0
NR 117
TC 7
Z9 7
U1 0
U2 4
PU IMR PRESS
PI ROBINSON
PA 112 ROBINSON RD, ROBINSON, SINGAPORE
SN 2768-6701
EI 2768-6698
J9 FRONT BIOSCI-LANDMRK
JI Front. Biosci.
PD APR
PY 2023
VL 28
IS 4
AR 69
DI 10.31083/j.fbl2804069
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA J6GD7
UT WOS:001010569800021
PM 37114536
OA gold
DA 2025-01-04
ER

PT J
AU Bi, MH
   Yang, JR
   Wang, YP
   Zhang, HR
   Gao, ZY
   Zhou, HR
   Shi, MH
AF Bi, Minghong
   Yang, Jingru
   Wang, Yaping
   Zhang, Haoran
   Gao, Zhenyuan
   Zhou, Hairong
   Shi, Mohan
TI Successful treatment of metastatic colorectal cancer with apatinib:
   report of two cases and literature review
SO ONCOTARGETS AND THERAPY
LA English
DT Review
DE vascular endothelial growth factor; large intestine cancer; apatinib;
   targeted therapy; antiangiogenesis; tyrosine kinase inhibitor
ID CLINICAL-PRACTICE GUIDELINES; FOLFIRI PLUS BEVACIZUMAB; DOUBLE-BLIND;
   OPEN-LABEL; 1ST-LINE THERAPY; NON-INFERIORITY; COLON-CANCER;
   OXALIPLATIN; PLACEBO; FLUOROURACIL
AB Apatinib, a novel small molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor-2, was approved for metastatic gastric adenocarcinoma in China in Oct 2014. This is the first report on its use for advanced colorectal cancer as a kind of third-line therapy to date. Here we report two Chinese patients who presented with metastatic colorectal cancer who received apatinib 850 mg daily as a third-line therapy. Both the patients achieved favorable benefits in outcomes after the administration of apatinib. Patient 1 benefited 4 months progression-free survival and 11 months overall survival, while patient 2's progression-free survival was over 10 months. Both the patients presented hand-foot syndrome, and one of them suffered a slight impairment of liver function, mild elevated blood pressure, and proteinuria. But these adverse events were manageable with symptomatic treatment and dose reduction or a short-time drug withdrawal.
C1 [Bi, Minghong; Yang, Jingru; Wang, Yaping; Zhang, Haoran; Gao, Zhenyuan; Zhou, Hairong; Shi, Mohan] Bengbu Med Coll, Affiliated Hosp 1, Dept Med Oncol, 287 Changhuai Rd, Bengbu 233000, Anhui, Peoples R China.
C3 Bengbu Medical University
RP Bi, MH (corresponding author), Bengbu Med Coll, Affiliated Hosp 1, Dept Med Oncol, 287 Changhuai Rd, Bengbu 233000, Anhui, Peoples R China.
EM ahbmh2000@163.com
OI Zhang, Haoran/0000-0001-9792-7600
FU Research Project of Anhui Provincial Health Bureau [09C171]; Science and
   Technology Development Fund of Bengbu Medical College [BYKF1403];
   Universities Natural Science Research Project in Anhui Province
   [KJ2016A483]
FX This study was supported in part by The Research Project of Anhui
   Provincial Health Bureau (09C171), Science and Technology Development
   Fund of Bengbu Medical College (BYKF1403), and the Universities Natural
   Science Research Project in Anhui Province (KJ2016A483). Written
   informed consent has been provided by the two patients to have the case
   details and any accompanying images published. The authors thank the two
   patients for participation, and the contributions of all in the
   treatment group in the Department of Medical Oncology.
CR [Anonymous], ANN ONCOL S2
   Aoyama T, 2016, NAT REV CLIN ONCOL, V13, P268, DOI 10.1038/nrclinonc.2016.53
   Bennouna J, 2013, LANCET ONCOL, V14, P29, DOI 10.1016/S1470-2045(12)70477-1
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Calvetti L, 2015, EXPERT OPIN BIOL TH, V15, P1359, DOI 10.1517/14712598.2015.1071350
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen XH, 2017, INT J CLIN EXP MED, V10, P2274
   Chung AS, 2010, NAT REV CANCER, V10, P505, DOI 10.1038/nrc2868
   Ciombor KK, 2014, CURR ONCOL REP, V16, DOI 10.1007/s11912-013-0368-7
   Fan MH, 2014, BREAST CANCER RES TR, V143, P141, DOI 10.1007/s10549-013-2793-6
   Geng RX, 2015, EXPERT OPIN PHARMACO, V16, P117, DOI 10.1517/14656566.2015.981526
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hamnvik OPR, 2015, CANCER-AM CANCER SOC, V121, P311, DOI 10.1002/cncr.28972
   Hegewisch-Becker S, 2015, LANCET ONCOL, V16, P1355, DOI 10.1016/S1470-2045(15)00042-X
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Iwamoto S, 2015, ANN ONCOL, V26, P1427, DOI 10.1093/annonc/mdv197
   Khan K, 2017, CURR DRUG TARGETS, V18, P56, DOI 10.2174/1389450116666150325231555
   Koeberle D, 2015, ANN ONCOL, V26, P709, DOI 10.1093/annonc/mdv011
   Li J, 2016, J CLIN ONCOL, V34, P1448, DOI 10.1200/JCO.2015.63.5995
   Li J, 2015, LANCET ONCOL, V16, P619, DOI 10.1016/S1470-2045(15)70156-7
   Li J, 2013, J CLIN ONCOL, V31, P3219, DOI 10.1200/JCO.2013.48.8585
   Li J, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-529
   Limaverde-Sousa G, 2014, CANCER TREAT REV, V40, P548, DOI 10.1016/j.ctrv.2013.11.009
   Lu D, 2002, INT J CANCER, V97, P393, DOI 10.1002/ijc.1634
   Masi G, 2015, ANN ONCOL, V26, P724, DOI 10.1093/annonc/mdv012
   Scott AJ, 2015, DRUG TODAY, V51, P223, DOI 10.1358/dot.2015.51.4.2320599
   Scudellari M, 2015, NATURE, V521, pS12, DOI 10.1038/521S12a
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tian S, 2011, CANCER SCI, V102, P1374, DOI 10.1111/j.1349-7006.2011.01939.x
   Tournigand C, 2015, LANCET ONCOL, V16, P1493, DOI 10.1016/S1470-2045(15)00216-8
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Wu L, 2017, IRAN J BASIC MED SCI, V20, P990, DOI 10.22038/IJBMS.2017.9263
   Yu J, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0340-8
NR 39
TC 3
Z9 4
U1 1
U2 7
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-6930
J9 ONCOTARGETS THER
JI OncoTargets Ther.
PY 2018
VL 11
BP 883
EP 890
DI 10.2147/OTT.S148412
PG 8
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA FW5IB
UT WOS:000425348900002
PM 29497319
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Goodspeed, A
   Jean, A
   Theodorescu, D
   Costello, JC
AF Goodspeed, Andrew
   Jean, Annie
   Theodorescu, Dan
   Costello, James C.
TI A Gene Expression Signature Predicts Bladder Cancer Cell Line
   Sensitivity to EGFR Inhibition
SO BLADDER CANCER
LA English
DT Article
DE Bladder cancer; EGFR; pharmacogenomics; gefitinib; cetuximab
ID GROWTH-FACTOR RECEPTOR; ROBUST MULTIARRAY ANALYSIS; PHASE-III TRIAL;
   LUNG-CANCER; UROTHELIAL CARCINOMA; COLORECTAL CANCERS; DRUG-SENSITIVITY;
   RANDOMIZED-TRIAL; BREAST-CANCER; KINASE DOMAIN
AB Background: Bladder cancer remains a cancer type in need of novel and alternative therapies. While multiple inhibitors of EGFR have been evaluated for efficacy in bladder cancer, the results have largely been disappointing with few patients responding to these therapies. Yet, there is a subset of patients that positively responds to EGFR inhibition with tumor shrinkage, indicating it is an effective treatment for a targeted set of bladder tumors.
   Objective: To derive a gene expression signature capable of predicting the response to EGFR inhibition in bladder cancer cell lines.
   Methods: The response to cetuximab for 68 colorectal cancer patients was used as training data to generate a gene expression signature. We applied this signature to bladder cancer cell lines and predictions were compared to the responses to seven EGFR inhibitors.
   Results: A novel 67-gene signature derived from colorectal cancer was able to significantly identify bladder cancer cell lines by their response to several EGFR inhibitors.
   Conclusions: The 67-gene signature can determine bladder cancer cell line sensitivity to EGFR inhibition. This work demonstrates a preclinical strategy to identify bladder cancer cell lines for EGFR-targeted therapy.
C1 [Goodspeed, Andrew; Jean, Annie; Theodorescu, Dan; Costello, James C.] Univ Colorado, Dept Pharmacol, Aurora, CO USA.
   [Theodorescu, Dan; Costello, James C.] Univ Colorado, Comprehens Canc Ctr, Anschutz Med Campus, Aurora, CO USA.
   [Theodorescu, Dan] Univ Colorado, Dept Surg Urol, Anschutz Med Campus, Aurora, CO USA.
C3 University of Colorado System; University of Colorado Anschutz Medical
   Campus; University of Colorado System; University of Colorado Anschutz
   Medical Campus; University of Colorado System; University of Colorado
   Anschutz Medical Campus
RP Costello, JC (corresponding author), Univ Colorado, Anschutz Med Campus,12801 E 17th Ave, Aurora, CO 80045 USA.
EM james.costello@ucdenver.edu
OI Theodorescu, Dan/0000-0002-8708-8206; Costello,
   James/0000-0003-3158-9682
FU Boettcher Foundation [T32GM007635]; Front Range Cancer Challenge; 
   [CA075115]
FX This work is supported by the Boettcher Foundation (J.C.C.), T32GM007635
   (A.G.), the Front Range Cancer Challenge (A.G.) and CA075115 (D.T.).
CR Al-Kuraya K, 2007, J CLIN PATHOL, V60, P768, DOI 10.1136/jcp.2006.038281
   [Anonymous], 2015, TARG THER DIR GEN TE
   Balko JM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-145
   Barber TD, 2004, NEW ENGL J MED, V351, P2883, DOI 10.1056/NEJM200412303512724
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Blehm KN, 2006, CLIN CANCER RES, V12, P4671, DOI 10.1158/1078-0432.CCR-06-0407
   Chaux A, 2012, HUM PATHOL, V43, P1590, DOI 10.1016/j.humpath.2011.11.016
   Choi W, 2014, CANCER CELL, V25, P152, DOI 10.1016/j.ccr.2014.01.009
   Chou CW, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0018087
   D'Amato V, 2014, BRIT J CANCER, V110, P2887, DOI 10.1038/bjc.2014.241
   Damrauer JS, 2014, P NATL ACAD SCI USA, V111, P3110, DOI 10.1073/pnas.1318376111
   de Reyniès A, 2008, J CLIN ONCOL, V26, P228, DOI 10.1200/JCO.2007.15.9186
   Dutta PR, 2007, CANCER LETT, V254, P165, DOI 10.1016/j.canlet.2007.02.006
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Goodspeed A, 2016, MOL CANCER RES, V14, P3, DOI 10.1158/1541-7786.MCR-15-0189
   Hastie T., 2015, Package "pamr"
   Havaleshko DM, 2007, MOL CANCER THER, V6, P578, DOI 10.1158/1535-7163.MCT-06-0497
   Hussain M, 2014, CANCER-AM CANCER SOC, V120, P2684, DOI 10.1002/cncr.28767
   Italiano A, 2008, ANN SURG ONCOL, V15, P649, DOI 10.1245/s10434-007-9667-2
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Kurai J, 2007, CLIN CANCER RES, V13, P1552, DOI 10.1158/1078-0432.CCR-06-1726
   Lee JK, 2007, P NATL ACAD SCI USA, V104, P13086, DOI 10.1073/pnas.0610292104
   Loeffler-Ragy J, 2006, EUR J CANCER, V42, P109, DOI 10.1016/j.ejca.2005.08.034
   LOEHRER PJ, 1992, J CLIN ONCOL, V10, P1066, DOI 10.1200/JCO.1992.10.7.1066
   LOGOTHETIS CJ, 1990, J CLIN ONCOL, V8, P1050, DOI 10.1200/JCO.1990.8.6.1050
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   McCall M., hgu133afrmavecs: Vectors used by frma for microarrays of type hgu133a
   McCall MN, 2012, BIOINFORMATICS, V28, P3153, DOI 10.1093/bioinformatics/bts588
   McCall MN, 2011, BMC BIOINFORMATICS, V12, DOI 10.1186/1471-2105-12-137
   McCall MN, 2011, NUCLEIC ACIDS RES, V39, pD1011, DOI 10.1093/nar/gkq1259
   McCall MN, 2010, BIOSTATISTICS, V11, P242, DOI 10.1093/biostatistics/kxp059
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mukohara T, 2005, JNCI-J NATL CANCER I, V97, P1185, DOI 10.1093/jnci/dji238
   Ooi A, 2004, MODERN PATHOL, V17, P895, DOI 10.1038/modpathol.3800137
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Petrylak DP, 2010, BJU INT, V105, P317, DOI 10.1111/j.1464-410X.2009.08799.x
   Powles T, 2017, J CLIN ONCOL, V35, P48, DOI 10.1200/JCO.2015.66.3468
   Powles T, 2014, NATURE, V515, P558, DOI 10.1038/nature13904
   Prat A, 2014, CLIN CANCER RES, V20, P511, DOI 10.1158/1078-0432.CCR-13-0239
   Pruthi RS, 2010, BJU INT, V106, P349, DOI 10.1111/j.1464-410X.2009.09101.x
   Rebouissou S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008970
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Ritz C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0146021
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Saeed AI, 2003, BIOTECHNIQUES, V34, P374, DOI 10.2144/03342mt01
   Sequist LV, 2008, J CLIN ONCOL, V26, P2442, DOI 10.1200/JCO.2007.14.8494
   Sheu JJC, 2009, CANCER RES, V69, P2568, DOI 10.1158/0008-5472.CAN-08-3199
   Siefker-Radtke AO, 2002, J CLIN ONCOL, V20, P1361, DOI 10.1200/JCO.20.5.1361
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sorlie T, 2001, P NATL ACAD SCI USA, V98, P10869, DOI 10.1073/pnas.191367098
   Stephenson JJ, 2009, CLIN COLORECTAL CANC, V8, P29, DOI 10.3816/CCC.2009.n.005
   Sternberg CN, 2001, J CLIN ONCOL, V19, P2638, DOI 10.1200/JCO.2001.19.10.2638
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Temam S, 2007, J CLIN ONCOL, V25, P2164, DOI 10.1200/JCO.2006.06.6605
   Tibshirani R, 2002, P NATL ACAD SCI USA, V99, P6567, DOI 10.1073/pnas.082099299
   von der Maase H, 2000, J CLIN ONCOL, V18, P3068, DOI 10.1200/JCO.2000.18.17.3068
   Weinstein JN, 2014, NATURE, V507, P315, DOI 10.1038/nature12965
   Wong YN, 2012, J CLIN ONCOL, V30, P3545, DOI 10.1200/JCO.2012.41.9572
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
NR 60
TC 8
Z9 10
U1 1
U2 5
PU IOS PRESS
PI AMSTERDAM
PA NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS
SN 2352-3727
EI 2352-3735
J9 BLADDER CANCER
JI Bladder Cancer
PY 2018
VL 4
IS 3
BP 269
EP 282
DI 10.3233/BLC-170161
PG 14
WC Oncology; Urology & Nephrology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Urology & Nephrology
GA GO8GO
UT WOS:000440325300003
PM 30112438
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Wang, Y
   Du, J
   Wu, XM
   Abdelrehem, A
   Ren, Y
   Liu, C
   Zhou, X
   Wang, SN
AF Wang, Yu
   Du, Jiang
   Wu, Xuemei
   Abdelrehem, Ahmed
   Ren, Yu
   Liu, Chao
   Zhou, Xuan
   Wang, Sinan
TI Crosstalk between autophagy and microbiota in cancer progression
SO MOLECULAR CANCER
LA English
DT Review
DE Autophagy; Microbiota; Cancer progression; Target therapy
ID HELICOBACTER-PYLORI INFECTION; TUMOR-CELL SURVIVAL;
   FUSOBACTERIUM-NUCLEATUM; PORPHYROMONAS-GINGIVALIS; COLORECTAL-CANCER;
   CHEMOTHERAPY RESISTANCE; VACUOLATING CYTOTOXIN; INDUCED APOPTOSIS;
   HEDGEHOG PATHWAY; KAPPA-B
AB Autophagy is a highly conserved catabolic process seen in eukaryotes and is essentially a lysosome-dependent protein degradation pathway. The dysregulation of autophagy is often associated with the pathogenesis of numerous types of cancers, and can not only promote the survival of cancer but also trigger the tumor cell death. During cancer development, the microbial community might predispose cells to tumorigenesis by promoting mucosal inflammation, causing systemic disorders, and may also regulate the immune response to cancer. The complex relationship between autophagy and microorganisms can protect the body by activating the immune system. In addition, autophagy and microorganisms can crosstalk with each other in multifaceted ways to influence various physiological and pathological responses involved in cancer progression. Various molecular mechanisms, correlating the microbiota disorders and autophagy activation, control the outcomes of protumor or antitumor responses, which depend on the cancer type, tumor microenvironment and disease stage. In this review, we mainly emphasize the leading role of autophagy during the interaction between pathogenic microorganisms and human cancers and investigate the various molecular mechanisms by which autophagy modulates such complicated biological processes. Moreover, we also highlight the possibility of curing cancers with multiple molecular agents targeting the microbiota/autophagy axis. Finally, we summarize the emerging clinical trials investigating the therapeutic potential of targeting either autophagy or microbiota as anticancer strategies, although the crosstalk between them has not been explored thoroughly.
C1 [Wang, Yu; Du, Jiang; Liu, Chao; Zhou, Xuan] Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Tianjin 300060, Peoples R China.
   [Wang, Yu; Du, Jiang; Liu, Chao; Zhou, Xuan] Tianjin Canc Inst, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
   [Wang, Yu; Du, Jiang; Liu, Chao; Zhou, Xuan] Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China.
   [Wu, Xuemei; Wang, Sinan] Tianjin Med Univ Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China.
   [Wu, Xuemei; Wang, Sinan] Tianjin Med Univ, Tianjin Gastroenterol & Hepatol Inst, Tianjin 300052, Peoples R China.
   [Wu, Xuemei; Wang, Sinan] Tianjin Med Univ, Key Lab Immune Microenvironm & Dis, Minist Educ, Tianjin 300070, Peoples R China.
   [Abdelrehem, Ahmed] Alexandria Univ, Fac Dent, Dept Craniomaxillofacial & Plast Surg, Alexandria, Egypt.
   [Ren, Yu] Tianjin Med Univ, Tianjin Res Ctr Basic Med Sci, Tianjin 300070, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University; Tianjin Medical
   University; Tianjin Medical University; Tianjin Medical University;
   Egyptian Knowledge Bank (EKB); Alexandria University; Tianjin Medical
   University
RP Wang, Y; Zhou, X (corresponding author), Tianjin Med Univ Canc Inst & Hosp, Dept Maxillofacial & Otorhinolaryngol Oncol, Tianjin 300060, Peoples R China.; Wang, Y; Zhou, X (corresponding author), Tianjin Canc Inst, Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.; Wang, Y; Zhou, X (corresponding author), Natl Clin Res Ctr Canc, Tianjin 300060, Peoples R China.; Wang, SN (corresponding author), Tianjin Med Univ Gen Hosp, Dept Gastroenterol & Hepatol, Tianjin, Peoples R China.; Wang, SN (corresponding author), Tianjin Med Univ, Tianjin Gastroenterol & Hepatol Inst, Tianjin 300052, Peoples R China.; Wang, SN (corresponding author), Tianjin Med Univ, Key Lab Immune Microenvironm & Dis, Minist Educ, Tianjin 300070, Peoples R China.
EM wangyu1991@tmu.edu.cn; xuanzhou@tmu.edu.cn; wangsinan@tmu.edu.cn
RI Ren, yu/KYY-9101-2024; wang, yifang/KEI-3766-2024; zhou,
   xuan/GZA-8157-2022
OI Abdelrehem, Ahmed/0000-0003-0523-3009
FU China National Natural Scientific Fund [82002892, 82073010, 82172764];
   Tianjin Education Commission [2019KJ188]; Fundamental Research Funds for
   the Central Universities [3332020079]
FX This work was supported by the China National Natural Scientific Fund
   No. 82002892 (to W.Y.), 82073010 (to Z.X.), 82172764 (to R.Y.); the
   Tianjin Education Commission Funded Projects No.2019KJ188 (to W.Y.); the
   Fundamental Research Funds for the Central Universities No.3332020079
   (to W.SN.)
CR Abdulamir AS, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-249
   Aita VM, 1999, GENOMICS, V59, P59, DOI 10.1006/geno.1999.5851
   Allemailem KS, 2021, INT J NANOMED, V16, P5065, DOI 10.2147/IJN.S321343
   Amaravadi R, 2016, GENE DEV, V30, P1913, DOI 10.1101/gad.287524.116
   Amaravadi RK, 2007, J CLIN INVEST, V117, P326, DOI 10.1172/JCI28833
   Amaravadi RK, 2019, CANCER DISCOV, V9, P1167, DOI 10.1158/2159-8290.CD-19-0292
   Amaravadi RK, 2011, CLIN CANCER RES, V17, P654, DOI 10.1158/1078-0432.CCR-10-2634
   Ambalam P, 2016, BEST PRACT RES CL GA, V30, P119, DOI 10.1016/j.bpg.2016.02.009
   Arnaout A, 2019, BREAST CANCER RES TR, V178, P327, DOI 10.1007/s10549-019-05381-y
   Avilés-Jiménez F, 2016, CLIN MICROBIOL INFEC, V22, DOI 10.1016/j.cmi.2015.10.008
   Ban LX, 2020, LIFE SCI, V254, DOI 10.1016/j.lfs.2020.117695
   Banerjee S, 2017, ONCOTARGET, V8, P36225, DOI 10.18632/oncotarget.16717
   Bélanger M, 2006, AUTOPHAGY, V2, P165, DOI 10.4161/auto.2828
   Bi YY, 2021, J CANCER RES CLIN, V147, P499, DOI 10.1007/s00432-020-03422-4
   Bialik S, 2008, ADV EXP MED BIOL, V615, P177, DOI 10.1007/978-1-4020-6554-5_9
   Blommaart EFC, 1997, EUR J BIOCHEM, V243, P240, DOI 10.1111/j.1432-1033.1997.0240a.x
   Brandt S, 2005, P NATL ACAD SCI USA, V102, P9300, DOI 10.1073/pnas.0409873102
   Cai JC, 2018, NAT CELL BIOL, V20, P465, DOI 10.1038/s41556-018-0065-8
   Castellarin M, 2012, GENOME RES, V22, P299, DOI 10.1101/gr.126516.111
   Cerniglia GJ, 2012, MOL PHARMACOL, V82, P1230, DOI 10.1124/mol.112.080408
   Chang CR, 2019, ACS INFECT DIS, V5, P1336, DOI 10.1021/acsinfecdis.9b00032
   Chen DF, 2020, CANCER LETT, V469, P456, DOI 10.1016/j.canlet.2019.11.019
   Chen XH, 2019, FRONT MICROBIOL, V10, DOI 10.3389/fmicb.2019.01261
   Chen YY, 2020, THERANOSTICS, V10, P323, DOI 10.7150/thno.38870
   Cho TJ, 2014, ARCH ORAL BIOL, V59, P370, DOI 10.1016/j.archoralbio.2014.01.001
   Choi AMK, 2013, NEW ENGL J MED, V368, P651, DOI 10.1056/NEJMc1303158
   Chung C, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00936-9
   de Martel C, 2012, LANCET ONCOL, V13, DOI 10.1016/S1470-2045(12)70137-7
   Debnath J, 2011, J MAMMARY GLAND BIOL, V16, P173, DOI 10.1007/s10911-011-9223-3
   Degenhardt K, 2006, CANCER CELL, V10, P51, DOI 10.1016/j.ccr.2006.06.001
   Deng HM, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02742-0
   Duarte VD, 2020, MICROORGANISMS, V8, DOI 10.3390/microorganisms8121994
   Edinger AL, 2004, CURR OPIN CELL BIOL, V16, P663, DOI 10.1016/j.ceb.2004.09.011
   El Khadir M, 2020, INT J CANCER, V147, P3206, DOI 10.1002/ijc.33158
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Eskelinen EL, 2009, BBA-MOL CELL RES, V1793, P664, DOI 10.1016/j.bbamcr.2008.07.014
   Eslami M, 2019, J CELL PHYSIOL, V234, P14800, DOI 10.1002/jcp.28279
   Fan XZ, 2018, GUT, V67, P120, DOI 10.1136/gutjnl-2016-312580
   Farrell JJ, 2012, GUT, V61, P582, DOI 10.1136/gutjnl-2011-300784
   Ferreira RM, 2018, GUT, V67, P226, DOI 10.1136/gutjnl-2017-314205
   Fox JG, 2010, GUT, V59, P88, DOI 10.1136/gut.2009.183749
   Gallimidi AB, 2015, ONCOTARGET, V6, P22613, DOI 10.18632/oncotarget.4209
   Garrett WS, 2015, SCIENCE, V348, P80, DOI 10.1126/science.aaa4972
   Glick D, 2010, J PATHOL, V221, P3, DOI 10.1002/path.2697
   Gnanasekaran J, 2020, CANCERS, V12, DOI 10.3390/cancers12082331
   Gomes LR, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18112351
   Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236
   Gozuacik D, 2004, ONCOGENE, V23, P2891, DOI 10.1038/sj.onc.1207521
   Guo JY, 2011, GENE DEV, V25, P460, DOI 10.1101/gad.2016311
   Guo J, 2020, J CELL MOL MED, V24, P4324, DOI 10.1111/jcmm.15093
   Guo XG, 2019, J CELL PHYSIOL, V234, P3478, DOI 10.1002/jcp.26828
   Hall DP, 2014, CANCER CELL, V26, P738, DOI 10.1016/j.ccell.2014.09.015
   Han TY, 2018, AUTOPHAGY, V14, P2035, DOI 10.1080/15548627.2018.1491493
   Hartwich A, 2001, INT J COLORECTAL DIS, V16, P202, DOI 10.1007/s003840100288
   He Z, 2019, GUT, V68, P289, DOI 10.1136/gutjnl-2018-317200
   Helmink BA, 2019, NAT MED, V25, P377, DOI 10.1038/s41591-019-0377-7
   Hu FQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23923-1
   Huang R, 2015, AUTOPHAGY, V11, P852, DOI 10.1080/15548627.2015.1038016
   Huang TZ, 2019, AUTOPHAGY, V15, P1100, DOI 10.1080/15548627.2019.1569947
   Irfan M, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.591088
   Ishibashi Y, 2019, ANTICANCER RES, V39, P649, DOI 10.21873/anticanres.13159
   Ito S, 2007, INT J ONCOL, V31, P261
   Jia JY, 2019, AUTOPHAGY, V15, P169, DOI 10.1080/15548627.2018.1505155
   Jiang HL, 2022, GASTROENTEROLOGY, V162, P590, DOI 10.1053/j.gastro.2021.09.066
   Jin CC, 2019, CELL, V176, P998, DOI 10.1016/j.cell.2018.12.040
   Karimi P, 2014, CANCER EPIDEM BIOMAR, V23, P700, DOI 10.1158/1055-9965.EPI-13-1057
   Kim YC, 2015, J CLIN INVEST, V125, P25, DOI 10.1172/JCI73939
   Ko JY, 2019, BIOMOL THER, V27, P337, DOI 10.4062/biomolther.2019.056
   Kostic AD, 2013, CELL HOST MICROBE, V14, P207, DOI 10.1016/j.chom.2013.07.007
   Kostic AD, 2012, GENOME RES, V22, P292, DOI 10.1101/gr.126573.111
   Kundu M, 2008, ANNU REV PATHOL-MECH, V3, P427, DOI 10.1146/annurev.pathmechdis.2.010506.091842
   Lebin JA, 2020, WEST J EMERG MED, V21, P760, DOI 10.5811/westjem.2020.5.47810
   Lee DS, 2007, EXPERT OPIN THER TAR, V11, P757, DOI 10.1517/14728222.11.6.757
   Lee YK, 2018, MSPHERE, V3, DOI 10.1128/mSphere.00587-18
   Levine B, 2008, CELL, V132, P27, DOI 10.1016/j.cell.2007.12.018
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li J, 2009, ANN SURG ONCOL, V16, P761, DOI 10.1245/s10434-008-0260-0
   Li N, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00417
   Li PY, 2012, CANCER LETT, V314, P213, DOI 10.1016/j.canlet.2011.09.031
   Li Q, 2021, GASTROENTEROLOGY, V160, P1179, DOI 10.1053/j.gastro.2020.09.003
   Li XH, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-1138-4
   Liang GF, 2020, ACS INFECT DIS, V6, P871, DOI 10.1021/acsinfecdis.0c00007
   Liang XH, 1999, NATURE, V402, P672, DOI 10.1038/45257
   Liao YN, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1165-4
   Lin EW, 2016, ONCOGENE, V35, P5337, DOI 10.1038/onc.2016.34
   Lin HJ, 2017, FRONT CELL INFECT MI, V7, DOI 10.3389/fcimb.2017.00223
   Lin J, 2014, AUTOPHAGY, V10, P2006, DOI 10.4161/auto.36293
   Liu BH, 2016, ONCOTARGET, V7, P22873, DOI 10.18632/oncotarget.8251
   Liu JL, 2011, CELL, V147, P223, DOI 10.1016/j.cell.2011.08.037
   Liu L, 2011, LEUKEMIA, V25, P23, DOI 10.1038/leu.2010.225
   Liu R, 2014, AUTOPHAGY, V10, P1241, DOI 10.4161/auto.28912
   Liu W D, 2017, Zhonghua Yi Xue Za Zhi, V97, P1510, DOI 10.3760/cma.j.issn.0376-2491.2017.19.017
   Liu W, 2012, CANCER RES, V72, P3677, DOI 10.1158/0008-5472.CAN-12-0080
   Liu XC, 2020, INT J ORAL SCI, V12, DOI 10.1038/s41368-020-00101-5
   Liu Y, 2021, BRIT J CANCER, V124, P963, DOI 10.1038/s41416-020-01198-5
   Lock R, 2011, MOL BIOL CELL, V22, P165, DOI 10.1091/mbc.E10-06-0500
   Long XH, 2019, NAT MICROBIOL, V4, P2319, DOI 10.1038/s41564-019-0541-3
   Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344
   Lu HP, 2018, J CELL PHYSIOL, V233, P9312, DOI 10.1002/jcp.26343
   Luo W, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/9986376
   Ma J, 2020, BMC MICROBIOL, V20, DOI 10.1186/s12866-020-01739-1
   Maiuri MC, 2007, NAT REV MOL CELL BIO, V8, P741, DOI 10.1038/nrm2239
   Mao QX, 2018, CANCER LETT, V415, P40, DOI 10.1016/j.canlet.2017.11.036
   Martinez GP, 2020, CURR PHARM DESIGN, V26, P4467, DOI 10.2174/1381612826666200707132920
   McAfee Q, 2012, P NATL ACAD SCI USA, V109, P8253, DOI 10.1073/pnas.1118193109
   Mima K, 2016, GUT, V65, P1973, DOI 10.1136/gutjnl-2015-310101
   Mimuro H, 2002, MOL CELL, V10, P745, DOI 10.1016/S1097-2765(02)00681-0
   Mizushima N, 2005, CELL DEATH DIFFER, V12, P1535, DOI 10.1038/sj.cdd.4401728
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Mizushima N, 2007, GENE DEV, V21, P2861, DOI 10.1101/gad.1599207
   Muhammad JS, 2017, INT J CANCER, V140, P2272, DOI 10.1002/ijc.30657
   Mysak J, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/476068
   Nejati S, 2018, MICROB PATHOGENESIS, V117, P43, DOI 10.1016/j.micpath.2018.02.016
   Odds FC, 2000, ANTIMICROB AGENTS CH, V44, P3180, DOI 10.1128/AAC.44.11.3180-3183.2000
   Ojha R, 2015, BIORESEARCH OPEN ACC, V4, P97, DOI 10.1089/biores.2014.0035
   Olsen I, 2019, J ORAL MICROBIOL, V11, DOI 10.1080/20002297.2018.1563410
   Parida S, 2021, CANCER DISCOV, V11, P1138, DOI 10.1158/2159-8290.CD-20-0537
   Parzych KR, 2014, ANTIOXID REDOX SIGN, V20, P460, DOI 10.1089/ars.2013.5371
   Pasquier B, 2015, AUTOPHAGY, V11, P725, DOI 10.1080/15548627.2015.1033601
   Pattingre S, 2008, BIOCHIMIE, V90, P313, DOI 10.1016/j.biochi.2007.08.014
   Petiot A, 2000, J BIOL CHEM, V275, P992, DOI 10.1074/jbc.275.2.992
   Pierard G E, 2000, Expert Opin Pharmacother, V1, P287, DOI 10.1517/14656566.1.2.287
   Ponticelli C, 2017, EXPERT OPIN DRUG SAF, V16, P411, DOI 10.1080/14740338.2017.1269168
   POWIS G, 1994, CANCER RES, V54, P2419
   Pushalkar S, 2018, CANCER DISCOV, V8, P403, DOI 10.1158/2159-8290.CD-17-1134
   Raju D, 2012, GASTROENTEROLOGY, V142, P1160, DOI 10.1053/j.gastro.2012.01.043
   Rebecca VW, 2017, CANCER DISCOV, V7, P1266, DOI 10.1158/2159-8290.CD-17-0741
   Revathi S, 2018, ANTI-CANCER AGENT ME, V18, P1875, DOI 10.2174/1871520618666180806104902
   Ricci V, 2016, TOXINS, V8, DOI 10.3390/toxins8070203
   Rubinstein MR, 2013, CELL HOST MICROBE, V14, P195, DOI 10.1016/j.chom.2013.07.012
   Russo M, 2018, BIOCHEM PHARMACOL, V153, P51, DOI 10.1016/j.bcp.2018.02.007
   Sasaki K, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-370
   Schulze M, 2014, RECENT RESULTS CANC, V201, P393, DOI 10.1007/978-3-642-54490-3_24
   Schwabe RF, 2013, NAT REV CANCER, V13, P800, DOI 10.1038/nrc3610
   Schwartz-Roberts JL, 2015, CANCER RES, V75, P1046, DOI 10.1158/0008-5472.CAN-14-1851
   Sears CL, 2014, J CLIN INVEST, V124, P4166, DOI 10.1172/JCI72334
   Sears CL, 2014, CELL HOST MICROBE, V15, P317, DOI 10.1016/j.chom.2014.02.007
   Seglen P O, 1990, Semin Cell Biol, V1, P441
   Selbach M, 2003, EMBO J, V22, P515, DOI 10.1093/emboj/cdg050
   Selvakumaran M, 2013, CLIN CANCER RES, V19, P2995, DOI 10.1158/1078-0432.CCR-12-1542
   Sfanos KS, 2008, PROSTATE, V68, P306, DOI 10.1002/pros.20680
   Shen JJ, 2020, ONCOGENE, V39, P2961, DOI 10.1038/s41388-020-1197-4
   Shi YY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1859-8
   Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255
   Sun JW, 2020, CANCER MED-US, V9, P6306, DOI 10.1002/cam4.3206
   Takeda M, 2019, CANCER RES, V79, P1426, DOI 10.1158/0008-5472.CAN-18-2192
   Teimoorian Fatemeh, 2018, Iran J Pathol, V13, P325
   Terebiznik MR, 2009, AUTOPHAGY, V5, P370, DOI 10.4161/auto.5.3.7663
   Tohidpour A, 2016, MICROB PATHOGENESIS, V93, P44, DOI 10.1016/j.micpath.2016.01.005
   Torres PJ, 2015, PEERJ, V3, DOI 10.7717/peerj.1373
   Tsay JCJ, 2018, AM J RESP CRIT CARE, V198, P1188, DOI 10.1164/rccm.201710-2118OC
   Tsoi H, 2017, GASTROENTEROLOGY, V152, P1419, DOI 10.1053/j.gastro.2017.01.009
   Tu SP, 2011, CANCER RES, V71, P4247, DOI 10.1158/0008-5472.CAN-10-4009
   Urbaniak C, 2016, APPL ENVIRON MICROB, V82, P5039, DOI 10.1128/AEM.01235-16
   Vítor JMB, 2011, FEMS IMMUNOL MED MIC, V63, P153, DOI 10.1111/j.1574-695X.2011.00865.x
   Wang FT, 2020, CANCER CHEMOTH PHARM, V86, P221, DOI 10.1007/s00280-020-04100-5
   Wang XY, 2017, CANCER LETT, V385, P128, DOI 10.1016/j.canlet.2016.10.034
   Wang Y, 2019, ADV EXP MED BIOL, V1206, P67, DOI 10.1007/978-981-15-0602-4_3
   Wang ZG, 2017, ONCOTARGET, V8, P31465, DOI 10.18632/oncotarget.16356
   Wei X, 2020, J CANCER RES CLIN, V146, P297, DOI 10.1007/s00432-019-03117-5
   Wilson MR, 2019, SCIENCE, V363, P709, DOI 10.1126/science.aar7785
   Wolpin BM, 2014, ONCOLOGIST, V19, P637, DOI 10.1634/theoncologist.2014-0086
   Wu J, 2018, J CANCER, V9, P4039, DOI 10.7150/jca.25280
   Wu SG, 2009, NAT MED, V15, P1016, DOI 10.1038/nm.2015
   Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796
   Xie C, 2020, GUT MICROBES, V11, P1567, DOI 10.1080/19490976.2020.1774311
   Yahiro K, 2012, J BIOL CHEM, V287, P31104, DOI 10.1074/jbc.M112.387498
   Yamamura K, 2016, CLIN CANCER RES, V22, P5574, DOI 10.1158/1078-0432.CCR-16-1786
   Yang JC, 2014, WORLD J GASTROENTERO, V20, P5283, DOI 10.3748/wjg.v20.i18.5283
   Yang LC, 2008, J NUTR, V138, P2084, DOI 10.3945/jn.108.090985
   Yang SH, 2011, GENE DEV, V25, P717, DOI 10.1101/gad.2016111
   Yang YZ, 2017, GASTROENTEROLOGY, V152, P851, DOI 10.1053/j.gastro.2016.11.018
   Yang ZF, 2009, CURR TOP MICROBIOL, V335, P1, DOI 10.1007/978-3-642-00302-8_1
   Yu TC, 2017, CELL, V170, P548, DOI 10.1016/j.cell.2017.07.008
   Yuan X, 2017, CANCER LETT, V404, P1, DOI 10.1016/j.canlet.2017.07.003
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zaffagnini G, 2016, J MOL BIOL, V428, P1714, DOI 10.1016/j.jmb.2016.02.004
   Zeng XH, 2006, J CELL SCI, V119, P259, DOI 10.1242/jcs.02735
   Zhang F, 2019, ONCOL LETT, V18, P6221, DOI 10.3892/ol.2019.10976
   Zhi Xiaoyong, 2015, F1000Prime Rep, V7, P18, DOI 10.12703/P7-18
   Zhong XL, 2021, CAN J INFECT DIS MED, V2021, DOI 10.1155/2021/6622092
   Zhou ST, 2012, CANCER LETT, V323, P115, DOI 10.1016/j.canlet.2012.02.017
NR 182
TC 37
Z9 39
U1 2
U2 38
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD DEC 11
PY 2021
VL 20
IS 1
AR 163
DI 10.1186/s12943-021-01461-0
PG 19
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA XN0TR
UT WOS:000729227800001
PM 34895252
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Wu, ZY
   Zou, JW
   Xie, H
   Wang, J
   Huang, Y
   Liu, F
   Xing, CE
AF Wu, Zhaoying
   Zou, Junwei
   Xie, Hao
   Wang, Jie
   Huang, Yong
   Liu, Fei
   Xing, Chungen
TI LncRNA ALMS1-IT1 modulates ferroptosis and immune evasion in colorectal
   cancer through activating STAT3
SO JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
LA English
DT Article
DE ALMS1-IT1; colorectal cancer; ferroptosis; immune evasion; STAT3
ID CELL-DEATH; IDENTIFICATION; RESPONSES; IRON
AB Colorectal cancer (CRC) represents a significant malignancy within the digestive system, characterized by high incidence and mortality rates. In recent years, molecular targeted therapy has been introduced as a supplementary strategy in CRC management, complementing traditional modalities such as surgery, radiation and chemotherapy. The identification of novel therapeutic targets for CRC remains critically important. Ferroptosis, a unique form of programmed cell death distinct from apoptosis and necrosis, is characterized by cellular damage resulting from iron-induced lipid peroxidation, leading to cell death. This study utilizes a combination of bioinformatics analysis and clinical specimen validation to demonstrate that the long non-coding RNA (lncRNA) ALMS1-IT1 is significantly upregulated in CRC tissues and strongly associated with ferroptosis. Through a series of experimental investigations, we have determined that ALMS1-IT1 negatively regulates ferroptosis in CRC cells, thereby promoting cancer growth and metastasis, acting as an oncogenic factor. Furthermore, we explored the molecular interactions of ALMS1-IT1, revealing its role in activating STAT3 protein phosphorylation. This activation enhances the immune evasion capabilities of CRC cells. Rescue experiments indicated that STAT3 activation is essential for ALMS1-IT1's suppression of ferroptosis, immune evasion and oncogenic behaviour in CRC. Our findings underscore the critical biological role of ALMS1-IT1 in the progression of CRC and suggest its potential as a target for drug development.
C1 [Wu, Zhaoying; Zou, Junwei; Xie, Hao; Wang, Jie; Huang, Yong] Wannan Med Coll, Affiliated Hosp 2, Dept Gastrointestinal Surg, Wuhu, Anhui, Peoples R China.
   [Wu, Zhaoying; Xing, Chungen] Soochow Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Suzhou, Jiangsu, Peoples R China.
   [Liu, Fei] Soochow Univ, Affiliated Hosp 2, Dept Gastroenterol, Suzhou, Jiangsu, Peoples R China.
C3 Wannan Medical College; Soochow University - China; Soochow University -
   China
RP Huang, Y (corresponding author), Wannan Med Coll, Affiliated Hosp 2, Dept Gastrointestinal Surg, Wuhu, Anhui, Peoples R China.; Xing, CE (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Suzhou, Jiangsu, Peoples R China.; Liu, F (corresponding author), Soochow Univ, Affiliated Hosp 2, Dept Gastroenterol, Suzhou, Jiangsu, Peoples R China.
EM huangyong018@wnmc.edu.cn; 948923510@qq.com; xingcg@suda.edu.cn
RI Zou, Junwei/HLG-6333-2023; Wu, Zhaoying/LPR-0172-2024
OI Zou, Junwei/0000-0002-9575-5347
FU Health research project of Anhui Province
FX The Climbing Scientific Peak Project for Talents, the Second Affiliated
   Hospital of Wannan Medical College, Grant/Award Number: DFJH2022016; The
   Key project of Natural Science Foundation of Wannan Medical College,
   Grant/Award Number: WK2023ZZD38; Pre-research fund of the Second
   Affiliated Hospital of Soochow University, Grant/Award Number:
   SDFEYLC2345; Health research project of Anhui Province, Grant/Award
   Number: AHWJ2023A30148
CR Bano I, 2022, MOLECULES, V27, DOI 10.3390/molecules27072129
   Bao GQ, 2021, IEEE J BIOMED HEALTH, V25, P2317, DOI 10.1109/JBHI.2020.3027680
   Chaudhary N, 2021, INT J CANCER, V149, P1495, DOI 10.1002/ijc.33711
   Chen X, 2021, AUTOPHAGY, V17, P2054, DOI 10.1080/15548627.2020.1810918
   Dixon SJ, 2012, CELL, V149, P1060, DOI 10.1016/j.cell.2012.03.042
   Dolma S, 2003, CANCER CELL, V3, P285, DOI 10.1016/S1535-6108(03)00050-3
   Gil N, 2020, NAT REV GENET, V21, P102, DOI 10.1038/s41576-019-0184-5
   Goodall GJ, 2021, NAT REV CANCER, V21, P22, DOI 10.1038/s41568-020-00306-0
   Guo C, 2021, AM J CANCER RES, V11, P3039
   Heichler C, 2020, GUT, V69, P1269, DOI 10.1136/gutjnl-2019-319200
   Ho HH, 2006, J BIOL CHEM, V281, P14111, DOI 10.1074/jbc.M511797200
   Jiang L, 2015, NATURE, V520, P57, DOI 10.1038/nature14344
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Kapranov P, 2007, SCIENCE, V316, P1484, DOI 10.1126/science.1138341
   La Vecchia S, 2020, SEMIN CELL DEV BIOL, V98, P63, DOI 10.1016/j.semcdb.2019.05.018
   Li N, 2022, INT J GEN MED, V15, P33, DOI 10.2147/IJGM.S331378
   Li ZY, 2016, CELL MOL LIFE SCI, V73, P377, DOI 10.1007/s00018-015-2070-4
   Luan T, 2021, FEBS OPEN BIO, V11, P1504, DOI 10.1002/2211-5463.13140
   Nishihara R, 2013, NEW ENGL J MED, V369, P1095, DOI 10.1056/NEJMoa1301969
   Qi X, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.692426
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Seiler A, 2008, CELL METAB, V8, P237, DOI 10.1016/j.cmet.2008.07.005
   Shao YF, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.711776
   Siegel RL., 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Sui XB, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01371
   Sun XY, 2024, BIOMOLECULES, V14, DOI 10.3390/biom14030266
   Tang XH, 2019, YONSEI MED J, V60, P319, DOI 10.3349/ymj.2019.60.4.319
   Torti SV, 2013, NAT REV CANCER, V13, P342, DOI 10.1038/nrc3495
   Tsai MH, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01448
   Xing L, 2019, ONCOL LETT, V18, P3304, DOI 10.3892/ol.2019.10670
   Yagoda N, 2007, NATURE, V447, P864, DOI 10.1038/nature05859
   Yang WS, 2014, CELL, V156, P317, DOI 10.1016/j.cell.2013.12.010
   Yao RW, 2019, NAT CELL BIOL, V21, P542, DOI 10.1038/s41556-019-0311-8
   Zhang BX, 2019, J CELL PHYSIOL, V234, P18781, DOI 10.1002/jcp.28517
   Zhang LY, 2022, PHARMACOL THERAPEUT, V230, DOI 10.1016/j.pharmthera.2021.107969
   Zhang WQ, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.709329
NR 36
TC 0
Z9 0
U1 2
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1582-1838
EI 1582-4934
J9 J CELL MOL MED
JI J. Cell. Mol. Med.
PD SEP
PY 2024
VL 28
IS 18
AR e70103
DI 10.1111/jcmm.70103
PG 13
WC Cell Biology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Research & Experimental Medicine
GA H2C2C
UT WOS:001321562100001
PM 39334527
OA gold, Green Accepted
DA 2025-01-04
ER

PT J
AU Sousa, N
   Sousa, O
   Santos, LL
   Henrique, R
   Teixeira, MR
   Dinis-Ribeiro, M
   Teixeira-Pinto, A
AF Sousa, Nuno
   Sousa, Olga
   Santos, Lucio Lara
   Henrique, Rui
   Teixeira, Manuel R.
   Dinis-Ribeiro, Mario
   Teixeira-Pinto, Armando
TI Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in
   RAS wild-type resectable rectal cancer, an adaptive randomized phase II
   trial (LaRRC trial): study protocol for a randomized controlled trial
SO TRIALS
LA English
DT Article
DE Rectal neoplasms; Radiotherapy; Capecitabine (capecitabine
   [supplementary concept]); Lapatinib (lapatinib [supplementary concept]);
   Neoadjuvant therapy; Clinical trial; Phase II; Randomized adaptive
   trial; Bayesian adaptive randomization
ID METASTATIC COLORECTAL-CANCER; PREOPERATIVE RADIOTHERAPY;
   RADIATION-THERAPY; CLINICAL-TRIALS; INFUSIONAL 5-FLUOROURACIL; TARGET
   VOLUME; COMBINATION; FLUOROURACIL; LEUCOVORIN; MUTATIONS
AB Background: Preoperative radiochemotherapy followed by surgical removal of the rectum with total mesorectum excision is the preferred treatment option for stages II and III rectal cancer. However, development of metastatic disease is the main cause of death for these patients with 5-year disease-free survival rates of 56 %. Anti-epidermal growth factor receptor (EGFR) targeted therapy is effective in metastatic rectal cancer, and human epidermal growth factor receptor 2 (HER-2) signaling may mediate resistance to EGFR inhibitors. Moreover, preclinical data support a synergistic effect of EGFR inhibition with radiation therapy.
   Methods/design: This Bayesian phase II trial with adaptive randomization was designed to assess the efficacy of adding lapatinib, a dual inhibitor of EGFR and HER-2, to standard radiochemotherapy with capecitabine in stages II and III rectal cancer.
   Discussion: The results of this trial will provide evidence of the feasibility and efficacy of the combination of lapatinib-capecitabine as radiosensitizers and explore potential predictive biomarkers for response to this novel neoadjuvant approach to resectable rectal cancer.
C1 [Sousa, Nuno] EPE, IPO Porto FG, Med Oncol Dept, Rua Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
   [Sousa, Olga] EPE, IPO Porto FG, Radioncol Dept, Rua Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
   [Santos, Lucio Lara] EPE, IPO Porto FG, Dept Surg Oncol, Rua Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
   [Henrique, Rui] EPE, IPO Porto FG, Dept Pathol, Rua Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
   [Henrique, Rui] Univ Porto, Abel Salazar Inst Biomed Sci, Dept Pathol & Mol Immunol, Rua Jorge Viterbo Ferreira 228, P-4050313 Oporto, Portugal.
   [Teixeira, Manuel R.] EPE, IPO Porto FG, Dept Genet, Rua Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
   [Teixeira, Manuel R.] Univ Porto, Biomed Sci Inst Abel Salazar ICBAS, Oporto, Portugal.
   [Dinis-Ribeiro, Mario] EPE, IPO Porto FG, Dept Gastroenterol, Rua Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
   [Dinis-Ribeiro, Mario] Univ Porto, Fac Med, Ctr Invest Med, CINTESIS Ctr Hlth Technol & Serv Res, Rua Dr Placido da Costa S-N, P-4200450 Oporto, Portugal.
   [Teixeira-Pinto, Armando] Univ Sydney, Sydney Sch Publ Hlth, STEP, Sydney, NSW 2006, Australia.
C3 Universidade do Porto; Universidade do Porto; Universidade do Porto;
   University of Sydney
RP Sousa, N (corresponding author), EPE, IPO Porto FG, Med Oncol Dept, Rua Antonio Bernardino de Almeida, P-4200072 Oporto, Portugal.
EM nuno.sousa@ipoporto.min-saude.pt
RI Santos, Lúcio/AAE-2822-2021; Teixeira de Sousa, Nuno/H-1678-2011;
   Dinis-Ribeiro, Mario/A-9248-2010; Henrique, Rui/I-2757-2013; Rodrigues
   Teixeira, Manuel Antonio/E-4885-2011; Teixeira-Pinto,
   Armando/H-7947-2013
OI Lara Santos, Lucio/0000-0002-0521-5655; Teixeira de Sousa,
   Nuno/0000-0003-2669-1199; Dinis-Ribeiro, Mario/0000-0003-0121-6850;
   Henrique, Rui/0000-0003-3171-4666; Rodrigues Teixeira, Manuel
   Antonio/0000-0002-4896-5982; Teixeira-Pinto, Armando/0000-0002-9389-2516
FU Instituto Portugues de Oncologia do Porto, EPE
FX The trial is funded by its sponsor: Instituto Portugues de Oncologia do
   Porto, EPE. GlaxoSmithKline provided lapatinib free of charge.
CR Ballonoff A, 2008, AM J CLIN ONCOL-CANC, V31, P264, DOI 10.1097/COC.0b013e318161dbd3
   Bentzen SM., 2009, Basic Clinical Radiobiology, V4th, P120
   Berry DA, 2006, NAT REV DRUG DISCOV, V5, P27, DOI 10.1038/nrd1927
   Bosset JF, 2011, CANCER RADIOTHER, V15, P431, DOI 10.1016/j.canrad.2011.07.236
   Bosset JF, 2006, NEW ENGL J MED, V355, P1114, DOI 10.1056/NEJMoa060829
   Ceelen WP, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006041.pub2
   Chu QSC, 2007, J CLIN ONCOL, V25, P3753, DOI 10.1200/JCO.2007.11.1765
   Coleman MP, 2008, LANCET ONCOL, V9, P730, DOI 10.1016/S1470-2045(08)70179-7
   Collette L, 2007, J CLIN ONCOL, V25, P4379, DOI 10.1200/JCO.2007.11.9685
   Curado MP, 2009, CANC INCIDENCE 5 CON, VIX
   Czito BG, 2006, J CLIN ONCOL, V24, P656, DOI 10.1200/JCO.2005.04.1749
   Dahabreh IJ, 2011, ANN INTERN MED, V154, P37, DOI 10.7326/0003-4819-154-1-201101040-00006
   De Paoli A, 2006, ANN ONCOL, V17, P246, DOI 10.1093/annonc/mdj041
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Drzymala M, 2009, BRIT J RADIOL, V82, P321, DOI 10.1259/bjr/57848689
   Dunst J, 2008, STRAHLENTHER ONKOL, V184, P450, DOI 10.1007/s00066-008-1751-4
   Edge S.B., 2010, AJCC cancer staging manual, V649
   Ferlay J, 2007, ANN ONCOL, V18, P581, DOI 10.1093/annonc/mdl498
   Fields AL, 2005, J CLIN ONCOL S, V23, P1
   Gérard JP, 2006, J CLIN ONCOL, V24, P4620, DOI 10.1200/JCO.2006.06.7629
   Giannopoulou E, 2009, CANCER CHEMOTH PHARM, V63, P973, DOI 10.1007/s00280-008-0820-9
   Hofheinz RD, 2011, ONKOLOGIE, V34, P199
   Kapiteijn E, 2002, BRIT J SURG, V89, P1142, DOI 10.1046/j.1365-2168.2002.02196.x
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kavanagh BD, 2010, INT J RADIAT ONCOL, V76, pS101, DOI 10.1016/j.ijrobp.2009.05.071
   Lee JL, 2008, CLIN TRIALS, V5, P93, DOI 10.1177/1740774508089279
   Magné N, 2008, EUR J CANCER, V44, P2133, DOI 10.1016/j.ejca.2008.06.029
   Marquardt F, 2009, STRAHLENTHER ONKOL, V185, P371, DOI 10.1007/s00066-009-1936-5
   Marsh RD, 2010, AM J CLIN ONCOL-CANC, V33, P251, DOI 10.1097/COC.0b013e3181a650e8
   Midgley RS, 2007, ANN ONCOL, V18, P2025, DOI 10.1093/annonc/mdm366
   Milano G, 2004, Cancer Radiother, V8, P380, DOI 10.1016/j.canrad.2004.09.002
   Myerson RJ, 2009, INT J RADIAT ONCOL, V74, P824, DOI 10.1016/j.ijrobp.2008.08.070
   Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
   Quesnelle KM, 2011, CLIN CANCER RES, V17, P5935, DOI 10.1158/1078-0432.CCR-11-0370
   Roels S, 2006, INT J RADIAT ONCOL, V65, P1129, DOI 10.1016/j.ijrobp.2006.02.050
   SALOMON DS, 1995, CRIT REV ONCOL HEMAT, V19, P183, DOI 10.1016/1040-8428(94)00144-I
   Sambade MJ, 2010, INT J RADIAT ONCOL, V77, P575, DOI 10.1016/j.ijrobp.2009.12.063
   Sambade MJ, 2009, RADIOTHER ONCOL, V93, P639, DOI 10.1016/j.radonc.2009.09.006
   Siegel-Lakhai WS, 2007, CLIN CANCER RES, V13, P4495, DOI 10.1158/1078-0432.CCR-07-0004
   Spalding AC, 2007, MED PHYS, V34, P521, DOI 10.1118/1.2426403
   Valentini V, 2008, INT J RADIAT ONCOL, V72, P644, DOI 10.1016/j.ijrobp.2008.01.046
   Valentini V, 2009, RADIOTHER ONCOL, V92, P148, DOI 10.1016/j.radonc.2009.06.027
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Velenik V, 2006, CROAT MED J, V47, P693
   Viswanathan AN, 2010, INT J RADIAT ONCOL, V76, pS116, DOI 10.1016/j.ijrobp.2009.02.090
   Wong RKS, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002102.pub2
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
   Zhou YF, 2006, CANCER RES, V66, P404, DOI 10.1158/0008-5472.CAN-05-2506
NR 50
TC 2
Z9 2
U1 0
U2 6
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1745-6215
J9 TRIALS
JI Trials
PD SEP 21
PY 2016
VL 17
AR 459
DI 10.1186/s13063-016-1583-y
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA DW5BY
UT WOS:000383658300001
PM 27655166
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Jouini, R
   Ferchichi, M
   BenBrahim, E
   Ayari, I
   Khancher, F
   Koubaa, W
   Saidi, O
   Allani, R
   Chadli-Debbiche, A
AF Jouini, Raja
   Ferchichi, Marwa
   BenBrahim, Ehsen
   Ayari, Imen
   Khancher, Fatma
   Koubaa, Wafa
   Saidi, Olfa
   Allani, Riadh
   Chadli-Debbiche, Aschraf
TI KRAS and NRAS pyrosequencing screening in Tunisian colorectal cancer
   patients in 2015
SO HELIYON
LA English
DT Article
DE Oncology; Genetics
ID ANTI-EGFR THERAPY; COLON-CANCER; MUTATIONS; RESISTANCE; PREVALENCE;
   MECHANISMS; FEATURES; SNAPSHOT; GENE; BRAF
AB Background: Mutations in KRAS and NRAS often result in constitutive activation of RAS in the epidermal growth factor receptor (EGFR) signaling pathway. Mutations in KRAS exon 2 (codon 12-13) predict resistance to anti-EGFR targeted therapy in patients with metastatic colorectal carcinoma (mCRC). However, it's currently known that a significant proportion of mCRC have RAS mutations outside KRAS exon 2, particularly in exons 3 and 4 of KRAS and exons 2, 3 and 4 of NRAS. No data about RAS mutations outside KRAS exon 2 are available for Tunisian mCRC. The aim of this study was to analyze RAS, using pyrosequencing, in nine hotspots mutations in Tunisian patients with mCRC.
   Methods: A series of 131 mCRC was enrolled. Nine hotspots sites mutations of KRAS and NRAS were analyzed (KRAS: codons 12-13, codons 59-61, codon 117 and codon 146, NRAS: codons 12-13, codon 59, codon 61, codon 117 and codon 146) using Therascreen KRAS and RAS extension pyrosequencing kits.
   Results: Analysis was successful in 129 cases (98.5%). Mutations were observed in 97 cases (75.2%) dominated by those in KRAS exon 2 (86.6%). KRAS G12V was the most dominated mutation, observed in 25 cases (25.8%), and followed by KRAS G12S and KRAS G12D, each in 17 cases (17.5%). Mutations outside of KRAS exon 2 presented 13.4% of mutated cases and almost a third (28.8%) of KRAS exon 2 wild type mCRC. Among those, 9 cases (69.3%) carried mutations in NRAS exons 2, 3 and 4 and 4 cases (30.7%) in KRAS exons 3 and 4.
   Conclusions: RAS mutations outside exon 2 of KRAS should be included in routine practice, since they predict also response to anti-EGFR. That would make certain these patients benefit from appropriate testing and treatment. In addition unjustified expenses of anti-EGFR targeted therapy could be avoided.
C1 [Jouini, Raja; Ferchichi, Marwa; BenBrahim, Ehsen; Ayari, Imen; Khancher, Fatma; Koubaa, Wafa; Chadli-Debbiche, Aschraf] Habib Thameur Hosp, Pathol Dept, Tunis, Tunisia.
   [Jouini, Raja; Allani, Riadh] Univ Med, Farhat Hached Campus, Tunis El Manar, Tunisia.
   [Ferchichi, Marwa; Ayari, Imen] Univ Sci, Farhat Hached Campus, Tunis El Manar, Tunisia.
   [Saidi, Olfa] Publ Hlth Inst, Tunis, Tunisia.
C3 Universite de Tunis-El-Manar; Hopital Habib Thameur; Universite de
   Tunis-El-Manar; Faculte de Medecine de Tunis (FMT)
RP Ferchichi, M (corresponding author), Habib Thameur Hosp, Pathol Dept, Tunis, Tunisia.; Ferchichi, M (corresponding author), Univ Sci, Farhat Hached Campus, Tunis El Manar, Tunisia.
EM marwaferchichi88@gmail.com
CR Abdelmaksoud-Dammak R., 2015, J I M SFAX, V21, P39
   Aissi S, 2013, MOL BIOL REP, V40, P6107, DOI 10.1007/s11033-013-2722-0
   Aissi S, 2013, WORLD J GASTROENTERO, V19, P5286, DOI 10.3748/wjg.v19.i32.5286
   Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   [Anonymous], 2017, NO CANC REG TUN DAT
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bougatef K., 2011, CANCER BIOMARK, V8, P331
   Bronte G, 2015, ONCOTARGET, V6, P24780, DOI 10.18632/oncotarget.4959
   Bruera G., 2017, J CLIN ONCOL
   Bruera Gemma, 2018, Oncotarget, V9, P26279, DOI 10.18632/oncotarget.25180
   Cercek A, 2017, CLIN CANCER RES, V23, P4753, DOI 10.1158/1078-0432.CCR-17-0400
   Foltran L, 2015, FUTURE ONCOL, V11, P629, DOI 10.2217/fon.14.279
   Franklin WA, 2010, J MOL DIAGN, V12, P43, DOI 10.2353/jmoldx.2010.080131
   Guo F., 2018, SCI REP, V8, P1
   Hecht JR, 2015, CANCER TREAT REV, V41, P653, DOI 10.1016/j.ctrv.2015.05.008
   Ihle MA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-13
   Ines C, 2014, TUMOR BIOL, V35, P7163, DOI 10.1007/s13277-014-1874-4
   Magnin S, 2011, J MOL DIAGN, V13, P485, DOI 10.1016/j.jmoldx.2011.05.010
   Normanno N, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029146
   Ouerhani S, 2013, MOL BIOL REP, V40, P4109, DOI 10.1007/s11033-013-2512-8
   Peeters M, 2015, EUR J CANCER, V51, P1704, DOI 10.1016/j.ejca.2015.05.017
   Sammoud S, 2012, APPL IMMUNOHISTO M M, V20, P146, DOI 10.1097/PAI.0b013e3182240de1
   Sarasqueta AF, 2011, J MOL DIAGN, V13, P199, DOI 10.1016/j.jmoldx.2010.10.006
   Schirripa M, 2015, INT J CANCER, V136, P83, DOI 10.1002/ijc.28955
   Sforza V, 2016, WORLD J GASTROENTERO, V22, P6345, DOI 10.3748/wjg.v22.i28.6345
   Stewart B., 2015, World cancer report 2014
   Tejpar S., 2014, J CLIN ONCOL S3, V32
   Zhao B, 2017, ONCOTARGET, V8, P3980, DOI 10.18632/oncotarget.14012
NR 28
TC 9
Z9 9
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
EI 2405-8440
J9 HELIYON
JI Heliyon
PD MAR
PY 2019
VL 5
IS 3
AR e01330
DI 10.1016/j.heliyon.2019.e01330
PG 14
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA HR3UZ
UT WOS:000463067400080
PM 30949599
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Wang, X
   Zhang, HB
   Lu, YW
AF Wang, Xiao
   Zhang, Haibo
   Lu, Yanwei
TI Breast metastasis of signet ring cell carcinoma from the colon: a case
   report
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE Colon cancer; Breast metastasis from colon; Mucinous adenocarcinoma;
   Signet ring cell carcinoma; Case report
ID CLINICOPATHOLOGICAL FEATURES; CANCER STATISTICS; ADENOCARCINOMA
AB Background Colon cancer is one of the most common diagnosed malignancies. Despite the use of surgery, chemotherapy, radiotherapy, targeted therapy, immunotherapy, and other comprehensive treatments, distant metastasis is still one of the main causes for dying of colon cancer. The common metastatic site of colon cancer is the liver, lung, and bone. In this article, we report a rare case of breast metastasis of signet ring cell carcinoma from the colon. Case presentation A 44-year-old woman was diagnosed with colon cancer and received a radical surgery of colon cancer in 2019. Combined with postoperative pathological and computed tomography (CT) images, a diagnosis of cT3N2M0 mucinous adenocarcinoma of colon (according to AJCC cancer staging manual, Version 8) was established. Adjuvant chemotherapy (XELOX: oxaliplatin 130 mg/m(2) on day 1 plus capecitabine 1000 mg/m(2) twice daily on days 1 to 14 every 3 weeks for 18 weeks) was performed followed by surgical resection. Fourteen months later, the patient underwent mastectomy for breast mass, which was diagnosed pathologically as metastasis of signet ring cell carcinoma from the colon. XELOX chemotherapy regimen (oxaliplatin 130 mg/m(2) on day 1 plus capecitabine 1000 mg/m(2) twice daily on days 1 to 14 every 3 weeks for 24 weeks) combined with bevacizumab (7.5 mg/kg on day 1) was used after the mastectomy. The patient had stable disease according to her last examination (RECIST criteria). Conclusion It is rare to find a report of a patient of colon cancer that metastasizes to breast. We hope to increase treatment experience for patients with this rare metastasis.
C1 [Wang, Xiao] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Canc Ctr,Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Zhang, Haibo; Lu, Yanwei] Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Canc Ctr,Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China.
C3 Hangzhou Medical College; Zhejiang Provincial People's Hospital;
   Hangzhou Medical College; Zhejiang Provincial People's Hospital
RP Zhang, HB; Lu, YW (corresponding author), Zhejiang Prov Peoples Hosp, Affiliated Peoples Hosp, Hangzhou Med Coll, Canc Ctr,Dept Radiat Oncol, Hangzhou, Zhejiang, Peoples R China.
EM zhbdoctor@163.com; luyanwei@hmc.edu.cn
RI Lu, Yanwei/AAI-1925-2020; Zhang, Haibo/HLP-9266-2023
OI Zhang, Haibo/0000-0002-5134-4167
FU Medical Science and Technology Project of Zhejiang Province; Zhejiang
   natural science foundation of China [2022KY537, 2021KY023]; 
   [LQ22H160036]
FX This study were supported in part by grants from the Medical Science and
   Technology Project of Zhejiang Province (Grant number: 2022KY537, to
   Yan-wei Lu; Grant number: 2021KY023, to Xiao Wang) and Zhejiang natural
   science foundation of China (Grant number: LQ22H160036, to Yanwei Lu).
CR Arnaout K, 2021, INT J SURG CASE REP, V81, DOI 10.1016/j.ijscr.2021.105759
   Barthelmes L, 2010, BREAST CARE, V5, P23, DOI 10.1159/000272303
   Baum, 1995, Breast Cancer, V2, P9, DOI 10.1007/BF02966891
   Benson AB, 2005, SEMIN ONCOL, V32, pS74, DOI 10.1053/j.seminoncol.2005.4.016
   Bonacho T, 2020, BIOTECH HISTOCHEM, V95, P71, DOI 10.1080/10520295.2019.1651901
   Conde J, 2016, NAT MATER, V15, P1128, DOI [10.1038/NMAT4707, 10.1038/nmat4707]
   de Bobadilla LF, 2004, REV ESP ENFERM DIG, V96, P415
   Goel S, 2015, J CANCER RES THER, V11, DOI 10.4103/0973-1482.147383
   Ho YY, 2009, J CLIN ULTRASOUND, V37, P239, DOI 10.1002/jcu.20490
   Hsieh TC, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000018016
   Jimi S, 2015, SURG TODAY, V45, P329, DOI 10.1007/s00595-014-0943-z
   Kakar S, 2005, MODERN PATHOL, V18, P244, DOI 10.1038/modpathol.3800298
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Li HC, 2009, RARE TUMORS, V1, DOI 10.4081/rt.2009.e22
   Luo C, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0361-0
   Mihai R, 2004, BREAST, V13, P155, DOI 10.1016/S0960-9776(03)00125-5
   Noor A, 2020, AM J CASE REP, V21, DOI 10.12659/AJCR.917376
   Pozos-Ochoa LI, 2018, PATHOL ONCOL RES, V24, P609, DOI 10.1007/s12253-017-0283-6
   Riihimäki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P177, DOI 10.3322/caac.21395
   Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Song IH, 2019, PATHOLOGY, V51, P384, DOI 10.1016/j.pathol.2019.03.001
   SYMONDS DA, 1976, CANCER, V37, P1891, DOI 10.1002/1097-0142(197604)37:4<1891::AID-CNCR2820370439>3.0.CO;2-Z
   Taccogna S, 2020, WORLD J GASTRO ONCOL, V12, P1073, DOI 10.4251/wjgo.v12.i9.1073
   Tsung SH, 2017, CASE REP ONCOL, V10, P77, DOI 10.1159/000455225
   Williams SA, 2007, CANCER-AM CANCER SOC, V110, P731, DOI 10.1002/cncr.22835
   Yoder Michael C, 2012, Semin Oncol, V39, pe1, DOI 10.1053/j.seminoncol.2012.04.001
NR 27
TC 1
Z9 1
U1 0
U2 1
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD DEC 1
PY 2022
VL 20
IS 1
AR 376
DI 10.1186/s12957-022-02840-7
PG 6
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA 6S4US
UT WOS:000892984700001
PM 36451153
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Chen, AQ
   Huang, HF
   Fang, SM
   Hang, QL
AF Chen, Anqi
   Huang, Haifeng
   Fang, Sumeng
   Hang, Qinglei
TI ROS: A "booster" for chronic inflammation and tumor metastasis
SO BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
LA English
DT Review
DE ROS; Chronic inflammation; Tumor metastasis; Ferroptosis
ID NF-KAPPA-B; ELECTRON-TRANSPORT-CHAIN; BREAST-CANCER METASTASIS;
   OXIDATIVE STRESS; COLORECTAL-CANCER; CELL MIGRATION; NADPH OXIDASES;
   TUMORIGENESIS; PROGRESSION; ACTIVATION
AB Reactive oxygen species (ROS) are a group of highly active molecules produced by normal cellular metabolism and play a crucial role in the human body. In recent years, researchers have increasingly discovered that ROS plays a vital role in the progression of chronic inflammation and tumor metastasis. The inflammatory tumor microenvironment established by chronic inflammation can induce ROS production through inflammatory cells. ROS can then directly damage DNA or indirectly activate cellular signaling pathways to promote tumor metastasis and development, including breast cancer, lung cancer, liver cancer, colorectal cancer, and so on. This review aims to elucidate the relationship between ROS, chronic inflammation, and tumor metastasis, explaining how chronic inflammation can induce tumor metastasis and how ROS can contribute to the evolution of chronic inflammation toward tumor metastasis. Interestingly, ROS can have a "double-edged sword" effect, promoting tumor metastasis in some cases and inhibiting it in others. This article also highlights the potential applications of ROS in inhibiting tumor metastasis and enhancing the precision of tumor-targeted therapy. Combining ROS with nanomaterials strategies may be a promising approach to enhance the efficacy of tumor treatment.
C1 [Huang, Haifeng] Yangzhou Univ, Med Coll, Yangzhou 225009, Peoples R China.
   [Huang, Haifeng] First Peoples Hosp Yancheng, Dept Lab Med, Yancheng 224006, Peoples R China.
   [Fang, Sumeng] Jiangsu Univ, Yancheng Clin Med Coll, Dept Lab Med, Yancheng 224006, Peoples R China.
   [Hang, Qinglei] Tianjin Univ, Sch Math, Tianjin 300350, Peoples R China.
   [Hang, Qinglei] Xuzhou Med Univ, Affiliated Hosp, Suining Peoples Hosp, Jiangsu Prov Innovat & Practice Base Postdoctors, Suining 221200, Peoples R China.
   [Hang, Qinglei] Yangzhou Univ, Key Lab Jiangsu Prov Univ Nucl Acid & Cell Fate Ma, Yangzhou 225009, Peoples R China.
   [Hang, Qinglei] Yangzhou Univ, Med Coll, Dept Lab Med, Yangzhou 225009, Peoples R China.
C3 Yangzhou University; Jiangsu University; Tianjin University; Xuzhou
   Medical University; Yangzhou University; Yangzhou University
RP Hang, QL (corresponding author), Xuzhou Med Univ, Affiliated Hosp, Suining Peoples Hosp, Jiangsu Prov Innovat & Practice Base Postdoctors, Suining 221200, Peoples R China.; Hang, QL (corresponding author), Yangzhou Univ, Key Lab Jiangsu Prov Univ Nucl Acid & Cell Fate Ma, Yangzhou 225009, Peoples R China.; Hang, QL (corresponding author), Yangzhou Univ, Med Coll, Dept Lab Med, Yangzhou 225009, Peoples R China.
EM qhang@yzu.edu.cn
FU National Natural Science Foundation of China [32201047]; China
   Post-doctoral Science Foundation [2023M741447]; Yan-cheng Municipal
   Health Commission Medical Science Foundation [YK2023012]
FX This work was partly supported by grants from the National Natural
   Science Foundation of China [No. 32201047 to Q.H.] , the China
   Post-doctoral Science Foundation [No. 2023M741447 to Q.H.] , and
   Yan-cheng Municipal Health Commission Medical Science Foundation [No.
   YK2023012 to H.H.] .
CR Accioly MT, 2008, CANCER RES, V68, P1732, DOI 10.1158/0008-5472.CAN-07-1999
   Achard C, 2018, EBIOMEDICINE, V31, P17, DOI 10.1016/j.ebiom.2018.04.020
   Afify SM, 2022, BRIT J CANCER, V127, P193, DOI 10.1038/s41416-022-01775-w
   Ahsan A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23105509
   Astarci E, 2012, FEBS J, V279, P2966, DOI 10.1111/j.1742-4658.2012.08677.x
   Auten RL, 2009, PEDIATR RES, V66, P121, DOI 10.1203/PDR.0b013e3181a9eafb
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005
   Bergers G, 2003, NAT REV CANCER, V3, P401, DOI 10.1038/nrc1093
   Bodac A, 2021, SEMIN IMMUNOL, V57, DOI 10.1016/j.smim.2021.101583
   Brabletz T, 2012, NAT REV CANCER, V12, P425, DOI 10.1038/nrc3265
   Brahma MK, 2021, ONCOGENE, V40, P5155, DOI 10.1038/s41388-021-01950-y
   Bronte V, 2003, J IMMUNOL, V170, P270, DOI 10.4049/jimmunol.170.1.270
   Broustas CG, 2014, RADIAT RES, V181, P111, DOI 10.1667/RR13515.1
   Broz MT, 2024, NAT COMMUN, V15, DOI 10.1038/s41467-024-46504-4
   Buddhiraju HS, 2023, BIOMED MATER, V18, DOI 10.1088/1748-605X/acf5b9
   Caligiuri A, 2024, ANTIOXIDANTS-BASEL, V13, DOI 10.3390/antiox13010028
   Canli Ö, 2017, CANCER CELL, V32, P869, DOI 10.1016/j.ccell.2017.11.004
   Carullo G, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9111077
   Chen BN, 2023, CLIN TRANSL MED, V13, DOI 10.1002/ctm2.1516
   Chen BN, 2022, CANCER LETT, V543, DOI 10.1016/j.canlet.2022.215783
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen H, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13404
   Chen LW, 2003, NAT MED, V9, P575, DOI 10.1038/nm849
   Chen MX, 2024, J TRANSL MED, V22, DOI 10.1186/s12967-024-05314-4
   Chen XQ, 2024, ONCOGENE, V43, P2517, DOI 10.1038/s41388-024-03100-6
   Chen Y, 2021, NAT REV CLIN ONCOL, V18, P792, DOI 10.1038/s41571-021-00546-5
   Chen YQ, 2007, J CELL SCI, V120, P4155, DOI 10.1242/jcs.011163
   Cheung EC, 2022, NAT REV CANCER, V22, P280, DOI 10.1038/s41568-021-00435-0
   Cheung EC, 2020, CANCER CELL, V37, P168, DOI 10.1016/j.ccell.2019.12.012
   Chiu WT, 2010, NEUROBIOL DIS, V37, P118, DOI 10.1016/j.nbd.2009.09.015
   Colomer C, 2017, BIOMEDICINES, V5, DOI 10.3390/biomedicines5020026
   Condeelis J, 2006, CELL, V124, P263, DOI 10.1016/j.cell.2006.01.007
   Cotte AK, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02732-5
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105
   Cucarull B, 2021, ANTIOXIDANTS-BASEL, V10, DOI 10.3390/antiox10091336
   de Visser KE, 2023, CANCER CELL, V41, P374, DOI 10.1016/j.ccell.2023.02.016
   Denk D, 2022, TRENDS CANCER, V8, P901, DOI 10.1016/j.trecan.2022.07.002
   Di Franco Simone, 2011, Cancers (Basel), V3, P1957, DOI 10.3390/cancers3021957
   El-Benna J, 2016, IMMUNOL REV, V273, P180, DOI 10.1111/imr.12447
   El-Kenawi A, 2017, CANCER CELL, V32, P727, DOI 10.1016/j.ccell.2017.11.015
   Elinav E, 2013, NAT REV CANCER, V13, P759, DOI 10.1038/nrc3611
   Fajardo AM, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151525
   Fang J, 2009, ADV DRUG DELIVER REV, V61, P290, DOI 10.1016/j.addr.2009.02.005
   Fang YJ, 2024, J NANOBIOTECHNOL, V22, DOI 10.1186/s12951-024-02688-x
   Feng B, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935-022-02599-7
   Fiorilla I, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12162048
   Fouani L, 2019, ANTIOXID REDOX SIGN, V30, P1096, DOI 10.1089/ars.2017.7387
   Furman D, 2019, NAT MED, V25, P1822, DOI 10.1038/s41591-019-0675-0
   Gabrilovich DI, 2017, CANCER IMMUNOL RES, V5, P3, DOI 10.1158/2326-6066.CIR-16-0297
   Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4
   Geiszt M, 2006, CARDIOVASC RES, V71, P289, DOI 10.1016/j.cardiores.2006.05.004
   Giannoni E, 2011, ANTIOXID REDOX SIGN, V14, P2361, DOI 10.1089/ars.2010.3727
   Glorieux C, 2024, NAT REV DRUG DISCOV, V23, P583, DOI 10.1038/s41573-024-00979-4
   Gothai S, 2018, BIOMED PHARMACOTHER, V107, P1514, DOI 10.1016/j.biopha.2018.08.112
   Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025
   Gu M, 2024, CANCER LETT, V588, DOI 10.1016/j.canlet.2024.216738
   Guan XQ, 2024, ADV SCI, V11, DOI 10.1002/advs.202307899
   Guerra J, 2022, ANTIOXIDANTS-BASEL, V11, DOI 10.3390/antiox11010035
   Guo CZ, 2024, ECOTOX ENVIRON SAFE, V278, DOI 10.1016/j.ecoenv.2024.116405
   Guo R, 2023, NANO LETT, V23, P3401, DOI 10.1021/acs.nanolett.3c00365
   Guo YJ, 2020, EXP THER MED, V19, P1997, DOI 10.3892/etm.2020.8454
   Hagemann T, 2008, J EXP MED, V205, P1261, DOI 10.1084/jem.20080108
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Handa O, 2010, INFLAMM RES, V59, P997, DOI 10.1007/s00011-010-0245-x
   Hawk MA, 2018, NAT CELL BIOL, V20, P272, DOI 10.1038/s41556-018-0034-2
   Hayes JD, 2020, CANCER CELL, V38, P167, DOI 10.1016/j.ccell.2020.06.001
   Holmström KM, 2014, NAT REV MOL CELL BIO, V15, P411, DOI 10.1038/nrm3801
   Hou Y, 2024, MED RES REV, V44, P1566, DOI 10.1002/med.22018
   Hu F, 2015, ONCOGENE, V34, P6007, DOI 10.1038/onc.2015.49
   Hu ZY, 2024, J EXP CLIN CANC RES, V43, DOI 10.1186/s13046-024-02989-x
   Huang D, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2210796120
   Huang JQ, 2020, JNCI-J NATL CANCER I, V112, P191, DOI 10.1093/jnci/djz077
   Huang QJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-18
   Huang WS, 2023, ANTIOXID REDOX SIGN, V39, P551, DOI 10.1089/ars.2023.0246
   Huang YF, 2024, CANCER CELL INT, V24, DOI 10.1186/s12935-024-03275-8
   Hussain SP, 2003, NAT REV CANCER, V3, P276, DOI 10.1038/nrc1046
   Irani K, 1997, SCIENCE, V275, P1649, DOI 10.1126/science.275.5306.1649
   Islam MO, 2019, OXID MED CELL LONGEV, V2019, DOI 10.1155/2019/2730896
   Jiang XJ, 2021, NAT REV MOL CELL BIO, V22, P266, DOI 10.1038/s41580-020-00324-8
   Jiang YJ, 2023, EXPERT REV MOL MED, V25, DOI 10.1017/erm.2023.20
   Kavanagh ME, 2014, CANCER LETT, V345, P182, DOI 10.1016/j.canlet.2013.08.017
   Kennel KB, 2021, REDOX BIOL, V42, DOI 10.1016/j.redox.2021.101891
   Khamidullina AI, 2024, INT J MOL SCI, V25, DOI 10.3390/ijms25021263
   Khandrika L, 2009, CANCER LETT, V282, P125, DOI 10.1016/j.canlet.2008.12.011
   Kodama R, 2013, GENES CELLS, V18, P32, DOI 10.1111/gtc.12015
   Kondo S, 1999, FREE RADICAL BIO MED, V27, P401, DOI 10.1016/S0891-5849(99)00087-8
   Kotsantis P, 2018, CANCER DISCOV, V8, P537, DOI 10.1158/2159-8290.CD-17-1461
   Kuo CY, 2023, OXID MED CELL LONGEV, V2023, DOI 10.1155/2023/7736638
   Kuo CL, 2022, J BIOMED SCI, V29, DOI 10.1186/s12929-022-00859-2
   Kuo CL, 2020, CANCER LETT, V474, P138, DOI 10.1016/j.canlet.2020.01.019
   Lee NR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249409
   Lee S, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419-023-05978-8
   Lei SQ, 2023, CELL REP, V42, DOI 10.1016/j.celrep.2023.113110
   Lennicke C, 2021, MOL CELL, V81, P3691, DOI 10.1016/j.molcel.2021.08.018
   Li PS, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18125-0
   Li YY, 2024, ADV SCI, V11, DOI 10.1002/advs.202310309
   Liang W, 2021, ONCOL REP, V46, DOI 10.3892/or.2021.8159
   Lin A, 2003, SEMIN CANCER BIOL, V13, P107, DOI 10.1016/S1044-579X(02)00128-1
   Lin SS, 2018, J CELL PHYSIOL, V233, P5119, DOI 10.1002/jcp.26356
   Lin WW, 2007, J CLIN INVEST, V117, P1175, DOI 10.1172/JCI31537
   Loetscher P, 1996, J IMMUNOL, V156, P322
   LOSCHEN G, 1973, FEBS LETT, V33, P84, DOI 10.1016/0014-5793(73)80165-6
   Lu TY, 2012, CLIN CANCER RES, V18, P4877, DOI 10.1158/1078-0432.CCR-11-2939
   Lu YQ, 2021, CANCER LETT, V522, P1, DOI 10.1016/j.canlet.2021.09.014
   Lukashchuk N, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1162644
   Lv W, 2016, CANCER LETT, V375, P245, DOI 10.1016/j.canlet.2016.02.005
   Ma Y, 2013, IMMUNITY, V38, P729, DOI 10.1016/j.immuni.2013.03.003
   Malla R, 2021, CRIT REV ONCOL HEMAT, V160, DOI 10.1016/j.critrevonc.2021.103285
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Martins C, 2024, SCI ADV, V10, DOI 10.1126/sciadv.adi2012
   Mathew R, 2009, CELL, V137, P1062, DOI 10.1016/j.cell.2009.03.048
   Maya-Mendoza A, 2015, MOL ONCOL, V9, P601, DOI 10.1016/j.molonc.2014.11.001
   McConnell D.D., 2018, Medicines (Basel), V5
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Meira LB, 2008, J CLIN INVEST, V118, P2516, DOI 10.1172/JCI35073
   Mierke CT, 2024, BIOMOLECULES, V14, DOI 10.3390/biom14020184
   Miller WH, 2002, ONCOLOGIST, V7, P14
   Molon B, 2011, J EXP MED, V208, P1949, DOI 10.1084/jem.20101956
   Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386
   Myung SK, 2010, ANN ONCOL, V21, P166, DOI 10.1093/annonc/mdp286
   Nagaraj S, 2007, NAT MED, V13, P828, DOI 10.1038/nm1609
   Nagpal A, 2019, BREAST CANCER RES, V21, DOI 10.1186/s13058-019-1177-1
   Nathan C, 2013, NAT REV IMMUNOL, V13, P349, DOI 10.1038/nri3423
   Netea MG, 2017, NAT IMMUNOL, V18, P826, DOI 10.1038/ni.3790
   Nguyen DX, 2009, NAT REV CANCER, V9, P274, DOI 10.1038/nrc2622
   Nickoloff BJ, 2005, J INVEST DERMATOL, V124, pX, DOI 10.1111/j.0022-202X.2005.23724.x
   Nicolas AM, 2022, CANCER CELL, V40, P168, DOI 10.1016/j.ccell.2022.01.004
   Öhlund D, 2017, J EXP MED, V214, P579, DOI 10.1084/jem.20162024
   Park MT, 2014, CELL DEATH DIFFER, V21, P1185, DOI 10.1038/cdd.2014.34
   Park SM, 2023, SCI REP-UK, V13, DOI 10.1038/s41598-023-45382-y
   Park SJ, 2017, J KOREAN MED SCI, V32, P628, DOI 10.3346/jkms.2017.32.4.628
   Perillo B, 2020, EXP MOL MED, V52, P192, DOI 10.1038/s12276-020-0384-2
   Petan T, 2018, MOLECULES, V23, DOI 10.3390/molecules23081941
   Poljsak B, 2018, CURR PHARM DESIGN, V24, P5234, DOI 10.2174/1381612825666190123112647
   Popov Y, 2006, J BIOL CHEM, V281, P15090, DOI 10.1074/jbc.M600030200
   Poyton RO, 2009, TRENDS ENDOCRIN MET, V20, P332, DOI 10.1016/j.tem.2009.04.001
   Qian BZ, 2010, CELL, V141, P39, DOI 10.1016/j.cell.2010.03.014
   Qin SS, 2024, J EXP CLIN CANC RES, V43, DOI 10.1186/s13046-024-03103-x
   Qin Y, 2024, CANCER LETT, V580, DOI 10.1016/j.canlet.2023.216482
   Reuter S, 2010, FREE RADICAL BIO MED, V49, P1603, DOI 10.1016/j.freeradbiomed.2010.09.006
   Rinkenbaugh AL, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020016
   Ritter B, 2019, J EXP MED, V216, P1234, DOI 10.1084/jem.20181739
   Rivera A, 2016, NAT IMMUNOL, V17, P356, DOI 10.1038/ni.3375
   Robb EL, 2018, J BIOL CHEM, V293, P9869, DOI 10.1074/jbc.RA118.003647
   Robinson BD, 2009, CLIN CANCER RES, V15, P2433, DOI 10.1158/1078-0432.CCR-08-2179
   Rogler G, 2014, CANCER LETT, V345, P235, DOI 10.1016/j.canlet.2013.07.032
   Rohan TE, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju136
   Roux C, 2019, P NATL ACAD SCI USA, V116, P4326, DOI 10.1073/pnas.1819473116
   Rubinfeld H, 2005, MOL BIOTECHNOL, V31, P151, DOI 10.1385/MB:31:2:151
   Sable KA, 2023, CUTIS, V111, P33, DOI 10.12788/cutis.0672
   Sami DH, 2023, ENVIRON SCI POLLUT R, V30, P80181, DOI 10.1007/s11356-023-27879-1
   Sampson N, 2018, INT J CANCER, V143, P383, DOI 10.1002/ijc.31316
   Sasaki A, 2024, J GASTROENTEROL, V59, P442, DOI 10.1007/s00535-024-02094-y
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Sebolt-Leopold JS, 1999, NAT MED, V5, P810, DOI 10.1038/10533
   Senkal CE, 2017, CELL METAB, V25, P686, DOI 10.1016/j.cmet.2017.02.010
   Shacter E, 2002, ONCOLOGY-NY, V16, P217
   Shah RS, 2024, METABOLISM, V151, DOI 10.1016/j.metabol.2023.155747
   Shimura T, 2018, MOL CANCER RES, V16, P1676, DOI 10.1158/1541-7786.MCR-18-0321
   Shui SF, 2021, REDOX BIOL, V45, DOI 10.1016/j.redox.2021.102056
   Siegel Rebecca L, 2024, CA Cancer J Clin, V74, P12, DOI 10.3322/caac.21820
   Sies H, 2020, NAT REV MOL CELL BIO, V21, P363, DOI 10.1038/s41580-020-0230-3
   Singh K, 2018, SAUDI PHARM J, V26, P177, DOI 10.1016/j.jsps.2017.12.013
   Singh SP, 2024, CANCER RES, V84, P1320, DOI 10.1158/0008-5472.CAN-23-1200
   Sokol CL, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016303
   Sosa V, 2013, AGEING RES REV, V12, P376, DOI 10.1016/j.arr.2012.10.004
   Sparmann A, 2004, CANCER CELL, V6, P447, DOI 10.1016/j.ccr.2004.09.028
   Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084
   Stieg DC, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23126702
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   Takahashi H, 2010, CANCER CELL, V17, P89, DOI 10.1016/j.ccr.2009.12.008
   Talmadge JE, 2010, CANCER RES, V70, P5649, DOI 10.1158/0008-5472.CAN-10-1040
   Tirinato L, 2020, GENES DIS, V7, P620, DOI 10.1016/j.gendis.2019.09.010
   Palomino DCT, 2015, EINSTEIN-SAO PAULO, V13, P469, DOI 10.1590/S1679-45082015RB3438
   Tuli HS, 2023, ARCH TOXICOL, V97, P103, DOI 10.1007/s00204-022-03421-z
   Turkez H, 2021, NEUROCHEM INT, V150, DOI 10.1016/j.neuint.2021.105168
   Ubellacker JM, 2020, NATURE, V585, P113, DOI 10.1038/s41586-020-2623-z
   van der Waals LM, 2018, AM J PATHOL, V188, P2369, DOI 10.1016/j.ajpath.2018.06.008
   Visconti R, 2009, CURR OPIN DRUG DISC, V12, P240
   Vitale I, 2019, CELL METAB, V30, P36, DOI 10.1016/j.cmet.2019.06.001
   Wang HY, 2023, ASIAN J PHARM SCI, V18, DOI 10.1016/j.ajps.2023.100829
   Wang HH, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.729367
   Wang K, 2021, ONCOIMMUNOLOGY, V10, DOI 10.1080/2162402X.2021.1923910
   Wang Y, 2024, MEDCOMM, V5, DOI 10.1002/mco2.486
   Watanabe S, 2019, J CLIN INVEST, V129, P2619, DOI 10.1172/JCI124615
   Wiel C, 2019, CELL, V178, P330, DOI 10.1016/j.cell.2019.06.005
   Wu YZ, 2014, CANCER LETT, V345, P164, DOI 10.1016/j.canlet.2013.08.014
   Xie XC, 2021, INT J BIOL SCI, V17, P3080, DOI 10.7150/ijbs.63963
   Xie XF, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419-023-05571-z
   Xing YH, 2022, AUTOPHAGY, V18, P1932, DOI 10.1080/15548627.2021.2008752
   Yang JQ, 2023, ANTIOXIDANTS-BASEL, V12, DOI 10.3390/antiox12020338
   Yang Q, 2021, J IMMUNOL RES, V2021, DOI 10.1155/2021/6664453
   Yin M., 2022, Metastasis, Exon Publications Copyright: The Authors.; The authors confirm that the materials included in this chapter do not violate copyright laws. Where relevant, appropriate permissions have been obtained from the original copyright holder(s), and all original sources have been appropriately acknowledged or referenced, Brisbane (AU), 2022.
   Yu WH, 2022, OXID MED CELL LONGEV, V2022, DOI 10.1155/2022/2606928
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
   Zhang JX, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/4350965
   Zhang L, 2023, J ZHEJIANG UNIV-SC B, V24, P32, DOI 10.1631/jzus.B2200269
   Zhang QY, 2022, BIOMATER SCI-UK, V10, P3637, DOI 10.1039/d1bm02022f
   Zhang X, 2022, FREE RADICAL BIO MED, V179, P213, DOI 10.1016/j.freeradbiomed.2021.11.024
   Zhao HK, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00658-5
   Zhao RZ, 2019, INT J MOL MED, V44, P3, DOI 10.3892/ijmm.2019.4188
   Zhao Y, 2024, GENES DIS, V11, P234, DOI 10.1016/j.gendis.2023.02.039
   Zhao YS, 2022, INT J BIOL SCI, V18, P3845, DOI 10.7150/ijbs.70958
   Zhao Y, 2023, CELL METAB, V35, P1688, DOI 10.1016/j.cmet.2023.09.004
   Zhou JH, 2024, FRONT PHARMACOL, V15, DOI 10.3389/fphar.2024.1350187
   Zhou J, 2023, J CONTROL RELEASE, V360, P564, DOI 10.1016/j.jconrel.2023.07.015
   Zhou RB, 2011, NATURE, V469, P221, DOI 10.1038/nature09663
   Zhu GN, 2020, J INVEST DERMATOL, V140, P666, DOI 10.1016/j.jid.2019.07.720
   Zou GY, 2024, J EXP MED, V221, DOI 10.1084/jem.20230561
NR 212
TC 3
Z9 3
U1 26
U2 26
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-419X
EI 1879-2561
J9 BBA-REV CANCER
JI Biochim. Biophys. Acta-Rev. Cancer
PD NOV
PY 2024
VL 1879
IS 6
AR 189175
DI 10.1016/j.bbcan.2024.189175
EA SEP 2024
PG 16
WC Biochemistry & Molecular Biology; Biophysics; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Oncology
GA G2Z3I
UT WOS:001315369900001
PM 39218404
DA 2025-01-04
ER

PT J
AU Osei, GY
   Adu-Amankwaah, J
   Koomson, S
   Beletaa, S
   Ahmad, MK
   Asiamah, EA
   Smith-Togobo, C
   Razak, SRA
AF Osei, George Yiadom
   Adu-Amankwaah, Joseph
   Koomson, Selina
   Beletaa, Solomon
   Ahmad, Muhammad Khairi
   Asiamah, Emmanuel Akomanin
   Smith-Togobo, Cecilia
   Razak, Siti Razila Abdul
TI Revolutionizing colorectal cancer treatment: unleashing the potential of
   miRNAs in targeting cancer stem cells
SO FUTURE ONCOLOGY
LA English
DT Review
DE cancer stem cells; colorectal cancer; miRNA; miRNA-based therapies;
   miRNA delivery; stemness; targeted therapy; therapy resistance
ID COLON; CHEMORESISTANCE; RESISTANCE; PROLIFERATION; METASTASIS; LINES;
   OLIGONUCLEOTIDES; INHIBITION; STERNNESS; CARCINOMA
AB Colorectal cancer (CRC) is a significant contributor to cancer mortality worldwide, and the presence of cancer stem cells (CSC) represents a major challenge for achieving effective treatment. miRNAs have emerged as critical regulators of gene expression, and recent studies have highlighted their role in regulating stemness and therapeutic resistance in CRC stem cells. This review highlights the mechanisms of CSC development, therapy resistance and the potential of miRNAs as therapeutic targets for CRC. It emphasizes the promise of miRNAs as a novel approach to CRC treatment and calls for further research to explore effective miRNA-based therapies and strategies for delivering miRNAs to CSCs in vivo.
C1 [Osei, George Yiadom; Ahmad, Muhammad Khairi; Razak, Siti Razila Abdul] Univ Sains Malaysia, Adv Med & Dent Inst, Dept Biomed Sci, Kepala Batas 13200, Pulau Pinang, Malaysia.
   [Osei, George Yiadom; Koomson, Selina; Beletaa, Solomon; Asiamah, Emmanuel Akomanin; Smith-Togobo, Cecilia] Univ Hlth & Allied Sci, Dept Med Lab Sci, PMB 31, Ho, Ghana.
   [Adu-Amankwaah, Joseph] Xuzhou Med Univ, Dept Physiol, Xuzhou, Peoples R China.
   [Asiamah, Emmanuel Akomanin] Univ KwaZulu Natal, Sch Nursing & Publ Hlth, Discipline Publ Hlth Med, ZA-4001 Durban, South Africa.
   [Asiamah, Emmanuel Akomanin] Univ KwaZulu Natal, Coll Hlth Sci, Canc & Infect Dis Epidemiol Res Unit CIDERU, ZA-4001 Durban, South Africa.
C3 Universiti Sains Malaysia; Xuzhou Medical University; University of
   Kwazulu Natal; University of Kwazulu Natal
RP Razak, SRA (corresponding author), Univ Sains Malaysia, Adv Med & Dent Inst, Dept Biomed Sci, Kepala Batas 13200, Pulau Pinang, Malaysia.
EM sitirazila@usm.my
RI ASIAMAH, EMMANUEL/CAA-5947-2022; Adu-Amankwaah, Joseph/ABE-2833-2021;
   Ahmad, Muhammad Khairi/ACS-0612-2022; Osei, George Yiadom/GQP-8514-2022;
   Abdul Razak, Siti Razila/R-2298-2016
OI Osei, George Yiadom/0000-0002-8378-0959; Koomson,
   Selina/0009-0009-5742-6508; ADU-AMANKWAAH, JOSEPH/0000-0003-2155-0864;
   ASIAMAH, EMMANUEL/0000-0001-7910-3704; Abdul Razak, Siti
   Razila/0000-0003-1398-7652
FU Universiti Sains Malaysia [1001/CIPPT.8012325]; Graduate Fellowship [USM
   1/2022]
FX This work was funded by a Research University Grant (1001/CIPPT.8012325)
   by the Universiti Sains Malaysia. The first author was funded by the
   Graduate Fellowship USM 1/2022. The authors have no financial
   involvement with any organization or entity with a financial interest in
   or financial conflict with the subject matter or materials discussed in
   the manuscript. This includes employment, consultancies, honoraria,
   stock ownership or options, expert testimony, grants or patents received
   or pending or royalties.
CR Akbarzadeh M, 2019, J CELL PHYSIOL, V234, P14759, DOI 10.1002/jcp.28271
   Ashley N, 2013, CANCER RES, V73, P5798, DOI 10.1158/0008-5472.CAN-13-0454
   Bamodu OA, 2018, CANCERS, V10, DOI 10.3390/cancers10080269
   Bhatti GK, 2021, METAB BRAIN DIS, V36, P1119, DOI 10.1007/s11011-021-00739-y
   Bi WP, 2018, ONCOL LETT, V15, P8744, DOI 10.3892/ol.2018.8364
   Butler SJ, 2017, BIOCHEM BIOPH RES CO, V490, P29, DOI 10.1016/j.bbrc.2017.05.176
   Cai MH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0836-x
   Chen BH, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317715155
   Chen JX, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2361-z
   Chen LY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01272-9
   Chen Q, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152872
   Chen Z, 2021, EVID-BASED COMPL ALT, V2021, DOI 10.1155/2021/2134942
   Christy L, 2022, CELL PHYSIOL BIOCHEM, V56, P436, DOI 10.33594/000000562
   Das PK, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061392
   Ding T, 2018, MOL THER NUCL ACIDS, V13, P244, DOI 10.1016/j.omtn.2018.09.004
   Ebrahimi N, 2023, CRIT REV ONCOL HEMAT, V182, DOI 10.1016/j.critrevonc.2023.103920
   Fu R, 2020, BIOCHEM BIOPH RES CO, V531, P465, DOI 10.1016/j.bbrc.2020.08.019
   Geng YT, 2019, CLIN SCI, V133, P1197, DOI 10.1042/CS20190286
   Goto S, 2020, STEM CELLS INT, V2020, DOI 10.1155/2020/8868849
   He JH, 2018, CELL PHYSIOL BIOCHEM, V49, P1539, DOI 10.1159/000493457
   Hu YB, 2019, ONCOGENE, V38, P1951, DOI 10.1038/s41388-018-0557-9
   Huang C, 2017, ONCOL REP, V37, P1637, DOI 10.3892/or.2017.5379
   Hussein GM, 2022, INT J BIOL MACROMOL, V219, P530, DOI 10.1016/j.ijbiomac.2022.07.253
   Hwang JH, 2020, INT J CANCER, V146, P2877, DOI 10.1002/ijc.32728
   Jiang SX, 2019, J CELL MOL MED, V23, P630, DOI 10.1111/jcmm.13968
   Jin YH, 2018, INT J BIOL MACROMOL, V117, P445, DOI 10.1016/j.ijbiomac.2018.05.151
   Lamichane BD, 2019, BIOCHEM BIOPH RES CO, V515, P600, DOI 10.1016/j.bbrc.2019.05.154
   Lee H, 2022, FEBS OPEN BIO, V12, P1523, DOI 10.1002/2211-5463.13438
   Lei X, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01488-9
   Li J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15146
   Lin XB, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0708-7
   Liu B, 2017, MOL CARCINOGEN, V56, P2669, DOI 10.1002/mc.22710
   Liu H, 2017, EUR REV MED PHARMACO, V21, P3193
   Liu HW, 2019, LIFE SCI, V221, P354, DOI 10.1016/j.lfs.2019.02.049
   Liu S, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-05111-1
   Lu WQ, 2017, ONCOTARGET, V8, P15242, DOI 10.18632/oncotarget.14839
   Lv L, 2019, EXP CELL RES, V385, DOI 10.1016/j.yexcr.2019.111597
   Mamoori A, 2019, GENE, V697, P165, DOI 10.1016/j.gene.2019.02.046
   Meng XM, 2018, ONCOTARGETS THER, V11, P1757, DOI 10.2147/OTT.S159093
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   Munz N, 2021, NON-CODING RNA, V7, DOI 10.3390/ncrna7020026
   Najafi S, 2023, J CANCER RES CLIN, V149, P2211, DOI 10.1007/s00432-022-04328-z
   Najafi S, 2022, INT J BIOL MACROMOL, V206, P939, DOI 10.1016/j.ijbiomac.2022.03.103
   Nedaeinia R, 2017, J CELL BIOCHEM, V118, P4129, DOI 10.1002/jcb.26047
   Pagotto S, 2022, CANCER GENE THER, V29, P4, DOI 10.1038/s41417-021-00298-5
   Pan Q, 2017, CANCER LETT, V392, P26, DOI 10.1016/j.canlet.2017.01.039
   Pathak S, 2023, CURR GENE THER, V23, P356, DOI 10.2174/1566523223666230418111613
   Pordel S, 2023, PATHOL RES PRACT, V249, DOI 10.1016/j.prp.2023.154729
   Reischmann N, 2020, ONCOGENE, V39, P6053, DOI 10.1038/s41388-020-01414-9
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Rouzbahani E, 2022, BIOMED PHARMACOTHER, V156, DOI 10.1016/j.biopha.2022.113906
   Ruis B, 2020, DNA REPAIR, V85, DOI 10.1016/j.dnarep.2019.102738
   Shaheen S, 2016, STEM CELL REV REP, V12, P492, DOI 10.1007/s12015-016-9664-6
   Sharapov MG, 2019, FREE RADICAL BIO MED, V134, P76, DOI 10.1016/j.freeradbiomed.2018.12.032
   Shirvani H, 2023, CELL SIGNAL, V101, DOI 10.1016/j.cellsig.2022.110504
   Silva VR, 2021, CANCER COMMUN, V41, P1275, DOI 10.1002/cac2.12235
   Slyskova J, 2018, NUCLEIC ACIDS RES, V46, P9537, DOI 10.1093/nar/gky764
   Song IS, 2021, REDOX BIOL, V48, DOI 10.1016/j.redox.2021.102190
   Stark VA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031424
   Sun C, 2017, WORLD J GASTROENTERO, V23, P1816, DOI 10.3748/wjg.v23.i10.1816
   Sun LH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65207-6
   Sun LN, 2019, THERANOSTICS, V9, P8409, DOI 10.7150/thno.36605
   Sur D, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.915226
   Tang HQ, 2020, EUR REV MED PHARMACO, V24, P7645, DOI 10.26355/eurrev_202007_22265
   Thapa P, 2023, ANTIOXIDANTS-BASEL, V12, DOI 10.3390/antiox12030677
   Vassalli G, 2019, STEM CELLS INT, V2019, DOI 10.1155/2019/3904645
   Wang LQ, 2018, MOL ONCOL, V12, P1949, DOI 10.1002/1878-0261.12376
   Wang X, 2021, CANCER CELL INT, V21, DOI 10.1186/s12935-021-02058-9
   Wang XY, 2020, MOL ONCOL, V14, P539, DOI 10.1002/1878-0261.12629
   Weng WH, 2018, ONCOL LETT, V16, P6188, DOI 10.3892/ol.2018.9408
   WHO, 2023, CANC FACTSH
   Wu FX, 2019, INT J ONCOL, V55, P671, DOI 10.3892/ijo.2019.4852
   Wu Ning, 2018, Oncotarget, V9, P8887, DOI 10.18632/oncotarget.22322
   Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5
   Yang Y, 2017, INT J ONCOL, V51, P515, DOI 10.3892/ijo.2017.4044
   Zhang LY, 2018, CELL PHYSIOL BIOCHEM, V47, P1432, DOI 10.1159/000490834
   Zhao Q, 2021, PLOS COMPUT BIOL, V17, DOI 10.1371/journal.pcbi.1009291
   Zhou CH, 2020, CANCER BIOL THER, V21, P790, DOI 10.1080/15384047.2020.1761238
   Zhou H, 2020, J CELL BIOCHEM, V121, P2510, DOI 10.1002/jcb.29473
   Zhou HM, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00430-1
NR 80
TC 3
Z9 3
U1 2
U2 7
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1479-6694
EI 1744-8301
J9 FUTURE ONCOL
JI Future Oncol.
PD NOV
PY 2023
VL 19
IS 35
BP 2369
EP 2382
DI 10.2217/fon-2023-0426
EA NOV 2023
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA Y4QZ1
UT WOS:001102200800001
PM 37970643
DA 2025-01-04
ER

PT J
AU Nikolaou, S
   Qiu, SY
   Fiorentino, F
   Rasheed, S
   Tekkis, P
   Kontovounisios, C
AF Nikolaou, Stella
   Qiu, Shengyang
   Fiorentino, Francesca
   Rasheed, Shahnawaz
   Tekkis, Paris
   Kontovounisios, Christos
TI The prognostic and therapeutic role of hormones in colorectal cancer: a
   review
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Review
DE Colorectal; Cancer; Hormones; Prognosis; Treatment
ID ADIPONECTIN LEVELS; NEUROKININ-1 RECEPTOR; CLINICAL-SIGNIFICANCE; PLASMA
   ADIPONECTIN; CYCLASE-C; EXPRESSION; COLON; GROWTH; TARGET; RISK
AB Colorectal cancer (CRC) is one of the commonest cancers in Western society with a poor prognosis in patients with advanced disease. Targeted therapy is of increasing interest and already, targeted hormone treatment for breast and prostate cancer has improved survival. The aim of this literature review is to summarise the role of hormones in CRC prognosis and treatment. A literature review of all human and animal in vivo and in vitro studies in the last 20 years, which assessed the role of hormones in CRC treatment or prognosis, was carried out. The hormones described in this review have been subdivided according to their secretion origin. Most of the studies are based on in vitro or animal models. The main findings point to adipokines, insulin and the insulin growth factor axis as key players in the link between obesity, type 2 diabetes mellitus and a subset of CRC. Gut-derived hormones, especially uroguanylin and guanylin are being increasingly investigated as therapeutic targets, with promising results. Using hormones as prognostic and therapeutic markers in CRC is still in the preliminary stages for only a fraction of the hormones affecting the GIT. In light of the increasing interest in tailoring treatment strategies, hormones are an important area of focus in the future of CRC management.
C1 [Nikolaou, Stella; Qiu, Shengyang; Rasheed, Shahnawaz; Tekkis, Paris; Kontovounisios, Christos] Chelsea & Westminster Hosp, Dept Colorectal Surg, London, England.
   [Nikolaou, Stella; Rasheed, Shahnawaz; Tekkis, Paris; Kontovounisios, Christos] Royal Marsden Hosp, Dept Colorectal Surg, London, England.
   [Nikolaou, Stella; Qiu, Shengyang; Fiorentino, Francesca; Rasheed, Shahnawaz; Tekkis, Paris; Kontovounisios, Christos] Imperial Coll, Dept Surg & Canc, London, England.
   [Nikolaou, Stella] Imperial Coll London, Royal Marsden Hosp, Dept Surg & Canc, Fulham Rd & Chelsea & Westminster Campus, London SW10 9NH, England.
C3 Imperial College London; Royal Marsden NHS Foundation Trust; Imperial
   College London; Imperial College London; Royal Marsden NHS Foundation
   Trust
RP Nikolaou, S (corresponding author), Chelsea & Westminster Hosp, Dept Colorectal Surg, London, England.; Nikolaou, S (corresponding author), Royal Marsden Hosp, Dept Colorectal Surg, London, England.; Nikolaou, S (corresponding author), Imperial Coll, Dept Surg & Canc, London, England.; Nikolaou, S (corresponding author), Imperial Coll London, Royal Marsden Hosp, Dept Surg & Canc, Fulham Rd & Chelsea & Westminster Campus, London SW10 9NH, England.
EM sn702@ic.ac.uk; S.qiu@imperial.ac.uk; f.fiorentino@imperial.ac.uk;
   s.rasheed@imperial.ac.uk; p.tekkis@imperial.ac.uk;
   c.kontovounisios@imperial.ac.uk
RI Kontovounisios, Christos/ABC-9225-2020
OI Fiorentino, Francesca/0000-0001-9817-6634; KONTOVOUNISIOS,
   CHRISTOS/0000-0002-1828-1395
CR Aka AA, 2017, EXPERT REV CLIN PHAR, V10, P549, DOI 10.1080/17512433.2017.1292124
   Akter H, 2018, MOL CELLS
   Almhanna K, 2016, CLIN CANCER RES, V22, P5049, DOI 10.1158/1078-0432.CCR-15-2474
   Alsubai J, 2016, CLIN TRANSL GASTROEN, V7, DOI 10.1038/ctg.2015.61
   Amos-Landgraf JM, 2014, P NATL ACAD SCI USA, V111, P16514, DOI 10.1073/pnas.1323064111
   [Anonymous], 2017, GASTROENTEROL RES PR, DOI DOI 10.1155/2017/6456257
   Ayyildiz T, 2014, ASIAN PAC J CANCER P, V15, P9385, DOI 10.7314/APJCP.2014.15.21.9385
   Baratto L, 2017, MOL IMAGING BIOL
   Bråkenhielm E, 2004, P NATL ACAD SCI USA, V101, P2476, DOI 10.1073/pnas.0308671100
   Bredt LC, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-391
   Brenner H, 2007, BRIT J CANCER, V96, P828, DOI 10.1038/sj.bjc.6603628
   Canhoroz M, 2014, J CANCER RES THER, V10, P347, DOI 10.4103/0973-1482.136634
   Chen JZ, 2012, CANCER CAUSE CONTROL, V23, P1767, DOI 10.1007/s10552-012-0066-z
   Chen XY, 2016, ONCOTARGETS THER, V9, P3595, DOI 10.2147/OTT.S102356
   Choe EK, 2018, J SURG ONCOL
   Chong DQ, 2015, CANCER PREV RES, V8, P1138, DOI 10.1158/1940-6207.CAPR-15-0175
   Chueca E, 2012, WORLD J GASTROENTERO, V18, P6560, DOI 10.3748/wjg.v18.i45.6560
   Darban SA, 2018, COLLOID SURFACE B, V164, P107, DOI 10.1016/j.colsurfb.2018.01.035
   DO C, 2012, PHILADELPHIA, V5, P675, DOI DOI 10.1158/1940-6207.CAPR-11-0408
   Duan BS, 2017, CANCER GENOM PROTEOM, V14, P277, DOI 10.21873/cgp.20038
   Endo H, 2011, GUT, V60, P1363, DOI 10.1136/gut.2010.235754
   Evangelou I, 2012, EUR J CLIN INVEST, V42, P777, DOI 10.1111/j.1365-2362.2012.02648.x
   Falciani C, 2011, CHEMMEDCHEM, V6, P678, DOI 10.1002/cmdc.201000463
   Ferrand A, 2005, CANCER RES, V65, P2770, DOI 10.1158/0008-5472.CAN-04-0978
   Ferroni P, 2007, ANTICANCER RES, V27, P483
   Foster PA, 2013, INT J COLORECTAL DIS, V28, P737, DOI 10.1007/s00384-012-1628-y
   Fujisawa T, 2008, GUT, V57, P1531, DOI 10.1136/gut.2008.159293
   Gallery M, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0191046
   Garnier A, 2015, INT J ONCOL, V47, P151, DOI 10.3892/ijo.2015.3016
   Gialamas SP, 2011, METABOLISM, V60, P1530, DOI 10.1016/j.metabol.2011.03.020
   Gillessen S, 2010, J NATL CANCER I, V102, P1760, DOI 10.1093/jnci/djq419
   Gonullu G, 2010, INT J COLORECTAL DIS, V25, P205, DOI 10.1007/s00384-009-0828-6
   GU S, MOL MED, V17, P48, DOI DOI 10.2119/MOLMED.2010.00120
   Guadagni F, 2009, ANTICANCER RES, V29, P3321
   Gui XY, 2008, PEPTIDES, V29, P1609, DOI 10.1016/j.peptides.2008.04.014
   Hernandez ME, 2014, NANOMED-NANOTECHNOL, V10, P745, DOI 10.1016/j.nano.2013.11.013
   Höpfner M, 2006, WORLD J GASTROENTERO, V12, P5635
   Jeong WK, 2015, ANN COLOPROCTOL, V31, P222, DOI 10.3393/ac.2015.31.6.222
   Kamimae S, 2015, ONCOTARGET, V6, P29975, DOI 10.18632/oncotarget.5034
   Kawashima K, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040866
   Kim AY, 2010, MOL ENDOCRINOL, V24, P1441, DOI 10.1210/me.2009-0498
   LEE J, 2014, LEEJ J, V9, DOI DOI 10.1371/JOURNAL.PONE.0103551
   Liu A, 2016, CANCER MED-US, V5, P2417, DOI 10.1002/cam4.723
   Liu Q, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0654-3
   Lochhead P, 2012, EUR J CANCER, V48, P3405, DOI 10.1016/j.ejca.2012.06.021
   Louie MC, 2017, AM J CANCER RES, V7, P1617
   Magee MS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1227897
   Malih S, 2015, TUMOR BIOL, V36, P6673, DOI 10.1007/s13277-015-3911-3
   Muppala S, 2017, CRIT REV ONCOL HEMAT, V116, P125, DOI 10.1016/j.critrevonc.2017.06.003
   Najib S, 2015, ONCOGENE, V34, P3120, DOI 10.1038/onc.2014.255
   Nigro E, 2018, MOL CELL BIOCH
   Paik KY, 2014, CANCER RES TREAT, V46, P65, DOI 10.4143/crt.2014.46.1.65
   Parks M, 2011, MOL CELL ENDOCRINOL, V331, P119, DOI 10.1016/j.mce.2010.08.017
   Perry JK, 2017, TRENDS ENDOCRIN MET, V28, P587, DOI 10.1016/j.tem.2017.05.003
   Pitari GM, 2001, P NATL ACAD SCI USA, V98, P7846, DOI 10.1073/pnas.141124698
   Rehfeld JF, 2015, SCAND J GASTROENTERO, V50, P668, DOI 10.3109/00365521.2015.1025831
   Renehan AG, 2006, TRENDS ENDOCRIN MET, V17, P328, DOI 10.1016/j.tem.2006.08.006
   Riondino S, 2014, WORLD J GASTROENTERO, V20, P5177, DOI 10.3748/wjg.v20.i18.5177
   Rivera CA, 2009, CLIN EXP METASTAS, V26, P663, DOI 10.1007/s10585-009-9265-8
   Ronnekleiv-Kelly SM, 2016, SURG ONCOL, V25, P190, DOI 10.1016/j.suronc.2016.05.018
   Roshan MHK, 2016, EPMA J, V7, DOI 10.1186/s13167-016-0071-5
   Rouet-Benzineb R, 2004, J BIOL CHEM, V279, P16495, DOI 10.1074/jbc.M312999200
   Sakellariou S, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2213-5
   Sanchez-Lopez E, 2016, ONCOGENE, V35, P2634, DOI 10.1038/onc.2015.326
   Sclafani F, 2017, INT J CANCER, V140, P431, DOI 10.1002/ijc.30453
   Snook A., 2015, Journal for immunotherapy of cancer, V3, pP450, DOI DOI 10.1186/2051-1426-3-S2-P450
   Stevanato Filho PR, 2017, PATHOL ONCOL RES, V05, P5
   Szepeshazi K, 2002, CANCER RES, V62, P781
   Tamakoshi K, 2005, ONCOLOGY-BASEL, V68, P454, DOI 10.1159/000086988
   Tripathi S, 2015, BMC SYST BIOL, V9, DOI 10.1186/s12918-015-0181-z
   Uddin S, 2009, CARCINOGENESIS, V30, P1832, DOI 10.1093/carcin/bgp145
   Uribe DJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179979
   Wang D, 2012, J BIOSCIENCES, V37, P91, DOI 10.1007/s12038-011-9172-4
   Wang J. J., 2017, ONCOTARGET, V8
   Waseem T, 2008, PEPTIDES, V29, P1369, DOI 10.1016/j.peptides.2008.03.020
   Wei EK, 2005, JNCI-J NATL CANCER I, V97, P1688, DOI 10.1093/jnci/dji376
   Zabeau L, 2012, BIOCHEM J, V441, P425, DOI 10.1042/BJ20110438
   Zhou WQ, 2014, EXPERT OPIN THER TAR, V18, P961, DOI 10.1517/14728222.2014.926889
NR 78
TC 15
Z9 16
U1 0
U2 8
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD FEB
PY 2019
VL 46
IS 1
BP 1477
EP 1486
DI 10.1007/s11033-018-4528-6
PG 10
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HP9OI
UT WOS:000462022300146
PM 30535551
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Cheng, KJ
   Mohammed, EHM
   Khong, TL
   Zain, SM
   Thavagnanam, S
   Ibrahim, ZA
AF Cheng, Kim Jun
   Mohammed, Elsa Haniffah Mejia
   Khong, Tak Loon
   Zain, Shamsul Mohd
   Thavagnanam, Surendran
   Ibrahim, Zaridatul Aini
TI IL-1α and colorectal cancer pathogenesis: Enthralling candidate for
   anti-cancer therapy
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Review
DE Colorectal cancer; Interleukin-1 alpha; DAMP; Inflammation; Metastasis;
   Cancer; Cytokine; Targeted therapy
ID NF-KAPPA-B; GROWTH-FACTOR RECEPTOR-2; COLON-CANCER; INSERTION/DELETION
   POLYMORPHISM; THYMIDINE PHOSPHORYLASE; DIHYDROPYRIMIDINE DEHYDROGENASE;
   CELLULAR-TRANSFORMATION; MIRNA-122-BINDING SITE; INTERLEUKIN-1 FAMILY;
   SYNTHASE EXPRESSION
AB Inflammation has been well-established as a hallmark of colorectal cancer (CRC). Interleukin-1 alpha (IL-1 alpha) is one of the primary inflammatory mediators driving the pathogenesis of inflammation-associated CRC. This systematic review presents the roles of IL-1 alpha in the pathogenesis of the disease. Bibliographic databases PubMed, Science Direct, Scopus and Web of Science were systematically searched for articles that addresses the relationship between IL-1 alpha and colorectal cancer. We highlighted various mechanisms by which IL-1 alpha promotes the pathogenesis of CRC including enhancement of angiogenesis, metastasis, resistance to therapy, and inhibition of tumour suppressive genes. We also discussed the potential mechanisms by which IL-1 alpha expression is induced or secreted in various studies. Beyond these, the systematic review also highlights several potential therapeutic strategies which should be further explored in the future; to target IL-1 alpha and/or its associated pathways; paving our way in finding effective treatments for CRC patients.
C1 [Cheng, Kim Jun; Mohammed, Elsa Haniffah Mejia; Zain, Shamsul Mohd; Ibrahim, Zaridatul Aini] Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia.
   [Khong, Tak Loon] Univ Malaya, Fac Med, Dept Surg, Kuala Lumpur 50603, Malaysia.
   [Thavagnanam, Surendran] Royal London Hosp, Dept Paediat, Whitechapel Rd, London E1 1FR, England.
C3 Universiti Malaya; Universiti Malaya; Barts Health NHS Trust; Royal
   London Hospital
RP Ibrahim, ZA (corresponding author), Univ Malaya, Fac Med, Dept Pharmacol, Kuala Lumpur 50603, Malaysia.
EM zaridatulaini@ummc.edu.my
RI Khong, Tak/S-4746-2017; Zain, Shamsul Mohd/U-8718-2019; Ibrahim,
   Zaridatul Aini/N-2626-2017; Cheng, Kim/AAI-3162-2020; MOHAMED,
   ELSA/B-8451-2010; Zain, Shamsul Mohd/N-6995-2013
OI Zain, Shamsul Mohd/0000-0002-3441-6659; Cheng, Kim
   Jun/0000-0001-9663-0629; Khong, Tak Loon/0000-0001-9277-1459; Mejia
   Mohamed, Elsa Haniffah/0000-0001-5091-2970
FU Universiti Malaya Faculty Research Grant [GPF006C-2019]
FX This work was supported by the Universiti Malaya Faculty Research Grant
   (Grant No: GPF006C-2019).
CR Akao Y, 2006, BIOL PHARM BULL, V29, P903, DOI 10.1248/bpb.29.903
   Al-Halabi R, 2011, CANCER BIOL THER, V12, P59, DOI 10.4161/cbt.12.1.15715
   Allavena P, 2008, CURR OPIN GENET DEV, V18, P3, DOI 10.1016/j.gde.2008.01.003
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   ATKINS E, 1984, J INFECT DIS, V149, P339, DOI 10.1093/infdis/149.3.339
   Atreya I, 2008, J INTERN MED, V263, P591, DOI 10.1111/j.1365-2796.2008.01953.x
   Atreya I, 2008, EXPERT REV ANTICANC, V8, P561, DOI 10.1586/14737140.8.4.561
   Awada A, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2504
   Bauvois B, 2012, BBA-REV CANCER, V1825, P29, DOI 10.1016/j.bbcan.2011.10.001
   BEESON PB, 1948, J CLIN INVEST, V27, P524
   Bendardaf R, 2017, LIBYAN J MED, V12, DOI 10.1080/19932820.2017.1290741
   Bendardaf R, 2008, ANTICANCER RES, V28, P3865
   Bersudsky M, 2014, GUT, V63, P598, DOI 10.1136/gutjnl-2012-303329
   Bie YQ, 2019, DIS MARKERS, V2019, DOI 10.1155/2019/8023460
   Bijnsdorp IV, 2010, BIOCHEM PHARMACOL, V80, P786, DOI 10.1016/j.bcp.2010.05.009
   Bivona TG, 2016, NAT MED, V22, P472, DOI 10.1038/nm.4091
   Braicu C, 2019, CANCERS, V11, DOI 10.3390/cancers11101618
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Chang CM, 2019, CANCERS, V11, DOI 10.3390/cancers11040489
   Chen YQ, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-08047-1
   Chiang GG, 2007, TRENDS MOL MED, V13, P433, DOI 10.1016/j.molmed.2007.08.001
   Choi S, 2015, ONCOTARGET, V6, P3874, DOI 10.18632/oncotarget.2885
   Cianchi F, 2003, AM J PATHOL, V162, P793, DOI 10.1016/S0002-9440(10)63876-X
   Coussens LM, 2002, NATURE, V420, P860, DOI 10.1038/nature01322
   Dabkeviciene D, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0703-y
   Dinarello CA, 1996, BLOOD, V87, P2095, DOI 10.1182/blood.V87.6.2095.bloodjournal8762095
   Dinarello CA, 2018, IMMUNOL REV, V281, P5, DOI 10.1111/imr.12624
   Dominici R, 2002, IMMUNOGENETICS, V54, P82, DOI 10.1007/s00251-002-0445-9
   DORUDI S, 1993, AM J PATHOL, V142, P981
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Friis S, 2015, ANN INTERN MED, V163, P347, DOI 10.7326/M15-0039
   Gao LB, 2014, TUMOR BIOL, V35, P3861, DOI 10.1007/s13277-013-1512-6
   Gao YZ, 2009, CARCINOGENESIS, V30, P2064, DOI 10.1093/carcin/bgp283
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Gavert N, 2010, J CELL SCI, V123, P2134, DOI 10.1242/jcs.069542
   Gelfo V, 2018, CANCERS, V10, DOI 10.3390/cancers10100355
   Gelfo V, 2016, ONCOTARGET, V7, P72167, DOI 10.18632/oncotarget.12354
   GEOFFROY FJ, 1994, ONCOL RES, V6, P581
   Gottardi CJ, 2001, J CELL BIOL, V153, P1049, DOI 10.1083/jcb.153.5.1049
   Greten FR, 2007, CELL, V130, P918, DOI 10.1016/j.cell.2007.07.009
   Grigaitis P, 2019, CYTOKINE, V114, P38, DOI 10.1016/j.cyto.2018.11.031
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   HANAUSKE AR, 1992, J IMMUNOTHER, V11, P155, DOI 10.1097/00002371-199204000-00001
   Hansen-Algenstaedt N, 2000, CANCER RES, V60, P4556
   Hata AN, 2004, PHARMACOL THERAPEUT, V103, P147, DOI 10.1016/j.pharmthera.2004.06.003
   Hayashi T, 2008, HEPATO-GASTROENTEROL, V55, P403
   Hickish T, 2017, LANCET ONCOL, V18, P192, DOI 10.1016/S1470-2045(17)30006-2
   Hillenbrand A, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-545
   Holmes K, 2007, CELL SIGNAL, V19, P2003, DOI 10.1016/j.cellsig.2007.05.013
   Hong DS, 2014, LANCET ONCOL, V15, P656, DOI 10.1016/S1470-2045(14)70155-X
   Huang J, 2015, GENET TEST MOL BIOMA, V19, P331, DOI 10.1089/gtmb.2015.0015
   Huynh N, 2010, BBA-MOL CELL RES, V1803, P1106, DOI 10.1016/j.bbamcr.2010.05.007
   Isambert N, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1474319
   Jaiswal M, 2000, CANCER RES, V60, P184
   Ji H, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5395-9
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kawaguchi Y, 2007, IMMUNOGENETICS, V59, P441, DOI 10.1007/s00251-007-0213-y
   Kim B, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00391
   Kim YH, 2019, J GASTROEN HEPATOL, V34, P544, DOI 10.1111/jgh.14526
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kumar MS, 2007, NAT GENET, V39, P673, DOI 10.1038/ng2003
   Kurzrock R, 2019, ONCOIMMUNOLOGY, V8, DOI 10.1080/2162402X.2018.1551651
   Kwon MJ, 2014, BIOCHEM BIOPH RES CO, V446, P487, DOI 10.1016/j.bbrc.2014.02.142
   Lakatos PL, 2008, WORLD J GASTROENTERO, V14, P3937, DOI 10.3748/wjg.14.3937
   Lamkanfi M, 2014, CELL, V157, P1013, DOI 10.1016/j.cell.2014.04.007
   Langenskiöld M, 2005, INT J COLORECTAL DIS, V20, P245, DOI 10.1007/s00384-004-0667-4
   Lee YS, 2012, BRIT J CANCER, V106, P1833, DOI 10.1038/bjc.2012.177
   Lind DS, 2001, SURGERY, V130, P363, DOI 10.1067/msy.2001.116672
   Ma QZ, 2018, INT J BIOL MARKER, V33, P401, DOI 10.1177/1724600818785069
   Maggio-Price L, 2006, CANCER RES, V66, P828, DOI 10.1158/0008-5472.CAN-05-2448
   Malik A, 2016, J CLIN INVEST, V126, P4469, DOI 10.1172/JCI88625
   Marnett LJ, 2000, CARCINOGENESIS, V21, P361, DOI 10.1093/carcin/21.3.361
   Matsuo Y, 2009, J SURG ONCOL, V99, P361, DOI 10.1002/jso.21245
   Medzhitov R, 2008, NATURE, V454, P428, DOI 10.1038/nature07201
   Mousa Shaker A., 1998, Drugs of the Future, V23, P51, DOI 10.1358/dof.1998.023.01.858340
   Nakayama Y, 2005, ANTICANCER RES, V25, P3755
   Naldini Antonella, 2005, Current Drug Targets - Inflammation and Allergy, V4, P3, DOI 10.2174/1568010053622830
   Nam KS, 2007, J MICROBIOL BIOTECHN, V17, P2042
   Nam KS, 2015, ONCOL LETT, V9, P483, DOI 10.3892/ol.2014.2660
   Okegawa T, 2002, J UROLOGY, V167, P1836, DOI 10.1016/S0022-5347(05)65245-7
   Parang B, 2016, METHODS MOL BIOL, V1422, P297, DOI 10.1007/978-1-4939-3603-8_26
   Rachiglio A.M., 2019, CANCERS BASEL, V11
   Rhim JH, 2008, J CANCER RES CLIN, V134, P45, DOI 10.1007/s00432-007-0243-8
   Sakamoto K, 2009, CLIN CANCER RES, V15, P2248, DOI 10.1158/1078-0432.CCR-08-1383
   Seeliger H, 2004, CLIN CANCER RES, V10, P1843, DOI 10.1158/1078-0432.CCR-1176-3
   Semenza GL, 2003, NAT REV CANCER, V3, P721, DOI 10.1038/nrc1187
   Shao JY, 2007, J IMMUNOL, V178, P4097, DOI 10.4049/jimmunol.178.7.4097
   Sheng HM, 1998, CARCINOGENESIS, V19, P543, DOI 10.1093/carcin/19.4.543
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Spalinger MR, 2018, CELL REP, V22, P1835, DOI 10.1016/j.celrep.2018.01.052
   Subramaniam S, 2004, DEV COMP IMMUNOL, V28, P415, DOI 10.1016/j.dci.2003.09.016
   TAKEBAYASHI Y, 1995, CANCER LETT, V95, P57, DOI 10.1016/0304-3835(95)03865-T
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Tjomsland V, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0400-5
   Urosevic J, 2014, NAT CELL BIOL, V16, P685, DOI 10.1038/ncb2977
   Viswanathan SR, 2009, NAT GENET, V41, P843, DOI 10.1038/ng.392
   Voboril R, 2006, NEOPLASMA, V53, P518
   Waldner Maximilian J., 2008, Inflammation & Allergy Drug Targets, V7, P187, DOI 10.2174/187152808785748137
   Wang JC, 2015, ONCOTARGET, V6, P42825, DOI 10.18632/oncotarget.5739
   Weber A, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.3105cm1
   Xia HR, 2019, ARTIF CELL NANOMED B, V47, P3138, DOI 10.1080/21691401.2019.1646750
   Xie JL, 2008, WORLD J GASTROENTERO, V14, P378, DOI 10.3748/wjg.14.378
   Xu ZB, 2019, ONCOTARGETS THER, V12, P11255, DOI 10.2147/OTT.S216829
   Yan H, 2015, GENET MOL RES, V14, P8490, DOI 10.4238/2015.July.28.17
   Yang Y, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0552-3
   Yang ZH, 2011, MOL CARCINOGEN, V50, P208, DOI 10.1002/mc.20706
   Yoshikawa T, 2017, GASTROENTEROLOGY, V152, P631, DOI 10.1053/j.gastro.2016.10.043
   Zeng XF, 2014, TUMOR BIOL, V35, P265, DOI 10.1007/s13277-013-1034-2
   Zhang Z, 2014, FAM CANCER, V13, P595, DOI 10.1007/s10689-014-9739-y
   Zhuo CH, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180580
NR 111
TC 12
Z9 13
U1 3
U2 16
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD JUL
PY 2021
VL 163
AR 103398
DI 10.1016/j.critrevonc.2021.103398
EA JUN 2021
PG 13
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA TG3FO
UT WOS:000671294100008
PM 34147647
DA 2025-01-04
ER

PT J
AU Li, GD
   Liu, JG
AF Li, Guodong
   Liu, Jiangang
TI RETRACTED: Analysis of Efficacy, Safety, and Prognostic Factors of
   mFOLFOX6 Regimen Combined with Cetuximab and Simvastatin in the
   Treatment of K-RAS Mutant Colorectal Cancer (Retracted Article)
SO EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE
LA English
DT Article; Retracted Publication
ID EGFR THERAPY; BEVACIZUMAB; PROGRESSION; RADIATION; SURVIVAL; FOLFIRI
AB Colorectal cancer (CRC) is one of the most common malignant tumors with high morbidity and mortality. The early symptoms are latent, and most patients are in the middle or late stage when they are diagnosed. The best opportunity for surgery has been lost, and surgical resection has failed to achieve good results. In clinical practice, targeted therapy or chemotherapy is usually the main treatment. The mFOLFOX6 regimen is a standardized regimen for the treatment of advanced CRC. The main drugs in this regimen are oxaliplatin and 5-fluorouracil (5-FU). Patients with advanced CRC combined with standard chemotherapy regimens can achieve a higher resection rate of liver metastases in unresectable patients, which can achieve significant survival improvement. Therefore, in this study, oxaliplatin + calcium folinate + 5-Fu + mFOLFOX6 regimen was combined with cetuximab and simvastatin to treat CRC patients, and the clinical efficacy and prognosis were analyzed, as well as the prognostic factors. The results showed that the addition of simvastatin on the basis of conventional mFOLFOX6 regimen combined with cetuximab chemotherapy could effectively improve the efficacy, reduce the total incidence of adverse reactions, improve the overall survival rate, and prolong the overall survival time of patients. Pathological grade and peritoneal metastasis were the factors affecting the mean survival time of CRC patients.
C1 [Li, Guodong; Liu, Jiangang] Shandong First Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Tai An 271021, Shandong, Peoples R China.
C3 Shandong First Medical University & Shandong Academy of Medical Sciences
RP Liu, JG (corresponding author), Shandong First Med Univ, Affiliated Hosp 2, Dept Gastrointestinal Surg, Tai An 271021, Shandong, Peoples R China.
EM jiangangliu517@163.com
CR Carlson RW, 2014, J NATL COMPR CANC NE, V12, P643, DOI 10.6004/jnccn.2014.0068
   Connell LC, 2017, CURR TREAT OPTION ON, V18, DOI 10.1007/s11864-017-0463-3
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Heinimann K, 2018, THER UMSCH, V75, P601, DOI 10.1024/0040-5930/a001046
   Jin KT, 2020, INT IMMUNOPHARMACOL, V89, DOI 10.1016/j.intimp.2020.107041
   Karagkounis G, 2018, SURG ENDOSC, V32, P1533, DOI 10.1007/s00464-017-5841-1
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Ketzer S, 2018, CLIN PHARMACOKINET, V57, P455, DOI 10.1007/s40262-017-0590-9
   Kucukoner M, 2019, J BUON, V24, P1501
   Lawan A I, 2020, West Afr J Med, V37, P100
   Lee J, 2011, JNCI-J NATL CANCER I, V103, P674, DOI 10.1093/jnci/djr070
   Lee JH, 2019, IN VIVO, V33, P447, DOI 10.21873/invivo.11493
   Lim T, 2015, INT J RADIAT ONCOL, V93, P316, DOI 10.1016/j.ijrobp.2015.05.023
   Liu YC, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110319
   Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007
   Mor E, 2021, ANN SURG ONCOL, V28, P3330, DOI 10.1245/s10434-020-09186-y
   Ng K, 2019, JAMA-J AM MED ASSOC, V321, P1370, DOI 10.1001/jama.2019.2402
   Patel Swati G, 2020, Gastrointest Endosc Clin N Am, V30, P441, DOI 10.1016/j.giec.2020.03.001
   Patel Swati G, 2018, Curr Gastroenterol Rep, V20, P15, DOI 10.1007/s11894-018-0618-9
   Perrod G, 2021, DIGEST ENDOSC, V33, P520, DOI 10.1111/den.13702
   Rui YY, 2015, HEPATO-GASTROENTEROL, V62, P19
   SHIKE M, 1990, B WORLD HEALTH ORGAN, V68, P377
   Simard J, 2019, CURR TREAT OPTION ON, V20, DOI 10.1007/s11864-019-0635-4
   Song QB, 2015, WORLD J GASTROENTERO, V21, P4365, DOI 10.3748/wjg.v21.i14.4365
   Tang WT, 2020, J CLIN ONCOL, V38, P3175, DOI 10.1200/JCO.20.00174
   Uemura M, 2016, MOL CLIN ONCOL, V5, P375, DOI 10.3892/mco.2016.938
   Uhlyarik Andrea, 2020, Magy Onkol, V64, P32
   Van Cutsem E, 2019, J CLIN ONCOL, V37, P1460, DOI 10.1200/JCO.18.02459
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Voutsadakis IA, 2018, BIOMARK MED, V12, P653, DOI 10.2217/bmm-2017-0369
   Xu WD, 2016, FRONT BIOSCI-LANDMRK, V21, P410, DOI 10.2741/4397
   Yamazaki K, 2016, ANN ONCOL, V27, P1539, DOI 10.1093/annonc/mdw206
   Yilmaz N, 2020, BRATISL MED J, V121, P554, DOI 10.4149/BLL_2020_092
   Yuan Ying, 2010, Zhonghua Wai Ke Za Zhi, V48, P1247
NR 35
TC 4
Z9 4
U1 0
U2 6
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1741-427X
EI 1741-4288
J9 EVID-BASED COMPL ALT
JI Evid.-based Complement Altern. Med.
PD SEP 14
PY 2021
VL 2021
AR 2280440
DI 10.1155/2021/2280440
PG 7
WC Integrative & Complementary Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Integrative & Complementary Medicine
GA UW7XE
UT WOS:000700365900002
PM 34557254
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Rocha, MR
   Barcellos-de-Souza, P
   Sousa-Squiavinato, ACM
   Fernandes, P
   de Oliveira, IM
   Boroni, M
   Morgado-Diaz, JA
AF Rocha, Murilo R.
   Barcellos-de-Souza, Pedro
   Sousa-Squiavinato, Annie Cristhine M.
   Fernandes, Priscila, V
   de Oliveira, Ivanir M.
   Boroni, Mariana
   Morgado-Diaz, Jose A.
TI Annexin A2 overexpression associates with colorectal cancer invasiveness
   and TGF-β induced epithelial mesenchymal transition via Src/ANXA2/STAT3
SO SCIENTIFIC REPORTS
LA English
DT Article
ID PHENOTYPE; STAT3
AB Annexin A2 (ANXA2) is upregulated in several malignancies, including colorectal cancer (CRC). However, there is little knowledge on the molecular mechanisms involved to its upregulation. The aim of this study was to identify the mechanism through which ANXA2 overexpression leads to CRC progression and evaluate its potential prognostic value. We used human CRC samples to analyse the correlation between ANXA2 levels and tumour staging. ANXA2 expression was increased in CRC tissues compared to normal colon tissues. In addition, we observe increased ANXA2 levels in stage IV tumours and metastasis, when compared to stage I-III. Whereas E-cadherin, an epithelial marker, decreased in stage II-IV and increased in metastasis. We've also shown that TGF-beta, a classic EMT inductor, caused upregulation of ANXA2, and internalization of both E-cadherin and ANXA2 in CRC cells. ANXA2 silencing hindered TGF-beta-induced invasiveness, and inhibitors of the Src/ANXA2/STAT3 pathway reversed the EMT. In silico analysis confirmed overexpression of ANXA2 and association to the consensus moleculars subtypes (CMS) with the worst prognosis. Therefore, ANXA2 overexpression play a pivotal role in CRC invasiveness through Src/ANXA2/STAT3 pathway activation. The association of ANXA2 to distinct CMSs suggests the possible use of ANXA2 as a prognostic marker or directed target therapy.
C1 [Rocha, Murilo R.; Barcellos-de-Souza, Pedro; Sousa-Squiavinato, Annie Cristhine M.; Morgado-Diaz, Jose A.] INCA, Inst Nacl Canc, Cellular & Mol Oncobiol Program, Rua Andre Cavalcanti 37, BR-20231050 Rio De Janeiro, Brazil.
   [Fernandes, Priscila, V; de Oliveira, Ivanir M.] INCA, Pathol Div DIPAT, Inst Nacl Canc, Av Cordeiro Graca 156, BR-20220400 Rio De Janeiro, Brazil.
   [Boroni, Mariana] INCA, Bioinformat Unit, Inst Nacl Canc, Rua Andre Cavalcanti 37, BR-20231050 Rio De Janeiro, Brazil.
C3 National Cancer Institute (Inca); National Cancer Institute (Inca);
   National Cancer Institute (Inca)
RP Rocha, MR; Morgado-Diaz, JA (corresponding author), INCA, Inst Nacl Canc, Cellular & Mol Oncobiol Program, Rua Andre Cavalcanti 37, BR-20231050 Rio De Janeiro, Brazil.
EM rochamr.2@gmail.com; jmorgado@inca.gov.br
RI Boroni, Mariana/AAQ-2019-2020; Squiavinato, Annie/B-4823-2019;
   Morgado-Diaz, Jose/A-9649-2010; Ramos Rocha, Murilo/M-9489-2017;
   Barcellos-de-Souza, Pedro/E-4957-2017
OI Ramos Rocha, Murilo/0000-0001-5499-6374; Barcellos-de-Souza,
   Pedro/0000-0003-1903-5089; Squiavinato, Annie/0000-0003-0345-1571;
   Boroni, Mariana/0000-0003-3495-9917
FU Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq)
   [312570/2014-7]; Coordenacao de Aperfeicoamento de Pessoal de Nivel
   Superior (CAPES); Ministerio da Saude - Brasil; Fundacao Carlos Chagas
   Filho de Amparo a Pesquisa do Estado de Rio de Janeiro (FAPERJ)
   [E-26/201.290/2014]; Instituto Nacional de Ciencia e Tecnologia em
   Cancer [573806/2008-0, 170.026/2008]
FX This study was sponsored by the Conselho Nacional de Desenvolvimento
   Cientifico e Tecnologico (CNPq) (Grant 312570/2014-7), Coordenacao de
   Aperfeicoamento de Pessoal de Nivel Superior (CAPES), Ministerio da
   Saude - Brasil, Fundacao Carlos Chagas Filho de Amparo a Pesquisa do
   Estado de Rio de Janeiro (FAPERJ) (Grant E-26/201.290/2014), and
   Instituto Nacional de Ciencia e Tecnologia em Cancer (573806/2008-0 and
   170.026/2008). We are grateful to the Centro Nacional de Bioimagem
   (CENABIO) for the use of the super-resolution microscopy facility. This
   text was revised by Editage from Rockfeller University Press.
CR Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   Bai DS, 2016, ONCOTARGET, V7, P32946, DOI 10.18632/oncotarget.8783
   Chojnacka K, 2017, BBA-MOL CELL RES, V1864, P527, DOI 10.1016/j.bbamcr.2016.12.012
   Cui L, 2017, ONCOL LETT, V13, P377, DOI 10.3892/ol.2016.5406
   de Marcondes PG, 2016, TUMOR BIOL, V37, P12411, DOI 10.1007/s13277-016-5120-0
   Bastos LGD, 2014, J CELL BIOCHEM, V115, P2175, DOI 10.1002/jcb.24896
   Gerke V, 2002, PHYSIOL REV, V82, P331, DOI 10.1152/physrev.00030.2001
   Gerke V, 2016, BIOL CHEM, V397, P995, DOI 10.1515/hsz-2016-0207
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Huang D, 2017, FRONT MED-PRC, V11, P410, DOI 10.1007/s11684-017-0527-6
   Keklikoglou I, 2015, ONCOGENE, V34, P4867, DOI 10.1038/onc.2014.408
   Keshamouni VG, 2009, J PROTEOME RES, V8, P35, DOI 10.1021/pr8006478
   Liu XY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0392-y
   Maji S, 2017, MOL CANCER RES, V15, P93, DOI 10.1158/1541-7786.MCR-16-0163
   Rankin CR, 2013, J BIOL CHEM, V288, P15229, DOI 10.1074/jbc.M112.440909
   Rucki AA, 2017, CANCER RES, V77, P41, DOI 10.1158/0008-5472.CAN-16-1383
   Torre LA, 2016, CANCER EPIDEM BIOMAR, V25, P16, DOI 10.1158/1055-9965.EPI-15-0578
   Wang CY, 2009, MOL BIOL CELL, V20, P4153, DOI 10.1091/mbc.E09-02-0174
   Wang T, 2015, ONCOTARGET, V6, P30975, DOI 10.18632/oncotarget.5199
   Yamada A, 2005, J BIOL CHEM, V280, P6016, DOI 10.1074/jbc.M408215200
   Yuan J, 2017, BREAST CANCER RES TR, V164, P327, DOI 10.1007/s10549-017-4271-z
   Zheng L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019390
NR 22
TC 59
Z9 63
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUL 26
PY 2018
VL 8
AR 11285
DI 10.1038/s41598-018-29703-0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA GO2MK
UT WOS:000439806700011
PM 30050103
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU He, X
   Lan, HR
   Jin, KT
   Liu, FL
AF He, Xing
   Lan, Huanrong
   Jin, Ketao
   Liu, Fanlong
TI Can immunotherapy reinforce chemotherapy efficacy? a new perspective on
   colorectal cancer treatment
SO FRONTIERS IN IMMUNOLOGY
LA English
DT Review
DE colorectal cancer; tumor treatment; chemotherapy; immunotherapy; cell
   therapy
ID CAR-T-CELLS; THYMIDINE PHOSPHORYLASE EXPRESSION; CONSENSUS MOLECULAR
   SUBTYPES; IMMUNE CHECKPOINT INHIBITORS; 1ST-LINE TREATMENT; TARGETED
   THERAPY; PHASE-II; INTRATUMOR HETEROGENEITY; ORAL CAPECITABINE; PLUS
   IRINOTECAN
AB As one of the main threats to human life (the fourth most dangerous and prevalent cancer), colorectal cancer affects many people yearly, decreases patients' quality of life, and causes irreparable financial and social damages. In addition, this type of cancer can metastasize and involve the liver in advanced stages. However, current treatments can't completely eradicate this disease. Chemotherapy and subsequent surgery can be mentioned among the current main treatments for this disease. Chemotherapy has many side effects, and regarding the treatment of this type of tumor, chemotherapy can lead to liver damage, such as steatohepatitis, steatosis, and sinus damage. These damages can eventually lead to liver failure and loss of its functions. Therefore, it seems that other treatments can be used in addition to chemotherapy to increase its efficiency and reduce its side effects. Biological therapies and immunotherapy are one of the leading suggestions for combined treatment. Antibodies (immune checkpoint blockers) and cell therapy (DC and CAR-T cells) are among the immune system-based treatments used to treat tumors. Immunotherapy targets various aspects of the tumor that may lead to 1) the recruitment of immune cells, 2) increasing the immunogenicity of tumor cells, and 3) leading to the elimination of inhibitory mechanisms established by the tumor. Therefore, immunotherapy can be used as a complementary treatment along with chemotherapy. This review will discuss different chemotherapy and immunotherapy methods for colorectal cancer. Then we will talk about the studies that have dealt with combined treatment.
C1 [He, Xing] Jinhua Wenrong Hosp, Dept Gastroenterol, Jinhua, Zhejiang, Peoples R China.
   [Lan, Huanrong] Hangzhou Canc Hosp, Dept Surg Oncol, Hangzhou, Zhejiang, Peoples R China.
   [Jin, Ketao] Zhejiang Univ, Affiliated Jinhua Hosp, Dept Colorectal Surg, Sch Med, Jinhua, Zhejiang, Peoples R China.
   [Liu, Fanlong] Zhejiang Univ, Affiliated Hosp 1, Dept Colorectal Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China.
C3 Zhejiang University; Zhejiang University
RP Jin, KT (corresponding author), Zhejiang Univ, Affiliated Jinhua Hosp, Dept Colorectal Surg, Sch Med, Jinhua, Zhejiang, Peoples R China.; Liu, FL (corresponding author), Zhejiang Univ, Affiliated Hosp 1, Dept Colorectal Surg, Sch Med, Hangzhou, Zhejiang, Peoples R China.
EM jinketao2001@zju.edu.cn; fanlong_liu@zju.edu.cn
CR Akdeniz N, 2021, INT J COLORECTAL DIS, V36, P1311, DOI 10.1007/s00384-021-03888-9
   Akkin S, 2021, MOLECULES, V26, DOI 10.3390/molecules26113382
   Aldahlawi Alia M, 2022, J Microsc Ultrastruct, V10, P107, DOI 10.4103/jmau.jmau_20_21
   Anaka M, 2021, CANCER MANAG RES, V14, P273, DOI 10.2147/CMAR.S273544
   André T, 1999, EUR J CANCER, V35, P1343, DOI 10.1016/S0959-8049(99)00150-1
   Antoniotti C, 2022, LANCET ONCOL, V23, P876, DOI 10.1016/S1470-2045(22)00274-1
   Arab A, 2020, ARCH IMMUNOL THER EX, V68, DOI 10.1007/s00005-019-00566-1
   Arango D, 2004, BRIT J CANCER, V91, P1931, DOI 10.1038/sj.bjc.6602215
   Bai ZY, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.808964
   Bailly C, 2019, PHARMACOL RES, V148, DOI 10.1016/j.phrs.2019.104398
   Lam BQ, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0366-y
   Baraibar I, 2021, CANCERS, V13, DOI 10.3390/cancers13246311
   Bartel F, 2004, MOL CANCER RES, V2, P29
   Bauer K, 2011, FAM CANCER, V10, P557, DOI 10.1007/s10689-011-9449-7
   Baulu E, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf3700
   Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879
   Bekaii-Saab TS, 2009, MOL CANCER THER, V8, P2983, DOI 10.1158/1535-7163.MCT-09-0820
   Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532
   Bodduluri SR, 2018, CANCER IMMUNOL RES, V6, P332, DOI 10.1158/2326-6066.CIR-17-0424
   Boland PM, 2017, CANCERS, V9, DOI 10.3390/cancers9050050
   Bordonaro R, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100270
   Branca JJV, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.643824
   Bratsos I, 2007, CHIMIA, V61, P692, DOI 10.2533/chimia.2007.692
   Bruni D, 2020, NAT REV CANCER, V20, P662, DOI 10.1038/s41568-020-0285-7
   Budithi A, 2021, CANCERS, V13, DOI 10.3390/cancers13112632
   Burness CB, 2016, DRUGS, V76, P1393, DOI 10.1007/s40265-016-0633-9
   Cao PH, 2019, INT J BIOL SCI, V15, P1676, DOI 10.7150/ijbs.35265
   Carlotto A, 2013, PHARMACOECONOMICS, V31, P753, DOI 10.1007/s40273-013-0081-2
   Carrassa L, 2017, CANCER TREAT REV, V60, P139, DOI 10.1016/j.ctrv.2017.08.013
   Cassidy J, 2004, J CLIN ONCOL, V22, P2084, DOI 10.1200/JCO.2004.11.069
   Ceilley RI, 2012, J DERMATOL TREAT, V23, P83, DOI 10.3109/09546634.2010.507704
   Chauhan DS, 2021, EUR J PHARM BIOPHARM, V163, P72, DOI 10.1016/j.ejpb.2021.03.010
   Chen L, 2022, CLIN IMMUNOL, V237, DOI 10.1016/j.clim.2022.108962
   Choi SM, 2001, J KOREAN MED SCI, V16, P328, DOI 10.3346/jkms.2001.16.3.328
   Chowdhury S, 2021, CANCERS, V13, DOI 10.3390/cancers13194923
   Chua W, 2009, BRIT J CANCER, V101, P998, DOI 10.1038/sj.bjc.6605239
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Cohen MH, 2007, ONCOLOGIST, V12, P713, DOI 10.1634/theoncologist.12-6-713
   Cohen MH, 2013, ONCOLOGIST, V18, P460, DOI 10.1634/theoncologist.2012-0458
   Comella Pasquale, 2009, Ther Clin Risk Manag, V5, P229
   Cremolini C, 2021, ANN ONCOL, V32, pS1294, DOI 10.1016/j.annonc.2021.08.2094
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cui GL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.573547
   Damato A., 2022, Am Soc Clin Oncol, DOI [10.3389/fonc.2021.766500, DOI 10.3389/FONC.2021.766500]
   De Smedt L, 2015, BRIT J CANCER, V113, P500, DOI 10.1038/bjc.2015.213
   Degirmencioglu S, 2019, J INT MED RES, V47, P2507, DOI 10.1177/0300060519848258
   Del Re M, 2019, PHARMACOGENOMICS J, V19, P556, DOI 10.1038/s41397-019-0077-1
   Dermani FK, 2019, J CELL PHYSIOL, V234, P1313, DOI 10.1002/jcp.27172
   Dianat-Moghadam H, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287-022-02829-9
   DIASIO RB, 1989, CLIN PHARMACOKINET, V16, P215, DOI 10.2165/00003088-198916040-00002
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Eisterer W, 2019, CARDIOVASC INTER RAD, V42, P1213, DOI 10.1007/s00270-019-02278-7
   Etienne-Grimaldi MC, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0175998
   Falcone A, 2006, J CLIN ONCOL, V24, p149S
   Falcone A, 2007, J CLIN ONCOL, V25, P1670, DOI 10.1200/JCO.2006.09.0928
   Feng M, 2021, CANCER LETT, V498, P201, DOI 10.1016/j.canlet.2020.10.040
   Förster I, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4400-z
   Fuchs C, 2006, CANCER TREAT REV, V32, P491, DOI 10.1016/j.ctrv.2006.07.001
   Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234
   Gabano E, 2009, CURR MED CHEM, V16, P4544, DOI 10.2174/092986709789760661
   Gai XD, 2013, BIOMED REP, V1, P207, DOI 10.3892/br.2012.35
   Gallois C, 2021, DIGEST LIVER DIS, V53, P1254, DOI 10.1016/j.dld.2021.06.009
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gavalas NG, 2012, BRIT J CANCER, V107, P1869, DOI 10.1038/bjc.2012.468
   Gill S, 2003, ALIMENT PHARM THER, V18, P683, DOI 10.1046/j.1365-2036.2003.01735.x
   Glimelius B, 2021, CANCER TREAT REV, V98, DOI 10.1016/j.ctrv.2021.102218
   Gong J, 2016, J GASTROINTEST ONCOL, V7, P687, DOI 10.21037/jgo.2016.06.12
   Goyle S, 2005, DIGEST SURG, V22, P401, DOI 10.1159/000091441
   Graham J, 2004, NAT REV DRUG DISCOV, V3, P549, DOI 10.1038/nrd1445
   Grzywa TM, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00938
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Hahn RZ, 2019, CURR MED CHEM, V26, P2085, DOI 10.2174/0929867325666180622141101
   Han SW, 2013, INT J CANCER, V132, P2209, DOI 10.1002/ijc.27888
   Hazrati A, 2022, BIOMARK RES, V10, DOI 10.1186/s40364-022-00374-4
   Hegde V S., 2020, Leucovorin
   Hénin E, 2009, CLIN PHARMACOL THER, V85, P418, DOI 10.1038/clpt.2008.220
   Herbst RS, 2016, LANCET, V387, P1540, DOI 10.1016/S0140-6736(15)01281-7
   Hiret S., 2016, Am Soc Clin Oncol, V34, DOI [10.1200/JCO.2016.34.15_suppl.3514, DOI 10.1200/JCO.2016.34.15_SUPPL.3514]
   Hirsch Bradford R, 2011, Cancer Manag Res, V3, P79, DOI 10.2147/CMR.S11250
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Hoos A, 2010, SEMIN ONCOL, V37, P533, DOI 10.1053/j.seminoncol.2010.09.015
   Hou XY, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.512
   Hou XY, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.725583
   Huang RY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1249561
   Huang WK, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.693009
   Hussain S, 2020, TRENDS CANCER, V6, P365, DOI 10.1016/j.trecan.2020.02.009
   Iachetta F, 2019, BRIT J CANCER, V120, P834, DOI 10.1038/s41416-019-0423-8
   Ibrahim A, 2004, ONCOLOGIST, V9, P8, DOI 10.1634/theoncologist.9-1-8
   Inamura K, 2021, SEMIN CANCER BIOL, V70, P11, DOI 10.1016/j.semcancer.2020.06.006
   Innocenti F, 2020, JCO ONCOL PRACT, V16, P793, DOI 10.1200/OP.20.00553
   Kaellberg J, 2023, CELL DEATH DIS, V14, DOI 10.1038/s41419-023-05806-z
   Katz SC, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001097
   Kciuk M, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21144919
   Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1
   Koshiji M, 1997, BIOCHEM BIOPH RES CO, V240, P376, DOI 10.1006/bbrc.1997.7657
   Kosti P, 2021, CELL REP MED, V2, DOI 10.1016/j.xcrm.2021.100227
   Kraus S, 2014, CANCER LETT, V347, P15, DOI 10.1016/j.canlet.2014.01.025
   Kreidieh M, 2020, BIOMED RES INT-UK, V2020, DOI 10.1155/2020/9037217
   Kubli SP, 2021, NAT REV DRUG DISCOV, V20, P899, DOI 10.1038/s41573-021-00155-y
   Kuhn JG, 1998, ONCOLOGY-NY, V12, P39
   Kumar A, 2022, MED ONCOL, V40, DOI 10.1007/s12032-022-01864-z
   Kwakman JJM, 2018, INT J CLIN ONCOL, V23, P482, DOI 10.1007/s10147-017-1220-0
   LAURENT PL, 1994, EUR J CANCER, V30A, P1859, DOI 10.1016/0959-8049(94)00341-2
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee B, 2019, BIOCHEM BIOPH RES CO, V514, P518, DOI 10.1016/j.bbrc.2019.04.009
   Leichsenring J, 2015, GASTROINTEST TUMORS, V1, P209, DOI 10.1159/000380790
   Li HL, 2021, J CANCER, V12, P1804, DOI 10.7150/jca.50509
   Li J, 2020, THER ADV CHRONIC DIS, V11, DOI 10.1177/2040622320904293
   Li K, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-019-1091-8
   Li ZN, 2020, GASTROENTEROL REP, V8, P192, DOI 10.1093/gastro/goaa022
   Limagne E, 2016, CANCER RES, V76, P5241, DOI 10.1158/0008-5472.CAN-15-3164
   Lin WY, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.1048980
   LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48
   Liu QF, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01735-9
   LOKICH JJ, 1989, J CLIN ONCOL, V7, P425, DOI 10.1200/JCO.1989.7.4.425
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Louvet C, 2002, J CLIN ONCOL, V20, P4543, DOI 10.1200/JCO.2002.02.021
   Lyskjær I, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-47708-1
   Machover D, 1997, CANCER, V80, P1179, DOI 10.1002/(SICI)1097-0142(19971001)80:7<1179::AID-CNCR1>3.0.CO;2-G
   Mackall CL, 1997, BLOOD, V89, P3700, DOI 10.1182/blood.V89.10.3700.3700_3700_3707
   Macrae FA., 2017, Colorectal cancer: Epidemiology, risk factors, and protective factors, V2016
   Madajewicz S, 2012, INVEST NEW DRUG, V30, P772, DOI 10.1007/s10637-010-9598-9
   Maeda K, 2011, ANTICANCER RES, V31, P4569
   Mahipal A, 2016, J ONCOL PRACT, V12, P1219, DOI 10.1200/JOP.2016.018382
   Maindrault-Goebel F, 1999, EUR J CANCER, V35, P1338, DOI 10.1016/S0959-8049(99)00149-5
   Marofi F, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287-022-02819-x
   Matos AI, 2019, J CONTROL RELEASE, V307, P108, DOI 10.1016/j.jconrel.2019.06.017
   Matsuoka K, 2017, CANCER RES, V77, DOI 10.1158/1538-7445.AM2017-1055
   Meropol NJ, 2006, J CLIN ONCOL, V24, P4069, DOI 10.1200/JCO.2005.05.2084
   Milano G, 2002, CHRONOBIOL INT, V19, P177, DOI 10.1081/CBI-120002597
   Miller TJ, 2021, CANCER SCI, V112, P1173, DOI 10.1111/cas.14781
   Miranda VC, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.3_suppl.601
   Miura Koh, 2010, Cancers (Basel), V2, P1717, DOI 10.3390/cancers2031717
   Modest DP, 2013, ACTA ONCOL, V52, P956, DOI 10.3109/0284186X.2012.752580
   Mohsenzadegan M, 2020, J CELL PHYSIOL, V235, P74, DOI 10.1002/jcp.28977
   Mulet-Margalef N, 2023, CANCERS, V15, DOI 10.3390/cancers15041022
   Mutharani B, 2020, SENSOR ACTUAT B-CHEM, V304, DOI 10.1016/j.snb.2019.127361
   Nagourney RA, 2021, EJSO-EUR J SURG ONC, V47, P738, DOI 10.1016/j.ejso.2020.09.017
   Nakayama Y, 2003, ANTICANCER RES, V23, P4423
   O'Sullivan D, 2019, NAT REV IMMUNOL, V19, P324, DOI 10.1038/s41577-019-0140-9
   PARKER WB, 1990, PHARMACOL THERAPEUT, V48, P381, DOI 10.1016/0163-7258(90)90056-8
   Passardi A, 2015, ANN ONCOL, V26, P1201, DOI 10.1093/annonc/mdv130
   Passardi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061324
   Payandeh Z, 2020, J CELL PHYSIOL, V235, P5461, DOI 10.1002/jcp.29494
   Petitprez A, 2013, CURR PHARM DESIGN, V19, P958, DOI 10.2174/138161213804547204
   Petrelli F, 2020, INT J COLORECTAL DIS, V35, P783, DOI 10.1007/s00384-020-03571-5
   Petrioli R, 2010, ANTI-CANCER DRUG, V21, P313, DOI 10.1097/CAD.0b013e328334d88a
   Pilot T, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000478
   Polk A, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-47
   Proctor M., 2021, Microreviews Cell Mol Biol, V8, P1
   Pullarkat S. T., 2001, Pharmacogenomics Journal, V1, P65
   Qin SK, 2018, J CLIN ONCOL, V36, P3031, DOI 10.1200/JCO.2018.78.3183
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Rao S, 2004, BRIT J CANCER, V91, P839, DOI 10.1038/sj.bjc.6602039
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Ray SK, 2021, CURR MOL MED, V21, P221, DOI 10.2174/1566524020666200824103749
   Reilly NM, 2019, MOL ONCOL, V13, P681, DOI 10.1002/1878-0261.12467
   Riera P, 2021, EXPERT OPIN DRUG MET, V17, P1157, DOI 10.1080/17425255.2021.1974397
   Robert C, 2015, NEW ENGL J MED, V372, P2521, DOI 10.1056/NEJMoa1503093
   Roda D, 2020, ANN ONCOL, V31, P1097, DOI 10.1016/j.annonc.2020.05.030
   Ros J, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1112276
   Sahin IH, 2019, BRIT J CANCER, V121, P809, DOI 10.1038/s41416-019-0599-y
   Sandhu J, 2019, J SURG ONCOL, V119, P564, DOI 10.1002/jso.25421
   Schlake T, 2019, CELL MOL LIFE SCI, V76, P301, DOI 10.1007/s00018-018-2935-4
   Schmitt M, 2021, NAT REV IMMUNOL, V21, P653, DOI 10.1038/s41577-021-00534-x
   Schrock AB, 2019, ANN ONCOL, V30, P1096, DOI 10.1093/annonc/mdz134
   Sharma BB, 2021, ONCOLOGIST, V26, P1008, DOI 10.1002/onco.13967
   Shi AP, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.785091
   Sillo TO, 2019, BRIT J SURG, V106, P1283, DOI 10.1002/bjs.11204
   Singh PP, 2015, GASTROENTEROL REP, V3, P289, DOI 10.1093/gastro/gov053
   Stein A, 2020, J CLIN ONCOL, V38
   Stein A, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.TPS3620
   Sterner RC, 2021, BLOOD CANCER J, V11, DOI 10.1038/s41408-021-00459-7
   Subtil B, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.724883
   Sun X, 2016, WORLD J GASTROENTERO, V22, P6362, DOI 10.3748/wjg.v22.i28.6362
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabemero JM., 2004, J. Clin. Oncol., V22, P3512
   Tabernero J, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100559
   Takano M, 2017, PHARMACOGEN PERS MED, V10, P61, DOI 10.2147/PGPM.S108656
   Takayama T, 2006, JPN J CLIN ONCOL, V36, P564, DOI 10.1093/jjco/hyl063
   Takebayashi Y, 1996, EUR J CANCER, V32A, P1227, DOI 10.1016/0959-8049(96)00061-5
   Tang PA, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3546
   Tavare AN, 2012, INT J CANCER, V130, P1237, DOI 10.1002/ijc.26448
   Tejpar S, 2008, J CLIN ONCOL, V26, DOI 10.1200/jco.2008.26.15_suppl.4001
   Terme M, 2013, CANCER RES, V73, P539, DOI 10.1158/0008-5472.CAN-12-2325
   Thomas DM, 1998, CLIN EXP PHARMACOL P, V25, P887, DOI 10.1111/j.1440-1681.1998.tb02339.x
   Tolmachev V, 2021, SEMIN CANCER BIOL, V72, P185, DOI 10.1016/j.semcancer.2020.10.005
   Trotta AM, 2016, CANCER IMMUNOL RES, V4, P366, DOI 10.1158/2326-6066.CIR-15-0184
   Truong NTH, 2021, CANCERS, V13, DOI 10.3390/cancers13092225
   TSUDA H, 1994, BRIT J CANCER, V70, P771, DOI 10.1038/bjc.1994.394
   Van Cutsem E, 2001, ONCOLOGIST, V6, P1, DOI 10.1634/theoncologist.6-suppl_4-1
   Van Cutsem E, 2001, J CLIN ONCOL, V19, P4097, DOI 10.1200/JCO.2001.19.21.4097
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Verma R, 2016, BREAST CANCER RES, V18, DOI 10.1186/s13058-015-0669-x
   Vodenkova S, 2020, PHARMACOL THERAPEUT, V206, DOI 10.1016/j.pharmthera.2019.107447
   Voutsadakis IA, 2021, J CLIN MED, V10, DOI 10.3390/jcm10235568
   Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang HF, 2023, MOL CELL BIOCHEM, V478, P967, DOI 10.1007/s11010-022-04568-0
   Wang L, 2017, CELL PHYSIOL BIOCHEM, V44, P1038, DOI 10.1159/000485404
   Wang M, 2023, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1096551
   Wang QM, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0759-9
   Wang W, 2019, SEMIN CANCER BIOL, V55, P37, DOI 10.1016/j.semcancer.2018.05.002
   Wang Y, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2018.1440169
   Wang Y, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01335-y
   Wang ZB, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1331807
   Weekes J, 2009, WORLD J GASTROENTERO, V15, P3597, DOI 10.3748/wjg.15.3597
   Weiner LM, 2012, CELL, V148, P1081, DOI 10.1016/j.cell.2012.02.034
   Westdorp H, 2016, CANCER IMMUNOL IMMUN, V65, P1249, DOI 10.1007/s00262-016-1832-7
   White T, 2017, CLIN J ONCOL NURS, V21, pE30, DOI 10.1188/17.CJON.E30-E37
   Wolchok JD, 2013, NEW ENGL J MED, V369, P122, DOI 10.1056/NEJMoa1302369
   Wu FL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00641-0
   Wu X, 2010, CANCER IMMUNOL IMMUN, V59, P279, DOI 10.1007/s00262-009-0749-9
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu J, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04100-0
   Xu RH, 2018, LANCET ONCOL, V19, P660, DOI 10.1016/S1470-2045(18)30140-2
   Xu T, 2017, ONCOTARGET, V8, P109079, DOI 10.18632/oncotarget.22606
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Ychou M, 2003, ANN ONCOL, V14, P481, DOI 10.1093/annonc/mdg119
   Yu IRE, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12020258
   Zaniboni A, 2012, CANCER CHEMOTH PHARM, V69, P1641, DOI 10.1007/s00280-012-1875-1
   Zarate R, 2010, BRIT J CANCER, V102, P987, DOI 10.1038/sj.bjc.6605595
   Zhao LP, 2022, BIOMED PHARMACOTHER, V150, DOI 10.1016/j.biopha.2022.112949
   Zhou C, 2021, CANCER LETT, V521, P119, DOI 10.1016/j.canlet.2021.07.023
NR 225
TC 4
Z9 6
U1 5
U2 17
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-3224
J9 FRONT IMMUNOL
JI Front. Immunol.
PD SEP 18
PY 2023
VL 14
AR 1237764
DI 10.3389/fimmu.2023.1237764
PG 19
WC Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology
GA T1KS7
UT WOS:001075650700001
PM 37790928
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Deng, LL
   Zhao, Y
   Liu, W
AF Deng, Lili
   Zhao, Yan
   Liu, Wen
TI PFKP is upregulated in 5-fluorouracil-resistant patients and suppresses
   the antitumor activity of 5-fluorouracil in colorectal cancer <i>in
   vitro</i> and <i>in vivo</i>
SO JOURNAL OF CHEMOTHERAPY
LA English
DT Article
DE Colorectal cancer; PFKP; glycolysis; 5-FU resistance; apoptosis;
   HCT116/5-FU cells; NF-kappa b
ID PLATELET ISOFORM; CELL-GROWTH; GLYCOLYSIS; RESISTANCE
AB As a long-established chemotherapy drug, 5-fluorouracil (5-FU) is widely used to clinically manage colorectal cancer (CRC). However, a substantial portion of patients develop 5-FU resistance at some stage, which poses a great challenge. Therefore, revealing the mechanisms that could guide the development of effective strategies to overcome 5-FU resistance is required. Here, we report that the expression of PFKP was higher in HCT116/5-FU CRC. Furthermore, genetic suppression of PFKP suppresses glycolysis, NF-kappa B activation, and expression of GLUT1 and HK2 in HCT116/5-FU cells. PFKP overexpression promotes glycolysis and expression of GLUT1 and HK2 via the NF-kappa B signaling pathway in HCT116 cells. Our functional assays demonstrated that PFKP silencing could sensitize HCT116/5-FU cells to 5-FU with an elevated population of apoptotic cells. In contrast, forced expression of PFKP conferred 5-FU resistance in HCT116 cells. Furthermore, PFKP silencing significantly inhibited CRC xenograft tumor growth. Notably, the combination of PFKP silencing and 5-FU inhibited tumor growth. Therefore, our results demonstrated that PFKP enhances 5-FU resistance by promoting glycolysis, indicating that PFKP could be a novel candidate for targeted therapy for 5-FU-resistant CRC.
C1 [Deng, Lili; Zhao, Yan; Liu, Wen] Fudan Univ, Jinshan Hosp, Dept Radiol, Shanghai, Peoples R China.
   [Zhao, Yan] Shanghai Univ Med & Hlth Sci, Dept Radiol, Chongming Branch, Shanghai, Peoples R China.
   [Liu, Wen] Fudan Univ, Jinshan Hosp, Dept Radiol, 1508 Longhang Rd, Shanghai 201508, Peoples R China.
C3 Fudan University; Shanghai University of Medicine & Health Sciences;
   Fudan University
RP Liu, W (corresponding author), Fudan Univ, Jinshan Hosp, Dept Radiol, 1508 Longhang Rd, Shanghai 201508, Peoples R China.
RI Li, Huang/IZE-8023-2023
FU Shanghai Municipal Commission of Health
FX No Statement Available
CR Bolaños-Suárez V, 2023, CANCER MED-US, V12, P15632, DOI 10.1002/cam4.6123
   Chen C, 2023, CLIN TRANSL ONCOL, V25, P2183, DOI 10.1007/s12094-023-03096-7
   Chen GH, 2018, EXP CELL RES, V370, P46, DOI 10.1016/j.yexcr.2018.06.007
   Chen L, 2020, ARCH BIOCHEM BIOPHYS, V680, DOI 10.1016/j.abb.2019.108244
   Chen LJ, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02531-x
   Cheng Y, 2014, BIOMED REP, V2, P188, DOI 10.3892/br.2013.211
   Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059
   Hoskin Ashley J, 2023, Explor Target Antitumor Ther, V4, P600, DOI 10.37349/etat.2023.00155
   Hsu PP, 2008, CELL, V134, P703, DOI 10.1016/j.cell.2008.08.021
   Huang CY, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01282
   Lee JH, 2018, MOL CELL, V70, P197, DOI 10.1016/j.molcel.2018.03.018
   Li MX, 2021, BIOCHEM PHARMACOL, V192, DOI 10.1016/j.bcp.2021.114741
   Li M, 2023, PATHOL RES PRACT, V246, DOI 10.1016/j.prp.2023.154480
   Li M, 2022, INT J ONCOL, V61, DOI 10.3892/ijo.2022.5396
   Lim JS, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-05449-6
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu TJ, 2023, J CANCER, V14, P943, DOI 10.7150/jca.82738
   Ma LS, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00005
   Mor I, 2011, COLD SH Q B, V76, P211, DOI 10.1101/sqb.2011.76.010868
   Motlagh AV, 2022, LIFE SCI, V303, DOI 10.1016/j.lfs.2022.120650
   Papanastasopoulos P, 2014, ANTICANCER RES, V34, P1531
   Sharma R, 2022, LANCET GASTROENTEROL, V7, P627, DOI 10.1016/S2468-1253(22)00044-9
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Vallböhmer D, 2006, INT J CANCER, V119, P2435, DOI 10.1002/ijc.22129
   Wang T, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4123-1
   Wang XJ, 2019, MOL CELL, V76, P148, DOI 10.1016/j.molcel.2019.07.007
   Wang YX, 2021, ONCOTARGETS THER, V14, P699, DOI 10.2147/OTT.S284211
NR 27
TC 1
Z9 1
U1 4
U2 16
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1120-009X
EI 1973-9478
J9 J CHEMOTHERAPY
JI J. Chemother.
PD JUL 3
PY 2024
VL 36
IS 5
BP 422
EP 434
DI 10.1080/1120009X.2023.2288742
EA NOV 2023
PG 13
WC Oncology; Infectious Diseases; Pathology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Infectious Diseases; Pathology; Pharmacology & Pharmacy
GA E3X6L
UT WOS:001119930100001
PM 38044588
DA 2025-01-04
ER

PT J
AU Valtorta, E
   Martino, C
   Sartore-Bianchi, A
   Penaullt-Llorca, F
   Viale, G
   Risio, M
   Rugge, M
   Grigioni, W
   Bencardino, K
   Lonardi, S
   Zagonel, V
   Leone, F
   Noe, J
   Ciardiello, F
   Pinto, C
   Labianca, R
   Mosconi, S
   Graiff, C
   Aprile, G
   Frau, B
   Garufi, C
   Loupakis, F
   Racca, P
   Tonini, G
   Lauricella, C
   Veronese, S
   Truini, M
   Siena, S
   Marsoni, S
   Gambacorta, M
AF Valtorta, Emanuele
   Martino, Cosimo
   Sartore-Bianchi, Andrea
   Penaullt-Llorca, Frederique
   Viale, Giuseppe
   Risio, Mauro
   Rugge, Massimo
   Grigioni, Walter
   Bencardino, Katia
   Lonardi, Sara
   Zagonel, Vittorina
   Leone, Francesco
   Noe, Johannes
   Ciardiello, Fortunato
   Pinto, Carmine
   Labianca, Roberto
   Mosconi, Stefania
   Graiff, Claudio
   Aprile, Giuseppe
   Frau, Barbara
   Garufi, Carlo
   Loupakis, Fotios
   Racca, Patrizia
   Tonini, Giuseppe
   Lauricella, Calogero
   Veronese, Silvio
   Truini, Mauro
   Siena, Salvatore
   Marsoni, Silvia
   Gambacorta, Marcello
TI Assessment of a HER2 scoring system for colorectal cancer: results from
   a validation study
SO MODERN PATHOLOGY
LA English
DT Article
ID GENE AMPLIFICATION; BREAST-CANCER; AMERICAN-SOCIETY; GASTRIC-CANCER;
   CLINICAL ONCOLOGY/COLLEGE; PROTEIN EXPRESSION; OVEREXPRESSION;
   TRASTUZUMAB; RECOMMENDATIONS; THERAPY
AB We sought to develop criteria for ERBB2-positivity (HER2) in colorectal cancer to ensure accurate identification of ERBB2-amplified metastatic colorectal cancer patients suitable for enrolment in a phase II trial of ERBB2-targeted therapy (HERACLES trial). A two-step approach was used. In step 1, a consensus panel of pathologists adapted existing protocols for use in colorectal cancer to test ERBB2 expression and amplification. Collegial revision of an archival test cohort of colorectal cancer samples led to specific recommendations for adapting current breast and gastric cancer criteria for scoring ERBB2 in colorectal cancer. In step 2, from September 2012 to January 2015, colorectal-specific ERBB2 testing protocols and ERBB2 scoring criteria were used to centrally screen for ERBB2-positive KRAS wild-type colorectal cancer patients to be enrolled in the HERACLES trial (clinical validation cohort). In both archival test (N=256) and clinical validation (N=830) cohorts, a clinically sizeable 5% fraction of KRAS wild-type colorectal cancer patients was found to be ERBB2-positive according to the colorectal cancer-specific ERBB2 scoring criteria. ERBB2-positive tumors showed ERBB2 immunostaining consisting of intense membranous ERBB2 protein expression, corresponding to homogenous ERBB2 amplification, in >50% of cells. None of the immunohistochemistry 0 or 1+ cases was amplified. Concordance between SISH and FISH was 100%. In conclusion, we propose specific criteria for defining ERBB2-positivity in colorectal cancer (HERACLES Diagnostic Criteria). In a phase II trial of trastuzumab and lapatinib in a cetuximab-resistant population, HERACLES Diagnostic Criteria shaped the selection of patients and defined ERBB2 as a predictive marker for response to ERBB2-targeted therapy in metastatic colorectal cancer.
C1 [Valtorta, Emanuele; Sartore-Bianchi, Andrea; Bencardino, Katia; Lauricella, Calogero; Veronese, Silvio; Truini, Mauro; Siena, Salvatore; Gambacorta, Marcello] Osped Niguarda Ca Granda, Niguarda Canc Ctr, Milan, Italy.
   [Martino, Cosimo; Risio, Mauro; Leone, Francesco; Marsoni, Silvia] FPO IRCCS, Ist Candiolo, Candiolo, Italy.
   [Penaullt-Llorca, Frederique] Univ Auvergne, Ctr Jean Perrin, Clermont Ferrand, France.
   [Viale, Giuseppe] Ist Europeo Oncol, Milan, Italy.
   [Rugge, Massimo] Azienda Osped Univ Padova, Anat Patol, Padua, Italy.
   [Grigioni, Walter; Pinto, Carmine] Policlin St Orsola Malpighi, Bologna, Italy.
   [Lonardi, Sara; Zagonel, Vittorina] IRCCS, Ist Oncol Veneto, Oncol Med 1, Padua, Italy.
   [Noe, Johannes] F Hoffmann La Roche & Co Ltd, CH-4002 Basel, Switzerland.
   [Ciardiello, Fortunato] Univ Naples 2, Naples, Italy.
   [Labianca, Roberto; Mosconi, Stefania] Osped Papa Giovanni XXIII, Bergamo, Italy.
   [Graiff, Claudio] Osped Bolzano Via Boehler, Bolzano, Italy.
   [Aprile, Giuseppe] Osped S Maria Misericordia, Udine, Italy.
   [Frau, Barbara] Policlin Univ Cagliari, Monserrato, Italy.
   [Garufi, Carlo] Ist Nazl Tumori Regina Elena, Rome, Italy.
   [Loupakis, Fotios] Azienda Osped Univ Pisana Via Roma, Pisa, Italy.
   [Racca, Patrizia] Azienda Osped Univ Citta Salute & Sci, Turin, Italy.
   [Tonini, Giuseppe] Policlin Univ Campus Biomed, Rome, Italy.
   [Siena, Salvatore] Univ Milan, Milan, Italy.
C3 IRCCS Ca Granda Ospedale Maggiore Policlinico; Ospedale Niguarda Ca'
   Granda; IRCCS Fondazione del Piemonte per l'Oncologia; UNICANCER; Centre
   Jean Perrin; Universite Clermont Auvergne (UCA); IRCCS European
   Institute of Oncology (IEO); University of Padua; Azienda Ospedaliera -
   Universita di Padova; IRCCS Azienda Ospedaliero-Universitaria di
   Bologna; IRCCS Istituto Oncologico Veneto (IOV); Roche Holding;
   Universita della Campania Vanvitelli; ASST Papa Giovanni XXIII; Hospital
   Santa Maria della Misericordia; University of Cagliari; Azienda
   Ospedaliero-Universitaria di Cagliari; IRCCS Istituti Fisioterapici
   Ospitalieri (IFO); IRCCS Regina Elena; University of Pisa; Azienda
   Ospedaliero Universitaria Pisana; A.O.U. Citta della Salute e della
   Scienza di Torino; Fondazione Policlinico Universitario Campus
   Bio-Medico; University Campus Bio-Medico - Rome Italy; University of
   Milan
RP Marsoni, S (corresponding author), Fdn Piemonte Oncol IRCCS, Ist Candiolo, Str Prov 142,Km 3-95, I-10060 Candiolo, Italy.
EM silvia.marsoni@ircc.it
RI Leone, Francesco/AAB-2355-2022; SIENA, SALVATORE/AAC-5806-2019; Garufi,
   Carlo/AAB-8730-2019; Viale, Giuseppe/AAE-8921-2019; Rugge,
   Massimo/K-7525-2016; Sartore-Bianchi, Andrea/AAB-9848-2019; Loupakis,
   Fotios/I-7243-2012; Labianca, Roberto/N-1847-2016; Lonardi,
   Sara/F-4228-2014; zagonel, vittorina/F-4226-2014; Pinto,
   Carmine/AAC-2184-2020; LEONE, Francesco/R-3248-2016
OI Loupakis, Fotios/0000-0001-9651-0395; Sartore-Bianchi,
   Andrea/0000-0003-0780-0409; Marsoni, Silvia/0000-0002-5361-7122;
   Ciardiello, Fortunato/0000-0002-3369-4841; Labianca,
   Roberto/0000-0001-7149-822X; SIENA, SALVATORE/0000-0002-2681-2846;
   Lonardi, Sara/0000-0002-7593-8138; Veronese, Silvio
   Marco/0000-0002-5280-3740; Martino, Cosimo/0000-0002-7286-9755; zagonel,
   vittorina/0000-0002-0829-2525; Pinto, Carmine/0000-0002-3159-5268;
   LEONE, Francesco/0000-0001-5422-9706; VALTORTA,
   EMANUELE/0000-0002-5087-6233
FU F. HOFFMANN-LA ROCHE LTD., Grenzacherstrasse Basel, Switzerland
   [CH-4070]; AIRC, Associazione Italiana per la Ricerca sul Cancro Special
   Program Molecular Clinical Oncology [9970]; Fondazione Oncologia
   Niguarda Ca' Granda Onlus, Progetto Terapia Molecolare Tumori
FX We thank Alberto Bardelli, Andrea Bertotti, Federica Di Nicolantonio,
   and Livio Trusolino for helpful suggestions in the study design and
   discussion; Valter Torri for statistical support; the technical staff of
   the Pathological Anatomy Department of Niguarda Cancer Center for
   technical support; Joana Caseiro, Donata Ronchi, Antonella Fico, and
   Gaetano Lazzarotto for secretarial and IT assistance, and Maren White
   for editorial assistance. Finally, Paolo Maria Comoglio for unrelenting
   scientific support. The main financial support for this work was
   provided by F. HOFFMANN-LA ROCHE LTD., Grenzacherstrasse 124, CH-4070
   Basel, Switzerland. Contribution from AIRC, Associazione Italiana per la
   Ricerca sul Cancro-2010 Special Program Molecular Clinical Oncology
   5x1000, project 9970 is also acknowledged. Investigators at Niguarda
   Cancer Center were partly supported by Fondazione Oncologia Niguarda Ca'
   Granda Onlus, Progetto Terapia Molecolare Tumori.
CR Arteaga CL, 2014, CANCER CELL, V25, P282, DOI 10.1016/j.ccr.2014.02.025
   Bang YJ, 2010, LANCET, V376, P1302
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Blok EJ, 2013, CLIN MED INSIGHTS-ON, V7, P41, DOI 10.4137/CMO.S10811
   Gomez-Martin C, 2013, J CLIN ONCOL, V31, P4445, DOI 10.1200/JCO.2013.48.9070
   Gown AM, 2008, MODERN PATHOL, V21, P1271, DOI 10.1038/modpathol.2008.83
   Guiu S, 2010, BRIT J CANCER, V103, P1335, DOI 10.1038/sj.bjc.6605939
   Gullo G, 2009, INVEST NEW DRUG, V27, P179, DOI 10.1007/s10637-008-9155-y
   Gutierrez C, 2011, ARCH PATHOL LAB MED, V135, P55, DOI 10.1043/2010-0454-RAR.1
   Hanna WM, 2008, MODERN PATHOL, V21, P1278, DOI 10.1038/modpathol.2008.131
   Hanna WM, 2008, MODERN PATHOL, V21, P80
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Herreros-Villanueva M, 2011, MOL BIOL REP, V38, P1315, DOI 10.1007/s11033-010-0232-x
   Hofmann M, 2008, HISTOPATHOLOGY, V52, P797, DOI 10.1111/j.1365-2559.2008.03028.x
   Jeung J, 2012, ARCH PATHOL LAB MED, V136, P610, DOI 10.5858/arpa.2011-0371-OA
   Kavanagh DO, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-1
   Kruszewski WJ, 2010, DIS MARKERS, V29, P207, DOI [10.1155/2010/109063, 10.3233/DMA-2010-0742]
   Marx AH, 2010, HUM PATHOL, V41, P1577, DOI 10.1016/j.humpath.2010.02.018
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Oncol JC, 2013, P AM SOC CLIN ONC AN
   Ooi A, 2004, MODERN PATHOL, V17, P895, DOI 10.1038/modpathol.3800137
   Park DI, 2007, INT J COLORECTAL DIS, V22, P491, DOI 10.1007/s00384-006-0192-8
   Pavlakis K, 2007, APPL IMMUNOHISTO M M, V15, P441, DOI 10.1097/01.pai.0000213156.94804.b5
   Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852
   Rüschoff J, 2010, VIRCHOWS ARCH, V457, P299, DOI 10.1007/s00428-010-0952-2
   Scaltriti M, 2015, CLIN CANCER RES, V21, P569, DOI 10.1158/1078-0432.CCR-14-1824
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Siena S, 2015, J CLIN ONCOL S3508, V33
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Song ZJ, 2014, INT J CLIN EXP PATHO, V7, P4454
   Tu JH, 2015, EXP THER MED, V9, P17, DOI 10.3892/etm.2014.2063
   Wolff AC, 2007, J CLIN ONCOL, V25, P118, DOI 10.1200/JCO.2006.09.2775
   Wolff AC, 2014, ARCH PATHOL LAB MED, V138, P241, DOI 10.5858/arpa.2013-0953-SA
   Wolff AC, 2013, J CLIN ONCOL, V31, P3997, DOI [10.1200/JCO.2013.50.9984, 10.5858/arpa.2013-0953-SA]
NR 36
TC 224
Z9 232
U1 0
U2 14
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0893-3952
EI 1530-0285
J9 MODERN PATHOL
JI Mod. Pathol.
PD NOV
PY 2015
VL 28
IS 11
BP 1481
EP 1491
DI 10.1038/modpathol.2015.98
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA CV4YZ
UT WOS:000364273700008
PM 26449765
OA Bronze
DA 2025-01-04
ER

PT J
AU Karan, C
   Tan, E
   Sarfraz, H
   Knepper, TC
   Walko, CM
   Felder, S
   Kim, R
   Sahin, IH
AF Karan, Canan
   Tan, Elaine
   Sarfraz, Humaira
   Knepper, Todd C.
   Walko, Christine M.
   Felder, Seth
   Kim, Richard
   Sahin, Ibrahim Halil
TI Human Epidermal Growth Factor Receptor 2-Targeting Approaches for
   Colorectal Cancer: Clinical Implications of Novel Treatments and Future
   Therapeutic Avenues
SO JCO ONCOLOGY PRACTICE
LA English
DT Review
ID METASTATIC BREAST-CANCER; CHROMOSOMAL INSTABILITY; TRASTUZUMAB
   DERUXTECAN; HER2; OVEREXPRESSION; PERTUZUMAB; MANAGEMENT; MECHANISM;
   LAPATINIB; TUCATINIB
AB The treatment paradigm for colorectal cancer (CRC) has changed significantly over the past decade with targeted therapeutics. Human epidermal growth factor receptor 2 (HER2) amplification is seen among 3%-4% of patients with metastatic CRC (mCRC). The biological discovery of HER2 amplification in cancer cells has led to practice-changing drug development for several solid tumors, including breast, gastric, and esophageal cancers. HER2 amplification is now highly actionable in CRC with distinct therapeutic combinations, including the combination of monoclonal antibodies and HER2 receptor-specific tyrosine kinase inhibitors, as well as antibody-drug conjugates, that delivers targeted cytotoxic agents. However, it is essential to define the therapeutic role and sequence of these different combinations, some of which are already part of standard clinical practice. In this review article, we discuss recent clinical studies demonstrating the clinical benefits of each distinct therapeutic approach and their impacts on the current management of HER2-amplified mCRC. We also review ongoing clinical trials targeting the HER2 pathway in mCRC and elaborate on novel therapeutic opportunities in this space that may further define the changing paradigm of HER2-targeted therapy for CRC.
C1 [Karan, Canan; Tan, Elaine; Sarfraz, Humaira; Felder, Seth; Kim, Richard; Sahin, Ibrahim Halil] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, 12902 Magnolia Dr, Tampa, FL 33647 USA.
   [Knepper, Todd C.; Walko, Christine M.] H Lee Moffitt Canc Ctr & Res Inst, Dept Individualized Canc Management, Tampa, FL 33647 USA.
C3 H Lee Moffitt Cancer Center & Research Institute; H Lee Moffitt Cancer
   Center & Research Institute
RP Sahin, IH (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, 12902 Magnolia Dr, Tampa, FL 33647 USA.
EM Ibrahim.sahin@moffitt.org
RI Karan, Canan/IZP-6252-2023; Şahin, İbrahim/HHY-8303-2022; Sarfraz,
   Humaira/JAO-4863-2023
OI Sarfraz, Humaira/0000-0003-2616-3425; Karan, Canan/0000-0002-1293-2046;
   Kim, Richard/0000-0002-8448-844X; Sahin, Ibrahim
   Halil/0000-0003-2758-3077; Tan, Elaine/0000-0002-1656-368X; Walko,
   Christine/0000-0001-8435-898X
CR André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   [Anonymous], 2003, P AM SOC CLIN ONCOL
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Capelan M, 2013, ANN ONCOL, V24, P273, DOI 10.1093/annonc/mds328
   Cenaj O, 2019, AM J CLIN PATHOL, V152, P97, DOI 10.1093/ajcp/aqz031
   Conradi LC, 2013, AM J SURG PATHOL, V37, P522, DOI 10.1097/PAS.0b013e318272ff4d
   García-Alonso S, 2020, TRENDS CANCER, V6, P130, DOI 10.1016/j.trecan.2019.12.010
   Guler I, 2019, EXPERT REV GASTROENT, V13, P919, DOI 10.1080/17474124.2019.1663174
   Gupta R, 2020, J CLIN ONCOL, V38
   Hudis CA, 2007, NEW ENGL J MED, V357, P39, DOI 10.1056/NEJMra043186
   Karunagaran D, 1996, EMBO J, V15, P254, DOI 10.1002/j.1460-2075.1996.tb00356.x
   Kopetz S, 2020, J CLIN ONCOL, V38
   Kulukian A, 2020, MOL CANCER THER, V19, P976, DOI 10.1158/1535-7163.MCT-19-0873
   Linehan AS, 2021, BREAST CANCER-TARGET, V13, P151, DOI 10.2147/BCTT.S245024
   Marx AH, 2010, HUM PATHOL, V41, P1577, DOI 10.1016/j.humpath.2010.02.018
   McKeage K, 2002, DRUGS, V62, P209, DOI 10.2165/00003495-200262010-00008
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Messersmith WA, 2019, J NATL COMPR CANC NE, V17, P599, DOI 10.6004/jnccn.2019.5014
   Moasser MM, 2007, ONCOGENE, V26, P6577, DOI 10.1038/sj.onc.1210478
   Moasser MM, 2007, ONCOGENE, V26, P6469, DOI 10.1038/sj.onc.1210477
   Modi S, 2020, J CLIN ONCOL, V38, P1887, DOI 10.1200/JCO.19.02318
   Nakamura Y, 2021, NAT MED, V27, P1899, DOI 10.1038/s41591-021-01553-w
   Okamoto W, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3555
   Park DI, 2007, INT J COLORECTAL DIS, V22, P491, DOI 10.1007/s00384-006-0192-8
   Penault-Llorca F, 2009, AM J CLIN PATHOL, V132, P539, DOI 10.1309/AJCPV2I0HGPMGBSQ
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Raghav KPS, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3517
   Rahib L, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.4708
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Richard S, 2016, AN ACAD BRAS CIENC, V88, P565
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Salem ME, 2017, ONCOTARGET, V8, P86356, DOI 10.18632/oncotarget.21169
   Sansregret L, 2018, NAT REV CLIN ONCOL, V15, P139, DOI 10.1038/nrclinonc.2017.198
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Segovia-Mendoza M, 2015, AM J CANCER RES, V5, P2531
   Shah M, 2021, CLIN CANCER RES, V27, P1220, DOI 10.1158/1078-0432.CCR-20-2701
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Strickler JH, 2019, ANN ONCOL, V30
   STRICKLER JH, 2021, J CLIN ONCOL, V39
   Tan E, 2021, EXPERT REV GASTROENT, V15, P735, DOI 10.1080/17474124.2021.1886077
   Tosi F, 2020, CLIN COLORECTAL CANC, V19, P256, DOI 10.1016/j.clcc.2020.06.009
   Wolff AC, 2018, J CLIN ONCOL, V36, P2105, DOI [10.1200/JCO.2018.77.8738, 10.5858/arpa.2018-0902-SA]
   Yoshino T., 2021, J. Clin. Oncol., V39
NR 48
TC 11
Z9 11
U1 1
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2688-1527
EI 2688-1535
J9 JCO ONCOL PRACT
JI JCO Oncol. Pract.
PD AUG
PY 2022
VL 18
IS 8
BP 545
EP +
DI 10.1200/OP.21.00904
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 3S5XO
UT WOS:000839669700006
PM 35613416
OA Bronze
DA 2025-01-04
ER

PT J
AU Ma, YF
   Wang, LH
   Neitzel, LR
   Loganathan, SN
   Tang, N
   Qin, LL
   Crispi, EE
   Guo, Y
   Knapp, S
   Beauchamp, RD
   Lee, E
   Wang, JL
AF Ma, Yufang
   Wang, Lihong
   Neitzel, Leif R.
   Loganathan, Sudan N.
   Tang, Nan
   Qin, Lili
   Crispi, Emily E.
   Guo, Yan
   Knapp, Stefan
   Beauchamp, R. Daniel
   Lee, Ethan
   Wang, Jialiang
TI The MAPK Pathway Regulates Intrinsic Resistance to BET Inhibitors in
   Colorectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID CHRONIC LYMPHOCYTIC-LEUKEMIA; BROMODOMAIN INHIBITION; COLON-CANCER;
   C-MYC; EPIGENETIC READERS; THERAPEUTIC TARGET; SMALL-INTESTINE; APC
   DEFICIENCY; ONCOGENIC KRAS; BREAST-CANCER
AB Purpose: The bromodomain and extra-terminal domain (BET) family proteins are epigenetic readers for acetylated histone marks. Emerging BET bromodomain inhibitors have exhibited antineoplastic activities in a wide range of human cancers through suppression of oncogenic transcription factors, including MYC. However, the preclinical activities of BET inhibitors in advanced solid cancers are moderate at best. To improve BET-targeted therapy, we interrogated mechanisms mediating resistance to BET inhibitors in colorectal cancer.
   Experimental Design: Using a panel of molecularly defined colorectal cancer cell lines, we examined the impact of BET inhibition on cellular proliferation and survival as well as MYC activity. We further tested the ability of inhibitors targeting the RAF/MEK/ERK (MAPK) pathway to enhance MYC suppression and circumvent intrinsic resistance to BET inhibitors. Key findings were validated using genetic approaches.
   Results: BET inhibitors as monotherapy moderately reduced colorectal cancer cell proliferation and MYC expression. Blockade of the MAPK pathway synergistically sensitized colorectal cancer cells to BET inhibitors, leading to potent apoptosis and MYC downregulation in vitro and in vivo. A combination of JQ1 and trametinib, but neither agent alone, induced significant regression of subcutaneous colorectal cancer xenografts.
   Conclusions: Our findings suggest that the MAPK pathway confers intrinsic resistance to BET inhibitors in colorectal cancer and propose an effective combination strategy for the treatment of colorectal cancer. (C) 2016 AACR.
C1 [Ma, Yufang; Qin, Lili; Wang, Jialiang] Vanderbilt Univ, Dept Neurol Surg, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Wang, Lihong; Beauchamp, R. Daniel] Vanderbilt Univ, Dept Surg, Nashville, TN 37240 USA.
   [Neitzel, Leif R.; Crispi, Emily E.; Lee, Ethan] Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Loganathan, Sudan N.] Meharry Med Coll, Dept Neurosci & Pharmacol, Nashville, TN 37208 USA.
   [Tang, Nan] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Wuhan, Peoples R China.
   [Guo, Yan; Wang, Jialiang] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA.
   [Knapp, Stefan] Univ Oxford, Struct Genom Consortium, Nuffield Dept Clin Med, Oxford, England.
   [Wang, Jialiang] Vanderbilt Univ, Dept Pharmacol, Nashville, TN USA.
C3 Vanderbilt University; Vanderbilt University; Vanderbilt University;
   Meharry Medical College; Huazhong University of Science & Technology;
   Vanderbilt University; University of Oxford; Vanderbilt University
RP Wang, JL (corresponding author), Vanderbilt Univ, Med Ctr North T4224, Nashville, TN 37232 USA.
EM jialiang.wang@vanderbilt.edu
RI Qin, Lili/J-7481-2016; Knapp, Stefan/AAG-2347-2019; Wang, Li/O-1425-2015
OI Neitzel, Leif/0000-0003-2621-6259; Knapp, Stefan/0000-0001-5995-6494
FU NIH [R01CA166492, R01GM103926, R01GM081635, 5T32HD007502, T32GM07628];
   Voice Against Brain Cancer Foundation; Structural Genomics Consortium, a
   registered charity [1097737]; AbbVie; Bayer; Boehringer Ingelheim;
   Genome Canada through Ontario Genomics Institute [OGI-055];
   GlaxoSmithKline; Janssen; Lilly Canada; Novartis Research Foundation;
   Ontario Ministry of Economic Development and Innovation; Pfizer; Takeda;
   Welcome Trust [092809/Z/10/Z];  [R01CA069457]; Wellcome Trust
   [092809/Z/10/Z] Funding Source: Wellcome Trust
FX J. Wang is supported by the NIH grant (R01CA166492) and the Voice
   Against Brain Cancer Foundation. E. Lee is supported by NIH grants
   R01GM103926 and R01GM081635, and R.D. Beauchamp is supported by
   R01CA069457. S. Knapp is grateful for support by the Structural Genomics
   Consortium, a registered charity (No. 1097737) that receives funds from
   AbbVie, Bayer, Boehringer Ingelheim, Genome Canada through Ontario
   Genomics Institute Grant OGI-055, GlaxoSmithKline, Janssen, Lilly
   Canada, the Novartis Research Foundation, the Ontario Ministry of
   Economic Development and Innovation, Pfizer, Takeda, and Welcome Trust
   Grant 092809/Z/10/Z. L.R. Neitzel is a recipient of NIH training grant
   5T32HD007502. S.N. Loganathan is supported by NIH training grant
   T32GM07628.
CR Ahmad I, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.7
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156
   [Anonymous], ANN ONCOL
   Athineos D, 2010, ONCOGENE, V29, P2585, DOI 10.1038/onc.2010.5
   Baratta MG, 2015, P NATL ACAD SCI USA, V112, P232, DOI 10.1073/pnas.1422165112
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Cheng ZX, 2013, CLIN CANCER RES, V19, P1748, DOI 10.1158/1078-0432.CCR-12-3066
   Chou TC, 2010, CANCER RES, V70, P440, DOI 10.1158/0008-5472.CAN-09-1947
   Conery AR, 2016, CANCER RES, V76, P1313, DOI 10.1158/0008-5472.CAN-15-1458
   Dawson MA, 2012, NEW ENGL J MED, V367, P647, DOI 10.1056/NEJMra1112635
   De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561
   Delmore JE, 2011, CELL, V146, P903, DOI 10.1016/j.cell.2011.08.017
   Filippakopoulos P, 2014, NAT REV DRUG DISCOV, V13, P339, DOI 10.1038/nrd4286
   Filippakopoulos P, 2010, NATURE, V468, P1067, DOI 10.1038/nature09504
   Fong CY, 2015, NATURE, V525, P538, DOI 10.1038/nature14888
   Guo Y, 2014, BRIEF BIOINFORM, V15, P879, DOI 10.1093/bib/bbt069
   He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509
   Horst D, 2012, CANCER RES, V72, P1547, DOI 10.1158/0008-5472.CAN-11-3222
   Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928
   Huang B, 2009, MOL CELL BIOL, V29, P1375, DOI 10.1128/MCB.01365-08
   Hung KE, 2010, P NATL ACAD SCI USA, V107, P1565, DOI 10.1073/pnas.0908682107
   Janssen KP, 2006, GASTROENTEROLOGY, V131, P1096, DOI 10.1053/j.gastro.2006.08.011
   Julien S, 2012, CLIN CANCER RES, V18, P5314, DOI 10.1158/1078-0432.CCR-12-0372
   Kim IJ, 2003, CLIN CANCER RES, V9, P2920
   Knoechel B, 2014, NAT GENET, V46, P364, DOI 10.1038/ng.2913
   Lemieux E, 2015, ONCOGENE, V34, P4914, DOI 10.1038/onc.2014.416
   McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265
   Mertz JA, 2011, P NATL ACAD SCI USA, V108, P16669, DOI 10.1073/pnas.1108190108
   Mologni L, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0051449
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Okamoto K, 2015, MOL CANCER RES, V13, P659, DOI 10.1158/1541-7786.MCR-14-0476
   Puissant A, 2013, CANCER DISCOV, V3, P308, DOI 10.1158/2159-8290.CD-12-0418
   Rathert P, 2015, NATURE, V525, P543, DOI 10.1038/nature14898
   Roberts AW, 2016, NEW ENGL J MED, V374, P311, DOI 10.1056/NEJMoa1513257
   Roberts AW, 2012, J CLIN ONCOL, V30, P488, DOI 10.1200/JCO.2011.34.7898
   Sansom OJ, 2007, NATURE, V446, P676, DOI 10.1038/nature05674
   Sears R, 2000, GENE DEV, V14, P2501, DOI 10.1101/gad.836800
   Shi J, 2014, CANCER CELL, V25, P210, DOI 10.1016/j.ccr.2014.01.028
   Shimamura T, 2013, CLIN CANCER RES, V19, P6183, DOI 10.1158/1078-0432.CCR-12-3904
   Shu SK, 2016, NATURE, V529, P413, DOI 10.1038/nature16508
   Singh A, 2012, CELL, V148, P639, DOI 10.1016/j.cell.2011.12.033
   Spreafico A, 2013, CLIN CANCER RES, V19, P4149, DOI 10.1158/1078-0432.CCR-12-3140
   Stratikopoulos EE, 2015, CANCER CELL, V27, P837, DOI 10.1016/j.ccell.2015.05.006
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Tang YJ, 2014, NAT MED, V20, P732, DOI 10.1038/nm.3613
   Tögel L, 2016, MOL CANCER THER, V15, P1217, DOI 10.1158/1535-7163.MCT-15-0724
   Toon CW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087456
   Trapnell C, 2012, NAT PROTOC, V7, P562, DOI 10.1038/nprot.2012.016
   Tripathi MK, 2014, CANCER RES, V74, P6947, DOI 10.1158/0008-5472.CAN-14-1592
   Whitehead RH, 2009, AM J PHYSIOL-GASTR L, V296, pG455, DOI 10.1152/ajpgi.90381.2008
   Zuber J, 2011, NATURE, V478, P524, DOI 10.1038/nature10334
NR 53
TC 53
Z9 54
U1 0
U2 16
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD APR 15
PY 2017
VL 23
IS 8
BP 2027
EP 2037
DI 10.1158/1078-0432.CCR-16-0453
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ES0AM
UT WOS:000399188300019
PM 27678457
OA Bronze, Green Accepted, Green Submitted
DA 2025-01-04
ER

PT J
AU Bogoevska, V
   Wolters-Eisfeld, G
   Hofmann, BT
   El Gammal, AT
   Mercanoglu, B
   Gebauer, F
   Vashist, YK
   Bogoevski, D
   Perez, D
   Gagliani, N
   Izbicki, JR
   Bockhorn, M
   Güngör, C
AF Bogoevska, V.
   Wolters-Eisfeld, G.
   Hofmann, B. T.
   El Gammal, A. T.
   Mercanoglu, B.
   Gebauer, F.
   Vashist, Y. K.
   Bogoevski, D.
   Perez, D.
   Gagliani, N.
   Izbicki, J. R.
   Bockhorn, M.
   Guengoer, C.
TI HRG/HER2/HER3 signaling promotes AhR-mediated Memo-1 expression and
   migration in colorectal cancer
SO ONCOGENE
LA English
DT Article
ID ARYL-HYDROCARBON RECEPTOR; EPITHELIAL-MESENCHYMAL TRANSITION; N-WASP;
   PROTEIN; GROWTH; TRANSCRIPTION; NETWORK; TARGETS
AB Colorectal cancer (CRC) is a complex disease with still unsatisfactory prognosis even in western societies, although substantial progress has been made in pre-screening programs, surgical techniques and targeted therapy options. Mediator of motility-1 (Memo-1) was previously recognized as an important effector of cell migration downstream of receptor tyrosine kinase signaling in breast cancer. This study identified Memo-1 as frequently overexpressed in CRC and established a close link between extracellular HER2 activation, AhR/ARNT transcriptional activity and Memo-1 expression. Dissection of the hMemo-1 gene promoter using reporter assays and chromatin IP techniques revealed recruitment of Aryl hydrocarbon receptor (AhR)/Aryl hydrocarbon receptor nuclear-translocator (ARNT) complex, which positively influenced Memo-1 expression in cancer cells. We found that Memo-1 depletion negatively influenced the cellular actin network and that its expression is required for HER2-mediated cell migration and invasion. Moreover, analyses of Memo-1 expression in primary CRC revealed correlation with clinical parameters that point to Memo-1 as a new prognostic factor of aggressive disease in CRC patients. Altogether, these observations demonstrate that Memo-1 is an important downstream regulator of HER2-driven CRC cell migration and invasion through connecting extracellular signals from membrane to the cytoskeletal actin network.
C1 [Bogoevska, V.] Cardiologicum Hamburg Res & Study Ctr, Hamburg, Germany.
   [Bogoevska, V.; Wolters-Eisfeld, G.; Hofmann, B. T.; El Gammal, A. T.; Mercanoglu, B.; Gebauer, F.; Vashist, Y. K.; Bogoevski, D.; Perez, D.; Gagliani, N.; Izbicki, J. R.; Bockhorn, M.; Guengoer, C.] Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Expt Oncol, Martinistr 52, D-20246 Hamburg, Germany.
   [Vashist, Y. K.] Kantonsspital Aarau AG, Sect Visceral Surg, Dept Surg, Aarau, Switzerland.
   [Gagliani, N.] Univ Med Ctr, Dept Med, Hamburg, Germany.
C3 University of Hamburg; University Medical Center Hamburg-Eppendorf;
   Kantonsspital Aarau AG (KSA); University of Hamburg; University Medical
   Center Hamburg-Eppendorf
RP Güngör, C (corresponding author), Univ Med Ctr Hamburg Eppendorf, Dept Gen Visceral & Thorac Surg, Expt Oncol, Martinistr 52, D-20246 Hamburg, Germany.
EM c.guengoer@uke.de
RI Vashist, Yogesh/ABE-4001-2020; Wolters-Eisfeld, Gerrit/H-8333-2019
OI Vashist, Yogesh/0000-0003-2030-6712; Wolters-Eisfeld,
   Gerrit/0000-0002-2984-6515; Perez, Daniel/0000-0002-3154-7311; Gagliani,
   Nicola/0000-0001-8514-1395
FU 'Roggenbuck Foundation', Hamburg, Germany
FX We thank A Heinecke, P Merkert and P Schroder for excellent technical
   assistance and Dr M Linnebacher for providing primary CRC cells. This
   work (CG) was partially funded by the 'Roggenbuck Foundation', Hamburg,
   Germany.
CR Applewhite DA, 2007, MOL BIOL CELL, V18, P2579, DOI 10.1091/mbc.E06-11-0990
   Atlas E, 2003, MOL CANCER RES, V1, P165
   Baselga J, 2009, NAT REV CANCER, V9, P463, DOI 10.1038/nrc2656
   Carvajal-Gonzalez JM, 2009, MOL BIOL CELL, V20, P1715, DOI 10.1091/mbc.E08-05-0451
   Chaffer CL, 2011, SCIENCE, V331, P1559, DOI 10.1126/science.1203543
   Feng SL, 2013, BBA-REV CANCER, V1836, P197, DOI 10.1016/j.bbcan.2013.05.001
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gramatzki D, 2009, ONCOGENE, V28, P2593, DOI 10.1038/onc.2009.104
   Güngör C, 2007, P NATL ACAD SCI USA, V104, P15000, DOI 10.1073/pnas.0703738104
   Hannafon BN, 2011, BREAST CANCER RES, V13, DOI 10.1186/bcr2839
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Iwatsuki M, 2010, CANCER SCI, V101, P293, DOI 10.1111/j.1349-7006.2009.01419.x
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jiang K, 2013, J BIOL CHEM, V288, P24590, DOI 10.1074/jbc.M113.467837
   Johnsen SA, 2009, CANCER RES, V69, P128, DOI 10.1158/0008-5472.CAN-08-1630
   Kovacs EM, 2011, NAT CELL BIOL, V13, P934, DOI 10.1038/ncb2290
   Lai DW, 2014, ONCOTARGET, V5, P7788, DOI 10.18632/oncotarget.2307
   Lemmon MA, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a020768
   MacDonald G, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004870
   Maletzki C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052485
   Marone R, 2004, NAT CELL BIOL, V6, P515, DOI 10.1038/ncb1134
   Momeny M, 2015, ONCOTARGET, V6, P3932, DOI 10.18632/oncotarget.2846
   Oberländer M, 2013, LANGENBECK ARCH SURG, V398, P251, DOI 10.1007/s00423-012-1043-4
   Opitz CA, 2011, NATURE, V478, P197, DOI 10.1038/nature10491
   Qiu C, 2008, J BIOL CHEM, V283, P2734, DOI 10.1074/jbc.M703523200
   Rawnaq T, 2014, MOL CANCER RES, V12, P670, DOI 10.1158/1541-7786.MCR-13-0467
   Rodriguez OC, 2003, NAT CELL BIOL, V5, P599, DOI 10.1038/ncb0703-599
   Romiti A, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0496-z
   Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002
   Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852
   Rotty JD, 2013, NAT REV MOL CELL BIO, V14, P7, DOI 10.1038/nrm3492
   Sorokin AV, 2013, ONCOGENE, V32, P3130, DOI 10.1038/onc.2012.327
   Stier S, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/271246
   Suetsugu S, 2002, DEV CELL, V3, P645, DOI 10.1016/S1534-5807(02)00324-6
   Takenawa T, 2007, NAT REV MOL CELL BIO, V8, P37, DOI 10.1038/nrm2069
   Yang MH, 2011, LEUKEMIA LYMPHOMA, V52, P298, DOI 10.3109/10428194.2010.538776
   Zaoui K, 2008, J CELL BIOL, V183, P401, DOI 10.1083/jcb.200805107
   Zegers Mirjam M, 2014, Small GTPases, V5, pe28997, DOI 10.4161/sgtp.28997
   Zhao S, 2013, CANCER LETT, V330, P41, DOI 10.1016/j.canlet.2012.11.021
NR 39
TC 24
Z9 26
U1 0
U2 5
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD APR 27
PY 2017
VL 36
IS 17
BP 2394
EP 2404
DI 10.1038/onc.2016.390
PG 11
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA ET4QE
UT WOS:000400268900006
PM 27941874
DA 2025-01-04
ER

PT J
AU Shao, ZW
   Pan, HQ
   Tu, S
   Zhang, JY
   Yan, S
   Shao, AW
AF Shao, Zhiwei
   Pan, Haoqi
   Tu, Sheng
   Zhang, Jingying
   Yan, Sheng
   Shao, Anwen
TI HGF/c-Met Axis: The Advanced Development in Digestive System Cancer
SO FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY
LA English
DT Review
DE hepatocyte growth factor; c-Met; molecular targeted therapy; digestive
   system cancer; inhibitors
ID GROWTH FACTOR/SCATTER FACTOR; RECEPTOR TYROSINE KINASE; COMPREHENSIVE
   MOLECULAR CHARACTERIZATION; TIVANTINIB ARQ 197; WILD-TYPE KRAS; PHASE-I
   TRIAL; C-MET; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER; THERAPEUTIC
   TARGET
AB Numerous studies have indicated that abnormal activation of the HGF/c-Met signaling pathway can lead to cell proliferation, invasiveness, and metastasis of cancers of the digestive system. Moreover, overexpression of c-Met has been implicated in poor prognosis of patients with these forms of cancer, suggesting the possibility for HGF/c-Met axis as a potential therapeutic target. Despite the large number of clinical and preclinical trials worldwide, no significant positive success in the use of anti-HGF/c-Met treatments on cancers of the digestive system has been achieved. In this review, we summarize advanced development of clinical research on HGF/c-Met antibody and small-molecule c-Met inhibitors of cancers of the digestive system and provide a possible direction for future research.
C1 [Shao, Zhiwei; Yan, Sheng] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China.
   [Pan, Haoqi] Zhejiang Univ, Sch Med, Sir Run Run Shaw Hosp, Dept Gen Surg, Hangzhou, Peoples R China.
   [Tu, Sheng] Zhejiang Univ, Collaborat Innovat Ctr Diag & Treatment Infect Di, State Key Lab Diag & Treatment Infect Dis, Affiliated Hosp 1,Coll Med, Hangzhou, Peoples R China.
   [Zhang, Jingying] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Gen Surg, Hangzhou, Peoples R China.
   [Shao, Anwen] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China.
C3 Zhejiang University; Zhejiang University; Zhejiang University;
   Collaborative Innovation Center for Diagnosis & Treatment of Infectious
   Diseases; Zhejiang University; Zhejiang University
RP Yan, S (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Hepatobiliary & Pancreat Surg, Hangzhou, Peoples R China.; Shao, AW (corresponding author), Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou, Peoples R China.
EM shengyan@zju.edu.cn; 21118116@zju.edu.cn
RI Shao, Anwen/R-9023-2019; Tu, Sheng/GXF-8910-2022
OI Shao, Anwen/0000-0001-9986-6290
FU China Postdoctoral Science Foundation [2017M612010]; National Natural
   Science Foundation of China [81701144]
FX This work was funded by the China Postdoctoral Science Foundation
   (2017M612010) and the National Natural Science Foundation of China
   (81701144).
CR Abou-Alfa GK, 2018, NEW ENGL J MED, V379, P54, DOI 10.1056/NEJMoa1717002
   Ang C, 2016, WORLD J GASTROENTERO, V22, P906, DOI 10.3748/wjg.v22.i3.906
   [Anonymous], 2015, J CLIN ONCOL S
   Avan A, 2013, CANCER RES, V73, P6745, DOI 10.1158/0008-5472.CAN-13-0837
   Bahrami A, 2017, J CELL PHYSIOL, V232, P2657, DOI 10.1002/jcp.25794
   Basilico C, 2013, CLIN CANCER RES, V19, P2381, DOI 10.1158/1078-0432.CCR-12-3459
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Bhushan B, 2019, HEPATOLOGY, V69, P1702, DOI 10.1002/hep.30109
   BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0
   Bouattour M, 2018, HEPATOLOGY, V67, P1132, DOI 10.1002/hep.29496
   Bradley Conor A, 2018, Nat Rev Clin Oncol, V15, P150, DOI 10.1038/nrclinonc.2018.13
   Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1
   Choueiri TK., 2020, JAMA ONCOL, V6, P1
   Chu YY, 2020, AM J CANCER RES, V10, P648
   COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0
   CREPALDI T, 1994, J BIOL CHEM, V269, P1750
   Delord JP, 2020, INVEST NEW DRUG, V38, P1774, DOI 10.1007/s10637-020-00928-z
   Dratkiewicz E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21010113
   Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014
   Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591
   Eder JP, 2009, CLIN CANCER RES, V15, P2207, DOI 10.1158/1078-0432.CCR-08-1306
   Elisei R, 2013, J CLIN ONCOL, V31, P3639, DOI 10.1200/JCO.2012.48.4659
   Eng C, 2016, INT J CANCER, V139, P177, DOI 10.1002/ijc.30049
   Falchook GS, 2020, CLIN CANCER RES, V26, P1237, DOI 10.1158/1078-0432.CCR-19-2860
   Fuse N, 2016, GASTRIC CANCER, V19, P183, DOI 10.1007/s10120-015-0471-6
   Gao SH, 2013, CHINESE MED J-PEKING, V126, P2705, DOI 10.3760/cma.j.issn.0366-6999.20123619
   Gao W, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0546-3
   García-Vilas JA, 2018, WORLD J GASTROENTERO, V24, P3695, DOI 10.3748/wjg.v24.i33.3695
   Gardian K, 2012, GASTROENT RES PRACT, V2012, DOI 10.1155/2012/585674
   Garouniatis A, 2013, INT J COLORECTAL DIS, V28, P9, DOI 10.1007/s00384-012-1520-9
   Gavine PR, 2015, MOL ONCOL, V9, P323, DOI 10.1016/j.molonc.2014.08.015
   Gherardi E, 2006, P NATL ACAD SCI USA, V103, P4046, DOI 10.1073/pnas.0509040103
   Gherardi E, 2012, NAT REV CANCER, V12, P89, DOI 10.1038/nrc3205
   Giordano S, 2014, J HEPATOL, V60, P442, DOI 10.1016/j.jhep.2013.09.009
   Glodde N, 2017, IMMUNITY, V47, P789, DOI 10.1016/j.immuni.2017.09.012
   Gomez-Martín C, 2014, CANCER LETT, V351, P30, DOI 10.1016/j.canlet.2014.05.019
   Hage C, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.158
   Holmes O, 2007, J MOL BIOL, V367, P395, DOI 10.1016/j.jmb.2006.12.061
   Hughes PE, 2016, MOL CANCER THER, V15, P1568, DOI 10.1158/1535-7163.MCT-15-0871
   Inagaki Y, 2011, BIOSCI TRENDS, V5, P52, DOI 10.5582/bst.2011.v5.2.52
   Iveson T, 2014, LANCET ONCOL, V15, P1007, DOI 10.1016/S1470-2045(14)70023-3
   Kang YK, 2014, INVEST NEW DRUG, V32, P355, DOI 10.1007/s10637-013-0057-2
   Kelley RK, 2017, ANN ONCOL, V28, P528, DOI 10.1093/annonc/mdw651
   Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567
   Kim JH, 2017, ONCOTARGET, V8, P90351, DOI 10.18632/oncotarget.20087
   Kim JH, 2017, ONCOTARGET, V8, P73098, DOI 10.18632/oncotarget.20392
   Korhan P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105278
   Kucerova L, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2341-y
   Kumar A, 2020, BRAIN SCI, V10, DOI 10.3390/brainsci10010043
   Lee J, 2019, CANCER DISCOV, V9, P1388, DOI 10.1158/2159-8290.CD-19-0442
   Lee J, 2015, ONCOTARGET, V6, P28211, DOI 10.18632/oncotarget.4721
   Lee SJ, 2018, CLIN COLORECTAL CANC, V17, P165, DOI 10.1016/j.clcc.2018.02.013
   Li WJ, 2019, J CLIN INVEST, V129, P2293, DOI 10.1172/JCI126428
   Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568
   Liu L, 2014, CLIN CANCER RES, V20, P6059, DOI 10.1158/1078-0432.CCR-14-0543
   Liu Y, 2015, WORLD J GASTROENTERO, V21, P3706, DOI 10.3748/wjg.v21.i12.3706
   Luke JJ, 2020, CLIN CANCER RES, V26, P804, DOI 10.1158/1078-0432.CCR-19-1223
   Marisi G, 2018, WORLD J GASTROENTERO, V24, P4152, DOI 10.3748/wjg.v24.i36.4152
   Markham A, 2020, DRUGS, V80, P829, DOI 10.1007/s40265-020-01317-9
   Merchant M, 2013, P NATL ACAD SCI USA, V110, pE2987, DOI 10.1073/pnas.1302725110
   Michalopoulos GK, 1997, SCIENCE, V276, P60, DOI 10.1126/science.276.5309.60
   Miranda O, 2018, CANCERS, V10, DOI 10.3390/cancers10090280
   Mok TSK, 2016, J THORAC ONCOL, V11, P1736, DOI 10.1016/j.jtho.2016.05.038
   Munshi N, 2010, MOL CANCER THER, V9, P1544, DOI 10.1158/1535-7163.MCT-09-1173
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nakagawa T, 2010, CANCER SCI, V101, P210, DOI 10.1111/j.1349-7006.2009.01343.x
   Ogunwobi OO, 2019, WORLD J GASTROENTERO, V25, P2279, DOI 10.3748/wjg.v25.i19.2279
   Padmanabhan N, 2017, NAT REV GASTRO HEPAT, V14, P467, DOI 10.1038/nrgastro.2017.53
   Paik PK, 2020, NEW ENGL J MED, V383, P931, DOI 10.1056/NEJMoa2004407
   Parikh PK, 2018, EUR J MED CHEM, V143, P1103, DOI 10.1016/j.ejmech.2017.08.044
   Parikh RA, 2014, ONCOTARGETS THER, V7, P969, DOI 10.2147/OTT.S40241
   Peng Z, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092924
   Peschard P, 2001, MOL CELL, V8, P995, DOI 10.1016/S1097-2765(01)00378-1
   Qin SK, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919889001
   Ren JL, 2017, PANMINERVA MED, V59, P97, DOI 10.23736/S0031-0808.16.03228-6
   Rimassa L, 2019, CLIN COLORECTAL CANC, V18, P125, DOI 10.1016/j.clcc.2019.02.004
   Rimassa L, 2018, LANCET ONCOL, V19, P682, DOI 10.1016/S1470-2045(18)30146-3
   Rimassa L, 2016, ONCOTARGET, V7, P72622, DOI 10.18632/oncotarget.11621
   RONG S, 1994, P NATL ACAD SCI USA, V91, P4731, DOI 10.1073/pnas.91.11.4731
   Sakai D, 2017, CANCER CHEMOTH PHARM, V80, P1197, DOI 10.1007/s00280-017-3445-z
   Salgia R, 2020, CANCER TREAT REV, V87, DOI 10.1016/j.ctrv.2020.102022
   Salian-Mehta S, 2013, MOL CELL ENDOCRINOL, V374, P92, DOI 10.1016/j.mce.2013.04.018
   Santoro A, 2013, LANCET ONCOL, V14, P55, DOI 10.1016/S1470-2045(12)70490-4
   Scagliotti GV, 2018, J THORAC ONCOL, V13, P849, DOI 10.1016/j.jtho.2017.12.009
   Shah MA, 2016, ONCOLOGIST, V21, P1085, DOI 10.1634/theoncologist.2016-0038
   Shah MA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054014
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557
   Steinway SN, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128159
   Strickler JH, 2020, MOL CANCER THER, V19, P1210, DOI 10.1158/1535-7163.MCT-19-0529
   Strickler JH, 2018, J CLIN ONCOL, V36, P3298, DOI 10.1200/JCO.2018.78.7697
   Sun X, 2020, AM J CANCER RES, V10, P564
   Tabernero J, 2014, CLIN CANCER RES, V20, P2793, DOI 10.1158/1078-0432.CCR-13-1837
   Takiguchi S, 2017, INT J ONCOL, V51, P184, DOI 10.3892/ijo.2017.3992
   Van Cutsem E, 2019, CLIN CANCER RES, V25, P2414, DOI 10.1158/1078-0432.CCR-18-1337
   Van Cutsem E, 2014, CLIN CANCER RES, V20, P4240, DOI 10.1158/1078-0432.CCR-13-2752
   Van Schaeybroeck S, 2011, NAT REV CLIN ONCOL, V8, P222, DOI 10.1038/nrclinonc.2011.15
   Wang JY, 2017, CLIN CANCER RES, V23, P992, DOI 10.1158/1078-0432.CCR-16-1568
   Wang JY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2138-z
   Wang R, 2001, J CELL BIOL, V153, P1023, DOI 10.1083/jcb.153.5.1023
   Xiang QF, 2014, CLIN CANCER RES, V20, P2959, DOI 10.1158/1078-0432.CCR-13-2620
   Xu J, 2020, ONCOLOGIST, V25, P652, DOI 10.1634/theoncologist.2020-0127
   Xu ZQ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1010-2
   Yakes FM, 2011, MOL CANCER THER, V10, P2298, DOI 10.1158/1535-7163.MCT-11-0264
   Yamamoto N, 2006, J CELL SCI, V119, P4623, DOI 10.1242/jcs.03236
   Yan HH, 2014, ONCOTARGET, V5, P9150, DOI 10.18632/oncotarget.2363
   Yang XB, 2020, ONCOLOGIST, V25, P470, DOI 10.1634/theoncologist.2019-0563
   Yau TCC, 2017, CLIN CANCER RES, V23, P2405, DOI 10.1158/1078-0432.CCR-16-1789
   Yi S, 2000, NEOPLASIA, V2, P226, DOI 10.1038/sj.neo.7900080
   Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049
   Zhang H., 2018, INT J MOL SCI, V19
   Zhang ZL, 2018, AUTOPHAGY, V14, P2083, DOI 10.1080/15548627.2018.1503146
   Zhen DB, 2016, INVEST NEW DRUG, V34, P733, DOI 10.1007/s10637-016-0376-1
   Zhu GH, 2011, DIGEST DIS SCI, V56, P1090, DOI 10.1007/s10620-010-1416-x
   Zielonka D, 2015, PARKINSONISM RELAT D, V21, P169, DOI 10.1016/j.parkreldis.2014.12.013
NR 115
TC 10
Z9 13
U1 1
U2 19
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2296-634X
J9 FRONT CELL DEV BIOL
JI Front. Cell. Dev. Biol.
PD OCT 26
PY 2020
VL 8
AR 801
DI 10.3389/fcell.2020.00801
PG 14
WC Cell Biology; Developmental Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Developmental Biology
GA OO4WZ
UT WOS:000587382100001
PM 33195182
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Cherri, S
   Oneda, E
   Zanotti, L
   Zaniboni, A
AF Cherri, Sara
   Oneda, Ester
   Zanotti, Laura
   Zaniboni, Alberto
TI Optimizing the first-line treatment for metastatic colorectal cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE coloncancer; chemotherapy; metastatic cancer; first line; target therapy
ID MOLECULAR SUBGROUP ANALYSES; OPEN-LABEL; PHASE-II; MUTATION STATUS;
   TUMOR LOCATION; PLUS CETUXIMAB; SINGLE-ARM; CHEMOTHERAPY; BEVACIZUMAB;
   EFFICACY
AB Colorectal cancer represents an important oncological challenge both for its incidence, which makes it an important health problem, and for its biological complexity, which has made clinical results very difficult in terms of outcome for this category of patients. To date these diseases should not be treated as a single entity but it is necessary to distinguish colorectal cancers based on characteristics that nowadays are essential to have greater therapeutic benefits. These include the sideness of the disease, the state of microsatellites, the presence of prognostic and predictive mutations of response to treatments currently available in clinical practice, which are associated with new therapeutic targets. The greatest challenge in the future will be to circumvent the resistance mechanisms that make this disease very difficult to treat with good long-term results by studying effective combination treatments with a good toxicity profile. Once such combinations or targeted treatments are consolidated, it will be desirable to shift the best therapies to the first line treatment to make them immediately accessible to the patient. It will also be essential to refine the selection of patients who can benefit from these treatments.
C1 [Cherri, Sara; Oneda, Ester; Zanotti, Laura; Zaniboni, Alberto] Fdn Poliambulanza, Dept Clin Oncol, Brescia, Italy.
RP Cherri, S (corresponding author), Fdn Poliambulanza, Dept Clin Oncol, Brescia, Italy.
EM sara.m.cherri@gmail.com
CR Abdel-Rahman O, 2019, INT J COLORECTAL DIS, V34, P2143, DOI 10.1007/s00384-019-03430-y
   Al Bitar S, 2023, WORLD J GASTROENTERO, V29, P1395, DOI 10.3748/wjg.v29.i9.1395
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Antoniotti C, 2022, LANCET ONCOL, V23, P876, DOI 10.1016/S1470-2045(22)00274-1
   Aranda E, 2018, EUR J CANCER, V101, P263, DOI 10.1016/j.ejca.2018.06.024
   Aspeslagh S, 2017, EUR J CANCER, V87, P65, DOI 10.1016/j.ejca.2017.09.027
   Barzi A, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.015
   Battaglin F, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4001-x
   Bendell JC, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.TPS870
   Besse B, 2021, MOL CANCER THER, V20, DOI 10.1158/1535-7163.TARG-21-P02-01
   Boeckx N, 2018, CRIT REV ONCOL HEMAT, V121, P1, DOI 10.1016/j.critrevonc.2017.11.003
   Boige V, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.33533
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Botta C, 2012, J IMMUNOTHER, V35, P440, DOI 10.1097/CJI.0b013e31825943aa
   Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Bui QL, 2022, CANCERS, V14, DOI 10.3390/cancers14020406
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chang JJ, 2022, CLIN COLORECTAL CANC, V21, P347, DOI 10.1016/j.clcc.2022.07.003
   Cousin Sophie, 2021, Clin Cancer Res, V27, P2139, DOI 10.1158/1078-0432.CCR-20-3416
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Diaz LA, 2022, LANCET ONCOL, V23, P659, DOI 10.1016/S1470-2045(22)00197-8
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Drilon A, 2017, CANCER DISCOV, V7, P963, DOI 10.1158/2159-8290.CD-17-0507
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Fakih M, 2023, ECLINICALMEDICINE, V58, DOI 10.1016/j.eclinm.2023.101917
   Fakih M, 2023, JAMA ONCOL, V9, P627, DOI 10.1001/jamaoncol.2022.7845
   Fakih MG, 2022, LANCET ONCOL, V23, P115, DOI 10.1016/S1470-2045(21)00605-7
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Friedrich T, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.118
   Fu XH, 2023, CANCER SCI, V114, P1067, DOI 10.1111/cas.15660
   Fumet JD, 2021, ANN ONCOL, V32, pS551, DOI 10.1016/j.annonc.2021.08.954
   Glebov OK, 2003, CANCER EPIDEM BIOMAR, V12, P755
   Goey KKH, 2017, ANN ONCOL, V28, P2128, DOI 10.1093/annonc/mdx322
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gupta R, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.22.00306
   Hellmann MD, 2019, ANN ONCOL, V30, P1134, DOI 10.1093/annonc/mdz113
   Hong DS, 2023, ANN M AM SOC OF CLIN, V41
   Hyman D, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-CT127
   Jing CW, 2020, MOL CARCINOGEN, V59, P478, DOI 10.1002/mc.23172
   Johnson B, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-005332
   Kessler D, 2021, CURR OPIN CHEM BIOL, V62, P109, DOI 10.1016/j.cbpa.2021.02.014
   Kopetz S, 2023, J CLIN ONCOL, V41
   Kuboki Y, 2022, ANN ONCOL, V33, pS680, DOI 10.1016/j.annonc.2022.07.453
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lenz HJ, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.008
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lima CMSPR, 2020, J CLIN ONCOL, V38
   Liu CW, 2013, CLIN CANCER RES, V19, P393, DOI 10.1158/1078-0432.CCR-12-1626
   Loree JM, 2018, CLIN CANCER RES, V24, P1062, DOI 10.1158/1078-0432.CCR-17-2484
   Martin-Romano P, 2020, EUR J CANCER, V137, P117, DOI 10.1016/j.ejca.2020.06.030
   Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915
   Meng MJ, 2021, BIOMED PHARMACOTHER, V140, DOI 10.1016/j.biopha.2021.111717
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Mettu NB, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.49040
   Modest DP, 2022, J CLIN ONCOL, V40, P72, DOI 10.1200/JCO.21.01332
   Morano F, 2022, J CLIN ONCOL, V40, P1562, DOI 10.1200/JCO.21.02583
   Morris V., 2023, J Clin Oncol, V41, P265, DOI [10.1200/JCO.2023.41.4_suppl.TPS265, DOI 10.1200/JCO.2023.41.4_SUPPL.TPS265]
   Morris VK, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.012
   Moscetti L, 2013, INVEST NEW DRUG, V31, P1035, DOI 10.1007/s10637-013-9936-9
   Motta Rodrigo, 2021, J Clin Transl Res, V7, P511
   Murciano-Goroff YR, 2020, CELL RES, V30, P507, DOI 10.1038/s41422-020-0337-2
   Network National Comprehensive Cancer, 2023, "NCCN giudelines Colon Cancer."
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Pashirzad M, 2021, CURR CANCER DRUG TAR, V21, P932, DOI 10.2174/1568009621666211103113339
   Patel MR, 2021, CANCER MED-US, V10, P1183, DOI 10.1002/cam4.3630
   Petrelli F, 2024, DIGEST LIVER DIS, V56, P242, DOI 10.1016/j.dld.2023.06.008
   Pietrantonio F, 2019, JAMA ONCOL, V5, P1268, DOI 10.1001/jamaoncol.2019.1467
   Ros J, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1112276
   Sabari JK, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.TPS146
   Salem ME, 2017, ONCOTARGET, V8, P86356, DOI 10.18632/oncotarget.21169
   Salvatore L, 2021, CANCER TREAT REV, V97, DOI 10.1016/j.ctrv.2021.102202
   Sargent DJ, 2009, J CLIN ONCOL, V27, P1948, DOI 10.1200/JCO.2008.20.2879
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Schirripa M, 2020, CLIN COLORECTAL CANC, V19, P219, DOI 10.1016/j.clcc.2020.04.009
   Shitara K, 2020, J CLIN ONCOL, V38
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Siena S, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS2659
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Siu HWD, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08644-4
   Stintzing S, 2017, EUR J CANCER, V84, P69, DOI 10.1016/j.ejca.2017.07.016
   Strickler JH, 2023, LANCET ONCOL, V24, P496, DOI 10.1016/S1470-2045(23)00150-X
   Tabernero J, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100559
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Tian J., 2022, Cancer Res, V82, DOI [10.1158/1538-7445.AM2022-LB003, DOI 10.1158/1538-7445.AM2022-LB003]
   Tian J, 2023, NAT MED, V29, P458, DOI 10.1038/s41591-022-02181-8
   Tie J, 2011, INT J CANCER, V128, P2075, DOI 10.1002/ijc.25555
   Tintelnot J, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.993611
   Tougeron D, 2020, J IMMUNOTHER CANCER, V8, pA206, DOI 10.1136/jitc-2020-SITC2020.0337
   Travers A, 2021, CLIN COLORECTAL CANC, V20, pE21, DOI 10.1016/j.clcc.2020.08.002
   Tuca A, 2020, J CLIN MED, V9, DOI 10.3390/jcm9124015
   Van Cutsem E, 2023, J CLIN ONCOL, V41, P2628, DOI 10.1200/JCO.22.01693
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   von Einem JC, 2014, J CANCER RES CLIN, V140, P1607, DOI 10.1007/s00432-014-1678-3
   Whittaker SR, 2015, MOL CANCER THER, V14, P2700, DOI 10.1158/1535-7163.MCT-15-0136-T
   Yaeger R, 2023, NEW ENGL J MED, V388, P44, DOI 10.1056/NEJMoa2212419
   Yalcin S, 2013, ONCOLOGY-BASEL, V85, P328, DOI 10.1159/000355914
   Ye T, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.785526
NR 100
TC 2
Z9 2
U1 0
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 16
PY 2023
VL 13
AR 1246716
DI 10.3389/fonc.2023.1246716
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA X0WW4
UT WOS:001095750100001
PM 37909027
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Kianpour, M
   Huang, CW
   Vejvisithsakul, PP
   Wang, JY
   Li, CF
   Shiao, MS
   Pan, CT
   Shiue, YL
AF Kianpour, Maryam
   Huang, Ching-Wen
   Vejvisithsakul, Pichpisith Pierre
   Wang, Jaw-Yuan
   Li, Chien-Feng
   Shiao, Meng-Shin
   Pan, Cheng-Tang
   Shiue, Yow-Ling
TI Aptamer/doxorubicin-conjugated nanoparticles target membranous CEMIP2 in
   colorectal cancer
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Cell migration inducing hyaluronidase 2; CEMIP2; Colorectal cancer;
   Aptamer; Mesoporous silica nanoparticle
ID MESOPOROUS SILICA NANOPARTICLES; ACTIVATED PROTEIN-KINASE;
   HYALURONIC-ACID; KAPPA-B; TUMOR; CELLS; TMEM2; CD44; TRANSMEMBRANE;
   EXPRESSION
AB The objectives were to identify the functional domains of a potential oncoprotein, cell migration inducing hyaluronidase 2 (CEMIP2), evaluate its expression levels and roles in colorectal cancer (CRC), and develop an aptamer-based nanoparticle for targeted therapy. Data mining on TCGA identified that CEMIP2 might play oncogenic roles in CRC. In a local cohort, CEMIP2 mRNA levels significantly stepwise increase in CRC patients with higher stages, and high CEMIP2 confers worse disease-free survival. In addition, CEMIP2 mRNA levels significantly correlated to hyaluronan levels in sera from CRC patients. Deletion mapping identified that CEMIP2 containing G8 and PANDER-like domains preserved hyaluronidase activity and oncogenic roles, including cell proliferation, anchorage-independent cell growth, cell migration and invasion, and human umbilical vein endothelial cell (HUVEC) tube formation in CRC-derived cells. A customized monoclonal mouse anti-human CEMIP2 antibody probing the PANDER-like domain (anti-289307) counteracted CEMIP2-mediated carcinogenesis in vitro. Cell-SELEX pinpointed an aptamer, aptCEMIP2(101), specifically interacted with the full-length CEMIP2, potentially involving its 3D structure. Treatments with aptCEMIP2(101) significantly reduced CEMIP2-mediated tumorigenesis in vitro. Mesoporous silica nanoparticles (MSN) carrying atpCEMIP2(101) and Dox were fabricated. Dox@MSN, MSN-aptCEMIP2(101), and Dox@MSN-aptCEMIP2(101) significantly suppressed tumorigenesis in vitro compared to the Mock, while Dox@MSN-aptCEMIP2(101) showed substantially higher effects compared to Dox@MSN and MSN-aptCEMIP2(101) in CRC-derived cells. Our study identified a novel oncogene and developed an effective aptamer-based targeted therapeutic strategy.
C1 [Kianpour, Maryam; Vejvisithsakul, Pichpisith Pierre; Shiue, Yow-Ling] Natl Sun Yat sen Univ, Inst Biomed Sci, Coll Med, Kaohsiung 80424, Taiwan.
   [Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung 80756, Taiwan.
   [Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg, Kaohsiung 80756, Taiwan.
   [Vejvisithsakul, Pichpisith Pierre] Mahidol Univ, Fac Med, Program Translat Med, Ramathibodi Hosp, Bangkok, Thailand.
   [Wang, Jaw-Yuan] Minist Hlth & Welf, Pingtung Hosp, Pingtung 900214, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 80756, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 80756, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung 80756, Taiwan.
   [Li, Chien-Feng] Chi Mei Med Ctr, Dept Med Res, Tainan, Taiwan.
   [Li, Chien-Feng] Chi Mei Med Ctr, Dept Anesthesiol, Tainan 73657, Taiwan.
   [Li, Chien-Feng] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan 70456, Taiwan.
   [Shiao, Meng-Shin] Mahidol Univ, Fac Med, Ramathibodi Hosp, Res Ctr, Bangkok 10400, Thailand.
   [Pan, Cheng-Tang] Natl Sun Yat Sen Univ, Inst Precis Med, Coll Med, Kaohsiung 80424, Taiwan.
   [Pan, Cheng-Tang; Shiue, Yow-Ling] Natl Sun Yat Sen Univ, Dept Mech & Electromech Engn, Kaohsiung 80424, Taiwan.
C3 National Sun Yat Sen University; Kaohsiung Medical University; Kaohsiung
   Medical University Hospital; Kaohsiung Medical University; Mahidol
   University; Kaohsiung Medical University; Kaohsiung Medical University;
   Kaohsiung Medical University; Chi Mei Hospital; Chi Mei Hospital;
   National Health Research Institutes - Taiwan; Mahidol University;
   National Sun Yat Sen University; National Sun Yat Sen University
RP Shiue, YL (corresponding author), Natl Sun Yat sen Univ, Inst Biomed Sci, Coll Med, Kaohsiung 80424, Taiwan.; Pan, CT (corresponding author), Natl Sun Yat Sen Univ, Inst Precis Med, Coll Med, Kaohsiung 80424, Taiwan.
EM pan@mem.nsysu.edu.tw; shirley@imst.nsysu.edu.tw
RI tang, cheng/KLD-8823-2024; Pan, CT/E-4776-2013; Jaw-Yuan,
   Wang/AFS-8845-2022; Shiao, Meng-Shin/KND-6610-2024
OI Wang, Jaw-Yuan/0000-0002-7705-2621
FU National Sun Yat-sen University; National Science and Technology
   Council, Taiwan [111-2320-B-110-011]; Center for NaooScience
   NanoTechnology
FX Center for NaooScience & NanoTechnology, National Sun Yat-sen
   University, and the National Science and Technology Council, Taiwan
   (111-2320-B-110-011) supported this project.
CR Alyane M, 2016, SAUDI PHARM J, V24, P165, DOI 10.1016/j.jsps.2015.02.014
   ARUFFO A, 1990, CELL, V61, P1303, DOI 10.1016/0092-8674(90)90694-A
   ASPLUND T, 1993, CANCER RES, V53, P388
   Baidoun F, 2021, CURR DRUG TARGETS, V22, P998, DOI 10.2174/1389450121999201117115717
   Charbgoo F, 2021, MAT SCI ENG C-MATER, V119, DOI 10.1016/j.msec.2020.111618
   De Angelis JE, 2017, DEV CELL, V40, P123, DOI 10.1016/j.devcel.2016.12.017
   de la Motte CA, 2011, AM J PHYSIOL-GASTR L, V301, pG945, DOI 10.1152/ajpgi.00063.2011
   Fagerberg L, 2014, MOL CELL PROTEOMICS, V13, P397, DOI 10.1074/mcp.M113.035600
   Fan JY, 2010, SMALL, V6, P2080, DOI 10.1002/smll.201000543
   Fu CH, 2013, BIOMATERIALS, V34, P2565, DOI 10.1016/j.biomaterials.2012.12.043
   GMACHL M, 1993, FEBS LETT, V336, P545, DOI 10.1016/0014-5793(93)80873-S
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Horton MR, 1998, J IMMUNOL, V160, P3023
   Irie F, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100481
   Jo H, 2016, EXP MOL MED, V48, DOI 10.1038/emm.2016.44
   Kalvari I, 2021, NUCLEIC ACIDS RES, V49, pD192, DOI 10.1093/nar/gkaa1047
   Kim MK, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13020184
   KNUDSON W, 1984, P NATL ACAD SCI-BIOL, V81, P6767, DOI 10.1073/pnas.81.21.6767
   Kudo Y, 2022, PANCREAS, V51, P800, DOI 10.1097/MPA.0000000000002106
   LEE HG, 1994, ANAL BIOCHEM, V219, P278, DOI 10.1006/abio.1994.1267
   Lee H, 2016, CANCER RES, V76, P4994, DOI 10.1158/0008-5472.CAN-15-2322
   Lepperdinger G, 1998, J BIOL CHEM, V273, P22466, DOI 10.1074/jbc.273.35.22466
   Li ZM, 2021, J CONTROL RELEASE, V338, P719, DOI 10.1016/j.jconrel.2021.09.005
   Manzano M, 2009, EXPERT OPIN DRUG DEL, V6, P1383, DOI 10.1517/17425240903304024
   McKee CM, 1997, J BIOL CHEM, V272, P8013, DOI 10.1074/jbc.272.12.8013
   Nairi V, 2018, COLLOID SURFACE B, V168, P50, DOI 10.1016/j.colsurfb.2018.02.019
   Ng EWM, 2006, NAT REV DRUG DISCOV, V5, P123, DOI 10.1038/nrd1955
   NOBLE PW, 1993, J CLIN INVEST, V91, P2368, DOI 10.1172/JCI116469
   Posey JT, 2003, CANCER RES, V63, P2638
   Profant V, 2019, PHYS CHEM CHEM PHYS, V21, P7367, DOI 10.1039/c9cp00472f
   Rayahin JE, 2015, ACS BIOMATER SCI ENG, V1, P481, DOI 10.1021/acsbiomaterials.5b00181
   Reese KL, 2010, MOL REPROD DEV, V77, P759, DOI 10.1002/mrd.21217
   Rohani N, 2019, CANCER RES, V79, P1952, DOI 10.1158/0008-5472.CAN-18-1604
   ROONEY P, 1995, INT J CANCER, V60, P632, DOI 10.1002/ijc.2910600511
   Ropponen K, 1998, CANCER RES, V58, P342
   SAARI H, 1991, ANN RHEUM DIS, V50, P389, DOI 10.1136/ard.50.6.389
   Sapudom J, 2017, ACTA BIOMATER, V50, P259, DOI 10.1016/j.actbio.2016.12.026
   Schinzel RT, 2019, CELL, V179, P1306, DOI 10.1016/j.cell.2019.10.018
   Schmaus A, 2014, BRIT J CANCER, V111, P559, DOI 10.1038/bjc.2014.332
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Sefah K, 2010, NAT PROTOC, V5, P1169, DOI 10.1038/nprot.2010.66
   Serbulea M, 1999, INT J ONCOL, V14, P733
   Shukla HD, 2012, PROTEOMICS, V12, P3085, DOI 10.1002/pmic.201100519
   Skandalis SS, 2020, SEMIN CANCER BIOL, V62, P20, DOI 10.1016/j.semcancer.2019.07.002
   Sohara Y, 2001, MOL BIOL CELL, V12, P1859, DOI 10.1091/mbc.12.6.1859
   Stern R, 2008, SEMIN CANCER BIOL, V18, P275, DOI 10.1016/j.semcancer.2008.03.017
   Stern R, 2006, EUR J CELL BIOL, V85, P699, DOI 10.1016/j.ejcb.2006.05.009
   Takasugi M, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16050-w
   Taniguchi K, 2018, NAT REV IMMUNOL, V18, P309, DOI 10.1038/nri.2017.142
   Thorne RF, 2004, J CELL SCI, V117, P373, DOI 10.1242/jcs.00954
   Triggs-Raine B, 1999, P NATL ACAD SCI USA, V96, P6296, DOI 10.1073/pnas.96.11.6296
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Wang KL, 2021, J CONTROL RELEASE, V339, P445, DOI 10.1016/j.jconrel.2021.10.005
   Winkler J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18794-x
   Wu WR, 2020, THERANOSTICS, V10, P707, DOI 10.7150/thno.39018
   Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174
   Xie XD, 2016, EUR J PHARM SCI, V83, P28, DOI 10.1016/j.ejps.2015.12.014
   Xin W, 2023, ASIAN J PHARM SCI, V18, DOI 10.1016/j.ajps.2023.100795
   Yamamoto H, 2017, J BIOL CHEM, V292, P7304, DOI 10.1074/jbc.M116.770149
   Zhao QF, 2019, J COLLOID INTERF SCI, V554, P239, DOI 10.1016/j.jcis.2019.07.005
   Zhou JH, 2017, NAT REV DRUG DISCOV, V16, P181, DOI 10.1038/nrd.2016.199
NR 61
TC 7
Z9 7
U1 9
U2 16
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD AUG 1
PY 2023
VL 245
AR 125510
DI 10.1016/j.ijbiomac.2023.125510
EA JUN 2023
PG 19
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA Q7TP8
UT WOS:001059515200001
PM 37353120
DA 2025-01-04
ER

PT J
AU Kuo, CY
   Liu, TY
   Chan, TY
   Tsai, SC
   Hardiansyah, A
   Huang, LY
   Yang, MC
   Lu, RH
   Jiang, JK
   Yang, CY
   Lin, CH
   Chiu, WY
AF Kuo, Chih-Yu
   Liu, Ting-Yu
   Chan, Tzu-Yi
   Tsai, Sung-Chen
   Hardiansyah, Andri
   Huang, Li-Ying
   Yang, Ming-Chien
   Lu, Ruey-Hwa
   Jiang, Jeng-Kai
   Yang, Chih-Yung
   Lin, Chi-Hung
   Chiu, Wen-Yen
TI Magnetically triggered nanovehicles for controlled drug release as a
   colorectal cancer therapy
SO COLLOIDS AND SURFACES B-BIOINTERFACES
LA English
DT Article
DE Targeting therapy; Magnetic nanovehicles; Drug controlled release;
   Stimuli-triggered release; Surface modification
ID DELIVERY-SYSTEM; INTERLEUKIN-4 RECEPTOR; NANOPARTICLES; SHELL; POLYMER;
   HYPERTHERMIA; CORE; NANOSPHERES; ASSEMBLIES; DESIGN
AB Magnetic silica core/shell nanovehicles presenting atherosclerotic plaque-specific peptide-1 (AP-1) as a targeting ligand (MPVA-AP1 nanovehicles) have been prepared through a double-emulsion method and surface modification. Amphiphilic poly(vinyl alcohol) was introduced as a polymer binder to encapsulate various drug molecules (hydrophobic, hydrophilic, polymeric) and magnetic iron oxide (Fe3O4) nanoparticles. Under a high-frequency magnetic field, magnetic carriers (diameter: ca. 50 nm) incorporating the anti-cancer drug doxorubicin collapsed, releasing approximately 80% of the drug payload, due to the heat generated by the rapidly rotating Fe3O4 nanoparticles, thereby realizing rapid and accurate controlled drug release. Simultaneously, the magnetic Fe3O4 themselves could also kill the tumor cells through a hyperthermia effect (inductive heating). Unlike their ungrafted congeners (MPVA nanovehicles), the AP1-grafted nanovehicles bound efficiently to colorectal cancer cells (CT26-IL4R alpha), thereby displaying tumor-cell selectivity. The combination of remote control, targeted dosing, drug-loading flexibility, and thermotherapy and chemotherapy suggests that magnetic nanovehicles such as MPVA-AP1 have great potential for application in cancer therapy. (C) 2015 Elsevier B.V. All rights reserved.
C1 [Kuo, Chih-Yu; Chiu, Wen-Yen] Natl Taiwan Univ, Inst Polymer Sci & Engn, Taipei 10617, Taiwan.
   [Liu, Ting-Yu; Chan, Tzu-Yi] Ming Chi Univ Technol, Dept Mat Engn, New Taipei 24301, Taiwan.
   [Tsai, Sung-Chen; Lin, Chi-Hung] Nation Yang Ming Univ, Inst Microbiol & Immunol, Sch Life Sci, Taipei 11221, Taiwan.
   [Hardiansyah, Andri; Huang, Li-Ying; Yang, Ming-Chien] Natl Taiwan Univ Sci & Technol, Dept Mat Sci & Engn, Taipei 10607, Taiwan.
   [Lu, Ruey-Hwa] Taipei City Hosp, Zhongxing Branch, Dept Surg, Taipei 10341, Taiwan.
   [Jiang, Jeng-Kai; Lin, Chi-Hung] Natl Yang Ming Univ, Sch Med, Dept Surg, Taipei 11221, Taiwan.
   [Jiang, Jeng-Kai] Taipei Vet Gen Hosp, Div Colon & Rectal Surg, Dept Surg, Taipei 11221, Taiwan.
   [Yang, Chih-Yung] Taipei City Hosp, Dept Educ & Res, Taipei 10629, Taiwan.
   [Chiu, Wen-Yen] Natl Taiwan Univ, Dept Chem Engn, Taipei 10617, Taiwan.
   [Chiu, Wen-Yen] Natl Taiwan Univ, Dept Mat Sci & Engn, Taipei 10617, Taiwan.
C3 National Taiwan University; Ming Chi University of Technology; National
   Taiwan University of Science & Technology; Taipei City Hospital;
   National Yang Ming Chiao Tung University; Taipei Veterans General
   Hospital; Taipei City Hospital; National Taiwan University; National
   Taiwan University
RP Liu, TY (corresponding author), Ming Chi Univ Technol, Dept Mat Engn, New Taipei 24301, Taiwan.
EM tyliu0322@gmail.com
RI Kuo, Chih-Yu/IXW-5575-2023; Liu, Tingyu/AAI-7945-2020; Li,
   Fajin/GVR-9384-2022
OI Kuo, Chih-Yu/0000-0002-1211-6700; Hardiansyah, Andri/0000-0002-9505-3716
CR Bae Y, 2003, ANGEW CHEM INT EDIT, V42, P4640, DOI 10.1002/anie.200250653
   Chou FY, 2012, POLYMER, V53, P2839, DOI 10.1016/j.polymer.2012.05.010
   Dobson J, 2008, NAT NANOTECHNOL, V3, P139, DOI 10.1038/nnano.2008.39
   Fang C, 2009, J MATER CHEM, V19, P6258, DOI 10.1039/b902182e
   He XF, 2011, MOL PHARMACEUT, V8, P430, DOI 10.1021/mp100266g
   Hong HY, 2008, J CELL MOL MED, V12, P2003, DOI 10.1111/j.1582-4934.2008.00189.x
   Hou ZQ, 2012, ULTRASONICS, V52, P836, DOI 10.1016/j.ultras.2011.10.009
   Hruby M, 2005, J CONTROL RELEASE, V103, P137, DOI 10.1016/j.jconrel.2004.11.017
   Hu SH, 2008, ADV MATER, V20, P2690, DOI 10.1002/adma.200800193
   Hu SH, 2012, ADV MATER, V24, P3627, DOI 10.1002/adma.201201251
   Ibrahim IsmailA.M., 2010, J AM SCI, V6, P985, DOI DOI 10.7537/MARSJAS061110.133
   Jordan A, 1999, J MAGN MAGN MATER, V194, P185, DOI 10.1016/S0304-8853(98)00558-7
   Kawakami K, 2000, CANCER RES, V60, P2981
   Kawakami M, 2002, CLIN CANCER RES, V8, P3503
   Kim J, 2008, ANGEW CHEM INT EDIT, V47, P8438, DOI 10.1002/anie.200802469
   Kim JH, 2012, J CONTROL RELEASE, V157, P493, DOI 10.1016/j.jconrel.2011.09.070
   Koo H, 2011, ACCOUNTS CHEM RES, V44, P1018, DOI 10.1021/ar2000138
   Lee CF, 2004, J POLYM SCI POL CHEM, V42, P3029, DOI 10.1002/pola.20085
   Lee CF, 2008, J POLYM SCI POL CHEM, V46, P5734, DOI 10.1002/pola.22887
   Lee SM, 2010, ANGEW CHEM INT EDIT, V49, P9960, DOI 10.1002/anie.201004867
   Lefaux CJ, 2004, J POLYM SCI POL PHYS, V42, P3654, DOI 10.1002/polb.20209
   Li TJ, 2013, BIOMATERIALS, V34, P7873, DOI 10.1016/j.biomaterials.2013.07.012
   Lin CL, 2005, J COLLOID INTERF SCI, V290, P397, DOI 10.1016/j.jcis.2005.04.055
   Liu TY, 2009, NANO TODAY, V4, P52, DOI 10.1016/j.nantod.2008.10.011
   Liu TY, 2009, ADV FUNCT MATER, V19, P616, DOI 10.1002/adfm.200801304
   Liu TY, 2008, LANGMUIR, V24, P13306, DOI 10.1021/la801451v
   Ma WF, 2012, J MATER CHEM, V22, P15206, DOI [10.1039/c2jm31721d, 10.1039/c2jm31721]
   Maeda H, 2000, J CONTROL RELEASE, V65, P271, DOI 10.1016/S0168-3659(99)00248-5
   Moroz P, 2002, INT J HYPERTHER, V18, P267, DOI 10.1080/02656730110108785
   Nasongkla N, 2004, ANGEW CHEM INT EDIT, V43, P6323, DOI 10.1002/anie.200460800
   OBIRI NI, 1994, CLIN EXP IMMUNOL, V95, P148
   Pauzauskie PJ, 2006, NAT MATER, V5, P97, DOI 10.1038/nmat1563
   Petros RA, 2010, NAT REV DRUG DISCOV, V9, P615, DOI 10.1038/nrd2591
   Ponce AM, 2006, INT J HYPERTHER, V22, P205, DOI 10.1080/02656730600582956
   Avendaño-Gómez JR, 2012, J COLLOID INTERF SCI, V380, P75, DOI 10.1016/j.jcis.2012.04.066
   Ruhland TM, 2012, J COLLOID INTERF SCI, V374, P45, DOI 10.1016/j.jcis.2012.01.028
   Santra R.P.B.S., 2005, ADV MAT, V17
   Scheinberg DA, 2010, NAT REV CLIN ONCOL, V7, P266, DOI 10.1038/nrclinonc.2010.38
   Seth A, 2012, ADV MATER, V24, P3544, DOI 10.1002/adma.201200757
   Shi DL, 2009, ADV MATER, V21, P2170, DOI 10.1002/adma.200803159
   Sun SH, 2004, J AM CHEM SOC, V126, P273, DOI 10.1021/ja0380852
   Tasciotti E, 2008, NAT NANOTECHNOL, V3, P151, DOI 10.1038/nnano.2008.34
   Torchilin V, 2011, ADV DRUG DELIVER REV, V63, P131, DOI 10.1016/j.addr.2010.03.011
   Tung WL, 2011, ACTA BIOMATER, V7, P2873, DOI 10.1016/j.actbio.2011.03.021
   Yang FY, 2012, J CONTROL RELEASE, V160, P652, DOI 10.1016/j.jconrel.2012.02.023
   Yang XQ, 2010, ACS NANO, V4, P6805, DOI 10.1021/nn101670k
   Yu S, 2004, J MATER CHEM, V14, P2781, DOI 10.1039/b404964k
   Zhang JX, 2010, ACS NANO, V4, P1049, DOI 10.1021/nn901213a
   Zhang SL, 2009, ADV MATER, V21, P419, DOI 10.1002/adma.200801393
NR 49
TC 30
Z9 33
U1 1
U2 72
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0927-7765
EI 1873-4367
J9 COLLOID SURFACE B
JI Colloid Surf. B-Biointerfaces
PD APR 1
PY 2016
VL 140
BP 567
EP 573
DI 10.1016/j.colsurfb.2015.11.008
PG 7
WC Biophysics; Chemistry, Physical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Chemistry; Materials Science
GA DF6DG
UT WOS:000371445500066
PM 26705859
DA 2025-01-04
ER

PT J
AU Bagheri, R
   Sanaat, Z
   Zarghami, N
AF Bagheri, Raana
   Sanaat, Zohreh
   Zarghami, Nosratollah
TI Synergistic Effect of Free and Nano-encapsulated Chrysin-Curcumin on
   Inhibition of hTERT Gene Expression in SW480 Colorectal Cancer Cell Line
SO DRUG RESEARCH
LA English
DT Article
DE Curcumin; Chrysin; PLGA-PEG; Nanoparticle; Telomerase; Colorectal Cancer
ID LOADED PLGA-PEG; TELOMERASE ACTIVITY; MAA NANOPARTICLES; DELIVERY;
   NANOFORMULATION; PROLIFERATION; MICRORNAS; APOPTOSIS; UPDATE
AB Background Telomerase is known as a global therapeutic target in cancer cells due to its main role in tumorigenesis. Nowadays, it is proposed new treatment methods based on molecular target therapy by bioactive substances such as curcumin and chrysin with fewer side effects than other chemical drugs. But due to their low aqueous solubility and high clearance in the bloodstream it can be used of nanoparticles to increase their half-life and biocompatibility of them. Therefore, the goal of this study was to evaluate the effect of Chrysin-Curcumin on the expression of telomerase gene in SW480 colorectal cancer cell line.
   Material and method PLGA-PEG nanoparticles synthesized and were confirmed using by the scanning electron microscope (SEM) and FTIR Spectroscopy. After treatment of SW480 cells by curcumin and chrysin loaded nanoparticles, their toxicity to cancer cells, was evaluated by MTT. Then, the inhibition of hTERT gene expression was measured using qRT-PCR method.
   Result The results of MTT test showed nanocapsulated curcumin and chrysin compared with free forms of these compounds have high synergistic effect on sw480 cells. Also, real time-PCR showed significant decrease in hTERT gene expression in SW480 cells that treated with nano-curcumin and nanochrysin compare to untreated cells.
   Conclusion Nano-encapsulation of curcumin and chrysin enhanced delivery of these compounds to SW480 colorectal cancer cells and therefore it can be conclude that PLGA-PEG nanoparticles promote anticancer effects of curcumin-chrysin by increasing bioavailability and the solubility of these drugs.
C1 [Bagheri, Raana] Islamic Azad Univ, Dept Mol Genet, Tabriz, Iran.
   [Sanaat, Zohreh; Zarghami, Nosratollah] Tabriz Univ Med Sci, Hematol & Oncol Res Ctr, Golgasht St, Tabriz 51664, Iran.
   [Zarghami, Nosratollah] Tabriz Univ Med Sci, Drug Appl Res Ctr, Tabriz, Iran.
   [Zarghami, Nosratollah] Tabriz Univ Med Sci, Fac Adv Med Sci, Dept Med Biotechnol, Tabriz, Iran.
C3 Islamic Azad University; Tabriz University of Medical Science; Tabriz
   University of Medical Science; Tabriz University of Medical Science
RP Zarghami, N (corresponding author), Tabriz Univ Med Sci, Hematol & Oncol Res Ctr, Golgasht St, Tabriz 51664, Iran.
EM zarghami@tbzmed.ac.ir
RI Zarghami, Nosratollah/A-7821-2017
CR Alibakhshi A, 2016, CURR MED CHEM, V23, P2380, DOI 10.2174/0929867323666160425113705
   Amirsaadat S, 2017, ARTIF CELL NANOMED B, V45, P1649, DOI 10.1080/21691401.2016.1276922
   Anari E, 2016, ARTIF CELL NANOMED B, V44, P1410, DOI 10.3109/21691401.2015.1029633
   Anganeh M. T., 2014, International Journal of Biosciences (IJB), V4, P134
   [Anonymous], J DRUG DELIVERY SCI
   [Anonymous], CELL TISSUE BANKING
   [Anonymous], NUTR CANC
   [Anonymous], ENDOSCOPY
   Aval SF, 2016, ARTIF CELL NANOMED B, V44, P188, DOI 10.3109/21691401.2014.934456
   Badrzadeh F, 2014, ASIAN PAC J CANCER P, V15, P8931, DOI 10.7314/APJCP.2014.15.20.8931
   Bozic I, 2013, ELIFE, V2, DOI 10.7554/eLife.00747
   Chen HP, 2013, EXP CELL RES, V319, P697, DOI 10.1016/j.yexcr.2012.12.026
   Cogulu O, 2009, INT J FOOD SCI NUTR, V60, P601, DOI 10.3109/09637480801994712
   Danafar H, 2016, DRUG RES, V66, P506, DOI 10.1055/s-0042-109865
   Deldar Yaghoub, 2018, Artif Cells Nanomed Biotechnol, V46, P706, DOI 10.1080/21691401.2017.1337022
   Durko L, 2014, CURR COLORECT CANC R, V10, P45, DOI 10.1007/s11888-013-0203-4
   Dwivedi M, 2014, J BIOMATER TISS ENG, V4, P198, DOI 10.1166/jbt.2014.1164
   Eatemadi A, 2016, BIOMED PHARMACOTHER, V84, P1915, DOI 10.1016/j.biopha.2016.10.095
   Farajzadeh R, 2017, ARTIF CELL NANOMED B, V1, P9
   Ghalhar MG, 2014, ASIAN PAC J CANCER P, V15, P7113, DOI 10.7314/APJCP.2014.15.17.7113
   Ghosh S, 2015, FOOD CHEM TOXICOL, V83, P111, DOI 10.1016/j.fct.2015.05.022
   Javan Maasomi Zahra, 2017, Asian Pac J Cancer Prev, V18, P1283
   Kazemi-Lomedasht F, 2013, ADV PHARM BULL, V3, P127, DOI 10.5681/apb.2013.021
   Makadia HK, 2011, POLYMERS-BASEL, V3, P1377, DOI 10.3390/polym3031377
   Mirakabad FST, 2016, ARTIF CELL NANOMED B, V44, P423, DOI 10.3109/21691401.2014.955108
   Mohammad P, 2010, AFR J BIOTECHNOL, V9, P912
   Mohammadi Z, 2017, DRUG RES, V67, P211, DOI 10.1055/s-0042-122136
   Mohammadian F, 2016, IRAN J CANCER PREV, V9, DOI 10.17795/ijcp-4190
   Mohammadian F, 2017, DRUG RES, V67, P509, DOI 10.1055/s-0042-119647
   Mohammadian F, 2017, ARTIF CELL NANOMED B, V45, P1201, DOI 10.1080/21691401.2016.1216854
   Mohammadian Farideh, 2015, Asian Pac J Cancer Prev, V16, P8259
   Montazeri M, 2017, ANTI-CANCER AGENT ME, V17, P662, DOI 10.2174/1871520616666160815124537
   Montazeri M, 2016, INT J PHARMACEUT, V509, P244, DOI 10.1016/j.ijpharm.2016.05.039
   Nejati-Koshki K, 2014, CANCER CELL INT, V14, DOI 10.1186/1475-2867-14-66
   Panahi Y, 2017, DRUG RES, V67, P77, DOI 10.1055/s-0042-115171
   Piwowarski JP, 2015, J ETHNOPHARMACOL, V170, P226, DOI 10.1016/j.jep.2015.05.017
   Pourhassan-Moghaddam M, 2014, MICRO NANO LETT, V9, P345, DOI 10.1049/mnl.2014.0063
   Ronnekleiv-Kelly SM, 2016, CANCER LETT, V370, P91, DOI 10.1016/j.canlet.2015.10.014
   Sadeghzadeh H, 2017, ANTI-CANCER AGENT ME, V17, P1363, DOI 10.2174/1871520617666170213115756
   Santos IS, 2013, BIOTECHNOL ADV, V31, P514, DOI 10.1016/j.biotechadv.2012.08.005
   Sheervalilou R, 2016, DIAGN CYTOPATHOL, V44, P442, DOI 10.1002/dc.23444
   Tong R, 2015, CANCER J, V21, P314, DOI 10.1097/PPO.0000000000000123
   Yallapu MM, 2010, COLLOID SURFACE B, V79, P113, DOI 10.1016/j.colsurfb.2010.03.039
   Zavari-Nematabad A, 2017, ANAL BIOANAL CHEM, V409, P1301, DOI 10.1007/s00216-016-0058-z
   Zeighamian V, 2016, ARTIF CELL NANOMED B, V44, P735, DOI 10.3109/21691401.2014.982803
NR 45
TC 23
Z9 23
U1 0
U2 18
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 2194-9379
EI 2194-9387
J9 DRUG RES
JI Drug Res.
PD JUN
PY 2018
VL 68
IS 6
BP 335
EP 343
DI 10.1055/s-0043-121338
PG 9
WC Chemistry, Medicinal; Chemistry, Multidisciplinary; Pharmacology &
   Pharmacy
WE Emerging Sources Citation Index (ESCI)
SC Pharmacology & Pharmacy; Chemistry
GA GI4MJ
UT WOS:000434345400005
PM 29294495
DA 2025-01-04
ER

PT J
AU Xu, HR
   Zhao, XY
   Nie, H
   Wang, H
   Zhang, QL
   Zhan, Q
AF Xu, Hao-Ran
   Zhao, Xiao-Yi
   Nie, He
   Wang, Hui
   Zhang, Qing-Lin
   Zhan, Qiang
TI Immunotherapy for Colorectal Cancer* *
SO PROGRESS IN BIOCHEMISTRY AND BIOPHYSICS
LA English
DT Article
DE colorectal cancer; immunotherapy; immune checkpoint inhibitors; immune
   vaccines; adoptive cell therapy
ID MISMATCH-REPAIR-DEFICIENT; OPEN-LABEL; PD-1 BLOCKADE; PHASE-I; THERAPY;
   PLUS; PEMBROLIZUMAB; MULTICENTER; NIVOLUMAB; TRIAL
AB Improving the prognosis of patients with colorectal cancer (CRC) holds important clinical and social significance. Immunotherapy is an emerging therapy approach for cancers, which mainly include immune checkpoint inhibitors (ICI), immune vaccine and adoptive cell therapy. ICI have achieved good clinical translation in treatment of metastatic CRC with deficient DNA mismatch repair/high microsatellite instability (dMMR/MSI-H) status. The application of some ICI, such as PD-1 inhibitors pembrolizumab and nivolumab, in this type patients have been approved by the FDA. In addition, numerous positive results are acquired in clinical trials of neoadjuvant therapy for resectable dMMR/MSI-H CRC. These results greatly bolstered the exploration enthusiasm of CRC immunotherapy. However, the proficient DNA mismatch repair/microsatellite stability (pMMR/MSS) CRC, which accounting for the vast majority in related patients, hardly benefit from ICI therapy. Various combination strategies, mainly including ICI combined with traditional chemotherapy, radiotherapy, or targeted therapy, have been attempted to alter the "cold tumors" microenvironment characteristics of pMMR/MSS CRC in clinical trials, whereas no breakthrough results were reached. Theoretically, tumor vaccines are ideal choice to break down the barrier of insufficient immune infiltration in solid tumors. However, the outcomes of related clinical trials in CRC patents are not satisfactory, and partially due to the weak specificity of the applied tumor-associated antigens. Clinical studies of adoptive cell therapy in CRC are also actively underway. The favorable efficacy of tumor-infiltrating lymphocyte, cytokine-induced killer (CIK) and dendritic cell-CIK in CRC have been confirmed, while the CAR-T and TCR-T therapies need more exploration based on screening more suitable antigens and optimizing engineering design. In this review, we made a summary based on the mainline of clinical studies related to diverse immunotherapies, so as to clarify the progress of CRC immunotherapy and provide bases for exploration of better treatment options.
C1 [Xu, Hao-Ran; Zhao, Xiao-Yi; Nie, He; Wang, Hui; Zhang, Qing-Lin; Zhan, Qiang] Nanjing Med Univ, Wuxi Med Ctr, Affiliated Wuxi Peoples Hosp,Natl Clin Res Ctr Dig, Wuxi Peoples Hosp,Dept Gastroenterol,Jiangsu Branc, Wuxi 214023, Peoples R China.
C3 Nanjing Medical University; Jiangnan University
RP Zhan, Q (corresponding author), Nanjing Med Univ, Wuxi Med Ctr, Affiliated Wuxi Peoples Hosp,Natl Clin Res Ctr Dig, Wuxi Peoples Hosp,Dept Gastroenterol,Jiangsu Branc, Wuxi 214023, Peoples R China.
EM zhang517068@126.com
RI 赵, 晓一/IYJ-4660-2023
FU Natural Science Foundation of Jiangsu Province [BK20231146]; General
   Program of Wuxi Medical Center, Nanjing Medical University [WMCG202326]
FX This work was supported by grants from the Natural Science Foundation of
   Jiangsu Province (BK20231146) and General Program of Wuxi Medical
   Center, Nanjing Medical University (WMCG202326) .
CR Al Zein M, 2023, DRUG DISCOV TODAY, V28, DOI 10.1016/j.drudis.2023.103669
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Andre T, 2024, J CLIN ONCOL, V42, pLBA768, DOI 10.1200/JCO.2024.42.3_suppl.LBA768
   André T, 2023, JAMA NETW OPEN, V6, DOI 10.1001/jamanetworkopen.2023.41165
   Andre T, 2021, LANCET ONCOL, V22, P665, DOI 10.1016/S1470-2045(21)00064-4
   Aparicio C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111781
   Arimoto KI, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1390263
   Baulu E, 2023, SCI ADV, V9, DOI 10.1126/sciadv.adf3700
   Bever KM, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01014-8
   Borgeaud M, 2023, CANCER TREAT REV, V120, DOI 10.1016/j.ctrv.2023.102614
   Bray F, 2024, CA-CANCER J CLIN, V74, P229, DOI 10.3322/caac.21834
   Caballero-Baños M, 2016, EUR J CANCER, V64, P167, DOI 10.1016/j.ejca.2016.06.008
   Cappell KM, 2023, NAT REV CLIN ONCOL, V20, P359, DOI 10.1038/s41571-023-00754-1
   Casak SJ, 2021, CLIN CANCER RES, V27, P4680, DOI 10.1158/1078-0432.CCR-21-0557
   Cercek A, 2022, NEW ENGL J MED, V386, P2363, DOI 10.1056/NEJMoa2201445
   Chalabi M, 2022, ANN ONCOL, V33, pS1389, DOI 10.1016/j.annonc.2022.08.016
   Chalabi M, 2024, NEW ENGL J MED, V390, P1949, DOI 10.1056/NEJMoa2400634
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chang SC, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1329615
   Chen G, 2023, LANCET GASTROENTEROL, V8, P422, DOI 10.1016/S2468-1253(22)00439-3
   Chen H, 2024, CANCER LETT, V589, DOI 10.1016/j.canlet.2024.216817
   Chow A, 2022, NAT REV CLIN ONCOL, V19, P775, DOI 10.1038/s41571-022-00689-z
   Cortes J, 2020, LANCET, V396, P1817, DOI 10.1016/S0140-6736(20)32531-9
   Cousin Sophie, 2021, Clin Cancer Res, V27, P2139, DOI 10.1158/1078-0432.CCR-20-3416
   Ding YD, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1278011
   Emiloju OE, 2023, JAMA ONCOL, V9, P1708, DOI 10.1001/jamaoncol.2023.3323
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Español-Rego M, 2023, CANCER IMMUNOL IMMUN, V72, P827, DOI 10.1007/s00262-022-03283-5
   Fakih M, 2023, ECLINICALMEDICINE, V58, DOI 10.1016/j.eclinm.2023.101917
   Fan T, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392-023-01674-3
   Fayyaz F, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964-022-00836-0
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Ganesh K, 2022, NAT REV GASTRO HEPAT, V19, P93, DOI 10.1038/s41575-021-00569-4
   Ganesh K, 2021, NAT MED, V27, P34, DOI 10.1038/s41591-020-01195-4
   Ghazi B, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.978195
   Gorzo A, 2022, LIFE-BASEL, V12, DOI 10.3390/life12020229
   Guo Y, 2023, EUR J CANCER, V181, P26, DOI 10.1016/j.ejca.2022.12.004
   Han J, 2024, CELL TRANSPLANT, V33, DOI 10.1177/09636897241231892
   Hato L, 2024, CANCERS, V16, DOI 10.3390/cancers16050981
   Hazama S, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-108
   Hellmann MD, 2019, ANN ONCOL, V30, P1134, DOI 10.1093/annonc/mdz113
   Herting CJ, 2021, CANCER IMMUNOL IMMUN, V70, P3337, DOI 10.1007/s00262-021-02986-5
   Hu HB, 2022, LANCET GASTROENTEROL, V7, P38, DOI 10.1016/S2468-1253(21)00348-4
   Hubbard JM, 2022, CLIN CANCER RES, V28, P2818, DOI 10.1158/1078-0432.CCR-22-0112
   Jia WQ, 2024, EXPERT OPIN BIOL TH, V24, P269, DOI 10.1080/14712598.2024.2341744
   Jia WQ, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.942235
   Jiang JJ, 2024, CLIN TRANSL ONCOL, V26, P2917, DOI 10.1007/s12094-024-03530-4
   Jin ZH, 2022, J CLIN ONCOL, V40, P2735, DOI 10.1200/JCO.21.02691
   Katsikis PD, 2024, NAT REV IMMUNOL, V24, P213, DOI 10.1038/s41577-023-00937-y
   Kawazoe A, 2024, J CLIN ONCOL, V42, DOI 10.1200/JCO.23.02736
   Kim R, 2024, CLIN COLORECTAL CANC, V23, DOI 10.1016/j.clcc.2024.03.001
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee MS, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.7
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Li CMY, 2024, CANCER TREAT REV, V122, DOI 10.1016/j.ctrv.2023.102665
   Li CMY, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2023-006764
   Li JJ, 2023, INT J GEN MED, V16, P1527, DOI 10.2147/IJGM.S408349
   Li YN, 2023, FASEB J, V37, DOI 10.1096/fj.202301018R
   Lin KX, 2023, CANCER IMMUNOL IMMUN, V72, P3875, DOI 10.1007/s00262-023-03520-5
   Loria A, 2024, JAMA ONCOL, V10, P79, DOI 10.1001/jamaoncol.2023.4845
   Maggadottir SM, 2024, MOL THER, V32, P2021, DOI 10.1016/j.ymthe.2024.04.009
   Marcus L, 2019, CLIN CANCER RES, V25, P3753, DOI 10.1158/1078-0432.CCR-18-4070
   Mettu NB, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.49040
   Morris VK, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.012
   Morton D, 2023, J CLIN ONCOL, V41, P1541, DOI 10.1200/JCO.22.00046
   Overman MJ, 2024, J IMMUNOTHER CANCER, V12, DOI 10.1136/jitc-2023-008689
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Paik J, 2022, DRUGS, V82, P925, DOI 10.1007/s40265-022-01723-1
   Pan QZ, 2024, SIGNAL TRANSDUCT TAR, V9, DOI 10.1038/s41392-024-01788-2
   Parikh AR, 2021, NAT CANCER, V2, P1124, DOI 10.1038/s43018-021-00269-7
   Parkhurst MR, 2011, MOL THER, V19, P620, DOI 10.1038/mt.2010.272
   Pelka K, 2021, CELL, V184, P4734, DOI 10.1016/j.cell.2021.08.003
   Pelly VS, 2021, CANCER DISCOV, V11, P2602, DOI 10.1158/2159-8290.CD-20-1815
   Prenen H, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.74
   Pu D, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.637504
   Qi CS, 2024, J CLIN ONCOL, V42
   Redman JM, 2022, ONCOLOGIST, V27, P198, DOI 10.1093/oncolo/oyab046
   Ree AH, 2024, BRIT J CANCER, V130, P1921, DOI 10.1038/s41416-024-02696-6
   Shenoy S, 2023, INDIAN J CANCER, V60, P415, DOI 10.4103/ijc.IJC_548_20
   Siegel RL, 2023, CA-CANCER J CLIN, V73, P233, DOI 10.3322/caac.21772
   Sun Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392-023-01522-4
   Taieb J, 2023, J CLIN ONCOL, V41, P1514, DOI 10.1200/JCO.22.02108
   Taieb J, 2022, EUR J CANCER, V175, P136, DOI 10.1016/j.ejca.2022.07.020
   Tawbi HA, 2022, NEW ENGL J MED, V386, P24, DOI 10.1056/NEJMoa2109970
   ten Ham RMT, 2024, J IMMUNOTHER CANCER, V12, DOI 10.1136/jitc-2023-008372
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Tzeng HT, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24054422
   Uyl-de Groot CA, 2005, VACCINE, V23, P2379, DOI 10.1016/j.vaccine.2005.01.015
   Verschoor YL, 2022, J CLIN ONCOL, V40
   Voronova V, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1035884
   Wang SY, 2024, EUR ARCH OTO-RHINO-L, V281, P5111, DOI 10.1007/s00405-024-08768-w
   Wang S, 2020, EXPERT OPIN BIOL TH, V20, P601, DOI 10.1080/14712598.2020.1728250
   Wang XF, 2024, FRONT IMMUNOL, V15, DOI 10.3389/fimmu.2024.1357101
   Xu RH, 2022, CANCER LETT, V546, DOI 10.1016/j.canlet.2022.215840
   Yarchoan M, 2020, CANCER MED-US, V9, P1485, DOI 10.1002/cam4.2763
   Ye T, 2021, ADV DRUG DELIVER REV, V177, DOI 10.1016/j.addr.2021.113927
   Yu YJ, 2023, CANCER IMMUNOL IMMUN, V72, P2045, DOI 10.1007/s00262-023-03386-7
   Yuki S, 2020, J CLIN ONCOL, V38
   Zhang CC, 2017, MOL THER, V25, P1248, DOI 10.1016/j.ymthe.2017.03.010
   Zhang PC, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01492-8
   Zhang TR, 2024, J CONTROL RELEASE, V368, P372, DOI 10.1016/j.jconrel.2024.02.033
   Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6
   Zhao W, 2022, CANCER LETT, V545, DOI 10.1016/j.canlet.2022.215816
   Zhen YH, 2015, CANCER IMMUNOL IMMUN, V64, P1083, DOI 10.1007/s00262-015-1715-3
NR 105
TC 0
Z9 0
U1 2
U2 2
PU CHINESE ACAD SCIENCES, INST BIOPHYSICS
PI BEIJING
PA 15 DATUN RD, CHAOYAND DISTRICT, BEIJING, 100101, PEOPLES R CHINA
SN 1000-3282
J9 PROG BIOCHEM BIOPHYS
JI Prog. Biochem. Biophys.
PD OCT
PY 2024
VL 51
IS 10
BP 2570
EP 2586
DI 10.16476/j.pibb.2024.0286
PG 17
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA K8X2H
UT WOS:001346664800022
DA 2025-01-04
ER

PT J
AU Shadeed, SH
   El-Desouky, MA
   Kotb, NS
   Elhakim, HKA
AF Shadeed, Shaimaa H.
   El-Desouky, Mohamed A.
   Kotb, Nahla S.
   Elhakim, Heba K. A.
TI Synergistic Effect of Cetuximab in Combination with Bee Venom: A Novel
   Approach for the Treatment of Colon Cancer
SO BIOINTERFACE RESEARCH IN APPLIED CHEMISTRY
LA English
DT Article
DE colon cancer; cetuximab; bee venom; MTT assay; apoptosis; cell cycle
ID COLORECTAL-CANCER; IN-VITRO; GROWTH; ARREST; CELLS
AB Anti-EGFR monoclonal antibody (cetuximab) is a promising new targeted therapy for cancer treatment currently approved to treat colon cancer. The synergistic effect of (Ce/BV) on two colon cancer cell lines (HCT116 and Caco-2) was investigated in this work to get the lowest lethal dosages of cetuximab. MTT assay was used to evaluate the cytotoxic effect of cetuximab, bee venom, and their combination. Flow cytometry analysis was used to look at cell cycle distribution and apoptosis induction. RT-PCR can identify changes in apoptotic genes expression. The results show that cetuximab and BV have IC50 against Caco-2 (686 and 10.5 g/ml, respectively) and HCT-116 (740 and 13 g/ml, respectively). According to the results, the combination treatment had a synergistic inhibitory impact on two cell lines (CI< 1). Both cell lines were arrested in the G2/M phase of the cell cycle. In addition, when combination therapy was used instead of cetuximab alone, apoptosis was dramatically increased in both cell lines. In addition, after treatment with (Ce/BV), Bcl2 and p53 were shown to be downregulated and up-regulated, respectively, in two cell lines. As a result, the combination of cetuximab and BV showed preclinical efficacy in the treatment of colon cancer
C1 [Shadeed, Shaimaa H.; Kotb, Nahla S.] Egyptian Drug Authority EDA, Biol & Innovat Cent Adm, Cairo, Egypt.
   [El-Desouky, Mohamed A.; Elhakim, Heba K. A.] Cairo Univ, Biochem Div, Fac Sci, Giza 12613, Egypt.
C3 Egyptian Knowledge Bank (EKB); Cairo University
RP Elhakim, HKA (corresponding author), Cairo Univ, Biochem Div, Fac Sci, Giza 12613, Egypt.
EM drheba_76@yahoo.com
CR Abd El-Hameed AM, 2021, METAB BRAIN DIS, V36, P2047, DOI 10.1007/s11011-021-00766-9
   Abdullah MN, 2022, CHEM BIOL DRUG DES, V100, P921, DOI 10.1111/cbdd.13974
   Alonezi S, 2017, METABOLITES, V7, DOI 10.3390/metabo7020014
   Aziz Abdel, 2017, INT J ADV RES, V5, P2036, DOI DOI 10.21474/IJAR01/3376
   Bhandari A, 2017, J INVEST MED, V65, P311, DOI 10.1136/jim-2016-000229
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Bourhis J, 2021, CANCER TREAT REV, V97, DOI 10.1016/j.ctrv.2021.102172
   Chand B., 2021, HONEY, P1
   Chen CF, 2018, ONCOL LETT, V16, P6323, DOI 10.3892/ol.2018.9418
   CHOU TC, 1994, JNCI-J NATL CANCER I, V86, P1517, DOI 10.1093/jnci/86.20.1517
   DiPaola RS, 2002, CLIN CANCER RES, V8, P3311
   Eichelmann F, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.0896
   El-Sayes N, 2021, CANCERS, V13, DOI 10.3390/cancers13040806
   Gu JJ, 2016, BIOCHEM RES INT, V2016, DOI 10.1155/2016/7016907
   Kim S, 2022, SOCIOL RACE ETHNIC, P1, DOI 10.1177/23326492221103629
   Kruiswijk F, 2015, NAT REV MOL CELL BIO, V16, P393, DOI 10.1038/nrm4007
   Liu X, 2002, J PHARM PHARMACOL, V54, P1083, DOI 10.1211/002235702320266235
   Luca T, 2014, CELL PROLIFERAT, V47, P435, DOI 10.1111/cpr.12125
   Lv SX, 2021, BIOMATERIALS, V277, DOI 10.1016/j.biomaterials.2021.121076
   Mendelsohn J, 2003, J CLIN ONCOL, V21, P2787, DOI 10.1200/JCO.2003.01.504
   Mohelnikova-Duchonova B, 2014, WORLD J GASTROENTERO, V20, P10316, DOI 10.3748/wjg.v20.i30.10316
   Nguyen PV, 2021, INT J PHARMACEUT, V605, DOI 10.1016/j.ijpharm.2021.120795
   Oh YJ, 2022, LWT-FOOD SCI TECHNOL, V153, DOI 10.1016/j.lwt.2021.112565
   Pirker R, 2013, TARGET ONCOL, V8, P47, DOI 10.1007/s11523-012-0244-7
   Qiu YR, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13050747
   Reynolds CP, 2005, METH MOLEC MED, V110, P173
   Sabra R, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118775
   Son DJ, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/397563
   Tang FQ, 2021, PAK J PHARM SCI, V34, P95, DOI 10.36721/PJPS.2021.34.1.REG.095-101.1
   Wang F, 2016, BANGL J PHARMACOL, V11, P285, DOI 10.3329/bjp.v11i2.25549
   Wu FL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00641-0
   Yaacoub C, 2021, MOLECULES, V26, DOI 10.3390/molecules26082264
   You B, 2012, J CLIN PHARMACOL, V52, P128, DOI 10.1177/0091270010395940
   You KS, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14060589
   Yuan JS, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-85
   Zhou JD, 2019, DIAGN PATHOL, V14, DOI 10.1186/s13000-019-0841-1
NR 36
TC 2
Z9 2
U1 1
U2 20
PU AMG TRANSCEND ASSOC
PI BUCHAREST
PA POLIZU ST 1-7, BUILDING I, ROOM, I-102, BUCHAREST, ROMANIA
SN 2069-5837
J9 BIOINTERFACE RES APP
JI Biointerface Res. Appl. Chem.
PD APR 15
PY 2023
VL 13
IS 2
AR 178
DI 10.33263/BRIAC132.178
PG 14
WC Chemistry, Applied
WE Emerging Sources Citation Index (ESCI)
SC Chemistry
GA 3C2ND
UT WOS:000828464500024
OA gold
DA 2025-01-04
ER

PT J
AU Maryam, S
   Krukiewicz, K
AF Maryam, Sajida
   Krukiewicz, Katarzyna
TI Sweeten the pill: Multi-faceted polysaccharide-based carriers for
   colorectal cancer treatment
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Polysaccharides; Colorectal cancer; Chemotherapy; Drug delivery
ID DRUG-DELIVERY-SYSTEMS; IN-VITRO EVALUATION; ORAL DELIVERY; GUAR GUM;
   POLYELECTROLYTE COMPLEXES; COMBINATION CHEMOTHERAPY; NATURAL
   POLYSACCHARIDES; CHITOSAN NANOPARTICLES; ANTITUMOR-ACTIVITY;
   CONTROLLED-RELEASE
AB Colorectal cancer (CRC) ranks as the second deadliest cancer globally and the third most common malignant tumor. While surgery remains the primary treatment for CRC, alternative therapies such as chemotherapy, molecular targeted therapy, and immunotherapy are also commonly used. The significant side effects and toxicity of conventional drugs drive the search for novel targeted therapies, including the design of advanced drug delivery systems. Polysaccharide-based biopolymers, with their low toxicity, non-immunogenic behavior, synergistic interactions with other biopolymers, and tissue and cell compatibility, emerge as excellent drug carriers for this application. This review aims to provide an in-depth overview of recent advancements in developing polysaccharide-based biopolymeric carriers for anticancer compounds in the treatment of CRC. We highlight the multifunctional nature of polysaccharides, showcasing their potential as standalone drug carriers or as integral components of intelligent robotic devices for biomedical therapeutic applications. In addition to exploring the opportunities for using carbohydrate polymers in CRC treatment, we address the challenges and failures that may limit their applicability in biomedical research, as well as summarize the recent preclinical and clinical trials, resulting in several commercialization attempts. This comprehensive overview critically summarizes the potential of polysaccharide-based biomaterials in CRC treatment.
C1 [Maryam, Sajida; Krukiewicz, Katarzyna] Silesian Tech Univ, Dept Phys Chem & Technol Polymers, Gliwice, Poland.
   [Maryam, Sajida] Silesian Tech Univ, Joint Doctoral Sch, Gliwice, Poland.
   [Krukiewicz, Katarzyna] Silesian Tech Univ, Ctr Organ & Nanohybrid Elect, Gliwice, Poland.
C3 Silesian University of Technology; Silesian University of Technology;
   Silesian University of Technology
RP Krukiewicz, K (corresponding author), Silesian Tech Univ, Dept Phys Chem & Technol Polymers, Gliwice, Poland.
EM katarzyna.krukiewicz@polsl.pl
RI Krukiewicz, Katarzyna/F-6936-2014; Maryam, Sajida/AEF-2276-2022
OI Maryam, Sajida/0000-0002-5485-3629
FU Silesian University of Tech-nology [04/040/RGJ24/0276,
   04/040/SDU/10-22-09, 04/040/SDU/10-07-01]
FX The Authors would like to thank the Silesian University of Tech-nology
   [04/040/RGJ24/0276, 04/040/SDU/10-22-09, 04/040/SDU/10-07-01] for the
   financial support.
CR Abid M, 2020, INT J PHARMACEUT, V586, DOI 10.1016/j.ijpharm.2020.119605
   Ablah N., 2020, Polymer science and innovative applications, P287, DOI DOI 10.1016/B978-0-12-816808-0.00009-3
   Vieira MGA, 2011, EUR POLYM J, V47, P254, DOI 10.1016/j.eurpolymj.2010.12.011
   Agarwal T, 2015, INT J BIOL MACROMOL, V75, P409, DOI 10.1016/j.ijbiomac.2014.12.052
   Alange VV, 2017, J BIOMAT SCI-POLYM E, V28, P139, DOI 10.1080/09205063.2016.1257083
   Albinali KE, 2019, INT J NANOMED, V14, P1707, DOI 10.2147/IJN.S193981
   Alfaro-Galarza O, 2020, LWT-FOOD SCI TECHNOL, V117, DOI 10.1016/j.lwt.2019.108686
   Alhaique F, 2015, J DRUG DELIV SCI TEC, V30, P300, DOI 10.1016/j.jddst.2015.06.005
   Alkader M.S., 2023, Cureus, V15
   Alkhader E, 2018, J BIOMAT SCI-POLYM E, V29, P2281, DOI 10.1080/09205063.2018.1541500
   Alshammari HA, 2021, AIP ADV, V11, DOI 10.1063/9.0000103
   [Anonymous], 2023, Chemotherapeutic synergistic targeting combined treatment nano-drug and application thereof in tumor treatment
   [Anonymous], 2023, Drug delivery system for platinum-based drugs
   [Anonymous], 2013, Oxaliplatin chitosan nanoparticle and application thereof
   [Anonymous], 2008, Colon selective drug delivery composition and pharmaceutical preparation using polysaccharides
   [Anonymous], 2022, Immune Magnetic Composition, Preparation Method and Application Thereof, and Kit for Treating Cancer
   [Anonymous], 2024, An improved two-stage microparticle-based topical therapeutic delivery system
   Arca HC, 2018, BIOMACROMOLECULES, V19, P2351, DOI 10.1021/acs.biomac.8b00517
   Ardean C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22147449
   Atta S, 2015, INT J BIOL MACROMOL, V80, P240, DOI 10.1016/j.ijbiomac.2015.06.044
   Awad A, 2022, ADV DRUG DELIVER REV, V181, DOI 10.1016/j.addr.2021.114076
   Aziz A, 2020, ACS NANO, V14, P10865, DOI 10.1021/acsnano.0c05530
   Badran MM, 2017, INT J BIOL MACROMOL, V95, P643, DOI 10.1016/j.ijbiomac.2016.11.098
   Bajaj G, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030899
   Barclay TG, 2019, CARBOHYD POLYM, V221, P94, DOI 10.1016/j.carbpol.2019.05.067
   Bayan MF, 2020, FUTUR J PHARM SCI, V6, DOI 10.1186/s43094-020-00057-7
   Benita S., 2015, Microspheres comprising nanocapsules containing a lipophilic drug
   Bertoli A, 2022, MAR DRUGS, V20, DOI 10.3390/md20110682
   BISSERY MC, 1991, CANCER RES, V51, P4845
   Bobo D, 2016, PHARM RES-DORDR, V33, P2373, DOI 10.1007/s11095-016-1958-5
   Boczar D, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14071389
   Bozuyuk U, 2018, ACS NANO, V12, P9617, DOI 10.1021/acsnano.8b05997
   Braga SS, 2022, J DRUG DELIV SCI TEC, V75, DOI 10.1016/j.jddst.2022.103650
   Bravo-Osuna I, 2007, BIOMATERIALS, V28, P2233, DOI 10.1016/j.biomaterials.2007.01.005
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brown KGM, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l4561
   Cabeza L, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01731-y
   Cai L, 2023, Biomed. Tech., V1, P30
   Calleja P, 2015, J PHARM SCI-US, V104, P2877, DOI 10.1002/jps.24354
   Cao LQ, 2020, CARBOHYD POLYM, V242, DOI 10.1016/j.carbpol.2020.116389
   Carvalho A., 2008, Starch: Major Sources, Properties and Applications as Thermoplastic Materials, P321
   Cernencu AI, 2019, CARBOHYD POLYM, V220, P12, DOI 10.1016/j.carbpol.2019.05.026
   Ceylan H, 2019, ACS NANO, V13, P3353, DOI 10.1021/acsnano.8b09233
   Chaudhary M., 2022, Stealth, targeted nanoparticles (STN) for oral drug delivery
   Chauhan S., 2013, Magnetic Nanoparticle Formulations, Methods for Making Such Formulations, and Methods for their Use
   Cheewatanakornkool K, 2017, CARBOHYD POLYM, V174, P493, DOI 10.1016/j.carbpol.2017.06.115
   Chehelgerdi M, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01865-0
   Cheng Y, 2012, MACROMOL BIOSCI, V12, P1326, DOI 10.1002/mabi.201200165
   Chuah LH, 2014, COLLOID SURFACE B, V116, P228, DOI 10.1016/j.colsurfb.2014.01.007
   Clark MA, 2000, ADV DRUG DELIVER REV, V43, P207, DOI 10.1016/S0169-409X(00)00070-3
   Colvin KM, 2011, PLOS PATHOG, V7, DOI 10.1371/journal.ppat.1001264
   Cruz LJ, 2011, MOL PHARMACEUT, V8, P520, DOI 10.1021/mp100356k
   Dalei G, 2023, CHEM ENG SCI, V269, DOI 10.1016/j.ces.2023.118482
   Dang Yu, 2020, Smart Mater Med, V1, P10, DOI 10.1016/j.smaim.2020.04.001
   Davis ME, 2009, ADV DRUG DELIVER REV, V61, P1189, DOI 10.1016/j.addr.2009.05.005
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   De SJ, 2003, J CONTROL RELEASE, V89, P101, DOI 10.1016/S0168-3659(03)00098-1
   Debele TA, 2016, MAT SCI ENG C-MATER, V68, P964, DOI 10.1016/j.msec.2016.05.121
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Devasier B., 2014, Application of Nanotechnology in Drug Delivery
   Dey M, 2019, INT J BIOL MACROMOL, V130, P34, DOI 10.1016/j.ijbiomac.2019.02.094
   Dey S, 2014, CARBOHYD POLYM, V99, P499, DOI 10.1016/j.carbpol.2013.08.067
   Din FU, 2017, INT J NANOMED, V12, P7291, DOI 10.2147/IJN.S146315
   Ding SL, 2022, BIOACT MATER, V17, P81, DOI 10.1016/j.bioactmat.2022.01.033
   Ding YB, 2018, COLLOID SURFACE B, V171, P656, DOI 10.1016/j.colsurfb.2018.08.007
   Dionísio M, 2012, J PHARM BIOALLIED SC, V4, P175, DOI 10.4103/0975-7406.99013
   dos Santos AM, 2021, EUR J PHARM BIOPHARM, V158, P371, DOI 10.1016/j.ejpb.2020.12.004
   Ebrahim SA, 2019, NANOSCALE RES LETT, V14, DOI 10.1186/s11671-019-2994-y
   Edman P., 1996, Therapeutical composition and process for its preparation
   El Zouhairi Majed, 2011, Gastrointest Cancer Res, V4, P15
   Elias EJ, 2010, NAT PROD COMMUN, V5, P915
   Elkatatny S, 2019, ENERGIES, V12, DOI 10.3390/en12081485
   Elzatahry AA, 2009, J APPL POLYM SCI, V111, P2452, DOI 10.1002/app.29221
   ESPEVIK T, 1993, EUR J IMMUNOL, V23, P255, DOI 10.1002/eji.1830230140
   Fan M, 2017, MAT SCI ENG C-MATER, V71, P67, DOI 10.1016/j.msec.2016.09.068
   Feng C, 2017, INT J BIOL MACROMOL, V94, P170, DOI 10.1016/j.ijbiomac.2016.10.012
   Feng C, 2015, COLLOID SURFACE B, V128, P439, DOI 10.1016/j.colsurfb.2015.02.042
   Fernández-Hervás MJ, 1998, INT J PHARM, V169, P115, DOI 10.1016/S0378-5173(98)00114-8
   Fetzer O.S., 2012, Cyclodextrinbased polymers for therapeutic delivery
   Friend DR, 2005, ADV DRUG DELIVER REV, V57, P247, DOI 10.1016/j.addr.2004.08.011
   Fu LH, 2019, J MATER CHEM B, V7, P1541, DOI 10.1039/c8tb02331j
   Fukamizu K, 2009, ANGEW CHEM INT EDIT, V48, P2534, DOI 10.1002/anie.200900392
   Gamal-Eldeen AM, 2006, CHEM-BIOL INTERACT, V161, P229, DOI 10.1016/j.cbi.2006.03.010
   Ganeshkumar M., 2018, Guar gum stabilized gold nanoparticles for colon cancer treatment, V3, P1539
   Gao CY, 2021, ADV MATER, V33, DOI 10.1002/adma.202000512
   Garcia-Valdez O, 2018, PROG POLYM SCI, V76, P151, DOI 10.1016/j.progpolymsci.2017.08.001
   Gattás-Asfura KM, 2009, BIOMACROMOLECULES, V10, P3122, DOI 10.1021/bm900789a
   Gebeyehu A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79325-8
   Goldberg M.N., 2019, Two-stage microparticle-based therapeutic delivery system and method
   Goldberg RM, 2005, ONCOLOGIST, V10, P40, DOI 10.1634/theoncologist.10-90003-40
   Goodisman J, 2006, CANCER CHEMOTH PHARM, V57, P257, DOI 10.1007/s00280-005-0041-4
   Gottesman MM, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv222
   Govender T, 2000, INT J PHARMACEUT, V199, P95, DOI 10.1016/S0378-5173(00)00375-6
   Grothey A, 2004, J CLIN ONCOL, V22, P1209, DOI 10.1200/JCO.2004.11.037
   Gulbake A, 2012, EXPERT OPIN DRUG DEL, V9, P713, DOI 10.1517/17425247.2012.682148
   Gupta KC, 2001, J MATER SCI-MATER M, V12, P753, DOI 10.1023/A:1017976014534
   Habibi H, 2017, BIOCATAL AGR BIOTECH, V10, P130, DOI 10.1016/j.bcab.2017.02.013
   Hamdani AM, 2018, FOOD CHEM, V240, P1201, DOI 10.1016/j.foodchem.2017.08.060
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Harish V, 2022, NANOMATERIALS-BASEL, V12, DOI 10.3390/nano12030457
   He ZH, 2020, MAT SCI ENG C-MATER, V106, DOI 10.1016/j.msec.2019.110298
   Healy AV, 2019, PHARMACEUTICS, V11, DOI 10.3390/pharmaceutics11120645
   Herbig S.M., 1997, PH-triggered osmotic bursting delivery devices
   Dang HP, 2020, ADV THER-GERMANY, V3, DOI 10.1002/adtp.202000056
   Hsieh HL, 2018, J AGR FOOD CHEM, V66, P1175, DOI 10.1021/acs.jafc.7b04150
   Hu H, 2016, ACS APPL MATER INTER, V8, P30833, DOI 10.1021/acsami.6b11932
   Jabeen N, 2023, POLYM ADVAN TECHNOL, DOI 10.1002/pat.6203
   Jaimes-Aguirre L, 2016, CURR PHARM DESIGN, V22, P2886, DOI 10.2174/1381612822666160217125028
   Jain A, 2007, J DRUG TARGET, V15, P285, DOI 10.1080/10611860601146134
   Jain A, 2010, NANOMED-NANOTECHNOL, V6, P179, DOI 10.1016/j.nano.2009.03.002
   Jambhekar SS, 2016, DRUG DISCOV TODAY, V21, P356, DOI 10.1016/j.drudis.2015.11.017
   Jayanth D, 2018, J POLYM ENVIRON, V26, P838, DOI 10.1007/s10924-017-0985-6
   Jin M, 2021, TISSUE ENG PART B-RE, V27, P604, DOI [10.1089/ten.teb.2020.0208, 10.1089/ten.TEB.2020.0208]
   Johdi NA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01624
   Kang RK, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-019-1589-3
   Katas H, 2017, J NANOMATER, V2017, DOI 10.1155/2017/4298218
   Kaushik D., 2009, International Journal of Pharmaceutical Sciences and Drug Research, P83
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Kim JY, 2018, SENSOR ACTUAT B-CHEM, V266, P276, DOI 10.1016/j.snb.2018.03.033
   Klemm D, 2005, ANGEW CHEM INT EDIT, V44, P3358, DOI 10.1002/anie.200460587
   Koopman M, 2007, LANCET, V370, P135, DOI 10.1016/S0140-6736(07)61086-1
   Kou M., 2022, Colorectal cancer: an overview, P1
   Krishnaiah YSR, 2002, EUR J PHARM SCI, V16, P185, DOI 10.1016/S0928-0987(02)00081-7
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kulkarni RV, 2008, DRUG DEV IND PHARM, V34, P1406, DOI [10.1080/03639040802130079, 10.1080/03639040802130079 ]
   Kumar B, 2017, COLLOID SURFACE B, V150, P352, DOI 10.1016/j.colsurfb.2016.10.049
   KUNCHANDY E, 1990, INT J PHARMACEUT, V58, P237, DOI 10.1016/0378-5173(90)90201-E
   Kwiecien I, 2018, GELS-BASEL, V4, DOI 10.3390/gels4020047
   Lai CK, 2014, NANOMEDICINE-UK, V9, P803, DOI [10.2217/nnm.13.54, 10.2217/NNM.13.54]
   Lamprecht A, 2001, J PHARMACOL EXP THER, V299, P775
   Lee KY, 2012, PROG POLYM SCI, V37, P106, DOI 10.1016/j.progpolymsci.2011.06.003
   Lee S.S., 2002, Composition and pharmaceutical dosage form for colonic drug delivery using polysaccharides
   Lee S, 2016, INT J PHARMACEUT, V515, P300, DOI 10.1016/j.ijpharm.2016.10.023
   Lehmann K., 1995, Oral dosage unit form
   Lerner E.I., 2003, Immediate release gastrointestinal drug delivery system
   Li J, 2016, INT J BIOL MACROMOL, V85, P1, DOI 10.1016/j.ijbiomac.2015.12.064
   Li JY, 2022, PHARMACEUTICALS-BASE, V15, DOI 10.3390/ph15050602
   Li JH, 2020, MAT SCI ENG R, V140, DOI 10.1016/j.mser.2020.100543
   Li JX, 2023, NANOMATERIALS-BASEL, V13, DOI 10.3390/nano13101590
   Li MQ, 2015, BIOMATERIALS, V51, P161, DOI 10.1016/j.biomaterials.2015.02.002
   Liu Q, 2020, INT J BIOL MACROMOL, V161, P481, DOI 10.1016/j.ijbiomac.2020.06.070
   Liu SS, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-69230-5
   Liu ZH, 2008, ADV DRUG DELIVER REV, V60, P1650, DOI 10.1016/j.addr.2008.09.001
   Loftsson Thorsteinn, 2005, Expert Opin Drug Deliv, V2, P335, DOI 10.1517/17425247.2.1.335
   Lokhande AS, 2023, INT J PHARMACEUT, V635, DOI 10.1016/j.ijpharm.2023.122729
   Long W, 2021, INT J BIOL MACROMOL, V182, P2066, DOI 10.1016/j.ijbiomac.2021.05.193
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Lu IL, 2022, ADV HEALTHC MATER, V11, DOI 10.1002/adhm.202201140
   Luo YC, 2014, INT J BIOL MACROMOL, V64, P353, DOI 10.1016/j.ijbiomac.2013.12.017
   Maciel D, 2013, BIOMACROMOLECULES, V14, P3140, DOI 10.1021/bm400768m
   Maeda H, 2001, ADV ENZYME REGUL, V41, P189, DOI 10.1016/S0065-2571(00)00013-3
   Maestrelli F, 2008, EUR J PHARM BIOPHARM, V69, P508, DOI 10.1016/j.ejpb.2007.12.004
   Maestrelli F, 2006, EUR J PHARM BIOPHARM, V63, P79, DOI 10.1016/j.ejpb.2005.12.006
   Mahmood A, 2017, CARBOHYD POLYM, V167, P250, DOI 10.1016/j.carbpol.2017.03.019
   Maiti S, 2019, WOODH PUBL SER BIOM, P1, DOI 10.1016/C2017-0-02351-0
   Marques-Marinho FD, 2013, CELLULOSE - MEDICAL, PHARMACEUTICAL AND ELECTRONIC APPLICATIONS, P141, DOI 10.5772/56637
   Masková E, 2020, J CONTROL RELEASE, V324, P695, DOI 10.1016/j.jconrel.2020.05.045
   Menezes PD, 2019, INT J PHARMACEUT, V559, P312, DOI 10.1016/j.ijpharm.2019.01.041
   Menon G., Colon Cancer
   MESHALI MM, 1993, INT J PHARMACEUT, V89, P177, DOI 10.1016/0378-5173(93)90241-7
   Messersmith WA, 2019, J NATL COMPR CANC NE, V17, P599, DOI 10.6004/jnccn.2019.5014
   Midhun Dominic C D, 2022, Int J Biol Macromol, V206, P92, DOI 10.1016/j.ijbiomac.2022.02.078
   Milivojevic M, 2023, GELS-BASEL, V9, DOI 10.3390/gels9080620
   Misra R, 2010, DRUG DISCOV TODAY, V15, P842, DOI 10.1016/j.drudis.2010.08.006
   Muhoza B, 2023, FOOD HYDROCOLLOID, V140, DOI 10.1016/j.foodhyd.2023.108650
   Mukherjee S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12020147
   Nesic A, 2020, MOLECULES, V25, DOI 10.3390/molecules25010135
   Niranjan K., 2013, Asian J. Pharm. Clin. Res., V6, P315
   Nowotnik D., Targeted Nanocarrier Systems for Delivery of Actives Across Biological Membranes
   Ntoutoume GMAN, 2016, BIOORG MED CHEM LETT, V26, P941, DOI 10.1016/j.bmcl.2015.12.060
   OCONNELL MJ, 1989, CANCER, V63, P1026, DOI 10.1002/1097-0142(19890315)63:6+<1026::AID-CNCR2820631307>3.0.CO;2-R
   Oerlemans C, 2010, PHARM RES-DORDR, V27, P2569, DOI 10.1007/s11095-010-0233-4
   Oh DY, 2020, NAT REV CLIN ONCOL, V17, P33, DOI 10.1038/s41571-019-0268-3
   Olmos-Juste R, 2021, CARBOHYD POLYM, V264, DOI 10.1016/j.carbpol.2021.118026
   Oprea A., 2013, JBNB, V4, P123
   Paharia A, 2007, AAPS PHARMSCITECH, V8
   Pai S.-S.L.-B.L., 1999, Patent No. [0888778A1, 0888778]
   Palumbo G, 2019, MATERIALS, V12, DOI 10.3390/ma12162620
   Pande S, 2012, INDIAN J MED RES, V135, P401
   Park HR, 2017, J FUNCT FOODS, V37, P460, DOI 10.1016/j.jff.2017.08.027
   Park JM, 2012, J MICROENCAPSUL, V29, P695, DOI 10.3109/02652048.2012.686526
   Patel J.J., 2014, Int. J. Pharm. Pharm. Sci, V6, P13
   Patel J, 2020, RSC ADV, V10, P27103, DOI 10.1039/d0ra04366d
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Pereira AGB, 2013, CARBOHYD POLYM, V98, P711, DOI 10.1016/j.carbpol.2013.06.013
   Pérez-Herrero E, 2015, EUR J PHARM BIOPHARM, V93, P52, DOI 10.1016/j.ejpb.2015.03.018
   Petrioli R, 2008, CANCER CHEMOTH PHARM, V61, P105, DOI 10.1007/s00280-007-0454-3
   Plucinski A, 2021, J MATER CHEM B, V9, P7030, DOI 10.1039/d1tb00628b
   Ponchel G, 1998, ADV DRUG DELIVER REV, V34, P191, DOI 10.1016/S0169-409X(98)00040-4
   Pooja C., 2011, Asian J. Pharm. Clin. Res., V4, P12
   Pooresmaeil M, 2019, INT J BIOL MACROMOL, V139, P994, DOI 10.1016/j.ijbiomac.2019.08.060
   Posocco B, 2015, MATERIALS, V8, P2569, DOI 10.3390/ma8052569
   Prakash P, 2022, NANOMATERIALS-BASEL, V12, DOI 10.3390/nano12010175
   Prasad YVR, 1998, J CONTROL RELEASE, V51, P281, DOI 10.1016/S0168-3659(97)00181-8
   Prasher P, 2021, COLLOID INTERFAC SCI, V42, DOI 10.1016/j.colcom.2021.100418
   Prata AS, 2015, CARBOHYD POLYM, V116, P292, DOI 10.1016/j.carbpol.2014.03.056
   Puga AM, 2013, CARBOHYD POLYM, V98, P331, DOI 10.1016/j.carbpol.2013.05.091
   Pushpamalar J, 2016, CHEMPLUSCHEM, V81, P504, DOI 10.1002/cplu.201600112
   Rahman Z, 2008, J PHARM PHARMACOL, V60, P615, DOI 10.1211/jpp.60.5.0007
   Rai G, 2016, DRUG DELIV, V23, P328, DOI 10.3109/10717544.2014.913733
   Railkar N.H.S.P., 1996, Colon-targeted delivery system
   Rajput H, 2024, INT J BIOL MACROMOL, V256, DOI 10.1016/j.ijbiomac.2023.128392
   Ramasamy T, 2014, PHARM RES-DORDR, V31, P1302, DOI 10.1007/s11095-013-1251-9
   Ramirez CAB, 2023, BIOMATER ADV, V153, DOI 10.1016/j.bioadv.2023.213525
   Rao W, 2015, ACS NANO, V9, P5725, DOI 10.1021/nn506928p
   Raveendran S, 2017, MATERIALS, V10, DOI 10.3390/ma10080929
   RINGEL I, 1991, J NATL CANCER I, V83, P288, DOI 10.1093/jnci/83.4.288
   Sabra R, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118775
   Sadik S.B.S., 2024, Capsaicinoids: From Natural Sources to Biosynthesis and Their Clinical Applications, P463
   Salave S, 2022, POLYSACCHARIDES-BASE, V3, P625, DOI 10.3390/polysaccharides3030037
   Sanadgol N, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12090831
   Sánchez-Gundín J, 2018, INT J MED SCI, V15, P659, DOI 10.7150/ijms.24453
   Sandhu J, 2019, J SURG ONCOL, V119, P564, DOI 10.1002/jso.25421
   Seymour MT, 2007, LANCET, V370, P143, DOI 10.1016/S0140-6736(07)61087-3
   Shams F, 2022, MOL BIOL REP, V49, P1389, DOI 10.1007/s11033-021-06876-y
   Shaqour B, 2020, MATERIALS, V13, DOI 10.3390/ma13153364
   Shi JJ, 2017, NAT REV CANCER, V17, P20, DOI 10.1038/nrc.2016.108
   Shih FY, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113625
   Singh N., 2016, Research Journal of Pharmacy and Technology, V9, P982
   Sohrabi S, 2020, RSC ADV, V10, P27560, DOI 10.1039/d0ra04566g
   Srivastava N, 2023, IND ENG CHEM RES, V62, P841, DOI 10.1021/acs.iecr.2c02779
   Subudhi MB, 2015, MATERIALS, V8, P832, DOI 10.3390/ma8030832
   Sullivan DJ, 2018, FOOD HYDROCOLLOID, V83, P355, DOI 10.1016/j.foodhyd.2018.05.010
   Sultana N, 2023, MOLECULES, V28, DOI 10.3390/molecules28247974
   Sun XY, 2023, CANCER DRUG RESIST, V6, P390, DOI 10.20517/cdr.2023.16
   Sun XX, 2019, INT J BIOL MACROMOL, V128, P468, DOI 10.1016/j.ijbiomac.2019.01.140
   Sun YL, 2012, CHIN J CANCER, V31, P51, DOI 10.5732/cjc.011.10466
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Sung YK, 2020, BIOMATER RES, V24, DOI 10.1186/s40824-020-00190-7
   Tang SS, 2020, SCI ROBOT, V5, DOI 10.1126/scirobotics.aba6137
   Tao YH, 2021, ACS OMEGA, V6, P9998, DOI 10.1021/acsomega.0c06131
   Temesgen S, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13071121
   Terwogt JMM, 2001, ANTI-CANCER DRUG, V12, P315, DOI 10.1097/00001813-200104000-00003
   Thomas D, 2020, INT J BIOL MACROMOL, V154, P888, DOI 10.1016/j.ijbiomac.2020.03.167
   Tian BR, 2020, CARBOHYD POLYM, V232, DOI 10.1016/j.carbpol.2019.115805
   Tian X, 2017, CANCER RES, V77, P112, DOI 10.1158/0008-5472.CAN-15-2951
   Troiani T, 2013, THER ADV MED ONCOL, V5, P51, DOI 10.1177/1758834012462462
   Udayakumar Gowthama Prabu, 2021, Biotechnol Adv, V52, P107815, DOI 10.1016/j.biotechadv.2021.107815
   Ulbrich K, 2016, CHEM REV, V116, P5338, DOI 10.1021/acs.chemrev.5b00589
   Umar S, 2003, CELL PROLIFERAT, V36, P361, DOI 10.1046/j.1365-2184.2003.00291.x
   Ünal S, 2023, BEILSTEIN J ORG CHEM, V19, P139, DOI 10.3762/bjoc.19.14
   Ussia M, 2023, SMALL, V19, DOI 10.1002/smll.202208259
   Vaidya A, 2015, J SAUDI CHEM SOC, V19, P257, DOI 10.1016/j.jscs.2012.03.001
   Valdez B., 2012, Scientific, Health and Social Aspects of the Food Industry
   van Steenwijk HP, 2021, NUTRIENTS, V13, DOI 10.3390/nu13041333
   van Vlerken LE, 2007, PHARM RES-DORDR, V24, P1405, DOI 10.1007/s11095-007-9284-6
   Veltkamp SA, 2008, CLIN CANCER RES, V14, P7535, DOI 10.1158/1078-0432.CCR-08-0438
   Verma Anita K., 2008, Current Drug Delivery, V5, P120, DOI 10.2174/156720108783954806
   Vitiello A, 2023, CARDIOVASC DRUG THER, V37, P277, DOI 10.1007/s10557-021-07251-6
   Vivek R, 2014, INT J BIOL MACROMOL, V65, P289, DOI 10.1016/j.ijbiomac.2014.01.054
   Voragen AGJ, 2009, STRUCT CHEM, V20, P263, DOI 10.1007/s11224-009-9442-z
   Wagh OV, 2022, INT J EARLY CHILD SP, V14, P2688, DOI 10.9756/INT-JECSE/V14I3.327
   Walko CM, 2005, CLIN THER, V27, P23, DOI 10.1016/j.clinthera.2005.01.005
   Wang B, 2021, ADV MATER, V33, DOI 10.1002/adma.202002047
   Wang HY, 2022, POLYMERS-BASEL, V14, DOI 10.3390/polym14245509
   Wang JM, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.201901710
   Wei H, 2008, INT J PHARMACEUT, V348, P35, DOI 10.1016/j.ijpharm.2007.07.005
   Wen YF, 2014, MACROMOL RAPID COMM, V35, P1819, DOI 10.1002/marc.201400406
   Weng WH, 2022, SEMIN CANCER BIOL, V80, P73, DOI 10.1016/j.semcancer.2020.02.011
   Whelehan M, 2011, J MICROENCAPSUL, V28, P669, DOI 10.3109/02652048.2011.586068
   Wijaya CJ, 2021, MOLECULES, V26, DOI 10.3390/molecules26030676
   Wong TW, 2011, AAPS PHARMSCITECH, V12, P201, DOI 10.1208/s12249-010-9564-z
   Wu QX, 2014, MAR DRUGS, V12, P6236, DOI 10.3390/md12126236
   Wu Y, 2019, IET NANOBIOTECHNOL, V13, P880, DOI 10.1049/iet-nbt.2019.0144
   Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174
   Xia WS, 2008, BIORESOURCE TECHNOL, V99, P6751, DOI 10.1016/j.biortech.2008.01.011
   Xiao HX, 2016, INT J BIOL MACROMOL, V89, P456, DOI 10.1016/j.ijbiomac.2016.04.037
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu PS, 2010, BIOMACROMOLECULES, V11, P2352, DOI 10.1021/bm100481r
   Xue YA, 2015, RSC ADV, V5, P73416, DOI 10.1039/c5ra13313k
   Yadav P, 2015, J CLIN DIAGN RES, V9, pZE21, DOI 10.7860/JCDR/2015/13907.6565
   Yan GH, 2020, CARBOHYD POLYM, V244, DOI 10.1016/j.carbpol.2020.116492
   Yang HW, 2012, NANOTECHNOL SCI APPL, V5, P73, DOI 10.2147/NSA.S35506
   Yang LB, 2002, INT J PHARM, V235, P1, DOI 10.1016/S0378-5173(02)00004-2
   Yao XK, 2019, PROG POLYM SCI, V93, P1, DOI 10.1016/j.progpolymsci.2019.03.004
   Yawalkar AN, 2022, J DRUG DELIV SCI TEC, V75, DOI 10.1016/j.jddst.2022.103659
   Yeh TH, 2011, BIOMATERIALS, V32, P6164, DOI 10.1016/j.biomaterials.2011.03.056
   Yi G, 2018, QUANT IMAG MED SURG, V8, P433, DOI 10.21037/qims.2018.05.04
   Yue S, 2022, BIOSENS BIOELECTRON, V198, DOI 10.1016/j.bios.2021.113822
   Yusefi M, 2023, INT J BIOL MACROMOL, V233, DOI 10.1016/j.ijbiomac.2023.123388
   Yusefi Mostafa, 2022, Int J Biol Macromol, V199, P372, DOI 10.1016/j.ijbiomac.2021.12.189
   Yusefi M, 2021, CARBOHYD POLYM, V273, DOI 10.1016/j.carbpol.2021.118523
   Zamboulis A, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14010145
   Zhang B, 2017, MAT SCI ENG C-MATER, V79, P185, DOI 10.1016/j.msec.2017.05.054
   Zhang H, 2002, INT J PHARMACEUT, V239, P197, DOI 10.1016/S0378-5173(02)00112-6
   Zhang J, 2022, ADV SCI, V9, DOI 10.1002/advs.202103444
   Zhang JH, 2018, CANCER-AM CANCER SOC, V124, P785, DOI 10.1002/cncr.31062
   Zhang LL, 2016, ENVIRON TOXICOL PHAR, V48, P31, DOI 10.1016/j.etap.2016.09.021
   Zhang YZ, 2017, INT J PHARMACEUT, V532, P384, DOI 10.1016/j.ijpharm.2017.09.023
   Zhang YY, 2020, INT J BIOL MACROMOL, V146, P1060, DOI 10.1016/j.ijbiomac.2019.09.231
   Zhao LP, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-01080-3
   Zheng ZQ, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-020-20697-w
   Zou YF, 2021, INT J PHARMACEUT, V606, DOI 10.1016/j.ijpharm.2021.120888
NR 294
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD DEC
PY 2024
VL 282
AR 136696
DI 10.1016/j.ijbiomac.2024.136696
EA OCT 2024
PN 1
PG 22
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA K4W7N
UT WOS:001343900800001
PM 39437958
OA hybrid
DA 2025-01-04
ER

PT J
AU Mao, ZL
   Wu, Y
   Yao, PA
   Xing, CE
AF Mao, Zonglei
   Wu, Yong
   Yao, Pingan
   Xing, Chungen
TI GOLM1 facilitates human colorectal cancer progression and metastasis via
   activating the AKT/GSK3?/EMT axis
SO NEOPLASMA
LA English
DT Article
DE GOLM1; AKT; GSK3?; EMT; CRC; metastasis
ID EPITHELIAL-MESENCHYMAL TRANSITION; EMT; SURVIVAL; SNAIL; INVASION; GP73
AB GOLM1 (Golgi membrane protein 1), a key tumor progression-and metastasis-related marker, is highly expressed in a variety of epithelium-derived human cancers. However, its expression and functions in human colorectal cancer (CRC) have been rarely explored. The present study verified the high expression of GOLM1 within CRC tissues and cell lines. GOLM1 was positively correlated with vascular invasion, TNM stage, and lymph node metastasis among CRC cases. In vitro experi-ments showed that GOLM1 downregulation inhibited the growth, migration, and invasion of Caco-2 and HCT116 cells, while the overexpression of GOLM1 facilitated the growth, migration, and invasion of SW480 cells. In vivo experiments revealed that the knockdown of GOLM1 reduced the growth of nude mouse xenografts and lung metastasis of HCT116 cells. Furthermore, GOLM1 was found to be a motivator for the epithelial-mesenchymal transition (EMT) phenotype and the AKT/GSK3 beta pathway in CRC cells. Finally, MK2206, an AKT inhibitor, could markedly reverse GOLM1-elicited prolif-eration, migration, invasion, and EMT phenotype by inhibiting the AKT/GSK3 beta pathway. Collectively, our data indicate that GOLM1 facilitates human CRC progression and metastasis via activating the AKT/GSK3 beta/EMT axis. Most impor-tantly, our study makes substantial support for the clinical translation of GOLM1 in CRC target therapy.
C1 [Mao, Zonglei] Zhejiang Univ, Affiliated Hangzhou Peoples Hosp 1, Dept Gastroenterol Surg, Sch Med, Hangzhou, Peoples R China.
   [Mao, Zonglei; Wu, Yong; Xing, Chungen] Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou, Peoples R China.
   [Yao, Pingan] Tongji Univ, Dept Gastrointestinal Surg, Shanghai East Hosp, Shanghai, Peoples R China.
C3 Zhejiang University; Soochow University - China; Tongji University
RP Xing, CE (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 2, Suzhou, Peoples R China.
EM xingcg@suda.edu.cn
FU Key Medi- cal Project of Jiangsu Commission of Health [ZD2021045];
   Health and Family Planning Commission Fund Project of Jiangsu Province
   [CXTDA2017016]; Open Projects of State Key Labo- ratory of Radiation
   Medicine and Protection [GZK1202010]; Postgraduate Research & Practice
   Innovation Program of Jiangsu Province [KYCX20_2679]
FX Acknowledgments: This work was supported by The Key Medi- cal Project of
   Jiangsu Commission of Health (ZD2021045) , the Health and Family
   Planning Commission Fund Project of Jiangsu Province (No CXTDA2017016) ,
   Open Projects of State Key Labo- ratory of Radiation Medicine and
   Protection (No GZK1202010) , Postgraduate Research & Practice Innovation
   Program of Jiangsu Province (No KYCX20_2679) .
CR Aruna Li LM, 2018, AM J CANCER RES, V8, P551
   Barrallo-Gimeno A, 2005, DEVELOPMENT, V132, P3151, DOI 10.1242/dev.01907
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Dang YZ, 2021, J CANCER, V12, P7158, DOI 10.7150/jca.61567
   Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4
   George JT, 2017, CANCER RES, V77, P6415, DOI 10.1158/0008-5472.CAN-16-3521
   Gu Y, 2016, J PATHOL, V239, P60, DOI 10.1002/path.4697
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kaufhold S, 2014, J EXP CLIN CANC RES, V33, DOI 10.1186/s13046-014-0062-0
   Kladney RD, 2000, GENE, V249, P53, DOI 10.1016/S0378-1119(00)00136-0
   Lee JJ, 2016, CLIN ADV HEMATOL ONC, V14, P46
   Li LK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038939
   Li PP, 2020, AGING-US, V12, P53, DOI 10.18632/aging.102564
   Liewen H, 2019, TARGET ONCOL, V14, P577, DOI 10.1007/s11523-019-00667-z
   Liu YM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.783860
   Mi L, 2017, ONCOGENE, V36, P4323, DOI 10.1038/onc.2017.74
   Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001
   Pastushenko I, 2018, NATURE, V556, P463, DOI 10.1038/s41586-018-0040-3
   Pu Y, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00535-1
   Roy HK, 2005, DIGEST DIS SCI, V50, P42, DOI 10.1007/s10620-005-1275-z
   Spaderna S, 2006, GASTROENTEROLOGY, V131, P830, DOI 10.1053/j.gastro.2006.06.016
   Sun JT, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1098-y
   Tang ZF, 2017, NUCLEIC ACIDS RES, V45, pW98, DOI 10.1093/nar/gkx247
   Wright LM, 2009, INT J CLIN EXP PATHO, V2, P34
   Xu R, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0665-3
   Yan G, 2018, PROSTATE, V78, P166, DOI 10.1002/pros.23461
   Ye QH, 2016, CANCER CELL, V30, P444, DOI 10.1016/j.ccell.2016.07.017
   Zavadil J, 2005, ONCOGENE, V24, P5764, DOI 10.1038/sj.onc.1208927
   Zhang JC, 2020, ONCOGENE, V39, P2550, DOI 10.1038/s41388-020-1165-z
   Zhou BHP, 2004, NAT CELL BIOL, V6, P931, DOI 10.1038/ncb1173
NR 30
TC 2
Z9 2
U1 0
U2 0
PU AEPRESS SRO
PI BRATISLAVA
PA BAJZOVA 7, BRATISLAVA, 821 08, SLOVAKIA
SN 0028-2685
EI 1338-4317
J9 NEOPLASMA
JI Neoplasma
PY 2023
VL 70
IS 1
BP 136
EP 144
DI 10.4149/neo_2023_220816N835
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA E8QA4
UT WOS:000978110900002
PM 36916929
OA Bronze
DA 2025-01-04
ER

PT J
AU Chia, PL
   Ang, KH
   Thura, M
   Zeng, Q
AF Chia, Pei Ling
   Ang, Koon Hwee
   Thura, Min
   Zeng, Qi
TI PRL3 as a therapeutic target for novel cancer immunotherapy in multiple
   cancer types
SO THERANOSTICS
LA English
DT Review
DE Phosphatase of Regenerating Liver-3 (PRL3); cancer metastasis;
   monoclonal antibody (mAb); immunotherapy; clinical trials
ID CELLS IN-VITRO; REGENERATING LIVER-3; GASTRIC-CANCER;
   HEPATOCELLULAR-CARCINOMA; TYROSINE-PHOSPHATASE; COLORECTAL-CANCER;
   MATRIX METALLOPROTEINASES; MALIGNANT PROGRESSION; MONOCLONAL-ANTIBODIES;
   PERITONEAL METASTASIS
AB Phosphatase of Regenerating Liver-3 (PRL3) was discovered in 1998 and was subsequently found to be correlated with cancer progression and metastasis in 2001. Extensive research in the past two decades has produced significant findings on PRL3-mediated cancer signaling and functions, as well as its clinical relevance in diverse types of cancer. PRL3 has been established to play a role in many cancer-related functions, including but not limited to metastasis, proliferation, and angiogenesis. Importantly, the tumor-specific expression of PRL3 protein in multiple cancer types has made it an attractive therapeutic target. Much effort has been made in developing PRL3-targeted therapy with small chemical inhibitors against intracellular PRL3, and notably, the development of PRL3-zumab as a novel cancer immunotherapy against PRL3. In this review, we summarize the current understanding of the role of PRL3 in cancer-related cellular functions, its prognostic value, as well as perspectives on PRL3 as a target for unconventional immunotherapy in the clinic with PRL3-zumab.
C1 [Chia, Pei Ling; Ang, Koon Hwee; Thura, Min; Zeng, Qi] ASTAR, Inst Mol & Cell Biol, Singapore 138673, Singapore.
C3 Agency for Science Technology & Research (A*STAR); A*STAR - Institute of
   Molecular & Cell Biology (IMCB)
RP Zeng, Q (corresponding author), ASTAR, Inst Mol & Cell Biol, Singapore 138673, Singapore.
EM chiapl@imcb.a-star.edu.sg; angkh@imcb.a-star.edu.sg;
   mthura@imcb.a-star.edu.sg; mcbzengq@imcb.a-star.edu.sg
RI Thura, Min/HMU-9618-2023
OI Chia, Pei Ling/0000-0002-1656-4770
FU Agency for Science, Technology and Research, Institute of Molecular and
   Cell Biology [C210812005]
FX This research was funded by Agency for Science, Technology and Research,
   Institute of Molecular and Cell Biology core fund and Career Development
   Fund [C210812005] .
CR Abdollahi P, 2021, FASEB J, V35, DOI 10.1096/fj.202001920RR
   Abdollahi P, 2017, MOL CANCER RES, V15, P69, DOI 10.1158/1541-7786.MCR-16-0212
   Ahn JH, 2006, BIOORG MED CHEM LETT, V16, P2996, DOI 10.1016/j.bmcl.2006.02.060
   Al-Aidaroos AQO, 2010, J CELL BIOCHEM, V111, P1087, DOI 10.1002/jcb.22913
   Al-aidaroos AQO, 2013, J CLIN INVEST, V123, P3459, DOI 10.1172/JCI66824
   Alsaab HO, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00561
   Baghba R, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0530-4
   Bardelli A, 2003, CLIN CANCER RES, V9, P5607
   Basak S, 2008, MOL CELL, V30, P303, DOI 10.1016/j.molcel.2008.04.002
   Boedtkjer E, 2020, ANNU REV PHYSIOL, V82, P103, DOI 10.1146/annurev-physiol-021119-034627
   Chames P, 2009, BRIT J PHARMACOL, V157, P220, DOI 10.1111/j.1476-5381.2009.00190.x
   Chan DA, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002394
   Chen XM, 2021, NEOPLASMA, V68, P832, DOI 10.4149/neo_2021_210301N265
   Chong PSY, 2019, CANCER RES, V79, P4679, DOI 10.1158/0008-5472.CAN-19-0343
   Chong PSY, 2019, ONCOGENE, V38, P1508, DOI 10.1038/s41388-018-0526-3
   Chong PSY, 2014, CANCER RES, V74, P3043, DOI 10.1158/0008-5472.CAN-13-2321
   Conroy M, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-27960-2
   Csoboz B, 2018, CELL COMMUN SIGNAL, V16, DOI 10.1186/s12964-018-0264-8
   Daouti S, 2008, CANCER RES, V68, P1162, DOI 10.1158/0008-5472.CAN-07-2349
   Darvin P, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0191-1
   den Hollander P, 2016, CANCER RES, V76, P1942, DOI 10.1158/0008-5472.CAN-14-0673
   Dong Q, 2016, J ORAL PATHOL MED, V45, P111, DOI 10.1111/jop.12331
   Duciel L, 2019, J MOL BIOL, V431, P3056, DOI 10.1016/j.jmb.2019.06.008
   Edwards DR, 2018, INT J ONCOL, V52, P402, DOI 10.3892/ijo.2017.4208
   Fagerli UM, 2008, BLOOD, V111, P806, DOI 10.1182/blood-2007-07-101139
   Fang XY, 2015, J INVEST DERMATOL, V135, P2273, DOI 10.1038/jid.2015.154
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Ferrara N, 2005, ONCOLOGY-BASEL, V69, P11, DOI 10.1159/000088479
   Ferrone S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002821
   Fiordalisi JJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064309
   Fiordalisi JJ, 2006, CANCER RES, V66, P3153, DOI 10.1158/0008-5472.CAN-05-3116
   Funato Y, 2022, J PHARMACOL SCI, V148, P14, DOI 10.1016/j.jphs.2021.09.004
   Funato Y, 2020, DEV CELL, V55, P387, DOI 10.1016/j.devcel.2020.08.009
   Funato Y, 2014, J CLIN INVEST, V124, P5398, DOI 10.1172/JCI76614
   Gao PP, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188562
   Garcia EG, 2021, LEUKEMIA, V35, P679, DOI 10.1038/s41375-020-0937-3
   García-Prat L, 2021, CELL STEM CELL, V28, P1838, DOI 10.1016/j.stem.2021.07.003
   Gari HH, 2016, ONCOGENESIS, V5, DOI 10.1038/oncsis.2016.50
   Gari HH, 2016, CANCER LETT, V380, P505, DOI 10.1016/j.canlet.2016.07.017
   Gari HH, 2016, ONCOTARGET, V7, P15757, DOI 10.18632/oncotarget.7462
   Goo K, 2006, CANCER RES, V66, P9625, DOI 10.1158/0008-5472.CAN-06-0726
   Gown AM, 2016, ARCH PATHOL LAB MED, V140, P893, DOI 10.5858/arpa.2016-0119-RA
   Guo K, 2004, CANCER BIOL THER, V3, P945, DOI 10.4161/cbt.3.10.1111
   Guo K, 2008, CANCER BIOL THER, V7, P750, DOI 10.4161/cbt.7.5.5764
   Guo K, 2012, ONCOTARGET, V3, P158
   Guo K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002296
   Guzinska-Ustymowicz K, 2013, ADV MED SCI-POLAND, V58, P221, DOI 10.2478/v10039-012-0079-6
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hao RT, 2010, J CANCER RES CLIN, V136, P1349, DOI 10.1007/s00432-010-0786-y
   Hardy S, 2015, ONCOGENE, V34, P986, DOI 10.1038/onc.2014.33
   Hardy S, 2019, P NATL ACAD SCI USA, V116, P2925, DOI 10.1073/pnas.1815361116
   Hjort MA, 2018, ONCOTARGET, V9, P3549, DOI 10.18632/oncotarget.23186
   Hjort MA, 2018, EXP HEMATOL ONCOL, V7, DOI 10.1186/s40164-018-0100-2
   Hoeger B, 2017, ACS OMEGA, V2, P9171, DOI 10.1021/acsomega.7b01208
   Hoeger B, 2014, EUR J MED CHEM, V88, P89, DOI 10.1016/j.ejmech.2014.08.060
   HOLMBERG B, 1961, CANCER RES, V21, P1386
   Hong CW, 2014, FEBS LETT, V588, P350, DOI 10.1016/j.febslet.2013.10.025
   Huang YH, 2014, AUTOPHAGY, V10, P1787, DOI 10.4161/auto.29989
   Imai K, 2006, NAT REV CANCER, V6, P714, DOI 10.1038/nrc1913
   Jeong KW, 2014, BIOCHEMISTRY-US, V53, P4814, DOI 10.1021/bi5003844
   Jiang YJ, 2011, CANCER RES, V71, P234, DOI 10.1158/0008-5472.CAN-10-1487
   Johansson JA, 2020, DEV CELL, V54, P317, DOI 10.1016/j.devcel.2020.06.013
   Johnson DB, 2017, CANCER-AM CANCER SOC, V123, P1904, DOI 10.1002/cncr.30642
   Kato H, 2004, CLIN CANCER RES, V10, P7318, DOI 10.1158/1078-0432.CCR-04-0485
   Kleiner DE, 1999, CANCER CHEMOTH PHARM, V43, pS42, DOI 10.1007/s002800051097
   Kong L, 2007, NEUROPATHOLOGY, V27, P516, DOI 10.1111/j.1440-1789.2007.00818.x
   Kozlov G, 2004, J BIOL CHEM, V279, P11882, DOI 10.1074/jbc.M312905200
   Kozlov G, 2020, J BIOL CHEM, V295, P11682, DOI 10.1074/jbc.RA120.014464
   Kraehenbuehl L, 2022, NAT REV CLIN ONCOL, V19, P37, DOI 10.1038/s41571-021-00552-7
   Lai W, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0566-z
   Lai W, 2011, ONCOL REP, V26, P909, DOI 10.3892/or.2011.1366
   Lan QS, 2018, MOL CANCER THER, V17, P276, DOI 10.1158/1535-7163.MCT-17-0507
   Laurent C, 2011, CANCER RES, V71, P666, DOI 10.1158/0008-5472.CAN-10-0605
   Lazo JS, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070969
   Lee SK, 2012, INT J CANCER, V131, pE190, DOI 10.1002/ijc.27381
   Leung WH, 2015, J IMMUNOL, V194, P2930, DOI 10.4049/jimmunol.1400817
   Li BH, 2018, MED SCI MONITOR, V24, P8105, DOI 10.12659/MSM.913307
   Li J, 2005, CLIN CANCER RES, V11, P2195, DOI 10.1158/1078-0432.CCR-04-1984
   Li QT, 2020, J INVEST MED, V68, P68, DOI 10.1136/jim-2019-001073
   Li X, 2015, INT J CANCER, V137, P512, DOI 10.1002/ijc.29405
   Li ZR, 2007, SURG TODAY, V37, P646, DOI 10.1007/s00595-006-3437-9
   Li ZR, 2006, BIOCHEM BIOPH RES CO, V348, P229, DOI 10.1016/j.bbrc.2006.07.043
   Lian SY, 2017, NUCLEIC ACIDS RES, V45, P6546, DOI 10.1093/nar/gkx392
   Liang FB, 2007, J BIOL CHEM, V282, P5413, DOI 10.1074/jbc.M608940200
   Liberti MV, 2016, TRENDS BIOCHEM SCI, V41, P211, DOI 10.1016/j.tibs.2015.12.001
   Lin LX, 2021, BIOORG MED CHEM LETT, V41, DOI 10.1016/j.bmcl.2021.127981
   Liu H, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-80
   Liu YH, 2009, CANCER BIOL THER, V8, P1352, DOI 10.4161/cbt.8.14.8695
   Luo TP, 2020, CANCER MANAG RES, V12, P5395, DOI 10.2147/CMAR.S249657
   Ma YX, 2011, MED ONCOL, V28, P775, DOI 10.1007/s12032-010-9514-3
   Machado E, 2015, SCI ADV, V1, DOI 10.1126/sciadv.1500603
   Martins F, 2019, NAT REV CLIN ONCOL, V16, P563, DOI 10.1038/s41571-019-0218-0
   Matsukawa Y, 2010, PATHOBIOLOGY, V77, P155, DOI 10.1159/000292649
   Matter WF, 2001, BIOCHEM BIOPH RES CO, V283, P1061, DOI 10.1006/bbrc.2001.4881
   McQueeney K.E., 2018, ONCOTARGET, V9, P8223, DOI 10.18632/oncotarget.23787
   Min G, 2013, BIOORG MED CHEM LETT, V23, P3769, DOI 10.1016/j.bmcl.2013.04.092
   Min SH, 2010, LIFE SCI, V86, P66, DOI 10.1016/j.lfs.2009.11.010
   Ming J, 2013, PATHOBIOLOGY, V81, P1, DOI 10.1159/000350310
   Ming J, 2009, PATHOLOGY, V41, P118, DOI 10.1080/00313020802579268
   Miskad UA, 2007, VIRCHOWS ARCH, V450, P303, DOI 10.1007/s00428-006-0361-8
   Morse MA, 2019, CLIN CANCER RES, V25, P912, DOI 10.1158/1078-0432.CCR-18-1254
   Mu N, 2018, THERANOSTICS, V8, P1527, DOI 10.7150/thno.22699
   Ooki A, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-122
   Ooki A, 2010, INT J CANCER, V127, P543, DOI 10.1002/ijc.25082
   Park H, 2008, BIOORG MED CHEM LETT, V18, P2250, DOI 10.1016/j.bmcl.2008.03.013
   Park JE, 2013, EMBO MOL MED, V5, P1351, DOI 10.1002/emmm.201202183
   Parker BS, 2004, CANCER RES, V64, P7857, DOI 10.1158/0008-5472.CAN-04-1976
   Pathak MK, 2002, MOL CANCER THER, V1, P1255
   Peng LR, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-110
   Peng LR, 2006, BIOCHEM BIOPH RES CO, V342, P179, DOI 10.1016/j.bbrc.2006.01.102
   Polato F, 2005, CLIN CANCER RES, V11, P6835, DOI 10.1158/1078-0432.CCR-04-2357
   Qi L, 2021, FREE RADICAL BIO MED, V162, P383, DOI 10.1016/j.freeradbiomed.2020.10.317
   Qian F, 2007, MOL MED, V13, P151, DOI 10.2119/2006-00076.Qian
   Qu S, 2014, CANCER-AM CANCER SOC, V120, P2130, DOI 10.1002/cncr.28668
   Reckzeh ES, 2020, CHEMBIOCHEM, V21, P45, DOI 10.1002/cbic.201900544
   Rivas DR, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89668-5
   Robert C, DURABLE COMPLETE RES
   Robert CA-O., DECADE IMMUNE CHECKP
   Saha S, 2001, SCIENCE, V294, P1343, DOI 10.1126/science.1065817
   Salamoun JM, 2016, ORG BIOMOL CHEM, V14, P6398, DOI 10.1039/c6ob00946h
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Scott AM, MONOCLONAL ANTIBODIE
   Shi Y, 2021, BIOCHEM BIOPH RES CO, V576, P108, DOI 10.1016/j.bbrc.2021.08.090
   Slordahl TS, 2016, ONCOTARGET, V7, P27295, DOI 10.18632/oncotarget.8422
   Song R, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004450
   Stamenkovic I, 2000, SEMIN CANCER BIOL, V10, P415, DOI 10.1006/scbi.2000.0379
   Stangl S, 2011, P NATL ACAD SCI USA, V108, P733, DOI 10.1073/pnas.1016065108
   Stephens BJ, 2005, MOL CANCER THER, V4, P1653, DOI 10.1158/1535-7163.MCT-05-0248
   Stine ZE, 2022, NAT REV DRUG DISCOV, V21, P141, DOI 10.1038/s41573-021-00339-6
   Sun FY, 2017, ONCOTARGETS THER, V10, P311, DOI 10.2147/OTT.S107076
   Takeda M, 2019, CANCER RES, V79, P1426, DOI 10.1158/0008-5472.CAN-18-2192
   Tang T, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-00489-x
   Thura M, 2021, COMMUN BIOL, V4, DOI 10.1038/s42003-021-02449-8
   Thura M, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10127-x
   Thura M, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87607
   Trenevska I, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01001
   Vandsemb EN, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0830-z
   Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5
   Walls CD, 2013, MOL CELL PROTEOMICS, V12, P3759, DOI 10.1074/mcp.M113.028886
   Wang HH, 2007, CANCER RES, V67, P2922, DOI 10.1158/0008-5472.CAN-06-3598
   Wang HH, 2010, CANCER CELL, V18, P52, DOI 10.1016/j.ccr.2010.04.028
   Wang YY, 2015, MOL ONCOL, V9, P1982, DOI 10.1016/j.molonc.2015.10.019
   Wei M, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0192-5
   Wei M, 2018, PHARMACOL THERAPEUT, V190, P128, DOI 10.1016/j.pharmthera.2018.05.014
   Weidle UH, 2011, CANCER GENOM PROTEOM, V8, P49
   Wu XP, 2004, AM J PATHOL, V164, P2039, DOI 10.1016/S0002-9440(10)63763-7
   Xie H, 2018, ONCOL LETT, V15, P2795, DOI 10.3892/ol.2017.7639
   Xing XF, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-309
   Xiong JB, 2016, ONCOL REP, V36, P1819, DOI 10.3892/or.2016.5030
   Xu HY, 2017, INT J ONCOL, V51, P1271, DOI 10.3892/ijo.2017.4090
   Xu HY, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-330
   Xu JL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027165
   Xu JP, 2019, AGING-US, V11, P7817, DOI 10.18632/aging.102290
   Xu YJ, 2010, PATHOL ONCOL RES, V16, P169, DOI 10.1007/s12253-009-9200-y
   Yang YY, 2018, CANCER MANAG RES, V10, P5071, DOI 10.2147/CMAR.S165344
   Yang YY, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0169665
   Ye Z, 2015, SCI REP-UK, V5, DOI 10.1038/srep17046
   Yu LX, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0048-z
   Zahavi D, 2020, ANTIBODIES, V9, DOI 10.3390/antib9030034
   Zeng Q, 2000, J BIOL CHEM, V275, P21444, DOI 10.1074/jbc.M000453200
   Zeng Q, 2003, CANCER RES, V63, P2716
   Zeng Q, 1998, BIOCHEM BIOPH RES CO, V244, P421, DOI 10.1006/bbrc.1998.8291
   Zhan H, 2016, HUM REPROD, V31, P723, DOI 10.1093/humrep/dew015
   Zhang C, 2019, CANCER RES, V79, P928, DOI 10.1158/0008-5472.CAN-18-0520
   Zhang C, 2016, J MOL MED, V94, P401, DOI 10.1007/s00109-015-1350-7
   Zhang J, 2012, BRIT J CANCER, V107, P352, DOI 10.1038/bjc.2012.251
   Zhang MM, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2019.100766
   Zhang SZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00242-3
   Zhang T, 2019, ONCOL REP, V41, P2790, DOI 10.3892/or.2019.7049
   Zhao WB, 2008, INT J MOL MED, V22, P187, DOI 10.3892/ijmm_00000007
   Zhou JB, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0581-9
   Zhou JB, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-72
   Zhou JB, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0019798
   Zhou J, 2009, INT J CANCER, V124, P1879, DOI 10.1002/ijc.24096
   Zhou QM, 2020, THERANOSTICS, V10, P10345, DOI 10.7150/thno.42069
   Zhu AX, 2011, NAT REV CLIN ONCOL, V8, P292, DOI 10.1038/nrclinonc.2011.30
   Zimmerman MW, 2014, J BIOL CHEM, V289, P5904, DOI 10.1074/jbc.M113.480038
   Zimmerman MW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0058300
NR 180
TC 8
Z9 8
U1 0
U2 10
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2023
VL 13
IS 6
BP 1876
EP 1891
DI 10.7150/thno.79265
PG 16
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA H1ZF4
UT WOS:000994010500009
PM 37064866
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Chen, JZ
   Han, M
   Saif, MW
AF Chen, Jiezhong
   Han, Mei
   Saif, Muhammad Wasif
TI TAS-102 an Emerging Oral Fluoropyrimidine
SO ANTICANCER RESEARCH
LA English
DT Review
DE Drug resistance; apoptosis; survival signaling; combination therapy;
   review
ID METASTATIC COLORECTAL-CANCER; FLUOROURACIL PLUS LEUCOVORIN; X-LINKED
   INHIBITOR; PI3K/AKT PATHWAY; PHASE-I; ANTITUMOR-ACTIVITY; THYMIDINE
   PHOSPHORYLASE; CHEMOTHERAPEUTIC-AGENT; DRUG DISCOVERY; COMBINATION
AB Colon cancer is a common type of cancer with high mortality. The standard therapy for colon cancer is 5-FU-based regimen, although the current response rate to 5-FU is only 10-15%. Various approaches have been used to improve the efficacy of 5-FU including inhibition of its degradation enzyme dihydropyrimidine dehydrogenase (DPD) such as S1, UTF, use of 5-FU pro-drug capecitabine to exploit thymidine phosphorylase (TP) and supplementation of reduced folate acid to increase cytotoxicity. TAS-102 is a newly-developed anti-folate drug containing the 5-FU analogue trifluridine (TFD) and tipiracil hydrochloride (TPI). TPI is an inhibitor of TFD degradation enzyme thymidine phosphorylase and thus increases the bioavailability of TFD. In the present review, we summarize recent progress with regard to TAS-102, including pre-clinical tests and clinical trials. We further propose several approaches to further improve the efficacy of TAS-102 including combination with targeted therapy and immune therapy.
C1 [Chen, Jiezhong] Univ Queensland, Sch Biomed Sci, St Lucia, Qld, Australia.
   [Han, Mei] Univ Wollongong, Illawarra Hlth & Med Res Inst, Wollongong, NSW, Australia.
   [Saif, Muhammad Wasif] Tufts Univ, Sch Med, Dept Med, Tufts Med Ctr, Boston, MA 02215 USA.
   [Saif, Muhammad Wasif] Tufts Univ, Sch Med, Ctr Canc, Tufts Med Ctr, Boston, MA 02215 USA.
C3 University of Queensland; Illawarra Health & Medical Research Institute;
   University of Wollongong; Tufts Medical Center; Tufts University; Tufts
   Medical Center; Tufts University
RP Saif, MW (corresponding author), Tufts Univ, Sch Med, Sect GI Canc & Expt Therapeut, 800 Washington St, Boston, MA 02215 USA.
EM wsaif@tuftsmedicalcenter.org
OI Chen, Jiezhong/0000-0003-1977-6143
CR Akao Y, 2011, CANCER LETT, V300, P197, DOI 10.1016/j.canlet.2010.10.006
   [Anonymous], 2006, CANC THERAPY
   ANSFIELD FJ, 1971, CANCER CHEMOTH REP 1, V55, P205
   Blank C, 2007, CANCER IMMUNOL IMMUN, V56, P739, DOI 10.1007/s00262-006-0272-1
   Chang F, 2003, LEUKEMIA, V17, P590, DOI 10.1038/sj.leu.2402824
   Chen C, 2014, CURR MED CHEM, V21, P3007, DOI 10.2174/092986732126140804160443
   Chen JZ, 2015, REV MED VIROL, V25, P24, DOI 10.1002/rmv.1823
   Chen JZ, 2011, J GASTROINTEST ONCOL, V2, P27, DOI 10.3978/j.issn.2078-6891.2010.028
   Chen Jiezhong, 2011, Curr Drug Discov Technol, V8, P119
   Cleghorn S, 2015, LANCET ONCOL, V16, pE314, DOI 10.1016/S1470-2045(15)70246-9
   Dan HC, 2004, J BIOL CHEM, V279, P5405, DOI 10.1074/jbc.M312044200
   DEXTER DL, 1972, CANCER RES, V32, P247
   Doi T, 2012, BRIT J CANCER, V107, P429, DOI 10.1038/bjc.2012.274
   Doi T, 2015, INVEST NEW DRUGS, P1
   Doorbar J, 2015, REV MED VIROL, V25, P2, DOI 10.1002/rmv.1822
   Emura T, 2005, INT J ONCOL, V27, P449
   Emura T, 2004, INT J ONCOL, V25, P571
   Emura T, 2004, INT J MOL MED, V13, P545
   Fukushima M, 2000, BIOCHEM PHARMACOL, V59, P1227, DOI 10.1016/S0006-2952(00)00253-7
   Garcia-Echeverria C, 2008, ONCOGENE, V27, P5511, DOI 10.1038/onc.2008.246
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Goldberg RM, 2004, J CLIN ONCOL, V22, P23, DOI 10.1200/JCO.2004.09.046
   Green M, 2006, ASCO ANN M P
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   Hennessy BT, 2005, NAT REV DRUG DISCOV, V4, P988, DOI 10.1038/nrd1902
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012
   Hirano F, 2005, CANCER RES, V65, P1089
   Hoff PM, 2001, J CLIN ONCOL, V19, P2282, DOI 10.1200/JCO.2001.19.8.2282
   Hong DS, 2006, CANCER-AM CANCER SOC, V107, P1383, DOI 10.1002/cncr.22125
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331
   Lee S, 2005, GYNECOL ONCOL, V97, P26, DOI 10.1016/j.ygyno.2004.11.051
   Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625
   Longley DB, 2003, NAT REV CANCER, V3, P330, DOI 10.1038/nrc1074
   Los M, 2007, ONCOLOGIST, V12, P443, DOI 10.1634/theoncologist.12-4-443
   Luo J, 2003, CANCER CELL, V4, P257, DOI 10.1016/S1535-6108(03)00248-4
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Mayor Susan, 2015, BMJ, V350, ph2620, DOI 10.1136/bmj.h2620
   Miyamoto Y, 2014, EXPERT OPIN PHARMACO, V15, P1761, DOI 10.1517/14656566.2014.937706
   Nakanishi C, 2005, NAT REV CANCER, V5, P297, DOI 10.1038/nrc1588
   Nukatsuka M, 2015, ANTICANCER RES, V35, P1437
   Overman MJ, 2008, CANCER INVEST, V26, P794, DOI 10.1080/07357900802087242
   Overman MJ, 2008, INVEST NEW DRUG, V26, P445, DOI 10.1007/s10637-008-9142-3
   Ribas A, 2012, NEW ENGL J MED, V366, P2517, DOI 10.1056/NEJMe1205943
   Roxburgh P, 2014, CANCER CHEMOTH PHARM, V74, P131, DOI 10.1007/s00280-014-2470-4
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Sanford M, 2013, DRUGS, V73, P845, DOI 10.1007/s40265-013-0062-y
   Shrader M, 2007, CANCER RES, V67, P1430, DOI 10.1158/0008-5472.CAN-06-1224
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Tanaka N, 2014, ONCOL REP, V32, P2319, DOI 10.3892/or.2014.3487
   Temmink OH, 2007, CANCER SCI, V98, P779, DOI 10.1111/j.1349-7006.2007.00477.x
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Topalian SL, 2012, CURR OPIN IMMUNOL, V24, P207, DOI 10.1016/j.coi.2011.12.009
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsukihara H, 2015, ONCOL REP, V33, P2135, DOI 10.3892/or.2015.3876
   Utsugi T, 2013, JPN J CLIN ONCOL, V43, P945, DOI 10.1093/jjco/hyt131
   Vara JAF, 2004, CANCER TREAT REV, V30, P193, DOI 10.1016/j.ctrv.2003.07.007
   West KA, 2002, DRUG RESIST UPDATE, V5, P234, DOI 10.1016/S1368-7646(02)00120-6
   Yamashita F, 2015, CANCER CHEMOTH PHARM, V76, P325, DOI 10.1007/s00280-015-2805-9
   Yang HY, 2012, MOL CARCINOGEN, V51, P185, DOI 10.1002/mc.20789
   Yoshino T, 2012, LANCET ONCOL, V13, P993, DOI 10.1016/S1470-2045(12)70345-5
   Zhang W, 2006, ANN MED, V38, P545, DOI 10.1080/09546630601070812
NR 62
TC 14
Z9 14
U1 0
U2 1
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN
PY 2016
VL 36
IS 1
BP 21
EP 26
PG 6
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ9XD
UT WOS:000367450000004
PM 26722024
DA 2025-01-04
ER

PT J
AU Turski, ML
   Vidwans, SJ
   Janku, F
   Garrido-Laguna, I
   Munoz, J
   Schwab, R
   Subbiah, V
   Rodon, J
   Kurzrock, R
AF Turski, Michelle L.
   Vidwans, Smruti J.
   Janku, Filip
   Garrido-Laguna, Ignacio
   Munoz, Javier
   Schwab, Richard
   Subbiah, Vivek
   Rodon, Jordi
   Kurzrock, Razelle
TI Genomically Driven Tumors and Actionability across Histologies:
   <i>BRAF</i>-Mutant Cancers as a Paradigm
SO MOLECULAR CANCER THERAPEUTICS
LA English
DT Review
ID ERDHEIM-CHESTER DISEASE; HAIRY-CELL LEUKEMIA; TARGETED THERAPY; V600E
   MUTATION; COLORECTAL-CANCER; INHIBITOR RESISTANCE; FUNCTIONAL-ANALYSIS;
   IMPROVED SURVIVAL; DOSE-ESCALATION; MEK INHIBITION
AB The diagnosis, classification, and management of cancer are traditionally dictated by the site of tumor origin, for example, breast or lung, and by specific histologic subtypes of site-oforigin cancers (e.g., non-small cell versus small cell lung cancer). However, with the advent of sequencing technologies allowing for rapid, low cost, and accurate sequencing of clinical samples, new observations suggest an expanded or different approach to the diagnosis and treatment of cancer-one driven by the unique molecular features of the tumor. We discuss a genomically driven strategy for cancer treatment using BRAF as an example. Several key points are highlighted: (i) molecular aberrations can be shared across cancers; (ii) approximately 15% of all cancers harbor BRAF mutations; and (iii) BRAF inhibitors, while approved only for melanoma, have reported activity across numerous cancers and related disease types bearing BRAF aberrations. However, BRAF-mutated colorectal cancer has shown poor response rate to BRAF inhibitor monotherapy, striking a cautionary note. Yet, even in this case, emerging data suggest BRAF-mutated colorectal cancers can respond well to BRAF inhibitors, albeit when administered in combination with other agents that impact resistance pathways. Taken together, these data suggest that molecular aberrations may be the basis for a new nosology for cancer. (C) 2016 AACR.
C1 [Turski, Michelle L.; Vidwans, Smruti J.] CollabRx Inc, San Francisco, CA USA.
   [Janku, Filip; Subbiah, Vivek] Univ Texas MD Anderson Canc Ctr, Dept Invest Canc Therapeut, Houston, TX 77030 USA.
   [Garrido-Laguna, Ignacio] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
   [Munoz, Javier] Banner MD Anderson Canc Ctr, Gilbert, AZ USA.
   [Schwab, Richard; Kurzrock, Razelle] Univ Calif San Diego, Ctr Personalized Canc Therapy, Moores Canc Ctr, San Diego, CA 92103 USA.
   [Rodon, Jordi] Vall dHebron Inst Oncol, Barcelona, Spain.
   [Rodon, Jordi] Univ Autonoma Barcelona, E-08193 Barcelona, Spain.
C3 University of Texas System; UTMD Anderson Cancer Center; Utah System of
   Higher Education; University of Utah; Huntsman Cancer Institute; Banner
   Research; Banner Health; University of Texas System; UTMD Anderson
   Cancer Center; University of California System; University of California
   San Diego; Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous
   University of Barcelona
RP Kurzrock, R (corresponding author), Univ Calif San Diego, Ctr Personalized Canc Therapy, Moores Canc Ctr, San Diego, CA 92103 USA.; Kurzrock, R (corresponding author), UCSD Moores Canc Ctr, 3855 Hlth Sci,MC 0658, La Jolla, CA 92093 USA.
EM rkurzrock@mail.ucsd.edu
RI Garrido-Laguna, Ignacio/ABD-1875-2020; Kurzrock, Razelle/AAU-9782-2020;
   Schwab, Richard/AAX-9262-2020; Janku, Filip/ABB-9136-2020; Subbiah,
   Vivek/O-3347-2019
OI Rodon, Jordi/0000-0001-6467-3632
FU Biocartis; Trovagene; Foundation Medicine; Illumina; Novartis; Biomed
   Valley Discoveries; Agios; Astellas; Plexxikon; Deciphera; Genentech;
   Merck Serono; Pfizer; Guardant; Sequenom
FX F. Janku has commercial research grants from Biocartis, Trovagene,
   Foundation Medicine, Illumina, Novartis, Biomed Valley Discoveries,
   Agios, Astellas, Plexxikon, and Deciphera; and is a consultant/advisory
   board member for Trovagene, Deciphera, Novartis, and Foundation
   Medicine. J. Rodon is a consultant/advisory board member for Novartis
   and Lilly. R. Kurzrock is the co-founder of RScueRX; has other
   commercial research support from Genentech, Merck Serono, Foundation
   Medicine, Pfizer, Guardant, and Sequenom; has ownership interest
   (including patents) in RScueRX; and is a consultant/advisory board
   member for Sequenom. No potential conflicts of interest were disclosed
   by the other authors.
CR Al-Marrawi MY, 2013, CANCER BIOL THER, V14, P703, DOI 10.4161/cbt.25191
   Andrulis M, 2013, CANCER DISCOV, V3, P862, DOI 10.1158/2159-8290.CD-13-0014
   [Anonymous], 2013, TAF PACK INS
   [Anonymous], J CLIN ONCOL S
   [Anonymous], 2011, ZELBORAF PACKAGE INS
   [Anonymous], 2014, MEKINIST PACKAGE INS
   [Anonymous], 2015, J CLIN ONCOL, DOI DOI 10.1158/2159-8290.CD-16-0050
   [Anonymous], J CLIN ONCOL S
   [Anonymous], 2014, ROCHE PRESENTS FINAL
   Bahadoran P, 2013, J CLIN ONCOL, V31, pE324, DOI 10.1200/JCO.2012.46.1061
   Bautista F, 2014, PEDIATR BLOOD CANCER, V61, P1101, DOI 10.1002/pbc.24891
   Benlloch S, 2006, J MOL DIAGN, V8, P540, DOI 10.2353/jmoldx.2006.060070
   Bösmüller H, 2013, HUM PATHOL, V44, P329, DOI 10.1016/j.humpath.2012.07.010
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   Bowyer SE, 2014, MELANOMA RES, V24, P504, DOI 10.1097/CMR.0000000000000099
   Brummer T, 2006, ONCOGENE, V25, P6262, DOI 10.1038/sj.onc.1209640
   Bubolz AM, 2014, ONCOTARGET, V5, P4060, DOI 10.18632/oncotarget.2061
   Callahan MK, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.tps3114
   Capalbo C, 2014, CANCER BIOL THER, V15, P826, DOI 10.4161/cbt.28878
   Capaldo BJ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0138210
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chamberlain MC, 2013, J NEURO-ONCOL, V114, P237, DOI 10.1007/s11060-013-1176-5
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen CR, 2011, CANC RES S, V71
   Choi J, 2014, PIGM CELL MELANOMA R, V27, DOI 10.1111/pcmr.12197
   Cin H, 2011, ACTA NEUROPATHOL, V121, P763, DOI 10.1007/s00401-011-0817-z
   Connolly K, 2014, CURR ONCOL, V21, pE151, DOI 10.3747/co.21.1661
   Cooper WA, 2013, J THORAC DIS, V5, pS479, DOI 10.3978/j.issn.2072-1439.2013.08.03
   Corcoran N, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.7_suppl.71
   Corcoran RB, 2013, J CLIN ONCOL S, V31
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Corcoran RB, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3517
   Corcoran RB, 2012, J CLIN ONCOL, V30
   Dahlman KB, 2012, CANCER DISCOV, V2, P791, DOI 10.1158/2159-8290.CD-12-0097
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   del Bufalo F, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0356-1
   Dienstmann R, 2013, J CLIN ONCOL, V31, P1874, DOI 10.1200/JCO.2012.45.2268
   Dienstmann R, 2012, MOL CANCER THER, V11, P2062, DOI 10.1158/1535-7163.MCT-12-0290
   Dietrich S, 2013, J CLIN ONCOL, V31, pE300, DOI 10.1200/JCO.2012.45.9495
   Dietrich S, 2012, NEW ENGL J MED, V366, P2038, DOI 10.1056/NEJMc1202124
   Domingo E, 2004, J MED GENET, V41, P664, DOI 10.1136/jmg.2004.020651
   El-Osta H, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025806
   Falchook GS, 2013, ONCOTARGET, V4, P310, DOI 10.18632/oncotarget.864
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Farley J, 2013, LANCET ONCOL, V14, P134, DOI 10.1016/S1470-2045(12)70572-7
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Follows GA, 2013, BRIT J HAEMATOL, V161, P150, DOI 10.1111/bjh.12201
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Garrido-Laguna I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038033
   Go H, 2014, HISTOPATHOLOGY, V65, P261, DOI 10.1111/his.12416
   Goeppert B, 2014, MODERN PATHOL, V27, P1028, DOI 10.1038/modpathol.2013.206
   Grisham RN, 2013, CANCER-AM CANCER SOC, V119, P548, DOI 10.1002/cncr.27782
   Gupta K, 2014, ACTA NEUROPATHOL COM, V2, DOI 10.1186/2051-5960-2-18
   Haroche J, 2013, BLOOD, V121, P1495, DOI 10.1182/blood-2012-07-446286
   Haroche J, 2012, BLOOD, V120, P2700, DOI 10.1182/blood-2012-05-430140
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Hayes DN, 2012, CLIN CANCER RES, V18, P2056, DOI 10.1158/1078-0432.CCR-11-0563
   Henary H, 2013, ANN ONCOL, V24, P2158, DOI 10.1093/annonc/mdt115
   Hirata E, 2015, CANCER CELL, V27, P574, DOI 10.1016/j.ccell.2015.03.008
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049
   Hocar O, 2012, DERMAT RES PRACT, V2012, DOI 10.1155/2012/984096
   Hodis E, 2012, CELL, V150, P251, DOI 10.1016/j.cell.2012.06.024
   Hostein I, 2010, AM J CLIN PATHOL, V133, P141, DOI 10.1309/AJCPPCKGA2QGBJ1R
   Hutchinson KE, 2013, CLIN CANCER RES, V19, P6696, DOI 10.1158/1078-0432.CCR-13-1746
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Hyman DM, 2014, BLOOD, V124, P635
   Ihle MA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-13
   Ikenoue T, 2003, CANCER RES, V63, P8132
   James J, 2012, MOL CANCER THER, V11, P930, DOI 10.1158/1535-7163.MCT-11-0645
   Janku F, 2014, CELL REP, V6, P377, DOI 10.1016/j.celrep.2013.12.035
   Janku F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022769
   Jebaraj BMC, 2013, LEUKEMIA LYMPHOMA, V54, P1177, DOI 10.3109/10428194.2012.742525
   Jones DTW, 2008, CANCER RES, V68, P8673, DOI 10.1158/0008-5472.CAN-08-2097
   Kainthla R, 2014, PHARMACOGEN PERS MED, V7, P21, DOI 10.2147/PGPM.S37220
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kieran Mark W, 2014, Am Soc Clin Oncol Educ Book, pe436, DOI 10.14694/EdBook_AM.2014.34.e436
   Kim KB, 2013, THYROID, V23, P1277, DOI 10.1089/thy.2013.0057
   Kim KB, 2013, J CLIN ONCOL, V31, P482, DOI 10.1200/JCO.2012.43.5966
   Kitagawa D, 2013, GENES CELLS, V18, P110, DOI 10.1111/gtc.12022
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Kopetz S., 2010, J. Clin. Oncol, V28, p15s
   Korshunov A, 2009, ACTA NEUROPATHOL, V118, P401, DOI 10.1007/s00401-009-0550-z
   Lee E, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.e11507
   Lohr JG, 2014, CANCER CELL, V25, P91, DOI 10.1016/j.ccr.2013.12.015
   Ma XH, 2014, J CLIN INVEST, V124, P1406, DOI 10.1172/JCI70454
   Mano H, 2012, CANCER DISCOV, V2, P495, DOI 10.1158/2159-8290.CD-12-0009
   Martinez-Garcia M, 2012, CLIN CANCER RES, V18, P4806, DOI 10.1158/1078-0432.CCR-12-0742
   Menzies AM, 2012, CLIN CANCER RES, V18, P3242, DOI 10.1158/1078-0432.CCR-12-0052
   Miranda C, 2012, CLIN CANCER RES, V18, P1769, DOI 10.1158/1078-0432.CCR-11-2230
   Munoz J, 2014, MAYO CLIN PROC, V89, P985, DOI 10.1016/j.mayocp.2014.01.023
   Munoz Javier, 2013, Am Soc Clin Oncol Educ Book, P127, DOI 10.1200/EdBook_AM.2013.33.127
   Munoz J, 2013, J CLIN ONCOL, V31, pE351, DOI 10.1200/JCO.2012.45.7739
   Nardi V, 2013, CLIN CANCER RES, V19, P480, DOI 10.1158/1078-0432.CCR-12-1842
   Ollikainen M, 2007, INT J CANCER, V121, P915, DOI 10.1002/ijc.22768
   Paik PK, 2011, J CLIN ONCOL, V29, P2046, DOI 10.1200/JCO.2010.33.1280
   Pakneshan S, 2013, PATHOLOGY, V45, P346, DOI 10.1097/PAT.0b013e328360b61d
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Ravnan MC, 2012, CLIN THER, V34, P1474, DOI 10.1016/j.clinthera.2012.06.009
   Ribas A, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.8509
   Robinson GW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-258
   Roskoski R, 2010, BIOCHEM BIOPH RES CO, V399, P313, DOI 10.1016/j.bbrc.2010.07.092
   Sakata-Yanagimoto M, 2014, CANCER SCI, V105, P623, DOI 10.1111/cas.12408
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Samuel J, 2014, NEW ENGL J MED, V370, P286, DOI 10.1056/NEJMc1310849
   Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6
   Schultz NA, 2012, PANCREAS, V41, P759, DOI 10.1097/MPA.0b013e31823cd9df
   Sievert AJ, 2013, P NATL ACAD SCI USA, V110, P5957, DOI 10.1073/pnas.1219232110
   Skrypek M, 2014, PEDIATR BLOOD CANCER, V61, P2099, DOI 10.1002/pbc.25084
   Smalley KSM, 2009, ONCOGENE, V28, P85, DOI 10.1038/onc.2008.362
   Stites EC, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2003354
   Stuart D, 2008, CANC RES S, V68
   Stuart DD, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-3790
   Subbiah V, 2014, J HEMATOL ONCOL, V7, DOI 10.1186/1756-8722-7-8
   Tabernero J, 2014, J CLIN ONCOL S, V32, p5s
   Tanami H, 2004, ONCOGENE, V23, P8796, DOI 10.1038/sj.onc.1208152
   Tannapfel A, 2003, GUT, V52, P706, DOI 10.1136/gut.52.5.706
   Tiacci E, 2015, NEW ENGL J MED, V373, P1733, DOI 10.1056/NEJMoa1506583
   Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209
   Tsimberidou AM, 2012, CLIN CANCER RES, V18, P6373, DOI 10.1158/1078-0432.CCR-12-1627
   Tzoulis Charalampos, 2015, BMC Res Notes, V8, P171, DOI 10.1186/s13104-015-1135-7
   Van Geel R, 2014, J CLIN ONCOL, V32
   Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022
   Vergote V, 2014, ANN HEMATOL, V93, P2087, DOI 10.1007/s00277-014-2104-2
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Wellbrock C, 2004, NAT REV MOL CELL BIO, V5, P875, DOI 10.1038/nrm1498
   Wellcome Trust Sanger Institute, COSMIC CAT SOM MUT C
   Wheler JJ, 2014, ONCOTARGET, V5, P2349, DOI 10.18632/oncotarget.1946
   Wilhelm S, 2006, NAT REV DRUG DISCOV, V5, P835, DOI 10.1038/nrd2130
   Wilhelm SM, 2011, INT J CANCER, V129, P245, DOI 10.1002/ijc.25864
   Wu H, 2015, PATHOL ONCOL RES, V21, P695, DOI 10.1007/s12253-014-9876-5
   Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978
NR 132
TC 60
Z9 63
U1 0
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1535-7163
EI 1538-8514
J9 MOL CANCER THER
JI Mol. Cancer Ther.
PD APR
PY 2016
VL 15
IS 4
BP 533
EP 547
DI 10.1158/1535-7163.MCT-15-0643
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA DI6GD
UT WOS:000373596300001
PM 27009213
DA 2025-01-04
ER

PT J
AU Huynh, JC
   Schwab, E
   Ji, JR
   Kim, E
   Joseph, A
   Hendifar, A
   Cho, M
   Gong, J
AF Huynh, Jasmine C.
   Schwab, Erin
   Ji, Jingran
   Kim, Edward
   Joseph, Anjali
   Hendifar, Andrew
   Cho, May
   Gong, Jun
TI Recent Advances in Targeted Therapies for Advanced Gastrointestinal
   Malignancies
SO CANCERS
LA English
DT Review
DE gastrointestinal cancer; molecular targets
ID PHASE-II; OPEN-LABEL; CANCER; BRAF; TUMORS; CHOLANGIOCARCINOMA;
   CHEMOTHERAPY; VEMURAFENIB; MUTATIONS; NIVOLUMAB
AB The treatment of advanced gastrointestinal (GI) cancers has become increasingly molecularly driven. Molecular profiling for HER2 and PD-L1 status is standard for metastatic gastroesophageal (GEJ) cancers to predict benefits from trastuzumab (HER2-targeted therapy) and pembrolizumab (anti-PD-1 therapy), while extended RAS and BRAF testing is standard in metastatic colorectal cancer to predict benefits from epidermal growth factor receptor (EGFR)-targeted therapies. Mismatch repair (MMR) or microsatellite instability (MSI) testing is standard for all advanced GI cancers to predict benefits from pembrolizumab and in metastatic colorectal cancer, nivolumab with or without ipilimumab. Here we review recent seminal trials that have further advanced targeted therapies in these cancers including Poly (adenosine diphosphate-ribose) polymerases (PARP) inhibition in pancreas cancer, BRAF inhibition in colon cancer, and isocitrate dehydrogenase (IDH) and fibroblast growth factor receptor (FGFR) inhibition in biliary tract cancer. Targeted therapies in GI malignancies constitute an integral component of the treatment paradigm in these advanced cancers and have widely established the need for standard molecular profiling to identify candidates.
C1 [Huynh, Jasmine C.; Schwab, Erin; Kim, Edward; Joseph, Anjali; Cho, May] Univ Calif Davis, Hematol Oncol, Sacramento, CA 95817 USA.
   [Ji, Jingran] Univ Calif Davis, Internal Med, Sacramento, CA 95817 USA.
   [Hendifar, Andrew; Gong, Jun] Cedars Sinai Med Ctr, Hematol Oncol, Los Angeles, CA 90048 USA.
C3 University of California System; University of California Davis;
   University of California System; University of California Davis; Cedars
   Sinai Medical Center
RP Huynh, JC; Schwab, E (corresponding author), Univ Calif Davis, Hematol Oncol, Sacramento, CA 95817 USA.
EM jachuynh@ucdavis.edu; erin@schwabmd.com; jinji@ucdavis.edu;
   jhkim@ucdavis.edu; ajoseph@ucdavis.edu; andrew.hendifar@cshs.org;
   maycho@ucdavis.edu; jun.gong@cshs.org
OI , Jasmine/0000-0003-4481-2783; Cho, May/0000-0002-7152-0017
CR AALTONEN LA, 1993, SCIENCE, V260, P812, DOI 10.1126/science.8484121
   Amé JC, 1999, J BIOL CHEM, V274, P17860, DOI 10.1074/jbc.274.25.17860
   Amé JC, 2004, BIOESSAYS, V26, P882, DOI 10.1002/bies.20085
   [Anonymous], 2019, ANN ONCOL, DOI [DOI 10.1016/S1470-2045(20)30157-1, 10.1093/annonc/mdz394..]
   Bang YJ, 2010, LANCET, V376, P1302
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Borger DR, 2012, EXPERT REV ANTICANC, V12, P543, DOI [10.1586/ERA.12.32, 10.1586/era.12.32]
   Bryant HE, 2005, NATURE, V434, P913, DOI 10.1038/nature03443
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chiu JW, 2018, CLIN COLORECTAL CANC, V17, P73, DOI 10.1016/j.clcc.2017.10.010
   Churi CR, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115383
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Derks S, 2016, ONCOTARGET, V7, P32925, DOI 10.18632/oncotarget.9076
   Ducreux M, 2019, THER ADV MED ONCOL, V11, DOI 10.1177/1758835919856494
   Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013
   Gervais R, 2005, ANN ONCOL, V16, P90, DOI 10.1093/annonc/mdi018
   Goeppert B, 2014, MODERN PATHOL, V27, P1028, DOI 10.1038/modpathol.2013.206
   Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387
   Gong J, 2016, J GASTROINTEST ONCOL, V7, P687, DOI 10.21037/jgo.2016.06.12
   Goyal L, 2015, ONCOLOGIST, V20, P1019, DOI 10.1634/theoncologist.2015-0210
   Grothey A., 2019, ANN ONCOL, V30, piv109, DOI [DOI 10.1093/ANNONC/MDZ155.399, 10.1093/annonc/mdz155.399]
   Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780
   Huang EJ, 2003, ANNU REV BIOCHEM, V72, P609, DOI 10.1146/annurev.biochem.72.121801.161629
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   IONOV Y, 1993, NATURE, V363, P558, DOI 10.1038/363558a0
   Janjigian YY, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.TPS4146
   Janjigian YY, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.62
   Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x
   Javle M, 2018, J CLIN ONCOL, V36, P276, DOI 10.1200/JCO.2017.75.5009
   Javle M, 2015, J HEMATOL ONCOL, V8, DOI 10.1186/s13045-015-0155-z
   Javle MM, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.402
   Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z
   Kojima T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.2
   Koopman M, 2009, BRIT J CANCER, V100, P266, DOI 10.1038/sj.bjc.6604867
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   KOPETZ S, 2020, J CLIN ONCOL S, V4, P8, DOI DOI 10.1200/JCO.2020.38.4_SUPPL.8
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Lavingia V, 2016, J GASTROINTEST ONCOL, V7, pE98, DOI 10.21037/jgo.2016.09.13
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Lorenzi M, 2020, J ONCOL, V2020, DOI 10.1155/2020/1807929
   Lowery MA, 2019, LANCET GASTROENTEROL, V4, P711, DOI 10.1016/S2468-1253(19)30189-X
   MARTINZANCA D, 1986, NATURE, V319, P743, DOI 10.1038/319743a0
   METGES J, 2019, ANN ONCOL         S4, V30, piv130, DOI DOI 10.1093/annonc/mdz154.011
   Murai J, 2012, CANCER RES, V72, P5588, DOI 10.1158/0008-5472.CAN-12-2753
   Oliveira AF, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00396
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   Pennathur A, 2013, LANCET, V381, P400, DOI 10.1016/S0140-6736(12)60643-6
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Shah MA, 2019, JAMA ONCOL, V5, P546, DOI 10.1001/jamaoncol.2018.5441
   Shitara K, 2019, ANN ONCOL, V30, P878
   Shitara K, 2019, LANCET ONCOL, V20, P827, DOI 10.1016/S1470-2045(19)30088-9
   Shukla N, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.215
   Tabernero J, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.18_suppl.LBA4007
   US Food and Drug Administration, FDA APPR ENC COMB CE
   Vaishnavi A, 2015, CANCER DISCOV, V5, P25, DOI 10.1158/2159-8290.CD-14-0765
   Vogel A, 2019, ANN ONCOL, V30, P876
   Wainberg ZA, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.187
   Yan M, 2015, CANCER METAST REV, V34, P157, DOI 10.1007/s10555-015-9552-6
NR 64
TC 7
Z9 7
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2020
VL 12
IS 5
AR 1168
DI 10.3390/cancers12051168
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LW6HT
UT WOS:000539246000109
PM 32384640
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Su, YH
   Goncalves, T
   Dias-Santagata, D
   Hoang, MP
AF Su, Yuhua
   Goncalves, Theodore
   Dias-Santagata, Dora
   Hoang, Mai P.
TI Immunohistochemical Detection of <i>ROS1</i> Fusion
SO AMERICAN JOURNAL OF CLINICAL PATHOLOGY
LA English
DT Article
DE ROS1; Immunohistochemistry; Lung carcinoma; Colorectal carcinoma;
   Translocation
ID ALK FUSIONS; LUNG; REARRANGEMENTS; IDENTIFICATION; CANCER
AB Objectives: Patients whose tumors harbor ROS1 translocation may benefit from targeted therapy. Detection of ROS1 rearrangement can be done by three methods: immunohistochemistry, fluorescence in situ hybridization, and molecular assays. Immunohistochemistry would be a cost-effective means to screen for ROS1 translocation, which is uncommon.
   Methods: ROS1 immunostain was performed on cases with known ROS1 translocation status detected either by fluorescence in situ hybridization or next-generation sequencing.
   Results: Fifty-seven cases, 10 lung carcinomas with ROS1 rearrangement and 47 cases without ROS1 rearrangement (25 lung carcinomas, 13 gastrointestinal carcinomas, three brain tumors, and six miscellaneous tumors), were included. ROS1 immunostain exhibited 100% sensitivity and 85% specificity, with staining seen in 10 (100%) of 10 cases with ROS1 rearrangement and in seven (15%) of 47 lung cases without ROS1 rearrangement. Weak or 1+ staining of reactive pneumocytes was seen in eight (14%) of 57 cases, and strong staining of osteoclast giant cells was seen in one case.
   Conclusions: Since ROS1 rearrangement is an infrequent event, immunohistochemistry is a cost-effective screening method. Confirmation of all positive and equivocal/weak staining with molecular assays would exclude the false positive cases.
C1 [Hoang, Mai P.] Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA.
   Harvard Med Sch, Boston, MA USA.
C3 Harvard University; Massachusetts General Hospital; Harvard University;
   Harvard Medical School
RP Hoang, MP (corresponding author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St,Warren 820, Boston, MA 02114 USA.
EM mhoang@mgh.harvard.edu
RI Hoang, Mai/LMP-7115-2024
CR Aisner DL, 2014, MOL CANCER RES, V12, P111, DOI 10.1158/1541-7786.MCR-13-0479-T
   Antonescu CR, 2015, AM J SURG PATHOL, V39, P957, DOI 10.1097/PAS.0000000000000404
   Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345
   Birch AH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028250
   Boyle TA, 2015, CLIN LUNG CANCER, V16, P106, DOI 10.1016/j.cllc.2014.10.003
   Cao B, 2015, ONCOTARGETS THER, V9, P131, DOI 10.2147/OTT.S94997
   Cha YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103333
   Charest A, 2003, GENE CHROMOSOME CANC, V37, P58, DOI 10.1002/gcc.10207
   Giacomini CP, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003464
   Gu TL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015640
   Hornick JL, 2015, MODERN PATHOL, V28, P732, DOI 10.1038/modpathol.2014.165
   Lee J, 2013, CANCER-AM CANCER SOC, V119, P1627, DOI 10.1002/cncr.27967
   Marieres J, J CLIN ONCOL
   Mescam-Mancini L, 2014, LUNG CANCER, V83, P168, DOI 10.1016/j.lungcan.2013.11.019
   Rimkunas VM, 2012, CLIN CANCER RES, V18, P4449, DOI 10.1158/1078-0432.CCR-11-3351
   Rogers TM, 2015, J THORAC ONCOL, V10, P611, DOI 10.1097/JTO.0000000000000465
   Shan L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120422
   Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766
   Sholl LM, 2013, AM J SURG PATHOL, V37, P1441, DOI 10.1097/PAS.0b013e3182960fa7
   Takeuchi K, 2012, NAT MED, V18, P378, DOI 10.1038/nm.2658
   Yoshida A, 2014, MODERN PATHOL, V27, P711, DOI 10.1038/modpathol.2013.192
   Zheng ZL, 2014, NAT MED, V20, P1479, DOI 10.1038/nm.3729
NR 22
TC 15
Z9 16
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9173
EI 1943-7722
J9 AM J CLIN PATHOL
JI Am. J. Clin. Pathol.
PD JAN
PY 2017
VL 147
IS 1
BP 77
EP 82
DI 10.1093/AJCP/AQW201
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA EP0QI
UT WOS:000397091400009
PM 28007702
OA Bronze
DA 2025-01-04
ER

PT J
AU Aparicio, T
   Canoui-Poitrine, F
   Caillet, P
   François, E
   Cudennec, T
   Carola, E
   Albrand, G
   Bouvier, AM
   Petri, C
   Couturier, B
   Phelip, JM
   Bengrine-Lefevre, L
   Paillaud, E
AF Aparicio, Thomas
   Canoui-Poitrine, Florence
   Caillet, Philippe
   Francois, Eric
   Cudennec, Tristan
   Carola, Elisabeth
   Albrand, Gilles
   Bouvier, Anne-Marie
   Petri, Camille
   Couturier, Berengere
   Phelip, Jean-Marc
   Bengrine-Lefevre, Leila
   Paillaud, Elena
TI Treatment guidelines of metastatic colorectal cancer in older patients
   from the French Society of Geriatric Oncology (SoFOG)
SO DIGESTIVE AND LIVER DISEASE
LA English
DT Article
DE Colorectal cancer; Chemotherapy; Metastasis; Older patient; Targeted
   therapy
ID IRINOTECAN-BASED CHEMOTHERAPY; SPANISH COOPERATIVE GROUP; RANDOMIZED
   PHASE-II; CETUXIMAB PLUS CAPECITABINE; SINGLE-AGENT PANITUMUMAB; FRAIL
   ELDERLY-PATIENTS; 1ST-LINE TREATMENT; SUBGROUP ANALYSIS;
   CLINICAL-TRIALS; COLON-CANCER
AB Background: Several guidelines dedicated to metastatic colorectal cancer (mCRC) are available. Since 2013 no recent guidelines are specifically dedicated to older patients and based on a systematic review.
   Materials and methods: A multidisciplinary Task Force with digestive oncologists, geriatricians and methodologists from the SoFOG was formed in 2016 to update recommendations on medical treatment of mCRC based on a systematic review of publications from 2000 to 2018. Search strategy has followed a standardized protocol from the formulation of clinical questions and definition of a search algorithm to the selection of complete articles for recommendations.
   Results: The four selected key questions were: For which older patients with mCRC can we considered: (1) Any chemotherapy, (2) Mono or poly-chemotherapy, (3) Anti-angiogenic therapy, (4) Other targeted therapy. Main recommendations for older patients are: (1) Omission of chemotherapy should be discussed with a geriatrician for patients with severe comorbidities, advanced dementia, uncontrolled psychiatric disorder or severe loss of autonomy. (2) If tumor response is not the main aim, a mono-chemotherapy with 5-fluorouracil combined with bevacizumab is recommended as first-line. (3) For patients with symptoms related to metastases or with a planned metastasis ablation, a doublet chemotherapy combined with bevacizumab or anti-EGFR antibody in the context of a RAS wild type tumor is recommended as first-line. Preliminary data suggest that regorafenib may be used, in its registered indication, in patients under 80 with a performance status of 0 and no autonomy alterations and that trifluridine-tipiracil may be used with a tight supervising of hematological function. (C) 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
C1 [Aparicio, Thomas] Univ Paris, St Louis Hosp, AP HP, Dept Gastroenterol & Digest Oncol, Paris, France.
   [Canoui-Poitrine, Florence; Petri, Camille; Couturier, Berengere] Univ Paris Est, Henri Mondor Hosp, AP HP, CEpiA IMRB,Clin Epidemiol & Ageing Unit,EA 7376, Crete, France.
   [Caillet, Philippe; Paillaud, Elena] Univ Paris, Georges Pompidou Hosp, AP HP, Dept Geriatry, Paris, France.
   [Francois, Eric] Univ Cote dAzur, Antoine Lacassagne Ctr, Dept Med Oncol, Nice, France.
   [Cudennec, Tristan] Univ Versailles St Quentin, Ambroise Pare Hosp, Dept Geriatry, Boulogne, France.
   [Carola, Elisabeth] Publ Sudde Oise Hosp, Dept Med Oncol, Creil, France.
   [Albrand, Gilles] Hosp Civils Lyon, Lyon Sud Hosp, Dept Geriatry, Pierre Benite, France.
   [Bouvier, Anne-Marie] Univ Burgundy Franche Comte, Digest Canc Registry Burgundy, INSERM, UMR1231,EPICAD, Dijon, France.
   [Phelip, Jean-Marc] Univ Jean Monnet, St Etienne Hosp, Dept Gastroenterol & Digest Oncol, St Priest En Jarez, France.
   [Bengrine-Lefevre, Leila] Georges Francois Leclerc Ctr, Dept Med Oncol, Dijon, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Saint-Louis - APHP; Assistance Publique Hopitaux
   Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital
   Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris
   (APHP); Universite Paris Cite; Hopital Universitaire Europeen
   Georges-Pompidou - APHP; UNICANCER; Centre Antoine Lacassagne;
   Universite Cote d'Azur; Assistance Publique Hopitaux Paris (APHP);
   Hopital Universitaire Ambroise-Pare - APHP; Universite Paris Saclay; CHU
   Lyon; Institut National de la Sante et de la Recherche Medicale
   (Inserm); Institut Agro; AgroSup Dijon; Universite de Bourgogne;
   UNICANCER; Centre Georges-Francois Leclerc
RP Aparicio, T (corresponding author), Hop St Louis, Serv Gastroenterol & Oncol Digest, 1 Ave Claude Vellefaux, F-75010 Paris, France.
EM thomas.aparicio@aphp.fr
RI Bouvier, Anne-Marie/R-6600-2017; Paillaud, Elena/K-5616-2017
OI COUTURIER, Berengere/0000-0002-4467-933X; Bouvier,
   Anne-Marie/0000-0001-9070-1027
CR Abdelwahab S, 2012, J CANCER RES CLIN, V138, P1487, DOI 10.1007/s00432-012-1229-8
   [Anonymous], J CLIN ONCOL
   [Anonymous], J CLIN ONCOL S
   Aparicio T, 2018, ANN ONCOL, V29, P156
   Aparicio T, 2018, EUR J CANCER, V97, P16, DOI 10.1016/j.ejca.2018.03.030
   Aparicio T, 2018, ANN ONCOL, V29, P2270, DOI 10.1093/annonc/mdx808
   Aparicio T, 2016, ANN ONCOL, V27, P121, DOI 10.1093/annonc/mdv491
   Aparicio T, 2003, BRIT J CANCER, V89, P1439, DOI 10.1038/sj.bjc.6601310
   Aparicio T, 2017, EUR J CANCER, V74, P98, DOI 10.1016/j.ejca.2016.09.029
   Aparicio T, 2016, DIGEST LIVER DIS, V48, P1112, DOI 10.1016/j.dld.2016.05.011
   Aparicio T, 2013, J CLIN ONCOL, V31, P1464, DOI 10.1200/JCO.2012.42.9894
   Aparicio T, 2013, DIGEST LIVER DIS, V45, P245, DOI 10.1016/j.dld.2012.09.013
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Asimakopoulou N, 2019, J GERIATR ONCOL, V10, P143, DOI 10.1016/j.jgo.2018.08.002
   Battaglin F, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4001-x
   Benavides M, 2012, CLIN COLORECTAL CANC, V11, P200, DOI 10.1016/j.clcc.2012.01.003
   Berretta M, 2012, ARCH GERONTOL GERIAT, V55, P271, DOI 10.1016/j.archger.2011.08.016
   Berretta M, 2011, ARCH GERONTOL GERIAT, V52, P89, DOI 10.1016/j.archger.2010.02.006
   Bikov KA, 2016, ONCOLOGIST, V21, P676, DOI 10.1634/theoncologist.2015-0199
   Bouche O, 2012, ANN ONCOL, V23, P190
   Bradley CJ, 2016, MED CARE, V54, P490, DOI 10.1097/MLR.0000000000000510
   Caillet P, 2011, J CLIN ONCOL, V29, P3636, DOI 10.1200/JCO.2010.31.0664
   Canouï-Poitrine F, 2017, ANN ONCOL, V28
   Chan M, 2017, CLIN COLORECTAL CANC, V16, P147, DOI 10.1016/j.clcc.2016.08.004
   Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
   Decoster L, 2015, ANN ONCOL, V26, P288, DOI 10.1093/annonc/mdu210
   Decoster L, 2018, J GERIATR ONCOL, V9, P93, DOI 10.1016/j.jgo.2017.10.002
   Di Bartolomeo M, 2014, TARGET ONCOL, V9, P155, DOI 10.1007/s11523-013-0283-8
   Doat S, 2014, EUR J CANCER, V50, P1276, DOI 10.1016/j.ejca.2013.12.026
   Duffour J, 2010, J CHEMOTHERAPY, V22, P179, DOI 10.1179/joc.2010.22.3.179
   Extermann M, 2005, CRIT REV ONCOL HEMAT, V55, P241, DOI 10.1016/j.critrevonc.2005.06.003
   Feliu J, 2005, J CLIN ONCOL, V23, P3104, DOI 10.1200/JCO.2005.06.035
   Figer A, 2007, CANCER, V110, P2666, DOI 10.1002/cncr.23091
   Folprecht G, 2010, ANN ONCOL, V21, P194
   Folprecht G, 2008, J CLIN ONCOL, V26, P1443, DOI 10.1200/JCO.2007.14.0509
   Fornaro L, 2011, CRIT REV ONCOL HEMAT, V78, P243, DOI 10.1016/j.critrevonc.2010.06.003
   François E, 2008, CANCER CHEMOTH PHARM, V62, P931, DOI 10.1007/s00280-008-0681-2
   Gouverneur A, 2018, J GERIATR ONCOL, V9, P15, DOI 10.1016/j.jgo.2017.08.001
   Gouverneur A, 2017, TARGET ONCOL, V12, P805, DOI 10.1007/s11523-017-0529-y
   Gouverneur A, 2017, FUND CLIN PHARMACOL, V31, P104, DOI 10.1111/fcp.12243
   Grande C, 2013, J GERIATR ONCOL, V4, P114, DOI 10.1016/j.jgo.2013.01.001
   Hong YS, 2013, AM J CLIN ONCOL-CANC, V36, P565, DOI 10.1097/COC.0b013e31825d52d5
   Jackson NA, 2009, CANCER-AM CANCER SOC, V115, P2617, DOI 10.1002/cncr.24305
   Jehn CF, 2014, EUR J CANCER, V50, P1269, DOI 10.1016/j.ejca.2014.01.005
   Jehn CF, 2012, BRIT J CANCER, V106, P274, DOI 10.1038/bjc.2011.554
   Kabbinavar FF, 2005, J CLIN ONCOL, V23, P3697, DOI 10.1200/JCO.2005.05.112
   Kawakami K, 2015, PATIENT PREFER ADHER, V9, P561, DOI 10.2147/PPA.S80327
   Kienle DL, 2019, J GERIATR ONCOL, V10, P304, DOI 10.1016/j.jgo.2018.11.011
   Koch Christine, 2018, Oncotarget, V9, P10272, DOI 10.18632/oncotarget.23475
   Kozloff MF, 2010, ONCOLOGY-BASEL, V78, P329, DOI 10.1159/000320222
   Kumar R, 2013, CANCER-AM CANCER SOC, V119, P722, DOI 10.1002/cncr.27802
   Kwakman JJM, 2017, ANN ONCOL, V28, P1288, DOI 10.1093/annonc/mdx122
   Landre T, 2018, INT J COLORECTAL DIS, V33, P1125, DOI 10.1007/s00384-018-3053-3
   Landre T, 2015, INT J COLORECTAL DIS, V30, P1305, DOI 10.1007/s00384-015-2296-5
   Lund CM, 2018, ACTA ONCOL, V57, P1445, DOI 10.1080/0284186X.2018.1531299
   Marmorino F, 2019, ANN ONCOL, V30, P1969, DOI 10.1093/annonc/mdz403
   Matsumoto T, 2015, INT J CLIN ONCOL, V20, P111, DOI 10.1007/s10147-014-0675-5
   Mayer RJ, 2018, CANCER CHEMOTH PHARM, V82, P961, DOI 10.1007/s00280-018-3686-5
   Meulenbeld HJ, 2008, ANN ONCOL, V19, P1600, DOI 10.1093/annonc/mdn176
   Mitry E, 2013, EUR J CANCER, V49, P2919, DOI 10.1016/j.ejca.2013.04.001
   Moehler M, 2010, ONKOLOGIE, V33, P684, DOI 10.1159/000322208
   Moriwaki T, 2018, ONCOLOGIST, V23, P7, DOI 10.1634/theoncologist.2017-0275
   Obeidat NA, 2009, AM J GERIATR PHARMAC, V7, P343, DOI 10.1016/j.amjopharm.2009.11.005
   Overman MJ, 2018, ANN ONCOL, V29, P139, DOI 10.1093/annonc/mdx688
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pallis AG, 2010, EUR J CANCER, V46, P1502, DOI 10.1016/j.ejca.2010.02.022
   Papamichael D, 2015, ANN ONCOL, V26, P463, DOI 10.1093/annonc/mdu253
   Petrioli R, 2018, CLIN COLORECTAL CANC, V17, P307, DOI 10.1016/j.clcc.2018.02.005
   Phelip JM, 2019, DIGEST LIVER DIS, V51, P1357, DOI 10.1016/j.dld.2019.05.035
   Pietrantonio F, 2015, ONCOLOGIST, V20, P1261, DOI 10.1634/theoncologist.2015-0171
   Price TJ, 2012, ANN ONCOL, V23, P1531, DOI 10.1093/annonc/mdr488
   Puts MTE, 2014, ANN ONCOL, V25, P564, DOI 10.1093/annonc/mdt433
   Reese ES, 2013, CANCER MED-US, V2, P907, DOI 10.1002/cam4.143
   Rosati G, 2010, ANN ONCOL, V21, P781, DOI 10.1093/annonc/mdp359
   Rosati G, 2018, J GERIATR ONCOL, V9, P243, DOI 10.1016/j.jgo.2018.01.009
   Ruff P, 2018, J GERIATR ONCOL, V9, P32, DOI 10.1016/j.jgo.2017.07.010
   Sastre J, 2005, J CLIN ONCOL, V23, P3545, DOI 10.1200/JCO.2005.03.004
   Sastre J, 2015, EUR J CANCER, V51, P1371, DOI 10.1016/j.ejca.2015.04.013
   Sastre J, 2011, CRIT REV ONCOL HEMAT, V77, P79, DOI 10.1016/j.critrevonc.2009.11.005
   Sastre J, 2012, ONCOLOGIST, V17, P339, DOI 10.1634/theoncologist.2011-0406
   Sastre J, 2009, CRIT REV ONCOL HEMAT, V70, P134, DOI 10.1016/j.critrevonc.2008.11.002
   Seymour MT, 2011, LANCET, V377, P1749, DOI 10.1016/S0140-6736(11)60399-1
   Shankaran V, 2013, CLIN COLORECTAL CANC, V12, P204, DOI 10.1016/j.clcc.2012.11.004
   Sorbye H, 2013, ANN ONCOL, V24, P2354, DOI 10.1093/annonc/mdt197
   Soubeyran P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115060
   Souglakos J, 2005, ONCOLOGY-BASEL, V69, P384, DOI 10.1159/000089992
   Vamvakas L, 2010, CRIT REV ONCOL HEMAT, V76, P61, DOI 10.1016/j.critrevonc.2009.08.003
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2019, ONCOLOGIST, V24, P185, DOI 10.1634/theoncologist.2018-0072
   Van Cutsem E, 2018, EUR J CANCER, V90, P63, DOI 10.1016/j.ejca.2017.10.009
   van Steenbergen LN, 2010, ANN ONCOL, V21, P1273, DOI 10.1093/annonc/mdp482
   Vijayvergia N, 2016, CANCER-AM CANCER SOC, V122, P3191, DOI 10.1002/cncr.30077
   Wells J, 2010, ARTECH HSE MOB COMM, P75
   Zhao CJ, 2018, J CANCER RES THER, V14, pS79, DOI 10.4103/0973-1482.158031
NR 94
TC 14
Z9 14
U1 0
U2 7
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1590-8658
EI 1878-3562
J9 DIGEST LIVER DIS
JI Dig. Liver Dis.
PD MAY
PY 2020
VL 52
IS 5
BP 493
EP 505
DI 10.1016/j.dld.2019.12.145
PG 13
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA LN2KE
UT WOS:000532771700002
PM 32029404
OA Green Published, Bronze
DA 2025-01-04
ER

PT J
AU Siraj, AK
   Parvathareddy, SK
   Siraj, N
   Al-Obaisi, K
   Aldughaither, SM
   AlManea, HM
   AlHussaini, HF
   Al-Dayel, F
   Al-Kuraya, KS
AF Siraj, Abdul K.
   Parvathareddy, Sandeep Kumar
   Siraj, Nabil
   Al-Obaisi, Khadija
   Aldughaither, Saud M.
   AlManea, Hadeel M.
   AlHussaini, Hussah F.
   Al-Dayel, Fouad
   Al-Kuraya, Khawla S.
TI Loss of ZNF677 expression is a predictive biomarker for lymph node
   metastasis in Middle Eastern Colorectal Cancer
SO SCIENTIFIC REPORTS
LA English
DT Article
ID MUCINOUS HISTOLOGY; SAUDI-ARABIA; CELL-GROWTH; ADENOCARCINOMA;
   PREVALENCE; PATHWAY; DEATH
AB Zinc-finger proteins are transcription factors with a "finger-like" domain that are widely involved in many biological processes. The zinc-finger protein 677 (ZNF677) belongs to the zinc-finger protein family. Previous reports have highlighted the tumor suppressive role of ZNF677 in thyroid and lung cancer. However, its role in colorectal cancer (CRC) has not been explored. ZNF677 protein expression was analyzed by immunohistochemistry in a large cohort of 1158 CRC patients. ZNF677 loss of expression was more frequent in CRC tissues (45.3%, 525/1158), when compared to that of normal tissue (5.1%, 11/214) (p < 0.0001) and was associated with mucinous histology (p = 0.0311), advanced pathological stage (p < 0.0001) and lymph node (LN) metastasis (p = 0.0374). Further analysis showed ZNF677 loss to be significantly enriched in LN metastatic CRC compared to overall cohort (p = 0.0258). More importantly, multivariate logistic regression analysis showed that ZNF677 loss is an independent predictor of LN metastasis in CRC (Odds ratio = 1.41; 95% confidence interval 1.05-1.87; p = 0.0203).The gain- and loss-of-function studies in CRC cell lines demonstrated that loss of ZNF677 protein expression prominently increased cell proliferation, progression of epithelial-mesenchymal transition and conferred chemoresistance, whereas its overexpression reversed the effect. In conclusion, loss of ZNF677 protein expression is common in Middle Eastern CRC and contributes to the prediction of biological aggressiveness of CRC. Therefore, ZNF677 could not only serve as a marker in predicting clinical prognosis in patient with CRC but also as a potential biomarker for personalized targeted therapy.
C1 [Siraj, Abdul K.; Parvathareddy, Sandeep Kumar; Siraj, Nabil; Al-Obaisi, Khadija; Aldughaither, Saud M.; Al-Kuraya, Khawla S.] King Faisal Specialist Hosp & Res Ctr, Res Ctr, Human Canc Genom Res, MBC 98-16,POB 3354, Riyadh 11211, Saudi Arabia.
   [AlManea, Hadeel M.; AlHussaini, Hussah F.; Al-Dayel, Fouad] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, POB 3354, Riyadh 11211, Saudi Arabia.
C3 King Faisal Specialist Hospital & Research Center; King Faisal
   Specialist Hospital & Research Center
RP Al-Kuraya, KS (corresponding author), King Faisal Specialist Hosp & Res Ctr, Res Ctr, Human Canc Genom Res, MBC 98-16,POB 3354, Riyadh 11211, Saudi Arabia.
EM kkuraya@kfshrc.edu.sa
RI Siraj, Abdul/IQW-1179-2023; Parvathareddy, Sandeep Kumar/JBI-9330-2023;
   Siraj, Nabil/IQU-4189-2023; Alkuraya, Khawla/AFQ-7946-2022
OI , Nabil/0000-0002-9412-5909; Alkuraya, Khawla/0000-0002-4126-3419; Al
   Dayel, Fouad/0000-0001-6175-9051
CR Alrawaji, 2018, SAUDI CANC REGISTRY
   Arafa Mostafa A, 2015, Asian Pac J Cancer Prev, V16, P7425
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Awad H, 2018, ANN SAUDI MED, V38, P427, DOI 10.5144/0256-4947.2018.427
   Bahrami F, 2017, Iranian Journal of Colorectal Research, V5, DOI DOI 10.5812/ACR.46292
   Bavi P, 2006, CANCER EPIDEM BIOMAR, V15, P1708, DOI 10.1158/1055-9965.EPI-05-0972
   Cai J, 2020, ONCOGENE, V39, P5995, DOI 10.1038/s41388-020-01416-7
   Cassandri M, 2017, CELL DEATH DISCOV, V3, DOI 10.1038/cddiscovery.2017.71
   Dekker JWT, 2014, EJSO-EUR J SURG ONC, V40, P1481, DOI 10.1016/j.ejso.2014.05.010
   Guo YJ, 2020, EXP THER MED, V19, P1997, DOI 10.3892/etm.2020.8454
   Han YY, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1869-4
   Heller G, 2015, ONCOTARGET, V6, P394, DOI 10.18632/oncotarget.2697
   Helling TS, 2014, ANN SURG ONCOL, V21, P501, DOI 10.1245/s10434-013-3297-7
   Jen JY, 2016, J BIOMED SCI, V23, DOI 10.1186/s12929-016-0269-9
   Jiang J, 2015, ONCOL LETT, V10, P810, DOI 10.3892/ol.2015.3353
   Kawamura T, 2009, NATURE, V460, P1140, DOI 10.1038/nature08311
   Kim SH, 2015, CELL DEATH DIFFER, V22, P1517, DOI 10.1038/cdd.2015.7
   Laity JH, 2001, CURR OPIN STRUC BIOL, V11, P39, DOI 10.1016/S0959-440X(00)00167-6
   Li YJ, 2018, CANCER RES, V78, P5216, DOI 10.1158/0008-5472.CAN-18-0003
   Liu B, 2018, CANCER MANAG RES, V10, P3159, DOI 10.2147/CMAR.S174745
   Ma XJ, 2016, J CANCER, V7, P60, DOI 10.7150/jca.12973
   Maisano R, 2012, J CHEMOTHERAPY, V24, P212, DOI 10.1179/1973947812Y.0000000013
   McCawley N, 2016, DIS COLON RECTUM, V59, P1200, DOI 10.1097/DCR.0000000000000635
   Mosli MH, 2012, ASIAN PAC J CANCER P, V13, P3809, DOI 10.7314/APJCP.2012.13.8.3809
   Negri FV, 2005, ANN ONCOL, V16, P1305, DOI 10.1093/annonc/mdi244
   Reynolds IS, 2020, PHARMACOGENOMICS J, V20, P524, DOI 10.1038/s41397-019-0137-6
   Siraj AK, 2007, J PATHOL, V213, P190, DOI 10.1002/path.2215
   Siraj AK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22157833
   Siraj AK, 2015, CANCER-AM CANCER SOC, V121, P1762, DOI 10.1002/cncr.29288
   Sobocinska J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22042212
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tsai JH, 2013, GENE DEV, V27, P2192, DOI 10.1101/gad.225334.113
   Wang C., 2020, ONCOL LETT, V20, P1
   Wang Y., 2017, CLIN MED INSIGHTS-TH, V9, P1, DOI DOI 10.1186/S13148-016-0308-0
   Yu TX, 2012, J BIOL CHEM, V287, P3760, DOI 10.1074/jbc.M111.316349
NR 35
TC 3
Z9 3
U1 0
U2 1
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD NOV 16
PY 2021
VL 11
IS 1
AR 22346
DI 10.1038/s41598-021-01869-0
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WY8ND
UT WOS:000719533100019
PM 34785764
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Shan, SH
   Niu, JP
   Yin, RP
   Shi, JY
   Zhang, LZ
   Wu, CH
   Li, HQ
   Li, ZY
AF Shan, Shuhua
   Niu, Jinping
   Yin, Ruopeng
   Shi, Jiangying
   Zhang, Lizhen
   Wu, Caihong
   Li, Hanqing
   Li, Zhuoyu
TI Peroxidase from foxtail millet bran exerts anti-colorectal cancer
   activity <i>via</i> targeting cell-surface GRP78 to inactivate STAT3
   pathway
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Article
DE Foxtail millet bran; FMBP; csGRP78; STAT3; ROS; Colorectal cancer
ID DRUG TARGET; PROTEIN GRP78; TUMOR-GROWTH; APOPTOSIS; MIGRATION;
   SENSITIZATION; EXPRESSION; INHIBITOR; INDUCTION; VIABILITY
AB Molecular targeted therapy has become an emerging promising strategy in cancer treatment, and screening the agents targeting at cancer cell specific targets is very desirable for cancer treatment. Our previous study firstly found that a secretory peroxidase of class III derived from foxtail millet bran (FMBP) exhibited excellent targeting anti-colorectal cancer (CRC) activity in vivo and in vitro, whereas its underlying target remains unclear. The highlight of present study focuses on the finding that cell surface glucose-regulated protein 78 (csGRP78) abnormally located on CRC is positively correlated with the anti-CRC effects of FMBP, indicating it serves as a potential target of FMBP against CRC. Further, we demonstrated that the combination of FMBP with the nucleotide binding domain (NBD) of csGRP78 interfered with the downstream activation of signal transducer and activator of transcription 3 (STAT3) in CRC cells, thus promoting the intracellular accumulation of reactive oxygen species (ROS) and cell grown inhibition. These phenomena were further confirmed in nude mice tumor model. Collectively, our study highlights csGRP78 acts as an underlying target of FMBP against CRC, uncovering the clinical potential of FMBP as a targeted agent for CRC in the future. (C) 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Shan, Shuhua; Niu, Jinping; Yin, Ruopeng; Shi, Jiangying; Wu, Caihong; Li, Zhuoyu] Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Natl Minist Educ, Taiyuan 030006, Peoples R China.
   [Zhang, Lizhen; Li, Hanqing; Li, Zhuoyu] Shanxi Univ, Sch Life Sci, Taiyuan 030006, Peoples R China.
C3 Shanxi University; Shanxi University
RP Li, ZY (corresponding author), Shanxi Univ, Inst Biotechnol, Key Lab Chem Biol & Mol Engn, Natl Minist Educ, Taiyuan 030006, Peoples R China.; Li, ZY (corresponding author), Shanxi Univ, Sch Life Sci, Taiyuan 030006, Peoples R China.
EM lzy@sxu.edu.cn
RI Zhuoyu, Li/GXZ-8401-2022
OI Yin, Ruopeng/0000-0002-1195-418X; zhang, lizhen/0000-0002-8418-4032
FU National Natural Science Foundation of China [31500630, 31770382,
   32072220, 81803238]; "1331 Project" Key Innovation Center and Team;
   National Key Research and Development Project, China [2020YFD1001405];
   hanxi Key Laboratory for Research and Development of Regional Plants,
   Higher Education Institution Project of Shanxi Province: Ecological
   Remediation of Soil Pollution Disciplines Group, China [20181401]; Open
   Project Program of Xinghuacun College of Shanxi University [Shanxi
   Institute of Brewing Technology and Industry (Preparation)], China
   [XCSXU-KF-202004]
FX This study was supported by National Natural Science Foundation of China
   (Nos. 31500630, 31770382, 32072220, and 81803238) ; "1331 Project" Key
   Innovation Center and Team, National Key Research and Development
   Project (No. 2020YFD1001405, China) ; Shanxi Key Laboratory for Research
   and Development of Regional Plants, Higher Education Institution Project
   of Shanxi Province: Ecological Remediation of Soil Pollution Disciplines
   Group (No. 20181401, China) ; the Open Project Program of Xinghuacun
   College of Shanxi University [Shanxi Institute of Brewing Technology and
   Industry (Preparation) ] (No. XCSXU-KF-202004, China).
CR Arap MA, 2004, CANCER CELL, V6, P275, DOI 10.1016/j.ccr.2004.08.018
   Augustine T, 2019, INVEST NEW DRUG, V37, P948, DOI 10.1007/s10637-018-00717-9
   Bailly C, 2019, BIOCHEM PHARMACOL, V163, P269, DOI 10.1016/j.bcp.2019.02.038
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Burikhanov R, 2009, CELL, V138, P377, DOI 10.1016/j.cell.2009.05.022
   Chang J, 2016, NAT PROD REP, V33, P719, DOI 10.1039/c5np00107b
   Chen M, 2014, CELL DEATH DIFFER, V21, P797, DOI 10.1038/cdd.2014.3
   Devitt G, 2007, J VIROL METHODS, V146, P298, DOI 10.1016/j.jviromet.2007.07.011
   Ermakova SP, 2006, CANCER RES, V66, P9260, DOI 10.1158/0008-5472.CAN-06-1586
   Farshbaf M, 2020, J CONTROL RELEASE, V328, P932, DOI 10.1016/j.jconrel.2020.10.055
   GE R., 2019, CANCERS, V11, P1787, DOI [DOI 10.3390/cancers11111787, 10.3390/cancers11111787]
   Gonzalez-Gronow M, 2012, CELLULAR TRAFFICKING, P229
   Guo LT, 2017, J CANCER, V8, P410, DOI 10.7150/jca.17144
   Guo M, 2020, J CANCER, V11, P2008, DOI 10.7150/jca.39972
   Ingham M, 2017, J CLIN ONCOL, V35, P2949, DOI 10.1200/JCO.2016.69.0032
   Jafari R, 2014, NAT PROTOC, V9, P2100, DOI 10.1038/nprot.2014.138
   Kang JM, 2012, ONCOGENE, V31, P5123, DOI 10.1038/onc.2012.18
   Kasiappan R, 2016, J BIOL CHEM, V291, P27122, DOI 10.1074/jbc.M116.746339
   La Xiaoqin, 2018, Oncotarget, V9, P15464, DOI 10.18632/oncotarget.24090
   Lee AS, 2007, CANCER RES, V67, P3496, DOI 10.1158/0008-5472.CAN-07-0325
   Lee AS, 2014, NAT REV CANCER, V14, P263, DOI 10.1038/nrc3701
   Lee H, 2019, BMB REP, V52, P415, DOI 10.5483/BMBRep.2019.52.7.152
   Lee YT, 2018, EUR J PHARMACOL, V834, P188, DOI 10.1016/j.ejphar.2018.07.034
   Li ZW, 2014, INT J BIOCHEM CELL B, V47, P68, DOI 10.1016/j.biocel.2013.11.022
   Li ZW, 2013, INT J BIOCHEM CELL B, V45, P987, DOI 10.1016/j.biocel.2013.02.002
   Liu R, 2013, CLIN CANCER RES, V19, P6802, DOI 10.1158/1078-0432.CCR-13-1106
   Lu L, 2018, ONCOGENE, V37, P5292, DOI 10.1038/s41388-018-0340-y
   Ma JH, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0527-z
   Martin S, 2013, BRIT J CANCER, V109, P433, DOI 10.1038/bjc.2013.325
   McFarland BC, 2009, CANCER RES, V69, P5537, DOI 10.1158/0008-5472.CAN-08-4841
   Molina DM, 2013, SCIENCE, V341, P84, DOI 10.1126/science.1233606
   Ni M, 2011, BIOCHEM J, V434, P181, DOI 10.1042/BJ20101569
   Nicolaï A, 2013, PLOS COMPUT BIOL, V9, DOI 10.1371/journal.pcbi.1003379
   Notaro A, 2014, INT J BIOL SCI, V10, P466, DOI 10.7150/ijbs.8337
   de Arellano AR, 2015, CANCER CELL INT, V15, DOI 10.1186/s12935-015-0234-9
   Rasche L, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063414
   Reddy PS, 2018, CURR COMPUT-AID DRUG, V14, P246, DOI 10.2174/1573409914666180228111433
   Reddy RK, 2003, J BIOL CHEM, V278, P20915, DOI 10.1074/jbc.M212328200
   Shan SH, 2020, J AGR FOOD CHEM, V68, P8295, DOI 10.1021/acs.jafc.0c03257
   Shan SH, 2015, FOOD FUNCT, V6, P2331, DOI 10.1039/c5fo00260e
   Shan SH, 2014, J FUNCT FOODS, V10, P444, DOI 10.1016/j.jff.2014.07.005
   Shan SH, 2014, TOXICOL LETT, V227, P129, DOI 10.1016/j.toxlet.2014.03.008
   Siveen KS, 2014, BBA-REV CANCER, V1845, P136, DOI 10.1016/j.bbcan.2013.12.005
   Tashima T, 2018, BIOORG MED CHEM LETT, V28, P3015, DOI 10.1016/j.bmcl.2018.07.012
   Tsai YL, 2015, J BIOL CHEM, V290, P8049, DOI 10.1074/jbc.M114.618736
   Tseng CC, 2019, NEOPLASIA, V21, P837, DOI 10.1016/j.neo.2019.05.008
   Wang SH, 2016, BIOMATERIALS, V94, P31, DOI 10.1016/j.biomaterials.2016.03.050
   Wang YY, 2017, EXP CELL RES, V351, P24, DOI 10.1016/j.yexcr.2016.12.017
   Wei QY, 2020, CANCERS, V12, DOI 10.3390/cancers12102783
   Yao XL, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125634
   Zhang LC, 2017, CELL SIGNAL, V37, P136, DOI 10.1016/j.cellsig.2017.06.008
   Zhang LC, 2016, BMC BIOTECHNOL, V16, DOI 10.1186/s12896-016-0294-5
   Zhang XY, 2020, THER ADV MED ONCOL, V12, DOI 10.1177/1758835920947976
NR 53
TC 12
Z9 14
U1 0
U2 14
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD MAR
PY 2022
VL 12
IS 3
BP 1254
EP 1270
DI 10.1016/j.apsb.2021.10.004
EA MAR 2022
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 0J0EW
UT WOS:000779784100006
PM 35530132
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Pieniadz, P
   Piet, M
   Paduch, R
AF Pieniadz, Paulina
   Piet, Mateusz
   Paduch, Roman
TI Characteristics of the Colorectal Cancer Microenvironment-Role in Cancer
   Progression and Therapeutic Possibilities
SO APPLIED SCIENCES-BASEL
LA English
DT Review
DE colorectal cancer; tumor microenvironment; therapeutic targets;
   intercellular communication
ID TUMOR-ASSOCIATED MACROPHAGES; ENDOTHELIAL GROWTH-FACTOR; COLON-CANCER;
   EXTRACELLULAR-MATRIX; INFILTRATING MACROPHAGES; CELL SUBSETS; T-CELLS;
   METASTASIS; PROMOTES; EXPRESSION
AB Colorectal cancer (CRC) is one of the most common and deadliest cancers worldwide. According to the GLOBOCAN (WHO) report in 2020, nearly 2 million patients were diagnosed globally. Despite the advances in cancer diagnosis and therapy, CRC remains a global challenge. Recently, attention has been paid to the tumor microenvironment (TME), which constitutes a significant part of the tumor and mainly includes various immune cells, fibroblasts, vascular cells, and extracellular elements, such as the extracellular matrix (ECM). Many components of the stroma initially exert an anti-tumor effect, but over time, they undergo functional transformation into elements that promote tumor growth. As a result, conditions conducive to further cancer development, invasion into local tissues, and distant metastasis arise. The microenvironment of colorectal cancer (CRC) may be an important direction in the search for therapeutic targets, but it requires further understanding. The main purpose of our review is to explain the role of the complex CRC microenvironment in the progression of this cancer and highlight the potential of targeted therapy directed at the TME. Therefore, continued research into its components and typical biomarkers is necessary to improve therapy and enhance the quality of life for patients.
C1 [Pieniadz, Paulina; Piet, Mateusz; Paduch, Roman] Marie Curie Sklodowska Univ, Inst Biol Sci, Dept Virol & Immunol, Akad 19, PL-20033 Lublin, Poland.
   [Paduch, Roman] Med Univ, Dept Gen & Pediat Ophthalmol, Chmielna 1, PL-20079 Lublin, Poland.
C3 Maria Curie-Sklodowska University; Medical University of Lublin
RP Pieniadz, P; Paduch, R (corresponding author), Marie Curie Sklodowska Univ, Inst Biol Sci, Dept Virol & Immunol, Akad 19, PL-20033 Lublin, Poland.; Paduch, R (corresponding author), Med Univ, Dept Gen & Pediat Ophthalmol, Chmielna 1, PL-20079 Lublin, Poland.
EM paulina.pieniadz@mail.umcs.pl; mateusz.piet@mail.umcs.pl;
   roman.paduch@mail.umcs.pl
OI Pieniadz-Feculak, Paulina/0000-0002-8016-6304; Paduch,
   Roman/0000-0001-9779-7252; Piet, Mateusz/0000-0003-3073-2512
CR Al Obeed OA, 2014, WORLD J GASTROENTERO, V20, P18390, DOI 10.3748/wjg.v20.i48.18390
   Al-Mterin Mohammad A, 2022, Explor Target Antitumor Ther, V3, P497, DOI 10.37349/etat.2022.00097
   Ålgars A, 2012, INT J CANCER, V131, P864, DOI 10.1002/ijc.26457
   AlMusawi S, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.308
   Anderson NM, 2020, CURR BIOL, V30, pR921, DOI 10.1016/j.cub.2020.06.081
   Andreu-Sanz D, 2023, CANCERS, V15, DOI 10.3390/cancers15061650
   Arkwright PD, 2010, CELL RES, V20, P72, DOI 10.1038/cr.2009.112
   Badawi Manal A, 2015, Open Access Maced J Med Sci, V3, P209, DOI 10.3889/oamjms.2015.044
   Baghba R, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-0530-4
   Bai ZY, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.808964
   Baker EA, 2000, J CLIN PATHOL-MOL PA, V53, P307
   Bebelman MP, 2018, PHARMACOL THERAPEUT, V188, P1, DOI 10.1016/j.pharmthera.2018.02.013
   Berendam SJ, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00816
   Berntsson J, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.587
   Bhat AA, 2022, CANCER COMMUN, V42, P689, DOI 10.1002/cac2.12295
   Bian XJ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0973-7
   Boring L, 1997, J CLIN INVEST, V100, P2552, DOI 10.1172/JCI119798
   Borowczak J, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10071670
   Braoudaki M, 2022, SEMIN CANCER BIOL, V86, P436, DOI 10.1016/j.semcancer.2022.06.002
   Brassart-Pasco S, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00397
   Brauchle E, 2018, MATRIX BIOL, V68-69, P180, DOI 10.1016/j.matbio.2018.03.016
   Braumüller H, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12010138
   Brücher BLDM, 2014, CELL PHYSIOL BIOCHEM, V34, P213, DOI 10.1159/000362978
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Chen G, 2018, NATURE, V560, P382, DOI 10.1038/s41586-018-0392-8
   Chen LL, 2017, BIOCHEM BIOPH RES CO, V487, P8, DOI 10.1016/j.bbrc.2017.03.039
   Chen QY, 2023, CANCER LETT, V552, DOI 10.1016/j.canlet.2022.215979
   Chen WZ, 2019, WORLD J GASTRO ONCOL, V11, P946, DOI 10.4251/wjgo.v11.i11.946
   Chen X, 2024, TRANSL ONCOL, V40, DOI 10.1016/j.tranon.2023.101851
   Chen XJ, 2021, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.582723
   Chen XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-019-1507-2
   Chen YF, 2021, MOL MED, V27, DOI 10.1186/s10020-021-00402-3
   Cho H, 2018, CLIN CANCER RES, V24, P5407, DOI 10.1158/1078-0432.CCR-18-0125
   Chun E, 2015, CELL REP, V12, P244, DOI 10.1016/j.celrep.2015.06.024
   Coca S, 1997, CANCER-AM CANCER SOC, V79, P2320, DOI 10.1002/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P
   Colasante A, 1997, AM J RESP CRIT CARE, V156, P968, DOI 10.1164/ajrccm.156.3.9701122
   Conciatori F, 2019, CANCER DRUG RESIST, V2, P968, DOI 10.20517/cdr.2019.56
   Conway EM, 2001, CARDIOVASC RES, V49, P507, DOI 10.1016/S0008-6363(00)00281-9
   Couch Y, 2021, J EXTRACELL VESICLES, V10, DOI 10.1002/jev2.12144
   Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945
   Crezee T, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1114
   CROWLEY CW, 1993, P NATL ACAD SCI USA, V90, P5021, DOI 10.1073/pnas.90.11.5021
   Dai XY, 2022, CANCER BIOL THER, V23, P76, DOI 10.1080/15384047.2021.2017222
   De Simone V, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26617
   Deng LF, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.733270
   Desir S, 2016, ONCOTARGET, V7, P43150, DOI 10.18632/oncotarget.9504
   Ding XS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0922-1
   Dominiak A, 2020, CANCERS, V12, DOI 10.3390/cancers12051232
   Dominiak A, 2019, POSTEP HIG MED DOSW, V73, P536, DOI 10.5604/01.3001.0013.5379
   Dong F, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-02926-8
   Dudley AC, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006536
   Edin S, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-56441-8
   Edin S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0047045
   Farc O, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9528
   Fei LY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.771210
   Fink K, 2012, POSTEP HIG MED DOSW, V66, P609, DOI 10.5604/17322693.1009705
   Florescu DN, 2023, LIFE-BASEL, V13, DOI 10.3390/life13122261
   Forssell J, 2007, CLIN CANCER RES, V13, P1472, DOI 10.1158/1078-0432.CCR-06-2073
   Fotsitzoudis C, 2022, CANCERS, V14, DOI 10.3390/cancers14184394
   Franchi M, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12121786
   Frantz C, 2010, J CELL SCI, V123, P4195, DOI 10.1242/jcs.023820
   Fryczkowski M., 2019, Ann. Acad. Med. Siles, V73, P182, DOI [10.18794/aams/110503, DOI 10.18794/AAMS/110503]
   Fuchs TL, 2020, AM J SURG PATHOL, V44, P536, DOI 10.1097/PAS.0000000000001409
   Gabrilovich DI, 2009, NAT REV IMMUNOL, V9, P162, DOI 10.1038/nri2506
   Galgani M, 2021, MOL ASPECTS MED, V77, DOI 10.1016/j.mam.2020.100936
   Galindo-Pumariño C, 2022, TOXICOL APPL PHARM, V450, DOI 10.1016/j.taap.2022.116171
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gao DD, 2023, BIOMED PHARMACOTHER, V167, DOI 10.1016/j.biopha.2023.115622
   Gao XY, 2023, J TRANSL MED, V21, DOI 10.1186/s12967-023-03918-w
   Geng YT, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-22-5270
   Ghazvinian Z, 2023, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1077053
   Giusti I, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.839880
   Glabman RA, 2022, CANCERS, V14, DOI 10.3390/cancers14163906
   Gong J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2434-z
   Gu JH, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1230681
   Gutiérrez-Melo N, 2023, TRENDS CANCER, V9, P309, DOI 10.1016/j.trecan.2022.12.007
   Ha H, 2017, THERANOSTICS, V7, P1543, DOI 10.7150/thno.15625
   Hanada T, 2000, INT J UROL, V7, P263, DOI 10.1046/j.1442-2042.2000.00190.x
   Hanna SJ, 2019, J CELL SCI, V132, DOI 10.1242/jcs.223321
   Harjunpää H, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01078
   Hou SC, 2021, FRONT MOL BIOSCI, V8, DOI 10.3389/fmolb.2021.708779
   Hou SY, 2024, J TRANSL MED, V22, DOI 10.1186/s12967-024-04856-x
   Hu H, 2016, TUMOR BIOL, V37, P8657, DOI 10.1007/s13277-015-4741-z
   Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x
   Hu M, 2022, J BIOL ENG, V16, DOI 10.1186/s13036-022-00292-x
   Hutajulu SH, 2018, J GASTROINTEST ONCOL, V9, P1099, DOI 10.21037/jgo.2018.07.01
   Hynes RO, 2009, SCIENCE, V326, P1216, DOI 10.1126/science.1176009
   Idos GE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60255-4
   Itatani Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235822
   Jiang MM, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11244106
   Jin ZC, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1018903
   Kang J, 2022, CANCERS, V14, DOI 10.3390/cancers14122881
   Kang JC, 2010, J SURG ONCOL, V102, P242, DOI 10.1002/jso.21617
   Kaplanov I, 2019, P NATL ACAD SCI USA, V116, P1361, DOI 10.1073/pnas.1812266115
   Kar R, 2012, ARCH BIOCHEM BIOPHYS, V524, P2, DOI 10.1016/j.abb.2012.03.008
   Karlsson S, 2022, CRIT REV ONCOL HEMAT, V175, DOI 10.1016/j.critrevonc.2022.103712
   Khan SU, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1166487
   Kiss M, 2021, CANCER IMMUNOL RES, V9, P309, DOI 10.1158/2326-6066.CIR-20-0431
   Klampfer L, 2011, CURR CANCER DRUG TAR, V11, P451, DOI 10.2174/156800911795538066
   Knüpfer H, 2010, INT J COLORECTAL DIS, V25, P135, DOI 10.1007/s00384-009-0818-8
   Ko SY, 2014, AM J PATHOL, V184, P271, DOI 10.1016/j.ajpath.2013.09.017
   Koelzer VH, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1106677
   Koh EK, 2023, ONCOL LETT, V25, DOI 10.3892/ol.2023.13818
   Koskensalo S, 2011, TUMOR BIOL, V32, P259, DOI 10.1007/s13277-010-0080-2
   Kotov DI, 2018, J IMMUNOL, V200, P2004, DOI 10.4049/jimmunol.1700420
   Kuehnemuth B, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-5117-8
   Kular JK, 2014, J TISSUE ENG, V5, DOI 10.1177/2041731414557112
   Lança T, 2013, J IMMUNOL, V190, P6673, DOI 10.4049/jimmunol.1300434
   Lee J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.625667
   Legitimo A, 2014, HUM VACC IMMUNOTHER, V10, P3224, DOI 10.4161/hv.29857
   Lendeckel U, 2022, CHEMTEXTS, V8, DOI 10.1007/s40828-022-00163-4
   Li JJ, 2020, INT J BIOL SCI, V16, P2323, DOI 10.7150/ijbs.46651
   Li J, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.869010
   Li K, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00670-9
   Li L, 2016, CANCER RES, V76, P1770, DOI 10.1158/0008-5472.CAN-15-1625
   Li S, 2022, BBA-REV CANCER, V1877, DOI 10.1016/j.bbcan.2022.188758
   Li TJ, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0663-z
   Li XS, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232214436
   Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
   Li ZL, 2020, WORLD J GASTRO ONCOL, V12, P267, DOI 10.4251/wjgo.v12.i3.267
   Lian GH, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819849068
   Liang D, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1186712
   Lin HX, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-021-03162-0
   Lin Y, 2020, ONCOTARGETS THER, V13, P13023, DOI 10.2147/OTT.S278013
   Liu JX, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964-021-00816-w
   Liu Q, 2020, CELL COMMUN SIGNAL, V18, DOI 10.1186/s12964-020-00557-2
   Liu YJ, 2022, J INFLAMM RES, V15, P2461, DOI 10.2147/JIR.S361362
   Liu ZY, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3578-9
   Lojko A., 2004, Contemp. Oncol, V8, P1
   Lou E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.559548
   Lou E, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00095
   Lu L, 2021, WORLD J GASTRO ONCOL, V13, P2013, DOI 10.4251/wjgo.v13.i12.2013
   Ma YS, 2021, MOL THER-ONCOLYTICS, V20, P484, DOI 10.1016/j.omto.2021.02.005
   Maeda K, 2002, ONCOL REP, V9, P511
   Majood M, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.966661
   Matsushima K, 2022, CYTOKINE, V153, DOI 10.1016/j.cyto.2022.155828
   Mazzone M, 2018, FEBS J, V285, P700, DOI 10.1111/febs.14295
   Melwani PK, 2023, BBA-REV CANCER, V1878, DOI 10.1016/j.bbcan.2023.189028
   Milne K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006412
   Miyahara Y, 2008, P NATL ACAD SCI USA, V105, P15505, DOI 10.1073/pnas.0710686105
   Mizukami Y, 2008, INT J CANCER, V122, P2286, DOI 10.1002/ijc.23392
   Momiyama M, 2003, CANCER SCI, V94, P501, DOI 10.1111/j.1349-7006.2003.tb01473.x
   Montfort A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01818
   Mukaida N, 2016, WORLD J GASTROENTERO, V22, P5301, DOI 10.3748/wjg.v22.i23.5301
   Nagasaki T, 2014, BRIT J CANCER, V110, P469, DOI 10.1038/bjc.2013.748
   Najafi M, 2019, J CELL BIOCHEM, V120, P2782, DOI 10.1002/jcb.27681
   Nandi B, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097566
   Nazemi M, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00239
   Nebuloni M, 2016, SCI REP-UK, V6, DOI 10.1038/srep22522
   Nengroo MA, 2022, CYTOKINE, V156, DOI 10.1016/j.cyto.2022.155916
   Nie J, 2023, CLIN TRANSL ONCOL, V25, P2832, DOI 10.1007/s12094-023-03160-2
   Nielsen MS, 2012, COMPR PHYSIOL, V2, P1981, DOI 10.1002/cphy.c110051
   Ning Y, 2012, MOL CANCER THER, V11, P1353, DOI 10.1158/1535-7163.MCT-11-0915
   Nishina T, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22450-3
   Ohue Y, 2019, CANCER SCI, V110, P2080, DOI 10.1111/cas.14069
   Olayinka T., 2023, Int. J. Health Sci. Res, V13, P48, DOI [10.52403/ijhsr.20230909, DOI 10.52403/IJHSR.20230909]
   Olguín JE, 2020, CANCERS, V12, DOI 10.3390/cancers12071888
   Önfelt B, 2006, J IMMUNOL, V177, P8476, DOI 10.4049/jimmunol.177.12.8476
   OuYang LY, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0410-7
   Paczek S, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820903384
   Paduch R, 2016, CELL ONCOL, V39, P397, DOI 10.1007/s13402-016-0281-9
   Paijens ST, 2021, CELL MOL IMMUNOL, V18, P842, DOI 10.1038/s41423-020-00565-9
   Pan A., 2023, StatPearls
   Pan YY, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.583084
   Panni RZ, 2013, IMMUNOTHERAPY-UK, V5, P1075, DOI 10.2217/imt.13.102
   Park PG, 2017, ONCOTARGET, V8, P80325, DOI 10.18632/oncotarget.18170
   Peddareddigari VG, 2010, CANCER MICROENVIRON, V3, P149, DOI 10.1007/s12307-010-0038-3
   Popova NV, 2022, CANCERS, V14, DOI 10.3390/cancers14010238
   Powell DW, 2005, AM J PHYSIOL-GASTR L, V289, pG2, DOI 10.1152/ajpgi.00075.2005
   Pradhan AK, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103180118
   Preuss CV., 2022, Prescription of Controlled Substances: Benefits and Risks
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Ratajska A, 2012, POSTEP HIG MED DOSW, V66, P901, DOI 10.5604/17322693.1020753
   Rendon A., 2024, StatPearls
   Reunanen N., 2013, Madame Curie Bioscience Database [Internet]
   Revilla SA, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.903564
   Riabov V, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00075
   Ruffell B, 2010, CYTOKINE GROWTH F R, V21, P3, DOI 10.1016/j.cytogfr.2009.11.002
   Saad P., 2023, StatPearls
   Saleh R, 2020, CANCER IMMUNOL IMMUN, V69, P1989, DOI 10.1007/s00262-020-02593-w
   Schellerer VS, 2007, LAB INVEST, V87, P1159, DOI 10.1038/labinvest.3700671
   Scheurlen KM, 2020, CANCER MED-US, V9, P6679, DOI 10.1002/cam4.3315
   Schito L, 2019, ADV EXP MED BIOL, V1136, P71, DOI 10.1007/978-3-030-12734-3_5
   Shen M, 2016, ONCOTARGET, V7, P55828, DOI 10.18632/oncotarget.10094
   Shimabukuro-Vornhagen A, 2014, ONCOTARGET, V5, P4651, DOI 10.18632/oncotarget.1701
   Sieminska I, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01526
   Singh N, 2019, ANN AFR MED, V18, P121, DOI 10.4103/aam.aam_56_18
   Sinyuk M, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00646
   Son GM, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015164
   Song WX, 2019, CANCER SCI, V110, P608, DOI 10.1111/cas.13905
   Spada S, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01908-8
   Spagnardi M, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.1010380
   Sreevalsan S, 2013, CURR COLORECT CANC R, V9, P350, DOI 10.1007/s11888-013-0190-5
   Stanilov N, 2014, BIOTECHNOL BIOTEC EQ, V28, P911, DOI 10.1080/13102818.2014.965047
   Sugita J, 2002, JPN J CANCER RES, V93, P320, DOI 10.1111/j.1349-7006.2002.tb02175.x
   Sun LH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65207-6
   Sun P, 2020, ACTA PHARMACOL SIN, V41, P1395, DOI 10.1038/s41401-020-00500-8
   Sun Q, 2007, J BIOL CHEM, V282, P21998, DOI 10.1074/jbc.M701737200
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tacconi C, 2015, GASTROENTEROLOGY, V148, P1438, DOI 10.1053/j.gastro.2015.03.005
   Tang YC, 2023, GENE, V870, DOI 10.1016/j.gene.2023.147413
   Tardito S, 2023, CANCERS, V15, DOI 10.3390/cancers15020491
   Terzic J, 2010, GASTROENTEROLOGY, V138, P2101, DOI 10.1053/j.gastro.2010.01.058
   Thuringer D, 2015, ONCOTARGET, V6, P28800, DOI 10.18632/oncotarget.4894
   Tosolini M, 2011, CANCER RES, V71, P1263, DOI 10.1158/0008-5472.CAN-10-2907
   Van Buren G, 2009, CANCER-AM CANCER SOC, V115, P3360, DOI 10.1002/cncr.24371
   Viktoriia K, 2023, INT IMMUNOPHARMACOL, V122, DOI 10.1016/j.intimp.2023.110583
   Vinnakota K, 2017, J CELL PHYSIOL, V232, P3468, DOI 10.1002/jcp.25808
   Walterskirchen N, 2022, CANCER LETT, V540, DOI 10.1016/j.canlet.2022.215737
   Wang D, 2020, CANCER LETT, V474, P36, DOI 10.1016/j.canlet.2020.01.005
   Wang H, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22168470
   Wang R, 2019, MOL CANCER RES, V17, P20, DOI 10.1158/1541-7786.MCR-18-0341
   Wang SS, 2019, CELL MOL IMMUNOL, V16, P6, DOI 10.1038/s41423-018-0027-x
   Wang Y, 2023, MEDIAT INFLAMM, V2023, DOI 10.1155/2023/3781091
   Wang YX, 2022, NANOTECHNOL REV, V11, P957, DOI 10.1515/ntrev-2022-0052
   Warsinggih Limanu F, 2021, Med Clinica Practica, V4, DOI [10.1016/j.mcpsp.2021.100224, DOI 10.1016/J.MCPSP.2021.100224]
   Wei C, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0976-4
   Wei X, 2016, TUMOR BIOL, V37, P6581, DOI 10.1007/s13277-015-4538-0
   Wenes M, 2016, CELL METAB, V24, P701, DOI 10.1016/j.cmet.2016.09.008
   WOLF P, 1967, BRIT J HAEMATOL, V13, P269, DOI 10.1111/j.1365-2141.1967.tb08741.x
   Wu D, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/436307
   Wu TC, 2018, CANCER RES, V78, P5243, DOI 10.1158/0008-5472.CAN-18-0413
   Wu XK, 2023, ELIFE, V12, DOI 10.7554/eLife.86032
   Wu YZ, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01657-y
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xiao Y, 2022, FRONT SURG, V8, DOI 10.3389/fsurg.2021.775194
   Xu HW, 2017, CARCINOGENESIS, V38, P281, DOI 10.1093/carcin/bgw121
   Xu Y, 2020, CLIN TRANSL ONCOL, V22, P1105, DOI 10.1007/s12094-019-02237-1
   Yahaya MAF, 2019, J IMMUNOL RES, V2019, DOI 10.1155/2019/2368249
   Yang CG, 2021, MOL THER, V29, P2088, DOI 10.1016/j.ymthe.2021.02.006
   Yang QY, 2020, ACTA PHARMACOL SIN B, V10, P2156, DOI 10.1016/j.apsb.2020.04.004
   Yang YH, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01371
   Yao LZ, 2023, REDOX BIOL, V67, DOI 10.1016/j.redox.2023.102923
   Yao PL, 2005, AM J RESP CELL MOL, V32, P540, DOI 10.1165/rcmb.2004-0223OC
   Yi WZ, 2016, ONCOL REP, V36, P3145, DOI 10.3892/or.2016.5177
   Yin Y, 2022, ADV SCI, V9, DOI 10.1002/advs.202102620
   Yuan ZN, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01744-8
   Zafari N, 2022, J CLIN LAB ANAL, V36, DOI 10.1002/jcla.24585
   Zeng J, 2017, WORLD J GASTROENTERO, V23, P1780, DOI 10.3748/wjg.v23.i10.1780
   Zeng Q, 2019, CURR OPIN BIOTECH, V60, P138, DOI 10.1016/j.copbio.2019.01.010
   Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w
   Zhang Q, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1314-9
   Zhang YR, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.685978
   Zhang Y, 2013, EUR J CANCER, V49, P3320, DOI 10.1016/j.ejca.2013.06.005
   Zhao H, 2018, BBA-REV CANCER, V1869, P64, DOI 10.1016/j.bbcan.2017.11.005
   Zhao HY, 2016, ELIFE, V5, DOI 10.7554/eLife.10250
   Zhao JW, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1094-5
   Zhao P, 2018, ONCOL LETT, V15, P3820, DOI 10.3892/ol.2018.7735
   Zhao SL, 2022, J EXTRACELL VESICLES, V11, DOI 10.1002/jev2.12186
   Zhong XM, 2018, CELL PHYSIOL BIOCHEM, V45, P356, DOI 10.1159/000486816
   Zhou MM, 2023, CELL COMMUN SIGNAL, V21, DOI 10.1186/s12964-022-01009-9
NR 251
TC 0
Z9 0
U1 3
U2 8
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-3417
J9 APPL SCI-BASEL
JI Appl. Sci.-Basel
PD APR
PY 2024
VL 14
IS 7
AR 2930
DI 10.3390/app14072930
PG 26
WC Chemistry, Multidisciplinary; Engineering, Multidisciplinary; Materials
   Science, Multidisciplinary; Physics, Applied
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Engineering; Materials Science; Physics
GA NN5L1
UT WOS:001201141600001
OA gold
DA 2025-01-04
ER

PT J
AU Bando, H
   Ohtsu, A
   Yoshino, T
AF Bando, Hideaki
   Ohtsu, Atsushi
   Yoshino, Takayuki
TI Therapeutic landscape and future direction of metastatic colorectal
   cancer
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
ID CONSENSUS MOLECULAR SUBTYPES; 1ST-IN-CLASS ORAL INHIBITOR; FOLFOXIRI
   PLUS BEVACIZUMAB; MISMATCH REPAIR-DEFICIENT; POSITIVE SOLID TUMORS;
   POOLED ANALYSIS; BRAF-MUTATION; MICROSATELLITE INSTABILITY; 1ST-LINE
   TREATMENT; OPEN-LABEL
AB In the era of targeted therapy based on genomic alterations, the treatment strategy for metastatic colorectal cancer (mCRC) has been changing. Before systemic treatment initiation, determination of tumour genomic status for KRAS and NRAS, BRAF(V600E) mutations, ERBB2, and microsatellite instability and/or mismatch repair (MMR) status is recommended. In patients with deficient MMR and BRAF(V600E) mCRC, randomized phase III trials have established the efficacy of pembrolizumab as first-line therapy and the combination of encorafenib and cetuximab as second-line or third-line therapy. In addition, new agents have been actively developed in other rare molecular fractions such as ERBB2 alterations and KRAS(G12C) mutations. In March 2022, the combination of pertuzumab and trastuzumab for ERBB2-positive mCRC was approved in Japan, thereby combining real-world evidence from the SCRUM-Japan Registry. As the populations are highly fragmented owing to rare genomic alterations, various strategies in clinical development are expected. Clinical development of a tumour-agnostic approach, such as NTRK fusion and tumour mutational burden, has successfully introduced corresponding drugs to clinical practice. Considering the difficulty of randomized trials owing to cost-benefit and rarity, a promising solution could be real-world evidence utilized as an external control from the molecular-based disease registry.
   The therapeutic landscape of metastatic colorectal cancer (mCRC) is changing. This Review provides a comprehensive overview discussing the current mCRC advances in precision oncology and suggests a treatment strategy for mCRC with rare genomic alterations.
C1 [Bando, Hideaki; Ohtsu, Atsushi; Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan.
C3 National Cancer Center - Japan
RP Yoshino, T (corresponding author), Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Japan.
EM tyoshino@east.ncc.go.jp
OI Bando, Hideaki/0000-0001-5041-2765; Yoshino,
   Takayuki/0000-0002-0489-4756
CR Advani SM, 2021, CLIN COLORECTAL CANC, V20, P137, DOI 10.1016/j.clcc.2020.09.007
   Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187
   André F, 2017, CANCER DISCOV, V7, P818, DOI 10.1158/2159-8290.CD-17-0151
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Andre T, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.9
   Antoniotti C, 2022, LANCET ONCOL, V23, P876, DOI 10.1016/S1470-2045(22)00274-1
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Awad MM, 2021, NEW ENGL J MED, V384, P2382, DOI 10.1056/NEJMoa2105281
   Bando H, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.21.00535
   Bando H, 2021, ONCOLOGY-NY, V35, P382, DOI 10.46883/ONC.2021.3507.0382
   Bekaii-Saab TS, 2009, MOL CANCER THER, V8, P2983, DOI 10.1158/1535-7163.MCT-09-0820
   Benson AB., 2021, J. Natl. Compr. Canc. Netw., V19, P329, DOI DOI 10.6004/JNCCN.2021.0012
   Bullock A, 2022, ANN ONCOL, V33, pS376, DOI 10.1016/j.annonc.2022.04.453
   Cervantes A, 2023, ANN ONCOL, V34, P10, DOI 10.1016/j.annonc.2022.10.003
   Chakravarty D, 2022, J CLIN ONCOL, V40, P1231, DOI 10.1200/JCO.21.02767
   Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chen D, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090607
   Chen EX, 2020, JAMA ONCOL, V6, P831, DOI 10.1001/jamaoncol.2020.0910
   Chida K, 2021, ONCOLOGIST, V26, P845, DOI 10.1002/onco.13870
   Clark JW., 2003, P AM SOC CLIN ONCOL, V22, pA
   Cocco E, 2019, CANCER RES, V79, P1047, DOI 10.1158/0008-5472.CAN-18-3126
   Cohen R, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.013
   Cohen R, 2021, J CLIN ONCOL, V39, P642, DOI 10.1200/JCO.20.01600
   Cohen R, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001499
   Corcoran R, 2020, ANN ONCOL, V31, pS226, DOI 10.1016/j.annonc.2020.04.041
   Cremolini C, 2021, ANN ONCOL, V32, pS1294, DOI 10.1016/j.annonc.2021.08.2094
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Crisafulli G, 2022, CANCER DISCOV, V12, P1656, DOI 10.1158/2159-8290.CD-21-1434
   Diaz LA, 2022, LANCET ONCOL, V23, P659, DOI 10.1016/S1470-2045(22)00197-8
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Doebele RC, 2020, LANCET ONCOL, V21, P271, DOI 10.1016/S1470-2045(19)30691-6
   Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448
   Drilon A, 2017, CANCER DISCOV, V7, P400, DOI 10.1158/2159-8290.CD-16-1237
   Ebi Hiromichi, 2019, JCO Precis Oncol, V3, DOI 10.1200/PO.19.00291
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Engstrom PF., 2022, J NATL COMPR CANC NE, V7, P778, DOI 10.6004/jnccn.2009.0056
   Fancello L, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0647-4
   Flaherty KT, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.19.03010
   Floudas CS, 2019, CLIN COLORECTAL CANC, V18, pE349, DOI 10.1016/j.clcc.2019.06.004
   Fujii S, 2020, JCO PRECIS ONCOL, V4, P6, DOI 10.1200/PO.19.00154
   Fujii S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3594
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Germano G, 2017, NATURE, V552, P116, DOI 10.1038/nature24673
   Gomez-Roca C, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.3_suppl.94
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Gupta R, 2020, J CLIN ONCOL, V38
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hendifar A, 2022, ANN ONCOL, V33, pS294, DOI 10.1016/j.annonc.2022.04.215
   Hendifar AE., 2022, J CLIN ONCOL, V40, P3579, DOI [10.1200/JCO.2022.40.16_suppl.3579, DOI 10.1200/JCO.2022.40.16_SUPPL.3579]
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Hong DS, 2020, LANCET ONCOL, V21, P531, DOI 10.1016/S1470-2045(19)30856-3
   Israeli E, 2022, ISR MED ASSOC J, V24, P481, DOI 10.1056/NEJMoa2200075
   Jin Z, 2022, J CLIN ONCOL, V40
   Johnson A, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00036
   Johnson Benny, 2019, JCO Precis Oncol, V3, DOI 10.1200/PO.19.00102
   Kagawa Y, 2022, J CLIN ONCOL, V40
   Kann BH, 2021, CANCER CELL, V39, P916, DOI 10.1016/j.ccell.2021.04.002
   Kawazoe A, 2020, CLIN CANCER RES, V26, P5887, DOI 10.1158/1078-0432.CCR-20-1803
   Koopman M, 2009, BRIT J CANCER, V100, P266, DOI 10.1038/sj.bjc.6604867
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S., 2022, J CLIN ONCOL, V39
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Kotani D, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2019-000624
   Kotani H, 2018, ONCOGENE, V37, P1775, DOI 10.1038/s41388-017-0035-9
   Latham A, 2019, J CLIN ONCOL, V37, P286, DOI 10.1200/JCO.18.00283
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Lenz HJ, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.008
   Lenz HJ, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.100
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Leporrier J, 2006, BRIT J SURG, V93, P465, DOI 10.1002/bjs.5278
   Li J, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.001
   Liu X, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1701-3
   Lochhead P, 2013, JNCI-J NATL CANCER I, V105, P1151, DOI 10.1093/jnci/djt173
   Loupakis F, 2014, EUR J CANCER, V50, P57, DOI 10.1016/j.ejca.2013.08.024
   Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
   Luchini C, 2022, BRIT J CANCER, V126, P4, DOI 10.1038/s41416-021-01633-1
   Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9
   Marchiò C, 2019, ANN ONCOL, V30, P1417, DOI 10.1093/annonc/mdz204
   Martinelli E, 2022, ANN ONCOL, V33, pS381, DOI 10.1016/j.annonc.2022.04.448
   Martinelli E, 2021, JAMA ONCOL, V7, P1529, DOI 10.1001/jamaoncol.2021.2915
   Masuishi T, 2020, BRIT J CANCER, V123, P1490, DOI 10.1038/s41416-020-01042-w
   McGrail DJ, 2021, ANN ONCOL, V32, P661, DOI 10.1016/j.annonc.2021.02.006
   Meiri E, 2020, J CLIN ONCOL, V38
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Meric-Bernstam F, 2022, LANCET ONCOL, V23, P1558, DOI 10.1016/S1470-2045(22)00621-0
   Mettu NB, 2022, JAMA NETW OPEN, V5, DOI 10.1001/jamanetworkopen.2021.49040
   Micheel CM, 2018, JCO CLIN CANCER INFO, V2, DOI 10.1200/CCI.17.00083
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Modest DP, 2016, ANN ONCOL, V27, P1746, DOI 10.1093/annonc/mdw261
   Monjazeb AM, 2021, CLIN CANCER RES, V27, P2470, DOI 10.1158/1078-0432.CCR-20-4632
   Montagut C, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.5245
   Morano F, 2022, J CLIN ONCOL, V40, P1562, DOI 10.1200/JCO.21.02583
   Morelli MP, 2015, ANN ONCOL, V26, P731, DOI 10.1093/annonc/mdv005
   Moretto R, 2021, CLIN COLORECTAL CANC, V20, P314, DOI 10.1016/j.clcc.2021.07.001
   Morris VK, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.012
   Morris V, 2023, J CLIN ONCOL, V41, P678, DOI 10.1200/JCO.22.01690
   Nakajima H, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08395-2
   Nakamura Y, 2021, NAT MED, V27, P1899, DOI 10.1038/s41591-021-01553-w
   Nakamura Y, 2021, CANCER SCI, V112, P4425, DOI 10.1111/cas.15132
   Nakamura Y, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2019-000600
   Nebot-Bral L, 2017, EUR J CANCER, V84, P290, DOI 10.1016/j.ejca.2017.07.026
   Oh CR, 2022, INT J CANCER, V150, P2038, DOI 10.1002/ijc.33966
   Osterlund E, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.826073
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pagès F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X
   Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9
   Parseghian CM, 2019, ANN ONCOL, V30, P243, DOI 10.1093/annonc/mdy509
   Patel SG, 2022, LANCET GASTROENTEROL, V7, P262, DOI 10.1016/S2468-1253(21)00426-X
   Pietrantonio F, 2018, ANN ONCOL, V29, P1394, DOI 10.1093/annonc/mdy090
   Pietrantonio F, 2014, ANN ONCOL, V25, P404, DOI 10.1093/annonc/mdt547
   Pietrantonio F, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx089
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Raghav K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00226
   Raghav K, 2016, ONCOTARGET, V7, P54627, DOI 10.18632/oncotarget.10559
   Raghav KPS, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.TPS3620
   Raghav KPS, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.TPS3620
   Ramanathan RK, 2004, CANCER INVEST, V22, P858, DOI 10.1081/CNV-200039645
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Riihimäki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Rousseau B, 2021, NEW ENGL J MED, V384, P1168, DOI 10.1056/NEJMc2031965
   Russo M, 2019, SCIENCE, V366, P1473, DOI 10.1126/science.aav4474
   Sakamoto Y, 2023, CLIN COLORECTAL CANC, V22, P45, DOI 10.1016/j.clcc.2022.10.003
   Salem ME, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.21.00245
   Sartore-Bianchi A, 2022, NAT MED, V28, P1612, DOI 10.1038/s41591-022-01886-0
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2020, JAMA ONCOL, V6, P927, DOI 10.1001/jamaoncol.2020.0571
   Sartore-Bianchi A, 2019, ONCOLOGIST, V24, P1395, DOI 10.1634/theoncologist.2018-0785
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sawada K, 2018, CLIN COLORECTAL CANC, V17, P198, DOI 10.1016/j.clcc.2018.05.006
   Schmoll HJ, 2018, J CANCER RES CLIN, V144, P1197, DOI 10.1007/s00432-018-2632-6
   Segal NH., 2021, CLIN CANCER RES, V27, P2200, DOI [10.1158/1078-0432.CCR-20-2474, DOI 10.1158/1078-0432.CCR-20-2474]
   Seligmann JF, 2021, J CLIN ONCOL, V39, P3705, DOI 10.1200/JCO.21.01435
   Sha D, 2020, CANCER DISCOV, V10, P1808, DOI 10.1158/2159-8290.CD-20-0522
   Siena S, 2021, ANN ONCOL, V32, pS532, DOI 10.1016/j.annonc.2021.08.908
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Stintzing S, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3502
   Strickler J, 2022, ANN ONCOL, V33, pS375, DOI 10.1016/j.annonc.2022.04.440
   Strickler JH, 2019, ANN ONCOL, V30
   Strickler JH, 2021, ONCOLOGIST, V26, P465, DOI 10.1002/onco.13678
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Taieb J, 2019, ANN ONCOL, V30, P1466, DOI 10.1093/annonc/mdz208
   Tanaka N, 2021, CANCER DISCOV, V11, P1913, DOI 10.1158/2159-8290.CD-21-0365
   Taniguchi H, 2021, CANCER SCI, V112, P2915, DOI 10.1111/cas.14926
   Thein KZ, 2021, TRENDS CANCER, V7, P1074, DOI 10.1016/j.trecan.2021.07.003
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160
   Tosi F, 2020, CLIN COLORECTAL CANC, V19, P256, DOI 10.1016/j.clcc.2020.06.009
   U.S. National Library of Medicine, 2020, US
   UMIN, 2018, cgi-open-bin/ctr/ctr_view.cgi?recptno=R000036377
   US National Library of Medicine, 2016, US
   US National Library of Medicine, 2022, US
   US National Library of Medicine, 2018, US
   US National Library of Medicine, 2021, US
   US National Library of Medicine, 2019, US
   US National Library of Medicine, 2015, US
   US National Library of Medicine-ClinicalTrials.gov, 2017, about us
   Van Cutsem E, 2021, ANN ONCOL, V32, pS222, DOI 10.1016/j.annonc.2021.05.014
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Vedeld HM, 2017, INT J CANCER, V141, P967, DOI 10.1002/ijc.30796
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Wang XL, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01688
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yao JF, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-52414-z
   Yoshino T, 2021, ANN ONCOL, V32, pS580, DOI 10.1016/j.annonc.2021.08.1025
   Yoshino T, 2020, ANN ONCOL, V31, P861, DOI 10.1016/j.annonc.2020.03.299
   Yoshino T, 2018, ANN ONCOL, V29, P44, DOI 10.1093/annonc/mdx738
   Yoshino T, 2022, J CLIN ONCOL, V40
   Yu JL, 2021, NAT MED, V27, P152, DOI 10.1038/s41591-020-1131-x
   Yuan Y, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.e15554
   Zaanan A, 2018, JAMA ONCOL, V4, P379, DOI 10.1001/jamaoncol.2017.2899
   Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333
NR 181
TC 59
Z9 62
U1 8
U2 61
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1759-5045
EI 1759-5053
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD MAY
PY 2023
VL 20
IS 5
BP 306
EP 322
DI 10.1038/s41575-022-00736-1
EA JAN 2023
PG 17
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA E8XV6
UT WOS:000918078900001
PM 36670267
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Krail, EB
   Wang, B
   Munoz, DM
   Ilic, N
   Raghavan, S
   Niederst, MJ
   Yu, K
   Ruddy, DA
   Aguirre, AJ
   Kim, JW
   Redig, AJ
   Gainor, JF
   Williams, JA
   Asara, JM
   Doench, JG
   Janne, PA
   Shaw, AT
   McDonald, RE
   Engelman, JA
   Stegmeier, F
   Schlabach, MR
   Hahn, WC
AF Krail, Elsa B.
   Wang, Belinda
   Munoz, Diana M.
   Ilic, Nina
   Raghavan, Srivatsan
   Niederst, Matthew J.
   Yu, Kristine
   Ruddy, David A.
   Aguirre, Andrew J.
   Kim, Jong Wook
   Redig, Amanda J.
   Gainor, Justin F.
   Williams, Juliet A.
   Asara, John M.
   Doench, John G.
   Janne, Pasi A.
   Shaw, Alice T.
   McDonald, Robert E., III
   Engelman, Jeffrey A.
   Stegmeier, Frank
   Schlabach, Michael R.
   Hahn, William C.
TI KEAP1 loss modulates sensitivity to kinase targeted therapy in lung
   cancer
SO ELIFE
LA English
DT Article
ID GROWTH-FACTOR-RECEPTOR; KRAS-MUTANT LUNG; ACQUIRED-RESISTANCE; RAF
   INHIBITION; HUMAN-CELLS; MEK INHIBITION; COLON-CANCER; E3 LIGASE; NRF2;
   MUTATIONS
AB Inhibitors that target the receptor tyrosine kinase (RTK)/Ras/mitogen-activated protein kinase (MAPK) pathway have led to clinical responses in lung and other cancers, but some patients fail to respond and in those that do resistance inevitably occurs (Balak et al., 2006; Kosaka et al., 2006; Rudin et al., 2013; Wagle et al., 2011). To understand intrinsic and acquired resistance to inhibition of MAPK signaling, we performed CRISPR-Cas9 gene deletion screens in the setting of BRAF, MEK, EGFR, and ALK inhibition. Loss of KEAP1, a negative regulator of NFE2L2/NRF2, modulated the response to BRAF, MEK, EGFR, and ALK inhibition in BRAF-, NRAS-, KRAS-, EGFR-, and ALK-mutant lung cancer cells. Treatment with inhibitors targeting the RTK/MAPK pathway increased reactive oxygen species (ROS) in cells with intact KEAP1, and loss of KEAP1 abrogated this increase. In addition, loss of KEAP1 altered cell metabolism to allow cells to proliferate in the absence of MAPK signaling. These observations suggest that alterations in the KEAP1/NRF2 pathway may promote survival in the presence of multiple inhibitors targeting the RTK/Ras/MAPK pathway.
C1 [Krail, Elsa B.; Wang, Belinda; Ilic, Nina; Raghavan, Srivatsan; Aguirre, Andrew J.; Kim, Jong Wook; Redig, Amanda J.; Janne, Pasi A.; Hahn, William C.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
   [Krail, Elsa B.; Wang, Belinda; Ilic, Nina; Raghavan, Srivatsan; Aguirre, Andrew J.; Kim, Jong Wook; Doench, John G.; Hahn, William C.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
   [Krail, Elsa B.; Wang, Belinda; Ilic, Nina; Raghavan, Srivatsan; Aguirre, Andrew J.; Kim, Jong Wook; Redig, Amanda J.; Janne, Pasi A.; Hahn, William C.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.
   [Krail, Elsa B.; Wang, Belinda; Ilic, Nina; Raghavan, Srivatsan; Aguirre, Andrew J.; Kim, Jong Wook; Redig, Amanda J.; Janne, Pasi A.; Hahn, William C.] Harvard Med Sch, Boston, MA 02115 USA.
   [Munoz, Diana M.; Niederst, Matthew J.; Yu, Kristine; Ruddy, David A.; Williams, Juliet A.; McDonald, Robert E., III; Engelman, Jeffrey A.; Stegmeier, Frank; Schlabach, Michael R.] Novartis Inst Biomed Res, Oncol Dis Area, Cambridge, MA USA.
   [Shaw, Alice T.] Massachusetts Gen Hosp, Dept Med, Harvard Med Sch, Boston, MA 02114 USA.
   [Asara, John M.] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Dept Med, Boston, MA 02215 USA.
   [Asara, John M.] Beth Israel Deaconess Med Ctr, Harvard Med Sch, Ctr Canc, Boston, MA 02215 USA.
C3 Harvard University; Dana-Farber Cancer Institute; Harvard University;
   Massachusetts Institute of Technology (MIT); Broad Institute; Harvard
   University; Brigham & Women's Hospital; Harvard University; Harvard
   Medical School; Novartis; Novartis USA; Harvard University; Harvard
   Medical School; Massachusetts General Hospital; Harvard University; Beth
   Israel Deaconess Medical Center; Harvard Medical School; Harvard
   University; Harvard Medical School; Beth Israel Deaconess Medical Center
RP Hahn, WC (corresponding author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.; Hahn, WC (corresponding author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.; Hahn, WC (corresponding author), Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA.; Hahn, WC (corresponding author), Harvard Med Sch, Boston, MA 02115 USA.
EM william_hahn@dfci.harvard.edu
RI Shaw, Alice/ABA-9204-2022; Gainor, Justin/T-5411-2019; Kim, Jong
   Wook/HTP-6808-2023; Doench, John/ABE-6251-2020; Hahn,
   Willliam/AEF-2878-2022
OI Wang, Belinda/0000-0001-5563-894X; Doench, John/0000-0002-3707-9889
FU National Cancer Institute [R01CA130998, U01CA176058, U01CA199253]; Hope
   Funds for Cancer Research Postdoctoral Fellowship [HFCR-11-03-03];
   National Institutes of Health [F32 CA189306]; Susan G. Komen Foundation
   [PDF12230602]; Terri Brodeur Breast Cancer Foundation; Pancreatic Cancer
   Action Network; American Society of Clinical Oncology; Dana-Farber
   Cancer Institute Hale Center for Pancreatic Cancer; Perry S. Levy
   Endowed Fellowship; Harvard Catalyst and Harvard Clinical and
   Translational Science Center [UL1TR001102]
FX National Cancer Institute R01CA130998 William C HahnNational Cancer
   Institute U01CA176058 William C HahnNational Cancer Institute
   U01CA199253 William C HahnHope Funds for Cancer Research Postdoctoral
   Fellowship HFCR-11-03-03 Elsa B KrallNational Institutes of Health
   Postdoctoral Fellowship F32 CA189306 Elsa B KrallSusan G. Komen
   Foundation Postdoctoral Fellowship PDF12230602 Nina IlicTerri Brodeur
   Breast Cancer Foundation Postdoctoral Fellowship Nina IlicPancreatic
   Cancer Action Network Samuel Stroum Fellowship Andrew J AguirreAmerican
   Society of Clinical Oncology Young Investigator Award Andrew J
   AguirreDana-Farber Cancer Institute Hale Center for Pancreatic Cancer
   Andrew J AguirrePerry S. Levy Endowed Fellowship Andrew J AguirreHarvard
   Catalyst and Harvard Clinical and Translational Science Center
   UL1TR001102 Andrew J Aguirre
CR Aguirre AJ, 2016, CANCER DISCOV, V6, P914, DOI 10.1158/2159-8290.CD-16-0154
   Balak MN, 2006, CLIN CANCER RES, V12, P6494, DOI 10.1158/1078-0432.CCR-06-1570
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Blumenschein GR, 2015, ANN ONCOL, V26, P894, DOI 10.1093/annonc/mdv072
   Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936
   Cerami E, 2012, CANCER DISCOV, V2, P401, DOI 10.1158/2159-8290.CD-12-0095
   Chen BH, 2013, CELL, V155, P1479, DOI 10.1016/j.cell.2013.12.001
   Chio IIC, 2016, CELL, V166, P963, DOI 10.1016/j.cell.2016.06.056
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   DeNicola GM, 2015, NAT GENET, V47, P1475, DOI 10.1038/ng.3421
   Ding L, 2008, NATURE, V455, P1069, DOI 10.1038/nature07423
   Doench JG, 2016, NAT BIOTECHNOL, V34, P184, DOI 10.1038/nbt.3437
   Doench JG, 2014, NAT BIOTECHNOL, V32, P1262, DOI 10.1038/nbt.3026
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Forbes SA, 2015, NUCLEIC ACIDS RES, V43, pD805, DOI 10.1093/nar/gku1075
   Gainor JF, 2016, CANCER DISCOV, V6, P1118, DOI 10.1158/2159-8290.CD-16-0596
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Hayes JD, 2014, TRENDS BIOCHEM SCI, V39, P199, DOI 10.1016/j.tibs.2014.02.002
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Johannessen CM, 2013, NATURE, V504, P138, DOI 10.1038/nature12688
   Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627
   Kim E, 2016, CANCER DISCOV, V6, P714, DOI 10.1158/2159-8290.CD-16-0160
   Kobayashi A, 2004, MOL CELL BIOL, V24, P7130, DOI 10.1128/MCB.24.16.7130-7139.2004
   Kosaka T, 2006, CLIN CANCER RES, V12, P5764, DOI 10.1158/1078-0432.CCR-06-0714
   Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600
   Mitsuishi Y, 2012, CANCER CELL, V22, P66, DOI 10.1016/j.ccr.2012.05.016
   Munoz DM, 2016, CANCER DISCOV, V6, P900, DOI 10.1158/2159-8290.CD-16-0178
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Ohta T, 2008, CANCER RES, V68, P1303, DOI 10.1158/0008-5472.CAN-07-5003
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Rudin CM, 2013, J THORAC ONCOL, V8, pE41, DOI 10.1097/JTO.0b013e31828bb1b3
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Shibata T, 2008, GASTROENTEROLOGY, V135, P1358, DOI 10.1053/j.gastro.2008.06.082
   Shibata T, 2008, P NATL ACAD SCI USA, V105, P13568, DOI 10.1073/pnas.0806268105
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Sun Z, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006588
   Tang J, 2013, FRONT PHARMACOL, V4, DOI 10.3389/fphar.2013.00015
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981
   Wang XJ, 2008, CARCINOGENESIS, V29, P1235, DOI 10.1093/carcin/bgn095
   Whittaker SR, 2013, CANCER DISCOV, V3, P350, DOI 10.1158/2159-8290.CD-12-0470
   Wilson FH, 2015, CANCER CELL, V27, P397, DOI 10.1016/j.ccell.2015.02.005
   Yuan M, 2012, NAT PROTOC, V7, P872, DOI 10.1038/nprot.2012.024
   Zhang P, 2010, MOL CANCER THER, V9, P336, DOI 10.1158/1535-7163.MCT-09-0589
NR 51
TC 118
Z9 128
U1 1
U2 13
PU ELIFE SCIENCES PUBLICATIONS LTD
PI CAMBRIDGE
PA SHERATON HOUSE, CASTLE PARK, CAMBRIDGE, CB3 0AX, ENGLAND
SN 2050-084X
J9 ELIFE
JI eLife
PD FEB 1
PY 2017
VL 6
AR e18970
DI 10.7554/eLife.18970
PG 21
WC Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Life Sciences & Biomedicine - Other Topics
GA EK9OY
UT WOS:000394255000001
PM 29087937
OA Green Submitted, gold, Green Published
DA 2025-01-04
ER

PT J
AU Miyamoto, Y
   Oki, E
   Emi, Y
   Tokunaga, S
   Shimokawa, M
   Ogata, Y
   Akagi, Y
   Sakamoto, Y
   Tanaka, T
   Saeki, H
   Maehara, Y
   Baba, H
AF Miyamoto, Yuji
   Oki, Eiji
   Emi, Yasunori
   Tokunaga, Shoji
   Shimokawa, Mototsugu
   Ogata, Yutaka
   Akagi, Yoshito
   Sakamoto, Yasuo
   Tanaka, Takaho
   Saeki, Hiroshi
   Maehara, Yoshihiko
   Baba, Hideo
TI Low Visceral Fat Content Is a Negative Predictive Marker for Bevacizumab
   in Metastatic Colorectal Cancer
SO ANTICANCER RESEARCH
LA English
DT Article
DE Visceral fat; bevacizumab; predictive marker; metastatic colorectal
   cancer; cachexia
ID ENDOTHELIAL GROWTH-FACTOR; PHASE-II TRIAL; BODY-MASS INDEX; 1ST-LINE
   BEVACIZUMAB; TARGETED THERAPY; PLUS BEVACIZUMAB; POOLED ANALYSIS; CELL
   CARCINOMA; OVARIAN-CANCER; COLON-CANCER
AB Aim: This study aimed to clarify the predictive impact of visceral fat on response to bevacizumab in patients with metastatic colorectal cancer (mCRC). Patients and Methods: Pretreatment computed tomography was used to measure visceral fat area (VFA) and patients with mCRC receiving first-line chemotherapy with/without bevacizumab were divided by median VFA value into two groups: high VFA and low VFA. Results: In the bevacizumab-treated group, patients with low VFA had significantly shorter overall survival (OS) than patients with high VFA in univariate (median=21.1 vs. 38.9 months; hazard ratio=1.70, 95% confidence interval=1.06-2.70, p=0.03) and multivariate analysis (hazard ratio=1.85, 95% confidence interval=1.15-3.03, p=0.01). No significant differences were seen in OS between groups treated with chemotherapy alone. The VFA had a marginally significant modifying effect on the relationship between bevacizumab and OS (p for interaction=0.07). Conclusion: Our findings provide the first evidence that a low VFA might be a negative predictive marker for response to bevacizumab in patients with mCRC.
C1 [Miyamoto, Yuji; Sakamoto, Yasuo; Baba, Hideo] Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, 1-1-1 Honjo, Kumamoto 8608556, Japan.
   [Oki, Eiji; Saeki, Hiroshi; Maehara, Yoshihiko] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Japan.
   [Emi, Yasunori] Saiseikai Fukuoka Gen Hosp, Dept Surg, Fukuoka, Japan.
   [Tokunaga, Shoji] Kyushu Univ Hosp, Med Informat Ctr, Fukuoka, Japan.
   [Shimokawa, Mototsugu] Natl Hosp Org Kyushu Canc Ctr, Dept Canc Informat Res, Fukuoka, Japan.
   [Ogata, Yutaka] Kurume Univ, Med Ctr, Dept Surg, Kurume, Fukuoka, Japan.
   [Akagi, Yoshito] Kurume Univ, Sch Med, Dept Surg, Kurume, Fukuoka, Japan.
   [Tanaka, Takaho] Social Insurance Tagawa Hosp, Dept Surg, Tagawa, Japan.
C3 Kumamoto University; Kyushu University; Kyushu University; Kyushu Cancer
   Center; Kurume University; Kurume University
RP Baba, H (corresponding author), Kumamoto Univ, Grad Sch Med Sci, Dept Gastroenterol Surg, 1-1-1 Honjo, Kumamoto 8608556, Japan.
EM hdobaba@kumamoto-u.ac.jp
RI Maehara, Yoshihiko/A-4867-2010; Oki, Eiji/AFO-6423-2022
OI Miyamoto, Yuji/0000-0003-3948-5044
FU Grants-in-Aid for Scientific Research [17K10640] Funding Source: KAKEN
CR Abajo A, 2012, BRIT J CANCER, V107, P287, DOI 10.1038/bjc.2012.242
   Aykan NF, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0679-4
   Bates DO, 2012, CLIN CANCER RES, V18, P6384, DOI 10.1158/1078-0432.CCR-12-2223
   Beppu T, 2014, ANTICANCER RES, V34, P6655
   Ding GX, 2013, UROL ONCOL-SEMIN ORI, V31, P1820, DOI 10.1016/j.urolonc.2012.03.021
   Doyle SL, 2013, NUTR RES, V33, P171, DOI 10.1016/j.nutres.2012.12.007
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Frezza EE, 2006, GUT, V55, P285, DOI 10.1136/gut.2005.073163
   Grignol VP, 2015, SURG ONCOL, V24, P353, DOI 10.1016/j.suronc.2015.09.002
   Guiu B, 2010, GUT, V59, P341, DOI 10.1136/gut.2009.188946
   Hicklin DJ, 2005, J CLIN ONCOL, V23, P1011, DOI 10.1200/JCO.2005.06.081
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz HI, 2013, ONCOLOGIST, V18, P1004, DOI 10.1634/theoncologist.2013-0107
   Jubb AM, 2006, J CLIN ONCOL, V24, P217, DOI 10.1200/JCO.2005.01.5388
   Kaidar-Person O, 2015, ANTI-CANCER DRUG, V26, P363, DOI 10.1097/CAD.0000000000000201
   Kanazawa M, 2005, WORLD REV NUTR DIET, V11, pS732
   Kopetz S, 2010, J CLIN ONCOL, V28, P453, DOI 10.1200/JCO.2009.24.8252
   KUSUMOTO T, 2011, J CLIN ONCOL S, V29
   Ladoire S, 2011, ONCOLOGIST, V16, P71, DOI 10.1634/theoncologist.2010-0227
   Lemoine AY, 2012, J CLIN ENDOCR METAB, V97, pE775, DOI 10.1210/jc.2011-2649
   Miwa K, 2016, INT J CLIN ONCOL, V21, P110, DOI 10.1007/s10147-015-0850-3
   Miyamoto Y, 2016, CLIN CANCER RES, V22, P3999, DOI 10.1158/1078-0432.CCR-16-0495
   Miyazawa-Hoshimoto S, 2003, DIABETOLOGIA, V46, P1483, DOI 10.1007/s00125-003-1221-6
   Moon HG, 2008, ANN SURG ONCOL, V15, P1918, DOI 10.1245/s10434-008-9891-4
   Ogata Y, 2016, INT J CLIN ONCOL, V21, P335, DOI 10.1007/s10147-015-0895-3
   Oki E, 2013, ONCOLOGY-BASEL, V84, P233, DOI 10.1159/000346690
   Patel GS, 2015, CANCER MED-US, V4, P1461, DOI 10.1002/cam4.490
   Renfro LA, 2016, J CLIN ONCOL, V34, P144, DOI 10.1200/JCO.2015.61.6441
   Rickles AS, 2013, J GASTROINTEST SURG, V17, P133, DOI 10.1007/s11605-012-2045-9
   Ronzoni M, 2010, ANN ONCOL, V21, P2382, DOI 10.1093/annonc/mdq261
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Scartozzi M, 2009, ANN ONCOL, V20, P227, DOI 10.1093/annonc/mdn637
   Schneider BP, 2012, LANCET ONCOL, V13, pE427, DOI 10.1016/S1470-2045(12)70275-9
   Simkens LHJ, 2011, EUR J CANCER, V47, P2560, DOI 10.1016/j.ejca.2011.06.038
   Slaughter KN, 2014, GYNECOL ONCOL, V133, P11, DOI 10.1016/j.ygyno.2014.01.031
   Steffens S, 2011, ONCOLOGIST, V16, P1565, DOI 10.1634/theoncologist.2011-0213
   Wagner K, 2004, GASTROENTEROLOGY, V126, P1828, DOI 10.1053/j.gastro.2004.03.011
   Watanabe T, 2013, BIOMED REP, V1, P197, DOI 10.3892/br.2013.54
   Xu XY, 2015, MOL MED REP, V11, P289, DOI 10.3892/mmr.2014.2730
NR 39
TC 12
Z9 13
U1 0
U2 3
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD JAN
PY 2018
VL 38
IS 1
BP 491
EP 499
DI 10.21873/anticanres.12249
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FR5TW
UT WOS:000419130100066
PM 29277814
OA Bronze
DA 2025-01-04
ER

PT J
AU Allegra, A
   Rizzo, V
   Mirabile, G
   Gangemi, S
AF Allegra, Alessandro
   Rizzo, Vincenzo
   Mirabile, Giuseppe
   Gangemi, Sebastiano
TI Cubosomes: The Next Generation of Nanomedicine Delivery Systems in
   Cancer Treatment
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Review
DE cubosomes; hexosomes; cancer; drug delivery; theragnostic; nanomedicine;
   chemotherapy; target therapy; breast cancer; lung cancer; colorectal
   cancer
ID DRUG-DELIVERY; IN-VITRO; ARTIFICIAL-INTELLIGENCE; ANTICANCER ACTIVITY;
   COLORECTAL-CANCER; OVARIAN-CANCER; CELL-DEATH; NANOPARTICLES;
   5-FLUOROURACIL; STABILIZATION
AB Many conventional and adjuvant anticancer therapies can have serious adverse effects or yield subpar therapeutic results, and thus nanomedicine has begun to gain appeal for treating cancer. A family of nanocarriers called cubosomes exhibits promis-ing theragnostic efficacy. They are self-assembling, honeycomb-like, three-dimensional structures in the bicontinuous cubic liquid crystalline phase. They have a large interfacial area, straightforward preparation, capacity to encapsulate hydropho-bic, hydrophilic, and amphiphilic moieties, biodegradability, and targeted and controlled release of bioactive freight. Targeted drug delivery and a decrease in drug resistance have been accomplished by cubosomes. Cubosomes have also been employed in immunotherapy as a component of cancer medication therapy. Studies have revealed that the pharmacokinetics and safety characteristics of loaded medicines are enhanced by cubosomes. Cubosomes have been used in numerous preclinical trials to treat cancer and for theragnostic purposes. This review reports the most recent studies on the application of cubosomes in vitro and in vivo experimental models for the treatment of various neoplastic illnesses. The review highlights that cubosomes provide a flexible and promising platform for the administration of medicinal drugs.
C1 [Allegra, Alessandro; Mirabile, Giuseppe] Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano Ba, Div Hematol, I-98125 Messina, Italy.
   [Rizzo, Vincenzo] Univ Messina, Polyclin Hosp, Dept Clin & Expt Med, I-98125 Messina, Italy.
   [Gangemi, Sebastiano] Univ Messina, Dept Clin & Expt Med, Allergy & Clin Immunol Unit, I-98125 Messina, Italy.
C3 University of Messina; University of Messina; University of Messina
RP Allegra, A (corresponding author), Univ Messina, Dept Human Pathol Adulthood & Childhood Gaetano Ba, Div Hematol, I-98125 Messina, Italy.
EM aallegra@unime.it
RI Allegra, Alessandro/LRT-2739-2024; Gangemi, Sebastiano/IQR-5110-2023
CR Abbasifarid E, 2021, PLOS ONE, V16, DOI 10.1371/journal.pone.0258599
   Adir O, 2020, ADV MATER, V32, DOI 10.1002/adma.201901989
   Agatonovic-Kustrin S, 2000, J PHARMACEUT BIOMED, V22, P717, DOI 10.1016/S0731-7085(99)00272-1
   Alcaraz N, 2018, BIOCONJUGATE CHEM, V29, P149, DOI 10.1021/acs.bioconjchem.7b00659
   Aleandri S, 2015, LANGMUIR, V31, P12770, DOI 10.1021/acs.langmuir.5b03469
   Alhakamy NA, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12040346
   Allegra A, 2022, CANCERS, V14, DOI 10.3390/cancers14030606
   Allegra A, 2021, CURR MED CHEM, V28, P2195, DOI 10.2174/0929867327999200817102154
   Allegra A, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9050448
   Allegra A, 2018, TOXICOL IN VITRO, V47, P186, DOI 10.1016/j.tiv.2017.12.001
   Allegra A, 2017, CANCER INVEST, V35, P1, DOI 10.1080/07357907.2016.1247166
   Allegra A, 2011, ANTI-CANCER AGENT ME, V11, P669, DOI 10.2174/187152011796817682
   Almoshari Y, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14030600
   Alshawwa SZ, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14040883
   Angelov B, 2015, SOFT MATTER, V11, P3686, DOI 10.1039/c5sm00169b
   Angelova A, 2005, LANGMUIR, V21, P4138, DOI 10.1021/la047745t
   Angelova A, 2017, ADV COLLOID INTERFAC, V249, P331, DOI 10.1016/j.cis.2017.04.006
   [Anonymous], 2017, J NANOMED NANOTECHNO, DOI DOI 10.4172/2157-7439.1000433
   Astolfi P, 2017, LANGMUIR, V33, P12369, DOI 10.1021/acs.langmuir.7b03173
   Azhari H, 2021, INT J PHARMACEUT, V600, DOI 10.1016/j.ijpharm.2021.120411
   Bahrami B, 2017, IMMUNOL LETT, V190, P64, DOI 10.1016/j.imlet.2017.07.015
   Ban DK, 2016, COLLOID SURFACE B, V146, P577, DOI 10.1016/j.colsurfb.2016.06.050
   Barkate AR, 2020, World J Pharm Res, V9, P1170
   Barriga HMG, 2019, ANGEW CHEM INT EDIT, V58, P2958, DOI 10.1002/anie.201804067
   Bazylinska U, 2022, ACS NANO, V16, P5427, DOI 10.1021/acsnano.1c09367
   Bei D, 2010, NANOMEDICINE-UK, V5, P1385, DOI [10.2217/nnm.10.117, 10.2217/NNM.10.117]
   Biffi S, 2017, NANOTECHNOLOGY, V28, DOI 10.1088/1361-6528/28/5/055102
   Boge L, 2016, LANGMUIR, V32, P4217, DOI 10.1021/acs.langmuir.6b00338
   Bourguignon LYW, 2009, J BIOL CHEM, V284, P2657, DOI 10.1074/jbc.M806708200
   Boyd BJ, 2007, INT J PHARM, V340, P52, DOI 10.1016/j.ijpharm.2007.03.020
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Caltagirone C, 2014, LANGMUIR, V30, P6228, DOI 10.1021/la501332u
   Caselli L, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22179268
   Chen SZ, 2019, CANCER LETT, V460, P1, DOI 10.1016/j.canlet.2019.114428
   Chen YY, 2015, J MATER CHEM B, V3, P7734, DOI 10.1039/c5tb01193k
   Chen YL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/815981
   Cheng FX, 2014, J AM MED INFORM ASSN, V21, pE278, DOI 10.1136/amiajnl-2013-002512
   Cheng T, 2016, J CHROMATOGR B, V1033, P353, DOI 10.1016/j.jchromb.2016.09.010
   Coisson M, 2022, APL MATER, V10, DOI 10.1063/5.0099498
   Cortesi R, 2014, NEW BIOTECHNOL, V31, P44, DOI 10.1016/j.nbt.2013.10.001
   Cytryniak A, 2022, MOL PHARMACEUT, V19, P2818, DOI 10.1021/acs.molpharmaceut.2c00182
   Cytryniak A, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10112272
   Danieli MG, 2022, AUTOIMMUN REV, V21, DOI 10.1016/j.autrev.2022.103105
   Das KP, 2023, FRONT MED TECHNOL, V4, DOI 10.3389/fmedt.2022.1067144
   Demurtas D, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms9915
   Di Paolo A, 2001, ANN ONCOL, V12, P1301, DOI 10.1023/A:1012294617392
   Elakkad YE, 2021, BREAST CANCER-TARGET, V13, P675, DOI 10.2147/BCTT.S336712
   Fahmy UA, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13010020
   Funston G, 2020, PLOS MED, V17, DOI [10.1371/journal.pmed.1003295, 10.1371/journal.pmed.1003295.r001, 10.1371/journal.pmed.1003295.r002, 10.1371/journal.pmed.1003295.r003, 10.1371/journal.pmed.1003295.r004, 10.1371/journal.pmed.1003295.r005]
   Gajda E, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145039
   Gajski G, 2019, SAUDI PHARM J, V27, P1216, DOI 10.1016/j.jsps.2019.10.005
   Garg G, 2007, BIOL PHARM BULL, V30, P350, DOI 10.1248/bpb.30.350
   Ghasemi F, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152556
   Ha SM, 2020, ACCOUNTS CHEM RES, V53, P620, DOI 10.1021/acs.accounts.9b00563
   Han C, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00239
   Han N, 2023, BIOFACTORS, V49, DOI 10.1002/biof.1591
   Han R, 2019, J CONTROL RELEASE, V311, P16, DOI 10.1016/j.jconrel.2019.08.030
   He HK, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14057
   He Y, 2020, J CONTROL RELEASE, V322, P274, DOI 10.1016/j.jconrel.2020.03.043
   Hedayatnasab Z, 2023, MATER RES BULL, V157, DOI 10.1016/j.materresbull.2022.112035
   Hierrezuelo J, 2010, LANGMUIR, V26, P15109, DOI 10.1021/la102912u
   Hong S, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12070604
   Huang JW, 1998, IEEE T BIO-MED ENG, V45, P213, DOI 10.1109/10.661269
   Iagaru A, 2010, MOL IMAGING BIOL, V12, P198, DOI 10.1007/s11307-009-0245-9
   Jiang JH, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14112257
   Jin JF, 2016, SCI REP-UK, V6, DOI 10.1038/srep27871
   Jin X, 2013, FITOTERAPIA, V84, P64, DOI 10.1016/j.fitote.2012.09.013
   Khan SA, 2023, CURR DRUG DELIV, V20, P643, DOI 10.2174/1567201819666220509164611
   Kim HJ, 2015, ACS NANO, V9, P10214, DOI 10.1021/acsnano.5b03902
   Kyle S, 2018, TRENDS BIOCHEM SCI, V43, P230, DOI 10.1016/j.tibs.2018.03.001
   Lai J, 2009, AAPS PHARMSCITECH, V10, P960, DOI 10.1208/s12249-009-9292-4
   Leu JSL, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15051421
   Li DS, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00216-5
   Li J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2298-2
   Li JW, 2015, ONCOL REP, V33, P2829, DOI 10.3892/or.2015.3891
   Man F, 2018, MOL IMAGING BIOL, V20, P683, DOI 10.1007/s11307-018-1255-2
   Mathews PD, 2022, J COLLOID INTERF SCI, V607, P440, DOI 10.1016/j.jcis.2021.08.187
   Mehanna MM, 2020, INT J NANOMED, V15, P9557, DOI 10.2147/IJN.S263797
   Menden MP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061318
   Mertins O, 2020, NANOMATERIALS-BASEL, V10, DOI 10.3390/nano10050963
   Michel MA, 2017, MOL CELL, V68, P233, DOI 10.1016/j.molcel.2017.08.020
   Mo SP, 2016, SCI REP-UK, V6, DOI 10.1038/srep36836
   Mokhtar S, 2022, FRONT CHEM, V10, DOI 10.3389/fchem.2022.847573
   Montis C, 2015, J COLLOID INTERF SCI, V449, P317, DOI 10.1016/j.jcis.2014.11.056
   Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0720-y
   Muir BW, 2012, BIOMATERIALS, V33, P2723, DOI 10.1016/j.biomaterials.2011.12.018
   Nangia-Makker P, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0084369
   Nasr M, 2015, ACTA PHARM SIN B, V5, P79, DOI 10.1016/j.apsb.2014.12.001
   Tran N, 2017, MAT SCI ENG C-MATER, V71, P584, DOI 10.1016/j.msec.2016.10.028
   Niculescu AG, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23095253
   Nilsson C, 2013, BIOMATERIALS, V34, P8491, DOI 10.1016/j.biomaterials.2013.07.055
   Nisha R, 2022, INT J PHARMACEUT, V622, DOI 10.1016/j.ijpharm.2022.121848
   Niu Gang, 2009, Drug Deliv (Lond), V3, P109
   Noorani L, 2015, J NANOBIOTECHNOL, V13, DOI 10.1186/s12951-015-0082-8
   O'Donnell EF, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013128
   Owens DE, 2006, INT J PHARMACEUT, V307, P93, DOI 10.1016/j.ijpharm.2005.10.010
   Parayath NN, 2018, NANO LETT, V18, P3571, DOI 10.1021/acs.nanolett.8b00689
   Patil SM, 2021, INT J PHARMACEUT, V607, DOI 10.1016/j.ijpharm.2021.121046
   Pavlova NN, 2016, CELL METAB, V23, P27, DOI 10.1016/j.cmet.2015.12.006
   Peng XS, 2015, DRUG DES DEV THER, V9, P4209, DOI 10.2147/DDDT.S86370
   Pramanik A, 2022, MOL PHARMACEUT, DOI 10.1021/acs.molpharmaceut.2c00439
   Pramanik A, 2022, ACS APPL MATER INTER, V14, P11078, DOI 10.1021/acsami.1c21655
   Pytel D, 2009, ANTI-CANCER AGENT ME, V9, P66, DOI 10.2174/187152009787047752
   Rajabi M, 2016, CURR PHARM BIOTECHNO, V17, P662, DOI 10.2174/1389201017666160415155457
   Ramalheiro A, 2020, INT J PHARMACEUT, V591, DOI 10.1016/j.ijpharm.2020.119942
   Rao GH, 2013, CLIN CANCER RES, V19, P785, DOI 10.1158/1078-0432.CCR-12-2788
   Rarokar N, 2018, MOJ Toxicol, V4, P19, DOI [10.15406/mojt.2018.04.00083, DOI 10.15406/MOJT.2018.04.00083]
   Romero-Cano MS, 2001, LANGMUIR, V17, P3505, DOI 10.1021/la001659l
   Rr W., J BIOEQUIV BIOAVAILA, DOI [DOI 10.4172/jbb.10000e77, 10.4172/jbb.10000e77]
   Saber MM, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4727-5
   Saber S, 2021, BIOMED PHARMACOTHER, V142, DOI 10.1016/j.biopha.2021.112029
   Seok HY, 2018, J CONTROL RELEASE, V280, P20, DOI 10.1016/j.jconrel.2018.04.050
   Serieye S, 2017, J COLLOID INTERF SCI, V496, P26, DOI 10.1016/j.jcis.2017.01.059
   Sethuraman V, 2019, CHEM PHYS LIPIDS, V224, DOI 10.1016/j.chemphyslip.2019.03.016
   Shamay Y, 2018, NAT MATER, V17, P361, DOI 10.1038/s41563-017-0007-z
   Shamsuddin SH, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-80354-6
   Siekmann B, 2002, INT J PHARMACEUT, V244, P33, DOI 10.1016/S0378-5173(02)00298-3
   Sivadasan D, 2023, BIOMEDICINES, V11, DOI 10.3390/biomedicines11041114
   Sohail A, 2019, J MOL LIQ, V285, P47, DOI 10.1016/j.molliq.2019.04.022
   Stewart C, 2019, SEMIN ONCOL NURS, V35, P151, DOI 10.1016/j.soncn.2019.02.001
   Stockwell BR, 2017, CELL, V171, P273, DOI 10.1016/j.cell.2017.09.021
   Sun TM, 2014, ANGEW CHEM INT EDIT, V53, P12320, DOI 10.1002/anie.201403036
   Tadros T, 2013, Encyclopedia of Colloid and Interface Science, P1334, DOI [10.1007/978-3-642-20665-8, DOI 10.1007/978-3-642-20665-8, DOI 10.1007/978-3-642-20665-8156]
   Tan HL, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00191
   Tan P, 2023, SEMIN CANCER BIOL, V89, P61, DOI 10.1016/j.semcancer.2023.01.005
   Thapa RK, 2016, BIOMATER SCI-UK, V4, P1340, DOI 10.1039/c6bm00376a
   Tian Y, 2017, MED SCI MONITOR, V23, DOI 10.12659/MSM.904683
   Tiede C, 2017, ELIFE, V6, DOI 10.7554/eLife.24903
   Tiede C, 2014, PROTEIN ENG DES SEL, V27, P145, DOI 10.1093/protein/gzu007
   Varghese R, 2022, COLLOID INTERFAC SCI, V46, DOI 10.1016/j.colcom.2021.100544
   Verkhovskii RA, 2023, PHARMACEUTICS, V15, DOI 10.3390/pharmaceutics15051566
   Victorelli FD, 2022, J COLLOID INTERF SCI, V620, P419, DOI 10.1016/j.jcis.2022.04.031
   Wakaskar RR, 2018, J DRUG TARGET, V26, P311, DOI 10.1080/1061186X.2017.1367006
   Wakaskar RR, 2017, Journal of Pharmacogenomics & Pharmacoproteomics, V8, P100
   Wang QS, 2016, INT J PHARMACEUT, V515, P176, DOI 10.1016/j.ijpharm.2016.10.002
   Wang W, 2021, J CONTROL RELEASE, V338, P119, DOI 10.1016/j.jconrel.2021.08.030
   White RM, 2011, NATURE, V471, P518, DOI 10.1038/nature09882
   Wu XM, 2018, BIOCHEM BIOPH RES CO, V495, P267, DOI 10.1016/j.bbrc.2017.10.136
   Yaghmur A, 2021, ACTA PHARM SIN B, V11, P871, DOI 10.1016/j.apsb.2021.02.013
   Yimer EM, 2019, EVID-BASED COMPL ALT, V2019, DOI 10.1155/2019/1528635
   Zabara A, 2013, SMALL, V9, P3602, DOI 10.1002/smll.201300348
   Zaman MS, 2016, SCI REP-UK, V6, DOI 10.1038/srep20051
   Zerkoune L, 2016, SOFT MATTER, V12, P7539, DOI 10.1039/c6sm00661b
   Zewail M, 2022, DRUG DELIV, V29, P1663, DOI 10.1080/10717544.2022.2079770
   Zewail M, 2021, THER DELIV, V12, P297, DOI 10.4155/tde-2020-0123
   Zhai JL, 2018, ACS APPL MATER INTER, V10, P25174, DOI 10.1021/acsami.8b08125
   Zhang CY, 2018, BIOCHEM BIOPH RES CO, V496, P726, DOI 10.1016/j.bbrc.2018.01.107
   Zhang LL, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-019-2182-0
   Zhang ZJ, 2011, DIABETES CARE, V34, P2323, DOI 10.2337/dc11-0512
NR 149
TC 0
Z9 0
U1 4
U2 9
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393-974X
EI 1724-6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD JAN
PY 2024
VL 38
IS 1
BP 11
EP 29
DI 10.23812/j.biol.regul.homeost.agents.20243801.2
PG 19
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA FT4B8
UT WOS:001148083800001
DA 2025-01-04
ER

PT J
AU Bando, H
   Nakamura, Y
   Kotani, D
   Yoshino, T
AF Bando, Hideaki
   Nakamura, Yoshiaki
   Kotani, Daisuke
   Yoshino, Takayuki
TI Comparing GOZILA and COLOMATE: Ongoing Umbrella/Basket Trials Examining
   Genetic Testing in Gastrointestinal Malignancies
SO ONCOLOGY-NEW YORK
LA English
DT Article
DE colorectal cancer; circulating tumor DNA; GOZILA; COLOMATE; companion
   trials; targeted therapy
AB Circulating tumor DNA (ctDNA)-based nextgeneration sequencing (NGS) assays have advantages over classic tissue-based analyses because of their low invasiveness and availability of repeated sampling. Because of the low incidence of target gene alterations such as HER2 or BRAF V600E in gastrointestinal cancers, very large screening platforms are needed to develop genome-based clinical trials. For those reasons, ctDNA-based screening studies are being actively conducted; among them are the GOZILA (Guardant Originates in Zipangu Liquid biopsy Arrival) study in Japan and the COLOMATE (COlorectal Cancer Liquid BiOpsy Screening Protocol for Molecularly Assigned ThErapy) study in the United States.
   Although only patients with metastatic colorectal cancer (mCRC) who had previously received standard chemotherapies are eligible for the COLOMATE study, patients with various types of solid tumors at any line of treatment are eligible for GOZILA. This broad coverage of the eligible population allows a target of 5000 patients. By contrast, effective screening of selected candidate patients for companion trials using rapid turnaround time by ctDNA-based NGS assay is the key for COLOMATE. The companion trials of targeted therapies in mCRC are similar between GOZILA and COLOMATE. Both studies have identified patients eligible for studies by examining ERBB2 (HER2), BRAF V600E, BRAF non-V600E, and FGFR alterations, as well as MET amplification and rechallenge with anti-EGFR antibodies. The existence of various companion trials for common alterations that can be potential therapy targets on the 2 platforms can lead to future international collaboration.
C1 [Bando, Hideaki; Nakamura, Yoshiaki; Kotani, Daisuke; Yoshino, Takayuki] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan.
C3 National Cancer Center - Japan
RP Bando, H (corresponding author), Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan.
FU AstraZeneca; Sysmex; Taiho Pharmaceutical; Chugai Pharmaceutical;
   Guardant Health; Genomedia; Daiichi-Sankyo; Seagen; Ono; MSD; Novartis;
   IQVIA; Syneos Health; CMIC ShiftZero; Sumitomo Dainippon; Ono
   Pharmaceutical; Amgen; Parexel International; Daiichi Sankyo; Sanofi
FX HB reports research funding from AstraZeneca, Sysmex, and honoraria from
   Taiho Pharmaceutical and Eli Lilly Japan; YN reports research grants
   from Taiho Pharmaceutical, Chugai Pharmaceutical, Guardant Health,
   Genomedia, Daiichi-Sankyo, and Seagen; DK reports honoraria from Taiho,
   Ono, DaiichiSankyo, Pfizer, Takeda, Lilly, Merck Biopharma, MSD,
   Bristol-Myers Squibb, Chugai, and Sysmex; research funding from Ono,
   MSD, Novartis, IQVIA, Syneos Health, and CMIC ShiftZero; TY reports
   research grants from Taiho Pharmaceutical, Sumitomo Dainippon, Ono
   Pharmaceutical, Chugai Pharmaceutical, Amgen, Parexel International,
   MSD, Daiichi Sankyo, Sanofi
NR 0
TC 3
Z9 3
U1 0
U2 0
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
EI 2767-7389
J9 ONCOLOGY-NY
JI Oncology-NY
PD JUL
PY 2021
VL 35
IS 7
BP 382
EP 389
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA VN0IC
UT WOS:001096522300008
PM 34286943
OA Bronze
DA 2025-01-04
ER

PT J
AU Lu, ZH
   Peng, Z
   Liu, C
   Wang, ZH
   Wang, YK
   Jiao, X
   Li, J
   Shen, L
AF Lu, Zhihao
   Peng, Zhi
   Liu, Chang
   Wang, Zhenghang
   Wang, Yakun
   Jiao, Xi
   Li, Jian
   Shen, Lin
TI Current Status and Future Perspective of Immunotherapy in
   Gastrointestinal Cancers
SO INNOVATION
LA English
DT Review
DE GASTROINTESTINAL CANCER; IMMUNE CHECKPOINT BLOCKADE; BIOMARKERS;
   PRECISION IMMUNOTHERAPY
ID GASTROESOPHAGEAL JUNCTION CANCER; ANTIGEN NANOVACCINE PVAC; T-CELL
   RECOGNITION; METASTATIC MELANOMA; CLINICAL-RESPONSE; CTLA-4 BLOCKADE;
   OPEN-LABEL; IPILIMUMAB TREATMENT; SOLID TUMORS; DOUBLE-BLIND
AB Gastrointestinal (GI) cancers represent a major public health problem worldwide. Due to the late detection and high heterogeneity of GI cancers, traditional treatments, including surgery, radiotherapy, chemotherapy, and targeted therapy, have shown limited effects, and the overall prognosis of these patients remains poor. Recently, immunotherapy, involving programmed cell death-1 (PD-1) and its ligand (PD-L1), has shown promising efficacy in several solid cancers and seems to have become a potential treatment option for GI cancers This review focuses on data on the development of immunotherapy-based clinical trials in esophageal cancer, gastric cancer, and colorectal cancer. The predictive biomarkers and combination strategies in clinical trials and translational medicine are also discussed. Finally, prospects for immunotherapy in the treatment of GI cancers are described. Although only a small proportion of patients with GI cancers respond to PD-1/PD-L1 blockade, we strongly believe that precision immunotherapy might improve the overall survival of many more GI cancer patients in the future.
C1 [Lu, Zhihao; Peng, Zhi; Liu, Chang; Wang, Zhenghang; Wang, Yakun; Jiao, Xi; Li, Jian; Shen, Lin] Peking Univ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Canc Hosp & Inst, 52 FuCheng Rd, Beijing 100142, Peoples R China.
C3 Peking University
RP Li, J; Shen, L (corresponding author), Peking Univ, Dept Gastrointestinal Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ Beijing,Canc Hosp & Inst, 52 FuCheng Rd, Beijing 100142, Peoples R China.
EM oncogene@163.com; shenlin@bjmu.edu.cn
RI wang, zongren/AAO-6888-2021; Shen, Lin/JPX-7656-2023; Peng,
   Zhiyu/GXV-5301-2022
FU National Key Research and Development Program of China [2018YFC1313303]
FX This study was supported by the National Key Research and Development
   Program of China (2017YFC1308900) and the National Key Research and
   Development Program of China (2018YFC1313303).
CR Abdul-Latif M, 2020, CANCER TREAT REV, V88, DOI 10.1016/j.ctrv.2020.102030
   Akondy RS, 2015, P NATL ACAD SCI USA, V112, P3050, DOI 10.1073/pnas.1500475112
   Akondy RS, 2009, J IMMUNOL, V183, P7919, DOI 10.4049/jimmunol.0803903
   Androulla MN, 2018, CURR PHARM BIOTECHNO, V19, P5, DOI 10.2174/1389201019666180418095526
   Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190
   Bang, 2019, ANN ONCOL, V30, pV477, DOI DOI 10.1093/ANNONC/MDZ253.018
   Bang YJ, 2018, ANN ONCOL, V29, P2052, DOI 10.1093/annonc/mdy264
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Boku N, 2019, ANN ONCOL, V30, P250, DOI 10.1093/annonc/mdy540
   Boni A, 2010, CANCER RES, V70, P5213, DOI 10.1158/0008-5472.CAN-10-0118
   Bradley SD, 2015, CANCER IMMUNOL RES, V3, P602, DOI 10.1158/2326-6066.CIR-15-0030
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Cardin, 2018, ANN ONCOL S8, V29, pVIII714, DOI [10.1093/annonc/mdy424.019, DOI 10.1093/ANNONC/MDY424.019]
   Catenacci DVT, 2020, LANCET ONCOL, V21, P1066, DOI 10.1016/S1470-2045(20)30326-0
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2
   Chao J, 2020, J CLIN ONCOL, V38
   Chau I, 2017, CLIN CANCER RES, V23, P6002, DOI 10.1158/1078-0432.CCR-17-0020
   Chen EX, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3512
   Chen EX, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.481
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chmielewski M, 2015, EXPERT OPIN BIOL TH, V15, P1145, DOI 10.1517/14712598.2015.1046430
   Chmielewski M, 2011, CANCER RES, V71, P5697, DOI 10.1158/0008-5472.CAN-11-0103
   Comin-Anduix B, 2010, CLIN CANCER RES, V16, P6040, DOI 10.1158/1078-0432.CCR-10-1911
   Comoli P, 2019, ANN ONCOL, V30, P1740, DOI 10.1093/annonc/mdz285
   Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593
   Cui YP, 2020, CELL RES, V30, P902, DOI 10.1038/s41422-020-0333-6
   Delyon J, 2013, ANN ONCOL, V24, P1697, DOI 10.1093/annonc/mdt027
   Doi T, 2018, J CLIN ONCOL, V36, P61, DOI 10.1200/JCO.2017.74.9846
   Efremova M, 2017, FRONT IMMUNOL, V8, DOI 10.3389/fimmu.2017.01679
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Ferrucci PF, 2016, ANN ONCOL, V27, P732, DOI 10.1093/annonc/mdw016
   Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630
   Fuchs CS, 2020, J CLIN ONCOL, V38
   Fuchs CS, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.0013
   Fukuoka S, 2020, J CLIN ONCOL, V38, P2053, DOI 10.1200/JCO.19.03296
   Garassino M, 2019, J THORAC ONCOL, V14, pS216, DOI 10.1016/j.jtho.2019.08.427
   Grothey A., 2018, Annals of oncology, V29, pviii714, DOI [10.1093/annonc/mdy424.020, DOI 10.1093/ANNONC/MDY424.020]
   Harel M, 2019, CELL, V179, P236, DOI 10.1016/j.cell.2019.08.012
   Heczey A, 2017, MOL THER, V25, P2214, DOI 10.1016/j.ymthe.2017.05.012
   Hodge JW, 2012, SEMIN ONCOL, V39, P323, DOI 10.1053/j.seminoncol.2012.02.006
   Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y
   Hong MH, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4027
   Huang J, 2020, LANCET ONCOL, V21, P832, DOI 10.1016/S1470-2045(20)30110-8
   Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065
   Inamori K, 2020, J CLIN ONCOL, V38
   Janjigian YY, 2020, LANCET ONCOL, V21, P821, DOI 10.1016/S1470-2045(20)30169-8
   Janjigian YY, 2018, J CLIN ONCOL, V36, P2836, DOI 10.1200/JCO.2017.76.6212
   Kakarla S, 2014, CANCER J, V20, P151, DOI 10.1097/PPO.0000000000000032
   Kang YK, 2017, LANCET, V390, P2461, DOI 10.1016/S0140-6736(17)31827-5
   Kato K, 2019, LANCET ONCOL, V20, P1506, DOI 10.1016/S1470-2045(19)30626-6
   Kato R, 2018, CANCER IMMUNOL IMMUN, V67, P1673, DOI 10.1007/s00262-018-2225-x
   Kelderman S, 2014, CANCER IMMUNOL IMMUN, V63, P449, DOI 10.1007/s00262-014-1528-9
   Kelly RJ, 2020, CLIN CANCER RES, V26, P846, DOI 10.1158/1078-0432.CCR-19-2443
   Kelly RJ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.142
   Kim ST, 2018, NAT MED, V24, P1449, DOI 10.1038/s41591-018-0101-z
   Kojima T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.2
   Kuai WT, 2020, BIOMED RES INT, V2020, DOI 10.1155/2020/5294043
   Langer C, 2019, J THORAC ONCOL, V14, pS216, DOI 10.1016/j.jtho.2019.08.426
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3514
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lee JJ, 2018, CLIN COLORECTAL CANC, V17, P258, DOI 10.1016/j.clcc.2018.06.004
   Lee JS, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011769
   Li S, 2020, CLIN IMMUNOL, V212, P40, DOI 10.1016/j.clim.2020.108345
   Liu J, 2016, CANCER DISCOV, V6, P1382, DOI 10.1158/2159-8290.CD-16-0577
   Liu Q, 2020, J CLIN ONCOL, V38
   Lordick F, 2016, NAT REV CLIN ONCOL, V13, P348, DOI 10.1038/nrclinonc.2016.15
   Loupakis F, 2020, ONCOLOGIST, V25, P481, DOI 10.1634/theoncologist.2019-0611
   Lu ZH, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.7621
   Ma S, 2019, INT J BIOL SCI, V15, P2548, DOI 10.7150/ijbs.34213
   Mei Z, 2014, BRIT J CANCER, V110, P1595, DOI 10.1038/bjc.2014.46
   Melief CJM, 2015, J CLIN INVEST, V125, P3401, DOI 10.1172/JCI80009
   Mezquita L, 2018, JAMA ONCOL, V4, P351, DOI 10.1001/jamaoncol.2017.4771
   Morgan RA, 2010, MOL THER, V18, P843, DOI 10.1038/mt.2010.24
   Mortenson ED, 2013, CLIN CANCER RES, V19, P1476, DOI 10.1158/1078-0432.CCR-12-2522
   Mougel A, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00467
   Muro K, 2016, LANCET ONCOL, V17, P717, DOI 10.1016/S1470-2045(16)00175-3
   O'Donnell JS, 2017, CANCER TREAT REV, V52, P71, DOI 10.1016/j.ctrv.2016.11.007
   O'Neil BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189848
   Ohmura H, 2020, BRIT J CANCER, V122, P1507, DOI 10.1038/s41416-020-0810-1
   Overman MJ, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw370.27
   Overman MJ, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.554
   Overman MJ, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.635
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Park S, 2010, CANCER CELL, V18, P160, DOI 10.1016/j.ccr.2010.06.014
   Peng J, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1734156
   Peng Z., 2020, PREDICTIVE BIOMARKER, P4298
   Puzanov I, 2016, J CLIN ONCOL, V34, P2619, DOI 10.1200/JCO.2016.67.1529
   Rao D, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-018-0076-8
   Ren C, 2020, EJSO-EUR J SURG ONC, V46, pE3, DOI 10.1016/j.ejso.2020.06.004
   Richard C, 2019, CLIN CANCER RES, V25, P957, DOI 10.1158/1078-0432.CCR-18-1940
   Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116
   Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706
   Saleh R, 2020, CANCER IMMUNOL IMMUN, V69, P1989, DOI 10.1007/s00262-020-02593-w
   Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8
   Satake H, 2020, J CLIN ONCOL, V38
   Schermers B, 2019, BRIT J SURG, V106, P519, DOI 10.1002/bjs.11168
   Schoenfeld AJ, 2020, CANCER CELL, V37, P443, DOI 10.1016/j.ccell.2020.03.017
   Schuler MH, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.4038
   Segal NH, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.670
   Shah MA, 2019, JAMA ONCOL, V5, P546, DOI 10.1001/jamaoncol.2018.5441
   Sharabi AB, 2015, LANCET ONCOL, V16, pE498, DOI 10.1016/S1470-2045(15)00007-8
   Shitara K, 2020, J CLIN ONCOL, V38
   Shitara K, 2018, LANCET, V392, P123, DOI 10.1016/S0140-6736(18)31257-1
   Shiu KK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.2020.38.18_suppl.LBA4
   Simeone E, 2014, CANCER IMMUNOL IMMUN, V63, P675, DOI 10.1007/s00262-014-1545-8
   Sivan A, 2015, SCIENCE, V350, P1084, DOI 10.1126/science.aac4255
   Smyth MJ, 2016, NAT REV CLIN ONCOL, V13, P143, DOI 10.1038/nrclinonc.2015.209
   Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498
   Tabernero J, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.18_suppl.LBA4007
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Taylor C, 2007, CLIN CANCER RES, V13, P5133, DOI 10.1158/1078-0432.CCR-07-0507
   Tetzlaff MT, 2018, ANN ONCOL, V29, P1861, DOI 10.1093/annonc/mdy226
   Topper MJ, 2020, NAT REV CLIN ONCOL, V17, P75, DOI 10.1038/s41571-019-0266-5
   Uboha NV, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4041
   Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095
   van den Ende T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.4045
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Vétizou M, 2015, SCIENCE, V350, P1079, DOI 10.1126/science.aad1329
   Wainberg ZA, 2020, J CLIN ONCOL, V38
   Wang F, 2019, ANN ONCOL, V30, P1479, DOI 10.1093/annonc/mdz197
   Wang WJ, 2019, ANN TRANSL MED, V7, DOI 10.21037/atm.2019.11.38
   Wang YY, 2018, ONCOL REP, V40, P2115, DOI 10.3892/or.2018.6627
   Wei J, 2020, J CLIN ONCOL, V38
   Wei WQ, 2020, LANCET ONCOL, V21, pE342, DOI 10.1016/S1470-2045(20)30073-5
   Weide B, 2016, CLIN CANCER RES, V22, P5487, DOI 10.1158/1078-0432.CCR-16-0127
   Wilgenhof S, 2013, J IMMUNOTHER, V36, P215, DOI 10.1097/CJI.0b013e31828eed39
   Wilmott JS, 2012, CLIN CANCER RES, V18, P1386, DOI 10.1158/1078-0432.CCR-11-2479
   Xie T, 2020, J IMMUNOTHER, V43, P139, DOI 10.1097/CJI.0000000000000316
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Yang LH, 2019, ONCOL LETT, V18, P5681, DOI 10.3892/ol.2019.10935
   Yau HL, 2019, TRENDS CELL BIOL, V29, P31, DOI 10.1016/j.tcb.2018.07.006
   Yoon HH, 2019, CLIN CANCER RES, V25, P125, DOI 10.1158/1078-0432.CCR-18-1984
   Yoshino T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3606
   Zhan XB, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.2509
   Zhang CC, 2017, MOL THER, V25, P1248, DOI 10.1016/j.ymthe.2017.03.010
   Zhang L, 2011, MOL THER, V19, P751, DOI 10.1038/mt.2010.313
   Zhang ZN, 2020, EJSO-EUR J SURG ONC, V46, pE33, DOI 10.1016/j.ejso.2020.06.034
   Zheng X, 2018, CELL PHYSIOL BIOCHEM, V45, P720, DOI 10.1159/000487164
NR 142
TC 53
Z9 53
U1 4
U2 17
PU CELL PRESS
PI CAMBRIDGE
PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA
SN 2666-6758
J9 INNOVATION-AMSTERDAM
JI Innovation-Amsterdam
PD AUG 28
PY 2020
VL 1
IS 2
AR 100041
DI 10.1016/j.xinn.2020.100041
PG 11
WC Multidisciplinary Sciences
WE Emerging Sources Citation Index (ESCI)
SC Science & Technology - Other Topics
GA VK7GO
UT WOS:000747222600021
PM 34557714
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Li, AL
   Huang, XZ
   Song, YX
   Chen, XW
   Sun, JX
   Xu, HM
   Wang, ZN
AF Li, Ailin
   Huang, Xuanzhang
   Song, Yongxi
   Chen, Xiaowan
   Sun, Jingxu
   Xu, Huimian
   Wang, Zhenning
TI Anti-epidermal growth factor receptor-targeted therapy in upper
   gastrointestinal tract cancers: a meta-analysis
SO GROWTH FACTORS
LA English
DT Article
DE Anti-epidermal growth factor receptor; esophageal cancer;
   esophagogastric junction cancer; gastric cancer; meta-analysis;
   capecitabine
ID CELL-LUNG-CANCER; ADVANCED ESOPHAGOGASTRIC CANCER; GASTRIC-CANCER;
   1ST-LINE TREATMENT; COLORECTAL-CANCER; PHASE-II; CETUXIMAB;
   CHEMOTHERAPY; MULTICENTER; CAPECITABINE
AB This meta-analysis evaluated the efficacy and safety of anti-epidermal growth factor receptor (EGFR) treatment of patients with upper gastrointestinal (GI) tract cancers. A systematic search of multiple databases identified seven randomized controlled trials. Anti-EGFR combination therapy improved disease control rate (DCR) in all patients and progression-free survival (PFS) in patients receiving the same dose of standard therapy as patients receiving standard therapy alone. Combinations of anti-EGFR with non-capecitabine chemotherapy further improved DCR, whereas combinations with capecitabine masked the benefits of DCR and worsened PFS. Overall survival was apparently lower in patients without metastasis, and PFS was apparently improved in patients with squamous cell carcinoma of the esophagus and esophagogastric junction. Anti-EGFR treatment was associated with higher rates of cardiac events, hand-foot syndrome, rash, hypomagnesemia, diarrhea and mucositis and lower rates of neutropenia. Combinations of anti-EGFR agents with non-capecitabine chemotherapy or better supportive care may benefit patients with upper GI tract cancers.
C1 [Li, Ailin; Huang, Xuanzhang; Song, Yongxi; Chen, Xiaowan; Sun, Jingxu; Xu, Huimian; Wang, Zhenning] China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, Shenyang 110001, Peoples R China.
   [Li, Ailin] China Med Univ, Dept Radiat Oncol, Hosp 1, Shenyang 110001, Peoples R China.
C3 China Medical University; China Medical University
RP Wang, ZN (corresponding author), China Med Univ, Dept Surg Oncol & Gen Surg, Hosp 1, 155 Nanjingbei St, Shenyang 110001, Peoples R China.
EM josieon826@sina.cn
RI ; Wang, Zhenning/E-1878-2011
OI Huang, Xuanzhang/0000-0001-9886-7152; Wang, Zhenning/0000-0003-0557-3097
FU National Science Foundation of China [81201888, 81372549, 81172370,
   81402520]; Specialized Research Fund for the Doctoral Program of Higher
   Education [20122104110009]; Research Foundation for the Doctoral Program
   [20141040]; Natural Science Foundation of Liaoning Province
   [2014029201]; Program of Education Department of Liaoning Province
   [L2014307]
FX This work was supported by the National Science Foundation of China (no.
   81201888, 81372549, 81172370 and 81402520), the Specialized Research
   Fund for the Doctoral Program of Higher Education (no. 20122104110009),
   the Research Foundation for the Doctoral Program (no. 20141040), the
   Natural Science Foundation of Liaoning Province (no. 2014029201) and the
   Program of Education Department of Liaoning Province (no. L2014307).
CR [Anonymous], 2015, NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Colorectal Cancer Screening
   [Anonymous], GASTRIC CANC
   [Anonymous], 2014, NCCN Clinical Practice Guidelines in Oncology Head and Neck Cancers Version 2
   Ayyappan S, 2013, ANTICANCER RES, V33, P4139
   BEGG CB, 1994, BIOMETRICS, V50, P1088, DOI 10.2307/2533446
   Chen P, 2011, EUR J CLIN PHARMACOL, V67, P235, DOI 10.1007/s00228-010-0965-4
   Crosby T, 2013, LANCET ONCOL, V14, P627, DOI 10.1016/S1470-2045(13)70136-0
   Dutton SJ, 2014, LANCET ONCOL, V15, P894, DOI 10.1016/S1470-2045(14)70024-5
   Egger M, 1997, BMJ-BRIT MED J, V315, P629, DOI 10.1136/bmj.315.7109.629
   Goss GD, 2013, J CLIN ONCOL, V31, P3320, DOI 10.1200/JCO.2013.51.1816
   Higgins JPT, 2003, BMJ-BRIT MED J, V327, P557, DOI 10.1136/bmj.327.7414.557
   Higgins JPT, 2008, Cochrane Handbook for Systematic Reviews of Interventions, DOI [10.1002/9780470712184, DOI 10.1002/9780470712184]
   Huang XZ, 2015, INT J CANCER, V136, P21, DOI 10.1002/ijc.28954
   Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4
   Janjigian YY, 2011, J THORAC ONCOL, V6, P569, DOI 10.1097/JTO.0b013e318202bffe
   Ku GY, 2012, CANCER CHEMOTH PHARM, V70, P231, DOI 10.1007/s00280-012-1898-7
   Laporte S, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2012-001802
   Lara PN, 2008, J CLIN ONCOL, V26, P463, DOI 10.1200/JCO.2007.13.0344
   Lee JK, 2014, JAMA-J AM MED ASSOC, V311, P1430, DOI 10.1001/jama.2014.3314
   Lordick F, 2010, BRIT J CANCER, V102, P500, DOI 10.1038/sj.bjc.6605521
   Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5
   Lorenzen S, 2009, ANN ONCOL, V20, P1667, DOI 10.1093/annonc/mdp069
   Luo HQ, 2014, ASIAN PAC J CANCER P, V15, P5343, DOI 10.7314/APJCP.2014.15.13.5343
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Moehler M, 2011, ANN ONCOL, V22, P1358, DOI 10.1093/annonc/mdq591
   Moher D, 2000, ONKOLOGIE, V23, P597, DOI 10.1159/000055014
   Pang XH, 2014, TUMOR BIOL, V35, P387, DOI 10.1007/s13277-013-1054-y
   Panic N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083138
   Petty RD, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.4016
   Qiu MZ, 2013, BIOMARK RES, V1, DOI 10.1186/2050-7771-1-32
   Rao S, 2010, ANN ONCOL, V21, P2213, DOI 10.1093/annonc/mdq247
   Richards D, 2013, EUR J CANCER, V49, P2823, DOI 10.1016/j.ejca.2013.04.022
   Tian W, 2013, PANCREATOLOGY, V13, P415, DOI 10.1016/j.pan.2013.04.195
   Tierney JF, 2007, TRIALS, V8, DOI 10.1186/1745-6215-8-16
   Villela DL, 2010, GROWTH FACTORS, V28, P111, DOI 10.3109/08977190903468185
   Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2
NR 36
TC 5
Z9 5
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 0897-7194
EI 1029-2292
J9 GROWTH FACTORS
JI Growth Factors
PD APR
PY 2015
VL 33
IS 2
BP 113
EP 127
DI 10.3109/08977194.2015.1010643
PG 15
WC Cell Biology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Endocrinology & Metabolism
GA CI1EZ
UT WOS:000354486700006
PM 25697183
DA 2025-01-04
ER

PT J
AU Xia, ZL
   Kong, FH
   Wang, KP
   Zhang, X
AF Xia, Zhelin
   Kong, Fanhua
   Wang, Kunpeng
   Zhang, Xin
TI Role of N6-Methyladenosine Methylation Regulators in the Drug Therapy of
   Digestive System Tumours
SO FRONTIERS IN PHARMACOLOGY
LA English
DT Review
DE digestive system tumors; N6-methyladenosine; drug resistance;
   chemotherapy; immunotherapy
ID HEPATOCELLULAR-CARCINOMA; SORAFENIB RESISTANCE; MOLECULAR-MECHANISMS;
   DEMETHYLASE ALKBH5; TARGETED THERAPY; 1ST-LINE THERAPY; COLON-CANCER;
   RNA; CISPLATIN; PROTEIN
AB Digestive system tumours, including stomach, colon, esophagus, liver and pancreatic tumours, are serious diseases affecting human health. Although surgical treatment and postoperative chemoradiotherapy effectively improve patient survival, current diagnostic and therapeutic strategies for digestive system tumours lack sensitivity and specificity. Moreover, the tumour's tolerance to drug therapy is enhanced owing to tumour cell heterogeneity. Thus, primary or acquired treatment resistance is currently the main hindrance to chemotherapy efficiency. N6-methyladenosine (m6A) has various biological functions in RNA modification. m6A modification, a key regulator of transcription expression, regulates RNA metabolism and biological processes through the interaction of m6A methyltransferase ( "writers ") and demethylase ( "erasers ") with the binding protein decoding m6A methylation ( "readers "). Additionally, m6A modification regulates the occurrence and development of tumours and is a potential driving factor of tumour drug resistance. This review systematically summarises the regulatory mechanisms of m6A modification in the drug therapy of digestive system malignancies. Furthermore, it clarifies the related mechanisms and therapeutic prospects of m6A modification in the resistence of digestive system malignancies to drug therapy.
C1 [Xia, Zhelin; Zhang, Xin] Taizhou Univ Hosp, Taizhou Cent Hosp, Dept Pharm, Taizhou, Peoples R China.
   [Kong, Fanhua] Wuhan Univ, Zhongnan Hosp, Inst Hepatobiliary Dis Wuhan Univ, Transplant Ctr Wuhan Univ,Natl Qual Control Ctr Do, Wuhan, Peoples R China.
   [Wang, Kunpeng] Taizhou Univ, Dept Gen Surg Taizhou Cent Hosp, Hosp, Taizhou, Peoples R China.
C3 Taizhou University; Wuhan University
RP Zhang, X (corresponding author), Taizhou Univ Hosp, Taizhou Cent Hosp, Dept Pharm, Taizhou, Peoples R China.
EM zx1360576@126.com
RI Wang, Kunpeng/HCH-0099-2022
OI Wang, Kunpeng/0000-0001-5088-2548
FU Science and Technology Plan Project of Taizhou [21ywb36, 20ywb41]
FX Funding This project was supported by the grants from Science and
   Technology Plan Project of Taizhou (Nos. 21ywb36 and 20ywb41).
CR Aik W, 2014, NUCLEIC ACIDS RES, V42, P4741, DOI 10.1093/nar/gku085
   Al-Salama ZT, 2019, DRUGS, V79, P665, DOI 10.1007/s40265-019-01116-x
   Allen WL, 2005, J CLIN ONCOL, V23, P4545, DOI 10.1200/JCO.2005.19.752
   Amrutkar M, 2017, CANCERS, V9, DOI 10.3390/cancers9110157
   Annapoorna PK, 2019, NEUROSCIENCE, V418, P15, DOI 10.1016/j.neuroscience.2019.08.021
   Bansal H, 2014, LEUKEMIA, V28, P1171, DOI 10.1038/leu.2014.16
   Benson AB., 2021, J. Natl. Compr. Canc. Netw., V19, P329, DOI DOI 10.6004/JNCCN.2021.0012
   Boku N, 2019, ANN ONCOL, V30, P250, DOI 10.1093/annonc/mdy540
   Cervello M, 2012, ONCOTARGET, V3, P236, DOI 10.18632/oncotarget.466
   Chen BE, 2012, J AM CHEM SOC, V134, P17963, DOI 10.1021/ja3064149
   Chen B, 2018, WORLD J CLIN CASES, V6, P650, DOI 10.12998/wjcc.v6.i13.650
   Chen MN, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01172-y
   Chen P, 2021, MOL THER-ONCOLYTICS, V20, P228, DOI 10.1016/j.omto.2021.01.001
   Chen WH, 2021, MEDICINE, V100, DOI 10.1097/MD.0000000000026265
   Chen YS, 2021, EMBO REP, V22, DOI 10.15252/embr.202052146
   Chen ZY, 2021, MOL THER-NUCL ACIDS, V26, P1270, DOI 10.1016/j.omtn.2021.10.023
   Chesney TR, 2021, EJSO-EUR J SURG ONC, V47, P888, DOI 10.1016/j.ejso.2020.09.009
   Cho Sung Hwan, 2018, Ann Hepatobiliary Pancreat Surg, V22, P305, DOI 10.14701/ahbps.2018.22.4.305
   Dagogo-Jack I, 2018, NAT REV CLIN ONCOL, V15, P81, DOI 10.1038/nrclinonc.2017.166
   Dai DJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0129-x
   Dasari S, 2014, EUR J PHARMACOL, V740, P364, DOI 10.1016/j.ejphar.2014.07.025
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Doxtader KA, 2018, MOL CELL, V71, P1001, DOI 10.1016/j.molcel.2018.07.025
   Feng ST, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20200842
   Galluzzi L, 2012, ONCOGENE, V31, P1869, DOI 10.1038/onc.2011.384
   Gan ZD, 2019, ACS OMEGA, V4, P17438, DOI 10.1021/acsomega.9b02236
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gerken T, 2007, SCIENCE, V318, P1469, DOI 10.1126/science.1151710
   Geuens T, 2016, HUM GENET, V135, P851, DOI 10.1007/s00439-016-1683-5
   Ghazi T, 2021, EPIGENETICS-US, V16, P79, DOI 10.1080/15592294.2020.1788324
   Guo XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01158-w
   Han ZF, 2010, NATURE, V464, P1205, DOI 10.1038/nature08921
   Harada K, 2021, GASTRIC CANCER, V24, P1264, DOI 10.1007/s10120-021-01206-4
   He LE, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1109-9
   Hsu PJ, 2017, CELL RES, V27, P1115, DOI 10.1038/cr.2017.99
   Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x
   Hu Y, 2020, CELL DEATH DIFFER, V27, P2468, DOI 10.1038/s41418-020-0516-1
   Huang HL, 2020, TRENDS GENET, V36, P44, DOI 10.1016/j.tig.2019.10.011
   Huang SH, 2021, MOL THER-NUCL ACIDS, V24, P542, DOI 10.1016/j.omtn.2021.02.020
   Huang WJ, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.827956
   Huff S, 2021, ACS CHEM BIOL, V16, P324, DOI 10.1021/acschembio.0c00841
   Huo FC, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12921
   Iacovelli R, 2015, CURR DRUG TARGETS, V16, P164, DOI 10.2174/1389450115666141120120145
   Jain S, 2017, ANN CARDIOTHORAC SUR, V6, P99, DOI 10.21037/acs.2017.03.06
   Jin D, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01161-1
   Johnston FM, 2019, CURR ONCOL REP, V21, DOI 10.1007/s11912-019-0820-4
   Kang YK, 2020, LANCET ONCOL, V21, P1045, DOI 10.1016/S1470-2045(20)30315-6
   Kant R, 2021, J MED CHEM, V64, P8992, DOI 10.1021/acs.jmedchem.1c00093
   Kong FH, 2021, THERANOSTICS, V11, P5464, DOI 10.7150/thno.54822
   Kong FH, 2019, WORLD J CLIN CASES, V7, P3734, DOI 10.12998/wjcc.v7.i22.3734
   Kong FH, 2020, PHOTODIAGN PHOTODYN, V29, DOI 10.1016/j.pdpdt.2020.101663
   Kong FH, 2020, INT J BIOCHEM CELL B, V122, DOI 10.1016/j.biocel.2020.105731
   Kong HF, 2022, BIOENGINEERED, V13, P3108, DOI 10.1080/21655979.2022.2025701
   Lan HR, 2021, MOL PHARMACEUT, V18, P1026, DOI 10.1021/acs.molpharmaceut.0c00961
   Lan L, 2021, ANGEW CHEM INT EDIT, V60, P18116, DOI 10.1002/anie.202103854
   Lee JC, 2022, CLIN CANCER RES, V28, P5, DOI 10.1158/1078-0432.CCR-21-1193
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li HF, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-022-04129-0
   Li JJ, 2022, J ONCOL, V2022, DOI 10.1155/2022/5490461
   Li JQ, 2021, COMPUT MATH METHOD M, V2021, DOI 10.1155/2021/1001446
   Li Q, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-020-00453-8
   Liang XY, 2021, BIOENGINEERED, V12, P10023, DOI 10.1080/21655979.2021.1994721
   Lin ZY, 2020, EMBO J, V39, DOI 10.15252/embj.2019103181
   Lipson EJ, 2015, SEMIN ONCOL, V42, P587, DOI 10.1053/j.seminoncol.2015.05.013
   Liu H, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01555-3
   Liu L, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01508-w
   Liu Q, 2022, J GASTROEN HEPATOL, V37, P700, DOI 10.1111/jgh.15775
   Liu X, 2019, ONCOTARGETS THER, V12, P10153, DOI 10.2147/OTT.S223668
   Liu ZC, 2021, CLIN TRANSL MED, V11, DOI 10.1002/ctm2.545
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Llovet JM, 2021, NAT REV DIS PRIMERS, V7, DOI 10.1038/s41572-020-00240-3
   Llovet JM, 2018, NAT REV CLIN ONCOL, V15, P599, DOI 10.1038/s41571-018-0073-4
   Lu JJ, 2020, CHIN J NAT MEDICINES, V18, P481, DOI 10.1016/S1875-5364(20)30057-1
   Luo MC, 2022, CELL MOL GASTROENTER, V13, P1223, DOI 10.1016/j.jcmgh.2021.12.011
   Ma S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0805-7
   Machlowska J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21114012
   López AM, 2021, GENES-BASEL, V12, DOI 10.3390/genes12071019
   Miller KD, 2020, CA-CANCER J CLIN, V70, P443, DOI 10.3322/caac.21637
   Mizrahi JD, 2020, LANCET, V395, P2008, DOI 10.1016/S0140-6736(20)30974-0
   Mou YH, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0720-y
   Palazzo A, 2010, CURR CANCER DRUG TAR, V10, P433, DOI 10.2174/156800910791517145
   Pan SL, 2022, INT J ONCOL, V60, DOI 10.3892/ijo.2022.5304
   Paul D, 2020, DRUG DISCOV TODAY, V26, P80, DOI 10.1016/j.drudis.2020.10.010
   Pavitra E, 2021, SEMIN CANCER BIOL, V69, P293, DOI 10.1016/j.semcancer.2019.06.017
   Peng SM, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aau7116
   Qiu XY, 2022, INT J GEN MED, V15, P523, DOI 10.2147/IJGM.S344146
   Qu JW, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01224-4
   Rafalska I, 2004, HUM MOL GENET, V13, P1535, DOI 10.1093/hmg/ddh167
   Relier S, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21758-4
   Sawicki T, 2021, CANCERS, V13, DOI 10.3390/cancers13092025
   Schizas D, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102016
   Schöller E, 2018, RNA, V24, P499, DOI 10.1261/rna.064063.117
   Seebacher NA, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1094-2
   Shen HF, 2020, BIOMARK RES, V8, DOI 10.1186/s40364-020-00203-6
   Shi RK, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03625-8
   Smyth EC, 2020, LANCET, V396, P635, DOI 10.1016/S0140-6736(20)31288-5
   Song ZY, 2021, LIFE SCI, V276, DOI 10.1016/j.lfs.2021.119399
   Su R, 2020, CANCER CELL, V38, P79, DOI 10.1016/j.ccell.2020.04.017
   Sun T, 2020, ONCOGENE, V39, P5358, DOI 10.1038/s41388-020-1338-9
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Taketo K, 2018, INT J ONCOL, V52, P621, DOI 10.3892/ijo.2017.4219
   Tang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-019-1128-6
   Uddin MB, 2019, BIOCHEM PHARMACOL, V160, P134, DOI 10.1016/j.bcp.2018.12.014
   Wang JW, 2016, GASTRIC CANCER, V19, P234, DOI 10.1007/s10120-015-0457-4
   Wang JY, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01450-1
   Wang KP, 2021, DRUG DES DEV THER, V15, P3749, DOI 10.2147/DDDT.S323360
   Wang LL, 2020, EMBO J, V39, DOI 10.15252/embj.2020104514
   Wang X, 2017, RNA BIOL, V14, P300, DOI 10.1080/15476286.2017.1282025
   Wang X, 2015, CELL, V161, P1388, DOI 10.1016/j.cell.2015.05.014
   Wang X, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-01871-4
   Wojtas MN, 2017, MOL CELL, V68, P374, DOI 10.1016/j.molcel.2017.09.021
   Xu JJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01281-8
   Xu KC, 2019, ANAL BIOCHEM, V578, P45, DOI 10.1016/j.ab.2019.05.005
   Xu WB, 2021, DRUG DES DEV THER, V15, P577, DOI 10.2147/DDDT.S291865
   Xu ZJ, 2020, BIOCHEM PHARMACOL, V182, DOI 10.1016/j.bcp.2020.114258
   Yan YL, 2021, PEERJ, V9, DOI 10.7717/peerj.12171
   Yang ZM, 2021, AM J CANCER RES, V11, P1428
   Yu SH, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01407
   Zeng CW, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00951-w
   Zeng SY, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184504
   Zhang B, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01170-0
   Zhang CJ, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.696371
   Zhang LF, 2019, FOOD FUNCT, V10, P216, DOI [10.1039/c8fo02004c, 10.1039/C8FO02004C]
   Zhang RH, 2021, NAT PROD REP, V38, P346, DOI 10.1039/d0np00043d
   Zhang XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01171-z
   Zhao BXS, 2017, NATURE, V542, P475, DOI 10.1038/nature21355
   Zheng FC, 2021, BIOMARK RES, V9, DOI 10.1186/s40364-021-00295-8
   Zhi Y., 2022, WIRES RNA, pe1719, DOI [10.1002/wrna.1719, DOI 10.1002/WRNA.1719]
   Zhou LL, 2021, RSC CHEM BIOL, V2, P1352, DOI 10.1039/d1cb00075f
   Zhu DH, 2019, J CELL PHYSIOL, V234, P8899, DOI 10.1002/jcp.27551
   Zhu LY, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1585-2
   Zhu YJ, 2017, ACTA PHARMACOL SIN, V38, P614, DOI 10.1038/aps.2017.5
   Zhu YR, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.703
   Zou J, 2021, BIOCHEM BIOPH RES CO, V580, P48, DOI 10.1016/j.bbrc.2021.05.048
NR 134
TC 4
Z9 4
U1 3
U2 29
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1663-9812
J9 FRONT PHARMACOL
JI Front. Pharmacol.
PD JUN 9
PY 2022
VL 13
AR 908079
DI 10.3389/fphar.2022.908079
PG 15
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA 2I4CF
UT WOS:000814927500001
PM 35754499
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Pu, WG
   Ma, CH
   Wang, BF
   Zhu, WD
   Chen, H
AF Pu, Weigao
   Ma, Chenhui
   Wang, Bofang
   Zhu, Weidong
   Chen, Hao
TI The "Heater" of "Cold" Tumors-Blocking IL-6
SO ADVANCED BIOLOGY
LA English
DT Review
DE immunotherapy; inflammation; interleukin-6; irAEs; targeted therapy;
   tumor
ID NECROSIS-FACTOR-ALPHA; HEPATOCELLULAR-CARCINOMA; COLORECTAL-CANCER;
   INTERLEUKIN-6; INFLAMMATION; IMMUNOTHERAPY; METASTASIS; ACTIVATION;
   CELLS; MICROENVIRONMENT
AB The resolution of inflammation is not simply the end of the inflammatory response but rather a complex process that involves various cells, inflammatory factors, and specialized proresolving mediators following the occurrence of inflammation. Once inflammation cannot be cleared by the body, malignant tumors may be induced. Among them, IL-6, as an immunosuppressive factor, activates a variety of signal transduction pathways and induces tumorigenesis. Monitoring IL-6 can be used for the diagnosis, efficacy evaluation and prognosis of tumor patients. In terms of treatment, improving the efficacy of targeted and immunotherapy remains a major challenge. Blocking IL-6 and its mediated signaling pathways can regulate the tumor immune microenvironment and enhance immunotherapy responses by activating immune cells. Even transform "cold" tumors that are difficult to respond to immunotherapy into immunogenic "hot" tumors, acting as a "heater" for "cold" tumors, restarting the tumor immune cycle, and reducing immunotherapy-related toxic reactions and drug resistance. In clinical practice, the combined application of IL-6 inhibition with targeted therapy and immunotherapy may produce synergistic results. Nevertheless, additional clinical trials are imperative to further validate the safety and efficacy of this therapeutic approach.
   Malignant tumor progression is intricately linked to inflammation and its impact on targeted and immunotherapy responses. IL-6, a vital cytokine, serves as a key biomarker for tumor development. Notably, inhibiting IL-6 and its signaling pathways has emerged as a strategy to transform resistant "cold" tumors into responsive "hot" tumors, enhancing the effectiveness of targeted and immunotherapies. image
C1 [Pu, Weigao; Ma, Chenhui; Wang, Bofang; Chen, Hao] Lanzhou Univ, Clin Med Coll 2, Lanzhou 730030, Peoples R China.
   [Pu, Weigao; Ma, Chenhui; Wang, Bofang; Chen, Hao] Lanzhou Univ, Dept Tumour Surg, Hosp 2, Lanzhou 730030, Peoples R China.
   [Zhu, Weidong] Lintao Cty Peoples Hosp Gansu Prov, Gen Surg Dept, Lanzhou 730030, Gansu, Peoples R China.
   [Chen, Hao] Gansu Prov Key Lab Environm Oncol, Lanzhou 730030, Gansu, Peoples R China.
C3 Lanzhou University; Lanzhou University
RP Chen, H (corresponding author), Lanzhou Univ, Clin Med Coll 2, Lanzhou 730030, Peoples R China.; Zhu, WD (corresponding author), Lintao Cty Peoples Hosp Gansu Prov, Gen Surg Dept, Lanzhou 730030, Gansu, Peoples R China.
EM zwd101@sina.com; ery_chenh@lzu.edu.cn
OI Pu, weigao/0000-0001-7824-0176
FU National Natural Science Foundation of China; Key Project of Science and
   Technology in Gansu province [22ZD6FA054]; Medical Innovation and
   Development Project of Lanzhou University [lzuyxcx-2022-45]; Gansu
   Province Innovation Driven Assistance Project [GXH20230817-14]; 
   [82160129]
FX This research was supported by the National Natural Science Foundation
   of China (82160129), Key Project of Science and Technology in Gansu
   province (22ZD6FA054), Medical Innovation and Development Project of
   Lanzhou University (lzuyxcx-2022-160), Medical Innovation and
   Development Project of Lanzhou University (lzuyxcx-2022-45), Gansu
   Province Innovation Driven Assistance Project (GXH20230817-14).
CR Abaurrea A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22158334
   Aigner P, 2019, CYTOKINE, V118, P27, DOI 10.1016/j.cyto.2018.07.014
   Ataie-Kachoie P, 2014, J CLIN PATHOL, V67, P932, DOI 10.1136/jclinpath-2014-202493
   Bader JE, 2020, MOL CELL, V78, P1019, DOI 10.1016/j.molcel.2020.05.034
   Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003
   Balkwill F, 2001, LANCET, V357, P539, DOI 10.1016/S0140-6736(00)04046-0
   Bayliss TJ, 2011, EXPERT OPIN BIOL TH, V11, P1663, DOI 10.1517/14712598.2011.627850
   Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808
   Blidner AG, 2020, SUPPORT CARE CANCER, V28, P6111, DOI 10.1007/s00520-020-05705-5
   Boige V, 2012, ONCOLOGIST, V17, P1063, DOI 10.1634/theoncologist.2011-0465
   Bose P, 2020, LEUKEMIA LYMPHOMA, V61, P1797, DOI 10.1080/10428194.2020.1749606
   Brábek J, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21217937
   Bridelance J, 2017, CURR DRUG TARGETS, V18, P964, DOI 10.2174/1389450117666161028142351
   Browning L, 2018, CANCER MANAG RES, V10, P6685, DOI 10.2147/CMAR.S179189
   Burkholder B, 2014, BBA-REV CANCER, V1845, P182, DOI 10.1016/j.bbcan.2014.01.004
   Ceschi A, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00557
   Chan LC, 2019, J CLIN INVEST, V129, P3324, DOI 10.1172/JCI126022
   Chen J, 2016, ONCOTARGETS THER, V9, P223, DOI 10.2147/OTT.S91420
   Chen MF, 2013, MOL CANCER, V12, DOI 10.1186/1476-4598-12-26
   Chen YQ, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0646-5
   Chu YY, 2022, AURIS NASUS LARYNX, V49, P1009, DOI 10.1016/j.anl.2022.04.009
   Crusz SM, 2015, NAT REV CLIN ONCOL, V12, P584, DOI 10.1038/nrclinonc.2015.105
   Culig Z, 2018, MOL CELL ENDOCRINOL, V462, P25, DOI 10.1016/j.mce.2017.03.012
   De Craene B, 2013, NAT REV CANCER, V13, P97, DOI 10.1038/nrc3447
   Delyon J, 2022, CANCER CELL, V40, P450, DOI 10.1016/j.ccell.2022.04.010
   Derosa G, 2016, PHARMACOL RES, V111, P394, DOI 10.1016/j.phrs.2016.07.004
   Drakaki A, 2023, CLIN CANCER RES, V29, P4373, DOI 10.1158/1078-0432.CCR-23-0798
   Elia G, 2020, BEST PRACT RES CL EN, V34, DOI 10.1016/j.beem.2019.101370
   Endo S, 2017, GASTROENTEROLOGY, V152, P1492, DOI 10.1053/j.gastro.2017.01.010
   Eriksson E, 2019, J IMMUNOL, V202, P787, DOI 10.4049/jimmunol.1800717
   Fan Y, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5471-1
   Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0
   Fang Y, 2022, CANCER LETT, V546, DOI 10.1016/j.canlet.2022.215839
   Fang ZQ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0062823
   Feurino LW, 2007, CANCER BIOL THER, V6, P1096, DOI 10.4161/cbt.6.7.4328
   Fountzilas C, 2020, BRIT J CANCER, V122, P963, DOI 10.1038/s41416-020-0737-6
   Gardner R, 2016, BLOOD, V128, DOI 10.1182/blood.V128.22.586.586
   Garnier L, 2018, J IMMUNOL, V201, P3218, DOI 10.4049/jimmunol.1800417
   Gérard A, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002512
   Ghandadi M, 2017, CURR PHARM DESIGN, V23, P921, DOI 10.2174/1381612822666161006151605
   Goldberg J, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.674192
   Goto H, 2015, J CANCER RES CLIN, V141, P465, DOI 10.1007/s00432-014-1842-9
   Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025
   Gukovsky I, 2013, GASTROENTEROLOGY, V144, P1199, DOI 10.1053/j.gastro.2013.02.007
   Guo DW, 2017, ONCOTARGET, V8, P39640, DOI 10.18632/oncotarget.17387
   Hailemichael Y, 2022, CANCER CELL, V40, P509, DOI 10.1016/j.ccell.2022.04.004
   Han IH, 2020, PLOS NEGLECT TROP D, V14, DOI 10.1371/journal.pntd.0008126
   Han XT, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.643986
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Handle F, 2018, MOL CANCER THER, V17, P2722, DOI 10.1158/1535-7163.MCT-18-0508
   Harrison CN, 2020, AM J HEMATOL, V95, P594, DOI 10.1002/ajh.25777
   Hashimoto S, 2022, SEMIN CANCER BIOL, V86, P310, DOI 10.1016/j.semcancer.2022.03.017
   Heo TH, 2016, ONCOTARGET, V7, P15460, DOI 10.18632/oncotarget.7102
   HIRANO T, 1986, NATURE, V324, P73, DOI 10.1038/324073a0
   Hirano T, 2021, INT IMMUNOL, V33, P127, DOI 10.1093/intimm/dxaa078
   Hou ZY, 2015, MED ONCOL, V32, DOI 10.1007/s12032-014-0328-6
   Huang QY, 2020, EUR J MED CHEM, V187, DOI 10.1016/j.ejmech.2019.111922
   Hunter CA, 2015, NAT IMMUNOL, V16, P448, DOI 10.1038/ni.3153
   Jaillon S, 2020, NAT REV CANCER, V20, P485, DOI 10.1038/s41568-020-0281-y
   Jara MDJ, 2020, CUREUS J MED SCIENCE, V12, DOI 10.7759/cureus.9969
   Jiang T, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00751-9
   Jin B, 2014, AGING CELL, V13, P879, DOI 10.1111/acel.12249
   Jo DH, 2019, GLIA, V67, P321, DOI 10.1002/glia.23542
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Johnson DH, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0412-0
   Johnston PA, 2018, METHODS MOL BIOL, V1683, P229, DOI 10.1007/978-1-4939-7357-6_14
   Jones SA, 2018, NAT REV IMMUNOL, V18, P773, DOI 10.1038/s41577-018-0066-7
   Kang SJ, 2020, J EXP MED, V217, DOI 10.1084/jem.20190347
   Kennedy LB, 2020, CA-CANCER J CLIN, V70, P86, DOI 10.3322/caac.21596
   Khan MGM, 2019, CYTOKINE, V121, DOI 10.1016/j.cyto.2019.154733
   Kim BH, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030722
   Kolomeyevskaya N, 2015, GYNECOL ONCOL, V138, P352, DOI 10.1016/j.ygyno.2015.05.009
   Korbecki J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910701
   Korn T, 2021, CYTOKINE, V146, DOI 10.1016/j.cyto.2021.155654
   Kowalski B, 2022, J CANCER RES CLIN, V148, P1711, DOI 10.1007/s00432-021-03750-z
   Lavy M, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.702785
   Leko V, 2020, CANCER CELL, V38, P454, DOI 10.1016/j.ccell.2020.07.013
   Li JJ, 2020, INT J BIOL SCI, V16, P2323, DOI 10.7150/ijbs.46651
   Lim AM, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.656611
   Lipe DN, 2021, CLIN TOXICOL, V59, P376, DOI 10.1080/15563650.2021.1880008
   Liu CM, 2022, BMC MED, V20, DOI 10.1186/s12916-022-02356-7
   Liu H, 2017, BIOCHEM BIOPH RES CO, V486, P239, DOI 10.1016/j.bbrc.2017.02.128
   Liu LL, 2023, J EXP CLIN CANC RES, V42, DOI 10.1186/s13046-023-02647-8
   Liu W, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12776
   Liu Y, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0959-0
   Luo GJ, 2017, RECENT PAT ANTI-CANC, V12, P221, DOI 10.2174/1574892812666170606123113
   Maeda Y, 2020, ESOPHAGUS-TOKYO, V17, P279, DOI 10.1007/s10388-019-00708-6
   Matsusaka S, 2016, CLIN CANCER RES, V22, P3218, DOI 10.1158/1078-0432.CCR-15-2422
   Mendez-Clemente A, 2022, ONCOL REP, V48, DOI 10.3892/or.2022.8349
   Mesquida M, 2017, AUTOIMMUN REV, V16, P1079, DOI 10.1016/j.autrev.2017.08.002
   Miller KD, 2019, CA-CANCER J CLIN, V69, P363, DOI 10.3322/caac.21565
   Mortezaee K, 2021, LIFE SCI, V286, DOI 10.1016/j.lfs.2021.120057
   Mu XM, 2018, CELL CYCLE, V17, P428, DOI 10.1080/15384101.2018.1444305
   Murakami M, 2019, IMMUNITY, V50, P812, DOI 10.1016/j.immuni.2019.03.027
   Murata M, 2018, ENVIRON HEALTH PREV, V23, DOI 10.1186/s12199-018-0740-1
   Muthusami S, 2021, ENDOCR METAB IMMUNE, V21, P77, DOI 10.2174/1871530320666200909092908
   Myojin Y, 2022, CANCERS, V14, DOI 10.3390/cancers14040883
   Niu X, 2022, SEMIN CANCER BIOL, V86, P273, DOI 10.1016/j.semcancer.2022.03.009
   Ohno Y, 2016, CANCER IMMUNOL IMMUN, V65, P193, DOI 10.1007/s00262-015-1791-4
   Okada F, 2021, CANCERS, V13, DOI 10.3390/cancers13040921
   Okamura S, 2013, ANTICANCER RES, V33, P1483
   Pedersen JG, 2022, CANCERS, V14, DOI 10.3390/cancers14143342
   Qin SK, 2020, CANCER SCI, V111, P4218, DOI 10.1111/cas.14641
   Radharani NNV, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935-022-02527-9
   Rashid M, 2021, GENE, V798, DOI 10.1016/j.gene.2021.145796
   Rasková M, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11223698
   Rupert JE, 2021, J EXP MED, V218, DOI 10.1084/jem.20190450
   Ruzzo A, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-357
   Salomon BL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00444
   Sanguinetti A, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0529-2
   Setrerrahmane S, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0721-9
   Shah SC, 2022, GASTROENTEROLOGY, V162, P715, DOI 10.1053/j.gastro.2021.10.035
   Shiravand Y, 2022, CURR ONCOL, V29, P3044, DOI 10.3390/curroncol29050247
   Siersbæk R, 2020, CANCER CELL, V38, P412, DOI 10.1016/j.ccell.2020.06.007
   Sobah ML, 2021, FRONT MED-LAUSANNE, V8, DOI 10.3389/fmed.2021.727987
   Spanko M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222011027
   Stroud CRG, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.e21712
   Tan T, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11235-4
   Tanaka T, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028456
   Taniguchi K, 2014, SEMIN IMMUNOL, V26, P54, DOI 10.1016/j.smim.2014.01.001
   Tannahill GM, 2013, NATURE, V496, P238, DOI 10.1038/nature11986
   Tao BR, 2023, BIOCHEM GENET, DOI 10.1007/s10528-023-10591-7
   Thompson JA, 2022, J NATL COMPR CANC NE, V20, P387, DOI 10.6004/jnccn.2022.0020
   Trovato M, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4940
   Tsukamoto H, 2018, CANCER RES, V78, P5011, DOI 10.1158/0008-5472.CAN-18-0118
   Tsukamoto H, 2017, CANCER RES, V77, P2279, DOI 10.1158/0008-5472.CAN-16-2446
   Tümen D, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10123202
   Uddin MJ, 2022, FITOTERAPIA, V158, DOI 10.1016/j.fitote.2022.105164
   Vainer Noomi, 2018, Oncotarget, V9, P29820, DOI 10.18632/oncotarget.25661
   Valença-Pereira F, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2103444118
   Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5
   Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923
   Wang Hanping, 2019, Zhongguo Fei Ai Za Zhi, V22, P605, DOI 10.3779/j.issn.1009-3419.2019.10.01
   Wang LM, 2017, ONCOTARGET, V8, P76116, DOI 10.18632/oncotarget.18814
   Wang ST, 2020, CELL DEATH DISCOV, V6, DOI 10.1038/s41420-020-0252-9
   Weber R, 2021, CELL IMMUNOL, V359, DOI 10.1016/j.cellimm.2020.104254
   Wu SY, 2021, INT J PHARMACEUT, V598, DOI 10.1016/j.ijpharm.2021.120333
   Xia TT, 2021, PHYTOTHER RES, V35, P6720, DOI 10.1002/ptr.7258
   Xiong GF, 2020, P NATL ACAD SCI USA, V117, P3748, DOI 10.1073/pnas.1911951117
   Xu S, 2018, MOL CANCER THER, V17, P1291, DOI 10.1158/1535-7163.MCT-17-0927
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yang F, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23832-3
   Yin Y, 2017, CLIN CANCER RES, V23, P7375, DOI 10.1158/1078-0432.CCR-17-1283
   Yoshimura A, 2018, CSH PERSPECT BIOL, V10, DOI 10.1101/cshperspect.a028571
   Yu JL, 2021, NAT MED, V27, P152, DOI 10.1038/s41591-020-1131-x
   Zanders L, 2022, J CACHEXIA SARCOPENI, V13, P713, DOI 10.1002/jcsm.12867
   Zhang HX, 2019, INT J BIOCHEM CELL B, V110, P130, DOI 10.1016/j.biocel.2019.02.006
   Zhang M, 2020, J HEPATOL, V73, P1118, DOI 10.1016/j.jhep.2020.05.039
   Zhang W., 2020, J IMMUNOTHER CANCER, V8
   Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6
   Zheng J, 2015, EUR J IMMUNOL, V45, P2834, DOI 10.1002/eji.201445344
   Zheng XB, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.617597
NR 152
TC 0
Z9 0
U1 1
U2 1
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 2701-0198
J9 ADV BIOL-GER
JI Adv. Biol.
PD JUL
PY 2024
VL 8
IS 7
DI 10.1002/adbi.202300587
EA MAY 2024
PG 16
WC Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Materials Science
GA ZC6E7
UT WOS:001228402500001
PM 38773937
OA hybrid
DA 2025-01-04
ER

PT J
AU Zhang, N
   Li, YS
AF Zhang, Nan
   Li, Yongsheng
TI Receptor tyrosine kinases: biological functions and anticancer targeted
   therapy
SO MEDCOMM
LA English
DT Review
DE classification; gene mutation; receptor activation; receptor tyrosine
   kinases; targeted therapy
ID FIBROBLAST-GROWTH-FACTOR; CELL LUNG-CANCER; MET ONCOGENIC REARRANGEMENT;
   PHASE-II TRIAL; BREAST-CANCER; PROSTATE-CANCER; STEM-CELLS;
   COLORECTAL-CANCER; C-MET; JUXTAMEMBRANE DOMAIN
AB Receptor tyrosine kinases (RTKs) are a class of protein kinases that play crucial roles in various cellular processes, including cell migration, morphological differentiation, cell growth, and angiogenesis. In humans, 58 RTKs have been identified and categorized into 20 distinct families based on the composition of their extracellular regions. RTKs are primarily activated by specific ligands that bind to their extracellular region. They not only regulate tumor transformation, proliferation, metastasis, drug resistance, and angiogenesis, but also initiate and maintain the self-renewal and cloning ability of cancer stem cells. Accurate diagnosis and grading of tumors with dysregulated RTKs are essential in clinical practice. There is a growing body of evidence supporting the benefits of RTKs-targeted therapies for cancer patients, and researchers are actively exploring new targets and developing targeted agents. However, further optimization of RTK inhibitors is necessary to effectively target the diverse RTK alterations observed in human cancers. This review provides insights into the classification, structure, activation mechanisms, and expression of RTKs in tumors. It also highlights the research advances in RTKs targeted anticancer therapy and emphasizes their significance in optimizing cancer diagnosis and treatment strategies.
   RTKs play a crucial role in the development of cancer. RTKs affect transcription-factor activation and histone/chromatin modification by activating downstream pathways such as MAPK/ERK and PI3K/AKT, which in turn cause proliferation, resistance, metastasis, angiogenesis, and invasion of tumors.image
C1 [Zhang, Nan; Li, Yongsheng] Chongqing Univ, Canc Hosp, Sch Med, Chongqing, Peoples R China.
   [Li, Yongsheng] Chongqing Univ, Dept Med Oncol, Canc Hosp, Chongqing, Peoples R China.
   [Li, Yongsheng] Chongqing Univ, Sch Med, Chongqing 400044, Peoples R China.
C3 Chongqing University; Chongqing University; Chongqing University
RP Li, YS (corresponding author), Chongqing Univ, Sch Med, Chongqing 400044, Peoples R China.
EM lys@cqu.edu.cn
RI zhang, nan/HLP-9573-2023
FU Major International (Regional) Joint Research Program of the National
   Natural Science Foundation of China
FX We sincerely thank the editors and reviewers for all of their efforts on
   improving this paper.
CR Achcar RDD, 2009, AM J CLIN PATHOL, V131, P694, DOI 10.1309/AJCPBS85VJEOBPDO
   Ai J, 2018, MOL CANCER THER, V17, P751, DOI 10.1158/1535-7163.MCT-17-0368
   Aisner DL, 2014, MOL CANCER RES, V12, P111, DOI 10.1158/1541-7786.MCR-13-0479-T
   Alexander SPH, 2017, BRIT J PHARMACOL, V174, pS225, DOI 10.1111/bph.13876
   Alitalo K, 2002, CANCER CELL, V1, P219, DOI 10.1016/S1535-6108(02)00051-X
   Apte RS, 2019, CELL, V176, P1248, DOI 10.1016/j.cell.2019.01.021
   Arvanitis D, 2008, GENE DEV, V22, P416, DOI 10.1101/gad.1630408
   Awad MM, 2021, NEW ENGL J MED, V384, P2382, DOI 10.1056/NEJMoa2105281
   Bassler J, 2018, CELL SIGNAL, V46, P135, DOI 10.1016/j.cellsig.2018.03.002
   Bender S, 2016, NAT MED, V22, P1314, DOI 10.1038/nm.4204
   Berger H, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00031
   Bertolini Francesco, 2012, Methods Mol Biol, V904, P165, DOI 10.1007/978-1-61779-943-3_14
   Bhardwaj B, 1996, CLIN CANCER RES, V2, P773
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bilancia D, 2007, ANN ONCOL, V18, P26, DOI 10.1093/annonc/mdm220
   Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912
   Brennan CW, 2013, CELL, V155, P462, DOI 10.1016/j.cell.2013.09.034
   Brummer T, 2010, FEBS J, V277, P4356, DOI 10.1111/j.1742-4658.2010.07865.x
   Brunello E, 2012, J EXP CLIN CANC RES, V31, DOI 10.1186/1756-9966-31-103
   Burden SJ, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009167
   Camidge DR, 2021, J THORAC ONCOL, V16, P1017, DOI 10.1016/j.jtho.2021.02.010
   Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]
   Cannarile MA, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0257-y
   Carraway KL, 2002, CANCER CELL, V1, P405, DOI 10.1016/S1535-6108(02)00076-4
   Carvalho I, 2005, BREAST CANCER RES, V7, pR788, DOI 10.1186/bcr1304
   Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1
   Cecchi F, 2023, CANCERS, V15, DOI 10.3390/cancers15020460
   Cerliani JP, 2012, BREAST CANCER RES TR, V133, P997, DOI 10.1007/s10549-011-1883-6
   Chauhan SK, 2015, ARTERIOSCL THROM VAS, V35, P1606, DOI 10.1161/ATVBAHA.114.305228
   Chen J, 2015, CYTOKINE GROWTH F R, V26, P1, DOI 10.1016/j.cytogfr.2014.05.001
   Chen WS, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11302
   Chen Z, 2010, CANCER RES, V70, P9827, DOI 10.1158/0008-5472.CAN-10-1671
   Cheng Y, 2021, MEDCOMM, V2, P692, DOI 10.1002/mco2.105
   Cheung EC, 2022, NAT REV CANCER, V22, P280, DOI 10.1038/s41568-021-00435-0
   Choueiri TK, 2021, NEW ENGL J MED, V384, P829, DOI 10.1056/NEJMoa2026982
   Chung I, 2010, NATURE, V464, P783, DOI 10.1038/nature08827
   Ciardiello F, 2001, CLIN CANCER RES, V7, P2958
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Comoglio PM, 2018, NAT REV CANCER, V18, P341, DOI 10.1038/s41568-018-0002-y
   Cooper AJ, 2022, NAT REV CLIN ONCOL, V19, P499, DOI 10.1038/s41571-022-00639-9
   COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   D'Haene N, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113536
   Dagogo-Jack I, 2020, CLIN CANCER RES, V26, P2535, DOI 10.1158/1078-0432.CCR-19-3906
   Datta K, 2010, FUTURE ONCOL, V6, P823, DOI 10.2217/FON.10.33
   Davies KD, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00117
   Davies KD, 2013, CLIN CANCER RES, V19, P4040, DOI 10.1158/1078-0432.CCR-12-2851
   de Visser KE, 2023, CANCER CELL, V41, P374, DOI 10.1016/j.ccell.2023.02.016
   DIAMOND J, 1995, BLOOD, V85, P2171, DOI 10.1182/blood.V85.8.2171.bloodjournal8582171
   Dines M, 2016, INT J NEUROPSYCHOPH, V19, DOI 10.1093/ijnp/pyv106
   Ding L, 2021, CANCERS, V13, DOI 10.3390/cancers13225729
   Dong SL, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01601-0
   Drilon A, 2018, NAT REV CLIN ONCOL, V15, P151, DOI [10.1038/nrclinonc.2017.188, 10.1038/nrclinonc.2017.175]
   Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014
   Druker BJ, 2001, NEW ENGL J MED, V344, P1031, DOI 10.1056/NEJM200104053441401
   Dunne PD, 2014, CLIN CANCER RES, V20, P164, DOI 10.1158/1078-0432.CCR-13-1354
   Durinck S, 2015, NAT GENET, V47, P13, DOI 10.1038/ng.3146
   Esposito I, 2002, LAB INVEST, V82, P1481, DOI 10.1097/01.LAB.0000036875.21209.F9
   Farnsworth RH, 2018, CURR OPIN IMMUNOL, V53, P64, DOI 10.1016/j.coi.2018.04.008
   Feng SJ, 1997, CANCER RES, V57, P5369
   Ferrari E, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115453
   Fizazi K, 2003, CLIN CANCER RES, V9, P2587
   Flucke U, 2017, GENE CHROMOSOME CANC, V56, P663, DOI 10.1002/gcc.22470
   Ford CE, 2013, INT J CANCER, V133, P779, DOI 10.1002/ijc.27984
   Formisano L, 2017, CLIN CANCER RES, V23, P6138, DOI 10.1158/1078-0432.CCR-17-1232
   Frampton GM, 2015, CANCER DISCOV, V5, P850, DOI 10.1158/2159-8290.CD-15-0285
   Fujii M, 2023, HUM CELL, V36, P775, DOI 10.1007/s13577-023-00857-y
   Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977
   Gandullo-Sánchez L, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02515-x
   Garcia J, 2020, CANCER TREAT REV, V86, DOI 10.1016/j.ctrv.2020.102017
   García-Aranda M, 2019, CANCERS, V11, DOI 10.3390/cancers11040433
   Gay CM, 2017, BRIT J CANCER, V116, P415, DOI 10.1038/bjc.2016.428
   Ghedini GC, 2018, EXPERT REV ANTICANC, V18, P861, DOI 10.1080/14737140.2018.1491795
   Gialeli C, 2014, CURR PHARM DESIGN, V20, P2843, DOI 10.2174/13816128113199990592
   Giordano P, 2016, CRIT REV ONCOL HEMAT, V97, P143, DOI 10.1016/j.critrevonc.2015.08.016
   Giri D, 1999, CLIN CANCER RES, V5, P1063
   Gounder MM, 2018, NEW ENGL J MED, V379, P2417, DOI 10.1056/NEJMoa1805052
   Graveel C, 2004, P NATL ACAD SCI USA, V101, P17198, DOI 10.1073/pnas.0407651101
   Green J, 2014, CSH PERSPECT BIOL, V6, DOI 10.1101/cshperspect.a009175
   Guise TA, 2006, CLIN CANCER RES, V12, p6213S, DOI 10.1158/1078-0432.CCR-06-1007
   Guo RB, 2020, NAT REV CLIN ONCOL, V17, P569, DOI 10.1038/s41571-020-0377-z
   Hanawa M, 2006, INT J CANCER, V118, P1173, DOI 10.1002/ijc.21454
   Harrison PT, 2020, SEMIN CANCER BIOL, V61, P167, DOI 10.1016/j.semcancer.2019.09.015
   Hazan RB, 1998, J BIOL CHEM, V273, P9078, DOI 10.1074/jbc.273.15.9078
   Heldin CH, 2013, CELL COMMUN SIGNAL, V11, DOI 10.1186/1478-811X-11-97
   Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147
   Herbst RS, 2023, J CLIN ONCOL, V41, P1830, DOI 10.1200/JCO.22.02186
   Hernández S, 2009, MODERN PATHOL, V22, P848, DOI 10.1038/modpathol.2009.46
   Hu HM, 2018, CELL, V175, P1665, DOI 10.1016/j.cell.2018.09.038
   Hu L, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1285-y
   Huang CY, 2017, ONCOTARGET, V8, P23459, DOI 10.18632/oncotarget.15589
   Hubbard SR, 2004, NAT REV MOL CELL BIO, V5, P464, DOI 10.1038/nrm1399
   Hubbard SR, 1999, PROG BIOPHYS MOL BIO, V71, P343, DOI 10.1016/S0079-6107(98)00047-9
   Hughes Veronica S, 2019, Oncotarget, V10, P184, DOI 10.18632/oncotarget.26546
   Huse M, 2002, CELL, V109, P275, DOI 10.1016/S0092-8674(02)00741-9
   Inamura K, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00193
   Inoue H, 2005, CANCER LETT, V223, P121, DOI 10.1016/j.canlet.2004.09.053
   Jackson RA, 2006, GENE, V379, P79, DOI 10.1016/j.gene.2006.04.028
   Jayson GC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07174-1
   Jeffers M, 1997, P NATL ACAD SCI USA, V94, P11445, DOI 10.1073/pnas.94.21.11445
   Jeltsch M, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a009183
   Jl S., 2023, Nat Cancer, V4, P330
   Jones N, 2001, NAT REV MOL CELL BIO, V2, P257, DOI 10.1038/35067005
   Katayama R, 2015, CLIN CANCER RES, V21, P2227, DOI 10.1158/1078-0432.CCR-14-2791
   Kawakami N, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202307157
   Keating GM, 2015, DRUGS, V75, P1903, DOI 10.1007/s40265-015-0483-x
   Kentsis A, 2012, NAT MED, V18, P1118, DOI 10.1038/nm.2819
   Kim B, 2015, ONCOGENE, V34, P1083, DOI 10.1038/onc.2014.51
   Kim HP, 2014, ONCOGENE, V33, P5434, DOI 10.1038/onc.2013.490
   Kim P, 2018, BRIEF BIOINFORM, V19, P450, DOI 10.1093/bib/bbw127
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Koziczak M, 2004, J BIOL CHEM, V279, P50004, DOI 10.1074/jbc.M404252200
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Krystal GW, 1996, CANCER RES, V56, P370
   Kwak Y, 2015, PATHOBIOLOGY, V82, P76, DOI 10.1159/000398807
   Laakkonen P, 2007, CANCER RES, V67, P593, DOI 10.1158/0008-5472.CAN-06-3567
   Lahiry P, 2010, NAT REV GENET, V11, P60, DOI 10.1038/nrg2707
   Lai YY, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.621147
   Lau EYT, 2016, CELL REP, V15, P1175, DOI 10.1016/j.celrep.2016.04.019
   Lau SCM, 2019, DRUGS, V79, P823, DOI 10.1007/s40265-019-01115-y
   Le Rolle AF, 2015, ONCOTARGET, V6, P28929, DOI 10.18632/oncotarget.4325
   Le XN, 2022, CLIN CANCER RES, V28, P1117, DOI 10.1158/1078-0432.CCR-21-2733
   Lee BS, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.119
   Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551
   Lee JC, 2006, PLOS MED, V3, P2264, DOI 10.1371/journal.pmed.0030485
   Li CW, 2011, GASTROENTEROLOGY, V141, P2218, DOI 10.1053/j.gastro.2011.08.009
   Li EL, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02055-w
   Li JY, 2021, CANCER DISCOV, V11, P736, DOI 10.1158/2159-8290.CD-20-0519
   Li MW, 2022, MOL CANCER, V21, DOI 10.1186/s12943-022-01654-1
   Li XK, 2016, SEMIN CELL DEV BIOL, V53, P155, DOI 10.1016/j.semcdb.2015.12.014
   Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568
   Liu J, 2019, J THORAC ONCOL, V14, pE126, DOI 10.1016/j.jtho.2019.01.025
   Liu JC, 2018, CANCER RES, V78, P4459, DOI 10.1158/0008-5472.CAN-17-3226
   Liu MM, 2021, MEDCOMM, V2, P587, DOI 10.1002/mco2.100
   Lorenzato A, 2002, CANCER RES, V62, P7025
   Luo Y, 2013, ONCOGENE, V32, P2037, DOI 10.1038/onc.2012.225
   Lutterbach B, 2007, CANCER RES, V67, P2081, DOI 10.1158/0008-5472.CAN-06-3495
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Lyons TR, 2014, J CLIN INVEST, V124, P3901, DOI 10.1172/JCI73777
   Ma PC, 2005, CLIN CANCER RES, V11, P2312, DOI 10.1158/1078-0432.CCR-04-1708
   Ma PC, 2005, CANCER RES, V65, P1479, DOI 10.1158/0008-5472.CAN-04-2650
   Ma PC, 2003, CANCER RES, V63, P6272
   Mabeta P, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232415585
   Maddalo D, 2014, NATURE, V516, P423, DOI 10.1038/nature13902
   Maiti GP, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063440
   Marino F, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00371
   Markham A, 2021, DRUGS, V81, P1665, DOI 10.1007/s40265-021-01584-0
   Markham A, 2020, DRUGS, V80, P829, DOI 10.1007/s40265-020-01317-9
   Martinelli E, 2015, ONCOTARGET, V6, P23281, DOI 10.18632/oncotarget.3962
   Matsuda Yoko, 2012, Patholog Res Int, V2012, P574768, DOI 10.1155/2012/574768
   Matsuo M, 2007, EUR J CANCER, V43, P1748, DOI 10.1016/j.ejca.2007.04.024
   McDonell LM, 2015, HUM MOL GENET, V24, pR60, DOI 10.1093/hmg/ddv254
   Medves S, 2012, J CELL MOL MED, V16, P237, DOI 10.1111/j.1582-4934.2011.01415.x
   MELO JV, 1993, BLOOD, V81, P158
   Meng XQ, 2018, CANCER LETT, V418, P109, DOI 10.1016/j.canlet.2018.01.018
   Mira A, 2017, ONCOTARGET, V8, P38193, DOI 10.18632/oncotarget.16942
   Mishel S, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-12408-1
   Mohan RR, 2001, EXP EYE RES, V72, P87, DOI 10.1006/exer.2000.0932
   Mol CD, 2004, J BIOL CHEM, V279, P31655, DOI 10.1074/jbc.M403319200
   Moloney JN, 2018, SEMIN CELL DEV BIOL, V80, P50, DOI 10.1016/j.semcdb.2017.05.023
   Mudduluru G, 2011, ONCOGENE, V30, P2888, DOI 10.1038/onc.2011.13
   Nagasaka M, 2020, CRIT REV ONCOL HEMAT, V151, DOI 10.1016/j.critrevonc.2020.102969
   Nair S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23073818
   Newton AC, 2016, CSH PERSPECT BIOL, V8, DOI 10.1101/cshperspect.a005926
   Ninomiya H, 2009, LUNG CANCER, V63, P235, DOI 10.1016/j.lungcan.2008.04.017
   Nolen B, 2004, MOL CELL, V15, P661, DOI 10.1016/j.molcel.2004.08.024
   Noonan SA, 2016, J THORAC ONCOL, V11, P1293, DOI 10.1016/j.jtho.2016.04.033
   Nowell PC, 2007, J CLIN INVEST, V117, P2033, DOI 10.1172/JCI31771
   O'Brien SG, 2003, NEW ENGL J MED, V348, P994, DOI 10.1056/NEJMoa022457
   Otte JM, 2000, DIGESTION, V61, P237, DOI 10.1159/000007764
   Paiva RS, 2020, J BONE ONCOL, V25, DOI 10.1016/j.jbo.2020.100315
   Pan YJ, 2019, J THORAC ONCOL, V14, P2003, DOI 10.1016/j.jtho.2019.07.022
   Pandini G, 2002, J BIOL CHEM, V277, P39684, DOI 10.1074/jbc.M202766200
   Patel S, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02872
   Paulsson J, 2009, AM J PATHOL, V175, P334, DOI 10.2353/ajpath.2009.081030
   Pawson T, 2001, TRENDS CELL BIOL, V11, P504, DOI 10.1016/S0962-8924(01)02154-7
   Peschard P, 2004, J BIOL CHEM, V279, P29565, DOI 10.1074/jbc.M403954200
   Petrini I, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.58
   Pinto MP, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-735
   Plenker D, 2018, CLIN CANCER RES, V24, P1337, DOI 10.1158/1078-0432.CCR-17-3001
   PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2
   Prager GW, 2023, NEW ENGL J MED, V388, P1657, DOI 10.1056/NEJMoa2214963
   Price JT, 1999, CANCER RES, V59, P5475
   Qi XQ, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001038
   Rankin EB, 2016, CANCERS, V8, DOI 10.3390/cancers8110103
   Ray AT, 2023, DEVELOPMENT, V150, DOI 10.1242/dev.201293
   Reams AB, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016592
   Reya T, 2005, NATURE, V434, P843, DOI 10.1038/nature03319
   Reznik TE, 2008, MOL CANCER RES, V6, P139, DOI 10.1158/1541-7786.MCR-07-0236
   Ribatti D, 2012, EXPERT OPIN THER TAR, V16, P1215, DOI 10.1517/14728222.2012.725047
   RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711
   Roma AA, 2006, MODERN PATHOL, V19, P392, DOI 10.1038/modpathol.3800546
   Roskoski R Jr, 2023, PHARMACOL RES, V187, DOI 10.1016/j.phrs.2022.106552
   Ross JS, 1998, STEM CELLS, V16, P413, DOI 10.1002/stem.160413
   Sabari JK, 2018, ANN ONCOL, V29, P2085, DOI 10.1093/annonc/mdy334
   Saigi M, 2018, CLIN TRANSL ONCOL, V20, P881, DOI 10.1007/s12094-017-1799-7
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Santos GD, 2011, ANNU REV PATHOL-MECH, V6, P49, DOI 10.1146/annurev-pathol-011110-130206
   Saplacan RM, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/4708076
   Schlessinger J, 2000, MOL CELL, V6, P743, DOI 10.1016/S1097-2765(00)00073-3
   Schlessinger J, 2000, CELL, V103, P211, DOI 10.1016/S0092-8674(00)00114-8
   Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68
   Schmidt L, 1999, ONCOGENE, V18, P2343, DOI 10.1038/sj.onc.1202547
   Schmitz R, 2016, ONCOTARGET, V7, P56355, DOI 10.18632/oncotarget.10889
   Schoppmann SF, 2004, ANN SURG, V240, P306, DOI 10.1097/01.sla.0000133355.48672.22
   Schrock AB, 2016, J THORAC ONCOL, V11, P1493, DOI 10.1016/j.jtho.2016.06.004
   Sequist LV, 2020, LANCET ONCOL, V21, P373, DOI 10.1016/S1470-2045(19)30785-5
   Sharma SV, 2007, NAT REV CANCER, V7, P169, DOI 10.1038/nrc2088
   Shaw AT, 2020, NEW ENGL J MED, V383, P2018, DOI 10.1056/NEJMoa2027187
   Shaw AT, 2019, J CLIN ONCOL, V37, P1370, DOI 10.1200/JCO.18.02236
   Shewchuk LM, 2000, STRUCTURE, V8, P1105, DOI 10.1016/S0969-2126(00)00516-5
   Shi HB, 2014, INT J CLIN EXP PATHO, V7, P1101
   Shibuya Masabumi, 2011, Genes Cancer, V2, P1097, DOI 10.1177/1947601911423031
   Shoji K, 2014, ONCOL REP, V32, P65, DOI 10.3892/or.2014.3200
   Silva CM, 2004, ONCOGENE, V23, P8017, DOI 10.1038/sj.onc.1208159
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Sirvent A, 2018, MOL CELL ONCOL, V5, DOI 10.1080/23723556.2018.1465882
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Smith NR, 2010, CLIN CANCER RES, V16, P3548, DOI 10.1158/1078-0432.CCR-09-2797
   Smolen GA, 2006, P NATL ACAD SCI USA, V103, P2316, DOI 10.1073/pnas.0508776103
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Soda M, 2008, P NATL ACAD SCI USA, V105, P19893, DOI 10.1073/pnas.0805381105
   Solomon BJ, 2023, LANCET RESP MED, V11, P354, DOI 10.1016/S2213-2600(22)00437-4
   SOMAN NR, 1991, P NATL ACAD SCI USA, V88, P4892, DOI 10.1073/pnas.88.11.4892
   SOMAN NR, 1990, P NATL ACAD SCI USA, V87, P738, DOI 10.1073/pnas.87.2.738
   SOOS MA, 1993, BIOCHEM J, V290, P419, DOI 10.1042/bj2900419
   Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006
   Srabovic N, 2013, INT J BREAST CANCER, V2013, DOI 10.1155/2013/746749
   Stransky N, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5846
   Su N, 2014, BONE RES, V2, DOI 10.1038/boneres.2014.3
   Sugano T, 2015, MOL CANCER THER, V14, P2433, DOI 10.1158/1535-7163.MCT-15-0050
   Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003
   Takeuchi K, 2008, CLIN CANCER RES, V14, P6618, DOI 10.1158/1078-0432.CCR-08-1018
   Tan CS, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0778-0
   Tan FL, 2015, FUTURE ONCOL, V11, P385, DOI 10.2217/fon.14.249
   Tang XN, 2005, CANCER RES, V65, P7568, DOI 10.1158/0008-5472.CAN-05-1705
   Templeton AJ, 2014, CANCER TREAT REV, V40, P1048, DOI 10.1016/j.ctrv.2014.08.003
   Timoshenko AV, 2006, BRIT J CANCER, V94, P1154, DOI 10.1038/sj.bjc.6603067
   Todaro M, 2014, CELL STEM CELL, V14, P342, DOI 10.1016/j.stem.2014.01.009
   Tomihara H, 2017, CANCER SCI, V108, P398, DOI 10.1111/cas.13159
   Trojan J, 2013, EXPERT OPIN INV DRUG, V22, P141, DOI 10.1517/13543784.2013.741586
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   Uribe DJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0179979
   van der Meer JHM, 2014, BLOOD, V123, P2460, DOI 10.1182/blood-2013-09-528752
   Van Laere SJ, 2007, BRIT J CANCER, V97, P659, DOI 10.1038/sj.bjc.6603906
   Vener C, 2020, BLOOD ADV, V4, P2723, DOI 10.1182/bloodadvances.2019001329
   Vigna E, 1999, ONCOGENE, V18, P4275, DOI 10.1038/sj.onc.1202791
   Vigneri PG, 2015, FRONT ONCOL, V5, DOI 10.3389/fonc.2015.00230
   Wang C, 2018, J BIOL CHEM, V293, P14839, DOI 10.1074/jbc.RA118.002907
   Wang F, 2002, CANCER RES, V62, P1898
   Wang JH, 2004, CLIN CANCER RES, V10, P6169, DOI 10.1158/1078-0432.CCR-04-0408
   Wang QW, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002451
   Wang XP, 2017, ONCOTARGET, V8, P67904
   Wang YD, 2010, NATURE, V465, P483, DOI 10.1038/nature09002
   Wehrman T, 2007, NEURON, V53, P25, DOI 10.1016/j.neuron.2006.09.034
   Wiesner C, 2008, NEOPLASIA, V10, P996, DOI 10.1593/neo.08618
   Winter SF, 2007, ONCOGENE, V26, P4897, DOI 10.1038/sj.onc.1210288
   Wirth LJ, 2021, J CLIN ONCOL, V39, P2359, DOI 10.1200/JCO.20.03093
   Wise R, 2017, BREAST CANCER RES TR, V166, P421, DOI 10.1007/s10549-017-4440-0
   Witton CJ, 2003, J PATHOL, V200, P290, DOI 10.1002/path.1370
   Wolf J, 2020, NEW ENGL J MED, V383, P944, DOI 10.1056/NEJMoa2002787
   Wu FL, 2021, SIGNAL TRANSDUCT TAR, V6, DOI 10.1038/s41392-021-00641-0
   Wybenga-Groot LE, 2001, CELL, V106, P745, DOI 10.1016/S0092-8674(01)00496-2
   Yan B, 2018, EXP CELL RES, V371, P63, DOI 10.1016/j.yexcr.2018.07.041
   YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513
   Yang J, 2013, STEM CELLS, V31, P248, DOI 10.1002/stem.1281
   Yatabe Y, 2010, CANCER METAST REV, V29, P23, DOI 10.1007/s10555-010-9205-8
   YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W
   Ye P, 2022, CRIT REV ONCOL HEMAT, V174, DOI 10.1016/j.critrevonc.2022.103681
   Yeh I, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8174
   Yi S, 2000, NEOPLASIA, V2, P226, DOI 10.1038/sj.neo.7900080
   Yu J, 2000, CANCER-AM CANCER SOC, V88, P1801, DOI 10.1002/(SICI)1097-0142(20000415)88:8<1801::AID-CNCR7>3.0.CO;2-U
   Yu JF, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.847835
   Yuzawa S, 2007, CELL, V130, P323, DOI 10.1016/j.cell.2007.05.055
   Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760
   Zhang XW, 2006, CELL, V125, P1137, DOI 10.1016/j.cell.2006.05.013
   Zhang YY, 2020, CELL MOL IMMUNOL, V17, P807, DOI 10.1038/s41423-020-0488-6
   Zhao D, 2015, ONCOGENE, V34, P3107, DOI 10.1038/onc.2014.257
   Zhao Y, 2019, BMJ-BRIT MED J, V367, DOI 10.1136/bmj.l5460
   Zhou BH, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00934-y
   Zhou CF, 2020, AUTOPHAGY, V16, P1786, DOI 10.1080/15548627.2019.1687212
   Zhou JK, 2017, ONCOTARGET, V8, P32864, DOI 10.18632/oncotarget.15860
   Zhu M, 2015, BRIT J CANCER, V112, P429, DOI 10.1038/bjc.2014.649
   Zhuang ZP, 1998, NAT GENET, V20, P66, DOI 10.1038/1727
   Zou SL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01258-7
   Zwaans BMM, 2007, MICROVASC RES, V74, P145, DOI 10.1016/j.mvr.2007.08.006
NR 286
TC 11
Z9 11
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2688-2663
J9 MEDCOMM
JI MedComm
PD DEC
PY 2023
VL 4
IS 6
AR e446
DI 10.1002/mco2.446
PG 27
WC Medicine, Research & Experimental
WE Emerging Sources Citation Index (ESCI)
SC Research & Experimental Medicine
GA Z8RO1
UT WOS:001114694400001
PM 38077251
OA gold
DA 2025-01-04
ER

PT J
AU Zhang, WW
   Yang, SF
   Chen, DT
   Yuwen, DL
   Zhang, J
   Wei, XW
   Han, X
   Guan, XX
AF Zhang, Wenwen
   Yang, Shuofei
   Chen, Datian
   Yuwen, Daolu
   Zhang, Juan
   Wei, Xiaowei
   Han, Xin
   Guan, Xiaoxiang
TI SOX2-OT induced by PAI-1 promotes triple-negative breast cancer cells
   metastasis by sponging miR-942-5p and activating PI3K/Akt signaling
SO CELLULAR AND MOLECULAR LIFE SCIENCES
LA English
DT Article
DE PAI-1; SERPINE1; ceRNA; PAI-039; LY294002; Lung and liver metastases
ID EPITHELIAL-MESENCHYMAL TRANSITION; GENE-EXPRESSION; COLORECTAL-CANCER;
   ENDOTHELIAL-CELLS; INHIBITOR-1; PROGRESSION; APOPTOSIS; STROMA; RNA
AB Triple-negative breast cancer (TNBC) has an aggressive biological behavior and poor outcome. Our published study showed that PAI-1 could induce the migration and metastasis of TNBC cells. However, the underlying mechanism by which PAI-1 regulates TNBC metastasis has not been addressed. Here, we demonstrated that PAI-1 is high expressed in TNBC and promotes TNBC cells tumorigenesis. Using microarray analysis of lncRNA expression profiles, we identified a lncRNA SOX2-OT, which is induced by PAI-1 and could function as an oncogenic lncRNA in TNBC. Mechanistic analysis demonstrated that SOX2-OT acts as a molecular sponge for miR-942-5p to regulate the expression of PIK3CA, ultimately leading to activating PI3K/Akt signaling pathway and promoting TNBC metastasis. Taken together, our findings suggest that SOX2-OT regulates PAI-1-induced TNBC cell metastasis through miR-942-5p/PIK3CA signaling and illustrate the great potential of developing new SOX2-OT-targeting therapy for TNBC patients.
C1 [Zhang, Wenwen; Yuwen, Daolu; Zhang, Juan; Wei, Xiaowei] Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, 68 Changle Rd, Nanjing 210006, Peoples R China.
   [Yang, Shuofei] Shanghai Jiao Tong Univ, Renji Hosp, Sch Med, Dept Vasc Surg, Shanghai, Peoples R China.
   [Chen, Datian] Nantong Univ, Haimen Peoples Hosp, Dept Oncol, Nantong, Peoples R China.
   [Han, Xin] Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Sch Med, Nanjing 210023, Peoples R China.
   [Han, Xin] Nanjing Univ Chinese Med, Holist Integrat Med, Nanjing 210023, Peoples R China.
   [Guan, Xiaoxiang] Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.
   [Guan, Xiaoxiang] Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China.
C3 Nanjing Medical University; Shanghai Jiao Tong University; Nantong
   University; Nanjing University of Chinese Medicine; Nanjing University
   of Chinese Medicine; Nanjing Medical University; Nanjing Medical
   University
RP Zhang, WW (corresponding author), Nanjing Med Univ, Nanjing Hosp 1, Dept Oncol, 68 Changle Rd, Nanjing 210006, Peoples R China.; Han, X (corresponding author), Nanjing Univ Chinese Med, Jiangsu Collaborat Innovat Ctr Chinese Med Resour, Sch Med, Nanjing 210023, Peoples R China.; Han, X (corresponding author), Nanjing Univ Chinese Med, Holist Integrat Med, Nanjing 210023, Peoples R China.; Guan, XX (corresponding author), Nanjing Med Univ, Dept Oncol, Affiliated Hosp 1, 300 Guangzhou Rd, Nanjing 210029, Peoples R China.; Guan, XX (corresponding author), Nanjing Med Univ, Collaborat Innovat Ctr Personalized Canc Med, Jiangsu Key Lab Canc Biomarkers Prevent & Treatme, Nanjing, Peoples R China.
EM wwzhang1022@hotmail.com; xhan0220@njucm.edu.cn; xguan@njmu.edu.cn
RI Yang, Shuofei/Y-1578-2018; Zhang, Juan/GRX-2638-2022; Wei,
   Xiaowei/KHT-4099-2024; Zhang, Wenwen/ABF-4970-2021; Han, Xin/K-4480-2017
OI Guan, Xiaoxiang/0000-0001-6145-0046; Zhang, Wenwen/0000-0003-1285-3118;
   Han, Xin/0000-0002-9620-7502
FU National Natural Science Foundation of China [81802667, 81773102];
   Natural Science Foundation of Jiangsu Province [BK20180133]; Nanjing
   Outstanding Youth Fund [JQX20009]; Key International Cooperation of the
   National Natural Science Foundation of China [81920108029]; Key
   Foundation for Social Development Project of the Jiangsu Province, China
   [BE2021741]
FX This research was supported by National Natural Science Foundation of
   China (No. 81802667, 81773102), Natural Science Foundation of Jiangsu
   Province (BK20180133), Nanjing Outstanding Youth Fund (No. JQX20009),
   Key International Cooperation of the National Natural Science Foundation
   of China (No. 81920108029), and Key Foundation for Social Development
   Project of the Jiangsu Province, China (BE2021741).
CR Bajou K, 2008, CANCER CELL, V14, P324, DOI 10.1016/j.ccr.2008.08.012
   Batista PJ, 2013, CELL, V152, P1298, DOI 10.1016/j.cell.2013.02.012
   Bianchini G, 2016, NAT REV CLIN ONCOL, V13, P674, DOI 10.1038/nrclinonc.2016.66
   Boyle P, 2012, ANN ONCOL, V23, P7, DOI 10.1093/annonc/mds187
   Cesana M, 2011, CELL, V147, P358, DOI 10.1016/j.cell.2011.09.028
   Chandrashekar DS, 2017, NEOPLASIA, V19, P649, DOI 10.1016/j.neo.2017.05.002
   Declerck PJ, 2013, SEMIN THROMB HEMOST, V39, P356, DOI 10.1055/s-0033-1334487
   Du ZH, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01666-1
   Hua JJ, 2019, TRENDS GENET, V35, P840, DOI 10.1016/j.tig.2019.08.004
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Humphries BA, 2019, MOL CANCER RES, V17, P1142, DOI 10.1158/1541-7786.MCR-18-0836
   Jaeger J, 2007, CLIN CANCER RES, V13, P806, DOI 10.1158/1078-0432.CCR-06-1820
   Jin X, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aat9820
   Karnoub AE, 2007, NATURE, V449, P557, DOI 10.1038/nature06188
   Koboldt DC, 2012, NATURE, V490, P61, DOI 10.1038/nature11412
   Lee E, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms5715
   Li ZH, 2018, ONCOGENE, V37, P3822, DOI 10.1038/s41388-018-0237-9
   Liu SJ, 2021, NAT REV CANCER, V21, P446, DOI 10.1038/s41568-021-00353-1
   Liu TY, 2021, CELL MOL LIFE SCI, V78, P1983, DOI 10.1007/s00018-020-03691-9
   Mei J, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12801
   Nagy A, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84787-5
   Ou RY, 2020, MOL THER-NUCL ACIDS, V20, P308, DOI 10.1016/j.omtn.2020.01.003
   Ouyang ZX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-2161-5
   Pandya G, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188423
   Provenzani A, 2006, CARCINOGENESIS, V27, P1323, DOI 10.1093/carcin/bgi377
   Rickman DS, 2008, ONCOGENE, V27, P6607, DOI 10.1038/onc.2008.251
   Ringnér M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017911
   Romer MU, 2008, NEOPLASIA, V10, P1083, DOI 10.1593/neo.08486
   Song W, 2017, SCI REP-UK, V7, DOI 10.1038/srep42319
   Song XY, 2018, CLIN CHIM ACTA, V484, P52, DOI 10.1016/j.cca.2018.05.038
   Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9
   Sung SY, 2008, CANCER RES, V68, P9996, DOI 10.1158/0008-5472.CAN-08-2492
   Tai Y, 2019, IUBMB LIFE, V71, P1230, DOI 10.1002/iub.2026
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Witzel Isabell, 2014, Onco Targets Ther, V7, P2205, DOI 10.2147/OTT.S65344
   Wong NK, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0673-6
   Xi XN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1986-2
   Xie J, 2019, J CELL MOL MED, V23, P3597, DOI 10.1111/jcmm.14260
   Xu J, 2018, GENE, V670, P7, DOI 10.1016/j.gene.2018.05.089
   Xu J, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12823
   Yang F, 2018, CELL DEATH DIFFER, V25, P2209, DOI 10.1038/s41418-018-0123-6
   Zemzoum I, 2003, J CLIN ONCOL, V21, P1022, DOI 10.1200/JCO.2003.04.170
   Zhang HW, 2019, CANCER RES, V79, P3347, DOI 10.1158/0008-5472.CAN-18-3418
   Zhang M, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12855
   Zhang WW, 2021, CELL PROLIFERAT, V54, DOI 10.1111/cpr.12966
   Zhang WW, 2018, FASEB J, V32, P276, DOI 10.1096/fj.201700237RR
   Zhang WW, 2016, CELL CYCLE, V15, P1344, DOI 10.1080/15384101.2016.1160986
   Zhang WW, 2016, SCI REP-UK, V6, DOI 10.1038/srep22034
   Zhang WW, 2015, ONCOTARGET, V6, P7608, DOI 10.18632/oncotarget.3263
   Zhou L, 2021, BIOMED RES INT, V2021, DOI 10.1155/2021/9951405
NR 50
TC 31
Z9 34
U1 2
U2 20
PU SPRINGER BASEL AG
PI BASEL
PA PICASSOPLATZ 4, BASEL, 4052, SWITZERLAND
SN 1420-682X
EI 1420-9071
J9 CELL MOL LIFE SCI
JI Cell. Mol. Life Sci.
PD JAN
PY 2022
VL 79
IS 1
AR 59
DI 10.1007/s00018-021-04120-1
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA YD3EB
UT WOS:000740256600001
PM 34997317
OA Green Published
DA 2025-01-04
ER

PT J
AU Roa, P
   Bremer, NV
   Foglizzo, V
   Cocco, E
AF Roa, Paola
   Bremer, Nicole Virginia
   Foglizzo, Valentina
   Cocco, Emiliano
TI Mutations in the Serine/Threonine Kinase BRAF: Oncogenic Drivers in
   Solid Tumors
SO CANCERS
LA English
DT Review
DE BRAF; solid tumors; NGS; targeted therapy; therapy resistance
ID MUTANT COLORECTAL-CANCER; PAPILLARY THYROID-CARCINOMA; DABRAFENIB PLUS
   TRAMETINIB; TARGETING RAF KINASE; ACQUIRED-RESISTANCE; LUNG
   ADENOCARCINOMA; V600E MUTATION; OPEN-LABEL; B-RAF; FEEDBACK INHIBITION
AB Since their discovery in 2002, BRAF mutations have been identified as clear drivers of oncogenesis in several cancer types. Currently, their incidence rate is nearly 7% of all solid tumors with BRAF V600E constituting approximately 90% of these diagnoses. In melanoma, thyroid cancer, and histiocytic neoplasms, BRAF hotspot mutations are found at a rate of about 50%, while in lung and colorectal cancers they range from 3% to 10% of reported cases. Though present in other malignancies such as breast and ovarian cancers, they constitute a small portion of diagnoses (<1%). Given their frequency along with advancements in screening technologies, various methods are used for the detection of BRAF-mutant cancers. Among these are targeted next-generation sequencing (NGS) on tumor tissue or circulating tumor DNA (ctDNA) and immunohistochemistry (IHC)-based assays. With advancements in detection technologies, several approaches to the treatment of BRAF-mutant cancers have been taken. In this review, we retrace the milestones that led to the clinical development of targeted therapies currently available for these tumors.
C1 [Roa, Paola; Bremer, Nicole Virginia; Foglizzo, Valentina; Cocco, Emiliano] Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
C3 University of Miami
RP Cocco, E (corresponding author), Univ Miami, Miller Sch Med, Dept Biochem & Mol Biol, Sylvester Comprehens Canc Ctr, Miami, FL 33136 USA.
EM pxr421@miami.edu; nvb29@miami.edu; vxf221@miami.edu; exc2752@miami.edu
FU Woman's Cancer Association Madelon Ravlin Memorial Grant Award; SCCC
   Tumor Biology Programmatic Award; Lung Cancer Research Foundation
FX This research was funded by the Woman's Cancer Association Madelon
   Ravlin Memorial Grant Award (E.C.), the SCCC Tumor Biology Programmatic
   Award (E.C.), and the Lung Cancer Research Foundation (LCRF) (E.C.).
CR Adeniran AJ, 2006, AM J SURG PATHOL, V30, P216, DOI 10.1097/01.pas.0000176432.73455.1b
   Adnane L, 2006, METHOD ENZYMOL, V407, P597, DOI 10.1016/S0076-6879(05)07047-3
   Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Al-Kateb H, 2015, MOL ONCOL, V9, P1737, DOI 10.1016/j.molonc.2015.05.004
   [Anonymous], 2023, Mekinist [Package Insert]
   [Anonymous], 2023, Tecentriq [Package Insert]
   [Anonymous], 2008, STATEMENT MEDICATION
   [Anonymous], 2017, Zelboraf
   [Anonymous], 2023, Braftovi [Package Insert]
   [Anonymous], 2021, Erbitux [Package Insert]
   [Anonymous], 2015, Cotellic [Package Insert]
   [Anonymous], 2023, Tafinlar [Package Insert]
   [Anonymous], 2023, Nexavar [Package Insert]
   Behling F, 2019, CANCERS, V11, DOI 10.3390/cancers11060794
   Bellevicine C, 2020, CANCER CYTOPATHOL, V128, P107, DOI 10.1002/cncy.22217
   Bellevicine C, 2016, CANCER CYTOPATHOL, V124, P776, DOI 10.1002/cncy.21780
   Benayed R, 2019, CLIN CANCER RES, V25, P4712, DOI 10.1158/1078-0432.CCR-19-0225
   Bertazza L, 2015, J CELL MOL MED, V19, P2244, DOI 10.1111/jcmm.12612
   Biteghe FAN, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8090327
   Bonfill-Teixidor E, 2022, CANCER RES, V82, P2552, DOI 10.1158/0008-5472.CAN-21-4152
   Boussemart L, 2013, ANN ONCOL, V24, P1691, DOI 10.1093/annonc/mdt015
   Bradish JR, 2014, HUM PATHOL, V45, P1315, DOI 10.1016/j.humpath.2014.04.001
   Brustugun OT, 2014, LUNG CANCER, V84, P36, DOI 10.1016/j.lungcan.2014.01.023
   Cancer Genome Atlas Research Network, 2014, Nature, V511, P543, DOI [10.1038/s41586-018-0228-6, 10.1038/nature13385]
   Capper D, 2011, ACTA NEUROPATHOL, V122, P11, DOI 10.1007/s00401-011-0841-z
   Chabner BA, 2005, NAT REV CANCER, V5, P65, DOI 10.1038/nrc1529
   Chen WJ, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241914837
   Cheng DT, 2015, J MOL DIAGN, V17, P251, DOI 10.1016/j.jmoldx.2014.12.006
   Cheng L, 2018, MODERN PATHOL, V31, P24, DOI 10.1038/modpathol.2017.104
   Chong H, 2001, EMBO J, V20, P3716, DOI 10.1093/emboj/20.14.3716
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Cocco E, 2019, CANCER RES, V79, P1047, DOI 10.1158/0008-5472.CAN-18-3126
   Cohen D, 2020, J THORAC ONCOL, V15, P1000, DOI 10.1016/j.jtho.2020.01.019
   Cohen Y, 2004, CLIN CANCER RES, V10, P2761, DOI 10.1158/1078-0432.CCR-03-0273
   Dankner M, 2018, ONCOGENE, V37, P3183, DOI 10.1038/s41388-018-0171-x
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Davies KD, 2018, J THORAC ONCOL, V13, P1474, DOI 10.1016/j.jtho.2018.05.041
   Davies MA, 2017, LANCET ONCOL, V18, P863, DOI 10.1016/S1470-2045(17)30429-1
   DENT P, 1992, SCIENCE, V257, P1404, DOI 10.1126/science.1326789
   Desmeules P, 2022, JTO CLIN RES REP, V3, DOI 10.1016/j.jtocrr.2022.100276
   Dhillon AS, 2002, EMBO J, V21, P64, DOI 10.1093/emboj/21.1.64
   Dhomen N, 2007, CURR OPIN GENET DEV, V17, P31, DOI 10.1016/j.gde.2006.12.005
   Diamond EL, 2019, NATURE, V567, P521, DOI 10.1038/s41586-019-1012-y
   Diamond EL, 2018, JAMA ONCOL, V4, P384, DOI 10.1001/jamaoncol.2017.5029
   Drilon A, 2017, J THORAC ONCOL, V12, P15, DOI 10.1016/j.jtho.2016.10.014
   Dummer R, 2018, LANCET ONCOL, V19, P603, DOI 10.1016/S1470-2045(18)30142-6
   Elisei R, 2008, J CLIN ENDOCR METAB, V93, P3943, DOI 10.1210/jc.2008-0607
   Falzone L, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01300
   Fariña-Sarasqueta A, 2010, ANN ONCOL, V21, P2396, DOI 10.1093/annonc/mdq258
   Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Foster SA, 2016, CANCER CELL, V29, P477, DOI 10.1016/j.ccell.2016.02.010
   Frisone D, 2020, CRIT REV ONCOL HEMAT, V152, DOI 10.1016/j.critrevonc.2020.103008
   Garcia-Carbonero N, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010219
   Garutti M, 2023, CANCERS, V15, DOI 10.3390/cancers15010141
   Gautschi O, 2012, J THORAC ONCOL, V7, pE23, DOI 10.1097/JTO.0b013e3182629903
   George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664
   Gibney GT, 2013, NAT REV CLIN ONCOL, V10, P390, DOI 10.1038/nrclinonc.2013.83
   Gonsalves WI, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/dju106
   Gouda MA, 2023, ESMO OPEN, V8, DOI 10.1016/j.esmoop.2023.100788
   Gouda MA, 2022, ANN ONCOL, V33, P1209, DOI 10.1016/j.annonc.2022.09.157
   Gouda MA, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2021.100357
   Gouda MA, 2022, ENDOCRINE, V76, P491, DOI 10.1007/s12020-022-03004-z
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo R, 2021, CLIN CANCER RES, V27, P799, DOI 10.1158/1078-0432.CCR-20-2861
   Guo RB, 2020, NAT REV CLIN ONCOL, V17, P569, DOI 10.1038/s41571-020-0377-z
   Hall-Jackson CA, 1999, CHEM BIOL, V6, P559, DOI 10.1016/S1074-5521(99)80088-X
   Hanrahan AJ, 2024, NAT REV CLIN ONCOL, V21, P224, DOI 10.1038/s41571-023-00852-0
   Harada G, 2023, NAT REV CLIN ONCOL, V20, P229, DOI 10.1038/s41571-023-00733-6
   Hartsough EJ, 2018, MOL CANCER THER, V17, P84, DOI 10.1158/1535-7163.MCT-17-0705
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Hayward NK, 2017, NATURE, V545, P175, DOI 10.1038/nature22071
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Hoadley KA, 2014, CELL, V158, P929, DOI 10.1016/j.cell.2014.06.049
   Horbinski C, 2012, NEURO-ONCOLOGY, V14, P777, DOI 10.1093/neuonc/nos077
   Ihle MA, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-13
   Imielinski M, 2012, CELL, V150, P1107, DOI 10.1016/j.cell.2012.08.029
   Iyer PC, 2018, JCO PRECIS ONCOL, V2, DOI 10.1200/PO.18.00173
   Jin T, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01274-0
   Jo YS, 2006, J CLIN ENDOCR METAB, V91, P3667, DOI 10.1210/jc.2005-2836
   Johnson DB, 2018, PIGM CELL MELANOMA R, V31, P432, DOI 10.1111/pcmr.12674
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Karki Sophiya, 2023, Fortune J Health Sci, V6, P167, DOI 10.26502/fjhs.112
   Karoulia Z, 2017, NAT REV CANCER, V17, P676, DOI 10.1038/nrc.2017.79
   Karoulia Z, 2016, CANCER CELL, V30, P485, DOI 10.1016/j.ccell.2016.06.024
   Kebebew E, 2007, ANN SURG, V246, P466, DOI 10.1097/SLA.0b013e318148563d
   Kim J, 2006, ANN SURG, V244, P799, DOI 10.1097/01.sla.0000224751.80858.13
   Kim TH, 2012, CANCER-AM CANCER SOC, V118, P1764, DOI 10.1002/cncr.26500
   Kim TY, 2006, CLIN ENDOCRINOL, V65, P364, DOI 10.1111/j.1365-2265.2006.02605.x
   Knauf JA, 2005, CANCER RES, V65, P4238, DOI 10.1158/0008-5472.CAN-05-0047
   Kolch W, 2000, BIOCHEM J, V351, P289, DOI 10.1042/0264-6021:3510289
   Kornev AP, 2015, TRENDS BIOCHEM SCI, V40, P628, DOI 10.1016/j.tibs.2015.09.002
   Krebs MG, 2022, JAMA ONCOL, V8, P1830, DOI 10.1001/jamaoncol.2022.4457
   KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0
   Larkin J, 2014, NEW ENGL J MED, V371, P1867, DOI 10.1056/NEJMoa1408868
   Lassaletta A, 2017, J CLIN ONCOL, V35, P2934, DOI 10.1200/JCO.2016.71.8726
   Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979
   Lee JH, 2007, CANCER-AM CANCER SOC, V110, P38, DOI 10.1002/cncr.22754
   Leighl NB, 2019, CLIN CANCER RES, V25, P4691, DOI 10.1158/1078-0432.CCR-19-0624
   Leonardi GC, 2018, INT J ONCOL, V52, P1071, DOI 10.3892/ijo.2018.4287
   Leonetti A, 2018, CANCER TREAT REV, V66, P82, DOI 10.1016/j.ctrv.2018.04.006
   Lin Q, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-2036-7
   Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009
   Liu L, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2662-2
   Long GV, 2017, ANN ONCOL, V28, P1631, DOI 10.1093/annonc/mdx176
   Long GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6694
   Long GV, 2011, J CLIN ONCOL, V29, P1239, DOI 10.1200/JCO.2010.32.4327
   Malapelle U, 2020, CRIT REV ONCOL HEMAT, V156, DOI 10.1016/j.critrevonc.2020.103118
   Malapelle U, 2016, J CLIN PATHOL, V69, P767, DOI 10.1136/jclinpath-2015-203403
   Malindi Z, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10092158
   Marchetti A, 2011, J CLIN ONCOL, V29, P3574, DOI 10.1200/JCO.2011.35.9638
   Martins-de-Barros AV, 2022, J ORAL PATHOL MED, V51, P223, DOI 10.1111/jop.13278
   Matallanas David, 2011, Genes Cancer, V2, P232, DOI 10.1177/1947601911407323
   Mazieres J, 2020, ANN ONCOL, V31, P289, DOI 10.1016/j.annonc.2019.10.022
   Mesa C, 2006, CANCER RES, V66, P6521, DOI 10.1158/0008-5472.CAN-06-0739
   Missiaglia E, 2014, ANN ONCOL, V25, P1995, DOI 10.1093/annonc/mdu275
   Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531
   MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013
   Morrison DK, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a011254
   Mosele F, 2020, ANN ONCOL, V31, P1491, DOI 10.1016/j.annonc.2020.07.014
   Namba H, 2003, J CLIN ENDOCR METAB, V88, P4393, DOI 10.1210/jc.2003-030305
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Nikiforov YE, 2011, NAT REV ENDOCRINOL, V7, P569, DOI 10.1038/nrendo.2011.142
   Nikiforova MN, 2003, J CLIN ENDOCR METAB, V88, P5399, DOI 10.1210/jc.2003-030838
   Niu YZ, 2019, CHEM BIOL DRUG DES, V93, P177, DOI 10.1111/cbdd.13399
   Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396
   Pan JH, 2018, CANCER MANAG RES, V10, P2289, DOI 10.2147/CMAR.S170105
   Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714
   Passiglia F, 2022, CANCER TREAT REV, V109, DOI 10.1016/j.ctrv.2022.102438
   Bracht JWP, 2019, CANCERS, V11, DOI 10.3390/cancers11091381
   Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002
   Peters S, 2013, J CLIN ONCOL, V31, pE341, DOI 10.1200/JCO.2012.47.6143
   Pisapia P, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122549
   Pisapia P, 2019, ACTA CYTOL, V63, P247, DOI 10.1159/000496478
   Planchard D, 2022, J THORAC ONCOL, V17, P103, DOI 10.1016/j.jtho.2021.08.011
   Popescu A, 2018, ROM J INTERN MED, V56, P122, DOI 10.1515/rjim-2017-0044
   Poulikakos PI, 2022, CLIN CANCER RES, V28, P4618, DOI 10.1158/1078-0432.CCR-21-2138
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   RAPP UR, 1983, P NATL ACAD SCI-BIOL, V80, P4218, DOI 10.1073/pnas.80.14.4218
   Ribas A, 2019, NAT MED, V25, P936, DOI 10.1038/s41591-019-0476-5
   Ribas A, 2011, NAT REV CLIN ONCOL, V8, P426, DOI 10.1038/nrclinonc.2011.69
   Robinson SD, 2014, LUNG CANCER, V85, P326, DOI 10.1016/j.lungcan.2014.05.009
   Brannon AR, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-24109-5
   Ross JS, 2016, INT J CANCER, V138, P881, DOI 10.1002/ijc.29825
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Schirripa M, 2019, CLIN CANCER RES, V25, P3954, DOI 10.1158/1078-0432.CCR-19-0311
   Schmid S, 2015, LUNG CANCER, V87, P85, DOI 10.1016/j.lungcan.2014.11.008
   Schrock AB, 2017, J THORAC ONCOL, V12, P932, DOI 10.1016/j.jtho.2017.03.005
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Singh AK, 2023, ACS OMEGA, V8, P27819, DOI 10.1021/acsomega.3c00332
   Smiech M, 2020, GENES-BASEL, V11, DOI 10.3390/genes11111342
   Song YL, 2023, GENES DIS, V10, P76, DOI 10.1016/j.gendis.2022.05.006
   Tabernero Josep, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_349561
   Tabernero J, 2013, CLIN CANCER RES, V19, P2541, DOI 10.1158/1078-0432.CCR-13-0107
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Tran NH, 2005, J BIOL CHEM, V280, P16244, DOI 10.1074/jbc.M501185200
   Trovisco V, 2005, VIRCHOWS ARCH, V446, P589, DOI 10.1007/s00428-005-1236-0
   Trovisco V, 2006, HUM PATHOL, V37, P781, DOI 10.1016/j.humpath.2006.03.013
   van der Kooij MK, 2020, CANCERS, V12, DOI 10.3390/cancers12082072
   VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213
   Vanni I, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00113
   Vidarsdottir L, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-89389-9
   Vijayan RSK, 2015, J MED CHEM, V58, P466, DOI 10.1021/jm501603h
   VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C
   Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631
   WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0
   Wichmann J, 2022, CLIN CANCER RES, V28, P770, DOI 10.1158/1078-0432.CCR-21-2761
   Wojnowski L, 1997, NAT GENET, V16, P293, DOI 10.1038/ng0797-293
   Wolchok JD, 2022, J CLIN ONCOL, V40, P127, DOI 10.1200/JCO.21.02229
   Wu P, 2015, TRENDS PHARMACOL SCI, V36, P422, DOI 10.1016/j.tips.2015.04.005
   Xing M, 2004, J CLIN ENDOCR METAB, V89, P1365, DOI 10.1210/jc.2003-031488
   Xing M, 2005, ENDOCR-RELAT CANCER, V12, P245, DOI 10.1677/erc.1.0978
   Xing MZ, 2005, J CLIN ENDOCR METAB, V90, P6373, DOI 10.1210/jc.2005-0987
   Xu XL, 2003, CANCER RES, V63, P4561
   Yang SR, 2021, CLIN CANCER RES, V27, P1316, DOI 10.1158/1078-0432.CCR-20-3208
   Yao HX, 2016, ARCH PHARM, V349, P808, DOI 10.1002/ardp.201600184
   Yao Z, 2019, NAT MED, V25, P284, DOI 10.1038/s41591-018-0274-5
   Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291
   Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982
   Zhang W, 2002, CELL RES, V12, P9, DOI 10.1038/sj.cr.7290105
   ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0
   Zuo Q, 2018, ONCOGENE, V37, P3275, DOI 10.1038/s41388-018-0205-4
NR 183
TC 0
Z9 0
U1 4
U2 4
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2024
VL 16
IS 6
AR 1215
DI 10.3390/cancers16061215
PG 23
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ME8C4
UT WOS:001192031600001
PM 38539548
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Fath, MK
   Ebrahimi, M
   Nourbakhsh, E
   Hazara, AZ
   Mirzaei, A
   Shafieyari, S
   Salehi, A
   Hoseinzadeh, M
   Payandeh, Z
   Barati, G
AF Fath, Mohsen Karami
   Ebrahimi, Menooa
   Nourbakhsh, Ehsan
   Hazara, Ahmad Zia
   Mirzaei, Ali
   Shafieyari, Saba
   Salehi, Azadeh
   Hoseinzadeh, Mahsa
   Payandeh, Zahra
   Barati, Ghasem
TI PI3K/Akt/mTOR signaling pathway in cancer stem cells
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Review
DE Cancer stem cell; PI3K; Akt; mTOR pathway; Targeted cancer therapy;
   Pathogenesis
ID TUMOR-INITIATING CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; ROTTLERIN
   INDUCES AUTOPHAGY; ACUTE MYELOID-LEUKEMIA; COLORECTAL-CANCER;
   DOWN-REGULATION; MTOR; RAPAMYCIN; CD44; ACTIVATION
AB Cancer stem cells (CSCs) as a small subpopulation in tumor bulk are believed to initiate tumor formation and are responsible for the resistance to cancer therapy. The proliferation and differentiation of CSCs result in heterogeneity in a tumor which increases the chance of tumor survival and invasion. Many signaling pathways are abnormally activated or repressed in CSCs. Understanding these pathways and the metabolisms in CSCs may help targeted therapy in drug-resistant tumors. The PI3K/Akt/mTOR pathway is one of the major signaling pathways in CSCs involved in the maintenance of stemness, proliferation, differentiation, epithelial to mesenchymal transition (EMT), migration, and autophagy. Thus, suppressing the PI3K/Akt/mTOR pathway with inhibitors might be a promising strategy for targeted cancer therapy. Although the pathway is well-recognized and reviewed in tumor bulks, the functions in CSCs have not been well focused. Here, we reviewed the PI3K/Akt/ mTOR signaling pathway and its functions in CSCs and addressed the potential therapeutic applications in drugresistant tumors.
C1 [Fath, Mohsen Karami] Kharazmi Univ, Fac Biol Sci, Dept Cellular & Mol Biol, Tehran, Iran.
   [Ebrahimi, Menooa] Qazvin Univ Med Sci, Shahid Babai Fac Med, Qazvin, Iran.
   [Nourbakhsh, Ehsan] Shahid Beheshti Univ Med Sci, Fac Med, Tehran, Iran.
   [Hazara, Ahmad Zia] Shahid Sadoughi Univ Med Sci, Dept Immunol, Yazd, Iran.
   [Mirzaei, Ali] Shiraz Univ Med Sci, Fac Nursing & Midwifery, Shiraz, Iran.
   [Shafieyari, Saba] Hamadan Univ Med Sci, Fac Med, Hamadan, Iran.
   [Salehi, Azadeh] Islamic Azad Univ, Tehran Branch, Fac Pharm, Tehran, Iran.
   [Hoseinzadeh, Mahsa] Islamic Azad Univ Jahrom, Dept Biol Sci & Technol, Jahrom, Fars, Iran.
   [Payandeh, Zahra] Karolinska Inst, Dept Med Biochem & Biophys, Div Med Inflammat Res, Solna, Sweden.
   [Barati, Ghasem] Stem Cell Technol Res Ctr, Tehran, Iran.
C3 Kharazmi University; Qazvin University of Medical Sciences (QUMS);
   Shahid Beheshti University Medical Sciences; Shiraz University of
   Medical Science; Hamadan University of Medical Sciences; Islamic Azad
   University; Islamic Azad University; Karolinska Institutet
RP Barati, G (corresponding author), Stem Cell Technol Res Ctr, Tehran, Iran.
EM m.gh.barati@gmail.com
RI payandeh, zahra/CAF-0179-2022; nabi afjadi, mohsen/HJA-1747-2022;
   Mirzaei, Ali/KLE-0180-2024; Hazara, Ahmad Zia/GOG-8202-2022
OI Karami Fath, Mohsen/0000-0003-2499-7960; Hazara, Ahmad
   Zia/0000-0001-6802-4613
CR Afify SM, 2021, EXPERT REV ANTICANC, V21, P605, DOI 10.1080/14737140.2021.1918001
   Aghajani M, 2019, J CELL PHYSIOL, V234, P21642, DOI 10.1002/jcp.28824
   Alessi DR, 1997, CURR BIOL, V7, P776, DOI 10.1016/S0960-9822(06)00336-8
   Asai R, 2019, CANCER MED-US, V8, P773, DOI 10.1002/cam4.1968
   Ayob AZ, 2018, J BIOMED SCI, V25, DOI 10.1186/s12929-018-0426-4
   Azpiazu I, 1996, J BIOL CHEM, V271, P5033
   Bahmad HF, 2021, FRONT GENET, V12, DOI 10.3389/fgene.2021.652747
   Bahmad Hisham F, 2018, Oncotarget, V9, P33549, DOI 10.18632/oncotarget.26088
   Bahmad HF, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00347
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Buhrmann C, 2020, MOLECULES, V25, DOI 10.3390/molecules25184292
   Chae WO, 2021, J CANCER PREV, V26, P183, DOI 10.15430/JCP.2021.26.3.183
   Chang L, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.407
   Cheaito K, 2022, ONCOL LETT, V23, DOI 10.3892/ol.2021.13124
   Chen JZ, 2015, CLIN EXP PHARMACOL P, V42, P1317, DOI 10.1111/1440-1681.12493
   Chen YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep27301
   Cournoyer S, 2012, GENE CHROMOSOME CANC, V51, P792, DOI 10.1002/gcc.21964
   Cui JJ, 2016, INT J MOL MED, V37, P1299, DOI 10.3892/ijmm.2016.2542
   Deng JL, 2019, BMC CANCER, V19, DOI 10.1186/s12885-019-5824-9
   Dillenburg-Pilla P, 2015, FASEB J, V29, P1056, DOI 10.1096/fj.14-260083
   Erdogan S, 2018, BIOMED PHARMACOTHER, V107, P793, DOI 10.1016/j.biopha.2018.08.061
   Espinoza I, 2013, CANCER LETT, V341, P41, DOI 10.1016/j.canlet.2013.08.027
   Falke Joseph J, 2007, Cellscience, V4, P25
   Fan QW, 2017, CANCER CELL, V31, P424, DOI 10.1016/j.ccell.2017.01.014
   Fang DD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067258
   Francipane MG, 2013, ONCOTARGET, V4, P1948, DOI 10.18632/oncotarget.1310
   Gazi M, 2017, CANCER LETT, V392, P9, DOI 10.1016/j.canlet.2017.01.035
   Ge YJ, 2017, CELL, V169, P636, DOI 10.1016/j.cell.2017.03.042
   Glinka Y, 2012, BIOCHEM BIOPH RES CO, V425, P775, DOI 10.1016/j.bbrc.2012.07.151
   Hall CP, 2016, CLIN CANCER RES, V22, P621, DOI 10.1158/1078-0432.CCR-15-0114
   He ML, 2019, EXP NEUROL, V311, P15, DOI 10.1016/j.expneurol.2018.09.006
   He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928
   Heng WS, 2021, LUNG CANCER, V154, P13, DOI 10.1016/j.lungcan.2021.02.002
   Hibdon ES, 2019, NEOPLASIA, V21, P702, DOI 10.1016/j.neo.2019.05.002
   Hsieh AC, 2012, NATURE, V485, P55, DOI 10.1038/nature10912
   Huang FF, 2013, CANCER LETT, V336, P96, DOI 10.1016/j.canlet.2013.04.006
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Jang JW, 2017, LIFE SCI, V184, P25, DOI 10.1016/j.lfs.2017.07.008
   Khan P, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-53134-0
   Kingham E, 2009, J CELL SCI, V122, P2311, DOI 10.1242/jcs.046557
   Kumar D, 2014, CANCER LETT, V343, P179, DOI 10.1016/j.canlet.2013.10.003
   Kuroshima K, 2020, CANCER SCI, V111, P1607, DOI 10.1111/cas.14395
   Kusoglu A, 2019, GENE, V681, P80, DOI 10.1016/j.gene.2018.09.052
   Kwasnicki A, 2015, ANTICANCER RES, V35, P689
   La Manna F, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01012
   LAPIDOT T, 1994, NATURE, V367, P645, DOI 10.1038/367645a0
   Lau EYT, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/3714190
   Le Tourneau C, 2008, BRIT J CANCER, V99, P1197, DOI 10.1038/sj.bjc.6604636
   Li J, 2014, CELL METAB, V19, P373, DOI 10.1016/j.cmet.2014.01.001
   Li XL, 2018, LIFE SCI, V196, P56, DOI 10.1016/j.lfs.2018.01.014
   Liou GY, 2019, INT J BIOCHEM CELL B, V106, P1, DOI 10.1016/j.biocel.2018.10.013
   Lv J, 2021, MOL MED REP, V24, DOI 10.3892/mmr.2021.12249
   Ma FL, 2016, SCI REP-UK, V6, DOI 10.1038/srep38805
   Matsubara S, 2013, SCI REP-UK, V3, DOI 10.1038/srep03230
   Menon S, 2008, Oncogene, V27 Suppl 2, pS43, DOI 10.1038/onc.2009.352
   Miller TW, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3103
   Miyazaki Y, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0534-2
   Morita M, 2013, CELL METAB, V18, P698, DOI 10.1016/j.cmet.2013.10.001
   Mu Xiaodong, 2013, Sarcoma, V2013, P480713, DOI 10.1155/2013/480713
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   Murakami M, 2004, MOL CELL BIOL, V24, P6710, DOI 10.1128/mcb.24.15.6710-6718.2004
   Nguyen K, 2018, MOL CANCER THER, V17, P2689, DOI 10.1158/1535-7163.MCT-18-0399
   Oricchio E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aak9969
   Paling NRD, 2004, J BIOL CHEM, V279, P48063, DOI 10.1074/jbc.M406467200
   Parekh D, 1999, J BIOL CHEM, V274, P34758, DOI 10.1074/jbc.274.49.34758
   Park SY, 2022, J DENT SCI, V17, P145, DOI 10.1016/j.jds.2021.05.013
   Pattabiraman DR, 2014, NAT REV DRUG DISCOV, V13, P497, DOI 10.1038/nrd4253
   Payne SN, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.28
   Popova NV, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041743
   Pópulo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Ravindran S, 2019, CANCER MICROENVIRON, V12, P133, DOI 10.1007/s12307-019-00233-1
   Reya T, 2001, NATURE, V414, P105, DOI 10.1038/35102167
   Ricardo S, 2011, J CLIN PATHOL, V64, P937, DOI 10.1136/jcp.2011.090456
   Rodrik-Outmezguine VS, 2016, NATURE, V534, P272, DOI 10.1038/nature17963
   Sabatini DM, 2006, NAT REV CANCER, V6, P729, DOI 10.1038/nrc1974
   Schaefer T, 2020, ONCOGENE, V39, P278, DOI 10.1038/s41388-019-0997-x
   Scheid MP, 2001, NAT REV MOL CELL BIO, V2, P760, DOI 10.1038/35096067
   Sell S, 2010, AM J PATHOL, V176, P2584, DOI 10.2353/ajpath.2010.091064
   Shariati M, 2019, EXPERT OPIN INV DRUG, V28, P977, DOI 10.1080/13543784.2019.1676726
   Sharif T, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0997-8
   Sharma N, 2015, ONCOTARGET, V6, P32039, DOI 10.18632/oncotarget.5055
   Shi HB, 2019, J CANCER RES THER, V15, P398, DOI 10.4103/jcrt.JCRT_639_18
   Singh BN, 2012, BIOCHEM PHARMACOL, V84, P1154, DOI 10.1016/j.bcp.2012.08.007
   Singh SK, 2003, CANCER RES, V63, P5821
   Song MQ, 2019, CANCER RES, V79, P1019, DOI 10.1158/0008-5472.CAN-18-2738
   Trapasso S, 2012, BIOL-TARGETS THER, V6, P379, DOI 10.2147/BTT.S37906
   Tysnes BB, 2007, BBA-REV CANCER, V1775, P283, DOI 10.1016/j.bbcan.2007.01.001
   Usui I, 2000, BIOCHEM BIOPH RES CO, V275, P115, DOI 10.1006/bbrc.2000.3201
   Varas-Godoy M, 2017, STEM CELLS INT, V2017, DOI 10.1155/2017/5263974
   Wang CX, 2012, ONCOL REP, V28, P1301, DOI 10.3892/or.2012.1951
   Wang KL, 2020, PHYTOMEDICINE, V68, DOI 10.1016/j.phymed.2020.153191
   Wang L, 2018, METHODS MOL BIOL, V1692, P31, DOI 10.1007/978-1-4939-7401-6_3
   Wang N, 2018, CELL PHYSIOL BIOCHEM, V50, P1804, DOI 10.1159/000494821
   Wang YL, 2013, BIOCHEM BIOPH RES CO, V434, P352, DOI 10.1016/j.bbrc.2013.03.077
   Wen W, 2013, MOL CANCER THER, V12, P1796, DOI 10.1158/1535-7163.MCT-13-0099
   White E, 2012, NAT REV CANCER, V12, P401, DOI 10.1038/nrc3262
   Workman P, 2010, CANCER RES, V70, P2146, DOI 10.1158/0008-5472.CAN-09-4355
   Wu YJ, 2009, STEM CELLS DEV, V18, P1127, DOI 10.1089/scd.2008.0338
   Xu ZR, 2020, APPL MICROBIOL BIOT, V104, P575, DOI 10.1007/s00253-019-10257-8
   Yaguchi SI, 2006, JNCI-J NATL CANCER I, V98, P545, DOI 10.1093/jnci/djj133
   Yang CG, 2015, INT J ONCOL, V47, P909, DOI 10.3892/ijo.2015.3100
   Yang LQ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0110-5
   Yang Z, 2016, ONCOTARGET, V7, P44478, DOI 10.18632/oncotarget.9873
   Yokogami K, 2000, CURR BIOL, V10, P47, DOI 10.1016/S0960-9822(99)00268-7
   Yu JSL, 2016, DEVELOPMENT, V143, P3050, DOI 10.1242/dev.137075
   Yueh AE, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148730
   Zhao H, 2019, INT J ONCOL, V54, P893, DOI 10.3892/ijo.2019.4683
   Zhao Q, 2015, INT J MOL MED, V36, P857, DOI 10.3892/ijmm.2015.2284
   Zhou BBS, 2009, NAT REV DRUG DISCOV, V8, P806, DOI 10.1038/nrd2137
   Zhou HY, 2019, ONCOGENE, V38, P3371, DOI 10.1038/s41388-018-0674-5
   Zhou JB, 2007, P NATL ACAD SCI USA, V104, P16158, DOI 10.1073/pnas.0702596104
NR 112
TC 67
Z9 69
U1 12
U2 33
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
EI 1618-0631
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD SEP
PY 2022
VL 237
AR 154010
DI 10.1016/j.prp.2022.154010
EA JUL 2022
PG 9
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA 4E9NB
UT WOS:000848144100006
PM 35843034
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Kalantari, E
   Taheri, T
   Fata, S
   Abolhasani, M
   Mehrazma, M
   Madjd, Z
   Asgari, M
AF Kalantari, Elham
   Taheri, Tahereh
   Fata, Saba
   Abolhasani, Maryam
   Mehrazma, Mitra
   Madjd, Zahra
   Asgari, Mojgan
TI Significant co-expression of putative cancer stem cell markers, EpCAM
   and CD166, correlates with tumor stage and invasive behavior in
   colorectal cancer
SO WORLD JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE Cancer stem cells; EpCAM; CD166; Colorectal cancer; Tissue microarray
ID ADHESION MOLECULE; EP-CAM; LYMPH-NODES; EXPRESSION; CARCINOMA;
   PREDICTOR; ALDH1; OVEREXPRESSION; PROSTATE; SURVIVAL
AB Background The crucial oncogenic role of cancer stem cells (CSCs) in tumor maintenance, progression, drug resistance, and relapse has been clarified in different cancers, particularly in colorectal cancer (CRC). The current study was conducted to evaluate the co-expression pattern and clinical significance of epithelial cell adhesion molecules (EpCAM) and activated leukocyte cell adhesion (CD166 or ALCAM) in CRC patients. Methods This study was carried out on 458 paraffin-embedded CRC specimens by immunohistochemistry on tissue microarray (TMA) slides. Results Elevated expression of EpCAM and CD166 was observed in 61.5% (246/427) and 40.5% (164/405) of CRC cases. Our analysis showed a significant positive association of EpCAM expression with tumor size (P = 0.02), tumor stage (P = 0.007), tumor differentiate (P = 0.005), vascular (P = 0.01), neural (P = 0.01), and lymph node (P = 0.001) invasion. There were no significant differences between CD166 expression and clinicopathological parameters. Moreover, the combined analysis demonstrated a reciprocal significant correlation between EpCAM and CD166 expression (P = 0.02). Interestingly, there was a significant positive correlation between EpCAM/CD166 phenotypes expression and tumor stage (P = 0.03), tumor differentiation (P = 0.05), neural, and lymph node invasion (P =0.01). Conclusions The significant correlation of EpCAM and CD166 expression and their association with tumor progression and aggressive behavior is the reason for the suggestion of these two CSC markers as promising targets to promote novel effective targeted-therapy strategies for cancer treatment in the present study.
C1 [Kalantari, Elham; Abolhasani, Maryam; Mehrazma, Mitra; Madjd, Zahra; Asgari, Mojgan] Iran Univ Med Sci, Oncopathol Res Ctr, Hemmat St Highway,Next Milad Tower, Tehran 1449614530, Iran.
   [Taheri, Tahereh; Fata, Saba] Iran Univ Med Sci, Dept Pathol, Tehran, Iran.
   [Abolhasani, Maryam; Asgari, Mojgan] Iran Univ Med Sci, Hasheminejad Kidney Ctr, Dept Pathol, Tehran, Iran.
   [Madjd, Zahra] Iran Univ Med Sci, Fac Adv Technol Med, Dept Mol Med, Tehran, Iran.
C3 Iran University of Medical Sciences; Iran University of Medical
   Sciences; Iran University of Medical Sciences; Iran University of
   Medical Sciences
RP Madjd, Z; Asgari, M (corresponding author), Iran Univ Med Sci, Oncopathol Res Ctr, Hemmat St Highway,Next Milad Tower, Tehran 1449614530, Iran.; Asgari, M (corresponding author), Iran Univ Med Sci, Hasheminejad Kidney Ctr, Dept Pathol, Tehran, Iran.; Madjd, Z (corresponding author), Iran Univ Med Sci, Fac Adv Technol Med, Dept Mol Med, Tehran, Iran.
EM Zahra.madjd@yahoo.com; mojgan_asgari@yahoo.com
RI Madjd, Zahra/AAP-8105-2021; Abolhasani, Maryam/KTI-1579-2024
OI Abolhasani, Maryam/0000-0002-3046-5429
FU Iran University of Medical Sciences [IR.IUMS.REC1395.28944]
FX This study was funded by grants from the Iran University of Medical
   Sciences (Grant No: IR.IUMS.REC1395.28944).
CR Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451
   Bilchik AJ, 2006, ARCH SURG-CHICAGO, V141, P527, DOI 10.1001/archsurg.141.6.527
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brunner A, 2008, J CLIN PATHOL, V61, P307, DOI 10.1136/jcp.2007.049460
   Camp RL., 1943, LAB INVEST, V2000, P80
   Cherciu Irina, 2014, Curr Health Sci J, V40, P153, DOI 10.12865/CHSJ.40.03.01
   Du WQ, 2013, DIGEST DIS SCI, V58, P1811, DOI 10.1007/s10620-013-2722-x
   Ensinger C, 2006, J IMMUNOTHER, V29, P569, DOI 10.1097/01.cji.0000211303.52503.da
   Erfani E, 2016, INT J BIOL MARKER, V31, pE53, DOI 10.5301/jbm.5000165
   Fan XH, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01995-5
   Fong D, 2008, J CLIN PATHOL, V61, P31, DOI 10.1136/jcp.2006.037333
   Gao F, 2015, BIOCHEM BIOPH RES CO, V462, P91, DOI 10.1016/j.bbrc.2015.04.029
   Ghods R, 2014, BIOTECHNOL APPL BIOC, V61, P363, DOI 10.1002/bab.1177
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Goossens-Beumer IJ, 2014, BRIT J CANCER, V110, P2935, DOI 10.1038/bjc.2014.226
   Gosens MJEM, 2007, MODERN PATHOL, V20, P221, DOI 10.1038/modpathol.3800733
   Guan SS, 2020, EJNMMI RES, V10, DOI 10.1186/s13550-020-0597-3
   Han SS, 2017, ONCOTARGET, V8, P64373, DOI 10.18632/oncotarget.17442
   Hansen AG, 2013, CANCER RES, V73, P2955, DOI 10.1158/0008-5472.CAN-12-2052
   HERLYN M, 1979, P NATL ACAD SCI USA, V76, P1438, DOI 10.1073/pnas.76.3.1438
   Hiraga T, 2016, INT J CANCER, V138, P1698, DOI 10.1002/ijc.29921
   Horst D, 2009, CANCER INVEST, V27, P844, DOI 10.1080/07357900902744502
   Huang L, 2018, INT J MOL MED, V42, P1771, DOI 10.3892/ijmm.2018.3764
   Ihnen M, 2008, BREAST CANCER RES TR, V112, P419, DOI 10.1007/s10549-007-9879-y
   Jiang JH, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1028-9
   Kadkhoda S, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957-021-02378-0
   Kalantari E, 2019, INT J EXP PATHOL, V100, P123, DOI 10.1111/iep.12314
   Kalantari E, 2017, CANCER BIOMARK, V20, P563, DOI 10.3233/CBM-170383
   Klatte T, 2009, CLIN CANCER RES, V15, P1162, DOI 10.1158/1078-0432.CCR-08-1229
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li JX, 2020, WORLD J SURG ONCOL, V18, DOI 10.1186/s12957-020-01817-8
   Li T, 2010, LAB INVEST, V90, P234, DOI 10.1038/labinvest.2009.127
   Liu D, 2014, ONCOL LETT, V7, P1544, DOI 10.3892/ol.2014.1907
   Lugli A, 2010, BRIT J CANCER, V103, P382, DOI 10.1038/sj.bjc.6605762
   Manfredi S, 2006, BRIT J SURG, V93, P1115, DOI 10.1002/bjs.5349
   MCCARTY KS, 1985, ARCH PATHOL LAB MED, V109, P716
   Meirelles K, 2012, P NATL ACAD SCI USA, V109, P2358, DOI 10.1073/pnas.1120733109
   Mezzanzanica D, 2008, CLIN CANCER RES, V14, P1726, DOI 10.1158/1078-0432.CCR-07-0428
   Minner S, 2011, HUM PATHOL, V42, P1946, DOI 10.1016/j.humpath.2011.02.017
   Mohtar MA, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020255
   Ni C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070958
   Piyathilake CJ, 2000, HUM PATHOL, V31, P482, DOI 10.1053/hp.2000.6711
   Poczatek RB, 1999, J UROLOGY, V162, P1462, DOI 10.1016/S0022-5347(05)68341-3
   Ralhan R, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-331
   Rasti A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-30168-4
   Roudi R, 2015, CANCER INVEST, V33, P294, DOI 10.3109/07357907.2015.1034869
   Sadeghi A, 2019, BIOMARK MED, V13, P419, DOI 10.2217/bmm-2018-0337
   Scheunemann P, 2008, LANGENBECK ARCH SURG, V393, P359, DOI 10.1007/s00423-007-0215-0
   Scheunemann P, 2009, LANGENBECK ARCH SURG, V394, P105, DOI 10.1007/s00423-008-0369-4
   Schmidt M, 2008, CLIN CANCER RES, V14, P5849, DOI 10.1158/1078-0432.CCR-08-0669
   Seligson DB, 2004, CLIN CANCER RES, V10, P2659, DOI 10.1158/1078-0432.CCR-1132-03
   Shafaei S, 2013, CASP J INTERN MED, V4, P768
   Shafiei S, 2019, EXP MOL PATHOL, V108, P164, DOI 10.1016/j.yexmp.2019.04.015
   Sim SH, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-241
   Spizzo G, 2011, J CLIN PATHOL, V64, P415, DOI 10.1136/jcp.2011.090274
   Tachezy M, 2012, J SURG RES, V177, pE15, DOI 10.1016/j.jss.2012.02.013
   van der Gun BTF, 2010, CARCINOGENESIS, V31, P1913, DOI 10.1093/carcin/bgq187
   Varga M, 2004, CLIN CANCER RES, V10, P3131, DOI 10.1158/1078-0432.CCR-03-0528
   Weichert W, 2004, J CLIN PATHOL, V57, P1160, DOI 10.1136/jcp.2004.016238
   Went P, 2006, BRIT J CANCER, V94, P128, DOI 10.1038/sj.bjc.6602924
   Went P, 2005, AM J SURG PATHOL, V29, P83, DOI 10.1097/01.pas.0000.146028.70868.7a
   Went PT, 2004, HUM PATHOL, V35, P122, DOI 10.1016/j.humpath.2003.08.026
   Wu XS, 2012, WORLD J SURG ONCOL, V10, DOI 10.1186/1477-7819-10-244
   Yang J, 2020, BIOCHEM BIOPH RES CO, V522, P903, DOI 10.1016/j.bbrc.2019.11.152
   Yang X, 2021, WORLD J SURG ONCOL, V19, DOI 10.1186/s12957-021-02335-x
   Zanjani LS, 2020, ANN DIAGN PATHOL, V46, DOI 10.1016/j.anndiagpath.2020.151483
   Zeki SS, 2011, NAT REV GASTRO HEPAT, V8, P90, DOI 10.1038/nrgastro.2010.211
   Zhang XS, 2020, CANCER BIOTHER RADIO, V35, P214, DOI 10.1089/cbr.2019.3089
   Zhou FQ, 2015, GENET MOL RES, V14, P4485, DOI 10.4238/2015.May.4.6
   Zolfaghari MA, 2020, COMP STUDY LONG INTE
NR 70
TC 18
Z9 19
U1 1
U2 3
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-7819
J9 WORLD J SURG ONCOL
JI World J. Surg. Oncol.
PD JAN 11
PY 2022
VL 20
IS 1
AR 15
DI 10.1186/s12957-021-02469-y
PG 11
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA YE8QO
UT WOS:000741384400002
PM 35016698
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Li, X
   Li, WM
   Wang, J
   Wang, Q
   Liang, MH
   Chen, S
   Ba, W
   Fang, J
AF Li, Xin
   Li, Wanming
   Wang, Jie
   Wang, Qun
   Liang, Menghu
   Chen, Shuo
   Ba, Wei
   Fang, Jin
TI Establishment of a novel microfluidic co-culture system for simultaneous
   analysis of multiple indicators of gefitinib sensitivity in colorectal
   cancer cells
SO MICROCHIMICA ACTA
LA English
DT Article
DE Microfluidic; Co-culture; Drug sensitivity; Gefitinib; Cancer associated
   fibroblasts; Colorectal cancer
ID PHASE-II TRIAL; TARGETED THERAPY; RESISTANCE; AUTOPHAGY
AB The therapeutic effect of gefitinib on colorectal cancer (CRC) is unclear, but it has been reported that stromal cells in the tumor microenvironment may have an impact on drug sensitivity. Herein, we established a microfluidic co-culture system and explored the sensitivity of CRC cells co-cultured with cancer-associated fibroblasts (CAFs) to gefitinib. The system consisted of a multichannel chip and a Petri dish. The chambers in the chip and dish were designed to continuously supply nutrients for long-term cell survival and create chemokine gradients for driving cell invasion without any external equipment. Using this system, the proliferation and invasiveness of cells were simultaneously evaluated by quantifying the area of cells and the migration distance of cells. In addition, the system combined with live cell workstation could evaluate the dynamic drug response of co-cultured cells and track individual cell trajectories in real-time. When CRC cells were co-cultured with CAFs, CAFs promoted CRC cell proliferation and invasion and reduced the sensitivity of cells to gefitinib through the exosomes secreted by CAFs. Furthermore, the cells that migrated out of the chip were collected, and EMT-related markers were determined by immunofluorescent and western blot assays. The results demonstrated that CAFs affected the response of CRC cells to gefitinib by inducing EMT, providing new ideas for further research on the resistance mechanism of gefitinib. This suggests that targeting CAFs or exosomes might be a new approach to enhance CRC sensitivity to gefitinib, and our system could be a novel platform for investigating the crosstalk between tumor cells and CAFs and understanding multiple biological changes of the tumor cells in the tumor microenvironment.
C1 [Li, Xin; Li, Wanming; Wang, Jie; Wang, Qun; Liang, Menghu; Chen, Shuo; Ba, Wei; Fang, Jin] China Med Univ, Minist Publ Hlth, Minist Educ,Key Lab Med Cell Biol, Dept Cell Biol,Key Lab Cell Biol, Shenyang 110122, Peoples R China.
C3 China Medical University
RP Fang, J (corresponding author), China Med Univ, Minist Publ Hlth, Minist Educ,Key Lab Med Cell Biol, Dept Cell Biol,Key Lab Cell Biol, Shenyang 110122, Peoples R China.
EM jfang@cmu.edu.cn
RI Fang, Jin/HKF-5214-2023
OI Fang, Jin/0000-0001-5188-5206
FU National Natural Science Foundation of China
FX No Statement Available
CR Bedard PL, 2020, LANCET, V395, P1078, DOI 10.1016/S0140-6736(20)30164-1
   Bonanini F, 2022, ANGIOGENESIS, V25, P455, DOI 10.1007/s10456-022-09842-9
   CARNEGIE JA, 1991, BIOL REPROD, V45, P572, DOI 10.1095/biolreprod45.4.572
   Chen L, 2016, APOPTOSIS, V21, P1291, DOI 10.1007/s10495-016-1287-5
   Chen ZZ, 2016, SCI REP-UK, V6, DOI 10.1038/srep38376
   Farin HF, 2023, CANCER DISCOV, V13, P2192, DOI 10.1158/2159-8290.CD-23-0050
   Gimondi S, 2023, ACS NANO, V17, P14205, DOI 10.1021/acsnano.3c01117
   Guan LY, 2018, DISCOV MED, V26, P219
   Hao GZ, 2016, J DRUG TARGET, V24, P557, DOI 10.3109/1061186X.2015.1113540
   Herrera-Juárez M, 2023, CANCER-AM CANCER SOC, V129, P1803, DOI 10.1002/cncr.34757
   Hu HC, 2021, CANCER CELL, V39, P1531, DOI 10.1016/j.ccell.2021.09.003
   Huang J, 2022, FLUIDS BARRIERS CNS, V19, DOI 10.1186/s12987-022-00342-y
   Katona BW, 2019, CANCER RES, V79, P2195, DOI 10.1158/0008-5472.CAN-18-2133
   Kim SK, 2020, CANCERS, V12, DOI 10.3390/cancers12051305
   Krakos A, 2023, MICROCHIM ACTA, V190, DOI 10.1007/s00604-023-05931-8
   Kumar P, 2023, RECENT PAT ANTI-CANC, V18, P448, DOI 10.2174/1574892818666221026164940
   Lee JH, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-017-0654-6
   Li PC, 2023, BIOSENSORS-BASEL, V13, DOI 10.3390/bios13010070
   Lu YY, 2023, SENSOR ACTUAT B-CHEM, V393, DOI 10.1016/j.snb.2023.134174
   MacKenzie MJ, 2005, INVEST NEW DRUG, V23, P165, DOI 10.1007/s10637-005-5862-9
   Makeen HA, 2020, DRUG DELIV, V27, P622, DOI 10.1080/10717544.2020.1754526
   Miyauchi E, 2022, J CLIN ONCOL, V40, P3587, DOI 10.1200/JCO.21.02911
   Nashimoto Y, 2020, BIOMATERIALS, V229, DOI 10.1016/j.biomaterials.2019.119547
   Niu MK, 2023, J HEMATOL ONCOL, V16, DOI 10.1186/s13045-023-01487-5
   Noronha V, 2020, J CLIN ONCOL, V38, P124, DOI 10.1200/JCO.19.01154
   Ochi K, 2022, CANCER SCI, V113, P3428, DOI 10.1111/cas.15502
   Ohishi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24021702
   Oppermann H, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0611-2
   Özyurt C, 2023, J PHARMACEUT BIOMED, V226, DOI 10.1016/j.jpba.2023.115266
   Rizzolio S, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02524-w
   Robinson NB, 2019, INT J SURG, V72, P9, DOI 10.1016/j.ijsu.2019.10.015
   Rothbauer M, 2018, LAB CHIP, V18, P249, DOI 10.1039/c7lc00815e
   Rothenberg ML, 2005, J CLIN ONCOL, V23, P9265, DOI 10.1200/JCO.2005.03.0536
   Saorin G, 2023, SEMIN CELL DEV BIOL, V144, P41, DOI 10.1016/j.semcdb.2022.10.001
   Singh S, 2023, BBA-REV CANCER, V1878, DOI 10.1016/j.bbcan.2023.188967
   Viktorsson K, 2023, STRAHLENTHER ONKOL, V199, P1091, DOI 10.1007/s00066-023-02064-y
   Wang J, 2023, BIOSENS BIOELECTRON, V227, DOI 10.1016/j.bios.2023.115159
   Wang WD, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24087150
   Wu XT, 2022, MOL THER, V30, P400, DOI 10.1016/j.ymthe.2021.07.004
   Xiao FQ, 2020, THORAC CANCER, V11, P3289, DOI 10.1111/1759-7714.13670
   Xing F, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01716-y
   Yamaguchi NH, 2014, J GASTROINTEST ONCOL, V5, P57, DOI 10.3978/j.issn.2078-6891.2013.056
   Yang KD, 2022, MOL CELL BIOCHEM, V477, P2493, DOI 10.1007/s11010-022-04436-x
   Yang QR, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01814-x
   Ye F, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01805-y
   Yuan ZN, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01744-8
   Zhang GZ, 2013, CANCER CHEMOTH PHARM, V72, P767, DOI 10.1007/s00280-013-2251-5
   Zhang MJ, 2023, J OVARIAN RES, V16, DOI 10.1186/s13048-023-01314-y
   Zhang YZ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-04709-9
   Zhao ZH, 2023, BMC CANCER, V23, DOI 10.1186/s12885-023-11011-0
   Zhou ZY, 2023, EPIGENETICS-US, V18, DOI 10.1080/15592294.2023.2217033
   Zhu LY, 2024, BIOFABRICATION, V16, DOI 10.1088/1758-5090/ad1116
NR 52
TC 1
Z9 1
U1 10
U2 14
PU SPRINGER WIEN
PI Vienna
PA Prinz-Eugen-Strasse 8-10, A-1040 Vienna, AUSTRIA
SN 0026-3672
EI 1436-5073
J9 MICROCHIM ACTA
JI Microchim. Acta
PD MAY
PY 2024
VL 191
IS 5
AR 279
DI 10.1007/s00604-024-06362-9
PG 15
WC Chemistry, Analytical
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA OH3N6
UT WOS:001206342500002
PM 38647729
DA 2025-01-04
ER

PT J
AU Ooi, VY
   Yeh, TY
AF Ooi, Vivian Y.
   Yeh, Ting-Yu
TI Recent Advances and Mechanisms of Phage-Based Therapies in Cancer
   Treatment
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE phage; peptide display; cancer therapy; gene therapy; immunity
ID NEUROENDOCRINE TUMORS; DIAGNOSIS; MANAGEMENT; MUTATIONS; ANTIGENS;
   DELIVERY; RECEPTOR; GROWTH
AB The increasing interest in bacteriophage technology has prompted its novel applications to treat different medical conditions, most interestingly cancer. Due to their high specificity, manipulability, nontoxicity, and nanosize nature, phages are promising carriers in targeted therapy and cancer immunotherapy. This approach is particularly timely, as current challenges in cancer research include damage to healthy cells, inefficiency in targeting, obstruction by biological barriers, and drug resistance. Some cancers are being kept at the forefront of phage research, such as colorectal cancer and HCC, while others like lymphoma, cervical cancer, and myeloma have not been retouched in a decade. Common mechanisms are immunogenic antigen display on phage coats and the use of phage as transporters to carry drugs, genes, and other molecules. To date, popular phage treatments being tested are gene therapy and phage-based vaccines using M13 and lambda phage, with some vaccines having advanced to human clinical trials. The results from most of these studies have been promising, but limitations in phage-based therapies such as reticuloendothelial system clearance or diffusion inefficiency must be addressed. Before phage-based therapies for cancer can be successfully used in oncology practice, more in-depth research and support from local governments are required.
C1 [Ooi, Vivian Y.; Yeh, Ting-Yu] Auxergen Inc, Agr Biotechnol Lab, Riti Rossi Colwell Ctr, 701 E Pratt St, Baltimore, MD 21202 USA.
   [Ooi, Vivian Y.] Walt Whitman High Sch, Bethesda, MD 20817 USA.
RP Yeh, TY (corresponding author), Auxergen Inc, Agr Biotechnol Lab, Riti Rossi Colwell Ctr, 701 E Pratt St, Baltimore, MD 21202 USA.
EM yehty@auxergen.com
OI Yeh, Ting/0000-0001-5333-5486; Ooi, Vivian/0009-0006-2076-4720
CR Abedon Stephen T, 2011, Bacteriophage, V1, P66
   Ackermann Hans-W, 2011, Bacteriophage, V1, P225
   Altun I, 2018, IRAN J PUBLIC HEALTH, V47, P1218
   Anfinsen KP, 2011, CANCER EPIDEM BIOMAR, V20, P1770, DOI 10.1158/1055-9965.EPI-11-0136
   [Anonymous], 2024, PDQ Cancer Information Summaries
   [Anonymous], 2020, Expanded access
   [Anonymous], Smoking and Cancer
   BAAS J, 1994, Z GASTROENTEROL, V32, P117
   Barati N, 2018, CANCER LETT, V424, P109, DOI 10.1016/j.canlet.2018.03.030
   Bazan J, 2012, HUM VACC IMMUNOTHER, V8, P1817, DOI 10.4161/hv.21703
   BLOCH HUBERT, 1940, ARCH GES VIRUSFORSCH, V1, P481, DOI 10.1007/BF01240654
   Brisar N, 2024, VIRUSES-BASEL, V16, DOI 10.3390/v16020232
   BROWN SL, 1989, BLOOD, V73, P651
   Chakraborty Sajib, 2012, Ecancermedicalscience, V6, ped16, DOI 10.3332/ecancer.2012.ed16
   Chang L, 2016, ONCOTARGET, V7, P23988, DOI 10.18632/oncotarget.8115
   Chongchai A, 2024, MOL THER ONCOL, V32, DOI 10.1016/j.omton.2024.200805
   Cieslewicz M, 2013, P NATL ACAD SCI USA, V110, P15919, DOI 10.1073/pnas.1312197110
   Clokie Martha Rj, 2011, Bacteriophage, V1, P31, DOI 10.4161/bact.1.1.14942
   Correia JH, 2021, PHARMACEUTICS, V13, DOI 10.3390/pharmaceutics13091332
   Cowan AJ, 2022, JAMA-J AM MED ASSOC, V327, P464, DOI 10.1001/jama.2022.0003
   Dai XY, 2015, EXP BIOL MED, V240, P760, DOI 10.1177/1535370215579167
   Damron TA, 2007, CLIN ORTHOP RELAT R, P40, DOI 10.1097/BLO.0b013e318059b8c9
   Das SK, 2015, J CELL PHYSIOL, V230, P259, DOI 10.1002/jcp.24791
   Davis LE, 2019, CANCER BIOL THER, V20, P1366, DOI 10.1080/15384047.2019.1640032
   Diallo K, 2023, ANTIBIOTICS-BASEL, V12, DOI 10.3390/antibiotics12040751
   Erez Z, 2017, NATURE, V541, P488, DOI 10.1038/nature21049
   Febvre HP, 2019, NUTRIENTS, V11, DOI 10.3390/nu11030666
   Foglizzo V, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14020161
   Fong KR, 2021, PHAGE-THER APPL RES, V2, P83, DOI 10.1089/phage.2020.0036
   Gazendam A, 2023, J CLIN MED, V12, DOI 10.3390/jcm12072506
   Ghaemi A, 2011, INTERVIROLOGY, V54, P105, DOI 10.1159/000320197
   González-Mora A, 2020, VACCINES-BASEL, V8, DOI 10.3390/vaccines8030504
   Gupta SL, 2022, VACCINES-BASEL, V10, DOI 10.3390/vaccines10060879
   Hallet J, 2015, CANCER-AM CANCER SOC, V121, P589, DOI 10.1002/cncr.29099
   Haq IU, 2012, VIROL J, V9, DOI 10.1186/1743-422X-9-9
   Huh H, 2019, ADV DRUG DELIVER REV, V145, P4, DOI 10.1016/j.addr.2019.01.003
   Hwang YJ, 2020, FRONT MICROBIOL, V11, DOI 10.3389/fmicb.2020.491001
   Institute for Quality and Efficiency in Health Care, 2021, InformedHealth.org Internet
   International Committee on Taxonomy of Viruses, Virus taxonomy
   Iqbal Nida, 2014, Chemother Res Pract, V2014, P357027, DOI [10.1155/2014/852748, 10.1155/2014/357027]
   Islam MS, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1290296
   Iwagami Y, 2017, HELIYON, V3, DOI 10.1016/j.heliyon.2017.e00407
   Jia LT, 2012, CANCER TREAT REV, V38, P868, DOI 10.1016/j.ctrv.2012.06.008
   Karimi M, 2016, ADV DRUG DELIVER REV, V106, P45, DOI 10.1016/j.addr.2016.03.003
   Kasman L.M., 2024, StatPearls Internet
   Li MJ, 2022, CELL BIOSCI, V12, DOI 10.1186/s13578-022-00823-5
   Lin Derek M, 2017, World J Gastrointest Pharmacol Ther, V8, P162, DOI 10.4292/wjgpt.v8.i3.162
   Lin YX, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0760-3
   Loc-Carrillo Catherine, 2011, Bacteriophage, V1, P111
   Lusiak-Szelachowska M, 2017, GUT PATHOG, V9, DOI 10.1186/s13099-017-0196-7
   Marcellinaro R, 2024, J CLIN MED, V13, DOI 10.3390/jcm13010040
   McNair K, 2012, BIOINFORMATICS, V28, P614, DOI 10.1093/bioinformatics/bts014
   Mittal M., 2024, OBM GENETICS, V8, P1, DOI [10.21926/obm.genet.2401219, DOI 10.21926/OBM.GENET.2401219]
   Mogi A, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/583929
   Naureen Zakira, 2020, Acta Biomed, V91, pe2020024, DOI 10.23750/abm.v91i13-S.10819
   Nguyen S, 2017, MBIO, V8, DOI 10.1128/mBio.01874-17
   Palma M, 2023, VACCINES-BASEL, V11, DOI 10.3390/vaccines11020436
   Pan YY, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.775758
   Petrov G, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232214245
   Pirnay JP, 2023, CLIN INFECT DIS, V77, pS360, DOI 10.1093/cid/ciad481
   Ponchon L, 2005, BBA-GEN SUBJECTS, V1724, P255, DOI 10.1016/j.bbagen.2005.04.016
   Pouyanfard S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049539
   Przystal JM, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201708492
   Ragothaman M, 2023, VACCINES-BASEL, V11, DOI 10.3390/vaccines11050919
   Rakhuba DV, 2010, POL J MICROBIOL, V59, P145, DOI 10.33073/pjm-2010-023
   Raphael MJ, 2017, CAN MED ASSOC J, V189, pE398, DOI 10.1503/cmaj.160771
   Rashidijahanabad Z, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202309744
   Raskov H, 2021, BRIT J CANCER, V124, P359, DOI 10.1038/s41416-020-01048-4
   Ren SX, 2009, ACTA PHARMACOL SIN, V30, P637, DOI 10.1038/aps.2009.44
   Ren SX, 2011, VACCINE, V29, P5802, DOI 10.1016/j.vaccine.2011.03.051
   Rigg A, 1997, MOL MED TODAY, V3, P359, DOI 10.1016/S1357-4310(97)01082-4
   Roehnisch T, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-119
   Roehnisch T, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-267
   Rosell R, 2009, NEW ENGL J MED, V361, P958, DOI 10.1056/NEJMoa0904554
   Santiago-Rodriguez TM, 2019, VIRUSES-BASEL, V11, DOI 10.3390/v11070656
   Scheller EL, 2009, J DENT RES, V88, P585, DOI 10.1177/0022034509337480
   Seguin L, 2022, CANCERS, V14, DOI 10.3390/cancers14071759
   Shadidi M, 2008, INT J ONCOL, V32, P241
   Shu YH, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188434
   Shukla GS, 2018, J IMMUNOL METHODS, V460, P51, DOI 10.1016/j.jim.2018.06.009
   Singh N, 2021, CANCER DRUG RESIST, V4, P17, DOI 10.20517/cdr.2020.79
   Sittiju P, 2024, NANOSCALE, V16, P6603, DOI 10.1039/d3nr05660k
   SMITH GP, 1985, SCIENCE, V228, P1315, DOI 10.1126/science.4001944
   Smith TL, 2016, P NATL ACAD SCI USA, V113, P2466, DOI 10.1073/pnas.1525709113
   Summers William C, 2012, Bacteriophage, V2, P130
   Sun ZJ, 2015, J CELL MOL MED, V19, P2691, DOI 10.1111/jcmm.12662
   Tejeda-Maldonado J, 2015, WORLD J HEPATOL, V7, P362, DOI 10.4254/wjh.v7.i3.362
   Turrini E, 2024, CELL MOL LIFE SCI, V81, DOI 10.1007/s00018-024-05174-7
   Veeranarayanan S, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23010402
   Voutsas IF, 2007, INT J CANCER, V121, P2031, DOI 10.1002/ijc.22936
   Wang HY, 2021, ACS SYNTH BIOL, V10, P2087, DOI 10.1021/acssynbio.1c00266
   Wang JB, 2022, CANCERS, V14, DOI 10.3390/cancers14164054
   Wang R, 2023, ANAL BIOANAL CHEM, V415, P3927, DOI 10.1007/s00216-023-04606-w
   who, GLOBAL CANC BURDEN G
   WHO, 2006, COMPR CERV CANC CONT, P1
   World Cancer Research Fund, International Liver Cancer Statistics
   Xue X, 2012, CHIN J CANCER, V31, P100, DOI 10.5732/cjc.011.10326
   Yang QM, 2023, FRONT MICROBIOL, V14, DOI 10.3389/fmicb.2023.1250848
   Zhang JW, 2021, EXP BIOL MED, V246, P2463, DOI 10.1177/15353702211035689
   Zhou JY, 2020, J CLIN MED, V9, DOI 10.3390/jcm9051498
   Zuo SG, 2019, ARCH VIROL, V164, P69, DOI 10.1007/s00705-018-4026-0
NR 101
TC 0
Z9 0
U1 7
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
SN 1661-6596
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2024
VL 25
IS 18
AR 9938
DI 10.3390/ijms25189938
PG 21
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA H4U1K
UT WOS:001323396900001
PM 39337427
OA gold
DA 2025-01-04
ER

PT J
AU Willems, H
   Jacobs, A
   Hadiwikarta, WW
   Venken, T
   Valkenborg, D
   Van Roy, N
   Vandesompele, J
   Hooyberghs, J
AF Willems, Hanny
   Jacobs, An
   Hadiwikarta, Wahyu Wijaya
   Venken, Tom
   Valkenborg, Dirk
   Van Roy, Nadine
   Vandesompele, Jo
   Hooyberghs, Jef
TI Thermodynamic framework to assess low abundance DNA mutation detection
   by hybridization
SO PLOS ONE
LA English
DT Article
ID METASTATIC COLORECTAL-CANCER; TARGETED THERAPY; MICROARRAYS; KRAS;
   PARAMETERS
AB The knowledge of genomic DNA variations in patient samples has a high and increasing value for human diagnostics in its broadest sense. Although many methods and sensors to detect or quantify these variations are available or under development, the number of underlying physico-chemical detection principles is limited. One of these principles is the hybridization of sample target DNA versus nucleic acid probes. We introduce a novel thermodynamics approach and develop a framework to exploit the specific detection capabilities of nucleic acid hybridization, using generic principles applicable to any platform. As a case study, we detect point mutations in the KRAS oncogene on a microarray platform. For the given platform and hybridization conditions, we demonstrate the multiplex detection capability of hybridization and assess the detection limit using thermodynamic considerations; DNA containing point mutations in a background of wild type sequences can be identified down to at least 1% relative concentration. In order to show the clinical relevance, the detection capabilities are confirmed on challenging formalin-fixed paraffin-embedded clinical tumor samples. This enzyme-free detection framework contains the accuracy and efficiency to screen for hundreds of mutations in a single run with many potential applications in molecular diagnostics and the field of personalised medicine.
C1 [Willems, Hanny; Jacobs, An; Hadiwikarta, Wahyu Wijaya; Venken, Tom; Valkenborg, Dirk; Hooyberghs, Jef] VITO, Flemish Inst Technol Res, Mol, Belgium.
   [Hadiwikarta, Wahyu Wijaya] KULeuven, Inst Theoret Phys, Leuven, Belgium.
   [Valkenborg, Dirk] Hasselt Univ, Interuniv Inst Biostat & Stat Bioinformat, Diepenbeek, Belgium.
   [Van Roy, Nadine; Vandesompele, Jo] Univ Ghent, CMGG, Ghent, Belgium.
   [Vandesompele, Jo] Univ Ghent, CRIG, Ghent, Belgium.
   [Hooyberghs, Jef] Hasselt Univ, Theoret Phys, Diepenbeek, Belgium.
C3 VITO; KU Leuven; Hasselt University; Ghent University; Ghent University;
   Hasselt University
RP Hooyberghs, J (corresponding author), VITO, Flemish Inst Technol Res, Mol, Belgium.; Hooyberghs, J (corresponding author), Hasselt Univ, Theoret Phys, Diepenbeek, Belgium.
EM jef.hooyberghs@vito.be
RI Hooyberghs, Jef/JWO-1837-2024; Hooyberghs, Jef/E-2157-2017;
   Vandesompele, Jo/W-3411-2018
OI VALKENBORG, Dirk/0000-0002-1877-3496; Willems,
   Hanny/0000-0001-9848-1997; Hooyberghs, Jef/0000-0003-3781-9645; Venken,
   Tom/0000-0003-0773-1810; Vandesompele, Jo/0000-0001-6274-0184;
   Hadiwikarta, Wahyu Wijaya/0000-0002-5909-4107
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Ben-Yoav H, 2015, BIOSENS BIOELECTRON, V64, P579, DOI 10.1016/j.bios.2014.09.069
   Burden CJ, 2010, PHYS BIOL, V7, DOI 10.1088/1478-3975/7/1/016004
   Camp ER, 2015, CLIN CANCER RES, V21, P3578, DOI 10.1158/1078-0432.CCR-14-2900
   Carlon E, 2006, PHYSICA A, V362, P433, DOI 10.1016/j.physa.2005.09.067
   Cornett EM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055919
   Fuchs J, 2010, BIOPHYS J, V99, P1886, DOI 10.1016/j.bpj.2010.07.002
   Gaudet M, 2009, METHODS MOL BIOL, V578, P415, DOI 10.1007/978-1-60327-411-1_26
   Ginot F, 1997, HUM MUTAT, V10, P1
   Hadiwikarta WW, 2015, BIOSENS BIOELECTRON, V64, P411, DOI 10.1016/j.bios.2014.09.043
   Hadiwikarta WW, 2012, NUCLEIC ACIDS RES, V40, DOI 10.1093/nar/gks475
   Hadiwikarta WW, 2013, NUCLEIC ACIDS RES, V41, DOI 10.1093/nar/gkt682
   Halperin A, 2006, J PHYS-CONDENS MAT, V18, pS463, DOI 10.1088/0953-8984/18/18/S01
   Harrison A, 2013, NUCLEIC ACIDS RES, V41, P2779, DOI 10.1093/nar/gks1358
   Hooyberghs J, 2010, PHYS REV E, V81, DOI 10.1103/PhysRevE.81.012901
   Hooyberghs J, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp109
   Hooyberghs J, 2010, BIOSENS BIOELECTRON, V26, P1692, DOI 10.1016/j.bios.2010.07.039
   Irving D, 2010, J PHYS CHEM B, V114, P7631, DOI 10.1021/jp100860z
   Joda H, 2015, ANAL BIOCHEM, V474, P66, DOI 10.1016/j.ab.2014.11.021
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Noguera DR, 2014, APPL MICROBIOL BIOT, V98, P9595, DOI 10.1007/s00253-014-6165-x
   Siena S, 2009, JNCI-J NATL CANCER I, V101, P1308, DOI 10.1093/jnci/djp280
   Stancescu M, 2016, J AM CHEM SOC, V138, P13465, DOI 10.1021/jacs.6b05628
   Trapp C, 2011, BMC BIOPHYS, V4, DOI 10.1186/2046-1682-4-20
   Tsiatis AC, 2010, J MOL DIAGN, V12, P425, DOI 10.2353/jmoldx.2010.090188
   van Grinsven B, 2011, LAB CHIP, V11, P1656, DOI 10.1039/c1lc20027e
   van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y
   Wei BM, 2015, ANAL CHEM, V87, P2058, DOI 10.1021/ac504797e
NR 28
TC 5
Z9 5
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 25
PY 2017
VL 12
IS 5
AR e0177384
DI 10.1371/journal.pone.0177384
PG 18
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA EV8VR
UT WOS:000402062800016
PM 28542229
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Sokolenko, AP
   Imyanitov, EN
AF Sokolenko, Anna P.
   Imyanitov, Evgeny N.
TI Molecular Tests for the Choice of Cancer Therapy
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Review
DE Predictive markers; cancer therapy; cytotoxic therapy; targeted therapy;
   mutation; expression
ID CELL LUNG-CANCER; METASTATIC BREAST-CANCER; COLORECTAL-CANCER; EGFR
   MUTATIONS; OPEN-LABEL; OVARIAN-CANCER; MICROSATELLITE INSTABILITY;
   THYMIDYLATE SYNTHASE; ESTROGEN-RECEPTORS; SOMATIC MUTATIONS
AB There are over a dozen of approved cancer drugs, whose administration is tailored to predictive laboratory tests. The examples include estrogen and progesterone receptor status determination for the use of endocrine therapy, HER2 assessment for the administration of HER2-targeting agents, EGFR and ALK gene testing for lung cancer treatment, BRAF analysis in melanoma, etc. While first predictive tests relied on relatively easy laboratory procedures, more recent developments require rather sophisticated assays. For example, administration of PARP inhibitors is tailored to a comprehensive testing of BRCA1 and BRCA2 genes, and is likely to be supplemented in the future by even more systematic assessment of DNA repair pathways. The detection of an androgen-independent splice-variant of androgen-receptor (AR-V7) in castration-resistant prostate cancer is achieved through the isolation of circulating tumor cells (CTCs). The efficacy of immune check-point inhibitors correlates with the overall mutational tumor load, therefore the companion diagnostic assays may involve genome-wide scanning. Integration of next-generation sequencing (NGS) into clinical oncology is expected to boost the use of predictive tests in the forthcoming years.
C1 [Sokolenko, Anna P.; Imyanitov, Evgeny N.] NN Petrov Inst Oncol, St Petersburg 197758, Russia.
   [Sokolenko, Anna P.; Imyanitov, Evgeny N.] St Petersburg Pediat Med Univ, St Petersburg 194100, Russia.
   [Imyanitov, Evgeny N.] II Mechnikov North Western Med Univ, St Petersburg 191015, Russia.
   [Imyanitov, Evgeny N.] St Petersburg State Univ, St Petersburg 199034, Russia.
C3 N.N. Petrov Research Institute of Oncology; Saint Petersburg State
   Pediatric Medical University; North-Western State Medical University
   named after I.I. Mechnikov; Saint Petersburg State University
RP Imyanitov, EN (corresponding author), NN Petrov Inst Oncol, Dept Tumor Biol, St Petersburg 197758, Russia.
EM evgeny@imyanitov.spb.ru
RI Sokolenko, Anna/G-3123-2013; Imyanitov, Evgeny/ABG-8619-2021
FU Russian Scientific Fund [14-25-00111]
FX This work has been supported by the Russian Scientific Fund (grant
   number 14-25-00111). We are cordially thankful to Dr. Mae Goldgraben
   (University of Cambridge) for helpful discussion on this manuscript.
CR Abysheva SN, 2011, MELANOMA RES, V21, P555, DOI 10.1097/CMR.0b013e32834bf398
   Almeida D, 2014, PATHOL RES PRACT, V210, P675, DOI 10.1016/j.prp.2014.06.017
   André F, 2014, LANCET ONCOL, V15, P267, DOI 10.1016/S1470-2045(13)70611-9
   [Anonymous], 2016, J CLIN ONCOL S
   Antonarakis ES, 2015, JAMA ONCOL, V1, P582, DOI 10.1001/jamaoncol.2015.1341
   Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815
   Ascierto PA, 2013, J CLIN ONCOL, V31, P3205, DOI 10.1200/JCO.2013.49.8691
   Ascierto PA, 2013, LANCET ONCOL, V14, P249, DOI 10.1016/S1470-2045(13)70024-X
   Azim HA, 2013, ANN ONCOL, V24, P647, DOI 10.1093/annonc/mds645
   Baguley BC, 2010, MOL BIOTECHNOL, V46, P308, DOI 10.1007/s12033-010-9321-2
   Bang YJ, 2010, LANCET, V376, P1302
   Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100
   Bepler G, 2013, J CLIN ONCOL, V31, P2404, DOI 10.1200/JCO.2012.46.9783
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Bhargava R, 2012, J CLIN ONCOL, V30, P4451, DOI 10.1200/JCO.2012.44.6955
   Boland CR, 1998, CANCER RES, V58, P5248
   Bollag G, 2012, NAT REV DRUG DISCOV, V11, P873, DOI 10.1038/nrd3847
   Boström PJ, 2015, EUR UROL, V68, P1033, DOI 10.1016/j.eururo.2015.04.008
   Brauch H, 2014, BRIT J CLIN PHARMACO, V77, P695, DOI 10.1111/bcp.12229
   Burton A, 2002, LANCET ONCOL, V3, P708, DOI 10.1016/S1470-2045(02)00938-5
   Buzyn A, 2016, NAT REV CLIN ONCOL, V13, P385, DOI 10.1038/nrclinonc.2016.31
   Calonge N, 2016, GENET MED, V18, P770, DOI 10.1038/gim.2015.173
   Cardarella S, 2013, CLIN CANCER RES, V19, P4532, DOI 10.1158/1078-0432.CCR-13-0657
   Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen Z, 2012, NATURE, V483, P613, DOI 10.1038/nature10937
   Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365
   COOMBES RC, 1987, LANCET, V2, P701
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Dabbs DJ, 2011, J CLIN ONCOL, V29, P4279, DOI 10.1200/JCO.2011.34.7963
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Davies KD, 2012, CLIN CANCER RES, V18, P4570, DOI 10.1158/1078-0432.CCR-12-0550
   Dezentje VO, 2013, BREAST CANCER RES TR, V140, P363, DOI 10.1007/s10549-013-2619-6
   Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011
   Dienstmann R, 2015, MOL ONCOL, V9, P940, DOI 10.1016/j.molonc.2014.06.014
   Dienstmann R, 2015, CANCER DISCOV, V5, P118, DOI 10.1158/2159-8290.CD-14-1118
   Domingo E, 2013, J CLIN ONCOL, V31, P4297, DOI 10.1200/JCO.2013.50.0322
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Drilon A, 2016, CLIN CANCER RES, V22, P2351, DOI 10.1158/1078-0432.CCR-15-2013
   Drilon A, 2012, LANCET ONCOL, V13, pE418, DOI 10.1016/S1470-2045(12)70291-7
   Dudley JC, 2016, CLIN CANCER RES, V22, P813, DOI 10.1158/1078-0432.CCR-15-1678
   Duffy MJ, 2014, CRIT REV CL LAB SCI, V51, P30, DOI 10.3109/10408363.2013.865700
   ENGELSMAN E, 1974, BRIT J CANCER, V30, P189, DOI 10.1038/bjc.1974.178
   Epstein AJ, 2015, J CLIN ONCOL, V33, P4259, DOI 10.1200/JCO.2015.61.9023
   Eroglu Z, 2016, THER ADV MED ONCOL, V8, P48, DOI 10.1177/1758834015616934
   Fehrenbacher L, 2016, LANCET, V387, P1837, DOI 10.1016/S0140-6736(16)00587-0
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Frampton GM, 2013, NAT BIOTECHNOL, V31, P1023, DOI 10.1038/nbt.2696
   Frank GA, 2016, MELANOMA RES, V26, P442, DOI 10.1097/CMR.0000000000000278
   Fribbens C, 2016, J CLIN ONCOL, V34, P2961, DOI 10.1200/JCO.2016.67.3061
   Gainor JF, 2013, J CLIN ONCOL, V31, P3987, DOI 10.1200/JCO.2012.45.2029
   Gautschi O, 2015, J THORAC ONCOL, V10, P1451, DOI 10.1097/JTO.0000000000000625
   Gennari R, 2004, CLIN CANCER RES, V10, P5650, DOI 10.1158/1078-0432.CCR-04-0225
   Gerlinger M, 2013, NEW ENGL J MED, V369, P1172, DOI [10.1056/NEJMoa1215530, 10.1056/NEJMc1309091]
   Gibney GT, 2013, EXPERT OPIN DRUG MET, V9, P893, DOI 10.1517/17425255.2013.794220
   Gillet JP, 2013, JNCI-J NATL CANCER I, V105, P452, DOI 10.1093/jnci/djt007
   Gorodnova TV, 2015, CANCER LETT, V369, P363, DOI 10.1016/j.canlet.2015.08.028
   Górski B, 2003, INT J CANCER, V106, P379, DOI 10.1002/ijc.11231
   Grisham RN, 2015, J CLIN ONCOL, V33, P4099, DOI 10.1200/JCO.2015.62.4726
   Gu D, 2007, HUM MUTAT, V28, P760, DOI 10.1002/humu.20512
   Guarnerio J, 2016, CELL, V165, P289, DOI 10.1016/j.cell.2016.03.020
   Hammerman PS, 2011, CANCER DISCOV, V1, P78, DOI 10.1158/2159-8274.CD-11-0005
   Heinrich MC, 2003, J CLIN ONCOL, V21, P4342, DOI 10.1200/JCO.2003.04.190
   Hennessy BTJ, 2010, J CLIN ONCOL, V28, P3570, DOI 10.1200/JCO.2009.27.2997
   HEUSON JC, 1977, CANCER-AM CANCER SOC, V39, P1971, DOI 10.1002/1097-0142(197705)39:5<1971::AID-CNCR2820390510>3.0.CO;2-8
   Hodi FS, 2013, J CLIN ONCOL, V31, P3182, DOI 10.1200/JCO.2012.47.7836
   Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Imyanitov EN, 2016, MOL DIAGN THER, V20, P401, DOI 10.1007/s40291-016-0213-4
   Imyanitov EN, 2011, HERED CANCER CLIN PR, V9, DOI 10.1186/1897-4287-9-5
   Iwama E, 2014, ONCOTARGETS THER, V7, P375, DOI 10.2147/OTT.S38868
   Iyevleva AG, 2007, ONKOLOGIE, V30, P295, DOI 10.1159/000102046
   Iyevleva AG, 2016, HERED CANCER CLIN PR, V14, DOI 10.1186/s13053-016-0057-2
   Iyevleva AG, 2015, CANCER LETT, V362, P116, DOI 10.1016/j.canlet.2015.03.028
   Iyevleva AG, 2014, J THORAC ONCOL, V9, pE31, DOI 10.1097/JTO.0000000000000106
   Jänne PA, 2015, NEW ENGL J MED, V372, P1689, DOI 10.1056/NEJMoa1411817
   Jänne PA, 2013, LANCET ONCOL, V14, P38, DOI 10.1016/S1470-2045(12)70489-8
   JENSEN EV, 1975, CANCER RES, V35, P3362
   Ji RR, 2012, CANCER IMMUNOL IMMUN, V61, P1019, DOI 10.1007/s00262-011-1172-6
   Jonas O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010564
   Karki R, 2013, EXPERT OPIN THER TAR, V17, P461, DOI 10.1517/14728222.2013.766170
   Karlovich C, 2016, CLIN CANCER RES, V22, P2386, DOI 10.1158/1078-0432.CCR-15-1260
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Kazandjian D, 2016, CLIN CANCER RES, V22, P1307, DOI 10.1158/1078-0432.CCR-15-2266
   Klinghoffer RA, 2015, SCI TRANSL MED, V7
   Knutson KL, 2016, CANCER RES, V76, P3702, DOI 10.1158/0008-5472.CAN-15-3091
   Kornmann M, 2012, EUR J CANCER, V48, P1443, DOI 10.1016/j.ejca.2011.11.007
   Kreahling JM, 2015, CANCER CONTROL, V22, P226, DOI 10.1177/107327481502200215
   Kwak EL, 2009, J CLIN ONCOL, V27
   Lazebnik Y, 2015, EMBO REP, V16, P1592, DOI 10.15252/embr.201541266
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6
   Ledermann J, 2014, LANCET ONCOL, V15, P852, DOI 10.1016/S1470-2045(14)70228-1
   Lee SH, 2017, ANN ONCOL, V28, P292, DOI 10.1093/annonc/mdw559
   Li BT, 2016, J THORAC ONCOL, V11, P414, DOI 10.1016/j.jtho.2015.10.025
   Liao XY, 2012, NEW ENGL J MED, V367, P1596, DOI 10.1056/NEJMoa1207756
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lin JJ, 2016, J CLIN ONCOL, V34, P3363, DOI 10.1200/JCO.2016.68.5891
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Loi S, 2013, P NATL ACAD SCI USA, V110, P11091, DOI 10.1073/pnas.1222251110
   Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21
   Lowery MA, 2011, ONCOLOGIST, V16, P1397, DOI 10.1634/theoncologist.2011-0185
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Mahjoubi L, 2016, INVEST NEW DRUG, V34, P397, DOI 10.1007/s10637-016-0332-0
   Malaney P, 2014, CANCER LETT, V344, P1, DOI 10.1016/j.canlet.2013.10.010
   Martins FC, 2012, CANCER DISCOV, V2, P503, DOI 10.1158/2159-8290.CD-11-0325
   Marx V, 2015, NATURE, V520, P389, DOI 10.1038/520389a
   Mateo J, 2015, NEW ENGL J MED, V373, P1697, DOI 10.1056/NEJMoa1506859
   Matulonis UA, 2016, ANN ONCOL, V27, P1013, DOI 10.1093/annonc/mdw133
   McCarthy M, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6568
   Mehra N, 2015, CURR OPIN ONCOL, V27, P267, DOI 10.1097/CCO.0000000000000182
   Meijers-Heijboer H, 2002, NAT GENET, V31, P55, DOI 10.1038/ng879
   Mitiushkina NV, 2016, TRANSL CANCER RES, V5, pS1393, DOI 10.21037/tcr.2016.12.69
   Mitiushkina NV, 2013, CANCER CYTOPATHOL, V121, P370, DOI 10.1002/cncy.21281
   Mitsudomi T, 2014, TRANSL LUNG CANCER R, V3, P205, DOI 10.3978/j.issn.2218-6751.2014.08.04
   Mohammed H, 2015, NATURE, V523, P313, DOI 10.1038/nature14583
   Moiseyenko VM, 2015, MED ONCOL, V32, DOI 10.1007/s12032-015-0514-1
   Moiseyenko VM, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0199-x
   Moiseyenko VM, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0545-4
   Moiseyenko VM, 2010, ONKOLOGIE, V33, P231, DOI 10.1159/000302729
   Moran T, 2014, ANN ONCOL, V25, P2147, DOI 10.1093/annonc/mdu389
   Mukhopadhyay S, 2014, J THORAC ONCOL, V9, P1714, DOI 10.1097/JTO.0000000000000323
   Mulligan JM, 2014, JNCI-J NATL CANCER I, V106, DOI 10.1093/jnci/djt335
   Nishida T, 2016, GASTRIC CANCER, V19, P3, DOI 10.1007/s10120-015-0526-8
   Norquist B, 2011, J CLIN ONCOL, V29, P3008, DOI 10.1200/JCO.2010.34.2980
   Novik AV, 2016, TARGET ONCOL, V11, P235, DOI 10.1007/s11523-015-0384-7
   Olivotto IA, 2004, J CLIN ONCOL, V22, P1769, DOI 10.1200/JCO.2004.99.251
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Patil Deepa T, 2015, Surg Pathol Clin, V8, P515, DOI 10.1016/j.path.2015.05.006
   Peeters M, 2013, CLIN CANCER RES, V19, P1902, DOI 10.1158/1078-0432.CCR-12-1913
   Perez EA, 2015, J CLIN ONCOL, V33, P701, DOI 10.1200/JCO.2014.57.6298
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Perucho M, 1999, CANCER RES, V59, P249
   Pfeifer W, 2014, BREAST CANCER RES TR, V148, P675, DOI 10.1007/s10549-014-3206-1
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Piper GL, 2004, AM SURGEON, V70, P1103
   Pirker R, 2015, TRANSL LUNG CANCER R, V4, P797, DOI 10.3978/j.issn.2218-6751.2015.03.08
   Planchard D, 2016, LANCET ONCOL, V17, P984, DOI 10.1016/S1470-2045(16)30146-2
   Planchard D, 2016, LANCET ONCOL, V17, P642, DOI 10.1016/S1470-2045(16)00077-2
   Popper HH, 2014, TRANSL LUNG CANCER R, V3, P291, DOI 10.3978/j.issn.2218-6751.2014.10.01
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prasad V, 2015, MAYO CLIN PROC, V90, P1639, DOI 10.1016/j.mayocp.2015.08.017
   Pritchard KI, 2008, CANCER-AM CANCER SOC, V112, P718, DOI 10.1002/cncr.23189
   Rahman N, 2007, NAT GENET, V39, P165, DOI 10.1038/ng1959
   Riaz N, 2016, NAT GENET, V48, P1327, DOI 10.1038/ng.3677
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Rivera LB, 2015, SCIENCE, V349, P694, DOI 10.1126/science.aad0862
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Robinson DR, 2013, NAT GENET, V45, P1446, DOI 10.1038/ng.2823
   Romano E, 2013, CLIN CANCER RES, V19, P5749, DOI 10.1158/1078-0432.CCR-13-0661
   Ross JS, 2009, DRUG NEWS PERSPECT, V22, P93, DOI 10.1358/dnp.2009.22.2.1334452
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Sartore-Bianchi A, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv306
   Sauter G, 2009, J CLIN ONCOL, V27, P1323, DOI 10.1200/JCO.2007.14.8197
   Scartozzi M, 2012, DIGEST LIVER DIS, V44, P74, DOI 10.1016/j.dld.2011.08.006
   Schilsky RL, 2014, NAT REV CLIN ONCOL, V11, P432, DOI 10.1038/nrclinonc.2014.54
   Schott AF, 2015, CANCER RES, V75, P1930, DOI 10.1158/0008-5472.CAN-15-0174
   Schroth W, 2009, JAMA-J AM MED ASSOC, V302, P1429, DOI 10.1001/jama.2009.1420
   Sequist LV, 2015, NEW ENGL J MED, V372, P1700, DOI 10.1056/NEJMoa1413654
   Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766
   Shaw AT, 2011, CLIN CANCER RES, V17, P2081, DOI 10.1158/1078-0432.CCR-10-1591
   Shea M, 2016, J THORAC ONCOL, V11, pE81, DOI 10.1016/j.jtho.2016.01.017
   Shibata T, 2015, JPN J CLIN ONCOL, V45, P895, DOI 10.1093/jjco/hyv122
   Silkin Sergey V, 2016, J Gastrointest Cancer, V47, P502
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Sokolenko AP, 2017, CANCER LETT, V397, P127, DOI 10.1016/j.canlet.2017.03.036
   Sokolenko AP, 2012, INT J CANCER, V130, P2867, DOI 10.1002/ijc.26342
   Song A, 2015, CLIN CANCER RES, V21, P2379, DOI 10.1158/1078-0432.CCR-14-1350
   Sonnenblick A, 2011, CANCER BIOL THER, V12, P165, DOI 10.4161/cbt.12.3.16292
   Soong R, 2008, ANN ONCOL, V19, P915, DOI 10.1093/annonc/mdm599
   Sparano JA, 2015, NEW ENGL J MED, V373, P2005, DOI 10.1056/NEJMoa1510764
   Stewart DJ, 2009, J CLIN ONCOL, V27, P328, DOI 10.1200/JCO.2008.18.9621
   Subbiah V, 2016, P NATL ACAD SCI USA, V113, pE1419, DOI 10.1073/pnas.1522052113
   Sullivan I, 2016, THER ADV MED ONCOL, V8, P32, DOI 10.1177/1758834015617355
   Sun JM, 2015, J CLIN ONCOL, V33, P2450, DOI 10.1200/JCO.2014.59.9324
   Suspitsin EN, 2014, MED ONCOL, V31, DOI 10.1007/s12032-013-0828-9
   Sweeney CJ, 2015, NEW ENGL J MED, V373, P737, DOI 10.1056/NEJMoa1503747
   Takano T, 2008, J CLIN ONCOL, V26, P5589, DOI 10.1200/JCO.2008.16.7254
   Teixidó C, 2014, TRANSL LUNG CANCER R, V3, P70, DOI 10.3978/j.issn.2218-6751.2014.02.02
   Thadani-Mulero M, 2014, CANCER RES, V74, P2270, DOI 10.1158/0008-5472.CAN-13-2876
   Thress KS, 2015, LUNG CANCER, V90, P509, DOI 10.1016/j.lungcan.2015.10.004
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Toy W, 2013, NAT GENET, V45, P1439, DOI 10.1038/ng.2822
   Tran TN, 2016, CLIN LUNG CANCER, V17, P30, DOI 10.1016/j.cllc.2015.08.002
   Tsimberidou AM, 2014, CLIN CANCER RES, V20, P4827, DOI 10.1158/1078-0432.CCR-14-0603
   UNDERWOOD JCE, 1983, DIAGN HISTOPATHOL, V6, P1
   Van Allen EM, 2014, CANCER DISCOV, V4, P1140, DOI 10.1158/2159-8290.CD-14-0623
   van't Veer LJ, 2002, NATURE, V415, P530, DOI 10.1038/415530a
   Varadan V, 2016, CLIN CANCER RES, V22, P3249, DOI 10.1158/1078-0432.CCR-15-2021
   Vecchione L, 2016, CELL, V165, P317, DOI 10.1016/j.cell.2016.02.059
   Vesprini Danny, 2011, Can Urol Assoc J, V5, pE31, DOI 10.5489/cuaj.10080
   Viaud S, 2013, SCIENCE, V342, P971, DOI 10.1126/science.1240537
   Villarroel MC, 2011, MOL CANCER THER, V10, P3, DOI 10.1158/1535-7163.MCT-10-0893
   Watkins JA, 2014, BREAST CANCER RES, V16, DOI 10.1186/bcr3670
   Wheler JJ, 2016, CANCER RES, V76, P3690, DOI 10.1158/0008-5472.CAN-15-3043
   Wilson TR, 2014, BREAST CANCER RES TR, V148, P315, DOI 10.1007/s10549-014-3163-8
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yang JCH, 2015, LANCET ONCOL, V16, P830, DOI 10.1016/S1470-2045(15)00026-1
   Yanus GA, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0686-5
   Yatabe Y, 2012, J THORAC ONCOL, V7, P775, DOI 10.1097/JTO.0b013e318251980b
   Yoh K, 2017, LANCET RESP MED, V5, P42, DOI 10.1016/S2213-2600(16)30322-8
   Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958
   Zhou XP, 1998, GENE CHROMOSOME CANC, V21, P101, DOI 10.1002/(SICI)1098-2264(199802)21:2<101::AID-GCC4>3.0.CO;2-4
   Zou HY, 2007, CANCER RES, V67, P4408, DOI 10.1158/0008-5472.CAN-06-4443
   Zou HLY, 2015, P NATL ACAD SCI USA, V112, P3493, DOI 10.1073/pnas.1420785112
NR 209
TC 6
Z9 7
U1 0
U2 7
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1381-6128
EI 1873-4286
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PY 2017
VL 23
IS 32
BP 4794
EP 4806
DI 10.2174/1381612823666170719110125
PG 13
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA FQ8WE
UT WOS:000418643100009
PM 28721808
DA 2025-01-04
ER

PT J
AU Takegawa, N
   Yonesaka, K
   Sakai, K
   Ueda, H
   Watanabe, S
   Nonagase, Y
   Okuno, T
   Takeda, M
   Maenishi, O
   Tsurutani, J
   Satoh, T
   Okamoto, I
   Nishio, K
   Tamura, T
   Nakagawa, K
AF Takegawa, Naoki
   Yonesaka, Kimio
   Sakai, Kazuko
   Ueda, Hiroto
   Watanabe, Satomi
   Nonagase, Yoshikane
   Okuno, Tatsuya
   Takeda, Masayuki
   Maenishi, Osamu
   Tsurutani, Junji
   Satoh, Taroh
   Okamoto, Isamu
   Nishio, Kazuto
   Tamura, Takao
   Nakagawa, Kazuhiko
TI HER2 genomic amplification in circulating tumor DNA from patients with
   cetuximab-resistant colorectal cancer
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; cetuximab; acquired resistance; human epidermal
   growth factor receptor 2; ctDNA
ID EGFR-TARGETED THERAPIES; PHASE-III TRIAL; ACQUIRED-RESISTANCE; 1ST-LINE
   TREATMENT; OXALIPLATIN; FLUOROURACIL; CHEMOTHERAPY; LEUCOVORIN;
   EVOLUTION; BLOCKADE
AB Background: Patients with metastatic colorectal cancer (mCRC) harboring wild-type KRAS benefit from epidermal growth factor receptor (EGFR)-targeted therapy. However, patients who are treated with anti-EGFR antibodies will eventually develop the resistance to those agents. HER2 amplification is one of the mechanisms conferring resistance to anti-EGFR antibody therapy and could therefore be a potential therapeutic target. The aim of this study was to detect HER2 amplification in circulating tumor DNA (ctDNA) from patients with CRC and acquired resistance to anti-EGFR antibody therapy
   Results: Our data showed that 22% (4/18) of patients in the cohort exhibited HER2 amplification. One of these patients was found to be positive for HER2 amplification in matched tumor specimens collected after cetuximab therapy, at which point the patient had acquired cetuximab resistance, despite being negative for HER2 amplification prior to therapy.
   Methods: We analyzed plasma ctDNA using digital polymerase chain reaction (PCR) from 18 patients with CRC, who had been treated with anti-EGFR antibody-based therapy (cetuximab) and subsequently acquired resistant cetuximab. HER2 gene copy number was analyzed using fluorescence in situ hybridization in tumor samples before and after acquisition of resistance to cetuximab-based therapy.
   Conclusion: Analysis of plasma ctDNA by digital PCR could be useful for detecting HER2 amplification in patients with CRC who were resistant to anti-EGFR antibody therapy.
C1 [Takegawa, Naoki; Yonesaka, Kimio; Ueda, Hiroto; Watanabe, Satomi; Nonagase, Yoshikane; Okuno, Tatsuya; Takeda, Masayuki; Tsurutani, Junji; Tamura, Takao; Nakagawa, Kazuhiko] Kinki Univ, Sch Med, Dept Med Oncol, Osaka 589, Japan.
   [Sakai, Kazuko; Nishio, Kazuto] Kinki Univ, Sch Med, Dept Genome Biol, Osaka 589, Japan.
   [Maenishi, Osamu] Kinki Univ, Sch Med, Dept Pathol, Osaka 589, Japan.
   [Satoh, Taroh] Osaka Univ, Grad Sch Med, Dept Frontier Sci Canc & Chemotherapy, Osaka, Japan.
   [Okamoto, Isamu] Kyushu Univ, Ctr Clin & Translat Res, Kyushu, Japan.
C3 Kindai University (Kinki University); Kindai University (Kinki
   University); Kindai University (Kinki University); Osaka University;
   Kyushu University
RP Yonesaka, K (corresponding author), Kinki Univ, Sch Med, Dept Med Oncol, Osaka 589, Japan.
EM yonesaka@sakai.med.kindai.ac.jp
RI Okuno, Tatsuya/ABD-6927-2020; Watanabe, Satomi/HCI-6317-2022; Takeda,
   Masayuki/J-6457-2019; Satoh, Taroh/AAF-7913-2020; NAKAGAWA,
   KAZUHIKO/ADM-9196-2022
FU Kinki University
FX This study was funded by Kinki University.
CR Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   de Gramont A, 2000, J CLIN ONCOL, V18, P2938, DOI 10.1200/JCO.2000.18.16.2938
   Deeken JF, 2015, CANCER-AM CANCER SOC, V121, P1645, DOI 10.1002/cncr.29224
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Gevensleben H, 2013, CLIN CANCER RES, V19, P3276, DOI 10.1158/1078-0432.CCR-12-3768
   Leto SM, 2014, J MOL MED, V92, P709, DOI 10.1007/s00109-014-1161-2
   Meriggi F, 2014, REV RECENT CLIN TRIA, V9, P8, DOI 10.2174/1568026614666140423121525
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Seo AN, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098528
   Siena S, 2015, THERAPEUTIC DUAL INH
   Siena S, 2015, J CLIN ONCOL, P33
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Sobrero AF, 2008, J CLIN ONCOL, V26, P2311, DOI 10.1200/JCO.2007.13.1193
   Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057
   Spindler KLG, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0108247
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Van Emburgh BO, 2014, MOL ONCOL, V8, P1084, DOI 10.1016/j.molonc.2014.05.003
   Witzel I, 2010, BREAST CANCER RES TR, V123, P437, DOI 10.1007/s10549-010-1030-9
   Yonesaka K, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002442
NR 25
TC 55
Z9 60
U1 0
U2 11
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JAN 19
PY 2016
VL 7
IS 3
BP 3443
EP 3450
DI 10.18632/oncotarget.6498
PG 8
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DD5GV
UT WOS:000369951800094
PM 26657506
OA gold, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU Wang, ZK
   Shi, JY
   Tao, DC
   Xie, SY
   Yang, Y
   Liu, YQ
AF Wang, Zhaokun
   Shi, Jiaying
   Tao, Dachang
   Xie, Shengyu
   Yang, Yuan
   Liu, Yunqiang
TI Nonsense suppression induces read-through of a novel <i>BMPR1A</i>
   variant in a Chinese family with hereditary colorectal cancer
SO ANNALS OF HUMAN GENETICS
LA English
DT Article
DE BMPR1A; colorectal cancer; juvenile polyposis syndrome;
   nonsense-mediated mRNA decay (NMD); premature termination codon;
   read-through inducing reagent
ID MUTATIONS; DIAGNOSIS; SMAD4
AB Background: BMPR1A-mediated signaling transduction plays an essential role in intestinal growth. Variations of BMPR1A lead to a rare autosomal dominant inherited juvenile polyposis syndrome (JPS) with high probability of developing into colorectal cancer (CRC). Nonsense and frameshift variations, generating premature termination codons (PTCs), are the most pathogenic variants in the BMPR1A gene.Objective: This study aimed to investigate the molecular genetic etiology in a Chinese family with three generations of CRC.Methods: Pathogenic variants of 18 known CRC susceptibility genes were examined in a Chinese CRC family through multigene panel testing using the next-generation sequencing platform. The candidate gene variant was validated in the family members by Sanger sequencing. Potential biological functions of the gene variant were further investigated in the RKO colon cancer cell line.Results: A novel nonsense variant (c.1114A > T, p.Lys372*) of BMPR1A was identified in the CRC family. This variant generated a PTC at the kinase domain and caused nonsense-mediated mRNA decay. Read-through inducing reagents G418 and PTC124 partially restored BMPR1A expression and its following signaling pathway.Conclusion: The identification of the novel BMPR1A variant enriched the genotype-phenotype spectrum of BMPR1A. Meanwhile, our finding also provided support for future PTC-targeting therapy for BMPR1A-mediated JPS and CRC.
C1 [Wang, Zhaokun; Shi, Jiaying; Tao, Dachang; Xie, Shengyu; Yang, Yuan; Liu, Yunqiang] Sichuan Univ, West China Hosp, West China Med Sch, Dept Med Genet,State Key Lab Biotherapy, Chengdu, Peoples R China.
   [Liu, Yunqiang] Sichuan Univ, West China Hosp, West China Med Sch, Dept Med Genet,State Key Lab Biotherapy, 1,Keyuan 4th Rd,Gaopeng Ave, Chengdu 610041, Sichuan, Peoples R China.
C3 Sichuan University; Sichuan University
RP Liu, YQ (corresponding author), Sichuan Univ, West China Hosp, West China Med Sch, Dept Med Genet,State Key Lab Biotherapy, 1,Keyuan 4th Rd,Gaopeng Ave, Chengdu 610041, Sichuan, Peoples R China.
EM yq_liu@scu.edu.cn
OI Liu, Yunqiang/0000-0001-7691-7630
FU National Natural Science Foundation of China;  [81773159]
FX We appreciated the participation of the proband and his family in this
   study. This work was supported by the National Natural Science
   Foundation of China (grant number 81773159).
CR Auclair BA, 2007, GASTROENTEROLOGY, V133, P887, DOI 10.1053/j.gastro.2007.06.066
   Bidou L, 2017, RNA BIOL, V14, P378, DOI 10.1080/15476286.2017.1285480
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Blatter RHE, 2015, GENE CHROMOSOME CANC, V54, P575, DOI 10.1002/gcc.22270
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   BURT RW, 1990, B WORLD HEALTH ORGAN, V68, P655
   Calva-Cerqueira D, 2009, CLIN GENET, V75, P79, DOI 10.1111/j.1399-0004.2008.01091.x
   Kanth P, 2017, AM J GASTROENTEROL, V112, P1509, DOI 10.1038/ajg.2017.212
   Kastrinos F, 2020, GASTROENTEROLOGY, V158, P389, DOI 10.1053/j.gastro.2019.11.029
   Kurosaki T, 2019, NAT REV MOL CELL BIO, V20, P406, DOI 10.1038/s41580-019-0126-2
   Malcovati L, 2016, BRIT J HAEMATOL, V174, P847, DOI 10.1111/bjh.14215
   Michorowska S, 2021, PHARMACEUTICALS-BASE, V14, DOI 10.3390/ph14080785
   Nagel-Wolfrum K, 2016, BIODRUGS, V30, P49, DOI 10.1007/s40259-016-0157-6
   Roy B, 2016, P NATL ACAD SCI USA, V113, P12508, DOI 10.1073/pnas.1605336113
   Supek F, 2021, TRENDS GENET, V37, P657, DOI 10.1016/j.tig.2020.11.002
   Venturini A, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111972
   Vössing C, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21228418
   Wakefield LM, 2013, NAT REV CANCER, V13, P328, DOI 10.1038/nrc3500
NR 18
TC 1
Z9 1
U1 0
U2 0
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-4800
EI 1469-1809
J9 ANN HUM GENET
JI Ann. Hum. Genet.
PD JUL
PY 2024
VL 88
IS 4
BP 300
EP 306
DI 10.1111/ahg.12549
EA JAN 2024
PG 7
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA TY1V5
UT WOS:001137613400001
PM 38192234
DA 2025-01-04
ER

PT J
AU Moghadasi, M
   Alivand, M
   Fardi, M
   Moghadam, KS
   Solali, S
AF Moghadasi, Maryam
   Alivand, Mohammadreza
   Fardi, Masoumeh
   Moghadam, Kobra Shojaei
   Solali, Saeed
TI Emerging molecular functions of microRNA-124: Cancer pathology and
   therapeutic implications
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Review
DE microRNA; Cancer; Drug; Target therapy; Leukemia
ID EPITHELIAL-MESENCHYMAL TRANSITION; INHIBITS CELL-PROLIFERATION;
   WNT/BETA-CATENIN PATHWAY; NONCODING RNA; DOWN-REGULATION;
   MULTIDRUG-RESISTANCE; COLORECTAL-CANCER; ESOPHAGEAL CANCER; INDUCED
   APOPTOSIS; BRAIN METASTASIS
AB MicroRNAs are characterized as small, single-stranded, non-coding RNA molecules that bind to their target mRNA to prevent protein synthesis. MicroRNAs regulate various normal processes; however, they are aberrantly regulated in many cancers. They control the expression of various genes, including cancer-related genes. This causes microRNAs to be considered as a good target for further investigations for designing novel therapeutic strategies.
   Since miR124 is known for some time already, it has a tumor-suppressing role in various cancers. Numerous studies indicate its definite roles in malignant processes such as epithelial-to-mesenchymal transition, cell cycle arrest, metastasis, cancer stem cell formation and induction of apoptosis. However, some studies have indicated a dual role for miR-124 in oncogenic processes like autophagy and multi-drug resistance. In this article, we will review recent researches on the biological functions and clinical implications of miR-124. Subsequently, we will discuss future perspectives in terms of the roles of this miRNA in cancers.
C1 [Moghadasi, Maryam] Tabriz Univ Med Sci, Student Res Comm, Tabriz, Iran.
   [Moghadasi, Maryam; Fardi, Masoumeh; Moghadam, Kobra Shojaei] Tabriz Univ Med Sci, IRC, Tabriz, Iran.
   [Alivand, Mohammadreza] Tabriz Univ Med Sci, Dept Med Genet, Tabriz, Iran.
   [Solali, Saeed] Tabriz Univ Med Sci, Mol Med Res Ctr, Tabriz, Iran.
   [Solali, Saeed] Tabriz Univ Med Sci, Fac Med, Dept Immunol, Div Hematol & Transfus Med, Tabriz, Iran.
C3 Tabriz University of Medical Science; Tabriz University of Medical
   Science; Tabriz University of Medical Science; Tabriz University of
   Medical Science; Tabriz University of Medical Science
RP Solali, S (corresponding author), Tabriz Univ Med Sci, Fac Med, Dept Immunol, Div Hematol & Transfus Med, Tabriz, Iran.
EM ssolali@gmail.com
RI Fardi, Masoumeh/D-9704-2017
CR Acloque H, 2009, J CLIN INVEST, V119, P1438, DOI 10.1172/JCI38019
   [Anonymous], [No title captured]
   Arend RC, 2013, GYNECOL ONCOL, V131, P772, DOI 10.1016/j.ygyno.2013.09.034
   Awasthi R, 2018, DRUG DELIV TRANSL RE, V8, P97, DOI 10.1007/s13346-017-0440-1
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Cai QQ, 2017, SCI REP-UK, V7, DOI 10.1038/srep40733
   Cai WL, 2018, MOL CANCER, V17, DOI 10.1186/s12943-017-0746-0
   Chen SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128472
   Cheng XF, 2019, BIOMED PHARMACOTHER, V110, P473, DOI 10.1016/j.biopha.2018.11.082
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   Du XX, 2017, TOXICOL LETT, V280, P195, DOI 10.1016/j.toxlet.2017.08.082
   Fardi M, 2019, J CELL PHYSIOL, V234, P14783, DOI 10.1002/jcp.28277
   Fardi M, 2018, GENES DIS, V5, P304, DOI 10.1016/j.gendis.2018.06.003
   Feng TB, 2016, ONCOTARGET, V7, P16205, DOI 10.18632/oncotarget.7578
   FOJO A, 1987, CANCER-AM CANCER SOC, V60, P2075, DOI 10.1002/1097-0142(19901015)60:8+<2075::AID-CNCR2820601521>3.0.CO;2-F
   Friedman HS, 2000, CLIN CANCER RES, V6, P2585
   Gillet JP, 2007, BBA-REV CANCER, V1775, P237, DOI 10.1016/j.bbcan.2007.05.002
   Gong X, 2016, AM J TRANSL RES, V8, P2127
   Gu H, 2016, CANCER MED-US, V5, P1174, DOI 10.1002/cam4.664
   Hashemi Mohammad, 2018, Oncotarget, V9, P24857, DOI 10.18632/oncotarget.25324
   Hong L, 2013, CURR DRUG TARGETS, V14, P1118, DOI 10.2174/13894501113149990183
   Hu FY, 2016, J HUAZHONG U SCI-MED, V36, P839, DOI 10.1007/s11596-016-1672-x
   Hu SL, 2019, J BUON, V24, P805
   Huang J, 2018, J CELL BIOCHEM, V119, P3853, DOI 10.1002/jcb.26464
   Huang TT, 2018, ONCOGENE, V37, P1159, DOI 10.1038/s41388-017-0029-7
   Ji P, 2003, ONCOGENE, V22, P8031, DOI 10.1038/sj.onc.1206928
   Jia H, 2019, PATHOL RES PRACT, V215, P697, DOI 10.1016/j.prp.2018.12.039
   Jun JH, 2016, INVEST OPHTH VIS SCI, V57, P12, DOI 10.1167/iovs.15-17111
   Kang QM, 2017, ONCOTARGET, V8, P24314, DOI 10.18632/oncotarget.15149
   Kim JC, 2018, CANCER METAST REV, V37, P5, DOI 10.1007/s10555-017-9712-y
   Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002
   la Cour JM, 2003, AM J PATHOL, V163, P81, DOI 10.1016/S0002-9440(10)63632-2
   Levy JMM, 2017, NAT REV CANCER, V17, P528, DOI 10.1038/nrc.2017.53
   Li JP, 2013, MOL CELL BIOCHEM, V380, P277, DOI 10.1007/s11010-013-1682-y
   Li L, 2016, MOL CANCER THER, V15, P2232, DOI 10.1158/1535-7163.MCT-16-0008
   Li SL, 2017, EUR REV MED PHARMACO, V21, P3389
   Li ZL, 2016, INT J CLIN PHARM TH, V54, P603, DOI 10.5414/CP202551
   Liang YN, 2017, J STEROID BIOCHEM, V172, P62, DOI 10.1016/j.jsbmb.2017.05.014
   Liang YJ, 2013, CARCINOGENESIS, V34, P713, DOI 10.1093/carcin/bgs383
   Long QZ, 2015, TUMOR BIOL, V36, P7017, DOI 10.1007/s13277-015-3369-3
   Luna JI, 2017, EXPERT OPIN BIOL TH, V17, P313, DOI 10.1080/14712598.2017.1271874
   Lv Xiao-Bin, 2011, Chin J Cancer, V30, P821, DOI 10.5732/cjc.011.10289
   Lv ZH, 2013, MOL MED REP, V8, P345, DOI 10.3892/mmr.2013.1561
   Ma J, 2018, EXP CELL RES, V366, P103, DOI 10.1016/j.yexcr.2018.02.037
   MacFarlane LA, 2010, CURR GENOMICS, V11, P537, DOI 10.2174/138920210793175895
   Marisetty AL, 2017, NEURO-ONCOLOGY, V19, P514, DOI 10.1093/neuonc/now232
   Mizushima N, 2008, NATURE, V451, P1069, DOI 10.1038/nature06639
   Murugan AK, 2016, J CELL PHYSIOL, V231, P1424, DOI 10.1002/jcp.25269
   Peng XH, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-186
   Perron MP, 2008, FRONT BIOSCI-LANDMRK, V13, P2537, DOI 10.2741/2865
   Rupaimoole R, 2017, NAT REV DRUG DISCOV, V16, P203, DOI 10.1038/nrd.2016.246
   Schouten M, 2015, SCI REP-UK, V5, DOI 10.1038/srep12448
   Shao QL, 2015, INT J CLIN EXP PATHO, V8, P14465
   Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425
   Shin JY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085205
   Tang DX, 2019, J CELL PHYSIOL, V234, P20816, DOI 10.1002/jcp.28687
   Tu HF, 2013, CURR OPIN OTOLARYNGO, V21, P104, DOI 10.1097/MOO.0b013e32835e1d6e
   Vogetseder A, 2013, INT J CANCER, V133, P2362, DOI 10.1002/ijc.28267
   Wang MJ, 2017, CELL PHYSIOL BIOCHEM, V44, P2017, DOI 10.1159/000485907
   Wang XX, 2016, SCI REP-UK, V6, DOI 10.1038/srep36796
   Wang YB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2862-4
   Wen XY, 2014, J VIROL, V88, P6906, DOI 10.1128/JVI.00023-14
   Wilting SM, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-167
   Wu Q, 2014, CANCER LETT, V347, P159, DOI 10.1016/j.canlet.2014.03.013
   Wu YJ, 2012, J NEURO-ONCOL, V110, P27, DOI 10.1007/s11060-012-0942-0
   Wu YJ, 2017, ANTICANCER RES, V37, P4029, DOI 10.21873/anticanres.11788
   Xia JT, 2012, J PATHOL, V227, P470, DOI 10.1002/path.4030
   Xie YK, 2012, J NEURO-ONCOL, V110, P179, DOI 10.1007/s11060-012-0961-x
   Xu XL, 2013, J TRANSL MED, V11, DOI 10.1186/1479-5876-11-276
   Yu B, 2018, MOL MED REP, V17, P6736, DOI 10.3892/mmr.2018.8637
   Yuan L, 2017, ONCOL LETT, V14, P7311, DOI 10.3892/ol.2017.7157
   Yun CW, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113466
   Zang RK, 2018, EUR REV MED PHARMACO, V22, P4532, DOI 10.26355/eurrev_201807_15508
   Zhang HW, 2013, J OVARIAN RES, V6, DOI 10.1186/1757-2215-6-84
   Zhang L, 2018, ONCOL LETT, V15, P984, DOI 10.3892/ol.2017.7358
   Zhang N, 2016, MOL PHARMACEUT, V13, P2466, DOI 10.1021/acs.molpharmaceut.6b00211
   Zhang TH, 2017, ONCOL REP, V37, P2087, DOI 10.3892/or.2017.5445
   Zhao Y, 2017, ONCOTARGET, V8, P25005, DOI 10.18632/oncotarget.15334
   Zheng F, 2012, GUT, V61, P278, DOI 10.1136/gut.2011.239145
   Zhou LQ, 2016, CELL PHYSIOL BIOCHEM, V38, P1785, DOI 10.1159/000443117
NR 80
TC 15
Z9 15
U1 0
U2 4
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
EI 1618-0631
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PY 2020
VL 216
IS 3
AR 152827
DI 10.1016/j.prp.2020.152827
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA KW1QS
UT WOS:000520946600001
PM 31983567
DA 2025-01-04
ER

PT J
AU Bhattacharya, S
   Bonde, S
   Hatware, K
   Sharma, S
   Anjum, MM
   Sahu, RK
AF Bhattacharya, Sankha
   Bonde, Smita
   Hatware, Ketan
   Sharma, Satyam
   Anjum, Md Meraj
   Sahu, Ram Kumar
TI Physicochemical characterization, in vitro and in vivo evaluation of
   chitosan/carrageenan encumbered with Imatinib mesylate-polysarcosine
   nanoparticles for sustained drug release and enhanced colorectal cancer
   targeted therapy
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MACROMOLECULES
LA English
DT Article
DE Colon cancer; Carrageenan; Chitosan
ID CHITOSAN; COLON; ACID
AB The objective of this investigation was to fabricate nanoparticles consisting of Imatinib mesylate-poly sarcosine-loaded chitosan/carrageenan in order to attain prolonged drug release and efficacious therapy for colorectal cancer. The study involved the synthesis of nanoparticles through the utilisation of ionic complexation and nanoprecipitation techniques. The subsequent nanoparticles were subjected to an assessment of their physico-chemical characteristics, anti-cancer efficacy using HCT116 cell line, and acute toxicity. The present study examined two distinct nanoparticle formulations, namely IMT-PSar-NPs and CS-CRG-IMT-NPs, with respect to their particle size, zeta potential, and morphology. Both formulations demonstrated satisfactory characteristics, as they displayed consistent and prolonged drug release for a duration of 24 h, with the highest level of release occurring at a pH of 5.5. The efficacy and safety of IMT-PSar-NPs and CS-CRG-IMT-PSar-NPs nanoparticles were evaluated through various tests including in vitro cytotoxicity, cellular uptake, apoptosis, scratch test, cell cycle analysis, MMP & ROS estimate, acute toxicity, and stability tests. The results suggest that these nanoparticles were well fabricated and have promising potential for in vivo applications. The prepared polysaccharide nanoparticles have great potential for active targeting and could potentially reduce dose-dependent toxicity in the treatment of colon cancer.
C1 [Bhattacharya, Sankha; Bonde, Smita; Hatware, Ketan] SVKMS NMIMS Deemed be Univ, Sch Pharm & Technol Management, Shirpur 425405, Maharashtra, India.
   [Sharma, Satyam] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharmacol & Toxicol, Export Promot Ind Pk EPIP, Zandaha Rd, NH322, Hajipur 844102, Bihar, India.
   [Anjum, Md Meraj] Babasaheb Bhimrao Ambedkar Univ, Dept Pharmaceut Sci, Lucknow, India.
   [Sahu, Ram Kumar] Cent Univ, HNB Garhwal Univ, Dept Pharmaceut Sci, Chauras Campus,PO Kilkileshwar, Via Kritinagar, Srinagar 249161, Uttaranchal, India.
C3 SVKM's NMIMS (Deemed to be University); National Institute of
   Pharmaceutical Education & Research, S.A.S. Nagar (Mohali); Babasaheb
   Bhimrao Ambedkar University; Hemwati Nandan Bahuguna Garhwal University
RP Bhattacharya, S (corresponding author), SVKMS NMIMS Deemed be Univ, Sch Pharm & Technol Management, Shirpur 425405, Maharashtra, India.
EM sankhabhatt@gmail.com
RI Bhattacharya, Sankha/AAM-5111-2020; Hatware, Ketan/LVR-1194-2024;
   SHARMA, SATYAM/JRX-6086-2023; Anjum, MdMeraj/LXB-2205-2024
OI Anjum, Md Meraj/0000-0001-5865-3950; Bonde, Smita/0000-0002-2667-6629
FU CRS Project-UGC-DAE Consortium for Scientific Research
   [2021/CRS/48/40/594]
FX The corresponding author of this manuscript would like to &
   nbsp;acknowledge the funding received from the CRS Project-UGC-DAE
   Consortium for Scientific Research [2021/CRS/48/40/594]
CR Ahmad A, 2021, ACS APPL BIO MATER, V4, P5324, DOI 10.1021/acsabm.1c00437
   Ahmad A, 2020, ACS BIOMATER SCI ENG, V6, P1102, DOI 10.1021/acsbiomaterials.9b01947
   Bader S, 2021, FREE RADICAL BIO MED, V174, P157, DOI 10.1016/j.freeradbiomed.2021.08.012
   Bayramoglu G, 2023, INT DAIRY J, V138, DOI 10.1016/j.idairyj.2022.105545
   Bhattacharya S, 2020, INT J BIOL MACROMOL, V151, P104, DOI 10.1016/j.ijbiomac.2020.02.151
   Boeding J.R.E., 2023, EUR J SURG ONCOL, DOI [10.1016/j.ejso, DOI 10.1016/J.EJSO]
   Bosio B, 2023, FOOD BIOPROD PROCESS, V138, P116, DOI 10.1016/j.fbp.2023.01.006
   Cabrera-Barjas G, 2023, INT J BIOL MACROMOL, V238, DOI 10.1016/j.ijbiomac.2023.124130
   Cao ZQ, 2023, INT J PHARMACEUT, V638, DOI 10.1016/j.ijpharm.2023.122933
   Chuong MD, 2023, ADV RADIAT ONCOL, V8, DOI 10.1016/j.adro.2022.101084
   Cumbrera FL, 2023, CERAM INT, V49, P18264, DOI 10.1016/j.ceramint.2023.02.198
   Dahabiyeh LA, 2023, EUR J PHARM SCI, V182, DOI 10.1016/j.ejps.2023.106378
   Di W, 2022, J RADIAT RES APPL SC, V15, DOI 10.1016/j.jrras.2022.100470
   Dols-Perez A, 2023, COLLOID SURFACE B, V222, DOI 10.1016/j.colsurfb.2022.113019
   El-Deeb NM, 2022, INT J BIOL MACROMOL, V205, P385, DOI 10.1016/j.ijbiomac.2022.02.058
   Galadima HI, 2021, CANCER EPIDEMIOL, V72, DOI 10.1016/j.canep.2021.101911
   Gupta A, 2018, BIOMACROMOLECULES, V19, P803, DOI 10.1021/acs.biomac.7b01607
   Hanna DH, 2023, INT J BIOL MACROMOL, V231, DOI 10.1016/j.ijbiomac.2023.123364
   Huang S, 2020, CHIN J NAT MEDICINES, V18, P81, DOI 10.1016/S1875-5364(20)30009-1
   Kaushik S, 2023, J COMPUT APPL MATH, V419, DOI 10.1016/j.cam.2022.114710
   Khan R, 2018, ENVIRON TOXICOL, V33, P1272, DOI 10.1002/tox.22635
   Khan R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056020
   Khan R, 2011, CHEM-BIOL INTERACT, V192, P193, DOI 10.1016/j.cbi.2011.03.009
   Ko B., 2024, GASTROINTESTINAL LIV, P91
   Krutzmann M.E., J PHARMACEUT BIOMED
   Kumar S, 2023, J ETHNOPHARMACOL, V302, DOI 10.1016/j.jep.2022.115849
   Lebleu C, 2023, INT J PHARMACEUT, V631, DOI 10.1016/j.ijpharm.2022.122501
   Luo W, 2023, CARBOHYD POLYM, V311, DOI 10.1016/j.carbpol.2023.120718
   Maheswari BU, 2019, ENVIRON CHEM ECOTOX, V1, P2, DOI 10.1016/j.enceco.2019.05.001
   Manjusha V, 2023, INT J BIOL MACROMOL, V235, DOI 10.1016/j.ijbiomac.2023.123900
   Meng QY, 2022, CARBOHYD POLYM, V279, DOI 10.1016/j.carbpol.2021.119013
   Mesiti AM, 2023, J SURG RES, V283, P658, DOI 10.1016/j.jss.2022.11.024
   Ming XQ, 2023, CHEM ENG J, V463, DOI 10.1016/j.cej.2023.142439
   Naik J, 2023, J DRUG DELIV SCI TEC, V80, DOI 10.1016/j.jddst.2022.104084
   Nazemi Z., 2023, INT J BIOL MACROMOL
   Niki E., 2022, ARCH BIOCHEM BIOPHYS, V726
   Ouyang YL, 2023, INT J BIOL MACROMOL, V227, P505, DOI 10.1016/j.ijbiomac.2022.12.032
   Öztürk AA, 2020, MICROVASC RES, V128, DOI 10.1016/j.mvr.2019.103961
   Palacios LRG, 2023, MICROCHEM J, V190, DOI 10.1016/j.microc.2023.108749
   Poulet L, 2023, ALGAL RES, V71, DOI 10.1016/j.algal.2023.103049
   Pradhan B, 2023, INT J BIOL MACROMOL, V238, DOI 10.1016/j.ijbiomac.2023.124085
   Rajagukguk Y.V., 2023, FOOD CHEM ADV, V2
   Rarokar N, 2023, J MOL LIQ, V369, DOI 10.1016/j.molliq.2022.120842
   Raut CP, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2018.4060
   Saleem S, 2023, J ETHNOPHARMACOL, V311, DOI 10.1016/j.jep.2023.116447
   Secme M, 2023, S AFR J BOT, V157, P19, DOI 10.1016/j.sajb.2023.03.046
   Sedlak JC, 2023, ANNU REV PATHOL-MECH, V18, P467, DOI 10.1146/annurev-pathmechdis-031521-041113
   Shen SH, 2020, JAMA ONCOL, V6, P358, DOI 10.1001/jamaoncol.2019.5868
   Shi FF, 2023, FOOD HYDROCOLLOID, V134, DOI 10.1016/j.foodhyd.2022.108081
   Sliwinska-Hill U, 2021, SPECTROCHIM ACTA A, V252, DOI 10.1016/j.saa.2021.119538
   Song XX, 2021, CARBOHYD POLYM, V255, DOI 10.1016/j.carbpol.2020.117379
   Srimongkol P, 2023, ALGAL RES, V69, DOI 10.1016/j.algal.2022.102919
   Suzuki C, 2023, BIOORGAN MED CHEM, V84, DOI 10.1016/j.bmc.2023.117260
   Tantawy MA, 2023, STEROIDS, V193, DOI 10.1016/j.steroids.2023.109187
   Ullah MA, 2022, HUM GENE, V33, DOI 10.1016/j.humgen.2022.201043
   Wei CZ, 2023, LWT-FOOD SCI TECHNOL, V181, DOI 10.1016/j.lwt.2023.114760
   Wilson BK, 2021, J COLLOID INTERF SCI, V604, P208, DOI 10.1016/j.jcis.2021.04.081
   Xie LM, 2023, FOOD SCI HUM WELL, V12, P1545, DOI 10.1016/j.fshw.2023.02.002
   Xu XQ, 2023, INT J BIOL MACROMOL, V224, P1065, DOI 10.1016/j.ijbiomac.2022.10.191
   Zhao X, 2023, REDOX BIOL, V62, DOI 10.1016/j.redox.2023.102678
   Zheng JW, 2023, MATER TODAY COMMUN, V35, DOI 10.1016/j.mtcomm.2023.105818
   Zheng M, 2012, SMALL, V8, P116, DOI 10.1002/smll.201100946
   Zhu HT, 2024, PARTICUOLOGY, V84, P53, DOI 10.1016/j.partic.2023.02.021
NR 63
TC 13
Z9 13
U1 7
U2 24
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0141-8130
EI 1879-0003
J9 INT J BIOL MACROMOL
JI Int. J. Biol. Macromol.
PD AUG 1
PY 2023
VL 245
AR 125529
DI 10.1016/j.ijbiomac.2023.125529
EA JUN 2023
PG 23
WC Biochemistry & Molecular Biology; Chemistry, Applied; Polymer Science
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry; Polymer Science
GA M5KV4
UT WOS:001030613600001
PM 37379942
DA 2025-01-04
ER

PT J
AU Hu, Y
   Liu, L
   Jiang, Q
   Fang, WP
   Chen, YZ
   Hong, YT
   Zhai, X
AF Hu, Yang
   Liu, Liang
   Jiang, Qi
   Fang, Weiping
   Chen, Yazhu
   Hong, Yuntian
   Zhai, Xiang
TI CRISPR/Cas9: a powerful tool in colorectal cancer research
SO JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
LA English
DT Review
DE CRISPR/Cas9; CRC; Gene editing tool; Target therapy; Precise medicine;
   Off-target
ID GENE-EXPRESSION; DNA CLEAVAGE; COLON-CANCER; TUMOR-GROWTH; IN-VITRO;
   RNA; MUTATIONS; CRISPR-CAS9; ACTIVATION; SEQUENCE
AB Colorectal cancer (CRC) is one of the most common malignant cancers worldwide and seriously threatens human health. The clustered regulatory interspaced short palindromic repeat/CRISPR-associate nuclease 9 (CRISPR/Cas9) system is an adaptive immune system of bacteria or archaea. Since its introduction, research into various aspects of treatment approaches for CRC has been accelerated, including investigation of the oncogenes, tumor suppressor genes (TSGs), drug resistance genes, target genes, mouse model construction, and especially in genome-wide library screening. Furthermore, the CRISPR/Cas9 system can be utilized for gene therapy for CRC, specifically involving in the molecular targeted drug delivery or targeted knockout in vivo. In this review, we elucidate the mechanism of the CRISPR/Cas9 system and its comprehensive applications in CRC. Additionally, we discussed the issue of off-target effects associated with CRISPR/Cas9, which serves to restrict its practical application. Future research on CRC should in-depth and systematically utilize the CRISPR/Cas9 system thereby achieving clinical practice.
C1 [Hu, Yang; Fang, Weiping] First Peoples Hosp Jiande, Dept Gastroenterol, Hangzhou 311600, Peoples R China.
   [Liu, Liang] Wuhan Univ, Zhongnan Hosp, Dept Orthoped Surg, Wuhan 430071, Peoples R China.
   [Jiang, Qi] Wuhan Univ, Zhongnan Hosp, Dept Biol Repositories, Wuhan 430071, Peoples R China.
   [Chen, Yazhu] Sichuan Univ, West China Hosp, Inst Orthopaed, Chengdu 610044, Peoples R China.
   [Hong, Yuntian] Wuhan Univ, Dept Gastroenterol, Zhongnan Hosp, Wuhan 430071, Peoples R China.
   [Zhai, Xiang] Wuhan Univ, Zhongnan Hosp, Dept Colorectal & Anal Surg, Wuhan 430071, Peoples R China.
C3 Wuhan University; Wuhan University; Sichuan University; Wuhan
   University; Wuhan University
RP Chen, YZ (corresponding author), Sichuan Univ, West China Hosp, Inst Orthopaed, Chengdu 610044, Peoples R China.; Hong, YT (corresponding author), Wuhan Univ, Dept Gastroenterol, Zhongnan Hosp, Wuhan 430071, Peoples R China.; Zhai, X (corresponding author), Wuhan Univ, Zhongnan Hosp, Dept Colorectal & Anal Surg, Wuhan 430071, Peoples R China.
EM yazhu.chen@qq.com; 3130101818@zju.edu.cn; zx1996@whu.edu.cn
RI Hong, Yuntian/JJG-1945-2023; Fang, WP/G-3442-2010
OI HONG, YUNTIAN/0000-0002-3546-1670
CR Anzalone AV, 2019, NATURE, V576, P149, DOI 10.1038/s41586-019-1711-4
   Bae S, 2014, BIOINFORMATICS, V30, P1473, DOI 10.1093/bioinformatics/btu048
   Barrangou R, 2007, SCIENCE, V315, P1709, DOI 10.1126/science.1138140
   Bikard D, 2013, NUCLEIC ACIDS RES, V41, P7429, DOI 10.1093/nar/gkt520
   Blin K, 2016, SYN SYST BIOTECHNO, V1, P118, DOI 10.1016/j.synbio.2016.01.003
   Blondy S, 2020, CANCER SCI, V111, P3142, DOI 10.1111/cas.14532
   Bolotin A, 2005, MICROBIOL-SGM, V151, P2551, DOI 10.1099/mic.0.28048-0
   Bonjoch L, 2020, GASTROENTEROLOGY, V159, P227, DOI 10.1053/j.gastro.2020.03.015
   Brinkman EK, 2014, NUCLEIC ACIDS RES, V42, DOI 10.1093/nar/gku936
   Capasso I, 2023, CANCERS, V15, DOI 10.3390/cancers15051400
   Carusillo A, 2023, NUCLEIC ACIDS RES, V51, P4660, DOI 10.1093/nar/gkad255
   Carvalho RF, 2021, CANCERS, V13, DOI 10.3390/cancers13215492
   Caspi M, 2021, ADV DRUG DELIVER REV, V169, P118, DOI 10.1016/j.addr.2020.12.010
   Chamberlain CA, 2022, MOL THER ONCOLYTICS, V24, P417, DOI 10.1016/j.omto.2022.01.004
   Chang HHY, 2017, NAT REV MOL CELL BIO, V18, P495, DOI 10.1038/nrm.2017.48
   Chari R, 2017, ACS SYNTH BIOL, V6, P902, DOI 10.1021/acssynbio.6b00343
   Chen HN, 2022, GUT, V71, P322, DOI 10.1136/gutjnl-2020-323703
   Chen HR, 2021, GASTROENTEROLOGY, V160, P1284, DOI 10.1053/j.gastro.2020.11.013
   Cheon DJ, 2011, ANNU REV PATHOL-MECH, V6, P95, DOI 10.1146/annurev.pathol.3.121806.154244
   Choudhary N, 2023, FRONT PLANT SCI, V14, DOI 10.3389/fpls.2023.1164461
   Chuang CK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22189872
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Clement K, 2019, NAT BIOTECHNOL, V37, P224, DOI 10.1038/s41587-019-0032-3
   Concordet JP, 2018, NUCLEIC ACIDS RES, V46, pW242, DOI 10.1093/nar/gky354
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Cradick TJ, 2014, MOL THER-NUCL ACIDS, V3, DOI 10.1038/mtna.2014.64
   Cyranoski D, 2016, NATURE, V539, P479, DOI 10.1038/nature.2016.20988
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Deltcheva E, 2011, NATURE, V471, P602, DOI 10.1038/nature09886
   Dienstmann R, 2017, ANN ONCOL, V28, P1023, DOI 10.1093/annonc/mdx052
   Dominguez AA, 2016, NAT REV MOL CELL BIO, V17, DOI 10.1038/nrm.2015.2
   Drost J, 2015, NATURE, V521, P43, DOI 10.1038/nature14415
   Evron T, 2021, ONCOGENESIS, V10, DOI 10.1038/s41389-021-00354-7
   Fang TT, 2022, ACS SYNTH BIOL, V11, P3004, DOI 10.1021/acssynbio.2c00182
   Feng SY, 2022, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.803252
   Fu YF, 2014, NAT BIOTECHNOL, V32, P279, DOI 10.1038/nbt.2808
   Fu YF, 2013, NAT BIOTECHNOL, V31, P822, DOI 10.1038/nbt.2623
   Garneau JE, 2010, NATURE, V468, P67, DOI 10.1038/nature09523
   Gasiunas G, 2012, P NATL ACAD SCI USA, V109, pE2579, DOI 10.1073/pnas.1208507109
   Ge YD, 2019, J AUTOIMMUN, V101, P109, DOI 10.1016/j.jaut.2019.04.014
   Gilbert LA, 2013, CELL, V154, P442, DOI 10.1016/j.cell.2013.06.044
   Guo CT, 2023, FRONT BIOENG BIOTECH, V11, DOI 10.3389/fbioe.2023.1143157
   Guo L, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-39156-3
   Hayashida G, 2019, EXP CELL RES, V377, P24, DOI 10.1016/j.yexcr.2019.02.020
   Heigwer F, 2021, (Clifton NJ), V2162, P3
   Heigwer F, 2014, NAT METHODS, V11, P122, DOI 10.1038/nmeth.2812
   Hinger SA, 2018, CELL REP, V25, P715, DOI 10.1016/j.celrep.2018.09.054
   Hruscha A, 2013, DEVELOPMENT, V140, P4982, DOI 10.1242/dev.099085
   Hu JH, 2018, NATURE, V556, P57, DOI 10.1038/nature26155
   Hu X, 2020, EBIOMEDICINE, V56, DOI 10.1016/j.ebiom.2020.102800
   Hudek AK, 2003, BIOINFORMATICS, V19, P1177, DOI 10.1093/bioinformatics/btg134
   Idris M, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188586
   ISHINO Y, 1987, J BACTERIOL, V169, P5429, DOI 10.1128/jb.169.12.5429-5433.1987
   Izumi D, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1493-5
   Jinek M, 2013, ELIFE, V2, DOI 10.7554/eLife.00471
   Jinek M, 2012, SCIENCE, V337, P816, DOI 10.1126/science.1225829
   Joung J, 2017, NATURE, V548, P343, DOI 10.1038/nature23451
   Jung HR, 2021, ONCOGENE, V40, P3287, DOI 10.1038/s41388-021-01777-7
   Kang MS, 2017, SEMIN IMMUNOL, V32, P3, DOI 10.1016/j.smim.2017.04.003
   Kapalczynska M, 2018, ARCH MED SCI, V14, P910, DOI 10.5114/aoms.2016.63743
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kawasaki K, 2020, GASTROENTEROLOGY, V158, P638, DOI 10.1053/j.gastro.2019.10.009
   Kerr D, 2003, NAT REV CANCER, V3, P615, DOI 10.1038/nrc1147
   Kim D, 2020, CELL, V183, P850, DOI 10.1016/j.cell.2020.09.044
   Kim HK, 2018, NAT BIOTECHNOL, V36, P239, DOI 10.1038/nbt.4061
   Kleinstiver BP, 2015, NAT BIOTECHNOL, V33, P1293, DOI 10.1038/nbt.3404
   Komor AC, 2016, NATURE, V533, P420, DOI 10.1038/nature17946
   Kosicki M, 2018, NAT BIOTECHNOL, V36, P765, DOI 10.1038/nbt.4192
   Kraus C, 2023, J MOL BIOL, V435, DOI 10.1016/j.jmb.2023.168120
   Krishnamurthy N, 2018, CANCER TREAT REV, V62, P50, DOI 10.1016/j.ctrv.2017.11.002
   Lee J, 2023, NAT COMMUN, V14, DOI 10.1038/s41467-023-37507-8
   Lei ZN, 2021, MEDCOMM, V2, P765, DOI 10.1002/mco2.106
   Li XV, 2022, NATURE, V603, P672, DOI 10.1038/s41586-022-04502-w
   Li YL, 2020, ONCOTARGETS THER, V13, P17, DOI 10.2147/OTT.S225556
   Liao TT, 2020, THERANOSTICS, V10, P6095, DOI 10.7150/thno.44147
   Liu HL, 2015, BIOINFORMATICS, V31, P3676, DOI 10.1093/bioinformatics/btv423
   Liu N, 2019, INT J RADIAT ONCOL, V104, P1153, DOI 10.1016/j.ijrobp.2019.04.021
   Liu Q, 2018, CLIN CANCER RES, V24, P4602, DOI 10.1158/1078-0432.CCR-17-3678
   Liu Y, 2020, SCIENCE, V368, P1265, DOI 10.1126/science.aay8204
   Luo MC, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188623
   Ma CY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01268-5
   Ma YW, 2016, RNA BIOL, V13, P605, DOI 10.1080/15476286.2016.1185591
   MacDonald BT, 2009, DEV CELL, V17, P9, DOI 10.1016/j.devcel.2009.06.016
   Makarova KS, 2006, BIOL DIRECT, V1, DOI 10.1186/1745-6150-1-7
   Makarova KS, 2020, NAT REV MICROBIOL, V18, P67, DOI 10.1038/s41579-019-0299-x
   Makarova KS, 2011, NAT REV MICROBIOL, V9, P467, DOI 10.1038/nrmicro2577
   Makarova KS, 2002, NUCLEIC ACIDS RES, V30, P482, DOI 10.1093/nar/30.2.482
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Malkomes P, 2021, ONCOGENE, V40, P4352, DOI 10.1038/s41388-021-01847-w
   Matano M, 2015, NAT MED, V21, P256, DOI 10.1038/nm.3802
   Means AL, 2018, CELL MOL GASTROENTER, V6, P257, DOI 10.1016/j.jcmgh.2018.05.006
   Michels BE, 2020, CELL STEM CELL, V26, P782, DOI 10.1016/j.stem.2020.04.003
   Michels BE, 2019, J EXP MED, V216, P704, DOI 10.1084/jem.20180823
   Miller KD., 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Mohanta TK, 2017, GENES-BASEL, V8, DOI 10.3390/genes8120399
   Nadeem MS, 2020, SEMIN CANCER BIOL, V64, P51, DOI 10.1016/j.semcancer.2019.05.001
   Nagao-Kitamoto H, 2022, CANCER METAST REV, V41, P301, DOI 10.1007/s10555-022-10028-4
   Niu YY, 2014, CELL, V156, P836, DOI 10.1016/j.cell.2014.01.027
   Palin K, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06132-1
   Pan Q, 2021, MOL CELL, V81, P2736, DOI 10.1016/j.molcel.2021.04.009
   Pang XL, 2023, J TRANSL MED, V21, DOI 10.1186/s12967-023-03881-6
   Park J, 2017, BIOINFORMATICS, V33, P286, DOI 10.1093/bioinformatics/btw561
   Park J, 2015, BIOINFORMATICS, V31, P4014, DOI 10.1093/bioinformatics/btv537
   Park SB, 2022, MOL THER NUCL ACIDS, V28, P656, DOI 10.1016/j.omtn.2022.04.013
   Pattanayak V, 2013, NAT BIOTECHNOL, V31, P839, DOI 10.1038/nbt.2673
   Perez-Pinera P, 2013, NAT METHODS, V10, P973, DOI [10.1038/NMETH.2600, 10.1038/nmeth.2600]
   Poghosyan S, 2022, CANCERS, V14, DOI 10.3390/cancers14030671
   Porter RJ, 2021, J CROHNS COLITIS, V15, P2131, DOI 10.1093/ecco-jcc/jjab102
   Pothuraju R, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01156-y
   Prykhozhij SV, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0119372
   Qi LS, 2013, CELL, V152, P1173, DOI 10.1016/j.cell.2013.02.022
   Qiu HB, 2021, CANCER COMMUN, V41, P1037, DOI 10.1002/cac2.12197
   Rath A, 2019, HUM MUTAT, V40, P2044, DOI 10.1002/humu.23848
   Ringel T, 2020, CELL STEM CELL, V26, P431, DOI 10.1016/j.stem.2020.02.007
   Roper J, 2017, NAT BIOTECHNOL, V35, P569, DOI 10.1038/nbt.3836
   Saeinasab M, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1169-0
   Sanson KR, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07901-8
   Schaefer KA, 2017, NAT METHODS, V14, P547, DOI 10.1038/nmeth.4293
   Schuster A, 2019, TRENDS BIOTECHNOL, V37, P38, DOI 10.1016/j.tibtech.2018.08.002
   Shah SC, 2022, GASTROENTEROLOGY, V162, P715, DOI 10.1053/j.gastro.2021.10.035
   Shen CC, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gky1165
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Slyskova J, 2018, NUCLEIC ACIDS RES, V46, P9537, DOI 10.1093/nar/gky764
   Sternberg SH, 2015, MOL CELL, V58, P568, DOI 10.1016/j.molcel.2015.02.032
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Sustic T, 2018, GENOME MED, V10, DOI 10.1186/s13073-018-0600-z
   Takeda H, 2019, P NATL ACAD SCI USA, V116, P15635, DOI 10.1073/pnas.1904714116
   Tan YY, 2019, P NATL ACAD SCI USA, V116, P20969, DOI 10.1073/pnas.1906843116
   Tanenbaum ME, 2014, CELL, V159, P635, DOI 10.1016/j.cell.2014.09.039
   Thakore PI, 2015, NAT METHODS, V12, P1143, DOI 10.1038/nmeth.3630
   Thoma CR, 2014, ADV DRUG DELIVER REV, V69, P29, DOI 10.1016/j.addr.2014.03.001
   Tong YJ, 2019, P NATL ACAD SCI USA, V116, P20366, DOI 10.1073/pnas.1913493116
   Wan CH, 2021, SCI ADV, V7, DOI 10.1126/sciadv.abf2567
   Wan T, 2021, NANO LETT, V21, P9761, DOI 10.1021/acs.nanolett.1c03708
   Wang AP, 2015, AM J PHYSIOL-GASTR L, V309, pG855, DOI 10.1152/ajpgi.00278.2015
   Wang DR, 2021, CANCER DISCOV, V11, P1192, DOI 10.1158/2159-8290.CD-20-1243
   Wang FY, 2016, TRENDS CELL BIOL, V26, P875, DOI 10.1016/j.tcb.2016.08.004
   Wang HY, 2013, CELL, V153, P910, DOI 10.1016/j.cell.2013.04.025
   Wang JW, 2018, NEOPLASIA, V20, P499, DOI 10.1016/j.neo.2018.03.001
   Wang S, 2022, ADV SCI, V9, DOI 10.1002/advs.202104789
   Wang X, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0860-7
   Watanabe S, 2021, BIOCHEM BIOPHYS REP, V26, DOI 10.1016/j.bbrep.2021.101031
   Wei N, 2023, FASEB J, V37, DOI 10.1096/fj.202202132RR
   Wong N, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0784-0
   Woznicki JA, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2263-0
   Xie HH, 2020, PLOS BIOL, V18, DOI 10.1371/journal.pbio.3000747
   Xie SS, 2019, BIOINFORMATICS, V35, P1566, DOI 10.1093/bioinformatics/bty852
   Xie SS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100448
   Xu H, 2019, CELL MOL GASTROENTER, V7, P19, DOI 10.1016/j.jcmgh.2018.08.005
   Xu PP, 2021, JCI INSIGHT, V6, DOI 10.1172/jci.insight.148931
   Xue CY, 2021, TRENDS GENET, V37, P639, DOI 10.1016/j.tig.2021.02.008
   Yan HHN, 2020, GUT, V69, P2165, DOI 10.1136/gutjnl-2019-320019
   Yang ZY, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1001444
   Yang ZX, 2023, GENOM PROTEOM BIOINF, V21, P1206, DOI 10.1016/j.gpb.2022.12.003
   Yau EH, 2017, CANCER RES, V77, P6330, DOI 10.1158/0008-5472.CAN-17-2043
   Yin H, 2018, NAT CHEM BIOL, V14, P311, DOI [10.1038/nchembio.2559, 10.1038/NCHEMBIO.2559]
   Yu CN, 2022, ONCOGENE, V41, P191, DOI 10.1038/s41388-021-02077-w
   Yu YJ, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0725-5
   Yue B, 2018, MOL THER, V26, P1287, DOI 10.1016/j.ymthe.2018.02.024
   Yuen CTL, 2022, NUCLEIC ACIDS RES, V50, P1650, DOI 10.1093/nar/gkab1291
   Yurgelun MB, 2017, J CLIN ONCOL, V35, P1086, DOI 10.1200/JCO.2016.71.0012
   Zeng KX, 2018, ONCOGENE, V37, P5534, DOI 10.1038/s41388-018-0352-7
   Zhan TZ, 2021, INT J CANCER, V148, P1948, DOI 10.1002/ijc.33393
   Zhang XY, 2018, CANCER DISCOV, V8, P108, DOI 10.1158/2159-8290.CD-17-0532
   Zhao CZ, 2019, INT J BIOL SCI, V15, P2641, DOI 10.7150/ijbs.37152
   Zhao CZ, 2017, INT J BIOL SCI, V13, P1470, DOI 10.7150/ijbs.21312
   Zhao LH, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04267-6
   Zhou XQ, 2015, CELL MOL LIFE SCI, V72, P1175, DOI 10.1007/s00018-014-1744-7
   Zhu GM, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01441-4
   Zhu LHJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0108424
NR 170
TC 4
Z9 5
U1 11
U2 24
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1756-9966
J9 J EXP CLIN CANC RES
JI J. Exp. Clin. Cancer Res.
PD NOV 22
PY 2023
VL 42
IS 1
AR 308
DI 10.1186/s13046-023-02901-z
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA Y9MC2
UT WOS:001108418500002
PM 37993945
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Xin, R
   Tang, XM
   Jiang, YJ
   Yu, F
   Li, S
   Jia, CY
   Wang, GR
   Fu, D
   Liu, JB
   Ma, YS
AF Xin, Rui
   Tang, Xiao-Mei
   Jiang, Ying-Jie
   Yu, Fei
   Li, Sha
   Jia, Cheng-You
   Wang, Gao-Ren
   Fu, Da
   Liu, Ji-Bin
   Ma, Yu-Shui
TI Construction of a Novel MYC-Associated ceRNA Regulatory Network to
   Identify Prognostic Biomarkers in Colon Adenocarcinoma
SO JOURNAL OF ONCOLOGY
LA English
DT Article
ID LONG NONCODING RNAS; COLORECTAL-CANCER; CHROMOSOMAL INSTABILITY;
   LOCALIZATION; PATH
AB Colorectal cancer (CRC) includes colon adenocarcinoma (COAD) and rectal adenocarcinoma (READ). Competitive endogenous RNA (ceRNA) is crucial for cancer pathogenesis. Abnormal expression of MYC is generally associated with a poor colon adenocarcinoma prognosis. The present study aimed to identify a novel MYC-associated ceRNA regulatory network and identify potential prognostic markers associated with COAD. We obtained the transcriptome sequencing profiles of 462 COAD cases from the TCGA database and analyzed differentially expressed genes (DEGs) in MYC high expression (MYChigh) and MYC low expression (Myc(low)) tumors. We identified an important lncRNA, LINC00114, which effectively predicts overall survival and plays a protective role in COAD. Moreover, the LINC00114/miR-216a-5p axis was identified as a clinical prognostic model. The predicted target genes of the LINC00114/miR-216a-5p axis include uromodulin Like 1 (UMODL1) and oncoprotein induced transcript 3 (OIT3), which are closely related to the survival and prognosis of COAD patients. In summary, we constructed a novel ceRNA regulatory network and identified potential biomarkers for the targeted therapy and prognosis of COAD.
C1 [Xin, Rui; Yu, Fei; Jia, Cheng-You; Fu, Da] Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Sch Med, Shanghai 200072, Peoples R China.
   [Xin, Rui; Li, Sha; Wang, Gao-Ren; Liu, Ji-Bin] Nantong Univ, Inst Oncol, Affiliated Tumor Hosp, Nantong 226631, Jiangsu, Peoples R China.
   [Tang, Xiao-Mei; Fu, Da] Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Pancreat Dis, Dept Gen Surg,Sch Med, Shanghai 200025, Peoples R China.
   [Jiang, Ying-Jie] Navy Mil Med Univ, Dept Pathol, Affiliated Changhai Hosp, Shanghai 200433, Peoples R China.
   [Ma, Yu-Shui] Shanghai Univ Tradit Chinese Med, Longhua Hosp, Canc Inst, Shanghai 200032, Peoples R China.
C3 Tongji University; Nantong University; Shanghai Jiao Tong University;
   Naval Medical University; Shanghai University of Traditional Chinese
   Medicine
RP Fu, D (corresponding author), Tongji Univ, Shanghai Peoples Hosp 10, Dept Nucl Med, Sch Med, Shanghai 200072, Peoples R China.; Liu, JB (corresponding author), Nantong Univ, Inst Oncol, Affiliated Tumor Hosp, Nantong 226631, Jiangsu, Peoples R China.; Fu, D (corresponding author), Shanghai Jiao Tong Univ, Ruijin Hosp, Inst Pancreat Dis, Dept Gen Surg,Sch Med, Shanghai 200025, Peoples R China.; Ma, YS (corresponding author), Shanghai Univ Tradit Chinese Med, Longhua Hosp, Canc Inst, Shanghai 200032, Peoples R China.
EM xinrui0906@tongji.edu.cn; txm40713@rjh.com.cn;
   jyj_blk059032@foxmail.com; yufei021@sina.com; lisha789@csu.edu.cn;
   jiachengyou@tongji.edu.cn; goldenwang2000@ntu.edu.cn; fu80da90@163.com;
   tians2008@ntu.edu.cn; mayushui@tongji.edu.cn
RI liu, James/E-9699-2014; ma, yushui/HGC-6206-2022; bai,
   yanpeng/HHZ-3923-2022; Fu, Da/GXF-2656-2022
OI Jiang, Yingjie/0009-0003-7031-2448; Ma, Yu-Shui/0000-0002-5728-7458;
   Rui, Xin/0000-0002-6479-1070; Fu, Da/0000-0002-0878-2575
FU National Natural Science Foundation of China [81972214]; Shanghai
   Committee of Science and Technology [21140903500]; Shanghai Natural
   Science Foundation [20ZR1472400]
FX AcknowledgmentsThis study was supported partly by grants from the
   National Natural Science Foundation of China (81972214), Shanghai
   Committee of Science and Technology (21140903500), and Shanghai Natural
   Science Foundation (20ZR1472400).
CR Adhikary S, 2005, NAT REV MOL CELL BIO, V6, P635, DOI 10.1038/nrm1703
   An N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137171
   Brenner H, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0498-x
   Cao Z, 2018, BIOINFORMATICS, V34, P2185, DOI 10.1093/bioinformatics/bty085
   Chang ZY, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00688
   Chen H, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0008-7
   Chen WG, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.00478
   Chin L, 2011, NAT MED, V17, P297, DOI 10.1038/nm.2323
   Dang CV, 2006, SEMIN CANCER BIOL, V16, P253, DOI 10.1016/j.semcancer.2006.07.014
   Dang CV, 2012, CELL, V149, P22, DOI 10.1016/j.cell.2012.03.003
   Dekker E, 2018, GASTROENTEROLOGY, V154, P1970, DOI 10.1053/j.gastro.2018.01.069
   Ferlay J, 2018, EUR J CANCER, V103, P356, DOI 10.1016/j.ejca.2018.07.005
   Gabay M, 2014, CSH PERSPECT MED, V4, DOI 10.1101/cshperspect.a014241
   Haggar Fatima A, 2009, Clin Colon Rectal Surg, V22, P191, DOI 10.1055/s-0029-1242458
   Hsieh AL, 2015, SEMIN CELL DEV BIOL, V43, P11, DOI 10.1016/j.semcdb.2015.08.003
   Jeggari A, 2012, BIOINFORMATICS, V28, P2062, DOI 10.1093/bioinformatics/bts344
   Karreth FA, 2013, CANCER DISCOV, V3, P1113, DOI 10.1158/2159-8290.CD-13-0202
   Kim JH, 2015, WORLD J GASTROENTERO, V21, P5158, DOI 10.3748/wjg.v21.i17.5158
   Kress TR, 2015, NAT REV CANCER, V15, P593, DOI 10.1038/nrc3984
   Lennox KA, 2016, NUCLEIC ACIDS RES, V44, P863, DOI 10.1093/nar/gkv1206
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   Liu SZ, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249359
   Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7
   Liu ZQ, 2021, J CELL MOL MED, V25, P6874, DOI 10.1111/jcmm.16696
   Long JL, 2020, CELL PROLIFERAT, V53, DOI 10.1111/cpr.12900
   Louis P, 2014, NAT REV MICROBIOL, V12, P661, DOI 10.1038/nrmicro3344
   Luke JJ, 2017, NAT REV CLIN ONCOL, V14, P463, DOI 10.1038/nrclinonc.2017.43
   Lv L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01383
   Mármol I, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010197
   Masugi Y, 2017, GUT, V66, P1463, DOI 10.1136/gutjnl-2016-311421
   Modest DP, 2019, EUR J CANCER, V109, P70, DOI 10.1016/j.ejca.2018.12.019
   Nadeem MS, 2020, SEMIN CANCER BIOL, V64, P51, DOI 10.1016/j.semcancer.2019.05.001
   Nguyen L, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19406-4
   Nolte W, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01130
   Novello S, 2016, ANN ONCOL, V27, pv1, DOI 10.1093/annonc/mdw326
   O'Connell MR, 2019, J MOL BIOL, V431, P66, DOI 10.1016/j.jmb.2018.06.029
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Poplineau M, 2013, CELL PROLIFERAT, V46, P127, DOI 10.1111/cpr.12021
   Puerta-García E, 2015, PHARMACOGENOMICS, V16, P1189, DOI 10.2217/PGS.15.63
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Reimand J, 2019, NAT PROTOC, V14, P482, DOI 10.1038/s41596-018-0103-9
   Safaralizadeh R, 2019, J GASTROINTEST CANC, V50, P78, DOI 10.1007/s12029-017-0019-6
   Sansregret L, 2018, NAT REV CLIN ONCOL, V15, P139, DOI 10.1038/nrclinonc.2017.198
   Shen XH, 2015, MODERN PATHOL, V28, P4, DOI 10.1038/modpathol.2014.75
   Shi ZQ, 2014, CRIT REV EUKAR GENE, V24, P39, DOI 10.1615/CritRevEukaryotGeneExpr.2014007896
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151
   Van Blarigan EL, 2018, JAMA ONCOL, V4, P783, DOI 10.1001/jamaoncol.2018.0126
   Wang W, 2012, CELL DEATH DIS, V3, DOI 10.1038/cddis.2012.169
   Xu XW, 2017, ONCOTARGET, V8, P91674, DOI 10.18632/oncotarget.21748
   Yachi K, 2018, SIGNAL TRANSDUCT TAR, V3, DOI 10.1038/s41392-018-0033-6
   Yang QQ, 2017, ONCOL LETT, V13, P1958, DOI 10.3892/ol.2017.5608
   Yang WG, 2001, CANCER RES, V61, P7840
   Ye LL, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02368
   Zeng X, 2019, CANCER MANAG RES, V11, P6981, DOI 10.2147/CMAR.S208983
   Zhang DD, 2021, MOL THER NUCL ACIDS, V24, P1033, DOI 10.1016/j.omtn.2021.04.019
NR 57
TC 0
Z9 1
U1 0
U2 7
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 1687-8450
EI 1687-8469
J9 J ONCOL
JI J. Oncol.
PD JUL 5
PY 2022
VL 2022
AR 3216285
DI 10.1155/2022/3216285
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 3D7FC
UT WOS:000829462200003
PM 35847359
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Xu, Y
   Zhou, X
   Mei, M
   Ren, Y
AF Xu, Y.
   Zhou, X.
   Mei, M.
   Ren, Y.
TI Reprograming Carcinoma Associated Fibroblasts by microRNAs
SO CURRENT MOLECULAR MEDICINE
LA English
DT Review
DE Carcinoma-associated fibroblasts; microRNA; reprogramming; signaling
   pathway; metabolic pathway; target therapy
ID CANCER-ASSOCIATED FIBROBLASTS; PHASE-II TRIAL; MONOCLONAL-ANTIBODY F-19;
   ACTIVATION PROTEIN; COLON-CANCER; STROMAL CELLS; TUMOR-GROWTH;
   MYOFIBROBLAST DIFFERENTIATION; MICROENVIRONMENTAL REGULATION; MALIGNANT
   PROGRESSION
AB Carcinoma-associated fibroblasts (CAFs) are activated fibroblasts during development of several cancer types, and therefore emerge as an attractive therapeutic target for cancer therapy. Drugs such as PT-100 and sibrotuzumab that block the functions of CAFs have already been in clinical trials. However, these drugs exhibit limited efficacy in patients, partially due to the fact that currently used biomarkers for determining efficacy are not CAF-specific. Furthermore, depletion of CAFs may promote carcinogenesis and accelerate cancer progression by inducing immunosuppression and hypoxia, leading to reduced survival. Accumulating evidence demonstrates that restoring the expression of key microRNA induces the functional conversion of CAFs into normal fibroblasts by targeting different signaling pathways and metabolic mechanisms. Therefore, reprograming CAFs into normal fibroblasts by altering specific expression of microRNAs, rather than targeted ablation, may be an effective, novel strategy for cancer treatment. This review focuses on specific microRNAs involved in the transformation of CAFs as well as their multiple roles during tumorigenesis and chemo-resistance.
C1 [Xu, Y.; Mei, M.; Ren, Y.] Tianjin Med Univ, Res Ctr Basic Med Sci, 22 Qi Xiang Tai Rd, Tianjin 300070, Peoples R China.
   [Zhou, X.] Tianjin Med Univ Canc Inst & Hosp, Natl Clin Res Ctr Canc, Dept Maxillofacial & Otorhinolaryngol Oncol, Tianjin Canc Inst,Key Lab Canc Prevent & Therapy, Tianjin 300060, Peoples R China.
C3 Tianjin Medical University; Tianjin Medical University
RP Ren, Y (corresponding author), Tianjin Med Univ, Res Ctr Basic Med Sci, 22 Qi Xiang Tai Rd, Tianjin 300070, Peoples R China.
EM yuren0925@tmu.edu.cn
FU China National Natural Scientific Fund [81673026, 81572492]; Committee
   of Tianjin Science and Technology [16JCZDJC34800]
FX This work was supported by the China National Natural Scientific Fund
   (81673026, 81572492), and Committee of Tianjin Science and Technology
   (16JCZDJC34800).
CR Akhurst RJ, 2012, NAT REV DRUG DISCOV, V11, P790, DOI 10.1038/nrd3810
   Augsten M, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00062
   Bae JY, 2014, NEOPLASIA, V16, P928, DOI 10.1016/j.neo.2014.09.003
   Bae S, 2008, BRIT J HAEMATOL, V142, P827, DOI 10.1111/j.1365-2141.2008.07241.x
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bhowmick NA, 2004, SCIENCE, V303, P848, DOI 10.1126/science.1090922
   Bowen T, 2013, J PATHOL, V229, P274, DOI 10.1002/path.4119
   Brennen WN, 2012, MOL CANCER THER, V11, P257, DOI 10.1158/1535-7163.MCT-11-0340
   Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396
   Bullock MD, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.213
   Bullock MD, 2015, ONCOTARGET, V6, P7262, DOI 10.18632/oncotarget.3225
   Casbas-Hernandez P, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3476
   Chen ZB, 2015, ONCOTARGET, V6, P38139, DOI 10.18632/oncotarget.5709
   Chou J, 2012, CANCER DISCOV, V2, P1078, DOI 10.1158/2159-8290.CD-12-0465
   Doldi V, 2015, ONCOTARGET, V6, P31441, DOI 10.18632/oncotarget.5056
   Donahue TR, 2014, J SURG ONCOL, V110, P952, DOI 10.1002/jso.23750
   Donnarumma E, 2017, ONCOTARGET, V8, P19592, DOI 10.18632/oncotarget.14752
   Eager RM, 2009, CLIN ONCOL-UK, V21, P464, DOI 10.1016/j.clon.2009.04.007
   Eager RM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-263
   Fearon DT, 2014, CANCER IMMUNOL RES, V2, P187, DOI 10.1158/2326-6066.CIR-14-0002
   Gandellini P, 2014, ANTIOXID REDOX SIGN, V20, P1045, DOI 10.1089/ars.2013.5292
   Gong C, 2014, CANCER RES, V74, P4341, DOI 10.1158/0008-5472.CAN-14-0125
   Green MC, 2000, CANCER TREAT REV, V26, P269, DOI 10.1053/ctrv.2000.0176
   Grugan KD, 2010, P NATL ACAD SCI USA, V107, P11026, DOI 10.1073/pnas.0914295107
   Guido C, 2012, ONCOTARGET, V3, P798, DOI 10.18632/oncotarget.574
   Haviv I, 2009, CELL CYCLE, V8, P589, DOI 10.4161/cc.8.4.7669
   Hedbäck N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095193
   Heiden MGV, 2009, SCIENCE, V324, P1029, DOI 10.1126/science.1160809
   Hofheinz RD, 2003, ONKOLOGIE, V26, P44, DOI 10.1159/000069863
   Hwang RF, 2008, CANCER RES, V68, P918, DOI 10.1158/0008-5472.CAN-07-5714
   Ilyas SI, 2014, J BIOL CHEM, V289, P22835, DOI 10.1074/jbc.M114.563064
   Ippolito L, 2016, ONCOTARGET, V7, P61890, DOI 10.18632/oncotarget.11301
   Joyce JA, 2009, NAT REV CANCER, V9, P239, DOI 10.1038/nrc2618
   Kadera BE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071978
   Kim H, 2016, DIS MARKERS, V2016, P1, DOI 10.1155/2016/4218989
   Kim HM, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0587-9
   Kjaer-Frifeldt S, 2012, BRIT J CANCER, V107, P1169, DOI 10.1038/bjc.2012.365
   Korpal M, 2008, J BIOL CHEM, V283, P14910, DOI 10.1074/jbc.C800074200
   Kubo N, 2016, WORLD J GASTROENTERO, V22, P6841, DOI 10.3748/wjg.v22.i30.6841
   Kurashige J, 2015, CARCINOGENESIS, V36, P133, DOI 10.1093/carcin/bgu232
   Kwon JJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep11450
   Lee HO, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-245
   Lewis BP, 2005, CELL, V120, P15, DOI 10.1016/j.cell.2004.12.035
   Li X, 2017, EXP CELL RES, V351, P100, DOI 10.1016/j.yexcr.2017.01.001
   Liu JQ, 2012, P NATL ACAD SCI USA, V109, P16618, DOI 10.1073/pnas.1117610109
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   MacKenzie TA, 2014, AM J PATHOL, V184, P3217, DOI 10.1016/j.ajpath.2014.08.020
   Martinez-Outschoorn UE, 2011, CELL CYCLE, V10, P2504, DOI 10.4161/cc.10.15.16585
   Mertens JC, 2013, CANCER RES, V73, P897, DOI 10.1158/0008-5472.CAN-12-2130
   Mitra AK, 2012, CANCER DISCOV, V2, P1100, DOI 10.1158/2159-8290.CD-12-0206
   Mongiat M, 2010, NEOPLASIA, V12, P294, DOI 10.1593/neo.91930
   Nam YJ, 2013, P NATL ACAD SCI USA, V110, P5588, DOI 10.1073/pnas.1301019110
   Narra K, 2007, CANCER BIOL THER, V6, P1691, DOI 10.4161/cbt.6.11.4874
   Nemunaitis J, 2006, CANCER INVEST, V24, P553, DOI 10.1080/07357900600894732
   Nie Y, 2017, CANCER RES, V77, P3605, DOI 10.1158/0008-5472.CAN-16-2709
   Nielsen BS, 2011, CLIN EXP METASTAS, V28, P27, DOI 10.1007/s10585-010-9355-7
   Öhlund D, 2014, J EXP MED, V211, P1503, DOI 10.1084/jem.20140692
   Özdemir BC, 2014, CANCER CELL, V25, P719, DOI [10.1016/j.ccr.2014.04.005, 10.1016/j.ccell.2015.11.002]
   Olumi AF, 1999, CANCER RES, V59, P5002
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Pietras K, 2010, EXP CELL RES, V316, P1324, DOI 10.1016/j.yexcr.2010.02.045
   Qiu W, 2008, NAT GENET, V40, P650, DOI 10.1038/ng.117
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Ren Y, 2015, CANCER LETT, V362, P174, DOI 10.1016/j.canlet.2015.03.038
   Saferding V, 2017, J AUTOIMMUN, V82, P74, DOI 10.1016/j.jaut.2017.05.006
   Santos AM, 2009, J CLIN INVEST, V119, P3613, DOI 10.1172/JCI38988
   Scott AM, 2003, CLIN CANCER RES, V9, P1639
   Shah MY, 2016, EBIOMEDICINE, V12, P34, DOI 10.1016/j.ebiom.2016.09.017
   Shen H, 2016, PLOS GENET, V12, DOI 10.1371/journal.pgen.1006244
   Shi XB, 2013, ONCOGENE, V32, P4130, DOI 10.1038/onc.2012.425
   Soon P, 2013, ENDOCR-RELAT CANCER, V20, pR257, DOI 10.1530/ERC-13-0119
   Stenvold H, 2014, BMC CLIN PATHOL, V14, DOI 10.1186/1472-6890-14-9
   SZATROWSKI TP, 1991, CANCER RES, V51, P794
   Taddei ML, 2014, MOL ONCOL, V8, P1729, DOI 10.1016/j.molonc.2014.07.009
   Tanswell P, 2001, BRIT J CLIN PHARMACO, V51, P177
   Tran E, 2013, J EXP MED, V210, P1125, DOI 10.1084/jem.20130110
   Uchida R, 2010, IEEE ENG MED BIO, P827, DOI 10.1109/IEMBS.2010.5626775
   Uozaki H, 2014, HISTOPATHOLOGY, V65, P775, DOI 10.1111/his.12491
   van Kouwenhove M, 2011, NAT REV CANCER, V11, P644, DOI 10.1038/nrc3107
   Verghese ET, 2013, J PATHOL, V231, P388, DOI 10.1002/path.4248
   Volinia S, 2006, P NATL ACAD SCI USA, V103, P2257, DOI 10.1073/pnas.0510565103
   von Ahrens D, 2017, J HEMATOL ONCOL, V10, DOI 10.1186/s13045-017-0448-5
   Wang B, 2012, J AM SOC NEPHROL, V23, P252, DOI 10.1681/ASN.2011010055
   Wang H, 2008, CANCER CELL, V14, P369, DOI 10.1016/j.ccr.2008.10.006
   Wartenberg M, 2016, EUR J CANCER, V65, P80, DOI 10.1016/j.ejca.2016.06.013
   Wellner U, 2009, NAT CELL BIOL, V11, P1487, DOI 10.1038/ncb1998
   WELT S, 1994, J CLIN ONCOL, V12, P1193, DOI 10.1200/JCO.1994.12.6.1193
   Wen YA, 2010, CANCER SCI, V101, P2325, DOI 10.1111/j.1349-7006.2010.01695.x
   Xia Q, 2017, IMMUNOPHARM IMMUNOT, V39, P37, DOI 10.1080/08923973.2016.1269337
   Xiao X, 2015, ARCH BIOCHEM BIOPHYS, V566, P49, DOI 10.1016/j.abb.2014.12.007
   Yan Y, 2015, WORLD J GASTROENTERO, V21, P9717, DOI 10.3748/wjg.v21.i33.9717
   Yeung CLA, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11150
   Zhang DX, 2015, CELL REP, V10, P1335, DOI 10.1016/j.celrep.2015.02.006
   Zhang ZC, 2017, CANCER LETT, V397, P33, DOI 10.1016/j.canlet.2017.03.004
NR 94
TC 8
Z9 9
U1 1
U2 6
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1566-5240
EI 1875-5666
J9 CURR MOL MED
JI Curr. Mol. Med.
PY 2017
VL 17
IS 5
BP 341
EP 349
DI 10.2174/1566524018666171205113959
PG 9
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FS0HL
UT WOS:000419454600002
PM 29210650
DA 2025-01-04
ER

PT J
AU Streb, J
   Püsküllüoglu, M
   Glanowska, I
   Ochenduszko, S
   Konopka, K
   Lupkowski, R
   Michalowska-Kaczmarczyk, A
   Bochenek-Cibor, J
   Majka, M
   Krzemieniecki, K
AF Streb, Joanna
   Pueskuellueoglu, Miroslawa
   Glanowska, Izabela
   Ochenduszko, Sebastian
   Konopka, Kamil
   Lupkowski, Radoslaw
   Michalowska-Kaczmarczyk, Anna
   Bochenek-Cibor, Justyna
   Majka, Marcin
   Krzemieniecki, Krzysztof
TI Assessment of frequency and severity of hypomagnesemia in patients with
   metastatic colorectal cancer treated with cetuximab, with a review of
   the literature
SO ONCOLOGY LETTERS
LA English
DT Article
DE cetuximab; colorectal cancer; hypomagnesemia; epidermal growth factor
   receptor; metastases
ID GROWTH-FACTOR RECEPTOR; PLUS IRINOTECAN; OPEN-LABEL; MAGNESIUM;
   CHEMOTHERAPY; THERAPY; METAANALYSIS; EFFICACY; PHASE-3; TRIAL
AB Currently, there are a few systemic treatment options for patients with metastatic colorectal cancer (mCRC). Targeted therapy used in this setting includes the use of monoclonal antibodies, such as cetuximab or panitumumab, directed against epidermal growth factor receptor. The aim of the present study was to estimate the frequency and severity of hypomagnesemia among patients with mCRC treated with cetuximab. The data from the Department of Clinical Oncology, University Hospital of Krakow (Krakow, Poland), concerning 52 patients treated between 2009 and 2013 were collected. Of these, 27 patients fulfilled the inclusion criteria to enter this retrospective study. The National Cancer Institute Common Terminology Criteria for Adverse Events version 4.0 were used to grade the level of hypomagnesemia. In total, 29.6% of all patients experienced hypomagnesemia during treatment, and the majority of cases were grade 1 (22.2%). There was no statistically significant correlation between magnesium (Mg) level and patient age, duration of treatment, localization of primary tumor or metastases, and the number of metastases. However, there was an upward trend in a logistic regression model showing that the risk of developing hypomagnesemia increases with age. Hypomagnesemia is a frequent problem among mCRC patients receiving cetuximab. It is essential to introduce guidelines regarding the monitoring of the Mg level and its supplementation in this group of patients.
C1 [Streb, Joanna; Pueskuellueoglu, Miroslawa; Glanowska, Izabela; Ochenduszko, Sebastian; Konopka, Kamil; Lupkowski, Radoslaw; Michalowska-Kaczmarczyk, Anna; Krzemieniecki, Krzysztof] Jagiellonian Univ, Coll Med, Univ Hosp, Dept Clin Oncol, PL-31008 Krakow, Poland.
   [Bochenek-Cibor, Justyna] St Lukes Hosp, Dept Radiat Therapy, PL-33100 Tarnow, Poland.
   [Majka, Marcin] Jagiellonian Univ, Coll Med, Polish Amer Inst Pediat, Dept Transplantat, PL-31008 Krakow, Poland.
C3 Jagiellonian University; Collegium Medicum Jagiellonian University;
   Jagiellonian University; Collegium Medicum Jagiellonian University
RP Püsküllüoglu, M (corresponding author), Jagiellonian Univ, Coll Med, Univ Hosp, Dept Clin Oncol, 10 Sniadeckich St, PL-31008 Krakow, Poland.
EM miroslawa.puskulluoglu@uj.edu.pl
RI Majka, Marcin/AAU-1603-2021; Konopka, Kamil/AAD-7068-2021
OI Ochenduszko, Sebastian/0000-0002-0126-8418; Konopka,
   Kamil/0000-0003-2848-9832
CR Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Boyle P, 2000, BRIT MED J, V321, P805, DOI 10.1136/bmj.321.7264.805
   Cao YF, 2010, CHEMOTHERAPY, V56, P459, DOI 10.1159/000321011
   Chen P, 2013, ONCOL LETT, V5, P1915, DOI 10.3892/ol.2013.1301
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Demizu Mutsuko, 2013, Gan To Kagaku Ryoho, V40, P897
   Edge SRB S.B., 2010, Colon and rectum, V7th, P143
   Fakih M, 2010, CURR ONCOL, V17, pS18
   Fakih M, 2007, LANCET ONCOL, V8, P366, DOI 10.1016/S1470-2045(07)70111-0
   Fakih MG, 2006, CLIN COLORECTAL CANC, V6, P152, DOI 10.3816/CCC.2006.n.033
   Groenestege WMT, 2007, J CLIN INVEST, V117, P2260, DOI 10.1172/JCI31680
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5
   Maliakal P, 2010, EXP THER MED, V1, P307, DOI 10.3892/etm_00000047
   Martin KJ, 2009, J AM SOC NEPHROL, V20, P2291, DOI 10.1681/ASN.2007111194
   Melichar B, 2012, HEPATO-GASTROENTEROL, V59, P366, DOI 10.5754/hge10330
   National Cancer Institute Common, 2009, COMM TOX CRIT VERS 4
   Pacek A, 2014, ACTA DERMATOVENER CR, V22, P137
   Pazo-Oubina Do F, 2013, J CLIN PHARM THER, V38, p101 103, DOI [10.1111/jcpt.12028, DOI 10.1111/JCPT.12028]
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Saif Muhammad Wasif, 2008, J Support Oncol, V6, P243
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Schrag D, 2005, J NATL CANCER I, V97, P1221, DOI 10.1093/jnci/dji242
   Stintzing S, 2013, ANTI-CANCER DRUG, V24, P969, DOI 10.1097/CAD.0b013e32836411bc
   Tejpar S, 2007, LANCET ONCOL, V8, P387, DOI 10.1016/S1470-2045(07)70108-0
   Thomas SE, 1998, J AM SOC NEPHROL, V9, P231
   Vickers MM, 2013, ANN ONCOL, V24, P953, DOI 10.1093/annonc/mds577
   Vincenzi B, 2011, ANN ONCOL, V22, P1141, DOI 10.1093/annonc/mdq550
   Vincenzi B, 2008, CLIN CANCER RES, V14, P4219, DOI 10.1158/1078-0432.CCR-08-0077
   Weickhardt AJ, 2012, J CLIN ONCOL, V30, P1505, DOI 10.1200/JCO.2011.38.6599
   Wolf FI, 2009, CANCER TREAT REV, V35, P378, DOI 10.1016/j.ctrv.2009.01.003
   Yang XD, 2001, CRIT REV ONCOL HEMAT, V38, P17, DOI 10.1016/S1040-8428(00)00134-7
NR 32
TC 8
Z9 10
U1 0
U2 1
PU SPANDIDOS PUBL LTD
PI ATHENS
PA POB 18179, ATHENS, 116 10, GREECE
SN 1792-1074
EI 1792-1082
J9 ONCOL LETT
JI Oncol. Lett.
PD DEC
PY 2015
VL 10
IS 6
BP 3749
EP 3755
DI 10.3892/ol.2015.3800
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CZ6SZ
UT WOS:000367232600070
PM 26788202
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Heydarian, M
   Mohammadtaghizadeh, M
   Shojaei, M
   Babazadeh, M
   Abbasian, S
   Amrovani, M
AF Heydarian, Mohammad
   Mohammadtaghizadeh, Mohammadjavad
   Shojaei, Mahboobeh
   Babazadeh, Marziyeh
   Abbasian, Sadegh
   Amrovani, Mehran
TI The effect of COVID-19 derived cytokine storm on cancer cells
   progression: double-edged sword
SO MOLECULAR BIOLOGY REPORTS
LA English
DT Review
DE Cytokine storm; Chemotherapy resistance; Pathogenesis; COVID-19
ID EPITHELIAL-MESENCHYMAL TRANSITION; GROWTH-FACTOR-BETA;
   COLORECTAL-CANCER; ACTIVATION; EMT; CHEMORESISTANCE; PATHWAY;
   PHOSPHORYLATION; INFLAMMATION; METASTASIS
AB Objective Severe acute respiratory syndrome coronavirus 2 (SARS-COV2) was first detected in Wuhan, China in December, 2019. The emerging virus causes a respiratory illness, that can trigger a cytokine storm in the body. Method Cytokine storm in patient's body is associated with severe forms of disease. It is one of the main complications of coronavirus disease-2019 (COVID-19), in which immune cells play a major role. Studies have shown immune cells in the tumor environment can be effective to induce resistance to chemotherapy in cancer patients. Result Therefore, considering the role of immune cells to induce cytokine storm in COVID-19 patients, and their role to cause resistance to chemotherapy, they are effective on disease progression and creation of severe form of disease. Conclusion By examining the signaling pathways and inducing resistance to chemotherapy in tumor cells and the cells affect them, it is possible to prevent the occurrence of severe forms of the disease in cancer patients with COVID-19; it is applicable using target therapy and other subsequent treatment strategies.
C1 [Heydarian, Mohammad] Lorestan Univ Med Sci, Khorramabad, Iran.
   [Mohammadtaghizadeh, Mohammadjavad] Ahvaz Jundishapur Univ Med Sci, Atherosclerosis Res Ctr, Ahvaz, Iran.
   [Shojaei, Mahboobeh; Amrovani, Mehran] High Inst Educ & Res Transfus Med, Tehran, Iran.
   [Babazadeh, Marziyeh] Shiraz Univ Med Sci, Sch Med, Dept Biochem, Shiraz, Iran.
   [Abbasian, Sadegh] Ilam Univ Med Sci, Sch Paramed Sci, Dept Lab Sci, Ilam, Iran.
C3 Lorestan University of Medical Sciences; Ahvaz Jundishapur University of
   Medical Sciences (AJUMS); Shiraz University of Medical Science
RP Amrovani, M (corresponding author), High Inst Educ & Res Transfus Med, Tehran, Iran.
EM reza.heidarian.1382@gmail.com; dr.taghizadeh87@gmail.com;
   mahboobehshojaei22@yahoo.com; marziyehbabazadehbio@gmail.com;
   abbasian_sadegh@yahoo.com; e.amrovani@gmail.com
RI abbasian, sadegh/AAR-6318-2021
OI Abbasian, Sadegh/0000-0002-0929-3060
CR Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4
   Barlow CA, 2008, APOPTOSIS, V13, P681, DOI 10.1007/s10495-008-0203-z
   Black M, 2016, ONCOTARGET, V7, P10557, DOI 10.18632/oncotarget.7235
   Bozzini S, 2021, J HEART LUNG TRANSPL, V40, pS151
   Bromberg J, 2009, CANCER CELL, V15, P79, DOI 10.1016/j.ccr.2009.01.009
   Cai JC, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15870
   Cao H, 2016, ONCOTARGET, V7, P61183, DOI 10.18632/oncotarget.11282
   Carfi A, 2020, JAMA-J AM MED ASSOC, V324, P603, DOI 10.1001/jama.2020.12603
   Carter BZ, 2019, CANCER RES, V79, P1165, DOI 10.1158/0008-5472.CAN-18-0921
   Chaidos A, 2020, BRIT J HAEMATOL, V190, pE9, DOI 10.1111/bjh.16787
   Chen JH, 2017, ONCOTARGET, V8, P9961, DOI 10.18632/oncotarget.14283
   Chen WL, 2018, CLIN TRANSL MED, V7, DOI 10.1186/s40169-018-0205-6
   Choi J, 2020, J CANCER PREV, V25, P152, DOI 10.15430/JCP.2020.25.3.152
   Choudhary KS, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1004924
   Coomes EA, 2020, REV MED VIROL, V30, DOI 10.1002/rmv.2141
   Daminov B, 2021, J RENAL INJ PREV, V10, DOI 10.34172/jrip.2021.17
   Darakhshandeh A, 2021, IMMUNOPATHOL PERSA, V7, DOI 10.34172/ipp.2021.20
   Dong C, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.628690
   Edwardson DW, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0183662
   Grände M, 2002, J CELL SCI, V115, P4227, DOI 10.1242/jcs.00091
   Gu FM, 2011, MOL CANCER, V10, DOI 10.1186/1476-4598-10-150
   Gu K, 2015, AM J CANCER RES, V5, P1169
   Guo C, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17834-w
   Guo X, 2017, ONCOTARGET, V8, P80358, DOI 10.18632/oncotarget.18673
   Hajsadeghi S, 2021, ECHOCARDIOGR-J CARD, V38, P1074, DOI 10.1111/echo.15061
   Hajsadeghi S, 2020, ECHOCARDIOGR-J CARD, V37, P469, DOI 10.1111/echo.14609
   Hajsadeghi S, 2020, ECHOCARDIOGR-J CARD, V37, P124, DOI 10.1111/echo.14565
   Hasanpour Dehkordi A, 2020, J NEPHROPATHOL, V9
   Henderson LA, 2020, ARTHRITIS RHEUMATOL, V72, P1059, DOI 10.1002/art.41285
   Hsu YL, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082427
   Huang HY, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0543-5
   Ireland LV, 2018, FRONT CELL DEV BIOL, V6, DOI 10.3389/fcell.2018.00131
   Itatani Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235822
   Jahromi AH, 2020, IMMUNOPATHOL PERSA, V6, DOI 10.34172/ipp.2020.17
   Janatmakan Farahzad, 2019, Anesth Pain Med, V9, pe83967, DOI 10.5812/aapm.83967
   Jiang JW, 2017, SIGNAL TRANSDUCT TAR, V2, DOI 10.1038/sigtrans.2017.36
   Jiménez-Gardnno AM, 2017, BIOCHEM BIOPH RES CO, V490, P780, DOI 10.1016/j.bbrc.2017.06.117
   Jin W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010217
   Kan JY, 2015, J CELL PHYSIOL, V230, P1883, DOI 10.1002/jcp.24918
   Kang R, 2013, CLIN CANCER RES, V19, P4046, DOI 10.1158/1078-0432.CCR-13-0495
   Kazanietz MG, 2019, FRONT ENDOCRINOL, V10, DOI 10.3389/fendo.2019.00471
   Khademi M, 2021, J COSMET DERMATOL-US, V20, P1411, DOI 10.1111/jocd.13990
   Kim J, 2016, ONCOTARGET, V7, P85021, DOI 10.18632/oncotarget.13116
   Kobayashi S, 2013, ARTHRITIS RHEUM-US, V65, P3063, DOI 10.1002/art.38173
   Lainetti PD, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12121193
   Li JS, 2017, BIOSCIENCE REP, V37, DOI 10.1042/BSR20170042
   Li YL, 2017, ONCOL LETT, V13, P1856, DOI 10.3892/ol.2017.5612
   Lin X, 2018, J CANCER, V9, P4430, DOI 10.7150/jca.24361
   Lv DJ, 2019, THERANOSTICS, V9, P5166, DOI 10.7150/thno.33972
   Ma J, 2019, CANCER RES TREAT, V51, P194, DOI 10.4143/crt.2018.031
   Ma ZH, 2017, ONCOTARGETS THER, V10, P4711, DOI 10.2147/OTT.S136915
   McCubrey JA, 2007, ADV ENZYME REGUL, V47, P64, DOI 10.1016/j.advenzreg.2006.12.013
   Meftahi GH, 2020, INFLAMM RES, V69, P825, DOI 10.1007/s00011-020-01372-8
   Mehta P, 2020, LANCET, V395, P1033, DOI 10.1016/S0140-6736(20)30628-0
   Murillo MM, 2007, BIOCHEM J, V405, P251, DOI 10.1042/BJ20061846
   Nakamura R, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8847
   Nantajit Danupon, 2015, J Cancer Res Clin Oncol, V141, P1697, DOI 10.1007/s00432-014-1840-y
   Nokhostin F., 2020, J ADV MED BIOMED RES, V28, P171, DOI [10.30699/jambs.28.128.171, DOI 10.30699/JAMBS.28.128.171]
   Pasquier J, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0787-z
   Peng H, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-1038
   Pouladzadeh M, 2021, FUTUR SCI OA, V7, DOI 10.2144/fsoa-2020-0199
   Pouladzadeh M, 2021, INTERN EMERG MED, V16, P2181, DOI 10.1007/s11739-021-02734-8
   Preca BT, 2017, ONCOTARGET, V8, P11530, DOI 10.18632/oncotarget.14563
   Ragab D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01446
   Rajaei E, 2019, CLIN RHEUMATOL, V38, P3211, DOI 10.1007/s10067-019-04682-3
   Reinhardt J, 2017, CANCER RES, V77, P4697, DOI 10.1158/0008-5472.CAN-17-0395
   Roohaninasab M, 2021, LASER MED SCI, V36, P1781, DOI 10.1007/s10103-020-03241-6
   Rowaiye AB, 2021, J INFLAMM RES, V14, P1487, DOI 10.2147/JIR.S301784
   de Porras VR, 2016, SCI REP-UK, V6, DOI 10.1038/srep24675
   Sadeghzadeh-Bazargan A, 2021, DERMATOL THER, V34, DOI 10.1111/dth.14438
   Salazar Y, 2020, J CLIN INVEST, V130, P3560, DOI 10.1172/JCI124037
   Sancisi V, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075489
   Seddigh-Shamsi M, 2021, IMMUNOPATHOL PERSA, V7, DOI 10.34172/ipp.2021.19
   Shen M, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00470
   Shien K, 2017, MOL CANCER THER, V16, P2234, DOI 10.1158/1535-7163.MCT-17-0148
   Singh S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050642
   Sinha P, 2020, JAMA INTERN MED, V180, P1152, DOI 10.1001/jamainternmed.2020.3313
   Trempolec N, 2020, CANCERS, V12, DOI 10.3390/cancers12051284
   van der Velden JLJ, 2011, AM J RESP CELL MOL, V44, P571, DOI 10.1165/rcmb.2009-0282OC
   Voloshin T, 2015, MOL CANCER THER, V14, P1385, DOI 10.1158/1535-7163.MCT-14-0969
   Wang J, 2019, J MOL CELL CARDIOL, V127, P105, DOI 10.1016/j.yjmcc.2018.12.005
   Wang M, 2017, ONCOTARGETS THER, V10, P3215, DOI 10.2147/OTT.S133055
   Wang N., 2018, CELL DEATH DIS, V9, P1
   Wang X, 2008, ACTA PHARMACOL SIN, V29, P1275, DOI 10.1111/j.1745-7254.2008.00889.x
   Wei C, 2019, ONCOTARGETS THER, V12, P3051, DOI 10.2147/OTT.S198126
   Weyemi U, 2016, CELL CYCLE, V15, P2398, DOI 10.1080/15384101.2016.1198864
   Wohlleber D, 2012, CELL REP, V2, P478, DOI 10.1016/j.celrep.2012.08.001
   Wu LY, 2020, ADV EXP MED BIOL, V1224, P1, DOI 10.1007/978-3-030-35723-8_1
   Xia Y, 2020, LANCET ONCOL, V21, pE180, DOI 10.1016/S1470-2045(20)30150-9
   Xiao W, 2019, CANCERS, V11, DOI 10.3390/cancers11081184
   Yang CC, 2019, INT J ONCOL, V55, P684, DOI 10.3892/ijo.2019.4840
   Zadeh FJ, 2020, MOL BIOL REP, V47, P5503, DOI 10.1007/s11033-020-05602-4
   Zhang DX, 2018, CANCER RES, V78, P1700, DOI 10.1158/0008-5472.CAN-17-1366
   Zhang K, 2014, ONCOTARGET, V5, P12916, DOI 10.18632/oncotarget.2682
   Zhang Yuheng, 2021, Am J Cancer Res, V11, P479
   Zhang ZG, 2019, INFLAMMOPHARMACOLOGY, V27, P627, DOI 10.1007/s10787-018-0534-5
   Zhao JZ, 2017, MICROB CELL FACT, V16, DOI 10.1186/s12934-017-0641-9
   Zhao YY, 2018, MOL ONCOL, V12, P305, DOI 10.1002/1878-0261.12162
   Zheng XR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1433-3
   Zhou CH, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2210
   Zhou L, 2020, J BONE ONCOL, V23, DOI 10.1016/j.jbo.2020.100299
   Zuo Y, 2021, J THROMB THROMBOLYS, V51, P446, DOI [10.1101/2020.04.30.20086736, 10.1101/2020.04.09.20059626, 10.1007/s11239-020-02324-z]
NR 102
TC 5
Z9 5
U1 0
U2 9
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0301-4851
EI 1573-4978
J9 MOL BIOL REP
JI Mol. Biol. Rep.
PD JAN
PY 2022
VL 49
IS 1
BP 605
EP 615
DI 10.1007/s11033-021-06800-4
EA OCT 2021
PG 11
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA YE3VB
UT WOS:000707690500002
PM 34657251
OA Green Published
DA 2025-01-04
ER

PT J
AU Mitani, Y
   Ohashi, S
   Kikuchi, O
   Nakai, Y
   Ida, T
   Mizumoto, A
   Yamamoto, Y
   Saito, T
   Kataoka, S
   Matsubara, J
   Yamada, A
   Kanai, M
   Matsumoto, S
   Sakai, H
   Yoshikawa, K
   Nakamura, E
   Muto, M
AF Mitani, Yosuke
   Ohashi, Shinya
   Kikuchi, Osamu
   Nakai, Yukie
   Ida, Tomomi
   Mizumoto, Ayaka
   Yamamoto, Yoshihiro
   Saito, Tomoki
   Kataoka, Shigeki
   Matsubara, Junichi
   Yamada, Atsushi
   Kanai, Masashi
   Matsumoto, Shigemi
   Sakai, Hiroaki
   Yoshikawa, Kiyotsugu
   Nakamura, Eijiro
   Muto, Manabu
TI <i>HER2</i> G776S mutation promotes oncogenic potential in colorectal
   cancer cells when accompanied by loss of APC function
SO SCIENTIFIC REPORTS
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; BA/F3 CELLS; CATENIN; INHIBITION; ACTIVATION;
   LANDSCAPE; AFATINIB; GENOME; DOMAIN; ERK
AB Clinical cancer genome sequencing detects oncogenic variants that are potential targets for cancer treatment, but it also detects variants of unknown significance. These variants may interact with each other to influence tumor pathophysiology, however, such interactions have not been fully elucidated. Additionally, the effect of target therapy for those variants also unclarified. In this study, we investigated the biological functions of a HER2 mutation (G776S mutation) of unknown pathological significance, which was detected together with APC mutation by cancer genome sequencing of samples from a colorectal cancer (CRC) patient. Transfection of the HER2 G776S mutation alone slightly increased the kinase activity and phosphorylation of HER2 protein, but did not activate HER2 downstream signaling or alter the cell phenotype. On the other hand, the HER2 G776S mutation was shown to have strong oncogenic potential when loss of APC function was accompanied. We revealed that loss of APC function increased Wnt pathway activity but also increased RAS-GTP, which increased ERK phosphorylation triggered by HER2 G776S transfection. In addition, afatinib, a pan-HER tyrosine kinase inhibitor, suppressed tumor growth in xenografts derived from HER2 G776S-transfected CRC cells. These findings suggest that this HER2 mutation in CRC may be a potential therapeutic target.
C1 [Mitani, Yosuke; Ohashi, Shinya; Kikuchi, Osamu; Nakai, Yukie; Ida, Tomomi; Mizumoto, Ayaka; Yamamoto, Yoshihiro; Saito, Tomoki; Kataoka, Shigeki; Matsubara, Junichi; Yamada, Atsushi; Kanai, Masashi; Matsumoto, Shigemi; Muto, Manabu] Kyoto Univ, Dept Therapeut Oncol, Grad Sch Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Sakai, Hiroaki] Kyoto Univ, Med Innovat Ctr, DSK Project, Grad Sch Med,Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
   [Yoshikawa, Kiyotsugu] Doshisha Womens Coll Liberal Arts, Dept Clin Pharm, Fac Pharmaceut Sci, 97-1 Minami Hodate Kodo,W604610-0395, Kyoto, Japan.
   [Nakamura, Eijiro] Natl Canc Ctr, Dept Urol, Chuo Ku, 5-1-1 Tsukiji, Tokyo 1040045, Japan.
C3 Kyoto University; Kyoto University; National Cancer Center - Japan
RP Muto, M (corresponding author), Kyoto Univ, Dept Therapeut Oncol, Grad Sch Med, Sakyo Ku, 54 Shogoin Kawahara Cho, Kyoto 6068507, Japan.
EM mmuto@kuhp.kyoto-u.ac.jp
RI Kataoka, Shigeki/HPE-1057-2023; Ohashi, Shinya/AAD-8920-2022
OI Yoshikawa, KIyotsugu/0009-0001-2186-4313; Mitani,
   Yosuke/0000-0003-1603-0004
FU Japan Society for the Promotion of Science KAKENHI [18H02692];
   Grants-in-Aid for Scientific Research [18H02692] Funding Source: KAKEN
FX This work was financially supported by Japan Society for the Promotion
   of Science KAKENHI (18H02692). The authors are grateful for technical
   assistance from the Center for Anatomical, Pathological and Forensic
   Medical Researches and the Medical Research Support Center, Kyoto
   University Graduate School of Medicine.
CR Alvarez A, 2014, JOVE-J VIS EXP, DOI 10.3791/51742
   Bang YJ, 2010, LANCET, V376, P687, DOI 10.1016/S0140-6736(10)61121-X
   Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
   Biesecker LG, 2014, NEW ENGL J MED, V371, P1170, DOI [10.1056/NEJMra1312543, 10.1056/NEJMc1408914]
   Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349
   Connell CM, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000279
   Eguchi M, 2005, MED CHEM, V1, P467, DOI 10.2174/1573406054864098
   Hyman DM, 2018, NATURE, V554, P189, DOI 10.1038/nature25475
   Hynes NE, 2005, NAT REV CANCER, V5, P341, DOI 10.1038/nrc1609
   Jeong WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0049-y
   Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242
   Jiang JR, 2005, CANCER RES, V65, P8968, DOI 10.1158/0008-5472.CAN-05-1829
   Johannessen CM, 2010, NATURE, V468, P968, DOI 10.1038/nature09627
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Kou T, 2017, CANCER SCI, V108, P1440, DOI 10.1111/cas.13265
   Lee JW, 2006, CLIN CANCER RES, V12, P57, DOI 10.1158/1078-0432.CCR-05-0976
   Liu G, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-13650-3
   Loree JM, 2018, JNCI-J NATL CANCER I, V110, P1409, DOI 10.1093/jnci/djy067
   Mar N, 2015, LUNG CANCER, V87, P220, DOI 10.1016/j.lungcan.2014.12.018
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Morin PJ, 1997, SCIENCE, V275, P1787, DOI 10.1126/science.275.5307.1787
   Ohashi S, 2020, MOL CANCER THER, V19, P1363, DOI 10.1158/1535-7163.MCT-19-0918
   Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779
   Patel SA, 2021, BRIT J CANCER, V124, P3, DOI 10.1038/s41416-020-01127-6
   Perera SA, 2009, P NATL ACAD SCI USA, V106, P474, DOI 10.1073/pnas.0808930106
   Ross JS, 2018, CANCER-AM CANCER SOC, V124, P1358, DOI 10.1002/cncr.31125
   Sanjana NE, 2014, NAT METHODS, V11, P783, DOI 10.1038/nmeth.3047
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Shimamura T, 2006, CANCER RES, V66, P6487, DOI 10.1158/0008-5472.CAN-06-0971
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Tsimberidou AM, 2014, CLIN CANCER RES, V20, P4827, DOI 10.1158/1078-0432.CCR-14-0603
   Warmuth M, 2007, CURR OPIN ONCOL, V19, P55, DOI 10.1097/CCO.0b013e328011a25f
   Wheler JJ, 2016, CANCER RES, V76, P3690, DOI 10.1158/0008-5472.CAN-15-3043
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Yamamoto H, 2018, ONCOLOGIST, V23, P150, DOI 10.1634/theoncologist.2017-0345
   Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8
   Yun MS, 2005, J CELL SCI, V118, P313, DOI 10.1242/jcs.01601
   Zabransky DJ, 2015, P NATL ACAD SCI USA, V112, pE6205, DOI 10.1073/pnas.1516853112
NR 39
TC 3
Z9 3
U1 0
U2 3
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD JUN 2
PY 2022
VL 12
IS 1
AR 9213
DI 10.1038/s41598-022-13189-y
PG 15
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 1U7AQ
UT WOS:000805561200043
PM 35654814
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Kim, HS
   Sung, YJ
   Paik, S
AF Kim, Hyun Seok
   Sung, Yeo-Jin
   Paik, Soonmyung
TI Cancer Cell Line Panels Empower Genomics-Based Discovery of Precision
   Cancer Medicine
SO YONSEI MEDICAL JOURNAL
LA English
DT Review
DE Targeted therapy; cancer genomics; biomarker; personalized medicine
ID SYNTHETIC LETHAL INTERACTION; DRUG-SENSITIVITY PREDICTION; COLON-CANCER;
   SYSTEMATIC IDENTIFICATION; ACQUIRED-RESISTANCE; SHRNA LIBRARIES; GENETIC
   SCREENS; MEK INHIBITION; TUMOR-MODELS; COPY NUMBER
AB Since the first human cancer cell line, HeLa, was established in the early 1950s, there has been a steady increase in the number and tumor type of available cancer cell line models. Cancer cell lines have made significant contributions to the development of various chemotherapeutic agents. Recent advances in multi-omics technologies have facilitated detailed characterizations of the genomic, transcriptomic, proteomic, and epigenomic profiles of these cancer cell lines. An increasing number of studies employ the power of a cancer cell line panel to provide predictive biomarkers for targeted and cytotoxic agents, including those that are already used in clinical practice. Different types of statistical and machine learning algorithms have been developed to analyze the large-scale data sets that have been produced. However, much work remains to address the discrepancies in drug assay results from different platfoints and the frequent failures to translate discoveries from canine models to the clinic. Nevertheless, continuous expansion of cancer cell line panels should provide unprecedented opportunities to identify new candidate targeted therapies, particularly for the so-called "dark matter" group of cancers, for which pharmacologically tractable driver mutations have not been identified.
C1 [Kim, Hyun Seok; Sung, Yeo-Jin] Yonsei Univ, Coll Med, Brain Korea PLUS Project Med Sci 21, Seoul 120752, South Korea.
   [Kim, Hyun Seok; Paik, Soonmyung] Yonsei Univ, Coll Med, Severance Biomed Sci Inst, Seoul 120752, South Korea.
C3 Yonsei University; Yonsei University Health System; Yonsei University;
   Yonsei University Health System
RP Paik, S (corresponding author), Yonsei Univ, Coll Med, Severance Biomed Sci Inst, 50-1 Yonsei Ro, Seoul 120752, South Korea.
EM soonmyungpaik@yuhs.ac
RI Kim, Kyu/F-6596-2010
OI Paik, Soonmyung/0000-0001-9688-6480; Kim, Hyun Seok/0000-0003-4498-8690
FU National R&D Program for Cancer Control, Ministry of Health & Welfare,
   Republic of Korea [1420100]
FX This study was supported by a grant from the National R&D Program for
   Cancer Control, Ministry of Health & Welfare, Republic of Korea
   (1420100).
CR Abaan OD, 2013, CANCER RES, V73, P4372, DOI 10.1158/0008-5472.CAN-12-3342
   Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Arumugam T, 2009, CANCER RES, V69, P5820, DOI 10.1158/0008-5472.CAN-08-2819
   Ashraf SQ, 2012, P NATL ACAD SCI USA, V109, P21046, DOI 10.1073/pnas.1218750110
   Barbie DA, 2009, NATURE, V462, P108, DOI 10.1038/nature08460
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003
   Beaufort CM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103988
   Behren A, 2013, PIGM CELL MELANOMA R, V26, DOI 10.1111/pcmr.12097
   Blanco R, 2009, HUM MUTAT, V30, P1199, DOI 10.1002/humu.21028
   Boj SF, 2015, CELL, V160, P324, DOI 10.1016/j.cell.2014.12.021
   Burdall SE, 2003, BREAST CANCER RES, V5, P89, DOI 10.1186/bcr577
   Bussey KJ, 2006, MOL CANCER THER, V5, P853, DOI 10.1158/1535-7163.MCT-05-0155
   Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558
   Chen RQ, 2014, IMMUNITY, V41, P325, DOI 10.1016/j.immuni.2014.08.002
   Cheung HW, 2011, P NATL ACAD SCI USA, V108, P12372, DOI 10.1073/pnas.1109363108
   Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007
   Costello JC, 2014, NAT BIOTECHNOL, V32, P1202, DOI 10.1038/nbt.2877
   Cross DAE, 2014, CANCER DISCOV, V4, P1046, DOI 10.1158/2159-8290.CD-14-0337
   Crystal AS, 2014, SCIENCE, V346, P1480, DOI 10.1126/science.1254721
   Dan S, 2010, CANCER RES, V70, P4982, DOI 10.1158/0008-5472.CAN-09-4172
   Dangles-Marie V, 2007, CANCER RES, V67, P398, DOI 10.1158/0008-5472.CAN-06-0594
   Dawson JC, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00118
   de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741
   Demuth T, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-54
   Domcke S, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3126
   Epstein RJ, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00304
   Forbes SA, 2011, NUCLEIC ACIDS RES, V39, pD945, DOI 10.1093/nar/gkq929
   Gao JJ, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004088
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Garraway LA, 2013, CELL, V153, P17, DOI 10.1016/j.cell.2013.03.002
   Gazdar AF, 2010, JNCI-J NATL CANCER I, V102, P1310, DOI 10.1093/jnci/djq279
   Gazdar AF, 2010, LUNG CANCER, V68, P309, DOI 10.1016/j.lungcan.2009.12.005
   Gazdar AF, 1998, INT J CANCER, V78, P766, DOI 10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L
   Gazdar AF, 1996, J CELL BIOCHEM, P1
   Gholami AM, 2013, CELL REP, V4, P609, DOI 10.1016/j.celrep.2013.07.018
   Gillet JP, 2011, P NATL ACAD SCI USA, V108, P18708, DOI 10.1073/pnas.1111840108
   Greshock J, 2010, CANCER RES, V70, P3677, DOI 10.1158/0008-5472.CAN-09-3788
   Haibe-Kains B, 2013, NATURE, V504, P389, DOI 10.1038/nature12831
   Hanahan D, 2000, CELL, V100, P57, DOI 10.1016/S0092-8674(00)81683-9
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hollestelle A, 2010, BREAST CANCER RES TR, V121, P53, DOI 10.1007/s10549-009-0460-8
   Hsu PD, 2014, CELL, V157, P1262, DOI 10.1016/j.cell.2014.05.010
   Jia PL, 2013, GENOME RES, V23, P1434, DOI 10.1101/gr.152322.112
   Jones S, 2008, SCIENCE, V321, P1801, DOI 10.1126/science.1164368
   Kao J, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006146
   Kessler JD, 2012, SCIENCE, V335, P348, DOI 10.1126/science.1212728
   Kim HS, 2013, CELL, V155, P552, DOI 10.1016/j.cell.2013.09.041
   Kong DX, 2012, BIOORGAN MED CHEM, V20, P1947, DOI 10.1016/j.bmc.2012.01.017
   Kranz D, 2014, EMBO J, V33, P181, DOI 10.1002/embj.201385686
   Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033
   Liu JF, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms4830
   Liu JF, 2012, GENOME RES, V22, P2315, DOI 10.1101/gr.140988.112
   Liu XF, 2012, AM J PATHOL, V180, P599, DOI 10.1016/j.ajpath.2011.10.036
   Liu Y, 2006, P NATL ACAD SCI USA, V103, P976, DOI 10.1073/pnas.0510146103
   Luo B, 2008, P NATL ACAD SCI USA, V105, P20380, DOI 10.1073/pnas.0810485105
   Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006
   Luo J, 2009, CELL, V136, P823, DOI 10.1016/j.cell.2009.02.024
   Marcotte R, 2012, CANCER DISCOV, V2, P172, DOI 10.1158/2159-8290.CD-11-0224
   Martens-de Kemp SR, 2013, CLIN CANCER RES, V19, P1994, DOI 10.1158/1078-0432.CCR-12-2539
   Masters JR, 2002, NAT REV CANCER, V2, P315, DOI 10.1038/nrc775
   McDermott U, 2007, P NATL ACAD SCI USA, V104, P19936, DOI 10.1073/pnas.0707498104
   Mendes-Pereira AM, 2012, P NATL ACAD SCI USA, V109, P2730, DOI 10.1073/pnas.1018872108
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Neve RM, 2006, CANCER CELL, V10, P515, DOI 10.1016/j.ccr.2006.10.008
   Oie HK, 1996, J CELL BIOCHEM, P24
   Paik S, 2004, NEW ENGL J MED, V351, P2817, DOI 10.1056/NEJMoa041588
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   PAULL KD, 1989, JNCI-J NATL CANCER I, V81, P1088, DOI 10.1093/jnci/81.14.1088
   Petrocca F, 2013, CANCER CELL, V24, P182, DOI 10.1016/j.ccr.2013.07.008
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   RHEINWALD JG, 1975, CELL, V6, P331, DOI 10.1016/S0092-8674(75)80001-8
   Ross DT, 2000, NAT GENET, V24, P227, DOI 10.1038/73432
   Sadanandam A, 2013, NAT MED, V19, P619, DOI 10.1038/nm.3175
   Sánchez-Rivera FJ, 2014, NATURE, V516, P428, DOI 10.1038/nature13906
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Schlabach MR, 2008, SCIENCE, V319, P620, DOI 10.1126/science.1149200
   Scholl C, 2009, CELL, V137, P821, DOI 10.1016/j.cell.2009.03.017
   Schreiber SL, 2010, NAT BIOTECHNOL, V28, P904, DOI 10.1038/nbt0910-904
   Shalem O, 2014, SCIENCE, V343, P84, DOI 10.1126/science.1247005
   Sharma SV, 2010, NAT REV CANCER, V10, P241, DOI 10.1038/nrc2820
   Shen LL, 2007, CANCER RES, V67, P11335, DOI 10.1158/0008-5472.CAN-07-1502
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Silva JM, 2005, NAT GENET, V37, P1281, DOI 10.1038/ng1650
   Silva JM, 2008, SCIENCE, V319, P617, DOI 10.1126/science.1149185
   Sims D, 2011, GENOME BIOL, V12, DOI 10.1186/gb-2011-12-10-r104
   Singh Nitin Kumar, 2013, Genomics & Informatics, V11, P55, DOI 10.5808/GI.2013.11.1.55
   Sobel RE, 2005, J UROLOGY, V173, P342, DOI 10.1097/01.ju.0000141580.30910.57
   Sobel RE, 2005, J UROLOGY, V173, P360, DOI 10.1097/01.ju.0000149989.01263.dc
   Sos ML, 2009, J CLIN INVEST, V119, P1727, DOI 10.1172/JCI37127
   Suggitt M, 2005, CLIN CANCER RES, V11, P971
   Toyoshima M, 2012, P NATL ACAD SCI USA, V109, P9545, DOI 10.1073/pnas.1121119109
   Turner NC, 2008, EMBO J, V27, P1368, DOI 10.1038/emboj.2008.61
   Wang T, 2014, SCIENCE, V343, P80, DOI 10.1126/science.1246981
   Whitehurst AW, 2007, NATURE, V446, P815, DOI 10.1038/nature05697
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Zaman N, 2013, CELL REP, V5, P216, DOI 10.1016/j.celrep.2013.08.028
   Zhang JH, 1999, J BIOMOL SCREEN, V4, P67, DOI 10.1177/108705719900400206
   Zheng C, 2011, ACTA PHARMACOL SIN, V32, P385, DOI 10.1038/aps.2010.214
   Zou H, 2005, J R STAT SOC B, V67, P301, DOI 10.1111/j.1467-9868.2005.00503.x
NR 100
TC 11
Z9 13
U1 0
U2 18
PU YONSEI UNIV COLL MEDICINE
PI SEOUL
PA 50-1 YONSEI-RO, SEODAEMUN-GU, SEOUL 120-752, SOUTH KOREA
SN 0513-5796
EI 1976-2437
J9 YONSEI MED J
JI Yonsei Med. J.
PD SEP 1
PY 2015
VL 56
IS 5
BP 1186
EP 1198
DI 10.3349/ymj.2015.56.5.1186
PG 13
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA CP4XP
UT WOS:000359886200004
PM 26256959
OA gold, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU Fejzo, MS
   Anderson, L
   Chen, HW
   Anghel, A
   Zhuo, JY
   Anchoori, R
   Roden, R
   Slamon, DJ
AF Fejzo, Marlena S.
   Anderson, Lee
   Chen, Hsiao-Wang
   Anghel, Adrian
   Zhuo, Jiaying
   Anchoori, Ravi
   Roden, Richard
   Slamon, Dennis J.
TI ADRM1-amplified metastasis gene in gastric cancer
SO GENES CHROMOSOMES & CANCER
LA English
DT Article
ID DEUBIQUITINATING ENZYME; PROTEASOME SUBUNIT; COPY NUMBER; PROTEIN;
   ADRM1; IDENTIFICATION; AMPLIFICATION; EXPRESSION; PROMOTES; DATABASE
AB The proteasome ubiquitin receptor ADRM1 has been shown to be a driver for 20q13.3 amplification in epithelial cancers including ovarian and colon cancer. We performed array-CGH on 16 gastric cancer cell lines and found 20q13.3 to be amplified in 19% with the minimal amplified region in gastric cancer cell line AGS spanning a 1 Mb region including ADRM1. Expression microarray analysis shows overexpression of only two genes in the minimal region, ADRM1 and OSBPL2. While RNAi knockdown of both ADRM1 and OSBPL2 led to a slight reduction in growth, only ADRM1 RNAi knockdown led to a significant reduction in migration and growth in soft-agar. Treatment of AGS cells with the ADRM1 inhibitor RA190 resulted in proteasome inhibition, but RNAi knockdown of ADRM1 did not. However, RNAi knockdown of ADRM1 led to a significant reduction in specific proteins including MNAT1, HRS, and EGFR. We hypothesize that ADRM1 may act in ADRM1-amplified gastric cancer to alter protein levels of specific oncogenes resulting in an increase in metastatic potential. Selective inhibition of ADRM1 independent of proteasome inhibition may result in a targeted therapy for ADRM1-amplified gastric cancer. In vivo models are now warranted to validate these findings. (c) 2015 Wiley Periodicals, Inc.
C1 [Fejzo, Marlena S.; Anderson, Lee; Chen, Hsiao-Wang; Anghel, Adrian; Zhuo, Jiaying; Slamon, Dennis J.] Univ Calif Los Angeles, Div Hematol Oncol, Dept Med, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA.
   [Anchoori, Ravi; Roden, Richard] Johns Hopkins Univ, Dept Oncol, Baltimore, MD 21231 USA.
   [Roden, Richard] Johns Hopkins Univ, Dept Pathol, Baltimore, MD 21231 USA.
   [Roden, Richard] Johns Hopkins Univ, Dept Gynecol & Obstet, Baltimore, MD 21231 USA.
C3 UCLA Jonsson Comprehensive Cancer Center; University of California
   System; University of California Los Angeles; Johns Hopkins University;
   Johns Hopkins University; Johns Hopkins University
RP Fejzo, MS (corresponding author), 675 Charles Young Dr S, Los Angeles, CA 90095 USA.
EM mfejzo@mednet.ucla.edu
RI Anghel, Adrian/M-6512-2019; Anghel, Adrian/C-1932-2013
OI Anghel, Adrian/0000-0002-4526-5913; Fejzo, Marlena/0000-0001-6800-687X
FU Adelson Medical Research Foundation (AMRF); Revlon/UCLA Women's Cancer
   Research Program; Allegheny Health Network-Johns Hopkins Research Fund
FX Supported by: Adelson Medical Research Foundation (AMRF) and Revlon/UCLA
   Women's Cancer Research Program (recipient Dennis Slamon); Allegheny
   Health Network-Johns Hopkins Research Fund (recipients Ravi Anchoori and
   Richard Roden).
CR Anchoori RK, 2013, CANCER CELL, V24, P791, DOI 10.1016/j.ccr.2013.11.001
   Barrett T, 2005, NUCLEIC ACIDS RES, V33, pD562
   Brenner Hermann, 2009, V472, P467, DOI 10.1007/978-1-60327-492-0_23
   Buffart TE, 2009, VIRCHOWS ARCH, V455, P213, DOI 10.1007/s00428-009-0814-y
   Chanut-Delalande H, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010245
   Chen Jie, 2009, Zhonghua Zhongliu Zazhi, V31, P15, DOI 10.3760/cma.j.issn.0253-3766.2009.01.004
   Chen W, 2009, ONCOL REP, V21, P531, DOI 10.3892/or_00000254
   Cheng L, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-14
   Cherix N, 2006, MOL BIOL CELL, V17, P4982, DOI 10.1091/mbc.E06-07-0619
   Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960
   Fejzo MS, 2008, GENE CHROMOSOME CANC, V47, P873, DOI 10.1002/gcc.20592
   Fejzo MS, 2013, INT J MOL SCI, V14, P3094, DOI 10.3390/ijms14023094
   Gyorffy B, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0082241
   Hamazaki J, 2006, EMBO J, V25, P4524, DOI 10.1038/sj.emboj.7601338
   Jang SH, 2014, CLIN EXP METASTAS, V31, P727, DOI 10.1007/s10585-014-9663-4
   Lamerant N, 2005, FEBS J, V272, P1833, DOI 10.1111/j.1742-4658.2005.04613.x
   Lou SY, 2013, STEM CELLS, V31, P1942, DOI 10.1002/stem.1444
   Pilarsky C, 2004, NEOPLASIA, V6, P744, DOI 10.1593/neo.04277
   Qiu XB, 2006, EMBO J, V25, P5742, DOI 10.1038/sj.emboj.7601450
   Rhodes DR, 2004, NEOPLASIA, V6, P1, DOI 10.1016/S1476-5586(04)80047-2
   Tabach Y, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014632
   Tsukamoto Y, 2008, J PATHOL, V216, P471, DOI 10.1002/path.2424
   Wainberg ZA, 2010, CLIN CANCER RES, V16, P1509, DOI 10.1158/1078-0432.CCR-09-1112
   Wang YC, 2013, J BIOL CHEM, V288, P9028, DOI 10.1074/jbc.M112.432005
NR 24
TC 19
Z9 19
U1 0
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-2257
EI 1098-2264
J9 GENE CHROMOSOME CANC
JI Gene Chromosomes Cancer
PD AUG
PY 2015
VL 54
IS 8
BP 506
EP 515
DI 10.1002/gcc.22262
PG 10
WC Oncology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Genetics & Heredity
GA CK7OV
UT WOS:000356422900006
PM 26052681
DA 2025-01-04
ER

PT J
AU Ginghina, O
   Hudita, A
   Zaharia, C
   Tsatsakis, A
   Mezhuev, Y
   Costache, M
   Galateanu, B
AF Ginghina, Octav
   Hudita, Ariana
   Zaharia, Catalin
   Tsatsakis, Aristidis
   Mezhuev, Yaroslav
   Costache, Marieta
   Galateanu, Bianca
TI Current Landscape in Organic Nanosized Materials Advances for Improved
   Management of Colorectal Cancer Patients
SO MATERIALS
LA English
DT Review
DE drug-delivery systems; nanoparticles; liposomes; colorectal cancer;
   target therapy; nanomedicine
ID POLYMER HYBRID NANOPARTICLES; FOLFOXIRI PLUS BEVACIZUMAB; III
   COLON-CANCER; 1ST-LINE TREATMENT; IN-VITRO; FOLATE RECEPTOR;
   CLINICAL-APPLICATIONS; TRIGGERED RELEASE; RANDOMIZED-TRIAL;
   DELIVERY-SYSTEM
AB Globally, colorectal cancer (CRC) ranks as one of the most prevalent types of cancers at the moment, being the second cause of cancer-related deaths. The CRC chemotherapy backbone is represented by 5-fluorouracil, oxaliplatin, irinotecan, and their combinations, but their administration presents several serious disadvantages, such as poor bioavailability, lack of tumor specificity, and susceptibility to multidrug resistance. To address these limitations, nanomedicine has arisen as a powerful tool to improve current chemotherapy since nanosized carriers hold great promise in improving the stability and solubility of the drug payload and enhancing the active concentration of the drug that reaches the tumor tissue, increasing, therefore, the safety and efficacy of the treatment. In this context, the present review offers an overview of the most recent advances in the development of nanosized drug-delivery systems as smart therapeutic tools in CRC management and highlights the emerging need for improving the existing in vitro cancer models to reduce animal testing and increase the success of nanomedicine in clinical trials.
C1 [Ginghina, Octav] Sf Ioan Emergency Clin Hosp, Dept Surg, 13 Vitan Barzesti St, Bucharest 042122, Romania.
   [Ginghina, Octav] Carol Davila Univ Med & Pharm Bucharest, Fac Med Dent, Dept 2, 17-21 Calea Plevnei St, Bucharest 010232, Romania.
   [Hudita, Ariana; Costache, Marieta; Galateanu, Bianca] Univ Bucharest, Dept Biochem & Mol Biol, 91-95 Splaiul Independentei St, Bucharest 050095, Romania.
   [Zaharia, Catalin] Univ Politehn Bucuresti, Dept Bioresources & Polymer Sci, Adv Polymer Mat Grp, 1-7 Gh Polizu St, Bucharest 011061, Romania.
   [Tsatsakis, Aristidis] Univ Crete, Fac Med, Dept Toxicol & Forens Sci, Iraklion 71003, Greece.
   [Mezhuev, Yaroslav] D Mendeleev Univ Chem Technol Russia, Ctr Biomat, Miusskaya Sq 9, Moscow 125047, Russia.
C3 Carol Davila University of Medicine & Pharmacy; University of Bucharest;
   National University of Science & Technology POLITEHNICA Bucharest;
   University of Crete; Mendeleev University of Chemical Technology of
   Russia
RP Hudita, A (corresponding author), Univ Bucharest, Dept Biochem & Mol Biol, 91-95 Splaiul Independentei St, Bucharest 050095, Romania.
EM octav.ginghina@umfcd.com; arianahudita@yahoo.com;
   zaharia.catalin@gmail.com; tsatsaka@uoc.gr; valsorja@mail.ru;
   marieta.costache@bio.unibuc.ro; bianca.galateanu@bio.unibuc.ro
RI Mezhuev, Yaroslav/F-8596-2017; Hudita, Ariana/GXV-7281-2022; Zaharia,
   Catalin/B-9587-2012; Galateanu, Bianca/AAU-5847-2020; Hudita,
   Ariana/I-5502-2016; Costache, Marieta/F-2806-2016; TSATSAKIS,
   ARISTIDIS/H-2890-2013; Galateanu, Bianca/D-1632-2015
OI Hudita, Ariana/0000-0002-9439-9432; Costache,
   Marieta/0000-0002-8103-3693; TSATSAKIS, ARISTIDIS/0000-0003-3824-2462;
   Zaharia, Catalin/0000-0002-7522-467X; Galateanu,
   Bianca/0000-0001-8093-1750
FU Romanian Ministry of Education and Research, CNCS-UEFISCDI within PNCDI
   III [PN-III-P1-1.1-PD-2019-0955]
FX This work was supported by a grant of the Romanian Ministry of Education
   and Research, CNCS-UEFISCDI, project number PN-III-P1-1.1-PD-2019-0955,
   within PNCDI III.
CR Abbasi E, 2014, NANOSCALE RES LETT, V9, DOI 10.1186/1556-276X-9-247
   Abedini F, 2012, INT J NANOMED, V7, P4159, DOI [10.2147/IJN.S30434, 10.2147/IJN.S29823]
   Ahmed F, 2018, PHARM RES-DORDR, V35, DOI 10.1007/s11095-018-2457-7
   Akbarzadeh A, 2013, NANOSCALE RES LETT, V8, DOI 10.1186/1556-276X-8-102
   Alavi M, 2017, ADV PHARM BULL, V7, P3, DOI 10.15171/apb.2017.002
   Alcindor T, 2011, CURR ONCOL, V18, P18
   Alexis F, 2008, MOL PHARMACEUT, V5, P505, DOI 10.1021/mp800051m
   Alibolandi M, 2017, INT J PHARMACEUT, V519, P352, DOI 10.1016/j.ijpharm.2017.01.044
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Ansari L, 2020, PHARM DEV TECHNOL, V25, P601, DOI 10.1080/10837450.2020.1725045
   Ashraf N, 2013, CURR COLORECT CANC R, V9, P398, DOI 10.1007/s11888-013-0185-2
   Balaure PC, 2015, CURR TOP MED CHEM, V15, P1424
   BANGHAM AD, 1965, J MOL BIOL, V13, P238, DOI 10.1016/S0022-2836(65)80093-6
   Basak S, 2000, ANN NY ACAD SCI, V910, P237
   Bauleth-Ramos T, 2020, J CONTROL RELEASE, V323, P398, DOI 10.1016/j.jconrel.2020.04.025
   Bevan R, 2018, CLIN ENDOSC, V51, P37, DOI 10.5946/ce.2017.141
   Bhattacharya S, 2021, RECENT PAT ANTI-CANC, V16, P84, DOI 10.2174/1574892815666201221121859
   Bhattarai DP, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9092122
   Blanco E, 2015, NAT BIOTECHNOL, V33, P941, DOI 10.1038/nbt.3330
   Braun Michael S, 2011, Ther Adv Med Oncol, V3, P43, DOI 10.1177/1758834010388342
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Bujko K, 2006, BRIT J SURG, V93, P1215, DOI 10.1002/bjs.5506
   Bulbake U, 2017, PHARMACEUTICS, V9, DOI 10.3390/pharmaceutics9020012
   Cabeza L, 2020, AAPS PHARMSCITECH, V21, DOI 10.1208/s12249-020-01731-y
   Cao YH, 2009, FRONT BIOSCI-LANDMRK, V14, P3962, DOI [10.2735/3504, 10.2741/3504]
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   Casadó A, 2018, INT J NANOMED, V13, P5301, DOI 10.2147/IJN.S166219
   Cekanova M, 2014, DRUG DES DEV THER, V8, P1911, DOI 10.2147/DDDT.S49584
   Chan JM, 2009, BIOMATERIALS, V30, P1627, DOI 10.1016/j.biomaterials.2008.12.013
   Chen RR, 2021, BIOMATER SCI-UK, V9, P2279, DOI 10.1039/d0bm01904f
   Chen YC, 2014, J BIOMED MATER RES A, V102, P2024, DOI 10.1002/jbm.a.34850
   Chen YQ, 2021, INT J NANOMED, V16, P269, DOI 10.2147/IJN.S270939
   Chen YL, 2012, MOL ONCOL, V6, P360, DOI 10.1016/j.molonc.2011.11.010
   Cheng GL, 2019, COLLOID SURFACE B, V181, P822, DOI 10.1016/j.colsurfb.2019.06.020
   Cheng XJ, 2016, ONCOTARGET, V7, P7096, DOI 10.18632/oncotarget.6898
   Chenthamara D, 2019, BIOMATER RES, V23, DOI 10.1186/s40824-019-0166-x
   Corpet DE, 2005, EUR J CANCER, V41, P1911, DOI 10.1016/j.ejca.2005.06.006
   Costa EC, 2016, BIOTECHNOL ADV, V34, P1427, DOI 10.1016/j.biotechadv.2016.11.002
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   García MC, 2020, WOODH PUBL SER BIOM, P71, DOI 10.1016/B978-0-08-102548-2.00004-4
   Cunningham D, 2013, LANCET ONCOL, V14, P1077, DOI 10.1016/S1470-2045(13)70154-2
   D'souza AA, 2016, EXPERT OPIN DRUG DEL, V13, P1257, DOI 10.1080/17425247.2016.1182485
   Daniels TR, 2006, CLIN IMMUNOL, V121, P144, DOI 10.1016/j.clim.2006.06.010
   Dave V, 2019, J MICROBIOL METH, V160, P130, DOI 10.1016/j.mimet.2019.03.017
   DIASIO RB, 1989, CLIN PHARMACOKINET, V16, P215, DOI 10.2165/00003088-198916040-00002
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Du L, 2008, CLIN CANCER RES, V14, P6751, DOI 10.1158/1078-0432.CCR-08-1034
   Englert C, 2018, PROG POLYM SCI, V87, P107, DOI 10.1016/j.progpolymsci.2018.07.005
   Fang J, 2011, ADV DRUG DELIVER REV, V63, P136, DOI 10.1016/j.addr.2010.04.009
   Fang Y, 2017, DRUG DELIV, V24, P22, DOI 10.1080/10717544.2017.1388451
   Farnsworth RH, 2014, ONCOGENE, V33, P3496, DOI 10.1038/onc.2013.304
   Ferlizza E, 2021, CANCERS, V13, DOI 10.3390/cancers13051101
   Fernández M, 2018, CHEM SCI, V9, P790, DOI 10.1039/c7sc04004k
   Fidler MM, 2016, INT J CANCER, V139, P2436, DOI 10.1002/ijc.30382
   Folkman J, 2002, SEMIN ONCOL, V29, P15, DOI 10.1053/sonc.2002.37263
   Folprecht G, 2016, ANN ONCOL, V27, P1273, DOI 10.1093/annonc/mdw176
   Fujita K, 2015, WORLD J GASTROENTERO, V21, P12234, DOI 10.3748/wjg.v21.i43.12234
   Gabizon AA, 2006, J LIPOSOME RES, V16, P175, DOI 10.1080/08982100600848769
   Garcia-Pinel B, 2020, PHARMACEUTICS, V12, DOI 10.3390/pharmaceutics12060589
   Gee MS, 2003, AM J PATHOL, V162, P183, DOI 10.1016/S0002-9440(10)63809-6
   George A, 2019, INT J PHARMACEUT, V561, P244, DOI 10.1016/j.ijpharm.2019.03.011
   Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059
   Gill S, 2003, ALIMENT PHARM THER, V18, P683, DOI 10.1046/j.1365-2036.2003.01735.x
   Gogineni VR, 2020, J CANCER, V11, P6982, DOI 10.7150/jca.48528
   Gonda Amber, 2019, Med One, V4, DOI 10.20900/mo.20190021
   Goodman TT, 2008, BIOCONJUGATE CHEM, V19, P1951, DOI 10.1021/bc800233a
   Graf C, 2012, LANGMUIR, V28, P7598, DOI 10.1021/la204913t
   Gu XL, 2019, J CONTROL RELEASE, V301, P110, DOI 10.1016/j.jconrel.2019.03.005
   Gulati NM, 2018, MOL PHARMACEUT, V15, P2900, DOI 10.1021/acs.molpharmaceut.8b00292
   Gustavsson B, 2015, CLIN COLORECTAL CANC, V14, P1, DOI 10.1016/j.clcc.2014.11.002
   Handali S, 2018, BIOMED PHARMACOTHER, V108, P1259, DOI 10.1016/j.biopha.2018.09.128
   Handali S, 2019, INT J BIOL MACROMOL, V124, P1299, DOI 10.1016/j.ijbiomac.2018.09.119
   Hashizume H, 2000, AM J PATHOL, V156, P1363, DOI 10.1016/S0002-9440(10)65006-7
   Hatakeyama H, 2013, BIOL PHARM BULL, V36, P892, DOI 10.1248/bpb.b13-00059
   He ZD, 2021, ACTA PHARMACOL SIN, V42, P1516, DOI 10.1038/s41401-020-00570-8
   HEALD RJ, 1986, LANCET, V1, P1479
   Herd H, 2013, ACS NANO, V7, P1961, DOI 10.1021/nn304439f
   Hirschhaeuser F, 2010, J BIOTECHNOL, V148, P3, DOI 10.1016/j.jbiotec.2010.01.012
   Hobbs SK, 1998, P NATL ACAD SCI USA, V95, P4607, DOI 10.1073/pnas.95.8.4607
   Hsu HH, 2018, J CELL PHYSIOL, V233, P5458, DOI 10.1002/jcp.26406
   Huang JR, 2019, CANCERS, V11, DOI 10.3390/cancers11030281
   Hubbard JM, 2015, NAT REV CLIN ONCOL, V12, P73, DOI 10.1038/nrclinonc.2014.233
   Iftode A, 2021, EXP THER MED, V21, DOI 10.3892/etm.2020.9532
   Immordino ML, 2006, INT J NANOMED, V1, P297
   Jing FF, 2015, INT J ONCOL, V46, P1582, DOI 10.3892/ijo.2015.2844
   Johnson MR, 1999, CLIN CANCER RES, V5, P2006
   Johnston APR, 2006, CURR OPIN COLLOID IN, V11, P203, DOI 10.1016/j.cocis.2006.05.001
   Jokerst JV, 2011, NANOMEDICINE-UK, V6, P715, DOI [10.2217/NNM.11.19, 10.2217/nnm.11.19]
   Juang V, 2019, SMALL, V15, DOI 10.1002/smll.201903296
   Kadletz L, 2015, ONCOL LETT, V10, P1281, DOI 10.3892/ol.2015.3487
   Kalyane D, 2019, MAT SCI ENG C-MATER, V98, P1252, DOI 10.1016/j.msec.2019.01.066
   Kapalczynska M, 2018, ARCH MED SCI, V14, P910, DOI 10.5114/aoms.2016.63743
   Kapiteijn E, 2001, NEW ENGL J MED, V345, P638, DOI 10.1056/NEJMoa010580
   Kapoor DN, 2015, THER DELIV, V6, P41, DOI [10.4155/tde.14.91, 10.4155/TDE.14.91]
   Kim JH, 2015, WORLD J GASTROENTERO, V21, P5158, DOI 10.3748/wjg.v21.i17.5158
   Kimlin LC, 2013, MOL CARCINOGEN, V52, P167, DOI 10.1002/mc.21844
   Knop K, 2010, ANGEW CHEM INT EDIT, V49, P6288, DOI 10.1002/anie.200902672
   Kou LF, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00027
   Krasanakis T, 2019, ONCOL REP, V42, P2228, DOI 10.3892/or.2019.7351
   Kumar CS, 2020, CARBOHYD POLYM, V231, DOI 10.1016/j.carbpol.2019.115682
   Kümler I, 2019, CANCER CHEMOTH PHARM, V83, P169, DOI 10.1007/s00280-018-3720-7
   Lamichhane N, 2018, MOLECULES, V23, DOI 10.3390/molecules23020288
   Ledermann JA, 2015, ANN ONCOL, V26, P2034, DOI 10.1093/annonc/mdv250
   Li MY, 2019, EUR J MED CHEM, V164, P640, DOI 10.1016/j.ejmech.2019.01.007
   Limbach LK, 2005, ENVIRON SCI TECHNOL, V39, P9370, DOI 10.1021/es051043o
   Liszbinski RB, 2020, MATERIALS, V13, DOI 10.3390/ma13020375
   Liu X, 2011, COMPREHENSIVE BIOTECHNOLOGY, VOL 5: MEDICAL BIOTECHNOLOGY AND HEALTHCARE, 2ND EDITION, P543
   Liu YL, 2012, THER DELIV, V3, P181, DOI 10.4155/TDE.11.156
   Lopez A, 2016, LANCET, V387, P907, DOI 10.1016/S0140-6736(15)60865-0
   Lopez-Garcia R., 2015, J. Cosmet. Dermatological Sci. Appl, V05, P62, DOI DOI 10.4236/JCDSA.2015.52008
   Loupakis F, 2014, EUR J CANCER, V50, P57, DOI 10.1016/j.ejca.2013.08.024
   Lu XY, 2011, PROG MOL BIOL TRANSL, V104, P299, DOI 10.1016/B978-0-12-416020-0.00007-3
   Luss AL, 2018, NANOMEDICINE-UK, V13, P703, DOI 10.2217/nnm-2017-0311
   Maiyo F, 2017, NANOMEDICINE-UK, V12, P1075, DOI 10.2217/nnm-2017-0024
   Mansoori B, 2020, J CELL PHYSIOL, V235, P6817, DOI 10.1002/jcp.29576
   Markman B, 2010, ADV CLIN CHEM, V51, P71, DOI 10.1016/S0065-2423(10)51004-7
   Marquard FE, 2020, BIOCHEM PHARMACOL, V172, DOI 10.1016/j.bcp.2019.113729
   Marquez J, 2018, INT J CANCER, V143, P709, DOI 10.1002/ijc.31343
   Martín MJ, 2021, EUR J PHARM SCI, V158, DOI 10.1016/j.ejps.2020.105681
   McDonald DM, 2002, CANCER RES, V62, P5381
   Meng H, 2018, BIOMATERIALS, V174, P41, DOI 10.1016/j.biomaterials.2018.04.056
   Miller CR, 2002, CANCER RES, V62, P773
   Moghimipour E, 2018, LIFE SCI, V194, P104, DOI 10.1016/j.lfs.2017.12.026
   Mokhtarzadeh A, 2016, TRAC-TREND ANAL CHEM, V82, P316, DOI 10.1016/j.trac.2016.06.018
   Nagtegaal ID, 2008, J CLIN ONCOL, V26, P303, DOI 10.1200/JCO.2007.12.7027
   Negrei C, 2016, FRONT PHARMACOL, V7, DOI 10.3389/fphar.2016.00172
   Nikolouzakis TK, 2019, ONCOL LETT, V17, P2703, DOI 10.3892/ol.2019.9895
   Okazaki F, 2010, CANCER RES, V70, P6238, DOI 10.1158/0008-5472.CAN-10-0184
   Oliveira ALCDL, 2021, MAT SCI ENG C-MATER, V120, DOI 10.1016/j.msec.2020.111678
   Ong SGM, 2016, PHARMACEUTICS, V8, DOI 10.3390/pharmaceutics8040036
   Osorio M, 2020, MOLECULES, V25, DOI 10.3390/molecules25102270
   Oun R, 2018, DALTON T, V47, P6645, DOI 10.1039/c8dt00838h
   Pampaloni F, 2007, NAT REV MOL CELL BIO, V8, P839, DOI 10.1038/nrm2236
   Pan DC, 2021, BIOENG TRANSL MED, V6, DOI 10.1002/btm2.10166
   Piñón-Castillo HA, 2021, APPL SCI-BASEL, V11, DOI 10.3390/app11051988
   Pittella F, 2011, BIOMATERIALS, V32, P3106, DOI 10.1016/j.biomaterials.2010.12.057
   Prutki M, 2006, CANCER LETT, V238, P188, DOI 10.1016/j.canlet.2005.07.001
   Qian K, 2015, INT J NANOMED, V10, DOI 10.2147/IJN.S83731
   Qu CY, 2015, INT J NANOMED, V10, P3911, DOI 10.2147/IJN.S83211
   Quici S, 2015, J MED CHEM, V58, P2003, DOI 10.1021/jm501945w
   Radu IC, 2019, DRUG DELIV, V26, P318, DOI 10.1080/10717544.2019.1582729
   Rajpoot K, 2020, INT J BIOL MACROMOL, V151, P830, DOI 10.1016/j.ijbiomac.2020.02.132
   Rawla P, 2019, GASTROENTEROL REV, V14, P89, DOI 10.5114/pg.2018.81072
   Riihimäki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Roskoski R Jr, 2019, PHARMACOL RES, V139, P395, DOI 10.1016/j.phrs.2018.11.014
   Ruman U, 2021, NANOMATERIALS-BASEL, V11, DOI 10.3390/nano11020497
   Sabourian P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218019
   Salmanpour M, 2019, EUR J PHARM SCI, V136, DOI 10.1016/j.ejps.2019.05.019
   Sardoiwala MN, 2020, ACS BIOMATER SCI ENG, V6, P3139, DOI 10.1021/acsbiomaterials.9b01844
   Sauraj, 2020, MAT SCI ENG C-MATER, V107, DOI 10.1016/j.msec.2019.110356
   Schaffazick SR, 2003, EUR J PHARM BIOPHARM, V56, P501, DOI 10.1016/S0939-6411(03)00139-5
   Montoto SS, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.587997
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Shad PM, 2020, TOXICOL IN VITRO, V65, DOI 10.1016/j.tiv.2019.104756
   Siegel R.L., 2019, CA-CANCER J CLIN, V69, P34, DOI 10.3322/caac.21551
   Siemann DW, 2011, CANCER TREAT REV, V37, P63, DOI 10.1016/j.ctrv.2010.05.001
   Simkens LHJ, 2015, LANCET, V385, P1843, DOI 10.1016/S0140-6736(14)62004-3
   Smith Taylor, 2018, J Nat Sci, V4
   Smith T, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-73218-6
   Soe ZC, 2019, ASIAN J PHARM SCI, V14, P40, DOI 10.1016/j.ajps.2018.09.004
   Süntar I, 2020, WOODHEAD PUBL FOOD S, P137, DOI 10.1016/B978-0-12-815354-3.00010-1
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tan C, 2019, ACS NANO, V13, P9016, DOI 10.1021/acsnano.9b03049
   Tang J, 2015, J MATER CHEM B, V3, P6805, DOI 10.1039/c5tb00912j
   Tariman JD, 2017, NURS CLIN N AM, V52, P65, DOI 10.1016/j.cnur.2016.10.004
   Tchoryk A, 2019, BIOCONJUGATE CHEM, V30, P1371, DOI 10.1021/acs.bioconjchem.9b00136
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Thomas RG, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.610533
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Tiernan JP, 2013, BRIT J CANCER, V108, P662, DOI 10.1038/bjc.2012.605
   Trastulli S, 2012, COLORECTAL DIS, V14, pE277, DOI 10.1111/j.1463-1318.2012.02985.x
   Tredan O, 2007, J NATL CANCER I, V99, P1441, DOI 10.1093/jnci/djm135
   Turecek PL, 2016, J PHARM SCI-US, V105, P460, DOI 10.1016/j.xphs.2015.11.015
   Üner M, 2007, INT J NANOMED, V2, P289
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   VAUPEL P, 1989, CANCER RES, V49, P6449
   Vlahov IR, 2012, BIOCONJUGATE CHEM, V23, P1357, DOI 10.1021/bc2005522
   Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592
   Wang JW, 2020, CANCER MED-US, V9, P361, DOI 10.1002/cam4.2673
   Wang ZP, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00309
   Wang ZX, 2017, METHODS MOL BIOL, V1652, P3, DOI 10.1007/978-1-4939-7219-7_1
   Wang ZY, 2020, DRUG DES DEV THER, V14, P1095, DOI 10.2147/DDDT.S230306
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052
   Wei YH, 2020, J CONTROL RELEASE, V319, P407, DOI 10.1016/j.jconrel.2020.01.012
   Wolf AMD, 2018, CA-CANCER J CLIN, V68, P250, DOI 10.3322/caac.21457
   Wu C, 2019, INT J NANOMED, V14, P75, DOI 10.2147/IJN.S187906
   Wu PP, 2020, INT J NANOMED, V15, P2777, DOI 10.2147/IJN.S215137
   Wu PP, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-06803-7
   Xiang B., 2017, Liposome-Based Drug Delivery Systems, P1
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xing J, 2019, INT J NANOMED, V14, P5201, DOI 10.2147/IJN.S204965
   Xu Y, 2002, ANN ONCOL, V13, P1841, DOI 10.1093/annonc/mdf337
   Xue X, 2013, NUTRIENTS, V5, P2333, DOI 10.3390/nu5072333
   Yan L, 2020, INT J BIOL MACROMOL, V162, P1303, DOI 10.1016/j.ijbiomac.2020.06.246
   Yang HL, 2019, INT J PHARMACEUT, V566, P585, DOI 10.1016/j.ijpharm.2019.06.020
   Yao FJ, 2020, INT J NANOMED, V15, P2119, DOI 10.2147/IJN.S240083
   Yu L, 2017, J CANCER, V8, P3430, DOI 10.7150/jca.21125
   YUAN F, 1995, CANCER RES, V55, P3752
   Zhang HW, 2017, METHODS MOL BIOL, V1522, P17, DOI 10.1007/978-1-4939-6591-5_2
   Zhang J, 2017, INT J NANOMED, V12, P8483, DOI 10.2147/IJN.S148359
   Zhang L, 2010, NANO LIFE, V1, P163, DOI 10.1142/S179398441000016X
   Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r
   Zhang N, 2008, MOLECULES, V13, P1551, DOI 10.3390/molecules13081551
   Zhang XY, 2020, BIOMATER SCI-UK, V8, P1885, DOI 10.1039/c9bm01927h
   Zielinska A, 2020, MOLECULES, V25, DOI 10.3390/molecules25163731
   Zuazo-Gaztelu I, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00248
NR 208
TC 14
Z9 14
U1 1
U2 21
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1996-1944
J9 MATERIALS
JI Materials
PD MAY
PY 2021
VL 14
IS 9
AR 2440
DI 10.3390/ma14092440
PG 23
WC Chemistry, Physical; Materials Science, Multidisciplinary; Metallurgy &
   Metallurgical Engineering; Physics, Applied; Physics, Condensed Matter
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Materials Science; Metallurgy & Metallurgical Engineering;
   Physics
GA SC3MW
UT WOS:000650580800001
PM 34066710
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Wang, H
   Mi, K
AF Wang, Hao
   Mi, Kun
TI Emerging roles of endoplasmic reticulum stress in the cellular
   plasticity of cancer cells
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE cellular plasticity; ER stress; epithelial-mesenchymal plasticity;
   resistance; cancer stem cell; vasculogenic mimicry
ID EPITHELIAL-MESENCHYMAL TRANSITION; VASCULOGENIC MIMICRY FORMATION;
   UNFOLDED PROTEIN RESPONSE; NEGATIVE BREAST-CANCER; ER-STRESS;
   COLORECTAL-CANCER; LUNG-CANCER; STEM-CELLS; EMT DOWNSTREAM; PROMOTES
AB Cellular plasticity is a well-known dynamic feature of tumor cells that endows tumors with heterogeneity and therapeutic resistance and alters their invasion-metastasis progression, stemness, and drug sensitivity, thereby posing a major challenge to cancer therapy. It is becoming increasingly clear that endoplasmic reticulum (ER) stress is a hallmark of cancer. The dysregulated expression of ER stress sensors and the activation of downstream signaling pathways play a role in the regulation of tumor progression and cellular response to various challenges. Moreover, mounting evidence implicates ER stress in the regulation of cancer cell plasticity, including epithelial-mesenchymal plasticity, drug resistance phenotype, cancer stem cell phenotype, and vasculogenic mimicry phenotype plasticity. ER stress influences several malignant characteristics of tumor cells, including epithelial-to-mesenchymal transition (EMT), stem cell maintenance, angiogenic function, and tumor cell sensitivity to targeted therapy. The emerging links between ER stress and cancer cell plasticity that are implicated in tumor progression and chemoresistance are discussed in this review, which may aid in formulating strategies to target ER stress and cancer cell plasticity in anticancer treatments.
C1 [Wang, Hao] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Breast Surg,Sch Med, Chengdu, Peoples R China.
   [Mi, Kun] Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Radiat Oncol Key Lab Sichuan Prov,Sch Med, Chengdu, Peoples R China.
C3 University of Electronic Science & Technology of China; University of
   Electronic Science & Technology of China
RP Mi, K (corresponding author), Univ Elect Sci & Technol China, Sichuan Canc Hosp & Inst, Sichuan Canc Ctr, Radiat Oncol Key Lab Sichuan Prov,Sch Med, Chengdu, Peoples R China.
EM mikun@uestc.edu.cn
CR Alexa-Stratulat T, 2019, DRUG RESIST UPDATE, V46, DOI 10.1016/j.drup.2019.100643
   Alnuqaydan AM, 2020, AM J CANCER RES, V10, P799
   Arozarena I, 2019, NAT REV CANCER, V19, P377, DOI 10.1038/s41568-019-0154-4
   Auf G, 2010, P NATL ACAD SCI USA, V107, P15553, DOI 10.1073/pnas.0914072107
   Bakir B, 2020, TRENDS CELL BIOL, V30, P764, DOI 10.1016/j.tcb.2020.07.003
   Bambang IF, 2009, LAB INVEST, V89, P1229, DOI 10.1038/labinvest.2009.87
   Binet F, 2015, CELL METAB, V22, P560, DOI 10.1016/j.cmet.2015.07.010
   Binet F, 2013, CELL METAB, V17, P353, DOI 10.1016/j.cmet.2013.02.003
   Bornes L, 2021, J CLIN MED, V10, DOI 10.3390/jcm10112403
   Boumahdi S, 2020, NAT REV DRUG DISCOV, V19, P39, DOI 10.1038/s41573-019-0044-1
   Bouvier N, 2012, J BIOL CHEM, V287, P14557, DOI 10.1074/jbc.M112.340570
   Cai YL, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0669-8
   Carlisle RE, 2012, AM J PHYSIOL-RENAL, V303, pF467, DOI 10.1152/ajprenal.00481.2011
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chen CY, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22010355
   Chen W, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/1740936
   Chen X, 2021, NAT REV CANCER, V21, P71, DOI 10.1038/s41568-020-00312-2
   Chen X, 2014, NATURE, V508, P103, DOI 10.1038/nature13119
   Chen YY, 2019, BBA-MOL BASIS DIS, V1865, P2563, DOI 10.1016/j.bbadis.2019.06.001
   Cole AJ, 2020, JCI INSIGHT, V5, DOI 10.1172/jci.insight.131486
   Condamine T, 2016, SCI IMMUNOL, V1, DOI 10.1126/sciimmunol.aaf8943
   Cubillos-Ruiz JR, 2015, CELL, V161, P1527, DOI 10.1016/j.cell.2015.05.025
   Cuevas EP, 2017, SCI REP-UK, V7, DOI 10.1038/srep44988
   da Silva-Diz V, 2018, SEMIN CANCER BIOL, V53, P48, DOI 10.1016/j.semcancer.2018.08.009
   Davis FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0036923
   de Jeude JFV, 2017, ONCOGENE, V36, P3397, DOI 10.1038/onc.2016.326
   Delbrel E, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20061299
   Dirkse A, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09853-z
   Du J, 2014, GYNECOL ONCOL, V133, P575, DOI 10.1016/j.ygyno.2014.02.034
   Epple LM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073267
   Feng YX, 2014, CANCER DISCOV, V4, P702, DOI 10.1158/2159-8290.CD-13-0945
   Ferrer AI, 2020, CANCER METAST REV, V39, P721, DOI 10.1007/s10555-020-09882-x
   Font-Clos F, 2018, P NATL ACAD SCI USA, V115, P5902, DOI 10.1073/pnas.1722609115
   Franco A, 2010, CELL IMMUNOL, V266, P1, DOI 10.1016/j.cellimm.2010.09.006
   Fuentes-Iglesias Alejandro, 2022, Methods Mol Biol, V2454, P743, DOI 10.1007/7651_2021_354
   Gao LL, 2021, J CELL MOL MED, V25, P10916, DOI 10.1111/jcmm.16983
   Gao L, 2022, MED ONCOL, V39, DOI 10.1007/s12032-022-01687-y
   Gao TB, 2020, J CELL MOL MED, V24, P362, DOI 10.1111/jcmm.14740
   Garg M, 2022, CANCER METAST REV, V41, P131, DOI 10.1007/s10555-021-10003-5
   Gong L, 2020, BMC PULM MED, V20, DOI 10.1186/s12890-020-01319-z
   Govaere O, 2016, J HEPATOL, V64, P609, DOI 10.1016/j.jhep.2015.11.011
   Gu CR, 2021, EXP CELL RES, V405, DOI 10.1016/j.yexcr.2021.112725
   Guallar D, 2020, CELL STEM CELL, V27, P300, DOI 10.1016/j.stem.2020.04.016
   Guo BQ, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04251-0
   Gupta PB, 2019, CELL STEM CELL, V24, P65, DOI 10.1016/j.stem.2018.11.011
   Heijmans J, 2013, CELL REP, V3, P1128, DOI 10.1016/j.celrep.2013.02.031
   Hendrix MJC, 2003, NAT REV CANCER, V3, P411, DOI 10.1038/nrc1092
   Janczar S, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.346
   Jia RJ, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.422
   Jiang YM, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19030844
   Jung E, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-21117-3
   Karimzadeh F, 2017, STEM CELL REP, V8, P1299, DOI 10.1016/j.stemcr.2017.03.018
   Kilinc AN, 2020, ONCOGENE, V39, P1498, DOI 10.1038/s41388-019-1081-2
   Kröger C, 2019, P NATL ACAD SCI USA, V116, P7353, DOI 10.1073/pnas.1812876116
   Kumar-Singh A, 2021, BIOLOGY-BASEL, V10, DOI 10.3390/biology10060521
   Kvokacková B, 2021, CANCERS, V13, DOI 10.3390/cancers13092188
   Lai ST, 2020, J THORAC DIS, V12, P3715, DOI 10.21037/jtd-20-2098
   Lambert AW, 2021, NAT REV CANCER, V21, P325, DOI 10.1038/s41568-021-00332-6
   Lei YP, 2021, BIOCHEM BIOPH RES CO, V557, P316, DOI 10.1016/j.bbrc.2021.03.041
   Lettnin AP, 2019, MOL BIOL REP, V46, P1873, DOI 10.1007/s11033-019-04639-4
   Li C, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03555-5
   Li J, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11213383
   Li RH, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11142136
   Liang HC, 2018, ONCOGENE, V37, P1961, DOI 10.1038/s41388-017-0089-8
   Liao CC, 2021, INT J BIOL SCI, V17, P3036, DOI 10.7150/ijbs.61566
   Limia CM, 2019, CANCERS, V11, DOI 10.3390/cancers11050631
   Lin JR, 2018, J INVEST DERMATOL, V138, P1609, DOI 10.1016/j.jid.2018.01.023
   Lin X, 2017, J MOL MED, V95, P53, DOI 10.1007/s00109-016-1452-x
   Lin YN, 2019, BIOMED PHARMACOTHER, V118, DOI 10.1016/j.biopha.2019.109249
   Liu DS, 2018, CELL PHYSIOL BIOCHEM, V46, P1821, DOI 10.1159/000489367
   Liu HF, 2021, FEBS OPEN BIO, V11, P2607, DOI 10.1002/2211-5463.13259
   Loinard C, 2012, CIRCULATION, V125, P1014, DOI 10.1161/CIRCULATIONAHA.111.041830
   Lu YJ, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-021-02208-x
   Mahdi SHA, 2015, ARCH BIOCHEM BIOPHYS, V583, P18, DOI 10.1016/j.abb.2015.07.008
   Marjanovic ND, 2020, CANCER CELL, V38, P229, DOI 10.1016/j.ccell.2020.06.012
   Marusyk A, 2020, CANCER CELL, V37, P471, DOI 10.1016/j.ccell.2020.03.007
   Matsumoto T, 2017, ONCOGENESIS, V6, DOI 10.1038/s41389-017-0009-3
   Matsumura Y, 2019, LIFE SCI ALLIANCE, V2, DOI 10.26508/lsa.201900425
   Mehdizadehtapeh L, 2021, TURK J BIOL, V45, P1, DOI 10.3906/biy-2010-62
   Mercedes SAV, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.807324
   Miao L, 2017, CANCER RES, V77, P3101, DOI 10.1158/0008-5472.CAN-16-2169
   Migault M, 2022, CELL MOL LIFE SCI, V79, DOI 10.1007/s00018-022-04199-0
   Moamer A, 2019, EBIOMEDICINE, V45, P92, DOI 10.1016/j.ebiom.2019.06.009
   Nan JN, 2022, BIOENGINEERED, V13, P10564, DOI 10.1080/21655979.2022.2062990
   Neftel C, 2019, CELL, V178, P835, DOI 10.1016/j.cell.2019.06.024
   Niederreiter L, 2013, J EXP MED, V210, P2041, DOI 10.1084/jem.20122341
   Nilchian A, 2019, CANCER RES, V79, P47, DOI 10.1158/0008-5472.CAN-18-1742
   Nobre AR, 2021, NAT CANCER, V2, P327, DOI 10.1038/s43018-021-00179-8
   Norgard RJ, 2021, EMBO REP, V22, DOI 10.15252/embr.202051872
   Ouyang S, 2022, FRONT BIOSCI-LANDMRK, V27, DOI 10.31083/j.fbl2702038
   Pastushenko I, 2019, TRENDS CELL BIOL, V29, P212, DOI 10.1016/j.tcb.2018.12.001
   Paul R, 2022, PHARMACOL THERAPEUT, V231, DOI 10.1016/j.pharmthera.2021.107985
   Perdigao-Henriques R, 2016, ONCOGENE, V35, P158, DOI 10.1038/onc.2015.69
   Pereira ER, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0012521
   Primeaux M, 2022, CLIN EXP METASTAS, V39, P391, DOI 10.1007/s10585-022-10146-x
   Rafehi S, 2016, ENDOCR-RELAT CANCER, V23, P147, DOI 10.1530/ERC-15-0383
   Ramirez M, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10690
   Ruscetti M, 2016, ONCOGENE, V35, P3781, DOI 10.1038/onc.2015.444
   Ryabaya O, 2018, ONCOL REP, V40, P385, DOI 10.3892/or.2018.6430
   Salaroglio IC, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0657-0
   Salminen A, 2020, J MOL MED, V98, P633, DOI 10.1007/s00109-020-01904-z
   Sansone P, 2017, P NATL ACAD SCI USA, V114, pE9066, DOI 10.1073/pnas.1704862114
   Santoni G, 2020, ADV EXP MED BIOL, V1131, P505, DOI 10.1007/978-3-030-12457-1_20
   Santos M, 2022, BIOLOGY-BASEL, V11, DOI 10.3390/biology11071046
   Sarró E, 2020, J MOL CELL BIOL, V12, P499, DOI 10.1093/jmcb/mjaa005
   Shah PP, 2017, ONCOTARGET, V8, P22625, DOI 10.18632/oncotarget.15150
   Shah PP, 2015, ONCOTARGET, V6, P17725, DOI 10.18632/oncotarget.3918
   Sheng WW, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01702-y
   Shinde A, 2019, CANCER RES, V79, P1831, DOI 10.1158/0008-5472.CAN-18-2636
   Sistigu A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02166
   Spaan CN, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1729-4
   Stewart TA, 2020, LAB INVEST, V100, P224, DOI 10.1038/s41374-019-0280-3
   Strietz J, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041808
   Su ZP, 2019, MOL MED REP, V19, P4645, DOI 10.3892/mmr.2019.10136
   Takayanagi T, 2015, HYPERTENSION, V65, P1349, DOI 10.1161/HYPERTENSIONAHA.115.05344
   Tang X, 2015, CELL PHYSIOL BIOCHEM, V35, P816, DOI 10.1159/000369740
   Tanjore H, 2011, J BIOL CHEM, V286, P30972, DOI 10.1074/jbc.M110.181164
   Tashireva LA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052504
   Tata PR, 2016, CURR OPIN CELL BIOL, V43, P46, DOI 10.1016/j.ceb.2016.07.005
   Tavernier Q, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67243-8
   Thevenot PT, 2014, IMMUNITY, V41, P389, DOI 10.1016/j.immuni.2014.08.015
   Tseng CN, 2014, MOLECULES, V19, P17464, DOI 10.3390/molecules191117464
   Tseng CN, 2013, MOLECULES, V18, P10242, DOI 10.3390/molecules180910242
   Ulianich L, 2020, FRONT ENDOCRINOL, V11, DOI 10.3389/fendo.2020.588685
   Ungefroren H, 2022, CANCERS, V14, DOI 10.3390/cancers14092057
   Verfaillie T, 2013, CANCER LETT, V332, P249, DOI 10.1016/j.canlet.2010.07.016
   Wang HF, 2019, CELL PROLIFERAT, V52, DOI 10.1111/cpr.12600
   Wang H, 2018, J CELL MOL MED, V22, P3768, DOI 10.1111/jcmm.13637
   Wang JM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aao4617
   Wielenga MCB, 2015, CELL REP, V13, P489, DOI 10.1016/j.celrep.2015.09.016
   Williams ED, 2019, NAT REV CANCER, V19, P716, DOI 10.1038/s41568-019-0213-x
   Wu J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0935-8
   Wu SM, 2023, CELL BIOL TOXICOL, V39, P1873, DOI 10.1007/s10565-021-09673-2
   Wu SM, 2016, J PINEAL RES, V60, P142, DOI 10.1111/jpi.12295
   Wu SX, 2022, J VIROL, V96, DOI [10.1128/jvi.01975-21, 10.1128/JVI.01975-21]
   Wu SX, 2021, CANCER LETT, V499, P175, DOI 10.1016/j.canlet.2020.11.032
   Xia T, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08712-9
   Xiao P, 2023, CELL MOL IMMUNOL, V20, P119, DOI 10.1038/s41423-022-00955-1
   Xie XP, 2022, DEV CELL, V57, P32, DOI 10.1016/j.devcel.2021.12.007
   Xu HM, 2014, J BIOL CHEM, V289, P26290, DOI 10.1074/jbc.M114.572560
   Xue YJ, 2017, PROTEIN CELL, V8, P178, DOI 10.1007/s13238-016-0330-1
   Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9
   Yang M, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2411-1
   Yang YS, 2022, ONCOGENE, V41, P2624, DOI 10.1038/s41388-022-02278-x
   Yao LL, 2016, J CELL MOL MED, V20, P1673, DOI 10.1111/jcmm.12862
   Ye LP, 2019, EMBO MOL MED, V11, DOI 10.15252/emmm.201910638
   Ye S, 2019, CANCER RES, V79, P4729, DOI 10.1158/0008-5472.CAN-19-1084
   Yoon S, 2021, MOL CELLS, V44, P569, DOI 10.14348/molcells.2021.0031
   Yuan HY, 2022, INT J BIOL SCI, V18, P4853, DOI 10.7150/ijbs.72838
   Yuan S, 2019, CANCER DISCOV, V9, P837, DOI 10.1158/2159-8290.CD-19-0015
   Yun J, 2016, EMBO REP, V17, P1343, DOI 10.15252/embr.201541852
   Zeindl-Eberhart E, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087386
   Zhang JY, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0073086
   Zhang R, 2022, SEMIN CANCER BIOL, V82, P11, DOI 10.1016/j.semcancer.2021.03.008
   Zhang X, 2020, ACTA BIOCH BIOPH SIN, V52, P411, DOI 10.1093/abbs/gmaa014
   Zhao H, 2022, LIFE-BASEL, V12, DOI 10.3390/life12030438
   Zhao J, 2020, CELL ONCOL, V43, P863, DOI 10.1007/s13402-020-00532-6
   Zhao N, 2016, SCI REP-UK, V6, DOI 10.1038/srep23091
   Zhao YY, 2021, METABOLITES, V11, DOI 10.3390/metabo11080562
   Zheng N, 2021, PHARMACOL RES, V166, DOI 10.1016/j.phrs.2021.105507
   Zhou S, 2020, MOL MED REP, V21, P173, DOI 10.3892/mmr.2019.10814
   Zhu NN, 2021, PLOS PATHOG, V17, DOI 10.1371/journal.ppat.1009873
   Zhu YF, 2019, ONCOGENE, V38, P5778, DOI 10.1038/s41388-019-0846-y
   Zhu Y, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-05099-8
   Zomer A, 2013, STEM CELLS, V31, P602, DOI 10.1002/stem.1296
NR 165
TC 13
Z9 14
U1 0
U2 20
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD FEB 20
PY 2023
VL 13
AR 1110881
DI 10.3389/fonc.2023.1110881
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 9O1JE
UT WOS:000943359900001
PM 36890838
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Bellio, H
   Fumet, JD
   Ghiringhelli, F
AF Bellio, Helene
   Fumet, Jean David
   Ghiringhelli, Francois
TI Targeting BRAF and RAS in Colorectal Cancer
SO CANCERS
LA English
DT Review
DE BRAF; KRAS; colorectal cancer; targeted therapy
ID KRAS CODON 12; WILD-TYPE; COLON-CANCER; PREDICTIVE BIOMARKER; MUTANT
   KRAS; SIGNALING PATHWAYS; 1ST-LINE TREATMENT; PROGNOSTIC-FACTOR; PLUS
   IRINOTECAN; MEK INHIBITION
AB Simple Summary
   In colorectal cancer, mutations of the KRAS and BRAF genes are quite common and can contribute to the activation of cell signaling pathways that lead to cell proliferation and differentiation. These processes promote cancer growth, and in some cases, they may cause cells to develop resistance to certain types of treatment, notably EGFR inhibitors. We summarize recent knowledge regarding the effects of KRAS and BRAF mutations in the setting of colorectal cancer and discuss the new therapies under development.
   Colorectal cancer (CRC) is still one of the most frequent forms of cancer in the world in terms of incidence. Around 40% of CRC patients carry a mutation of the Kirsten rat sarcoma (KRAS) gene, while 10% have a mutation in the B-Raf proto-oncogene serine/threonine kinase (BRAF) gene. These mutations are responsible for dysregulation of the mitogen-associated protein kinase (MAPK) pathway, leading to the proliferation, differentiation, angiogenesis, and resistance to apoptosis of cells. Activation of the MAPK pathway results in adaptive therapeutic resistance, rendering EGFR inhibitors ineffective. This review aims to highlight the recent findings that have improved our understanding of KRAS and BRAF mutations in colorectal cancer and to describe new targeted therapies, used alone or in combination.
C1 [Bellio, Helene; Fumet, Jean David; Ghiringhelli, Francois] Univ Burgundy Franche Comte, Maison Univ Esplanade Erasme, F-21000 Dijon, France.
   [Bellio, Helene; Fumet, Jean David; Ghiringhelli, Francois] UNICANCER, Georges Francois Leclerc Canc Ctr, Dept Med Oncol, 1 Rue Professeur Marion, F-21000 Dijon, France.
   [Fumet, Jean David; Ghiringhelli, Francois] UNICANCER, Georges Francois Leclerc Canc Ctr, Platform Transfer Biol Oncol, 1 Rue Professeur Marion, F-21000 Dijon, France.
   [Fumet, Jean David; Ghiringhelli, Francois] UMR INSERM 1231, 7 Blvd Jeanne Arc, F-21000 Dijon, France.
   [Fumet, Jean David; Ghiringhelli, Francois] Dijon Univ Hosp, Genom & Immunotherapy Med Inst, 14 Rue Paul Gaffarel, F-21000 Dijon, France.
C3 Universite de Bourgogne; UNICANCER; Centre Georges-Francois Leclerc;
   Institut Agro; AgroSup Dijon; UNICANCER; Centre Georges-Francois
   Leclerc; Universite de Bourgogne; Universite de Bourgogne; Institut
   Agro; AgroSup Dijon; Institut National de la Sante et de la Recherche
   Medicale (Inserm); CHU Dijon Bourgogne
RP Ghiringhelli, F (corresponding author), Univ Burgundy Franche Comte, Maison Univ Esplanade Erasme, F-21000 Dijon, France.; Ghiringhelli, F (corresponding author), UNICANCER, Georges Francois Leclerc Canc Ctr, Dept Med Oncol, 1 Rue Professeur Marion, F-21000 Dijon, France.; Ghiringhelli, F (corresponding author), UNICANCER, Georges Francois Leclerc Canc Ctr, Platform Transfer Biol Oncol, 1 Rue Professeur Marion, F-21000 Dijon, France.; Ghiringhelli, F (corresponding author), UMR INSERM 1231, 7 Blvd Jeanne Arc, F-21000 Dijon, France.; Ghiringhelli, F (corresponding author), Dijon Univ Hosp, Genom & Immunotherapy Med Inst, 14 Rue Paul Gaffarel, F-21000 Dijon, France.
EM hbellio@cgfl.fr; jdfumet@cgfl.fr; fghiringhelli@cgfl.fr
OI ghiringhelli, francois/0000-0002-5465-8305
CR Adamopoulos C, 2021, CANCER DISCOV, V11, P1716, DOI 10.1158/2159-8290.CD-20-1351
   Aderka D, 2019, LANCET ONCOL, V20, pE274, DOI 10.1016/S1470-2045(19)30172-X
   Aguilera O, 2018, ADV EXP MED BIOL, V1110, P23, DOI 10.1007/978-3-030-02771-1_3
   Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187
   Barault L, 2008, CANCER RES, V68, P8541, DOI 10.1158/0008-5472.CAN-08-1171
   Bindea G, 2011, SEMIN IMMUNOPATHOL, V33, P335, DOI 10.1007/s00281-011-0264-x
   Bläker H, 2019, CLIN GASTROENTEROL H, V17, P455, DOI 10.1016/j.cgh.2018.04.015
   BOS JL, 1989, CANCER RES, V49, P4682
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Catalano V, 2009, BRIT J CANCER, V100, P881, DOI 10.1038/sj.bjc.6604955
   Chauvenet M, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-282
   Chen JQ, 2014, BMC CANCER, V14, DOI [10.1186/1471-2407-14-802, 10.1186/1471-2407-14-15]
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Deng G, 2008, EUR J CANCER, V44, P1290, DOI 10.1016/j.ejca.2008.03.014
   Dobre M, 2015, ROM J MORPHOL EMBRYO, V56, P671
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Ewing I, 2014, FRONTLINE GASTROENTE, V5, P26, DOI 10.1136/flgastro-2013-100329
   Fang JY, 2005, LANCET ONCOL, V6, P322, DOI 10.1016/S1470-2045(05)70168-6
   Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093
   Galluzzi L, 2020, TRENDS PHARMACOL SCI, V41, P1, DOI 10.1016/j.tips.2019.11.004
   Glebov OK, 2003, CANCER EPIDEM BIOMAR, V12, P755
   Goff SL, 2016, J CLIN ONCOL, V34, P2389, DOI 10.1200/JCO.2016.66.7220
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167
   Hamarsheh S, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19288-6
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Hofmann MH, 2021, CANCER DISCOV, V11, P142, DOI 10.1158/2159-8290.CD-20-0142
   Hong A, 2021, CANCER DISCOV, V11, P714, DOI 10.1158/2159-8290.CD-20-0873
   Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006
   Jeng HH, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms2173
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Kessler D, 2019, P NATL ACAD SCI USA, V116, P15823, DOI 10.1073/pnas.1904529116
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4
   Krasinskas Alyssa M, 2011, Patholog Res Int, V2011, P932932, DOI 10.4061/2011/932932
   Lee SK, 2018, EMBO REP, V19, DOI 10.15252/embr.201846060
   Licitra L, 2013, EUR J CANCER, V49, P1161, DOI 10.1016/j.ejca.2012.11.018
   Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Luo C, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0361-0
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Molinari F, 2011, CLIN CANCER RES, V17, P4901, DOI 10.1158/1078-0432.CCR-10-3137
   Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6
   Müller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3
   Nakhaeizadeh H, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0167145
   Oliveira C, 2007, ONCOGENE, V26, P158, DOI 10.1038/sj.onc.1209758
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Pagès F, 2020, ANN ONCOL, V31, P921, DOI 10.1016/j.annonc.2020.03.310
   Pagès F, 2018, LANCET, V391, P2128, DOI 10.1016/S0140-6736(18)30789-X
   Pan JH, 2018, CANCER MANAG RES, V10, P2289, DOI 10.2147/CMAR.S170105
   Parseghian CM, 2019, CLIN CANCER RES, V25, P6899, DOI 10.1158/1078-0432.CCR-19-0823
   Peti W, 2013, PROTEIN SCI, V22, P1698, DOI 10.1002/pro.2374
   Petrelli F, 2017, JAMA ONCOL, V3, P211, DOI 10.1001/jamaoncol.2016.4227
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Pritchard CC, 2011, GUT, V60, P116, DOI 10.1136/gut.2009.206250
   Rebersek M, 2020, RADIOL ONCOL, V54, P272, DOI 10.2478/raon-2020-0031
   Reichling C, 2020, GUT, V69, P681, DOI 10.1136/gutjnl-2019-319292
   Sahin IH, 2013, J CANCER, V4, P320, DOI 10.7150/jca.3619
   Sanz-Garcia E, 2017, ANN ONCOL, V28, P2648, DOI 10.1093/annonc/mdx401
   Schirripa M, 2015, INT J CANCER, V136, P83, DOI 10.1002/ijc.28955
   Seligmann JF, 2016, JAMA ONCOL, V2, P633, DOI 10.1001/jamaoncol.2015.6065
   Seymour MT, 2013, LANCET ONCOL, V14, P749, DOI 10.1016/S1470-2045(13)70163-3
   Shen WD, 2014, CHINESE J CANCER RES, V26, P59, DOI 10.3978/j.issn.1000-9604.2014.01.10
   Shi ZQ, 2000, MOL CELL BIOL, V20, P1526, DOI 10.1128/MCB.20.5.1526-1536.2000
   Sinicrope FA, 2019, CLIN GASTROENTEROL H, V17, P391, DOI 10.1016/j.cgh.2018.06.038
   Stahler A, 2016, INT J CANCER, V138, P739, DOI 10.1002/ijc.29807
   Taieb J, 2018, JAMA ONCOL, V4, DOI 10.1001/jamaoncol.2017.3695
   Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272
   Takane K, 2017, CANCER MED-US, V6, P1023, DOI 10.1002/cam4.1061
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   van Brummelen EMJ, 2017, ONCOLOGIST, V22, P864, DOI 10.1634/theoncologist.2017-0031
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052
   Whiffin N, 2014, HUM MOL GENET, V23, P4729, DOI 10.1093/hmg/ddu177
   World Health Organization, 2022, CANC TOD
   Xue JY, 2020, NATURE, V577, P421, DOI 10.1038/s41586-019-1884-x
   Yaeger R, 2019, CLIN CANCER RES, V25, P7089, DOI 10.1158/1078-0432.CCR-19-2004
   Yaeger R, 2019, CANCER DISCOV, V9, P329, DOI 10.1158/2159-8290.CD-18-1321
   Yahagi M, 2016, J GASTROINTEST SURG, V20, P648, DOI 10.1007/s11605-015-3026-6
   Yang YC, 2018, CANCER MANAG RES, V10, P3911, DOI 10.2147/CMAR.S169649
   Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291
   Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001
   Yarden Y, 2001, EUR J CANCER, V37, pS3
   Yokota T, 2011, BRIT J CANCER, V104, P856, DOI 10.1038/bjc.2011.19
   Yoon HH, 2014, CLIN CANCER RES, V20, P3033, DOI 10.1158/1078-0432.CCR-13-3140
   Zarkavelis G, 2017, ANN GASTROENTEROL, V30, P613, DOI 10.20524/aog.2017.0191
NR 96
TC 31
Z9 31
U1 0
U2 13
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2021
VL 13
IS 9
AR 2201
DI 10.3390/cancers13092201
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA SB2VP
UT WOS:000649859000001
PM 34063682
OA Green Published
DA 2025-01-04
ER

PT J
AU Cao, HH
   Wang, Q
   Gao, ZY
   Yu, Z
   Wu, YG
   Lu, QC
AF Cao, Huihua
   Wang, Qing
   Gao, Zhenyan
   Yu, Zhan
   Wu, Yugang
   Lu, Qicheng
TI Programmed death-ligand 1 and survival in colorectal cancers: A
   meta-analysis
SO INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS
LA English
DT Article
DE Programmed death-ligand 1; PD-L1; colorectal cancer; prognosis; survival
ID TUMOR-INFILTRATING LYMPHOCYTES; PD-L1 EXPRESSION; B7-H1 EXPRESSION;
   PROGNOSTIC VALUE; RECTAL-CANCER; SAFETY; CELLS; RECURRENCE; MOLECULES;
   IMPACT
AB Background: Programmed death-ligand 1 (PD-L1) is a programmed death 1 (PD-1) ligand that plays a pivotal role in the inhibition of the T-cell-mediated immune response. The expression of PD-L1 is associated with the prognosis and clinical outcomes of multiple tumors. However, the prognostic value of PD-L1 overexpression in colorectal cancer is still controversial. In this study, we sought to clarify this by presenting a meta-analysis of relevant studies. Methods: Databases including PubMed, Web of Science, and EMBASE were systematically searched for studies concerning the expression of PD-L1 and survival in colorectal cancer. The reported hazard ratios (HR) with 95% confidence intervals (CI) of overall survival, disease-free survival, and recurrence-free survival in the included studies were analyzed by fixed effects/random effects models. Results: Fifteen studies involving 3078 patients with colorectal cancer were included in our meta-analysis. Overexpression of PD-L1 was found to be associated with poor overall survival (HR 1.83; 95% CI 1.21, 2.79; P = 0.005) and poor recurrence-free survival (HR 2.78; 95% CI 1.43, 5.42; P = 0.003). However, no correlation was found between PD-L1 overexpression and poor disease-free survival (HR 1.23; 95% CI 0.83, 1.82; P = 0.305). Overexpression of PD-L1 indicating poor survival held true across different geographical areas, sample sizes, analysis types, sources of HRs, and cell types. Conclusion: Overexpression of PD-L1 is associated with worse prognosis in patients with colorectal cancer and can guide physicians in the application of PD-1/PD-L1 immune checkpoint-targeted therapy.
C1 [Cao, Huihua; Wang, Qing; Gao, Zhenyan; Yu, Zhan; Wu, Yugang; Lu, Qicheng] Soochow Univ, Dept Gen Surg, Affiliated Hosp 3, 185 Juqian St, Changzhou 213000, Jiangsu, Peoples R China.
   [Cao, Huihua; Wang, Qing; Gao, Zhenyan; Yu, Zhan; Wu, Yugang; Lu, Qicheng] First Peoples Hosp Changzhou, 185 Juqian St, Changzhou 213000, Jiangsu, Peoples R China.
C3 Soochow University - China
RP Wu, YG; Lu, QC (corresponding author), Soochow Univ, Dept Gen Surg, Affiliated Hosp 3, 185 Juqian St, Changzhou 213000, Jiangsu, Peoples R China.; Wu, YG; Lu, QC (corresponding author), First Peoples Hosp Changzhou, 185 Juqian St, Changzhou 213000, Jiangsu, Peoples R China.
EM czyywyg89@163.com; czyyluqicheng123@163.com
RI Zhang, Jiaqi/JCO-6818-2023; gao, zhenguo/K-3038-2019
FU Changzhou Municipal Scientific Research grant [CE20125020]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: The
   present study was supported by the Changzhou Municipal Scientific
   Research grant (grant no. CE20125020).
CR Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Chen LP, 2013, NAT REV IMMUNOL, V13, P227, DOI 10.1038/nri3405
   Chen LJ, 2014, INT J CLIN EXP PATHO, V7, P6015
   Chen Xiao-Ling, 2009, Ai Zheng, V28, P1328
   Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015
   Gao Q, 2009, CLIN CANCER RES, V15, P971, DOI 10.1158/1078-0432.CCR-08-1608
   Geng YT, 2015, INT J CLIN ONCOL, V20, P273, DOI 10.1007/s10147-014-0701-7
   Goltz D, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2016.1257454
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Hino R, 2010, CANCER-AM CANCER SOC, V116, P1757, DOI 10.1002/cncr.24899
   Hou JY, 2014, EXP MOL PATHOL, V96, P284, DOI 10.1016/j.yexmp.2014.03.005
   Huang RY, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000010446
   Koganemaru S, 2017, CANCER SCI, V108, P853, DOI 10.1111/cas.13229
   Konishi J, 2004, CLIN CANCER RES, V10, P5094, DOI 10.1158/1078-0432.CCR-04-0428
   Lee LH, 2016, MODERN PATHOL, V29, P1433, DOI 10.1038/modpathol.2016.139
   Lee SJ, 2018, J CANCER RES CLIN, V144, P1005, DOI 10.1007/s00432-018-2620-x
   Li YQ, 2016, MOL CANCER, V15, DOI 10.1186/s12943-016-0539-x
   Liang M, 2014, TUMOR BIOL, V35, P55, DOI 10.1007/s13277-013-1006-6
   LIU R, 2018, BIOMED RES INT, V2018
   Mahoney KM, 2015, CLIN THER, V37, P764, DOI 10.1016/j.clinthera.2015.02.018
   Mu CY, 2011, MED ONCOL, V28, P682, DOI 10.1007/s12032-010-9515-2
   Narayanan S, 2018, ANN SURG ONCOL, V25, P2323, DOI 10.1245/s10434-018-6506-6
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Oliphant R, 2013, ANN SURG ONCOL, V20, P2132, DOI 10.1245/s10434-013-2959-9
   Page DB, 2014, ANNU REV MED, V65, P185, DOI 10.1146/annurev-med-092012-112807
   Parmar MKB, 1998, STAT MED, V17, P2815, DOI 10.1002/(SICI)1097-0258(19981230)17:24<2815::AID-SIM110>3.0.CO;2-8
   Passardi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061324
   Qing Y, 2015, DRUG DES DEV THER, V9, P901, DOI 10.2147/DDDT.S75152
   Saigusa S, 2016, INT J CLIN ONCOL, V21, P946, DOI 10.1007/s10147-016-0962-4
   Satelli A, 2016, SCI REP-UK, V6, DOI 10.1038/srep28910
   Shao LD, 2017, CANCER MANAG RES, V9, P249, DOI 10.2147/CMAR.S139889
   Shi SJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076012
   Stang A, 2010, EUR J EPIDEMIOL, V25, P603, DOI 10.1007/s10654-010-9491-z
   Taube JM, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003689
   Topalian SL, 2014, J CLIN ONCOL, V32, P1020, DOI 10.1200/JCO.2013.53.0105
   Wang LS, 2018, HUM PATHOL, V71, P20, DOI 10.1016/j.humpath.2017.07.014
   Wang LS, 2016, MOL DIAGN THER, V20, P175, DOI 10.1007/s40291-016-0188-1
   Wang X, 2016, ONCOTARGETS THER, V9, P5023, DOI 10.2147/OTT.S105862
   Wu CP, 2006, ACTA HISTOCHEM, V108, P19, DOI 10.1016/j.acthis.2006.01.003
   Wu P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0131403
   Yang CY, 2016, EUR J CANCER, V57, P91, DOI 10.1016/j.ejca.2015.12.033
   Yang CY, 2014, EUR J CANCER, V50, P1361, DOI 10.1016/j.ejca.2014.01.018
   Yu Z, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0188139
   Zhu HL, 2015, INT J CLIN EXP PATHO, V8, P9351
   Zhu JJ, 2014, HUM IMMUNOL, V75, P348, DOI 10.1016/j.humimm.2014.01.006
NR 46
TC 8
Z9 8
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0393-6155
EI 1724-6008
J9 INT J BIOL MARKER
JI Int. J. Biol. Markers
PD DEC
PY 2019
VL 34
IS 4
BP 356
EP 363
DI 10.1177/1724600819876952
PG 8
WC Biotechnology & Applied Microbiology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Oncology
GA JW2BN
UT WOS:000502863300004
PM 31564188
OA gold
DA 2025-01-04
ER

PT J
AU Mulla, N
   Alshareef, A
   Syed, AR
   Al-Jahel, M
AF Mulla, Nasser
   Alshareef, Abdulraheem
   Syed, Abdul Rahman
   Al-Jahel, Majid
TI Clinico-Pathological Study of K-ras Mutations in Colorectal Tumors: A
   Single-Center Retrospective Study of 51 Patients in Madinah, Saudi
   Arabia
SO CUREUS JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE colorectal cancer; crc; k-ras mutations; madinah; saudi arabia
ID CANCER; CETUXIMAB; EGFR
AB Background
   Colorectal cancer (CRC) is one of the leading types of cancer worldwide and in Saudi Arabia. At the molecular level, CRC is very complicated and requires establishing comprehensive patient stratification models through identification of patients who will benefit or will not benefit from targeted therapy. We retrospectively investigated and analyzed the frequency of Kirsten-ras (K-ras) mutation and its correlation with patients' characteristics as weel as its association with clinicopathological features (i.e age, gender, clinical stage, anatomical site, histological subtype, degree of histological differentiation and metastatic site) in patients with CRC.
   Methods
   Medical records and paraffin-embedded tumor samples from 51 patients with histologically proven colorectal adenocarcinoma referred to Madinah center in Saudi Arabia were analyzed for the occurrence of rat sarcoma virus (RAS) mutations.
   Results
   RAS mutations occurred in 43% of the patients; 91% of these mutations were in K-ras. Seventy-five percent of these K-ras mutations were in codon 12, most commonly p.G12D. Codon 13 mutations occurred in 20% of tumors: all of these were p.G13D (100%). The percentage of K-ras mutations occurrence was higher in young patients (<= 50) compared with the older patients (>50) (54.5% and 35%, respectively). Similarly, the percentage of K-ras mutations occurrence was higher in the right-sided tumors compared with the left-sided tumors (57.1% and 32.4%, respectively). Patients' characteristics and clinicopathological features were not significantly associated with K-ras mutations.
   Conclusions
   K-ras mutations are common among Saudi patients diagnosed with CRC in Madinah, especially pG12V and pG12D in codon 12. Further investigation would be required to establish correlation of K-ras mutations in larger cohorts.
C1 [Mulla, Nasser] Taibah Univ, Dept Internal Med, Coll Med, Madinah, Saudi Arabia.
   [Alshareef, Abdulraheem] Taibah Univ, Dept Med Labs Technol, Coll Med, Madinah, Saudi Arabia.
   [Syed, Abdul Rahman] King Fahad Hosp, Dept Pathol, Minist Hlth, Madinah, Saudi Arabia.
   [Al-Jahel, Majid] King Fahad Hosp, Dept Oncol, Minist Hlth, Madinah, Saudi Arabia.
C3 Taibah University; Taibah University
RP Mulla, N (corresponding author), Taibah Univ, Dept Internal Med, Coll Med, Madinah, Saudi Arabia.
EM dr_nasser_m@hotmail.com
CR Abulkair O, 2016, PAJO, V9, P12
   Ahmed M, 2020, GASTROENTEROL RES, V13, P1, DOI 10.14740/gr1239
   Al-Zahrani W, 2018, CANC INCIDENCE REPOR
   ALZAHRANI W, 2019, CANC INCIDENCE REPOR
   Arrington AK, 2012, INT J MOL SCI, V13, P12153, DOI 10.3390/ijms131012153
   Aziz MA, 2018, SAUDI J GASTROENTERO, V24, P196, DOI 10.4103/sjg.SJG_164_18
   Bader T, 2014, ALEX J MED, V50, P203, DOI 10.1016/j.ajme.2014.01.003
   Bresler SC, 2014, CANCER CELL, V26, P682, DOI 10.1016/j.ccell.2014.09.019
   Dinu D, 2014, J Med Life, V7, P581
   Domingo E, 2013, J PATHOL, V229, P441, DOI 10.1002/path.4139
   Fernandes E, 2020, THERANOSTICS, V10, P4903, DOI 10.7150/thno.42480
   Ibrahim EM, 2010, INT J COLORECTAL DIS, V25, P713, DOI 10.1007/s00384-010-0927-4
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kishiki T, 2014, ONCOL REP, V32, P57, DOI 10.3892/or.2014.3179
   Kudryavtseva AV, 2016, ONCOTARGET, V7, P53959, DOI 10.18632/oncotarget.9796
   Li ZN, 2020, GASTROENTEROL REP, V8, P192, DOI 10.1093/gastro/goaa022
   O'Bryan JP, 2019, PHARMACOL RES, V139, P503, DOI 10.1016/j.phrs.2018.10.021
   Powell B, 2000, CLIN CANCER RES, V6, P443
   Seo Y, 2014, ONCOL REP, V31, P2115, DOI 10.3892/or.2014.3077
   Shen H, 2011, WORLD J GASTROENTERO, V17, P809, DOI 10.3748/wjg.v17.i6.809
   Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Zahrani A, 2014, TUMORI, V100, P75, DOI 10.1700/1430.15819
   Zalis MG, 2009, J CLIN ONCOL, V27
   Zekri J, 2017, GENET MOL RES, V16, DOI 10.4238/gmr16019369
   Zekri J., 2012, Open Colorectal Cancer J, V5, P22, DOI [10.2174/1876820201205010022, DOI 10.2174/1876820201205010022]
NR 26
TC 6
Z9 6
U1 0
U2 2
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2168-8184
J9 CUREUS J MED SCIENCE
JI Cureus J Med Sci
PD AUG 24
PY 2020
VL 12
IS 8
AR e9978
DI 10.7759/cureus.9978
PG 9
WC Medicine, General & Internal
WE Emerging Sources Citation Index (ESCI)
SC General & Internal Medicine
GA ND6KL
UT WOS:000562011600001
PM 32983680
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Sardou, HS
   Nazari, SE
   Abbaspour, M
   Akhgari, A
   Sheikh, A
   Kesharwani, P
   Sahebkar, A
AF Sardou, Hossein Shahdadi
   Nazari, Seyedeh Elnaz
   Abbaspour, Mohammadreza
   Akhgari, Abbas
   Sheikh, Afsana
   Kesharwani, Prashant
   Sahebkar, Amirhossein
TI Nano-curcumin formulations for targeted therapy of colorectal cancer
SO JOURNAL OF DRUG DELIVERY SCIENCE AND TECHNOLOGY
LA English
DT Review
DE Colorectal cancer; Curcumin; Colon delivery; Nano -formulations;
   Chemotherapy drugs; Side effect
ID DRUG-DELIVERY-SYSTEMS; COLON-CANCER; IN-VITRO; ANTICANCER EFFICACY; GOLD
   NANOPARTICLES; FUMONISIN B1; TUMOR-GROWTH; NANOCARRIERS; RELEASE; PH
AB Colorectal cancer (CRC) is the third most common cause of cancer death in men and women. Chemotherapeutic drugs such as 5-fluorouracil (5-FU), irinotecan, and oxaliplatin are widely used to treat the growth and prolif-eration of cancer cells. However, these agents lead to unwanted side effects in the patients. Anti-cancer herbal drugs could be used to overcome such major roadblocks and minimize the adverse effects. Curcumin (CUR), a yellow polyphenolic pigment, is derived from the rhizome of turmeric (Curcuma longa L.). Many studies have shown that CUR could regulate inflammatory pathways, angiogenesis, and metastasis in cancer development. CUR intake is restricted due to significant drawbacks like poor water solubility, chemical instability, low bioavailability, and rapid metabolism, which is an important obstacle to its effectiveness. Therefore, specific attention has been paid to delivery systems based on CUR nano-formulations to overcome such hurdles. In the current review, we have highlighted the colonic delivery aspects along with the strategical approach of using nano-formulations for CRC therapy.
C1 [Sardou, Hossein Shahdadi; Abbaspour, Mohammadreza; Akhgari, Abbas] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Targeted Drug Delivery Res Ctr, Mashhad, Iran.
   [Sardou, Hossein Shahdadi; Abbaspour, Mohammadreza; Akhgari, Abbas] Mashhad Univ Med Sci, Sch Pharm, Dept Pharmaceut, Mashhad, Iran.
   [Nazari, Seyedeh Elnaz] Mashhad Univ Med Sci, Fac Med, Dept Med Physiol, Mashhad, Iran.
   [Sheikh, Afsana; Kesharwani, Prashant] Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.
   [Kesharwani, Prashant] Saveetha Univ, Saveetha Med Coll & Hosp, Saveetha Inst Med & Tech Sci, Ctr Global Hlth Res, Chennai, India.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran.
   [Sahebkar, Amirhossein] Mashhad Univ Med Sci, Appl Biomed Res Ctr, Mashhad, Iran.
C3 Mashhad University of Medical Sciences; Mashhad University of Medical
   Sciences; Mashhad University of Medical Sciences; Jamia Hamdard
   University; Saveetha Institute of Medical & Technical Science; Saveetha
   Medical College & Hospital; Mashhad University of Medical Sciences;
   Mashhad University of Medical Sciences
RP Kesharwani, P (corresponding author), Jamia Hamdard, Sch Pharmaceut Educ & Res, Dept Pharmaceut, New Delhi 110062, India.; Sahebkar, A (corresponding author), Mashhad Univ Med Sci, Pharmaceut Technol Inst, Biotechnol Res Ctr, Mashhad, Iran.
EM prashantdops@gmail.com; amir_saheb2000@yahoo.com
RI Sahebkar, Amirhossein/B-5124-2018; Abbaspour, Mohammadreza/A-9817-2009
OI Shahdadi Sardou, Hossein/0000-0003-3874-3048; Abbaspour,
   Mohammadreza/0000-0002-5490-8052
CR Abbasi M, 2023, INT J BIOL MACROMOL, V233, DOI 10.1016/j.ijbiomac.2023.123585
   Abd-Elsatar AG, 2019, PROG BIOMATER, V8, P101, DOI 10.1007/s40204-019-0115-8
   Afshari A.R., 2022, SEMIN CANCER BIOL
   Agarwal A, 2018, NUTR RES, V51, P67, DOI 10.1016/j.nutres.2017.12.011
   Agarwala VK, Polysaccharide: Carrier in Colon Targeted Drug Delivery System
   Ahmadi A, 2022, PHARMACOL RES, V184, DOI 10.1016/j.phrs.2022.106414
   Akbari B, 2022, BIOFACTORS, V48, P611, DOI 10.1002/biof.1831
   Akhgari A, 2023, J PHARM INNOV, V18, P861, DOI 10.1007/s12247-022-09685-3
   Akhgari A, 2013, JUNDISHAPUR J NAT PH, V8, P81, DOI 10.17795/jjnpp-8350
   Akhtar S, 2022, ARAB J CHEM, V15, DOI 10.1016/j.arabjc.2021.103594
   Akinyemiju T, 2022, FRONT PUBLIC HEALTH, V10, DOI 10.3389/fpubh.2022.884678
   Akl MA, 2016, J DRUG DELIV SCI TEC, V32, P10, DOI 10.1016/j.jddst.2016.01.007
   Al-Ani LA, 2020, HELIYON, V6, DOI 10.1016/j.heliyon.2020.e05360
   Alamdari SG, 2022, J CONTROL RELEASE, V349, P269, DOI 10.1016/j.jconrel.2022.06.050
   Alibolandi M, 2018, INT J PHARMACEUT, V549, P67, DOI 10.1016/j.ijpharm.2018.07.052
   Alizadeh AM, 2012, EUR J PHARMACOL, V689, P226, DOI 10.1016/j.ejphar.2012.06.016
   Aljabali A.A., 2021, Handbook of Nanocelluloses: Classification, Properties, Fabrication, and Emerging Applications, P1, DOI DOI 10.1007/978-3-030-62976-2_36-1
   Allen J, 2022, MICROBIOL SPECTR, V10, DOI 10.1128/spectrum.01055-22
   Almeida A, 2022, J CONTROL RELEASE, V349, P731, DOI 10.1016/j.jconrel.2022.07.029
   Anitha A, 2014, EUR J PHARM BIOPHARM, V88, P238, DOI 10.1016/j.ejpb.2014.04.017
   Araghi M, 2019, INT J CANCER, V144, P2992, DOI 10.1002/ijc.32055
   Arévalo-Pérez R, 2020, J CONTROL RELEASE, V327, P703, DOI 10.1016/j.jconrel.2020.09.026
   Asgharian P, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935-022-02677-w
   Ataei M, 2023, CURR MED CHEM, V30, P286, DOI 10.2174/0929867329666220322110348
   Auría-Soro C, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9101365
   Awad A, 2022, ADV DRUG DELIVER REV, V181, DOI 10.1016/j.addr.2021.114076
   Ayatollahi M, 2018, COLLOID INTERFAC SCI, V24, P45, DOI 10.1016/j.colcom.2018.03.006
   Balahura LR, 2020, J IMMUNOL RES, V2020, DOI 10.1155/2020/2549763
   Banerjee A, 2017, DRUG DISCOV TODAY, V22, P1224, DOI 10.1016/j.drudis.2017.05.006
   Bassetti M, 2021, LANCET INFECT DIS, V21, P226, DOI 10.1016/S1473-3099(20)30796-9
   Batool S, 2023, DRUG DELIV, V30, DOI 10.1080/10717544.2023.2183815
   Bayón-Cordero L, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9030474
   Bhattacharya S, 2023, NANOMEDICINE-UK, V18, P713, DOI 10.2217/nnm-2022-0240
   Borah PK, 2020, J COLLOID INTERF SCI, V580, P561, DOI 10.1016/j.jcis.2020.07.056
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brenner H, 2018, BRIT J CANCER, V119, P785, DOI 10.1038/s41416-018-0264-x
   Cao LY, 2019, J FOOD BIOCHEM, V43, DOI 10.1111/jfbc.12836
   Carlsen L., 2006, Oncotarget, V12
   Chandrakala V, 2022, EMERGENT MATER, V5, P1593, DOI 10.1007/s42247-021-00335-x
   Chaurasia S, 2015, CARBOHYD POLYM, V130, P9, DOI 10.1016/j.carbpol.2015.04.062
   Chen MM, 2021, CARBOHYD POLYM, V265, DOI 10.1016/j.carbpol.2021.118077
   Chen TY, 2021, CELL BIOL INT, V45, P976, DOI 10.1002/cbin.11541
   Chourasia MK, 2004, DRUG DELIV, V11, P129, DOI 10.1080/10717540490280778
   Cianfruglia L, 2019, ANTIOXIDANTS-BASEL, V8, DOI 10.3390/antiox8090382
   Curry T, 2014, CONTRAST MEDIA MOL I, V9, P53, DOI 10.1002/cmmi.1563
   Dang Yu, 2020, Smart Mater Med, V1, P10, DOI 10.1016/j.smaim.2020.04.001
   Danhier F, 2010, J CONTROL RELEASE, V148, P135, DOI 10.1016/j.jconrel.2010.08.027
   Davidson BA, 2018, HUM MUTAT, V39, P1739, DOI 10.1002/humu.23611
   De ANDT, 2023, EXPERT OPIN DRUG DEL, V20, P75, DOI 10.1080/17425247.2023.2153832
   De Chiara L., 2022, Foundations of Colorectal Cancer, P45
   de Freitas CF, 2020, MAT SCI ENG C-MATER, V112, DOI 10.1016/j.msec.2020.110853
   De R, 2022, ADV SCI, V9, DOI 10.1002/advs.202105373
   Decker KM, 2021, JAMA NETW OPEN, V4, DOI 10.1001/jamanetworkopen.2021.17556
   Deng Z., 2022, Front. Pharmacol., V13
   Desai N, 2020, DRUG DELIV TRANSL RE, V10, P1288, DOI 10.1007/s13346-020-00756-x
   Dou Y, 2020, J CONTROL RELEASE, V327, P641, DOI 10.1016/j.jconrel.2020.09.008
   Ebrahimi M, 2021, INT J PHARMACEUT, V601, DOI 10.1016/j.ijpharm.2021.120592
   Elbaz NM, 2021, FOOD HYDROCOLLOID, V121, DOI 10.1016/j.foodhyd.2021.107005
   Enayati A, 2022, BIOMED PHARMACOTHER, V146, DOI 10.1016/j.biopha.2021.112242
   Esmaeili Y, 2022, INT J BIOL MACROMOL, V202, P241, DOI 10.1016/j.ijbiomac.2022.01.063
   Fabianowska-Majewska K, 2021, NUTRIENTS, V13, DOI 10.3390/nu13020332
   Farooqi AA, 2022, SEMIN CELL DEV BIOL, V124, P72, DOI 10.1016/j.semcdb.2021.04.002
   Fernández-Lázaro D, 2020, NUTRIENTS, V12, DOI 10.3390/nu12020501
   Fischer J, 2019, ANZ J SURG, V89, P1224, DOI 10.1111/ans.15074
   Flora G, 2013, CRIT REV THER DRUG, V30, P331, DOI 10.1615/CritRevTherDrugCarrierSyst.2013007236
   Garvey WT, 2022, ENDOCR PRACT, V28, P214, DOI 10.1016/j.eprac.2021.11.082
   Ghasemi F, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152556
   Ghasemi F, 2019, NEUROTOX RES, V36, P12, DOI 10.1007/s12640-019-00030-0
   Gielecinska A, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12070986
   Goel A, 2008, BIOCHEM PHARMACOL, V75, P787, DOI 10.1016/j.bcp.2007.08.016
   Goel Surya, 2019, Recent Pat Drug Deliv Formul, V13, P91, DOI 10.2174/1872211313666190614151615
   Goradel NH, 2018, J CELL PHYSIOL, V233, P2902, DOI 10.1002/jcp.26029
   Goyanes A, 2015, INT J PHARMACEUT, V484, P103, DOI 10.1016/j.ijpharm.2015.02.051
   Guo Y, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951-022-01586-4
   Habib SM, 2020, INT J PHARMACEUT, V590, DOI 10.1016/j.ijpharm.2020.119897
   Hadji H, 2022, ADV DRUG DELIVER REV, V181, DOI 10.1016/j.addr.2021.114101
   Hamzehzadeh L, 2018, J CELL PHYSIOL, V233, P6530, DOI 10.1002/jcp.26620
   Hari SK, 2023, DRUG DELIV TRANSL RE, V13, P135, DOI 10.1007/s13346-022-01197-4
   Hasankhan S, 2020, INT J BIOL MACROMOL, V163, P1538, DOI 10.1016/j.ijbiomac.2020.08.045
   Hasanzadeh S, 2020, PHARMACOL RES, V159, DOI 10.1016/j.phrs.2020.104921
   Heidari H, 2023, PHYTOTHER RES, V37, P1462, DOI 10.1002/ptr.7737
   Heidari Z, 2022, PHYTOTHER RES, V36, P1442, DOI 10.1002/ptr.7350
   Hekmatimoghaddam S, 2019, J NEUROIMMUNOL, V326, P79, DOI 10.1016/j.jneuroim.2018.11.011
   Herdiana Y, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2021.e08674
   Hong Y, 2019, BIOMED PHARMACOTHER, V114, DOI 10.1016/j.biopha.2019.108764
   Huang XL, 2021, INT J BIOL MACROMOL, V180, P739, DOI 10.1016/j.ijbiomac.2021.03.075
   Huang YZ, 2023, J CONTROL RELEASE, V353, P650, DOI 10.1016/j.jconrel.2022.12.003
   Ionescu C, 2022, MEDICINA-LITHUANIA, V58, DOI 10.3390/medicina58070903
   Iranpour S, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-01056-3
   Iranshahi M, 2010, PHYTOMEDICINE, V17, P269, DOI 10.1016/j.phymed.2009.05.020
   Jain AK, 2019, ARTIF CELL NANOMED B, V47, P524, DOI 10.1080/21691401.2018.1561457
   Jain KK, 2020, METHODS MOL BIOL, V2059, P1, DOI 10.1007/978-1-4939-9798-5_1
   Jash A, 2021, J MATER CHEM B, V9, P4773, DOI 10.1039/d1tb00126d
   Jayaprakasha GK, 2016, EUR J PHARMACOL, V789, P291, DOI 10.1016/j.ejphar.2016.07.017
   Jebali A, 2015, COLLOID SURFACE B, V126, P437, DOI 10.1016/j.colsurfb.2014.12.047
   Jia F, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00981-7
   Kaffash E, 2019, J DRUG DELIV SCI TEC, V52, P177, DOI 10.1016/j.jddst.2019.04.006
   Kanwal T, 2019, J MOL LIQ, V289, DOI 10.1016/j.molliq.2019.111098
   Kashkooli FM, 2020, J CONTROL RELEASE, V327, P316, DOI 10.1016/j.jconrel.2020.08.012
   Katouzian I, 2016, TRENDS FOOD SCI TECH, V53, P34, DOI 10.1016/j.tifs.2016.05.002
   Kaushik N, 2022, J NANOBIOTECHNOL, V20, DOI 10.1186/s12951-022-01364-2
   Keihanian F, 2018, J CELL PHYSIOL, V233, P4497, DOI 10.1002/jcp.26249
   Khayatan D., 2022, Biomed. Pharmacother., P154
   Kotla NG, 2019, ADV DRUG DELIVER REV, V146, P248, DOI 10.1016/j.addr.2018.06.021
   Kunnumakkara AB, 2023, ACS PHARMACOL TRANSL, V6, P447, DOI 10.1021/acsptsci.2c00012
   Le TT, 2019, MAT SCI ENG C-MATER, V101, P464, DOI 10.1016/j.msec.2019.03.100
   Li N, 2018, DRUG DEV IND PHARM, V44, P1966, DOI 10.1080/03639045.2018.1505904
   Li SY, 2022, DRUG DELIV, V29, P1142, DOI 10.1080/10717544.2022.2058646
   Li Y., 2022, Oncol. Rep., V48
   Li YJ, 2022, PHARMACOL RES, V176, DOI 10.1016/j.phrs.2022.106080
   Li ZY, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-00792-w
   Liang Y, 2020, PHARMACOL RES, V161, DOI 10.1016/j.phrs.2020.105164
   Lohiya N, 2019, Nanomed. Nanotechnol. J, P1
   Ma ZY, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14020434
   Malla M, 2022, J CLIN ONCOL, V40, P2846, DOI 10.1200/JCO.21.02615
   Manju S, 2012, J COLLOID INTERF SCI, V368, P144, DOI 10.1016/j.jcis.2011.11.024
   Mansouri K, 2020, BMC CANCER, V20, DOI 10.1186/s12885-020-07256-8
   Pontes-Quero GM, 2021, MAT SCI ENG C-MATER, V121, DOI 10.1016/j.msec.2020.111793
   Marjaneh RM, 2018, J CELL PHYSIOL, V233, P6785, DOI 10.1002/jcp.26538
   Marynczak K, 2022, J CLIN MED, V11, DOI 10.3390/jcm11030866
   Matos AI, 2019, J CONTROL RELEASE, V307, P108, DOI 10.1016/j.jconrel.2019.06.017
   Mbese Z, 2019, MOLECULES, V24, DOI 10.3390/molecules24234386
   McClelland PHT, 2022, CLIN COLORECTAL CANC, V21, pE135, DOI 10.1016/j.clcc.2021.11.003
   Mir R.H., 2022, Stud. Nat. Prod. Chem, V73, P405, DOI DOI 10.1016/B978-0-323-91097-2.00010-8
   Mirzaei S, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02406-1
   Misra K., 2017, Comparative in Silico
   Moghimipour E, 2018, J DRUG DELIV SCI TEC, V43, P50, DOI 10.1016/j.jddst.2017.09.010
   Mohajeri M, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104765
   Mohajeri M, 2018, CRIT REV ONCOL HEMAT, V122, P30, DOI 10.1016/j.critrevonc.2017.12.005
   Mohamed JM, 2021, CARBOHYD POLYM, V252, DOI 10.1016/j.carbpol.2020.117180
   Mohammed ES, 2021, ARCH MED SCI, V17, P218, DOI 10.5114/aoms.2020.93739
   Mohanty C, 2010, BIOMATERIALS, V31, P6597, DOI 10.1016/j.biomaterials.2010.04.062
   Mokhtari-Zaer A, 2019, J CELL PHYSIOL, V234, P214, DOI 10.1002/jcp.26848
   Naeem M, 2020, ARCH PHARM RES, V43, P153, DOI 10.1007/s12272-020-01219-0
   Naeem M, 2018, NANOMED-NANOTECHNOL, V14, P823, DOI 10.1016/j.nano.2018.01.003
   Naeini MB, 2019, J CELL PHYSIOL, V234, P14743, DOI 10.1002/jcp.28262
   Nahler G, 2022, PHARM MED, V36, P99, DOI 10.1007/s40290-022-00420-4
   Nakamura Y, 2016, BIOCONJUGATE CHEM, V27, P2225, DOI 10.1021/acs.bioconjchem.6b00437
   Pan K, 2018, FOOD CHEM, V246, P82, DOI 10.1016/j.foodchem.2017.11.002
   Pan X, 2021, J NANOBIOTECHNOL, V19, DOI 10.1186/s12951-021-01069-y
   Panahi Y, 2017, COMPLEMENT THER MED, V33, P1, DOI 10.1016/j.ctim.2017.05.006
   Pang XC, 2019, PHARMACOL RES, V144, P235, DOI 10.1016/j.phrs.2019.04.030
   Parsamanesh N, 2018, PHARMACOL RES, V136, P181, DOI 10.1016/j.phrs.2018.09.012
   Patel BB, 2009, NUTR CANCER, V61, P842, DOI 10.1080/01635580903285106
   Pathak Y.V., 2019, Surface modification of nanoparticles for targeted drug delivery
   Patra JK, 2018, J NANOBIOTECHNOL, V16, DOI 10.1186/s12951-018-0392-8
   Ng PQ, 2020, CURR PHARM DESIGN, V26, P4580, DOI 10.2174/1381612826666200610111013
   Pouton CW, 2006, EUR J PHARM SCI, V29, P278, DOI 10.1016/j.ejps.2006.04.016
   Prasanth V.V., 2012, J. Appl. Pharm. Sci, P163
   Priyadarsini KI, 2013, CURR PHARM DESIGN, V19, P2093
   Qiao X, 2021, CHIN J NAT MEDICINES, V19, P545, DOI 10.1016/S1875-5364(21)60055-9
   Rajwar TK, 2023, J DRUG TARGET, V31, P354, DOI 10.1080/1061186X.2022.2164290
   Rao KM, 2015, INT J PHARMACEUT, V478, P788, DOI 10.1016/j.ijpharm.2014.12.001
   Ray L, 2017, BIOACT MATER, V2, P82, DOI 10.1016/j.bioactmat.2017.02.003
   Rommasi F, 2021, NANOSCALE RES LETT, V16, DOI 10.1186/s11671-021-03553-8
   Sabouni N, 2023, J DRUG TARGET, V31, P243, DOI 10.1080/1061186X.2022.2141755
   Sabra R, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118775
   Sadeghi-Abandansari H, 2021, EUR POLYM J, V157, DOI 10.1016/j.eurpolymj.2021.110646
   Sahebkar A, 2010, FERTIL STERIL, V94, pE75, DOI 10.1016/j.fertnstert.2010.07.1071
   Sánchez-López E, 2019, NANOMATERIALS-BASEL, V9, DOI 10.3390/nano9060821
   Sardo HS, 2019, INT J PHARMACEUT, V558, P367, DOI 10.1016/j.ijpharm.2019.01.022
   Sardou HS, 2023, INFLAMMOPHARMACOLOGY, V31, P1095, DOI 10.1007/s10787-023-01140-0
   Sardou HS, 2022, EUR J PHARM SCI, V168, DOI 10.1016/j.ejps.2021.106072
   Sardou HS, 2021, INT J PHARMACEUT, V597, DOI 10.1016/j.ijpharm.2021.120347
   Sardou HS, 2020, COLLOID SURFACE B, V185, DOI 10.1016/j.colsurfb.2019.110619
   Sardou HS, 2019, INT J PHARMACEUT, V568, DOI 10.1016/j.ijpharm.2019.118527
   Sarfraz M, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14091909
   Sauraj, 2020, MAT SCI ENG C-MATER, V107, DOI 10.1016/j.msec.2019.110356
   Scholz OA, 2008, DRUG DISCOV TODAY, V13, P247, DOI 10.1016/j.drudis.2007.10.018
   Seok HY, 2018, J CONTROL RELEASE, V280, P20, DOI 10.1016/j.jconrel.2018.04.050
   Sesarman A, 2018, PHARMACOL REP, V70, P331, DOI 10.1016/j.pharep.2017.10.004
   Shahiwala AF, 2023, CURR DRUG TARGETS, V24, P521, DOI 10.2174/1389450124666230314110800
   Shakeri F, 2022, CURR MED CHEM, V29, P2878, DOI 10.2174/0929867329666220210145033
   Sharma Shailja, 2020, Journal of Drug Delivery and Therapeutics, V10, P86, DOI 10.22270/jddt.v10i3-s.4092
   Shaukat A, 2021, AM J GASTROENTEROL, V116, P458, DOI 10.14309/ajg.0000000000001122
   Shetty NP, 2021, PHYTOTHER RES, V35, P5397, DOI 10.1002/ptr.7158
   Shinji S, 2022, J NIPPON MED SCH, V89, P246, DOI 10.1272/jnms.JNMS.2022_89-310
   Singh AK, 2018, INFLAMM RES, V67, P633, DOI 10.1007/s00011-018-1156-5
   Singh SP, 2015, INT J BIOL MACROMOL, V74, P162, DOI 10.1016/j.ijbiomac.2014.11.037
   Slika L, 2020, MAT SCI ENG C-MATER, V109, DOI 10.1016/j.msec.2019.110550
   Soleimani V, 2018, PHYTOTHER RES, V32, P985, DOI 10.1002/ptr.6054
   Soliman WE, 2021, POLYMERS-BASEL, V13, DOI 10.3390/polym13040577
   Soltani S, 2021, PHYTOTHER RES, V35, P2854, DOI 10.1002/ptr.6991
   Somadder PD, 2023, COMPUT BIOL MED, V155, DOI 10.1016/j.compbiomed.2023.106630
   Somade Oluwatobi T, 2019, Pathophysiology, V26, P305, DOI 10.1016/j.pathophys.2019.07.005
   Song LJ, 2019, ASIAN J PHARM SCI, V14, P413, DOI 10.1016/j.ajps.2018.05.012
   Sorasitthiyanukarn FN, 2019, J DRUG DELIV SCI TEC, V53, DOI 10.1016/j.jddst.2019.06.015
   Sufi SA, 2020, INT J PHARMACEUT, V588, DOI 10.1016/j.ijpharm.2020.119738
   Sultana F., 2013, J Appl Pharm Sci, V3, pS95, DOI DOI 10.7324/JAPS.2013.38.S15
   Sureban SM, 2011, J NANOBIOTECHNOL, V9, DOI 10.1186/1477-3155-9-40
   Tamane P, 2022, J DRUG DELIV SCI TEC, V68, DOI 10.1016/j.jddst.2022.103105
   Tandon P, 2011, CANCER RES, V71, P314, DOI 10.1158/0008-5472.CAN-10-2629
   Thakral S, 2013, EXPERT OPIN DRUG DEL, V10, P131, DOI 10.1517/17425247.2013.736962
   Thummarati P, 2021, J DRUG DELIV SCI TEC, V61, DOI 10.1016/j.jddst.2021.102323
   Tian MP, 2018, INT J BIOL MACROMOL, V120, P702, DOI 10.1016/j.ijbiomac.2018.08.146
   Tomeh MA, 2021, J COLLOID INTERF SCI, V594, P513, DOI 10.1016/j.jcis.2021.03.086
   Trigo-Gutierrez JK, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22137130
   Tsai MH, 2024, J CANCER SURVIV, V18, P541, DOI 10.1007/s11764-022-01258-0
   Vareed SK, 2008, CANCER EPIDEM BIOMAR, V17, P1411, DOI 10.1158/1055-9965.EPI-07-2693
   Varshosaz J, 2018, POLYM TEST, V65, P217, DOI 10.1016/j.polymertesting.2017.11.020
   Varthya SB, 2020, J FAM MED PRIM CARE, V9, P1272, DOI 10.4103/jfmpc.jfmpc_1218_19
   Vinayak M, 2018, NUTR CANCER, V70, P1199, DOI 10.1080/01635581.2018.1539187
   WalyEldeen AA, 2023, CHEM-BIOL INTERACT, V369, DOI 10.1016/j.cbi.2022.110297
   Wen YH, 2019, ENVIRON CHEM LETT, V17, P1539, DOI 10.1007/s10311-019-00895-9
   Wong KE, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00152
   Xie ZL, 2019, POULTRY SCI, V98, P422, DOI 10.3382/ps/pey315
   Xue JJ, 2019, CHEM REV, V119, P5298, DOI 10.1021/acs.chemrev.8b00593
   Yadav A.R., 2020, Res J Pharm Dosage Forms Technol, V12, P205, DOI [10.5958/0975-4377.2020.00035.X, DOI 10.5958/0975-4377.2020.00035.X]
   Yadav P, 2022, CHEM REC, V22, DOI 10.1002/tcr.202200152
   Yang L, 2022, ONCOL REP, V47, DOI 10.3892/or.2022.8293
   Yasini SA, 2015, COLLOID SURFACE B, V135, P518, DOI 10.1016/j.colsurfb.2015.08.005
   Yin LX, 2023, INT J CANCER, V152, P807, DOI 10.1002/ijc.34256
   Zadeh MHB, 2015, COLLOID SURFACE B, V134, P26, DOI 10.1016/j.colsurfb.2015.06.037
   Zaher S, 2023, ADV TRADIT MED, V23, P1035, DOI 10.1007/s13596-022-00668-w
   Zang ER, 2023, FOOD REV INT, V39, P5132, DOI 10.1080/87559129.2022.2062764
   Zhang C, 2022, CHINESE CHEM LETT, V33, P4924, DOI 10.1016/j.cclet.2022.03.110
   Zhang SH, 2023, J CONTROL RELEASE, V360, P514, DOI 10.1016/j.jconrel.2023.07.005
   Zhang X, 2022, INT J BIOL MACROMOL, V211, P368, DOI 10.1016/j.ijbiomac.2022.05.086
   Zhang YM, 2016, SCI REP-UK, V6, DOI 10.1038/srep21225
   Zhao ZM, 2020, CELL, V181, P151, DOI 10.1016/j.cell.2020.02.001
   Zheng ZD, 2022, FOOD FUNCT, V13, P9208, DOI [10.1039/d2fo01663j, 10.1039/D2FO01663J]
   Zoetemelk M, 2020, MOLECULES, V25, DOI 10.3390/molecules25112614
   Zoi V, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9091086
NR 223
TC 6
Z9 6
U1 5
U2 13
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1773-2247
EI 2588-8943
J9 J DRUG DELIV SCI TEC
JI J. Drug Deliv. Sci. Technol.
PD OCT
PY 2023
VL 88
AR 104943
DI 10.1016/j.jddst.2023.104943
PG 17
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA GB2J4
UT WOS:001150129600001
DA 2025-01-04
ER

PT J
AU Cheng, FF
   Su, L
   Qian, C
AF Cheng, Feifei
   Su, Li
   Qian, Cheng
TI Circulating tumor DNA: a promising biomarker in the liquid biopsy of
   cancer
SO ONCOTARGET
LA English
DT Review
DE liquid biopsy; circulating tumor DNA; biology; biomarker; targeted
   therapies
ID CELL LUNG-CANCER; COPY NUMBER ABERRATIONS; FREE NUCLEIC-ACIDS;
   COLORECTAL-CANCER; PLASMA DNA; BREAST-CANCER; CARCINOEMBRYONIC ANTIGEN;
   ACQUIRED-RESISTANCE; MOLECULAR INSIGHTS; MUTATION DETECTION
AB Tissue biopsy is the standard diagnostic procedure for cancers and also provides a material for genotyping, which can assist in the targeted therapies of cancers. However, tissue biopsy-based cancer diagnostic procedures have limitations in their assessment of cancer development, prognosis and genotyping, due to tumor heterogeneity and evolution. Circulating tumor DNA (ctDNA) is single- or double-stranded DNA released by the tumor cells into the blood and it thus harbors the mutations of the original tumor. In recent years, liquid biopsy based on ctDNA analysis has shed a new light on the molecular diagnosis and monitoring of cancer. Studies found that the screening of genetic mutations using ctDNA is highly sensitive and specific, suggesting that ctDNA analysis may significantly improve current systems of tumor diagnosis, even facilitating early-stage detection. Moreover, ctDNA analysis is capable of accurately determining the tumor progression, prognosis and assisting in targeted therapy. Therefore, using ctDNA as a liquid biopsy may herald a revolution for tumor management. Herein, we review the biology of ctDNA, its detection methods and potential applications in tumor diagnosis, treatment and prognosis.
C1 [Cheng, Feifei; Su, Li; Qian, Cheng] Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing, Peoples R China.
   [Cheng, Feifei; Su, Li; Qian, Cheng] Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing, Peoples R China.
   [Cheng, Feifei] Zhejiang Sci Tech Univ, Sch Life Sci, Hangzhou, Zhejiang, Peoples R China.
C3 Army Medical University; Army Medical University; Zhejiang Sci-Tech
   University
RP Qian, C (corresponding author), Third Mil Med Univ, Inst Pathol, Southwest Hosp, Chongqing, Peoples R China.; Qian, C (corresponding author), Third Mil Med Univ, Southwest Canc Ctr, Southwest Hosp, Chongqing, Peoples R China.
EM cqian8634@gmail.com
RI cheng, qian/KFB-6227-2024; Cheng, Feifei/GXG-8734-2022
OI Qian, Cheng/0000-0003-1500-9991; Cheng, Feifei/0000-0002-3234-513X
FU National Natural Sciences Foundation of China [81330048, 81520108025]
FX This work was supported by funds from National Natural Sciences
   Foundation of China (No. 81330048 and 81520108025).
CR Ahrens MJ, 2013, PROSTATE, V73, P1731, DOI 10.1002/pros.22714
   Anker P, 1999, CANCER METAST REV, V18, P65, DOI 10.1023/A:1006260319913
   [Anonymous], SCI REP
   [Anonymous], ONCOTARGET
   Atas E, 2012, ELECTROPHORESIS, V33, P3437, DOI 10.1002/elps.201200266
   Balgkouranidou I, 2014, BRIT J CANCER, V110, P2054, DOI 10.1038/bjc.2014.104
   Ballehaninna UK, 2011, INDIA J SURG ONCOL, V2, P88, DOI 10.1007/s13193-011-0042-1
   Bayley H, 2015, CLIN CHEM, V61, P25, DOI 10.1373/clinchem.2014.223016
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Bidard FC, 2014, INT J CANCER, V134, P1207, DOI 10.1002/ijc.28436
   Boesch M, 2014, ONCOTARGET, V5, P7027, DOI 10.18632/oncotarget.2053
   Campbell PJ, 2010, NATURE, V467, P1109, DOI 10.1038/nature09460
   Campitelli M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043393
   Chan KCA, 2008, CLIN CHEM, V54, P1528, DOI 10.1373/clinchem.2008.104653
   Chan KCA, 2013, P NATL ACAD SCI USA, V110, P18761, DOI 10.1073/pnas.1313995110
   Chan KCA, 2013, CANCER-AM CANCER SOC, V119, P1838, DOI 10.1002/cncr.28001
   Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014
   Chaudhuri AA, 2015, SEMIN RADIAT ONCOL, V25, P305, DOI 10.1016/j.semradonc.2015.05.001
   Damkier P, 2014, BRIT J CLIN PHARMACO, V78, P431, DOI 10.1111/bcp.12329
   Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261
   Derrington IM, 2010, P NATL ACAD SCI USA, V107, P16060, DOI 10.1073/pnas.1001831107
   Diamandis EP, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-87
   Diaz LA, 2014, J CLIN ONCOL, V32, P579, DOI 10.1200/JCO.2012.45.2011
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Duffy MJ, 2001, CLIN CHEM, V47, P624
   Fleischhacker M, 2007, BBA-REV CANCER, V1775, P181, DOI 10.1016/j.bbcan.2006.10.001
   Forshew T, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003726
   Freidin MB, 2015, CLIN CHEM, V61, P1299, DOI 10.1373/clinchem.2015.242453
   Gahan PB, 2010, CELL BIOCHEM FUNCT, V28, P529, DOI 10.1002/cbf.1690
   Gao YJ, 2010, CLIN CHEM LAB MED, V48, P1651, DOI 10.1515/CCLM.2010.311
   Garcia-Murillas I, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aab0021
   García-Olmo D, 2001, ANN NY ACAD SCI, V945, P265
   García-Olmo D, 1999, HISTOL HISTOPATHOL, V14, P1159, DOI 10.14670/HH-14.1159
   García-Olmo DC, 2005, CANCER LETT, V217, P115, DOI 10.1016/j.canlet.2004.06.043
   García-Olmo DC, 2008, HISTOL HISTOPATHOL, V23, P1205, DOI 10.14670/HH-23.1205
   García-Olmo DC, 2006, ANN SURG ONCOL, V13, P1136, DOI 10.1245/ASO.2006.05.032
   Garcia-Olmo Dolores C., 2013, Critical Reviews in Oncogenesis, V18, P153
   García-Olmo DC, 2010, CANCER RES, V70, P560, DOI 10.1158/0008-5472.CAN-09-3513
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gomella LG, 2011, CAN J UROL, V18, P5875
   Hamakawa T, 2015, BRIT J CANCER, V112, P352, DOI 10.1038/bjc.2014.609
   Han SX, 2015, ONCOTARGET, V6, P19907, DOI 10.18632/oncotarget.4529
   Han SX, 2014, J IMMUNOL RES, V2014, DOI 10.1155/2014/262385
   He CZ, 2013, BMC GASTROENTEROL, V13, DOI 10.1186/1471-230X-13-87
   Hewer E, 2014, NEUROPATHOLOGY, V34, P323, DOI 10.1111/neup.12097
   Holdenrieder S, 2008, ANN NY ACAD SCI, V1137, P180, DOI 10.1196/annals.1448.012
   Huh WK, 2015, APPL HEALTH ECON HEA, V13, P95, DOI 10.1007/s40258-014-0135-4
   Ilie M, 2014, ANN TRANSL MED, V2, DOI 10.3978/j.issn.2305-5839.2014.08.11
   Jiang PY, 2015, P NATL ACAD SCI USA, V112, pE1317, DOI 10.1073/pnas.1500076112
   Jiang T, 2015, LUNG CANCER, V90, P128, DOI 10.1016/j.lungcan.2015.09.013
   Kidess E, 2015, ONCOTARGET, V6, P2549, DOI 10.18632/oncotarget.3041
   Kosaka N, 2010, CANCER SCI, V101, P2087, DOI 10.1111/j.1349-7006.2010.01650.x
   Kreiter S, 2015, NATURE, V520, P692, DOI 10.1038/nature14426
   Kruglyak KM, 2014, EXPERT REV MOL DIAGN, V14, P635, DOI 10.1586/14737159.2014.916213
   Laszlo AH, 2014, NAT BIOTECHNOL, V32, P829, DOI 10.1038/nbt.2950
   Lebofsky R, 2015, MOL ONCOL, V9, P783, DOI 10.1016/j.molonc.2014.12.003
   LEON SA, 1977, CANCER RES, V37, P646
   Li TH, 2013, J CLIN ONCOL, V31, P1039, DOI 10.1200/JCO.2012.45.3753
   Lipson EJ, 2014, J IMMUNOTHER CANCER, V2, DOI 10.1186/s40425-014-0042-0
   Lo YMD, 1999, CANCER RES, V59, P1188
   López-Otín C, 2007, NAT REV CANCER, V7, P800, DOI 10.1038/nrc2228
   Madhavan D, 2014, BREAST CANCER RES TR, V146, P163, DOI 10.1007/s10549-014-2946-2
   Mäbert K, 2014, INT J RADIAT BIOL, V90, P659, DOI 10.3109/09553002.2014.892229
   Mardis ER, 2009, NEW ENGL J MED, V361, P1058, DOI 10.1056/NEJMoa0903840
   Martignetti JA, 2014, NEOPLASIA, V16, P97, DOI 10.1593/neo.131900
   Mazzucchelli R, 2000, Adv Clin Path, V4, P111
   Mouliere F, 2015, P NATL ACAD SCI USA, V112, P3178, DOI 10.1073/pnas.1501321112
   Mouliere F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023418
   Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
   Navin N, 2011, NATURE, V472, P90, DOI 10.1038/nature09807
   Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519
   Nie K, 2015, TUMOR BIOL, V36, P7, DOI 10.1007/s13277-014-2758-3
   Parsons DW, 2008, SCIENCE, V321, P1807, DOI 10.1126/science.1164382
   Qiu MT, 2015, CANCER EPIDEM BIOMAR, V24, P206, DOI 10.1158/1055-9965.EPI-14-0895
   Reinert T., 2015, Gut
   Romero D, 2015, NAT REV CLIN ONCOL, V12, P624, DOI [10.1038/nrclinonc.2015.144, 10.1038/nrclinonc.2015.159]
   Roschewski M, 2015, LANCET ONCOL, V16, P541, DOI 10.1016/S1470-2045(15)70106-3
   Rosenstein J, 2014, IEEE PULSE, V5, P52, DOI 10.1109/MPUL.2014.2321214
   Roth C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-4
   Ruibal Morell A., 1992, International Journal of Biological Markers, V7, P160
   Shen J, 2014, ONCOTARGET, V5, P5284, DOI 10.18632/oncotarget.2014
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Smith CC, 2012, NATURE, V485, P260, DOI 10.1038/nature11016
   SORENSON GD, 1994, CANCER EPIDEM BIOMAR, V3, P67
   Stachler MD, 2015, HUM PATHOL, V46, P507, DOI 10.1016/j.humpath.2015.01.005
   Steinbock LJ, 2015, NANOTECHNOLOGY, V26, DOI 10.1088/0957-4484/26/7/074003
   Stroun M, 2001, CLIN CHIM ACTA, V313, P139, DOI 10.1016/S0009-8981(01)00665-9
   Tachibana M, 1998, J AM COLL SURGEONS, V187, P64, DOI 10.1016/S1072-7515(98)00133-1
   Taniguchi K, 2011, CLIN CANCER RES, V17, P7808, DOI 10.1158/1078-0432.CCR-11-1712
   Thierry AR, 2010, NUCLEIC ACIDS RES, V38, P6159, DOI 10.1093/nar/gkq421
   Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177
   Trejo-Becerril C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0052754
   Valastyan S, 2011, CELL, V147, P275, DOI 10.1016/j.cell.2011.09.024
   van der Vaart M, 2007, CLIN CHEM, V53, P2215, DOI 10.1373/clinchem.2007.092734
   VASIOUKHIN V, 1994, BRIT J HAEMATOL, V86, P774, DOI 10.1111/j.1365-2141.1994.tb04828.x
   Wang BG, 2003, CANCER RES, V63, P3966
   Wong IHN, 1999, CANCER RES, V59, P71
   Yap TA, 2014, CLIN CANCER RES, V20, P2553, DOI 10.1158/1078-0432.CCR-13-2664
   Yong E, 2014, NATURE, V511, P524, DOI 10.1038/511524a
   Yung TKF, 2009, CLIN CANCER RES, V15, P2076, DOI 10.1158/1078-0432.CCR-08-2622
NR 102
TC 234
Z9 251
U1 0
U2 63
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 26
PY 2016
VL 7
IS 30
BP 48832
EP 48841
DI 10.18632/oncotarget.9453
PG 10
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DY8WP
UT WOS:000385413000149
PM 27223063
OA gold, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU De Souza, A
   Daly, KP
   Yoo, J
   Saif, MW
AF De Souza, Andre
   Daly, Kevin Pelham
   Yoo, James
   Saif, Muhammad Wasif
TI Safety and Efficacy of Combined Yttrium 90 Resin Radioembolization with
   Aflibercept and FOLFIRI in a Patient with Metastatic Colorectal Cancer
SO CASE REPORTS IN ONCOLOGICAL MEDICINE
LA English
DT Article
ID 1ST-LINE TREATMENT; PHASE-III; Y-90 RADIOEMBOLIZATION; LIVER METASTASES;
   RANDOMIZED-TRIAL; MICROSPHERES; FLUOROURACIL; CHEMOTHERAPY; OXALIPLATIN;
   LEUCOVORIN
AB Background. When associated with isolated four or fewer liver foci, metastatic colorectal cancer is amenable to surgical resection. Alternative therapeutic methods for isolated liver metastases include radioembolization with yttrium 90 (Y90) and transarterial chemoembolization (TACE). We present here a case of a patient with two sites of liver metastatic disease from colorectal cancer who underwent Y90 radioembolization combined with aflibercept and FOLFIRI. Case Report. A 56-year-old female with history of bilateral breast cancer and metastatic colon cancer with prior hemicolectomy and 4 previous chemotherapy regimens developed liver metastasis. She was started on aflibercept and FOLFIRI and concurrently underwent two treatments of radioembolization with Y90, initially targeting the largest right lobe tumor, and then a subsequent treatment targeting the smaller left lobe tumor with retreatment of the right lobe tumor. Her liver metastases exhibited partial response on imaging utilizing the modified RECIST criteria. Interestingly, the patient CEA levels decreased after the procedure. Discussion. This is the first reported case of a patient managed with radioembolization with Y90 combined with aflibercept, an anti-VEGF treatment, and FOLFIRI. An ongoing randomized clinical trial aims to define the role of combined targeted therapy and chemotherapy with radioembolization with Y90.
C1 [De Souza, Andre; Saif, Muhammad Wasif] Tufts Med Ctr, Dept Hematol Oncol, 800 Washington St, Boston, MA 02111 USA.
   [Daly, Kevin Pelham] Tufts Med Ctr, Intervent Radiol Dept, Boston, MA 02111 USA.
   [Yoo, James] Tufts Med Ctr, Dept Surg, Boston, MA 02111 USA.
C3 Tufts Medical Center; Tufts Medical Center; Tufts Medical Center
RP Saif, MW (corresponding author), Tufts Med Ctr, Dept Hematol Oncol, 800 Washington St, Boston, MA 02111 USA.
EM wsaif@tuftsmedicalcenter.org
OI Daly, Kevin/0000-0002-1457-932X
CR [Anonymous], US CANC STAT 1999 20
   Cianni R, 2009, CARDIOVASC INTER RAD, V32, P1179, DOI 10.1007/s00270-009-9658-8
   Cosimelli M, 2010, BRIT J CANCER, V103, P324, DOI 10.1038/sj.bjc.6605770
   Díaz-Rubio E, 2012, ONCOLOGIST, V17, P1426, DOI 10.1634/theoncologist.2012-0075
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Fiorentini G, 2012, ANTICANCER RES, V32, P1387
   Gray B, 2001, ANN ONCOL, V12, P1711, DOI 10.1023/A:1013569329846
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Hendlisz A, 2010, J CLIN ONCOL, V28, P3687, DOI 10.1200/JCO.2010.28.5643
   HUNT TM, 1990, BRIT J SURG, V77, P779
   Kim JH, 2012, ONCOL LETT, V4, P751, DOI 10.3892/ol.2012.782
   Lencioni R, 2010, SEMIN LIVER DIS, V30, P52, DOI 10.1055/s-0030-1247132
   Pericay C, 2012, ANN ONCOL, V23, P16, DOI 10.1016/S0923-7534(19)66488-4
   Rafi S, 2013, CARDIOVASC INTER RAD, V36, P440, DOI 10.1007/s00270-012-0463-4
   Saif Muhammad Wasif, 2006, Oncology (Williston Park), V20, P11
   Saif MW, 2014, CASE REP ONCOL MED, V2014, DOI 10.1155/2014/790192
   Saxena A, 2014, J CANCER RES CLIN, V140, P537, DOI 10.1007/s00432-013-1564-4
   Seidensticker R, 2012, CARDIOVASC INTER RAD, V35, P1109, DOI 10.1007/s00270-011-0295-7
   Seidensticker R, 2012, CARDIOVASC INTER RAD, V35, P1066, DOI 10.1007/s00270-011-0234-7
   Sharma RA, 2007, J CLIN ONCOL, V25, P1099, DOI 10.1200/JCO.2006.08.7916
   Tabernero J, 2013, CLIN CANCER RES, V19, P2541, DOI 10.1158/1078-0432.CCR-13-0107
   Van Cutsem E, 2010, ANN ONCOL, V21, pv93, DOI 10.1093/annonc/mdq222
   Van Cutsem E., 2007, J CLIN ONCOLOGY, V25
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
NR 24
TC 6
Z9 6
U1 0
U2 2
PU HINDAWI LTD
PI LONDON
PA ADAM HOUSE, 3RD FLR, 1 FITZROY SQ, LONDON, W1T 5HF, ENGLAND
SN 2090-6706
EI 2090-6714
J9 CASE REP ONCOL MED
JI Case Rep. Oncol. Med.
PY 2015
VL 2015
AR 461823
DI 10.1155/2015/461823
PG 6
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA CX1WY
UT WOS:000365487600001
PM 25866690
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Takei, N
   Yoneda, A
   Sakai-Sawada, K
   Kosaka, M
   Minomi, K
   Tamura, Y
AF Takei, Norio
   Yoneda, Akihiro
   Sakai-Sawada, Kaori
   Kosaka, Marina
   Minomi, Kenjiro
   Tamura, Yasuaki
TI Hypoxia-inducible ERO1aα promotes cancer progression through modulation
   of integrin-β1 modification and signalling in HCT116 colorectal cancer
   cells
SO SCIENTIFIC REPORTS
LA English
DT Article
ID OXIDOREDUCTASE ERO1-ALPHA DRIVES; E-CADHERIN; DISULFIDE OXIDASE;
   PROTEIN; EXPRESSION; GLYCOSYLATION; BETA-1-INTEGRIN; SECRETION;
   MECHANISM; PATHWAY
AB Endoplasmic reticulum disulphide oxidase 1 alpha (ERO1 alpha) is an oxidase localized in the endoplasmic reticulum that plays a role in the formation of disulphide bonds of secreted and cell-surface proteins. We previously showed that ERO1a is overexpressed in various types of cancer and we further identified ERO1 alpha expression as a novel factor related to poor prognosis in cancer. However, the biological functions of ERO1 alpha in cancer remain unclear. Here, we investigated the cell biological roles of ERO1 alpha in the human colon-cancer cell line HCT116. ERO1 alpha knockout (KO) by using CRISPR/Cas9 resulted in decreased tumourigenicity in vivo and reduced cell proliferation only under hypoxia in vitro, which suggested that ERO1 alpha promotes cancer progression specifically in a low-oxygen environment. Thus, we evaluated the function of ERO1 alpha in cell proliferation under hypoxia, and found that under hypoxic conditions, ERO1 alpha KO resulted in a contact-inhibited morphology and diminished motility of cells. We further showed that ERO1 alpha KO induced a change in integrin-beta 1 glycosylation and thus an attenuation of cell-surface integrin-beta 1 expression, which resulted in the aforementioned phenotype. Our study has established a previously unrecognized link between ERO1 alpha expression and integrin activation, and thus provides new evidence for the effectiveness of ERO1 alpha-targeted therapy for colorectal carcinoma.
C1 [Takei, Norio; Yoneda, Akihiro; Sakai-Sawada, Kaori; Kosaka, Marina; Tamura, Yasuaki] Hokkaido Univ, Dept Mol Therapeut, Ctr Food & Med Innovat, Inst Promot Business Reg Collaborat,Kita Ku, Kita 21 Nishi 11, Sapporo, Hokkaido 0010021, Japan.
   [Kosaka, Marina; Minomi, Kenjiro] Nitto Denko Corp, Nucle Acid Med Business Div, Res & Dev Dept, Osaka, Japan.
C3 Hokkaido University; Nitto Denko Corporation
RP Takei, N (corresponding author), Hokkaido Univ, Dept Mol Therapeut, Ctr Food & Med Innovat, Inst Promot Business Reg Collaborat,Kita Ku, Kita 21 Nishi 11, Sapporo, Hokkaido 0010021, Japan.
EM ntakei@fmi.hokudai.ac.jp
FU Ministry of Education, Culture, Sports, Science and Technology (MEXT) in
   Japan [16K20874]; Nitto Denko Corporation (Osaka, Japan); Grants-in-Aid
   for Scientific Research [16K20874] Funding Source: KAKEN
FX This work was supported in part by a Grant-in-Aid for Scientific
   Research (16K20874 to N.T.) from the Ministry of Education, Culture,
   Sports, Science and Technology (MEXT) in Japan. N.T. also acknowledges
   the support of Nitto Denko Corporation (Osaka, Japan). We give special
   thanks to Dr. Takayuki Sakurai (Shinshu University) for supplying
   materials and for technical advice and discussion related to gene
   editing. We are indebted to Dr. Mami Yamaguchi, Dr. Michitoshi Kimura,
   and Eriko Iwai for their technical support in the histological analysis.
CR Araki K, 2012, ANTIOXID REDOX SIGN, V16, P790, DOI 10.1089/ars.2011.4418
   Bellis SL, 2004, BBA-BIOMEMBRANES, V1663, P52, DOI 10.1016/j.bbamem.2004.03.012
   Blandin AF, 2015, FRONT PHARMACOL, V6, DOI 10.3389/fphar.2015.00279
   Bouvard D, 2013, NAT REV MOL CELL BIO, V14, P430, DOI 10.1038/nrm3599
   Cong L, 2013, SCIENCE, V339, P819, DOI 10.1126/science.1231143
   Desgrosellier JS, 2010, NAT REV CANCER, V10, P9, DOI 10.1038/nrc2748
   DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8
   Geng F, 2004, CELL RES, V14, P423, DOI 10.1038/sj.cr.7290243
   Gess B, 2003, EUR J BIOCHEM, V270, P2228, DOI 10.1046/j.1432-1033.2003.03590.x
   Guo HB, 2009, J BIOL CHEM, V284, P34986, DOI 10.1074/jbc.M109.060806
   Guo WJ, 2004, NAT REV MOL CELL BIO, V5, P816, DOI 10.1038/nrm1490
   HOU S, 2016, SCI REP UK, V6
   HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425
   Huttenlocher A, 1998, J CELL BIOL, V141, P515, DOI 10.1083/jcb.141.2.515
   Huveneers S, 2008, J CELL SCI, V121, P2452, DOI 10.1242/jcs.033001
   Isaji T, 2009, J BIOL CHEM, V284, P12207, DOI 10.1074/jbc.M807920200
   Jeanes A, 2008, ONCOGENE, V27, P6920, DOI 10.1038/onc.2008.343
   Kukita K, 2015, J IMMUNOL, V194, P4988, DOI 10.4049/jimmunol.1303228
   Kutomi G, 2013, CANCER SCI, V104, P1091, DOI 10.1111/cas.12177
   Lee SL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067149
   Li G, 2009, J CELL BIOL, V186, P783, DOI 10.1083/jcb.200904060
   May D, 2005, ONCOGENE, V24, P1011, DOI 10.1038/sj.onc.1208325
   Moremen KW, 2012, NAT REV MOL CELL BIO, V13, P448, DOI 10.1038/nrm3383
   MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9
   Nita-Lazar M, 2010, EXP CELL RES, V316, P1871, DOI 10.1016/j.yexcr.2010.02.008
   Pinho SS, 2011, CELL MOL LIFE SCI, V68, P1011, DOI 10.1007/s00018-010-0595-0
   Rutkevich LA, 2010, MOL BIOL CELL, V21, P3093, DOI 10.1091/mbc.E10-04-0356
   Sakurai T, 2016, SCI REP-UK, V6, DOI 10.1038/srep20011
   Sakurai T, 2014, BMC BIOTECHNOL, V14, DOI 10.1186/1472-6750-14-69
   Schulman S, 2010, P NATL ACAD SCI USA, V107, P15027, DOI 10.1073/pnas.1009972107
   Song J, 2014, ONCOL REP, V32, P302, DOI 10.3892/or.2014.3168
   Takei N, 2015, J BIOL CHEM, V290, P987, DOI 10.1074/jbc.M114.599852
   Tanaka T, 2016, BRIT J CANCER, V114, P1227, DOI 10.1038/bjc.2016.105
   Tanaka T, 2015, J IMMUNOL, V194, P2004, DOI 10.4049/jimmunol.1402538
   Zheng KB, 2015, ONCOL REP, V34, P272, DOI 10.3892/or.2015.3983
   Zito E, 2015, FREE RADICAL BIO MED, V83, P299, DOI 10.1016/j.freeradbiomed.2015.01.011
   Zito E, 2012, MOL CELL, V48, P39, DOI 10.1016/j.molcel.2012.08.010
   Zito E, 2010, MOL CELL, V40, P787, DOI 10.1016/j.molcel.2010.11.010
   Zito E, 2010, J CELL BIOL, V188, P821, DOI 10.1083/jcb.200911086
NR 39
TC 35
Z9 37
U1 0
U2 8
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD AUG 24
PY 2017
VL 7
AR 9389
DI 10.1038/s41598-017-09976-7
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA FE8FS
UT WOS:000408441600113
PM 28839225
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Montoro-García, S
   Alburquerque-González, B
   Bernabé-García, A
   Bernabé-García, M
   Rodrigues, PC
   den-Haan, H
   Luque, I
   Nicolás, FJ
   Pérez-Sánchez, H
   Cayuela, ML
   Salo, T
   Conesa-Zamora, P
AF Montoro-Garcia, Silvia
   Alburquerque-Gonzalez, Begona
   Bernabe-Garcia, Angel
   Bernabe-Garcia, Manuel
   Rodrigues, Priscila Campioni
   den-Haan, Helena
   Luque, Irene
   Jose Nicolas, Francisco
   Perez-Sanchez, Horacio
   Luisa Cayuela, Maria
   Salo, Tuula
   Conesa-Zamora, Pablo
TI Novel anti-invasive properties of a Fascin1 inhibitor on colorectal
   cancer cells
SO JOURNAL OF MOLECULAR MEDICINE-JMM
LA English
DT Article
DE Fascin1; Migrastatin; Invasion; Migration; Zebrafish xenograft;
   Colorectal cancer
ID BASAL-LIKE PHENOTYPE; BREAST-CANCER; EXPRESSION; PROGRESSION; MIGRATION;
   ADENOCARCINOMA; ASSOCIATION; BIOMARKERS; MUTATIONS; PROTEINS
AB Tumor invasion and metastasis involve processes in which actin cytoskeleton rearrangement induced by Fascin1 plays a crucial role. Indeed, Fascin1 has been found overexpressed in tumors with worse prognosis. Migrastatin and its analogues target Fascin1 and inhibit its activity. However, there is need for novel and smaller Fascin1 inhibitors. The aim of this study was to assess the effect of compound G2 in colorectal cancer cell lines and compare it to migrastatin in in vitro and in vivo assays. Molecular modeling, actin-bundling, cell viability, inmunofluorescence, migration, and invasion assays were carried out in order to test anti-migratory and anti-invasive properties of compound G2. In addition, the in vivo effect of compound G2 was evaluated in a zebrafish model of invasion. HCT-116 cells exhibited the highest Fascin1 expression from eight tested colorectal cancer cell lines. Compound G2 showed important inhibitory effects on actin bundling, filopodia formation, migration, and invasion in different cell lines. Moreover, compound G2 treatment resulted in significant reduction of invasion of DLD-1 overexpressing Fascin1 and HCT-116 in zebrafish larvae xenografts; this effect being less evident in Fascin1 known-down HCT-116 cells. This study proves, for the first time, the in vitro and in vivo anti-tumoral activity of compound G2 on colorectal cancer cells and guides to design improved compound G2-based Fascin1 inhibitors. Key messages center dot Fascin is crucial for tumor invasion and metastasis and is overexpressed in bad prognostic tumors. center dot Several adverse tumors overexpress Fascin1 and lack targeted therapy. center dot Anti-fascin G2 is for the first time evaluated in colorectal carcinoma and compared with migrastatin. center dot Filopodia formation, migration activity, and invasion in vitro and in vivo assays were performed. center dot G2 blocks actin structures, migration, and invasion of colorectal cancer cells as fascin-dependent.
C1 [Montoro-Garcia, Silvia] Univ Catolica Murcia UCAM, Cell Culture Lab, Hlth Fac, Campus Jeronimos S-N, Murcia 30107, Spain.
   [Alburquerque-Gonzalez, Begona; Conesa-Zamora, Pablo] Univ Catolica Murcia UCAM, Pathol & Histol Dept, Heatlh Fac, Campus Jeronimos S-N, Murcia 30107, Spain.
   [Bernabe-Garcia, Angel; Jose Nicolas, Francisco] Biomed Res Inst Murcia IMIB Arrixaca, Mol Oncol & TGF Ss Lab, Carretera Madrid Cartagena El Palmar, Murcia, Spain.
   [Bernabe-Garcia, Manuel; Luisa Cayuela, Maria] Univ Clin Hosp Virgen de la Arrixaca, Biomed Res Inst Murcia IMIB Arrixaca Murcia, Telomerase Canc & Aging Grp, Murcia, Spain.
   [Rodrigues, Priscila Campioni; Salo, Tuula] Univ Oulu, Fac Med, Canc & Translat Med Res Unit, Aapistie 5A, FI-90220 Oulu, Finland.
   [Rodrigues, Priscila Campioni; Salo, Tuula] Univ Oulu, Oulu Univ Hosp, Med Res Ctr Oulu, Oulu, Finland.
   [den-Haan, Helena] Eurofins Villapharma Res, Parque Tecnol Fuente Alamo, Murcia 30320, Spain.
   [Luque, Irene] Univ Granada, Dept Phys Chem, Campus Fuentenueva S-N, E-18071 Granada, Granada, Spain.
   [Luque, Irene] Univ Granada, Inst Biotechnol, Campus Fuentenueva S-N, E-18071 Granada, Granada, Spain.
   [Perez-Sanchez, Horacio] Univ Catolica Murcia UCAM, Struct Bioinformat & High Performance Comp BIOHPC, Guadalupe, Spain.
   [Salo, Tuula] Univ Helsinki, Inst Oral & Maxillofacial Dis, Helsinki, Finland.
   [Salo, Tuula] Helsinki Univ Hosp, Dept Pathol, HUSLAB, Helsinki, Finland.
   [Conesa-Zamora, Pablo] Hosp Univ Santa Lucia, Biomed Res Inst Murcia IMIB, Clin Anal Dept, Grp Mol Pathol & Pharmacogenet, C Mezquita Sn, Cartagena 30202, Spain.
C3 Universidad Catolica de Murcia; Universidad Catolica de Murcia; Hospital
   Clinico Universitario Virgen de la Arrixaca; Hospital Clinico
   Universitario Virgen de la Arrixaca; University of Oulu; University of
   Oulu; University of Granada; University of Granada; Universidad Catolica
   de Murcia; University of Helsinki; University of Helsinki; Helsinki
   University Central Hospital
RP Montoro-García, S (corresponding author), Univ Catolica Murcia UCAM, Cell Culture Lab, Hlth Fac, Campus Jeronimos S-N, Murcia 30107, Spain.; Conesa-Zamora, P (corresponding author), Univ Catolica Murcia UCAM, Pathol & Histol Dept, Heatlh Fac, Campus Jeronimos S-N, Murcia 30107, Spain.; Conesa-Zamora, P (corresponding author), Hosp Univ Santa Lucia, Biomed Res Inst Murcia IMIB, Clin Anal Dept, Grp Mol Pathol & Pharmacogenet, C Mezquita Sn, Cartagena 30202, Spain.
EM smontoro@ucam.edu; Priscila.CampioniRodrigues@oulu.fi;
   pablo.conesa@carm.es
RI Alonso, Helena/O-8539-2016; Nicolás, Francisco/H-9422-2019; ,
   tuula/ABG-2051-2021; cayuela, maria/S-1148-2019; Pérez-Sánchez,
   Horacio/O-5017-2016; Bernabé-García, Ángel/AAB-2934-2020; Alburquerque
   González, Begoña/HKW-3633-2023; Luque, Irene/K-4758-2012;
   Montoro-Garcia, Silvia/K-8101-2014
OI Bernabe-Garcia, Angel/0000-0002-2266-5949; Luque,
   Irene/0000-0003-2757-4779; Alburquerque Gonzalez,
   Begona/0000-0003-3413-5889; Bernabe Garcia, Manuel/0000-0003-4334-0059;
   Salo, Tuula/0000-0001-6039-0088; Nicolas, Francisco
   Jose/0000-0002-3969-1430; Montoro-Garcia, Silvia/0000-0002-1948-1022;
   Conesa-Zamora, Pablo/0000-0003-0190-3044
FU Instituto de Salud Carlos III (Spanish Ministry of Health) [PI12/1232,
   PI15/00626]; FEDER funds [PI12/1232, PI15/00626]; Spanish Ministry of
   Economy and Competitiveness MINECO [CTQ2017-87974-R]; Fundacion Seneca
   del Centro de Coordinacion de la Investigacion de la Region de Murcia
   [18946/JLI/13, 20646/JLI/18]; UCAM; Finnish Cultural Foundation Grant
   (2017-2018)
FX This project received grants from Instituto de Salud Carlos III (Spanish
   Ministry of Health) and FEDER funds (ref: PI12/1232 and PI15/00626),
   Spanish Ministry of Economy and Competitiveness MINECO
   (CTQ2017-87974-R), and by the Fundacion Seneca del Centro de
   Coordinacion de la Investigacion de la Region de Murcia under Projects
   18946/JLI/13 and 20646/JLI/18. BAG belongs to the "Programa de Doctorado
   en Ciencias de la Salud, Universidad Catolica de Murcia (UCAM)" and
   holds a grant of the UCAM. PCR was supported by Finnish Cultural
   Foundation Grant (2017-2018).
CR Albini A, 1998, Pathol Oncol Res, V4, P230
   Åström P, 2018, METHODS MOL BIOL, V1731, P213, DOI 10.1007/978-1-4939-7595-2_19
   Cao HH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106007
   Chen L, 2010, NATURE, V464, P1062, DOI 10.1038/nature08978
   Conesa-Zamora P, 2013, INT J CANCER, V132, P297, DOI 10.1002/ijc.27674
   Esnakula AK, 2014, J CLIN PATHOL, V67, P153, DOI 10.1136/jclinpath-2013-201698
   García-Solano J, 2012, INT J CANCER, V131, P1790, DOI 10.1002/ijc.27454
   García-Solano J, 2016, CELL ONCOL, V39, P243, DOI 10.1007/s13402-016-0269-5
   García-Solano J, 2012, HUM PATHOL, V43, P1094, DOI 10.1016/j.humpath.2011.08.020
   García-Solano J, 2011, HISTOPATHOLOGY, V59, P1046, DOI 10.1111/j.1365-2559.2011.04043.x
   García-Solano J, 2010, HUM PATHOL, V41, P1359, DOI 10.1016/j.humpath.2010.04.002
   GASTEIGER J, 1980, TETRAHEDRON, V36, P3219, DOI 10.1016/0040-4020(80)80168-2
   Gaul C, 2004, J AM CHEM SOC, V126, P11326, DOI 10.1021/ja048779q
   Ghebeh H, 2014, BRIT J CANCER, V111, P1552, DOI 10.1038/bjc.2014.453
   Han SQ, 2016, MOL ONCOL, V10, P966, DOI 10.1016/j.molonc.2016.03.006
   Hashimoto Y, 2005, INT J BIOCHEM CELL B, V37, P1787, DOI 10.1016/j.biocel.2005.05.004
   Hashimoto Y, 2011, J PATHOL, V224, P289, DOI 10.1002/path.2894
   Huang JY, 2018, J MOL BIOL, V430, P1324, DOI 10.1016/j.jmb.2018.03.009
   Jelassi B, 2011, ONCOGENE, V30, P2108, DOI 10.1038/onc.2010.593
   Jones RP, 2015, BIOMARK MED, V9, P763, DOI 10.2217/BMM.15.48
   Kanda Y, 2014, PROTEOMICS, V14, P1031, DOI 10.1002/pmic.201300414
   Li A, 2014, GASTROENTEROLOGY, V146, P1386, DOI 10.1053/j.gastro.2014.01.046
   Machesky Laura M, 2010, Commun Integr Biol, V3, P263
   Morris GM, 2009, J COMPUT CHEM, V30, P2785, DOI 10.1002/jcc.21256
   Nurmenniemi S, 2009, AM J PATHOL, V175, P1281, DOI 10.2353/ajpath.2009.081110
   Omran OM, 2015, J ENVIRON PATHOL TOX, V34, P201, DOI 10.1615/JEnvironPatholToxicolOncol.2015013663
   Rodrigues PC, 2017, ONCOTARGET, V8, P74736, DOI 10.18632/oncotarget.20360
   Rodríguez-Pinilla SM, 2006, CLIN CANCER RES, V12, P1533, DOI 10.1158/1078-0432.CCR-05-2281
   Salo T, 2018, PHILOS T R SOC B, V372, DOI 10.1098/rstb.2016.0482
   Sánchez-Linares I, 2012, BMC BIOINFORMATICS, V13, DOI 10.1186/1471-2105-13-S14-S13
   Stefanius K, 2011, HISTOPATHOLOGY, V58, P679, DOI 10.1111/j.1365-2559.2011.03821.x
   Stevenson RP, 2012, J CELL SCI, V125, P1073, DOI 10.1242/jcs.093799
   Stewart CJR, 2015, HUM PATHOL, V46, P1514, DOI 10.1016/j.humpath.2015.06.011
   Tan VY, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-52
   Wang CQ, 2016, CANCER MED-US, V5, P1983, DOI 10.1002/cam4.746
   Zhao Wei, 2015, Onco Targets Ther, V8, P2571, DOI 10.2147/OTT.S81915
NR 36
TC 20
Z9 21
U1 0
U2 17
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0946-2716
EI 1432-1440
J9 J MOL MED
JI J. Mol. Med.
PD MAR
PY 2020
VL 98
IS 3
BP 383
EP 394
DI 10.1007/s00109-020-01877-z
EA JAN 2020
PG 12
WC Genetics & Heredity; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity; Research & Experimental Medicine
GA KV4FZ
UT WOS:000510104200001
PM 31996952
DA 2025-01-04
ER

PT J
AU Nusrat, M
   Yaeger, R
AF Nusrat, Maliha
   Yaeger, Rona
TI KRAS inhibition in metastatic colorectal cancer: An update
SO CURRENT OPINION IN PHARMACOLOGY
LA English
DT Article
ID T-CELL; MUTANT KRAS; RESISTANCE; MUTATIONS; COMBINATION; DEFINES; MEK
AB About half of colorectal cancers harbor mutations in the KRAS gene. The presence of these mutations is associated with worse prognosis and, until now, the absence of matched targeted therapy options. In this review, we discuss clinical efforts to target KRAS in colorectal cancer from studies of downstream inhibitors to recent direct inhibitors of KRASG12C and other KRAS mutants. Early clinical trial data, however, suggest more limited activity for these novel inhibitors in colorectal cancer compared to other cancer types, and we discuss the role of receptor tyrosine kinase signaling and parallel signaling pathways in modulating response to these inhibitors. We also review the effect of KRAS mutations on the tumor-immune microenvironment and efforts to induce an immune response against these tumors.
C1 [Nusrat, Maliha; Yaeger, Rona] Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY 10065 USA.
C3 Memorial Sloan Kettering Cancer Center
RP Yaeger, R (corresponding author), Mem Sloan Kettering Canc Ctr, Dept Med, Gastrointestinal Oncol Serv, New York, NY 10065 USA.
EM yaegerr@mskcc.org
RI Nusrat, Maliha/ABB-5805-2020
OI Nusrat, Maliha/0000-0002-0417-0416
FU National Institutes of Health Cancer Center Support Grant [P30 CA08748]
FX This work was funded by a National Institutes of Health Cancer Center
   Support Grant to Memorial Sloan Kettering Cancer Center (P30 CA08748) .
CR Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187
   Awad MM, 2021, NEW ENGL J MED, V384, P2382, DOI 10.1056/NEJMoa2105281
   Bardia A, 2020, ONCOL, V25, P160
   Bob TL, 2022, J CLIN ONCOL, V40
   Briere DM, 2019, MOL CANCER THER
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024
   Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909
   Eng C, 2019, LANCET ONCOL, V20, P849, DOI 10.1016/S1470-2045(19)30027-0
   Garraway LA, 2012, CANCER DISCOV, V2, P214, DOI 10.1158/2159-8290.CD-12-0012
   Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409
   Henry JT, 2021, JCO PRECIS ONCOL, V5, P613, DOI 10.1200/PO.20.00256
   Hofmann MH, 2021, CANCER RES, V81
   Hofmann MH, 2021, CANCER DISCOV, V11, P142, DOI 10.1158/2159-8290.CD-20-0142
   Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239
   Hunter JC, 2015, MOL CANCER RES, V13, P1325, DOI 10.1158/1541-7786.MCR-15-0203
   Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X
   Jones RP, 2017, BRIT J CANCER, V116, P923, DOI 10.1038/bjc.2017.37
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Koltun ES, 2022, CANCER RES, V82
   Kopetz S, 2022, ANN ONCOL, V33, pS704, DOI 10.1016/j.annonc.2022.07.504
   Kuboki Y, 2022, Ann Oncol, V33, pS136, DOI [10.1016/annonc/annonc1048, DOI 10.1016/ANNONC/ANNONC1048]
   Lal N, 2018, CLIN CANCER RES, V24, P224, DOI 10.1158/1078-0432.CCR-17-1090
   Lal N, 2015, ONCOIMMUNOLOGY, V4, DOI 10.4161/2162402X.2014.976052
   Lee M T., 2009, Journal of clinical oncology
   Lee MS, 2016, ONCOTARGET, V7, P39595, DOI 10.18632/oncotarget.9153
   Lenz H-J, 2022, J CLIN ONCOL
   Li BT, 2022, J THORAC ONCOL, V17, pS10
   Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008
   Loree JM, 2018, CLIN CANCER RES, V24, P1062, DOI 10.1158/1078-0432.CCR-17-2484
   Lou K, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9450
   Maoz A, 2017, NEW ENGL J MED, V376, DOI 10.1056/NEJMc1616637
   Nusrat M, 2020, J CLIN ONCOL, V38
   Peeters M, 2015, CLIN CANCER RES, V21, P5469, DOI 10.1158/1078-0432.CCR-15-0526
   Pek M, 2017, ONCOGENE, V36, P4975, DOI 10.1038/onc.2017.120
   Prenen H, 2022, ANN ONCOL, V33, pS373, DOI 10.1016/j.annonc.2022.04.437
   Ramalingam S, 2021, MOL CANCER THER, V20, DOI 10.1158/1535-7163.TARG-21-P05-01
   Ryan MB, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110993
   Ryan MB, 2020, CLIN CANCER RES, V26, P1633, DOI 10.1158/1078-0432.CCR-19-3523
   Serebriiskii IG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11530-0
   Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695
   Tanaka N, 2021, CANCER DISCOV, V11, P1913, DOI 10.1158/2159-8290.CD-21-0365
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Wang QJ, 2016, CANCER IMMUNOL RES, V4, P204, DOI 10.1158/2326-6066.CIR-15-0188
   Wang XL, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01688
   Yaeger R, 2023, NEW ENGL J MED, V388, P44, DOI 10.1056/NEJMoa2212419
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
NR 47
TC 8
Z9 8
U1 0
U2 3
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 1471-4892
EI 1471-4973
J9 CURR OPIN PHARMACOL
JI Curr. Opin. Pharmacol.
PD FEB
PY 2023
VL 68
AR 102343
DI 10.1016/j.coph.2022.102343
EA JAN 2023
PG 11
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA E5QS5
UT WOS:000976091800001
PM 36638742
OA Bronze, Green Accepted
DA 2025-01-04
ER

PT J
AU Yeom, DH
   Lee, YS
   Ryu, I
   Lee, S
   Sung, B
   Lee, HB
   Kim, D
   Ahn, JH
   Ha, E
   Choi, YS
   Lee, SH
   You, WK
AF Yeom, Dong-Hoon
   Lee, Yo-Seob
   Ryu, Ilhwan
   Lee, Sunju
   Sung, Byungje
   Lee, Han-Byul
   Kim, Dongin
   Ahn, Jin-Hyung
   Ha, Eunsin
   Choi, Yong-Soo
   Lee, Sang Hoon
   You, Weon-Kyoo
TI ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with
   Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft
   Models
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Article
DE anti-angiogenesis; delta-like ligand; irinotecan; paclitaxel;
   therapeutic antibody; VEGF
ID GROWTH; BLOCKADE; CANCER; THERAPY; NORMALIZATION; METASTASIS;
   RESISTANCE; APTAMERS; CELLS
AB Delta-like-ligand 4 (DLL4) is a promising target to augment the effects of VEGF inhibitors. A simultaneous blockade of VEGF/VEGFR and DLL4/Notch signaling pathways leads to more potent anti-cancer effects by synergistic anti-angiogenic mechanisms in xenograft models. A bispecific antibody targeting VEGF and DLL4 (ABL001/NOV1501/TR009) demonstrates more potent in vitro and in vivo biological activity compared to VEGF or DLL4 targeting monoclonal antibodies alone and is currently being evaluated in a phase 1 clinical study of heavy chemotherapy or targeted therapy pre-treated cancer patients (ClinicalTrials.gov Identifier: NCT03292783). However, the effects of a combination of ABL001 and chemotherapy on tumor vessels and tumors are not known. Hence, the effects of ABL001, with or without paclitaxel and irinotecan were evaluated in human gastric or colon cancer xenograft models. The combination treatment synergistically inhibited tumor progression compared to each monotherapy. More tumor vessel regression and apoptotic tumor cell induction were observed in tumors treated with the combination therapy, which might be due to tumor vessel normalization. Overall, these findings suggest that the combination therapy of ABL001 with paclitaxel or irinotecan would be a better clinical strategy for the treatment of cancer patients.
C1 [Yeom, Dong-Hoon; Lee, Yo-Seob; Ryu, Ilhwan; Lee, Sunju; Sung, Byungje; Lee, Han-Byul; Kim, Dongin; Ahn, Jin-Hyung; Ha, Eunsin; Lee, Sang Hoon; You, Weon-Kyoo] ABL Bio Inc, R&D Ctr, 2F,16 Daewangpangyo Ro,712 Beon Gil, Seongnam Si 13488, Gyeonggi Do, South Korea.
   [Yeom, Dong-Hoon; Choi, Yong-Soo] CHA Univ, Dept Biotechnol, Pangyo Ro 335, Seongnam Si 13488, Gyeonggi Do, South Korea.
C3 Pochon Cha University
RP You, WK (corresponding author), ABL Bio Inc, R&D Ctr, 2F,16 Daewangpangyo Ro,712 Beon Gil, Seongnam Si 13488, Gyeonggi Do, South Korea.
EM donghoon.yeom@ablbio.com; yoseob.lee@ablbio.com; ilhwan.ryu@ablbio.com;
   sunju.lee@ablbio.com; byungje.sung@ablbio.com; hanbyul.lee@ablbio.com;
   dongin.kim@ablbio.com; jinhyung.ahn@ablbio.com; eunsin.ha@ablbio.com;
   yschoi@cha.ac.kr; sang.lee@ablbio.com; weonkyoo.you@ablbio.com
RI lee, wj/JNR-4926-2023
FU National OncoVenture Program [HI11C1191]
FX This work was supported by the National OncoVenture Program (No.
   HI11C1191).
CR Bergers G, 2008, NAT REV CANCER, V8, P592, DOI 10.1038/nrc2442
   Campesato LF, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2017.10.12
   Comunanza V, 2017, FRONT CELL DEV BIOL, V5, DOI 10.3389/fcell.2017.00101
   Ebos JML, 2009, CANCER CELL, V15, P232, DOI 10.1016/j.ccr.2009.01.021
   Finn RS, 2020, NEW ENGL J MED, V382, P1894, DOI 10.1056/NEJMoa1915745
   Gale NW, 2004, P NATL ACAD SCI USA, V101, P15949, DOI 10.1073/pnas.0407290101
   Han J, 2020, J CANCER, V11, P6902, DOI 10.7150/jca.49532
   Hashizume H, 2010, CANCER RES, V70, P2213, DOI 10.1158/0008-5472.CAN-09-1977
   Hoey T, 2009, CELL STEM CELL, V5, P168, DOI 10.1016/j.stem.2009.05.019
   Jászai J, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8091102
   Jenkins DW, 2012, MOL CANCER THER, V11, P1650, DOI 10.1158/1535-7163.MCT-11-1027
   Kang MX, 2013, CANCER LETT, V330, P11, DOI 10.1016/j.canlet.2012.11.015
   Kaur H, 2018, THERANOSTICS, V8, P4016, DOI 10.7150/thno.25958
   Kerbel RS, 2008, NEW ENGL J MED, V358, P2039, DOI 10.1056/NEJMra0706596
   Kim DH, 2020, BMB REP, V53, P533, DOI 10.5483/BMBRep.2020.53.10.103
   Kuhnert F, 2015, CANCER RES, V75, P4086, DOI 10.1158/0008-5472.CAN-14-3773
   Kuramoto T, 2012, MOL CANCER THER, V11, P2578, DOI 10.1158/1535-7163.MCT-12-0640
   Lee D, 2016, MABS-AUSTIN, V8, P892, DOI 10.1080/19420862.2016.1171432
   Lee J, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3023
   Li JL, 2011, CANCER RES, V71, P6073, DOI 10.1158/0008-5472.CAN-11-1704
   Li JL, 2009, FRONT BIOSCI-LANDMRK, V14, P3094, DOI 10.2741/3438
   Mancuso MR, 2006, J CLIN INVEST, V116, P2610, DOI 10.1172/JCI24612
   Marvin JS, 2005, ACTA PHARMACOL SIN, V26, P649, DOI 10.1111/j.1745-7254.2005.00119.x
   Meadows KL, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006577
   Miles KM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112371
   Motzer RJ, 2019, NEW ENGL J MED, V380, P1103, DOI 10.1056/NEJMoa1816047
   Mpekris F, 2020, P NATL ACAD SCI USA, V117, P3728, DOI 10.1073/pnas.1919764117
   Neufeld G, 1999, FASEB J, V13, P9, DOI 10.1096/fasebj.13.1.9
   Noguera-Troise I, 2006, NATURE, V444, P1032, DOI 10.1038/nature05355
   Ohr M, 2012, EXPERT OPIN PHARMACO, V13, P585, DOI 10.1517/14656566.2012.658368
   Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714
   Ruckman J, 1998, J BIOL CHEM, V273, P20556, DOI 10.1074/jbc.273.32.20556
   Sainson RCA, 2007, TRENDS MOL MED, V13, P389, DOI 10.1016/j.molmed.2007.07.002
   Shams Naveed, 2006, Ophthalmol Clin North Am, V19, P335
   Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948
   Tang J, 2018, ANN ONCOL, V29, P84, DOI 10.1093/annonc/mdx755
   Teicher BA, 1996, CANCER METAST REV, V15, P247, DOI 10.1007/BF00437479
   Wildiers H, 2003, BRIT J CANCER, V88, P1979, DOI 10.1038/sj.bjc.6601005
   You WK, 2011, CANCER RES, V71, P4758, DOI 10.1158/0008-5472.CAN-10-2527
   Yu JX, 2020, NAT REV DRUG DISCOV, V19, P163, DOI 10.1038/d41573-019-00182-w
   Zhang QB, 2011, MOL CANCER THER, V10, P1173, DOI 10.1158/1535-7163.MCT-11-0008
   Zhou B, 2006, EXP EYE RES, V83, P615, DOI 10.1016/j.exer.2006.02.010
   Zirlik K, 2018, ONCOL RES TREAT, V41, P166, DOI 10.1159/000488087
NR 43
TC 22
Z9 25
U1 0
U2 7
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD JAN
PY 2021
VL 22
IS 1
AR 241
DI 10.3390/ijms22010241
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA PP7WI
UT WOS:000606068000001
PM 33383646
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Sokolenko, AP
   Imyanitov, EN
AF Sokolenko, Anna P.
   Imyanitov, Evgeny N.
TI Molecular Diagnostics in Clinical Oncology
SO FRONTIERS IN MOLECULAR BIOSCIENCES
LA English
DT Review
DE carcinoma of unknown primary site; hereditary cancer syndromes; liquid
   biopsy; molecular diagnostics; predictive markers; review
ID GROWTH-FACTOR RECEPTOR; UNKNOWN PRIMARY SITE; CANCER SUSCEPTIBILITY
   GENE; OF-AMERICAN-PATHOLOGISTS; CELL LUNG-CANCER; BREAST-CANCER;
   OVARIAN-CANCER; COLORECTAL-CANCER; ESTROGEN-RECEPTORS; TARGETED THERAPY
AB There are multiple applications of molecular tests in clinical oncology. Mutation analysis is now routinely utilized for the diagnosis of hereditary cancer syndromes. Healthy carriers of cancer-predisposing mutations benefit from tight medical surveillance and various preventive interventions. Cancers caused by germ-line mutations often require significant modification of the treatment strategy. Personalized selection of cancer drugs based on the presence of actionable mutations has become an integral part of cancer therapy. Molecular tests underlie the administration of EGFR, BRAF, ALK, ROS1, PARP inhibitors as well as the use of some other cytotoxic and targeted drugs. Tumors almost always shed their fragments (single cells or their clusters, DNA, RNA, proteins) into various body fluids. So-called liquid biopsy, i.e., the analysis of circulating DNA or some other tumor-derived molecules, holds a great promise for non-invasive monitoring of cancer disease, analysis of drug-sensitizing mutations and early cancer detection. Some tumor- or tissue-specific mutations and expression markers can be efficiently utilized for the diagnosis of cancers of unknown primary origin (CUPs). Systematic cataloging of tumor molecular portraits is likely to uncover a multitude of novel medically relevant DNA- and RNA-based markers.
C1 [Sokolenko, Anna P.; Imyanitov, Evgeny N.] NN Petrov Inst Oncol, Dept Tumor Growth Biol, St Petersburg, Russia.
   [Sokolenko, Anna P.; Imyanitov, Evgeny N.] St Petersburg Pediat Med Univ, Dept Med Genet, St Petersburg, Russia.
   [Imyanitov, Evgeny N.] II Mechnikov North Western Med Univ, Dept Oncol, St Petersburg, Russia.
   [Imyanitov, Evgeny N.] St Petersburg State Univ, Dept Oncol, St Petersburg, Russia.
C3 N.N. Petrov Research Institute of Oncology; Saint Petersburg State
   Pediatric Medical University; North-Western State Medical University
   named after I.I. Mechnikov; Saint Petersburg State University
RP Sokolenko, AP; Imyanitov, EN (corresponding author), NN Petrov Inst Oncol, Dept Tumor Growth Biol, St Petersburg, Russia.; Sokolenko, AP; Imyanitov, EN (corresponding author), St Petersburg Pediat Med Univ, Dept Med Genet, St Petersburg, Russia.; Imyanitov, EN (corresponding author), II Mechnikov North Western Med Univ, Dept Oncol, St Petersburg, Russia.; Imyanitov, EN (corresponding author), St Petersburg State Univ, Dept Oncol, St Petersburg, Russia.
EM annasokolenko@mail.ru; evgeny@imyanitov.spb.ru
RI Imyanitov, Evgeny/ABG-8619-2021; Sokolenko, Anna/G-3123-2013
OI Sokolenko, Anna/0000-0001-6304-1609
FU Russian Science Foundation [14-25-00111]; Russian Science Foundation
   [17-25-00010] Funding Source: Russian Science Foundation
FX This work was supported by the Russian Science Foundation (grant number
   14-25-00111).
CR Abbosh C, 2017, NATURE, V545, P446, DOI 10.1038/nature22364
   Abbott A, 2000, NATURE, V406, P340, DOI 10.1038/35019167
   Adam R, 2016, AM J HUM GENET, V99, P337, DOI 10.1016/j.ajhg.2016.06.015
   Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   Amirouchene-Angelozzi N, 2017, CANCER DISCOV, V7, P805, DOI 10.1158/2159-8290.CD-17-0343
   Antonarakis ES, 2014, NEW ENGL J MED, V371, P1028, DOI 10.1056/NEJMoa1315815
   Antoniou A, 2003, AM J HUM GENET, V72, P1117, DOI 10.1086/375033
   Antoniou AC, 2014, NEW ENGL J MED, V371, P1651, DOI [10.1056/NEJMoa1400382, 10.1056/NEJMc1410673, 10.1056/NEJMc1410673#SA1]
   Auprich M, 2011, EUR UROL, V60, P1045, DOI 10.1016/j.eururo.2011.08.003
   Bartley AN, 2017, J CLIN ONCOL, V35, P446, DOI 10.1200/JCO.2016.69.4836
   Baselga J, 2002, ONCOLOGIST, V7, P2
   Baselga J, 2002, J CLIN ONCOL, V20, P4292, DOI 10.1200/JCO.2002.03.100
   Bellido F, 2016, GENET MED, V18, P325, DOI 10.1038/gim.2015.75
   Ben-David U, 2017, NAT GENET, V49, P1567, DOI 10.1038/ng.3967
   Berry SA, 2013, GENET MED, V15, P591, DOI 10.1038/gim.2013.10
   Bidard FC, 2018, JNCI-J NATL CANCER I, V110, P560, DOI 10.1093/jnci/djy018
   Bogdanova N, 2013, HERED CANCER CLIN PR, V11, DOI 10.1186/1897-4287-11-12
   BOOKSTEIN R, 1988, P NATL ACAD SCI USA, V85, P2210, DOI 10.1073/pnas.85.7.2210
   Briggs S, 2013, J PATHOL, V230, P148, DOI 10.1002/path.4185
   BRONNER CE, 1994, NATURE, V368, P258, DOI 10.1038/368258a0
   Bullman S, 2017, SCIENCE, V358, P1443, DOI 10.1126/science.aal5240
   Buza N, 2016, EXPERT REV MOL DIAGN, V16, P591, DOI 10.1586/14737159.2016.1156533
   Cassidy JW, 2015, CANCER RES, V75, P2963, DOI 10.1158/0008-5472.CAN-15-0727
   Cavanagh H, 2015, HERED CANCER CLIN PR, V13, DOI 10.1186/s13053-015-0038-x
   Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741
   Cheng L, 2018, MODERN PATHOL, V31, P24, DOI 10.1038/modpathol.2017.104
   Chowell D, 2018, SCIENCE, V359, P582, DOI 10.1126/science.aao4572
   Christensen JG, 2007, MOL CANCER THER, V6, P3314, DOI 10.1158/1535-7163.MCT-07-0365
   Cohen JD, 2018, SCIENCE, V359, P926, DOI 10.1126/science.aar3247
   COOMBES RC, 1987, LANCET, V2, P701
   COONS AH, 1950, J EXP MED, V91, P1, DOI 10.1084/jem.91.1.1
   Custodio A, 2013, CRIT REV ONCOL HEMAT, V85, P45, DOI 10.1016/j.critrevonc.2012.05.001
   Cybulski C, 2015, NAT GENET, V47, P643, DOI 10.1038/ng.3284
   Dasgupta A, 2017, MOL ONCOL, V11, P40, DOI 10.1002/1878-0261.12022
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Dietrich S, 2016, BLOOD, V127, P2847, DOI 10.1182/blood-2015-11-680074
   Duffy MJ, 2013, MED PRIN PRACT, V22, P4, DOI 10.1159/000338393
   Easton DF, 2015, NEW ENGL J MED, V372, P2243, DOI 10.1056/NEJMsr1501341
   Economopoulou P, 2015, CANCER TREAT REV, V41, P598, DOI 10.1016/j.ctrv.2015.05.010
   Eerola H, 2005, BREAST CANCER RES, V7, pR93, DOI 10.1186/bcr953
   Engel C, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4029-y
   ENGELSMAN E, 1974, BRIT J CANCER, V30, P189, DOI 10.1038/bjc.1974.178
   Evans KW, 2017, CLIN CANCER RES, V23, P6468, DOI 10.1158/1078-0432.CCR-17-0615
   Ewald IP, 2009, GENET MOL BIOL, V32, P437, DOI 10.1590/S1415-47572009005000049
   Fatouros M, 2008, ANN SURG ONCOL, V15, P21, DOI 10.1245/s10434-007-9612-4
   Ferla R, 2007, ANN ONCOL, V18, P93, DOI 10.1093/annonc/mdm234
   FEY MF, 1988, BLOOD REV, V2, P78, DOI 10.1016/0268-960X(88)90028-8
   Figlioli G, 2013, MUTAT RES-REV MUTAT, V752, P36, DOI 10.1016/j.mrrev.2012.09.002
   Fior R, 2017, P NATL ACAD SCI USA, V114, pE8234, DOI 10.1073/pnas.1618389114
   FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3
   FitzGerald MG, 1996, P NATL ACAD SCI USA, V93, P8541, DOI 10.1073/pnas.93.16.8541
   Foulkes WD, 2016, NAT REV CLIN ONCOL, V13, P41, DOI 10.1038/nrclinonc.2015.173
   Friedrich CA, 1999, CANCER-AM CANCER SOC, V86, P2478, DOI 10.1002/(SICI)1097-0142(19991201)86:11+<2478::AID-CNCR4>3.0.CO;2-5
   Fujii T, 2017, ANN ONCOL, V28, P2420, DOI 10.1093/annonc/mdx397
   Fukuoka M, 2003, J CLIN ONCOL, V21, P2237, DOI 10.1200/JCO.2003.10.038
   Gambacorti-Passerini C, 2018, AM J HEMATOL, V93, P607, DOI 10.1002/ajh.25043
   Garber K, 2018, NAT REV DRUG DISCOV, V17, P227, DOI 10.1038/nrd.2018.6
   Garlan F, 2017, CLIN CANCER RES, V23, P5416, DOI 10.1158/1078-0432.CCR-16-3155
   Geller LT, 2017, SCIENCE, V357, P1156, DOI 10.1126/science.aah5043
   Gelsomino F, 2016, CANCER TREAT REV, V51, P19, DOI 10.1016/j.ctrv.2016.10.005
   Goldberg SB, 2018, CLIN CANCER RES, V24, P1872, DOI 10.1158/1078-0432.CCR-17-1341
   Goodall J, 2017, CANCER DISCOV, V7, P1006, DOI 10.1158/2159-8290.CD-17-0261
   Greco FA, 2012, ANN ONCOL, V23, P298, DOI 10.1093/annonc/mdr306
   Greco FA, 2010, ONCOLOGIST, V15, P500, DOI 10.1634/theoncologist.2009-0328
   Gremel G, 2016, ANN ONCOL, V27, P1959, DOI 10.1093/annonc/mdw278
   Hainsworth JD, 2014, VIRCHOWS ARCH, V464, P393, DOI 10.1007/s00428-014-1545-2
   Hainsworth JD, 2013, J CLIN ONCOL, V31, P217, DOI 10.1200/JCO.2012.43.3755
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Hayes JH, 2014, JAMA-J AM MED ASSOC, V311, P1143, DOI 10.1001/jama.2014.2085
   HEUSON JC, 1977, CANCER-AM CANCER SOC, V39, P1971, DOI 10.1002/1097-0142(197705)39:5<1971::AID-CNCR2820390510>3.0.CO;2-8
   Horn S, 2013, SCIENCE, V339, P959, DOI 10.1126/science.1230062
   HORSTHEMKE B, 1987, LANCET, V1, P511
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Iyer G, 2012, SCIENCE, V338, P221, DOI 10.1126/science.1226344
   Iyevleva AG, 2016, HERED CANCER CLIN PR, V14, DOI 10.1186/s13053-016-0057-2
   Iyevleva AG, 2009, UROL ONCOL-SEMIN ORI, V27, P548, DOI 10.1016/j.urolonc.2008.03.022
   Izumchenko E, 2017, ANN ONCOL, V28, P2595, DOI 10.1093/annonc/mdx416
   Jagga Z, 2015, PERS MED, V12, P371, DOI [10.2217/PME.15.5, 10.2217/pme.15.5]
   Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288
   Järvinen HJ, 2000, GASTROENTEROLOGY, V118, P829, DOI 10.1016/S0016-5085(00)70168-5
   JENSEN EV, 1975, CANCER RES, V35, P3362
   Jonas O, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010564
   Jones S, 2009, SCIENCE, V324, P217, DOI 10.1126/science.1171202
   Kamposioras K, 2011, CRIT REV ONCOL HEMAT, V78, P112, DOI 10.1016/j.critrevonc.2010.04.007
   Kanth P, 2017, AM J GASTROENTEROL, V112, P1509, DOI 10.1038/ajg.2017.212
   Kiiski JI, 2014, P NATL ACAD SCI USA, V111, P15172, DOI 10.1073/pnas.1407909111
   KINZLER KW, 1991, SCIENCE, V253, P661, DOI 10.1126/science.1651562
   Klinghoffer RA, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa7489
   Kobayashi E, 2012, CANCER EPIDEM BIOMAR, V21, P1902, DOI 10.1158/1055-9965.EPI-12-0646
   Krall JA, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan3464
   Kreahling JM, 2015, CANCER CONTROL, V22, P226, DOI 10.1177/107327481502200215
   Kuligina ES, 2013, FAM CANCER, V12, P129, DOI 10.1007/s10689-012-9575-x
   Kumar R, 2017, CURR PROB CANCER, V41, P111, DOI 10.1016/j.currproblcancer.2016.12.002
   Kurian AW, 2014, J CLIN ONCOL, V32, P2001, DOI 10.1200/JCO.2013.53.6607
   Kurian AW, 2010, CURR OPIN OBSTET GYN, V22, P72, DOI 10.1097/GCO.0b013e328332dca3
   Kwak EL, 2009, J CLIN ONCOL, V27
   Kwiatkowski DJ, 2016, CLIN CANCER RES, V22, P2445, DOI 10.1158/1078-0432.CCR-15-2631
   Lamb YN, 2017, TARGET ONCOL, V12, P555, DOI 10.1007/s11523-017-0519-0
   LATIF F, 1993, SCIENCE, V260, P1317, DOI 10.1126/science.8493574
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6
   Lee JW, 2005, INT J CANCER, V113, P510, DOI 10.1002/ijc.20591
   Lee RJ, 2018, ANN ONCOL, V29, P490, DOI 10.1093/annonc/mdx717
   Leonetti A, 2018, CANCER TREAT REV, V66, P82, DOI 10.1016/j.ctrv.2018.04.006
   Lincoln SE, 2015, J MOL DIAGN, V17, P533, DOI 10.1016/j.jmoldx.2015.04.009
   Lohmann DR, 1999, HUM MUTAT, V14, P283, DOI 10.1002/(SICI)1098-1004(199910)14:4<283::AID-HUMU2>3.3.CO;2-A
   Lord CJ, 2016, NAT REV CANCER, V16, P110, DOI 10.1038/nrc.2015.21
   Lord CJ, 2013, NAT MED, V19, P1381, DOI 10.1038/nm.3369
   Lynch HT, 2015, NAT REV CANCER, V15, P181, DOI 10.1038/nrc3878
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757
   Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396
   Massard C, 2011, NAT REV CLIN ONCOL, V8, P701, DOI 10.1038/nrclinonc.2011.158
   Maxwell KN, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00388-9
   McGranahan N, 2017, CELL, V168, P613, DOI 10.1016/j.cell.2017.01.018
   MCGUIRE WL, 1973, J CLIN INVEST, V52, P73, DOI 10.1172/JCI107175
   Mehnert JM, 2016, J CLIN INVEST, V126, P2334, DOI 10.1172/JCI84940
   Merker JD, 2018, J CLIN ONCOL, V36, P1631, DOI 10.1200/JCO.2017.76.8671
   MIKI Y, 1994, SCIENCE, V266, P66, DOI 10.1126/science.7545954
   Moiseyenko VM, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0545-4
   Moller P, 2013, BREAST CANCER RES TR, V139, P155, DOI 10.1007/s10549-013-2540-z
   Nebot-Bral L, 2017, EUR J CANCER, V84, P290, DOI 10.1016/j.ejca.2017.07.026
   Neff RT, 2017, THER ADV MED ONCOL, V9, P519, DOI 10.1177/1758834017714993
   Nicholson RI, 2001, EUR J CANCER, V37, pS9, DOI 10.1016/s0959-8049(01)00231-3
   NISHISHO I, 1991, SCIENCE, V253, P665, DOI 10.1126/science.1651563
   Nolan E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4922
   Norton JA, 2015, SURG ONCOL CLIN N AM, V24, P795, DOI 10.1016/j.soc.2015.06.008
   Oliveira C, 2009, BEST PRACT RES CL GA, V23, P147, DOI 10.1016/j.bpg.2009.02.003
   Oxnard GR, 2016, J CLIN ONCOL, V34, P3375, DOI 10.1200/JCO.2016.66.7162
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Palles C, 2013, NAT GENET, V45, P136, DOI 10.1038/ng.2503
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Pauli C, 2017, CANCER DISCOV, V7, P462, DOI 10.1158/2159-8290.CD-16-1154
   Pavlidis N, 2009, CRIT REV ONCOL HEMAT, V69, P271, DOI 10.1016/j.critrevonc.2008.09.005
   Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863
   Pilotto S, 2017, ANN TRANSL MED, V5, DOI 10.21037/atm.2016.12.33
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prasad V, 2018, JAMA ONCOL, V4, P157, DOI 10.1001/jamaoncol.2017.4182
   Preobrazhenskaya EV, 2017, BREAST CANCER RES TR, V165, P765, DOI 10.1007/s10549-017-4357-7
   Protsenko SA, 2015, INVEST NEW DRUG, V33, P1136, DOI 10.1007/s10637-015-0280-0
   Riaz N, 2016, NAT GENET, V48, P1327, DOI 10.1038/ng.3677
   Risch HA, 2006, JNCI-J NATL CANCER I, V98, P1694, DOI 10.1093/jnci/djj465
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Robles-Espinoza CD, 2014, NAT GENET, V46, P478, DOI 10.1038/ng.2947
   Routy B, 2018, SCIENCE, V359, P91, DOI 10.1126/science.aan3706
   Ruijs MWG, 2010, J MED GENET, V47, P421, DOI 10.1136/jmg.2009.073429
   Santin AD, 2016, CLIN CANCER RES, V22, P5682, DOI 10.1158/1078-0432.CCR-16-1031
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Satagopan JM, 2001, CANCER EPIDEM BIOMAR, V10, P467
   Sauter G, 2009, J CLIN ONCOL, V27, P1323, DOI 10.1200/JCO.2007.14.8197
   Schöffski P, 2018, LANCET RESP MED, V6, P431, DOI 10.1016/S2213-2600(18)30116-4
   Shaw AT, 2014, NEW ENGL J MED, V371, P1963, DOI 10.1056/NEJMoa1406766
   Shaw AT, 2011, CLIN CANCER RES, V17, P2081, DOI 10.1158/1078-0432.CCR-10-1591
   Siddiqui AD, 2010, ANN SURG ONCOL, V17, P1168, DOI 10.1245/s10434-009-0811-z
   Silkin Sergey V, 2016, J Gastrointest Cancer, V47, P502
   Siravegna G, 2017, NAT REV CLIN ONCOL, V14, P531, DOI 10.1038/nrclinonc.2017.14
   Sluiter MD, 2011, BREAST CANCER RES TR, V125, P325, DOI 10.1007/s10549-010-0817-z
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Sokolenko A, 2017, CHIN CLIN ONCOL, V6, DOI 10.21037/cco.2017.03.02
   Sokolenko AP, 2017, CANCER LETT, V397, P127, DOI 10.1016/j.canlet.2017.03.036
   Sokolenko AP, 2015, CANCER LETT, V369, P274, DOI 10.1016/j.canlet.2015.09.014
   Sokolenko AP, 2012, INT J CANCER, V130, P2867, DOI 10.1002/ijc.26342
   Strausbaugh SD, 2007, CLIN CHEST MED, V28, P279, DOI 10.1016/j.ccm.2007.02.011
   Suda K, 2010, CLIN CANCER RES, V16, P5489, DOI 10.1158/1078-0432.CCR-10-1371
   Suspitsin E, 2018, NEOPLASMA, V65, P461, DOI 10.4149/neo_2018_170423N304
   Talantov D, 2006, J MOL DIAGN, V8, P320, DOI 10.2353/jmoldx.2006.050136
   Thompson ER, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002894
   Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219
   Ugurel S, 2017, EUR J CANCER, V83, P247, DOI 10.1016/j.ejca.2017.06.028
   Van Allen EM, 2015, SCIENCE, V350, P207, DOI 10.1126/science.aad0095
   van Brummelen EMJ, 2017, ONCOLOGIST, V22, P864, DOI 10.1634/theoncologist.2017-0031
   van der Velde NM, 2009, INT J CANCER, V124, P919, DOI 10.1002/ijc.24038
   Varadhachary GR, 2014, NEW ENGL J MED, V371, P757, DOI 10.1056/NEJMra1303917
   Varghese AM, 2017, ANN ONCOL, V28, P3015, DOI 10.1093/annonc/mdx545
   VAZQUEZ JJ, 1956, J EXP MED, V104, P727, DOI 10.1084/jem.104.5.727
   Waring P, 2016, CLIN COLORECTAL CANC, V15, P95, DOI 10.1016/j.clcc.2015.10.006
   Weren RDA, 2015, NAT GENET, V47, P668, DOI 10.1038/ng.3287
   Wheler JJ, 2016, CANCER RES, V76, P3690, DOI 10.1158/0008-5472.CAN-15-3043
   WOOSTER R, 1994, SCIENCE, V265, P2088, DOI 10.1126/science.8091231
   Xi Xiaochen, 2017, Non-Coding RNA, V3, P9, DOI 10.3390/ncrna3010009
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yamamoto H, 2016, HISTOPATHOLOGY, V69, P72, DOI 10.1111/his.12910
   Yanus GA, 2018, CLIN GENET, V93, P1015, DOI 10.1111/cge.13228
   Yao YMM, 2017, CLIN CANCER RES, V23, P5547, DOI 10.1158/1078-0432.CCR-16-3250
   Zaporozhchenko IA, 2018, EXPERT REV MOL DIAGN, V18, P133, DOI 10.1080/14737159.2018.1425143
   Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333
NR 187
TC 88
Z9 95
U1 0
U2 13
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-889X
J9 FRONT MOL BIOSCI
JI Front. Mol. Biosci.
PD AUG 27
PY 2018
VL 5
AR 76
DI 10.3389/fmolb.2018.00076
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA HG8MX
UT WOS:000455257600001
PM 30211169
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU De Robertis, M
   Loiacono, L
   Fusilli, C
   Poeta, ML
   Mazza, T
   Sanchez, M
   Marchionni, L
   Signori, E
   Lamorte, G
   Vescovi, AL
   Garcia-Foncillas, J
   Fazio, VM
AF De Robertis, Mariangela
   Loiacono, Luisa
   Fusilli, Caterina
   Poeta, Maria Luana
   Mazza, Tommaso
   Sanchez, Massimo
   Marchionni, Luigi
   Signori, Emanuela
   Lamorte, Giuseppe
   Vescovi, Angelo Luigi
   Garcia-Foncillas, Jesus
   Fazio, Vito Michele
TI Dysregulation of EGFR Pathway in EphA2 Cell Subpopulation Significantly
   Associates with Poor Prognosis in Colorectal Cancer
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID TARGETED THERAPY; TYROSINE KINASE; BREAST-CANCER; EPHRIN A2; EXPRESSION;
   RESISTANCE; OVEREXPRESSION; METASTASIS; ACTIVATION; RECEPTORS
AB Purpose: EphA2 receptor is involved in multiple cross-talks with other cellular networks, including EGFR, FAK, and VEGF pathways, with which it collaborates to stimulate cell migration, invasion, and metastasis. Colorectal cancer (CRC) EphA2 overexpression has also been correlated to stem-like properties of cells and tumor malignancy. We investigated the molecular cross-talk and miRNAs modulation of the EphA2 and EGFR pathways. We also explored the role of EphA2/EGFR pathway mediators as prognostic factors or predictors of cetuximab benefit in patients with CRC.
   Experimental Design: Gene expression analysis was performed in EphA2(high) cells isolated from CRC of the AOM/DSS murine model by FACS-assisted procedures. Six independent cohorts of patients were stratified by EphA2 expression to determine the potential prognostic role of a EphA2/EGFR signature and its effect on cetuximab treatment response.
   Results: We identified a gene expression pattern (EphA2, Efna1, Egfr, Ptpn12, and Atf2) reflecting the activation of EphA2 and EGFR pathways and a coherent dysregulation of mir-26b and mir-200a. Such a pattern showed prognostic significance in patients with stage I-III CRC, in both univariate and multivariate analysis. In patients with stage IV and WT KRAS, EphA2/Efna1/Egfr gene expression status was significantly associated with poor response to cetuximab treatment. Furthermore, EphA2 and EGFR overexpression showed a combined effect relative to cetuximab resistance, independently from KRAS mutation status.
   Conclusions: These results suggest that EphA2/Efna1/Egfr genes, linked to a possible control by miR-200a and miR-26b, could be proposed as novel CRC prognostic biomarkers. Moreover, EphA2 could be linked to a mechanism of resistance to cetuximab alternative to KRAS mutations. (C) 2016 AACR.
C1 [De Robertis, Mariangela; Loiacono, Luisa; Fazio, Vito Michele] Univ Campus Biomed Rome, Lab Genet & Clin Pathol, Via Alvaro del Portillo 21, I-00128 Rome, Italy.
   [Loiacono, Luisa; Fazio, Vito Michele] IRCCS Casa Sollievo Sofferenza, Lab Oncol, San Giovanni Rotondo, Fg, Italy.
   [Fusilli, Caterina; Mazza, Tommaso] IRCCS Casa Sollievo Sofferenza, Unit Bioinformat, San Giovanni Rotondo, Fg, Italy.
   [Poeta, Maria Luana] Univ Bari, Dept Biosci Biotechnol & Biopharmaceut, Bari, Italy.
   [Sanchez, Massimo] Ist Super Sanita, Dept Cell Biol & Neurosci, Rome, Italy.
   [Marchionni, Luigi] Johns Hopkins Univ, Sch Med, Ctr Computat Genom, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
   [Signori, Emanuela] Natl Res Council CNR, Inst Translat Pharmacol, Lab Mol Pathol & Expt Oncol, Rome, Italy.
   [Lamorte, Giuseppe; Vescovi, Angelo Luigi] IRCCS Casa Sollievo Sofferenza, San Giovanni Rotondo, Fg, Italy.
   [Garcia-Foncillas, Jesus] FIIS Fdn Jimenez Diaz, Oncohlth Inst, Translat Oncol Div, Madrid, Spain.
   [Loiacono, Luisa] Univ Foggia, Expt & Regenerat Med, Dept Med & Surg Sci, I-71100 Foggia, Italy.
C3 University Campus Bio-Medico - Rome Italy; IRCCS Casa Sollievo Della
   Sofferenza; IRCCS Casa Sollievo Della Sofferenza; Universita degli Studi
   di Bari Aldo Moro; Istituto Superiore di Sanita (ISS); Johns Hopkins
   University; Johns Hopkins Medicine; Consiglio Nazionale delle Ricerche
   (CNR); Istituto di Farmacologia Traslazionale (IFT-CNR); IRCCS Casa
   Sollievo Della Sofferenza; University of Foggia
RP Fazio, VM (corresponding author), Univ Campus Biomed Rome, Lab Genet & Clin Pathol, Via Alvaro del Portillo 21, I-00128 Rome, Italy.; De Robertis, M (corresponding author), Univ Campus Biomed Rome, Rome, Italy.
EM mariangela.derobertis@gmail.com; fazio@unicampus.it
RI De Robertis, Mariangela/K-7028-2019; Garcia-Foncillas,
   Jesus/E-6857-2010; Mazza, Tommaso/I-4531-2019; Sanchez,
   Massimo/AAD-1746-2021; poeta, maria/G-6014-2015; Signori,
   Emanuela/H-5134-2019; vescovi, angelo/A-4919-2015; Mazza,
   Tommaso/H-6414-2016; Fazio, Vito Michele/H-3007-2016; Fusilli,
   Caterina/K-3016-2016; Marchionni, Luigi/S-6774-2017; Sanchez,
   Massimo/K-4385-2018
OI POETA, Maria Luana/0000-0002-6364-727X; Mazza,
   Tommaso/0000-0003-0434-8533; Fazio, Vito Michele/0000-0002-7751-1867;
   Fusilli, Caterina/0000-0001-7497-0657; Lamorte,
   Giuseppe/0000-0001-9377-7537; Marchionni, Luigi/0000-0002-7336-8071; J,
   Garcia-Foncillas/0000-0002-7591-8006; signori,
   emanuela/0000-0003-0286-7401; Sanchez, Massimo/0000-0003-3696-7582; De
   Robertis, Mariangela/0000-0002-5409-639X
FU Regione Lazio-Progetti Imprenditoriali [ITINERIS 2]; Italian Ministry of
   Education, University and Research (MIUR) [PON02_00576_3329762/3
   AMIDERHA]; Italian Association for Cancer Research [AIRC IG 14368, AIRC
   MFAG 10520]; National Institute of Health [P30CA006973, UL1 TR 001079]
FX This work was supported by grants from Regione Lazio-Progetti
   Imprenditoriali (ITINERIS 2; to V.M. Fazio), Italian Ministry of
   Education, University and Research (MIUR) national research program and
   PON02_00576_3329762/3 AMIDERHA (to V.M. Fazio), Italian Association for
   Cancer Research (AIRC IG 14368; to A.L. Vescovi and AIRC MFAG 10520; to
   M.L. Poeta), National Institute of Health (P30CA006973 and UL1 TR
   001079; to L. Marchionni).
CR Amato KR, 2016, CANCER RES, V76, P305, DOI 10.1158/0008-5472.CAN-15-0717
   Aydogdu E, 2012, CARCINOGENESIS, V33, P1502, DOI 10.1093/carcin/bgs161
   Batlle E, 2002, CELL, V111, P251, DOI 10.1016/S0092-8674(02)01015-2
   Bin Fang W, 2005, ONCOGENE, V24, P7859, DOI 10.1038/sj.onc.1208937
   Binda E, 2012, CANCER CELL, V22, P765, DOI 10.1016/j.ccr.2012.11.005
   Boivin GP, 2003, GASTROENTEROLOGY, V124, P762, DOI 10.1053/gast.2003.50094
   Boyd AW, 2014, NAT REV DRUG DISCOV, V13, P39, DOI 10.1038/nrd4175
   Brand TM, 2011, CANCER BIOL THER, V11, P777, DOI 10.4161/cbt.11.9.15050
   Brantley-Sieders DM, 2008, J CLIN INVEST, V118, P64, DOI 10.1172/JCI33154
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Carracedo A, 2008, ONCOGENE, V27, P5527, DOI 10.1038/onc.2008.247
   Coulthard MG, 2012, AM J PATHOL, V181, P1493, DOI 10.1016/j.ajpath.2012.06.043
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   Danielsen SA, 2015, BBA-REV CANCER, V1855, P104, DOI 10.1016/j.bbcan.2014.09.008
   De Robertis M, 2015, ONCOTARGET, V6, P41237, DOI 10.18632/oncotarget.5652
   De Robertis Mariangela, 2011, J Carcinog, V10, P9, DOI 10.4103/1477-3163.78279
   De Sousa E Melo F, 2013, NAT MED, V19, P614, DOI 10.1038/nm.3174
   Dunne PD, 2016, CLIN CANCER RES, V22, P230, DOI 10.1158/1078-0432.CCR-15-0603
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Gozdecka M, 2012, BIOCHEM SOC T, V40, P230, DOI 10.1042/BST20110630
   Guo DL, 2006, CARCINOGENESIS, V27, P454, DOI 10.1093/carcin/bgi259
   Herath NI, 2010, INT J CANCER, V126, P2003, DOI 10.1002/ijc.25147
   Huang J, 2014, CLIN CANCER RES, V20, P1846, DOI 10.1158/1078-0432.CCR-13-2141
   Jorissen RN, 2009, CLIN CANCER RES, V15, P7642, DOI 10.1158/1078-0432.CCR-09-1431
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Kikuchi S, 2015, GASTRIC CANCER, V18, P485, DOI 10.1007/s10120-014-0390-y
   Kinch MS, 2003, CLIN EXP METASTAS, V20, P59, DOI 10.1023/A:1022546620495
   Kotoula V, 2011, TRANSL ONCOL, V4, P47, DOI 10.1593/tlo.10217
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Larsen AB, 2010, CELL SIGNAL, V22, P636, DOI 10.1016/j.cellsig.2009.11.018
   Lee KW, 2015, CLIN CANCER RES, V21, P357, DOI 10.1158/1078-0432.CCR-14-1374
   Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Merlos-Suárez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Miao BC, 2015, CANCER DISCOV, V5, P274, DOI 10.1158/2159-8290.CD-14-0295
   Muñoz J, 2012, EMBO J, V31, P3079, DOI 10.1038/emboj.2012.166
   Paraiso KHT, 2015, CANCER DISCOV, V5, P264, DOI 10.1158/2159-8290.CD-14-0293
   Roederer M, 2001, CYTOMETRY, V45, P194, DOI 10.1002/1097-0320(20011101)45:3<194::AID-CYTO1163>3.0.CO;2-C
   Schuijers J, 2015, CELL STEM CELL, V16, P158, DOI 10.1016/j.stem.2014.12.006
   Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Smith JJ, 2010, GASTROENTEROLOGY, V138, P958, DOI 10.1053/j.gastro.2009.11.005
   Strimpakos A, 2013, CLIN COLORECTAL CANC, V12, P267, DOI 10.1016/j.clcc.2013.07.001
   Sun TT, 2011, CELL, V144, P703, DOI 10.1016/j.cell.2011.02.003
   Tsouko E, 2015, CARCINOGENESIS, V36, P1051, DOI 10.1093/carcin/bgv087
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Workman P, 2010, BRIT J CANCER, V102, P1555, DOI 10.1038/sj.bjc.6605642
   WU N, 2011, PLOS ONE, V6
   Wykosky J, 2005, MOL CANCER RES, V3, P541, DOI 10.1158/1541-7786.MCR-05-0056
   Zelinski DP, 2001, CANCER RES, V61, P2301
   Zhuang GL, 2010, CANCER RES, V70, P299, DOI 10.1158/0008-5472.CAN-09-1845
NR 52
TC 64
Z9 70
U1 1
U2 9
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JAN 1
PY 2017
VL 23
IS 1
BP 159
EP 170
DI 10.1158/1078-0432.CCR-16-0709
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA EK4DC
UT WOS:000393876300020
PM 27401248
OA Green Submitted, Bronze, Green Accepted, Green Published
DA 2025-01-04
ER

PT J
AU Qiao, X
   Ma, D
   Zhang, X
AF Qiao, Xia
   Ma, Duan
   Zhang, Xu
TI Identification of hub genes and potential molecular mechanisms in
   MSS/MSI classifier primary colorectal cancer based on multiple datasets
SO DISCOVER ONCOLOGY
LA English
DT Article
DE Colorectal cancer; Microsatellite instability; Microsatellite stability;
   Biomarkers; Immune checkpoint inhibitors
ID MICROSATELLITE INSTABILITY; TUMOR PROGRESSION; MESSENGER-RNA;
   EXPRESSION; DIAGNOSIS; CATENIN; HNRNPL
AB ObjectiveMSI has a better prognosis than MSS in colorectal cancer patients, and the main objective of this study was to screen for differentially expressed molecules between MSI and MSS primary colorectal cancers using bioinformatics.Material and methodsTwo gene expression datasets (GSE13294 and GSE13067) were downloaded from GEO, and differential expressed genes (DEGs) were analyzed using GEO2R. Gene Ontology, Kyoto Encyclopedia of Genomes, and Gene Set Enrichment Analysis were conducted using the DEGs. Furthermore, a Protein-Protein Interaction Networks (PPI) was constructed to screen for significant modules and identify hub genes. The hub genes were analyzed in colorectal cancer using GEPIA. The expression of hub genes in clinical samples was visualized using the online Human Protein Atlas (HPA).ResultsA total of 265 common DEGs were identified in MSS primary colorectal cancer compared to MSI primary colorectal cancer. Among these, 178 DEGs were upregulated, and 87 DEGs were downregulated. Enrichment analysis showed that these DEGs were associated with the response to mechanical stimulus, regulation of cellular response to stress, G protein-coupled receptor binding, and other processes. A total of 5 hub genes was identified by cytoHubba: HNRNPL, RBM39, HNRNPH1, TRA2A, SRSF6. GEPIA software online analysis, 5 hub gene expression in colorectal cancer survival curve did not have significant differences. The expression of RBM39 was significantly different in different stages of colorectal cancer. The HPA online database results showed that the expression of the five hub proteins varied widely in CRC patients.ConclusionThe hub genes, such as HNRNPH1and RBM39, and the spliceosome resulting from DEGs, which may provide novel insights and evidence for the future diagnosis and targeted therapy of MSS/MSI PCRC.
C1 [Qiao, Xia; Ma, Duan; Zhang, Xu] Ningxia Med Univ, Gen Hosp, Inst Med Sci, Yinchuan 750004, Peoples R China.
C3 Ningxia Medical University
RP Ma, D; Zhang, X (corresponding author), Ningxia Med Univ, Gen Hosp, Inst Med Sci, Yinchuan 750004, Peoples R China.
EM duanma@fudan.edu.cn; xuzhang1012@163.com
CR Andre T, 2021, LANCET ONCOL, V22, P665, DOI 10.1016/S1470-2045(21)00064-4
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Burnett-Hartman AN, 2021, GASTROENTEROLOGY, V160, P1041, DOI 10.1053/j.gastro.2020.12.068
   Bussiere DE, 2020, NAT CHEM BIOL, V16, P15, DOI 10.1038/s41589-019-0411-6
   Canzler S, 2020, BMC BIOINFORMATICS, V21, DOI 10.1186/s12859-020-03910-x
   Clough E, 2016, METHODS MOL BIOL, V1418, P93, DOI 10.1007/978-1-4939-3578-9_5
   Courtney RJ, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-13
   Dekker E, 2019, LANCET, V394, P1467, DOI 10.1016/S0140-6736(19)32319-0
   Doncheva NT, 2019, J PROTEOME RES, V18, P623, DOI 10.1021/acs.jproteome.8b00702
   Faherty N, 2016, SCI REP-UK, V6, DOI 10.1038/srep28210
   Gelsomino F, 2016, CANCER TREAT REV, V51, P19, DOI 10.1016/j.ctrv.2016.10.005
   Gonzalez JN, 2021, NUCLEIC ACIDS RES, V49, pD1046, DOI 10.1093/nar/gkaa1070
   Gu JY, 2020, CLIN CHIM ACTA, V507, P286, DOI 10.1016/j.cca.2020.04.040
   Han T, 2017, SCIENCE, V356, DOI 10.1126/science.aal3755
   He XY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01232-3
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Hung LH, 2008, RNA, V14, P284, DOI 10.1261/rna.725208
   Ji JX, 2019, CLIN CANCER RES, V25, P6868, DOI 10.1158/1078-0432.CCR-19-0747
   Ji M, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-04040-9
   Johdi NA, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01624
   Joranger P, 2020, EUR J HEALTH ECON, V21, P321, DOI 10.1007/s10198-019-01130-6
   Jorissen RN, 2008, CLIN CANCER RES, V14, P8061, DOI 10.1158/1078-0432.CCR-08-1431
   Kanehisa M, 2023, NUCLEIC ACIDS RES, V51, pD587, DOI 10.1093/nar/gkac963
   Kuenzi BM, 2020, NAT REV CANCER, V20, P233, DOI 10.1038/s41568-020-0240-7
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Liu TJ, 2017, MOL CANCER THER, V16, P1377, DOI 10.1158/1535-7163.MCT-17-0026
   Lu SX, 2021, CELL, V184, P4032, DOI 10.1016/j.cell.2021.05.038
   Luke JJ, 2019, CLIN CANCER RES, V25, P3074, DOI 10.1158/1078-0432.CCR-18-1942
   Luo X, 2019, ONCOTARGETS THER, V12, P4269, DOI 10.2147/OTT.S203046
   Menter David G, 2019, Curr Gastroenterol Rep, V21, P5, DOI 10.1007/s11894-019-0674-9
   Miyaki M, 1999, CANCER RES, V59, P4506
   Szklarczyk D, 2019, NUCLEIC ACIDS RES, V47, pD607, DOI [10.1093/nar/gky1131, 10.1093/nar/gkac1000]
   Wang WY, 2014, J SURG ONCOL, V109, P440, DOI 10.1002/jso.23503
   Wu QN, 2022, INT J BIOL SCI, V18, P4824, DOI 10.7150/ijbs.71234
   Xiu BQ, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1115-y
   Xu CP, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00598-7
   Xu H, 2018, CLIN CHEM LAB MED, V56, P479, DOI 10.1515/cclm-2017-0327
   Xu YW, 2022, BRIT J PHARMACOL, V179, P2795, DOI 10.1111/bph.15331
   Yu XJ, 2021, DNA CELL BIOL, V40, P1251, DOI 10.1089/dna.2021.0165
   Zhang R, 2022, J CELL MOL MED, V26, P4859, DOI 10.1111/jcmm.17517
   Zhang Y, 2021, BIOSCIENCE REP, V41, DOI 10.1042/BSR20211280
   Zhao YB, 2021, PATHOL RES PRACT, V218, DOI 10.1016/j.prp.2020.153320
   Zhou YY, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09234-6
   Zhu GW, 2022, CANCER SCI, V113, P1393, DOI 10.1111/cas.15302
   Zygulska AL, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020852
NR 45
TC 0
Z9 0
U1 3
U2 3
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
EI 2730-6011
J9 DISCOV ONCOL
JI Discov. Oncol.
PD JUL 18
PY 2024
VL 15
IS 1
AR 290
DI 10.1007/s12672-024-01148-0
PG 15
WC Oncology; Endocrinology & Metabolism
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Endocrinology & Metabolism
GA YX2C9
UT WOS:001271709300002
PM 39023715
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Yang, Y
   Meng, WJ
   Wang, ZQ
AF Yang, Ying
   Meng, Wen-Jian
   Wang, Zi-Qiang
TI MicroRNAs (miRNAs): Novel potential therapeutic targets in colorectal
   cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE colorectal cancer; MicroRNAs; drug resistance; metastasis; signaling
   pathways; therapeutic targets
ID MESENCHYMAL TRANSITION; NUCLEAR EXPORT; UP-REGULATION; SMALL RNAS;
   METASTASIS; CELL; CHEMORESISTANCE; GENE; 5-FLUOROURACIL; RESISTANCE
AB Colorectal cancer (CRC) is the most common malignant tumor and one of the most lethal malignant tumors in the world. Despite treatment with a combination of surgery, radiotherapy, and/or systemic treatment, including chemotherapy and targeted therapy, the prognosis of patients with advanced CRC remains poor. Therefore, there is an urgent need to explore novel therapeutic strategies and targets for the treatment of CRC. MicroRNAs (miRNAs/miRs) are a class of short noncoding RNAs (approximately 22 nucleotides) involved in posttranscriptional gene expression regulation. The dysregulation of its expression is recognized as a key regulator related to the development, progression and metastasis of CRC. In recent years, a number of miRNAs have been identified as regulators of drug resistance in CRC, and some have gained attention as potential targets to overcome the drug resistance of CRC. In this review, we introduce the miRNAs and the diverse mechanisms of miRNAs in CRC and summarize the potential targeted therapies of CRC based on the miRNAs.
C1 [Yang, Ying; Meng, Wen-Jian; Wang, Zi-Qiang] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, Chengdu, Peoples R China.
C3 Sichuan University
RP Meng, WJ (corresponding author), Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, Chengdu, Peoples R China.
EM mengwenjian@126.com
RI wang, ziqiang/JDV-9934-2023; Yang, Ying/ADL-4165-2022
CR Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Calin GA, 2002, P NATL ACAD SCI USA, V99, P15524, DOI 10.1073/pnas.242606799
   Chen B, 2019, OPEN BIOL, V9, DOI 10.1098/rsob.180212
   Chen HF, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01322-w
   Chen XX, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-018-1188-3
   Chen XX, 2018, AGING-US, V10, P3421, DOI 10.18632/aging.101656
   Chendrimada TP, 2005, NATURE, V436, P740, DOI 10.1038/nature03868
   Chua BA, 2020, CELL STEM CELL, V26, P138, DOI 10.1016/j.stem.2020.01.005
   DeGorter MK, 2012, ANNU REV PHARMACOL, V52, P249, DOI 10.1146/annurev-pharmtox-010611-134529
   Denli AM, 2004, NATURE, V432, P231, DOI 10.1038/nature03049
   Ding XL, 2021, DIGEST DIS SCI, V66, P2272, DOI 10.1007/s10620-020-06518-6
   Eckford PDW, 2009, CHEM REV, V109, P2989, DOI 10.1021/cr9000226
   Fang C, 2021, MOL ONCOL, V15, P3513, DOI 10.1002/1878-0261.13044
   Fang YT, 2019, GENE, V699, P37, DOI 10.1016/j.gene.2019.03.004
   Fernandez-Piñeiro I, 2017, BIOTECHNOL ADV, V35, P350, DOI 10.1016/j.biotechadv.2017.03.002
   Gebert LFR, 2019, NAT REV MOL CELL BIO, V20, P21, DOI 10.1038/s41580-018-0045-7
   Ghafouri-Fard S, 2021, BIOMED PHARMACOTHER, V140, DOI 10.1016/j.biopha.2021.111759
   Gregory RI, 2005, CELL, V123, P631, DOI 10.1016/j.cell.2005.10.022
   Gregory RI, 2004, NATURE, V432, P235, DOI 10.1038/nature03120
   Gremke N, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18504-7
   Han H, 2022, CANCER CELL INT, V22, DOI 10.1186/s12935-022-02460-x
   Han JJ, 2004, GENE DEV, V18, P3016, DOI 10.1101/gad.1262504
   He JM, 2017, J CANCER, V8, P1187, DOI 10.7150/jca.18171
   Heyam A, 2017, NUCLEIC ACIDS RES, V45, P12577, DOI 10.1093/nar/gkx928
   Hong S, 2018, BIOCHEM CELL BIOL, V96, P761, DOI 10.1139/bcb-2018-0081
   Hu FY, 2016, BIOCHEM BIOPH RES CO, V474, P35, DOI 10.1016/j.bbrc.2016.04.055
   Huang LF, 2020, PHARMACOL RES, V156, DOI 10.1016/j.phrs.2020.104774
   Hur K, 2017, GUT, V66, P654, DOI 10.1136/gutjnl-2014-308737
   Ibrahim AF, 2011, CANCER RES, V71, P5214, DOI 10.1158/0008-5472.CAN-10-4645
   Ijsselsteijn ME, 2019, BRIT J CANCER, V120, P815, DOI 10.1038/s41416-019-0421-x
   Imaoka H, 2016, ANN ONCOL, V27, P1879, DOI 10.1093/annonc/mdw279
   Jia L, 2017, DIGEST DIS SCI, V62, P3447, DOI 10.1007/s10620-017-4755-z
   Jiang HP, 2017, J BIOCHEM MOL TOXIC, V31, DOI 10.1002/jbt.21888
   Jiang T, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01474-9
   Jin FF, 2019, CANCER LETT, V440, P211, DOI 10.1016/j.canlet.2018.10.025
   Jin HF, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818758108
   Jin YH, 2018, INT J BIOL MACROMOL, V117, P445, DOI 10.1016/j.ijbiomac.2018.05.151
   Kanaan Z, 2013, ANN SURG, V258, P400, DOI 10.1097/SLA.0b013e3182a15bcc
   Kim ST, 2017, J CANCER, V8, P2809, DOI 10.7150/jca.18286
   Kim Taewan, 2021, Semin Cancer Biol, V75, P3, DOI 10.1016/j.semcancer.2020.12.025
   Kingston ER, 2019, GENOME RES, V29, P1777, DOI 10.1101/gr.251421.119
   Kwak B, 2018, INT J ONCOL, V53, P1800, DOI 10.3892/ijo.2018.4505
   Lagos-Quintana M, 2001, SCIENCE, V294, P853, DOI 10.1126/science.1064921
   Lai X, 2019, NUCLEIC ACIDS RES, V47, P7753, DOI 10.1093/nar/gkz638
   Lau NC, 2001, SCIENCE, V294, P858, DOI 10.1126/science.1065062
   Lee RC, 2001, SCIENCE, V294, P862, DOI 10.1126/science.1065329
   LEE RC, 1993, CELL, V75, P843, DOI 10.1016/0092-8674(93)90529-Y
   Lee SWL, 2019, J CONTROL RELEASE, V313, P80, DOI 10.1016/j.jconrel.2019.10.007
   Lee Y, 2004, EMBO J, V23, P4051, DOI 10.1038/sj.emboj.7600385
   Lei X, 2021, MED ONCOL, V38, DOI 10.1007/s12032-021-01488-9
   Li DD, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12480
   Li HH, 2017, GASTROENTEROLOGY, V153, P505, DOI 10.1053/j.gastro.2017.04.017
   Li J, 2018, CELL DEATH DIFFER, V25, P1612, DOI 10.1038/s41418-018-0065-z
   Li JL, 2018, ARCH BIOCHEM BIOPHYS, V640, P53, DOI 10.1016/j.abb.2018.01.002
   Li LH, 2014, J PATHOL, V234, P488, DOI 10.1002/path.4407
   Li TT, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0879-z
   Li TT, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0287-1
   Liang G, 2016, GENE THER, V23, P829, DOI 10.1038/gt.2016.60
   Lin SB, 2015, NAT REV CANCER, V15, P321, DOI 10.1038/nrc3932
   Lin XB, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0708-7
   Ling H, 2016, GUT, V65, P977, DOI 10.1136/gutjnl-2015-309372
   Liu B, 2017, MOL CARCINOGEN, V56, P2669, DOI 10.1002/mc.22710
   Liu G, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190249
   Liu HY, 2016, PATHOL RES PRACT, V212, P643, DOI 10.1016/j.prp.2016.04.011
   Liu SR, 2016, CELL HOST MICROBE, V19, P32, DOI 10.1016/j.chom.2015.12.005
   Liu T, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0981-7
   Liu YK, 2017, CELL DEATH DIS, V8, DOI 10.1038/cddis.2017.61
   Lou TT, 2022, OPEN MED-WARSAW, V17, P847, DOI 10.1515/med-2022-0474
   Lu YY, 2017, NAT MED, V23, P1331, DOI 10.1038/nm.4424
   Lund E, 2004, SCIENCE, V303, P95, DOI 10.1126/science.1090599
   Luo MC, 2021, BBA-REV CANCER, V1876, DOI 10.1016/j.bbcan.2021.188623
   Lyu JY, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2020.12408
   Ma WQ, 2018, BIOMED PHARMACOTHER, V105, P670, DOI 10.1016/j.biopha.2018.06.025
   Ma ZH, 2021, CYTOKINE, V140, DOI 10.1016/j.cyto.2021.155433
   Mattesen TB, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16000-6
   Michael MZ, 2003, MOL CANCER RES, V1, P882
   Mitchell PS, 2008, P NATL ACAD SCI USA, V105, P10513, DOI 10.1073/pnas.0804549105
   Mizutani A, 2018, CANCER SCI, V109, P4003, DOI 10.1111/cas.13805
   Mo XW, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1832347
   Ng EKO, 2009, GUT, V58, P1375, DOI 10.1136/gut.2008.167817
   Niu Y, 2019, INT J BIOCHEM CELL B, V117, DOI 10.1016/j.biocel.2019.105641
   Ozawa T, 2018, GASTROENTEROLOGY, V154, P844, DOI 10.1053/j.gastro.2017.11.275
   Pan GT, 2021, CANCER COMMUN, V41, P199, DOI 10.1002/cac2.12138
   Pan S, 2020, LIFE SCI, V244, DOI 10.1016/j.lfs.2020.117300
   Park JE, 2011, NATURE, V475, P201, DOI 10.1038/nature10198
   Park YR, 2017, J CANCER RES CLIN, V143, P1915, DOI 10.1007/s00432-017-2440-4
   Park YR, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180664
   Park YR, 2016, INT J ONCOL, V48, P2135, DOI 10.3892/ijo.2016.3430
   Qian XL, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.638537
   Qin AC, 2018, INT J MOL MED, V42, P2503, DOI 10.3892/ijmm.2018.3864
   Sabry D, 2019, MOL CELL BIOCHEM, V454, P177, DOI 10.1007/s11010-018-3462-1
   Shi L, 2019, BIOMED PHARMACOTHER, V109, P902, DOI 10.1016/j.biopha.2018.10.080
   Shi LP, 2022, EXP THER MED, V23, DOI 10.3892/etm.2022.11155
   Siegel Rebecca L, 2020, CA Cancer J Clin, V70, P7, DOI 10.3322/caac.21590
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Stang A, 2021, MOL ONCOL, V15, P2480, DOI 10.1002/1878-0261.13065
   Sui H, 2017, CANCER LETT, V403, P86, DOI 10.1016/j.canlet.2017.05.013
   Sun L, 2021, GUT, V70, P1698, DOI 10.1136/gutjnl-2020-320652
   Sun NH, 2020, CELL MOL BIOL LETT, V25, DOI 10.1186/s11658-020-00210-3
   Sun W, 2020, THERANOSTICS, V10, P1981, DOI 10.7150/thno.37621
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Suski JM, 2021, CANCER CELL, V39, P759, DOI 10.1016/j.ccell.2021.03.010
   Tang WM, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08225-3
   Tong Z, 2019, NUCLEIC ACIDS RES, V47, pD253, DOI 10.1093/nar/gky1023
   Tormo E, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-41472-y
   Tsai HL, 2019, J CELL MOL MED, V23, P3572, DOI 10.1111/jcmm.14257
   Ukai S, 2021, CANCER SCI, V112, P1196, DOI 10.1111/cas.14805
   Van Cutsem E, 2018, ANN ONCOL, V29, P1955, DOI 10.1093/annonc/mdy241
   Wang QD, 2018, CANCER RES, V78, P3163, DOI 10.1158/0008-5472.CAN-17-3107
   Wen XQ, 2020, ONCOTARGETS THER, V13, P10851, DOI [10.2147/JOTT.S265580, 10.2147/OTT.S265580]
   Wu FX, 2019, INT J ONCOL, V55, P671, DOI 10.3892/ijo.2019.4852
   Wu QB, 2018, INT J MOL MED, V42, P665, DOI 10.3892/ijmm.2018.3632
   Wu YZ, 2020, J GENE MED, V22, DOI 10.1002/jgm.3178
   Xia CF, 2022, BIOENGINEERED, V13, P2450, DOI 10.1080/21655979.2021.2012918
   Xing J, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.804689
   Xu F, 2020, CANCER SCI, V111, P1528, DOI 10.1111/cas.14356
   Xu K, 2019, MOL THER, V27, P1810, DOI 10.1016/j.ymthe.2019.05.017
   Yi R, 2003, GENE DEV, V17, P3011, DOI 10.1101/gad.1158803
   Yu FB, 2020, WORLD J GASTROENTERO, V26, P627, DOI 10.3748/wjg.v26.i6.627
   Yuan C, 2019, GENES-BASEL, V10, DOI 10.3390/genes10040270
   Zhang J, 2017, MOL MED REP, V16, P7864, DOI 10.3892/mmr.2017.7552
   Zhang YZ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0796-y
   Zhao FQ, 2021, CANCERS, V13, DOI 10.3390/cancers13133323
   Zhao L, 2022, CANCER CHEMOTH PHARM, V89, P595, DOI 10.1007/s00280-021-04393-0
   Zhao YB, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.688882
   Zheng KH, 2016, CANCER LETT, V376, P178, DOI 10.1016/j.canlet.2016.03.024
   Zhou H, 2017, CELL PROLIFERAT, V50, DOI 10.1111/cpr.12341
   Zhou J, 2021, J EXP CLIN CANC RES, V40, DOI 10.1186/s13046-021-02130-2
   Zhou QX, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2016.306
   Zhou TC, 2018, ONCOL LETT, V16, P6940, DOI 10.3892/ol.2018.9506
NR 130
TC 9
Z9 9
U1 2
U2 7
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD DEC 14
PY 2022
VL 12
AR 1054846
DI 10.3389/fonc.2022.1054846
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 7J6ZI
UT WOS:000904730700001
PM 36591525
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Crutcher, M
   Waldman, S
AF Crutcher, Madison
   Waldman, Scott
TI Biomarkers in the development of individualized treatment regimens for
   colorectal cancer
SO FRONTIERS IN MEDICINE
LA English
DT Review
DE adjuvant chemotherapy; targeted therapies; colorectal cancer;
   individualized medicine; biomarkers
ID III COLON-CANCER; CIRCULATING TUMOR-CELLS; MICROSATELLITE INSTABILITY;
   STAGE-II; ADJUVANT CHEMOTHERAPY; BRAF-MUTATION; OPEN-LABEL; MOLECULAR
   SUBTYPES; POOLED ANALYSIS; SURVIVAL
AB IntroductionColorectal cancer (CRC) is the third most common and second most deadly malignancy in the world with an estimated 1. 9 million cases and 0.9 million deaths in 2020. The 5-year overall survival for stage I disease is 92% compared to a dismal 11% in stage IV disease. At initial presentation, up to 35% of patients have metastatic colorectal cancer (mCRC), and 20-50% of stage II and III patients eventually progress to mCRC. These statistics imply both that there is a proportion of early stage patients who are not receiving adequate treatment and that we are not adequately treating mCRC patients. BodyTargeted therapies directed at CRC biomarkers are now commonly used in select mCRC patients. In addition to acting as direct targets, these biomarkers also could help stratify which patients receive adjuvant therapies and what types. This review discusses the role of RAS, microsatellite instability, HER2, consensus molecular subtypes and ctDNA/CTC in targeted therapy and adjuvant chemotherapy. DiscussionGiven the relatively high recurrence rate in early stage CRC patients as well as the continued poor survival in mCRC patients, additional work needs to be done beyond surgical management to limit recurrence and improve survival. Biomarkers offer both a potential target and a predictive method of stratifying patients to determine those who could benefit from adjuvant treatment.
C1 [Crutcher, Madison] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA USA.
   [Waldman, Scott] Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA.
C3 Jefferson University; Jefferson University
RP Waldman, S (corresponding author), Thomas Jefferson Univ, Dept Pharmacol & Expt Therapeut, Philadelphia, PA 19107 USA.
EM scott.waldman@jefferson.edu
FU National Institutes of Health [R01 CA204881, R01 CA206026, P30 CA56036];
   Defense Congressionally Directed Medical Research Program
   [W81XWH-17-PRCRP-TTSA]; Courtney Anne Diacont Memorial Foundation;
   Lorraine and David Swoyer; Targeted Diagnostic & Therapeutics, Inc.; NIH
   institutional award [T32 GM008562]
FX This work was supported by the National Institutes of Health (R01
   CA204881, R01 CA206026, and P30 CA56036), the Defense Congressionally
   Directed Medical Research Program W81XWH-17-PRCRP-TTSA, a grant from the
   Courtney Anne Diacont Memorial Foundation, Lorraine and David Swoyer,
   and Targeted Diagnostic & Therapeutics, Inc. to SW. MC was supported by
   NIH institutional award T32 GM008562 for Postdoctoral Training in
   Clinical Pharmacology. SW is the Samuel M.V. Hamilton Professor of
   Thomas Jefferson University.
CR Advani SM, 2021, CLIN COLORECTAL CANC, V20, P137, DOI 10.1016/j.clcc.2020.09.007
   Aghabozorgi AS, 2019, BIOCHIMIE, V157, P64, DOI 10.1016/j.biochi.2018.11.003
   Allen WL, 2018, JCO PRECIS ONCOL, V2, P1, DOI 10.1200/PO.17.00241
   Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   [Anonymous], 2016, Surveillance, Epidemiology, and End Results Program
   Auclin E, 2017, ANN ONCOL, V28, P958, DOI 10.1093/annonc/mdx030
   Babcock BD, 2018, ANN SURG ONCOL, V25, P1980, DOI 10.1245/s10434-018-6484-8
   Battaglin F, 2018, CLIN ADV HEMATOL ONC, V16, P735
   Baxter NN, 2022, J CLIN ONCOL, V40, P892, DOI 10.1200/JCO.21.02538
   Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879
   Bedin C, 2017, INT J CANCER, V140, P1888, DOI 10.1002/ijc.30565
   Cerretelli G, 2020, J PATHOL, V250, P518, DOI 10.1002/path.5422
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chan GHJ, 2019, J GASTROINTEST ONCOL, V10, P1183, DOI 10.21037/jgo.2019.06.03
   Cohen R, 2021, J CLIN ONCOL, V39, P642, DOI 10.1200/JCO.20.01600
   Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Crutcher MM, 2022, EXPERT OPIN THER TAR, V26, P207, DOI 10.1080/14728222.2022.2039119
   De' Angelis Gian Luigi, 2018, Acta Biomed, V89, P97, DOI 10.23750/abm.v89i9-S.7960
   Domingo E, 2005, ONCOGENE, V24, P3995, DOI 10.1038/sj.onc.1208569
   FEARON ER, 1990, CELL, V61, P759, DOI 10.1016/0092-8674(90)90186-I
   Feng Y, 2019, EJSO-EUR J SURG ONC, V45, P167, DOI 10.1016/j.ejso.2018.10.059
   Fiegle E, 2019, NEOPLASIA, V21, P932, DOI 10.1016/j.neo.2019.07.006
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Guidoboni M, 2001, AM J PATHOL, V159, P297, DOI 10.1016/S0002-9440(10)61695-1
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Igaue S, 2022, ONCOL LETT, V24, DOI 10.3892/ol.2022.13332
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Jover R, 2009, EUR J CANCER, V45, P365, DOI 10.1016/j.ejca.2008.07.016
   Jung YS, 2020, EXP MOL MED, V52, P183, DOI 10.1038/s12276-020-0380-6
   Kambara T, 2004, GUT, V53, P1137, DOI 10.1136/gut.2003.037671
   Khan K, 2019, CRIT REV ONCOL HEMAT, V143, P153, DOI 10.1016/j.critrevonc.2019.09.001
   Kidess E, 2015, ONCOTARGET, V6, P2549, DOI 10.18632/oncotarget.3041
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Krebs MG, 2014, NAT REV CLIN ONCOL, V11, P129, DOI 10.1038/nrclinonc.2013.253
   Kumar A, 2015, CANCER-AM CANCER SOC, V121, P527, DOI 10.1002/cncr.29072
   Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Li YQ, 2020, ONCOLOGIST, V25, pE1968, DOI 10.1002/ONCO.13521
   Lim KHT, 2022, ASIA-PAC J CLIN ONCO, V18, P394, DOI 10.1111/ajco.13727
   Marcus L, 2021, CLIN CANCER RES, V27, P928, DOI 10.1158/1078-0432.CCR-20-2771
   Modest DP, 2016, ANN ONCOL, V27, P1746, DOI 10.1093/annonc/mdw261
   Mooi JK, 2018, ANN ONCOL, V29, P2240, DOI 10.1093/annonc/mdy410
   Nojadeh JN, 2018, EXCLI J, V17, P159, DOI 10.17179/excli2017-948
   Overman Michael J, 2018, Am Soc Clin Oncol Educ Book, V38, P239, DOI 10.1200/EDBK_200821
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Parikh A, 2021, CLIN CANCER RES, V27, P5586, DOI [DOI 10.1158/1078-0432.CCR-21-0410, 10.1158/1078-0432.CCR-21-0410]
   Patelli G, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100156
   Piawah S, 2019, CANCER-AM CANCER SOC, V125, P4139, DOI 10.1002/cncr.32163
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prior IA, 2020, CANCER RES, V80, P2969, DOI 10.1158/0008-5472.CAN-19-3682
   Pu X H, 2022, Zhonghua Bing Li Xue Za Zhi, V51, P103, DOI 10.3760/cma.j.cn112151-20210716-00512
   Reinert T, 2019, JAMA ONCOL, V5, P1124, DOI 10.1001/jamaoncol.2019.0528
   Sargent DJ, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3507
   Sartore-Bianchi A, 2019, ONCOLOGIST, V24, P1395, DOI 10.1634/theoncologist.2018-0785
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Serebriiskii IG, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-11530-0
   Siegel RL, 2022, CA-CANCER J CLIN, V72, P7, DOI 10.3322/caac.21708
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Song LL, 2015, CLIN COLORECTAL CANC, V14, P133, DOI 10.1016/j.clcc.2015.02.001
   Spindler BA, 2017, J GASTROINTEST SURG, V21, P770, DOI 10.1007/s11605-017-3391-4
   Sun BL, 2021, CLIN COLORECTAL CANC, V20, pE12, DOI 10.1016/j.clcc.2020.08.001
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Taieb J, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw272
   Taieb J, 2014, LANCET ONCOL, V15, P862, DOI 10.1016/S1470-2045(14)70227-X
   Takagawa R, 2008, ANN SURG ONCOL, V15, P3433, DOI 10.1245/s10434-008-0168-8
   Takegawa N, 2017, CLIN COLORECTAL CANC, V16, P247, DOI 10.1016/j.clcc.2017.03.001
   Tan E, 2022, ONCOLOGIST, V27, P191, DOI 10.1093/oncolo/oyab055
   Tanaka N, 2017, MOL CANCER THER, V16, P752, DOI 10.1158/1535-7163.MCT-16-0578
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177
   Tie J, 2021, PLOS MED, V18, DOI 10.1371/journal.pmed.1003620
   Tie J, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf6219
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Wan ML, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200265
   Wilkinson NW, 2010, ANN SURG ONCOL, V17, P959, DOI 10.1245/s10434-009-0881-y
   Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174
   Zacharakis M, 2010, ANTICANCER RES, V30, P653
NR 85
TC 6
Z9 6
U1 0
U2 6
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 2296-858X
J9 FRONT MED-LAUSANNE
JI Front. Med.
PD NOV 30
PY 2022
VL 9
AR 1062423
DI 10.3389/fmed.2022.1062423
PG 10
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA 7A0XO
UT WOS:000898189300001
PM 36530921
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Kumagai, S
   Koyama, S
   Nishikawa, H
AF Kumagai, Shogo
   Koyama, Shohei
   Nishikawa, Hiroyoshi
TI Antitumour immunity regulated by aberrant ERBB family signalling
SO NATURE REVIEWS CANCER
LA English
DT Review
ID GROWTH-FACTOR RECEPTOR; CELL LUNG-CANCER; MHC CLASS-I; TYROSINE KINASE
   INHIBITORS; EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-INFILTRATING
   LYMPHOCYTES; METASTATIC COLORECTAL-CANCER; PERTUZUMAB PLUS TRASTUZUMAB;
   RANDOMIZED PHASE-III; HLA CLASS-I
AB Aberrant signalling of ERBB family members plays an important role in tumorigenesis and in the escape from antitumour immunity in multiple malignancies. Molecular-targeted agents against these signalling pathways exhibit robust clinical efficacy, but patients inevitably experience acquired resistance to these molecular-targeted therapies. Although cancer immunotherapies, including immune checkpoint inhibitors (ICIs), have shown durable antitumour response in a subset of the treated patients in multiple cancer types, clinical efficacy is limited in cancers harbouring activating gene alterations of ERBB family members. In particular, ICI treatment of patients with non-small cell lung cancers with epidermal growth factor receptor (EGFR) alterations and breast cancers with HER2 alterations failed to show clinical benefits, suggesting that EGFR and HER2 signalling may have an essential role in inhibiting antitumour immune responses. Here, we discuss the mechanisms by which the signalling of ERBB family members affects not only autonomous cancer hallmarks, such as uncontrolled cell proliferation, but also antitumour immune responses in the tumour microenvironment and the potential application of immune-genome precision medicine into immunotherapy and molecular-targeted therapy focusing on the signalling of ERBB family members.
C1 [Kumagai, Shogo; Nishikawa, Hiroyoshi] Nagoya Univ, Grad Sch Med, Dept Immunol, Nagoya, Aichi, Japan.
   [Kumagai, Shogo; Koyama, Shohei; Nishikawa, Hiroyoshi] Natl Canc Ctr, Res Inst, Div Canc Immunol, Tokyo, Japan.
   [Kumagai, Shogo; Koyama, Shohei; Nishikawa, Hiroyoshi] Natl Canc Ctr, Div Canc Immunol, Exploratory Oncol Res & Clin Trial Ctr EPOC, Chiba, Japan.
C3 Nagoya University; National Cancer Center - Japan; National Cancer
   Center - Japan
RP Nishikawa, H (corresponding author), Nagoya Univ, Grad Sch Med, Dept Immunol, Nagoya, Aichi, Japan.; Nishikawa, H (corresponding author), Natl Canc Ctr, Res Inst, Div Canc Immunol, Tokyo, Japan.; Nishikawa, H (corresponding author), Natl Canc Ctr, Div Canc Immunol, Exploratory Oncol Res & Clin Trial Ctr EPOC, Chiba, Japan.
EM hnishika@ncc.go.jp
RI Koyama, Shohei/AAU-4113-2021
OI Kumagai, Shogo/0009-0001-0895-6846; Koyama, Shohei/0000-0002-6897-9417
FU Ministry of Education, Culture, Sports, Science and Technology of Japan
   [17H06162]; Projects for Cancer Research by Therapeutic Evolution
   (P-CREATE) [16cm0106301h0001, 19cm0106335h0002, 19cm0106310h0004];
   Development of Technology for Patient Stratification Biomarker Discovery
   grant from the Japan Agency for Medical Research and Development (AMED)
   [19ae0101074s0401]; National Cancer Center Research and Development Fund
   [28-A-7, 31-A-7]; Grants-in-Aid for Scientific Research [17H06162]
   Funding Source: KAKEN
FX This study was supported by Grants-in-Aid for Scientific Research grant
   no. 17H06162 (to H.N.) from the Ministry of Education, Culture, Sports,
   Science and Technology of Japan, the Projects for Cancer Research by
   Therapeutic Evolution (P-CREATE; no. 16cm0106301h0001 to H.N. and no.
   19cm0106335h0002 and 19cm0106310h0004 to S.Ko.), the Development of
   Technology for Patient Stratification Biomarker Discovery grant (no.
   19ae0101074s0401 to H.N.) from the Japan Agency for Medical Research and
   Development (AMED), and the National Cancer Center Research and
   Development Fund (no. 28-A-7 and 31-A-7 to H.N.).
CR Accolla RS, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00032
   Agus DB, 2002, CANCER CELL, V2, P127, DOI 10.1016/S1535-6108(02)00097-1
   Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310
   Ali HR, 2014, ANN ONCOL, V25, P1536, DOI 10.1093/annonc/mdu191
   Allard B, 2013, CLIN CANCER RES, V19, P5626, DOI 10.1158/1078-0432.CCR-13-0545
   Ayers M, 2017, J CLIN INVEST, V127, P2930, DOI 10.1172/JCI91190
   Balz LM, 2012, J PATHOL, V227, P234, DOI 10.1002/path.3991
   Bang YJ, 2010, LANCET, V376, P1302
   Baselga J, 2012, NEW ENGL J MED, V366, P109, DOI 10.1056/NEJMoa1113216
   Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104
   Beavis PA, 2015, CANCER IMMUNOL RES, V3, P506, DOI 10.1158/2326-6066.CIR-14-0211
   Beck A, 2017, NAT REV DRUG DISCOV, V16, P315, DOI 10.1038/nrd.2016.268
   Berns K, 2007, CANCER CELL, V12, P395, DOI 10.1016/j.ccr.2007.08.030
   Birrer MJ, 2019, JNCI-J NATL CANCER I, V111, P538, DOI 10.1093/jnci/djz035
   Blakely CM, 2015, CELL REP, V11, P98, DOI 10.1016/j.celrep.2015.03.012
   Borghaei H, 2015, NEW ENGL J MED, V373, P1627, DOI 10.1056/NEJMoa1507643
   Brea EJ, 2016, CANCER IMMUNOL RES, V4, P936, DOI 10.1158/2326-6066.CIR-16-0177
   Budczies J, 2016, GENE CHROMOSOME CANC, V55, P626, DOI 10.1002/gcc.22365
   Burr ML, 2017, NATURE, V549, P101, DOI 10.1038/nature23643
   Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558
   Casalini P, 2004, J CELL PHYSIOL, V200, P343, DOI 10.1002/jcp.20007
   Chaganty BKR, 2018, CANCER LETT, V430, P47, DOI 10.1016/j.canlet.2018.05.009
   Chaib I, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djx014
   Chakrabarty A, 2010, ONCOGENE, V29, P5193, DOI 10.1038/onc.2010.257
   Chalmers ZR, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0424-2
   Chandrasekaran S, 2019, MOL CANCER RES, V17, P2395, DOI 10.1158/1541-7786.MCR-19-0545
   Chen KY, 2020, LUNG CANCER, V142, P98, DOI 10.1016/j.lungcan.2020.02.010
   Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500
   Chen XH, 2015, MOL IMMUNOL, V65, P34, DOI 10.1016/j.molimm.2014.12.017
   Chen YJ, 2020, CELL, V182, P226, DOI 10.1016/j.cell.2020.06.012
   Cheng HY, 2017, CLIN CANCER RES, V23, P825, DOI 10.1158/1078-0432.CCR-15-3071
   Choudhury A, 2004, INT J CANCER, V108, P71, DOI 10.1002/ijc.11497
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Clynes RA, 2000, NAT MED, V6, P443, DOI 10.1038/74704
   Colomiere M, 2009, BRIT J CANCER, V100, P134, DOI 10.1038/sj.bjc.6604794
   Concha-Benavente F, 2018, CANCER IMMUNOL RES, V6, P1548, DOI 10.1158/2326-6066.CIR-18-0062
   Cortot AB, 2013, CANCER RES, V73, P834, DOI 10.1158/0008-5472.CAN-12-2066
   Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011
   Costa C, 2014, CLIN CANCER RES, V20, P2001, DOI 10.1158/1078-0432.CCR-13-2233
   Cremasco V, 2018, CANCER IMMUNOL RES, V6, P1472, DOI 10.1158/2326-6066.CIR-18-0098
   Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593
   Dave B, 2011, J CLIN ONCOL, V29, P166, DOI 10.1200/JCO.2009.27.7814
   de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741
   Deaglio S, 2007, J EXP MED, V204, P1257, DOI 10.1084/jem.20062512
   DeSandro A, 1999, AM J HUM GENET, V65, P279, DOI 10.1086/302519
   Desrichard A, 2018, JNCI-J NATL CANCER I, V110, P1386, DOI 10.1093/jnci/djy060
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Dirix LY, 2018, BREAST CANCER RES TR, V167, P671, DOI 10.1007/s10549-017-4537-5
   Dogan S, 2012, CLIN CANCER RES, V18, P6169, DOI 10.1158/1078-0432.CCR-11-3265
   Dong ZY, 2017, ONCOIMMUNOLOGY, V6, DOI 10.1080/2162402X.2017.1356145
   Dongre A, 2017, CANCER RES, V77, P3982, DOI 10.1158/0008-5472.CAN-16-3292
   Douillard JY, 2014, CLIN COLORECTAL CANC, V13, P14, DOI 10.1016/j.clcc.2013.11.009
   Eichhorn PJA, 2008, CANCER RES, V68, P9221, DOI 10.1158/0008-5472.CAN-08-1740
   Emens LA, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.SABCS18-PD3-01
   Engelman JA, 2005, P NATL ACAD SCI USA, V102, P3788, DOI 10.1073/pnas.0409773102
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Engelman JA, 2006, J CLIN INVEST, V116, P2695, DOI 10.1172/JCI28656
   Ercan D, 2012, CANCER DISCOV, V2, P934, DOI 10.1158/2159-8290.CD-12-0103
   Evans M, 2019, PATHOL ONCOL RES, V25, P1401, DOI 10.1007/s12253-018-0460-2
   Faber AC, 2011, CANCER DISCOV, V1, P352, DOI 10.1158/2159-8290.CD-11-0106
   Fan QW, 2013, CANCER CELL, V24, P438, DOI 10.1016/j.ccr.2013.09.004
   Fridman WH, 2017, NAT REV CLIN ONCOL, V14, P717, DOI 10.1038/nrclinonc.2017.101
   Fujimoto N, 2005, CANCER RES, V65, P11478, DOI 10.1158/0008-5472.CAN-05-1977
   Gainor JF, 2016, CLIN CANCER RES, V22, P4585, DOI 10.1158/1078-0432.CCR-15-3101
   Gao L, 2018, NAT IMMUNOL, V19, P233, DOI 10.1038/s41590-017-0043-5
   Gao SZP, 2016, SCI SIGNAL, V9, DOI 10.1126/scisignal.aac8460
   Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871
   Garrett JT, 2011, P NATL ACAD SCI USA, V108, P5021, DOI 10.1073/pnas.1016140108
   Garrido F, 2010, INT J CANCER, V127, P249, DOI 10.1002/ijc.25270
   George S, 2017, IMMUNITY, V46, P197, DOI 10.1016/j.immuni.2017.02.001
   Gettinger S, 2018, J THORAC ONCOL, V13, P1363, DOI 10.1016/j.jtho.2018.05.015
   Ghatak S, 2002, J BIOL CHEM, V277, P38013, DOI 10.1074/jbc.M202404200
   Ghosh R, 2011, CANCER RES, V71, P1871, DOI 10.1158/0008-5472.CAN-10-1872
   Gianni L, 2012, LANCET ONCOL, V13, P25, DOI 10.1016/S1470-2045(11)70336-9
   Gilbertson R, 2001, GENE CHROMOSOME CANC, V31, P288, DOI 10.1002/gcc.1146
   Gong K, 2020, NAT CANCER, V1, P394, DOI 10.1038/s43018-020-0048-0
   GOTO T, 1983, J IMMUNOL, V130, P1350
   Gourd K, 2015, LANCET RESP MED, V3, P926, DOI 10.1016/S2213-2600(15)00464-6
   Green JA, 2017, J EXP MED, V214, P3565, DOI 10.1084/jem.20170356
   Guix M, 2008, J CLIN INVEST, V118, P2609, DOI 10.1172/JCI34588
   Gullick WJ, 2003, J PATHOL, V200, P279, DOI 10.1002/path.1335
   Haag R, 2006, ANGEW CHEM INT EDIT, V45, P1198, DOI 10.1002/anie.200502113
   Han JJ, 2016, CLIN LUNG CANCER, V17, P263, DOI 10.1016/j.cllc.2015.11.006
   Hanker AB, 2017, CANCER DISCOV, V7, P575, DOI 10.1158/2159-8290.CD-16-1431
   Haratani K, 2017, ANN ONCOL, V28, P1532, DOI 10.1093/annonc/mdx183
   Haratani K, 2020, J CLIN INVEST, V130, P374, DOI 10.1172/JCI126598
   Hashimoto Y, 2019, CLIN CANCER RES, V25, P7151, DOI 10.1158/1078-0432.CCR-19-1745
   Hastings K, 2019, ANN ONCOL, V30, P1311, DOI 10.1093/annonc/mdz141
   Hastings KT, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00429
   Hata A, 2017, LUNG CANCER, V111, P182, DOI 10.1016/j.lungcan.2017.07.022
   Heigener DF, 2018, J THORAC ONCOL, V13, P1060, DOI 10.1016/j.jtho.2018.06.001
   Hellmann MD, 2018, CANCER CELL, V33, P843, DOI 10.1016/j.ccell.2018.03.018
   Herrmann F, 2004, CANCER RES, V64, P215, DOI 10.1158/0008-5472.CAN-2522-2
   Ho CC, 2017, J THORAC ONCOL, V12, P567, DOI 10.1016/j.jtho.2016.11.2231
   Holbro T, 2003, EXP CELL RES, V284, P99, DOI 10.1016/S0014-4827(02)00099-X
   Holbro T, 2003, P NATL ACAD SCI USA, V100, P8933, DOI 10.1073/pnas.1537685100
   Hori S, 2003, SCIENCE, V299, P1057, DOI 10.1126/science.1079490
   Hu-Lieskovan S, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aaa4691
   Hynes NE, 2006, CANCER CELL, V10, P7, DOI 10.1016/j.ccr.2006.06.012
   Hynes NE, 2009, CURR OPIN CELL BIOL, V21, P177, DOI 10.1016/j.ceb.2008.12.010
   Hynes NE, 2001, ENDOCR-RELAT CANCER, V8, P151, DOI 10.1677/erc.0.0080151
   Isomoto K, 2020, CLIN CANCER RES, V26, P2037, DOI 10.1158/1078-0432.CCR-19-2027
   Iwata TN, 2018, MOL CANCER THER, V17, P1494, DOI 10.1158/1535-7163.MCT-17-0749
   Jacob W, 2018, CANCER TREAT REV, V68, P111, DOI 10.1016/j.ctrv.2018.06.011
   Jaiswal BS, 2013, CANCER CELL, V23, P603, DOI 10.1016/j.ccr.2013.04.012
   Janjigian YY, 2020, LANCET ONCOL, V21, P821, DOI 10.1016/S1470-2045(20)30169-8
   Ji M, 2016, CANCER BIOL THER, V17, P407, DOI 10.1080/15384047.2016.1156256
   Jia YJ, 2019, INT J CANCER, V145, P1432, DOI 10.1002/ijc.32191
   Jin DC, 2010, CANCER RES, V70, P2245, DOI 10.1158/0008-5472.CAN-09-3109
   Jonker DJ, 2007, NEW ENGL J MED, V357, P2040, DOI 10.1056/NEJMoa071834
   Jorissen RN, 2003, EXP CELL RES, V284, P31, DOI 10.1016/S0014-4827(02)00098-8
   Junttila TT, 2011, BREAST CANCER RES TR, V128, P347, DOI 10.1007/s10549-010-1090-x
   Junttila TT, 2009, CANCER CELL, V15, P429, DOI 10.1016/j.ccr.2009.03.020
   Junttila TT, 2000, TRENDS CARDIOVAS MED, V10, P304, DOI 10.1016/S1050-1738(01)00065-2
   Kanda R, 2013, CANCER RES, V73, P6243, DOI 10.1158/0008-5472.CAN-12-4502
   Kataoka K, 2016, NATURE, V534, P402, DOI 10.1038/nature18294
   Kawazoe A, 2020, LANCET ONCOL, V21, P1057, DOI 10.1016/S1470-2045(20)30271-0
   Khan M, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000011936
   Kim R, 2006, CANCER RES, V66, P5527, DOI 10.1158/0008-5472.CAN-05-4128
   Kinneer K, 2018, CLIN CANCER RES, V24, P6570, DOI 10.1158/1078-0432.CCR-18-1300
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Koinis F, 2016, J THORAC ONCOL, V11, P1263, DOI 10.1016/j.jtho.2016.04.026
   Konecny GE, 2006, CANCER RES, V66, P1630, DOI 10.1158/0008-5472.CAN-05-1182
   Kosaka T, 2017, CANCER RES, V77, P2712, DOI 10.1158/0008-5472.CAN-16-3404
   Kotekar AS, 2008, MOL CELL BIOL, V28, P7323, DOI 10.1128/MCB.00889-08
   Kovtun YV, 2010, CANCER RES, V70, P2528, DOI 10.1158/0008-5472.CAN-09-3546
   Koyama S, 2016, CANCER RES, V76, P999, DOI 10.1158/0008-5472.CAN-15-1439
   Krop IE, 2014, LANCET ONCOL, V15, P689, DOI 10.1016/S1470-2045(14)70178-0
   Kubota Y, 2020, CLIN CANCER RES, V26, P3784, DOI 10.1158/1078-0432.CCR-20-0075
   Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023
   Kumagai S, 2020, NAT IMMUNOL, V21, P1346, DOI 10.1038/s41590-020-0769-3
   Kumagai S, 2020, IMMUNITY, V53, P187, DOI 10.1016/j.immuni.2020.06.016
   Kumai T, 2013, BRIT J CANCER, V109, P2155, DOI 10.1038/bjc.2013.577
   Kumai T, 2015, SCI REP-UK, V5, DOI 10.1038/srep16280
   LAHAT N, 1992, CANCER-AM CANCER SOC, V69, P1799, DOI 10.1002/1097-0142(19920401)69:7<1799::AID-CNCR2820690723>3.0.CO;2-8
   Lanaya H, 2014, NAT CELL BIOL, V16, P972, DOI 10.1038/ncb3031
   Lastwika KJ, 2016, CANCER RES, V76, P227, DOI 10.1158/0008-5472.CAN-14-3362
   Lee B, 2016, ONCOTARGET, V7, P23874, DOI 10.18632/oncotarget.8074
   Lee CK, 2017, J THORAC ONCOL, V12, P403, DOI 10.1016/j.jtho.2016.10.007
   Lee JE, 2016, BIOCHEM BIOPH RES CO, V474, P154, DOI 10.1016/j.bbrc.2016.04.089
   Lee J, 2019, THORAC CANCER, V10, P103, DOI 10.1111/1759-7714.12917
   Lee-Hoeflich ST, 2008, CANCER RES, V68, P5878, DOI 10.1158/0008-5472.CAN-08-0380
   Li CL, 2016, NAT COMMUN, V7, DOI [10.1038/ncomms12574, 10.1038/ncomms12632]
   Li CW, 2018, CANCER CELL, V33, P187, DOI 10.1016/j.ccell.2018.01.009
   Li GM, 2018, MOL CANCER THER, V17, P1441, DOI 10.1158/1535-7163.MCT-17-0296
   Li J, 2017, J THORAC DIS, V9, P2560, DOI 10.21037/jtd.2017.07.117
   Lian GH, 2019, TECHNOL CANCER RES T, V18, DOI 10.1177/1533033819849068
   Lohinai Z, 2015, J THORAC ONCOL, V10, P738, DOI 10.1097/JTO.0000000000000492
   Loi S, 2019, LANCET ONCOL, V20, P371, DOI 10.1016/S1470-2045(18)30812-X
   Loi S, 2013, J CLIN ONCOL, V31, P860, DOI 10.1200/JCO.2011.41.0902
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Ma WB, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0203402
   MacDonald F, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00575
   Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501
   Marijt KA, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0627-8
   Marincola F M, 2000, Adv Immunol, V74, P181, DOI 10.1016/S0065-2776(08)60911-6
   Marteau F, 2005, BLOOD, V106, P3860, DOI 10.1182/blood-2005-05-1843
   Mascia F, 2003, AM J PATHOL, V163, P303, DOI 10.1016/S0002-9440(10)63654-1
   Massagué J, 2008, CELL, V134, P215, DOI 10.1016/j.cell.2008.07.001
   Matsuda N, 2018, JAMA ONCOL, V4, P1207, DOI 10.1001/jamaoncol.2018.1436
   Matsuzaki S, 2010, J IMMUNOL, V185, P4863, DOI 10.4049/jimmunol.1000904
   Maynard A, 2020, CELL, V182, P1232, DOI 10.1016/j.cell.2020.07.017
   McGranahan N, 2016, SCIENCE, V351, P1463, DOI 10.1126/science.aaf1490
   Mezzadra R, 2017, NATURE, V549, P106, DOI 10.1038/nature23669
   Mimura K, 2013, J IMMUNOL, V191, P6261, DOI 10.4049/jimmunol.1301597
   Minuti G, 2012, BRIT J CANCER, V107, P793, DOI 10.1038/bjc.2012.335
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Modi S, 2020, NEW ENGL J MED, V382, P610, DOI 10.1056/NEJMoa1914510
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Molina MA, 2001, CANCER RES, V61, P4744
   Montagut C, 2012, NAT MED, V18, P221, DOI 10.1038/nm.2609
   Morello S, 2014, ONCOIMMUNOLOGY, V3, DOI 10.4161/onci.27989
   Mortenson ED, 2013, CLIN CANCER RES, V19, P1476, DOI 10.1158/1078-0432.CCR-12-2522
   Motoyama AB, 2002, CANCER RES, V62, P3151
   Müller P, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.aac4925
   Musolino A, 2008, J CLIN ONCOL, V26, P1789, DOI 10.1200/JCO.2007.14.8957
   Nabeshima A, 2015, BRIT J CANCER, V112, P547, DOI 10.1038/bjc.2014.637
   Nagarsheth N, 2017, NAT REV IMMUNOL, V17, P559, DOI 10.1038/nri.2017.49
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Nagy P, 2005, CANCER RES, V65, P473
   Nahta R, 2004, CANCER RES, V64, P3981, DOI 10.1158/0008-5472.CAN-03-3900
   Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713
   Niederst MJ, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms7377
   Nowak M, 2010, EUR J IMMUNOL, V40, P682, DOI 10.1002/eji.200939897
   O'Brien NA, 2010, MOL CANCER THER, V9, P1489, DOI 10.1158/1535-7163.MCT-09-1171
   Offin M, 2019, CLIN CANCER RES, V25, P1063, DOI 10.1158/1078-0432.CCR-18-1102
   Ogitani Y, 2016, CLIN CANCER RES, V22, P5097, DOI 10.1158/1078-0432.CCR-15-2822
   Ohashi K, 2012, P NATL ACAD SCI USA, V109, pE2127, DOI 10.1073/pnas.1203530109
   Ohta A, 2009, J IMMUNOL, V183, P5487, DOI 10.4049/jimmunol.0901247
   Okita R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139809
   Ou SHI, 2017, LUNG CANCER, V108, P228, DOI 10.1016/j.lungcan.2017.04.003
   Oxnard GR, 2020, ANN ONCOL, V31, P507, DOI 10.1016/j.annonc.2020.01.013
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Pályi-Krekk Z, 2007, EUR J CANCER, V43, P2423, DOI 10.1016/j.ejca.2007.08.018
   Panther E, 2003, BLOOD, V101, P3985, DOI 10.1182/blood-2002-07-2113
   Panther E, 2001, FASEB J, V15, P1963, DOI 10.1096/fj.01-0169com
   Pao W, 2004, P NATL ACAD SCI USA, V101, P13306, DOI 10.1073/pnas.0405220101
   Pao W, 2010, NAT REV CANCER, V10, P760, DOI 10.1038/nrc2947
   Paplomata E, 2014, THER ADV MED ONCOL, V6, P154, DOI 10.1177/1758834014530023
   Pardoll DM, 2012, NAT REV CANCER, V12, P252, DOI 10.1038/nrc3239
   Park LC, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.12050
   Passarelli A, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01479
   Peng DJ, 2015, NATURE, V527, P249, DOI 10.1038/nature15520
   Peng WY, 2016, CANCER DISCOV, V6, P202, DOI 10.1158/2159-8290.CD-15-0283
   Perez EA, 2017, J CLIN ONCOL, V35, P141, DOI 10.1200/JCO.2016.67.4887
   Piccart-Gebhart MJ, 2005, NEW ENGL J MED, V353, P1659, DOI 10.1056/NEJMoa052306
   Pollack BP, 2012, ONCOIMMUNOLOGY, V1, P71, DOI 10.4161/onci.1.1.18073
   Pollack BP, 2011, CLIN CANCER RES, V17, P4400, DOI 10.1158/1078-0432.CCR-10-3283
   Pozzi C, 2016, NAT MED, V22, P624, DOI 10.1038/nm.4078
   Prenzel N, 2001, ENDOCR-RELAT CANCER, V8, P11, DOI 10.1677/erc.0.0080011
   Prickett TD, 2009, NAT GENET, V41, P1127, DOI 10.1038/ng.438
   Reck M, 2019, LANCET RESP MED, V7, P387, DOI 10.1016/S2213-2600(19)30084-0
   Reck M, 2016, NEW ENGL J MED, V375, P1823, DOI 10.1056/NEJMoa1606774
   Ring S, 2010, J IMMUNOL, V184, P3408, DOI 10.4049/jimmunol.0901751
   Rini BI, 2019, NEW ENGL J MED, V380, P1116, DOI 10.1056/NEJMoa1816714
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Robert N, 2006, J CLIN ONCOL, V24, P2786, DOI 10.1200/JCO.2005.04.1764
   Roche PA, 2015, NAT REV IMMUNOL, V15, P203, DOI 10.1038/nri3818
   Romond EH, 2005, NEW ENGL J MED, V353, P1673, DOI 10.1056/NEJMoa052122
   Rooney MS, 2015, CELL, V160, P48, DOI 10.1016/j.cell.2014.12.033
   Rosenthal R, 2019, NATURE, V567, P479, DOI 10.1038/s41586-019-1032-7
   Roskoski R, 2004, BIOCHEM BIOPH RES CO, V319, P1, DOI 10.1016/j.bbrc.2004.04.150
   Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002
   Rusnak DW, 2001, MOL CANCER THER, V1, P85
   Sabbatino F, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv435
   Saito H, 2019, LANCET ONCOL, V20, P625, DOI 10.1016/S1470-2045(19)30035-X
   Sakai T, 2018, LUNG CANCER, V126, P64, DOI 10.1016/j.lungcan.2018.10.021
   Sapkota B, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22890
   Scaltriti M, 2007, J NATL CANCER I, V99, P628, DOI 10.1093/jnci/djk134
   Schneeweiss A, 2013, ANN ONCOL, V24, P2278, DOI 10.1093/annonc/mdt182
   Schoeberl B, 2010, CANCER RES, V70, P2485, DOI 10.1158/0008-5472.CAN-09-3145
   SCHREIBER AB, 1984, J CELL BIOL, V98, P725, DOI 10.1083/jcb.98.2.725
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Schumacher TN, 2015, SCIENCE, V348, P69, DOI 10.1126/science.aaa4971
   Seliger B, 2008, CANCER IMMUNOL IMMUN, V57, P1719, DOI 10.1007/s00262-008-0515-4
   Seliger B, 2014, J IMMUNOTOXICOL, V11, P308, DOI 10.3109/1547691X.2013.875084
   Seliger B, 2008, J IMMUNOTOXICOL, V5, P361, DOI 10.1080/15476910802482870
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Serra V, 2008, CANCER RES, V68, P8022, DOI 10.1158/0008-5472.CAN-08-1385
   Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617
   Sharma SV, 2009, EXP CELL RES, V315, P557, DOI 10.1016/j.yexcr.2008.07.026
   Shen JF, 2018, NAT MED, V24, P556, DOI 10.1038/s41591-018-0012-z
   Sheng Q, 2010, CANCER CELL, V17, P298, DOI 10.1016/j.ccr.2009.12.047
   Shi FM, 2010, P NATL ACAD SCI USA, V107, P7692, DOI 10.1073/pnas.1002753107
   Shi Y, 2014, J THORAC ONCOL, V9, P154, DOI 10.1097/JTO.0000000000000033
   Shibahara D, 2018, J THORAC ONCOL, V13, P926, DOI 10.1016/j.jtho.2018.03.012
   Shigematsu H, 2006, INT J CANCER, V118, P257, DOI 10.1002/ijc.21496
   Shih Andrew J, 2011, Cancers (Basel), V3, P1195, DOI 10.3390/cancers3011195
   Shitara K, 2020, NEW ENGL J MED, V382, P2419, DOI 10.1056/NEJMoa2004413
   Shou JW, 2016, CANCER LETT, V379, P124, DOI 10.1016/j.canlet.2016.06.002
   Sidders B, 2020, CLIN CANCER RES, V26, P2176, DOI 10.1158/1078-0432.CCR-19-2183
   Sivaram N, 2019, J CLIN INVEST, V129, P3264, DOI 10.1172/JCI123540
   Skoulidis F, 2018, CANCER DISCOV, V8, P822, DOI 10.1158/2159-8290.CD-18-0099
   Slamon DJ, 2001, NEW ENGL J MED, V344, P783, DOI 10.1056/NEJM200103153441101
   SLAMON DJ, 1987, SCIENCE, V235, P177, DOI 10.1126/science.3798106
   Smith LM, 2006, MOL CANCER THER, V5, P1474, DOI 10.1158/1535-7163.MCT-06-0026
   Socinski MA, 2018, NEW ENGL J MED, V378, P2288, DOI 10.1056/NEJMoa1716948
   Sos ML, 2009, CANCER RES, V69, P3256, DOI 10.1158/0008-5472.CAN-08-4055
   SPORN MB, 1985, NATURE, V313, P745, DOI 10.1038/313745a0
   Spranger S, 2013, SCI TRANSL MED, V5, DOI 10.1126/scitranslmed.3006504
   Srivatsa S, 2017, GASTROENTEROLOGY, V153, P178, DOI 10.1053/j.gastro.2017.03.053
   Streicher K, 2017, J CLIN ONCOL, V35, P1150
   Suda K, 2017, EXPERT REV ANTICANC, V17, P779, DOI 10.1080/14737140.2017.1355243
   SUGAWA N, 1990, P NATL ACAD SCI USA, V87, P8602, DOI 10.1073/pnas.87.21.8602
   Sugiyama E, 2020, SCI IMMUNOL, V5, DOI 10.1126/sciimmunol.aav3937
   Sun LH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-65207-6
   Sundvall M, 2008, J MAMMARY GLAND BIOL, V13, P259, DOI 10.1007/s10911-008-9079-3
   Sung M, 2018, MOL CANCER THER, V17, P243, DOI 10.1158/1535-7163.MCT-17-0403
   Tada Y, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0403-1
   Takada K, 2018, LUNG CANCER, V116, P1, DOI 10.1016/j.lungcan.2017.12.003
   Takezawa K, 2012, CANCER DISCOV, V2, P922, DOI 10.1158/2159-8290.CD-12-0108
   Thorsson V, 2019, IMMUNITY, V51, P411, DOI [10.1016/j.immuni.2019.08.004, 10.1016/j.immuni.2018.03.023]
   Thress KS, 2015, NAT MED, V21, P560, DOI 10.1038/nm.3854
   Todorovic-Rakovic N, 2013, J INTERF CYTOK RES, V33, P563, DOI 10.1089/jir.2013.0023
   Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7
   Tricker EM, 2015, CANCER DISCOV, V5, P960, DOI 10.1158/2159-8290.CD-15-0063
   Trivedi S, 2016, CLIN CANCER RES, V22, P5229, DOI 10.1158/1078-0432.CCR-15-2971
   Trotta AM, 2016, CANCER IMMUNOL RES, V4, P366, DOI 10.1158/2326-6066.CIR-15-0184
   Tseng PC, 2016, ONCOTARGET, V7, P15150, DOI 10.18632/oncotarget.7750
   Tu E, 2014, CYTOKINE GROWTH F R, V25, P423, DOI 10.1016/j.cytogfr.2014.07.014
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   van den Elsen PJ, 2011, FRONT IMMUNOL, V2, DOI 10.3389/fimmu.2011.00048
   van der Burg SH, 2016, NAT REV CANCER, V16, P219, DOI 10.1038/nrc.2016.16
   Van Raemdonck K, 2015, CYTOKINE GROWTH F R, V26, P311, DOI 10.1016/j.cytogfr.2014.11.009
   VANDERBRUGGEN P, 1991, SCIENCE, V254, P1643, DOI 10.1126/science.1840703
   Vantourout P, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007579
   Varadan V, 2016, CLIN CANCER RES, V22, P3249, DOI 10.1158/1078-0432.CCR-15-2021
   Verma S, 2012, NEW ENGL J MED, V367, P1783, DOI 10.1056/NEJMoa1209124
   Wang CH, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000005539
   Wang SX, 2018, ONCOGENE, V37, P3924, DOI 10.1038/s41388-018-0245-9
   Wang Xiaoping, 2017, Oncotarget, V8, P67904, DOI 10.18632/oncotarget.18958
   Watanabe S, 2019, CANCER SCI, V110, P52, DOI 10.1111/cas.13860
   Whipple CA, 2016, MELANOMA RES, V26, P223, DOI 10.1097/CMR.0000000000000244
   Wilson TR, 2012, NATURE, V487, P505, DOI 10.1038/nature11249
   Wintterle S, 2003, CANCER RES, V63, P7462
   Witta SE, 2006, CANCER RES, V66, P944, DOI 10.1158/0008-5472.CAN-05-1988
   Wu JY, 2008, CLIN CANCER RES, V14, P4877, DOI 10.1158/1078-0432.CCR-07-5123
   Wu SY, 2019, NAT CELL BIOL, V21, P1027, DOI 10.1038/s41556-019-0352-z
   Xia WL, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3480
   Xu XW, 2017, CLIN CANCER RES, V23, P5123, DOI 10.1158/1078-0432.CCR-16-2191
   Yakes FM, 2002, CANCER RES, V62, P4132
   Yamada T, 2019, CANCER MED-US, V8, P1521, DOI 10.1002/cam4.2037
   Yamaguchi R, 2012, HUM PATHOL, V43, P1688, DOI 10.1016/j.humpath.2011.12.013
   Yang JCH, 2019, J THORAC ONCOL, V14, P553, DOI 10.1016/j.jtho.2018.11.028
   Yang JCH, 2019, J THORAC ONCOL, V14, P933, DOI 10.1016/j.jtho.2019.02.001
   Yano S, 2008, CANCER RES, V68, P9479, DOI 10.1158/0008-5472.CAN-08-1643
   Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107
   Yarchoan M, 2017, NEW ENGL J MED, V377, P2500, DOI 10.1056/NEJMc1713444
   Yarden Y, 2001, NAT REV MOL CELL BIO, V2, P127, DOI 10.1038/35052073
   Yarden Y, 2012, NAT REV CANCER, V12, P553, DOI 10.1038/nrc3309
   Yoshida T, 2010, CANCER SCI, V101, P167, DOI 10.1111/j.1349-7006.2009.01368.x
   Yoshida T, 2015, CLIN CANCER RES, V21, P642, DOI 10.1158/1078-0432.CCR-14-0846
   Yuen KC, 2020, NAT MED, V26, P693, DOI 10.1038/s41591-020-0860-1
   Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023
   Zarek PE, 2008, BLOOD, V111, P251, DOI 10.1182/blood-2007-03-081646
   Zhang H, 2004, J IMMUNOL, V173, P932, DOI 10.4049/jimmunol.173.2.932
   Zhang N, 2016, INT J ONCOL, V49, P1360, DOI 10.3892/ijo.2016.3632
   Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330
   Zhao RH, 2013, P NATL ACAD SCI USA, V110, P9879, DOI 10.1073/pnas.1303524110
   Zhou Q, 2012, BRIT J PHARMACOL, V166, P1756, DOI 10.1111/j.1476-5381.2012.01875.x
NR 321
TC 156
Z9 166
U1 15
U2 32
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1474-175X
EI 1474-1768
J9 NAT REV CANCER
JI Nat. Rev. Cancer
PD MAR
PY 2021
VL 21
IS 3
BP 181
EP 197
DI 10.1038/s41568-020-00322-0
EA JAN 2021
PG 17
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA QP8JY
UT WOS:000608680300004
PM 33462501
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Pandya, K
   Overman, MJ
   Gulhati, P
AF Pandya, Karan
   Overman, Michael J.
   Gulhati, Pat
TI Molecular Landscape of Small Bowel Adenocarcinoma
SO CANCERS
LA English
DT Article
DE small bowel adenocarcinoma; BRAF alteration; ERBB2/HER2 alteration;
   microsatellite instability (MSI); tumor mutational burden (TMB);
   colorectal cancer (CRC); gastric cancer (GC)
ID ISLAND METHYLATOR PHENOTYPE; COLORECTAL-CANCER; MICROSATELLITE
   INSTABILITY; SMALL-INTESTINE; RISK-FACTORS; CHROMOSOMAL INSTABILITY;
   MISMATCH-REPAIR; CROHNS-DISEASE; UNITED-STATES; E-CADHERIN
AB Simple Summary: Small bowel adenocarcinoma (SBA) is a rare malignancy with worse prognosis compared to other cancers of the gastrointestinal tract. Over 90% of SBA tumors harbor targetable genetic alterations. Molecular analysis to identify these alterations, using tissue- or blood-based next generation sequencing, is critical and may impact treatment decisions. The aim of our review is to highlight molecular drivers of SBA tumorigenesis. We highlight key mutational and transcriptomic differences between SBA and colorectal cancer, from which much of the clinical management of SBA is currently extrapolated. We provide evidence that SBA is a molecularly unique intestinal malignancy, with distinct genomic alterations predictive of response to targeted therapy and immunotherapy.
   Abstract: Small bowel adenocarcinoma (SBA) is a rare malignancy, with lower incidence, later stage at diagnosis, and poor overall prognosis compared to other cancers of the gastrointestinal tract. Owing to the rarity of the disease along with the paucity of high-quality tissue samples and preclinical models, little is known about the molecular alterations characteristic of SBA. This is reflected by the fact that the clinical management of SBA is primarily extrapolated from colorectal cancer (CRC). Recent advances in genomic profiling have highlighted key differences between these tumors, establishing SBA as a molecularly unique intestinal cancer. Moreover, comprehensive molecular analysis has identified a relatively high incidence of potentially targetable genomic alterations in SBA, predictive of response to targeted and immunotherapies. Further advances in our knowledge of the mutational and transcriptomic landscape of SBA, guided by an increased understanding of the molecular drivers of SBA, will provide opportunities to develop novel diagnostic tools and personalized therapeutic strategies.
C1 [Pandya, Karan; Gulhati, Pat] Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Div Med Oncol, New Brunswick, NJ 08901 USA.
   [Pandya, Karan; Gulhati, Pat] Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.
   [Overman, Michael J.] MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Div Canc Med, Houston, TX 77030 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers Cancer Institute of New Jersey; University of Texas
   System; UTMD Anderson Cancer Center
RP Gulhati, P (corresponding author), Rutgers State Univ, Robert Wood Johnson Med Sch, Dept Med, Div Med Oncol, New Brunswick, NJ 08901 USA.; Gulhati, P (corresponding author), Rutgers State Univ, Rutgers Canc Inst New Jersey, New Brunswick, NJ 08901 USA.
EM karan.pandya@rutgers.edu; moverman@mdanderson.org;
   pat.gulhati@rutgers.edu
CR Aarnio M, 1995, INT J CANCER, V64, P430, DOI 10.1002/ijc.2910640613
   Adam L, 2019, CLIN CANCER RES, V25, P641, DOI 10.1158/1078-0432.CCR-18-1480
   Akhtar-Zaidi B, 2012, SCIENCE, V336, P736, DOI 10.1126/science.1217277
   Alvi MA, 2015, ONCOTARGET, V6, P20863, DOI 10.18632/oncotarget.4576
   Anfossi S, 2018, ADV EXP MED BIOL, V1056, P87, DOI 10.1007/978-3-319-74470-4_6
   Aparicio T, 2013, BRIT J CANCER, V109, P3057, DOI 10.1038/bjc.2013.677
   Aparicio T, 2014, DIGEST LIVER DIS, V46, P97, DOI 10.1016/j.dld.2013.04.013
   Bariol C, 2003, AM J PATHOL, V162, P1361, DOI 10.1016/S0002-9440(10)63932-6
   Bläker H, 2004, SCAND J GASTROENTERO, V39, P748, DOI 10.1080/00365520410005847
   Blandino G, 2014, FEBS LETT, V588, P2639, DOI 10.1016/j.febslet.2014.03.033
   Bonadona V, 2011, JAMA-J AM MED ASSOC, V305, P2304, DOI 10.1001/jama.2011.743
   Brannon AR, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0454-7
   BULOW S, 1995, INT J COLORECTAL DIS, V10, P43, DOI 10.1007/BF00337586
   Cahill C, 2014, WORLD J GASTROENTERO, V20, P11486, DOI 10.3748/wjg.v20.i33.11486
   Caio G, 2019, BMC GASTROENTEROL, V19, DOI 10.1186/s12876-019-0964-6
   CALMAN KC, 1974, GUT, V15, P552, DOI 10.1136/gut.15.7.552
   Cancer Genome Atlas Network, 2012, Nature, V487, P330, DOI 10.1038/nature11252
   Chan TL, 2001, ONCOGENE, V20, P4871, DOI 10.1038/sj.onc.1204653
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen H, 2019, J CELL MOL MED, V23, P3050, DOI 10.1111/jcmm.14209
   Cheng YW, 2008, CLIN CANCER RES, V14, P6005, DOI 10.1158/1078-0432.CCR-08-0216
   CHOW WH, 1993, CANCER CAUSE CONTROL, V4, P163, DOI 10.1007/BF00053158
   Chu Y, 2013, NETH J MED, V71, P69
   CIRESI DL, 1995, AM SURGEON, V61, P698
   Cross AJ, 2008, CANCER RES, V68, P9274, DOI 10.1158/0008-5472.CAN-08-2015
   Delaunoit T, 2005, AM J GASTROENTEROL, V100, P703, DOI 10.1111/j.1572-0241.2005.40605.x
   Dennis KL, 2015, CANCER IMMUNOL RES, V3, P806, DOI 10.1158/2326-6066.CIR-14-0169
   DeSesso JM, 2001, FOOD CHEM TOXICOL, V39, P209, DOI 10.1016/S0278-6915(00)00136-8
   Diaz LA, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3003
   Diosdado B, 2010, CLIN CANCER RES, V16, P1391, DOI 10.1158/1078-0432.CCR-09-1773
   El Bairi K, 2018, CANCER GENET-NY, V220, P49, DOI 10.1016/j.cancergen.2017.11.001
   Fleisher AS, 1999, CANCER RES, V59, P1090
   Gao YB, 2014, NAT GENET, V46, P1097, DOI 10.1038/ng.3076
   Garcia-Foncillas J, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00849
   Giannakis M, 2016, CELL REP, V15, P857, DOI 10.1016/j.celrep.2016.03.075
   Giannakis M, 2014, NAT GENET, V46, P1264, DOI 10.1038/ng.3127
   Giardiello FM, 2000, GASTROENTEROLOGY, V119, P1447, DOI 10.1053/gast.2000.20228
   Goel A, 2007, GASTROENTEROLOGY, V132, P127, DOI 10.1053/j.gastro.2006.09.018
   Grasso CS, 2012, NATURE, V487, P239, DOI 10.1038/nature11125
   Green PHR, 2003, AM J MED, V115, P191, DOI 10.1016/S0002-9343(03)00302-4
   Groves CJ, 2002, GUT, V50, P636, DOI 10.1136/gut.50.5.636
   Gulhati P, 2018, ONCOLOGIST, V23, P277, DOI 10.1634/theoncologist.2017-0568
   Guo YC, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18040890
   Haan JC, 2012, ANN ONCOL, V23, P367, DOI 10.1093/annonc/mdr122
   Hänninen UA, 2018, PLOS GENET, V14, DOI 10.1371/journal.pgen.1007200
   Haselkorn T, 2005, CANCER CAUSE CONTROL, V16, P781, DOI 10.1007/s10552-005-3635-6
   Hawkins NJ, 2001, BRIT J CANCER, V84, P232, DOI 10.1054/bjoc.2000.1554
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Herman JG, 1999, SEMIN CANCER BIOL, V9, P359, DOI 10.1006/scbi.1999.0138
   Howdle PD, 2004, GUT, V53, P470
   Huarte M, 2015, NAT MED, V21, P1253, DOI 10.1038/nm.3981
   Issa JP, 2008, CLIN CANCER RES, V14, P5939, DOI 10.1158/1078-0432.CCR-08-1596
   Ivkovic TC, 2017, CANCER LETT, V407, P113, DOI 10.1016/j.canlet.2017.04.007
   JAGELMAN DG, 1988, LANCET, V1, P1149
   Jass JR, 2007, HISTOPATHOLOGY, V50, P113, DOI 10.1111/j.1365-2559.2006.02549.x
   Kaerlev L, 2000, CANCER CAUSE CONTROL, V11, P791, DOI 10.1023/A:1008920502888
   Kantidakis T, 2016, GENE DEV, V30, P408, DOI 10.1101/gad.275453.115
   Kelsey CR, 2007, INT J RADIAT ONCOL, V69, P1436, DOI 10.1016/j.ijrobp.2007.05.006
   Kim H, 2003, J PATHOL, V200, P23, DOI 10.1002/path.1325
   Koo BK, 2015, P NATL ACAD SCI USA, V112, P7548, DOI 10.1073/pnas.1508113112
   Koo BK, 2012, NATURE, V488, P665, DOI 10.1038/nature11308
   Laforest A, 2014, EUR J CANCER, V50, P1740, DOI 10.1016/j.ejca.2014.04.007
   Lannagan TRM, 2019, GUT, V68, P684, DOI 10.1136/gutjnl-2017-315920
   Lao VV, 2011, NAT REV GASTRO HEPAT, V8, P686, DOI 10.1038/nrgastro.2011.173
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee HJ, 2013, AM J CLIN PATHOL, V139, P167, DOI 10.1309/AJCPS54RTFCTHGWX
   Liu WL, 2022, ONCOGENE, V41, P72, DOI 10.1038/s41388-021-02072-1
   Loregger A, 2015, SCI SIGNAL, V8, DOI 10.1126/scisignal.aac6757
   LOWENFELS AB, 1973, LANCET, V1, P24
   Malczewska A, 2021, ANN SURG, V274, pE1, DOI 10.1097/SLA.0000000000003502
   Migliore L, 2011, J BIOMED BIOTECHNOL, DOI 10.1155/2011/792362
   Miller HC, 2016, ENDOCR-RELAT CANCER, V23, P711, DOI 10.1530/ERC-16-0044
   MIYAKI M, 1994, CANCER RES, V54, P3011
   Mohammadi A, 2016, BIOMED PHARMACOTHER, V84, P705, DOI 10.1016/j.biopha.2016.09.099
   Muhammad S, 2014, WORLD J GASTROENTERO, V20, P17011, DOI 10.3748/wjg.v20.i45.17011
   Negri E, 1999, INT J CANCER, V82, P171, DOI 10.1002/(SICI)1097-0215(19990719)82:2<171::AID-IJC3>3.0.CO;2-T
   Neugut AI, 1998, CANCER EPIDEM BIOMAR, V7, P243
   Oom AL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/959461
   Orang AV, 2014, ASIAN PAC J CANCER P, V15, P6989, DOI 10.7314/APJCP.2014.15.17.6989
   Orellana EA, 2015, CANCERS, V7, P1388, DOI 10.3390/cancers7030842
   Overman MJ, 2010, BRIT J CANCER, V103, P1306, DOI 10.1038/sj.bjc.6605899
   Overman M.J., 2016, SMALL BOWEL CANC APP
   Overman MJ, 2012, ANN SURG ONCOL, V19, P1439, DOI 10.1245/s10434-011-2173-6
   Palascak-Juif V, 2005, INFLAMM BOWEL DIS, V11, P828, DOI 10.1097/01.mib.0000179211.03650.b6
   Pedersen KS, 2019, J NATL COMPR CANC NE, V17, P1135, DOI 10.6004/jnccn.2019.7344
   Pichler M, 2015, BRIT J CANCER, V113, P569, DOI 10.1038/bjc.2015.253
   Poddar N, 2011, CASE REP ONCOL, V4, P458, DOI 10.1159/000332043
   Porcellini E, 2018, CANCER LETT, V419, P84, DOI 10.1016/j.canlet.2018.01.049
   Potter DD, 2004, CANCER RES, V64, P7073, DOI 10.1158/0008-5472.CAN-04-1096
   Raghav K, 2013, NAT REV CLIN ONCOL, V10, P534, DOI 10.1038/nrclinonc.2013.132
   Rampertab SD, 2003, GUT, V52, P1211, DOI 10.1136/gut.52.8.1211
   Rao RC, 2015, NAT REV CANCER, V15, P334, DOI 10.1038/nrc3929
   Rodriguez-Bigas MA, 1998, CANCER, V83, P240
   Romano G, 2017, CARCINOGENESIS, V38, P485, DOI 10.1093/carcin/bgx026
   Sanders LM, 2004, CANCER LETT, V208, P155, DOI 10.1016/j.canlet.2003.12.007
   Santini D, 2010, BRIT J CANCER, V103, P1305, DOI 10.1038/sj.bjc.6605898
   Sausen M, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8686
   Schetter AJ, 2012, CANCER J, V18, P244, DOI 10.1097/PPO.0b013e318258b78f
   Schottenfeld D, 2009, ANN EPIDEMIOL, V19, P58, DOI 10.1016/j.annepidem.2008.10.004
   Schrock AB, 2017, JAMA ONCOL, V3, P1546, DOI 10.1001/jamaoncol.2017.1051
   Siegel R. L., 2021, CA-CANCER J CLIN, V71, P7, DOI [DOI 10.3322/caac.21387, DOI 10.3322/CAAC.21654]
   Spit M, 2020, EMBO J, V39, DOI 10.15252/embj.2019103932
   Suzuki H, 2015, AM J PATHOL, V185, P550, DOI 10.1016/j.ajpath.2014.10.006
   Talamonti MS, 2002, ARCH SURG-CHICAGO, V137, P564, DOI 10.1001/archsurg.137.5.564
   Tang RP, 2004, CARCINOGENESIS, V25, P841, DOI 10.1093/carcin/bgh074
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Tubbs A, 2017, CELL, V168, DOI 10.1016/j.cell.2017.01.002
   Vasen HFA, 1996, GASTROENTEROLOGY, V110, P1020, DOI 10.1053/gast.1996.v110.pm8612988
   von Roon AC, 2007, DIS COLON RECTUM, V50, P839, DOI 10.1007/s10350-006-0848-z
   Warth A, 2011, MODERN PATHOL, V24, P564, DOI 10.1038/modpathol.2010.223
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Wu AH, 1997, INT J CANCER, V70, P512, DOI 10.1002/(SICI)1097-0215(19970304)70:5<512::AID-IJC4>3.0.CO;2-0
   Yaeger R, 2016, GASTROENTEROLOGY, V151, P278, DOI 10.1053/j.gastro.2016.04.001
   Yao J, 1999, INT J CANCER, V80, P667, DOI 10.1002/(SICI)1097-0215(19990301)80:5<667::AID-IJC6>3.0.CO;2-0
   Young JI, 2016, DIS COLON RECTUM, V59, P306, DOI 10.1097/DCR.0000000000000562
NR 115
TC 12
Z9 12
U1 0
U2 5
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2022
VL 14
IS 5
AR 1287
DI 10.3390/cancers14051287
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA ZT4BD
UT WOS:000769102600001
PM 35267592
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Thomsen, CB
   Andersen, RF
   Lindebjerg, J
   Hansen, TF
   Jensen, LH
   Jakobsen, A
AF Thomsen, Caroline Brenner
   Andersen, Rikke Fredslund
   Lindebjerg, Jan
   Hansen, Torben Frostrup
   Jensen, Lars Henrik
   Jakobsen, Anders
TI Plasma Dynamics of <i>RAS</i>/<i>RAF</i> Mutations in Patients With
   Metastatic Colorectal Cancer Receiving Chemotherapy and Anti-<i>EGFR</i>
   Treatment
SO CLINICAL COLORECTAL CANCER
LA English
DT Article
DE Biomarkers; ctDNA; Liquid biopsy; Precision medicine; Targeted therapy
ID CIRCULATING TUMOR DNA; ACQUIRED-RESISTANCE; RAS MUTATIONS; CETUXIMAB;
   EVOLUTION; BLOCKADE; THERAPY; HETEROGENEITY; EMERGENCE
AB This study aimed to investigate the clinical aspects of RAS/RAF mutations during chemotherapy and anti-EGFR treatment in tumor wild-type patients. Blood samples were collected from 46 patients at every treatment cycle until progressive disease or censoring. Emergence of mutations was not correlated with treatment effect.
   Background: RAS and RAF mutations in colorectal cancer (CRC) hold value in precision medicine. Liquid biopsy is an alternative to tumor tissue biopsy, and circulating tumor DNA (ctDNA) has been intensively investigated, but the clinical relevance of RAS and RAF mutations in plasma is yet to be determined. This study aimed to investigate the clinical aspects of RAS/RAF mutations during combination treatment. Patients and Methods: Patients with RAS/RAF tumor wild-type metastatic CRC treated with combination chemotherapy and an EGFR inhibitor were included. Blood samples were collected at baseline and every treatment cycle and analyzed for 31 RAS, RAF, and EGFR mutations until progressive disease or censoring using droplet digital PCR. Results: Forty-six patients were prospectively enrolled onto the study. At baseline, 7% had detectable RAS/RAF mutations in ctDNA. During the treatment course, the fraction of patients with mutated ctDNA increased to 22%. The emergence of mutations did not correlate with response or risk of progression while receiving treatment (P = 1.0). Conclusion: Emergence of plasma RAS/RAF mutations was not correlated with the effect of combination chemotherapy and EGFR inhibition in patients with RAS/RAF wild-type metastatic CRC. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Thomsen, Caroline Brenner; Andersen, Rikke Fredslund; Lindebjerg, Jan; Hansen, Torben Frostrup; Jensen, Lars Henrik; Jakobsen, Anders] Vejle Hosp, Danish Colorectal Canc Ctr South, Beriderbakken 4, DK-7100 Vejle, Denmark.
   [Thomsen, Caroline Brenner; Lindebjerg, Jan; Hansen, Torben Frostrup; Jensen, Lars Henrik; Jakobsen, Anders] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark.
C3 University of Southern Denmark; Lillebaelt Hospital; University of
   Southern Denmark
RP Thomsen, CB (corresponding author), Vejle Hosp, Danish Colorectal Canc Ctr South, Beriderbakken 4, DK-7100 Vejle, Denmark.
EM Caroline.Emilie.Brenner.Thomsen@rsyd.dk
RI Hansen, Torben/J-8065-2012; Andersen, Rikke/GRS-3064-2022; Jensen, Lars
   Henrik/P-6252-2018
OI Thomsen, Caroline Emilie Brenner/0000-0003-4481-6274; Andersen, Rikke
   Fredslund/0000-0002-5894-7745; Hansen, Torben/0000-0001-7476-671X;
   Jensen, Lars Henrik/0000-0002-0020-1537; Jakobsen,
   Anders/0000-0003-2110-2615
CR Andersen RF, 2016, CLIN CHIM ACTA, V458, P138, DOI 10.1016/j.cca.2016.05.007
   Arena S, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aad5640
   Arena S, 2015, CLIN CANCER RES, V21, P2157, DOI 10.1158/1078-0432.CCR-14-2821
   De Mattos-Arruda L, 2014, ANN ONCOL, V25, P1729, DOI 10.1093/annonc/mdu239
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Grasselli J, 2017, ANN ONCOL, V28, P1294, DOI 10.1093/annonc/mdx112
   Guren TK, 2017, BRIT J CANCER, V116, P1271, DOI 10.1038/bjc.2017.93
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kim TW, 2016, EUR J CANCER, V69, pS13, DOI 10.1016/S0959-8049(16)32628-4
   Klein-Scory S, 2018, TRANSL ONCOL, V11, P213, DOI 10.1016/j.tranon.2017.12.010
   McShane LM, 2005, NAT CLIN PRACT UROL, V2, pA416, DOI 10.1038/ncponc0252
   Merker JD, 2018, J CLIN ONCOL, V36, P1631, DOI 10.1200/JCO.2017.76.8671
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Morelli MP, 2015, ANN ONCOL, V26, P731, DOI 10.1093/annonc/mdv005
   Normanno N, 2017, ANN ONCOL, V29, P1
   Pallisgaard N, 2015, CLIN CHIM ACTA, V446, P141, DOI 10.1016/j.cca.2015.04.015
   Pietrantonio F, 2017, CLIN CANCER RES, V23, P2414, DOI 10.1158/1078-0432.CCR-16-1863
   Siena S, 2018, ANN ONCOL, V29, P119, DOI 10.1093/annonc/mdx504
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Thierry AR, 2017, ANN ONCOL, V28, P2149, DOI 10.1093/annonc/mdx330
   Thierry AR, 2017, CLIN CANCER RES, V23, P4578, DOI 10.1158/1078-0432.CCR-17-0232
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   van Emburgh BO, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms13665
   Vidal J, 2017, ANN ONCOL, V28, P1325, DOI 10.1093/annonc/mdx125
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
NR 26
TC 10
Z9 10
U1 0
U2 0
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1533-0028
EI 1938-0674
J9 CLIN COLORECTAL CANC
JI Clin. Colorectal Canc.
PD MAR
PY 2019
VL 18
IS 1
BP 28
EP +
DI 10.1016/j.clcc.2018.10.004
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HP9VM
UT WOS:000462041100019
PM 30459076
OA Green Submitted
DA 2025-01-04
ER

PT J
AU Han, J
   Zhao, ZT
   Zhang, N
   Yang, Y
   Ma, LY
   Feng, L
   Zhang, X
   Zuo, J
   Fan, ZS
   Wang, YD
   Song, YM
   Wang, GY
AF Han, Jing
   Zhao, Zitong
   Zhang, Nan
   Yang, Yang
   Ma, Liying
   Feng, Li
   Zhang, Xue
   Zuo, Jing
   Fan, Zhisong
   Wang, Yudong
   Song, Yongmei
   Wang, Guiying
TI Transcriptional dysregulation of TRIM29 promotes colorectal cancer
   carcinogenesis via pyruvate kinase-mediated glucose metabolism
SO AGING-US
LA English
DT Article
DE colorectal cancer; TRIM29; transcriptional regulation; PKM1; glucose
   metabolism
ID BLADDER-CANCER; OVEREXPRESSION; IDENTIFICATION; PROLIFERATION; REGULATOR
AB Targeted molecular therapy is the most effective treatment for cancer. An effective therapeutic target for colorectal cancer (CRC) is urgently needed. However, the mechanisms of CRC remain poorly understood, which has hampered research and development of CRC-targeted therapy. TRIM29 is a ubiquitin E3 ligase that has been reported as an oncogene in several human tumors. In this study, we show that increased levels of TRIM29 were detected in CRC compared with normal tissues and were associated with poor clinical outcome, advanced stage and lymph node metastasis, particularly those with right-sided colorectal cancer (RSCC). Notably, GATA2 (GATA Binding Protein 2) transcriptionally repressed TRIM29 expression. The loss of GATA2 and high expression of TRIM29 occur more frequently in RSCC than in left-sided colorectal cancer (LSCC). Functional assays revealed that TRIM29 promotes the malignant CRC phenotype in vitro and in vivo. Mechanistic analyses indicate that TRIM29 promotes pyruvate kinase (mainly PKM1) degradation via the ubiquitin-proteasome pathway. TRIM29 directly targets PKM1 to reduce PKM1/PKM2 ratio, which results in PKM2-mediated aerobic glycolysis (Warburg effect) acting as the dominant energy source in CRC. Our findings suggest that TRIM29 acts as a tumor promoter in CRC, especially in RSCC, and is a potential therapeutic target for CRC treatment.
C1 [Han, Jing; Feng, Li; Zhang, Xue; Zuo, Jing; Fan, Zhisong; Wang, Yudong] Hebei Med Univ, Dept Med Oncol, Affiliated Hosp 4, Shijiazhuang 050000, Hebei, Peoples R China.
   [Han, Jing; Zhang, Nan; Yang, Yang; Feng, Li; Zhang, Xue; Zuo, Jing; Fan, Zhisong; Wang, Yudong; Wang, Guiying] Hebei Prov Tumor Hosp, Shijiazhuang 050000, Hebei, Peoples R China.
   [Zhao, Zitong; Ma, Liying; Song, Yongmei] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China.
   [Zhang, Nan] Hebei Med Univ, Dept Thorac Surg, Affiliated Hosp 4, Shijiazhuang 050000, Hebei, Peoples R China.
   [Yang, Yang; Wang, Guiying] Hebei Med Univ, Dept Gen Surg, Affiliated Hosp 4, Shijiazhuang 050000, Hebei, Peoples R China.
   [Wang, Guiying] Hebei Med Univ, Affiliated Hosp 3, Dept Gen Surg, Shijiazhuang 050000, Hebei, Peoples R China.
C3 Hebei Medical University; Chinese Academy of Medical Sciences - Peking
   Union Medical College; Peking Union Medical College; Cancer Institute &
   Hospital - CAMS; Hebei Medical University; Hebei Medical University;
   Hebei Medical University
RP Wang, GY (corresponding author), Hebei Prov Tumor Hosp, Shijiazhuang 050000, Hebei, Peoples R China.; Song, YM (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, State Key Lab Mol Oncol,Natl Canc Ctr, Beijing 100021, Peoples R China.; Wang, GY (corresponding author), Hebei Med Univ, Dept Gen Surg, Affiliated Hosp 4, Shijiazhuang 050000, Hebei, Peoples R China.; Wang, GY (corresponding author), Hebei Med Univ, Affiliated Hosp 3, Dept Gen Surg, Shijiazhuang 050000, Hebei, Peoples R China.
EM songym@cicams.ac.cn; wangguiying@hebmu.edu.cn
RI Fan, Zhisong/AAH-9736-2019; Wang, Yu-Dong/JEZ-9111-2023
OI song, yongmei/0000-0002-7789-0158; Wang, Yu-Dong/0000-0001-8302-5518
FU National Key Research and Development Program of China [2016YFA0500303];
   National Natural Science Foundation of China [81872398]; CAMS Innovation
   Fund for Medical Sciences (CIFMS) [2019-I2M-1-003]
FX This work was supported by funding from the National Key Research and
   Development Program of China (no. 2016YFA0500303) , the National Natural
   Science Foundation of China (no. 81872398) , and the CAMS Innovation
   Fund for Medical Sciences (CIFMS; grant no. 2019-I2M-1-003) .
CR Al-Khayal K, 2016, ONCOL REP, V35, P1281, DOI 10.3892/or.2015.4494
   Bhalla A, 2018, CLIN LAB MED, V38, P311, DOI 10.1016/j.cll.2018.02.008
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Calero-Nieto FJ, 2014, EMBO J, V33, P1212, DOI 10.1002/embj.201386825
   Campos-da-Paz Mariana, 2018, Recent Pat Biotechnol, V12, P269, DOI 10.2174/1872208312666180731104244
   Castano J, 2019, STEM CELL REP, V13, P515, DOI 10.1016/j.stemcr.2019.07.009
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Cong JJ, 2018, CELL METAB, V28, P243, DOI 10.1016/j.cmet.2018.06.021
   Dou YL, 2019, J IMMUNOL, V203, P873, DOI 10.4049/jimmunol.1900171
   Dulson SJ, 2019, J IMMUNOL, V203, P2472, DOI 10.4049/jimmunol.1900719
   Fujiwara T, 2009, MOL CELL, V36, P667, DOI 10.1016/j.molcel.2009.11.001
   Gonzalez-Pons M, 2015, BIOMED RES INT, V2015, DOI 10.1155/2015/149014
   Graziano F, 2017, PHARMACOGENOMICS J, V17, P258, DOI 10.1038/tpj.2016.13
   He CY, 2017, GENE DEV, V31, P1666, DOI 10.1101/gad.300384.117
   Jiang L, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1428-0
   Jiang T, 2013, MED ONCOL, V30, DOI 10.1007/s12032-013-0715-4
   Katsumura KR, 2018, P NATL ACAD SCI USA, V115, pE10109, DOI 10.1073/pnas.1813015115
   Khan R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20184338
   Li M, 2018, CANCER MED-US, V7, P4650, DOI 10.1002/cam4.1696
   Li R, 2018, GENE DEV, V32, P96, DOI 10.1101/gad.309583.117
   Li YY, 2018, BIOCHEM BIOPH RES CO, V505, P1161, DOI 10.1016/j.bbrc.2018.10.056
   Luk IY, 2018, MOLECULES, V23, DOI 10.3390/molecules23092191
   Ogino Y, 2018, J STEROID BIOCHEM, V184, P38, DOI 10.1016/j.jsbmb.2018.06.002
   Plymate SR, 2015, CANCER CELL, V27, P158, DOI 10.1016/j.ccell.2015.01.008
   Qiu F, 2015, INT J CLIN EXP PATHO, V8, P5053
   Rahman MR, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55010020
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Rooper LM, 2018, AM J SURG PATHOL, V42, P665, DOI 10.1097/PAS.0000000000001037
   Ruzycki PA, 2018, EPIGENET CHROMATIN, V11, DOI 10.1186/s13072-018-0212-2
   Srivastava J, 2016, MOL CARCINOGEN, V55, P1889, DOI 10.1002/mc.22438
   Sun JT, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1098-y
   Tan ST, 2016, CANCER RES TREAT, V48, P1302, DOI 10.4143/crt.2015.381
   Tian HL, 2019, CHEM-BIOL INTERACT, V308, P244, DOI 10.1016/j.cbi.2019.05.042
   Vicente C, 2012, LEUKEMIA, V26, P550, DOI 10.1038/leu.2011.235
   Vidal SJ, 2015, CANCER CELL, V27, P223, DOI 10.1016/j.ccell.2014.11.013
   Wang LD, 2014, CANCER RES, V74, P1778, DOI 10.1158/0008-5472.CAN-13-2289
   Wang XY, 2020, MOL ONCOL, V14, P539, DOI 10.1002/1878-0261.12629
   Wittchen ES, 2011, INVEST OPHTH VIS SCI, V52, P7455, DOI 10.1167/iovs.11-7295
   Wu CJ, 2020, CANCERS, V12, DOI 10.3390/cancers12010024
   Xing JJ, 2016, NAT IMMUNOL, V17, P1373, DOI 10.1038/ni.3580
NR 40
TC 21
Z9 21
U1 0
U2 8
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
SN 1945-4589
J9 AGING-US
JI Aging-US
PD FEB 28
PY 2021
VL 13
IS 4
BP 5034
EP 5054
PG 21
WC Cell Biology; Geriatrics & Gerontology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Geriatrics & Gerontology
GA QQ7FZ
UT WOS:000624688500018
PM 33495406
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Zouki, DN
   Giannopoulou, I
   Alexandrou, PT
   Karatrasoglou, EA
   Pilichos, G
   Stamopoulos, K
   Kanellis, T
   Roupou, E
   Saetta, AA
   Thymara, I
   Kavantzas, N
   Lazaris, AC
AF Zouki, Dionysia N.
   Giannopoulou, Ioanna
   Alexandrou, Paraskevi Th
   Karatrasoglou, Eleni A.
   Pilichos, Georgios
   Stamopoulos, Konstantinos
   Kanellis, Theodore
   Roupou, Eirini
   Saetta, Angelica A.
   Thymara, Irini
   Kavantzas, Nikolaos
   Lazaris, Andreas C.
TI MTOR/4EBP1 signaling and MMR status in colorectal cancer: New
   correlations and arising perspectives
SO PATHOLOGY RESEARCH AND PRACTICE
LA English
DT Article
DE PmTOR; P4EBP1; MMR status; Prognosis; MTOR targeted therapy
ID PHASE-II TRIAL; MICROSATELLITE INSTABILITY; POOR-PROGNOSIS; MTOR KINASE;
   EVEROLIMUS; 4E-BP1; PHOSPHORYLATION; COMBINATION; BEVACIZUMAB;
   IRINOTECAN
AB This is the first study aiming to investigate mTOR signaling and its relation to mismatch repair status (MMR status) in colorectal cancer (CRC). MMR status and the phosphorylated proteins, pmTOR and p4EBP1, have been immunohistochemically analyzed in 108 formalin-fixed, paraffin-embedded CRC specimens. The correlations between them and with clinicopathological data, MAPK pathway (KRAS, NRAS, BRAF) as well as their impact on patients' overall survival have been statistically analyzed. Our results indicated that positive pmTOR expression was significantly associated with KRAS mutations (p = 0.004). From multivariate survival analysis, only p4EBP1 expression emerged as independent adverse prognostic factor for overall survival (HR, 3.322; 95%CI, 1.110-9.945; p = 0.032). Furthermore, MMR deficient carcinomas tend to express low p4EBP1 protein levels (p = 0.002). A survival analysis stratified by MMR status and p4EBP1 expression, showed that MMR proficient tumours with high p4EBP1 expression had the worst overall survival compared with the other examined subgroups (p = 0.019). In conclusion, MAPK and PI3k/Akt pathways seem to be simultaneously overactivated in CRC. P4EBP1 could be used as a prognostic biomarker. By further analyzing the significant association between MMR status and p4EBP1 expression, we suggest that MMR deficient tumours could represent a subpopulation most likely to derive treatment benefit from mTOR inhibition.
C1 [Zouki, Dionysia N.; Giannopoulou, Ioanna; Alexandrou, Paraskevi Th; Roupou, Eirini; Saetta, Angelica A.; Thymara, Irini; Kavantzas, Nikolaos; Lazaris, Andreas C.] Natl & Kapodistrian Univ Athens, Dept Pathol 1, Med Sch, Laiko Gen Hosp, Mikras Asias 75, Athens 11527, Greece.
   [Karatrasoglou, Eleni A.] St Savvas Anticanc Hosp, Med Oncol Clin 1, L Alexandras 171, Athens 11522, Greece.
   [Pilichos, Georgios] Karlstad Cent Hosp, Dept Surg, Rosenborgsgatan 9, S-65230 Karlstad, Sweden.
   [Stamopoulos, Konstantinos] Gen & Oncol Hosp Kifissia Agioi Anargyroi, Dept Internal Med 2, Kifissia Noufaron & Timiou Stavrou 14, Athens 14564, Greece.
   [Kanellis, Theodore] European Univ Cyprus, Sch Med, Diogenis 6, CY-1516 Nicosia, Cyprus.
C3 National & Kapodistrian University of Athens; Laiko General Hospital;
   European University Cyprus
RP Zouki, DN (corresponding author), Natl & Kapodistrian Univ Athens, Dept Pathol 1, Med Sch, Laiko Gen Hosp, Mikras Asias 75, Athens 11527, Greece.
EM dzouki@med.uoa.gr
CR Aasebo KO, 2019, CANCER MED-US, V8, P3623, DOI 10.1002/cam4.2205
   Aksamitiene E, 2012, BIOCHEM SOC T, V40, P139, DOI 10.1042/BST20110609
   Altomare I, 2011, ONCOLOGIST, V16, P1131, DOI 10.1634/theoncologist.2011-0078
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Ashktorab H, 2003, CLIN CANCER RES, V9, P1112
   Bendell JC, 2015, INVEST NEW DRUG, V33, P187, DOI 10.1007/s10637-014-0177-3
   Chen Y, 2017, NEOPLASMA, V64, P787, DOI 10.4149/neo_2017_518
   Chen YT, 2017, PATHOL RES PRACT, V213, P490, DOI 10.1016/j.prp.2017.02.004
   Ducker GS, 2014, ONCOGENE, V33, P1590, DOI 10.1038/onc.2013.92
   Gelsomino F, 2016, CANCER TREAT REV, V51, P19, DOI 10.1016/j.ctrv.2016.10.005
   Jin ZH, 2018, ONCOLOGIST, V23, P1083, DOI 10.1634/theoncologist.2017-0289
   Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2
   Loibl S., 2016, CLIN CANCER RES, V22
   Marginean EC, 2018, ARCH PATHOL LAB MED, V142, P17, DOI 10.5858/arpa.2017-0040-RA
   Melling N, 2015, INT J CLIN EXP PATHO, V8, P7009
   Miao YF, 2017, MOL MED REP, V15, P3099, DOI 10.3892/mmr.2017.6352
   Nagtegaal ID., 2019, WHO CLASSIFICATION T, P157, DOI [10.1111/his.13975, DOI 10.1111/HIS.13975]
   National Comprehensive Cancer Network (NCCN), NCCN CLIN PRACTICE G, P2021
   Ng K, 2013, CLIN CANCER RES, V19, P3987, DOI 10.1158/1078-0432.CCR-13-0027
   Nojadeh JN, 2018, EXCLI J, V17, P159, DOI 10.17179/excli2017-948
   Pitts TM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113037
   Pópulo H, 2012, INT J MOL SCI, V13, P1886, DOI 10.3390/ijms13021886
   Qin XY, 2016, CELL CYCLE, V15, P781, DOI 10.1080/15384101.2016.1151581
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Smith B, 2020, J CLIN ONCOL, V38
   Spindler KLG, 2013, ACTA ONCOL, V52, P963, DOI 10.3109/0284186X.2013.776175
   Tian T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20030755
   Tolcher A.W., ANN
   Tsikalakis S, 2018, PATHOL RES PRACT, V214, P826, DOI 10.1016/j.prp.2018.04.019
   Vuik FER, 2019, GUT, V68, P1820, DOI 10.1136/gutjnl-2018-317592
   Wan ML, 2020, BIOSCIENCE REP, V40, DOI 10.1042/BSR20200265
   Wolpin BM, 2013, ONCOLOGIST, V18, P377, DOI 10.1634/theoncologist.2012-0378
   Wu SH, 2015, INT J CLIN EXP PATHO, V8, P3882
   Zhang T, 2018, ONCOTARGET, V9, P2761, DOI 10.18632/oncotarget.23031
   Zhang YJ, 2012, CELL CYCLE, V11, P594, DOI 10.4161/cc.11.3.19096
NR 35
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER GMBH
PI MUNICH
PA HACKERBRUCKE 6, 80335 MUNICH, GERMANY
SN 0344-0338
EI 1618-0631
J9 PATHOL RES PRACT
JI Pathol. Res. Pract.
PD DEC
PY 2021
VL 228
AR 153655
DI 10.1016/j.prp.2021.153655
EA OCT 2021
PG 8
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA XG9DB
UT WOS:000725045500001
PM 34749209
DA 2025-01-04
ER

PT J
AU Janani, B
   Vijayakumar, M
   Priya, K
   Kim, JH
   Prabakaran, DS
   Shahid, M
   Al-Ghamdi, S
   Alsaidan, M
   Bahakim, NO
   Abdelzaher, MH
   Ramesh, T
AF Janani, Balakarthikeyan
   Vijayakumar, Mayakrishnan
   Priya, Kannappan
   Kim, Jin Hee
   Prabakaran, D. S.
   Shahid, Mohammad
   Al-Ghamdi, Sameer
   Alsaidan, Mohammed
   Othman Bahakim, Nasraddin
   Hassan Abdelzaher, Mohammad
   Ramesh, Thiyagarajan
TI EGFR-Based Targeted Therapy for Colorectal Cancer-Promises and
   Challenges
SO VACCINES
LA English
DT Review
DE colorectal cancer; EGFR; nanocarriers; nanomedicine; cetuximab
ID GROWTH-FACTOR RECEPTOR; MONOCLONAL-ANTIBODIES; CARBON NANOTUBES;
   COLON-CANCER; CETUXIMAB; NANOPARTICLES; ACTIVATION; CARCINOMA; MICELLES
AB Colorectal carcinoma (CRC) is the most lethal and common form of cancer in the world. It was responsible for almost 881,000 cancer deaths in 2018. Approximately 25% of cases are diagnosed at advanced stages with metastasis-this poses challenges for effective surgical control and future tumor-related mortality. There are numerous diagnostic methods that can be used to reduce the risk of colorectal carcinoma. Among these, targeted nanotherapy aims to eliminate the tumor and any metastasis. Active targeting can increase the effectiveness and quantity of drugs delivered to the target site. Antibodies that target overexpressed receptors on cell surfaces and indicators are coupled with drug-loaded carriers. The major target receptors of chemotherapeutic drugs delivery include VEGFR, EGFR, FGFR, HER2, and TGF. On account of its major and diverse roles in cancer, it is important to target EGFR in particular for better tumor selection, as EGFR is overexpressed in 25 to 82% of colorectal carcinoma cases. The EGFR monoclonal immunoglobulins cetuximab/panitumumab can thus be used to treat colorectal cancer. This review examines carriers that contain cetuximab-conjugated therapeutic drugs as well as their efficacy in anticancer activities.
C1 [Janani, Balakarthikeyan; Priya, Kannappan] Bharathiar Univ, Dept Biochem, PSG Coll Arts & Sci Autonomous, Coimbatore 641014, Tamil Nadu, India.
   [Vijayakumar, Mayakrishnan; Kim, Jin Hee] Sejong Univ, Dept Integrat Biosci & Biotechnol, Coll Life Sci, 209 Neugdong Ro, Seoul 05006, South Korea.
   [Prabakaran, D. S.] Chungbuk Natl Univ, Coll Med, Dept Radiat Oncol, Chungdae Ro 1, Cheongju 28644, South Korea.
   [Prabakaran, D. S.] Ayya Nadar Janaki Ammal Coll Autonomous, Dept Biotechnol, Srivilliputhur Main Rd, Sivakasi 626124, Tamil Nadu, India.
   [Shahid, Mohammad; Othman Bahakim, Nasraddin; Hassan Abdelzaher, Mohammad; Ramesh, Thiyagarajan] Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Basic Med Sci, Al Kharj 11942, Saudi Arabia.
   [Al-Ghamdi, Sameer] Prince Sattam Bin Abdulaziz Univ, Coll Med, Family & Community Med Dept, Al Kharj 11942, Saudi Arabia.
   [Alsaidan, Mohammed] Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Internal Med, Al Kharj 11942, Saudi Arabia.
   [Hassan Abdelzaher, Mohammad] Al Azhar Univ, Dept Med Biochem, Fac Med, Assiut Branch, Assiut 71515, Egypt.
C3 Bharathiar University; PSG College of Arts & Science; Sejong University;
   Chungbuk National University; Prince Sattam Bin Abdulaziz University;
   Prince Sattam Bin Abdulaziz University; Prince Sattam Bin Abdulaziz
   University; Egyptian Knowledge Bank (EKB); Al Azhar University; Assiut
   University
RP Priya, K (corresponding author), Bharathiar Univ, Dept Biochem, PSG Coll Arts & Sci Autonomous, Coimbatore 641014, Tamil Nadu, India.; Ramesh, T (corresponding author), Prince Sattam Bin Abdulaziz Univ, Coll Med, Dept Basic Med Sci, Al Kharj 11942, Saudi Arabia.
EM jananijana025@gmail.com; marulbiochem@rediffmail.com;
   priyak08@gmail.com; jhkim777@sejong.ac.kr; prababio@chungbuk.ac.kr;
   dr.shahid90@yahoo.com; sh.alghamdi@psau.edu.sa; dr.saidan@hotmail.com;
   nasroden2010@gmail.com; abdelzaher_gerga@yahoo.com;
   thiyagaramesh@gmail.com
RI MOHAMMAD, SHAHID/CAH-3217-2022; Prabakaran, D.S/GLN-3671-2022; Ramesh,
   Thiyagarajan/AAH-2631-2021; Kim, Jin/AET-7817-2022; Al-Ghamdi,
   Sameer/JBJ-7121-2023; Abdelzaher, Mohammad/JRW-0495-2023; Alsaidan,
   Mohammed/AAA-3706-2021; Bahakim, Dr. Nasraddin/HJA-8231-2022
OI Abdelzaher, Mohammad/0000-0002-0182-5456; Shahid, PhD., Professor
   Mohammad/0000-0002-9659-2041; Ramesh, Dr.
   Thiyagarajan/0000-0001-6478-0833; Alsaidan,
   Mohammed/0000-0001-6163-8292; KIM, JIN HEE/0000-0003-1204-7079;
   Al-Ghamdi, Sameer/0000-0003-0506-0574; Balakarthikeyan,
   Janani/0000-0002-6647-8651; D.S, Dr. Prabakaran/0000-0002-2486-5290
CR Abdellatif AAH, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-61605-y
   Banerjee S, 2010, CANCER BIOL THER, V9, P563, DOI 10.4161/cbt.9.8.11403
   Bou-Assaly W, 2010, AM J NEURORADIOL, V31, P626, DOI 10.3174/ajnr.A2054
   Burgess AW, 2003, MOL CELL, V12, P541, DOI 10.1016/S1097-2765(03)00350-2
   Chang SS, 2008, J SURG ONCOL, V97, P640, DOI 10.1002/jso.21023
   Chen F, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06271-5
   Cho YS, 2010, CANCER LETT, V299, P63, DOI 10.1016/j.canlet.2010.08.004
   Dariya B., 2018, EGFR FGFR GROWTH MET
   Dawson JP, 2005, MOL CELL BIOL, V25, P7734, DOI 10.1128/MCB.25.17.7734-7742.2005
   Debnath SK, 2021, FRONT NANOTECHNOL, V3, DOI 10.3389/fnano.2021.644564
   Duwa R, 2020, J DRUG DELIV SCI TEC, V60, DOI 10.1016/j.jddst.2020.101928
   Ebisumoto K, 2018, AURIS NASUS LARYNX, V45, P637, DOI 10.1016/j.anl.2017.08.005
   El Guerrab A, 2016, ONCOTARGET, V7, P73618, DOI 10.18632/oncotarget.12037
   El Hallal R, 2021, MOLECULES, V26, DOI 10.3390/molecules26030567
   Fay F, 2011, IMMUNOTHERAPY-UK, V3, P381, DOI [10.2217/imt.11.5, 10.2217/IMT.11.5]
   Ferrara N, 2003, NAT MED, V9, P669, DOI 10.1038/nm0603-669
   Frattini M., 2015, Gastrointest. Cancer: Targets Ther., P21, DOI [10.2147/GICTT. S49002, 10.2147/GICTT.S49002, DOI 10.2147/GICTT.S49002]
   Gil HM, 2021, ISCIENCE, V24, DOI 10.1016/j.isci.2021.102189
   Gulbake A, 2016, WORLD J GASTROENTERO, V22, P582, DOI 10.3748/wjg.v22.i2.582
   Hanck-Silva G, 2020, CRIT REV ANAL CHEM, V50, P125, DOI 10.1080/10408347.2019.1581984
   Hashemkhani M, 2021, NANOSCALE, V13, P14879, DOI 10.1039/d1nr03507j
   Iqbal Jamshed, 2017, Infectious Disorders - Drug Targets, V17, P149, DOI 10.2174/1871526517666170606102623
   Itatani Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20235822
   Jain A, 2018, ACS BIOMATER SCI ENG, V4, P3939, DOI 10.1021/acsbiomaterials.8b01098
   Koyen AE, 2018, ROLE OF TYROSINE KINASES IN GASTROINTESTINAL MALIGNANCIES, P225, DOI 10.1007/978-981-13-1486-5_15
   Krasinskas Alyssa M, 2011, Patholog Res Int, V2011, P932932, DOI 10.4061/2011/932932
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Kumar S, 2017, CHEM SOC REV, V46, P158, DOI 10.1039/c6cs00517a
   Lee PC, 2013, BIOMATERIALS, V34, P8756, DOI 10.1016/j.biomaterials.2013.07.067
   Leve F, 2019, NANOMEDICINE-UK, V14, P1565, DOI 10.2217/nnm-2019-0023
   Li QH, 2020, GASTROENTEROL REP, V8, P179, DOI 10.1093/gastro/goaa026
   Li Y, 2018, NANOSCALE, V10, P16738, DOI 10.1039/c8nr05803b
   Luo H, 2020, ONCOL LETT, V20, P2525, DOI 10.3892/ol.2020.11858
   Martinelli E, 2009, CLIN EXP IMMUNOL, V158, P1, DOI 10.1111/j.1365-2249.2009.03992.x
   Masood F, 2016, MAT SCI ENG C-MATER, V60, P569, DOI 10.1016/j.msec.2015.11.067
   Maya S, 2014, J BIOMED NANOTECHNOL, V10, P1416, DOI 10.1166/jbn.2014.1841
   Milane L, 2011, MOL PHARMACEUT, V8, P185, DOI 10.1021/mp1002653
   Mochida Y, 2017, EXPERT OPIN DRUG DEL, V14, P1423, DOI 10.1080/17425247.2017.1307338
   Noguchi T, 2013, IMMUNOTHERAPY-UK, V5, P533, DOI [10.2217/IMT.13.35, 10.2217/imt.13.35]
   Okuyama K, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-84877-4
   Othman MH, 2020, DRUG DEV IND PHARM, V46, P2081, DOI 10.1080/03639045.2020.1844730
   Pabla B, 2015, WORLD J CLIN ONCOL, V6, P133, DOI 10.5306/wjco.v6.i5.133
   Peng JW, 2019, MEDICINE, V98, DOI 10.1097/MD.0000000000015311
   Pérez-Herrero E, 2015, EUR J PHARM BIOPHARM, V93, P52, DOI 10.1016/j.ejpb.2015.03.018
   Piawah S, 2019, CANCER-AM CANCER SOC, V125, P4139, DOI 10.1002/cncr.32163
   Sabra R, 2019, INT J PHARMACEUT, V572, DOI 10.1016/j.ijpharm.2019.118775
   Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617
   Shih YH, 2017, J CONTROL RELEASE, V258, P196, DOI 10.1016/j.jconrel.2017.04.031
   Siena S, 2018, ANN ONCOL, V29, P1108, DOI 10.1093/annonc/mdy100
   Spano JP, 2005, ANN ONCOL, V16, P189, DOI 10.1093/annonc/mdi057
   Sun M, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.702445
   Thomas R, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00800
   Tseng SH, 2015, INT J NANOMED, V10, P3663, DOI 10.2147/IJN.S80134
   Vale CL, 2012, CANCER TREAT REV, V38, P618, DOI 10.1016/j.ctrv.2011.11.002
   van Krieken JHJM, 2008, VIRCHOWS ARCH, V453, P417, DOI 10.1007/s00428-008-0665-y
   Wee P, 2017, CANCERS, V9, DOI 10.3390/cancers9050052
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xu YF, 2007, HUM MOL GENET, V16, pR14, DOI 10.1093/hmg/ddl486
   Yao YH, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00193
   Ye ZX, 2021, INT J NANOMED, V16, P2443, DOI 10.2147/IJN.S289228
   Yoo J, 2019, CANCERS, V11, DOI 10.3390/cancers11050640
   You B, 2012, J CLIN PHARMACOL, V52, P128, DOI 10.1177/0091270010395940
   Zalba S, 2015, J CONTROL RELEASE, V210, P26, DOI 10.1016/j.jconrel.2015.05.271
   Zhang J, 2021, COLLOID SURFACE B, V197, DOI 10.1016/j.colsurfb.2020.111399
   Zhang Y, 2021, MATER EXPRESS, V11, P1619, DOI 10.1166/mex.2021.2005
NR 65
TC 45
Z9 47
U1 3
U2 26
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2076-393X
J9 VACCINES-BASEL
JI Vaccines
PD APR
PY 2022
VL 10
IS 4
AR 499
DI 10.3390/vaccines10040499
PG 15
WC Immunology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Immunology; Research & Experimental Medicine
GA 0T2HW
UT WOS:000786794200001
PM 35455247
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Sastre, J
   García-Alfonso, P
   Viéitez, JM
   Cano, MT
   Rivera, F
   Reina-Zoilo, JJ
   Salud-Salvia, A
   Quintero, G
   Robles-Díaz, L
   Safont, MJ
   La Casta, A
   Gil, S
   Polo, E
   Asensio-Martínez, E
   García-Paredes, B
   López, RL
   Guillot, M
   Valladares-Ayerbes, M
   Aranda, E
   Díaz-Rubio, E
AF Sastre, J.
   Garcia-Alfonso, P.
   Vieitez, J. M.
   Cano, M. T.
   Rivera, F.
   Reina-Zoilo, J. J.
   Salud-Salvia, A.
   Quintero, G.
   Robles-Diaz, L.
   Safont, M. J.
   La Casta, A.
   Gil, S.
   Polo, E.
   Asensio-Martinez, E.
   Garcia-Paredes, B.
   Lopez, R. L.
   Guillot, M.
   Valladares-Ayerbes, M.
   Aranda, E.
   Diaz-Rubio, E.
CA Spanish Cooperative Grp Treatment
TI Influence of <i>BRAF</i> and <i>PIK3CA</i> mutations on the efficacy of
   FOLFIRI plus bevacizumab or cetuximab as first-line therapy in patients
   with RAS wild-type metastatic colorectal carcinoma and &lt;3 baseline
   circulating tumour cells: the randomised phase II VISNU-2 study
SO ESMO OPEN
LA English
DT Article
DE BRAF; colorectal cancer; PIK3CA; RAS; targeted therapy
ID PROGRESSION-FREE; CANCER; CHEMOTHERAPY; SURVIVAL; KRAS
AB Background: We explored the influence of BRAF and PIK3CA mutational status on the efficacy of bevacizumab or cetuximab plus 5-fluorouracil/leucovorin and irinotecan (FOLFIRI) as first-line therapy in patients with RAS wild-type metastatic colorectal cancer (mCRC).
   Patients and methods: VISNU-2 was a multicentre, randomised, phase II study. Patients with RAS wild-type mCRC and <3 circulating tumour cells/7.5 ml blood were stratified by BRAF/PIK3CA status (wild-type versus mutated) and number of affected organs (1 versus >1), and allocated to bevacizumab (5 mg/kg every 2 weeks) or cetuximab (400 mg/m(2) then 250 mg/m(2) weekly) plus FOLFIRI [irinotecan 180 mg/m(2), leucovorin 400 mg/m(2), 5-fluorouracil 400 mg/m(2) (bolus) then 2400 mg/m(2) (46-h continuous infusion) every 2 weeks]. The primary endpoint was progression-free survival (PFS). All analyses were exploratory.
   Results: Two hundred and forty patients with BRAF/PIK3CA wild-type (n = 196) or BRAF- and/or PIK3CA-mutated tumours (n = 44) were enrolled. Median PFS was 12.7 and 8.8 months in patients with BRAF/PIK3CA wild-type and BRAF/PIK3CA-mutated tumours, respectively [hazard ratio (HR) = 1.22; 95% confidence interval (CI) 0.80-1.85; P = 0.3602]. In the BRAF- and/or PIK3CA-mutated cohort, median PFS was 2.8, 8.8 and 15.0 months in patients with BRAF/PI3KCA-mutated (n = 8), BRAF-mutated/PI3KCA wild-type (n = 16) and BRAF wild-type/PI3KCA-mutated (n = 20) tumours, respectively (P = 0.0002). PFS was similar with bevacizumab plus FOLFIRI versus cetuximab plus FOLFIRI in BRAF/PIK3CA wild-type (HR = 0.99; 95% CI 0.67-1.45; P = 0.9486) and BRAF/PIK3CA-mutated tumours (HR = 1.11; 95% CI 0.53-2.35; P = 0.7820). The most common grade 3/4 treatment-related adverse events were neutropenia, diarrhoea and asthenia in both treatment groups.
   Conclusions: BRAF/PIK3CA status influences outcomes in patients with RAS wild-type mCRC but does not appear to assist with the selection of first-line targeted therapy.
C1 [Sastre, J.; Garcia-Paredes, B.; Diaz-Rubio, E.] Hosp Clin San Carlos, Inst Invest Hosp Clin San Carlos IdISSC, Med Oncol, CIBERONC, Calle Prof Martin Lagos, Madrid 28040, Spain.
   [Garcia-Alfonso, P.] Hosp Univ Gregorio Maranon, Med Oncol, Madrid, Spain.
   [Vieitez, J. M.] Hosp Univ Cent Asturias, Med Oncol, Oviedo, Spain.
   [Cano, M. T.; Aranda, E.] Univ Cordoba, Reina Sofia Hosp, Inst Salud Carlos III, CIBERONC,Med Oncol,IMIBIC, Cordoba, Spain.
   [Rivera, F.] Hosp Univ Marques de Valdecilla, IDIVAL, Med Oncol, Santander, Spain.
   [Reina-Zoilo, J. J.] Complejo Hosp Virgen de la Macarena, Med Oncol, Seville, Spain.
   [Salud-Salvia, A.] Hosp Univ Arnau de Vilanova Lleida, Lleida, Spain.
   [Quintero, G.] Hosp Lucus Augusti, Med Oncol, Lugo, Spain.
   [Robles-Diaz, L.] Hosp 12 Octubre, Med Oncol, Madrid, Spain.
   [Safont, M. J.] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain.
   [La Casta, A.] Hosp Donostia, Med Oncol, Guipuzcoa, Spain.
   [Gil, S.] Hosp Univ Reg & Virgen de la Victoria, Med Oncol, Malaga, Spain.
   [Polo, E.] Hosp Miguel Servet, Med Oncol, Zaragoza, Spain.
   [Asensio-Martinez, E.] Hosp Gen Univ Elche, Med Oncol, Alicante, Spain.
   [Lopez, R. L.] Santiago de Compostela Univ, Univ Clin Hosp & Hlth Res Inst IDIS, CIBERONC, Med Oncol,Sch Med, Santiago De Compostela, Spain.
   [Guillot, M.] Hosp Son Espases, Med Oncol, Palma De Mallorca, Spain.
   [Valladares-Ayerbes, M.] Complejo Hosp Univ A Coruna, Inst Invest Biomed INIBIC, Med Oncol, La Coruna, Spain.
C3 Hospital Clinico San Carlos; CIBER - Centro de Investigacion Biomedica
   en Red; CIBERONC; General University Gregorio Maranon Hospital; Central
   University Hospital Asturias; Universidad de Cordoba; Instituto de Salud
   Carlos III; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC;
   Hospital Universitario Marques de Valdecilla (HUMV); University Hospital
   Arnau de Vilanova; Hospital Universitario Lucus Augusti-Lugo; Hospital
   Universitario 12 de Octubre; University Hospital Donostia; Miguel Servet
   University Hospital; Universidade de Santiago de Compostela; CIBER -
   Centro de Investigacion Biomedica en Red; CIBERONC; Hospital
   Universitari Son Espases; Universidade da Coruna; Instituto de
   Investigacion Biomedica de A Coruna (INIBIC); Complejo Hospitalario
   Universitario A Coruna
RP Sastre, J (corresponding author), Hosp Clin San Carlos, Inst Invest Hosp Clin San Carlos IdISSC, Med Oncol, CIBERONC, Calle Prof Martin Lagos, Madrid 28040, Spain.
EM jsastrev@salud.madrid.org
RI Lacasta, Ana/J-1063-2014; Valladares'Ayerbes, MANUEL/LDG-3881-2024;
   Ruiz-Casado, Ana/E-3554-2019
OI Aranda Aguilar, Enrique/0000-0002-5471-2842; Lopez Lopez,
   Rafael/0000-0003-1315-655X; Garcia-Carbonero, Rocio/0000-0002-3342-397X;
   Ruiz-Casado, Ana/0000-0002-7672-2638; Gonzalez Flores,
   Encarnacion/0000-0002-2077-5060
FU Roche Farma S.A - Roche Farma S.A
FX This work was supported by Roche Farma S.A (no grant number). Medical
   writing support was funded by Roche Farma S.A and provided by H. Lamb
   and L. Miller of Miller Medical Communications Ltd.
CR Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Aranda E, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000944
   Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Cohen SJ, 2008, J CLIN ONCOL, V26, P3213, DOI 10.1200/JCO.2007.15.8923
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Innocenti F, 2019, J CLIN ONCOL, V37, P1217, DOI 10.1200/JCO.18.01798
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Rowland A, 2015, BRIT J CANCER, V112, P1888, DOI 10.1038/bjc.2015.173
   Sastre J, 2012, ONCOLOGIST, V17, P947, DOI 10.1634/theoncologist.2012-0048
   Schwartzberg LS, 2014, J CLIN ONCOL, V32, P2240, DOI 10.1200/JCO.2013.53.2473
   Tol J, 2010, ANN ONCOL, V21, P1006, DOI 10.1093/annonc/mdp463
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
NR 15
TC 9
Z9 9
U1 1
U2 7
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
EI 2059-7029
J9 ESMO OPEN
JI ESMO Open
PD APR
PY 2021
VL 6
IS 2
AR 100062
DI 10.1016/j.esmoop.2021.100062
EA MAR 2021
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA RT8FB
UT WOS:000644690600016
PM 33711671
OA gold, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU Jiao, YP
   Li, JH
   Qian, CQ
   Fei, SM
AF Jiao, Yiping
   Li, Junhong
   Qian, Chenqi
   Fei, Shumin
TI Deep learning-based tumor microenvironment analysis in colon
   adenocarcinoma histopathological whole-slide images
SO COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE
LA English
DT Article
DE Tumor microenvironment; Colon adenocarcinoma; Survival analysis; Digital
   pathology; Computer-aided diagnosis
ID SURVIVAL; INFLAMMATION; PROGRESSION; PROGNOSIS; NECROSIS
AB Background and Objective: : Colon cancer is a fatal disease, and a comprehensive understanding of the tumor microenvironment (TME) could lead to better risk stratification, prognosis prediction, and ther-apy management. In this paper, we focused on the automatic evaluation of TME in giga-pixel digital histopathology whole-slide images.
   Methods: : A convolutional neural network is used to recognize nine different content presented in colon cancer whole-slide images. Several implementation details, including the foreground filtering and stain normalization are discussed. Based on the whole-slide segmentation, several TME descriptors are quan-tified and correlated with the clinical outcome by Kaplan-Meier analysis and Cox regression. Specifically, the stroma, tumor, necrosis, and lymphocyte components are discussed.
   Results: : We validated the method on colon adenocarcinoma cases from The Cancer Genome Atlas project. The result shows that the stroma is an independent predictor of progression-free interval (PFI) after corrected by age and pathological stage, with a hazard ratio of 1.665 (95%CI: 1.110-2.495, p = 0.014). High-level necrosis component and lymphocytes component tend to be correlated with poor PFI, with a hazard ratio of 1.552 (95%CI: 0.943-2.554, p = 0.084) and 1.512 (95%CI: 0.979-2.336, p = 0.062), respec-tively.
   Conclusions: : The result reveals the complex role of the tumor microenvironment in colon adenocarci-noma, and the quantified descriptors are potential predictors of disease progression. The method could be considered for risk stratification and targeted therapy and extend to other types of cancer, leading to a better understanding of the tumor microenvironment. (c) 2021 Elsevier B.V. All rights reserved.
C1 [Jiao, Yiping; Fei, Shumin] Southeast Univ, Shool Automat, 2nd Sipailou Rd, Nanjing, Peoples R China.
   [Li, Junhong] Zhengzhou Univ, Luoyang Cent Hosp, Luoyang, Peoples R China.
   [Qian, Chenqi] Jiangsu Chunyu Educ Grp CO, 88th Zhongshan North Rd, Nanjing, Peoples R China.
C3 Southeast University - China; Zhengzhou University
RP Fei, SM (corresponding author), Southeast Univ, Shool Automat, 2nd Sipailou Rd, Nanjing, Peoples R China.
EM ping@seu.edu.cn; smfei@seu.edu.cn
CR Angel H, 2013, CURR OPIN IMMUNOL, V25, P261, DOI 10.1016/j.coi.2013.03.004
   Atanasov G, 2019, WORLD J SURG ONCOL, V17, DOI 10.1186/s12957-019-1756-8
   Babic A, 2016, BRIT J CANCER, V114, P995, DOI 10.1038/bjc.2016.85
   Barua S, 2018, LUNG CANCER, V117, P73, DOI 10.1016/j.lungcan.2018.01.022
   Bejnordi BE, 2017, JAMA-J AM MED ASSOC, V318, P2199, DOI 10.1001/jama.2017.14585
   Bremnes RM, 2016, J THORAC ONCOL, V11, P789, DOI 10.1016/j.jtho.2016.01.015
   Bug Daniel, 2019, Oncotarget, V10, P4587, DOI 10.18632/oncotarget.27069
   Catteau X, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210263
   Cheng J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15671-5
   Clark TG, 2003, BRIT J CANCER, V89, P232, DOI 10.1038/sj.bjc.6601118
   Coudray N, 2018, NAT MED, V24, P1559, DOI 10.1038/s41591-018-0177-5
   Eroglu Z, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.9584
   Fujiwara A, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67904-8
   Gocheva V, 2017, P NATL ACAD SCI USA, V114, pE5625, DOI 10.1073/pnas.1707054114
   Greten FR, 2019, IMMUNITY, V51, P27, DOI 10.1016/j.immuni.2019.06.025
   Horie M, 2012, BIOCHEM BIOPH RES CO, V423, P158, DOI 10.1016/j.bbrc.2012.05.104
   Karsch-Bluman A, 2019, ONCOGENE, V38, P1920, DOI 10.1038/s41388-018-0555-y
   Kather JN, 2019, NAT MED, V25, P1054, DOI 10.1038/s41591-019-0462-y
   Kather JN, 2019, PLOS MED, V16, DOI 10.1371/journal.pmed.1002730
   Khan AM, 2014, IEEE T BIO-MED ENG, V61, P1729, DOI 10.1109/TBME.2014.2303294
   Khosravi P, 2018, EBIOMEDICINE, V27, P317, DOI 10.1016/j.ebiom.2017.12.026
   Li ZQ, 2020, INT J GEOGR INF SCI, V34, P1378, DOI 10.1080/13658816.2020.1720692
   Liu JF, 2018, CELL, V173, P400, DOI 10.1016/j.cell.2018.02.052
   Luo X, 2017, J THORAC ONCOL, V12, P501, DOI 10.1016/j.jtho.2016.10.017
   Macenko M, 2009, I S BIOMED IMAGING, P1107, DOI 10.1109/ISBI.2009.5193250
   Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425
   Padmavathi G, 2018, CANCER LETT, V432, P260, DOI 10.1016/j.canlet.2018.06.017
   Pedrosa L, 2019, CANCERS, V11, DOI 10.3390/cancers11081172
   Rathore S, 2019, CANCERS, V11, DOI 10.3390/cancers11111700
   Ronneberger O, 2015, LECT NOTES COMPUT SC, V9351, P234, DOI 10.1007/978-3-319-24574-4_28
   Saltz J, 2018, CELL REP, V23, P181, DOI 10.1016/j.celrep.2018.03.086
   Salvi M, 2021, COMPUT BIOL MED, V128, DOI 10.1016/j.compbiomed.2020.104129
   Siegel Rebecca L, 2020, CA Cancer J Clin, V70, P7, DOI 10.3322/caac.21590
   Silva-Rodríguez J, 2020, COMPUT METH PROG BIO, V195, DOI 10.1016/j.cmpb.2020.105637
   Simonyan K, 2015, Arxiv, DOI arXiv:1409.1556
   Valkenburg KC, 2018, NAT REV CLIN ONCOL, V15, P366, DOI 10.1038/s41571-018-0007-1
   van Pelt GW, 2018, HISTOPATHOLOGY, V73, P197, DOI 10.1111/his.13489
   Wang SD, 2020, CANCER RES, V80, P2056, DOI 10.1158/0008-5472.CAN-19-1629
   Yakhini, 2020, SPATIAL TRANSCRIPTOM, DOI [10.1101/2020.07.02.183814, DOI 10.1101/2020.07.02.183814]
   Yu KH, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms12474
   Zhao K, 2020, EBIOMEDICINE, V61, DOI 10.1016/j.ebiom.2020.103054
   Zhou Y, 2020, CANCER CELL, V38, P818, DOI 10.1016/j.ccell.2020.09.015
NR 42
TC 44
Z9 45
U1 1
U2 29
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
   IRELAND
SN 0169-2607
EI 1872-7565
J9 COMPUT METH PROG BIO
JI Comput. Meth. Programs Biomed.
PD JUN
PY 2021
VL 204
AR 106047
DI 10.1016/j.cmpb.2021.106047
EA MAR 2021
PG 8
WC Computer Science, Interdisciplinary Applications; Computer Science,
   Theory & Methods; Engineering, Biomedical; Medical Informatics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Computer Science; Engineering; Medical Informatics
GA RZ2OG
UT WOS:000648437700005
PM 33789213
DA 2025-01-04
ER

PT J
AU Kim, YI
   Park, IJ
   Kim, JE
   Kim, SY
   Park, JH
   Lee, JH
   Ha, TY
   Hong, YS
   Kim, SY
   Kim, TW
   Lim, SB
   Yu, CS
   Kim, JC
AF Kim, Young Il
   Park, In Ja
   Kim, Jeong Eun
   Kim, So Yeon
   Park, Jin-Hong
   Lee, Jae Hoon
   Ha, Tae Yong
   Hong, Yong Sang
   Kim, Sun Young
   Kim, Tae Won
   Lim, Seok-Byung
   Yu, Chang Sik
   Kim, Jin Cheon
TI Hepatic resection after neoadjuvant chemotherapy for patients with liver
   metastases from colorectal cancer: need for cautious planning
SO ANNALS OF SURGICAL TREATMENT AND RESEARCH
LA English
DT Article
DE Colorectal cancer; Liver metastases; Neoadjuvant chemotherapy; Survival
   outcome
ID SURGICAL MARGIN; SCORING SYSTEM; CLINICAL SCORE; RECURRENCE; SURVIVAL;
   HEPATECTOMY; IMPACT; CONTRAINDICATION; DISEASE; R1
AB Purpose: Current neoadjuvant chemotherapy (NAC) may enable therapies such as surgical resection and local ablation of metastases in patients with colorectal liver metastasis (CLM). We evaluated outcomes in CLM patients who underwent resection and/or local treatment after NAC and identified prognostic factors for oncologic outcomes.
   Methods: Patients who received NAC followed by resection and/or local treatment of hepatic metastasis from 2013 to 2015 were included. Treatment and tumor-related variables were tabulated. Recurrence-free survival (RFS) and overall survival (OS) were analyzed using the Kaplan-Meier method. Cox regression analysis was used to identify factors associated with RFS and OS.
   Results: Sixty-eight patients received NAC followed by resection and/or local treatment of hepatic metastases. Targeted therapy was administered in 50% of the patients. RFS was 35.8% at 1 year and 19.4% at 2 years postoperatively. OS was 95.6% at 1 year and 88.2% at 2 years postoperatively. In the multivariable analysis, R1 resection margin (hazard ratio [HR], 3.95; P = 0.008) of the liver metastases and ypN1/ypN2 (HR, 2.356 and 1.983, respectively; P = 0.041) were associated with poor RFS. Both factors were also significantly related to OS.
   Conclusion: Resection margin of the metastatic tumor and ypN status are the only relevant factors for RFS and OS in CLM patients treated with NAC. Despite early and high rates of recurrence, CLM patients treated with NAC who undergo resection and/or local treatment have acceptable OS. Multidisciplinary review of candidates for surgery and cautious planning are crucial for achieving optimal outcomes.
C1 [Kim, Young Il; Park, In Ja; Lim, Seok-Byung; Yu, Chang Sik; Kim, Jin Cheon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Colon & Rectal Surg, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
   [Kim, Jeong Eun; Hong, Yong Sang; Kim, Sun Young; Kim, Tae Won] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
   [Kim, So Yeon] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiol, Seoul, South Korea.
   [Park, Jin-Hong] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Radiat Oncol, Seoul, South Korea.
   [Lee, Jae Hoon] Univ Ulsan, Coll Med, Asan Med Ctr, Div Hepatobiliary & Pancreat Surg, Seoul, South Korea.
   [Ha, Tae Yong] Univ Ulsan, Coll Med, Asan Med Ctr, Div Hepatobiliary Surg & Liver Transplantat, Seoul, South Korea.
C3 University of Ulsan; University of Ulsan; Asan Medical Center;
   University of Ulsan; Asan Medical Center; University of Ulsan; Asan
   Medical Center; University of Ulsan; Asan Medical Center; University of
   Ulsan; Asan Medical Center
RP Park, IJ (corresponding author), Univ Ulsan, Coll Med, Asan Med Ctr, Dept Colon & Rectal Surg, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea.
EM ipark@amc.seoul.kr
RI Bin Kim, Hong/J-5452-2012; Kim, Tae Won/GRX-7323-2022; Park,
   In/U-2371-2019; Park, Jin-Hong/F-1829-2014
OI Park, In Ja/0000-0001-5355-3969; Kim, Young Il/0000-0002-0212-9196
CR Adam R, 2004, ANN SURG, V240, P1052, DOI 10.1097/01.sla.0000145964.08365.01
   Allen PJ, 2003, J GASTROINTEST SURG, V7, P109, DOI 10.1016/S1091-255X(02)00121-X
   Ayez N, 2012, ANN SURG ONCOL, V19, P1618, DOI 10.1245/s10434-011-2114-4
   Ayez N, 2011, ANN SURG ONCOL, V18, P2757, DOI 10.1245/s10434-011-1819-8
   BENGTSSON G, 1981, AM J SURG, V141, P586, DOI 10.1016/0002-9610(81)90057-X
   Bismuth H, 1996, ANN SURG, V224, P509, DOI 10.1097/00000658-199610000-00009
   Cady B, 1998, ANN SURG, V227, P566, DOI 10.1097/00000658-199804000-00019
   Cucchetti A, 2019, BJS OPEN, V3, P186, DOI 10.1002/bjs5.100
   de Haas RJ, 2008, ANN SURG, V248, P626, DOI 10.1097/SLA.0b013e31818a07f1
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Figueras J, 2007, ANN ONCOL, V18, P1190, DOI 10.1093/annonc/mdm106
   Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004
   Gallagher DJ, 2009, ANN SURG ONCOL, V16, P1844, DOI 10.1245/s10434-009-0348-1
   Gomez D, 2010, HPB, V12, P227, DOI 10.1111/j.1477-2574.2010.00158.x
   Hallet J, 2016, BRIT J SURG, V103, P1366, DOI 10.1002/bjs.10191
   Jung SW, 2016, ANN SURG TREAT RES, V90, P257, DOI 10.4174/astr.2016.90.5.257
   Konopke R, 2009, LIVER INT, V29, P89, DOI 10.1111/j.1478-3231.2008.01845.x
   Margonis GA, 2017, ANN SURG, V266, P641, DOI 10.1097/SLA.0000000000002367
   Nagashima I, 2006, WORLD J GASTROENTERO, V12, P6305, DOI 10.3748/wjg.v12.i39.6305
   Nordlinger B, 1996, CANCER, V77, P1254, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1254::AID-CNCR5>3.3.CO;2-R
   Nuzzo G, 2008, SURGERY, V143, P384, DOI 10.1016/j.surg.2007.09.038
   Poultsides GA, 2010, HPB, V12, P43, DOI 10.1111/j.1477-2574.2009.00121.x
   Serayssol C, 2019, WORLD J GASTRO ONCOL, V11, P295, DOI 10.4251/wjgo.v11.i4.295
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Viganò L, 2016, ANN SURG ONCOL, V23, P1352, DOI 10.1245/s10434-015-5009-y
   Wakai T, 2008, ANN SURG ONCOL, V15, P2472, DOI 10.1245/s10434-008-0023-y
   Wein A, 2003, ONCOLOGY-BASEL, V64, P131, DOI 10.1159/000067772
   Weiser MR, 2013, ONCOLOGY-NY, V27, P1074
   Wimmer K, 2017, ANN SURG ONCOL, V24, P236, DOI 10.1245/s10434-016-5615-3
   Wray CJ, 2005, ANN SURG ONCOL, V12, P374, DOI 10.1245/ASO.2005.06.038
NR 30
TC 4
Z9 5
U1 1
U2 5
PU KOREAN SURGICAL SOCIETY
PI SEOUL
PA 3304HO, 101 DONG, BROWNSTONE SEOUL, 335, JUNGMIN-DONG, JUNG-GU, SEOUL,
   100-859, SOUTH KOREA
SN 2288-6575
EI 2288-6796
J9 ANN SURG TREAT RES
JI Ann. Surg. Treat. Res.
PD NOV
PY 2019
VL 97
IS 5
BP 245
EP 253
DI 10.4174/astr.2019.97.5.245
PG 9
WC Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Surgery
GA JM9JM
UT WOS:000496522400004
PM 31742209
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Fernando, RI
   Hamilton, DH
   Dominguez, C
   David, JM
   McCampbell, KK
   Palena, C
AF Fernando, Romaine I.
   Hamilton, Duane H.
   Dominguez, Charli
   David, Justin M.
   McCampbell, Kristen K.
   Palena, Claudia
TI IL-8 signaling is involved in resistance of lung carcinoma cells to
   erlotinib
SO ONCOTARGET
LA English
DT Article
DE erlotinib; tumor resistance; IL-8; epithelial-mesenchymal transition
ID EPITHELIAL-MESENCHYMAL TRANSITION; TRANSCRIPTION FACTOR BRACHYURY; EGFR
   KINASE DOMAIN; ACQUIRED-RESISTANCE; TARGETED THERAPY;
   COLORECTAL-CARCINOMA; MONOCLONAL-ANTIBODY; MET AMPLIFICATION; CANCER;
   GROWTH
AB A signaling pathway that is frequently deregulated in human carcinomas and has been explored as a therapeutic target involves the activation of the epidermal growth factor receptor (EGFR). Inhibition of EGFR via the small molecule inhibitors erlotinib and gefitinib commonly results in tumor resistance, even in patients with EGFR-mutant tumors that initially show substantial clinical responses. This study was designed to broaden our understanding of the molecular mechanisms of acquired resistance to erlotinib in lung cancer cells bearing wild type or mutated EGFR. We report here that generation of erlotinib-resistant lung cancer cells in vitro resulted in a phenotypic alteration reminiscent of an epithelial-mesenchymal transition (EMT) concomitant with a robust upregulation of the IL-8/IL-8R axis. Our results also demonstrate that upregulation of p38 MAPK signaling is responsible for the enhanced IL-8 secretion in the erlotinib-resistant tumor cells. Blockade of IL-8 signaling effectively reduced mesenchymal features of the resistant cells and also markedly enhanced their susceptibility to erlotinib. These results provide a rationale for the development of new therapeutic approaches involving blockade of IL-8 signaling for the management of acquired resistance to EGFR inhibition in patients with lung cancer.
C1 [Fernando, Romaine I.; Hamilton, Duane H.; Dominguez, Charli; David, Justin M.; McCampbell, Kristen K.; Palena, Claudia] NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
C3 National Institutes of Health (NIH) - USA; NIH National Cancer Institute
   (NCI)
RP Palena, C (corresponding author), NCI, Lab Tumor Immunol & Biol, Ctr Canc Res, NIH, Bethesda, MD 20892 USA.
EM palenac@mail.nih.gov
RI Palena, Claudia/D-5167-2017
OI David, Justin/0000-0003-2151-605X; Hamilton, Duane/0000-0002-9730-8209
FU NIH Intramural Research Program, National Cancer Institute, Center for
   Cancer Research
FX This research was supported by funds of the NIH Intramural Research
   Program, National Cancer Institute, Center for Cancer Research.
CR Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Nieto MA, 2013, SCIENCE, V342, P708, DOI 10.1126/science.1234850
   Barr S, 2008, CLIN EXP METASTAS, V25, P685, DOI 10.1007/s10585-007-9121-7
   Bates RC, 2004, EXP CELL RES, V299, P315, DOI 10.1016/j.yexcr.2004.05.033
   Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104
   Bivona TG, 2011, NATURE, V471, P523, DOI 10.1038/nature09870
   Byers LA, 2013, CLIN CANCER RES, V19, P279, DOI 10.1158/1078-0432.CCR-12-1558
   Camidge DR, 2014, NAT REV CLIN ONCOL, V11, P473, DOI 10.1038/nrclinonc.2014.104
   Desbaillets I, 1997, J EXP MED, V186, P1201, DOI 10.1084/jem.186.8.1201
   Dorion S, 2002, CELL STRESS CHAPERON, V7, P200, DOI 10.1379/1466-1268(2002)007<0200:AOTMAP>2.0.CO;2
   Fernando RI, 2011, CANCER RES, V71, P5296, DOI 10.1158/0008-5472.CAN-11-0156
   Gabellini C, 2009, EUR J CANCER, V45, P2618, DOI 10.1016/j.ejca.2009.07.007
   Gao SP, 2007, J CLIN INVEST, V117, P3846, DOI 10.1172/JCI31871
   Gazdar AF, 2005, PLOS MED, V2, P1085, DOI 10.1371/journal.pmed.0020377
   Gazdar AF, 2004, TRENDS MOL MED, V10, P481, DOI 10.1016/j.molmed.2004.08.008
   Giles KM, 2013, MOL CANCER THER, V12, P2541, DOI 10.1158/1535-7163.MCT-13-0170
   Gujral TS, 2014, CELL, V159, P844, DOI 10.1016/j.cell.2014.10.032
   Hamilton DH, 2015, ONCOTARGET, V6, P4853, DOI 10.18632/oncotarget.3086
   Hamilton DH, 2014, CANCER RES, V74, P2510, DOI 10.1158/0008-5472.CAN-13-1894
   Hoffmann E, 2002, J LEUKOCYTE BIOL, V72, P847
   Holtmann H, 1999, MOL CELL BIOL, V19, P6742
   Huang B, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.208
   Hwang WL, 2011, GASTROENTEROLOGY, V141, P279, DOI 10.1053/j.gastro.2011.04.008
   Jutten B, 2014, CELL CYCLE, V13, P42, DOI 10.4161/cc.27518
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Landi L, 2013, CURR OPIN ONCOL, V25, P130, DOI 10.1097/CCO.0b013e32835daf37
   Liu CL, 2016, ONCOTARGET, V7, P14279, DOI 10.18632/oncotarget.7306
   Liu YN, 2015, ONCOTARGET, V6, P10415, DOI 10.18632/oncotarget.3389
   Lynch TJ, 2004, NEW ENGL J MED, V350, P2129, DOI 10.1056/NEJMoa040938
   Ning Y, 2012, MOL CANCER THER, V11, P1353, DOI 10.1158/1535-7163.MCT-11-0915
   Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018
   Paez JG, 2004, SCIENCE, V304, P1497, DOI 10.1126/science.1099314
   Palena C, 2012, FUTURE ONCOL, V8, P713, DOI [10.2217/FON.12.59, 10.2217/fon.12.59]
   Pao W, 2005, PLOS MED, V2, P225, DOI 10.1371/journal.pmed.0020073
   Roberts PJ, 2010, J CLIN ONCOL, V28, P4769, DOI 10.1200/JCO.2009.27.4365
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Sharma B, 2013, MOL CANCER THER, V12, P799, DOI 10.1158/1535-7163.MCT-12-0529
   Shepherd FA, 2005, NEW ENGL J MED, V353, P123, DOI 10.1056/NEJMoa050753
   Singh A, 2010, ONCOGENE, V29, P4741, DOI 10.1038/onc.2010.215
   Skov L, 2008, J IMMUNOL, V181, P669, DOI 10.4049/jimmunol.181.1.669
   Thiery JP, 2009, CELL, V139, P871, DOI 10.1016/j.cell.2009.11.007
   Thomson S, 2005, CANCER RES, V65, P9455, DOI 10.1158/0008-5472.CAN-05-1058
   Tsao MS, 2005, NEW ENGL J MED, V353, P133, DOI 10.1056/NEJMoa050736
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Waugh DJJ, 2008, CLIN CANCER RES, V14, P6735, DOI 10.1158/1078-0432.CCR-07-4843
   Wilson C, 2014, ONCOTARGET, V5, P7328, DOI 10.18632/oncotarget.2397
   Xie KP, 2001, CYTOKINE GROWTH F R, V12, P375, DOI 10.1016/S1359-6101(01)00016-8
   Yao Z, 2010, P NATL ACAD SCI USA, V107, P15535, DOI 10.1073/pnas.1009472107
   Yuan A, 2000, AM J RESP CRIT CARE, V162, P1957, DOI 10.1164/ajrccm.162.5.2002108
   Zhang ZF, 2012, NAT GENET, V44, P852, DOI 10.1038/ng.2330
NR 50
TC 48
Z9 54
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUL 5
PY 2016
VL 7
IS 27
BP 42031
EP 42044
DI 10.18632/oncotarget.9662
PG 14
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA DS7DI
UT WOS:000380942600084
PM 27248176
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Li, YC
   Li, CF
   Xu, RS
   Wang, Y
   Li, DD
   Zhang, B
AF Li, Yongchao
   Li, Changfeng
   Xu, Ruisi
   Wang, Yun
   Li, Dandan
   Zhang, Bin
TI A novel circFMN2 promotes umor proliferation in CRC by regulating the
   miR-1182/hTERT signaling pathways
SO CLINICAL SCIENCE
LA English
DT Article
ID CIRCULAR RNA; HEPATOCELLULAR-CARCINOMA; CANCER; BIOMARKER; EXOSOMES;
   GROWTH
AB Background: Circular RNAs (circRNAs) are a class of non-coding RNAs broadly expressed 8 in cells of various species. However, the molecular mechanisms that link circRNAs with colorectal cancer (CRC) are not well understood. In the present study, we attempted to provide novel basis for targeted therapy for CRC from the aspect of circRNA-microRNA (miRNA)-rnRNA interaction.
   Methods: We investigated the expression of circRNAs in five paired CRC tissues and adjacent non-tumor tissues by microarray analysis. Differentially expressed circRNAs were identified between CRC tissues and non-cancerous matched tissues. We focused on hsa_circ_0005100, which is located on chromosome 1 and derived from FMN2, and thus we named it as circFMN2. The expression of circFMN2 was detected in 88 CRC tissues and cell lines by quantitative real-time PCR. Functional assays were performed to evaluate the effects of circFMN2 on proliferation in vitro, and on tumorigenesis in vivo. The relation ship between circFMN2 and miR-1182 was confirmed by luciferase reporter assay.
   Results: circFMN2 was found to be significantly up-regulated in CRC tissues and cell lines. Moreover, knockdown of circFMN2 significantly inhibited cell proliferation and migration in vitro. Bioinformatics analysis predicted that there is a circFMN2/miR-1182/hTERT axis in CRC progression. Dual-luciferase reporter system validated the direct interaction of circFMN2, miR-1182, hTERT. Western blot verified that inhibition of circFMN2 decreased hTERT expression. Importantly, we demonstrated that circFMN2 was up-regulated in serum exosomes from CRC patients.
   Conclusion: In conclusion, circFMN2 is a central component linking circRNAs to progression of CRC via an miR-1182/hTERT axis.
C1 [Li, Yongchao] Jilin Univ, Dept Gastrointestinal Colorectal Surg, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China.
   [Li, Changfeng; Xu, Ruisi; Li, Dandan; Zhang, Bin] Jilin Univ, Dept Endoscopy Ctr, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China.
   [Wang, Yun] Jilin Prov, Dept Med, Liver & Biliary Dis Hosp, Changchun 130033, Jilin, Peoples R China.
C3 Jilin University; Jilin University
RP Li, CF (corresponding author), Jilin Univ, Dept Endoscopy Ctr, China Japan Union Hosp, Changchun 130033, Jilin, Peoples R China.
EM zhangtang1619@163.com
RI Zhang, Bin/HCP-1386-2022; Li, Yongchao/I-6241-2015
FU National Natural Science Foundation of China [81872323]; Science and
   Technology Department of Jilin Province [20190303149SF]
FX This study was approved by National Natural Science Foundation of China
   [grant number 81872323] and the Science and Technology Department of
   Jilin Province [grant number 20190303149SF].
CR Ambros V, 2004, NATURE, V431, P350, DOI 10.1038/nature02871
   Barrett SP, 2016, DEVELOPMENT, V143, P1838, DOI 10.1242/dev.128074
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Chen WQ, 2015, CHINESE J CANCER RES, V27, P2, DOI 10.3978/j.issn.1000-9604.2015.01.06
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Dai XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0485-1
   Fan XY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0706-1
   Granados-Riveron JT, 2016, BBA-GENE REGUL MECH, V1859, P1245, DOI 10.1016/j.bbagrm.2016.07.009
   Guo JU, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0409-z
   Han B, 2018, PHARMACOL THERAPEUT, V187, P31, DOI 10.1016/j.pharmthera.2018.01.010
   Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270
   Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82
   Li ZY, 2015, NAT STRUCT MOL BIOL, V22, P256, DOI 10.1038/nsmb.2959
   Liu H, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0902-1
   Liu J, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0630-y
   Memczak S, 2013, NATURE, V495, P333, DOI 10.1038/nature11928
   PAN BT, 1985, J CELL BIOL, V101, P942, DOI 10.1083/jcb.101.3.942
   Qu SB, 2015, CANCER LETT, V365, P141, DOI 10.1016/j.canlet.2015.06.003
   Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733
   Siegel Rebecca L, 2018, CA Cancer J Clin, V68, P7, DOI 10.3322/caac.21442
   Song J, 2018, EXP MOL MED, V50, DOI 10.1038/s12276-018-0125-y
   Su HW, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0951-0
   Wang RJ, 2018, CANCER RES, V78, P4812, DOI 10.1158/0008-5472.CAN-18-0532
   Williams C, 2014, CELL RES, V24, P766, DOI 10.1038/cr.2014.44
   Xiao J, 2019, ONCOTARGETS THER, V12, P4481, DOI 10.2147/OTT.S207397
   Yang R, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0933-7
   Zhang D, 2015, CANCER LETT, V360, P151, DOI 10.1016/j.canlet.2015.01.044
   Zhang HY, 2019, ONCOGENE, V38, P2844, DOI 10.1038/s41388-018-0619-z
   Zheng LL, 2019, PATHOL RES PRACT, V215, P373, DOI 10.1016/j.prp.2018.12.031
   Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027
NR 30
TC 67
Z9 69
U1 0
U2 17
PU PORTLAND PRESS LTD
PI LONDON
PA 1ST FLR, 10 QUEEN STREET PLACE, LONDON, ENGLAND
SN 0143-5221
EI 1470-8736
J9 CLIN SCI
JI Clin. Sci.
PD DEC
PY 2019
VL 133
IS 24
BP 2463
EP 2479
DI 10.1042/CS20190715
PG 17
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA KI2SI
UT WOS:000511200000003
PM 31738400
OA hybrid
DA 2025-01-04
ER

PT J
AU Lee, SM
   Sung, CO
AF Lee, Sun Mi
   Sung, Chang Ohk
TI Comprehensive analysis of mutational and clinicopathologic
   characteristics of poorly differentiated colorectal neuroendocrine
   carcinomas
SO SCIENTIFIC REPORTS
LA English
DT Article
ID BRAF MUTATIONS; COLON; SURVIVAL; TUMORS
AB Poorly differentiated neuroendocrine carcinoma (NEC) is a rare subtype of colorectal cancer (CRC). This study aimed to investigate clinicopathologic characteristics of colorectal NECs and elucidate genomic differences and similarities between colorectal NECs and colorectal adenocarcinomas (ACs). A total of 30 colorectal NECs were screened for frequently identified CRC oncogenic driver genes by targeted next-generation sequencing of 382 genes. The median age of the patients was 67 years (range, 44 to 88 years). NECs occurred predominantly in the rectum (47%) and exhibited multiple adverse prognostic pathologic factors, including frequent lymphatic and vascular invasions, high rates of lymph node metastasis and distant metastasis and advanced TNM stage. The 1-, 3-, and 5-year overall survival rates of NEC patients were 46.7%, 36.4%, and 32.7%, respectively, with a median overall survival period of 11.5 months. In a molecular analysis, NECs showed high rates of BRAF mutation (23%), predominantly p.V600E (71%), and alterations in RB1 (47%), particularly deletion (57%). The frequencies and distributions of other genes, such as KRAS, APC, SMAD4, and PIK3CA, and microsatellite instability status were similar to those of ACs. These findings provide beneficial information for selecting therapeutic options, including targeted therapy, and a better understanding of the histogenesis of this tumour.
C1 [Lee, Sun Mi] Jeju Natl Univ Hosp, Dept Pathol, 15 Aran 13 Gil, Jeju Si 63241, Jeju Do, South Korea.
   [Sung, Chang Ohk] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul, South Korea.
   [Sung, Chang Ohk] Univ Ulsan, Coll Med, Asan Med Ctr, Mol Diagnost Lab, Seoul, South Korea.
C3 Jeju National University; University of Ulsan; Asan Medical Center;
   University of Ulsan; Asan Medical Center
RP Lee, SM (corresponding author), Jeju Natl Univ Hosp, Dept Pathol, 15 Aran 13 Gil, Jeju Si 63241, Jeju Do, South Korea.
EM drsunmi@yahoo.com
OI Lee, Sun Mi/0009-0006-9516-1780
FU Jeju National University Hospital
FX We thank all the specimen donors and research groups of data sets. This
   work was supported by a research grant from Jeju National University
   Hospital in 2018 (2018-30).
CR Aggarwal RR, 2019, MOL CANCER RES, V17, P1235, DOI 10.1158/1541-7786.MCR-18-1101
   Amin MB., 2017, AJCC Cancer Staging Manual, V8, P251
   Bernick PE, 2004, DIS COLON RECTUM, V47, P163, DOI 10.1007/s10350-003-0038-1
   Burkart J, 2018, J NATL COMPR CANC NE, V16, P1035, DOI 10.6004/jnccn.2018.7043
   Center for Genomic Science of Korea National Research Institute of Health, 2016, KOR REF GEN VAR DAT
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Conte B, 2016, CLIN COLORECTAL CANC, V15, pE1, DOI 10.1016/j.clcc.2015.12.007
   Fields AC, 2019, ANN SURG ONCOL, V26, P1127, DOI 10.1245/s10434-019-07203-3
   Garcia-Carbonero R, 2016, NEUROENDOCRINOLOGY, V103, P186, DOI 10.1159/000443172
   George J, 2015, NATURE, V524, P47, DOI 10.1038/nature14664
   Giacinti C, 2006, ONCOGENE, V25, P5220, DOI 10.1038/sj.onc.1209615
   Ishida H, 2017, MODERN PATHOL, V30, P660, DOI 10.1038/modpathol.2016.222
   Jesinghaus M, 2017, MODERN PATHOL, V30, P610, DOI 10.1038/modpathol.2016.220
   Kim JE, 2019, J MOL DIAGN, V21, P241, DOI 10.1016/j.jmoldx.2018.09.005
   Klempner SJ, 2016, CANCER DISCOV, V6, P594, DOI 10.1158/2159-8290.CD-15-1192
   Lai ZW, 2016, NUCLEIC ACIDS RES, V44, DOI 10.1093/nar/gkw227
   Lee MS, 2017, J NATL COMPR CANC NE, V15, P411, DOI 10.6004/jnccn.2017.0038
   Lek M, 2016, NATURE, V536, P285, DOI 10.1038/nature19057
   McKenna A, 2010, GENOME RES, V20, P1297, DOI 10.1101/gr.107524.110
   McLaren W, 2010, BIOINFORMATICS, V26, P2069, DOI 10.1093/bioinformatics/btq330
   Olevian DC, 2016, HUM PATHOL, V49, P124, DOI 10.1016/j.humpath.2015.11.004
   Robinson JT, 2011, NAT BIOTECHNOL, V29, P24, DOI 10.1038/nbt.1754
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Shafqat H, 2015, DIS COLON RECTUM, V58, P294, DOI 10.1097/DCR.0000000000000298
   Shamir ER, 2019, MODERN PATHOL, V32, P290, DOI 10.1038/s41379-018-0131-6
   Sherry ST, 2001, NUCLEIC ACIDS RES, V29, P308, DOI 10.1093/nar/29.1.308
   Shia J., 2019, Digetive System tumours, V5th, P188
   Smith JD, 2014, ANN SURG ONCOL, V21, P2956, DOI 10.1245/s10434-014-3725-3
   Sorbye H, 2013, ANN ONCOL, V24, P152, DOI 10.1093/annonc/mds276
   Sorbye H, 2014, CANCER-AM CANCER SOC, V120, P2814, DOI 10.1002/cncr.28721
   Takizawa N, 2015, HUM PATHOL, V46, P1890, DOI 10.1016/j.humpath.2015.08.006
   Woischke C, 2017, MODERN PATHOL, V30, P95, DOI 10.1038/modpathol.2016.150
NR 32
TC 14
Z9 13
U1 0
U2 6
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 2045-2322
J9 SCI REP-UK
JI Sci Rep
PD MAR 18
PY 2021
VL 11
IS 1
AR 6203
DI 10.1038/s41598-021-85593-9
PG 11
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA TA9RH
UT WOS:000667581800003
PM 33737597
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Radke, J
   Schumann, E
   Onken, J
   Koll, R
   Acker, G
   Bodnar, B
   Senger, C
   Tierling, S
   Möbs, M
   Vajkoczy, P
   Vidal, A
   Högler, S
   Kodajova, P
   Westphal, D
   Meier, F
   Heppner, F
   Kreuzer-Redmer, S
   Grebien, F
   Jürchott, K
   Redmer, T
AF Radke, Josefine
   Schumann, Elisa
   Onken, Julia
   Koll, Randi
   Acker, Guliz
   Bodnar, Bohdan
   Senger, Carolin
   Tierling, Sascha
   Moebs, Markus
   Vajkoczy, Peter
   Vidal, Anna
   Hoegler, Sandra
   Kodajova, Petra
   Westphal, Dana
   Meier, Friedegund
   Heppner, Frank
   Kreuzer-Redmer, Susanne
   Grebien, Florian
   Juerchott, Karsten
   Redmer, Torben
TI Decoding molecular programs in melanoma brain metastases
SO NATURE COMMUNICATIONS
LA English
DT Article
ID EPITHELIAL-MESENCHYMAL TRANSITION; DABRAFENIB PLUS TRAMETINIB; P75
   NEUROTROPHIN RECEPTOR; MINIMAL RESIDUAL DISEASE; CENTRAL-NERVOUS-SYSTEM;
   MALIGNANT-MELANOMA; COLORECTAL-CANCER; ANTI-PD-1 THERAPY; TARGETED
   THERAPY; DNA METHYLATION
AB Melanoma brain metastases (MBM) variably respond to therapeutic interventions; thus determining patient's prognosis. However, the mechanisms that govern therapy response are poorly understood. Here, we use a multi-OMICS approach and targeted sequencing (TargetSeq) to unravel the programs that potentially control the development of progressive intracranial disease. Molecularly, the expression of E-cadherin (Ecad) or NGFR, the BRAF mutation state and level of immune cell infiltration subdivides tumors into proliferative/pigmented and invasive/stem-like/therapy-resistant irrespective of the intracranial location. The analysis of MAPK inhibitor-naive and refractory MBM reveals switching from Ecad-associated into NGFR-associated programs during progression. NGFR-associated programs control cell migration and proliferation via downstream transcription factors such as SOX4. Moreover, global methylome profiling uncovers 46 differentially methylated regions that discriminate BRAF(mut) and wildtype MBM. In summary, we propose that the expression of Ecad and NGFR sub- classifies MBM and suggest that the Ecad-to-NGFR phenotype switch is a rate-limiting process which potentially indicates drug-response and intracranial progression states in melanoma patients.
   Melanoma brain metastases (MBM) show heterogeneous therapeutic response determined by incompletely understood mechanisms. Here, the authors use a multi-OMICS approach and targeted sequencing (TargetSeq) to decipher programs that may define molecular subsets of MBM and their response to therapy.
C1 [Radke, Josefine] Univ Med Greifswald, Dept Pathol, Greifswald, Germany.
   [Radke, Josefine; Acker, Guliz; Heppner, Frank] Berlin Inst Hlth BIH, Berlin, Germany.
   [Radke, Josefine; Schumann, Elisa; Onken, Julia; Koll, Randi; Heppner, Frank] German Canc Consortium DKTK, Partner Site Berlin, CCCC Campus Mitte, Berlin, Germany.
   [Radke, Josefine; Schumann, Elisa; Koll, Randi; Heppner, Frank] Charite Univ Med Berlin, Dept Neuropathol, Berlin, Germany.
   [Radke, Josefine; Schumann, Elisa; Onken, Julia; Koll, Randi; Acker, Guliz; Bodnar, Bohdan; Senger, Carolin; Moebs, Markus; Vajkoczy, Peter; Heppner, Frank] Free Univ Berlin, Berlin, Germany.
   [Radke, Josefine; Schumann, Elisa; Onken, Julia; Koll, Randi; Acker, Guliz; Bodnar, Bohdan; Senger, Carolin; Moebs, Markus; Vajkoczy, Peter; Heppner, Frank] Humboldt Univ, Berlin, Germany.
   [Onken, Julia; Acker, Guliz; Bodnar, Bohdan; Vajkoczy, Peter] Charite Univ Med Berlin, Dept Neurosurg, Berlin, Germany.
   [Onken, Julia; Acker, Guliz; Bodnar, Bohdan; Senger, Carolin; Moebs, Markus; Vajkoczy, Peter] Berlin Inst Hlth, Berlin, Germany.
   [Senger, Carolin] Charite Univ Med Berlin, Charite CyberKnife Ctr, Dept Radiat Oncol, Berlin, Germany.
   [Tierling, Sascha] Saarland Univ, Fac NT, Dept Genet Epigenet, Saarbrucken, Germany.
   [Moebs, Markus] Charite Univ Med Berlin, Dept Pathol, Berlin, Germany.
   [Vidal, Anna; Grebien, Florian; Redmer, Torben] Univ Vet Med Vienna, Inst Med Biochem, Vienna, Austria.
   [Hoegler, Sandra; Kodajova, Petra; Redmer, Torben] Univ Vet Med Vienna, Inst Pathol, Unit Lab Anim Pathol, Vienna, Austria.
   [Westphal, Dana; Meier, Friedegund] Tech Univ Dresden, Dept Dermatol, Univ Hosp Carl Gustav Carus, Dresden, Germany.
   [Westphal, Dana; Meier, Friedegund] Natl Ctr Tumor Dis NCT, Dresden, Germany.
   [Westphal, Dana; Meier, Friedegund] Helmholtz Zentrum Dresden Rossendorf HZDR, Dresden, Germany.
   [Westphal, Dana; Meier, Friedegund] German Canc Res Ctr, Fac Med, Heidelberg, Germany.
   [Meier, Friedegund] Tech Univ Dresden, Univ Canc Ctr Dresden, Univ Hosp Carl Gustav Carus, Skin Canc Ctr, Dresden, Germany.
   [Kreuzer-Redmer, Susanne] Univ Vet Med Vienna, Inst Anim Nutr & Funct Plant Cpds, Nutrigen Unit, Vienna, Austria.
   [Juerchott, Karsten] Charite Univ Med Berlin, Ctr Regenerat Therapies BCRT, Berlin Inst Hlth, Berlin, Germany.
C3 Greifswald Medical School; Berlin Institute of Health; Helmholtz
   Association; German Cancer Research Center (DKFZ); Berlin Institute of
   Health; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt
   University of Berlin; Berlin Institute of Health; Free University of
   Berlin; Humboldt University of Berlin; Charite Universitatsmedizin
   Berlin; Berlin Institute of Health; Berlin Institute of Health; Free
   University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin; Saarland University; Berlin Institute of
   Health; Free University of Berlin; Humboldt University of Berlin;
   Charite Universitatsmedizin Berlin; University of Veterinary Medicine
   Vienna; University of Veterinary Medicine Vienna; Technische Universitat
   Dresden; Carl Gustav Carus University Hospital; Helmholtz Association;
   German Cancer Research Center (DKFZ); Ruprecht Karls University
   Heidelberg; Helmholtz Association; Helmholtz-Zentrum Dresden-Rossendorf
   (HZDR); Helmholtz Association; German Cancer Research Center (DKFZ);
   Technische Universitat Dresden; Carl Gustav Carus University Hospital;
   University of Veterinary Medicine Vienna; Berlin Institute of Health;
   Free University of Berlin; Humboldt University of Berlin; Charite
   Universitatsmedizin Berlin
RP Radke, J (corresponding author), Univ Med Greifswald, Dept Pathol, Greifswald, Germany.; Radke, J (corresponding author), Berlin Inst Hlth BIH, Berlin, Germany.; Radke, J (corresponding author), German Canc Consortium DKTK, Partner Site Berlin, CCCC Campus Mitte, Berlin, Germany.; Radke, J (corresponding author), Charite Univ Med Berlin, Dept Neuropathol, Berlin, Germany.; Radke, J (corresponding author), Free Univ Berlin, Berlin, Germany.; Redmer, T (corresponding author), Univ Vet Med Vienna, Inst Med Biochem, Vienna, Austria.; Redmer, T (corresponding author), Univ Vet Med Vienna, Inst Pathol, Unit Lab Anim Pathol, Vienna, Austria.
EM josefine.radke@med.uni-greifswald.de; torben.redmer@vetmeduni.ac.at
RI Grebien, Florian/H-9234-2019; VAJKOCZY, Peter/LMP-7680-2024; Heppner,
   Frank/ABH-8393-2020; Redmer, Torben/ABF-3893-2020; Radke,
   Josefine/GQH-8274-2022; Senger, Carolin/LIC-0921-2024; Kreuzer-Redmer,
   Susanne/AAV-4840-2020; Meier, Friedegund/HTN-0745-2023
OI Kreuzer-Redmer, Susanne/0000-0001-9425-3356; Mobs,
   Markus/0000-0002-1502-3032; Westphal, Dana/0000-0003-4340-0402; Meier,
   Friedegund/0000-0003-4340-9706; Onken, Julia/0000-0002-2859-4395; Vidal,
   Anna/0000-0001-6172-0130; Radke, Josefine/0000-0001-9860-2007; Acker,
   Guliz/0000-0002-8946-6426; Redmer, Torben/0000-0002-0050-9478; Heppner,
   Frank/0000-0001-9816-8917; Grebien, Florian/0000-0003-4289-2281;
   Jurchott, Karsten/0000-0003-1589-0037; Vajkoczy,
   Peter/0000-0003-4350-392X
FU University of Veterinary Medicine Vienna (Vetmeduni Vienna)
FX Open Access funding for this article was provided by the University of
   Veterinary Medicine Vienna (Vetmeduni Vienna).
CR Abu-Thuraia A, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17415-x
   Acker G, 2020, EUR J CANCER, V126, P106, DOI 10.1016/j.ejca.2019.12.005
   Altshuler DM, 2015, NATURE, V526, P68, DOI 10.1038/nature15393
   [Anonymous], 2015, Cell, V161, P1681, DOI DOI 10.1016/J.CELL.2015.05.044
   Bamji SX, 1998, J CELL BIOL, V140, P911, DOI 10.1083/jcb.140.4.911
   Bander ED, 2021, CANCER-AM CANCER SOC, V127, P2062, DOI 10.1002/cncr.33459
   Berghoff AS, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1057388
   Biermann J, 2022, CELL, V185, P2591, DOI 10.1016/j.cell.2022.06.007
   Boiko AD, 2010, NATURE, V466, P133, DOI 10.1038/nature09161
   Boshuizen J, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17739-8
   Capper D, 2018, NATURE, V555, P469, DOI 10.1038/nature26000
   CHASON JL, 1963, CANCER-AM CANCER SOC, V16, P781, DOI 10.1002/1097-0142(196306)16:6<781::AID-CNCR2820160614>3.0.CO;2-M
   Chen SF, 2018, BIOINFORMATICS, V34, P884, DOI 10.1093/bioinformatics/bty560
   Cheng Q, 2017, INT J MOL MED, V40, P447, DOI 10.3892/ijmm.2017.3030
   Czyz M, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123844
   D'Arcy C, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11081213
   Dankort D, 2009, NAT GENET, V41, P544, DOI 10.1038/ng.356
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Davies MA, 2017, LANCET ONCOL, V18, P863, DOI 10.1016/S1470-2045(17)30429-1
   Davies MA, 2011, CANCER-AM CANCER SOC, V117, P1687, DOI 10.1002/cncr.25634
   Diener J, 2021, STEM CELL TRANSL MED, V10, P522, DOI 10.1002/sctm.20-0351
   Du WB, 2020, EUR REV MED PHARMACO, V24, P655, DOI 10.26355/eurrev_202001_20042
   Du Y, 2019, STEM CELLS, V37, P865, DOI 10.1002/stem.3013
   EDDLESTON M, 1993, NEUROSCIENCE, V54, P15, DOI 10.1016/0306-4522(93)90380-X
   Eichler AF, 2011, NAT REV CLIN ONCOL, V8, P344, DOI 10.1038/nrclinonc.2011.58
   El-Maarri Osman, 2004, Methods Mol Biol, V287, P195
   Fidler IJ, 1999, CANCER METAST REV, V18, P387, DOI 10.1023/A:1006329410433
   Fischer GM, 2019, CANCER DISCOV, V9, P628, DOI 10.1158/2159-8290.CD-18-1489
   Fujikawa A, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-05931-8
   Furuta J, 2014, J INVEST DERMATOL, V134, P1369, DOI 10.1038/jid.2013.490
   Gibert J, 2020, LUNG CANCER, V140, P42, DOI 10.1016/j.lungcan.2019.12.003
   Gu ZG, 2016, BIOINFORMATICS, V32, P2847, DOI 10.1093/bioinformatics/btw313
   Guglielmi L, 2020, CANCERS, V12, DOI 10.3390/cancers12061635
   Guo RF, 2014, INT J CLIN EXP PATHO, V7, P8947
   Haueis SA, 2017, MELANOMA RES, V27, P231, DOI 10.1097/CMR.0000000000000338
   Heppt MV, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3529-5
   Hoek KS, 2008, CANCER RES, V68, P650, DOI 10.1158/0008-5472.CAN-07-2491
   Hölzel M, 2016, TRENDS IMMUNOL, V37, P364, DOI 10.1016/j.it.2016.03.009
   Hoon DSB, 2001, J INVEST DERMATOL, V117, P375, DOI 10.1046/j.0022-202x.2001.01417.x
   Hugo W, 2016, CELL, V165, P35, DOI 10.1016/j.cell.2016.02.065
   Hurst RE, 2016, THER ADV MED ONCOL, V8, P126, DOI 10.1177/1758834015624277
   Imafuku K, 2017, CASE REP ONCOL, V10, P290, DOI 10.1159/000461576
   Indini A, 2021, MELANOMA RES, V31, P190, DOI 10.1097/CMR.0000000000000725
   Izraely S, 2012, INT J CANCER, V131, P1071, DOI 10.1002/ijc.27324
   Jakob JA, 2012, CANCER-AM CANCER SOC, V118, P4014, DOI 10.1002/cncr.26724
   Jiang HS, 2014, BMC BIOINFORMATICS, V15, DOI 10.1186/1471-2105-15-182
   Johnston ST, 2015, BMC SYST BIOL, V9, DOI 10.1186/s12918-015-0182-y
   Kim D, 2013, GENOME BIOL, V14, DOI 10.1186/gb-2013-14-4-r36
   Krauthammer M, 2012, NAT GENET, V44, P1006, DOI 10.1038/ng.2359
   Lake BB, 2018, NAT BIOTECHNOL, V36, P70, DOI 10.1038/nbt.4038
   Phi LTH, 2018, STEM CELLS INT, V2018, DOI 10.1155/2018/5416923
   Landsberg J, 2012, NATURE, V490, P412, DOI 10.1038/nature11538
   Larue L, 2005, ONCOGENE, V24, P7443, DOI 10.1038/sj.onc.1209091
   Lau PKH, 2021, J IMMUNOTHER CANCER, V9, DOI 10.1136/jitc-2021-002995
   Lehraiki A, 2015, CELL DISCOV, V1, DOI 10.1038/celldisc.2015.30
   Li Y, 2021, CELL COMMUN SIGNAL, V19, DOI 10.1186/s12964-020-00627-5
   Liao Y, 2019, NUCLEIC ACIDS RES, V47, DOI 10.1093/nar/gkz114
   Lionarons DA, 2019, CANCER CELL, V36, P68, DOI 10.1016/j.ccell.2019.05.015
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Long GV, 2018, LANCET ONCOL, V19, P672, DOI 10.1016/S1470-2045(18)30139-6
   Love MI, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0550-8
   Luskin MR, 2018, NAT REV CANCER, V18, P255, DOI 10.1038/nrc.2017.125
   MADAJEWICZ S, 1984, CANCER-AM CANCER SOC, V53, P2550, DOI 10.1002/1097-0142(19840601)53:11<2550::AID-CNCR2820531129>3.0.CO;2-B
   Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07
   Marin-Bejar O., 2020, BIORXIV, DOI [10.1101/2020.12.15.422929, DOI 10.1101/2020.12.15.422929]
   Masago K, 2018, J THORAC DIS, V10, pS1982, DOI 10.21037/jtd.2018.04.155
   Meacham CE, 2013, NATURE, V501, P328, DOI 10.1038/nature12624
   Mohan A. S, 2018, BIORXIV, DOI [10.1101/326710, DOI 10.1101/326710]
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Müller F, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1664-9
   Ngo M, 2016, CELL REP, V16, P1701, DOI 10.1016/j.celrep.2016.07.004
   Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336
   Padmanaban V, 2019, NATURE, V573, P439, DOI 10.1038/s41586-019-1526-3
   Pagès C, 2008, HUM PATHOL, V39, P1136, DOI 10.1016/j.humpath.2007.12.006
   Parakh S, 2017, BRIT J CANCER, V116, P1558, DOI 10.1038/bjc.2017.142
   PATEL JK, 1978, AM J SURG, V135, P807, DOI 10.1016/0002-9610(78)90171-X
   Pidsley R, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-293
   Planchard D, 2017, LANCET ONCOL, V18, P1307, DOI 10.1016/S1470-2045(17)30679-4
   Rabbie R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18060-0
   Radke J, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10129-z
   Rajapakse VN, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaz4125
   Rambow F, 2018, CELL, V174, P843, DOI 10.1016/j.cell.2018.06.025
   Redmer T, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2016.88
   Redmer T, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0854-5
   Redmer T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092596
   Redmer T, 2011, EMBO REP, V12, P720, DOI 10.1038/embor.2011.88
   Restivo G, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01573-6
   Ribas A, 2015, CANCER DISCOV, V5, P915, DOI 10.1158/2159-8290.CD-15-0563
   Sandru A, 2014, J Med Life, V7, P572
   Schatton T, 2010, J INVEST DERMATOL, V130, P1769, DOI 10.1038/jid.2010.135
   Schouten LJ, 2002, CANCER, V94, P2698, DOI 10.1002/cncr.10541
   Schroeder T, 2020, J NEURO-ONCOL, V147, P229, DOI 10.1007/s11060-020-03419-6
   Schwartz H, 2016, CANCER RES, V76, P4359, DOI 10.1158/0008-5472.CAN-16-0485
   Sevenich L, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00163
   Singh R, 2020, NEURO-ONCOL ADV, V2, DOI 10.1093/noajnl/vdaa041
   Smid M, 2008, CANCER RES, V68, P3108, DOI 10.1158/0008-5472.CAN-07-5644
   Sofroniew MV, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a020420
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   TANG A, 1994, J CELL SCI, V107, P983
   Tas F, 2012, J ONCOL, V2012, DOI 10.1155/2012/647684
   Thankamony AP, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00079
   Tiwari N, 2013, CANCER CELL, V23, P768, DOI 10.1016/j.ccr.2013.04.020
   Tsoi J, 2018, CANCER CELL, V33, P890, DOI 10.1016/j.ccell.2018.03.017
   Vidal A, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23031199
   Vidal A, 2020, CANCERS, V12, DOI 10.3390/cancers12092460
   Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631
   Wang JW, 2018, CANCER DISCOV, V8, P1130, DOI 10.1158/2159-8290.CD-17-1263
   Wang TC, 2015, CLIN EXP METASTAS, V32, P73, DOI 10.1007/s10585-014-9692-z
   Winkler F, 2015, J MOL MED, V93, P1213, DOI 10.1007/s00109-015-1357-0
   Wu TZ, 2021, INNOVATION-AMSTERDAM, V2, DOI 10.1016/j.xinn.2021.100141
   Xu L, 2008, MOL CANCER RES, V6, P760, DOI 10.1158/1541-7786.MCR-07-0344
   YAAR M, 1991, J CELL BIOL, V115, P821, DOI 10.1083/jcb.115.3.821
   Yushkevich PA, 2006, NEUROIMAGE, V31, P1116, DOI 10.1016/j.neuroimage.2006.01.015
   Zhang J, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01568-2
   Zhang YH, 2021, CANCER IMMUNOL RES, V9, P967, DOI 10.1158/2326-6066.CIR-20-0879
   Zhang YH, 2020, FRONT GENET, V11, DOI 10.3389/fgene.2020.604336
   Zubrilov I, 2015, CANCER LETT, V361, P86, DOI 10.1016/j.canlet.2015.02.041
NR 117
TC 7
Z9 7
U1 1
U2 5
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
EI 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD NOV 26
PY 2022
VL 13
IS 1
AR 7304
DI 10.1038/s41467-022-34899-x
PG 24
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA 6M4XI
UT WOS:000888871600014
PM 36435874
OA Green Submitted, gold, Green Published
DA 2025-01-04
ER

PT B
AU Zirlik, K
   Duyster, J
AF Zirlik, Katja
   Duyster, Justus
BE Marme, D
TI Combination of Anti-angiogenics and Other Targeted Therapies
SO TUMOR ANGIOGENESIS: A KEY TARGET FOR CANCER THERAPY
LA English
DT Article; Book Chapter
DE Angiogenesis; VEGF; Angiogenesis inhibitor; Monoclonal antibodies;
   Bevacizumab; Cetuximab; Panitumumab; Targeted therapy; Preclinical
   studies; Clinical trials; Cancer; Tyrosine kinase inhibitors
ID ANTIEPIDERMAL GROWTH-FACTOR; PHASE-II TRIAL; METASTATIC
   COLORECTAL-CANCER; TYROSINE KINASE INHIBITOR; INDUCIBLE FACTOR 1-ALPHA;
   LONG-TERM SAFETY; CELL LUNG-CANCER; BREAST-CANCER; MONOCLONAL-ANTIBODY;
   ACQUIRED-RESISTANCE
AB Angiogenesis is a hallmark of tumor development and metastasis and is now a validated target for cancer treatment. However, the overall benefits of anti-angiogenic drugs from the perspective of impacting survival have left much to desire, endorsing a need for developing more effective therapeutic regimens, e.g., combining anti-angiogenic drugs with established chemotherapeutic drugs. In this review, we discuss progress in the synergistic design of anti-angiogenic agents in combination with targeted therapies. Targeted cancer therapies include monoclonal antibodies and small-molecule inhibitors that have significantly changed the treatment of cancer over the past years. We focus on anti-angiogenic agents combined with targeted therapies inhibiting the epidermal growth factor receptor (EGFR) pathway and the PI3K (phosphoinositide 3-kinase)/AKT (protein kinase B)/mTOR (mammalian target of rapamycin) pathway and inhibiting immune checkpoint receptors, such as CTLA-4 (cytotoxic T lymphocyte-associated antigen 4) and PD1/PDL1 (programmed cell death protein 1/PD1 ligand). Of note, not always, encouraging preclinical data particularly of VEGF and EGFR inhibitor combinations did translate into the clinics. In addition, we highlight the rapidly developing field of VEGF-based humanized tri-specific nanobodies and novel VEGFR2-targeted antibody-based fusion proteins, potentially providing a new inspiration for antitumor treatment.
C1 [Zirlik, Katja; Duyster, Justus] Univ Med Ctr Freiburg, Dept Med Hematol Oncol & Stem Cell Transplantat 1, Freiburg, Germany.
C3 University of Freiburg
RP Zirlik, K (corresponding author), Univ Med Ctr Freiburg, Dept Med Hematol Oncol & Stem Cell Transplantat 1, Freiburg, Germany.
EM katja.zirlik@uniklinik-freiburg.de; justus.duyster@uniklinik-freiburg.de
CR Andersen JB, 2012, GASTROENTEROLOGY, V142, P1021, DOI 10.1053/j.gastro.2011.12.005
   [Anonymous], J CLIN ONCOL S3
   Baselga J, 1996, J CLIN ONCOL, V14, P737, DOI 10.1200/JCO.1996.14.3.737
   Bukowski RM, 2007, J CLIN ONCOL, V25, P4536, DOI 10.1200/JCO.2007.11.5154
   Ciardiello F, 2000, CLIN CANCER RES, V6, P3739
   Ciardiello F, 2004, CLIN CANCER RES, V10, P784, DOI 10.1158/1078-0432.CCR-1100-03
   Ciuleanu T, 2013, LUNG CANCER, V82, P276, DOI 10.1016/j.lungcan.2013.08.002
   Dickler MN, 2008, CLIN CANCER RES, V14, P7878, DOI 10.1158/1078-0432.CCR-08-0141
   Dormond O, 2007, J BIOL CHEM, V282, P23679, DOI 10.1074/jbc.M700563200
   Dotan Efrat, 2012, J Gastrointest Cancer, V43, P562
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Drooger JC, 2016, CANCER-AM CANCER SOC, V122, P2961, DOI 10.1002/cncr.30141
   du Manoir JM, 2006, CLIN CANCER RES, V12, P904, DOI 10.1158/1078-0432.CCR-05-1109
   Falchook GS, 2015, INVEST NEW DRUG, V33, P177, DOI 10.1007/s10637-014-0173-7
   Falchook GS, 2013, ONCOTARGET, V4, P118, DOI 10.18632/oncotarget.763
   FOLKMAN J, 1971, NEW ENGL J MED, V285, P1182
   Folkman J, 1995, NEW ENGL J MED, V333, P1757, DOI 10.1056/NEJM199512283332608
   Gabrilovich DI, 1999, CLIN CANCER RES, V5, P2963
   Hecht JR, 2009, J CLIN ONCOL, V27, P672, DOI 10.1200/JCO.2008.19.8135
   Herbst RS, 2005, J CLIN ONCOL, V23, P2544, DOI 10.1200/JCO.2005.02.477
   Heskamp S, 2014, MOL PHARMACEUT, V11, P4249, DOI 10.1021/mp500460g
   Heskamp S, 2013, INT J CANCER, V133, P307, DOI 10.1002/ijc.28046
   Hodi FS, 2014, CANCER IMMUNOL RES, V2, P632, DOI 10.1158/2326-6066.CIR-14-0053
   Huang YH, 2012, P NATL ACAD SCI USA, V109, P17561, DOI 10.1073/pnas.1215397109
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kasahara K, 2010, CLIN CANCER RES, V16, P4616, DOI 10.1158/1078-0432.CCR-10-0383
   Kerbel RS, 1998, MOL MED, V4, P286, DOI 10.1007/BF03401737
   Konecny GE, 2004, CLIN CANCER RES, V10, P1706, DOI 10.1158/1078-0432.CCR-0951-3
   Larsen AK, 2011, PHARMACOL THERAPEUT, V131, P80, DOI 10.1016/j.pharmthera.2011.03.012
   Larsen FO, 2011, ACTA ONCOL, V50, P574, DOI 10.3109/0284186X.2010.546369
   Liu XC, 2016, ONCOTARGET, V7, P23227, DOI 10.18632/oncotarget.7594
   Liu YG, 2015, ONCOTARGETS THER, V8, P1061, DOI 10.2147/OTT.S81442
   Lubner SJ, 2010, J CLIN ONCOL, V28, P3491, DOI 10.1200/JCO.2010.28.4075
   Lv YQ, 2015, INT J CLIN EXP MED, V8, P334
   Mahoney KM, 2016, CLIN GENITOURIN CANC, V14, P304, DOI 10.1016/j.clgc.2016.02.007
   Maity A, 2000, CANCER RES, V60, P5879
   Martinelli E, 2010, CLIN CANCER RES, V16, P4990, DOI 10.1158/1078-0432.CCR-10-0923
   McDermott DF, 2016, J CLIN ONCOL, V34, P833, DOI 10.1200/JCO.2015.63.7421
   McDermott DF, 2015, J CLIN ONCOL, V33, P2013, DOI 10.1200/JCO.2014.58.1041
   Monk BJ, 2014, LANCET ONCOL, V15, P799, DOI 10.1016/S1470-2045(14)70244-X
   Motzer RJ, 2015, NEW ENGL J MED, V373, P1803, DOI 10.1056/NEJMoa1510665
   Ocean AJ, 2010, CLIN COLORECTAL CANC, V9, P290, DOI 10.3816/CCC.2010.n.042
   Osada T, 2008, CANCER IMMUNOL IMMUN, V57, P1115, DOI 10.1007/s00262-007-0441-x
   Oyama T, 1998, J IMMUNOL, V160, P1224
   Park BK, 2006, AM J CLIN ONCOL-CANC, V29, P138, DOI 10.1097/01.coc.0000204402.29830.08
   Piha-Paul SA, 2014, ONCOTARGET, V5, P1846, DOI 10.18632/oncotarget.1834
   Poindessous V, 2011, CLIN CANCER RES, V17, P6522, DOI 10.1158/1078-0432.CCR-11-1607
   Prewett M, 1998, CLIN CANCER RES, V4, P2957
   Rak J, 2000, CANCER RES, V60, P490
   Riggs H, 2013, CLIN LUNG CANCER, V14, P224, DOI 10.1016/j.cllc.2012.09.004
   Riley E, 2011, ONCOLOGIST, V16, pE1, DOI 10.1634/theoncologist.2008-0196
   Rini BI, 2011, CANCER-AM CANCER SOC, V117, P758, DOI 10.1002/cncr.25639
   Rugo HS, 2012, BREAST CANCER RES TR, V134, P13, DOI 10.1007/s10549-011-1918-z
   Saltz L, 2012, CLIN COLORECTAL CANC, V11, P101, DOI 10.1016/j.clcc.2011.05.006
   Sato K, 2000, GENES CELLS, V5, P749, DOI 10.1046/j.1365-2443.2000.00358.x
   Scartozzi M, 2009, ANN ONCOL, V20, P227, DOI 10.1093/annonc/mdn637
   Seto T, 2014, LANCET ONCOL, V15, P1236, DOI 10.1016/S1470-2045(14)70381-X
   Soto-Ortiz L, 2016, J THEOR BIOL, V394, P197, DOI 10.1016/j.jtbi.2016.01.026
   Tabernero J, 2007, MOL CANCER RES, V5, P203, DOI 10.1158/1541-7786.MCR-06-0404
   Tanaka S, 2011, TRIALS, V12, DOI 10.1186/1745-6215-12-120
   Thomas MB, 2009, J CLIN ONCOL, V27, P843, DOI 10.1200/JCO.2008.18.3301
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tortora G, 2008, NAT CLIN PRACT ONCOL, V5, P521, DOI 10.1038/ncponc1161
   Tripathy D, 2004, J CLIN ONCOL, V22, P1063, DOI 10.1200/JCO.2004.06.557
   Viloria-Petit A, 2001, CANCER RES, V61, P5090
   Vlahovic G, 2012, CANCER CHEMOTH PHARM, V70, P95, DOI 10.1007/s00280-012-1889-8
   Wang YX, 2010, TARGET ONCOL, V5, P237, DOI 10.1007/s11523-010-0164-3
   Wells SA, 2012, J CLIN ONCOL, V30, P134, DOI 10.1200/JCO.2011.35.5040
   Wu JD, 2004, J CLIN INVEST, V114, P560, DOI 10.1172/JCI200422206
   Xie S, 2014, MED ONCOL, V31, DOI 10.1007/s12032-014-0035-3
   Xie W, 2014, CANCER IMMUNOL IMMUN, V63, P877, DOI 10.1007/s00262-014-1560-9
   Yen L, 2000, ONCOGENE, V19, P3460, DOI 10.1038/sj.onc.1203685
   Yoshikawa D, 2008, BRIT J CANCER, V98, P418, DOI 10.1038/sj.bjc.6604129
   Zhong H, 1999, CANCER RES, V59, P5830
   Zhong H, 2000, CANCER RES, V60, P1541
   Zhu CQ, 2008, J CLIN ONCOL, V26, P4268, DOI 10.1200/JCO.2007.14.8924
NR 76
TC 0
Z9 0
U1 0
U2 2
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
BN 978-3-319-33673-2; 978-3-319-33671-8
PY 2019
BP 359
EP 376
DI 10.1007/978-3-319-33673-2_14
D2 10.1007/978-3-319-33673-2
PG 18
WC Oncology; Pharmacology & Pharmacy
WE Book Citation Index – Science (BKCI-S)
SC Oncology; Pharmacology & Pharmacy
GA BP5UJ
UT WOS:000558265700019
DA 2025-01-04
ER

PT J
AU Zhao, HY
   Su, WY
   Kang, QM
   Xing, Z
   Lin, X
   Wu, ZJ
AF Zhao, Haiyan
   Su, Wuyun
   Kang, Qingmei
   Xing, Ze
   Lin, Xue
   Wu, Zhongjun
TI Natural killer cells inhibit oxaliplatin-resistant colorectal cancer by
   repressing WBSCR22 via upregulating microRNA-146b-5p
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Natural killer cells; oxaliplatin; colorectal cancer; WBSCR22;
   microRNA-146b-5p
ID PROSTATE-CANCER; NK CELLS; IDENTIFICATION; MICRORNAS; GENES
AB Natural killer (NK) cells have exhibited promising efficacy in inhibiting cancer growth. We aimed to explorer the effect of NK cells on oxaliplatin-resistant colorectal cancer and the underlying molecular mechanism. Oxaliplatin-resistant colorectal cancer cell lines were co-cultured with NK cells to evaluate the effect on viability, proliferation, migration and invasion in vitro. Oxaliplatin-resistant colorectal cancer cells were also co-injected with NK cells into mice to establish xenograft tumor model, to assess the in vivo effect of NK cells on tumorigenesis of the oxaliplatin-resistant colorectal cancer cells. Expression of WBSCR22 gene was assessed in the oxaliplatin-resistant colorectal cancer cells following NK cell treatment to elucidate the mechanism. NK cell treatment significantly reduces growth of oxaliplatin-resistant colorectal cancer cells both in vitro and in vivo, as well as reduced WBSCR22 expression. MicroRNAs potentially targeting WBSCR22 were analyzed, and microRNA-146b-5p was found to be significantly upregulated following NK cell treatment. MicroRNA-146b-5p directly targeted WBSCR22 mRNA 3'-UTR to inhibit its expression, which was required for NK cell-induced inhibition of oxaliplatin-resistant colorectal cancer cell lines. NK cells inhibit oxaliplatin-resistant colorectal cancer by repressing WBSCR22 via upregulating microRNA-146b-5p, both of which could serve as candidates for targeted therapy against oxaliplatin-resistant colorectal cancer.
C1 [Zhao, Haiyan; Wu, Zhongjun] Chongqing Med Univ, Affiliated Hosp 1, Hepatobiliary Surg, Friendship Rd,Yuan Jiagang 1, Chongqing Yuzhong Dist, Peoples R China.
   [Kang, Qingmei] Southwest Med Univ, Affiliated Hosp, Dept Pathol, Luzhou 646000, Sichuan, Peoples R China.
   [Lin, Xue] Chongqing Med Univ, Affiliated Hosp 1, Dept Lab Med, Friendship Rd,Yuan Jiagang 1, Chongqing Yuzhong Dist, Peoples R China.
   [Zhao, Haiyan; Su, Wuyun; Xing, Ze] Inner Mongolia Med Univ, Affiliated Hosp, Dept Oncol, Hohhot 010050, Mongolia, Mongolia.
C3 Chongqing Medical University; Southwest Medical University; Chongqing
   Medical University; Inner Mongolia Medical University
RP Wu, ZJ (corresponding author), Chongqing Med Univ, Affiliated Hosp 1, Hepatobiliary Surg, Friendship Rd,Yuan Jiagang 1, Chongqing Yuzhong Dist, Peoples R China.
EM 2427249336@qq.com
RI Zhao, Haiyan/HHC-6088-2022; wu, zhongjun/HTM-5946-2023
OI wu, zhongjun/0000-0002-1627-0633
CR Bellugi U, 1999, TRENDS NEUROSCI, V22, P197, DOI 10.1016/S0166-2236(99)01397-1
   Cheng Min, 2012, Front Med, V6, P56, DOI 10.1007/s11684-012-0177-7
   Clancy C, 2015, CANCER BIOMARK, V15, P103, DOI 10.3233/CBM-140456
   Ding HY, 2016, J BUON, V21, P434
   Doll A, 2001, CYTOGENET CELL GENET, V95, P20, DOI 10.1159/000057012
   Farooqi AA, 2012, ARCH IMMUNOL THER EX, V60, P191, DOI 10.1007/s00005-012-0169-y
   Hong SP, 2009, INT J CANCER, V125, P2323, DOI 10.1002/ijc.24573
   Kunin V, 2003, GENOME BIOL, V4, DOI 10.1186/gb-2003-4-2-401
   Li C, 2017, ONCOTARGET, V8, P28683, DOI 10.18632/oncotarget.15640
   Lin SJ, 2017, CANCER LETT, V398, P62, DOI 10.1016/j.canlet.2017.03.035
   Ljunggren HG, 2007, NAT REV IMMUNOL, V7, P329, DOI 10.1038/nri2073
   Merla G, 2002, HUM GENET, V110, P429, DOI 10.1007/s00439-002-0710-x
   MORRIS CA, 1988, J PEDIATR-US, V113, P318, DOI 10.1016/S0022-3476(88)80272-5
   Nakazawa Y, 2011, CANCER RES, V71, P1146, DOI 10.1158/0008-5472.CAN-10-2695
   Ounap K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075686
   Petrossian TC, 2011, MOL CELL PROTEOMICS, V10, DOI 10.1074/mcp.M110.000976
   Pober BR, 2010, NEW ENGL J MED, V362, P239, DOI 10.1056/NEJMra0903074
   Segal NH, 2009, ANNU REV MED, V60, P207, DOI 10.1146/annurev.med.60.041807.132435
   Stefanska B, 2014, CLIN CANCER RES, V20, P3118, DOI 10.1158/1078-0432.CCR-13-0283
   Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044
   Thomas J, 2015, INT J MOL SCI, V16, P28063, DOI 10.3390/ijms161226080
   Tiedemann RE, 2012, CANCER RES, V72, P757, DOI 10.1158/0008-5472.CAN-11-2781
   Tournigand C, 2004, J CLIN ONCOL, V22, P229, DOI 10.1200/JCO.2004.05.113
   Vacca P, 2008, INT IMMUNOL, V20, P1395, DOI 10.1093/intimm/dxn105
   Vivier E, 2012, NAT REV IMMUNOL, V12, P239, DOI 10.1038/nri3174
   Vivier E, 2011, SCIENCE, V331, DOI 10.1126/science.1198687
   Wu Da-Long, 2003, Ai Zheng, V22, P441
   Wu PY, 2014, HUM PATHOL, V45, P1664, DOI 10.1016/j.humpath.2014.04.002
   Yan DM, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-15749-z
   Yan Y, 1998, CLIN CANCER RES, V4, P2859
   Yang W, 2016, ONCOTARGET, V7, P41505, DOI 10.18632/oncotarget.9214
NR 31
TC 15
Z9 17
U1 1
U2 8
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2018
VL 8
IS 5
BP 824
EP +
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GH4GL
UT WOS:000433361200005
PM 29888105
DA 2025-01-04
ER

PT J
AU Smits, R
   Domracheva, I
   Turovska, B
AF Smits, Rufus
   Domracheva, Ilona
   Turovska, Baiba
TI Cytotoxicity of dihydropyridone and dihydropyrimidone curcumin
   derivatives against colon (HCT-116) and breast (MDA-MB-231) cancer cell
   lines
SO INTERNATIONAL JOURNAL OF SURGERY-ONCOLOGY
LA English
DT Article
DE curcumin; dihydropyridone; dihydropyrimidone; breast cancer; colorectal
   cancer; oxidation potentials; MTT assay
ID STAGE-II; ANTICANCER; RECURRENCE; SURVIVAL
AB Breast cancer is the most common invasive cancer and colorectal cancer (CRC) the second most diagnosed malignancy in women worldwide. In men CRC is the third most common cancer. Despite the recent advances in targeted therapy, the clinical efficacy is often limited, noncurative, with a high toxicity profile, and exorbitant costs. Therefore, there is a growing interest in identifying natural compounds that are safe and affordable as adjunctive treatments to the conventional therapy currently offered for these patients. Curcumin from the roots of the Curcuma longa, is one such compound that has become one of the leading and most studied natural medicines for its role in cancer prevention and powerful antioxidant activity. However, its fast metabolism, low bioavailability, and the lack of specificity call for curcumin analogues to be synthesized with increased potency and higher specificity. In search of lead compounds in the present study the cytotoxic effects of curcumin and 14 heterocyclic curcumin derivatives have been screened using the MTT assay on two cancer cell lines HCT-116 and MDA-MB-231 and also on the normal GM08402 (human fibroblast) cell line. Electrochemical oxidation potentials were determined for selected compounds to reveal their electron-donating capacity and as a general indicator of their radical scavenging ability. Two dihydropyridone lead compounds have been identified which compared to curcumin have higher cytotoxicity on both cancer cell lines and at the same time with reduced cytotoxicity on the normal cell line.
C1 [Smits, Rufus; Domracheva, Ilona; Turovska, Baiba] Latvian Inst Organ Synth, Aizkraukles 21, Riga, Latvia.
C3 Latvian Institute of Organic Synthesis
RP Smits, R (corresponding author), Latvian Inst Organ Synth, Aizkraukles 21, Riga, Latvia.; Smits, R (corresponding author), Latvijas Organiskas Sintezes Inst, Riga, Latvia.
EM rusmits@gmail.com
FU ERDF project [1.1.1.2/VIAA/1/16/241]
FX This research was funded by ERDF project No.1.1.1.2/VIAA/1/16/241
   'Synthesis of Curcumin Heterocyclic Derivatives'.
CR Aggarwal BB, 2003, ANTICANCER RES, V23, P363
   André T, 2009, J CLIN ONCOL, V27, P3109, DOI 10.1200/JCO.2008.20.6771
   Banik U, 2017, J EXP CLIN CANC RES, V36, DOI 10.1186/s13046-017-0566-5
   ben Moussa S, 2020, J MOL STRUCT, V1200, DOI 10.1016/j.molstruc.2019.127111
   Chaurasia S, 2016, DRUG DEV IND PHARM, V42, P694, DOI 10.3109/03639045.2015.1064941
   Chen D, 2016, MED SCI MONITOR, V22, P3215, DOI 10.12659/MSM.900802
   dos Anjos JV, 2012, MOLECULES, V17, P809, DOI 10.3390/molecules17010809
   Fadus Matthew C, 2017, J Tradit Complement Med, V7, P339, DOI 10.1016/j.jtcme.2016.08.002
   García-Aranda M, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18122543
   Ghasemi M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312827
   Han X, 2016, FOOD NUTR RES, V60, DOI 10.3402/fnr.v60.30616
   Hossain Dewan Md Sakib, 2012, Front Biosci (Schol Ed), V4, P335
   Huang G, 2013, J CLIN IMMUNOL, V33, P550, DOI 10.1007/s10875-012-9839-0
   Imran M, 2018, CRIT REV FOOD SCI, V58, P1271, DOI 10.1080/10408398.2016.1252711
   Jayaprakasha GK, 2016, EUR J PHARMACOL, V789, P291, DOI 10.1016/j.ejphar.2016.07.017
   Kappe CO, 2000, EUR J MED CHEM, V35, P1043, DOI 10.1016/S0223-5234(00)01189-2
   Ko Eun-Yi, 2015, J Cancer Prev, V20, P223, DOI 10.15430/JCP.2015.20.4.223
   Lal J, 2016, CHINESE CHEM LETT, V27, P1067, DOI 10.1016/j.cclet.2016.03.032
   Lee JW, 2010, KOREAN J UROL, V51, P870, DOI 10.4111/kju.2010.51.12.870
   Li J, 2019, J Electrochem Soc, V166, pD3120
   Liu JL, 2017, ONCOL LETT, V14, P5581, DOI 10.3892/ol.2017.6860
   Liu WD, 2016, J DRUG TARGET, V24, P694, DOI 10.3109/1061186X.2016.1157883
   Masek A, 2013, ELECTROCHIM ACTA, V107, P441, DOI 10.1016/j.electacta.2013.06.037
   Mbese Z, 2019, MOLECULES, V24, DOI 10.3390/molecules24234386
   Noureddin SA, 2019, EUR J MED CHEM, V182, DOI 10.1016/j.ejmech.2019.111631
   O'Connell MJ, 2008, J CLIN ONCOL, V26, P2336, DOI 10.1200/JCO.2007.15.8261
   Obrand DI, 1997, DIS COLON RECTUM, V40, P15, DOI 10.1007/BF02055676
   Ojo OA, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.881641
   Noguez MO, 2011, INT J MOL SCI, V12, P2641, DOI 10.3390/ijms12042641
   Pröhl M, 2016, COORDIN CHEM REV, V307, P32, DOI 10.1016/j.ccr.2015.09.001
   Rodrigues FC, 2021, PHARMACOL RES, V166, DOI 10.1016/j.phrs.2021.105489
   Sahu PK, 2016, EUR J MED CHEM, V121, P510, DOI 10.1016/j.ejmech.2016.05.037
   Shishodia S, 2005, ANN NY ACAD SCI, V1056, P206, DOI 10.1196/annals.1352.010
   Smits R, 2021, Patent No. [WO2021/234468Al, 2021234468]
   Smits R., 2019, 8 EFMC INT S ADV SYN, P264
   Smits R, 2022, Chem Heterocycl Compd, V58, P687
   Smits R, 2016, CHEM PHYS LETT, V649, P84, DOI 10.1016/j.cplett.2016.02.045
   Song XQ, 2019, MOL MED REP, V19, P23, DOI 10.3892/mmr.2018.9665
   Sun YS, 2017, INT J BIOL SCI, V13, P1387, DOI 10.7150/ijbs.21635
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Toden Shusuke, 2017, J Restor Med, V6, P27, DOI 10.14200/jrm.2017.6.0101
   van Tonder Alet, 2015, BMC Res Notes, V8, P47, DOI 10.1186/s13104-015-1000-8
   Wang YW, 2016, JALA-J LAB AUTOM, V21, P723, DOI 10.1177/2211068216655524
   Weng WH, 2022, SEMIN CANCER BIOL, V80, P73, DOI 10.1016/j.semcancer.2020.02.011
   Xi Y, 2021, TRANSL ONCOL, V14, DOI 10.1016/j.tranon.2021.101174
   Ye JC, 2018, BREAST, V38, P66, DOI 10.1016/j.breast.2017.12.005
   Yoon MJ, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.85
   Zhang JR, 2017, AM J CANCER RES, V7, P275
   Zheng J, 2016, NUTRIENTS, V8, DOI 10.3390/nu8080495
   Zhou HY, 2011, CURR DRUG TARGETS, V12, P332, DOI 10.2174/138945011794815356
NR 50
TC 0
Z9 0
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 2471-3864
J9 INT J SURG-ONCOL
JI Int. J. Surg.-Oncol.
PD DEC
PY 2023
VL 8
IS 4
BP 27
EP 34
DI 10.1097/IJ9.0000000000000120
PG 8
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA JL5C4
UT WOS:001173326500001
OA hybrid
DA 2025-01-04
ER

PT J
AU Golubovskaya, V
   O'Brien, S
   Ho, B
   Heffler, M
   Conroy, J
   Hu, Q
   Wang, D
   Liu, S
   Cance, WG
AF Golubovskaya, Vita
   O'Brien, Shalana
   Ho, Baotran
   Heffler, Melissa
   Conroy, Jeffrey
   Hu, Quang
   Wang, Dan
   Liu, Song
   Cance, William G.
TI Down-regulation of ALDH1A3, CD44 or MDR1 sensitizes resistant cancer
   cells to FAK autophosphorylation inhibitor Y15
SO JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
LA English
DT Article
DE Focal adhesion kinase; Resistance; Autophosphorylation; Inhibitor;
   Cancer
ID FOCAL ADHESION KINASE; SMALL-MOLECULE INHIBITOR; DECREASES TUMOR-GROWTH;
   HUMAN BREAST-CANCER; GENE-EXPRESSION; STEM-CELLS; OVEREXPRESSION;
   TUMORIGENESIS; PHENOTYPE; PROTEIN
AB Focal adhesion kinase is an important survival signal in cancer. Recently, we demonstrated that the autophosphorylation inhibitor of FAK, Y15, effectively inhibited cancer cell growth. We detected many cancer cell lines sensitive to Y15 and also detected several cell lines such as colon cancer Lovo-1 and thyroid K1 more resistant to Y15. We sought to determine the main players responsible for the resistance.
   To reveal the signaling pathways responsible for the increased resistance of these cancer cells to the inhibitor of FAK, we performed a microarray gene profile study in both sensitive and resistant cells treated with Y15 inhibitor to compare with the more sensitive cells.
   Among unique genes up-regulated by Y15 in Lovo-1 and K1 resistant cells, a stem cell marker-ALDH1A3-was detected to be up-regulated > twofold. The resistant Lovo-1 and thyroid K1 cells overexpressed ALDH1A3 and CD44 versus sensitive cells. Treatment with ALDH1A3 siRNAs or ALDH inhibitor, DEAB sensitized resistant Lovo-1 and K1 cells to Y15 inhibitor, decreased viability and caused G1 cell cycle arrest more effectively than each agent alone. In addition, down-regulation of CD44 that was overexpressed in resistant Lovo-1 cells with CD44 siRNA effectively decreased the viability of cells in combination with Y15. In addition, down-regulation of overexpressed MDR1 with specific inhibitor, PSC-833, also sensitized resistant colon cancer cells to Y15.
   This report clearly demonstrates the mechanism of resistance to FAK autophosphorylation inhibitor and the mechanism to overcome it that is important for developing FAK-targeted therapy approaches.
C1 [Golubovskaya, Vita; O'Brien, Shalana; Ho, Baotran; Heffler, Melissa; Cance, William G.] Roswell Pk Canc Inst, Dept Surg Oncol, Buffalo, NY 14263 USA.
   [Conroy, Jeffrey] Roswell Pk Canc Inst, Ctr Personalized Med, Genom Shared Resource, Buffalo, NY 14263 USA.
   [Hu, Quang; Wang, Dan; Liu, Song] Roswell Pk Canc Inst, Bioinformat Core, Biostat, Buffalo, NY 14263 USA.
C3 Roswell Park Comprehensive Cancer Center; Roswell Park Comprehensive
   Cancer Center; Roswell Park Comprehensive Cancer Center
RP Golubovskaya, V (corresponding author), Roswell Pk Canc Inst, Dept Surg Oncol, Elm & Carlton Str, Buffalo, NY 14263 USA.
EM Vita.Golubovskaya@roswellpark.org; William.Cance@roswellpark.org
FU NIH [CA65910, 5 T32 CA 108456-7]; NCI Cancer Center Support Grant [CA
   16056]
FX We would like to thank Dr. Craig Jones and the Flow Cytometry Core
   Facility for cell cycle analysis (Roswell Park Cancer Institute). We
   would like to thank the Genomics and Bioinformatics Core Facilities
   (Roswell Park Cancer Institute) for microarray and bioinformatics
   analyses. We would like to thank Dr. Liu Biao for help with GEO numbers
   at NCBI. We would like to thank Animal Core Facility (Roswell Park
   Cancer Institute) for mice maintaining help. We would like to thank Dr.
   Carl Morrison, Dr. Lourdes Ylagan Logan and Pathology Core Facility for
   help with breast cancer TMA staining and scoring. We would like to thank
   Timothy Marlowe for his suggestions. The study was supported by NIH
   Grant CA65910 (WGC), NIH Grant # 5 T32 CA 108456-7 (Roswell Park Cancer
   Institute) and partly by the NCI Cancer Center Support Grant to the
   Roswell Park Cancer Institute (CA 16056).
CR Allred DC, 1998, MODERN PATHOL, V11, P155
   Beierle EA, 2010, CELL CYCLE, V9, P1005, DOI 10.4161/cc.9.5.10936
   Bourguignon LYW, 2008, J BIOL CHEM, V283, P17635, DOI 10.1074/jbc.M800109200
   Cance WG, 2013, SCI SIGNAL, V6, DOI 10.1126/scisignal.2004021
   Deng S, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010277
   Dylla SJ, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002428
   Fonar Y, 2011, MOL BIOL CELL, V22, P2409, DOI 10.1091/mbc.E10-12-0932
   Gabarra-Niecko V, 2003, CANCER METAST REV, V22, P359, DOI 10.1023/A:1023725029589
   Golubovskaya VM, 2007, INT REV CYTOL, V263, P103, DOI 10.1016/S0074-7696(07)63003-4
   Golubovskaya VM, 2013, MOL CANCER THER, V12, P162, DOI 10.1158/1535-7163.MCT-12-0701
   Golubovskaya VM, 2009, INT J CANCER, V125, P1735, DOI 10.1002/ijc.24486
   Golubovskaya VM, 2008, J MED CHEM, V51, P7405, DOI 10.1021/jm800483v
   Heffler M, 2013, CANCER BIOL THER, V14, P761, DOI 10.4161/cbt.25185
   Heffler M, 2013, ANTI-CANCER AGENT ME, V13, P584, DOI 10.2174/1871520611313040008
   Ho BT, 2012, J BIOL CHEM, V287, P18656, DOI 10.1074/jbc.M111.322883
   Hochwald SN, 2009, CELL CYCLE, V8, P2435, DOI 10.4161/cc.8.15.9145
   Huang EH, 2009, CANCER RES, V69, P3382, DOI 10.1158/0008-5472.CAN-08-4418
   ILLC D, 1995, NATURE, V377, P539
   Kang Y, 2013, JNCI-J NATL CANCER I, V105, P1485, DOI 10.1093/jnci/djt210
   Krech T, 2012, CANCER LETT, V315, P153, DOI 10.1016/j.canlet.2011.09.038
   Lark AL, 2005, MODERN PATHOL, V18, P1289, DOI 10.1038/modpathol.3800424
   Luo M, 2013, CANCER RES, V69, P466
   Luo M, 2009, CANCER RES, V69, P466, DOI 10.1158/0008-5472.CAN-08-3078
   Marcato P, 2011, STEM CELLS, V29, P32, DOI 10.1002/stem.563
   OWENS LV, 1995, CANCER RES, V55, P2752
   Scheel C, 2012, SEMIN CANCER BIOL, V22, P396, DOI 10.1016/j.semcancer.2012.04.001
   Xu LH, 2000, J BIOL CHEM, V275, P30597, DOI 10.1074/jbc.M910027199
NR 27
TC 18
Z9 21
U1 0
U2 23
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0171-5216
EI 1432-1335
J9 J CANCER RES CLIN
JI J. Cancer Res. Clin. Oncol.
PD SEP
PY 2015
VL 141
IS 9
BP 1613
EP 1631
DI 10.1007/s00432-015-1924-3
PG 19
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CP1RY
UT WOS:000359654100011
PM 25656374
DA 2025-01-04
ER

PT J
AU O'Connor, J
   Torrecillas-Torres, L
   Alvarado, F
   Colombero, C
   Sasse, A
AF O'Connor, Juan
   Torrecillas-Torres, Laura
   Alvarado, Francisco
   Colombero, Cecilia
   Sasse, Andre
TI Biomarkers and treatment characteristics in metastatic colorectal cancer
   RA Swt patients in Latin America
SO GACETA MEXICANA DE ONCOLOGIA
LA English
DT Article
DE Metastatic colorectal cancer; Biomarkers; RAS wild type; Target therapy;
   Latin America
AB Objective: To describe the use of biomarker testing and therapy options for RASwt patients with metastatic colorectal cancer (mCRC) in Argentina, Brazil, and Mexico during the 2017-2019 period. Methods: We conducted descriptive analysis using datasets from privately-owned research tools. Results: There was an increase in the use of tests performed for RAS, BRAF and MSI in all three countries. Between 2018 and 2019, RAS testing increased 15% in Argentina, 29% in Brazil and 3% in Mexico. MSI testing increased 18% in Argentina and 19% in Brazil but remained stable in Mexico at 12%. BRAF testing increased 45% in Brazil, in Argentina 46% and 29% in Mexico. Main first-line available options for mCRC were: Chemotherapy (CT), CT+ (EGFR inhibitor/anti-VEGF). Conclusions: Given the paucity of publicly available information on access to mCRC treatments in Latin America, findings from this private data-based study may be useful for decision-making processes among healthcare institutions.
C1 [O'Connor, Juan] Inst Alexander Fleming, Gastrointestinal Unit, Buenos Aires, DF, Argentina.
   [Torrecillas-Torres, Laura] ISSSTE, Ctr Med Nacl 20 Noviembre, Gastrointestina Tumor Clin, Mexico City, DF, Mexico.
   [Alvarado, Francisco] Merck SA, Dept Med Affairs, Cdad De Guatemala, Guatemala.
   [Colombero, Cecilia] Merck SA, Dept Med Affairs, Buenos Aires, DF, Argentina.
   [Sasse, Andre] Radium Inst Oncol, Med Management, Campinas, SP, Brazil.
RP Colombero, C (corresponding author), Merck SA, Dept Med Affairs, Buenos Aires, DF, Argentina.
EM cecilia.colombero@merckgroup.com
RI Sasse, Andre/P-7272-2019
FU Merck KGaA
FX This work was financially supported by Merck KGaA. An independent vendor
   was hired to collect and perform an analysis of private databases
   designed for market research purposes.
CR Bekaii-Saab T, 2019, CLIN COLORECTAL CANC, V18, pE117, DOI 10.1016/j.clcc.2018.11.002
   Boleij A, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2810-3
   Chu JE, 2020, CLIN CANCER RES, V26, P4599, DOI 10.1158/1078-0432.CCR-20-1024
   Cremolini C, 2019, JAMA ONCOL, V5, P343, DOI 10.1001/jamaoncol.2018.5080
   Henry JT, 2019, CHIN CLIN ONCOL, V8, DOI 10.21037/cco.2019.08.08
   Hernández-Sandoval JA, 2020, J INVEST MED, V68, P985, DOI 10.1136/jim-2020-001301
   Khan K, 2019, CRIT REV ONCOL HEMAT, V143, P153, DOI 10.1016/j.critrevonc.2019.09.001
   Modest DP, 2019, EUR J CANCER, V109, P70, DOI 10.1016/j.ejca.2018.12.019
   National Comprehensive Cancer Network, 2020, COL CANC VERS 4 2020
   NCCN (National Comprehensive Cancer Network), 2020, GEN FAM HIGH RISK AS
   Piñeros M, 2017, REV PANAM SALUD PUBL, V41, DOI 10.26633/RPSP.2017.2
   Shiu KK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.2020.38.18_suppl.LBA4
   Taieb J, 2019, BRIT J CANCER, V121, P434, DOI 10.1038/s41416-019-0526-2
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
NR 15
TC 0
Z9 0
U1 0
U2 0
PU SOC MEXICANA ONCOLOGIA, A C
PI MEXICO
PA TUXPAN NO 59 PH, COL ROMA SUR, MEXICO, DF 06760, MEXICO
SN 1665-9201
J9 GAC MEX ONCOL
JI Gac. Mex. Oncol.
PD JAN-MAR
PY 2023
VL 22
IS 1
BP 24
EP 33
DI 10.24875/j.gamo.22000074
PG 10
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA 9B3RK
UT WOS:000934657400003
OA gold
DA 2025-01-04
ER

PT J
AU Torke, S
   Walther, W
   Stein, U
AF Torke, Sebastian
   Walther, Wolfgang
   Stein, Ulrike
TI Immune Response and Metastasis-Links between the Metastasis Driver MACC1
   and Cancer Immune Escape Strategies
SO CANCERS
LA English
DT Review
DE metastasis; MACC1; immune evasion
ID POTENTIAL ROLE; CELLS; PROGRESSION; GROWTH; PD-L1; NANOG; STAT1
AB Simple Summary While both the fields of cancer metastasis research and cancer immunology have been heavily investigated, their combination-the immunology of metastasis-is underrepresented given the fact that metastasis is responsible for up to 90% of cancer deaths. Additionally, evading detection by the immune system is a key prerequisite for the spread of tumor cells to distant organs. In this review, we explore the connections between a master regulator of metastasis, MACC1, and both its direct and indirect links with immunological processes. Specifically, we highlight MACC1-induced alterations of signaling pathways and secreted factors and how this translates into changed immunological outcomes including effects on immune cell infiltration, activity, and their regulation through immunological checkpoints.Abstract Metastasis remains the most critical factor limiting patient survival and the most challenging part of cancer-targeted therapy. Identifying the causal drivers of metastasis and characterizing their properties in various key aspects of cancer biology is essential for the development of novel metastasis-targeting approaches. Metastasis-associated in colon cancer 1 (MACC1) is a prognostic and predictive biomarker that is now recognized in more than 20 cancer entities. Although MACC1 can already be linked with many hallmarks of cancer, one key process-the facilitation of immune evasion-remains poorly understood. In this review, we explore the direct and indirect links between MACC1 and the mechanisms of immune escape. Therein, we highlight the signaling pathways and secreted factors influenced by MACC1 as well as their effects on the infiltration and anti-tumor function of immune cells.
C1 [Torke, Sebastian] Charite Med Ctr Berlin, Expt & Clin Res Ctr, D-13125 Berlin, Germany.
   Max Delbruck Ctr Mol Med, D-13125 Berlin, Germany.
C3 Berlin Institute of Health; Free University of Berlin; Humboldt
   University of Berlin; Charite Universitatsmedizin Berlin; Helmholtz
   Association; Max Delbruck Center for Molecular Medicine
RP Torke, S (corresponding author), Charite Med Ctr Berlin, Expt & Clin Res Ctr, D-13125 Berlin, Germany.
EM sebastian.torke@mdc-berlin.de; wowalt@mdc-berlin.de;
   ustein@mdc-berlin.de
RI Torke, Sebastian/IWV-1253-2023
OI Stein, Ulrike/0000-0001-7006-282X; Walther, Wolfgang/0000-0003-2360-1370
CR Ali DA, 2021, MEDICINA-LITHUANIA, V57, DOI 10.3390/medicina57090934
   Bähr I, 2022, INT J ONCOL, V60, DOI 10.3892/ijo.2022.5307
   Balan M, 2015, J BIOL CHEM, V290, P8110, DOI 10.1074/jbc.M114.612689
   Bettum IJ, 2014, CANCER LETT, V344, P28, DOI 10.1016/j.canlet.2013.10.036
   Birgisdottir AB, 2020, J CELL SCI, V133, DOI 10.1242/jcs.228114
   Choe EJ, 2022, PHARMACEUTICS, V14, DOI 10.3390/pharmaceutics14081660
   Collins NB, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2021-003402
   Cruz-Bermúdez A, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9040361
   Dersh D, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI144344
   Dillekås H, 2019, CANCER MED-US, V8, P5574, DOI 10.1002/cam4.2474
   Erdem M, 2024, CANCERS, V16, DOI 10.3390/cancers16030604
   Fares J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0134-x
   Futamatsu H, 2005, CIRC RES, V96, P823, DOI 10.1161/01.RES.0000163016.52653.2e
   Galassi C, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10092361
   Geindreau M, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22094871
   Gohlke BO, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.726
   Hagemann C, 2019, CANCERS, V11, DOI 10.3390/cancers11060825
   Hendry SA, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00621
   Heuser C, 2023, SEMIN CANCER BIOL, V88, P32, DOI 10.1016/j.semcancer.2022.12.001
   Hohmann T, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1165676
   Hu Y, 2021, MATH BIOSCI ENG, V18, P8331, DOI 10.3934/mbe.2021413
   Imbastari F, 2021, CELL MOL LIFE SCI, V78, P3525, DOI 10.1007/s00018-020-03734-1
   Juneja M, 2017, PLOS BIOL, V15, DOI 10.1371/journal.pbio.2000784
   Kansal V, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2022-005940
   Katoh M, 2022, ESSAYS BIOCHEM, V66, P319, DOI 10.1042/EBC20220016
   Khan I, 2021, BRIT J CANCER, V124, P66, DOI 10.1038/s41416-020-01179-8
   Kim HJ, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0899-9
   Kim KH, 2014, NAT REV ENDOCRINOL, V10, P322, DOI 10.1038/nrendo.2014.35
   Kobelt D, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00980
   Kortüm B, 2022, ONCOGENE, V41, P4446, DOI 10.1038/s41388-022-02407-6
   Lei MML, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.692940
   Lemos C, 2016, CLIN CANCER RES, V22, P2812, DOI 10.1158/1078-0432.CCR-15-1425
   Leone RD, 2020, NAT REV CANCER, V20, P516, DOI 10.1038/s41568-020-0273-y
   Li YL, 2016, CANCER BIOL MED, V13, P206, DOI 10.20892/j.issn.2095-3941.2015.0070
   Lin L, 2015, ONCOGENE, V34, P2700, DOI 10.1038/onc.2014.204
   Link T, 2019, MOL ONCOL, V13, P1268, DOI 10.1002/1878-0261.12484
   Lisec J, 2021, CANCERS, V13, DOI 10.3390/cancers13050978
   Liu BX, 2022, J ONCOL, V2022, DOI 10.1155/2022/8179208
   Liu FR, 2020, CANCER BIOL THER, V21, P963, DOI 10.1080/15384047.2020.1824479
   Liu J, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0302-1
   Lv MM, 2023, BIOLOGY-BASEL, V12, DOI 10.3390/biology12030455
   Ma TJ, 2021, CANCER RES, V81, P2457, DOI 10.1158/0008-5472.CAN-20-2489
   Martin-Orozco E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02854
   Melvin VS, 2013, DEV DYNAM, V242, P817, DOI 10.1002/dvdy.23969
   Meng FJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060821
   Nguyen PHD, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-29122-w
   Ni YH, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.835997
   Nirala Bikesh, 2017, Oncoscience, V4, P166, DOI 10.18632/oncoscience.377
   Noh KH, 2012, J CLIN INVEST, V122, P4077, DOI 10.1172/JCI64057
   Owen KL, 2019, CANCERS, V11, DOI 10.3390/cancers11122002
   Papaccio F, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19113595
   Patterson LFS, 2021, TRENDS IMMUNOL, V42, P975, DOI 10.1016/j.it.2021.09.002
   Qian LQ, 2017, ONCOL LETT, V14, P4897, DOI 10.3892/ol.2017.6790
   Radhakrishnan H, 2018, CANCER METAST REV, V37, P805, DOI 10.1007/s10555-018-9771-8
   Radhakrishnan H, 2017, CANCER LETT, V403, P231, DOI 10.1016/j.canlet.2017.06.020
   Rathmell JC, 2021, NEW ENGL J MED, V384, P1160, DOI 10.1056/NEJMcibr2035081
   Seyfried Thomas N., 2013, Critical Reviews in Oncogenesis, V18, P43
   Sheng XJ, 2014, ONCOL LETT, V8, P891, DOI 10.3892/ol.2014.2184
   Shiozawa Y, 2013, PHARMACOL THERAPEUT, V138, P285, DOI 10.1016/j.pharmthera.2013.01.014
   Steinbichler TB, 2020, SEMIN CANCER BIOL, V60, P148, DOI 10.1016/j.semcancer.2019.09.007
   Tao WW, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16827-z
   Tong GL, 2019, CANCER MED-US, V8, P7044, DOI 10.1002/cam4.2542
   Treese C, 2022, CANCERS, V14, DOI 10.3390/cancers14071773
   Tsai CH, 2023, CELL METAB, V35, P118, DOI 10.1016/j.cmet.2022.12.003
   Tsuchiya H, 2021, REGEN THER, V17, P20, DOI 10.1016/j.reth.2021.02.006
   Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6
   Vos WG, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-005611
   Wang JK, 2017, MOL MED REP, V16, P8747, DOI 10.3892/mmr.2017.7721
   Wang L, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157137
   Wen J, 2020, FRONT CELL DEV BIOL, V8, DOI 10.3389/fcell.2020.00825
   Wu B, 2023, MOL CANCER, V22, DOI 10.1186/s12943-023-01748-4
   Wu B, 2022, CELL COMMUN SIGNAL, V20, DOI 10.1186/s12964-022-00968-3
   Wu X, 2022, CLIN EXP IMMUNOL, V210, P309, DOI 10.1093/cei/uxac102
   Xia HJ, 2021, NAT REV CANCER, V21, P281, DOI 10.1038/s41568-021-00344-2
   Yu H, 2009, NAT REV CANCER, V9, P798, DOI 10.1038/nrc2734
   Zambelli A, 2021, ADV EXP MED BIOL, V1270, P31, DOI 10.1007/978-3-030-47189-7_2
   Zhang Y, 2017, DISCOV MED, V24, P19
NR 77
TC 2
Z9 2
U1 0
U2 1
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD APR
PY 2024
VL 16
IS 7
AR 1330
DI 10.3390/cancers16071330
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NN0E0
UT WOS:001201004500001
PM 38611008
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Grossauer, S
   Koeck, K
   Murphy, NE
   Meyers, ID
   Daynac, M
   Truffaux, N
   Truong, AY
   Nicolaides, TP
   McMahon, M
   Berger, MS
   Phillips, JJ
   James, CD
   Petritsch, CK
AF Grossauer, Stefan
   Koeck, Katharina
   Murphy, Nicole E.
   Meyers, Ian D.
   Daynac, Mathieu
   Truffaux, Nathalene
   Truong, Albert Y.
   Nicolaides, Theodore P.
   McMahon, Martin
   Berger, Mitchel S.
   Phillips, Joanna J.
   James, C. David
   Petritsch, Claudia K.
TI Concurrent MEK targeted therapy prevents MAPK pathway reactivation
   during BRAF<SUP>V600E</SUP> targeted inhibition in a novel syngeneic
   murine glioma model
SO ONCOTARGET
LA English
DT Article
DE MAPK pathway reactivation; dabrafenib; primary adaptive therapy
   resistance; syngeneic high-grade astrocytoma model
ID BRAF INHIBITORS; B-RAF; MALIGNANT ASTROCYTOMA; MUTATION ANALYSIS;
   COLON-CANCER; CELL-LINES; STEM-CELLS; MELANOMA; DABRAFENIB; RESISTANCE
AB Inhibitors of BRAF(V600E) kinase are currently under investigations in preclinical and clinical studies involving BRAF(V600E) glioma. Studies demonstrated clinical response to such individualized therapy in the majority of patients whereas in some patients tumors continue to grow despite treatment. To study resistance mechanisms, which include feedback activation of mitogen-activated protein kinase (MAPK) signaling in melanoma, we developed a luciferase-modified cell line (2341(luc)) from a BRAF(V600E) mutant and Cdkn2a- deficient murine high-grade glioma, and analyzed its molecular responses to BRAF(V600E)- and MAPK kinase (MEK)-targeted inhibition. Immunocompetent, syngeneic FVB/N mice with intracranial grafts of 2341(luc) were tested for effects of BRAF(V600E) and MEK inhibitor treatments, with bioluminescence imaging up to 14-days after start of treatment and survival analysis as primary indicators of inhibitor activity. Intracranial injected tumor cells consistently generated high-grade glioma-like tumors in syngeneic mice. Intraperitoneal daily delivery of BRAF(V600E) inhibitor dabrafenib only transiently suppressed MAPK signaling, and rather increased Akt signaling and failed to extend survival for mice with intracranial 2341(luc) tumor. MEK inhibitor trametinib delivered by oral gavage daily suppressed MAPK pathway more effectively and had a more durable anti-growth effect than dabrafenib as well as a significant survival benefit. Compared with either agent alone, combined BRAF(V600E) and MEK inhibitor treatment was more effective in reducing tumor growth and extending animal subject survival, as corresponding to sustained MAPK pathway inhibition. Results derived from the 2341(luc) engraftment model application have clinical implications for the management of BRAF(V600E) glioma.
C1 [Grossauer, Stefan; Koeck, Katharina; Murphy, Nicole E.; Meyers, Ian D.; Daynac, Mathieu; Truffaux, Nathalene; Truong, Albert Y.; Nicolaides, Theodore P.; Berger, Mitchel S.; Phillips, Joanna J.; Petritsch, Claudia K.] Brain Tumor Res Ctr, Dept Neurol Surg, San Francisco, CA 94158 USA.
   [Truong, Albert Y.; Nicolaides, Theodore P.] Univ Calif San Francisco, Dept Pediat, San Francisco, CA 94158 USA.
   [McMahon, Martin] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
   [James, C. David] Northwestern Univ, Feinberg Sch Med, Dept Neurol Surg, Chicago, IL 60611 USA.
   [Petritsch, Claudia K.] Univ Calif San Francisco, Helen Diller Comprehens Canc Res Ctr, San Francisco, CA 94158 USA.
   [Petritsch, Claudia K.] Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94158 USA.
C3 University of California System; University of California San Francisco;
   Utah System of Higher Education; University of Utah; Huntsman Cancer
   Institute; Northwestern University; Feinberg School of Medicine;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center; University of California System; University of California San
   Francisco
RP Petritsch, CK (corresponding author), Brain Tumor Res Ctr, Dept Neurol Surg, San Francisco, CA 94158 USA.; Petritsch, CK (corresponding author), Univ Calif San Francisco, Helen Diller Comprehens Canc Res Ctr, San Francisco, CA 94158 USA.; Petritsch, CK (corresponding author), Univ Calif San Francisco, Eli & Edythe Broad Ctr Regenerat Med & Stem Cell, San Francisco, CA 94158 USA.
EM Claudia.petritsch@ucsf.edu
RI Petritsch, Claudia/AAP-9597-2021
OI Daynac, Mathieu/0000-0002-4956-6289; Truong, Albert/0000-0002-9551-4519;
   Nicolaides, Theodore/0000-0002-0637-1086
FU National Institute of Health/National Cancer Institute [CA16476-04];
   National Institute of Neurological Disorders and Stroke [NS080619];
   Childhood Brain Tumor Foundation; Loglio Research Program; Research
   Allocation Program Investigator Grant CTSI-UCSF; California Institute of
   Regenerative Medicine [TB1-01190]
FX National Institute of Health/National Cancer Institute (CA16476-04 to
   C.K.P); National Institute of Neurological Disorders and Stroke
   (NS080619 to C.K.P and C.D.J); Childhood Brain Tumor Foundation (to
   C.K.P.); the Loglio Research Program (to C.K.P), the Research Allocation
   Program Investigator Grant CTSI-UCSF (to C.K.P) and California Institute
   of Regenerative Medicine (TB1-01190 to I.D.M).
CR Aguirre AJ, 2003, GENE DEV, V17, P3112, DOI 10.1101/gad.1158703
   Basto D, 2005, ACTA NEUROPATHOL, V109, P207, DOI 10.1007/s00401-004-0936-x
   Bollag G, 2010, NATURE, V467, P596, DOI 10.1038/nature09454
   BRENNER M, 1994, J NEUROSCI, V14, P1030, DOI 10.1523/JNEUROSCI.14-03-01030.1994
   Callahan MK, 2015, SEMIN ONCOL, V42, P573, DOI 10.1053/j.seminoncol.2015.05.008
   Chamberlain MC, 2013, J NEURO-ONCOL, V114, P237, DOI 10.1007/s11060-013-1176-5
   Dankort D, 2007, GENE DEV, V21, P379, DOI 10.1101/gad.1516407
   Daynac M, 2015, JOVE-J VIS EXP, DOI 10.3791/53247
   del Bufalo F, 2014, J TRANSL MED, V12, DOI 10.1186/s12967-014-0356-1
   Dias-Santagata D, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0017948
   Dougherty MJ, 2010, NEURO-ONCOLOGY, V12, P621, DOI 10.1093/neuonc/noq007
   Eisenhardt AE, 2011, INT J CANCER, V129, P2297, DOI 10.1002/ijc.25893
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Hauschild A, 2012, LANCET, V380, P358, DOI 10.1016/S0140-6736(12)60868-X
   Hemmati HD, 2003, P NATL ACAD SCI USA, V100, P15178, DOI 10.1073/pnas.2036535100
   Hugo W, 2015, CELL, V162, P1271, DOI 10.1016/j.cell.2015.07.061
   Huillard E, 2012, P NATL ACAD SCI USA, V109, P8710, DOI 10.1073/pnas.1117255109
   Kieran M, 2015, J CLIN O
   King AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067583
   Knobbe CB, 2004, ACTA NEUROPATHOL, V108, P467, DOI 10.1007/s00401-004-0929-9
   Lee J, 2006, CANCER CELL, V9, P391, DOI 10.1016/j.ccr.2006.03.030
   Lerner RG, 2015, CANCER RES, V75, P5355, DOI 10.1158/0008-5472.CAN-14-3689
   Li AG, 2008, MOL CANCER RES, V6, P21, DOI 10.1158/1541-7786.MCR-07-0280
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Mistry M, 2015, J CLIN ONCOL, V33, P1015, DOI 10.1200/JCO.2014.58.3922
   Mittapalli RK, 2013, J PHARMACOL EXP THER, V344, P655, DOI 10.1124/jpet.112.201475
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Nicolaides TP, 2011, CLIN CANCER RES, V17, P7595, DOI 10.1158/1078-0432.CCR-11-1456
   Oh T, 2014, J TRANSL MED, V12, DOI 10.1186/1479-5876-12-107
   Olow A, 2016, CLIN CANCER RES, V22, P5312, DOI 10.1158/1078-0432.CCR-15-1101
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Robinson GW, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-258
   Roth AD, 2010, J CLIN ONCOL, V28, P466, DOI 10.1200/JCO.2009.23.3452
   Rush S, 2013, J CLIN ONCOL, V31, pE159, DOI 10.1200/JCO.2012.44.1568
   Sanlorenzo M, 2014, J AM ACAD DERMATOL, V71, P1102, DOI 10.1016/j.jaad.2014.09.002
   Schiffman JD, 2010, CANCER RES, V70, P512, DOI 10.1158/0008-5472.CAN-09-1851
   Schindler G, 2011, ACTA NEUROPATHOL, V121, P397, DOI 10.1007/s00401-011-0802-6
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727
   Sloot S, 2014, EXPERT OPIN PHARMACO, V15, P589, DOI 10.1517/14656566.2014.881471
   Su F, 2012, NEW ENGL J MED, V366, P207, DOI 10.1056/NEJMoa1105358
   Sugiarto S, 2011, CANCER CELL, V20, P328, DOI 10.1016/j.ccr.2011.08.011
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Yao TW, 2015, ONCOTARGET, V6, P21993, DOI 10.18632/oncotarget.4014
NR 46
TC 23
Z9 24
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD NOV 15
PY 2016
VL 7
IS 46
BP 75839
EP 75853
DI 10.18632/oncotarget.12419
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA EE5GF
UT WOS:000389632800110
PM 27713119
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Ilisso, CP
   Sapio, L
   Delle Cave, D
   Illiano, M
   Spina, A
   Cacciapuoti, G
   Naviglio, S
   Porcelli, M
AF Ilisso, Concetta Paola
   Sapio, Luigi
   Delle Cave, Donatella
   Illiano, Michela
   Spina, Annamaria
   Cacciapuoti, Giovanna
   Naviglio, Silvio
   Porcelli, Marina
TI S-Adenosylmethionine Affects ERK1/2 and Stat3 Pathways and Induces
   Apotosis in Osteosarcoma Cells
SO JOURNAL OF CELLULAR PHYSIOLOGY
LA English
DT Article
ID ADENOSYL-L-METHIONINE; COLON-CANCER CELLS; INORGANIC-PHOSPHATE;
   SIGNALING PATHWAY; METHYL DONOR; IN-VITRO; HYPOMETHYLATION STATUS;
   TARGETED THERAPY; DNA METHYLATION; LIVER-DISEASE
AB Osteosarcoma is a very aggressive bone tumor. Its clinical outcome remains discouraging despite intensive surgery, radiotherapy, and chemotherapy. Thus, novel therapeutic approaches are demanded. S-Adenosylmethionine (AdoMet) is a naturally occurring molecule that is synthesized in our body by methionine adenosyltransferase isoenzymes and is also available as a nutritional supplement. AdoMet is the principal methyl donor in numerous methylation reactions and is involved in many biological functions. Interestingly, AdoMet has been shown to exert antiproliferative action in various cancer cells. However, the underlying molecular mechanisms are just starting to be studied. Here, we investigated the effects of AdoMet on the proliferation of osteosarcoma U2OS cells and the underlying mechanisms. We carried out direct cell number counting, MTT and flow cytometry-based assays, and immunoblotting experiments in response to AdoMet treatment. We found that AdoMet strongly inhibits proliferation of U2OS cells by slowing-down cell cycle progression and by inducing apoptosis. We also report that AdoMet consistently causes an increase of p53 and p21 cell-cycle inhibitor, a decrease of cyclin A and cyclin E protein levels, and a marked increase of pro-apoptotic Bax/Bcl-2 ratio, with caspase-3 activation and PARP cleavage. Moreover, the AdoMet-induced antiproliferative effects were dynamically accompanied by profound changes in ERK1/2 and STAT3 protein and phosphorylation levels. Altogether, our data enforce the evidence of AdoMet acting as a biomolecule with antiproliferative action in osteosarcoma cells, capable of down-regulating ERK1/2 and STAT3 pathways leading to cell cycle inhibition and apoptosis, and provide a rationale for the possible use of AdoMet in osteosarcoma therapy. J. Cell. Physiol. 231: 428-435, 2016. (c) 2015 Wiley Periodicals, Inc.
C1 [Ilisso, Concetta Paola; Sapio, Luigi; Delle Cave, Donatella; Illiano, Michela; Spina, Annamaria; Cacciapuoti, Giovanna; Naviglio, Silvio; Porcelli, Marina] Univ Naples 2, Dept Biochem Biophys & Gen Pathol, I-80138 Naples, Italy.
C3 Universita della Campania Vanvitelli
RP Naviglio, S (corresponding author), Univ Naples 2, Dept Biochem Biophys & Gen Pathol, Via L De Crecchio 7, I-80138 Naples, Italy.
EM silvio.naviglio@unina2.it
RI Delle Cave, Donatella/AAM-2941-2021; Sapio, Luigi/AAH-6334-2021
OI SPINA, Annamaria/0000-0002-2877-3158; NAVIGLIO,
   Silvio/0000-0003-1771-8265; Delle Cave, Donatella/0000-0002-4019-2778
CR Abrams SL, 2010, CELL CYCLE, V9, P1781, DOI 10.4161/cc.9.9.11483
   Ansorena E, 2002, HEPATOLOGY, V35, P274, DOI 10.1053/jhep.2002.30419
   Anstee QM, 2012, J HEPATOL, V57, P1097, DOI 10.1016/j.jhep.2012.04.041
   BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0
   Bottiglieri T, 2002, AM J CLIN NUTR, V76, p1151S, DOI 10.1093/ajcn/76.5.1151S
   BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
   Cai Y, 2014, J CELL BIOCHEM, V115, P625, DOI 10.1002/jcb.24708
   CANTONI GL, 1975, ANNU REV BIOCHEM, V44, P435, DOI 10.1146/annurev.bi.44.070175.002251
   CANTONI GL, 1953, J BIOL CHEM, V204, P403
   Chen H, 2007, GASTROENTEROLOGY, V133, P207, DOI 10.1053/j.gastro.2007.03.114
   Chen L, 2013, FEBS LETT, V587, P1366, DOI 10.1016/j.febslet.2013.03.007
   Chiang PK, 1996, FASEB J, V10, P471, DOI 10.1096/fasebj.10.4.8647346
   Chik F, 2014, CARCINOGENESIS, V35, P138, DOI 10.1093/carcin/bgt284
   Choy E, 2014, OSTEOSARCOMA SYMPTOM
   Cragg GM, 2014, J NAT PROD, V77, P703, DOI 10.1021/np5000796
   Da MX, 2014, BRAZ J MED BIOL RES, V47, P1021, DOI 10.1590/1414-431X20144005
   Dawson VL, 2004, J BIOENERG BIOMEMBR, V36, P287, DOI 10.1023/B:JOBB.0000041755.22613.8d
   FINBLOOM DS, 1995, CELL SIGNAL, V7, P739, DOI 10.1016/0898-6568(95)02004-7
   Fontecave M, 2004, TRENDS BIOCHEM SCI, V29, P243, DOI 10.1016/j.tibs.2004.03.007
   Fossey SL, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-112
   Frey PA, 2008, CRIT REV BIOCHEM MOL, V43, P63, DOI [10.1080/10409230701829169, 10.1080/10409230701829169 ]
   Gérard C, 2014, INTERFACE FOCUS, V4, DOI 10.1098/rsfs.2013.0075
   Germain D, 2007, CLIN CANCER RES, V13, P5665, DOI 10.1158/1078-0432.CCR-06-2491
   Gomez-Santos L, 2012, METHODS MOL BIOL, V826, P133, DOI 10.1007/978-1-61779-468-1_12
   Hussain Z, 2013, GENET MOL RES, V12, P1106, DOI 10.4238/2013.April.10.6
   Ilisso CP, 2015, ENDOCRINE, V50, P212, DOI 10.1007/s12020-014-0484-7
   Johnston PA, 2011, MOL INTERV, V11, P18, DOI 10.1124/mi.11.1.4
   KOTB M, 1993, PHARMACOL THERAPEUT, V59, P125, DOI 10.1016/0163-7258(93)90042-C
   Kreis NN, 2014, ONCOGENE, V33, P5716, DOI 10.1038/onc.2013.518
   Li TWH, 2015, MOL PHARMACOL, V87, P77, DOI 10.1124/mol.114.095679
   Li TWH, 2012, CARCINOGENESIS, V33, P427, DOI 10.1093/carcin/bgr295
   Li TWH, 2009, MOL PHARMACOL, V76, P192, DOI 10.1124/mol.108.054411
   Lu SC, 2000, INT J BIOCHEM CELL B, V32, P391, DOI 10.1016/S1357-2725(99)00139-9
   Lu SC, 2005, ALCOHOL, V35, P227, DOI 10.1016/j.alcohol.2005.03.011
   Lu SC, 2012, PHYSIOL REV, V92, P1515, DOI 10.1152/physrev.00047.2011
   Lu SC, 2009, MOL ASPECTS MED, V30, P42, DOI 10.1016/j.mam.2008.05.005
   Lucero CMJ, 2013, J CELL PHYSIOL, V228, P714, DOI 10.1002/jcp.24218
   Luo J, 2010, INT J BIOL SCI, V6, P784
   Markham GD, 2009, CELL MOL LIFE SCI, V66, P636, DOI 10.1007/s00018-008-8516-1
   Martinez-Lopez N, 2008, BIOCHEM SOC T, V36, P848, DOI 10.1042/BST0360848
   Mato JM, 1997, PHARMACOL THERAPEUT, V73, P265, DOI 10.1016/S0163-7258(96)00197-0
   Mato JM, 2002, FASEB J, V16, P15, DOI 10.1096/fj.01-0401rev
   Mato JM, 2013, ANN HEPATOL, V12, P183, DOI 10.1016/S1665-2681(19)31355-9
   Morana A, 2002, BBA-GEN SUBJECTS, V1573, P105, DOI 10.1016/S0304-4165(02)00333-1
   Naviglio S, 1998, EMBO J, V17, P3241, DOI 10.1093/emboj/17.12.3241
   Naviglio S, 2013, FUTURE ONCOL, V9, P1249, DOI 10.2217/fon.13.95
   Nishikawa K, 2015, NAT MED, V21, P281, DOI 10.1038/nm.3774
   Pajares Maria A, 2011, Adv Enzymol Relat Areas Mol Biol, V78, P449
   Pakneshan P, 2004, J BIOL CHEM, V279, P31735, DOI 10.1074/jbc.M401669200
   Papakostas GI, 2012, CAN J PSYCHIAT, V57, P406, DOI 10.1177/070674371205700703
   Parashar S, 2015, CANCER MED-US, V4, P732, DOI 10.1002/cam4.386
   PEGG AE, 1986, BIOCHEM J, V234, P249, DOI 10.1042/bj2340249
   Pignochino Y, 2009, MOL CANCER, V8, DOI 10.1186/1476-4598-8-118
   PORCELLI M, 1988, EUR J BIOCHEM, V177, P273, DOI 10.1111/j.1432-1033.1988.tb14373.x
   Reytor E, 2009, FASEB J, V23, P3347, DOI 10.1096/fj.09-130187
   Ryu K, 2010, J ORTHOP RES, V28, P971, DOI 10.1002/jor.21088
   Salas S, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-606
   Salvatore F., 1977, BIOCH ADENOSYLMETHIO, P1
   Santarpia L, 2012, EXPERT OPIN THER TAR, V16, P103, DOI 10.1517/14728222.2011.645805
   Sauter M, 2013, BIOCHEM J, V451, P145, DOI 10.1042/BJ20121744
   Shukeir N, 2006, CANCER RES, V66, P9202, DOI 10.1158/0008-5472.CAN-06-1954
   Shukeir N, 2015, BRIT J PHARMACOL, V172, P2769, DOI 10.1111/bph.13102
   Si HP, 2012, INT J ONCOL, V40, P1291, DOI 10.3892/ijo.2011.1303
   Soeken KL, 2002, J FAM PRACTICE, V51, P425
   Spina A, 2013, CURR PHARM DESIGN, V19, P5394, DOI 10.2174/1381612811319300008
   Spina A, 2013, J CELL PHYSIOL, V228, P198, DOI 10.1002/jcp.24124
   Struck AW, 2012, CHEMBIOCHEM, V13, P2642, DOI 10.1002/cbic.201200556
   Sullivan R, 2011, LANCET ONCOL, V12, P933, DOI 10.1016/S1470-2045(11)70141-3
   Usdin E, 1982, BIOCH S ADENOSYLMETH, P1
   VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I
   Wang XC, 2014, ANTICANCER RES, V34, P6537
   Yan J, 2015, MOL MED REP, V12, P498, DOI 10.3892/mmr.2015.3439
   Yang HP, 2004, HEPATOLOGY, V40, P221, DOI 10.1002/hep.20274
   Yang JL, 2013, CURR OPIN ONCOL, V25, P398, DOI 10.1097/CCO.0b013e3283622c1b
   Yao WT, 2014, ONCOL RES, V22, P21, DOI [10.3727/096504014X14077751730351, 10.3727/096504015X14386062091442]
   Yu Y, 2011, ANTICANCER RES, V31, P1147
NR 76
TC 32
Z9 36
U1 0
U2 93
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-9541
EI 1097-4652
J9 J CELL PHYSIOL
JI J. Cell. Physiol.
PD FEB
PY 2016
VL 231
IS 2
BP 428
EP 435
DI 10.1002/jcp.25089
PG 8
WC Cell Biology; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology; Physiology
GA CU4BG
UT WOS:000363470400018
PM 26174106
DA 2025-01-04
ER

PT J
AU Xiao, WT
   Qu, KM
   Zhang, W
   Lai, LH
   He, L
   Cheng, F
   Wang, LH
AF Xiao, Wentao
   Qu, Kuiming
   Zhang, Wei
   Lai, Lunhui
   He, Lei
   Cheng, Fang
   Wang, Lianhui
TI High Immunogenic Cuproptosis Evoked by In Situ Sulfidation-Activated
   Pyroptosis for Tumor-Targeted Immunotherapy of Colorectal Cancer
SO SMALL SCIENCE
LA English
DT Article
DE cuproptosis; immunotherapy; in situ sulfidation; MOF-199; pyroptosis
ID CYTOCHROME-C RELEASE; CELL-DEATH; HYDROGEN-SULFIDE; MICROENVIRONMENT;
   MITOCHONDRIA; FERROPTOSIS
AB Despite the great potential of cuproptosis in tumor therapy, the current cuproptosis-based therapy still suffers from compromised efficiency of immune activation. Pyroptosis, a proinflammatory cell death modality, provides a good opportunity to induce immunogenic cell death (ICD) and promote systemic immune response. However, the synergistic cuproptosis and pyroptosis therapy has not been fully explored. Herein, it is discovered that Cu(II)-based metal-organic framework (MOF) nanoparticles (NPs) can synergistically induce cuproptosis and pyroptosis to evoke ICD for high-efficiency tumor-targeted immunotherapy. Although MOF-199 has been widely used in tumor therapy, the immunogenicity is still unclear. Pluronic F127-modified MOF-199 NPs (F127MOF-199 NPs) show dual-responsiveness to glutathione (GSH) and hydrogen sulfide (H2S). Once entering cancer cells, F127MOF-199 NPs dissociate in GSH-enriched tumor microenvironment (TME) to release copper ion and induce copper-overload-mediated cuproptosis. Meanwhile, F127MOF-199 NPs transform to Cu2-xS NPs by in situ sulfidation under H2S-enriched colorectal cancer (CRC) TME. Under photothermal and chemodynamic therapy (PTT/CDT) of Cu2-xS NPs, caspase-3 is activated and gasdermin E (GSDME)-related pyroptosis is triggered. The synergistic cuproptosis and pyroptosis have proved the superior antitumor immunity effect in both in vitro and in vivo experiments. This work provides a new strategy to achieve tumor-targeted immunotherapy with high efficiency by simple F127MOF-199 NPs.
   MOF-199 nanoparticles (NPs) with dual-responsiveness to the tumor microenvironment (TME) are developed as nanoinducers to evoke high immunogenic cuproptosis through in situ sulfidation-activated pyroptosis. The induced immunogenic cell death (ICD) exhibits a superior antitumor immunity effect for tumor-targeted therapy of colorectal cancer (CRC).image (c) 2024 WILEY-VCH GmbH
C1 [Xiao, Wentao; Qu, Kuiming; Zhang, Wei; Lai, Lunhui; He, Lei; Cheng, Fang; Wang, Lianhui] Nanjing Univ Posts & Telecommun, Inst Adv Mat IAM, State Key Lab Organ Elect & Informat Displays, Nanjing 210023, Peoples R China.
   [Xiao, Wentao; Qu, Kuiming; Zhang, Wei; Lai, Lunhui; He, Lei; Cheng, Fang; Wang, Lianhui] Nanjing Univ Posts & Telecommun, Inst Adv Mat IAM, Jiangsu Key Lab Biosensors, Nanjing 210023, Peoples R China.
C3 Nanjing University of Posts & Telecommunications; Nanjing University of
   Posts & Telecommunications
RP Cheng, F; Wang, LH (corresponding author), Nanjing Univ Posts & Telecommun, Inst Adv Mat IAM, State Key Lab Organ Elect & Informat Displays, Nanjing 210023, Peoples R China.; Cheng, F; Wang, LH (corresponding author), Nanjing Univ Posts & Telecommun, Inst Adv Mat IAM, Jiangsu Key Lab Biosensors, Nanjing 210023, Peoples R China.
EM iamfcheng@njupt.edu.cn; iamlhwang@njupt.edu.cn
RI Zhang, Lu/KHE-5879-2024; Zhang, Wei/ABA-9882-2020; Cheng,
   Fan/JXX-8930-2024
FU National Natural Science Foundation of China; Natural Science Foundation
   of Jiangsu Province-Major Project [BK20212012]; Project of State Key
   Laboratory of Organic Electronics and Information Displays, Nanjing
   University of Posts and Telecommunications [GZR2022010028];  [22371127];
    [21902079];  [62235008];  [62288102]
FX This work was financially supported by the National Natural Science
   Foundation of China (grant nos. 22371127, 21902079, 62235008, and
   62288102), Natural Science Foundation of Jiangsu Province-Major Project
   (grant no. BK20212012), the Project of State Key Laboratory of Organic
   Electronics and Information Displays, Nanjing University of Posts and
   Telecommunications, (grant no. GZR2022010028). All animal experiments
   were performed in accordance with the protocols and approved by the
   Experimental Animal Ethics Committee of Nanjing Surui Medical Technology
   Co., Ltd.
CR An L, 2018, ANGEW CHEM INT EDIT, V57, P15782, DOI 10.1002/anie.201810082
   Chen DS, 2017, NATURE, V541, P321, DOI 10.1038/nature21349
   Chen WY, 2019, ADV SCI, V6, DOI 10.1002/advs.201901724
   Ding JJ, 2016, NATURE, V535, P111, DOI 10.1038/nature18590
   Dong CH, 2020, ADV SCI, V7, DOI 10.1002/advs.202001549
   Dong SM, 2020, ADV MATER, V32, DOI 10.1002/adma.202002439
   Drake CG, 2014, NAT REV CLIN ONCOL, V11, P24, DOI 10.1038/nrclinonc.2013.208
   Duan XP, 2019, ANGEW CHEM INT EDIT, V58, P670, DOI 10.1002/anie.201804882
   Fulda S, 2009, INT J CANCER, V124, P511, DOI 10.1002/ijc.24064
   Galluzzi L, 2017, NAT REV IMMUNOL, V17, P97, DOI 10.1038/nri.2016.107
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Galon J, 2019, NAT REV DRUG DISCOV, V18, P197, DOI 10.1038/s41573-018-0007-y
   Gao WT, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-01046-3
   Garrido C, 2006, CELL DEATH DIFFER, V13, P1423, DOI 10.1038/sj.cdd.4401950
   Ge EJ, 2022, NAT REV CANCER, V22, P102, DOI 10.1038/s41568-021-00417-2
   Goto N, 2020, METALLOMICS, V12, P868, DOI 10.1039/d0mt00015a
   Guo BD, 2023, ADV MATER, V35, DOI 10.1002/adma.202212267
   Kahlson Martha A, 2022, Science, V375, P1231, DOI 10.1126/science.abo3959
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Li SS, 2019, ANGEW CHEM INT EDIT, V58, P12624, DOI 10.1002/anie.201904751
   Li YH, 2021, CHEM COMMUN, V57, P12087, DOI 10.1039/d1cc04604g
   Li ZL, 2022, ADV SCI, V9, DOI 10.1002/advs.202201734
   Liu Q, 2012, CHEM COMMUN, V48, P8814, DOI 10.1039/c2cc34192a
   Ma BJ, 2019, J AM CHEM SOC, V141, P849, DOI 10.1021/jacs.8b08714
   Martinou JC, 2000, NAT CELL BIOL, V2, pE41, DOI 10.1038/35004069
   Meng XQ, 2021, ACS NANO, V15, P5735, DOI 10.1021/acsnano.1c01248
   Mi Y, 2019, ADV SCI, V6, DOI 10.1002/advs.201801847
   Ning SP, 2023, ACS NANO, V17, P10206, DOI 10.1021/acsnano.3c00326
   Niu X, 2022, SEMIN CANCER BIOL, V86, P273, DOI 10.1016/j.semcancer.2022.03.009
   Peng SJ, 2022, ADV SCI, V9, DOI 10.1002/advs.202103836
   Qin W., 2023, ADV FUNCT MATER, V33, P2209748
   Shao F, 2021, NAT REV IMMUNOL, V21, P620, DOI 10.1038/s41577-021-00613-z
   Shen JY, 2021, ACS APPL BIO MATER, V4, P5753, DOI 10.1021/acsabm.1c00521
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Szabo C, 2013, P NATL ACAD SCI USA, V110, P12474, DOI 10.1073/pnas.1306241110
   Tang DL, 2022, CELL RES, V32, P417, DOI 10.1038/s41422-022-00653-7
   Tian HL, 2021, J COLLOID INTERF SCI, V587, P358, DOI 10.1016/j.jcis.2020.12.028
   Tsang T, 2021, CURR BIOL, V31, pR421, DOI 10.1016/j.cub.2021.03.054
   Tsvetkov P, 2022, SCIENCE, V375, P1254, DOI 10.1126/science.abf0529
   Wan J, 2023, ADV HEALTHC MATER, V12, DOI 10.1002/adhm.202202710
   Wang H, 2023, ADV FUNCT MATER, V33, DOI 10.1002/adfm.202214499
   Wang K, 2020, CELL, V180, P941, DOI 10.1016/j.cell.2020.02.002
   Wang YB, 2021, ANGEW CHEM INT EDIT, V60, P14945, DOI 10.1002/anie.202017350
   Wang YB, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.202002431
   Wang YB, 2019, ACS NANO, V13, P6879, DOI 10.1021/acsnano.9b01665
   Wang YP, 2017, NATURE, V547, P99, DOI 10.1038/nature22393
   Wang Z, 2021, ACS NANO, V15, P12342, DOI 10.1021/acsnano.1c04280
   Wu LY, 2018, J AM CHEM SOC, V140, P16340, DOI 10.1021/jacs.8b10176
   Xiang QQ, 2022, SMALL, V18, DOI 10.1002/smll.202107809
   Xiao Y, 2021, ADV SCI, V8, DOI 10.1002/advs.202101840
   Xu WJ, 2022, ADV FUNCT MATER, V32, DOI 10.1002/adfm.202205013
   Xu YZ, 2022, ADV MATER, V34, DOI 10.1002/adma.202204733
   Yang L, 2022, NANO LETT, V22, P4207, DOI 10.1021/acs.nanolett.2c01131
   Yang ZB, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202007991
   Yin HF, 2021, MOL ONCOL, V15, P3490, DOI 10.1002/1878-0261.13064
   Zhang J, 2022, ADV SCI, V9, DOI 10.1002/advs.202103444
   Zhang WJ, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-09566-3
   Zhang ZB, 2020, NATURE, V579, P415, DOI 10.1038/s41586-020-2071-9
   Zhong XY, 2020, ADV FUNCT MATER, V30, DOI 10.1002/adfm.201907954
   Zhou J, 2023, ANGEW CHEM INT EDIT, V62, DOI 10.1002/anie.202213922
   Zhu Y, 2021, ANGEW CHEM INT EDIT, V60, P9480, DOI 10.1002/anie.202017152
NR 62
TC 10
Z9 10
U1 46
U2 89
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2688-4046
J9 SMALL SCI
JI Small Sci.
PD MAR
PY 2024
VL 4
IS 3
DI 10.1002/smsc.202300164
EA JAN 2024
PG 13
WC Nanoscience & Nanotechnology; Materials Science, Multidisciplinary
WE Emerging Sources Citation Index (ESCI)
SC Science & Technology - Other Topics; Materials Science
GA PN3D5
UT WOS:001143839200001
OA gold
DA 2025-01-04
ER

PT J
AU Dai, LR
   Li, Z
   Tao, YR
   Liang, WL
   Hu, WH
   Zhou, SL
   Fu, XD
   Wang, XJ
AF Dai, Lirui
   Li, Zian
   Tao, Yiran
   Liang, Wulong
   Hu, Weihua
   Zhou, Shaolong
   Fu, Xudong
   Wang, Xinjun
TI Emerging roles of suppressor of cytokine signaling 3 in human cancers
SO BIOMEDICINE & PHARMACOTHERAPY
LA English
DT Review
DE SOCS3; Cancer; MicroRNAs; Target gene; Target therapy
ID PROMOTES CELL-GROWTH; PROSTATE-CANCER; SOCS PROTEINS; CIRCULAR RNA;
   COLON-CANCER; LUNG-CANCER; STEM-CELLS; PROLIFERATION; PATHWAY; STAT3
AB As a member of the suppressor of cytokine signaling (SOCS) family, SOCS3 is a cytokine-inducible protein that inhibits cytokine signaling in a variety of signaling pathways. Increasing evidence shows that SOCS3 regulates tumor development through multiple pathological and physiological processes. It is worth mentioning that SOCS3 negatively regulates JAK/STAT signaling by binding to JAK/cytokine receptors or phosphorylation docking sites on STAT receptors, thus preventing tumor cell proliferation and inhibiting tumor cell invasion and metastasis. The kinase inhibitory region KIR of SOCS3 is the key to JAK inhibition. In addition, SOCS3 may also regulate tumor progression through other molecules or signaling pathways, such as microRNAs (miRNAs), IL-6 and NF-kappa B signaling pathway. MicroRNAs inhibit SOCS3 expression by binding to the 3' untranslated region of SOCS3 mRNA, thus regulating tumor development processes, including tumor cell proliferation, invasion, metastasis, differentiation, cell cycle and apoptosis, as well as tumor metastasis and chemotherapy resistance. On the whole, SOCS3 acts as an inhibitor of the majority of tumors through various pathways. In the present review, the role of SOCS3 in multitudinous tumors was comprehensively summarized, the molecular mechanisms and modes of action of SOCS3 in tumors were discussed, and the association between SOCS3 expression and the clinical characteristics of patients with cancer were emphasized.
C1 [Dai, Lirui; Li, Zian; Tao, Yiran; Zhou, Shaolong; Fu, Xudong; Wang, Xinjun] Zhengzhou Univ, Affiliated Hosp 5, Dept Neurosurg, Zhengzhou 450052, Peoples R China.
   [Dai, Lirui; Li, Zian; Tao, Yiran; Liang, Wulong; Hu, Weihua; Zhou, Shaolong; Fu, Xudong; Wang, Xinjun] Henan Int Joint Lab Glioma Metab & Microenvironm, Zhengzhou, Henan, Peoples R China.
C3 Zhengzhou University
RP Wang, XJ (corresponding author), Zhengzhou Univ, Affiliated Hosp 5, Dept Neurosurg, Zhengzhou 450052, Peoples R China.
EM wangxj@zzu.edu.cn
RI fu, xudong/KSM-6835-2024; Zhou, Shaolong/HNS-4285-2023
OI Zhou, Shaolong/0000-0002-9781-4320; Dai, Lirui/0000-0001-8460-7632
FU National Natural Science Foundation of China [81972361]; Natural Science
   Foundation of Henan Province [182300410379]
FX The National Natural Science Foundation of China (81972361) ; the
   Natural Science Foundation of Henan Province (182300410379) .
CR Ali Syeda Z, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21051723
   Babon JJ, 2008, J MOL BIOL, V381, P928, DOI 10.1016/j.jmb.2008.06.038
   Baetz A, 2004, J BIOL CHEM, V279, P54708, DOI 10.1074/jbc.M410992200
   Baker BJ, 2009, TRENDS IMMUNOL, V30, P392, DOI 10.1016/j.it.2009.07.001
   Bao LD, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116067
   Boyle K, 2009, CELL SIGNAL, V21, P394, DOI 10.1016/j.cellsig.2008.11.002
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brook L, 2019, J CELL BIOCHEM, V120, P533, DOI 10.1002/jcb.27408
   Chen LX, 2020, J CANCER, V11, P5440, DOI 10.7150/jca.46158
   Chen M, 2020, AGING-US, V12, P10896, DOI 10.18632/aging.103303
   Chu QJ, 2017, GENE, V627, P114, DOI 10.1016/j.gene.2017.06.013
   Sandoval-Usme MC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087769
   Croker BA, 2008, SEMIN CELL DEV BIOL, V19, P414, DOI 10.1016/j.semcdb.2008.07.010
   Demircan Tan Berna, 2020, Medeni Med J, V35, P99, DOI 10.5222/MMJ.2020.58708
   Du YX, 2020, HUM CELL, V33, P252, DOI 10.1007/s13577-019-00298-6
   Ernst M, 2012, CLIN EXP PHARMACOL P, V39, P711, DOI 10.1111/j.1440-1681.2011.05659.x
   Feng Y, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0091829
   Fu WH, 2014, CELL PHYSIOL BIOCHEM, V33, P195, DOI 10.1159/000356662
   Fukui H, 2020, ONCOL LETT, V19, P3542, DOI 10.3892/ol.2020.11462
   Ge Y, BENZOAPYRENE STIMULA, V2021
   Gura T, 1997, SCIENCE, V277, P768, DOI 10.1126/science.277.5327.768
   Han D, 2017, HEPATOLOGY, V66, P1151, DOI 10.1002/hep.29270
   Han Q, 2020, J GASTROEN HEPATOL, V35, P1347, DOI 10.1111/jgh.15021
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Handle F, 2016, MOL CANCER RES, V14, P574, DOI 10.1158/1541-7786.MCR-15-0495
   He B, 2003, P NATL ACAD SCI USA, V100, P14133, DOI 10.1073/pnas.2232790100
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Hirahara K, 2012, IMMUNITY, V36, P1017, DOI 10.1016/j.immuni.2012.03.024
   Hsiao KY, 2017, CANCER RES, V77, P2339, DOI 10.1158/0008-5472.CAN-16-1883
   Hu YW, 2021, LIFE SCI, V277, DOI 10.1016/j.lfs.2021.119501
   Huang L, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-016-0301-7
   Huang S, 2019, J CELL PHYSIOL, V234, P3500, DOI 10.1002/jcp.26863
   Ji YY, 2012, CELL PHYSIOL BIOCHEM, V29, P863, DOI 10.1159/000171034
   Jiang BG, 2017, ONCOTARGET, V8, P28621, DOI 10.18632/oncotarget.16157
   Kaphle P, 2019, J CELL PHYSIOL, V234, P3948, DOI 10.1002/jcp.27209
   Kneitz B, 2014, CANCER RES, V74, P2591, DOI 10.1158/0008-5472.CAN-13-1606
   Krebs M, 2019, BIOMED RES INT, V2019, DOI 10.1155/2019/6392748
   Kudo M, 2019, WORLD J GASTROENTERO, V25, P789, DOI 10.3748/wjg.v25.i7.789
   Li L, 2020, CANCER MED-US, V9, P2491, DOI 10.1002/cam4.2866
   Li M, 2020, EUR REV MED PHARMACO, V24, P11462, DOI 10.26355/eurrev_202011_23747
   Li MZ, 2020, EUR REV MED PHARMACO, V24, P11985, DOI 10.26355/eurrev_202012_23949
   Li ZY, 2020, CELL CYCLE, V19, P2811, DOI 10.1080/15384101.2020.1824717
   Lin XM, 2019, EUR REV MED PHARMACO, V23, P6906, DOI 10.26355/eurrev_201908_18730
   Lindemann C, 2011, ACTA NEUROPATHOL, V122, P241, DOI 10.1007/s00401-011-0832-0
   Lü LS, 2017, ONCOTARGET, V8, P44096, DOI 10.18632/oncotarget.17307
   Martini M, 2008, INT J CANCER, V123, P2955, DOI 10.1002/ijc.23805
   McFarland BC, 2013, MOL CANCER RES, V11, P494, DOI 10.1158/1541-7786.MCR-12-0528
   Mei J, 2020, BIOMED PHARMACOTHER, V123, DOI 10.1016/j.biopha.2019.109799
   Muhammad N, 2016, ONCOTARGET, V7, P58595, DOI 10.18632/oncotarget.11193
   Neuwirt H, 2007, ENDOCR-RELAT CANCER, V14, P1007, DOI 10.1677/ERC-07-0172
   Nicholson SE, 1998, J LEUKOCYTE BIOL, V63, P665, DOI 10.1002/jlb.63.6.665
   Niwa Y, 2005, ONCOGENE, V24, P6406, DOI 10.1038/sj.onc.1208788
   Pastuszak-Lewandoska D, 2018, MOL DIAGN THER, V22, P621, DOI 10.1007/s40291-018-0355-7
   Patel K, 2014, CANCER LETT, V347, P54, DOI 10.1016/j.canlet.2014.01.020
   Pauli EK, 2008, PLOS PATHOG, V4, DOI 10.1371/journal.ppat.1000196
   Peng HY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0158440
   Puhr M, 2010, ENDOCR-RELAT CANCER, V17, P525, DOI 10.1677/ERC-10-0007
   Qin HW, 2008, J IMMUNOL, V181, P3167, DOI 10.4049/jimmunol.181.5.3167
   Qin ML, 2016, CANCER BIOMARK, V16, P161, DOI 10.3233/CBM-150552
   Ren D, 2017, ONCOTARGET, V8, P49807, DOI 10.18632/oncotarget.17971
   Rossa C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045197
   Ruan ZY, 2019, CANCER MANAG RES, V11, P389, DOI 10.2147/CMAR.S180418
   Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486
   Sasi W, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-178
   Shang AQ, 2017, CANCER BIOL THER, V18, P314, DOI 10.1080/15384047.2017.1310343
   Shi J, 2020, NEOPLASMA, V67, P267, DOI 10.4149/neo_2019_190414N328
   Shuai K, 2003, NAT REV IMMUNOL, V3, P900, DOI 10.1038/nri1226
   Siegel RL, 2021, CA-CANCER J CLIN, V71, P7, DOI 10.3322/caac.21654
   Singh S, 2017, FEBS LETT, V591, P1371, DOI 10.1002/1873-3468.12655
   Speth JM, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.131340
   Sutherland KD, 2006, EMBO J, V25, P5805, DOI 10.1038/sj.emboj.7601455
   Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464
   Tirino V, 2013, FASEB J, V27, P13, DOI 10.1096/fj.12-218222
   Torre LA, 2018, CA-CANCER J CLIN, V68, P284, DOI 10.3322/caac.21456
   Travis WD, 2011, CLIN CHEST MED, V32, P669, DOI 10.1016/j.ccm.2011.08.005
   Tu CL, 2021, CANCER MANAG RES, V13, P1999, DOI 10.2147/CMAR.S281925
   Turchinoyich A, 2016, TRENDS BIOCHEM SCI, V41, P883, DOI 10.1016/j.tibs.2016.08.004
   Wan J, 2015, MOL MED REP, V12, P83, DOI 10.3892/mmr.2015.3368
   Wang HL, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08597-8
   Wang H, 2020, J CELL PHYSIOL, V235, P1615, DOI 10.1002/jcp.29080
   Wang J, 2020, EUR REV MED PHARMACO, V24, P12625, DOI 10.26355/eurrev_202012_24143
   Wang J, 2014, J MOL MED, V92, P1257, DOI 10.1007/s00109-014-1184-8
   Wang JF, 2017, ONCOTARGET, V8, P114956, DOI 10.18632/oncotarget.22565
   Wang XW, 2016, CELL PHYSIOL BIOCHEM, V38, P1796, DOI 10.1159/000443118
   Wei F, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0694-8
   Wei HM, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.607001
   Xie J, 2018, EUR REV MED PHARMACO, V22, P1914, DOI 10.26355/eurrev_201804_14714
   Xiong HJ, 2017, ONCOTARGET, V8, P64083, DOI 10.18632/oncotarget.19321
   Xu CH, 2019, J CELL PHYSIOL, V234, P22272, DOI 10.1002/jcp.28794
   Xu JZ, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1382-y
   Yabe Michihiro, 2018, Oncotarget, V9, P31697, DOI 10.18632/oncotarget.25851
   Yan ZK, 2021, CANCER MANAG RES, V13, P3029, DOI 10.2147/CMAR.S266153
   Ye T, 2021, EXP THER MED, V21, DOI 10.3892/etm.2021.10084
   Ying X, 2016, ONCOTARGET, V7, P43076, DOI 10.18632/oncotarget.9246
   Yokogami K, 2013, BRAIN TUMOR PATHOL, V30, P135, DOI 10.1007/s10014-012-0122-0
   Yuan J, 2015, SCI REP-UK, V5, DOI 10.1038/srep17663
   Zhang KJ, 2020, MOL ONCOL, V14, P309, DOI 10.1002/1878-0261.12622
   Zhang X, 2018, MOL THER-NUCL ACIDS, V11, P142, DOI 10.1016/j.omtn.2018.01.004
   Zhang Y, 2017, J EXP MED, V214, P2523, DOI 10.1084/jem.20161427
   Zhang Y, 2018, FRONT MED-PRC, V12, P361, DOI 10.1007/s11684-018-0656-6
   Zhou H, 2007, CLIN CANCER RES, V13, P2344, DOI 10.1158/1078-0432.CCR-06-2303
   Zhou X, 2015, ACTA OBSTET GYN SCAN, V94, P1112, DOI 10.1111/aogs.12708
NR 102
TC 33
Z9 33
U1 4
U2 31
PU ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER
PI ISSY-LES-MOULINEAUX
PA 65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE
SN 0753-3322
EI 1950-6007
J9 BIOMED PHARMACOTHER
JI Biomed. Pharmacother.
PD DEC
PY 2021
VL 144
AR 112262
DI 10.1016/j.biopha.2021.112262
EA OCT 2021
PG 10
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA WD4MS
UT WOS:000704917500007
PM 34607102
OA gold
DA 2025-01-04
ER

PT J
AU Gedye, C
   Navani, V
AF Gedye, Craig
   Navani, Vishal
TI Find the path of least resistance: Adaptive therapy to delay treatment
   failure and improve outcomes
SO BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
LA English
DT Review
ID METASTATIC PROSTATE-CANCER; RENAL-CELL CARCINOMA; BREAST-CANCER;
   ACQUIRED-RESISTANCE; COLORECTAL-CANCER; TARGETED THERAPY; OPEN-LABEL;
   PHASE-II; EVOLUTIONARY; CHEMOTHERAPY
AB Cytotoxic chemotherapy and targeted therapies help people with advanced cancers, but for most, treatment fails. Cancer heterogeneity is one cause of treatment failure, but also suggests an opportunity to improve outcomes; reconceptualising cancer therapy as an ecological problem offers the strategy of adaptive therapy. If an agent is active against a patient's cancer, instead of traditional continuous dosing at the maximum tolerated dose until treatment failure, the patient and their oncologist may instead choose to pause treatment as soon as the cancer responds. When tumour burden increases, the cancer is rechallenged with the same agent in hope of delivering another response, ideally before symptoms occur or quality-of-life is impacted. These 'loops' of 'pause/restart' allows an active treatment to be used strategically, to delay the development of evolutionary selection within the cancer, delaying the onset of treatment resistance, controlling the cancer for longer. Modelling predicts patients can navigate several 'loops', potentially increasing the utility of an active treatment by multiples, and early trials suggest at least doubling of progression-free survival. In this narrative review we confront how cancer heterogeneity limits treatment effectiveness, re-examine cancer as an ecological problem, review the data supporting adaptive therapy and outline the challenges and opportunities faced in clinical practice to implement this evolutionary concept. In an era where multiple novel active anti-neoplastic agents are being used with ancient inflexibile maximum tolerated dose for maximum duration approaches, adaptive dosing offers a personalised, n = 1 approach to cancer therapy selection.
C1 [Gedye, Craig] Calvary Mater Newcastle, Waratah, NSW 2298, Australia.
   [Gedye, Craig] Hunter Med Res Inst, Clin Trial Unit, New Lambton Hts, NSW, Australia.
   [Navani, Vishal] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
   [Gedye, Craig] Univ Newcastle, Sch Med & Publ Hlth, Callaghan, NSW, Australia.
C3 Calvary Mater Newcastle Hospital; University of Newcastle; Hunter
   Medical Research Institute; Tom Baker Cancer Clinic; University of
   Calgary; University of Newcastle
RP Navani, V (corresponding author), Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
EM craig.gedye@newcastle.edu.au; vishal.navani@albertahealthservices.ca
RI Navani, Vishal/AAY-9936-2020
OI Navani, Vishal/0000-0002-6795-009X; Gedye, Craig/0000-0002-1629-4352
CR Ackland SP, 2005, BRIT J CANCER, V93, P1236, DOI 10.1038/sj.bjc.6602841
   Adams RA, 2011, LANCET ONCOL, V12, P642, DOI 10.1016/S1470-2045(11)70102-4
   Aktipis CA, 2013, NAT REV CANCER, V13, P883, DOI 10.1038/nrc3606
   Aktipis CA, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026100
   [Anonymous], CANC DEATH RAT AR FA
   Beckman RA, 2020, CANCER CONTROL, V27, DOI 10.1177/1073274820962008
   Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
   Belkhir S, 2021, CANCERS, V13, DOI 10.3390/cancers13174448
   Berry SR, 2015, ANN ONCOL, V26, P477, DOI 10.1093/annonc/mdu272
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chen BB, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2494-8
   Chen PY, 2018, CANCER RES, V78, P985, DOI 10.1158/0008-5472.CAN-17-2129
   Choi S, 2018, NEURO-ONCOLOGY, V20, P1300, DOI 10.1093/neuonc/noy016
   Corazzelli G, 2012, BRIT J HAEMATOL, V156, P234, DOI 10.1111/j.1365-2141.2011.08947.x
   Cunningham JJ, 2019, NAT ECOL EVOL, V3, P996, DOI 10.1038/s41559-019-0927-x
   Cunningham JJ, 2018, J THEOR BIOL, V459, P67, DOI 10.1016/j.jtbi.2018.09.022
   de Bono JS, 2010, LANCET, V376, P1147, DOI 10.1016/S0140-6736(10)61389-X
   Del Paggio JC, 2021, JAMA ONCOL, V7, P728, DOI 10.1001/jamaoncol.2021.0379
   Denmeade SR, 2021, J CLIN ONCOL, V39, P1371, DOI 10.1200/JCO.20.02759
   Dujon AM, 2021, EVOL APPL, V14, P877, DOI 10.1111/eva.13190
   Enriquez-Navas PM, 2015, CANCER RES, V75, P4675, DOI 10.1158/0008-5472.CAN-15-1337
   Evans CP, 2018, LANCET ONCOL, V19, P8, DOI 10.1016/S1470-2045(17)30907-5
   Feeley KM, 2001, HISTOPATHOLOGY, V38, P87, DOI 10.1046/j.1365-2559.2001.01042.x
   Fojo T, 2014, JAMA OTOLARYNGOL, V140, P1225, DOI 10.1001/jamaoto.2014.1570
   Gallaher J.A., 2017, ADAPTIVE THERAPY HET
   Gatenby RA, 2009, CANCER RES, V69, P4894, DOI 10.1158/0008-5472.CAN-08-3658
   Gedye C., 2021, BASIC SCI ONCOLOGY, V6th
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Gide TN, 2018, CLIN CANCER RES, V24, P1260, DOI 10.1158/1078-0432.CCR-17-2267
   Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298
   Hammers HJ, 2010, MOL CANCER THER, V9, P1525, DOI 10.1158/1535-7163.MCT-09-1106
   Hansen E, 2020, CANCERS, V12, DOI 10.3390/cancers12123556
   Hansen E, 2017, PLOS BIOL, V15, DOI [10.1371/journal.pbio.2001110, 10.1371/journal.pbio.200110]
   Holland JF, 2013, J CLIN ONCOL, V31, P3727, DOI 10.1200/JCO.2013.51.8126
   Iliopoulos D, 2011, P NATL ACAD SCI USA, V108, P1397, DOI 10.1073/pnas.1018898108
   Iranzo J, 2018, P NATL ACAD SCI USA, V115, pE6010, DOI 10.1073/pnas.1803155115
   Jamal-Hanjani M, 2017, NEW ENGL J MED, V376, P2109, DOI 10.1056/NEJMoa1616288
   Jamal-Hanjani M, 2015, CLIN CANCER RES, V21, P1258, DOI 10.1158/1078-0432.CCR-14-1429
   Jansen G, 2015, P NATL ACAD SCI USA, V112, P937, DOI 10.1073/pnas.1420297111
   Jiapaer S, 2018, NEUROL MED-CHIR, V58, P405, DOI 10.2176/nmc.ra.2018-0141
   Jolly MK, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00050
   Kim C, 2018, CELL, V173, P879, DOI 10.1016/j.cell.2018.03.041
   Kim E, 2021, CANCERS, V13, DOI 10.3390/cancers13040823
   Ko B, 2017, LUNG CANCER-TARGETS, V8, P147, DOI 10.2147/LCTT.S117944
   Kurata T, 2004, ANN ONCOL, V15, P173, DOI 10.1093/annonc/mdh006
   Kuukasjarvi T, 1996, J CLIN ONCOL, V14, P2584, DOI 10.1200/JCO.1996.14.9.2584
   Ladanie A, 2020, JAMA NETW OPEN, V3, DOI 10.1001/jamanetworkopen.2020.24406
   Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6
   Lin L, 2019, RADIOLOGY, V291, P677, DOI 10.1148/radiol.2019182012
   Locke WJ, 2019, FRONT GENET, V10, DOI 10.3389/fgene.2019.01150
   Lofters A, 2002, J UROLOGY, V168, P2516, DOI 10.1016/S0022-5347(05)64180-8
   Markowski MC, 2021, EUR UROL, V79, P692, DOI 10.1016/j.eururo.2020.06.042
   Martincorena I, 2017, CELL, V171, P1029, DOI 10.1016/j.cell.2017.09.042
   Martincorena I, 2015, SCIENCE, V349, P1483, DOI 10.1126/science.aab4082
   Mason NT, 2021, AM HEALTH DRUG BENEF, V14, P15
   Merlo LMF, 2006, NAT REV CANCER, V6, P924, DOI 10.1038/nrc2013
   Nik-Zainal S, 2012, CELL, V149, DOI 10.1016/j.cell.2012.04.023
   Ornstein MC, 2017, J CLIN ONCOL, V35, P1764, DOI 10.1200/JCO.2016.71.1184
   Parker PA, 2006, GYNECOL ONCOL, V100, P495, DOI 10.1016/j.ygyno.2005.08.057
   Prasad V, 2017, BMJ-BRIT MED J, V359, DOI 10.1136/bmj.j4528
   Redmond KM, 2008, FRONT BIOSCI-LANDMRK, V13, P5138, DOI 10.2741/3070
   Rini BI, 2016, LANCET ONCOL, V17, P1317, DOI 10.1016/S1470-2045(16)30196-6
   Rovithi M, 2019, J CLIN ONCOL, V37, P411, DOI 10.1200/JCO.18.00725
   Ryan CJ, 2013, NEW ENGL J MED, V368, P138, DOI 10.1056/NEJMoa1209096
   Salvioli M., 2021, IS SUCCESS ADAPTIVE, pe1021
   Seghers AC, 2012, MELANOMA RES, V22, P466, DOI 10.1097/CMR.0b013e3283541541
   Seton-Rogers S, 2020, NAT REV CANCER, V20, P481, DOI 10.1038/s41568-020-0293-7
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Silva AS, 2012, CANCER RES, V72, P6362, DOI 10.1158/0008-5472.CAN-12-2235
   Smalley I, 2019, EBIOMEDICINE, V48, P178, DOI 10.1016/j.ebiom.2019.09.023
   Stackelberg H.V., 1952, The Theory of the Market Economy
   Stanková K, 2019, JAMA ONCOL, V5, P96, DOI 10.1001/jamaoncol.2018.3395
   Tandstad T, 2016, ANN ONCOL, V27, P1299, DOI 10.1093/annonc/mdw164
   Teply BA, 2018, LANCET ONCOL, V19, P76, DOI 10.1016/S1470-2045(17)30906-3
   Thavaneswaran S, 2018, MED J AUSTRALIA, V209, DOI 10.5694/mja18.00227
   Thirlwell C, 2010, GASTROENTEROLOGY, V138, P1441, DOI 10.1053/j.gastro.2010.01.033
   Tomasetti C, 2015, P NATL ACAD SCI USA, V112, P118, DOI 10.1073/pnas.1421839112
   Tsimberidou AM, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.17.00002
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   van den Bent M, 2020, NEURO-ONCOLOGY, V22, P684, DOI 10.1093/neuonc/noz222
   Vander Velde R, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16212-w
   Vendrell JA, 2019, CLIN CANCER RES, V25, P4280, DOI 10.1158/1078-0432.CCR-18-2683
   Vogelstein B, 2013, SCIENCE, V339, P1546, DOI 10.1126/science.1235122
   Watson PA, 2015, NAT REV CANCER, V15, P701, DOI 10.1038/nrc4016
   West JB, 2019, CLIN CANCER RES, V25, P4413, DOI 10.1158/1078-0432.CCR-19-0006
   Zhang JS, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01968-5
NR 86
TC 8
Z9 10
U1 0
U2 1
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0304-419X
EI 1879-2561
J9 BBA-REV CANCER
JI Biochim. Biophys. Acta-Rev. Cancer
PD MAR
PY 2022
VL 1877
IS 2
AR 188681
DI 10.1016/j.bbcan.2022.188681
EA JAN 2022
PG 10
WC Biochemistry & Molecular Biology; Biophysics; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics; Oncology
GA 0V3WR
UT WOS:000788277100002
PM 35051527
DA 2025-01-04
ER

PT J
AU Wang, SC
   Liu, YW
   Feng, YB
   Zhang, J
   Swinnen, J
   Li, Y
   Ni, YC
AF Wang, Shuncong
   Liu, Yewei
   Feng, Yuanbo
   Zhang, Jian
   Swinnen, Johan
   Li, Yue
   Ni, Yicheng
TI A Review on Curability of Cancers: More Efforts for Novel Therapeutic
   Options Are Needed
SO CANCERS
LA English
DT Review
DE cancer treatment; survival; theragnostics; curability and cancer
   epidemiology
ID CELL LUNG-CANCER; EARLY GASTRIC-CANCER; LONG-TERM SURVIVAL; ACUTE
   LYMPHOBLASTIC-LEUKEMIA; BONE-MARROW-TRANSPLANTATION; BREAST-CANCER;
   RADIATION-THERAPY; PROSTATE-CANCER; COLORECTAL-CANCER;
   HEPATOCELLULAR-CARCINOMA
AB Cancer remains a major cause of death globally. Given its relapsing and fatal features, curing cancer seems to be something hardly possible for the majority of patients. In view of the development in cancer therapies, this article summarizes currently available cancer therapeutics and cure potential by cancer type and stage at diagnosis, based on literature and database reviews. Currently common cancer therapeutics include surgery, chemotherapy, radiotherapy, targeted therapy, and immunotherapy. However, treatment with curative intent by these methods are mainly eligible for patients with localized disease or treatment-sensitive cancers and therefore their contributions to cancer curability are relatively limited. The prognosis for cancer patients varies among different cancer types with a five-year relative survival rate (RSR) of more than 80% in thyroid cancer, melanoma, breast cancer, and Hodgkin's lymphoma. The most dismal prognosis is observed in patients with small-cell lung cancer, pancreatic cancer, hepatocellular carcinoma, oesophagal cancer, acute myeloid leukemia, non-small cell lung cancer, and gastric cancer with a five-year RSR ranging between 7% and 28%. The current review is intended to provide a general view about how much we have achieved in curing cancer as regards to different therapies and cancer types. Finally, we propose a small molecule dual-targeting broad-spectrum anticancer strategy called OncoCiDia, in combination with emerging highly sensitive liquid biopsy, with theoretical curative potential for the management of solid malignancies, especially at the micro-cancer stage.
C1 [Wang, Shuncong; Liu, Yewei; Feng, Yuanbo; Swinnen, Johan; Ni, Yicheng] Katholieke Univ Leuven, Fac Med, Campus Gasthuisberg, B-3000 Leuven, Belgium.
   [Zhang, Jian] Jiangsu Prov Acad Tradit Chinese Med, Labs Translat Med, Nanjing 210028, Jiangsu, Peoples R China.
   [Li, Yue] Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.
C3 KU Leuven; Nanjing University of Chinese Medicine; Shanghai University
   of Medicine & Health Sciences
RP Ni, YC (corresponding author), Katholieke Univ Leuven, Fac Med, Campus Gasthuisberg, B-3000 Leuven, Belgium.; Li, Y (corresponding author), Shanghai Univ Med & Hlth Sci, Shanghai Key Lab Mol Imaging, Shanghai 201318, Peoples R China.
EM shuncong.wang@kuleuven.be; yyewei.liu@outlook.com;
   yuanbo.feng@kuleuven.be; zjwonderful@hotmail.com; j.swinnen@kuleuven.be;
   liy_16@sumhs.edu.cn; yicheng.ni@med.kuleuven.be
RI Swinnen, Johannes/AAA-2214-2022
OI Wang, Shun-Cong/0000-0003-0656-2760; Liu, Yewei/0000-0002-4360-0132;
   Swinnen, Johannes/0000-0002-7720-5077; Ni, Yicheng/0000-0002-8553-7565
FU National Natural Science Foundation of China [81771870, 81603142];
   Oncocidia Ltd., London, UK
FX This work was partially supported by the National Natural Science
   Foundation of China (81771870 and 81603142) and a financial subsidy by
   Oncocidia Ltd., London, UK.
CR Adam MA, 2017, JAMA SURG, V152, P336, DOI 10.1001/jamasurg.2016.4753
   Albano D, 2018, LUNG CANCER-TARGETS, V9, P65, DOI 10.2147/LCTT.S166320
   Alexander EJ, 2010, INDIAN J UROL, V26, P82, DOI 10.4103/0970-1591.60451
   Ali Syed Yousuf, 2010, Int J Trichology, V2, P118, DOI 10.4103/0974-7753.77528
   Anderson ML, 2000, AM J GASTROENTEROL, V95, P3418, DOI 10.1111/j.1572-0241.2000.03356.x
   Ando N, 2003, J CLIN ONCOL, V21, P4592, DOI 10.1200/JCO.2003.12.095
   Andrews Audrey, 2015, Am Health Drug Benefits, V8, P9
   [Anonymous], CAUTION WHEN USING R
   [Anonymous], DEF HEAV ION
   [Anonymous], 2016, BMJ BRIT MED J, DOI DOI 10.1136/BMJ.I5792
   [Anonymous], 2014, LANCET, DOI DOI 10.1016/S0140-6736(13)62146-7
   [Anonymous], 2000, ONCOLOGIST, DOI DOI 10.1634/THEONCOLOGIST.5-SUPPL_2-1
   [Anonymous], UGENT IS LOOKING DOG
   [Anonymous], PART THER PAT STAT P
   [Anonymous], 2016, INT J ENDOCRINOL, DOI DOI 10.1155/2016/2586512
   Apolone G, 2005, BRIT J CANCER, V93, P504, DOI 10.1038/sj.bjc.6602750
   Apperley JF, 2015, LANCET, V385, P1447, DOI 10.1016/S0140-6736(13)62120-0
   Armitage JO, 2017, LANCET, V390, P298, DOI 10.1016/S0140-6736(16)32407-2
   Arruebo Manuel, 2011, Cancers (Basel), V3, P3279, DOI 10.3390/cancers3033279
   Ashdown Martin L, 2015, F1000Res, V4, P232, DOI 10.12688/f1000research.6760.1
   Atkin WS, 2010, LANCET, V375, P1624, DOI 10.1016/S0140-6736(10)60551-X
   Bach PB, 2011, NEW ENGL J MED, V365, P2036, DOI 10.1056/NEJMc1110293
   Backes Y, 2017, AM J GASTROENTEROL, V112, P785, DOI 10.1038/ajg.2017.58
   Baker-Kubiczek E. K., 2012, Experimental Oncology, V34, P277
   Bang YJ, 2010, LANCET, V376, P1302
   Barlas Stephen, 2016, P T, V41, P290
   Belderbos TDG, 2017, CLIN GASTROENTEROL H, V15, P403, DOI 10.1016/j.cgh.2016.08.041
   Bergethon K, 2012, J CLIN ONCOL, V30, P863, DOI 10.1200/JCO.2011.35.6345
   Bezjak A, 2019, J CLIN ONCOL, V37, P1316, DOI 10.1200/JCO.18.00622
   Bianco A, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20194931
   BIGGS JC, 1992, BLOOD, V80, P1090, DOI 10.1182/blood.V80.4.1090.1090
   Bleyer A, 2012, NEW ENGL J MED, V367, P1998, DOI 10.1056/NEJMoa1206809
   Blumenthal GM, 2015, J CLIN ONCOL, V33, P1008, DOI 10.1200/JCO.2014.59.0489
   BOFFETTA P, 1994, ACTA ONCOL, V33, P591, DOI 10.3109/02841869409121767
   Bolenz C, 2014, EUR UROL, V65, P316, DOI 10.1016/j.eururo.2012.08.059
   Bonvalot S, 2019, LANCET ONCOL, V20, P1148, DOI 10.1016/S1470-2045(19)30326-2
   Bonvalot S, 2017, CLIN CANCER RES, V23, P908, DOI 10.1158/1078-0432.CCR-16-1297
   Boutros J, 2008, PEDIATR SURG INT, V24, P1177, DOI 10.1007/s00383-008-2240-7
   Brabander T, 2017, CLIN CANCER RES, V23, P4617, DOI 10.1158/1078-0432.CCR-16-2743
   Bradley J, 2004, INT J RADIAT ONCOL, V59, P78, DOI 10.1016/j.ijrobp.2003.10.044
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   Bretthauer M, 2016, JAMA INTERN MED, V176, P894, DOI 10.1001/jamainternmed.2016.0960
   Brown JM, 2014, INT J RADIAT ONCOL, V88, P254, DOI 10.1016/j.ijrobp.2013.07.022
   Brown JR, 2007, BIOL BLOOD MARROW TR, V13, P1057, DOI 10.1016/j.bbmt.2007.05.012
   Cabanillas ME, 2016, LANCET, V388, P2783, DOI 10.1016/S0140-6736(16)30172-6
   Capitanio U, 2016, LANCET, V387, P894, DOI 10.1016/S0140-6736(15)00046-X
   Carmeliet P, 2000, NATURE, V407, P249, DOI 10.1038/35025220
   CARTER HB, 1990, J UROLOGY, V143, P742, DOI 10.1016/S0022-5347(17)40078-4
   Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741
   Chan BA, 2015, TRANSL LUNG CANCER R, V4, P36, DOI 10.3978/j.issn.2218-6751.2014.05.01
   Chang CH, 2002, MOL CANCER THER, V1, P553
   Chargari C, 2019, CA-CANCER J CLIN, V69, P386, DOI 10.3322/caac.21578
   Chaudhuri AA, 2015, LUNG CANCER, V89, P50, DOI 10.1016/j.lungcan.2015.04.014
   Chen HHW, 2017, ONCOTARGET, V8, P62742, DOI 10.18632/oncotarget.18409
   Chen J, 2017, ACS NANO, V11, P12849, DOI 10.1021/acsnano.7b08225
   Chen MS, 2006, ANN SURG, V243, P321, DOI 10.1097/01.sla.0000201480.65519.b8
   Chen Q, 2019, ADV MATER, V31, DOI 10.1002/adma.201802228
   Chen WQ, 2016, CA-CANCER J CLIN, V66, P115, DOI 10.3322/caac.21338
   Chen YP, 2019, LANCET, V394, P64, DOI 10.1016/S0140-6736(19)30956-0
   Chera BS, 2019, J CLIN ONCOL, V37, P2661, DOI 10.1200/JCO.19.01007
   Chicas-Sett R, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20092173
   Choi YY, 2013, J SURG ONCOL, V108, P550, DOI 10.1002/jso.23438
   Choi Young Il, 2008, Cancer Res Treat, V40, P33, DOI 10.4143/crt.2008.40.1.33
   Cohen PA, 2019, LANCET, V393, P169, DOI 10.1016/S0140-6736(18)32470-X
   Coiffier B, 2002, NEW ENGL J MED, V346, P235, DOI 10.1056/NEJMoa011795
   Coughlin GD, 2018, LANCET ONCOL, V19, P1051, DOI 10.1016/S1470-2045(18)30357-7
   Cramer JD, 2019, NAT REV CLIN ONCOL, V16, P669, DOI 10.1038/s41571-019-0227-z
   Cunningham D, 2008, NEW ENGL J MED, V358, P36, DOI 10.1056/NEJMoa073149
   Das A, 2008, AM J GASTROENTEROL, V103, P1340, DOI 10.1111/j.1572-0241.2008.01889.x
   Davies L, 2014, JAMA OTOLARYNGOL, V140, P317, DOI 10.1001/jamaoto.2014.1
   Dawson LA, 2005, SEMIN RADIAT ONCOL, V15, P279, DOI 10.1016/j.semradonc.2005.04.005
   Dawson LA, 2010, INT J RADIAT ONCOL, V76, pS108, DOI 10.1016/j.ijrobp.2009.02.089
   de Gonzalez AB, 2011, LANCET ONCOL, V12, P353, DOI 10.1016/S1470-2045(11)70061-4
   de Heredia CD, 1999, BONE MARROW TRANSPL, V24, P163, DOI 10.1038/sj.bmt.1701874
   De Sanctis V, 2017, HEMATOL ONCOL, V35, P554, DOI 10.1002/hon.2377
   Delaney G, 2005, CANCER-AM CANCER SOC, V104, P1129, DOI 10.1002/cncr.21324
   Denisenko TV, 2016, DRUG RESIST UPDATE, V24, P1, DOI 10.1016/j.drup.2015.11.002
   Descotes F, 2017, BRIT J CANCER, V117, P583, DOI 10.1038/bjc.2017.210
   Döhner H, 2015, NEW ENGL J MED, V373, P1136, DOI 10.1056/NEJMra1406184
   Dudley JC, 2019, CANCER DISCOV, V9, P500, DOI 10.1158/2159-8290.CD-18-0825
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Eroglu Z, 2015, EUR J CANCER, V51, P2689, DOI 10.1016/j.ejca.2015.08.012
   Etzioni R, 1998, AM J EPIDEMIOL, V148, P775
   Etzioni R, 2002, J NATL CANCER I, V94, P981
   Finn RS, 2018, HEPATOLOGY, V67, P422, DOI 10.1002/hep.29486
   Fojo T, 2014, JAMA OTOLARYNGOL, V140, P1225, DOI 10.1001/jamaoto.2014.1570
   Fonseca AZ, 2014, WORLD J HEPATOL, V6, P107, DOI 10.4254/wjh.v6.i3.107
   Fujitani K, 2016, LANCET ONCOL, V17, P309, DOI 10.1016/S1470-2045(15)00553-7
   Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005
   Gazdar AF, 2017, NAT REV CANCER, V17, P725, DOI [10.1038/nrc.2017.87, 10.1038/nrc.2017.106]
   Goldsmith SJ, 2017, MOL IMAGING RADIONUC, V26, P74, DOI 10.4274/2017.26.suppl.08
   Gong J, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0316-z
   Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004
   Grossman DC, 2018, JAMA-J AM MED ASSOC, V319, P1901, DOI 10.1001/jama.2018.3710
   Grothey A, 2018, NEW ENGL J MED, V378, P1177, DOI 10.1056/NEJMoa1713709
   Guarneri V, 2019, ANN ONCOL, V30, P921, DOI 10.1093/annonc/mdz055
   Hainfeld JF, 2004, PHYS MED BIOL, V49, pN309, DOI 10.1088/0031-9155/49/18/N03
   Hamilton JP, 2006, CLIN GASTROENTEROL H, V4, P701, DOI 10.1016/j.cgh.2006.03.007
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hanna NH, 2014, NEW ENGL J MED, V371, P2005, DOI 10.1056/NEJMra1407550
   Harper KL, 2016, NATURE, V540, P588, DOI 10.1038/nature20609
   Hartmann J, 2017, EMBO MOL MED, V9, P1183, DOI 10.15252/emmm.201607485
   Haslam A, 2019, JAMA NETW OPEN, V2, DOI 10.1001/jamanetworkopen.2019.2535
   Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x
   Hay AE, 2019, J MED ECON, V22, P613, DOI 10.1080/13696998.2019.1582059
   Haymart MR, 2011, JAMA-J AM MED ASSOC, V306, P721, DOI 10.1001/jama.2011.1139
   Hayn MH, 2010, EUR UROL, V58, P197, DOI 10.1016/j.eururo.2010.04.024
   Hellmann MD, 2019, NEW ENGL J MED, V381, P2020, DOI 10.1056/NEJMoa1910231
   HENSON DE, 1995, CANCER-AM CANCER SOC, V76, P1687, DOI 10.1002/1097-0142(19951115)76:10<1687::AID-CNCR2820761002>3.0.CO;2-I
   Heo J, 2014, SURG ENDOSC, V28, P3435, DOI 10.1007/s00464-014-3618-3
   Her S, 2017, ADV DRUG DELIVER REV, V109, P84, DOI 10.1016/j.addr.2015.12.012
   Higgins KA, 2017, INT J RADIAT ONCOL, V97, P128, DOI 10.1016/j.ijrobp.2016.10.001
   Hiom SC, 2015, BRIT J CANCER, V112, pS1, DOI 10.1038/bjc.2015.23
   Hirsch FR, 2017, LANCET, V389, P299, DOI 10.1016/S0140-6736(16)30958-8
   Hodi FS, 2010, NEW ENGL J MED, V363, P711, DOI 10.1056/NEJMoa1003466
   Hofmann S, 2019, J CLIN MED, V8, DOI 10.3390/jcm8020200
   Horwich A, 2014, BRIT J CANCER, V110, P256, DOI 10.1038/bjc.2013.551
   Hosseini H, 2016, NATURE, V540, P552, DOI 10.1038/nature20785
   Hu X, 2019, ONCOLOGIST, V24, P803, DOI 10.1634/theoncologist.2017-0600
   Hu Z, 2019, NAT GENET, V51, P1113, DOI 10.1038/s41588-019-0423-x
   Hucks G, 2019, BLOOD CANCER J, V9, DOI 10.1038/s41408-018-0164-6
   Hunger SP, 2015, NEW ENGL J MED, V373, P1541, DOI 10.1056/NEJMra1400972
   Jahangeer S, 2013, CANCER TREAT REV, V39, P862, DOI 10.1016/j.ctrv.2013.03.007
   Jermann M., 2015, INT J PART THER, V2, P50, DOI 10.14338/IJPT-15-00013
   Jimenez RB, 2019, J CLIN ONCOL, V37, P2778, DOI 10.1200/JCO.18.02366
   Johnson DH, 2004, J CLIN ONCOL, V22, P2184, DOI 10.1200/JCO.2004.11.022
   Kaidar-Person O, 2017, ANTI-CANCER DRUG, V28, P669, DOI 10.1097/CAD.0000000000000497
   Kamat AM, 2016, LANCET, V388, P2796, DOI 10.1016/S0140-6736(16)30512-8
   Kamisawa T, 2016, LANCET, V388, P73, DOI 10.1016/S0140-6736(16)00141-0
   Keall PJ, 2018, INT J RADIAT ONCOL, V102, P922, DOI 10.1016/j.ijrobp.2018.04.016
   Kim JK, 2012, PHYS MED BIOL, V57, DOI 10.1088/0031-9155/57/24/8309
   Kim SR, 2012, EUR J RADIOL, V81, P395, DOI 10.1016/j.ejrad.2010.12.091
   Knudsen AB, 2016, JAMA-J AM MED ASSOC, V315, P2595, DOI 10.1001/jama.2016.6828
   Kojima T, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.2
   Kokurewicz K, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-46630-w
   Kotb S, 2016, THERANOSTICS, V6, P418, DOI 10.7150/thno.14018
   Kroemer G, 2009, CELL DEATH DIFFER, V16, P3, DOI 10.1038/cdd.2008.150
   KURNICK JE, 1972, ARCH INTERN MED, V130, P790, DOI 10.1001/archinte.130.5.790
   Lai ECH, 2013, AM J SURG, V205, P697, DOI 10.1016/j.amjsurg.2012.08.015
   Landy R, 2016, BRIT J CANCER, V115, P1140, DOI 10.1038/bjc.2016.290
   Lara PN, 2011, J CLIN ONCOL, V29, P2965, DOI 10.1200/JCO.2011.35.0660
   Larkin J, 2019, NEW ENGL J MED, V381, P1535, DOI 10.1056/NEJMoa1910836
   Lawrie TA, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004706.pub5
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lencioni R, 2013, SEMIN INTERVENT RAD, V30, P3, DOI 10.1055/s-0033-1333648
   Li JJ, 2011, RADIOLOGY, V260, P799, DOI 10.1148/radiol.11102120
   Litwin MS, 2017, JAMA-J AM MED ASSOC, V317, P2532, DOI 10.1001/jama.2017.7248
   Liu C, 2019, NAT BIOMED ENG, V3, P183, DOI 10.1038/s41551-018-0343-6
   Liu YW, 2017, ONCOTARGET, V8, P55204, DOI 10.18632/oncotarget.19339
   Lönn S, 2010, CANCER EPIDEM BIOMAR, V19, P464, DOI 10.1158/1055-9965.EPI-09-0892
   Logghe P, 2016, INT BRAZ J UROL, V42, P906, DOI 10.1590/S1677-5538.IBJU.2015.0542
   Lowenstein LM, 2019, NAT REV CLIN ONCOL, V16, P168, DOI 10.1038/s41571-018-0116-x
   Lu GM, 2018, CANCER MANAG RES, V10, P4899, DOI 10.2147/CMAR.S173099
   Lux F, 2018, BRIT J RADIOL, V92, DOI 10.1259/bjr.20180365
   Ma KW, 2017, J HEPATOCELL CARCINO, V4, P1, DOI 10.2147/JHC.S96085
   Máca J, 2018, THER CLIN RISK MANAG, V14, P999, DOI 10.2147/TCRM.S153359
   Macarulla T, 2019, J CLIN ONCOL, V37, P230, DOI 10.1200/JCO.18.00089
   Makin G, 2000, CELL TISSUE RES, V301, P143, DOI 10.1007/s004419900160
   Makkar N, 2018, CANCER MED-US, V7, P4773, DOI 10.1002/cam4.1706
   Manjelievskaia J, 2017, JAMA SURG, V152, P452, DOI 10.1001/jamasurg.2016.5050
   Marcheselli R, 2015, J BREAST CANCER, V18, P378, DOI 10.4048/jbc.2015.18.4.378
   Mariotto Angela B, 2014, J Natl Cancer Inst Monogr, V2014, P145, DOI 10.1093/jncimonographs/lgu024
   Martin PJ, 2010, J CLIN ONCOL, V28, P1011, DOI 10.1200/JCO.2009.25.6693
   Mateos MK, 2013, PEDIATR BLOOD CANCER, V60, P1520, DOI 10.1002/pbc.24559
   Mehta S R, 2010, Med J Armed Forces India, V66, P158, DOI 10.1016/S0377-1237(10)80132-7
   Melamed A, 2018, NEW ENGL J MED, V379, P1905, DOI 10.1056/NEJMoa1804923
   Menon SP, 2008, CANCER-AM CANCER SOC, V112, P1522, DOI 10.1002/cncr.23336
   Michalski JM, 2010, INT J RADIAT ONCOL, V76, pS123, DOI 10.1016/j.ijrobp.2009.03.078
   Milano MT, 2007, SEMIN RADIAT ONCOL, V17, P131, DOI 10.1016/j.semradonc.2006.11.009
   Miller K, 2013, J ONCOL PRACT, V9, pE136, DOI 10.1200/JOP.2012.000806
   Mohamad O, 2019, LANCET ONCOL, V20, P674, DOI 10.1016/S1470-2045(18)30931-8
   Mohan R, 2017, ADV DRUG DELIVER REV, V109, P26, DOI 10.1016/j.addr.2016.11.006
   Mok TS, 2017, NEW ENGL J MED, V376, P629, DOI 10.1056/NEJMoa1612674
   Mok TS, 2009, NEW ENGL J MED, V361, P947, DOI 10.1056/NEJMoa0810699
   Mok TSK, 2019, LANCET, V393, P1819, DOI 10.1016/S0140-6736(18)32409-7
   Molenaar RJ, 2018, J CLIN ONCOL, V36, P1831, DOI 10.1200/JCO.2017.75.0232
   Monk BJ, 2016, J CLIN ONCOL, V34, P2279, DOI 10.1200/JCO.2015.65.8153
   Morgan G, 2004, CLIN ONCOL-UK, V16, P549, DOI 10.1016/j.clon.2004.06.007
   Morice P, 2016, LANCET, V387, P1094, DOI 10.1016/S0140-6736(15)00130-0
   Morschhauser F, 2008, J CLIN ONCOL, V26, P5156, DOI 10.1200/JCO.2008.17.2015
   Mulier S, 2002, BRIT J SURG, V89, P1206, DOI 10.1046/j.1365-2168.2002.02168.x
   Murray I, 2017, EUR J NUCL MED MOL I, V44, P1832, DOI 10.1007/s00259-017-3744-y
   Nabhan C, 2014, JAMA-J AM MED ASSOC, V312, P2265, DOI 10.1001/jama.2014.14553
   Naci H, 2019, BMJ-BRIT MED J, V366, DOI 10.1136/bmj.l5221
   Nelson HD, 2009, ANN INTERN MED, V151, P727, DOI 10.7326/0003-4819-151-10-200911170-00009
   Newhauser WD, 2016, FRONT ONCOL, V6, DOI 10.3389/fonc.2016.00013
   Ni Y, 2005, ABDOM IMAGING, V30, P381, DOI 10.1007/s00261-004-0253-9
   Nurgali K, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00245
   Oba K, 2013, JNCI-J NATL CANCER I, V105, P1600, DOI 10.1093/jnci/djt270
   Otto SJ, 2003, LANCET, V361, P1411, DOI 10.1016/S0140-6736(03)13132-7
   Otto SJ, 2012, CANCER EPIDEM BIOMAR, V21, P66, DOI 10.1158/1055-9965.EPI-11-0476
   Paik S, 2007, ONCOLOGIST, V12, P631, DOI 10.1634/theoncologist.12-6-631
   Palm Å, 2007, ACTA ONCOL, V46, P462, DOI 10.1080/02841860701218626
   Palma D, 2019, INT J RADIAT ONCOL, V103, P788, DOI 10.1016/j.ijrobp.2018.10.008
   Pan HC, 2017, NEW ENGL J MED, V377, P1836, DOI 10.1056/NEJMoa1701830
   Pan HY, 2018, J CLIN ONCOL, V36, P1823, DOI 10.1200/JCO.2017.75.5371
   Pantel K, 2019, NAT REV CLIN ONCOL, V16, P409, DOI 10.1038/s41571-019-0187-3
   Pazdur R, 2008, ONCOLOGIST, V13, P19, DOI 10.1634/theoncologist.13-S2-19
   Petrelli A, 2008, CURR MED CHEM, V15, P422
   PICCI P, 1985, CANCER-AM CANCER SOC, V56, P1515, DOI 10.1002/1097-0142(19851001)56:7<1515::AID-CNCR2820560707>3.0.CO;2-6
   Pickhardt PJ, 2013, LANCET ONCOL, V14, P711, DOI 10.1016/S1470-2045(13)70216-X
   Pinato DJ, 2019, JAMA ONCOL, V5, P1774, DOI 10.1001/jamaoncol.2019.2785
   Porter PL, 1999, J NATL CANCER I, V91, P2020, DOI 10.1093/jnci/91.23.2020
   Pouliot J., 2010, Leibel and Phillips Textbook of Radiation Oncology, Vthird, P224, DOI [10.1016/B978-1-4160-5897-7.00013-5, DOI 10.1016/B978-1-4160-5897-7.00013-5]
   Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6
   Pyo JH, 2016, AM J GASTROENTEROL, V111, P240, DOI 10.1038/ajg.2015.427
   Qin S, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0718-5
   Qin SK, 2013, J CLIN ONCOL, V31, P3501, DOI 10.1200/JCO.2012.44.5643
   Ramalingam S, 2008, ONCOLOGIST, V13, P5, DOI 10.1634/theoncologist.13-S1-5
   Ramirez PT, 2018, NEW ENGL J MED, V379, P1895, DOI 10.1056/NEJMoa1806395
   Ramroth J, 2016, INT J RADIAT ONCOL, V96, P736, DOI 10.1016/j.ijrobp.2016.07.022
   REUBI JC, 1993, J CLIN ENDOCR METAB, V77, P1323, DOI 10.1210/jc.77.5.1323
   Ribeiro Maria Sylvia, 2015, Gastroenterol Hepatol (N Y), V11, P445
   Robert C, 2018, J CLIN ONCOL, V36, P1668, DOI 10.1200/JCO.2017.75.6270
   Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
   Rolleman EJ, 2007, EUR J NUCL MED MOL I, V34, P1854, DOI 10.1007/s00259-007-0457-7
   Rosenzweig KE, 2017, J CLIN ONCOL, V35, P6, DOI 10.1200/JCO.2016.69.9678
   Rudin CM, 2011, J CLIN ONCOL, V29, P1075, DOI 10.1200/JCO.2010.32.5944
   Sänger N, 2011, INT J CANCER, V129, P2522, DOI 10.1002/ijc.25895
   Samimi Mozhgan Aalam, 2014, Int J Hematol Oncol Stem Cell Res, V8, P5
   Santomasso Bianca, 2019, Am Soc Clin Oncol Educ Book, V39, P433, DOI 10.1200/EDBK_238691
   Saunders NA, 2012, EMBO MOL MED, V4, P675, DOI 10.1002/emmm.201101131
   Scagliotti GV, 2008, J CLIN ONCOL, V26, P3543, DOI 10.1200/JCO.2007.15.0375
   Schadendorf D, 2018, LANCET, V392, P971, DOI 10.1016/S0140-6736(18)31559-9
   Schadendorf D, 2015, J CLIN ONCOL, V33, P1889, DOI 10.1200/JCO.2014.56.2736
   Schiffman Joshua D, 2015, Am Soc Clin Oncol Educ Book, P57, DOI 10.14694/EdBook_AM.2015.35.57
   Schoen RE, 2012, NEW ENGL J MED, V366, P2345, DOI 10.1056/NEJMoa1114635
   Seam P, 2009, CANCER J, V15, P150, DOI 10.1097/PPO.0b013e3181a27018
   SELLERS AH, 1971, CAN MED ASSOC J, V105, P836
   Seymour L, 2017, LANCET ONCOL, V18, pE143, DOI 10.1016/S1470-2045(17)30074-8
   Shanbhag S, 2018, CA-CANCER J CLIN, V68, P116, DOI 10.3322/caac.21438
   Sheetz KH, 2019, JAMA-J AM MED ASSOC, V321, P1971, DOI 10.1001/jama.2019.3736
   Shih YCT, 2015, J CLIN ONCOL, V33, P2190, DOI 10.1200/JCO.2014.58.2320
   Shmatov ML, 2017, PHYS PART NUCLEI LET, V14, P533, DOI 10.1134/S1547477117030153
   Shridhar R, 2015, CA-CANCER J CLIN, V65, P139, DOI 10.3322/caac.21259
   Siegel RL, 2015, CA-CANCER J CLIN, V65, P5, DOI 10.3322/caac.21254
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI DOI 10.3322/CAAC.21442
   Sieghart W, 2015, J HEPATOL, V62, P1187, DOI 10.1016/j.jhep.2015.02.010
   Siu AL, 2016, ANN INTERN MED, V164, P279, DOI 10.7326/M15-2886
   Smith JJ, 2015, J CLIN ONCOL, V33, P1797, DOI 10.1200/JCO.2014.60.1054
   Smyth EC, 2017, NAT REV DIS PRIMERS, V3, DOI 10.1038/nrdp.2017.48
   Soda M, 2007, NATURE, V448, P561, DOI 10.1038/nature05945
   Solomon BJ, 2014, NEW ENGL J MED, V371, P2167, DOI [10.1056/NEJMoa1408440, 10.1056/NEJMx150034]
   Spencer KL, 2019, EUR RESPIR J, V53, DOI 10.1183/13993003.01568-2018
   Stacey R, 2014, THER ADV CHRONIC DIS, V5, P15, DOI 10.1177/2040622313510730
   Strecker TE, 2015, CANCER LETT, V369, P229, DOI 10.1016/j.canlet.2015.08.021
   Strobel O, 2019, LANCET GASTROENTEROL, V4, P186, DOI 10.1016/S2468-1253(19)30006-8
   Sullivan R, 2015, LANCET ONCOL, V16, P1193, DOI 10.1016/S1470-2045(15)00223-5
   Sun TT, 2018, LEUKEMIA LYMPHOMA, V59, P49, DOI 10.1080/10428194.2017.1335398
   Surveillance Epidemiology and End Results (SEER) Program, 1969, SURV EP END RES SEER
   Sutton P, 2015, LANCET, V385, P95
   Takagi T, 2016, BJU INT, V117, pE52, DOI 10.1111/bju.13200
   Talenfeld AD, 2018, ANN INTERN MED, V169, P69, DOI 10.7326/M17-0585
   Teng CJ, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv314
   Terwilliger T, 2017, BLOOD CANCER J, V7, DOI 10.1038/bcj.2017.53
   Teunissen JJM, 2004, J CLIN ONCOL, V22, P2724, DOI 10.1200/JCO.2004.10.016
   Thomas J, 2018, INT J RADIAT ONCOL, V100, P1133, DOI 10.1016/j.ijrobp.2017.10.015
   Thompson IM, 2004, NEW ENGL J MED, V350, P2239, DOI 10.1056/NEJMoa031918
   Timmerman R, 2006, J CLIN ONCOL, V24, P4833, DOI 10.1200/JCO.2006.07.5937
   Tohme S, 2017, CANCER RES, V77, P1548, DOI 10.1158/0008-5472.CAN-16-1536
   Trad D, 2017, PRESSE MED, V46, P1000, DOI 10.1016/j.lpm.2017.09.025
   Trakarnsanga A, 2012, WORLD J GASTROENTERO, V18, P5521, DOI 10.3748/wjg.v18.i39.5521
   Turkington RC, 2019, GUT, V68, P1918, DOI 10.1136/gutjnl-2018-317624
   Uedo N, 2012, ANN GASTROENTEROL, V25, P281
   Van Cutsem E, 2016, LANCET, V388, P2654, DOI 10.1016/S0140-6736(16)30354-3
   van Hilst J, 2019, LANCET GASTROENTEROL, V4, P199, DOI 10.1016/S2468-1253(19)30004-4
   Vapiwala N, 2013, NEW ENGL J MED, V369, P276, DOI 10.1056/NEJMe1304041
   Varzaneh FN, 2018, EUR RADIOL, V28, P3032, DOI 10.1007/s00330-017-5198-9
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Verry C, 2019, BMJ OPEN, V9, DOI 10.1136/bmjopen-2018-023591
   Villanueva A, 2019, NEW ENGL J MED, V380, P1450, DOI 10.1056/NEJMra1713263
   Vincent L, 2005, J CLIN INVEST, V115, P2992, DOI 10.1172/JCI24586
   Waks AG, 2019, JAMA-J AM MED ASSOC, V321, P288, DOI 10.1001/jama.2018.19323
   Wallis CJD, 2016, BMJ-BRIT MED J, V352, DOI 10.1136/bmj.i851
   Wang DY, 2018, JAMA ONCOL, V4, P1721, DOI 10.1001/jamaoncol.2018.3923
   Wang SC, 2017, J CANCER, V8, P1759, DOI 10.7150/jca.17349
   Wang SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-01571-0
   Wang SC, 2016, ONCOTARGET, V7, P59820, DOI 10.18632/oncotarget.10930
   Welch HG, 2016, NEW ENGL J MED, V375, P1438, DOI 10.1056/NEJMoa1600249
   Welch HG, 2010, J NATL CANCER I, V102, P605, DOI 10.1093/jnci/djq099
   Welch HG, 2005, BRIT MED J, V331, P481, DOI 10.1136/bmj.38516.649537.E0
   Werner RA, 2017, ONCOTARGET, V8, P7039, DOI 10.18632/oncotarget.12402
   Wissing MD, 2017, J CLIN ONCOL, V35, P1861, DOI 10.1200/JCO.2017.72.6497
   Wong JR, 2014, J CLIN ONCOL, V32, P3284, DOI 10.1200/JCO.2013.54.7844
   Xu RH, 2017, NAT MATER, V16, P1155, DOI [10.1038/NMAT4997, 10.1038/nmat4997]
   Yoon GS, 2008, J UROLOGY, V179, P2203, DOI 10.1016/j.juro.2008.01.114
   Zarrin B, 2017, J RES MED SCI, V22, DOI 10.4103/jrms.JRMS_182_17
   Zeng YK, 2012, ANN SURG, V256, P39, DOI 10.1097/SLA.0b013e3182583e2e
   Zhang JJ, 2018, J NUCL MED, V59, P1699, DOI 10.2967/jnumed.118.209841
   Zhong WZ, 2018, LANCET ONCOL, V19, P139, DOI 10.1016/S1470-2045(17)30729-5
   Zhou CG, 2016, ONCOL LETT, V11, P3813, DOI 10.3892/ol.2016.4436
   Zimmermann M, 2016, RADIAT ONCOL, V11, DOI 10.1186/s13014-016-0690-y
NR 292
TC 65
Z9 69
U1 0
U2 37
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD NOV
PY 2019
VL 11
IS 11
AR 1782
DI 10.3390/cancers11111782
PG 32
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JV3UB
UT WOS:000502290100164
PM 31766180
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Zhang, L
   Liu, FJ
AF Zhang, L.
   Liu, F. -J.
TI Expression of SLP-2 gene and CCBE1 are associated with prognosis of
   rectal cancer
SO EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES
LA English
DT Article
DE Rectal cancer; Lymphatic vessels; SLP-2; Ccbe1; Targeted therapy
ID STOMATIN-LIKE PROTEIN-2; OVEREXPRESSION
AB OBJECTIVE: This study aims to investigate the clinical significance of SLP-2 gene for patients with rectal cancer. To analyze the effect of CCBE1 (Collagen and calcium-binding EGF domain-containing protein 1) on rectal cancer tissue and lymph vessels of para-carcinoma tissue.
   MATERIALS AND METHODS: A total of 50 samples of rectal cancer tissues were enrolled in the experimental group, confirmed by pathological examination. 50 samples of para-carcinoma normal tissues were collected as control group. Protein expression of SLP-2 and CCBE1 was examined with immunohistochemical staining. mRNA expression of SLP-2 was examined with RT-PCR. Lymphatic vessel density (LVD) was evaluated with LYVE-1 immunohistochemical staining. Correlation analysis was performed to assess the relationship between patient survival data and clinical pathological features of rectal cancer.
   RESULTS: Immunohistochemical staining showed that, compared with the control group, a positive expression rate of SLP-2 in the experimental group was significantly higher (68.0% vs. 24.0%, p<0.05), and mRNA of SLP-2 was also significantly increased (p<0.05). Compared with the control group, protein expression of CCBE1 in the experimental group was significantly higher (p<0.05). Moreover, the expression level of SLP-2 was remarkably associated with TNM classification and lymphatic metastasis. Further analysis demonstrated that a positive expression of CCBE1 was associated with lymphatic metastasis, LVD and Ducks classification, and had a negative correlation with survival rate.
   CONCLUSIONS: Increased expression of SLP-2 promoted the formation of lymph vessels and exacerbated lymphatic metastasis of rectal cancer via up-regulating CCBE1. As a risk factor related to lymphatic metastasis, CCBE1 could be a novel biomarker for diagnosis and prognosis of rectal cancer.
C1 [Zhang, L.; Liu, F. -J.] Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan, Peoples R China.
   [Zhang, L.] Dezhou Peoples Hosp, Dept Anorectal Surg, Dezhou, Peoples R China.
C3 Shandong University
RP Liu, FJ (corresponding author), Shandong Univ, Dept Gen Surg, Qilu Hosp, Jinan, Peoples R China.
EM fengjunliuzxc@163.com
CR Barton CA, 2014, BRIT J CANCER, V102, P87
   Cao W, 2013, AM J CLIN PATHOL, V128, P430
   Cao WF, 2007, HUM PATHOL, V38, P747, DOI 10.1016/j.humpath.2006.11.004
   Cao WF, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063890
   Cao WF, 2011, PATHOLOGY, V43, P713, DOI 10.1097/PAT.0b013e32834c34ed
   Chang D, 2010, BIOMARKERS, V15, P104, DOI 10.3109/13547500903311910
   Christie DA, 2011, MOL CELL BIOL, V31, P3845, DOI 10.1128/MCB.05393-11
   ers M, 2013, NAT GENET, V41, P1272
   Ghose P, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1004063
   Hájek P, 2007, J BIOL CHEM, V282, P5670, DOI 10.1074/jbc.M608168200
   Harijan RK, 2016, PROTEINS, V84, P1075, DOI 10.1002/prot.25054
   Hogan BM, 2009, NAT GENET, V41, P396, DOI 10.1038/ng.321
   Lin ZF, 2012, EUR REV MED PHARMACO, V16, P1249
   Liu DN, 2013, GASTRIC CANCER, V16, P498, DOI 10.1007/s10120-013-0232-3
   Liu QZ, 2015, EUR REV MED PHARMACO, V19, P1803
   Mitsopoulos P, 2015, MOL CELL BIOL, V35, P1838, DOI 10.1128/MCB.00047-15
   Sprenger RR, 2004, ELECTROPHORESIS, V25, P156, DOI 10.1002/elps.200305675
   Wang WX, 2014, TUMOR BIOL, V35, P419, DOI 10.1007/s13277-013-1058-7
   Wang Y, 2015, BIOL CHEM, V27, P8062
   Wang Y., 2012, GREY SYSTEMS THEORY, V2, P2, DOI DOI 10.1371/J0URNAL.P0NE.0043436
   Zacharek A, 2011, CEREB BLOOD FLOW MET, V27, P1684
   Zhang I, 2013, CLIN CANER RES, V12, P1639
NR 22
TC 9
Z9 9
U1 1
U2 1
PU VERDUCI PUBLISHER
PI ROME
PA VIA GREGORIO VII, ROME, 186-00165, ITALY
SN 1128-3602
J9 EUR REV MED PHARMACO
JI Eur. Rev. Med. Pharmacol. Sci.
PD MAR
PY 2017
VL 21
IS 6
BP 1214
EP 1218
PG 5
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA ET0CM
UT WOS:000399929300006
PM 28387911
DA 2025-01-04
ER

PT J
AU Gan, Y
   Hao, Q
   Han, T
   Tong, J
   Yan, QY
   Zhong, HG
   Gao, B
   Li, YA
   Xuan, ZS
   Li, PF
   Yao, LT
   Xu, YY
   Jiang, YZ
   Shao, ZM
   Deng, J
   Chen, JX
   Zhou, X
AF Gan, Yu
   Hao, Qian
   Han, Tao
   Tong, Jing
   Yan, Qingya
   Zhong, Hongguang
   Gao, Bo
   Li, Yanan
   Xuan, Zhisheng
   Li, Pengfei
   Yao, Litong
   Xu, Yingying
   Jiang, Yi-Zhou
   Shao, Zhi-Ming
   Deng, Jun
   Chen, Jiaxiang
   Zhou, Xiang
TI Targeting BRIX1 via Engineered Exosomes Induces Nucleolar Stress to
   Suppress Cancer Progression
SO ADVANCED SCIENCE
LA English
DT Article
DE BRIX1; engineered exosomes; nucleolar stress; p53; ribosome biogenesis;
   targeted therapy
ID RNA-POLYMERASE I; RIBOSOMAL-PROTEINS; EXTRACELLULAR VESICLES; C-MYC;
   TUMOR SUPPRESSION; BIOGENESIS; L11; P53; INHIBITION; PES1
AB Elevated ribosome biogenesis correlates with the rapid growth and progression of cancer. Targeted blockade of ribosome biogenesis induces nucleolar stress, which preferentially leads to the elimination of malignant cells. In this study, it is reported that the nucleolar protein BRIX1 is a critical regulator for the homeostasis between ribosome biogenesis and p53 activation. BRIX1 facilitated the processing of pre-rRNA by supporting the formation of the PeBoW complex. In addition, BRIX1 prevented p53 activation in response to nucleolar stress by impairing the interactions between MDM2 and the ribosomal proteins, RPL5, and RPL11, thereby triggering the resistance of cancer cells to chemotherapy. Conversely, depletion of BRIX1 induced nucleolar stress, which in turn activated p53 through RPL5 and RPL11, consequently inhibiting the growth of tumors. Moreover, engineered exosomes are developed, which are surface-decorated with iRGD, a tumor-homing peptide, and loaded with siRNAs specific to BRIX1, for the treatment of cancer. iRGD-Exo-siBRIX1 significantly suppressed the growth of colorectal cancer and enhanced the efficacy of 5-FU chemotherapy in vivo. Overall, the study uncovers that BRIX1 functions as an oncoprotein to promote rRNA synthesis and dampen p53 activity, and also implies that targeted inhibition of BRIX1 via engineered exosomes can be a potent approach for cancer therapy.
C1 [Gan, Yu; Hao, Qian; Tong, Jing; Zhou, Xiang] Fudan Univ, Shanghai Canc Ctr, Shanghai 200032, Peoples R China.
   [Gan, Yu; Hao, Qian; Tong, Jing; Zhou, Xiang] Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.
   [Gan, Yu; Hao, Qian; Tong, Jing; Jiang, Yi-Zhou; Shao, Zhi-Ming; Zhou, Xiang] Fudan Univ, Shanghai Med Coll, Dept Oncol, Shanghai 200032, Peoples R China.
   [Han, Tao; Yan, Qingya] Xinxiang Key Lab Mol Neurol, Xinxiang 453003, Henan, Peoples R China.
   [Zhong, Hongguang; Deng, Jun] Nanchang Univ, Affiliated Hosp 1, Jiangxi Med Coll, Dept Oncol, Nanchang 330006, Jiangxi, Peoples R China.
   [Zhong, Hongguang; Deng, Jun] Jiangxi Key Lab Individual Canc Therapy, Nanchang 330006, Jiangxi, Peoples R China.
   [Gao, Bo; Li, Yanan; Xuan, Zhisheng] Advantest China Co Ltd, Shanghai 201210, Peoples R China.
   [Li, Pengfei] Shaanxi Univ Chinese Med, Lab Anim Ctr, Med Expt Ctr, Xianyang 712046, Peoples R China.
   [Yao, Litong; Xu, Yingying] China Med Univ, Hosp 1, Dept Breast Surg, Shenyang 110001, Liaoning, Peoples R China.
   [Jiang, Yi-Zhou; Shao, Zhi-Ming; Zhou, Xiang] Fudan Univ, Shanghai Canc Ctr, Dept Breast Surg, Key Lab Breast Canc Shanghai, R China, Shanghai 200032, Peoples R China.
   [Chen, Jiaxiang] Nanchang Univ, Jiangxi Med Coll, Sch Basic Med Sci, Dept Physiol, Nanchang 330006, Peoples R China.
   [Zhou, Xiang] Fudan Univ, Inst Biomed Sci, Shanghai Key Lab Med Epigenet, Int Colab Med Epigenet & Metab,Minist Sci & Techn, Shanghai 200032, Peoples R China.
C3 Fudan University; Fudan University; Fudan University; Nanchang
   University; Advantest Corporation; Shaanxi University of Chinese
   Medicine; China Medical University; Fudan University; Nanchang
   University; Fudan University
RP Zhou, X (corresponding author), Fudan Univ, Inst Biomed Sci, Shanghai 200032, Peoples R China.; Deng, J (corresponding author), Jiangxi Key Lab Individual Canc Therapy, Nanchang 330006, Jiangxi, Peoples R China.; Chen, JX (corresponding author), Nanchang Univ, Jiangxi Med Coll, Sch Basic Med Sci, Dept Physiol, Nanchang 330006, Peoples R China.
EM dengjun19871106@ncu.edu.cn; chenjiaxiang@ncu.edu.cn;
   xiangzhou@fudan.edu.cn
RI Peng-Fei, Li/JNS-7223-2023
OI Li, Pengfei/0000-0003-1334-8770
FU National Natural Science Foundation of China; Innovative Research Team
   of High-level Local University in Shanghai; Major Discipline Academic
   and Technical Leaders Training Program of Jiangxi Province
   [20204BCJ22031, jxsq2023201108, 338937]; Key Projects of Jiangxi
   Province [20232ACB206044]; Postdoctoral Fellowship Program of CPSF
   [GZC20230494];  [82273098];  [82072879];  [82173022];  [82171591]; 
   [82060278];  [82202869];  [82260491];  [82172891];  [82002731]
FX The authors thank the laboratory members for active and helpful
   discussion. Funding: This work was supported by the National Natural
   Science Foundation of China (82273098 and 82072879 to X.Z., 82173022 to
   Q.H., 82171591 and 82060278 to J.C., 82202869 and 82260491 to J.D.,
   82172891 and 82002731 to T.H.), the Innovative Research Team of
   High-level Local University in Shanghai, Major Discipline Academic and
   Technical Leaders Training Program of Jiangxi Province (20204BCJ22031 to
   J.C.) Jiangxi Province "Double Thousand Program" (jxsq2023201108 to
   J.D.), the Postdoctoral grant (338937 to J.D.), the Key Projects of
   Jiangxi Province (20232ACB206044 to J.D.), and the Postdoctoral
   Fellowship Program of CPSF (GZC20230494 to Y.G.).
CR Abbas T, 2009, NAT REV CANCER, V9, P400, DOI 10.1038/nrc2657
   Burger K, 2010, J BIOL CHEM, V285, P12416, DOI 10.1074/jbc.M109.074211
   Bursac S, 2012, P NATL ACAD SCI USA, V109, P20467, DOI 10.1073/pnas.1218535109
   Bywater MJ, 2012, CANCER CELL, V22, P51, DOI 10.1016/j.ccr.2012.05.019
   Challagundla KB, 2011, MOL CELL BIOL, V31, P4007, DOI 10.1128/MCB.05810-11
   Chen YJ, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.2026813118
   Chen Y, 2024, J CONTROL RELEASE, V366, P395, DOI 10.1016/j.jconrel.2023.12.058
   Chou TC, 2006, PHARMACOL REV, V58, P621, DOI 10.1124/pr.58.3.10
   Cui KS, 2022, ONCOGENE, V41, P5397, DOI 10.1038/s41388-022-02530-4
   Dai MS, 2004, J BIOL CHEM, V279, P44475, DOI 10.1074/jbc.M403722200
   Dai MS, 2007, EMBO J, V26, P3332, DOI 10.1038/sj.emboj.7601776
   Dalla Venezia N, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20051226
   de la C. J., 2018, CURR GENET, V64, P393
   de la Cruz J, 2015, ANNU REV BIOCHEM, V84, P93, DOI 10.1146/annurev-biochem-060614-033917
   Dong HZ, 2023, SCI CHINA LIFE SCI, V66, P2684, DOI 10.1007/s11427-023-2386-9
   Drygin D, 2011, CANCER RES, V71, P1418, DOI 10.1158/0008-5472.CAN-10-1728
   Elhamamsy AR, 2022, CANCER RES, V82, P2344, DOI 10.1158/0008-5472.CAN-21-4087
   Espinoza JA, 2024, NUCLEIC ACIDS RES, V52, P4151, DOI 10.1093/nar/gkae069
   FISHER CJ, 1994, BRIT J CANCER, V69, P26, DOI 10.1038/bjc.1994.4
   Gan Y, 2023, REDOX BIOL, V62, DOI 10.1016/j.redox.2023.102705
   Gong L, 2023, J CONTROL RELEASE, V364, P672, DOI 10.1016/j.jconrel.2023.11.013
   Grimm T, 2006, NUCLEIC ACIDS RES, V34, P3030, DOI 10.1093/nar/gkl378
   Han Q, 2021, THERANOSTICS, V11, P6526, DOI 10.7150/thno.53886
   Han T., 2024, J MOL CELL BIOL, P025
   Han T, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.821366
   Hao Q, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2393-4
   Hart G., 2023, ENCY CELL BIOL, V5, P57
   Hölzel M, 2005, J CELL BIOL, V170, P367, DOI 10.1083/jcb.200501141
   Jiang CH, 2024, J GENE MED, V26, DOI 10.1002/jgm.3632
   Kalluri R, 2023, CELL, V186, P1610, DOI 10.1016/j.cell.2023.03.010
   Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341
   Kara G, 2022, ADV DRUG DELIVER REV, V182, DOI 10.1016/j.addr.2022.114113
   Kaser A, 2001, BIOL CHEM, V382, P1637, DOI 10.1515/BC.2001.199
   Kim DS, 2019, MOL CELL, V75, P1270, DOI 10.1016/j.molcel.2019.06.020
   Lai CP, 2014, ACS NANO, V8, P483, DOI 10.1021/nn404945r
   Lapik YR, 2004, MOL CELL, V15, P17, DOI 10.1016/j.molcel.2004.05.020
   Liao JM, 2014, ONCOGENE, V33, P4916, DOI 10.1038/onc.2013.430
   Lohrum MAE, 2003, CANCER CELL, V3, P577, DOI 10.1016/S1535-6108(03)00134-X
   Macias E, 2010, CANCER CELL, V18, P231, DOI 10.1016/j.ccr.2010.08.007
   Montanaro L, 2008, AM J PATHOL, V173, P301, DOI 10.2353/ajpath.2008.070752
   Orsolic I, 2016, SEMIN CANCER BIOL, V37-38, P36, DOI 10.1016/j.semcancer.2015.12.004
   Peltonen K, 2014, CANCER CELL, V25, P77, DOI 10.1016/j.ccr.2013.12.009
   Pi FM, 2018, NAT NANOTECHNOL, V13, P82, DOI 10.1038/s41565-017-0012-z
   Qing OY, 2018, BIOMATERIALS, V178, P170, DOI 10.1016/j.biomaterials.2018.06.016
   Raposo G, 2023, EXTRACELL VESICLES C, V4, P240, DOI 10.20517/evcna.2023.18
   Rohrmoser M, 2007, MOL CELL BIOL, V27, P3682, DOI 10.1128/MCB.00172-07
   Sanij E, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-16393-4
   Setten RL, 2019, NAT REV DRUG DISCOV, V18, P421, DOI 10.1038/s41573-019-0017-4
   Shimoji K, 2012, NUCLEIC ACIDS RES, V40, P4574, DOI 10.1093/nar/gks057
   Sugahara KN, 2009, CANCER CELL, V16, P510, DOI 10.1016/j.ccr.2009.10.013
   Sun XX, 2007, J BIOL CHEM, V282, P8052, DOI 10.1074/jbc.M610621200
   Tafforeau L, 2013, MOL CELL, V51, P539, DOI 10.1016/j.molcel.2013.08.011
   Tian YH, 2014, BIOMATERIALS, V35, P2383, DOI 10.1016/j.biomaterials.2013.11.083
   van Riggelen J, 2010, NAT REV CANCER, V10, P301, DOI 10.1038/nrc2819
   Xiong C, 2024, SCI CHINA LIFE SCI, DOI 10.1007/s11427-023-2589-1
   Xu H, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14432
   Zhang M, 2016, ONCOTARGET, V7, P78255, DOI 10.18632/oncotarget.13126
   Zhang Q, 2014, ELIFE, V3, DOI 10.7554/eLife.03077
   Zhang YP, 2009, CANCER CELL, V16, P369, DOI 10.1016/j.ccr.2009.09.024
   Zhang YP, 2003, MOL CELL BIOL, V23, P8902, DOI 10.1128/MCB.23.23.8902-8912.2003
   Zheng Z, 2019, J CONTROL RELEASE, V311, P43, DOI 10.1016/j.jconrel.2019.08.021
   Zhou X, 2015, CELL DEATH DIFFER, V22, P755, DOI 10.1038/cdd.2014.167
   Zhou X, 2013, ONCOGENE, V32, P388, DOI 10.1038/onc.2012.63
   Zhou X, 2016, ELIFE, V5, DOI 10.7554/eLife.15099
   Zhou X, 2015, J MOL CELL BIOL, V7, P92, DOI 10.1093/jmcb/mjv014
   Zhou X, 2013, J BIOL CHEM, V288, DOI 10.1074/jbc.M112.445122
NR 66
TC 0
Z9 0
U1 10
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2198-3844
J9 ADV SCI
JI Adv. Sci.
PD DEC
PY 2024
VL 11
IS 47
DI 10.1002/advs.202407370
EA OCT 2024
PG 18
WC Chemistry, Multidisciplinary; Nanoscience & Nanotechnology; Materials
   Science, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA Q2N3Y
UT WOS:001344877800001
PM 39475053
OA gold
DA 2025-01-04
ER

PT S
AU Fanale, D
   Castiglia, M
   Bazan, V
   Russo, A
AF Fanale, Daniele
   Castiglia, Marta
   Bazan, Viviana
   Russo, Antonio
BE Slaby, O
   Calin, GA
TI Involvement of Non-coding RNAs in Chemo- and Radioresistance of
   Colorectal Cancer
SO NON-CODING RNAS IN COLORECTAL CANCER
SE Advances in Experimental Medicine and Biology
LA English
DT Article; Book Chapter
DE Chemoresistance; Chemotherapy; miRNAs; Non-coding RNA; Predictive
   biomarkers; Radioresistance; Radiotherapy; Targeted therapy; Therapy
   response
ID MODULATES MULTIDRUG-RESISTANCE; BINDING SITE POLYMORPHISM; ANTI-EGFR
   THERAPY; COLON-CANCER; STEM-CELLS; DRUG-RESISTANCE;
   MOLECULAR-MECHANISMS; POOR-PROGNOSIS; DNA-REPAIR; 5-FLUOROURACIL
   RESISTANCE
AB Despite recent progress in understanding the cancer signaling pathways and in developing new therapeutic strategies, however, the resistance of colorectal cancer (CRC) cells to chemo-and radiotherapy represents the main hurdle to the successful treatment, leading to tumor recurrence and, consequently, a poor prognosis. Therefore, overcoming drug and radiation resistance, enhancing drug and radiation sensitivity of CRC cells, and improving the effi cacy of chemo-and radiotherapy have an important signifi cance in the treatment of CRC. The identifi cation of new molecular biomarkers which can predict therapy response and prognosis is one of the most signifi cant aims in pharmacogenomics and cancer research.
   Recent studies showed that non-coding RNAs (ncRNAs), such as microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), may play important roles in the regulation of chemo-and radioresistance of CRC, by controlling several signaling pathways, including cell cycle, proliferation, apoptosis and DNA damage repair. Recent data have demonstrated that selective modulation of the ncRNA activity can improve the response to chemo-and radiotherapy, providing an innovative anti-tumor approach based on a ncRNA-related gene therapy. Therefore, ncRNAs could not only be useful as predictive and prognostic biomarkers but also serve as targets for the development of novel therapeutic strategies to overcome drug and radiation resistance in CRC. In this chapter, we discuss the involvement of ncRNAs in chemo-and radiotherapy resistance of CRC, highlighting the impact of these molecules in prediction of the treatment response and modification of the therapy, and describing possible intracellular pathways involved in these processes.
C1 [Fanale, Daniele; Castiglia, Marta; Bazan, Viviana; Russo, Antonio] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Via Vespro 129, I-90127 Palermo, Italy.
C3 University of Palermo
RP Russo, A (corresponding author), Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Via Vespro 129, I-90127 Palermo, Italy.
EM fandan@libero.it; martacastiglia@gmail.com; viviana.bazan@unipa.it;
   antonio.russo@usa.net
RI Fanale, Daniele/K-8630-2016; Castiglia, Marta/K-6569-2016
OI Castiglia, Marta/0000-0002-6299-7235
CR Ahsan A, 2009, CANCER RES, V69, P5108, DOI 10.1158/0008-5472.CAN-09-0466
   Akao Y, 2014, INT J MOL SCI, V15, P1392, DOI 10.3390/ijms15011392
   Akao Y, 2011, CANCER LETT, V300, P197, DOI 10.1016/j.canlet.2010.10.006
   Al-Ejeh F, 2010, ONCOGENE, V29, P6085, DOI 10.1038/onc.2010.407
   Amankwatia EB, 2015, BRIT J CANCER, V112, P1480, DOI 10.1038/bjc.2015.125
   [Anonymous], 2015, TUMOUR BIOL
   Arndt GM, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-374
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Begg AC, 2011, NAT REV CANCER, V11, P239, DOI 10.1038/nrc3007
   Bitarte N, 2011, STEM CELLS, V29, P1661, DOI 10.1002/stem.741
   Boni V, 2011, PHARMACOGENOMICS J, V11, P429, DOI 10.1038/tpj.2010.58
   Boni V, 2010, MOL CANCER THER, V9, P2265, DOI 10.1158/1535-7163.MCT-10-0061
   Borralho PM, 2009, FEBS J, V276, P6689, DOI 10.1111/j.1742-4658.2009.07383.x
   Braendengen M, 2008, J CLIN ONCOL, V26, P3687, DOI 10.1200/JCO.2007.15.3858
   Bronte G, 2015, ONCOTARGET, V6, P24780, DOI 10.18632/oncotarget.4959
   Bronte G, 2014, EXPERT OPIN BIOL TH, V14, P743, DOI 10.1517/14712598.2014.902926
   Burnet Neil G, 2004, Cancer Imaging, V4, P153, DOI 10.1102/1470-7330.2004.0054
   Burotto M, 2012, COLORECTAL CANCER, V1, P433, DOI [10.2217/crc.12.52, 10.2217/CRC.12.52]
   Calascibetta A, 2010, J NUCLEIC ACIDS, V2010, DOI 10.4061/2010/306754
   Cappuzzo F, 2014, CLIN COLORECTAL CANC, V13, P37, DOI 10.1016/j.clcc.2013.11.006
   Caruso S, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.33
   Chai HJ, 2011, ACTA BIOCH BIOPH SIN, V43, P217, DOI 10.1093/abbs/gmq125
   Chaney SG, 2005, CRIT REV ONCOL HEMAT, V53, P3, DOI 10.1016/j.critrevonc.2004.08.008
   Chen Y, 2012, INT J BIOL MARKER, V27, P203, DOI 10.5301/JBM.2012.9584
   Coppedè F, 2014, CANCER LETT, V342, P238, DOI 10.1016/j.canlet.2011.12.030
   Corsini LR, 2012, EXPERT OPIN THER TAR, V16, pS103, DOI 10.1517/14728222.2011.650632
   Crea F, 2011, DRUG RESIST UPDATE, V14, P280, DOI 10.1016/j.drup.2011.08.001
   Crea F, 2009, MOL CANCER THER, V8, P1964, DOI 10.1158/1535-7163.MCT-09-0027
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Dalhus B, 2009, FEMS MICROBIOL REV, V33, P1044, DOI 10.1111/j.1574-6976.2009.00188.x
   De Mattia E, 2015, DRUG RESIST UPDATE, V20, P39, DOI 10.1016/j.drup.2015.05.003
   Deng J, 2014, BIOCHEM BIOPH RES CO, V443, P789, DOI 10.1016/j.bbrc.2013.11.064
   Diaz T, 2014, J SURG ONCOL, V109, P676, DOI 10.1002/jso.23572
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Dong YJ, 2013, MOL CANCER RES, V11, P1051, DOI 10.1158/1541-7786.MCR-13-0061
   Donzelli Sara, 2014, Mol Cell Ther, V2, P16
   Edwards BK, 2010, CANCER-AM CANCER SOC, V116, P544, DOI 10.1002/cncr.24760
   Faivre S, 2003, BIOCHEM PHARMACOL, V66, P225, DOI 10.1016/S0006-2952(03)00260-0
   Faltejskova P, 2012, INT J COLORECTAL DIS, V27, P1401, DOI 10.1007/s00384-012-1461-3
   de Mattos SF, 2008, MOL CANCER THER, V7, P3237, DOI 10.1158/1535-7163.MCT-08-0398
   Findlay VJ, 2014, MOL CANCER THER, V13, P2713, DOI 10.1158/1535-7163.MCT-14-0207
   Gill S, 2004, J CLIN ONCOL, V22, P1797, DOI 10.1200/JCO.2004.09.059
   Grothey A, 2012, THER ADV MED ONCOL, V4, P301, DOI 10.1177/1758834012454464
   Grothey A, 2009, NAT REV CLIN ONCOL, V6, P507, DOI 10.1038/nrclinonc.2009.110
   Guo ST, 2013, ONCOGENE, V32, P1910, DOI 10.1038/onc.2012.214
   Hansen TF, 2015, BRIT J CANCER, V112, P624, DOI 10.1038/bjc.2014.652
   Hansen TF, 2013, BRIT J CANCER, V109, P1243, DOI 10.1038/bjc.2013.448
   Hansen TF, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-83
   He JX, 2014, CELL BIOCHEM BIOPHYS, V70, P1343, DOI 10.1007/s12013-014-0062-x
   Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011
   Huang TZ, 2013, CHIN J CANCER, V32, P582, DOI 10.5732/cjc.013.10170
   Humeniuk R, 2009, MOL CANCER THER, V8, P1037, DOI 10.1158/1535-7163.MCT-08-0716
   Hummel R, 2010, EUR J CANCER, V46, P298, DOI 10.1016/j.ejca.2009.10.027
   Joaquin M, 2003, CELL MOL LIFE SCI, V60, P2389, DOI 10.1007/s00018-003-3037-4
   Karaayvaz M, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.193
   Kim JG, 2013, INT J MOL SCI, V14, P15059, DOI 10.3390/ijms140715059
   Kinsella TJ, 2009, CLIN CANCER RES, V15, P1853, DOI 10.1158/1078-0432.CCR-08-1307
   Kitade Y, 2010, J PHARMACOL SCI, V114, P276, DOI 10.1254/jphs.10R12FM
   Koopman M, 2009, EUR J CANCER, V45, P1999, DOI 10.1016/j.ejca.2009.04.017
   Kurokawa K, 2012, J GASTROENTEROL, V47, P883, DOI 10.1007/s00535-012-0547-6
   Lee H, 2014, MOL CELLS, V37, P540, DOI 10.14348/molcells.2014.0151
   Li J, 2010, EUR J CANCER, V46, P1900, DOI 10.1016/j.ejca.2010.02.021
   Li T, 2015, ONCOL REP, V33, P607, DOI 10.3892/or.2014.3646
   Li XY, 2015, MOL MED REP, V11, P577, DOI 10.3892/mmr.2014.2726
   Lieu CH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0077117
   Liu RL, 2015, TUMOR BIOL, V36, P5011, DOI 10.1007/s13277-015-3152-5
   Lombardi L, 2010, CANCER TREAT REV, V36, pS34, DOI 10.1016/S0305-7372(10)70018-9
   Longley DB, 2006, BBA-REV CANCER, V1766, P184, DOI 10.1016/j.bbcan.2006.08.001
   Longley DB, 2005, J PATHOL, V205, P275, DOI 10.1002/path.1706
   Luo XY, 2011, CANCER EPIDEM BIOMAR, V20, P1272, DOI 10.1158/1055-9965.EPI-11-0035
   Ma LN, 2013, RNA BIOL, V10, P925, DOI 10.4161/rna.24604
   Ma WH, 2015, ONCOTARGET, V6, P15984, DOI 10.18632/oncotarget.3762
   Magrini R, 2002, INT J CANCER, V101, P23, DOI 10.1002/ijc.10565
   Marin JJG, 2012, DRUG METAB REV, V44, P148, DOI 10.3109/03602532.2011.638303
   Martin LP, 2008, CLIN CANCER RES, V14, P1291, DOI 10.1158/1078-0432.CCR-07-2238
   Mlcochova J, 2015, ONCOTARGET, V6, P38695, DOI 10.18632/oncotarget.5735
   Mlcochova J, 2013, J CANCER RES CLIN, V139, P1615, DOI 10.1007/s00432-013-1470-9
   Mullangi R, 2010, BIOMED CHROMATOGR, V24, P104, DOI 10.1002/bmc.1345
   Mussnich P, 2015, EXPERT OPIN THER TAR, V19, P1017, DOI 10.1517/14728222.2015.1057569
   Nakajima Go, 2006, Cancer Genomics & Proteomics, V3, P317
   Neelakandan K, 2012, CURR CANCER DRUG TAR, V12, P716, DOI 10.2174/156800912801784875
   Nie L, 2012, AM J TRANSL RES, V4, P127
   Nishida N, 2012, ANN SURG ONCOL, V19, P3065, DOI 10.1245/s10434-012-2246-1
   Okugawa Y, 2015, GASTROENTEROLOGY, V149, P1204, DOI 10.1053/j.gastro.2015.07.011
   Passiglia F, 2015, EXPERT OPIN BIOL TH, V15, P1553, DOI 10.1517/14712598.2015.1071348
   Prensner JR, 2011, CANCER DISCOV, V1, P391, DOI 10.1158/2159-8290.CD-11-0209
   Qian X, 2013, CELL CYCLE, V12, P1385, DOI 10.4161/cc.24477
   Ragusa M, 2010, MOL CANCER THER, V9, P3396, DOI 10.1158/1535-7163.MCT-10-0137
   Rajesh C, 2011, NUCLEIC ACIDS RES, V39, P132, DOI 10.1093/nar/gkq738
   Ramos P, 2015, ONCOGENE, V34, P3617, DOI 10.1038/onc.2014.314
   Rasmussen MH, 2013, MOL ONCOL, V7, P637, DOI 10.1016/j.molonc.2013.02.016
   Raza U, 2014, J MOL MED, V92, P321, DOI 10.1007/s00109-014-1129-2
   Rizzo S, 2010, CANCER TREAT REV, V36, pS56, DOI 10.1016/S0305-7372(10)70021-9
   Rodrigues AS, 2012, CURR PHARM BIOTECHNO, V13, P651
   Rolfo C, 2014, CURR PHARM BIOTECHNO, V15, P475, DOI 10.2174/1389201015666140519123219
   Rossi L, 2007, PHARMACOL RES, V56, P248, DOI 10.1016/j.phrs.2007.07.001
   Ruzzo A, 2012, ONCOLOGIST, V17, P823, DOI 10.1634/theoncologist.2012-0081
   Salendo J, 2013, RADIOTHER ONCOL, V108, P451, DOI 10.1016/j.radonc.2013.06.032
   Salton M, 2010, CELL CYCLE, V9, P1568, DOI 10.4161/cc.9.8.11298
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Sana J, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-103
   Saridaki Z, 2014, CLIN CANCER RES, V20, P4499, DOI 10.1158/1078-0432.CCR-14-0348
   Sawyers CL, 2008, NATURE, V452, P548, DOI 10.1038/nature06913
   Scarpati GD, 2012, INT J RADIAT ONCOL, V83, P1113, DOI 10.1016/j.ijrobp.2011.09.030
   Schimanski CC, 2009, WORLD J GASTROENTERO, V15, P2089, DOI 10.3748/wjg.15.2089
   Seetharam RN, 2009, ECANCERMEDICALSCIENC, V3, DOI 10.3332/ecancer.2009.153
   Seiwert TY, 2007, NAT CLIN PRACT ONCOL, V4, P86, DOI 10.1038/ncponc0714
   Senfter D, 2015, HUM MOL GENET, V24, P3689, DOI 10.1093/hmg/ddv113
   Sengupta S, 2005, NAT REV MOL CELL BIO, V6, P44, DOI 10.1038/nrm1546
   Shang JL, 2014, J CELL BIOCHEM, V115, P772, DOI 10.1002/jcb.24721
   Siemens H, 2013, ONCOTARGET, V4, P1399, DOI 10.18632/oncotarget.1202
   Sierra JR, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-75
   Skvortsova I, 2015, SEMIN CANCER BIOL, V35, P39, DOI 10.1016/j.semcancer.2015.09.009
   Smits KM, 2011, CLIN CANCER RES, V17, P7723, DOI 10.1158/1078-0432.CCR-11-0990
   Song B, 2009, ONCOGENE, V28, P4065, DOI 10.1038/onc.2009.274
   Song B, 2010, MOL CANCER, V9, DOI 10.1186/1476-4598-9-96
   Song B, 2008, CLIN CANCER RES, V14, P8080, DOI 10.1158/1078-0432.CCR-08-1422
   Stiegelbauer V, 2014, WORLD J GASTROENTERO, V20, P11727, DOI 10.3748/wjg.v20.i33.11727
   Suto T, 2015, CARCINOGENESIS, V36, P338, DOI 10.1093/carcin/bgu242
   Takahashi M, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046684
   Tanaka S, 2015, BIOL PHARM BULL, V38, P435, DOI 10.1248/bpb.b14-00695
   Tanei T, 2009, CLIN CANCER RES, V15, P4234, DOI 10.1158/1078-0432.CCR-08-1479
   Tichy ED, 2008, EXP CELL RES, V314, P1929, DOI 10.1016/j.yexcr.2008.02.007
   To KKW, 2015, EXP CELL RES, V338, P222, DOI 10.1016/j.yexcr.2015.09.011
   Toden S, 2015, CARCINOGENESIS, V36, P355, DOI 10.1093/carcin/bgv006
   Tokarz P, 2012, ACTA BIOCHIM POL, V59, P467
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Valencia CA, 2007, BIOCHEM BIOPH RES CO, V364, P495, DOI 10.1016/j.bbrc.2007.10.018
   Valeri N, 2010, P NATL ACAD SCI USA, V107, P21098, DOI 10.1073/pnas.1015541107
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Wang CJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-616
   Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047
   Wang LL, 2014, WORLD J GASTROENTERO, V20, P11340, DOI 10.3748/wjg.v20.i32.11340
   Watson RG, 2010, EUR J CANCER, V46, P3358, DOI 10.1016/j.ejca.2010.07.011
   Weickhardt AJ, 2015, BRIT J CANCER, V113, P37, DOI 10.1038/bjc.2015.209
   Wilson AJ, 2008, MOL BIOL CELL, V19, P4062, DOI 10.1091/mbc.E08-02-0139
   Xu K, 2013, MOL CARCINOGEN, V52, P70, DOI 10.1002/mc.21832
   Xu K, 2012, BIOCHEM J, V446, P291, DOI 10.1042/BJ20120386
   Xu K, 2012, EXP CELL RES, V318, P2168, DOI 10.1016/j.yexcr.2012.04.014
   Yang XD, 2015, AM J CANCER RES, V5, P545
   Yoon WH, 2015, ANN SURG TREAT RES, V88, P15, DOI 10.4174/astr.2015.88.1.15
   Yu YJ, 2013, TRANSL ONCOL, V6, P180, DOI 10.1593/tlo.12397
   Zhang HH, 2015, CANCER LETT, V356, P781, DOI 10.1016/j.canlet.2014.10.029
   Zhang JX, 2013, LANCET ONCOL, V14, P1295, DOI 10.1016/S1470-2045(13)70491-1
   Zhang JJ, 2011, CANCER-AM CANCER SOC, V117, P86, DOI 10.1002/cncr.25522
   Zhang L, 2013, CANCER RES, V73, P6435, DOI 10.1158/0008-5472.CAN-12-3308
   Zhang W, 2011, ANN ONCOL, V22, P104, DOI 10.1093/annonc/mdq315
   Zhang XC, 2013, WORLD J GASTRO ONCOL, V5, P12, DOI 10.4251/wjgo.v5.i2.12
   Zhang Y, 2015, J BIOL CHEM, V290, P6215, DOI 10.1074/jbc.M114.620252
   Zhang YQ, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120884
   Zheng HT, 2014, INT J CLIN EXP PATHO, V7, P3174
   Zheng L, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0592-z
   Zheng TS, 2010, INT J CANCER, V126, P2, DOI 10.1002/ijc.24782
   Zhou YF, 2014, MOL ONCOL, V8, P83, DOI 10.1016/j.molonc.2013.09.004
NR 154
TC 53
Z9 56
U1 1
U2 9
PU SPRINGER INTERNATIONAL PUBLISHING AG
PI CHAM
PA GEWERBESTRASSE 11, CHAM, CH-6330, SWITZERLAND
SN 0065-2598
EI 2214-8019
BN 978-3-319-42059-2; 978-3-319-42057-8
J9 ADV EXP MED BIOL
JI Adv.Exp.Med.Biol.
PY 2016
VL 937
BP 207
EP 228
DI 10.1007/978-3-319-42059-2_11
D2 10.1007/978-3-319-42059-2
PG 22
WC Oncology; Gastroenterology & Hepatology; Medicine, Research &
   Experimental
WE Book Citation Index – Science (BKCI-S); Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Gastroenterology & Hepatology; Research & Experimental
   Medicine
GA BH2LZ
UT WOS:000399043400012
PM 27573902
DA 2025-01-04
ER

PT J
AU Li, J
   Qi, CL
   Li, Q
   Liu, F
AF Li, Jian
   Qi, Cunling
   Li, Qing
   Liu, Fei
TI Construction and validation of an aging-related gene signature for
   prognosis prediction of patients with breast cancer
SO CANCER REPORTS
LA English
DT Article
DE aging; breast cancer; immune; nomogram; TCGA
ID EXPRESSION
AB Background Breast cancer (BC) is an aging-related disease. Aging-related genes (ARGs) participate in the initiation and development of lung and colon cancer, but the prognosis signature of ARGs in BC has not been clearly studied. Aims This study aimed to construct an ARGs signature to predict the prognosis of patients with breast cancer. Method Firstly, the expression data of ARGs from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) were collected. Then COX and least absolulute shrinkage and selection operator(LASSO) were performed to construct the ARGs prognostic signature. The correlation between the signature and immune cell infiltration, immunotherapeutic response and drug sensitivity were subsequently analysed. The TCGA nomogram was constructed by combining the signature with other clinical features, and was validated by using GEO database. Results After LASSO and COX regression analyses, a prognostic signature based on nine ARGs, namely, HSP90AA1, NFKB2, PLAU, PTK2, RECQL4, CLU, JAK2, MAP3K5, and S100B, was built by using the TCGA dataset. Moreover, this risk signature is closely related to immune cell infiltration, immunotherapeutic response, and responses to chemotherapy and targeted therapy. Subsequently, The calibration curve demonstrates that the nomogram agrees well with practical prediction results. The receiver operating characteristic curve and decision-making curve analysis demonstrate that ARG signature has the better prognosis diagnosis ability and clinical net benefits. Conclusions Therefore, the proposed ARG prognosis signature is a new prognosis molecular marker of patients with BC, and it can provide good references to individual clinical therapy.
C1 [Li, Jian; Liu, Fei] Qingdao Univ, Dept Breast Surg, Affiliated Taian City Cent Hosp, Tai An 271000, Shandong, Peoples R China.
   [Li, Jian] Liaocheng Peoples Hosp, Postdoctoral Workstn, Liaocheng, Shandong, Peoples R China.
   [Qi, Cunling] Qingdao Univ, Dept Lab, Affiliated Taian City Cent Hosp, Tai An, Shandong, Peoples R China.
   [Li, Qing] Qingdao Univ, Dept Pharm, Affiliated Taian City Cent Hosp, Tai An, Shandong, Peoples R China.
C3 Qingdao University; Qingdao University; Qingdao University
RP Liu, F (corresponding author), Qingdao Univ, Dept Breast Surg, Affiliated Taian City Cent Hosp, Tai An 271000, Shandong, Peoples R China.
EM liufei0228@163.com
RI Liu, Fei/AAM-3601-2021
OI Li, Jian/0000-0002-6633-4340
FU Tai'an Science and Technology Development Plan (Guiding Plan)
   [2018NS0222]
FX This study was support and funded by the Tai'an Science and Technology
   Development Plan (Guiding Plan) (No. 2018NS0222).
CR Adelman Emmalee R, 2019, Cancer Discov, V9, P1080, DOI 10.1158/2159-8290.CD-18-1474
   Anaganti S, 2011, CANCER LETT, V300, P215, DOI 10.1016/j.canlet.2010.10.008
   [Anonymous], 2014, Oxidative Medicine and Cellular Longevity, DOI DOI 10.1155/2014/376515
   Charmsaz S, 2017, BMC MED, V15, DOI 10.1186/s12916-017-0836-2
   Chatterjee B, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.00997
   Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12
   Chen WQ, 2015, CHIN J CANCER, V34, DOI 10.1186/s40880-015-0042-6
   Das J, 2015, BMC GENOMICS, V16, DOI 10.1186/s12864-015-1465-9
   de la Rosa J, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3268
   Du JX, 2020, GENE, V762, DOI 10.1016/j.gene.2020.144974
   Emadali A, 2013, EMBO MOL MED, V5, P1180, DOI 10.1002/emmm.201202034
   Fan ZY, 2019, CANCER LETT, V450, P132, DOI 10.1016/j.canlet.2019.02.040
   Fang HB, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069600
   Freedman RA, 2017, JAMA ONCOL, V3, P402, DOI 10.1001/jamaoncol.2016.3931
   Gade P, 2014, MOL CELL BIOL, V34, P4033, DOI 10.1128/MCB.00397-14
   Hansen M, 2018, NAT REV MOL CELL BIO, V19, P579, DOI 10.1038/s41580-018-0033-y
   Huang ZX, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3227-8
   Lv W., 2021, FRONT ONCOL, V16
   Lyu Z, 2020, INT J MOL MED, V46, P1321, DOI 10.3892/ijmm.2020.4692
   Mertins P, 2016, NATURE, V534, P55, DOI 10.1038/nature18003
   Rahem SM, 2020, EBIOMEDICINE, V61, DOI 10.1016/j.ebiom.2020.103047
   Redondo M, 2009, ADV CANCER RES, V105, P21, DOI 10.1016/S0065-230X(09)05002-7
   Tian ZL, 2020, CANCER MED-US, V9, P9471, DOI 10.1002/cam4.3523
   Wang YY, 2021, CELL DEATH DIS, V12, DOI 10.1038/s41419-021-03960-w
   Xiang X, 2018, ONCOTARGETS THER, V11, P3013, DOI 10.2147/OTT.S159432
   Xu Q., 2021, FRONT CELL DEV BIOL, V9, P1703
   Yen MC, 2018, INT J ONCOL, V52, P433, DOI 10.3892/ijo.2017.4226
   Yuan J, 2021, INT J WOMENS HEALTH, V13, P1053, DOI 10.2147/IJWH.S334756
   Yue TH, 2021, AGING-US, V13, P7330, DOI 10.18632/aging.202589
   Zhang D, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.596087
   Zhao B, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14652-y
NR 31
TC 1
Z9 1
U1 0
U2 8
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
EI 2573-8348
J9 CANCER REP-US
JI Cancer Rep.-US
PD MAR
PY 2023
VL 6
IS 3
DI 10.1002/cnr2.1741
EA NOV 2022
PG 15
WC Oncology
WE Emerging Sources Citation Index (ESCI)
SC Oncology
GA A2RN9
UT WOS:000877788400001
PM 36323529
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Yin, HF
   Xie, JY
   Jiang, P
   Jiang, X
   Duan, DY
   Qi, JH
   Luo, ZF
   Ma, CQ
   Hong, HH
AF Yin, Haofan
   Xie, Jinye
   Jiang, Ping
   Jiang, Xi
   Duan, Deyu
   Qi, Junhua
   Luo, Zhaofan
   Ma, Caiqi
   Hong, Honghai
TI Chiauranib selectively inhibits colorectal cancer with <i>KRAS</i>
   wild-type by modulation of ROS through activating the p53 signaling
   pathway
SO AMERICAN JOURNAL OF CANCER RESEARCH
LA English
DT Article
DE Colorectal cancer; chiauranib; ROS
ID PHOSPHORYLATION; STATISTICS; SURVIVAL; MUTATION
AB Colorectal cancer (CRC) is one of the top three most deadly cancers despite using chemotherapy based on oxaliplatin or irinotecan combined with targeted therapy. Chiauranib has recently been identified to be a promising anticancer candidate with impressive efficacy and safety. However, the role and molecular mechanisms of Chiauranib in the treatment of CRC remain to be elucidated. Our study shows that Chiauranib inhibits cell proliferation and induces apoptosis in KRAS wild-type CRC cells in a doseand time-dependent manner, but not mutation ones. Meanwhile, Chiauranib increases ROS production in KRAS wild-type CRC cells. Moreover, Chiauranib selectively suppresses KRAS wild-type CRC cells growth in vivo. Mechanistically, Chiauranib inhibits KRAS wild-type CRC cells by triggering ROS production via activating the p53 signaling pathway. Further, KRAS mutation CRC cells are resistant to Chiauranib by increasing Nrf2 to stably elevate the basal antioxidant program and thereby lower intracellular ROS induced by Chiauranib. Our findings provide the rationale for further clinical evaluation of Chiauranib as a therapeutic agent in treating KRAS wild-type CRC.
C1 [Yin, Haofan; Jiang, Xi; Duan, Deyu; Qi, Junhua; Luo, Zhaofan] Sun Yat Sen Univ, Affiliated Hosp 7, Dept Clin Lab, Shenzhen, Guangdong, Peoples R China.
   [Hong, Honghai] Guangzhou Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Guangdong, Peoples R China.
   [Xie, Jinye] Zhongshan Peoples Hosp, Dept Lab Med, Zhongshan, Guangdong, Peoples R China.
   [Ma, Caiqi] Sun Yat Sen Univ, Guangzhou Women & Childrens Med Ctr, Reprod Med Ctr, Guangzhou, Guangdong, Peoples R China.
   [Jiang, Ping] South China Univ Technol, Guangzhou People Hosp 1, Sch Med, Dept Clin Med Lab, Guangzhou, Guangdong, Peoples R China.
C3 Sun Yat Sen University; Guangzhou Medical University; Sun Yat Sen
   University; South China University of Technology
RP Luo, ZF (corresponding author), Sun Yat Sen Univ, Affiliated Hosp 7, Dept Clin Lab, Shenzhen, Guangdong, Peoples R China.; Hong, HH (corresponding author), Guangzhou Med Univ, Affiliated Hosp 3, Dept Clin Lab, Guangzhou, Guangdong, Peoples R China.; Ma, CQ (corresponding author), Sun Yat Sen Univ, Guangzhou Women & Childrens Med Ctr, Reprod Med Ctr, Guangzhou, Guangdong, Peoples R China.
EM luozhaofan@qq.com; phelix-ma@foxmail.com; gaolaosao@126.com
RI Yin, Haofan/LEM-2551-2024
OI Yin, Haofan/0000-0003-0800-4455
FU Guangzhou Institute of Pediatrics/Guangzhou Women and Children's Medical
   Center [YIP-2019-021]; National Nature Science Found-ation of China
   [81902693]; Natural Science Foundation of Guangdong Province
   [2018A030310298]; Educational Commission of Guangdong Province
   [2017KTSCX155]; Guangdong Basic and Applied Basic Research Foundation
   [2019A1515011318]; Shenzhen Science and Technology Innovation Commission
   Basic Research Foundation [JCYJ20180307150637015]
FX This study was supported by the fund from Guangzhou Institute of
   Pediatrics/Guangzhou Women and Children's Medical Center (YIP-2019-021).
   National Nature Science Found-ation of China (81902693); the Natural
   Science Foundation of Guangdong Province (2018A030310298); Educational
   Commission of Guangdong Province (2017KTSCX155); Guangdong Basic and
   Applied Basic Research Foundation (NO 2019A1515011318); Shenzhen Science
   and Technology Innovation Commission Basic Research Foundation (NO
   JCYJ20180307150637015). All animal experimental protocols were approved
   by the Institutional Animal Care and Use Committee of Sun Yat-sen
   University (Guangdong Province, China).
CR Ahmed D, 2013, ONCOGENESIS, V2, DOI 10.1038/oncsis.2013.35
   Allegra CJ, 2016, J CLIN ONCOL, V34, P179, DOI 10.1200/JCO.2015.63.9674
   Bond CE, 2012, INT J CANCER, V130, P1567, DOI 10.1002/ijc.26175
   Chang TC, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210274
   Chen PJ, 2017, FREE RADICAL BIO MED, V104, P280, DOI 10.1016/j.freeradbiomed.2017.01.033
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   De Nicola GM, 2011, NATURE, V475, P106, DOI 10.1038/nature10189
   Deng MM, 2019, EUR J PHARMACOL, V853, P193, DOI 10.1016/j.ejphar.2019.03.041
   Deng MM, 2018, EXP CELL RES, V369, P356, DOI 10.1016/j.yexcr.2018.05.038
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Drott J, 2019, CANCER NURS, V42, pE40, DOI 10.1097/NCC.0000000000000674
   Ferino A, 2020, J PHOTOCH PHOTOBIO B, V202, DOI [10.1016/j.photobiol.2019.111672, 10.1016/j.jphotobiol.2019.111672]
   Galan-Cobo A, 2019, CANCER RES, V79, P3251, DOI 10.1158/0008-5472.CAN-18-3527
   Jiang P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1414-6
   Ju HQ, 2019, JNCI-J NATL CANCER I, V111, P584, DOI 10.1093/jnci/djy160
   Kanda A, 2005, ONCOGENE, V24, P7266, DOI 10.1038/sj.onc.1208884
   Kosik A, 2009, J CELL BIOCHEM, V106, P33, DOI 10.1002/jcb.21974
   Kutuk O, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0182809
   Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796
   Meek DW, 2015, BIOCHEM J, V469, P325, DOI 10.1042/BJ20150517
   Neitzel C, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8080794
   Pohl A, 2011, PHARMACOGENOMICS J, V11, P93, DOI 10.1038/tpj.2010.18
   Saini H, 2019, J ONCOL, V2019, DOI 10.1155/2019/6164807
   Satoh H, 2013, CANCER RES, V73, P4158, DOI 10.1158/0008-5472.CAN-12-4499
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sijare F, 2015, VIRCHOWS ARCH, V466, P503, DOI 10.1007/s00428-015-1727-6
   Srinivas US, 2019, REDOX BIOL, V25, DOI 10.1016/j.redox.2018.101084
   Sun YK, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0695-0
   Tan KK, 2009, J GASTROINTEST SURG, V13, P642, DOI 10.1007/s11605-008-0757-7
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wu LM, 2011, J BIOL CHEM, V286, P2236, DOI 10.1074/jbc.M110.174755
   Xie JY, 2020, P NATL ACAD SCI USA, V117, P13012, DOI 10.1073/pnas.1918845117
   Xu Y, 2020, J CLIN PHARM THER, V45, P1363, DOI 10.1111/jcpt.13228
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Zhang YB, 2020, CANCER LETT, V470, P84, DOI 10.1016/j.canlet.2019.10.016
   Zhao ZJ, 2019, MOL CARCINOGEN, V58, P1056, DOI 10.1002/mc.22993
   Zhou J, 2019, THERANOSTICS, V9, P5577, DOI 10.7150/thno.34663
   Zhou Y, 2019, ANTI-CANCER DRUG, V30, P909, DOI 10.1097/CAD.0000000000000791
   Zhou Y, 2017, CANCER SCI, V108, P469, DOI 10.1111/cas.13141
NR 40
TC 6
Z9 6
U1 0
U2 11
PU E-CENTURY PUBLISHING CORP
PI MADISON
PA 40 WHITE OAKS LN, MADISON, WI 53711 USA
SN 2156-6976
J9 AM J CANCER RES
JI Am. J. Cancer Res.
PY 2020
VL 10
IS 11
BP 3666
EP +
PG 24
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OZ9VY
UT WOS:000595267700009
PM 33294260
DA 2025-01-04
ER

PT J
AU Islam, MS
   Aktar, S
   Moetamedirad, N
   Xie, N
   Lu, CT
   Gopalan, V
   Lam, AK
   Shiddiky, MJA
AF Islam, Md Sajedul
   Aktar, Sharmin
   Moetamedirad, Neda
   Xie, Nan
   Lu, Cu Tai
   Gopalan, Vinod
   Lam, Alfred K.
   Shiddiky, Muhammad J. A.
TI A novel platform for mutation detection in colorectal cancer using a
   PNA-LNA molecular switch
SO BIOSENSORS & BIOELECTRONICS
LA English
DT Article
DE Colorectal cancer; KRAS; Isothermal amplification; PNA; LNA
ID KRAS; RAS
AB Detection of KRAS mutation in colorectal cancer (CRC) is important in the prediction of response to target therapy. The study aims to develop a novel mutation detection platform called the "PNA-LNA molecular switch" for the detection of KRAS mutation in CRC. We employed the enhanced binding specificity of peptide nucleic acid (PNA) and locked nucleic acid (LNA) in conjunction with a loop-mediated isothermal amplification (LAMP) approach to identify the mutation status of KRAS oncogene codon 12 (c.35G>T/G12V and c.35G>A/G12D) using synthetic oligonucleotides and colon cancer cell lines (Caco-2 and SW480). This method specifically blocked the amplification of the wild-type sequences while substantially amplifying the mutated ones, which was visualized by both colorimetric and fluorescence assays. We then checked the mutation profile of KRAS codon 12 in the DNA derived from tumor tissue samples (number of samples, n = 30) and circulating tumor cells (n = 24) from CRC patients. Finally, we validated the results by comparing them with the data obtained from DNA sequencing of colon tumors (n = 21) of the same CRC patients. This method showed excellent sensitivity (1 DNA copy/mu l), reproducibility [relative standard deviation (%RSD) < 5%, for n = 3], and linear dynamic range (1 ag/ mu l-10 pg/mu l, R2 = 0.94). This platform is significantly faster, relatively cheaper, has superior sensitivity and specificity, and does not require any high-end equipment. To conclude, this method has the potential to be translated into clinical settings for the detection of mutations in diverse diseases and conditions.
C1 [Islam, Md Sajedul; Aktar, Sharmin; Moetamedirad, Neda; Xie, Nan; Lu, Cu Tai; Gopalan, Vinod; Lam, Alfred K.] Griffith Univ, Sch Med & Dent, Gold Coast Campus, Southport, Qld 4222, Australia.
   [Lu, Cu Tai] Gold Coast Univ Hosp, Dept Surg, Southport, Qld 4215, Australia.
   [Lam, Alfred K.] Gold Coast Univ Hosp, Pathol Queensland, Southport, Qld 4215, Australia.
   [Shiddiky, Muhammad J. A.] Charles Sturt Univ, Rural Hlth Res Inst, Orange, NSW 2800, Australia.
C3 Griffith University; Griffith University - Gold Coast Campus; Gold Coast
   University Hospital; Gold Coast University Hospital; Charles Sturt
   University
RP Gopalan, V; Lam, AK (corresponding author), Griffith Univ, Sch Med & Dent, Gold Coast Campus, Southport, Qld 4222, Australia.; Lam, AK (corresponding author), Gold Coast Univ Hosp, Pathol Queensland, Southport, Qld 4215, Australia.; Shiddiky, MJA (corresponding author), Charles Sturt Univ, Rural Hlth Res Inst, Orange, NSW 2800, Australia.
EM v.gopalan@griffith.edu.au; a.lam@griffith.edu.au; mshiddiky@csu.edu.au
RI Islam, Sajedul/AAL-9709-2021; Aktar, Sharmin/IYJ-8317-2023; Lam,
   Alfred/C-1652-2008; Gopalan, Vinod/C-4269-2016
OI Islam, Md Sajedul/0000-0002-3649-8037; Lam, Alfred/0000-0003-2771-564X;
   Gopalan, Vinod/0000-0003-0366-9482; Aktar, Sharmin/0000-0001-9483-8960
FU Griffith University Post-graduate Research Scholarship
FX M.S.I. acknowledges the support from Griffith University Post-graduate
   Research Scholarship. M.S.I. conveys his gratitude to Tanzena Tanny for
   sharing Biorender.
CR Alvarez-Garcia V, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-22473-9
   Anderson SM, 2011, EXPERT REV MOL DIAGN, V11, P635, DOI [10.1586/ERM.11.42, 10.1586/erm.11.42]
   Badolo A, 2012, MALARIA J, V11, DOI 10.1186/1475-2875-11-227
   Cao GJ, 2018, ANAL CHIM ACTA, V1024, P123, DOI 10.1016/j.aca.2018.04.022
   Choate KA, 2024, BIOL METHODS PROTOC, V9, DOI 10.1093/biomethods/bpae012
   Dai DJ, 2020, PEERJ, V8, DOI 10.7717/peerj.9149
   Formica V, 2022, JNCI-J NATL CANCER I, V114, P517, DOI 10.1093/jnci/djab190
   Haigis KM, 2017, TRENDS CANCER, V3, P686, DOI 10.1016/j.trecan.2017.08.006
   Islam MS, 2023, BIOSENS BIOELECTRON, V239, DOI 10.1016/j.bios.2023.115611
   Itonaga M, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151654
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Lade-Keller J, 2013, J MOL DIAGN, V15, P70, DOI 10.1016/j.jmoldx.2012.08.003
   Li JG, 2022, FRONT CELL INFECT MI, V12, DOI 10.3389/fcimb.2022.953027
   Liu PY, 2019, ACTA PHARM SIN B, V9, P871, DOI 10.1016/j.apsb.2019.03.002
   Liu Y, 2020, ANAL CHEM, V92, P5708, DOI 10.1021/acs.analchem.9b04183
   Malumbres M, 2003, NAT REV CANCER, V3, P459, DOI 10.1038/nrc1097
   Mariotto AB, 2020, CANCER EPIDEM BIOMAR, V29, P1304, DOI 10.1158/1055-9965.EPI-19-1534
   Menchise V, 2003, P NATL ACAD SCI USA, V100, P12021, DOI 10.1073/pnas.2034746100
   Mourah S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0120232
   Nagai Y, 2005, CANCER RES, V65, P7276, DOI 10.1158/0008-5472.CAN-05-0331
   Obika S, 1997, TETRAHEDRON LETT, V38, P8735, DOI 10.1016/S0040-4039(97)10322-7
   Pan L, 2015, PEST MANAG SCI, V71, P123, DOI 10.1002/ps.3777
   Qu K, 2013, J MOL DIAGN, V15, P790, DOI 10.1016/j.jmoldx.2013.07.003
   Schubbert S, 2007, NAT REV CANCER, V7, P295, DOI 10.1038/nrc2109
   Sharma N, 2023, PLANT DIS, V107, P3238, DOI 10.1094/PDIS-09-22-2027-RE
   Shin AE, 2023, TRENDS PHARMACOL SCI, V44, P222, DOI 10.1016/j.tips.2023.01.003
   Sun XY, 2002, NAT BIOTECHNOL, V20, P186, DOI 10.1038/nbt0202-186
   Ung L, 2014, CLIN TRANSL ONCOL, V16, P425, DOI 10.1007/s12094-013-1154-6
NR 28
TC 0
Z9 0
U1 2
U2 2
PU ELSEVIER ADVANCED TECHNOLOGY
PI OXFORD
PA OXFORD FULFILLMENT CENTRE THE BOULEVARD, LANGFORD LANE, KIDLINGTON,
   OXFORD OX5 1GB, OXON, ENGLAND
SN 0956-5663
EI 1873-4235
J9 BIOSENS BIOELECTRON
JI Biosens. Bioelectron.
PD JAN 1
PY 2025
VL 267
AR 116813
DI 10.1016/j.bios.2024.116813
EA OCT 2024
PG 8
WC Biophysics; Biotechnology & Applied Microbiology; Chemistry, Analytical;
   Electrochemistry; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biophysics; Biotechnology & Applied Microbiology; Chemistry;
   Electrochemistry; Science & Technology - Other Topics
GA I4T1D
UT WOS:001330187200001
PM 39357493
OA hybrid
DA 2025-01-04
ER

PT J
AU Jia, JB
   Ling, XX
   Xing, MZ
   Ludwig, JM
   Bai, MF
   Kim, HS
AF Jia, Jemianne B.
   Ling, Xiaoxi
   Xing, Minzhi
   Ludwig, Johannes M.
   Bai, Mingfeng
   Kim, Hyun S.
TI Novel TSPO-targeted Doxorubicin Prodrug for Colorectal Carcinoma Cells
SO ANTICANCER RESEARCH
LA English
DT Article
DE Targeted therapy; colorectal carcinoma; doxorubicin; TSPO; prodrug
ID PERIPHERAL BENZODIAZEPINE-RECEPTOR; TRANSLOCATOR PROTEIN TSPO;
   BINDING-SITES; IN-VITRO; CANCER; EXPRESSION; CHEMOEMBOLIZATION;
   METASTASES; THERAPY; TUMORS
AB Background/Aim: 18 kDa Translocator protein (TSPO) is a mitochondrial protein up-regulated in colorectal carcinoma (CRC). Our purpose was to develop a TSPO-targeted doxorubicin prodrug (Dox-TSPO) which can be loaded onto drug-eluting beads for transarterial chemoembolization. Furthermore, we evaluated its loading and release kinetics and effects on cell viability. Materials and Methods: N-Fmoc-DOX-14-O-hemiglutarate was coupled with a TSPO ligand, 6-TSPOmbb732, using classical N,N,N',N'-tetramethyl-O-(1H-benzotriazol-1-yl)uranium hexafluorophosphate coupling to produce Dox-TSPO. Loading and elution studies were performed using DC beadsT. Cell viability studies were performed using CellTiter-Glo (R) Luminescent Cell Viability Assay. Results: Dox-TSPO was successfully synthesized and readily loaded onto and eluted from DC beads (TM), albeit at a slower rate than free doxorubicin. CRC cell lines expressing TSPO were 2- to 4-fold more sensitive to Dox-TSPO compared to free doxorubicin at 72 h. Conclusion: Dox-TSPO is a promising candidate for targeted and directed cancer treatment of CRC liver metastases.
C1 [Jia, Jemianne B.; Xing, Minzhi; Ludwig, Johannes M.; Kim, Hyun S.] Univ Pittsburgh, Sch Med, Intervent Oncol Translat Lab, Pittsburgh, PA USA.
   [Jia, Jemianne B.] Kaiser Permanente, Dept Radiol, Los Angeles Med Ctr, Los Angeles, CA USA.
   [Ling, Xiaoxi] Univ Pittsburgh, Sch Med, Dept Med, Pittsburgh, PA 15213 USA.
   [Xing, Minzhi; Ludwig, Johannes M.; Kim, Hyun S.] Yale Sch Med, Dept Radiol & Biomed Imaging, Sect Intervent Radiol, POB 208042, New Haven, CT 06510 USA.
   [Bai, Mingfeng] Univ Pittsburgh, Sch Med, Dept Radiol, Pittsburgh, PA USA.
   [Bai, Mingfeng] Univ Pittsburgh, Dept Bioengn, Sch Med, Pittsburgh, PA USA.
   [Bai, Mingfeng; Kim, Hyun S.] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA.
   [Kim, Hyun S.] Yale Sch Med, Dept Med, Sect Med Oncol, New Haven, CT 06510 USA.
   [Kim, Hyun S.] Yale Univ, Yale Canc Ctr, New Haven, CT USA.
C3 Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Kaiser Permanente; University of California System;
   University of California Los Angeles; University of California Los
   Angeles Medical Center; Pennsylvania Commonwealth System of Higher
   Education (PCSHE); University of Pittsburgh; Yale University;
   Pennsylvania Commonwealth System of Higher Education (PCSHE); University
   of Pittsburgh; Pennsylvania Commonwealth System of Higher Education
   (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of
   Higher Education (PCSHE); University of Pittsburgh; Yale University;
   Yale University
RP Kim, HS (corresponding author), Yale Sch Med, Dept Radiol & Biomed Imaging, Sect Intervent Radiol, POB 208042, New Haven, CT 06510 USA.; Bai, MF (corresponding author), Vanderbilt Univ, Sch Med, Inst Imaging Sci, 1161 21st Ave S AA-1105, Nashville, TN 37232 USA.
EM mingfeng.bai@vanderbilt.edu; kevin.kim@yale.edu
RI Ling, Xiaoxi/F-3509-2011
CR Austin CJD, 2013, INT J BIOCHEM CELL B, V45, P1212, DOI 10.1016/j.biocel.2013.03.004
   Bai M, 2007, BIOCONJUGATE CHEM, V18, P2018, DOI 10.1021/bc700251e
   BENAVIDES J, 1988, ANN NEUROL, V24, P708, DOI 10.1002/ana.410240603
   BOOSER DJ, 1994, DRUGS, V47, P223, DOI 10.2165/00003495-199447020-00002
   de Menezes DEL, 1999, J LIPOSOME RES, V9, P199, DOI 10.3109/08982109909024786
   Faivre J, 2003, B ACAD NAT MED PARIS, V187, P815, DOI 10.1016/S0001-4079(19)33967-6
   Fiorentini G, 2012, ANTICANCER RES, V32, P1387
   Han ZQ, 2003, J RECEPT SIG TRANSD, V23, P225, DOI 10.1081/RRS-120025210
   Jemal A, 2008, CA-CANCER J CLIN, V58, P71, DOI 10.3322/CA.2007.0010
   Jordan O, 2010, J VASC INTERV RADIOL, V21, P1084, DOI 10.1016/j.jvir.2010.02.042
   Kalva Sanjeeva P, 2011, Gastrointest Cancer Res, V4, P2
   KATZ Y, 1988, EUR J PHARMACOL, V148, P483, DOI 10.1016/0014-2999(88)90135-5
   KATZ Y, 1990, CLIN SCI, V78, P155, DOI 10.1042/cs0780155
   Leporrier J, 2006, BRIT J SURG, V93, P465, DOI 10.1002/bjs.5278
   Lewis AL, 2007, J MATER SCI-MATER M, V18, P1691, DOI 10.1007/s10856-007-3068-8
   Margiotta N, 2010, J MED CHEM, V53, P5144, DOI 10.1021/jm100429r
   MIETTINEN H, 1995, CANCER RES, V55, P2691
   Nagler R, 2010, BBA-MOL BASIS DIS, V1802, P454, DOI 10.1016/j.bbadis.2010.01.008
   Nagy A, 1996, P NATL ACAD SCI USA, V93, P7269, DOI 10.1073/pnas.93.14.7269
   Papadopoulos V, 1997, STEROIDS, V62, P21, DOI 10.1016/S0039-128X(96)00154-7
   Samuelson LE, 2009, BIOCONJUGATE CHEM, V20, P2082, DOI 10.1021/bc9002053
   Scherf U, 2000, NAT GENET, V24, P236, DOI 10.1038/73439
   Tellez C, 1998, CANCER, V82, P1250, DOI 10.1002/(SICI)1097-0142(19980401)82:7<1250::AID-CNCR7>3.0.CO;2-J
   URRY DW, 1992, J AM CHEM SOC, V114, P8716, DOI 10.1021/ja00048a064
   Wyatt SK, 2010, MOL IMAGING BIOL, V12, P349, DOI 10.1007/s11307-009-0270-8
   Zhang SJ, 2015, ACTA BIOMATER, V28, P160, DOI 10.1016/j.actbio.2015.09.033
NR 26
TC 7
Z9 7
U1 2
U2 19
PU INT INST ANTICANCER RESEARCH
PI ATHENS
PA EDITORIAL OFFICE 1ST KM KAPANDRITIOU-KALAMOU RD KAPANDRITI, PO BOX 22,
   ATHENS 19014, GREECE
SN 0250-7005
EI 1791-7530
J9 ANTICANCER RES
JI Anticancer Res.
PD OCT
PY 2020
VL 40
IS 10
BP 5371
EP 5378
DI 10.21873/anticanres.14545
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OH6DP
UT WOS:000582679500006
PM 32988856
OA Bronze
DA 2025-01-04
ER

PT J
AU Chuang, KT
   Chiou, SS
   Hsu, SH
AF Chuang, Kai-Ting
   Chiou, Shyh-Shin
   Hsu, Shih-Hsien
TI Recent Advances in Transcription Factors Biomarkers and Targeted
   Therapies Focusing on Epithelial-Mesenchymal Transition
SO CANCERS
LA English
DT Review
DE transcription factor; epithelial-mesenchymal transition; cancer targeted
   therapy
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; PROSTATE-CANCER CELLS; C-JUN; ANDROGEN
   RECEPTOR; BREAST-CANCER; MOLECULAR-MECHANISMS; GENE-TRANSCRIPTION;
   COLORECTAL-CANCER; SIGNALING PATHWAY; BLADDER-CANCER
AB Simple Summary The study discusses the potential of targeting transcription factors (TFs) for cancer therapy and provide a systematic classification of various types of TFs involved in the epithelial-mesenchymal transition (EMT) process based on their DNA-binding domain (DBD) structure and highlights some of the main TFs that have the potential to be cancer biomarkers or targeted therapies. Various strategies for targeting TFs, such as small molecules, RNA interference, and immunotherapies, and examples of drugs currently in clinical trials are listed in this study, providing an insight into the role of TFs in EMT and targeted therapies. Transcription factors involve many proteins in the process of transactivating or transcribing (none-) encoded DNA to initiate and regulate downstream signals, such as RNA polymerase. Their unique characteristic is that they possess specific domains that bind to specific DNA element sequences called enhancer or promoter sequences. Epithelial-mesenchymal transition (EMT) is involved in cancer progression. Many dysregulated transcription factors-such as Myc, SNAIs, Twists, and ZEBs-are key drivers of tumor metastasis through EMT regulation. This review summarizes currently available evidence related to the oncogenic role of classified transcription factors in EMT editing and epigenetic regulation, clarifying the roles of the classified conserved transcription factor family involved in the EMT and how these factors could be used as therapeutic targets in future investigations.
C1 [Chuang, Kai-Ting; Hsu, Shih-Hsien] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 80708, Taiwan.
   [Chuang, Kai-Ting] Kaohsiung Med Univ, Coll Med, Sch Med, Kaohsiung 807, Taiwan.
   [Chiou, Shyh-Shin] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pediat, Div Pediat Hematol & Oncol, Kaohsiung 807, Taiwan.
   [Chiou, Shyh-Shin] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan.
   [Chiou, Shyh-Shin; Hsu, Shih-Hsien] Kaohsiung Med Univ, Ctr Appl Genom, Kaohsiung 807, Taiwan.
   [Hsu, Shih-Hsien] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University Hospital; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University Hospital
RP Hsu, SH (corresponding author), Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung 80708, Taiwan.; Chiou, SS (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Pediat, Div Pediat Hematol & Oncol, Kaohsiung 807, Taiwan.; Chiou, SS (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, Kaohsiung 807, Taiwan.; Chiou, SS; Hsu, SH (corresponding author), Kaohsiung Med Univ, Ctr Appl Genom, Kaohsiung 807, Taiwan.; Hsu, SH (corresponding author), Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Med Res, Kaohsiung 807, Taiwan.
EM ti880808@gmail.com; chiouss@kmu.edu.tw; jackhsu@kmu.edu.tw
RI Chuang, Kai-Ting/KVZ-0075-2024; Hsu, Shih-Hsien/D-5139-2009
OI Hsu, Shih Hsien/0000-0003-2102-0505; Chiou, Shyh
   shin/0000-0001-7639-9116
FU Kaohsiung Medical University Hospital [KMUH108-8R44, KMUH111-1M36];
   Ministry of Science and Technology, Taiwan [MOST108-2314-B-037-065-MY3,
   110-2314-B-037-072-MY3, 111-2320-B-037-031]; Kaohsiung Medical
   University [DK(A)112002]
FX This work was supported in part by research grants KMUH108-8R44 and
   KMUH111-1M36 from the Kaohsiung Medical University Hospital, and
   MOST108-2314-B-037-065-MY3, 110-2314-B-037-072-MY3, 111-2320-B-037-031
   from the Ministry of Science and Technology, Taiwan, Kaohsiung Medical
   University grant (DK(A)112002).
CR Abadi AJ, 2021, INT J BIOL MACROMOL, V180, P608, DOI 10.1016/j.ijbiomac.2021.02.202
   Ahram M, 2021, ENDOCR RES, V46, P114, DOI 10.1080/07435800.2021.1895829
   Nieto MA, 2016, CELL, V166, P21, DOI 10.1016/j.cell.2016.06.028
   [Anonymous], 2009, FOOD ANIMAL PRACTICE
   Ariffin NS, 2022, CLIN BREAST CANCER, V22, P499, DOI 10.1016/j.clbc.2022.04.006
   Ashrafizadeh M, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10071040
   Auricchio F., 2020, J MOL ENDOCRINOL, V65, pT35, DOI [10.3410/f.737633380.793577792, DOI 10.3410/F.737633380.793577792]
   Babaei G, 2021, MOL BIOL REP, V48, P7545, DOI 10.1007/s11033-021-06706-1
   Bai F, 2018, NUCLEIC ACIDS RES, V46, P546, DOI 10.1093/nar/gkx1241
   Bakiri L, 2015, CELL DEATH DIFFER, V22, P336, DOI 10.1038/cdd.2014.157
   Bolt MJ, 2013, NUCLEIC ACIDS RES, V41, P4036, DOI 10.1093/nar/gkt100
   Brabletz S, 2010, EMBO REP, V11, P670, DOI 10.1038/embor.2010.117
   Brabletz T, 2018, NAT REV CANCER, V18, P128, DOI 10.1038/nrc.2017.118
   Brennan A, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01686-9
   Brown G, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032373
   Byers SA, 2005, MOL CANCER THER, V4, P1260, DOI 10.1158/1535-7163.MCT-05-0109
   Capaci V, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-17596-5
   Chalaskiewicz K, 2023, EUR J PHARMACOL, V949, DOI 10.1016/j.ejphar.2023.175728
   Chartoumpekis DV, 2020, ANTIOXIDANTS-BASEL, V9, DOI 10.3390/antiox9090884
   Chen P, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.839005
   Chen ZY, 2020, INT J RADIAT BIOL, V96, P1281, DOI 10.1080/09553002.2020.1793015
   Cheng HH, 2018, PROSTATE, V78, P121, DOI 10.1002/pros.23452
   Chuang KT, 2021, CANCER MED-US, V10, P5545, DOI 10.1002/cam4.4094
   Cui ZQ, 2019, BMC CANCER, V19, DOI 10.1186/s12885-018-5225-5
   Culig Z, 2019, BBA-MOL CELL RES, V1866, P1368, DOI 10.1016/j.bbamcr.2019.05.003
   Debnath P, 2022, BIOSCIENCE REP, V42, DOI 10.1042/BSR20211754
   di Masi A, 2015, MOL ASPECTS MED, V41, P1, DOI 10.1016/j.mam.2014.12.003
   Di Nicolantonio F, 2004, MOL CANCER THER, V3, P1631
   Doi A, 2015, MOL ONCOL, V9, P355, DOI 10.1016/j.molonc.2014.09.005
   Dongre A, 2019, NAT REV MOL CELL BIO, V20, P69, DOI 10.1038/s41580-018-0080-4
   Du BW, 2016, MOLECULES, V21, DOI 10.3390/molecules21070965
   Du HY, 2021, OXID MED CELL LONGEV, V2021, DOI 10.1155/2021/2337818
   Bach H, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19103279
   Duffy MJ, 2021, INT J CANCER, V148, P8, DOI 10.1002/ijc.33197
   Durham GA, 2019, TRENDS PHARMACOL SCI, V40, P298, DOI 10.1016/j.tips.2019.03.001
   Fan LL, 2020, THERANOSTICS, V10, P5895, DOI 10.7150/thno.43198
   Fedele M, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23020800
   Feldker N, 2020, EMBO J, V39, DOI 10.15252/embj.2019103209
   Fenaux P, 2020, NEW ENGL J MED, V382, P140, DOI 10.1056/NEJMoa1908892
   Gallinari P, 2007, CELL RES, V17, P195, DOI 10.1038/sj.cr.7310149
   Gaptulbarova K. A., 2020, Experimental Oncology, V42, P263, DOI 10.32471/exp-oncology.2312-8852.vol-42-no-4.15414
   Georgakopoulos-Soares I, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00499
   Ghyselinck NB, 2019, DEVELOPMENT, V146, DOI 10.1242/dev.167502
   Gong L, 2018, CELL BIOL INT, V42, P1050, DOI 10.1002/cbin.10982
   Gonzalez DM, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005189
   Goodwin PJ, 2022, JAMA-J AM MED ASSOC, V327, P1963, DOI 10.1001/jama.2022.6147
   Grimm D, 2020, SEMIN CANCER BIOL, V67, P122, DOI 10.1016/j.semcancer.2019.03.004
   Han JH, 2022, CANCER COMMUN, V42, P716, DOI 10.1002/cac2.12332
   Han M, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317718404
   Hanieh H, 2020, SEMIN CANCER BIOL, V67, P91, DOI 10.1016/j.semcancer.2019.06.022
   Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767
   Hassin O, 2023, NAT REV DRUG DISCOV, V22, P127, DOI 10.1038/s41573-022-00571-8
   Heppler LN, 2022, J BIOL CHEM, V298, DOI 10.1016/j.jbc.2021.101531
   Hsiao YJ, 2016, ONCOTARGET, V7, P44417, DOI 10.18632/oncotarget.10088
   Hsu SH, 2013, CANCER RES, V73, P508, DOI 10.1158/0008-5472.CAN-12-2795
   Hu JH, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01169-0
   Huang GL, 2017, CELL CYCLE, V16, P685, DOI 10.1080/15384101.2017.1295180
   Huang Q, 2022, OPEN LIFE SCI, V17, P447, DOI 10.1515/biol-2022-0047
   Huang YH, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01347-8
   Igarashi Kazuhiko, 2022, Subcell Biochem, V100, P67, DOI 10.1007/978-3-031-07634-3_2
   Igarashi K, 2021, J BIOL CHEM, V297, DOI 10.1016/j.jbc.2021.101032
   Islam MS, 2020, ENDOCR REV, V41, DOI 10.1210/endrev/bnaa012
   Jayachandran A, 2016, J HEMATOL ONCOL, V9, DOI 10.1186/s13045-016-0307-9
   Jiang FZ, 2015, ONCOTARGET, V6, P44660, DOI 10.18632/oncotarget.6350
   Jiang XM, 2021, ACTA PHARMACOL SIN, V42, P451, DOI 10.1038/s41401-020-0457-8
   Jin W, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010217
   Jin Y, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9010258
   Jing C, 2021, THERANOSTICS, V11, P5847, DOI 10.7150/thno.46109
   Jing YF, 2014, CANCER LETT, V348, P135, DOI 10.1016/j.canlet.2014.03.018
   Johnson DE, 2018, NAT REV CLIN ONCOL, V15, P234, DOI 10.1038/nrclinonc.2018.8
   Jonckheere S, 2022, CELLS TISSUES ORGANS, V211, P157, DOI 10.1159/000512218
   Jonker DJ, 2018, LANCET GASTROENTEROL, V3, P263, DOI 10.1016/S2468-1253(18)30009-8
   Kalra RS, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0048-4
   Kamide D, 2016, CANCER SCI, V107, P666, DOI 10.1111/cas.12914
   Kastenhuber ER, 2017, CELL, V170, P1062, DOI 10.1016/j.cell.2017.08.028
   Katoh M, 2013, CANCER LETT, V328, P198, DOI 10.1016/j.canlet.2012.09.017
   Khan MA, 2013, TUMOR BIOL, V34, P2497, DOI 10.1007/s13277-013-1002-x
   Kim BG, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01053-x
   Kimura K, 2015, J MOL MED, V93, P749, DOI 10.1007/s00109-015-1289-8
   Kobayashi Y, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-90618-4
   Kudo-Saito C, 2009, CANCER CELL, V15, P195, DOI 10.1016/j.ccr.2009.01.023
   Laissue P, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0938-x
   Lamouille S, 2014, NAT REV MOL CELL BIO, V15, P178, DOI 10.1038/nrm3758
   Lee O, 2020, CLIN CANCER RES, V26, P25, DOI 10.1158/1078-0432.CCR-19-0443
   Lee YL, 2021, P NATL ACAD SCI USA, V118, DOI 10.1073/pnas.1922864118
   Li HM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aaw8500
   Li J, 2021, NUCLEIC ACIDS RES, V49, P3573, DOI 10.1093/nar/gkab086
   Li QY, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1330-9
   Lin C, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0953-6
   Lin CY, 2018, CANCER SCI, V109, P3564, DOI 10.1111/cas.13776
   Lin GX, 2018, ONCOTARGETS THER, V11, P3805, DOI 10.2147/OTT.S162700
   Lin TC, 2022, BBA-REV CANCER, V1877, DOI 10.1016/j.bbcan.2022.188715
   Liu Xingxing, 2014, Nucl Recept Signal, V12, pe004, DOI 10.1621/nrs.12004
   Liu Y, 2021, SEMIN CELL DEV BIOL, V114, P126, DOI 10.1016/j.semcdb.2021.01.002
   López-Menéndez C, 2021, CANCER RES, V81, P4529, DOI 10.1158/0008-5472.CAN-20-2685
   Lu Y, 2020, NAT MED, V26, P732, DOI 10.1038/s41591-020-0840-5
   Luo LW, 2017, INT J GYNECOL CANCER, V27, P1422, DOI 10.1097/IGC.0000000000001032
   Luo YZ, 2018, EUR REV MED PHARMACO, V22, P8609, DOI 10.26355/eurrev_201812_16624
   Ma S, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.738435
   Madden SK, 2021, MOL CANCER, V20, DOI 10.1186/s12943-020-01291-6
   Mandalos N, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00345
   Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912
   Massó-Vallés D, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9040883
   Mathas S, 2002, EMBO J, V21, P4104, DOI 10.1093/emboj/cdf389
   Mego M, 2022, INVEST NEW DRUG, V40, P1080, DOI 10.1007/s10637-022-01271-1
   Meng QH, 2011, PROTEIN CELL, V2, P889, DOI 10.1007/s13238-011-1113-3
   López-Novoa JM, 2009, EMBO MOL MED, V1, P303, DOI 10.1002/emmm.200900043
   Miklossy G, 2013, NAT REV DRUG DISCOV, V12, P611, DOI 10.1038/nrd4088
   Mill CP, 2019, BLOOD, V134, P59, DOI 10.1182/blood.2018893982
   Millour J, 2010, ONCOGENE, V29, P2983, DOI 10.1038/onc.2010.47
   Mirzaei S, 2022, J CELL PHYSIOL, V237, P2770, DOI 10.1002/jcp.30759
   Mishra DK, 2017, CANCER MICROENVIRON, V10, P95, DOI 10.1007/s12307-017-0202-0
   Mitra Partha, 2020, Explor Target Antitumor Ther, V1, P401, DOI 10.37349/etat.2020.00025
   Mohammadinejad R, 2020, CELL MOL LIFE SCI, V77, P2701, DOI 10.1007/s00018-020-03449-3
   Mrkvicova A, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0210889
   Olbromski M, 2020, CANCERS, V12, DOI 10.3390/cancers12113235
   Owen KL, 2019, CANCERS, V11, DOI 10.3390/cancers11122002
   Padilla J, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10030634
   Park MK, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232315127
   Paskeh MDA, 2021, BIOMED PHARMACOTHER, V144, DOI 10.1016/j.biopha.2021.112335
   Pei HX, 2017, MEDCHEMCOMM, V8, P268, DOI 10.1039/c6md00561f
   Pi WC, 2020, BLOOD, V136, P11, DOI 10.1182/blood.2019003312
   Prescott JA, 2021, BIOCHEM J, V478, P2619, DOI 10.1042/BCJ20210139
   Puisieux A, 2014, NAT CELL BIOL, V16, P488, DOI 10.1038/ncb2976
   Qi Yi-Jun, 2020, PLoS Biol, V18, pe3000825, DOI 10.1371/journal.pbio.3000825
   Ramadass V, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21145164
   Ren D, 2013, INT J ONCOL, V42, P1473, DOI 10.3892/ijo.2013.1825
   Ropke M, 1996, P NATL ACAD SCI USA, V93, P14704, DOI 10.1073/pnas.93.25.14704
   Saha S, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.620214
   Sarais F, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312815
   Sato M, 2020, CANCER RES, V80, P1279, DOI 10.1158/0008-5472.CAN-18-4099
   Savolainen K, 2020, BMC RES NOTES, V13, DOI 10.1186/s13104-020-05155-6
   Scheller K, 2003, EXP PHYSIOL, V88, P129, DOI 10.1113/eph8802507
   Schmitz M, 2007, BRIT J CANCER, V96, P1293, DOI 10.1038/sj.bjc.6603696
   Seino Y, 2008, J BIOL CHEM, V283, P4905, DOI 10.1074/jbc.M707928200
   Semenov O, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.928399
   Shah Swikant, 2020, Indian J Dent Res, V31, P718, DOI 10.4103/ijdr.IJDR_822_18
   She ZY, 2015, EUR J CELL BIOL, V94, P547, DOI 10.1016/j.ejcb.2015.08.002
   Shi WW, 2019, J MOL CELL BIOL, V11, P1042, DOI 10.1093/jmcb/mjz001
   Shorstova T, 2021, BRIT J CANCER, V124, P1478, DOI 10.1038/s41416-021-01321-0
   Sivaganesh V, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222312865
   Slattery C, 2006, FEBS LETT, V580, P4021, DOI 10.1016/j.febslet.2006.06.039
   Soleymani L, 2021, CURR CANCER DRUG TAR, V21, P749, DOI 10.2174/1568009621666210601114631
   Sood R, 2017, BLOOD, V129, P2070, DOI 10.1182/blood-2016-10-687830
   Stemmler MP, 2020, EMBO REP, V21, DOI 10.15252/embr.201949766
   Stevens LE, 2023, CANCER RES, V83, P264, DOI 10.1158/0008-5472.CAN-22-0423
   Stolzenburg S, 2012, NUCLEIC ACIDS RES, V40, P6725, DOI 10.1093/nar/gks360
   Sue S, 2016, J GASTROENTEROL, V51, P949, DOI 10.1007/s00535-016-1176-2
   Sweeney CJ, 2005, MOL CANCER THER, V4, P1004, DOI 10.1158/1535-7163.MCT-05-0030
   Syed V, 2016, J CELL BIOCHEM, V117, P1279, DOI 10.1002/jcb.25496
   Szabo E, 1996, CANCER RES, V56, P305
   Takemoto K, 2023, CANCER SCI, V114, P436, DOI 10.1111/cas.15607
   Tam SY, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00486
   Tan YE, 2020, AGING-US, V12, P25060, DOI 10.18632/aging.103979
   Tang HM, 2016, CELL DEATH DISCOV, V2, DOI 10.1038/cddiscovery.2016.41
   Tarin D, 2005, CANCER RES, V65, P5996, DOI 10.1158/0008-5472.CAN-05-0699
   Tripathi A, 2020, ASIAN J UROL, V7, P284, DOI 10.1016/j.ajur.2020.05.011
   Truong TH, 2018, ENDOCRINOLOGY, V159, P3897, DOI 10.1210/en.2018-00831
   Tuo ZT, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09632-y
   Veloso ES, 2020, RES VET SCI, V131, P7, DOI 10.1016/j.rvsc.2020.04.007
   Vey N, 2006, LEUKEMIA, V20, P2155, DOI 10.1038/sj.leu.2404420
   Villarino AV, 2015, J IMMUNOL, V194, P21, DOI 10.4049/jimmunol.1401867
   Vleugel MM, 2006, HUM PATHOL, V37, P668, DOI 10.1016/j.humpath.2006.01.022
   Voutsadakis IA, 2016, J CLIN MED, V5, DOI 10.3390/jcm5010011
   Walerych D, 2016, NAT CELL BIOL, V18, P897, DOI 10.1038/ncb3380
   Wang GC, 2021, TRANSL ANDROL UROL, V10, P4275, DOI 10.21037/tau-21-964
   Wang HL, 2000, CARCINOGENESIS, V21, P1313, DOI 10.1093/carcin/21.7.1313
   Wang LT, 2020, EMBO REP, V21, DOI 10.15252/embr.201948795
   Wang LT, 2017, CANCER RES, V77, P4065, DOI 10.1158/0008-5472.CAN-17-0090
   Wang SN, 2016, ONCOTARGET, V7, P36924, DOI 10.18632/oncotarget.9228
   Wang YF, 2013, CURR CANCER DRUG TAR, V13, P963, DOI 10.2174/15680096113136660102
   Williams Kendra A, 2018, Oncotarget, V9, P28532, DOI 10.18632/oncotarget.25536
   Wingender E, 2018, NUCLEIC ACIDS RES, V46, pD343, DOI 10.1093/nar/gkx987
   Wingender E, 2015, NUCLEIC ACIDS RES, V43, pD97, DOI 10.1093/nar/gku1064
   Wingender E, 2013, J BIOINF COMPUT BIOL, V11, DOI 10.1142/S0219720013400076
   Wu RY, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-001037
   Xia LZ, 2018, ONCOTARGETS THER, V11, P2063, DOI 10.2147/OTT.S161109
   Xie M, 2022, THERANOSTICS, V12, P1097, DOI 10.7150/thno.65775
   Xin P, 2020, INT IMMUNOPHARMACOL, V80, DOI 10.1016/j.intimp.2020.106210
   Yang MY, 2014, INT J MOL SCI, V15, P11013, DOI 10.3390/ijms150611013
   Yeh JE, 2013, CURR OPIN ONCOL, V25, P652, DOI 10.1097/01.cco.0000432528.88101.1a
   Yu H, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00312-6
   Zhang M, 2019, ONCOL RES, V27, P1061, DOI 10.3727/096504019X15565325878380
   Zhang YL, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22115949
   Zhao HC, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1261-5
   Zhao Y, 2021, CANCER MED-US, V10, P3413, DOI 10.1002/cam4.3884
   Zheng LL, 2022, CURR MED SCI, V42, P1285, DOI 10.1007/s11596-022-2661-x
   Zheng XR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1433-3
   Zhong S, 2019, AGING-US, V11, P9043, DOI 10.18632/aging.102372
   Zhou BQ, 2021, AM J HEMATOL, V96, P1461, DOI 10.1002/ajh.26324
   Zhou T, 2018, EBIOMEDICINE, V31, P217, DOI 10.1016/j.ebiom.2018.04.023
   Zhou WH, 2019, J CELL SCI, V132, DOI 10.1242/jcs.235127
   Zou SL, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01258-7
NR 193
TC 6
Z9 6
U1 1
U2 11
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD JUL
PY 2023
VL 15
IS 13
AR 3338
DI 10.3390/cancers15133338
PG 37
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA M6GB4
UT WOS:001031170100001
PM 37444447
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Jones, DT
   Cruz, G
   Lugue, MT
   Heer, MS
   Sai, M
   Pace, C
   Bui, L
   Silver, SA
AF Jones, Daniel T.
   Cruz, Gabriel
   Lugue, Maria Theresa
   Heer, Manvir S.
   Sai, Marlai
   Pace, Christopher
   Bui, Linsey
   Silver, Scott A.
TI Fruquintinib-Induced Cerebellar Hemorrhage in Left-Sided Descending
   Metastatic Colorectal Adenocarcinoma: A Case Report and Risk Assessment
SO CUREUS JOURNAL OF MEDICAL SCIENCE
LA English
DT Article
DE chemotherapy; targeted therapy; vegfr inhibitor; cerebellar hemorrhage;
   side effects; fruzaqla; fruquintinib; metastatic colorectal cancer
   (mcrc); metastatic colorectal adenocarcinoma
ID INHIBITOR; CANCER
AB Colorectal adenocarcinoma is the most prevalent form of colorectal cancer, representing the majority of cases in the United States. The disease is driven by a series of genetic mutations, including alterations in the epidermal growth factor receptor 2 immunohistochemistry 3+ (HER-2 IHC3+), checkpoint kinase 2 (CHEK-2) and tumor protein P53 (TP53) genes, which lead to malignant transformation. While the standard treatment for metastatic colorectal cancer (mCRC) typically involves chemotherapy and targeted therapies, many patients experience disease progression, necessitating the exploration of novel treatments. Fruquintinib, a highly selective vascular endothelial growth factor (VEGFR) inhibitor, has emerged as a promising option for mCRC patients who have exhausted conventional therapies. However, its use is associated with significant bleeding risks, including rare but severe complications such as cerebellar hemorrhage. This case report presents a patient with mCRC who developed a cerebellar hemorrhage shortly after initiating fruquintinib therapy, highlighting the need for careful patient monitoring and individualized risk assessment to mitigate such serious adverse events.
C1 [Jones, Daniel T.; Cruz, Gabriel] Touro Univ Nevada, Internal Med, Henderson, NV 89014 USA.
   [Lugue, Maria Theresa] Touro Univ Calif, Internal Med, Vallejo, CA USA.
   [Heer, Manvir S.] Kansas City Univ, Med, Joplin, MO USA.
   [Sai, Marlai] Valley Hosp Med Ctr, Neurol Residency Program, Neurol, Las Vegas, NV USA.
   [Pace, Christopher; Bui, Linsey; Silver, Scott A.] Valley Hosp Med Ctr, Internal Med Residency Program, Internal Med, Las Vegas, NV USA.
C3 Touro University California; Kansas City University
RP Jones, DT (corresponding author), Touro Univ Nevada, Internal Med, Henderson, NV 89014 USA.
EM danieljones81@hotmail.com
OI , Daniel T. Jones/0009-0000-3625-1790
CR Ahnen DJ, 2014, MAYO CLIN PROC, V89, P216, DOI 10.1016/j.mayocp.2013.09.006
   Alzahrani SM, 2021, MOL CLIN ONCOL, V15, DOI 10.3892/mco.2021.2433
   de Moraes FCA, 2024, BMC CANCER, V24, DOI 10.1186/s12885-024-12447-8
   Holtedahl K, 2021, BMC FAM PRACT, V22, DOI 10.1186/s12875-021-01452-6
   le Noble FAC, 2023, HYPERTENSION, V80, P901, DOI 10.1161/HYPERTENSIONAHA.122.19427
   Li J, 2018, JAMA-J AM MED ASSOC, V319, P2486, DOI 10.1001/jama.2018.7855
   Stolarova L, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9122675
   Sun QL, 2014, CANCER BIOL THER, V15, P1635, DOI 10.4161/15384047.2014.964087
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Zhang Y, 2019, CANCER MANAG RES, V11, P7787, DOI 10.2147/CMAR.S215533
   Zhuang Y, 2021, BMC CANCER, V21, DOI 10.1186/s12885-021-08108-9
NR 11
TC 0
Z9 0
U1 1
U2 1
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
EI 2168-8184
J9 CUREUS J MED SCIENCE
JI Cureus J Med Sci
PD AUG 30
PY 2024
VL 16
IS 8
AR e68203
DI 10.7759/cureus.68203
PG 7
WC Medicine, General & Internal
WE Emerging Sources Citation Index (ESCI)
SC General & Internal Medicine
GA E9V8U
UT WOS:001306415200008
PM 39221315
OA gold
DA 2025-01-04
ER

PT J
AU Russo, M
   Pompei, S
   Sogari, A
   Corigliano, M
   Crisafulli, G
   Puliafito, A
   Lamba, S
   Erriquez, J
   Bertotti, A
   Gherardi, M
   Di Nicolantonio, F
   Bardelli, A
   Lagomarsino, MC
AF Russo, Mariangela
   Pompei, Simone
   Sogari, Alberto
   Corigliano, Mattia
   Crisafulli, Giovanni
   Puliafito, Alberto
   Lamba, Simona
   Erriquez, Jessica
   Bertotti, Andrea
   Gherardi, Marco
   Di Nicolantonio, Federica
   Bardelli, Alberto
   Lagomarsino, Marco Cosentino
TI A modified fluctuation-test framework characterizes the population
   dynamics and mutation rate of colorectal cancer persister cells
SO NATURE GENETICS
LA English
DT Article
ID ANTI-EGFR THERAPY; ACQUIRED-RESISTANCE; TUMOR HETEROGENEITY; TARGETED
   THERAPY; DRUG-RESISTANCE; DNA-POLYMERASES; EVOLUTION; EMERGENCE; MODEL;
   STATE
AB A modified fluctuation test applied to colorectal cancer cells shows that EGFR/BRAF inhibitor-induced persisters slowly proliferate and have an increased mutation rate. Error-prone DNA polymerases are identified as potential targets to avoid tumor recurrence following treatment with these drugs.
   Compelling evidence shows that cancer persister cells represent a major limit to the long-term efficacy of targeted therapies. However, the phenotype and population dynamics of cancer persister cells remain unclear. We developed a quantitative framework to study persisters by combining experimental characterization and mathematical modeling. We found that, in colorectal cancer, a fraction of persisters slowly replicates. Clinically approved targeted therapies induce a switch to drug-tolerant persisters and a temporary 7- to 50-fold increase of their mutation rate, thus increasing the number of persister-derived resistant cells. These findings reveal that treatment may influence persistence and mutability in cancer cells and pinpoint inhibition of error-prone DNA polymerases as a strategy to restrict tumor recurrence.
C1 [Russo, Mariangela; Sogari, Alberto; Crisafulli, Giovanni; Puliafito, Alberto; Bertotti, Andrea; Di Nicolantonio, Federica; Bardelli, Alberto] Univ Turin, Dept Oncol, Candiolo, Italy.
   [Russo, Mariangela; Sogari, Alberto; Crisafulli, Giovanni; Puliafito, Alberto; Lamba, Simona; Erriquez, Jessica; Bertotti, Andrea; Di Nicolantonio, Federica; Bardelli, Alberto] FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy.
   [Pompei, Simone; Corigliano, Mattia; Gherardi, Marco; Lagomarsino, Marco Cosentino] IFOM Fdn, FIRC Inst Mol Oncol, Milan, Italy.
   [Corigliano, Mattia; Gherardi, Marco; Lagomarsino, Marco Cosentino] Univ Milan, Dept Phys, Milan, Italy.
   [Corigliano, Mattia; Gherardi, Marco; Lagomarsino, Marco Cosentino] Ist Nazl Fis Nucl, Milan, Italy.
C3 University of Turin; IRCCS Fondazione del Piemonte per l'Oncologia; IFOM
   - FIRC Institute of Molecular Oncology; University of Milan; Istituto
   Nazionale di Fisica Nucleare (INFN)
RP Bardelli, A (corresponding author), Univ Turin, Dept Oncol, Candiolo, Italy.; Bardelli, A (corresponding author), FPO IRCCS, Candiolo Canc Inst, Candiolo, Italy.; Lagomarsino, MC (corresponding author), IFOM Fdn, FIRC Inst Mol Oncol, Milan, Italy.; Lagomarsino, MC (corresponding author), Univ Milan, Dept Phys, Milan, Italy.; Lagomarsino, MC (corresponding author), Ist Nazl Fis Nucl, Milan, Italy.
EM alberto.bardelli@unito.it; marco.cosentino-lagomarsino@ifom.eu
RI Gherardi, Marco/KCZ-2547-2024; Di Nicolantonio, Federica/A-2503-2011;
   Lagomarsino, Marco/B-7233-2012; Sogari, Alberto/GQA-5770-2022; Bardelli,
   Alberto/J-9721-2018; Puliafito, Alberto/K-2462-2018; Crisafulli,
   Giovanni/AAB-6256-2019; Russo, Mariangela/K-1900-2018; erriquez,
   jessica/HSH-7225-2023
OI Bertotti, Andrea/0000-0001-8196-7608; Pompei,
   Simone/0000-0002-6673-7991; Sogari, Alberto/0000-0003-0612-6109;
   Gherardi, Marco/0000-0002-7745-8269; Puliafito,
   Alberto/0000-0002-0096-1536; Corigliano, Mattia/0000-0002-6645-6778;
   Crisafulli, Giovanni/0000-0002-5511-1555; Russo,
   Mariangela/0000-0003-4625-1449; erriquez, jessica/0000-0002-7152-0930
FU FONDAZIONE AIRC under 5 per Mille 2018 [21091]; Associazione Italiana
   per la Ricerca sul Cancro AIRC IG [23258]; AIRC IG 2017 [20697];
   European Research Council (ERC) [724748]; AIRC IG 2018 [21923]; AIRC
   under MFAG 2021 [26439]; AIRC under MFAG 2020 [25040]; Cancer Research
   UK [A26825, A28223]; FC AECC [GEACC18004TAB]; AIRC [22795]; Ministero
   Salute (RC 2020); European Research Council (ERC) under the European
   Union's Horizon 2020 research and innovation program [101020342]; IMI
   [101007937 PERSIST-SEQ]; BiLiGeCT [PON ARS01_00492]; Fondazione Umberto
   Veronesi; European Research Council (ERC) [101020342] Funding Source:
   European Research Council (ERC)
FX We thank A. Ciliberto, M. Osella, L. Trusolino and A. Amir for useful
   discussions and critical reading of the manuscript. This work was
   supported by the following: FONDAZIONE AIRC under 5 per Mille 2018 (ID.
   21091 program) to A. Bardelli, group leaders F.D.N. and A. Bertotti;
   Associazione Italiana per la Ricerca sul Cancro AIRC IG (grant no.
   23258) to M.C.L.; AIRC IG 2017 no. 20697 to A. Bertotti; European
   Research Council (ERC) Consolidator (grant no. 724748, BEAT) to A.
   Bertotti; AIRC IG 2018 (ID. 21923 project) to A. Bardelli; AIRC under
   MFAG 2021-ID 26439 project to M.R.; AIRC under MFAG 2020-ID 25040
   project to A.P.; International Accelerator Award, ACRCelerate, jointly
   funded by Cancer Research UK (nos. A26825 and A28223), FC AECC (no.
   GEACC18004TAB) and AIRC (no. 22795) to A. Bardelli; Ministero Salute (RC
   2020) to A. Bardelli; European Research Council (ERC) under the European
   Union's Horizon 2020 research and innovation program (grant no.
   101020342) to A. Bardelli; IMI contract no. 101007937 PERSIST-SEQ to A.
   Bardelli and M.R.; BiLiGeCT (Progetto PON ARS01_00492) to A. Bardelli.
   S.P. was supported by Fondazione Umberto Veronesi.
CR Attolini CSO, 2009, ANN NY ACAD SCI, V1168, P23, DOI 10.1111/j.1749-6632.2009.04880.x
   Bailey N.T.J., 1964, The elements of stochastic processes with applications to the natural sciences, V1st
   Balaban NQ, 2019, NAT REV MICROBIOL, V17, P441, DOI 10.1038/s41579-019-0196-3
   Berg S, 2019, NAT METHODS, V16, P1226, DOI 10.1038/s41592-019-0582-9
   Bozic I, 2013, ELIFE, V2, DOI 10.7554/eLife.00747
   Brauner A, 2016, NAT REV MICROBIOL, V14, P320, DOI 10.1038/nrmicro.2016.34
   Chatterjee N, 2020, P NATL ACAD SCI USA, V117, P28918, DOI 10.1073/pnas.2016064117
   Cipponi A, 2020, SCIENCE, V368, P1127, DOI 10.1126/science.aau8768
   Crisafulli G, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2019-000572
   De Conti G, 2021, CANCERS, V13, DOI 10.3390/cancers13051118
   Di Nicolantonio F, 2008, P NATL ACAD SCI USA, V105, P20864, DOI 10.1073/pnas.0808757105
   Gardner SN, 2000, CANCER RES, V60, P1417
   Gillespie DT, 2007, ANNU REV PHYS CHEM, V58, P35, DOI 10.1146/annurev.physchem.58.032806.104637
   Goodman MF, 2002, ANNU REV BIOCHEM, V71, P17, DOI 10.1146/annurev.biochem.71.083101.124707
   Hata AN, 2016, NAT MED, V22, P262, DOI 10.1038/nm.4040
   Hoffman MD, 2014, J MACH LEARN RES, V15, P1593
   Iwasa Y, 2006, GENETICS, V172, P2557, DOI 10.1534/genetics.105.049791
   KENDAL WS, 1988, CANCER RES, V48, P1060
   Komarova NL, 2005, P NATL ACAD SCI USA, V102, P9714, DOI 10.1073/pnas.0501870102
   Kopetz S, 2020, NEW ENGL J MED, V382, P877, DOI 10.1056/NEJMc1915676
   Kussell E, 2005, GENETICS, V169, P1807, DOI 10.1534/genetics.104.035352
   Lang GI, 2008, GENETICS, V178, P67, DOI 10.1534/genetics.107.071506
   Lupo B, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aax8313
   Luria SE, 1943, GENETICS, V28, P491
   Medico E, 2015, NAT COMMUN, V6, DOI 10.1038/ncomms8002
   Michor F, 2005, NATURE, V435, P1267, DOI 10.1038/nature03669
   Misale S, 2014, CANCER DISCOV, V4, P1269, DOI 10.1158/2159-8290.CD-14-0462
   Misale S, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007947
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396
   Oren Y, 2021, NATURE, V596, P576, DOI 10.1038/s41586-021-03796-6
   Parikh AR, 2019, NAT MED, V25, P1415, DOI 10.1038/s41591-019-0561-9
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Rattray AJ, 2003, ANNU REV GENET, V37, P31, DOI 10.1146/annurev.genet.37.042203.132748
   Rehman SK, 2021, CELL, V184, P226, DOI 10.1016/j.cell.2020.11.018
   Rosenberg SM, 2012, BIOESSAYS, V34, P885, DOI 10.1002/bies.201200050
   Russo M., MENDELEY DATA, DOI [10.17632/mvfm7hs9kw.2(2022), DOI 10.17632/MVFM7HS9KW.2(2022)]
   Russo M, 2019, SCIENCE, V366, P1473, DOI 10.1126/science.aav4474
   Russo M, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-04506-z
   Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283
   Salgia R, 2018, TRENDS CANCER, V4, P110, DOI 10.1016/j.trecan.2018.01.001
   Sharma SV, 2010, CELL, V141, P69, DOI 10.1016/j.cell.2010.02.027
   Shen SS, 2020, CELL, V183, P860, DOI 10.1016/j.cell.2020.10.027
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Sommer C, 2011, I S BIOMED IMAGING, P230, DOI 10.1109/ISBI.2011.5872394
   Vallette FM, 2019, BIOCHEM PHARMACOL, V162, P169, DOI 10.1016/j.bcp.2018.11.004
   Van Kampen N. G., 1981, Stochastic processes in physics and chemistry
   Wagle N, 2011, J CLIN ONCOL, V29, P3085, DOI 10.1200/JCO.2010.33.2312
   Werner B, 2016, CANCER RES, V76, P1705, DOI 10.1158/0008-5472.CAN-15-2069
   Wojtaszek JL, 2019, CELL, V178, P152, DOI 10.1016/j.cell.2019.05.028
   Woolston A, 2021, NAT ECOL EVOL, V5, P1024, DOI 10.1038/s41559-021-01470-8
NR 51
TC 22
Z9 24
U1 0
U2 4
PU NATURE PORTFOLIO
PI BERLIN
PA HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY
SN 1061-4036
EI 1546-1718
J9 NAT GENET
JI Nat. Genet.
PD JUL
PY 2022
VL 54
IS 7
BP 976
EP +
DI 10.1038/s41588-022-01105-z
PG 26
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA 2W9ZC
UT WOS:000824873300020
PM 35817983
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Shibata, T
AF Shibata, Tatsuhiro
TI Current and future molecular profiling of cancer by next-generation
   sequencing
SO JAPANESE JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
DE sequencing; driver gene; immunotherapy; tumor heterogeneity; liquid
   biopsy
ID CELL LUNG-CANCER; SOMATIC MUTATIONS; BREAST-CANCER; PD-1 BLOCKADE;
   ACQUIRED-RESISTANCE; ONCOGENE ADDICTION; COLORECTAL CANCERS;
   COLON-CANCER; EGFR; EVOLUTION
AB Advances in the new sequencing technologies have enabled us to explore global genetic alterations including driver genes in a wide range of cancers. Concordantly, successes of molecular target therapy promoted the validity of tumor classification based on the combination of targetable genetic abnormalities, and next-generation sequencing-based genetic profiling using target gene capturing or multiplex-polymerase chain reaction has already been tested or adapted in many cancer centers. Driver gene-based classification may be applicable beyond organs, and clinical trials incorporating this genomic information, called as a basket trial, have been executed, although it should be considered that similar therapeutic efficacies against driver mutations are not invariably maintained among different cancer types. Research efforts to identify still missing driver genes in rare cancers, to complete functional annotation of infrequent driver genes, and multiple-layered omics approaches are further expected for better classification of tumor. Emerging clinical interests in the development of immunotherapies postulate a new molecular classification of tumors. Recent studies reported that total number of mutations and the frequent appearance of neo-antigens by protein-coding mutations were associated with a better response, and genetic evaluation of both tumor and host immune system by sequencing is expected to contribute to the personalized immunotherapies in the near future. Lastly intratumoral molecular heterogeneity challenges the current 'static' molecular classification of tumor. For example, dynamic change in clonal constitution within tumor plays an important role in acquired drug resistance. It has been extensively explored whether liquid biopsy-based molecular profiling can resolve currently confronting difficulties.
C1 [Shibata, Tatsuhiro] Univ Tokyo, Inst Med Sci, Lab Mol Med, Tokyo, Japan.
   [Shibata, Tatsuhiro] Natl Canc Ctr, Res Inst, Div Canc Genom, Tokyo 104, Japan.
C3 University of Tokyo; National Cancer Center - Japan
RP Shibata, T (corresponding author), 4-6-1 Shirokanedai,Minato Ku, Tokyo, Japan.
EM tshibata@ims.u-tokyo.ac.jp
RI Shibata, Tatsuhiro/AAO-1278-2021
FU Ministry of Health, Labor and Welfare; Japan Agency for Medical Research
   and Development (Health and Labor Sciences Research Expenses for
   Commission); Japan Agency for Medical Research and Development (Applied
   Research for Innovative Treatment of Cancer); National Cancer Center
   Research and Development Funds [26-A-5]
FX This work was supported by Grants-in-Aid from the Ministry of Health,
   Labor and Welfare, and Japan Agency for Medical Research and Development
   (Health and Labor Sciences Research Expenses for Commission and Applied
   Research for Innovative Treatment of Cancer), and National Cancer Center
   Research and Development Funds (26-A-5).
CR Albert TJ, 2007, NAT METHODS, V4, P903, DOI 10.1038/NMETH1111
   Ansell SM, 2015, NEW ENGL J MED, V372, P311, DOI 10.1056/NEJMoa1411087
   Brahmer JR, 2013, J CLIN ONCOL, V31, P1021, DOI 10.1200/JCO.2012.45.8703
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Chen X, 2015, ONCOGENE, DOI [10.1038/onc.2014.474, DOI 10.1038/0NC.2014.474]
   Ciriello G, 2013, NAT GENET, V45, P1127, DOI 10.1038/ng.2762
   Collisson EA, 2014, NATURE, V511, P543, DOI 10.1038/nature13385
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Dawson SJ, 2013, NEW ENGL J MED, V368, P1199, DOI 10.1056/NEJMoa1213261
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Eckel-Passow JE, 2015, NEW ENGL J MED, V372, P2499, DOI 10.1056/NEJMoa1407279
   Fong PC, 2010, J CLIN ONCOL, V28, P2512, DOI 10.1200/JCO.2009.26.9589
   Gerlinger M, 2014, NAT GENET, V46, P225, DOI 10.1038/ng.2891
   Gerlinger M, 2012, NEW ENGL J MED, V366, P883, DOI 10.1056/NEJMoa1113205
   Jamal-Hanjani M, 2015, CLIN CANCER RES, V21, P1258, DOI 10.1158/1078-0432.CCR-14-1429
   Kohno T, 2013, CANCER SCI, V104, P1396, DOI 10.1111/cas.12275
   Landau DA, 2013, CELL, V152, P714, DOI 10.1016/j.cell.2013.01.019
   Leiserson MDM, 2015, NAT GENET, V47, P106, DOI 10.1038/ng.3168
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Llovet JM, 2015, NAT REV CLIN ONCOL, V12, P408, DOI [10.1038/nrclinonc.2015.103, 10.1038/nrclinonc.2015.121]
   Marchetti A, 2005, J CLIN ONCOL, V23, P857, DOI 10.1200/JCO.2005.08.043
   Murtaza M, 2013, NATURE, V497, P108, DOI 10.1038/nature12065
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Ojesina AI, 2014, NATURE, V506, P371, DOI 10.1038/nature12881
   Pagliarini R, 2015, EMBO REP, V16, P280, DOI 10.15252/embr.201439949
   Perou CM, 2000, NATURE, V406, P747, DOI 10.1038/35021093
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Rizvi NA, 2015, SCIENCE, V348, P124, DOI 10.1126/science.aaa1348
   Robert C, 2015, NEW ENGL J MED, V372, P320, DOI 10.1056/NEJMoa1412082
   Roychowdhury S, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3003161
   Sharma SV, 2007, GENE DEV, V21, P3214, DOI 10.1101/gad.1609907
   Shaw AT, 2009, J CLIN ONCOL, V27, P4247, DOI 10.1200/JCO.2009.22.6993
   Shlien A, 2015, NAT GENET, V47, P257, DOI 10.1038/ng.3202
   Smith AG, 2012, TISSUE ANTIGENS, V79, P359, DOI 10.1111/j.1399-0039.2012.01868.x
   Snyder A, 2014, NEW ENGL J MED, V371, P2189, DOI 10.1056/NEJMoa1406498
   Sotiriou C, 2009, NEW ENGL J MED, V360, P790, DOI 10.1056/NEJMra0801289
   Stratton MR, 2009, NATURE, V458, P719, DOI 10.1038/nature07943
   Tiacci E, 2011, NEW ENGL J MED, V364, P2305, DOI 10.1056/NEJMoa1014209
   Topalian SL, 2011, J CLIN ONCOL, V29, P4828, DOI 10.1200/JCO.2011.38.0899
   Tran B, 2012, J CLIN ONCOL, V30, P647, DOI 10.1200/JCO.2011.39.2316
   Tumeh PC, 2014, NATURE, V515, P568, DOI 10.1038/nature13954
   Turke AB, 2010, CANCER CELL, V17, P77, DOI 10.1016/j.ccr.2009.11.022
   Waddell N, 2015, NATURE, V518, P495, DOI 10.1038/nature14169
   Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397
   Zardavas D, 2015, NAT REV CLIN ONCOL, V12, P381, DOI 10.1038/nrclinonc.2015.73
NR 45
TC 10
Z9 11
U1 0
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0368-2811
EI 1465-3621
J9 JPN J CLIN ONCOL
JI Jpn. J. Clin. Oncol.
PD OCT
PY 2015
VL 45
IS 10
BP 895
EP 899
DI 10.1093/jjco/hyv122
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CT5EH
UT WOS:000362830300001
PM 26292697
OA Bronze
DA 2025-01-04
ER

PT J
AU Di Nardo, P
   Garattini, SK
   Torrisi, E
   Fanotto, V
   Miolo, G
   Buonadonna, A
   Puglisi, F
AF Di Nardo, Paola
   Garattini, Silvio Ken
   Torrisi, Elena
   Fanotto, Valentina
   Miolo, Gianmaria
   Buonadonna, Angela
   Puglisi, Fabio
TI Systemic Treatments for Advanced Small Bowel Adenocarcinoma: A
   Systematic Review
SO CANCERS
LA English
DT Review
DE small bowel adenocarcinoma; clinical trials; chemotherapy; target
   therapy; immunotherapy; systematic review
ID PHASE-II; SOLID TUMORS; OPEN-LABEL; AMPULLA; CAPECITABINE; OXALIPLATIN;
   CANCER; CHEMOTHERAPY; THERAPY
AB Simple Summary Small bowel adenocarcinoma is a rare disease that is usually treated following the protocols in use for colorectal cancer. The aim of this systematic review was to identify the optimal treatment for this disease according to the currently available evidence. We concluded that there is some evidence regarding the use of chemotherapy doublets in this setting, but not to support the use of biological agents. There are encouraging results regarding the use of immunotherapy in selected patients. Small bowel adenocarcinoma (SBA) is a rare disease for which scarce evidence is available. We summarized data available on systemic treatment of advanced SBA. Methods: Scientific literature was evaluated to find phase II or phase III clinical trials on systemic treatment for advanced SBA. MeSH terms were selected and combined for the initial search, then inclusion and exclusion criteria were set in a search protocol. Four medical oncologists looked for evidence on Medline, EMBASE and Cochrane databases. Moreover, abstracts from 2016 to June 2021 from the American Society for Clinical Oncology, European Society for Medical Oncology, Gastrointestinal Cancer Symposium and World Congress on Gastrointestinal Cancer were browsed. The selected studies, matching the inclusion and exclusion criteria, were finally tabulated and analyzed. Results: The trials finally selected were 18 phase II/III clinical trials. Four small phase II trials support the activity of oxaliplatin-based doublets in first-line treatment (CAPOX and mFOLFOX). Conclusion: No good level evidence is available on the use of bevacizumab, anti-epidermal growth factor receptor, targeted agents or immunotherapy. First-line treatments are largely derived from colorectal cancer protocols, mainly oxaliplatin-based doublets.
C1 [Di Nardo, Paola; Miolo, Gianmaria; Buonadonna, Angela; Puglisi, Fabio] IRCCS, Natl Canc Inst, CRO Aviano, Dept Med Oncol, I-33081 Aviano, Italy.
   [Garattini, Silvio Ken; Fanotto, Valentina] ASUFC Univ Hosp Udine, Dept Oncol, I-33100 Udine, Italy.
   [Torrisi, Elena] Dept Med Oncol, PO San Vincenzo, I-98039 Taormina, Italy.
   [Puglisi, Fabio] Univ Udine, Dept Med DAME, I-33100 Udine, Italy.
C3 IRCCS Aviano (CRO); University of Udine
RP Di Nardo, P (corresponding author), IRCCS, Natl Canc Inst, CRO Aviano, Dept Med Oncol, I-33081 Aviano, Italy.
EM paola.dinardo@cro.it; silvioken.garattini@asufc.sanita.fvg.it;
   torrisi@oncologiataormina.it; valentina.fanotto@asufc.sanita.fvg.it;
   gmiolo@cro.it; abuonadonna@cro.it; fabio.puglisi@cro.it
RI Fanotto, Valentina/ABE-6997-2020; Buonadonna, Angela/ABE-2374-2020;
   Garattini, Silvio/ABB-1956-2020; Miolo, Gianmaria/AAC-2351-2020; Di
   Nardo, Paola/GQI-2350-2022; Puglisi, Fabio/N-3863-2017
OI Miolo, Gianmaria/0000-0001-5084-295X; Garattini,
   Silvio/0000-0003-0647-9297; Di Nardo, Paola/0000-0002-8918-1201;
   Puglisi, Fabio/0000-0003-0573-4938; Garattini, Silvio
   Ken/0000-0001-6420-0333
FU Italian Ministry of Health (Ricerca Corrente)
FX This work was supported by the Italian Ministry of Health (Ricerca
   Corrente).
CR Bilimoria KY, 2009, ANN SURG, V249, P63, DOI 10.1097/SLA.0b013e31818e4641
   Cardin DB, 2020, J CLIN ONCOL, V38
   Dabaja BS, 2004, CANCER, V101, P518, DOI 10.1002/cncr.20404
   Diaz L, 2017, ANN ONCOL, V28
   Diaz LA, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3071
   Diaz LA, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3003
   Falcone R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009672
   Gibson MK, 2005, ONCOLOGIST, V10, P132, DOI 10.1634/theoncologist.10-2-132
   Gulhati P, 2018, ONCOLOGIST, V23, P277, DOI 10.1634/theoncologist.2017-0568
   Gulhati P, 2017, CANCER-AM CANCER SOC, V123, P1011, DOI 10.1002/cncr.30445
   Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780
   Halfdanarson TR, 2010, AM J SURG, V199, P797, DOI 10.1016/j.amjsurg.2009.05.037
   Horimatsu T, 2017, INT J CLIN ONCOL, V22, P905, DOI 10.1007/s10147-017-1138-6
   Kim HS, 2013, TOHOKU J EXP MED, V231, P21, DOI 10.1620/tjem.231.21
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Le DT, 2016, J CLIN ONCOL, V34, DOI 10.1200/jco.2016.34.4_suppl.195
   Marabelle A, 2020, J CLIN ONCOL, V38, P1, DOI 10.1200/JCO.19.02105
   McWilliams RR, 2017, CANCER-AM CANCER SOC, V123, P3494, DOI 10.1002/cncr.30766
   Overman MJ, 2018, ANN ONCOL, V29, P139, DOI 10.1093/annonc/mdx688
   Overman MJ, 2009, J CLIN ONCOL, V27, P2598, DOI 10.1200/JCO.2008.19.7145
   Patel SP, 2020, CLIN CANCER RES, V26, P2290, DOI 10.1158/1078-0432.CCR-19-3356
   Pedersen KS, 2021, CLIN CANCER RES, V27, P3641, DOI 10.1158/1078-0432.CCR-21-0159
   Siegel RL, 2017, CA-CANCER J CLIN, V67, P7, DOI 10.3322/caac.21387
   Subbiah V, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.TPS2604
   Tournigand C, 2019, ANN ONCOL, V30, P506
   Williams AS, 2013, PATHOLOGY, V45, P540, DOI 10.1097/PAT.0b013e3283653307
   Xiang XJ, 2012, ANTI-CANCER DRUG, V23, P561, DOI 10.1097/CAD.0b013e328350dd0d
NR 27
TC 5
Z9 5
U1 0
U2 2
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAR
PY 2022
VL 14
IS 6
AR 1502
DI 10.3390/cancers14061502
PG 12
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 0E9JP
UT WOS:000776988800001
PM 35326652
OA gold, Green Published, Green Submitted
DA 2025-01-04
ER

PT J
AU Ho, CC
   Wen, PC
   Yu, WC
   Hu, YW
   Yang, CC
AF Ho, Chin-Chin
   Wen, Pin-Chun
   Yu, Wen-Chung
   Hu, Yu-Wen
   Yang, Chen-Chang
TI Pre-existing chronic kidney disease and hypertension increased the risk
   of cardiotoxicity among colorectal cancer patients treated with
   anticancer drugs
SO JOURNAL OF THE CHINESE MEDICAL ASSOCIATION
LA English
DT Article
DE Chemotherapy; Chronic kidney disease; Colorectal cancer; Drug-related
   cardiotoxicity; Hypertension; Targeted therapy
ID CLINICAL-PRACTICE GUIDELINES; CARDIOVASCULAR-DISEASE; HEART-FAILURE;
   CHEMOTHERAPY; BEVACIZUMAB; PREVENTION; THERAPY; SOCIETY; EVENTS;
   5-FLUOROURACIL
AB Background: This population-based study was to investigate the potential risk factors of cardiotoxicity among colorectal cancer (CRC) patients treated with anticancer drugs. Methods: This was a retrospective cohort study using the National Health Insurance Research Database to identify the CRC patients receiving chemotherapy (CT) alone or CT combined with targeted therapies between 2000 and 2013. The patients enrolled were those who had the first diagnosis of CRC established >= 20 years and had no cancer history three years before the incident diagnosis of CRC. The outcomes of cardiotoxicity were defined by the diagnosis of acute myocarditis, cardiomyopathy, heart failure, hypertensive heart disease, and so on. Results: A total of 11 819 CRC patients were identified and 3781 were eligible; 556 (14.7%) patients developed cardiotoxicity after receiving anticancer treatment. Patients showed a similar risk of having primary outcome (hazard ratio [HR], 0.7; p = 0.3662) between CT and CT combined with targeted therapy groups, whereas the risk of developing secondary outcome was significantly different between the two groups (HR, 0.7; p = 0.0339). The hazard was found to be increased with age (60-69, HR 2.1, p = 0.0236; 70-79, HR 3.3, p = 0.0003; and >= 80, HR 3.7, p < 0.0001). CRC patients who had a prior history of hypertension exhibited a higher risk than those without hypertension (HR 1.6, p < 0.0001). The hazard of having cardiotoxicity among patients with a prior history of severe chronic kidney disease was 2.4 times than that in those without renal dysfunction, regardless of the stage of cancer (HR 2.4, p < 0.0001). Conclusion: CRC patients over 60 years of age run a higher risk of developing cardiotoxicity when treated with anticancer drugs. For CRC patients who have a previous history of hypertension or chronic kidney disease, physicians must be careful in evaluating the risk of anticancer drugs-related cardiotoxicity. Prescribe drugs may prevent cardiotoxicity if necessary.
C1 [Ho, Chin-Chin] Taipei Vet Gen Hosp, Dept Pharm, Taipei, Taiwan.
   [Ho, Chin-Chin] Taipei Med Univ, Sch Pharm, Taipei, Taiwan.
   [Ho, Chin-Chin; Wen, Pin-Chun; Yang, Chen-Chang] Natl Yang Ming Chiao Tung Univ, Coll Med, Inst Environm & Occupat Hlth Sci, Taipei, Taiwan.
   [Yu, Wen-Chung] Taipei Vet Gen Hosp, Dept Med, Div Cardiol, Taipei, Taiwan.
   [Yu, Wen-Chung] Natl Yang Ming Chiao Tung Univ, Fac Med, Taipei, Taiwan.
   [Hu, Yu-Wen] Taipei Vet Gen Hosp, Dept Oncol, Div Radiat Oncol, Taipei, Taiwan.
   [Hu, Yu-Wen] Natl Yang Ming Chiao Tung Univ, Sch Med, Taipei, Taiwan.
   [Hu, Yu-Wen] Natl Yang Ming Chiao Tung Univ, Inst Publ Hlth, Taipei, Taiwan.
   [Yang, Chen-Chang] Taipei Vet Gen Hosp, Dept Med, Div Clin Toxicol & Occupat Med, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
C3 Taipei Veterans General Hospital; Taipei Medical University; National
   Yang Ming Chiao Tung University; Taipei Veterans General Hospital;
   National Yang Ming Chiao Tung University; Taipei Veterans General
   Hospital; National Yang Ming Chiao Tung University; National Yang Ming
   Chiao Tung University; Taipei Veterans General Hospital
RP Yang, CC (corresponding author), Taipei Vet Gen Hosp, Dept Med, Div Clin Toxicol & Occupat Med, 201,Sect 2,Shi Pai Rd, Taipei 112, Taiwan.
EM ccyang@vghtpe.gov.tw
RI Chen, Chen/B-2080-2014; Cheng, Ching-Yu/Y-2229-2019; Hung,
   Chi-Feng/AAL-4977-2021
FU Ministry of Science Technology [105-2314B-010-021, 108-2314-B-010-039];
   Taipei Veterans General Hospital [V108C-097, V110C-089]; Taipei, Taiwan,
   ROC
FX This study was partly supported by grants from the Ministry of Science &
   Technology (Grant number: MOST 105-2314B-010-021 and MOST
   108-2314-B-010-039) and grants from Taipei Veterans General Hospital
   (Grant number: V108C-097 and V110C-089), Taipei, Taiwan, ROC.
CR Allegra CJ, 2009, J CLIN ONCOL, V27, P3385, DOI 10.1200/JCO.2009.21.9220
   Allen LA, 2014, MED CARE, V52, pe30, DOI 10.1097/MLR.0b013e31825a8c22
   [Anonymous], 2014, ESSENTIAL EPIDEMIOLO
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Berardi R, 2013, CRIT REV ONCOL HEMAT, V88, P75, DOI 10.1016/j.critrevonc.2013.02.007
   Bock JS, 2010, CIRCULATION, V121, P2592, DOI 10.1161/CIRCULATIONAHA.109.886473
   Brana I, 2010, ANN ONCOL, V21, P173, DOI 10.1093/annonc/mdq295
   Bulsink A, 2013, INT J CLIN PHARM-NET, V35, P401, DOI 10.1007/s11096-012-9747-7
   Carver JR, 2007, J CLIN ONCOL, V25, P3991, DOI 10.1200/JCO.2007.10.9777
   Chen MH, 2008, CIRCULATION, V118, P84, DOI 10.1161/CIRCULATIONAHA.108.776831
   Chen XX, 2017, J CANCER RES THER, V13, P869, DOI 10.4103/jcrt.JCRT_833_17
   Deeken JF, 2013, CANCER CHEMOTH PHARM, V71, P1473, DOI 10.1007/s00280-013-2146-5
   Dyhl-Polk A, 2020, ACTA ONCOL, V59, P475, DOI 10.1080/0284186X.2019.1711164
   El-Shami K, 2015, CA-CANCER J CLIN, V65, P427, DOI 10.3322/caac.21286
   Giantonio BJ, 2007, J CLIN ONCOL, V25, P1539, DOI 10.1200/JCO.2006.09.6305
   Go AS, 2004, NEW ENGL J MED, V351, P1296, DOI 10.1056/NEJMoa041031
   Hawkes AL, 2011, EUR J CANCER, V47, P267, DOI 10.1016/j.ejca.2010.10.002
   Jensen SA, 2006, CANCER CHEMOTH PHARM, V58, P487, DOI 10.1007/s00280-005-0178-1
   Jiji RS, 2012, J NUCL CARDIOL, V19, P377, DOI 10.1007/s12350-012-9512-2
   Jones RL, 2006, EXPERT REV ANTICANC, V6, P1249, DOI 10.1586/14737140.6.9.1249
   Kalam K, 2013, EUR J CANCER, V49, P2900, DOI 10.1016/j.ejca.2013.04.030
   Kapelakis I, 2017, HELL J CARDIOL, V58, P215, DOI 10.1016/j.hjc.2016.11.022
   Kenzik KM, 2018, J CLIN ONCOL, V36, P609, DOI 10.1200/JCO.2017.74.9739
   Kosmas C, 2008, J CANCER RES CLIN, V134, P75, DOI 10.1007/s00432-007-0250-9
   Kottgen A, 2007, J AM SOC NEPHROL, V18, P1307, DOI 10.1681/ASN.2006101159
   Kwakman JJM, 2017, EUR J CANCER, V76, P93, DOI 10.1016/j.ejca.2017.02.009
   Launay-Vacher V, 2007, CANCER-AM CANCER SOC, V110, P1376, DOI 10.1002/cncr.22904
   Lestuzzi C, 2001, AM J MED, V111, P316, DOI 10.1016/S0002-9343(01)00808-7
   Meyer CC, 1997, PHARMACOTHERAPY, V17, P729
   Nowakowska M, 2020, ARCH MED SCI, V16, P1295, DOI 10.5114/aoms.2020.100401
   Polk A, 2014, BMC PHARMACOL TOXICO, V15, DOI 10.1186/2050-6511-15-47
   Polk A, 2013, CANCER TREAT REV, V39, P974, DOI 10.1016/j.ctrv.2013.03.005
   Riechelmann RP, 2007, JNCI-J NATL CANCER I, V99, P592, DOI 10.1093/jnci/djk130
   Ronco C, 2008, J AM COLL CARDIOL, V52, P1527, DOI 10.1016/j.jacc.2008.07.051
   Scappaticci FA, 2007, JNCI-J NATL CANCER I, V99, P1232, DOI 10.1093/jnci/djm086
   Suter TM, 2013, EUR HEART J, V34, P1102, DOI 10.1093/eurheartj/ehs181
   Tang XM, 2017, MEDICINE, V96, DOI 10.1097/MD.0000000000005946
   Truong J, 2014, CAN J CARDIOL, V30, P869, DOI 10.1016/j.cjca.2014.04.029
   Weiner DE, 2004, J AM SOC NEPHROL, V15, P1307, DOI 10.1097/01.ASN.0000123691.46138.E2
   Yancy CW, 2017, CIRCULATION, V136, pE137, DOI [10.1161/CIR.0000000000000509, 10.1016/j.cardfail.2017.04.014]
   Yeh ETH, 2009, J AM COLL CARDIOL, V53, P2231, DOI 10.1016/j.jacc.2009.02.050
NR 41
TC 4
Z9 4
U1 0
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1726-4901
EI 1728-7731
J9 J CHIN MED ASSOC
JI J. Chin. Med. Assoc.
PD SEP
PY 2021
VL 84
IS 9
BP 877
EP 884
DI 10.1097/JCMA.0000000000000590
PG 8
WC Medicine, General & Internal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC General & Internal Medicine
GA UM5OI
UT WOS:000693379600012
PM 34320515
OA hybrid
DA 2025-01-04
ER

PT J
AU He, QL
   Long, JL
   Yin, YT
   Li, YL
   Lei, X
   Li, ZQ
   Zhu, W
AF He, Qinglian
   Long, Jiali
   Yin, Yuting
   Li, Yuling
   Lei, Xue
   Li, Ziqi
   Zhu, Wei
TI Emerging Roles of lncRNAs in the Formation and Progression of Colorectal
   Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE lncRNAs; colorectal cancer; transcription; polypeptide; treatment
ID LONG NONCODING RNA; EPITHELIAL-MESENCHYMAL TRANSITION;
   CELL-PROLIFERATION; PROMOTES PROLIFERATION; DOWN-REGULATION;
   UP-REGULATION; ROR PROMOTES; RESISTANCE; SUPPRESSES; EXPRESSION
AB Colorectal cancer (CRC) is the primary cause of cancer-related death worldwide; however, specific and sensitive tools for the early diagnosis and targeted therapy of CRC are currently lacking. High-throughput sequencing technology revealed that gene expression of long-chain non-coding RNAs (lncRNAs) in a number of cancers directly or indirectly interferes with various biological processes. Emerging evidence suggests that lncRNAs regulate target genes and play an important role in the biological processes of malignancies, including CRC. Many carcinostatic/oncogenic lncRNAs have been identified as biomarkers for metastasis and prognosis in CRC; hence, they serve as therapeutic tools. In this article, we systematically review the literature on the disordered lncRNAs in CRC from four aspects: DNA transcription, RNA level regulation, post-translational level, and the translation of lncRNAs into polypeptides. Subsequently, we analyze the mechanism through which lncRNAs participate in the biological process of CRC. Finally, we discuss the application and prospects of these lncRNAs in CRC.
C1 [He, Qinglian; Long, Jiali; Yin, Yuting; Lei, Xue; Li, Ziqi; Zhu, Wei] Guangdong Med Univ, Dept Pathol, Dongguan, Peoples R China.
   [Li, Yuling] Southern Med Univ, Dept Pathol, Dongguan Hosp, Dongguan, Peoples R China.
C3 Guangdong Medical University; Southern Medical University - China
RP Zhu, W (corresponding author), Guangdong Med Univ, Dept Pathol, Dongguan, Peoples R China.
EM zhuwei@gdmu.edu.cn
RI li, ziqi/JDC-9141-2023; 雷, 雪/ABD-3365-2020
FU National Natural Science Foundation of China [81472275, 81702399];
   Natural Science Foundation of Guangdong Province [2014A030313542,
   2017A030313618]
FX This research was founded by National Natural Science Foundation of
   China (81472275 and 81702399), Natural Science Foundation of Guangdong
   Province (2014A030313542 and 2017A030313618).
CR Ai XH, 2019, ONCOL REP, V41, P483, DOI 10.3892/or.2018.6834
   Baldassarre A, 2012, INT J MOL SCI, V13, P16708, DOI 10.3390/ijms131216708
   Baralle FE, 2017, NAT REV MOL CELL BIO, V18, P437, DOI 10.1038/nrm.2017.27
   Ben-Sahra I, 2017, CURR OPIN CELL BIOL, V45, P72, DOI 10.1016/j.ceb.2017.02.012
   Bhan A, 2017, CANCER RES, V77, P3965, DOI 10.1158/0008-5472.CAN-16-2634
   Brandi G, 2016, WORLD J GASTROENTERO, V22, P519, DOI 10.3748/wjg.v22.i2.519
   Cao LM, 2017, ELIFE, V6, DOI 10.7554/eLife.30433
   Chen G, 2019, MOL MED REP, V19, P719, DOI 10.3892/mmr.2018.9651
   Cho SJ, 2010, NUCLEIC ACIDS RES, V38, P2256, DOI 10.1093/nar/gkp1229
   Climente-González H, 2017, CELL REP, V20, P2215, DOI 10.1016/j.celrep.2017.08.012
   Dhamija S, 2016, INT J CANCER, V139, P269, DOI 10.1002/ijc.30039
   Ding DY, 2018, MOL CELLS, V41, P423, DOI 10.14348/molcells.2018.2258
   Engreitz JM, 2014, CELL, V159, P188, DOI 10.1016/j.cell.2014.08.018
   Faghihi MA, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-5-r56
   Fan H, 2018, MOL MED REP, V17, P8309, DOI 10.3892/mmr.2018.8907
   Fanale D, 2016, ADV EXP MED BIOL, V937, P207, DOI 10.1007/978-3-319-42059-2_11
   Gao RR, 2019, ARCH BIOCHEM BIOPHYS, V663, P183, DOI 10.1016/j.abb.2019.01.005
   Gerstberger S, 2014, NAT REV GENET, V15, P829, DOI 10.1038/nrg3813
   Gulhati P, 2011, CANCER RES, V71, P3246, DOI 10.1158/0008-5472.CAN-10-4058
   Gupta RA, 2010, NATURE, V464, P1071, DOI 10.1038/nature08975
   Han P, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0583-1
   Han Y, 2014, PATHOLOGY, V46, P396, DOI 10.1097/PAT.0000000000000125
   He SM, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-236
   He XQ, 2017, ONCOTARGET, V8, P9451, DOI 10.18632/oncotarget.14276
   Huang FT, 2018, BIOCHEM BIOPH RES CO, V503, P2949, DOI 10.1016/j.bbrc.2018.08.075
   Huang JG, 2016, NUCLEIC ACIDS RES, V44, P3059, DOI 10.1093/nar/gkv1353
   Huang KB, 2019, J CELL BIOCHEM, V120, P6071, DOI 10.1002/jcb.27893
   Jarroux J, 2017, ADV EXP MED BIOL, V1008, P1, DOI 10.1007/978-981-10-5203-3_1
   Ji Q, 2014, BRIT J CANCER, V111, P736, DOI 10.1038/bjc.2014.383
   Jia ZM, 2019, GENE, V685, P222, DOI 10.1016/j.gene.2018.11.072
   Kimmelman AC, 2017, CELL METAB, V25, P1037, DOI 10.1016/j.cmet.2017.04.004
   Kino T, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2000568
   Klingenberg M, 2018, HEPATOLOGY, V68, P1817, DOI 10.1002/hep.30102
   Kong YW, 2019, COMPR PHYSIOL, V9, P933, DOI 10.1002/cphy.c180032
   Lampada A, 2017, CELL DEATH DIFFER, V24, P1045, DOI 10.1038/cdd.2017.41
   Lan Y, 2018, NUCLEIC ACIDS RES, V46, P5809, DOI 10.1093/nar/gky214
   Levengood JD, 2019, SEMIN CELL DEV BIOL, V86, P150, DOI 10.1016/j.semcdb.2018.04.001
   Levine B, 2004, DEV CELL, V6, P463, DOI 10.1016/S1534-5807(04)00099-1
   Li CF, 2017, BIOCHEM BIOPH RES CO, V491, P552, DOI 10.1016/j.bbrc.2017.03.042
   Li H, 2017, ONCOTARGET, V8, P39859, DOI 10.18632/oncotarget.16339
   Li J, 2018, ONCOL REP, V39, P217, DOI 10.3892/or.2017.6082
   Li J, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-017-0478-7
   Li PL, 2017, MOL THER-NUCL ACIDS, V8, P356, DOI 10.1016/j.omtn.2017.07.007
   Li XK, 2017, INT J BIOL MARKER, V32, pE218, DOI 10.5301/jbm.5000249
   Li XL, 2017, CELL REP, V20, P2408, DOI 10.1016/j.celrep.2017.08.041
   Li Y, 2018, J HEMATOL ONCOL, V11, DOI 10.1186/s13045-018-0632-2
   Li YH, 2016, CANCER RES, V76, P293, DOI 10.1158/0008-5472.CAN-14-3607
   Li Y, 2016, TUMOR BIOL, V37, P14205, DOI 10.1007/s13277-016-5254-0
   Li ZW, 2017, CELL DEATH DIFFER, V24, P59, DOI 10.1038/cdd.2016.95
   Lin K, 2018, DIGEST DIS SCI, V63, P2320, DOI 10.1007/s10620-018-5127-z
   Littlewood T D, 1990, Adv Dent Res, V4, P69
   Liu L, 2018, CANCER BIOMARK, V22, P283, DOI 10.3233/CBM-171011
   Lu M, 2017, J CANCER RES CLIN, V143, P71, DOI 10.1007/s00432-016-2252-y
   Ma SP, 2018, AGING-US, V10, P2062, DOI 10.18632/aging.101530
   Malakar P, 2017, CANCER RES, V77, P1155, DOI 10.1158/0008-5472.CAN-16-1508
   Martens-Uzunova ES, 2014, EUR UROL, V65, P1140, DOI 10.1016/j.eururo.2013.12.003
   Matsumoto A, 2017, NATURE, V541, P228, DOI 10.1038/nature21034
   Mirnezami R, 2013, SURG ONCOL, V22, P22, DOI 10.1016/j.suronc.2012.11.001
   Mokarram P, 2017, AUTOPHAGY, V13, P781, DOI 10.1080/15548627.2017.1290751
   Nassour J, 2019, NATURE, V565, P659, DOI 10.1038/s41586-019-0885-0
   Neve B, 2018, CANCERS, V10, DOI 10.3390/cancers10110440
   Ohtsuka M, 2016, EBIOMEDICINE, V13, P113, DOI 10.1016/j.ebiom.2016.10.026
   Paraskevopoulou MD, 2016, METHODS MOL BIOL, V1402, P271, DOI 10.1007/978-1-4939-3378-5_21
   Peng WX, 2017, ONCOGENE, V36, P5661, DOI 10.1038/onc.2017.184
   Ping GF, 2018, AM J TRANSL RES, V10, P138
   Pruszko M, 2017, EMBO REP, V18, P1331, DOI 10.15252/embr.201643370
   Qi XL, 2015, J MED GENET, V52, P710, DOI 10.1136/jmedgenet-2015-103334
   Qiao L, 2018, MOL CELL BIOCHEM, V441, P99, DOI 10.1007/s11010-017-3177-8
   Rabanal-Ruiz Y, 2017, ESSAYS BIOCHEM, V61, P565, DOI 10.1042/EBC20170027
   Rashed MH, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18030538
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Roos M, 2016, ACS CHEM BIOL, V11, P2773, DOI 10.1021/acschembio.6b00232
   Shan TD, 2016, ONCOTARGET, V7, P961, DOI 10.18632/oncotarget.5830
   Shi JX, 2019, CELL BIOCHEM FUNCT, V37, P11, DOI 10.1002/cbf.3368
   Smith CWJ, 2000, TRENDS BIOCHEM SCI, V25, P381, DOI 10.1016/S0968-0004(00)01604-2
   Song FL, 2019, J CELL PHYSIOL, V234, P7420, DOI 10.1002/jcp.27500
   Song JP, 2019, J CELL BIOCHEM, V120, P6937, DOI 10.1002/jcb.27743
   Sun QY, 2018, TRENDS GENET, V34, P142, DOI 10.1016/j.tig.2017.11.005
   Sun XH, 2017, BIOCHEM J, V474, P2925, DOI 10.1042/BCJ20170280
   Tang Y, 2017, CANCER LETT, V391, P12, DOI 10.1016/j.canlet.2017.01.010
   Thoreen CC, 2017, BIOCHEM SOC T, V45, P213, DOI 10.1042/BST20160072
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Tsai MC, 2010, SCIENCE, V329, P689, DOI 10.1126/science.1192002
   Varshavsky A, 2017, ANNU REV BIOCHEM, V86, P123, DOI 10.1146/annurev-biochem-061516-044859
   Wang CY, 2018, MOL MED REP, V17, P6598, DOI 10.3892/mmr.2018.8669
   Wang GY, 2014, ONCOL REP, V31, P1839, DOI 10.3892/or.2014.3047
   Wang JY, 2014, CELL SIGNAL, V26, P1048, DOI 10.1016/j.cellsig.2014.01.022
   Wang J, 2015, ONCOTARGET, V6, P37852, DOI 10.18632/oncotarget.5635
   Wang L, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180790
   Wang LQ, 2019, INT J BIOCHEM CELL B, V106, P46, DOI 10.1016/j.biocel.2018.09.015
   Wang M, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1187-4
   Wang XK, 2019, INT J MED SCI, V16, P51, DOI 10.7150/ijms.27359
   Wang YY, 2015, CELL STEM CELL, V16, P413, DOI 10.1016/j.stem.2015.03.003
   Wu BH, 2019, HUM CELL, V32, P31, DOI 10.1007/s13577-018-0217-y
   Xiao ZG, 2018, CELL PHYSIOL BIOCHEM, V46, P1275, DOI 10.1159/000489110
   Xiong YB, 2018, ONCOL REP, V39, P967, DOI 10.3892/or.2018.6204
   Xu M, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-018-0690-5
   Yan Y, 2019, BIOCHEM BIOPH RES CO, V509, P441, DOI 10.1016/j.bbrc.2018.12.090
   Yang PX, 2017, J GASTROEN HEPATOL, V32, P837, DOI 10.1111/jgh.13606
   Yang XD, 2018, ONCOL REP, V40, P1554, DOI 10.3892/or.2018.6573
   Yang Y, 2017, ONCOL LETT, V13, P3151, DOI 10.3892/ol.2017.5841
   Yang YN, 2018, CANCER CELL INT, V18, DOI 10.1186/s12935-018-0660-6
   Yang ZY, 2017, CANCER BIOMARK, V18, P95, DOI 10.3233/CBM-161715
   Yoon JH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3939
   Zhai HY, 2013, CLIN COLORECTAL CANC, V12, P261, DOI 10.1016/j.clcc.2013.06.003
   Zhang ML, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06862-2
   Zhang W, 2018, BIOCHIMIE, V144, P21, DOI 10.1016/j.biochi.2017.10.002
   Zhang Z, 2018, BIOSCIENCE REP, V38, DOI 10.1042/BSR20180620
   Zheng YS, 2019, J CELL BIOCHEM, V120, P3922, DOI 10.1002/jcb.27676
   Zhou JW, 2018, BIOCHEM BIOPH RES CO, V503, P1848, DOI 10.1016/j.bbrc.2018.07.125
   Zhou QW, 2019, CANCER SCI, V110, P1194, DOI 10.1111/cas.13951
   Zhou R, 2017, NUCLEIC ACIDS RES, V45, P606, DOI 10.1093/nar/gkw851
   Zhu J, 2018, CELL PHYSIOL BIOCHEM, V51, P113
   Zou YM, 2018, EUR J CELL BIOL, V97, P369, DOI 10.1016/j.ejcb.2018.04.005
NR 115
TC 33
Z9 34
U1 0
U2 11
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD JAN 17
PY 2020
VL 9
AR 1542
DI 10.3389/fonc.2019.01542
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KH5GN
UT WOS:000510677800001
PM 32010629
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Zhou, JY
   Zou, YY
   Hu, G
   Lin, CW
   Guo, YH
   Gao, K
   Wu, MR
AF Zhou, Jianyu
   Zou, Yueyi
   Hu, Gui
   Lin, Changwei
   Guo, Yihang
   Gao, Kai
   Wu, Mayrong
TI Facilitating colorectal cancer cell metastasis by targeted binding of
   long non-coding RNA ENSG00000231881 with miR-133b via VEGFC signaling
   pathway
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE Long non-coding RNA; ENSG00000231881; miR-133b; VEGFC; Colorectal
   cancer; Metastasis
ID IN-VITRO; GROWTH
AB Background: Colorectal cancer mainly metastasizes through the lymphatic pathways and is associated with a high mortality rate. It is one of the leading causes of cancer-related deaths. In this study, the effects of long non-coding RNA (IncRNA) ENSG00000231881 on the metastasis of colorectal cancer cells were evaluated.
   Methods: The expression level of ENSG00000231881 in colorectal cancer tissues was detected with bioinformatics analysis and quantitative polymerase chain reaction (qPCR) assay. Functional colorectal cancer cell models for the overexpression and interference expression of ENSG00000231881 were established. MTT, transwell, tube formation, qPCR, and western blot assays were performed to detect changes in various cellular functions and expression levels of key factors (miR-133b and vascular endothelial growth factor C [VEGFC]) in ENSG00000231881 functional models. Dual luciferase assay was performed to verify the binding relationship between ENSG00000231881 and miR-133b.
   Results: ENSG00000231881 expression level was substantially higher in colorectal cancer tissues than in paracancerous tissues and correlated with malignancy and prognosis. In colorectal cancer cells, ENSG00000231881 overexpression significantly promoted cell proliferation, metastasis, and tube formation in lymphatic epithelium, decreased miR-133b expression, and increased VEGFC expression. On the contrary, ENSG00000231881 interference expression showed exactly opposite results. ENSG00000231881 could bind to miR-133b and consequently affect the cell functions through the regulation of VEGFC expression via miR-133b.
   Conclusion: ENSG00000231881 binds to miR-133b via competitive endogenous RNA (ceRNA) mechanism and regulates the VEGFC signaling pathway, consequently leading to the metastasis of colorectal cancer cells. Our study provides a theoretical basis for the use of ENSG00000231881 as a therapeutic target for gene-targeted therapy in colorectal cancer. (C) 2018 Elsevier Inc. All rights reserved.
C1 [Zhou, Jianyu; Zou, Yueyi; Hu, Gui; Lin, Changwei; Guo, Yihang; Gao, Kai] Ctr South Univ, Xiangya Hosp 3, Gastrointestinal Surg Ward, Changsha 410013, Hunan, Peoples R China.
   [Wu, Mayrong] Ctr South Univ, Xiangya Hosp 3, Operat Ctr, 168 Tongzi Slope Rd, Changsha 410013, Hunan, Peoples R China.
C3 Central South University; Central South University
RP Wu, MR (corresponding author), Ctr South Univ, Xiangya Hosp 3, Operat Ctr, 168 Tongzi Slope Rd, Changsha 410013, Hunan, Peoples R China.
EM Xiaorongli1407@163.com
CR Akbari Abolfazl, 2017, Asian Pac J Cancer Prev, P2101
   [Anonymous], J CELL PHYSL
   Bevan R, 2018, CLIN ENDOSC, V51, P37, DOI 10.5946/ce.2017.141
   Carrieri C, 2012, NATURE, V491, P454, DOI 10.1038/nature11508
   Geisler S, 2013, NAT REV MOL CELL BIO, V14, P699, DOI 10.1038/nrm3679
   Guo YH, 2015, MOL MED REP, V11, P2805, DOI 10.3892/mmr.2014.3075
   Hong S, 2015, ONCOL REP, V33, P507, DOI 10.3892/or.2014.3615
   Hu G, 2010, CANCER BIOL THER, V10, P190, DOI 10.4161/cbt.10.2.12186
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Kornfeld JW, 2014, FRONT GENET, V5, DOI 10.3389/fgene.2014.00057
   Kornienko AE, 2013, BMC BIOL, V11, DOI 10.1186/1741-7007-11-59
   Lewandowska-Sabat AM, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-018-4591-3
   Li XM, 2011, MED ONCOL, V28, P1054, DOI 10.1007/s12032-010-9637-6
   Lin CW, 2014, BRIT J CANCER, V110, P2310, DOI 10.1038/bjc.2014.118
   Maida M, 2017, EXPERT REV ANTICANC, V17, P1131, DOI 10.1080/14737140.2017.1392243
   Mirzaei A, 2016, CANCER BIOMARK, V17, P301, DOI 10.3233/CBM-160642
   Rinn JL, 2012, ANNU REV BIOCHEM, V81, P145, DOI 10.1146/annurev-biochem-051410-092902
   Rokavec M, 2017, CANCER RES, V77, P1854, DOI 10.1158/0008-5472.CAN-16-3236
   Sakima M, 2018, EXP CELL RES, V368, P13, DOI 10.1016/j.yexcr.2018.04.007
   Sundar SS, 2007, J CLIN ONCOL, V25, P4298, DOI 10.1200/JCO.2006.07.1092
   Swain AC, 2018, MOL ONCOL, V12, P855, DOI 10.1002/1878-0261.12198
   Toyama K, 2018, ARTERIOSCL THROM VAS, V38, P1392, DOI 10.1161/ATVBAHA.118.310822
   Tripathi V, 2010, MOL CELL, V39, P925, DOI 10.1016/j.molcel.2010.08.011
   Wissmann C, 2006, CLIN CANCER RES, V12, P6865, DOI 10.1158/1078-0432.CCR-06-1800
   Wu H, 2017, ONCOTARGET, V8, P21095, DOI 10.18632/oncotarget.15045
   Xiang KM, 2014, ASIAN PAC J CANCER P, V15, P3767, DOI 10.7314/APJCP.2014.15.8.3767
NR 26
TC 13
Z9 15
U1 1
U2 7
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD JAN 29
PY 2019
VL 509
IS 1
BP 1
EP 7
DI 10.1016/j.bbrc.2018.08.004
PG 7
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA HI5KV
UT WOS:000456491800001
PM 30581003
DA 2025-01-04
ER

PT J
AU Anestis, A
   Zoi, I
   Karamouzis, MV
AF Anestis, Aristomenis
   Zoi, Ilianna
   Karamouzis, Michalis V.
TI Current advances of targeting HGF/c-Met pathway in gastric cancer
SO ANNALS OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Gastric cancer; hepatocyte growth factor (HGF); c-Met; molecular
   targeted therapy; personalized medicine
ID HEPATOCYTE GROWTH-FACTOR; METASTATIC COLORECTAL-CANCER; TYROSINE KINASE
   INHIBITORS; LABEL PHASE-3 TRIAL; C-MET; FACTOR-RECEPTOR;
   DOWN-REGULATION; SIGNALING PATHWAY; MEDIATES RESISTANCE;
   MONOCLONAL-ANTIBODY
AB Despite the advances in systemic chemotherapy, gastric adenocarcinoma (GC) remains the third most common cause of cancer-related deaths with poor prognosis. The heterogeneity of GC indicates that novel biomarkers should be established in order to further classify tumors and develop individual targeted therapies. High-quality preclinical and clinical research has demonstrated that growth factor (HGF)-hepatocyte growth factor receptor (c-Met) pathway plays a pivotal role on the growth, survival and invasiveness of GC. In particular, aberrant activation of HGF/c-Met signaling pathway has been associated with poor clinical outcomes, suggesting the therapeutic potential of c-Met. This has stimulated the development and evaluation of a number of c-Met targeted agents in an advance disease setting. In this review, we summarize the current state of the art in the advances on the inhibition of c-Met pathway, with particular emphasis on the clinical testing of c-Met targeted therapeutic agents. Furthermore, we discuss the challenges facing the incorporation of c-Met targeted agents in randomized trials, with the idea that the definition of the appropriate genetic and molecular context for the use of these agents remains the priority.
C1 [Anestis, Aristomenis; Zoi, Ilianna; Karamouzis, Michalis V.] Univ Athens, Med Sch, Mol Oncol Unit, Dept Biol Chem,Laiko Gen Hosp, Athens, Greece.
   [Karamouzis, Michalis V.] Univ Athens, Med Sch, Laiko Gen Hosp, Dept Internal Med 1, Athens, Greece.
C3 Laiko General Hospital; National & Kapodistrian University of Athens;
   Laiko General Hospital; National & Kapodistrian University of Athens
RP Karamouzis, MV (corresponding author), Univ Athens, Med Sch, Dept Biol Chem, 75 M Asias St, Athens 11527, Greece.
EM mkaramouz@med.uoa.gr
RI Karamouzis, Michalis/AAD-2860-2020
OI Zoi, Ilianna/0000-0002-0435-2463
CR Ajani Jaffer A, 2008, J Natl Compr Canc Netw, V6, P813
   Amemiya H, 2002, ONCOLOGY-BASEL, V63, P286, DOI 10.1159/000065477
   [Anonymous], 2010, J CLIN ONCOL
   [Anonymous], 2014, J CLIN ONCOL S
   Appleman LJ, 2011, J CLIN ONCOL, V29, P4837, DOI 10.1200/JCO.2011.37.7929
   Avan A, 2013, CURR PHARM DESIGN, V19, P940, DOI 10.2174/138161213804547312
   Bachleitner-Hofmann T, 2008, MOL CANCER THER, V7, P3499, DOI 10.1158/1535-7163.MCT-08-0374
   Bang YJ, 2010, LANCET, V376, P1302
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bass AJ, 2014, NATURE, V513, P202, DOI 10.1038/nature13480
   Bendell JC, 2017, ONCOLOGIST, V22, P264, DOI 10.1634/theoncologist.2016-0223
   Bhowmick NA, 2004, NATURE, V432, P332, DOI 10.1038/nature03096
   Bosetti C, 2008, ANN ONCOL, V19, P631, DOI 10.1093/annonc/mdm597
   Bradley CA, 2017, NAT REV CLIN ONCOL, V14, P562, DOI 10.1038/nrclinonc.2017.40
   Burgess TL, 2010, MOL CANCER THER, V9, P400, DOI 10.1158/1535-7163.MCT-09-0824
   Carson R, 2015, CLIN CANCER RES, V21, P3230, DOI 10.1158/1078-0432.CCR-14-2701
   Catenacci DVT, 2017, LANCET ONCOL, V18, P1467, DOI 10.1016/S1470-2045(17)30566-1
   Cecchi F, 2012, EXPERT OPIN THER TAR, V16, P553, DOI 10.1517/14728222.2012.680957
   Cepero V, 2010, CANCER RES, V70, P7580, DOI 10.1158/0008-5472.CAN-10-0436
   Chen CT, 2012, MOL CANCER THER, V11, P660, DOI 10.1158/1535-7163.MCT-11-0754
   Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530
   Corso S, 2008, ONCOGENE, V27, P684, DOI 10.1038/sj.onc.1210697
   De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093
   Deng NT, 2012, GUT, V61, P673, DOI 10.1136/gutjnl-2011-301839
   Doi T, 2015, J CLIN ONCOL, V33
   Dulak AM, 2013, NAT GENET, V45, P478, DOI 10.1038/ng.2591
   Edakuni G, 2001, PATHOL INT, V51, P172, DOI 10.1046/j.1440-1827.2001.01182.x
   Fischer OM, 2004, J BIOL CHEM, V279, P28970, DOI 10.1074/jbc.M402508200
   Fixman ED, 1996, J BIOL CHEM, V271, P13116, DOI 10.1074/jbc.271.22.13116
   Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969
   Goscinski MA, 2009, SCAND J SURG, V98, P214, DOI 10.1177/145749690909800404
   Grabsch H, 2010, CELL ONCOL, V32, P57, DOI 10.3233/CLO-2009-0497
   Graveel C, 2004, P NATL ACAD SCI USA, V101, P17198, DOI 10.1073/pnas.0407651101
   Haghighat Peyman, 2008, J Natl Compr Canc Netw, V6, P895
   Hammond DE, 2001, ONCOGENE, V20, P2761, DOI 10.1038/sj.onc.1204475
   Hara T, 1998, LAB INVEST, V78, P1143
   Hattori Y, 1996, CLIN CANCER RES, V2, P1373
   HUMPHREY PA, 1995, AM J PATHOL, V147, P386
   Inoue T, 2004, CANCER SCI, V95, P803, DOI 10.1111/j.1349-7006.2004.tb02185.x
   Iveson T, 2014, LANCET ONCOL, V15, P1007, DOI 10.1016/S1470-2045(14)70023-3
   Janjigian YY, 2011, CANCER EPIDEM BIOMAR, V20, P1021, DOI 10.1158/1055-9965.EPI-10-1080
   Jo MJ, 2000, J BIOL CHEM, V275, P8806, DOI 10.1074/jbc.275.12.8806
   Kamangar F, 2006, J CLIN ONCOL, V24, P2137, DOI 10.1200/JCO.2005.05.2308
   Khoury H, 2005, MOL BIOL CELL, V16, P550, DOI 10.1091/mbc.E04-07-0567
   Kim DC, 2016, ONCOL LETT, V11, P991, DOI 10.3892/ol.2015.4029
   Kim J, 2014, J CLIN INVEST, V124, P5145, DOI 10.1172/JCI75200
   Kitadai Y, 2003, BIOCHEM BIOPH RES CO, V311, P809, DOI 10.1016/j.bbrc.2003.10.077
   Kobayashi M, 1999, P NATL ACAD SCI USA, V96, P4874, DOI 10.1073/pnas.96.9.4874
   KOMADA M, 1993, FEBS LETT, V328, P25, DOI 10.1016/0014-5793(93)80958-W
   Kwak EL, 2016, CANCER DISCOV, V6, P1402, DOI 10.1158/2159-8290.CD-16-1271
   Kwak EL, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.15_suppl.tps3087
   Li YB, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113186
   Lieto E, 2008, ANN SURG ONCOL, V15, P69, DOI 10.1245/s10434-007-9596-0
   Liska D, 2011, CLIN CANCER RES, V17, P472, DOI 10.1158/1078-0432.CCR-10-0568
   Liu XD, 2008, EXPERT OPIN INV DRUG, V17, P997, DOI [10.1517/13543784.17.7.997, 10.1517/13543784.17.7.997 ]
   Liu XD, 2010, TRENDS MOL MED, V16, P37, DOI 10.1016/j.molmed.2009.11.005
   Lordick F, 2013, LANCET ONCOL, V14, P490, DOI 10.1016/S1470-2045(13)70102-5
   Malka D, 2015, J CLIN ONCOL S, V33
   Merchant M, 2013, P NATL ACAD SCI USA, V110, pE2987, DOI 10.1073/pnas.1302725110
   Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032
   Murayama T, 2009, BRIT J CANCER, V100, P782, DOI 10.1038/sj.bjc.6604915
   Nath D, 2014, J CELL SCI, V127, P1620, DOI 10.1242/jcs.152595
   Parkin DM, 2005, CA-CANCER J CLIN, V55, P74, DOI 10.3322/canjclin.55.2.74
   PELICCI G, 1995, ONCOGENE, V10, P1631
   Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0
   Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103
   Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297
   Qi J, 2011, CANCER RES, V71, P1081, DOI 10.1158/0008-5472.CAN-10-1623
   Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435
   Schulte N, 2015, GASTROINTEST TUMORS, V1, P180, DOI 10.1159/000380786
   Shah MA, 2015, J CLIN ONCOL, V33, DOI 10.1200/jco.2015.33.3_suppl.2
   Sierra J Rafael, 2011, Ther Adv Med Oncol, V3, pS21, DOI 10.1177/1758834011422557
   Tabernero J, 2014, CLIN CANCER RES, V20, P2793, DOI 10.1158/1078-0432.CCR-13-1837
   Tian S, 2011, CANCER SCI, V102, P1374, DOI 10.1111/j.1349-7006.2011.01939.x
   Tsuta K, 2012, J THORAC ONCOL, V7, P331, DOI 10.1097/JTO.0b013e318241655f
   Van Cutsem E, 2014, CLIN CANCER RES, V20, P4240, DOI 10.1158/1078-0432.CCR-13-2752
   Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032
   Waddell T, 2013, LANCET ONCOL, V14, P481, DOI 10.1016/S1470-2045(13)70096-2
   Wang JY, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2138-z
   Wang XL, 2012, ACTA PHARMACOL SIN, V33, P513, DOI 10.1038/aps.2011.205
   Zeng ZS, 2008, CANCER LETT, V265, P258, DOI 10.1016/j.canlet.2008.02.049
   Zhang YW, 2002, ONCOGENE, V21, P217, DOI 10.1038/sj/onc/1205004
   Zucali PA, 2008, ANN ONCOL, V19, P1605, DOI 10.1093/annonc/mdn240
NR 83
TC 30
Z9 35
U1 0
U2 26
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2305-5839
EI 2305-5847
J9 ANN TRANSL MED
JI ANN. TRANSL. MED.
PD JUN
PY 2018
VL 6
IS 12
AR 247
DI 10.21037/atm.2018.04.42
PG 10
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA GL9CI
UT WOS:000437527200005
PM 30069449
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Bhattacharya, S
   Page, A
   Shinde, P
AF Bhattacharya, Sankha
   Page, Amit
   Shinde, Prafull
TI Capecitabine loaded potato starch-chitosan nanoparticles: A novel
   approach for targeted therapy and improved outcomes in aggressive colon
   cancer
SO EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS
LA English
DT Article
DE Carbohydrate-based nanoparticles; Capecitabine delivery; Colon cancer;
   Tumor targeting; Antitumor activity; Balb/c mice
ID DELIVERY; CELLS; CYTOTOXICITY; ANTIOXIDANT; FORMULATION
AB Aggressive colon cancer treatment poses significant challenges. This study investigates the potential of innovative carbohydrate-based nanoparticles for targeted Capecitabine (CTB) delivery. CTB nanoparticles were synthesized by conjugating CTB with potato starch and chitosan using ultrasonication, hydrolysis, and ionotropic gelation. Characterization included drug loading, rheology, Surface-Enhanced Raman Spectroscopy (SERS), Fourier-Transform Infrared Spectroscopy (FTIR), Differential Scanning Calorimetry (DSC), X-ray Diffraction (XRD), and Thermogravimetric Analysis (TGA). In vitro and in vivo antitumor activity was evaluated using HT29 cells and N, N-dimethylhydrazine-induced Balb/c mice, respectively. Cellular assays assessed angiogenesis, migration, proliferation, and apoptosis. Nanoparticles exhibited a mean size of 245 nm, positive zeta potential (+30 mV), high loading efficacy (76 %), and sustained drug release (92 % over 100 h). CTB-loaded nanoparticles displayed superior colon histology, reduced tumour scores, and inhibited VEGD and CD31 expression compared to free CTB. Cellular assays confirmed significant antitumor effects, including reduced tube formation, migration, and proliferation, and increased apoptosis. This study demonstrates the promise of CTB-loaded potato starchchitosan nanoparticles for aggressive colon cancer treatment. These findings highlight the potential of these nanoparticles for further evaluation in diverse cancer models.
C1 [Bhattacharya, Sankha; Page, Amit] SVKMS NMIMS Deemed To Be Univ, Sch Pharm & Technol Management, Dept Pharmaceut, Shirpur 425405, Maharashtra, India.
   [Shinde, Prafull] NMIMS Deemed Univ, SVKMs Narsee Monjee Inst Management Studies NMIMS, Shobhaben Pratapbhai Patel Sch Pharm & Technol Man, Mumbai, India.
C3 SVKM's NMIMS (Deemed to be University); SVKM's NMIMS (Deemed to be
   University)
RP Bhattacharya, S (corresponding author), SVKMS NMIMS Deemed To Be Univ, Sch Pharm & Technol Management, Dept Pharmaceut, Shirpur 425405, Maharashtra, India.
EM sankhabhatt@gmail.com
RI Bhattacharya, Sankha/AAM-5111-2020; Shinde, Prafull/AFI-5015-2022
OI Shinde, Prafull/0000-0002-4654-0083; Page, Amit/0000-0001-9735-1197
FU NMIMS Deemed-to-be University Seed grant
FX The corresponding author acknowledges the NMIMS Deemed-to-be University
   Seed grant (issued on 11th July 2022) for generously supporting this
   project, which facilitated the acquisition of essential chemicals and
   glassware.
CR Abdullah, 2022, J SAUDI CHEM SOC, V26, DOI 10.1016/j.jscs.2022.101486
   Abdullah S., 2024, Pharmacol. Res. - Modern Chin. Med.
   Ahmad M, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60380-0
   Ahmad M, 2018, INT J BIOL MACROMOL, V109, P435, DOI 10.1016/j.ijbiomac.2017.11.122
   Akram MU, 2023, CHEMOSPHERE, V313, DOI 10.1016/j.chemosphere.2022.137332
   Amador CI, 2021, J MICROBIOL METH, V190, DOI 10.1016/j.mimet.2021.106343
   Ameli H, 2022, RSC ADV, V12, P4681, DOI 10.1039/d1ra07791k
   Amin H, 2023, SAUDI PHARM J, V31, P29, DOI 10.1016/j.jsps.2022.11.004
   Arrua EC, 2023, INT J PHARMACEUT, V642, DOI 10.1016/j.ijpharm.2023.123120
   Bakrania AK, 2018, EUR J PHARM BIOPHARM, V122, P37, DOI 10.1016/j.ejpb.2017.10.007
   Banerjee A, 2024, ELECTRON J BIOTECHN, V68, P11, DOI 10.1016/j.ejbt.2023.11.005
   Bhattacharya S, 2020, INT J BIOL MACROMOL, V151, P104, DOI 10.1016/j.ijbiomac.2020.02.151
   Chacon WDC, 2019, STARCH-STARKE, V71, DOI 10.1002/star.201800081
   Chang LZ, 2024, BBA-MOL BASIS DIS, V1870, DOI 10.1016/j.bbadis.2024.167035
   Cheng H, 2022, CHEM ENG J, V427, DOI 10.1016/j.cej.2021.131672
   Clemente N, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00776
   Dardeer HM, 2022, INT J BIOL MACROMOL, V219, P1062, DOI 10.1016/j.ijbiomac.2022.07.249
   Dash KK, 2019, INT J BIOL MACROMOL, V139, P449, DOI 10.1016/j.ijbiomac.2019.07.193
   Dewi FRP, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e11418
   Dhull SB, 2024, HELIYON, V10, DOI 10.1016/j.ifset.2024.103581
   Ding KX, 2022, LANCET DIGIT HEALTH, V4, pE787, DOI 10.1016/S2589-7500(22)00168-6
   Dong AC, 2005, ARCH BIOCHEM BIOPHYS, V436, P154, DOI 10.1016/j.abb.2005.01.006
   Dong HM, 2021, FOOD HYDROCOLLOID, V119, DOI 10.1016/j.foodhyd.2021.106828
   Dongsar TT, 2023, J DRUG DELIV SCI TEC, V82, DOI 10.1016/j.jddst.2023.104371
   Doshi AS, 2022, J CONTROL RELEASE, V345, P721, DOI 10.1016/j.jconrel.2022.03.054
   Du JB, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-01519-x
   Dudhipala N, 2018, DRUG DEV IND PHARM, V44, P1572, DOI 10.1080/03639045.2018.1445264
   Farnad N, 2023, FOOD CHEM, V398, DOI 10.1016/j.foodchem.2022.133910
   Ganugula R, 2023, ACS NANO, V17, P6857, DOI 10.1021/acsnano.3c00535
   Ganugula R, 2019, ACS CHEM NEUROSCI, V10, P1801, DOI 10.1021/acschemneuro.8b00703
   Gericke M, 2024, CARBOHYD POLYM, V326, DOI 10.1016/j.carbpol.2023.121633
   Gnerucci A, 2020, MATH BIOSCI, V330, DOI 10.1016/j.mbs.2020.108482
   Gong LS, 2024, CARBOHYD POLYM, V327, DOI 10.1016/j.carbpol.2023.121647
   Guan YF, 2022, FOOD CHEM X, V16, DOI 10.1016/j.fochx.2022.100495
   Guimaraes ML, 2022, SYNTHETIC MET, V287, DOI 10.1016/j.synthmet.2022.117055
   Guktur RE, 2024, INT J PHARMACEUT, V652, DOI 10.1016/j.ijpharm.2023.123766
   Gupta A, 2024, J DRUG DELIV SCI TEC, V93, DOI 10.1016/j.jddst.2024.105401
   Haque S, 2021, CANCERS, V13, DOI 10.3390/cancers13236114
   Hejjaji EMA, 2017, FOOD HYDROCOLLOID, V71, P290, DOI 10.1016/j.foodhyd.2016.12.020
   Heyns IM, 2023, ACS APPL MATER INTER, V15, P45651, DOI 10.1021/acsami.3c09866
   Hu YY, 2024, FOOD CHEM, V440, DOI 10.1016/j.foodchem.2023.138131
   Huang JS, 2022, BIOMED PHARMACOTHER, V155, DOI 10.1016/j.biopha.2022.113829
   Huang JX, 2022, ACTA BIOMATER, V152, P171, DOI 10.1016/j.actbio.2022.08.069
   Huang X, 2022, HELIYON, V8, DOI 10.1016/j.heliyon.2022.e11058
   Ihsanpuro SI, 2022, ARAB J CHEM, V15, DOI 10.1016/j.arabjc.2022.104310
   Jafari AM, 2024, INT J BIOL MACROMOL, V260, DOI 10.1016/j.ijbiomac.2024.129360
   Jayasinghe AMK, 2024, J ETHNOPHARMACOL, V321, DOI 10.1016/j.jep.2023.117529
   Jiang T, 2024, INT IMMUNOPHARMACOL, V128, DOI 10.1016/j.intimp.2024.111540
   Jin LL, 2023, BIOACT MATER, V19, P38, DOI 10.1016/j.bioactmat.2022.03.040
   Jin W, 2016, J THEOR BIOL, V390, P136, DOI 10.1016/j.jtbi.2015.10.040
   Kaul S, 2022, CARBOHYD POLYM, V282, DOI 10.1016/j.carbpol.2022.119107
   Khan A, 2024, FOOD HYDROCOLLOID, V149, DOI 10.1016/j.foodhyd.2023.109537
   Kim N, 2024, FOOD PACKAGING SHELF, V42, DOI 10.1016/j.fpsl.2023.101228
   Ko JH, 2022, BIOMACROMOLECULES, V23, P3383, DOI 10.1021/acs.biomac.2c00511
   Kovacs MA, 2024, AM J PATHOL, V194, P225, DOI 10.1016/j.ajpath.2023.11.008
   Kuhn H, 2023, TRANSL ONCOL, V27, DOI 10.1016/j.tranon.2022.101566
   Laborda-Illanes A, 2023, BIOMED PHARMACOTHER, V157, DOI 10.1016/j.biopha.2022.114041
   Phuc LTM, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061301
   Li J, 2023, INORG CHEM COMMUN, V155, DOI 10.1016/j.inoche.2023.111002
   Ma HP, 2023, EUR J PHARM SCI, V182, DOI 10.1016/j.ejps.2023.106373
   Mo CE, 2019, INT J PHARMACEUT, V557, P293, DOI 10.1016/j.ijpharm.2018.12.070
   Mohan HM, 2024, EJSO-EUR J SURG ONC, V50, DOI 10.1016/j.ejso.2023.107937
   Mondal A, 2019, INT J BIOL MACROMOL, V140, P1091, DOI 10.1016/j.ijbiomac.2019.08.094
   Mondal H, 2021, CHEM PHYS LETT, V774, DOI 10.1016/j.cplett.2021.138623
   Moriiwa Y, 2023, TALANTA, V252, DOI 10.1016/j.talanta.2022.123827
   Nandi G., 2023, TAILOR MADE POLYSACC, P177, DOI [10.1016/B978-0-12-821286-8.00009-4, DOI 10.1016/B978-0-12-821286-8.00009-4]
   Ndlovu LN, 2024, CHEM ENG RES DES, V203, P149, DOI 10.1016/j.cherd.2024.01.044
   Niu HR, 2024, CHEM ENG SCI, V284, DOI 10.1016/j.ces.2023.119484
   Pandey S, 2017, CURR DRUG DELIV, V14, P887, DOI 10.2174/1567201813666160817150621
   Rahmatpour A, 2024, CARBOHYD POLYM, V328, DOI 10.1016/j.carbpol.2023.121721
   Razavi MS, 2023, J DRUG DELIV SCI TEC, V85, DOI 10.1016/j.jddst.2023.104587
   Ren JY, 2024, J PHARM SCI-US, V113, P471, DOI 10.1016/j.xphs.2023.10.033
   Ruiz-Zambrana C, 2021, ANGEW CHEM INT EDIT, V60, P20003, DOI 10.1002/anie.202107973
   Sahu P, 2019, INT J BIOL MACROMOL, V128, P740, DOI 10.1016/j.ijbiomac.2019.01.147
   Santhosh R, 2024, INT J BIOL MACROMOL, V260, DOI 10.1016/j.ijbiomac.2024.129625
   Saravanakumar K, 2021, INT J BIOL MACROMOL, V182, P1409, DOI 10.1016/j.ijbiomac.2021.05.036
   Sathiyaseelan A, 2022, INT J BIOL MACROMOL, V220, DOI 10.1016/j.ijbiomac.2022.09.045
   Shabana S, 2022, INT J BIOL MACROMOL, V222, P1709, DOI 10.1016/j.ijbiomac.2022.09.225
   Sherif AY, 2022, AAPS PHARMSCITECH, V23, DOI 10.1208/s12249-022-02332-7
   Shields A, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110817
   Sun SB, 2015, INT J CLIN EXP MED, V8, P19670
   Tang J, 2021, FOOD CHEM, V365, DOI 10.1016/j.foodchem.2021.130448
   Upadhyay M, 2019, MAT SCI ENG C-MATER, V104, DOI 10.1016/j.msec.2019.109958
   Waliullah MH, 2021, J FOOD PROCESS PRES, V45, DOI 10.1111/jfpp.15650
   Wan YH, 2022, DISCOV ONCOL, V13, DOI 10.1007/s12672-022-00586-y
   Wang JT, 2024, COMP MATER SCI, V231, DOI 10.1016/j.commatsci.2023.112608
   Wang XP, 2022, ENGINEERING-PRC, V10, P81, DOI 10.1016/j.eng.2021.05.023
   Wang XZ, 2024, MATTER-US, V7, DOI 10.1016/j.matt.2023.10.023
   Wang XZ, 2009, CHEM ENG RES DES, V87, P874, DOI 10.1016/j.cherd.2008.12.014
   Wang ZR, 2022, J CONTROL RELEASE, V349, P929, DOI 10.1016/j.jconrel.2022.07.042
   Wu GR, 2012, INT J BIOL MACROMOL, V50, P1011, DOI 10.1016/j.ijbiomac.2012.02.017
   Wu L, 2023, FOOD HYDROCOLLOID, V137, DOI 10.1016/j.foodhyd.2022.108329
   Yan XX, 2022, FOOD CHEM, V369, DOI 10.1016/j.foodchem.2021.130824
   Yao L., 2023, J. Natl. Cancer Center
   Yong HM, 2020, INT J BIOL MACROMOL, V156, P462, DOI 10.1016/j.ijbiomac.2020.04.035
   Zaw ZCT, 2022, J DENT SCI, V17, P1160, DOI 10.1016/j.jds.2022.01.006
   Zhai YH, 2022, J CONTROL RELEASE, V350, P761, DOI 10.1016/j.jconrel.2022.08.054
   Zhang ZP, 2022, TOXICOL APPL PHARM, V449, DOI 10.1016/j.taap.2022.116110
   Zheng JG, 2022, J SAUDI CHEM SOC, V26, DOI 10.1016/j.jscs.2022.101543
   Zheng MC, 2021, BIOACT MATER, V6, P1878, DOI 10.1016/j.bioactmat.2020.12.001
NR 100
TC 1
Z9 1
U1 3
U2 6
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0939-6411
EI 1873-3441
J9 EUR J PHARM BIOPHARM
JI Eur. J. Pharm. Biopharm.
PD JUL
PY 2024
VL 200
AR 114328
DI 10.1016/j.ejpb.2024.114328
EA MAY 2024
PG 24
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA TW5L4
UT WOS:001244308600001
PM 38763329
DA 2025-01-04
ER

PT J
AU Tan, E
   Sahin, IH
AF Tan, Elaine
   Sahin, Ibrahim Halil
TI Defining the current role of immune checkpoint inhibitors in the
   treatment of mismatch repair-deficient/microsatellite stability-high
   colorectal cancer and shedding light on future approaches
SO EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
DE MSI-H; MMR-D; colorectal cancer; immune checkpoint inhibitor;
   biomarkers; BRAF V600E; MLH1; PMS2; MSH2; MSH6; immunotherapy
ID MICROSATELLITE INSTABILITY; NIVOLUMAB; MUTATION; DEFECTS
AB Introduction: Mismatch repair deficient (MMR-D)/microsatellite instability-high (MSI-H) colorectal cancer (CRC) carries unique biologic features including high tumor mutation burden, increased amount of mutation-associated neoantigen generation, and the presence of marked tumor-infiltrating lymphocytes. Immune checkpoint inhibitor (ICI) therapy has rapidly changed the treatment algorithm of MMR-D/MSI-H CRC.
   Areas covered: In this review article, we discuss the recent data regarding the use of ICIs in metastatic MMR-D/MSI-H CRC patients. We also elaborated on potential biomarkers of ICI response and innovative therapeutic approaches that may prevail resistance mechanisms for the treatment of MMR-D/MSI-H colorectal cancer.
   Expert opinion: Pembrolizumab was recently granted approval by the FDA as first-line therapy for metastatic MMR-D/MSI-H CRC based on the results of the Keynote 177 study. The combination of nivolumab and ipilimumab will also likely be a choice for the initial therapy of MMR-D/MSI-H CRC in the near future. More therapeutic modalities with novel immunomodulatory agents as well as targeted therapy directed to immune resistance pathways are needed. The novel approaches discussed in this review article will define potential treatment options for the management of MMR-D/MSI-H CRC patients who progress on first-line ICI therapy.
C1 [Tan, Elaine; Sahin, Ibrahim Halil] H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL 33612 USA.
C3 H Lee Moffitt Cancer Center & Research Institute
RP Sahin, IH (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL 33612 USA.
EM Ibrahim.sahin@moffitt.org
RI Şahin, İbrahim/HHY-8303-2022
CR Ahadova A, 2016, FAM CANCER, V15, P579, DOI 10.1007/s10689-016-9899-z
   Ahnen DJ, 2014, MAYO CLIN PROC, V89, P216, DOI 10.1016/j.mayocp.2013.09.006
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   [Anonymous], 2018, EXPLORATORY ANAL JAN
   Bicknell DC, 1996, CURR BIOL, V6, P1695, DOI 10.1016/S0960-9822(02)70795-1
   BOYER JC, 1995, CANCER RES, V55, P6063
   Cercek A, 2020, CLIN CANCER RES, V26, P3271, DOI 10.1158/1078-0432.CCR-19-3728
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Engel C, 2020, GASTROENTEROLOGY, V158, P1326, DOI 10.1053/j.gastro.2019.12.032
   Frederick DT, 2013, CLIN CANCER RES, V19, P1225, DOI 10.1158/1078-0432.CCR-12-1630
   French AJ, 2008, CLIN CANCER RES, V14, P3408, DOI 10.1158/1078-0432.CCR-07-1489
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guler I, 2019, EXPERT REV GASTROENT, V13, P919, DOI 10.1080/17474124.2019.1663174
   Huang J, 2015, BIOCHEM BIOPH RES CO, V463, P551, DOI 10.1016/j.bbrc.2015.05.083
   Jenkins MA, 2007, GASTROENTEROLOGY, V133, P48, DOI 10.1053/j.gastro.2007.04.044
   Khalili JS, 2012, CLIN CANCER RES, V18, P5329, DOI 10.1158/1078-0432.CCR-12-1632
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lee J.J., 2019, COLORECTAL CANC META
   Li ZD, 2016, DNA REPAIR, V38, P94, DOI 10.1016/j.dnarep.2015.11.019
   LIU B, 1995, NAT GENET, V9, P48, DOI 10.1038/ng0195-48
   Markman B., 2017, PHASE 1B STUDY ANTIP
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Pansky A, 2000, INT J CANCER, V85, P720, DOI 10.1002/(SICI)1097-0215(20000301)85:5<720::AID-IJC20>3.0.CO;2-O
   Parc YR, 2000, CANCER RES, V60, P2225
   PARSONS R, 1993, CELL, V75, P1227, DOI 10.1016/0092-8674(93)90331-J
   Pawlik TM, 2004, DIS MARKERS, V20, P199, DOI 10.1155/2004/368680
   Pumpalova, 2020, CLIN MOL MARKERS IMM
   Retz M., 2019, KEYNOTE 365 COHORT A
   Sahin IH, 2019, BRIT J CANCER, V121, P809, DOI 10.1038/s41416-019-0599-y
   Salipante SJ, 2014, CLIN CHEM, V60, P1192, DOI 10.1373/clinchem.2014.223677
   Shiu KK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.2020.38.18_suppl.LBA4
   Siegel RL, 2019, CA-CANCER J CLIN, V69, P7, DOI 10.3322/caac.21551
   Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404
   Stewart RA, 2018, CANCER RES, V78, P6717, DOI 10.1158/0008-5472.CAN-18-2652
   Strauss BS, 1999, MUTAT RES-REV MUTAT, V437, P195, DOI 10.1016/S1383-5742(99)00066-6
   Sumimoto H, 2006, J EXP MED, V203, P1651, DOI 10.1084/jem.20051848
   Timmermann B, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015661
   Toyota M, 1999, P NATL ACAD SCI USA, V96, P8681, DOI 10.1073/pnas.96.15.8681
   Umar A, 1996, EUR J BIOCHEM, V238, P297, DOI 10.1111/j.1432-1033.1996.0297z.x
   Vinayak S, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.1011
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   You YN, 2012, ARCH INTERN MED, V172, P287, DOI 10.1001/archinternmed.2011.602
   Zagonel V., 2021, SUBGROUP ANALYSES PA
   Zaretsky JM, 2016, NEW ENGL J MED, V375, P819, DOI 10.1056/NEJMoa1604958
NR 48
TC 15
Z9 15
U1 0
U2 9
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1747-4124
EI 1747-4132
J9 EXPERT REV GASTROENT
JI Expert Rev. Gastroenterol. Hepatol.
PD JUL 3
PY 2021
VL 15
IS 7
BP 735
EP 742
DI 10.1080/17474124.2021.1886077
EA FEB 2021
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA TJ8UR
UT WOS:000619332300001
PM 33539189
DA 2025-01-04
ER

PT J
AU García-Foncillas, J
   Alba, E
   Aranda, E
   Díaz-Rubio, E
   López-López, R
   Tabernero, J
   Vivancos, A
AF Garcia-Foncillas, J.
   Alba, E.
   Aranda, E.
   Diaz-Rubio, E.
   Lopez-Lopez, R.
   Tabernero, J.
   Vivancos, A.
TI Incorporating BEAMing technology as a liquid biopsy into clinical
   practice for the management of colorectal cancer patients: an expert
   taskforce review
SO ANNALS OF ONCOLOGY
LA English
DT Review
DE colorectal cancer; mutation testing; liquid biopsy; EGFR; tumor
   resistance
ID CIRCULATING TUMOR DNA; ANTI-EGFR THERAPY; PLUS CETUXIMAB TREATMENT; RAS
   MUTATIONS; ACQUIRED-RESISTANCE; 1ST-LINE TREATMENT; TARGETED THERAPY;
   MUTANT-DNA; PLASMA; FOLFIRI
AB The importance of mutation identification for advanced colorectal cancer treatment with anti-epidermal growth factor receptor agents is well established. However, due to delays in turnaround time, low-quality tissue samples, and/ or lack of standardization of testing methods a significant proportion of patients are being treated without the information that Kirsten rat sarcoma and neuroblastoma rat sarcoma (RAS) testing can provide. The detection of mutated circulating tumor DNA by BEAMing technology addresses this gap in care and allows these patients to receive international guideline-recommended expanded RAS testing with rapid turnaround times. Furthermore, the overall concordance between OncoBEAM RAS colorectal cancer testing and standard of care tissue testing is very high (93.3%). This article presents an overview of the clinical utility and potential applications of this minimally invasive method, such as early detection of emergent resistance to anti-epidermal growth factor receptor therapy. If appropriately implemented, BEAMing technology holds considerable promise to enhance the quality of patient care and improve clinical outcomes.
C1 [Garcia-Foncillas, J.] Autonomous Univ, Fdn Jimenez Diaz, Univ Hosp, Inst Canc, Madrid, Spain.
   [Alba, E.] Reg Univ Hosp Virgen de la Victoria, Med Oncol Unit, IBIMA, Malaga, Spain.
   [Aranda, E.] Univ Cordoba, Fac Med, Hosp Reina Sofia, Biomed Res Inst IMIBIC,CIBERONC, Cordoba, Spain.
   [Diaz-Rubio, E.] Univ Complutense Madrid, Fac Med, Hosp Clin San Carlos, Res Inst IdISSC,CIBERONC, Madrid, Spain.
   [Lopez-Lopez, R.] Univ Clin Hosp, Dept Med Oncol, Santiago De Compostela, Spain.
   [Lopez-Lopez, R.] Univ Clin Hosp, Hlth Res Inst IDIS, Santiago De Compostela, Spain.
   [Lopez-Lopez, R.] Santiago de Compostela Univ, Sch Med, CIBERONC, Santiago De Compostela, Spain.
   [Tabernero, J.] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain.
   [Tabernero, J.] Univ Autonoma Barcelona, Inst Oncol VHIO, CIBERONC, Barcelona, Spain.
   [Vivancos, A.] Vall dHebron Inst Oncol VHIO, Canc Genom Lab, Barcelona, Spain.
C3 Fundacion Jimenez Diaz; Autonomous University of Madrid; Instituto de
   Investigacion Biomedica de Malaga y Plataforma en Nanomedicina (IBIMA);
   Universidad de Malaga; Universidad de Cordoba; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERONC; Complutense University of
   Madrid; Hospital Clinico San Carlos; CIBER - Centro de Investigacion
   Biomedica en Red; CIBERONC; Complexo Hospitalario Universitario de
   Santiago de Compostela; Complexo Hospitalario Universitario de Santiago
   de Compostela; Universidade de Santiago de Compostela; CIBER - Centro de
   Investigacion Biomedica en Red; CIBERONC; Hospital Universitari Vall
   d'Hebron; CIBER - Centro de Investigacion Biomedica en Red; CIBERONC;
   Vall d'Hebron Institut d'Oncologia (VHIO); Autonomous University of
   Barcelona; Vall d'Hebron Institut d'Oncologia (VHIO)
RP García-Foncillas, J (corresponding author), Autonomous Univ Madrid, Fdn Jimenez Diaz, Univ Hosp, Translat Oncol Div,Hlth Res Inst, Madrid 28040, Spain.
EM jgfoncillas@gmail.com
RI Alba, Emilio/S-1435-2019; Garcia-Foncillas, Jesus/E-6857-2010; Aranda,
   Enrique/AAA-4147-2019; Tabernero, Josep/AAG-5026-2019; Vivancos,
   Ana/AAG-8331-2019
OI Aranda Aguilar, Enrique/0000-0002-5471-2842; Vivancos,
   Ana/0000-0003-2888-6512; J, Garcia-Foncillas/0000-0002-7591-8006;
   Tabernero, Josep/0000-0002-2495-8139; Alba Conejo,
   Emilio/0000-0002-3364-2603; Lopez Lopez, Rafael/0000-0003-1315-655X
FU Sysmex-Inostics
FX Unrestricted grant from Sysmex-Inostics (no grant number applied).
CR Allegra CJ, 2016, J ONCOL PRACT, V12, P180, DOI 10.1200/JOP.2015.007898
   Benson AB III, 2014, J NATL COMPR CANC NE, V12, P1028, DOI 10.6004/jnccn.2014.0099
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Board RE, 2010, BREAST CANCER RES TR, V120, P461, DOI 10.1007/s10549-010-0747-9
   Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Denis JA, 2017, MOL DIAGN THER, V21, P587, DOI 10.1007/s40291-017-0287-7
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Diehl F, 2005, P NATL ACAD SCI USA, V102, P16368, DOI 10.1073/pnas.0507904102
   Diehl F, 2008, NAT MED, V14, P985, DOI 10.1038/nm.1789
   Diehl F, 2008, GASTROENTEROLOGY, V135, P489, DOI 10.1053/j.gastro.2008.05.039
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Grasselli J, 2017, ANN ONCOL, V28, P1294, DOI 10.1093/annonc/mdx112
   Hahn S, 2015, EUR J CANCER, V51, pS79, DOI 10.1016/S0959-8049(16)30236-2
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Hofman P, 2016, VIRCHOWS ARCH, V469, P601, DOI 10.1007/s00428-016-2004-z
   Kimura T, 2004, ANN NY ACAD SCI, V1022, P55, DOI 10.1196/annals.1318.010
   Kopetz S, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.3509
   Lamy A, 2011, MODERN PATHOL, V24, P1090, DOI 10.1038/modpathol.2011.60
   Li M, 2006, NAT METHODS, V3, P95, DOI 10.1038/NMETH850
   Li ZQ, 2011, HEPATO-GASTROENTEROL, V58, P411
   Malapelle U, 2014, J CLIN PATHOL, V67, P1, DOI 10.1136/jclinpath-2013-201835
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Morelli MP, 2015, ANN ONCOL, V26, P731, DOI 10.1093/annonc/mdv005
   Olsson E, 2015, EMBO MOL MED, V7, P1034, DOI 10.15252/emmm.201404913
   Ouakrim DA, 2015, BMJ-BRIT MED J, V351, DOI 10.1136/bmj.h4970
   Pantel K, 2013, CANCER RES, V73, P6384, DOI 10.1158/0008-5472.CAN-13-2030
   Peeters M, 2015, CLIN CANCER RES, V21, P5469, DOI 10.1158/1078-0432.CCR-15-0526
   Qiu LX, 2010, EUR J CANCER, V46, P2781, DOI 10.1016/j.ejca.2010.05.022
   Russo M, 2016, CANCER DISCOV, V6, P147, DOI 10.1158/2159-8290.CD-15-1283
   Santini D, 2012, ANN ONCOL, V23, P2313, DOI 10.1093/annonc/mdr623
   Schmiegel W, 2017, MOL ONCOL, V11, P208, DOI 10.1002/1878-0261.12023
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Siravegna G, 2015, NAT MED, V21, P795, DOI [10.1038/nm.3870, 10.1038/nm0715-827b]
   Siravegna G, 2014, GENOME BIOL, V15, DOI 10.1186/s13059-014-0449-4
   Sorich MJ, 2015, ANN ONCOL, V26, P13, DOI 10.1093/annonc/mdu378
   SYSMEX INOSTICS, INSTR US ONCOBEAM RA
   Tabernero J, 2015, LANCET ONCOL, V16, P937, DOI 10.1016/S1470-2045(15)00138-2
   Tack V, 2015, ONCOLOGIST, V20, P257, DOI 10.1634/theoncologist.2014-0382
   Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177
   Toledo RA, 2017, ONCOTARGET, V8, P35289, DOI 10.18632/oncotarget.13311
   Vallée A, 2013, LUNG CANCER, V82, P373, DOI 10.1016/j.lungcan.2013.08.014
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Vidal J, 2017, ANN ONCOL, V28, P1325, DOI 10.1093/annonc/mdx125
NR 45
TC 73
Z9 75
U1 0
U2 17
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0923-7534
EI 1569-8041
J9 ANN ONCOL
JI Ann. Oncol.
PD DEC
PY 2017
VL 28
IS 12
BP 2943
EP 2949
DI 10.1093/annonc/mdx501
PG 7
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FR1VH
UT WOS:000418855200008
PM 28945877
OA Green Published, hybrid, Green Submitted
DA 2025-01-04
ER

PT J
AU Caiazza, F
   Elliott, L
   Fennelly, D
   Sheahan, K
   Doherty, GA
   Ryan, EJ
AF Caiazza, Francesco
   Elliott, Louise
   Fennelly, David
   Sheahan, Kieran
   Doherty, Glen A.
   Ryan, Elizabeth J.
TI Targeting EGFR in metastatic colorectal cancer beyond the limitations of
   KRAS status: alternative biomarkers and therapeutic strategies
SO BIOMARKERS IN MEDICINE
LA English
DT Review
DE biomarkers; cetuximab; colorectal cancer; EGFR; ErbB; KRAS; monoclonal
   antibodies; targeted therapy
ID PREDICTING CLINICAL BENEFIT; RANDOMIZED PHASE-III;
   MONOCLONAL-ANTIBODIES; ACQUIRED-RESISTANCE; COLON-CANCER; 1ST-LINE
   TREATMENT; ANTITUMOR-ACTIVITY; SIGNALING PATHWAY; PIK3CA MUTATIONS;
   DOWN-REGULATION
AB Patients with metastatic colorectal cancer have a very poor prognosis. Incorporation of targeted molecular therapies, such as the anti-EGFR receptor monoclonal antibodies cetuximab and panitumumab, into treatment regimens has improved outcomes for patients with wild-type RAS tumors. Yet, response rates remain low and overall survival times are short. Increased understanding of oncogenic signaling pathways within the tumor, and how these are regulated by the inflammatory tumor microenvironment, is a priority to facilitate the development of biomarkers to better guide the use of existing therapies and to develop new ones. Here, we review recent preclinical and clinical progress in the development of biomarkers for predicting response to anti-EGFR therapy in metastatic colorectal cancer.
C1 [Caiazza, Francesco; Elliott, Louise; Fennelly, David; Sheahan, Kieran; Doherty, Glen A.; Ryan, Elizabeth J.] St Vincents Univ Hosp, Ctr Colorectal Dis, Dublin 4, Ireland.
   [Caiazza, Francesco; Elliott, Louise; Fennelly, David; Sheahan, Kieran; Doherty, Glen A.; Ryan, Elizabeth J.] Univ Coll Dublin, Sch Med & Med Sci, Dublin 2, Ireland.
   [Sheahan, Kieran] St Vincents Univ Hosp, Dept Pathol, Dublin 4, Ireland.
   [Caiazza, Francesco] St Vincents Univ Hosp, Educ & Res Ctr, Dublin 4, Ireland.
C3 University College Dublin; Saint Vincent's University Hospital;
   University College Dublin; University College Dublin; Saint Vincent's
   University Hospital; University College Dublin; Saint Vincent's
   University Hospital
RP Caiazza, F (corresponding author), St Vincents Univ Hosp, Ctr Colorectal Dis, Elm Pk, Dublin 4, Ireland.
EM francesco.caiazza@ucdconnect.ie
RI Ryan, Elizabeth/H-9758-2019; Caiazza, Francesco/H-9477-2019
OI Doherty, Glen/0000-0003-4384-5049; Caiazza,
   Francesco/0000-0003-4228-1130; Ryan, Elizabeth/0000-0002-5137-1253
FU Newman Fellowship - UCD Foundation - Merck Serono
FX F Caiazza is supported by a Newman Fellowship awarded by the UCD
   Foundation funded by a donation from Merck Serono. The authors have no
   other relevant affiliations or financial involvement with any
   organization or entity with a financial interest in or financial
   conflict with the subject matter or materials discussed in the
   manuscript apart from those disclosed.
CR Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310
   Al-Marrawi MY, 2013, CANCER BIOL THER, V14, P703, DOI 10.4161/cbt.25191
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   [Anonymous], BR J CANC
   Ashraf SQ, 2012, P NATL ACAD SCI USA, V109, P21046, DOI 10.1073/pnas.1218750110
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Beji A, 2012, CLIN CANCER RES, V18, P956, DOI 10.1158/1078-0432.CCR-11-1186
   Benvenuti S, 2007, CANCER RES, V67, P2643, DOI 10.1158/0008-5472.CAN-06-4158
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Calemma R, 2012, J TRANSL MED, V10, DOI 10.1186/1479-5876-10-232
   Calonge N, 2013, GENET MED, V15, P517, DOI 10.1038/gim.2012.184
   Chivukula RR, 2014, CELL, V157, P1104, DOI 10.1016/j.cell.2014.03.055
   Ciardiello F, 2014, J CLIN ONCOL S15, V32
   Custodio A, 2013, CRIT REV ONCOL HEMAT, V85, P45, DOI 10.1016/j.critrevonc.2012.05.001
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Leva G, 2014, ANNU REV PATHOL-MECH, V9, P287, DOI 10.1146/annurev-pathol-012513-104715
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Douillard JY, 2013, NEW ENGL J MED, V369, P1023, DOI 10.1056/NEJMoa1305275
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Dunn EF, 2011, ONCOGENE, V30, P561, DOI 10.1038/onc.2010.430
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Eng C, 2010, ONCOLOGIST, V15, P73, DOI 10.1634/theoncologist.2009-0167
   Engelman JA, 2009, NAT REV CANCER, V9, P550, DOI 10.1038/nrc2664
   Esplin ED, 2014, WORLD J CLIN ONCOL, V5, P1036, DOI 10.5306/wjco.v5.i5.1036
   Ferlay J, 2013, EUR J CANCER, V49, P1374, DOI 10.1016/j.ejca.2012.12.027
   Garrido-Laguna I, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038033
   Hagan Suzanne, 2013, EPMA J, V4, P3, DOI 10.1186/1878-5085-4-3
   Hochster HS, 2015, CANCER CHEMOTH PHARM, V75, P17, DOI 10.1007/s00280-014-2609-3
   Huang LL, 2014, ARCH MED SCI, V10, P1, DOI 10.5114/aoms.2014.40728
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kent OA, 2013, ONCOGENE, V32, P2576, DOI 10.1038/onc.2012.266
   Khambata-Ford S, 2007, J CLIN ONCOL, V25, P3230, DOI 10.1200/JCO.2006.10.5437
   Klinger B, 2013, MOL SYST BIOL, V9, DOI 10.1038/msb.2013.29
   Kohrt HE, 2014, J CLIN INVEST, V124, P2668, DOI 10.1172/JCI73014
   Kubach J, 2015, INT J CANCER, V136, P821, DOI 10.1002/ijc.29037
   Kumar Shalini Sree, 2014, Gastrointest Cancer Res, V7, P23
   Kyula JN, 2010, CLIN CANCER RES, V16, P3378, DOI 10.1158/1078-0432.CCR-10-0014
   Lamba S, 2014, CELL REP, V8, P1475, DOI 10.1016/j.celrep.2014.07.033
   Lédel F, 2014, EUR J CANCER, V50, P656, DOI 10.1016/j.ejca.2013.11.008
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lièvre A, 2008, J CLIN ONCOL, V26, P374, DOI 10.1200/JCO.2007.12.5906
   Lim CM, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.24677
   Lin JS, 2011, AM J CANCER RES, V1, P650
   Loupakis F, 2009, BRIT J CANCER, V101, P715, DOI 10.1038/sj.bjc.6605177
   Luraghi P, 2014, CANCER RES, V74, P1857, DOI 10.1158/0008-5472.CAN-13-2340-T
   Malapelle U, 2015, J CLIN PATHOL, V68, P64, DOI 10.1136/jclinpath-2014-202691
   Manceau G, 2014, CLIN CANCER RES, V20, P3338, DOI 10.1158/1078-0432.CCR-13-2750
   Mao C, 2011, MOL BIOL REP, V38, P2219, DOI 10.1007/s11033-010-0351-4
   Martin V, 2013, BRIT J CANCER, V108, P668, DOI 10.1038/bjc.2013.4
   Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236
   McGowan PM, 2013, ANN ONCOL, V24, P362, DOI 10.1093/annonc/mds279
   Merchant NB, 2008, CLIN CANCER RES, V14, P1182, DOI 10.1158/1078-0432.CCR-07-1216
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Mlcochova J, 2013, J CANCER RES CLIN, V139, P1615, DOI 10.1007/s00432-013-1470-9
   Murphy G, 2008, NAT REV CANCER, V8, P929, DOI 10.1038/nrc2459
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Normanno N, 2006, GENE, V366, P2, DOI 10.1016/j.gene.2005.10.018
   Olayioye MA, 2000, EMBO J, V19, P3159, DOI 10.1093/emboj/19.13.3159
   Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495
   Patel Dipa, 2010, Human Antibodies, V19, P89, DOI 10.3233/HAB-2010-0232
   Peeters M, 2013, CLIN CANCER RES, V19, P1902, DOI 10.1158/1078-0432.CCR-12-1913
   Peeters M, 2010, J CLIN ONCOL, V28, P4706, DOI 10.1200/JCO.2009.27.6055
   Pentheroudakis G, 2013, BMC CANCER, V13, DOI 10.1186/1471-2407-13-49
   Petrelli F, 2013, TARGET ONCOL, V8, P173, DOI 10.1007/s11523-013-0257-x
   Pichler M, 2012, BRIT J CANCER, V106, P1826, DOI 10.1038/bjc.2012.175
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prenen H, 2009, CLIN CANCER RES, V15, P3184, DOI 10.1158/1078-0432.CCR-08-2961
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Richards FM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040597
   Rossi S, 2010, INT J BIOCHEM CELL B, V42, P1291, DOI 10.1016/j.biocel.2009.05.018
   Rubinson DA, 2014, INVEST NEW DRUG, V32, P113, DOI 10.1007/s10637-013-9956-5
   Sartore-Bianchi A, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007287
   Sartore-Bianchi A, 2009, CANCER RES, V69, P1851, DOI 10.1158/0008-5472.CAN-08-2466
   Scheller J, 2011, TRENDS IMMUNOL, V32, P380, DOI 10.1016/j.it.2011.05.005
   Schirripa M, 2015, INT J CANCER, V136, P83, DOI 10.1002/ijc.28955
   Schou JV, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099886
   Sclafani F, 2013, CRIT REV ONCOL HEMAT, V87, P55, DOI 10.1016/j.critrevonc.2012.11.003
   Sisto M, 2014, Clin Exp Med
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Tabernero J, 2010, J CLIN ONCOL, V28, P1181, DOI 10.1200/JCO.2009.22.6043
   Thompson H, 2013, NAT MED, V19, P949, DOI 10.1038/nm0813-949
   Tian S, 2013, GUT, V62, P540, DOI 10.1136/gutjnl-2012-302423
   Troiani T, 2014, CLIN CANCER RES, V20, P3775, DOI 10.1158/1078-0432.CCR-13-2181
   Tsuda M, 2013, J GASTROEN HEPATOL, V28, P1616, DOI 10.1111/jgh.12287
   Van Schaeybroeck S, 2014, CELL REP, V7, P1940, DOI 10.1016/j.celrep.2014.05.032
   Van Schaeybroeck S, 2011, CANCER RES, V71, P1071, DOI 10.1158/0008-5472.CAN-10-0714
   Xynos ID, 2013, ONCOLOGY-BASEL, V84, P273, DOI 10.1159/000343282
   Yang H, 2012, CANCER RES, V72, P779, DOI 10.1158/0008-5472.CAN-11-2941
   Yang ZY, 2013, INT J CANCER, V133, P1914, DOI 10.1002/ijc.28153
   Yin H, 2014, NAT REV GENET, V15, P541, DOI 10.1038/nrg3763
   Yoon HH, 2014, CLIN CANCER RES, V20, P3033, DOI 10.1158/1078-0432.CCR-13-3140
   Zhao L, 2008, P NATL ACAD SCI USA, V105, P2652, DOI 10.1073/pnas.0712169105
NR 96
TC 11
Z9 11
U1 0
U2 12
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
   1QB, ENGLAND
SN 1752-0363
EI 1752-0371
J9 BIOMARK MED
JI Biomark. Med.
PY 2015
VL 9
IS 4
BP 363
EP 375
DI 10.2217/BMM.15.5
PG 13
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA CE5KJ
UT WOS:000351872200007
PM 25808440
DA 2025-01-04
ER

PT J
AU Hong, ST
   Lin, H
   Wang, CS
   Chang, CH
   Lin, AMY
   Yang, JCH
   Lo, YL
AF Hong, Shu-Ting
   Lin, Huaching
   Wang, Chen-Shen
   Chang, Chih-Hsien
   Lin, Anya Maan-Yuh
   Yang, James Chih-Hsin
   Lo, Yu-Li
TI Improving the anticancer effect of afatinib and microRNA by using lipid
   polymeric nanoparticles conjugated with dual pH-responsive and targeting
   peptides
SO JOURNAL OF NANOBIOTECHNOLOGY
LA English
DT Article
DE Afatinib; Epidermal growth factor receptor (EGFR); Nanoparticles;
   Cell-penetrating peptides; Colorectal cancer; Targeting delivery
ID COLORECTAL-CANCER; HYBRID NANOPARTICLES; EGFR EXPRESSION; IN-VITRO;
   CELL; DELIVERY; FAMILY; RESISTANCE; INHIBITORS; EFFICIENCY
AB Background: The emergence of resistance to chemotherapy or target therapy, tumor metastasis, and systemic toxicity caused by available anticancer drugs hamper the successful colorectal cancer (CRC) treatment. The rise in epidermal growth factor receptor (EGFR; human epidermal growth factor receptor 1; HER1) expression and enhanced phosphorylation of HER2 and HER3 are associated with tumor resistance, metastasis and invasion, thus resulting in poor outcome of anti-CRC therapy. The use of afatinib, a pan-HER inhibitor, is a potential therapeutic approach for resistant CRC. Additionally, miR-139 has been reported to be negatively correlated with chemoresistance, metastasis, and epithelial-mesenchymal transition (EMT) of CRC. Hence, we develop a nanoparticle formulation consisting of a polymer core to carry afatinib or miR-139, which is surrounded by lipids modified with a targeting ligand and a pH-sensitive penetrating peptide to improve the anticancer effect of cargos against CRC cells.
   Results: Our findings show that this formulation displays a spherical shape with core/shell structure, homogeneous particle size distribution and negative zeta potential. The prepared formulations demonstrate a pH-sensitive release profile and an enhanced uptake of cargos into human colorectal adenocarcinoma Caco-2 cells in response to the acidic pH. This nanoparticle formulation incorporating afatinib and miR-139 exhibits low toxicity to normal cells but shows a better inhibitory effect on Caco-2 cells than other formulations. Moreover, the encapsulation of afatinib and miR-139 in peptide-modified nanoparticles remarkably induces apoptosis and inhibits migration and resistance of Caco-2 cells via suppression of pan-HER tyrosine kinase/multidrug resistance/metastasis pathways.
   Conclusion: This study proposes a multifunctional nanoparticle formulation for targeted modulation of apoptosis/EGFR/HER/EMT/resistance/progression pathways to increase the sensitivity of colon cancer cells to afatinib.
C1 [Hong, Shu-Ting; Wang, Chen-Shen; Chang, Chih-Hsien; Lin, Anya Maan-Yuh; Lo, Yu-Li] Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan.
   [Lin, Huaching] Cheng Hsin Gen Hosp, Div Colorectal Surg, Taipei, Taiwan.
   [Lin, Anya Maan-Yuh; Lo, Yu-Li] Natl Yang Ming Univ, Fac Pharm, Taipei 112, Taiwan.
   [Lo, Yu-Li] Natl Yang Ming Univ, Ctr Adv Pharmaceut & Drug Delivery Res, Taipei 112, Taiwan.
   [Lin, Anya Maan-Yuh] Taipei Vet Gen Hosp, Dept Med Res, Taipei 112, Taiwan.
   [Yang, James Chih-Hsin] Natl Taiwan Univ, Inst Oncol, Taipei 106, Taiwan.
C3 National Yang Ming Chiao Tung University; Cheng Hsin General Hospital;
   National Yang Ming Chiao Tung University; National Yang Ming Chiao Tung
   University; Taipei Veterans General Hospital; National Taiwan University
RP Lo, YL (corresponding author), Natl Yang Ming Univ, Inst Pharmacol, Taipei 112, Taiwan.; Lo, YL (corresponding author), Natl Yang Ming Univ, Fac Pharm, Taipei 112, Taiwan.; Lo, YL (corresponding author), Natl Yang Ming Univ, Ctr Adv Pharmaceut & Drug Delivery Res, Taipei 112, Taiwan.
EM yulilo@ym.edu.tw
RI Yang, James/W-1587-2019
OI Lo, Yu-Li/0000-0002-6548-3280; Yang, James Chih-Hsin/0000-0002-5586-5138
FU Ministry of Science and Technology of Taiwan [MOST 106-2320-B-010-005,
   MOST 107-2320-B-010-015-MY3]; Veterans General Hospitals and University
   System of Taiwan [VGHUST106-G7-7-3, VGHUST108-G2-1-2]; National
   Yang-Ming University; Cheng Hsin General Hospital [CY10726, CY10839];
   Center for Advanced Pharmaceutics and Drug Delivery Research, National
   Yang-Ming University; School of Medicine, National Yang-Ming University
   (Development and Construction Plan); Ministry of Education of Taiwan
   (Aiming for the Top University Plan)
FX This project was financially supported by grants from Ministry of
   Science and Technology of Taiwan (MOST 106-2320-B-010-005; MOST
   107-2320-B-010-015-MY3); Veterans General Hospitals and University
   System of Taiwan (VGHUST106-G7-7-3; VGHUST108-G2-1-2); National
   Yang-Ming University and Cheng Hsin General Hospital (CY10726; CY10839);
   Center for Advanced Pharmaceutics and Drug Delivery Research, National
   Yang-Ming University; School of Medicine, National Yang-Ming University
   (Development and Construction Plan); Ministry of Education of Taiwan
   (Aiming for the Top University Plan).
CR Amin K, 2006, J PHARM SCI-US, V95, P1173, DOI 10.1002/jps.20627
   [Anonymous], PATHOLOG RES INT
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Bahreyni A, 2019, COLLOID SURFACE B, V175, P231, DOI 10.1016/j.colsurfb.2018.12.006
   Bao W, 2011, GASTROENTEROLOGY, V141, P2076, DOI 10.1053/j.gastro.2011.08.050
   Boulares AH, 1999, J BIOL CHEM, V274, P22932, DOI 10.1074/jbc.274.33.22932
   Coelho SC, 2016, EXPERT OPIN DRUG DEL, V13, P133, DOI 10.1517/17425247.2015.1083973
   Cryer AM, 2019, ACS APPL MATER INTER, V11, P16336, DOI 10.1021/acsami.9b02986
   D'Arcangelo M, 2014, BIOL-TARGETS THER, V8, P183, DOI 10.2147/BTT.S40567
   Falcone R, 2018, MEDICINE, V97, DOI 10.1097/MD.0000000000009672
   Fanotto V, 2016, ONCOTARGET, V7, P69060, DOI 10.18632/oncotarget.11264
   Guan SS, 2014, ONCOTARGET, V5, P4868, DOI 10.18632/oncotarget.2050
   Guo ZR, 2016, BIOMED REP, V4, P528, DOI 10.3892/br.2016.639
   Hadinoto K, 2013, EUR J PHARM BIOPHARM, V85, P427, DOI 10.1016/j.ejpb.2013.07.002
   Herceg Z, 2001, MUTAT RES-FUND MOL M, V477, P97, DOI 10.1016/S0027-5107(01)00111-7
   Hirsh V, 2015, BIODRUGS, V29, P167, DOI 10.1007/s40259-015-0130-9
   Hoskin DW, 2008, BBA-BIOMEMBRANES, V1778, P357, DOI 10.1016/j.bbamem.2007.11.008
   Hurvitz SA, 2014, EXPERT OPIN INV DRUG, V23, P1039, DOI 10.1517/13543784.2014.924505
   Ichiki M, 2017, ONCOTARGETS THER, V10, P5107, DOI 10.2147/OTT.S145613
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Khelwatty SA, 2015, BRIT J CANCER, V113, P1010, DOI 10.1038/bjc.2015.319
   Khelwatty Said Abdullah, 2019, Oncotarget, V10, P1704, DOI 10.18632/oncotarget.26722
   Khelwatty SA, 2013, FRONT BIOSCI-LANDMRK, V18, P394, DOI 10.2741/4110
   Kim J, 2014, ANTICANCER RES, V34, P3807
   Lampropoulou A, 2014, BIOCHEM SOC T, V42, P1623, DOI 10.1042/BST20140244
   Lashof-Sullivan MM, 2014, P NATL ACAD SCI USA, V111, P10293, DOI 10.1073/pnas.1406979111
   Li QG, 2016, SCI REP-UK, V6, DOI 10.1038/srep27157
   Li S, 2014, DISCOVERIES REP, V1, DOI [10.15190/drep.2014.1, DOI 10.15190/DREP.2014.1]
   Liu D, 2019, EUR J PHARM SCI, V133, P104, DOI 10.1016/j.ejps.2019.03.023
   Liu HY, 2016, PATHOL RES PRACT, V212, P643, DOI 10.1016/j.prp.2016.04.011
   Loree JM, 2017, THER ADV MED ONCOL, V9, P551, DOI 10.1177/1758834017714997
   Malik S, 2019, J NANOBIOTECHNOL, V17, DOI 10.1186/s12951-019-0490-2
   McIlwain DR, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008656
   Oh N, 2014, INT J NANOMED, V9, P51, DOI 10.2147/IJN.S26592
   Parikh AA, 2004, AM J PATHOL, V164, P2139, DOI 10.1016/S0002-9440(10)63772-8
   Reed JC, 1997, SEMIN HEMATOL, V34, P9
   Plaza JGR, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040125
   Rosenblatt KM, 2017, EUR J PHARM BIOPHARM, V117, P49, DOI 10.1016/j.ejpb.2017.03.010
   Shen K, 2012, BIOCHEM PHARMACOL, V84, P320, DOI 10.1016/j.bcp.2012.04.017
   Shen SH, 2017, INT J NANOMED, V12, P4085, DOI 10.2147/IJN.S132780
   Spano JP, 2005, ANN ONCOL, V16, P102, DOI 10.1093/annonc/mdi006
   Teesalu T, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00216
   Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106
   Tu ZG, 2009, J PEPT SCI, V15, P790, DOI 10.1002/psc.1180
   Van der Jeught K, 2018, WORLD J GASTROENTERO, V24, P3834, DOI 10.3748/wjg.v24.i34.3834
   Xie SY, 2008, COLLOID SURFACE B, V67, P199, DOI 10.1016/j.colsurfb.2008.08.018
   Yang JCH, 2015, LANCET ONCOL, V16, P141, DOI 10.1016/S1470-2045(14)71173-8
   Yonesaka K, 2015, ONCOTARGET, V6, P33602, DOI 10.18632/oncotarget.5286
   Zhang LF, 2008, ACS NANO, V2, P1696, DOI 10.1021/nn800275r
   Zhang Y, 2018, J CELL BIOCHEM, V119, P414, DOI 10.1002/jcb.26194
   Zhao BX, 2012, BIOMATERIALS, V33, P2508, DOI 10.1016/j.biomaterials.2011.11.078
   Zheng XC, 2018, INT J NANOMED, V13, P1495, DOI 10.2147/IJN.S157082
   Zou FY, 2016, FEBS J, V283, P1438, DOI 10.1111/febs.13678
NR 53
TC 40
Z9 40
U1 1
U2 31
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1477-3155
J9 J NANOBIOTECHNOL
JI J. Nanobiotechnol.
PD AUG 19
PY 2019
VL 17
IS 1
AR 89
DI 10.1186/s12951-019-0519-6
PG 20
WC Biotechnology & Applied Microbiology; Nanoscience & Nanotechnology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Science & Technology - Other
   Topics
GA IU0BK
UT WOS:000483243200002
PM 31426807
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Kim, HJ
   Lee, SY
   Oh, SC
AF Kim, Hong Jun
   Lee, Suk-young
   Oh, Sang Cheul
TI The Inositide Signaling Pathway As a Target for Treating Gastric Cancer
   and Colorectal Cancer
SO FRONTIERS IN PHYSIOLOGY
LA English
DT Review
DE phosphoinositide; PI3K; mTOR; Akt; colorectal cancer; gastric cancer;
   targeted therapy
AB Gastric cancer and colorectal cancer are the leading cause of cancer mortality and have a dismal prognosis. The introduction of biological agents to treat these cancers has resulted in improved outcomes, and combination chemotherapy with targeted agents and conventional chemotherapeutic agents is regarded as standard therapy. Additional newly clarified mechanisms of oncogenesis and resistance to targeted agents require the development of new biologic agents. Aberrant activation of the inositide signaling pathway by a loss of function PTEN mutation or gain of function mutation/amplification of PIK3CA is an oncogenic mechanism in gastric cancer and colorectal cancer. Clinical trials with biologic agents that target the inositide signaling pathway are being performed to further improve treatment outcomes of patients with advanced gastric cancer and metastatic colorectal cancer (CRC). In this review we summarize the inositide signaling pathway, the targeted agents that inhibit abnormal activation of this signaling pathway and the clinical trials currently being performed in patients with advanced or metastatic gastric cancer and metastatic CRC using these targeted agents.
C1 [Kim, Hong Jun; Lee, Suk-young; Oh, Sang Cheul] Korea Univ, Coll Med, Dept Internal Med, Div Oncol Hematol, Seoul, South Korea.
C3 Korea University; Korea University Medicine (KU Medicine)
RP Oh, SC (corresponding author), Korea Univ, Coll Med, Dept Internal Med, Div Oncol Hematol, Seoul, South Korea.
EM sachoh@korea.ac.kr
RI Lee, Joo Yong/ADE-2110-2022; Kim, Sung/I-2997-2017
CR Al-Batran SE, 2012, INT J CANCER, V130, P491, DOI 10.1002/ijc.26396
   Alessi DR, 1997, CURR BIOL, V7, P261, DOI 10.1016/S0960-9822(06)00122-9
   Barker N, 2010, CELL STEM CELL, V6, P25, DOI 10.1016/j.stem.2009.11.013
   Bendell JC, 2012, J CLIN ONCOL, V30, P282, DOI 10.1200/JCO.2011.36.1360
   Berndt N, 2010, CELL DEATH DIFFER, V17, P1795, DOI 10.1038/cdd.2010.63
   Bunney TD, 2010, NAT REV CANCER, V10, P342, DOI 10.1038/nrc2842
   Cantley LC, 2002, SCIENCE, V296, P1655, DOI 10.1126/science.296.5573.1655
   Cathomas G, 2014, FRONT ONCOL, V4, DOI 10.3389/fonc.2014.00035
   CHEN J, 1995, P NATL ACAD SCI USA, V92, P4947, DOI 10.1073/pnas.92.11.4947
   Choi JW, 1996, SCIENCE, V273, P239, DOI 10.1126/science.273.5272.239
   Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388
   Davies BR, 2012, MOL CANCER THER, V11, P873, DOI 10.1158/1535-7163.MCT-11-0824-T
   DEVITA V.T., 2008, DeVita, Hellman, and Rosenberg's cancer : principles practice of oncology
   Di Paolo G, 2006, NATURE, V443, P651, DOI 10.1038/nature05185
   Eklöf V, 2013, BRIT J CANCER, V108, P2153, DOI 10.1038/bjc.2013.212
   Engelman JA, 2006, NAT REV GENET, V7, P606, DOI 10.1038/nrg1879
   Fakih MG, 2015, J CLIN ONCOL, V33, P1809, DOI 10.1200/JCO.2014.59.7633
   Feldman ME, 2009, PLOS BIOL, V7, P371, DOI 10.1371/journal.pbio.1000038
   Fingar DC, 2004, MOL CELL BIOL, V24, P200, DOI 10.1128/MCB.24.1.200-216.2004
   Fruman DA, 1998, ANNU REV BIOCHEM, V67, P481, DOI 10.1146/annurev.biochem.67.1.481
   Furet P, 2013, BIOORG MED CHEM LETT, V23, P3741, DOI 10.1016/j.bmcl.2013.05.007
   Garrett CR, 2011, INVEST NEW DRUG, V29, P1381, DOI 10.1007/s10637-010-9479-2
   Gonzalez E, 2009, CELL CYCLE, V8, P2502, DOI 10.4161/cc.8.16.9335
   Han Z, 2008, DIGEST DIS SCI, V53, P1801, DOI 10.1007/s10620-007-9824-2
   Haramis APG, 2004, SCIENCE, V303, P1684, DOI 10.1126/science.1093587
   He XC, 2007, NAT GENET, V39, P189, DOI 10.1038/ng1928
   Hidalgo M, 2006, CLIN CANCER RES, V12, P5755, DOI 10.1158/1078-0432.CCR-06-0118
   Hirai H, 2010, MOL CANCER THER, V9, P1956, DOI 10.1158/1535-7163.MCT-09-1012
   Hong DS, 2012, CLIN CANCER RES, V18, P4173, DOI 10.1158/1078-0432.CCR-12-0714
   Howe JR, 2001, NAT GENET, V28, P184, DOI 10.1038/88919
   Ihle NT, 2004, MOL CANCER THER, V3, P763
   Iida S, 2012, ONCOL LETT, V3, P565, DOI 10.3892/ol.2011.544
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Jessen K., 2011, AACRNCI EORTC INT C
   Jimeno A., 2010, ASCO ANN M P CHIC IL
   Juric D, 2012, CANCER RES, V72, DOI 10.1158/0008-5472.SABCS12-P8-10-07
   Juric D., 2015, ASCO ANN M P
   Katso R, 2001, ANNU REV CELL DEV BI, V17, P615, DOI 10.1146/annurev.cellbio.17.1.615
   Kumar CC, 2005, ONCOGENE, V24, P7493, DOI 10.1038/sj.onc.1209087
   KUNZ J, 1993, TRENDS BIOCHEM SCI, V18, P334, DOI 10.1016/0968-0004(93)90069-Y
   Lee SJ, 2013, INVEST NEW DRUG, V31, P1580, DOI 10.1007/s10637-013-0022-0
   Leslie NR, 2008, ONCOGENE, V27, P5464, DOI 10.1038/onc.2008.243
   Li VSW, 2005, BMC CANCER, V5, DOI 10.1186/1471-2407-5-29
   Liu JF, 2010, WORLD J GASTROENTERO, V16, P4986, DOI 10.3748/wjg.v16.i39.4986
   Lombardo Y, 2011, GASTROENTEROLOGY, V140, P297, DOI 10.1053/j.gastro.2010.10.005
   Lowry WE, 2005, GENE DEV, V19, P1596, DOI 10.1101/gad.1324905
   Luke RW, 2011, CANCER RES, V71, DOI 10.1158/1538-7445.AM2011-4478
   Luo J, 2006, CELL, V127, P42, DOI 10.1016/j.cmet.2006.04.003
   Manning BD, 2007, CELL, V129, P1261, DOI 10.1016/j.cell.2007.06.009
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Martini M, 2013, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00108
   Merlos-Suárez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683
   Mouradov D, 2013, AM J GASTROENTEROL, V108, P1785, DOI 10.1038/ajg.2013.292
   Nobukuni T, 2005, P NATL ACAD SCI USA, V102, P14238, DOI 10.1073/pnas.0506925102
   Ohtsu A, 2013, J CLIN ONCOL, V31, P3935, DOI 10.1200/JCO.2012.48.3552
   Ooms LM, 2009, BIOCHEM J, V419, P29, DOI 10.1042/BJ20081673
   Pedersen JV, 2011, J CLIN ONCOL, V29, DOI 10.1200/jco.2011.29.15_suppl.2577
   Persad S, 2001, J CELL BIOL, V153, P1161, DOI 10.1083/jcb.153.6.1161
   Phipps AI, 2013, INT J COLORECTAL DIS, V28, P1637, DOI 10.1007/s00384-013-1715-8
   Potter CJ, 2002, NAT CELL BIOL, V4, P658, DOI 10.1038/ncb840
   POWIS G, 1994, CANCER RES, V54, P2419
   Raimondi Claudio, 2012, Adv Biol Regul, V52, P166
   Ramanathan RK, 2015, CANCER-AM CANCER SOC, V121, P2193, DOI 10.1002/cncr.29363
   Rini BI, 2008, CLIN CANCER RES, V14, P1286, DOI 10.1158/1078-0432.CCR-07-4719
   Rivero RA, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-2913
   Rodon J, 2013, NAT REV CLIN ONCOL, V10, P143, DOI 10.1038/nrclinonc.2013.10
   Roper J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025132
   Samuels Y, 2005, CANCER CELL, V7, P561, DOI 10.1016/j.ccr.2005.05.014
   Samuels Y, 2004, SCIENCE, V304, P554, DOI 10.1126/science.1096502
   Sancho E, 2004, ANNU REV CELL DEV BI, V20, P695, DOI 10.1146/annurev.cellbio.20.010403.092805
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Sarbassov DD, 2005, SCIENCE, V307, P1098, DOI 10.1126/science.1106148
   Sasaki T, 2009, PROG LIPID RES, V48, P307, DOI 10.1016/j.plipres.2009.06.001
   Shi J, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-50
   Shimizu T, 2012, CLIN CANCER RES, V18, P2316, DOI 10.1158/1078-0432.CCR-11-2381
   Singh SS, 2015, WORLD J GASTROENTERO, V21, P12261, DOI 10.3748/wjg.v21.i43.12261
   Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7
   Vadas O, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2002165
   Velho S, 2005, EUR J CANCER, V41, P1649, DOI 10.1016/j.ejca.2005.04.022
   Voliva cF, 2010, Cancer Research, V70, P4498
   Walker EH, 2000, MOL CELL, V6, P909, DOI 10.1016/S1097-2765(00)00088-5
   Wymann MP, 2003, BIOCHEM SOC T, V31, P275, DOI 10.1042/bst0310275
   Wymann MP, 1996, MOL CELL BIOL, V16, P1722
   Xing CG, 2009, WORLD J GASTROENTERO, V15, P5044, DOI 10.3748/wjg.15.5044
   Yang Q, 2007, CELL RES, V17, P666, DOI 10.1038/cr.2007.64
   Yap TA, 2011, J CLIN ONCOL, V29, P4688, DOI 10.1200/JCO.2011.35.5263
   Yu K, 2008, CANCER BIOL THER, V7, P307
   Yuan TL, 2008, ONCOGENE, V27, P5497, DOI 10.1038/onc.2008.245
   Zhou HY, 2010, ANTI-CANCER AGENT ME, V10, P571, DOI 10.2174/187152010793498663
   Zhu YF, 2012, WORLD J GASTROENTERO, V18, P3745, DOI 10.3748/wjg.v18.i28.3745
   Zoncu R, 2011, NAT REV MOL CELL BIO, V12, P21, DOI 10.1038/nrm3025
NR 92
TC 10
Z9 10
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1664-042X
J9 FRONT PHYSIOL
JI Front. Physiol.
PD MAY 9
PY 2016
VL 7
AR 168
DI 10.3389/fphys.2016.00168
PG 8
WC Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Physiology
GA VF7RY
UT WOS:000443547100001
PM 27242542
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Schmidt, O
   Brueckner, M
   Bernkopf, DB
AF Schmidt, Olivia
   Brueckner, Martina
   Bernkopf, Dominic B.
TI AXIN2 promotes degradation of AXIN1 through tankyrase in colorectal
   cancer cells
SO FEBS JOURNAL
LA English
DT Article; Early Access
DE AXIN1; AXIN2; colorectal cancer; TNKS; Wnt pathway
ID BETA-CATENIN; WNT PATHWAY; CONDUCTIN/AXIN2; INHIBITION
AB AXIN1 and AXIN2 are homologous proteins that inhibit the Wnt/beta-catenin signaling pathway, which is frequently hyperactive in colorectal cancer. Stabilization of AXIN1 and AXIN2 by inhibiting their degradation through tankyrase (TNKS) allows the attenuation of Wnt signaling in cancer, attracting interest for potential targeted therapy. Here, we found that knockout or knockdown of AXIN2 in colorectal cancer cells increased the protein stability of AXIN1. The increase in AXIN1 overcompensated for the loss of AXIN2 with respect to protein levels; however, functionally it did not because loss of AXIN2 activated the pathway. Moreover, AXIN2 was highly essential in the context of TNKS inhibition because TNKS-targeting small-molecule inhibitors completely failed to inhibit Wnt signaling and to stabilize AXIN1 in AXIN2 knockout cells. The increased AXIN1 protein stability and the impaired stabilization by TNKS inhibitors indicated disrupted TNKS-AXIN1 regulation in AXIN2 knockout cells. Concordantly, mechanistic studies revealed that co-expression of AXIN2 recruited TNKS to AXIN1 and stimulated TNKS-mediated degradation of transiently expressed AXIN1 wild-type and AXIN1 mutants with impaired TNKS binding. Taken together, our data suggest that AXIN2 promotes degradation of AXIN1 through TNKS in colorectal cancer cells by directly linking the two proteins, and these findings may be relevant for TNKS inhibition-based colorectal cancer therapies.
C1 [Schmidt, Olivia; Brueckner, Martina; Bernkopf, Dominic B.] Friedrich Alexander Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr, Expt Med 2, Gluckstr 6, D-91054 Erlangen, Germany.
C3 University of Erlangen Nuremberg
RP Bernkopf, DB (corresponding author), Friedrich Alexander Univ Erlangen Nurnberg, Nikolaus Fiebiger Ctr, Expt Med 2, Gluckstr 6, D-91054 Erlangen, Germany.
EM dominic.bernkopf@fau.de
OI Bernkopf, Dominic B./0000-0003-4870-5248
FU Deutsche Forschungsgemeinschaft [BE 7055/2-1]; Wilhelm Sander-Stiftung
   [2018.017.2]
FX We thank Gabriele Daum for excellent technical assistance and the
   core-unit Cell-sorting with Immunomonitoring (Friedrich-Alexander
   University Erlangen-Nurnberg). This study was funded by grants from the
   Deutsche Forschungsgemeinschaft (BE 7055/2-1) and from the Wilhelm
   Sander-Stiftung (2018.017.2) to DBB.
CR Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596
   Bernkopf DB, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-12203-8
   Bernkopf DB, 2015, J CELL SCI, V128, P33, DOI 10.1242/jcs.159145
   Cadigan KM, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007906
   Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Fagotto F, 1999, J CELL BIOL, V145, P741, DOI 10.1083/jcb.145.4.741
   Fiedler M, 2011, P NATL ACAD SCI USA, V108, P1937, DOI 10.1073/pnas.1017063108
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Jho EH, 2002, MOL CELL BIOL, V22, P1172, DOI 10.1128/MCB.22.4.1172-1183.2002
   Kim DY, 2022, EUR J CANCER, V173, P41, DOI 10.1016/j.ejca.2022.06.031
   Kinzler KW, 1996, CELL, V87, P159, DOI 10.1016/S0092-8674(00)81333-1
   Klement K, 2023, J CELL SCI, V136, DOI 10.1242/jcs.261214
   Leenders RGG, 2021, J MED CHEM, V64, P17936, DOI 10.1021/acs.jmedchem.1c01264
   Leung JY, 2002, J BIOL CHEM, V277, P21657, DOI 10.1074/jbc.M200139200
   Lustig B, 2002, MOL CELL BIOL, V22, P1184, DOI 10.1128/MCB.22.4.1184-1193.2002
   MacDonald BT, 2012, CSH PERSPECT BIOL, V4, DOI 10.1101/cshperspect.a007880
   Miete C, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28286-9
   Morrone S, 2012, P NATL ACAD SCI USA, V109, P1500, DOI 10.1073/pnas.1116618109
   Ran FA, 2013, NAT PROTOC, V8, P2281, DOI 10.1038/nprot.2013.143
   Stamos JL, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a007898
   Thorvaldsen TE, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0170508
   Zeng L, 1997, CELL, V90, P181, DOI 10.1016/S0092-8674(00)80324-4
NR 22
TC 1
Z9 1
U1 3
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1742-464X
EI 1742-4658
J9 FEBS J
JI FEBS J.
PD 2024 JUL 18
PY 2024
DI 10.1111/febs.17226
EA JUL 2024
PG 15
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA YX8C3
UT WOS:001271868000001
PM 39022865
OA hybrid
DA 2025-01-04
ER

PT J
AU Liu, YJ
   Li, CY
   Liu, HW
   Tan, ST
AF Liu, Yajun
   Li, Chenyao
   Liu, Hongwei
   Tan, Shutao
TI Combination therapy involving HSP90 inhibitors for combating cancer: an
   overview of clinical and preclinical progress
SO ARCHIVES OF PHARMACAL RESEARCH
LA English
DT Review
DE HSP90 inhibitors; Cancer therapy; Drug combination; Synergistic effect;
   Drug resistance
ID SHOCK-PROTEIN 90; CELL LUNG-CANCER; I DOSE-ESCALATION; PHASE-I;
   OVERCOMES RESISTANCE; THYMIDYLATE SYNTHASE; ANTITUMOR-ACTIVITY;
   ONALESPIB AT13387; COLORECTAL-CANCER; DRUG-RESISTANCE
AB The molecular chaperone heat shock protein 90 (HSP90) regulates multiple crucial signalling pathways in cancer by driving the maturation of key signalling components, thereby playing a crucial role in tumorigenesis and drug resistance in cancer. Inhibition of HSP90 results in metastable conformational collapse of its client proteins and their proteasomal degradation. Considerable efforts have been devoted to the development of small-molecule inhibitors targeting HSP90, and more than 20 inhibitors have been evaluated in clinical trials for cancer therapy. However, owing to disadvantages such as organ toxicity and drug resistance, only one HSP90 inhibitor has been approved for use in clinical settings. In recent years, HSP90 inhibitors used in combination with other anti-cancer therapies have shown remarkable potential in the treatment of cancer. HSP90 inhibitors work synergistically with various anti-cancer therapies, including chemotherapy, targeted therapy, radiation therapy and immunotherapy. HSP90 inhibitors can improve the pharmacological effects of the above-mentioned therapies and reduce treatment resistance. This review provides an overview of the use of combination therapy with HSP90 inhibitors and other anti-cancer therapies in clinical and preclinical studies reported in the past decade and summarises design strategies and prospects for these combination therapies. Altogether, this review provides a theoretical basis for further research and application of these combination therapies in the treatment of cancer.
C1 [Liu, Yajun] Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Wenhua Rd 103, Shenyang 110016, Peoples R China.
   [Li, Chenyao] Dalian Univ Technol, Sch Life & Pharmaceut Sci, Dagong Rd 2, Panjin 124221, Peoples R China.
   [Liu, Hongwei] Liaoning Canc Hosp & Inst, Dept Head & Neck Surg, Shenyang 110042, Peoples R China.
   [Liu, Hongwei] Dalian Univ Technol, Affiliated Canc Hosp, Shenyang 110042, Peoples R China.
   [Tan, Shutao] China Med Univ, Dept Urol, Shengjing Hosp, Sanhao St 36, Shenyang 110004, Peoples R China.
C3 Shenyang Pharmaceutical University; Dalian University of Technology;
   Dalian University of Technology; China Medical University
RP Liu, YJ (corresponding author), Shenyang Pharmaceut Univ, Sch Pharmaceut Engn, Wenhua Rd 103, Shenyang 110016, Peoples R China.; Liu, HW (corresponding author), Liaoning Canc Hosp & Inst, Dept Head & Neck Surg, Shenyang 110042, Peoples R China.; Liu, HW (corresponding author), Dalian Univ Technol, Affiliated Canc Hosp, Shenyang 110042, Peoples R China.; Tan, ST (corresponding author), China Med Univ, Dept Urol, Shengjing Hosp, Sanhao St 36, Shenyang 110004, Peoples R China.
EM yjliu85@dlut.edu.cn; hwliu1425@163.com; tanst@sj-hospital.org
RI Liu, Yajun/ABE-5076-2020
FU Key Technologies Research and Development Program [2017YFC1702006];
   National Key Research and Development Program [2020-MS-105]; Natural
   Science Foundation of Liaoning Province of China [DUT22YG111];
   Fundamental Research Funds for the Central Universities
FX This work is funded by the National Key Research and Development Program
   [Grant No. 2017YFC1702006], the Natural Science Foundation of Liaoning
   Province of China [Grant No. 2020-MS-105], and the Fundamental Research
   Funds for the Central Universities [Grant No. DUT22YG111].
CR Abu Lila AS, 2016, INT J ONCOL, V48, P1399, DOI 10.3892/ijo.2016.3367
   Albadari N, 2019, EXPERT OPIN DRUG DIS, V14, P667, DOI 10.1080/17460441.2019.1613370
   Ali MMU, 2006, NATURE, V440, P1013, DOI 10.1038/nature04716
   Bagatell R, 2004, MOL CANCER THER, V3, P1021
   Bai XP, 2018, CANCER TREAT REV, V69, P152, DOI 10.1016/j.ctrv.2018.07.004
   Biondini M, 2022, ONCOGENE, V41, P1701, DOI 10.1038/s41388-022-02206-z
   Bussenius J, 2012, BIOORG MED CHEM LETT, V22, P5396, DOI 10.1016/j.bmcl.2012.07.052
   Cavenagh J, 2017, BRIT J CANCER, V117, P1295, DOI 10.1038/bjc.2017.302
   Cercek A, 2014, CLIN COLORECTAL CANC, V13, P207, DOI 10.1016/j.clcc.2014.09.001
   Chen H, 2020, FRONT PHARMACOL, V11, DOI 10.3389/fphar.2020.00974
   Chen TML, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01039-9
   Chettiar ST, 2016, CANCER BIOL THER, V17, P457, DOI 10.1080/15384047.2016.1156258
   Choi YE, 2014, ONCOTARGET, V5, P2678, DOI 10.18632/oncotarget.1929
   Chon J, 2017, MOL ASPECTS MED, V53, P48, DOI 10.1016/j.mam.2016.11.005
   Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388
   Codony-Servat J, 2019, TRANSL LUNG CANCER R, V8, P340, DOI 10.21037/tlcr.2019.08.22
   Cohen P, 2022, NAT REV DRUG DISCOV, DOI 10.1038/s41573-022-00418-2
   De Raedt T, 2011, CANCER CELL, V20, P400, DOI 10.1016/j.ccr.2011.08.014
   Demetri GD, 2011, J CLIN ONCOL, V29
   Derakhshani A, 2020, J CELL PHYSIOL, V235, P3142, DOI 10.1002/jcp.29216
   Do KT, 2020, CANCER CHEMOTH PHARM, V86, P815, DOI 10.1007/s00280-020-04176-z
   Doi T, 2019, EUR J CANCER, V121, P29, DOI 10.1016/j.ejca.2019.08.009
   Donnelly A, 2008, CURR MED CHEM, V15, P2702, DOI 10.2174/092986708786242895
   Erlichman C, 2009, EXPERT OPIN INV DRUG, V18, P861, DOI 10.1517/13543780902953699
   Ernst A, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01668
   Eroglu Z, 2018, CLIN CANCER RES, V24, P5516, DOI 10.1158/1078-0432.CCR-18-0565
   Ewers KM, 2021, CANCERS, V13, DOI 10.3390/cancers13246163
   Fennell D, 2018, J THORAC ONCOL, V13, pS397, DOI 10.1016/j.jtho.2018.08.415
   Ferraldeschi R, 2016, CANCER RES, V76, P2731, DOI 10.1158/0008-5472.CAN-15-2186
   Friedman JA, 2013, TRANSL ONCOL, V6, P429, DOI 10.1593/tlo.13292
   Ge FF, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241512476
   Giulino-Roth L, 2017, MOL CANCER THER, V16, P1779, DOI 10.1158/1535-7163.MCT-16-0848
   Graner MW, 2021, CELL CHEM BIOL, V28, P118, DOI 10.1016/j.chembiol.2021.02.002
   Graner MW, 2016, ADV CANCER RES, V129, P191, DOI 10.1016/bs.acr.2015.10.001
   Grbovic-Huezo O, 2020, P NATL ACAD SCI USA, V117, P30670, DOI 10.1073/pnas.1920240117
   Gutierrez M, 2021, LUNG CANCER, V162, P23, DOI 10.1016/j.lungcan.2021.10.001
   Haarberg HE, 2013, MOL CANCER THER, V12, P901, DOI 10.1158/1535-7163.MCT-12-1003
   He JY, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5270
   Hirano H, 2021, JPN J CLIN ONCOL, V51, P10, DOI 10.1093/jjco/hyaa200
   Honma Y, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.11524
   Hoter A, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19092560
   Huang KH, 2009, J MED CHEM, V52, P4288, DOI 10.1021/jm900230j
   Huang XP, 2010, CANCER RES, V70, P1204, DOI 10.1158/0008-5472.CAN-09-3321
   Infante JR, 2014, EUR J CANCER, V50, P2897, DOI 10.1016/j.ejca.2014.07.017
   Jhaveri K, 2012, ADV PHARMACOL, V65, P471, DOI 10.1016/B978-0-12-397927-8.00015-4
   Kabakov AE, 2010, J MOL MED, V88, P241, DOI 10.1007/s00109-009-0562-0
   Kale S, 2020, N-S ARCH PHARMACOL, V393, P253, DOI 10.1007/s00210-019-01725-z
   Kawazoe A, 2021, CLIN CANCER RES, V27, P6709, DOI 10.1158/1078-0432.CCR-21-1929
   Do K, 2015, INVEST NEW DRUG, V33, P921, DOI 10.1007/s10637-015-0255-1
   Kim AeRang, 2020, Sarcoma, V2020, P5784876, DOI 10.1155/2020/5784876
   Kim BM, 2015, INT J MOL SCI, V16, P26880, DOI 10.3390/ijms161125991
   Kim HJ, 2020, YONSEI MED J, V61, P587, DOI 10.3349/ymj.2020.61.7.587
   Konstantinopoulos PA, 2022, BRIT J CANCER, V126, P1027, DOI 10.1038/s41416-021-01664-8
   Kurokawa Y, 2022, ANN ONCOL, V33, P959, DOI 10.1016/j.annonc.2022.05.518
   Kwak EL, 2013, J CLIN ONCOL, V31
   Lang BJ, 2021, ARCH TOXICOL, V95, P1943, DOI 10.1007/s00204-021-03070-8
   Lang JE, 2022, NPJ BREAST CANCER, V8, DOI 10.1038/s41523-022-00493-z
   Lee HJ, 2020, CANCERS, V12, DOI 10.3390/cancers12092630
   Li L, 2021, EXPERT OPIN THER PAT, V31, P67, DOI 10.1080/13543776.2021.1829595
   Li L, 2020, J MED CHEM, V63, P1798, DOI 10.1021/acs.jmedchem.9b00940
   Liu LX, 2021, MOL CANCER THER, V20, P1880, DOI 10.1158/1535-7163.MCT-21-0215
   Liu ZJ, 2020, PHARMACOL RES, V151, DOI 10.1016/j.phrs.2019.104512
   Lu ZW, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.864194
   Lundsten S, 2020, EUR J NUCL MED MOL I, V47, P980, DOI 10.1007/s00259-019-04673-1
   Marine JC, 2006, CELL DEATH DIFFER, V13, P927, DOI 10.1038/sj.cdd.4401912
   Mathieu C, 2019, CANCER DRUG RESIST, V2, P381, DOI 10.20517/cdr.2019.26
   Mbofung RM, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00449-z
   McCombs JR, 2021, INT J PHARMACEUT, V610, DOI 10.1016/j.ijpharm.2021.121272
   Mehta RK, 2020, CLIN CANCER RES, V26, P5246, DOI 10.1158/1078-0432.CCR-19-3102
   Meister S, 2007, CANCER RES, V67, P1783, DOI 10.1158/0008-5472.CAN-06-2258
   Miyata Y, 2013, CURR PHARM DESIGN, V19, P347, DOI 10.2174/138161213804143725
   Mohajershojai T, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.849338
   Moita AJR, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21218300
   Mooradian MJ, 2023, CANCER-AM CANCER SOC, V129, P1904, DOI 10.1002/cncr.34730
   Mortensen ACL, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.532285
   Mosca L, 2021, DRUG RESIST UPDATE, V54, DOI 10.1016/j.drup.2020.100742
   Nagaraju GP, 2019, INT J CANCER, V145, P1529, DOI 10.1002/ijc.32227
   Nagaraju GP, 2014, ONCOTARGET, V5, P9980, DOI 10.18632/oncotarget.2484
   Namba R, 2006, CLIN CANCER RES, V12, P2613, DOI 10.1158/1078-0432.CCR-05-2170
   Nassar ZD, 2020, MOL CANCER RES, V18, P1500, DOI 10.1158/1541-7786.MCR-20-0570
   Naz S, 2021, INT J RADIAT ONCOL, V110, P1295, DOI 10.1016/j.ijrobp.2021.03.048
   Neffendorf JE, 2013, NEW ENGL J MED, V369, P1277, DOI 10.1056/NEJMc1309710
   Nguyen DM, 2001, ANN THORAC SURG, V72, P371, DOI 10.1016/S0003-4975(01)02787-4
   Nowosielska EM, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22126309
   Ohkubo S, 2015, MOL CANCER THER, V14, P14, DOI 10.1158/1535-7163.MCT-14-0219
   Orth M, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.612354
   Paik J, 2021, TARGET ONCOL, V16, P847, DOI 10.1007/s11523-021-00842-1
   Paraiso KHT, 2012, CLIN CANCER RES, V18, P2502, DOI 10.1158/1078-0432.CCR-11-2612
   Parsels LA, 2021, MOL CANCER THER, V20, P263, DOI 10.1158/1535-7163.MCT-20-0365
   Pennisi R, 2015, BIOMOLECULES, V5, P2589, DOI 10.3390/biom5042589
   Pillai RN, 2020, J CLIN ONCOL, V38, P613, DOI 10.1200/JCO.19.00816
   Proia DA, 2014, CANCER RES, V74, P1294, DOI 10.1158/0008-5472.CAN-13-3263
   Rahmy S, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.1005045
   Rajan A, 2011, CLIN CANCER RES, V17, P6831, DOI 10.1158/1078-0432.CCR-11-0821
   Ramalingam S, 2015, ANN ONCOL, V26, P1741, DOI 10.1093/annonc/mdv220
   Rao A, 2012, CANCER RES, V72, P3196, DOI 10.1158/0008-5472.CAN-12-0538
   Ray-Coquard I, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00832
   Reddy N, 2013, CL LYMPH MYELOM LEUK, V13, P385, DOI 10.1016/j.clml.2013.03.010
   Ren XD, 2022, CELLS-BASEL, V11, DOI 10.3390/cells11162556
   Rice MA, 2022, CELL REP MED, V3, DOI 10.1016/j.xcrm.2021.100502
   Rice MA, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00801
   Roh JL, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.488
   Rose AAN, 2017, PHARMACOL THERAPEUT, V179, P127, DOI 10.1016/j.pharmthera.2017.05.010
   Rossi G, 2018, EXPERT OPIN PHARMACO, V19, P1969, DOI 10.1080/14656566.2018.1536746
   Sabbah DA, 2020, CURR TOP MED CHEM, V20, P815, DOI 10.2174/1568026620666200303123102
   Saber S, 2023, BIOMED PHARMACOTHER, V164, DOI 10.1016/j.biopha.2023.114918
   Saber S, 2023, BIOMED PHARMACOTHER, V158, DOI 10.1016/j.biopha.2022.114196
   Saito Y, 2020, BRIT J CANCER, V122, P658, DOI 10.1038/s41416-019-0688-y
   Sanchez JN, 2021, MELANOMA RES, V31, P197, DOI 10.1097/CMR.0000000000000734
   Sasame J, 2022, CLIN CANCER RES, V28, P2425, DOI 10.1158/1078-0432.CCR-21-3622
   Savoia P, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21249730
   Sawaki A, 2022, ANN ONCOL, V33, pS467, DOI 10.1016/j.annonc.2022.05.071
   Schilling D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0031110
   Schmidt L, 2022, CANCER CHEMOTH PHARM, V89, P431, DOI 10.1007/s00280-022-04407-5
   Schopf FH, 2017, NAT REV MOL CELL BIO, V18, P345, DOI 10.1038/nrm.2017.20
   Scutigliani EM, 2022, CANCERS, V14, DOI 10.3390/cancers14215250
   Sequist LV, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002003
   Serwetnyk MA, 2021, ACTA PHARM SIN B, V11, P1446, DOI 10.1016/j.apsb.2020.11.015
   Shapiro GI, 2015, CLIN CANCER RES, V21, P87, DOI 10.1158/1078-0432.CCR-14-0979
   Sharma P, 2015, SCIENCE, V348, P56, DOI 10.1126/science.aaa8172
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Shimamura T, 2008, CANCER RES, V68, P5827, DOI 10.1158/0008-5472.CAN-07-5428
   Shimomura A, 2019, MOL CANCER THER, V18, P531, DOI 10.1158/1535-7163.MCT-18-0831
   Shkedi A, 2021, J MED CHEM, V64, P14809, DOI 10.1021/acs.jmedchem.1c01342
   Sikov WM, 2015, CURR ONCOL REP, V17, DOI 10.1007/s11912-014-0428-7
   Skeie M, 2020, J CELL MOL MED, V24, P10258, DOI 10.1111/jcmm.15643
   Slovin S, 2019, CLIN CANCER RES, V25, P4624, DOI 10.1158/1078-0432.CCR-18-3212
   Smith JR, 2015, ONCOGENE, V34, P15, DOI 10.1038/onc.2013.519
   Smyth T, 2014, MOL CANCER THER, V13, P2793, DOI 10.1158/1535-7163.MCT-14-0452
   Snigireva AV, 2014, B EXP BIOL MED+, V157, P476, DOI 10.1007/s10517-014-2595-9
   Soós AA, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241411585
   Soudan H, 2020, ACTA BIOCHIM POL, V67, P561, DOI 10.18388/abp.2020_5418
   Spiegelberg D, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-62293-4
   Student S, 2020, EUR J PHARMACOL, V866, DOI 10.1016/j.ejphar.2019.172783
   Subaiea G, 2023, PHARMACEUTICALS-BASE, V16, DOI 10.3390/ph16020230
   Sun C, 2021, LIFE SCI, V282, DOI 10.1016/j.lfs.2021.119762
   Swain SM, 2023, NAT REV DRUG DISCOV, V22, P101, DOI 10.1038/s41573-022-00579-0
   Tan CRC, 2019, CLIN PHARMACOKINET, V58, P157, DOI 10.1007/s40262-018-0679-9
   Tang WW, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0187-x
   Teranishi R, 2023, INT J CANCER, V152, P2580, DOI 10.1002/ijc.34461
   Togashi Y, 2019, NAT REV CLIN ONCOL, V16, P356, DOI 10.1038/s41571-019-0175-7
   Uno T, 2019, J MED CHEM, V62, P531, DOI 10.1021/acs.jmedchem.8b01085
   Vaidya R, 2014, ANN ONCOL, V25, P2124, DOI 10.1093/annonc/mdu109
   Vannas C, 2022, BIOMEDICINES, V10, DOI 10.3390/biomedicines10030624
   Vasan N, 2019, NATURE, V575, P299, DOI 10.1038/s41586-019-1730-1
   Vaseva AV, 2011, CELL DEATH DIS, V2, DOI 10.1038/cddis.2011.39
   Vriend LEM, 2017, ONCOTARGET, V8, P97490, DOI 10.18632/oncotarget.22142
   Wagner AJ, 2016, EUR J CANCER, V61, P94, DOI 10.1016/j.ejca.2016.03.076
   Wainberg ZA, 2013, MOL CANCER THER, V12, P509, DOI 10.1158/1535-7163.MCT-12-0507
   Wang YF, 2016, CLIN CANCER RES, V22, P5876, DOI 10.1158/1078-0432.CCR-15-2190
   Wei W, 2020, BMC CANCER, V20, DOI 10.1186/s12885-019-6489-0
   WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324
   Whitesell L, 2005, NAT REV CANCER, V5, P761, DOI 10.1038/nrc1716
   Woodhead AJ, 2010, J MED CHEM, V53, P5956, DOI 10.1021/jm100060b
   Wright JJ, 2010, CLIN CANCER RES, V16, P4094, DOI 10.1158/1078-0432.CCR-09-2882
   Wyatt PG, 2008, J MED CHEM, V51, P4986, DOI 10.1021/jm800382h
   Xiao Y, 2020, CURR DRUG TARGETS, V21, P302, DOI 10.2174/1389450120666190829162544
   Xu JH, 2022, CLIN CANCER RES, V28, P1979, DOI 10.1158/1078-0432.CCR-20-0468
   Ye M, 2021, FRONT PHARMACOL, V12, DOI 10.3389/fphar.2021.651516
   Yong K, 2016, BRIT J CANCER, V114, P7, DOI 10.1038/bjc.2015.422
   Yu J, 2017, LEUKEMIA, V31, P1333, DOI 10.1038/leu.2016.368
   Yu J, 2022, EUR J MED CHEM, V238, DOI 10.1016/j.ejmech.2022.114516
   Zaidi S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035436
   Zavareh RB, 2021, CELL CHEM BIOL, V28, P158, DOI 10.1016/j.chembiol.2020.10.005
   Zhang ZM, 2015, INT J CLIN EXP MED, V8, P6687
   Zhao RM, 2005, CELL, V120, P715, DOI 10.1016/j.cell.2004.12.024
   Zhao S, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-00150-8
   Zhou BQ, 2021, COORDIN CHEM REV, V442, DOI 10.1016/j.ccr.2021.214009
   Zininga T, 2018, MOLECULES, V23, DOI 10.3390/molecules23112846
NR 169
TC 1
Z9 1
U1 2
U2 4
PU PHARMACEUTICAL SOC KOREA
PI SEOUL
PA 1489-3 SUHCHO-DONG, SUHCHO-KU, SEOUL 137-071, SOUTH KOREA
SN 0253-6269
EI 1976-3786
J9 ARCH PHARM RES
JI Arch. Pharm. Res.
PD MAY
PY 2024
VL 47
IS 5
BP 442
EP 464
DI 10.1007/s12272-024-01494-1
EA APR 2024
PG 23
WC Chemistry, Medicinal; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA UR2T2
UT WOS:001204620800001
PM 38632167
DA 2025-01-04
ER

PT J
AU Singh, VV
   Alauddin, S
AF Singh, Vindhya Vikram
   Alauddin, Shafqat
TI <i>In silico</i> ANALYSIS OF NOVEL ANTICANCER AGENTS AS BRD4 INHIBITORS
SO APPLIED BIOLOGICAL RESEARCH
LA English
DT Article
DE Anticancer drugs; BET BRD4 proteins; molecular docking; protein
   inhibition; quinazolinone derivatives; targeted therapy
ID PROTEIN; CANCER; DOCKING
AB The BET BRD4 proteins, involved in cancer, are of prime importance in developing anticancer drugs. Cancer is marked by the uncontrolled growth of abnormal cells anywhere in the body with the potential to spread or invade other body parts. The core nature of disease lies in defying normal cell signals, be it anti-growth signals, death signals or apoptosis, and tissue invasion metastasis. In present work, we have designed and tested novel quinazolinone-based derivatives to establish them as a better anticancer agent against the BRD4 target. The selection of BRD4 protein in this work is based on earlier findings that reported the role of BRD4 in various cancers such as lymphoma, multiple myeloma, acute myeloid leukemia, acute lymphoblastic leukemia, chronic myeloid leukemia, solid tumours, prostate cancer, nervous system tumour, colorectal cancer, and breast cancer. Molecular docking was performed by using Glide docking module of the Schrodinger suite. The XP Glide docking studies, ADME (absorption, distribution, metabolism, excretion) profile test, binding energy calculations, and drug-likeness was performed to get the best BRD4 inhibitor ligand. Out of 16 quinazolinone derivates, ten ligands had better XP Glide score, 4 were marginally less, and 2 gave poor score than the standard drug LY2 (-6.779 kcal mol(-1)). The best ligand had a score of -9.866 kcal mol(-1) which was 45% more efficient than LY2, so appears to be more effective and potent anticancer inhibitor ligands for BRD4 protein.
C1 [Singh, Vindhya Vikram; Alauddin, Shafqat] Shibli Natl Coll, Dept Chem, Cheminformat & Mol Modelling Lab, Azamgarh 276001, Uttar Pradesh, India.
RP Singh, VV (corresponding author), Shibli Natl Coll, Dept Chem, Cheminformat & Mol Modelling Lab, Azamgarh 276001, Uttar Pradesh, India.
EM vindhyavikrams@gmail.com
CR Ajani OO, 2016, BANGL J PHARMACOL, V11, P716, DOI 10.3329/bjp.v11i3.25731
   Allen BK, 2017, ACS OMEGA, V2, P4760, DOI 10.1021/acsomega.7b00553
   Crisci S, 2019, MEDICINA-LITHUANIA, V55, DOI 10.3390/medicina55080414
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   Dhananjayan K., 2015, J CANCER RES CLIN, V2015, P1, DOI [10.1155/2015/762716, DOI 10.1155/2015/762716]
   Donati B, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0915-9
   Ferreira LG, 2015, MOLECULES, V20, P13384, DOI 10.3390/molecules200713384
   Friesner RA, 2006, J MED CHEM, V49, P6177, DOI 10.1021/jm051256o
   Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Jacobson MP, 2004, PROTEINS, V55, P351, DOI 10.1002/prot.10613
   Jung M, 2014, J BIOL CHEM, V289, P9304, DOI 10.1074/jbc.M113.523019
   Kavitha K, 2018, World J. Pharm. Pharm. Sci, V7, P628
   Muvva C, 2014, MOL BIOSYST, V10, P2384, DOI 10.1039/c4mb00243a
   Nagaraju G, 2015, INDOAMERICAN J PHARM, V2, P827
   Padma VV, 2015, BIOMEDICINE-TAIWAN, V5, P1, DOI 10.7603/s40681-015-0019-4
   Pucci C, 2019, ECANCERMEDICALSCIENC, V13, DOI 10.3332/ecancer.2019.961
   Saranath D., 2014, Boimed Res J, V1, P1
   Sastry GM, 2013, J COMPUT AID MOL DES, V27, P221, DOI 10.1007/s10822-013-9644-8
   Singh L.R., 2013, J PHARM BIOANALYTICA, V2, P35
   Stathis A, 2018, CANCER DISCOV, V8, P24, DOI 10.1158/2159-8290.CD-17-0605
   Subramaniam R., 2011, J COMPUTATIONAL METH, V1, P69
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tahir A, 2018, MOLECULES, V23, DOI 10.3390/molecules23071527
   Tiwary B.K., 2015, IMPLICATION QUINAZOL, V1, P1, DOI [DOI 10.4172/JCBT.1000104, 110.4172/jcbt.1000104]
   Wang LM, 2020, J CLIN INVEST, V130, P1782, DOI 10.1172/JCI126327
   Weinstein IB, 2008, CANCER RES, V68, P3077, DOI 10.1158/0008-5472.CAN-07-3293
   White ME, 2019, CELL IMMUNOL, V337, P48, DOI 10.1016/j.cellimm.2019.02.001
   Xu YL, 2017, CSH PERSPECT MED, V7, DOI 10.1101/cshperspect.a026674
   Zhou P, 2010, MINI-REV MED CHEM, V10, P309, DOI 10.2174/138955710791331016
NR 30
TC 1
Z9 1
U1 0
U2 1
PU CENTRE ADVANCEMENT APPLIED SCIENCES
PI JAMMU & KASHMIR
PA SHALIMAAR BAUGH, NEAR SKUAST K, SRINAGAR, JAMMU & KASHMIR, 190 001,
   INDIA
SN 0972-0979
EI 0974-4517
J9 APPL BIOL RES
JI Appl. Biol. Res.
PD DEC
PY 2022
VL 24
IS 4
BP 429
EP 439
DI 10.5958/0974-4517.2022.00051.9
PG 11
WC Biotechnology & Applied Microbiology
WE Emerging Sources Citation Index (ESCI)
SC Biotechnology & Applied Microbiology
GA E6BI0
UT WOS:000976370000004
DA 2025-01-04
ER

PT J
AU Tomasello, G
   Mazzola, M
   Jurjus, A
   Cappello, F
   Carini, F
   Damiani, P
   Geagea, AG
   Zeenny, MN
   Leone, A
AF Tomasello, G.
   Mazzola, M.
   Jurjus, A.
   Cappello, F.
   Carini, F.
   Damiani, P.
   Geagea, A. Gerges
   Zeenny, M. N.
   Leone, A.
TI THE FINGERPRINT OF THE HUMAN GASTROINTESTINAL TRACT MICROBIOTA: A
   HYPOTHESIS OF MOLECULAR MAPPING
SO JOURNAL OF BIOLOGICAL REGULATORS AND HOMEOSTATIC AGENTS
LA English
DT Article
DE microbiota; dysbiosis; inflammatory bowel diseases; fingerprint
   microbiota
ID PHYLOGENETIC MICROARRAY; INTESTINAL MICROBIOTA; PATHOGENESIS; DIVERSITY
AB The precise etiology of Inflammatory Bowel Disease (IDB) remains unclear and several factors are believed to play a role in its development and progression, including the composition of microbial communities resident in the gastrointestinal tract. Human intestinal microbiota are extensive with at least 15,000-36,000 bacterial species. However, thanks to the new development in sequencing and molecular taxonomic methodologies, our understanding of the microbiota population composition, dynamics, and ecology has greatly increased. Intestinal microbiota play a critical role in the maintenance of the host intestinal barrier homeostasis, while dysbiosis, which involves reduction in the microbiome diversity, can lead to progression of inflammatory disorders, such as IBD and colorectal cancer. It is hypothesized that fingerprinting characterization of the microbiota community composition is the first step in the study of this complex bacterial ecosystem and a crucial step in the targeted therapy. Molecular fingerprinting of human gastrointestinal tract microbiota could be performed by different techniques including the semi quantitation, 16SrRNA, the DNA-microarray as well as other relatively new methods which were developed to study many complex bacterial ecosystems. These techniques provide individual data and profiles, using fast and sensitive tools for the high taxonomic level fingerprint of the human intestinal microbiota and provide estimation of the relative presence of the microbial target groups within each individual. Such personalized information serves as a remarkable and unprecedented opportunity to improve targeted medical treatment and probably develop strategies to prevent disease.
C1 [Tomasello, G.; Cappello, F.] Euromediterranean Inst Sci & Technol IEMEST, Palermo, Italy.
   [Tomasello, G.; Damiani, P.] Univ Palermo, Sch Med, AOUP P Giaccone, Palermo, Italy.
   [Tomasello, G.; Cappello, F.; Carini, F.] Univ Palermo, Sect Human Anat, Dept Expt Biomed & Clin Neurosci, Palermo, Italy.
   [Mazzola, M.; Jurjus, A.; Geagea, A. Gerges; Zeenny, M. N.] Amer Univ Beirut, Dept Anat Cell Biol & Physiol, Beirut, Lebanon.
   [Leone, A.] Univ Palermo, Sect Histol, Dept Expt Biomed & Clin Neurosci, Palermo, Italy.
C3 University of Palermo; University of Palermo; American University of
   Beirut; University of Palermo
RP Leone, A (corresponding author), Univ Palermo, Sch Med, Sect Histol & Embriol, BioNec, Via Vesrpo 129, I-90127 Palermo, Italy.
EM angelo.leone@unipa.it
RI ; Cappello, Francesco/F-9153-2012
OI carini, francesco/0000-0001-9442-1671; Zeenny,
   Marie-Noel/0009-0006-4681-5098; TOMASELLO, GIOVANNI/0000-0002-3071-822X;
   Cappello, Francesco/0000-0001-9288-1148; ,
   Margherita/0000-0002-5057-4868
CR Bellavia M, 2014, J BIOL REG HOMEOS AG, V28, P251
   Bellavia M, 2013, MED MICROBIOL IMMUN, V202, P393, DOI 10.1007/s00430-013-0305-2
   Bull TJ, 2003, J CLIN MICROBIOL, V41, P2915, DOI 10.1128/JCM.41.7.2915-2923.2003
   Candela M, 2010, BMC MICROBIOL, V10, DOI 10.1186/1471-2180-10-116
   Claesson MJ, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006669
   He Q, 2013, BMC MICROBIOL, V13, DOI 10.1186/1471-2180-13-289
   Lopez Joanna, 2016, Gastroenterol Hepatol (N Y), V12, P374
   Mandal RS, 2015, GENOM PROTEOM BIOINF, V13, P148, DOI 10.1016/j.gpb.2015.02.005
   Palmer C, 2007, PLOS BIOL, V5, P1556, DOI 10.1371/journal.pbio.0050177
   Peterson DA, 2008, CELL HOST MICROBE, V3, P417, DOI 10.1016/j.chom.2008.05.001
   Rajilic-Stojanovic M, 2007, ENVIRON MICROBIOL, V9, P2125, DOI 10.1111/j.1462-2920.2007.01369.x
   Rajilic-Stojanovic M, 2009, ENVIRON MICROBIOL, V11, P1736, DOI 10.1111/j.1462-2920.2009.01900.x
   Saitoh S, 2002, CLIN DIAGN LAB IMMUN, V9, P54, DOI 10.1128/CDLI.9.1.54-59.2002
   Tannock GW, 1999, ANTON LEEUW INT J G, V76, P265, DOI 10.1023/A:1002038308506
   Tomasello G., 2015, EUROMEDITERRANEAN BI, V10), P65, DOI [10.3269/1970-5492.2015.10.1, DOI 10.3269/1970-5492.2015.10.1]
   Tomasello G, 2014, WORLD J GASTROENTERO, V20, P18121, DOI 10.3748/wjg.v20.i48.18121
   Tralongo Pietro., 2014, Euromediterranean Biomedical Journal, V9, P24
   Vanderpool C, 2008, INFLAMM BOWEL DIS, V14, P1585, DOI 10.1002/ibd.20525
   Zoetendal EG, 2008, GUT, V57, P1605, DOI 10.1136/gut.2007.133603
NR 19
TC 12
Z9 13
U1 0
U2 5
PU BIOLIFE SAS
PI SILVA MARINA (TE)
PA VIA S STEFANO 39 BIS, 64029 SILVA MARINA (TE), ITALY
SN 0393-974X
EI 1724-6083
J9 J BIOL REG HOMEOS AG
JI J. Biol. Regul. Homeost. Agents
PD JAN-MAR
PY 2017
VL 31
IS 1
BP 245
EP 249
PG 5
WC Endocrinology & Metabolism; Immunology; Medicine, Research &
   Experimental; Physiology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Endocrinology & Metabolism; Immunology; Research & Experimental
   Medicine; Physiology
GA EW6MM
UT WOS:000402624700037
PM 28337900
DA 2025-01-04
ER

PT J
AU Ma, XD
   Luo, J
   Zhang, Y
   Sun, DL
   Lin, YY
AF Ma, Xudong
   Luo, Jing
   Zhang, Yi
   Sun, Dali
   Lin, Yueying
TI LncRNA MCM3AP-AS1 Upregulates CDK4 by Sponging miR-545 to Suppress G1
   Arrest in Colorectal Cancer
SO CANCER MANAGEMENT AND RESEARCH
LA English
DT Article
DE MCM3AP-AS1; colorectal cancer; miR-545; CDK4; G1 arrest
ID MOLECULAR PATHWAYS; TARGETED THERAPY
AB Introduction: This study aimed to investigate the role of lncRNA MCM3AP-AS1 in colorectal cancer (CRC).
   Methods: Paired tumor and non-tumor tissues were collected from 60 CRC patients. Expression of MCM3AP-AS1 was determined by RT-qPCR. Overexpression of MCM3AP-AS1, miR-545, and CDK4 in CRC cells was achieved to explore the interactions between them. Cell cycle assay was performed to analyze the roles of MCM3AP-AS1, miR-545, and CDK4 in regulating the cell cycle progression of CRC cells.
   Results: We found that MCM3AP-AS1 was upregulated in CRC and its high expression levels predicted poor survival of CRC patients. MCM3AP-AS1 is predicted to interact with miR-545. In CRC cells, overexpression of MCM3AP-AS1 and miR-545 was achieved, while their overexpression did not affect the expression of each other. Instead, overexpression of MCM3AP-AS1 led to the increased expression levels of CDK4, which is a downstream target of miR-545. Cell cycle analysis showed that overexpression of MCM3AP-AS1 and CDK4 suppressed G1 arrest induced by miR-545. In addition, overexpression of MCM3APAS1 reduced the enhancing effects of overexpressing miR-545 on cell cycle progression.
   Conclusion: MCM3AP-AS1 may upregulate CDK4 by sponging miR-545 to induce G1 arrest in CRC cells.
C1 [Ma, Xudong; Luo, Jing; Sun, Dali; Lin, Yueying] Kunming Med Univ, Affiliated Hosp 2, Gastrointestinal Surg, Kunming 650031, Yunnan, Peoples R China.
   [Zhang, Yi] Teng Chong Peoples Hosp, Gen Surg Dept, Tengchong City 679100, Yunan Province, Peoples R China.
C3 Kunming Medical University
RP Lin, YY (corresponding author), Kunming Med Univ, Affiliated Hosp 2, Gastrointestinal Surg, Kunming 650031, Yunnan, Peoples R China.
EM us5010@163.com
RI Li, Ye/JBS-2949-2023
FU National Natural Science Foundation of China [81860098]
FX We thank the financial support from National Natural Science Foundation
   of China (81860098).
CR Al-Sohaily S, 2012, J GASTROEN HEPATOL, V27, P1423, DOI 10.1111/j.1440-1746.2012.07200.x
   Anastasiadou E, 2018, NAT REV CANCER, V18, P5, DOI 10.1038/nrc.2017.99
   [Anonymous], 2018, FRONT MOL NEUROSCI, DOI DOI 10.3389/FNMO1.2017.00437
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Du BW, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088022
   Favoriti P, 2016, UPDATES SURG, V68, P7, DOI 10.1007/s13304-016-0359-y
   Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011
   Karoui M, 2011, DIS COLON RECTUM, V54, P930, DOI 10.1097/DCR.0b013e31821cced0
   Liang MH, 2019, ENDOCRINE, V65, P318, DOI 10.1007/s12020-019-01939-4
   Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240
   Liu ZH, 2016, ONCOTARGET, V7, P25350, DOI 10.18632/oncotarget.8129
   Moghimi-Dehkordi B, 2012, WORLD J GASTRO ONCOL, V4, P71, DOI 10.4251/wjgo.v4.i4.71
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   Wang YF, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0957-7
NR 15
TC 22
Z9 22
U1 0
U2 4
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1179-1322
J9 CANCER MANAG RES
JI Cancer Manag. Res.
PY 2020
VL 12
BP 8117
EP 8124
DI 10.2147/CMAR.S247330
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA NR9SF
UT WOS:000571901700001
PM 32982409
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Takada, I
   Makishima, M
AF Takada, Ichiro
   Makishima, Makoto
TI Control of Inflammatory Bowel Disease and Colorectal Cancer by Synthetic
   Vitamin D Receptor Ligands
SO CURRENT MEDICINAL CHEMISTRY
LA English
DT Review
DE Vitamin D receptor; inflammatory bowel disease; colorectal cancer;
   vitamin D analogues; bile acids; hypercalcemia; selective VDR modulator
ID BILE-ACID METABOLISM; D ANALOG; NUCLEAR RECEPTORS; INDUCED COLITIS;
   COLON-CANCER; DEFICIENCY; MECHANISMS; PATHWAY; CELLS; MODEL
AB Vitamin D deficiency and insufficiency are associated with an increased risk of cancer, autoimmune disease, inflammation, infection, cardiovascular disease and metabolic disease, as well as bone and mineral disorders. The vitamin D receptor (VDR), a member of the nuclear receptor superfamily, is a receptor for the active form of vitamin D, 1a, 25-dihydroxyvitamin D-3 [1,25(OH)(2)D-3], and mediates vitamin D regulation of specific target gene expression. The secondary bile acid lithocholic acid, which is produced by intestinal bacteria, is another natural VDR ligand. VDR signaling has been suggested to be involved in reciprocal communication between intestinal cells, including immune and epithelial cells, and intestinal microflora. In addition to epidemiological studies on vitamin D status, genome-wide analyses and cellular and animal experiments have shown that VDR is involved in the prevention of inflammatory bowel disease (IBD) and colorectal cancer (CRC). VDR deletion in mice exaggerates colitis and colon tumorigenesis in experimental models, and treatment of mice with synthetic vitamin D analogues ameliorates pathological changes in these diseases. Several VDR ligands are less active in increasing serum calcium levels, showing higher therapeutic efficiency than the natural hormone 1,25(OH)(2)D-3. VDR plays a role in intestinal homeostasis and in protection against IBD and CRC. The development of VDR ligands with reduced or no calcemic activity will be necessary to expand clinical application of VDR-targeting therapy.
C1 [Takada, Ichiro; Makishima, Makoto] Nihon Univ, Sch Med, Dept Biomed Sci, Div Biochem,Itabashi ku, 30-1 Oyaguchi Kamicho, Tokyo 1738610, Japan.
C3 Nihon University
RP Makishima, M (corresponding author), Nihon Univ, Sch Med, Dept Biomed Sci, Div Biochem,Itabashi ku, 30-1 Oyaguchi Kamicho, Tokyo 1738610, Japan.
EM makishima.makoto@nihon-u.ac.jp
FU Japan Society for the Promotion of Science (JSPS) [JP 16K08632];
   Grants-in-Aid for Scientific Research [16K08632] Funding Source: KAKEN
FX All individuals listed as authors have contributed substantially to the
   collection and discussion of the reported published work. The authors
   thank Dr. Andrew I. Shulman for his editorial assistance. This work was
   supported in part by the Japan Society for the Promotion of Science
   (JSPS) under KAKENHI Grant Number JP 16K08632.
CR Adams JS, 2012, ARCH BIOCHEM BIOPHYS, V523, P95, DOI 10.1016/j.abb.2012.02.016
   Armas LAG, 2004, J CLIN ENDOCR METAB, V89, P5387, DOI 10.1210/jc.2004-0360
   Bodin K, 2005, BBA-MOL CELL BIOL L, V1687, P84, DOI 10.1016/j.bbalip.2004.11.003
   Bruce D., 2011, VITAMIN D, P1879
   Cantorna MT, 2000, J NUTR, V130, P2648, DOI 10.1093/jn/130.11.2648
   Carlberg C, 2013, STEROIDS, V78, P127, DOI 10.1016/j.steroids.2012.10.019
   Cheng J, 2014, J LIPID RES, V55, P455, DOI 10.1194/jlr.M044420
   Choi M, 2009, EXPERT OPIN THER PAT, V19, P593, DOI 10.1517/13543770902877717
   Clevers H, 2006, CELL, V127, P469, DOI 10.1016/j.cell.2006.10.018
   Cross HS, 2011, MOL CELL ENDOCRINOL, V347, P70, DOI 10.1016/j.mce.2011.07.022
   Cross HS, 2011, VITAMIN D, P1711
   Daniel C, 2005, EUR J CLIN INVEST, V35, P343, DOI 10.1111/j.1365-2362.2005.01492.x
   Daniel C, 2008, J PHARMACOL EXP THER, V324, P23, DOI 10.1124/jpet.107.127209
   Daniel C, 2006, J PHARMACOL EXP THER, V319, P622, DOI 10.1124/jpet.106.107599
   Di Rosa M, 2013, CRIT REV ONCOL HEMAT, V88, P594, DOI 10.1016/j.critrevonc.2013.07.016
   Froicu M, 2003, MOL ENDOCRINOL, V17, P2386, DOI 10.1210/me.2003-0281
   Froicu M, 2007, BMC IMMUNOL, V8, DOI 10.1186/1471-2172-8-5
   GARLAND CF, 1989, LANCET, V2, P1176, DOI 10.1016/s0140-6736(89)91789-3
   Goff JP, 2012, AM J PHYSIOL-GASTR L, V302, pG460, DOI 10.1152/ajpgi.00156.2011
   Golan MA, 2015, DIGEST DIS SCI, V60, P1941, DOI 10.1007/s10620-015-3634-8
   Haussler MR, 2013, CALCIFIED TISSUE INT, V92, P77, DOI 10.1007/s00223-012-9619-0
   Holick MF, 2007, NEW ENGL J MED, V357, P266, DOI 10.1056/NEJMra070553
   Huerta S, 2002, CANCER RES, V62, P741
   Larriba MJ, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0023524
   Kallay E, 2001, CARCINOGENESIS, V22, P1429, DOI 10.1093/carcin/22.9.1429
   Kim JH, 2013, BBA-GEN SUBJECTS, V1830, P2118, DOI 10.1016/j.bbagen.2012.09.020
   Kong J, 2008, AM J PHYSIOL-GASTR L, V294, pG208, DOI 10.1152/ajpgi.00398.2007
   Laverny G, 2010, IMMUNOL LETT, V131, P49, DOI 10.1016/j.imlet.2010.03.006
   Li YC, 2015, J STEROID BIOCHEM, V148, P179, DOI 10.1016/j.jsbmb.2015.01.011
   Liu PT, 2006, SCIENCE, V311, P1770, DOI 10.1126/science.1123933
   Liu WC, 2013, J CLIN INVEST, V123, P3983, DOI 10.1172/JCI65842
   Makishima M, 2005, J PHARMACOL SCI, V97, P177, DOI 10.1254/jphs.FMJ04008X4
   Makishima M, 2002, SCIENCE, V296, P1313, DOI 10.1126/science.1070477
   Makishima M, 2011, VITAMIN D, P1509
   Meeker S, 2016, WORLD J GASTROENTERO, V22, P933, DOI 10.3748/wjg.v22.i3.933
   Nagpal S, 2005, ENDOCR REV, V26, P662, DOI 10.1210/er.2004-0002
   Nishida S, 2009, DRUG METAB DISPOS, V37, P2037, DOI 10.1124/dmd.109.027334
   Ohtani N, 2014, CANCER RES, V74, P1885, DOI 10.1158/0008-5472.CAN-13-3501
   Pálmer HG, 2001, J CELL BIOL, V154, P369, DOI 10.1083/jcb.200102028
   Pike JW, 2014, J STEROID BIOCHEM, V144, P5, DOI 10.1016/j.jsbmb.2013.11.004
   Plum LA, 2010, NAT REV DRUG DISCOV, V9, P941, DOI 10.1038/nrd3318
   Ramagopalan SV, 2010, GENOME RES, V20, P1352, DOI 10.1101/gr.107920.110
   Rosenfeld MG, 2006, GENE DEV, V20, P1405, DOI 10.1101/gad.1424806
   Sakaki T, 2014, ANTI-CANCER AGENT ME, V14, P97, DOI 10.2174/18715206113139990307
   Shah S, 2006, MOL CELL, V21, P799, DOI 10.1016/j.molcel.2006.01.037
   Shulman AI, 2005, NEW ENGL J MED, V353, P604, DOI 10.1056/NEJMra043590
   Stio M, 2007, J STEROID BIOCHEM, V103, P51, DOI 10.1016/j.jsbmb.2006.07.008
   Strauch UG, 2007, WORLD J GASTROENTERO, V13, P6529, DOI 10.3748/wjg.v13.i48.6529
   Takada I, 2015, EXPERT OPIN THER PAT, V25, P1373, DOI 10.1517/13543776.2015.1093113
   Van Belle TL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109194
   Verlinden L, 2013, J STEROID BIOCHEM, V136, P107, DOI 10.1016/j.jsbmb.2012.09.017
   Wang TT, 2010, J BIOL CHEM, V285, P2237, DOI 10.1074/jbc.C109.071225
   Watarai Y, 2015, J MED CHEM, V58, P9510, DOI 10.1021/acs.jmedchem.5b00792
   Wierzbicka JM, 2015, INT J ONCOL, V47, P1084, DOI 10.3892/ijo.2015.3088
   Wu SP, 2015, AM J PHYSIOL-GASTR L, V309, pG341, DOI 10.1152/ajpgi.00105.2015
   Wu SP, 2015, GUT, V64, P1082, DOI 10.1136/gutjnl-2014-307436
   Xie W, 2001, P NATL ACAD SCI USA, V98, P3375, DOI 10.1073/pnas.051014398
   Xu HB, 2010, CARCINOGENESIS, V31, P1434, DOI 10.1093/carcin/bgq098
   Yamada S, 2014, TRENDS PHARMACOL SCI, V35, P324, DOI 10.1016/j.tips.2014.04.008
   Yu SH, 2008, P NATL ACAD SCI USA, V105, P5207, DOI 10.1073/pnas.0711558105
   Zhu T, 2015, INT J MOL MED, V35, P1213, DOI 10.3892/ijmm.2015.2150
NR 61
TC 13
Z9 13
U1 0
U2 13
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 0929-8673
EI 1875-533X
J9 CURR MED CHEM
JI Curr. Med. Chem.
PY 2017
VL 24
IS 9
BP 868
EP 875
DI 10.2174/0929867323666161202145509
PG 8
WC Biochemistry & Molecular Biology; Chemistry, Medicinal; Pharmacology &
   Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Pharmacology & Pharmacy
GA EU0JO
UT WOS:000400697700003
PM 27915991
DA 2025-01-04
ER

PT J
AU Kusumaningrum, AE
   Makaba, S
   Ali, E
   Singh, M
   Fenjan, MN
   Rasulova, I
   Misra, N
   Musawi, SGA
   Alsalamy, A
AF Kusumaningrum, Anggraeni E.
   Makaba, Sarce
   Ali, Eyhab
   Singh, Mandeep
   Fenjan, Mohammed N.
   Rasulova, Irodakhon
   Misra, Neeti
   Al- Musawi, Sada G.
   Alsalamy, Ali
TI A perspective on emerging therapies in metastatic colorectal cancer:
   Focusing on molecular medicine and drug resistance
SO CELL BIOCHEMISTRY AND FUNCTION
LA English
DT Review
DE angiogenesis; CRC; drug resistance; metastasis; personalized medicine;
   tissue-based biomarkers
ID CELL LUNG-CANCER; ENDOTHELIAL GROWTH-FACTOR; MICROSATELLITE INSTABILITY;
   CLINICAL-IMPLICATIONS; TARGETED THERAPY; TYROSINE KINASES; INHIBITOR;
   RECEPTOR; EGFR; CHEMOTHERAPY
AB The majority of cancer cases are colorectal cancer, which is also the second largest cause of cancer-related deaths worldwide. Metastasis is the leading cause of death for patients with colorectal cancer. Metastatic colorectal cancer incidence are on the rise due to a tiny percentage of tumors developing resistant to medicines despite advances in treatment tactics. Cutting-edge targeted medications are now the go-to option for customized and all-encompassing CRC care. Specifically, multitarget kinase inhibitors, antivascular endothelial growth factors, and epidermal growth factor receptors are widely used in clinical practice for CRC-targeted treatments. Rare targets in metastatic colorectal cancer are becoming more well-known due to developments in precision diagnostics and the extensive use of second-generation sequencing technology. These targets include the KRAS mutation, the BRAF V600E mutation, the HER2 overexpression/amplification, and the MSI-H/dMMR. Incorporating certain medications into clinical trials has significantly increased patient survival rates, opening new avenues and bringing fresh viewpoints for treating metastatic colorectal cancer. These focused therapies change how cancer is treated, giving patients new hope and better results. These markers can significantly transform and individualize therapy regimens. They could open the door to precisely customized and more effective medicines, improving patient outcomes and quality of life. The fast-growing body of knowledge regarding the molecular biology of colorectal cancer and the latest developments in gene sequencing and molecular diagnostics are directly responsible for this advancement.
   Tissue-based biomarkers are intensely involved in the pathogenesis of metastatic colorectal cancer (mCRC).It has been shown that the relationship between new drug resistance mechanisms with signaling pathways, cell surface markers, and oncogenic targets is involved in the pathogenesis of mCRC.Tissue-based biomarkers and their involvement in mCRC drug resistance can potentially revolutionize and personalize treatment protocols.
C1 [Kusumaningrum, Anggraeni E.] Univ 17 Agustus 1945, Semarang, Indonesia.
   [Makaba, Sarce] Univ Cenderawasih Jayapura, Jayapura, Indonesia.
   [Ali, Eyhab] Al Zahraa Univ Women, Coll Pharm, Karbala, Iraq.
   [Singh, Mandeep] Univ Jammu, Directorate Sports & Phys Educ, Jammu, India.
   [Fenjan, Mohammed N.] Al Ayen Univ, Coll Hlth & Med Technol, Thi Qar, Iraq.
   [Rasulova, Irodakhon] New Uzbekistan Univ, Sch Humanities Nat & Social Sci, Tashkent, Uzbekistan.
   [Rasulova, Irodakhon] Samarkand State Med Univ, Dept Publ Hlth, Samarkand, Uzbekistan.
   [Misra, Neeti] Uttaranchal Univ, Uttaranchal Inst Management, Dept Management, Dehra Dun, India.
   [Al- Musawi, Sada G.] Natl Univ Sci & Technol, Coll Pharm, Dhi Qar, Iraq.
   [Alsalamy, Ali] Imam Jaafar Al Sadiq Univ, Coll Tech Engn, Muthanna, Iraq.
C3 Cenderawasih University; Al-Zahraa University for Women; University of
   Jammu; Al-Ayen University; Samarkand State Medical University;
   Uttaranchal University; National University of Science & Technology -
   Iraq; Imam Jaa'far al-Sadiq University
RP Kusumaningrum, AE (corresponding author), Univ 17 Agustus 1945, Semarang, Indonesia.
EM anggraeni@untagsmg.ac.id
OI Gh.TAHER, Sada/0000-0002-1685-6175
CR Aggarwal N, 2022, INT J COLORECTAL DIS, V37, P35, DOI 10.1007/s00384-021-04046-x
   Ahcene Djaballah Selma, 2022, Am Soc Clin Oncol Educ Book, V42, P1, DOI 10.1200/EDBK_351354
   Ahmad R, 2021, INT J MOL MED, V47, DOI 10.3892/ijmm.2021.4847
   Al Bitar S, 2023, WORLD J GASTROENTERO, V29, P1395, DOI 10.3748/wjg.v29.i9.1395
   Bahar E, 2022, CANCERS, V14, DOI 10.3390/cancers14061462
   Battaglin F, 2018, CLIN ADV HEMATOL ONC, V16, P735
   Bencsikova B, 2015, BMC GASTROENTEROL, V15, DOI 10.1186/s12876-015-0266-6
   Berger MF, 2018, NAT REV CLIN ONCOL, V15, P353, DOI 10.1038/s41571-018-0002-6
   Biller LH, 2021, JAMA-J AM MED ASSOC, V325, P669, DOI 10.1001/jama.2021.0106
   Birch Cierra A, 2021, Curr Opin Endocr Metab Res, V16, P37, DOI 10.1016/j.coemr.2020.07.011
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Brockmueller A., 2023, Resveratrol as sensitizer in colorectal cancer plasticity
   Bronte G, 2015, ONCOTARGET, V6, P24780, DOI 10.18632/oncotarget.4959
   Brooks AJ, 2020, CANCERS, V12, DOI 10.3390/cancers12071971
   Brown TC, 2021, BIOMOLECULES, V11, DOI 10.3390/biom11070956
   Bubin R, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24087030
   Carvalho PD, 2018, CANCER RES, V78, P7, DOI 10.1158/0008-5472.CAN-17-2084
   Chan GHJ, 2019, J GASTROINTEST ONCOL, V10, P1183, DOI 10.21037/jgo.2019.06.03
   Chevallier M, 2021, WORLD J CLIN ONCOL, V12, P217, DOI 10.5306/wjco.v12.i4.217
   Claesson-Welsh L, 2015, UPSALA J MED SCI, V120, P135, DOI 10.3109/03009734.2015.1064501
   Cocco E, 2018, NAT REV CLIN ONCOL, V15, P731, DOI 10.1038/s41571-018-0113-0
   Cohen R, 2020, CANCERS, V12, DOI 10.3390/cancers12092350
   Czajkowski D, 2022, J MED IMAG RADIAT ON, V66, P546, DOI 10.1111/1754-9485.13413
   Das PK, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9061392
   Debbi K, 2023, CANCERS, V15, DOI 10.3390/cancers15082278
   Deschoolmeester V, 2010, ONCOLOGIST, V15, P699, DOI 10.1634/theoncologist.2010-0025
   Dey A, 2023, TECHNOL CANCER RES T, V22, DOI 10.1177/15330338231178403
   Diao ZL, 2021, CRIT REV ONCOL HEMAT, V157, DOI 10.1016/j.critrevonc.2020.103171
   Duggirala KB, 2022, BIOMOL THER, V30, P19, DOI 10.4062/biomolther.2021.047
   Egile C, 2015, MOL CANCER THER, V14, P384, DOI 10.1158/1535-7163.MCT-14-0428
   Engle K, 2022, EUR J MED CHEM, V239, DOI 10.1016/j.ejmech.2022.114542
   Fanelli GN, 2020, CANCER CELL INT, V20, DOI 10.1186/s12935-020-1117-2
   Feng YF, 2022, CANCER MANAG RES, V14, P2379, DOI 10.2147/CMAR.S369175
   Florescu-Tenea R M, 2019, Curr Health Sci J, V45, P134, DOI 10.12865/CHSJ.45.02.02
   Frank MH, 2021, GASTROENTEROLOGY, V160, P1947, DOI 10.1053/j.gastro.2020.12.080
   Gang W, 2018, CANCER MED-US, V7, P1578, DOI 10.1002/cam4.1386
   García-Aranda M, 2019, CANCERS, V11, DOI 10.3390/cancers11040433
   Giampieri R, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.736104
   Gires O, 2020, CANCER METAST REV, V39, P969, DOI 10.1007/s10555-020-09898-3
   Groenendijk FH, 2014, MOL ONCOL, V8, P1067, DOI 10.1016/j.molonc.2014.05.004
   Gu Q, 2020, ADV CLIN EXP MED, V29, P1277, DOI 10.17219/acem/126051
   Guarini C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136813
   Guo S, 2018, INT J BIOL SCI, V14, P2083, DOI 10.7150/ijbs.25720
   Guo YJ, 2020, EXP THER MED, V19, P1997, DOI 10.3892/etm.2020.8454
   Gupta MK, 2003, WORLD J GASTROENTERO, V9, P1144, DOI 10.3748/wjg.v9.i6.1144
   Haibe Y, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00221
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Hasbullah HH, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms222111941
   He K, 2023, J TRANSL MED, V21, DOI 10.1186/s12967-023-04460-5
   Hoda Daanish, 2008, Ther Clin Risk Manag, V4, P1221
   Hopirtean Claudiu, 2018, Clujul Med, V91, P12, DOI 10.15386/cjmed-881
   Hsu JL, 2016, CANCER METAST REV, V35, P575, DOI 10.1007/s10555-016-9649-6
   Hua H, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01137-8
   Huang A, 2021, WORLD J GASTRO SURG, V13, P1567, DOI 10.4240/wjgs.v13.i12.1567
   Huang MP, 2018, BMC GASTROENTEROL, V18, DOI 10.1186/s12876-018-0870-3
   Hubbard Joleen M, 2013, Gastrointest Cancer Res, V6, P47
   Hussain MRM, 2015, SAUDI J BIOL SCI, V22, P359, DOI 10.1016/j.sjbs.2014.10.002
   Innominato PF, 2021, INT J CANCER, V148, P2512, DOI 10.1002/ijc.33422
   Iqbal Nida, 2014, Chemother Res Pract, V2014, P357027, DOI [10.1155/2014/852748, 10.1155/2014/357027]
   Ivanova M, 2022, LIFE-BASEL, V12, DOI 10.3390/life12091403
   Jiang HF, 2023, FRONT PHARMACOL, V14, DOI 10.3389/fphar.2023.1189799
   Jonckheere S, 2022, CELLS TISSUES ORGANS, V211, P157, DOI 10.1159/000512218
   Ju F, 2022, STEM CELL RES THER, V13, DOI 10.1186/s13287-022-02904-1
   Jurkovicova D, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232314672
   Keyvani-Ghamsari S, 2021, CLIN EPIGENETICS, V13, DOI 10.1186/s13148-021-01107-4
   Koch S, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006502
   Kopetz S, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2022.100477
   Kopetz S, 2019, ANN ONCOL, V30
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Lai E, 2020, CANCERS, V12, DOI 10.3390/cancers12051214
   Li JJ, 2023, INT J GEN MED, V16, P1527, DOI 10.2147/IJGM.S408349
   Li J, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.869010
   Li YH, 2023, J PATHOL CLIN RES, V9, P89, DOI 10.1002/cjp2.307
   Liang KH, 2019, CANCER RES, V79, DOI 10.1158/1538-7445.AM2019-4670
   Lin AQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02039
   Lin KX, 2023, CANCER IMMUNOL IMMUN, V72, P3875, DOI 10.1007/s00262-023-03520-5
   Liu JQ, 2023, CANCERS, V15, DOI 10.3390/cancers15061893
   Lizardo DY, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188447
   Lopez JS, 2017, NAT REV CLIN ONCOL, V14, P57, DOI 10.1038/nrclinonc.2016.96
   Lu J, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241914815
   Manning BD, 2017, CELL, V169, P381, DOI 10.1016/j.cell.2017.04.001
   Meng MJ, 2021, BIOMED PHARMACOTHER, V140, DOI 10.1016/j.biopha.2021.111717
   Mohtar MA, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10020255
   Mokhtari Mojhgan, 2017, Adv Biomed Res, V6, P56, DOI 10.4103/2277-9175.205529
   Moriarity A, 2016, THER ADV MED ONCOL, V8, P276, DOI 10.1177/1758834016646734
   Mousavi S, 2019, J CELL PHYSIOL, V234, P12422, DOI 10.1002/jcp.28080
   Mulet-Margalef N, 2023, CANCERS, V15, DOI 10.3390/cancers15041022
   Nabariya DK, 2020, BBA-REV CANCER, V1874, DOI 10.1016/j.bbcan.2020.188426
   Nakayama I, 2020, CANCERS, V12, DOI 10.3390/cancers12113236
   Neijssen J, 2021, J BIOL CHEM, V296, DOI 10.1016/j.jbc.2021.100641
   Niu G, 2010, CURR DRUG TARGETS, V11, P1000, DOI 10.2174/138945010791591395
   Ogino S, 2009, CLIN CANCER RES, V15, P7322, DOI 10.1158/1078-0432.CCR-09-1570
   Ohishi T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24021702
   Oikonomou E, 2014, ONCOTARGET, V5, P11752, DOI 10.18632/oncotarget.2555
   Silla IO, 2014, WORLD J GASTROENTERO, V20, P17288, DOI 10.3748/wjg.v20.i46.17288
   Osumi H, 2019, INT J CANCER, V145, P2488, DOI 10.1002/ijc.32320
   Pagani F, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20215319
   Panczyk M, 2014, WORLD J GASTROENTERO, V20, P9775, DOI 10.3748/wjg.v20.i29.9775
   Pandey H, 2023, CANCERS, V15, DOI 10.3390/cancers15030866
   Parakh S, 2022, CANCERS, V14, DOI 10.3390/cancers14061454
   Parisi A, 2020, CANCERS, V12, DOI 10.3390/cancers12051259
   Parizadeh SM, 2019, IUBMB LIFE, V71, P802, DOI 10.1002/iub.2063
   Patel SA, 2023, CLIN CANCER RES, V29, P30, DOI 10.1158/1078-0432.CCR-22-1366
   Perillo F, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155389
   Piawah S, 2019, CANCER-AM CANCER SOC, V125, P4139, DOI 10.1002/cncr.32163
   Ponomaryova AA, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241512407
   Popova NV, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22041743
   Porru M, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0719-1
   Prat M, 2014, BIOMEDICINES, V2, P359, DOI 10.3390/biomedicines2040359
   Qin SK, 2018, J CLIN ONCOL, V36, P3031, DOI 10.1200/JCO.2018.78.3183
   Ramesh P, 2021, CELL DEATH DIFFER, V28, P3282, DOI 10.1038/s41418-021-00816-w
   Rawla Prashanth, 2019, Med Sci (Basel), V7, DOI 10.3390/medsci7080083
   Rodríguez F, 2022, BIOMOLECULES, V12, DOI 10.3390/biom12060784
   Rodriquenz MG, 2022, CRIT REV ONCOL HEMAT, V173, DOI 10.1016/j.critrevonc.2022.103657
   Ros J, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835921992974
   Roskoski R, 2014, PHARMACOL RES, V79, P34, DOI 10.1016/j.phrs.2013.11.002
   Sahu PK, 2020, PLANTS-BASEL, V9, DOI 10.3390/plants9101355
   Saif Muhammad Wasif, 2013, Cancer Manag Res, V5, P103, DOI 10.2147/CMAR.S45193
   Sanaei MJ, 2022, TRANSL ONCOL, V18, DOI 10.1016/j.tranon.2022.101364
   Sandhu J, 2019, J SURG ONCOL, V119, P564, DOI 10.1002/jso.25421
   Saraon P, 2021, ONCOGENE, V40, P4079, DOI 10.1038/s41388-021-01841-2
   Seebacher NA, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1094-2
   Shin AE, 2023, TRENDS PHARMACOL SCI, V44, P222, DOI 10.1016/j.tips.2023.01.003
   Shiravand Y, 2022, CURR ONCOL, V29, P3044, DOI 10.3390/curroncol29050247
   Sinicrope FA, 2009, CURR OPIN ONCOL, V21, P369, DOI 10.1097/CCO.0b013e32832c94bd
   Smith AG, 2019, J PATHOL, V247, P708, DOI 10.1002/path.5222
   Sotelo MJ, 2014, WORLD J GASTROENTERO, V20, P4208, DOI 10.3748/wjg.v20.i15.4208
   Stefani C, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms221910260
   Suwaidan AA, 2022, CANCER TREAT REV, V105, DOI 10.1016/j.ctrv.2022.102363
   Szymonowicz K, 2018, CANCERS, V10, DOI 10.3390/cancers10030078
   Tang YL, 2023, WORLD J GASTROENTERO, V29, P926, DOI 10.3748/wjg.v29.i6.926
   Troiani T, 2012, EXPERT OPIN INV DRUG, V21, P949, DOI 10.1517/13543784.2012.689287
   Uemura A, 2021, PROG RETIN EYE RES, V84, DOI 10.1016/j.preteyeres.2021.100954
   Wang CK, 2021, CURR ONCOL REP, V23, DOI 10.1007/s11912-021-01022-0
   Wang J, 2016, ONCOTARGETS THER, V9, P3711, DOI 10.2147/OTT.S106399
   Wang NN, 2022, CANCERS, V14, DOI 10.3390/cancers14205160
   Wasik A, 2022, CANCERS, V14, DOI 10.3390/cancers14174225
   Wei P, 2020, J EXTRACELL VESICLES, V9, DOI 10.1080/20013078.2020.1809765
   Whiteside TL, 2016, ADV CLIN CHEM, V74, P103, DOI 10.1016/bs.acc.2015.12.005
   Wicki A, 2015, J CONTROL RELEASE, V200, P138, DOI 10.1016/j.jconrel.2014.12.030
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Yaeger R, 2023, CANCER DISCOV, V13, P41, DOI 10.1158/2159-8290.CD-22-0405
   Yang YCSH, 2021, J BIOMED SCI, V28, DOI 10.1186/s12929-021-00719-5
   Zhai ZH, 2017, SEMIN CELL DEV BIOL, V64, P107, DOI 10.1016/j.semcdb.2016.08.033
   Zhang Y, 2019, CANCER MANAG RES, V11, P7787, DOI 10.2147/CMAR.S215533
   Zhao H, 2014, ELIFE, V3, DOI 10.7554/eLife.02725
   Zhao Y, 2022, FRONT PHARMACOL, V13, DOI 10.3389/fphar.2022.808855
   Zhao YS, 2022, INT J BIOL SCI, V18, P3845, DOI 10.7150/ijbs.70958
   Zhong MY, 2020, INT J BIOL SCI, V16, P272, DOI 10.7150/ijbs.37906
   Zubair T, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032651
NR 150
TC 2
Z9 2
U1 3
U2 7
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0263-6484
EI 1099-0844
J9 CELL BIOCHEM FUNCT
JI Cell Biochem. Funct.
PD JAN
PY 2024
VL 42
IS 1
AR e3906
DI 10.1002/cbf.3906
PG 16
WC Biochemistry & Molecular Biology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology
GA DZ0A4
UT WOS:001135783600001
PM 38269502
DA 2025-01-04
ER

PT J
AU Huang, TX
   Tan, XY
   Huang, HS
   Li, YT
   Liu, BL
   Liu, KS
   Chen, XC
   Chen, Z
   Guan, XY
   Zou, C
   Fu, L
AF Huang, Tu-Xiong
   Tan, Xiang-Yu
   Huang, Hui-Si
   Li, Yu-Ting
   Liu, Bei-Lei
   Liu, Kai-Sheng
   Chen, Xinchun
   Chen, Zhe
   Guan, Xin-Yuan
   Zou, Chang
   Fu, Li
TI Targeting cancer-associated fibroblast-secreted WNT2 restores dendritic
   cell-mediated antitumour immunity
SO GUT
LA English
DT Article
DE antibody targeted therapy; cancer immunobiology; colorectal cancer;
   molecular carcinogenesis; oesophageal cancer
ID TUMOR-GROWTH; ACTIVATION; EXPRESSION; DIFFERENTIATION; IMMUNOTHERAPY;
   SUPPRESSION; PROGRESSION; PATHWAY; STAT3
AB Objective Solid tumours respond poorly to immune checkpoint inhibitor (ICI) therapies. One major therapeutic obstacle is the immunosuppressive tumour microenvironment (TME). Cancer-associated fibroblasts (CAFs) are a key component of the TME and negatively regulate antitumour T-cell response. Here, we aimed to uncover the mechanism underlying CAFs-mediated tumour immune evasion and to develop novel therapeutic strategies targeting CAFs for enhancing ICI efficacy in oesophageal squamous cell carcinoma (OSCC) and colorectal cancer (CRC). Design Anti-WNT2 monoclonal antibody (mAb) was used to treat immunocompetent C57BL/6 mice bearing subcutaneously grafted mEC25 or CMT93 alone or combined with anti-programmed cell death protein 1 (PD-1), and the antitumour efficiency and immune response were assessed. CAFs-induced suppression of dendritic cell (DC)-differentiation and DC-mediated antitumour immunity were analysed by interfering with CAFs-derived WNT2, either by anti-WNT2 mAb or with short hairpin RNA-mediated knockdown. The molecular mechanism underlying CAFs-induced DC suppression was further explored by RNA-sequencing and western blot analyses. Results A negative correlation between WNT2(+) CAFs and active CD8(+) T cells was detected in primary OSCC tumours. Anti-WNT2 mAb significantly restored antitumour T-cell responses within tumours and enhanced the efficacy of anti-PD-1 by increasing active DC in both mouse OSCC and CRC syngeneic tumour models. Directly interfering with CAFs-derived WNT2 restored DC differentiation and DC-mediated antitumour T-cell responses. Mechanistic analyses further demonstrated that CAFs-secreted WNT2 suppresses the DC-mediated antitumour T-cell response via the SOCS3/p-JAK2/p-STAT3 signalling cascades. Conclusions CAFs could suppress antitumour immunity through WNT2 secretion. Targeting WNT2 might enhance the ICI efficacy and represent a new anticancer immunotherapy.
C1 [Huang, Tu-Xiong; Tan, Xiang-Yu; Huang, Hui-Si; Li, Yu-Ting; Chen, Xinchun; Fu, Li] Shenzhen Univ, Hlth Sci Ctr, Guangdong Prov Key Lab Reg Immun & Dis, Dept Pharmacol, Shenzhen, Peoples R China.
   [Huang, Tu-Xiong; Tan, Xiang-Yu; Huang, Hui-Si; Li, Yu-Ting; Chen, Xinchun; Fu, Li] Shenzhen Univ, Hlth Sci Ctr, Int Canc Ctr, Shenzhen, Peoples R China.
   [Huang, Tu-Xiong; Liu, Kai-Sheng; Zou, Chang] Southern Univ Sci & Technol, Jinan Univ, Shenzhen Peoples Hosp, Clin Med Coll 2,Affiliated Hosp 1, Shenzhen, Peoples R China.
   [Liu, Bei-Lei; Guan, Xin-Yuan] Univ Hong Kong, Dept Clin Oncol, Hong Kong, Peoples R China.
   [Chen, Zhe] Zhejiang Chinese Med Univ, Affiliated Hosp 1, Key Lab Digest Pathophysiol Zhejiang Prov, Hangzhou, Peoples R China.
C3 Shenzhen University; Shenzhen University; Southern University of Science
   & Technology; Jinan University; University of Hong Kong; Zhejiang
   Chinese Medical University
RP Fu, L (corresponding author), Shenzhen Univ, Pharmacol, Shenzhen, Guangdong, Peoples R China.
EM gracelfu@szu.edu.cn
RI Li, Yuting/IVH-4108-2023; Guan, Xin-Yuan/A-3639-2009; Liu,
   beilei/HZI-4459-2023; liu, kaiwen/GVS-5259-2022; Fu, Li/F-7182-2010
OI , Yuting/0000-0003-2541-7024; Fu, Li/0000-0003-2643-6278; Liu,
   Kaisheng/0000-0002-4755-0523
FU National Key R&D Programme of China [2017YFA0503900]; National Natural
   Science Foundation of China [81372583, 81772957]; Science and Technology
   Programme of Guangdong Province in China [2019B030301009]; Industry and
   Information Technology Foundation of Shenzhen [20180309100135860];
   Shenzhen Basic Research Programme [JCYJ20200109113810154]
FX This work was supported by grants from the National Key R&D Programme of
   China (2017YFA0503900), the National Natural Science Foundation of China
   (81372583 and 81772957), the Science and Technology Programme of
   Guangdong Province in China (2019B030301009), the Industry and
   Information Technology Foundation of Shenzhen (20180309100135860), the
   Shenzhen Basic Research Programme (JCYJ20200109113810154),
CR Ahmed K, 2016, CANCERS, V8, DOI 10.3390/cancers8070066
   Alshamsan A, 2010, J PHARM PHARM SCI, V13, P21, DOI 10.18433/J37598
   [Anonymous], 2018, NAT REV DRUG DISCOV, V17, P854, DOI 10.1038/nrd.2018.210
   Baumeister SH, 2016, ANNU REV IMMUNOL, V34, P539, DOI 10.1146/annurev-immunol-032414-112049
   Bui TD, 1997, BRIT J CANCER, V75, P1131, DOI 10.1038/bjc.1997.195
   Chen LP, 2015, J CLIN INVEST, V125, P3384, DOI 10.1172/JCI80011
   Czyz M, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8060540
   Dale TC, 1996, CANCER RES, V56, P4320
   Ferreira JC, 2011, EPIGENETICS-US, V6, P441, DOI 10.4161/epi.6.4.14554
   Frinchi M, 2008, NEUROSCI LETT, V447, P20, DOI 10.1016/j.neulet.2008.09.059
   Fu L, 2011, GUT, V60, P1635, DOI 10.1136/gut.2011.241638
   Gardner A, 2016, TRENDS IMMUNOL, V37, P855, DOI 10.1016/j.it.2016.09.006
   Huang TX, 2019, CANCER COMMUN, V39, DOI 10.1186/s40880-019-0427-z
   Huang TX, 2020, CANCER COMMUN, V40, P316, DOI 10.1002/cac2.12066
   Huang TX, 2015, PATHOG DIS, V73, DOI 10.1093/femspd/ftv008
   Katoh M, 2003, INT J MOL MED, V12, P811
   Kraman M, 2010, SCIENCE, V330, P827, DOI 10.1126/science.1195300
   Kramer N, 2017, ONCOGENE, V36, P5460, DOI 10.1038/onc.2017.144
   Krishnamurthy A, 2018, CANCER RES, V78, P5398, DOI 10.1158/0008-5472.CAN-18-0316
   Li CG, 2005, DEV BIOL, V287, P86, DOI 10.1016/j.ydbio.2005.08.035
   Li CG, 2002, DEV BIOL, V248, P68, DOI 10.1006/dbio.2002.0729
   Li Y, 2012, CYTOKINE GROWTH F R, V23, P127, DOI 10.1016/j.cytogfr.2012.04.005
   Li YH, 2006, J IMMUNOL, V177, P1679, DOI 10.4049/jimmunol.177.3.1679
   Loeffler M, 2006, J CLIN INVEST, V116, P1955, DOI 10.1172/JCI26532
   Logan CY, 2004, ANNU REV CELL DEV BI, V20, P781, DOI 10.1146/annurev.cellbio.20.010403.113126
   Meliilo JA, 2010, J IMMUNOL, V184, P2638, DOI 10.4049/jimmunol.0902960
   Orimo A, 2005, CELL, V121, P335, DOI 10.1016/j.cell.2005.02.034
   Rabinovich GA, 2007, ANNU REV IMMUNOL, V25, P267, DOI 10.1146/annurev.immunol.25.022106.141609
   Shigematsu A, 2010, STEM CELLS DEV, V19, P1679, DOI 10.1089/scd.2009.0370
   Spranger S, 2015, NATURE, V523, P231, DOI 10.1038/nature14404
   Staal FJT, 2008, NAT REV IMMUNOL, V8, P581, DOI 10.1038/nri2360
   Teng MWL, 2015, CANCER RES, V75, P2139, DOI 10.1158/0008-5472.CAN-15-0255
   Wang BJ, 2018, TRENDS PHARMACOL SCI, V39, P648, DOI 10.1016/j.tips.2018.03.008
   Wen YA, 2010, CANCER SCI, V101, P2325, DOI 10.1111/j.1349-7006.2010.01695.x
   Xiao J, 2016, CELL MOL IMMUNOL, V13, P593, DOI 10.1038/cmi.2015.39
   Xiu DH, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1100-8
   Yan J, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-018-08271-x
   Zhang CY, 2009, CLIN CANCER RES, V15, P4017, DOI 10.1158/1078-0432.CCR-08-2824
   Zhang ZR, 2018, ONCOL LETT, V16, P2857, DOI 10.3892/ol.2018.9050
   Zhao F, 2018, IMMUNITY, V48, P147, DOI 10.1016/j.immuni.2017.12.004
   Zhao PF, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0738-1
   Zhong JX, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0009593
   Zhou J, 2009, IMMUNITY, V30, P845, DOI 10.1016/j.immuni.2009.03.021
NR 43
TC 106
Z9 110
U1 7
U2 57
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD FEB
PY 2022
VL 71
IS 2
BP 333
EP 344
DI 10.1136/gutjnl-2020-322924
EA MAR 2021
PG 12
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA YI2EX
UT WOS:000728865400001
PM 33692094
OA hybrid, Green Published
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Arai, H
   Elliott, A
   Millstein, J
   Xiu, J
   Ou, FS
   Innocenti, F
   Wang, JY
   Battaglin, F
   Jayachandran, P
   Kawanishi, N
   Soni, S
   Zhang, W
   Sohal, D
   Goldberg, RM
   Hall, MJ
   Scott, AJ
   Khushman, M
   Hwang, JJ
   Lou, E
   Weinberg, BA
   Lockhart, AC
   Shields, AF
   Abraham, JP
   Magee, D
   Stafford, P
   Zhang, J
   Venook, AP
   Korn, WM
   Lenz, HJ
AF Arai, Hiroyuki
   Elliott, Andrew
   Millstein, Joshua
   Xiu, Joanne
   Ou, Fang-Shu
   Innocenti, Federico
   Wang, Jingyuan
   Battaglin, Francesca
   Jayachandran, Priya
   Kawanishi, Natsuko
   Soni, Shivani
   Zhang, Wu
   Sohal, Davendra
   Goldberg, Richard M.
   Hall, Michael J.
   Scott, Aaron J.
   Khushman, Mohd
   Hwang, Jimmy J.
   Lou, Emil
   Weinberg, Benjamin A.
   Lockhart, Albert Craig
   Shields, Anthony Frank
   Abraham, Jim P.
   Magee, Daniel
   Stafford, Phillip
   Zhang, Jian
   Venook, Alan P.
   Korn, W. Michael
   Lenz, Heinz-Josef
TI Molecular characteristics and clinical outcomes of patients with
   <i>Neurofibromin 1</i>-altered metastatic colorectal cancer
SO ONCOGENE
LA English
DT Article
ID EGFR INHIBITION; RESISTANCE; LANDSCAPE; ACTIVATION; CETUXIMAB; PATHWAY
AB Loss-of-function alterations of Neurofibromin 1 (NF1) activate RAS, a driver of colorectal cancer. However, the clinical implications of NF1 alterations are largely unknown. We performed a comprehensive molecular profiling of NF1-mutant colorectal cancer using data from 8150 patients included in a dataset of commercial CLIA-certified laboratory (Caris Life Sciences). In addition, NF1 expression levels were tested for associations with clinical outcomes using data from 431 patients in the CALGB/SWOG 80405 trial. In the Caris dataset, 2.2% of patients had pathogenic or presumed pathogenic NF1 mutations. NF1-mutant tumors more frequently harbored PIK3CA (25.0% vs. 16.7%) and PTEN mutations (24.0% vs. 4.2%) than wild type tumors. Gene set enrichment analysis revealed that MAPK and PI3K pathway signatures were enriched in NF1-mutant tumors. In the CALGB/SWOG 80405 cohort, low NF1 expression was associated with poor prognosis, and high NF1 expression was associated with better efficacy of cetuximab than bevacizumab. Together, we revealed concurrent genetic alterations in the PI3K pathways in NF1-mutant tumors, suggesting the need to simultaneously block MAPK and PI3K pathways in treatment. The potential of NF1 alteration as a novel biomarker for targeted therapy was highlighted, warranting further investigations in clinical settings.
C1 [Arai, Hiroyuki; Wang, Jingyuan; Battaglin, Francesca; Jayachandran, Priya; Kawanishi, Natsuko; Soni, Shivani; Zhang, Wu; Lenz, Heinz-Josef] Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.
   [Elliott, Andrew; Xiu, Joanne; Abraham, Jim P.; Magee, Daniel; Stafford, Phillip; Zhang, Jian; Korn, W. Michael] Caris Life Sci, Med Affairs, Clin & Translat Res, Phoenix, AZ USA.
   [Millstein, Joshua] Univ Southern Calif, Dept Prevent Med, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.
   [Ou, Fang-Shu] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA.
   [Innocenti, Federico] Univ N Carolina, UNC Eshelman Sch Pharm, Chapel Hill, NC 27515 USA.
   [Sohal, Davendra] Univ Cincinnati, Div Hematol Oncol, Cincinnati, OH USA.
   [Goldberg, Richard M.] West Virginia Univ, Canc Inst, Morgantown, WV 26506 USA.
   [Hall, Michael J.] Fox Chase Canc Ctr, Dept Clin Genet, Philadelphia, PA 19111 USA.
   [Scott, Aaron J.] Banner Univ Arizona, Dept Med, Div Hematol & Oncol, Tucson, AZ USA.
   [Khushman, Mohd] Univ S Alabama, Mitchell Canc Inst, Med Oncol, Mobile, AL 36688 USA.
   [Hwang, Jimmy J.] Levine Canc Inst, GI Med Oncol, Dept Solid Tumor Oncol, Charlotte, NC USA.
   [Lou, Emil] Univ Minnesota, Div Hematol Oncol & Transplantat, Minneapolis, MN USA.
   [Weinberg, Benjamin A.] Georgetown Univ, Lombardi Comprehens Canc Ctr, Ruesch Ctr Cure Gastrointestinal Canc, Washington, DC USA.
   [Lockhart, Albert Craig] Univ Miami, Miller Sch Med, Dept Med, Div Oncol, Miami, FL 33136 USA.
   [Shields, Anthony Frank] Wayne State Univ, Karmanos Canc Inst, Dept Oncol, Detroit, MI USA.
   [Venook, Alan P.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
C3 University of Southern California; University of Southern California;
   Mayo Clinic; University of North Carolina; University of North Carolina
   Chapel Hill; University System of Ohio; University of Cincinnati; West
   Virginia University; Fox Chase Cancer Center; University of Arizona;
   University of South Alabama; University of Minnesota System; University
   of Minnesota Twin Cities; Georgetown University; University of Miami;
   Wayne State University; Barbara Ann Karmanos Cancer Institute;
   University of California System; University of California San Francisco;
   UCSF Medical Center; UCSF Helen Diller Family Comprehensive Cancer
   Center
RP Lenz, HJ (corresponding author), Univ Southern Calif, Div Med Oncol, Norris Comprehens Canc Ctr, Los Angeles, CA 90007 USA.
EM lenz@usc.edu
RI Millstein, Joshua/AFU-6153-2022; Battaglin, Francesca/C-2746-2017
OI Battaglin, Francesca/0000-0002-9869-0163; Arai,
   Hiroyuki/0000-0002-1886-7070; Jayachandran, Priya/0009-0002-2480-4057
FU National Cancer Institute of the National Institutes of Health
   [U10CA180821, U10CA180882, UG1CA233163, P30CA 014089]; Gloria Borges
   WunderGlo Foundation; Dhont Family Foundation; Victoria and Philip
   Wilson Research Fund; San Pedro Peninsula Cancer Guild; Daniel Butler
   Research Fund; Bristol-Myers Squibb; Genentech; Pfizer; National Cancer
   Institute [UG1CA233163, UG1CA233373] Funding Source: NIH RePORTER
FX We thank all patients who contributed to this study. Research reported
   in this publication was supported by the National Cancer Institute of
   the National Institutes of Health under Award Numbers U10CA180821 and
   U10CA180882 (to the Alliance for Clinical Trials in Oncology),
   UG1CA233163, P30CA 014089 [to H-JL], Gloria Borges WunderGlo Foundation,
   Dhont Family Foundation, Victoria and Philip Wilson Research Fund, San
   Pedro Peninsula Cancer Guild, and Daniel Butler Research Fund. Also
   supported in part by funds from Bristol-Myers Squibb, Genentech, and
   Pfizer. tThe content is solely the responsibility of the authors and
   does not necessarily represent the official views of the National
   Institutes of Health.
CR Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310
   Arai H, 2021, CLIN CANCER RES, V27, P3234, DOI 10.1158/1078-0432.CCR-20-3635
   Bertotti A, 2015, NATURE, V526, P263, DOI 10.1038/nature14969
   Campbell BB, 2017, CELL, V171, P1042, DOI 10.1016/j.cell.2017.09.048
   de Bruin EC, 2014, CANCER DISCOV, V4, P606, DOI 10.1158/2159-8290.CD-13-0741
   Díez D, 2011, NUCLEIC ACIDS RES, V39, P5526, DOI 10.1093/nar/gkr154
   Georgiou A, 2020, MOL CANCER RES, V18, P835, DOI 10.1158/1541-7786.MCR-19-1201
   Kumagai S, 2021, NAT REV CANCER, V21, P181, DOI 10.1038/s41568-020-00322-0
   Loi S, 2016, CLIN CANCER RES, V22, P1499, DOI 10.1158/1078-0432.CCR-15-1125
   Maertens O, 2014, CANCER DISCOV, V4, P519, DOI 10.1158/2159-8290.CD-14-0286
   Magnuson AM, 2018, P NATL ACAD SCI USA, V115, pE10672, DOI 10.1073/pnas.1810580115
   Markowitz SD, 2009, NEW ENGL J MED, V361, P2449, DOI 10.1056/NEJMra0804588
   Mauri G, 2020, ANN ONCOL, V31, P1135, DOI 10.1016/j.annonc.2020.05.027
   Moore AR, 2020, NAT REV DRUG DISCOV, V19, P533, DOI 10.1038/s41573-020-0068-6
   Post Jasmin B, 2019, Oncotarget, V10, P1440, DOI 10.18632/oncotarget.26677
   Price TJ, 2014, LANCET ONCOL, V15, P569, DOI 10.1016/S1470-2045(14)70118-4
   Rad E, 2016, SEMIN CELL DEV BIOL, V52, P39, DOI 10.1016/j.semcdb.2016.02.007
   Riaz N, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00921-w
   Sepulveda AR, 2017, J CLIN ONCOL, V35, P1453, DOI 10.1200/JCO.2016.71.9807
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Vanderwalde A, 2018, CANCER MED-US, V7, P746, DOI 10.1002/cam4.1372
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Vidotto T, 2020, BRIT J CANCER, V122, P1732, DOI 10.1038/s41416-020-0834-6
   Wagle MC, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0051-4
   Woolston A, 2019, CANCER CELL, V36, P35, DOI 10.1016/j.ccell.2019.05.013
NR 25
TC 7
Z9 7
U1 0
U2 0
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD JAN 5
PY 2022
VL 41
IS 2
BP 260
EP 267
DI 10.1038/s41388-021-02074-z
EA NOV 2021
PG 8
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA YC1XK
UT WOS:000713936100002
PM 34728807
OA Green Accepted
DA 2025-01-04
ER

PT J
AU Hou, PP
   Wang, YA
AF Hou, Pingping
   Wang, Y. Alan
TI Conquering oncogenic KRAS and its bypass mechanisms
SO THERANOSTICS
LA English
DT Review
DE KRAS; RAF; MEK; targeted therapy resistance; cancer
ID MUTANT COLORECTAL-CANCER; CELL LUNG-CANCER; ACQUIRED-RESISTANCE; MEK
   INHIBITION; PANCREATIC-CANCER; RAF INHIBITORS; BRAF INHIBITOR; FEEDBACK
   ACTIVATION; MAPK PATHWAY; KRAS(G12C) INHIBITION
AB Aberrant activation of KRAS signaling is common in cancer, which has catalyzed heroic drug development efforts to target KRAS directly or its downstream signaling effectors. Recent works have yielded novel small molecule drugs with promising preclinical and clinical activities. Yet, no matter how a cancer is addicted to a specific target ??? cancer???s genetic and biological plasticity fashions a variety of resistance mechanisms as a fait accompli, limiting clinical benefit of targeted interventions. Knowledge of these mechanisms may inform combination strategies to attack both oncogenic KRAS and subsequent bypass mechanisms.
C1 [Hou, Pingping] Rutgers New Jersey Med Sch, Ctr Cell Signaling, Newark, NJ 07103 USA.
   [Hou, Pingping] Rutgers New Jersey Med Sch, Dept Microbiol Biochem & Mol Genet, Newark, NJ 07103 USA.
   [Hou, Pingping] Rutgers Canc Inst New Jersey, New Brunswick, NJ 08903 USA.
   [Wang, Y. Alan] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.
C3 Rutgers University System; Rutgers University New Brunswick; Rutgers
   University Biomedical & Health Sciences; Rutgers University System;
   Rutgers University New Brunswick; Rutgers University Biomedical & Health
   Sciences; Rutgers University System; Rutgers University New Brunswick;
   Rutgers University Biomedical & Health Sciences; Rutgers Cancer
   Institute of New Jersey; University of Texas System; UTMD Anderson
   Cancer Center
RP Wang, YA (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA.; Hou, PP (corresponding author), Univ Med & Dent New Jersey, Canc Ctr, 205 S Orange Ave F1230, Newark, NJ 07103 USA.
EM pingping.hou@rutgers.edu; yalanwang@mdanderson.org
RI Wang, Qianghu/HJI-9741-2023
FU NIH [1RO1CA23 1349-01A1, 1K22CA251491-01]; DOD [W811XWH2010924];
   National Cancer Institute [K22CA251491, R01CA231349] Funding Source: NIH
   RePORTER
FX We thank Dr. Ronald A. Depinho for helpful discussions. This work was
   supported by grants from NIH 1K22CA251491-01 (to P.H.), NIH 1RO1CA23
   1349-01A1 (to Y.A.W.) and DOD W811XWH2010924 (to Y.A.W). Figures are
   created with BioRender.com.
CR Adachi Y, 2020, CLIN CANCER RES, V26, P5962, DOI 10.1158/1078-0432.CCR-20-2077
   Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020
   Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187
   Anastas JN, 2014, J CLIN INVEST, V124, P2877, DOI 10.1172/JCI70156
   [Anonymous], 2019, BIORXIV
   Athuluri-Divakar SK, 2016, CELL, V165, P643, DOI 10.1016/j.cell.2016.03.045
   Awad MM, 2021, NEW ENGL J MED, V384, P2382, DOI 10.1056/NEJMoa2105281
   Bhargava A., 2016, ELIFE, V5
   Bhargava A, 2016, ELIFE, V5, DOI 10.7554/eLife.09976
   Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116
   Braicu C, 2019, CANCERS, V11, DOI 10.3390/cancers11101618
   Brannon A III, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-67814-9
   Brea EJ, 2016, CANCER IMMUNOL RES, V4, P936, DOI 10.1158/2326-6066.CIR-16-0177
   Briere DM, 2021, Mol Cancer Ther
   Brighton HE, 2018, CANCER RES, V78, P542, DOI 10.1158/0008-5472.CAN-17-1653
   Bryant KL, 2019, NAT MED, V25, P628, DOI 10.1038/s41591-019-0368-8
   Bugide S, 2020, ONCOGENESIS, V9, DOI 10.1038/s41389-020-0228-x
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Carson R, 2015, CLIN CANCER RES, V21, P3230, DOI 10.1158/1078-0432.CCR-14-2701
   Chao MW, 2019, CLIN EPIGENETICS, V11, DOI 10.1186/s13148-019-0681-6
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Chen PY, 2018, CANCER RES, V78, P985, DOI 10.1158/0008-5472.CAN-17-2129
   Chen YNP, 2016, NATURE, V535, P148, DOI 10.1038/nature18621
   Cheng Y, 2017, MOLECULES, V22, DOI 10.3390/molecules22101551
   Chien YC, 2006, CELL, V127, P157, DOI 10.1016/j.cell.2006.08.034
   Coelho MA, 2017, IMMUNITY, V47, P1083, DOI 10.1016/j.immuni.2017.11.016
   Collisson EA, 2012, CANCER DISCOV, V2, P685, DOI 10.1158/2159-8290.CD-11-0347
   Commisso C, 2013, NATURE, V497, P633, DOI 10.1038/nature12138
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Corcoran RB, 2010, SCI SIGNAL, V3, DOI 10.1126/scisignal.2001148
   Dai BB, 2011, CANCER RES, V71, P3658, DOI 10.1158/0008-5472.CAN-10-3647
   De Raedt T, 2014, NATURE, V514, P247, DOI 10.1038/nature13561
   Desai J, 2020, J CLIN ONCOL, V38, P2140, DOI 10.1200/JCO.19.02654
   Dey P, 2020, CANCER DISCOV, V10, P608, DOI 10.1158/2159-8290.CD-19-0297
   Dillon M, 2021, CANCERS, V13, DOI 10.3390/cancers13205059
   Dow LE, 2015, CELL, V161, P1539, DOI 10.1016/j.cell.2015.05.033
   Dummer R, 2018, LANCET ONCOL, V19, P1315, DOI 10.1016/S1470-2045(18)30497-2
   Ebi H, 2011, J CLIN INVEST, V121, P4311, DOI 10.1172/JCI57909
   El-Jawhari J, 2014, MOL IMMUNOL, V58, P160, DOI 10.1016/j.molimm.2013.11.020
   Emery CM, 2009, P NATL ACAD SCI USA, V106, P20411, DOI 10.1073/pnas.0905833106
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   Faiao-Flores F, 2019, CLIN CANCER RES, V25, P5686, DOI 10.1158/1078-0432.CCR-18-3382
   Fallahi-Sichani M, 2017, MOL SYST BIOL, V13, DOI 10.15252/msb.20166796
   Fan P, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1044-z
   Fedele C, 2021, J EXP MED, P218
   Fedele C, 2020, BIORXIV
   Fedorenko IV, 2015, J INVEST DERMATOL, V135, P3115, DOI 10.1038/jid.2015.329
   Fernandez ML, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0725-1
   Flanigan SA, 2013, CLIN CANCER RES, V19, P6219, DOI 10.1158/1078-0432.CCR-13-0145
   Gao YJ, 2019, CANCER DISCOV, V9, P1182, DOI 10.1158/2159-8290.CD-19-0356
   GIBBS JB, 1984, P NATL ACAD SCI-BIOL, V81, P5704, DOI 10.1073/pnas.81.18.5704
   Gimple RC, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00965
   Girotti MR, 2013, CANCER DISCOV, V3, P158, DOI 10.1158/2159-8290.CD-12-0386
   Gruber JJ, 2019, MOL CELL, V75, P711, DOI 10.1016/j.molcel.2019.05.034
   Guerra SL, 2020, CANCER CELL, V37, P705, DOI 10.1016/j.ccell.2020.03.004
   Guerriero JL, 2017, NATURE, V543, P428, DOI 10.1038/nature21409
   Halilovic E, 2010, CANCER RES, V70, P6804, DOI 10.1158/0008-5472.CAN-10-0409
   Hallin J, 2020, CANCER DISCOV, V10, P54, DOI 10.1158/2159-8290.CD-19-1167
   Han N, 2017, ONCOTARGET, V8, P89970, DOI 10.18632/oncotarget.21205
   Hartsough EJ, 2014, MOL CANCER RES, V12, P795, DOI 10.1158/1541-7786.MCR-13-0581
   Hata AN, 2014, CANCER RES, V74, P3146, DOI 10.1158/0008-5472.CAN-13-3728
   Hatzivassiliou G, 2013, NATURE, V501, P232, DOI 10.1038/nature12441
   Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010
   Hatzivassiliou G, 2010, NATURE, V464, P431, DOI 10.1038/nature08833
   Hazar-Rethinam M, 2018, CANCER DISCOV, V8, P417, DOI 10.1158/2159-8290.CD-17-1227
   Heidorn SJ, 2010, CELL, V140, P209, DOI 10.1016/j.cell.2009.12.040
   Hong DS, 2020, NEW ENGL J MED, V383, P1207, DOI 10.1056/NEJMoa1917239
   Hou PP, 2021, GENE DEV, V35, P1327, DOI 10.1101/gad.348787.121
   Hou PP, 2020, CANCER DISCOV, V10, P1058, DOI 10.1158/2159-8290.CD-19-0597
   Hou PP, 2019, GENE DEV, V33, P1361, DOI 10.1101/gad.326314.119
   JAMES GL, 1995, J BIOL CHEM, V270, P6221, DOI 10.1074/jbc.270.11.6221
   Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006
   Janku F, 2018, MOL CANCER THER, V17, DOI 10.1158/1535-7163.TARG-17-B176
   Janku F, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.2586
   JOHN J, 1993, J BIOL CHEM, V268, P923
   Johnson DB, 2018, PIGM CELL MELANOMA R, V31, P432, DOI 10.1111/pcmr.12674
   Jones HE, 2004, ENDOCR-RELAT CANCER, V11, P793, DOI 10.1677/erc.1.00799
   Kale J, 2018, CELL DEATH DIFFER, V25, P65, DOI 10.1038/cdd.2017.186
   Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341
   Kapoor A, 2014, CELL, V158, P185, DOI [10.1016/j.cell.2014.06.003, 10.1016/j.cell.2019.10.037]
   Karnoub AE, 2008, NAT REV MOL CELL BIO, V9, P517, DOI 10.1038/nrm2438
   Katoh M, 2017, INT J ONCOL, V51, P1357, DOI 10.3892/ijo.2017.4129
   Kauko O, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aaq1093
   Kemper K, 2015, EMBO MOL MED, V7, P1104, DOI 10.15252/emmm.201404914
   Kinsey CG, 2019, NAT MED, V25, P620, DOI 10.1038/s41591-019-0367-9
   Kitai H, 2016, CANCER DISCOV, V6, P754, DOI 10.1158/2159-8290.CD-15-1377
   Kitajima S, 2018, CANCER CELL, V34, P439, DOI 10.1016/j.ccell.2018.08.009
   Knauf JA, 2018, J CLIN INVEST, V128, P4086, DOI 10.1172/JCI120966
   Kochenderfer JN, 2012, BLOOD, V119, P2709, DOI 10.1182/blood-2011-10-384388
   Koga T, 2021, J THORAC ONCOL, V16, P1321, DOI 10.1016/j.jtho.2021.04.015
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kurppa KJ, 2020, CANCER CELL, V37, P104, DOI 10.1016/j.ccell.2019.12.006
   Lavoie H, 2020, NAT REV MOL CELL BIO, V21, P607, DOI 10.1038/s41580-020-0255-7
   Lee HJ, 2014, CANCER CELL, V26, P207, DOI 10.1016/j.ccr.2014.05.019
   LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0
   Liao WT, 2019, CANCER CELL, V35, P559, DOI 10.1016/j.ccell.2019.02.008
   Lin LP, 2015, NAT GENET, V47, P250, DOI 10.1038/ng.3218
   Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204
   Lito P, 2014, CANCER CELL, V25, P697, DOI 10.1016/j.ccr.2014.03.011
   Lito P, 2012, CANCER CELL, V22, P668, DOI 10.1016/j.ccr.2012.10.009
   Little AS, 2011, SCI SIGNAL, V4, DOI 10.1126/scisignal.2001752
   Lou K, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aaw9450
   Mainardi S, 2018, NAT MED, V24, P961, DOI 10.1038/s41591-018-0023-9
   Manchado E, 2016, NATURE, V534, P647, DOI 10.1038/nature18600
   Maoz A, 2017, NEW ENGL J MED, V376, DOI 10.1056/NEJMc1616637
   Martinelli E, 2013, INT J CANCER, V133, P2089, DOI 10.1002/ijc.28236
   Mazur PK, 2014, NATURE, V510, P283, DOI 10.1038/nature13320
   McAllister F, 2014, CANCER CELL, V25, P621, DOI 10.1016/j.ccr.2014.03.014
   MCGRATH JP, 1984, NATURE, V310, P644, DOI 10.1038/310644a0
   Mendt M, 2018, JCI INSIGHT, V3, DOI 10.1172/jci.insight.99263
   Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683
   Misale S, 2019, CLIN CANCER RES, V25, P796, DOI 10.1158/1078-0432.CCR-18-0368
   Mo Hong-Nan, 2017, Chronic Dis Transl Med, V3, P148, DOI 10.1016/j.cdtm.2017.06.002
   Molina-Arcas M, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaw7999
   Molina-Arcas M, 2013, CANCER DISCOV, V3, P548, DOI 10.1158/2159-8290.CD-12-0446
   Montero-Conde C, 2013, CANCER DISCOV, V3, P520, DOI 10.1158/2159-8290.CD-12-0531
   Moon JH, 2019, BRIT J CANCER, V120, P941, DOI 10.1038/s41416-019-0434-5
   Moriceau G, 2015, CANCER CELL, V27, P240, DOI 10.1016/j.ccell.2014.11.018
   Muzumdar MD, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00942-5
   Nazarian R, 2010, NATURE, V468, P973, DOI 10.1038/nature09626
   Neel Nicole F, 2011, Genes Cancer, V2, P275, DOI 10.1177/1947601911407329
   Nichols RJ, 2018, NAT CELL BIOL, V20, P1064, DOI 10.1038/s41556-018-0169-1
   NOONAN T, 1991, J MED CHEM, V34, P1302, DOI 10.1021/jm00108a010
   Obenauf AC, 2015, NATURE, V520, P368, DOI 10.1038/nature14336
   Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396
   Okimoto RA, 2016, P NATL ACAD SCI USA, V113, P13456, DOI 10.1073/pnas.1610456113
   Östman A, 2006, NAT REV CANCER, V6, P307, DOI 10.1038/nrc1837
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Ostrem JML, 2016, NAT REV DRUG DISCOV, V15, P771, DOI 10.1038/nrd.2016.139
   Ozkan-Dagliyan I, 2020, CELL REP, V31, DOI 10.1016/j.celrep.2020.107764
   Paraiso KHT, 2010, BRIT J CANCER, V102, P1724, DOI 10.1038/sj.bjc.6605714
   Pardi N, 2018, NAT REV DRUG DISCOV, V17, P261, DOI 10.1038/nrd.2017.243
   Park KS, 2016, CANCER LETT, V372, P75, DOI 10.1016/j.canlet.2015.12.015
   Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105
   Peng DH, 2019, SCI TRANSL MED, V11, DOI 10.1126/scitranslmed.aaq1238
   Peng SB, 2015, CANCER CELL, V28, P384, DOI 10.1016/j.ccell.2015.08.002
   Pettazzoni P, 2015, CANCER RES, V75, P1091, DOI 10.1158/0008-5472.CAN-14-1854
   Poulikakos PI, 2011, NATURE, V480, P387, DOI 10.1038/nature10662
   Poulikakos PI, 2010, NATURE, V464, P427, DOI 10.1038/nature08902
   Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Pupo E, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00848
   Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Rangarajan A, 2004, CANCER CELL, V6, P171, DOI 10.1016/j.ccr.2004.07.009
   Rao GH, 2018, EUR J CANCER, V99, P37, DOI 10.1016/j.ejca.2018.05.013
   Robbins PF, 2015, CLIN CANCER RES, V21, P1019, DOI 10.1158/1078-0432.CCR-14-2708
   Robert C, 2019, NEW ENGL J MED, V381, P626, DOI 10.1056/NEJMoa1904059
   Rodriguez-Viciana P, 2006, MOL CELL, V22, P217, DOI 10.1016/j.molcel.2006.03.027
   Rosenberg SA, 2011, CLIN CANCER RES, V17, P4550, DOI 10.1158/1078-0432.CCR-11-0116
   Ruess DA, 2018, NAT MED, V24, P954, DOI 10.1038/s41591-018-0024-8
   Rusan M, 2018, CANCER DISCOV, V8, P59, DOI 10.1158/2159-8290.CD-17-0461
   Ruscetti M, 2020, CELL, V181, P424, DOI 10.1016/j.cell.2020.03.008
   Ryan MB, 2020, CLIN CANCER RES, V26, P1633, DOI 10.1158/1078-0432.CCR-19-3523
   Saei A, 2018, J EXP MED, V215, P1913, DOI 10.1084/jem.20171960
   Sahu N, 2017, MOL CANCER THER, V16, P1729, DOI 10.1158/1535-7163.MCT-17-0009
   Sanchez-Vega F, 2018, CELL, V173, P321, DOI 10.1016/j.cell.2018.03.035
   Santamaría PG, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050676
   Santana-Codina N, 2020, CELL REP, V30, P4584, DOI 10.1016/j.celrep.2020.03.021
   Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333
   Shao DD, 2014, CELL, V158, P171, DOI 10.1016/j.cell.2014.06.004
   Sharma V, 2016, ELIFE, P5
   Shi HB, 2014, CANCER DISCOV, V4, P80, DOI 10.1158/2159-8290.CD-13-0642
   Shi HB, 2012, NAT COMMUN, V3, DOI 10.1038/ncomms1727
   Shi JW, 2014, MOL CELL, V54, P728, DOI 10.1016/j.molcel.2014.05.016
   Shin SM, 2020, SCI ADV, V6, DOI 10.1126/sciadv.aay2174
   Shin SM, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15090
   Sim MJW, 2020, P NATL ACAD SCI USA, V117, P12826, DOI 10.1073/pnas.1921964117
   Simanshu DK, 2017, CELL, V170, P17, DOI 10.1016/j.cell.2017.06.009
   Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695
   STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320
   Sui XK, 2020, ANN TRANSL MED, V8, DOI 10.21037/atm-20-5622
   Sulahian R, 2019, CELL REP, V29, P118, DOI 10.1016/j.celrep.2019.08.090
   Sullivan RJ, 2020, MOL CANCER THER, V19, P460, DOI 10.1158/1535-7163.MCT-19-0681
   Sun C, 2014, CELL REP, V7, P86, DOI 10.1016/j.celrep.2014.02.045
   Sun Y, 2014, CANCER METAB, V2, DOI 10.1186/2049-3002-2-20
   Suzuki R, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0143847
   SWEET RW, 1984, NATURE, V311, P273, DOI 10.1038/311273a0
   Tanaka N, 2021, CANCER DISCOV, V11, P1913, DOI 10.1158/2159-8290.CD-21-0365
   Tang ZY, 2015, MOL CANCER THER, V14, P2187, DOI 10.1158/1535-7163.MCT-15-0262
   Tape CJ, 2016, CELL, V165, P1818, DOI [10.1016/j.cell.2016.05.079, 10.1016/j.cell.2016.03.029]
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Tran E, 2014, SCIENCE, V344, P641, DOI 10.1126/science.1251102
   Tsubaki M, 2019, CANCERS, V11, DOI 10.3390/cancers11121866
   Tu B, 2019, JCI INSIGHT, V4, DOI 10.1172/jci.insight.130811
   Valenciano A, 2012, TRANSL ONCOL, V5, P1, DOI 10.1593/tlo.11265
   Viale A, 2014, NATURE, V514, P628, DOI 10.1038/nature13611
   Vido MJ, 2018, CELL REP, V25, P1501, DOI 10.1016/j.celrep.2018.10.049
   Villanueva J, 2010, CANCER CELL, V18, P683, DOI 10.1016/j.ccr.2010.11.023
   Vu HL, 2014, MOL CANCER RES, V12, P1509, DOI 10.1158/1541-7786.MCR-14-0204
   Wagle N, 2014, CANCER DISCOV, V4, P61, DOI 10.1158/2159-8290.CD-13-0631
   Wagner S, 2019, ONCOGENE, V38, P1717, DOI 10.1038/s41388-018-0554-z
   Wang QJ, 2016, CANCER IMMUNOL RES, V4, P204, DOI 10.1158/2326-6066.CIR-15-0188
   Wang ZT, 2020, CANCER CELL, V37, P834, DOI 10.1016/j.ccell.2020.04.014
   Warshamana-Greene GS, 2005, CLIN CANCER RES, V11, P1563, DOI 10.1158/1078-0432.CCR-04-1544
   Whittaker SR, 2015, MOL CANCER THER, V14, P2700, DOI 10.1158/1535-7163.MCT-15-0136-T
   Willems E, 2018, CELL DIV, V13, DOI 10.1186/s13008-018-0040-6
   Wyce A, 2018, ONCOGENESIS, V7, DOI 10.1038/s41389-018-0043-9
   Xue JY, 2020, NATURE, V577, P421, DOI 10.1038/s41586-019-1884-x
   Yaeger R, 2017, CANCER RES, V77, P6513, DOI 10.1158/0008-5472.CAN-17-0768
   Yamamoto K, 2020, NATURE, V581, P100, DOI 10.1038/s41586-020-2229-5
   Yan L, 2021, CANCER RES, V81, P4054, DOI 10.1158/0008-5472.CAN-20-3792
   Yao WT, 2019, NATURE, V568, P410, DOI 10.1038/s41586-019-1062-1
   Yap J, 2021, SCI ADV, P7
   Ying HQ, 2012, CELL, V149, P656, DOI 10.1016/j.cell.2012.01.058
   Yuan JM, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aar6795
   Zanconato F, 2016, CANCER CELL, V29, P783, DOI 10.1016/j.ccell.2016.05.005
   Zawistowski JS, 2017, CANCER DISCOV, V7, P302, DOI 10.1158/2159-8290.CD-16-0653
   Zdanov S, 2016, CANCER IMMUNOL RES, V4, P354, DOI 10.1158/2326-6066.CIR-15-0241
   Zeng M, 2017, CELL CHEM BIOL, V24, P1005, DOI 10.1016/j.chembiol.2017.06.017
   Zhang C, 2015, NATURE, V526, P583, DOI 10.1038/nature14982
   Zhang JZ, 2019, ARTIF CELL NANOMED B, V47, P1207, DOI 10.1080/21691401.2019.1593857
   Zhao YL, 2021, NATURE, V599, P679, DOI 10.1038/s41586-021-04065-2
   Zhu ZH, 2014, CANCER DISCOV, V4, P452, DOI 10.1158/2159-8290.CD-13-0646
NR 216
TC 9
Z9 10
U1 1
U2 5
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2022
VL 12
IS 12
BP 5691
EP 5709
DI 10.7150/thno.71260
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA 3D1WC
UT WOS:000829099700014
PM 35966590
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Huang, R
   Liao, XW
   Li, QC
AF Huang, Rui
   Liao, Xiwen
   Li, Qiaochuan
TI Integrative genomic analysis of a novel small nucleolar RNAs prognostic
   signature in patients with acute myelocytic leukemia
SO MATHEMATICAL BIOSCIENCES AND ENGINEERING
LA English
DT Article
DE small nucleolar RNA; RNA sequencing; acute myeloid leukemia; the cancer
   genome atlas; prognostic signature
ID NF-KAPPA-B; ACUTE MYELOID-LEUKEMIA; ENDOPLASMIC-RETICULUM STRESS;
   THERAPEUTIC TARGET; INTERACTION NETWORKS; CONNECTIVITY MAP; SMALL
   MOLECULES; COLON-CANCER; STEM-CELLS; FLUOXETINE
AB This study mainly used The Cancer Genome Atlas (TCGA) RNA sequencing dataset to screen prognostic snoRNAs of acute myeloid leukemia (AML), and used for the construction of prognostic snoRNAs signature for AML. A total of 130 AML patients with RNA sequencing dataset were used for prognostic snoRNAs screenning. SnoRNAs co-expressed genes and differentially expressed genes (DEGs) were used for functional annotation, as well as gene set enrichment analysis (GSEA). Connectivity Map (CMap) also used for potential targeted drugs screening. Through genome-wide screening, we identified 30 snoRNAs that were significantly associated with the prognosis of AML. Then we used the step function to screen a prognostic signature composed of 14 snoRNAs (SNORD72, SNORD38, U3, SNORA73B, SNORD79, SNORA73, SNORD12B, SNORA74, SNORD116-12, SNORA65, SNORA14, snoU13, SNORA75, SNORA31), which can significantly divide AML patients into high-and low-risk groups. Through GSEA, snoRNAs co-expressed genes and DEGs functional enrichment analysis, we screened a large number of potential functional mechanisms of this prognostic signature in AML, such as phosphatidylinositol 3-kinase-Akt, Wnt, epithelial to mesenchymal transition, T cell receptors, NF-kappa B, mTOR and other classic cancer-related signaling pathways. In the subsequent targeted drug screening using CMap, we also identified six drugs that can be used for AML targeted therapy, they were alimemazine, MG-262, fluoxetine, quipazine, naltrexone and oxybenzone. In conclusion, our current study was constructed an AML prognostic signature based on the 14 prognostic snoRNAs, which may serve as a novel prognostic biomarker for AML.
C1 [Huang, Rui; Li, Qiaochuan] Guangxi Med Univ, Dept Hematol, Affiliated Hosp 1, Nanning 530021, Peoples R China.
   [Liao, Xiwen] Guangxi Med Univ, Dept Hepatobiliary Surg, Affiliated Hosp 1, Nanning 530021, Peoples R China.
C3 Guangxi Medical University; Guangxi Medical University
RP Li, QC (corresponding author), Guangxi Med Univ, Dept Hematol, Affiliated Hosp 1, Nanning 530021, Peoples R China.
EM liqiaochuan@sohu.com
FU National Natural Science Foundation of China [81160075, 81960038];
   Natural Science Foundation of Guangxi [0728124]; Self-raised Scientific
   Research Fund of the Ministry of Health of Guangxi Province [Z2014035]
FX This work was supported in part by the National Natural Science
   Foundation of China (No.81160075, 81960038); Natural Science Foundation
   of Guangxi (No.0728124); Self-raised Scientific Research Fund of the
   Ministry of Health of Guangxi Province (Z2014035). The authors thank the
   contributors of The Cancer Genome Atlas (https://portal.gdc.cancer.gov/)
   for their contribution to share the AML dataset on open access. In
   addition, we also would like to acknowledge the helpful comments on this
   paper received from our reviewers.
CR Abelson S, 2018, NATURE, V559, P400, DOI 10.1038/s41586-018-0317-6
   [Anonymous], 2019, NUCLEIC ACIDS RES, DOI DOI 10.1093/NAR/GKY1033
   Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2
   Bertacchini Jessika, 2018, Advances in Biological Regulation, V68, P2, DOI 10.1016/j.jbior.2018.03.001
   Bertacchini J, 2015, CELL MOL LIFE SCI, V72, P2337, DOI 10.1007/s00018-015-1867-5
   Bignotti E, 2016, J CELL MOL MED, V20, P2341, DOI 10.1111/jcmm.12927
   Bosman MCJ, 2016, CRIT REV ONCOL HEMAT, V98, P35, DOI 10.1016/j.critrevonc.2015.10.001
   Bosman MCJ, 2014, BLOOD, V124, P3130, DOI 10.1182/blood-2014-04-569780
   Bowie M, 2015, WORLD J CLIN ONCOL, V6, P299, DOI 10.5306/wjco.v6.i6.299
   Bratkovic T, 2020, NUCLEIC ACIDS RES, V48, P1627, DOI 10.1093/nar/gkz1140
   Breccia M, 2010, EXPERT OPIN THER TAR, V14, P1157, DOI 10.1517/14728222.2010.522570
   Bullinger L, 2004, NEW ENGL J MED, V350, P1605, DOI 10.1056/NEJMoa031046
   Chapuis AG, 2019, NAT MED, V25, P1064, DOI 10.1038/s41591-019-0472-9
   Chen BB, 2018, METHODS MOL BIOL, V1711, P243, DOI 10.1007/978-1-4939-7493-1_12
   Chikne V, 2019, NUCLEIC ACIDS RES, V47, P2609, DOI 10.1093/nar/gky1287
   Choi CH, 2007, LEUKEMIA RES, V31, P1267, DOI 10.1016/j.leukres.2006.11.006
   Coombs CC, 2016, NAT REV CLIN ONCOL, V13, P305, DOI 10.1038/nrclinonc.2015.210
   Davanian H, 2017, ONCOTARGET, V8, P4530, DOI 10.18632/oncotarget.13889
   Estey E, 2006, LANCET, V368, P1894, DOI 10.1016/S0140-6736(06)69780-8
   Feng YH, 2017, BIOCHEM BIOPH RES CO, V483, P897, DOI 10.1016/j.bbrc.2017.01.031
   Gasparini C, 2014, CELL MOL LIFE SCI, V71, P2083, DOI 10.1007/s00018-013-1545-4
   Gong J, 2017, CELL REP, V21, P1968, DOI 10.1016/j.celrep.2017.10.070
   Griffiths EA, 2010, LEUKEMIA LYMPHOMA, V51, P1711, DOI 10.3109/10428194.2010.496505
   Gruszka AM, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8111403
   Guo NX, 2019, TRANSL ONCOL, V12, P602, DOI 10.1016/j.tranon.2019.01.001
   Herschbein L, 2018, BLOOD REV, V32, P235, DOI 10.1016/j.blre.2017.11.006
   Hsu LC, 2020, BIOMED PHARMACOTHER, V126, DOI 10.1016/j.biopha.2020.110054
   Huang DW, 2009, NAT PROTOC, V4, P44, DOI 10.1038/nprot.2008.211
   Huang L, 2020, PATHOL RES PRACT, V216, DOI 10.1016/j.prp.2020.152937
   Huang R, 2017, ONCOTARGETS THER, V10, P5243, DOI 10.2147/OTT.S147717
   Kabel AM, 2016, TISSUE CELL, V48, P89, DOI 10.1016/j.tice.2016.02.002
   Kannen V, 2015, CELL SIGNAL, V27, P1781, DOI 10.1016/j.cellsig.2015.05.008
   Kannen V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050043
   Khin PP, 2020, N-S ARCH PHARMACOL, V393, P537, DOI 10.1007/s00210-019-01739-7
   Khing TM, 2019, ANTICANCER RES, V39, P6155, DOI 10.21873/anticanres.13823
   Khwaja A, 2016, NAT REV DIS PRIMERS, V2, DOI 10.1038/nrdp.2016.10
   Koh SJ, 2011, AM J PHYSIOL-GASTR L, V301, pG9, DOI 10.1152/ajpgi.00267.2010
   Kuhn M, 2008, NUCLEIC ACIDS RES, V36, pD684, DOI 10.1093/nar/gkm795
   Kuhn M, 2010, NUCLEIC ACIDS RES, V38, pD552, DOI 10.1093/nar/gkp937
   Lafaille FG, 2019, NAT MED, V25, P1873, DOI 10.1038/s41591-019-0672-3
   Lamb J, 2007, NAT REV CANCER, V7, P54, DOI 10.1038/nrc2044
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Ley TJ, 2013, NEW ENGL J MED, V368, P2059, DOI 10.1056/NEJMoa1301689
   Liao XW, 2019, J CANCER, V10, P3267, DOI 10.7150/jca.29986
   Liao XW, 2018, CANCER MANAG RES, V10, P2537, DOI 10.2147/CMAR.S168351
   Liberzon A, 2015, CELL SYST, V1, P417, DOI 10.1016/j.cels.2015.12.004
   Liberzon A, 2011, BIOINFORMATICS, V27, P1739, DOI 10.1093/bioinformatics/btr260
   Liu KH, 2015, ONCOTARGET, V6, P5088, DOI 10.18632/oncotarget.3243
   Liu N, 2020, INT IMMUNOPHARMACOL, V86, DOI 10.1016/j.intimp.2020.106718
   Ma J, 2016, ONCOL REP, V36, P676, DOI 10.3892/or.2016.4860
   Ma MX, 2020, INT IMMUNOPHARMACOL, V83, DOI 10.1016/j.intimp.2020.106388
   Mao LH, 2020, AGING-US, V12, P4527, DOI 10.18632/aging.102907
   Marcinkute M, 2019, EUR J PHARMACOL, V857, DOI 10.1016/j.ejphar.2019.172441
   Menezes AC, 2018, TOXICOL IN VITRO, V47, P72, DOI 10.1016/j.tiv.2017.11.011
   Meyer SC, 2014, LANCET ONCOL, V15, pE382, DOI 10.1016/S1470-2045(14)70008-7
   Mootha VK, 2003, NAT GENET, V34, P267, DOI 10.1038/ng1180
   Mun AR, 2013, ANTICANCER RES, V33, P3691
   Nepstad I, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21082907
   Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X
   Otasek D, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-019-1758-4
   Papaemmanuil E, 2016, NEW ENGL J MED, V374, P2209, DOI 10.1056/NEJMoa1516192
   Richardson PG, 2006, ANNU REV MED, V57, P33, DOI 10.1146/annurev.med.57.042905.122625
   Robinson MD, 2010, BIOINFORMATICS, V26, P139, DOI 10.1093/bioinformatics/btp616
   Ronchetti D, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-27
   Sayers EW, 2020, NUCLEIC ACIDS RES, V48, pD9, DOI [10.1093/nar/gkz899, 10.1093/nar/gkv1290, 10.1093/nar/gkaa892]
   Shannon P, 2003, GENOME RES, V13, P2498, DOI 10.1101/gr.1239303
   Staal FJT, 2016, CANCERS, V8, DOI 10.3390/cancers8090078
   Stauss HJ, 2008, BLOOD CELL MOL DIS, V40, P113, DOI 10.1016/j.bcmd.2007.06.018
   Stavropoulou V, 2016, CANCER CELL, V30, P43, DOI 10.1016/j.ccell.2016.05.011
   Stopper H, 2014, WORLD J GASTRO ONCOL, V6, P11, DOI 10.4251/wjgo.v6.i1.11
   Su YW, 2018, BIOCHEM PHARMACOL, V148, P13, DOI 10.1016/j.bcp.2017.11.022
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Sun DJ, 2018, CELL PROLIFERAT, V51, DOI 10.1111/cpr.12402
   Szklarczyk D, 2016, NUCLEIC ACIDS RES, V44, pD380, DOI 10.1093/nar/gkv1277
   Tabe Y, 2017, EXPERT OPIN THER TAR, V21, P705, DOI 10.1080/14728222.2017.1333600
   Takezawa J, 2008, CANCER SCI, V99, P863, DOI 10.1111/j.1349-7006.2008.00764.x
   Tyner JW, 2018, NATURE, V562, P526, DOI 10.1038/s41586-018-0623-z
   Valencia A, 2009, LEUKEMIA, V23, P1658, DOI 10.1038/leu.2009.86
   Volk A, 2014, J EXP MED, V211, P1093, DOI 10.1084/jem.20130990
   Wang Wen-Xia, 2008, Zhonghua Fu Chan Ke Za Zhi, V43, P690
   Wang YZ, 2010, SCIENCE, V327, P1650, DOI 10.1126/science.1186624
   Wei GG, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.03.007
   Wu JY, 2018, ANTICANCER RES, V38, P5201, DOI 10.21873/anticanres.12843
   Wu JQ, 2017, J CELL MOL MED, V21, P1171, DOI 10.1111/jcmm.13049
   Wu SR, 2018, J TRANSL MED, V16, DOI 10.1186/s12967-018-1539-y
   Xing L, 2020, J CELL PHYSIOL, V235, P8071, DOI 10.1002/jcp.29462
   Yoshihara K, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms3612
   Zavrski I, 2003, J CANCER RES CLIN, V129, P383, DOI 10.1007/s00432-003-0454-6
   Zhang TJ, 2017, CLIN CHEM LAB MED, V55, P123, DOI 10.1515/cclm-2016-0205
   Zhao YY, 2020, J CELL MOL MED, V24, P2215, DOI 10.1111/jcmm.14886
   Zhong L, 2018, ONCOL LETT, V16, P2279, DOI 10.3892/ol.2018.8966
   Zhou JB, 2015, ONCOTARGET, V6, P5490, DOI 10.18632/oncotarget.3545
NR 92
TC 6
Z9 6
U1 1
U2 10
PU AMER INST MATHEMATICAL SCIENCES-AIMS
PI SPRINGFIELD
PA PO BOX 2604, SPRINGFIELD, MO 65801-2604, UNITED STATES
SN 1547-1063
EI 1551-0018
J9 MATH BIOSCI ENG
JI Math. Biosci. Eng.
PY 2022
VL 19
IS 3
BP 2424
EP 2452
DI 10.3934/mbe.2022112
PG 29
WC Mathematical & Computational Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Mathematical & Computational Biology
GA YH4KW
UT WOS:000743138600011
PM 35240791
OA gold
DA 2025-01-04
ER

PT J
AU Konishi, H
   Fujiya, M
   Ueno, N
   Moriichi, K
   Sasajima, J
   Ikuta, K
   Tanabe, H
   Tanaka, H
   Kohgo, Y
AF Konishi, Hiroaki
   Fujiya, Mikihiro
   Ueno, Nobuhiro
   Moriichi, Kentaro
   Sasajima, Junpei
   Ikuta, Katsuya
   Tanabe, Hiroki
   Tanaka, Hiroki
   Kohgo, Yutaka
TI microRNA-26a and-584 inhibit the colorectal cancer progression through
   inhibition of the binding of hnRNP A1-CDK6 mRNA
SO BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
LA English
DT Article
DE microRNA; Colon cancer; hnRNP A1; CDK6
ID NUCLEAR RIBONUCLEOPROTEIN A1
AB While the progress of chemotherapy and molecular targeted therapy has improved the outcome of colorectal cancer patients, the mortality of colon cancer remains high, indicating the need to develop novel therapeutic targets for improving the outcome of colon cancer. Heterogeneous ribonucleoprotein A1 (hnRNP A1) is highly expressed in colorectal cancer and its expression correlates with malignant transformation. In this study, we performed a microarray analysis with the RNA immunoprecipitation (RNA-IP) method and identified hnRNP A1-interacting miRs, including miR-26a and -584, in a colorectal cancer cell line, SW620. A SRB assay revealed the tumor suppressive effect of miR-26a and -584, and the tumor suppressive effect of these miRs was diminished by the downregulation of hnRNP A1. The combined method of a transcriptome analysis and RNA-IP revealed hnRNP A1-interacting mRNAs, including cyclin dependent kinase 6 (CDK6). A Western blot analysis revealed the downregulation of CDK6 in miR-26a and -584 overexpression cells, as well as hnRNP A1 knockdown cells. The binding assay indicated that the binding of hnRNP A1-CDK6 mRNA was reduced by transfection of miR-26a and -584. The expression of cleaved caspase-3 was induced in miR-26a and -584 overexpression cells. These data indicate that miR-26a and -584 inhibit the binding of hnRNP A1-CDK6 mRNA and induce colorectal cancer cell apoptosis. (C) 2015 Elsevier Inc. All rights reserved.
C1 [Konishi, Hiroaki; Fujiya, Mikihiro; Ueno, Nobuhiro; Moriichi, Kentaro; Sasajima, Junpei; Ikuta, Katsuya; Tanaka, Hiroki; Kohgo, Yutaka] Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa, Hokkaido 0788510, Japan.
   [Tanabe, Hiroki; Kohgo, Yutaka] Int Hlth & Sci Univ Hosp, Dept Gastroenterol, Ishaka, Japan.
C3 Asahikawa Medical College
RP Fujiya, M (corresponding author), Asahikawa Med Univ, Dept Med, Div Gastroenterol & Hematol Oncol, Asahikawa 2-1, Asahikawa, Hokkaido 0788510, Japan.
EM fjym@asahikawa-med.ac.jp; yk1950@asahikawa-med.ac.jp
RI Ikuta, Katsuya/AAU-3106-2020; Kohgo, Yutaka/AAN-4863-2020
OI Tanabe, Hiroki/0000-0001-9029-5081; dokoshi,
   tatsuya/0000-0003-3678-6781; Tanaka, Hiroki/0000-0003-0011-3454
FU Ministry of Health, Labour and Welfare; Ishidsu Shun Memorial
   Scholarship Japan;  [26460956]
FX We thank Akemi Kita and Kotoe Shibusa for their valuable technical
   assistance. This paper was supported by Grants-in-Aid for Scientific
   Research, No. 26460956 (M. Fujiya), Intractable Disease Health and
   Labour Sciences Research Grants from the Ministry of Health, Labour and
   Welfare, and Ishidsu Shun Memorial Scholarship Japan (H. Konishi).
CR Choi YJ, 2014, ONCOGENE, V33, P1890, DOI 10.1038/onc.2013.137
   Cunningham D, 2010, LANCET, V375, P1030, DOI 10.1016/S0140-6736(10)60353-4
   David CJ, 2010, NATURE, V463, P364, DOI 10.1038/nature08697
   Eiring AM, 2010, CELL, V140, P652, DOI 10.1016/j.cell.2010.01.007
   Fujiya M, 2014, ONCOGENE, V33, P4847, DOI 10.1038/onc.2013.429
   Jo OD, 2008, J BIOL CHEM, V283, P23274, DOI 10.1074/jbc.M801185200
   LaBranche H, 1998, NAT GENET, V19, P199, DOI 10.1038/575
   Ma YL, 2009, J PROTEOME RES, V8, P4525, DOI 10.1021/pr900365e
   Michlewski G, 2008, MOL CELL, V32, P383, DOI 10.1016/j.molcel.2008.10.013
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(19)32319-0
NR 10
TC 27
Z9 27
U1 0
U2 5
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0006-291X
EI 1090-2104
J9 BIOCHEM BIOPH RES CO
JI Biochem. Biophys. Res. Commun.
PD NOV 27
PY 2015
VL 467
IS 4
BP 847
EP 852
DI 10.1016/j.bbrc.2015.10.055
PG 6
WC Biochemistry & Molecular Biology; Biophysics
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Biophysics
GA CW6YV
UT WOS:000365145300038
PM 26494299
DA 2025-01-04
ER

PT J
AU Ordaz, DJG
   Whitelaw, S
   Kaouache, M
   Moustaqim-Barrette, A
   Gresham, L
   Ramchatesingh, B
   Redpath, M
   Chergui, M
   Litvinov, IV
AF Ordaz, Daniel Josue Guerra
   Whitelaw, Sera
   Kaouache, Mohammed
   Moustaqim-Barrette, Amina
   Gresham, Louise
   Ramchatesingh, Brandon
   Redpath, Margaret
   Chergui, May
   Litvinov, Ivan V.
TI Evaluating the Implementation and Impact of BRAF Reflex Mutation Testing
   in Melanoma, Lung, and Colorectal Cancers
SO JOURNAL OF CUTANEOUS MEDICINE AND SURGERY
LA English
DT Article; Early Access
DE BRAF mutation; melanoma; testing delay; reflex testing; time to
   treatment
AB Background: Reflex molecular testing, the process of profiling specimens at diagnosis, is emerging in oncology, allowing for prompt therapy initiation, and potentially improving outcomes. This study evaluates the impact of reflex BRAF testing on treatment timelines and outcomes in melanoma, lung and colorectal cancers at the McGill University Health Center (MUHC).Methods: A retrospective chart review was conducted at the MUHC. The study included patients with melanoma, lung, and colorectal cancers who underwent BRAF testing from 2017 to 2022. Data on demographics, cancer type, stage, test ordering specialist, testing method, and treatment outcomes were extracted. Statistical analyses included descriptive and multivariate regression analyses.Results: 518 BRAF molecular tests were performed, with 173 patients meeting the inclusion criteria [median age 72 (IQR 60-80 years), 46.2% female]. Of these, 75.7% had melanoma, 23.7% colorectal cancer and 0.58% lung cancer. Pathologists ordered 71.1% of BRAF tests, primarily relying on immunohistochemistry. By 2022, all BRAF results were available before oncology consultations. Patients with pre-consultation BRAF results were more likely to receive targeted therapy (59.4% vs 36.4%). The availability of BRAF test results was associated with quicker treatment initiation and better alignment of therapy with mutation status.Conclusion: This study underscores the success of the pathology team at MUHC in implementing reflex BRAF mutation testing, enhancing clinical care by ensuring the timely availability of test results. Delays in testing may adversely affect clinical decision-making and therapy selection, highlighting the need for standardized reflex testing protocols across Canada to optimize patient outcomes in melanoma, lung, and colorectal cancers.
C1 [Ordaz, Daniel Josue Guerra; Whitelaw, Sera; Moustaqim-Barrette, Amina] McGill Univ, Fac Med & Hlth Sci, Montreal, PQ, Canada.
   [Kaouache, Mohammed; Gresham, Louise; Ramchatesingh, Brandon; Litvinov, Ivan V.] McGill Univ, Hlth Ctr, Res Inst, Montreal, PQ, Canada.
   [Kaouache, Mohammed] McGill Univ, Dept Clin Epidemiol, Montreal, PQ, Canada.
   [Ramchatesingh, Brandon; Litvinov, Ivan V.] McGill Univ Hlth Ctr, Div Dermatol, 1001 Decarie Boulevard,Rm. E02.6236, Montreal, PQ H4A 3J1, Canada.
   [Redpath, Margaret] Jewish Gen Hosp, Dept Pathol, Montreal, PQ, Canada.
   [Chergui, May] McGill Univ, Hlth Ctr, Dept Pathol, Montreal, PQ, Canada.
C3 McGill University; McGill University; McGill University; McGill
   University; McGill University; McGill University
RP Litvinov, IV (corresponding author), McGill Univ Hlth Ctr, Div Dermatol, 1001 Decarie Boulevard,Rm. E02.6236, Montreal, PQ H4A 3J1, Canada.
EM ivan.litvinov@mcgill.ca
RI Kaouache, Mohammed/LKJ-8221-2024
FU CIHR [426655]; Fonds de la recherche du Quebec - Sante [296643]
FX The author(s) disclosed receipt of the following financial support for
   the research, authorship, and/or publication of this article: This
   research is funded by the CIHR Project Scheme Grant #426655 to Dr.
   Litvinov and by the Fonds de la recherche du Quebec - Sante (296643).
CR Alli S, 2023, CANCERS, V15, DOI 10.3390/cancers15194726
   Berardi R, 2020, CANCER MANAG RES, V12, P9363, DOI 10.2147/CMAR.S220976
   Berman-Rosa M, 2022, DERMATOLOGY, V238, P1006, DOI 10.1159/000524949
   Cheema PK, 2017, CURR ONCOL, V24, P16, DOI 10.3747/co.24.3266
   Conte S, 2024, J CUTAN MED SURG, DOI 10.1177/12034754241265694
   Conte S, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.830254
   Dobry AS, 2018, CANCER IMMUNOL IMMUN, V67, P1833, DOI 10.1007/s00262-018-2241-x
   Ghazawi FM, 2019, J CUTAN MED SURG, V23, P394, DOI 10.1177/1203475419852048
   Ghazawi FM, 2019, J AM ACAD DERMATOL, V80, P1157, DOI 10.1016/j.jaad.2018.10.055
   Ghazawi FM, 2019, J AM ACAD DERMATOL, V80, P448, DOI 10.1016/j.jaad.2018.07.041
   Jeremian R, 2024, J INVEST DERMATOL, V144, P1897, DOI 10.1016/j.jid.2024.01.012
   Jeremian R, 2023, CANCER EPIDEM BIOMAR, V32, P1599, DOI 10.1158/1055-9965.EPI-23-0545
   Lagacé F, 2024, CANCERS, V16, DOI 10.3390/cancers16173093
   Lagacé F, 2023, CANCERS, V15, DOI 10.3390/cancers15153753
   McCain Jack, 2013, P T, V38, P96
   Moustaqim-Barrette A, 2024, JAAD INT, V16, P264, DOI 10.1016/j.jdin.2024.05.009
   Muntyanu A, 2021, J CUTAN MED SURG, V25, P59, DOI 10.1177/1203475420943260
   Novartis, BRAF mutation testing survey
   Ribas A, 2011, NAT REV CLIN ONCOL, V8, P426, DOI 10.1038/nrclinonc.2011.69
   Society CC, Melanoma skin cancer statistics
   Society CC, Survival statistics for melanoma
   Swetter SM, 2021, J NATL COMPR CANC NE, V19, P365, DOI 10.6004/jnccn.2021.0018
   Tanda ET, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00154
   Urban K, 2021, JAAD INT, V2, P98, DOI 10.1016/j.jdin.2020.10.013
   Zhou S, 2022, J CUTAN MED SURG, V26, P201, DOI 10.1177/12034754211045380
   Zhou SR, 2021, CANCERS, V13, DOI 10.3390/cancers13092282
NR 26
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1203-4754
EI 1615-7109
J9 J CUTAN MED SURG
JI J. Cutan. Med. Surg.
PD 2024 DEC 4
PY 2024
DI 10.1177/12034754241302821
EA DEC 2024
PG 6
WC Dermatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Dermatology
GA O2Q6J
UT WOS:001369642200001
PM 39629857
DA 2025-01-04
ER

PT J
AU Rassomakhina, NV
   Ryazanova, AY
   Likhov, AR
   Bruskin, SA
   Maloshenok, LG
   Zherdeva, VV
AF Rassomakhina, Natalia V.
   Ryazanova, Alexandra Yu.
   Likhov, Astemir R.
   Bruskin, Sergey A.
   Maloshenok, Liliya G.
   Zherdeva, Victoria V.
TI Tumor Organoids: The Era of Personalized Medicine
SO BIOCHEMISTRY-MOSCOW
LA English
DT Review
DE 3D tumor organoids; precision medicine; patient-derived tumor organoids
   (PDTOs); induced pluripotent stem cells (iPSCs); chemotherapy; targeted
   therapy; immunotherapy; immune checkpoints; personalized therapy;
   programmed cell death
ID IV COLORECTAL-CANCER; IN-VITRO; MOUSE MODELS; CELL-LINE; CRISPR-CAS9
   SYSTEM; TARGETED THERAPIES; DRUG-SENSITIVITY; CONNECTIVITY MAP;
   INTRACELLULAR PH; XENOGRAFT
AB The strategies of future medicine are aimed to modernize and integrate quality approaches including early molecular-genetic profiling, identification of new therapeutic targets and adapting design for clinical trials, personalized drug screening (PDS) to help predict and individualize patient treatment regimens. In the past decade, organoid models have emerged as an innovative in vitro platform with the potential to realize the concept of patient-centered medicine. Organoids are spatially restricted three-dimensional clusters of cells ex vivo that self-organize into complex functional structures through genetically programmed determination, which is crucial for reconstructing the architecture of the primary tissue and organs. Currently, there are several strategies to create three-dimensional (3D) tumor systems using (i) surgically resected patient tissue (PDTOs, patient-derived tumor organoids) or (ii) single tumor cells circulating in the patient's blood. Successful application of 3D tumor models obtained by co-culturing autologous tumor organoids (PDTOs) and peripheral blood lymphocytes have been demonstrated in a number of studies. Such models simulate a 3D tumor architecture in vivo and contain all cell types characteristic of this tissue, including immune system cells and stem cells. Components of the tumor microenvironment, such as fibroblasts and immune system cells, affect tumor growth and its drug resistance. In this review, we analyzed the evolution of tumor models from two-dimensional (2D) cell cultures and laboratory animals to 3D tissue-specific tumor organoids, their significance in identifying mechanisms of antitumor response and drug resistance, and use of these models in drug screening and development of precision methods in cancer treatment.
C1 [Rassomakhina, Natalia V.; Ryazanova, Alexandra Yu.; Likhov, Astemir R.; Bruskin, Sergey A.; Maloshenok, Liliya G.; Zherdeva, Victoria V.] Russian Acad Sci, Fed Res Ctr Biotechnol, Bach Inst Biochem, Moscow 119071, Russia.
   [Bruskin, Sergey A.; Maloshenok, Liliya G.] Russian Acad Sci, Vavilov Inst Gen Genet, Moscow 119991, Russia.
C3 Russian Academy of Sciences; Research Center of Biotechnology RAS;
   Russian Academy of Sciences; Vavilov Institute of General Genetics
RP Zherdeva, VV (corresponding author), Russian Acad Sci, Fed Res Ctr Biotechnol, Bach Inst Biochem, Moscow 119071, Russia.
EM vjerdeva@inbi.ras.ru
RI Rassomakhina, Nataliya/AAG-8036-2019
OI Rassomakhina, Nataliya/0000-0002-5188-9255
FU Ministry of Health of the Russian Federation
FX The authors are deeply thankful to O. A. Bezborodova (National Medical
   Radiology Research Center of the Ministry of Health of the Russian
   Federation, P. Hertsen Moscow Oncology Research Institute) for valuable
   comments in the process of review preparation.
CR Anderson NM, 2020, CURR BIOL, V30, pR921, DOI 10.1016/j.cub.2020.06.081
   Annaratone L, 2021, VIRCHOWS ARCH, V479, P233, DOI 10.1007/s00428-021-03151-0
   Antonelli F, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms241310620
   Arutyunyan IV, 2023, B EXP BIOL MED+, V175, P576, DOI 10.1007/s10517-023-05906-y
   Ashfaq R, 2012, CLIN EXP METASTAS, V29, P653, DOI 10.1007/s10585-012-9483-3
   Bakhoum SF, 2018, NATURE, V553, P467, DOI 10.1038/nature25432
   Barretina J, 2012, NATURE, V483, P603, DOI 10.1038/nature11003
   Basu A, 2013, CELL, V154, P1151, DOI 10.1016/j.cell.2013.08.003
   Bergin CJ, 2022, STAR PROTOC, V3, DOI 10.1016/j.xpro.2022.101218
   Berish RB, 2018, NAT REV UROL, V15, P403, DOI 10.1038/s41585-018-0020-2
   Bezborodova OA, 2018, DOKL BIOCHEM BIOPHYS, V483, P326, DOI 10.1134/S1607672918060091
   Bin Emran T, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.891652
   Bogomiakova ME, 2021, STEM CELL RES, V55, DOI 10.1016/j.scr.2021.102451
   Brown JM, 1997, ONCOL RES, V9, P213
   Cham CM, 2005, J IMMUNOL, V174, P4670, DOI 10.4049/jimmunol.174.8.4670
   Chen AN, 2023, CANCERS, V15, DOI 10.3390/cancers15112989
   Chen JY, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.1066869
   Chen LP, 2021, J COLLOID INTERF SCI, V600, P243, DOI 10.1016/j.jcis.2021.04.131
   Cheng FF, 2016, ONCOTARGET, V7, P48832, DOI 10.18632/oncotarget.9453
   Cho SY, 2016, MOL CELLS, V39, P77, DOI 10.14348/molcells.2016.2350
   Chuprin J, 2023, NAT REV CLIN ONCOL, V20, P192, DOI 10.1038/s41571-022-00721-2
   Clinton James, 2019, Curr Protoc Cell Biol, V82, pe66, DOI 10.1002/cpcb.66
   Courau T, 2019, J IMMUNOTHER CANCER, V7, DOI 10.1186/s40425-019-0553-9
   Dahodwala H, 2019, CURR OPIN BIOTECH, V60, P128, DOI 10.1016/j.copbio.2019.01.011
   De Magalhaes Nzola, 2010, J Biomed Sci Eng, V3, P20, DOI 10.4236/jbise.2010.31003
   de Poel E, 2023, J CYST FIBROS, V22, P548, DOI 10.1016/j.jcf.2023.03.004
   Demchenko A, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24076293
   Di Baldassarre A, 2018, CELLS-BASEL, V7, DOI 10.3390/cells7060048
   DiMasi JA, 2013, CLIN PHARMACOL THER, V94, P329, DOI 10.1038/clpt.2013.117
   Doctor A, 2020, CANCERS, V12, DOI 10.3390/cancers12102765
   Dong YW, 2021, CANCERS, V13, DOI 10.3390/cancers13081949
   Dong YY, 2017, EUR UROL FOCUS, V3, P590, DOI 10.1016/j.euf.2016.08.005
   Dutta D, 2017, TRENDS MOL MED, V23, P393, DOI 10.1016/j.molmed.2017.02.007
   El Harane S, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12071001
   Eremeev A, 2021, JOVE-J VIS EXP, DOI 10.3791/62987
   FARRELL CL, 1987, J NEURO-ONCOL, V4, P403, DOI 10.1007/BF00195612
   Feder-Mengus C, 2008, TRENDS MOL MED, V14, P333, DOI 10.1016/j.molmed.2008.06.001
   Ferlay J, 2021, INT J CANCER, V149, P778, DOI 10.1002/ijc.33588
   Fernandez TD, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/430290
   Firuzi O, 2019, CANCERS, V11, DOI 10.3390/cancers11050638
   Garnett MJ, 2012, NATURE, V483, P570, DOI 10.1038/nature11005
   Garrido-Laguna I, 2011, CLIN CANCER RES, V17, P5793, DOI 10.1158/1078-0432.CCR-11-0341
   Geurts M H., 2023, Nature Reviews Bioengineering, V1, P32, DOI [10.1038/s44222-022-00013-5, DOI 10.1038/S44222-022-00013-5]
   Gezgin G, 2022, OPHTHALMOL SCI, V2, DOI 10.1016/j.xops.2022.100132
   Giraudo MV, 2020, BIOMEDICINES, V8, DOI 10.3390/biomedicines8100436
   Gottfried E, 2006, BLOOD, V107, P2013, DOI 10.1182/blood-2005-05-1795
   Guo LB, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.01508
   Hagens MJ, 2022, J NUCL MED, V63, P1531, DOI 10.2967/jnumed.121.263139
   Harada K, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.1067207
   Haverty PM, 2016, NATURE, V533, P333, DOI 10.1038/nature17987
   He JY, 2021, INT J ONCOL, V59, DOI 10.3892/ijo.2021.5270
   Hemminki O, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00922-1
   Hendriks D, 2021, NAT PROTOC, V16, P182, DOI 10.1038/s41596-020-00411-2
   Hepburn AC, 2019, ONCOGENE, V38, P4412, DOI 10.1038/s41388-019-0712-y
   Hirano T, 2015, ONCOTARGET, V6, P38789, DOI 10.18632/oncotarget.5887
   Huo KG, 2020, TRANSL LUNG CANCER R, V9, P2214, DOI 10.21037/tlcr-20-154
   Hutchinson L, 2011, NAT REV CLIN ONCOL, V8, P189, DOI [10.1038/nrclinonc.2010.204, 10.1038/nrclinonc.2011.34]
   Hutmacher DW, 2010, TRENDS BIOTECHNOL, V28, P125, DOI 10.1016/j.tibtech.2009.12.001
   INCH WR, 1970, GROWTH, V34, P271
   Iorio F, 2016, CELL, V166, P740, DOI 10.1016/j.cell.2016.06.017
   Ireson CR, 2019, BRIT J CANCER, V121, P101, DOI 10.1038/s41416-019-0495-5
   Jeong SY, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0159013
   Jin MZ, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-00280-x
   Johnson JI, 2001, BRIT J CANCER, V84, P1424, DOI 10.1054/bjoc.2001.1796
   Kalluri R, 2006, NAT REV CANCER, V6, P392, DOI 10.1038/nrc1877
   Kastner C, 2021, CANCERS, V13, DOI 10.3390/cancers13194812
   Kazachkina NI, 2022, NMR BIOMED, V35, DOI 10.1002/nbm.4708
   Keles H, 2023, ACS PHARMACOL TRANSL, V6, P12, DOI 10.1021/acsptsci.2c00200
   Kenny PA, 2007, MOL ONCOL, V1, P84, DOI 10.1016/j.molonc.2007.02.004
   Klijn C, 2015, NAT BIOTECHNOL, V33, P306, DOI 10.1038/nbt.3080
   Koga Y, 2019, CELLS-BASEL, V8, DOI 10.3390/cells8050418
   Kondratyeva E, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms231810377
   Kozin SV, 1998, BRIT J CANCER, V77, P1580, DOI 10.1038/bjc.1998.260
   Küçükköse E, 2022, J IMMUNOTHER CANCER, V10, DOI 10.1136/jitc-2022-005345
   Kumar S, 2023, BIOCHEM PHARMACOL, V213, DOI 10.1016/j.bcp.2023.115589
   L'Espérance S, 2008, BMC GENOMICS, V9, DOI 10.1186/1471-2164-9-99
   Lamb J, 2006, SCIENCE, V313, P1929, DOI 10.1126/science.1132939
   Le Bao C, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms232314604
   Leach DR, 1996, SCIENCE, V271, P1734, DOI 10.1126/science.271.5256.1734
   Li XD, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-05190-9
   Liu T, 2016, ONCOTARGET, V7, P83502, DOI 10.18632/oncotarget.13148
   Ma X, 2024, GENES DIS, V11, P614, DOI 10.1016/j.gendis.2023.02.052
   Madonna MC, 2021, CANCERS, V13, DOI 10.3390/cancers13010148
   Magré L, 2023, J IMMUNOTHER CANCER, V11, DOI 10.1136/jitc-2022-006290
   Mali P, 2013, SCIENCE, V339, P823, DOI 10.1126/science.1232033
   Maloshenok L, 2023, MATERIALS, V16, DOI 10.3390/ma16030940
   Maloshenok LG, 2023, BIOCHEMISTRY-MOSCOW+, V88, pS123, DOI 10.1134/S0006297923140080
   Marcolin JC, 2023, CURR PROB CANCER, V47, DOI 10.1016/j.currproblcancer.2023.100996
   Marshall LJ, 2020, ANIMALS-BASEL, V10, DOI 10.3390/ani10101923
   Meads MB, 2009, NAT REV CANCER, V9, P665, DOI 10.1038/nrc2714
   Medle B, 2022, CANCERS, V14, DOI 10.3390/cancers14092062
   Mehta G, 2012, J CONTROL RELEASE, V164, P192, DOI 10.1016/j.jconrel.2012.04.045
   Miserocchi G, 2022, J PERS MED, V12, DOI 10.3390/jpm12060854
   Mittler F, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00293
   Mo SB, 2022, ADV SCI, V9, DOI 10.1002/advs.202204097
   Mohiuddin TM, 2023, INT J MOL SCI, V24, DOI 10.3390/ijms24032655
   Momcilovic M, 2019, NATURE, V575, P380, DOI 10.1038/s41586-019-1715-0
   Morton CL, 2007, NAT PROTOC, V2, P247, DOI 10.1038/nprot.2007.25
   Munagala R, 2011, INDIAN J PHARMACOL, V43, P236, DOI 10.4103/0253-7613.81497
   Murali Anuradha K, 2011, J Clin Cell Immunol, VS3, P2
   Napoli GC, 2022, FRONT MED-LAUSANNE, V9, DOI 10.3389/fmed.2022.912641
   Narasimhan V, 2020, CLIN CANCER RES, V26, P3662, DOI 10.1158/1078-0432.CCR-20-0073
   Nicolson F, 2019, THERANOSTICS, V9, P5899, DOI 10.7150/thno.36321
   Norouzi-Barough L, 2018, IRAN J BASIC MED SCI, V21, P181, DOI 10.22038/IJBMS.2017.25145.6230
   Onaciu A, 2020, DIAGNOSTICS, V10, DOI 10.3390/diagnostics10090660
   Ooft SN, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100103
   Ou LL, 2023, EBIOMEDICINE, V92, P1, DOI 10.1016/j.ebiom.2023.104614
   Ou LL, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.814
   Pamarthy S, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01426-3
   Peng F, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-01110-y
   Pham TND, 2021, CANCERS, V13, DOI 10.3390/cancers13030440
   Porcelli L, 2022, PHARMACOL RES, V182, DOI 10.1016/j.phrs.2022.106323
   Porter RJ, 2020, BRIT J CANCER, V123, P1209, DOI 10.1038/s41416-020-0993-5
   Lu QA, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22031203
   Romanovsky G. B., 2020, Sci. Soc. State, V8, P54, DOI [10.21685/2307-9525-2020-8-1-7, DOI 10.21685/2307-9525-2020-8-1-7]
   Roudsari LC, 2016, SCI REP-UK, V6, DOI 10.1038/srep32726
   RYGAARD J, 1969, Acta Pathologica et Microbiologica Scandinavica, V77, P758
   Santana-Krímskaya SE, 2022, RES VET SCI, V152, P364, DOI 10.1016/j.rvsc.2022.08.026
   Sato T, 2011, GASTROENTEROLOGY, V141, P1762, DOI 10.1053/j.gastro.2011.07.050
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Schmidt KM, 2016, METHODS MOL BIOL, V1464, P129, DOI 10.1007/978-1-4939-3999-2_12
   Sell SA, 2010, POLYMERS-BASEL, V2, P522, DOI 10.3390/polym2040522
   Shin K, 2023, BMB REP, V56, P1, DOI 10.5483/BMBRep.2022-0210
   Shirmanova MV, 2015, BBA-GEN SUBJECTS, V1850, P1905, DOI 10.1016/j.bbagen.2015.05.001
   Shirshin EA, 2022, P NATL ACAD SCI USA, V119, DOI 10.1073/pnas.2118241119
   Shuel SL, 2022, CAN FAM PHYSICIAN, V68, DOI 10.46747/cfp.6807515
   Sieh S, 2010, ORGANOGENESIS, V6, P181, DOI 10.4161/org.6.3.12041
   Singh N, 2023, IMMUNITY, V56, P2296, DOI 10.1016/j.immuni.2023.09.010
   Sobczuk P, 2020, TRANSL ONCOL, V13, DOI 10.1016/j.tranon.2020.100745
   Song Q, 2018, IMMUNOL LETT, V196, P11, DOI 10.1016/j.imlet.2018.01.011
   Song TY, 2024, ADV HEALTHC MATER, V13, DOI 10.1002/adhm.202300984
   Sridharan S, 2016, SCI REP-UK, V6, DOI 10.1038/srep33818
   Subramanian A, 2017, CELL, V171, P1437, DOI 10.1016/j.cell.2017.10.049
   Sun Q, 2023, SIGNAL TRANSDUCT TAR, V8, DOI 10.1038/s41392-023-01522-4
   Szade K, 2016, TUMOR BIOL, V37, P2481, DOI 10.1007/s13277-015-4065-z
   Takahashi K, 2006, CELL, V126, P663, DOI 10.1016/j.cell.2006.07.024
   Takebe T, 2018, CTS-CLIN TRANSL SCI, V11, P597, DOI 10.1111/cts.12577
   Tang XY, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-01024-9
   Trujillo-de Santiago G, 2019, MATERIALS, V12, DOI 10.3390/ma12182945
   Tucker LH, 2019, ANAL CHEM, V91, P9522, DOI 10.1021/acs.analchem.9b00661
   Uramoto H, 2014, TRANSL LUNG CANCER R, V3, P242, DOI 10.3978/j.issn.2218-6751.2013.12.05
   Urbischek M, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-42604-0
   Valcourt DM, 2020, ADV HEALTHC MATER, V9, DOI 10.1002/adhm.202000110
   Van Hemelryk A., 2022, Eur.J. Cancer, V174, DOI [10.1016/S0959-8049(22)00913-3, DOI 10.1016/S0959-8049(22)00913-3]
   Vanneman M, 2012, NAT REV CANCER, V12, P237, DOI 10.1038/nrc3237
   Visalakshan RM, 2023, FRONT IMMUNOL, V14, DOI 10.3389/fimmu.2023.1162905
   Vivarelli S, 2020, CANCERS, V12, DOI 10.3390/cancers12123636
   Waldman AD, 2020, NAT REV IMMUNOL, V20, P651, DOI 10.1038/s41577-020-0306-5
   Walsh NC, 2017, ANNU REV PATHOL-MECH, V12, P187, DOI 10.1146/annurev-pathol-052016-100332
   Wang BR, 2022, FRONT IMMUNOL, V13, DOI 10.3389/fimmu.2022.902060
   Wang H, 2019, SCIENCE, V365, P1301, DOI 10.1126/science.aax7852
   Wang T, 2023, DIS COLON RECTUM, V66, P733, DOI 10.1097/DCR.0000000000002511
   Wang T, 2021, DIS COLON RECTUM, V64, P833, DOI 10.1097/DCR.0000000000001971
   Ward Carol, 2020, Explor Target Antitumor Ther, V1, P71, DOI 10.37349/etat.2020.00005
   Wei Y, 2022, INT J MOL SCI, V23, DOI 10.3390/ijms23116305
   Wen J, 2023, CNS NEUROSCI THER, V29, P2725, DOI 10.1111/cns.14272
   Wilkes GM, 2018, ASIA-PAC J ONCOL NUR, V5, P137, DOI 10.4103/apjon.apjon_79_17
   Wu SH, 2022, ANNU REV PATHOL-MECH, V17, P367, DOI 10.1146/annurev-pathmechdis-051821-114223
   Wuputra K, 2021, STEM CELL RES THER, V12, DOI 10.1186/s13287-021-02521-4
   Wuputra K, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01584-0
   Xia T, 2021, J CELL MOL MED, V25, P5829, DOI 10.1111/jcmm.16578
   Xiao Y, 2021, PHARMACOL THERAPEUT, V221, DOI 10.1016/j.pharmthera.2020.107753
   Xu SF, 2023, CANCERS, V15, DOI 10.3390/cancers15174339
   Xu X, 2012, BIOMATERIALS, V33, P9049, DOI 10.1016/j.biomaterials.2012.08.061
   Xu XQ, 2019, SCI ADV, V5, DOI 10.1126/sciadv.aat2953
   Yamamoto A, 2023, P NATL ACAD SCI USA, V120, DOI 10.1073/pnas.2214888120
   Yang C, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-1067-8
   Yang HHN, 2018, CELL STEM CELL, V23, P882, DOI 10.1016/j.stem.2018.09.016
   Yang WJ, 2013, NUCLEIC ACIDS RES, V41, pD955, DOI 10.1093/nar/gks1111
   Yao Y, 2020, CELL STEM CELL, V26, P17, DOI 10.1016/j.stem.2019.10.010
   Yin XL, 2016, CELL STEM CELL, V18, P25, DOI 10.1016/j.stem.2015.12.005
   Yu YY, 2022, BIOMARK RES, V10, DOI 10.1186/s40364-022-00421-0
   Zagaynova EV, 2017, ADV EXP MED BIOL, V1035, P105, DOI 10.1007/978-3-319-67358-5_7
   Zhang W, 2023, FRONT ONCOL, V13, DOI 10.3389/fonc.2023.1122322
   Zhang Y, 2023, INT J NANOMED, V18, P5511, DOI 10.2147/IJN.S424737
   Zhao JZ, 2023, CELLS-BASEL, V12, DOI 10.3390/cells12081165
   Zhao XM, 2012, NEURO-ONCOLOGY, V14, P574, DOI 10.1093/neuonc/nos061
   Zheng HC, 2023, INFECT AGENTS CANCER, V18, DOI 10.1186/s13027-023-00524-9
   Zherdeva V, 2018, J BIOMED OPT, V23, DOI 10.1117/1.JBO.23.3.035002
   Zhou GY, 2022, BRIT J CANCER, V127, P649, DOI 10.1038/s41416-022-01839-x
   Zhu JL, 2023, CELL DEATH DISCOV, V9, DOI 10.1038/s41420-023-01354-9
   Zitvogel L, 2016, NAT REV CANCER, V16, P759, DOI 10.1038/nrc.2016.91
NR 182
TC 2
Z9 2
U1 6
U2 8
PU MAIK NAUKA/INTERPERIODICA/SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013-1578 USA
SN 0006-2979
EI 1608-3040
J9 BIOCHEMISTRY-MOSCOW+
JI Biochem.-Moscow
PD JAN
PY 2024
VL 89
IS SUPPL 1
SU 1
BP S127
EP S147
DI 10.1134/S0006297924140086
PG 21
WC Biochemistry & Molecular Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology
GA KE3H4
UT WOS:001178237600004
PM 38621748
DA 2025-01-04
ER

PT J
AU Baniebrahimi, G
   Mir, F
   Khanmohammadi, R
AF Baniebrahimi, Ghazaleh
   Mir, Fatemeh
   Khanmohammadi, Razieh
TI Cancer stem cells and oral cancer: insights into molecular mechanisms
   and therapeutic approaches
SO CANCER CELL INTERNATIONAL
LA English
DT Review
DE Oral cancer stem cells; Pathogenesis; Molecular pathways
ID EPITHELIAL-MESENCHYMAL TRANSITION; TUMOR-INITIATING CELLS; SIDE
   POPULATION CELLS; ALDEHYDE DEHYDROGENASE 1; NECK-CANCER; HISTONE
   DEMETHYLASE; COLORECTAL-CANCER; POOR-PROGNOSIS; DIAGNOSTIC BIOMARKER;
   SPHERE-FORMATION
AB Cancer stem cells (CSCs) have been identified as a little population of cancer cells, which have features as the same as the cells normal stem cells. There is enough knowledge of the CSCs responsibility for metastasis, medicine resistance, and cancer outbreak. Therefore, CSCs control possibly provides an efficient treatment intervention inhibiting tumor growth and invasion. In spite of the significance of targeting CSCs in treating cancer, few study comprehensively explored the nature of oral CSCs. It has been showed that oral CSCs are able to contribute to oral cancer progression though activation/inhibition a sequences of cellular and molecular pathways (microRNA network, histone modifications and calcium regulation). Hence, more understanding about the properties of oral cancers and their behaviors will help us to develop new therapeutic platforms. Head and neck CSCs remain a viable and intriguing option for targeted therapy. Multiple investigations suggested the major contribution of the CSCs to the metastasis, tumorigenesis, and resistance to the new therapeutic regimes. Therefore, experts in the field are examining the encouraging targeted therapeutic choices. In spite of the advancements, there are not enough information in this area and thus a magic bullet for targeting and eliminating the CSCs deviated us. Hence, additional investigations on the combined therapies against the head and neck CSCs could offer considerable achievements. The present research is a review of the recent information on oral CSCs, and focused on current advancements in new signaling pathways contributed to their stemness regulation. Moreover, we highlighted various therapeutic approaches against oral CSCs.
C1 [Baniebrahimi, Ghazaleh; Khanmohammadi, Razieh] Univ Tehran Med Sci, Sch Dent, Dept Pediat Dent, Tehran, Iran.
   [Mir, Fatemeh] Zahedan Univ Med Sci, Sch Dent, Dept Pediat Dent, Zahedan, Iran.
C3 Tehran University of Medical Sciences; Zahedan University of Medical
   Sciences
RP Khanmohammadi, R (corresponding author), Univ Tehran Med Sci, Sch Dent, Dept Pediat Dent, Tehran, Iran.
EM razie.khanmohammadi@yahoo.com
RI mir, fatemeh/A-2809-2019; baniebrahimi, ghazaleh/N-8903-2018;
   khanmohammadi, Razieh/O-3090-2018
FU Tehran University of Medical Sciences, in Iran
FX The present study was founded by a grant from the Vice Chancellor for
   Research, Tehran University of Medical Sciences, in Iran.
CR ABBASZADEHGOUDA.K, 2020, CURR MOL MED
   Agger K, 2009, GENE DEV, V23, P1171, DOI 10.1101/gad.510809
   Aghdam AM, 2019, CRIT REV EUKAR GENE, V29, P127, DOI 10.1615/CritRevEukaryotGeneExpr.2019025273
   Ahmed S, 2019, EUR J MED CHEM, V183, DOI 10.1016/j.ejmech.2019.111658
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Amente S, 2013, BBA-GENE REGUL MECH, V1829, P981, DOI 10.1016/j.bbagrm.2013.05.002
   AMIRI A, 2019, CURR MED CHEM
   [Anonymous], FISH PHYSL BIOCH
   Banikazemi Z, 2018, J CELL BIOCHEM, V119, P185, DOI 10.1002/jcb.26244
   Bano N, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0205518
   Beck B, 2013, NAT REV CANCER, V13, P727, DOI 10.1038/nrc3597
   Berglund BA, 1999, ADV EXP MED BIOL, V469, P527
   Berridge MJ, 2003, NAT REV MOL CELL BIO, V4, P517, DOI 10.1038/nrm1155
   Bertrand G, 2014, STEM CELL REV REP, V10, P114, DOI 10.1007/s12015-013-9467-y
   Beynon RA, 2018, INT J CANCER, V143, P1114, DOI 10.1002/ijc.31416
   Birkeland AC, 2015, J DENT RES, V94, P1516, DOI 10.1177/0022034515601960
   Boeckel JN, 2011, P NATL ACAD SCI USA, V108, P3276, DOI 10.1073/pnas.1008098108
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Borujeni MJS, 2019, J CELL PHYSIOL, V234, P8411, DOI 10.1002/jcp.27755
   Bourguignon LYW, 2012, J BIOL CHEM, V287, P32800, DOI 10.1074/jbc.M111.308528
   Braunholz D, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0163149
   Brennan M, 2007, ORAL SURG ORAL MED O, V103, pS19, DOI 10.1016/j.tripleo.2006.10.015
   Cao L, 2011, BMC GASTROENTEROL, V11, DOI 10.1186/1471-230X-11-71
   Cavallaro U, 2004, NAT REV CANCER, V4, P118, DOI 10.1038/nrc1276
   Chang BS, 2007, SCIENCE, V318, P444, DOI 10.1126/science.1145801
   Chang CW, 2014, CANCER RES, V74, P6291, DOI 10.1158/0008-5472.CAN-14-0626
   Chen CYC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0015939
   Chen DM, 2017, CELL STEM CELL, V20, P621, DOI 10.1016/j.stem.2017.02.003
   Chen YC, 2009, BIOCHEM BIOPH RES CO, V385, P307, DOI 10.1016/j.bbrc.2009.05.048
   Chen YK, 2014, INT J ORAL SCI, V6, P212, DOI 10.1038/ijos.2014.32
   Chiou SH, 2008, CLIN CANCER RES, V14, P4085, DOI 10.1158/1078-0432.CCR-07-4404
   Chiu CC, 2013, CANCER GENE THER, V20, P606, DOI 10.1038/cgt.2013.64
   Choi SH, 2006, LARYNGOSCOPE, V116, P1228, DOI 10.1097/01.mlg.0000224499.93774.77
   Chu PY, 2013, ORAL ONCOL, V49, P34, DOI 10.1016/j.oraloncology.2012.07.012
   Clay MR, 2010, HEAD NECK-J SCI SPEC, V32, P1195, DOI 10.1002/hed.21315
   Colnot DR, 2000, J NUCL MED, V41, P1999
   Cui HG, 2015, CURR DRUG TARGETS, V16, P1356, DOI 10.2174/1389450116666150330113506
   Damek-Poprawa M, 2011, J DENT RES, V90, P638, DOI 10.1177/0022034510393511
   Davoodvandi A, 2019, CURR PHARM DESIGN, V25, P3225, DOI 10.2174/1381612825666190829154934
   Deng W, 2016, DIGEST DIS SCI, V61, P1553, DOI 10.1007/s10620-015-4029-6
   Dieter SM, 2011, CELL STEM CELL, V9, P357, DOI 10.1016/j.stem.2011.08.010
   Dittmar T, 2009, MED HYPOTHESES, V73, P542, DOI 10.1016/j.mehy.2009.05.044
   Eun K, 2017, BMB REP, V50, P117, DOI 10.5483/BMBRep.2017.50.3.222
   Fan F, 2012, CANCER MED-US, V1, P5, DOI 10.1002/cam4.4
   Fathullahzadeh S, 2016, CANCER GENE THER, V23, P327, DOI 10.1038/cgt.2016.34
   Felthaus O, 2011, BIOCHEM BIOPH RES CO, V407, P28, DOI 10.1016/j.bbrc.2011.02.084
   Feske S, 2006, NATURE, V441, P179, DOI 10.1038/nature04702
   Flourakis M, 2010, CELL DEATH DIS, V1, DOI 10.1038/cddis.2010.52
   Fujii H, 2009, INT J ONCOL, V34, P1381, DOI 10.3892/ijo_00000265
   Gan GN, 2014, CANCER RES, V74, P7024, DOI 10.1158/0008-5472.CAN-14-1346
   Garner JM, 2013, J BIOL CHEM, V288, P26167, DOI 10.1074/jbc.M113.477950
   Gatta G, 2015, EUR J CANCER, V51, P2130, DOI 10.1016/j.ejca.2015.07.043
   Gerlach K, 2012, CANCER RES, V72, P4340, DOI 10.1158/0008-5472.CAN-11-4155
   Ghasemi F, 2019, PATHOL RES PRACT, V215, DOI 10.1016/j.prp.2019.152556
   Gholamin S, 2018, J CELL PHYSIOL, V233, P866, DOI 10.1002/jcp.25793
   Ghuwalewala S, 2016, STEM CELL RES, V16, P405, DOI 10.1016/j.scr.2016.02.028
   Gibbs CP, 2005, NEOPLASIA, V7, P967, DOI 10.1593/neo.05394
   Giles RH, 2003, BBA-REV CANCER, V1653, P1, DOI 10.1016/S0304-419X(03)00005-2
   Gillison ML, 2008, JNCI-J NATL CANCER I, V100, P407, DOI 10.1093/jnci/djn025
   Ginestier C, 2007, CELL STEM CELL, V1, P555, DOI 10.1016/j.stem.2007.08.014
   Golabchi K, 2018, J CELL PHYSIOL, V233, P3016, DOI 10.1002/jcp.26070
   Golebiewska A, 2011, CELL STEM CELL, V8, P136, DOI 10.1016/j.stem.2011.01.007
   Goradel NH, 2018, J CELL PHYSIOL, V233, P2902, DOI 10.1002/jcp.26029
   Grimm M, 2012, EUR J CANCER, V48, P3186, DOI 10.1016/j.ejca.2012.05.027
   Grimshaw MJ, 2008, BREAST CANCER RES, V10, DOI 10.1186/bcr2106
   Gwack Y, 2007, CELL CALCIUM, V42, P145, DOI 10.1016/j.ceca.2007.03.007
   Gwack Y, 2007, J BIOL CHEM, V282, P16232, DOI 10.1074/jbc.M609630200
   Han ZW, 2019, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01544
   Hao J, 2014, INT J CANCER, V135, P1019, DOI 10.1002/ijc.28761
   Harmeyer KM, 2017, TRENDS CANCER, V3, P713, DOI 10.1016/j.trecan.2017.08.004
   Hayashi S, 2013, EXP CELL RES, V319, P1220, DOI 10.1016/j.yexcr.2013.03.004
   Hesari A, 2019, INT J CANCER, V144, P1215, DOI 10.1002/ijc.31947
   Hessmann E, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5272498
   Hill R, 2009, J BIOL CHEM, V284, P11755, DOI 10.1074/jbc.R800071200
   HOLLSTEIN M, 1994, NUCLEIC ACIDS RES, V22, P3551
   Horikiri Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0076785
   Hsia DA, 2010, P NATL ACAD SCI USA, V107, P9671, DOI 10.1073/pnas.1000401107
   Huang CX, 2013, ASIAN PAC J CANCER P, V14, P4533, DOI 10.7314/APJCP.2013.14.8.4533
   Huang CE, 2014, INT J MOL SCI, V15, P14935, DOI 10.3390/ijms150914935
   Jafari SH, 2018, J CELL PHYSIOL, V233, P5200, DOI 10.1002/jcp.26379
   Jamali L, 2018, J CELL PHYSIOL, V233, P8538, DOI 10.1002/jcp.26850
   Kageyama R, 2000, MOL CELLS, V10, P1, DOI 10.1007/s10059-000-0001-0
   Kalluri R, 2009, J CLIN INVEST, V119, P1420, DOI 10.1172/JCI39104
   Kang MK, 2010, CELL CYCLE, V9, P2704, DOI 10.4161/cc.9.14.12322
   Katayama R, 2009, CANCER SCI, V100, P2060, DOI 10.1111/j.1349-7006.2009.01288.x
   Kathawala RJ, 2015, DRUG RESIST UPDATE, V18, P1, DOI 10.1016/j.drup.2014.11.002
   Kerk SA, 2017, CLIN CANCER RES, V23, P2516, DOI 10.1158/1078-0432.CCR-16-1834
   Keshavarzi M, 2017, J CELL BIOCHEM, V118, P3055, DOI 10.1002/jcb.26042
   Keymoosi H, 2014, ASIAN PAC J CANCER P, V15, P2013, DOI 10.7314/APJCP.2014.15.5.2013
   Keysar SB, 2020, CANCER RES, V80, P1183, DOI 10.1158/0008-5472.CAN-19-3232
   KHAN H, 2019, SEMIN CANC BIOL
   Khani P, 2019, J NEUROCHEM, V148, P188, DOI 10.1111/jnc.14616
   Kim J, 2017, ONCOTARGET, V8, P52345, DOI 10.18632/oncotarget.17017
   Kim JH, 2014, BIOCHEM BIOPH RES CO, V448, P76, DOI 10.1016/j.bbrc.2014.04.064
   Kim RH, 2007, EXP CELL RES, V313, P462, DOI 10.1016/j.yexcr.2006.10.025
   Kim T, 2011, J EXP MED, V208, P875, DOI 10.1084/jem.20110235
   Kooistra SM, 2012, NAT REV MOL CELL BIO, V13, P297, DOI 10.1038/nrm3327
   Ku TKS, 2007, MOL CANCER RES, V5, P351, DOI 10.1158/1541-7786.MCR-06-0238
   Kuo SZ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-556
   Lee CR, 2016, CARCINOGENESIS, V37, P119, DOI 10.1093/carcin/bgv169
   Lee SH, 2016, ONCOTARGET, V7, P43239, DOI 10.18632/oncotarget.9755
   Lee SH, 2015, PAPILLOMAVIRUS RES, V1, P116, DOI 10.1016/j.pvr.2015.08.001
   Lee SH, 2012, BIOCHEM BIOPH RES CO, V424, P58, DOI 10.1016/j.bbrc.2012.06.065
   Lee YF, 2012, BREAST CANCER RES, V14, DOI 10.1186/bcr3200
   Leong KG, 2006, BLOOD, V107, P2223, DOI 10.1182/blood-2005-08-3329
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Li J, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15146
   Liu C, 2011, NAT MED, V17, P211, DOI 10.1038/nm.2284
   Liu HL, 2011, EXP MOL PATHOL, V91, P753, DOI 10.1016/j.yexmp.2011.09.005
   Liu JM, 2013, INT J ONCOL, V42, P453, DOI 10.3892/ijo.2012.1720
   Liu J, 2013, P NATL ACAD SCI USA, V110, P20224, DOI 10.1073/pnas.1314239110
   Liu R, 2007, NEW ENGL J MED, V356, P217, DOI 10.1056/NEJMoa063994
   Liu SL, 2006, CANCER RES, V66, P6063, DOI 10.1158/0008-5472.CAN-06-0054
   Liu ZH, 2015, CANCER BIOL THER, V16, P353, DOI 10.1080/15384047.2015.1016662
   Ma L, 2013, FEBS J, V280, P2027, DOI 10.1111/febs.12226
   Mackenzie IC, 2004, J ORAL PATHOL MED, V33, P71, DOI 10.1111/j.1600-0714.2004.00157.x
   MARCIAL VA, 1990, CANCER-AM CANCER SOC, V66, P1861, DOI 10.1002/1097-0142(19901101)66:9<1861::AID-CNCR2820660902>3.0.CO;2-I
   Marziliano A, 2020, HEAD NECK-J SCI SPEC, V42, P732, DOI 10.1002/hed.26023
   Mashreghi M, 2018, J CELL PHYSIOL, V233, P2949, DOI 10.1002/jcp.26049
   Masoudi MS, 2018, J CELL BIOCHEM, V119, P1285, DOI 10.1002/jcb.26300
   Maul-Pavicic A, 2011, P NATL ACAD SCI USA, V108, P3324, DOI 10.1073/pnas.1013285108
   McDermott Sarah C, 2018, Oncotarget, V9, P25148, DOI 10.18632/oncotarget.25358
   McKallip RJ, 2005, J IMMUNOL, V174, P3281, DOI 10.4049/jimmunol.174.6.3281
   Metzger E, 2017, CANCER RES, V77, P5900, DOI 10.1158/0008-5472.CAN-17-1754
   Mirzaei H, 2016, CANCER GENE THER, V23, P45, DOI 10.1038/cgt.2015.68
   Mirzaei H, 2018, J CELL PHYSIOL, V233, P3004, DOI 10.1002/jcp.26055
   Mirzaei H, 2018, J CELL PHYSIOL, V233, P2815, DOI 10.1002/jcp.25990
   Mirzaei H, 2018, J CELL PHYSIOL, V233, P856, DOI 10.1002/jcp.25787
   Mirzaei H, 2017, J CELL BIOCHEM, V118, P4191, DOI 10.1002/jcb.26130
   Mirzaei H, 2017, ADV CLIN CHEM, V82, P47, DOI 10.1016/bs.acc.2017.06.004
   Mirzaei H, 2017, BIOMED PHARMACOTHER, V85, P102, DOI 10.1016/j.biopha.2016.11.098
   Mirzaei H, 2016, INT J CANCER, V139, P1683, DOI 10.1002/ijc.30224
   Mirzaei H, 2016, J CANCER RES THER, V12, P498, DOI 10.4103/0973-1482.153661
   Mirzaei H, 2016, CURR MED CHEM, V23, P455, DOI 10.2174/0929867323666151217122033
   Mirzaei HR, 2018, CANCER LETT, V423, P95, DOI 10.1016/j.canlet.2018.03.010
   Mirzaei HR, 2016, CANCER LETT, V380, P413, DOI 10.1016/j.canlet.2016.07.001
   Mirzaei HR, 2016, J CANCER RES THER, V12, P520, DOI 10.4103/0973-1482.176167
   Mishra L, 2005, ONCOGENE, V24, P5775, DOI 10.1038/sj.onc.1208924
   Misuno K, 2013, STEM CELL RES THER, V4, DOI 10.1186/scrt386
   Mohammadi M, 2016, CANCER GENE THER, V23, P371, DOI 10.1038/cgt.2016.45
   Mohammadi M, 2016, CANCER GENE THER, V23, P285, DOI 10.1038/cgt.2016.35
   Monteith GR, 2007, NAT REV CANCER, V7, P519, DOI 10.1038/nrc2171
   Morata-Tarifa C, 2016, SCI REP-UK, V6, DOI 10.1038/srep18772
   Moridikia A, 2018, J CELL PHYSIOL, V233, P901, DOI 10.1002/jcp.25801
   Murillo-Sauca O, 2014, ONCOTARGET, V5, P6854, DOI 10.18632/oncotarget.2269
   Murohashi M, 2010, BRIT J CANCER, V102, P206, DOI 10.1038/sj.bjc.6605468
   Naeli P, 2020, CRIT REV ONCOL HEMAT, V145, DOI 10.1016/j.critrevonc.2019.102854
   Naeli P, 2020, CURR MOL MED, V20, P90, DOI 10.2174/1566524019666191001113511
   Nahand JS, 2020, HIV MED, V21, P246, DOI 10.1111/hiv.12822
   Nahand JS, 2020, IUBMB LIFE, V72, P343, DOI 10.1002/iub.2222
   Nahand JS, 2020, INT J CANCER, V146, P305, DOI 10.1002/ijc.32688
   Nahand JS, 2019, J CELL PHYSIOL, V234, P17064, DOI 10.1002/jcp.28457
   Nassar D, 2016, ANNU REV PATHOL-MECH, V11, P47, DOI 10.1146/annurev-pathol-012615-044438
   Neumeister V, 2010, AM J PATHOL, V176, P2131, DOI 10.2353/ajpath.2010.090712
   O'Brien CA, 2010, CLIN CANCER RES, V16, P3113, DOI 10.1158/1078-0432.CCR-09-2824
   Odenthal J, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-28059-9
   Ota N, 2014, INT J ONCOL, V44, P435, DOI 10.3892/ijo.2013.2188
   PAI S, 2019, CD47 SIRPALPHA SIGNA, V8
   Pakshir K, 2020, MYCOSES, V63, P4, DOI 10.1111/myc.13017
   Parekh AB, 2005, PHYSIOL REV, V85, P757, DOI 10.1152/physrev.00057.2003
   Parekh AB, 2007, CELL CALCIUM, V42, P111, DOI 10.1016/j.ceca.2007.02.012
   Pastrana E, 2011, CELL STEM CELL, V8, P486, DOI 10.1016/j.stem.2011.04.007
   Patrawala L, 2006, ONCOGENE, V25, P1696, DOI 10.1038/sj.onc.1209327
   Paver EC, 2020, PATHOLOGY, V52, P179, DOI 10.1016/j.pathol.2019.10.008
   Perotti V, 2016, ONCOGENE, V35, P2862, DOI 10.1038/onc.2015.355
   Prakriya M, 2006, NATURE, V443, P230, DOI 10.1038/nature05122
   Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4
   Prevarskaya N, 2011, NAT REV CANCER, V11, P609, DOI 10.1038/nrc3105
   Prince ME, 2007, P NATL ACAD SCI USA, V104, P973, DOI 10.1073/pnas.0610117104
   Prince MEP, 2016, ORAL ONCOL, V59, P30, DOI 10.1016/j.oraloncology.2016.05.013
   Rae C, 2013, J NUCL MED, V54, P953, DOI 10.2967/jnumed.112.113324
   Ramadoss S, 2012, J BIOL CHEM, V287, P44508, DOI 10.1074/jbc.M112.424903
   Ramesh PS, 2020, CRIT REV ONCOL HEMAT, V148, DOI 10.1016/j.critrevonc.2020.102885
   Rashidi B, 2017, J CELL PHYSIOL, V232, P2968, DOI 10.1002/jcp.25738
   Reynolds DS, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-10863-4
   Richard V, 2013, CANCER LETT, V338, P300, DOI 10.1016/j.canlet.2013.06.011
   Rinkenbaugh AL, 2016, CELLS-BASEL, V5, DOI 10.3390/cells5020016
   Roderick HL, 2008, NAT REV CANCER, V8, P361, DOI 10.1038/nrc2374
   Saadatpour L, 2016, CANCER GENE THER, V23, P415, DOI 10.1038/cgt.2016.48
   Saadatpour Z, 2017, CANCER GENE THER, V24, P1, DOI 10.1038/cgt.2016.61
   SAADATPOUR Z, 2016, CANC GENE THER
   Sadeghi S, 2019, EUR J MED CHEM, V178, P131, DOI 10.1016/j.ejmech.2019.05.067
   SAEEDIBORUJENI MJ, 2018, J CELL BIOCHEM, V119, P1257, DOI DOI 10.1002/jcb.26271
   Salarinia R, 2016, CURR CANCER DRUG TAR, V16, P773, DOI 10.2174/1568009616666151207110143
   Saleem S, 2014, CANCER CELL INT, V14, DOI 10.1186/s12935-014-0143-3
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Shabaninejad Z, 2020, EUR J MED CHEM, V188, DOI 10.1016/j.ejmech.2020.112040
   Shabaninejad Z, 2019, J OVARIAN RES, V12, DOI 10.1186/s13048-019-0558-5
   Shabaninejad Z, 2019, ANAL BIOCHEM, V581, DOI 10.1016/j.ab.2019.113349
   Shafabakhsh R, 2019, PHARMACOL RES, V147, DOI 10.1016/j.phrs.2019.104353
   Sherry-Lynes MM, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0174775
   Shrivastava S, 2015, SCI REP-UK, V5, DOI 10.1038/srep07819
   Shukla S, 2011, CURR DRUG TARGETS, V12, P621, DOI 10.2174/138945011795378540
   Siddique HR, 2012, STEM CELLS, V30, P372, DOI 10.1002/stem.1035
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Simonian M, 2018, J CANCER RES THER, V14, P475, DOI 10.4103/0973-1482.175428
   Singh SK, 2003, CANCER RES, V63, P5821
   Song J, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011456
   Song SJ, 2013, CELL, V154, P311, DOI 10.1016/j.cell.2013.06.026
   Srikanth S, 2013, CURR TOP MEMBR, V71, P181, DOI 10.1016/B978-0-12-407870-3.00008-1
   Srikanth S, 2013, MOL CELLS, V35, P182, DOI 10.1007/s10059-013-0073-2
   STOOPLER ET, 2018, DENT CLIN N AM, V62, P9
   Sun JW, 2014, J CELL BIOL, V207, P535, DOI 10.1083/jcb.201407082
   Sun SY, 2014, CANCER RES, V74, P7546, DOI 10.1158/0008-5472.CAN-14-0826
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Taghavipour M, 2020, CELL BIOSCI, V10, DOI 10.1186/s13578-020-0381-0
   Tavakolizadeh J, 2018, J CELL BIOCHEM, V119, P3783, DOI 10.1002/jcb.26599
   Todoroki K, 2016, INT J ONCOL, V48, P99, DOI 10.3892/ijo.2015.3261
   Tomita H, 2016, ONCOTARGET, V7, P11018, DOI 10.18632/oncotarget.6920
   Vafadar A, 2019, CURR PHARM DESIGN, V25, P3563, DOI 10.2174/1381612825666190830161528
   Vakili-Ghartavol R, 2018, J CELL PHYSIOL, V233, P9223, DOI 10.1002/jcp.27027
   Vlashi E, 2016, INT J RADIAT ONCOL, V94, P1198, DOI 10.1016/j.ijrobp.2016.01.005
   Waldron NN, 2011, MOL CANCER THER, V10, P1829, DOI 10.1158/1535-7163.MCT-11-0206
   Wan GL, 2010, HEAD NECK-J SCI SPEC, V32, P1302, DOI 10.1002/hed.21325
   Wang J, 2007, CANCER RES, V67, P3716, DOI 10.1158/0008-5472.CAN-06-4343
   Wang LQ, 2018, ASIAPAC SIGN INFO PR, P31, DOI 10.23919/APSIPA.2018.8659520
   Wang Q, 2017, CANCER CELL INT, V17, DOI 10.1186/s12935-017-0481-z
   Wang Y, 2011, ONCOGENE, V30, P1470, DOI 10.1038/onc.2010.531
   Warnakulasuriya S, 2008, J ORAL PATHOL MED, V37, P127, DOI 10.1111/j.1600-0714.2007.00584.x
   Webby CJ, 2009, SCIENCE, V325, P90, DOI 10.1126/science.1175865
   Xia JL, 2016, CANCER LETT, V381, P31, DOI 10.1016/j.canlet.2016.07.014
   Xiao ZJ, 2017, ELIFE, V6, DOI 10.7554/eLife.26733
   Yamamoto S, 2013, CARCINOGENESIS, V34, P2380, DOI 10.1093/carcin/bgt174
   YAN Q, 2017, FASEB J S1, V31, P468
   Yan YM, 2015, STEM CELL TRANSL MED, V4, P1033, DOI 10.5966/sctm.2015-0048
   Yanamoto S, 2011, ORAL ONCOL, V47, P855, DOI 10.1016/j.oraloncology.2011.06.501
   Yang SY, 2009, CANCER CELL, V15, P124, DOI 10.1016/j.ccr.2008.12.019
   Ye L, 2012, CELL STEM CELL, V11, P50, DOI 10.1016/j.stem.2012.04.009
   YOSHIDA A, 1992, PHARMACOGENETICS, V2, P139, DOI 10.1097/00008571-199208000-00001
   Yoshida R, 2013, LAB INVEST, V93, P1068, DOI 10.1038/labinvest.2013.95
   Yu CC, 2013, CANCER RES, V73, P3425, DOI 10.1158/0008-5472.CAN-12-3840
   Zeisberg M, 2009, J CLIN INVEST, V119, P1429, DOI 10.1172/JCI36183
   Zhan ZY, 2015, INT J CLIN EXP PATHO, V8, P5080
   Zhang LJ, 2016, ONCOTARGET, V7, P78206, DOI 10.18632/oncotarget.12151
   Zhang P, 2009, CANCER LETT, V277, P227, DOI 10.1016/j.canlet.2008.12.015
   Zhang QZ, 2010, CANCER LETT, V289, P151, DOI 10.1016/j.canlet.2009.08.010
   Zhang ZC, 2012, ORAL ONCOL, V48, P1, DOI 10.1016/j.oraloncology.2011.10.004
   Zhao W, 2013, CANCER CELL, V23, P541, DOI 10.1016/j.ccr.2013.02.025
   Zhu H, 2014, ONCOTARGET, V5, P3455, DOI 10.18632/oncotarget.1903
   Zhu LX, 2000, J IMMUNOL, V165, P373, DOI 10.4049/jimmunol.165.1.373
NR 240
TC 27
Z9 27
U1 0
U2 2
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1475-2867
J9 CANCER CELL INT
JI Cancer Cell Int.
PD APR 7
PY 2020
VL 20
IS 1
DI 10.1186/s12935-020-01192-0
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LC7DA
UT WOS:000525491700005
PM 32280305
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Shao, QW
   Xu, J
   Deng, R
   Wei, W
   Zhou, B
   Yue, C
   Zhu, ML
   Zhu, HT
AF Shao, Qianwen
   Xu, Jing
   Deng, Rong
   Wei, Wei
   Zhou, Bing
   Yue, Chao
   Zhu, Miaoling
   Zhu, Haitao
TI SNHG 6 promotes the progression of Colon and Rectal adenocarcinoma via
   miR-101-3p and Wnt/β-catenin signaling pathway
SO BMC GASTROENTEROLOGY
LA English
DT Article
DE Small nucleolar RNA host gene 6; ceRNA; Sponging; Target therapy; Cell
   signal pathway
ID TUMOR-SUPPRESSOR MICRORNA-101; NONCODING RNAS; LUNG-CANCER; CLIP-SEQ;
   STARBASE; NETWORKS
AB Background: Small nucleolar RNA host gene 6 (SNHG6) regulates diverse biological processes in cancers. Potential function of SNHG6 in human colon and rectal adenocarcinoma (CRC) was evaluated.
   Methods: Quantitative real-time polymerase chain reaction, MTT assays, Colony formation assays, Transwell assay, Western Blotting and Luciferase reporter assays were performed to measure the biological functions and potential molecular mechanisms of SNHG6 in CRC.
   Results: SNHG6 was over-expressed in CRC, and high expression of s SNHG6 were associated with short survival times. We then identified miR-101-3p as an inhibitory target of SNHG6. Knockdown of SNHG6 significantly decreased miR-101-3p expression. Moreover, silenced SNHG6 obviously inhibited CRC cell growth, weakened cell invasion capacity and blocked the Wnt/beta-catenin signaling pathway.
   Conclusion: SNHG6 could regulate the progression of CRC via modulating the expression levels of miR-101-3p and the activity of Wnt/beta-catenin signaling.
C1 [Shao, Qianwen] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Nanjing 210029, Jiangsu, Peoples R China.
   [Xu, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Oncol, Genet Testing Ctr, Nanjing 210029, Jiangsu, Peoples R China.
   [Deng, Rong; Wei, Wei; Zhou, Bing; Yue, Chao] Nanjing Med Univ, Canc Hosp, Gen Dept, Nanjing 210009, Jiangsu, Peoples R China.
   [Zhu, Miaoling] Nanjing Med Univ, Canc Hosp, Pathol Dept, Nanjing 210009, Jiangsu, Peoples R China.
   [Zhu, Haitao] Nanjing Med Univ, Jiangsu Prov Canc Hosp, Affiliated Canc Hosp,Colorectal Canc Ctr, Gen Surg Dept,Jiangsu Canc Inst, 42 Baiziting Rd, Nanjing 210009, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University; Nanjing Medical
   University; Nanjing Medical University; Nanjing Medical University
RP Zhu, HT (corresponding author), Nanjing Med Univ, Jiangsu Prov Canc Hosp, Affiliated Canc Hosp,Colorectal Canc Ctr, Gen Surg Dept,Jiangsu Canc Inst, 42 Baiziting Rd, Nanjing 210009, Jiangsu, Peoples R China.
EM co87r5@163.com
RI Yue, Chao/C-2535-2015; zhu, HAITAO/GVL-0589-2022
FU Key Project of and Technology Department of Jiangsu Province of China
   [BL2014092]; Natural Science Foundation of Jiangsu Province
   [BK20131438]; Six talent peaks project in Jiangsu Province [WSW-038];
   Key Project of Cancer hospital of NanJing Medical University [4]
FX This work was supported by the [Key Project of and Technology Department
   of Jiangsu Province of China #1] under Grant [number BL2014092];
   [Natural Science Foundation of Jiangsu Province #2] under Grant [number
   BK20131438]; [Six talent peaks project in Jiangsu Province #3] under
   Grant [number WSW-038]; and [Key Project of Cancer hospital of NanJing
   Medical University #4] under Grant. The funding body supported the data
   collection used in this study. The funding body has no role in the
   design of the study and analysis and interpretation of data and in
   writing the manuscript.
CR [Anonymous], PATHOLOGY ONCOLOGY R
   [Anonymous], 2010, BMJ CLIN EVID
   Chang L, 2016, CANCER LETT, V383, P183, DOI 10.1016/j.canlet.2016.09.034
   Clevers H, 2012, CELL, V149, P1192, DOI 10.1016/j.cell.2012.05.012
   Cui Y, 2017, ONCOTARGET, V8, P17785, DOI 10.18632/oncotarget.14854
   Ding XF, 2017, ONCOTARGET, V8, P58210, DOI 10.18632/oncotarget.17356
   Friedman JM, 2009, CELL CYCLE, V8, P2313, DOI 10.4161/cc.8.15.9168
   Friedman JM, 2009, CANCER RES, V69, P2623, DOI 10.1158/0008-5472.CAN-08-3114
   Gutschner T, 2013, CANCER RES, V73, P1180, DOI 10.1158/0008-5472.CAN-12-2850
   Jalali S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0053823
   Li JH, 2014, NUCLEIC ACIDS RES, V42, pD92, DOI 10.1093/nar/gkt1248
   LI M, 2018, PATHOLOGY RES PRACTI
   Niehrs C, 2012, NAT REV MOL CELL BIO, V13, P767, DOI 10.1038/nrm3470
   Ortega J, 2010, CANCER CONTROL, V17, P7, DOI 10.1177/107327481001700102
   Ostankovitch M, 2013, J MOL BIOL, V425, P3577, DOI 10.1016/j.jmb.2013.07.032
   Paraskevopoulou MD, 2013, NUCLEIC ACIDS RES, V41, pD239, DOI 10.1093/nar/gks1246
   Siegel R. L., 2018, CA CANC J CLIN, V2018
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Sun W, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0418-z
   Wang HR, 2016, SCI REP-UK, V6, DOI 10.1038/srep36988
   Wang P, 2014, SCIENCE, V344, P310, DOI 10.1126/science.1251456
   Yan K, 2017, CELL PHYSIOL BIOCHEM, V42, P999, DOI 10.1159/000478682
   Yang JH, 2011, NUCLEIC ACIDS RES, V39, pD202, DOI 10.1093/nar/gkq1056
   Yang L, 2014, TRENDS BIOCHEM SCI, V39, P35, DOI 10.1016/j.tibs.2013.10.002
   Yarmishyn AA, 2015, FRONT GENET, V6, DOI 10.3389/fgene.2015.00145
   Yu FJ, 2017, CELL PHYSIOL BIOCHEM, V41, P1970, DOI 10.1159/000472410
NR 26
TC 35
Z9 38
U1 0
U2 4
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-230X
J9 BMC GASTROENTEROL
JI BMC Gastroenterol.
PD SEP 18
PY 2019
VL 19
IS 1
AR 163
DI 10.1186/s12876-019-1080-3
PG 8
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA JZ1FL
UT WOS:000504850600001
PM 31533634
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Piringer, G
   Decker, J
   Trommet, V
   Kühr, T
   Heibl, S
   Dörfler, K
   Thaler, J
AF Piringer, Gudrun
   Decker, Jorn
   Trommet, Vera
   Kuehr, Thomas
   Heibl, Sonja
   Doerfler, Konrad
   Thaler, Josef
TI Ongoing complete response after treatment cessation with dabrafenib,
   trametinib, and cetuximab as third-line treatment in a patient with
   advanced BRAF<SUP>V600E</SUP> mutated, microsatellite-stable colon
   cancer: A case report and literature review
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE combination targeted therapy; dabrafenib; trametinib; MSS; BRAF-V600
   mutation
ID FOLFOXIRI PLUS BEVACIZUMAB; MEK INHIBITION; 1ST-LINE TREATMENT;
   DOSE-ESCALATION; POOLED ANALYSIS; COMBINED BRAF; OPEN-LABEL; SURVIVAL;
   ENCORAFENIB; COMBINATION
AB Metastatic BRAF(V600E) mutated colorectal cancer is associated with poor overall survival and modest effectiveness to standard therapies. Furthermore, survival is influenced by the microsatellite status. Patients with microsatellite-stable and BRAF(V600E) mutated colorectal cancer have the worst prognosis under the wide range of genetic subgroups in colorectal cancer. Herein, we present a patient case of an impressive therapeutic efficacy of dabrafenib, trametinib, and cetuximab as later-line therapy in a 52-year-old woman with advanced BRAF(V600E) mutated, microsatellite-stable colon cancer. This patient achieved a complete response after 1 year of triple therapy. Due to skin toxicity grade 3 and recurrent urinary tract infections due to mucosal toxicity, a therapy de-escalation to dabrafenib and trametinib was performed, and the double therapy was administered for further 41 months with ongoing complete response. For 1 year, the patient was off therapy and is still in complete remission.
C1 [Piringer, Gudrun; Trommet, Vera; Kuehr, Thomas; Heibl, Sonja; Thaler, Josef] Wels Grieskirchen Med Hosp, Dept Internal Med 4, Wels, Austria.
   [Piringer, Gudrun] Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria.
   [Piringer, Gudrun; Kuehr, Thomas; Heibl, Sonja; Doerfler, Konrad; Thaler, Josef] Johannes Kepler Univ Linz, Med Fac, Linz, Austria.
   [Decker, Jorn] Klinikum Rohrbach, Dept Internal Med, Rohrbach, Austria.
C3 Kepler University Hospital; Johannes Kepler University Linz
RP Piringer, G (corresponding author), Wels Grieskirchen Med Hosp, Dept Internal Med 4, Wels, Austria.; Piringer, G (corresponding author), Kepler Univ Hosp, Dept Hematol & Oncol, Linz, Austria.; Piringer, G (corresponding author), Johannes Kepler Univ Linz, Med Fac, Linz, Austria.
EM gudrun.piringer@kepleruniklinikum.at
CR André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Barras David, 2015, Biomark Cancer, V7, P9, DOI 10.4137/BIC.S25248
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Chu JE, 2020, CLIN CANCER RES, V26, P4599, DOI 10.1158/1078-0432.CCR-20-1024
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024
   Elez E, 2022, NAT MED, V28, P2162, DOI 10.1038/s41591-022-01976-z
   Flaherty KT, 2012, NEW ENGL J MED, V367, P1694, DOI 10.1056/NEJMoa1210093
   Flaherty KT, 2012, NEW ENGL J MED, V367, P107, DOI 10.1056/NEJMoa1203421
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Grassi E, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.601722
   Hong A, 2021, CANCER DISCOV, V11, P714, DOI 10.1158/2159-8290.CD-20-0873
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Infante JR, 2012, LANCET ONCOL, V13, P773, DOI 10.1016/S1470-2045(12)70270-X
   Jeong WJ, 2018, NPJ PRECIS ONCOL, V2, DOI 10.1038/s41698-018-0049-y
   Kanemitsu Y, 2009, JPN J CLIN ONCOL, V39, P406, DOI 10.1093/jjco/hyp035
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.162
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Mitry E, 2008, J CLIN ONCOL, V26, P4906, DOI 10.1200/JCO.2008.17.3781
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Samowitz WS, 2005, CANCER RES, V65, P6063, DOI 10.1158/0008-5472.CAN-05-0404
   Sonbol MB, 2022, ONCOLOGIST, V27, P1034, DOI 10.1093/oncolo/oyac212
   Tabernero J, 2022, ANN ONCOL, V33, pS1392, DOI 10.1016/j.annonc.2022.08.022
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Tian J, 2023, NAT MED, V29, P458, DOI 10.1038/s41591-022-02181-8
   Van Cutsem E, 2023, J CLIN ONCOL, V41, P2628, DOI 10.1200/JCO.22.01693
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Wirapati P, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3538
   Xu T, 2022, THER ADV MED ONCOL, V14, DOI 10.1177/17588359221105022
   Yaeger R, 2017, CANCER RES, V77, P6513, DOI 10.1158/0008-5472.CAN-17-0768
   Yoshino T, 2019, ANN ONCOL, V30, P124, DOI 10.1093/annonc/mdy461
NR 44
TC 3
Z9 4
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD MAY 5
PY 2023
VL 13
AR 1166545
DI 10.3389/fonc.2023.1166545
PG 8
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA G5GI9
UT WOS:000989434900001
PM 37213293
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Andrijes, R
   Hejmadi, RK
   Pugh, M
   Rajesh, S
   Novitskaya, V
   Ibrahim, M
   Overduin, M
   Tselepis, C
   Middleton, GW
   Gyorffy, B
   Beggs, AD
   Berditchevski, F
AF Andrijes, Regina
   Hejmadi, Rahul K.
   Pugh, Matthew
   Rajesh, Sundaresan
   Novitskaya, Vera
   Ibrahim, Maha
   Overduin, Michael
   Tselepis, Chris
   Middleton, Gary W.
   Gyorffy, Balazs
   Beggs, Andrew D.
   Berditchevski, Fedor
TI Tetraspanin 6 is a regulator of carcinogenesis in colorectal cancer
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
   AMERICA
LA English
DT Article
DE colorectal cancer; tetraspanin; EGFR; TGF alpha; APCmin
ID CETUXIMAB; GENE
AB Early stages of colorectal cancer (CRC) development are characterized by a complex rewiring of transcriptional networks resulting in changes in the expression of multiple genes. Here, we demonstrate that the deletion of a poorly studied tetraspanin protein Tspan6 in Apcmin/+ mice, a well-established model for premalignant CRC, resulted in increased incidence of adenoma formation and tumor size. We demonstrate that the effect of Tspan6 deletion results in the activation of EGF-dependent signaling pathways through increased production of the transmembrane form of TGF-alpha (tmTGF-alpha) associated with extracellular vesicles. This pathway is modulated by an adaptor protein syntenin-1, which physically links Tspan6 and tmTGF-alpha. In support of this, the expression of Tspan6 is frequently decreased or lost in CRC, and this correlates with poor survival. Furthermore, the analysis of samples from the epidermal growth factor receptor (EGFR)-targeting clinical trial (COIN trial) has shown that the expression of Tspan6 in CRC correlated with better patient responses to EGFR-targeted therapy involving Cetuximab. Importantly, Tspan6positive patients with tumors in the proximal colon (right-sided) and those with KRAS mutations had a better response to Cetuximab than the patients that expressed low Tspan6 levels. These results identify Tspan6 as a regulator of CRC development and a potential predictive marker for EGFR-targeted therapies in CRC beyond RAS pathway mutations.
C1 [Andrijes, Regina; Pugh, Matthew; Rajesh, Sundaresan; Novitskaya, Vera; Ibrahim, Maha; Overduin, Michael; Tselepis, Chris; Middleton, Gary W.; Beggs, Andrew D.; Berditchevski, Fedor] Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England.
   [Hejmadi, Rahul K.] Univ Hosp Birmingham Natl Hlth Serv Fdn Trust, Birmingham B15 2TH, W Midlands, England.
   [Ibrahim, Maha] Assiut Univ, South Egypt Canc Inst, Assiut 71515, Egypt.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Bioinformat, H-1094 Budapest, Hungary.
   [Gyorffy, Balazs] Semmelweis Univ, Dept Paediat 2, H-1094 Budapest, Hungary.
   [Gyorffy, Balazs] TTK Canc Biomarker Res Grp, H-1117 Budapest, Hungary.
C3 University of Birmingham; Egyptian Knowledge Bank (EKB); Assiut
   University; Semmelweis University; Semmelweis University; Hungarian
   Research Network; HUN-REN Research Centre for Natural Sciences
RP Berditchevski, F (corresponding author), Univ Birmingham, Inst Canc & Genom Sci, Birmingham B15 2TT, W Midlands, England.
EM f.berditchevski@bham.ac.uk
RI Beggs, Andrew/A-6912-2013; Gyorffy, Balazs/AAA-9135-2021; Overduin,
   Michael/AAG-3632-2020
OI Overduin, Michael/0000-0002-3114-6585; Middleton,
   Gary/0000-0001-5695-3474; Pugh, Matthew/0000-0002-6324-661X; Andrijes,
   Regina/0000-0002-9953-4787; Beggs, Andrew/0000-0003-0784-2967; Gyorffy,
   Balazs/0000-0002-5772-3766
FU Medical Research Council (MRC) research studentship [1575158]; MRC;
   Cancer Research United Kingdom (CRUK) [C1210/A4850]; CRUK; MRC
   Stratified Medicine Award for the S-CORT project [MR/M016587/1]; CRUK
   Ad-vanced Clinician Scientist Award [C31641/A23923]; MRC [MR/M016587/1,
   MR/T001755/1] Funding Source: UKRI
FX The work was supported by the Medical Research Council (MRC) research
   studentship to F.B., C.T., and A.D.B. (Ref No. 1575158) . We are
   grateful for the use of tissue samples and data from the COIN trial
   funded by the MRC and Cancer Research United Kingdom (CRUK) (Grant
   C1210/A4850) . The Stratification in Colorectal Cancer (S-CORT)
   consortium was supported by the CRUK and MRC Stratified Medicine Award
   for the S-CORT project (Ref. MR/M016587/1) . A.D.B. is currently
   supported by a CRUK Ad-vanced Clinician Scientist Award (Ref.
   C31641/A23923) . We are grateful for Mr. Steven Hayward for technical
   assistance.
CR Bilger A, 2008, CARCINOGENESIS, V29, P1825, DOI 10.1093/carcin/bgn038
   Cao DD, 2017, ONCOTARGET, V8, P53631, DOI 10.18632/oncotarget.19022
   Cushman SM, 2015, CLIN CANCER RES, V21, P1078, DOI 10.1158/1078-0432.CCR-14-2313
   Druliner BR, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21525-4
   Ghossoub R, 2020, P NATL ACAD SCI USA, V117, P5913, DOI 10.1073/pnas.1922447117
   Greco C, 2010, CANCER RES, V70, P7674, DOI 10.1158/0008-5472.CAN-09-4482
   Guix FX, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0165-0
   Hemler ME, 2014, NAT REV CANCER, V14, P49, DOI 10.1038/nrc3640
   Higginbotham JN, 2011, CURR BIOL, V21, P779, DOI 10.1016/j.cub.2011.03.043
   Ivanov AI, 2008, J CELL SCI, V121, P1803, DOI 10.1242/jcs.015842
   Kaprio T, 2020, HISTOL HISTOPATHOL, V35, P887, DOI 10.14670/HH-18-209
   Koveitypour Z, 2019, CELL BIOSCI, V9, DOI 10.1186/s13578-019-0361-4
   Latifkar A, 2018, BIOCHEM SOC T, V46, P1137, DOI 10.1042/BST20180523
   Liu J, 2017, AM J TRANSL RES, V9, P812
   Maeda K, 1998, GENOMICS, V52, P240, DOI 10.1006/geno.1998.5415
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Mauri G, 2019, CANCER TREAT REV, V73, P41, DOI 10.1016/j.ctrv.2018.12.006
   Mizukami T, 2019, DRUGS, V79, P633, DOI 10.1007/s40265-019-01113-0
   Romanska HM, 2011, J PATHOL, V223, P4, DOI 10.1002/path.2779
   Sato T, 2009, NATURE, V459, P262, DOI 10.1038/nature07935
   Shimada T, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174171
   Srivatsa S, 2017, GASTROENTEROLOGY, V153, P178, DOI 10.1053/j.gastro.2017.03.053
   Tabernero J, 2010, J CLIN ONCOL, V28, P1181, DOI 10.1200/JCO.2009.22.6043
   Uhlyarik A, 2020, CANCERS, V12, DOI 10.3390/cancers12030614
   Wang YT, 2012, J BIOL CHEM, V287, P34626, DOI 10.1074/jbc.M112.390401
   Xu L, 2017, ONCOTARGET, V8, P74703, DOI 10.18632/oncotarget.20345
   Yang J, 2016, TUMOR BIOL, V37, P11645, DOI 10.1007/s13277-016-5140-9
NR 28
TC 22
Z9 25
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD SEP 28
PY 2021
VL 118
IS 39
AR e2011411118
DI 10.1073/pnas.2011411118
PG 10
WC Multidisciplinary Sciences
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics
GA WC1DN
UT WOS:000704004200010
PM 34521767
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Nemeth, Z
   Wijker, W
   Lengyel, Z
   Hitre, E
   Borbely, K
AF Nemeth, Zsuzsanna
   Wijker, Wouter
   Lengyel, Zsolt
   Hitre, Erika
   Borbely, Katalin
TI Metabolic Parameters as Predictors for Progression Free and Overall
   Survival of Patients with Metastatic Colorectal Cancer
SO PATHOLOGY & ONCOLOGY RESEARCH
LA English
DT Article
DE Standardized added metabolic activity; FDG-PET; CT; Interim; Metastatic
   colorectal cancer; Overall survival; Progression free survival; Response
ID POSITRON-EMISSION-TOMOGRAPHY; TUMOR RESPONSE; F-18-FDG PET/CT;
   FDG-PET/CT; CHEMOTHERAPY; MUTATIONS; CETUXIMAB
AB We tested the prognostic relevance of metabolic parameters and their relative changes in patients with metastatic colorectal cancer (mCRC) treated with monoclonal antibody and chemotherapy. SUVmax(standardized uptake volume), SAM (standardized added metabolic activity) and TLG (total lesion glycolysis) are assessed with(18)F-fluorodeoxyglucosepositron emission tomography and computed tomography (FDG-PET/CT) to evaluate total metabolic activity of malignant processes. Our purpose was to investigate the change of glucose metabolism in relation to PFS (progression free survival) and OS (overall survival). Fifty-three patients with mCRC with at least one measurable liver metastasis were included in this prospective, multi-center, early exploratory study. All patients were treated with first-line chemotherapy and targeted therapy. Metabolic parameters, like SUVmax, SAM, normalized SAM (NSAM) and TLG were assessed by FDG-PET/CT, carried out at baseline (scan-1) and after two therapeutic cycle (scan-2). Our results suggested neither SUVmax nor TLG have such prognostic value as NSAM in liver metastases of colorectal cancer. The parameters after the two cycles of chemotherapy proved to be better predictors of the clinical outcome. NSAM after two cycles of treatment has a statistically significant predictive value on OS, while SAM was predictive to the PFS. The follow up normalized SAM after 2 cycles of first line oncotherapy was demonstrated to be useful as prognostic biomarkers for OS in metastatic colorectal cancer. We should introduce this measurement in metastatic colorectal cancer if there is at least one metastasis in the liver.
C1 [Nemeth, Zsuzsanna; Hitre, Erika] Natl Inst Oncol, Chemotherapy & Clin Pharmacol Dept B, Rath Gyorgy Utca 7-9, H-1122 Budapest, Hungary.
   [Nemeth, Zsuzsanna] Szent Margit Hosp, Oncol Dept, Becsi Ut 132, H-1032 Budapest, Hungary.
   [Wijker, Wouter] Auxiliis Pharma Ltd, Bokor Utca 17, H-1037 Budapest, Hungary.
   [Lengyel, Zsolt] Pozitron Diagnost Ltd, Hunyadi Ut 9-11, H-1117 Budapest, Hungary.
   [Borbely, Katalin] Natl Inst Oncol, PET Ambulatory Dept, Rath Gyorgy Utca 7-9, H-1122 Budapest, Hungary.
C3 National Institute of Oncology Hungary; National Institute of Oncology
   Hungary
RP Nemeth, Z (corresponding author), Natl Inst Oncol, Chemotherapy & Clin Pharmacol Dept B, Rath Gyorgy Utca 7-9, H-1122 Budapest, Hungary.; Nemeth, Z (corresponding author), Szent Margit Hosp, Oncol Dept, Becsi Ut 132, H-1032 Budapest, Hungary.
EM zsnemethzsuzsanna@gmail.com; wouter.wijler@auxiliis-pharma.com;
   zsolt.lengyel@pet.hu; hitre@oncol.hu; k.borbely@oncol.hu
FU National Institute of Oncology; Pozitron Diagnosztika Kft.
FX Open access funding provided by National Institute of Oncology. This
   research did not receive any specific grant from funding agencies in the
   public, commercial, or not-for-profit sectors. The PET/CT examinations
   were co-financed by the Pozitron Diagnosztika Kft., workplace of the
   author Lengyel Zsolt.
CR Adam R, 2012, ONCOLOGIST, V17, P1225, DOI 10.1634/theoncologist.2012-0121
   Biasco G, 2006, CANCER TREAT REV, V32, P214, DOI 10.1016/j.ctrv.2005.12.011
   Brulé SY, 2015, EUR J CANCER, V51, P1405, DOI 10.1016/j.ejca.2015.03.015
   Buvat I, 2012, EUR J NUCL MED MOL I, V39, P1628, DOI 10.1007/s00259-012-2172-2
   Byström P, 2009, ANN ONCOL, V20, P1057, DOI 10.1093/annonc/mdn744
   de Geus-Oei LF, 2009, J NUCL MED, V50, p43S, DOI 10.2967/jnumed.108.057224
   Dempke WCM, 2010, ANTICANCER RES, V30, P4673
   Engelmann BE, 2014, ONCOLOGIST, V19, P164, DOI 10.1634/theoncologist.2013-0229
   Gerber DE, 2008, AM FAM PHYSICIAN, V77, P311
   Hendlisz A, 2012, ANN ONCOL, V23, P1687, DOI 10.1093/annonc/mdr554
   Kawada K, 2012, CLIN CANCER RES, V18, P1696, DOI 10.1158/1078-0432.CCR-11-1909
   Kim DH, 2012, EUR J RADIOL, V81, P3542, DOI 10.1016/j.ejrad.2012.02.012
   Krikelis D, 2014, ANTICANCER RES, V34, P2571
   Liu FY, 2015, CLIN NUCL MED, V40, P200, DOI 10.1097/RLU.0000000000000693
   Lovinfosse P, 2016, BRIT J RADIOL, V89, DOI 10.1259/bjr.20160212
   Maisonobe JA, 2013, EUR J NUCL MED MOL I, V40, P166, DOI 10.1007/s00259-012-2274-x
   Maus MKH, 2013, J CLIN ONCOL, V31
   Mertens J, 2013, EUR J NUCL MED MOL I, V40, P1214, DOI 10.1007/s00259-013-2421-z
   Sheth Ketan R, 2005, Clin Colon Rectal Surg, V18, P215, DOI 10.1055/s-2005-916282
   Ulanja MB, 2019, J ONCOL, V2019, DOI 10.1155/2019/4315032
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Votrubova J, 2006, EUR J NUCL MED MOL I, V33, P779, DOI 10.1007/s00259-006-0072-z
   Young H, 1999, EUR J CANCER, V35, P1773, DOI 10.1016/S0959-8049(99)00229-4
NR 23
TC 6
Z9 6
U1 0
U2 1
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 1219-4956
EI 1532-2807
J9 PATHOL ONCOL RES
JI Pathol. Oncol. Res.
PD OCT
PY 2020
VL 26
IS 4
BP 2683
EP 2691
DI 10.1007/s12253-020-00865-5
EA JUL 2020
PG 9
WC Oncology; Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Pathology
GA NJ1KL
UT WOS:000548093000003
PM 32661836
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Eskandari, E
   Mahjoubi, F
   Motalebzadeh, J
AF Eskandari, Elaheh
   Mahjoubi, Frouzandeh
   Motalebzadeh, Jamshid
TI An integrated study on TFs and miRNAs in colorectal cancer metastasis
   and evaluation of three co-regulated candidate genes as prognostic
   markers
SO GENE
LA English
DT Article
DE Colorectal cancer metastasis; Prognosis; Target therapy; Wnt signaling
   pathway; Hippo signaling pathway; DETFs; DEmiRs; GRN; LEF1; ETV4; FABP6
ID BOX PROTEIN A1; C-MYC; REGULATORY NETWORKS; EXPRESSION DATA; BIGLYCAN;
   ETV4; OVEREXPRESSION; PROLIFERATION; PROGRESSION; ALGORITHM
AB Molecular alterations that occur in cancer have the potential to be considered as either cancer biomarkers or targeted therapies or even both. In the presented study, we aimed to elucidate the gene regulatory network of metastatic colorectal cancer using data acquired from microarrays to reach the most common DEGs in colorectal cancer metastasis and find their possible regulatory mechanism by DETFs and DEmiRs. In this regards, seven microarray datasets were employed to assess the most important DEGs, DETFs and DEmiRs in colorectal cancer metastasis. Afterward, GRN based on DETFs and DEmiRs were constructed. Also ARACNE algorithm was used to construct an accurate GRN. GRN was analyzed structurally and then, two DETFs (LEF1 and ETV4) and a less-well known DEG (FABP6) by real time qRT-PCR in 50 patients with colorectal cancer were quantified. The constructed GRN highlighted the importance of some DETFs and DEmiRs in colorectal cancer metastasis. Interestingly the gene expression analysis by qRT-PCR on three candidate genes (LEF1, ETV4 and FABP6) indicated that the three genes were co-expressed in tumor samples, and were significantly associated with metastasis in colorectal cancer. Therefore, our experimental results proved a part of our comprehensive data analysis and system biology results. In summary, according to our empirical study we found the importance of three candidate genes as the potent prognostic factors in colorectal cancer metastasis. Also our study in a holistic insight on gene regulatory mechanism revealed the importance of some gene regulatory factors (DETFs and DEmiRs) and their potential as prognostic factors and/or targets in molecular targeted therapies in colorectal cancer.
C1 [Eskandari, Elaheh; Mahjoubi, Frouzandeh; Motalebzadeh, Jamshid] NIGEB, Inst Med Biotechnol, Dept Clin Genet, Km 15,Tehran Karaj Highway,POB 14965-161, Tehran, Iran.
RP Motalebzadeh, J (corresponding author), NIGEB, Inst Med Biotechnol, Dept Clin Genet, Km 15,Tehran Karaj Highway,POB 14965-161, Tehran, Iran.
EM motalebzade@gmail.com
RI Motalebzadeh, Jamshid/AAM-7499-2021; mahjoubi, frouzandeh/AHC-2557-2022
OI Mahjoubi, Frouzandeh/0000-0002-6880-3606; Eskandari,
   Elaheh/0000-0003-2457-3682; Motalebzadeh, Jamshid/0000-0002-7780-0933
FU NIGEB
FX This research was partially supported by NIGEB.
CR Alexandrov LB, 2013, NATURE, V500, P415, DOI 10.1038/nature12477
   [Anonymous], CANC EPIDEMIOL BIOMA
   [Anonymous], J CLIN INVEST
   [Anonymous], CANC RES
   [Anonymous], 2017, ONCOTARGET, DOI DOI 10.18632/ONCOTARGET.23173
   Aytes A, 2013, P NATL ACAD SCI USA, V110, pE3506, DOI 10.1073/pnas.1303558110
   Bayrer JR, 2015, P NATL ACAD SCI USA, V112, P2467, DOI 10.1073/pnas.1500978112
   Carvalho BS, 2010, BIOINFORMATICS, V26, P2363, DOI 10.1093/bioinformatics/btq431
   Chibon F, 2010, NAT MED, V16, P781, DOI 10.1038/nm.2174
   Del Rio M, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0074599
   Edge SB, 2010, ANN SURG ONCOL, V17, P1471, DOI 10.1245/s10434-010-0985-4
   Garcia O, 2007, BIOINFORMATICS, V23, P394, DOI 10.1093/bioinformatics/btl605
   Gu XH, 2012, CLIN EXP MED, V12, P195, DOI 10.1007/s10238-011-0155-4
   Helling TS, 2014, ANN SURG ONCOL, V21, P501, DOI 10.1245/s10434-013-3297-7
   Hu L, 2014, ONCOTARGET, V5, P1885, DOI 10.18632/oncotarget.1871
   Jacobsen F, 2017, NEOPLASIA, V19, P707, DOI 10.1016/j.neo.2017.06.003
   Jägle S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1007109
   Jiang Q., 2008, NUCL ACIDS RES, V37, P098
   Jin HJ, 2013, CANCER RES, V73, P3725, DOI 10.1158/0008-5472.CAN-12-3468
   Kim M, 2014, BMB REP, V47, P540, DOI 10.5483/BMBRep.2014.47.10.177
   Klamt S, 2007, BMC SYST BIOL, V1, DOI 10.1186/1752-0509-1-2
   Kriegl L, 2010, J TRANSL MED, V8, DOI 10.1186/1479-5876-8-123
   Lachmann A, 2010, BIOINFORMATICS, V26, P2438, DOI 10.1093/bioinformatics/btq466
   Le DH, 2011, BIOINFORMATICS, V27, P2767, DOI 10.1093/bioinformatics/btr466
   Lee KS, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2770-7
   Levin B, 2008, CA-CANCER J CLIN, V58, P130, DOI 10.3322/CA.2007.0018
   Liu F, 2016, PLOS COMPUT BIOL, V12, DOI 10.1371/journal.pcbi.1005024
   Liu W, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166115
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lu J, 2005, NATURE, V435, P834, DOI 10.1038/nature03702
   Ma WQ, 2016, MOL MED REP, V14, P2625, DOI 10.3892/mmr.2016.5583
   Maak M, 2013, ANN SURG, V257, P1053, DOI 10.1097/SLA.0b013e31827c1180
   Mandrekar Sumithra J, 2011, Clin Investig (Lond), V1, P1629
   Margolin AA, 2006, BMC BIOINFORMATICS, V7, DOI 10.1186/1471-2105-7-S1-S7
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Mi HY, 2017, NUCLEIC ACIDS RES, V45, pD183, DOI 10.1093/nar/gkw1138
   Moss AC, 2006, BIOCHEM BIOPH RES CO, V345, P216, DOI 10.1016/j.bbrc.2006.04.094
   Nadolny C, 2015, CANCER BIOL THER, V16, P997, DOI 10.1080/15384047.2015.1045693
   Najdi R., 2011, J Carcinog, V10
   Obenauf AC, 2015, TRENDS CANCER, V1, P76, DOI 10.1016/j.trecan.2015.07.009
   Ohmachi T, 2006, CLIN CANCER RES, V12, P5090, DOI 10.1158/1078-0432.CCR-05-2045
   Pellecchia A, 2012, ONCOGENESIS, V1, DOI 10.1038/oncsis.2012.20
   Pizzini S, 2013, BMC GENOMICS, V14, DOI 10.1186/1471-2164-14-589
   Praslickova D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050810
   Reid JF, 2012, MOL CANCER RES, V10, P504, DOI 10.1158/1541-7786.MCR-11-0342
   Ritchie ME, 2015, NUCLEIC ACIDS RES, V43, DOI 10.1093/nar/gkv007
   Rochlitz CF, 1996, ONCOLOGY, V53, P448
   Ruepp A, 2010, GENOME BIOL, V11, DOI 10.1186/gb-2010-11-1-r6
   Said AH, 2014, CANCERS, V6, P366, DOI 10.3390/cancers6010366
   Sandelin A, 2004, NUCLEIC ACIDS RES, V32, pD91, DOI 10.1093/nar/gkh012
   Santiago L, 2017, AM J CANCER RES, V7, P1389
   SATO K, 1994, EUR J CANCER, V30A, P1113, DOI 10.1016/0959-8049(94)90468-5
   Scardoni G, 2009, BIOINFORMATICS, V25, P2857, DOI 10.1093/bioinformatics/btp517
   Schoonjans K, 2005, P NATL ACAD SCI USA, V102, P2058, DOI 10.1073/pnas.0409756102
   Sheffer M, 2009, P NATL ACAD SCI USA, V106, P7131, DOI 10.1073/pnas.0902232106
   Siegel R. L., 2017, CA-CANCER J CLIN, V67, P177, DOI DOI 10.3322/caac.21395
   Singovski G, 2016, J MOL CELL BIOL, V8, P157, DOI 10.1093/jmcb/mjv034
   Tsukamoto S, 2011, CLIN CANCER RES, V17, P2444, DOI 10.1158/1078-0432.CCR-10-2884
   Wang J, 2010, NUCLEIC ACIDS RES, V38, pD119, DOI 10.1093/nar/gkp803
   Wang WJ, 2013, DIS MARKERS, V2013, DOI 10.1155/2013/983981
   Wingender E, 1996, NUCLEIC ACIDS RES, V24, P238, DOI 10.1093/nar/24.1.238
   Wrzodek C, 2013, BIOINFORMATICS, V29, P506, DOI 10.1093/bioinformatics/bts709
   Xiao J, 2017, BIOCHEM BIOPH RES CO, V486, P1062, DOI 10.1016/j.bbrc.2017.03.163
   Yamaguchi N, 2017, J BIOL CHEM, V292, P8136, DOI 10.1074/jbc.M116.763276
   Yang JH, 2013, NUCLEIC ACIDS RES, V41, pD177, DOI 10.1093/nar/gks1060
   Yuan ZY, 2014, ONCOTARGETS THER, V7, P1733, DOI 10.2147/OTT.S66692
   Zack TI, 2013, NAT GENET, V45, P1134, DOI 10.1038/ng.2760
   Zhang XJ, 2012, BIOINFORMATICS, V28, P98, DOI 10.1093/bioinformatics/btr626
NR 68
TC 19
Z9 19
U1 0
U2 32
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 0378-1119
EI 1879-0038
J9 GENE
JI Gene
PD DEC 30
PY 2018
VL 679
BP 150
EP 159
DI 10.1016/j.gene.2018.09.003
PG 10
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA GX9CO
UT WOS:000448096300018
PM 30193961
DA 2025-01-04
ER

PT J
AU Del Vecchio, F
   Mastroiaco, V
   Di Marco, A
   Compagnoni, C
   Capece, D
   Zazzeroni, F
   Capalbo, C
   Alesse, E
   Tessitore, A
AF Del Vecchio, Filippo
   Mastroiaco, Valentina
   Di Marco, Antinisca
   Compagnoni, Chiara
   Capece, Daria
   Zazzeroni, Francesca
   Capalbo, Carlo
   Alesse, Edoardo
   Tessitore, Alessandra
TI Next-generation sequencing: recent applications to the analysis of
   colorectal cancer
SO JOURNAL OF TRANSLATIONAL MEDICINE
LA English
DT Review
DE Next-generation sequencing; Colorectal cancer; Precision medicine;
   Targeted therapy
ID HUMAN BREAST; 1ST-LINE TREATMENT; CLINICAL-ONCOLOGY; LIVER METASTASES;
   GUT MICROBIOTA; TUMOR; MUTATION; GENE; PLATFORMS; CETUXIMAB
AB Since the establishment of the Sanger sequencing method, scientists around the world focused their efforts to progress in the field to produce the utmost technology. The introduction of next-generation sequencing (NGS) represents a revolutionary step and promises to lead to massive improvements in our understanding on the role of nucleic acids functions. Cancer research began to use this innovative and highly performing method, and interesting results started to appear in colorectal cancer (CRC) analysis. Several studies produced high-quality data in terms of mutation discovery, especially about actionable or less frequently mutated genes, epigenetics, transcriptomics. Analysis of results is unveiling relevant perspectives aiding to evaluate the response to therapies. Novel evidences have been presented also in other directions such as gut microbiota or CRC circulating tumor cells. However, despite its unquestioned potential, NGS poses some issues calling for additional studies. This review intends to offer a view of the state of the art of NGS applications to CRC through examination of the most important technologies and discussion of recent published results.
C1 [Del Vecchio, Filippo] Univ Southampton, Div Canc Sci, Southampton SO16 6YD, Hants, England.
   [Mastroiaco, Valentina; Di Marco, Antinisca; Compagnoni, Chiara; Zazzeroni, Francesca; Alesse, Edoardo; Tessitore, Alessandra] Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.
   [Capece, Daria] Imperial Coll London, Dept Med, Ctr Cell Signaling & Inflammat, London W12 0NN, England.
   [Capalbo, Carlo] Univ Roma La Sapienza, Dept Mol Med, I-00161 Rome, Italy.
C3 University of Southampton; University of L'Aquila; Imperial College
   London; Sapienza University Rome
RP Tessitore, A (corresponding author), Univ Aquila, Dept Biotechnol & Appl Clin Sci, I-67100 Laquila, Italy.
EM alessandra.tessitore@univaq.it
RI Di Marco, Andrea/ABU-6027-2022; Capece, Daria/AFR-1769-2022; Del
   Vecchio, Filippo/AAL-7354-2021
OI tessitore, alessandra/0000-0002-7663-2210; Capece,
   Daria/0000-0003-3126-2014; Del Vecchio, Filippo/0000-0003-1894-888X;
   Compagnoni, Chiara/0000-0002-3620-1854
FU MIUR-FIRB [RBAP10A9H9]; Programma Operativo Nazionale Ricerca e
   Innovazione (PON RI) [DOT13SR6G7]
FX This work was supported by MIUR-FIRB Grant No. RBAP10A9H9 to Edoardo
   Alesse. Fellowship to C. Compagnoni funded by the "Programma Operativo
   Nazionale Ricerca e Innovazione (PON R&I 2014-2020, PhD Programme code
   DOT13SR6G7)".
CR Adua D, 2017, MOL CLIN ONCOL, V7, P113, DOI 10.3892/mco.2017.1270
   Ahn J, 2013, JNCI-J NATL CANCER I, V105, P1907, DOI 10.1093/jnci/djt300
   [Anonymous], BR J CANC
   [Anonymous], J CLIN ONCOL
   [Anonymous], GLOBOCAN 2012 V 1 0
   [Anonymous], MOL ONCOL
   [Anonymous], MOL DIAGN THER
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Ashktorab Hassan, 2016, Next Gener Seq Appl, V3
   Ashktorab H, 2017, ONCOTARGET, V8, P7852, DOI 10.18632/oncotarget.13977
   Ashktorab H, 2013, EPIGENETICS-US, V8, P807, DOI 10.4161/epi.25497
   Bai J, 2015, J HUM GENET, V60, P589, DOI 10.1038/jhg.2015.71
   Bánky B, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-83
   Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bentley DR, 2008, NATURE, V456, P53, DOI 10.1038/nature07517
   Berman BP, 2012, NAT GENET, V44, P40, DOI 10.1038/ng.969
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Boland CR, 2010, GASTROENTEROLOGY, V138, P2073, DOI [10.1053/j.gastro.2009.12.064, 10.1053/j.gastro.2010.04.024]
   Bruera G, 2015, CRIT REV ONCOL HEMAT, V93, P190, DOI 10.1016/j.critrevonc.2014.10.004
   Carneiro MO, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-375
   Chan AOO, 2002, AM J PATHOL, V160, P1823, DOI 10.1016/S0002-9440(10)61128-5
   Chen JH, 2016, SCI REP-UK, V6, DOI 10.1038/srep34420
   Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230
   Cirulli ET, 2010, NAT REV GENET, V11, P415, DOI 10.1038/nrg2779
   Claesson MJ, 2010, NUCLEIC ACIDS RES, V38, DOI 10.1093/nar/gkq873
   Darwanto A, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3328-z
   Ding L, 2012, NATURE, V481, P506, DOI 10.1038/nature10738
   Dohm JC, 2008, NUCLEIC ACIDS RES, V36, DOI 10.1093/nar/gkn425
   Dong L, 2015, CURR GENOMICS, V16, P253, DOI 10.2174/1389202915666150511205313
   Eid J, 2009, SCIENCE, V323, P133, DOI 10.1126/science.1162986
   Endrullat C, 2016, APPL TRANSL GENOM, V10, P2, DOI 10.1016/j.atg.2016.06.001
   Fodde R, 2002, EUR J CANCER, V38, P867, DOI 10.1016/S0959-8049(02)00040-0
   Frey KG, 2014, BMC GENOMICS, V15, DOI 10.1186/1471-2164-15-96
   Fu YG, 2011, GENOME RES, V21, P741, DOI 10.1101/gr.115295.110
   Gagnière J, 2016, WORLD J GASTROENTERO, V22, P501, DOI 10.3748/wjg.v22.i2.501
   Gao R, 2017, EUR J CLIN MICROBIOL, V36, P757, DOI 10.1007/s10096-016-2881-8
   Geissler AL, 2017, ONCOTARGET, V8, P17164, DOI 10.18632/oncotarget.15211
   Gong J, 2017, ONCOTARGET, V8, P42198, DOI 10.18632/oncotarget.15030
   Goodwin S, 2016, NAT REV GENET, V17, P333, DOI 10.1038/nrg.2016.49
   Goswami RS, 2016, AM J CLIN PATHOL, V145, P222, DOI 10.1093/ajcp/aqv023
   Grada A, 2013, J INVEST DERMATOL, V133, pE1, DOI 10.1038/jid.2013.248
   Guan YF, 2012, CHIN J CANCER, V31, P463, DOI 10.5732/cjc.012.10216
   Hamfjord J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034150
   Han SW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064271
   Hansen KD, 2011, NAT GENET, V43, P768, DOI 10.1038/ng.865
   Harismendy O, 2009, GENOME BIOL, V10, DOI 10.1186/gb-2009-10-3-r32
   Harlé A, 2016, TARGET ONCOL, V11, P363, DOI 10.1007/s11523-015-0404-7
   Heitzer E, 2013, CANCER RES, V73, P2965, DOI 10.1158/0008-5472.CAN-12-4140
   Hinoue T, 2012, GENOME RES, V22, P271, DOI 10.1101/gr.117523.110
   Hinrichs JWJ, 2015, AM J CLIN PATHOL, V143, P573, DOI 10.1309/AJCP40XETVYAMJPY
   Hodges E, 2007, NAT GENET, V39, P1522, DOI 10.1038/ng.2007.42
   Hoppman-Chaney N, 2010, CLIN CHEM, V56, P1297, DOI 10.1373/clinchem.2010.145441
   Hsu HC, 2016, ONCOTARGET, V7, P22257, DOI 10.18632/oncotarget.8076
   Jain M, 2016, GENOME BIOL, V17, DOI 10.1186/s13059-016-1103-0
   Jaratlerdsiri W, 2017, ONCOTARGET, V8, P23588, DOI 10.18632/oncotarget.15802
   Jobin C, 2012, NAT REV GASTRO HEPAT, V9, P694, DOI 10.1038/nrgastro.2012.220
   Ju YS, 2011, NAT GENET, V43, P745, DOI 10.1038/ng.872
   Kalla R, 2014, BMJ-BRIT MED J, V349, DOI 10.1136/bmj.g6670
   Kamalakaran S, 2013, MOL ONCOL, V7, P743, DOI 10.1016/j.molonc.2013.04.008
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kastrinos F, 2011, CANCER J, V17, P405, DOI 10.1097/PPO.0b013e318237e408
   Koduru Srinivas V, 2017, J Genomics, V5, P16, DOI 10.7150/jgen.18856
   Koren S, 2012, NAT BIOTECHNOL, V30, P692, DOI 10.1038/nbt.2280
   Kothari N, 2014, J CLIN PATHOL, V67, P764, DOI 10.1136/jclinpath-2014-202405
   Labianca R, 2010, CRIT REV ONCOL HEMAT, V74, P106, DOI 10.1016/j.critrevonc.2010.01.010
   Lee CY, 2013, TRANSL CANCER RES, V2, P33, DOI 10.3978/j.issn.2218-676X.2013.02.09
   Lee JR, 2016, BMC CANCER, V16, DOI 10.1186/s12885-016-2596-3
   Lee SJ, 2015, ONCOTARGET, V6, P39028, DOI 10.18632/oncotarget.5494
   Li MM, 2017, J MOL DIAGN, V19, P4, DOI 10.1016/j.jmoldx.2016.10.002
   Li XX, 2014, INT J CLIN EXP PATHO, V7, P3763
   Li XX, 2014, INT J CLIN EXP PATHO, V7, P2729
   Liu LF, 2013, DIS COLON RECTUM, V56, P158, DOI 10.1097/DCR.0b013e318279eb30
   Liu L, 2012, J BIOMED BIOTECHNOL, DOI 10.1155/2012/251364
   Loman NJ, 2012, NAT BIOTECHNOL, V30, P434, DOI 10.1038/nbt.2198
   Loose MW, 2017, HUM MOL GENET, V26, pR202, DOI 10.1093/hmg/ddx287
   Luo HM, 2011, BMC GENOMICS, V12, DOI 10.1186/1471-2164-12-S5-S5
   Malapelle U, 2016, J CLIN PATHOL, V69, P767, DOI 10.1136/jclinpath-2015-203403
   Matthijs G, 2016, EUR J HUM GENET, V24, P1515, DOI 10.1038/ejhg.2016.63
   Meyerson M, 2010, NAT REV GENET, V11, P685, DOI 10.1038/nrg2841
   Misyura M, 2016, J MOL DIAGN, V18, P842, DOI 10.1016/j.jmoldx.2016.06.004
   Morris AR, 2012, CLIN CANCER RES, V18, P5256, DOI 10.1158/1078-0432.CCR-12-0543
   Mu WB, 2016, J MOL DIAGN, V18, P923, DOI 10.1016/j.jmoldx.2016.07.006
   Nakamura K, 2011, NUCLEIC ACIDS RES, V39, DOI 10.1093/nar/gkr344
   Neerincx M, 2015, ONCOGENESIS, V4, DOI 10.1038/oncsis.2015.29
   Nielsen M., 1993, GeneReviews
   Ozretic L, 2012, ONKOLOGIE, V35, P8, DOI 10.1159/000334823
   Peeters M, 2013, CLIN CANCER RES, V19, P1902, DOI 10.1158/1078-0432.CCR-12-1913
   Quail MA, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-341
   Rachiglio AM, 2016, ONCOTARGET, V7, P66595, DOI 10.18632/oncotarget.10704
   Röhr C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067461
   Russo G, 2015, APPL TRANSL GENOM, V7, P32, DOI 10.1016/j.atg.2015.08.006
   SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463
   Schadt EE, 2010, HUM MOL GENET, V19, pR227, DOI 10.1093/hmg/ddq416
   Sebastian S, 2014, J CROHNS COLITIS, V8, P5, DOI 10.1016/j.crohns.2013.04.008
   Seshagiri S, 2012, NATURE, V488, P660, DOI 10.1038/nature11282
   Shanmugam V, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-36
   Sinha R, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0152126
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Slattery ML, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0292-9
   Slattery ML, 2017, GENES CHROMOSOM CANC
   Smith BC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040425
   Snezhkina AV, 2016, BMC GENOMICS, V17, DOI 10.1186/s12864-016-3351-5
   Stadler ZK, 2016, J CLIN ONCOL, V34, P2141, DOI 10.1200/JCO.2015.65.1067
   Sultan M, 2008, SCIENCE, V321, P956, DOI 10.1126/science.1160342
   Taieb J, 2017, ANN ONCOL, V28, P824, DOI 10.1093/annonc/mdw687
   Talseth-Palmer BA, 2016, CANCER MED-US, V5, P929, DOI 10.1002/cam4.628
   Tessitore A, 2016, ANTI-CANCER AGENT ME, V16, P7, DOI 10.2174/1871520615666150824153358
   Van Blarigan EL, 2015, J CLIN ONCOL, V33, P1825, DOI 10.1200/JCO.2014.59.7799
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Vasen HFA, 2013, GUT, V62, P812, DOI 10.1136/gutjnl-2012-304356
   Vilar E, 2010, NAT REV CLIN ONCOL, V7, P153, DOI 10.1038/nrclinonc.2009.237
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Watanabe T, 2012, J CLIN ONCOL, V30, P2256, DOI 10.1200/JCO.2011.38.6490
   Wei XM, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029500
   Winter SE, 2013, EMBO REP, V14, P319, DOI 10.1038/embor.2013.27
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Worthley Daniel L, 2010, Clin Biochem Rev, V31, P31
   Wu YA, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041001
   Yang BY, 2015, J CLIN ONCOL, V33, P885, DOI 10.1200/JCO.2014.58.3831
NR 120
TC 67
Z9 69
U1 0
U2 19
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1479-5876
J9 J TRANSL MED
JI J. Transl. Med.
PD DEC 8
PY 2017
VL 15
AR 246
DI 10.1186/s12967-017-1353-y
PG 19
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FP4CG
UT WOS:000417564000001
PM 29221448
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Cui, J
   Xiong, Y
   Sun, M
   Gu, XY
   Liu, YT
   Zhong, LH
   Hong, XH
   Liu, L
AF Cui, Jin
   Xiong, Ying
   Sun, Min
   Gu, Xinyue
   Liu, Yuting
   Zhong, Luhui
   Hong, Xiaohua
   Liu, Li
TI Trends in immune-related adverse events for colorectal cancer: A
   bibliometric analysis
SO FRONTIERS IN ONCOLOGY
LA English
DT Article
DE colorectal cancer; bibliometric analysis; adverse events; immune;
   co-occurrence
ID SOLID TUMORS; NIVOLUMAB; SAFETY
AB PurposeWe used bibliometric methods to assess the global scientific output on the IRAEs for colorectal cancer and to explore the current status and trends in the field over the last three decades. MethodsStudies on immune-related adverse events for colorectal cancer published from 1996 to 2022 were retrieved from the Web of Science. For quantitative and qualitative assessments of publication outputs and author contributions, the R bibliometrix package was used. VOSviewer was used to construct networks based on the co-authorship of countries/institutions/authors, co-citation analysis of journals/references, citation analysis of documents, and co-occurrence of keywords. ResultsA total of 237 relevant articles were included in the final analysis. The number of publications has increased significantly over time. The countries and institutions that contributed most to the field were the USA and the University of Texas MD Anderson Cancer Center. Jefferey Schlom was the most productive author, ranking first in cited authors. The most cited document was Topalian et al. in The New England Journal of Medicine (2012). The journals with the highest number of selected articles and citations were The New England Journal of Medicine and the Journal of Clinical Oncology, respectively. Co-occurrence analysis showed that IRAEs for colorectal cancer were associated with immunotherapy, open-label, chemotherapy, nivolumab, and PD-1. Trend analysis showed that immune checkpoint inhibitors, gut-microbiota, inflammatory-bowel disease, and PD-1has been on the rise in recent years to IRAEs for colorectal cancer. ConclusionOur bibliometric analysis showed that studying IRAEs for colorectal cancer is increasingly a hot topic. The focus of the research had evolved from traditional treatment modalities such as targeted therapy to gut microbiota. Inflammatory bowel disease may be a future research hotspot of IRAEs for colorectal cancer.
C1 [Cui, Jin; Xiong, Ying; Sun, Min; Gu, Xinyue; Liu, Yuting; Zhong, Luhui; Hong, Xiaohua; Liu, Li] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China.
C3 Huazhong University of Science & Technology
RP Hong, XH; Liu, L (corresponding author), Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Canc Ctr, Wuhan, Hubei, Peoples R China.
EM hongxiaohua008@163.com; liulist2013@163.com
RI Cui, Jin/HDL-7327-2022
OI Sun, Min/0000-0002-0918-5254; Cui, Jin/0000-0002-1238-0990;
   /0009-0006-1337-808X
CR Akkin S, 2021, MOLECULES, V26, DOI 10.3390/molecules26113382
   Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937
   Aria M, 2017, J INFORMETR, V11, P959, DOI 10.1016/j.joi.2017.08.007
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   BRAY F, 2018, CA-CANCER J CLIN, V68, P394, DOI [DOI 10.3322/CANJCLIN.49.1.33, DOI 10.3322/CAAC.21492]
   Brzezianska E, 2006, MUTAT RES-FUND MOL M, V599, P26, DOI 10.1016/j.mrfmmm.2005.12.013
   Cheng TL, 1999, BIOCONJUGATE CHEM, V10, P520, DOI 10.1021/bc980143z
   Clemente JC, 2018, BMJ-BRIT MED J, V360, DOI 10.1136/bmj.j5145
   Diaz-Ruiz A, 2018, NEUROL INDIA, V66, P96, DOI 10.4103/0028-3886.222880
   Guzman-Ortiz E, 2021, J ADV NURS, V77, P537, DOI 10.1111/jan.14594
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Roldan-Valadez E, 2019, IRISH J MED SCI, V188, P939, DOI 10.1007/s11845-018-1936-5
   Schmitt M, 2021, NAT REV IMMUNOL, V21, P653, DOI 10.1038/s41577-021-00534-x
   Shah SM, 2021, PSYCHOTHER PSYCHOSOM, V90, P425, DOI 10.1159/000516185
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   van Eck NJ, 2017, SCIENTOMETRICS, V111, P1053, DOI 10.1007/s11192-017-2300-7
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Weng JY, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01294-4
   Xavier RJ, 2007, NATURE, V448, P427, DOI 10.1038/nature06005
   Yachida S, 2019, NAT MED, V25, P968, DOI 10.1038/s41591-019-0458-7
NR 23
TC 1
Z9 1
U1 3
U2 25
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD OCT 27
PY 2022
VL 12
AR 1024321
DI 10.3389/fonc.2022.1024321
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA 6J1AR
UT WOS:000886561800001
PM 36387099
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Kamalapuram, SK
   Kanwar, RK
   Roy, K
   Chaudhary, R
   Sehgal, R
   Kanwar, JR
AF Kamalapuram, Sishir K.
   Kanwar, Rupinder K.
   Roy, Kislay
   Chaudhary, Rajneesh
   Sehgal, Rakesh
   Kanwar, Jagat R.
TI Theranostic multimodular potential of zinc-doped ferrite-saturated
   metal-binding protein-loaded novel nanocapsules in cancers
SO INTERNATIONAL JOURNAL OF NANOMEDICINE
LA English
DT Article
DE theranostic; multimodular cancer therapy; nanocapsules; nanomedicine;
   real-time imaging
ID IRON; LACTOFERRIN; CALCIUM; SURVIVIN; THERAPY; CELLS; THERAPEUTICS;
   MANAGEMENT; INHIBITOR; APOPTOSIS
AB The present study successfully developed orally deliverable multimodular zinc (Zn) iron oxide (Fe3O4)-saturated bovine lactoferrin (bLf)-loaded polymeric nanocapsules (NCs), and evaluated their theranostic potential (antitumor efficacy, magnetophotothermal efficacy and imaging capability) in an in vivo human xenograft CpG-island methylator phenotype (CIMP)-1(+)/CIMP2(-)/chromosome instability-positive colonic adenocarcinoma (Caco2) and claudin-low, triple-negative (ER-/PR-/HER2(-); MDA-MB-231) breast cancer model. Mice fed orally on the Zn-Fe-bLf NC diet showed downregulation in tumor volume and complete regression in tumor volume after 45 days of feeding. In human xenograft colon cancer, vehicle-control NC diet-group (n=5) mice showed a tumor volume of 52.28 +/- 11.55 mm(3), and Zn-Fe-bLf NC diet (n=5)-treated mice had a tumor-volume of 0.10 +/- 0.073 mm(3). In the human xenograft breast cancer model, Zn-Fe-bLf NC diet (n=5)-treated mice showed a tumor volume of 0.051 +/- 0.062 mm(3) within 40 days of feeding. Live mouse imaging conducted by near-infrared fluorescence imaging of Zn-Fe-bLf NCs showed tumor site-specific localization and regression of colon and breast tumor volume. Ex vivo fluorescence-imaging analysis of the vital organs of mice exhibited sparse localization patterns of Zn-Fe-bLf NCs and also confirmed tumor-specific selective localization patterns of Zn-Fe-bLf NCs. Dual imaging using magnetic resonance imaging and computerized tomography scans revealed an unprecedented theranostic ability of the Zn-Fe-bLf NCs. These observations warrant consideration of multimodular Zn-Fe-bLf NCs for real-time cancer imaging and simultaneous cancer-targeted therapy.
C1 [Kamalapuram, Sishir K.; Kanwar, Rupinder K.; Roy, Kislay; Chaudhary, Rajneesh; Kanwar, Jagat R.] Deakin Univ, Nanomed Lab Immunol & Mol Biomed Res, Sch Med, Ctr Mol & Med Res,Fac Hlth, Geelong, Vic 3217, Australia.
   [Sehgal, Rakesh] Postgrad Inst Med Educ & Res, Dept Med Parasitol, Chandigarh 160012, India.
C3 Deakin University; Post Graduate Institute of Medical Education &
   Research (PGIMER), Chandigarh
RP Kanwar, JR (corresponding author), Deakin Univ, Nanomed Lab Immunol & Mol Biol, Sch Med, Ctr Mol & Med Res,Fac Hlth, 75 Pigdons Rd, Geelong, Vic 3217, Australia.
EM jagat.kanwar@deakin.edu.au
RI Kanwar, Dr Rupinder Kaur/JBS-5937-2023; Kanwar, Jagat/JDO-1829-2023
OI Kumar Ph.D, Dr.Sishir/0000-0002-3481-6417
FU Australia-India Strategic Research Fund [AISRF BF030016, BF060042];
   National Health and Medical Research Council [NHMRC APP1050286]
FX The authors would like to thank the Australia-India Strategic Research
   Fund (AISRF BF030016, BF060042) and the National Health and Medical
   Research Council (NHMRC APP1050286) for financial support. The authors
   would like to thank Dr Prasad for the animal work. The authors would
   also like to thank Dr Nick Branson and Dr Rod Collins from Animal Ethics
   Committee, Geelong for providing their valuable and necessary help in
   this study. The authors would also like to thank Dr James Pearson, Dr
   Qi-Zhu Wu, and Mr Aldo Besmer from the Monash Biomedical Imaging center,
   Melbourne for their help with the MRI and CT imaging.
CR Agarwal VR, 2014, CANCER RES, V74, DOI 10.1158/1538-7445.AM2014-4521
   Akhavan O, 2014, J MAT CHEM B, V2, P3306
   [Anonymous], GUID IND FOOD LAB GU
   Arriaga JM, 2014, MOL CANCER THER, V13, P1369, DOI 10.1158/1535-7163.MCT-13-0944
   Caltagirone C, 2014, LANGMUIR, V30, P6228, DOI 10.1021/la501332u
   Chakravarty Prabir K, 2011, World J Oncol, V2, P16, DOI 10.4021/wjon256e
   Conde J, 2014, J CONTROL RELEASE, V183, P87, DOI 10.1016/j.jconrel.2014.03.045
   COX JD, 1995, INT J RADIAT ONCOL, V31, P1341, DOI 10.1016/0360-3016(95)00060-C
   Degirolamo C, 2015, J LIPID RES, V56, P1262, DOI 10.1194/jlr.R052704
   Gibbons JA, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1441-4
   Harmaza Yu. M., 2014, Biofizika, V59, P322, DOI 10.1134/S0006350914020092
   Imai K, 2014, ANN SURG ONCOL, V21, P3817, DOI 10.1245/s10434-014-3786-3
   Kanwar JR, 2008, IMMUNOL CELL BIOL, V86, P277, DOI 10.1038/sj.icb.7100163
   Kanwar JR, 2016, NANOMEDICINE-UK, V11, P249, DOI 10.2217/nnm.15.199
   Kanwar JR, 2015, NANOMEDICINE-UK, V10, P35, DOI 10.2217/nnm.14.132
   Kanwar JR, 2014, DRUG DISCOV TODAY, V19, P1309, DOI 10.1016/j.drudis.2014.02.009
   Kanwar JR, 2012, NANOMEDICINE-UK, V7, P1521, DOI [10.2217/NNM.12.29, 10.2217/nnm.12.29]
   Kanwar JR, 2013, MED RES REV, V33, P765, DOI 10.1002/med.21264
   Kanwar JR, 2011, DRUG DISCOV TODAY, V16, P485, DOI 10.1016/j.drudis.2011.04.001
   Kanwar JR, 2011, DRUG DISCOV TODAY, V16, P188, DOI 10.1016/j.drudis.2011.01.007
   KANWAR RK, 1995, BBA-MOL BASIS DIS, V1270, P179, DOI 10.1016/0925-4439(95)00045-6
   Kanwar RK, 2013, PROTEIN PEPTIDE LETT, V20, P450
   Kanwar RK, 2012, NANOMEDICINE-UK, V7, P899, DOI [10.2217/nnm.12.57, 10.2217/NNM.12.57]
   Kiessling F, 2014, ADV DRUG DELIVER REV, V72, P15, DOI 10.1016/j.addr.2013.11.013
   Laurent S, 2014, EXPERT OPIN DRUG DEL, V11, P1449, DOI 10.1517/17425247.2014.924501
   Lee HJ, 2015, INT J NANOMED, V10, P271, DOI 10.2147/IJN.S73128
   Lee SY, 2014, ADV DRUG DELIVER REV, V76, P60, DOI 10.1016/j.addr.2014.07.009
   Leung AWY, 2014, NANOMEDICINE-UK, V9, P501, DOI 10.2217/nnm.13.220
   Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782
   Mahidhara G, 2015, INT J NANOMED, V10, P4081, DOI 10.2147/IJN.S75877
   Marra P, 2014, CANCER RES, V74, P4908, DOI 10.1158/0008-5472.CAN-14-0637
   Meksawan K, 2014, ANTICANCER RES, V34, P295
   Mocchegiani E, 2014, IMMUNOLOGY OF AGING, P295
   Patra HK, 2014, ADV HEALTHC MATER, V3, P526, DOI 10.1002/adhm.201300225
   Patra HK, 2014, TRENDS BIOTECHNOL, V32, P21, DOI 10.1016/j.tibtech.2013.10.004
   Rodgers GM, 2012, J NATL COMPR CANC NE, V10, P628, DOI 10.6004/jnccn.2012.0064
   Schwartz RN, 2007, AM J HEALTH-SYST PH, V64, pS5, DOI 10.2146/ajhp060601
   Shah BP, 2014, ACS NANO, V8, P9379, DOI 10.1021/nn503431x
   Shin J, 2014, J BIOL CHEM, V289, P25306, DOI 10.1074/jbc.M114.557546
   Spivak JL, 2009, ONCOLOGIST, V14, P43, DOI 10.1634/theoncologist.2009-S1-43
   Tan YM, 2014, CANCER RES, V74, P2006, DOI 10.1158/0008-5472.CAN-13-1263
   Tseng YC, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv274
   Wang Z, 2014, PHARM RES-DORDR, V31, P1358, DOI 10.1007/s11095-013-1103-7
   Wang ZY, 2014, BIOTECHNOL ADV, V32, P831, DOI 10.1016/j.biotechadv.2013.08.020
NR 44
TC 16
Z9 16
U1 0
U2 21
PU DOVE MEDICAL PRESS LTD
PI ALBANY
PA PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND
SN 1178-2013
J9 INT J NANOMED
JI Int. J. Nanomed.
PY 2016
VL 11
BP 1349
EP 1366
DI 10.2147/IJN.S95253
PG 18
WC Nanoscience & Nanotechnology; Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Science & Technology - Other Topics; Pharmacology & Pharmacy
GA DI0QH
UT WOS:000373201500001
PM 27099495
OA gold, Green Published, Green Submitted
DA 2025-01-04
ER

PT J
AU Wang, CK
   Fakih, M
AF Wang, Chongkai
   Fakih, Marwan
TI Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer
   Harboring HER2 Amplification and HER2 S310F Mutation
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID DOMAIN MUTATIONS; TRANSMEMBRANE; ACQUISITION; RESISTANCE; BLOCKADE
AB Dual HER2-targeted therapy has been associated with clinical responses and prolonged progression-free survival and overall survival in RAS-wild type HER2-amplified colorectal cancer (CRC). However, no clinical benefits have been reported in patients with CRC with HER2 mutations. Activated HER2 mutations have been largely deemed resistant to trastuzumab and to dual HER2 targeting. This report describes a patient with metastatic CRC with concurrent HER2 amplification and a HER2 S310F mutation, which is an active mutation located in the extracellular dimerization domain of HER2. Treatment with trastuzumab + lapatinib resulted in an excellent response that lasted for 10 months. Upon disease progression, treatment with the antibody-drug conjugate trastuzumab-deruxtecan resulted in a short-lived response. This is the first case report of successful HER2 targeting in metastatic CRC with concurrent HER2 amplification and a HER2 S310F mutation.
C1 [Wang, Chongkai; Fakih, Marwan] City Hope Natl Med Ctr, Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, 1500 East Duarte Rd, Duarte, CA 91010 USA.
C3 City of Hope
RP Fakih, M (corresponding author), City Hope Natl Med Ctr, Comprehens Canc Ctr, Dept Med Oncol & Therapeut Res, 1500 East Duarte Rd, Duarte, CA 91010 USA.
EM mfakih@coh.org
CR Azuma K, 2011, BIOCHEM BIOPH RES CO, V407, P219, DOI 10.1016/j.bbrc.2011.03.002
   Bai J, 2015, J HUM GENET, V60, P589, DOI 10.1038/jhg.2015.71
   Ben-Baruch NE, 2015, J NATL COMPR CANC NE, V13, P1061, DOI 10.6004/jnccn.2015.0131
   Benson AB, 2021, NCCN CLIN PRACTICE G
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Bose R, 2013, CANCER DISCOV, V3, P224, DOI 10.1158/2159-8290.CD-12-0349
   Bregni G, 2019, JAMA ONCOL, V5, P605, DOI 10.1001/jamaoncol.2018.7229
   Cocco E, 2018, SCI SIGNAL, V11, DOI 10.1126/scisignal.aat9773
   Greulich H, 2012, P NATL ACAD SCI USA, V109, P14476, DOI 10.1073/pnas.1203201109
   Hanker AB, 2017, CLIN CANCER RES, V23, P4323, DOI 10.1158/1078-0432.CCR-16-2287
   Heppner BI, 2014, BRIT J CANCER, V111, P1977, DOI 10.1038/bjc.2014.483
   Kavuri SM, 2015, CANCER DISCOV, V5, P832, DOI 10.1158/2159-8290.CD-14-1211
   Kovacs E, 2015, MOL CELL BIOL, V35, P3083, DOI 10.1128/MCB.00248-15
   Kovacs E, 2015, ANNU REV BIOCHEM, V84, P739, DOI 10.1146/annurev-biochem-060614-034402
   Martin V, 2013, BRIT J CANCER, V108, P668, DOI 10.1038/bjc.2013.4
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Nagano M, 2018, CLIN CANCER RES, V24, P5112, DOI 10.1158/1078-0432.CCR-18-0991
   Nakamura Y, 2019, ANN ONCOL, V30
   Ou SHI, 2017, J THORAC ONCOL, V12, P446, DOI 10.1016/j.jtho.2016.11.2224
   Pahuja KB, 2018, CANCER CELL, V34, P792, DOI 10.1016/j.ccell.2018.09.010
   Raghav K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00226
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Ross JS, 2018, CANCER-AM CANCER SOC, V124, P1358, DOI 10.1002/cncr.31125
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Siena S, 2020, J CLIN ONCOL, V38
   Siravegna G, 2019, CLIN CANCER RES, V25, P3046, DOI 10.1158/1078-0432.CCR-18-3389
   Siravegna G, 2018, CANCER CELL, V34, P148, DOI 10.1016/j.ccell.2018.06.004
   Strickler JH, 2019, ANN ONCOL, V30
   Xu XW, 2017, CLIN CANCER RES, V23, P5123, DOI 10.1158/1078-0432.CCR-16-2191
   Zuo WJ, 2016, CLIN CANCER RES, V22, P4859, DOI 10.1158/1078-0432.CCR-15-3036
NR 30
TC 4
Z9 4
U1 0
U2 1
PU HARBORSIDE PRESS
PI HUNTINGTON
PA 94 NORTH WOODHULL RD, HUNTINGTON, NY 11743 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2021
VL 19
IS 6
BP 670
EP 674
DI 10.6004/jnccn.2021.7023
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA TI5RH
UT WOS:000672859700005
PM 34214965
OA Bronze
DA 2025-01-04
ER

PT J
AU Singh, AP
   Shum, E
   Rajdev, L
   Cheng, HY
   Goel, S
   Perez-Soler, R
   Halmos, B
AF Singh, Aditi P.
   Shum, Elaine
   Rajdev, Lakshmi
   Cheng, Haiying
   Goel, Sanjay
   Perez-Soler, Roman
   Halmos, Balazs
TI Impact and Diagnostic Gaps of Comprehensive Genomic Profiling in
   Real-World Clinical Practice
SO CANCERS
LA English
DT Article
DE comprehensive genomic profiling; molecular genotyping
ID CELL LUNG-CANCER; OUTCOMES; ACTIONABILITY; PEMBROLIZUMAB; THERAPY;
   TRIAL; TMB
AB Purpose: next-generation sequencing based comprehensive genomic profiling (CGP) is becoming common practice. Although numerous studies have shown its feasibility to identify actionable genomic alterations in most patients, its clinical impact as part of routine management across all cancers in the community remains unknown. Methods: we conducted a retrospective study of all patients that underwent CGP as part of routine cancer management from January 2013 to June 2017 at an academic community-based NCI-designated cancer center. CGP was done in addition to established first tier reflex molecular testing as per national guidelines (e.g., EGFR/ALK for non-small cell lung cancer (NSCLC) and extended-RAS for colorectal cancer). Results: 349 tests were sent for CGP from 333 patients and 95% had at least one actionable genomic alteration reported. According to the reported results, 23.2% had a Food and Drug Administration (FDA) approved therapy available, 61.3% had an off-label therapy available and 77.9% were potentially eligible for a clinical trial. Treatment recommendations were also reviewed within the OncoKB database and 47% of them were not clinically validated therapies. The CGP results led to treatment change in only 35 patients (10%), most commonly in NSCLC. Nineteen of these patients (54% of those treated and 5% of total) had documented clinical benefit with targeted therapy. Conclusion: we demonstrate that routine use of CGP in the community across all cancer types detects potentially actionable genomic alterations in a majority of patients, however has modest clinical impact enriched in the NSCLC subset.
C1 [Singh, Aditi P.] Univ Penn, Abramson Canc Ctr, Div Hematol & Oncol, Philadelphia, PA 19104 USA.
   [Shum, Elaine] NYU, Langone Perlmutter Canc Ctr, Div Med Oncol & Hematol, New York, NY 10016 USA.
   [Rajdev, Lakshmi; Cheng, Haiying; Goel, Sanjay; Perez-Soler, Roman; Halmos, Balazs] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA.
C3 University of Pennsylvania; New York University; Yeshiva University;
   Montefiore Medical Center; Albert Einstein College of Medicine
RP Halmos, B (corresponding author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10467 USA.
EM aditi.singh@pennmedicine.upenn.edu; elaine.shum@nyumc.org;
   lrajdev@montefiore.org; hcheng@montefiore.org; sgoel@montefiore.org;
   rperezso@montefiore.org; bahalmos@montefiore.org
RI Singh, Anil/JUU-2219-2023
OI GOEL, SANJAY/0000-0002-2798-7568; Shum, Elaine/0000-0002-0390-5716
CR Administration USFaD, FDA GRANTS ACC APPR
   André F, 2019, NEW ENGL J MED, V380, P1929, DOI 10.1056/NEJMoa1813904
   Batth IS, 2019, TRANSL RES, V212, P14, DOI 10.1016/j.trsl.2019.07.003
   Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011
   Dalton WB, 2017, JCO PRECIS ONCOL, V1, DOI 10.1200/PO.16.00046
   Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448
   Fakih M, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3003
   Garassino M, 2019, J THORAC ONCOL, V14, pS216, DOI 10.1016/j.jtho.2019.08.427
   Golan T, 2019, NEW ENGL J MED, V381, P317, DOI 10.1056/NEJMoa1903387
   Gupta R, 2020, ONCOLOGIST, V25, P235, DOI 10.1634/theoncologist.2019-0441
   Gutierrez ME, 2017, CLIN LUNG CANCER, V18, P651, DOI 10.1016/j.cllc.2017.04.004
   Hilal T, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3587-8
   Hilal T, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.e18018
   Hirshfield KM, 2016, ONCOLOGIST, V21, P1315, DOI 10.1634/theoncologist.2016-0049
   Imperial R, 2019, CANCERS, V11, DOI 10.3390/cancers11091399
   Inal C, 2014, J CLIN ONCOL, V32, DOI 10.1200/jco.2014.32.15_suppl.8098
   Keller L, 2019, NAT REV CANCER, V19, P553, DOI 10.1038/s41568-019-0180-2
   Kelley SO, 2020, CLIN CHEM, V66, P89, DOI 10.1373/clinchem.2019.303339
   Langer C, 2019, J THORAC ONCOL, V14, pS216, DOI 10.1016/j.jtho.2019.08.426
   Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6
   Lim SB, 2019, NPJ PRECIS ONCOL, V3, DOI 10.1038/s41698-019-0095-0
   Lin PH, 2020, CANCER SCI, V111, P1375, DOI 10.1111/cas.14313
   Marquart J, 2018, JAMA ONCOL, V4, P1093, DOI 10.1001/jamaoncol.2018.1660
   Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396
   multicenter collaboration group of Department of S Technology of Guangdong P Health Commission of Guangdong Province for chloroquine in the treatment of novel coronavirus p, 2020, ZHONGHUA JIE HE HE H, V43, pE019, DOI DOI 10.3760/cma.j.cn112147-20200221-00138
   National Cancer Institute, 2017, GEN PROF TESTS CLEAR
   NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ), 2020, NON SMALL CELL LUNG
   Nesline Mary K, 2019, Oncotarget, V10, P4616, DOI 10.18632/oncotarget.27047
   Patel JM, 2016, ONCOTARGET, V7, P22064, DOI 10.18632/oncotarget.8017
   Pennell Nathan A, 2019, Am Soc Clin Oncol Educ Book, V39, P531, DOI 10.1200/EDBK_237863
   Pennell NA, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.9031
   Pezo RC, 2018, BREAST CANCER RES TR, V168, P159, DOI 10.1007/s10549-017-4580-2
   Prasad V, 2018, ANN ONCOL, V29, P298, DOI 10.1093/annonc/mdx786
   Remon J, 2018, ANN ONCOL, V29, pI20, DOI 10.1093/annonc/mdx704
   Russo A, 2019, EXPERT REV MOL DIAGN, V19, P1099, DOI 10.1080/14737159.2020.1680287
   Schwaederle M, 2015, MOL CANCER THER, V14, P1488, DOI 10.1158/1535-7163.MCT-14-1061
   Sholl LM, 2016, JCI INSIGHT, V1, DOI 10.1172/jci.insight.87062
   Signorovitch J, 2019, J MED ECON, V22, P140, DOI 10.1080/13696998.2018.1549056
   Signorovitch J, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.6605
   Singal G, 2019, JAMA-J AM MED ASSOC, V321, P1391, DOI 10.1001/jama.2019.3241
   Sireci AN, 2017, J MOL DIAGN, V19, P277, DOI 10.1016/j.jmoldx.2016.10.008
   Spizzo G, 2019, COST EFFECT RESOUR A, V17, DOI 10.1186/s12962-019-0191-6
   Stockley TL, 2016, GENOME MED, V8, DOI 10.1186/s13073-016-0364-2
   Tafe LJ, 2015, ONCOLOGIST, V20, P1011, DOI 10.1634/theoncologist.2015-0097
   Unger Joseph M, 2016, Am Soc Clin Oncol Educ Book, V35, P185, DOI 10.14694/EDBK_156686
   Wheler JJ, 2016, CANCER RES, V76, P3690, DOI 10.1158/0008-5472.CAN-15-3043
   Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333
NR 47
TC 22
Z9 23
U1 0
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD MAY
PY 2020
VL 12
IS 5
AR 1156
DI 10.3390/cancers12051156
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA LW6HT
UT WOS:000539246000097
PM 32375398
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Qin, BD
   Jiao, XD
   Liu, K
   Wu, Y
   He, X
   Liu, J
   Qin, WX
   Wang, Z
   Zang, YS
AF Qin, Bao-Dong
   Jiao, Xiao-Dong
   Liu, Ke
   Wu, Ying
   He, Xi
   Liu, Jun
   Qin, Wen-Xing
   Wang, Zhan
   Zang, Yuan-Sheng
TI Basket Trials for Intractable Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE basket trial; intractable cancer; molecular alteration; personalized
   precision therapy; genome-driven oncology; refractory cancer
ID UNRESECTABLE HEPATOCELLULAR-CARCINOMA; BILIARY-TRACT CANCER;
   QUALITY-OF-LIFE; PHASE-III; SOLID TUMORS; OPEN-LABEL; RARE CANCERS;
   MUTATIONAL LANDSCAPE; 1ST-LINE TREATMENT; TARGETED THERAPY
AB Currently, genomic characterization has become standard of care for tumor types such as non-small cell lung cancer, breast cancer, melanoma, and colorectal cancer. A deep understanding of genomic alterations in different tumor types would help identify potentially actionable genomic changes which occur across a wide variety of tumor types. A basket trial is a new type of clinical trial for which eligibility is based on the presence of a specific genomic alteration, irrespective of histology. Basket trials are phase II screening trials for the off-label use of a targeted drug in patients with the same genomic alterations for which it was approved. Intractable cancer refers to a type or condition of cancer which is unresponsive or resistant to treatment; intractable cancers may be classified into five subtypes as follows: hard-to-treat condition of common advanced cancer after multiple-line therapy, rare cancer in which no standard of care has been recommended, advanced cancer in which standard of care does not work well, cancer accompanied with organ dysfunction, and cancers in older or younger cancer patients. Previous studies have demonstrated that in basket trials, genomic-guided therapy yields clinical benefits in intractable cancer, thereby providing novel insights into the optimal clinical management of such cancers. In this review, we describe a novel way to classify intractable cancer, and summarize the current knowledge on such cancers. We additionally provide information on the role of basket trials in intractable cancer.
C1 [Qin, Bao-Dong; Jiao, Xiao-Dong; Liu, Ke; Wu, Ying; He, Xi; Liu, Jun; Qin, Wen-Xing; Wang, Zhan; Zang, Yuan-Sheng] Naval Med Univ, Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China.
C3 Naval Medical University
RP Zang, YS (corresponding author), Naval Med Univ, Changzheng Hosp, Dept Med Oncol, Shanghai, Peoples R China.
EM doctorzangys@163.com
RI Qin, Baodong/ABA-3303-2021
OI Jiao, Xiao-Dong/0000-0002-9663-8548
FU Shanghai Sailing Program [17YF1425200]; Chinese National Natural Science
   Funding [81702249]; Science and Technology Commission of Shanghai
   Municipality [17511103403]
FX This study was supported by the Shanghai Sailing Program [grant number
   17YF1425200, 2017]; Chinese National Natural Science Funding [grant
   number 81702249, 2017]; Science and Technology Commission of Shanghai
   Municipality [grant number 17511103403, 2017]; The funder has no role in
   the study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR André F, 2018, NEW ENGL J MED, V378, P763, DOI 10.1056/NEJMe1716821
   Astsaturov I, 2017, SURG ONCOL CLIN N AM, V26, P791, DOI 10.1016/j.soc.2017.05.014
   Belin L, 2017, ANN ONCOL, V28, P590, DOI 10.1093/annonc/mdw666
   Bogaerts J, 2015, EUR J CANCER, V51, P271, DOI 10.1016/j.ejca.2014.10.027
   Boyd N, 2016, LANCET ONCOL, V17, pE52, DOI 10.1016/S1470-2045(15)00386-1
   Cainap C, 2015, J CLIN ONCOL, V33, P172, DOI 10.1200/JCO.2013.54.3298
   Chapman PB, 2011, NEW ENGL J MED, V364, P2507, DOI 10.1056/NEJMoa1103782
   Cheng AL, 2013, J CLIN ONCOL, V31, P4067, DOI 10.1200/JCO.2012.45.8372
   Cheng AL, 2009, LANCET ONCOL, V10, P25, DOI 10.1016/S1470-2045(08)70285-7
   Cohn AL, 2017, ONCOTARGETS THER, V10, P965, DOI 10.2147/OTT.S120440
   Demetri GD, 2018, LBA17 EFFICACY SAFET
   Diamond EL, 2018, JAMA ONCOL, V4, P384, DOI 10.1001/jamaoncol.2017.5029
   Drilon A, 2018, NEW ENGL J MED, V378, P731, DOI 10.1056/NEJMoa1714448
   Druker BJ, 2006, NEW ENGL J MED, V355, P2408, DOI 10.1056/NEJMoa062867
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Fleming GF, 2003, ANN ONCOL, V14, P1142, DOI 10.1093/annonc/mdg302
   Fossella FV, 2000, J CLIN ONCOL, V18, P2354, DOI 10.1200/JCO.2000.18.12.2354
   Garraway LA, 2013, J CLIN ONCOL, V31, P1806, DOI 10.1200/JCO.2012.46.8934
   Gatta G, 2017, LANCET ONCOL, V18, P1022, DOI 10.1016/S1470-2045(17)30445-X
   Gatta G, 2011, EUR J CANCER, V47, P2493, DOI 10.1016/j.ejca.2011.08.008
   Genestreti G, 2014, FUTURE ONCOL, V10, P2081, DOI [10.2217/FON.14.96, 10.2217/fon.14.96]
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Gundgaard MG, 2008, CANCER CHEMOTH PHARM, V61, P1, DOI 10.1007/s00280-007-0573-x
   Hainsworth JD, 2018, J CLIN ONCOL, V36, P536, DOI 10.1200/JCO.2017.75.3780
   Han BH, 2018, JAMA ONCOL, V4, P1569, DOI 10.1001/jamaoncol.2018.3039
   Harttrampf AC, 2017, CLIN CANCER RES, V23, P6101, DOI 10.1158/1078-0432.CCR-17-0381
   Hasegawa K, 2017, INVEST NEW DRUG, V35, P800, DOI 10.1007/s10637-017-0504-6
   Heinrich MC, 2008, CLIN CANCER RES, V14, P2717, DOI 10.1158/1078-0432.CCR-07-4575
   Hurria A, 2006, J AM GERIATR SOC, V54, P1119, DOI 10.1111/j.1532-5415.2006.00789.x
   Hutchins LF, 1999, NEW ENGL J MED, V341, P2061, DOI 10.1056/NEJM199912303412706
   Hyman DM, 2017, J CLIN ONCOL, V35, P2251, DOI 10.1200/JCO.2017.73.0143
   Hyman DM, 2017, CELL, V168, P584, DOI 10.1016/j.cell.2016.12.015
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Hyman DM, 2017, ANN M AM ASS CANC RE
   Johnson PJ, 2013, J CLIN ONCOL, V31, P3517, DOI 10.1200/JCO.2012.48.4410
   Kaley T, 2018, J CLIN ONCOL, V36, P3477, DOI 10.1200/JCO.2018.78.9990
   Kandoth C, 2013, NATURE, V502, P333, DOI 10.1038/nature12634
   Kato S, 2018, ONCOLOGIST, V23, P171, DOI 10.1634/theoncologist.2017-0199
   Kaufman B, 2015, J CLIN ONCOL, V33, P244, DOI 10.1200/JCO.2014.56.2728
   Kudo M, 2018, LANCET, V391, P1163, DOI 10.1016/S0140-6736(18)30207-1
   Lamarca A, 2014, ANN ONCOL, V25, P2328, DOI 10.1093/annonc/mdu162
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Le Tourneau C, 2015, LANCET ONCOL, V16, P1324, DOI 10.1016/S1470-2045(15)00188-6
   Li BT, 2018, J CLIN ONCOL, V36, P2532, DOI 10.1200/JCO.2018.77.9777
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Macchini M, 2019, CANCER TREAT REV, V72, P1, DOI 10.1016/j.ctrv.2018.10.013
   Marosi C, 2016, ESMO OPEN, V1, DOI 10.1136/esmoopen-2015-000020
   Massard C, 2017, CANCER DISCOV, V7, P586, DOI 10.1158/2159-8290.CD-16-1396
   Massarelli E, 2003, LUNG CANCER-J IASLC, V39, P55, DOI 10.1016/S0169-5002(02)00308-2
   McNeil C, 2015, JNCI-J NATL CANCER I, V107, DOI 10.1093/jnci/djv193
   Meric-Bemstam F, 2019, LANCET ONCOL, V20, P518, DOI 10.1016/S1470-2045(18)30904-5
   Mita AC, 2006, J CLIN ONCOL, V24, P552, DOI 10.1200/JCO.2004.00.9720
   Ogino H, 2019, RESPIR INVESTIG, V57, P40, DOI 10.1016/j.resinv.2018.10.003
   Okusaka T, 2010, BRIT J CANCER, V103, P469, DOI 10.1038/sj.bjc.6605779
   Pallis AG, 2010, EUR J CANCER, V46, P1502, DOI 10.1016/j.ejca.2010.02.022
   Pereira FM, 2016, ANN ONCOL, V27, DOI 10.1093/annonc/mdw390.22
   Qin BD, 2018, LUNG CANCER, V126, P174, DOI 10.1016/j.lungcan.2018.11.010
   Qin BD, 2018, CANCER MANAG RES, V10, P439, DOI 10.2147/CMAR.S144850
   Qin BD, 2018, LUNG CANCER, V116, P67, DOI 10.1016/j.lungcan.2017.12.015
   Quinten C, 2015, EUR J CANCER, V51, P2808, DOI 10.1016/j.ejca.2015.08.027
   Rotz SJ, 2017, J ADOLESC YOUNG ADUL, V6, P406, DOI 10.1089/jayao.2017.0007
   Sargent DJ, 2001, NEW ENGL J MED, V345, P1091, DOI 10.1056/NEJMoa010957
   Schram AM, 2017, ANN ONCOL, V28, P2298, DOI 10.1093/annonc/mdx294
   Shepherd FA, 2000, J CLIN ONCOL, V18, P2095, DOI 10.1200/JCO.2000.18.10.2095
   Simon R, 2017, CLIN PHARMACOL THER, V102, P934, DOI 10.1002/cpt.814
   Superfin D, 2007, ONCOLOGIST, V12, P1070, DOI 10.1634/theoncologist.12-9-1070
   Tao JJ, 2018, ANNU REV MED, V69, P319, DOI 10.1146/annurev-med-062016-050343
   Tredan O, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.18_suppl.LBA100
   Valle JW, 2014, ANN ONCOL, V25, P391, DOI 10.1093/annonc/mdt540
   Valle J, 2010, NEW ENGL J MED, V362, P1273, DOI 10.1056/NEJMoa0908721
   Von Hoff DD, 2010, J CLIN ONCOL, V28, P4877, DOI 10.1200/JCO.2009.26.5983
   Xie FH, 2018, HEPATOBIL SURG NUTR, V7, P221, DOI 10.21037/hbsn.2018.06.06
   Zehir A, 2017, NAT MED, V23, P703, DOI 10.1038/nm.4333
   Zhou F, 2018, LUNG CANCER, V116, P30, DOI 10.1016/j.lungcan.2017.12.009
   Zhu AX, 2015, J CLIN ONCOL, V33, P559, DOI 10.1200/JCO.2013.53.7746
NR 75
TC 21
Z9 21
U1 0
U2 4
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD APR 12
PY 2019
VL 9
AR 229
DI 10.3389/fonc.2019.00229
PG 11
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HT2DK
UT WOS:000464373200001
PM 31032221
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Gelfo, V
   Romaniello, D
   Mazzeschi, M
   Sgarzi, M
   Grilli, G
   Morselli, A
   Manzan, B
   Rihawi, K
   Lauriola, M
AF Gelfo, Valerio
   Romaniello, Donatella
   Mazzeschi, Martina
   Sgarzi, Michela
   Grilli, Giada
   Morselli, Alessandra
   Manzan, Beatrice
   Rihawi, Karim
   Lauriola, Mattia
TI Roles of IL-1 in Cancer: From Tumor Progression to Resistance to
   Targeted Therapies
SO INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
LA English
DT Review
DE IL-1; cancer; resistance
ID COLORECTAL-CANCER; SUPPRESSOR-CELLS; T-CELLS; IN-VIVO; KAPPA-B;
   INFLAMMATION; INTERLEUKIN-1; PROMOTES; IL-1-ALPHA; INVASIVENESS
AB IL-1 belongs to a family of 11 members and is one of the seven receptor-agonists with pro-inflammatory activity. Beyond its biological role as a regulator of the innate immune response, IL-1 is involved in stress and chronic inflammation, therefore it is responsible for several pathological conditions. In particular, IL-1 is known to exert a critical function in malignancies, influencing the tumor microenvironment and promoting cancer initiation and progression. Thus, it orchestrates immunosuppression recruiting pro-tumor immune cells of myeloid origin. Furthermore, new recent findings showed that this cytokine can be directly produced by tumor cells in a positive feedback loop and contributes to the failure of targeted therapy. Activation of anti-apoptotic signaling pathways and senescence are some of the mechanisms recently proposed, but the role of IL-1 in tumor cells refractory to standard therapies needs to be further investigated.
C1 [Gelfo, Valerio; Romaniello, Donatella; Mazzeschi, Martina; Sgarzi, Michela; Grilli, Giada; Morselli, Alessandra; Manzan, Beatrice; Lauriola, Mattia] Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, I-40138 Bologna, Italy.
   [Gelfo, Valerio; Romaniello, Donatella; Lauriola, Mattia] Bologna Univ Hosp Author, St Orsola Malpighi Polyclin, Ctr Appl Biomed Res CRBA, I-40138 Bologna, Italy.
   [Rihawi, Karim] Univ Bologna, Dept Oncol, Policlin S Orsola Malpighi, I-40138 Bologna, Italy.
C3 University of Bologna; IRCCS Azienda Ospedaliero-Universitaria di
   Bologna; IRCCS Azienda Ospedaliero-Universitaria di Bologna; University
   of Bologna
RP Lauriola, M (corresponding author), Univ Bologna, Dept Expt Diagnost & Specialty Med DIMES, I-40138 Bologna, Italy.; Lauriola, M (corresponding author), Bologna Univ Hosp Author, St Orsola Malpighi Polyclin, Ctr Appl Biomed Res CRBA, I-40138 Bologna, Italy.
EM valerio.gelfo2@unibo.it; donatella.romaniello@unibo.it;
   martina.mazzeschi2@unibo.it; michela.sgarzi2@unibo.it;
   giada.grilli2@unibo.it; alessandra.morselli2@studio.unibo.it;
   beatrice.manzan@studio.unibo.it; karim.rihawi@gmail.com;
   mattia.lauriola2@unibo.it
RI Sgarzi, Michela/AAD-6772-2022; lauriola, mattia/N-6435-2014; Rihawi,
   Karim/AAC-5431-2021; Romaniello, Donatella/AAC-3527-2022; Morselli,
   Alessandra/LRU-3904-2024; Mazzeschi, Martina/AAD-6770-2022
OI Gelfo, Valerio/0000-0001-9312-8406; Sgarzi, Michela/0000-0003-0949-7810;
   Mazzeschi, Martina/0000-0002-4695-9175; Morselli,
   Alessandra/0009-0002-4825-8695; rihawi, karim/0000-0002-3915-466X
FU PRIN2017 [2017TATYMP_002]; ALMAIDEA grant 2018; Fondazione Carisbo
FX This research was funded by PRIN2017, grant number 2017TATYMP_002 and
   ALMAIDEA grant 2018 and Fondazione Carisbo.
CR Allen IC, 2010, J EXP MED, V207, P1045, DOI 10.1084/jem.20100050
   Apte RN, 2017, J LEUKOCYTE BIOL, V102, P293, DOI 10.1189/jlb.3MR1216-523R
   Apte RN, 2006, CANCER METAST REV, V25, P387, DOI 10.1007/s10555-006-9004-4
   Baker K, 2019, FOREST POLICY ECON, V100, P1, DOI 10.1016/j.forpol.2018.11.001
   Balkwill FR, 2012, SEMIN CANCER BIOL, V22, P33, DOI 10.1016/j.semcancer.2011.12.005
   Bent R, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19082155
   Bozinovski S, 2016, BRIT J PHARMACOL, V173, P635, DOI 10.1111/bph.13198
   Bunt SK, 2006, J IMMUNOL, V176, P284, DOI 10.4049/jimmunol.176.1.284
   Carmi Y, 2013, J IMMUNOL, V190, P3500, DOI 10.4049/jimmunol.1202769
   Cataisson C, 2012, J EXP MED, V209, P1689, DOI 10.1084/jem.20101355
   Cohen I, 2010, P NATL ACAD SCI USA, V107, P2574, DOI 10.1073/pnas.0915018107
   Cui GL, 2018, PATHOL RES PRACT, V214, P986, DOI 10.1016/j.prp.2018.05.011
   Das S, 2020, CANCER RES, V80, P1088, DOI 10.1158/0008-5472.CAN-19-2080
   Dekker SK, 1997, MELANOMA RES, V7, P223, DOI 10.1097/00008390-199706000-00006
   Dinarello CA, 2018, IMMUNOL REV, V281, P8, DOI 10.1111/imr.12621
   Dinarello CA, 2012, NAT REV DRUG DISCOV, V11, P633, DOI 10.1038/nrd3800
   Dinarello CA, 2011, BLOOD, V117, P3720, DOI 10.1182/blood-2010-07-273417
   Dinarello CA, 2010, CANCER METAST REV, V29, P317, DOI 10.1007/s10555-010-9229-0
   Elaraj DM, 2006, CLIN CANCER RES, V12, P1088, DOI 10.1158/1078-0432.CCR-05-1603
   Elkabets M, 2009, J IMMUNOL, V182, P4874, DOI 10.4049/jimmunol.0803916
   Ewald JA, 2010, JNCI-J NATL CANCER I, V102, P1536, DOI 10.1093/jnci/djq364
   Fahey E, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01426
   Filippi I, 2015, MEDIAT INFLAMM, V2015, DOI 10.1155/2015/789414
   Garlanda C, 2013, IMMUNITY, V39, P1003, DOI 10.1016/j.immuni.2013.11.010
   Gelfo V, 2018, CANCERS, V10, DOI 10.3390/cancers10100355
   Gelfo V, 2016, ONCOTARGET, V7, P72167, DOI 10.18632/oncotarget.12354
   Grivennikov SI, 2013, SEMIN IMMUNOPATHOL, V35, P229, DOI 10.1007/s00281-012-0352-6
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo BC, 2016, SCI REP-UK, V6, DOI 10.1038/srep36107
   Haabeth OAW, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2015.1039763
   Hickish T, 2017, LANCET ONCOL, V18, P192, DOI 10.1016/S1470-2045(17)30006-2
   Holen I, 2016, ONCOTARGET, V7, P75571, DOI 10.18632/oncotarget.12289
   Huang J, 2020, ONCOGENE, V39, P1739, DOI 10.1038/s41388-019-1099-5
   Jagielska J, 2012, ARTERIOSCL THROM VAS, V32, P1280, DOI 10.1161/ATVBAHA.111.243477
   Jiang HH, 2015, INT J CANCER, V136, P2352, DOI 10.1002/ijc.29297
   Jiménez-Gardnno AM, 2017, BIOCHEM BIOPH RES CO, V490, P780, DOI 10.1016/j.bbrc.2017.06.117
   Jones VS, 2016, BBA-REV CANCER, V1865, P255, DOI 10.1016/j.bbcan.2016.03.005
   Jose RJ, 2020, LANCET RESP MED, V8, pE46, DOI 10.1016/S2213-2600(20)30216-2
   Kang HW, 2006, LAB INVEST, V86, P599, DOI 10.1038/labinvest.3700421
   Kaplanov I, 2019, P NATL ACAD SCI USA, V116, P1361, DOI 10.1073/pnas.1812266115
   KAPLANSKI G, 1994, BLOOD, V84, P4242, DOI 10.1182/blood.V84.12.4242.bloodjournal84124242
   Karin M, 2006, NATURE, V441, P431, DOI 10.1038/nature04870
   Koch AT, 2015, CANCER RES, V75, P1657, DOI 10.1158/0008-5472.CAN-14-2061
   Krelin Y, 2007, CANCER RES, V67, P1062, DOI 10.1158/0008-5472.CAN-06-2956
   Kryczek I, 2007, J IMMUNOL, V179, P1423, DOI 10.4049/jimmunol.179.3.1423
   Lau L, 2019, MOL CELL BIOL, V39, DOI 10.1128/MCB.00586-18
   Lecot P, 2016, BRIT J CANCER, V114, P1180, DOI 10.1038/bjc.2016.115
   Lee JG, 2012, INVEST OPHTH VIS SCI, V53, P1530, DOI 10.1167/iovs.11-9102
   León X, 2015, ONCOTARGET, V6, P37407, DOI 10.18632/oncotarget.6054
   Li YJ, 2012, MOL CANCER, V11, DOI 10.1186/1476-4598-11-87
   Litmanovich A, 2018, ONCOL THER, V6, P109, DOI 10.1007/s40487-018-0089-z
   Lu L, 2020, INT J MED SCI, V17, P1257, DOI 10.7150/ijms.44285
   Lust JA, 2009, MAYO CLIN PROC, V84, P114, DOI 10.4065/84.2.114
   Malik A, 2018, IMMUNOL REV, V281, P124, DOI 10.1111/imr.12615
   Mantovani A, 2008, NATURE, V454, P436, DOI 10.1038/nature07205
   Mantovani A, 2018, IMMUNOL REV, V281, P57, DOI 10.1111/imr.12614
   Maria F.F.M., 2015, J INFLAMM UK, DOI [10.1016/j.ecolecon.2015.05.006, DOI 10.1016/J.ECOLECON.2015.05.006]
   Mendoza-Rodríguez MG, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20020270
   Michael-Robinson JM, 2001, GUT, V48, P360, DOI 10.1136/gut.48.3.360
   Milanovic M, 2018, NATURE, V553, P96, DOI 10.1038/nature25167
   Müller MF, 2016, VIRCHOWS ARCH, V469, P125, DOI 10.1007/s00428-016-1956-3
   Musolino C, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/1852517
   Nakamura S., 1986, JPN J CANC RES GANN, DOI [10.20772/cancersci1985.77.8_767, DOI 10.20772/CANCERSCI1985.77.8_767]
   Nicolini A, 2018, ENDOCR-RELAT CANCER, V25, pR577, DOI 10.1530/ERC-18-0142
   Qian SH, 2019, EPMA J, V10, P365, DOI 10.1007/s13167-019-00194-x
   Qu XL, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00563
   Rider P, 2012, FRONT IMMUNOL, V3, DOI 10.3389/fimmu.2012.00290
   Ridker PM, 2017, LANCET, V390, P1833, DOI 10.1016/S0140-6736(17)32247-X
   Rogovskii VS, 2017, CURR CANCER DRUG TAR, V17, P325, DOI 10.2174/1568009617666170109110816
   Saijo Y, 2002, J IMMUNOL, V169, P469, DOI 10.4049/jimmunol.169.1.469
   Salven P, 2002, FASEB J, V16, P1471, DOI 10.1096/fj.02-0134fje
   Schweighofer B, 2009, THROMB HAEMOSTASIS, V102, P544, DOI 10.1160/TH08-12-0830
   Sheikpranbabu Sardarpasha, 2009, Journal of Nanobiotechnology, V7, P8, DOI 10.1186/1477-3155-7-8
   Shimizu T, 2012, CANCER SCI, V103, P1201, DOI 10.1111/j.1349-7006.2012.02293.x
   Sims JE, 2010, NAT REV IMMUNOL, V10, P89, DOI 10.1038/nri2691
   Song XP, 2005, J IMMUNOL, V175, P8200, DOI 10.4049/jimmunol.175.12.8200
   Stanam A, 2016, ONCOTARGET, V7, P76087, DOI 10.18632/oncotarget.12590
   Stewart AG, 2016, BRIT J PHARMACOL, V173, P631, DOI 10.1111/bph.13389
   Sutton C, 2006, J EXP MED, V203, P1685, DOI 10.1084/jem.20060285
   Tu S, 2008, CANCER CELL, V14, P408, DOI 10.1016/j.ccr.2008.10.011
   Vidal-Vanaclocha F, 2000, P NATL ACAD SCI USA, V97, P734, DOI 10.1073/pnas.97.2.734
   VIDALVANACLOCHA F, 1994, CANCER RES, V54, P2667
   Voronov E, 2003, P NATL ACAD SCI USA, V100, P2645, DOI 10.1073/pnas.0437939100
   Voronov E., 2020, CURR PHARM DESIGN, DOI [10.2174/138161282366617061308091928606052, DOI 10.2174/138161282366617061308091928606052]
   Voronov E, 2015, CANCER MICROENVIRON, V8, P187, DOI 10.1007/s12307-015-0177-7
   Voronov E, 2014, FRONT PHYSIOL, V5, DOI 10.3389/fphys.2014.00114
   Voronov E, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00177
   Werman A, 2004, P NATL ACAD SCI USA, V101, P2434, DOI 10.1073/pnas.0308705101
   West NR, 2015, NAT REV IMMUNOL, V15, P615, DOI 10.1038/nri3896
   Xuan Y, 2017, J DIGEST DIS, V18, P511, DOI 10.1111/1751-2980.12496
   Zhang WZ, 2020, ADV EXP MED BIOL, V1240, P1, DOI 10.1007/978-3-030-38315-2_1
NR 91
TC 100
Z9 103
U1 1
U2 19
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1422-0067
J9 INT J MOL SCI
JI Int. J. Mol. Sci.
PD SEP
PY 2020
VL 21
IS 17
AR 6009
DI 10.3390/ijms21176009
PG 14
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA NO8OE
UT WOS:000569746200001
PM 32825489
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Sedighi, M
   Bialvaei, AZ
   Hamblin, MR
   Ohadi, E
   Asadi, A
   Halajzadeh, M
   Lohrasbi, V
   Mohammadzadeh, N
   Amiriani, T
   Krutova, M
   Amini, A
   Kouhsari, E
AF Sedighi, Mansour
   Bialvaei, Abed Zahedi
   Hamblin, Michael R.
   Ohadi, Elnaz
   Asadi, Arezoo
   Halajzadeh, Masoumeh
   Lohrasbi, Vahid
   Mohammadzadeh, Nima
   Amiriani, Taghi
   Krutova, Marcela
   Amini, Abolfazl
   Kouhsari, Ebrahim
TI Therapeutic bacteria to combat cancer; current advances, challenges, and
   opportunities
SO CANCER MEDICINE
LA English
DT Review
DE bacteriotherapy; cancer; chemotherapy; immunotherapy; radiotherapy;
   tumoricidal agents
ID TUMOR-TARGETING SALMONELLA; GENETICALLY-ENGINEERED SALMONELLA;
   CHEMOTHERAPY-INDUCED DIARRHEA; RADIATION-INDUCED DIARRHEA;
   COLORECTAL-CANCER; CYTOSINE DEAMINASE; GENE-THERAPY;
   CLOSTRIDIUM-ONCOLYTICUM; PROTEIN DELIVERY; RADIO-FREQUENCY
AB Successful treatment of cancer remains a challenge, due to the unique pathophysiology of solid tumors, and the predictable emergence of resistance. Traditional methods for cancer therapy including radiotherapy, chemotherapy, and immunotherapy all have their own limitations. A novel approach is bacteriotherapy, either used alone, or in combination with conventional methods, has shown a positive effect on regression of tumors and inhibition of metastasis. Bacteria-assisted tumor-targeted therapy used as therapeutic/gene/drug delivery vehicles has great promise in the treatment of tumors. The use of bacteria only, or in combination with conventional methods was found to be effective in some experimental models of cancer (tumor regression and increased survival rate). In this article, we reviewed the major advantages, challenges, and prospective directions for combinations of bacteria with conventional methods for tumor therapy.
C1 [Sedighi, Mansour; Bialvaei, Abed Zahedi; Ohadi, Elnaz; Asadi, Arezoo; Halajzadeh, Masoumeh; Lohrasbi, Vahid; Mohammadzadeh, Nima; Kouhsari, Ebrahim] Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran.
   [Hamblin, Michael R.] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
   [Hamblin, Michael R.] Harvard Med Sch, Dept Dermatol, Boston, MA 02115 USA.
   [Hamblin, Michael R.] Harvard Mit Div Hlth Sci & Technol, Cambridge, MA USA.
   [Amiriani, Taghi] Golestan Univ Med Sci, Golestan Res Ctr Gastroenterol & Hepatol, Gorgan, Golestan, Iran.
   [Krutova, Marcela] Charles Univ Prague, Dept Med Microbiol, Fac Med 2, Prague, Czech Republic.
   [Krutova, Marcela] Motol Univ Hosp, Prague, Czech Republic.
   [Amini, Abolfazl; Kouhsari, Ebrahim] Golestan Univ Med Sci, Lab Sci Res Ctr, Gorgan, Golestan, Iran.
C3 Iran University of Medical Sciences; Harvard University; Massachusetts
   General Hospital; Harvard University; Harvard Medical School; Harvard
   University; Golestan University of Medical Sciences; Charles University
   Prague; Motol University Hospital; Motol University Hospital; Golestan
   University of Medical Sciences
RP Kouhsari, E (corresponding author), Iran Univ Med Sci, Sch Med, Dept Microbiol, Tehran, Iran.
EM Ekouhsari1987@gmail.com
RI Hamblin, Michael/H-2758-2019; Hallajzadeh, masoume/AAX-8596-2021;
   Sedighi, Mansour/AEC-3916-2022; Amiriani, Taghi/AAT-7496-2020; ohadi,
   elnaz/AAQ-6016-2020; bialvaei, Abed/AAN-5324-2021; Kouhsari,
   Ebrahim/GRJ-1090-2022; Krutova, Marcela/I-6452-2019; Amini,
   Abolfazl/J-9131-2013
OI Sedighi, Mansour/0000-0002-8361-2904; Amini,
   Abolfazl/0000-0002-2495-5368; Krutova, Marcela/0000-0002-4511-9430;
   Hamblin, Michael R/0000-0001-6431-4605; Kouhsari,
   Ebrahim/0000-0001-5893-6483; Zahedi bialvaei, Abed/0000-0003-3564-9566
FU US NIH [R01AI050875, R21AI121700]
FX Dr Hamblin was supported by US NIH Grants R01AI050875 and R21AI121700.
CR Abdollahi H, 2015, J MED HYPOTHESES IDE, V9, P67, DOI 10.1016/j.jmhi.2015.04.001
   Abdollahi H, 2015, MED HYPOTHESES, V84, P194, DOI 10.1016/j.mehy.2014.12.021
   Abdollahi H, 2014, NUTRITION, V30, P495, DOI 10.1016/j.nut.2013.09.006
   Agrawal N, 2004, P NATL ACAD SCI USA, V101, P15172, DOI 10.1073/pnas.0406242101
   Ahmed N, 2012, DRUG DISCOV TODAY, V17, P928, DOI 10.1016/j.drudis.2012.03.010
   Ali RAR, 2018, GASTROENTEROLOGY, V154, pS414
   Ansiaux R, 2007, EXPERT OPIN INV DRUG, V16, P209, DOI 10.1517/13543784.16.2.209
   Avogadri F, 2005, CANCER RES, V65, P3920, DOI 10.1158/0008-5472.CAN-04-3002
   Barbé S, 2005, FEMS MICROBIOL LETT, V246, P67, DOI 10.1016/j.femsle.2005.03.037
   Benoit MR, 2009, CLIN CANCER RES, V15, P5170, DOI 10.1158/1078-0432.CCR-08-3206
   Bermudes D, 2002, CURR OPIN DRUG DISC, V5, P194
   Bermudes D, 2000, METH MOLEC MED, V35, P419, DOI 10.1385/1-59259-086-1:419
   Bettegowda C, 2003, P NATL ACAD SCI USA, V100, P15083, DOI 10.1073/pnas.2036598100
   Bhatt AP, 2017, CA-CANCER J CLIN, V67, P327, DOI 10.3322/caac.21398
   Binder DC, 2017, TRENDS MOL MED, V23, P580, DOI 10.1016/j.molmed.2017.05.008
   Bowen JM, 2007, CANCER BIOL THER, V6, P1449, DOI 10.4161/cbt.6.9.4622
   BRAY F, 2018, CA-CANCER J CLIN, V68, P394, DOI [DOI 10.3322/CANJCLIN.49.1.33, DOI 10.3322/CAAC.21492]
   Brizel DM, 2000, J CLIN ONCOL, V18, P3339, DOI 10.1200/JCO.2000.18.19.3339
   Burdelya LG, 2008, SCIENCE, V320, P226, DOI 10.1126/science.1154986
   Burdelya LG, 2012, INT J RADIAT ONCOL, V83, P228, DOI 10.1016/j.ijrobp.2011.05.055
   Busch W., 1868, Berl Klin Wochenschr, V5, P137, DOI DOI 10.1177/1534735416649916
   CARSWELL EA, 1975, P NATL ACAD SCI USA, V72, P3666, DOI 10.1073/pnas.72.9.3666
   Chang CW, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00983
   Cheong I, 2006, SCIENCE, V314, P1308, DOI 10.1126/science.1130651
   Cheong I, 2009, METHOD ENZYMOL, V465, P251, DOI 10.1016/S0076-6879(09)65013-8
   Chitapanarux I, 2010, RADIAT ONCOL, V5, DOI 10.1186/1748-717X-5-31
   Coley WB., 1906, Trans Southern Surg Gynecol Ass, V18, P197
   Dang L, 2011, United States patent, Patent No. [US 8,007,782, 8007782]
   Dang LH, 2001, P NATL ACAD SCI USA, V98, P15155, DOI 10.1073/pnas.251543698
   Dang LH, 2004, CANCER BIOL THER, V3, P326, DOI 10.4161/cbt.3.3.704
   Datta NR, 2015, CANCER TREAT REV, V41, P742, DOI 10.1016/j.ctrv.2015.05.009
   Davis A J, 2000, Lancet Oncol, V1, P86, DOI 10.1016/S1470-2045(00)00019-X
   Davis Alison J, 2002, Cancer Treat Res, V112, P1
   Delia P, 2007, WORLD J GASTROENTERO, V13, P912, DOI 10.3748/wjg.v13.i6.912
   Delia P, 2002, AM J GASTROENTEROL, V97, P2150
   Demirer S, 2006, NUTRITION, V22, P179, DOI 10.1016/j.nut.2005.08.003
   Diaz LA, 2005, TOXICOL SCI, V88, P562, DOI 10.1093/toxsci/kfi316
   DIETZEL F, 1977, STRAHLENTHER ONKOL, V153, P263
   DIETZEL F, 1976, STRAHLENTHER ONKOL, V152, P537
   Dresselaers T, 2003, BRIT J CANCER, V89, P1796, DOI 10.1038/sj.bjc.6601345
   Dubois L, 2007, BRIT J CANCER, V96, P758, DOI 10.1038/sj.bjc.6603624
   El-Atti SA, 2009, JPEN-PARENTER ENTER, V33, P569, DOI 10.1177/0148607109332004
   Evrard A, 1999, BRIT J CANCER, V80, P1726, DOI 10.1038/sj.bjc.6690589
   Falnes PO, 2000, J BIOL CHEM, V275, P4363, DOI 10.1074/jbc.275.6.4363
   Fehleisen F., 1882, Dtsch Med Wochenschr, V8, P553, DOI DOI 10.1055/S-0029-1196806
   Felgner S, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1382791
   Felgner S, 2017, MICROB BIOTECHNOL, V10, P1074, DOI 10.1111/1751-7915.12787
   Fiorentini C, 1998, EXP CELL RES, V242, P341, DOI 10.1006/excr.1998.4057
   Flentie K, 2012, CANCER DISCOV, V2, P624, DOI 10.1158/2159-8290.CD-11-0201
   Forbes NS, 2010, NAT REV CANCER, V10, P784, DOI 10.1038/nrc2934
   Furumoto K, 2004, J CLIN INVEST, V113, P774, DOI 10.1172/JCI200419762
   Ganai S, 2009, BRIT J CANCER, V101, P1683, DOI 10.1038/sj.bjc.6605403
   Gardlik R, 2010, IDRUGS, V13, P701
   Gelman AE, 2003, NAT MED, V9, P1465, DOI 10.1038/nm1203-1465
   GERICKE D, 1979, ZBL BAKT-INT J MED M, V243, P102
   Ginn SL, 2018, J GENE MED, V20, DOI 10.1002/jgm.3015
   Giralt J, 2008, INT J RADIAT ONCOL, V71, P1213, DOI 10.1016/j.ijrobp.2007.11.009
   Groot AJ, 2007, BIOCHEM BIOPH RES CO, V364, P985, DOI 10.1016/j.bbrc.2007.10.126
   Hajitou A, 2006, CELL, V125, P385, DOI 10.1016/j.cell.2006.02.042
   Harrison LB, 2002, ONCOLOGIST, V7, P492, DOI 10.1634/theoncologist.7-6-492
   Hatefi A, 2009, GENE THER MOL BIOL, V13, P15
   He JY, 2018, MED HYPOTHESES, V119, P37, DOI 10.1016/j.mehy.2018.07.024
   Heimann DM, 2003, J IMMUNOTHER, V26, P179, DOI 10.1097/00002371-200303000-00011
   Higgins DE, 1999, MOL MICROBIOL, V31, P1631, DOI 10.1046/j.1365-2958.1999.01272.x
   Ho CL, 2018, NAT BIOMED ENG, V2, P27, DOI 10.1038/s41551-017-0181-y
   Hoffman RM, 2006, NAT PROTOC, V1, P2988, DOI 10.1038/nprot.2006.376
   Ibsen S, 2013, DRUG DES DEV THER, V7, P375, DOI 10.2147/DDDT.S31564
   Jahanban-Esfahlan R, 2018, J CELL PHYSIOL, V233, P2019, DOI 10.1002/jcp.25859
   Jia LJ, 2007, INT J CANCER, V121, P666, DOI 10.1002/ijc.22688
   Jia LJ, 2007, CANCER SCI, V98, P1107, DOI 10.1111/j.1349-7006.2007.00503.x
   Jiang SN, 2010, MOL THER, V18, P635, DOI 10.1038/mt.2009.295
   Kamta J, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00064
   Kasinskas RW, 2006, BIOTECHNOL BIOENG, V94, P710, DOI 10.1002/bit.20883
   Kay AB, 2001, NEW ENGL J MED, V344, P30, DOI 10.1056/NEJM200101043440106
   Khademi S, 2014, IRAN J PUBLIC HEALTH, V43, P1018
   Ki Y, 2014, J KOREAN MED SCI, V29, P1372, DOI 10.3346/jkms.2014.29.10.1372
   Ki Y, 2013, INT J RADIAT ONCOL, V87, P646, DOI 10.1016/j.ijrobp.2013.07.038
   Kizaka-Kondoh S, 2003, CANCER SCI, V94, P1021, DOI 10.1111/j.1349-7006.2003.tb01395.x
   KLASTERSKY J, 1989, DIAGN MICR INFEC DIS, V12, pS201
   Kominsky SL, 2004, AM J PATHOL, V164, P1627, DOI 10.1016/S0002-9440(10)63721-2
   Kouhsari E, 2018, CLIN TRANSL ONCOL, V20, P127, DOI 10.1007/s12094-017-1701-7
   Kramer MG, 2018, FRONT MICROBIOL, V9, DOI 10.3389/fmicb.2018.00016
   Lee CH, 2005, MOL THER, V11, P707, DOI 10.1016/j.ymthe.2005.01.008
   Lemmon MA, 1997, EMBO J, V16, P281, DOI 10.1093/emboj/16.2.281
   Liu XD, 2016, EXP ANIM TOKYO, V65, P413, DOI 10.1538/expanim.16-0033
   Low KB, 1999, NAT BIOTECHNOL, V17, P37, DOI 10.1038/5205
   Luo CH, 2016, NANO LETT, V16, P3493, DOI 10.1021/acs.nanolett.6b00262
   MALMGREN RA, 1955, CANCER RES, V15, P473
   Maroccia Z, 2018, BIOMED PHARMACOTHER, V101, P929, DOI 10.1016/j.biopha.2018.02.140
   Marshall J.C., 1999, CURR OPIN CRIT CARE, V5, P119, DOI DOI 10.1097/00075198-199904000-00005
   MARTH E, 1987, ZBL BAKT-INT J MED M, V265, P33
   Mego M, 2013, COMPLEMENT THER MED, V21, P712, DOI 10.1016/j.ctim.2013.08.018
   Mei SP, 2002, ANTICANCER RES, V22, P3261
   Mengesha A, 2007, FRONT BIOSCI-LANDMRK, V12, P3880, DOI 10.2741/2357
   Min JJ, 2008, NAT PROTOC, V3, P629, DOI 10.1038/nprot.2008.32
   Min JJ, 2008, MOL IMAGING BIOL, V10, P54, DOI 10.1007/s11307-007-0120-5
   Minton NP, 2003, NAT REV MICROBIOL, V1, P237, DOI 10.1038/nrmicro777
   Murphy C, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0180034
   Nallar SC, 2017, CYTOKINE, V89, P160, DOI 10.1016/j.cyto.2016.01.002
   Nemunaitis J, 2003, CANCER GENE THER, V10, P737, DOI 10.1038/sj.cgt.7700634
   Nguyen VH, 2010, CANCER RES, V70, P18, DOI 10.1158/0008-5472.CAN-09-3453
   Nougayrède JP, 2005, TRENDS MICROBIOL, V13, P103, DOI 10.1016/j.tim.2005.01.002
   Nuyts S, 2001, RADIAT RES, V155, P716, DOI 10.1667/0033-7587(2001)155[0716:TUORIB]2.0.CO;2
   Nuyts S, 2001, GENE THER, V8, P1197, DOI 10.1038/sj.gt.3301499
   Nuyts S, 2001, ANTICANCER RES, V21, P857
   Oren Aharon, 2013, Life-Basel, V3, P1, DOI 10.3390/life3010001
   Österlund P, 2007, BRIT J CANCER, V97, P1028, DOI 10.1038/sj.bjc.6603990
   OSWALD E, 1994, P NATL ACAD SCI USA, V91, P3814, DOI 10.1073/pnas.91.9.3814
   Parsonnet J, 1995, ENVIRON HEALTH PERSP, V103, P263, DOI 10.2307/3432323
   Patyar S, 2010, J BIOMED SCI, V17, DOI 10.1186/1423-0127-17-21
   Pawelek JM, 1997, CANCER RES, V57, P4537
   Pearl R, 1929, AM J HYG, V9, P97, DOI 10.1093/oxfordjournals.aje.a121646
   Pfeifer F, 2012, NAT REV MICROBIOL, V10, P705, DOI 10.1038/nrmicro2834
   Platt J, 2000, EUR J CANCER, V36, P2397, DOI 10.1016/S0959-8049(00)00336-1
   Puri RK, 1999, TOXICOL PATHOL, V27, P53, DOI 10.1177/019262339902700111
   Quispe-Tintaya W, 2013, P NATL ACAD SCI USA, V110, P8668, DOI 10.1073/pnas.1211287110
   Reuter URM, 2018, TRANSL ONCOL, V11, P330, DOI 10.1016/j.tranon.2018.01.019
   Riglar DT, 2018, NAT REV MICROBIOL, V16, P214, DOI 10.1038/nrmicro.2017.172
   Ryan RM, 2009, GENE THER, V16, P329, DOI 10.1038/gt.2008.188
   SCHLECHTE H, 1988, ZBL BAKT-INT J MED M, V268, P347, DOI 10.1016/S0176-6724(88)80019-1
   Shao F, 2014, CELL BIOCHEM BIOPHYS, V69, P357, DOI 10.1007/s12013-013-9807-1
   Shapiro MG, 2014, NAT NANOTECHNOL, V9, P311, DOI [10.1038/nnano.2014.32, 10.1038/NNANO.2014.32]
   Sharma A, 2012, EUR J CANCER, V48, P875, DOI 10.1016/j.ejca.2011.06.010
   Song SY, 2018, INFECT AGENTS CANCER, V13, DOI 10.1186/s13027-018-0180-y
   Springer CJ, 2000, J CLIN INVEST, V105, P1161, DOI 10.1172/JCI10001
   Taniguchi S, 2010, CANCER SCI, V101, P1925, DOI 10.1111/j.1349-7006.2010.01628.x
   Thamm DH, 2005, CLIN CANCER RES, V11, P4827, DOI 10.1158/1078-0432.CCR-04-2510
   Theys J, 2006, BRIT J CANCER, V95, P1212, DOI 10.1038/sj.bjc.6603367
   Theys J, 2001, CANCER GENE THER, V8, P294, DOI 10.1038/sj.cgt.7700303
   Theys J, 1999, APPL ENVIRON MICROB, V65, P4295
   Theys J, 2015, ANN TRANSL MED, V3, DOI 10.3978/j.issn.2305-5839.2015.03.39
   Thomsen M, 2018, INTEGR CANCER THER, V17, P1027, DOI 10.1177/1534735418794885
   Thun MJ, 2010, CARCINOGENESIS, V31, P100, DOI 10.1093/carcin/bgp263
   Tietze R, 2015, BIOCHEM BIOPH RES CO, V468, P463, DOI 10.1016/j.bbrc.2015.08.022
   Tjuvajev J, 2001, J CONTROL RELEASE, V74, P313, DOI 10.1016/S0168-3659(01)00340-6
   Toso JF, 2002, J CLIN ONCOL, V20, P142, DOI 10.1200/JCO.2002.20.1.142
   Urbanska AM, 2015, CELL BIOCHEM BIOPHYS, V72, P757, DOI 10.1007/s12013-015-0528-5
   Van Mellaert L, 2006, TRENDS MICROBIOL, V14, P190, DOI 10.1016/j.tim.2006.02.002
   Nguyen VH, 2017, NUCL MED MOLEC IMAG, V51, P118, DOI 10.1007/s13139-016-0415-z
   Wachsberger P, 2003, CLIN CANCER RES, V9, P1957
   Wai SN, 2003, CELL, V115, P25, DOI 10.1016/S0092-8674(03)00754-2
   Wang C, 2016, PHARMACOL RES, V105, P164, DOI 10.1016/j.phrs.2016.01.028
   Wang K, 2016, PHARMACOL RES, V114, P56, DOI 10.1016/j.phrs.2016.10.016
   Wei D, 2018, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008831.pub3
   Wei MQ, 2007, EUR J CANCER, V43, P490, DOI 10.1016/j.ejca.2006.10.005
   Weill FS, 2013, BRIT J NUTR, V109, P457, DOI 10.1017/S0007114512001225
   Whitford EJ, 2009, CANCER BIOL THER, V8, P505, DOI 10.4161/cbt.8.6.7594
   Wood LM, 2008, IMMUNOL RES, V42, P233, DOI 10.1007/s12026-008-8087-0
   Xie J, 2010, ADV DRUG DELIVER REV, V62, P1064, DOI 10.1016/j.addr.2010.07.009
   Xiong GS, 2010, INT J CANCER, V126, P2622, DOI 10.1002/ijc.24957
   Xu G, 2001, CLIN CANCER RES, V7, P3314
   Yam C, 2010, J SURG RES, V164, P248, DOI 10.1016/j.jss.2009.02.023
   Yazawa K, 2001, BREAST CANCER RES TR, V66, P165, DOI 10.1023/A:1010644217648
   Yu YA, 2004, NAT BIOTECHNOL, V22, P313, DOI 10.1038/nbt937
   Zahaf NI, 2017, TOXINS, V9, DOI 10.3390/toxins9080236
   Zhang S, 2014, REV MED MICROBIOL, V25, P71, DOI 10.1097/MRM.0000000000000005
   Zhao M, 2005, P NATL ACAD SCI USA, V102, P755, DOI 10.1073/pnas.0408422102
   Zheng DW, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03233-9
   Zheng Jin Hai, 2016, Chonnam Med J, V52, P173, DOI 10.4068/cmj.2016.52.3.173
   Zhou S., 2018, J OPTICAL COMMUNICAT, V1, pA20
   Zurkiya O, 2008, MAGN RESON MED, V59, P1225, DOI 10.1002/mrm.21606
NR 161
TC 171
Z9 188
U1 4
U2 89
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD JUN
PY 2019
VL 8
IS 6
BP 3167
EP 3181
DI 10.1002/cam4.2148
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA IH1YO
UT WOS:000474292100045
PM 30950210
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Park, R
   Winnicki, M
   Liu, E
   Chu, WM
AF Park, Ryan
   Winnicki, Mary
   Liu, Evan
   Chu, Wen-Ming
TI Immune checkpoints and cancer in the immunogenomics era
SO BRIEFINGS IN FUNCTIONAL GENOMICS
LA English
DT Review
DE CTLA-4; PD-1; PD-L1; immune checkpoint blockade; immunogenomics; MMR
   deficiency; POLE; somatic; mutation; resistance to checkpoint blockade;
   neoantigen
ID COLORECTAL-CANCER; MISMATCH-REPAIR; PD-L1 EXPRESSION; TARGETED-THERAPY;
   PARP INHIBITION; BLOCKADE; ACTIVATION; MUTATIONS; ANTIBODY; BREAST
AB Immune checkpoints have been the subject of a wave of new studies. Among these checkpoints are tytotoxic T-lymphocyte-associated antigen 4, checkpoints programmed death-1 and programmed death-ligand 1; their blockades have been approved by the Food and Drug Administration for therapy of melanoma and other types of cancers. Immunogenomics, which combines the latest nucleic acid sequencing strategy with immunotherapy, provides precise information about genomic alterations (e.g. mutations) and enables a paradigm shift of immune checkpoint therapy from tumor types to molecular signatures. Studying these critical checkpoints in relation to genomic mutations and neoantigens has produced groundbreaking results. This article examines these studies and delves into the relationships between immune checkpoint blockade and tumors harboring certain genomic mutations. Moreover, this article reviews recent studies on resistance to immune checkpoint therapy.
C1 [Chu, Wen-Ming] Univ Hawaii, Ctr Canc, Honolulu, HI 96822 USA.
   [Park, Ryan; Winnicki, Mary; Liu, Evan] Univ Hawaii, Ctr Canc, Dr Chus Lab, Honolulu, HI 96822 USA.
C3 University of Hawaii System; Cancer Research Center of Hawaii; Cancer
   Research Center of Hawaii; University of Hawaii System
RP Chu, WM (corresponding author), Univ Hawaii, Ctr Canc, Canc Biol Program, Honolulu, HI 96813 USA.
EM wchu@cc.hawaii.edu
OI Liu, Evan/0000-0003-4493-6225; Park, Ryan/0000-0002-7426-2068
FU National Institute of Health/National Cancer Institute [U01CA188387-01];
   University of Hawaii Pilot Awards; University of Hawaii Star-up fund
FX This article was supported in part by National Institute of
   Health/National Cancer Institute grant U01CA188387-01 to Jia and Chu and
   University of Hawaii Pilot Awards and Star-up fund to Chu.
CR Akbay EA, 2013, CANCER DISCOV, V3, P1355, DOI 10.1158/2159-8290.CD-13-0310
   Anagnostou V, 2017, CANCER DISCOV, V7, P264, DOI 10.1158/2159-8290.CD-16-0828
   Anderson AC, 2012, CURR OPIN IMMUNOL, V24, P213, DOI 10.1016/j.coi.2011.12.005
   [Anonymous], 2013, Cancer Discov, V3, pOF14, DOI 10.1158/2159-8290.CD-NB2013-074
   Azuma K, 2014, ANN ONCOL, V25, P1935, DOI 10.1093/annonc/mdu242
   Bourdais R, 2017, CRIT REV ONCOL HEMAT, V113, P242, DOI 10.1016/j.critrevonc.2017.03.027
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Cai T, 2018, CANC MED
   Cao C, 2009, SCI SIGNAL, V2, DOI 10.1126/scisignal.2000118
   Castro MP, 2015, J IMMUNOTHER CANCER, V3, DOI 10.1186/s40425-015-0104-y
   Chae Young Kwang, 2018, Oncotarget, V9, P7949, DOI 10.18632/oncotarget.23742
   Champiat S, 2017, CLIN CANCER RES, V23, P1920, DOI 10.1158/1078-0432.CCR-16-1741
   Chang LS, 2018, APPL IMMUNOHISTO M M, V26, pE15, DOI 10.1097/PAI.0000000000000575
   Chen N, 2015, J THORAC ONCOL, V10, P910, DOI 10.1097/JTO.0000000000000500
   Chuk MK, 2017, CLIN CANCER RES, V23, P5666, DOI 10.1158/1078-0432.CCR-16-0663
   Cooper WA, 2015, LUNG CANCER, V89, P181, DOI 10.1016/j.lungcan.2015.05.007
   Czink E, 2017, COLD SPRING HARB MOL, V3, P1
   Denkert C, 2017, LANCET, V389, P2430, DOI 10.1016/S0140-6736(16)32454-0
   Domingo E, 2016, LANCET GASTROENTEROL, V1, P207, DOI 10.1016/S2468-1253(16)30014-0
   Du Y, 2016, NAT MED, V22, P194, DOI 10.1038/nm.4032
   Easton D F, 1999, Breast Cancer Res, V1, P14, DOI 10.1186/bcr6
   Erasimus H, 2016, MUTAT RES-REV MUTAT, V769, P19, DOI 10.1016/j.mrrev.2016.05.005
   Fong PC, 2009, NEW ENGL J MED, V361, P123, DOI 10.1056/NEJMoa0900212
   Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396
   Hamid O, 2013, NEW ENGL J MED, V369, P134, DOI 10.1056/NEJMoa1305133
   Hassan S, 2017, MOL CANCER THER, V16, P2892, DOI 10.1158/1535-7163.MCT-17-0170
   Heong V, 2017, J GYNECOL ONCOL, V28, DOI 10.3802/jgo.2017.28.e20
   Higuchi T, 2015, CANCER IMMUNOL RES, V3, P1257, DOI 10.1158/2326-6066.CIR-15-0044
   Hulpke S, 2013, TRENDS BIOCHEM SCI, V38, P412, DOI 10.1016/j.tibs.2013.06.003
   Iyevleva AG, 2016, HERED CANCER CLIN PR, V14, DOI 10.1186/s13053-016-0057-2
   Izzedine H, 2017, NEPHROL DIAL TRANSPL, V32, P936, DOI 10.1093/ndt/gfw382
   Jiang RQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15129
   Johanns TM, 2016, CANCER DISCOV, V6, P1230, DOI 10.1158/2159-8290.CD-16-0575
   Johnson A, 2017, ONCOLOGIST, V22, P1478, DOI 10.1634/theoncologist.2017-0242
   June CH, 2017, NAT MED, V23, P540, DOI 10.1038/nm.4321
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Lee DH, 2017, PHARMACOL THERAPEUT, V174, P1, DOI 10.1016/j.pharmthera.2017.02.001
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Luckheeram RV, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/925135
   Maker AV, 2005, ANN SURG ONCOL, V12, P1005, DOI 10.1245/ASO.2005.03.536
   Mehnert JM, 2016, J CLIN INVEST, V126, P2334, DOI 10.1172/JCI84940
   Modrich P, 1996, ANNU REV BIOCHEM, V65, P101, DOI 10.1146/annurev.bi.65.070196.000533
   Nolan E, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aal4922
   Pentcheva-Hoang T, 2004, IMMUNITY, V21, P401, DOI 10.1016/j.immuni.2004.06.017
   Prakash R, 2015, CSH PERSPECT BIOL, V7, DOI 10.1101/cshperspect.a016600
   Robert C, 2011, NEW ENGL J MED, V364, P2517, DOI 10.1056/NEJMoa1104621
   Sjöblom T, 2006, SCIENCE, V314, P268, DOI 10.1126/science.1133427
   Sloan EA, 2017, AM J SURG PATHOL, V41, P326, DOI 10.1097/PAS.0000000000000783
   Stordal B, 2013, MOL ONCOL, V7, P567, DOI 10.1016/j.molonc.2012.12.007
   Sunshine J, 2015, CURR OPIN PHARMACOL, V23, P32, DOI 10.1016/j.coph.2015.05.011
   Syn NL, 2017, LANCET ONCOL, V18, pE731, DOI 10.1016/S1470-2045(17)30607-1
   Tang YN, 2015, ONCOTARGET, V6, P14209, DOI 10.18632/oncotarget.3694
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   van Gool IC, 2015, CLIN CANCER RES, V21, P3347, DOI 10.1158/1078-0432.CCR-15-0057
   Wang ZW, 2014, CELL COMMUN SIGNAL, V12, DOI 10.1186/1478-811X-12-10
   Weber J, 2007, ONCOLOGIST, V12, P864, DOI 10.1634/theoncologist.12-7-864
   Xiao YP, 2015, CANCER DISCOV, V5, P16, DOI 10.1158/2159-8290.CD-14-1397
   Yang CY, 2016, EUR J CANCER, V57, P91, DOI 10.1016/j.ejca.2015.12.033
   Yung WKA, 2000, BRIT J CANCER, V83, P588, DOI 10.1054/bjoc.2000.1316
   Zaiss DMW, 2013, IMMUNITY, V38, P275, DOI 10.1016/j.immuni.2012.09.023
   Zhang LY, 2008, J MOL DIAGN, V10, P301, DOI 10.2353/jmoldx.2008.080062
   Zhu J, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00784-1
NR 62
TC 19
Z9 20
U1 0
U2 12
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 2041-2649
EI 2041-2657
J9 BRIEF FUNCT GENOMICS
JI Brief. Funct. Genomics
PD MAR
PY 2019
VL 18
IS 2
BP 133
EP 139
DI 10.1093/bfgp/ely027
PG 7
WC Biotechnology & Applied Microbiology; Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Genetics & Heredity
GA HQ8WF
UT WOS:000462706800008
PM 30137232
OA Green Published
DA 2025-01-04
ER

PT J
AU Ronnekleiv-Kelly, SM
   Burkhart, RA
   Pawlik, TM
AF Ronnekleiv-Kelly, Sean M.
   Burkhart, Richard A.
   Pawlik, Timothy M.
TI Molecular markers of prognosis and therapeutic targets in metastatic
   colorectal cancer
SO SURGICAL ONCOLOGY-OXFORD
LA English
DT Article
DE Colorectal; Targeted therapy; Metastatic colorectal cancer; Molecular
   markers; Biologic therapy
ID CETUXIMAB PLUS IRINOTECAN; CIRCULATING TUMOR-CELLS; RANDOMIZED
   PHASE-III; CLINICAL RISK SCORE; ANTI-EGFR THERAPY; LIVER METASTASES;
   1ST-LINE TREATMENT; MUTATION STATUS; RAS MUTATIONS; BRAF MUTATION
AB Metastatic disease ultimately occurs in approximately 50-70% of patients presenting with colorectal cancer. In patients with advanced disease, there is significant variability in individual patient outcomes. To improve understanding of tumor behavior, markers such as KRAS and BRAF mutation status are increasingly utilized. Additionally, newer surrogates of tumor biology, such as telomerase activity and the prevalence of circulating tumor cells and circulating tumor DNA, have generated increasing interest due to clinical potential. While the extent to which these newer markers can predict outcome and guide therapy is yet to be determined, KRAS mutation status is currently used to guide systemic therapy in selected patients. Furthermore, advances in our understanding of various tumorigenic pathways (such as the mitogen activated protein kinase pathway) have enabled newer targeted agents, including BRAF inhibitors. Interestingly, although inhibition of BRAF in patients has not translated into improved outcomes, characterization of BRAF mutations led to an association with microsatellite instability. A unique histologic characteristic of certain tumors in patients with microsatellite instability is the infiltration by lymphocytes at the tumor-stromal interface. This feature highlights the biology of the tumor in its microenvironment and underlies the efficacy of the programmed-death inhibitor, pembrolizumab, in patients with microsatellite unstable metastatic colorectal cancer. With an increasing number of prognostic markers and therapeutic options in metastatic colorectal cancer, the multidisciplinary approach becomes critical for appropriate treatment decisions. (C) 2016 Elsevier Ltd. All rights reserved.
C1 [Ronnekleiv-Kelly, Sean M.; Burkhart, Richard A.; Pawlik, Timothy M.] Johns Hopkins Univ, Sch Med, Dept Surg, Baltimore, MD 21205 USA.
C3 Johns Hopkins University
RP Pawlik, TM (corresponding author), Johns Hopkins Univ Hosp, Div Surg Oncol, Dept Surg, 600 N Wolfe St,Blalock 688, Baltimore, MD 21287 USA.
EM tpawlik1@jhmi.edu
RI Pawlik, Timothy/AAO-9335-2020
OI Ronnekleiv-Kelly, Sean/0000-0001-6664-996X
FU NCI NIH HHS [T32 CA126607] Funding Source: Medline
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Allegra CJ, 2011, J CLIN ONCOL, V29, P11, DOI 10.1200/JCO.2010.30.0855
   Andreyev HJN, 2001, BRIT J CANCER, V85, P692, DOI 10.1054/bjoc.2001.1964
   Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675
   [Anonymous], 2014, Colorectal cancer facts & figures 2014-2016
   Barbazán J, 2014, INT J CANCER, V135, P2633, DOI 10.1002/ijc.28910
   Bendell J. C. A. C., 2014, J CLIN ONCOL, P32
   Benson AB III, 2014, J NATL COMPR CANC NE, V12, P1028, DOI 10.6004/jnccn.2014.0099
   Bertorelle R, 2013, BRIT J CANCER, V108, P278, DOI 10.1038/bjc.2012.602
   Bertorelle R, 2014, WORLD J GASTROENTERO, V20, P1940, DOI 10.3748/wjg.v20.i8.1940
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   Blazer DG, 2008, J CLIN ONCOL, V26, P5344, DOI 10.1200/JCO.2008.17.5299
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bokemeyer C, 2012, EUR J CANCER, V48, P1466, DOI 10.1016/j.ejca.2012.02.057
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Boonsirikamchai P, 2011, AM J ROENTGENOL, V197, pW1060, DOI 10.2214/AJR.11.6459
   Bredt LC, 2014, WORLD J SURG ONCOL, V12, DOI 10.1186/1477-7819-12-391
   Chua TC, 2010, ANN SURG ONCOL, V17, P492, DOI 10.1245/s10434-009-0781-1
   Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755
   Chung WS, 2012, AM J ROENTGENOL, V199, P809, DOI 10.2214/AJR.11.7910
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Douillard JY, 2010, J CLIN ONCOL, V28, P4697, DOI 10.1200/JCO.2009.27.4860
   Eisenhauer EA, 2009, EUR J CANCER, V45, P228, DOI 10.1016/j.ejca.2008.10.026
   Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004
   Goldstein J, 2014, ANN ONCOL, V25, P1032, DOI 10.1093/annonc/mdu100
   Gruenberger B, 2008, BMC CANCER, V8, DOI 10.1186/1471-2407-8-120
   Gruenberger B, 2008, J CLIN ONCOL, V26, P1830, DOI 10.1200/JCO.2007.13.7679
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Hurwitz HI, 2009, ONCOLOGIST, V14, P22, DOI 10.1634/theoncologist.2008-0213
   Ivanecz A, 2014, HPB, V16, P235, DOI 10.1111/hpb.12089
   Kabbinavar F, 2003, J CLIN ONCOL, V21, P60, DOI 10.1200/JCO.2003.10.066
   Karagkounis G, 2013, CANCER-AM CANCER SOC, V119, P4137, DOI 10.1002/cncr.28347
   Koch M, 2005, ANN SURG, V241, P199, DOI 10.1097/01.sla.0000151795.15068.27
   Koerkamp BG, 2013, ANN SURG ONCOL, V20, P2156, DOI 10.1245/s10434-013-2907-8
   Koopman M, 2009, BRIT J CANCER, V100, P266, DOI 10.1038/sj.bjc.6604867
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Macedo LT, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-89
   Maithel SK, 2012, SURGERY, V151, P162, DOI 10.1016/j.surg.2011.07.020
   Mao C, 2012, ANN ONCOL, V23, P1518, DOI 10.1093/annonc/mdr464
   Margonis G, 2015, ANN SURG ONCOL, V22, P4158, DOI 10.1245/s10434-015-4587-z
   Margonis GA, 2015, JAMA SURG, V150, P722, DOI 10.1001/jamasurg.2015.0313
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Neal CP, 2006, EUR J CANCER, V42, P1728, DOI 10.1016/j.ejca.2006.01.056
   Okines A, 2009, BRIT J CANCER, V101, P1033, DOI 10.1038/sj.bjc.6605259
   Peeters M, 2015, CLIN CANCER RES, V21, P5469, DOI 10.1158/1078-0432.CCR-15-0526
   Price TJ, 2015, BRIT J CANCER, V112, P963, DOI 10.1038/bjc.2015.37
   Primrose J, 2014, LANCET ONCOL, V15, P601, DOI 10.1016/S1470-2045(14)70105-6
   Pucciarelli S, 2012, ANN SURG ONCOL, V19, P3089, DOI 10.1245/s10434-012-2272-z
   Rubbia-Brandt L, 2007, ANN ONCOL, V18, P299, DOI 10.1093/annonc/mdl386
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Schirripa M, 2015, BRIT J CANCER, V112, P1921, DOI 10.1038/bjc.2015.142
   Shaib W, 2013, J GASTROINTEST ONCOL, V4, P308, DOI 10.3978/j.issn.2078-6891.2013.029
   Sinicrope FA, 2011, JNCI-J NATL CANCER I, V103, P863, DOI 10.1093/jnci/djr153
   Spolverato G, 2013, WORLD J GASTRO ONCOL, V5, P207, DOI 10.4251/wjgo.v5.i12.207
   Tabernero J, 2015, LANCET ONCOL, V16, P499, DOI 10.1016/S1470-2045(15)70127-0
   Tan C, 2012, WORLD J GASTROENTERO, V18, P5171, DOI 10.3748/wjg.v18.i37.5171
   Terrin L, 2008, CLIN CANCER RES, V14, P7444, DOI 10.1158/1078-0432.CCR-08-0478
   Tie J, 2015, ANN ONCOL, V26, P1715, DOI 10.1093/annonc/mdv177
   Tie J, 2015, TARGET ONCOL, V10, P179, DOI 10.1007/s11523-014-0330-0
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Vale CL, 2012, CANCER TREAT REV, V38, P618, DOI 10.1016/j.ctrv.2011.11.002
   Van Cutsem E, 2009, ANN ONCOL, V20, P1842, DOI 10.1093/annonc/mdp233
   Van Cutsem E, 2007, J CLIN ONCOL, V25, P1658, DOI 10.1200/JCO.2006.08.1620
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Vauthey JN, 2013, ANN SURG, V258, P619, DOI 10.1097/SLA.0b013e3182a5025a
   Vilar E, 2013, CANCER DISCOV, V3, P502, DOI 10.1158/2159-8290.CD-12-0471
   Vogelaar FJ, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-153
   Wanebo HJ, 2012, CLIN EXP METASTAS, V29, P821, DOI 10.1007/s10585-012-9517-x
   Wilke H, 2008, J CLIN ONCOL, V26, P5335, DOI 10.1200/JCO.2008.16.3758
   Yaeger R, 2015, CANCER-AM CANCER SOC, V121, P1195, DOI 10.1002/cncr.29196
   Ye LC, 2013, J CLIN ONCOL, V31, P1931, DOI 10.1200/JCO.2012.44.8308
NR 76
TC 13
Z9 13
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0960-7404
EI 1879-3320
J9 SURG ONCOL
JI Surg. Oncol.-Oxf.
PD SEP
PY 2016
VL 25
IS 3
BP 190
EP 199
DI 10.1016/j.suronc.2016.05.018
PG 10
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA DU5EA
UT WOS:000382233800011
PM 27566022
OA Green Accepted
DA 2025-01-04
ER

PT J
AU Vigna, E
   Chiriaco, C
   Cignetto, S
   Fontani, L
   Basilico, C
   Petronzelli, F
   Comoglio, PM
AF Vigna, Elisa
   Chiriaco, Cristina
   Cignetto, Simona
   Fontani, Lara
   Basilico, Cristina
   Petronzelli, Fiorella
   Comoglio, Paolo M.
TI Inhibition of ligand-independent constitutive activation of the Met
   oncogenic receptor by the engineered chemically-modified antibody DN30
SO MOLECULAR ONCOLOGY
LA English
DT Article
DE Cancer targeted therapy; Met; MvDN30; Anti-Met antibody; HGF
ID HEPATOCYTE GROWTH-FACTOR; TYROSINE KINASE-ACTIVITY; INVASIVE GROWTH;
   C-MET; SOMATIC MUTATIONS; MET/HGF RECEPTOR; DOWN-REGULATION;
   LUNG-CANCER; AMPLIFICATION; PROTOONCOGENE
AB An awesome number of experimental and clinical evidences indicate that constitutive activation of the Met oncogenic receptor plays a critical role in the progression of cancer toward metastasis and/or resistance to targeted therapies. While mutations are rare, the common mechanism of Met activation is overexpression, either by gene amplification ('addiction') or transcriptional activation ('expedience'). In the first instance ligand-independent kinase activation plays a major role in sustaining the transformed phenotype. Anti-Met antibodies directed against the receptor binding site behave essentially as ligand (Hepatocyte Growth Factor, HGF) antagonists and are ineffective to counteract ligand-independent activation. The monovalent chimeric MvDN30 antibody fragment, PEGylated to extend its half-life, binds the fourth IPT domain and induces 'shedding' of the Met extracellular domain, dramatically reducing both the number of receptors on the surface and their phosphorylation. Downstream signaling is thus inhibited, both in the absence or in the presence of the ligand. In vitro, MvDN30 is a strong inhibitor not only of ligand-dependent invasive growth, sustained by both paracrine and autocrine HGF, but notably, also of ligand-independent growth of 'Met-addicted' cells. In immunocompromised mice, lacking expression of Hepatocyte Growth Factor cross-reacting with the human receptor thus providing, by definition, a model of 'ligand-independent' Met activation PEGylated MvDN30 impairs growth of Met 'addicted' human gastric carcinoma cells. In a Metamplified patient-derived cob-rectal tumor (xenopatient) MvDN30-PEG overcomes the resistance to EGFR targeted therapy (Cetuximab). The PEGylated MvDN30 is thus a strong candidate for targeting tumors sustained by ligand-independent Met oncogenic activation. (c) 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.
C1 [Vigna, Elisa; Chiriaco, Cristina; Cignetto, Simona; Fontani, Lara; Basilico, Cristina; Comoglio, Paolo M.] FPO IRCCS, Candiolo Canc Inst, I-10060 Candiolo, Italy.
   [Vigna, Elisa; Cignetto, Simona; Comoglio, Paolo M.] Univ Turin, Dept Oncol, I-10060 Candiolo, Italy.
   [Petronzelli, Fiorella] Sigma Tau SpA R&D, I-00040 Pomezia, Italy.
C3 IRCCS Fondazione del Piemonte per l'Oncologia; University of Turin
RP Vigna, E (corresponding author), FPO IRCCS, Candiolo Canc Inst, Str Prov 142, I-10060 Candiolo, Italy.
EM elisa.vigna@ircc.it; pcomoglio@gmail.com
RI Vigna, Elisa/JWO-5055-2024; Comoglio, Paolo/G-6323-2011; Cignetto,
   Simona/J-5359-2018
OI Vigna, Elisa/0000-0001-9787-5732; Cignetto, Simona/0000-0001-5515-7185;
   Comoglio, Paolo/0000-0002-7056-5328; Fontani, Lara/0000-0003-3593-5781
FU AIRC [11852, 15572]; Special Program Molecular Clinical Oncology 5xMille
   [9970]; 'Metheresis Translational Research SA' grant
FX This work was supported by AIRC grants (IG Project no 11852, IG Project
   no 15572 and 2010 Special Program Molecular Clinical Oncology 5xMille,
   Project no 9970) to PMC and by 'Metheresis Translational Research SA'
   grant to the University of Torino.
CR Baneyx F, 1999, CURR OPIN BIOTECH, V10, P411, DOI 10.1016/S0958-1669(99)00003-8
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Basilico C, 2008, J BIOL CHEM, V283, P21267, DOI 10.1074/jbc.M800727200
   Bean J, 2007, P NATL ACAD SCI USA, V104, P20932, DOI 10.1073/pnas.0710370104
   Birchmeier C, 2003, NAT REV MOL CELL BIO, V4, P915, DOI 10.1038/nrm1261
   Blumenschein GR, 2012, J CLIN ONCOL, V30, P3287, DOI 10.1200/JCO.2011.40.3774
   Boccaccio C, 2006, NAT REV CANCER, V6, P637, DOI 10.1038/nrc1912
   Borset M, 1996, BLOOD, V88, P3998, DOI 10.1182/blood.V88.10.3998.bloodjournal88103998
   Chi AS, 2012, J CLIN ONCOL, V30, pE30, DOI 10.1200/JCO.2011.38.4586
   Comoglio PM, 2008, NAT REV DRUG DISCOV, V7, P504, DOI 10.1038/nrd2530
   Cui JJ, 2014, J MED CHEM, V57, P4427, DOI 10.1021/jm401427c
   Danilkovitch-Miagkova A, 2002, J CLIN INVEST, V109, P863
   De Bacco F, 2011, J NATL CANCER I, V103, P645, DOI 10.1093/jnci/djr093
   DIRENZO MF, 1995, CLIN CANCER RES, V1, P147
   Engelman JA, 2007, SCIENCE, V316, P1039, DOI 10.1126/science.1141478
   FERRACINI R, 1995, ONCOGENE, V10, P739
   Ferracini R, 1996, ONCOGENE, V12, P1697
   Foveau B, 2009, MOL BIOL CELL, V20, P2495, DOI 10.1091/mbc.E08-09-0969
   FRAKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849, DOI 10.1016/0006-291X(78)91322-0
   GAMBAROTTA G, 1994, J BIOL CHEM, V269, P12852
   GIORDANO S, 1988, MOL CELL BIOL, V8, P3510, DOI 10.1128/MCB.8.8.3510
   Harris JM, 2003, NAT REV DRUG DISCOV, V2, P214, DOI 10.1038/nrd1033
   Hildebrandt Bert, 2007, V176, P135
   HOSONO M, 1992, BRIT J CANCER, V65, P197, DOI 10.1038/bjc.1992.41
   HOULDSWORTH J, 1990, CANCER RES, V50, P6417
   Ikebuchi F, 2013, CELL BIOCHEM FUNCT, V31, P298, DOI 10.1002/cbf.2898
   Lee JM, 2014, ONCOGENE, V33, P34, DOI 10.1038/onc.2012.551
   Lennerz JK, 2011, J CLIN ONCOL, V29, P4803, DOI 10.1200/JCO.2011.35.4928
   Liu L, 2014, CLIN CANCER RES, V20, P6059, DOI 10.1158/1078-0432.CCR-14-0543
   Lorenzato A, 2002, CANCER RES, V62, P7025
   Michieli P, 2004, CANCER CELL, V6, P61, DOI 10.1016/j.ccr.2004.05.032
   Michieli P, 1999, ONCOGENE, V18, P5221, DOI 10.1038/sj.onc.1202899
   Migliardi G, 2012, CLIN CANCER RES, V18, P2515, DOI 10.1158/1078-0432.CCR-11-2683
   Miller M, 2001, PROTEINS, V44, P32, DOI 10.1002/prot.1069
   Mukohara T, 2005, CLIN CANCER RES, V11, P8122, DOI 10.1158/1078-0432.CCR-05-1191
   Nakamura Y, 2008, CANCER SCI, V99, P14, DOI 10.1111/j.1349-7006.2007.00640.x
   NALDINI L, 1991, ONCOGENE, V6, P501
   Ou SHI, 2011, J THORAC ONCOL, V6, P942, DOI 10.1097/JTO.0b013e31821528d3
   Pacchiana G, 2010, J BIOL CHEM, V285, P36149, DOI 10.1074/jbc.M110.134031
   PARK M, 1986, CELL, V45, P895, DOI 10.1016/0092-8674(86)90564-7
   Pennacchietti S, 2003, CANCER CELL, V3, P347, DOI 10.1016/S1535-6108(03)00085-0
   Petrelli A, 2006, P NATL ACAD SCI USA, V103, P5090, DOI 10.1073/pnas.0508156103
   Plosker GL, 2003, DRUGS, V63, P803, DOI 10.2165/00003495-200363080-00005
   Prat M, 1998, J CELL SCI, V111, P237
   Schelter F, 2010, J BIOL CHEM, V285, P26335, DOI 10.1074/jbc.M110.106435
   Schmidt L, 1997, NAT GENET, V16, P68, DOI 10.1038/ng0597-68
   SHAWLER DL, 1985, J IMMUNOL, V135, P1530
   Stella GM, 2011, HUM MUTAT, V32, P44, DOI 10.1002/humu.21374
   Tamhane UU, 2008, EXPERT OPIN DRUG SAF, V7, P809, DOI 10.1517/14740330802500353 
   Tong CYK, 2004, J NEUROSURG, V100, P187, DOI 10.3171/ped.2004.100.2.0187
   Trusolino L, 2010, NAT REV MOL CELL BIO, V11, P834, DOI 10.1038/nrm3012
   Wen PY, 2011, NEURO-ONCOLOGY, V13, P437, DOI 10.1093/neuonc/noq198
NR 52
TC 17
Z9 20
U1 0
U2 3
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1574-7891
EI 1878-0261
J9 MOL ONCOL
JI Mol. Oncol.
PD NOV
PY 2015
VL 9
IS 9
BP 1760
EP 1772
DI 10.1016/j.molonc.2015.05.007
PG 13
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA CW3LB
UT WOS:000364892700003
PM 26119717
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Chamberlain, ED
   Costantini, CL
   Xavier, MF
AF Chamberlain, Erin D.
   Costantini, Carrie L.
   Xavier, Marin F.
TI Circulating tumor DNA use in a community oncology practice
SO TRANSLATIONAL CANCER RESEARCH
LA English
DT Article
DE Circulating tumor DNA (ctDNA); comprehensive genomic profiling (CGP);
   community/health; advanced solid tumors
ID MOLECULAR TESTING GUIDELINE; LUNG-CANCER PATIENTS; ASSOCIATION;
   SELECTION; COLLEGE
AB Background: This retrospective single center study aimed to describe circulating tumor DNA (ctDNA) comprehensive genomic profiling (COP) utilization in a community practice for patients with advanced solid tumors.
   Methods: All patients were induded who were seen at the Scripps Hillcrest Oncology Clinic (San Diego, CA, USA) between September 2016 to March 2018 who had ctDNA assay testing performed. In this cohort, all ctDNA testing was performed to aid therapeutic decision making with wide variety in both the type of advanced solid tumor, as well as the line of therapy.
   Results: Of the assays performed in the 41 patients included in this review, 42% of therapeutic actions following ctDNA assay results were influenced by the ctDNA result, induding initiation of the corresponding Federal Drug Administration (FDA) approved therapy, placement on clinical trial, and initiation of off labeltargeted options. In addition, COP results guided clinicians away from futile or harmful treatments, such as EGFR inhibition in colorectal cancer patients with discovered KRAS mutations. No additional prognostic or therapeutic information was gathered in one quarter of patients for which ctDNA was drawn. Furthermore, discovered genomic alterations by ctDNA testing did not influence therapeutic action in 58% of cases.
   Conclusions: These results highlight the conundrum that having additional information regarding an individual's tumor biology does not yet translate into meaningful targeted therapy in the majority of cases. Further studies are needed regarding ctDNA utilization to help guide community oncologists who will continue to face the choice between targeted therapy, immunotherapy, and cytotoxic chemotherapy as science advances.
C1 [Chamberlain, Erin D.; Costantini, Carrie L.; Xavier, Marin F.] Scripps Hillcrest Oncol Clin, San Diego, CA USA.
RP Chamberlain, ED (corresponding author), 10666N Torrey Pines Rd, La Jolla, CA 92037 USA.
EM chamberlain.erin@scrippshealth.org
CR Aggarwal C., 2018, JAMA Oncol, P1
   Ettinger DS, 2018, J NATL COMPR CANC NE, V16, P807, DOI 10.6004/jnccn.2018.0062
   Gutierrez ME, 2017, CLIN LUNG CANCER, V18, P651, DOI 10.1016/j.cllc.2017.04.004
   Kalemkerian GP, 2018, J CLIN ONCOL, V36, P911, DOI 10.1200/JCO.2017.76.7293
   Lindeman NI, 2018, J THORAC ONCOL, V13, P323, DOI 10.1016/j.jtho.2017.12.001
   Odegaard JI, 2018, CLIN CANCER RES, V24, P3539, DOI 10.1158/1078-0432.CCR-17-3831
   Pectasides E, 2018, CANCER DISCOV, V8, P37, DOI 10.1158/2159-8290.CD-17-0395
   Thompson JC, 2016, CLIN CANCER RES, V22, P5772, DOI 10.1158/1078-0432.CCR-16-1231
NR 8
TC 1
Z9 1
U1 0
U2 3
PU AME PUBLISHING COMPANY
PI SHATIN
PA FLAT-RM C 16F, KINGS WING PLAZA 1, NO 3 KWAN ST, SHATIN, HONG KONG
   00000, PEOPLES R CHINA
SN 2218-676X
EI 2219-6803
J9 TRANSL CANCER RES
JI Transl. Cancer Res.
PD APR
PY 2019
VL 8
IS 2
BP 552
EP 556
DI 10.21037/tcr.2019.03.15
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA HW2IN
UT WOS:000466506700024
PM 35116787
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Mokgautsi, N
   Kuo, YC
   Huang, YJ
   Chen, CH
   Mukhopadhyay, D
   Wu, ATH
   Huang, HS
AF Mokgautsi, Ntlotlang
   Kuo, Yu-Cheng
   Huang, Yan-Jiun
   Chen, Chien-Hsin
   Mukhopadhyay, Debabrata
   Wu, Alexander T. H.
   Huang, Hsu-Shan
TI Preclinical Evaluation of a Novel Small Molecule LCC-21 to Suppress
   Colorectal Cancer Malignancy by Inhibiting Angiogenic and Metastatic
   Signatures
SO CELLS
LA English
DT Article
DE colorectal cancer (CRC); LCC-21; niclosamide; angiogenesis; metastasis;
   stemness; therapeutic resistance
ID ENDOTHELIAL GROWTH-FACTOR; VASCULAR-PERMEABILITY FACTOR; INTERACTION
   NETWORK ANALYSIS; NF-KAPPA-B; MATRIX METALLOPROTEINASES;
   GENE-EXPRESSION; BETA-CATENIN; COLON-CANCER; STEM-CELLS; TARGETED
   THERAPY
AB Colorectal cancer (CRC) is one of the most common cancers, and it frequently metastasizes to the liver and lymph nodes. Despite major advances in treatment modalities, CRC remains a poorly characterized biological malignancy, with high reported cases of deaths globally. Moreover, cancer stem cells (CSCs) and their microenvironment have been widely shown to promote colon cancer development, progression, and metastasis. Therefore, an understanding of the underlying mechanisms that contribute to the maintenance of CSCs and their markers in CRC is crucial in efforts to treat cancer metastasis and develop specific therapeutic targets for augmenting current standard treatments. Herein, we applied computational simulations using bioinformatics to identify potential theranostic markers for CRC. We identified the overexpression of vascular endothelial growth factor-alpha (VEGFA)/beta-catenin/matrix metalloproteinase (MMP)-7/Cluster of Differentiation 44 (CD44) in CRC to be associated with cancer progression, stemness, resistance to therapy, metastasis, and poor clinical outcomes. To further investigate, we explored in silico molecular docking, which revealed potential inhibitory activities of LCC-21 as a potential multitarget small molecule for VEGF-A/CTNNB1/MMP7/CD44 oncogenic signatures, with the highest binding affinities displayed. We validated these finding in vitro and demonstrated that LCC-21 inhibited colony and sphere formation, migration, and invasion, and these results were further confirmed by a Western blot analysis in HCT116 and DLD-1 cells. Thus, the inhibitory effects of LCC-21 on these angiogenic and onco-immunogenic signatures could be of translational relevance as potential CRC biomarkers for early diagnosis.
C1 [Mokgautsi, Ntlotlang; Huang, Hsu-Shan] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei 11031, Taiwan.
   [Mokgautsi, Ntlotlang; Huang, Hsu-Shan] Acad Sinica, Taipei 11031, Taiwan.
   [Mokgautsi, Ntlotlang; Huang, Hsu-Shan] Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei 11031, Taiwan.
   [Kuo, Yu-Cheng] Taipei Med Univ, Coll Med, Sch Med, Dept Pharmacol, Taipei 11031, Taiwan.
   [Kuo, Yu-Cheng] China Med Univ, Coll Chinese Med, Sch Postbaccalaureate Chinese Med, Taichung 40402, Taiwan.
   [Huang, Yan-Jiun] Taipei Med Univ, Taipei Med Univ Hosp, Dept Surg, Div Colorectal Surg, Taipei 11031, Taiwan.
   [Huang, Yan-Jiun] Taipei Med Univ, Coll Med, Dept Surg, Taipei 11031, Taiwan.
   [Huang, Yan-Jiun] Taipei Med Univ, Coll Med, Sch Med, Taipei 11031, Taiwan.
   [Chen, Chien-Hsin] Taipei Med Univ, WanFang Hosp, Dept Surg, Div Colorectal Surg, 111 Sec 3 Xinglong Rd, Taipei 11031, Taiwan.
   [Mukhopadhyay, Debabrata] Mayo Clin, Dept Biochem & Mol Biol, PhD Program Biotechnol Res & Dev, Rochester, MN 55905 USA.
   [Wu, Alexander T. H.] Taipei Med Univ, TMU Res Ctr Canc Translat Med, Taipei 11031, Taiwan.
   [Wu, Alexander T. H.] Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei 11031, Taiwan.
   [Wu, Alexander T. H.] Taipei Med Univ, Taipei Med Univ Hosp, Clin Res Ctr, Taipei 11031, Taiwan.
   [Wu, Alexander T. H.] Natl Def Med Ctr, Grad Inst Med Sci, Taipei 11031, Taiwan.
   [Huang, Hsu-Shan] Natl Def Med Ctr, Sch Pharm, Taipei 11031, Taiwan.
C3 Taipei Medical University; Academia Sinica - Taiwan; Taipei Medical
   University; Taipei Medical University; China Medical University Taiwan;
   Taipei Medical University Hospital; Taipei Medical University; Taipei
   Medical University; Taipei Medical University; Taipei Municipal WanFang
   Hospital; Taipei Medical University; Mayo Clinic; Taipei Medical
   University; Taipei Medical University; Taipei Medical University
   Hospital; Taipei Medical University; National Defense Medical Center;
   National Defense Medical Center
RP Huang, HS (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Canc Biol & Drug Discovery, Taipei 11031, Taiwan.; Huang, HS (corresponding author), Acad Sinica, Taipei 11031, Taiwan.; Huang, HS (corresponding author), Taipei Med Univ, Grad Inst Canc Biol & Drug Discovery, Coll Med Sci & Technol, Taipei 11031, Taiwan.; Wu, ATH (corresponding author), Taipei Med Univ, TMU Res Ctr Canc Translat Med, Taipei 11031, Taiwan.; Wu, ATH (corresponding author), Taipei Med Univ, Coll Med Sci & Technol, PhD Program Translat Med, Taipei 11031, Taiwan.; Wu, ATH (corresponding author), Taipei Med Univ, Taipei Med Univ Hosp, Clin Res Ctr, Taipei 11031, Taiwan.; Wu, ATH (corresponding author), Natl Def Med Ctr, Grad Inst Med Sci, Taipei 11031, Taiwan.; Huang, HS (corresponding author), Natl Def Med Ctr, Sch Pharm, Taipei 11031, Taiwan.
EM chaw1211@tmu.edu.tw; huanghs99@tmu.edu.tw
RI Wu, Alexander/AAD-8826-2022
OI Huang, Hsu-Shan/0000-0001-6193-5182; Huang, Yan
   Jiun/0000-0002-5920-0053; Wu, Alexander/0000-0002-0178-6530
FU National Science and Technology Council, Taiwan [111-2314-B-038-098,
   111-2314-B-038-142]; Ministry of Science and Technology, Taiwan
   [MOST111-2314-B-038-122]
FX The National Science and Technology Council, Taiwan, grant number
   NSTC111-2314-B-038-017 and the Ministry of Science and Technology,
   Taiwan, grant number MOST111-2314-B-038-122 awarded to H.-S. Huang. ATH
   Wu is also funded by, The National Science and Technology Council,
   Taiwan, Grant # (111-2314-B-038-098) and (111-2314-B-038-142).
CR Achen MG, 1998, P NATL ACAD SCI USA, V95, P548, DOI 10.1073/pnas.95.2.548
   Adachi Y, 1999, GUT, V45, P252, DOI 10.1136/gut.45.2.252
   Azcárate-Peril MA, 2011, AM J PHYSIOL-GASTR L, V301, pG401, DOI 10.1152/ajpgi.00110.2011
   Brabletz T, 1999, AM J PATHOL, V155, P1033, DOI 10.1016/S0002-9440(10)65204-2
   Brenner H, 2014, LANCET, V383, P1490, DOI 10.1016/S0140-6736(13)61649-9
   BROWN LF, 1993, CANCER RES, V53, P4727
   Calviello G, 2007, CARCINOGENESIS, V28, P1202, DOI 10.1093/carcin/bgl254
   Cascio S, 2009, J CELL PHYSIOL, V221, P189, DOI 10.1002/jcp.21843
   Chen B, 2021, CELL, V184, P6262, DOI 10.1016/j.cell.2021.11.031
   Chen W, 2010, AM J PHYSIOL-GASTR L, V299, pG293, DOI 10.1152/ajpgi.00005.2010
   Cheng XF, 2019, BIOMED PHARMACOTHER, V110, P473, DOI 10.1016/j.biopha.2018.11.082
   Cook AD, 2005, ANN SURG ONCOL, V12, P637, DOI 10.1245/ASO.2005.06.012
   Cousins KR, 2011, J AM CHEM SOC, V133, P8388, DOI 10.1021/ja204075s
   Crawford HC, 2002, J CLIN INVEST, V109, P1437, DOI 10.1172/JCI200215051
   Daina A, 2017, SCI REP-UK, V7, DOI 10.1038/srep42717
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   De Simone M, 2016, IMMUNITY, V45, P1135, DOI 10.1016/j.immuni.2016.10.021
   Deryugina EI, 2015, MATRIX BIOL, V44-46, P94, DOI 10.1016/j.matbio.2015.04.004
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Dotse E, 2016, CYTOTECHNOLOGY, V68, P609, DOI 10.1007/s10616-014-9806-0
   Dvorak HF, 1999, CURR TOP MICROBIOL, V237, P97
   Edgar R, 2002, NUCLEIC ACIDS RES, V30, P207, DOI 10.1093/nar/30.1.207
   Ellis L M, 2000, Oncologist, V5 Suppl 1, P11
   Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246
   Fang YJ, 2009, INT J COLORECTAL DIS, V24, P875, DOI 10.1007/s00384-009-0725-z
   Fernando NH, 2003, SEMIN ONCOL, V30, P39, DOI 10.1016/S0093-7754(03)00124-6
   Ferrara N, 2002, NAT REV CANCER, V2, P795, DOI 10.1038/nrc909
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
   Fu YH, 2013, J ETHNOPHARMACOL, V145, P193, DOI 10.1016/j.jep.2012.10.051
   Gao RL, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00244-w
   George ML, 2001, NEOPLASIA, V3, P420, DOI 10.1038/sj.neo.7900186
   Gfeller D, 2014, NUCLEIC ACIDS RES, V42, pW32, DOI 10.1093/nar/gku293
   Gillies RJ, 2012, NAT REV CANCER, V12, P487, DOI 10.1038/nrc3298
   Hanahan D, 1996, CELL, V86, P353, DOI 10.1016/S0092-8674(00)80108-7
   Hauptman N, 2018, BIOMED RES INT, V2018, DOI 10.1155/2018/9416515
   He F, 2016, ONCOTARGET, V7, P81156, DOI 10.18632/oncotarget.13215
   Hoeben A, 2004, PHARMACOL REV, V56, P549, DOI 10.1124/pr.56.4.3
   Hu Jia, 2020, Nan Fang Yi Ke Da Xue Xue Bao, V40, P922, DOI 10.12122/j.issn.1673-4254.2020.07.02
   Hu TH, 2014, CANCER LETT, V354, P417, DOI 10.1016/j.canlet.2014.08.012
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Hui YF, 1997, AM J HEALTH-SYST PH, V54, P162, DOI 10.1093/ajhp/54.2.162
   Isbister WH, 2002, ANZ J SURG, V72, P271, DOI 10.1046/j.1445-2197.2002.02369.x
   Ito TK, 2009, BLOOD, V113, P2363, DOI 10.1182/blood-2008-08-172742
   Jeffery N, 2009, HISTOPATHOLOGY, V54, P820, DOI 10.1111/j.1365-2559.2009.03301.x
   Joukov V, 1996, EMBO J, V15, P290
   Kasprzak A, 2020, CANCERS, V12, DOI 10.3390/cancers12123601
   KECK PJ, 1989, SCIENCE, V246, P1309, DOI 10.1126/science.2479987
   Kellam P., 2001, GENOME BIOL, V2, P4011
   Kelland L, 2007, NAT REV CANCER, V7, P573, DOI 10.1038/nrc2167
   Kitajima K, 2004, J GASTROENTEROL, V39, P534, DOI 10.1007/s00535-004-1339-4
   Kumar A, 2018, BIOCHEM BIOPH RES CO, V500, P731, DOI 10.1016/j.bbrc.2018.04.144
   Kuo WL, 2013, PHYTOCHEMISTRY, V85, P153, DOI 10.1016/j.phytochem.2012.08.014
   Kurmyshkina O, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21186515
   Lajous H, 2019, TRENDS PHARMACOL SCI, V40, P342, DOI 10.1016/j.tips.2019.03.003
   Lee CC, 2015, BIOORGAN MED CHEM, V23, P4522, DOI 10.1016/j.bmc.2015.06.007
   Lee CC, 2015, EUR J MED CHEM, V98, P115, DOI 10.1016/j.ejmech.2015.05.015
   Lee HO, 2020, NAT GENET, V52, P594, DOI 10.1038/s41588-020-0636-z
   Li TW, 2017, CANCER RES, V77, pE108, DOI 10.1158/0008-5472.CAN-17-0307
   Li TL, 2018, ONCOL LETT, V16, P687, DOI 10.3892/ol.2018.8733
   Li Y, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.684309
   Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240
   Lipinski CA, 2001, ADV DRUG DELIVER REV, V46, P3, DOI 10.1016/S0169-409X(00)00129-0
   Liu D, 2009, NEUROMOL MED, V11, P28, DOI 10.1007/s12017-009-8058-1
   Liu HB, 2014, J CHEM INF MODEL, V54, P1050, DOI 10.1021/ci500004h
   Lizárraga-Verdugo E, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.00413
   Lu ML, 2019, EUR REV MED PHARMACO, V23, P121, DOI 10.26355/eurrev_201901_16756
   Ma R, 2017, MAT SCI ENG C-MATER, V77, P352, DOI 10.1016/j.msec.2017.03.161
   Sayagués JM, 2016, ONCOTARGET, V7, P72908, DOI 10.18632/oncotarget.12140
   Marijnen CAM, 2002, J CLIN ONCOL, V20, P817, DOI 10.1200/JCO.20.3.817
   Masaki T, 2003, ANTICANCER RES, V23, P4169
   Maurel J, 2007, INT J CANCER, V121, P1066, DOI 10.1002/ijc.22799
   McDermott DF, 2018, NAT MED, V24, P749, DOI 10.1038/s41591-018-0053-3
   Mokgautsi N, 2021, CANCERS, V13, DOI 10.3390/cancers13112523
   Mokgautsi N, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22052464
   Mottaghi S, 2022, NUTR CANCER, V74, P761, DOI 10.1080/01635581.2021.1931364
   Munro MJ, 2018, J CLIN PATHOL, V71, P110, DOI 10.1136/jclinpath-2017-204739
   NEWELL KJ, 1994, MOL CARCINOGEN, V10, P199, DOI 10.1002/mc.2940100404
   Newman DJ, 2020, J NAT PROD, V83, P770, DOI 10.1021/acs.jnatprod.9b01285
   Overall CM, 2006, NAT REV CANCER, V6, P227, DOI 10.1038/nrc1821
   Pathan M, 2015, PROTEOMICS, V15, P2597, DOI 10.1002/pmic.201400515
   Quintero-Fabián S, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01370
   Rehman SK, 2021, CELL, V184, P226, DOI 10.1016/j.cell.2020.11.018
   Roy R, 2006, EXP CELL RES, V312, P608, DOI 10.1016/j.yexcr.2005.11.022
   Schmieder R, 2014, INT J CANCER, V135, P1487, DOI 10.1002/ijc.28669
   Seeliger Daniel, 2010, J Comput Aided Mol Des, V24, P417, DOI 10.1007/s10822-010-9352-6
   SENGER DR, 1983, SCIENCE, V219, P983, DOI 10.1126/science.6823562
   Shan ZM, 2018, BIOMED PHARMACOTHER, V101, P769, DOI 10.1016/j.biopha.2018.02.123
   Shangguan WQ, 2017, CANCER SCI, V108, P1357, DOI 10.1111/cas.13262
   Sharma P, 2015, CELL, V161, P205, DOI 10.1016/j.cell.2015.03.030
   Shoemaker RH, 2006, NAT REV CANCER, V6, P813, DOI 10.1038/nrc1951
   Siegel R, 2014, CA-CANCER J CLIN, V64, P104, DOI [10.3322/caac.21220, 10.3322/caac.21395]
   StetlerStevenson WG, 1996, SEMIN CANCER BIOL, V7, P147, DOI 10.1006/scbi.1996.0020
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Takada K, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003808
   Tang R, 2020, PEERJ, V8, DOI 10.7717/peerj.9602
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Vlachavas EI, 2019, COMPUT STRUCT BIOTEC, V17, P177, DOI 10.1016/j.csbj.2019.01.007
   White BD, 2012, GASTROENTEROLOGY, V142, P219, DOI 10.1053/j.gastro.2011.12.001
   Willett CG, 2004, NAT MED, V10, P145, DOI 10.1038/nm988
   Wilson CL, 1996, INT J BIOCHEM CELL B, V28, P123, DOI 10.1016/1357-2725(95)00121-2
   Woenne EC, 2010, ANTICANCER RES, V30, P703
   Xia JG, 2014, NUCLEIC ACIDS RES, V42, pW167, DOI 10.1093/nar/gku443
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xue ZZ, 2016, PHYTOCHEMISTRY, V127, P50, DOI 10.1016/j.phytochem.2016.03.011
   Yoshida N, 2015, ANTICANCER RES, V35, P4403
   Zeuner A, 2014, CELL STEM CELL, V15, P692, DOI 10.1016/j.stem.2014.11.012
   Zhao CG, 2015, ONCOTARGET, V6, P14472, DOI 10.18632/oncotarget.3991
   Zhou GY, 2019, NUCLEIC ACIDS RES, V47, pW234, DOI 10.1093/nar/gkz240
   Zugazagoitia J, 2016, CLIN THER, V38, P1551, DOI 10.1016/j.clinthera.2016.03.026
NR 111
TC 0
Z9 0
U1 0
U2 0
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2073-4409
J9 CELLS-BASEL
JI Cells
PD JAN
PY 2023
VL 12
IS 2
AR 266
DI 10.3390/cells12020266
PG 26
WC Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Cell Biology
GA 7X7ZC
UT WOS:000914414600001
PM 36672201
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Kowal, M
   Douglas, F
   Jayne, D
   Meads, D
AF Kowal, Mikolaj
   Douglas, Francesca
   Jayne, David
   Meads, David
TI Patient choice in colorectal cancer treatment - A systematic review and
   narrative synthesis of attribute-based stated preference studies
SO COLORECTAL DISEASE
LA English
DT Review
DE colonic neoplasms; colorectal neoplasms; humans; patient preference;
   research
ID RECTAL-CANCER; CONJOINT-ANALYSIS; PHYSICIAN PREFERENCES;
   DECISION-MAKING; COLON-CANCER; CHEMOTHERAPY; OUTCOMES; THERAPY; LUNG
AB Aim The global burden of colorectal cancer (CRC) is set to increase by 60% by 2030. An aging population and increasing treatment complexity add difficulties for patients and clinicians in CRC management. Patient preferences can be investigated using attribute-based stated preference (AbSP) techniques to explore trade-offs between different treatments. These techniques include discrete-choice experiments (DCEs), conjoint analysis and time-trade off (TTO) methods. This systematic review with a narrative synthesis aimed to determine the use and design of AbSP studies in CRC treatment and to identify patient choice themes. Methods The searches were performed using MEDLINE, Embase, PsycInfo and Cochrane Library in March 2021. All manuscripts featuring the use of AbSP techniques in CRC treatment were included. Data synthesis was performed using a narrative approach. Results The search strategy returned 271 articles. Eighteen AbSP studies were included featuring 1890 patients and 296 clinicians. AbSP techniques compromised DCE (38.9%, n = 7), TTO (38.9%, n = 7) and conjoint analysis (22.2%, n = 4). Eleven studies (61.1%) involved piloting of tasks and the average task completion rate was 75%. CRC treatments included chemotherapy (33%, n = 6), combined treatments (33%, n = 6), surgery (17%, n = 3), targeted therapy (11%, n = 2) and radiotherapy (6%, n = 1). The most examined domain was physical health, investigated with 49 (59.8%) attributes. Conclusions Life expectancy was the main attribute in chemotherapy treatment. With surgery, patients were willing to trade life-expectancy to avoid adverse outcomes or a permanent stoma. Communication skills, treatment cost, and clinicians' views were important attributes for patients in cancer services. Further research in the elderly population, and other quality of life domains, are needed to deliver patient-centred CRC care.
C1 [Kowal, Mikolaj; Douglas, Francesca; Jayne, David] St James Univ Hosp, John Goligher Colorectal Surg Unit, Beckett St, Leeds, W Yorkshire, England.
   [Kowal, Mikolaj; Douglas, Francesca; Jayne, David] Univ Leeds, Fac Med & Hlth, Leeds Inst Med Res, Leeds, W Yorkshire, England.
   [Meads, David] Univ Leeds, Leeds Inst Hlth Sci, Leeds, W Yorkshire, England.
C3 Saint James's University Hospital; University of Leeds; University of
   Leeds
RP Kowal, M (corresponding author), St James Univ Hosp, John Goligher Colorectal Surg Unit, Beckett St, Leeds, W Yorkshire, England.
EM mikolajkowal@doctors.org.uk
RI Kowal, Mikolaj/AAM-5550-2021
OI Jayne, David/0000-0002-8725-3283; Meads, David/0000-0003-1369-2483;
   Kowal, Mikolaj/0000-0001-5628-4880
CR Albassam A, 2011, VALUE HEALTH, V14, pA169, DOI 10.1016/j.jval.2011.02.939
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Attema AE, 2013, EUR J HEALTH ECON, V14, pS53, DOI 10.1007/s10198-013-0508-x
   Blinman P, 2010, EUR J CANCER, V46, P1800, DOI 10.1016/j.ejca.2009.12.032
   Bossema E, 2008, EJSO-EUR J SURG ONC, V34, P42, DOI 10.1016/j.ejso.2007.08.007
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Bridges JFP, 2011, VALUE HEALTH, V14, P403, DOI 10.1016/j.jval.2010.11.013
   Campbell M, 2018, BMJ OPEN, V8, DOI 10.1136/bmjopen-2017-020064
   Coast J, 2012, HEALTH ECON, V21, P730, DOI 10.1002/hec.1739
   Couture J, 2005, DIS COLON RECTUM, V48, P2055, DOI 10.1007/s10350-005-0174-x
   Currie A, 2015, COLORECTAL DIS, V17, P17, DOI 10.1111/codi.12754
   Damm K, 2014, EUR J CANCER CARE, V23, P762, DOI 10.1111/ecc.12207
   Florescu-Tenea R M, 2019, Curr Health Sci J, V45, P134, DOI 10.12865/CHSJ.45.02.02
   Flynn TN, 2007, J HEALTH ECON, V26, P171, DOI 10.1016/j.jhealeco.2006.04.002
   González JM, 2017, CANCER MANAG RES, V9, P149, DOI 10.2147/CMAR.S125245
   Harrison JD, 2008, ARCH SURG-CHICAGO, V143, P389, DOI 10.1001/archsurg.143.4.389
   Klojgaard ME, 2012, J CHOICE MODEL, V5, P1, DOI 10.1016/S1755-5345(13)70050-2
   Kordatou Z, 2014, THER ADV MED ONCOL, V6, P128, DOI 10.1177/1758834014523328
   Leavitt M, 2001, MedGenMed, V3, P2
   Masya LM, 2009, DIS COLON RECTUM, V52, P1994, DOI 10.1007/DCR.0b013e3181c001b9
   Millan M, 2015, WORLD J GASTRO ONCOL, V7, P204, DOI 10.4251/wjgo.v7.i10.204
   Miller Paul J E, 2013, J Med Econ, V16, P1179, DOI 10.3111/13696998.2013.832257
   Osoba D, 2006, QUAL LIFE RES, V15, P273, DOI 10.1007/s11136-005-0580-5
   Page M.J., 2021, BMJ, V372, DOI [DOI 10.1136/BMJ.N71, 10.1136/bmj.n71]
   Pieterse AH, 2007, BRIT J CANCER, V97, P717, DOI 10.1038/sj.bjc.6603954
   Pieterse AH, 2019, ACTA ONCOL, V58, P1069, DOI 10.1080/0284186X.2019.1594363
   Pieterse AH, 2010, HEALTH EXPECT, V13, P392, DOI 10.1111/j.1369-7625.2010.00595.x
   Post Marcel W M, 2014, Top Spinal Cord Inj Rehabil, V20, P167, DOI 10.1310/sci2003-167
   Rosato R, 2020, CURR MED RES OPIN, V36, P73, DOI 10.1080/03007995.2019.1670475
   Ryan M, 2000, BMJ-BRIT MED J, V320, P1530, DOI 10.1136/bmj.320.7248.1530
   Salkeld G, 2005, BRIT J SURG, V92, P742, DOI 10.1002/bjs.4917
   Schmidt K, 2017, PATIENT PREFER ADHER, V11, P1647, DOI 10.2147/PPA.S138863
   Shea BJ, 2017, BMJ-BRIT MED J, V358, DOI 10.1136/bmj.j4008
   Soekhai V, 2019, PHARMACOECONOMICS, V37, P201, DOI 10.1007/s40273-018-0734-2
   Solomon MJ, 2003, DIS COLON RECTUM, V46, P1351, DOI 10.1007/s10350-004-6749-0
   van der Valk MJM, 2020, EJSO-EUR J SURG ONC, V46, P1634, DOI 10.1016/j.ejso.2020.04.014
   Wong XY, 2020, CURR MED RES OPIN, V36, P1677, DOI 10.1080/03007995.2020.1790348
NR 37
TC 7
Z9 7
U1 3
U2 10
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1462-8910
EI 1463-1318
J9 COLORECTAL DIS
JI Colorectal Dis.
PD NOV
PY 2022
VL 24
IS 11
BP 1295
EP 1307
DI 10.1111/codi.16242
EA JUL 2022
PG 13
WC Gastroenterology & Hepatology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology; Surgery
GA 6M4UM
UT WOS:000826397700001
PM 35776854
OA Green Published, hybrid
DA 2025-01-04
ER

PT J
AU Yeh, YS
   Tsai, HL
   Chen, PJ
   Chen, YC
   Su, WC
   Chang, TK
   Huang, CW
   Wang, JY
AF Yeh, Yung-Sung
   Tsai, Hsiang-Lin
   Chen, Po-Jung
   Chen, Yen-Cheng
   Su, Wei-Chih
   Chang, Tsung-Kun
   Huang, Ching-Wen
   Wang, Jaw-Yuan
TI Identifying and clinically validating biomarkers for immunotherapy in
   colorectal cancer
SO EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
LA English
DT Review
DE Biomarker; immunotherapy; colorectal cancer; microsatellite instability
   (MSI)
ID MISMATCH REPAIR-DEFICIENT; MICROSATELLITE INSTABILITY; BRAF MUTATION;
   OPEN-LABEL; EXPRESSION; DNA; MASPIN; PEMBROLIZUMAB; METASTASES;
   NIVOLUMAB
AB IntroductionColorectal cancer (CRC) is a leading cause of death. For three decades, chemotherapy with or without targeted therapy (provided before or after tumor resection surgery) has been the standard treatment for patients with CRC. Biomarkers are key tools for performing early detection, prognostication, and survival and treatment response predictions. Notably, immune checkpoint inhibitors (ICIs) have transformed prognoses for solid tumors (including CRC).Area coveredAlthough immunotherapy has developed considerably, it is only effective for a small number of microsatellite instability-high (MSIH) cancer cases; such cases represent only 5% of metastatic CRC (mCRC) cases, which are characterized by an immune-inflamed microenvironment that can be rewired against cancer cells through ICI administration. Immunotherapy research is gradually uncovering the mechanism underlying immune resistance in patients with CRC and discovering new biomarkers. For example, studies have clinically validated the associations of deficient mismatch repair system/microsatellite instability, tumor mutation burden, programmed death ligand 1 expression, and polymerase epsilon with CRC in patients undergoing immunotherapy.Expert opinionsClinical trials documenting the effect of immune checkpoints were performed to produce long-lasting effects for patients with mCRC. Consequently, therapeutic decision-making models are further refined by the inclusion of powerful molecular biomarkers in patients with CRC.
C1 [Yeh, Yung-Sung] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Trauma & Surg Crit Care, Kaohsiung, Taiwan.
   [Yeh, Yung-Sung] Kaohsiung Med Univ, Coll Med, Fac Postbaccalaureate Med, Dept Emergency Med, Kaohsiung, Taiwan.
   [Yeh, Yung-Sung] Taipei Med Univ, Grad Inst Injury Prevent & Control, Coll Publ Hlth, Taipei, Taiwan.
   [Tsai, Hsiang-Lin; Chen, Po-Jung; Chen, Yen-Cheng; Su, Wei-Chih; Chang, Tsung-Kun; Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Dept Surg, Div Colorectal Surg, Kaohsiung, Taiwan.
   [Tsai, Hsiang-Lin; Huang, Ching-Wen; Wang, Jaw-Yuan] Kaohsiung Med Univ, Coll Med, Fac Med, Dept Surg, Kaohsiung, Taiwan.
   [Chen, Po-Jung; Chen, Yen-Cheng; Su, Wei-Chih; Chang, Tsung-Kun; Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, 100,Tzyou 1st Road, Kaohsiung 80708, Taiwan.
   [Chang, Tsung-Kun] Kaohsiung Med Univ, Coll Med, Fac Postbaccalaureate Med, Dept Surg, Kaohsiung, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Grad Inst Med, Coll Med, Kaohsiung, Taiwan.
   [Wang, Jaw-Yuan] Kaohsiung Med Univ, Ctr Canc Res, Kaohsiung, Taiwan.
   [Wang, Jaw-Yuan] Minist Hlth & Welf, Pingtung Hosp, Pingtung, Taiwan.
C3 Kaohsiung Medical University; Kaohsiung Medical University Hospital;
   Kaohsiung Medical University; Taipei Medical University; Kaohsiung
   Medical University; Kaohsiung Medical University Hospital; Kaohsiung
   Medical University; Kaohsiung Medical University; Kaohsiung Medical
   University; Kaohsiung Medical University; Kaohsiung Medical University
RP Wang, JY (corresponding author), Kaohsiung Med Univ, Grad Inst Clin Med, Coll Med, 100,Tzyou 1st Road, Kaohsiung 80708, Taiwan.
EM cy614112@ms14.hinet.net
RI Jaw-Yuan, Wang/AFS-8845-2022
OI Wang, Jaw-Yuan/0000-0002-7705-2621
FU Ministry of Science and Technology [MOST 109-2314-B-037-046-MY3, MOST
   111-2314-B-037-070-MY3, MOST 111-2314-B-037-049]; Ministry of Health and
   Welfare [12D1-IVMOHW02]; health and welfare surcharge of on tobacco
   products; Kaohsiung Medical University Hospital [KMUH111-1R31,
   KMUH111-1R32, KMUH111-1M28, KMUH111-1M29, KMUH111-1M31]; Kaohsiung
   Medical University; Grant of Taiwan Precision Medicine Initiative;
   Taiwan Biobank, Academia Sinica, Taiwan, R.O.C.
FX This work was supported by grants through funding from the Ministry of
   Science and Technology (MOST 109-2314-B-037-046-MY3, MOST
   111-2314-B-037-070-MY3, MOST 111-2314-B-037-049) and the Ministry of
   Health and Welfare (12D1-IVMOHW02) and funded by the health and welfare
   surcharge of on tobacco products, and the Kaohsiung Medical University
   Hospital (KMUH111-1R31, KMUH111-1R32, KMUH111-1M28, KMUH111-1M29,
   KMUH111-1M31) and Kaohsiung Medical University. In addition, this study
   was supported by the Grant of Taiwan Precision Medicine Initiative and
   Taiwan Biobank, Academia Sinica, Taiwan, R.O.C.
CR Agarwal P, 2021, ADV CANCER RES, V151, P137, DOI 10.1016/bs.acr.2021.03.002
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   André T, 2015, J CLIN ONCOL, V33, P4176, DOI 10.1200/JCO.2015.63.4238
   Antonia SJ, 2017, NEW ENGL J MED, V377, P1919, DOI 10.1056/NEJMoa1709937
   Arnold M, 2017, GUT, V66, P683, DOI 10.1136/gutjnl-2015-310912
   Banias L, 2020, ONCOL LETT, V19, P1487, DOI 10.3892/ol.2019.11228
   Banias L, 2017, PATHOL RES PRACT, V213, P1227, DOI 10.1016/j.prp.2017.07.025
   Baraibar I, 2020, EXPERT REV MOL DIAGN, V20, P653, DOI 10.1080/14737159.2020.1782194
   Benatti P, 2005, CLIN CANCER RES, V11, P8332, DOI 10.1158/1078-0432.CCR-05-1030
   Benson A, 2021, J NATL COMPR CANC NE, V19, P329, DOI 10.6004/jnccn.2021.0012
   Berger MD, 2016, EXPERT OPIN DRUG SAF, V15, P799, DOI 10.1517/14740338.2016.1167186
   Blaeschke F, 2019, CYTOTHERAPY, V21, P973, DOI 10.1016/j.jcyt.2019.06.009
   Bodenstine TM, 2012, CANCER METAST REV, V31, P529, DOI 10.1007/s10555-012-9361-0
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Branchoux S, 2022, ESMO OPEN, V7, DOI 10.1016/j.esmoop.2021.100340
   Carlsen L, 2022, CANCERS, V14, DOI 10.3390/cancers14041028
   Cercek A, 2022, NEW ENGL J MED, V386, P2363, DOI 10.1056/NEJMoa2201445
   Chalabi M, 2020, NAT MED, V26, P566, DOI 10.1038/s41591-020-0805-8
   Chen HH, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.764912
   Cristescu R, 2018, SCIENCE, V362, P197, DOI 10.1126/science.aar3593
   Damato A, 2022, LIFE-BASEL, V12, DOI 10.3390/life12081137
   Demisse R, 2020, J NATL COMPR CANC NE, V18, P798, DOI 10.6004/jnccn.2020.7558
   Diaz LA, 2022, LANCET ONCOL, V23, P659, DOI 10.1016/S1470-2045(22)00197-8
   Droeser RA, 2013, EUR J CANCER, V49, P2233, DOI 10.1016/j.ejca.2013.02.015
   Fares J, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0134-x
   Fusco MJ, 2021, JAMA ONCOL, V7, P316, DOI 10.1001/jamaoncol.2020.6371
   Garon EB, 2015, NEW ENGL J MED, V372, P2018, DOI 10.1056/NEJMoa1501824
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Guo M, 2021, WORLD J GASTRO ONCOL, V13, P1043, DOI 10.4251/wjgo.v13.i9.1043
   Guo WJ, 2022, ACS APPL MATER INTER, V14, P31634, DOI 10.1021/acsami.2c06001
   Gurzu S, 2021, CANCERS, V13, DOI 10.3390/cancers13030366
   Gurzu S, 2016, WORLD J GASTROENTERO, V22, P6764, DOI 10.3748/wjg.v22.i30.6764
   Gurzu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057699
   Hennequart M, 2017, CANCER IMMUNOL RES, V5, P695, DOI 10.1158/2326-6066.CIR-16-0400
   Hu KP, 2017, FEBS OPEN BIO, V7, P1144, DOI 10.1002/2211-5463.12254
   Huang MY, 2016, TRANSL ONCOL, V9, P340, DOI 10.1016/j.tranon.2016.06.006
   Huyghe N, 2022, CANCERS, V14, DOI 10.3390/cancers14092241
   Intlekofer AM, 2013, J LEUKOCYTE BIOL, V94, P25, DOI 10.1189/jlb.1212621
   Jemal A, 2007, CA-CANCER J CLIN, V57, P43, DOI 10.3322/canjclin.57.1.43
   Keshinro A, 2021, JCO PRECIS ONCOL, V5, P817, DOI 10.1200/PO.20.00456
   Khorsandi L, 2020, ENVIRON SCI POLLUT R, V27, P38300, DOI 10.1007/s11356-020-09986-5
   Kishore C, 2021, EUR J PHARMACOL, V893, DOI 10.1016/j.ejphar.2020.173819
   Lee WS, 2007, INT J COLORECTAL DIS, V22, P699, DOI 10.1007/s00384-006-0218-2
   Lenz HJ, 2022, J CLIN ONCOL, V40, P161, DOI 10.1200/JCO.21.01015
   Liang L, 2022, J PHYSIOL PHARMACOL, V73, DOI 10.26402/jpp.2022.2.04
   Liao LL, 2022, FRONT BIOENG BIOTECH, V10, DOI 10.3389/fbioe.2022.822835
   Lipson EJ, 2013, CLIN CANCER RES, V19, P462, DOI 10.1158/1078-0432.CCR-12-2625
   Lombardi G, 2020, CANCERS, V12, DOI 10.3390/cancers12082283
   Lui YNYN, 2002, CLIN CHEM, V48, P421
   Ma XT, 2022, J EXP CLIN CANC RES, V41, DOI 10.1186/s13046-022-02422-1
   Marabelle A, 2020, LANCET ONCOL, V21, P1353, DOI 10.1016/S1470-2045(20)30445-9
   Marcus Leigh, 2021, Clin Cancer Res, V27, P4685, DOI 10.1158/1078-0432.CCR-21-0327
   Marisa L, 2018, JNCI-J NATL CANCER I, V110, DOI 10.1093/jnci/djx136
   Mazzoli G, 2022, EUR J CANCER, V172, P171, DOI 10.1016/j.ejca.2022.05.044
   Min L, 2023, J CLIN MED, V12, DOI 10.3390/jcm12020408
   Neumann J, 2012, PATHOLOGE, V33, P39, DOI 10.1007/s00292-011-1543-y
   Ogunwobi OO, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21155311
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Patel TH., 2022, CLIN CANCER RES, DOI [10.1158/1078-0432.CCR-22-2036, DOI 10.1158/1078-0432.CCR-22-2036]
   Rousseau B, 2020, JAMA ONCOL, V6, P589, DOI 10.1001/jamaoncol.2020.0065
   Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8
   Sha D, 2020, CANCER DISCOV, V10, P1808, DOI 10.1158/2159-8290.CD-20-0522
   Shun-Long O., 2022, FRONT IMMUNOL, V13, P953761
   Su WC, 2022, CURR ISSUES MOL BIOL, V44, P1552, DOI 10.3390/cimb44040106
   Takahashi H, 2022, J PATHOL CLIN RES, V8, P458, DOI 10.1002/cjp2.285
   Taube JM, 2014, CLIN CANCER RES, V20, P5064, DOI 10.1158/1078-0432.CCR-13-3271
   Toyoda A, 2009, INT J ONCOL, V34, P53, DOI 10.3892/ijo_00000128
   Trullas A, 2021, ESMO OPEN, V6, DOI 10.1016/j.esmoop.2021.100145
   Tsai HL, 2021, ONCOL RES, V29, P47, DOI 10.3727/096504022X16451187313084
   Tsai HL, 2020, EUR J CANCER, V138, P19, DOI 10.1016/j.ejca.2020.05.031
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Vinayak S, 2019, JAMA ONCOL, V5, P1132, DOI 10.1001/jamaoncol.2019.1029
   Wang PP, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.672677
   Wang PY, 2022, MOL CANCER THER, V21, P974, DOI 10.1158/1535-7163.MCT-21-0599
   Wang SW, 2022, BMC MED GENOMICS, V15, DOI 10.1186/s12920-022-01329-2
   Weng JY, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01294-4
   Yang TR, 2021, HUM VACC IMMUNOTHER, V17, P546, DOI 10.1080/21645515.2020.1782692
   Zheng YWL, 2012, CLIN CHEM, V58, P549, DOI 10.1373/clinchem.2011.169318
NR 79
TC 3
Z9 3
U1 4
U2 14
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 1473-7159
EI 1744-8352
J9 EXPERT REV MOL DIAGN
JI Expert Rev. Mol. Diagn.
PD MAR 4
PY 2023
VL 23
IS 3
BP 231
EP 241
DI 10.1080/14737159.2023.2188195
EA MAR 2023
PG 11
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA A7VN5
UT WOS:000949447500001
PM 36908268
DA 2025-01-04
ER

PT J
AU Zhang, HL
   Zhang, AH
   Miao, JH
   Sun, H
   Yan, GL
   Wu, FF
   Wang, XJ
AF Zhang, Hong-lian
   Zhang, Ai-hua
   Miao, Jian-hua
   Sun, Hui
   Yan, Guang-li
   Wu, Fang-fang
   Wang, Xi-jun
TI Targeting regulation of tryptophan metabolism for colorectal cancer
   therapy: a systematic review
SO RSC ADVANCES
LA English
DT Review
ID PERFORMANCE LIQUID-CHROMATOGRAPHY; ARYL-HYDROCARBON RECEPTOR; GUT
   MICROBIAL-METABOLISM; HIGH-THROUGHPUT; BIOMARKER DISCOVERY;
   COLON-CANCER; INDOLEAMINE 2,3-DIOXYGENASE; DENDRITIC CELLS; KYNURENIC
   ACID; T-CELLS
AB Colorectal cancer (CRC) is one of the most malignant cancers resulting from abnormal metabolism alterations. As one of the essential amino acids, tryptophan has a variety of physiological functions, closely related to regulation of immune system, central nervous system, gastrointestinal nervous system and intestinal microflora. Colorectal cancer, a type of high-grade malignancy disease, stems from a variety of factors and often accompanies inflammatory reactions, dysbacteriosis, and metabolic disorders. Colorectal cancer accompanies inflammation and imbalance of intestinal microbiota and affects tryptophan metabolism. It is known that metabolites, rate-limiting enzymes, and ARH in tryptophan metabolism are associated with the development of CRC. Specifically, IDO1 may be a potential therapeutic target in colorectal cancer treatment. Furthermore, the reduction of tryptophan amount is proportional to the poor quality of life for colorectal cancer patients. This paper aims to discuss the role of tryptophan metabolism in a normal organism and investigate the relationship between this amino acid and colorectal cancer. This study is expected to provide theoretical support for research related to targeted therapy for colorectal cancer. Furthermore, strategies that modify tryptophan metabolism, effectively inhibiting tumor progression, may be more effective for CRC treatment.
C1 [Zhang, Hong-lian; Miao, Jian-hua; Wu, Fang-fang; Wang, Xi-jun] Guangxi Bot Garden Med Plant, Natl Engn Lab Dev Southwestern Endangered Med Mat, Nanning, Guangxi, Peoples R China.
   [Zhang, Hong-lian; Zhang, Ai-hua; Sun, Hui; Yan, Guang-li; Wu, Fang-fang; Wang, Xi-jun] Heilongjiang Univ Chinese Med, Sinoamer Chinmed Technol Collaborat Ctr, Natl TCM Key Lab Serum Pharmacochem,Lab Metab, Chinmed Res Ctr State Adm TCM,Dept Pharmaceut Ana, Heping Rd 24, Harbin, Heilongjiang, Peoples R China.
C3 Heilongjiang University of Chinese Medicine
RP Wang, XJ (corresponding author), Guangxi Bot Garden Med Plant, Natl Engn Lab Dev Southwestern Endangered Med Mat, Nanning, Guangxi, Peoples R China.; Sun, H; Wang, XJ (corresponding author), Heilongjiang Univ Chinese Med, Sinoamer Chinmed Technol Collaborat Ctr, Natl TCM Key Lab Serum Pharmacochem,Lab Metab, Chinmed Res Ctr State Adm TCM,Dept Pharmaceut Ana, Heping Rd 24, Harbin, Heilongjiang, Peoples R China.
EM xijunwangls@126.com
RI Wang, Xijun/C-4477-2014
OI Wang, Xijun/0000-0002-0949-3492
FU Key Program of Natural Science Foundation of State [81830110, 81430093,
   81373930, 81673586, 81703685, 81302905, 81503386]; National Key Subject
   of Drug Innovation [2015ZX09101043-005, 2015ZX09101043-011]; TCM State
   Administration Subject of Public Welfare [2015468004]; Major Projects of
   Application Technology Research and Development Plan in Heilongjiang
   Province [GX16C003]; Specialized Research Fund for the Doctoral Program
   of Higher Education [20132327130001, 20122327120006]; University Nursing
   Program for Young Scholars with Creative Talents in Heilongjiang
   Province [UNPYSCT-2016213, UNPYSCT-2015118, UNPYSCT-2016212]; Young
   Talent Lift Engineering Project of China Association of Traditional
   Chinese Medicine [QNRC2-B06]; Outstanding Talents Foundation of
   Heilongjiang University of Chinese Medicine [2018jc01]; Doctoral
   Innovation Fund of Heilongjiang University of Chinese Medicine
   [2018bs02]; Application Technology and Development of Youth Talents
   Project in Harbin [2014RFQXJ116]; Chinese Postdoctoral Science
   Foundation [2017M621319b]; Returned Overseas Scholars Program of
   Heilongjiang Province [2017QD0025]; Natural Science Foundation of
   Heilongjiang Province of China [QC2018117]
FX This work was supported by grants from the Key Program of Natural
   Science Foundation of State (Grant No. 81830110, 81430093, 81373930,
   81673586, 81703685, 81302905, 81503386), National Key Subject of Drug
   Innovation (Grant No. 2015ZX09101043-005, 2015ZX09101043-011), TCM State
   Administration Subject of Public Welfare (Grant No. 2015468004), Major
   Projects of Application Technology Research and Development Plan in
   Heilongjiang Province (GX16C003), TCM State Administration Subject of
   Public Welfare (Grant No. 2015468004), Specialized Research Fund for the
   Doctoral Program of Higher Education (20132327130001, 20122327120006),
   University Nursing Program for Young Scholars with Creative Talents in
   Heilongjiang Province (UNPYSCT-2015118, UNPYSCT-2016213), Young Talent
   Lift Engineering Project of China Association of Traditional Chinese
   Medicine (QNRC2-B06), Outstanding Talents Foundation of Heilongjiang
   University of Chinese Medicine (2018jc01), Doctoral Innovation Fund of
   Heilongjiang University of Chinese Medicine (2018bs02), University
   Nursing Program for Young Scholars with Creative Talents in Heilongjiang
   Province (UNPYSCT-2015118, UNPYSCT-2016213, UNPYSCT-2016212),
   Application Technology and Development of Youth Talents Project in
   Harbin (2014RFQXJ116), Chinese Postdoctoral Science Foundation
   (2017M621319b), Returned Overseas Scholars Program of Heilongjiang
   Province (2017QD0025), and Natural Science Foundation of Heilongjiang
   Province of China (QC2018117).
CR Ahn J, 2013, JNCI-J NATL CANCER I, V105, P1907, DOI 10.1093/jnci/djt300
   Alkhalaf LM, 2015, CHEM BIOL, V22, P317, DOI 10.1016/j.chembiol.2015.02.005
   Arthur JC, 2012, SCIENCE, V338, P120, DOI 10.1126/science.1224820
   Atarashi K, 2013, NATURE, V500, P232, DOI 10.1038/nature12331
   Atkin W, 2017, LANCET ONCOL, V18, P823, DOI 10.1016/S1470-2045(17)30187-0
   Bai M., 2016, AMINO ACIDS, V49, P1
   Belcheva A, 2015, BIOESSAYS, V37, P403, DOI 10.1002/bies.201400204
   Belcheva A, 2014, CELL, V158, P288, DOI 10.1016/j.cell.2014.04.051
   Bellono NW, 2017, CELL, V170, DOI 10.1016/j.cell.2017.05.034
   Bertrand F, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-02358-7
   Breda C, 2016, P NATL ACAD SCI USA, V113, P5435, DOI 10.1073/pnas.1604453113
   Cao HX, 2015, PROTEOMICS, V15, P3699, DOI 10.1002/pmic.201500062
   Cervantes-Barragan L, 2017, SCIENCE, V357, P806, DOI 10.1126/science.aah5825
   Cervenka I, 2017, SCIENCE, V357, DOI 10.1126/science.aaf9794
   Chudnovskiy A, 2016, CELL, V167, P444, DOI 10.1016/j.cell.2016.08.076
   Cross AJ, 2014, CARCINOGENESIS, V35, P1516, DOI 10.1093/carcin/bgu071
   Crotti S, 2017, METABOLOMICS, V13, DOI 10.1007/s11306-017-1288-6
   Engin A, 2015, MOLEC INTEGR TOXICOL, P335, DOI 10.1007/978-3-319-15630-9_14
   Engin AB, 2015, WORLD J GASTROENTERO, V21, P3636, DOI 10.3748/wjg.v21.i12.3636
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fernstrom JD, 2016, J NUTR, V146, P2601, DOI 10.3945/jn.115.228643
   Freewan M, 2013, J BIOL CHEM, V288, P1548, DOI 10.1074/jbc.M112.410993
   Gao HL, 2018, J CHROMATOGR B, V1092, P286, DOI 10.1016/j.jchromb.2018.06.032
   Gao J, 2018, FRONT CELL INFECT MI, V8, DOI 10.3389/fcimb.2018.00013
   Gao YF, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-21048-y
   García-González AP, 2017, CELL, V169, P431, DOI 10.1016/j.cell.2017.03.046
   Gopalakrishnan V, 2018, SCIENCE, V359, P97, DOI 10.1126/science.aan4236
   Gregorieff A, 2015, NATURE, V526, P715, DOI 10.1038/nature15382
   Hanninen A., 2017, GUT, V67, P1373
   Houlston RS, 2012, MUTAGENESIS, V27, P143, DOI 10.1093/mutage/ger059
   Huang A., 2003, TRYPTOPHAN QUALITY L, P353
   Islam J, 2017, J NUTR BIOCHEM, V42, P43, DOI 10.1016/j.jnutbio.2016.12.019
   Jenkins TA, 2016, NUTRIENTS, V8, DOI 10.3390/nu8010056
   Jie C., 2015, NAT COMMUN, V6, P7209
   Katuna-Czaplinska J, 2017, TRENDS FOOD SCI TECH, V70, P105, DOI 10.1016/j.tifs.2017.10.010
   Kaminski MF, 2017, GASTROENTEROLOGY, V153, P98, DOI 10.1053/j.gastro.2017.04.006
   Kang DH, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00054-0
   Kennedy PJ, 2017, NEUROPHARMACOLOGY, V112, P399, DOI 10.1016/j.neuropharm.2016.07.002
   Keum N. N., 2017, EPIDEMIOLOGY COLOREC
   Lamas B, 2016, NAT MED, V22, P598, DOI 10.1038/nm.4102
   Lasry A, 2016, NAT IMMUNOL, V17, P230, DOI 10.1038/ni.3384
   Lee J, 2015, HEMATOL ONCOL CLIN N, V29, P1, DOI 10.1016/j.hoc.2014.09.005
   Lee K, 2016, FOOD FUNCT, V7, P3073, DOI 10.1039/c6fo00187d
   Lee P, 2018, NAT REV UROL, V15, P235, DOI 10.1038/nrurol.2018.10
   Lemieux GA, 2015, CELL, V160, P119, DOI 10.1016/j.cell.2014.12.028
   Li QG, 2017, SCI REP-UK, V7, DOI 10.1038/srep46345
   Liu C, 2018, RSC ADV, V8, P647, DOI 10.1039/c7ra09353e
   Liu Q. L., 2014, THESIS, P32
   Liu YH, 2015, NATURE, V520, P697, DOI 10.1038/nature14418
   Liu YY, 2018, CANCER CELL, V33, P480, DOI 10.1016/j.ccell.2018.02.005
   Lu Y, 2012, BLOOD, V119, P1075, DOI 10.1182/blood-2010-12-322891
   Luissint AC, 2016, GASTROENTEROLOGY, V151, P616, DOI 10.1053/j.gastro.2016.07.008
   Marsland BJ, 2016, NAT MED, V22, P581, DOI 10.1038/nm.4117
   Matson V, 2018, SCIENCE, V359, P104, DOI 10.1126/science.aao3290
   Maya Kaelberer M., 2018, SCIENCE, V361, P6408
   McGrail DJ, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03730-x
   Messori S, 2013, VET MICROBIOL, V162, P173, DOI 10.1016/j.vetmic.2012.09.001
   Mondanelli G, 2017, IMMUNITY, V46, P233, DOI 10.1016/j.immuni.2017.01.005
   Morris JS, 2018, BRIT J CANCER, V118, P920, DOI 10.1038/bjc.2017.496
   Munn DH, 2016, TRENDS IMMUNOL, V37, P193, DOI 10.1016/j.it.2016.01.002
   Naxerova K, 2017, SCIENCE, V357, P55, DOI 10.1126/science.aai8515
   O'Mahony SM, 2015, BEHAV BRAIN RES, V277, P32, DOI 10.1016/j.bbr.2014.07.027
   Ock CY, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-01018-0
   Oluyemi AO, 2014, CANCER-AM CANCER SOC, V120, P2106, DOI 10.1002/cncr.28707
   Puccetti P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0122046
   Andrade MER, 2015, CLIN NUTR, V34, P1080, DOI 10.1016/j.clnu.2015.01.012
   Ramos A, 2017, CELL, V170, P411, DOI 10.1016/j.cell.2017.07.018
   Reigstad CS, 2015, FASEB J, V29, P1395, DOI 10.1096/fj.14-259598
   Rimbert J, 2018, MODERN PATHOL, V31, P517, DOI 10.1038/modpathol.2017.119
   Romani L, 2014, EUR J IMMUNOL, V44, P3192, DOI 10.1002/eji.201344406
   Rosshart SP, 2017, CELL, V171, P1015, DOI 10.1016/j.cell.2017.09.016
   Rothhammer V, 2016, NAT MED, V22, P586, DOI 10.1038/nm.4106
   Ruan Z, 2014, AMINO ACIDS, V46, P2681, DOI 10.1007/s00726-014-1823-y
   Santhanam S, 2016, TRANSL RES, V167, P67, DOI 10.1016/j.trsl.2015.07.003
   Schell MJ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11743
   Schiering C, 2017, NATURE, V542, P242, DOI 10.1038/nature21080
   Schirmer M, 2016, CELL, V167, P1125, DOI 10.1016/j.cell.2016.10.020
   Song MY, 2015, GASTROENTEROLOGY, V148, P1244, DOI 10.1053/j.gastro.2014.12.035
   Sridharan GV, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6492
   Strasser B, 2016, NUTRIENTS, V8, DOI 10.3390/nu8110752
   Sun H, 2018, RSC ADV, V8, P30061, DOI 10.1039/c8ra04886j
   Sun H, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0093384
   Sun H, 2013, MOL CELL PROTEOMICS, V12, P710, DOI 10.1074/mcp.M112.019141
   Sun YL, 2016, SCI REP-UK, V6, DOI [10.1038/srep28083, 10.1038/srep38865]
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Thaker AI, 2013, GASTROENTEROLOGY, V145, P416, DOI 10.1053/j.gastro.2013.05.002
   Vieira AR, 2017, ANN ONCOL, V28, P1788, DOI 10.1093/annonc/mdx171
   Walczak K, 2014, AMINO ACIDS, V46, P2393, DOI 10.1007/s00726-014-1790-3
   Wang ML, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11478
   Wang XJ, 2013, HEPATOLOGY, V57, P2072, DOI 10.1002/hep.26130
   Wettersten HI, 2017, NAT REV NEPHROL, V13, P410, DOI 10.1038/nrneph.2017.59
   Wlodarska M, 2017, CELL HOST MICROBE, V22, P25, DOI 10.1016/j.chom.2017.06.007
   Wunderlich CM, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-03773-0
   Xing WJ, 2017, CELL DEATH DIFFER, V24, P929, DOI 10.1038/cdd.2017.50
   Xue Y, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0389-0
   Yang HL, 2018, AM J REPROD IMMUNOL, V80, DOI 10.1111/aji.12839
   Yano JM, 2015, CELL, V161, P264, DOI 10.1016/j.cell.2015.02.047
   Yu JB, 2017, J PROTEOME RES, V16, P3219, DOI 10.1021/acs.jproteome.7b00206
   Zelante T, 2013, IMMUNITY, V39, P372, DOI 10.1016/j.immuni.2013.08.003
   Zhai LJ, 2018, CELL MOL IMMUNOL, V15, P447, DOI 10.1038/cmi.2017.143
   Zhai LJ, 2015, CLIN CANCER RES, V21, P5427, DOI 10.1158/1078-0432.CCR-15-0420
   Zhang A, 2013, OBES REV, V14, P344, DOI 10.1111/obr.12011
   Zhang A. H., 2014, MED CHEM, V4, P6
   Zhang AH, 2018, PHYTOMEDICINE, V45, P84, DOI 10.1016/j.phymed.2018.04.004
   Zhang AH, 2013, CLIN CHIM ACTA, V424, P3, DOI 10.1016/j.cca.2013.05.003
   Zhang AH, 2013, MOL BIOSYST, V9, P2259, DOI 10.1039/c3mb70171a
   Zhang AH, 2017, RSC ADV, V7, P14966, DOI 10.1039/c6ra28715h
   Zhang AH, 2016, MOL BIOSYST, V12, P262, DOI 10.1039/c5mb00603a
   Zhang AH, 2014, APPL BIOCHEM BIOTECH, V174, P6, DOI 10.1007/s12010-014-0955-6
   Zhang AH, 2014, INT UROL NEPHROL, V46, P1025, DOI 10.1007/s11255-013-0600-2
   Zhang AH, 2014, CANCER LETT, V345, P17, DOI 10.1016/j.canlet.2013.11.011
   Zhang AH, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064381
   Zhang XC, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-017-0176-3
   Zhang YJJ, 2013, CELL, V155, P1296, DOI 10.1016/j.cell.2013.10.045
   Zhang YY, 2017, ONCOTARGET, V8, P85526, DOI 10.18632/oncotarget.20241
   Zhang YZ, 2014, MOL BIOSYST, V10, P65, DOI 10.1039/c3mb70352e
   Zhao LJ, 2017, ANAL CHEM, V89, P5565, DOI 10.1021/acs.analchem.7b00660
   Zhao QQ, 2017, RSC ADV, V7, P44186, DOI 10.1039/c7ra05722a
NR 118
TC 52
Z9 54
U1 5
U2 51
PU ROYAL SOC CHEMISTRY
PI CAMBRIDGE
PA THOMAS GRAHAM HOUSE, SCIENCE PARK, MILTON RD, CAMBRIDGE CB4 0WF, CAMBS,
   ENGLAND
EI 2046-2069
J9 RSC ADV
JI RSC Adv.
PD JAN 24
PY 2019
VL 9
IS 6
BP 3072
EP 3080
DI 10.1039/c8ra08520j
PG 9
WC Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Chemistry
GA HK4GQ
UT WOS:000457880900020
PM 35518968
OA gold, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU Cha, N
   Han, XH
   Jia, BQ
   Liu, YH
   Wang, XL
   Gao, YW
   Ren, J
AF Cha, Nier
   Han, Xiuhua
   Jia, Baoqing
   Liu, Yanheng
   Wang, Xiaoli
   Gao, Yanwei
   Ren, Jun
TI Structure-based design of peptides against HER2 with cytotoxicity on
   colon cancer
SO ARTIFICIAL CELLS NANOMEDICINE AND BIOTECHNOLOGY
LA English
DT Article
DE Colon cancer; Herstatin; peptide; rational design; target therapy
ID GROWTH-FACTOR RECEPTOR; RATIONAL DESIGN; COMPLEX STRUCTURES;
   COLORECTAL-CANCER; EXPRESSION; AUTOINHIBITOR; ROSETTADOCK; HERSTATIN;
   PROTEINS; THERAPY
AB In this study, we found that four novel peptides designed by molecular modeling techniques were successfully applicated with cytotoxicity on colon cancer cells sw620. First, the interactions between the Herstatin and the HER2 were explored by ational-designed approaches, which were combined with homology modeling, protein/protein docking, and structural superimposition analysis. Then, based on the results derived from theoretical analysis, four novel peptides were designed, synthesized, and experimentally evaluated for biological function; it was found that they showed a remarkable enhancement on Herceptin to inhibit the genesis and development of colon cancers, and no significant side effects on normal colon cells NCM460 were observed but Doxorubicin had. These results indicated that it is a feasible way to use the well-designed peptides derived from Herstatin to enhance the efficacy of clinical drugs Herceptin and to kill colon cancer cells selectively without harming normal colon cells. We believe that our research might provide a new way to develop the potential therapies for colon cancers.
C1 [Cha, Nier; Wang, Xiaoli; Ren, Jun] Capital Med Univ, Beijing Shijitan Hosp, Beijing Key Lab Therapeut Canc Vaccines, Canc Ctr, Beijing, Peoples R China.
   [Cha, Nier; Han, Xiuhua; Jia, Baoqing; Liu, Yanheng; Gao, Yanwei] Inner Mongolia Peoples Hosp, Dept Surg Oncol, Hohhot, Inner Mongolia, Peoples R China.
C3 Capital Medical University
RP Ren, J (corresponding author), CMU, Beijing Shijitan Hosp, 10 Tieyi Rd, Beijing 100038, Peoples R China.
EM nier99@126.com
RI Zhang, Liping/ABC-7060-2021
CR Almaaytah A, 2015, INT J PEPT RES THER, V21, P165, DOI 10.1007/s10989-014-9444-6
   Arteaga C, 2003, SEMIN ONCOL, V30, P3, DOI 10.1016/S0093-7754(03)00185-4
   Chen D, 2015, J PEPT SCI, V21, P826, DOI 10.1002/psc.2824
   COHEN JA, 1989, ONCOGENE, V4, P81
   Cui W, 2010, J CHEM INF MODEL, V50, P380, DOI 10.1021/ci900404p
   DEMILIA J, 1989, ONCOGENE, V4, P1233
   Doherty JK, 1999, P NATL ACAD SCI USA, V96, P10869, DOI 10.1073/pnas.96.19.10869
   Fukuhara N, 2008, NUCLEIC ACIDS RES, V36, pW185, DOI 10.1093/nar/gkn218
   Kapitanovic S, 1997, GASTROENTEROLOGY, V112, P1103, DOI 10.1016/S0016-5085(97)70120-3
   KAPITANOVIC S, 1994, CANCER DETECT PREV, V18, P97
   Kilambi KP, 2013, PROTEINS, V81, P2201, DOI 10.1002/prot.24425
   Littlefield P, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2005786
   Lv M, 2012, MOL BIOTECHNOL, V51, P174, DOI 10.1007/s12033-011-9454-y
   Lyskov S, 2008, NUCLEIC ACIDS RES, V36, pW233, DOI 10.1093/nar/gkn216
   Mann M, 2001, GASTROENTEROLOGY, V120, P1713, DOI 10.1053/gast.2001.24844
   Mendelsohn J, 2001, ENDOCR-RELAT CANCER, V8, P3, DOI 10.1677/erc.0.0080003
   Ross JS, 2001, CANCER INVEST, V19, P554, DOI 10.1081/CNV-100103852
   Shamieh LS, 2004, FEBS LETT, V568, P163, DOI 10.1016/j.febslet.2004.05.027
   Shi YN, 2009, DIAGN MOL PATHOL, V18, P11, DOI 10.1097/PDM.0b013e31818cbdb2
   Sormanni P, 2015, P NATL ACAD SCI USA, V112, P9902, DOI 10.1073/pnas.1422401112
   Staverosky JA, 2005, CLIN CANCER RES, V11, P335
   Takai N, 2005, CANCER-AM CANCER SOC, V104, P2701, DOI 10.1002/cncr.21533
   TSIOULIAS GJ, 1990, JPN J EXP MED, V60, P343
   VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217
   Yang LY, 2015, MACROMOL RAPID COMM, V36, P1559, DOI 10.1002/marc.201500243
NR 25
TC 4
Z9 4
U1 0
U2 11
PU TAYLOR & FRANCIS LTD
PI ABINGDON
PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND
SN 2169-1401
EI 2169-141X
J9 ARTIF CELL NANOMED B
JI Artif. Cell. Nanomed. Biotechnol.
PY 2017
VL 45
IS 3
BP 649
EP 654
DI 10.3109/21691401.2016.1167705
PG 6
WC Biotechnology & Applied Microbiology; Engineering, Biomedical; Materials
   Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biotechnology & Applied Microbiology; Engineering; Materials Science
GA EL4NQ
UT WOS:000394598300032
PM 27068253
OA Bronze
DA 2025-01-04
ER

PT J
AU Huang, RR
   Chen, ZS
   He, L
   He, NY
   Xi, ZJ
   Li, ZY
   Deng, Y
   Zeng, X
AF Huang, Rongrong
   Chen, Zhongsi
   He, Lei
   He, Nongyue
   Xi, Zhijiang
   Li, Zhiyang
   Deng, Yan
   Zeng, Xin
TI Mass spectrometry-assisted gel-based proteomics in cancer biomarker
   discovery: approaches and application
SO THERANOSTICS
LA English
DT Article
DE mass spectrometry; proteomics; cancer biomarkers
ID DATA-INDEPENDENT ACQUISITION; POTENTIAL SERUM BIOMARKERS; LC-MS/MS
   ANALYSIS; SWATH-MS DATA; LUNG-CANCER; TARGETED PROTEOMICS;
   COLORECTAL-CANCER; QUANTITATIVE PROTEOMICS; GASTRIC-CANCER; LABEL-FREE
AB There is a critical need for the discovery of novel biomarkers for early detection and targeted therapy of cancer, a major cause of deaths worldwide. In this respect, proteomic technologies, such as mass spectrometry (MS), enable the identification of pathologically significant proteins in various types of samples. MS is capable of high-throughput profiling of complex biological samples including blood, tissues, urine, milk, and cells. MS-assisted proteomics has contributed to the development of cancer biomarkers that may form the foundation for new clinical tests. It can also aid in elucidating the molecular mechanisms underlying cancer. In this review, we discuss MS principles and instrumentation as well as approaches in MS-based proteomics, which have been employed in the development of potential biomarkers. Furthermore, the challenges in validation of MS biomarkers for their use in clinical practice are also reviewed.
C1 [Huang, Rongrong; Chen, Zhongsi; He, Lei; He, Nongyue; Li, Zhiyang; Deng, Yan] Southeast Univ, State Key Lab Bioelect, Sch Biol Sci & Med Engn, Nanjing 210096, Jiangsu, Peoples R China.
   [Xi, Zhijiang] Yangtze Univ, Sch Med, Jingzhou 434023, Peoples R China.
   [Xi, Zhijiang] Nanjing Univ, Affiliated Drum Tower Hosp, Sch Med, Dept Clin Lab, Nanjing 210008, Peoples R China.
   [He, Nongyue; Deng, Yan] Hunan Univ Technol, Hunan Key Lab Green Chem & Applicat Biol Nanotech, Econ Forest Cultivat & Utilizat Collaborat Innova, Zhuzhou 412007, Peoples R China.
   [Zeng, Xin] Nanjing Med Univ, Obstet & Gynecol Hosp, Nanjing Matern & Child Hlth Med Inst, Nanjing 210004, Jiangsu, Peoples R China.
C3 Southeast University - China; Yangtze University; Nanjing University;
   Hunan University of Technology; Nanjing Medical University
RP He, NY; Deng, Y (corresponding author), Southeast Univ, State Key Lab Bioelect, Sch Biol Sci & Med Engn, Nanjing 210096, Jiangsu, Peoples R China.; He, NY; Deng, Y (corresponding author), Hunan Univ Technol, Hunan Key Lab Green Chem & Applicat Biol Nanotech, Econ Forest Cultivat & Utilizat Collaborat Innova, Zhuzhou 412007, Peoples R China.; Zeng, X (corresponding author), Nanjing Med Univ, Obstet & Gynecol Hosp, Nanjing Matern & Child Hlth Med Inst, Nanjing 210004, Jiangsu, Peoples R China.
EM nyhe@seu.edu.cn; hndengyan@126.com; august555482@126.com
RI 李, 智洋/AAH-3884-2021; Deng, Yan/ACS-0330-2022; Huang,
   Rongrong/IAM-8146-2023; HE, NONGYUE/AFM-9087-2022
OI Li, Zhiyang/0000-0002-4970-8494
FU NSFC [61527806, 61401217, 61471168]; Chinese 863 Project [2015AA020502];
   National Key Research and Development Program of China [2017YFA0205300];
   Open Funding of State Key Laboratory of Oral Diseases [SKLOD2017OF04];
   China Postdoctoral Science Foundation [2016T90403]; Economical Forest
   Cultivation and Utilization of Collaborative Innovation Center in Hunan
   Province [(2013) 448]
FX This research was financially supported by NSFC (61527806, 61401217 and
   61471168), Chinese 863 Project (2015AA020502), the National Key Research
   and Development Program of China (2017YFA0205300), Open Funding of State
   Key Laboratory of Oral Diseases (SKLOD2017OF04) China Postdoctoral
   Science Foundation (2016T90403), and the Economical Forest Cultivation
   and Utilization of 2011 Collaborative Innovation Center in Hunan
   Province [(2013) 448].
CR Aebersold R, 2016, NATURE, V537, P347, DOI 10.1038/nature19949
   Aebersold R, 2016, PROTEOMICS, V16, P2065, DOI 10.1002/pmic.201600203
   Ahsan N, 2016, J PROTEOMICS, V143, P15, DOI 10.1016/j.jprot.2016.04.018
   Aichler M, 2015, LAB INVEST, V95, P422, DOI 10.1038/labinvest.2014.156
   An Juan, 2013, Zhongguo Fei Ai Za Zhi, V16, P233, DOI 10.3779/j.issn.1009-3419.2013.05.04
   [Anonymous], J DATA MINING GENOMI
   [Anonymous], INT SCH RES NOTICES
   [Anonymous], J NATL CANC I
   [Anonymous], MASS SPECTROMETRY BA
   [Anonymous], ACTA BIOCH BIOPHYS S
   [Anonymous], ADV CLIN CHEM  EMERG
   [Anonymous], ACTA OPHTHALMOL COPE
   [Anonymous], GASTROENTEROL RES PR
   [Anonymous], GLYCOBIOLOGY
   [Anonymous], PROTEOMICS
   [Anonymous], FASEB J
   [Anonymous], J PROTEOME RES
   [Anonymous], MOL CELL PROTEOMICS
   [Anonymous], MOL SYST BIOL
   [Anonymous], MOL CELL PROTEOMICS
   Antohe F, 2015, ACTA ENDOCRINOL-BUCH, V11, P139, DOI 10.4183/aeb.2015.139
   Bakkum-Gamez J, 2014, CLIN CHEM, V60, P22, DOI 10.1373/clinchem.2013.204933
   Tran BQ, 2016, BBA-PROTEINS PROTEOM, V1864, P123, DOI 10.1016/j.bbapap.2015.05.015
   Barrera L, 2015, ANN ONCOL, V26, P428, DOI 10.1093/annonc/mdu549
   Batrla R, 2015, ANN NY ACAD SCI, V1346, P71, DOI 10.1111/nyas.12754
   Bausch-Fluck D, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121314
   Beretov J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141876
   Birse CE, 2015, CLIN PROTEOM, V12, DOI 10.1186/s12014-015-9090-9
   Boja E, 2010, BIOMARK MED, V4, P799, DOI 10.2217/BMM.10.92
   Bosch LJW, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-1563
   Boylan KLM, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-30
   Byrum Stephanie D, 2013, J Proteomics Bioinform, V6, P43
   Catenacci DVT, 2016, GASTRIC CANCER, V19, P1066, DOI 10.1007/s10120-015-0566-0
   Catherman AD, 2014, BIOCHEM BIOPH RES CO, V445, P683, DOI 10.1016/j.bbrc.2014.02.041
   Chambers AG, 2014, EXPERT REV PROTEOMIC, V11, P137, DOI 10.1586/14789450.2014.877346
   Chan KCA, 2013, CLIN CHEM, V59, P211, DOI 10.1373/clinchem.2012.196014
   Chappell NP, 2012, J PROTEOME RES, V11, P4605, DOI 10.1021/pr300403d
   Chen JF, 2016, THERANOSTICS, V6, P1425, DOI 10.7150/thno.15359
   Chick JM, 2015, NAT BIOTECHNOL, V33, P743, DOI 10.1038/nbt.3267
   Chouaib S, 2010, CRIT REV IMMUNOL, V30, P529, DOI 10.1615/CritRevImmunol.v30.i6.30
   Christiansen MN, 2014, PROTEOMICS, V14, P525, DOI 10.1002/pmic.201300387
   Cojoc M, 2015, SEMIN CANCER BIOL, V31, P16, DOI 10.1016/j.semcancer.2014.06.004
   Colgrave ML, 2016, ANAL CHEM, V88, P9127, DOI 10.1021/acs.analchem.6b02108
   Colignon B, 2013, PROTEOMICS, V13, P2077, DOI 10.1002/pmic.201200494
   Crabb JW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0135543
   Cramer DW, 2011, CANCER PREV RES, V4, P365, DOI 10.1158/1940-6207.CAPR-10-0195
   Croote D, 2016, NPJ SYST BIOL APPL, V2, DOI 10.1038/npjsba.2016.22
   Cui JA, 2011, NUCLEIC ACIDS RES, V39, P1197, DOI 10.1093/nar/gkq960
   De Marchi T, 2016, MOL ONCOL, V10, P24, DOI 10.1016/j.molonc.2015.07.004
   Deng JL, 2016, EXPERT REV PROTEOMIC, V13, P905, DOI 10.1080/14789450.2016.1233065
   Diamandis EP, 2014, CLIN CHEM LAB MED, V52, P791, DOI 10.1515/cclm-2014-0317
   Diamandis EP, 2012, BMC MED, V10, DOI 10.1186/1741-7015-10-87
   Domon B, 2010, NAT BIOTECHNOL, V28, P710, DOI 10.1038/nbt.1661
   Dowling P, 2015, METABOLOMICS, V11, P620, DOI 10.1007/s11306-014-0723-1
   Egertson JD, 2013, NAT METHODS, V10, P744, DOI 10.1038/nmeth.2528
   Ekström EJ, 2014, MOL CANCER, V13, DOI 10.1186/1476-4598-13-88
   Evans C, 2012, ANAL BIOANAL CHEM, V404, P1011, DOI 10.1007/s00216-012-5918-6
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Frantzi M, 2015, NAT REV UROL, V12, P317, DOI 10.1038/nrurol.2015.100
   Frese CK, 2011, J PROTEOME RES, V10, P2377, DOI 10.1021/pr1011729
   Füzéry AK, 2013, CLIN PROTEOM, V10, DOI 10.1186/1559-0275-10-13
   Gallien S, 2014, J PROTEOMICS, V100, P147, DOI 10.1016/j.jprot.2013.10.029
   Gallien S, 2013, J PROTEOMICS, V81, P148, DOI 10.1016/j.jprot.2012.11.005
   Gallien S, 2012, PROTEOMICS, V12, P1122, DOI 10.1002/pmic.201100533
   Gallien S, 2011, J MASS SPECTROM, V46, P298, DOI 10.1002/jms.1895
   Gao W, 2015, CELL PHYSIOL BIOCHEM, V37, P2339, DOI 10.1159/000438588
   Gao W, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1343-5
   Gao YY, 2017, SCI REP-UK, V7, DOI 10.1038/srep45913
   Gillet LC, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.O111.016717
   Gingras AC, 2016, CURR OPIN STRUC BIOL, V41, P128, DOI 10.1016/j.sbi.2016.07.008
   Goossens N, 2015, TRANSL CANCER RES, V4, P256, DOI 10.3978/j.issn.2218-676X.2015.06.04
   Guo J, 2016, J PROTEOME RES, V15, P2164, DOI 10.1021/acs.jproteome.6b00106
   Hanash S, 2010, NAT REV CANCER, V10, P652, DOI 10.1038/nrc2918
   Henderson MC, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0157692
   Hernández B, 2014, PROTEOMICS, V14, P1587, DOI 10.1002/pmic.201300377
   Hong S, 2012, YONSEI MED J, V53, P111, DOI 10.3349/ymj.2012.53.1.111
   Hood JL, 2011, CANCER RES, V71, P3792, DOI 10.1158/0008-5472.CAN-10-4455
   Hu LZ, 2016, BBA-PROTEINS PROTEOM, V1864, P20, DOI 10.1016/j.bbapap.2015.10.003
   Huang Q, 2015, PROTEOMICS, V15, P1215, DOI 10.1002/pmic.201400270
   Huang YA, 2016, NEUROCOMPUTING, V218, P131, DOI 10.1016/j.neucom.2016.08.063
   Hudler P, 2014, SCI WORLD J, DOI 10.1155/2014/260348
   Humphris JL, 2012, ANN ONCOL, V23, P1713, DOI 10.1093/annonc/mdr561
   Ilkhani H, 2015, BIOSENS BIOELECTRON, V74, P491, DOI 10.1016/j.bios.2015.06.063
   Jedrychowski MP, 2015, CELL METAB, V22, P734, DOI 10.1016/j.cmet.2015.08.001
   Jin C, 2016, ANALYST, V141, P461, DOI 10.1039/c5an01918d
   Jin HW, 2016, J PROTEOMICS, V136, P77, DOI 10.1016/j.jprot.2015.12.012
   Kang C, 2016, WORLD J GASTROENTERO, V22, P8283, DOI 10.3748/wjg.v22.i37.8283
   Kern SE, 2012, CANCER RES, V72, P6097, DOI 10.1158/0008-5472.CAN-12-3232
   Kim MS, 2014, NATURE, V509, P575, DOI 10.1038/nature13302
   Kim YJ, 2015, J PROTEOME RES, V14, P1412, DOI 10.1021/pr5010828
   Kim Y, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11906
   Kimhofer T, 2015, BRIT J CANCER, V112, P1141, DOI 10.1038/bjc.2015.38
   Klein O, 2013, PROTEOM CLIN APPL, V7, P813, DOI 10.1002/prca.201300056
   Knowles MA, 2015, NAT REV CANCER, V15, P25, DOI 10.1038/nrc3817
   Koshiyama A, 2013, BIOMED CHROMATOGR, V27, P440, DOI 10.1002/bmc.2811
   Kreso A, 2014, CELL STEM CELL, V14, P275, DOI 10.1016/j.stem.2014.02.006
   Law KP, 2013, EXPERT REV PROTEOMIC, V10, P551, DOI 10.1586/14789450.2013.858022
   Lazar I, 2015, PIGM CELL MELANOMA R, V28, DOI 10.1111/pcmr.12380
   Leprevost FV, 2014, MOL CELL PROTEOMICS, V13, P2480, DOI 10.1074/mcp.M113.037002
   Leung F, 2016, CLIN CANCER RES, V22, DOI 10.1158/1557-3265.OVCA15-B13
   Li PF, 2015, CLIN CHIM ACTA, V444, P132, DOI 10.1016/j.cca.2015.02.018
   Li YY, 2015, BIOCHEM BIOPH RES CO, V457, P177, DOI 10.1016/j.bbrc.2014.12.083
   Liebler DC, 2013, BIOCHEMISTRY-US, V52, P3797, DOI 10.1021/bi400110b
   Lin C, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000004527
   Lin SY, 2016, SCI REP-UK, V6, DOI 10.1038/srep34446
   Lin SN, 2014, CANCER CYTOPATHOL, V122, P221, DOI 10.1002/cncy.21369
   Liu MX, 2013, PROTEOMICS, V13, P1200, DOI 10.1002/pmic.201200489
   Liu NQ, 2014, METHODS MOL BIOL, V1156, P307, DOI 10.1007/978-1-4939-0685-7_21
   Liu NQ, 2013, J PROTEOME RES, V12, P4627, DOI 10.1021/pr4005794
   Liu R, 2011, EUR J CANCER, V47, P784, DOI 10.1016/j.ejca.2010.10.025
   Liu YS, 2014, MOL CELL PROTEOMICS, V13, P1753, DOI 10.1074/mcp.M114.038273
   Liu Y, 2013, EXPERT REV MOL DIAGN, V13, P811, DOI 10.1586/14737159.2013.845089
   Liu YS, 2013, PROTEOMICS, V13, P1247, DOI 10.1002/pmic.201200417
   Mäbert K, 2014, INT J RADIAT BIOL, V90, P659, DOI 10.3109/09553002.2014.892229
   Maes E, 2015, CRIT REV ONCOL HEMAT, V96, P437, DOI 10.1016/j.critrevonc.2015.07.006
   MAGNANI JL, 1983, CANCER RES, V43, P5489
   Mahfoud OK, 2014, RSC ADV, V4, P3422, DOI 10.1039/c3ra45401k
   Mangé A, 2016, J PROTEOMICS, V142, P114, DOI 10.1016/j.jprot.2016.04.050
   Mao L, 2013, PROTEOM CLIN APPL, V7, P723, DOI 10.1002/prca.201300111
   Masuda G, 2015, CANCER RES, V75, DOI 10.1158/1538-7445.AM2015-992
   Matsuda K, 2010, BIOCHEM BIOPH RES CO, V394, P947, DOI 10.1016/j.bbrc.2010.03.089
   Maurizio E, 2016, MOL CELL PROTEOMICS, V15, P109, DOI 10.1074/mcp.M115.050401
   Megger DA, 2013, MOL CELL PROTEOMICS, V12, P2006, DOI 10.1074/mcp.M113.028027
   Milman BL, 2015, TRAC-TREND ANAL CHEM, V69, P24, DOI 10.1016/j.trac.2014.12.009
   Molina R, 2011, TUMOR BIOL, V32, P1087, DOI 10.1007/s13277-011-0204-3
   Mordente A, 2015, ADV EXP MED BIOL, V867, P9, DOI 10.1007/978-94-017-7215-0_2
   Muntel J, 2015, J PROTEOME RES, V14, P4752, DOI 10.1021/acs.jproteome.5b00826
   Na SS, 2015, BBA-PROTEINS PROTEOM, V1854, P668, DOI 10.1016/j.bbapap.2014.11.002
   Naboulsi W, 2016, J PROTEOME RES, V15, P38, DOI 10.1021/acs.jproteome.5b00420
   Neely BA, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0154074
   Nepomuceno AI, 2015, ANAL BIOANAL CHEM, V407, P6851, DOI 10.1007/s00216-015-8862-4
   Newsome GA, 2013, J AGR FOOD CHEM, V61, P5659, DOI 10.1021/jf3015238
   Oliveira BM, 2014, J PROTEOMICS, V104, P140, DOI 10.1016/j.jprot.2014.03.035
   Ortea I, 2016, J PROTEOMICS, V138, P106, DOI 10.1016/j.jprot.2016.02.010
   Overbye A, 2015, ONCOTARGET, V6, P30357, DOI 10.18632/oncotarget.4851
   Overgaard Anne Julie, 2010, Clin Proteomics, V6, P105
   Ovrehus MA, 2015, CLIN PROTEOM, V12, DOI 10.1186/s12014-015-9092-7
   Pan S, 2013, PROTEOMICS, V13, P710, DOI 10.1002/pmic.201200319
   Parente F, 2015, DIGEST LIVER DIS, V47, P68, DOI 10.1016/j.dld.2014.09.015
   Parker CE, 2014, MOL ONCOL, V8, P840, DOI 10.1016/j.molonc.2014.03.006
   Patris S, 2014, TALANTA, V130, P164, DOI 10.1016/j.talanta.2014.06.069
   Pavlou MP, 2013, CLIN CHEM, V59, P147, DOI 10.1373/clinchem.2012.184614
   Peinado H, 2012, NAT MED, V18, P883, DOI 10.1038/nm.2753
   Peltier J, 2016, J PROTEOMICS, V148, P139, DOI 10.1016/j.jprot.2016.07.031
   Peterson AC, 2012, MOL CELL PROTEOMICS, V11, P1475, DOI 10.1074/mcp.O112.020131
   Picotti P, 2013, NATURE, V494, P266, DOI 10.1038/nature11835
   Picotti P, 2012, NAT METHODS, V9, P555, DOI [10.1038/NMETH.2015, 10.1038/nmeth.2015]
   Pinho SS, 2015, NAT REV CANCER, V15, P540, DOI 10.1038/nrc3982
   Poersch A, 2016, J PROTEOMICS, V145, P226, DOI 10.1016/j.jprot.2016.05.005
   Popescu ID, 2014, PROTEOME SCI, V12, DOI 10.1186/s12953-014-0047-0
   Qendro V, 2014, J PROTEOME RES, V13, P5031, DOI 10.1021/pr5006789
   Rabilloud T, 2011, J PROTEOMICS, V74, P1829, DOI 10.1016/j.jprot.2011.05.040
   Reck M, 2014, ANN ONCOL, V25
   Reis H, 2015, BBA-PROTEINS PROTEOM, V1854, P641, DOI 10.1016/j.bbapap.2014.10.024
   Reymond N, 2013, NAT REV CANCER, V13, P858, DOI 10.1038/nrc3628
   Riches A, 2014, EUR J CANCER, V50, P1025, DOI 10.1016/j.ejca.2013.12.019
   Robinson D, 2015, CELL, V161, P1215, DOI [10.1016/j.cell.2015.05.001, 10.1016/j.cell.2015.06.053]
   Röst HL, 2014, NAT BIOTECHNOL, V32, P219, DOI 10.1038/nbt.2841
   Rogowska-Wrzesinska A, 2013, J PROTEOMICS, V88, P4, DOI 10.1016/j.jprot.2013.01.010
   Romero I, 2012, ENDOCRINOLOGY, V153, P1593, DOI 10.1210/en.2011-2123
   Rovithi M, 2016, PROTEOM CLIN APPL, V10, P743, DOI 10.1002/prca.201600025
   Ryan BM, 2014, J THORAC ONCOL, V9, P1494, DOI 10.1097/JTO.0000000000000278
   Sandim V, 2016, UROL ONCOL-SEMIN ORI, V34, DOI 10.1016/j.urolonc.2015.07.016
   Schubert OT, 2015, NAT PROTOC, V10, DOI 10.1038/nprot.2015.015
   Schwamborn K, 2010, NAT REV CANCER, V10, P639, DOI 10.1038/nrc2917
   Selevsek N, 2015, MOL CELL PROTEOMICS, V14, P739, DOI 10.1074/mcp.M113.035550
   Sengupta D, 2016, J PROTEOM BIOINFORM, V9, pe29, DOI DOI 10.4172/JPB.1000E29
   Sethi MK, 2016, ACCOUNTS CHEM RES, V49, P2099, DOI 10.1021/acs.accounts.6b00193
   Shao SY, 2015, BBA-PROTEINS PROTEOM, V1854, P519, DOI 10.1016/j.bbapap.2014.12.012
   Shetty V, 2012, J PROTEOMICS, V75, P3270, DOI 10.1016/j.jprot.2012.03.044
   Shin J, 2016, CANCER SCI, V107, P828, DOI 10.1111/cas.12935
   Siegel R, 2013, CA-CANCER J CLIN, V63, P11, DOI 10.3322/caac.21166
   Siegel R, 2012, CA-CANCER J CLIN, V62, P10, DOI 10.3322/caac.20138
   Skates SJ, 2013, J PROTEOME RES, V12, P5383, DOI 10.1021/pr400132j
   Skubitz APN, 2016, CLIN CANCER RES, V22, DOI 10.1158/1557-3265.OVCA15-B34
   Song GG, 2015, CLIN CHIM ACTA, V440, P44, DOI 10.1016/j.cca.2014.11.010
   Stewart B., 2016, World cancer report 2014
   Sun YZ, 2016, BIOCHEM BIOPH RES CO, V471, P142, DOI 10.1016/j.bbrc.2016.01.162
   Surinova S, 2015, EMBO MOL MED, V7, P1153, DOI 10.15252/emmm.201404874
   Tabernero J, 2015, LANCET ONCOL, V16, P937, DOI 10.1016/S1470-2045(15)00138-2
   Takadate T, 2013, INT J CANCER, V132, P1368, DOI 10.1002/ijc.27797
   Tanase CP, 2017, ONCOTARGET, V8, P18497, DOI 10.18632/oncotarget.14501
   TEMPERO MA, 1987, CANCER RES, V47, P5501
   Toiyarna Y, 2014, BIOCHEM BIOPH RES CO, V455, P43, DOI 10.1016/j.bbrc.2014.08.001
   Tomonaga Takeshi, 2015, Rinsho Byori, V63, P322
   Tsou CC, 2015, NAT METHODS, V12, P258, DOI [10.1038/nmeth.3255, 10.1038/NMETH.3255]
   Varga D, 2010, ARCH GYNECOL OBSTET, V282, P427, DOI 10.1007/s00404-009-1339-y
   Vargas AJ, 2016, NAT REV CANCER, V16, P525, DOI 10.1038/nrc.2016.56
   Walker MJ, 2015, EBIOMEDICINE, V2, P841, DOI 10.1016/j.ebiom.2015.06.013
   Wan-Ibrahim WI, 2015, MOL MED, V21, P861, DOI 10.2119/molmed.2015.00183
   Wang CL, 2009, J PROTEOME RES, V8, P4428, DOI 10.1021/pr900160h
   Wang RC, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0139232
   Wang Y, 2016, J PROTEOMICS, V132, P31, DOI 10.1016/j.jprot.2015.11.013
   Wang ZY, 2012, BBA-PROTEINS PROTEOM, V1824, P692, DOI 10.1016/j.bbapap.2012.01.016
   Wei H, 2014, DRUG DISCOV TODAY, V19, P95, DOI 10.1016/j.drudis.2013.07.019
   Weisbrod CR, 2012, J PROTEOME RES, V11, P1621, DOI 10.1021/pr2008175
   Werner S, 2015, INT J CANCER, V136, P2243, DOI 10.1002/ijc.28807
   Wohlgemuth I, 2015, PROTEOMICS, V15, P862, DOI 10.1002/pmic.201400466
   Wu JX, 2016, MOL CELL PROTEOMICS, V15, P2501, DOI 10.1074/mcp.M115.055558
   Wu W, 2016, PROTEOMICS, V16, P2921, DOI 10.1002/pmic.201600194
   Wu W, 2013, J PROTEOMICS, V90, P3, DOI 10.1016/j.jprot.2013.04.035
   Xiao H, 2016, SCI REP-UK, V6, DOI 10.1038/srep22165
   Xiao H, 2012, MOL CELL PROTEOMICS, V11, DOI 10.1074/mcp.M111.012112
   Yadav D, 2013, GASTROENTEROLOGY, V144, P1252, DOI 10.1053/j.gastro.2013.01.068
   Yang J, 2016, PROTEOMICS, V16, P925, DOI 10.1002/pmic.201500321
   Yang J, 2015, TUMOR BIOL, V36, P5109, DOI 10.1007/s13277-015-3163-2
   Yang M, 2016, NAT REV CANCER, V16, P650, DOI 10.1038/nrc.2016.81
   Yoneyama T, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0161009
   Yu L, 2014, CLIN LUNG CANCER, V15, P372, DOI 10.1016/j.cllc.2014.05.003
   Yuana Y, 2013, BLOOD REV, V27, P31, DOI 10.1016/j.blre.2012.12.002
   Zhang H, 2016, CELL, V166, P755, DOI 10.1016/j.cell.2016.05.069
   Zhang KC, 2017, THERANOSTICS, V7, P213, DOI 10.7150/thno.16044
   Zhang QB, 2013, J EXP MED, V210, P191, DOI 10.1084/jem.20111843
   Zhang SF, 2015, AUTOPHAGY, V11, P225, DOI 10.1080/15548627.2014.998931
   Zhang Y, 2014, CLIN PROTEOM, V11, DOI 10.1186/1559-0275-11-18
   Zhao ZH, 2015, TUMOR BIOL, V36, P939, DOI 10.1007/s13277-014-2694-2
   Zhong N, 2015, TUMOR BIOL, V36, P1221, DOI 10.1007/s13277-014-2742-y
   Zhuo HQ, 2014, J PROTEOME RES, V13, P4717, DOI 10.1021/pr5006229
   Zi J, 2014, ANAL CHEM, V86, P7242, DOI 10.1021/ac501828a
NR 219
TC 126
Z9 130
U1 1
U2 184
PU IVYSPRING INT PUBL
PI LAKE HAVEN
PA PO BOX 4546, LAKE HAVEN, NSW 2263, AUSTRALIA
SN 1838-7640
J9 THERANOSTICS
JI Theranostics
PY 2017
VL 7
IS 14
BP 3559
EP 3572
DI 10.7150/thno.20797
PG 14
WC Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Research & Experimental Medicine
GA FE8FY
UT WOS:000408442200004
PM 28912895
OA Green Submitted, Green Published, gold
DA 2025-01-04
ER

PT J
AU Salvatore, L
   Calegari, MA
   Loupakis, F
   Fassan, M
   Di Stefano, B
   Bensi, M
   Bria, E
   Tortora, G
AF Salvatore, Lisa
   Calegari, Maria Alessandra
   Loupakis, Fotios
   Fassan, Matteo
   Di Stefano, Brunella
   Bensi, Maria
   Bria, Emilio
   Tortora, Giampaolo
TI PTEN in Colorectal Cancer: Shedding Light on Its Role as Predictor and
   Target
SO CANCERS
LA English
DT Review
DE PTEN; colorectal cancer; target therapy; bevacizumab; anti-EGFR
ID MAMMALIAN TARGET; LUNG-CANCER; PHASE-I; PHOSPHATASE-ACTIVITY; HUMAN
   COLON; EXPRESSION; CELLS; INHIBITION; GENE; BEVACIZUMAB
AB Molecular assessment of colorectal cancer (CRC) is receiving growing attention, beyond RAS and BRAF, because of its influence on prognosis and prediction in cancer treatment. PTEN (phosphatase and tensin homologue), a tumor suppressor, regulating cell division and apoptosis, has been explored, and significant evidence suggests a role in cetuximab and panitumumab resistance linked to the epidermal growth factor receptor (EGFR) signal transduction pathway. Factors influencing PTEN activity should be analyzed to develop strategies to maximize the tumor suppressor role and to improve tumor response to cancer treatment. Therefore, an in-depth knowledge of the PI3K-Akt pathway-one of the major cancer survival pathways-and the role of PTEN-a major brake of this pathway-is essential in the era of precision medicine. The purpose of this literature review is to summarize the role of PTEN as a predictive factor and possible therapeutic target in CRC, focusing on ongoing studies and the possible implications in clinical practice.
C1 [Salvatore, Lisa; Calegari, Maria Alessandra; Di Stefano, Brunella; Bensi, Maria; Bria, Emilio; Tortora, Giampaolo] Fdn Policlin Univ A Gemelli IRCCS, Comprehens Canc Ctr, I-00168 Rome, Italy.
   [Salvatore, Lisa; Calegari, Maria Alessandra; Di Stefano, Brunella; Bensi, Maria; Bria, Emilio; Tortora, Giampaolo] Univ Cattolica Sacro Cuore, Med Oncol, I-00168 Rome, Italy.
   [Loupakis, Fotios] Veneto Inst Oncol IOV IRCCS, Dept Oncol, Unit Oncol 1, I-35128 Padua, Italy.
   [Fassan, Matteo] Univ Padua, Dept Med, Unit Surg Pathol, I-35122 Padua, Italy.
C3 Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli;
   IRCCS Istituto Oncologico Veneto (IOV); University of Padua
RP Salvatore, L (corresponding author), Fdn Policlin Univ A Gemelli IRCCS, Comprehens Canc Ctr, I-00168 Rome, Italy.; Salvatore, L (corresponding author), Univ Cattolica Sacro Cuore, Med Oncol, I-00168 Rome, Italy.
EM lisa.salvatore@policlinicogemelli.it;
   mariaalessandra.calegari@gmail.com; fotios.loupakis@iov.veneto.it;
   matteo.fassan@gmail.com; brunelladistefano89@gmail.com;
   mariabensi@hotmail.it; emilio.bria@policlinicogemelli.it;
   giampaolo.tortora@policlinicogemelli.it
RI Tortora, Giampaolo/HGB-6261-2022; Loupakis, Fotios/I-7243-2012; Bria,
   Emilio/A-8574-2019; calegari, maria alessandra/K-3929-2018; Bensi,
   Maria/AAC-5711-2022; Fassan, Matteo/F-5152-2012; Salvatore,
   Lisa/L-7746-2019
OI calegari, maria alessandra/0000-0001-6856-2593; Bensi,
   Maria/0000-0002-5647-0525; Fassan, Matteo/0000-0001-6515-5482;
   Salvatore, Lisa/0000-0003-3864-0719; Tortora,
   Giampaolo/0000-0002-1378-4962
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) under
   Investigator Grant (IG) [IG18599]
FX This work was supported by the Associazione Italiana per la Ricerca sul
   Cancro (AIRC) under Investigator Grant (IG) No. IG18599 to G.T.
CR Agoston EI, 2016, DIAGN PATHOL, V11, DOI 10.1186/s13000-016-0508-0
   Colakoglu T, 2008, AM J SURG, V195, P719, DOI 10.1016/j.amjsurg.2007.05.061
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Coronel-Hernández J, 2019, CANCER CELL INT, V19, DOI 10.1186/s12935-019-0802-5
   Day FL, 2013, CLIN CANCER RES, V19, P3285, DOI 10.1158/1078-0432.CCR-12-3614
   Dedes KJ, 2010, SCI TRANSL MED, V2, DOI 10.1126/scitranslmed.3001538
   Di Nicolantonio F, 2010, J CLIN INVEST, V120, P2858, DOI 10.1172/JCI37539
   Dillon LM, 2014, CURR DRUG TARGETS, V15, P65, DOI 10.2174/1389450114666140106100909
   Fine B, 2009, SCIENCE, V325, P1261, DOI 10.1126/science.1173569
   Forster MD, 2011, NAT REV CLIN ONCOL, V8, P302, DOI 10.1038/nrclinonc.2011.42
   Frattini M, 2007, BRIT J CANCER, V97, P1139, DOI 10.1038/sj.bjc.6604009
   Furnari FB, 1998, CANCER RES, V58, P5002
   Garrido-Laguna I, 2013, INVEST NEW DRUG, V31, P1257, DOI 10.1007/s10637-013-9947-6
   Gilcrease GW, 2019, INVEST NEW DRUG, V37, P482, DOI 10.1007/s10637-018-0645-2
   Grépin R, 2010, J ONCOL, V2010, DOI 10.1155/2010/835680
   Guertin DA, 2007, CANCER CELL, V12, P9, DOI 10.1016/j.ccr.2007.05.008
   He CJ, 2012, CANCER SCI, V103, P528, DOI 10.1111/j.1349-7006.2011.02177.x
   He LZ, 2010, J CLIN INVEST, V120, P2094, DOI 10.1172/JCI40778
   Hopkins BD, 2013, SCIENCE, V341, P399, DOI 10.1126/science.1234907
   Hudson CC, 2002, MOL CELL BIOL, V22, P7004, DOI 10.1128/MCB.22.20.7004-7014.2002
   Janku F, 2014, CELL REP, V6, P377, DOI 10.1016/j.celrep.2013.12.035
   Jansen YJL, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2018-000464
   Jhawer M, 2008, CANCER RES, V68, P1953, DOI 10.1158/0008-5472.CAN-07-5659
   Jiang BH, 2008, CURR CANCER DRUG TAR, V8, P19, DOI 10.2174/156800908783497122
   Jiang YA, 2003, WORLD J GASTROENTERO, V9, P491, DOI 10.3748/wjg.v9.i3.491
   Kara O, 2012, ASIAN PAC J CANCER P, V13, P6397, DOI 10.7314/APJCP.2012.13.12.6397
   Karapetis CS, 2014, CLIN CANCER RES, V20, P744, DOI 10.1158/1078-0432.CCR-13-0606
   Karar J, 2011, FRONT MOL NEUROSCI, V4, DOI 10.3389/fnmol.2011.00051
   Kokubo Y, 2005, BRIT J CANCER, V92, P1711, DOI 10.1038/sj.bjc.6602559
   Kotelevets L, 2001, J CELL BIOL, V155, P1129, DOI 10.1083/jcb.200105109
   Kotelevets L, 2018, ADV EXP MED BIOL, V1110, P55, DOI 10.1007/978-3-030-02771-1_5
   Kudinov AE, 2017, CLIN CANCER RES, V23, P2143, DOI 10.1158/1078-0432.CCR-16-2728
   Laurent-Puig P, 2009, J CLIN ONCOL, V27, P5924, DOI 10.1200/JCO.2008.21.6796
   Lavictoire SJ, 2018, MOL THER-METH CLIN D, V9, P12, DOI 10.1016/j.omtm.2017.11.006
   Leslie NR, 2011, TRENDS PHARMACOL SCI, V32, P131, DOI 10.1016/j.tips.2010.12.005
   Li HL, 2014, ONCOTARGET, V5, P587, DOI 10.18632/oncotarget.1782
   Li J, 1997, SCIENCE, V275, P1943, DOI 10.1126/science.275.5308.1943
   Li XH, 2009, ONCOL REP, V22, P757, DOI 10.3892/or_00000497
   Lin MS, 2011, ONCOL LETT, V2, P1219, DOI 10.3892/ol.2011.414
   Lin PC, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0601-y
   Liu G, 2019, BIOSCIENCE REP, V39, DOI 10.1042/BSR20190249
   Loges S, 2009, CANCER CELL, V15, P167, DOI 10.1016/j.ccr.2009.02.007
   Loupakis F, 2009, J CLIN ONCOL, V27, P2622, DOI 10.1200/JCO.2008.20.2796
   Majumder PK, 2004, NAT MED, V10, P594, DOI 10.1038/nm1052
   Marsit CJ, 2005, HUM PATHOL, V36, P768, DOI 10.1016/j.humpath.2005.05.006
   Matarlo JS, 2019, CELL CHEM BIOL, V26, P1133, DOI 10.1016/j.chembiol.2019.04.011
   McEllin B, 2010, CANCER RES, V70, P5457, DOI 10.1158/0008-5472.CAN-09-4295
   Mendes-Pereira AM, 2009, EMBO MOL MED, V1, P315, DOI 10.1002/emmm.200900041
   Minami D, 2013, MOL CANCER RES, V11, P140, DOI 10.1158/1541-7786.MCR-12-0401
   Molinari F, 2014, FRONT ONCOL, V3, DOI 10.3389/fonc.2013.00326
   Moroney J, 2012, CLIN CANCER RES, V18, P5796, DOI 10.1158/1078-0432.CCR-12-1158
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022
   Négrier S, 2011, LANCET ONCOL, V12, P673, DOI 10.1016/S1470-2045(11)70124-3
   Ng K, 2013, CLIN CANCER RES, V19, P3987, DOI 10.1158/1078-0432.CCR-13-0027
   Noorolyai S, 2019, J CELL PHYSIOL, V234, P5664, DOI 10.1002/jcp.27415
   O'Donnell A, 2008, J CLIN ONCOL, V26, P1588, DOI 10.1200/JCO.2007.14.0988
   Perren A, 1999, AM J PATHOL, V155, P1253, DOI 10.1016/S0002-9440(10)65227-3
   Pishvaian MJ, 2018, CANCER-AM CANCER SOC, V124, P2337, DOI 10.1002/cncr.31309
   Poliseno L, 2010, NATURE, V465, P1033, DOI 10.1038/nature09144
   Price TJ, 2013, CANCER MED-US, V2, P277, DOI 10.1002/cam4.75
   Rabinovsky R, 2009, MOL CELL BIOL, V29, P5377, DOI 10.1128/MCB.01649-08
   Ready N, 2011, J THORAC ONCOL, V6, P781, DOI 10.1097/JTO.0b013e31820a0ea6
   Sawai H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-56
   Sclafani F, 2015, INT J BIOL MARKER, V30, pE73, DOI 10.5301/jbm.5000097
   Shang H, 2019, EUR REV MED PHARMACO, V23, P3080, DOI 10.26355/eurrev_201904_17591
   Shen WH, 2007, CELL, V128, P157, DOI 10.1016/j.cell.2006.11.042
   Song MS, 2012, NAT REV MOL CELL BIO, V13, P283, DOI 10.1038/nrm3330
   Sonpavde G, 2012, ANN ONCOL, V23, P1803, DOI 10.1093/annonc/mdr555
   Steck PA, 1997, NAT GENET, V15, P356, DOI 10.1038/ng0497-356
   Sveen A, 2020, NAT REV CLIN ONCOL, V17, P11, DOI 10.1038/s41571-019-0241-1
   Szado T, 2008, P NATL ACAD SCI USA, V105, P2427, DOI 10.1073/pnas.0711324105
   Tabernero J, 2008, J CLIN ONCOL, V26, P1603, DOI 10.1200/JCO.2007.14.5482
   Tanaka R, 2016, ANTICANCER RES, V36, P4537, DOI 10.21873/anticanres.11001
   Tang Y, 2015, CLIN TRANSL ONCOL, V17, P306, DOI 10.1007/s12094-014-1228-0
   Therkildsen C, 2014, ACTA ONCOL, V53, P852, DOI 10.3109/0284186X.2014.895036
   Wang QY, 2019, CANCER LETT, V451, P68, DOI 10.1016/j.canlet.2019.02.041
   Xue Q, 2013, WORLD J GASTROENTERO, V19, P9307, DOI 10.3748/wjg.v19.i48.9307
   Zhou XP, 2002, AM J PATHOL, V161, P439, DOI 10.1016/S0002-9440(10)64200-9
   Zou JJ, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-97
NR 80
TC 60
Z9 62
U1 3
U2 23
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2072-6694
J9 CANCERS
JI Cancers
PD NOV
PY 2019
VL 11
IS 11
AR 1765
DI 10.3390/cancers11111765
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA JV3UB
UT WOS:000502290100147
PM 31717544
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Feng, JJ
   Hu, ZW
   Xia, XT
   Liu, XG
   Lian, ZK
   Wang, H
   Wang, LR
   Wang, C
   Zhang, XL
   Pang, XF
AF Feng, Juanjuan
   Hu, Zhongwei
   Xia, Xinting
   Liu, Xiaogu
   Lian, Zhengke
   Wang, Hui
   Wang, Liren
   Wang, Cun
   Zhang, Xueli
   Pang, Xiufeng
TI Feedback activation of EGFR/wild-type RAS signaling axis limits
   KRAS<SUP>G12D</SUP> inhibitor efficacy in
   <i>KRAS</i><SUP>G12D</SUP>-mutated colorectal cancer
SO ONCOGENE
LA English
DT Article
ID TARGETED THERAPY; RECEPTOR; MIG6; RESISTANCE; POTENT; CELLS
AB Colorectal cancer (CRC), which shows a high degree of heterogeneity, is the third most deadly cancer worldwide. Mutational activation of KRAS(G12D) occurs in approximately 10-12% of CRC cases, but the susceptibility of KRAS(G12D)-mutated CRC to the recently discovered KRAS(G12D) inhibitor MRTX1133 has not been fully defined. Here, we report that MRTX1133 treatment caused reversible growth arrest in KRAS(G12D)-mutated CRC cells, accompanied by partial reactivation of RAS effector signaling. Through a drug-anchored synthetic lethality screen, we discovered that epidermal growth factor receptor (EGFR) inhibition was synthetic lethal with MRTX1133. Mechanistically, MRTX1133 treatment downregulated the expression of ERBB receptor feedback inhibitor 1 (ERRFI1), a crucial negative regulator of EGFR, thereby causing EGFR feedback activation. Notably, wild-type isoforms of RAS, including H-RAS and N-RAS, but not oncogenic K-RAS, mediated signaling downstream of activated EGFR, leading to RAS effector signaling rebound and reduced MRTX1133 efficacy. Blockade of activated EGFR with clinically used antibodies or kinase inhibitors suppressed the EGFR/wild-type RAS signaling axis, sensitized MRTX1133 monotherapy, and caused the regression of KRAS(G12D)-mutant CRC organoids and cell line-derived xenografts. Overall, this study uncovers feedback activation of EGFR as a prominent molecular event that restricts KRAS(G12D) inhibitor efficacy and establishes a potential combination therapy consisting of KRAS(G12D) and EGFR inhibitors for patients with KRAS(G12D)-mutated CRC.
   [GRAPHICS]
   .
C1 [Feng, Juanjuan; Hu, Zhongwei; Liu, Xiaogu; Zhang, Xueli] Southern Med Univ, Sch Clin Med 3, Affiliated Fengxian Hosp, Guangzhou 510515, Guangdong, Peoples R China.
   [Feng, Juanjuan; Xia, Xinting; Lian, Zhengke; Wang, Liren; Pang, Xiufeng] East China Normal Univ, Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
   [Wang, Hui; Wang, Cun] Shanghai Jiao Tong Univ, Renji Hosp, Shanghai Canc Inst, Sch Med,State Key Lab Oncogenes & Related Genes, Shanghai 200240, Peoples R China.
C3 Southern Medical University - China; East China Normal University;
   Shanghai Jiao Tong University
RP Zhang, XL (corresponding author), Southern Med Univ, Sch Clin Med 3, Affiliated Fengxian Hosp, Guangzhou 510515, Guangdong, Peoples R China.; Pang, XF (corresponding author), East China Normal Univ, Sch Life Sci, Shanghai Key Lab Regulatory Biol, Shanghai 200241, Peoples R China.
EM lejing1996@aliyun.com; xfpang@bio.ecnu.edu.cn
OI wang, cun/0000-0002-4977-2189; hu, zhongwei/0000-0001-6160-907X; lian,
   zhengke/0000-0001-8010-4616; Xia, Xinting/0000-0003-3890-7807
FU National Natural Science Foundation of China [82122045, 82073073,
   81874207]; Natural Science Foundation of Shanghai [23ZR1418900]; Science
   and Technology Commission of Shanghai Municipality [20140900800,
   23YF1435700]; Innovative Research Team of High-level Local Universities
   in Shanghai [SHSMU-ZDCX20210802]; ECNU multifunctional platform for
   innovation
FX AcknowledgementsThis work was sponsored by the National Natural Science
   Foundation of China (82122045, 82073073, and 81874207), the Natural
   Science Foundation of Shanghai (23ZR1418900), the Science and Technology
   Commission of Shanghai Municipality (20140900800 and 23YF1435700),
   Innovative Research Team of High-level Local Universities in Shanghai
   (SHSMU-ZDCX20210802), and the ECNU multifunctional platform for
   innovation (011).
CR Amodio V, 2020, CANCER DISCOV, V10, P1129, DOI 10.1158/2159-8290.CD-20-0187
   Awad MM, 2021, NEW ENGL J MED, V384, P2382, DOI 10.1056/NEJMoa2105281
   Bien J, 2021, JAMA-J AM MED ASSOC, V325, P2404, DOI 10.1001/jama.2021.6021
   Boutin AT, 2017, GENE DEV, V31, P370, DOI 10.1101/gad.293449.116
   Cancer Genome Atlas Network, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Cook JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22125-z
   Cooper AJ, 2022, NAT REV CLIN ONCOL, V19, P499, DOI 10.1038/s41571-022-00639-9
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Descot A, 2009, MOL CELL, V35, P291, DOI 10.1016/j.molcel.2009.07.015
   Di Nicolantonio F, 2021, NAT REV CLIN ONCOL, V18, P506, DOI 10.1038/s41571-021-00495-z
   Drost J, 2018, NAT REV CANCER, V18, P407, DOI 10.1038/s41568-018-0007-6
   Endo H, 2017, ONCOGENE, V36, P2824, DOI 10.1038/onc.2016.431
   Fakih MG, 2022, LANCET ONCOL, V23, P115, DOI 10.1016/S1470-2045(21)00605-7
   Frosi Y, 2010, J CELL BIOL, V189, P557, DOI 10.1083/jcb.201002032
   Guo JW, 2021, J CLIN INVEST, V131, DOI 10.1172/JCI133090
   Hallin J, 2022, NAT MED, V28, P2171, DOI 10.1038/s41591-022-02007-7
   Jiang RQ, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms15129
   Jin HJ, 2021, NATURE, V595, P730, DOI 10.1038/s41586-021-03741-7
   Keum N, 2019, NAT REV GASTRO HEPAT, V16, P713, DOI 10.1038/s41575-019-0189-8
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Kuipers EJ, 2015, NAT REV DIS PRIMERS, V1, DOI 10.1038/nrdp.2015.65
   Li CC, 2021, ACTA PHARM SIN B, V11, P2670, DOI 10.1016/j.apsb.2021.06.013
   Li SQ, 2018, NAT REV CANCER, V18, P767, DOI 10.1038/s41568-018-0076-6
   Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240
   Liu C, 2021, CLIN CANCER RES, V27, P342, DOI 10.1158/1078-0432.CCR-20-2718
   Maity TK, 2015, CANCER DISCOV, V5, P534, DOI 10.1158/2159-8290.CD-14-0750
   Martinelli E, 2020, ANN ONCOL, V31, P30, DOI 10.1016/j.annonc.2019.10.007
   Misale S, 2019, CLIN CANCER RES, V25, P796, DOI 10.1158/1078-0432.CCR-18-0368
   Picard E, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.00369
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Prior IA, 2020, CANCER RES, V80, P2969, DOI 10.1158/0008-5472.CAN-19-3682
   Punekar SR, 2022, NAT REV CLIN ONCOL, V19, P637, DOI 10.1038/s41571-022-00671-9
   Ryan MB, 2022, CELL REP, V39, DOI 10.1016/j.celrep.2022.110993
   Skoulidis F, 2021, NEW ENGL J MED, V384, P2371, DOI 10.1056/NEJMoa2103695
   Sorokin AV, 2022, CANCER RES, V82, P3335, DOI 10.1158/0008-5472.CAN-22-0198
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Thein KZ, 2021, ANNU REV MED, V72, P349, DOI 10.1146/annurev-med-080819-033145
   Tsai YS, 2022, J CLIN INVEST, V132, DOI 10.1172/JCI155523
   Wang XL, 2021, J MED CHEM, DOI 10.1021/acs.jmedchem.1c01688
   Wu QB, 2022, CANCER DISCOV, V12, P1378, DOI 10.1158/2159-8290.CD-21-1168
   Xie C, 2017, FRONT PHARMACOL, V8, DOI 10.3389/fphar.2017.00823
   Xie YH, 2020, SIGNAL TRANSDUCT TAR, V5, DOI 10.1038/s41392-020-0116-z
   Xue JY, 2020, NATURE, V577, P421, DOI 10.1038/s41586-019-1884-x
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Yao Y, 2020, CELL STEM CELL, V26, P17, DOI 10.1016/j.stem.2019.10.010
   Yoo JY, 2022, NAT COMMUN, V13, DOI 10.1038/s41467-022-28608-x
   Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231
   Zhang XW, 2007, NATURE, V450, P741, DOI 10.1038/nature05998
   Zhang Z, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.182
   Zhao M., 2021, CLIN CANCER RES, V27, P1681, DOI DOI 10.1158/1078-0432.CCR-20-3017
NR 53
TC 24
Z9 26
U1 5
U2 30
PU SPRINGERNATURE
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON, N1 9XW, ENGLAND
SN 0950-9232
EI 1476-5594
J9 ONCOGENE
JI Oncogene
PD MAY 12
PY 2023
VL 42
IS 20
BP 1620
EP 1633
DI 10.1038/s41388-023-02676-9
EA APR 2023
PG 14
WC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology; Cell Biology; Genetics &
   Heredity
GA F7PA7
UT WOS:000964663400006
PM 37020035
OA hybrid, Green Published
DA 2025-01-04
ER

PT J
AU Zhang, QG
   Wang, WW
   Zhou, QB
   Chen, C
   Yuan, WT
   Liu, JB
   Li, XL
   Sun, ZQ
AF Zhang, Qiuge
   Wang, Weiwei
   Zhou, Quanbo
   Chen, Chen
   Yuan, Weitang
   Liu, Jinbo
   Li, Xiaoli
   Sun, Zhenqiang
TI Roles of circRNAs in the tumour microenvironment
SO MOLECULAR CANCER
LA English
DT Review
DE CircRNAs; Tumour microenvironment; Immunoregulation; Angiogenesis
ID LONG NONCODING RNAS; CANCER STEM-CELLS; CIRCULAR RNA; BREAST-CANCER;
   ENDOTHELIAL-CELLS; COLORECTAL-CANCER; HEPATOCELLULAR-CARCINOMA;
   EXTRACELLULAR VESICLES; EMERGING ROLE; PROMOTES
AB The tumour microenvironment (TME) constitutes the area surrounding the tumour during its development and has been demonstrated to play roles in cancer-related diseases through crosstalk with tumour cells. Circular RNAs (circRNAs) are a subpopulation of endogenous noncoding RNAs (ncRNAs) that are ubiquitously expressed in eukaryotes and have multiple biological functions in the regulation of cancer onset and progression. An increasing number of studies have shown that circRNAs participate in the multifaceted biological regulation of the TME. However, details on the mechanisms involved have remained elusive until now. In this review, we analyse the effects of circRNAs on the TME from various perspectives, including immune surveillance, angiogenesis, hypoxia, matrix remodelling, exo-circRNAs and chemoradiation resistance. Currently, the enormous potential for circRNA use in targeted therapy and as noninvasive biomarkers have drawn our attention. We emphasize the prospect of targeting circRNAs as an essential strategy to regulate TME, overcome cancer resistance and improve therapeutic outcomes.
C1 [Zhou, Quanbo; Chen, Chen; Yuan, Weitang; Liu, Jinbo; Sun, Zhenqiang] Zhengzhou Univ, Affiliated Hosp 1, Dept Colorectal Surg, Zhengzhou 450052, Peoples R China.
   [Zhang, Qiuge; Li, Xiaoli] Zhengzhou Univ, Affiliated Hosp 1, Dept Geriatr Med, Zhengzhou 450052, Peoples R China.
   [Zhang, Qiuge; Chen, Chen; Sun, Zhenqiang] Zhengzhou Univ, Acad Med Sci, Zhengzhou 450052, Peoples R China.
   [Wang, Weiwei] Zhengzhou Univ, Affiliated Hosp 1, Dept Pathol, Zhengzhou 450052, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; Zhengzhou University;
   Zhengzhou University
RP Liu, JB; Sun, ZQ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Colorectal Surg, Zhengzhou 450052, Peoples R China.; Li, XL (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, Dept Geriatr Med, Zhengzhou 450052, Peoples R China.
EM 1999liujb@163.com; fcclixl2@zzu.edu.cn; zqsun82@csu.edu.cn
RI zhou, bolin/KHX-0072-2024; Li, Xiaoli/GYQ-7384-2022
OI Sun, Zhenqiang/0000-0002-9098-7296
FU National Natural Science Foundation of China [81560385]; Medical
   Scientific and Technological Research Project of Henan Province
   [201702027]; Youth Innovation Fund Project of The First Affiliated
   Hospital of Zhengzhou University [YNQN2017035]; China Postdoctoral
   Science Foundation [2017M610462, 2019T120648]; National Natural Science
   Foundation of Henan Province [182300410342]; Health Commission
   Technology Talents Overseas Training Project of Henan Province [2018140]
FX This study was supported by The National Natural Science Foundation of
   China (81560385), The Medical Scientific and Technological Research
   Project of Henan Province (201702027), Youth Innovation Fund Project of
   The First Affiliated Hospital of Zhengzhou University (YNQN2017035), The
   China Postdoctoral Science Foundation (2017M610462, 2019T120648), The
   National Natural Science Foundation of Henan Province (182300410342) and
   The Health Commission Technology Talents Overseas Training Project of
   Henan Province (2018140).
CR Abdelmohsen K, 2017, RNA BIOL, V14, P361, DOI 10.1080/15476286.2017.1279788
   Altorki NK, 2019, NAT REV CANCER, V19, P9, DOI 10.1038/s41568-018-0081-9
   Aprelikova O, 2010, CELL CYCLE, V9, P4387, DOI 10.4161/cc.9.21.13674
   Bach DH, 2019, MOL THER-NUCL ACIDS, V16, P118, DOI 10.1016/j.omtn.2019.02.005
   Bai HT, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0986-2
   Balaj L, 2011, NAT COMMUN, V2, DOI 10.1038/ncomms1180
   Balkwill FR, 2012, J CELL SCI, V125, P5591, DOI 10.1242/jcs.116392
   Barbagallo D, 2019, CANCERS, V11, DOI 10.3390/cancers11020194
   Barbalat R, 2011, ANNU REV IMMUNOL, V29, P185, DOI 10.1146/annurev-immunol-031210-101340
   Boeckel JN, 2015, CIRC RES, V117, P884, DOI 10.1161/CIRCRESAHA.115.306319
   Bourquin C, 2020, PHARMACOL RES, V154, DOI 10.1016/j.phrs.2019.03.001
   Bronisz A, 2012, NAT CELL BIOL, V14, P159, DOI 10.1038/ncb2396
   Cao WF, 2019, CANCER BIOMARK, V25, P101, DOI 10.3233/CBM-182380
   Ocaña MC, 2019, MED RES REV, V39, P70, DOI 10.1002/med.21511
   Chen B, 2018, CANCER LETT, V418, P41, DOI 10.1016/j.canlet.2018.01.011
   Chen B, 2018, THERANOSTICS, V8, P4003, DOI 10.7150/thno.24106
   Chen F, 2015, BMC MED, V13, DOI 10.1186/s12916-015-0278-7
   Chen LL, 2015, RNA BIOL, V12, P381, DOI 10.1080/15476286.2015.1020271
   Chen SJ, 2017, CLIN CHIM ACTA, V466, P167, DOI 10.1016/j.cca.2017.01.025
   Chen TC, 2019, THORAC CANCER, V10, P930, DOI 10.1111/1759-7714.13032
   Chen WZ, 2017, J IMMUNOL RES, V2017, DOI 10.1155/2017/1073947
   Chen YG, 2017, MOL CELL, V67, P228, DOI 10.1016/j.molcel.2017.05.022
   Chen YX, 2019, ADV SCI, V6, DOI 10.1002/advs.201802070
   Cheng CC, 2019, ONCOTARGETS THER, V12, P8217, DOI 10.2147/OTT.S217468
   Chou J, 2013, CELL CYCLE, V12, P3262, DOI 10.4161/cc.26087
   Chouaib S, 2010, CRIT REV IMMUNOL, V30, P529, DOI 10.1615/CritRevImmunol.v30.i6.30
   Claesson-Welsh L, 2013, J INTERN MED, V273, P114, DOI 10.1111/joim.12019
   Conn SJ, 2015, CELL, V160, P1125, DOI 10.1016/j.cell.2015.02.014
   Dai XY, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0485-1
   Danan M, 2012, NUCLEIC ACIDS RES, V40, P3131, DOI 10.1093/nar/gkr1009
   Dang RY, 2017, BIOCHEM BIOPH RES CO, V490, P104, DOI 10.1016/j.bbrc.2017.05.164
   Dong R, 2017, RNA BIOL, V14, P1064, DOI 10.1080/15476286.2016.1269999
   Dou YC, 2016, SCI REP-UK, V6, DOI 10.1038/srep37982
   Du WW, 2017, EUR HEART J, V38, P1402, DOI 10.1093/eurheartj/ehw001
   Du WW, 2017, CELL DEATH DIFFER, V24, P357, DOI 10.1038/cdd.2016.133
   Du WW, 2016, NUCLEIC ACIDS RES, V44, P2846, DOI 10.1093/nar/gkw027
   Dunn GP, 2004, IMMUNITY, V21, P137, DOI 10.1016/j.immuni.2004.07.017
   Fan XY, 2015, GENOME BIOL, V16, DOI 10.1186/s13059-015-0706-1
   Gevensleben H, 2016, CLIN CANCER RES, V22, P1969, DOI 10.1158/1078-0432.CCR-15-2042
   Ghods FJ, 2018, ADV EXP MED BIOL, V1087, P131, DOI 10.1007/978-981-13-1426-1_11
   Gilbert MR, 2014, NEW ENGL J MED, V370, P699, DOI 10.1056/NEJMoa1308573
   Guo JB, 2019, BIOCHEM BIOPH RES CO, V513, P812, DOI 10.1016/j.bbrc.2019.03.214
   Hameed S, 2018, SCI CHINA LIFE SCI, V61, P380, DOI 10.1007/s11427-017-9256-1
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hanahan D, 2011, CELL, V144, P646, DOI 10.1016/j.cell.2011.02.013
   Hansen TB, 2013, CANCER RES, V73, P5609, DOI 10.1158/0008-5472.CAN-13-1568
   He CP, 2019, ONCOTARGETS THER, V12, P6349, DOI 10.2147/OTT.S204741
   He QR, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-018-0990-1
   He QR, 2018, MOL THER-NUCL ACIDS, V10, P331, DOI 10.1016/j.omtn.2017.12.014
   He YY, 2018, DRUG DES DEV THER, V12, P981, DOI 10.2147/DDDT.S163304
   He ZW, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1065-7
   Henry NL, 2012, MOL ONCOL, V6, P140, DOI 10.1016/j.molonc.2012.01.010
   Horsman MR, 2012, NAT REV CLIN ONCOL, V9, P674, DOI 10.1038/nrclinonc.2012.171
   Hu M, 2008, CURR OPIN GENET DEV, V18, P27, DOI 10.1016/j.gde.2007.12.006
   Huang YQ, 2017, SCI CHINA LIFE SCI, V60, P1114, DOI 10.1007/s11427-017-9178-y
   Hui R, 2017, ANN ONCOL, V28, P874, DOI 10.1093/annonc/mdx008
   Ishii H, 2008, CANCER SCI, V99, P1871, DOI 10.1111/j.1349-7006.2008.00914.x
   Iurescia S, 2018, RECENT PAT ANTI-CANC, V13, P2, DOI 10.2174/1574892812666171030163804
   Jeck WR, 2013, RNA, V19, P141, DOI 10.1261/rna.035667.112
   Jin PC, 2018, BIOCHEM BIOPH RES CO, V503, P1570, DOI 10.1016/j.bbrc.2018.07.081
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kahlert C, 2014, J BIOL CHEM, V289, P3869, DOI 10.1074/jbc.C113.532267
   Karar J, 2009, CANCER BIOL THER, V8, P1994, DOI 10.4161/cbt.8.21.9988
   Keir ME, 2008, ANNU REV IMMUNOL, V26, P677, DOI 10.1146/annurev.immunol.26.021607.090331
   Kim R, 2007, IMMUNOLOGY, V121, P1, DOI 10.1111/j.1365-2567.2007.02587.x
   Lasda E, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0148407
   Lee CG, 2000, CANCER RES, V60, P5565
   Lee Y, 2012, HUM MOL GENET, V21, pR125, DOI 10.1093/hmg/dds317
   Li CY, 2017, BIOMED PHARMACOTHER, V95, P1514, DOI 10.1016/j.biopha.2017.09.064
   Li DL, 2019, EXP CELL RES, V380, P20, DOI 10.1016/j.yexcr.2019.03.025
   Li J, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0822-3
   Li J, 2019, MOL GENET GENOM MED, V7, DOI 10.1002/mgg3.749
   Li PF, 2017, BRIT J CANCER, V116, P626, DOI 10.1038/bjc.2016.451
   Li PY, 2016, FRONT IMMUNOL, V7, DOI 10.3389/fimmu.2016.00574
   Li X, 2018, MOL CELL, V71, P428, DOI 10.1016/j.molcel.2018.06.034
   Li Y, 2010, CURR CANCER DRUG TAR, V10, P782, DOI 10.2174/156800910793605857
   Li Y, 2015, CELL RES, V25, P981, DOI 10.1038/cr.2015.82
   Li YW, 2017, EMBO REP, V18, P1646, DOI 10.15252/embr.201643581
   Li ZH, 2019, CLIN CHIM ACTA, V492, P37, DOI 10.1016/j.cca.2019.02.001
   Liang GH, 2017, ANTICANCER RES, V37, P4337, DOI 10.21873/anticanres.11827
   Lin YH, 2018, INT J MOL SCI, V19, DOI 10.3390/ijms19123742
   Lu RD, 2017, TUMOR BIOL, V39, P1, DOI 10.1177/1010428317704175
   Lu TT, 2015, RNA, V21, P2076, DOI 10.1261/rna.052282.115
   Luo ZY, 2016, CANCER LETT, V377, P174, DOI 10.1016/j.canlet.2016.04.038
   Ma YM, 2019, ONCOL LETT, V17, P388, DOI 10.3892/ol.2018.9606
   Martin M, 2016, ONCOTARGET, V7, P52575, DOI 10.18632/oncotarget.9824
   Marusyk A, 2010, BBA-REV CANCER, V1805, P105, DOI 10.1016/j.bbcan.2009.11.002
   Mattern J, 2001, ANTICANCER RES, V21, P4265
   Maybruck BT, 2017, J IMMUNOTHER CANCER, V5, DOI 10.1186/s40425-017-0269-7
   McCall NS, 2018, CLIN CANCER RES, V24, P1271, DOI 10.1158/1078-0432.CCR-17-3269
   McGee HM, 2019, CLIN CANCER RES, V25, P2969, DOI 10.1158/1078-0432.CCR-18-3781
   Mendoza M, 2009, INT J BIOCHEM CELL B, V41, P1452, DOI 10.1016/j.biocel.2009.01.015
   Meng Q, 2019, MOL THER-NUCL ACIDS, V17, P669, DOI 10.1016/j.omtn.2019.06.022
   Moeller BJ, 2005, CANCER CELL, V8, P99, DOI 10.1016/j.ccr.2005.06.016
   Motz GT, 2011, NAT REV IMMUNOL, V11, P702, DOI 10.1038/nri3064
   Nelson AR, 2000, J CLIN ONCOL, V18, P1135, DOI 10.1200/JCO.2000.18.5.1135
   Nicolet BP, 2018, NUCLEIC ACIDS RES, V46, P8168, DOI 10.1093/nar/gky721
   Nie WB, 2018, EUR REV MED PHARMACO, V22, P6239, DOI 10.26355/eurrev_201810_16030
   Ning YL, 2018, IMMUNOL LETT, V199, P36, DOI 10.1016/j.imlet.2018.05.002
   Ou ZL, 2019, RNA BIOL, V16, P1592, DOI 10.1080/15476286.2019.1649585
   Paget S., LANCET, V1, P571, DOI DOI 10.1016/S0140-6736(00)49915-0
   Passardi A, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061324
   Patel A, 2016, BIOTECHNOL ADV, V34, P803, DOI 10.1016/j.biotechadv.2016.04.005
   Ren SS, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1398-2
   Roma-Rodrigues C, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18010162
   Rybak-Wolf A, 2015, MOL CELL, V58, P870, DOI 10.1016/j.molcel.2015.03.027
   Salzman J, 2013, PLOS GENET, V9, DOI 10.1371/journal.pgen.1003777
   Salzman J, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030733
   Sang YT, 2019, MOL THER, V27, P1638, DOI 10.1016/j.ymthe.2019.05.011
   Schreiber RD, 2011, SCIENCE, V331, P1565, DOI 10.1126/science.1203486
   Shao F, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.00584
   Shao HL, 2018, CHEM REV, V118, P1917, DOI 10.1021/acs.chemrev.7b00534
   Shen YD, 2017, FEBS LETT, V591, P213, DOI 10.1002/1873-3468.12500
   Shi Min-hua, 2013, Zhonghua Zhong Liu Za Zhi, V35, P85, DOI 10.3760/cma.j.issn.0253-3766.2013.02.002
   Sonpavde G, 2017, NEW ENGL J MED, V376, P1073, DOI 10.1056/NEJMe1701182
   Su HF, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-0977-7
   Su H, 2019, CELL MOL BIOL LETT, V24, DOI 10.1186/s11658-019-0149-x
   Sun ZQ, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0831-z
   Tang HL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0946-x
   Tetta C, 2013, ENDOCRINE, V44, P11, DOI 10.1007/s12020-012-9839-0
   Theocharis AD, 2016, ADV DRUG DELIVER REV, V97, P4, DOI 10.1016/j.addr.2015.11.001
   Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596
   Viallard C, 2017, ANGIOGENESIS, V20, P409, DOI 10.1007/s10456-017-9562-9
   Wang KF, 2017, CANCER LETT, V394, P1, DOI 10.1016/j.canlet.2016.12.036
   Wang MN, 2017, J CANCER, V8, P761, DOI 10.7150/jca.17648
   Wang PL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090859
   Wang Q, 2018, ONCOL REP, V39, P1813, DOI 10.3892/or.2018.6263
   Wang RJ, 2018, CANCER RES, V78, P4812, DOI 10.1158/0008-5472.CAN-18-0532
   Wang T, 2019, BIOCHEM BIOPH RES CO, V513, P904, DOI 10.1016/j.bbrc.2019.04.108
   Wang WT, 2018, J CANCER RES CLIN, V144, P449, DOI 10.1007/s00432-017-2568-2
   Wang Z, 2016, J TRANSL MED, V14, DOI 10.1186/s12967-016-1056-9
   Weng QY, 2019, J MED GENET, V56, P32, DOI 10.1136/jmedgenet-2018-105440
   Weng WH, 2017, CLIN CANCER RES, V23, P3918, DOI 10.1158/1078-0432.CCR-16-2541
   Westholm JO, 2014, CELL REP, V9, P1966, DOI 10.1016/j.celrep.2014.10.062
   Wu JX, 2014, ANNU REV IMMUNOL, V32, P461, DOI 10.1146/annurev-immunol-032713-120156
   Wu J, 2018, CANCER LETT, V430, P179, DOI 10.1016/j.canlet.2018.05.033
   Wu KM, 2017, CELL CYCLE, V16, P1295, DOI 10.1080/15384101.2017.1317416
   Wu YY, 2018, CELL PHYSIOL BIOCHEM, V47, P1696, DOI 10.1159/000490992
   Xie WB, 2018, CELL PHYSIOL BIOCHEM, V46, P654, DOI 10.1159/000488634
   Xiong W, 2017, BIOMED RES INT, V2017, DOI 10.1155/2017/8421614
   Xu B, 2016, ONCOTARGET, V7, P74904, DOI 10.18632/oncotarget.12484
   Xu CX, 2014, CANCER CELL, V25, P590, DOI 10.1016/j.ccr.2014.03.033
   Xu HC, 2019, MOL CANCER, V18, DOI 10.1186/s12943-018-0932-8
   Xu ZH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.00009
   Yamamoto K, 2015, MATRIX BIOL, V44-46, P255, DOI 10.1016/j.matbio.2015.02.007
   Yang JH, 2019, J ONCOL, V2019, DOI 10.1155/2019/7630894
   Yang P, 2016, ONCOTARGET, V7, P63449, DOI 10.18632/oncotarget.11523
   Yang Q, 2017, CELL DEATH DIFFER, V24, P1609, DOI 10.1038/cdd.2017.86
   Yang W, 2019, CELL SIGNAL, V60, P122, DOI 10.1016/j.cellsig.2019.04.011
   Yang ZG, 2017, MOL THER, V25, P2062, DOI 10.1016/j.ymthe.2017.05.022
   Ye CY, 2015, NEW PHYTOL, V208, P88, DOI 10.1111/nph.13585
   Ye LS, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0451-6
   Yin WB, 2018, CLIN CHIM ACTA, V487, P363, DOI 10.1016/j.cca.2017.10.011
   Yoshimura A, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4974-5
   Yu J, 2018, J HEPATOL, V68, P1214, DOI 10.1016/j.jhep.2018.01.012
   Yuan Y, 2016, ONCOL REP, V35, P2499, DOI 10.3892/or.2016.4660
   Zang JK, 2020, J NEUROSCI RES, V98, P87, DOI 10.1002/jnr.24356
   Zhang HY, 2019, ONCOGENE, V38, P2844, DOI 10.1038/s41388-018-0619-z
   Zhang HY, 2019, INT J CANCER, V144, P2501, DOI 10.1002/ijc.31977
   Zhang PL, 2017, TUMOR BIOL, V39, DOI 10.1177/1010428317694546
   Zhang QY, 2018, FRONT PHARMACOL, V9, DOI 10.3389/fphar.2018.01253
   Zhang XL, 2017, CELL BIOL INT, V41, P1056, DOI 10.1002/cbin.10826
   Zhang Y, 2013, MOL CELL, V51, P792, DOI 10.1016/j.molcel.2013.08.017
   Zhao QF, 2018, J CLIN LAB ANAL, V32, DOI 10.1002/jcla.22333
   Zheng XB, 2017, NEOPLASMA, V64, P321, DOI 10.4149/neo_2017_301
   Zheng X, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1010-6
   Zhong ZY, 2017, CANCER LETT, V403, P305, DOI 10.1016/j.canlet.2017.06.027
NR 167
TC 167
Z9 173
U1 1
U2 31
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD JAN 23
PY 2020
VL 19
IS 1
AR 14
DI 10.1186/s12943-019-1125-9
PG 16
WC Biochemistry & Molecular Biology; Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Oncology
GA KL0YE
UT WOS:000513157900002
PM 31973726
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Sneha, S
   Nagare, RP
   Priya, SK
   Sidhanth, C
   Pors, K
   Ganesan, TS
AF Sneha, Smarakan
   Nagare, Rohit Pravin
   Priya, Syama Krishna
   Sidhanth, Chirukandath
   Pors, Klaus
   Ganesan, Trivadi Sundaram
TI Therapeutic antibodies against cancer stem cells: a promising approach
SO CANCER IMMUNOLOGY IMMUNOTHERAPY
LA English
DT Review
DE Monoclonal antibodies; Cancer stem cells; Targeted therapy;
   Antibody-dependent cell-mediated cytotoxicity
ID TUMOR-INITIATING CELLS; IL-3 RECEPTOR-ALPHA; ANTI-CD44
   MONOCLONAL-ANTIBODIES; COLONY-STIMULATING FACTOR; ACUTE
   MYELOID-LEUKEMIA; BREAST-CANCER; OVARIAN-CANCER; PANCREATIC-CANCER;
   COLORECTAL-CANCER; GENE-EXPRESSION
AB Monoclonal antibodies have been extensively used to treat malignancy along with routine chemotherapeutic drugs. Chemotherapy for metastatic cancer has not been successful in securing long-term remission of disease. This is in part due to the resistance of cancer cells to drugs. One aspect of the drug resistance is the inability of conventional drugs to eliminate cancer stem cells (CSCs) which often constitute less than 1-2% of the whole tumor. In some tumor types, it is possible to identify these cells using surface markers. Monoclonal antibodies targeting these CSCs are an attractive option for a new therapeutic approach. Although administering antibodies has not been effective, when combined with chemotherapy they have proved synergistic. This review highlights the potential of improving treatment efficacy using functional antibodies against CSCs, which could be combined with chemotherapy in the future.
C1 [Sneha, Smarakan; Nagare, Rohit Pravin; Priya, Syama Krishna; Sidhanth, Chirukandath; Ganesan, Trivadi Sundaram] Canc Inst WIA, Lab Canc Biol, Dept Med Oncol & Clin Res, 38,Sardar Patel Rd, Chennai 600036, Tamil Nadu, India.
   [Pors, Klaus] Univ Bradford, Inst Canc Therapeut, Bradford BD7 1DP, W Yorkshire, England.
C3 University of Bradford
RP Ganesan, TS (corresponding author), Canc Inst WIA, Lab Canc Biol, Dept Med Oncol & Clin Res, 38,Sardar Patel Rd, Chennai 600036, Tamil Nadu, India.
EM ts.ganesan@cancerinstitutewia.org
RI Syama, Krishna Priya/IVH-6674-2023; GANESAN, Trivadi/AAU-1499-2020
OI Pors, Klaus/0000-0002-0837-5208; Krishnapriya,
   Syama/0000-0002-3607-5501; NAGARE, ROHIT/0000-0002-2667-2871
FU University Grants Commission (UGC), Indian Council for Medical Research
   (ICMR); Department of Biotechnology (DBT), Govt. of India; University
   Grants Commission; Department of Biotechnology (DBT)
FX Supported by University Grants Commission (UGC), Indian Council for
   Medical Research (ICMR). Department of Biotechnology (DBT), Govt. of
   India.Smarakan Sneha is a University Grants Commission Senior Research
   Fellow (UGC-SRF) awardee. Syama Krishna Priya and Rohit Pravin Nagare
   are Indian Council for Medical Research Senior Research fellows (ICMR -
   SRF) and Chirukandath Sidhanth is supported by Department of
   Biotechnology (DBT).
CR Ahmadi H, 2007, CURR NEUROVASC RES, V4, P153
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Al-Zoobi L, 2014, INT IMMUNOL, V26, P451, DOI 10.1093/intimm/dxu046
   Almåsbak H, 2016, J IMMUNOL RES, V2016, DOI 10.1155/2016/5474602
   Ammons WS, 2003, NEOPLASIA, V5, P146, DOI 10.1016/S1476-5586(03)80006-4
   Bagley CJ, 1997, BLOOD, V89, P1471, DOI 10.1182/blood.V89.5.1471.1471_1471_1482
   Barclay AN, 2006, NAT REV IMMUNOL, V6, P457, DOI 10.1038/nri1859
   Beuzeboc P, 1999, B CANCER, V86, P544
   Bharti R, 2016, CANCER LETT, V375, P51, DOI 10.1016/j.canlet.2016.02.048
   Blazar BR, 2001, J EXP MED, V194, P541, DOI 10.1084/jem.194.4.541
   Bonnet D, 1997, NAT MED, V3, P730, DOI 10.1038/nm0797-730
   Bruttel VS, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00360
   Chaffer CL, 2013, CELL, V154, P61, DOI 10.1016/j.cell.2013.06.005
   Chao MP, 2011, CANCER RES, V71, P1374, DOI 10.1158/0008-5472.CAN-10-2238
   Charrad RS, 2002, BLOOD, V99, P290, DOI 10.1182/blood.V99.1.290
   Chen W, 2010, HYBRIDOMA, V29, P305, DOI 10.1089/hyb.2010.0019
   Cui TX, 2013, IMMUNITY, V39, P611, DOI 10.1016/j.immuni.2013.08.025
   Dai HR, 2016, JNCI-J NATL CANCER I, V108, DOI 10.1093/jnci/djv439
   Damelin M, 2011, CANCER RES, V71, P4236, DOI 10.1158/0008-5472.CAN-10-3919
   deGast GC, 1997, CANCER IMMUNOL IMMUN, V45, P121, DOI 10.1007/s002620050412
   Deonarain MP, 2009, MABS-AUSTIN, V1, P12, DOI 10.4161/mabs.1.1.7347
   Diessner J, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.115
   Du YR, 2013, INT J GYNECOL CANCER, V23, P1367, DOI 10.1097/IGC.0b013e3182a1d023
   Dunning NL, 2011, CANCER IMMUNOL IMMUN, V60, P1181, DOI 10.1007/s00262-011-1065-8
   Edris B, 2012, P NATL ACAD SCI USA, V109, P6656, DOI 10.1073/pnas.1121629109
   Emlet DR, 2014, CANCER RES, V74, P1238, DOI 10.1158/0008-5472.CAN-13-1407
   Eppert K, 2011, NAT MED, V17, P1086, DOI 10.1038/nm.2415
   Fang D, 2005, CANCER RES, V65, P9328, DOI 10.1158/0008-5472.CAN-05-1343
   Gadhoum Z, 2004, LEUKEMIA LYMPHOMA, V45, P1501, DOI 10.1080/1042819042000206687
   Gao MQ, 2010, ONCOGENE, V29, P2672, DOI 10.1038/onc.2010.35
   Gao QL, 2009, ULTRASTRUCT PATHOL, V33, P175, DOI 10.1080/01913120903086072
   Gires O, 2009, NAT REV CANCER, V9, P143, DOI 10.1038/nrc2499-c1
   GUO YJ, 1993, CELL IMMUNOL, V152, P186, DOI 10.1006/cimm.1993.1278
   Guo YQ, 2012, CANCER TREAT REV, V38, P904, DOI 10.1016/j.ctrv.2012.04.007
   Heider KH, 2004, CANCER IMMUNOL IMMUN, V53, P567, DOI 10.1007/s00262-003-0494-4
   Hemler ME, 2005, NAT REV MOL CELL BIO, V6, P801, DOI 10.1038/nrm1736
   Hermann PC, 2007, CELL STEM CELL, V1, P313, DOI 10.1016/j.stem.2007.06.002
   HIGASHIYAMA M, 1995, CANCER RES, V55, P6040
   Hori H, 2004, J SURG RES, V117, P208, DOI 10.1016/j.jss.2004.01.014
   Horst D, 2009, EUR J CANCER, V45, P2034, DOI 10.1016/j.ejca.2009.04.004
   Houle CD, 2002, GYNECOL ONCOL, V86, P69, DOI 10.1006/gyno.2002.6729
   Huang CI, 1998, AM J PATHOL, V153, P973, DOI 10.1016/S0002-9440(10)65639-8
   Huang CL, 2004, ONCOGENE, V23, P7475, DOI 10.1038/sj.onc.1208063
   Ithimakin S, 2013, CANCER RES, V73, P1635, DOI 10.1158/0008-5472.CAN-12-3349
   Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046
   Jin LQ, 2006, NAT MED, V12, P1167, DOI 10.1038/nm1483
   Jin LQ, 2009, CELL STEM CELL, V5, P31, DOI 10.1016/j.stem.2009.04.018
   JONES PT, 1986, NATURE, V321, P522, DOI 10.1038/321522a0
   Kerk SA, 2017, CLIN CANCER RES, V23, P2516, DOI 10.1158/1078-0432.CCR-16-1834
   Kim D, 2012, LEUKEMIA, V26, P2538, DOI 10.1038/leu.2012.141
   Kristiansen G, 2004, J MOL HISTOL, V35, P255
   Kryczek I, 2014, IMMUNITY, V40, P772, DOI 10.1016/j.immuni.2014.03.010
   Kryczek I, 2012, INT J CANCER, V130, P29, DOI 10.1002/ijc.25967
   Li CW, 2007, CANCER RES, V67, P1030, DOI 10.1158/0008-5472.CAN-06-2030
   Liu QH, 2009, J NEURO-ONCOL, V94, P1, DOI 10.1007/s11060-009-9919-z
   Logtenberg T, 2007, TRENDS BIOTECHNOL, V25, P390, DOI 10.1016/j.tibtech.2007.07.005
   Lonberg N., 2008, V181, P69
   Luginbühl B, 2006, J MOL BIOL, V363, P75, DOI 10.1016/j.jmb.2006.07.027
   Maccalli C, 2015, CANCER IMMUNOL IMMUN, V64, P91, DOI 10.1007/s00262-014-1592-1
   Majetl R, 2009, P NATL ACAD SCI USA, V106, P3396, DOI 10.1073/pnas.0900089106
   Marangoni E, 2009, BRIT J CANCER, V100, P918, DOI 10.1038/sj.bjc.6604953
   Masuko K, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029728
   Maus MV, 2014, BLOOD, V123, P2625, DOI 10.1182/blood-2013-11-492231
   McNeil C, 1998, J NATL CANCER I, V90, P882, DOI 10.1093/jnci/90.12.882
   Menendez J, 2008, CANCER RES, V68, P3993
   Merlos-Suárez A, 2011, CELL STEM CELL, V8, P511, DOI 10.1016/j.stem.2011.02.020
   MIYAJIMA A, 1993, BLOOD, V82, P1960
   Molejon Maria Ines, 2015, Oncoscience, V2, P572
   Mori M, 1998, CLIN CANCER RES, V4, P1507
   NADLER LM, 1980, CANCER RES, V40, P3147
   Nagare RP, 2017, CURR STEM CELL RES T, V12, P37, DOI 10.2174/1574888X11666160607211436
   Nakamoto T, 2009, J GASTROENTEROL, V44, P889, DOI 10.1007/s00535-009-0081-3
   Naujokat C, 2014, IMMUNOTHERAPY-UK, V6, P291, DOI 10.2217/imt.14.4
   Naundorf S, 2002, INT J CANCER, V100, P101, DOI 10.1002/ijc.10443
   Nievergall E, 2014, BLOOD, V123, P1218, DOI 10.1182/blood-2012-12-475194
   O'Brien CA, 2007, NATURE, V445, P106, DOI 10.1038/nature05372
   Okazawa H, 2005, J IMMUNOL, V174, P2004, DOI 10.4049/jimmunol.174.4.2004
   Oldenborg PA, 2001, J EXP MED, V193, P855, DOI 10.1084/jem.193.7.855
   Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051
   Perez A, 2012, CANCER RES, V72, DOI 10.1158/1538-7445.AM2012-2521
   Pivot X, 2013, LANCET ONCOL, V14, P741, DOI 10.1016/S1470-2045(13)70225-0
   Pors K, 2014, DRUG DISCOV TODAY, V19, P1953, DOI 10.1016/j.drudis.2014.09.009
   Priya SK, 2016, INT J CANCER, V139, P729, DOI 10.1002/ijc.30067
   Reichert JM, 2005, NAT BIOTECHNOL, V23, P1073, DOI 10.1038/nbt0905-1073
   Richter CE, 2010, AM J OBSTET GYNECOL, V203, DOI 10.1016/j.ajog.2010.07.041
   Riethmüller G, 1998, J CLIN ONCOL, V16, P1788, DOI 10.1200/JCO.1998.16.5.1788
   Sachlos E, 2012, CELL, V149, P1284, DOI 10.1016/j.cell.2012.03.049
   Sagiv E, 2008, CANCER RES, V68, P2803, DOI 10.1158/0008-5472.CAN-07-6463
   Salles G, 2011, LANCET, V377, P42, DOI 10.1016/S0140-6736(10)62175-7
   SAMMAR M, 1994, INT IMMUNOL, V6, P1027, DOI 10.1093/intimm/6.7.1027
   Sapra P, 2013, MOL CANCER THER, V12, P38, DOI 10.1158/1535-7163.MCT-12-0603
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Sho M, 1998, INT J CANCER, V79, P509, DOI 10.1002/(SICI)1097-0215(19981023)79:5<509::AID-IJC11>3.0.CO;2-X
   Singh JK, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3436
   Singh JK, 2013, CLIN CANCER RES, V19, P643, DOI 10.1158/1078-0432.CCR-12-1063
   Singh SK, 2004, NATURE, V432, P396, DOI 10.1038/nature03128
   Smith PJ, 2013, CYTOM PART A, V83A, P161, DOI 10.1002/cyto.a.22224
   Sun QY, 1996, BLOOD, V87, P83
   Szotek PP, 2006, P NATL ACAD SCI USA, V103, P11154, DOI 10.1073/pnas.0603672103
   TAI MS, 1990, BIOCHEMISTRY-US, V29, P8024, DOI 10.1021/bi00487a005
   Tanha J, 2002, J IMMUNOL METHODS, V263, P97, DOI 10.1016/S0022-1759(02)00027-3
   Thiagarajan PS, 2015, STEM CELLS, V33, P2114, DOI 10.1002/stem.2021
   Tseng D, 2013, P NATL ACAD SCI USA, V110, P11103, DOI 10.1073/pnas.1305569110
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Waldron NN, 2014, TARGET ONCOL, V9, P239, DOI 10.1007/s11523-013-0290-9
   Walter RB, 2012, BLOOD, V119, P6198, DOI 10.1182/blood-2011-11-325050
   Wang J, 2008, INT J CANCER, V122, P761, DOI 10.1002/ijc.23130
   Wesolowski R, 2013, J IMMUNOTHER CANCER, V1, DOI 10.1186/2051-1426-1-10
   Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109
   Xu JF, 2015, ONCOTARGET, V6, P23662, DOI 10.18632/oncotarget.4282
   Yamashita M, 2007, CYTOTECHNOLOGY, V55, P55, DOI 10.1007/s10616-007-9072-5
   Yamashita T, 2007, CANCER RES, V67, P10831, DOI 10.1158/0008-5472.CAN-07-0908
   Yamashita T, 2009, GASTROENTEROLOGY, V136, P1012, DOI 10.1053/j.gastro.2008.12.004
   Ye J, 2014, TUMOR BIOL, V35, P3945, DOI 10.1007/s13277-013-1561-x
   Yip YL, 2002, CANCER IMMUNOL IMMUN, V50, P569, DOI 10.1007/s002620100226
   Yoshida K, 2015, CANCER MED-US, V4, P1322, DOI 10.1002/cam4.478
   Zhang Hao, 2016, Int J Biol Sci, V12, P718, DOI 10.7150/ijbs.14405
   Zhang Long-Zhen, 2010, Zhonghua Xue Ye Xue Za Zhi, V31, P398
   Zhang SP, 2013, P NATL ACAD SCI USA, V110, P6127, DOI 10.1073/pnas.1221841110
   Zou W., 2015, ONCOSCIENCE, V2, P615, DOI [10.18632/oncoscience.181, DOI 10.18632/ONCOSCIENCE.181]
NR 120
TC 12
Z9 12
U1 0
U2 16
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0340-7004
EI 1432-0851
J9 CANCER IMMUNOL IMMUN
JI Cancer Immunol. Immunother.
PD NOV
PY 2017
VL 66
IS 11
BP 1383
EP 1398
DI 10.1007/s00262-017-2049-0
PG 16
WC Oncology; Immunology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Immunology
GA FK1NH
UT WOS:000413248100001
PM 28840297
OA Green Published
DA 2025-01-04
ER

PT J
AU Yang, YY
   Zhan, JY
   Li, XS
   Hua, J
   Lei, HK
   Chen, XL
AF Yang, Yuanyuan
   Zhan, Jiayi
   Li, Xiaosheng
   Hua, Jun
   Lei, Haike
   Chen, Xiaoliang
TI A nomogram to predict the risk of venous thromboembolism in patients
   with colon cancer in China
SO CANCER MEDICINE
LA English
DT Article
DE colon cancer; nomogram; predictive model; venous thromboembolism
ID CHEMOTHERAPY; MORTALITY; SURGERY; MODEL; LUNG
AB Objective: To create a nomogram for predicting the likelihood of venous thromboembolism (VTE) in colon cancer patients from China. Methods: The data of colon cancer patients from Chongqing University Cancer Hospital between 2019 and 2022 were analyzed. Patients were divided into training set and internal validation set by random split-sample method in a split ratio of 7:3. The univariable and multivariable logistic analysis gradually identified the independent risk factors for VTE. A nomogram was created using all the variables that had a significance level of p < 0.05 in the multivariable logistic analysis and those with clinical significance. Calibration curves and clinical decision curve analysis (DCA) were used to assess model's fitting performance and clinical value. Harrell's C-index (concordance statistic) and the area under the receiver operating characteristic curves (AUC) were used to evaluate the predictive effectiveness of models. Results: A total of 1996 patients were ultimately included. There were 1398 patients in the training set and 598 patients in the internal validation set. The nomogram included age, chemotherapy, targeted therapy, hypertension, activated partial thromboplastin time, prothrombin time, platelet, absolute lymphocyte count, and D-dimer. The C-index of nomogram and Khorana score were 0.754 (95% CI 0.711-0.798), 0.520 (95% CI 0.477-0.563) in the training cohort and 0.713 (95% CI 0.643-0.784), 0.542 (95% CI 0.473-0.612) in the internal validation cohort. Conclusions: We have established and validated a nomogram to predict the VTE risk of colon cancer patients in China, which encompasses a diverse age range, a significant population size, and various clinical factors. It facilitates the identification of high-risk groups and may enable the implementation of targeted preventive measures.
C1 [Yang, Yuanyuan; Hua, Jun; Chen, Xiaoliang] Chongqing Univ, Canc Hosp, Dept Nucl Med, Chongqing 400030, Peoples R China.
   [Zhan, Jiayi] Chongqing Univ Canc Hosp, Dept Tradit Chinese Med, Chongqing, Peoples R China.
   [Li, Xiaosheng; Lei, Haike] Chongqing Univ, Canc Hosp, Chongqing Canc Multiomics Big Data Applicat Engn R, Chongqing 400030, Peoples R China.
C3 Chongqing University; Chongqing University
RP Chen, XL (corresponding author), Chongqing Univ, Canc Hosp, Dept Nucl Med, Chongqing 400030, Peoples R China.; Lei, HK (corresponding author), Chongqing Univ, Canc Hosp, Chongqing Canc Multiomics Big Data Applicat Engn R, Chongqing 400030, Peoples R China.
EM tohaike@163.com; chenxiaoliang26@163.com
OI Chen, Xiaoliang/0000-0002-3505-5314; LEI, HAIKE/0000-0003-0284-2052
FX Not applicable.
CR Bartholomew JR, 2017, CLEV CLIN J MED, V84, P39, DOI 10.3949/ccjm.84.s3.04
   Blom JW, 2005, JAMA-J AM MED ASSOC, V293, P715, DOI 10.1001/jama.293.6.715
   Chen S, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01287-2
   Chou SC, 2022, J FORMOS MED ASSOC, V121, P360, DOI 10.1016/j.jfma.2021.04.025
   Cohen O, 2022, J THROMB HAEMOST, V20, P366, DOI 10.1111/jth.15574
   Collins GS, 2015, J CLIN EPIDEMIOL, V68, P112, DOI [10.7326/M14-0697, 10.1136/bmj.g7594, 10.1016/j.jclinepi.2014.11.010, 10.7326/M14-0698, 10.1016/j.eururo.2014.11.025, 10.1002/bjs.9736, 10.1186/s12916-014-0241-z, 10.1038/bjc.2014.639]
   Devani K, 2017, CLIN COLORECTAL CANC, V16, pE199, DOI 10.1016/j.clcc.2016.09.006
   Faccia M, 2022, INTERN EMERG MED, V17, P1327, DOI 10.1007/s11739-022-02928-8
   Gao BS, 2022, FRONT ENDOCRINOL, V13, DOI 10.3389/fendo.2022.963559
   Hanna N, 2012, ONCOLOGIST, V17, P1191, DOI 10.1634/theoncologist.2012-0093
   Hu S, 2023, THROMB HAEMOSTASIS, V123, P913, DOI 10.1055/a-2040-4850
   Huang X, 2022, ANN SURG ONCOL, V29, P5784, DOI 10.1245/s10434-022-11968-5
   Ikeda M, 2022, CANCER SCI, V113, P3901, DOI 10.1111/cas.15527
   Khorana AA, 2008, BLOOD, V111, P4902, DOI 10.1182/blood-2007-10-116327
   Khorana AA, 2013, CLINICOECONOMIC OUTC, V5, P101, DOI 10.2147/CEOR.S39964
   Khorana AA, 2013, CANCER-AM CANCER SOC, V119, P648, DOI 10.1002/cncr.27772
   Klemen ND, 2020, LANCET HAEMATOL, V7, pE583, DOI 10.1016/S2352-3026(20)30211-8
   Lei HK, 2023, CANCER CELL INT, V23, DOI 10.1186/s12935-023-02882-1
   Li A, 2023, J CLIN ONCOL, V41, P2926, DOI 10.1200/JCO.22.01542
   Li HM, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.988287
   Li T, 2023, J ORTHOP SURG RES, V18, DOI 10.1186/s13018-023-03592-0
   Metcalf RL, 2017, WORLD J GASTRO ONCOL, V9, P363, DOI 10.4251/wjgo.v9.i9.363
   Oi M, 2020, J THROMB THROMBOLYS, V49, P551, DOI 10.1007/s11239-019-01964-0
   Otten HMMB, 2004, ARCH INTERN MED, V164, P190, DOI 10.1001/archinte.164.2.190
   Qiu CJ, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.769685
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tawil N, 2022, BEST PRACT RES CL HA, V35, DOI 10.1016/j.beha.2022.101349
   Vendler MMI, 2017, COLORECTAL DIS, V19, pO393, DOI 10.1111/codi.13910
   Puteh SEW, 2022, SEMIN THROMB HEMOST, V48, P490, DOI 10.1055/s-0042-1744365
   Wu CC, 2019, SCI CHINA LIFE SCI, V62, P640, DOI 10.1007/s11427-018-9461-5
   Wu J, 2020, CANCER COMMUN, V40, P301, DOI 10.1002/cac2.12067
   Xu Y, 2021, GYNECOL ONCOL, V160, P610, DOI 10.1016/j.ygyno.2020.11.010
   Yang JS, 2021, LEUKEMIA LYMPHOMA, V62, P2383, DOI 10.1080/10428194.2021.1913149
   Yang SS, 2011, WORLD J SURG, V35, P881, DOI 10.1007/s00268-011-0957-2
   Yhim HY, 2023, THROMB RES, V231, P50, DOI 10.1016/j.thromres.2023.10.005
   Zakai NA, 2008, AM J MED, V121, P231, DOI 10.1016/j.amjmed.2007.10.025
   Zhang L, 2022, MEDIAT INFLAMM, V2022, DOI 10.1155/2022/9215311
   Zhang YH, 2016, SCI REP-UK, V6, DOI 10.1038/srep19603
NR 38
TC 1
Z9 1
U1 4
U2 4
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2045-7634
J9 CANCER MED-US
JI Cancer Med.
PD MAY
PY 2024
VL 13
IS 9
AR e7231
DI 10.1002/cam4.7231
PG 15
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA WY4S5
UT WOS:001258427200001
PM 38698697
OA Green Published
DA 2025-01-04
ER

PT J
AU He, R
   Lao, YF
   Yu, WY
   Zhang, XH
   Jiang, M
   Zhu, CR
AF He, Rui
   Lao, Yefang
   Yu, Wenyan
   Zhang, Xiaohui
   Jiang, Min
   Zhu, Chunrong
TI Progress in the Application of Immune Checkpoint Inhibitor-Based
   Immunotherapy for Targeting Different Types of Colorectal Cancer
SO FRONTIERS IN ONCOLOGY
LA English
DT Review
DE immunotherapy; colorectal cancer; immune checkpoint inhibitors;
   microsatellite; ICI combination therapy
ID CONSENSUS MOLECULAR SUBTYPES; COLONY-STIMULATING FACTOR; IMMUNOGENIC
   CELL-DEATH; MICROSATELLITE INSTABILITY; T-CELL; DENDRITIC CELLS;
   OPEN-LABEL; PHASE-I; TUMOR MICROENVIRONMENT; ANTI-PD-1 ANTIBODY
AB Colorectal cancer (CRC), a common malignant disease, has the second highest mortality rate among all cancer types. Due to the diversity and heterogeneity of CRC, few effective treatment strategies have been developed in recent years, except for surgical resection. As immunotherapy has become a revolutionary treatment after surgery, along with chemoradiotherapy and targeted therapy, numerous basic research studies and clinical trials have been conducted on CRC. Therefore, immune checkpoint inhibitor (ICI) therapy has become the main anti-CRC immunotherapy method used at present. With the rapid development of biotechnology and cell research, an increasing number of monotherapy or combination therapy strategies using ICIs for CRC have been designed in recent years. Methods to classify and review ICI strategies for different types of CRC to better guide treatment are continuously investigated. However, the identification of why the ICIs would be more effective in targeting particular subtypes of CRC such as high microsatellite instability (MSI-H) is more important because of the different immune backgrounds in patients. This review intends to classify different subtypes of CRC and summarizes the basic and clinical studies on ICIs for each subtype of CRC currently available. In addition, we also attempt to briefly discuss the progress in immunotherapy methods other than ICI therapy, such as chemoimmunotherapy strategy, chimeric antigen receptor-modified T (CAR-T) cells, or immunotherapy based on oncolytic viruses. Finally, we provide a perspective on the development of immunotherapy in the treatment of CRC and attempt to propose a new systematic classification of CRC based on immunological strategies, which may improve guidance for the selection of immunotherapy strategies for different subtypes of CRC in the future.
C1 [He, Rui; Lao, Yefang; Zhang, Xiaohui; Jiang, Min; Zhu, Chunrong] Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China.
   [Yu, Wenyan] Shanghai Int Med Ctr, Dept Oncol, Shanghai, Peoples R China.
C3 Soochow University - China
RP Jiang, M; Zhu, CR (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Oncol, Suzhou, Peoples R China.
EM jiangmin1023@suda.edu.cn; zcr050311@163.com
RI Zhang, Xiaohui/AAN-2994-2020
FU transverse project "Studies on the effect and mechanism of GSG2 in the
   occurrence and development of colon cancer" [Z0S0001]
FX The authors thank the financial support by the transverse project
   "Studies on the effect and mechanism of GSG2 in the occurrence and
   development of colon cancer" (No. Z0S0001).
CR Avvaru AK, 2020, NUCLEIC ACIDS RES, V48, pD155, DOI 10.1093/nar/gkz886
   Becht E, 2016, CLIN CANCER RES, V22, P4057, DOI 10.1158/1078-0432.CCR-15-2879
   Bindea G, 2013, IMMUNITY, V39, P782, DOI 10.1016/j.immuni.2013.10.003
   Blankenstein T, 2015, CURR OPIN IMMUNOL, V33, P112, DOI 10.1016/j.coi.2015.02.005
   Bommareddy PK, 2018, NAT REV IMMUNOL, V18, P498, DOI 10.1038/s41577-018-0014-6
   Bouchkouj N, 2019, CLIN CANCER RES, V25, P1702, DOI 10.1158/1078-0432.CCR-18-2743
   Bracci L, 2014, CELL DEATH DIFFER, V21, P15, DOI 10.1038/cdd.2013.67
   Brahmer JR, 2012, NEW ENGL J MED, V366, P2455, DOI 10.1056/NEJMoa1200694
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Brudno JN, 2019, BLOOD REV, V34, P45, DOI 10.1016/j.blre.2018.11.002
   Caraglia M, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01102
   Cassetta L, 2019, CANCER CELL, V35, P588, DOI 10.1016/j.ccell.2019.02.009
   Chan TA, 2019, ANN ONCOL, V30, P44, DOI 10.1093/annonc/mdy495
   Chen EX, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.4_suppl.481
   Chen LM, 2011, ATL AMB PERVAS INTEL, V4, P1, DOI 10.1097/COC.0b013e3181fe41ed
   Chen Q, 2019, CHEM SOC REV, V48, P5506, DOI 10.1039/c9cs00271e
   Chen W, 2017, DIAGN PATHOL, V12, P1, DOI 10.1186/s13000-017-0613-8
   Ciardiello D, 2019, CANCER TREAT REV, V76, P22, DOI 10.1016/j.ctrv.2019.04.003
   Cohen R, 2020, CANCERS, V12, DOI 10.3390/cancers12071990
   Coley W B, 1891, Ann Surg, V14, P199, DOI 10.1097/00000658-189112000-00015
   Copur MS, 2019, ONCOLOGY-NY, V33, P410
   Correale P, 2005, J IMMUNOL, V175, P820, DOI 10.4049/jimmunol.175.2.820
   Correale P, 2008, CLIN CANCER RES, V14, P4192, DOI 10.1158/1078-0432.CCR-07-5278
   Correale Pierpaolo, 2018, Oncotarget, V9, P20539, DOI 10.18632/oncotarget.24993
   Correale P, 2014, J IMMUNOTHER, V37, P26, DOI 10.1097/CJI.0000000000000004
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Davila ML, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008226
   de la Chapelle A, 2010, J CLIN ONCOL, V28, P3380, DOI 10.1200/JCO.2009.27.0652
   de Weger VA, 2012, CLIN CANCER RES, V18, P882, DOI 10.1158/1078-0432.CCR-11-1716
   De' Angelis Gian Luigi, 2018, Acta Biomed, V89, P97, DOI 10.23750/abm.v89i9-S.7960
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Dieu-Nosjean MC, 2014, TRENDS IMMUNOL, V35, P571, DOI 10.1016/j.it.2014.09.006
   Doroshow DB, 2019, CLIN CANCER RES, V25, P4592, DOI 10.1158/1078-0432.CCR-18-1538
   Duan XP, 2019, ANGEW CHEM INT EDIT, V58, P670, DOI 10.1002/anie.201804882
   Ebert PJR, 2016, IMMUNITY, V44, P609, DOI 10.1016/j.immuni.2016.01.024
   Fernando NH, 2004, ONCOLOGIST, V9, P11, DOI 10.1634/theoncologist.9-suppl_1-11
   Fleisher AS, 2000, CANCER RES, V60, P4864
   Franke AJ, 2019, JNCI-J NATL CANCER I, V111, P1131, DOI 10.1093/jnci/djz093
   Galon J, 2006, SCIENCE, V313, P1960, DOI 10.1126/science.1129139
   Gandhi L, 2018, NEW ENGL J MED, V378, P2078, DOI 10.1056/NEJMoa1801005
   Ganesh K, 2019, NAT REV GASTRO HEPAT, V16, P361, DOI 10.1038/s41575-019-0126-x
   Gatti-Mays ME, 2017, HUM VACC IMMUNOTHER, V13, P2561, DOI 10.1080/21645515.2017.1364322
   Ge Y, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2020-000710
   Giannakis M, 2016, CELL REP, V17, P1206, DOI 10.1016/j.celrep.2016.10.009
   Goel A, 2001, GASTROENTEROLOGY, V121, P1497, DOI 10.1053/gast.2001.29978
   Gologan A, 2005, CLIN LAB MED, V25, P179, DOI 10.1016/j.cll.2004.12.001
   Goodman AM, 2020, GENOME MED, V12, DOI 10.1186/s13073-020-00743-4
   Gopal AK, 2015, BLOOD, V125, P1236, DOI 10.1182/blood-2014-08-595801
   Greenson JK, 2003, AM J SURG PATHOL, V27, P563, DOI 10.1097/00000478-200305000-00001
   Gros A, 2019, J CLIN INVEST, V129, P4992, DOI 10.1172/JCI127967
   Gryfe R, 2000, NEW ENGL J MED, V342, P69, DOI 10.1056/NEJM200001133420201
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hampel H, 2005, NEW ENGL J MED, V352, P1851, DOI 10.1056/NEJMoa043146
   Hanahan D, 2012, CANCER CELL, V21, P309, DOI 10.1016/j.ccr.2012.02.022
   Hanse RJ, 2016, NAT MED, V22, P1342, DOI 10.1038/nm.4191
   Hermiston T, 2000, J CLIN INVEST, V105, P1169, DOI 10.1172/JCI9973
   Hill CS, 2021, ERKENNTNIS, V86, P1391, DOI 10.1007/s10670-019-00160-z
   Hochster HS, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.673
   Hollingsworth RE, 2019, NPJ VACCINES, V4, DOI 10.1038/s41541-019-0103-y
   Hou L, 2020, ACS NANO, V14, P3927, DOI 10.1021/acsnano.9b06111
   Idorn M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1412029
   Innocenti F, 2019, J CLIN ONCOL, V37, P1217, DOI 10.1200/JCO.18.01798
   Jackstadt R, 2019, CANCER CELL, V36, P319, DOI 10.1016/j.ccell.2019.08.003
   Janji B, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1809936
   Junttila MR, 2013, NATURE, V501, P346, DOI 10.1038/nature12626
   Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2
   Kelly B, 2015, CELL RES, V25, P771, DOI 10.1038/cr.2015.68
   Kim CG, 2019, SCI IMMUNOL, V4, DOI 10.1126/sciimmunol.aay0555
   Klingbiel D, 2015, ANN ONCOL, V26, P126, DOI 10.1093/annonc/mdu499
   Kloor M, 2020, CLIN CANCER RES, V26, P4503, DOI 10.1158/1078-0432.CCR-19-3517
   Korneev KV, 2017, CYTOKINE, V89, P127, DOI 10.1016/j.cyto.2016.01.021
   Kroemer G, 2013, ANNU REV IMMUNOL, V31, P51, DOI 10.1146/annurev-immunol-032712-100008
   Krysko DV, 2012, NAT REV CANCER, V12, P860, DOI 10.1038/nrc3380
   Kuwabara T, 2017, MEDIAT INFLAMM, V2017, DOI 10.1155/2017/3908061
   Latchman Y, 2001, NAT IMMUNOL, V2, P261, DOI 10.1038/85330
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Le DT, 2017, SCIENCE, V357, P409, DOI 10.1126/science.aan6733
   Lei X, 2020, CANCER LETT, V470, P126, DOI 10.1016/j.canlet.2019.11.009
   Levine AG, 2017, NATURE, V546, P421, DOI 10.1038/nature22360
   Lichtenstern CR, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9030618
   Lin AQ, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02039
   Liu L, 2015, CLIN CANCER RES, V21, P1639, DOI 10.1158/1078-0432.CCR-14-2339
   Llosa NJ, 2015, CANCER DISCOV, V5, P43, DOI 10.1158/2159-8290.CD-14-0863
   Lv MZ, 2020, CELL RES, V30, P966, DOI 10.1038/s41422-020-00395-4
   Malekzadeh P, 2019, J CLIN INVEST, V129, P1109, DOI 10.1172/JCI123791
   Maletzki C, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1408748
   Maltzman JS, 1996, MOL CELL BIOL, V16, P2283
   Marei HE, 2019, BIOCHEM PHARMACOL, V166, P335, DOI 10.1016/j.bcp.2019.06.002
   MARTUZA RL, 1991, SCIENCE, V252, P854, DOI 10.1126/science.1851332
   McCarthy Edward F, 2006, Iowa Orthop J, V26, P154
   McNamara MA, 2015, J IMMUNOL RES, V2015, DOI 10.1155/2015/794528
   Meyerhardt JA, 2005, NEW ENGL J MED, V352, P476, DOI 10.1056/NEJMra040958
   Mishra S, 2019, ONCOGENE, V38, P5817, DOI 10.1038/s41388-019-0845-z
   Mlecnik B, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007240
   Mlecnik B, 2011, J CLIN ONCOL, V29, P610, DOI 10.1200/JCO.2010.30.5425
   Mlecnik B, 2010, GASTROENTEROLOGY, V138, P1429, DOI 10.1053/j.gastro.2009.10.057
   Morse MA, 2020, ONCOLOGIST, V25, P33, DOI 10.1634/theoncologist.2019-0176
   Muzny DM, 2012, NATURE, V487, P330, DOI 10.1038/nature11252
   NAP M, 1988, TUMOR BIOL, V9, P145, DOI 10.1159/000217555
   O'Leary MC, 2019, CLIN CANCER RES, V25, P1142, DOI 10.1158/1078-0432.CCR-18-2035
   O'Neil BH, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0189848
   Obara W, 2018, CANCER SCI, V109, P550, DOI 10.1111/cas.13506
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Park AK, 2020, SCI TRANSL MED, V12, DOI 10.1126/scitranslmed.aaz1863
   Pecina-Slaus N, 2020, FRONT MOL BIOSCI, V7, DOI 10.3389/fmolb.2020.00122
   Pellegrino M, 2021, CELLS-BASEL, V10, DOI 10.3390/cells10010014
   Pino MS, 2011, EXPERT REV GASTROENT, V5, P385, DOI [10.1586/egh.11.25, 10.1586/EGH.11.25]
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Rodig N, 2003, EUR J IMMUNOL, V33, P3117, DOI 10.1002/eji.200324270
   Roelands J, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102229
   Rong L, 2019, BIOMATERIALS, V225, DOI 10.1016/j.biomaterials.2019.119515
   Sagaert X, 2018, PATHOBIOLOGY, V85, P72, DOI 10.1159/000486721
   Sahin U, 2018, SCIENCE, V359, P1355, DOI 10.1126/science.aar7112
   Samstein RM, 2019, NAT GENET, V51, P202, DOI 10.1038/s41588-018-0312-8
   Schildberg FA, 2016, IMMUNITY, V44, P955, DOI 10.1016/j.immuni.2016.05.002
   Shang N, 2017, AM J CANCER RES, V7, P2091
   Shen YY, 2020, J CLIN ONCOL, V38
   Shih YCT, 2010, CANCER INVEST, V28, P46, DOI 10.3109/07357900902783187
   Siegel Rebecca L, 2020, CA Cancer J Clin, V70, P7, DOI 10.3322/caac.21590
   SMIALOWICZ RJ, 1984, J IMMUNOPHARMACOL, V6, P1
   Steinman RM, 2007, NATURE, V449, P419, DOI 10.1038/nature06175
   STEINMAN RM, 1991, ANNU REV IMMUNOL, V9, P271, DOI 10.1146/annurev.iy.09.040191.001415
   Tada Y, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0403-1
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Temraz S, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20174155
   Tenti S, 2012, J CHEMOTHERAPY, V24, P245, DOI 10.1179/1973947812Y.0000000008
   Thanikachalam K, 2019, NUTRIENTS, V11, DOI 10.3390/nu11010164
   Thommen DS, 2018, NAT MED, V24, P994, DOI 10.1038/s41591-018-0057-z
   Tintelnot J, 2019, WORLD J GASTROENTERO, V25, P3920, DOI 10.3748/wjg.v25.i29.3920
   Topalian SL, 2012, NEW ENGL J MED, V366, P2443, DOI 10.1056/NEJMoa1200690
   Toussaint B, 2013, EXPERT REV VACCINES, V12, P1139, DOI 10.1586/14760584.2013.836914
   Tran E, 2016, NEW ENGL J MED, V375, P2255, DOI 10.1056/NEJMoa1609279
   Turtle CJ, 2016, J CLIN INVEST, V126, P2123, DOI 10.1172/JCI85309
   Vanmeerbeek I, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2019.1703449
   Vilar E, 2013, CANCER DISCOV, V3, P502, DOI 10.1158/2159-8290.CD-12-0471
   Villalba M, 2017, CELL TISSUE RES, V370, P29, DOI 10.1007/s00441-017-2633-9
   Voron T, 2015, J EXP MED, V212, P139, DOI 10.1084/jem.20140559
   Wheeler JMD, 2000, GUT, V47, P148, DOI 10.1136/gut.47.1.148
   Willemen Y, 2015, CANCER IMMUNOL IMMUN, V64, P831, DOI 10.1007/s00262-015-1688-2
   Yamamoto N, 2017, INVEST NEW DRUG, V35, P207, DOI 10.1007/s10637-016-0411-2
   Yang YP, 2015, J CLIN INVEST, V125, P3335, DOI 10.1172/JCI83871
   Yearley JH, 2017, CLIN CANCER RES, V23, P3158, DOI 10.1158/1078-0432.CCR-16-1761
   Ying ZT, 2019, NAT MED, V25, P947, DOI 10.1038/s41591-019-0421-7
   Yong SB, 2019, BIOMATERIALS, V219, DOI 10.1016/j.biomaterials.2019.119401
   Zhang CC, 2017, MOL THER, V25, P1248, DOI 10.1016/j.ymthe.2017.03.010
   Zhang LH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01578
   Zhang XH, 2020, MOL THER NUCL ACIDS, V22, P298, DOI 10.1016/j.omtn.2020.08.030
   Zuo SG, 2021, EBIOMEDICINE, V64, DOI 10.1016/j.ebiom.2021.103240
NR 150
TC 23
Z9 23
U1 3
U2 18
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
SN 2234-943X
J9 FRONT ONCOL
JI Front. Oncol.
PD NOV 23
PY 2021
VL 11
AR 764618
DI 10.3389/fonc.2021.764618
PG 16
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA XK5SR
UT WOS:000727525600001
PM 34888243
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Bedau, T
   Heydt, C
   Siebolts, U
   Zander, T
   Kraemer, M
   Loeser, H
   Buettner, R
   Quaas, A
AF Bedau, Tillmann
   Heydt, Carina
   Siebolts, Udo
   Zander, Thomas
   Kraemer, Max
   Loeser, Heike
   Buettner, Reinhard
   Quaas, Alexander
TI Concurrent <i>KRAS</i> p.G12C mutation and <i>ANK3::RET</i> fusion in a
   patient with metastatic colorectal cancer: a case report
SO DIAGNOSTIC PATHOLOGY
LA English
DT Article
DE KRAS p.G12C mutation; ANK3::RET fusion.; Metastatic colorectal cancer;
   Molecular diagnostics; Targeted therapy; Precision oncology; Genetic
   profiling; RET kinase inhibitors; KRAS inhibitors; Novel therapeutic
   strategies
ID GENE FUSIONS; OPEN-LABEL; RET; SELPERCATINIB; EFFICACY; LUNG
AB Background Colorectal cancer (CRC) frequently involves mutations in the KRAS gene, impacting therapeutic strategies and prognosis. The occurrence of KRAS mutations typically precludes the presence of RET fusions, with current medical literature suggesting a mutual exclusivity between these two genetic alterations. We present a unique case that challenges this notion. Case Presentation An 85-year-old female with metastatic CRC was found to have a combination of genetic anomalies that is to the best of our knowledge not yet described in the medical literature: a KRAS p.G12C mutation, associated with oncogenesis and treatment resistance, and an ANK3::RET fusion, an infrequent but targetable mutation in CRC. This molecular profile was uncovered through comprehensive genomic sequencing after the patient experienced metachronous tumor dissemination. The presence of both genetic events complicates the treatment approach. Conclusions The identification of both a KRAS p.G12C mutation and an ANK3::RET fusion in the same CRC patient adds a new layer to the oncogenic landscape and treatment considerations for CRC. It highlights the intricate decision-making required in the era of precision medicine, where targeted therapies must be carefully chosen and potentially combined to combat complex genetic profiles. The case emphasizes the urgency of investigating the clinical effects of concurrent or sequential use of KRAS p.G12C and RET inhibitors to inform future therapeutic guidelines and improve patient outcomes in similar cases.
C1 [Bedau, Tillmann; Heydt, Carina; Siebolts, Udo; Buettner, Reinhard; Quaas, Alexander] Univ Hosp Cologne, Dept Pathol, Cologne, Germany.
   [Zander, Thomas; Kraemer, Max] Univ Cologne, Ctr Integrated Oncol CIO, Dept Internal Med 1, Cologne, Germany.
   [Loeser, Heike] Inst Pathol Koln Deutz, Cologne, Germany.
C3 University of Cologne; University of Cologne
RP Bedau, T (corresponding author), Univ Hosp Cologne, Dept Pathol, Cologne, Germany.
EM tillmann.bedau@uk-koeln.de
RI Quaas, Alexander/LXB-4339-2024
OI Bedau, Tillmann/0000-0001-7510-2261
FU Universittsklinikum Kln (8977)
FX Not applicable.
CR Bailey MH, 2018, CELL, V173, P371, DOI [10.1016/j.cell.2018.02.060, 10.1016/j.cell.2018.07.034]
   Chakravarty Debyani, 2017, JCO Precis Oncol, V2017, DOI 10.1200/PO.17.00011
   Cook JH, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-22125-z
   Drìlon A, 2020, NEW ENGL J MED, V383, P813, DOI 10.1056/NEJMoa2005653
   Fakih MG, 2023, NEW ENGL J MED, V389, P2125, DOI 10.1056/NEJMoa2308795
   Gainor JF, 2021, LANCET ONCOL, V22, P959, DOI 10.1016/S1470-2045(21)00247-3
   Kloosterman WP, 2017, CANCER RES, V77, P3814, DOI 10.1158/0008-5472.CAN-16-3563
   Le Rolle AF, 2015, ONCOTARGET, V6, P28929, DOI 10.18632/oncotarget.4325
   Li BH, 2021, NPJ PRECIS ONCOL, V5, DOI 10.1038/s41698-021-00221-z
   Li SQ, 2018, NAT REV CANCER, V18, P767, DOI 10.1038/s41568-018-0076-6
   Meng Y, 2022, ANN TRANSL MED, V10, DOI 10.21037/atm-22-1237
   Pietrantonio F, 2018, ANN ONCOL, V29, P1394, DOI 10.1093/annonc/mdy090
   Regua AT, 2022, FRONT ONCOL, V12, DOI 10.3389/fonc.2022.932353
   Shi MK, 2022, CANCER SCI, V113, P308, DOI 10.1111/cas.15181
   Strickler JH, 2023, ONCOLOGIST, DOI 10.1093/oncolo/oyad138
   Subbiah V, 2022, LANCET ONCOL, V23, P1261, DOI 10.1016/S1470-2045(22)00541-1
   Subbiah V, 2020, J CLIN ONCOL, V38, P1209, DOI 10.1200/JCO.19.02551
   Suehnholz SP, 2024, CANCER DISCOV, V14, P49, DOI 10.1158/2159-8290.CD-23-0467
   Uhrig S, 2021, GENOME RES, V31, P448, DOI 10.1101/gr.257246.119
   Urbanska EM, 2022, JCO PRECIS ONCOL, V6, DOI 10.1200/PO.22.00040
   Wirth LJ, 2020, NEW ENGL J MED, V383, P825, DOI 10.1056/NEJMoa2005651
   Yaeger R, 2023, NEW ENGL J MED, V388, P44, DOI 10.1056/NEJMoa2212419
   Yaeger R, 2018, CANCER CELL, V33, P125, DOI 10.1016/j.ccell.2017.12.004
   Yang SR, 2021, CLIN CANCER RES, V27, P1316, DOI 10.1158/1078-0432.CCR-20-3208
NR 24
TC 0
Z9 0
U1 0
U2 0
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1746-1596
J9 DIAGN PATHOL
JI Diagn. Pathol.
PD MAR 27
PY 2024
VL 19
IS 1
AR 55
DI 10.1186/s13000-024-01478-1
PG 6
WC Pathology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pathology
GA MR7W2
UT WOS:001195435200001
PM 38539256
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Chaudhary, S
   Kanwar, RK
   Kanwar, JR
AF Chaudhary, Suman
   Kanwar, Rupinder Kaur
   Kanwar, Jagat Rakesh
TI Targeted Theranostics Against Solid Cancer Using Metal Bond Milk Protein
   and Aptamers
SO CURRENT TOPICS IN MEDICINAL CHEMISTRY
LA English
DT Review
DE Aptamers; Lactoferrin; Cancer; Multimodular; Nanoparticle; Theranostics
ID METASTATIC COLORECTAL-CANCER; SATURATED BOVINE LACTOFERRIN; IRON-OXIDE
   NANOPARTICLES; CELL ADHESION MOLECULE; COLON-CANCER; DRUG-DELIVERY; DNA
   APTAMERS; STEM-CELLS; THERAPY; EGFR
AB Targeted therapeutics is a new generation therapy that can increase the efficacy of chemotherapeutic drugs, by facilitating site-specific delivery with minimum off-target effects. Amongst the targeted therapy, nucleic-acid based aptamers are increasingly gaining interest due to their small size, long shelf-life and ease in synthesis. Further, lactoferrin, a milk protein belonging to the transferrin family is now an established multi-functional iron-binding protein. Its applicability as an immunomodulator, antimicrobial and an anti-cancer agent has made this protein highly valuable. Recent research has been focusing towards increasing the efficacy of lactoferrin by encapsulating them in novel nanoparticles, that facilities in providing their controlled and sustained release. This review focuses on the application of aptamers against solid tumors, specifically colorectal cancer (CRC) indicating the different anti-cancer targeted strategies to target anti-angiogenic vascular endothelial growth factor -A (VEGF-A) and epidermal growth factor receptor (EGFR) signalling. Additionally, it highlights the synergistic approach of functionalising aptamers with drug loaded nanoparticles to facilitate enhanced uptake, stability and increase in the retention time. Special emphasis is given on lactoferrin loaded aptamer functionalised nanoparticles as anticancer drug delivery systems. Apart from highlighting the role of these aptamer-nanocarriers in tumor specific targeting and induction of apoptosis, there applicability in nano-theranostics, involving detection, diagnosis and treatment is also discussed here.
C1 [Chaudhary, Suman; Kanwar, Rupinder Kaur; Kanwar, Jagat Rakesh] Deakin Univ, Fac Hlth, Ctr Mol & Med Res C MMR, NLIMBR,Sch Med,Strateg Res Ctr, Waurn Ponds, Vic 3217, Australia.
C3 Deakin University
RP Kanwar, JR (corresponding author), Deakin Univ, Fac Hlth, Ctr Mol & Med Res C MMR, NLIMBR,Sch Med, Waurn Ponds, Vic 3217, Australia.
EM jagat.kanwar@deakin.edu.au
RI Kanwar, Jagat/JDO-1829-2023; Kanwar, Dr Rupinder Kaur/JBS-5937-2023
OI Chaudhary, Suman/0000-0003-2260-6444
FU Australia-India Strategic Research Fund (AISRF); National Health and
   Medical Research Council (NHMRC)
FX The authors would like to thank the Australia-India Strategic Research
   Fund (AISRF) and National Health and Medical Research Council (NHMRC)
   for financial support.
CR AISEN P, 1972, BIOCHIM BIOPHYS ACTA, V257, P314, DOI 10.1016/0005-2795(72)90283-8
   Allen TM, 2002, NAT REV CANCER, V2, P750, DOI 10.1038/nrc903
   [Anonymous], 2011, PLOS ONE
   [Anonymous], CLIN COLORECTAL CANC
   [Anonymous], J ONCOL
   [Anonymous], EUR J PHARM SCI
   [Anonymous], ENG MED BIOL SOC EMB
   [Anonymous], J NATL CANC I
   Armstrong A, 2003, CANCER BIOL THER, V2, P320, DOI 10.4161/cbt.2.4.451
   Athyala PK, 2016, BIOCHEM BIOPH RES CO, V469, P257, DOI 10.1016/j.bbrc.2015.11.109
   Azhdarzadeh M, 2016, COLLOID SURFACE B, V143, P224, DOI 10.1016/j.colsurfb.2016.02.058
   Balaburski GM, 2013, MOL CANCER RES, V11, P219, DOI 10.1158/1541-7786.MCR-12-0547-T
   Bardelli A, 2010, J CLIN ONCOL, V28, P1254, DOI 10.1200/JCO.2009.24.6116
   Bidwell GL, 2012, THER DELIV, V3, P609, DOI 10.4155/TDE.12.37
   Burke DH, 1998, RNA, V4, P1165, DOI 10.1017/S1355838298980542
   Campoli M, 2010, CLIN CANCER RES, V16, P11, DOI 10.1158/1078-0432.CCR-09-2345
   Chari RVJ, 2008, ACCOUNTS CHEM RES, V41, P98, DOI 10.1021/ar700108g
   Chaudhary R, 2016, J NANOBIOTECHNOL, V14, DOI 10.1186/s12951-016-0157-1
   CHEN CM, 1991, J BIOL CHEM, V266, P7754
   Chen J, 2012, LAB CHIP, V12, P1753, DOI 10.1039/c2lc21273k
   Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388
   Ciardiello F, 2008, NEW ENGL J MED, V358, P1160, DOI 10.1056/NEJMra0707704
   Das M, 2009, EXPERT OPIN DRUG DEL, V6, P285, DOI 10.1517/17425240902780166
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   Douillard JY, 2000, LANCET, V355, P1041, DOI 10.1016/S0140-6736(00)02034-1
   Esposito CL, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024071
   Ferrara N, 2004, NAT REV DRUG DISCOV, V3, P391, DOI 10.1038/nrd1381
   Fujita K, 2004, CARCINOGENESIS, V25, P1961, DOI 10.1093/carcin/bgh205
   Gavhane YN., 2011, INT J PHARMA SCI RES, V2, P1
   Ginisty H, 1999, J CELL SCI, V112, P761
   González-Chávez SA, 2009, INT J ANTIMICROB AG, V33, DOI 10.1016/j.ijantimicag.2008.07.020
   Groner B, 2008, SEMIN CELL DEV BIOL, V19, P341, DOI 10.1016/j.semcdb.2008.06.005
   GUO PX, 1987, SCIENCE, V236, P690, DOI 10.1126/science.3107124
   Gupta I, 2015, NANOMEDICINE-UK, V10, P1289, DOI 10.2217/nnm.14.209
   He L, 2004, NAT REV GENET, V5, P522, DOI 10.1038/nrg1379
   Heinemann V, 2013, CANCER TREAT REV, V39, P592, DOI 10.1016/j.ctrv.2012.12.011
   Hernandez FJ, 2013, CHEM COMMUN, V49, P1285, DOI 10.1039/c2cc37370j
   Hirata I, 2007, WORLD J GASTROENTERO, V13, P1569, DOI 10.3748/wjg.v13.i10.1569
   Ho LC, 2015, ANAL CHEM, V87, P4925, DOI 10.1021/acs.analchem.5b00569
   Hovanessian AG, 2000, EXP CELL RES, V261, P312, DOI 10.1006/excr.2000.5071
   Huang YF, 2009, CHEMBIOCHEM, V10, P862, DOI 10.1002/cbic.200800805
   Hurwitz H, 2004, NEW ENGL J MED, V350, P2335, DOI 10.1056/NEJMoa032691
   Ilkhani H, 2015, BIOSENS BIOELECTRON, V74, P491, DOI 10.1016/j.bios.2015.06.063
   Jacobson O, 2015, J NUCL MED, V56, P1780, DOI 10.2967/jnumed.115.160960
   Jemal Ahmedin, 2011, CA Cancer J Clin, V61, P69, DOI 10.3322/caac.20107
   Jiang GH, 2012, LEUKEMIA RES, V36, P1347, DOI 10.1016/j.leukres.2012.07.004
   Jin J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0082315
   Kamalapuram SK, 2016, INT J NANOMED, V11, P1349, DOI 10.2147/IJN.S95253
   Kanwar JR, 2008, IMMUNOL CELL BIOL, V86, P277, DOI 10.1038/sj.icb.7100163
   Kanwar JR, 2016, NANOMEDICINE-UK, V11, P249, DOI 10.2217/nnm.15.199
   Kanwar JR, 2015, CURR MED CHEM, V22, P2539, DOI 10.2174/0929867322666150227144909
   Kanwar JR, 2015, MOLECULES, V20, P9703, DOI 10.3390/molecules20069703
   Kanwar JR, 2015, NANOMEDICINE-UK, V10, P35, DOI 10.2217/nnm.14.132
   Kanwar JR, 2012, NANOMEDICINE-UK, V7, P1521, DOI [10.2217/NNM.12.29, 10.2217/nnm.12.29]
   Kanwar JR, 2011, CRIT REV BIOCHEM MOL, V46, P459, DOI 10.3109/10409238.2011.614592
   Kanwar JR, 2010, NANOMEDICINE-UK, V5, P1435, DOI 10.2217/NNM.10.115
   Kanwar JR., 2012, J CANC SCI THER, V4, P31, DOI DOI 10.4172/1948-5956.1000107
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kaur H, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0050964
   Kim E, 2010, BIOMATERIALS, V31, P4592, DOI 10.1016/j.biomaterials.2010.02.030
   Kobayashi S, 2005, NEW ENGL J MED, V352, P786, DOI 10.1056/NEJMoa044238
   Kreso A, 2014, NAT MED, V20, P29, DOI 10.1038/nm.3418
   Lee YJ, 2012, GASTROENTEROLOGY, V143, P155, DOI 10.1053/j.gastro.2012.03.039
   Lessard J, 2003, NATURE, V423, P255, DOI 10.1038/nature01572
   Li L, 2014, INT J NANOMED, V9, P1083, DOI 10.2147/IJN.S59779
   Liao ZY, 2010, COLLOID SURFACE A, V370, P1, DOI 10.1016/j.colsurfa.2010.06.025
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   LONNERDAL B, 1995, ANNU REV NUTR, V15, P93, DOI 10.1146/annurev.nu.15.070195.000521
   Lu YJ, 2012, ADV DRUG DELIVER REV, V64, P342, DOI 10.1016/j.addr.2012.09.020
   Mader JS, 2005, MOL CANCER THER, V4, P612, DOI 10.1158/1535-7163.MCT-04-0077
   Mahidhara G, 2015, INT J NANOMED, V10, P4081, DOI 10.2147/IJN.S75877
   Maremanda NG, 2015, BIOMICROFLUIDICS, V9, DOI 10.1063/1.4930983
   Meng L, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0014018
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Munz M, 2009, CANCER RES, V69, P5627, DOI 10.1158/0008-5472.CAN-09-0654
   Nagaraj Srinivas, 2009, Cancer Res, V69, P7503, DOI 10.1158/0008-5472.CAN-09-2152
   Ng KP, 2012, NAT MED, V18, P521, DOI 10.1038/nm.2713
   Orava EW, 2013, MOL ONCOL, V7, P799, DOI 10.1016/j.molonc.2013.03.005
   Orum H, 2001, CURR OPIN MOL THER, V3, P239
   Pagliuca A, 2013, ONCOGENE, V32, P4806, DOI 10.1038/onc.2012.495
   Park IK, 2003, NATURE, V423, P302, DOI 10.1038/nature01587
   Pillay V, 2011, NEW BIOTECHNOL, V28, P518, DOI 10.1016/j.nbt.2011.03.021
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   RETTIG WJ, 1989, ANNU REV IMMUNOL, V7, P481, DOI 10.1146/annurev.immunol.7.1.481
   Rimmele M, 2003, CHEMBIOCHEM, V4, P963, DOI 10.1002/cbic.200300648
   Rodrigues L, 2009, CRIT REV FOOD SCI, V49, P203, DOI 10.1080/10408390701856157
   Roy K, 2016, INT J NANOMED, V11, P25, DOI 10.2147/IJN.S91810
   Roy K, 2015, BIOMATERIALS, V71, P84, DOI 10.1016/j.biomaterials.2015.07.055
   Roy K, 2015, RSC ADV, V5, P29008, DOI 10.1039/c5ra03791c
   Rychahou P, 2015, ACS NANO, V9, P1108, DOI 10.1021/acsnano.5b00067
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Sampson T., 2003, World Patent Information, V25, P123, DOI 10.1016/S0172-2190(03)00035-8
   Sapra P, 2003, PROG LIPID RES, V42, P439, DOI 10.1016/S0163-7827(03)00032-8
   Sawyers C, 2004, NATURE, V432, P294, DOI 10.1038/nature03095
   Schrama D, 2006, NAT REV DRUG DISCOV, V5, P147, DOI 10.1038/nrd1957
   Scott AM, 2012, NAT REV CANCER, V12, P278, DOI 10.1038/nrc3236
   Segal NH, 2009, ANNU REV MED, V60, P207, DOI 10.1146/annurev.med.60.041807.132435
   Siqueiros-Cendón T, 2014, ACTA PHARMACOL SIN, V35, P557, DOI 10.1038/aps.2013.200
   Song YL, 2013, ANAL CHEM, V85, P4141, DOI 10.1021/ac400366b
   Subramanian N, 2015, NUCLEIC ACID THER, V25, P317, DOI 10.1089/nat.2015.0550
   Subramanian N, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0132407
   Subramanian N, 2015, CHEM COMMUN, V51, P6940, DOI 10.1039/c5cc00939a
   Subramanian N, 2015, J BIOMED SCI, V22, DOI 10.1186/s12929-014-0108-9
   Subramanian N, 2014, CHEM COMMUN, V50, P11810, DOI 10.1039/c4cc02996h
   Sunkireddy P, 2016, NANOMEDICINE-UK, V11, P495, DOI 10.2217/nnm.15.205
   Thayer AM, 2011, CHEM ENG NEWS, V89, P13
   THOMAS P, 1992, BIOCHEM BIOPH RES CO, V188, P671, DOI 10.1016/0006-291X(92)91108-3
   Thundimadathil Jyothi, 2012, J Amino Acids, V2012, P967347, DOI 10.1155/2012/967347
   Tsuda H, 2010, BIOMETALS, V23, P399, DOI 10.1007/s10534-010-9331-3
   Varey AHR, 2008, BRIT J CANCER, V98, P1366, DOI 10.1038/sj.bjc.6604308
   Visvader JE, 2008, NAT REV CANCER, V8, P755, DOI 10.1038/nrc2499
   Weber A, 2012, HORM MOL BIOL CLIN I, V10, P273, DOI 10.1515/hmbci-2012-0014
   Wheeler DL, 2010, NAT REV CLIN ONCOL, V7, P493, DOI 10.1038/nrclinonc.2010.97
   Yu CC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024077
   Zhu HY, 2011, MOL CANCER RES, V9, P960, DOI 10.1158/1541-7786.MCR-10-0531
   Zimmer R, 2001, CANCER RES, V61, P2822
NR 116
TC 2
Z9 2
U1 2
U2 37
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
   EMIRATES
SN 1568-0266
EI 1873-4294
J9 CURR TOP MED CHEM
JI Curr. Top. Med. Chem.
PY 2017
VL 17
IS 18
BP 2100
EP 2111
DI 10.2174/1568026617666170130110021
PG 12
WC Chemistry, Medicinal
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA EY2TY
UT WOS:000403825700008
PM 28137239
DA 2025-01-04
ER

PT J
AU Bolhuis, K
   Kos, M
   van Oijen, MG
   Swijnenburg, RJ
   Punt, CJA
AF Bolhuis, Karen
   Kos, Milan
   van Oijen, Martijn G. H.
   Swijnenburg, Rutger-Jan
   Punt, Cornelis J. A.
TI Conversion strategies with chemotherapy plus targeted agents for
   colorectal cancer liver-only metastases: A systematic review
SO EUROPEAN JOURNAL OF CANCER
LA English
DT Review
DE Colorectal cancer; Liver metastases; Colorectal liver-only metastases;
   Conversion therapy; Chemotherapy; Targeted therapy; Systemic therapy;
   Resection; Surgery; Outcomes; Survival
ID RANDOMIZED PHASE-III; 1ST-LINE TREATMENT; OPEN-LABEL; CETUXIMAB;
   BEVACIZUMAB; SURVIVAL; FOLFOXIRI; RAS; FOLFIRI; TRIAL
AB Background: There is no consensus on the optimal systemic conversion therapy in patients with unresectable colorectal cancer liver-only metastases (CRLM) to achieve a complete resection. Interpretation of trials is complicated by heterogeneity of patients caused by emerging prognostic and predictive characteristics, such as RAS/BRAF mutation status, lack of consensus on unresectability criteria and lack of data on clinical outcome of secondary resections. A systematic review was performed of characteristics of study populations and methodology of trials regarding patients with initially unresectable colorectal cancer liver-only metastases.
   Methods: Phase II/III randomised trials, published after 2008, regarding first-line systemic conversion therapy in patients or subgroups of patients with CRLM were included. Data on secondary resection outcomes were collected.
   Results: Overall, 20 trials were included for analysis: seven prospective trials in patients with unresectable CRLM and 13 trials in the overall population of unresectable metastatic colorectal cancer (mCRC) with retrospective subgroup analysis of CRLM patients. Fourteen trials did not provide unresectability criteria at baseline, and criteria differed among the remaining studies. Trials and study populations were heterogeneous in prognostic/predictive factors, use of primary end-points, and reporting on long-term clinical outcomes. R0-resection rates in CRLM patients varied between CRLM studies and mCRC studies, with rates of 22-57% and 11-38%, respectively.
   Conclusions: Cross-study comparison of (subgroups of) studies regarding first-line systemic treatment in patients with unresectable CRLM is hampered by heterogeneity in study populations, trial designs, use of (K)RAS/BRAF mutational tumour status, and differences/absence of unresectability criteria. No optimal conversion systemic regimen can be selected from available data. Prospective studies with well-defined criteria of these issues are warranted. (C) 2020 Elsevier Ltd. All rights reserved.
C1 [Bolhuis, Karen; Kos, Milan; van Oijen, Martijn G. H.; Punt, Cornelis J. A.] Univ Amsterdam, Dept Med Oncol, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
   [Swijnenburg, Rutger-Jan] Univ Amsterdam, Amsterdam UMC, Dept Surg, Amsterdam, Netherlands.
   [Punt, Cornelis J. A.] Univ Med Ctr Utrecht, Julius Ctr Hlth Sci & Primary Care, Utrecht, Netherlands.
C3 University of Amsterdam; University of Amsterdam; Utrecht University;
   Utrecht University Medical Center
RP Bolhuis, K (corresponding author), Univ Amsterdam, Dept Med Oncol, Amsterdam UMC, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands.
EM k.bolhuis@amsterdamumc.nl
OI Swijnenburg, Rutger-Jan/0000-0002-3980-4634
CR Adam R, 2019, ANN GASTROENT SURG, V3, P50, DOI 10.1002/ags3.12227
   Adam R, 2012, ONCOLOGIST, V17, P1225, DOI 10.1634/theoncologist.2012-0121
   [Anonymous], SURVEILLANCE E END R
   Arnold D, 2017, ANN ONCOL, V28, P1713, DOI 10.1093/annonc/mdx175
   Bartlett EK, 2015, CANCER-AM CANCER SOC, V121, P747, DOI 10.1002/cncr.29134
   Benson AB III, 2017, J NATL COMPR CANC NE, V15, P370, DOI 10.6004/jnccn.2017.0036
   Bokemeyer C, 2015, EUR J CANCER, V51, P1243, DOI 10.1016/j.ejca.2015.04.007
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bokemeyer C, 2009, J CLIN ONCOL, V27, P663, DOI 10.1200/JCO.2008.20.8397
   Borelli B, 2018, ESMO OPEN, V3, DOI 10.1136/esmoopen-2018-000403
   Carrato A, 2017, EUR J CANCER, V81, P191, DOI 10.1016/j.ejca.2017.04.024
   Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2019, J CLIN ONCOL, V37, DOI 10.1200/JCO.2019.37.15_suppl.3508
   Cremolini C, 2018, JAMA ONCOL, V4, P529, DOI 10.1001/jamaoncol.2017.5314
   Cremolini C, 2017, BMC CANCER, V17, DOI 10.1186/s12885-017-3360-z
   Cremolini C, 2017, EUR J CANCER, V73, P74, DOI 10.1016/j.ejca.2016.10.028
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   de Ridder JAM, 2016, EUR J CANCER, V59, P13, DOI 10.1016/j.ejca.2016.02.003
   Douillard JY, 2014, ANN ONCOL, V25, P1346, DOI 10.1093/annonc/mdu141
   Douillard JY, 2015, EUR J CANCER, V51, P1231, DOI 10.1016/j.ejca.2015.03.026
   Falcone A, 2013, J CLIN ONCOL, V31
   Folprecht G, 2005, ANN ONCOL, V16, P1311, DOI 10.1093/annonc/mdi246
   Folprecht G, 2014, ANN ONCOL, V25, P1018, DOI 10.1093/annonc/mdu088
   Folprecht G, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-521
   Folprecht G, 2010, LANCET ONCOL, V11, P38, DOI 10.1016/S1470-2045(09)70330-4
   Garufi C, 2010, BRIT J CANCER, V103, P1542, DOI 10.1038/sj.bjc.6605940
   Golfinopoulos V, 2007, LANCET ONCOL, V8, P898, DOI 10.1016/S1470-2045(07)70281-4
   Gruenberger T, 2015, ANN ONCOL, V26, P702, DOI 10.1093/annonc/mdu580
   Heinemann V, 2014, LANCET ONCOL, V15, P1065, DOI 10.1016/S1470-2045(14)70330-4
   Held S, 2018, ANN ONCOL, V29, pV108, DOI DOI 10.1093/ANNONC/MDY149
   Holch JW, 2018, INT J CANCER, V142, P1047, DOI 10.1002/ijc.31114
   Huiskens J, 2019, J AM COLL SURGEONS, V229, P523, DOI 10.1016/j.jamcollsurg.2019.08.1445
   Huiskens J, 2015, BMC CANCER, V15, DOI 10.1186/s12885-015-1323-9
   Hurwitz H, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.4_suppl.657
   Hurwitz HI, 2019, ONCOLOGIST, V24, P921, DOI 10.1634/theoncologist.2018-0344
   Jones RP, 2014, EUR J CANCER, V50, P1590, DOI 10.1016/j.ejca.2014.02.024
   Köhne CH, 2016, EJSO-EUR J SURG ONC, V42, P1540, DOI 10.1016/j.ejso.2016.05.038
   Loupakis F, 2014, NEW ENGL J MED, V371, P1609, DOI 10.1056/NEJMoa1403108
   Maughan TS, 2011, LANCET, V377, P2103, DOI 10.1016/S0140-6736(11)60613-2
   Modest DP, 2018, EUR J CANCER, V88, P77, DOI 10.1016/j.ejca.2017.10.028
   Moher D, 2010, INT J SURG, V8, P658, DOI [10.1136/bmj.i4086, 10.1016/j.ijsu.2010.07.299, 10.1371/journal.pmed.1000097, 10.1016/j.ijsu.2010.02.007, 10.1136/bmj.b2535, 10.1136/bmj.b2700, 10.1186/2046-4053-4-1]
   Oki E, 2019, BRIT J CANCER, V121, P222, DOI 10.1038/s41416-019-0518-2
   Okines A, 2009, BRIT J CANCER, V101, P1033, DOI 10.1038/sj.bjc.6605259
   Okuno M, 2017, EJSO-EUR J SURG ONC, V43, P1003, DOI 10.1016/j.ejso.2016.08.019
   Parikh AR, 2019, CLIN CANCER RES, V25, P2988, DOI 10.1158/1078-0432.CCR-18-1221
   Peeters M, 2018, BRIT J CANCER, V119, P303, DOI 10.1038/s41416-018-0165-z
   Petrelli F, 2012, INT J COLORECTAL DIS, V27, P997, DOI 10.1007/s00384-012-1438-2
   Pozzo C, 2004, ANN ONCOL, V15, P933, DOI 10.1093/annonc/mdh217
   Punt CJA, 2018, ACTA ONCOL, V57, P681, DOI 10.1080/0284186X.2017.1374556
   Punt CJA, 2017, NAT REV CLIN ONCOL, V14, P235, DOI 10.1038/nrclinonc.2016.171
   Rivera F, 2017, INT J COLORECTAL DIS, V32, P1179, DOI 10.1007/s00384-017-2800-1
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Schmoll HJ, 2012, J CLIN ONCOL, V30, P3588, DOI 10.1200/JCO.2012.42.5355
   Shiu KK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.2020.38.18_suppl.LBA4
   Tang WT, 2020, J CLIN ONCOL, V38, P3175, DOI 10.1200/JCO.20.00174
   Tol J, 2009, NEW ENGL J MED, V360, P563, DOI 10.1056/NEJMoa0808268
   Tomasello G, 2017, JAMA ONCOL, V3, DOI 10.1001/jamaoncol.2017.0278
   Uetake H, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.734
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2013, EUR J CANCER, V49, pS490
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   Van Cutsem E, 2009, NEW ENGL J MED, V360, P1408, DOI 10.1056/NEJMoa0805019
   Venook AP, 2017, JAMA-J AM MED ASSOC, V317, P2392, DOI 10.1001/jama.2017.7105
   Wei Y, 2019, ANN ONCOL, V30
   Ychou M, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.15_suppl.3535
   Ye LC, 2013, J CLIN ONCOL, V31, P1931, DOI 10.1200/JCO.2012.44.8308
NR 67
TC 34
Z9 35
U1 0
U2 4
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0959-8049
EI 1879-0852
J9 EUR J CANCER
JI Eur. J. Cancer
PD DEC
PY 2020
VL 141
BP 225
EP 238
DI 10.1016/j.ejca.2020.09.037
PG 14
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA PA9JY
UT WOS:000595945200022
PM 33189037
OA hybrid
DA 2025-01-04
ER

PT J
AU Kozlowska-Geller, M
   Gluszek, S
   Lewitowicz, P
AF Kozlowska-Geller, Monika
   Gluszek, Stanislaw
   Lewitowicz, Piotr
TI Five-year follow-up study of stage I-IV rectal cancer including EGFR
   immunoexpression and p21 immunoactivity
SO GASTROENTEROLOGY REVIEW-PRZEGLAD GASTROENTEROLOGICZNY
LA English
DT Article
DE rectal cancer; follow-up; EGFR; P21
ID GROWTH-FACTOR RECEPTOR; METASTATIC COLORECTAL-CANCER;
   PROGNOSTIC-FACTORS; TARGETED THERAPY; SURVIVAL; RESECTION; EXPRESSION;
   RESISTANCE; CARCINOMA; PATHOLOGY
AB Introduction: Both environmental and genetic factors increase the likelihood of developing rectal cancer.
   Aim: To assess the EGFR and p21 immunoreactivity in rectal cancer and to assess its relationship with the clinical outcome.
   Material and methods: Applying exclusion criteria, 102 patients with stage I-IV rectal cancer, who had undergone scheduled surgery during the period 2005-2011, were included in the study. There was a follow-up study with a span of 5 years from the date of the surgery. Immunohistochemistry using epidermal growth factor receptor (EGFR Ab10, Clone111.6) and antibodies against p21 (p21(WAF1) (Clone H252)) was performed to detect overexpression of the targeted receptor. Digital analysis of positive reactions of membranes and nuclei was performed utilizing Visiopharm.
   Results: The degree of EGFR intensity (log OR = 0.854, OR = 2.35, 95% CI: 1.14-4.85, p = 0.021) is a significant factor in the prognosis of death within 2 years after surgery. The OS curve showed a significant decrease after 40 months from the date of surgery in the cases where EGFR had high expression. The ROC curve for cancer stage, according to the UICC classification and EGFR expression, in order to predict 2-year RFS, reached a high specificity value (ROC = 0.81, p = 0.0408). The analysis showed no statistically significant differences in the survival curves of patients in groups with immunoreactivity of p21 protein at 0, 1, 2, 3 (p = 0.6453 in the log-rank test). Also, it is not a significant risk factor for death (HR = 0.915, p = 0.7842) or for tumor dissemination (HR = 0.94, p = 0.9426).
   Conclusions: The determination of EGFR immunoreactivity is important in the monitoring and treatment of patients with rectal cancer, as opposed to p21.
C1 [Kozlowska-Geller, Monika] Jan Kochanowski Univ, Coll Med, Inst Med Sci, Dept Physiol, Kielce, Poland.
   [Gluszek, Stanislaw] Jan Kochanowski Univ, Dept Surg & Surg Nursing, Coll Med, Kielce, Poland.
   [Lewitowicz, Piotr] Jan Kochanowski Univ, Dept Pathol, Coll Med, Kielce, Poland.
C3 Jan Kochanowski University; Jan Kochanowski University; Jan Kochanowski
   University
RP Kozlowska-Geller, M (corresponding author), Jan Kochanowski Univ, Coll Med, Al IX Wiekow Kielc 19a, PL-25317 Kielce, Poland.
EM monika.kozlowska.chir@onet.pl
RI Stanisław, Gluszek/S-3303-2019; Lewitowicz, Piotr/O-7137-2015
FU  [RN.20.177]
FX Project financed under the research work no. SMGR. RN.20.177.
CR BUHRE LMD, 1994, BRIT J SURG, V81, P1227, DOI 10.1002/bjs.1800810851
   Cerottini JP, 1999, ONCOL REP, V6, P409
   Dent OF, 2017, ANZ J SURG, V87, P39, DOI 10.1111/ans.13772
   Dharwadkar P, 2021, CLIN GASTROENTEROL H, V19, P192, DOI 10.1016/j.cgh.2019.10.028
   DOGLIETTO GB, 1991, COLOPROCTOLOGY, V1, P51
   EKER R, 1963, Acta Chir Scand, V126, P636
   ELLIOT MS, 1979, BRIT J SURG, V66, P621
   Feigelson HS, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094977
   Formica V, 2015, WORLD J GASTROENTERO, V21, P2871, DOI 10.3748/wjg.v21.i10.2871
   GODWIN JD, 1975, J CHRON DIS, V28, P441, DOI 10.1016/0021-9681(75)90055-7
   Grass F, 2020, EJSO-EUR J SURG ONC, V46, P455, DOI 10.1016/j.ejso.2019.11.513
   Gupta S, 2014, CANCER PREV RES, V7, P1023, DOI 10.1158/1940-6207.CAPR-14-0140
   Herbst RS, 2002, J CLIN ONCOL, V20, P3815, DOI 10.1200/JCO.2002.03.038
   Hohla F, 2014, WORLD J GASTROENTERO, V20, P6102, DOI 10.3748/wjg.v20.i20.6102
   Jeong WJ, 2014, WORLD J GASTROENTERO, V20, P9862, DOI 10.3748/wjg.v20.i29.9862
   Kanemitsu Y, 2003, DIS COLON RECTUM, V46, P160, DOI 10.1007/s10350-004-6518-0
   Karantanos T, 2014, WORLD GASTROENTEROL, V20
   Karantanos T, 2014, WORLD J GASTROENTERO, V20, P1986, DOI 10.3748/wjg.v20.i8.1986
   Kishiki T, 2014, ONCOL REP, V32, P57, DOI 10.3892/or.2014.3179
   Kozlowska-Geller MA, 2020, WSPOLCZESNA ONKOL, V24, P247, DOI 10.5114/wo.2020.102632
   Kozlowska-Geller MA, 2018, MED STUD, V34, P337, DOI 10.5114/ms.2018.80951
   Kucejko RJ, 2020, DIS COLON RECTUM, V63, P172, DOI 10.1097/DCR.0000000000001525
   Lawday S, 2018, COLORECTAL DIS, V20, P350, DOI 10.1111/codi.14046
   Lydrup ML, 2015, COLORECTAL DIS, V17, P390, DOI 10.1111/codi.12871
   MAYER A, 1993, CANCER, V71, P2454, DOI 10.1002/1097-0142(19930415)71:8<2454::AID-CNCR2820710805>3.0.CO;2-2
   Nakamura Y, 2020, CANCER MED-US, V9, P653, DOI 10.1002/cam4.2758
   Nara Atsushi, 2020, Gan To Kagaku Ryoho, V47, P114
   Neumann JHL, 2015, PATHOLOGE, V36, P137, DOI 10.1007/s00292-015-0005-3
   NEWLAND RC, 1994, CANCER, V73, P2076, DOI 10.1002/1097-0142(19940415)73:8<2076::AID-CNCR2820730811>3.0.CO;2-6
   OKUNO M, 1988, AM SURGEON, V54, P681
   Platell C, 2007, COLORECTAL DIS, V9, P71, DOI 10.1111/j.1463-1318.2006.01002.x
   Skonieczna K, 2020, ARCH MED SCI, V16, P366, DOI 10.5114/aoms.2018.80893
   Szpon Lukasz, 2016, Pol Przegl Chir, V88, P15, DOI 10.1515/pjs-2016-0021
   Vaish V, 2014, CELL BIOCHEM BIOPHYS, V68, P301, DOI 10.1007/s12013-013-9711-8
   Zareba KP, 2020, GASTROENTEROL REV, V15, P247, DOI 10.5114/pg.2020.98542
   Zhang SL, 2018, ONCOL LETT, V16, P3517, DOI 10.3892/ol.2018.9075
   Zhang Y, 2015, J BIOL CHEM, V290, P6215, DOI 10.1074/jbc.M114.620252
NR 37
TC 0
Z9 0
U1 0
U2 1
PU TERMEDIA PUBLISHING HOUSE LTD
PI POZNAN
PA KLEEBERGA 2, POZNAN, 61-615, POLAND
SN 1895-5770
EI 1897-4317
J9 GASTROENTEROL REV
JI Gastroenterol. Rev.
PY 2021
VL 16
IS 4
BP 330
EP 338
DI 10.5114/pg.2021.104980
PG 9
WC Gastroenterology & Hepatology
WE Emerging Sources Citation Index (ESCI)
SC Gastroenterology & Hepatology
GA YW5YN
UT WOS:000753489700007
PM 34976241
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Bulajic, P
   Bidzic, N
   Djordjevic, V
   Ceranic, M
   Basaric, D
   Pesic, V
   Djordjevic-Pesic, J
AF Bulajic, P.
   Bidzic, N.
   Djordjevic, V
   Ceranic, M.
   Basaric, D.
   Pesic, V
   Djordjevic-Pesic, J.
TI IMPACT OF GENETICS ON NEOADJUVANT THERAPY WITH COMPLETE PATHOLOGICAL
   RESPONSE IN METASTATIC COLORECTAL CANCER: CASE REPORT AND REVIEW OF THE
   LITERATURE
SO BALKAN JOURNAL OF MEDICAL GENETICS
LA English
DT Review
DE Bevacizumab; KRAS (Kirsten rat sarcoma) gene mutation; Metastatic
   colorectal cancer; Pathological complete response; Vanishing metastases
ID RESECTABLE LIVER METASTASES; HEPATIC RESECTION; PHASE-II; CHEMOTHERAPY;
   BEVACIZUMAB; SURVIVAL; OXALIPLATIN; COMBINATION; CETUXIMAB; SURGERY
AB Treatment of colorectal metastatic cancer is still challenging, despite recent improvements in chemotherapy. A genetic cancer profile, such as the KRAS (Kirsten rat sarcoma) gene status, plays a key role in individualized tailored therapy. Molecular targeted therapy added to neoadjuvant chemotherapy can achieve a better pathological response and prolong survival. Pathological complete response of colorectal cancer stage N is rare. A 47-year-old female patient presented with rectal adenocarcinoma and three liver metastases (cT3d/4, N2, M1). After seven cycles of Bevacizumab and CAPOX in neoadjuvant setting, we noted more than 70.0% regression of metastases and complete regression of the primary tumor. We performed low anterior resection of rectum and synchronous subsegmental resection of S3, because the other two lesions were not detectable. Pathology revealed complete response of the primary and also secondary tumors. After 8 months, diagnostic tests did not show any sign of recurrence and the remaining liver lesions disappeared. Colorectal cancer is a heterogeneous disease and it is necessary to identify patients who are at-risk of recurrence and suitable for neoadjuvant therapy. Genetic biomarkers play an important role in metastatic colorectal cancer treatment. Because of the mutated KRAS gene, Bevacizumab was added to cytotoxic therapy achieving a complete pathological response of primary tumor and metastasis. This case is unique because all reported cases with similar results, described staged surgery and one of reverse staged surgery, but with similar results. This neoadjuvant therapy has extra ordinary results for colorectal cancer stage IV and can help disease-free and long-term survival.
C1 [Bulajic, P.; Bidzic, N.; Djordjevic, V; Ceranic, M.; Basaric, D.] Clin Ctr Serbia, Surg Clin 1, Clin Digest Surg, Belgrade, Serbia.
   [Ceranic, M.; Basaric, D.] Univ Belgrade, Med Fac, Belgrade, Serbia.
   [Pesic, V] Univ Belgrade, Fac Agr, Dept Genet, Belgrade, Serbia.
   [Djordjevic-Pesic, J.] Med Sch Dr Milenko Hadzic, Nish, Serbia.
C3 Clinical Centre of Serbia; University of Belgrade; University of
   Belgrade
RP Bidzic, N (corresponding author), Clin Ctr Serbia, Clin Digest Surg, Koste Todorov 6, Belgrade 11000, Serbia.
OI Djordjevic, Vladimir/0009-0008-6206-3820
CR Adam R, 2001, ANN SURG ONCOL, V8, P347
   Adam R, 2008, J CLIN ONCOL, V26, P1635, DOI 10.1200/JCO.2007.13.7471
   Andre T, 2004, NEW ENGL J MED, V350, P2343, DOI 10.1056/NEJMoa032709
   Arata R, 2016, SURG CASE REP, V2, DOI 10.1186/s40792-016-0231-9
   Ayez N, 2011, ANN SURG ONCOL, V18, P2757, DOI 10.1245/s10434-011-1819-8
   Balachandran VP, 2016, CLIN CANCER RES, V22, P2575, DOI 10.1158/1078-0432.CCR-15-1071
   Bokemeyer C, 2011, ANN ONCOL, V22, P1535, DOI 10.1093/annonc/mdq632
   Bujko K, 2006, BRIT J SURG, V93, P1215, DOI 10.1002/bjs.5506
   Chua TC, 2010, ANN SURG ONCOL, V17, P492, DOI 10.1245/s10434-009-0781-1
   Chun YS, 2009, JAMA-J AM MED ASSOC, V302, P2338, DOI 10.1001/jama.2009.1755
   Ferlay J, 2015, INT J CANCER, V136, pE359, DOI 10.1002/ijc.29210
   Fong Y, 1999, ANN SURG, V230, P309, DOI 10.1097/00000658-199909000-00004
   Gruenberger B, 2008, J CLIN ONCOL, V26, P1830, DOI 10.1200/JCO.2007.13.7679
   Klinger M, 2010, ANN SURG ONCOL, V17, P2059, DOI 10.1245/s10434-010-0972-9
   Linardou H, 2008, LANCET ONCOL, V9, P962, DOI 10.1016/S1470-2045(08)70206-7
   Malavasi N, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-35
   Manne U, 2016, CURR COLORECT CANC R, V12, P332, DOI 10.1007/s11888-016-0338-1
   Naiken SP, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-4
   Nordlinger B, 2008, LANCET, V371, P1007, DOI 10.1016/S0140-6736(08)60455-9
   Nordlinger B, 2013, LANCET ONCOL, V14, P1208, DOI 10.1016/S1470-2045(13)70447-9
   Rubbia-Brandt L, 2007, ANN ONCOL, V18, P299, DOI 10.1093/annonc/mdl386
   Saltz LB, 2008, J CLIN ONCOL, V26, P2013, DOI 10.1200/JCO.2007.14.9930
   Schirripa M, 2015, ANN ONCOL, V26, P2503, DOI 10.1093/annonc/mdv385
   Schreckenbach T, 2015, SURG TODAY, V45, P1527, DOI 10.1007/s00595-014-1108-9
   Small RM, 2009, J SURG ONCOL, V99, P93, DOI 10.1002/jso.21207
   Tomlinson JS, 2007, J CLIN ONCOL, V25, P4575, DOI 10.1200/JCO.2007.11.0833
   Uetake H, 2015, ANN SURG ONCOL, V22, P908, DOI 10.1245/s10434-014-4094-7
   van Vledder MG, 2010, ANN SURG ONCOL, V17, P2756, DOI 10.1245/s10434-010-1108-y
   Yokota T, 2011, ONCOL LETT, V2, P201, DOI 10.3892/ol.2011.256
NR 29
TC 3
Z9 3
U1 0
U2 1
PU MACEDONIAN ACAD SCIENCES ARTS
PI SKOPJE
PA BULEVAR KRSTE MISIRKOV 2, P. O. B. 428, SKOPJE, 1000, MACEDONIA
SN 1311-0160
J9 BALK J MED GENET
JI Balk. J. Med. Gen.
PD JUN
PY 2019
VL 22
IS 1
BP 75
EP 80
DI 10.2478/bjmg-2019-0004
PG 6
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA IV0FP
UT WOS:000483955200011
PM 31523624
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Sung, YJ
   Hong, ST
   Jang, M
   Kim, ES
   Kim, C
   Jung, YM
   Youn, I
   Kwon, IC
   Cho, SW
   Ryu, JH
AF Sung, Yejin
   Hong, Seung Taek
   Jang, Mihue
   Kim, Eun Sun
   Kim, Chansoo
   Jung, Youngmee
   Youn, Inchan
   Kwon, Ick Chan
   Cho, Seung-Woo
   Ryu, Ju Hee
TI Predicting response to anti-EGFR antibody, cetuximab, therapy by
   monitoring receptor internalization and degradation
SO BIOMATERIALS
LA English
DT Article
DE Receptor degradation; Predicting response; Fluorescence imaging;
   EGFR-targeted therapy; Activatable probe
ID GROWTH-FACTOR RECEPTOR; COLORECTAL-CANCER PATIENTS; MONOCLONAL-ANTIBODY;
   PROTEIN-DEGRADATION; CATHEPSIN-B; INHIBITION; CHLOROQUINE; ACTIVATION;
   MUTATIONS; TUMORS
AB Anti-epidermal growth factor receptor (EGFR) antibody, cetuximab, therapy has significantly improved the clinical outcomes of patients with colorectal cancer, but the response to cetuximab can vary widely among individuals. We thus need strategies for predicting the response to this therapy. However, the current methods are unsatisfactory in their predictive power. Cetuximab can promote the internalization and degradation of EGFR, and its therapeutic efficacy is significantly correlated with the degree of EGFR degradation. Here, we present a new approach to predict the response to anti-EGFR therapy, cetuximab by evaluating the degree of EGFR internalization and degradation of colorectal cancer cells in vitro and in vivo. Our newly developed fluorogenic cetuximab-conjugated probe (Cetux-probe) was confirmed to undergo EGFR binding, internalization, and lysosomal degradation to yield fluorescence activation; it thus shares the action mechanism by which cetuximab exerts its anti-tumor effects. Cetux-probe-activated fluorescence could be used to gauge EGFR degradation and showed a strong linear correlation with the cytotoxicity of cetuximab in colorectal cancer cells and tumorbearing mice. The predictive ability of Cetux-probe-activated fluorescence was much higher than those of EGFR expression or KRAS mutation status. The Cetux-probes may become useful tools for predicting the response to cetuximab therapy by assessing EGFR degradation.
C1 [Sung, Yejin; Hong, Seung Taek; Jang, Mihue; Jung, Youngmee; Youn, Inchan; Kwon, Ick Chan; Ryu, Ju Hee] Korea Inst Sci & Technol KIST, Biomed Res Div, Seoul 02792, South Korea.
   [Sung, Yejin; Cho, Seung-Woo] Yonsei Univ, Coll Life Sci & Biotechnol, Grad Program Bioind Engn, Seoul 03722, South Korea.
   [Hong, Seung Taek] Daejin Univ, Dept Echo Appl Chem, Div Biohealthcare, 1007 Hoguk Ro, Pocheon Si 11159, Gyeonggi Do, South Korea.
   [Kim, Eun Sun] Korea Univ, Coll Med, Dept Internal Med, Div Gastroenterol & Hepatol, Seoul 20841, South Korea.
   [Kim, Chansoo] Korea Inst Sci & Technol KIST, Computat Sci Ctr, AI R Lab, Hwarangno 14-Gil 5, Seoul 02792, South Korea.
   [Kim, Chansoo] ASSIST, Korea Inst Sci & Technol KIST, Hwarangno 14-Gil 5, Seoul 02792, South Korea.
   [Kwon, Ick Chan] Korea Univ, KU KIST Grad Sch Converging Sci & Technol, Seoul 02841, South Korea.
   [Cho, Seung-Woo] Yonsei Univ, Coll Life Sci & Biotechnol, Dept Biotechnol, Seoul 03722, South Korea.
   [Cho, Seung-Woo] Inst Basic Sci IBS, Ctr Nanomed, Seoul 03722, South Korea.
C3 Korea Institute of Science & Technology (KIST); Yonsei University;
   Daejin University; Korea University; Korea University Medicine (KU
   Medicine); Korea Institute of Science & Technology (KIST); Korea
   Institute of Science & Technology (KIST); Korea University; Yonsei
   University; Institute for Basic Science - Korea (IBS)
RP Ryu, JH (corresponding author), Korea Inst Sci & Technol KIST, Biomed Res Div, Seoul 02792, South Korea.; Cho, SW (corresponding author), Yonsei Univ, Coll Life Sci & Biotechnol, Grad Program Bioind Engn, Seoul 03722, South Korea.
EM seungwoocho@yonsei.ac.kr; jhryu@kist.re.kr
RI Jung, Young/AAQ-3557-2020; Kim, Se Young/GSE-5296-2022
OI Kim, Eun Sun/0000-0003-1820-459X; RYU, JU HEE/0000-0003-3422-3272; Jung,
   Youngmee/0000-0002-4778-4629
FU Korea government (the Ministry of Science and ICT, the Ministry of
   Health Welfare) [21A0504L1-11]; Korea government (the Ministry of
   Science and ICT) under the grant the Institute for Information &
   communication Technology Planning & evaluation (IITP) [21A0504L1-11];
   Intramural Research Program of Korea Institute of Science and
   Technology; Institute for Basic Science [2021-0-02076]; Yonsei Fellow
   Program; Intramural Research Program of Korea Institute of Science and
   Technology; Institute for Basic Science;  [IBS-R026-D1]
FX This work was supported by the Korea government (the Ministry of Science
   and ICT, the Ministry of Health & Welfare) under the grant the Korean
   Fund for Regenerative Medicine (KFRM; 21A0504L1-11) , the Korea
   government (the Ministry of Science and ICT) under the grant the
   Institute for Information & communication Technology Planning &
   evaluation (IITP; 2021-0-02076) , the Intramural Research Program of
   Korea Institute of Science and Technology, the Institute for Basic
   Science (IBS-R026-D1) , and the Yonsei Fellow Program funded by Lee Youn
   Jae.
CR Ahn G, 2021, NAT CHEM BIOL, V17, P937, DOI 10.1038/s41589-021-00770-1
   Allegra CJ, 2009, J CLIN ONCOL, V27, P2091, DOI 10.1200/JCO.2009.21.9170
   Banik SM, 2020, NATURE, V584, P291, DOI 10.1038/s41586-020-2545-9
   Békés M, 2022, NAT REV DRUG DISCOV, V21, P181, DOI 10.1038/s41573-021-00371-6
   Cai WQ, 2020, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.01249
   Chong CR, 2013, NAT MED, V19, P1389, DOI 10.1038/nm.3388
   Chung KY, 2005, J CLIN ONCOL, V23, P1803, DOI 10.1200/JCO.2005.08.037
   Cunningham D, 2004, NEW ENGL J MED, V351, P337, DOI 10.1056/NEJMoa033025
   De Roock W, 2008, ANN ONCOL, V19, P508, DOI 10.1093/annonc/mdm496
   Ducharme J, 1996, CLIN PHARMACOKINET, V31, P257, DOI 10.2165/00003088-199631040-00003
   Firer MA, 2021, ADV FUNCT MATER, V31, DOI 10.1002/adfm.202100032
   Fu ZW, 2022, SIGNAL TRANSDUCT TAR, V7, DOI 10.1038/s41392-022-00947-7
   Galizia G, 2007, ONCOGENE, V26, P3654, DOI 10.1038/sj.onc.1210381
   Gurdal H, 2019, INT J ONCOL, V54, P1345, DOI 10.3892/ijo.2019.4697
   Jones S, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-019-57153-9
   Kawaguchi Y, 2007, INT J CANCER, V120, P781, DOI 10.1002/ijc.22370
   Kim HY, 2020, J CONTROL RELEASE, V328, P222, DOI 10.1016/j.jconrel.2020.08.046
   Liao HJ, 2009, CANCER RES, V69, P6179, DOI 10.1158/0008-5472.CAN-09-0049
   Lièvre A, 2006, CANCER RES, V66, P3992, DOI 10.1158/0008-5472.CAN-06-0191
   Lin JY, 2023, SMALL, V19, DOI 10.1002/smll.202207778
   Linebaugh BE, 1999, EUR J BIOCHEM, V264, P100, DOI 10.1046/j.1432-1327.1999.00582.x
   Lopez-Hernandez FJ, 2003, MOL CANCER THER, V2, P255
   Ma HR, 2018, INT J CANCER, V142, P2578, DOI 10.1002/ijc.31274
   Mendelsohn J, 2015, CLIN CANCER RES, V21, P227, DOI 10.1158/1078-0432.CCR-14-2491
   Okada Y, 2017, MOL CANCER RES, V15, P1445, DOI 10.1158/1541-7786.MCR-16-0383
   Patel D, 2007, ANTICANCER RES, V27, P3355
   Pedersen MW, 2010, CANCER RES, V70, P588, DOI 10.1158/0008-5472.CAN-09-1417
   Perez-Torres M, 2006, J BIOL CHEM, V281, P40183, DOI 10.1074/jbc.M607958200
   Qi J, 2022, ADV MATER, V34, DOI 10.1002/adma.202203309
   Raina K, 2016, P NATL ACAD SCI USA, V113, P7124, DOI 10.1073/pnas.1521738113
   Ryu JH, 2013, BIOMATERIALS, V34, P9149, DOI 10.1016/j.biomaterials.2013.08.026
   Saltz LB, 2004, J CLIN ONCOL, V22, P1201, DOI 10.1200/JCO.2004.10.182
   Shah C, 2009, CLIN CANCER RES, V15, P4712, DOI 10.1158/1078-0432.CCR-08-2635
   Shen CH, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.642625
   Shim MK, 2016, ANGEW CHEM INT EDIT, V55, P14698, DOI 10.1002/anie.201608504
   Sun R, 2015, CELL PHYSIOL BIOCHEM, V35, P1877, DOI 10.1159/000373998
   SUNADA H, 1986, P NATL ACAD SCI USA, V83, P3825, DOI 10.1073/pnas.83.11.3825
   Tveten K, 2009, ACTA BIOCH BIOPH SIN, V41, P246, DOI 10.1093/abbs/gmp008
   VANDEVIJVER MJ, 1991, J BIOL CHEM, V266, P7503
   Wang K., 2023, Adv. Sci., V10
   WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430
   Wu JYZ, 2022, ADV MATER, V34, DOI 10.1002/adma.202200062
   Wu SY, 2022, ADV MATER, V34, DOI 10.1002/adma.202109210
   Yen LC, 2010, ANN SURG, V251, P254, DOI 10.1097/SLA.0b013e3181bc9d96
   Yu JF, 2022, FRONT MOL BIOSCI, V9, DOI 10.3389/fmolb.2022.847835
   Yuan ZQ, 2009, CANCER RES, V69, P7811, DOI 10.1158/0008-5472.CAN-09-0986
NR 46
TC 3
Z9 3
U1 3
U2 14
PU ELSEVIER SCI LTD
PI London
PA 125 London Wall, London, ENGLAND
SN 0142-9612
EI 1878-5905
J9 BIOMATERIALS
JI Biomaterials
PD DEC
PY 2023
VL 303
AR 122382
DI 10.1016/j.biomaterials.2023.122382
EA NOV 2023
PG 13
WC Engineering, Biomedical; Materials Science, Biomaterials
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Engineering; Materials Science
GA Z7DT6
UT WOS:001113648700001
PM 37977005
OA hybrid
DA 2025-01-04
ER

PT J
AU Zheng-Lin, B
   Bekaii-Saab, TS
AF Zheng-Lin, Binbin
   Bekaii-Saab, Tanios S.
TI Treatment options for HER2-expressing colorectal cancer: updates and
   recent approvals
SO THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
LA English
DT Review
DE colorectal cancer; ERBB2; HER2; targeted therapy; trastuzumab deruxtecan
AB Colorectal cancer is a leading cause of cancer-related mortality worldwide. Approximately 3-5% of colorectal tumors harbor human epidermal growth factor receptor (HER2) amplification which is associated with a higher incidence of intracranial metastasis and overall worse outcomes. In the setting of refractory metastatic RAS wild-type tumors, evidence supports the use of various HER2-blocking agents, including monoclonal antibodies, tyrosine kinase inhibitors, and novel antibody-drug conjugates. With a number of relatively active agents clinically available and even more in development, it is crucial for clinicians to familiarize themselves with the mechanisms of action, efficacy data, and safety profiles of these treatments. In this review, we aim to summarize key findings from past and ongoing trials with anti-HER2 agents in metastatic colorectal cancer.
C1 [Bekaii-Saab, Tanios S.] Mayo Clin, Div Hematol & Med Oncol, 5881 East Mayo Blvd, Phoenix, AZ 85054 USA.
   [Zheng-Lin, Binbin] Mayo Clin, Div Hematol & Oncol, Phoenix, AZ USA.
C3 Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix
RP Bekaii-Saab, TS (corresponding author), Mayo Clin, Div Hematol & Med Oncol, 5881 East Mayo Blvd, Phoenix, AZ 85054 USA.
EM Bekaii-Saab.Tanios@mayo.edu
RI Bekaii-Saab, Tanios/AGD-6851-2022
OI Zheng-Lin, Binbin/0000-0002-2478-8299
CR [Anonymous], 2022, Global cancer facts & figures, V4th
   Bang YJ, 2010, LANCET, V376, P1302
   Bartley AN, 2016, ARCH PATHOL LAB MED, V140, P1345, DOI 10.5858/arpa.2016-0331-CP
   Bekaii-Saab TS, 2023, ONCOLOGIST, V28, P885, DOI 10.1093/oncolo/oyad200
   Bertotti A, 2011, CANCER DISCOV, V1, P508, DOI 10.1158/2159-8290.CD-11-0109
   Cenaj O, 2019, AM J CLIN PATHOL, V152, P97, DOI 10.1093/ajcp/aqz031
   Conlon NT, 2021, BRIT J CANCER, V124, P1249, DOI 10.1038/s41416-020-01257-x
   DiPeri TP, 2023, MOL CANCER THER, V22, P976, DOI 10.1158/1535-7163.MCT-22-0630
   Gupta R, 2020, J CLIN ONCOL, V38
   Huang WB, 2022, J CANCER RES CLIN, V148, P993, DOI 10.1007/s00432-021-03655-x
   Jhaveri K, 2022, ANN ONCOL, V33, pS749, DOI 10.1016/j.annonc.2022.07.589
   Johnston SRD, 2006, DRUG TODAY, V42, P441, DOI 10.1358/dot.2006.42.7.985637
   Keshamouni VG, 2002, J BIOL CHEM, V277, P22558, DOI 10.1074/jbc.M202351200
   Leto SM, 2015, CLIN CANCER RES, V21, P5519, DOI 10.1158/1078-0432.CCR-14-3066
   Li BT, 2022, NEW ENGL J MED, V386, P241, DOI 10.1056/NEJMoa2112431
   Li WH, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.097
   Meric-Bernstam F, 2022, LANCET ONCOL, V23, P1558, DOI 10.1016/S1470-2045(22)00621-0
   Meric-Bernstam F, 2021, J CLIN ONCOL, V39, DOI 10.1200/JCO.2021.39.15_suppl.3004
   Modi S, 2022, NEW ENGL J MED, V387, P9, DOI 10.1056/NEJMoa2203690
   Nakamura Y, 2021, NAT MED, V27, P1899, DOI 10.1038/s41591-021-01553-w
   Nam SK, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0151865
   Ogitani Y, 2016, CANCER SCI, V107, P1039, DOI 10.1111/cas.12966
   Pheneger T, 2009, CANCER RES, V69
   Raghav K, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00226
   Raghav KPS, 2023, J CLIN ONCOL, V41
   Richman SD, 2016, J PATHOL, V238, P562, DOI 10.1002/path.4679
   Salem ME, 2017, ONCOTARGET, V8, P86356, DOI 10.18632/oncotarget.21169
   Sartore-Bianchi A, 2020, ESMO OPEN, V5, DOI 10.1136/esmoopen-2020-000911
   Sartore-Bianchi A, 2020, JAMA ONCOL, V6, P927, DOI 10.1001/jamaoncol.2020.0571
   Sartore-Bianchi A, 2016, LANCET ONCOL, V17, P738, DOI 10.1016/S1470-2045(16)00150-9
   Shitara K, 2020, NEW ENGL J MED, V382, P2419, DOI 10.1056/NEJMoa2004413
   Siena S, 2021, LANCET ONCOL, V22, P779, DOI 10.1016/S1470-2045(21)00086-3
   Song N, 2023, J CLIN ONCOL, V41
   Strickler J., 2022, Ann Oncol, V33
   Strickler JH., 2023, J Natl Compr Canc Netw, V12, pe1
   Strickler JH., 2023, J Clin Oncol, V41, P3528, DOI [10.1200/JCO.2023.41.16_suppl.3528, DOI 10.1200/JCO.2023.41.16_SUPPL.3528]
   Strickler JH., 2022, ESMO WORLD C GASTROI
   Strickler JH, 2022, JAMA ONCOL, V8, P760, DOI 10.1001/jamaoncol.2021.8196
   Vaghi C, 2023, CANCER TREAT REV, V112, DOI 10.1016/j.ctrv.2022.102488
   Valtorta E, 2015, MODERN PATHOL, V28, P1481, DOI 10.1038/modpathol.2015.98
   Wells A, 1999, INT J BIOCHEM CELL B, V31, P637, DOI 10.1016/S1357-2725(99)00015-1
   Xu YY, 2021, GASTRIC CANCER, V24, P913, DOI 10.1007/s10120-021-01168-7
   Yagisawa M, 2021, CLIN COLORECTAL CANC, V20, P113, DOI 10.1016/j.clcc.2020.11.002
NR 43
TC 3
Z9 3
U1 0
U2 5
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1758-8340
EI 1758-8359
J9 THER ADV MED ONCOL
JI Ther. Adv. Med. Oncol.
PY 2024
VL 16
AR 17588359231225037
DI 10.1177/17588359231225037
PG 10
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA FG7B6
UT WOS:001144664500001
PM 38249334
OA gold
DA 2025-01-04
ER

PT J
AU Suh, SS
   Kim, TK
   Kim, JE
   Hong, JM
   Nguyen, TTT
   Han, SJ
   Youn, UJ
   Yim, JH
   Kim, IC
AF Suh, Sung-Suk
   Kim, Tai Kyoung
   Kim, Jung Eun
   Hong, Ju-Mi
   Trang Thu Thi Nguyen
   Han, Se Jong
   Youn, Ui Joung
   Yim, Joung Han
   Kim, Il-Chan
TI Anticancer Activity of Ramalin, a Secondary Metabolite from the
   Antarctic Lichen <i>Ramalina terebrata</i>, against Colorectal Cancer
   Cells
SO MOLECULES
LA English
DT Article
DE colorectal cancer; ramalin; Antarctic lichen; cell cycle arrest; HCT116
ID MOLECULAR PATHOLOGICAL EPIDEMIOLOGY; COLON-CANCER; APOPTOSIS;
   INSTABILITY; METASTASIS; DISEASE; ROLES; P53
AB Colorectal cancer is a leading cause of death worldwide and occurs through the highly complex coordination of multiple cellular pathways, resulting in carcinogenesis. Recent studies have increasingly revealed that constituents of lichen extracts exhibit potent pharmaceutical activities, including anticancer activity against various cancer cells, making them promising candidates for new anticancer therapeutic drugs. The main objective of this study was to evaluate the anticancer capacities of ramalin, a secondarymetabolite from the Antarctic lichen Ramalina terebrata, in the human colorectal cancer cell line HCT116. In this study, ramalin displayed concentration-dependent anticancer activity against HCT116 cells, significantly suppressing proliferation and inducing apoptosis. Furthermore, ramalin induced cell cycle arrest in the gap 2/mitosis (G2/M) phase through the modulation of hallmark genes involved in the G2/M phase transition, such as tumour protein p53 (TP53), cyclin-dependent kinase inhibitor 1A (CDKN1A), cyclin-dependent kinase 1 (CDK1) and cyclin B1 (CCNB1). At both the transcriptional and translational level, ramalin caused a gradual increase in the expression of TP53 and its downstream gene CDKN1A, while decreasing the expression of CDK1 and CCNB1 in a concentration-dependent manner. In addition, ramalin significantly inhibited the migration and invasion of colorectal cancer cells in a concentration-dependent manner. Taken together, these data suggest that ramalin may be a therapeutic candidate for the targeted therapy of colorectal cancer.
C1 [Suh, Sung-Suk; Kim, Tai Kyoung; Kim, Jung Eun; Hong, Ju-Mi; Han, Se Jong; Youn, Ui Joung; Yim, Joung Han; Kim, Il-Chan] Korea Polar Res Inst, Div Polar Life Sci, Incheon 21990, South Korea.
   [Han, Se Jong; Yim, Joung Han; Kim, Il-Chan] Univ Sci & Technol, Dept Polar Life Sci, Incheon 21990, South Korea.
   [Kim, Jung Eun] Sungkyunkwan Univ, Dept Pharm, Grad Sch, Suwon 16419, South Korea.
   [Trang Thu Thi Nguyen] Univ Sci & Technol Hanoi, Dept Pharmacol Med & Agron Biotechnol, Hanoi 100000, Vietnam.
C3 Korea Polar Research Institute (KOPRI); Sungkyunkwan University (SKKU);
   Vietnam Academy of Science & Technology (VAST); University of Science &
   Technology of Hanoi (USTH)
RP Kim, IC (corresponding author), Korea Polar Res Inst, Div Polar Life Sci, Incheon 21990, South Korea.; Kim, IC (corresponding author), Univ Sci & Technol, Dept Polar Life Sci, Incheon 21990, South Korea.
EM sung-suk.suh@kopri.re.kr; tkkim@kopri.re.kr; je2202@kopri.re.kr;
   wnal5555@kopri.re.kr; buffson192@gmail.com; hansj@kopri.re.kr;
   ujyoun@kopri.re.kr; jhyim@kopri.re.kr; ickim@kopri.re.kr
RI Kim, Heui-Soo/ABF-3773-2021
OI HAN, Se Jong/0000-0001-9576-2179
FU Korea Polar Research Institute, Korea [PE17100]
FX This research was supported by the research project (PE17100) of Korea
   Polar Research Institute, Korea.
CR Armaghany Tannaz, 2012, Gastrointest Cancer Res, V5, P19
   Baig S, 2016, CELL DEATH DIS, V7, DOI 10.1038/cddis.2015.275
   Colussi D, 2013, INT J MOL SCI, V14, P16365, DOI 10.3390/ijms140816365
   Delker DA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088367
   Duronio RJ, 2013, CSH PERSPECT BIOL, V5, DOI 10.1101/cshperspect.a008904
   Elmore S, 2007, TOXICOL PATHOL, V35, P495, DOI 10.1080/01926230701320337
   Fadeel B, 2009, CRIT REV BIOCHEM MOL, V44, P264, DOI 10.1080/10409230903193307
   Fernández-Moriano C, 2016, PHARM BIOL, V54, P1, DOI 10.3109/13880209.2014.1003354
   Hassan M, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/150845
   Iacopetta B, 2010, ASIA-PAC J CLIN ONCO, V6, P260, DOI 10.1111/j.1743-7563.2010.01335.x
   Labi V, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.20
   Lee E, 2016, PHYTOTHER RES, V30, P426, DOI 10.1002/ptr.5544
   Lim SH, 2013, DEVELOPMENT, V140, P3079, DOI 10.1242/dev.091744
   Martin G. Steven, 2003, Cancer Cell, V4, P167, DOI 10.1016/S1535-6108(03)00216-2
   Mirzayans R, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18050928
   Müller K, 2001, APPL MICROBIOL BIOT, V56, P9, DOI 10.1007/s002530100684
   Nazemalhosseini Mojarad Ehsan, 2013, Gastroenterol Hepatol Bed Bench, V6, P120
   Ng JMK, 2015, INT J MOL SCI, V16, P2472, DOI 10.3390/ijms16022472
   Ogino S, 2016, EPIDEMIOLOGY, V27, P602, DOI 10.1097/EDE.0000000000000471
   Ogino S, 2011, GUT, V60, P397, DOI 10.1136/gut.2010.217182
   Okayama H, 2012, DIGEST DIS, V30, P9, DOI 10.1159/000341882
   Park HJ, 2016, PHYTOTHER RES, V30, P1978, DOI 10.1002/ptr.5703
   Paudel B, 2011, PHYTOMEDICINE, V18, P1285, DOI 10.1016/j.phymed.2011.06.007
   Pino MS, 2010, GASTROENTEROLOGY, V138, P2059, DOI 10.1053/j.gastro.2009.12.065
   Riihimäki M, 2016, SCI REP-UK, V6, DOI 10.1038/srep29765
   Suh SS, 2017, INT J MED SCI, V14, P560, DOI 10.7150/ijms.18702
   Taylor WR, 2001, ONCOGENE, V20, P1803, DOI 10.1038/sj.onc.1204252
   Thadhani VM, 2017, OXID MED CELL LONGEV, V2017, DOI 10.1155/2017/2079697
   van Zijl F, 2011, MUTAT RES-REV MUTAT, V728, P23, DOI 10.1016/j.mrrev.2011.05.002
   Zambare VP, 2012, PHARM BIOL, V50, P778, DOI 10.3109/13880209.2011.633089
NR 30
TC 23
Z9 25
U1 1
U2 6
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 1420-3049
J9 MOLECULES
JI Molecules
PD AUG
PY 2017
VL 22
IS 8
AR 1361
DI 10.3390/molecules22081361
PG 12
WC Biochemistry & Molecular Biology; Chemistry, Multidisciplinary
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Chemistry
GA FF0PF
UT WOS:000408602900124
PM 28817102
OA Green Published, Green Submitted, gold
DA 2025-01-04
ER

PT J
AU Corsini, EM
   Datar, SS
   Mitchell, KG
   Zhou, N
   Hofstetter, WL
   Mehran, RJ
   Rajaram, R
   Rice, DC
   Roth, JA
   Sepesi, B
   Swisher, SG
   Vaporciyan, AA
   Walsh, GL
   Blackmon, SH
   Loree, JM
   Morris, V
   Antonoff, MB
AF Corsini, Erin M.
   Datar, Saumil S.
   Mitchell, Kyle G.
   Zhou, Nicolas
   Hofstetter, Wayne L.
   Mehran, Reza J.
   Rajaram, Ravi
   Rice, David C.
   Roth, Jack A.
   Sepesi, Boris
   Swisher, Stephen G.
   Vaporciyan, Ara A.
   Walsh, Garrett L.
   Blackmon, Shanda H.
   Loree, Jonathan M.
   Morris, Van K.
   Antonoff, Mara B.
TI High mutational concordance between primary colorectal tumors and
   associated pulmonary metastases
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE colorectal cancer; concordance; genes; mutations; pulmonary metastases
ID CONSENSUS MOLECULAR SUBTYPES; CANCER; KRAS; DISCORDANCE; BRAF
AB Background and Objectives Precision medicine has altered the management of colorectal cancer (CRC). However, the concordance of mutational findings between primary CRC tumors and associated pulmonary metastases (PM) is not well-described. This study aims to determine the concordance of genomic profiles between primary CRC and PM.
   Methods Patients treated for colorectal PM at a single institution from 2000 to 2017 were identified. Mutational concordance was defined as either both wild-type or both mutant alleles in lung and colorectal lesion; genes with opposing mutational profiles were reported as discordant.
   Results Thirty-eight patients met inclusion criteria, among whom KRAS, BRAF, NRAS, MET, RET, and PIK3CA were examined for concordance. High concordance was demonstrated among all evaluated genes, ranging from 86% (KRAS) to 100% concordance (NRAS, RET, and MET). De novo KRAS mutations were detected in the PM of 4 from 35 (11%) patients, 3 of whom had previously received anti-epidermal growth factor receptor (EGFR) therapy. Evaluation of Cohen's kappa statistic demonstrated moderate to perfect correlation among evaluated genes.
   Conclusions Because high intertumoral genomic homogeneity exists, it may be reasonable to use primary CRC mutational profiles to guide prognostication and targeted therapy for PM. However, the possibility of de novo KRAS-mutant PM should be considered, particularly among patients previously treated with anti-EGFR therapy.
C1 [Corsini, Erin M.; Datar, Saumil S.; Mitchell, Kyle G.; Zhou, Nicolas; Hofstetter, Wayne L.; Mehran, Reza J.; Rajaram, Ravi; Rice, David C.; Roth, Jack A.; Sepesi, Boris; Swisher, Stephen G.; Vaporciyan, Ara A.; Walsh, Garrett L.; Antonoff, Mara B.] Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA.
   [Blackmon, Shanda H.] Mayo Clin, Dept Surg, Div Gen Thorac Surg, Rochester, MN USA.
   [Loree, Jonathan M.] BC Canc, Dept Med Oncol, Vancouver, BC, Canada.
   [Morris, Van K.] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Div Canc Med, Houston, TX 77030 USA.
C3 University of Texas System; UTMD Anderson Cancer Center; Mayo Clinic;
   University of Texas System; UTMD Anderson Cancer Center
RP Antonoff, MB (corresponding author), Univ Texas MD Anderson Canc Ctr, Dept Thorac & Cardiovasc Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA.
EM MBAntonoff@mdanderson.org
RI Morris, Van/KIE-0809-2024; Corsini, Erin/AAG-6248-2020
OI Loree, Jonathan/0000-0001-8189-2132; Bayley, Erin/0000-0003-4715-0244;
   Zhou, Nicolas/0000-0002-8340-9113
CR Boeckx N, 2017, ANN ONCOL, V28, P1862, DOI 10.1093/annonc/mdx119
   de Macedo MP, 2017, AM J CANCER RES, V7, P1978
   De Stefano A, 2017, INT J BIOL MARKER, V32, pE474, DOI 10.5301/ijbm.5000273
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Dienstmann R, 2015, J CLIN ONCOL, V33, P1787, DOI 10.1200/JCO.2014.60.0213
   Fujiyoshi K, 2017, ONCOL REP, V37, P785, DOI 10.3892/or.2016.5323
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Kim MJ, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-347
   Kim TM, 2015, CLIN CANCER RES, V21, P4461, DOI 10.1158/1078-0432.CCR-14-2413
   LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310
   Lee KH, 2015, J SURG ONCOL, V111, P1059, DOI 10.1002/jso.23936
   Li ZZ, 2016, MED ONCOL, V33, DOI 10.1007/s12032-016-0787-z
   Loree JM, 2018, CLIN CANCER RES, V24, P1062, DOI 10.1158/1078-0432.CCR-17-2484
   Mao C, 2015, SCI REP-UK, V5, DOI 10.1038/srep08065
   Meric-Bernstam F, 2015, J CLIN ONCOL, V33, P2753, DOI 10.1200/JCO.2014.60.4165
   Mostert B, 2013, INT J CANCER, V133, P130, DOI 10.1002/ijc.27987
   Shan LN, 2018, J CANCER RES CLIN, V144, P2275, DOI 10.1007/s00432-018-2744-z
   Wei Q, 2017, ANN ONCOL, V28, P2135, DOI 10.1093/annonc/mdx278
NR 18
TC 1
Z9 1
U1 0
U2 2
PU WILEY
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD MAY
PY 2020
VL 121
IS 6
BP 984
EP 989
DI 10.1002/jso.25871
EA FEB 2020
PG 6
WC Oncology; Surgery
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Surgery
GA LC0RW
UT WOS:000514331100001
PM 32077113
DA 2025-01-04
ER

PT J
AU Liu, HW
   Xu, HF
   Liu, Y
   Zhao, YQ
   Zhang, X
   Yu, YQ
   Du, LB
   Liu, YY
   Wang, WJ
   Cao, HL
   Ma, L
   Huang, JX
   Cao, J
   Li, L
   Fan, YP
   Gu, XF
   Feng, CY
   Zhu, Q
   Wang, XH
   Du, JC
   Zhang, SK
   Qiao, YL
AF Liu, Hongwei
   Xu, Huifang
   Liu, Yin
   Zhao, Yuqian
   Zhang, Xi
   Yu, Yanqin
   Du, Lingbin
   Liu, Yunyong
   Wang, Wenjun
   Cao, Helu
   Ma, Li
   Huang, Juanxiu
   Cao, Ji
   Li, Li
   Fan, Yanping
   Gu, Xiaofen
   Feng, Changyan
   Zhu, Qian
   Wang, Xiaohui
   Du, Jingchang
   Zhang, Shaokai
   Qiao, Youlin
TI Comparative characteristics of early-onset vs. late-onset advanced
   colorectal cancer: a nationwide study in China
SO BMC CANCER
LA English
DT Article
DE Early-onset colorectal cancer; Late-onset colorectal cancer; Clinical
   epidemiology features; Health-related quality of life
ID YOUNG; GUIDELINES; VERSION
AB Background The incidence of early-onset colorectal cancer (EOCRC, diagnosed in patients under the age of 50 years) has been increasing around the world. Here, we aimed to systematically identify distinctive features of EOCRC.Methods From 2020 to 2021, we conducted a nationwide survey in 19 hospitals, collecting data on advanced CRC patients' demographics, clinical features, disease knowledge, medical experiences, expenditures, and health-related quality of life (HRQOL). We compared these features between EOCRC and late-onset colorectal cancer (LOCRC, >= 50 years old) groups and analyzed the association between EOCRC and HRQOL using multivariate linear regression.Findings In total, 991 patients with EOCRC and 3581 patients with LOCRC were included. Compared to the LOCRC group, the EOCRC group had higher levels of education, were more informed about the risk factors for CRC, were more likely to have widespread metastases throughout the body, were more inclined to undergo gene testing, and were more likely to opt for targeted therapy, radiotherapy, and chemotherapy. However, HRQOL in the EOCRC group was similar to that of the LOCRC group, and no significant association was observed between EOCRC and HRQOL (beta: -0.753, P value: 0.307).Interpretation In Chinese patients, EOCRC patients had more aggressive features. Despite undergoing more intensified treatments and gene testing, they had similar HRQOL compared with LOCRC. These findings advocate for a more tailored approach to treatment, especially for young CRC patients with advanced TNM stages and metastasis.
C1 [Liu, Hongwei; Xu, Huifang; Liu, Yin; Zhang, Shaokai; Qiao, Youlin] Zhengzhou Univ, Affiliated Canc Hosp, Dept Canc Epidemiol, Henan Canc Hosp, Zhengzhou 450008, Peoples R China.
   [Liu, Hongwei; Xu, Huifang; Liu, Yin; Zhang, Shaokai; Qiao, Youlin] Henan Canc Hosp, Zhengzhou 450008, Peoples R China.
   [Zhao, Yuqian] Univ Elect Sci & Technol China, Sichuan Clin Res Ctr Canc, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst,Affiliated Canc Hosp,Off, Chengdu, Peoples R China.
   [Zhang, Xi] Peking Univ, Canc Hosp & Inst, Beijing Off Canc Prevent & Control, Minist Educ Beijing,Key Lab Carcinogenesis & Trans, Beijing, Peoples R China.
   [Yu, Yanqin] Baotou Med Coll, Affiliated Hosp 1, Clin Epidemiol Res Ctr, Dept Dermatol, Baotou, Peoples R China.
   [Du, Lingbin] Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Canc Prevent, Hangzhou, Peoples R China.
   [Liu, Yunyong] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Clin Res Ctr Canc, Off Shenzhen Canc Prevent & Control Ctr,Natl Canc, Shenzhen, Peoples R China.
   [Liu, Yunyong] Chinese Acad Med Sci & Peking Union Med Coll, Shenzhen Hosp, Shenzhen, Peoples R China.
   [Wang, Wenjun] Jining Med Univ, Sch Nursing, Jining, Peoples R China.
   [Cao, Helu] Xinxiang Cent Hosp, Dept Prevent Hlth, Xinxiang, Peoples R China.
   [Ma, Li] Dalian Med Univ, Publ Hlth Sch, Dalian, Peoples R China.
   [Huang, Juanxiu] Wuzhou Red Cross Hosp, Dept Gastroenterol, Wuzhou, Peoples R China.
   [Cao, Ji] Guangxi Med Univ, Affiliated Hosp 1, Dept Canc Prevent & Control Off, Nanning, Guangxi, Peoples R China.
   [Li, Li] Jinan Univ, Affiliated Hosp 1, Dept Clin Res, Guangzhou, Peoples R China.
   [Fan, Yanping] Sun Yat Sen Univ, Collaborat Innovat Ctr Canc Med, Canc Ctr, State Key Lab Oncol South China, Guangzhou, Peoples R China.
   [Gu, Xiaofen] Xinjiang Med Univ, Affiliated Tumor Hosp, Dept Student Affairs, Urumqi, Xinjiang, Peoples R China.
   [Feng, Changyan] Chongqing Univ, Canc Hosp, Chongqing Key Lab Translat Res Canc Metastasis & I, Chongqing, Peoples R China.
   [Zhu, Qian] Chongqing Med Univ, Sch Publ Hlth & Management, Chongqing, Peoples R China.
   [Wang, Xiaohui] Gansu Prov Canc Hosp, Dept Publ Hlth, Lanzhou, Peoples R China.
   [Du, Jingchang] Chengdu Med Coll, Sch Publ Hlth, Chengdu, Peoples R China.
   [Qiao, Youlin] Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Ctr Global Hlth, Beijing 100005, Peoples R China.
C3 Zhengzhou University; Zhengzhou University; University of Electronic
   Science & Technology of China; Peking University; Baotou Medical
   College; Zhejiang Cancer Hospital; Chinese Academy of Sciences;
   University of Chinese Academy of Sciences, CAS; Chinese Academy of
   Medical Sciences - Peking Union Medical College; Peking Union Medical
   College; Chinese Academy of Medical Sciences - Peking Union Medical
   College; Peking Union Medical College; Jining Medical University; Dalian
   Medical University; Guangxi Medical University; Jinan University; Sun
   Yat Sen University; State Key Lab Oncology South China; Xinjiang Medical
   University; Chongqing University; Chongqing Medical University; Chengdu
   Medical College; Chinese Academy of Medical Sciences - Peking Union
   Medical College; Peking Union Medical College
RP Zhang, SK; Qiao, YL (corresponding author), Zhengzhou Univ, Affiliated Canc Hosp, Dept Canc Epidemiol, Henan Canc Hosp, Zhengzhou 450008, Peoples R China.; Zhang, SK; Qiao, YL (corresponding author), Henan Canc Hosp, Zhengzhou 450008, Peoples R China.; Qiao, YL (corresponding author), Chinese Acad Med Sci & Peking Union Med Coll, Sch Populat Med & Publ Hlth, Ctr Global Hlth, Beijing 100005, Peoples R China.
EM shaokaizhang@zzu.edu.cn; qiaoy@cicams.ac.cn
RI Yu, Yanqin/AFX-9220-2022; zhao, yuqian/JED-8246-2023
FU Beijing LoveBook Cancer Foundation; Merck Serono Co., Ltd
FX This work was funded by the Beijing LoveBook Cancer Foundation and Merck
   Serono Co., Ltd.
CR Abdelsattar ZM, 2016, CANCER-AM CANCER SOC, V122, P929, DOI 10.1002/cncr.29716
   Ahnen DJ, 2014, MAYO CLIN PROC, V89, P216, DOI 10.1016/j.mayocp.2013.09.006
   Brusco NK, 2015, BMC HEALTH SERV RES, V15, DOI 10.1186/s12913-015-1039-1
   CELLA DF, 1993, J CLIN ONCOL, V11, P570, DOI 10.1200/JCO.1993.11.3.570
   Cercek A, 2021, JNCI-J NATL CANCER I, V113, P1683, DOI 10.1093/jnci/djab124
   Chen FW, 2017, CLIN GASTROENTEROL H, V15, P728, DOI 10.1016/j.cgh.2016.10.038
   Chen YL, 2022, INT J CLIN ONCOL, V27, P749, DOI 10.1007/s10147-021-02101-9
   Cheng JX, 2011, BMC MED RES METHODOL, V11, DOI 10.1186/1471-2288-11-56
   Dong CX, 2021, CHINESE J CANCER RES, V33, P302, DOI 10.21147/j.issn.1000-9604.2021.03.02
   Eng C, 2022, LANCET ONCOL, V23, pE116, DOI 10.1016/S1470-2045(21)00588-X
   Gao XH, 2022, INT J SURG, V104, DOI 10.1016/j.ijsu.2022.106780
   Hospital Authority of National Health and Family Planning Commission of the Peoples Republic of China, 2018, Zhonghua Wai Ke Za Zhi, V56, P241, DOI 10.3760/cma.j.issn.0529-5815.2018.E001
   Kirzin S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103159
   Kneuertz PJ, 2015, JAMA SURG, V150, P402, DOI 10.1001/jamasurg.2014.3572
   Liu Y, 2022, BMJ OPEN, V12, DOI 10.1136/bmjopen-2021-054403
   Lui RN, 2019, CANCER EPIDEM BIOMAR, V28, P1275, DOI [10.1158/1055-9965.epi-18-1111, 10.1158/1055-9965.EPI-18-1111]
   Messersmith WA, 2019, J NATL COMPR CANC NE, V17, P599, DOI 10.6004/jnccn.2019.5014
   National Cancer Center China Expert Group of the Development of China Guideline for the Screening Early Detection and Early Treatment of Colorectal Cancer, 2021, Zhonghua Zhong Liu Za Zhi, V43, P16, DOI 10.3760/cma.j.cn112152-20210105-00010
   Patel SG, 2022, LANCET GASTROENTEROL, V7, P262, DOI 10.1016/S2468-1253(21)00426-X
   Roberts RO, 1996, J CLIN EPIDEMIOL, V49, P989, DOI 10.1016/0895-4356(96)00143-6
   Saraste D, 2020, BRIT J SURG, V107, P301, DOI 10.1002/bjs.11333
   Siegel RL, 2023, CA-CANCER J CLIN, V73, P17, DOI 10.3322/caac.21763
   Siegel RL, 2017, JNCI-J NATL CANCER I, V109, DOI 10.1093/jnci/djw322
   Vuik FER, 2021, ALIMENT PHARM THER, V54, P1463, DOI 10.1111/apt.16638
   Watson R, 2016, HUM PATHOL, V56, P163, DOI 10.1016/j.humpath.2016.06.010
   Wong CKH, 2012, J EVAL CLIN PRACT, V18, P1186, DOI 10.1111/j.1365-2753.2011.01753.x
   Zaborowski AM, 2020, BRIT J SURG, V107, P606, DOI 10.1002/bjs.11526
   Zaborowski A, 2021, JAMA SURG, V156, P865, DOI 10.1001/jamasurg.2021.2380
   Zhao H, 2004, J EPIDEMIOL, V14, P193, DOI 10.2188/jea.14.193
NR 29
TC 2
Z9 2
U1 4
U2 6
PU BMC
PI LONDON
PA CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
EI 1471-2407
J9 BMC CANCER
JI BMC Cancer
PD APR 20
PY 2024
VL 24
IS 1
AR 503
DI 10.1186/s12885-024-12278-7
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA OD9Q3
UT WOS:001205444300001
PM 38643082
OA gold
DA 2025-01-04
ER

PT J
AU Cerrito, MG
   Grassilli, E
AF Cerrito, Maria Grazia
   Grassilli, Emanuela
TI Identifying Novel Actionable Targets in Colon Cancer
SO BIOMEDICINES
LA English
DT Review
DE colon cancer; drug resistance; target therapy; high-throughput screen;
   si; sh-RNA screen; CRISPR; Cas9 knockout screen; drug re-purposing; drug
   re-positioning
ID HUMAN COLORECTAL-CANCER; SYNTHETIC LETHAL INTERACTIONS; CONSENSUS
   MOLECULAR SUBTYPES; GLYCOGEN-SYNTHASE KINASE-3; GROWTH-FACTOR
   RECEPTOR-1; ACQUIRED-RESISTANCE; BETA-CATENIN; PANCREATIC-CANCER;
   OSTEOSARCOMA CELLS; 3-BETA INHIBITION
AB Colorectal cancer is the fourth cause of death from cancer worldwide, mainly due to the high incidence of drug-resistance toward classic chemotherapeutic and newly targeted drugs. In the last decade or so, the development of novel high-throughput approaches, both genome-wide and chemical, allowed the identification of novel actionable targets and the development of the relative specific inhibitors to be used either to re-sensitize drug-resistant tumors (in combination with chemotherapy) or to be synthetic lethal for tumors with specific oncogenic mutations. Finally, high-throughput screening using FDA-approved libraries of "known" drugs uncovered new therapeutic applications of drugs (used alone or in combination) that have been in the clinic for decades for treating non-cancerous diseases (re-positioning or re-purposing approach). Thus, several novel actionable targets have been identified and some of them are already being tested in clinical trials, indicating that high-throughput approaches, especially those involving drug re-positioning, may lead in a near future to significant improvement of the therapy for colon cancer patients, especially in the context of a personalized approach, i.e., in defined subgroups of patients whose tumors carry certain mutations.
C1 [Cerrito, Maria Grazia; Grassilli, Emanuela] Univ Milano Bicocca, Dept Med & Surg, Via Cadore 48, I-20900 Monza, Italy.
C3 University of Milano-Bicocca
RP Grassilli, E (corresponding author), Univ Milano Bicocca, Dept Med & Surg, Via Cadore 48, I-20900 Monza, Italy.
EM mariagrazia.cerrito@unimib.it; emanuela.grassilli@unimib.it
RI Cerrito, Maria/AAA-1190-2019; grassilli, emanuela/L-7296-2013
OI Cerrito, Maria Grazia/0000-0002-3347-5817; grassilli,
   emanuela/0000-0001-5387-5925
CR Agafonov DE, 2016, SCIENCE, V351, P1416, DOI 10.1126/science.aad2085
   Ahluwalia A, 2013, BIOCHEM BIOPH RES CO, V437, P515, DOI 10.1016/j.bbrc.2013.06.096
   Ahn SY, 2017, ONCOTARGET, V8, P31842, DOI 10.18632/oncotarget.16252
   Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Al-Hadiya Badraddin M H, 2005, Profiles Drug Subst Excip Relat Methodol, V32, P67, DOI 10.1016/S0099-5428(05)32002-8
   Alazzouzi H, 2005, CLIN CANCER RES, V11, P2606, DOI 10.1158/1078-0432.CCR-04-1458
   Amado RG, 2008, J CLIN ONCOL, V26, P1626, DOI 10.1200/JCO.2007.14.7116
   Ando K, 2017, ONCOTARGET, V8, P43733, DOI 10.18632/oncotarget.16376
   Angerilli V, 2021, BIOMEDICINES, V9, DOI 10.3390/biomedicines9030318
   Bae JM, 2017, BRIT J CANCER, V116, P1012, DOI 10.1038/bjc.2017.52
   Barbosa EJ, 2019, EUR J PHARM BIOPHARM, V141, P58, DOI 10.1016/j.ejpb.2019.05.004
   Bardelli A, 2013, CANCER DISCOV, V3, P658, DOI 10.1158/2159-8290.CD-12-0558
   Basile D, 2019, CANCERS, V11, DOI 10.3390/cancers11060880
   Basler M, 2020, GENES IMMUN, V21, P273, DOI 10.1038/s41435-020-00109-1
   Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Behrens J, 1998, SCIENCE, V280, P596, DOI 10.1126/science.280.5363.596
   BOS JL, 1987, NATURE, V327, P293, DOI 10.1038/327293a0
   Bousquet MS, 2016, ACS CHEM BIOL, V11, P1322, DOI 10.1021/acschembio.5b00860
   Budenholzer L, 2017, J MOL BIOL, V429, P3500, DOI 10.1016/j.jmb.2017.05.027
   Burger JA, 2019, CANCER J, V25, P386, DOI 10.1097/PPO.0000000000000412
   Cai J, 2017, BIOCHEM BIOPH RES CO, V486, P184, DOI 10.1016/j.bbrc.2017.03.025
   Canon J, 2019, NATURE, V575, P217, DOI 10.1038/s41586-019-1694-1
   Caponigro F, 2009, EUR J CANCER, V45, P48, DOI 10.1016/j.ejca.2008.08.011
   Carethers JM, 2015, GASTROENTEROLOGY, V149, P1177, DOI 10.1053/j.gastro.2015.06.047
   Cerezo M, 2016, CANCER CELL, V29, P805, DOI 10.1016/j.ccell.2016.04.013
   Cerles O, 2017, MOL CANCER THER, V16, P300, DOI 10.1158/1535-7163.MCT-16-0326
   Cha PH, 2016, NAT CHEM BIOL, V12, P593, DOI [10.1038/NCHEMBIO.2103, 10.1038/nchembio.2103]
   Chakrabarti A, 2011, BIOTECHNOL BIOENG, V108, P2777, DOI 10.1002/bit.23282
   Chang DZ, 2009, J HEMATOL ONCOL, V2, DOI 10.1186/1756-8722-2-18
   Chen BZ, 2009, NAT CHEM BIOL, V5, P100, DOI 10.1038/nchembio.137
   Chen JF, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0098882
   Chen MY, 2009, BIOCHEMISTRY-US, V48, P10267, DOI 10.1021/bi9009677
   Cho YH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-19173-2
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Condrat CE, 2020, CELLS-BASEL, V9, DOI 10.3390/cells9020276
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cowley GS, 2014, SCI DATA, V1, DOI 10.1038/sdata.2014.35
   Cremolini C, 2015, NAT REV CLIN ONCOL, V12, P607, DOI 10.1038/nrclinonc.2015.129
   Dariya Begum, 2020, Critical Reviews in Oncogenesis, V25, P71, DOI 10.1615/CritRevOncog.2020035067
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Robertis M, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0912-z
   De Robertis M, 2017, CLIN CANCER RES, V23, P159, DOI 10.1158/1078-0432.CCR-16-0709
   Diaz LA, 2012, NATURE, V486, P537, DOI 10.1038/nature11219
   Dienstmann R, 2017, NAT REV CANCER, V17, P79, DOI 10.1038/nrc.2016.126
   Dietlein F, 2014, CANCER DISCOV, V4, P592, DOI 10.1158/2159-8290.CD-13-0907
   Ding KK, 2019, ONCOGENE, V38, P6414, DOI 10.1038/s41388-019-0888-1
   Domoto T, 2016, CANCER SCI, V107, P1363, DOI 10.1111/cas.13028
   Dong L, 2020, ISCIENCE, V23, DOI 10.1016/j.isci.2020.101351
   Effenberger KA, 2017, WIRES RNA, V8, DOI 10.1002/wrna.1381
   Emami KH, 2004, P NATL ACAD SCI USA, V101, P12682, DOI 10.1073/pnas.0404875101
   Fan F, 2005, ONCOGENE, V24, P2647, DOI 10.1038/sj.onc.1208246
   Fan F, 2011, BRIT J CANCER, V104, P1270, DOI 10.1038/bjc.2011.81
   Fang L, 2016, CANCER RES, V76, P891, DOI 10.1158/0008-5472.CAN-15-1519
   Flaherty KT, 2010, NEW ENGL J MED, V363, P809, DOI 10.1056/NEJMoa1002011
   Fleming NI, 2013, CANCER RES, V73, P725, DOI 10.1158/0008-5472.CAN-12-2706
   Floyd SR, 2013, NATURE, V498, P246, DOI 10.1038/nature12147
   Forde JE, 2007, CELL MOL LIFE SCI, V64, P1930, DOI 10.1007/s00018-007-7045-7
   Forsythe N, 2018, MOL CANCER THER, V17, P1280, DOI 10.1158/1535-7163.MCT-17-0603
   Fraile JM, 2017, J BIOL CHEM, V292, P4164, DOI 10.1074/jbc.M116.762757
   Francescangeli F, 2012, STEM CELLS, V30, P1819, DOI 10.1002/stem.1163
   Fransén K, 2004, CARCINOGENESIS, V25, P527, DOI 10.1093/carcin/bgh049
   Gan ZH, 2017, BIOL RES, V50, DOI 10.1186/s40659-017-0121-z
   Giatromanolaki A, 2007, EUR J CLIN INVEST, V37, P878, DOI 10.1111/j.1365-2362.2007.01866.x
   Giordano F, 2019, J EXP CLIN CANC RES, V38, DOI 10.1186/s13046-019-1199-7
   Grassilli E, 2016, ONCOGENE, V35, P4368, DOI 10.1038/onc.2015.504
   Grassilli E, 2013, CLIN CANCER RES, V19, P3820, DOI 10.1158/1078-0432.CCR-12-3289
   Guardavaccaro D, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002921
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hafner A, 2019, NAT REV MOL CELL BIO, V20, P199, DOI 10.1038/s41580-019-0110-x
   Hahne JC, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00226
   Hammond WA, 2016, THER ADV MED ONCOL, V8, P57, DOI 10.1177/1758834015614530
   Hasbal-Celikok G, 2021, ONCOL LETT, V21, DOI 10.3892/ol.2021.12470
   He ZS, 2020, ONCOGENE, V39, P3571, DOI 10.1038/s41388-020-1238-z
   Hinrichsen I, 2017, MOL CARCINOGEN, V56, P1816, DOI 10.1002/mc.22640
   Housman G, 2014, CANCERS, V6, P1769, DOI 10.3390/cancers6031769
   Hsu CW, 2016, ONCOTARGET, V7, P8172, DOI 10.18632/oncotarget.6995
   Hu Y, 2015, INT J MOL SCI, V16, P1928, DOI 10.3390/ijms16011928
   Huang SMA, 2009, NATURE, V461, P614, DOI 10.1038/nature08356
   Hwang SY, 2016, CELL REP, V16, P28, DOI 10.1016/j.celrep.2016.05.071
   Ibrahim IM, 2019, LIFE SCI, V226, P156, DOI 10.1016/j.lfs.2019.04.022
   Jackson DN, 2004, FASEB J, V18, P627, DOI 10.1096/fj.03-0979rev
   Jeon SH, 2007, J BIOL CHEM, V282, P14482, DOI 10.1074/jbc.M611129200
   Jeong WJ, 2012, SCI SIGNAL, V5, DOI 10.1126/scisignal.2002242
   Jiang J, 2018, AM J CANCER RES, V8, P1764
   Joseph RE, 2017, STRUCTURE, V25, P1481, DOI 10.1016/j.str.2017.07.014
   Kaelin WG, 2005, NAT REV CANCER, V5, P689, DOI 10.1038/nrc1691
   Karaman S, 2018, DEVELOPMENT, V145, DOI 10.1242/dev.151019
   Karapetis CS, 2008, NEW ENGL J MED, V359, P1757, DOI 10.1056/NEJMoa0804385
   Kawazoe H, 2012, BIOCHEM BIOPH RES CO, V423, P490, DOI 10.1016/j.bbrc.2012.05.147
   Khare Sharad, 2012, Methods Mol Biol, V863, P177, DOI 10.1007/978-1-61779-612-8_10
   Kitano A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055289
   Klotz-Noack K, 2020, CELL REP, V32, DOI 10.1016/j.celrep.2020.108184
   Kocarnik JM, 2015, GASTROENTEROL REP, V3, P269, DOI 10.1093/gastro/gov046
   Koerner J, 2017, ONCOTARGET, V8, P50873, DOI 10.18632/oncotarget.15141
   Kotliarova S, 2008, CANCER RES, V68, P6643, DOI 10.1158/0008-5472.CAN-08-0850
   Koulis C, 2020, CANCERS, V12, DOI 10.3390/cancers12040812
   Kreis NN, 2015, ONCOTARGET, V6, P6611, DOI 10.18632/oncotarget.2844
   Lavitrano M, 2020, J PATHOL, V250, P134, DOI 10.1002/path.5347
   Lee E, 2003, PLOS BIOL, V1, P116, DOI 10.1371/journal.pbio.0000010
   Lee SCW, 2016, NAT MED, V22, P976, DOI 10.1038/nm.4165
   Lepourcelet M, 2004, CANCER CELL, V5, P91, DOI 10.1016/S1535-6108(03)00334-9
   Li QH, 2021, FRONT ONCOL, V10, DOI 10.3389/fonc.2020.586789
   Lim YW, 2020, INT J MOL SCI, V21, DOI 10.3390/ijms21197151
   Lin JT, 2020, BBA-MOL CELL RES, V1867, DOI 10.1016/j.bbamcr.2020.118659
   Lin PC, 2015, WORLD J SURG ONCOL, V13, DOI 10.1186/s12957-015-0601-y
   Lin ZF, 2016, MOL CELL BIOCHEM, V422, P97, DOI 10.1007/s11010-016-2809-8
   Lisurek M, 2010, MOL DIVERS, V14, P401, DOI 10.1007/s11030-009-9187-z
   Liu YX, 2010, J PHARMACOL EXP THER, V335, P351, DOI 10.1124/jpet.110.172387
   Lund-Andersen C, 2014, RADIOTHER ONCOL, V110, P355, DOI 10.1016/j.radonc.2013.12.014
   Luo J, 2009, CELL, V137, P835, DOI 10.1016/j.cell.2009.05.006
   Mackay H, 2005, CLIN CANCER RES, V11, P5526, DOI 10.1158/1078-0432.CCR-05-0081
   Makarova OV, 2001, EMBO J, V20, P2553, DOI 10.1093/emboj/20.10.2553
   Marin JJG, 2020, CANCERS, V12, DOI 10.3390/cancers12092605
   Marisa L, 2013, PLOS MED, V10, DOI 10.1371/journal.pmed.1001453
   Masuda M, 2015, PHARMACOL THERAPEUT, V156, P1, DOI 10.1016/j.pharmthera.2015.10.009
   McCleland ML, 2016, J CLIN INVEST, V126, P639, DOI 10.1172/JCI83265
   Misale S, 2012, NATURE, V486, P532, DOI 10.1038/nature11156
   Miyaki M, 1999, ONCOGENE, V18, P3098, DOI 10.1038/sj.onc.1202642
   Miyashita K, 2009, CLIN CANCER RES, V15, P887, DOI 10.1158/1078-0432.CCR-08-0760
   Nagano H, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20225608
   Naik S, 2009, CLIN CANCER RES, V15, P7529, DOI 10.1158/1078-0432.CCR-09-0336
   Nygren P, 2014, ACTA ONCOL, V53, P427, DOI 10.3109/0284186X.2013.844359
   Nygren P, 2013, J CANCER RES CLIN, V139, P2133, DOI 10.1007/s00432-013-1539-5
   Ogino S, 2009, CANCER EPIDEM BIOMAR, V18, P2513, DOI 10.1158/1055-9965.EPI-09-0451
   Osada T, 2011, CANCER RES, V71, P4172, DOI 10.1158/0008-5472.CAN-10-3978
   Pan GT, 2021, CANCER COMMUN, V41, P199, DOI 10.1002/cac2.12138
   Pan Z, 2015, BIOL RES, V48, DOI 10.1186/s40659-015-0006-y
   Papageorgis P, 2011, CANCER RES, V71, P998, DOI 10.1158/0008-5472.CAN-09-3269
   Park KS, 2006, J CELL SCI, V119, P819, DOI 10.1242/jcs.02779
   Park SY, 2019, CLIN CANCER RES, V25, P1415, DOI 10.1158/1078-0432.CCR-18-1232
   Park YL, 2019, INT J CANCER, V144, P389, DOI 10.1002/ijc.31662
   Patnaik S, 2019, FRONT PHARMACOL, V10, DOI 10.3389/fphar.2019.00588
   Picardo F, 2019, CANCERS, V11, DOI 10.3390/cancers11101598
   Poli G, 2017, CHEMMEDCHEM, V12, P1917, DOI 10.1002/cmdc.201700563
   Popovici V, 2012, J CLIN ONCOL, V30, P1288, DOI 10.1200/JCO.2011.39.5814
   Prahallad A, 2015, CELL REP, V12, P1978, DOI 10.1016/j.celrep.2015.08.037
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Pyko IV, 2013, CARCINOGENESIS, V34, P2206, DOI 10.1093/carcin/bgt182
   Qian LW, 2002, CLIN CANCER RES, V8, P1223
   Reyland ME, 2016, PHARMACOL THERAPEUT, V165, P1, DOI 10.1016/j.pharmthera.2016.05.001
   Rodriguez RM, 2012, J MOL MED, V90, P587, DOI 10.1007/s00109-011-0837-0
   Romano G, 2016, ONCOTARGET, V7, P22077, DOI 10.18632/oncotarget.7895
   Rousseau A, 2018, NAT REV MOL CELL BIO, V19, P697, DOI 10.1038/s41580-018-0040-z
   Sabnis AJ, 2019, TRENDS MOL MED, V25, P185, DOI 10.1016/j.molmed.2018.12.009
   Sack U, 2011, JNCI-J NATL CANCER I, V103, P1018, DOI 10.1093/jnci/djr190
   Sala L, 2019, FRONT MOL NEUROSCI, V12, DOI 10.3389/fnmol.2019.00002
   Salovaara R, 2002, GUT, V51, P56, DOI 10.1136/gut.51.1.56
   Salvatore L, 2019, CANCERS, V11, DOI 10.3390/cancers11111765
   Sarvizadeh M, 2019, J CELL PHYSIOL, V234, P8533, DOI 10.1002/jcp.27806
   Shaik F, 2020, BIOMOLECULES, V10, DOI 10.3390/biom10121673
   Shakeel I, 2021, J DRUG TARGET, V29, P168, DOI 10.1080/1061186X.2020.1818760
   Shav-Tal Y, 2002, FEBS LETT, V531, P109, DOI 10.1016/S0014-5793(02)03447-6
   Shi CX, 2021, ONCOGENE, V40, P937, DOI 10.1038/s41388-020-01580-w
   Shimasaki T, 2012, J GASTROENTEROL, V47, P321, DOI 10.1007/s00535-011-0484-9
   Simbulan-Rosenthal CM, 2017, ONCOTARGET, V8, P12576, DOI 10.18632/oncotarget.14990
   Simons M, 2016, NAT REV MOL CELL BIO, V17, P611, DOI 10.1038/nrm.2016.87
   Singh SP, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0779-z
   Son DS, 2020, IMMUNE NETW, V20, DOI 10.4110/in.2020.20.e29
   Soulières D, 2010, CURR ONCOL, V17, pS31
   Steckel M, 2012, CELL RES, V22, P1227, DOI 10.1038/cr.2012.82
   Suliman MA, 2016, INT J MOL MED, V38, P776, DOI 10.3892/ijmm.2016.2689
   Sun SF, 2016, GENE, V584, P90, DOI 10.1016/j.gene.2016.03.020
   Tachiwana H, 2021, CURR MED CHEM, V28, P5098, DOI 10.2174/0929867328666210215114506
   Tang YA, 2018, P NATL ACAD SCI USA, V115, pE5990, DOI 10.1073/pnas.1801348115
   Thorne CA, 2015, NAT CHEM BIOL, V11, P58, DOI 10.1038/nchembio.1690
   Tie J, 2011, INT J CANCER, V128, P2075, DOI 10.1002/ijc.25555
   Tomé M, 2019, CANCER RES, V79, P5008, DOI 10.1158/0008-5472.CAN-19-0086
   Torres FC, 2015, CURR MED CHEM, V22, P1312, DOI 10.2174/0929867322666150114164032
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   Tsukamoto H, 2007, GYNECOL ONCOL, V107, P500, DOI 10.1016/j.ygyno.2007.08.058
   Valsasina B, 2012, MOL CANCER THER, V11, P1006, DOI 10.1158/1535-7163.MCT-11-0765
   van Leuken RJ, 2008, CELL CYCLE, V7, P2710, DOI 10.4161/cc.7.17.6553
   VOGELSTEIN B, 1988, NEW ENGL J MED, V319, P525, DOI 10.1056/NEJM198809013190901
   Wang LZ, 2019, INT J ONCOL, V55, P277, DOI 10.3892/ijo.2019.4818
   Wang RR, 2012, J BIOL CHEM, V287, P10738, DOI 10.1074/jbc.M111.323493
   Wang XB, 2016, MOL MED REP, V14, P301, DOI 10.3892/mmr.2016.5252
   Weichert W, 2005, WORLD J GASTROENTERO, V11, P5644, DOI 10.3748/wjg.v11.i36.5644
   White ME, 2019, CELL IMMUNOL, V337, P48, DOI 10.1016/j.cellimm.2019.02.001
   Wood LD, 2007, SCIENCE, V318, P1108, DOI 10.1126/science.1145720
   Worthley DL, 2007, WORLD J GASTROENTERO, V13, P3784
   Wu QB, 2018, MOL CLIN ONCOL, V8, P523, DOI 10.3892/mco.2018.1578
   Xing ZY, 2018, ONCOL LETT, V15, P5443, DOI [10.3892/ol.2018.808061, 10.3892/ol.2018.8061]
   Xu Y, 2018, MOL MED REP, V17, P4729, DOI 10.3892/mmr.2018.8421
   Yan CC, 2019, MED ONCOL, V36, DOI 10.1007/s12032-019-1308-7
   Yan P, 2016, CLIN CANCER RES, V22, P3037, DOI 10.1158/1078-0432.CCR-15-0939
   Younis NS, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-55666-x
   Yuan XW, 2017, ONCOL REP, V37, P2398, DOI 10.3892/or.2017.5454
   Yuan XW, 2015, ONCOL REP, V34, P823, DOI 10.3892/or.2015.4065
   Zhang B, 2018, ONCOL LETT, V16, P27, DOI 10.3892/ol.2018.8651
   Zhao Y, 2016, TUMOR BIOL, V37, P13167, DOI 10.1007/s13277-016-5212-x
   Zitvogel L, 2015, SCI TRANSL MED, V7, DOI 10.1126/scitranslmed.3010473
NR 192
TC 14
Z9 14
U1 0
U2 10
PU MDPI
PI BASEL
PA ST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND
EI 2227-9059
J9 BIOMEDICINES
JI Biomedicines
PD MAY
PY 2021
VL 9
IS 5
AR 579
DI 10.3390/biomedicines9050579
PG 40
WC Biochemistry & Molecular Biology; Medicine, Research & Experimental;
   Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Research & Experimental Medicine;
   Pharmacology & Pharmacy
GA SG4MN
UT WOS:000653415400001
PM 34065438
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Marvin, DL
   Heijboer, R
   ten Dijke, P
   Ritsma, L
AF Marvin, Dieuwke L.
   Heijboer, Rosan
   ten Dijke, Peter
   Ritsma, Laila
TI TGF-β signaling in liver metastasis
SO CLINICAL AND TRANSLATIONAL MEDICINE
LA English
DT Review
DE cancer; immunotherapy; liver metastasis; targeted therapy; transforming
   growth factor beta; tumor microenvironment
ID GROWTH-FACTOR-BETA; HEPATIC STELLATE CELLS; EPITHELIAL-MESENCHYMAL
   TRANSITION; SINUSOIDAL ENDOTHELIAL-CELLS; CCR1(+) MYELOID CELLS;
   COLORECTAL-CANCER; TUMOR-CELLS; PANCREATIC-CANCER;
   HEPATOCELLULAR-CARCINOMA; MIMICRY FORMATION
AB The presence of liver metastases drastically worsens the prognosis of cancer patients. The liver is the second most prevalent metastatic site in cancer patients, but systemic therapeutic opportunities that target liver metastases are still limited. To aid the discovery of novel treatment options for metastatic liver disease, we provide insight into the cellular and molecular steps required for liver colonization. For successful colonization in the liver, adaptation of tumor cells and surrounding stroma is essential. This includes the formation of a pre-metastatic niche, the creation of a fibrotic and immune suppressive environment, angiogenesis, and adaptation of tumor cells. We illustrate that transforming growth factor beta (TGF-beta) is a central cytokine in all these processes. At last, we devise that future research should focus on TGF-beta inhibitory strategies, especially in combination with immunotherapy. This promising systemic treatment strategy has potential to eliminate distant metastases as the efficacy of immunotherapy will be enhanced.
C1 [Marvin, Dieuwke L.; Heijboer, Rosan; ten Dijke, Peter; Ritsma, Laila] Leiden Univ, Dept Cell & Chem Biol, Med Ctr, NL-2333 ZC Leiden, Netherlands.
   [Marvin, Dieuwke L.; Heijboer, Rosan; ten Dijke, Peter; Ritsma, Laila] Leiden Univ, Oncode Inst, Med Ctr, NL-2333 ZC Leiden, Netherlands.
C3 Leiden University; Leiden University Medical Center (LUMC); Leiden
   University - Excl LUMC; Leiden University - Excl LUMC; Leiden
   University; Leiden University Medical Center (LUMC)
RP Ritsma, L (corresponding author), Leiden Univ, Dept Cell & Chem Biol, Med Ctr, NL-2333 ZC Leiden, Netherlands.; Ritsma, L (corresponding author), Leiden Univ, Oncode Inst, Med Ctr, NL-2333 ZC Leiden, Netherlands.
EM L.M.A.Ritsma@lumc.nl
RI Ritsma, Laila/AAZ-6620-2020; ten Dijke, Peter/AAG-4660-2021
OI Marvin, Dieuwke/0000-0001-6953-0489; Ritsma, Laila/0000-0002-0214-2008;
   ten Dijke, Peter/0000-0002-7234-342X
FU Dutch Organization for Scientific Research (NWO) [016.176.081]; LUMC
   Gisela Their Fellowship; Leids Universiteits fonds (LUF) [CWB 7204];
   Cancer Genomics consortium
FX This work is part of the research program 016.176.081 (Veni, L. Ritsma),
   which is financed by the Dutch Organization for Scientific Research
   (NWO). Also, we would like to thank the financial support of the LUMC
   Gisela Their Fellowship grant, and a subsidy from the Leids
   Universiteits fonds (LUF, CWB 7204, L. Ritsma), and subsidies from the
   Cancer Genomics consortium (L. Ritsma and P. ten Dijke).
CR Agarwala SS, 2014, CANCER-AM CANCER SOC, V120, P781, DOI 10.1002/cncr.28480
   Ai X, 2013, CANCER BIOL THER, V14, P1059, DOI 10.4161/cbt.26427
   Antognelli C, 2018, J CELL MOL MED, V22, P2865, DOI 10.1111/jcmm.13581
   Are C, 2010, HPB, V12, P498, DOI 10.1111/j.1477-2574.2010.00219.x
   Barkan D, 2010, CANCER RES, V70, P5706, DOI 10.1158/0008-5472.CAN-09-2356
   Batlle E, 2019, IMMUNITY, V50, P924, DOI 10.1016/j.immuni.2019.03.024
   Batlle R, 2019, NAT COMMUN, V10, DOI 10.1038/s41467-019-10946-y
   Bayon LG, 1996, HEPATOLOGY, V23, P1224, DOI 10.1002/hep.510230542
   Beerling E, 2011, J CELL SCI, V124, P299, DOI 10.1242/jcs.072728
   Benedicto A, 2019, SCI REP-UK, V9, DOI 10.1038/s41598-019-49473-7
   Bird TG, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan1230
   BOUWENS L, 1988, CANCER IMMUNOL IMMUN, V27, P137
   Brandes AA, 2016, NEURO-ONCOLOGY, V18, P1146, DOI 10.1093/neuonc/now009
   Brodt P, 2016, CLIN CANCER RES, V22, P5971, DOI 10.1158/1078-0432.CCR-16-0460
   Budczies J, 2015, ONCOTARGET, V6, P570, DOI 10.18632/oncotarget.2677
   Burnier JV, 2011, ONCOGENE, V30, P3766, DOI 10.1038/onc.2011.89
   Cai XB, 2018, J CELL MOL MED, V22, P5050, DOI 10.1111/jcmm.13787
   Calon A, 2015, NAT GENET, V47, P320, DOI 10.1038/ng.3225
   Calon A, 2012, CANCER CELL, V22, P571, DOI 10.1016/j.ccr.2012.08.013
   Carvajal RD, 2017, BRIT J OPHTHALMOL, V101, P38, DOI 10.1136/bjophthalmol-2016-309034
   Chen LM, 2014, NAT COMMUN, V5, DOI 10.1038/ncomms6241
   Chow FCL, 2019, WORLD J HEPATOL, V11, P150, DOI 10.4254/wjh.v11.i2.150
   Colak S, 2017, TRENDS CANCER, V3, P56, DOI 10.1016/j.trecan.2016.11.008
   Costa-Silva B, 2015, NAT CELL BIOL, V17, P816, DOI 10.1038/ncb3169
   Cox TR, 2014, CLIN CANCER RES, V20, P3637, DOI 10.1158/1078-0432.CCR-13-1059
   Cox TR, 2013, CANCER RES, V73, P1721, DOI 10.1158/0008-5472.CAN-12-2233
   DeBleser PJ, 1997, J HEPATOL, V26, P886, DOI 10.1016/S0168-8278(97)80257-7
   Derynck R, 2019, SCI SIGNAL, V12, DOI 10.1126/scisignal.aav5183
   Dillekås H, 2019, CANCER MED-US, V8, P5574, DOI 10.1002/cam4.2474
   Erin N, 2018, BREAST CANCER RES TR, V170, P235, DOI 10.1007/s10549-018-4752-8
   Ewing J., 1928, British Journal of Surgery, V16, P174, DOI DOI 10.1097/00000441-192808000-00014
   Fabregat I, 2018, FRONT ONCOL, V8, DOI 10.3389/fonc.2018.00357
   Fabregat I, 2016, FEBS J, V283, P2219, DOI 10.1111/febs.13665
   Fionda C, 2020, J CLIN MED, V9, DOI 10.3390/jcm9010143
   FOLKMAN J, 1990, JNCI-J NATL CANCER I, V82, P4, DOI 10.1093/jnci/82.1.4
   Formenti SC, 2018, CLIN CANCER RES, V24, P2493, DOI 10.1158/1078-0432.CCR-17-3322
   Frey RS, 1997, CANCER RES, V57, P628
   Friedman SL, 2008, GASTROENTEROLOGY, V134, P1655, DOI 10.1053/j.gastro.2008.03.003
   FRIESS H, 1993, GASTROENTEROLOGY, V105, P1846, DOI 10.1016/0016-5085(93)91084-U
   Ganesh K, 2018, IMMUNITY, V48, P626, DOI 10.1016/j.immuni.2018.03.037
   Gonzalez-Zubeldia I, 2015, CELL TISSUE RES, V359, P829, DOI 10.1007/s00441-014-2075-6
   Gordon-Weeks AN, 2017, HEPATOLOGY, V65, P1920, DOI 10.1002/hep.29088
   Groeneveldt C, 2020, TRENDS IMMUNOL, V41, P406, DOI 10.1016/j.it.2020.03.003
   Gupta P, 2019, PLOS ONE, V14, DOI 10.1371/journal.pone.0214534
   Hammad S, 2018, ARCH TOXICOL, V92, P2297, DOI 10.1007/s00204-018-2231-y
   Hao Y, 2019, INT J MOL SCI, V20, DOI 10.3390/ijms20112767
   Havel JJ, 2019, NAT REV CANCER, V19, P133, DOI 10.1038/s41568-019-0116-x
   Hess KR, 2006, CANCER, V106, P1624, DOI 10.1002/cncr.21778
   Holmgaard RB, 2018, J IMMUNOTHER CANCER, V6, DOI 10.1186/s40425-018-0356-4
   Horn LA, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000326
   Hoshino A, 2015, NATURE, V527, P329, DOI 10.1038/nature15756
   Hsu YL, 2020, ONCOGENE, V39, P739, DOI 10.1038/s41388-019-1024-y
   Hu CT, 2015, ONCOTARGET, V6, P22410, DOI 10.18632/oncotarget.4198
   Hu X, 2020, CLIN TRANSL MED, V9, DOI 10.1186/s40169-020-0264-3
   Huang CB, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14035
   Huang XM, 2013, J GASTROINTEST SURG, V17, P1283, DOI 10.1007/s11605-013-2194-5
   Huynh LK, 2019, BIOMOLECULES, V9, DOI 10.3390/biom9110743
   Itatani Y, 2013, GASTROENTEROLOGY, V145, P1064, DOI 10.1053/j.gastro.2013.07.033
   Ivanovic V, 2006, CLIN CHIM ACTA, V371, P191, DOI 10.1016/j.cca.2006.02.027
   JAQUES DP, 1995, ANN SURG, V221, P392, DOI 10.1097/00000658-199504000-00010
   Ji Q, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-14869-x
   Jin X, 2018, EXP CELL RES, V373, P34, DOI 10.1016/j.yexcr.2018.07.045
   Kanas Gena P, 2012, Clin Epidemiol, V4, P283, DOI 10.2147/CLEP.S34285
   Khatib AM, 2005, AM J PATHOL, V167, P749, DOI 10.1016/S0002-9440(10)62048-2
   Khatib AM, 1999, CANCER RES, V59, P1356
   Kitamura T, 2007, NAT GENET, V39, P467, DOI 10.1038/ng1997
   Korkut A, 2018, CELL SYST, V7, P422, DOI 10.1016/j.cels.2018.08.010
   Koudelkova P, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18102119
   Kow AWC, 2019, J GASTROINTEST ONCOL, V10, P1274, DOI 10.21037/jgo.2019.08.06
   Lambert AW, 2017, CELL, V168, P670, DOI 10.1016/j.cell.2016.11.037
   Lan Y, 2018, SCI TRANSL MED, V10, DOI 10.1126/scitranslmed.aan5488
   Lee JW, 2019, NATURE, V567, P249, DOI 10.1038/s41586-019-1004-y
   Li Q, 2019, EBIOMEDICINE, V49, P157, DOI 10.1016/j.ebiom.2019.10.037
   Li S, 2020, ONCOIMMUNOLOGY, V9, DOI 10.1080/2162402X.2020.1746113
   Lind H, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000433
   Liu CS, 2013, J CLIN INVEST, V123, P1138, DOI 10.1172/JCI63836
   LORIGAN JG, 1991, AM J ROENTGENOL, V157, P1279, DOI 10.2214/ajr.157.6.1950883
   Luangmonkong T, 2017, BRIT J PHARMACOL, V174, P3107, DOI 10.1111/bph.13945
   Luo Dianzhong, 2002, Comp Hepatol, V1, P2, DOI 10.1186/1476-5926-1-2
   Luzzi KJ, 1998, AM J PATHOL, V153, P865, DOI 10.1016/S0002-9440(10)65628-3
   Ma R, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0425-0
   Mao RF, 2011, CELL SIGNAL, V23, P222, DOI 10.1016/j.cellsig.2010.09.006
   Mariathasan S, 2018, NATURE, V554, P544, DOI 10.1038/nature25501
   Massagué J, 2012, NAT REV MOL CELL BIO, V13, P616, DOI 10.1038/nrm3434
   Medina-Echeverz J, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0096799
   Mekala S, 2018, CAN J PHYSIOL PHARM, V96, P728, DOI 10.1139/cjpp-2017-0768
   Melisi D, 2018, BRIT J CANCER, V119, P1208, DOI 10.1038/s41416-018-0246-z
   Mendoza L, 2004, CANCER RES, V64, P304, DOI 10.1158/0008-5472.CAN-03-1829
   Mielgo A, 2020, CSH PERSPECT MED, V10, DOI 10.1101/cshperspect.a037259
   Morris JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090353
   Ng S, 2016, CANCER RES, V76, P5683, DOI 10.1158/0008-5472.CAN-16-0386
   Oh SH, 2018, J HEPATOL, V69, P359, DOI 10.1016/j.jhep.2018.05.008
   Olaso E, 1997, HEPATOLOGY, V26, P634, DOI 10.1002/hep.510260315
   Olaso E, 2003, HEPATOLOGY, V37, P674, DOI 10.1053/jhep.2003.50068
   Ou JJ, 2014, CARCINOGENESIS, V35, P1661, DOI 10.1093/carcin/bgu090
   Paschos KA, 2010, ANTICANCER RES, V30, P2161
   Penafuerte C, 2011, J IMMUNOL, V186, P6933, DOI 10.4049/jimmunol.1003816
   Picon A, 1998, CANCER EPIDEM BIOMAR, V7, P497
   Poisson J, 2017, J HEPATOL, V66, P212, DOI 10.1016/j.jhep.2016.07.009
   Quaranta V, 2018, CANCER RES, V78, P4253, DOI 10.1158/0008-5472.CAN-17-3876
   Rani B, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0384-5
   REED JA, 1994, AM J PATHOL, V145, P97
   Ritsma L, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3004394
   Sawada T, 2006, Adv Med Sci, V51, P60
   Scherbarth S, 1997, CANCER RES, V57, P4105
   Shimizu S, 2000, JPN J CANCER RES, V91, P1285, DOI 10.1111/j.1349-7006.2000.tb00916.x
   SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7
   SMEDSROD B, 1994, GUT, V35, P1509, DOI 10.1136/gut.35.11.1509
   Tan HX, 2020, CANCER BIOL THER, V21, P258, DOI 10.1080/15384047.2019.1685157
   Tauriello DVF, 2018, NATURE, V554, P538, DOI 10.1038/nature25492
   Teraoka H, 2001, BRIT J CANCER, V85, P612, DOI 10.1054/bjoc.2001.1941
   Teraoka H, 2001, INT J ONCOL, V19, P709
   Trefts E, 2017, CURR BIOL, V27, pR1147, DOI 10.1016/j.cub.2017.09.019
   Tsuchida T, 2017, NAT REV GASTRO HEPAT, V14, P397, DOI 10.1038/nrgastro.2017.38
   Tsushima H, 2001, CLIN CANCER RES, V7, P1258
   Tu KS, 2015, HEPATOLOGY, V61, P361, DOI 10.1002/hep.27251
   Tumeh PC, 2017, CANCER IMMUNOL RES, V5, P417, DOI 10.1158/2326-6066.CIR-16-0325
   van Beuge MM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056442
   Vidal-Vanaclocha F, 2008, CANCER MICROENVIRON, V1, P113, DOI 10.1007/s12307-008-0011-6
   Vollmar B, 2009, PHYSIOL REV, V89, P1269, DOI 10.1152/physrev.00027.2008
   Voorneveld PW, 2013, EUR J CANCER PREV, V22, P420, DOI 10.1097/CEJ.0b013e32835e88e2
   Wirz W, 2008, DIFFERENTIATION, V76, P784, DOI 10.1111/j.1432-0436.2007.00260.x
   Woodward JKL, 2005, INVEST OPHTH VIS SCI, V46, P3473, DOI 10.1167/iovs.04-1311
   Yamashita M, 2008, MOL CELL, V31, P918, DOI 10.1016/j.molcel.2008.09.002
   Yang JN, 2016, CANCER LETT, V383, P18, DOI 10.1016/j.canlet.2016.09.012
   Yang J, 2020, NAT REV MOL CELL BIO, V21, P341, DOI 10.1038/s41580-020-0237-9
   Yang YA, 2002, J CLIN INVEST, V109, P1607, DOI 10.1172/JCI200215333
   Yeung OWH, 2015, J HEPATOL, V62, P607, DOI 10.1016/j.jhep.2014.10.029
   Yi Y, 2013, J HEPATOL, V58, P977, DOI 10.1016/j.jhep.2012.12.015
   Zeisberg M, 2007, J BIOL CHEM, V282, P23337, DOI 10.1074/jbc.M700194200
   Zeng ZC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-07810-w
   Zhang BX, 2010, GASTROENTEROLOGY, V138, P969, DOI 10.1053/j.gastro.2009.11.004
   Zhang BX, 2009, CANCER LETT, V277, P114, DOI 10.1016/j.canlet.2008.11.035
   Zhang CJ, 2018, TECHNOL CANCER RES T, V17, DOI 10.1177/1533033818764497
   Zhang F, 2016, ONCOTARGET, V7, P52294, DOI 10.18632/oncotarget.10561
   Zhang X, 2020, ACTA BIOCH BIOPH SIN, V52, P411, DOI 10.1093/abbs/gmaa014
   Zhang YE, 2017, CSH PERSPECT BIOL, V9, DOI 10.1101/cshperspect.a022129
   Zhao F, 2018, CANCER IMMUNOL RES, V6, P1459, DOI 10.1158/2326-6066.CIR-18-0086
   Zubeldia IG, 2013, EXP CELL RES, V319, P12, DOI 10.1016/j.yexcr.2012.11.004
NR 140
TC 27
Z9 27
U1 1
U2 17
PU JOHN WILEY & SONS LTD
PI CHICHESTER
PA THE ATRIUM, SOUTHERN GATE, CHICHESTER PO19 8SQ, W SUSSEX, ENGLAND
SN 2001-1326
J9 CLIN TRANSL MED
JI Clin. Transl. Med.
PD NOV
PY 2020
VL 10
IS 7
AR e160
DI 10.1002/ctm2.160
PG 20
WC Oncology; Medicine, Research & Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Research & Experimental Medicine
GA PA7LZ
UT WOS:000595813500008
PM 33252863
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Liu, PY
   Wang, YJ
   Li, X
AF Liu, Pingyu
   Wang, Yijun
   Li, Xin
TI Targeting the untargetable KRAS in cancer therapy
SO ACTA PHARMACEUTICA SINICA B
LA English
DT Review
DE KRAS; Oncogene; Mutation; Cancer; Inhibitor; Targeted therapy
ID ONCOGENIC KRAS; RAS MUTATIONS; COLORECTAL-CANCER; TUMOR-DEVELOPMENT;
   MUTANT; INHIBITORS; BRAF; INFLAMMATION; ASSOCIATION; PROMOTES
AB RAS is one of the most well-known proto-oncogenes. Its gain-of-function mutations occur in approximately 30% of all human cancers. As the most frequently mutated RAS isoform, KRAS is intensively studied in the past years. Despite its well-recognized importance in cancer malignancy, continuous efforts in the past three decades failed to develop approved therapies for KRAS mutant cancer. KRAS has thus long been considered to be undruggable. Encouragingly, recent studies have aroused renewed interest in the development of KRAS inhibitors either directly towards mutant KRAS or against the crucial steps required for KRAS activation. This review summarizes the most recent progress in the exploration of KRAS-targeted anticancer strategies and hopefully provides useful insights for the field. (C) 2019 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.
C1 [Liu, Pingyu; Wang, Yijun] Nanjing Med Univ, Pharm Dept, Affiliated Hosp 2, Nanjing 210011, Jiangsu, Peoples R China.
   [Li, Xin] Nanjing Med Univ, Sch Pharm, Dept Clin Pharm, Nanjing 211166, Jiangsu, Peoples R China.
C3 Nanjing Medical University; Nanjing Medical University
RP Liu, PY (corresponding author), Nanjing Med Univ, Pharm Dept, Affiliated Hosp 2, Nanjing 210011, Jiangsu, Peoples R China.
EM judy_liupy@163.com
CR Aguirre AJ, 2018, CSH PERSPECT MED, V8, DOI 10.1101/cshperspect.a031518
   Ahearn IM, 2012, NAT REV MOL CELL BIO, V13, P39, DOI 10.1038/nrm3255
   Ambrogio C, 2018, CELL, V172, P857, DOI 10.1016/j.cell.2017.12.020
   Andreyev HJN, 1998, J NATL CANCER I, V90, P675, DOI 10.1093/jnci/90.9.675
   Bayne LJ, 2012, CANCER CELL, V21, P822, DOI 10.1016/j.ccr.2012.04.025
   Berndt N, 2011, NAT REV CANCER, V11, P775, DOI 10.1038/nrc3151
   Bos JL, 2007, CELL, V129, P865, DOI 10.1016/j.cell.2007.05.018
   Bryant KL, 2014, TRENDS BIOCHEM SCI, V39, P91, DOI 10.1016/j.tibs.2013.12.004
   Burgess MR, 2017, CELL, V168, P817, DOI 10.1016/j.cell.2017.01.020
   Chan DA, 2011, NAT REV DRUG DISCOV, V10, P351, DOI 10.1038/nrd3374
   Chandra A, 2012, NAT CELL BIOL, V14, P148, DOI 10.1038/ncb2394
   Cong JJ, 2018, CELL METAB, V28, P243, DOI 10.1016/j.cmet.2018.06.021
   Corcoran RB, 2013, CANCER CELL, V23, P121, DOI 10.1016/j.ccr.2012.11.007
   Cox AD, 2015, CLIN CANCER RES, V21, P1819, DOI 10.1158/1078-0432.CCR-14-3214
   Cox AD, 2014, NAT REV DRUG DISCOV, V13, P828, DOI 10.1038/nrd4389
   De Roock W, 2010, JAMA-J AM MED ASSOC, V304, P1812, DOI 10.1001/jama.2010.1535
   di Magliano MP, 2013, GASTROENTEROLOGY, V144, P1220, DOI 10.1053/j.gastro.2013.01.071
   Dietlein F, 2015, CELL, V162, P146, DOI 10.1016/j.cell.2015.05.053
   Dong ZY, 2017, CLIN CANCER RES, V23, P3012, DOI 10.1158/1078-0432.CCR-16-2554
   Edkins S, 2006, CANCER BIOL THER, V5, P928, DOI 10.4161/cbt.5.8.3251
   Fukuda A, 2011, CANCER CELL, V19, P441, DOI 10.1016/j.ccr.2011.03.002
   Huang M, 2014, TRENDS PHARMACOL SCI, V35, P41, DOI 10.1016/j.tips.2013.11.004
   Hutton JE, 2016, MOL CELL PROTEOMICS, V15, P2924, DOI 10.1074/mcp.M116.058925
   Jancík S, 2010, J BIOMED BIOTECHNOL, DOI 10.1155/2010/150960
   Janes MR, 2018, CELL, V172, P578, DOI 10.1016/j.cell.2018.01.006
   Keohavong P, 1996, CLIN CANCER RES, V2, P411
   Kompier LC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013821
   Konstantinopoulos PA, 2007, NAT REV DRUG DISCOV, V6, P540, DOI 10.1038/nrd2221
   Kortlever RM, 2017, CELL, V171, P1301, DOI 10.1016/j.cell.2017.11.013
   Kumar MS, 2012, CELL, V149, P642, DOI 10.1016/j.cell.2012.02.059
   Lavoie H, 2015, NAT REV MOL CELL BIO, V16, P281, DOI 10.1038/nrm3979
   Lito P, 2016, SCIENCE, V351, P604, DOI 10.1126/science.aad6204
   Liu FF, 2018, ACTA PHARM SIN B, V8, P552, DOI 10.1016/j.apsb.2018.01.008
   Liu M, 2010, P NATL ACAD SCI USA, V107, P6471, DOI 10.1073/pnas.0908396107
   Mayers JR, 2016, SCIENCE, V353, P1161, DOI 10.1126/science.aaf5171
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070
   Ostrem JM, 2013, NATURE, V503, P548, DOI 10.1038/nature12796
   Ostrem JML, 2016, NAT REV DRUG DISCOV, V15, P771, DOI 10.1038/nrd.2016.139
   Padanad MS, 2016, CELL REP, V16, P1614, DOI 10.1016/j.celrep.2016.07.009
   Papke B, 2017, SCIENCE, V355, P1158, DOI 10.1126/science.aam7622
   Papke B, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11360
   Patricelli MP, 2016, CANCER DISCOV, V6, P316, DOI 10.1158/2159-8290.CD-15-1105
   Prior IA, 2012, CANCER RES, V72, P2457, DOI 10.1158/0008-5472.CAN-11-2612
   Pylayeva-Gupta Y, 2012, CANCER CELL, V21, P836, DOI 10.1016/j.ccr.2012.04.024
   Pylayeva-Gupta Y, 2011, NAT REV CANCER, V11, P761, DOI 10.1038/nrc3106
   Sakamoto K, 2017, BIOCHEM BIOPH RES CO, V484, P605, DOI 10.1016/j.bbrc.2017.01.147
   Scheffzek K, 1997, SCIENCE, V277, P333, DOI 10.1126/science.277.5324.333
   Shipman L, 2016, NAT REV CANCER, V16, P127, DOI 10.1038/nrc.2016.13
   Singh A, 2018, FASEB J, V32, P7018, DOI 10.1096/fj.201800204
   Singh H, 2015, J CLIN ONCOL, V33, P3650, DOI 10.1200/JCO.2015.62.1052
   Son J, 2013, NATURE, V496, P101, DOI 10.1038/nature12040
   Stephen AG, 2014, CANCER CELL, V25, P272, DOI 10.1016/j.ccr.2014.02.017
   Tyner JW, 2009, BLOOD, V113, P1749, DOI 10.1182/blood-2008-04-152157
   Vallejo A, 2017, NAT COMMUN, V8, DOI 10.1038/ncomms14294
   Westcott PMK, 2015, NATURE, V517, P489, DOI 10.1038/nature13898
   Young A, 2013, CANCER DISCOV, V3, P112, DOI 10.1158/2159-8290.CD-12-0231
   Yun J, 2015, SCIENCE, V350, P1391, DOI 10.1126/science.aaa5004
   Yuneva MO, 2012, CELL METAB, V15, P157, DOI 10.1016/j.cmet.2011.12.015
   Zimmermann G, 2013, NATURE, V497, P638, DOI 10.1038/nature12205
NR 59
TC 243
Z9 297
U1 18
U2 204
PU INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
PI BEIJING
PA C/O EDITORIAL BOARD OF ACTA PHARMACEUTICA SINICA, 1 XIANNONGTAN ST,
   BEIJING, 100050, PEOPLES R CHINA
SN 2211-3835
EI 2211-3843
J9 ACTA PHARM SIN B
JI Acta Pharm. Sin. B
PD SEP
PY 2019
VL 9
IS 5
BP 871
EP 879
DI 10.1016/j.apsb.2019.03.002
PG 9
WC Pharmacology & Pharmacy
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Pharmacology & Pharmacy
GA IZ7NU
UT WOS:000487282700001
PM 31649840
OA gold, Green Published
HC Y
HP N
DA 2025-01-04
ER

PT J
AU Evrard, D
   Szturz, P
   Tijeras-Raballand, A
   Astorgues-Xerri, L
   Abitbol, C
   Paradis, V
   Raymond, E
   Albert, S
   Barry, B
   Faivre, S
AF Evrard, Diane
   Szturz, Petr
   Tijeras-Raballand, Annemilai
   Astorgues-Xerri, Lucile
   Abitbol, Chloe
   Paradis, Valerie
   Raymond, Eric
   Albert, Sebastien
   Barry, Beatrix
   Faivre, Sandrine
TI Macrophages in the microenvironment of head and neck cancer: potential
   targets for cancer therapy
SO ORAL ONCOLOGY
LA English
DT Review
DE Tumor-associated macrophages (TAMs); Tumor microenvironment; Protumoral
   activities; Targeted therapy; Cancer treatment; CSF-1R inhibitor
ID TUMOR-ASSOCIATED MACROPHAGES; SQUAMOUS-CELL CARCINOMA; ENCAPSULATED
   MURAMYL TRIPEPTIDE; STIMULATING FACTOR-I; COLORECTAL-CANCER;
   PANCREATIC-CANCER; INFILTRATING MACROPHAGES; PD-1 EXPRESSION; MYELOID
   CELLS; LUNG-CANCER
AB The microenvironment of solid tumors has become a promising target for future therapies modulating immune cells. Patients with advanced head and neck cancer, which still portends a poor outcome, are particularly in need of innovative approaches. In oral squamous cell carcinoma, high density of tumor-associated macrophages (TAMs) appears consistently associated with poor prognosis, whereas data are currently limited for other head and neck sites. Several approaches to block TAMs have been investigated, including TAMs inactivation by means of the colony stimulating factor 1 (CSF-1)/CSF-1 receptor (CSF-1R) inhibitors or strategies to reprogram TAMs from M2 protumoral phenotype toward M1 antitumoral phenotype. This review focuses on both prognostic and therapeutic aspects related to TAMs in head and neck carcinomas.
C1 [Evrard, Diane; Abitbol, Chloe; Albert, Sebastien; Barry, Beatrix] Hop Bichat Claude Bernard, Head & Neck Surg Dept, Paris, France.
   [Szturz, Petr] CHU Vaudois, Oncol Dept, Lausanne, Switzerland.
   [Tijeras-Raballand, Annemilai; Astorgues-Xerri, Lucile] Hop Lariboisiere, AFR Oncol, Paris, France.
   [Paradis, Valerie] Hop Beaujon, Pathol Dept, Clichy, France.
   [Raymond, Eric] Grp Hosp Paris St Joseph, Med Oncol Dept, Paris, France.
   [Faivre, Sandrine] Hop Univ Paris Nord Val de Seine HUPVNS, Med Oncol Dept, Paris, France.
   [Faivre, Sandrine] Univ Paris 07, Paris, France.
C3 Assistance Publique Hopitaux Paris (APHP); Universite Paris Cite;
   Hopital Universitaire Bichat-Claude Bernard - APHP; University of
   Lausanne; Centre Hospitalier Universitaire Vaudois (CHUV); Assistance
   Publique Hopitaux Paris (APHP); Universite Paris Cite; Hopital
   Universitaire Lariboisiere-Fernand-Widal - APHP; Universite Paris Cite;
   Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Beaujon
   - APHP; Universite Paris Cite; Hopital Paris Saint-Joseph; Assistance
   Publique Hopitaux Paris (APHP); Universite Paris Cite
RP Faivre, S (corresponding author), Beaujon Univ Hosp, AP HP, Dept Med Oncol, 6th Floor,100 Blvd Gen, F-92110 Clichy, France.
EM prof.faivre@gmail.com
RI Szturz, Petr/AAJ-3278-2021; Paradis, Valerie/X-9097-2019
OI evrard, diane/0000-0003-2462-4902; Szturz, Petr/0000-0001-9705-4168
FU Fondation Nelia et Amadeo Barletta (FNAB)
FX D. Evrard is a recipient of a research grant from Fondation Nelia et
   Amadeo Barletta (FNAB).
CR Alves AM, 2018, J ORAL PATHOL MED, V47, P460, DOI 10.1111/jop.12643
   [Anonymous], J IMMUNOL BALTIM MD
   [Anonymous], J IMMUNOL BALTIM MD
   [Anonymous], J IMMUNOL BALTIM MD
   [Anonymous], J IMMUNOL BALTIM MD
   [Anonymous], PLOS ONE
   Bagul N, 2016, J CLIN DIAGN RES, V10, pZC81, DOI 10.7860/JCDR/2016/13924.7670
   Bility MT, 2014, PLOS PATHOG, V10, DOI 10.1371/journal.ppat.1004032
   Biswas SK, 2010, NAT IMMUNOL, V11, P889, DOI 10.1038/ni.1937
   Brown EJ, 2001, TRENDS CELL BIOL, V11, P130, DOI 10.1016/S0962-8924(00)01906-1
   Brown JR, 2005, J CLIN ONCOL, V23, P2840, DOI 10.1200/JCO.2005.09.051
   Butowski N, 2016, NEURO-ONCOLOGY, V18, P557, DOI 10.1093/neuonc/nov245
   Chen J, 2012, CANCER IMMUNOL IMMUN, V61, P101, DOI 10.1007/s00262-011-1094-3
   Chen TH, 1999, PLAST RECONSTR SURG, V104, P1276, DOI 10.1097/00006534-199910000-00006
   Chen XJ, 2017, J CANCER, V8, P3868, DOI 10.7150/jca.21444
   Chitu V, 2006, CURR OPIN IMMUNOL, V18, P39, DOI 10.1016/j.coi.2005.11.006
   Coward J, 2011, CLIN CANCER RES, V17, P6083, DOI 10.1158/1078-0432.CCR-11-0945
   De Palma M, 2013, CANCER CELL, V23, P277, DOI 10.1016/j.ccr.2013.02.013
   Deligeoroglou Efthimios, 2013, Infect Dis Obstet Gynecol, V2013, P540850, DOI 10.1155/2013/540850
   Dheilly E, 2017, MOL THER, V25, P523, DOI 10.1016/j.ymthe.2016.11.006
   Dovas A, 2013, J MICROSC-OXFORD, V251, P261, DOI 10.1111/j.1365-2818.2012.03667.x
   Edelman MJ, 2008, J CLIN ONCOL, V26, P848, DOI 10.1200/JCO.2007.13.8081
   Edelman MJ, 2017, J CLIN ONCOL, V35, P2184, DOI 10.1200/JCO.2016.71.3743
   FIDLER IJ, 1985, J BIOL RESP MODIF, V4, P298
   Fujii N, 2012, J ORAL PATHOL MED, V41, P444, DOI 10.1111/j.1600-0714.2012.01127.x
   Galdiero MR, 2013, J CELL PHYSIOL, V228, P1404, DOI 10.1002/jcp.24260
   Gianan MAV, 1998, CANCER BIOTHER RADIO, V13, P363, DOI 10.1089/cbr.1998.13.363
   Gordon S, 2010, IMMUNITY, V32, P593, DOI 10.1016/j.immuni.2010.05.007
   Gordon SR, 2017, NATURE, V545, P495, DOI 10.1038/nature22396
   Hamilton JA, 2008, NAT REV IMMUNOL, V8, P533, DOI 10.1038/nri2356
   Hammes LS, 2007, GYNECOL ONCOL, V105, P157, DOI 10.1016/j.ygyno.2006.11.023
   He KF, 2014, BIOMED RES INT-UK, V2014, DOI 10.1155/2014/838632
   Heusinkveld M, 2011, J TRANSL MED, V9, DOI 10.1186/1479-5876-9-216
   Hoves S, 2011, J IMMUNOL, V187, P1166, DOI 10.4049/jimmunol.1001670
   Howlader N., 2017, SEER Cancer Statistics Review
   Hu Y, 2016, J EXP CLIN CANC RES, V35, DOI 10.1186/s13046-015-0281-z
   Hume DA, 2012, BLOOD, V119, P1810, DOI 10.1182/blood-2011-09-379214
   Jaiswal S, 2009, CELL, V138, P271, DOI 10.1016/j.cell.2009.05.046
   Kioi M, 2010, J CLIN INVEST, V120, P694, DOI 10.1172/JCI40283
   Klimp AH, 2000, ANTICANCER RES, V20, P2585
   Kostine M, 2018, ONCOIMMUNOLOGY, V7, DOI 10.1080/2162402X.2017.1386828
   Kurahara H, 2011, J SURG RES, V167, pE211, DOI 10.1016/j.jss.2009.05.026
   Lee CH, 2014, ANN SURG ONCOL, V21, P1031, DOI 10.1245/s10434-013-3400-0
   Lee CC, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-018-06268-0
   Lepique AP, 2009, CLIN CANCER RES, V15, P4391, DOI 10.1158/1078-0432.CCR-09-0489
   Lewis CE, 2006, CANCER RES, V66, P605, DOI 10.1158/0008-5472.CAN-05-4005
   Li EC, 2015, ONCOTARGET, V6, P8900, DOI 10.18632/oncotarget.3561
   Lin Jia-Ying, 2011, Chin J Cancer, V30, P280
   Liu J, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0137345
   Liu SY, 2008, ORAL ONCOL, V44, P277, DOI 10.1016/j.oraloncology.2007.02.007
   Lyford-Pike S, 2013, CANCER RES, V73, P1733, DOI 10.1158/0008-5472.CAN-12-2384
   Ma JL, 2010, BMC CANCER, V10, DOI 10.1186/1471-2407-10-112
   MacEwen EG, 1999, CLIN CANCER RES, V5, P4249
   Majeti R, 2009, CELL, V138, P286, DOI 10.1016/j.cell.2009.05.045
   Mantovani A, 2008, LANCET, V371, P771, DOI 10.1016/S0140-6736(08)60241-X
   Mantovani A, 2007, EUR J IMMUNOL, V37, P14, DOI 10.1002/eji.200636910
   Mantovani A, 2017, NAT REV CLIN ONCOL, V14, P399, DOI 10.1038/nrclinonc.2016.217
   Mantovani A, 2010, CURR OPIN IMMUNOL, V22, P231, DOI 10.1016/j.coi.2010.01.009
   Marcus B, 2004, CANCER-AM CANCER SOC, V101, P2779, DOI 10.1002/cncr.20701
   Martin AW., 2011, Diagnostic Immunohistochemistry, P156, DOI 10.1016/B978-1-4160-5766-6.00010-8
   Matlung HL, 2017, IMMUNOL REV, V276, P145, DOI 10.1111/imr.12527
   Mattox AK, 2017, CANCER RES, V77, P6365, DOI 10.1158/0008-5472.CAN-16-3453
   Mitchem JB, 2013, CANCER RES, V73, P1128, DOI 10.1158/0008-5472.CAN-12-2731
   Murdoch C, 2004, BLOOD, V104, P2224, DOI 10.1182/blood-2004-03-1109
   Murray PJ, 2014, IMMUNITY, V41, P14, DOI 10.1016/j.immuni.2014.06.008
   Naeim F., 2018, ATLAS HEMATOPATHOLOG, P29, DOI [DOI 10.1016/B978-0-12-809843-1.00002-4, 10.1016/B978-0-12-809843-1.00002-4]
   Nardin A, 2006, CURR CANCER DRUG TAR, V6, P123, DOI 10.2174/156800906776056473
   Nywening TM, 2016, LANCET ONCOL, V17, P651, DOI 10.1016/S1470-2045(16)00078-4
   Oguejiofor K, 2017, ONCOTARGET, V8, P14416, DOI 10.18632/oncotarget.14796
   Ohri CM, 2009, EUR RESPIR J, V33, P118, DOI 10.1183/09031936.00065708
   Oldenborg PA, 2000, SCIENCE, V288, P2051, DOI 10.1126/science.288.5473.2051
   Ong CJ, 2007, BLOOD, V110, P1942, DOI 10.1182/blood-2007-03-079699
   Ong SM, 2012, EUR J IMMUNOL, V42, P89, DOI 10.1002/eji.201141825
   Oronsky B, 2017, EXPERT OPIN INV DRUG, V26, P109, DOI 10.1080/13543784.2017.1268600
   Papadopoulos KP, 2017, CLIN CANCER RES, V23, P5703, DOI 10.1158/1078-0432.CCR-16-3261
   Pass HI, 2016, ONCOTARGET, V7, P56408, DOI 10.18632/oncotarget.10895
   Peng Juan, 2006, Ai Zheng, V25, P1340
   Peyraud F, 2017, CURR ONCOL REP, V19, DOI 10.1007/s11912-017-0634-1
   Pyonteck SM, 2013, NAT MED, V19, P1264, DOI 10.1038/nm.3337
   Qian BZ, 2011, NATURE, V475, P222, DOI 10.1038/nature10138
   Rauh MJ, 2004, BIOCHEM SOC T, V32, P785, DOI 10.1042/BST0320785
   Reid T, 2015, LANCET ONCOL, V16, P1133, DOI 10.1016/S1470-2045(15)00089-3
   Ries CH, 2014, CANCER CELL, V25, P846, DOI 10.1016/j.ccr.2014.05.016
   Ruffell B, 2012, TRENDS IMMUNOL, V33, P119, DOI 10.1016/j.it.2011.12.001
   Sakakura K, 2016, LAB INVEST, V96, P994, DOI 10.1038/labinvest.2016.70
   Sanford DE, 2013, CLIN CANCER RES, V19, P3404, DOI 10.1158/1078-0432.CCR-13-0525
   Scognamiglio T, 2018, HEAD NECK PATHOL, V12, P221, DOI 10.1007/s12105-017-0857-3
   Seminerio Imelda, 2018, Oncotarget, V9, P11046, DOI 10.18632/oncotarget.24306
   Shabo I, 2008, INT J CANCER, V123, P780, DOI 10.1002/ijc.23527
   Shiga K, 2004, TOHOKU J EXP MED, V204, P163, DOI 10.1620/tjem.204.163
   Shiga K, 2012, ONCOL LETT, V3, P238, DOI 10.3892/ol.2011.451
   Shree T, 2011, GENE DEV, V25, P2465, DOI 10.1101/gad.180331.111
   Smola S, 2017, VIRUSES-BASEL, V9, DOI 10.3390/v9090254
   Soeda S, 2008, GYNECOL ONCOL, V109, P122, DOI 10.1016/j.ygyno.2007.12.033
   Strachan DC, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.26968
   Tap WD, 2015, NEW ENGL J MED, V373, P428, DOI 10.1056/NEJMoa1411366
   Tassa C, 2011, ACCOUNTS CHEM RES, V44, P842, DOI 10.1021/ar200084x
   Teske E, 1998, ANTICANCER RES, V18, P1015
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Uehara T, 2015, BIOMED RES INT-UK, V2015, DOI 10.1155/2015/820813
   Vail DM, 1995, CLIN CANCER RES, V1, P1165
   Weiskopf K, 2017, EUR J CANCER, V76, P100, DOI 10.1016/j.ejca.2017.02.013
   Weissleder R, 2014, NAT MATER, V13, P125, DOI [10.1038/nmat3780, 10.1038/NMAT3780]
   Willingham SB, 2012, P NATL ACAD SCI USA, V109, P6662, DOI 10.1073/pnas.1121623109
   Wynn TA, 2013, NATURE, V496, P445, DOI 10.1038/nature12034
   Xu JY, 2013, CANCER RES, V73, P2782, DOI 10.1158/0008-5472.CAN-12-3981
   Yamauchi K, 2012, ANTICANCER RES, V32, P39
   Yang L, 2017, BIOMARK RES, V5, DOI 10.1186/s40364-017-0106-7
   Ye XJ, 2016, ONCOTARGET, V7, P81305, DOI 10.18632/oncotarget.12874
   Yu GT, 2015, ONCOTARGET, V6, P42067, DOI 10.18632/oncotarget.5955
   Zeng DD, 2016, ONCOTARGET, V7, P83040, DOI 10.18632/oncotarget.13349
   Zhang Y, 2013, EUR J CANCER, V49, P3320, DOI 10.1016/j.ejca.2013.06.005
   Zhao L, 2013, HEPATOLOGY, V57, P829, DOI 10.1002/hep.26094
   Zhu Y, 2014, CANCER RES, V74, P5057, DOI 10.1158/0008-5472.CAN-13-3723
   Zijlmans HJMAA, 2007, CANCER, V109, P556, DOI 10.1002/cncr.22428
NR 115
TC 69
Z9 70
U1 2
U2 21
PU ELSEVIER
PI AMSTERDAM
PA RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS
SN 1368-8375
EI 1879-0593
J9 ORAL ONCOL
JI Oral Oncol.
PD JAN
PY 2019
VL 88
BP 29
EP 38
DI 10.1016/j.oraloncology.2018.10.040
PG 10
WC Oncology; Dentistry, Oral Surgery & Medicine
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Dentistry, Oral Surgery & Medicine
GA HG3QY
UT WOS:000454890700006
PM 30616794
DA 2025-01-04
ER

PT J
AU Ros, J
   Saoudi, N
   Baraibar, I
   Salva, F
   Tabernero, J
   Elez, E
AF Ros, Javierd
   Saoudi, Nadia
   Baraibar, Iosune
   Salva, Francesc
   Tabernero, Josep
   Elez, Elena
TI Encorafenib plus cetuximab for the treatment of
   <i>BRAF-V600E</i>-mutated metastatic colorectal cancer
SO THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
LA English
DT Review
DE BRAF mutation; cetuximab; colorectal cancer; consensus molecular
   subtype; encorafenib; transcriptomic signatures
ID BRAF MUTATION; 1ST-LINE TREATMENT; SUBGROUP ANALYSES; RANDOMIZED-TRIAL;
   RAS MUTATIONS; COLON CANCERS; OPEN-LABEL; PHASE IB; INHIBITION; SURVIVAL
AB B-type RAF (BRAF)-V600E mutations in metastatic colorectal cancer (mCRC) have been described in up to 12% of the patients. This mutation confers a bad prognostic and poor response with standard chemotherapy. Unlike the scenario for BRAF mutant melanoma, successful BRAF blockade in mCRC has emerged as a complex path, primarily due to the complex underlying biology of mCRC. The BEACON trial has reshaped the therapeutic landscape of BRAF mCRC demonstrating the benefit of the BRAF inhibitor encorafenib in combination with the anti-epidermal growth factor receptor cetuximab. This paper aims to review the main features of BRAF mCRC as well as to review the development of targeted therapy and biomarkers in this specific population. Finally, a deep insight into the underlying biology and molecular classification of BRAF-V600E mCRC has also been performed. The words 'BRAF-V600E mutation', 'colorectal cancer', 'BRAF inhibitors', 'consensus molecular subtypes', 'encorafenib', and 'cetuximab' were used to identify the clinical trials from phase I to phase III related to the development of BRAF inhibitors in this population. A deep search among international meetings (American Society of Clinical Oncology and European Society of Medical Oncology) has been performed to incorporate the last trials presented. BRAF-V600E mCRC is a challenging disease, mostly because of its molecular biology. The BEACON trial has been the most important therapeutic change in the last decade. Nevertheless, new information regarding biomarkers or novel combinations including BRAF inhibitors plus immune checkpoint inhibitors are also promising.
C1 [Elez, Elena] Vall Dhebron Inst Oncol, Dept Med Oncol, Ctr Cellex, Carrer de Natzaret 115 117, Barcelona 08035, Spain.
   [Ros, Javierd; Saoudi, Nadia; Baraibar, Iosune; Salva, Francesc; Tabernero, Josep] Vall Dhebron Inst Oncol, Dept Med Oncol, Barcelona, Spain.
   [Ros, Javierd] Univ Campania Luigi Vanvitelli, Dept Precis Med, Med Oncol, Naples, Italy.
C3 Vall d'Hebron Institut d'Oncologia (VHIO); Vall d'Hebron Institut
   d'Oncologia (VHIO); Universita della Campania Vanvitelli
RP Elez, E (corresponding author), Vall Dhebron Inst Oncol, Dept Med Oncol, Ctr Cellex, Carrer de Natzaret 115 117, Barcelona 08035, Spain.
EM meelez@vhio.net
RI Gonzalez, Nadia/AAM-9354-2021; Baraibar, Iosune/GXF-7067-2022; Ros,
   Javier/HKF-1171-2023
OI Ros, Javier/0000-0002-8137-5415; Salva, Francesc/0000-0001-9240-4907;
   Saoudi Gonzalez, Nadia/0000-0001-6044-1703
CR Aderka D, 2021, ANN ONCOL, V32, pS214, DOI 10.1016/j.annonc.2021.05.052
   André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140
   [Anonymous], 2020, CA Cancer J Clin, V70, P313, DOI [10.3322/caac.21492, 10.3322/caac.21609]
   Clarke CN, 2015, J GASTROINTEST ONCOL, V6, P660, DOI 10.3978/j.issn.2078-6891.2015.077
   Corcoran R, 2020, ANN ONCOL, V31, pS226, DOI 10.1016/j.annonc.2020.04.041
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2015, J CLIN ONCOL, V33, P4023, DOI 10.1200/JCO.2015.63.2471
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Cremolini C, 2017, ESMO OPEN, V2, DOI 10.1136/esmoopen-2017-000241
   Cremolini C, 2015, LANCET ONCOL, V16, P1306, DOI 10.1016/S1470-2045(15)00122-9
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Roock W, 2010, LANCET ONCOL, V11, P753, DOI 10.1016/S1470-2045(10)70130-3
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Élez E, 2021, ANN ONCOL, V32, pS226, DOI 10.1016/j.annonc.2021.06.010
   Gomez-Roca C. A., 2014, Ann Oncol, DOI [10.1093/annonc/mdu333.38, DOI 10.1093/ANNONC/MDU333.38]
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534
   Kopetz S, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.162
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Le DT, 2020, J CLIN ONCOL, V38, P11, DOI 10.1200/JCO.19.02107
   Loree JM, 2021, CLIN CANCER RES, V27, P52, DOI 10.1158/1078-0432.CCR-20-2710
   Loupakis F, 2019, EUR J CANCER, V118, P121, DOI 10.1016/j.ejca.2019.06.008
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Mayer RJ, 2015, NEW ENGL J MED, V372, P1909, DOI 10.1056/NEJMoa1414325
   Morris VK, 2022, J CLIN ONCOL, V40, DOI 10.1200/JCO.2022.40.4_suppl.012
   Overman MJ, 2018, J CLIN ONCOL, V36, P773, DOI 10.1200/JCO.2017.76.9901
   Pietrantonio F, 2016, CANCER DISCOV, V6, P963, DOI 10.1158/2159-8290.CD-16-0297
   Pietrantonio F, 2015, EUR J CANCER, V51, P587, DOI 10.1016/j.ejca.2015.01.054
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   Randon G, 2022, EUR J CANCER, V161, P90, DOI 10.1016/j.ejca.2021.11.018
   Ros J, 2021, THER ADV MED ONCOL, V13, DOI 10.1177/1758835921992974
   Montañá JR, 2020, J CLIN ONCOL, V38
   Siegel RL., 2020, CA-CANCER J CLIN, V70, P145
   Stintzing S, 2017, EUR J CANCER, V79, P50, DOI 10.1016/j.ejca.2017.03.023
   Sullivan RJ, 2020, CLIN CANCER RES, V26, P5102, DOI 10.1158/1078-0432.CCR-19-3550
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Van Cutsem E, 2021, ANN ONCOL, V32, pS222, DOI 10.1016/j.annonc.2021.05.014
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Van Cutsem E, 2015, J CLIN ONCOL, V33, P692, DOI 10.1200/JCO.2014.59.4812
   Van Cutsem E, 2012, J CLIN ONCOL, V30, P3499, DOI 10.1200/JCO.2012.42.8201
   Van Cutsem E, 2011, J CLIN ONCOL, V29, P2011, DOI 10.1200/JCO.2010.33.5091
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   Vecchione L, 2016, CELL, V165, P317, DOI 10.1016/j.cell.2016.02.059
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Wan PTC, 2004, CELL, V116, P855, DOI 10.1016/S0092-8674(04)00215-6
   Weisenberger DJ, 2006, NAT GENET, V38, P787, DOI 10.1038/ng1834
   Yaeger R, 2019, CLIN CANCER RES, V25, P7089, DOI 10.1158/1078-0432.CCR-19-2004
   Yaeger R, 2017, CANCER RES, V77, P6513, DOI 10.1158/0008-5472.CAN-17-0768
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001
NR 58
TC 5
Z9 5
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
EI 1756-2848
J9 THER ADV GASTROENTER
JI Ther. Adv. Gastroenterol.
PD JUL
PY 2022
VL 15
AR 17562848221110644
DI 10.1177/17562848221110644
PG 14
WC Gastroenterology & Hepatology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Gastroenterology & Hepatology
GA 3B1SF
UT WOS:000827727300001
PM 35812780
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Rodriquenz, MG
   Ciardiello, D
   Latiano, TP
   Maiorano, BA
   Martinelli, E
   Silvestris, N
   Ciardiello, F
   Maiello, E
AF Rodriquenz, Maria Grazia
   Ciardiello, Davide
   Latiano, Tiziana Pia
   Maiorano, Brigida Anna
   Martinelli, Erika
   Silvestris, Nicola
   Ciardiello, Fortunato
   Maiello, Evaristo
TI Exploring biological heterogeneity and implications on novel treatment
   paradigm in BRAF-mutant metastatic colorectal cancer
SO CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
LA English
DT Review
DE BRAF; Colorectal cancer; V600E mutation; Non-V600E mutation; Targeted
   therapy; Treatment algorithm; Secondary resistance; Immunotherapy
ID ACQUIRED-RESISTANCE; MUTATION STATUS; MICROSATELLITE INSTABILITY;
   CHEMOTHERAPY TOXICITY; DOSE-ESCALATION; OLDER PATIENTS; COLON-CANCER;
   PHASE IB; INHIBITION; MEK
AB Approximatively 8-15% of patients with metastatic colorectal cancer (mCRC) harbor mutation in BRAF gene. Recent advances in molecular biology enabled a better knowledge of the molecular heterogeneity within BRAF mutant (BRAFMT) CRCs, including high rate of overlapping with MSI-H status and detection of non-V600E mutations related to more favorable behavior. Treatment armamentarium has been rapidly growing in this subgroup and includes targeted combinations and immunotherapy for concomitant MSI-H patients, thereby making BRAFMT mCRC an innovative model for precision oncology. Nevertheless, duration of responses to targeted strategies remains unsatisfactory due to the development of secondary resistance, which is currently the field of major clinical research on BRAFMT mCRC. This review explores the molecular, clinical and therapeutic landscape of BRAFMT mCRC as well as an update on current treatment strategies and future perspectives in light of the heterogeneity of BRAF-mutated disease. Furthermore, a novel treatment algorithm for BRAFMT mCRC will be proposed.
C1 [Rodriquenz, Maria Grazia; Ciardiello, Davide; Latiano, Tiziana Pia; Maiorano, Brigida Anna; Maiello, Evaristo] Fdn Casa Sollievo Sofferenza IRCCS, Oncol Unit, I-71013 San Giovanni Rotondo, Italy.
   [Ciardiello, Davide; Martinelli, Erika; Ciardiello, Fortunato] Univ Campania L Vanvitelli, Dipartimento Med Precis, Oncol Med, Naples, Italy.
   [Maiorano, Brigida Anna] Fdn A Gemelli Policlin IRCCS, Comprehens Canc Ctr, Med Oncol Unit, I-00168 Rome, Italy.
   [Silvestris, Nicola] Univ Messina, Dept Human Pathol G Barresi, Med Oncol Unit, Messina, Italy.
C3 Universita della Campania Vanvitelli; University of Messina
RP Rodriquenz, MG (corresponding author), Fdn Casa Sollievo Sofferenza IRCCS, Oncol Unit, I-71013 San Giovanni Rotondo, Italy.
EM mg.rodriquenz@operapadrepio.it
RI Latiano, Tiziana/AAB-4088-2021; rodriquenz, maria/AAR-9176-2020;
   Maiello, Evaristo/C-5224-2017; Ciardiello, Davide/AAC-4613-2022;
   Maiorano, Brigida/AHB-1496-2022
OI Maiorano, Brigida Anna/0000-0001-5423-3158
FU Bayer; Roche; Merck-Serono; Amgen; AstraZeneca; Takeda
FX The authors declare the following financial interests/personal
   relationships which may be considered as potential competing interests.
   Maria Grazia Rodriquenz, Tiziana Pia Latiano, Brigida Anna Maiorano
   declare no conflict of interest, Davide Ciardiello has received travel
   support from Sanofi. Erika Martinelli has served as advisor and speaker
   for Astra Zeneca, Amgen, Bayer, Merck-Serono, Roche, Sanofi, Servier,
   Pierre Fabre. Fortunato Ciardiello has served as advisor and speaker for
   Roche, Amgen, Merck-Serono, Pfizer, Sanofi, Bayer, Servier, BMS,
   Cellgene, Lilly. Received institutional Research Grants form Bayer,
   Roche, Merck-Serono, Amgen, AstraZeneca, Takeda. Nicola Silvestris has
   served as advisor and speaker for Roche, Celgene, Lilly and MSD.
   Evaristo Maiello has served as advisor and speaker for Astra Zeneca, Eli
   Lilly, Servier, Sanofi Genzyme, Roche, Merck, Eisai, Pfize
CR Ahronian LG, 2015, CANCER DISCOV, V5, P358, DOI 10.1158/2159-8290.CD-14-1518
   Barras D, 2017, CLIN CANCER RES, V23, P104, DOI 10.1158/1078-0432.CCR-16-0140
   BIG BANG study (EPOC1703), 2020, ESMO OPEN, V5
   Chen GM, 2018, MOL CANCER THER, V17, P806, DOI 10.1158/1535-7163.MCT-17-0561
   Chen SH, 2018, ONCOGENE, V37, P821, DOI 10.1038/onc.2017.384
   Chin H.M., 2019, J. Immunother. Precis. Oncol, V2, P10
   Chu JE, 2020, CLIN CANCER RES, V26, P4599, DOI 10.1158/1078-0432.CCR-20-1024
   Ciardiello F, 2014, ANN ONCOL, V25, P1756, DOI 10.1093/annonc/mdu230
   Clancy C., 2013, COLORECTAL DIS, V15, P711
   Concoran R.B., 2015, J CLIN ONCOL, V33, P4023
   Corcoran R, 2020, ANN ONCOL, V31, pS226, DOI 10.1016/j.annonc.2020.04.041
   Corcoran RB, 2018, CANCER DISCOV, V8, P428, DOI 10.1158/2159-8290.CD-17-1226
   Corcoran RB, 2012, CANCER DISCOV, V2, P227, DOI 10.1158/2159-8290.CD-11-0341
   Cremolini C, 2015, ANN ONCOL, V26, P2092, DOI 10.1093/annonc/mdv290
   Cremolini C, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.20.01225
   Cremolini C, 2020, LANCET ONCOL, V21, P497, DOI 10.1016/S1470-2045(19)30862-9
   Dankner M., J CLIN ONCOL, V39, P3089
   Davies H, 2002, NATURE, V417, P949, DOI 10.1038/nature00766
   De Falco V, 2019, ESMO OPEN, V4, DOI 10.1136/esmoopen-2020-000813
   Dhillon AS, 2007, ONCOGENE, V26, P3279, DOI 10.1038/sj.onc.1210421
   Di Nicolantonio F, 2021, NAT REV CLIN ONCOL, V18, P506, DOI 10.1038/s41571-021-00495-z
   Elez E., 2021, 2021 WORLD C GASTROI
   Extermann M, 2012, CANCER-AM CANCER SOC, V118, P3377, DOI 10.1002/cncr.26646
   Falchook GS, 2012, LANCET, V379, P1893, DOI 10.1016/S0140-6736(12)60398-5
   Gagnière J, 2020, ANN SURG, V271, P147, DOI 10.1097/SLA.0000000000002968
   Gelsomino F, 2020, CANCERS, V12, DOI 10.3390/cancers12041022
   Gomez-Roca C. A., 2014, Ann Oncol, DOI [10.1093/annonc/mdu333.38, DOI 10.1093/ANNONC/MDU333.38]
   Grothey A, 2013, LANCET, V381, P303, DOI 10.1016/S0140-6736(12)61900-X
   Guinney J, 2015, NAT MED, V21, P1350, DOI 10.1038/nm.3967
   Hatzivassiliou G, 2012, MOL CANCER THER, V11, P1143, DOI 10.1158/1535-7163.MCT-11-1010
   Hochster H., 2015, ANN ONCOL, V26, piv108
   Hong DS, 2016, CANCER DISCOV, V6, P1352, DOI 10.1158/2159-8290.CD-16-0050
   Huijberts S.C.F.A., BJC, V124, P176
   Huijberts SCFA, 2021, BRIT J CANCER, V124, P176, DOI 10.1038/s41416-020-01147-2
   Hurria A, 2016, J CLIN ONCOL, V34, P2366, DOI 10.1200/JCO.2015.65.4327
   Hyman DM, 2015, NEW ENGL J MED, V373, P726, DOI 10.1056/NEJMoa1502309
   Isnaldi E, 2019, J TRANSL MED, V17, DOI 10.1186/s12967-019-1879-2
   Johnson B., 2018, ONCOLOGIST, V23, P1306
   Jones JC, 2017, J CLIN ONCOL, V35, P2624, DOI 10.1200/JCO.2016.71.4394
   Kopetz S, 2019, NEW ENGL J MED, V381, P1632, DOI 10.1056/NEJMoa1908075
   Kopetz S, 2010, J CLIN ONCOL, V28, DOI 10.1200/jco.2010.28.15_suppl.3534
   Kopetz S., 2021, JCO, V39, pTPS3619
   Kopetz S., JCO, V39, P3513
   Kopetz S., J CLIN ONCOL, V38, P3583
   Kopetz S., 2021, J CLIN ONCOL, V39, P3513
   Kopetz S., J CLIN ONCOL, V39, P3583
   Kopetz S, 2021, J CLIN ONCOL, V39, P285, DOI 10.1200/JCO.20.01994
   Kopetz S, 2020, J CLIN ONCOL, V38
   Kopetz S, 2015, J CLIN ONCOL, V33, P4032, DOI 10.1200/JCO.2015.63.2497
   Loupakis F, 2019, EUR J CANCER, V118, P121, DOI 10.1016/j.ejca.2019.06.008
   Loupakis F, 2016, BRIT J CANCER, V114, P30, DOI 10.1038/bjc.2015.399
   Manzano JL, 2016, ANN TRANSL MED, V4, DOI 10.21037/atm.2016.06.07
   Mao ML, 2013, CLIN CANCER RES, V19, P657, DOI 10.1158/1078-0432.CCR-11-1446
   Martinez-Tapia C, 2017, EUR J CANCER, V83, P211, DOI 10.1016/j.ejca.2017.06.027
   Memorial Sloan Kattering Cancer Center, STUD BIN ENC ADV BRA
   Michaloglou C, 2008, ONCOGENE, V27, P877, DOI 10.1038/sj.onc.1210704
   Middleton G, 2020, CLIN CANCER RES, V26, P2466, DOI 10.1158/1078-0432.CCR-19-3579
   Moretto R, 2021, EUR J CANCER, V153, P16, DOI 10.1016/j.ejca.2021.04.039
   Morkel M, 2015, ONCOTARGET, V6, P20785, DOI 10.18632/oncotarget.4750
   Morris EJ, 2013, CANCER DISCOV, V3, P742, DOI 10.1158/2159-8290.CD-13-0070
   Morris V, 2014, CLIN COLORECTAL CANC, V13, P164, DOI 10.1016/j.clcc.2014.06.001
   N.C.C. Network, 2021, NCCN CLIN PRACTICE G
   Oddo D, 2017, BRIT J CANCER, V117, P347, DOI 10.1038/bjc.2017.196
   Oddo D, 2016, CANCER RES, V76, P4504, DOI 10.1158/0008-5472.CAN-16-0396
   Ogino S, 2009, GUT, V58, P90, DOI 10.1136/gut.2008.155473
   Owusu C, 2017, J GERIATR ONCOL, V8, P356, DOI 10.1016/j.jgo.2017.07.004
   Pek M, 2017, ONCOGENE, V36, P4975, DOI 10.1038/onc.2017.120
   Prahallad A, 2012, NATURE, V483, P100, DOI 10.1038/nature10868
   RAK J, 1995, CANCER RES, V55, P4575
   Rak J, 2000, CANCER RES, V60, P490
   Randon G, 2022, EUR J CANCER, V161, P90, DOI 10.1016/j.ejca.2021.11.018
   Montañá JR, 2020, J CLIN ONCOL, V38
   Safaee Ardekani Gholamreza, 2012, PLoS One, V7, pe47054, DOI 10.1371/journal.pone.0047054
   Schirripa M, 2019, CLIN CANCER RES, V25, P3954, DOI 10.1158/1078-0432.CCR-19-0311
   Seligmann JF, 2017, ANN ONCOL, V28, P562, DOI 10.1093/annonc/mdw645
   Shimada Y, 2018, J SURG RES, V232, P72, DOI 10.1016/j.jss.2018.06.020
   Shiu KK, 2020, J CLIN ONCOL, V38, DOI 10.1200/JCO.2020.38.18_suppl.LBA4
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P145, DOI 10.3322/caac.21601
   Smeby J, 2018, ANN ONCOL, V29, P1227, DOI 10.1093/annonc/mdy085
   Solit DB, 2006, NATURE, V439, P358, DOI 10.1038/nature04304
   Tabernero J, 2021, J CLIN ONCOL, V39, P273, DOI 10.1200/JCO.20.02088
   Tabernero J, 2016, J CLIN ONCOL, V34, DOI 10.1200/JCO.2016.34.15_suppl.3544
   Taieb J, 2016, JAMA ONCOL, V2, P643, DOI 10.1001/jamaoncol.2015.5225
   Tol J, 2009, NEW ENGL J MED, V361, P98, DOI 10.1056/NEJMc0904160
   Tosi F., 2017, CLIN CLORECTAL CANC, V16, P153
   Tran B, 2011, CANCER-AM CANCER SOC, V117, P4623, DOI 10.1002/cncr.26086
   University Health Network Toronto, TOR BIN ENC TREATM
   Ursem Carling, 2018, Gastrointest Cancer, V8, P13, DOI 10.2147/GICTT.S125940
   Vakana E, 2017, ONCOTARGET, V8, P9251, DOI 10.18632/oncotarget.14002
   Van Cutsem E, 2021, ANN ONCOL, V32, pS222, DOI 10.1016/j.annonc.2021.05.014
   Van Cutsem E, 2014, ANN ONCOL, V25, P1, DOI 10.1093/annonc/mdu260
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   van Geel RMJM, 2017, CANCER DISCOV, V7, P610, DOI 10.1158/2159-8290.CD-16-0795
   Venderbosch S, 2014, CLIN CANCER RES, V20, P5322, DOI 10.1158/1078-0432.CCR-14-0332
   Wang JH, 2019, J CANCER, V10, P2332, DOI 10.7150/jca.30789
   Wirapati P, 2017, J CLIN ONCOL, V35, DOI 10.1200/JCO.2017.35.15_suppl.3538
   Yaeger R, 2019, CLIN CANCER RES, V25, P7089, DOI 10.1158/1078-0432.CCR-19-2004
   Yaeger R, 2017, CANCER RES, V77, P6513, DOI 10.1158/0008-5472.CAN-17-0768
   Yaeger R, 2015, CLIN CANCER RES, V21, P1313, DOI 10.1158/1078-0432.CCR-14-2779
   Yao Z, 2017, NATURE, V548, P234, DOI 10.1038/nature23291
   Yao Z, 2015, CANCER CELL, V28, P370, DOI 10.1016/j.ccell.2015.08.001
   Yoshino T, 2018, J CLIN ONCOL, V36, DOI 10.1200/JCO.2018.36.4_suppl.622
NR 102
TC 7
Z9 7
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA
SN 1040-8428
EI 1879-0461
J9 CRIT REV ONCOL HEMAT
JI Crit. Rev. Oncol./Hematol.
PD MAY
PY 2022
VL 173
AR 103657
DI 10.1016/j.critrevonc.2022.103657
EA MAR 2022
PG 15
WC Oncology; Hematology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Hematology
GA 1F8SA
UT WOS:000795430500002
PM 35337969
DA 2025-01-04
ER

PT J
AU Xu, T
   Lu, JZ
   An, HX
AF Xu, Tong
   Lu, Jiezhen
   An, Hanxiang
TI The relative change in regulatory T cells/T helper lymphocytes ratio as
   parameter for prediction of therapy efficacy in metastatic colorectal
   cancer patients
SO ONCOTARGET
LA English
DT Article
DE colorectal cancer; regulatory T cells; therapy efficacy; T helper
   lymphocytes; change
ID IMMUNE-INFLAMMATION INDEX; NEUTROPHIL-LYMPHOCYTE; TUMOR RESPONSE;
   CHEMOTHERAPY; SUPPRESSION; PROGNOSIS; FOXP3; IMMUNOTHERAPY; EXPRESSION
AB Purpose: The evaluation of regulatory T (Treg) (CD4+CD25(high) CD127(neg)) lymphocyte count with respect to the T helper (TH) (CD4) number has been shown to represent the main immune parameters capable of signifying the functional status of the anticancer immunity in cancer patients. This study is aimed to explore a correlation between therapy efficacy and changes in Treg/TH ratio and other biochemical and haematological parameters in patients with metastatic colorectal cancer (mCRC).
   Experimental Design: Measurements of regulatory T cells were performed by flow cytometric analysis pre-and post-therapies in a prospective study.
   Results: We investigated levels of Treg/TH ratio in the peripheral blood of 25 mCRC patients pre-and post-chemotherapy +/- targeted therapy. There were significant differences in levels of Treg/TH ratio pre-and post-treatments among patients on study, patients with partial response (PR), stable disease (SD) and progressive disease (PD) (P= 0.012, P= 0.011, and P= 0.043, respectively). Moreover, the relative change in Treg/TH ratio showed statistically significant difference among patients with PD as compared to those with PR and SD. Our findings demonstrated a statistically significant strong correlation between the relative change in Treg/TH ratio and therapeutic response. (Spearman's rho= 0.788/p< 0.001).
   Conclusions: The monitoring of the relative change in Treg/TH ratio could constitute a promising clinical index for response prediction and a timely change in regimen. Further prospective evaluations of these parameters investigated, particularly their association with overall survival, are warranted.
C1 [Xu, Tong; Lu, Jiezhen; An, Hanxiang] Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen Canc Hosp, Xiamen, Fujian, Peoples R China.
C3 Xiamen University
RP Xu, T; An, HX (corresponding author), Xiamen Univ, Affiliated Hosp 1, Dept Med Oncol, Xiamen Canc Hosp, Xiamen, Fujian, Peoples R China.
EM tong_xu@126.com; anhanxiang@xmu.edu.cn
OI An, Han-Xiang/0000-0002-3453-9149
FU Fujian Provincial Department of Science and Technology [2060203]
FX This study was supported by the Fujian Provincial Department of Science
   and Technology under Grant (No. 2060203).
CR Adotevi O, 2010, J IMMUNOTHER, V33, P991, DOI 10.1097/CJI.0b013e3181f4c208
   [Anonymous], VACCINES
   Bacic D, 2011, COLLEGIUM ANTROPOL, V35, P65
   Betts G, 2012, GUT, V61, P1163, DOI 10.1136/gutjnl-2011-300970
   Burton OT, 2010, J IMMUNOL, V185, P2754, DOI 10.4049/jimmunol.1001365
   Chaput N, 2009, GUT, V58, P520, DOI 10.1136/gut.2008.158824
   Clarke SL, 2006, PLOS ONE, V1, DOI 10.1371/journal.pone.0000129
   deLeeuw RJ, 2012, CLIN CANCER RES, V18, P3022, DOI 10.1158/1078-0432.CCR-11-3216
   Finke JH, 2008, CLIN CANCER RES, V14, P6674, DOI 10.1158/1078-0432.CCR-07-5212
   Finotello F, 2017, GENOME MED, V9, DOI 10.1186/s13073-017-0402-8
   Gavin MA, 2006, P NATL ACAD SCI USA, V103, P6659, DOI 10.1073/pnas.0509484103
   Hong X, 2015, TOHOKU J EXP MED, V236, P297, DOI 10.1620/tjem.236.297
   Hu B, 2014, CLIN CANCER RES, V20, P6212, DOI 10.1158/1078-0432.CCR-14-0442
   Jafarinia M, 2016, TUMOR BIOL, V37, P14659, DOI 10.1007/s13277-016-5345-y
   Jin HT, 2011, CURR TOP MICROBIOL, V350, P17, DOI 10.1007/82_2010_116
   Kim IY, 2014, BMC SURG, V14, DOI 10.1186/1471-2482-14-94
   Krauthamer M, 2013, ONCOLOGY-BASEL, V85, P27, DOI 10.1159/000348385
   Li MX, 2014, INT J CANCER, V134, P2403, DOI 10.1002/ijc.28536
   Lissoni P, 2009, ANTICANCER RES, V29, P1847
   Masi G, 2010, LANCET ONCOL, V11, P845, DOI 10.1016/S1470-2045(10)70175-3
   Ménétrier-Caux C, 2012, TARGET ONCOL, V7, P15, DOI 10.1007/s11523-012-0208-y
   Mougiakakos Dimitrios, 2011, Cancers (Basel), V3, P1708, DOI 10.3390/cancers3021708
   Nishikawa H, 2014, CURR OPIN IMMUNOL, V27, P1, DOI 10.1016/j.coi.2013.12.005
   Passardi A, 2016, ONCOTARGET, V7, P33210, DOI 10.18632/oncotarget.8901
   Roselli M, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1188243
   Roselli M, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.27025
   Schauer D, 2016, ONCOIMMUNOLOGY, V5, DOI 10.1080/2162402X.2016.1160185
   Shen LS, 2009, CLIN IMMUNOL, V131, P109, DOI 10.1016/j.clim.2008.11.010
   Shimabukuro-Vornhagen A, 2014, ONCOTARGET, V5, P4651, DOI 10.18632/oncotarget.1701
   Sierzega M, 2017, ANN SURG ONCOL, V24, P808, DOI 10.1245/s10434-016-5634-0
   Tan W, 2011, NATURE, V470, P548, DOI 10.1038/nature09707
   Tanaka A, 2017, CELL RES, V27, P109, DOI 10.1038/cr.2016.151
   TEMPLETON AJ, 2014, JNCI J NATL CANCER I, V106
   Torre LA, 2015, CA-CANCER J CLIN, V65, P87, DOI 10.3322/caac.21262
   Trillet-Lenoir V, 2002, BRIT J RADIOL, V75, P903, DOI 10.1259/bjr.75.899.750903
   Wang J, 2007, EUR J IMMUNOL, V37, P129, DOI 10.1002/eji.200636435
   Wang KP, 2016, IMMUNOL INVEST, V45, P797, DOI 10.1080/08820139.2016.1197242
   Whiteside TL, 2012, SEMIN CANCER BIOL, V22, P327, DOI 10.1016/j.semcancer.2012.03.004
   Wolchok JD, 2009, CLIN CANCER RES, V15, P7412, DOI 10.1158/1078-0432.CCR-09-1624
   Wu YC, 2016, WORLD J SURG ONCOL, V14, DOI 10.1186/s12957-016-1044-9
   Zhang XH, 2015, J GASTROINTEST ONCOL, V6, P307, DOI 10.3978/j.issn.2078-6891.2015.017
NR 41
TC 8
Z9 9
U1 0
U2 7
PU IMPACT JOURNALS LLC
PI ORCHARD PARK
PA 6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA
EI 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD DEC 12
PY 2017
VL 8
IS 65
BP 109079
EP 109093
DI 10.18632/oncotarget.22606
PG 15
WC Oncology; Cell Biology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology; Cell Biology
GA FS1UY
UT WOS:000419565400064
PM 29312592
OA gold, Green Submitted, Green Published
DA 2025-01-04
ER

PT J
AU Suyama, K
   Iwase, H
AF Suyama, Koichi
   Iwase, Hirotaka
TI Lenvatinib: A Promising Molecular Targeted Agent for Multiple Cancers
SO CANCER CONTROL
LA English
DT Review
DE targeted therapy; lenvatinib; hypertension; thyroid cancer; KIT
ID TYROSINE KINASE INHIBITOR; ANTITUMOR ACTIVITIES; PHASE-I; E7080; PLACEBO
AB Lenvatinib is a small-molecule tyrosine kinase inhibitor that inhibits vascular endothelial growth factor receptor (VEGFR1-3), fibroblast growth factor receptor (FGFR1-4), platelet-derived growth factor receptor (PDGFR), stem cell factor receptor (KIT), and rearranged during transfection (RET). These receptors are important for tumor angiogenesis, and lenvatinib inhibits tumor angiogenesis by inhibiting function of these receptors. Phase I trials of lenvatinib were conducted at the same time in Japan, Europe, and the United States, and tumor shrinkage effects were observed in thyroid cancer, endometrial cancer, melanoma, renal cell carcinoma, sarcoma, and colon cancer. Lenvatinib is a promising drug that has shown therapeutic effects against various solid tumors. Adverse events, such as hypertension, proteinuria, diarrhea, and delayed wound healing, can occur with lenvatinib treatment. Managing these adverse events is also important for the use of lenvatinib. In this mini-review article, we outline the current state, toxicity, and future prospects of lenvatinib toward thyroid cancer, hepatocellular carcinoma, renal cell carcinoma, and lung cancer.
C1 [Suyama, Koichi; Iwase, Hirotaka] Kumamoto Univ, Kumamoto Univ Hosp, Grad Sch Life Sci, Canc Ctr, Kumamoto 8608556, Japan.
   [Iwase, Hirotaka] Kumamoto Univ, Dept Breast & Endocrine Surg, Kumamoto, Japan.
C3 Kumamoto University; Kumamoto University
RP Suyama, K (corresponding author), Kumamoto Univ, Kumamoto Univ Hosp, Grad Sch Life Sci, Canc Ctr, Kumamoto 8608556, Japan.
EM kou_susan@yahoo.co.jp
CR [Anonymous], J CLIN ONCOL S15
   [Anonymous], ESMO 2016 COP DENM 7
   [Anonymous], 2014 ASCO ANN M CHIC
   Boss DS, 2012, BRIT J CANCER, V106, P1598, DOI 10.1038/bjc.2012.154
   Brose MS, 2017, J CLIN ONCOL, V35, P2692, DOI 10.1200/JCO.2016.71.6472
   Guo M, 2015, EUR J CANCER, V51, pS559, DOI 10.1016/S0959-8049(16)31549-0
   Hong DS, 2015, CLIN CANCER RES, V21, P4801, DOI 10.1158/1078-0432.CCR-14-3063
   Ikeda K, 2017, J GASTROENTEROL, V52, P512, DOI 10.1007/s00535-016-1263-4
   Ikeda M, 2016, CLIN CANCER RES, V22, P1385, DOI 10.1158/1078-0432.CCR-15-1354
   Iniguez-Ariza NM, 2017, THYROID, V27, P923, DOI 10.1089/thy.2016.0627
   Keizer RJ, 2010, J PHARMACOKINET PHAR, V37, P347, DOI 10.1007/s10928-010-9164-2
   Koyama N, 2014, BMC CANCER, V14, DOI 10.1186/1471-2407-14-530
   Llovet JM, 2008, NEW ENGL J MED, V359, P378, DOI 10.1056/NEJMoa0708857
   Matsui J, 2008, CLIN CANCER RES, V14, P5459, DOI 10.1158/1078-0432.CCR-07-5270
   Matsui J, 2008, INT J CANCER, V122, P664, DOI 10.1002/ijc.23131
   Nakamichi S, 2015, CANCER CHEMOTH PHARM, V76, P1153, DOI 10.1007/s00280-015-2899-0
   Okamoto K, 2013, CANCER LETT, V340, P97, DOI 10.1016/j.canlet.2013.07.007
   Schlumberger M, 2016, CLIN CANCER RES, V22, P44, DOI 10.1158/1078-0432.CCR-15-1127
   Schlumberger M, 2015, NEW ENGL J MED, V372, P621, DOI 10.1056/NEJMoa1406470
   Suyama K, 2017, MOL CLIN ONCOL, V7, P24, DOI 10.3892/mco.2017.1265
   Tahara M, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00025
   Yamada K, 2011, CLIN CANCER RES, V17, P2528, DOI 10.1158/1078-0432.CCR-10-2638
   Yamamoto Y, 2014, VASC CELL, V6, DOI 10.1186/2045-824X-6-18
   Zhu CJ, 2016, ONCOTARGET, V7, P44545, DOI 10.18632/oncotarget.10019
NR 24
TC 100
Z9 109
U1 1
U2 46
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1073-2748
EI 1526-2359
J9 CANCER CONTROL
JI Cancer Control
PD JUL 23
PY 2018
VL 25
IS 1
DI 10.1177/1073274818789361
PG 5
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA GO0CA
UT WOS:000439586700001
PM 30032643
OA Green Published, gold
DA 2025-01-04
ER

PT J
AU Nguyen, HT
   Tran, DH
   Ngo, QD
   Pham, HAT
   Tran, TT
   Tran, VU
   Pham, TVN
   Le, TK
   Le, NAT
   Nguyen, NM
   Vo, BT
   Nguyen, LT
   Nguyen, TCV
   Bui, QTN
   Nguyen, HN
   Luong, BA
   Le, LGH
   Do, DM
   Do, TTT
   Hoang, AV
   Dinh, KT
   Phan, MD
   Tran, LS
   Giang, H
   Nguyen, HN
AF Huu Thinh Nguyen
   Duc Huy Tran
   Quoc Dat Ngo
   Hong-Anh Thi Pham
   Thanh-Truong Tran
   Vu-Uyen Tran
   Truong-Vinh Ngoc Pham
   Trung Kien Le
   Ngoc-An Trinh Le
   Ngoc Mai Nguyen
   Binh Thanh Vo
   Luan Thanh Nguyen
   Thien-Chi Van Nguyen
   Quynh Tram Nguyen Bui
   Huu-Nguyen Nguyen
   Bac An Luong
   Linh Gia Hoang Le
   Duc Minh Do
   Thanh-Thuy Thi Do
   Anh Vu Hoang
   Kiet Truong Dinh
   Minh-Duy Phan
   Le Son Tran
   Hoa Giang
   Hoai-Nghia Nguyen
TI Evaluation of a Liquid Biopsy Protocol using Ultra-Deep Massive Parallel
   Sequencing for Detecting and Quantifying Circulation Tumor DNA in
   Colorectal Cancer Patients
SO CANCER INVESTIGATION
LA English
DT Article
DE Liquid biopsy; colorectal cancer; actionable mutation; ultra-deep
   sequencing; circulating tumor DNA
ID DROPLET DIGITAL PCR; KRAS MUTATIONS; EGFR MUTATIONS; QUANTIFICATION;
   CELL
AB The identification and quantification of actionable mutations are critical for guiding targeted therapy and monitoring drug response in colorectal cancer. Liquid biopsy (LB) based on plasma cell-free DNA analysis has emerged as a noninvasive approach with many clinical advantages over conventional tissue sampling. Here, we developed a LB protocol using ultra-deep massive parallel sequencing and validated its clinical performance for detection and quantification of actionable mutations in three major driver genes (KRAS, NRAS and BRAF). The assay showed a 92% concordance for mutation detection between plasma and paired tissues and great reliability in quantification of variant allele frequency.
C1 [Huu Thinh Nguyen; Duc Huy Tran; Truong-Vinh Ngoc Pham; Trung Kien Le; Ngoc-An Trinh Le] Univ Med Ctr, Ho Chi Minh City, Vietnam.
   [Quoc Dat Ngo; Bac An Luong; Linh Gia Hoang Le; Duc Minh Do; Thanh-Thuy Thi Do; Anh Vu Hoang; Hoai-Nghia Nguyen] Univ Med & Pharm, Ho Chi Minh City, Vietnam.
   [Hong-Anh Thi Pham; Thanh-Truong Tran; Vu-Uyen Tran; Ngoc Mai Nguyen; Binh Thanh Vo; Luan Thanh Nguyen; Thien-Chi Van Nguyen; Quynh Tram Nguyen Bui; Huu-Nguyen Nguyen; Minh-Duy Phan; Le Son Tran; Hoa Giang] Gene Solut, Ho Chi Minh City, Vietnam.
   [Hong-Anh Thi Pham; Thanh-Truong Tran; Vu-Uyen Tran; Ngoc Mai Nguyen; Binh Thanh Vo; Luan Thanh Nguyen; Thien-Chi Van Nguyen; Quynh Tram Nguyen Bui; Huu-Nguyen Nguyen; Thanh-Thuy Thi Do; Kiet Truong Dinh; Hoa Giang] Med Genet Inst, Ho Chi Minh City, Vietnam.
   [Minh-Duy Phan] Univ Queensland, Sch Chem & Mol Biosci, Brisbane, Qld, Australia.
   [Le Son Tran] ASTAR, Inst Mol & Cellular Biol, Singapore, Singapore.
C3 Hochiminh City University of Medicine & Pharmacy; University of
   Queensland; Agency for Science Technology & Research (A*STAR); A*STAR -
   Institute of Molecular & Cell Biology (IMCB)
RP Nguyen, HN (corresponding author), Univ Med & Pharm, Ho Chi Minh City, Vietnam.; Tran, LS; Giang, H (corresponding author), Gene Solut, Ho Chi Minh City, Vietnam.
EM leson1808@gmail.com; gianghoa@gmail.com; nhnghia81@gmail.com
RI Huy, Nguyen Tien/B-2573-2010; Nguyen, Loan/JXN-0126-2024; Nguyen,
   Tung/HDN-1889-2022; Nguyen, Loc/AAR-4726-2021; Do, Minh/AAS-8857-2021;
   Nguyen, HuuTung/AAD-6670-2019; LUONG, BAC AN/KPA-2590-2024; Phan,
   Minh-Duy/I-9147-2012
OI Nguyen, Huu-Thinh/0000-0002-0981-7274; Tran, Le Son/0000-0002-5382-3903;
   LUONG, BAC AN/0000-0002-5560-0869; Pham, Anh/0000-0003-2041-3964; Phan,
   Minh-Duy/0000-0002-3426-1044; Do, Minh Duc/0000-0002-9997-6390; huy,
   tran/0000-0003-4830-2334
FU Ho Chi Minh city Department of Science and Technology
   [257/2017/HD-SKHCN, GS-003]
FX This research is funded by Ho Chi Minh city Department of Science and
   Technology under grant number 257/2017/HD-SKHCN (to HNN) and Gene
   Solutions (GS-003).
CR Antoniotti C, 2019, JCO PRECIS ONCOL, V3, DOI 10.1200/PO.18.00397
   Basu AS, 2017, SLAS TECHNOL, V22, P369, DOI 10.1177/2472630317705680
   Bettegowda C, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3007094
   *BIOR LAB I, RAR MUT DET BEST PRA
   Burriesci MS, 2012, BIOINFORMATICS, V28, P1324, DOI 10.1093/bioinformatics/bts123
   Cibulskis K, 2013, NAT BIOTECHNOL, V31, P213, DOI 10.1038/nbt.2514
   Cohen Roger B, 2003, Clin Colorectal Cancer, V2, P246, DOI 10.3816/CCC.2003.n.006
   Crowley E, 2013, NAT REV CLIN ONCOL, V10, P472, DOI 10.1038/nrclinonc.2013.110
   Demuth C, 2018, TRANSL ONCOL, V11, P1220, DOI 10.1016/j.tranon.2018.07.013
   Deprez Liesbet, 2016, Biomol Detect Quantif, V9, P29, DOI 10.1016/j.bdq.2016.08.002
   deVos T, 2009, CLIN CHEM, V55, P1337, DOI 10.1373/clinchem.2008.115808
   Di Nicolantonio F, 2008, J CLIN ONCOL, V26, P5705, DOI 10.1200/JCO.2008.18.0786
   Feng WN, 2018, TRANSL ONCOL, V11, P542, DOI 10.1016/j.tranon.2018.02.007
   Gamer M, 2010, Irr: Various Coefficients of Interrater Reliability and Agreement.
   Gu JC, 2017, ONCOTARGET, V8, P67810, DOI 10.18632/oncotarget.18866
   Gyawali B, 2019, JAMA ONCOL, V5, P148, DOI 10.1001/jamaoncol.2018.4304
   Hindson BJ, 2011, ANAL CHEM, V83, P8604, DOI 10.1021/ac202028g
   Hrebien S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165023
   Kastrisiou M, 2019, CANCERS, V11, DOI 10.3390/cancers11101573
   Kim SS, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-017-18642-x
   Li H, 2009, BIOINFORMATICS, V25, P2078, DOI 10.1093/bioinformatics/btp352
   Li HZ, 2019, ONCOL LETT, V17, P1409, DOI 10.3892/ol.2018.9794
   MacConaill LE, 2018, BMC GENOMICS, V19, DOI 10.1186/s12864-017-4428-5
   MANDEL P, 1948, CR SOC BIOL, V142, P241
   MEADOR C, 2018, J CLIN ONCOL S, V36
   Melosky B, 2017, FRONT ONCOL, V7, DOI 10.3389/fonc.2017.00038
   Newman AM, 2014, NAT MED, V20, P552, DOI 10.1038/nm.3519
   Osumi H, 2019, CANCER SCI, V110, P1148, DOI 10.1111/cas.13972
   Osumi H, 2019, CANCER MED-US, V8, P408, DOI 10.1002/cam4.1913
   Petrackova A, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00851
   Phallen J, 2017, SCI TRANSL MED, V9, DOI 10.1126/scitranslmed.aan2415
   Plagnol V, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0193802
   Quan PL, 2018, SENSORS-BASEL, V18, DOI 10.3390/s18041271
   Raponi M, 2008, CURR OPIN PHARMACOL, V8, P413, DOI 10.1016/j.coph.2008.06.006
   Revelle W., OVERVIEW PSYCH PACKA
   Salas NR, 2018, J CLIN ONCOL, V36
   Salk JJ, 2018, NAT REV GENET, V19, P269, DOI 10.1038/nrg.2017.117
   Seshacharyulu P, 2012, EXPERT OPIN THER TAR, V16, P15, DOI 10.1517/14728222.2011.648617
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI 10.3322/caac.21660
   Tang M, 2017, INT J BIOL MARKER, V32, pE421, DOI 10.5301/ijbm.5000295
   Taylor SC, 2017, SCI REP-UK, V7, DOI 10.1038/s41598-017-02217-x
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   Warton K, 2015, FRONT MOL BIOSCI, V2, DOI 10.3389/fmolb.2015.00013
   Weitz J, 2005, LANCET, V365, P153, DOI 10.1016/S0140-6736(19)32319-0
   Wickham H., ggplot2: Elegant Graphics for Data Analysis
   Yang X, 2016, ONCOTARGET, V7, P20810, DOI 10.18632/oncotarget.8021
   Zhang HY, 2019, TRANSL ONCOL, V12, P426, DOI 10.1016/j.tranon.2018.11.015
   Zhu YZ, 2018, ONCOL LETT, V15, P2905, DOI 10.3892/ol.2017.7679
NR 49
TC 15
Z9 16
U1 1
U2 10
PU TAYLOR & FRANCIS INC
PI PHILADELPHIA
PA 530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA
SN 0735-7907
EI 1532-4192
J9 CANCER INVEST
JI Cancer Invest.
PD FEB 7
PY 2020
VL 38
IS 2
BP 85
EP 93
DI 10.1080/07357907.2020.1713350
EA JAN 2020
PG 9
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA KK4FS
UT WOS:000509293600001
PM 31939681
DA 2025-01-04
ER

PT J
AU Dhamani, AM
   Sheth, HS
   Bhattacharyya, S
   Shaikh, IN
AF Dhamani, Anjum Mehmood
   Sheth, Hardik Sanjeev
   Bhattacharyya, Susrita
   Shaikh, Imran Nisar
TI Paradigm shift from palliation to cure in metastatic microsatellite high
   colorectal carcinoma with immune checkpoint inhibitors
SO JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
LA English
DT Article
DE Colorectal cancer; immunotherapy; microsatellite instability; nivolumab
ID PHASE-I; CANCER; INSTABILITY; TUMORS
AB Colorectal carcinoma (CRC) is one of the most frequently diagnosed malignancies worldwide with a high mortality rate. CRC is often plagued with significant treatment-related morbidity and mortality, and metastatic progression is common. With the advent of immunotherapy, inoperable and advanced cancers have shown favorable response. Immunotherapy has paved the way for survival of all those with advanced metastatic disease whose treatment was limited to palliative care. We explore the case of a 28-year-old female with advanced metastatic CRC refractory to chemotherapy and targeted therapy, managed with PD-1 inhibitor with complete clinical and pathological response in a relatively short period of time. The notion of upfront immunotherapy for advanced metastatic CRC with microsatellite instability is definitely reinforced by the favorable response seen in our case, and we hope that these findings would help reduce the dependence on chemotherapy as the mainstay therapeutic for advanced CRC.
C1 [Dhamani, Anjum Mehmood; Sheth, Hardik Sanjeev; Bhattacharyya, Susrita; Shaikh, Imran Nisar] Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Ctr Canc, Mumbai, Maharashtra, India.
RP Shaikh, IN (corresponding author), Kokilaben Dhirubhai Ambani Hosp & Med Res Inst, Mumbai 400053, Maharashtra, India.
EM imran.shaikh@kokilabenhospitals.com
CR André T, 2020, NEW ENGL J MED, V383, P2207, DOI 10.1056/NEJMoa2017699
   [Anonymous], GLOBOCAN 2012 EST CA
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Boland CR, 1998, CANCER RES, V58, P5248
   Brahmer JR, 2010, J CLIN ONCOL, V28, P3167, DOI 10.1200/JCO.2009.26.7609
   Emens LA, 2015, CANCER IMMUNOL RES, V3, P436, DOI 10.1158/2326-6066.CIR-15-0064
   Hoos A, 2012, ONCOIMMUNOLOGY, V1, P334, DOI 10.4161/onci.19268
   Kawakami H, 2015, CURR TREAT OPTION ON, V16, DOI 10.1007/s11864-015-0348-2
   Kim PS, 2010, CURR OPIN IMMUNOL, V22, P223, DOI 10.1016/j.coi.2010.02.005
   Lam M, 2020, CANCER MANAG RES, V12, P5819, DOI 10.2147/CMAR.S213236
   Le DT, 2015, NEW ENGL J MED, V372, P2509, DOI 10.1056/NEJMoa1500596
   Overman MJ, 2017, LANCET ONCOL, V18, P1182, DOI 10.1016/S1470-2045(17)30422-9
   Patnaik A, 2015, CLIN CANCER RES, V21, P4286, DOI 10.1158/1078-0432.CCR-14-2607
   Van Cutsem E, 2016, ANN ONCOL, V27, P1386, DOI 10.1093/annonc/mdw235
   van der Pool AEM, 2012, COLORECTAL DIS, V14, P56, DOI 10.1111/j.1463-1318.2010.02539.x
NR 15
TC 2
Z9 2
U1 0
U2 3
PU WOLTERS KLUWER MEDKNOW PUBLICATIONS
PI MUMBAI
PA WOLTERS KLUWER INDIA PVT LTD , A-202, 2ND FLR, QUBE, C T S  NO 1498A-2
   VILLAGE MAROL, ANDHERI EAST, MUMBAI, Maharashtra, INDIA
SN 0973-1482
EI 1998-4138
J9 J CANCER RES THER
JI J. Canc. Res. Ther.
PD OCT-DEC
PY 2021
VL 17
IS 6
BP 1552
EP 1555
DI 10.4103/jcrt.jcrt_156_21
PG 4
WC Oncology
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Oncology
GA YY1MO
UT WOS:000754558000038
PM 34916394
OA gold
DA 2025-01-04
ER

PT J
AU Wang, YB
   Liu, J
   Ren, FH
   Chu, YJ
   Cui, BB
AF Wang, Yanbo
   Liu, Jing
   Ren, Fenghai
   Chu, Yanjie
   Cui, Binbin
TI Identification and Validation of a Four-Long Non-coding RNA Signature
   Associated With Immune Infiltration and Prognosis in Colon Cancer
SO FRONTIERS IN GENETICS
LA English
DT Article
DE long non-coding RNAs; colon cancer; immune microenvironment; tumor
   immune infiltration; integrative analysis
ID COLORECTAL-CANCER; TARGETED THERAPY; HETEROGENEITY; BIOMARKERS; PROFILES
AB The emerging evidence has demonstrated the critical roles of long non-coding RNAs (lncRNAs) as regulators in the tumor immune microenvironment (TIME). However, the tumor immune infiltration-associated lncRNAs and their clinical significance in colon cancer have not yet been thoroughly investigated. This study performed an integrative analysis of lncRNA expression profiles and immune cell infiltration profiles and identified 258 immune infiltration-associated lncRNAs. Of them, four lncRNAs (AC008494.3, LINC00926, AC022034.1, and SNHG26) were significantly and independently associated with the patient's overall survival. Finally, we developed a tumor immune infiltration-associated lncRNA signature (TIILncSig) comprising of these four lncRNAs, which can divide colon cancer patients of The Cancer Genome Atlas (TCGA) into high-risk and low-risk groups with a significantly different outcome [Hazard ratio (HR) = 2.718, 95% CI = 1.955-3.779, p < 0.001]. Prognostic performance of the TIILncSig was further validated in another independent colon cancer cohort (HR = 1.832, 95% CI = 1.045-3.21, p = 0.034). Results of multivariate Cox regression and stratification analysis demonstrated that the TIILncSig is an independent predictive factor from other clinical features (HR = 2.687, 95% CI = 1.912-3.776, p < 0.001 for TCGA cohort and HR = 1.837, 95% CI = 1.047-3.223, p = 0.034 for GSE17538 cohort). Literature analysis provided experimental evidence supporting roles of the TIILncSig in cancer carcinogenesis and progression and immune regulation. Summary, our study will help to understand the mechanisms of lncRNAs in immune regulation in the tumor microenvironment and provide novel biomarkers or targets for prognosis prediction and therapy decision-making for patients with colon cancer.
C1 [Wang, Yanbo; Ren, Fenghai] Harbin Med Univ Canc Hosp, Dept Thorac Surg, Harbin, Peoples R China.
   [Liu, Jing; Chu, Yanjie] Harbin Med Univ, Affiliated Hosp 2, Dept Gastroenterol & Hepatol, Harbin, Peoples R China.
   [Cui, Binbin] Harbin Med Univ Canc Hosp, Dept Colorectal Surg, Harbin, Peoples R China.
C3 Harbin Medical University; Harbin Medical University; Harbin Medical
   University
RP Cui, BB (corresponding author), Harbin Med Univ Canc Hosp, Dept Colorectal Surg, Harbin, Peoples R China.
EM cbbhrb@163.com
FU Heilongjiang Province Science Foundation for Youths [JJ2018QN0724]; Nn10
   Program of Harbin Medical University Cancer Hospital [Nn102017-02]
FX This study was supported by Heilongjiang Province Science Foundation for
   Youths (JJ2018QN0724) and the Nn10 Program of Harbin Medical University
   Cancer Hospital (Nn102017-02).
CR Bam M, 2019, J IMMUNOL, V202
   Bao ZY, 2017, ONCOTARGET, V8, P10485, DOI 10.18632/oncotarget.14441
   Binnewies M, 2018, NAT MED, V24, P541, DOI 10.1038/s41591-018-0014-x
   Budinska E, 2013, J PATHOL, V231, P63, DOI 10.1002/path.4212
   Catalano I, 2019, TRENDS CANCER, V5, P779, DOI 10.1016/j.trecan.2019.10.006
   Chen HY, 2014, MOL ONCOL, V8, P1393, DOI 10.1016/j.molonc.2014.05.010
   Chen YG, 2017, NAT IMMUNOL, V18, P962, DOI 10.1038/ni.3771
   Chew V, 2012, J ONCOL, V2012, DOI 10.1155/2012/608406
   Idos GE, 2020, SCI REP-UK, V10, DOI 10.1038/s41598-020-60255-4
   Koncina E, 2020, CANCERS, V12, DOI 10.3390/cancers12020319
   Liang YX, 2020, ARCH MED SCI, V16, P1411, DOI 10.5114/aoms.2020.98839
   Linnekamp JF, 2015, CANCER RES, V75, P245, DOI 10.1158/0008-5472.CAN-14-2240
   Ma W, 2020, J TRANSL MED, V18, DOI 10.1186/s12967-020-02522-6
   Newman AM, 2015, NAT METHODS, V12, P453, DOI [10.1038/NMETH.3337, 10.1038/nmeth.3337]
   Perez-Villamil B, 2012, BMC CANCER, V12, DOI 10.1186/1471-2407-12-260
   Sarver AL, 2009, BMC CANCER, V9, DOI 10.1186/1471-2407-9-401
   Schlicker A, 2012, BMC MED GENOMICS, V5, DOI 10.1186/1755-8794-5-66
   Shen RF, 2020, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.01497
   Siegel RL, 2020, CA-CANCER J CLIN, V70, P7, DOI 10.3322/caac.21590
   Slattery ML, 2016, MODERN PATHOL, V29, P915, DOI 10.1038/modpathol.2016.73
   Sun J, 2020, J IMMUNOTHER CANCER, V8, DOI 10.1136/jitc-2019-000110
   Turner M, 2014, NAT IMMUNOL, V15, P484, DOI 10.1038/ni.2887
   Vacante M, 2018, WORLD J CLIN CASES, V6, P869, DOI 10.12998/wjcc.v6.i15.869
   Wang F, 2018, MOL MED REP, V18, P1473, DOI 10.3892/mmr.2018.9139
   Ye Y, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0198055
   Zhai ZH, 2017, SEMIN CELL DEV BIOL, V64, P107, DOI 10.1016/j.semcdb.2016.08.033
   Zhang LH, 2018, FRONT IMMUNOL, V9, DOI 10.3389/fimmu.2018.01578
   Zhang YL, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01727-3
   Zhang ZC, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa075
   Zhao P, 2021, FASEB J, V35, DOI 10.1096/fj.202000732RR
   Zhou M, 2021, BRIEF BIOINFORM, V22, DOI 10.1093/bib/bbaa047
   Zhou M, 2018, MOL THER-NUCL ACIDS, V12, P518, DOI 10.1016/j.omtn.2018.06.007
   Zhou M, 2018, MOL NEUROBIOL, V55, P3684, DOI 10.1007/s12035-017-0572-9
   Zhou M, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0580-4
NR 34
TC 13
Z9 13
U1 0
U2 2
PU FRONTIERS MEDIA SA
PI LAUSANNE
PA AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND
EI 1664-8021
J9 FRONT GENET
JI Front. Genet.
PD JUL 5
PY 2021
VL 12
AR 671128
DI 10.3389/fgene.2021.671128
PG 9
WC Genetics & Heredity
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Genetics & Heredity
GA TK6JQ
UT WOS:000674262800001
PM 34290738
OA gold, Green Published
DA 2025-01-04
ER

PT J
AU Peng, ZW
   Tong, ZW
   Ren, ZH
   Ye, MP
   Hu, KW
AF Peng, Zhiwei
   Tong, Zhiwei
   Ren, Zihao
   Ye, Manping
   Hu, Kongwang
TI Cancer-associated fibroblasts and its derived exosomes: a new
   perspective for reshaping the tumor microenvironment
SO MOLECULAR MEDICINE
LA English
DT Review
DE Cancer-associated fibroblasts; Exosomes; Tumor microenvironment;
   Diagnosis; Therapy
ID CARCINOMA-ASSOCIATED FIBROBLASTS; MESENCHYMAL STEM-CELLS; BREAST-CANCER;
   EXTRACELLULAR VESICLES; COLORECTAL-CANCER; PROGRESSION; ANGIOGENESIS;
   SECRETION; PROMOTE; PROLIFERATION
AB Cancer-associated fibroblasts (CAFs) are the most abundant stromal cells within the tumor microenvironment (TME). They extensively communicate with the other cells. Exosome-packed bioactive molecules derived from CAFs can reshape the TME by interacting with other cells and the extracellular matrix, which adds a new perspective for their clinical application in tumor targeted therapy. An in-depth understanding of the biological characteristics of CAF-derived exosomes (CDEs) is critical for depicting the detailed landscape of the TME and developing tailored therapeutic strategies for cancer treatment. In this review, we have summarized the functional roles of CAFs in the TME, particularly focusing on the extensive communication mediated by CDEs that contain biological molecules such as miRNAs, proteins, metabolites, and other components. In addition, we have also highlighted the prospects for diagnostic and therapeutic applications based on CDEs, which could guide the future development of exosome-targeted anti-tumor drugs.
C1 [Peng, Zhiwei; Tong, Zhiwei; Ren, Zihao; Hu, Kongwang] Anhui Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hefei 230022, Anhui, Peoples R China.
   [Ye, Manping] Anhui Med Univ, Anhui Inst Innovat Drugs, Sch Pharm, Anhui Prov Key Lab Major Autoimmune Dis, Hefei 230032, Anhui, Peoples R China.
   [Hu, Kongwang] Anhui Med Univ, Fuyang Affiliated Hosp, Dept Gen Surg, Fuyang 236000, Anhui, Peoples R China.
C3 Anhui Medical University; Anhui Medical University; Anhui Medical
   University
RP Hu, KW (corresponding author), Anhui Med Univ, Affiliated Hosp 1, Dept Gen Surg, Hefei 230022, Anhui, Peoples R China.; Hu, KW (corresponding author), Anhui Med Univ, Fuyang Affiliated Hosp, Dept Gen Surg, Fuyang 236000, Anhui, Peoples R China.
EM hukw@sina.com
CR Acerbi I, 2015, INTEGR BIOL-UK, V7, P1120, DOI 10.1039/c5ib00040h
   Al-Hajj M, 2003, P NATL ACAD SCI USA, V100, P3983, DOI 10.1073/pnas.0530291100
   Alguacil-Núñez C, 2018, CRIT REV ONCOL HEMAT, V125, P102, DOI 10.1016/j.critrevonc.2018.02.015
   Arandkar S, 2018, P NATL ACAD SCI USA, V115, P6410, DOI 10.1073/pnas.1719076115
   Arina A, 2016, P NATL ACAD SCI USA, V113, P7551, DOI 10.1073/pnas.1600363113
   Bader JE, 2020, MOL CELL, V78, P1019, DOI 10.1016/j.molcel.2020.05.034
   Bae YH, 2014, SCI SIGNAL, V7, DOI 10.1126/scisignal.2004838
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Bastos N, 2018, SEMIN CELL DEV BIOL, V78, P13, DOI 10.1016/j.semcdb.2017.08.009
   Bates JP, 2018, BMC CANCER, V18, DOI 10.1186/s12885-018-4441-3
   Batlle E, 2017, NAT MED, V23, P1124, DOI 10.1038/nm.4409
   Bejarano L, 2021, CANCER DISCOV, V11, P933, DOI 10.1158/2159-8290.CD-20-1808
   Bian YJ, 2020, NATURE, V585, P277, DOI 10.1038/s41586-020-2682-1
   Boutilier AJ, 2021, INT J MOL SCI, V22, DOI 10.3390/ijms22136995
   Brechbuhl HM, 2017, CLIN CANCER RES, V23, P1710, DOI 10.1158/1078-0432.CCR-15-2851
   Busch S, 2015, ONCOGENE, V34, P27, DOI 10.1038/onc.2013.527
   Calvo F, 2013, NAT CELL BIOL, V15, P637, DOI 10.1038/ncb2756
   Chen B, 2021, THERANOSTICS, V11, P3932, DOI 10.7150/thno.53412
   Chen JF, 2021, METABOLISM, V122, DOI 10.1016/j.metabol.2021.154834
   Chen L, 2021, CANCER LETT, V505, P49, DOI 10.1016/j.canlet.2021.02.004
   Chen PW, 2021, CELL REP, V34, DOI 10.1016/j.celrep.2020.108597
   Chen XM, 2019, NAT REV DRUG DISCOV, V18, P99, DOI 10.1038/s41573-018-0004-1
   Chen Y, 2017, ONCOGENE, V36, P4692, DOI 10.1038/onc.2017.100
   Chen Y, 2021, NAT REV CLIN ONCOL, V18, P792, DOI 10.1038/s41571-021-00546-5
   Chen ZH, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-18916-5
   Cheng YS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-0458-4
   Chida S, 2016, CARCINOGENESIS, V37, P878, DOI 10.1093/carcin/bgw069
   Cho S, 2019, BIOSENS BIOELECTRON, V146, DOI 10.1016/j.bios.2019.111749
   Christianson HC, 2013, P NATL ACAD SCI USA, V110, P17380, DOI 10.1073/pnas.1304266110
   Cohen N, 2017, ONCOGENE, V36, P4457, DOI 10.1038/onc.2017.65
   Colombo M, 2014, ANNU REV CELL DEV BI, V30, P255, DOI 10.1146/annurev-cellbio-101512-122326
   Corn KC, 2020, PROG LIPID RES, V80, DOI 10.1016/j.plipres.2020.101055
   Correia AL, 2012, DRUG RESIST UPDATE, V15, P39, DOI 10.1016/j.drup.2012.01.006
   Costa A, 2018, CANCER CELL, V33, P463, DOI 10.1016/j.ccell.2018.01.011
   Dai XY, 2022, CANCER BIOL THER, V23, P76, DOI 10.1080/15384047.2021.2017222
   Datta A, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-26411-7
   Datta A, 2017, CANCER LETT, V408, P73, DOI 10.1016/j.canlet.2017.08.020
   De Francesco EM, 2013, BREAST CANCER RES, V15, DOI 10.1186/bcr3458
   de Palma M, 2017, NAT REV CANCER, V17, P457, DOI 10.1038/nrc.2017.51
   Demircioglu F, 2020, NAT COMMUN, V11, DOI 10.1038/s41467-020-15104-3
   Deng X, 2020, INT J CANCER, V146, P1700, DOI 10.1002/ijc.32608
   Dey P, 2021, CANCER DISCOV, V11, P1067, DOI 10.1158/2159-8290.CD-20-1211
   Ding YX, 2019, CANCER LETT, V442, P351, DOI 10.1016/j.canlet.2018.10.039
   Dou DW, 2020, FRONT IMMUNOL, V11, DOI 10.3389/fimmu.2020.02026
   Eble JA, 2019, CLIN EXP METASTAS, V36, P171, DOI 10.1007/s10585-019-09966-1
   Saw PE, 2022, TRENDS CANCER, V8, P527, DOI 10.1016/j.trecan.2022.03.001
   Erin N, 2020, DRUG RESIST UPDATE, V53, DOI 10.1016/j.drup.2020.100715
   Escrevente C, 2011, BMC CANCER, V11, DOI 10.1186/1471-2407-11-108
   Fang F, 2022, REPROD SCI, V29, P1809, DOI 10.1007/s43032-021-00820-y
   Fang T, 2018, NAT COMMUN, V9, DOI 10.1038/s41467-017-02583-0
   Fanhchaksai K, 2016, INT J CANCER, V138, P630, DOI 10.1002/ijc.29804
   Feig C, 2013, P NATL ACAD SCI USA, V110, P20212, DOI 10.1073/pnas.1320318110
   Fiori ME, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-0994-2
   Francescone R, 2021, CANCER DISCOV, V11, P446, DOI 10.1158/2159-8290.CD-20-0775
   Franzen CA, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/619829
   Galindo-Pumariño C, 2022, TOXICOL APPL PHARM, V450, DOI 10.1016/j.taap.2022.116171
   Ganig N, 2021, CANCERS, V13, DOI 10.3390/cancers13061351
   Gao Y, 2020, ADV SCI, V7, DOI 10.1002/advs.202002518
   Gilkes DM, 2014, NAT REV CANCER, V14, P430, DOI 10.1038/nrc3726
   Gilligan KE, 2017, INT J MOL SCI, V18, DOI 10.3390/ijms18061122
   Glentis A, 2017, NAT COMMUN, V8, DOI 10.1038/s41467-017-00985-8
   Gong J, 2020, CELL DEATH DIS, V11, DOI 10.1038/s41419-020-2434-z
   Gu C, 2020, BIOCHEM BIOPH RES CO, V527, P638, DOI 10.1016/j.bbrc.2020.04.142
   Guo XR, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.764151
   Hanahan D, 2022, CANCER DISCOV, V12, P31, DOI 10.1158/2159-8290.CD-21-1059
   Hazan-Halevy I, 2015, CANCER LETT, V364, P59, DOI 10.1016/j.canlet.2015.04.026
   Hegde PS, 2020, IMMUNITY, V52, P17, DOI 10.1016/j.immuni.2019.12.011
   Herrera M, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01367-x
   Hou X, 2010, P NATL ACAD SCI USA, V107, P12216, DOI 10.1073/pnas.1004143107
   Hu HC, 2021, CANCER CELL, V39, P1531, DOI 10.1016/j.ccell.2021.09.003
   Hu JL, 2019, MOL CANCER, V18, DOI 10.1186/s12943-019-1019-x
   Hu SC, 2021, ACTA BIOMATER, V135, P567, DOI 10.1016/j.actbio.2021.09.003
   Hu YB, 2019, ONCOGENE, V38, P1951, DOI 10.1038/s41388-018-0557-9
   Hu YB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125625
   Huang-Doran I, 2017, TRENDS ENDOCRIN MET, V28, P3, DOI 10.1016/j.tem.2016.10.003
   Iwano M, 2002, J CLIN INVEST, V110, P341, DOI 10.1172/JCI200215518
   Jena BC, 2021, CANCER LETT, V520, P222, DOI 10.1016/j.canlet.2021.08.002
   Jenkins L, 2022, CANCER RES, V82, P2904, DOI 10.1158/0008-5472.CAN-21-4141
   Jiang XJ, 2020, J EXP CLIN CANC RES, V39, DOI 10.1186/s13046-020-01709-5
   Jiang Y, 2021, MOL IMMUNOL, V140, P47, DOI 10.1016/j.molimm.2021.10.002
   Jin YF, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-05129-5
   Johnson JL, 2016, J BIOL CHEM, V291, P25965, DOI 10.1074/jbc.M116.741884
   Jung YH, 2013, NAT COMMUN, V4, DOI 10.1038/ncomms2766
   Jungwirth U, 2021, NAT COMMUN, V12, DOI 10.1038/s41467-021-23583-1
   Kalluri R, 2020, SCIENCE, V367, P640, DOI 10.1126/science.aau6977
   Kalluri R, 2016, NAT REV CANCER, V16, P582, DOI 10.1038/nrc.2016.73
   Kamerkar S, 2017, NATURE, V546, P498, DOI 10.1038/nature22341
   Kanninen KM, 2016, BBA-MOL BASIS DIS, V1862, P403, DOI 10.1016/j.bbadis.2015.09.020
   Katakowski M, 2013, CANCER LETT, V335, P201, DOI 10.1016/j.canlet.2013.02.019
   Kato K, 2022, ANN SURG ONCOL, V29, P7135, DOI 10.1245/s10434-022-11862-0
   Kaur A, 2019, CANCER DISCOV, V9, P64, DOI 10.1158/2159-8290.CD-18-0193
   Kawamoto T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034045
   Kesh K, 2020, CANCERS, V12, DOI 10.3390/cancers12103067
   Khalaf K, 2021, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.656364
   Kieffer Y, 2020, CANCER DISCOV, V10, P1330, DOI 10.1158/2159-8290.CD-19-1384
   Kobayashi H, 2019, NAT REV GASTRO HEPAT, V16, P282, DOI 10.1038/s41575-019-0115-0
   Kourembanas S, 2015, ANNU REV PHYSIOL, V77, P13, DOI 10.1146/annurev-physiol-021014-071641
   Kunou S, 2021, ONCOGENE, V40, P3989, DOI 10.1038/s41388-021-01829-y
   Lallemand T, 2018, ARTERIOSCL THROM VAS, V38, P1479, DOI 10.1161/ATVBAHA.118.311208
   Landskron G, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01394
   Lee JJ, 2014, P NATL ACAD SCI USA, V111, pE3091, DOI 10.1073/pnas.1411679111
   Lei YL, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01105-2
   Li C, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01463-y
   Li WH, 2013, MOL MED REP, V8, P1876, DOI 10.3892/mmr.2013.1738
   Li WQ, 2017, ONCOTARGET, V8, P96035, DOI 10.18632/oncotarget.21635
   Li Y, 2020, APPL BIOCHEM BIOTECH, V191, P1084, DOI 10.1007/s12010-020-03244-7
   Li YY, 2018, EBIOMEDICINE, V36, P209, DOI 10.1016/j.ebiom.2018.09.006
   Lin WY, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.02019
   Liu JY, 2021, ACTA PHARM SIN B, V11, P2783, DOI 10.1016/j.apsb.2021.01.001
   Liu JS, 2022, CLIN TRANSL ONCOL, V24, P2285, DOI 10.1007/s12094-022-02906-8
   Liu L, 2020, EXP CELL RES, V391, DOI 10.1016/j.yexcr.2020.111956
   Liu TY, 2019, J HEMATOL ONCOL, V12, DOI 10.1186/s13045-019-0770-1
   Liu YJ, 2022, J INFLAMM RES, V15, P2461, DOI 10.2147/JIR.S361362
   Luga V, 2012, CELL, V151, P1542, DOI 10.1016/j.cell.2012.11.024
   Luo M, 2018, CELL PHYSIOL BIOCHEM, V51, P315, DOI 10.1159/000495232
   Maeda S, 2009, NATURE, V458, P597, DOI 10.1038/nature07869
   Mantovani A, 2004, TRENDS IMMUNOL, V25, P677, DOI 10.1016/j.it.2004.09.015
   Mao XQ, 2021, MOL CANCER, V20, DOI 10.1186/s12943-021-01428-1
   Maris P, 2015, PLOS MED, V12, DOI 10.1371/journal.pmed.1001871
   Martin LA, 2007, MOL CANCER THER, V6, P2458, DOI 10.1158/1535-7163.MCT-06-0452
   Martínez-Reyes I, 2021, NAT REV CANCER, V21, P669, DOI 10.1038/s41568-021-00378-6
   Masyuk AI, 2013, J HEPATOL, V59, P621, DOI 10.1016/j.jhep.2013.03.028
   Mathieu M, 2019, NAT CELL BIOL, V21, P9, DOI 10.1038/s41556-018-0250-9
   McAndrews KM., 2022, CANCER DISCOV, V12, P1580, DOI [10.1158/2159-8290.CD-20-1484, DOI 10.1158/2159-8290.CD-20-1484]
   Menezes S, 2022, J PATHOL, V257, P526, DOI 10.1002/path.5926
   Milane L, 2015, J CONTROL RELEASE, V219, P278, DOI 10.1016/j.jconrel.2015.06.029
   Mizutani Y, 2019, CANCER RES, V79, P5367, DOI 10.1158/0008-5472.CAN-19-0454
   Monteran L, 2019, FRONT IMMUNOL, V10, DOI 10.3389/fimmu.2019.01835
   Najafi M, 2019, J CELL BIOCHEM, V120, P2782, DOI 10.1002/jcb.27681
   Nakaoka HJ, 2017, ONCOGENESIS, V6, DOI 10.1038/oncsis.2017.27
   Nicolas AM, 2022, CANCER CELL, V40, P168, DOI 10.1016/j.ccell.2022.01.004
   O'Brien KP, 2018, ONCOGENE, V37, P2137, DOI 10.1038/s41388-017-0116-9
   Özdemir BC, 2014, CANCER CELL, V25, P719, DOI [10.1016/j.ccr.2014.04.005, 10.1016/j.ccell.2015.11.002]
   Okumura T, 2019, INT J CANCER, V144, P1401, DOI 10.1002/ijc.31775
   Omary MB, 2007, J CLIN INVEST, V117, P50, DOI 10.1172/JCI30082
   Oshi M, 2021, AM J CANCER RES, V11, P1659
   Paauwe M, 2018, CLIN CANCER RES, V24, P6331, DOI 10.1158/1078-0432.CCR-18-0329
   Pan XY, 2021, J HEMATOL ONCOL, V14, DOI 10.1186/s13045-021-01203-1
   Park D, 2020, CELL, V181, P486, DOI 10.1016/j.cell.2020.03.013
   Paskeh MDA, 2022, J HEMATOL ONCOL, V15, DOI 10.1186/s13045-022-01305-4
   Pathan M, 2019, NUCLEIC ACIDS RES, V47, pD516, DOI 10.1093/nar/gky1029
   Peng LS, 2022, FRONT IMMUNOL, V12, DOI 10.3389/fimmu.2021.795372
   Peng SY, 2021, MOL ONCOL, V15, P1391, DOI 10.1002/1878-0261.12917
   Peng ZW, 2022, J TRANSL MED, V20, DOI 10.1186/s12967-022-03510-8
   Pinto G, 2020, TRENDS CANCER, V6, P874, DOI 10.1016/j.trecan.2020.04.012
   Prasetyanti PR, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0600-4
   Qin W, 2022, MOL CARCINOGEN, V61, P764, DOI 10.1002/mc.23416
   Qin X, 2019, GENOME BIOL, V20, DOI 10.1186/s13059-018-1604-0
   Qin X, 2018, THERANOSTICS, V8, P921, DOI 10.7150/thno.22182
   Qiu LQ, 2022, CANCER LETT, V546, DOI 10.1016/j.canlet.2022.215860
   Qu Z, 2022, EXP CELL RES, V418, DOI 10.1016/j.yexcr.2022.113266
   Quail DF, 2013, NAT MED, V19, P1423, DOI 10.1038/nm.3394
   Reina-Campos M, 2017, CURR OPIN CELL BIOL, V48, P47, DOI 10.1016/j.ceb.2017.05.006
   Ren FF, 2021, CANCER SCI, V112, P3569, DOI 10.1111/cas.15057
   Ren J, 2018, THERANOSTICS, V8, P3932, DOI 10.7150/thno.25541
   Ren Y, 2018, MOL CANCER, V17, DOI 10.1186/s12943-018-0758-4
   Ricci-Vitiani L, 2007, NATURE, V445, P111, DOI 10.1038/nature05384
   Richards KE, 2017, ONCOGENE, V36, P1770, DOI 10.1038/onc.2016.353
   Richards KE, 2022, CANCERS, V14, DOI 10.3390/cancers14112812
   Roehlecke C, 2020, CANCERS, V12, DOI 10.3390/cancers12040857
   Sahai E, 2020, NAT REV CANCER, V20, P174, DOI 10.1038/s41568-019-0238-1
   Saliminejad K, 2019, J CELL PHYSIOL, V234, P5451, DOI 10.1002/jcp.27486
   Schmitt AM, 2016, CANCER CELL, V29, P452, DOI 10.1016/j.ccell.2016.03.010
   Serrels A, 2015, CELL, V163, P160, DOI 10.1016/j.cell.2015.09.001
   Shan G, 2021, CELL ONCOL, V44, P45, DOI 10.1007/s13402-020-00500-0
   Shan G, 2020, EXP MOL MED, V52, P1809, DOI 10.1038/s12276-020-0431-z
   Shi H, 2021, FRONT CELL DEV BIOL, V9, DOI 10.3389/fcell.2021.676319
   Shi L, 2022, CLIN TRANSL MED, V12, DOI 10.1002/ctm2.989
   Shi Y, 2022, ANTI-CANCER DRUG
   Shibue T, 2017, NAT REV CLIN ONCOL, V14, P611, DOI 10.1038/nrclinonc.2017.44
   Shin K, 2014, CANCER CELL, V26, P521, DOI 10.1016/j.ccell.2014.09.001
   Song MJ, 2021, HEPATOLOGY, V73, P1717, DOI 10.1002/hep.31792
   Statello L, 2021, NAT REV MOL CELL BIO, V22, P96, DOI 10.1038/s41580-020-00315-9
   Su T, 2021, FRONT ONCOL, V11, DOI 10.3389/fonc.2021.631703
   Sung H, 2021, CA-CANCER J CLIN, V71, P209, DOI DOI 10.3322/caac.21492
   Tan BH, 2018, CANCER RES, V78, P4929, DOI 10.1158/0008-5472.CAN-18-0152
   Tan HX, 2020, CANCER BIOL THER, V21, P258, DOI 10.1080/15384047.2019.1685157
   Tanaka R, 2022, BMC CANCER, V22, DOI 10.1186/s12885-022-09847-z
   Théry C, 2018, J EXTRACELL VESICLES, V7, DOI 10.1080/20013078.2018.1535750
   Tkach M, 2016, CELL, V164, P1226, DOI 10.1016/j.cell.2016.01.043
   Trajkovic K, 2008, SCIENCE, V319, P1244, DOI 10.1126/science.1153124
   Unterleuthner D, 2020, ANGIOGENESIS, V23, P159, DOI 10.1007/s10456-019-09688-8
   Verderio C, 2018, J LIPID RES, V59, P1325, DOI 10.1194/jlr.R083915
   Wan XY, 2021, THERANOSTICS, V11, P4975, DOI 10.7150/thno.55074
   Wang HB, 2020, MOL THER-NUCL ACIDS, V19, P654, DOI 10.1016/j.omtn.2019.11.024
   Wang M, 2022, HEAD NECK-J SCI SPEC, V44, P2437, DOI 10.1002/hed.27155
   Wang S, 2022, CELL DEATH DISCOV, V8, DOI 10.1038/s41420-022-01163-6
   Wang Y, 2021, CELL DISCOV, V7, DOI 10.1038/s41421-021-00271-4
   Weber CE, 2015, ONCOGENE, V34, P4821, DOI 10.1038/onc.2014.410
   Wei LS, 2018, CELL DEATH DIS, V9, DOI 10.1038/s41419-018-1104-x
   Wen SY, 2019, CANCER LETT, V442, P320, DOI 10.1016/j.canlet.2018.10.015
   Wiklander OPB, 2015, J EXTRACELL VESICLES, V4, DOI 10.3402/jev.v4.26316
   Wikström P, 2009, PROSTATE, V69, P799, DOI 10.1002/pros.20927
   Wu DJ, 2017, SEMIN CELL DEV BIOL, V64, P125, DOI 10.1016/j.semcdb.2016.11.003
   Wu SZ, 2020, EMBO J, V39, DOI 10.15252/embj.2019104063
   Wu TQ, 2022, CELL DEATH DIS, V13, DOI 10.1038/s41419-022-05086-z
   Xu ZJ, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01278-3
   Yang FM, 2017, MOL CANCER, V16, DOI 10.1186/s12943-017-0718-4
   Yang HT, 2022, THERANOSTICS, V12, P3104, DOI 10.7150/thno.69590
   Yang H, 2016, CLIN CHEM LAB MED, V54, P1871, DOI 10.1515/cclm-2016-0029
   Yang X, 2019, FRONT ONCOL, V9, DOI 10.3389/fonc.2019.00356
   Yeung TL, 2013, CANCER RES, V73, P5016, DOI 10.1158/0008-5472.CAN-13-0023
   Yin CY, 2013, J CLIN INVEST, V123, P1902, DOI 10.1172/JCI66369
   Yin H, 2021, CELL SIGNAL, V84, DOI 10.1016/j.cellsig.2021.110029
   Zeisberg EM, 2007, CANCER RES, V67, P10123, DOI 10.1158/0008-5472.CAN-07-3127
   Zhan YX, 2021, CELL DEATH DISCOV, V7, DOI 10.1038/s41420-021-00506-z
   Zhang HY, 2020, MOL CANCER, V19, DOI 10.1186/s12943-020-01168-8
   Zhang HR, 2020, J ENZYM INHIB MED CH, V35, P1322, DOI 10.1080/14756366.2020.1754814
   Zhang L, 2019, BBA-REV CANCER, V1871, P455, DOI 10.1016/j.bbcan.2019.04.004
   Zhang RS, 2019, CELL DEATH DIS, V10, DOI 10.1038/s41419-019-1435-2
   Zhang S, 2022, BIOCHEM BIOPH RES CO, V621, P46, DOI 10.1016/j.bbrc.2022.07.004
   Zhang XX, 2020, THERANOSTICS, V10, P12044, DOI 10.7150/thno.47901
   Zhang Y, 2017, DNA CELL BIOL, V36, P202, DOI 10.1089/dna.2016.3496
   Zhao HY, 2016, ELIFE, V5, DOI 10.7554/eLife.10250
   Zhao MK, 2022, J ONCOL, V2022, DOI 10.1155/2022/9514697
   Zhao QT, 2021, CANCER LETT, V518, P35, DOI 10.1016/j.canlet.2021.06.009
   Zhao XY, 2020, BIOMED PHARMACOTHER, V128, DOI 10.1016/j.biopha.2020.110237
   Zhou L, 2021, J TRANSL MED, V19, DOI 10.1186/s12967-020-02648-7
   Zhou XC, 2018, J EXP CLIN CANC RES, V37, DOI 10.1186/s13046-018-0911-3
   Zhu L, 2020, J HEMATOL ONCOL, V13, DOI 10.1186/s13045-020-00987-y
   Zhu Q, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.263
   Zhu ZW, 2020, NAT METAB, V2, P775, DOI 10.1038/s42255-020-0226-5
NR 222
TC 19
Z9 20
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES
SN 1076-1551
EI 1528-3658
J9 MOL MED
JI Mol. Med.
PD MAY 22
PY 2023
VL 29
IS 1
AR 66
DI 10.1186/s10020-023-00665-y
PG 24
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
   Experimental
WE Science Citation Index Expanded (SCI-EXPANDED)
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
   Medicine
GA H1UZ8
UT WOS:000993898200001
PM 37217855
OA gold, Green Published
DA 2025-01-04
ER

EF